Wherever the art of medicine is loved, there is also a love of humanity.

– Hippocrates
Dedicated to all
past and present contributors
and
supporters of Toronto Notes
who have made the production of the 2017 edition possible!

The Toronto Notes is dedicated to helping fund many charitable endeavours and medical student initiatives at the University of Toronto’s Faculty of Medicine. Programs that have received Toronto Notes funding include:

**Community Affairs Projects**
- Saturday Program for Inner City High School and Grade 8 students
- St. Felix Mentorship Program for Inner City children
- Parkdale Mentorship Program for Grade 10-12 students
- WoodGreen Community Centre
- Let’s Talk Science
- Growing Up Healthy

**Annual Faculty Showcase Events**
- Bruce Tovee Lecture Series
- Daffydid, in support of the Canadian Cancer Society
- Earthones Benefit Concert
- Convocation and Ceremonies

**Medical School Clubs**
- Books with Wings
- Women in Medicine
- University of Toronto International Health Program
- Complementary and Alternative Medicine
- Peer Support for Students
- History of Medicine Society
- Faculty of Medicine Yearbook

**Scholarships and Bursaries**
- Nishant Fozdar Memorial Award
- Graduating Medical Class Scholarships and Bursaries

**Note:**
Many of you have wondered about the Toronto Notes logo, which is based on the rod of Asclepius, the Greek god of medicine. The rod of Asclepius consists of a single serpent entwined around a staff. This icon symbolizes both rebirth, by way of a snake shedding its skin, and also authority, by way of the staff.

In ancient Greek mythology, Asclepius was the son of Apollo and a skilled practitioner of medicine who learned the medical arts from the centaur Chiron. Asclepius’ healing abilities were so great that he was said to be able to bring back people from the dead. These powers displeased the gods, who punished Asclepius by placing him in the sky as the constellation Orphiuchus.

The rod of Asclepius is at times confused with the caduceus, or wand, of Hermes, a staff entwined with two serpents and often depicted with wings. The caduceus is often used as a symbol of medicine or medical professionals, but there is little historical basis for this symbolism.

As you may have guessed, our logo uses the rod of Asclepius that is modified to also resemble the CN Tower – our way of recognizing the university and community in which we have been privileged to learn the art and science of medicine.

Thomas O’Brien, MD
Class of 2009
M.D. Program, University of Toronto
Dear Readers,

As the Editors-in-Chief of Toronto Notes 2017, we are proud to present this updated edition.

Toronto Notes began humbly in 1985 from a set of student notes circulated among medical students at the University of Toronto. Over time, Toronto Notes has grown into one of the premier study resources for generations of Canadian medical trainees. This rich history solidified our commitment to publish a comprehensive study resource for medical students engaged in clinical rotations and studying for both the Canadian MCCQE Part 1 and USMLE Step 2.

For the past 32 years we have remained committed to our original vision. The 2017 edition of Toronto Notes contains significant improvements including:

1. A new emphasis on ‘Approaches to Common Clinical Presentations’ in addition to traditional content organized by disease.
2. A completely revised Psychiatry chapter incorporating the DSM-V in a quick-to-reference and readable format.
3. The Toronto Notes Quiz App, which is available for free on iTunes and Google Play. This app contains hundreds of questions allowing users to test themselves on the content contained within Toronto Notes.
4. A significantly improved interactive eBook with many new high-quality colour images.
5. A brand-new Clinical Handbook that is more concise, has numerous new figures, and features approaches to hundreds of common clinical situations.

Toronto Notes 2017 is produced by Toronto Notes for Medical Students Inc., which is a non-for-profit organization supporting various charity organizations in the city of Toronto. This year Toronto Notes for Medical Students has supported organizations including medical school clubs, community outreach groups, student bursaries and scholarships, and the Canadian Cancer Society. Your purchase of Toronto Notes 2017 is much appreciated by these well-deserving groups.

We would like to highlight the exceptional work of our team, composed of over 150 medical students, medical illustrators/artists, and faculty members at the University of Toronto Faculty of Medicine. Without the tireless effort expended by these individuals the production of Toronto Notes 2017 would not have been possible. In particular, we would like to highlight the work of the executive team, all of whom made personal sacrifices in balancing their clinical and academic duties with the responsibilities asked of them: our production managers, Tina Binesh Marvasti and Sydney McQueen, our associate editors, Narayan Chattergoon, Desmond She, Claudia Frankfurter, Inna Gong, Dhruvin Hirpara, and Sneha Raju, and our EBM editors, Arnav Agarwal, Quynh Huynh, Robert Vanner, Brittany Prevost, Simran Mundi, and Valerie Lemieux. We also want to highlight the work of Rajkumari Chatterjee from University of Toronto Bookstore, who has contributed to the production of Toronto Notes for the past ten years, and has been instrumental in the annual launch of the Toronto Notes Ebook. Lastly, we would like to thank our partners at Type & Graphics Inc., particularly Enrica Aguilera, for their assistance during the production of Toronto Notes 2017.

We hope that Toronto Notes 2017 enhances your medical knowledge and allows you to perform better on both your clinical rotations and licensing exams. We continue to encourage feedback – this year, we have read and incorporated every piece of feedback we received regarding the previous edition of Toronto Notes. On behalf of the Toronto Notes 2017 team, we wish you success in your studies and academic endeavours.

Sincerely,

Jieun Kim, MSc, MD/PhD Candidate and
Ilya Mukovozov, MSc, PhD, MD Candidate
Editors-in-Chief, Toronto Notes 2017
MD Program, University of Toronto
Acknowledgements

We would like to acknowledge the exceptional work of all previous Toronto Notes (formerly MCCQE Notes) Editors-in-Chief and their editorial teams. The 33rd edition of this text was made possible with their contributions.

2016 (32nd ed.): Zamir Merali and Justin D. Woodfine
2015 (31st ed.): Justin Hall and Azra Premji
2014 (30th ed.): Miliana Vojvodic and Ann Young
2013 (29th ed.): Curtis Woodford and Christopher Yao
2012 (28th ed.): Jesse M. Klostranec and David L. Kolin
2011 (27th ed.): Yingming Amy Chen and Christopher Tran
2010 (26th ed.): Simon Baxter and Gordon McSheffrey
2009 (25th ed.): Sagar Dugani and Danica Lam
2008 (24th ed.): Rebecca Colman and Ron Somogyi
2007 (23rd ed.): Marilyn Heng and Joseph Ari Greenwald
2006 (22nd ed.): Carolyn Jane Shiau and Andrew Jonathan Toren
2005 (21st ed.): Blair John Normand Leonard and Jonathan Chi-Wai Yeung
2004 (20th ed.): Andrea Molckovsky and Kashif S. Pirzada
2003 (19th ed.): Prateek Lala and Andrea Waddell
2002 (18th ed.): Neety Panu and Sunny Wong
2001 (17th ed.): Jason Yue and Gagan Ahuja
2000 (16th ed.): Marcus Law and Brian Rotenberg
1999 (15th ed.): Sofia Ahmed and Matthew Cheung
1998 (14th ed.): Marilyn Abraham and M Appleby
1997 (13th ed.): William Harris and Paul Kurdyak
1996 (12th ed.): Michael B. Chang and Laura J. Macnow
1995 (11th ed.): Ann L. Mai and Brian J. Murray
1994 (10th ed.): Kenneth Pace and Peter Fergusson
1993 (9th ed.): Joan Cheng and Russell Goldman
1992 (8th ed.): Gideon Cohen-Nehemia and Shanthi Vasudevan
All former Chief Editors from 1991 (7th ed.) to 1985 (1st ed.)
** PRIMARY AND OTHER SPECIALTIES **

** MEDICINE **

** SURGERY **

** CHAPTER EDITORS **

** PRIMARY AND OTHER SPECIALTIES **

** MEDICINE **

** SURGERY **

** CHAPTER EDITORS **

** PRIMARY AND OTHER SPECIALTIES **

** MEDICINE **

** SURGERY **

** CHAPTER EDITORS **

** PRIMARY AND OTHER SPECIALTIES **

** MEDICINE **

** SURGERY **

** CHAPTER EDITORS **

** PRIMARY AND OTHER SPECIALTIES **

** MEDICINE **

** SURGERY **

** CHAPTER EDITORS **

** PRIMARY AND OTHER SPECIALTIES **

** MEDICINE **

** SURGERY **

** CHAPTER EDITORS **

** PRIMARY AND OTHER SPECIALTIES **

** MEDICINE **

** SURGERY **

** CHAPTER EDITORS **

** PRIMARY AND OTHER SPECIALTIES **

** MEDICINE **

** SURGERY **

** CHAPTER EDITORS **

** PRIMARY AND OTHER SPECIALTIES **

** MEDICINE **

** SURGERY **

** CHAPTER EDITORS **
All contributing professors have been appointed at the University of Toronto.

David Adam, MD, FRCPC
Division of Dermatology
Department of Medicine
St. Michael's Hospital

Iqbal Ahmed, MD, FRCSC
Department of Ophthalmology and Vision Science
University of Toronto

Ruby Alvi, MD, CCFP, MHSc
Department of Family and Community Medicine
University of Toronto

Meyer Balter, MD, FRCPC
Division of Respiratory Medicine
Department of Medicine
Mount Sinai Hospital

Abdollah Behzadi, MD, MBA, FRCSC, FACS
Division of Thoracic Surgery
Department of Surgery
University of Toronto

Nirit Bernhard, MSc, MD, FRCPC
Department of Pediatrics
Hospital for Sick Children

Katherine Bingham, MD, MPH, CCFP-EM
Faculty of Medicine
University of Toronto

Matthew Binnie, MD
Division of Respiriology
University Health Network
St. Michael's Hospital

Ari Bitnun, MD, MSc, FRCPC
Division of Infectious Diseases
The Hospital for Sick Children

Andrea Boggild, MSc, MD, FRCPC
Tropical Disease Unit and Division of Infectious Diseases
University Health Network
Toronto General Hospital

Arthur Bookman, MD, FRCPC
Division of Rheumatology
Department of Medicine
University Health Network
Toronto Western Hospital

Mark Boulos, MD, MSc, CSCN(EEG), FRCPC
Division of Neurology and Sleep Medicine
Department of Medicine
Sunnybrook Health Sciences Centre

John Byrne, MD, MB, BCh, BAO
Division of Vascular Surgery
Department of Surgery
University of Toronto

Simon Carette, MD, FRCPC
Division of Rheumatology
Department of Medicine
Mount Sinai Hospital

Vicky Chau, MD, MScCH, FRCPC
Division of Geriatric Medicine
Department of Medicine
University Health Network

Alice Cheung, MD, FRCPC
Division of Endocrinology and Metabolism
Department of Medicine
St. Michael's Hospital

Chi-Ming Chow, MDCM, MSc, FRCPC
Division of Cardiology
Department of Medicine
St. Michael's Hospital

Allison Chris, MD, MSc, FRCPC
Division of Clinical Public Health
Dalla Lana School of Public Health

Maria Cino, HonBSc, MSc, MD, FRCPC
Division of Gastroenterology
University Health Network
Toronto Western Hospital

Alfonso Fasano, MD, PhD, FRCPC
Division of Neurology
University Health Network
Toronto Western Hospital

Mark Freedman, MD, FRCPC
Department of Emergency Medicine
Sunnybrook Health Sciences Centre

Natasha Gakhar, MD, FRCPC
Division of Rheumatology
Department of Medicine
Women's College Hospital

Barry J. Goldlist, MD, FRCPC
Division of Geriatric Medicine
Department of Medicine
University Health Network

David Hall, MD, PhD, FRCPC
Divisions of Respiriology and Critical Care Medicine
Department of Medicine
University Health Network
St. Michael's Hospital

Jeremy Hall, MD, FRCSC
Division of Orthopedic Surgery
Department of Surgery
St. Michael's Hospital

Philip C. Hébert, MA, PhD, MD, FCFPC
Department of Family and Community Medicine
Joint Centre for Bioethics
Sunnybrook Health Sciences Centre

Sender Herschorn, MD, FRCSC
Division of Urology
Department of Surgery
Sunnybrook Health Sciences Centre and Women's College Hospital

Jonathan C. Irish, MD, MSc, FRCSC
Department of Otolaryngology - Head and Neck Surgery
University Health Network

Nasir Jaffer, MD, FRCPC
Division of Abdominal Imaging
Department of Medical Imaging
Joint Department of Medical Imaging
University of Toronto

David Juurlink, BPhm, MD, PhD, FRCPC
Division of Clinical Pharmacology and Toxicology
Departments of Medicine and Pediatrics
Sunnybrook Health Sciences Centre

Gabor Kandel, MD, FRCPC
Division of Gastroenterology, Department of Medicine
St. Michael's Hospital

Sari L. Kives, MD, FRCSC
Department of Obstetrics and Gynecology
St. Michael's Hospital and The Hospital for Sick Children

Wai-Ching Lam, MD, FRCSC
Department of Ophthalmology and Vision Science
University Health Network
Toronto Western Hospital

Chloe Leon, MD, FRCPC
Division of Brain and Therapeutics
Department of Psychiatry
Centre for Addiction and Mental Health

Armando Lorenzo, MD, FRCSC
Division of Urology
Department of Surgery
The Hospital for Sick Children

Todd Mainprize, MD, FRCSC
Department of Neurosurgery
Sunnybrook Health Sciences Centre
Faculty Contributors, University of Toronto

Eric Massicotte, MD, MSc, FRCSC
Department of Neurosurgery
University Health Network
Toronto Western Hospital

Michael McDonald, MD, FRCP
Division of Cardiology and
The Multi-Organ Transplant Program
Department of Medicine
University Health Network
Toronto General Hospital

Adam C. Millar, MD, MScCH
Division of Endocrinology and Metabolism
Department of Medicine
Mount Sinai Hospital

Azadeh Moaveni, MD, CCFP
Department of Family and
Community Medicine
University Health Network
Toronto Western Hospital

Ally Murji, MD, MPH, FRCS(C)
Department of Obstetrics and Gynecology
Mount Sinai Hospital

Melinda Musgrave, MD, PhD, FRCS
Division of Plastic and Reconstructive Surgery
Department of Surgery
St. Michael's Hospital

Sharon Naymark, MD, FRCP
Department of Pediatrics
St. Joseph's Health Centre

George Oreopoulos, MD, MSc, FRCSC
Division of Vascular Surgery
Department of Surgery
University Health Network

Richard Pittini, MD, MEd, FRCS, FACOG
Department of Obstetrics and Gynaecology
University of Toronto
Sunnybrook Health Sciences Centre

Susan Poutanen, MD, MPH, FRCP
Department of Microbiology
University Health Network and
Mount Sinai Hospital

Ramesh Prasad, MBBS, MSc, FRCP
Division of Nephrology
Department of Medicine
St. Michael's Hospital

Mary Preisman, MD, FRCP
Department of Psychiatry
Mount Sinai Hospital

Evan Probst, MD, MSc, FRCS
Division of Head and Neck Surgery
Department of Otolaryngology
The Hospital for Sick Children

Angela Punnett, MD, FRCP
Department of Pediatrics
The Hospital for Sick Children

Amanda Selk, MD, FRCS
Department of Obstetrics and Gynecology
Mount Sinai Hospital

Marisa Sit, MD, FRCS
Department of Ophthalmology
and Vision Science
University Health Network
Toronto Western Hospital

Michelle Sholzberg, MDCM, MSc, FRCP
Division of Hematology
Department of Medicine
St. Michael's Hospital

Kevin Skarratt, MD, FRCP
Department of Emergency Medicine
Sunnybrook Health Sciences Centre

Elizabeth Slow, MD, PhD, FRCP
Division of Neurology
University Health Network

Peter Tai, MD, FRCP
Division of Neurology
University Health Network
Toronto Western Hospital

Diana Tamir, MD, FRCP
Department of Anesthesia and
Pain Management
University Health Network

Gemini Tanna, MD, FRCP
Division of Nephrology
Department of Medicine
Sunnybrook Health Sciences Centre

Piero Tartaro, MD, FRCP
Division of Gastroenterology
Department of Medicine
Sunnybrook Health Sciences Centre

Fernando Teixeira, MD, FRCP
Department of Emergency Medicine
St. Michael's Hospital

Martina Trinkaus, MD, FRCP
Division of Hematology
Department of Medicine
St. Michael's Hospital

Herbert P. von Schroeder, MD, MSc, FRCSC
Divisions of Orthopedic Surgery and
Plastic Surgery
Department of Surgery
University Health Network

Oshrit Wanono, MD, FRCP
Division of Child and Adolescent Psychiatry
Department of Psychiatry
Centre for Addiction and Mental Health

Kyle R. Wanzel, MD, MEd, FRCS
Division of Plastic Surgery
St. Joseph's Health Centre

Jeffrey Wassermann, MD, FRCP
Department of Anesthesia
St. Michael's Hospital

Alice Wei, MD CM, MSc, FRCS
Division of General Surgery
Department of Surgery
University Health Network

Michael J. Weinberg, MD, MSc, FRCS(c)
Division of Plastic Surgery
Department of Surgery
University of Toronto
Trillium Health Centre

Fay Weisberg, MD, FRCS
Division of Reproductive Endocrinology
and Infertility
Department of Obstetrics and Gynecology
University of Toronto

Anna Woo, MD CM, SM, DABIM, FRCP
Division of Cardiology
Department of Medicine
University Health Network
Toronto General Hospital

Jensen Yeung, MD, FRCP
Division of Dermatology
Department of Medicine
Women's College Hospital

Eugene Yu, MD, FRCP
Division of Neuroradiology
Department of Medical Imaging
University Health Network
# Table of Contents

1. Common Unit Conversions
2. Commonly Measured Laboratory Values
3. Ethical, Legal, and Organizational Medicine .......................... ELOM
4. Anesthesia and Perioperative Medicine ............................. A
5. Cardiology and Cardiac Surgery ........................................ C
6. Clinical Pharmacology ................................................... CP
7. Dermatology ................................................................... D
8. Emergency Medicine ...................................................... ER
9. Endocrinology .................................................................. E
10. Family Medicine .......................................................... FM
11. Gastroenterology ............................................................ G
12. General Surgery and Thoracic Surgery ............................ GS
13. Geriatric Medicine ........................................................ GM
14. Gynecology ................................................................. GY
15. Hematology .................................................................... H
16. Infectious Diseases ........................................................ ID
17. Medical Imaging ............................................................. MI
18. Nephrology ................................................................. NP
19. Neurology ..................................................................... N
20. Neurosurgery ............................................................... NS
21. Obstetrics ................................................................... OB
22. Ophthalmology ............................................................. OP
23. Orthopedics ................................................................. OR
24. Otolaryngology ............................................................. OT
25. Pediatrics .................................................................... P
26. Plastic Surgery ............................................................. PL
27. Population Health and Epidemiology ............................... PH
28. Psychiatry ................................................................. PS
29. Respiratory ................................................................. R
30. Rheumatology .............................................................. RH
31. Urology ....................................................................... U
32. Vascular Surgery ........................................................ VS
33. Index
How to Use This Book

This book has been designed to remain as one book or to be taken apart into smaller booklets. Identify the beginning and end of a particular section, then carefully bend the pages along the perforated line next to the spine of the book. Then tear the pages out along the perforation.

The layout of Toronto Notes allows easy identification of important information. These items are indicated by icons interspersed throughout the text:

<table>
<thead>
<tr>
<th>Icon</th>
<th>Icon Name</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Key Objectives</td>
<td>This icon is found next to headings in the text. It identifies key objectives and conditions as determined by the Medical Council of Canada or the National Board of Medical Examiners in the USA. If it appears beside a dark title bar, all subsequent subheadings should be considered key topics.</td>
</tr>
<tr>
<td></td>
<td>Clinical Pearl</td>
<td>This icon is found in sidebars of the text. It identifies concise, important information which will aid in the diagnosis or management of conditions discussed in the accompanying text.</td>
</tr>
<tr>
<td></td>
<td>Memory Aid</td>
<td>This icon is found in sidebars of the text. It identifies helpful mnemonic devices and other memory aids.</td>
</tr>
<tr>
<td></td>
<td>Clinical Flag</td>
<td>This icon is found in sidebars of the text. It indicates information or findings that require urgent management or specialist referral.</td>
</tr>
<tr>
<td></td>
<td>Cross-Reference</td>
<td>This icon is found in sidebars of the text. It indicates a cross-reference for information that is discussed in a separate chapter.</td>
</tr>
<tr>
<td></td>
<td>Evidence Based Medicine</td>
<td>This icon is found in sidebars of the text. It identifies key research studies for evidence-based clinical decision making related to topics discussed in the accompanying text.</td>
</tr>
<tr>
<td></td>
<td>Colour Photo Atlas</td>
<td>This icon is found next to headings in the text. It indicates topics that correspond with images found in the Colour Photo Atlas available online (<a href="http://www.torontonotes.ca">www.torontonotes.ca</a>).</td>
</tr>
<tr>
<td></td>
<td>Radiology Atlas</td>
<td>This icon is found next to headings in the text. It indicates topics that correspond to images found in the Radiology Atlas available online (<a href="http://www.torontonotes.ca">www.torontonotes.ca</a>).</td>
</tr>
<tr>
<td></td>
<td>Online Resources</td>
<td>This icon is found next to headings in the text. It indicates topics that correspond with electronic resources such as Functional Neuroanatomy or ECGs Made Simple, available online (<a href="http://www.torontonotes.ca">www.torontonotes.ca</a>).</td>
</tr>
</tbody>
</table>

Chapter Divisions
To aid in studying and finding relevant material quickly, each chapter is organized in the following general framework:

**Basic Anatomy/Physiology Review**
- features the high-yield, salient background information students are often assumed to have remembered from their early medical school education

**Common Differential Diagnoses**
- aims to outline a clinically useful framework to tackle the common presentations and problems faced in the area of expertise

**Diagnoses**
- the bulk of the book
  - etiology, epidemiology, pathophysiology, clinical features, investigations, management, complications, and prognosis

**Common Medications**
- a quick reference section for review of medications commonly prescribed
**Common Unit Conversions**

To convert from the conventional unit to the SI unit, **multiply** by conversion factor.

To convert from the SI unit to the conventional unit, **divide** by conversion factor.

<table>
<thead>
<tr>
<th>Conventional Unit</th>
<th>Conversion Factor</th>
<th>SI Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTH pg/mL</td>
<td>0.22</td>
<td>pmol/L</td>
</tr>
<tr>
<td>Albumin g/dL</td>
<td>10</td>
<td>g/L</td>
</tr>
<tr>
<td>Bilirubin mg/dL</td>
<td>17.1</td>
<td>µmol/L</td>
</tr>
<tr>
<td>Calcium mg/dL</td>
<td>0.25</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Cholesterol µg/dL</td>
<td>0.0259</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Cortisol µg/dL</td>
<td>27.59</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Creatinine mg/dL</td>
<td>88.4</td>
<td>µmol/L</td>
</tr>
<tr>
<td>Creatinine clearance mL/min</td>
<td>0.0167</td>
<td>mL/s</td>
</tr>
<tr>
<td>Ethanol mg/dL</td>
<td>0.217</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Ferritin ng/mL</td>
<td>2.247</td>
<td>pmol/L</td>
</tr>
<tr>
<td>Glucose mg/dL</td>
<td>0.0555</td>
<td>mmol/L</td>
</tr>
<tr>
<td>HbA1c %</td>
<td>0.01</td>
<td>proportion of 1.0</td>
</tr>
<tr>
<td>Hemoglobin g/dL</td>
<td>10</td>
<td>g/L</td>
</tr>
<tr>
<td>HDL cholesterol mg/dL</td>
<td>0.0259</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Iron, total µg/dL</td>
<td>0.179</td>
<td>µmol/L</td>
</tr>
<tr>
<td>Lactate (lactic acid) mg/dL</td>
<td>0.111</td>
<td>mmol/L</td>
</tr>
<tr>
<td>LDL cholesterol mg/dL</td>
<td>0.0259</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Leukocytes x 10^3 cells/mm^3</td>
<td>1</td>
<td>x 10^9 cells/L</td>
</tr>
<tr>
<td>Magnesium mg/dL</td>
<td>0.411</td>
<td>mmol/L</td>
</tr>
<tr>
<td>MCV µm^3</td>
<td>1</td>
<td>fL</td>
</tr>
<tr>
<td>Platelets x 10^3 cells/mm^3</td>
<td>1</td>
<td>x 10^9 cells/L</td>
</tr>
<tr>
<td>Reticulocytes % of RBCs</td>
<td>0.01</td>
<td>proportion of 1.0</td>
</tr>
<tr>
<td>Salicylate mg/L</td>
<td>0.00724</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Testosterone ng/dL</td>
<td>0.0347</td>
<td>nmol/L</td>
</tr>
<tr>
<td>Thyroxine (T4) ng/dL</td>
<td>12.87</td>
<td>pmol/L</td>
</tr>
<tr>
<td>Total Iron Binding Capacity µg/dL</td>
<td>0.179</td>
<td>µmol/L</td>
</tr>
<tr>
<td>Triiodothyronine (T3) pg/dL</td>
<td>0.0154</td>
<td>pmol/L</td>
</tr>
<tr>
<td>Triglycerides mg/dL</td>
<td>0.0113</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Urea nitrogen mg/dL</td>
<td>0.357</td>
<td>mmol/L</td>
</tr>
<tr>
<td>Uric acid mg/dL</td>
<td>59.48</td>
<td>µmol/L</td>
</tr>
</tbody>
</table>

**Celsius → Fahrenheit**  \( F = (C \times 1.8) + 32 \)

**Fahrenheit → Celsius**  \( C = (F – 32) \times 0.5555 \)

**Kilograms → Pounds**  \( 1 \text{ kg} = 2.2 \text{ lbs} \)

**Pounds → Ounces**  \( 1 \text{ lb} = 16 \text{ oz} \)

**Ounces → Grams**  \( 1 \text{ oz} = 28.3 \text{ g} \)

**Inches → Centimetres**  \( 1 \text{ in} = 2.54 \text{ cm} \)
### Commonly Measured Laboratory Values

<table>
<thead>
<tr>
<th>Test</th>
<th>Conventional Units</th>
<th>SI Units</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Arterial Blood Gases</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>7.35-7.45</td>
<td>7.35-7.45</td>
</tr>
<tr>
<td>PCO(_2)</td>
<td>35-45 mmHg</td>
<td>4.7-6.0 kPa</td>
</tr>
<tr>
<td>PO(_2)</td>
<td>80-105 mmHg</td>
<td>10.6-14 kPa</td>
</tr>
<tr>
<td><strong>Serum Electrolytes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>22-28 mEq/L</td>
<td>22-28 mmol/L</td>
</tr>
<tr>
<td>Calcium</td>
<td>8.4-10.2 mg/dL</td>
<td>2.1-2.5 mmol/L</td>
</tr>
<tr>
<td>Chloride</td>
<td>95-106 mEq/L</td>
<td>95-106 mmol/L</td>
</tr>
<tr>
<td>Magnesium</td>
<td>1.3-2.1 mEq/L</td>
<td>0.65-1.05 mmol/L</td>
</tr>
<tr>
<td>Phosphate</td>
<td>2.7-4.5 mg/dL</td>
<td>0.87-1.45 mmol/L</td>
</tr>
<tr>
<td>Potassium</td>
<td>3.5-5.0 mEq/L</td>
<td>3.5-5.0 mmol/L</td>
</tr>
<tr>
<td>Sodium</td>
<td>136-145 mEq/L</td>
<td>136-145 mmol/L</td>
</tr>
<tr>
<td><strong>Serum Nonelectrolytes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albumin</td>
<td>3.5-5.0 g/dL</td>
<td>35-50 g/L</td>
</tr>
<tr>
<td>ALP</td>
<td>35-100 U/L</td>
<td>35-100 U/L</td>
</tr>
<tr>
<td>ALT</td>
<td>8-20 U/L</td>
<td>8-20 U/L</td>
</tr>
<tr>
<td>Amylase</td>
<td>25-125 U/L</td>
<td>25-125 U/L</td>
</tr>
<tr>
<td>AST</td>
<td>8-20 U/L</td>
<td>8-20 U/L</td>
</tr>
<tr>
<td>Bilirubin (direct)</td>
<td>0-0.3 mg/dL</td>
<td>0-5 µmol/L</td>
</tr>
<tr>
<td>Bilirubin (total)</td>
<td>0.1-1.0 mg/dL</td>
<td>2-17 µmol/L</td>
</tr>
<tr>
<td>BUN</td>
<td>7-18 mg/dL</td>
<td>2.5-7.1 mmol/L</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>&lt;200 mg/dL</td>
<td>&lt;5.2 mmol/L</td>
</tr>
<tr>
<td>Creatinine (female)</td>
<td>10-70 U/L</td>
<td>10-70 U/L</td>
</tr>
<tr>
<td>Creatinine (male)</td>
<td>25-90 U/L</td>
<td>25-90 U/L</td>
</tr>
<tr>
<td>Creatine Kinase – MB fraction</td>
<td>0-12 U/L</td>
<td>0-12 U/L</td>
</tr>
<tr>
<td>Ferritin (female)</td>
<td>12-150 ng/mL</td>
<td>12-150 µg/L</td>
</tr>
<tr>
<td>Ferritin (male)</td>
<td>15-200 ng/mL</td>
<td>15-200 µg/L</td>
</tr>
<tr>
<td>Glucose (fasting)</td>
<td>70-110 mg/dL</td>
<td>3.8-6.1 mmol/L</td>
</tr>
<tr>
<td>HbA1c</td>
<td>&lt;6%</td>
<td>&lt;0.06</td>
</tr>
<tr>
<td>LDH</td>
<td>100-250 U/L</td>
<td>100-250 U/L</td>
</tr>
<tr>
<td>Osmolality</td>
<td>275-300 mOsm/kg</td>
<td>275-300 mOsm/kg</td>
</tr>
<tr>
<td><strong>Serum Hormones</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACTH (0800h)</td>
<td>&lt;60 pg/mL</td>
<td>&lt;13.2 pmol/L</td>
</tr>
<tr>
<td>Cortisol (0800h)</td>
<td>5-23 µg/dL</td>
<td>138-635 nmol/L</td>
</tr>
<tr>
<td>Prolactin</td>
<td>&lt;20 ng/mL</td>
<td>&lt;20 ng/mL</td>
</tr>
<tr>
<td>Testosterone (male, free)</td>
<td>9-30 ng/dL</td>
<td>0.31-1 pmol/L</td>
</tr>
<tr>
<td>Thyroxine (T(_4))</td>
<td>5-12 ng/dL</td>
<td>64-155 nmol/L</td>
</tr>
<tr>
<td>Triiodothyronine (T(_3))</td>
<td>115-190 ng/dL</td>
<td>1.8-2.9 nmol/L</td>
</tr>
<tr>
<td>TSH</td>
<td>0.5-5 µU/mL</td>
<td>0.5-5 µU/mL</td>
</tr>
<tr>
<td><strong>Hematologic Values</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESR (female)</td>
<td>0-20 mm/h</td>
<td>0-20 mm/h</td>
</tr>
<tr>
<td>ESR (male)</td>
<td>0-15 mm/h</td>
<td>0-15 mm/h</td>
</tr>
<tr>
<td>Hemoglobin (female)</td>
<td>12.3-15.7 g/dL</td>
<td>123-157 g/L</td>
</tr>
<tr>
<td>Hemoglobin (male)</td>
<td>13.5-17.5 g/dL</td>
<td>140-174 g/L</td>
</tr>
<tr>
<td>Hematocrit (female)</td>
<td>36-46%</td>
<td>36-46%</td>
</tr>
<tr>
<td>Hematocrit (male)</td>
<td>41-53%</td>
<td>41-53%</td>
</tr>
<tr>
<td>INR</td>
<td>1.0-1.1</td>
<td>1.0-1.1</td>
</tr>
<tr>
<td>Leukocytes</td>
<td>4.5-11 x 10(^3) cells/mm(^3)</td>
<td>4.5-11 x 10(^9) cells/L</td>
</tr>
<tr>
<td>MCV</td>
<td>88-100 µm(^3)</td>
<td>88-100 fL</td>
</tr>
<tr>
<td>Platelets</td>
<td>150-400 x 10(^3)/mm(^3)</td>
<td>150-400 x 10(^9)/L</td>
</tr>
<tr>
<td>PTT</td>
<td>25-35 s</td>
<td>25-35 s</td>
</tr>
<tr>
<td>Reticulocytes</td>
<td>0.5-1.5% of RBC</td>
<td>20-84 x 10(^9)/L</td>
</tr>
</tbody>
</table>
Further information on these topics can be found in the Objectives of the Considerations of the Legal, Ethical and Organizational Aspects of the Practice of Medicine (CLEO) – which can be downloaded free of charge from the Medical Council of Canada website at http://mcc.ca/wp-content/uploads/CLEO.pdf

Canadian law applicable to medical practice varies between jurisdictions and changes over time. Criminal law is nationwide, but non-criminal (civil) law varies between provinces. This section is meant to serve only as a guide. Students and physicians should ensure that their practices conform to local and current laws.
The Canadian Health Care System

Overview of Canadian Health Care System

- one federal, three territorial, and ten provincial systems
- major complexities involved in establishment of Canadian health policy include geographical diversity, socioeconomic divisions, and international pressures
- financed by both the public (70%) and private (30%) sectors
- each provincial plan must cover all medically necessary health services delivered in hospitals and by physicians; may choose to cover services such as home care and prescription drugs
- non-insured health services and fees are either covered by private insurance or by the individual
- workers’ compensation funds cover treatment for work-related injuries and diseases

Table 1. Division of Government Responsibilities in Health Care

<table>
<thead>
<tr>
<th>Federal Government</th>
<th>Provincial Government</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marine hospitals and quarantine (Constitution Act, 1867)</td>
<td>Establishment, maintenance and management of hospitals, asylums, charities, and charitable institutions (Constitution Act, 1867)</td>
</tr>
<tr>
<td>Health care services for Aboriginal people, federal government employees (RCMP and armed forces), immigrants, and civil aviation personnel</td>
<td>Licensing of physicians, nurses and other health professionals</td>
</tr>
<tr>
<td>Investigations into public health</td>
<td>Determining the standards for licensing all hospitals</td>
</tr>
<tr>
<td>Regulation of food and drugs</td>
<td>Administering provincial medical insurance plans</td>
</tr>
<tr>
<td>Inspection of medical devices</td>
<td>Financing health care facilities</td>
</tr>
<tr>
<td>Administration of health care insurance</td>
<td>Delivery of certain public health services</td>
</tr>
<tr>
<td>General information services related to health conditions and practices</td>
<td>Role in health derived from government’s constitutional powers over criminal law (basis for legislation such as Food and Drugs Act and Controlled Substances Act), spending, and “peace, order, and good government”</td>
</tr>
</tbody>
</table>

Legal Foundation

- the legal foundation of the Canadian health system is based on two constitutional documents:
  1. Constitution Act (1867): deals primarily with the jurisdictional power between federal and provincial governments
  2. The Canadian Charter of Rights and Freedoms (1982): does not guarantee a right to health care but, given government’s decision to finance health care, they are constitutionally obliged to do so consistently with the rights and freedoms outlined in the Charter (including the right to equality, physicians’ mobility rights, etc.)

- and two statutes:
  1. Canada Health Act (1984): outlines the national terms and conditions that provincial health systems must meet in order to receive federal transfer payments
  2. Canada Health and Social Transfer Act (1996): federal government gives provinces a single grant for health care, social programs, and post-secondary education; division of resources at provinces’ discretion

History of the Canadian Health Care System

1867 British North America Act (now Constitution Act) establishes Canada as a confederacy

1965 Royal Commission on Health Services (Hall Commission) recommends federal leadership and financial support with provincial government operation
Canada Health Act passed by federal government
- replaces Medical Care Act (1966) and Hospital Insurance and Diagnostic Services Act (1957)
- provides federal funds to provinces with universal hospital insurance
- maintains federal government contribution at 50% on average, with poorer provinces receiving more funds
- medical insurance must be 'comprehensive, portable, universal, and publicly administered'
- bans extra-billing by new fift criterion: accessibility

Canada Health and Social Transfer Act passed by federal government
- federal government gives provinces a single grant for health care, social programs, and post-secondary education; division of resources at provinces' discretion

Kirby and Romanow Commissions appointed
- Kirby Commission (final report, October 2002)
  - examines history of health care system in Canada, pressures and constraints of current health care system, role of federal government, and health care systems in foreign jurisdictions
- Romanow Commission (final report, November 2002)
  - dialogue with Canadians on the future of Canada’s public health care system

First Ministers’ Meeting on the Future of Health Care produces a 10 year plan
- priorities include reductions in waiting times, development of a national pharmacare plan, and primary care reform

Choulli v. Québec, Supreme Court of Canada decision
- rules that Québec’s banning of private insurance is unconstitutional under the Québec Charter of Rights, given that patients do not have access to those services under the public system in a timely way

First progress report by the Health Council reviews progress (2004 First Ministers’ 10 year plan)
- significant reductions in wait times for specific areas (such as cancer, joint replacement and sight restoration), but may have inadvertently caused increases in wait times of other services
- despite large investments into EMRs, Canada continues to have very low uptake, ranking last in the Commonwealth Fund International Health Policy survey, with only 37% use among primary care physicians
- little progress in creating a national strategy for equitable access to pharmaceuticals; however, there has been some success in increasing pharmacists’ scope of practice, reducing generic drugs costs, and implementing drug info systems
- increases in funding to provinces at 6% per annum until the 2016-2017 fiscal year; from then onwards, increases tied to nominal GDP at a minimum of 3% per annum

Second progress report by the Health Council reviews progress towards 2004 First Ministers’ 10 year plan
- funding is sufficient; however, more innovation is needed including incentivizing through models of remuneration
- 46 recommendations made to address the lack of progress

Health Care Expenditure and Delivery in Canada
- projected total health care expenditure in 2014 was $214.9 billion, 11% of the GDP, approximately $6,045 CDN per person

Sources of Health Care Funding
- 71% of total health expenditure in 2015 came from public-sector funding with 66% coming from the provincial and territorial governments and 5% from other parts of the public sector: federal direct government, municipal, and social security funds. 29% is from private sources including out of pocket (14%), private insurance (12%) and other (3%)
- public sector covers services offered on a either a fee for service, capitation, or alternate payment plan in physicians’ offices and in hospitals
- public sector does not cover services provided by privately practicing health professionals (e.g. dentists, chiropractors, optometrists, massage therapists, osteopaths, physiotherapists, podiatrists, psychologists, private duty nurses, and naturopaths), prescription drugs, OTC drugs, personal health supplies, and use of residential care facilities
Delivery of Health Care

- hospital services in Canada are publicly funded but delivered through private, not-for-profit institutions owned and operated by communities, religious organizations, and regional health authorities
- other countries, such as the United States (a mix of public and private funding, as well as private for-profit and private not-for-profit delivery) and the United Kingdom (primarily public funding and delivery) have different systems of delivery

Physician Licensure and Certification

- physician certification is governed nationally, while the medical profession in Canada self-regulates under the authority of provincial legislation
- self-regulation is based on the premise that the licensing authority must act first and foremost in the interest of the public

Table 2. Key Physician Certification and Licensing Bodies in Canada

<table>
<thead>
<tr>
<th>Certifying Body</th>
<th>Description</th>
</tr>
</thead>
</table>
| MCC             | Certifies physicians with the LMCC  
The LMCC is acquired by passing the MCC Qualifying Examination Parts I and II |
| RCPSC           | Certifies specialists who complete an accredited residency program and pass the appropriate exam  
Voluntary membership of the RCPSC is designated FRCPC or FRSC |
| CFPC            | Certifies family physicians who complete an accredited residency program and pass the Certification Examination in Family Medicine |

<table>
<thead>
<tr>
<th>Licensing Body</th>
<th>Description</th>
</tr>
</thead>
</table>
| CPSO           | Membership to the provincial licensing authority is mandatory  
Licensing authority functions include:  
Provide non-transferable licensure to physicians  
Maintaining ethical, legal, and competency standards and developing policies to guide doctors  
Investigating complaints against doctors  
Disciplining doctors guilty of professional misconduct or incompetence  
At times of license revocation and renewal, physicians must disclose if they have a condition (such as HIV positivity, drug addiction, or other illnesses that may impact their ability to practice safely) |

- the RCPSC and CFPC are responsible for monitoring ongoing CME and professional development
- certification by the LMCC plus either the RCPSC or CFPC is a minimum requirement for licensure by most provincial licensing authorities

Role of Professional Associations

Table 3. Key Professional Associations

<table>
<thead>
<tr>
<th>Association</th>
<th>Description</th>
</tr>
</thead>
</table>
| CMA              | Provides leadership to doctors and advocates for access to high quality care in Canada  
Represents physician and population concerns at the national level  
Membership is voluntary |
| OMA and Other PTMAs | Negotiates fee and benefit schedules with provincial governments  
Represents the economic and professional interests of doctors  
Membership is voluntary |
| CMPA             | Physician-run organization that protects the integrity of member physicians  
Provides legal defence against allegations of malpractice or negligence  
Provides risk management and educational programs  
Membership is voluntary |
| RDoC and PHO     | Upholds economic and professional interests of residents across Canada  
Facilitates discussion amongst PHOs regarding policy and advocacy items |
| CMFS and FMEQ    | Medical students are represented at their universities by student bodies, which collectively form the CFMS or FMEQ  
The FMEQ membership includes that of francophone medical schools |
Introduction to the Principles of Ethics

- Ethics addresses:
  1. Principles and values that help define what is morally right and wrong
  2. Rights, duties, and obligations of individuals and groups
- The practice of medicine assumes there is one code of professional ethics for all doctors and that they will be held accountable by that code and its implications
- The doctor-patient relationship is formed on trust, which is recognized in the concept of fiduciary duty/responsibility of physician towards patient
- A fiduciary duty is a legal duty to act solely in another party’s interest; one may not profit from the relationship with principals unless he/she has the principal’s express consent

Table 4. The Four Principles Approach to Medical Ethics

<table>
<thead>
<tr>
<th>Principle</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autonomy</td>
<td>Recognizes an individual’s right and ability to decide for himself/herself according to his/her beliefs and values Not applicable in situations where informed consent and choice are not possible or may not be appropriate</td>
</tr>
<tr>
<td>Beneficence</td>
<td>The patient-based ‘best interests’ standard that combines doing good, avoiding harm, taking into account the patient’s values, beliefs, and preferences, so far as these are known Autonomy should be integrated with the physician’s conception of a patient’s medically-defined best interests The aim is to minimize harmful outcomes and maximize beneficial ones Paramount in situations where consent/choice is not possible or may not be appropriate</td>
</tr>
<tr>
<td>Non-Maleficence</td>
<td>Obligation to avoid causing harm; primum non nocere (“First, do no harm”) A limit condition of the Beneficence principle</td>
</tr>
<tr>
<td>Justice</td>
<td>Fair distribution of benefits and harms within a community, regardless of geography or privilege Concept of fairness: Is the patient receiving what he/she deserves – his/her fair share? Is he/she treated the same as equally situated patients? How does one set of treatment decisions impact others? Basic human rights, such as freedom from persecution and the right to have one’s interests considered and respected</td>
</tr>
</tbody>
</table>

CMA Code of Ethics

- The CMA developed a Code of Ethics that acts as a common ethical framework for Canadian physicians. The Code of Ethics is:
  - Prepared by physicians for physicians and applies to physicians, residents, and medical students
  - Based on the fundamental ethical principles of medicine
  - Sources include the Hippocratic Oath, developments in human rights, recent bioethical discussion
  - CMA policy statements address specific ethical issues not mentioned by the code (e.g. abortion, transplantation, and euthanasia)

Confidentiality

Overview of Confidentiality

- A full and open exchange of information between patient and physician is central to a therapeutic relationship
- Privacy is the right of patients (which they may forego) while confidentiality is the duty of doctors (which they must respect barring patient consent or the requirements of the law)
- If inappropriately breached by a doctor, he/she can be sanctioned by the hospital, court, or regulatory authority
- Based on the ethical principle of patient autonomy, patients have the right to the following:
  - Control of their own information
  - The expectation that information concerning them will receive proper protection from unauthorized access by others (see Privacy of Medical Records, ELOM6)
- Confidentiality may be ethically and legally breached in certain circumstances (e.g. the threat of harm to others)
- Unlike the solicitor-client privilege, there is no ‘physician-patient privilege’ by which a physician, even a psychiatrist, can promise the patient absolute confidentiality
- Physicians should seek advice from their local health authority or the CMPA before disclosing HIV status of a patient to someone else
- Many jurisdictions make mandatory not only the reporting of serious communicable diseases (e.g. HIV), but also the reporting of those who harbour the agent of the communicable disease
- Physicians failing to abide by such regulations could be subject to professional or civil actions
- The legal duty to maintain patient confidentiality is imposed by provincial health information legislation and precedent-setting cases in the common law

Confidentiality

- Disclose your patients’ personal health information to third parties only with their consent, or as provided for by law, such as when the maintenance of confidentiality would result in a significant risk of substantial harm to others or, in the case of incompetent patients, to the patients themselves. In such cases take all reasonable steps to inform the patients that the usual requirements for confidentiality will be breached

Legal Aspects of Confidentiality

- Advice should always be sought from provincial licensing authorities and/or legal counsel when in doubt

CMA Code of Ethics

- The CMA Code of Ethics is a quasi-legal standard for physicians; if the law sets a minimal moral standard for doctors, the Code augments these standards
Statutory Reporting Obligations
- legislation has defined specific instances where public interest overrides the patient's right to confidentiality; varies by province, but may include
  1. suspected child abuse or neglect – report to local child welfare authorities (e.g. Children's Aid Society)
  2. fitness to drive a vehicle or fly an airplane – report to provincial Ministry of Transportation (see Geriatric Medicine, GM11)
  3. communicable diseases – report to local public health authority (see Population Health and Epidemiology, PH24)
  4. improper conduct of other physicians or health professionals – report to College or regulatory body of the health professional (sexual impropriety by physicians is required reporting in some provinces)
  5. vital statistics must be reported; reporting varies by province (e.g. in Ontario, births are required to be reported within 30 days to Office of Registrar General or local municipality; death certificates must be completed by a MD then forwarded to municipal authorities)
  6. reporting to coroners (see Physician Responsibilities Regarding Death, ELOM14)

- physicians who fail to report in these situations are subject to prosecution and penalty, and may be liable if a third party has been harmed

Duty to Protect/Warn
- the physician has a duty to protect the public from a known dangerous patient; this may involve taking appropriate clinical action (e.g. involuntary detention of violent patients for clinical assessment), informing the police, or warning the potential victim(s) if a patient expresses an intent to harm
- first established by a Supreme Court of California decision in 1976 (Tarasoff v. Regents of the University of California); supported by Canadian courts
- obliged by the CMA Code of Ethics and recognized by some provincial/territorial regulatory authorities
- concerns of breaching confidentiality should not prevent the MD from exercising the duty to protect; however, the disclosed information should not exceed that required to protect others
- applies in a situation where
  1. there is a clear risk to identifiable person(s);
  2. there is a risk of serious bodily harm or death; and
  3. the danger is imminent (i.e. more likely to occur than not)

Disclosure for Legal Proceedings
- disclosure of health records can be compelled by a court order, warrant, or subpoena

Privacy of Medical Records
- privacy of health information is protected by professional codes of ethics, provincial and federal legislation, the Canadian Charter of Rights and Freedoms, and the physician's fiduciary duty
- the federal government created the PIPEDA in 2000 which established principles for the collection, use, and disclosure of information that is part of commercial activity (e.g. physician practices, pharmacies, private labs)
- PIPEDA has been superseded by provincial legislation in many provinces, such as the Ontario Personal Health Information Protection Act, which applies more specifically to health information

Duties of Physicians with Respect to the Privacy of Health Information
- inform patients of information-handling practices through various means (e.g. posting notices, brochures and pamphlets, and/or through discussions with patients)
- obtain the patient's expressed consent to disclose information to third parties
  - under Ontario privacy legislation, the patient's expressed consent need not be obtained to share information between health care team members involved in the "circle of care." However, the patient may withdraw consent for this sharing of information and may put parts of the chart in a "lock box"
  - provide the patient with access to their entire medical record; exceptions include instances where there is potential for serious harm to the patient or a third party
  - provide secure storage of information and implement measures to limit access to patient records
  - ensure proper destruction of information that is no longer necessary
  - regarding taking pictures or videos of patients, findings, or procedures, in addition to patient consent and privacy laws, trespassing laws apply in some provinces

Consent and Capacity

Ethical Principles Underlying Consent and Capacity
- consent is the autonomous authorization of a medical intervention by a patient
- usually the principle of respect for patient autonomy overrides the principle of beneficence
- where a patient cannot make an autonomous decision (i.e. incapable), it is the duty of the SDM (or the physician in an emergency) to act on the patient's known prior wishes or, failing that, to act in the patient's best interests
- there is a duty to discover, if possible, what the patient would have wanted when capable
- central to determining best interests is understanding the patient's values, beliefs, and cultural or religious background
- more recently expressed wishes take priority over remote ones
• patient wishes may be verbal or written
• patients found incapable to make a specific decision should still be involved in that decision as much as possible
• agreement or disagreement with medical advice does not determine findings of capacity/incapacity
• however, patients opting for care that puts them at risk of serious harm that most people would want to avoid should have their capacity carefully assessed

Four Basic Requirements of Valid Consent
1. Voluntary
   • consent must be given free of coercion or pressure (e.g. from parents or other family members who might exert ‘undue influence’)
   • the physician must not deliberately mislead the patient about the proposed treatment

2. Capable
   • the patient must be able to understand and appreciate the nature and effect of the proposed treatment

3. Specific
   • the consent provided is specific to the procedure being proposed and to the provider who will carry out the procedure (e.g. the patient must be informed if students will be involved in providing the treatment)

4. Informed
   • sufficient information and time must be provided to allow the patient to make choices in accordance with his/her wishes, including
     • the nature of the treatment or investigation proposed and its expected effects
     • all significant risks and special or unusual risks
     • alternative treatments or investigations and their anticipated effects and significant risks
     • the consequences of declining treatment
     • risks that are common sense need not be disclosed (i.e. bruising after venipuncture)
     • answers to any questions the patient may have
   • the reasonable person test – the physician must provide all information that would be needed “by a reasonable person in the patient’s position” to be able to make a decision
   • disclose common adverse events (>1/200 chance of occurrence) and serious risks (e.g. death), even if remote
   • it is the physician’s responsibility to make reasonable attempts to ensure that the patient understands the information
   • physicians should not withold information about a legitimate therapeutic option based on personal conscience (e.g. not discussing the option of emergency contraception)

---

**Figure 2. Ontario consent flowchart**

Adapted by Hébert P from Sunnybrook Health Sciences Centre Consent Guidelines

CCB = consent and capacity board; SDM = substitute decision-maker
Obtaining Legal Consent
- Consent of the patient must be obtained before any medical intervention is provided; consent can be:
  - Verbal or written, although written is usually preferred
  - A signed consent form is only evidence of consent—it does not replace the process for obtaining valid consent
  - What matters is what the patient understands and appreciates, not what the signed consent form states
  - Implied (e.g., a patient holding their arm for an immunization) or expressed
- Consent is an ongoing process and can be withdrawn or changed after it is given, unless stopping a procedure would put the patient at risk of serious harm
- HCAA of Ontario (1996) covers consent to treatment, admission to a facility, and personal assistance services (e.g., home care)

Exceptions to Consent
1. Emergencies
   - Treatment can be provided without consent where a patient is experiencing severe suffering, or where a delay in treatment would lead to serious harm or death and consent cannot be obtained from the patient or their SDM
   - Emergency treatment should not violate a prior expressed wish of the patient (e.g., a signed Jehovah’s Witness card)
   - If patient is incapable, MD must document reasons for incapacity and why situation is emergent
   - Patients have a right to challenge a finding of incapacity as it removes their decision-making ability
   - If a SDM is not available, MD can treat without consent until the SDM is available or the situation is no longer emergent

2. Legislation
   - Mental Health legislation allows for:
     - The detention of patients without their consent
     - Psychiatric outpatients may be required to adhere to a care plan in accordance with Community Treatment Orders (see Psychiatry, PS51)
   - Public Health legislation allows medical officers of health to detain, examine, and treat patients without their consent (e.g., a patient with TB refusing to take medication) to prevent transmission of communicable diseases

3. Special situations
   - Public health emergencies (e.g., an epidemic or communicable disease treatment)
   - Warrant for information by police

Consequences of Failure to Obtain Valid Consent
- Treatment without consent is battery (an offense in tort), even if the treatment is life-saving (excluding situations outlined in exceptions section above)
- Treatment of a patient on the basis of poorly informed consent may constitute negligence, also an offense in tort
- The onus of proof that valid consent was not obtained rests with the plaintiff (usually the patient)

Overview of Capacity
- Capacity is the ability to:
  - Understand information relevant to a treatment decision
  - Appreciate the reasonably foreseeable consequences of a decision or lack of a decision
  - Capacity is specific for each decision (e.g., a person may be capable to consent to having a chest x-ray, but not for a bronchoscopy)
  - Capacity can change over time (e.g., temporary incapacity secondary to delirium)
  - Most Canadian jurisdictions distinguish capacity to make healthcare decisions from capacity to make financial decisions; a patient may be deemed capable of one, but not the other
  - A person is presumed capable unless there is good evidence to the contrary
  - Capable patients are entitled to make their own decisions
  - Capable patients can refuse treatment even if it leads to serious harm or death; however, decisions that put patients at risk of serious harm or death require careful scrutiny

Assessment of Capacity
- Capacity assessments must be conducted by a physician and, if appropriate, in consultation with other healthcare professionals (e.g., another physician, a mental health nurse)
- Clinical capacity assessment may include:
  - Specific capacity assessment (i.e., capacity specific to the decision at hand)
    1. Effective disclosure of information and evaluation of patient’s reason for decision
    2. Understanding of:
       - His/her condition
       - The nature of the proposed treatment
       - Alternatives to the treatment
       - The consequences of accepting and rejecting the treatment
       - The risks and benefits of the various options
3. for the appreciation needed for decision making capacity, a person must
– acknowledge the condition that affects him/herself
– be able to assess how the various options would affect him or her
– be able to reach a decision and adhere to it, and make a choice, not based primarily upon
delusional belief
  ▪ general impressions
  ▪ input from psychiatrists, neurologists, etc.
  ▪ employ “Aid to Capacity Evaluation”
  ▪ a decision of incapacity may warrant further assessment by psychiatrist(s), legal review boards (e.g. in
    Ontario, the Consent and Capacity Review Board), or the courts
  ▪ judicial review is open to patients if found incapable

Treatment of the Incapable Patient in a Non-Emergent Situation
• obtain informed consent from SDM
  • an incapable patient can only be detained against his/her will to receive treatment if he/she
    meets criteria for certification under the Mental Health Act (see Psychiatry, PSS1); in such a
    situation:
      ▪ document assessment in chart
      ▪ notify patient of assessment using appropriate Mental Health Form(s) (Form 42 in Ontario)
      ▪ notify Rights Advisor

Substitute Decision-Makers
• SDMs must follow the following principles when giving informed consent:
  ▪ act in accordance with wishes previously expressed by the patient while capable
  ▪ if wishes unknown, act in the patient's best interest, taking the following into account:
    1. values and beliefs held by the patient while capable
    2. whether well-being is likely to improve with vs. without treatment
    3. whether the expected benefit outweighs the risk of harm
    4. whether a less intrusive treatment would be as beneficial as the one proposed
  ▪ the final decision of the SDM may and should be challenged by the MD if the MD believes the SDM
    is not abiding by the above principles

Instructional Advance Directives
• allow patients to exert control over his/her care once they are no longer capable
  • the patient sets out his/her decisions about future health care, including who he/she would allow to
    make treatment decisions on his/her behalf and what types of interventions he/she would want
  • takes effect once the patient is incapable with respect to treatment decisions
  • in Ontario, a person can appoint a power of attorney for personal care to carry out his/her advance
directives
  • patients should be encouraged to review these documents with their family and physicians and to
    reevaluate them often to ensure they are current with their wishes

POWERS OF ATTORNEY
• all Guardians and Attorneys have fiduciary duties for the dependent person

Definitions
• Power of Attorney for Personal Care
  ▪ a legal document in which one person gives another the authority to make personal care decisions
    (health care, nutrition, shelter, clothing, hygiene, and safety) on their behalf if they become mentally
    incapable
• Guardian of the Person
  ▪ someone who is appointed by the Court to make decisions on behalf of an incapable person in some
    or all areas of personal care, in the absence of a POA for personal care
• Continuing Power of Attorney for Property
  ▪ a legal document in which a person gives another the legal authority to make decisions about their
    finances if they become unable to make those decisions
• Guardian of Property
  ▪ someone who is appointed by the Public Guardian and Trustee or the Courts to look after an
    incapable person’s property or finances
• Public Guardian and Trustee
  ▪ acts as a SDM of last resort on behalf of mentally incapable people who do not have another
    individual to act on their behalf
• Pediatric Aspects of Capacity Covered
  ▪ no age of consent in all provinces and territories except Québec; consent depends on patient’s
    decision-making capacity
  ▪ Quebec has a specific age of consent, but common law and case law deem underage legal minors
    capable, allowing them to make their own choices
  ▪ infants and children are assumed to lack mature decision-making capacity for consent but they
    should still be involved (i.e. be provided with information appropriate to their comprehension level)
Ethical and Legal Issues in Canadian Medicine

Negligence

Ethical Basis
• the doctor-patient relationship is formed on trust, which is recognized in the concept of fiduciary duty/responsibility of physician towards patient
• negligence or malpractice is a form of failure on the part of the physician in fulfilling his/her fiduciary duty in providing appropriate care and leading to harm of the patient (and/or abuse of patient's trust)

Legal Basis
• physicians are legally liable to their patients for causing harm (tort) through a failure to meet the standard of care applicable under the circumstances
• standard/duty of care is defined as one that would reasonably be expected under similar circumstances of an ordinary, prudent physician of the same training, experience, specialization, and standing
• liability arises from physician’s common law duty of care to his/her patients in the doctor/patient relationship (or, in Québec, from the Civil Code provisions regarding general civil liability)
• action(s) in negligence (or civil liability) against a physician must be launched by a patient within a specific prescribed period required by the respective province in which the actions occurred

Truth-Telling

Ethical Basis
• helps to promote and maintain a trusting physician-patient relationship
• patients have a right to be told important information that physicians have regarding their care
• enables patients to make informed decisions about health care and their lives

Legal Basis
• required for valid patient consent (see Consent and Capacity, ELOM6)
  • goal is to disclose information that a reasonable person in the patient’s position would need in order to make an informed decision ("standard of disclosure")
  • withholding information can be a breach of fiduciary duty and duty of care
  • obtaining consent on the basis of misleading information can be seen as negligent

Evidence about Truth-Telling
• most patients want to know what is wrong with them
• although many patients want to protect family members from bad news, they themselves would want to be informed in the same situation
• truth-telling improves adherence and health outcomes
• informed patients are more satisfied with their care
• negative consequences of truth-telling can include decreased emotional well-being, anxiety, worry, social stigmatization, and loss of insurability

Challenges in Truth-Telling

Medical Error
• medical error may be defined as ‘preventable adverse events (AEs)’ caused by the patient’s medical care and not the patient’s underlying illness; some errors may be identified before they harm the patient, so not all error is truly ‘adverse’
• many jurisdictions and professional associations expect and require physicians to disclose medical error; that is, any event that harms or threatens to harm patients must be disclosed to the patient or the patient’s family and reported to the appropriate health authorities
• physicians should disclose to patients the occurrence of AEs or errors caused by medical management, but should not suggest that they resulted from negligence because:
  • negligence is a legal determination
  • error is not equal to negligence (see Negligence)
• disclosure allows the injured patient to seek appropriate corrective treatment promptly
• physicians should avoid simple attributions as to cause and sole responsibility of others or oneself
• physicians should offer apologies or empathic expressions of regret (e.g. “I wish things had turned out differently”) as these can increase trust and are not admissions of guilt or liability
• Apology Acts across Canada protect apologies, both as expressions of regret and admissions of responsibility, from being used as evidence of liability and negligence

Errors of care are compatible with non-negligent care if they are ones that a reasonably cautious and skilled MD could make (i.e. mistakes can be made due to ‘honest error’)

Four basic elements for action against a physician to succeed in negligence:
1. A duty of care owed to the patient (i.e. doctor/patient relationship must be established)
2. A breach of the standard of care
3. Some harm or injury to the patient
4. The harm or injury must have been caused by the breach of the duty of care

CPSO Policy on Truth-Telling
Physicians should provide patients with whatever information will, from the patient’s perspective, have a bearing on medical decision-making and communicate that information in a way that is comprehensible to the patient

Adverse Event
An unintended injury or complication from health care management resulting in disability, death, or prolonged hospital stay

Open Disclosure of AEs: Transparency and Safety in Health Care
Health care providers have a fiduciary duty to disclose AEs to their patients. Professional societies codify medical providers’ ethical requirement to disclose AEs to patients in accordance with the four principles of biomedical ethics. Transparency and honesty in relationships with patients create opportunities for learning that lead to systems improvements in health care organizations. Disclosure invariably becomes a component of broad systems improvement and is closely linked to improving patient safety.

Examples of Warning of Impending Bad News
“I have something difficult to tell you…”
“This may come as a shock to you, but the tests indicate…”
“There is no easy way for me to tell you this, so I will tell you straight away that you have a serious problem…”
Breaking Bad News
- "bad news" may be any information that reveals conditions or illnesses threatening the patient's sense of well-being
- caution patients in advance of serious tests about possible bad findings
- give warnings of impending bad news and make sure you provide time for the patient
- poorly done disclosure may be as harmful as non-disclosure
- truth-telling may be a process requiring multiple visits
- adequate support should be provided along with the disclosure of difficult news
- SPIKES protocol was developed to facilitate “breaking bad news”

Arguments Against Truth-Telling
- may go against certain cultural norms and expectations
- may lead to patient harm and increased anxiety
- 10–20% of patients prefer not to be informed
- medical uncertainty may result in the disclosure of uncertain or inaccurate information

Exceptions to Truth-Telling
- a patient may waive his/her right to know the truth about their situation (i.e. decline information that would normally be disclosed) when
  - the patient clearly declines to be informed
  - a strong cultural component exists that should be respected and acknowledged
  - the patient may wish others to be informed and make the medical decisions for him/her
  - the more weighty the consequences for the patient from non-disclosure, the more carefully one must consider the right to ignorance
  - ‘emergencies’: an urgent need to treat may legitimately delay full disclosure; the presumption is that most people would want such treatment and the appropriate SDM cannot be found
  - ‘therapeutic privilege’
  - withholding of information by the clinician in the belief that disclosure of the information would itself lead to severe anxiety, psychological distress or physical harm to the patient
  - clinicians should avoid invoking therapeutic privilege due to its paternalistic overtones and is a defence of non-disclosure that is rarely accepted anymore
  - it is often not the truth that is unpalatable; it is how it is conveyed that can harm the patient

Ethical Issues in Health Care

Managing Controversial and Ethical Issues in Practice
- discuss in a non-judgmental manner
- ensure patients have full access to relevant and necessary information
- identify if certain options lie outside of your moral boundaries and refer to another physician if appropriate
- consult with appropriate ethics committees or boards
- protect freedom of moral choice for students or trainees

Reproductive Technologies

Overview of the Maternal-Fetal Relationship
- in general, maternal and fetal interests align
- in some situations, a conflict between maternal autonomy and the best interests of the fetus may arise

Ethical Issues and Arguments
- principle of reproductive freedom: women have the right to make their own reproductive choices
- coercion of a woman to accept efforts to promote fetal well-being is an unacceptable infringement of her personal autonomy

Legal Issues and Arguments
- the law upholds a woman’s right to life, liberty, and security of person, and does not recognize fetal rights; key aspects of the mother's rights include
  - if a woman is competent and refuses medical advice, her decision must be respected even if the fetus will suffer
  - the fetus does not have legal rights until it is born alive and with complete delivery from the body of the woman

Royal Commission on New Reproductive Technologies (1993) recommendations:
1. medical treatment must never be imposed upon a competent pregnant woman against her wishes
2. no law should be used to confine a pregnant woman in the interest of her fetus
3. the conduct of a pregnant woman in relation to her fetus should not be criminalized
4. child welfare should never be used to control a woman's behaviour during pregnancy
5. civil liability should never be imposed upon a woman for harm done to her fetus during pregnancy
Examples involving the use of established guidelines
• a woman is permitted to refuse HIV testing during pregnancy, even if vertical transmission to fetus results
• a woman is permitted to refuse Caesarean section in labour that is not progressing, despite evidence of fetal distress

Advanced Reproductive Therapies
• includes non-coital insemination, hormonal ovarian stimulation, and IVF
• topics with ethical concerns
  ■ donor anonymity vs. child-centred reproduction (i.e. knowledge about genetic medical history)
  ■ preimplantation genetic testing for diagnosis before pregnancy
  ■ use of new techniques without patients appreciating their experimental nature
  ■ embryo status – the Supreme Court of Canada maintains that fetuses are “unique” but not persons under law; this view would likely apply to embryos as well
  ■ access to ART
  ■ private vs. public funding of ART
  ■ social factors limiting access to ART (e.g. same-sex couples)
  ■ the ‘commercialization’ of reproduction

Fetal Tissue
• pluripotent stem cells can currently be derived from human embryonic and fetal tissue
• potential uses of stem cells in research
  ■ studying human development and factors that direct cell specialization
  ■ evaluating drugs for efficacy and safety in human models
  ■ cell therapy: using stem cells grown in vitro to repair or replace degenerated/destroyed/malignant tissues (e.g. Parkinson’s disease)
  ■ genetic treatment aimed at altering somatic cells (e.g. myocardial or immunological cells) is acceptable and ongoing

Induced Abortion
• CMA definition of induced abortion: the active termination of a pregnancy before fetal viability (fetus >500 g or >20 wk GA)
• CMA policy on induced abortion
  1. induced abortion should not be used as an alternative to contraception
  2. counselling on contraception must be readily available
  3. full and immediate counselling services must be provided in the event of unwanted pregnancy
  4. there should be no delay in the provision of abortion services
  5. no patient should be compelled to have a pregnancy terminated
  6. physicians should not be compelled to participate in abortion – if morally opposed, the physician should inform the patient so she may consult another physician
  7. no discrimination should be directed towards either physicians who do not perform or assist at induced abortions or physicians who do
  8. induced abortion should be uniformly available to all women in Canada and health care insurance should cover all the costs (note: the upper limit of GA for which coverage is provided varies between provinces)
  9. elective termination of pregnancy after fetal viability may be indicated under exceptional circumstances

Ethical and Legal Concerns and Arguments
• no law currently regulates abortion in Canada
• it is a woman’s medical decision to be made in consultation with whom she wishes; there is no mandatory role for spouse/family
• 2nd and even 3rd trimester abortions are not illegal in Canada, but are usually only carried out when there are serious risks to the woman’s health, or if the fetus has died in utero or has major malformations (e.g. anencephaly)

Prenatal/Antenatal Genetic Testing
• uses
  1. to confirm a clinical diagnosis
  2. to detect genetic predisposition to a disease
  3. allows preventative steps to be taken and helps patient prepare for the future
  4. gives parents the option to terminate a pregnancy or begin early treatment
• ethical dilemmas arise because of the sensitive nature of genetic information; important considerations of genetic testing include:
  ■ the individual and familial implications
  ■ its pertinence to future disease
  ■ its ability to identify disorders for which there are no effective treatments or preventive steps
  ■ its ability to identify the sex of the fetus
• ethical issues and arguments regarding the use of prenatal/antenatal genetic testing include:
  ■ obtaining informed consent is difficult due to the complexity of genetic information
  ■ doctor’s duty to maintain confidentiality vs. duty to warn family members
  ■ risk of social discrimination (e.g. insurance) and psychological harm
Legal Aspects
- no current specific legislation exists
- testing requires informed consent
- no standard of care exists for clinical genetics, but physicians are legally obligated to inform patients that prenatal testing exists and is available
- a physician can breach confidentiality terms in order to warn family members about a condition if harm can possibly be prevented via treatment or prevention (e.g. familial adenomatous polyposis, Gastroenterology, G34)

Genetic Testing: Ethically Appropriate Actions
- thorough discussion and realistic planning with patient before testing is done
- genetic counselling for delivery of complex information

End-of-Life Care

Overview of Palliative and End-of-Life Care
- focus of care is comfort and respect for person nearing death and maximizing quality of life for patient, family, and loved ones
- appropriate for any patient at any stage of a serious or life-limiting illness
- may occur in a hospital, hospice, in the community, or at home
- often involves an interdisciplinary team of caregivers
- addresses the medical, psychosocial, and spiritual dimensions of care

Euthanasia and Physician-Assisted Suicide
- **euthanasia**: a deliberate act undertaken by one person with the intention of ending the life of another person to relieve that person's suffering, where the act is the cause of death
- **physician-assisted suicide**: the act of intentionally killing oneself with the assistance of a physician who deliberately provides the knowledge and/or the means

Common Ethical Arguments/Opinions
- patient has the right to make autonomous choices about the time and manner of their own death
- belief that there is no ethical difference between the acts of euthanasia/assisted suicide and forgoing life-sustaining treatments
- belief that these acts benefit terminally ill patients by relieving suffering
- patient autonomy has limits
- death should be the consequence of the morally justified withdrawal of life-sustaining treatments only in cases where there is a fatal underlying condition, and it is the condition (not the withdrawal of treatment) that causes death

Legal Aspect
- in Canada, euthanasia is no longer a punishable offence under the Criminal Code of Canada
- in the Carter v. Canada decision of February 2015, physician-assisted suicide ruled to be not criminal, with the decision taking effect in 2016, now postponed to June 2016
- until June 2016, applicants for assistance in dying (MAID - 'Medical Aid in Dying') must obtain court sanction (as an exemption to the Criminal Code)

Criteria for MAID
- grievously and irreversibly ill / injured
- suffering intolerable to the patient
- not treatable by means acceptable to the patient
- adult, competent patient, clear and freely given consent

Acceptable Use of Palliative and End-of-Life Care
- the use of palliative sedation with opioids in end-of-life care, knowing that death may occur as an unintended consequence (principle of double effect) is distinguished from euthanasia and assisted suicide where death is the primary intent
- the appropriate withdrawal of life-support is distinguished from euthanasia and assisted suicide as it is seen as allowing the underlying disease to take its 'natural course' but this distinction may be more theoretical than real
- consent for withdrawal of life-support must be sought from SDMs, as ruled in Cuthbertson v. Rasouli in 2013, as palliative care would be instituted and consent for that would require SDM consent
- refusals of care by the patient that may lead to death as well as requests for a hastened death, ought to be carefully explored by the physician to rule out any 'reversible factors' (e.g. poor palliation, depression, poverty, ill-education, isolation) that may be hindering authentic choice
Physician Responsibilities Regarding Death
- physicians are required by law to complete a medical certificate of death unless the coroner needs notification; failure to report death is a criminal offence
- Coroners Act, 1990 (specific to Ontario, similar in other provinces) requires physicians to notify a coroner or police officer if death occurs
  - due to violence, negligence, misconduct, misadventure, or malpractice
  - during pregnancy or is attributable to pregnancy
  - suddenly and unexpectedly
  - from disease which was not treated by a legally qualified medical practitioner
  - from any cause other than disease
  - under suspicious circumstances
- coroner investigates these deaths, as well as deaths that occur in psychiatric institutions, jails, foster homes, nursing homes, hospitals to which a person was transferred from a facility, institution or home, etc.
- in consultation with forensic pathologists and other specialists, the coroner establishes:
  - the identity of the deceased
  - where and when the death occurred
  - the medical cause of death
  - the means of death (i.e. natural, accidental, suicide, homicide, or undetermined)
- coroners do not make decisions regarding criminality or legal responsibility
- unclear as yet whether physicians who object to MAID on grounds of conscience will have to refer to willing physicians and also unclear what patients seeking MAID in religious affiliated hospitals will do

Physician Competence and Professional Conduct

CanMEDS Competencies (Ethical/Policy Statement)
- a framework of professional competencies established by the MCC as objectives for the MCC Qualifying Exam
- further information on MCC objectives can be found at www.mcc.ca

Legal Considerations
- physicians’ conduct and competence are legally regulated to protect patients and society via mandatory membership to provincial governing bodies (e.g. the CPSO)
- physicians are legally required to maintain a license with the appropriate authority, and are thus legally bound to outlined policies on matters of conduct within his/her medical practice
- the ultimate constraint on MD behaviour as regards to unprofessionalism is ‘conduct unbecoming physicians are legally required to maintain a license with the appropriate authority, and are thus legally bound to outlined policies on matters of conduct within his/her medical practice

Common Policies on Physician Conduct
- physicians must ensure that patients have access to continuous on-call coverage and are never abandoned
- sexual conduct with patients, even when consented to by the patient, is a serious matter that can lead to accusations of battery by the patient and provincial governing body. Important notes on this topic include:
  - inappropriate sexual conduct includes intercourse, undue touching, references to sexual matters, sexual jokes, and physician presence when capable patients undress or dress
  - in specified situations, physicians may have a personal relationship with a patient provided a year has passed since the last therapeutic contact
  - physicians are permanently prohibited from personal relationships with patients whom they saw for psychotherapy
  - in Ontario, physicians must report any colleagues of whom they have information regarding sexual impropriety (as per CPSO Code of Ethics)
- physicians must maintain adequate records for each patient, which include:
  - demonstration that care has been continuous and comprehensive
  - minimal standards for record-keeping, including readability, diagnosis, differential diagnosis, appropriate tests and referrals, and a coherent patient record, including drugs, a Cumulative Patient profile, all aspects of charting that are required for safe patient care (full standards available at www.cpsso.on.ca). Another physician should be able to take over the safe care of the patient based on the record
  - records stored for 10 years in most jurisdictions
  - although the medical record is the property of the physician or an institution, the patient or the patient's delegate must be allowed full access to information in the medical record in a reasonable period of time, and can charge a reasonable fee, upon (usually written) request
  - in the hospital, physicians must ensure their own competence, respect hospital by-laws and regulations, practice only within the limits of granted privileges, cooperate with other hospital personnel, and maintain adequate hospital records

Notify Coroner if Death Occurs due to:
- Violence, negligence, misconduct
- Pregnancy
- Sudden or unexpected causes
- Disease not treated
- Cause other than disease
- Suspicious circumstances

CanMEDS Competencies
- Communicator
- Collaborator
- Health Advocate
- Leader
- Professional
- Scholar
- Medical Expert

CPSO Policy: Treating Self and Family Members
Physicians will not diagnose or treat themselves or family members except for minor conditions or in emergencies and then only if no other physician is readily available

CPSO Policy: Ending the Physician-Patient Relationship
Discontinuing services that are needed is an act of professional misconduct unless done by patient request, alternative services are arranged, or adequate notice has been given

CMA Code of Ethics
Report any unprofessional conduct by colleagues to the appropriate authority
Research Ethics

- involves the systematic analysis of ethical dilemmas arising during research involving human subjects to ensure that:
  - study participants are protected
  - clinical research is conducted to serve the interests of the participants and/or society as a whole
  - major ethical dilemmas arise when a participant’s obligation to the patient comes into conflict with other obligations and incentives
- any exceptions to disclosure for therapeutic consent do not apply in an experimental situation
- important ethical principles to consider when conducting research on human subjects were laid out in the Declaration of Helsinki, the Belmont Report, and the Tri-Council Policy Statement: Ethical Conduct on Research Involving Human Subjects

Table 5. Ethical Principles for Research Involving Human Subjects

<table>
<thead>
<tr>
<th>Principle</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right to Privacy</td>
<td>Patient’s voluntary and informed choice is usually required, except in special circumstances (i.e. chart reviews without patient contact) or unexpected situations for which there is no agreed or helpful standard of care and the proposed intervention is not likely to cause more harm than such patients already face</td>
</tr>
<tr>
<td>Right to a Safe Research Environment</td>
<td>Access to the treatment that is considered standard (i.e. placebo-controlled trials are generally acceptable where patients all receive the standard of care, or, if not, are informed about the placebo arm and what that entails)</td>
</tr>
<tr>
<td>Right to知情</td>
<td>Must employ a scientifically valid design to answer the research question (ensured via peer review, expert opinion)</td>
</tr>
<tr>
<td>Right to a Procedure that Works</td>
<td>Must demonstrate sufficient value to justify any risk posed to participants</td>
</tr>
<tr>
<td>Right to an Accurate Procedure</td>
<td>Must be conducted honestly (i.e. carried out as stated in the approved protocol)</td>
</tr>
<tr>
<td>Right to be Involved in Research</td>
<td>Findings must be reported promptly and accurately without exaggeration, to allow practicing clinicians to draw reasonable conclusions</td>
</tr>
<tr>
<td>Right to Be Informed about Potential Risks</td>
<td>Patients must not be enticed into risky research by the lure of money and investigators must not trade the interests of patients for disproportionate recompense by a sponsor; both participants and investigators are due fair recompense for their time and efforts</td>
</tr>
<tr>
<td>Right to Be Informed about the Ongoing Trial</td>
<td>Any significant interventional trial ought to have a data safety monitoring board that is independent of the sponsor and can ensure safety of the ongoing trial</td>
</tr>
</tbody>
</table>

Physician-Industry Relations

- health care delivery in Canada involves collaboration between physicians and the pharmaceutical and health supply industries in the areas of research, education, and clinical evaluation packages (i.e. product samples)
- physicians have a responsibility to ensure that their participation in such collaborative efforts is in keeping with their duties to their patients and society
- gifts or free products from the pharmaceutical industry are usually inappropriate
- sponsorship for travel and fees for conference attendance may be accepted only where the physician is a conference presenter and not just in attendance
- physicians receiving such sponsorship must disclose this at presentations and/or in written articles

Resource Allocation

- definition: the distribution of goods and services to programs and people
- physicians have the duty to inform patients about therapeutic options even if they are not available
- physicians must make health care resources available to patients in a manner which is fair and equitable, without bias or discrimination
  - need and benefit are morally relevant criteria for resource allocation
  - gender, sexual orientation, religion, level of education, or age alone are morally irrelevant criteria
  - ethical dilemmas that arise when deciding how best to allocate resources
  - fair chances versus best outcome: favouring best outcome vs. giving all patients fair access to limited resources (e.g. transplant list prioritization)
  - priorities problem: how much priority should the sickest patients receive?
  - aggregation problem: modest benefits to many vs. significant benefits to few
  - democracy problem: when to rely on a fair democratic process to arrive at a decision

Guidelines for Appropriately Allocating Resources

- the physician’s primary obligation is to:
  - protect and promote the welfare and best interests of his/her patients
  - choose interventions known to be beneficial on the basis of evidence of effectiveness
  - seek the tests or treatments that will accomplish the diagnostic or therapeutic goal for the least cost
  - advocate for one’s patients, but avoid manipulating the system to gain unfair advantage for them
  - resolve conflicting claims for scarce resources jointly, on the basis of morally relevant criteria such as need and benefit, using fair and publicly defendable procedures
  - inform patients of the impact of cost constraints on care, but in a sensitive way
  - seek resolution of unacceptable shortages at the level of hospital management or government
Conscientious Objection

Patients Refusing Treatment
• in accordance with the principle of autonomy, it is generally acceptable for competent patients to refuse medical interventions for themselves or others, although exceptions may occur
• if parents or SDMs make decisions that are clearly not in the “best interests” of an incapable child, physicians may have ethical grounds for administering treatment, depending on the acuity of the clinical situation
  • in high-acuity scenarios (e.g., refusing blood transfusion based on religious grounds for a child in hemorrhagic shock), physicians have a stronger obligation to act in the child’s best interests
  • in lower acuity scenarios (e.g., refusing childhood immunization in a developed nation) there is a stronger obligation to respect the autonomy of the decision-makers
• physicians healing (in conjunction or in the place of standard biomedical therapy) is legally considered a constitutionally protected right, which can be made by a SDM, as ruled in Hamilton Health Sciences v. DH in 2014

Physicians Refusing to Provide Treatment
• physicians may refuse to provide treatment or discontinue relationships with patients, but must ensure these patients can access services elsewhere (e.g., a pediatrician who refuses to treat an unvaccinated child should refer the family to another practice)

References

Bioethics
Bioethics for Clinicians Series. CMAJ.

Governing Organizations

Health Care Delivery

Important Acts/Charters
Health and Protect Health Protection and Promotion Act - R.S.O., 1990, c. 7; D. Re. e. 559/91, amended to O. Reg. 96/03.

Law

Research Ethics
Acronyms ........................................ 2
Overview of Anesthesia ....................... 2
Types of Anesthesia

Pre-Operative Assessment .................... 2
History and Physical
Pre-Operative Investigations
American Society of Anesthesiology Classification

Pre-Operative Optimization .................. 4
Medications
Hypertension
Coronary Artery Disease
Respiratory Diseases
Aspiration
Fasting Guidelines
Hematological Disorders
Endocrine Disorders
Obesity and Obstructive Sleep Apnea

Monitoring ....................................... 6

Airway Management ............................ 7
Airway Anatomy
Methods of Supporting Airways
Tracheal Intubation
Difficult Airway
Oxygen Therapy
Ventilation

Intraoperative Management .................. 12
Temperature
Heart Rate
Blood Pressure
Fluid Balance and Resuscitation
IV Fluids
Blood Products

Induction ......................................... 15
Routine Induction vs. Rapid Sequence Induction
Induction Agents
Muscle Relaxesants and Reversing Agents
Analgesia

Maintenance ..................................... 19

Extubation ....................................... 20
Complications of Extubation

Regional Anesthesia ......................... 20
Epidural and Spinal Anesthesia
Peripheral Nerve Blocks

Local Anesthesia ............................... 22
Local Anesthetic Agents
Systemic Toxicity
Local Infiltration and Hematoma Blocks
Topical Anesthetics

Post-Operative Care ........................... 23
Common Post-Operative Anesthetic Complications

Pain Management .............................. 24
Acute Pain
Neuropathic Pain
Chronic Pain

Obstetrical Anesthesia ....................... 26

Pediatric Anesthesia ........................... 27

Uncommon Complications .................... 28
Malignant Hyperthermia
Abnormal Pseudocholinesterase

Appendices ....................................... 29
Difficult Tracheal Intubation in Unconscious Patient
Difficult Tracheal Intubation
Advanced Cardiac Life Support Guidelines

References ........................................ 33
Overview of Anesthesia

- anesthesia: lack of sensation/perception

**approach to anesthesia**

1. pre-operative assessment
2. patient optimization
3. plan anesthetic
4. post-operative care

**Types of Anesthesia**

- **general**
  - general anesthesia (GA)
  - total IV anesthesia (TIVA)

- **regional**
  - spinal, epidural
  - peripheral nerve block
  - IV regional

**Pre-Operative Assessment**

**Purpose**

- identify concerns for medical and surgical management of patient
- allow for questions to help allay any fears or concerns patient and/or family may have
- arrange further investigations, consultations and treatments for patients not yet optimized
- plan and consent for anesthetic techniques

**History and Physical**

**History**

- age, gender
- indication for surgery
- surgical/anesthetic Hx: previous anesthetics, any complications, previous intubations, medications, drug allergies, post-operative N/V
- FHx: abnormal anesthetic reactions, malignant hyperthermia, pseudocholinesterase deficiency (*see Uncommon Complications, A28*).
**PMHx**
- CNS: seizures, TIA/strokes, raised ICP, spinal disease, aneurysm
- CVS: angina/CAD, MI, CHF, HTN, valvular disease, dysrhythmias, peripheral vascular disease (PVD), conditions requiring endocarditis prophylaxis, exercise tolerance, CCS/NYHA class (Cardiology and Cardiac Surgery, C35 sidebar for NYHA Classification)
- respiratory: smoking, asthma, COPD, recent upper respiratory tract infection, sleep apnea
- GI: GERD, liver disease, NPO status
- renal: insufficiency, dialysis, chronic kidney disease
- hematologic: anemia, coagulopathies, blood dyscrasias
- MSK: conditions associated with difficult intubations – arthritides (e.g. rheumatoid arthritis), cervical tumours, cervical infections/abscesses, trauma to cervical spine, previous cervical spine surgery, Trisomy 21, scleroderma, conditions affecting neuromuscular junction (e.g. myasthenia gravis)
- endocrine: DM, thyroid disorders, adrenal disorders
- other: morbid obesity, pregnancy, ethanol/other drug use

**Physical Exam**
- weight, height, BP, pulse, respiratory rate, oxygen saturation
- focused physical exam of the CNS, CVS, and respiratory systems
- general assessment of nutrition, hydration, and mental status
- airway assessment is done to determine intubation difficulty (no single test is specific or sensitive) and ventilation difficulty
  - cervical spine stability and neck movement – upper cervical spine extension, lower cervical spine flexion (“sniffing position”)
  - Mallampati classification
    - “3-2-1 rule”
      - thyromental distance (distance of lower mandible in midline from the mentum to the thyroid notch); <3 finger breadths (<6 cm) is associated with difficult intubation
      - mouth opening (<2 finger breadths associated with difficult intubation)
      - anterior jaw subluxation (<1 finger breadth is associated with difficult intubation)
  - tongue size
  - dentition, dental appliances/prosthetic caps, existing chipped/loose teeth – pose aspiration risk if dislodged and must inform patients of rare possibility of damage
  - nasal passage patency (if planning nasotracheal intubation)
  - assess potential for difficult ventilation
- examination of anatomical sites relevant to lines and blocks
  - bony landmarks and suitability of anatomy for regional anesthesia (if relevant)
  - sites for IV, central venous pressure (CVP), and pulmonary artery (PA) catheters

---

**Figure 1. Mallampati classification of oral opening**
Pre-Operative Investigations

- routine pre-operative investigations are only necessary if there are comorbidities or certain indications

Table 1. Suggested Indications for Specific Investigations in the Pre-Operative Period

<table>
<thead>
<tr>
<th>Test</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBC</td>
<td>Major surgery requiring group and screen or cross and match; chronic cardiovascular, pulmonary, renal, or hepatic disease; malignancy; known or suspected anemia; bleeding diathesis or myelosuppression; patient &gt; 1 yr of age</td>
</tr>
<tr>
<td>Sickle Cell Screen</td>
<td>Patients from geographic areas with high prevalence of sickle cell disease and/or genetically predisposed patients (hemoglobin electrophoresis if screen is positive)</td>
</tr>
<tr>
<td>INR, aPTT</td>
<td>Anticoagulant therapy, bleeding diathesis, liver disease</td>
</tr>
<tr>
<td>Electrolytes and Creatinine</td>
<td>Hypertension, renal disease, DM, pituitary or adrenal disease; vascular disease, digoxin, diuretic, or other drug therapies affecting electrolytes</td>
</tr>
<tr>
<td>Fasting Glucose Level</td>
<td>DM (repeat on day of surgery)</td>
</tr>
<tr>
<td>Pregnancy (β-hCG)</td>
<td>Women of reproductive age</td>
</tr>
<tr>
<td>ECG</td>
<td>Heart disease, DM, other risk factors for cardiac disease; subarachnoid or intracranial hemorrhage, cerebrovascular accident, head trauma</td>
</tr>
<tr>
<td>Chest Radiograph</td>
<td>Patients with new or worsening respiratory symptoms/signs</td>
</tr>
</tbody>
</table>

American Society of Anesthesiology Classification

- common classification of physical status at the time of surgery
- a gross predictor of overall outcome, NOT used as stratification for anesthetic risk (mortality rates)
- ASA 1: a healthy, fit patient
- ASA 2: a patient with mild systemic disease
  - e.g. controlled Type 2 DM, controlled essential HTN, obesity, smoker
- ASA 3: a patient with severe systemic disease that limits activity
  - e.g. stable CAD, COPD, DM, obesity
- ASA 4: a patient with incapacitating disease that is a constant threat to life
  - e.g. unstable CAD, renal failure, acute respiratory failure
- ASA 5: a moribund patient not expected to survive 24 h without surgery
  - e.g. ruptured abdominal aortic aneurysm (AAA), head trauma with increased ICP
- ASA 6: declared brain dead, a patient whose organs are being removed for donation purposes
- for emergency operations, add the letter E after classification (e.g. ASA 3E)

Pre-Operative Optimization

- in general, prior to elective surgery
  - any fluid and/or electrolyte imbalance should be corrected
  - extent of existing comorbidities should be understood and these conditions should be optimized prior to surgery
  - medications may need adjustment

Medications

- pay particular attention to cardiac and respiratory medications, opioids and drugs with many side effects and interactions
- pre-operative medications to consider
  - prophylaxis
    - risk of GE reflux: sodium citrate and/or ranitidine and/or metoclopramide 30 min-1 h prior to surgery
    - risk of infective endocarditis, GI/GU interventions: antibiotics
    - risk of adrenal suppression: steroid coverage
    - anxiety: consider benzodiazepines
    - COPD, asthma: bronchodilators
    - CAD risk factors: nitroglycerin and β-blockers
- pre-operative medications to stop
  - oral antihyperglycemics: stop on morning of surgery
  - ACE inhibitors and angiotension receptor blockers: may stop on morning of surgery (controversial)
- warfarin (consider bridging with heparin), anti-platelet agents (e.g. clopidogrel)
  - discuss perioperative use of ASA, NSAIDs with surgeon (± patient’s cardiologist/internist)
  - in patients undergoing non-cardiac surgery, starting or continuing low-dose aspirin in the perioperative period does not appear to protect against post-operative MI or death, but increases the risk of major bleeding
  - note: this does not apply to patients with bare metal stents or drug-eluting coronary stents
- **pre-operative medications to adjust**
  - insulin (consider insulin/dextrose infusion or holding dose), prednisone, bronchodilators

### Hypertension

- BP <180/110 is not an independent risk factor for perioperative cardiovascular complications
- target SBP <180 mmHg, DBP <110 mmHg
- assess for end-organ damage and treat accordingly

### Coronary Artery Disease

- ACC/AHA Guidelines (2014) recommend that at least 60 days should elapse after a MI before a non-cardiac surgery in the absence of a coronary intervention
  - this period carries an increased risk of re-infarction/death
  - if operative procedure is essential and cannot be delayed then invasive intra- and post-operative ICU monitoring is required to reduce the above risk
- mortality with perioperative MI is 20-50%
- perioperative β-blockers
  - may decrease cardiac events and mortality (controversial, as recent data suggests stroke risk)
  - continue β-blocker if patient is routinely taking it prior to surgery
  - consider initiation of β-blocker in
    - patients with CAD or indication for β-blocker
    - intermediate or high risk surgery, especially vascular surgery

### Respiratory Diseases

- smoking
  - adverse effects: altered mucus secretion and clearance, decreased small airway calibre, and altered immune response
  - abstain at least 8 wk pre-operatively if possible
  - if unable, abstaining even 24 h pre-operatively has been shown to increase oxygen availability to tissues
- asthma
  - pre-operative management depends on degree of baseline asthma control
  - increased risk of bronchospasm from intubation
    - administration of short course (up to 1 wk) pre-operative corticosteroids and inhaled β2-agonists decreases the risk of bronchospasm and does not increase the risk of infection or delay wound healing
  - avoid non-selective β-blockers due to risk of bronchospasm
  - cardioselective β-blockers (metoprolol, atenolol) do not increase risk of bronchospasm in the short-term
  - delay elective surgery for poorly controlled asthma (increased cough or sputum production, active wheezing)
  - delay elective surgery by a minimum of 6 wk if patient develops URTI
- COPD
  - anesthesia, surgery (especially abdominal surgery, in particular upper abdominal surgery) and pain predispose the patient to atelectasis, bronchospasm, pneumonia, prolonged need for mechanical ventilation, and respiratory failure
  - pre-operative ABG is needed for all COPD stage II and III patients to assess baseline respiratory acidosis and plan post-operative management of hypercapnea
  - cancel/delay elective surgery for acute exacerbation

### Aspiration

- increased risk of aspiration with
  - decreased LOC
  - trauma
  - meals within 8 h
  - suspected sphincter incompetence (GERD, hiatus hernia, nasogastric tube)
  - increased abdominal pressure (pregnancy, obesity, bowel obstruction, acute abdomen)
  - laryngeal mask vs. endotracheal tube (ETT)
• management
  • reduce gastric volume and acidity
  • delay inhibiting airway reflexes with muscular relaxants
  • employ rapid sequence induction (see Rapid Sequence Induction, A15)

Fasting Guidelines

Fasting Guidelines Prior to Surgery (Canadian Anesthesiologists’ Society)
• 8 h after a meal that includes meat, fried or fatty foods
• 6 h after a light meal (such as toast or crackers) or after ingestion of infant formula or non-human milk
• 4 h after ingestion of breast milk
• 2 h after clear fluids (water, black coffee, tea, carbonated beverages, juice without pulp)

Hematological Disorders

• history of congenital or acquired conditions (sickle cell anemia, factor VIII deficiency, ITP, liver disease)
• evaluate hemoglobin, hematocrit and coagulation profiles when indicated (Table 1)
• anemia
  • pre-operative treatments to increase hemoglobin (erythropoietin or pre-admission blood collection in certain populations)
• coagulopathies
  • discontinue or modify anticoagulation therapies (warfarin, clopidogrel, ASA) in advance of elective surgeries
  • administration of reversal agents if necessary: vitamin K, FFP, prothrombin complex concentrate, recombinant activated factor VII

Endocrine Disorders

• diabetes mellitus
  • clarify type 1 vs. type 2
  • clarify treatment – oral anti-hyperglycemics and/or insulin
  • assess glucose control with history and HbA1c; well controlled diabetics have more stable glucose levels intraoperatively
  • end organ damage: be aware of damage to cardiovascular, renal, and nervous systems, including autonomic neuropathy
  • formulate intraoperative glucose management plan based on type (1 vs. 2), glucose control, and extent of end organ damage
• hyperthyroidism
  • can experience sudden release of thyroid hormone (thyroid storm) if not treated or well-controlled preoperatively
  • treatment: β-blockers and pre-operative prophylaxis
• adrenocortical insufficiency (Addison’s, exogenous steroid use)
  • consider intraoperative steroid supplementation

Obesity and Obstructive Sleep Apnea

• assess for co-morbid conditions in obese patient (independent risk factor for CVD, DM, OSA, cholelithiasis, HTN)
• previously undiagnosed conditions may require additional testing to characterize severity
• both obesity and OSA increase risk of difficult ventilation, intubation and post-operative respiratory complications
  • risk may be magnified with both diseases present

Monitoring

Canadian Guidelines to the Practice of Anesthesia and Patient Monitoring
• an anesthetist present: “the only indispensable monitor”
• a completed pre-anesthetic checklist: including ASA class, NPO policy, Hx and investigations
• a perioperative anesthetic record: HR and BP every 5 min, O2 saturation, End Tidal CO2, dose and route of drugs and fluids
• continuous monitoring: see Routine Monitors for All Cases

Routine Monitors for All Cases
• pulse oximeter, BP monitor, electrocardiography and capnography are required for general anesthesia and sedation (Ramsay Sedation Scale 4–6), agent-specific anesthetic gas monitor when inhalational anesthetic agents are used
• the following must also be available: temperature probe, peripheral nerve stimulator, stethoscope, appropriate lighting, spirometer
Elements to Monitor
- anesthetic depth
  - inadequate: blink reflex present when eyelashes lightly touched, HTN, tachycardia, tearing or sweating
  - excessive: hypotension, bradycardia
- oxygenation: pulse oximetry, fraction of inspired O₂ (FiO₂)
- ventilation: verify correct position of ETT, chest excursions, breath sounds, ETCO₂ analysis, end tidal inhaled anesthesia analysis
- circulation: pulse, rhythm, BP, telemetry, oximetry, CVP, pulmonary capillary wedge pressure
- temperature
- hourly urine output

![Figure 2. Typical anesthesia monitor](image)

Airway Management

Airway Anatomy
- resistance to airflow through nasal passages accounts for approximately 2/3 of total airway resistance
- pharyngeal airway extends from posterior aspect of the nose to cricoid cartilage
- glottic opening (triangular space formed between the true vocal cords) is the narrowest segment of the laryngeal opening in adults
- the glottic opening is the space through which one visualizes proper placement of the ETT
- the trachea begins at the level of the thyroid cartilage, C6, and bifurcates into the right and left main bronchi at T4-T5 (approximately the sternal angle)

Methods of Supporting Airways

1. non-definitive airway (patent airway)
   - jaw thrust/chin lift
   - oropharyngeal and nasopharyngeal airway
   - bag mask ventilation
   - LMA
2. definitive airway (patent and protected airway)
   - ETT
   - surgical airway (cricothyrotomy or tracheostomy)
Table 2. Methods of Supporting the Airway

<table>
<thead>
<tr>
<th>Method</th>
<th>Bag and Mask</th>
<th>Laryngeal Mask Airway (LMA)</th>
<th>Endotracheal Tube (ETT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advantages/Indications</td>
<td>Basic</td>
<td>Easy to insert</td>
<td>Indications for intubation (5 Ps)</td>
</tr>
<tr>
<td></td>
<td>Non-invasive</td>
<td>Less airway trauma/irritation than ETT</td>
<td>Patent airway</td>
</tr>
<tr>
<td></td>
<td>Readily available</td>
<td>Frees up hands (vs. face mask)</td>
<td>Protects against aspiration</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Primarily used in spontaneously ventilating patient</td>
<td>Positive pressure ventilation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pulmonary toilet (suction)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pharmacologic administration</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>also hemodynamic instability</td>
</tr>
<tr>
<td>Disadvantages/Contraindications</td>
<td>Risk of aspiration if decreased LOC</td>
<td>Risk of gastric aspiration</td>
<td>Insertion can be difficult</td>
</tr>
<tr>
<td></td>
<td>Cannot ensure airway patency</td>
<td>PPV &lt; 20 cm H₂O needed</td>
<td>Muscle relaxant usually needed</td>
</tr>
<tr>
<td></td>
<td>Inability to deliver precise tidal volume</td>
<td>Oropharyngeal/retrahypopharyngeal pathology or foreign body</td>
<td>Most invasive – see Complications During Laryngoscopy and Intubation, A9</td>
</tr>
<tr>
<td></td>
<td>Operator fatigue</td>
<td>Does not protect against laryngospasm or gastric aspiration</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>Facilitate airway patency with jaw thrust and chin lift</td>
<td>Sizing by body weight (approx)</td>
<td>Auscultate to avoid endobronchial intubation</td>
</tr>
</tbody>
</table>
|                         | Can use oropharyngeal/nasophasyngeal airway | 40-50 kg: 3 | Sizing (approx):
|                         |              | 50-70 kg: 4 | Male: 8.0-9.0 mm
|                         |              | 70-110 kg: 5 | Female: 7.0-8.0 mm
|                         |              |                | Pediatric Uncuffed (>age 2): (age/4) + 4 mm |

Tracheal Intubation

Preparing for Intubation
- failed attempts at intubation can make further attempts more difficult due to tissue trauma
- plan, prepare, and assess for potential difficulties (see Pre-Operative Assessment, A2)
- ensure equipment is available and working (test ETT cuff, check laryngoscope light and suction, machine check)
- pre-oxygenate/denitrogenate: patient breathes 100% O₂ for 3-5 min or for 4-8 vital capacity breaths
- may need to suction mouth and pharynx first

Proper Positioning for Intubation
- align the three axes (mouth, pharynx, and larynx) to allow visualization from oral cavity to glottis
  - “sniffing position”: flexion of lower C-spine (CS-C6), bow head forward, and extension of upper C-spine at atlanto-occipital joint (C1), nose in the air
  - contraindicated in known/suspected C-spine fracture/instability
- laryngoscope tip placed in the epiglottic vallecula in order to visualize cord

Figure 4. Saggital view of airway with laryngoscope in vallecula
Tube Insertion
- Laryngoscopy and ETT insertion can incite a significant sympathetic response via stimulation of cranial nerves 9 and 10 due to a "foreign body reflex" in the trachea, including tachycardia, dysrhythmias, myocardial ischemia, increased BP and coughing
- A malpositioned ETT is a potential hazard for the intubated patient
  - If too deep, may result in right endobronchial intubation, which is associated with left-sided atelectasis and right-sided tension pneumothorax
  - If too shallow, may lead to accidental extubation, vocal cord trauma, or laryngeal paralysis as a result of pressure injury by the ETT cuff
- The tip of ETT should be located at the midpoint of the trachea at least 2 cm above the carina and the proximal end of the cuff should be placed at least 2 cm below the vocal cords
  - Approximately 20-23 cm mark at the right corner of the mouth for men and 19-21 cm for women

Confirmation of Tracheal Placement of ETT
- Direct
  - Visualization of ETT passing through cords
  - Bronchoscopic visualization of ETT in trachea
- Indirect
  - ETCO2 in exhaled gas measured by capnography – a mandatory method for confirming the ETT is in the airway
  - Auscultate for equal breath sounds bilaterally and absent breath sounds over epigastrium
  - Bilateral chest movement, condensation of water vapour in ETT visible during exhalation and no abdominal distention
  - Refilling of reservoir bag during exhalation
  - CXR (rarely done): only confirms position of the tip of ETT and not that ETT is in the trachea
  - Esophageal intubation suspected when
    - ETCO2 zero or near zero on capnograph
    - Abnormal sounds during assisted ventilation
    - Impairment of chest excursion
    - Hypoxia/cyanosis
    - Presence of gastric contents in ETT
    - Breath sounds heard when auscultating over epigastrium/LUQ
    - Distention of stomach/epigastrium with ventilation

Complications During Laryngoscopy and Intubation
- Dental damage
- Laceration (lips, gums, tongue, pharynx, vallecula, esophagus)
- Laryngeal trauma
- Esophageal or endobronchial intubation
- Accidental extubation
- Insufficient cuff inflation or cuff laceration: results in leaking and aspiration
- Laryngospasm (see Extubation, A20 for definition)
- Bronchospasm

Difficult Airway
- Difficulties with bag-mask ventilation, supraglottic airway, laryngoscopy, passage of ETT through the cords, infraglottic airway or surgical airway
- Pre-operative assessment (history of previous difficult airway, airway examination) and pre-oxygenation are important preventative measures
- If difficult airway expected, consider
  - Awake intubation
  - Intubating with bronchoscope, trachlight (lighted stylet), fibre optic laryngoscope, glidescope, etc.
- If intubation unsuccessful after induction
  1. CALL FOR HELP
  2. Ventilate with 100% O2 via bag and mask
  3. Consider returning to spontaneous ventilation and/or waking patient
- If bag and mask ventilation inadequate
  1. CALL FOR HELP
  2. Attempt ventilation with oral airway
  3. Consider/attempt LMA
  4. Emergency invasive airway access (e.g. rigid bronchoscope, cricothyrotomy, or tracheostomy)
Oxygen Therapy

- in general, the goal of oxygen therapy is to maintain arterial oxygen saturation (SaO₂) > at a minimum, 90%
- small decrease in saturation below SaO₂ of 90% corresponds to a large drop in arterial partial pressure of oxygen (PaO₂)
- in intubated patients, oxygen is delivered via the ETT
- in patients not intubated, there are many oxygen delivery systems available; the choice depends on oxygen requirements (FiO₂) and the degree to which precise control of delivery is needed
- cyanosis can be detected at SaO₂ <85%, frank cyanosis at SaO₂ = 67%

Low Flow Systems

- provide O₂ at flows between 0-10 L/min
- acceptable if tidal volume 300-700 mL, respiratory rate (RR) <25, consistent ventilation pattern
- dilution of oxygen with room air results in a decrease in FiO₂
- an increase in minute ventilation (tidal volume × RR) results in a decrease in FiO₂
- e.g. nasopharynx (prongs)
  - well tolerated if flow rates <5-6 L/min; drying of nasal mucosa at higher flows
  - nasopharynx acts as an anatomic reservoir that collects O₂
  - delivered oxygen concentration (FiO₂) can be estimated by adding 4% for every additional litre of O₂ delivered
  - provides FiO₂ of 24-44% at O₂ flow rates of 1-6 L/min

Reservoir Systems

- use a volume reservoir to accumulate oxygen during exhalation thus increasing the amount of oxygen available for the next breath
- simple face mask
  - covers patient’s nose and mouth and provides an additional reservoir beyond nasopharynx
  - fed by small bore O₂ tubing at a rate of at least 6 L/min to ensure that exhaled CO₂ is flushed through the exhalation ports and not rebreathed
  - provides FiO₂ of 55% at O₂ flow rates of 10 L/min
- non-rebreather mask
  - a reservoir bag and a series of one-way valves prevent expired gases from re-entering the bag
  - during the exhalation phase, the bag accumulates with oxygen
  - provides FiO₂ of 80% at O₂ flow rates of 10-15 L/min

High Flow Systems

- generate flows of up to 50-60 L/min
- meet/exceed patient’s inspiratory flow requirement
- deliver consistent and predictable concentration of O₂
- Venturi mask
  - delivers specific FiO₂ by varying the size of air entrapment
  - oxygen concentration determined by mask’s port and NOT the wall flow rate
  - enables control of gas humidity
  - FiO₂ ranges from 24-50%

Ventilation

- ventilation is maintained with PPV in patients given muscle relaxants
- assisted or controlled ventilation can also be used to assist spontaneous respirations in patients not given muscle relaxants as an artificial means of supporting ventilation and oxygenation

Mechanical Ventilation

- indications for mechanical ventilation
  - apnea
  - hypoventilation/acute respiratory acidosis
  - intraoperative positioning limiting respiratory excursion (e.g. prone, Trendelenburg)
  - required hyperventilation (to lower ICP)
  - deliver positive end expiratory pressure (PEEP)
  - increased intrathoracic pressure (e.g. laparoscopic procedure)
- complications of mechanical ventilation
  - airway complications
    - tracheal stenosis, laryngeal edema
    - alveolar complications
    - ventilator-induced lung injury (barotrauma, volutrauma, atelectrauma), ventilator-associated pneumonia (nosocomial pneumonia), inflammation, auto-PEEP, patient-ventilator asynchrony
  - cardiovascular complications
    - reduced venous return (secondary to increased intrathoracic pressure), reduced cardiac output, hypotension
neuromuscular complications
• muscle atrophy
• increased intracranial pressure
• metabolic
• decreased CO₂ due to hyperventilation
• alkalemia with over correction of chronic hypercarbia

Ventilator Strategies
• mode and settings are determined based on patient factors (e.g. ideal body weight, compliance, resistance) and underlying reason for mechanical ventilation
• hypoxic respiratory failure: ventilator provides supplemental oxygen, recruits atelectatic lung segments, helps improve V/Q mismatch, and decreases intrapulmonary shunt
• hypercapnic respiratory failure: ventilator augments alveolar ventilation; may decrease the work of breathing, allowing respiratory muscles to rest

Modes of Ventilation
• assist-control ventilation (ACV) or volume control (VC)
• every breath is delivered with a pre-set tidal volume and rate or minute ventilation
• extra controlled breaths may be triggered by patient effort; if no effort is detected within a specified amount of time the ventilator will initiate the breath
• pressure control ventilation (PCV)
• a minimum frequency is set and patient may trigger additional breaths above the ventilator
• all breaths delivered at a preset constant inspiratory pressure
• synchronous intermittent mandatory ventilation (SIMV)
• ventilator provides controlled breaths (either at a set volume or pressure depending on whether in VC or PCV, respectively)
• patient can breathe spontaneously (these breaths may be pressure supported) between controlled breaths
• pressure support ventilation (PSV)
• patient initiates all breaths and the ventilator supports each breath with a pre-set inspiratory pressure
• useful for weaning off ventilator
• high-frequency oscillatory ventilation (HFOV)
• high breathing rate (up to 900 breaths/min in an adult), very low tidal volumes
• used commonly in neonatal and pediatric respiratory failure
• occasionally used in adults when conventional mechanical ventilation is failing
• non-invasive positive pressure ventilation (NPPV)
• achieved without intubation by using a nasal or face mask
• BiPAP: increased pressure (like PSV) on inspiration and lower constant pressure on expiration (i.e. PEEP)
• CPAP: delivers constant pressure on both inspiration and expiration

Table 3. Causes of Abnormal End Tidal CO₂ Levels

<table>
<thead>
<tr>
<th>Hypocapnea (Decreased CO₂)</th>
<th>Hypercapnea (Increased CO₂)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypoventilation</td>
<td>Hypoventilation</td>
</tr>
<tr>
<td>Hypothermia (decreased metabolic rate)</td>
<td>Hyperthermia and other hypermetabolic states</td>
</tr>
<tr>
<td>Decreased pulmonary blood flow (decreased cardiac output)</td>
<td>Improved pulmonary blood flow after resuscitation or hypotension</td>
</tr>
<tr>
<td>Technical issues</td>
<td>Technical issues</td>
</tr>
<tr>
<td>Incorrect placement of sampling catheter</td>
<td>Water in capnography device</td>
</tr>
<tr>
<td>Inadequate sampling volume</td>
<td>Anesthetic breathing circuit error</td>
</tr>
<tr>
<td></td>
<td>Inadequate fresh gas flow</td>
</tr>
<tr>
<td></td>
<td>Rebreathing</td>
</tr>
<tr>
<td></td>
<td>Exhausted soda lime</td>
</tr>
<tr>
<td>V/Q mismatch</td>
<td>Faulty circuit absorber valves</td>
</tr>
<tr>
<td>Pulmonary thromboembolism</td>
<td>Low bicarbonate</td>
</tr>
<tr>
<td>Incipient pulmonary edema</td>
<td></td>
</tr>
<tr>
<td>Air embolism</td>
<td></td>
</tr>
</tbody>
</table>

Conclusions: Once-daily or multiple trials of spontaneous breathing led to extubation more quickly than intermittent mandatory or pressure-support ventilation.
Intraoperative Management

Temperature

Causes of Hypothermia (<36.0°C)
- intraoperative temperature losses are common (e.g. 90% of intraoperative heat loss is transcutaneous), due to
  - OR environment (cold room, IV fluids, instruments)
  - open wound
  - prevent with forced air warming blanket and warmed IV fluids

Causes of Hyperthermia (>37.5-38.3°C)
- drugs (e.g. atropine)
- blood transfusion reaction
- infection/sepsis
- medical disorder (e.g. thyrotoxicosis)
- malignant hyperthermia (see Uncommon Complications, A28)
- over-zealous warming efforts

Heart Rate

Cardiac Arrest
- pulseless arrest occurs due to 4 cardiac rhythms divided into shockable and non-shockable rhythms
  - shockable: ventricular fibrillation (VF) and ventricular tachycardia (VT)
  - non-shockable: asystole and pulseless electrical activity (PEA)
- for VF/VT, key to survival is good early CPR and defibrillation
- for asystole/PEA, key to survival is good early CPR and exclusion of all reversible causes
- reversible causes of PEA arrest (5 Hs and 5 Ts)
  - 5 Hs: hypothermia, hypovolemia, hypoxia, hydrogen ions (acidosis), hypo/hyperkalemia
  - 5 Ts: tamponade (cardiac), thrombosis (pulmonary), thrombosis (coronary), tension pneumothorax, toxins (overdose/poisoning)
- when a patient sustains a cardiac arrest during anesthesia, it is important to remember that there are other causes on top the Hs and Ts to consider (i.e. local anesthetic systemic toxicity (LAST), excessive anesthetic dosing and others)
- for management of cardiac arrest, see ACLS Guidelines (Figure 16), A31

Intraoperative Tachycardia
- tachycardia = HR >150 bpm; divided into narrow complex supraventricular tachycardias (SVT) or wide complex tachycardias
  - SVT: sinus tachycardia, atrial fibrillation/flutter, accessory pathway mediated tachycardia, paroxysmal atrial tachycardia
  - wide complex tachycardia: VT, SVT with aberrant conduction
- causes of sinus tachycardia
  - shock/hypovolemia/blood loss
  - anxiety/pain/light anesthesia
  - full bladder
  - anemia
  - febrile illness/sepsis
  - drugs (e.g. atropine, cocaine, dopamine, epinephrine, ephedrine, isoflurane, isoproterenol, pancuronium) and withdrawal
  - Addisonian crisis, hypoglycemia, transfusion reaction, malignant hyperthermia
- for management of tachycardia, see ACLS Guidelines (Figure 17), A32

Intraoperative Bradycardia
- bradycardia = HR <50 bpm; most concerning are 2nd degree (Mobitz type II) and 3rd degree heart block, which can both degenerate into asystole
- causes of sinus bradycardia
  - increased parasympathetic tone vs. decreased sympathetic tone
  - must rule out hypoxemia
  - arrhythmias (see Cardiology and Cardiac Surgery, C16)
  - baroreceptor reflex due to increased ICP or increased BP
  - vagal reflex (oculocardiac reflex, carotid sinus reflex, airway manipulation)
  - drugs (e.g. Sch, opioids, edrophonium, neostigmine, halothane, digoxin, β-blockers)
  - high spinal/epidural anesthesia
- for management of bradycardia, see ACLS Guidelines (Figure 18), A32
Blood Pressure

Causes of Intraoperative Hypotension/Shock
- shock: condition characterized by inability of cardiovascular system to maintain adequate end-organ perfusion and delivery of oxygen to tissues
  a) hypovolemic/hemorrhagic shock
    - most common form of shock, due to decrease in intravascular volume
  b) obstructive shock
    - obstruction of blood into or out of the heart
    - increased JVP, distended neck veins, increased systemic vascular resistance, insufficient cardiac output (CO)
    - e.g. tension pneumothorax, cardiac tamponade, pulmonary embolism (and other emboli – i.e. fat, air)
  c) cardiogenic shock
    - increased JVP, distended neck veins, increased systemic vascular resistance, decreased CO
    - e.g. myocardial dysfunction, dysrhythmias, ischemia/infarct, cardiomyopathy, acute valvular dysfunction
  d) septic shock
    - see Infectious Diseases, ID21
  e) spinal/neurogenic shock
    - decreased sympathetic tone
  f) anaphylactic shock
    - see Emergency Medicine, ER38
  g) drugs
    - vasodilators, high spinal anesthetic interfering with sympathetic outflow
  h) other
    - transfusion reaction, Addisonian crisis, thyrotoxicosis, hypothyroid, aortocaval syndrome
    - see Hematology, H52 and Endocrinology, E33

Causes of Intraoperative Hypertension
- inadequate anesthesia causing pain and anxiety
- pre-existing HTN, coarctation, or preeclampsia
- hypoxemia/hypercarbia
- hypervolemia
- increased intracranial pressure
- full bladder
- drugs (e.g. ephedrine, epinephrine, cocaine, phencyclidine, ketamine) and withdrawal
- allergic/anaphylactic reaction
- hypermetabolic states: malignant hyperthermia, neuroleptic malignant syndrome, serotonin syndrome (see Psychiatry, PS44), thyroid storm, pheochromocytoma (see Endocrinology, E25)

Fluid Balance and Resuscitation
- total requirement = maintenance + deficit + ongoing loss
- in surgical settings this formula must take into account multiple factors including pre-operative fasting/descreased fluid intake, increased losses during or before surgery, fluid shifting during surgery, fluids given with blood products and medications

What is the Maintenance?
- average healthy adult requires approximately 2500 mL water/d
  - 200 mL/d GI losses
  - 800 mL/d insensible losses (respiration, perspiration)
  - 1500 mL/d urine (beware of renal failure)
- 4:2:1 rule to calculate maintenance requirements (applies to crystalloids only)
  - 4 mL/kg/h first 10 kg
  - 2 mL/kg/h second 10 kg
  - 1 mL/kg/h for remaining weight >20 kg
- increased requirements with fever, sweating, GI losses (vomiting, diarrhea, NG suction), adrenal insufficiency, hyperventilation, and polyuric renal disease
- decreased requirements with anuria/oliguria, SIADH, highly humidified atmospheres, and CHF
- maintenance electrolytes
  - Na+: 3 mEq/kg/d
  - K+: 1 mEq/kg/d
- 50 kg patient maintenance requirements
  - fluid = 40 + 20 + 30 = 90 mL/h = 2160 mL/d = 2.16 L/d
  - Na+ = 150 mEq/d (therefore 150 mEq / 2.16 L/d = 69 mEq/L)
  - K+ = 50 mEq/d (therefore 50 mEq / 2.16 L/d = 23 mEq/L)
- above patient’s requirements roughly met with 2/3 D5W, 1/3 NS
  - 2/3 + 1/3 at 100 mL/h with 20 mEq KCl per litre
What is the Deficit?
• patients should be adequately hydrated prior to anesthesia
• total body water (TBW) = 60% or 50% of total body weight for an adult male or female, respectively (e.g. for a 70 kg adult male TBW = 70 x 0.6 = 42 L)
• total Na⁺ content determines ECF volume; [Na⁺] determines ICF volume
• hypovolemia due to volume contraction
  • extra-renal Na⁺ loss
  • GI: vomiting, NG suction, drainage, fistulae, diarrhea
  • skin/respiratory: insensible losses (fever), sweating, burns
  • vascular: hemorrhage
• renal Na⁺ and H₂O loss
  • diuretics
  • osmotic diuresis
  • hypoaldosteronism
  • salt-wasting nephropathies
• renal H₂O loss
  • diabetes insipidus (central or nephrogenic)
• hypovolemia with normal or expanded ECF volume
  • decreased CO
  • redistribution
    – hypoalbuminemia: cirrhosis, nephrotic syndrome
    – capillary leakage: acute pancreatitis, rhabdomyolysis, ischemic bowel, sepsis, anaphylaxis
• replace water and electrolytes as determined by patient's needs
• with chronic hyponatremia, correction must be done gradually over >48 h to avoid central pontine myelinolysis

What are the Ongoing Losses?
• losses from Foley catheter, NG, surgical drains
• third-spacing (other than ECF, ICF)
  • pleura, GI, retroperitoneal, peritoneal
  • evaporation via exposed viscera, burns
• blood loss
• ongoing loss due to surgical exposure and evaporative losses

Table 4. Signs and Symptoms of Dehydration

<table>
<thead>
<tr>
<th>Percentage of Body Water Loss</th>
<th>Severity</th>
<th>Signs and Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>3%</td>
<td>Mild</td>
<td>Decreased skin turgor, sunken eyes, dry mucus membranes, dry tongue, reduced sweating</td>
</tr>
<tr>
<td>6%</td>
<td>Moderate</td>
<td>Oliguria, orthostatic hypotension, tachycardia, low volume pulse, cool extremities, reduced filling of peripheral veins and CVP, hemocoagulation, apathy</td>
</tr>
<tr>
<td>9%</td>
<td>Severe</td>
<td>Profound oliguria or anuria and compromised CNS function with or without altered sensorium</td>
</tr>
</tbody>
</table>

IV Fluids
• replacement fluids include crystalloid and colloid solutions
• IV fluids improve perfusion but NOT O₂ carrying capacity of blood

Initial Distribution of IV Fluids
• H₂O follows ions/molecules to their respective compartments

Crystalloid Infusion
• salt-containing solutions that distribute only within ECF
• maintain euvolemia in patient with blood loss: 3 mL crystalloid infusion per 1 mL of blood loss for volume replacement (i.e. 3:1 replacement)
• if large volumes are to be given, use balanced fluids such as Ringer’s lactate or Plasmalyte”, as too much normal saline (NS) may lead to hyperchloremic metabolic acidosis

Colloid Infusion (see Blood Products, A15)
• includes protein colloids (albumin and gelatin solutions) and non-protein colloids (dextran and starches e.g. hydroxyethyl starch [HES])
• distributes within intravascular volume
• 1:1 ratio (infusion:blood loss) only in terms of replacing intravascular volume
• HES colloids remain in intravascular space (metabolized by plasma serum amylase and renally excreted); two available in Canada: Voluven” and Pentaspan”
• the use of HES solutions is controversial because of recent RCTs and meta-analyses highlighting their renal (especially in septic patients) and coagulopathic side effects, as well as a lack of specific indications for their use
• colloids are being used based on mechanistic and experimental evidence but there is a paucity of definitive studies investigating their safety and efficacy; routine use of colloids should be avoided

Colloids vs. Crystalloids for Fluid Resuscitation in Critically Ill Patients
Cochrane DB Syst Rev 2012;6:CD000567
Purpose: To evaluate the effects of colloids compared to crystalloids for fluid resuscitation, specifically when used in critically ill patients.
Methods: A meta-analysis was performed looking at randomized controlled trials comparing colloid vs. crystalloid use in patients requiring volume replacement. Pregnant women and neonates were excluded. Primary outcome was overall mortality.
Results: Results were broken down based on specific colloid. For albumin (or plasma protein fraction) the relative risk (RR) was 1.01 (95% CI 0.93-1.09) as compared to crystalloid. For hydroxyethyl starch the RR was 1.10 (95% CI 0.91-1.32). Modified gelatin had a RR of 0.91 (95% CI 0.82-1.12) and Dextran had a RR of 1.24 (95% CI 0.84-1.65). For colloids mixed in a hypertonic crystalloid as compared to isotonic crystalloid the RR was 0.89 (95% CI 0.71-1.16).
Conclusions: There is no evidence that use of colloids improves survival in trauma patients, burn patients, or post-operative patients when compared to crystalloid solutions. Given the increased cost of colloids as compared to crystalloids, it is recommended that crystalloids be the fluid of choice in these patients.
Table 5. IV Fluid Solutions

<table>
<thead>
<tr>
<th>ECF</th>
<th>Ringer's Lactate</th>
<th>0.9% NS</th>
<th>0.45% NS in D5W</th>
<th>D5W</th>
<th>2/3 D5W + 1/3 NS</th>
<th>Plasmalyte</th>
</tr>
</thead>
<tbody>
<tr>
<td>mEq/L</td>
<td>Na⁺</td>
<td>142</td>
<td>130</td>
<td>154</td>
<td>77</td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>K⁺</td>
<td>4</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Ca²⁺</td>
<td>4</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Mg²⁺</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Cl⁻</td>
<td>103</td>
<td>109</td>
<td>154</td>
<td>77</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>HCO₃⁻</td>
<td>27</td>
<td>28 *</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>mOsml/L</td>
<td>280-310</td>
<td>273</td>
<td>308</td>
<td>154</td>
<td>252</td>
<td>269</td>
</tr>
<tr>
<td>pH</td>
<td>7.4</td>
<td>6.5</td>
<td>5.0</td>
<td>4.5</td>
<td>4.0</td>
<td>4.3</td>
</tr>
</tbody>
</table>

*Converted from lactate

Table 6. Colloid HES Solutions

<table>
<thead>
<tr>
<th>Concentration</th>
<th>Plasma Volume Expansion</th>
<th>Duration (h)</th>
<th>Maximum Daily Dose (mL/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Voluven®</td>
<td>6%</td>
<td>1:1</td>
<td>4-6</td>
</tr>
<tr>
<td>Pentaspan®</td>
<td>10%</td>
<td>1:1.2-1.5</td>
<td>18-24</td>
</tr>
</tbody>
</table>

Blood Products

- see Hematology, H52

Induction

Routine Induction vs. Rapid Sequence Induction

- routine induction is the standard in general anesthesia, however a RSI is indicated in patients at risk of regurgitation/aspiration (see Aspiration, A5)
- RSI uses pre-determined doses of induction drugs given in rapid succession to minimize the time patient is at risk for aspiration (i.e. from the time when they are asleep without an ETT until the time when the ETT is in and the cuff inflated)

Table 7. Comparison of Routine Induction vs. RSI

<table>
<thead>
<tr>
<th>Steps</th>
<th>Routine Induction</th>
<th>RSI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Equipment Preparation</td>
<td>Check equipment, drugs, suction, and monitors; prepare an alternative laryngoscope blade and a second ETT tube one size smaller</td>
<td>Check equipment, drugs, suction, and monitors; prepare an alternative laryngoscope blade and a second ETT tube one size smaller; suction on</td>
</tr>
<tr>
<td>2. Pre-Oxygenation/</td>
<td>100% O₂ for 3 min or 4-8 vital capacity breaths</td>
<td>Use agent of choice to blunt physiologic responses to airway manipulation 3 min prior to laryngoscopy</td>
</tr>
<tr>
<td>Denitrogenation</td>
<td></td>
<td>Use agent of choice to blunt physiologic responses to airway manipulation; if possible, give 3 min prior to laryngoscopy, but can skip this step in an emergent situation</td>
</tr>
<tr>
<td>3. Pre-Treatment Agents</td>
<td>Muscle relaxant of choice given after the onset of the induction agent</td>
<td>Use pre-determined dose of fast acting muscle relaxant (e.g. SCh) given IMMEDIATELY after induction agent</td>
</tr>
<tr>
<td>4. Induction Agents</td>
<td>Use IV or inhalation induction agent of choice</td>
<td>Use pre-determined dose of fast acting induction agent of choice</td>
</tr>
<tr>
<td>5. Muscle Relaxants</td>
<td>Muscle relaxant of choice given after the onset of the induction agent</td>
<td>Pre-determined dose of fast acting muscle relaxant (e.g. SCh) given IMMEDIATELY after induction agent</td>
</tr>
<tr>
<td>6. Ventilation</td>
<td>Bag-mask ventilation</td>
<td>DO NOT bag ventilate – can increase risk of aspiration</td>
</tr>
<tr>
<td>7. Cricoid Pressure</td>
<td>Backwards upwards rightwards pressure (BURP) on thyroid cartilage to assist visualization if indicated</td>
<td>Sellick maneuver, also known as cricoid pressure, to prevent regurgitation and assist in visualization (2 kg pressure with drowsiness, 3 kg with loss of consciousness)</td>
</tr>
<tr>
<td>8. Intubation</td>
<td>Intubate, inflate cuff, confirm ETT position</td>
<td>Intubate once paralyzed (1-45 s after SCh given), inflate cuff, confirm ETT position; cricoid pressure maintained until ETT cuff inflated and placement confirmed</td>
</tr>
</tbody>
</table>

Calculating Acceptable Blood Losses (ABL)

- Blood volume
  - term infant 80 mL/kg
  - adult male 70 mL/kg
  - adult female 60 mL/kg
- Calculate estimated blood volume (EBV) (e.g. in a 70 kg male, approx. 70 mL/kg)
  - EBV = 70 kg × 70 mL/kg = 4900 mL
- Decide on a transfusion trigger, i.e. the Hb level at which you would begin transfusion, (e.g. 70 g/L, for a person with Hb(i) = 150 g/L)
  - Hb(i) = 70 g/L
  - Calculate
    - ABL = Hb(i) – Hb(f) × EBV
      - Hb(f) = 150 – 70 × 4900
      - 150
      - 2613 mL
- Therefore in order to keep the Hb level above 70 g/L, RBCs would have to be given after approximately 2.6 L of blood has been lost

Transfusion Infection Risks

| Virus                  | Risk per 1 unit pRBCs |
|                       |                       |
| HIV                   | 1 in 21 million       |
| Hepatitis C virus     | 1 in 13 million       |
| Hepatitis B virus     | 1 in 7.5 million      |
| HTLV                  | 1 in 1-3 million      |
| Symptomatic Bacterial Sepsis | 1 in 40,000 from platelets and 1 in 250,000 from RBC |
| West Nile virus       | No cases since 2003    |

Source: Callum JL, Pinkerton PH. Bloody Easy. Fourth Edition ed. Toronto: Sunnybrook and Women’s College Health Science Centre; 2016
Induction Agents

- Induction in general anesthesia may be achieved with intravenous agents, volatile inhalation agents, or both

Intravenous Agents

- see Table 8
- IV induction agents are non-opioid drugs used to provide hypnosis, amnesia and blunt reflexes
- these are initially used to draw the patient into the maintenance phase of general anesthesia rapidly, smoothly and with minimal adverse effects
  - examples include propofol, sodium thiopental (not available in North America), or ketamine
  - a continuous propofol infusion may also be used for the maintenance phase of GA

Table 8. Intravenous Induction Agents

<table>
<thead>
<tr>
<th>Propofol (Diprivan®)</th>
<th>Thiopental (sodium thiopental, sodium thiomepentone)</th>
<th>Ketamine (Ketalar®, Ketavect®)</th>
<th>Benzodiazepines (midazolam [Versed®], diazepam [Valium®], lorazepam [Ativan®])</th>
<th>Etomidate</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Class</strong></td>
<td>Alkylphenol – hypnotic</td>
<td>Ultra-short acting thiobarbiturates – hypnotic</td>
<td>Phencyclidine (PCP) derivative – dissociative</td>
<td>Benzodiazepines – anxiolytic</td>
</tr>
<tr>
<td><strong>Action</strong></td>
<td>Inhibitory at GABA synapse</td>
<td>Decreased time Cl– channels open, facilitating GABA and suppressing glutamic acid</td>
<td>May act on NMDA, opioid, and other receptors</td>
<td>Causes increased glycine inhibitory neurotransmitter, facilitates GABA</td>
</tr>
<tr>
<td></td>
<td>Decreased cerebral metabolic rate and blood flow, decreased ICP, decreased SVR, decreased BP and decreased SV</td>
<td>Decreased cerebral metabolism and blood flow, decreased CPP, decreased CO, decreased BP, decreased reflex tachycardia, decreased respiration</td>
<td>Increased HR, increased BP, increased SVR, increased coronary flow, increased myocardial O2 uptake</td>
<td>Producer anti-anxiety and skeletal muscle relaxant effects</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CNS and respiratory depression, bronchial smooth muscle relaxation</td>
<td>Minimal cardiac depression</td>
</tr>
<tr>
<td><strong>Indications</strong></td>
<td>Induction</td>
<td>Induction</td>
<td>Major trauma, hypovolemia, obstetric bleeding, severe asthma because</td>
<td>Used for sedation, amnesia, and anxiolyis</td>
</tr>
<tr>
<td></td>
<td>Maintenance</td>
<td>Control of convulsive states, obstetric patients</td>
<td>sympathomimetic</td>
<td>Induction</td>
</tr>
<tr>
<td></td>
<td>Total intravenous anesthesia (TIVA)</td>
<td></td>
<td></td>
<td>Poor cardiac function, severe valve lesions, uncontrolled hypertension</td>
</tr>
<tr>
<td><strong>Caution</strong></td>
<td>Patients who cannot tolerate sudden decreased BP (e.g. fixed cardiac output or shock)</td>
<td>Allergy to barbiturates</td>
<td>Ketamine allergy</td>
<td>Marked respiratory depression</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TCA medication (interaction causes HTN and dysrhythmias)</td>
<td>Post-operative nausea and vomiting</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>History of psychosis</td>
<td>Venous irritation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Patients who cannot tolerate HTN (e.g. CHF, increased ICP, aneurysm)</td>
<td></td>
</tr>
<tr>
<td><strong>Dosing</strong></td>
<td>IV induction: 2.5-3.0 mg/kg (less with opioids) Unconscious &lt; 1 min</td>
<td>IV induction: 3-5 mg/kg Unconscious about 30 s Lasts 5 min Accumulation with repeat dosing – not for maintenance</td>
<td>IV induction 1-2 mg/kg Dissociation in 15 s, analgesia, amnesia, and unconsciousness in 45-60 s Unconscious for 10-15 min, analgesia for 40 min, amnesia for 1-2 h</td>
<td>Onset less than 5 min if given IV Duration of action long but variable/somewhat unpredictable</td>
</tr>
<tr>
<td></td>
<td>Lasts 4-6 min t½ = 55 min Decreased post-operative sedation, recovery time, N/V</td>
<td>Onset less than 5 min if given IV Duration of action long but variable/somewhat unpredictable</td>
<td></td>
<td>IV induction 0.3 mg/kg Onset 30-60 seconds Lasts 4-8 minutes</td>
</tr>
<tr>
<td><strong>Special Considerations</strong></td>
<td>0-30% decreased BP due to vasodilation Reduce burning at IV site by mixing with lidocaine</td>
<td>Combining with rocuronium causes precipitates to form</td>
<td>High incidence of emergence reactions (vivid dreaming, out-of-body sensation, illusions)</td>
<td>Antagonist: flumazenil (Anexate®) competitive inhibitor, 0.2 mg IV over 15 s, repeat with 0.1 mg/min (max of 2 mg), t½ of 60 min</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pretreat with glycopyrrolate to decrease salivation</td>
<td>Midazolam also has amnesic (antegrade) effect and decreased risk of thrombophlebitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adrenal suppression after first dose, cannot repeat dose or use as infusion</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Myoclonic movements during induction</td>
</tr>
</tbody>
</table>

Volatile Inhalational Agents

- examples include sevoflurane, desflurane, isoflurane, enflurane, halothane, and nitrous oxide
- see Table 9
Anesthesia

Table 9. Volatile Inhalational Agents

<table>
<thead>
<tr>
<th></th>
<th>Sevoflurane</th>
<th>Desflurane</th>
<th>Isoflurane</th>
<th>Enflurane</th>
<th>Halothane</th>
<th>Nitrous oxide (N₂O)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAC (% gas in O₂)</td>
<td>2.0</td>
<td>6.0</td>
<td>1.2</td>
<td>1.7</td>
<td>0.8</td>
<td>104</td>
</tr>
<tr>
<td>CNS</td>
<td>Increased ICP</td>
<td>Increased ICP</td>
<td>Decreased cerebral metabolic rate</td>
<td>Increased ICP</td>
<td>Increased ICP and cerebral blood flow</td>
<td>—</td>
</tr>
<tr>
<td>Resp</td>
<td>Respiratory depression (severely decreased TV, increased RR), decreased response to respiratory CO₂ reflexes, bronchodilation</td>
<td>—</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVS</td>
<td>Less decrease of contractility, stable HR</td>
<td>Tachycardia with rapid increase in concentration</td>
<td>Decreased BP and CO, increased HR, theoretical chance of coronary steal**</td>
<td>Stable HR, decreased contractility</td>
<td>Decreased BP, CO, HR, and conduction</td>
<td>Sensitizes myocardium to epinephrine-induced arrhythmias</td>
</tr>
<tr>
<td>MSK</td>
<td>Muscle relaxation, potentiation of other muscle relaxants, uterine relaxation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*N Properties and Adverse Effects of N₂O
Due to its high MAC, nitrous oxide is combined with other anesthetic gases to attain surgical anesthesia. A MAC of 104% is possible in a pressurized chamber only

Second Gas Effect
Expansion of closed spaces: closed spaces such as a pneumothorax, the middle ear, bowel lumen and ETT cuff will markedly enlarge if N₂O is administered

Diffusion hypoxia: during anesthesia, the washout of N₂O from body stores into alveoli can dilute the alveolar O₂, creating a hypoxic mixture if the original O₂ is low

**Coronary steal: isoflurane causes small vessel dilation which may compromise blood flow to areas of the heart with fixed perfusion (e.g. stents, atherosclerosis)

MAC (Minimum Alveolar Concentration)
- the alveolar concentration of a volatile anesthetic at one atmosphere (atm) of pressure that will prevent movement in 50% of patients in response to a surgical stimulus (e.g. abdominal incision)
- potency of inhalational agents is compared using MAC
- 1.2-1.3 times MAC will often ablate response to stimuli in the general population
- MAC values are roughly additive when mixing N₂O with another volatile agent; however, this only applies to movement, not other effects such as BP changes (e.g. 0.5 MAC of a potent agent + 0.5 MAC of N₂O = 1 MAC of potent agent)
- MAC-intubation: the MAC of anesthetic that will inhibit movement and coughing during endotracheal intubation, generally 1.3 MAC
- MAC-block adrenergic response (MAC-BAR): the MAC necessary to blunt the sympathetic response to noxious stimuli, generally 1.5 MAC
- MAC-awake: the MAC of a given volatile anesthetic at which a patient will open their eyes to command, generally 0.3-0.4 of the usual MAC

Muscle Relaxants and Reversing Agents

![Figure 8. Review of anatomy and physiology of the neuromuscular junction (NMJ)](image)

© Julie Man 2012
**Muscle Relaxants**

- two types of muscle relaxants
  1. depolarizing muscle relaxants: succinylcholine (SCh)
  2. non-depolarizing muscle relaxants: rocuronium, mivacurium, vecuronium, cisatracurium, pancuronium

- block nicotinic cholinergic receptors in NMJ
- provides skeletal muscle paralysis, including the diaphragm, but spares involuntary muscles such as the heart and smooth muscle
- never use muscle relaxants without adequate preparation and equipment to maintain airway and ventilation
- muscle relaxation produces the following desired effects
  1. facilitates intubation
  2. assists with mechanical ventilation
  3. prevents muscle stretch reflex and decreases muscle tone
  4. allows access to the surgical field (intraoperative surgery)

- nerve stimulator (i.e. train of four) is used intraoperatively to assess the degree of nerve block; no twitch response seen with complete neuromuscular blockade
- see Tables 10 and 11, for more details including mechanism of action

---

**Table 10. Depolarizing Muscle Relaxants (Non-Competitive): Succinylcholine (SCh)**

<table>
<thead>
<tr>
<th>Mechanism of Action</th>
<th>Mimics ACh and binds to ACh receptors causing prolonged depolarization; initial fasciculation may be seen, followed by temporary paralysis secondary to blocked ACh receptors by SCh</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intubating Dose (mg/kg)</td>
<td>1-1.5</td>
</tr>
<tr>
<td>Onset</td>
<td>30-60 s – rapid (fastest of all muscle relaxants)</td>
</tr>
<tr>
<td>Duration</td>
<td>3-5 min – short (no reversing agent for SCh)</td>
</tr>
<tr>
<td>Metabolism</td>
<td>SCh is hydrolyzed by plasma cholinesterase (pseudocholinesterase), found only in plasma and not at the NMJ</td>
</tr>
</tbody>
</table>
| Indications         | Assist intubation
  
  Increased risk of aspiration (need rapid paralysis and airway control (e.g. full stomach), hiatus herna, obesity, pregnancy, trauma)

  Short procedures

  Electrocortical therapy (ECT)

  Laryngospasm

| Side Effects | 1. SCh also stimulates muscarinic cholinergic autonomic receptors (in addition to nicotinic receptors; may cause bradycardia, dysrhythmias, sinus arrest, increased secretions of salivary glands (especially in children)
  
  2. Hyperkalemia

  Disruption of motor nerve activity causes proliferation of extrajunctional (outside NMJ) cholinergic receptors

  Depolarization of an increased number of receptors by SCh may lead to massive release of potassium out of muscle cells

  Patients at risk

  3rd degree burns 24 h-6 mo after injury

  Traumatic paralysis or neuromuscular diseases (e.g. muscular dystrophy)

  Severe intra-abdominal infections

  Severe closed head injury

  Upper motor neuron lesions

  3. Can trigger MH (see Malignant Hyperthermia, A28)

  4. Increased ICP/intracavitary pressure/intragastric pressure (no increased risk of aspiration if competent lower esophageal sphincter)

  5. Fasciculations, post-operative myalgia – may be minimized if small dose of non-depolarizing agent given before SCh administration |

| Contraindications |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Absolute          | Known hypersensitivity or allergy, positive history of malignant hyperthermia, myotonia (m. congenita, m. dystrophica, paramyotonia congenital), high risk for hyperkalemic response |
| Relative          | Known history of plasma cholinesterase deficiency, myasthenia gravis, myasthenic syndrome, familial periodic paralysis, open eye injury |
### Table 11. Non-Depolarizing Muscle Relaxants (Competitive)

<table>
<thead>
<tr>
<th>Classification</th>
<th>Short</th>
<th>Intermediate</th>
<th>Long</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intubating Dose (mg/kg)</td>
<td>Mivacuronium</td>
<td>Rocuronium</td>
<td>Vecuronium</td>
</tr>
<tr>
<td>Onset (min)</td>
<td>2-3</td>
<td>1.5</td>
<td>2-3</td>
</tr>
<tr>
<td>Duration (min)</td>
<td>15-25</td>
<td>30-45</td>
<td>45-60</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Plasma cholinesterase</td>
<td>Liver (major)</td>
<td>Liver</td>
</tr>
<tr>
<td>Indications</td>
<td>Assist intubation, assist mechanical ventilation in some ICU patients, reduce fasciculations and post-operative myalgias secondary to SCh</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Reversing Agents
- neostigmine, pyridostigmine, edrophonium
- reversal agents are acetylcholinesterase inhibitors
  - inhibits enzymatic degradation of ACh; increases amount of ACh at nicotinic and muscarinic receptors, displacing non-depolarizing muscle relaxant
  - administer reversal agents when there has been some recovery of blockade (i.e. muscle twitch)
  - can only reverse the effect of non-depolarizing muscle relaxants
- anticholinergic agents (e.g. atropine, glycopyrrolate) are simultaneously administered to minimize muscarinic effect of reversal agents (i.e. bradycardia, salivation and increased bowel peristalsis)

### Table 12. Reversal Agents for Non-Depolarizing Relaxants

<table>
<thead>
<tr>
<th>Cholinesterase Inhibitor</th>
<th>Neostigmine</th>
<th>Pyridostigmine</th>
<th>Edrophonium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset and Duration</td>
<td>Intermediate</td>
<td>Longest</td>
<td>Shortest</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>Inhibits enzymatic degradation of ACh, increases ACh at nicotinic and muscarinic receptors, displaces non-depolarizing muscle relaxants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muscarinic effects of reversing agents include unwanted bradycardia, salivation, and increased bowel peristalsis*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dose</td>
<td>0.04-0.08 mg/kg</td>
<td>0.1-0.4 mg/kg</td>
<td>0.5-1 mg/kg</td>
</tr>
<tr>
<td>Recommended Anticholinergic</td>
<td>Glycopyrrolate</td>
<td>Glycopyrrolate</td>
<td>Atropine</td>
</tr>
<tr>
<td>Dose of Anticholinergic (per mg)</td>
<td>0.2 mg</td>
<td>0.05 mg</td>
<td>0.014 mg</td>
</tr>
</tbody>
</table>

*Atropine and glycopyrrolate are anticholinergic agents administered during the administration of reversal agents to minimize muscarinic effects

### Analgesia
- options include opioids (e.g. morphine, fentanyl, hydromorphone), NSAIDS, acetaminophen, ketamine, gabapentin, local, and regional anesthetic (see Table 15, A25)

### Maintenance
- general anesthesia is maintained using volatile inhalation agents and/or IV agents (i.e. propofol infusion)
- analgesia (usually IV opioids) and muscle relaxants are also given as needed
Extubation

- criteria: patient must no longer have intubation requirements (see Table 2, A8)
  - patency: airway must be patent
  - protection: airway reflexes intact
  - patient must be oxygenating and ventilating spontaneously
- general guidelines
  - ensure patient has normal neuromuscular function (peripheral nerve stimulator monitoring) and hemodynamic status
  - ensure patient is breathing spontaneously with adequate rate and tidal volume
  - allow ventilation (spontaneous or controlled) with 100% O₂ for 3-5 min
  - suction secretions from pharynx, deflate cuff, remove ETT on inspiration (vocal cords abducted)
  - ensure patient is breathing adequately after extubation
  - ensure face mask for O₂ delivery available
  - proper positioning of patient during transfer to recovery room (supine, head elevated)

Complications of Extubation

- early extubation: aspiration, laryngospasm
- late extubation: transient vocal cord incompetence, edema (glottic, subglottic), pharyngitis, tracheitis

Laryngospasm
- defined as forceful involuntary spasm of laryngeal muscles caused by stimulation of superior laryngeal nerve (by oropharyngeal secretions, blood, extubation)
- causes partial or total airway obstruction
- more likely to occur in semi-conscious patients
- prevention: extube while patient is still deeply under anesthesia or fully awake
- treatment: apply sustained positive pressure with bag-mask ventilation with 100% oxygen, low-dose propofol (0.5-1.0 mg/kg) optional, low-dose succinylcholine (approximately 0.25 mg/kg) and reintubation if hypoxia develops

Regional Anesthesia

- local anesthetic (LA) applied around a peripheral nerve at any point along the length of the nerve (from spinal cord up to, but not including, the nerve endings) for the purpose of reducing or preventing impulse transmission
- no CNS depression (unless overdose of local anesthetic); patient remains conscious
- regional anesthetic techniques categorized as follows:
  - epidural and spinal anesthesia (neuraxial anesthesia)
  - peripheral nerve blocks
  - IV regional anesthesia (e.g. Bier block)

Patient Preparation
- sedation may be indicated before block
- monitoring should be as extensive as for general anesthesia

Benefits of Regional Anesthesia
- Reduced perioperative pulmonary complications
- Reduced perioperative analgesia requirements
- Decreased PONV
- Reduced perioperative blood loss
- Ability to monitor CNS status during procedure
- Improved perfusion
- Lower incidence of VTE
- Shorter recovery and improved rehabilitation
- Pain blockade with preserved motor function

Epidural and Spinal Anesthesia

- most useful for surgeries performed below level of umbilicus

Anatomy of Spinal/Epidural Area
- spinal cord extends to L2, dural sac to S2 in adults
- nerve roots (cauda equina) from L2 to S2
- needle inserted below L2 should not encounter cord, thus L3-L4, L4-L5 interspace commonly used
- structures penetrated (outside to inside)
  - skin
  - subcutaneous fat
  - supraspinous ligament
  - interspinous ligament
  - ligamentum flavum (last layer before epidural space)
  - dura + arachnoid for spinal anesthesia

Landmarking Epidural/Spinal Anesthesia
- Spinous processes should be maximally flexed
- L4 spinous processes found between iliac crests
- Common sites of insertion are L3-L4 and L4-L5

Classic Presentation of Dural Puncture
- Headache
  - Onset 6 h-3 d after dural puncture
  - Postural component (worse when sitting)
  - Occipital or frontal localization
  - ± tinnitus, diplopia
### Table 13. Epidural vs. Spinal Anesthesia

<table>
<thead>
<tr>
<th></th>
<th>Epidural</th>
<th>Spinal</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Deposition Site</strong></td>
<td>LA injected in epidural space (space between ligamentum flavum and dura)</td>
<td>LA injected into subarachnoid space in the dural sac surrounding the spinal cord and nerve roots</td>
</tr>
<tr>
<td><strong>Onset</strong></td>
<td>Significant blockade requires 10-15 min</td>
<td>Rapid blockade (onset in 2-5 min)</td>
</tr>
<tr>
<td><strong>Effectiveness</strong></td>
<td>Effectiveness of blockade can be variable</td>
<td>Very effective blockade</td>
</tr>
<tr>
<td><strong>Difficulty</strong></td>
<td>Technically more difficult; greater failure rate</td>
<td>Easier to perform due to visual confirmation of CSF flow</td>
</tr>
<tr>
<td><strong>Patient Positioning</strong></td>
<td>Position of patient not as important; specific gravity not an issue</td>
<td>Hyperbaric LA solution – position of patient important</td>
</tr>
<tr>
<td><strong>Specific Gravity/Spread</strong></td>
<td>Epidural injections spread throughout the potential space; specific gravity of solution does not affect spread</td>
<td>LA solution may be made hyperbaric (of greater specific gravity than the cerebrospinal fluid by mixing with 10% dextrose, thus increasing spread of LA to the dependent (low) areas of the subarachnoid space)</td>
</tr>
<tr>
<td><strong>Dosage</strong></td>
<td>Larger volume/dose of LA (usually &gt; toxic IV dose)</td>
<td>Smaller dose of LA required (usually &lt; toxic IV dose)</td>
</tr>
<tr>
<td><strong>Continuous Infusion</strong></td>
<td>Use of catheter allows for continuous infusion or repeat injections</td>
<td>None</td>
</tr>
<tr>
<td><strong>Complications</strong></td>
<td>Failure of technique, Hypotension, Bradycardia if cardiac sympathetics blocked (only if ~T2-4 block), e.g. “high spinal”, Epidural or subarachnoid hematoma, Accidental subarachnoid injection can produce spinal anesthesia (and any of the above complications), Systemic toxicity of LA (accidental intravenous), Catheter complications (shearing, kinking, vascular or subarachnoid placement), Infection, Dural puncture</td>
<td>Failure of technique, Hypotension, Bradycardia if cardiac sympathetics blocked (only if ~T2-4 block), e.g. “high spinal”, Epidural or subarachnoid hematoma, Post-spinal headache (CSF leak), Transient paresthesias, Spinal cord trauma, infection</td>
</tr>
<tr>
<td><strong>Combined Spinal-Epidural</strong></td>
<td>Combines the benefits of rapid, reliable, intense blockade of spinal anesthesia together with the flexibility of an epidural catheter</td>
<td></td>
</tr>
</tbody>
</table>

### Contraindications to Spinal/Epidural Anesthesia

- **absolute contraindications**
  - lack of resuscitative drugs/equipment
  - patient refusal
  - allergy to local anesthetic
  - infection at puncture site or underlying tissues
  - coagulopathies/bleeding diathesis
  - raised ICP
  - sepsis/bacteremia
  - severe hypovolemia
  - cardiac lesion with fixed output states (severe mitral/aortic stenosis)
  - lack of IV access
- **relative contraindications**
  - pre-existing neurological disease (demyelinating lesions)
  - previous spinal surgery, severe spinal deformity
  - prolonged surgery
  - major blood loss or maneuvers that can compromise reaction
Peripheral Nerve Blocks
- deposition of LA around the target nerve or plexus
- ultrasound guidance and peripheral nerve stimulation (needle will stimulate target nerve/plexus) may be used to guide needle to target nerve while avoiding neural trauma or intraneural injection
- most major nerves or nerve plexi can be targeted (brachial plexus block, femoral nerve block, sciatic nerve block, etc.)
- performed with standard monitors
- approximately 2-4 per 10,000 risk of late neurologic injury
- resuscitation equipment must be available

Contraindications to Peripheral Nerve Blockade
- absolute contraindications
  - allergy to LA
  - patient refusal
- relative contraindications
  - certain types of pre-existing neurological dysfunction (e.g. ALS, MS, diabetic neuropathy)
  - local infection at block site
  - bleeding disorder

Local Anesthesia
Local Anesthetic Agents
- see Table 14, for list of LA agents

Definition and Mode of Action
- LA are drugs that block the generation and propagation of impulses in excitable tissues: nerves, skeletal muscle, cardiac muscle, brain
- LA bind to receptors on the cytosolic side of the Na⁺ channel, inhibiting Na⁺ flux and thus blocking impulse conduction
- different types of nerve fibres undergo blockade at different rates

Absorption, Distribution, Metabolism
- LA readily crosses the blood-brain barrier (BBB) once absorbed into the bloodstream
- ester-type LA (procaine, tetracaine) are broken down by plasma and hepatic esterases; metabolites excreted via kidneys
- amide-type LA (lidocaine, bupivacaine) are broken down by hepatic mixed-function oxidases (P450 system); metabolites excreted via kidneys

Selection of LA
- choice of LA depends on
  - onset of action: influenced by pKa (the lower the pKa, the higher the concentration of the base form of the LA, and the faster the onset of action)
  - duration of desired effects: influenced by protein binding (longer duration of action when protein binding of LA is strong)
  - potency: influenced by lipid solubility (agents with high lipid solubility penetrate the nerve membrane more easily)
  - unique needs (e.g. sensory blockade with relative preservation of motor function by bupivacaine at low doses)
  - potential for toxicity

Table 14. Local Anesthetic Agents

<table>
<thead>
<tr>
<th>Anesthetic Agent</th>
<th>Maximum Dose with Epinephrine</th>
<th>Potency</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>chloroprocaine</td>
<td>11 mg/kg 14 mg/kg</td>
<td>Low</td>
<td>15-30 min</td>
</tr>
<tr>
<td>lidocaine</td>
<td>5 mg/kg 7 mg/kg</td>
<td>Medium</td>
<td>1-2 h</td>
</tr>
<tr>
<td>bupivacaine</td>
<td>2.5 mg/kg 3 mg/kg</td>
<td>High</td>
<td>3-8 h</td>
</tr>
<tr>
<td>ropivacaine</td>
<td>2.5 mg/kg 3 mg/kg</td>
<td>High</td>
<td>2-8 h</td>
</tr>
</tbody>
</table>
**Systemic Toxicity**

- see Table 16, A25 for maximum doses, potency, and duration of action for common LA agents
- occurs by accidental intravascular injection, LA overdose, or unexpectedly rapid absorption

**CNS Effects**
- CNS effects first appear to be excitatory due to initial block of inhibitory fibres, then subsequent block of excitatory fibres
- effects in order of appearance
  - numbness of tongue, perioral tingling, metallic taste
  - disorientation, drowsiness
  - tinnitus
  - visual disturbances
  - muscle twitching, tremors
  - unconsciousness
  - convulsions, seizures
  - generalized CNS depression, coma, respiratory arrest

**CVS Effects**
- vasodilation, hypotension
- decreased myocardial contractility
- dose-dependent delay in cardiac impulse transmission
  - prolonged PR, QRS intervals
  - sinus bradycardia
- CVS collapse

**Treatment of Systemic Toxicity**
- early recognition of signs, get help
- 100% O₂, manage ABCs
- diazepam or sodium thiopental may be used to increase seizure threshold
- manage arrhythmias (see ACLS Guidelines, A31-32)
- Intralipid ²⁰% to bind local anesthetic in circulation

**Local Infiltration and Hematoma Blocks**

**Local Infiltration**
- injection of tissue with LA, producing a lack of sensation in the infiltrated area due to LA acting on nerves
- suitable for small incisions, suturing, excising small lesions
- can use fairly large volumes of dilute LA to infiltrate a large area
- low concentrations of epinephrine (1:100,000-1:200,000) cause vasoconstriction, thus reducing bleeding and prolonging the effects of LA by reducing systemic absorption

**Fracture Hematoma Block**
- special type of local infiltration for pain control during manipulation of certain fractures
- hematoma created by fracture is infiltrated with LA to anesthetize surrounding tissues
- sensory blockade may only be partial
- no muscle relaxation

**Topical Anesthetics**
- various preparations of local anesthetics available for topical use, may be a mixture of agents (EMLA cream is a combination of 2.5% lidocaine and prilocaine)
- must be able to penetrate the skin or mucous membrane

**Post-Operative Care**
- pain management should be continuous from OR to post-anesthetic care unit (PACU) to hospital ward and home

**Common Post-Operative Anesthetic Complications**

**Nausea and Vomiting**
- hypotension and bradycardia must be ruled out
- pain and surgical manipulation also cause nausea
- often treated with dimenhydrinate (Gravolᵀᴹ), metoclopramide (Maxeranᵀᴹ; not with bowel obstruction), prochlorperazine (Stemetilᵀᴹ), ondansetron (Zofranᵀᴹ), granisetron (Kytrilᵀᴹ)
Confusion and Agitation
• ABCs first – confusion or agitation can be caused by airway obstruction, hypercapnea, hypoxemia
• neurologic status (Glasgow Coma Scale, pupils), residual paralysis from anesthetic
• pain, distended bowel/bladder
• fear/anxiety/separation from caregivers, language barriers
• metabolic disturbance (hypoglycemia, hypercalcaemia, hyponatremia – especially post-TURP)
• intracranial cause (stroke, raised intracranial pressure)
• drug effect (ketamine, anticholinergics, serotonin)
• elderly patients are more susceptible to post-operative delirium

Respiratory Complications
• susceptible to aspiration of gastric contents due to PONV and unreliable airway reflexes
• airway obstruction (secondary to reduced muscle tone from residual anesthetic, soft tissue trauma and edema, or pooled secretions) may lead to inadequate ventilation, hypercapnea, and hypoxemia
• airway obstruction can often be relieved with head tilt, jaw elevation, and anterior displacement of the mandible. If the obstruction is not reversible, a nasal or oral airway may be used

Hypotension
• must be identified and treated quickly to prevent inadequate perfusion and ischemic damage
• reduced cardiac output (hypovolemia, most common cause) and/or peripheral vasodilation (residual anesthetic agent)
• first step in treatment is usually the administration of fluids ± inotropic agents

Hypertension
• pain, hypercapnia, hypoxemia, increased intravascular fluid volume, and sympathomimetic drugs can cause hypertension
• sodium nitroprusside or β-blocking drugs (e.g. esmolol and metoprolol) can be used to treat hypertension

Pain Management

Definitions
• pain: perception of noiception, which occurs in the brain
• noiception: detection, transduction, and transmission of noxious stimuli

Pain Classifications
• temporal: acute vs. chronic
• mechanism: noiceptive vs. neuropathic

Acute Pain
• pain of short duration (<6 wk) usually associated with surgery, trauma, or acute illness; often associated with inflammation
• usually limited to the area of damage/trauma and resolves with healing
Pharmacological Management of Acute Pain
- ask the patient to rate the pain out of 10, or use visual analog scale, to determine severity
- pharmacological treatment guided by WHO analgesia ladder
- patient controlled analgesia (PCA)
  - involves the use of computerized pumps that can deliver a constant infusion and bolus breakthrough doses of parenterally-administered opioid analgesics
  - limited by lockout intervals
  - most commonly used agents: morphine and hydromorphone
  - see Table 17, A26 for suggested infusion rate, PCA dose and lockout intervals

Table 15. Commonly Used Analgesics

<table>
<thead>
<tr>
<th>Acetaminophen</th>
<th>NSAIDs</th>
<th>Opioids</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tylenol&lt;sup&gt;®&lt;/sup&gt;</td>
<td>Aspirin&lt;sup&gt;®&lt;/sup&gt;, ibuprofen, naproxen</td>
<td>Oral: codeine, oxycodeone, morphine, hydromorphone</td>
</tr>
<tr>
<td>Parenteral: morphine, hydromorphone, fentanyl</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>First-line for mild acute pain</th>
<th>Mild-moderate pain</th>
<th>Oral: moderate acute pain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parenteral: moderate-severe acute pain</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mechanism of Action</th>
<th>Indications</th>
<th>Mechanism of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unclear, hypothesized cyclooxygenase-2 (COX-2) inhibition</td>
<td>Unclear, hypothesized modulation of endogenous cannabinoid system</td>
<td>Non-selective COX-1 and 2 inhibition reducing proinflammatory prostaglandin synthesis</td>
</tr>
<tr>
<td>Dampens nociceptive transmission between 1st and 2nd order neurons in the dorsal horn</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Activates ascending modulatory pathways resulting in release of inhibitory neurotransmitters</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inhibits peripheral inflammatory response and hyperalgesia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Affects mood and anxiety – alleviates the affective component of perceived pain</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dosing/ Administration</th>
<th>Side Effects/ Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Limited by analgesic ceiling beyond which there is no additional analgesia</td>
<td>Considered relatively safe Liver toxicity in elevated doses</td>
</tr>
<tr>
<td>Opioid-sparing</td>
<td>Gastric ulceration/bleeding</td>
</tr>
<tr>
<td>Max dose of 4 g/24 h</td>
<td>Decreased renal perfusion</td>
</tr>
<tr>
<td>Significant inter-individual variation in efficacy</td>
<td>Photosensitivity</td>
</tr>
<tr>
<td>No analgesic ceiling (except for codeine)</td>
<td>Premature closure of the ductus arteriosus in pregnancy</td>
</tr>
<tr>
<td>Can be administered intrathecally (spinal block) or by continuous infusion</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Advantages of PCA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improved patient satisfaction</td>
</tr>
<tr>
<td>Fewer side effects</td>
</tr>
<tr>
<td>Accommodates patient variability</td>
</tr>
<tr>
<td>Accommodates changes in opioid requirements</td>
</tr>
</tbody>
</table>

Table 16. Opioids

<table>
<thead>
<tr>
<th>Agent</th>
<th>Relative Dose to 10 mg Morphine IV</th>
<th>Moderate Dose</th>
<th>Onset</th>
<th>Duration</th>
<th>Special Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine</td>
<td>200 mg PO</td>
<td>15-30 mg PO</td>
<td>Late (30-60 min)</td>
<td>Moderate (4-6 h)</td>
<td>Primarily post-operative use, not for IV use</td>
</tr>
<tr>
<td>Meperidine (Demerol&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>75 mg IV</td>
<td>2-3 mg/kg IV</td>
<td>Moderate (10 min)</td>
<td>Moderate (2-4 h)</td>
<td>Anticholinergic, hallucinations, less pupillary constriction than morphine, metabolite build up may cause seizures</td>
</tr>
<tr>
<td>Morphine</td>
<td>10 mg IV</td>
<td>0.2-0.3 mg/kg IV</td>
<td>Moderate (5-10 min)</td>
<td>Moderate (4-5 h)</td>
<td>Histamine release leading to decrease in BP</td>
</tr>
<tr>
<td></td>
<td>20 mg PO</td>
<td>0.4-0.6 mg/kg IV</td>
<td>PO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxycodone Controlled Release (Oxynorm®)</td>
<td>15 mg PO</td>
<td>10-20 mg PO (no IV)</td>
<td>Late (30-45 min)</td>
<td>Long (8-12 h)</td>
<td>Do not split, crush, or chew tablet</td>
</tr>
<tr>
<td>Oxycodone Regular Tablet (Oxy IR®)</td>
<td>15 mg PO (no IV)</td>
<td>5-15 mg PO</td>
<td>Moderate (15 min)</td>
<td>Moderate (3-6 h)</td>
<td>Percocet® = oxycodone 5 mg + acetaminophen 325 mg</td>
</tr>
<tr>
<td>Hydrocodone (Dilaudid&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>2 mg IV</td>
<td>40-60 µg/kg IV</td>
<td>Moderate (15 min)</td>
<td>Moderate (4-5 h)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10 mg PO</td>
<td>2-4 mg PO</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fentanyl</td>
<td>100 µg IV</td>
<td>2-3 µg/kg IV</td>
<td>Rapid (&lt;5 min)</td>
<td>Short (0.5-1 h)</td>
<td>Transient muscle rigidity in very high doses</td>
</tr>
<tr>
<td>Remifentanil</td>
<td>100 µg IV</td>
<td>0.5-1.5 µg/kg IV</td>
<td>Rapid (1-3 min)</td>
<td>Ultra short (&lt;10 min)</td>
<td>Only use during induction and maintenance of anesthesia</td>
</tr>
</tbody>
</table>

In general, parenteral route is 2.5x more potent than oral
Table 17. Opioid PCA Doses

<table>
<thead>
<tr>
<th>Agent</th>
<th>PCA Dose</th>
<th>PCA Lockout Interval</th>
<th>PCA 4 h Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine</td>
<td>1 mg</td>
<td>5 min</td>
<td>30 mg</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>0.2 mg</td>
<td>5 min</td>
<td>6 mg</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>25-50 µg</td>
<td>5 min</td>
<td>400 µg</td>
</tr>
</tbody>
</table>

Opioid Antagonists (naloxone, naltrexone)
- indication: opioid overdose (manifests primarily at CNS, e.g. respiratory depression)
- mechanism of action: competitively inhibit opioid receptors, predominantly µ receptors
  - naloxone is short-acting (t_{1/2} = 1 h); effects of narcotic may return when naloxone wears off; therefore, the patient must be observed closely following its administration
  - naltrexone is longer-acting (t_{1/2} = 10 h); less likely to see return of opioid effects
- side effects: relative overdose of naloxone may cause nausea, agitation, sweating, tachycardia, hypertension, re-emergence of pain, pulmonary edema, seizures (essentially opioid withdrawal)

Neuropathic Pain
- see Neurology, N41

Chronic Pain
- chronic pain: greater than 3 mo, or recurrent pain that occurs at least 3 times throughout three month period
- pain of duration or intensity that persists beyond normal tissue healing and adversely affects functioning
- may have nociceptive and neuropathic components; dysregulation of analgesic pathways implicated
- in the perioperative period, consider continuing regular long-acting analgesics and augmenting with regional techniques, adjuvants, additional opioid analgesia and non-pharmacological techniques

Obstetrical Anesthesia

Anesthesia Considerations in Pregnancy
- airway
  - possible difficult airway as tissues becomes edematous and friable especially in labour
- respiratory
  - decreased FRC and increased O₂ consumption cause more rapid desaturation during apnea
- cardiovascular system
  - increased blood volume > increased RBC mass results in mild anemia
  - decreased SVR proportionately greater than increased CO results in decreased BP
- prone to decreased BP due to aorticaval compression – therefore for surgery, a pregnant patient is positioned in left uterine displacement using a wedge under her right flank
- central nervous system
  - decreased MAC due to hormonal effects
  - increased block height due to engorged epidural veins
- gastrointestinal system
  - delayed gastric emptying
  - increased volume and acidity of gastric fluid
  - decreased LES tone
  - increased abdominal pressure
- combined, these lead to an increased risk of aspiration – therefore for surgery, a pregnant patient is given sodium citrate 30 cc PO immediately before surgery to neutralize gastric acidity

Options for Analgesia during Labour
- psychoprophylaxis – Lamaze method
  - patterns of breathing and focused attention on fixed object
- systemic medication
  - easy to administer, but risk of maternal or neonatal respiratory depression
  - opioids most commonly used if delivery is not expected within 4 h
- inhalational analgesia
  - easy to administer, makes uterine contractions more tolerable, but does not relieve pain completely
  - 50% nitrous oxide
- neuraxial anesthesia
  - provides excellent analgesia with minimal depressant effects
  - hypotension is the most common complication
  - maternal BP monitored q2-5 min for 15-20 min after initiation and regularly thereafter
  - epidural usually given as it preferentially blocks sensation, leaving motor function intact

Nociceptive Pathways in Labour and Delivery

Labour
- Convoluntary dilatation and effacement stimulates visceral nerve fibres entering the spinal cord at T10-L1

Delivery
- Distention of lower vagina and perineum causes somatic nociceptive impulses via the pudendal nerve entering the spinal cord at S2-S4
Options for Caesarean Section
- neuraxial: spinal or epidural
- general: used if contraindications or time precludes regional blockade

Pediatric Anesthesia

Respiratory System
- in comparison to adults, anatomical differences in infants include:
  - large head, short trachea/neck, large tongue, adenoids, and tonsils
  - narrow nasal passages (obligate nasal breathers until 5 mo)
  - narrowest part of airway at the level of the cricoid vs. glottis in adults
  - epiglottis is longer, U shaped and angled at 45º; carina is wider and is at the level of T2 (T4 in adults)
- physiologic differences include
  - faster RR, immature respiratory centres which are depressed by hypoxia/hypercapnea (airway closure occurs in the neonate at the end of expiration)
  - less oxygen reserve during apnea – decreased total lung volume, vital and functional reserve capacity together with higher metabolic needs
  - greater V/Q mismatch – lower lung compliance due to immature alveoli (mature at 8 yr)
  - greater work of breathing – greater chest wall compliance, weaker intercostals/diaphragm, and higher resistance to airflow

Cardiovascular System
- blood volume at birth is approximately 80 mL/kg; transfusion should be started if >10% of blood volume lost
- children have a high HR and low BP
- CO is dependent on HR, not stroke volume because of low heart wall compliance; therefore, bradycardia severe compromise in CO

Temperature Regulation
- vulnerable to hypothermia
- minimize heat loss by use of warming blankets, covering the infant’s head, humidification of inspired gases, and warming of infused solutions

Central Nervous System
- MAC of halothane is increased compared to the adult (0.75% adult, 1.2% infant, 0.87% neonate)
- NMJ is immature for the first 4 wk of life and thus there is an increased sensitivity to non-depolarizing relaxants
- parasympathetics mature at birth, sympathetics mature at 4-6 mo thus autonomic imbalance
- infant brain is 12% of body weight and receives 34% of CO (adult: 2% body weight and 14% CO)

Glucose Maintenance
- infants less than 1 yr old can become seriously hypoglycemic during pre-operative fasting and post-operatively if feeding is not recommenced as soon as possible
- after 1 yr, children are able to maintain normal glucose homeostasis in excess of 8 h

Pharmacology
- higher dose requirements because of higher TBW (75% vs. 60% in adults) and greater volume of distribution
- barbiturates/opioids more potent due to greater permeability of BBB
- muscle relaxants
  - non-depolarizing
    - immature NMJ, variable response
  - depolarizing
    - must pre-treat with atropine or may experience profound bradycardia and/or sinus node arrest due to PNS > SNS (also dries oral secretions)
    - more susceptible to arrhythmias, hyperkalemia, rhabdomyolysis, myoglobinemia, masseter spasm and malignant hyperthermia
Uncommon Complications

Malignant Hyperthermia

- hypermetabolic disorder of skeletal muscle
- due to an uncontrolled increase in intracellular Ca\(^{2+}\) (because of an anomaly of the ryanodine receptor which regulates Ca\(^{2+}\) channel in the sarcoplasmic reticulum of skeletal muscle)
- autosomal dominant inheritance
- incidence of 1-5 in 100,000, may be associated with skeletal muscle abnormalities such as dystrophy or myopathy
- anesthetic drugs triggering MH include
  - all inhalational agents except nitrous oxide
  - depolarizing muscle relaxants: SCh

Clinical Picture

- onset: immediate or hours after contact with trigger agent
  - increased oxygen consumption
  - increased $ET_{CO_2}$ on capnograph
  - tachycardia/dysrhythmia
  - tachypnea/cyanosis
  - diaphoresis
  - hypertension
  - increased temperature (late sign)
- muscular symptoms
  - trismus (masseter spasm) common but not specific for MH (occurs in 1% of children given SCh with halothane anesthesia)
  - tender, swollen muscles due to rhabdomyolysis
  - trunk or total body rigidity

Complications

- coma
- DIC
- rhabdomyolysis
- myoglobinuric renal failure/hepatic dysfunction
- electrolyte abnormalities (e.g. hyperkalemia) and secondary arrhythmias
- ARDS
- pulmonary edema
- can be fatal if untreated

Prevention

- suspect MH in patients with a family history of problems/death with anesthetic
- avoid all trigger medications, use vapour free equipment, use regional anesthesia if possible
- central body temp and $ET_{CO_2}$ monitoring

Malignant Hyperthermia Management (Based on Malignant Hyperthermia Association of the U.S. [MHAUS] Guidelines, 2008)

1. notify surgeon, discontinue volatile agents and succinylcholine, hyperventilate with 100% oxygen at flows of 10 L/min or more, halt the procedure as soon as possible
2. dantrolene 2.5 mg/kg IV, through large-bore IV if possible
   - repeat until there is control of signs of MH; up to 30 mg/kg as necessary
3. bicarbonate 1-2 mEq/kg if blood gas values are not available for metabolic acidosis
4. cool patients with core temperature >39°C
   - lavage open body cavities, stomach, bladder, rectum; apply ice to surface; infuse cold saline IV
   - stop cooling if temperature is <36°C to prevent drift to <36°C
5. dysrhythmias usually respond to treatment of acidosis and hyperkalemia
   - use standard drug therapy except Ca\(^{2+}\) channel blockers as they may cause hyperkalemia and cardiac arrest in presence of dantrolene
6. hyperkalemia
   - treat with hyperventilation, bicarbonate, glucose/insulin, calcium
   - bicarbonate 1-2 mEq/kg IV, calcium chloride 10 mg/kg or calcium gluconate 10-50 mg/kg for life-threatening hyperkalemia and check glucose levels hourly
7. follow $ET_{CO_2}$, electrolytes, blood gases, creatine kinase (CK), core temperature, urine output/color with Foley catheter, coagulation studies
   - if CK and/or potassium rises persistently or urine output falls to <0.5 mL/kg/h, induce diuresis to >1 mL/kg/h urine to avoid myoglobinuric renal failure
8. maintain anesthesia with benzodiazepines, opioids, and propofol
9. transfer to ICU bed

Signs of Malignant Hyperthermia

- Unexplained rise in $ET_{CO_2}$
- Increase in minute ventilation
- Tachycardia
- Rigidity
- Hyperthermia (late sign)

Basic Principles of MH Management

“Some Hot Dude Better Get Iced Fluids Fast”

- Stop all triggering agents, give 100% O\(_2\)
- Hyperventilate
- Dantrolene 2.5 mg/kg every 5 min
- Bicarbonate
- Glucose and insulin
- IV fluids; cool patient to 38°C
- Fluid output; consider furosemide
- Tachycardia: be prepared to treat VT
**Abnormal Pseudocholinesterase**

- pseudocholinesterase hydrolyzes SCh and mivacurium
- individuals with abnormal pseudocholinesterase will have prolonged muscular blockade
- SCh and mivacurium are contraindicated in those with abnormal pseudocholinesterase
- if SCh or mivacurium are given accidentally, treat with mechanical ventilation until function returns to normal (do not use cholinesterase inhibitors rebound neuromuscular blockade once drug effect is terminated)

---

**Appendices**

**Difficult Tracheal Intubation in Unconscious Patient**

---

**Figure 14. Difficult tracheal intubation encountered in the unconscious patient**

*SGD = supraglottic device*

Difficult Tracheal Intubation

Airway exam or history predicts **difficult tracheal intubation**

If general anesthesia is induced . . .

1. Is tracheal intubation predicted to success in no more than 3 attempts?
2. If tracheal intubation fails, will face mask or SGD ventilation succeed?

. . . and are other patient and contextual issues favourable?

1. Rapid oxygen desaturation unlikely with onset of apnea?
2. Little risk of aspiration once unconscious?
3. No obstructing airway pathology?
4. Additional skilled help available?
5. Clinician skilled in planned technique(s) and equipment available?

Low risk of failed oxygenation if induced

Consider intubation after induction of general anesthesia

• e.g. IV induction (e.g. RSI)
• e.g. inhalational induction

Significant risk of failed oxygenation if induced

Is awake intubation feasible?

• Patient can cooperate
• Situation acuity permits

Consider awake intubation/techniques

• e.g. awake oral/nasal
• e.g. awake tracheotomy

Other options

• e.g. induction with "double set-up" preparation for immediate cricothyrotomy or tracheotomy

---

Figure 15. Anticipated difficult tracheal intubation

IV = intravenous; RSI = rapid sequence induction/intubation; SGD = supraglottic device

Figure 16. Adult cardiac arrest algorithm
Adult Bradycardia
(With Pulse)

1. Assess appropriateness for clinical condition
   Heart rate typically <50/min if bradyarrhythmia

2. Identify and treat underlying cause
   • Maintain patent airway; assist breathing as necessary
   • Oxygen (if hypoxemic)
   • Cardiac monitor to identify rhythm; monitor blood pressure and oximetry
   • IV access
   • 12-Lead ECG if available; do not delay therapy

3. Persistent bradyarrhythmia causing:
   • Hypotension?
   • Acutely altered mental status?
   • Signs of shock?
   • Ischemic chest discomfort?
   • Acute heart failure?

4. Monitor and observe

5. Yes
   Atropine
   If atropine ineffective:
   • Transcutaneous pacing
     OR
   • Dopamine infusion
     OR
   • Epinephrine infusion

6. Consider:
   • Expert consultation
   • Transvenous pacing

Doses/Details
Atropine IV Dose:
First dose: 0.5 mg bolus
Repeat every 3-5 min
Maximum: 3 mg

Dopamine IV Infusion:
2-10 mcg/kg per min

Epinephrine IV Infusion:
2-10 mcg per min

Figure 17. Adult tachycardia algorithm
**Adult Tachycardia**

(With Pulse)

1. Assess appropriateness for clinical condition
   - Heart rate typically ≥150/min if tachyarrhythmia

2. Identify and treat underlying cause
   - Maintain patent airway; assist breathing as necessary
   - Oxygen (if hypoxic)
   - Cardiac monitor to identify rhythm; monitor blood pressure and oximetry

3. Persistent tachyarrhythmia causing:
   - Hypotension?
   - Acutely altered mental status?
   - Signs of shock?
   - Ischemic chest discomfort?
   - Acute heart failure?

4. Synchronized cardioversion
   - Consider sedation
   - If regular narrow complex, consider adenosine

5. Wide QRS? ≥0.12 second
   - Yes
   - IV access and 12-lead ECG if available
   - Consider adenosine only if regular and monomorphic
   - Consider antiarrhythmic infusion
   - Consider expert consultation
   - No

6. No

Doses/Details

**Synchronized Cardioversion**
- Initial recommended doses:
  - Narrow regular: 50-100 J
  - Narrow irregular: 120-200 J biphasic or 200 J monophasic
  - Wide regular: 100 J
  - Wide regular: defibrillation dose (NOT synchronized)

**Adenosine IV Dose**:
- First dose: 6 mg rapid IV push; follow with NS flush
- Second dose: 12 mg if required

**Antiarrhythmic Infusions for Stable Wide-QRS Tachycardia**

**Procainamide IV Dose**:
- 20-50 mg/min until arrhythmia suppressed, hypotension ensues, QRS duration increases >50%, or maximum dose 17 mg/kg given
- Maintenance infusion: 1-4 mg/min
- Avoid if prolonged QT or CHF

**Amiodarone IV Dose**:
- First dose: 150 mg over 10 min
- Repeat as needed if VT recurs
- Follow by maintenance infusion of 1 mg/min for 1st 6 h

**Sotalol IV Dose**:
- 100 mg (1.5 mg/kg) over 5 min
- Avoid if prolonged QT

---

Figure 18. Adult bradycardia algorithm
References


# Cardiology and Cardiac Surgery

**Sean Cai, Shun Chi, Ryan Lo, and Zain Sohail**, chapter editors  
**Claudia Frankfurter and Inna Gong**, associate editors  
**Brittany Prevost and Robert Vanner**, EBM editors  
**Dr. Chi-Ming Chow, Dr. Michael McDonald, and Dr. Anna Woo**, staff editors

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acronyms</td>
<td>2</td>
</tr>
<tr>
<td>Basic Anatomy Review</td>
<td>2</td>
</tr>
<tr>
<td>Coronary Circulation</td>
<td></td>
</tr>
<tr>
<td>Cardiac Anatomy</td>
<td></td>
</tr>
<tr>
<td>Differential Diagnoses of Common Presentations</td>
<td>4</td>
</tr>
<tr>
<td>Chest Pain</td>
<td></td>
</tr>
<tr>
<td>Loss of Consciousness</td>
<td></td>
</tr>
<tr>
<td>Local Edema</td>
<td></td>
</tr>
<tr>
<td>Generalized Edema</td>
<td></td>
</tr>
<tr>
<td>Palpitations</td>
<td></td>
</tr>
<tr>
<td>Dyspnea</td>
<td></td>
</tr>
<tr>
<td>Cardiac Diagnostic Tests</td>
<td>5</td>
</tr>
<tr>
<td>Electrocardiography Basics</td>
<td></td>
</tr>
<tr>
<td>Approach to ECGs</td>
<td>6</td>
</tr>
<tr>
<td>Classical Approach to ECGs</td>
<td></td>
</tr>
<tr>
<td>Alternative PQRSTU Approach to ECGs</td>
<td></td>
</tr>
<tr>
<td>Cardiac Biomarkers</td>
<td></td>
</tr>
<tr>
<td>Ambulatory ECG</td>
<td></td>
</tr>
<tr>
<td>Echocardiography</td>
<td></td>
</tr>
<tr>
<td>Stress Testing</td>
<td></td>
</tr>
<tr>
<td>Cardiac Catheterization and Angiography</td>
<td></td>
</tr>
<tr>
<td>Coronary Angiography</td>
<td></td>
</tr>
<tr>
<td>Contrast-Enhanced CT Coronary Angiography</td>
<td></td>
</tr>
<tr>
<td>Magnetic Resonance Imaging</td>
<td></td>
</tr>
<tr>
<td>CARDIAC DISEASE</td>
<td></td>
</tr>
<tr>
<td>Arrhythmias</td>
<td>16</td>
</tr>
<tr>
<td>Mechanisms of Arrhythmias</td>
<td></td>
</tr>
<tr>
<td>Bradyarrhythmias</td>
<td></td>
</tr>
<tr>
<td>Supraventricular Tachyarrhythmias</td>
<td></td>
</tr>
<tr>
<td>Pre-Excitation Syndromes</td>
<td></td>
</tr>
<tr>
<td>Ventricular Tachyarrhythmias</td>
<td></td>
</tr>
<tr>
<td>Sudden Cardiac Arrest</td>
<td></td>
</tr>
<tr>
<td>Electrophysiology Studies</td>
<td></td>
</tr>
<tr>
<td>Electrical Pacing</td>
<td></td>
</tr>
<tr>
<td>Implantable Cardioverter Defibrillators</td>
<td></td>
</tr>
<tr>
<td>Catheter Ablation</td>
<td></td>
</tr>
<tr>
<td>Ischemic Heart Disease</td>
<td>25</td>
</tr>
<tr>
<td>Chronic Stable Angina</td>
<td></td>
</tr>
<tr>
<td>Acute Coronary Syndromes</td>
<td></td>
</tr>
<tr>
<td>Treatment Algorithm for Chest Pain</td>
<td></td>
</tr>
<tr>
<td>Coronary Revascularization</td>
<td></td>
</tr>
<tr>
<td>Heart Failure</td>
<td>34</td>
</tr>
<tr>
<td>Congestive Heart Failure</td>
<td></td>
</tr>
<tr>
<td>Sleep-Disordered Breathing</td>
<td></td>
</tr>
<tr>
<td>Cardiac Transplantation</td>
<td>38</td>
</tr>
<tr>
<td>Ventricular Assist Devices</td>
<td></td>
</tr>
<tr>
<td>Myocardial Disease</td>
<td>39</td>
</tr>
<tr>
<td>Myocarditis</td>
<td></td>
</tr>
<tr>
<td>Dilated Cardiomyopathy</td>
<td></td>
</tr>
<tr>
<td>Hypertrophic Cardiomyopathy</td>
<td></td>
</tr>
<tr>
<td>Restrictive Cardiomyopathy</td>
<td></td>
</tr>
<tr>
<td>Valvular Heart Disease</td>
<td>43</td>
</tr>
<tr>
<td>Rheumatic Fever</td>
<td></td>
</tr>
<tr>
<td>Valve Repair and Valve Replacement</td>
<td></td>
</tr>
<tr>
<td>Choice of Valve Prosthesis</td>
<td></td>
</tr>
<tr>
<td>Summary of Valvular Disease</td>
<td></td>
</tr>
<tr>
<td>Pericardial Disease</td>
<td>47</td>
</tr>
<tr>
<td>Acute Pericarditis</td>
<td></td>
</tr>
<tr>
<td>Pericardial Effusion</td>
<td></td>
</tr>
<tr>
<td>Cardiac Tamponade</td>
<td></td>
</tr>
<tr>
<td>Constrictive Pericarditis</td>
<td></td>
</tr>
<tr>
<td>Common Medications</td>
<td>49</td>
</tr>
<tr>
<td>Antiarrhythmics</td>
<td></td>
</tr>
<tr>
<td>Landmark Cardiac Trials</td>
<td>52</td>
</tr>
<tr>
<td>References</td>
<td>55</td>
</tr>
</tbody>
</table>

---

*Toronto Notes 2017*  
*Cardiology C1*
Figure 1. Anatomy of the coronary arteries (right anterior oblique projection)
Cardiac Anatomy

- layers of the heart
  - endocardium, myocardium, epicardium, visceral pericardium, pericardial cavity, parietal pericardium
- valves
  - semilunar valves:
    - aortic valve, 3 valve leaflets: separates LV and ascending aorta
    - pulmonic valve, 3 valve leaflets: separates RV and main pulmonary artery (PA)
  - atrioventricular valves: subvalvular apparatus present in the form of chordae tendinae and papillary muscles
    - tricuspid valve, 3 valve leaflets: separates RA and RV
    - mitral/bicuspid valve, 2 valve leaflets: separates LA and LV
- conduction system
  - SA node governs pacemaking control
  - anterior-, middle-, and posterior-internodal nodal tracts carry impulses in the right atrium and along Bachmann's bundle in the left atrium
  - atrial impulses converge at the AV node
    - the AV node is the only conducting tract from the atria to the ventricles because of electrical isolation by the annulus fibrosis (except when accessory pathways are present)
  - the bundle of His bifurcates into left and right bundle branches (LBB and RBB)
  - LBB further splits into anterior and posterior fascicles
  - RBB and fascicles of LBB give off Purkinje fibres which conduct impulses into the ventricular myocardium

Legend:
- AV – aortic valve
- LA – left atrium
- LV – left ventricle
- MV – mitral valve

Features of Abnormal JVP Wave Formation
- Atrial fibrillation: absent a wave
- 3rd degree heart block: cannon a waves
- Tricuspid regurgitation: cv wave, elevated JVP
- Cardiac tamponade: x descent only, absent y descent
- Constrictive pericarditis: prominent y descent, Kussmaul's sign (paradoxical increase in JVP with inspiration)
• cardiovascular innervation
  ■ sympathetic nerves
    • innervate the SA node, AV node, ventricular myocardium and vasculature
    • SA node (β1 fibres increase pacemaking activity (chronotropy - HR)
    • cardiac muscle (β1 fibres increase contractility (inotropy - SV)
    • stimulation of β1- and β2-receptors in the skeletal and coronary circulation causes vasodilatation
  ■ parasympathetic nerves
    • innervate the SA node, AV node, atrial myocardium but few vascular beds
    • basal vagal tone dominates the tonic sympathetic stimulation of the SA node and AV node
      resulting in slowing of pacemaker activity and conduction (i.e. reduced dromotropy – if only affecting AV node conduction)
    • parasympathetics have very little impact on total peripheral vascular resistance

---

**Differential Diagnoses of Common Presentations**

Note: **bold** text indicates most common, **underlined** text indicates life threatening condition

---

### Chest Pain

- cardiac
  - MI/angina, myocarditis, pericarditis/Dressler's syndrome
- pulmonary
  - PE, pneumothorax/hemothorax, tension pneumothorax, pneumonia, empyema, pulmonary neoplasm, bronchiectasis, TB
- gastrointestinal
  - esophageal: GERD, esophageal rupture, spasm, esophagitis, ulceration, achalasia, neoplasm, Mallory-Weiss syndrome
  - other structures: PUD, gastritis, pancreatitis, biliary colic
- mediastinal
  - lymphoma, thymoma
- vascular
  - dissecting aortic aneurysm, aortic rupture
- surface structures
- costochondritis
- rib fracture
- skin (bruising, herpes zoster)
- breast
- anxiety/psychosomatic

### Loss of Consciousness

- hypovolemia
- vasovagal
- cardiac
  - structural or obstructive causes
    - ACS, AS, HCM, cardiac tamponade, constrictive pericarditis
  - arrhythmias (*see Arrhythmias, C16*)
- respiratory
  - massive pulmonary embolism, pulmonary hypertension, hypoxia, hypercapnia
- neurologic
  - stroke/TIA (esp. vertebrobasilar insufficiency), migraine, seizure
- metabolic
  - anemia, hypoglycemia
- drugs
  - antihypertensives, antiarrhythmics, diuretics
- autonomic dysfunction
- diabetic neuropathy
- psychiatric
  - panic attack

### Local Edema

- inflammation/infection
- venous or lymphatic obstruction
  - thrombophlebitis/deep vein thrombosis, venous insufficiency, chronic lymphangitis, lymphatic tumour infiltration, filariasis
Generalized Edema

- increased hydrostatic pressure/fluid overload
  - heart failure, pregnancy, drugs (e.g. CCBs), iatrogenic (e.g. IV fluids)
- decreased oncotic pressure/hypoalbuminemia
  - liver cirrhosis, nephrotic syndrome, malnutrition
- increased capillary permeability
  - severe sepsis
- hormonal
  - hypothyroidism, exogenous steroids, pregnancy, estrogens

Palpitations

- cardiac
  - arrhythmias (PAC, PVC, SVT, VT), valvular heart disease, HCM
- endocrine
  - thyrotoxicosis, pheochromocytoma, hypoglycemia
- systemic
  - anemia, fever
- drugs
  - stimulants and anticholinergics
- psychiatric
  - panic attack

Dyspnea

- cardiovascular
  - acute MI, CHF/LV failure, aortic/mitral stenosis, aortic/mitral regurgitation, arrhythmia, cardiac tamponade, constrictive pericarditis, left-sided obstructive lesions (e.g. left atrial myxoma), elevated pulmonary venous pressure
- respiratory
  - airway disease
    - asthma, COPD exacerbation, upper airway obstruction (anaphylaxis, foreign body, mucus plugging)
  - parenchymal lung disease
    - ARDS, pneumonia, interstitial lung disease
  - pulmonary vascular disease
    - PE, pulmonary HTN, pulmonary vasculitis
  - pleural disease
    - pneumothorax, pleural effusion
- neuromuscular and chest wall disorders
  - C-spine injury
    - polymyositis, myasthenia gravis, Guillain-Barré syndrome, kyphoscoliosis
- anxiety/psychosomatic
- hematological/metabolic
  - anemia, acidosis, hypercapnia

Cardiac Diagnostic Tests

Electrocardiography Basics

Description

- a graphical representation (time versus amplitude of electrical vector projection) of the electrical activity of the heart
- on the ECG graph
  - the horizontal axis represents time (at usual paper speed 25 mm/s)
    - 1 mm (1 small square) = 40 msec
    - 5 mm (1 large square) = 200 msec
  - the vertical axis represents voltage (at usual standard gain setting 10 mm/mV)
    - 1 mm (1 small square) = 0.1 mV
    - 10 mm (2 large squares) = 1 mV
- leads
  - standard 12-lead ECG
    - limb leads: I, II, III, aVL, aVR, aVF
    - precordial leads: V1-V6 (V1-V2 septal, V3-V4 anterior, V5-V6 lateral)
  - additional leads
    - right-sided leads: V3R-V6R (useful in RV infarction and dextrocardia)
  - lateral = I, aVL, V5, V6; inferior = II, III, aVF; anterior = V1-V4
Approach to ECGs

Indications
- detect myocardial injury, ischemia, and the presence of prior infarction
- palpitations, syncope, antiarrhythmic drug monitoring
- arrhythmia surveillance in patients with documented or potentially abnormal rhythms
- surveillance of non-sustained arrhythmias that can lead to prophylactic intervention

Contraindications
- no absolute contraindications except patient refusal or electrode latex adhesive allergy

Approach to ECGs

Introduction
Below, we are presenting both the Classical Approach and the newer PQRSTU Approach to provide students with different ways to view the ECG. Despite methodological differences, the rigor and final result is the same. These two approaches should help you better understand the concepts of ECG interpretation and equip you with the necessary skills to interpret ECGs in exam scenarios and clinical practice.

Classical Approach to ECGs

RATE
- normal = 60-100 bpm (atrial rate: 150-250 bpm = paroxysmal tachycardia, 250-350 bpm = atrial flutter, >350 bpm = AFib)
- regular rhythm
  - to calculate the rate, divide 300 by number of large squares between 2 QRS complexes (there are 300 large squares in 1 min: 300 x 200 msec = 60 sec)
  - or remember 300-150-100-75-60-50-43 (rate falls in this sequence with the number of large squares between 2 QRS complexes)
- irregular rhythm
  - rate = 6 x number of R-R intervals in 10 s (the “rhythm strips” are 10 sec recordings)
  - atrial escape rhythm = 60-80 bpm; junctional escape rhythm = 40-60 bpm;
  - ventricular escape rhythm = 20-40 bpm

RHYTHM
- regular: R-R interval is the same across the tracing
- irregular: R-R interval varies across the tracing
- regularly irregular: repeating pattern of varying R-R intervals e.g. A. Flutter
- irregularly irregular: R-R intervals vary erratically e.g. A. Fib, V. Fib
- normal sinus rhythm (NSR)
  - P wave precedes each QRS; QRS follows each P wave
  - P wave axis is normal (positive in 2 out of the 3 following leads I, II, aVF)
  - rate between 60-100 bpm

AXIS
- mean axis indicates the direction of the mean vector
- can be determined for any waveform (P, QRS, T)
- the standard ECG reported QRS axis usually refers to the mean axis of the frontal plane – it indicates the mean direction of ventricular depolarization forces
- QRS axis in the frontal plane
  - normal axis: -30° to 90° (i.e. positive QRS in leads I and II)
  - left axis deviation (LAD): axis < -30°
  - right axis deviation (RAD): axis > 90°
- QRS axis in the horizontal plane is not routinely calculated
  - transition from negative to positive is usually in lead V3

Differential Diagnosis for Left Axis Deviation (LAD)
- Left anterior hemiblock
- Inferior MI
- WPW
- RV pacing
- Normal variant
- Elevated diaphragm
- Lead displacement
- Endocardial cushion defect

Differential Diagnosis for Right Axis Deviation (RAD)
- RVH
- Left posterior hemiblock
- Pulmonary embolism
- COPD
- Lateral MI
- WPW
- Dextrocardia
- Septal defects
Table 1. Conduction Abnormalities

<table>
<thead>
<tr>
<th>Left Bundle Branch Block (LBBB)</th>
<th>Right Bundle Branch Block (RBBB)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Complete LBBB</strong></td>
<td><strong>Complete RBBB</strong></td>
</tr>
<tr>
<td>QRS duration &gt; 120 msec</td>
<td>QRS duration &gt; 120 msec</td>
</tr>
<tr>
<td>Broad notched R waves in leads V4, V5, and usually I, aVL</td>
<td>Positive QRS in lead V1 (rSR’ or occasionally broad R wave)</td>
</tr>
<tr>
<td>Deep broad S waves in leads V1-2</td>
<td>Broad S waves in leads I, V5-6 (&gt;40 msec)</td>
</tr>
<tr>
<td>Secondary ST-T changes -ve in leads with broad notched R waves, +ve in V1-2 are usually present</td>
<td>Usually secondary T wave inversion in leads V1-2</td>
</tr>
<tr>
<td>LBBB can mask ECG signs of MI</td>
<td>Frontoal axis determination using only the first 60 msec</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Left Anterior Fascicular Block (LAFB) (Left Anterior Hemiblock)</th>
<th>Left Posterior Fascicular Block (LPFB) (Left Posterior Hemiblock)</th>
<th>Bifascicular Block</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Left Axis Deviation (-30° to -90°)</strong></td>
<td><strong>Right Axis Deviation (110° to 180°)</strong></td>
<td></td>
</tr>
<tr>
<td>Small q and prominent R in leads I and aVL</td>
<td>Small r and prominent S in leads I and aVL</td>
<td></td>
</tr>
<tr>
<td>Small r and prominent S in leads II, III, and aVF</td>
<td>Small q and prominent R in leads II, III, and aVF</td>
<td></td>
</tr>
<tr>
<td><strong>Nonspecific Intraventricular Block</strong></td>
<td><strong>Equiphasic Block</strong></td>
<td></td>
</tr>
<tr>
<td>QRS duration &gt;120 msec</td>
<td>QRS duration &gt;120 msec</td>
<td></td>
</tr>
<tr>
<td>absence of definitive criteria for LBBB or RBBB</td>
<td>absence of definitive criteria for LBBB or RBBB</td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Hypertrophy/Chamber Enlargement

<table>
<thead>
<tr>
<th>Left Ventricular Hypertrophy (LVH)</th>
<th>Right Ventricular Hypertrophy (RVH)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S in V1 + R in V5 or V6 &gt;35 mm above age 40, (&gt;40 mm for age 31-40, &gt;45 mm for age 21-30)</td>
<td>Right axis deviation</td>
</tr>
<tr>
<td>R in aVL, &gt;11 mm</td>
<td>R/S ratio &gt; 1 or qR in lead V1</td>
</tr>
<tr>
<td>R in I + S in III &gt;25 mm</td>
<td>RV strain pattern: ST segment depression and T wave inversion</td>
</tr>
<tr>
<td>Additional criteria</td>
<td>in leads V1-2</td>
</tr>
<tr>
<td>LV strain pattern (asymmetric ST depression and T wave inversion in leads I, aVL, V4-V6)</td>
<td></td>
</tr>
<tr>
<td>Left atrial enlargement</td>
<td>Left atrial enlargement</td>
</tr>
<tr>
<td>N.B. The more criteria present, the more likely LVH is present.</td>
<td>N.B. The more criteria present, the more likely RVH is present.</td>
</tr>
<tr>
<td>If only one voltage criteria present, it is called minimal voltage criteria for LVH which could be a normal variant</td>
<td>If only one voltage criteria present, it is called minimal voltage criteria for RVH which could be a normal variant</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Left Atrial Enlargement (LAE)</th>
<th>Right Atrial Enlargement (RAE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biphasic P wave with the negative terminal component of the P wave in lead V1 ≥1 mm wide and ≥1 mm deep</td>
<td>P wave &gt;2.5 mm in height in leads II, III, or aVF (”P pulmonale”)</td>
</tr>
<tr>
<td>P wave &gt;100 msec, could be notched in lead II (“P mitrale”)</td>
<td></td>
</tr>
</tbody>
</table>

**ISCHEMIA/INFARCTION**

- look for the anatomic distribution of the following ECG abnormalities (see Table 3, C8)
  - ischemia
    - ST segment depression
    - T wave inversion (most commonly in V1-V6)
  - injury/infarct
    - transmural (involving the epicardium)
    - ST elevation in the leads facing the area injured/infarcted
    - subendocardial
    - marked ST depression in the leads facing the affected area
    - may be accompanied by enzyme changes and other signs of MI

*Figure 10. Typical ECG changes with infarction*

- ST elevation: at least 1 mm in 2 adjacent limb leads or at least 1-2 mm in adjacent precordial leads in STEMI (signifies complete occlusion and transmural ischemic injury) vs. diffuse pattern in early pericarditis vs. transient ST elevation in patients with coronary artery spasm (e.g. Prinzmetal angina) which can be slight or prominent (>10 mm)
• “typical” sequential changes of evolving MI
  1. hyperacute T waves (tall, symmetric T waves) in the leads facing the infarcted area, with or without ST elevation
  2. ST elevation (injury pattern) in the leads facing the infarcted area
     • usually in the first hours post infarct
     • in acute posterior MI, there is ST depression in V1-V3 (reciprocal to ST elevation in the posterior leads, that are not recorded in the standard 12-lead ECG) - get a 15-lead ECG
  3. significant Q waves: >40 msec or >1/3 of the total QRS and present in at least 2 consecutive leads in the same territory (hours to days post-infarct)
     • Q waves of infarction may appear in the very early stages, with or without ST changes
     • non-Q wave infarction: there may be only ST or T changes despite clinical evidence of infarction
  4. inverted T waves (one day to weeks after infarction)
• completed infarction
  • abnormal Q waves (Q waves may be present in leads III and aVL in normal individuals due to initial septal depolarization)
  • duration >40 msec (>30 msec in aVF for inferior infarction)
  • Q/QRS voltage ratio is >33%
  • present in at least 2 consecutive leads in the same territory
  • abnormal R waves (R/S ratio >1, duration >40 msec) in V1 and occasionally in V2 are found in posterior infarction (usually in association with signs of inferior and/or lateral infarction)

Table 3. Areas of Infarction/Ischemia (right dominant anatomy)

<table>
<thead>
<tr>
<th>Vessel Usually Involved (LAD)</th>
<th>Infarct Area (LAD and LC)</th>
<th>Leads (LAD and LC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left anterior descending (LAD)</td>
<td>Anteroseptal</td>
<td>V1, V2</td>
</tr>
<tr>
<td></td>
<td>Anterior</td>
<td>V3, V4</td>
</tr>
<tr>
<td></td>
<td>Anterolateral</td>
<td>I, aVL, V3-6</td>
</tr>
<tr>
<td></td>
<td>Extensive anterior</td>
<td>I, aVL, V1-6</td>
</tr>
<tr>
<td>Right coronary artery (RCA)</td>
<td>Inferior</td>
<td>II, III, aVF</td>
</tr>
<tr>
<td></td>
<td>Right ventricle</td>
<td>V3R, V4R (right sided chest leads)</td>
</tr>
<tr>
<td></td>
<td>Posterior MI (assoc. with inf. MI)</td>
<td>V1, V2 (prominent R waves)</td>
</tr>
<tr>
<td>Left circumflex (LCX)</td>
<td>Lateral</td>
<td>I, aVL, V5-6</td>
</tr>
<tr>
<td></td>
<td>Isolated posterior MI</td>
<td>V1, V2 (prominent R waves)</td>
</tr>
</tbody>
</table>

**MISCELLANEOUS ECG CHANGES**

**Electrolyte Disturbances**

- **hyperkalemia**
  - mild to moderate (K⁺ >5-7 mmol/L): tall peaked T waves
  - severe (K⁺ >7 mmol/L): progressive changes whereby P waves flatten and disappear, QRS widens and may show bizarre patterns, axis shifts left or right, ST shift with tall T waves, eventually becomes a “sine wave” pattern
- **hypokalemia**
  - ST segment depression, prolonged QT interval, low T waves, prominent U waves (U>T)
  - enhances the toxic effects of digitalis
- **hypercalcemia**
  - shortened QT interval (more extracellular Ca²⁺ means shorter plateau in cardiac action potential)
- **hypocalcemia**
  - prolonged QT interval (less extracellular Ca²⁺ means longer plateau in cardiac action potential)

**Hypothermia**

- sinus bradycardia
- when severe, prolonged QRS and QT intervals
- AFib with slow ventricular response and other atrial/ventricular dysrhythmias
- Osborne J waves: “hump-like” waves at the junction of the J point and the ST segment

**Pericarditis**

- early: diffuse ST segment elevation ± PR segment depression, upright T waves
- later: isoelectric ST segment, flat or inverted T waves
- ± tachycardia
**Drug Effects**

- **digitalis**
  - therapeutic levels may be associated with “digitalis effect”
  - ST downsloping or “scooping”
  - T wave depression or inversion
  - QT shortening ± U waves
  - slowing of ventricular rate in AFib
  - toxic levels associated with
  - arrhythmias: paroxysmal atrial tachycardia (PAT) with conduction block, severe bradycardia in AFib, accelerated junctional rhythms, PVCs, ventricular tachycardia (*see Arrhythmias, C16*)
  - “regularization” of ventricular rate in AFib due to a junctional rhythm and AV dissociation
- amiodarone, quinidine, phenothiazines, tricyclic antidepressants, antipsychotics, some antihistamines, some antibiotics: prolonged QT interval, U waves

**Pulmonary Disorders**

- *cor pulmonale* (often secondary to COPD)
  - low voltage, right axis deviation (RAD), poor R wave progression in precordial leads
  - RAE and RVH with strain
  - multifocal atrial tachycardia (MAT)
- massive pulmonary embolism (PE)
  - sinus tachycardia and A. Fib/atrial flutter are the most common arrhythmias
  - RAD, RVH with strain
  - most specific sign is S1Q3T3 (S in I, Q and inverted T wave in III) but rather uncommon

### Alternative PQRSTU Approach to ECGs

Note: the information seen in this alternative approach – the PQRSTU Approach – is the same as the information in the Classical Approach; it is just organized in a different way based on the anatomy of the ECG
P WAVE
• the P wave represents atrial contraction; best leads: II, VI
  - lead II: the P wave should be rounded, <120 msec and <2.5 mm in height
  - lead VI: the P wave is biphasic with a negative phase slightly greater than the positive phase
• atrial flutter: sawtooth P wave (Hint: flip the ECG upside-down to see it better if unclear)
• atrial fibrillation: absent P wave, may have fibrillatory wave, irregular rhythm
• right atrial enlargement: tall P wave (>2.5 mm) in II or V1 (P pulmonale)
• left atrial enlargement: negative deflection >1 mm deep or >1 mm wide in V1, wide (>100 msec) notched P wave in II may be present (P mitrale)

P-R INTERVAL
• the P-R interval shows the delay between atrial and ventricular contraction that is mediated by the AV node; the magnitude of the delay is referred to as "dromotropy"
• positive dromotropy increases conduction velocity (e.g., epinephrine stimulation), negative dromotropy decreases velocity (e.g., vagal stimulation)
• P-R interval should be 120-200 msec
• long P-R interval (>200 msec)
  - heart block
    • first degree: fixed, prolonged P-R interval
    • second degree Mobitz I/Wenckebach: steadily prolonging P-R interval to eventual dropped beat
    • second degree Mobitz II/Hay: fixed P-R interval with ratio of beat to dropped beat (e.g., for every 3 beats, there is one dropped beat [3:1])
    • third degree/complete: variable P-R intervals, P-P and R-R intervals individually constant but not in sync
  - atrial flutter
  - sinus bradycardia (normal to have long P-R if heart rate slow)
  - hypokalemia
  - "trifascicular" block -1st degree AV block with LAHF and complete RBBB
• short P-R interval (<120 msec)
  - pre-excitation syndrome (delta wave: upswooping of the P-R segment into the QRS complex indicating pre-excitation)
  - accessory pathways
  - WPW
  - low atrial rhythm

QRS COMPLEX
• the QRS is where ventricular contraction is visualized
• rate: check the R-R interval to see if it matches the P-P interval
• amplitude: check for hypertrophy (see Table 2, C7)
• narrow width (<120 msec) QRS means that the His-Purkinje system is being used
• wide width (>120 msec) QRS means that the His-Purkinje system is being bypassed or is diseased
  - BBB, VT, ventricular hypertrophy, cardiomyopathy, WPW, ectopic ventricular beat, hyperkalemia, drugs (e.g., TCAs, antiarrhythmics)
• Q wave: the first downward deflection of the QRS complex
  - significant Q wave: >40 msec or >33% of total QRS amplitude; indicate myocardial necrosis (new or historical)
• R and S wave abnormalities typically show pathology in terms of BBB or intraventricular abnormalities

ST SEGMENT
• located between QRS complex and the beginning of T wave
• corresponds to the completion of ventricular depolarization
• normally at the same level as "baseline/TP segment"
• ST elevation: please see the infarct section above
• ST depression: ischemia
• ischemia which causes ST depression can result in myocardial damage (NSTEMI)
• lateral ST depression (leads I, aVL, V5, V6) may actually indicate a STEMI in the right heart

T WAVE
• this is the repolarization phase of the ventricles (repolarization of the atria are obscured by the QRS complex)
• typically positive (except in aVR and V1) on ECG but normal isolated negative T waves may be present (esp. in V1 and V2)
• pathology when T wave variation occur in consecutive leads
  - inversion: BBB, ischemia, hypertrophy, drugs (e.g., digitalis), pulmonary embolism (lead III as part of S1Q3T3 sign)
  - elevation: infarction (STEMI, Prinzmetal, hyperacute), hyperkalemia (wider, peaked)
  - flattened: hypokalemia, pericarditis, drugs (e.g., digitalis), pericardial effusion
• variations: T wave alters; beat-to-beat variations due to PVC overlap (R on T phenomenon which may precipitate VT or VFib)
• appropriate T wave discordance: in BBB, T wave deflection should be opposite to that of the terminal QRS deflection (i.e., T wave negative if ends with R or R'; positive if ends with S)
• inappropriate T wave concordance suggests ischemia or infarction

Significant ECG Changes
• Look for ST changes starting at 60 msec from J point
• J point = the junction between the QRS complex and the ST segment
• ST elevation: at least 1 mm in 2 adjacent limb leads, or at least 1-2 mm in adjacent precordial leads
• ST depression: downsloping or horizontal
• Q Wave: pathological if Q wave >1 small square (>40 msec) or >33% of the total QRS

Insignificant Q Wave
• Septal depolarization by the left bundle
• Seen in leads I, II, III, aVL, V5, V6
• <40 msec
Q-T INTERVAL
- this represents the duration of ventricular depolarization and repolarization and is often difficult to interpret
- corrected QT (QTc) is often used instead in practice to correct for the repolarization duration; QTc = QT / √RR
- normal QTc is 360-450 msec for males and 360-460 for females
  - increased (>450 msec for males and >460 for females); risk of Torsades de Pointes (a lethal tachyarrhythmia)
  - genetic Long QT Syndrome (often a channelopathy)
  - drugs: antibiotics, SSRIs, antipsychotics, antiarrhythmics
  - electrolytes: low Ca++, low Mg++, low K+
  - others: hypothyroidism, hyperthermia, cardiomyopathy
- decreased (<360 msec): risk of VFib
  - electrolytes: high Ca++, drugs: digoxin
  - others: hyperthermia

U WAVE
- origin unclear but may be repolarization of Purkinje fibres or delayed/prolonged repolarization of the myocardium
- more visible at slower heart rates
- deflection follows T wave with <25% of the amplitude
- variations from norm could indicate pathologic conditions:
  - prominent (>25% of T wave): electrolyte (low K+), drugs (digoxin, antiarrhythmics)
  - inverted (from T wave): ischemia, volume overload

Cardiac Biomarkers
- provide diagnostic and prognostic information in acute coronary syndromes and in heart failure

<table>
<thead>
<tr>
<th>Table 4. Cardiac Enzymes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enzyme</td>
</tr>
<tr>
<td>-------</td>
</tr>
<tr>
<td>Troponin T</td>
</tr>
<tr>
<td>CK-MB</td>
</tr>
</tbody>
</table>

- check troponin I at presentation and 8 h later ± creatine kinase-MB (CK-MB; depends on local laboratory protocol)
- new CK-MB elevation can be used to diagnose re-infarction
- other biomarkers of cardiac disease
  - AST and LDH also increased in MI (low specificity)
  - BNP and NT-proBNP: secreted by ventricles in response to increased end-diastolic pressure and volume
  - DDxs of elevated BNP: CHF, AFib, PE, COPD exacerbation, pulmonary HTN

Ambulatory ECG
- description
  - extended ambulatory ECG of 24 or 48 h or 14 or 30 d duration
  - provides a view of only two or three leads of electrocardiographic data over an extended period of time
  - permits evaluation of changing dynamic cardiac electrical phenomena that are often transient and of brief duration
  - continuous loop: a small, lightweight, battery operated recorder that records two or three channels of electrocardiographic data
    - patient activated event markers
    - minimum of 24-48 h
  - implantable device: subcutaneous monitoring device for the detection of cardiac arrhythmias
    - typically implanted in the left pectoral region and stores events when the device is activated automatically according to programmed criteria or manually with magnet application
    - can be used for months to years
- indications
  - evaluation of cardiac rhythm abnormalities
  - has also been used for assessing pacemaker and implantable cardioverter-defibrillator function, evidence of myocardial ischemia, late potentials, and heart rate variability
- contraindications
  - no absolute contraindications
  - patient refusal
  - allergies (sensitivities to latex adhesive)
- risks: no absolute risks

Differential Diagnosis of ST Segment Changes
- ST Elevation I HELP A PAL
  - Ischemia with reciprocal changes
  - Hypotension (Osborne waves)
  - Early repolarization (normal variant, need old ECGs to confirm)
  - LBBB
  - Post-MI
- Acute STEMl
- Prinzmetal’s (Vasospastic) angina
- Acute pericarditis (diffuse changes)
- Left/right ventricular aneurysm

ST Depression WAR SHIP
- WPW syndrome
- Acute NSTEMI
- RBBI/BBB
- STEMl with reciprocal changes
- Hypertrophy (LVH or RVH) with strain
- Ischemia
- Post-MI

Use of B-Type Natriuretic Peptide in the Evaluation and Management of Acute Dyspnea (BASEL)
- NEJM 2004;350;647-54
- Study: Prospective, RCT.
- Population: 452 patients (mean age 71 yr 58% male) with acute dyspnea; patients with severe renal disease or cardiogenic shock were excluded.
- Intervention: Assessment including measurement of B-type natriuretic peptide or standard assessment.
- Outcome: Time to discharge and total cost of treatment.
- Results: Median time to discharge was significantly shorter in the intervention group when compared with the control group (8.0 vs. 11.0 d, p=0.001).
  - Total cost was also significantly lower in the intervention group ($5410 vs. $7264, p=0.006).
  - In addition, the measurement of B-type natriuretic peptide significantly reduced the need for admission to hospital and intensive care. The 30-d mortality rates were similar (10% vs. 12%, p=0.45).
- Conclusions: In patients with acute dyspnea, measurement of B-type natriuretic peptide improves clinical outcomes (need for hospitalization or intensive care) and reduces time to discharge and total cost of treatment.
Echocardiography

Transthoracic Echocardiography (TTE)

- **description:** ultrasound beams are directed across the chest wall to obtain images of the heart
- **indications**
  - evaluation of LVEF, wall motion abnormalities, myocardial ischemia and complications of MI
  - evaluation of chamber size, wall thickness, valve morphology, proximal great vessel morphology, pericardial effusion
  - evaluation of unexplained hypotension, murmurs, syncope, congenital heart disease

Transoesophageal Echocardiography (TEE)

- **description:** invasive procedure used to complement transthoracic echocardiography
  - ultrasound probe inserted into the esophagus to allow for better resolution of the heart and structures
  - better visualization of posterior structures, including left atrium, mitral and aortic valves, inter-atrial septum
- **indications**
  - should be performed as the initial test in certain life-threatening situations, (e.g. aortic dissection) when other tests contraindicated (e.g. CT angiography in patient with renal failure)
  - intracardiac thrombi, tumours, valvular vegetations (infective endocarditis), aortic dissection, aortic atheromas, prosthetic valve function, shunt, technically inadequate transthoracic study
  - evaluation for left atrial/left atrial appendage thrombus in a patient with atrial fibrillation/atrial flutter to facilitate clinical decision making regarding electrical cardioversion or ablation
- **risks**
  - serious complications are extremely rare (<1 in 5,000)
  - esophageal perforation
  - gastrointestinal bleeding
  - pharyngeal hematoma

Stress Echocardiography (SE)

- **description:** echocardiography using either exercise (treadmill or bicycle) or pharmacologic agents (dobutamine) as the stress mechanism
- **indications**
  - useful alternative to other stress imaging modalities
  - when ECG cannot be interpreted appropriately
  - intermediate pre-test probability with normal/equivocal exercise ECG
  - post-ACS when used to decide on potential efficacy of revascularization
  - to evaluate the clinical significance of valvular heart disease
  - evaluation of myocardial viability, dyspnea of possible cardiac origin, mitral valve disease, aortic stenosis, mitral regurgitation, pulmonary hypertension, patients with hypertrophic cardiomyopathy (for LVOT obstruction)
  - dobutamine
    - pharmacologic stress for patients who are physically unable to exercise; same indications as exercise stress echo
    - low dose dobutamine stress echo can be used to assess myocardial viability and for assessing aortic stenosis with LV systolic dysfunction
- **contraindications**
  - contraindications to exercise testing
  - contraindications to dobutamine stress echocardiography: tachyarrhythmias and systemic hypertension
  - AAA has been considered as a relative contraindication to exercise testing or dobutamine stress echocardiography

Contrast Echocardiography with Agitated Saline Contrast

- **description:** improves resolution and provides real-time assessment of intracardiac blood flow
  - conventional agent is agitated saline (contains microbubbles of air)
  - allows visualization of right heart and intracardiac shunts, most commonly patent foramen ovale (PFO) and intrapulmonary shunt

Contrast Echocardiography with Transpulmonary Contrast Agents

- **description:** newer contrast agents are capable of crossing the pulmonary bed and achieving left heart opacification following intravenous injection; these contrast agents improve visualization of endocardial borders and enhance evaluation of LV ejection fraction and wall motion abnormalities (in patients with technically inadequate echocardiograms), and intracardiac mass
- **risks**
  - risk of non-fatal MI and death are rare
  - ultrasound contrast agents may cause back pain, headache, urticaria, and anaphylaxis
Stress Testing

**EXERCISE TESTING**
- **description**: cardiovascular stress test that uses treadmill or bicycle exercise with electrocardiographic and blood pressure monitoring
- **indications**
  - patients with intermediate (10-90%) pretest probability of CAD based on age, gender, and symptoms
  - ST depression <1 mm at rest, no left bundle branch block, no digoxin or estrogen use
- **exercise test results stratify patients into risk groups**
  1. low risk patients can be treated medically without invasive testing
  2. intermediate risk patients may need additional testing in the form of exercise imaging studies or cardiac catheterization
  3. high risk patients should be referred for cardiac catheterization
- **contraindications**
  - acute myocardial infarction (within two days)
  - unstable angina pectoris
  - uncontrolled arrhythmias causing symptoms of hemodynamic compromise
  - symptomatic severe valvular stenosis
  - uncontrolled symptomatic heart failure
  - active endocarditis or acute myocarditis or pericarditis
  - acute aortic dissection
  - acute pulmonary or systemic embolism
  - acute non-cardiac disorders that may affect exercise performance or may be aggravated by exercise
  - termination of exercise testing
    - patient's desire to stop
    - drop in systolic blood pressure of >10 mmHg from baseline despite an increase in workload, when accompanied by other evidence of ischemia
    - moderate to severe angina
    - ST elevation (>1 mm) in leads without diagnostic Q-waves (other than V1 or aVR)
    - increasing nervous system symptoms (e.g. ataxia, dizziness, or near syncope)
    - signs of poor perfusion (cyanosis or pallor)
    - technical difficulties in monitoring ECG or systolic blood pressure
    - sustained ventricular tachycardia
- **risks**: death, myocardial infarction, arrhythmia, hemodynamic instability, and orthopedic injury (<1-5/10,000 supervised tests)

**NUCLEAR CARDIOLOGY**
- **description**
  - myocardial perfusion imaging (MPI) with ECG-gated single photon emission computed tomography (SPECT), using radiolabelled tracer
  - evaluates myocardial viability, detects ischemia, and assesses perfusion and LV function simultaneously
  - predicts the likelihood of further cardiac event rates independent of the patient's history, examination, resting ECG, and stress ECG
  - often denoted as MIBI scan with reference to radiolabelled tracer (sestamibi)
  - stress with either treadmill or IV vasodilator stress (dipyridamole, adenosine, regadenoson)
  - images of the heart obtained during stress and at rest 3-4 h later
  - tracers
    - Thallium-201 (201Tl, a K+ analogue)
    - Technetium-99 (99Tc)-labeled tracer (sestamibi/Cardiolite® or hexamibi/Myoview®)
- **indications**
  - exercise MPI
    - when ECG cannot be interpreted appropriately
    - intermediate pre-test probability with normal/equivocal exercise ECG
    - in patients with previous imaging whose symptoms have changed
    - to diagnose ischemia
    - dipyridamole/adenosine MPI
  - to diagnose CAD in possible ACS patients with non-diagnostic ECG and negative serum biomarkers
  - when ECG is cannot be interpreted appropriately due to LBBB or V-paced rhythm among patients unable to exercise, with the same indications as exercise MPI
- **contraindications**
  - contraindications to exercise testing
    - vasodilators (i.e. adenosine, regadenoson, and dipyridamole) are contraindicated in patients with hypotension, sick sinus syndrome, high-degree AV block (in the absence of backup pacemaker capability), and reactive airways disease
    - pregnancy
  - **risks**: radiation exposure

**STRESS ECHOCARDIOGRAPHY**
- see Echocardiography, C12
Cardiac Catheterization and Angiography

Right Heart Catheterization (Swan-Ganz Catheter)

- **Description:** Also known as pulmonary artery catheterization
  - Obtain direct measurements of central venous, right-sided intracardiac, pulmonary artery, and pulmonary artery occlusion pressures
  - Can estimate cardiac output, systemic and pulmonary vascular resistance as well as mixed venous oxyhemoglobin saturation, oxygen delivery, and oxygen uptake
  - Right atrial, right ventricular, and pulmonary artery pressures are recorded
  - Can also be used to measure the Cardiac Index (CI)
    - \( \text{CI} = \frac{\text{CO}}{\text{body surface area}} \)
    - Cardiac index is a measure of cardiac function
    - \(< 1.8 \text{ L/min/m}^2 \) usually means cardiogenic shock
    - \(2.6-4.2 \text{ L/min/m}^2\) is considered normal
  - Pulmonary capillary wedge pressure (PCWP)
    - Obtained by advancing the catheter to wedge in the distal pulmonary artery
    - Records pressure measured from the pulmonary venous system
    - In the absence of pulmonary venous disease reflects left atrial pressure

- **Indications**
  - Unexplained or unknown volume status in shock
  - Severe cardiogenic shock (e.g. acute valvular disease, suspected pericardial tamponade)
  - Suspected or known pulmonary artery hypertension
  - Severe underlying cardiopulmonary disease (e.g. congenital heart disease, left-to-right shunt, severe valvular disease, pulmonary hypertension) and undergoing corrective or other surgery

- **Contraindications**
  - Lack of consent
  - Infection at the insertion site
  - The presence of a right ventricular assist device
  - Insertion during cardiopulmonary bypass

- **Risks**
  - Complications for diagnostic catheterization <1%
  - Inadequate diagnostic procedures occur in <1% of cases
  - Complications of insertion: atrial and/or ventricular arrhythmias (~3% of patients)
  - Catheter misplacement or knotting (uncommon)
  - Perforation of a cardiac chamber and rupture of a cardiac valve or the pulmonary artery (rare)
  - Complications of catheterization: pulmonary artery rupture, pulmonary infarction, thromboembolic events, infection, and data misinterpretation
  - Within 24 h of catheterization: death, MI, or stroke (0.2% to 0.3% of patients)

![Figure 17. Swan-Ganz catheter placement](image-url)
Left Heart Catheterization

- description
  - accomplished by introducing a catheter into the brachial or femoral artery and advancing it through the aorta, across the aortic valve, and into the left ventricle
  - evaluates mitral and aortic valvular defects and myocardial disease
  - systolic and end-diastolic pressure tracings recorded
  - LV size, wall motion and ejection fraction can be assessed by injecting contrast into the LV (left ventriculography) via femoral/radial artery catheterization
  - cardiac output (measured by the Fick oxygen method or the indicator dilution method)

- indications
  - identification of the extent and severity of CAD and evaluation of left ventricular function
  - assessment of the severity of valvular or myocardial disorders (e.g. aortic stenosis or insufficiency, mitral stenosis or insufficiency, and various cardiomyopathies) to determine the need for surgical correction
  - collection of data to confirm and complement noninvasive studies
  - determination of the presence of CAD in patients with confusing clinical presentations or chest pain of uncertain origin

- contraindications
  - severe uncontrolled hypertension
  - ventricular arhythmias
  - acute stroke
  - severe anemia
  - active gastrointestinal bleeding
  - allergy to radiographic contrast
  - acute renal failure
  - uncontrolled congestive failure (so that the patient cannot lie flat)
  - unexplained febrile illness or untreated active infection
  - electrolyte abnormalities (e.g. hypokalemia)
  - severe coagulopathy

- risks
  - complications for diagnostic catheterization <1%
  - inadequate diagnostic procedures occur in <1% of cases
  - within 24 h of catheterization: death, MI, or stroke (0.2% to 0.3% of patients)

Coronary Angiography

- description
  - radiographic visualization of the coronary vessels after injection of radiopaque contrast media
  - coronary vasculature accessed via the coronary ostia

- indications
  - to define the coronary anatomy and the degree of luminal obstruction of the coronary arteries
  - to determine the presence and extent of obstructive CAD
  - to assess the feasibility and appropriateness of various forms of therapy, such as revascularization by percutaneous or surgical interventions
  - can also be used when the diagnosis of CAD is uncertain and CAD cannot be reasonably excluded by noninvasive techniques

- contraindications: severe renal failure (due to contrast agent toxicity – must check patient’s renal status)

- risks: major complications <2%, but increased in patients with pre-existing renal failure (especially in diabetic patients)

ACC/AHA 2011 Recommended Indications for Coronary Angiography

- Disabling (CCS classes III and IV) chronic stable angina despite medical therapy
- High-risk criteria on clinical assessment or non-invasive testing
- Serious ventricular arhythmia or CHF
- Uncertain diagnosis or prognosis after non-invasive testing
- Inability to undergo non-invasive testing

Coronary Angiography

Gold standard for localizing and quantifying CAD

Hemodynamically significant stenosis is defined as 70% or more narrowing of the luminal diameter

Figure 18. Coronary angiogram schematic

AM = acute marginal; LAD = left anterior descending; OM = obtuse marginal; RCA = right coronary artery
Diagnostic Catheterization
- complications for diagnostic catheterization <1%
- inadequate diagnostic procedures occur in fewer than 1% of cases
- provocative pharmacological agents can be used to unmask pathology
  - fluid loading may unmask latent pericardial constriction
  - afterload reduction or inotropic stimulation may be used to increase the outflow tract gradient in HCM
  - coronary vasoreactive agents (e.g. methylergonovine, acetylcholine)
  - a variety of pulmonary vasoreactive agents in primary pulmonary HTN (e.g. oxygen, calcium channel blockers, adenosine, nitric oxide, or prostacyclin)

Contrast-Enhanced CT Coronary Angiography
- description: fast ECG-synchronized multi-slice CT image acquisition in the heart to enable non-invasive imaging of the coronary arterial tree
- indications: often used to assess coronary artery and previous graft stenosis/viability that could not be seen during coronary angiography
- sensitivity = 85%, specificity = 90% for the diagnosis of obstructive coronary disease with >50% stenosis
- contraindications: allergy to contrast dye; severe renal dysfunction
- risks: radiation exposure

Magnetic Resonance Imaging
- description: offers high spatial resolution, eliminates the need for iodinated contrast, and does not involve exposure to ionizing radiation
- indications: valuable in assessment of congenital cardiac anomalies, abnormalities of the aorta, assessment of viable myocardium, and assessment of cardiomyopathies
- contraindications: metallic foreign bodies/implants
- risks: hazards posed by certain metallic devices inside patients

CAR DiSC HE S

Arrhythmias

Mechanisms of Arrhythmias

Alterations in Impulse Formation

A. Abnormal Automaticity
- automaticity is a property of certain cardiomyocytes to spontaneously depolarize to their threshold voltage to generate action potentials in a rhythmic fashion
- under normal circumstances only cells in the specialized conduction system (SA node, AV node, and ventricular conduction system) exhibit natural automaticity. These cells are pacemaking cells. The automaticity of these cells can become abnormally increased or decreased
- in disease (e.g. post-MI ventricular ischemia) cells in the myocardium outside the conduction system may inappropriately acquire the property of automaticity and contribute to abnormal depolarization. If these ectopic generators depolarize at a rate greater than the SA node, they assume pacemaking control and become the source of abnormal rhythm
- automaticity can be influenced by:
  - neurohormonal tone (sympathetic and parasympathetic stimulation)
  - abnormal metabolic conditions (hypoxia, acidosis, hypothermia)
  - electrolyte abnormalities
  - drugs (e.g. digitalis)
  - local ischemia/infarction
  - other cardiac pathology
- this mechanism is responsible for the accelerated idioventricular rhythm and ventricular tachycardia that often occurs 24-72 h post MI

B. Triggered Activity due to Afterdepolarizations

1. Early Afterdepolarizations
- occur in the context of action potential prolongation
- consequence of the membrane potential becoming more positive during repolarization (e.g. not returning to baseline)
- result in self-maintaining depolarizing oscillations of action potential, generating a tachyarrhythmia (e.g. new baseline voltage is greater than threshold, which automatically triggers a new action potential after the refractory period ends)
- basis for the degeneration of QT prolongation, either congenital or acquired, into Torsades de Pointes
2. Delayed Afterdepolarizations
   - occur after the action potential has fully repolarized, but before the next usual action potential, thus
called a delayed afterdepolarization
   - commonly occurs in situations of high intracellular calcium (e.g. digitalis intoxication, ischemia) or
during enhanced catecholamine stimulation (e.g. "twitchy" pacemaker cells)

**Alterations in Impulse Conduction**

A. Re-Entry Circuits
   - the presence of self-sustaining re-entry circuit causes rapid repeated depolarizations in a region of
myocardium (see Figure 26, C20, for an example in the context of AV nodal re-entrant tachycardia)
     - e.g. myocardium that is infarcted/ischemic will consist of non-excitable and partially excitable
       zones which will promote the formation of re-entry circuits

B. Conduction Block
   - ischemia, fibrosis, trauma, and drugs can cause transient, permanent, unidirectional or bidirectional
     block
   - most common cause of block is due to refractory myocardium (cardiomyocytes are in refractory
     period or zone of myocardium unexcitable due to fibrosis)
   - if block occurs along the specialized conduction system distal zones of the conduction system can
     assume pacemaking control
   - conduction block can lead to bradycardia or tachycardia when impaired conduction leads to re-
     entry phenomenon

C. Bypass Tracts
   - normally the only conducting tract from the atria to the ventricles is the AV node into the His-
     Purkinje system
   - congenital/acquired accessory conducting tracts bypass the AV node and facilitate premature
     ventricular activation before normal AV node conduction
   - see Pre-Excitation Syndromes, C21

---

**Figure 19. Clinical approach to arrhythmias**

- **Bradyarrhythmias (<60 bpm)**
  - Sinus bradycardia
  - Sinoatrial block
  - Sinus arrest
  - AV block (2nd and 3rd degree)
  - Junctional rhythm
  - Idioventricular rhythm

- **Tachyarrhythmias (>100 bpm)**
  - Regular
    - Narrow QRS (SVTs)
      - Sinus tachycardia
      - Atrial tachycardia
      - Junctional tachycardia
      - AVNRT
      - AVRT (orthodromic)
      - Atrial flutter
    - Wide QRS
      - SVT with aberrancy/BBB
      - Ventricular tachycardia
      - AVRT (antidromic)
  - Irregular
    - Narrow QRS (SVTs)
      - Atrial fibrillation
      - A. flutter with variable block
      - Multifocal atrial tachycardia
      - Premature atrial contraction
    - Wide QRS
      - Atrial fibrillation with BBB
      - A. flutter with BBB and variable block
      - Polymorphic VT (torsades)
      - Premature ventricular contraction
Bradyarrhythmias

1. SA NODAL DYSFUNCTION

A. Sinus Bradycardia

- P axis normal (P waves positive in I and aVF)
- Rate < 60 bpm; marked sinus bradycardia (< 50 bpm)
- May be seen in normal adults, particularly athletes, and in elderly individuals
- Increased vagal tone or vagal stimulation; drugs (β-blockers, calcium channel blockers, etc.); ischemia/infarction

- Atropine; pacing for sick sinus syndrome

Figure 20. Sinus bradycardia

2. AV CONDUCTION BLOCKS

A. First Degree AV Block

- Prolonged PR interval (> 200 msec)
- Frequently found among otherwise healthy adults

- No treatment required

Figure 21. First degree AV block

B. Second Degree AV Block: Type I (Mobitz I)

- A gradual prolongation of the PR interval precedes the failure of conduction of a P wave (Wenckebach phenomenon)
- AV block is usually in AV node (proximal triggers; usually reversible); increased vagal tone (e.g. following surgery), RCA-mediated ischemia

B. Second Degree AV Block: Type II (Mobitz II)

- The PR interval is constant; there is an abrupt failure of conduction of a P wave
- AV block is usually distal to the AV node (i.e. bundle of His); increased risk of high grade or 3rd degree AV block

B. Third Degree AV Block

- Complete failure of conduction of the supraventricular impulses to the ventricles; ventricular depolarization initiated by an escape pacemaker distal to the block
- Wide or narrow QRS, P-P and R-R intervals are constant, variable PR intervals; no relationship between P waves and QRS complexes (P waves “marching through”)

- Management (see Electrical Pacing, C24)

Figure 22. Second degree AV block with Wenckebach phenomenon (Mobitz I) (4:3 conduction) (lead V1)

Figure 23. Second degree AV block (Mobitz II) (3:2 conduction) (lead V1)

Figure 24. Third degree AV block (complete heart block) (lead II)

Supraventricular Tachyarrhythmias

Presentation for SVT (and Pre-Excitation Syndromes)
- Presentation can include: palpitations, dizziness, dyspnea, chest discomfort, presyncope/syncope
- May precipitate CHF, hypotension, or ischemia in patients with underlying disease
- Untreated tachycardias can cause cardiomyopathy (rare, potentially reversible with treatment of SVTs)
- Includes supraventricular and ventricular rhythms

Supraventricular Tachyarrhythmias
- Tachyarrhythmias that originate in the atria or AV junction
- This term is used when a more specific diagnosis of mechanism and site of origin cannot be made
- Characterized by narrow QRS, unless there is pre-existing bundle branch block or aberrant ventricular conduction (abnormal conduction due to a change in cycle length)

1. Sinus Tachycardia
- Sinus rhythm with rate > 100 bpm
- Occurs in normal subjects with increased sympathetic tone (e.g. exercise, emotions, pain), alcohol use, caffeinated beverages, drugs (e.g. β-adrenergic agonists, anticholinergic drugs, etc.)
- Etiology: fever, hypotension, hypovolemia, anemia, thyrotoxicosis, CHF, MI, shock, PE, etc.
- Treatment: treat underlying disease; consider β-blocker if symptomatic, calcium channel blocker if β-blockers contraindicated
2. Premature Beats
- premature atrial contraction
  - ectopic supraventricular beat originating in the atria
  - P wave morphology of the PAC usually differs from that of a normal sinus beat
- junctional premature beat
  - ectopic supraventricular beat that originates in the vicinity of the AV node
  - P wave is usually not seen or an inverted P wave is seen and may be before or closely follow the QRS complex (referred to as a retrograde, or “traveling backward” P wave)
- treatment usually not required

3. Atrial Flutter
- rapid, regular atrial depolarization from a macro re-entry circuit within the atrium (most commonly the right atrium)
- atrial rate 250-350 bpm, usually 300 bpm
- AV block usually occurs; it may be fixed (2:1, 3:1, 4:1, etc.) or variable
- etiology: CAD, thyrotoxicosis, mitral valve disease, cardiac surgery, COPD, PE, pericarditis
- ECG: sawtooth flutter waves (most common type of flutter) in inferior leads (II, III, aVF); narrow QRS (unless aberrancy); commonly see HR of 150
- in atrial flutter with 2:1 block, carotid sinus massage (first check for bruits), Valsalva maneuver, or adenosine may decrease AV conduction and bring out flutter waves
- treatment of acute atrial flutter
  - acute and if unstable (e.g. hypotension, CHF, angina): electrical cardioversion
  - if unstable (e.g. hypotension, CHF, angina): electrical cardioversion
  - if stable
    - 1. rate control: β-blocker, diltiazem, verapamil, or digoxin
    - 2. chemical cardioversion: sotalol, amiodarone, type I antiarrhythmics, or electrical cardioversion
  - anticoagulation guidelines same as for patients with AFib
- treatment of long-term atrial flutter: antiarrhythmics, catheter radiofrequency (RF) ablation (success rate dependent on site of origin of atrial flutter – i.e. whether right-sided isthmus-dependent or left-sided origin)

4. Multifocal Atrial Tachycardia (MAT)
- irregular rhythm caused by presence of 3 or more foci (may mimic AFib)
- atrial rate 100-200 bpm – 3 or more distinct P wave morphologies and PR intervals vary, some P waves may not be conducted
- occurs more commonly in patients with COPD, and hypoxemia; less commonly in patients with hypokalemia, hypomagnesemia, sepsis, theophylline, or digitalis toxicity
- treatment: treat the underlying cause; calcium channel blockers may be used (e.g. diltiazem, verapamil), β-blockers may be contraindicated because of severe pulmonary disease
- no role for electrical cardioversion, antiarrhythmics, or ablation

5. Atrial Fibrillation
- see CCS Atrial Fibrillation Guidelines 2014 for details (free mobile app – iCCS available on iOS and Android)
- most common sustained arrhythmia
- incidence increases with age (10% of population >80 yr old)
- symptoms: palpitations, fatigue, syncope, may precipitate or worsen heart failure
- classification
  - lone: occurs in persons younger than 60 yr and in whom no clinical or echocardiographic causes are found
  - nonvalvular: not caused by valvular disease, prosthetic heart valves, or valve repair
  - paroxysmal: episodes that terminate spontaneously
  - persistent: AFib sustained for more than 7 d or AFib that terminates only with cardioversion
  - permanent/chronic: continuous AFib that is unresponsive to cardioversion or in which clinical judgement has led to a decision not to pursue cardioversion
  - recurrent: two or more episodes of AFib
  - secondary: caused by a separate underlying condition or event (e.g. myocardial infarction, cardiac surgery, pulmonary disease, hyperthyroidism)
  - may be associated with thromboembolic events (stroke risk can be assessed by CHADS2 score in nonvalvular AFib; CHA2DS2-VASc if the former gives a score of 0 or 1)
- initiation
  - single circuit re-entry and/or ectopic foci act as aberrant generators producing atrial tachycardia (350-600 bpm)
  - impulses conduct irregularly across the atrial myocardium to give rise to fibrillation
  - in some cases, ectopic foci have also been mapped to the pulmonary vein ostia and can be ablated
- maintenance
  - the tachycardia causes atrial structural and electrophysiological remodelling changes that further promote AFib; the longer the patient is in AFib the more difficult it is to convert back to sinus rhythm
- consequences
  - the AV node irregularly filters incoming atrial impulses producing an irregular ventricular response of <200 bpm and the tachycardia leads to suboptimal cardiac output
  - fibrillatory conduction of the atria promotes blood stasis increasing the risk of thrombus formation – AFib is an important risk factor for stroke
Table 5. CHADS2 Risk Prediction for Non-Valvular AFib and Refer to AHA/ACC/HRS AFib Guidelines 2014 for more details

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Points</th>
<th>CHADS2 Score</th>
<th>Stroke Risk (%/Yr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congestive Heart Failure</td>
<td>1</td>
<td>0</td>
<td>1.9 (low)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>1</td>
<td>1</td>
<td>2.8 (low-mod)</td>
</tr>
<tr>
<td>Age &gt; 75</td>
<td>1</td>
<td>2-3</td>
<td>4.0-5.9 (mod)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1</td>
<td>4-6</td>
<td>8.5-18.2 (high)</td>
</tr>
<tr>
<td>Stroke/TIA (prior)</td>
<td>2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ECG findings
- no organized P waves due to rapid atrial activity (350-600 bpm) causing a chaotic fibrillatory baseline
- irregularly irregular ventricular response (typically 100-180 bpm), narrow QRS (unless aberrancy or previous BBB)
- wide QRS complexes due to aberrancy may occur following a long-short cycle sequence ("Ashman phenomenon")
- loss of atrial contraction, thus no "a" wave seen in JVP, no S4 on auscultation

Management (adapted from CCS Atrial Fibrillation Guidelines 2012 & 2014)
- major objectives (RACE): all patients with AF (paroxysmal, persistent, or permanent), should be stratified using a predictive index for stroke risk and for the risk of bleeding, and most patients should receive either an oral anticoagulant or ASA (see below)
- Rate control: β-blockers, diltiazem, verapamil (in patients with heart failure: digoxin, amiodarone)
- 2. Anticoagulation: use either warfarin or direct oral anticoagulant (DOACs) e.g. apixaban, dabigatran, rivaroxaban to prevent thromboembolism
  - for patients with non-valvular AF (NVAF): oral anticoagulant (OAC) is recommended for most patients aged > 65 years or CHADS2 >= 1. ASA 81 mg is recommended only for patients with none of the risk outlined in the CCS algorithm (age < 65 and no CHADS2 risk factors) who have arterial disease (coronary, aortic, or peripheral). Novel oral anticoagulant (NOAC) is to be used in preference to warfarin
- 3. Cardioversion (electrical)
  - if AFib <24-48 h, can usually cardiovert without anticoagulation
  - if AFib >24-48 h, anticoagulate for 3 wk prior and 4 wk after cardioversion due to risk of unstable intra-atrial thrombus
  - if patient unstable (hypotensive, active angina due to tachycardia, uncontrolled heart failure) should cardiovert immediately
- 4. Etiology
  - I – HTN, CAD, valvular disease, pericarditis, cardiomyopathy, myocarditis, ASD, post-operative, PE, COPD, thyrotoxicosis, sick sinus syndrome, alcohol ("holiday heart")
  - may present in young patients without demonstrable disease ("lone AFib") and in the elderly without underlying heart disease
- studies of patients with AFib suggest that there is no difference in long-term survival when treating patients with a rhythm-control versus rate-control strategy
- however, many patients with a significant underlying structural heart lesion (e.g. valve disease, cardiomyopathy) will not tolerate AFib well (since may be dependent on atrial kick) and these patients should be cardioverted (chemical or electrical) as soon as possible
- newly discovered AFib
  - anticoagulants may be beneficial if high risk for stroke
  - if the episode is self-limited and not associated with severe symptoms, no need for antiarrhythmic drugs
  - if AFib persists, 2 options
    1. rate control and anticoagulation (as indicated above)
    2. cardioversion (as above)
- recurrent or permanent AFib
  - if episodes are brief or minimally symptomatic, antiarrhythmic drugs may be avoided; rate control and anticoagulation are appropriate
  - patients who have undergone at least one attempt to restore sinus rhythm may remain in AFib after recurrence; permanent AFib may be accepted (with rate control and antithrombotics as indicated by CHADS2 score) in certain clinical situations
  - if symptoms are bothersome or episodes are prolonged, antiarrhythmic drugs should be used
    - no or minimal heart disease: flecainide, propafenone, or sotalol
    - LV dysfunction: amiodarone
    - CAD: β-blockers, amiodarone

Rivaroxaban for Stroke Prevention in AFib – ROCKET-AF Trial
AJEJM 2011;365:883-891
Study: Prospective, non-inferiority, double-blind, RCT, median follow-up of 1.9 yr.
Population: 14,264 patients with AFib (mean CHADS2=3.5). Patients either had previous thromboembolism or ≥3 risk factors.
Intervention: Patients were randomized to receiving rivaroxaban or warfarin.
Outcome: Composite of strokes and systemic thromboembolic event (STE).
Results: The hazard ratio of the primary outcome for rivaroxaban compared to warfarin was 0.88, 95% CI 0.74-1.03; p<0.001 for noninferiority; p=0.12 for superiority. Furthermore, the hazard ratio for major and non-major, but clinically relevant, bleeding was 1.03, 95% CI 0.96-1.11; p=0.64. There were also significant reductions in intracranial hemorrhage (0.5% vs. 0.7%, p=0.02) and fatal bleeding (0.2% vs. 0.5%, p=0.003) for rivaroxaban.
Conclusions: In patients with AFib, rivaroxaban is non-inferior to warfarin for stroke prevention and major and non-major bleeding.

Rivaroxaban for Stroke Prevention in AFib – ROCKET-AF Trial
AJEJM 2011;365:883-891
Study: Prospective, non-inferiority, double-blind, RCT, median follow-up of 1.9 yr.
Population: 14,264 patients with AFib (mean CHADS2=3.5). Patients either had previous thromboembolism or ≥3 risk factors.
Intervention: Patients were randomized to receiving rivaroxaban or warfarin.
Outcome: Composite of strokes and systemic thromboembolic event (STE).
Results: The hazard ratio of the primary outcome for rivaroxaban compared to warfarin was 0.88, 95% CI 0.74-1.03; p<0.001 for noninferiority; p=0.12 for superiority. Furthermore, the hazard ratio for major and non-major, but clinically relevant, bleeding was 1.03, 95% CI 0.96-1.11; p=0.64. There were also significant reductions in intracranial hemorrhage (0.5% vs. 0.7%, p=0.02) and fatal bleeding (0.2% vs. 0.5%, p=0.003) for rivaroxaban.
Conclusions: In patients with AFib, rivaroxaban is non-inferior to warfarin for stroke prevention and major and non-major bleeding.
6. AV NODAL RE-ENTRANT TACHYCARDIA (AVNRT)

• re-entrant circuit using dual pathways (fast conducting β-fibres and slow conducting α-fibres) within or near the AV node; often found in the absence of structural heart disease – cause is commonly idiopathic, although familial AVNRT has been reported
• sudden onset and offset
• fast regular rhythm: rate 150-250 bpm
• usually initiated by a supraventricular or ventricular premature beat
• AVNRT accounts for 60-70% of all paroxysmal SVTs
• retrograde P waves may be seen but are usually lost in the QRS complex (see Figure 27)
• treatment
  • acute: Valsalva maneuver or carotid sinus pressure technique, adenosine is first choice if unresponsive to vagal maneuvers; if no response, try metoprolol, digoxin, diltiazem, electrical cardioversion if patient hemodynamically unstable (hypotension, angina, or CHF)
  • long-term: 1st line – β-blocker, diltiazem, digoxin; 2nd line – flecainide, propafenone; 3rd line – catheter ablation

Pre-Excitation Syndromes

• refers to a subset of SVTs mediated by an accessory pathway which can lead to ventricular pre-excitation

Wolff-Parkinson-White Syndrome

• congenital defect present in 1.5-2/1,000 of the general population
• an accessory conduction tract (Bundle of Kent; can be in right or left atrium) abnormally allows early electrical activation of part of one ventricle
• impulses travel at a greater conduction velocity across the Bundle of Kent thereby effectively ‘bypassing’ AV node
• since the ventricles are activated earlier, the ECG shows early ventricular depolarization in the form of initial slurring of the QRS complex – the so-called “delta wave”
• atrial impulses that conduct to the ventricles through both the Bundle of Kent and the normal AV node/His-Purkinje system generate a broad “fusion complex”
• ECG features of WPW
  • PR interval <120 msec
  • delta wave: slurred upstroke of the QRS (the leads with the delta wave vary with site of bypass)
  • widening of the QRS complex due to premature activation
  • secondary ST segment and T wave changes
  • tachyarrhythmias may occur – most often AVRT and AFib
**Ventricular Tachyarrhythmias**

**Premature Ventricular Contraction (PVC) or Ventricular Premature Beat (VPB)**
- QRS width >120 msec, no preceding P wave, bizarre QRS morphology
- origin: LBBB morphology of VT = RV origin; RBBB morphology of VT = LV origin
- PVCs may be benign but are usually significant in the following situations:
  - consecutive (≥3 = VT) or multiform (varied origin)
  - PVC falling on the T wave of the previous beat ("R on T phenomenon"): may precipitate ventricular tachycardia or VF

**Accelerated Idioventricular Rhythm**
- ectopic ventricular rhythm with rate 50-100 bpm
- more frequently occurs in the presence of sinus bradycardia and is easily overdriven by a faster supraventricular rhythm
- frequently occurs in patients with acute MI or other types of heart disease (cardiomyopathy, hypertensive, valvular) but it does not affect prognosis and does not usually require treatment

**Ventricular Tachycardia (VT)**
- 3 or more consecutive ectopic ventricular complexes
  - rate >100 bpm (usually 140-200)
  - ventricular flutter: if rate >200 bpm and complexes resemble a sinusoidal pattern
  - "sustained VT" if it lasts longer than 30 s
  - ECG characteristics: wide regular QRS tachycardia (QRS usually >140 msec)
  - AV dissociation; bizarre QRS pattern
  - also favour Dx of VT: left axis or right axis deviation, nonspecific intraventricular block pattern, monophasic or biphasic QRS in V1 with RBBB, QRS concordance in V1-V6
  - occasionally during VT supraventricular impulses may be conducted to the ventricles generating QRS complexes with normal or aberrant supraventricular morphology ("ventricular capture") or summation pattern ("fusion complexes")

**monomorphic VT**
- identical complexes with uniform morphology
- more common than polymorphic VT
- typically result from intraventricular re-entry circuit
- potential causes: chronic infarct scarring, acute MI/ischemia, cardiomyopathies, myocarditis, arrhythmogenic right ventricular dysplasia, idiopathic, drugs (e.g. cocaine), electrolyte disturbances

**polymorphic VT**
- complexes with constantly changing morphology, amplitude, and polarity
- more frequently associated with hemodynamic instability due to faster rates (typically 200-250 bpm) vs. monomorphic VT
- potential causes: acute MI, severe or silent ischemia, and predisposing factors for QT prolongation

**treatment**
- sustained VT (>30 s) is an emergency, requiring immediate treatment
- hemodynamic compromise: electrical cardioversion
- no hemodynamic compromise: electrical cardioversion, lidocaine, amiodarone, type Ia agents (procainamide, quinidine)

**AV Re-Entrant Tachycardia**
- re-entrant loop via accessory pathway and normal conduction system
- initiated by a premature atrial or ventricular complex
- orthodromic AVRT: stimulus from a premature complex travels up the bypass tract (V to A) and down the AV node (A to V) with narrow QRS complex (no delta wave because stimulus travels through normal conduction system)
- comprises 95% of the reentrant tachycardias associated with WPW syndrome
- antidromic AVRT: more rarely the stimulus goes up the AV node (V to A) and down the bypass tract (A to V); wide and abnormal QRS as ventricular activation is only via the bypass tract
- treatment
  - acute: similar to AVNRT except avoid long-acting AV nodal blockers (e.g. digoxin and verapamil)
  - long-term: for recurrent arrhythmias ablation of the bypass tract is recommended
  - drugs such as flecainide and procainamide can be used

**AFib in WPW Patients**
- AFib is the index arrhythmia in up to 20% of patients with WPW syndrome
  - it is usually intermittent rather than persistent or permanent
  - rapid atrial depolarizations in AFib are conducted through the bypass tract which is not able to filter impulses like the AV node can
  - consequently the ventricular rate becomes extremely rapid (>200 bpm) and the QRS complex widens
  - treatment: electrical cardioversion, IV procainamide, or IV amiodarone
  - do not use drugs that slow AV node conduction (digoxin, β-blockers) as this may cause preferential conduction through the bypass tract and precipitate VF
  - long-term: ablation of bypass tract if possible

**Arrhythmias**
Table 6. Wide Complex Tachycardia: Clues for Differentiating VT vs. SVT with Aberrancy*

<table>
<thead>
<tr>
<th>Clinical Clues</th>
<th>ECG Clues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presenting symptoms</td>
<td>Not helpful</td>
</tr>
<tr>
<td>History of CAD and previous MI</td>
<td>VT</td>
</tr>
<tr>
<td>Physical exam</td>
<td>Capture or fusion beats</td>
</tr>
<tr>
<td>Cannon “a” waves Variable S1</td>
<td>VT</td>
</tr>
<tr>
<td>Carotid sinus massage/adenosine terminates arrhythmia</td>
<td>VT</td>
</tr>
</tbody>
</table>

*If patient >65 yr and previous MI or structural heart disease, then chance of VT >95%
**May terminate VT in some patients with no structural heart disease

Torsades de Pointes
- a variant of polymorphic VT that occurs in patients with baseline QT prolongation – “twisting of the points”
- looks like usual VT except that QRS complexes “rotate around the baseline” changing their axis and amplitude
- ventricular rate >100 bpm, usually 150-300 bpm
- etiology: predisposition in patients with prolonged QT intervals
  - congenital long QT syndromes
  - drugs: e.g. class IA (quinidine), class III (sotalol), phenothiazines (TCAs), erythromycin, quinolones, antihistamines
  - electrolyte disturbances: hypokalemia, hypomagnesemia
  - nutritional deficiencies causing above electrolyte abnormalities
- treatment: IV magnesium, temporary pacing, isoproterenol and correct underlying cause of prolonged QT, electrical cardioversion if hemodynamic compromise

Ventricular Fibrillation (VFib)
- chaotic ventricular arrhythmia, with very rapid irregular ventricular fibrillatory waves of varying morphology
- terminal event, unless advanced cardiac life-support (ACLS) procedures are promptly initiated to maintain ventilation and cardiac output, and electrical defibrillation is carried out
- most frequent cause of sudden death
- refer to ACLS algorithm for complete therapeutic guidelines
**Sudden Cardiac Arrest**

**Definition**
- unanticipated, non-traumatic cardiac death in a stable patient which occurs within 1 h of symptom onset; VFib is most common cause

**Etiology**
- primary cardiac pathology
  - ischemia/MI
  - LV dysfunction
  - severe ventricular hypertrophy
  - HCM
  - AS
  - congenital heart disease e.g. arrhythmogenic right ventricular dysplasia
  - mutations in cardiac ion channels e.g. long QT syndrome, Brugada syndrome

**Management**
- acute: resuscitate with prompt CPR and defibrillation
- investigate underlying cause (cardiac catheterization, electrophysiologic studies, echo)
- treat underlying cause
- antiarrhythmic drug therapy: amiodarone, β-blockers
- implantable cardioverter defibrillator (ICD)
- refer to ACLS guidelines (see Anesthesia and Perioperative Medicine, A31)

**Electrophysiology Studies**
- invasive test for the investigation and treatment of cardiac rhythm disorders using intracardiac catheters
- provide detailed analysis of the arrhythmia mechanism and precise site of origin when ECG data are nondiagnostic or unobtainable
- bradyarrhythmias: define the mechanisms of SA node dysfunction and localize site of AV conduction block
- tachyarrhythmias: map for possible ablation or to assess inducibility of VT

**Electrical Pacing**
- the decision to implant a pacemaker usually is based on symptoms of a bradyarrhythmia or tachyarrhythmia in the setting of heart disease

**Pacemaker Indications**
- SA node dysfunction (most common): symptomatic bradycardia ± hemodynamic instability
- common manifestations include: syncope, presyncope, or severe fatigue
- SA node dysfunction is commonly caused by: intrinsic disease within the SA node (e.g. idiopathic degeneration, fibrosis, ischemia, or surgical trauma), abnormalities in autonomic nervous system function, and drug effects
- AV nodal-infranodal block: Mobitz II, complete heart block

**Pacemaker Complications**
- complications related to surgical implantation include venous access (pneumothorax, hemothorax, air embolism), pacemaker leads (perforation, malposition), pocket hematomas and infection
- complications specific to the pacemaker include a failure to pace, failure to sense, pulse generator failure, pacemaker syndrome and pacemaker mediated tachycardia

**Pacing Techniques**
- temporary: transvenous (jugular, subclavian, femoral) or external (transcutaneous) pacing
- permanent: transvenous into RA, apex of RV, or both
- can sense and pace atrium, ventricle, or both
- new generation: rate responsive, able to respond to physiologic demand
- biventricular

**Implantable cardioverter defibrillators**
- sudden cardiac death (SCD) usually results from ventricular fibrillation (VFib), sometimes preceded by monomorphic or polymorphic ventricular tachycardia (VT)
- ICDs detect ventricular tachyarrhythmias and are highly effective in terminating VT/VFib and in aborting SCD
- mortality benefit vs. antiarrhythmics in secondary prevention
- benefit seen in patients with ischemic and non-ischemic cardiomyopathy, depressed left ventricular ejection fraction (LVEF), prolonged QRS
- see Heart Failure, C34 for current treatment recommendations
Catheter Ablation

Techniques
- radiofrequency (RF) ablation: a low-voltage high-frequency form of electrical energy (similar to cautery); RF ablation produces small, homogeneous, necrotic lesions approximately 5-7 mm in diameter and 3-5 mm in depth
- cryoablation: new technology which uses a probe with a tip that can decrease in temperature to -20˚C and -70˚C. Produces small, necrotic lesions similar to RF ablation; when brought to -20˚C, the catheter tip reversibly freezes the area; bringing the tip down to -70˚C for 5 min permanently scars the tissue
  - advantage: can “test” areas before committing to an ablation
  - disadvantage: takes much longer than RF (5 min per cryoablation vs. 1 min per RF ablation)

Indications
- paroxysmal SVT
  - AVNRT: accounts for more than half of all cases
- accessory pathway (orthodromic reciprocating tachycardia): 30% of SVT
  - re-entrant rhythm, with an accessory AV connection as the retrograde limb
  - corrected by targeting the accessory pathway
- atrial flutter: reentry pathway in right atrium
- AFib: potential role for pulmonary vein ablation
- ventricular tachycardia: focus arises from the right ventricular outflow tract and less commonly originates in the inferoseptal left ventricle near the apex (note: majority of cases of VT are due to scarring from previous MI and cannot be ablated)

Major Complications
- 1% of patients
- death: 0.1-0.2%
- cardiac: high grade AV block requiring permanent pacemaker (less risk with cryoablation), tamponade, pericarditis
- vascular: hematoma, vascular injury, thromboembolism, TIA/stroke
- pulmonary: PE

Ischemic Heart Disease

Epidemiology
- most common cause of cardiovascular morbidity and mortality
- Canadian-led INTERHEART study showed that 9 modifiable risk factors accounted for >90% of MI
- atherosclerosis and thrombosis are the most important pathogenetic mechanisms
- M:F = 2:1 with all age groups included (Framingham study), 8:1 for age <40, 1:1 for age >70
  - according to the Framingham Heart Study, men develop coronary heart disease at a rate double that of women for age <60; incidence in women triples shortly after menopause
- peak incidence of symptomatic IHD is age 50-60 (men) and 60-70 (women)
- for primary prevention of ischemic heart disease see Family Medicine, FM7

Table 7. Risk Factors and Markers for Atherosclerotic Heart Disease

<table>
<thead>
<tr>
<th>Non-Modifiable Risk Factors</th>
<th>Modifiable Risk Factors</th>
<th>Markers of Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Hyperlipidemia*</td>
<td>Elevated lipoprotein(a)</td>
</tr>
<tr>
<td>Male, postmenopausal female</td>
<td>HTN*</td>
<td>Hyperhomocysteinemia</td>
</tr>
<tr>
<td>Family history (FHx) of MI*</td>
<td>DM*</td>
<td>Elevated high-sensitivity C-reactive protein (hsCRP)</td>
</tr>
<tr>
<td>First degree male relative &lt;55</td>
<td>Cigarette smoking*</td>
<td>Coronary artery calcification</td>
</tr>
<tr>
<td>First degree female relative &lt;65</td>
<td>Psychosocial stress</td>
<td>Carotid IMT/plaque</td>
</tr>
<tr>
<td></td>
<td>Obesity</td>
<td>Ankle-brachial index</td>
</tr>
<tr>
<td></td>
<td>Sedentary lifestyle</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Heavy alcohol intake</td>
<td></td>
</tr>
</tbody>
</table>

* Major risk factor
Figure 35. Pathophysiology of atherosclerosis

**Definition**
- symptom complex resulting from an imbalance between oxygen supply and demand in the myocardium

**Etiology and Pathophysiology**
- factors that decrease myocardial oxygen supply
  - decreased luminal diameter: atherosclerosis, vasospasm
  - decreased duration of diastole: tachycardia (decreased duration of diastolic coronary perfusion)
  - decreased hemoglobin: anemia
  - decreased SaO₂: hypoxemia
  - congenital anomalies
- factors that increase myocardial oxygen demand
  - increased heart rate: hyperthyroidism
  - increased contractility: hyperthyroidism
  - increased wall stress: myocardial hypertrophy, aortic stenosis

**Signs and Symptoms**
- typical: (1) retrosternal chest pain, tightness or discomfort radiating to left (+ right) shoulder/arm/neck/jaw, associated with diaphoresis, nausea, anxiety; (2) predictably precipitated by the "3 Es": exertion, emotion, eating; (3) brief duration, lasting <10-15 min and typically relieved by rest and nitrates
- atypical/probable angina (meets 2 of the above); non-cardiac chest pain (meets <1 of the above)
- Levine's sign: clenching fist over sternum when describing chest pain
- anginal equivalents: dyspnea, acute LV failure, flash pulmonary edema

**Clinical Assessment**
- history including directed risk factor assessment and physical exam
- labs: Hb, fasting glucose, fasting lipid profile
- ECG (at rest and during episode of chest pain if possible)
- CXR (suspected heart failure, valvular disease, pericardial disease, aortic dissection/aneurysm, or signs or symptoms of pulmonary disease)
- stress testing (see Stress Testing, C13) or angiography
- echo
- to assess systolic murmur suggestive of aortic stenosis, mitral regurgitation, and/or HCM
- to assess LV function in patients with Hx of prior MI, pathological Q waves, signs or symptoms of CHF

**Differential Diagnosis**
- see Differential Diagnosis of Common Presentations, C4
Treatment of Chronic Stable Angina

1. General Measures
   - goals: to reduce myocardial oxygen demand and/or increase oxygen supply
   - lifestyle modification (diet, exercise)
   - treatment of risk factors: statins (see Endocrinology, E5, Family Medicine, FM9 for target lipid guidelines), antihypertensives, etc.
   - pharmacological therapy to stabilize the coronary plaque to prevent rupture and thrombosis

2. Antiplatelet Therapy (first-line therapy)
   - ASA
   - clopidogrel when ASA absolutely contraindicated

3. β-blockers (first-line therapy – improve survival in patients with hypertension)
   - increase coronary perfusion and decrease demand (HR, contractility) and BP (afterload)
   - cardioselective agents preferred (e.g. metoprolol, atenolol) to avoid peripheral effects (inhibition of vasodilation and bronchodilation via β2 receptors)
   - avoid intrinsic sympathomimetics (e.g. acebutolol) which increase demand

4. Nitrates (symptomatic control, no clear impact on survival)
   - decrease preload (venous dilatation) and afterload (arteriolar dilatation), and increase coronary perfusion
   - maintain daily nitrate-free intervals to prevent tolerance (tachyphylaxis)

5. Calcium Channel Blockers (CCBs, second-line or combination)
   - increase coronary perfusion and decrease demand (HR, contractility) and BP (afterload)
   - caution: verapamil/diltiazem combined with β-blockers may cause symptomatic sinus bradycardia or AV block

6. ACE Inhibitors (ACEI, not used to treat symptomatic angina)
   - angina patients tend to have risk factors for CV disease which warrant use of an ACEI (e.g. HTN, DM, proteinuric renal disease, previous MI with LV dysfunction)
   - benefit in all patients at high risk for CV disease (concomitant DM, renal dysfunction, or LV systolic dysfunction)
   - angiotensin II receptor blockers (ARBs) can be used when ACEI contraindicated

7. Invasive Strategies
   - revascularization (see Coronary Revascularization, C31 and COURAGE trial sidebar)

VARIANT ANGINA (PRINZMETAL’S ANGINA)
   - myocardial ischemia secondary to coronary artery vasospasm, with or without atherosclerosis
   - uncommonly associated with infarction or LV dysfunction
   - typically occurs between midnight and 8 am, unrelated to exercise, relieved by nitrates
   - typically ST elevation on ECG
   - diagnosed by provocative testing with ergot vasoconstrictors (rarely done)
   - treat with nitrates and CCBs

SYNDROME X
   - typical symptoms of angina but normal angiogram
   - may show definite signs of ischemia with exercise testing
   - thought to be due to inadequate vasodilator reserve of coronary resistance vessels
   - better prognosis than overt epicardial atherosclerosis

Acute Coronary Syndromes

Definition
   - ACS includes the spectrum of UA, NSTEMI, and STEMI; this distinction aids in providing the appropriate therapeutic intervention
   - MI is defined by evidence of myocardial necrosis. It is diagnosed by a rise/fall of serum markers plus any one of
     - symptoms of ischemia (chest/upper extremity/mandibular/epigastric discomfort; dyspnea)
     - ECG changes (ST-T changes, new BBB or pathological Q waves)
     - imaging evidence (myocardial loss of viability, wall motion abnormality, or intracoronary thrombus)
     - if biomarker changes are unattainable, cardiac symptoms combined with new ECG changes is sufficient
   - NSTEMI meets criteria for myocardial infarction without ST elevation or BBB
   - STEMI meets criteria for myocardial infarction characterized by ST elevation or new BBB
• UA is clinically defined by any of the following
  ▪ accelerating pattern of pain: increased frequency, increased duration, decreased threshold of 
    exertion, decreased response to treatment
  ▪ angina at rest
  ▪ new-onset angina
  ▪ angina post-MI or post-procedure (e.g. percutaneous coronary intervention [PCI], coronary artery 
    bypass grafting [CABG])

Investigations
• history and physical
  ▪ note that up to 30% of MIs are unrecognized or “silent” due to atypical symptoms – more common 
    in women, DM, elderly, post-heart transplant (because of denervation)
• ECG
• CXR
• labs
  ▪ serum cardiac biomarkers for myocardial damage (repeat 8 h later) (see Cardiac Biomarkers, C11)
  ▪ CBC, INR/PTT, electrolytes and magnesium, creatinine, urea, glucose, serum lipids
  ▪ draw serum lipids within 24-48 h because values are unreliable from 2-48 d post-MI

MANAGEMENT OF ACUTE CORONARY SYNDROMES

1. General Measures
  ▪ ABCs: assess and correct hemodynamic status first
  ▪ bed rest, cardiac monitoring, oxygen
  ▪ nitroglycerin SL followed by IV
  ▪ morphine IV

2. Anti-Platelet and Anticoagulation Therapy
  ▪ see also CCS Antiplatelet Guidelines 2012 for details (free mobile apps available on iOS and Android 
    platforms in the CCS app stores)
  ▪ ASA chewed
  ▪ NSTE
  ▪ ticagrelor in addition to ASA or if ASA contraindicated, subcutaneous low molecular weight 
    heparin or IV unfractionated heparin (UFH) (LMWH preferable, except in renal failure or if 
    CABG is planned within 24 h)
  ▪ clopidogrel used if patient ineligible for ticagrelor
  ▪ if PCI is planned: ticagrelor or prasugrel and consider IV GP IIb/IIIa inhibitor (e.g. abciximab)
  ▪ clopidogrel used if patient ineligible for ticagrelor and prasugrel
  ▪ prasugel contraindicated in those with a history of stroke/TIA, and avoidance of or lower dose is 
    recommended for those >75 yr old or weighing under 60 kg (TRITON-TIMI 38)
  ▪ anticoagulation options depend on reperfusion strategy:
    ▪ primary PCI: UFH during procedure; bivalirudin is a possible alternative
    ▪ thrombolysis: LMWH (enoxaparin) until discharge from hospital; can use UFH as alternative
    because of possible rescue PCI
    ▪ no reperfusion: LMWH (enoxaparin) until discharge from hospital
  ▪ continue LMWH or UFH followed by oral anticoagulation at discharge if at high risk for 
    thromboembolic event (large anterior MI, AFib, severe LV dysfunction, CHF, previous DVT or PE, 
    or echo evidence of mural thrombus)

3. β-blockers
  ▪ STEMI: contraindications include signs of heart failure, low output states, risk of cardiogenic shock, 
    heart block, asthma or airway disease; initiate orally within 24 h of diagnosis when indicated
  ▪ if β-blockers are contraindicated or if β-blockers/nitrates fail to relieve ischemia, non-
    dihydropyridine calcium channel blockers (e.g. diltiazem, verapamil) may be used as second-line 
    therapy in the absence of severe LV dysfunction or pulmonary vascular congestion (calcium channel 
    blockers do not prevent MI or decrease mortality)

4. Invasive Strategies and Reperfusion Options
  ▪ UA/NSTEMI: early coronary angiography ± revascularization if possible is recommended with any 
    of the following high-risk indicators:
    ▪ recurrent angina/ischemia at rest despite intensive anti-ischemic therapy
    ▪ CHF or LV dysfunction
    ▪ hemodynamic instability
    ▪ high (≥3) TIMI risk score (tool used to estimate mortality following an ACS)
    ▪ sustained ventricular tachycardia
    ▪ dynamic ECG changes
    ▪ high-risk findings on non-invasive stress testing
    ▪ PCI within the previous 6 mo
    ▪ repeated presentations for ACS despite treatment and without evidence of ongoing ischemia or 
      high risk features
    ▪ note: thrombolysis is NOT administered for UA/NSTEMI

![TIMI Risk Score for UA/NSTEMI](image-url)
Ischemic Heart Disease

Toronto Notes 2017

C29
Cardiology and Cardiac Surgery

STEMI
- after diagnosis of STEMI is made, do not wait for results of further investigations before implementing reperfusion therapy
- goal is to re-perfuse artery: thrombolysis ("EMS-to-needle") within 30 min or primary PCI ("EMS-to-balloon") within 90 min (depending on capabilities of hospital and access to hospital with PCI facility)
- thrombolysis
  - preferred if patient presents ≤12 h of symptom onset, and <30 min after presentation to hospital, has contraindications to PCI, or PCI cannot be administered within 90 min
- PCI
  - early PCI (≤12 h after symptom onset and <90 min after presentation) improves mortality vs. thrombolysis with fewer intra-cranial hemorrhages and recurrent MIs
  - primary PCI: without prior thrombolytic therapy – method of choice for reperfusion in experienced centres (JAMA 2004;291:736-739)
  - rescue PCI: following failed thrombolytic therapy (diagnosed when following thrombolysis, ST segment elevation fails to resolve below half its initial magnitude and patient still having chest pain)

![Diagnosis STEMI: basic treatment diagram]

**Figure 36. Reperfusion strategy in STEMI**

**Table 8. Contraindications for Thrombolysis in STEMI**

<table>
<thead>
<tr>
<th>Absolute</th>
<th>Relative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior intracranial hemorrhage</td>
<td>Chronic, severe, poorly controlled HTN</td>
</tr>
<tr>
<td>Known structural cerebral vascular lesion</td>
<td>Uncontrolled HTN (sBP &gt;180, dBP &gt;110)</td>
</tr>
<tr>
<td>Known malignant intracranial neoplasm</td>
<td>Current anticoagulation</td>
</tr>
<tr>
<td>Significant closed-head or facial trauma (≤3 mo)</td>
<td>Noncompressible vascular punctures</td>
</tr>
<tr>
<td>Ischemic stroke (≤3 mo)</td>
<td>Ischemic stroke (≥3 mo)</td>
</tr>
<tr>
<td>Active bleeding</td>
<td>Recent internal bleeding (≤2-4 wk)</td>
</tr>
<tr>
<td>Suspected aortic dissection</td>
<td>Prolonged CPR or major surgery (≥3 wk)</td>
</tr>
<tr>
<td></td>
<td>Pregnancy</td>
</tr>
<tr>
<td></td>
<td>Active peptic ulcer disease</td>
</tr>
</tbody>
</table>

**Long-Term Management of ACS**
- risk of progression to MI or recurrence of MI or death is highest within 1 mo
- at 1-3 mo after the acute phase, most patients resume a clinical course similar to that in patients with chronic stable coronary disease
- pre-discharge workup: ECG and echo to assess residual LV systolic function
- drugs required in hospital to control ischemia should be continued after discharge in all patients
- other medications for long-term management of ACS are summarized below

1. **General Measures**
   - education
   - risk factor modification

2. **Antiplatelet and Anticoagulation Therapy**
   - see also CCS Antiplatelet Guidelines 2012 for details (free mobile apps available on iOS and Android platforms in the CCS app stores)
   - ECASA 81 mg daily
   - ticagrelor 90 mg twice daily or prasugrel 10 mg daily (at least 1 mo, up to 9-12 mo, if stent placed at least 12 mo)
   - clopidogrel 75 mg daily can be used as alternatives to ticagrelor and prasugrel when indicated
   - ± warfarin x 3 mo if high risk (large anterior MI, LV thrombus, LVEF <30%, history of VTE, chronic AFib)
3. **β-Blockers** (e.g. metoprolol 25-50 mg bid or atenolol 50-100 mg daily)

4. **Nitrates**
   - alleviate ischemia but do not improve outcome
   - use with caution in right-sided MI patients who have become preload dependent

5. **Calcium Channel Blockers** (NOT recommended as first line treatment, consider as alternative to β-blockers)

6. **Angiotensin-Converting Enzyme Inhibitors**
   - prevent adverse ventricular remodelling
   - recommended for asymptomatic high-risk patients (e.g. diabetics), even if LVEF >40%
   - recommended for symptomatic CHF, reduced LVEF (<40%), anterior MI
   - use ARBs in patients who are intolerant of ACEI; avoid combing ACE and ARB

7. ± **Aldosterone Antagonists**
   - if on ACEI and β-blockers and LVEF <40% and CHF or DM
   - significant mortality benefit shown with eplerenone by 30d

8. **Statins** (early, intensive, irrespective of cholesterol level; e.g. atorvastatin 80 mg daily)

9. **Invasive Cardiac Catheterization if indicated** (risk stratification)

### Figure 37. Post-MI risk stratification

**Prognosis following STEMI**

- 5-15% of hospitalized patients will die
  - risk factors
  - infarct size/severity
  - age
  - comorbid conditions
  - development of heart failure or hypotension
- post-discharge mortality rates
  - 6-8% within first year, half of these within first 3 mo
  - 4% per year following first yr
  - risk factors
    - LV dysfunction
    - residual myocardial ischemia
    - ventricular arrhythmias
    - history of prior MI

### Table 9. Complications of Myocardial Infarction

<table>
<thead>
<tr>
<th>Complication</th>
<th>Etiology</th>
<th>Presentation</th>
<th>Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arrhythmia</td>
<td>Sinus, AFib, VT, VFib</td>
<td>First 48 h</td>
<td>See Arrhythmias, C16</td>
</tr>
<tr>
<td>Bradycardia</td>
<td>Sinus, AV block</td>
<td>First 48 h</td>
<td></td>
</tr>
<tr>
<td><strong>Myocardial Rupture</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. LV free wall</td>
<td>Transmural infarction</td>
<td>1-7 d</td>
<td>Surgery</td>
</tr>
<tr>
<td>2. Papillary muscle (± MR)</td>
<td>Inferior infarction</td>
<td>1-7 d</td>
<td>Surgery</td>
</tr>
<tr>
<td>3. Ventricular septum (± VSD)</td>
<td>Septal infarction</td>
<td>1-7 d</td>
<td>Surgery</td>
</tr>
<tr>
<td><strong>Shock/CHF</strong></td>
<td>Infarction or aneurysm</td>
<td>Within 48 h</td>
<td>Inotropes, intra-aortic balloon pump</td>
</tr>
<tr>
<td><strong>Post-Infarct Angina</strong></td>
<td>Persistent coronary stenosis</td>
<td>Anytime</td>
<td>Aggressive medical therapy</td>
</tr>
<tr>
<td><strong>Recurrent MI</strong></td>
<td>Reocclusion</td>
<td>Anytime</td>
<td>PCI or CABG</td>
</tr>
<tr>
<td><strong>Thromboembolism</strong></td>
<td>Mural/apical thrombus</td>
<td>7-10 d up to 6 mo</td>
<td>Anticoagulation</td>
</tr>
<tr>
<td><strong>Pericarditis</strong></td>
<td>Inflammatory</td>
<td>1-7 d</td>
<td>ASA</td>
</tr>
<tr>
<td><strong>Dressler’s Syndrome</strong></td>
<td>Autoimmune</td>
<td>2-8 wk</td>
<td></td>
</tr>
</tbody>
</table>
Treatment Algorithm for Chest Pain

Figure 38. Treatment algorithm for patients with symptoms suggestive of an acute coronary syndrome


Coronary Revascularization

PERCUTANEOUS CORONARY INTERVENTION
- interventional cardiology technique aimed at relieving significant coronary stenosis
- main techniques: balloon angioplasty, stenting
- less common techniques: rotational/directional/extraction atherectomy

Indications
- medically refractory angina
- NSTEMI/UA with high risk features (e.g., high TIMI risk score, see sidebar C28)
- primary/rescue PCI for STEMI

Balloon Angioplasty and Intracoronary Stenting
- coronary lesions dilated with balloon inflation
- major complication is restenosis (approximately 15% at 6 mo), felt to be due to elastic recoil and neointimal hyperplasia
- majority of patients receive intracoronary stent(s) to prevent restenosis
  - bare metal stent (BMS) versus drug-eluting stents: PRAMI trial demonstrated stenting non-culprit lesions results in 14% absolute risk reduction of cardiac death, nonfatal MI, or refractory angina
  - coated with antiproliferative drugs (sirolimus, paclitaxel, everolimus)
  - reduced rate of neointimal hyperplasia and restenosis compared to BMS (5% vs. 20%)
  - complication: late stent thrombosis (5 events per 1,000 stents implanted)

Intensive vs. Moderate Lipid Lowering with Statins after Acute Coronary Syndromes

- Study: Prospective, double blind, RCT; mean follow-up of 2 yr
- Population: 4,162 patients who had been hospitalized for an ACS within the preceding 10 d.
- Intervention: Patients were randomized to receiving pravastatin 40 mg or atorvastatin 80 mg daily.
- Primary Outcome: Composite of death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization (performed at least 30 d after randomization), and stroke.
- Results: High dose atorvastatin was associated with a 16% hazard ratio reduction (p=0.005; 95% CI 5-26%) in the primary outcome compared to standard dose pravastatin.
- Conclusions: In patients who recently experienced an ACS, high dose statin therapy provides greater protection against death and major cardiovascular events than standard dose therapy.
Adjunctive Therapies

- ASA and heparin decrease post-procedural complications
- Further reduction in ischemic complications has been demonstrated using GPIIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) in coronary angiography and stenting
- Following stent implantation
  - Dual antiplatelet therapy (ASA and clopidogrel) for 1 mo with BMS or ≥12 mo with DES
  - DAPT study showed benefit of dual antiplatelet therapy beyond 12 mo
- ASA and prasugrel can be considered for those at increased risk of stent thrombosis

Procedural Complications

- Mortality and emergency bypass rates <1%
- Nonfatal MI: approximately 2-3%

CORONARY ARTERY BYPASS GRAFT SURGERY

- Objective of CABG is complete reperfusion of the myocardium

Indications

- CABG
  - ≥50% diameter stenosis in the left main coronary artery
  - ≥70% diameter stenosis in three major coronary arteries
  - ≥70% diameter stenosis in the proximal LAD artery plus one other major coronary artery
  - Survivors of sudden cardiac arrest with presumed ischemia-mediated VT caused by significant (≥70% diameter) stenosis in a major coronary artery
- Other
  - ≥70% diameter stenosis in two major coronary arteries (without proximal LAD disease) and evidence of extensive ischemia
  - ≥70% diameter stenosis in the proximal LAD artery and evidence of extensive ischemia
  - Multivessel CAD in patients with diabetes
  - LV systolic dysfunction (LVEF 35% to 50%) and significant multivessel CAD or proximal LAD stenosis where viable myocardium is present in the region of intended revascularization
- PCI
  - UA/NSTEMI if not a CABG candidate
  - STEMI when PCI can be performed more rapidly and safely than CABG
- CABG or PCI
  - One or more significant (≥70% diameter) coronary artery stenosis amenable to revascularization and unacceptable angina despite medical therapy

Table 10. Choice of Revascularization Procedure

<table>
<thead>
<tr>
<th>PCI</th>
<th>CABG</th>
</tr>
</thead>
</table>
| **Advantages** | Less invasive technique  
Decreased peri-procedural morbidity and mortality  
Shorter peri-procedural hospitalization |
| **Indications** | Single or double-vessel disease  
Inability to tolerate surgery |
| **CABG** | Greater ability to achieve complete revascularization  
Decreased need for repeated revascularization procedures |
| **Triple-vessel or left main disease** |
| **DM** |
| **Plaque morphology unfavourable for PCI** |

Table 11. Conduits for CABG

<table>
<thead>
<tr>
<th>Conduit</th>
<th>Occlusion/Patency Rate</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saphenous Vein (SVG)</td>
<td>10-90% occluded, 25% stenotic, 25% angiographically normal</td>
<td>Used when arterial grafts are not available or many grafts are required, such as triple or quadruple bypass</td>
</tr>
</tbody>
</table>
| Left Internal Thoracic/Mammary Artery (LITA/LIMA) (LIMA to LAD) | 90-95% patency at 15 yr | Most preferred option because of excellent patency  
Improved event-free survival (angina, MI)  
Decreased late cardiac events  
No increase in operative risk |
| Right Internal Thoracic/Mammary Artery (RITA/RIMA) | Pedicled RIMA patency comparable to LIMA  
Free RIMA patency less | Used in bilateral ITA/RMA grafting  
Patients receiving bilateral ITAs/RMAs have less risk of recurrent angina, late MI, angioplasty |
| Radial Artery (free graft) | 85-90% patency at 5 yr | Prone to severe vasospasm post-operatively due to muscular wall |
| Right Gastroepiploic Artery | 80-90% patency at 5 yr | Primarily used as an in situ graft to bypass the RCA  
Use limited because of the fragile quality of the artery, other technical issues, increased operative time (laparotomy incision), and incisional discomfort with associated ileus |
| Complete Arterial Revascularization | For younger patients (< 60 yr of age)  
Is preferred due to longer term graft patency |
| Redo Bypass Grafting | Operative mortality 2-3x higher than first operation  
10% perioperative MI rate  
Reoperation undertaken only in symptomatic patients who have failed medical therapy and in whom angiography has documented progression of the disease  
Increased risk with redo-sternotomy secondary to adhesions which may result in laceration to aorta, RV, IMA/ITA, and other bypass grafts |
Operative Issues
• left ventricular (LV) function is an important determinant of outcome of all heart diseases
• patients with severe LV dysfunction usually have poor prognosis, but surgery can sometimes dramatically improve LV function
• assess viability of non-functioning myocardial segments in patients with significant LV dysfunction using delayed thallium myocardial imaging, stress echocardiography, PET scanning, or MRI

CABG and Antiplatelet Regimens
• please refer to CCS guidelines – 2012 update on antiplatelet therapy – for more information if possible
• prior to CABG, clopidogrel and ticagrelor should be discontinued for 5 d and prasugrel for 7 d before surgery
• dual antiplatelet therapy should be continued for 12 mo in patients with ACS within 48-72 h after CABG
• ASA (81 mg) continued indefinitely (can be started 6 h after surgery)
• patients requiring CABG after PCI should continue their dual antiplatelet therapy as recommended in the post-PCI guidelines

Table 12. Risk Factors for CABG Mortality and Morbidity (decreasing order of significance)

<table>
<thead>
<tr>
<th>Risk Factors for CABG Mortality</th>
<th>Risk Factors for CABG Post-Operative Morbidity or Increased Length of Stay</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urgency of surgery (emergent or urgent)</td>
<td>Reoperation</td>
</tr>
<tr>
<td>Reoperation</td>
<td>CHF</td>
</tr>
<tr>
<td>Older age</td>
<td>CABG + valve surgery</td>
</tr>
<tr>
<td>Poor left ventricular function (see below)</td>
<td>Older age</td>
</tr>
<tr>
<td>Female gender</td>
<td>Renal dysfunction</td>
</tr>
<tr>
<td>Left main disease</td>
<td>COPD</td>
</tr>
<tr>
<td>Others include catastrophic conditions (cardiogenic shock, ventricular septal rupture, ongoing CPR), dialysis-dependent renal failure, end-stage COPD, DM, cerebrovascular disease, and peripheral vascular disease</td>
<td>DM</td>
</tr>
</tbody>
</table>

Procedural Complications
• CABG using cardiopulmonary bypass (CPB)
  • stroke and neurocognitive defects (macroembolization of gaseous and particulate matter)
  • immunosuppression
  • systemic inflammatory response leading to
    • myocardial dysfunction
    • renal dysfunction
    • neurological injury
    • respiratory dysfunction
    • coagulopathies

OFF-PUMP CORONARY ARTERY BYPASS SURGERY

Procedure
• avoids the use of CPB by allowing surgeons to operate on a beating heart
  • stabilization devices (e.g. Genzyme Immobilizer®) hold heart in place allowing operation while positioning devices (Medtronic Octopus® and Starfish® system) allow the surgeon to lift the beating heart to access the lateral and posterior vessels
  • procedure is safe and well tolerated by most patients; however, this surgery remains technically more demanding

Indications
• used in poor candidates for CPB who have: calcified aorta, poor LVEF, severe peripheral vascular disease (PVD), severe COPD, chronic renal failure, coagulopathy, transfusion objections (e.g. Jehovah’s Witness), good target vessels, anterior/lateral wall revascularization, target revascularization in older, sicker patients
• absolute contraindications: hemodynamic instability, poor quality target vessels including intramyocardial vessels, diffusely diseased vessels, and calcified coronary vessels
• relative contraindications: cardiomegaly/CHF, critical left main disease, small distal targets, recent or current acute MI, cardiogenic shock, LVEF <35%

Outcomes
• OPCAB decreases in-hospital morbidity (decreased incidence of chest infection, inotropic requirement, supraventricular arrhythmia), blood product transfusion, ICU stay, length of hospitalization, and CK-MB and troponin I levels
• no significant difference in terms of survival at 2 yr, frequency of cardiac events (MI, PCI, CHF, recurrent angina, redo CABG), or medication usage compared to on-pump CABG
Heart Failure

- see also CCS Heart Failure Guidelines 2012 for details (free mobile apps available on iOS and Android platforms in the CCS app stores) as well as the CCS Heart Failure Guidelines Compendium available at CCS.ca

### Congestive Heart Failure

#### Low-Output HF due to decreased cardiac output

**Systolic Dysfunction**
- Injury and ischemia in myocardium
- Infarction and inflammation
- Thin, weakened muscle
- Ineffective ventricular contraction

**Diastolic Dysfunction**
- Infiltration and fibrosis
- Thick, stiffened myocardium
- Ineffective ventricular filling

#### High-Output HF due to increased cardiac demand

**Increased Cardiac Workload**
- Myocardial stress
- Volume overload
- Pressure overload

**Compensation**
- Increased heart rate and myocardial contractility
- Increased blood volume

#### Decompensation

- Deterioration of heart function
- Heart unable to maintain blood circulation

#### Systemic Response

- Activation of SNS and RAAS activity

#### Left-Sided HF

- Forward Failure
  - Inability to maintain cardiac output
  - Pulmonary vascular congestion
  - Fluid accumulation in lungs, apnea, shortness of breath, fatigue, weakness

- Backward Failure
  - Elevated ventricular filling pressures
  - Vascular congestion in vena cava
  - Fluid accumulation in lower extremities (edema in feet, ankles, legs, lower back, liver, abdomen), nausea

#### Right-Sided HF

- Backward Failure
  - Elevated ventricular filling pressures
  - Vascular congestion in vena cava
  - Fluid accumulation in lower extremities

- Forward Failure
  - Inability to maintain cardiac output
  - Pulmonary vascular congestion
  - Fluid accumulation in lungs, apnea, shortness of breath, fatigue, weakness

#### Biventricular HF

- Due to long-term left-sided failure leading to right-sided failure
- Disorders affecting entire myocardium

---

**Figure 39. Congestive Heart Failure**

**Table 13. Signs and Symptoms of Left vs. Right Heart Failure**

<table>
<thead>
<tr>
<th>Left Failure</th>
<th>Right Failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Cardiac Output (Forward)</td>
<td>Left failure symptoms if decreased RV output leads to LV underfilling</td>
</tr>
<tr>
<td>Fatigue</td>
<td>Tricuspid regurgitation</td>
</tr>
<tr>
<td>Syncope</td>
<td>S3 (right-sided)</td>
</tr>
<tr>
<td>Systemic hypotension</td>
<td></td>
</tr>
<tr>
<td>Cool extremities</td>
<td></td>
</tr>
<tr>
<td>Slow capillary refill</td>
<td></td>
</tr>
<tr>
<td>Peripheral cyanosis</td>
<td></td>
</tr>
<tr>
<td>Pulsus alternans</td>
<td></td>
</tr>
<tr>
<td>Mitral regurgitation</td>
<td></td>
</tr>
<tr>
<td>S3</td>
<td></td>
</tr>
<tr>
<td>Venous Congestion (Backward)</td>
<td></td>
</tr>
<tr>
<td>Dyspnea, orthopnea, PND</td>
<td>Peripheral edema</td>
</tr>
<tr>
<td>Cough</td>
<td>Elevated JVP with abdominojugular reflux, and Kussmaul’s sign</td>
</tr>
<tr>
<td>Crackles</td>
<td>Hepatomegaly</td>
</tr>
<tr>
<td></td>
<td>Pulsatile liver</td>
</tr>
</tbody>
</table>

---

**Does this Dyspneic Patient in the Emergency Department have Congestive Heart Failure?**

*JAMA* 2000;284:1944-1956

<table>
<thead>
<tr>
<th>LR + (95% CI)</th>
<th>LR – (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial clinical judgment</td>
<td>4.4</td>
</tr>
<tr>
<td>(1.8-10.0)</td>
<td>(0.28-0.73)</td>
</tr>
<tr>
<td>Past Medical History</td>
<td></td>
</tr>
<tr>
<td>Heart failure</td>
<td>5.8</td>
</tr>
<tr>
<td>(4.1-8.0)</td>
<td>(0.38-0.53)</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>3.1</td>
</tr>
<tr>
<td>(2.0-4.9)</td>
<td>(0.58-0.82)</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>1.8</td>
</tr>
<tr>
<td>(1.1-2.0)</td>
<td>(0.48-0.96)</td>
</tr>
<tr>
<td>Symptoms</td>
<td></td>
</tr>
<tr>
<td>Pansystolic tachycardia</td>
<td>2.6</td>
</tr>
<tr>
<td>(1.3-5.7)</td>
<td>(0.54-0.91)</td>
</tr>
<tr>
<td>Orthopnea</td>
<td>2.2</td>
</tr>
<tr>
<td>(1.3-3.9)</td>
<td>(0.49-0.92)</td>
</tr>
<tr>
<td>Dyspnea on exertion</td>
<td>1.3</td>
</tr>
<tr>
<td>(1.2-1.4)</td>
<td>(0.35-0.67)</td>
</tr>
<tr>
<td>Physical Exam</td>
<td></td>
</tr>
<tr>
<td>Third heart sound</td>
<td>11</td>
</tr>
<tr>
<td>(4.9-25)</td>
<td>(0.03-0.94)</td>
</tr>
<tr>
<td>Jugular venous distension</td>
<td>5.1</td>
</tr>
<tr>
<td>(3.2-7.9)</td>
<td>(0.57-0.77)</td>
</tr>
<tr>
<td>Rales</td>
<td>2.8</td>
</tr>
<tr>
<td>(1.9-4.1)</td>
<td>(0.37-0.70)</td>
</tr>
<tr>
<td>Lower extremity edema</td>
<td>2.3</td>
</tr>
<tr>
<td>(1.5-3.7)</td>
<td>(0.47-0.87)</td>
</tr>
<tr>
<td>Chest Radiograph</td>
<td></td>
</tr>
<tr>
<td>Pulmonary venous congestion</td>
<td>12</td>
</tr>
<tr>
<td>(6.8-21)</td>
<td>(0.28-0.83)</td>
</tr>
<tr>
<td>Intestinal edema</td>
<td>12</td>
</tr>
<tr>
<td>(5.2-27)</td>
<td>(0.54-0.85)</td>
</tr>
<tr>
<td>Cardiomegaly</td>
<td>3.3</td>
</tr>
<tr>
<td>(2.4-4.7)</td>
<td>(0.23-0.48)</td>
</tr>
<tr>
<td>ECG</td>
<td></td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>3.8</td>
</tr>
<tr>
<td>(1.7-8.8)</td>
<td>(0.55-0.96)</td>
</tr>
<tr>
<td>Any abnormal finding</td>
<td>2.2</td>
</tr>
<tr>
<td>(1.6-3.1)</td>
<td>(0.47-0.88)</td>
</tr>
</tbody>
</table>

---

**Dichotomies of Heart Failure**

- Forward vs. backward
- Left-sided vs. right-sided
- Systolic vs. diastolic dysfunction
- Low output vs. high output

**Use Ejection Fraction to Grade LV Dysfunction**

- Grade I (EF > 60%) (Normal)
- Grade II (EF = 40-59%)
- Grade III (EF = 21-39%)
- Grade IV (EF ≤20%)
Pathophysiology
- most common causes are ischemic heart disease, hypertension and valvular heart disease
- myocardial insult causes pump dysfunction/impaired filling leading to myocardial remodelling
  - pressure overload (e.g. AS or HTN) leads to compensatory hypertrophy (concentric remodelling) and eventually interstitial fibrosis
  - volume overload (e.g. AI) leads to dilatation (eccentric remodelling)
- both processes lead to maladaptive changes contributing to disease process
- results in decreased volume cardiac output resulting in activation of the SNS and RAAS
- Na+ and water retention, increasing preload and afterload, tachycardia
- perpetuates cycle of increasing cardiac demand and decompensation

Heart Failure with Reduced Ejection Fraction
- impaired myocardial contractile function → decreased LVEF and SV → decreased CO

Volume Overload and Eccentric Remodelling is the Typical Phenotype
- findings: apex beat displaced, S3, cardiothoracic ratio >0.5, decreased LVEF; LV dilatation
- causes
  - ischemic (e.g. extensive CAD, previous MI)
  - non-ischemic
    - HTN
    - DM
    - alcohol (and other toxins)
    - myocarditis
    - dilated cardiomyopathy (multiple causes – see Dilated Cardiomyopathy, C40)

Heart Failure with Preserved Ejection Fraction
- previously known as “diastolic heart failure”
- concentric remodelling with a “stiff” left ventricle is the typical phenotype
- 1/2 of patients with heart failure have preserved EF; confers similar prognosis to HFrEF; more common in the elderly and females
- reduced LV compliance causes increased LV filling pressures, increased LA pressure/volume, and pulmonary congestion
- findings: HTN, apex beat sustained, S4, normal-sized heart on CXR, LVH on ECG/echo, normal EF
- causes
  - transient: ischemia (relaxation of myocardium is active and requires ATP)
  - permanent
    - severe hypertrophy (HTN, aortic stenosis, HCM)
    - restrictive cardiomyopathy (e.g. amyloid)
  - MI

High-Output Heart Failure
- caused by demand for increased cardiac output
- often exacerbates existing heart failure or decompensates a patient with other cardiac pathology
- differential diagnosis: anemia, thiamine deficiency (beriberi), hyperthyroidism, A-V fistula or L-R shunting, Paget’s disease, renal disease, hepatic disease

Precipitants of Symptomatic Exacerbations
- consider natural progression of disease vs. new precipitant
- always search for reversible cause
- differential diagnosis can also be organized as follows:
  - new cardiac insult/disease: MI, arrhythmia, valvular disease
  - new demand on CV system: HTN, anemia, thyrotoxicosis, infection, etc.
  - medication non-compliance
  - dietary indiscretion e.g. salt intake
  - obstructive sleep apnea

Investigations
- identify and assess precipitating factors and treatable causes of CHF
- blood work: CBC, electrolytes (including calcium and magnesium), BUN, creatinine, fasting blood glucose, HbA1c, lipid profile, liver function tests, serum TSH ± ferritin, BNP, uric acid
- ECG: look for chamber enlargement, arrhythmia, ischemia/infarction
- CXR: cardiomegaly, pleural effusion, redistribution, Kerley B lines, bronchial-alveolar cuffing
- echo: systolic function (LVEF), diastolic function (E/A ratio, E/e’), cardiac dimensions, wall motion abnormalities, RVSP (from TR jet), valvular disease, pericardial effusion
- radionuclide angiography: LVEF
- myocardial perfusion scintigraphy (thallium or sestamibi SPECT)

A Validated Clinical and Biochemical Score for the Diagnosis of Acute Heart Failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Possible Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>0-5</td>
</tr>
<tr>
<td>Intermediate</td>
<td>6-8</td>
</tr>
<tr>
<td>High</td>
<td>9-14</td>
</tr>
</tbody>
</table>

Likelihood of heart failure
- Low = 0.5
- Intermediate = 6-8
- High = 9-14

Brain natriuretic peptide (BNP) is secreted by ventricles due to LV stretch and wall tension. Cardiomyocytes secrete BNP precursor that is cleaved into proBNP. After secretion into ventricles, proBNP is cleaved into the active C-terminal portion and the inactive NT-proBNP. The above scoring algorithm developed by Briaud et al. is commonly used. A score of <4 has a negative predictive value of 98%, while scores ≥6 had a sensitivity of 86% and specificity of 84% (p < 0.001) for the diagnosis of acute heart failure.

New York Heart Association (NYHA)

- Class I: ordinary physical activity does not cause symptoms of HF
- Class II: comfortable at rest, ordinary physical activity results in symptoms
- Class III: marked limitation of ordinary activity, less than ordinary physical activity results in symptoms
- Class IV: inability to carry out any physical activity without discomfort; symptoms may be present at rest

Five Most Common Causes of CHF
- CAD (60-70%)
- HTN
- Idiopathic (often dilated cardiomyopathy)
- Valvular (e.g. AS, AR, and MR)
- Alcohol (dilated cardiomyopathy)

Precipitants of Heart Failure

HEART FAILED
- Hypertension (common)
- Endocarditis/environment (e.g. heat wave)
- Anemia
- Rheumatic heart disease and other valvular disease
- Thyrotoxicosis
- Failure to take meds (very common)
- Arrhythmia (common)
- Infection/Ischemia/Infarction (common)
- Lung problems (PE, pneumonia, COPD)
- Endocrine (pheochromocytoma, hyperadrenocorticism)
- Dietary indiscretions (common)
Acute Treatment of Pulmonary Edema
• treat acute precipitating factors (e.g. ischemia, arrhythmias)
• L – Lasix® (furosemide) 40-500 mg IV
• M – morphine 2-4 mg IV: decreases anxiety and preload (venodilation)
• N – nitroglycerin: topical/IV/SL - use with caution in preload-dependent patients (e.g. right HF or RV infarction) as it may precipitate CV collapse
• O – oxygen: in hypoxicemic patients
• P – positive airway pressure (CPAP/BiPAP): decreases preload and need for ventilation when appropriate
• P – position: sit patient up with legs hanging down unless patient is hypotensive
• in ICU setting or failure of LMNOPP, other interventions may be necessary
  - nitroprusside IV
  - hydralazine PO
  - sympathomimetics
    • dopamine
      – low dose: selective renal vasodilation (high potency D1 agonist)
      – medium dose: inotropic support (medium potency β1 agonist)
      – high dose: increases SVR (low potency β1 agonist), which is undesirable
    • dobutamine
      – β1-selective agonist causing inotropy, tachycardia, hypotension (low dose) or hypertension (high dose); most serious side effect is arrhythmia, especially AF
    • phosphodiesterase inhibitors (milrinone)
      – inotropic effect and vascular smooth muscle relaxation (decreased SVR), similar to dobutamine
• consider pulmonary artery catheter to monitor pulmonary capillary wedge pressure (PCWP) if patient is unstable or a cardiac etiology is uncertain (PCWP >18 indicates likely cardiac etiology)
• mechanical ventilation as needed
• rarely used, but potentially life-saving measures:
  - intra-aortic balloon pump (IABP) - reduces afterload via systolic unloading and improves coronary perfusion via diastolic augmentation
  - left or right ventricular assist device (LVAD/RVAD)
  - cardiac transplant

Long-Term Management
• overwhelming majority of evidence-based management applies to HREF
• currently no proven pharmacologic therapies shown to reduce mortality in HFPEF; control risk factors (e.g. hypertension)

Conservative Measures
• symptomatic measures: oxygen in hospital, bedrest, elevate the head of bed
• lifestyle measures: diet, exercise, DM control, smoking cessation, decrease alcohol consumption, patient education, sodium and fluid restriction
• multidisciplinary heart failure clinics: for management of individuals at higher risk, or with recent hospitalization

Non-Pharmacological Management
• from CCS guidelines (2013 update)
• cardiac rehabilitation: participation in a structured exercise program for NYHA class I-III with LVEF <40%

Pharmacological Therapy
1. Renin-angiotensin-aldosterone blockade
• ACEI: standard of care – slows progression of LV dysfunction and improves survival
  • all asymptomatic patients functional classes II-IV
  • all asymptomatic patients with LVEF <40%
  • post-MI
  • angiotensin II receptor blockers
    • second-line to ACEI if not tolerated, or as adjunct to ACEI if β-blockers not tolerated
      – combination with ACEI is not routinely recommended and should be used with caution as it may precipitate hyperkalemia, renal failure, the need for dialysis and increase (CHARM, ONTARGET)
    • combination angiotensin II receptor blockers with neprilysin inhibitors (ARNI) is a new class of medication that has morbidity and mortality benefit over ACEI alone; it has been recommended to replace ACEI or ARBs for patients who have persistent symptoms (PARADIGM HF)

2. β-blockers: slow progression and improve survival
• class I-III with LVEF <40%
• stable class IV patients
• carvedilol improves survival in class IV HF (COMET)
• note: should be used cautiously, titrate slowly because may initially worsen CHF
3. **Mineralocorticoid receptor (aldosterone) antagonists:** mortality benefit in symptomatic heart failure and severely depressed ejection fraction
   - spironolactone or eplerenone symptomatic heart failure in patients already on ACEI, beta blocker and loop diuretic
   - note: potential for life threatening hyperkalemia
   - monitor K+ after initiation and avoid if Cr >220 μmol/L or K+ >5.2 mmol/L

4. **Diuretics:** symptom control, management of fluid overload
   - furosemide (40-500 mg daily) for potent diuresis
   - metolazone may be used with furosemide to increase diuresis
   - furosemide, metolazone, and thiazides oppose the hyperkalemia that can be induced by β-blockers, ACEI, ARBs, and aldosterone antagonists

5. **Digoxin and cardiac glycosides:** digoxin improves symptoms and decreases hospitalizations, no effect on mortality
   - indications: patient in sinus rhythm and symptomatic on ACEI, or CHF and AFib
   - patients on digitalis glycosides may worsen if these are withdrawn

6. **Antiarrhythmic agents:** for use in CHF with arrhythmia
   - can use amiodarone, β-blocker, or digoxin

7. **Anticoagulants:** warfarin for prevention of thromboembolic events
   - prior thromboembolic event or AFib, presence of LV thrombus on echo

**Procedural Interventions**
- resynchronization therapy: symptomatic improvement with biventricular pacemaker
- consider if QRS >130 msec, LVEF <35%, and persistent symptoms despite optimal therapy
- greatest benefit likely with marked LV enlargement, mitral regurgitation, QRS >150 msec.
- ICD: mortality benefit in 1° prevention of sudden cardiac death
- prior MI, optimal medical therapy, LVEF <30%, clinically stable
- prior MI, non-sustained VT, LVEF 30-40%, EPS inducible VT
- LVAD/RVAD (see Ventricular Assist Devices, C38)
- cardiac transplantation (see Cardiac Transplantation, C38)
- valve repair if patient is surgical candidate and has significant valve disease contributing to CHF (see Valvular Heart Disease, C38)

**Sleep-Disordered Breathing**
- 45-55% of patients with CHF have sleep disturbances, including Cheyne-Stokes breathing and sleep apnea (central or obstructive)
- associated with a worse prognosis and greater LV dysfunction
- nasal continuous positive airway pressure (CPAP) is effective in treating symptoms of sleep apnea with secondary beneficial effects in cardiac function and symptoms

**Figure 40. Effect of heart failure treatment on the Frank-Starling curve**

**Chronic Treatment of CHF**
- ACEI
- β-blockers
- Mineralocorticoid receptor antagonists
- Diuretic
- Inotrope
- Antiarrhythmic
- Anticoagulant

**Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients**
- Circulation 2005;112:3738-3744
- **Purpose:** Understand the relationship between ejection fractions and cardiovascular risk in patients with heart failure.
- **Methods:** 7,590 patients from the CHARM study (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity; RCT comparing placebo vs. candesartan in patients with NYHA class II vs. IV). Compared LVEF to cardiovascular outcomes and causes of death.
- **Results:** All-cause mortality increased by 30% per 10% reduction in LVEF below 45% (Hazard ratio 1.39, 95% CI 1.32-1.46). For LVEF>45%, ejection fraction does not further contribute to assessment of cardiovascular risk in HF patients.
- **Conclusions:** At LVEF<45%, lower ejection fractions were associated with poorer cardiovascular outcomes.

<table>
<thead>
<tr>
<th>LVEF (%)</th>
<th>CHF Hospitalization</th>
<th>All-Cause Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;22%</td>
<td>14.9%</td>
<td>15.4%</td>
</tr>
<tr>
<td>23-32%</td>
<td>10.9%</td>
<td>10.8%</td>
</tr>
<tr>
<td>33-42%</td>
<td>7.2%</td>
<td>7.4%</td>
</tr>
<tr>
<td>43-52%</td>
<td>5.7%</td>
<td>5.2%</td>
</tr>
<tr>
<td>&gt;52%</td>
<td>4.9%</td>
<td>5.7%</td>
</tr>
</tbody>
</table>

**Higher New York Heart Association Classes and Increased Mortality and Hospitalization in Patients with Heart Failure and Preserved Left Ventricular Function**
- Am Heart J 2006;151:444-450
- **Purpose:** To establish the association between NYHA classes and outcomes with heart failure and preserved systolic function.
- **Methods:** Retrospective follow-up study (median 38.5 mo) of 988 patients with heart failure with ejection fraction >45%. Estimated risks of various outcomes using Cox proportional hazard models.
- **Results:** Adjusted hazard ratio for all-cause mortality for NYHA class II, III, IV patients was 1.54, 2.56, and 8.46, respectively. Adjusted hazard ratio for all-cause hospitalization for NYHA class II, III, IV patients was 1.23, 1.71, and 3.4, respectively.
- **Conclusions:** Higher NYHA classes were associated with poorer outcomes in patients with heart failure and preserved systolic function. Proportions of NYHA I, II, III, and IV patients who died of all causes during the study were 14.3%.
Cardiac Transplantation

- treatment for end-stage heart disease; due to ischemic or non-ischemic cardiomyopathy
- worldwide 1 yr survival is 85-90%, 5 yr survival about 60%, annual mortality rate of 4%
- matching is according to blood type, body size and weight (should be within 25%), and HLA tissue matching (if time allows)

Indications for Surgery
- severe cardiac disability despite maximal medical therapy (e.g. recurrent hospitalizations for CHF; NYHA III or IV; peak metabolic oxygen consumption <14 mL/kg/min in absence of β-blocker)
- symptomatic cardiac ischemia refractory to conventional treatment (e.g. unstable angina not amenable to CABG or PCI with LVEF <30%; recurrent, symptomatic ventricular arrhythmias)
- exclusion of all surgical alternatives to cardiac transplantation

Prerequisites
- psychosocial stability
- medically compliant and motivated
- relative contraindications: incurable malignancy, major systemic illness, irreversible major organ disease, active systemic infection, obesity, irreversible pulmonary HTN (pulmonary vascular resistance [PVR] >6 Wood units), severe COPD (FEV1 <1 L) or active drug addiction or alcoholism

Complications
- rejection
  - common, <5% have serious hemodynamic compromise
  - gold standard to detect rejection: endomyocardial biopsy
  - risk of acute rejection is greatest during the first 3 mo after transplant
- infection
  - leading cause of morbidity and mortality after cardiac transplantation
  - risk peaks early during the first few months after transplantation and then declines to a low persistent rate
- allograft CAD
  - approximately 50% develop graft CAD within 5 yr of transplantation
  - most common cause of late death following transplantation
- malignancy
  - develops in 15% of cardiac transplant recipients due to immunosuppressive medication
  - second most common cause of late death following transplantation
- cutaneous neoplasms most common, followed by non-Hodgkin's lymphoma and lung cancer
- immunosuppressive medication side effects (prednisone, cyclosporine, tacrolimus, sirolimus)

Ventricular Assist Devices

- work to unload the ventricle while maintaining output; also results in decreased myocardial oxygen consumption permitting recovery of the myocardium that is not irreversibly injured
- can support the left (LVAD), right (RVAD), or both ventricles (BVAD)
- indications
  - bridge to transplantation, bridge to decision (for transplant), or long term permanent therapy (“destination therapy”)
  - post-operative mechanical support when unable to separate from cardiopulmonary bypass despite inotropic and intra-aortic balloon pump (IABP) support
  - IABP is a catheter based device inserted into the femoral artery and advanced to the descending aorta that decreases myocardial O2 demand and increases blood flow to coronary arteries
  - inflation of the balloon occurs during diastole to increase ascending aorta and coronary artery perfusion pressure; deflation occurs at systole to reduce intra-aortic pressure thus reducing afterload
- post-operative cardiogenic shock
Myocardial Disease

Definition of Cardiomyopathy
- intrinsic or primary myocardial disease not secondary to congenital, hypertensive, coronary, valvular, or pericardial disease
- functional classification: dilated, hypertrophic, or restrictive
- LV dysfunction 2° to MI often termed “ischemic cardiomyopathy”, is not a true cardiomyopathy (i.e. primary myocardial disorder) since the primary pathology is obstructive CAD

Table 14. Summary Table for CHF and Myocardial Disease

<table>
<thead>
<tr>
<th>Heart Failure Reduced Ejection Fraction</th>
<th>Heart Failure Preserved Ejection Fraction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dilated Cardiomyopathy</td>
<td>Secondary Causes</td>
</tr>
<tr>
<td>Idiopathic, infectious (e.g. myocarditis), alcohol, familial, collagen vascular disease, etc.</td>
<td>CAD, MI, DM, valvular (e.g. AR, MR)</td>
</tr>
<tr>
<td>Restrictive Cardiomyopathy</td>
<td>Amyloidosis, sarcoidosis, scleroderma, hemochromatosis, Fabry’s, Pompe’s Disease, Loeffler’s, etc.</td>
</tr>
</tbody>
</table>

Myocarditis

Definition
- inflammatory process involving the myocardium ranging from acute to chronic; an important cause of dilated cardiomyopathy

Etiology
- idiopathic
- infectious
  - viral (most common): parvovirus B19, influenza, coxsackie B, echovirus, poliovirus, HIV, mumps
  - bacterial: S. aureus, C. perfringens, C. diphtheriae, Mycoplasma, Rickettsia
  - fungi
  - spirochetal (Lyme disease – Borelia burgdorferi)
  - Chagas disease (Trypanosoma cruzi), toxoplasmosis
  - toxic: catecholamines, chemotherapy, cocaine
  - hypersensitivity/eosinophilic: drugs (antibiotics, diuretics, lithium, clozapine), insect/snake bites
  - systemic diseases: collagen vascular diseases (SLE, rheumatoid arthritis, others), sarcoidosis, autoimmune
  - other: giant cell myocarditis, acute rheumatic fever

Signs and Symptoms
- constitutional symptoms
- acute CHF - dyspnea, tachycardia, elevated JVP
- chest pain – due to pericarditis or cardiac ischemia
- arrhythmias
- systemic or pulmonary emboli
- pre-syncpe/syncope/sudden death

Investigations
- ECG: non-specific ST-T changes ± conduction defects
- blood work
  - increased CK, troponin, LDH, and AST with acute myocardial necrosis ± increased WBC, ESR, ANA, rheumatoid factor, complement levels
  - blood culture, viral titres and cold agglutinins for Mycoplasma
- CXR: enlarged cardiac silhouette
- echo: dilated, hypokinetic chambers, segmental wall motion abnormalities
- cardiovascular magnetic resonance: functional and morphological abnormalities as well as tissue pathology (gadolinium enhancement)
- myocardial biopsy

Management
- supportive care
- restrict physical activity
- treat CHF
- treat arrhythmias
- anticoagulation
- treat underlying cause if possible
Prognosis
- often unrecognized, and may be self-limited
- myocarditis treatment trial showed 5 yr mortality between 25-50%
- giant cell myocarditis, although rare can present with fulminant CHF and be rapidly fatal, with 5 yr mortality >80%
- sudden death in young adults
- may progress to dilated cardiomyopathy

Dilated Cardiomyopathy

Definition
- unexplained dilation and impaired systolic function of one or both ventricles

Etiology
- idiopathic (presumed viral or idiopathic) ~50% of DCM
- alcohol
- familial/genetic
- uncontrolled tachycardia (e.g. persistent rapid AFib)
- collagen vascular disease: SLE, polyarteritis nodosa, dermatomyositis, progressive systemic sclerosis
- infectious: viral (coxsackie B, HIV), Chagas disease, Lyme disease, Rickettsial diseases, acute rheumatic fever, toxoplasmosis
- neuromuscular disease: Duchenne muscular dystrophy, myotonic dystrophy, Friedreich’s ataxia
- metabolic: uremia, nutritional deficiency (thiamine, selenium, carnitine)
- endocrine: hyper/hypothyroidism, DM, pheochromocytoma
- peripartum
toxic: cocaine, heroin, organic solvents
drugs: chemotherapies (doxorubicin, cyclophosphamide), anti-retrovirals, chloroquine, clozapine, TCA
radiation

Signs and Symptoms
- may present as
  - CHF
  - systemic or pulmonary emboli
  - arrhythmias
  - sudden death (major cause of mortality due to fatal arrhythmia)

Investigations
- blood work: CBC, electrolytes, Cr, bicarbonate, BNP, CK, troponin, LFTs, TSH, TIBC
- ECG: variable ST-T wave abnormalities, poor R wave progression, conduction defects (e.g. BBB), arrhythmias (non-sustained VT)
- CXR: global cardiomegaly (globular heart), signs of CHF, pleural effusion
- echo: chamber enlargement, global hypokinesis, depressed LVEF, MR and TR, mural thrombi
- endomyocardial biopsy: not routine, used to rule out a treatable cause
- coronary angiography: in selected patients to exclude ischemic heart disease

Management
- treat underlying disease: e.g. abstinence from alcohol
- treat CHF: see Heart Failure, C34
- thromboembolism prophylaxis: anticoagulation with warfarin
  - indicated for: AFib, history of thromboembolism or documented thrombus
- treat symptomatic or serious arrhythmias
- immunize against influenza and S. pneumoniae
- consider surgical options (e.g. LVAD, transplant, volume reduction surgery) in appropriate candidates with severe, drug refractory disease
- consider ICD among patients with a LVEF <30%

Prognosis
- depends on etiology
- better with reversible underlying cause, worst with infiltrative diseases, HIV, drug-induced
- cause of death usually CHF (due to pump failure) or sudden death 2° to ventricular arrhythmias
- systemic emboli are significant source of morbidity
- 20% mortality in 1st yr, 10% per year after
Hypertrophic Cardiomyopathy

- see 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy for details

Definition
- defined as unexplained ventricular hypertrophy
- various patterns of HCM are classified, but most causes involve pattern of septal hypertrophy

Etiology and Pathophysiology
- histopathologic features include myocyte disarray, myocyte hypertrophy, and interstitial fibrosis
- cause is felt to be a genetic defect involving one of the cardiac sarcomeric proteins (>400 mutations associated with autosomal dominant inheritance, incomplete penetrance)
- prevalence of 1/500-1/1,000 in general population
- generally presents in early adulthood

Hemodynamic Classification
- hypertrophic obstructive cardiomyopathy (HOCM): dynamic LV outflow tract (LVOT) obstruction, either at rest or with provocation, defined as LVOT gradient of at least 30 mmHg
  - dynamic i.e. obstruction (and the murmur) is reduced with maneuvers that increase preload, and augmented with maneuvers that reduce preload
- non-obstructive HCM: no LVOT obstruction
- many patients have diastolic dysfunction (impaired ventricular filling secondary to LV hypertrophy which decreases compliance)

Signs and Symptoms
- clinical manifestations: asymptomatic (common, therefore screening is important), SOB on exertion, angina, presyncope/syncope (due to LV outflow obstruction or arrhythmia), CHF, arrhythmias, SCD
- pulses: rapid upstroke, “spike and dome” pattern in carotid pulse (in HCM with outflow tract obstruction)
- precordial palpation: PMI localized, sustained, double impulse, ‘triple ripple’ (triple apical impulse in HOCM), LV lift
- precordial auscultation: normal or paradoxically split S2, S4, harsh systolic diamond-shaped murmur at LLSB or apex, enhanced by squat to standing or Valsalva (murmur secondary to LVOT obstruction as compared to AS); often with pansystolic murmur due to mitral regurgitation

Investigations
- ECG/Holter monitor: LVH, high voltages across precordium, prominent Q waves (lead I, aVL, V5, V6), tall R wave in V1, P wave abnormalities
- transthoracic echocardiography and echo-Doppler study: asymmetric septal hypertrophy (less commonly apical), systolic anterior motion (SAM) of mitral valve and MR, LVOT gradient can be estimated by Doppler measurement
- genetic studies (± magnetic resonance imaging) can be helpful when echocardiography is inconclusive for diagnosis
- cardiac catheterization (only when patient being considered for invasive therapy)

Management
- avoid factors which increase obstruction (e.g. volume depletion)
  - avoidance of all competitive sports
- treatment of obstructive HCM
  - medical agents: β-blockers, disopyramide, verapamil (started only in monitored setting), phenylephrine (in setting of cardiogenic shock)
  - avoid nitrates, diuretics, and ACEI as they increase LVOT gradient and worsen symptoms
- patients with obstructive HCM and drug-refractory symptoms
  - surgical myectomy
  - alcohol septal ablation - percutaneous Intervention that ablates the hypertrophic septum with 100% ethanol via the septal artery
  - dual chamber pacing (rarely done)
- treatment of patients at high risk of sudden death : ICD
  - first-degree relatives (children, siblings, parents) of patients with HCM should be screened (physical, ECG, 2D echo) every 12-18 mo during adolescence, then serially every 5 yr during adulthood

Prognosis
- potential complications: AFib, VT, CHF, sudden cardiac death (1% risk/yr; most common cause of SCD in young athletes)
  - major risk factors for sudden death (consider ICD placement)
  - history of survived cardiac arrest/sustained VT
  - family history of multiple premature sudden deaths
  - other factors associated with increased risk of sudden cardiac death
    - syncope (presumed to be arrhythmic in origin)
    - non-sustained VT on ambulatory monitoring
    - marked ventricular hypertrophy (maximum wall thickness ≥30 mm)
    - abnormal BP in response to exercise (in patients <40 yr old with HCM)

RCM vs. Constrictive Pericarditis (CP)
Present similarly but CP is treatable with surgery
## Restrictive Cardiomyopathy

### Definition
- impaired ventricular filling with preserved systolic function in a non-dilated, non-hypertrophied ventricle secondary to factors that decrease myocardial compliance (fibrosis and/or infiltration)

### Etiology
- infiltrative: amyloidosis, sarcoidosis
- non-infiltrative: scleroderma, idiopathic myocardial fibrosis
- storage diseases: hemochromatosis, Fabry’s disease, Gaucher’s disease, glycogen storage diseases
- endomyocardial
  - endomyocardial fibrosis, Loeffler’s endocarditis, or eosinophilic endomyocardial disease
  - radiation heart disease
  - carcinoid syndrome (may have associated tricuspid valve or pulmonary valve dysfunction)

### Clinical Manifestations
- CHF (usually with preserved LV systolic function), arrhythmias
- elevated JVP with prominent x and y descents, Kussmaul’s sign
- S3, S4, MR, TR
- thromboembolic events

### Investigations
- ECG: low voltage, non-specific, diffuse ST-T wave changes ± non-ischemic Q waves
- CXR: mild cardiac enlargement
- Echo: LAE, RAE; specific Doppler findings with no significant respiratory variation
- cardiac catheterization: increased end-diastolic ventricular pressures
- endomyocardial biopsy: to determine etiology (especially for infiltrative RCM)

### Management
- exclude constrictive pericarditis
- treat underlying disease: control HR, anticoagulate if AFib
- supportive care and treatment for CHF, arrhythmias
- heart transplant: might be considered for CHF refractory to medical therapy

### Prognosis
- depends on etiology
Valvular Heart Disease

- see Guidelines on the Management of Valvular Heart Disease. JACC Jun 10;63(22):2438-88 for details

Infected Endocarditis
- see Infectious Diseases, ID16
- American Heart Association (AHA) 2007 guidelines recommend IE prophylaxis
  - only for patients with
    - prosthetic valve material
    - past history of IE
    - certain types of congenital heart disease
    - cardiac transplant recipients who develop valvulopathy
  - only for the following procedures
    - dental
    - respiratory tract
    - procedures on infected skin/skin structures/MSK structures
    - not GI/GU procedures specifically

Increased risk of hemorrhage: 1-2%/yr

Target INR

Requires long-term anticoagulation with coumadin

Decreased risk of thromboembolism: long-term anticoagulation not needed for aortic valves

Mitrail Valve Repair vs. Replacement for Severe Ischemic Mitral Regurgitation
NEJM 2014;370:23-32

Purpose: Ischemic mitral regurgitation is associated with significant mortality risk. The purpose of this study was to compare the effectiveness and safety of repairing versus replacing the mitral valve in patients with severe chronic ischemic mitral regurgitation.

Study Design: RCT with 251 patients with severe ischemic mitral regurgitation were randomly assigned to mitral valve repair or chordal-sparing replacement. The primary endpoint was the left ventricular end-systolic volume index (LVESVI) at 12 mo.

Results: There were no significant between-group differences in LVESVI, in the rate of major adverse cardiac or cerebrovascular events, in functional status, or in quality of life at 12 mo. The rate of moderate or severe mitral regurgitation recurrence at 12 mo was significantly higher in the repair group than in the replacement group (22.8% vs. 2.3%, respectively).

Conclusions: No significant difference in left ventricular reverse remodeling or survival at 12 mo between patients who underwent mitral valve repair or replacement. Replacement provided more durable correction of mitral regurgitation, but there were no significant differences in clinical outcomes.

Rheumatic Fever
- see Pediatrics, PS8

Prognosis
- acute complications: myocarditis (DCM/CHF), conduction abnormalities (sinus tachycardia, AFib), valvulitis (acute MR), acute pericarditis (not constrictive pericarditis)
- chronic complications: rheumatic valvular heart disease – fibrous thickening, adhesion, calcification of valve leaflets resulting in stenosis/regurgitation, increased risk of IE ± thromboembolism
- onset of symptoms usually after 10-20 yr latency from acute carditis of rheumatic fever
- mitral valve most commonly affected

Valve Repair and Valve Replacement

- indication for valve repair or replacement depends on the severity of the pathology; typically recommended when medical management has failed to adequately improve the symptoms or reduce the risk of morbidity and mortality
- pathologies that may require surgical intervention include congenital defects, infections, rheumatic heart disease as well as a variety of valve diseases associated with aging
- valve repair: balloon valvuloplasty, surgical valvuloplasty (commissurotomy, annuloplasty), chordae tendinae shortening, tissue patch
- valve replacement: typically for aortic or mitral valves only; mitral valve repair is favoured in younger individuals; percutaneous techniques being established

Choice of Valve Prosthesis

Table 15. Mechanical Valve vs. Bioprosthetic Valve

<table>
<thead>
<tr>
<th>Mechanical Valve</th>
<th>Bioprosthetic Valve</th>
</tr>
</thead>
<tbody>
<tr>
<td>Good durability</td>
<td>Limited long-term durability (mitral &lt; aortic)</td>
</tr>
<tr>
<td>Less preferred in small aortic root sizes</td>
<td>Good flow in small aortic root sizes</td>
</tr>
<tr>
<td>Increased risk of thromboembolism (1-3%/yr): requires long-term anticoagulation with coumadin</td>
<td>Decreased risk of thromboembolism: long-term anticoagulation not needed for aortic valves</td>
</tr>
<tr>
<td>Target INR</td>
<td>Some recommendation for limited anticoagulation for mitral valves</td>
</tr>
<tr>
<td>Aortic valves: 2.0-3.0 (mean 2.5)</td>
<td>Increased risk of hemorrhage: 1-2%/yr</td>
</tr>
<tr>
<td>Mitral valves: 2.5-3.5 (mean 3.0)</td>
<td>Decreased risk of hemorrhage</td>
</tr>
</tbody>
</table>

Decreased risk of hemorrhage
# Summary of Valvular Disease

## Aortic Stenosis (AS)

### Etiology
- Congenital (bicuspid, unicuspid valve)
- Calcification (wear and tear)
- Rheumatic disease

### Definition
- Normal aortic valve area = 3-4 cm²
- Mild AS: 1.5 to 3 cm²
- Moderate AS: 1.0 to 1.5 cm²
- Severe AS: < 1.0 cm²
- Critical AS: < 0.5 cm²

### Pathophysiology
- Outflow obstruction → increased EDP → concentric LVH → LV failure → CHF
- Subendocardial ischemia

### Symptoms
- Exertional angina, syncope, dyspnea, PND, orthopnea, peripheral edema

### Physical Exam
- Narrow pulse pressure, brachial-radial delay, pulsed parvus et tardus, sustained PMI
- Auscultation: crescendo-decrescendo SEM radiating to R clavicle and carotid, musical quality at apex (Gallavardin phenomenon)

### Investigations
- ECG: LV strain, BBBB, LAE, A fib
- CXR: post-stenotic aortic root dilatation, calcified valve, LVH, LAE, CHF
- Echo: reduced valve area, pressure gradient, LVH, reduced LV function

### Treatment
- Asymptomatic: serial echos, avoid exertion
- Symptomatic: avoid nitrates/arterial dilators and ACEI in severe AS
- Symptomatic: decrease preload (diuretics), increase afterload (ACEI) for severe MR and LV dysfunction

### Intervventional Options
- Percutaneous valve replacement (transfemoral or transapical approach)
- is an option in selected patients who are not considered good candidates for surgery

## Mitral Stenosis (MS)

### Etiology
- Rheumatic disease most common
- Cause, congenital (rare)

### Definition
- Severe MS is mitral valve area (MVA) < 1.5 cm²

### Pathophysiology
- MS → fixed CD and LAE → increased LA pressure → pulmonary vascular resistance and CHF; worse with Afib (no atrial kick), tachycardia (decreased atrial emptying time) and pregnancy (increased preload)

### Symptoms
- SOB on exertion, orthopnea, fatigue, palpitations, peripheral edema, molar flush, pinched and blue facies (severe MS)

### Physical Exam
- Afib, no "a" wave on JVP, left parasternal lift palpable diastolic thrill at apex
- Auscultation: mid-diastolic rumble at apex, best heard with bell in left lateral decubitus position following exertion, loud S1 OS following loud P2 (heard best during expiration), long diastolic murmur and short A2-OS interval correlate with worse MS

### Investigations
- ECG: HSRAFib, RVH, RAD
- CXR: LAE, CHF, mitral valve calcification
- Echo/TTE: shows restricted opening of mitral valve
- Cath: indicated in concurrent CAD if > 40 yr (male) or > 50 yr (female)

### Treatment
- Avoid exertion, fever (increased LA pressure), treat Afib and CHF, increase diastolic filling time (β-blockers, digitalis)
- Surgery if: NYHA class III-IV CHF and failure of medical therapy

### Invasive Options
- Percutaneous balloon valvuloplasty: young rheumatic pts and good leaflet morphology (can be determined by echo), asymptomatic pts with moderate-severe MS, pulmonary HTN
- Contraindication: left atrial thrombus, moderate MR
- Open Mitral Commissurotomy: if mild calcification + leaflet/chordal thickening
- Restenosis in 50% pts in 8 yr
- Valve replacement: indicated in moderate-severe calcification and severely scarred leaflets

## Mitral Regurgitation (MR)

### Etiology
- Mitral valve prolapse, congenital cleft leaflets, LV dilatation/aneurysm (CHF, DCM, myocarditis)
- JE abscess, Marfan’s syndrome, HOCM, acute MI, myxoma
- Mitral valve annulus calcification, chordae/papillary muscle trauma/ischemia/rupture (acute), rheumatic disease

### Pathophysiology
- Reduced CO → increased LV and LA pressure → LV dilatation → CHF and pulmonary HTN

### Symptoms
- Dyspnea, PND, orthopnea, palpitations, peripheral edema

### Physical Exam
- Displaced hyperdynamic apex, left parasternal lift, apical thrill
- Auscultation: holosystolic murmur at apex, radiating to axilla ± mid-diastolic rumble, loud S2 (if pulmonary HTN), S3

### Investigations
- ECG: LAE, RVH, RAD
- CXR: LAH, pulmonary venous HTN
- Echo: etiology and severity of MR, LV function, leaflets
- Swan-Ganz Catheter: prominent LA "v" wave

### Treatment
- Asymptomatic: serial echos
- Symptomatic: decrease preload (diuretics), decrease afterload (ACEI) for severe MR and poor surgical candidates; stabilize acute MR with vasodilators before surgery
- Surgery if: acute MR with CHF, papillary muscle rupture, NYHA class III-IV CHF; AF; increasing LV size or worsening LV function, earlier surgery if valve repairable (>90% likelihood) and patient is low-risk for surgery

### Surgical Options
- Valve repair: > 70% of pts with MR and myxomatous mitral valve prolapse – annuloplasty rings, leaflet repair, chordae transfers/shorten/replacement
- Valve replacement: failure of repair, heavily calcified annulus
- Advantage of repair: low rate of endocarditis, no anticoagulation, less chance of re-operation

## Aortic Regurgitation (AR)

### Etiology
- Supravalvular: aortic root disease
- (Marfan’s, atherosclerosis and dissecting aneurysm, connective tissue disease)
- Valvular: congenital (bicuspid aortic valve, large VSD), IE

### Pathophysiology
- Volume overload → LV dilatation → increased SV, high sBP and low dBP → increased wall tension → pressure overload → LVH (low dBP → decreased coronary perfusion)

### Symptoms
- Usually only becomes symptomatic late in disease when LV failure develops
- Dyspnea, orthopnea, PND, syncope, angina

### Physical Exam
- Waterhammer pulse, bisferiens pulse, femoral-brachial sBP > 20 (Hill’s test wide pulse pressure), hyperdynamic apex, displaced PMI, heaving apex
- Auscultation: early decrescendo diastolic murmur at LLB (cuspid pathology) or RLSB (aortic root pathology), best heard sitting, leaning forward, on full expiration, soft S1, absent S2, S3 (late)

### Investigations
- ECG: LVH, LAE
- CXR: LVH, LAE, aortic root dilation
- Echo/TTE: quantity AR, leaflet or aortic root anomalies
- Cath: if > 40 yr and surgical candidate – to assess for ischemic heart disease

### Exercise testing: hypotension with exercise

### Treatment
- Asymptomatic: serial echos, afterload reduction (e.g. ACEI, nifedipine, hydralazine)
- Symptomatic: avoid exertion, treat CHF
- Surgery if: NYHA class III-IV CHF; LV dilatation and/or LVEF < 50% with/without symptoms

### Surgical Options
- Valve replacement: most patients
- Valve repair: very limited role
- Aortic root replacement (Bentall procedure):
  - when ascending aortic aneurysm present, valved conduit used

---

C44  Cardiology and Cardiac Surgery

Valvular Heart Disease

Toronto Notes 2017

© Anas Nader 2011

© Anas Nader 2011

© Anas Nader 2011

© Anas Nader 2011

© Anas Nader 2011

© Anas Nader 2011
Table 16. Valvular Heart Disease (continued)

**Mitral Valve Stenosis (MS)**
- **Etiology**: Rheumatic disease, congenital, carcinoid syndrome, fibroelastosis; usually accompanied by MS
- **Pathophysiology**: Increased RA pressure → right heart failure → decreased CD and fixed on exertion
- **Symptoms**: Peripheral edema, fatigue, palpitations
- **Physical Exam**: Prominent "a" waves in JVP. +ve abdominojugular reflux, Kussmaul’s sign, diastolic rumble 4th left intercostal space
- **Investigations**: ECG: RAE
- **Treatment**: Preload reduction (diuretics), slow HR
- **Surgical Options**: Valve Replacement: – if severely diseased valve – bioprosthesis preferred

**Mitral Valve Prolapse (MVP)**
- **Etiology**: Myxomatous degeneration of chordae, thick, bulky leaflets that crowd orifice, associated with Marfan’s syndrome, pectus excavatum, straight back syndrome, other MSK abnormalities; <3% of population
- **Pathophysiology**: Mitral valve displaced into LA during systole; no causal mechanisms found for symptoms
- **Symptoms**: Prolonged, stabbing chest pain, dyspnea, anxiety/panic, palpitations, fatigue, presyncope
- **Physical Exam**: Auscultation: mid-systolic click (due to billowing of mitral leaflet into LA); tensing of redundant valve tissue; mid to late systolic murmur at apex, accentuated by Valsalva or squat-to-stand maneuvers
- **Investigations**: ECG: non-specific ST-T wave changes, paroxysmal SVT, ventricular ectopy Echo: systolic displacement of thickened mitral valve leaflets into LA
- **Treatment**: Asymptomatic: no treatment; reassurance Symptomatic: β-blockers and avoidance of stimulants (caffeine) for significant palpitations, anticoagulation if AFib
- **Surgical Options**: Mitral valve surgery (repair favoured over replacement) if symptomatic and significant MR

**Pulmonary Stenosis (PS)**
- **Etiology**: Usually congenital, rheumatic disease (rare), carcinoid syndrome
- **Pathophysiology**: Increased RV pressure → RV hypertrophy → right heart failure
- **Symptoms**: Chest pain, syncope, fatigue, peripheral edema
- **Physical Exam**: Systolic murmur at 2nd left intercostal space accentuated by inspiration, pulmonary ejection click, right-sided S4
- **Investigations**: ECG: RVR
- **Treatment**: Balloon valvuloplasty if severe symptoms
- **Surgical Options**: Percutaneous or open balloon valvuloplasty

**Tricuspid Stenosis (TS)**
- **Etiology**: Rheumatic disease, congenital, carcinoid syndrome, fibroelastosis; usually accompanied by MS
- **Pathophysiology**: Increased RA pressure → right heart failure → decreased CD and fixed on exertion
- **Symptoms**: Peripheral edema, fatigue, palpitations
- **Physical Exam**: Prominent "a" waves in JVP. +ve abdominojugular reflux, Kussmaul’s sign, diastolic rumble 4th left intercostal space
- **Investigations**: ECG: RAE
- **Treatment**: Preload reduction (diuretics), slow HR
- **Surgical Options**: Valve Replacement: – if severely diseased valve – bioprosthesis preferred

**Tricuspid Regurgitation (TR)**
- **Etiology**: RV dilatation, IE (particularly due to IV drug use), rheumatic disease, congenital (Ebstein anomaly), carcinoid
- **Pathophysiology**: RV dilatation → TR further RV dilatation → right heart failure
- **Symptoms**: Peripheral edema, fatigue, palpitations
- **Physical Exam**: "cv" waves in JVP. +ve abdominojugular reflux, Kussmaul’s sign, holosystolic murmur at LLSB accentuated by inspiration, left parasternal lift
- **Investigations**: ECG: RAE, RVH, AFib
- **Treatment**: Preload reduction (diuretics) Surgery if: only if other surgery required (e.g. mitral valve replacement)
- **Surgical Options**: Annuloplasty (i.e. repair, rarely replacement)

**Pulmonary Regurgitation (PR)**
- **Etiology**: Pulmonary HTN, IE, rheumatic disease, tetrology of Fallot (post-repair)
- **Pathophysiology**: Increased RV volume → increased wall tension → RV hypertrophy → right heart failure
- **Symptoms**: Chest pain, syncope, fatigue, peripheral edema
- **Physical Exam**: Early diastolic murmur at LLSB, Graham Steell (diastolic) murmur 2nd and 3rd left intercostal space increasing with inspiration
- **Investigations**: ECG: RAE, RVH
- **Treatment**: Rarely requires treatment; valve replacement (rarely done)
- **Surgical Options**: Pulmonary valve replacement

**Pulmonary Valve Replacement**
- **Surgical Options**: Rarely requires treatment; valve replacement (rarely done)
Valvular Heart Disease

C46  Cardiology and Cardiac Surgery

Figure 41. Hemodynamics of aortic stenosis
Stenosis across the aortic valve results in the generation of a significant pressure gradient between the left ventricle and the aorta and a crescendo-decrescendo murmur during systolic contraction. The stenosis decreases the intensity of aortic valve closure hence diminishing S2.

Figure 42. Hemodynamics of aortic regurgitation
Regurgitation across the aortic valve during diastole causes the aortic pressure to rapidly decrease and a decrescendo murmur can be heard at the onset of diastole (after S2 is audible). The presence of regurgitant blood from the aorta increases left-ventricular end-diastolic volume.

Figure 43. Hemodynamics of acute mitral regurgitation
During systolic contraction, blood regurgitates from the left ventricle into the left atrium across the incompetent mitral valve resulting in an audible holosystolic murmur between S1 and S2. The portion of left ventricular end-diastolic volume that regurgitates into the left atrial myocardium increases left atrial pressures resulting in a tall V-wave (in the JVP).

Figure 44. Hemodynamics of mitral stenosis
First note that the left atrial pressure exceeds the left ventricular pressure during diastole due to mitral stenosis and the consequent generation of a pressure gradient across the left atrium and left ventricle. In diastole the stenotic mitral valve opens which corresponds to the opening snap (OS) and the passage of blood across the mitral stenosis results in an audible decrescendo murmur. Left atrial contraction prior to S1 increases the pressure gradient resulting in accentuation of the murmur before S1 is audible.
**Pericardial Disease**

**Acute Pericarditis**

**Etiology of Pericarditis/Pericardial Effusion**
- idiopathic is most common: presumed to be viral
- infectious
  - viral: Coxsackie virus A, B (most common), echovirus
  - bacterial: *S. pneumoniae*, *S. aureus*
  - TB
- fungal: histoplasmosis, blastomycosis
- post-MI: acute (direct extension of myocardial inflammation, 1-7 d post-MI), Dressler’s syndrome (autoimmune reaction, 2-8 wk post-MI)
- post-cardiac surgery (e.g. CABG), other trauma
- metabolic: uremia (common), hypothyroidism
- neoplasm: Hodgkin’s, breast, lung, renal cell carcinoma, melanoma
- collagen vascular disease: SLE, polyarteritis, rheumatoid arthritis, scleroderma
- vascular: dissecting aneurysm
- other: drugs (e.g. hydralazine), radiation, infiltrative disease (sarcoid)

**Signs and Symptoms**
- diagnostic triad: chest pain, friction rub and ECG changes (diffuse ST elevation and PR depression with reciprocal changes in aVR)
- pleuritic chest pain: alleviated by sitting up and leaning forward
- pericardial friction rub: may be uni-, bi-, or triphasic; evanescent and rare
- ± fever, malaise

**Investigations**
- ECG: initially diffused elevated ST segments ± depressed PR segment, the elevation in the ST segment is concave upwards → 2-5 d later ST isoelectric with T wave flattening and inversion
- CXR: normal heart size, pulmonary infiltrates
- Echo: performed to assess for pericardial effusion

**Treatment**
- treat the underlying disease
- anti-inflammatory agents (high dose NSAIDs/ASA, steroids use controversial), analgesics

**Complications**
- recurrent episodes of pericarditis, atrial arrhythmia, pericardial effusion, tamponade, constrictive pericarditis

**Pericardial Effusion**

**Etiology**
- transudative (serous)
- CHF, hypoalbuminemia/hypoproteinemia, hypothyroidism
- exudative (serosanguinous or bloody)
  - causes similar to the causes of acute pericarditis
  - may develop acute effusion secondary to hemopericardium (trauma, post-MI myocardial rupture, aortic dissection)
- physiologic consequences depend on type and volume of effusion, rate of effusion development, and underlying cardiac disease

**Signs and Symptoms**
- may be asymptomatic or similar to acute pericarditis
- dyspnea, cough
- extra-cardiac (esophageal/recurrent laryngeal nerve/tracheo-bronchial/phrenic nerve irritation)
- JVP increased with dominant “x” descent
- arterial pulse normal to decreased volume, decreased pulse pressure
- auscultation: distant heart sounds ± rub
- Ewart’s sign

**Investigations**
- ECG: low voltage, flat T waves, electrical alternans (classic, but not sensitive to exclude effusion)
  - be cautious in diagnosing STEMI in a patient with pericarditis and an effusion - antiplatelets may precipitate hemorrhagic effusion
- CXR: cardiomegaly, rounded cardiac contour
- ER: bedside ultrasound with subxiphoid view showing fluid in pericardial sac
- Echo (procedure of choice): fluid in pericardial sac
- pericardiocentesis: definitive method of determining transudate vs. exudate, identify infectious agents, neoplastic involvement
### Treatment
- mild: frequent observation with serial echos, treat underlying cause, anti-inflammatory agents
- severe: treat as in tamponade (see Cardiac Tamponade)

### Cardiac Tamponade

#### Etiology
- major complication of rapidly accumulating pericardial effusion
- cardiac tamponade is a clinical diagnosis
- any cause of pericarditis but especially trauma, malignancy, uremia, proximal aortic dissection with rupture

#### Pathophysiology
- high intra-pericardial pressure → decreased venous return → decreased diastolic ventricular filling → decreased CO → hypotension and venous congestion

#### Signs and Symptoms
- tachypnea, dyspnea, shock, muffled heart sounds
- pulsus paradoxus (inspiratory fall in systolic BP >10 mmHg during quiet breathing)
- JVP “x” descent only, blunted “y” descent
- hepatic congestion/peripheral edema

#### Investigations
- ECG: electrical alternans (pathognomonic variation in R wave amplitude), low voltage
- echo: pericardial effusion, compression of cardiac chambers (RA and RV) in diastole
- cardiac catheterization

#### Treatment
- pericardiocentesis: Echo-guided
- pericardiotomy
- avoid diuretics and vasodilators (these decrease venous return to already under-filled RV → decrease LV preload → decrease CO)
- IV fluid may increase CO
- treat underlying cause

### Constrictive Pericarditis

#### Etiology
- chronic pericarditis resulting in fibrosed, thickened, adherent, and/or calcified pericardium
- any cause of acute pericarditis may result in chronic pericarditis
- major causes are idiopathic, post-infectious (viral, TB), radiation, post-cardiac surgery, uremia, MI, collagen vascular disease

#### Signs and Symptoms
- dyspnea, fatigue, palpitations
- abdominal pain
- may mimick CHF (especially right-sided HF)
  - ascites, hepatosplenomegaly, edema
- increased JVP, Kussmaul's sign (paradoxical increase in JVP with inspiration), Friedreich's sign (prominent “y” descent)
- BP usually normal (and usually no pulsus paradoxus)
- precordial examination: + pericardial knock (early diastolic sound)
- see Table 17 for differentiation from cardiac tamponade

#### Investigations
- ECG: non-specific – low voltage, flat T wave, ± AFib
- CXR: pericardial calcification, effusions
- echo/CT/MRI: pericardial thickening, ± characteristic echo-Doppler findings
- cardiac catheterization: equalization of end-diastolic chamber pressures (diagnostic)

#### Treatment
- medical: diuretics, salt restriction
- surgical: pericardiectomy (only if refractory to medical therapy)
- prognosis best with idiopathic or infectious cause and worst in post-radiation; death may result from heart failure
Table 17. Differentiation of Constrictive Pericarditis vs. Cardiac Tamponade

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Constrictive Pericarditis</th>
<th>Cardiac Tamponade</th>
</tr>
</thead>
<tbody>
<tr>
<td>JVP</td>
<td>“y” &gt; “x”</td>
<td>“x” &gt; “y”</td>
</tr>
<tr>
<td>Kussmaul’s sign</td>
<td>Present</td>
<td>Absent</td>
</tr>
<tr>
<td>Pulsus paradoxus</td>
<td>Uncommon</td>
<td>Always</td>
</tr>
<tr>
<td>Pericardial knock</td>
<td>Present</td>
<td>Absent</td>
</tr>
<tr>
<td>Hypotension</td>
<td>Variable</td>
<td>Severe</td>
</tr>
</tbody>
</table>

Table 18. Commonly Used Cardiac Therapeutics

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Examples</th>
<th>Mechanism of Action</th>
<th>Indications</th>
<th>Side Effects</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEI)</td>
<td>enalapril ( Vasotec®), perindopril ( Coversyl®), ramipril ( Altace®), lisinopril ( Zestril®)</td>
<td>Inhibit ACE-mediated conversion of angiotensin I to angiotensin II (AT II), causing peripheral vasodilation and decreased aldosterone synthesis</td>
<td>HTN, CAD, CHF, post-MI, DM</td>
<td>Dry cough, 10% hypotension, fatigue, hyperkalemia, renal insufficiency, angioedema</td>
<td>Bilateral renal artery stenosis, pregnancy, caution in decreased GFR</td>
</tr>
<tr>
<td>ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs)</td>
<td>candesartan, irbesartan, valsartan</td>
<td>Block AT II receptors, causing similar effects to ACEI</td>
<td>Same as ACEI, although evidence is generally less for ARBs; often used when ACEI are not tolerated</td>
<td>Similar to ACEI, but do not cause dry cough</td>
<td>Same as ACEI</td>
</tr>
<tr>
<td>DIRECT RENIN INHIBITORS (DRIs)</td>
<td>aliskiren</td>
<td>Directly blocks renin thus inhibiting the conversion of angiotensigen to angiotensin I; this also causes a decrease in AT II</td>
<td>HTN (exact role of this drug remains unclear)</td>
<td>Diarrhea, hyperkalemia (higher risk if used with an ACEI), rash, cough, angioedema, reflex, hypotension, rhabdomyolysis, seizure</td>
<td>Pregnancy, severe renal impairment</td>
</tr>
<tr>
<td>( \beta )-BLOCKERS</td>
<td>( \beta_1 ) antagonists</td>
<td>atenolol, metoprolol, bisoprolol, propranolol, labetalol, carvedilol, acebutalol</td>
<td>Block ( \beta )-adrenergic receptors, decreasing HR, BP, contractility, and myocardial oxygen demand, slow conduction through the AV node</td>
<td>HTN, CAD, acute MI, post-MI, CHF (start low and go slow), AFib, SVT</td>
<td>Hypotension, fatigue, light-headedness, depression, bradycardia, hyperkalemia, bronchospasm, impotence, depression of counterregulatory response to hypoglycemia, exacerbation of Raynaud’s phenomenon, and claudication</td>
</tr>
<tr>
<td></td>
<td>( \beta_{1,2} ) antagonists</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>( \alpha_1, \beta_1 ) antagonists</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>with intrinsic sympathomimetic activity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Block smooth muscle and myocardial calcium channels causing effects similar to ( \beta )-blockers Also vasodilate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CALCIUM CHANNEL BLOCKERS (CCBs)</td>
<td>amlodipine (Norvasc®), nifedipine ( Adalat®), felodipine ( Plendil®)</td>
<td>Block smooth muscle calcium channels causing peripheral vasodilation</td>
<td>HTN, CAD</td>
<td>Hypotension, edema, flushing, headache, light-headedness</td>
<td>Severe aortic stenosis and liver failure</td>
</tr>
<tr>
<td>DIURETICS</td>
<td>diltiazem verapamil</td>
<td>Block smooth muscle and myocardial calcium channels causing effects similar to ( \beta )-blockers Also vasodilate</td>
<td>HTN, CAD, SVT, diastolic dysfunction</td>
<td>Hypotension, bradycardia, edema Negative inotrope</td>
<td>Sinus bradycardia, 2nd or 3rd degree heart block, hypotension, WPW, CHF</td>
</tr>
<tr>
<td>Loop diuretics</td>
<td>furosemide (Lasix®)</td>
<td>Blocks Na(^+/K(^+)/ATPase in thick ascending limb of the loop of Henle</td>
<td>CHF, pulmonary or peripheral edema</td>
<td>Hypovolemia, hypokalemic metabolic alkalosis</td>
<td>Hypovolemia, hypokalemia</td>
</tr>
<tr>
<td>Aldosterone receptor antagonists</td>
<td>spironolactone, eplerenone</td>
<td>Antagonize aldosterone receptors</td>
<td>HTN, CHF, hypokalemia</td>
<td>Edema, hypokalemia, gynecomastia</td>
<td>Renal insufficiency, hyperkalemia, pregnancy</td>
</tr>
<tr>
<td>INOTROPES</td>
<td>digoxin ( Lanoxin®)</td>
<td>Inhibit Na(^+/K(^+)/ATPase, leading to increased intracellular Na(^+) and Ca(^++) concentration and increased myocardial contractility Also slows conduction through the AV node</td>
<td>CHF, AFib</td>
<td>AV block, tachyarhythmias, bradynhythmias, blurred or yellow vision (van Gogh syndrome), anorexia, N/V</td>
<td>2nd or 3rd degree AV block, hypokalemia, WPW</td>
</tr>
</tbody>
</table>
**Table 18. Commonly Used Cardiac Therapeutics (continued)**

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Examples</th>
<th>Mechanism of Action</th>
<th>Indications</th>
<th>Side Effects</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANTICOAGULANTS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coumarins</td>
<td>warfarin (Coumadin®)</td>
<td>Antagonizes vitamin K, leading to decreased synthesis of clotting factors II, VII, IX, and X</td>
<td>AFib, LV dysfunction, prosthetic valves</td>
<td>Bleeding (by far the most important side effect), paradoxical thrombosis, skin necrosis</td>
<td>Recent surgery or bleeding, bleeding diathesis, pregnancy</td>
</tr>
<tr>
<td>Heparins</td>
<td>Unfractionated heparin, LMWHs: dalteparin, enoxaparin, tinzaparin</td>
<td>Antithrombin III agonist, leading to decreased clotting factor activity</td>
<td>Acute MI/ACS; when immediate anticoagulant effect needed</td>
<td>Bleeding, osteoporosis, heparin-induced thrombocytopenia (less in LMWHs)</td>
<td>Recent surgery or bleeding, bleeding diathesis, thrombocytopenia, renal insufficiency (for LMWHs)</td>
</tr>
<tr>
<td>Direct thrombin inhibitors</td>
<td>dabigatran, melagatran</td>
<td>Competitive, direct thrombin inhibitor; thrombin enables fibrinogen conversion to fibrin during the coagulation cascade, thereby preventing thrombus development</td>
<td>AFib</td>
<td>Bleeding, GI upset</td>
<td>Severe renal impairment, recent surgery, active bleeding</td>
</tr>
<tr>
<td>Direct Factor Xa inhibitors</td>
<td>rivaroxaban, apixaban, edoxaban</td>
<td>Direct, selective and reversible inhibition of factor Xa in both the intrinsic and extrinsic coagulation pathways</td>
<td>AFib</td>
<td>Bleeding, GI upset, elevated liver enzymes</td>
<td>Hepatic disease, active bleeding, bleeding diathesis, pregnancy, lactation</td>
</tr>
<tr>
<td><strong>ANTIPLATELETS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salicylates</td>
<td>ASA (Aspirin®)</td>
<td>Irreversibly acetylates platelet COX-1, preventing thromboxane A2-mediated platelet aggregation</td>
<td>CAD, acute MI, post-MI, post-PCI, CABG</td>
<td>Bleeding, GI upset, GI ulceration, impaired renal perfusion</td>
<td>Active bleeding or PUD</td>
</tr>
<tr>
<td>Thienopyridines</td>
<td>clopidogrel (Plavix®), ticlopidine (Ticlid®), prasugrel (Effient®)</td>
<td>P2Y12 antagonist (block platelet ADP receptors)</td>
<td>Acute MI, post-MI, post-PCI, CABG</td>
<td>Bleeding, thrombotic thrombocytopenic purpura, neutropenia (ticlopidine)</td>
<td>Active bleeding or PUD</td>
</tr>
<tr>
<td>Nucleoside analogues</td>
<td>ticagrelor (Brilinta®)</td>
<td>P2Y12 antagonist (but different binding site than thienopyridines)</td>
<td>Acute MI, particularly if PCI is planned</td>
<td>Bleeding</td>
<td></td>
</tr>
<tr>
<td>GPIIb/IIIa inhibitors</td>
<td>eptifibatide, tirofiban, abciximab</td>
<td>Block binding of fibrinogen to Gp IIb/IIIa receptors</td>
<td>Acute MI, particularly if PCI is planned</td>
<td>Bleeding</td>
<td>Recent surgery or bleeding, bleeding diathesis</td>
</tr>
<tr>
<td><strong>THROMBOLYICS</strong></td>
<td>alteplase, reteplase, tenecteplase, streptokinase</td>
<td>Convert circulating plasminogen to plasmin, which lysed cross-linked fibrin</td>
<td>Acute STEMI</td>
<td>Bleeding</td>
<td>See Table 8, C29</td>
</tr>
<tr>
<td><strong>NITRATES</strong></td>
<td>nitroglycerin</td>
<td>Relax vascular smooth muscle, producing venous and arteriolar dilation</td>
<td>CAD, MI, CHF (isosorbide dinitrate plus hydralazine)</td>
<td>Headache, dizziness, weakness, postural hypotension</td>
<td>Concurrent use of cGMP phosphodiesterase inhibitors, angle closure glaucoma, increased intracranial pressure</td>
</tr>
<tr>
<td><strong>LIPID LOWERING AGENTS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statins</td>
<td>atorvastatin (Lipitor®), pravastatin (Pravachol®), rosuvastatin (Crestor®), simvastatin (Zocor®), lovastatin (Meracor®)</td>
<td>Inhibit HMG-CoA reductase, which catalyzes the rate-limiting step in cholesterol synthesis</td>
<td>Dyslipidemia (1st prevention of CAD), MI, post-MI (2nd prevention of CV events)</td>
<td>Myalgia, rhabdomyolysis, abdominal pain</td>
<td>Liver or muscle disease</td>
</tr>
<tr>
<td>Cholesterol absorption inhibitor</td>
<td>ezetimibe (Zetral®)</td>
<td>Inhibits gut absorption of cholesterol</td>
<td>Decreases LDL but does not reduce mortality</td>
<td>Myalgia, rhabdomyolysis, abdominal pain</td>
<td>Liver or renal impairment</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>fibrates, bile acid sequestrates, niacin</td>
<td>Primarily in familial hypercholesterolemia</td>
<td>GI side effects common</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigational</td>
<td>PSCK9 inhibitor</td>
<td>monoclonal antibody</td>
<td>hypercholesterolemia</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Antiarrhythmics**

**Table 19. Antiarrhythmic* Drugs (Vaughan-Williams Classification)**

<table>
<thead>
<tr>
<th>Class</th>
<th>Agent</th>
<th>Indications</th>
<th>Side Effects</th>
<th>Mechanism of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ia</td>
<td>quinidine</td>
<td>SVT, VT</td>
<td>Torsades de Pointes (all Ia), diarrhea</td>
<td>Moderate Na+ channel blockade</td>
</tr>
<tr>
<td></td>
<td>procainamide</td>
<td></td>
<td>Lupus-like syndrome</td>
<td>Prolongs repolarization, slowing conduction</td>
</tr>
<tr>
<td></td>
<td>disopyramide</td>
<td></td>
<td>Anticholinergic effects</td>
<td></td>
</tr>
<tr>
<td>Ib</td>
<td>lidocaine</td>
<td>VT</td>
<td>Confusion, stupor, seizures</td>
<td>Mild Na+ channel blockade</td>
</tr>
<tr>
<td></td>
<td>mexiletine</td>
<td></td>
<td>GI upset, tremor</td>
<td>Shortens phase 3 repolarization</td>
</tr>
<tr>
<td>Ic</td>
<td>propafenone</td>
<td>SVT, VT, AFib</td>
<td>Exacerbation of VT (all Ic)</td>
<td>Marked Na+ channel blockade</td>
</tr>
<tr>
<td></td>
<td>flecainide</td>
<td></td>
<td>Negative inotropy (all Ic)</td>
<td>Markedly slows phase 0 upstroke</td>
</tr>
<tr>
<td></td>
<td>encainide</td>
<td></td>
<td>Bradycardia and heart block (all Ic)</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>propranolol</td>
<td>SVT, AFib</td>
<td>Bronchospasm, negative inotropy, bradycardia, AV block, impotence, fatigue</td>
<td>β-blocker Decreases phase 4 depolarization</td>
</tr>
<tr>
<td></td>
<td>metoprolol, etc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>amiodarone**</td>
<td>SVT, VT, AFib</td>
<td>Amiodarone: Photosensitivity, pulmonary toxicity, hepatotoxicity, thyroid disease, increased INR</td>
<td>Blocks K+ channel Prolongs phase 3 repolarization, which prolongs refractory period</td>
</tr>
<tr>
<td></td>
<td>sotalol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>verapamil</td>
<td>SVT, AFib</td>
<td>Bradycardia, AV block, Hypotension</td>
<td>Calcium channel blocker Slows phase 4 spontaneous depolarization, slowing AV node conduction</td>
</tr>
<tr>
<td></td>
<td>diltiazem</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*All antiarrhythmics have potential to be proarrhythmic**

**Table 20. Actions of α and β Adrenergic Receptors**

<table>
<thead>
<tr>
<th>Target System</th>
<th>α RECEPTORS</th>
<th>β RECEPTORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constriction of vascular smooth muscle</td>
<td>Constriction of skin, skeletal muscle, and splanchnic vessels</td>
<td>Same as α1</td>
</tr>
<tr>
<td>Increased myocardial contractility</td>
<td>Decreased heart rate</td>
<td>Peripherally act to modulate vessel tone Vasoconstrict and dilate; oppose α1 vasoconstrictor activity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td></td>
<td>Bronchodilation</td>
</tr>
<tr>
<td>Dermal</td>
<td>Pilomotor smooth muscle contraction</td>
<td>Apocrine constriction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ocular</td>
<td>Radial muscle contraction</td>
<td>Ciliary muscle relaxation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Inhibition of myenteric plexus</td>
<td>Anal sphincter contraction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genitourinary</td>
<td>Pregnant uterine contraction</td>
<td>Penile and seminal vesicle ejaculation Urinary bladder contraction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolic</td>
<td>Stimulate liver gluconeogenesis and glycolysis at the liver</td>
<td>Same as α1 Fat cell lipolysis</td>
</tr>
</tbody>
</table>

Adapted from the Family Practice Notebook (www.fpnotebook.com/NEU194.htm)
Table 21. Commonly Used Drugs that Act on \( \alpha \) and \( \beta \) Adrenergic Receptors

<table>
<thead>
<tr>
<th>( \alpha ) RECEPTORS</th>
<th>( \alpha_1 ) and ( \alpha_2 )</th>
<th>( \beta_1 )</th>
<th>( \beta_1 ) and ( \beta_2 )</th>
<th>( \beta_2 )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agonist</td>
<td>Phenytoine</td>
<td>Epinephrine</td>
<td>Norepinephrine</td>
<td>Isoproterenol</td>
</tr>
<tr>
<td></td>
<td>Methoxamine</td>
<td>Norepinephrine</td>
<td>Methyldopa</td>
<td>Epinephrine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clonidine</td>
<td>Dobutamine</td>
<td>Dobutamine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Albuterol</td>
</tr>
</tbody>
</table>

| Antagonist             | Prazosin        | Phentolamine    | Metoprolol    | Propranolol  |
|                        | Phenoxbenzamine | Yohimbine       | Acebutolol    | Timolol      |
|                        |                 | Mitrazepine     | Alprenolol    | Nadolol      |
|                        |                 |                 | Atenolol      | Pindolol     |
|                        |                 |                 | Esmolol       | Carvedilol   |

Adapted from the Family Practice Notebook (http://www.fpnotebook.com/NEU194.htm)

Landmark Cardiac Trials

<table>
<thead>
<tr>
<th>Trial</th>
<th>Reference</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASCOT-LLA</td>
<td>Lancet 2003; 361:1149-58</td>
<td>In hypertensive patients with risk factors for CHD and average or below-average cholesterol, atorvastatin reduced nonfatal MI, fatal CHD, fatal/nonfatal stroke, coronary events but not all-cause mortality</td>
</tr>
<tr>
<td>CAPRIE</td>
<td>Lancet 1996; 348:1329-39</td>
<td>In atherosclerotic vascular disease clopidogrel reduced the primary combined endpoint of stroke, MI, or vascular death and improved PAD compared to ASA</td>
</tr>
<tr>
<td>CARE</td>
<td>NEJM 1996; 335:1001-9</td>
<td>Pravastatin reduced MI and stroke in patients with previous MI and average cholesterol</td>
</tr>
<tr>
<td>CDURAGE</td>
<td>NEJM 2007; 356:1503-16</td>
<td>Compared with optimal medical therapy alone PCI + medical therapy did not reduce all-cause mortality and non fatal MI, and it did not reduce the incidence of major cardiovascular events</td>
</tr>
<tr>
<td>CURE</td>
<td>NEJM 2001; 345:494-502</td>
<td>Clopidogrel plus ASA reduced death from CV causes, non fatal MI, or stroke but increased bleeding complications</td>
</tr>
<tr>
<td>EUROPA</td>
<td>Lancet 2003; 362:782-88</td>
<td>With stable CAD and no CHF perindopril reduced cardiovascular death, MI, and total mortality</td>
</tr>
<tr>
<td>HOPE</td>
<td>NEJM 2000; 342:154-60</td>
<td>In high-risk patients without low LVEF or CHF ramipril reduced rates of death, MI, stroke, revascularization, new diagnosis of DM and complications due to DM; vitamin E had no effect on outcomes</td>
</tr>
<tr>
<td>HPS</td>
<td>Lancet 2002; 360:7-22</td>
<td>In high-risk patients with various cholesterol values simvastatin reduced all-cause mortality, coronary deaths, and major vascular events</td>
</tr>
<tr>
<td>INTERHEART</td>
<td>Lancet 2004; 364:937-52</td>
<td>Nine modifiable risk factors account for 90% of myocardial infarction</td>
</tr>
<tr>
<td>JUPITER</td>
<td>NEJM 2008; 359:2195-2007</td>
<td>With low to normal LDL-C and elevated hsCRP treatment with rosuvastatin significantly reduced major cardiovascular events; NNT with rosuvastatin for 2 yr to prevent one primary endpoint = 95</td>
</tr>
<tr>
<td>SYNTAX</td>
<td>NEJM 2009; 360:961-972</td>
<td>CABB has lower rate of major cardiac or cerebrovascular events; the rate of stroke was increased with CABB, whereas the rate of repeat revascularization was increased with PCI</td>
</tr>
<tr>
<td>TNT</td>
<td>NEJM 2005; 352:1425-35</td>
<td>Lipid-lowering therapy with atorvastatin 80 mg/d in patients with stable CHD provides clinical benefit beyond atorvastatin 10 mg/d</td>
</tr>
<tr>
<td>WHI</td>
<td>JAMA 2002; 288:321-333</td>
<td>Estrogen plus progestin therapy is associated with increased risks of cardiovascular disease and breast cancer but decreased risks of hip fracture and colorectal cancer in postmenopausal women</td>
</tr>
</tbody>
</table>

MYOCARDIAL INFARCTION

<table>
<thead>
<tr>
<th>Trial</th>
<th>Reference</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>BHAT</td>
<td>JAMA 1982; 247:1707-14</td>
<td>In acute MI pranopanol reduced all-cause mortality, cardiovascular death, and sudden death from atherosclerotic heart disease</td>
</tr>
<tr>
<td>CDURAGE</td>
<td>NEJM 2007; 356:1503-16</td>
<td>Compared with optimal medical therapy alone PCI + medical therapy did not reduce all-cause mortality and non fatal MI, and it did not reduce the incidence of major cardiovascular events</td>
</tr>
<tr>
<td>DAPT</td>
<td>NEJM 2014; 371: 2155-66</td>
<td>Dual antiplatelet therapy beyond one year confers additional benefit</td>
</tr>
</tbody>
</table>
## MYOCARDIAL INFARCTION

<table>
<thead>
<tr>
<th>Trial</th>
<th>Reference</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISIS-4</td>
<td><em>Lancet</em> 1995; 345:669-85</td>
<td>In patients with suspected or definite acute MI early treatment with captopril reduced all-cause mortality at 35 d and during long-term follow up.</td>
</tr>
<tr>
<td>OASIS-5</td>
<td><em>NEJM</em> 2006; 354:1464-76</td>
<td>Compared to enoxaparin, fondaparinux reduced mortality rates, major bleeds at 9 and MI at 30 and 180 d.</td>
</tr>
<tr>
<td>PEGASUS-TIMI 54</td>
<td><em>NEJM</em> 2015 EPUB</td>
<td>Ticagrelor on top of ASA reduces CV events and in patients with a history of MI.</td>
</tr>
<tr>
<td>PLATO</td>
<td><em>NEJM</em> 2009; 361:1045-57</td>
<td>ACS patients with either STEMI or NSTEMI, regardless of reperfusion strategy, ticagrelor reduced mortality, MI and stroke without increased bleeding compared to clopidogrel.</td>
</tr>
<tr>
<td>PROVE IT – TIMI 22</td>
<td><em>NEJM</em> 2004; 350:1495-1504</td>
<td>In patients hospitalized for ACS high-dose atorvastatin reduced all-cause mortality, MI, unstable angina, revascularization, and stroke compared with pravastatin.</td>
</tr>
<tr>
<td>TRITON-TIMI 38</td>
<td><em>NEJM</em> 2007; 357:2001-15</td>
<td>In ACS patients scheduled for PCI, prasugrel reduced ischemic events but increased major bleeding compared to clopidogrel; no change in mortality.</td>
</tr>
</tbody>
</table>

## HEART FAILURE

<table>
<thead>
<tr>
<th>Trial</th>
<th>Reference</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIRE</td>
<td><em>Lancet</em> 1993; 342:821-8</td>
<td>Ramipril commenced 3-10 d after MI and continued for a mean 15-month period significantly reduced all-cause mortality in patients with non-severe CHF.</td>
</tr>
<tr>
<td>COMET</td>
<td><em>Lancet</em> 2003; 362:7-13</td>
<td>Carvedilol was associated with a reduction in all cause mortality compared with metoprolol.</td>
</tr>
<tr>
<td>CONSENSUS</td>
<td><em>NEJM</em> 1987; 316:1429-35</td>
<td>Enalapril reduced all-cause mortality, death due to progression of heart failure.</td>
</tr>
<tr>
<td>COPERNICUS</td>
<td><em>NEJM</em> 2001; 344:1651-8</td>
<td>Carvedilol in addition to standard treatment significantly reduced the risk of death or hospitalization in patients with severe CHF.</td>
</tr>
<tr>
<td>I-PRESERVE</td>
<td><em>NEJM</em> 2008; 359:2466-2467</td>
<td>In patients with CHF and normal LVEF treatment with ARB (irbesartan) did not improve mortality or cardiovascular morbidity compared to placebo.</td>
</tr>
<tr>
<td>MERIT-HF</td>
<td><em>Lancet</em> 1999; 353:2001-7</td>
<td>Metoprolol CR/XL daily in addition to optimum standard therapy improved survival in clinically stable patients equating to prevention of 1 death per 27 patients treated per year.</td>
</tr>
<tr>
<td>PARADIGM-HF</td>
<td><em>NEJM</em> 2014; 371:993-1004</td>
<td>Novel drug (LCZ696 containing valsartan and a neprilysin inhibitor (prevents degradation of natriuretic peptides) reduces hospitalization and mortality.</td>
</tr>
<tr>
<td>RALES</td>
<td><em>NEJM</em> 1999; 341:709-17</td>
<td>In severe CHF (class III/IV) and LVEF &lt;35% spironolactone reduced all-cause mortality, sudden death, and death due to progression of heart failure.</td>
</tr>
<tr>
<td>SAVE</td>
<td><em>NEJM</em> 1992; 327:669-77</td>
<td>Patients with LV dysfunction post-MI long-term captopril over 3.5 yr reduced the risk of death due to cardiovascular causes, recurrent MI, development of severe CHF, and CHF hospitalization.</td>
</tr>
<tr>
<td>SCD-HeFT</td>
<td><em>NEJM</em> 2005; 352:225-237</td>
<td>In mild-to-moderate CHF shock-only ICD significantly reduces risk of death; amiodarone had no benefit compared with placebo in treating patients with mild-to-moderate CHF.</td>
</tr>
<tr>
<td>SOLVD</td>
<td><em>NEJM</em> 1991; 325:293-302</td>
<td>In stable chronic CHF with decreased LVEF (&lt;0.35) long-term enalapril reduced death due to all causes and death or hospitalization due to CHF.</td>
</tr>
<tr>
<td>TRACE</td>
<td><em>NEJM</em> 1995; 333:1870-6</td>
<td>In patients with LV dysfunction post-MI long-term trandolapril reduced the risk of death or progression to severe CHF and reduced risk of sudden death.</td>
</tr>
<tr>
<td>V-HeFT II</td>
<td><em>NEJM</em> 1991; 325:303-10</td>
<td>In chronic CHF enalapril reduced mortality more than hydralazine-isosorbide for at least 2 yr; treatment with either enalapril or hydralazine-isosorbide increased LVEF.</td>
</tr>
</tbody>
</table>

## DIABETES

<table>
<thead>
<tr>
<th>Trial</th>
<th>Reference</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARDS</td>
<td><em>Lancet</em> 2004; 264:685-96</td>
<td>Atorvastatin reduces the risk of cardiovascular events in patients with type 2 DM.</td>
</tr>
<tr>
<td>ONTARGET</td>
<td><em>NEJM</em> 2008; 359:1547-59</td>
<td>In patients with vascular disease or DM without CHF telmisartan is equally as effective as ramipril, with telmisartan causing a reduced risk of cough and angioedema, and an increased risk of hypotensive symptoms; combination therapy offers no advantage.</td>
</tr>
<tr>
<td>Trial</td>
<td>Reference</td>
<td>Results</td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>AFFIRM</td>
<td>NEJM 2002: 347:1825-33</td>
<td>No significant difference in mortality rates between rate or rhythm control of AFib</td>
</tr>
<tr>
<td>AF-CHF</td>
<td>NEJM 2008: 358:2667-77</td>
<td>In patients with AFib and CHF there is no significant difference in mortality rates from cardiovascular causes between rate and rhythm control</td>
</tr>
<tr>
<td>ARISTOTLE</td>
<td>NEJM 2011: 365:981-92</td>
<td>AF patients treated with apixaban had a lower incidence of stroke, major bleeding and mortality compared to warfarin</td>
</tr>
<tr>
<td>ENGAGE AF-TIMI48</td>
<td>NEJM 2013: 369:2093-2104</td>
<td>AF patients treated with edoxaban had similar rates of stroke and lower rates of major bleeding compared to warfarin</td>
</tr>
<tr>
<td>RE-LY</td>
<td>NEJM 2009: 361:1139-51</td>
<td>AF patients treated with dabigatran had a lower incidence of stroke compared to warfarin, with similar rates of major bleeding</td>
</tr>
<tr>
<td>ROCKET-AF</td>
<td>NEJM 2011: 365:883-891</td>
<td>In patients with AFib rivoxaban is non-inferior to warfarin for stroke prevention, and major and non-major bleeding</td>
</tr>
<tr>
<td>HYVET</td>
<td>NEJM 2008: 358:1887-98</td>
<td>In hypertensive patients &gt;80 yr treatment with indapamide, with or without perindopril, showed a trend towards reduced relative risk of fatal or non-fatal stroke</td>
</tr>
<tr>
<td>SIPLICITY-HTN 3</td>
<td>NEJM 2014: 370:1393-1401</td>
<td>Renal denervation does not reduce blood pressure in patients with resistant hypertension compared to sham procedure</td>
</tr>
<tr>
<td>SPRINT</td>
<td>NEJM 2015: 372:2103-2116</td>
<td>In patients with high risk of cardiovascular events excluding diabetes, strict systolic BP control (&lt;120 mmHg) is associated with fewer cardiovascular events and lower all-cause mortality</td>
</tr>
<tr>
<td>UKHDS (UKPDS)</td>
<td>BMJ 1998: 317:703-13</td>
<td>Hypertensive patients with DM and tight BP control at &lt;150/85 mmHg by use of ACEI or β-blocker reduced risk of diabetic complications and death related to DM and reduced risk of end-organ damage</td>
</tr>
<tr>
<td>VALUE</td>
<td>Lancet 2004: 362:2022-2031</td>
<td>Valsartan group had higher incidence of MI than amlodipine group, whereas amlodipine had a higher incidence of new-onset DM</td>
</tr>
</tbody>
</table>
Ischemic Heart Disease

Cardiomyopathies

Guidelines
American College of Cardiology (clinical guidelines, etc.). Available from: http://www.acc.org.

Ambulatory ECG

Stress Testing

Echocardiography

Nuclear Cardiology
Sah开办al M, Lahiri A. Role of myocardial perfusion imaging for risk stratification in suspected or known coronary artery disease. Heart 2003;89:1291-1297.

MR

CT
Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE</td>
<td>angiotensin converting enzyme</td>
</tr>
<tr>
<td>ACh</td>
<td>acetylcholine</td>
</tr>
<tr>
<td>ADR</td>
<td>adverse drug reaction</td>
</tr>
<tr>
<td>ARB</td>
<td>angiotensin receptor blocker</td>
</tr>
<tr>
<td>BBB</td>
<td>blood brain barrier</td>
</tr>
<tr>
<td>Cl</td>
<td>clearance</td>
</tr>
<tr>
<td>Cr</td>
<td>creatinine</td>
</tr>
<tr>
<td>CSF</td>
<td>cerebrospinal fluid</td>
</tr>
<tr>
<td>CSFa</td>
<td>certain safety factor</td>
</tr>
<tr>
<td>CYP</td>
<td>cytochrome P450 protein</td>
</tr>
<tr>
<td>DIN</td>
<td>drug identification number</td>
</tr>
<tr>
<td>F</td>
<td>bioavailability</td>
</tr>
<tr>
<td>GFR</td>
<td>glomerular filtration rate</td>
</tr>
<tr>
<td>HH</td>
<td>Henderson Hasselbalch</td>
</tr>
<tr>
<td>NE</td>
<td>norepinephrine</td>
</tr>
<tr>
<td>P450</td>
<td>partition coefficient of a drug</td>
</tr>
<tr>
<td>PD</td>
<td>pharmacodynamics</td>
</tr>
<tr>
<td>PDE</td>
<td>phosphodiesterase</td>
</tr>
<tr>
<td>Pgp</td>
<td>p-glycoprotein</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetics</td>
</tr>
<tr>
<td>RCT</td>
<td>randomized controlled trial</td>
</tr>
<tr>
<td>TBW</td>
<td>total body water</td>
</tr>
<tr>
<td>TDM</td>
<td>therapeutic drug monitoring</td>
</tr>
<tr>
<td>TI</td>
<td>therapeutic index</td>
</tr>
<tr>
<td>Vd</td>
<td>volume of distribution</td>
</tr>
</tbody>
</table>

General Principles

Drug Nomenclature

- **chemical name**: describes chemical structure; consistent in all countries (e.g. N-(4-hydroxyphenyl) acetamide is acetaminophen)
- **DIN or NDC**: DIN assigned by Health Canada; NDC assigned by FDA (US)
- **non-proprietary name**: approved name (post-phase III trial), official name (listed in pharmacopoeia), or generic name (off-patent) such as acetaminophen
- **proprietary (trade) name**: the brand name or registered trademark (e.g. Tylenol™)

Phases of Clinical Drug Testing

- **pre-clinical**: testing a drug in a controlled environment (lab) on animal or human cells before human testing to discern the PK and toxicological profile
- **phase I**: first administration to healthy human volunteers, following animal studies; to determine PK and PD
- **phase II**: first administration to patients, small sample sizes; to determine initial safety and efficacy, dose range, PK, and PD
- **phase III**: large sample sizes, often double-blinded RCT; comparative (new drug vs. placebo or standard of care) to establish safety and efficacy
- **phase IV**: post-marketing surveillance, wide distribution; to determine effects of long-term use, rare ADRs, ideal dosing, and effects in real-world practice

Drug Administration

- choice of route of administration depends on: drug properties, local and systemic effects, desired onset and/or duration of action, and patient characteristics

### Table 1. Routes of Drug Administration

<table>
<thead>
<tr>
<th>Route</th>
<th>Advantage</th>
<th>Disadvantage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral (PO)</td>
<td>Convenient, easy to administer</td>
<td>Incomplete absorption, Hepatic first-pass effect</td>
</tr>
<tr>
<td></td>
<td>Large surface area for absorption</td>
<td>Potential GI irritation</td>
</tr>
<tr>
<td></td>
<td>Inexpensive relative to parenteral administration</td>
<td></td>
</tr>
<tr>
<td>Buccal/Sublingual (SL)</td>
<td>Rapid onset of action</td>
<td>Must be lipid-soluble, non-irritating, Short duration of action</td>
</tr>
<tr>
<td>Rectal (PR)</td>
<td>Almost no hepatic first-pass effect</td>
<td>Inconvenient, irritation at site of application</td>
</tr>
<tr>
<td></td>
<td>Use when NPO, vomiting, or unconscious</td>
<td>Erratic absorption</td>
</tr>
<tr>
<td>Intravenous (IV)</td>
<td>No hepatic first-pass effect</td>
<td>Hard to remove once administered</td>
</tr>
<tr>
<td></td>
<td>Slow infusion or rapid onset of action</td>
<td>Risk of infection, bleeding, vascular injury extravasation</td>
</tr>
<tr>
<td></td>
<td>Easy to titrate dose</td>
<td>Expensive</td>
</tr>
<tr>
<td>Intramuscular (IM)</td>
<td>Depot storage if oil-based = slow release of drug</td>
<td>Pain/hematoma at site of injection</td>
</tr>
<tr>
<td></td>
<td>Aqueous solution = rapid onset of action</td>
<td></td>
</tr>
<tr>
<td>Subcutaneous (SC)</td>
<td>Non-irritating drugs, small volumes</td>
<td>Pain at site of injection, Smaller volumes than IM, May have tissue damage from multiple injections</td>
</tr>
<tr>
<td></td>
<td>Constant, even absorption</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alternative to IV</td>
<td></td>
</tr>
<tr>
<td>Intrathecal</td>
<td>Direct into CSF, Bypass BBB and blood-CSF barrier</td>
<td>Risk of infection</td>
</tr>
<tr>
<td>Inhalation</td>
<td>Immediate action in lungs, Rapid delivery to blood</td>
<td>Must be gas, vapour, or aerosol</td>
</tr>
<tr>
<td>Topical</td>
<td>Easy to administer, Localized (limited systemic absorption)</td>
<td>Effects are mainly limited to site of application</td>
</tr>
<tr>
<td>Transdermal</td>
<td>Drug absorption through intact skin</td>
<td>Irritation at site of application, Delayed onset of action</td>
</tr>
<tr>
<td></td>
<td>No hepatic first-pass effect</td>
<td>Hydrophilic drugs not easily absorbed</td>
</tr>
<tr>
<td>Others (intraperitoneal, intra-articular)</td>
<td>Local effect</td>
<td>Risk of infection</td>
</tr>
</tbody>
</table>
Pharmacokinetics

- **study of “what the body does to a drug”**
- **definition**: relationship between drug administration, time-course/rate of absorption and distribution, concentration changes in the body compartments, and the drug's removal from the body

### Absorption

- **definition**: movement of the drug from the site of administration into plasma

#### Mechanisms of Drug Absorption
- most drugs are absorbed into the systemic circulation via passive diffusion
- other mechanisms include active transport, facilitated diffusion, and pinocytosis/phagocytosis

#### Factors Affecting the Rate and Extent of Drug Absorption
- \( P_{ow} \)
  - local blood flow at the site of administration (e.g. sublingual vessels facilitate rapid absorption of sublingual medications)
- **molecular size** (e.g. drugs with smaller molecular weight absorb faster)
- **pH and drug ionization**
  - drugs are usually weak acids (e.g. ASA) or weak bases (e.g. ketoconazole) and thus exist in ionized and non-ionized forms
  - non-ionized forms cross cell membranes much faster than ionized (charged) forms
  - the ratio of ionized to non-ionized forms is determined by body compartment pH and drug pKa
    - (HH equation)
- **total surface area for absorption**
  - small intestinal villi are the primary site of absorption for most oral drugs

#### Bioavailability (F)
- **definition**: proportion of dose that reaches systemic circulation in an unchanged state
- decreased by limited drug absorption or first-pass effect
- IV dose has 100% bioavailability (F = 1)

#### First-Pass Effect
- **definition**: drug metabolism by the liver and/or the gut before it reaches systemic circulation, resulting in reduced F
- occurs with PO administration of a drug: GI tract (absorption) → portal vein to liver (first-pass metabolism) → systemic circulation
- occurs less with PR administration because drug absorbed in colon bypasses the portal system

#### Efflux Pump
- Pgp is a protein found in various parts of the body that acts as a multidrug efflux pump involved in the transport of drugs out of cells
- for example, opposes intestinal absorption (e.g. dabigatran etexilate) and also enhances renal elimination of certain drugs (e.g. digoxin, etoposide, paclitaxel, tacrolimus, cyclosporine)
- some drugs (e.g. macrolide antibiotics) inhibit Pgp function, leading to increased serum levels of drugs transported by Pgp: Pgp inducers (e.g. St. John's wort) do the opposite
- some tumours overexpress Pgp leading to multidrug resistance to chemotherapeutic agents

### Distribution

- **definition**: movement of drugs between different body compartments and to the site of action
- major body fluid compartments include plasma, interstitial fluid, intracellular fluid, transcellular fluid (e.g. CSF, peritoneal, pleural)
- tissue compartments include fat, brain

#### Factors Affecting the Rate and Extent of Drug Distribution
- physicochemical properties of the drug (e.g. \( P_{ow} \) and pK)
- pH of fluid
- plasma protein binding
- binding within compartments (i.e. depots)
- regional blood flow

---

**Figure 1. Distribution of total body water (TBW)**

- **Total Body Water**: 60% of body weight
- **Extracellular Fluid**: 16-20%
  - **Intravascular Plasma**: 4%
  - **Interstitial Fluid**: 12-15%
- **Intracellular Fluid**: 40-44%

- **P<sub>ow</sub>**: Ratio of a drug's solubility in oil/lipid (e.g. cell membrane) as compared to water (e.g. extracellular fluid)
- A large \( P_{ow} \) (e.g. anesthetics) means that a drug is highly soluble in lipid and will cross cell membranes easily

**Examples of Drugs with High First-Pass Effect**
- Levodopa
- Morphine
- Propranolol
- Lidocaine
- Organic nitrates

**Examples of Drugs with Low First-Pass Effect**
- Diazepam
- Digosin
- Phenytoin
- Warfarin
Volume of Distribution
- $V_d$: the apparent volume of fluid into which a drug distributes
- maximum actual $V_d$ (anatomic fluid volume accessible to drug) = TBW (TBW ~ 40 L for average adult)
  - a calculated value ($V_d$) = amount of drug in body ÷ plasma drug concentration
  - a theoretical value that does not correspond to an anatomical space (i.e. can exceed TBW)
- small $V_d$ corresponds to a drug that concentrates in plasma and/or binds plasma proteins to a high degree
- large $V_d$ corresponds to a drug that distributes into tissues (fat, muscle, etc.); most is not in blood (measured) space, and it therefore "appears" to distribute in a large volume
- $V_d$ of plasma protein bound drugs can be altered by liver and kidney disease
- example: amiodarone distributes into TBW (actual $V_d$ = 40 L), but it also concentrates in fat tissues giving instead an apparent $V_d$ of 400 L; therefore, to achieve a given plasma concentration of amiodarone, we dose as though the drug distributes into 400 L of body fluid

Plasma Protein Binding
- drug molecules in the blood exist in an equilibrium of two forms:
  1. bound to plasma protein: acidic drugs bind to albumin, basic drugs bind to α1-acid glycoprotein
  2. free or unbound: can leave the circulation to distribute into tissues and exert an effect, subject to metabolism and elimination
- bound fraction is determined by drug concentration, binding affinity, and plasma protein concentration (number of binding sites)
- reduced number of binding sites (e.g. hypoalbuminemia) or saturation of binding sites (e.g. competition/displacement) may result in increased concentration of free drug, which is often metabolized with no harmful effects, although toxicity is possible

Depots
- a body compartment in which drug molecules tend to be stored and released slowly over a long period of time
- fat is a depot for very lipid soluble drugs (e.g. diazepam)
- some oil-based medications are injected IM for slow release (e.g. depot medroxyprogesterone acetate q3mo; depot risperidone q2wk)

Barriers (relative)
- body structures that limit or prevent diffusion of drug molecules, such as the placenta or BBB (a barrier composed of tight junctions between capillary endothelial cells and astrocytes)
- many of these barriers result, in part, from the activity of multidrug efflux pumps (e.g. Pgp), which serve as a natural defense mechanism against drugs and xenobiotics
- need to consider dosing route if drugs are meant to cross these barriers

Metabolism (Biotransformation)
- definition: chemical transformation of a drug in vivo to enhance elimination
- sites of biotransformation include liver (main), GI tract, lung, plasma, kidney
- as a result of the process of biotransformation:
  - an inactive prodrug may be activated (e.g. tamoxifen to endoxifen; codeine to morphine)
  - a drug may be changed to another active metabolite (e.g. diazepam to oxazepam)
  - a drug may be changed to a toxic metabolite (e.g. meperidine to normeperidine)
  - a drug may be inactivated (most drugs)

Drug Metabolizing Pathways
- phase I (P450) reactions
  - minor molecular changes introduce or unmask polar groups on a parent compound to increase water solubility (e.g. oxidation-reduction, hydrolysis, hydroxylation); the change in $P_{\text{app}}$ is typically minimal compared to phase II, and often phase I places a polar 'handle' on a lipophilic drug to allow for phase II
  - mediated by CYPs found in the endoplasmic reticulum
  - product of the reaction can be excreted or undergo further phase II reactions
- phase II (conjugation) reactions
  - conjugation with large polar endogenous substrates (e.g. glucuronidation, glutathione conjugation, sulfation)
  - dramatically increases water solubility and renal elimination
  - can result in biologically active metabolites (e.g. glucuronides of morphine)
  - can occur independently of phase I reactions
Factors Affecting Drug Biotransformation
- genetic polymorphisms of metabolizing enzymes
  - individual genotypes may determine rate of drug metabolism (e.g. poor, intermediate, extensive, or ultrarapid metabolizers)
  - may lead to toxicity or ineffectiveness of a drug at a normal dose
    - tamoxifen and codeine are prodrugs activated by CYP2D6 (nonfunctional alleles reduce effectiveness, whereas overactive/duplicated alleles impart “ultrarapid metabolizer” phenotype)
    - warfarin is metabolized by CYP2C9 (nonfunctional alleles lead to greater effect and lower dose requirements)
- enzyme inhibition may sometimes be due to other drugs
  - CYP inhibition leads to an increased concentration and bioavailability of the substrate drug (e.g. erythromycin [CYP3A4 inhibitor] can predispose patients to simvastatin toxicity [metabolized by CYP3A4])
- enzyme induction
  - certain medications enhance gene transcription leading to an increase in the activity of a metabolizing enzyme
  - a drug may induce its own metabolism (e.g. carbamazepine) or that of other drugs (e.g. phenobarbital can induce the metabolism of OCPs) by inducing the CYP system
- liver dysfunction (e.g. hepatitis, alcoholic liver, biliary cirrhosis, or hepatocellular carcinoma) may decrease drug metabolism but this may not be clinically significant due to the liver’s reserve capacity
- renal disease often results in decreased drug clearance
- extremes of age (neonates or elderly) have reduced biotransformation capacity, and doses should be adjusted accordingly
- nutrition: insufficient protein and fatty acid intake decreases CYP biotransformation, and vitamin/mineral deficiencies may also impact other metabolizing enzymes
- alcohol: while acute alcohol ingestion inhibits CYP2E1, chronic consumption can induce CYP2E1 and increase risk of hepatocellular damage from acetaminophen by increasing the generation of acetaminophen’s toxic metabolite
- smoking can induce CYP1A2, thus increasing the metabolism of some drugs (e.g. theophylline, antipsychotic)

Elimination
- definition: removal of drug from the body

Routes of Drug Elimination
- kidney (main organ of elimination): two mechanisms
  1. glomerular filtration
     - a passive process, so that only the free drug fraction can be eliminated
     - drug filtration rate depends on GFR, degree of protein binding of drug, and size of drug
  2. tubular secretion
     - an active process that is saturable allowing both protein-bound and free drug fractions to be excreted
     - distinct transport mechanisms for weak acids (e.g. penicillin, salicylic acid, probenecid, chlorothiazide) and weak bases (e.g. quinine, quaternary ammonium compounds such as choline)
     - drugs may competitively block mutual secretion if both use the same secretion system (e.g. probenecid can reduce the excretion of penicillin)
- tubular reabsorption: drugs can be passively reabsorbed back to the systemic circulation, countering elimination mechanisms
- renal function (assessed using serum Cr levels) decreases with age and is affected by many disease states such as diabetes
- stool: some drugs and metabolites are actively excreted in the bile or directly into the GI tract
  - enterohepatic reabsorption counteracts stool elimination, and can prolong the drug’s duration in the body
  - some glucuronic acid conjugates that are excreted in bile may be hydrolyzed in the intestines by bacteria back to their original form and can be systemically reabsorbed
- lungs: elimination of anesthetic gases and vapours by exhalation
- saliva: saliva concentrations of some drugs parallel their plasma levels (e.g. rifampin)
Pharmacokinetic Calculation

- **definition:** the quantitative description of the rates of the various steps of drug disposition (i.e. how drugs move through the body)
- the pharmacokinetic principles of ADME (absorption, distribution, metabolism, and elimination) can be graphically represented on a concentration vs. time graph

**Time Course of Drug Action**
- many kinetic parameters are measured using IV dosing, such that absorption is immediate and distribution for most drugs is rapid; thus elimination is the main process being measured
- the concentration axis is converted to a log10 concentration to allow for easier mathematical calculations
- drugs such as warfarin can exhibit hysteresis (for a single drug concentration, there may be two different response levels)

**Half-Life**
- **definition:** time taken for the serum drug level to fall 50% during elimination
- drugs with first order kinetics require five half-lives to reach steady state with repeated dosing or for complete drug elimination once dosing is stopped

<table>
<thead>
<tr>
<th># of Half-Lives</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>3.3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of Steady State Concentration</td>
<td>50</td>
<td>75</td>
<td>87.5</td>
<td>90</td>
<td>93.8</td>
<td>96.9</td>
</tr>
</tbody>
</table>

**Steady State**
- drug concentration remains constant when amount of drug entering the system is eliminated from the system
- drug levels in therapeutic drug monitoring are of greatest utility when the steady state has been reached
- special situations
  - use a loading dose for drugs with a long half-life and when there is clinical need to rapidly achieve therapeutic levels (e.g. amiodarone, digoxin, phenytoin)
  - use continuous infusion for drugs with a very short half-life and when there is need for a long-term effect and multiple or frequently repeated doses are too inconvenient (e.g. nitroprusside, insulin, unfractionated heparin)

**Clearance**
- a quantitative measurement of the body fluid volume from which a substance is removed per unit time
- **Cl** = rate of elimination of drug/plasma drug concentration
- must consider Cl from a specific part of the body and total body Cl

**Elimination Kinetics**
- first-order kinetics (most common type)
  - constant fraction of drug eliminated per unit time
  - some drugs can follow first-order kinetics until elimination is saturated (usually at large doses) at which point the Cl decreases
  - becomes linear relationship when plotted on a log (concentration) vs. time graph
- zero-order kinetics (less common, associated with overdose, e.g. alcohol)
  - drug is eliminated at a constant rate regardless of concentration; concept of half-life does not apply
  - the concentration axis is converted to a log (concentration) to allow for easier mathematical calculations

**Table 2. Loading vs. Maintenance Dosing**

<table>
<thead>
<tr>
<th>Loading Dose</th>
<th>Maintenance Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use when you need an IMMEDIATE effect</td>
<td>After a loading dose OR beginning with maintenance doses</td>
</tr>
<tr>
<td>Often parenteral medication</td>
<td>Steady-state levels achieved after —5 half-lives</td>
</tr>
<tr>
<td>Rationale: give large dose of medication to &quot;fill up&quot; the volume of distribution</td>
<td>Can be given as either a continuous infusion (relatively rare, short half-life drug) OR much more commonly as intermittent doses</td>
</tr>
</tbody>
</table>

---

**Rationale:** give large dose of medication to “fill up” the volume of distribution

**Use when you need an IMMEDIATE effect**

For most drugs it takes 5 half-lives to reach steady state with repeated dosing or to eliminate a drug once dosing is stopped.

**Figure 2. Time course of drug action**

For most drugs it takes 5 half-lives to reach steady state with repeated dosing or to eliminate a drug once dosing is stopped.

**Figure 3. Steady state of a drug displaying first-order kinetics**

In first order kinetics (solid line), a constant fraction of the drug is eliminated per unit time; in zero-order kinetics (dashed line), a constant amount of the drug is eliminated per unit time.
Pharmacodynamics

- study of "what the drug does to the body"

### Dose-Response Relationship

- graded dose-response relationships: relates dose to intensity of effect

#### Efficacy

- the maximum biological response produced by a drug
- measured by Emax (the maximal response that a drug can elicit in a RCT or under optimal circumstances)

#### Potency

- measured by EC50 (the concentration of a drug needed to produce 50% of Emax)
- a drug that reaches its EC50 at a lower dose is more potent

<table>
<thead>
<tr>
<th>Potency: A &gt; B &gt; C (both B and C are less potent than A)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efficacy: A = C &gt; B</td>
</tr>
</tbody>
</table>

![Figure 5. Log(dose)-response curve illustrating efficacy and potency](image)

**Effects of Drugs on Receptors**

#### Agonists

- drugs that mimic the effects of the endogenous ligand and evoke a response when bound to the receptor
  - affinity: the ability of the agonist to bind to the receptor (e.g. the β2-agonist salbutamol has greater affinity for β2-receptors than β1-receptors)
  - efficacy: the ability to recapitulate endogenous response via the receptor interaction (e.g. binding of salbutamol to β2-receptors results in smooth muscle relaxation)
  - full agonists: can elicit a maximal effect at a receptor
  - partial agonists: can only elicit a partial effect, no matter the concentration at the receptor (i.e. reduced efficacy compared to full agonists)

#### Antagonists

- drugs that block the action of an agonist or of an endogenous ligand
- chemical antagonism: direct chemical interaction between agonist and antagonist prevents agonist-receptor binding (e.g. chelating agents for removal of heavy metals)
- functional antagonism: two agonists that act independently at different receptors and have opposite physiological effects (e.g. acetylcholine at the muscarinic receptor compared to epinephrine at the adrenergic receptor)

#### Reversible and irreversible competitive antagonism

- drugs that exert no direct effect upon binding to a given receptor
- reversible competitive antagonists reversibly bind to the same receptor as the agonist, thus displacing it (e.g. naloxone is an antagonist to morphine or heroin)
- irreversible antagonists form a covalent bond with the receptor, thus irreversibly blocking substrates from binding (e.g. phenoxybenzamine forms a covalent bond with adrenergic receptors preventing adrenaline and NE from binding)

#### Non-competitive antagonism

- antagonist binds to an alternate site near the agonist site, producing allosteric effects that change the ability of the agonist to bind (e.g. organophosphates irreversibly bind acetylcholinesterase)

**Efficacy vs. Potency**

- Efficacy measures the maximal effect of a drug
- Potency measures the concentration of a drug needed to produce a certain effect

![Figure 6. The log(dose)-response curve for competitive reversible antagonism](image)

![Figure 7. The log(dose)-response curve for irreversible antagonism](image)
Effectiveness and Safety

Effectiveness
- **ED$_{50}$** (effective dose): the dose of a drug needed to cause a therapeutic effect in 50% of a test population of subjects

Safety
- **LD$_{50}$** (lethal dose): the dose of a drug needed to cause death in 50% of a test population of subjects
- **TD$_{50}$** (toxic dose): the dose needed to cause a harmful effect in 50% of a test population of subjects

Therapeutic Indices

**Therapeutic Index:** TD$_{50}$/ED$_{50}$
- reflects the "margin of safety" for a drug – the likelihood of a therapeutic dose to cause serious toxicity or death
- the larger the TI, the safer a drug (e.g. warfarin has a narrow TI and requires drug monitoring)
- factors that can change the TI
  - presence of interacting drugs
  - changes in drug ADME

**Certain Safety Factor:** TD$_{1}$/ED$_{99}$
- >1 translates to a dose effective in at least 99% of the population and toxic in less than 1% of the population
Therapeutic Drug Monitoring

- **Definition**: using serum drug concentration data to optimize drug therapy (e.g. dose adjustment, monitor compliance)
  - Serum drug samples are usually taken when the drug has reached steady state (after approximately 5 half-lives)
  - TDM is often used for drugs that have: narrow TIs, unpredictable dose-response relationships, significant consequences associated with therapeutic failure or toxicity, and wide inter-patient PK variability

Adverse Drug Reactions

Table 3. Characteristics of Type A-E Adverse Drug Reactions

<table>
<thead>
<tr>
<th>Classification</th>
<th>Definition</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A (Augmented)</strong></td>
<td>Dose related</td>
<td>Predictable extension of drug’s pharmacologic effect (e.g. β-blockers causing bradycardia) &gt; 80% of all ADRs</td>
</tr>
<tr>
<td><strong>B (Bizarre)</strong></td>
<td>Non-dose related</td>
<td>Reactions unrelated to the known pharmacological actions of the drug Examples include: drug hypersensitivity syndromes, immunologic reactions (penicillin hypersensitivity), and idiosyncratic reactions (malignant hyperthermia)</td>
</tr>
<tr>
<td><strong>C (Chronic)</strong></td>
<td>Dose and time related</td>
<td>Related to cumulative doses Effects are well-known and can be anticipated (e.g. atypical femoral fracture from bisphosphonates)</td>
</tr>
<tr>
<td><strong>D (Delayed)</strong></td>
<td>Time related</td>
<td>Occurs some time after use of drug (e.g. carcinogen) May also be dose-related</td>
</tr>
<tr>
<td><strong>E (End of use)</strong></td>
<td>Withdrawal</td>
<td>Occurs after cessation of drug use (e.g. opiate withdrawal)</td>
</tr>
</tbody>
</table>

Approach to Suspected Adverse Drug Reactions

- History and physical exam: signs and symptoms of reaction (e.g. rash, fever, hepatitis, anaphylaxis), timing, risk factors, detailed medication history including all drugs and timing, de-challenge (response when drug is removed), and re-challenge (response when drug is given again)
- Differentiate between drug therapy vs. disease pathophysiology
- Treatment: stop the drug, supportive care, symptomatic relief
- Resources: check recent literature, Health Canada, and FDA; contact the pharmaceutical company; call Poison Control (1-888-268-9017) if overdose or poisoning suspected; check with Motherisk (www.motherisk.org) in cases involving pregnant or breastfeeding women
- Report all suspected ADRs that are: 1) unexpected, 2) serious, or 3) reactions to recently marketed drugs (on the market <5 yr) regardless of nature or severity
  - Canadian Adverse Drug Reaction Monitoring Program available for online reporting

Examples of drugs whose levels need to be monitored include warfarin (via INR levels), digoxin, lithium, anti-epileptics (e.g. phenytoin, carbamazepine)

Sample of Clinically Relevant Adverse Drug Reactions

<table>
<thead>
<tr>
<th>Classification</th>
<th>Drug(s)</th>
<th>ADR</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>β-blockers</td>
<td>Bradycardia</td>
</tr>
<tr>
<td>A</td>
<td>ACEIs</td>
<td>Cough</td>
</tr>
<tr>
<td>A</td>
<td>NSAIDs</td>
<td>GI bleeding</td>
</tr>
<tr>
<td>A</td>
<td>Opiates</td>
<td>GI upset, constipation, urinary retention, respiratory depression</td>
</tr>
<tr>
<td>A</td>
<td>Acetaminophen</td>
<td>Hepatotoxicity</td>
</tr>
<tr>
<td>A</td>
<td>Warfarin</td>
<td>Red-blue syndrome</td>
</tr>
<tr>
<td>A</td>
<td>Aminoglycosides</td>
<td>Ototoxicity, nephrotoxicity</td>
</tr>
<tr>
<td>B</td>
<td>Sulfonamides</td>
<td>Stevens-Johnson syndrome, toxic epidermal necrolysis</td>
</tr>
<tr>
<td>B</td>
<td>Penicillins</td>
<td>Rash</td>
</tr>
<tr>
<td>B</td>
<td>Magnesium, Chinese herbs</td>
<td>Hepatotoxicity</td>
</tr>
</tbody>
</table>
Variability in Drug Response

- recommended patient dosing is based on clinical research and represents mean values for a select population, but each person may be unique in their dosing requirements
- possible causes of individual variability in drug response include problems with:
  - intake: patient adherence
  - PK
    - absorption: vomiting, diarrhea, or steatorrhea; first pass effect increased due to enzyme induction or decreased due to liver disease
    - drug interactions (e.g. calcium carbonate complexes with iron, thyroxine, and fluoroquinolones)
    - distribution: very high or low percentage body fat; intact or disrupted BBB; patient is elderly or a neonate, or has liver dysfunction
    - biotransformation and elimination: certain genetic polymorphisms or enzyme deficiencies related to drug metabolism (e.g. acetylcholinesterase deficiency, CYP polymorphism); kidney or liver dysfunction
  - PD: genetic variability in drug response (e.g. immune-mediated reactions); diseases that affect drug PD; drug tolerance or cross-tolerance

Drug Interactions

- concomitant prescriptions: one drug alters the effect of another by changing its PK and/or PD
- PK interactions involve changes in drug concentration
  - absorption: alterations in gastrointestinal pH, gastric emptying, intestinal motility, gut mucosal function
  - biotransformation: alterations in drug metabolizing enzymes
  - excretion: alterations in renal elimination
- PD interactions are due to two drugs that exert similar effects (additive) or opposing effects (subtractive)
- drug interactions can also involve herbal medications (e.g. St. John's wort) and food (e.g. grapefruit)

Autonomic Pharmacology

![Autonomic Pharmacology Diagram](image)

- most organs are innervated by both sympathetic and parasympathetic nerves, which have opposing effects (see Neurology, N8)
- ACh and NE are the main neurotransmitters of the autonomic NS
- ACh binds to cholinergic receptors, which include nicotinic and muscarinic receptors
- NE binds to adrenergic receptors, which principally include β1, β2, α1, and α2
- ACh action is terminated by metabolism in the synaptic cleft by acetylcholinesterase and in the plasma by pseudocholinesterase
- acetylcholinesterase inhibitors (pyridostigmine, donepezil, galantamine, rivastigmine) can be used to increase ACh levels in conditions such as myasthenia gravis or Alzheimer's disease
- NE action is terminated by reuptake at the presynaptic membrane, diffusion from the synaptic cleft, and degradation at monoamine oxidase (MAO) and catechol-O-methyl transferase (COMT)

Parasympathetic Nervous System

- blood vessels, adrenals, sweat glands, spleen capsule, and adrenal medulla do NOT have parasympathetic innervation
- parasympathetic pre-ganglionic fibres originate in the lower brainstem from cranial nerves III, VII, IX, X, and in the sacral spinal cord at levels S2-S4 and connect with post-ganglionic fibres via nicotinic receptors in ganglionic cells located near or within the target organ
- post-ganglionic fibres connect with effector tissues via:
  - M: muscarinic receptors located in the CNS
  - M: muscarinic receptors located in smooth muscle, cardiac muscle, and glandular epithelium
### Sympathetic Nervous System

- sympathetic pre-ganglionic fibres originate in the spinal cord at spinal levels T1-L2/L3
- pre-ganglionic fibres connect with post-ganglionic fibres via nicotinic receptors located in one of two groups of ganglia:
  1. paravertebral ganglia (i.e. the sympathetic trunk) that lie in a chain close to the vertebral column
  2. pre-vertebral ganglia (i.e. celiac and mesenteric ganglia) that lie within the abdomen
- post-ganglionic fibres connect with effector tissues via:
  - β1 receptors in cardiac tissue
  - β2 receptors in smooth muscle of bronchi and GI tract
  - α1 receptors in vascular smooth muscle
  - α2 receptors in vascular smooth muscle
  - M3 muscarinic receptors located in sweat glands

#### Table 4. Direct Effects of Autonomic Innervation on the Cardiorespiratory System

<table>
<thead>
<tr>
<th>Organ</th>
<th>Sympathetic NS</th>
<th>Parasympathetic NS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Receptor</td>
<td>Action</td>
</tr>
<tr>
<td>Heart</td>
<td>1. Sinoatrial</td>
<td>β1</td>
</tr>
<tr>
<td></td>
<td>2. Atrioventricular node</td>
<td>β1</td>
</tr>
<tr>
<td></td>
<td>3. Atria</td>
<td>β1</td>
</tr>
<tr>
<td></td>
<td>4. Ventricles</td>
<td>β1</td>
</tr>
<tr>
<td>Blood Vessels</td>
<td>1. Skin, splanchnic</td>
<td>α1, β2</td>
</tr>
<tr>
<td></td>
<td>2. Skeletal muscle</td>
<td>a</td>
</tr>
<tr>
<td></td>
<td>3. Coronary</td>
<td>β2 (large muscles)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>α1, β2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>β2</td>
</tr>
<tr>
<td>Lungs</td>
<td>1. Bronchiolar smooth muscle</td>
<td>β2</td>
</tr>
<tr>
<td></td>
<td>2. Bronchiolar glands</td>
<td>α1, β2</td>
</tr>
</tbody>
</table>

#### Table 5. Common Drug Endings

<table>
<thead>
<tr>
<th>Ending</th>
<th>Category</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>-afil</td>
<td>5-PDE inhibitor</td>
<td>sildenafil</td>
</tr>
<tr>
<td>-ane</td>
<td>Inhaled general anesthetic</td>
<td>halothane</td>
</tr>
<tr>
<td>-azepam</td>
<td>Benzodiazepine</td>
<td>lorazepam</td>
</tr>
<tr>
<td>-azole</td>
<td>Antifungal</td>
<td>ketoconazole</td>
</tr>
<tr>
<td>-caine</td>
<td>Local anesthetic</td>
<td>lidocaine</td>
</tr>
<tr>
<td>-olol</td>
<td>β-blocker</td>
<td>propranolol</td>
</tr>
<tr>
<td>-prazole</td>
<td>Proton pump inhibitor</td>
<td>omeprazole</td>
</tr>
<tr>
<td>-pril</td>
<td>ACE inhibitor</td>
<td>captopril</td>
</tr>
<tr>
<td>-sartan</td>
<td>ARB</td>
<td>candesartan</td>
</tr>
<tr>
<td>-statin</td>
<td>HMG-CoA inhibitor</td>
<td>atorvastatin</td>
</tr>
<tr>
<td>-terol</td>
<td>β2 agonist</td>
<td>albuterol</td>
</tr>
<tr>
<td>-tidine</td>
<td>HZ antagonist</td>
<td>cimetidine</td>
</tr>
<tr>
<td>-tropin</td>
<td>Pituitary hormone</td>
<td>somatropin</td>
</tr>
<tr>
<td>-vir</td>
<td>Antiviral</td>
<td>acyclovir</td>
</tr>
<tr>
<td>-zosin</td>
<td>α1 antagonist</td>
<td>prazosin</td>
</tr>
</tbody>
</table>

Note: Some medications are exceptions to the rule, e.g. methimazole (antithyroid)
References

Principles of Clinical Pharmacology


Adverse Drug Reactions


Drug Interactions

# Dermatology

Danny Mansour, Cristina Olteanu, and Venus Valbuena, chapter editors  
Narayan Chattergoon and Desmond She, associate editors  
Arnav Agarwal and Quynh Huynh, EBM editors  
Dr. David Adam and Dr. Jensen Yeung, staff editors

## Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acn</td>
<td>Acne</td>
</tr>
<tr>
<td>Act</td>
<td>Actinic</td>
</tr>
<tr>
<td>Ap</td>
<td>Acroplasia</td>
</tr>
<tr>
<td>Aster</td>
<td>Astereosclerosis</td>
</tr>
<tr>
<td>At</td>
<td>Atopic</td>
</tr>
<tr>
<td>Bcc</td>
<td>Basal Cell Carcinoma</td>
</tr>
<tr>
<td>Cc</td>
<td>Clinical Cancer</td>
</tr>
<tr>
<td>CHD</td>
<td>Congenital Heart Defect</td>
</tr>
<tr>
<td>CSF</td>
<td>Cerebrospinal Fluid</td>
</tr>
<tr>
<td>CV</td>
<td>Congestive Heart Failure</td>
</tr>
<tr>
<td>DLB</td>
<td>Dementia with Lewy Bodies</td>
</tr>
<tr>
<td>E</td>
<td>Epidermal</td>
</tr>
<tr>
<td>EM</td>
<td>Electron Microscopy</td>
</tr>
<tr>
<td>ES</td>
<td>Epithelial</td>
</tr>
<tr>
<td>FAP</td>
<td>Familial Adenomatous Polyposis</td>
</tr>
<tr>
<td>GFR</td>
<td>Glomerular Filtration Rate</td>
</tr>
<tr>
<td>HCC</td>
<td>Hepatocellular Carcinoma</td>
</tr>
<tr>
<td>HP</td>
<td>Histiocytosis</td>
</tr>
<tr>
<td>HTN</td>
<td>Hypertension</td>
</tr>
<tr>
<td>IBD</td>
<td>Inflammatory Bowel Disease</td>
</tr>
<tr>
<td>ICH</td>
<td>Intracerebral Hemorrhage</td>
</tr>
<tr>
<td>ICI</td>
<td>Immunotherapy</td>
</tr>
<tr>
<td>IL</td>
<td>Interleukin</td>
</tr>
<tr>
<td>IBD</td>
<td>Inflammatory Bowel Disease</td>
</tr>
<tr>
<td>IHC</td>
<td>Immunohistochemistry</td>
</tr>
<tr>
<td>JIA</td>
<td>Juvenile Idiopathic Arthritis</td>
</tr>
<tr>
<td>K</td>
<td>Keratin</td>
</tr>
<tr>
<td>KCS</td>
<td>Keratoconjunctivitis Sicca</td>
</tr>
<tr>
<td>L</td>
<td>Lymphatic</td>
</tr>
<tr>
<td>M</td>
<td>Mitochondria</td>
</tr>
<tr>
<td>MS</td>
<td>Multiple Sclerosis</td>
</tr>
<tr>
<td>N</td>
<td>Nerve</td>
</tr>
<tr>
<td>OA</td>
<td>Osteoarthritis</td>
</tr>
<tr>
<td>OI</td>
<td>Osteogenesis Imperfecta</td>
</tr>
<tr>
<td>PA</td>
<td>Pathology Association</td>
</tr>
<tr>
<td>PD</td>
<td>Parkinson’s Disease</td>
</tr>
<tr>
<td>PCP</td>
<td>Pneumocystis Pneumonia</td>
</tr>
<tr>
<td>PDA</td>
<td>Patent Ductus Arteriosus</td>
</tr>
<tr>
<td>PCI</td>
<td>Percutaneous Coronary Intervention</td>
</tr>
<tr>
<td>PS</td>
<td>Pulmonary</td>
</tr>
<tr>
<td>RA</td>
<td>Rheumatoid Arthritis</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomized Controlled Trial</td>
</tr>
<tr>
<td>RSD</td>
<td>Reflex Sympathetic Dystrophy</td>
</tr>
<tr>
<td>SLE</td>
<td>Systemic Lupus Erythematosus</td>
</tr>
<tr>
<td>T</td>
<td>Tissue</td>
</tr>
<tr>
<td>T2DM</td>
<td>Type 2 Diabetes Mellitus</td>
</tr>
<tr>
<td>TNM</td>
<td>Tumor, Node, Metastasis</td>
</tr>
<tr>
<td>TVE</td>
<td>Transvenous Electrical</td>
</tr>
<tr>
<td>U</td>
<td>Urinary</td>
</tr>
<tr>
<td>V</td>
<td>Vascular</td>
</tr>
<tr>
<td>W</td>
<td>Wound</td>
</tr>
</tbody>
</table>

## Introduction to Skin

1. **Skin Anatomy**
2. **Skin Function**

### Definitions

- Primary Morphological Lesions
- Secondary Morphological Lesions
- Other Morphological Lesions
- Patterns and Distribution

### Differential Diagnoses of Common Presentations

### Common Skin Lesions

<table>
<thead>
<tr>
<th>Lesion Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cysts</td>
<td>A fluid-filled sac that contains a liquid or semi-solid material</td>
</tr>
<tr>
<td>Fibrous Lesions</td>
<td>Lesions characterized by fibrous tissue</td>
</tr>
<tr>
<td>Hyperkeratotic Lesions</td>
<td>Lesions characterized by thickening of the epidermal layer due to excessive keratin production</td>
</tr>
<tr>
<td>Keloids</td>
<td>Lesions characterized by excessive growth of scar tissue</td>
</tr>
<tr>
<td>Pigmented Lesions</td>
<td>Lesions characterized by increased pigmentation</td>
</tr>
<tr>
<td>Vascular Lesions</td>
<td>Lesions characterized by abnormal vessels</td>
</tr>
</tbody>
</table>

### Acneiform Eruptions

- Acne Vulgaris/Common Acne
- Perioral Dermatitis
- Rosacea

### Dermatitis (Eczema)

- Asteatotic Dermatitis
- Atopic Dermatitis
- Contact Dermatitis
- Dyshidrotic Dermatitis
- Nummular Dermatitis
- Seborrheic Dermatitis
- Stasis Dermatitis
- Lichen Simplex Chronicus

### Papulosquamous Diseases

- Lichen Planus
- Pityriasis Rosea
- Psoriasis

### Vescicobullous Diseases

- Bullous Pemphigoid
- Pemphigus Vulgaris
- Dermatitis Herpetiformis
- Porphyria Cutanea Tarda

### Drug Eruptions

- Exanthematous
- Urticarial
- Pustular
- Bullous
- Other

### Heritable Disorders

- Ichthyosis Vulgaris
- Neurofibromatosis (Type I; von Recklinghausen’s Disease)
- Vitiligo

### Infections

- Bacterial Infections
- Dermatophytoses
- Parasitic Infections
- Viral Infections
- Yeast Infections
- Sexually Transmitted Infections

### Pre-Malignant Skin Conditions

- Actinic Keratosis (Solar Keratosis)
- Leukoplakia

### Malignant Skin Tumours

- Non-Melanoma Skin Cancers
- Malignant Melanoma
- Other Cutaneous Cancers

### Diseases of Hair Density

- Hair Growth
- Non-Scarring (Non-Cicatricial) Alopecia
- Scarring (Cicatricial) Alopecia

### Nails and Disorders of the Nail Apparatus

### Skin Manifestations of Systemic Disease

### Pediatric Exanthems

### Miscellaneous Lesions

- Angioedema and Urticaria
- Erythema Nodosum
- Pruritus
- Wounds and Ulcers
- Sunscreens and Preventative Therapy
- Topical Steroids
- Dermatologic Therapies

### References
### Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-hCG</td>
<td>β-human chorionic gonadotropin</td>
</tr>
<tr>
<td>AAFP</td>
<td>American Academy of Family Physicians</td>
</tr>
<tr>
<td>AD</td>
<td>atopic dermatitis</td>
</tr>
<tr>
<td>AK</td>
<td>actinic keratosis</td>
</tr>
<tr>
<td>ASO</td>
<td>anti-streptolysin O</td>
</tr>
<tr>
<td>BCC</td>
<td>basal cell carcinoma</td>
</tr>
<tr>
<td>BSA</td>
<td>body surface area</td>
</tr>
<tr>
<td>BUN</td>
<td>blood urea nitrogen</td>
</tr>
<tr>
<td>C3C</td>
<td>complete blood count</td>
</tr>
<tr>
<td>CMV</td>
<td>cytomegalovirus</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>Cr</td>
<td>creatinine</td>
</tr>
<tr>
<td>CXR</td>
<td>chest x-ray</td>
</tr>
<tr>
<td>DM</td>
<td>diabetes mellitus</td>
</tr>
<tr>
<td>DVT</td>
<td>deep vein thrombosis</td>
</tr>
<tr>
<td>EM</td>
<td>erythema multiforme</td>
</tr>
<tr>
<td>Fe</td>
<td>iron</td>
</tr>
<tr>
<td>FTA-ABS</td>
<td>fluorescent treponemal</td>
</tr>
<tr>
<td>GAS</td>
<td>group A β-hemolytic Streptococcus</td>
</tr>
<tr>
<td>GHVD</td>
<td>graft-versus-host disease</td>
</tr>
<tr>
<td>HRA</td>
<td>hypothyroidic-pituitary-adrenal</td>
</tr>
<tr>
<td>HPV</td>
<td>human papillomavirus</td>
</tr>
<tr>
<td>HRN</td>
<td>hormone replacement therapy</td>
</tr>
<tr>
<td>HSV</td>
<td>herpes simplex virus</td>
</tr>
<tr>
<td>HZV</td>
<td>herpes zoster virus</td>
</tr>
<tr>
<td>IFN</td>
<td>interferon</td>
</tr>
<tr>
<td>IVg</td>
<td>intravenous immunoglobulin</td>
</tr>
<tr>
<td>IFT</td>
<td>liver function test</td>
</tr>
<tr>
<td>MAOI</td>
<td>monoamine oxidase inhibitor</td>
</tr>
<tr>
<td>MM</td>
<td>malignant melanoma</td>
</tr>
<tr>
<td>MMR</td>
<td>measles/mumps/ubulba</td>
</tr>
<tr>
<td>MRM</td>
<td>methicillin-resistant Staphylococcus aureus</td>
</tr>
<tr>
<td>MTP</td>
<td>metastatic phalangeous</td>
</tr>
<tr>
<td>NB-UVB</td>
<td>narrow band ultraviolet wavelength</td>
</tr>
<tr>
<td>NCN</td>
<td>neocellular nevus</td>
</tr>
<tr>
<td>Nle. Yag</td>
<td>neodymium-doped yttrium</td>
</tr>
<tr>
<td>NMA</td>
<td>nonsteroidal anti-inflammatory drug</td>
</tr>
<tr>
<td>NMI</td>
<td>neomelanotic skin cancers</td>
</tr>
<tr>
<td>NMSSC</td>
<td>nevus melanoma skin cancers</td>
</tr>
<tr>
<td>NSAI</td>
<td>nonsteroidal anti-inflammatory drug</td>
</tr>
<tr>
<td>OCP</td>
<td>oral contraceptive pill</td>
</tr>
<tr>
<td>OTC</td>
<td>over-the-counter</td>
</tr>
<tr>
<td>PA3A</td>
<td>para-amino benzoic acid</td>
</tr>
<tr>
<td>PASI</td>
<td>Psoriasis Area and Severity Index</td>
</tr>
<tr>
<td>PPD</td>
<td>purified protein derivative</td>
</tr>
<tr>
<td>PVA</td>
<td>psoriasis and UVA</td>
</tr>
<tr>
<td>RA</td>
<td>rheumatoid arthritis</td>
</tr>
<tr>
<td>SCC</td>
<td>squamous cell carcinoma</td>
</tr>
<tr>
<td>SHBG</td>
<td>sex hormone-binding globulin</td>
</tr>
<tr>
<td>SJS</td>
<td>Stevens-Johnson syndrome</td>
</tr>
<tr>
<td>SLLE</td>
<td>systemic lupus erythematosus</td>
</tr>
<tr>
<td>SPF</td>
<td>sun protection factor</td>
</tr>
<tr>
<td>SSRI</td>
<td>selective serotonin receptor inhibitor</td>
</tr>
<tr>
<td>SSSS</td>
<td>staphylococcal scalded skin syndrome</td>
</tr>
<tr>
<td>STI</td>
<td>sexually transmitted infection</td>
</tr>
<tr>
<td>TB</td>
<td>tuberculosis</td>
</tr>
<tr>
<td>TEN</td>
<td>toxic epidermal necrosis</td>
</tr>
<tr>
<td>TMSX</td>
<td>trimethoprim-sulfamethoxazole</td>
</tr>
<tr>
<td>TSH</td>
<td>thyroid stimulating hormone</td>
</tr>
<tr>
<td>UC</td>
<td>ulcerative colitis</td>
</tr>
<tr>
<td>URTI</td>
<td>upper respiratory tract infection</td>
</tr>
<tr>
<td>UV</td>
<td>ultraviolet</td>
</tr>
<tr>
<td>UVA</td>
<td>ultraviolet A</td>
</tr>
<tr>
<td>UVB</td>
<td>ultraviolet B</td>
</tr>
<tr>
<td>UVC</td>
<td>ultraviolet C</td>
</tr>
<tr>
<td>VDRL</td>
<td>venereal disease research laboratory</td>
</tr>
<tr>
<td>VZV</td>
<td>varicella zoster virus</td>
</tr>
</tbody>
</table>

### Introduction to Skin

#### Skin Anatomy

![Figure 1. Histologic layers of the skin. Epidermal layer is detailed in A](image)

**Skin**
- divided anatomically into epidermis, dermis, and subcutaneous tissue
- **epidermis**
  - avascular: receives its nutrition from the dermal capillaries
  - derived from keratinocytes with the youngest presenting at the stratum basale
  - cells progress from stratum basale to stratum corneum in about 4 wk
  - stratum basale (germinativum): mitotic figures that give rise to keratinocytes
  - stratum spinosum (prickle cells): junctions in this layer (tonofilaments) give the epidermis its strength
  - stratum granulosum: flat cells containing basophilic granules which characterize skin
  - stratum lucidum: transparent layers of packed dead cells
  - stratum corneum: flat scales of the water-resistant protein keratin
- cells of the epidermis
  - keratinocytes: located in all layers of the epidermis, except the stratum corneum; connected to each other by desmosomes
  - melanocytes: located in the stratum basale; keratinocyte to melanocyte ratio in the basal layer is 10:1; melanocyte number is equal among races; produce melanosomes containing melanin, which are transferred to keratinocytes
  - Langerhans cells: dendritic cells which are important for immune surveillance
  - Merkel cells: located in the basal layer; involved in touch sensation
- **dermis**: comprised of connective tissue divided into two regions
  - papillary: contains numerous capillaries that supply nutrients to the dermis and epidermis
  - reticular: provides a strong structure for skin; consists of collagen bundles woven together along with elastic fibres, fibroblasts, and macrophages
- cells of dermis
  - fibroblasts: produces collagen, elastic, and ground substance
  - mast cells: releases histamines which mediate type I hypersensitivity
  - other components of dermis include: blood vessels, nerves, pilosebaceous units, and sweat glands
- **subcutaneous tissue** (hypodermis)
  - consists primarily of adipose cells, larger calibre vessels, nerves and fascia
Epidermal Appendages
- epidermal in origin, can extend into the dermis; includes hair, nails, and cutaneous glands
- pilosebaceous unit = hair + hair follicle + sebaceous gland + arrector pili muscle

Cutaneous Glands
- sebaceous gland: part of pilosebaceous unit, produces sebum which is secreted into the hair follicle via the sebaceous duct, where it covers the skin surface (protective function)
  - sebum has some antifungal properties
  - these glands cover entire skin surface and are absent only in non-hair bearing areas (e.g. palms, soles, lips)
- apocrine sweat gland: apocrine duct empties into hair follicle above sebaceous gland
  - found in axillae and perineum
  - likely a vestigial structure, functions in other species to produce scent (e.g. pheromones)
- eccrine sweat gland: not part of pilosebaceous unit
  - found over entire skin surface except lips, nail beds, and glans penis
  - important in temperature regulation via secretion of sweat to cool skin surface

Skin Function
- protection
  - due to continuous recycling and avascularity of epidermis
  - barrier to UV radiation (melanin), mechanical/chemical insults (sensory/mechano receptors), pathogens (immune cells), and dehydration (lipid rich barrier)
- thermal regulation
  - insulation to maintain body temperature in cool environments via peripheral vasoconstriction, hair, and subcutaneous adipose tissue
  - dissipation of heat in warm environments via increased activity of sweat glands and increased blood flow within dermal vascular networks
- sensation
  - touch, pain, and temperature sensation
- metabolic function
  - vitamin D synthesis
  - energy storage (mainly in the form of triglycerides)

Definitions

Primary Morphological Lesions
Definition
- an initial lesion that has not been altered by trauma or manipulation, and has not regressed

Table 1. Types of Primary Morphological Lesions
<table>
<thead>
<tr>
<th>Profile</th>
<th>&lt;1 cm Diameter</th>
<th>≥1 cm Diameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flat lesion</td>
<td>Macule (e.g. freckle)</td>
<td>Patch (e.g. vitiligo)</td>
</tr>
<tr>
<td>Raised superficial lesion</td>
<td>Papule (e.g. wart)</td>
<td>Plaque (e.g. psoriasis)</td>
</tr>
<tr>
<td>Deep palpable (dermal or subcutaneous)</td>
<td>Nodule (e.g. dermatofibroma)</td>
<td>Tumour (e.g. lipoma)</td>
</tr>
<tr>
<td>Elevated fluid-filled lesions</td>
<td>Vesicle (e.g. HSV)</td>
<td>Bulla (e.g. bullous pemphigoid)</td>
</tr>
</tbody>
</table>

Secondary Morphological Lesions
Definition
- develop during the evolutionary process of skin disease, or created by manipulation, or due to complication of primary lesion (e.g. rubbing, scratching, infection)
- crust: dried fluid (serum, blood, or purulent exudate) originating from a lesion (e.g. impetigo)
- scale: excess keratin (e.g. seborrheic dermatitis)
- lichenification: thickening of the skin and accentuation of normal skin markings (e.g. chronic atopic dermatitis)
- fissure: a linear slit-like cleavage of the skin
- excoriation: a scratch mark
- erosion: a disruption of the skin involving the epidermis alone; heals without scarring
- ulcer: a disruption of the skin that extends into the dermis or deeper; may heal with scarring
- xerosis: pathologic dryness of skin (xeroderma), conjunctiva (xerophthalmia), or mucous membranes (xerostomia)
- atrophy: histological decrease in size or number of cells or tissues, resulting in thinning or depression of the skin
Other Morphological Lesions

- **cyst**: an epithelial-lined collection containing semi-solid or fluid material
- **pustule**: an elevated lesion containing purulent fluid (white, grey, yellow, green)
- **scar**: replacement fibrosis of dermis and subcutaneous tissue (hypertrophic or atrophic)
- **wheal**: a special form of papule or plaque that is transient (<24 h) and blanchable often with a halo and central clearing, formed by edema in the dermis (e.g. urticaria)
- **comedone**: a special collection of sebum and keratin
  - open comedo (blackhead)
  - closed comedo (not a pustule; rather a minute dome-shaped, skin-coloured papule)
- **petechiae**: pinpoint extravasation of blood into dermis resulting in hemorrhagic lesions; non-blanchable, <3 mm in size
- **purpura**: larger than petechia, 3 mm-1 cm in size
- **ecchymosis**: larger than purpura, >1 cm in size (i.e. a “bruise”)
- **telangiectasia**: dilated superficial blood vessels; often blanchable, reticulated, and of small calibre, can be associated with benign or malignant entities

Patterns and Distribution

- **acral**: relating to the hands and feet (e.g. perniosis, secondary syphilis)
- **annular**: ring-shaped (e.g. granuloma annulare)
- **follicular**: involving hair follicles (e.g. folliculitis)
- **guttate**: lesions following a “drop-like” pattern (e.g. guttate psoriasis)
- **Koebner phenomenon**: i.e. isomorphic response, appearance of lesions at an injury site (e.g. lichen planus, psoriasis, vitiligo)
- **morbilliform**: literally means “measles-like”, an eruption composed of macules and papules with truncal predominance
- **reticular**: lesions following a net-like pattern (e.g. livedo reticularis)
- **satellite**: small lesions scattered around the periphery of a larger lesion (e.g. candida diaper dermatitis)
- **serpiginous**: lesions following a snake-like pattern (e.g. cutaneous larva migrans)
- **target/targetoid**: concentric ring lesions, like a dartboard (e.g. erythema multiforme)
- **other descriptive terms**: discrete, clustered, linear, confluent, dermatitic, indurated (i.e. hard or firm)
### Differential Diagnoses of Common Presentations

#### Table 2. Differential Diagnosis of Common Presenting Problems

<table>
<thead>
<tr>
<th>Lesion</th>
<th>Infectious</th>
<th>Inflammatory</th>
<th>Drug/Toxin</th>
<th>Miscellaneous</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discrete Red Papule</td>
<td>Furuncle Scabies</td>
<td>Acne vulgaris, Rosacea Psoriasis Urticaria</td>
<td>Bites/stings</td>
<td>Autoimmune: lichen planus; see Papulosquamous Diseases, D16 Vascular: hemangoma, pyogenic granuloma Other: dermatofibroma, milianra rubra</td>
</tr>
<tr>
<td>Red Scales</td>
<td>Pityriasis rosea Secondary syphilis Tinea</td>
<td>Dermatitis (atopic, contact, nummular, seborrheic) Discoid lupus Psoriasis</td>
<td>Gold</td>
<td>Autoimmune: lichen planus; see Papulosquamous Diseases, D16 Neoplasic: mycosis fungoides</td>
</tr>
<tr>
<td>Vesicle</td>
<td>Cat scratch disease Impetigo Viral: HSV, HZV, VZV, Molluscum, Coxsackie Scabies</td>
<td>Acute contact dermatitis Dyshidrotic eczema</td>
<td>Other: dermatitis herpetiformis, porphyria cutanea tarda</td>
<td></td>
</tr>
<tr>
<td>Bulla</td>
<td>Bullous impetigo</td>
<td>Acute dermatitis EM, SJS, TEN, SLE</td>
<td>Fixed drug enunciation</td>
<td>Autoimmune: bullous pemphigoid, pemphigus vulgaris Other: dermatitis herpetiformis, porphyria cutanea tarda</td>
</tr>
<tr>
<td>Pustule</td>
<td>Candida Dermatophyte Impetigo Sepsis Varicella</td>
<td>Acne vulgaris Rosacea Dyshidrotic dermatitis Pustular folliculitis Pustular psoriasis Hidradenitis suppurativa</td>
<td>Acute generalized exanthematosus pustulosis (usually secondary to drug reaction)</td>
<td>Other: dermatitis herpetiformis, porphyria cutanea tarda</td>
</tr>
<tr>
<td>Skin Ulcer</td>
<td>Plague Syphilis TB Tularemia</td>
<td>RA, SLE, vasculitis UC (pyoderma gangrenosum)</td>
<td>Other: dermatitis herpetiformis, porphyria cutanea tarda</td>
<td></td>
</tr>
</tbody>
</table>

#### Cysts

##### Table 3. Cysts

<table>
<thead>
<tr>
<th>Clinical Presentation</th>
<th>Pathophysiology</th>
<th>Epidemiology</th>
<th>Clinical Course</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidermal Cyst</td>
<td>Epithelial cells displaced into dermis, epidermal lining becomes filled with keratin and lipid-rich debris May be post-traumatic, rarely syndromic</td>
<td>Most common cutaneous cyst in youth – middle age</td>
<td>Central punctum may rupture (foul, cheesy odour, creamy colour) and produce inflammatory reaction Increase in size and number over time, especially in pregnancy</td>
<td>Excise completely before it becomes infected</td>
</tr>
<tr>
<td>Pilar Cyst (Trichilemmal)</td>
<td>Thick-walled cyst lined with stratified squamous epithelium and filled with dense keratin Idiopathic Post-trauma, often familial</td>
<td>2nd most common cutaneous cyst F&gt;M</td>
<td>Rupture causes pain and inflammation</td>
<td>Excision</td>
</tr>
<tr>
<td>Dermoid Cyst</td>
<td>Rare, congenital hamartomas, which arise from inclusion of epidermis along embryonal cleft closure lines, creating a thick-walled cyst filled with dense keratin</td>
<td>Rare</td>
<td>If nasal midline, risk of extension into CNS</td>
<td>Excision</td>
</tr>
<tr>
<td>Ganglion Cyst</td>
<td>Cystic lesion that originates from joint or tendon sheath, called a digital mucous cyst when found on fingertip Associated with osteoarthrits</td>
<td>Older age</td>
<td>Stable</td>
<td>Incision and expression of contents Laser ablation and electrodesiccation</td>
</tr>
<tr>
<td>Milium</td>
<td>Small epidermoid cyst, primarily arising from pluripotential cells in epidermal or adnexal epithelium Can be secondary to blistering, ulceration, trauma, topical corticosteroid atrophy, or cosmetic procedures</td>
<td>Any age 40-50% of infants</td>
<td>In newborns, spontaneously resolves in first 4 wk of life</td>
<td>Incision and expression of contents Laser ablation and electrodesiccation Multiples facial milia respond to topical retinoid therapy</td>
</tr>
</tbody>
</table>
**Fibrous Lesions**

**DERMATOFIBROMA**

**Clinical Presentation**
- button-like, firm dermal papule or nodule, skin-coloured to red-brown colouring
- majority are asymptomatic but may be pruritic and/or tender
- site: legs > arms > trunk
- dimple sign (Fitzpatrick’s sign): lateral compression causes dimpling of the lesion

**Pathophysiology**
- benign tumour due to fibroblast proliferation in the dermis

**Etiology**
- unknown; may be associated with history of minor trauma (e.g. shaving or insect bites)
- eruptive dermatofibromata can be associated with SLE

**Epidemiology**
- adults, F>M

**Differential Diagnosis**
- dermatofibrosarcoma protuberans, malignant melanoma, Kaposi’s sarcoma, blue nevus

**Investigations**
- biopsy if diagnosis is uncertain

**Management**
- no treatment required
- excision or cryosurgery if bothersome

**Skin Tags**

**Clinical Presentation**
- small (1-10 mm), soft, skin-coloured or darker pedunculated papule, often polypoid
- sites: eyelids, neck, axillae, inframammary, and groin

**Pathophysiology**
- benign outgrowth of skin

**Epidemiology**
- middle-aged and elderly, F>M, obese, can increase in size and number during pregnancy

**Differential Diagnosis**
- pedunculated seborrheic keratosis, compound or dermal melanocytic nevus, neurofibroma, fibroepithelioma of Pinkus (rare variant of BCC)

**Management**
- excision, electrodessication, cryosurgery

**Hyperkeratotic Lesions**

**SEBORRHEIC KERATOSIS**

**Clinical Presentation**
- known as ‘wisdom spots,’ ‘age spots,’ or ‘barnacles of life’
- well-demarcated waxy papule/plaque with classic “stuck on” appearance
- rarely pruritic
- over time lesions appear more warty, greasy and pigmented
- sites: face, trunk, upper extremities (may occur at any site except palms or soles)

**Pathophysiology**
- very common benign epithelial tumour due to proliferation of keratinocytes and melanocytes

**Epidemiology**
- unusual <30 yr old
- M>F
- autosomal dominant inheritance
- Leser-Trelat: sudden appearance of SK that can be associated with malignancy, commonly gastric adenocarcinomas
**Differential Diagnosis**
- malignant melanoma (lentigo maligna, nodular melanoma), melanocytic nevi, pigmented BCC, solar lentigo, spreading pigmented AK

**Investigations**
- biopsy only if diagnosis uncertain

**Management**
- none required, for cosmetic purposes only
- cryotherapy, curettage

**ACTINIC KERATOSIS (SOLAR KERATOSIS)**
- see Pre-Malignant Skin Conditions, D33

**KERATOACANTHOMA**
- see Malignant Skin Tumours, D35

**CORNS (HELOMATA)**

**Clinical Presentation**
- firm papule with a central, translucent, cone-shaped, hard keratin core
- painful with direct pressure
- sites: most commonly on dorsolateral fifth toe and dorsal aspects of other toes

**Pathophysiology**
- localized hyperkeratosis induced by pressure on hands and feet

**Epidemiology**
- F>M, can be caused by chronic microtrauma

**Differential Diagnosis**
- tinea pedis, plantar warts

**Management**
- relieve pressure with padding or alternate footwear, orthotics
- paring, curettage

---

**Keloids**

**Clinical Presentation**
- firm, shiny, skin-coloured or red-bluish papules/nodules that most often arise from cutaneous injury (e.g. piercing, surgical scar, acne), but may appear spontaneously
- extends beyond the margins of the original injury, and may continue to expand in size for years with claw-like extensions
- can be pruritic and painful
- sites: earlobes, shoulders, sternum, scapular area, angle of mandible

**Pathophysiology**
- excessive deposition of randomly organized collagen fibres following trauma to skin

**Epidemiology**
- most common in black patients, followed by those of Asian descent (predilection for darker skin)
- M=F, all age groups

**Management**
- intralesional corticosteroid injections
- cryotherapy
- silicone compression
Pigmented Lesions

CONGENITAL NEVOMELANOCYTIC NEVI (CNMN)

Clinical Presentation
- sharply demarcated pigmented papule or plaque with regular borders ± coarse hairs
- classified by size: small (<1.5 cm), medium (M1: 1.5-10 cm, M2: >10-20 cm), large (L1: >20-30 cm, L2 >30-40 cm), giant (G1: >40-60 cm, G2: >60 cm)
- may be surrounded by smaller satellite nevi

Pathophysiology
- nevomelanocytes in epidermis (clusters) and dermis (strands)

Epidemiology
- present at birth or develops in early infancy to childhood
- malignant transformation is rare (1-5%) and more correlated with size of the lesion
- neurocutaneous melanosis can occur in giant CNMN (melanocytes in the central nervous system)

Management
- surgical excision if suspicious, due to increased risk of melanoma
- MRI if suspicious for neurological involvement

OTHER CONGENITAL PIGMENTED LESIONS

Table 4. Comparison of Other Congenital Pigmented Lesions

<table>
<thead>
<tr>
<th></th>
<th>Clinical Presentation</th>
<th>Pathophysiology</th>
<th>Epidemiology</th>
<th>Differential Diagnosis</th>
<th>Clinical Course and Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Café-au-lait macule</td>
<td>Flat light brown lesions with smooth or jagged borders</td>
<td>Areas of increased melanogenesis</td>
<td>6 or more is suggestive of neurofibromatosis type I. Also associated with McCune-Albright syndrome</td>
<td>Flat congenital melanocytic nevus, speckled lentiginous nevus</td>
<td>Enlarge in proportion to the child. Laser can be used to treat for cosmesis</td>
</tr>
<tr>
<td>Speckled lentiginous nevus (nevus spilus)</td>
<td>Brown pigmented macular background (café-au-lait macule-like) with dark macular or papular speckles</td>
<td>Increased melanocyte concentration</td>
<td>Risk of melanoma similar to that of a CNMN of the same size</td>
<td>Café-au-lait macule, agminated lentigines, Becker’s nevus</td>
<td>Usually the light macular background is present at birth and speckles develop over time. Management is similar to that of CNMNs</td>
</tr>
<tr>
<td>Dermal Melanocytosis (historically known as Mongolian Spot)</td>
<td>Congenital grey-blue solitary or grouped macules commonly on lumbosacral area</td>
<td>Ectopic melanocytes in dermis</td>
<td>99% occurs in Asian and Aboriginal infants</td>
<td>Echymosis</td>
<td>Usually fades in early childhood but may persist into adulthood</td>
</tr>
</tbody>
</table>

ACQUIRED NEVOMELANOCYTIC NEVI

Clinical Presentation
- common mole: well circumscribed, round, uniformly pigmented macules/papules <1.5 cm
- average number of moles per person: 18-40
- 3 stages of evolution: junctional NMN, compound NMN, and dermal NMN

Table 5. Evolution of Acquired Nevomelanocytic Nevi

<table>
<thead>
<tr>
<th>Type</th>
<th>Age of Onset</th>
<th>Clinical Presentation</th>
<th>Histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Junctional</td>
<td>Childhood</td>
<td>Flat, irregularly bordered, uniformly tan-dark brown, sharply demarcated smooth macule</td>
<td>Melanocytes at dermal-epidermal junction above basement membrane</td>
</tr>
<tr>
<td>Compound</td>
<td>Any age</td>
<td>Dome-shaped, regular, round, tan-dark brown papule</td>
<td>Melanocytes at dermal-epidermal junction; migration into dermis</td>
</tr>
<tr>
<td>Dermal</td>
<td>Adults</td>
<td>Soft, dome-shaped, skin-coloured to tan’ brown papules or nodules, often with telangiectasia</td>
<td>Melanocytes exclusively in dermis</td>
</tr>
</tbody>
</table>

Other Nevi
- Halo nevus: often a typical appearing nevus surrounded by a ring of depigmentation; not rare in children; uncommonly associated with vitiligo; no treatment required unless irregular colour or borders
- Blue nevus: round to oval macule/papule with homogenous blue to blue-black colour; often appears in childhood and late adolescence; no treatment required unless atypical features are noted
Management

- new or changing pigmented lesions should be evaluated for atypical features which could indicate a melanoma
- excisional biopsy can be considered if the lesion demonstrates asymmetry, varied colours, irregular borders, pruritus or persistent bleeding

OTHER ACQUIRED PIGMENTED LESIONS

Table 6. Comparison of Other Acquired Pigmented Lesions

<table>
<thead>
<tr>
<th>Clinical Presentation</th>
<th>Pathophysiology</th>
<th>Epidemiology</th>
<th>Differential Diagnosis</th>
<th>Clinical Course and Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atypical nevus (Dysplastic Nevus)</td>
<td>Variegated macule/papule with irregular distinct melanocytes in the basal layer</td>
<td>Hyperplasia and proliferation of melanocytes extending beyond dermal compartment of the nevus</td>
<td>&gt;5 atypical nevi increases risk for melanoma; Numerous dysplastic nevi may be part of Familial Atypical Mole and Melanoma syndrome</td>
<td>Follow with colour photographs for changes; Excisional biopsy if lesion changing or highly atypical</td>
</tr>
<tr>
<td>Ephelides (Freckles)</td>
<td>Small (&lt;5 mm) well-demarcated light brown macules</td>
<td>Increased melanin within basal layer keratinocytes secondary to sun exposure</td>
<td>Skin phototypes III-IV</td>
<td>Multiply and darken with sun exposure, fade in winter; No treatment required; Sunscreen may prevent the appearance of new freckles</td>
</tr>
<tr>
<td>Solar Lentigo (Liver Spot)</td>
<td>Well-demarcated brown/black irregular macules</td>
<td>Benign melanocytic proliferation in dermal-epidermal junction due to chronic sun exposure</td>
<td>Most common in Caucasians; &gt;40 yr; Skin phototypes III-IV</td>
<td>Lentigo maligna; seborrheic keratosis, pigmented solar keratosis; Laser therapy; shave excisions, cryotherapy</td>
</tr>
<tr>
<td>Becker’s Nevus</td>
<td>Hairy, light brown macule/patch with a papular verrucous surface</td>
<td>Pigmented hamartoma with increased melanin in basal cells</td>
<td>M&gt;F; Often becomes noticeable at puberty</td>
<td>Hairy congenital melanocytic nevus; Hair growth follows onset of pigmentation; Cosmetic management (usually too large to remove)</td>
</tr>
<tr>
<td>Melasma</td>
<td>Dark, usually symmetrical, skin discoloration on sun-exposed areas of face (forehead, upper lip, cheeks, chin)</td>
<td>Increase in number and activity of melanocytes associated with estrogen and progesterone</td>
<td>F&gt;M; Common in pregnancy and women taking DCP or HRT; Risk factors: sun exposure, dark skin tone; Can occur with mild endocrine disturbances, antiepileptic medications, and other photosensitizing drugs</td>
<td>Post-inflamatory hyperpigmentation, Reit melanosis; Often fades over several months after stopping hormone treatment or delivering baby; Treatment: hydroquinone, azelaic acid, retinoic acid, topical steroid, combination creams, destructive modalities (chemical peels, laser treatment), camouflage make-up, sunscreen, sun avoidance</td>
</tr>
</tbody>
</table>

Vascular Lesions

Table 7. Vascular Tumours Compared to Vascular Malformations

<table>
<thead>
<tr>
<th>Vascular Tumours</th>
<th>Vascular Malformations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definition</td>
<td>Endothelial hyperplasia; Congenital malformation with normal endothelial turnover</td>
</tr>
<tr>
<td>Presence at Birth</td>
<td>Usually postnatal; 100% at birth (not always obvious)</td>
</tr>
<tr>
<td>M:F</td>
<td>1:3-5:1</td>
</tr>
<tr>
<td>Natural History</td>
<td>Phases: Proliferating, Involuting, Involved; Proportionate growth (can expand)</td>
</tr>
</tbody>
</table>

HEMANGIOMAS

Clinical Presentation

- red or blue subcutaneous mass that is soft/compressible, blanches with pressure; feels like a “bag of worms” when palpated

Pathophysiology

- benign vascular tumour
- includes: cavernous hemangioma, capillary/infantile hemangioma, spider hemangioma

A spider angioma will blanch when the tip of a paperclip is applied to the centre of the lesion
## Vascular Malformations

### Table 8. Vascular Tumours

<table>
<thead>
<tr>
<th>Type</th>
<th>Clinical Presentation</th>
<th>Pathophysiology</th>
<th>Epidemiology</th>
<th>Clinical Course</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemangioma of infancy</td>
<td>Hot, firm red to blue plaques or tumours</td>
<td>Benign vascular proliferation of endothelial lining</td>
<td>Appears shortly after birth; rarely may be congenital</td>
<td>Appears shortly after birth, increases in size over months, then regresses</td>
<td>10% require treatment due to functional impairment (visual compromise, airway obstruction, high output cardiac failure) or cosmesis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>50% of lesions resolve spontaneously by 5 yr</td>
<td>Consider treatment if not gone by school age; propranolol; systemic corticosteroids; laser treatment; surgery</td>
</tr>
<tr>
<td>Spider Angioma (Campbell De Morgan Spot)</td>
<td>Central red arteriole with slender branches, faintly pulsatile, blanchable</td>
<td>Can be associated with hyperestrogenic state (e.g. in hepatocellular disease, pregnancy, OCP) but often is not</td>
<td>Increase in number over time</td>
<td>Reassurance</td>
<td>Electrodesiccation or laser surgery if patient wishes</td>
</tr>
<tr>
<td>Cherry Angioma (Campbell De Morgan Spot)</td>
<td>Bright red to deep maroon, dome-shaped vascular papules, 1-5 mm Site: trunk Less friable compared to pyogenic granulomas</td>
<td>Benign vascular neoplasm</td>
<td>&gt;30 yr old</td>
<td>Lesions do not fade in time Lesions bleed infrequently</td>
<td>Usually no treatment needed Laser or electrocautery for small lesions Excision of large lesions if necessary</td>
</tr>
<tr>
<td>Pyogenic Granuloma</td>
<td>Bright red, dome-shaped sessile or pedunculated friable nodule Sites: fingers, lips, mouth, trunk, toes DDx: glomus tumour, nodular MM, SCL, nodular BCC</td>
<td>Rapidly developing hemangioma Proliferation of capillaries with erosion of epidermis and neutrophilia</td>
<td>&lt;30 yr old</td>
<td>Surgical excision with histologic examination Electrocautery; laser; cryotherapy</td>
<td></td>
</tr>
</tbody>
</table>

### Table 9. Vascular Malformations

<table>
<thead>
<tr>
<th>Type</th>
<th>Clinical Presentation</th>
<th>Pathophysiology</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nevus Flammeus (Port-wine stain)</td>
<td>Red to blue macule present at birth that follows a dermalatal distribution, rarely crosses midline Most common site: nape of neck Never spontaneously regresses but grows in proportion to the child</td>
<td>Congenital vascular malformation of dermal capillaries; rarely associated with Sturge-Weber syndrome (V1, V2 distribution)</td>
<td>Laser or make-up</td>
</tr>
<tr>
<td>Nevus Simplex (salmon patch)</td>
<td>Pink-red irregular patches Midline macule on glabella known as “Angel Kiss”; on nuchal region known as “Stork Bites” Present in 1/3 of newborns Majority regress spontaneously</td>
<td>Congenital dilation of dermal capillaries</td>
<td>No treatment required</td>
</tr>
</tbody>
</table>

### Lipoma

**Clinical Presentation**
- Single or multiple non-tender subcutaneous tumours that are soft and mobile
- Occurs most frequently on the trunk, and extremities but can be anywhere on the body

**Pathophysiology**
- Adipocytes enclosed in a fibrous capsule

**Epidemiology**
- Often solitary or few in number; if multiple can be associated with rare syndromes

**Differential Diagnosis**
- Angiolipoma, liposarcoma

**Investigations**
- Biopsy only if atypical features (painful, rapid growth, firm)

**Management**
- Reassurance
- Excision or liposuction only if desired for cosmetic purposes
## Acneiform Eruptions

### Acne Vulgaris/Common Acne

#### Clinical Presentation
- A common inflammatory pilosebaceous disease categorized with respect to severity
  - Type I: comedonal, sparse, no scarring
  - Type II: comedonal, papular, moderate ± little scarring
  - Type III: comedonal, papular, and pustular, with scarring
  - Type IV: nodulocystic acne, risk of severe scarring
- Sites of predilection: face, neck, upper chest, and back

#### Pathophysiology
- Hyperkeratinization at the follicular ostia (opening) blocks the secretion of sebum leading to the formation of microcomedones
- Androgens promote excess sebum production
- *Propionibacterium* acnes metabolize sebum to free fatty acids and produces pro-inflammatory mediators

#### Epidemiology
- Age of onset in puberty (10-17 yr in females, 14-19 yr in males)
- In prepubertal children consider underlying hormonal abnormality (e.g. late onset congenital adrenal hyperplasia)
- More severe in males than in females
- Incidence decreases in adulthood
- Genetic predisposition: majority of individuals with cystic acne have parent(s) with history of severe acne

#### Differential Diagnosis
- Folliculitis, keratosis pilaris (upper arms, face, thighs), perioral dermatitis, rosacea

### Table 10. Management of Acne

<table>
<thead>
<tr>
<th>Compound/Drug Class</th>
<th>Product Names</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MILD ACNE: Topical Therapies OTC</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzoyl peroxide (BPO)</td>
<td>Solugel, Benzac, Desquam, Fostex</td>
<td>Helps prevent <em>P. acnes</em> resistance, is a bactericidal agent (targets <em>P. acnes</em>) and is comedolytic</td>
</tr>
<tr>
<td>Salicylic acid</td>
<td>Akurza® Cream, DermalZone</td>
<td>Used when patients cannot tolerate a topical retinoid due to skin irritation</td>
</tr>
<tr>
<td><strong>MILD ACNE: Prescription Topical Therapies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antimicrobials</td>
<td>Clindamycin (Dalacin T), Erythromycin</td>
<td>High rate of resistance when used as monotherapy</td>
</tr>
<tr>
<td>Retinoids</td>
<td>Vitamin A Acid (Tretinoin, Stieva-A, Retin A) Adapalene (Differin)</td>
<td>Backbone of topical acne therapy All regimens should include a retinoid unless patient cannot tolerate</td>
</tr>
<tr>
<td>Combination products</td>
<td>Clindoxyl (Clindamycin and BPO) Benzacnil (Clindamycin and BPO) Tactuo (Adapalene and BPO) Stievamycine (Tretinoin and Erythromycin) Benzamycine (BPO and Erythromycin)</td>
<td>Allows for greater adherence and efficacy Combines different mechanisms of action to increase efficacy and maximize tolerability</td>
</tr>
<tr>
<td><strong>MODERATE ACNE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetracycline/Minocycline/ Doxycycline</td>
<td>Sumycin/Minocin/Vibramycin</td>
<td>Use caution with regard to drug interactions: do not use with isotretinoin Sun sensitivity Antibiotics require 3 mo of use before assessing efficacy</td>
</tr>
<tr>
<td>Cyproterone acetate- ethinyl estradiol</td>
<td>Diane-35®</td>
<td>After 35 yr of age, estrogen/progesterone should only be considered in exceptional circumstances, carefully weighing the risk/benefit ratio with physician guidance</td>
</tr>
<tr>
<td>Spironolactone (source ADA)</td>
<td>Aldactone</td>
<td>May cause hyperkalemia at higher doses Black box warning for breast cancer</td>
</tr>
<tr>
<td><strong>SEVERE ACNE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isotretinoin</td>
<td>Accutane®, Clanus®, Epuris®</td>
<td>See Table 27 for full side effect profile Most adverse effects are temporary and will resolve when the drug is discontinued Baseline lipid profile (risk of hypertriglyceridemia), LFTs and β-hCG before treatment May transiently exacerbate acne before patient sees improvement Refractory cases may require multiple courses of isotretinoin</td>
</tr>
</tbody>
</table>

### Acne Myths Debunked
- Acne is not caused by poor hygiene; on the contrary, excessive washing of face can be an aggravator

### Acne Exacerbating Factors
- Systemic medications: lithium, phenytoin, steroids, halogens, androgens, iodides, bromides, danazol
- Topical agents: steroids, tars, ointments, oily cosmetics
- Mechanical pressure or occlusion, such as leaning face on hands
- Emotional stress

### Intrallesional Injections
- A combination of topical retinoids and topical erythromycin or clindamycin is more effective than either agent used alone

### Isotretinoin and Pregnancy
- Use of isotretinoin during pregnancy is associated with spontaneous abortion and major birth defects such as facial dysmorphism and cognitive impairment
- Pregnancy should be ruled out before starting isotretinoin
- Ideally, patients should use 2 forms of contraception while on isotretinoin
**Perioral Dermatitis**

**Clinical Presentation**
- discrete erythematous micropapules that often become confluent, forming inflammatory plaques on perioral, perinasal, and periorbital skin
- commonly symmetrical, rim of sparing around vermillion border of lips

**Epidemiology**
- 15-40 yr old, occasionally in younger children
- predominantly females

**Differential Diagnosis**
- contact dermatitis, rosacea, acne vulgaris

**Management**
- avoid all topical steroids
- topical: metronidazole 0.75% gel or 0.75-1% cream to affected area bid
- systemic: tetracycline family antibiotic (utilized for its anti-inflammatory properties)
- occasional use of a non-steroidal anti-inflammatory cream (i.e. tacrolimus or pimecrolimus)

**Rosacea**

**Clinical Presentation**
- dome-shaped inflammatory papules ± pustules
- flushing, non-transient erythema, and telangiectasia
- distribution: typically on central face including forehead, nose, cheeks, and chin; rarely on scalp, neck, and upper body
- characterized by remissions and exacerbations
- exacerbating factors: heat, cold, wind, sun, stress, drinking hot liquids, alcohol, caffeine, spices
- all forms of rosacea can progress from mild to moderate to severe
- rarely in longstanding rosacea, signs of thickening, induration and lymphedema in the skin can develop
- phyma: a distinct swelling caused by lymphedema and hypertrophy of subcutaneous tissue, particularly affecting the nose (rhinophyma)
- ocular manifestations: blepharoconjunctivitis, keratitis, iritis

**Pathophysiology**
- unknown

**Epidemiology**
- although found in all skin types, highest prevalence in fair-skinned people
- 30-50 yr old; F>M

**Differential Diagnosis**
- acne vulgaris, seborrheic dermatitis, perioral dermatitis, contact dermatitis

**Management**
- trigger avoidance and daily sunscreen use for long-term management
- avoid topical corticosteroids
- telangiectasia: treated by physical ablation; electrical hyfrecators, vascular lasers, and intense pulsed light therapies
- phymas: treated by physical ablation or removal; paring, electro surgery, cryotherapy, laser therapy (CO₂, argon, Nd:YAG)

**Table 11. Specific Rosacea Treatments**

<table>
<thead>
<tr>
<th>1st Line</th>
<th>2nd Line</th>
<th>3rd Line</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral tetracyclines (250-500 mg PO bid)</td>
<td>Topical clindamycin</td>
<td>Oral retinoids</td>
</tr>
<tr>
<td>Topical metronidazole</td>
<td>Topical erythromycin 2% solution</td>
<td>Topical sulfur</td>
</tr>
<tr>
<td>Oral erythromycin (250-500 mg PO bid)</td>
<td>Topical benzoyl peroxide</td>
<td></td>
</tr>
<tr>
<td>Topical azelaic acid</td>
<td>Oral metronidazole</td>
<td>Ampicillin</td>
</tr>
</tbody>
</table>

**Important Controversies Associated with Isotretinoin Therapy for Acne**

- **Study:** Review on isotretinoin and (1) depression and suicide, (2) inflammatory bowel disease (IBD), (3) pregnancy prevention programs.
- **Conclusions**
  1. The evidence on whether isotretinoin causes depression and suicide is inconsistent; however, numerous controlled studies have shown an improvement in anxiety and depression scores in those taking isotretinoin.
  2. There is no association between IBD and isotretinoin use. Only one study showed a significantly increased risk of UC. When considering using isotretinoin in a patient with IBD or with a strong family history, consider involving a gastroenterologist.

**Guidelines for the Diagnosis of Rosacea**

- Presence of one or more of the following primary features:
  - Flushing (transient erythema)
  - Nontransient erythema
  - Papules and pustules
  - Telangiectasia
- May include one or more of the following secondary features:
  - Burning or stinging
  - Dry appearance
  - Edema
  - Phymatous changes
  - Ocular manifestations
  - Peripheral location
Dermatitis (Eczema)

Definition
- inflammation of the skin

Clinical Presentation
- poorly demarcated erythematous patches or plaques
- symptoms include pruritus and pain
- acute dermatitis: papules, vesicles
- subacute dermatitis: scaling, crusting, excoriations
- chronic dermatitis: lichenification, xerosis, fissuring

Asteatotic Dermatitis

Clinical Presentation
- diffuse, mild pruritic dermatitis secondary to dry skin
- very common in elderly, especially in the winter (i.e. "winter itch") but starts in the fall
- shins predominate, looks like a "dried river bed"

Management
- skin rehydration with moisturizing routine ± mild corticosteroid creams

Atopic Dermatitis

Clinical Presentation
- subacute and chronic eczematous reaction associated with prolonged severe pruritus
- distribution depends on age
- inflammation, lichenification, excoriations are secondary to relentless scratching
- atopic palms: hyperlinearity of the palms (associated with ichthyosis vulgaris)
- associated with: keratosis pilaris (hyperkeratosis of hair follicles, "chicken skin"), xerosis, occupational hand dryness

Epidemiology
- frequently affects infants, children, and young adults
- almost 15% of children in developed countries under the age of 5 are affected
- associated with personal or family history of atopy (asthma, hay fever), anaphylaxis, eosinophilia
- polygenic inheritance: one parent >60% chance for child; two parents >80% chance for child
- the earlier the onset, the more severe and persistent the disease
- long-term condition with 1/3 of patients continuing to show signs of AD into adulthood

Pathophysiology
- a T-cell driven process with epidermal barrier dysfunction

Investigations
- clinical diagnosis
- consider: skin biopsy, immunoglobulin serum levels (often elevated serum IgE level), patch testing, and skin prick tests

Management
- goal: reduce signs and symptoms, prevent or reduce recurrences/flare
- better outcome (e.g. less flare-ups, modified course of disease) if diagnosis made early and treatment plan individualized
- avoid triggers of AD
- non-pharmacologic therapy
  - moisturizers
    - apply liberally and reapply frequently with goal of minimizing xerosis
    - include in treatment of mild to severe disease as well as in maintenance therapy
  - bathing practices
    - bathe in plain warm water for a short period of time once daily followed by lightly but not completely drying the skin with a towel; immediately apply topical agents or moisturizers after this
    - use fragrance-free hypoallergenic non-soap cleansers
- pharmacologic therapy
  - topical corticosteroids
    - effective in reducing acute and chronic symptoms as well as prevention of flares
    - choice of steroid potency depends on age, body site, short vs. long-term use
    - apply 1 adult fingertip unit (0.5 g) to an area the size of 2 adult palms bid for acute flares, and 1-2x/wk for maintenance therapy
  - local side effects: skin atrophy, purpura, telangiectasia, striae, hypertrichosis, and acneiform eruption are all very rarely seen

Triggers for Atopic Dermatitis
- Irritants (detergents, solvents, clothing, water hardness)
- Contact allergens
- Environmental allergens (e.g. dust mites)
- Inappropriate bathing habits (e.g. long hot showers)
- Sweating
- Microbes (e.g. S. aureus)
- Stress
Contact Dermatitis

Clinical Presentation
- cutaneous inflammation caused by an external agent(s)

Table 12. Contact Dermatitis

<table>
<thead>
<tr>
<th>Mechanism of Reaction</th>
<th>Irritant Contact Dermatitis</th>
<th>Allergic Contact Dermatitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxic injury to skin; non-immune mechanism</td>
<td>Erythema, dryness, fine scale, burning</td>
<td>Cell-mediated delayed (Type IV) hypersensitivity reaction (see Rheumatology, RH2)</td>
</tr>
<tr>
<td>Visible or invisible</td>
<td>Acute: quick reaction, sharp margins (e.g. from acid/alkali exposure)</td>
<td>Erythema with a papulovesicular eruption, swelling, pruritus</td>
</tr>
<tr>
<td>Cumulative insult: slow to appear, poorly defined margins (e.g. from soap), more common</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Frequency | Majority; will occur in anyone given sufficient concentration of irritants | Minority; patient acquires susceptibility to allergen that persists indefinitely |
| Distribution | Hands are the most common site | Areas exposed to allergen |
| Examples | Soaps, weak alkali, detergents, organic solvents, alcohol, oils | Many allergens are irritants, so may coincide with irritant dermatitis |
| Management | Avoidance of irritants, wet compressors with Burow’s solution, barrier moisturizers | Patch testing to determine specific allergen, avoid allergen and its cross-reactants |
| | Topical/oral steroids | Steroid cream (e.g. hydrocortisone 1%, betamethasone valerate 0.05% or 0.1%, cream; bid) |
| | | Systemic steroids pm (prednisone 1 mg/kg, taper over 2 wk) |
**Dyshidrotic Dermatitis**

**Clinical Presentation**
- "tapioca pudding" papulovesicular dermatitis of hands and feet that coalesce into plaques, followed by painful fissuring
- acute stage often very pruritic
- secondary infections common
- lesions heal with desquamation and may lead to chronic lichenification
- sites: palms and soles ± dorsal surfaces of hands and feet

**Pathophysiology**
- NOT caused by hyperhidrosis (excessive sweating)
- emotional stress may precipitate flares

**Management**
- topical: high potency corticosteroid with plastic cling wrap occlusion to increase penetration
- intralesional triamcinolone injection
- systemic:
  - prednisone in severe cases
  - antibiotics for secondary *S. aureus* infection

**Nummular Dermatitis**

**Clinical Presentation**
- annular, coin-shaped, pruritic, dry, scaly, erythematous plaques, can become lichenified
- often associated with atopic and dyshidrotic dermatitis
- secondary infection common

**Pathophysiology**
- little is known, but it is often accompanied by xerosis, which results from a dysfunction of the epidermal lipid barrier; this in turn can allow permeation of environmental agents, which can induce an allergic or irritant response

**Management**
- moisturization
- mid to high potency corticosteroid ointment bid

**Seborrheic Dermatitis**

**Clinical Presentation**
- greasy, erythematous, yellow, scaling, minimally elevated papules and plaques in areas rich in sebaceous glands, can look moist and superficially eroded in flexural regions
- infants: "cradle cap"
- children: may be generalized with flexural and scalp involvement
- adults: diffuse involvement of scalp margin with yellow to white flakes, pruritus, and underlying erythema
- sites: scalp, eyebrows, eyelashes, beard, glabella, post-auricular, over sternum, trunk, body folds, genitalia

**Pathophysiology**
- possible etiologic association with *Malassezia* spp. (yeast)

**Epidemiology**
- common in infants and adolescents
- increased incidence and severity in immunocompromised patients
- in adults, can cause dandruff (pityriasis siccata)

**Management**
- face: ketoconazole (Nizoral®) cream daily or bid + mild steroid cream daily or bid
- scalp: salicylic acid in olive oil or Derma-Smoothe FS® lotion (peanut oil, mineral oil, fluocinolone acetonide 0.01%) to remove dense scales, 2% ketoconazole shampoo (Nizoral®), ciclopirox (Stieprox®) shampoo, selenium sulfide (e.g. Selsun®) or zinc pyrithione (e.g. Head and Shoulders®) shampoo, steroid lotion (e.g. betamethasone valerate 0.1% lotion bid)
**Stasis Dermatitis**

**Clinical Presentation**
- erythematous, scaly, pruritic plaques in lower legs, particularly the medial ankle
- brown hemosiderin deposition, woody fibrosis, atrophy blanche, and lipodermatosclerosis in late stages
- usually bilateral, accompanied by swelling, oozing, crusting, may have accompanying varicosities

**Pathophysiology**
- chronic venous insufficiency leads to venous stasis
- surrounding soft tissue inflammation and fibrosis results

**Investigations**
- Doppler and colour-coded Duplex sonography if suspicious for DVT
- culture for MRSA if there is crusting

**Management**
- compression stockings
- rest and elevate legs (above the level of the heart)
- moisturizer to treat xerosis
- mid-high potency topical corticosteroids to control inflammation

**Complications**
- ulceration (common at medial malleolus), secondary bacterial infections

**Lichen Simplex Chronicus**

**Clinical Presentation**
- well-defined plaque(s) of lichenified skin with increased skin markings ± excoriations
- common sites: neck, scalp, lower extremities, urogenital area
- often seen in patients with atopy

**Pathophysiology**
- skin hyperexcitable to itch, continued rubbing/scratching of skin results
- eventually lichenification occurs

**Investigations**
- if patient has generalized pruritus, rule out systemic cause: CBC with differential count, transaminases, bilirubin, renal and thyroid function tests
- CXR if lymphoma suspected

**Management**
- antipruritics (e.g. antihistamines, topical or intralesional glucocorticoids, Unna boot)

**Papulosquamous Diseases**

**Lichen Planus**

**Clinical Presentation**
- acute or chronic inflammation of mucous membranes or skin, especially on flexural surfaces
- morphology: pruritic, well-demarcated, violaceous, polygonal, flat-topped papules
- common sites: wrists, ankles, mucous membranes in 60% (mouth, vulva, glans), nails, scalp
- distribution: symmetrical and bilateral
- Wickham's striae: reticulate white-grey lines over surface; pathognomonic but may not be present
- mucous membrane lesions: lacy, whitish reticular network, milky-white plaques/papules; increased risk of SCC in erosions and ulcers
- nails: longitudinal ridging; dystrophic; pterygium formation
- scalp: scarring alopecia with perifollicular hyperkeratosis
- spontaneously resolves but may last for weeks, months or years (mouth and skin lesions)
- rarely associated with hepatitis C
- Koebner phenomenon

**Pathophysiology**
- autoimmune, antigen unknown
- lymphocyte activation leads to keratinocyte apoptosis

**Epidemiology**
- 1%
- 30-60 yr old, F>M
Investigations
• biopsy
• hepatitis C serology if patient has risk factors

Management
• topical or intralesional corticosteroids
• short courses of oral prednisone (rarely)
• phototherapy for generalized or resistant cases
• oral retinoids for erosive lichen planus in mouth
• systemic immunosuppressants (e.g. azathioprine, methotrexate, cyclosporine)

Pityriasis Rosea

Clinical Presentation
• acute, self-limiting eruption characterized by red, oval plaques/patches with central scale that does not extend to edge of lesion
• long axis of lesions follows skin tension lines (i.e. Langer's Lines) parallel to ribs producing “Christmas tree” pattern on back
• varied degree of pruritus
• most start with a “herald” patch which precedes other lesions by 1-2 wk
• common sites: trunk, proximal aspects of arms and legs

Etiology
• suspected HHV-7 or HHV-6 reactivation

Investigations
• none required

Management
• none required; clears spontaneously in 6-12 wk
• symptomatic: topical glucocorticoids if pruritic, cool compresses, emollients

Psoriasis

Classification
1. plaque psoriasis 2. guttate psoriasis 3. erythrodermic psoriasis
4. pustular psoriasis 5. inverse psoriasis

Pathophysiology
• not fully understood, genetic and immunologic factors
• shortened keratinocyte cell cycle leads to Th1- and Th17-mediated inflammatory response

Epidemiology
• 1.5-2%, M=F
• all ages: peaks of onset: 20-30 and 50-60
• polygenic inheritance: 8% with 1 affected parent, 41% with both parents affected
• risk factors: smoking, obesity, alcohol, drugs, infections

Differential Diagnosis
• AD, mycosis fungoides (cutaneous T-cell lymphoma), seborrheic dermatitis, tinea, nummular dermatitis, lichen planus

Investigations
• biopsy (if atypical presentation, rarely needed)

1. PLAQUE PSORIASIS

Clinical Presentation
• chronic and recurrent disease characterized by well-circumscribed erythematous papules/plaques with silvery-white scales
• often worse in winter (lack of sun and humidity)
• Auspitz sign: bleeds from minute points when scale is removed
• common sites: scalp, extensor surfaces of elbows and knees, trunk (especially buttocks), nails, pressure areas
Management
• principles of management depends on severity of disease, as defined by BSA affected or less commonly Psoriasis Area and Severity Index (PASI)
  • mild (<5% BSA)
    • topical steroids, topical vitamin D3 analogues, or a combinations of the two are first line
    • topical retinoid ± topical steroid combination, anthralin, and tar are also effective but tend to have more side effects than first line therapies
    • emollients potentiate the effect of topical therapies
    • phototherapy or systemic treatment may be necessary if the lesions are scattered or if it involves sites that are difficult to treat such as palms, soles, scalp, genitals
  • moderate (5-10% BSA) to severe (>10% BSA)
    • goal of treatment is to attain symptom control that is adequate from patient’s perspective
    • phototherapy if accessible
    • systemic or biological therapy based on patient’s treatment history and comorbidities
    • topical steroid ± topical vitamin D3 analogue as adjunct therapy

Table 13. Topical Treatment of Psoriasis

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Mechanism</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emollients</td>
<td>Reduce fissure formation</td>
<td>Petrolatum is effective</td>
</tr>
<tr>
<td>Salicylic acid 1-12%</td>
<td>Remove scales</td>
<td></td>
</tr>
<tr>
<td>Tar (LCD: liquor carbonis detergens)</td>
<td>Inhibits DNA synthesis, increases cell turnover</td>
<td>Poor long-term compliance</td>
</tr>
<tr>
<td>Topical Corticosteroids</td>
<td>Reduce scaling and thickness</td>
<td>Use appropriate potency steroid in different areas for degree of psoriasis</td>
</tr>
<tr>
<td>Vitamin D3 analogues: Calcipotriene / calcipotriol (Dovonex®, Siliks®)</td>
<td>Binds to skin 1,25-dihydroxyvitamin D3 to inhibit keratinocyte proliferation</td>
<td>Can be used on face and skin folds</td>
</tr>
<tr>
<td>Betamethasone + calcipotriene (Dovobet®)</td>
<td>Combined corticosteroid and vitamin D3 analogue. See above mechanisms</td>
<td>Not to be used on face and folds</td>
</tr>
<tr>
<td>Tazarotene (Tazorac®) (gel/cream)</td>
<td>Retinoid derivative, decreased scaling</td>
<td>Use on nails</td>
</tr>
</tbody>
</table>

Table 14. Systemic Treatment of Psoriasis

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Considerations</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acitretin</td>
<td>More effective when used in combination with phototherapy</td>
<td>Alopecia, cheilitis, teratogenicity, hepatotoxicity, photosensitivity, epistaxis, xerosis, hypertriglyceridemia</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>Used for intermittent control rather than continuouslyAvoid using for &gt;1 yr</td>
<td>Renal toxicity, hypertension, hypertriglyceridemia, immunosuppression, lymphoma</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>Has been used for over 50 yr</td>
<td>Bone marrow toxicity, hepatic cirrhosis, teratogenicity</td>
</tr>
<tr>
<td>Apremilast (Otezla®)</td>
<td>Extremely safe</td>
<td>GI upset, headache, weight loss</td>
</tr>
<tr>
<td>PUVA</td>
<td>Highly effective in achieving remission Avoid &gt;200 sessions in lifetime</td>
<td>Pruritus, burning, cataracts, skin cancer</td>
</tr>
<tr>
<td>UVB and “Narrow band” UVB (311-312 nm)</td>
<td>Much less carcinogenic than PUVA</td>
<td>Rare burning</td>
</tr>
</tbody>
</table>

Table 15. Biologics Approved in Canada

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Dosing Schedule</th>
<th>Effectiveness</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etanercept (Enbrel®)*</td>
<td>SC</td>
<td>50 mg twice weekly for 3 mo, then 50 mg weekly</td>
<td>++++</td>
<td>Anti-TNF</td>
</tr>
<tr>
<td>Adalimumab (Humira®)*</td>
<td>SC</td>
<td>80 mg x 1, then 40 mg at wk 1 and every 2 wk thereafter</td>
<td>++++</td>
<td>Anti-TNF</td>
</tr>
<tr>
<td>Infliximab (Remicade®)*</td>
<td>IV</td>
<td>5 mg/kg at wk 0, 2, 6 and every 8 wk thereafter</td>
<td>++++</td>
<td>Anti-TNF</td>
</tr>
<tr>
<td>Ustekinumab (Stelara®)</td>
<td>SC</td>
<td>45 mg or 90 mg at wk 0, 4 and every 12 wk thereafter</td>
<td>++++</td>
<td>Anti-IL 12/23</td>
</tr>
<tr>
<td>Secukinumab (Cosentyx®)</td>
<td>SC</td>
<td>300 mg at week 0, 1, 2, 3, 4 and every 4 wk thereafter</td>
<td>++++</td>
<td>Anti-IL 17A</td>
</tr>
</tbody>
</table>

*Can also be used to treat psoriatic arthritis

• biologics under study for treatment of psoriasis: secukinumab, brodalumab, ixekizumab, tildrakizumab, guselkumab
2. GUTTATE PSORIASIS (“DROP-LIKE”)

Clinical Presentation
- discrete, scattered salmon-pink small scaling papules
- sites: diffuse, usually on trunk and legs, sparing palms and soles
- often antecedent streptococcal pharyngitis

Management
- UVB phototherapy, sunlight, lubricants
- penicillin V or erythromycin if Group A β-hemolytic Streptococcus on throat culture

3. ERYTHRODERMIC PSORIASIS

Clinical Presentation
- generalized erythema (> 90% of body surface area) with fine desquamative scale on surface
- associated signs and symptoms: arthralgia, pruritus, dehydration, electrolyte imbalance
- aggravating factors: lithium, β-blockers, NSAIDs, antimalarials, phototoxic reaction, infection

Management
- IV fluids, monitor fluids and electrolytes, may require hospitalization
- treat underlying aggravating condition, sun avoidance
- cyclosporine, acitretin, UV, biologics

4. PUSTULAR PSORIASIS

Clinical Presentation
- sudden onset of erythematous macules and papules which evolve rapidly into pustules, can be painful
- may be generalized or localized to palms/soles
- patient usually has a history of psoriasis; may occur with sudden withdrawal from steroid therapy

Management
- methotrexate, cyclosporine, acitretin, biologics

5. INVERSE PSORIASIS

Clinical Presentation
- erythematous plaques on flexural surfaces such as axillae, inframammary folds, gluteal fold, inguinal folds
- lesions may be macerated

Management
- low potency topical corticosteroids
- topical vitamin D derivatives such as calcipotriene or calcitriol
- topical calcineurin inhibitors such as tacrolimus or pimecrolimus

6. PSORIATIC ARTHRITIS
- 5-30% of patients with psoriasis can also be suffering from psoriatic arthritis
- psoriatic patients with nail or scalp involvement are at a higher risk for developing psoriatic arthritis
- see Rheumatology, RH23

Vesiculobullous Diseases

Bullous Pemphigoid

Clinical Presentation
- chronic autoimmune bullous eruption characterized by pruritus, pruritic, tense, subepidermal bullae on an erythematous or normal skin base
- can present as urticarial plaques without bullae
- common sites: flexor aspect of forearms, axillae, medial thighs, groin, abdomen, mouth in 33%

Pathophysiology
- IgG produced against dermal-epidermal basement membrane proteins (hemidesmosomes) leads to subepidermal bullae

Epidemiology
- mean age of onset: 60-80 yr old, F=M
Investigations
• immunofluorescence shows linear deposition of IgG and C3 along the basement membrane
• anti-basement membrane antibody (IgG) (pemphigoid antibody detectable in serum)

Prognosis
• heals without scarring, usually chronic
• rarely fatal

Management
• prednisone 0.5-1 mg/kg/day until clear, then taper ± steroid-sparing agents (e.g. azathioprine, methotrexate)
• topical potent steroids (clobetasol) may be as effective as systemic steroids in limited disease
• tetracycline ± nicotinamide is effective for some cases
• immunosuppressants such as azathioprine, mycophenolate mofetil, cyclosporine
• IV Ig and plasmapheresis for refractory cases

**Pemphigus Vulgaris**

Clinical Presentation
• autoimmune blistering disease characterized by flaccid, non-pruritic intraepidermal bullae/vesicles on an erythematous or normal skin base
• may present with erosions and secondary bacterial infection
• sites: mouth (90%), scalp, face, chest, axillae, groin, umbilicus
• Nikolsky’s sign: epidermal detachment with shear stress
• Asboe-Hansen sign: pressure applied to bulla causes it to extend laterally

Pathophysiology
• IgG against epidermal desmoglein-1 and -3 lead to loss of intercellular adhesion in the epidermis

Epidemiology
• 40-60 yr old, M=F, higher prevalence in Jewish, Mediterranean, Asian populations
• paraneoplastic pemphigus may be associated with thymoma, myasthenia gravis, malignancy, and use of D-penicillamine

Investigations
• immunofluorescence: shows IgG and C3 deposition intraepidermally
• circulating serum anti-desmoglein IgG antibodies

Prognosis
• lesions heal with hyperpigmentation but do not scar
• may be fatal unless treated with immunosuppressive agents

Management
• prednisone 1-2 mg/kg until no new blisters, then 1-1.5 mg/kg until clear, then taper ± steroid-sparing agents (e.g. azathioprine, methotrexate, gold, cyclophosphamide, cyclosporine, IV Ig, mycophenolate mofetil, rituximab)

**Dermatitis Herpetiformis**

Clinical Presentation
• grouped papules/vesicles/urticarial wheals on an erythematous base, associated with intense pruritus, burning, stinging, excoriations
• lesions grouped, bilaterally symmetrical
• common sites: extensor surfaces of elbows/knees, sacrum, buttocks, scalp

Pathophysiology
• transglutaminase IgA deposits in the skin alone or in immune complexes leading to eosinophil and neutrophil infiltration
• 90% have HLA B8, DR3, DQWZ
• 90-100% associated with an often subclinical gluten-sensitive enteropathy (i.e. celiac disease)
• 30% have thyroid disease; increased risk of intestinal lymphoma in untreated comorbid celiac disease; iron/folate deficiency is common

Epidemiology
• 20-60 yr old, M:F = 2:1

Investigations
• biopsy
• immunofluorescence shows IgA deposits in perilesional skin
Management
• dapsone (sulfapyridine if contraindicated or poorly tolerated)
• gluten-free diet for life – this can reduce risk of lymphoma

Porphyria Cutanea Tarda

Clinical Presentation
• skin fragility followed by formation of tense vesicles/bullae and erosions on photoexposed skin
• gradual healing to scars, milia
• periorbital violaceous discoloration, diffuse hypermelanosis, facial hypertrichosis
• common sites: light-exposed areas subjected to trauma, dorsum of hands and feet, nose, and upper trunk

Pathophysiology
• uroporphyrinogen decarboxylase deficiency leads to excess heme precursors
• can be associated with hemochromatosis, alcohol abuse, DM, drugs (estrogen therapy, NSAIDs), HIV, hepatitis C, increased iron indices

Epidemiology
• 30–40 yr old, M>F

Investigations
• urine + 5% HCl shows orange-red fluorescence under Wood’s lamp (UV rays)
• 24 h urine for uroporphyrins (elevated)
• stool contains elevated coproporphyrins
• immunofluorescence shows IgE at dermal-epidermal junctions

Management
• discontinue aggravating substances (alcohol, estrogen therapy)
• phlebotomy to decrease body iron load
• low dose hydroxychloroquine

Drug Eruptions

Exanthematous

Exanthematous Drug Reaction

Clinical Presentation
• morphology: erythematous macules and papules ± scale
• spread: symmetrical, trunk to extremities
• time course: 7-14 d after drug initiation, fades 7-14 d after withdrawal

Epidemiology
• most common cutaneous drug reaction; increased in presence of infections
• common causative agents: penicillin, sulfonamides, phenytoin

Management
• weigh risks and benefits of drug discontinuation
• antihistamines, emollients, topical steroids

Drug Induced Hypersensitivity Syndrome (DIHS) / Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

Clinical Presentation
• morphology: morbilliform rash involving face, trunk, arms; can have facial edema
• systemic features: fever, malaise, cervical lymphadenopathy, internal organ involvement (e.g. hepatitis, arthralgia, nephritis, pneumonitis, lymphadenopathy, hematologic abnormalities, thyroid abnormalities)
• spread: starts with face or periorbitally and spreads caudally, no mucosal involvement
• time course: onset 1-6 weeks after first exposure to drug, persists weeks after withdrawal of drug

Epidemiology
• rare: incidence varies considerably depending on drug
• common causative agents: anticonvulsants (e.g. phenytoin, phenobarbital, carbamazepine, lamotrigine), sulfonamides, and allopurinol
• 10% mortality if severe, undiagnosed, and untreated

Management
• discontinue offending drug ± prednisone 0.5mg/kg per day, consider cyclosporine in severe cases
• may progress to generalized exfoliative dermatitis/erythroderma if drug is not discontinued
Urticarial

DRUG INDUCED URTICARIA AND ANGIOEDEMA

Clinical Presentation
- morphology: wheals lasting <24hrs, angioedema (face and mucous membranes)
- systemic features: may be associated with systemic anaphylaxis (bronchospasm, laryngeal edema, shock)
- time course: hours to days after exposure depending on the mechanism

Epidemiology
- second most common cutaneous drug reaction
- common causative agents: penicillins, ACEI, analgesics/anti-inflammatories, radiographic contrast media

Management
- discontinue offending drug, antihistamines, steroids, epinephrine if anaphylactic

SERUM SICKNESS-LIKE REACTION

Clinical Presentation
- morphology: symmetrical cutaneous eruption (usually urticarial)
- systemic features: malaise, low grade fever, arthralgia, lymphadenopathy
- time course: appears 1-3 wks after drug initiation, resolve 2-3 wks after withdrawal

Epidemiology
- more prevalent in kids 0.02-0.2%
- common causative agents: cefaclor in kids; bupropion in adults

Management
- discontinue offending drug ± topical/oral corticosteroids

Pustular

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS (AGEP)

Clinical Presentation
- morphology: erythematous edema and sterile pustules prominent in intertriginous areas
- systemic features: high fever, leukocytosis with neutrophilia
- spread: starts in face and intertriginous areas and spread to trunk and extremities
- time course: appears 1 wk after drug initiation, resolve 2 wks after withdrawal

Epidemiology
- rare: 1-5/million
- common causative agents: aminopenicillins, cephalosporins, clindamycin, calcium channel blockers

Management
- discontinue offending drug and systemic corticosteroids

Bullous

STEVEN-JOHNSON SYNDROME (SJS)/TOXIC EPIDERMAL NECROLYSIS (TEN)

Clinical Presentation
- morphology: prodromal rash (morbilliform/targetoid lesions ± purpura, or diffuse erythema), confluent of flaccid blisters, positive Nikolsky sign (epidermal detachment with shear stress), full thickness epidermal loss; dusky tender skin, bullae, desquamation/skin sloughing, atypical targets
- classification: BSA with epidermal detachment: <10% in SJS, 10-30% in SJS/TEN overlap, and >30% in TEN
- spread: face and extremities; may generalize; scalp, palms, soles relatively spared; erosion of mucous membranes (lips, oral mucosa, conjunctiva, GU mucosa)
- systemic features: fever (higher in TEN), cytopenias, renal tubular necrosis/AKI, tracheal erosion, infection, contractures, corneal scarring, phimosis, vaginal synechiae
- time course: appears 1-3 wk after drug initiation; progression <4 d; epidermal regrowth in 3 wk
- can have constitutional symptoms: malaise, fever, hypotension, tachycardia

Epidemiology
- SJS: 1.2-6/million; TEN: 0.4-1.2/million
- risk factors: SLE, HIV/AIDS, HLA-B1502 (associated with carbamazepine), HLA-B5801 (associated with allopurinol)
- common causative agents: drugs (allopurinol, anti-epileptics, sulfonamides, NSAIDs, cephalosporins) responsible in 50% of SJS and 80% of TEN; viral or mycoplasma infections;
- prognosis: 5% mortality in SJS, 30% in TEN due to fluid loss and infection
Differential Diagnosis
• Scarlet fever, phototoxic eruption, GVHD, SSSS, exfoliative dermatitis, AGEP, paraneoplastic pemphigus

Management
• discontinue offending drug
• admit to intermediate/intensive care/burn unit
• supportive care: IV fluids, electrolyte replacement, nutritional support, pain control, wound care, sterile handling, monitor for and treat infection
• IVIg or cyclosporine

Other

FIXED DRUG ERUPTION

Clinical Presentation
• morphology: sharply demarcated erythematous oval patches on the skin or mucous membranes
• spread: commonly face, mucosa, genitalia, acral; recurs in same location upon subsequent exposure to the drug (fixed location)

Epidemiology
• common causative agents: antimicrobials (tetracycline, sulfonamides), anti-inflammatories, psychoactive agents (barbiturates), phenolphthalein

Management
• discontinue offending drug ± prednisone 1mg/kg/d x 2 wk for generalized lesions ± potent topical corticosteroids for non-eroded lesions or antimicrobial ointment for eroded lesions

PHOTOSENSITIVITY REACTION

Clinical Presentation
• phototoxic reaction: “exaggerated sunburn” (erythema, edema, vesicles, bullae) confined to sun-exposed areas
• photoallergic reaction: pruritic eczematous eruption with papules, vesicles, scaling, and crusting that may spread to areas not exposed to light

Pathophysiology
• phototoxic reaction: direct tissue injury
• photoallergic reaction: type IV delayed hypersensitivity

Epidemiology
• common causative agents: chlorpromazine, doxycycline, thiazide diuretics, procainamide

Management
• sun protection ± topical/oral corticosteroids

Heritable Disorders

Ichthyosis Vulgaris

Clinical Presentation
• xerosis with fine scaling as well as large adherent scales (“fish-scales”)
• affects arms, legs, palms, soles, back, forehead, and cheeks; spares flexural creases
• improves in summer, with humidity, and as the child grows into adulthood

Pathophysiology
• genetic deficiency in filaggrin protein leads to abnormal retention of keratinocytes (hyperkeratosis)
• scaling without inflammation

Epidemiology
• 1:300 incidence
• autosomal dominant inheritance
• associated with AD and keratosis pilaris

Investigations
• electron microscopy: keratohyalin granules

Management
• immersion in bath and oils followed by an emollient cream, humectant cream, or creams/oil containing urea or α- or β-hydroxy acids
• intermittent systemic retinoids for severe cases
Neurofibromatosis (Type I; von Recklinghausen’s Disease)

Clinical Presentation
- diagnostic criteria includes 2 or more of the following
  1. more than 5 café-au-lait patches >1.5 cm in an adult or more than 5 café-au-lait macules >0.5 cm in a child under 5 yr
  2. axillary or inguinal freckling
  3. iris hamartomas (Lisch nodules)
  4. optic gliomas
  5. neurofibromas
  6. distinctive bony lesion (sphenoid wing dysplasia or thinning of long bone cortex)
  7. first degree relative with neurofibromatosis type 1
- associated with pheochromocytoma, astrocytoma, bilateral acoustic neuromas, bone cysts, scoliosis, precocious puberty, developmental delay, and renal artery stenosis
- skin lesions less prominent in neurofibromatosis Type II (see Pediatrics, P84)

Pathophysiology
- autosomal dominant disorder with excessive and abnormal proliferation of neural crest elements (Schwann cells, melanocytes), high incidence of spontaneous mutation
- linked to absence of neurofibromin (a tumour suppressor gene)

Epidemiology
- incidence 1:3,000

Investigations
- Wood’s lamp examination to detect café-au-lait macules in patients with pale skin

Management
- refer to orthopedics, ophthalmology, plastics, and psychology for relevant management
- follow-up annually for brain tumours such as astrocytoma
- excise suspicious or painful lesions
- see Pediatrics, P84

Vitiligo

Clinical Presentation
- primary pigmentary disorder characterized by depigmentation
- acquired destruction of melanocytes characterized by sharply margined white patches
- associated with streaks of depigmented hair, chorioretinitis
- sites: extensor surfaces and periorificial areas (mouth, eyes, anus, genitalia)
- Koebner phenomenon, may be precipitated by trauma

Pathophysiology
- acquired autoimmune destruction of melanocytes

Epidemiology
- 1% incidence, polygenic
- 30% with positive family history

Investigations
- rule out associated autoimmune diseases: thyroid disease, pernicious anemia, Addison’s disease, Type I DM
- Wood’s lamp to detect lesions: illuminates UV light onto skin to detect amelanosis (porcelain white discoulouration)

Management
- sun avoidance and protection
- topical calcineurin inhibitor (e.g. tacrolimus, pimecrolimus) or topical corticosteroids
- PUVA or Narrow band UVB
- make-up
- “bleaching” normal pigmented areas (i.e. monobenzyl ether of hydroquinone 20%) if widespread loss of pigmentation

Interventions for Vitiligo
Study: Systematic review of 96 randomized controlled trials with 4,512 participants with vitiligo.
Intervention: Topical treatments, light therapies, oral treatments, surgical methods.
Outcome Measures: Quality of life, >75% repigmentation, adverse effects
Results: Some evidence of therapies for vitiligo but further research required due to differences in design and outcome measures. Evidence exists to support use of combination therapies to be more effective than single agent. Narrowband UVB light, alone or in combination, show better results. Use of topical corticosteroids reported most adverse effects.
Infections

Bacterial Infections

EPIDERMIS

IMPETIGO

Clinical Presentation
- acute purulent infection which appears vesicular; progresses to golden yellow “honey-crusted” lesions surrounded by erythema
- can present with bullae
- common sites: face, arms, legs, and buttocks

Etiology
- GAS, S.aureus, or both

Epidemiology
- preschool and young adults living in crowded conditions, poor hygiene, neglected minor trauma

Differential Diagnosis
- infected eczema, HSV, VZV

Investigations
- Gram stain and culture of lesion fluid or biopsy

Management
- remove crusts, use saline compresses, and topical antiseptic soaks bid
- topical antibacterials such as 2% mupirocin or fusidic acid (Canada only) tid; continue for 7-10 d after resolution
- systemic antibiotics such as cloxacillin or cephalaxin for 7-10 d

Location Matters!
- e.g. Group A Strep Infections
  - Impetigo → just below stratum corneum
  - Erysipelas → epidermis and upper dermis only
  - Cellulitis → primarily lower dermis and subcutis (primarily not raised, and demarcation less distinct than erysipelas)
  - Necrotizing fasciitis → deep fascia and muscle


**DERMIS**

### Table 16. Comparison of Erysipelas and Cellulitis

<table>
<thead>
<tr>
<th>Clinical Presentation</th>
<th>Etiology</th>
<th>Complications</th>
<th>Differential Diagnosis</th>
<th>Investigations</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erysipelas</td>
<td></td>
<td>Scarlet fever, streptococcal gangrene, fat necrosis, coagulopathy</td>
<td>DVT (less red, less hot, smoother), superficial phlebitis, contact dermatitis, photosensitivity reaction, stasis dermatitis, panniculitis, vasculitis</td>
<td>Clinical diagnosis: rarely do skin/blood culture If suspect necrotizing fasciitis: do immediate biopsy and frozen section, histopathology</td>
<td>1st line: penicillin, cloxacillin or cefazolin 2nd line: clindamycin or cephalaxin If allergic to penicillin, use erythromycin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spreads via lymphatics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cellulitis</td>
<td></td>
<td>GAS, S. aureus (large sized wounds), H. influenzae (periorbital), Pasteurella multocida (dog/cat bite)</td>
<td>Uncommon Same as erysipelas</td>
<td>Same as erysipelas</td>
<td>1st line: cloxacillin or cefazolin/cephalexin 2nd line: erythromycin or clindamycin Children: cefuroxime If DM (foot infections): TMP/SMX and metronidazole</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### COMMON HAIR FOLLICLE INFECTIONS

### Table 17. Comparison of Superficial Folliculitis, Furuncles, and Carbuncles

<table>
<thead>
<tr>
<th>Clinical Presentation</th>
<th>Etiology</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Superficial Folliculitis</td>
<td>Normal non-pathogenic bacteria (Staphylococcus – most common; Pseudomonas – hot tub)</td>
<td>Antiseptic (Hibiclens™) Topical antibacterial ( fusidic acid, mupirocin, erythromycin or clindamycin) Oral cloxacillin for 7-10 d</td>
</tr>
<tr>
<td>Furuncles (Boils)</td>
<td>S. aureus</td>
<td>Incise and drain large furuncles to relieve pressure and pain If afebrile: hot wet packs, topical antibiotic If febrile: hot wet packs, aspirate pustules (Gram stain and CSF) Cloxacillin for 1-2 wk (especially for lesions near external auditory canal/nose, with surrounding cellulitis, and not responsive to topical therapy)</td>
</tr>
<tr>
<td>Carbuncles</td>
<td>S. aureus</td>
<td>Same as for furuncles</td>
</tr>
</tbody>
</table>

### Dermatophytoeses

**Clinical Presentation**
- infection of skin, hair, and nails caused by dermatophytes (fungi that live within the epidermal keratin or hair follicle and do not penetrate into deeper structures)

**Pathophysiology**
- digestion of keratin by dermatophytes results in scaly skin, broken hairs, crumbling nails/onycholysis

**Etiology**
- **Trichophyton**, **Microsporum**, **Epidermophyton** species (*Pityrosporum* is a superficial yeast and not a dermatophyte)

**Investigations**
- skin scrapings, hair, and/or nail clippings analyzed with potassium hydroxide (KOH) prep to look for hyphae and mycelia

**Management**
- topicals as first line agents for tinea corporis/cruris and tinea pedis (interdigital type): clotrimazole, or terbinafine or ciclopirox olamine cream applied bid
- oral therapy is indicated for onychomycosis or tinea capitis: terbinafine (Lamisil™ – liver toxicity, CYP2D6 inhibitor) or itraconazole (Sporanox™ – CYP3A4 inhibitor, liver toxicity)
### Table 18. Different Manifestations of Dermatophyte Infection

<table>
<thead>
<tr>
<th>Clinical Presentation</th>
<th>Differential Diagnosis</th>
<th>Investigations</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tinea Capitis</strong></td>
<td>Round, scaly patches of alopecia, possibly with broken off hairs; pruritic Sites: scalp, eyelashes, and eyebrows; involving hair shafts and follicles Kerion (boggy, elevated, purulent inflamed nodule/plaque) may form secondary to infection by bacteria and result in scarring May have occipital lymphadenopathy Affects children (mainly black), immunocompromised adults Very contagious and may be transmitted from barber, hats, theatre seats, pets</td>
<td>Alopecia areata, psoriasis, seborheic dermatitis, trichotillomania</td>
<td>Wood’s light examination of hair: green fluorescence only for Microsporum infection Culture of scales/hair shaft Microscopic examination of KOH preparation of scales or hair shafts</td>
</tr>
<tr>
<td><strong>Tinea Corporis</strong> (Ringworm)</td>
<td>Pruritic, scaly, round/oval plaque with active erythematous margin, and central clearing Site: trunk, limbs, face</td>
<td>Granuloma annulare, pityriasis rosea, psoriasis, seborheic dermatitis</td>
<td>Microscopic examinations of KOH prep of scales shows hyphae Culture of scales</td>
</tr>
<tr>
<td><strong>Tinea Cruris</strong> (“Jock Itch”)</td>
<td>Scaly patch/plaque with a well-defined, curved border and central clearing Pruritic, erythematous, dry/macerated Site: medial thigh</td>
<td>Candidiasis (involvement of scrotum and satellite lesions), contact dermatitis, erythrasma</td>
<td>Same as for tinea corporis Same as for tinea corporis</td>
</tr>
<tr>
<td><strong>Tinea Pedis</strong> (Athlete’s Foot)</td>
<td>Pruritic scaling and/or maceration of the web spaces, and powdery scaling of soles Acute infection: interdigital (esp. 4th web space) red/white scales, vesicles, bullae, often with maceration Secondary bacterial infection may occur Chronic: non-pruritic, pink, scaling keratosis on soles and sides of feet May present as flare-up of chronic tinea pedis Predisposing factors: heat, humidity, occlusive footwear</td>
<td>AD, contact dermatitis, dyshidrotic dermatitis, erythrasma, intertrigo, inverse psoriasis</td>
<td>Same as for tinea corporis Same as for tinea corporis</td>
</tr>
<tr>
<td><strong>Tinea Manuum</strong></td>
<td>Primary fungal infection of the hand is rare; usually associated with tinea pedis Acute: blisters at edge of red areas on hands Chronic: single dry scaly patch</td>
<td>AD, contact dermatitis, granuloma annulare, psoriasis</td>
<td>Same as for tinea corporis Same as for tinea corporis</td>
</tr>
<tr>
<td><strong>Tinea Unguim</strong> (Onychomycosis)</td>
<td>Crumbling, distally dystrophic nails; yellowish, opaque with subungal hyperkeratotic debris Toenail infections usually precede fingernail infections T. rubrum (90% of all toenail infections)</td>
<td>Psoriasis, lichen planus, contact dermatitis, traumatic onychodystrophies, bacterial infections</td>
<td>Microscopic examinations of KOH prep of scales from subungal scraping shows hyphae Culture of subungal scraping or nail clippings on Sabouraud’s agar PAS stain of nail clippings by pathology</td>
</tr>
</tbody>
</table>

## Parasitic Infections

### SCABIES

**Clinical Presentation**
- characterized by superficial burrows, intense pruritus (especially nocturnal), and secondary infection
- primary lesion: superficial linear burrows; inflammatory papules and nodules in the axilla and groin
- secondary lesion: small urticarial crustred papules, eczematous plaques, excoriations
- common sites: axillae, groin, buttocks, hands/feet (especially web spaces), sparing of head and neck (except in infants)

**Pathophysiology**
- scabies mite remains alive 2-3 d on clothing/sheets
- incubation of 1 mo, then pruritus begins
- re-infection followed by hypersensitivity in 24 h

**Etiology**
- Sarcoptes scabiei (a mite)
- risk factors: sexual promiscuity, crowding, poverty, nosocomial, immunocompromised
Differential Diagnosis
• atopic eczema, dermatitis herpetiformis, lichen simplex chronicus (neurodermatitis)

Investigations
• microscopic examination of root and content of burrow and mineral oil mount for mite, eggs, feces
• skin biopsy may sometimes show scabies mite

Management
• bathe, then apply permethrin 5% cream (i.e. Nix®) from neck down to soles of feet (must be left on for 8-14 h and requires second treatment 7 d after first treatment)
• change underwear and linens; wash twice with detergent in hot water cycle then machine dry
• treat family and close contacts
• pruritus may persist for 2-3 wk after effective treatment due to prolonged hypersensitivity reaction
• mid potency topical steroids and antihistamines for symptom management

LICE (PEDICULOSIS)

Clinical Presentation
• intensely pruritic, red excoriations, morbilliform rash, caused by louse (a parasite)
• scalp lice: nits (i.e. louse eggs) on hairs; red, excoriated skin with secondary bacterial infection, lymphadenopathy
• pubic lice: nits on hairs; excoriations
• body lice: nits and lice in seams of clothing; excoriations and secondary infection mainly on shoulders, belt-line and buttocks

Etiology
• Phthirus pubis (pubic), Pediculus humanus capitis (scalp), Pediculus humanus humanus (body): attaches to body hair and feeds
• can transmit infectious agents such as Bartonella quintana and Rickettsia prowazekii

Differential Diagnosis
• bacterial infection of scalp, seborrheic dermatitis

Diagnosis
• lice visible on inspection of affected area or clothing seams

Management
• permethrin 1% (Nix® cream rinse) (ovicidal) or permethrin 1% (RC & Cor®, Kwellada-P® shampoo)
• comb hair with fine-toothed comb using dilute vinegar solution to remove nits
• repeat in 7 d after first treatment
• shave hair if feasible, change clothing and linens; wash with detergent in hot water cycle then machine dry

BED BUGS (HEMIPTERA)

Clinical Presentation
• burning wheals, turning to firm papules, often in groups of three – “breakfast, lunch and dinner” – in areas with easy access (face, neck, arms, legs, hands)

Etiology
• caused by Cimex lectularius, a small insect that feeds mainly at night (hide in crevices in walls and furniture during the day)

Differential Diagnosis
• dermatitis herpetiformis, drug eruptions, ecthyma, other insect bites, scabies

Investigations
• none required, but lesional biopsy can confirm insect bite reaction

Management
• professional fumigation
• topical steroids and oral H1-antagonists for symptomatic relief
• definitive treatment is removal of clutter in home and application of insecticides to walls and furniture
**Viral Infections**

**HERPES SIMPLEX**

**Clinical Presentation**
- herpetiform (i.e. grouped) vesicles on an erythematous base on skin or mucous membranes
- transmitted via contact with erupted vesicles or via asymptomatic viral shedding
- **primary**
  - children and young adults
  - usually asymptomatic; may have high fever, regional lymphadenopathy, malaise
  - followed by antibody formation and latency of virus in dorsal nerve root ganglion
- **secondary**
  - recurrent form seen in adults; much more common than primary
  - prodrome: tingling, pruritus, pain
  - triggers for recurrence: fever, excess sun exposure, physical trauma, menstruation, emotional stress, URTI
- **complications:** dendritic corneal ulcer, EM, herpes simplex encephalitis (infants at risk), HSV infection on AD causing Kaposi’s varicelliform eruption (eczema herpeticum)

**Etiology**
- HSV-1: typically “cold sores” (grouped vesicles at the mucocutaneous junction which quickly burst)
- HSV-2: recurrent on face, lips and hard palate, but NOT on soft, non-keratinized mucous membranes (unlike aphthous ulcers)

**Clinical Presentation**
- HSV-2: usually sexually transmitted; incubation 2-20 d
- gingivostomatitis: entire buccal mucosa involved with erythema and edema of gingiva
- vulvovaginitis: edematous, erythematous, extremely tender, profuse vaginal discharge
- urethritis: watery discharge in males
- recurrent on vulva, vagina, penis for 5-7 d
- differential diagnosis of genital ulcers: *Candida balanitis*, chancroid, syphilitic chancres

**Investigations**
- Tzanck smear with Giemsa stain shows multinucleated giant epithelial cells
- viral culture, electron microscopy, and direct fluorescent antibody test of specimen taken from the base of a relatively new lesion
- serologic testing for antibody for current or past infection if necessary

**Management**
- **HSV-1**
  - treat during prodrome to prevent vesicle formation
  - topical antiviral (Zovirax®/Xerese®) cream, apply 5-6x/d x 4-7 d for facial/genital lesions
  - oral antivirals (e.g. acyclovir, famciclovir, valacyclovir) are far more effective and have an easier dosing schedule than topicals
- **HSV-2**
  - rupture vesicle with sterile needle if you wish to culture it
  - wet dressing with aluminum subacetate solution, Burow’s compression, or betadine solution
  - 1st episode: acyclovir 200 mg PO 5x/d x 10 d
    - maintenance: acyclovir 400 mg PO bid
  - famciclovir and valacyclovir may be substituted and have better enteric absorption and less frequent dosing
  - in case of herpes genitalis, look for and treat any other sexually-transmitted infections STIs
  - for active lesions in pregnancy, see Obstetrics, OB29

**HERPES ZOSTER (SHINGLES)**

**Clinical Presentation**
- unilateral dermalomal eruption occurring 3-5 d after pain and paresthesia of that dermatome
- vesicles, bullae, and pustules on an erythematous, edematous base
- lesions may become eroded/ulcerated and last days to weeks
- pain can be pre-herpetic, synchronous with rash, or post-herpetic
- severe post-herpetic neuralgia often occurs in elderly
- Hutchinson’s sign: shingles on the tip of the nose signified ocular involvement. Shingles in this area involves the nasociliary branch of the ophthalmic branch of the trigeminal nerve (V1)
- distribution: thoracic (50%), trigeminal (10-20%), cervical (10-20%); disseminated in HIV

**Etiology**
- caused by reactivation of VZV
- risk factors: immunosuppression, old age, occasionally associated with hematologic malignancy
Infections

**Differential Diagnosis**
- before thoracic skin lesions occur, must consider other causes of chest pain
- contact dermatitis, localized bacterial infection, zosteriform HSV (more pathogenic for the eyes than VZV)

**Investigations**
- none required, but can do Tzanck test, direct fluorescence antibody test, or viral culture to rule out HSV

**Management**
- compress with normal saline, Burow’s, or betadine solution
- analgesics (NSAIDs, amitriptyline)
- famciclovir, valacyclovir, or acyclovir for 7 d; must initiate within 72 h to be of benefit
- gabapentin 300-600 mg PO tid for post-herpetic neuralgia

**MOLLUSCUM CONTAGIOSUM**

**Clinical Presentation**
- discrete dome-shaped and umbilicated pearly, white papules caused by DNA Pox virus (Molluscum contagiosum virus)
- common sites: eyelids, beard (likely spread by shaving), neck, axillae, trunk, perineum, buttocks

**Etiology**
- virus is spread via direct contact, auto-inoculation, sexual contact
- common in children and sexually active young adults (giant molluscum and severe cases can be seen in the setting of HIV)
- virus is self-limited and can take 1-2 yr to resolve

**Investigations**
- none required, however can biopsy to confirm diagnosis

**Management**
- topical cantharidin (a vesicant)
- cryotherapy
- curettage
- topical retinoids
- Aldara* (imiquimod): immune modulator that produces a cytokine inflammation

**WARTS (VERRUCA VULGARIS) (HUMAN PAPILLOMAVIRUS INFECTIONS)**

<table>
<thead>
<tr>
<th>Definition and Clinical Features</th>
<th>Differential Diagnosis</th>
<th>Distribution</th>
<th>HPV Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verruca Vulgaris (Common Warts)</td>
<td>Hyperkeratotic, elevated discrete epithelial growths with papillated surface caused by HPV Paring of surface reveals punctate, red-brown specks (thrombosed capillaries)</td>
<td>Molluscum contagiosum, seborheic keratosis</td>
<td>Located at trauma sites: fingers, hands, knees of children and teens</td>
</tr>
<tr>
<td>Verruca Plantaris (Plantar Warts) and Verruca Palmaris (Palmar Warts)</td>
<td>Hyperkeratotic, shiny, sharply margined growths Paring of surface reveals red-brown specks (capillaries), interruption of epidermal ridges</td>
<td>May need to scrape (“pare”) lesions to differentiate wart from callus and corn</td>
<td>Located at pressure sites: metatarsal heads, heels, toes</td>
</tr>
<tr>
<td>Verruca Planae (Flat Warts)</td>
<td>Multiple discrete, skin coloured, flat topped papules grouped or in linear configuration Common in children</td>
<td>Syringoma, seborheic keratosis, molluscum contagiosum, lichen planus</td>
<td>Sites: face, dorsa of hands, shins, knees</td>
</tr>
<tr>
<td>Condyloma Acuminata (Genital Warts)</td>
<td>Skin-coloured pinhead papules to soft cauliflower like masses in clusters Often occurs in young adults, infants, children Can be asymptomatic, lasting months to years Highly contagious, transmitted sexually and non-sexually (e.g. Koebner phenomenon via scratching, shaving), and can spread without clinically apparent lesions Investigations: acetowhiteness (subclinical lesions seen with 5% acetic acid x 5 min and hand lens) Complications: fairy-ring warts (satellite warts at periphery of treated area of original warts)</td>
<td>Condyloma lata (secondary syphilitic lesion, dark field strongly +ve), molluscum contagiosum</td>
<td>Sites: genitalia and perianal areas</td>
</tr>
</tbody>
</table>
Treatment for Warts
• first line therapies
  ■ salicylic acid preparations (patches, solutions, creams, ointments), cryotherapy, topical cantharone
• second line therapies
  ■ topical imiquimod, topical 5-fluorouracil, topical tretinoin, podophyllotoxin
• third line therapies
  ■ curettage, cautery, surgery for non plantar warts, CO₂ laser, oral cimetidine (particularly children),
    intralesional bleomycin (plantar warts), trichloroacetic acid, diphenycprone
• other viruses associated with skin changes, such as measles, roseola, fifth disease, etc.
  • see Pediatrics, Pediatric Exanthems, P55

Yeast Infections

CANDIDIASIS

Etiology
• many species of Candida (70-80% of infections are from Candida albicans)
• opportunistic infection in those with predisposing factors (e.g. trauma, malnutrition, immunodeficiency)

Candidal Paronychia
• clinical presentation: painful red swellings of periungal skin
• management: topical agents not as effective; oral antifungals recommended

Candidal Intertrigo
• clinical presentation
  ■ macerated/eroded erythematous patches that may be covered with papules and pustules, located in
    intertriginous areas often under breast, groin, or interdigitally
  ■ peripheral “satellite” pustules
  ■ starts as non-infectious maceration from heat, moisture, and friction
• predisposing factors: obesity, DM, systemic antibiotics, immunosuppression, malignancy
• management: keep area dry, terbinafine, ciclopirox olamine, ketoconazole/clotrimazole cream bid until
  rash clears

PITYRIASIS (TINEA) VERSICOLOR

Clinical Presentation
• asymptomatic superficial fungal infection with brown/white scaling macules
• affected skin darker than surrounding skin in winter, lighter in summer (does not tan)
• common sites: upper chest and back

Pathophysiology
• microbe produces azelaic acid → inflammatory reaction inhibiting melanin synthesis yielding variable
  pigmentation
• affinity for sebaceous glands; require fatty acids to survive

Etiology
• Pityrosporum ovale (Malassezia furfur)
• also associated with folliculitis and seborrheic dermatitis
• predisposing factors: summer, tropical climates, excessive sweating, Cushing’s syndrome, prolonged
  corticosteroid use

Investigations
• clinical diagnosis but can perform microscopic examination, KOH prep of scales for hyphae and spores

Management
• ketoconazole shampoo or cream daily
• topical terbinafine or ciclopirox olamine bid
• systemic fluconazole or itraconazole for 7 d if extensive

Sexually Transmitted Infections

SYPHILIS

Clinical Presentation
• characterized initially by a painless ulcer (chancre)
• following inoculation, systemic infection with secondary and tertiary stages

Etiology
• Treponema pallidum
• transmitted sexually, congenitally, or rarely by transfusion
Table 20. Stages of Syphilis

<table>
<thead>
<tr>
<th>Clinical Presentation</th>
<th>Investigations</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Syphilis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single red, indurated, painless chancre, that develops into painless ulcer with raised border and scanty serous exudate</td>
<td>CANNOT be based on clinical presentation alone</td>
<td>Penicillin G, 2.4 million units IM, single dose</td>
</tr>
<tr>
<td>Chancre develops at site of inoculation after 3 wk of incubation and heals in 4-6 wk; chancre may also develop on lips or anus</td>
<td>VDRL negative – repeat weekly for 1 mo</td>
<td></td>
</tr>
<tr>
<td>Regional non-tender lymphadenopathy appears &lt;1 wk after onset of chancre</td>
<td>Fluorescent treponemal antibody-syphilis (FTA-ABS) test has greater sensitivity and may detect disease earlier in course</td>
<td></td>
</tr>
<tr>
<td>DDx: chancreoid (painful), HSV (multiple lesions)</td>
<td>Dark field examination – spirochete in chancre fluid or lymph node aspirate</td>
<td></td>
</tr>
<tr>
<td><strong>Secondary Syphilis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presents 2-6 mo after primary infection (patient may not recall presence of primary chancre)</td>
<td>VDRL positive</td>
<td>As for primary syphilis</td>
</tr>
<tr>
<td>Associated with generalized lymphadenopathy, splenomegaly, headache, chills, fever, arthralgias, myalgias, malaise, photophobia</td>
<td>FTA-ABS +ve – ve after 1 yr following appearance of chancre</td>
<td></td>
</tr>
<tr>
<td>Lesions heal in 1-5 wk and may recur for 1 yr</td>
<td>Dark field +ve in all secondary</td>
<td></td>
</tr>
<tr>
<td>3 types of lesions:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Macules and papules: flat top, scaling, non-pruritic, sharply defined, circular/annular rash (DDx: pityriasis rosea, tinea corporis, drug eruptions, lichen planus)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Condyloma lata: wart-like moist papules around genital/perianal region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Mucous patches: macerated patches mainly found in oral mucosa</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tertiary Syphilis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extremely rare</td>
<td>As in primary syphilis, VDRL can be falsely negative</td>
<td>Treatment: penicillin G, 2.4 million units IM weekly x 3 wk</td>
</tr>
<tr>
<td>3-7 yr after secondary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Main skin lesion: ‘Gumma’ – a granulomatous non-tender nodule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**GONOCOCCEMIA**

**Clinical Presentation**
- disseminated gonococcal infection
- hemorrhagic, tender, pustules on a purpuric/petechial background
- common sites: distal aspects of extremities
- associated with fever, arthritis, urethritis, proctitis, pharyngitis, and tenosynovitis
- neonatal conjunctivitis if infected via birth canal

**Etiology**
- *Neisseria gonorrhoeae*

**Investigations**
- requires high index of clinical suspicion plays because tests are often negative
- bacterial culture of blood, joint fluid, and skin lesions
- joint fluid cell count and Gram stain

**Management**
- notify Public Health authorities
- screen for other STIs
- cefixime 400 mg PO (drug of choice) or ceftriaxone 1 g IM

**HSV**
- see *Viral Infections*, D29

**HPV**
- see *Viral Infections*, D30

**Latent Syphilis**
- 70% of untreated patients will remain in this stage for the rest of their lives and are immune to new primary infection

**Natural History of Untreated Syphilis**
- Inoculation
- Primary syphilis (10-90 d after infection)
- Secondary syphilis (simultaneous to primary syphilis or up to 6 mo after healing of primary lesion)
- Latent syphilis
- Tertiary syphilis (2-20 yr)
Pre-Malignant Skin Conditions

Actinic Keratosis (Solar Keratosis)

Clinical Presentation
- ill-defined, scaly erythematous papules or plaques on a background of sun-damaged skin (solar heliosis)
- sandpaper-like, gritty sensation felt on palpation, often easier to appreciate on palpation rather than inspection
- sites: areas of sun exposure (face, ears, scalp if bald, neck, sun-exposed limbs)

Pathophysiology
- UV radiation damage to keratinocytes from repeated sun exposure (especially UVB)
- risk of transformation of AK to SCC (~1/1,000), but higher likelihood if AK is persistent
- UV-induced p53 gene mutation
- risk factors: increased age, light skin/eyes/hair, immunosuppression, syndromes such as albinism or xeroderma pigmentosum
- risk factors for malignancy: immunosuppression, history of skin cancer, persistence of the AK

Epidemiology
- common with increasing age, outdoor occupation, M>F
- skin phototypes I-III, rare in darker skin as melanin is protective

Differential Diagnosis
- SCC in situ, superficial BCC, seborrheic keratosis, cutaneous lupus erythematosus

Investigations
- biopsy lesions that are refractory to treatment

Management
- destructive: cryotherapy, electrodessication, and curettage
- topical pharmacotherapy (mechanism: destruction of rapidly growing cells or immune system modulation)
  - topical 5-Fluorouracil cream (for 2-4 wk), Imiquimod 5% (2 times per wk for 16 wk), Imiquimod 3.75% (daily for 2 wk then none for 2 wk then daily for 2 wk), Ingenol Mebutate gel 0.015% (daily for 3 d on the head and neck), Ingenol mebutate 0.05% gel (daily for 2 d on the body)
  - photodynamic therapy
  - excision

Leukoplakia

Clinical Presentation
- a morphologic term describing homogenous or speckled white plaques with sharply demarcated borders
- sites: oropharynx, most often floor of the mouth, soft palate, and ventral/lateral surfaces of the tongue

Pathophysiology
- precancerous or premalignant condition
- oral form is strongly associated with tobacco use and alcohol consumption

Epidemiology
- 1%-5% prevalence in adult population after 30 yr of age; peak at age 50
- M>F, fair-skinned
- most common oral mucosal premalignant lesion

Differential Diagnosis
- lichen planus, oral hairy leukoplakia

Investigations
- biopsy is mandatory because it is premalignant

Management
- low risk sites on buccal/labial mucosal or hard palate: eliminate carcinogenic habits, follow-up
- moderate/dysplastic lesions: excision, cryotherapy

Types of AK
- Erythematous: typical AK lesion
- Hypertrophic: thicker, rough papule/plaque
- Cutaneous horn: firm hyperkeratotic outgrowth
- Actinic cheilitis: confluent AKs on the lip
- Pigmented: flat, tan-brown, scaly plaque
- Spreading pigmented
- Proliferative
- Conjunctival: pinguecula, pterygium
Malignant Skin Tumours

Non-Melanoma Skin Cancers

BASAL CELL CARCINOMA

Subtypes
- noduloulcerative (typical)
  - skin-coloured papule/nodule with rolled, translucent ("pearly") telangiectatic border, and depressed/eroded/ulcered centre
- pigmented variant
  - flecks of pigment in translucent lesion with surface telangiectasia
- superficial variant
  - flat, tan to red-brown plaque, often with scaly, pearly border and fine telangiectasia at margin
- least aggressive subtype
- sclerosing (morpheiform) variant
  - flesh/yellowish-coloured, shiny papule/plaque with indistinct borders, indurated

Pathophysiology
- malignant proliferation of basal keratinocytes of the epidermis
  - low grade cutaneous malignancy, locally aggressive (primarily tangential growth), rarely metastatic
  - usually due to UVB light exposure, therefore >80% on face
  - may also occur in previous scars, radiation, trauma, arsenic exposure, or genetic predisposition (Gorlin syndrome)

Epidemiology
- most common malignancy in humans
- 75% of all malignant skin tumours >40 yr, increased prevalence in the elderly
- M>F, skin phototypes I and II, chronic sun exposure

Differential Diagnosis
- benign: sebaceous hyperplasia, intradermal melanocytic nevus, dermatofibroma
- malignant: nodular malignant melanoma, SCC

Management
- imiquimod 5% cream (Aldara*) or cryotherapy is indicated for superficial BCCs on the trunk
- fluorouracil and photodynamic therapy can also be used for superficial BCC
- shave excision + electrodessication and curettage for most types of BCCs, not including morpheiform
- Mohs surgery: microscopically controlled, minimally invasive, stepwise excision for lesions on the face or in areas that are difficult to reconstruct
- radiotherapy used in advanced cases of BCC where surgical intervention is not an option
- vismodegib is approved for metastatic BCC
- life-long follow up every 6 mo to 1 yr
- 95% cure rate if lesion <2 cm in diameter or if treated early

SQUAMOUS CELL CARCINOMA

Clinical Presentation
- indurated, pink/red/skin-coloured papule/plaque/nodule with surface scale/crust ± ulceration
- more rapid enlargement than BCC
- exophytic (grows outward), may present as a cutaneous horn
- sites: face, ears, scalp, forearms, dorsum of hands

Pathophysiology
- malignant neoplasm of keratinocytes (primarily vertical growth)
- predisposing factors include: UV radiation, PUVA, ionizing radiation therapy/exposure, chemical carcinogens (such as arsenic, tar, and nitrogen mustards), HPV 16, 18, immunosuppression
- may occur in previous scar (SCC more commonly than BCC)

Epidemiology
- second most common type of cutaneous neoplasm
- primarily on sun-exposed skin in the elderly, M>F, skin phototypes I and II, chronic sun exposure
- in organ transplant recipients SCC is most common cutaneous malignancy, with increased mortality as compared to non-immunocompromised population

Differential Diagnosis
- benign: nummular eczema, psoriasis, irritated seborrhoeic keratosis
- malignant: keratoacanthoma, Bowen's disease, BCC
Management
- surgical excision with primary closure, skin flaps or grafting
- Mohs surgery
- lifelong follow-up (more aggressive treatment than BCC)

Prognosis
- good prognostic factors: early treatment, negative margins, and small size of lesion
- SCCs that arise from AK metastasize less frequently (~1%) than other SCCs arising de novo in old burns (2-5% of cases)
- overall control is 75% over 5 yr, 5-10% metastasize
- metastasis rates are higher if diameter > 2 cm, depth > 4 mm, recurrent, involvement of bone/muscle/nerve, location on scalp/ears/nose/lips, immunosuppressed, caused by arsenic ingestion, or tumour arose from scar/chronic ulcer/burn/genital tract/sinus tract

BOWEN’S DISEASE (SQUAMOUS CELL CARCINOMA IN SITU)

Clinical Presentation
- sharply demarcated erythematous patch/thin plaque with scale and/or crusting
- often 1-3 cm in diameter and found on the skin and mucous membranes
- evolves to SCC in 10-20% of cutaneous lesions and >20% of mucosal lesions

Management
- same as for BCC
- biopsy required for diagnosis
- topical 5-fluorouracil (Efudex®) or imiquimod (Aldara®) used if extensive and as a tool to identify margins of poorly defined tumours
- cryosurgery
- shave excision with electrodesiccation and curettage

KERATOACANTHOMA

Clinical Presentation
- rapidly growing, firm, dome-shaped, erythematous or skin-coloured nodule with central keratin-filled crater, resembling an erupting volcano
- may spontaneously regress within a year, leaving a scar
- sites: sun-exposed skin

Pathophysiology
- epithelial neoplasm with atypical keratinocytes in epidermis
- low grade variant of SCC

Etiology
- HPV, UV radiation, chemical carcinogens (tar, mineral oil)

Epidemiology
- >50 yr, rare <20 yr

Differential Diagnosis
- treat as SCC until proven otherwise
- hypertrophic solar keratosis, verruca vulgaris

Management
- surgical excision or saucerization (shave biopsy) followed by electrodesiccation of the base, treated similarly to SCC

Malignant Melanoma

Clinical Presentation
- malignant characteristics of a mole: “ABCDE” mnemonic
- sites: skin, mucous membranes, eyes, CNS

Clinical Subtypes of Malignant Melanoma
- lentigo maligna
  - malignant melanoma in situ (normal and malignant melanocytes confined to the epidermis)
  - 2-6 cm, tan/brown/black uniformly flat macule or patch with irregular borders
  - lesion grows radially and produces complex colours
  - often seen in the elderly
  - 10% evolve to lentigo maligna melanoma

Does this Patient have a Mole or Melanoma?

**ABCDE checklist**

- Asymmetry
- Border (irregular and/or indistinct)
- Colour (varied)
- Diameter (increasing or >6 mm)
- Enlargement, elevation, evolution (i.e. change in colour, size, or shape)

Sensitivity 92% (CI 82-96%)
Specificity 100% (CI 94-100%)

JAMA 1998;279:696-701
• **lentigo maligna melanoma** (15% of all melanomas)
  - malignant melanocytes invading into the dermis
  - associated with pre-existing solar lentigo, not pre-existing nevi
  - flat, brown, stain-like, gradually enlarging with loss of skin surface markings
  - with time, colour changes from uniform brown to dark brown with black and blue
  - found on all skin surfaces, especially those often exposed to sun, such as the face and hands
• **superficial spreading melanoma** (60-70% of all melanomas)
  - atypical melanocytes initially spread laterally in epidermis then invade the dermis
  - irregular, indurated, enlarging plaques with red/white/blue discolouration, focal papules or nodules
  - ulcerate and bleed with growth
• **nodular melanoma** (30% of all melanomas)
  - atypical melanocytes that initially grow vertically with little lateral spread
  - uniformly ulcerated, blue-black, and sharply delineated plaque or nodule
  - rapidly fatal
  - may be pink or have no colour at all, this is called an amelanotic melanoma
  - "EFG" Elevated, FIRM, Growing
• **acrolentiginous melanoma** (5% of all melanomas)
  - ill-defined dark brown, blue-black macule
  - palmar, plantar, subungal skin
  - melanomas on mucous membranes have poor prognosis

**Pathophysiology**
• malignant neoplasm of pigment forming cells (melanocytes and nevus cells)

**Epidemiology**
• incidence 1/75 (Canada) 1/50 (US)
• risk factors: numerous moles, fair skin, red hair, positive personal/family history, 1 large congenital nevus (>20 cm), familial dysplastic nevus syndrome, any dysplastic nevi, immunosuppression, > 50 common nevi, and sun exposure with sunburns, tanning beds
• most common sites: back (M), calves (F)
• worse prognosis if: male, on scalp, hands, feet, late lesion, no pre-existing nevus present

**Differential Diagnosis**
• benign: nevi, solar lentigo, seborrheic keratosis
• malignant: pigmented BCC

**Management**
• excisional biopsy preferable, otherwise incisional biopsy
• remove full depth of dermis and extend beyond edges of lesion only after histologic diagnosis
• beware of lesions that regress – tumour is usually deeper than anticipated
• high dose IFN for stage II (regional), chemotherapy (cis-platinum, BCG) and high dose IFN for stage III (distant) disease
• newer chemotherapeutic, gene therapies, and vaccines starting to be used in metastatic melanoma
• radiotherapy may be used as adjunctive treatment

**Table 21. American Joint Committee on Cancer Staging System Based on Breslow’s Thickness of Invasion**

<table>
<thead>
<tr>
<th>Tumour Depth</th>
<th>Stage</th>
<th>Approximate 5 Yr Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1 &lt; 1.0 mm</td>
<td>Stage I T1a – T2a</td>
<td>5-yr survival 90%</td>
</tr>
<tr>
<td>T2 1.01-2.0 mm</td>
<td>Stage II T2b – T4b</td>
<td>5-yr survival 70%</td>
</tr>
<tr>
<td>T3 2.01-4.0 mm</td>
<td>Stage III any nodes</td>
<td>5-yr survival 45%</td>
</tr>
<tr>
<td>T4 &gt; 4.0 mm</td>
<td>Stage IV any mets</td>
<td>5-yr survival 10%</td>
</tr>
</tbody>
</table>

a = no ulceration; b = ulceration

**Other Cutaneous Cancers**

**CUTANEOUS T-CELL LYMPHOMA**

**Clinical Presentation**
• **Mycosis fungoides** (limited superficial type)
  - characterized by erythematous patches/plaques/nodules/tumours, which may be pruritic and poikilodermic (atrophy, telangiectasia, hyperpigmentation, hypopigmentation)
  - common sites include: trunk, buttocks, proximal limbs
  - mildly symptomatic, usually excellent prognosis for early disease
• **Sézary syndrome** (widespread systemic type)
  - rare variant characterized by erythroderma, lymphadenopathy, WBC >20 x 10^9/L with Sézary cells
  - associated with intense pruritus, alopecia, palmoplantar hyperkeratosis, and systemic symptoms (fatigue, fever)
  - often fatal
Pathophysiology
• clonal proliferation of skin-homing CD4 T-cells

Epidemiology
• >50 yr old, M:F 2:1

Differential Diagnosis
• tinea corporis, nummular dermatitis, psoriasis, DLE, Bowen's disease

Investigations
• skin biopsy (histology, "lymphocyte antigen cell" markers, TcR gene arrangement)
• blood smear looking for Sézary cells or flow cytometry (e.g. CD4:CD8 >10 is Sézary)
• imaging (for systemic involvement)

Management
• Mycosis fungoides
  ■ depends on stage of disease
  ■ topical steroids and/or PUVA, narrow band UVB (NBUVB, 311-313nm)
• Sézary syndrome
  ■ oral retinoids and IFN
  ■ extra-corporeal photopheresis
  ■ may need radiotherapy for total skin electron beam radiation
  ■ may maintain on UV therapy
  ■ other chemotherapy agents

Diseases of Hair Density

Hair Growth
• hair grows in a cyclic pattern that is defined in 3 stages (most scalp hairs are in anagen phase)
  1. growth stage = anagen phase
  2. transitional stage = catagen stage
  3. resting stage = telogen phase
• total duration of the growth stage reflects the type and location of hair: eyebrow, eyelash, and axillary hairs have a short growth stage in relation to the resting stage
• growth of the hair follicles is also based on the hormonal response to testosterone and DHT; this response is genetically controlled

Non-Scarring (Non-Cicatricial) Alopecia

ANDROGENETIC ALOPECIA

Clinical Presentation
• male- or female-pattern alopecia
• males: fronto-temporal areas progressing to vertex, entire scalp may be bald
• females: widening of central part, “Christmas tree” pattern

Pathophysiology
• action of testosterone on hair follicles

Epidemiology
• males: early 20s-30s
• females: 40s-50s

Management
• minoxidil (Rogaine®) solution or foam to reduce rate of loss/partial restoration
• females: spironolactone (anti-androgenic effects), cyproterone acetate (Diane-35®)
• males: finasteride (Propecia®) (5-α-reductase inhibitor) 1 mg/d
• hair transplant

PHYSICAL
• trichotillomania: impulse-control disorder characterized by compulsive hair pulling with irregular patches of hair loss, and with remaining hairs broken at varying lengths
• traumatic (e.g. tight “corn-row” braiding of hair, wearing tight pony tails, tight tying of turbans)
TELOGEN EFFLUVIUM

Clinical Presentation
- uniform decrease in hair density secondary to hairs leaving the growth (anagen) stage and entering the resting (telogen) stage of the cycle

Pathophysiology
- variety of precipitating factors
- hair loss typically occurs 2-4 mo after exposure to precipitant
- regrowth occurs within a few months but may not be complete

ANAGEN EFFLUVIUM

Clinical Presentation
- hair loss due to insult to hair follicle impairing its mitotic activity (growth stage)

Pathophysiology
- precipitated by chemotherapeutic agents (most common), other meds (bismuth, levodopa, colchicine, cyclosporine), exposure to chemicals (thallium, boron, arsenic)
- dose-dependent effect
- hair loss 7-14 d after single pulse of chemotherapy; most clinically apparent after 1-2 mo
- reversible effect; follicles resume normal mitotic activity few weeks after agent stopped

ALOPECIA AREATA

Clinical Presentation
- autoimmune disorder characterized by patches of complete hair loss often localized to scalp but can affect eyebrows, beard, eyelashes, etc.
- may be associated with dystrophic nail changes – fine stippling, pitting
- “exclamation mark” pattern (hairs fractured and have tapered shafts, i.e. looks like “!“)
- may be associated with pernicious anemia, vitiligo, thyroid disease, Addison’s disease
- spontaneous regrowth may occur within months of first attack (worse prognosis if young at age of onset and extensive loss)
- frequent recurrence often precipitated by emotional distress

Management
- generally unsatisfactory
- intralesional triamcinolone acetonide (corticosteroids) can be used for isolated patches
- UV or PUVA therapy
- immunomodulatory (diphencyprone)

Scarring (Cicatricial) Alopecia

Clinical Presentation
- irreversible loss of hair follicles with fibrosis

Etiology
- physical: radiation, burns
- infections: fungal, bacterial, TB, leprosy, viral (HZV)
- inflammatory
  - lichen planus (lichen planopilaris)
  - DLE (note that SLE can cause an alopecia unrelated to DLE lesions which are non-scarring)
  - morphea: “coup de sabre” with involvement of centre of scalp
  - central centrifugal cicatricial alopecia (CCCA); seen in up to 40% of black women, starting at central scalp; one of most commonly diagnosed scarring alopecias, may be associated with hair care practices in this population

Investigations
- biopsy from active border

Management
- infections: treat underlying infection
- inflammatory: topical/intralesional steroids, anti-inflammatory antibiotics, antimalarials

DDx of Scarring (Cicatricial) Alopecia

Developmental/Hereditary Disorders
- Aplasia cutis congenita
- Epidermal nevi
- Romberg’s syndrome
- Generalized follicular hamartoma

Primary Causes
- Group 1: Lymphocytic
  - DLE
  - Lichen planopilaris
  - Central centrifugal cicatricial alopecia
- Classic pseudopelade
- Group 2: Neutrophilic
  - Folliculitis decalvans
  - Dissecting scalp cellulitis
- Group 3: Mixed
  - Acne keloidalis nuchae

Secondary Causes
- Infectious agents
- Bacterial (e.g. post-cellulitis)
- Fungal (e.g. kerion tinea capitis)
- Neoplasms (e.g. BCC, SCC, lymphomas, and metastatic tumours)
- Physical agents
  - Mechanical trauma
  - Burns
  - Radiotherapy
  - Caustic chemicals
<table>
<thead>
<tr>
<th>Nail Abnormality</th>
<th>Definition/Etiology</th>
<th>Associated Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NAIL PLATE CHANGES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clubbing</td>
<td>Proximal nail plate has greater than 180° angle to nail fold, watch-glass nails, bulbous digits</td>
<td>Cyanotic heart disease, bacterial endocarditis, pulmonary disorders, GI disorders, etc.</td>
</tr>
<tr>
<td>Koilonychia</td>
<td>Spoon shaped nails</td>
<td>Iron deficiency, malnutrition, DM</td>
</tr>
<tr>
<td>Onycholysis</td>
<td>Separation of nail plate from nail bed</td>
<td>Psoriasis, dermatophytes, thyroid disease</td>
</tr>
<tr>
<td>Onychogryphosis</td>
<td>Hypertrophy of the nail plate producing a curved, clawlike deformity</td>
<td>Poor circulation, chronic inflammation, tinea</td>
</tr>
<tr>
<td>Onychohemia</td>
<td>Subungual hematoma</td>
<td>Trauma to nail bed</td>
</tr>
<tr>
<td>Onychomycosis</td>
<td>Fungal infection of nail (e.g. dermatophyte, yeast, mould)</td>
<td>HIV, DM, peripheral arterial disease</td>
</tr>
<tr>
<td>Onychocryptosis</td>
<td>Ingrown toenail often hallux with congenital malalignment, painful inflammation, granulation tissue</td>
<td>Tight fitting shoes, excessive nail clipping</td>
</tr>
<tr>
<td><strong>SURFACE CHANGES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V-shaped nicking</td>
<td>Distal margin has v-shaped loss of the nail plate</td>
<td>Darier’s disease (keratosis follicularis)</td>
</tr>
<tr>
<td>Pterygium inversus unguixum</td>
<td>Distal nail plate does not separate from underlying nail bed</td>
<td>Scleroderma</td>
</tr>
<tr>
<td>Pitting</td>
<td>Punctate depressions that migrate distally with growth</td>
<td>Psoriasis (random pattern), alopecia areata (geometric, gridshaped arrangement), eczema</td>
</tr>
<tr>
<td>Transverse ridging</td>
<td>Transverse depressions often more in central portion of nail plate</td>
<td>Serious acute illness slows nail growth (when present in all nails = Beau’s lines), eczema, chronic paronychia, trauma</td>
</tr>
<tr>
<td>Transverse white lines</td>
<td>Bands of white discolouration</td>
<td>Poisons, hypoalbuminemia (Muehrcke’s lines)</td>
</tr>
<tr>
<td><strong>COLOUR CHANGES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yellow</td>
<td></td>
<td>Tinea, jaundice, tetracycline, pityriasis rubra planis, yellow nail syndrome, psoriasis, tobacco use</td>
</tr>
<tr>
<td>Green</td>
<td></td>
<td>Pseudomonas</td>
</tr>
<tr>
<td>Black</td>
<td></td>
<td>Melanoma, hematoma</td>
</tr>
<tr>
<td>Brown</td>
<td></td>
<td>Nicotine use, psoriasis, poisons, longitudinal melanonychia (ethic)</td>
</tr>
<tr>
<td>Splinter hemorrhages</td>
<td>Extravasation of blood from longitudinal vessels of nail bed, blood attaches to overlying nail plate and moves distally as it grows</td>
<td>Trauma, bacterial endocarditis, blood dyscrasias, psoriasis</td>
</tr>
<tr>
<td>Oil spots</td>
<td>Brown-yellow discolouration</td>
<td>Psoriasis</td>
</tr>
<tr>
<td><strong>NAIL FOLD CHANGES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herpetic whitlow</td>
<td>HSV infection of distal phalanx</td>
<td>HSV infection</td>
</tr>
<tr>
<td>Paronychia</td>
<td>Local inflammation of the nail fold around the nail bed</td>
<td>Acute: painful infection, Chronic: constant wetting (e.g. dishwashing, thumbsucking)</td>
</tr>
<tr>
<td>Nail fold telangiectasias</td>
<td>Cuticular hemorrhages, roughness, capillary changes</td>
<td>Scleroderma, SLE, dermatomyositis</td>
</tr>
</tbody>
</table>
# Skin Manifestations of Systemic Disease

## Table 23. Skin Manifestations of Internal Conditions

<table>
<thead>
<tr>
<th>Disease</th>
<th>Related Dermatoses</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AUTOIMMUNE DISORDERS</strong></td>
<td></td>
</tr>
<tr>
<td>Behçet’s disease</td>
<td>Painful aphthous ulcers in oral cavity = genital mucous membranes, erythema nodosum, acniform papulovesicles</td>
</tr>
<tr>
<td>Buerger’s disease</td>
<td>Superficial migratory thrombophlebitis, pallor, cyanosis, gangrene, ulcerations, digital resorptions</td>
</tr>
<tr>
<td>Dermatomyositis</td>
<td>Periorbital and extensor violaceous erythema, heliotrope with edema, Gottron’s papules (violaceous flat-topped papules with atrophy), periungual erythema, telangiectasia, calcinosis cutis</td>
</tr>
<tr>
<td>Polycythemia nodosa</td>
<td>Subcutaneous nodules,stellate purpura, erythema, gangrene, splinter hemorrhages, livedo reticularis, ulceration</td>
</tr>
<tr>
<td>Reactive arthritis</td>
<td>Keratoderma blennorrhagica (on feet), balanitis cinerina (on male penis)</td>
</tr>
<tr>
<td>Rheumatic fever</td>
<td>Petechiae, urticaaria, erythema nodosum, rheumatic nodules, evanescent rash</td>
</tr>
<tr>
<td>Scleroderma</td>
<td>Raynaud’s, nonpitting edema, waxy/shiny/tense atrophic skin (morphea), ulcers, cutaneous calcification, periungual telangiectasia, acrocalcinosis, salt-and-pepper pigmentation</td>
</tr>
<tr>
<td>SLE</td>
<td>Malar erythema, discoid rash (erythematosus papules or plaques with keratotic scale, follicular plugging, atrophic scarring on face, hands, and arms), hemorrhagic bullae, palpable purpura, urticarial purpura, patchy/diffuse alopecia, mucosal ulcers, photosensitivity</td>
</tr>
<tr>
<td>Crohn’s disease/UC</td>
<td>Pyoderma gangrenosum, erythema nodosum, Sweet’s syndrome</td>
</tr>
<tr>
<td><strong>ENDOCRINE DISORDERS</strong></td>
<td></td>
</tr>
<tr>
<td>Addison’s disease</td>
<td>Generalized hyperpigmentation or limited to skin folds, buccal mucosa, and scars</td>
</tr>
<tr>
<td>Cushing’s syndrome</td>
<td>Moon facies, purple striae, acne, hyperpigmentation, hirsutism, atrophic skin with telangiectasia</td>
</tr>
<tr>
<td>DM</td>
<td>Infections (e.g. boils, carbuncles, Candidiasis, S. aureus, dermatophytoes, linea pedis and cruris, infectious eczematoid dermatitis), pruritus, eruptive xanthomas, necrobiosis lipoidica diabeticorum, granuloma annulare, diabetic foot, diabetic bullae, acanthosis nigricans, calciphylaxis</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>Moist, warm skin, seborrhea, acne, nail atrophy, hyperpigmentation, toxic alopecia, pretibial myxedema, acrochord, onycholysis</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>Cool, dry, scaly, thickened, hyperpigmented skin; toxic alopecia with dry, coarse hair, brittle nails, myxedema, loss of lateral 1/3 eyebrows</td>
</tr>
<tr>
<td><strong>HIV-RELATED</strong></td>
<td></td>
</tr>
<tr>
<td>Infections</td>
<td>Viral (e.g. HSV, HZV, HPV, CMV, molluscum contagiosum, oral hairy leukoplakia), bacterial (impetigo, acneform folliculitis, dental caries, cellulitis, bacillary epithelioid angiomatosus, syphilis), fungal (candidiasis, histoplasmosis, cryptococcus, blastomycosis)</td>
</tr>
<tr>
<td>Inflammatory dermatoses</td>
<td>Seborrhea, psoriasis, pityriasis rosea, vasculitis</td>
</tr>
<tr>
<td>Malignancies</td>
<td>Kaposi’s sarcoma, lymphoma, BCC, SCC, MM</td>
</tr>
<tr>
<td><strong>MALIGNANCY</strong></td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>Peutz-Jeghers: pigmented macules on lips/oral mucosa</td>
</tr>
<tr>
<td>Gastrointestinal Carcinoma</td>
<td>Paget’s disease: eroding scaling plaques of perineum</td>
</tr>
<tr>
<td>Carcinoma</td>
<td>Paget’s disease, eczematous and crusting lesions of the skin of the nipple and usually areola of the breast, Palmoplantar keratodes: thickened skin of palms/toes</td>
</tr>
<tr>
<td>Breast GI</td>
<td>Palmoplantar keratoderma: thickened skin of palms/toes</td>
</tr>
<tr>
<td>Thyroid</td>
<td>Sipple’s syndrome: multiple mucosal nevians</td>
</tr>
<tr>
<td>Breast/ovary</td>
<td>Dermatomyositis: heliotrope erythema of eyelids and violaceous plaques over knuckles</td>
</tr>
<tr>
<td>Lymphoma/leukemia</td>
<td>Ataxia Telangiectasia: telangiectasia on pinna, bulbar conjunctiva</td>
</tr>
<tr>
<td>Hodgkin’s Acute leukemia</td>
<td>Ichtyosis: generalized scaling especially on extremities, Sweet’s syndrome</td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td>Bloom’s syndrome: butterfly erythema on face, associated with short stature</td>
</tr>
<tr>
<td><strong>OTHERS</strong></td>
<td></td>
</tr>
<tr>
<td>Liver disease</td>
<td>Prunules, hyperpigmentation, spider nevi, palmar erythema, white nails (Terry’s nails), porphyria cutanea tarda, xanthomas, hair loss, jaundice</td>
</tr>
<tr>
<td>Renal disease</td>
<td>Prunules, pigmentation, half and half nails, perforating dermatosis, calciphylaxis</td>
</tr>
<tr>
<td>Pruritic urticarial papules and plaques of pregnancy</td>
<td>Erythematous papules or urticarial plaques in distribution of striae distensae: buttocks, thighs, upper inner arms and lower back</td>
</tr>
<tr>
<td>Cryoglobulinemia</td>
<td>Palpable purpura in cold-exposed areas, Raynaud’s, cold urticaria, aural hemorrhagic necrosis, bleeding disorders, associated with hepatitis C infection</td>
</tr>
</tbody>
</table>

**Raynaud’s Phenomenon DDx**

**COLD HAND**
- Cryoglobulins/Cryofibrinogens
- Obstruction/Closure
- Lupus erythematosus, other connective tissue disease
- DM/Drugs
- Hematologic problems (polycythemia, leukemia, etc)
- Arterial problems (atherosclerosis)
- Neurologic problems (vascular tone)
- Disease of unknown origin (idiopathic)

**Acanthosis Nigricans**

An asymptomatic dark thickened velvety hyperpigmentation of flexural skin most commonly around the neck. Associated with DM, obesity, and other endocrine disorders and malignancy. It is a cutaneous marker of tissue insulin resistance.
Pediatric Exanthems

**Miscellaneous Lesions**

**Angioedema and Urticaria**

**Angioedema**
- deeper swelling of the skin involving subcutaneous tissues; often involves the eyes, lips, and tongue
- may or may not accompany urticaria
- hereditary or acquired forms
- hereditary angioedema (does not occur with urticaria)
  - onset in childhood; 80% have positive family history
  - recurrent attacks; 25% die from laryngeal edema
- triggers: minor trauma, emotional upset, temperature changes
- types of acquired angioedema
  - acute allergic angioedema (allergens include food, drugs, contrast media, insect venom, latex)
  - non-allergic drug reaction (drugs include ACEI)
  - acquired C1 inhibitor deficiency
- treatment
  - prophylaxis with danazol or stanozolol for hereditary angioedema
  - epinephrine pen to temporize until patient reaches hospital in acute attack

**Urticaria**
- also known as “hives”
- transient, red, pruritic well-demarcated wheals
- each individual lesion lasts less than 24 h
- second most common type of drug reaction
- results from release of histamine from mast cells in dermis
- can also result after physical contact with allergen

<table>
<thead>
<tr>
<th>Type</th>
<th>Etiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute Urticaria</td>
<td>Drugs: especially ASA, NSAIDs</td>
</tr>
<tr>
<td>&gt;2/3 of cases</td>
<td>Foods: nuts, shellfish, eggs, fruit</td>
</tr>
<tr>
<td>Attacks last &lt; 6 wk</td>
<td>Idiopathic (vast majority)</td>
</tr>
<tr>
<td>Individual lesions last &lt; 24 h</td>
<td>Infection</td>
</tr>
<tr>
<td></td>
<td>Insect stings (bees, wasps, hornets)</td>
</tr>
<tr>
<td></td>
<td>Percutaneous absorption: cosmetics, work exposures</td>
</tr>
<tr>
<td></td>
<td>Stress</td>
</tr>
<tr>
<td></td>
<td>Systemic diseases: SLE, endocrinopathy, neoplasm</td>
</tr>
<tr>
<td>Chronic Urticaria</td>
<td>IgE-dependent: trigger associated</td>
</tr>
<tr>
<td>&lt;1/3 of cases</td>
<td>Idiopathic (80% of chronic urticaria patients)</td>
</tr>
<tr>
<td>Attacks last &gt; 6 wk</td>
<td>Aeroallergens</td>
</tr>
<tr>
<td>Individual lesion lasts &lt; 24 h</td>
<td>Drugs (antibiotics, hormones, local anesthetics)</td>
</tr>
<tr>
<td></td>
<td>Foods and additives</td>
</tr>
<tr>
<td></td>
<td>Insect stings</td>
</tr>
<tr>
<td></td>
<td>Parasitic infections</td>
</tr>
<tr>
<td></td>
<td>Physical contact (animal saliva, plant resins, latex, metals, lotions, soap)</td>
</tr>
<tr>
<td></td>
<td>Direct mast cell release</td>
</tr>
<tr>
<td></td>
<td>Opiates, muscle relaxants, radio-contrast agents</td>
</tr>
<tr>
<td></td>
<td>Complement-mediated</td>
</tr>
<tr>
<td></td>
<td>Serum sickness, transfusion reactions</td>
</tr>
<tr>
<td></td>
<td>Infections, viral/bacterial (&gt; 80% of urticaria in pediatric patients)</td>
</tr>
<tr>
<td></td>
<td>Urticarial vasculitis</td>
</tr>
<tr>
<td></td>
<td>Arachidonic acid metabolism</td>
</tr>
<tr>
<td></td>
<td>ASA, NSAIDs</td>
</tr>
<tr>
<td></td>
<td>Physical</td>
</tr>
<tr>
<td></td>
<td>Dermatographism (friction, rubbing skin), cold (ice cube, cold water), cholnergic (hot shower, exercise), solar pressure (shoulder strap, buttocks), aqueagenic (exposure to water), adrenergic (stress), heat</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td></td>
<td>Mastocytosis, urticaria pigmentosa</td>
</tr>
</tbody>
</table>

**Table 24. Classification of Urticaria**

**Approach to Urticaria**
- Thorough Hx and P/E
- Acute: no immediate investigations needed; consider referral for allergy testing
- Chronic: further investigations required: CBC and differential, urinalysis, ESR, TSH, LFTs to help identify underlying cause
- Vascular: biopsy of lesion and referral to dermatology

**Wheal**
- Typically erythematous flat-topped, palpable lesions varying in size with circumscribed dermal edema
- Individual lesion lasts < 24 h
- Associated with mast cell release of histamine
- May be pruritic

**Mastocytosis (Urticaria Pigmentosa)**
- Rare disease due to excessive infiltration of the skin by mast cells. It manifests as many reddish-brown elevated plaques and macules. Friction to a lesion produces a wheal surrounded by intense erythema (Darier’s sign), due to mast cell degranulation; this occurs within minutes
**Erythema Nodosum**

**Clinical Presentation**
- acute or chronic inflammation of subcutaneous fat (panniculitis)
- round, red, tender, poorly demarcated nodules
- sites: asymmetrically arranged on extensor lower legs, knees, arms, (typically shins)
- associated with arthralgia, fever, malaise

**Etiology**
- 40% are idiopathic
- drugs: sulfonamides, OCPs (also pregnancy), analgesics, trans retinoic acid
- infections: GAS, TB, histoplasmosis, Yersinia
- inflammation: sarcoidosis, Crohn's > UC
- malignancy: acute leukemia, Hodgkin's lymphoma

**Epidemiology**
- 15-30 yr old; F:M = 3:1
- lesions last for days and spontaneously resolve in 6 wk

**Investigations**
- chest x-ray (to rule out chest infection and sarcoidosis)
- throat culture, ASO titre, PPD skin test

**Management**
- symptomatic: bed rest, compressive bandages, wet dressings
- NSAIDs, intralesional steroids
- treat underlying cause

---

**Pruritus**

**Clinical Presentation**
- a sensation provoking a desire to scratch, with or without skin lesions
- lesions may arise from the underlying disease, or from excoriation causing crusts, lichenified plaques, or wheals

**Etiology**
- dermatologic – generalized
  - asthenic dermatitis ("winter itch" due to dry skin)
  - pruritus of senescent skin (may not have dry skin, any time of year)
  - infestations: scabies, lice
  - drug eruptions: ASA, antidepressants, opiates
  - psychogenic states
- dermatologic – local
  - atopic and contact dermatitis, lichen planus, urticaria, insect bites, dermatitis herpetiformis
  - infection: varicella, candidiasis
  - lichen simplex chronicus
  - prurigo nodularis
- systemic disease – usually generalized
  - hepatic: obstructive biliary disease, cholestatic liver disease of pregnancy
  - renal: chronic renal failure, uremia secondary to hemodialysis
  - hematologic: Hodgkin's lymphoma, multiple myeloma, leukemia, polycythemia vera, hemochromatosis, Fe deficiency anemia, cutaneous T-cell lymphoma
  - neoplastic: lung, breast, gastric (internal solid tumours), non-Hodgkin's lymphoma
  - endocrine: carcinoid, DM, hypothyroid/thyrotoxicosis
  - infectious: HIV, trichinosis, echinococcosis, hepatitis C
  - psychiatric: depression, psychosis
  - neurologic: post-herpetic neuralgia, multiple sclerosis

**Investigations**
- blood work: CBC, ESR, Cr/BUN, LFT, TSH, fasting blood sugar, stool culture and serology for parasites

**Management**
- treat underlying cause
- cool water compresses to relieve pruritus
- bath oil and emollient ointment (especially if xerosis is present)
- topical corticosteroid and antipruritics (e.g. menthol, camphor, phenol, mirtazapine, capsaicin)
- systemic antihistamines: H1 blockers are most effective, most useful for urticaria
- phototherapy with UVB or PUVA
- doxepin, amitriptyline
- immunosuppressive agents if severe: steroids and steroid-sparing
Wounds and Ulcers

- see Plastic Surgery, PL8, PL15

Sunburn

- erythema 2-6 h post UV exposure often associated with edema, pain and blistering with subsequent desquamation of the dermis, and hyperpigmentation
- chronic UVA and UVB exposure leads to photoaging, immunosuppression, photocarcinogenesis
- prevention: avoid peak UVR (10 am-4 pm), wear appropriate clothing, wide-brimmed hat, sunglasses, and broad-spectrum sunscreen
- clothing with UV protection expressed as UV protection factor (UPF) is analogous to SPF of sunscreen

Sunscreens

- under ideal conditions an SPF of 10 means that a person who normally burns in 20 min will burn in 200 min following the application of the sunscreen
- topical chemical: absorbs UV light
  - requires application at least 15-30 min prior to exposure, should be reapplied every 2 h (more often if sweating, swimming)
  - UVB absorbers: PABA, salicylates, cinnamates, benzylidene camphor derivatives
  - UVA absorbers: benzophenones, anthranilates, dibenzoylmethanes, benzylidene camphor derivatives
- topical physical: reflects and scatters UV light
  - titanium dioxide, zinc oxide, kaolin, talc, ferric chloride, and melanin
    - all are effective against the UVA and UVB spectrum
    - less risk of sensitization than chemical sunscreens and waterproof, but may cause folliculitis or miliaria
- some sunscreen ingredients may cause contact or photocontact allergic reactions, but are uncommon

Management

- sunburn: if significant blistering present, consider treatment in hospital; otherwise, symptomatic treatment (cool wet compresses, oral anti-inflammatory, topical corticosteroids)
- antioxidants, both oral and topical are being studied for their abilities to protect the skin; topical agents are limited by their ability to penetrate the skin

Topical Steroids

### Table 25. Potency Ranking of Topical Steroids

<table>
<thead>
<tr>
<th>Relative Potency</th>
<th>Relative Strength</th>
<th>Generic Names</th>
<th>Trade Names</th>
<th>Usage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weak</td>
<td>x1</td>
<td>hydrocortisone – 2.5% (1% available over-the-counter)</td>
<td>Emo Cort®</td>
<td>Intertriginous areas, children, face, thin skin</td>
</tr>
<tr>
<td>Moderate</td>
<td>x3</td>
<td>hydrocortisone 17-valerate – 0.2% desonide mometasone furoate</td>
<td>Westcort® Tridesson®</td>
<td>Arm, leg, trunk</td>
</tr>
<tr>
<td>Potent</td>
<td>x6</td>
<td>betamethasone – 0.1% 17-valerate – 0.1% amcinonide</td>
<td>Betnovate® Celestoderm – V® Cyclocort®</td>
<td>Body</td>
</tr>
<tr>
<td>Very Potent</td>
<td>x9</td>
<td>betamethasone dipropionate – 0.05% fluocinonide – 0.05% halcinonide</td>
<td>Diprosone® Lidex, Topsyln gel® Lyderm® Halog®</td>
<td>Palms and soles</td>
</tr>
<tr>
<td>Extremely Potent</td>
<td>x12</td>
<td>clobetasol propionate – 0.05% (most potent) betamethasone dipropionate ointment halobetasol propionate – 0.05%</td>
<td>Dermovate® Diproline® Ultravate®</td>
<td>Palms and soles</td>
</tr>
</tbody>
</table>

**Side Effects of Topical Steroids**

- Local: atrophy, perioral dermatitis, steroid acne, rosacea, contact dermatitis, tachyphylaxis (tolerance), telangiectasia, striae, hypopigmentation
- Systemic: suppression of HPA axis
### Dermatologic Therapies

#### Table 26. Common Topical Therapies

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Schedule</th>
<th>Indications</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcipotriol (Dovonex*)</td>
<td>0.005% cream, ointment, scalp solution, apply bid For maintenance therapy apply OD</td>
<td>Psoriasis</td>
<td>Burning, itching, skin irritation, worsening of psoriasis Avoid face, mucous membranes, eyes; wash hands after application Maximum weekly dosage of cream by age: 2.5-5 yr – 25 g/wk 6-10 yr – 50 g/wk 11-14 yr – 75 g/wk &gt; 14 yr – 100 g/wk Inactivated by light (do not apply before phototherapy)</td>
</tr>
<tr>
<td>Imiquimod (Aldara®)</td>
<td>5% cream applied 3x/wk Apply at bedtime, leave on 6-10 h, then wash off with mild soap and water Max duration 16 wk</td>
<td>Genital warts Cutaneous warts AK Superficial BCC</td>
<td>Avoid natural/artificial UV exposure Local skin and application site reactions Erythema, ulceration, edema, flu-like symptoms Works best for warts on mucosal surfaces May induce inflammation and erosion</td>
</tr>
<tr>
<td>Permethrin (Kwellada® P Lotion and Nix® Dermal Cream)</td>
<td>1% or 5% cream, applied once overnight to all skin areas from neck down, repeated one week later</td>
<td>Scabies (Kwellada-P Lotion, Nix® Dermal Cream) Pediculosis (Kwellada-P Crème Rinse®, Nix Crème Rinse®)</td>
<td>Do not use in children &lt; 2 yr Hypersensitivity to drug, or known sensitivity to chrysanthemums Local reactions only (resolve rapidly); including burning, pruritus Low toxicity, excellent results Consider second application after 7 d</td>
</tr>
<tr>
<td>Pimecrolimus (Elidel®)</td>
<td>1% cream bid Use for as long as lesions persist and discontinue upon resolution of symptoms</td>
<td>AD (mild to moderate)</td>
<td>Burning Lacks adverse effects of steroids May be used on all skin surfaces including head, neck, and intertriginous areas Expensive</td>
</tr>
<tr>
<td>Tacrolimus Topical (Protopic®)</td>
<td>0.03% (children) or 0.1% (adults) ointment bid Continue for duration of disease PLUS 1 wk after clearing</td>
<td>AD (mild to moderate)</td>
<td>Burning Lacks adverse effects of steroids May be used on all skin surfaces including head, neck, and intertriginous areas Expensive</td>
</tr>
</tbody>
</table>

#### Table 27. Common Oral Therapies

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Schedule</th>
<th>Indications</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acitretin (Soriatane®)</td>
<td>25-50 mg PO OD; maximum 75 mg/d</td>
<td>Severe psoriasis Other disorders of hyperkeratinization (ichthyosis, Darier’s disease)</td>
<td>Monitoring strategies Monitor lipids, LFTs at baseline and q1-2wk until stable Long-term effects preclude use of cyclosporine for &gt;2 yr; discontinue earlier if possible May consider rotating therapy with other drugs to minimize adverse effects of each drug</td>
</tr>
<tr>
<td>Antivirals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>famciclovir (Famvir®)</td>
<td>250 mg PO tid x 7-10 d (for 1st episode of genital herpes) 125 mg PO bid x 5 d (for recurrent genital herpes)</td>
<td>Chickenpox Herpes zoster Genital herpes Acute and prophylactic to reduce transmission in infected patients Herpes labialis</td>
<td>Side effects Headache, nausea, diarrhea, abdominal pain Reduce dose if impaired renal function</td>
</tr>
<tr>
<td>valacyclovir (Valtrex®)</td>
<td>1000 mg PO bid x 7-10 d (for 1st episode of genital herpes) 500 mg PO bid x 5 d (for recurrent genital herpes)</td>
<td></td>
<td>Side effects Dizziness, depression, abdominal pain Reduce dose if impaired renal function Drug interactions cimetidine</td>
</tr>
<tr>
<td>Cyclosporine (Neoral®)</td>
<td>2.5-4 mg/kg/d PO divided bid Max 4 mg/kg/d After 4 wk may increase by 0.5 mg/kg q2wk Concomitant dose of magnesium may protect the kidneys</td>
<td>Psoriasis May also be effective in: Lichen planus EM Recalcitrant urticaria Recalcitrant AD</td>
<td>Monitoring strategies Blood pressure, renal function Drug interactions Abnormal renal function, uncontrolled hypertension, malignancy (except NMOSD), uncontrolled infection, immunodeficiency (excluding autoimmune disease), hypersensitivity to drug Long-term effects preclude use of cyclosporine for &gt;2 yr; discontinue earlier if possible May consider rotating therapy with other drugs to minimize adverse effects of each drug</td>
</tr>
<tr>
<td>Dapsone</td>
<td>50-100-150 mg PO OD tapering to 25-50 mg PO OD to as low as 50 mg 2x/wk</td>
<td>Dermatitis herpetiformis, neutrophic dermatoses</td>
<td>Monitoring strategies Obtain G6PD levels before initiating; in the initial two wk obtain methemoglobin levels and follow the blood counts carefully for the first few months Side effects Neuropathy Hemolysis (Vitamin C and E supplementation can help prevent this) Drug interactions Substrate of CYP2C8/9 (minor), 2C19 (minor), 2E1 (minor), 3A4 (major) Often a dramatic response within hours</td>
</tr>
</tbody>
</table>
## Table 27. Common Oral Therapies (continued)

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Schedule</th>
<th>Indications</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Isotretinoin</strong> <em>(Accutane®)</em></td>
<td>0.5-1 mg/kg/d given OD, to achieve a total dose of 120 mg/kg (20-24 wk)</td>
<td>Severe nodular and/or inflammatory acne Acne conglobata Recalcitrant acne Widespread comedonal acne</td>
<td>Monitoring strategies Baseline lipid profile and LFTs before treatment, β-hCG Contraindications Teratogenic – in sexually active females, 2 forms of reliable contraception necessary Generally regarded as unsafe in lactation Side effects Night blindness, decreased tolerance to contact lenses, dry mucous membranes May transiently exacerbate acne, dry skin Depression, myalgia Drug interactions Do not use at the same time as tetracycline or minocycline – both may cause pseudotumour cerebri Discontinue vitamin A supplements Drug may be discontinued at 16-20 wk when nodule count has dropped by &gt;70%; a second course may be initiated after 2 mo prn Refractory cases may require &gt;3 courses</td>
</tr>
<tr>
<td><strong>Itraconazole</strong> <em>(Sporanox®)</em></td>
<td>100-400 mg PO OD, depending on infection Tinea corporis/cruris/versicolor: 200 mg PO OD x 7 d Tinea pedis: 200 mg PO bid x 7 d Toenails: 200 mg PO bid x 7 d once per month, repeated 3x Fingernail involvement only: 200 mg PO bid x 7 d once per month, repeated 2x</td>
<td>Onychomycosis Tinea corporis, cruris, pedis, versicolor, capitis</td>
<td>Contraindications CHF Side effects Serious hepatotoxicity Drug Interactions Inhibits CYP3A4 Increases concentration of some drugs metabolized by this enzyme (i.e. statins, diabetic drugs) Give capsules with food, capsules must be swallowed whole</td>
</tr>
<tr>
<td><strong>Ivermectin</strong> <em>(Mectizan®, Stromectol®)</em></td>
<td>200-250 µg/kg PO qweekly x 2 Take once as directed; repeat one wk later</td>
<td>Onchocerciasis (USA only) Not licensed for use in Canada Also effective for: scabies</td>
<td>No significant serious side effects Efficacious</td>
</tr>
<tr>
<td><strong>Methotrexate</strong> <em>(Trexall®)</em></td>
<td>10-25 mg qwk, PO, IM, or IV Max: 30 mg/qwk To minimize side effects, administer with folic acid supplementation: 1-5 mg OD</td>
<td>Psoriasis AD Lymphomatoid papulosis May also be effective in: cutaneous sarcoidosis</td>
<td>Monitoring strategies Baseline renal, liver, and hematological studies Contraindications Pregnancy, lactation, alcohol abuse, liver dysfunction, immunodeficiency syndrome, blood dyscrasias, hypersensitivity to drug Restricted to severe, recalcitrant or disabling psoriasis not adequately responsive to other forms of therapy May be combined with cyclosporine to allow lower doses of both drugs</td>
</tr>
<tr>
<td><strong>Minocycline</strong> <em>(Minocin®)</em></td>
<td>50-100 mg PO bid Taper to 50 mg PO OD as acne lessens</td>
<td>Acne vulgaris Rosacea</td>
<td>Contraindications Caution if impaired renal or liver function Drug interactions Do not use with isotretinoin (Accutane®) Extensive; affects multiple organ systems including CNS, teeth, eyes, bones, renal, and skin (photosensitivity and blue pigmentation) Drug-induced lupus (check p-ANCA) Alternative to tetracycline</td>
</tr>
<tr>
<td><strong>OCPs</strong> <em>(TriCyclen®, Diane 35®, Alesse®)</em></td>
<td>1 pill PO once daily</td>
<td>Hormonal acne (chin, jawline) Acne associated with polycystic ovarian syndrome or other endocrine abnormalities</td>
<td>All combined OCPs are helpful in acne but those listed on the left have undergone RCTs Contraindications Smoking, HTN, migraines with aura, pregnancy Routine gynecological health maintenance should be up to date</td>
</tr>
<tr>
<td><strong>Spironolactone</strong></td>
<td>50-100 mg PO OD alone or with OCPs</td>
<td>Hormonal acne (chin, jawline) Acne with endocrine abnormality</td>
<td>Contraindications Pregnancy Side effects Menstrual irregularities at higher doses if not on OCPs Breast tenderness, mild diuresis common Risk of hyperkalemia – counsel patients to reduce intake of potassium rich foods such as bananas</td>
</tr>
<tr>
<td><strong>Terbinafine</strong> <em>(Lamisil®)</em></td>
<td>250 mg PO OD x 2 wk Fingernails x 6 wk Toenails x 12 wk Confirm diagnosis prior to treatment</td>
<td>Onychomycosis Tinea corporis, cruris, pedis, capitis</td>
<td>Contraindications Pregnancy, chronic or active liver disease Drug interactions Potent inhibitor of CYP2D6; use with caution when also taking β-blockers, certain anti-arrhythmic agents, MAOI type B, and/or antipsychotics Drug concentrates rapidly in skin, hair, and nails at levels associated with fungicidal activity</td>
</tr>
<tr>
<td><strong>Tetracycline</strong></td>
<td>250-500 mg PO bid to tid Taken 1 h before or 2 h after a meal</td>
<td>Acne vulgaris Rosacea Bullous pemphigoid</td>
<td>Contraindications Severe renal or hepatic dysfunction</td>
</tr>
</tbody>
</table>
References


deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA 1997;278:1895-1900.


Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severe variants of the same disease which differs from erythema multiforme. J Dermatol 1997;24:726-729.


White JD, Grimble JM. The rational clinical examination. Does this patient have a mole or a melanoma? JAMA 1998;279:696-701.


Acronyms .................................................. 2

Patient Assessment/Management ................. 2
1. Rapid Primary Survey
2. Resuscitation
3. Secondary Survey
Ethical Considerations

Traumatology .............................................. 7
Considerations for Traumatic Injury
Head Trauma
Mild Traumatic Brain Injury
Spine and Spinal Cord Trauma
Chest Trauma
Abdominal Trauma
Genitourinary Tract Injuries
Orthopedic Injuries
Wound Management

Approach to Common ED Presentations .......... 18
Abdominal Pain
Acute Pelvic Pain
Altered Level of Consciousness
Chest Pain
Headache
Joint and Back Pain
Seizures
Shortness of Breath
Syncope
Sexual Assault

Medical Emergencies .................................. 28
Anaphylaxis and Allergic Reactions
Asthma
Cardiac Dysrhythmias
Acute Exacerbation of COPD (AECOPD)
Acute Decompensated Heart Failure (ADHF)
Venous Thromboembolism (VTE)
Diabetic Emergencies
Electrolyte Disturbances
Hypertensive Emergencies
Acute Coronary Syndrome (ACS)
Sepsis
Stroke and TIA

Otolaryngological Presentations and Emergencies ............................................ 39
Epistaxis

Gynecologic/Urologic Emergencies .................. 40
Vaginal Bleeding
Pregnant Patient in the ED
Nephrolithiasis (Renal Colic)

Ophthalmologic Emergencies ......................... 42

Dermatologic Emergencies ............................. 43

Environmental Injuries ............................... 45
Heat Exhaustion and Heat Stroke
Hypothermia and Cold Injuries
Burns
Inhalation Injury
Bites
Near Drowning

Toxicology .................................................. 49
“ABCD: EFG” of Toxicology
D1 – Universal Antidotes
D2 – Draw Bloods
D3 – Decontamination and Enhanced Elimination
E – Expose and Examine the Patient
F – Full Vitals, ECG Monitor, Foley, X-Rays
G – Give Specific Antidotes and Treatments
Alcohol Related Emergencies
Approach to the Overdose Patient
Disposition from the Emergency Department

Psychiatric Emergencies ............................... 56
Approach to Common Psychiatric Presentations
Acute Psychosis
Suicidal Patient

Common Pediatric ED Presentations ............... 57
Modified Glasgow Coma Score
Respiratory Distress
Febrile Infant and Febrile Seizures
Abdominal Pain
Common Infections
Child Abuse and Neglect

Common Medications ................................. 60

References ................................................. 62
Patient Assessment/Management

1. Rapid Primary Survey

- Airway maintenance with C-spine control
- Breathing and ventilation
- Circulation (pulses, hemorrhage control)
- Disability (neurological status)
- Exposure (complete) and Environment (temperature control)
  - continually reassessed during secondary survey
  - changes in hemodynamic and/or neurological status necessitates a return to the primary survey beginning with airway assessment
- IMPORTANT: Always watch for signs of shock while doing primary survey

A. AIRWAY
- first priority is to secure airway
- assume a cervical injury in every trauma patient and immobilize with collar
- assess ability to breathe and speak
- can change rapidly, therefore reassess frequently
- assess for facial fractures/edema/burns (impending airway collapse)

Airway Management
- anatomic optimization to allow for oxygenation and ventilation

1. Basic Airway Management
- protect the C-spine
- head-tilt (if C-spine injury not suspected) or jaw thrust to open the airway
- sweep and suction to clear mouth of foreign material

2. Temporizing Measures
- nasopharyngeal airway (if gag reflex present, i.e. conscious)
- oropharyngeal airway (if gag reflex absent, i.e. unconscious)
- "rescue" airway devices (e.g. laryngeal mask airway, Combitube®)
- transtracheal jet ventilation through cricothyroid membrane (last resort)

3. Definitive Airway Management
- ETT intubation with in-line stabilization of C-spine
  - orotracheal ± RSI preferred
  - nasotracheal may be better tolerated in conscious patient
  - relatively contraindicated with basal skull fracture
  - does not provide 100% protection against aspiration
- surgical airway (if unable to intubate using oral/nasal route and unable to ventilate)
- cricothyroidotomy

Contraindications to Intubation
- supraglottic/glottic pathology that would preclude successful intubation
**B. BREATHING**

- **Look**
  - mental status (anxiety, agitation, decreased LOC), colour, chest movement (bilateral vs. asymmetrical), respiratory rate/effort, nasal flaring
- **Listen**
  - auscultate for signs of obstruction (e.g. stridor), breath sounds, symmetry of air entry, air escaping
- **Feel**
  - tracheal shift, chest wall for crepitus, flail segments, sucking chest wounds, subcutaneous emphysema

**Breathing Assessment**
- objective measures of respiratory function: rate, oximetry, ABG, A-a gradient

**Management of Breathing**
- nasal prongs → simple face mask → non-rebreather mask → CPAP/BiPAP (in order of increasing FiO₂)
- Bag-Valve mask and CPAP to supplement inadequate ventilation

**C. CIRCULATION**

**Definition of Shock**
- inadequate organ and tissue perfusion with oxygenated blood (brain, kidney, extremities)

**Table 1. Major Types of Shock**

<table>
<thead>
<tr>
<th>Hypovolemic</th>
<th>Cardiogenic</th>
<th>Distributive (vasodilation)</th>
<th>Obstructive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemorrhage (external and internal)</td>
<td>Myocardial ischemia</td>
<td>Septic</td>
<td>Cardiac tamponade</td>
</tr>
<tr>
<td>Severe burns</td>
<td>Dysrhythmias</td>
<td>Anaphylactic</td>
<td>Tension pneumothorax</td>
</tr>
<tr>
<td>High output fistulas</td>
<td>CHF</td>
<td>Neurogenic (spinal cord injury)</td>
<td>PE</td>
</tr>
<tr>
<td>Dehydration (diarrhea, DKA)</td>
<td>Cardiomyopathies</td>
<td></td>
<td>Aortic stenosis</td>
</tr>
<tr>
<td></td>
<td>Cardiac valve problems</td>
<td></td>
<td>Constrictive pericarditis</td>
</tr>
</tbody>
</table>

**Clinical Evaluation**
- early: tachypnea, tachycardia, narrow pulse pressure, reduced capillary refill, cool extremities, and reduced central venous pressure
- late: hypotension and altered mental status, reduced urine output

**Table 2. Estimation of Degree of Hemorrhagic Shock**

<table>
<thead>
<tr>
<th>Class</th>
<th>I</th>
<th>II</th>
<th>III</th>
<th>IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood loss</td>
<td>&lt; 750 cc</td>
<td>750-1,500 cc</td>
<td>1,500-2,000 cc</td>
<td>&gt; 2,000 cc</td>
</tr>
<tr>
<td>% of blood volume</td>
<td>&lt; 15%</td>
<td>15-30%</td>
<td>30-40%</td>
<td>&gt; 40%</td>
</tr>
<tr>
<td>Pulse</td>
<td>&lt; 100</td>
<td>&gt; 100</td>
<td>&gt; 120</td>
<td>&gt; 140</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>Normal</td>
<td>Normal</td>
<td>Decreased</td>
<td>Decreased</td>
</tr>
<tr>
<td>Respiratory rate</td>
<td>20</td>
<td>30</td>
<td>35</td>
<td>&gt; 45</td>
</tr>
<tr>
<td>Capillary refill</td>
<td>Normal</td>
<td>Decreased</td>
<td>Decreased</td>
<td>Decreased</td>
</tr>
<tr>
<td>Urinary output</td>
<td>30 cc/h</td>
<td>20 cc/h</td>
<td>10 cc/h</td>
<td>None</td>
</tr>
<tr>
<td>Fluid replacement</td>
<td>Crystalloid</td>
<td>Crystalloid</td>
<td>Crystalloid + blood</td>
<td>Crystalloid + blood</td>
</tr>
</tbody>
</table>

**Indications for Intubation**
- Unable to protect airway (e.g. GCS < 8; airway trauma)
- Inadequate oxygenation with spontaneous respiration (O₂ saturation < 93% with 100% O₂, or rising pCO₂)
- Anticipatory: in trauma, overdose, CHF, asthma, COPD, and smoke inhalation injury
- Anticipated transfer of critically ill patients

**Rescue Techniques in Intubation**
- Bougie (used like a guidewire)
- Glide scope
- Louped stylet (use light through skin to determine if ETT in correct place)
- Fiberoptic intubation – indirect visualization using fiberoptic cable

**Medications that can be Delivered via ETT**

- NALOXONE (Narcotan®)
- Atropine
- Epinephrine
- Lidocaine

**Shock in a trauma patient is hemorrhagic until proven otherwise**

**Estimated Systolic Blood Pressure Based on Position of Most Distal Palpable Pulse**

<table>
<thead>
<tr>
<th>sBP (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radial</td>
</tr>
<tr>
<td>Femoral</td>
</tr>
<tr>
<td>Carotid</td>
</tr>
</tbody>
</table>
Management of Hemorrhagic Shock
• clear airway and breathing either first or simultaneously
• apply direct pressure on external wounds while elevating extremities. Do not remove impaled objects in
the emergency room setting as they may tamponade bleeds
• start TWO LARGE BORE (14-16G) IVs in the brachial/cephalic vein of each arm
• run 1-2 L bolus of IV Normal Saline/Ringer's Lactate (warmed, if possible)
• if continual bleeding or no response to crystalloids, consider pRBC transfusion, ideally crossmatched. If
crossmatched blood is unavailable, consider O- for women of childbearing age and O+ for men. Use
FFP, platelets or tranexamic acid in early bleeding
• consider common sites of internal bleeding (abdomen, chest, pelvis, long bones) where surgical
intervention may be necessary

D. DISABILITY
• assess LOC using GCS
• pupils
  ▪ assess equality, size, symmetry, reactivity to light
  ▪ inequality/slugghish suggests local eye problem or lateralizing CNS lesion
  ▪ relative afferent pupillary defect (swinging light test) – optic nerve damage
  ▪ extraocular movements and nystagmus
  ▪ fundoscopy (papilledema, hemorrhages)
  ▪ reactive pupils + decreased LOC: metabolic or structural cause
  ▪ non-reactive pupils + decreased LOC: structural cause (especially if asymmetric)

Glasgow Coma Scale
• for use in trauma patients with decreased LOC; good indicator of severity of injury and neurosurgical
  prognosis
• most useful if repeated; change in GCS with time is more relevant than the absolute number
• less meaningful for metabolic coma
• patient with deteriorating GCS needs immediate attention
• prognosis based on best post-resuscitation GCS
• reported as a 3 part score: Eyes + Verbal + Motor = Total
• if patient intubated, GCS score reported out of 10 + T (T = tubed, i.e. no verbal component)

Table 3. Glasgow Coma Scale

<table>
<thead>
<tr>
<th>Eyes Open</th>
<th>Best Verbal Response</th>
<th>Best Motor Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spontaneously</td>
<td>4 Answers questions appropriately</td>
<td>5 Obey commands</td>
</tr>
<tr>
<td>To voice</td>
<td>3 Confused, disoriented</td>
<td>4 Localizes to pain</td>
</tr>
<tr>
<td>To pain</td>
<td>2 Inappropriate words</td>
<td>3 Withdraws from pain</td>
</tr>
<tr>
<td>No response</td>
<td>1 Incomprehensible sounds</td>
<td>2 Decorticate (flexion)</td>
</tr>
<tr>
<td></td>
<td>No verbal response</td>
<td>1 Decerebrate (extension)</td>
</tr>
<tr>
<td></td>
<td>No response</td>
<td></td>
</tr>
</tbody>
</table>

13-15 = mild injury, 9-12 = moderate injury, ≤8 = severe injury

E. EXPOSURE/ENVIRONMENT
• expose patient completely and assess entire body for injury; log roll to examine back
• DRE
• keep patient warm with a blanket ± radiant heaters; avoid hypothermia
• warm IV fluids/blood
• keep providers safe (contamination, combative patient)

2. Resuscitation
• done concurrently with primary survey
• attend to ABCs
• manage life-threatening problems as they are identified
• vital signs q5-15 min
• ECG, BP, and O₂ monitors
• Foley catheter and NG tube if indicated
• tests and investigations: CBC, electrolytes, BUN, Cr, glucose, amylase, INR/PTT, β-hCG, toxicology
  screen, cross and type
### Table 4. 2010 AHA CPR Guidelines

<table>
<thead>
<tr>
<th>Step/Action</th>
<th>Adult: &gt;8 yr</th>
<th>Child: 1-8 yr</th>
<th>Infant: &lt;1 yr</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Airway</strong></td>
<td>Head tilt-chin lift</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Breaths</strong></td>
<td>2 breaths at 1 second/breath – stop once see chest rise</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Foreign-Body Airway Obstruction</strong></td>
<td>Abdominal thrust</td>
<td>Back slaps and chest thrusts</td>
<td></td>
</tr>
<tr>
<td><strong>Compressions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compression landmarks</td>
<td>In the centre of the chest, between nipples</td>
<td>Just below nipple line</td>
<td></td>
</tr>
<tr>
<td>Compression method: push hard and fast, and allow for complete recoil</td>
<td>2 hands: heel of 1 hand with second hand on top</td>
<td>2 hands: heel of 1 hand with second on top, or 1 hand: heel of 1 hand only</td>
<td>2 fingers, or thumbs</td>
</tr>
<tr>
<td>Compression depth</td>
<td>2-2.4 inches</td>
<td>About 1/3 to 1/2 the depth of the chest</td>
<td></td>
</tr>
<tr>
<td>Compression rate</td>
<td>100-120/min with complete chest wall recoil between compressions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compression-ventilation ratio</td>
<td>30 compressions to 2 ventilations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compression-only CPR</td>
<td>Hands-only CPR is preferred if the bystander is not trained or does not feel confident in their ability to provide conventional CPR or if the bystander is trained but chooses to use compressions only</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Defibrillation</strong></td>
<td>Immediate defibrillation for all rescuers responding to a sudden witnessed collapse</td>
<td>Compressions (5 cycles/2 min) before AED is considered if unwitnessed arrest</td>
<td>Manual defibrillators are preferred for children and infants but can use adult dose AED if a manual defibrillator is not available</td>
</tr>
</tbody>
</table>

#### 3. Secondary Survey

- done after primary survey once patient is hemodynamically and neurologically stabilized
- identifies major injuries or areas of concern
- full physical exam and x-rays (C-spine, chest, pelvis – required in blunt trauma, consider T-spine and L-spine)

**HISTORY**

- "SAMPLE": Signs and symptoms, Allergies, Medications, Past medical history, Last meal, Events related to injury

![Figure 2. Four areas of a FAST](image-url)
**PHYSICAL EXAM**

**Head and Neck**
- palpation of facial bones, scalp

**Chest**
- inspect for: 1. midline trachea and 2. flail segment: ≥2 rib fractures in ≥2 places; if present look for associated hemorhorax, pneumothorax, and contusions
- ausculate lung fields
- palpate for subcutaneous emphysema

**Abdomen**
- assess for peritonitis, abdominal distention, and evidence of intra-abdominal bleeding
- DRE for GI bleed, high riding prostate and anal tone

**Musculoskeletal**
- examine all extremities for swelling, deformity, contusions, tenderness, ROM
- check for pulses (using Doppler probe) and sensation in all injured limbs
- log roll and palpate thoracic and lumbar spines
- palpate iliac crests and pubic symphysis and assess pelvic stability (lateral, AP, vertical)

**Neurological**
- GCS
- full cranial nerve exam
- alterations of rate and rhythm of breathing are signs of structural or metabolic abnormalities with progressive deterioration in breathing indicating a failing CNS
- assess spinal cord integrity
- conscious patient: assess distal sensation and motor function
- unconscious patient: response to painful or noxious stimulus applied to extremities

**INITIAL IMAGING**
- non-contrast CT head/face/C-spine (rule out fractures and bleeds)
- chest x-ray
- FAST (see Figure 2) or CT abdomen/pelvis (if stable)
- pelvis x-ray

---

**Ethical Considerations**

**Consent to Treatment: Adults**
- see Ethical, Legal, and Organizational Medicine, ELOM6
- Emergency Rule: consent is not needed when a patient is at imminent risk from a serious injury AND obtaining consent is either: a) not possible, OR b) would increase risk to the patient
  - assumes that most people would want to be saved in an emergency
- any capable and informed patient can refuse treatment or part of treatment, even if it is life-saving
- exceptions to the Emergency Rule - treatment cannot be initiated if
  - a competent patient has previously refused the same or similar treatment and there is no evidence to suggest the patient’s wishes have changed
  - an advanced directive is available (e.g. do not resuscitate order)
  - NOTE: refusal of help in a suicide situation is NOT an exception; care must be given
- if in doubt, initiate treatment
- care can be withdrawn if necessary at a later time or if wishes are clarified by family

**Consent to Treatment: Children**
- treat immediately if patient is at imminent risk
- parents/guardians have the right to make treatment decisions
- if parents refuse treatment that is life-saving or will potentially alter the child’s quality of life, CAS must be contacted – consent of CAS is needed to treat

**Other Issues of Consent**
- need consent for HIV testing, as well as for administration of blood products
- however, if delay in substitute consent for blood transfusions puts patient at risk, transfusions can be given

**Duty to Report**
- law may vary depending on province and/or state
- examples: gunshot wounds, suspected child abuse, various communicable diseases, medical unsuitability to drive, risk of substantial harm to others
Traumatology

- epidemiology
  - leading cause of death in patients <45 yr
  - 4th highest cause of death in North America
  - causes more deaths in children/adolescents than all diseases combined
- trimodal distribution of death
  - minutes: lethal injuries, death usually at the scene
  - early: death within 4-6 h – “golden hour” (decreased mortality with trauma care)
  - days-weeks: death from multiple organ dysfunction, sepsis, etc.
- injuries fall into two categories
  - blunt (most common): MVC, pedestrian-automobile impact, motorcycle collision, fall, assault, sports
  - penetrating (increasing in incidence): gunshot wound, stabbing, impalement

Considerations for Traumatic Injury

- important to know the mechanism of injury in order to anticipate traumatic injuries
- always look for an underlying cause (alcohol, medications, illicit substances, seizure, suicide attempt, medical problem)
- always inquire about HI, loss of consciousness, amnesia, vomiting, headache, and seizure activity

Table 5. Mechanisms and Considerations of Traumatic Injuries

<table>
<thead>
<tr>
<th>Mechanism of Injury</th>
<th>Special Considerations</th>
<th>Associated Injuries</th>
</tr>
</thead>
<tbody>
<tr>
<td>MVC</td>
<td>Vehicle(s) involved: weight, size, speed, damage</td>
<td>Head-on collision: head/facial, thoracic (aortic), lower extremity</td>
</tr>
<tr>
<td></td>
<td>Location of patient in vehicle</td>
<td>Lateral/T-bone collision: head, C-spine, thoracic, abdominal, pelvic, and lower extremity</td>
</tr>
<tr>
<td></td>
<td>Use and type of seatbelt</td>
<td>Rear-end collision: hyper-extension of C-spine (whiplash injury)</td>
</tr>
<tr>
<td></td>
<td>Ejection of patient from vehicle</td>
<td>Rollover</td>
</tr>
<tr>
<td></td>
<td>Entrapment of patient under vehicle</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Airbag deployment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Helmet use in motorcycle collision</td>
<td></td>
</tr>
<tr>
<td>Pedestrian-Automobile Impact</td>
<td>High morbidity and mortality</td>
<td>Children at increased risk of being run over (multisystem injuries)</td>
</tr>
<tr>
<td></td>
<td>Vehicle speed is an important factor</td>
<td>Adults tend be struck in lower legs (lower extremity injuries), impacted against car (truncal injuries), and thrown to ground (HI)</td>
</tr>
<tr>
<td></td>
<td>Site of impact on car</td>
<td></td>
</tr>
<tr>
<td>Falls</td>
<td>1 storey = 12 ft = 3.6 m</td>
<td>Vertical: lower extremity, pelvic, and spine fractures; HI</td>
</tr>
<tr>
<td></td>
<td>Distance of fall: 50% mortality at 4 storeys and 95% mortality at 7 storeys</td>
<td>Horizontal: facial, upper extremity, and rib fractures; abdominal, thoracic, and HI</td>
</tr>
<tr>
<td></td>
<td>Landing position (vertical vs. horizontal)</td>
<td></td>
</tr>
</tbody>
</table>

Head Trauma

- see Neurosurgery, NS29
- 60% of MVC-related deaths are due to HI

Specific Injuries

- fractures
  - Dx: non-contrast head CT and physical exam
  - A. skull fractures
    - vault fractures
      - linear, non-depressed
        - most common
        - typically occur over temporal bone, in area of middle meningeal artery (commonest cause of epidural hematoma)
      - depressed
        - open (associated overlying scalp laceration and torn dura, skull fracture disrupting paranasal sinuses or middle ear) vs. closed
  - basal skull
    - typically occur through floor of anterior cranial fossa (longitudinal more common than transverse)
    - clinical diagnosis superior as poorly visualized on CT
  - B. facial fractures (see Plastic Surgery, PL29)
    - zygomatic injury
    - beware of open fracture or sinus fractures (risk of infection)
    - severe facial fractures may pose risk to airway from profuse bleeding

Signs of Basal Skull Fracture

- Battle’s sign (bruised mastoid process)
- Hemoptyanum
- Raccoon eyes (periorbital bruising)
- CSF rhinorrhea/otorrhea
• **scalp laceration**
  - can be a source of significant bleeding
  - achieve hemostasis, inspect and palpate for skull bone defects ± CT head (rule-out skull fracture)

• **neuronal injury**
  A. diffuse
    - mild TBI = concussion
      - transient alteration in mental status that may involve loss of consciousness
        - hallmarks of concussion: confusion and amnesia, which may occur immediately after the trauma or minutes later
        - loss of consciousness (if present) must be less than 30 min, initial GCS must be between 13-15, and post-traumatic amnesia must be less than 24 h
  B. focal injuries
    - contusions
    - intracranial hemorrhage (epidural, subdural, intracerebral)

**ASSSESSMENT OF BRAIN INJURY**

**History**
- pre-hospital status
- mechanism of injury

**Physical Exam**
- assume C-spine injury until ruled out
- vital signs
  - shock (not likely due to isolated brain injury, except in infants)
  - Cushing’s response to increasing ICP (bradycardia, HTN, irregular respirations)
- severity of injury determined by
  1. LOC
    - GCS ≤ 8 intubate, any change in score of 3 or more = serious injury
    - mild TBI = 13-15, moderate = 9-12, severe = 3-8
  2. pupils: size, anisocoria >1 mm (in patient with altered LOC), response to light
  3. lateralizing signs (motor/sensory)
    - may become more subtle with increasing severity of injury
- reassess frequently

**Investigations**
- labs: CBC, electrolytes, PT/PTT or INR/PTT, glucose, toxicology screen
- CT scan (non-contrast) to exclude intracranial hemorrhage/hematoma
- C-spine imaging, often with CT head and neck to exclude intracranial hemorrhage/hematoma

**Management**
- goal in ED: reduce secondary injury by avoiding hypoxia, ischemia, decreased CPP, seizure
- general
  - ABCs
  - ensure oxygen delivery to brain through intubation and prevent hypercarbia
  - maintain BP (sBP > 90)
  - treat other injuries
- early neurosurgical consultation for acute and subsequent patient management
- medical management
  - seizure treatment/prophylaxis
    - benzodiazepines, phenytoin, phenobarbital
    - steroids are of no proven value
  - treat suspected raised ICP, consider if HI with signs of increased ICP:
    - intubate
    - calm (sedate) if risk for high airway pressures or agitation
    - paralyze if agitated
    - hyperventilate (100% O₂) to a pCO₂ of 30-35 mmHg
    - elevate head of bed to 20°
    - adequate BP to ensure good cerebral perfusion
    - diurese with mannitol 1 g/kg infused rapidly (contraindicated in shock/renal failure)

**Disposition**
- neurosurgical ICU admission for severe HI
- in hemodynamically unstable patient with other injuries, prioritize most life-threatening injuries and maintain cerebral perfusion
- for minor HI not requiring admission, provide 24 h HI protocol to competent caregiver, follow-up with neurology as even seemingly minor HI may cause lasting deficits
Mild Traumatic Brain Injury

**Epidemiology**
- TBI results in 1.7 million deaths, hospitalizations, and ED visits each year (US)
- 75% are estimated to be mild TBI; remainder are moderate or severe (see Neurosurgery, NS29)
- highest rates in children 0-4 yr, adolescents 15-19 yr, and elderly >65 yr

**Clinical Features**
- somatic: headache, sleep disturbance, N/V, blurred vision
- cognitive dysfunction: attentional impairment, reduced processing speed, drowsiness, amnesia
- emotion and behaviour: impulsivity, irritability, depression
- severe concussion: may precipitate seizure, bradycardia, hypotension, sluggish pupils

**Etiology**
- falls, MVC, struck by an object, assault, sports

**Investigations**
- neurological exam
- concussion recognition tool (see thinkfirst.ca)
- imaging – CT as per Canadian CT Head Rules, or MRI if worsening symptoms despite normal CT

**Treatment**
- close observation and follow-up; for patients at risk of intracranial complications, give appropriate discharge instructions to patient and family; watch for changes to clinical features above, and if change, return to ED
- hospitalization with normal CT (GCS <15, seizures, bleeding diathesis), or with abnormal CT
- early rehabilitation to maximize outcomes
- pharmacological management of pain, depression, headache
- follow Return to Play guidelines

**Prognosis**
- most recover with minimal treatment
- athletes with previous concussion are at increased risk of cumulative brain injury
- repeat TBI can lead to life-threatening cerebral edema or permanent impairment

Spine and Spinal Cord Trauma

- assume cord injury with significant falls (>12 ft), deceleration injuries, blunt trauma to head, neck, or back
- spinal immobilization (cervical collar, spine board during patient transport only) must be maintained until spinal injury has been ruled out (Figure 3)
- vertebral injuries may be present without spinal cord injury; normal neurologic exam does not exclude spinal injury
- cord may be injured despite normal C-spine x-ray (SCIWORA = spinal cord injury without radiologic abnormality)
- injuries can include: complete/incomplete transection, cord edema, spinal shock

**History**
- mechanism of injury, previous deficits, SAMPLE
- neck pain, paralysis weakness, paresthesia

**Physical Exam**
- ABCs
- abdominal: ecchymosis, tenderness
- neurological: complete exam, including mental status
- spine: maintain neutral position, palpate C-spine; log roll, then palpate T-spine and L-spine, assess rectal tone
- when palpating, assess for tenderness, muscle spasm, bony deformities, step-off, and spinous process malalignment
- extremities: check capillary refill, suspect thoracolumbar injury with calcaneal fractures

**Investigations**
- bloodwork: CBC, electrolytes, Cr, glucose, coagulation profile, cross and type, toxicology screen
- imaging
  - full C-spine x-ray series for trauma (AP, lateral, odontoid)
  - thoracolumbar x-rays
  - AP and lateral views
- indications
  - patients with C-spine injury
  - unconscious patients (with appropriate mechanism of injury)
  - patients with neurological symptoms or findings
  - patients with deformities that are palpable when patient is log rolled
  - patients with back pain
  - patients with bilateral calcaneal fractures (due to fall from height)
  - concurrent burst fractures of the lumbar or thoracic spine in 10% (T11-L2)
  - consider CT (for subtle bony injuries), MRI (for soft tissue injuries) if appropriate

---

**Suspected C-Spine Injury**

<table>
<thead>
<tr>
<th>History: midline neck pain, numbness or paresthesia, presence of distracting pain, head injury, intoxication, loss of consciousness or past history of spinal mobility disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Physical exam:</strong> posterior neck spasm, tenderness or crepitus, any neurologic deficit or autonomic dysfunction, altered mental state</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C-spine cleared</th>
<th>C-spine cleared</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>1. Plain x-rays, 3 views</td>
</tr>
<tr>
<td>Abnormal</td>
<td>2. CT scan if</td>
</tr>
<tr>
<td>Flexion/extension films</td>
<td>• Inadequate plain film survey</td>
</tr>
<tr>
<td></td>
<td>• Suspicious plain film findings</td>
</tr>
<tr>
<td></td>
<td>• To better delineate injuries seen on plain films</td>
</tr>
<tr>
<td>Neck pain</td>
<td>• Any clinical suspicion of atlanto-axial subluxation</td>
</tr>
<tr>
<td></td>
<td>• High clinical suspicion of injury despite normal x-ray</td>
</tr>
<tr>
<td></td>
<td>• To include C1-C3 when head CT is indicated in head trauma</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Normal films</th>
<th>Abnormal films</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>Remain immobilized, consult spine service</td>
</tr>
<tr>
<td>Abnormal</td>
<td>MRI</td>
</tr>
<tr>
<td>MRI</td>
<td>Abnormal neurological exam</td>
</tr>
<tr>
<td>Abnormal neurological exam</td>
<td>C-spine cleared</td>
</tr>
</tbody>
</table>

**Management of Cord Injury**

- immobilize
- evaluate ABCs
- treat neurogenic shock (maintain sBP >100 mmHg)
- insert NG and Foley catheter
- high dose steroids: methylprednisolone 30 mg/kg bolus, then 5.4 mg/kg/h drip, start within 6-8 h of injury (controversial and recently has less support)
- complete imaging of spine and consult spine service if available
- continually reassess high cord injuries as edema can travel up cord
- if cervical cord lesion, watch for respiratory insufficiency
- low cervical transection (C5-T1) produces abdominal breathing (phrenic innervation of diaphragm still intact but loss of innervation of intercostals and other accessory muscles of breathing)
- high cervical cord injury (above C4) may require intubation and ventilation
- treatment: warm blanket, Trendelenburg position (occasionally), volume infusion, consider vasopressors

**Approach to C-Spine X-Rays**

- 3-view C-spine series is the screening modality of choice
  1. lateral C1-T1 ± swimmer’s view
     - lateral view is best, identifies 90-95% of injuries
  2. odontoid view (open mouth or oblique submentum view)
     - examine the dens for fractures
       - if unable to rule out fracture, repeat view or consider CT or plain film tomography
     - examine lateral aspects of C1 and spacing relative to C2

---

**The Canadian C-Spine Rule**

*JAAM 2001;286:1841-1848*

**For Alert (GCS Score < 15) and Stable Trauma Patients where C-Spine Injury is a Concern**

1. Any high-risk factor that mandates radiography?
   - Age >65 yr
   - Dangerous mechanism*
   - Paraparesis in extremities

**Radiography**

2. Any one low-risk factor that allows safe assessment of ROM?
   - Simple rear-end MVC or 5 star vehicle
   - Sitting position in ED or Ambulatory at any time
   - Delayed onset of neck pain
   - Absence of midline C-spine tenderness

**No**

3. Able to actively rotate neck >45° left and right
   - Yes
   - No

**No radiography**

*Dangerous Mechanism:
- Fall from >1 meter/5 stairs
- Axial load to head (e.g. diving)
- MVC high-speed (>100 km/h), rollover, ejection
- Motorized recreational vehicles
- Bicycle collision

Simple rear-end MVC excludes:
- Pushed into oncoming traffic
- Hit by bus/large truck
- Rollover
- Hit by high-speed vehicle

9 Delayed: net immediate onset of neck pain

---

**Figure 3. Approach to clearing the C-spine**

**Can Clear C-Spine if**

- oriented to person, place, time, and event
- no evidence of intoxication
- no posterior midline cervical tenderness
- no focal neurological deficits
- no painful distracting injuries (e.g. long bone fracture)

**Approach to C-Spine x-rays**

1. Anterior vertebral line
2. Posterior vertebral line (anterior margin of spinal canal)
3. Posterior border of facets
4. Laminar fusion line (posterior margin of spinal canal)
5. Posterior spinous line (along tips of spinous processes)

**Figure 4. Lines of contour on a lateral C-spine x-ray**

Prevertebral soft tissue swelling is only 49% sensitive for injury
3. AP view
- alignment of spinous processes in the midline
- spacing of spinous processes should be equal
- check vertebral bodies and facet dislocations

Table 6. Interpretation of Lateral View: The ABCS

<table>
<thead>
<tr>
<th>A</th>
<th>Adequacy and Alignment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Must see C1 to C7-T1 junction; if not, downward traction of shoulders, swimmer’s view, bilateral supine obliques, or CT scan needed</td>
</tr>
<tr>
<td></td>
<td>Lines of contour in children &lt;8 yr of age, can see physiologic subluxation of C2 on C3, and C3 on C4, but the spinolaminar line is maintained</td>
</tr>
<tr>
<td></td>
<td>Fanning of spinous processes suggests posterior ligamentous disruption</td>
</tr>
<tr>
<td></td>
<td>Widening of facet joints</td>
</tr>
<tr>
<td></td>
<td>Check atlanto-occipital joint</td>
</tr>
<tr>
<td></td>
<td>Line extending inferiorly from clivus should transect odontoid</td>
</tr>
<tr>
<td></td>
<td>Atlanto-axial articulation, widening of predental space (normal: &lt;3 mm in adults, &lt;5 mm in children) indicates injury of C1 or C2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B</th>
<th>Bones</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Height, width, and shape of each vertebral body</td>
</tr>
<tr>
<td></td>
<td>Pedicles, facets, and laminae should appear as one – doubling suggests rotation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C</th>
<th>Cartilage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Intervertebral disc spaces – wedging anteriorly or posteriorly suggests vertebral compression</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S</th>
<th>Soft Tissues</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Widening of retropharyngeal (normal: &lt;7 mm at C1-4, may be wide in children &lt;2 yr on expiration) or retrotracheal spaces (normal: &lt;22 mm at C6-T1, &lt;14 mm in children &lt;5 yr)</td>
</tr>
</tbody>
</table>

Sequelaes of C-Spine Fractures
- see Neurosurgery NS32
- acute phase of SCI
  - spinal shock: absence of all voluntary and reflex activity below level of injury
  - decreased reflexes, no sensation, flaccid paralysis below level of injury, lasting days to months
  - neurogenic shock: loss of vasomotor tone, SNS tone
  - watch for: hypotension (lacking SNS), bradycardia (unopposed PNS), poikilothermia (lacking SNS so no shunting of blood from extremities to core)
  - occurs within 30 min of SCI at level T6 or above, lasting up to 6 wk
  - provide airway support, fluids, atropine (for bradycardia), vasopressors for BP support
  - chronic phase of SCI
  - autonomic dysreflexia: in patients with an SCI at level T6 or above
  - signs and symptoms: pounding headache, nasal congestion, feeling of apprehension or anxiety, visual changes, dangerously increased sBP and dBP
  - common triggers
    - GU causes: bladder distention, urinary tract infection, and kidney stones
    - GI causes: fecal impaction or bowel distension
  - treatment: monitoring and controlling BP, prior to addressing causative issue

Chest Trauma
- two types: those found and managed in 1st survey and those found and managed in 2nd survey

Table 7. Life-Threatening Chest Injuries Found in 1st Survey

<table>
<thead>
<tr>
<th>Physical Exam</th>
<th>Investigations</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Airway Obstruction</td>
<td>Anxiety, stridor, hoarseness, altered mental status, Apnea, cyanosis</td>
<td>Do not wait for ABG to intubate</td>
</tr>
<tr>
<td>Tension Pneumothorax</td>
<td>Respiratory distress, tachycardia, distorted neck veins, cyanosis, asymmetry of chest wall motion, Tracheal deviation away from pneumothorax, Percussion hyperresonance, Unilateral absence of breath sounds</td>
<td>Non-radiographic diagnosis</td>
</tr>
</tbody>
</table>

Trauma to the chest accounts for 50% of trauma deaths
80% of all chest injuries can be managed non-surgically with simple measures such as intubation, chest tubes, and pain control.
Table 7. Life-Threatening Chest Injuries Found in 1st Survey (continued)

<table>
<thead>
<tr>
<th>Physical Exam</th>
<th>Investigations</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Open Pneumothorax</td>
<td>Gunshot or other wound (hole &gt;2/3 tracheal diameter) ± exit wound</td>
<td>Air-tight dressing sealed on 3 sides Chest tube Surgery</td>
</tr>
<tr>
<td>Massive Hemothorax                    &gt;1,500 cc blood loss in chest cavity</td>
<td>Pallor, flat neck veins, shock Unilateral dullness Absent breath sounds, hypotension</td>
<td>Usually only able to do supine CXR – entire lung appears radiopaque as blood spreads out over posterior thoracic cavity Restore blood volume Thoracotomy if &gt;1,500 cc total blood loss ≥200 cc/h continued drainage</td>
</tr>
<tr>
<td>Flail Chest</td>
<td>Paradoxical movement of flail segment Palpable crepitus of ribs Decreased air entry on affected side</td>
<td>ABO: decreased pO2, increased pCO2: CXR: rib fractures, lung contusion</td>
</tr>
<tr>
<td>Cardiac Tamponade</td>
<td>Penetrating wound (usually) Beck’s triad: hypotension, distended neck veins, muffled heart sounds Tachycardia, tachypnea Pulsus paradoxus Kussmaul’s sign (increased JVP with inspiration)</td>
<td>Echocardiogram FAST IV fluids Pericardiocentesis Open thoracotomy</td>
</tr>
</tbody>
</table>

Table 8. Potentially Life-Threatening Chest Injuries Found in 2nd Survey

<table>
<thead>
<tr>
<th>Physical Exam</th>
<th>Investigations</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary Contusion</td>
<td>Blunt trauma to chest Interstitial edema impairs compliance and gas exchange</td>
<td>CXR: areas of opacification of lung within 6 h of trauma Maintain adequate ventilation Monitor with ABG, pulse oximeter, and ECG Chest physiotherapy Positive pressure ventilation if severe</td>
</tr>
<tr>
<td>Ruptured Diaphragm</td>
<td>Blunt trauma to chest or abdomen (e.g. high lap belt in MVC)</td>
<td>CXR: abnormality of diaphragm/lower lung fields/ NG tube placement CT scan and endoscopy; sometimes helpful for diagnosis Laparotomy for diaphragm repair and associated intra-abdominal injuries</td>
</tr>
<tr>
<td>Esophageal Injury</td>
<td>Usually penetrating trauma (pain out of proportion to degree of injury)</td>
<td>CXR: mediastinal air (not always) Esophagram (Gastrograffin®) Flexible esophagoscopy Early repair (within 24 h) improves outcome but all require repair</td>
</tr>
<tr>
<td>Aortic Tear</td>
<td>Sudden high speed deceleration (e.g. MVC, fall, airplane crash), complaints of chest pain, dyspnea, hoarseness (frequently absent) Decreased femoral pulses, differential arm BP (arch tear)</td>
<td>CXR, CT scan, transesophageal echo, aortography (gold standard) Thoracotomy (may treat other severe injuries first)</td>
</tr>
<tr>
<td>Blunt Myocardial Injury (rare)</td>
<td>Blunt trauma to chest (usually in setting of multi-system trauma and therefore difficult to diagnose) Physical exam: overlying injury, e.g. fractures, chest wall contusion</td>
<td>ECG: dysrhythmias, ST changes Patients with a normal ECG and normal hemodynamics never get dysrhythmias O2: Antidysrhythmic agents Analgesia</td>
</tr>
</tbody>
</table>

Other Potentially Life-Threatening Injuries Related to the Chest

Penetrating Neck Trauma
- includes all penetrating trauma to the three zones of the neck
- management: injuries deep to platysma require further evaluation by angiography, contrast CT, or surgery
- do not explore penetrating neck wounds except in the OR
Airway Injuries
- always maintain a high index of suspicion
- larynx
  - history: strangulation, direct blow, blunt trauma, any penetrating injury involving platysma
  - triad: hoarseness, subcutaneous emphysema, palpable fracture
  - other symptoms: hemoptysis, dyspnea, dysphonia
- investigations: CXR, CT scan, arteriography (if penetrating)
- management
  - airway: manage early because of edema
  - C-spine may also be injured, consider mechanism of injury
  - surgical: tracheotomy vs. repair
- trachea/bronchus
  - frequently missed
  - history: deceleration, penetration, increased intra-thoracic pressure, complaints of dyspnea, hemoptysis
  - examination: subcutaneous air, Hamman’s sign (crunching sound synchronous with heart beat)
  - CXR: mediastinal air, persistent pneumothorax or persistent air leak after chest tube inserted for pneumothorax
- management: surgical repair if >1/3 circumference

Abdominal Trauma
- two mechanisms
  - blunt: usually causes solid organ injury (spleen = most common, liver = 2nd)
  - penetrating: usually causes hollow organ injury or liver injury (most common)

BLUNT TRAUMA
- results in two types of hemorrhage: intra-abdominal and retroperitoneal
- adopt high clinical suspicion of bleeding in multi-system trauma

History
- mechanism of injury, SAMPLE history

Physical Exam
- often unreliable in multi-system trauma, wide spectrum of presentations
  - slow blood loss not immediately apparent
  - tachycardia, tachypnea, oliguria, febrile, hypotension
  - other injuries may mask symptoms
  - serial examinations are required
- abdomen
  - inspect: contusions, abrasions, seat-belt sign, distention
  - auscultate: bruits, bowel sounds
  - palpate: tenderness, rebound tenderness, rigidity, guarding
  - DRE: rectal tone, blood, bone fragments, prostate location
  - placement of NG, Foley catheter should be considered part of the abdominal exam
- other systems to assess: cardiovascular, respiratory (possibility of diaphragm rupture), genitourinary, pelvis, back/neurological

Investigations
- labs: CBC, electrolytes, coagulation, cross and type, glucose, Cr, CK, lipase, amylase, liver enzymes, ABG, blood EtOH, β-hCG, U/A, toxicology screen

Table 9. Imaging in Abdominal Trauma

<table>
<thead>
<tr>
<th>Imaging</th>
<th>Strengths</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>X-Ray</td>
<td>Chest (looking for free air under diaphragm, diaphragmatic hernia, air-fluid levels), pelvis, cervical, thoracic, lumbar spines</td>
<td>Soft tissue not well visualized</td>
</tr>
<tr>
<td>CT Scan</td>
<td>Most specific test</td>
<td>Radiation exposure 20x more than x-ray</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cannot use if hemodynamic instability</td>
</tr>
<tr>
<td>Diagnostic Peritoneal Lavage (rarely used)</td>
<td>Most sensitive test</td>
<td>Cannot test for retroperitoneal bleed or diaphragmatic rupture</td>
</tr>
<tr>
<td></td>
<td>Tests for intra-peritoneal bleed</td>
<td>Cannot distinguish lethal from trivial bleed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Results can take up to 1 h</td>
</tr>
<tr>
<td>Ultrasound: FAST</td>
<td>Identifies presence/absence of free fluid in peritoneal cavity</td>
<td>NOT used to identify specific organ injuries</td>
</tr>
<tr>
<td></td>
<td>RAPID exam: less than 5 min</td>
<td>If patient has ascites, FAST will be</td>
</tr>
<tr>
<td></td>
<td>Can also examine pericardium and pleural cavities</td>
<td>falsely positive</td>
</tr>
</tbody>
</table>

Table of Zones of the Neck

<table>
<thead>
<tr>
<th>Zone I</th>
<th>Zone II</th>
<th>Zone III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Base of neck (thoracic inlet to cricoid cartilage)</td>
<td>Midportion of neck (cricoid to the angle of mandible)</td>
<td>Superior aspect of neck</td>
</tr>
</tbody>
</table>

Figure 6. Zones of the neck in trauma

Seatbelt Injuries May Cause
- Retroperitoneal duodenal trauma
- Intraparenchymal bowel transection
- Mesenteric injury
- L-spine injury

Indications for Foley and NG Tube in Abdominal Trauma
Foley catheter: unconscious or patient with multiple injuries who cannot void spontaneously
NG tube: used to decompress the stomach and proximal small bowel
Contraindications: facial fractures or basal skull fractures suspected

Criteria for Positive Lavage
- >10 cc gross blood
- Bile, bacteria, foreign material
- RBC count >100,000 x 106/L
- WBC >500 x 106/L
- Amylase >175 IU
imaging must be done if
- equivocal abdominal examination, altered sensorium, or distracting injuries (e.g. head trauma, spinal cord injury resulting in abdominal anesthesia)
- unexplained shock/hypotension
- patients have multiple traumas and must undergo general anesthesia for orthopedic, neurosurgical, or other injuries
- fractures of lower ribs, pelvis, spine
- positive FAST

**Management**
- general: ABCs, fluid resuscitation, and stabilization
- surgical: watchful waiting vs. laparotomy
- solid organ injuries: decision based on hemodynamic stability, not the specific injuries
- hemodynamically unstable or persistently high transfusion requirements: laparotomy
- hollow organ injuries: laparotomy
- even if low suspicion of injury: admit and observe for 24 h

**PENETRATING TRAUMA**
- high risk of gastrointestinal perforation and sepsis
- history: size of blade, calibre/distance from gun, route of entry
- local wound exploration under direct vision may determine lack of peritoneal penetration (not reliable in inexperienced hands) with the following exceptions:
  - thoracoabdominal region (may cause pneumothorax)
  - back or flanks (muscles too thick)

**Management**
- general: ABCs, fluid resuscitation, and stabilization
- gunshot wounds always require laparotomy

### Genitourinary Tract Injuries

- see Urology, U32

**Etiology**
- blunt trauma: often associated with pelvic fractures
  - upper tract
    - renal
      - contusions (minor injury – parenchymal ecchymoses with intact renal capsule)
      - parenchymal tears/laceration: non-communicating (hematoma) vs. communicating (urine extravasation, hematuria)
    - ureter: rare, at uretero-pelvic junction
  - lower tract
    - bladder
      - extraperitoneal rupture of bladder from pelvic fracture fragments
      - intraperitoneal rupture of bladder from trauma and full bladder
    - urethra
      - posterior urethral injuries: MVCs, falls, pelvic fractures
      - anterior urethral injuries: blunt trauma to perineum, straddle injuries/direct strikes
  - external genitalia
  - penetrating trauma
    - damage to: kidney, bladder, ureter (rare), external genitalia
  - acceleration/deceleration injury
    - renal pedicle injury: high mortality rate (laceration and thrombosis of renal artery, renal vein, and their branches)
  - iatrogenic
    - ureter and urethra (from instrumentation)

**History**
- mechanism of injury
- hematuria (microscopic or gross), blood on underwear
- dysuria, urinary retention
- history of hypotension

**Physical Exam**
- abdominal pain, flank pain, CVA tenderness, upper quadrant mass, perineal lacerations
- DRE: sphincter tone, position of prostate, presence of blood
- scrotum: ecchymoses, lacerations, testicular disruption, hematomas
- bimanual exam, speculum exam
- extraperitoneal bladder rupture: pelvic instability, suprapubic tenderness from mass of urine or extravasated blood
- intraperitoneal bladder rupture: acute abdomen
- urethral injury: perineal ecchymosis, scrotal hematoma, blood at penile meatus, high riding prostate, pelvic fractures
**Investigations**
- urethra: retrograde urethrography
- bladder: U/A, CT scan, urethrogram ± retrograde cystoscopy ± cystogram (distended bladder + post-void)
- ureter: retrograde ureterogram
- renal: CT scan (best, if hemodynamically stable), intravenous pyelogram

**Management**
- urology consult
- renal
  - minor injuries: conservative management
  - bedrest, hydration, analgesia, antibiotics
- major injuries: admit
  - conservative management with frequent reassessments, serial U/A ± re-imaging
  - surgical repair (exploration, nephrectomy): hemodynamically unstable or continuing to bleed
  - >48 h, major urine extravasation, renal pedicle injury, all penetrating wounds and major lacerations, infections, renal artery thrombosis
- ureter
  - ureteroureterostomy
- bladder
  - extraperitoneal
    - minor rupture: Foley drainage x 10-14 d
  - major rupture: surgical repair
- intraperitoneal
  - drain abdomen and surgical repair
- urethra
  - anterior: conservative, if cannot void, Foley or suprapubic cystostomy and antibiotics
  - posterior: suprapubic cystostomy (avoid catheterization) ± surgical repair

---

**Orthopedic Injuries**

- see Orthopedics (see Shoulder OR10, Knee OR31, Wrist OR20, Ankle OR27)

**Goals of ED Treatment**
- diagnose potentially life/limb threatening injuries
- reduce and immobilize fractures (cast/splint) as appropriate
- provide adequate pain relief
- arrange proper follow-up if necessary

**History**
- use SAMPLE
- mechanism of injury may be very important

**Physical Exam**
- look (inspection): “SEADS” swelling, erythema, atrophy, deformity, and skin changes (e.g. bruises)
- feel (palpation): all joints/bones for local tenderness, swelling, warmth, crepitus, joint effusions, and subtle deformity
- move: joints affected plus those above and below injury – active ROM preferred to passive
- neurovascular status: distal to injury (before and after reduction)

---

**LIFE- AND LIMB-THREATENING INJURIES**

**Table 10. Life- and Limb-Threatening Orthopedic Injuries**

<table>
<thead>
<tr>
<th>Life-Threatening Injuries (usually blood loss)</th>
<th>Limb-Threatening Injuries (usually interruption of blood supply)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major pelvic fractures</td>
<td>Fracture/dislocation of ankle (talar AVN)</td>
</tr>
<tr>
<td>Traumatic amputations</td>
<td>Crush injuries</td>
</tr>
<tr>
<td>Massive long bone injuries and associated fat emboli syndrome</td>
<td>Compartment syndrome</td>
</tr>
<tr>
<td>Vascular injury proximal to knee/elbow</td>
<td>Dislocations of knee/hip</td>
</tr>
<tr>
<td></td>
<td>Fractures above knee/elbow</td>
</tr>
</tbody>
</table>

**Open Fractures**
- communication between fracture site and external surface of skin – increased risk of osteomyelitis
- remove gross debris, irrigate, cover with sterile dressing – formal irrigation and debridement often done in the OR
- control bleeding with pressure (no clamping)
- splint
- antibiotics (1st generation cephalosporin and aminoglycoside) and tetanus prophylaxis
- standard of care is to secure definitive surgical management within 6 h, time to surgery may vary from case-to-case
Vascular Injuries
- realign limb/apply longitudinal traction and reassess pulses (e.g. Doppler probe)
- surgical consult
- direct pressure if external bleeding

Compartment Syndrome
- when the intracompartmental pressure within an anatomical area (e.g. forearm or lower leg) exceeds the capillary perfusion pressure, eventually leading to muscle/nerve necrosis
- clinical diagnosis: maintain a high index of suspicion
  - pain out of proportion to the injury
  - pain worse with passive stretch
  - tense compartment
  - look for “the 6 Ps” (note: radial pulse pressure is 120/80 mmHg while capillary perfusion pressure is 30 mmHg, seeing any of the 6ps indicates advanced compartment syndrome, therefore do not wait for these signs to diagnose and treat)
- requires prompt decompression: remove constrictive casts, dressings; emergent fasciotomy may be needed

UPPER EXTREMITY INJURIES
- anterior shoulder dislocation
  - axillary nerve (lateral aspect of shoulder) and musculocutaneous nerve (extensor aspect of forearm) at risk
  - seen on lateral view: humeral head anterior to glenoid
  - reduce (traction, scapular manipulation), immobilize in internal rotation, repeat x-ray, out-patient follow-up with orthopedics
  - with forceful injury, look for fracture
- Colles’ fracture
  - distal radius fracture with dorsal displacement from “Fall on Outstretched Hand” (FOOSH)
  - AP film: shortening, radial deviation, radial displacement
  - lateral film: dorsal displacement, volar angulation
  - reduce, immobilize with splint, out-patient follow-up with orthopedics or immediate orthopedic referral if complicated fracture
  - if involvement of articular surface, emergent orthopedic referral
- scaphoid fracture
  - tenderness in anatomical snuff box, pain on scaphoid tubercle, pain on axial loading of thumb
  - negative x-ray: thumb spica splint, repeat x-ray in 1 wk ± CT scan/bone scan
  - positive x-ray: thumb spica splint x 6-8 wk, repeat x-ray in 2 wk
  - risk of AVN of scaphoid if not immobilized
  - outpatient orthopedics follow-up

LOWER EXTREMITY INJURIES
- ankle and foot fractures
  - see Ottawa Ankle and Foot Rules
- knee injuries
  - see Ottawa Knee Rules
  - avulsion of the base of 5th metatarsal
    - occurs with inversion injury
    - supportive tensor or below knee walking cast for 3 wk
  - calcaneal fracture
    - associated with fall from height
    - associated injuries may involve ankles, knees, hips, pelvis, lumbar spine

A knee x-ray examination is required only for acute injury patients with one or more of:
- Age 55 yr or older
- Tenderness at head of fibula
- Isolated tenderness of patella
- Inability to flex to 90°
- Inability to bear weight both immediately and in the ED (four steps)
Wound Management

Goals of ED Treatment
- identify injuries and stop any active bleeding – direct pressure
- manage pain
- wound examination and exploration (history and physical)
- cleansing ± antibiotic and tetanus prophylaxis
- closure and dressing

Tetanus Prophylaxis
- both tetanus toxoid (Td) and immunoglobulin (TIG) are safe in pregnancy

Table 11. Guidelines for Tetanus Prophylaxis for Wounds

<table>
<thead>
<tr>
<th>Vaccination History</th>
<th>Clean, minor wounds</th>
<th>All other wounds*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unknown or fewer than 3 doses</td>
<td>Tdap or Td†</td>
<td>TIG</td>
</tr>
<tr>
<td>3 or more doses</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

*Such as, but not limited to, wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; avulsions; and wounds resulting from missiles, crushing, burns, and frostbite.
†Tdap is preferred to Td for adults who have never received Tdap. Single antigen tetanus toxoid (TT) is no longer available in the United States.
‡Yes, if more than ten years since the last tetanus toxoid-containing vaccine dose.
§Yes, if more than five years since the last tetanus toxoid-containing vaccine dose.


Bruises
- non-palpable = ecchymosis
- palpable collection (not swelling) = hematoma following blunt trauma
- assess for coagulopathy (e.g. liver disease), anticoagulant use

Abrasions
- partial to full thickness break in skin
- management
  - clean thoroughly with brush to prevent foreign body impregnation ± local anesthetic antiseptic ointment (Polysporin® or Vaseline®) for 7 d for facial and complex abrasions
  - tetanus prophylaxis

Lacerations
- see Plastic Surgery, PL8
- consider every structure deep to a laceration injured until proven otherwise
- in hand injury patients, include the following in history: handedness, occupation, mechanism of injury, previous history of injury

Acute Treatment of Contusions
RICE
- Rest
- Ice
- Compression
- Elevation

High Risk Factors for Infection
Wound Factors
- Puncture wounds
- Crush injuries
- Wounds >12 h old
- Hand or foot wounds
- Immunocompromised

Patient Factors
- Age >50 yr
- Prosthetic joints or valves (risk of endocarditis)

Suture Use and Duration

<table>
<thead>
<tr>
<th>Suture to:</th>
<th>Close with</th>
<th>Approx. Duration (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Face</td>
<td>Non-absorbable Suture</td>
<td>5</td>
</tr>
<tr>
<td>Nat.Joint</td>
<td>4-0</td>
<td>7</td>
</tr>
<tr>
<td>Joint</td>
<td>3-0</td>
<td>10</td>
</tr>
<tr>
<td>Scalp</td>
<td>4-0</td>
<td>7</td>
</tr>
<tr>
<td>Mucous Membrane</td>
<td>absorbable (vicryl)/N/A</td>
<td></td>
</tr>
</tbody>
</table>

N.B. Patients on steroid therapy may need sutures for longer periods of time
• physical exam
  ■ think about underlying anatomy
  ■ examine tendon function actively against resistance and neurovascular status distally
  ■ clean and explore under local anesthetic; look for partial tendon injuries
  ■ x-ray or U/S wounds if a foreign body is suspected (e.g. shattered glass) and not found when exploring wound (remember: not all foreign bodies are radioopaque), or if suspect intra-articular involvement
• management
  ■ disinfect skin/use sterile techniques
  ■ irrigate copiously with normal saline
  ■ analgesia ± anesthetics
  ■ maximum dose of lidocaine
    • 7 mg/kg with epinephrine
    • 5 mg/kg without epinephrine
  ■ in children, topical anesthetics such as LLET (lidocaine, epinephrine, and tetracaine), and in selected cases a short-acting benzodiazepine (midazolam or other agents) for sedation and amnesia are useful
  ■ secure hemostasis
  ■ evacuate hematomas, debride non-viable tissue, remove hair and foreign bodies
  ■ ± prophylactic antibiotics (consider for animal/human bites, intra-oral lesion, or puncture wounds to the foot)
  ■ suture unless: delayed presentation (>6-8 h), puncture wound, mammalian bite, crush injury, or retained foreign body
  ■ take into account patient and wound factors when considering suturing
  ■ advise patient when to have sutures removed
  ■ cellulitis and necrotizing fasciitis (see Plastic Surgery, PL15)

### Approach to Common ED Presentations

## Abdominal Pain

### Table 12. Selected Differential Diagnosis of Abdominal Pain

<table>
<thead>
<tr>
<th></th>
<th>Emergent</th>
<th>Usually Less Emergent</th>
</tr>
</thead>
<tbody>
<tr>
<td>GI</td>
<td>Perforated viscus, bowel obstruction, ischemic bowel, appendicitis, strangulated herna, IBD flare, esophageal rupture, peptic ulcer disease</td>
<td>Diverticulitis, gastroenteritis, GERD, esophagitis, gastritis, IBS</td>
</tr>
<tr>
<td>Hepatobiliary</td>
<td>Hepatic/splenic injury, pancreatitis, cholangitis, spontaneous bacterial peritonitis</td>
<td>Biliary colic, cholecystitis, hepatitis</td>
</tr>
<tr>
<td>Genital</td>
<td>Female: Ovarian torsion, PID, ectopic pregnancy Male: Testicular torsion</td>
<td>Female: tubo-ovarian abscess, ovarian cyst, salpingitis, endometriosis Male: epididymitis, prostateitis</td>
</tr>
<tr>
<td>Urinary</td>
<td>Pyelonephritis</td>
<td>Renal colic, cystitis</td>
</tr>
<tr>
<td>CVS</td>
<td>MI, aortic dissection, AAA</td>
<td>Pericarditis</td>
</tr>
<tr>
<td>Respiratory</td>
<td>PE, empyema</td>
<td>Pneumonia</td>
</tr>
<tr>
<td>Metabolic</td>
<td>DKA, sickle cell crisis, toxin, Addisonian crisis</td>
<td>Lead poisoning, porphyria</td>
</tr>
<tr>
<td>Other</td>
<td>Significant trauma, acute angle closure glaucoma</td>
<td>Abdominal wall injury, herpes zoster, psychiatric, abscess, herna, mesenteric adenitis</td>
</tr>
</tbody>
</table>

• differential can be focused anatomically by location of pain: RUQ, LUQ, RLQ, LLQ, epigastric, periumbilical, diffuse

### History

• pain: OPQRST
• review symptoms from GU, gynecological, GI, respiratory, and CV systems
• abdominal trauma/surgeries most recent colonoscopy

### Physical Exam

• vitals, abdominal (including DRE, CVA tenderness), pelvic/genital, respiratory, and cardiac exams as indicated by history

### Investigations

• ABCs, do not delay management and consultation if patient unstable
• CBC, electrolytes, glucose, BUN/Cr, U/A ± liver enzymes, LFTs, lipase, β-hCG, ECG, troponins, ± VBG/lactate
• AXR: look for calcifications, free air, gas pattern, air fluid levels
• CXR upright: look for pneumoperitoneum (free air under diaphragm), lung disease
• U/S: biliary tract, ectopic pregnancy, AAA, free fluid
• CT: trauma, AAA, pancreatitis, nephro-/uroolithiasis, appendicitis, and diverticulitis

Early wound irrigation and debridement are the most important factors in decreasing infection risk

Where NOT to use local anesthetic with epinephrine:
- Ears, Nose, Fingers, Toes, and Penis

Alternatives to Sutures
- Tissue glue
- Steristrips®
- Staples

Be vigilant: very young, elderly, alcoholics, immunosuppressed patients often present atypically
Old age, pregnancy (T3), and chronic corticosteroid use can blunt peritoneal findings, so have an increased level of suspicion for an intra-abdominal process in these individuals

Unstable patients should not be sent for imaging

If elevated AST and ALT
Think hepatocellular injury
AST > ALT: alcohol-related
ALT > AST: viral, drug, toxin

If elevated ALP and GGT
Think biliary tree obstruction
Management
• NPO, IV, NG tube, analgesics, consider antibiotics and anti-emetics
• growing evidence that small amounts of opioid analgesics improve diagnostic accuracy of physical exam of surgical abdomen
• consult as necessary: general surgery, vascular surgery, gynecology, etc.

Disposition
• admission: surgical abdomen, workup of significant abnormal findings, need for IV antibiotics or pain control
• discharge: patients with a negative lab and imaging workup who improve clinically during their stay; instruct the patient to return if severe pain, fever, or persistent vomiting develops

Acute Pelvic Pain

Etiology
• gynecological
  - second most common gynecological complaint (after vaginal bleeding)
  - ovaries: ruptured ovarian cysts (most common cause of pelvic pain), ovarian abscess, ovarian torsion (rare, 50% will have ovarian mass)
  - fallopian tubes: salpingitis, tubal abscess, hydrosalpinx
  - uterus: leiomyomas (uterine fibroids) – especially with torsion of a pedunculated fibroid or in a pregnant patient (degeneration), PID, endometriosis
  - other: ectopic pregnancy (ruptured/expanding/leaking), spontaneous abortion (threatened or incomplete), endometriosis and dysmenorrhea, sexual or physical abuse
• non-gynecological (see causes of lower abdominal pain above)

History and Physical Exam
• pain: OPQRST
• associated symptoms: vaginal bleeding, discharge, dyspareunia, bowel or bladder symptoms
• pregnancy and sexual history
• vitals
gynecological exam: assess for cervical motion tenderness/"chandelier sign" (suggests PID)
• abdominal exam

Investigations
• β-hCG for all women of childbearing age
• CBC and differential, electrolytes, glucose, Cr, BUN, G&S, PTT/INR
• vaginal and cervical swabs for C&S during physical exam
• pelvic and abdominal U/S: evaluate adnexa, thickness of endometrium, pregnancy, free fluid or masses in the pelvis
• Doppler flow studies for ovarian torsion

Management
general: analgesia, determine if admission and consults are needed
• specific
  - ovarian cysts
    • unruptured or ruptured and hemodynamically stable: analgesia and follow-up
    • ruptured with significant hemoperitoneum: may require surgery
  - ovarian torsion: surgical detorsion or removal of ovary
  - uncomplicated leiomyomas, endometriosis, and secondary dysmenorrhea can usually be treated on an outpatient basis, discharge with gynecology follow-up
  - PID: requires broad spectrum antibiotics

Disposition
• referral: gynecological or obstetrical causes requiring surgical intervention, requiring admission, or oncological in nature
• admission: patients requiring surgery, IV antibiotics/pain management
• discharge: negative workup and resolving symptoms; give clear instructions for appropriate follow-up

Altered Level of Consciousness

Definitions
• altered mental status: collective, non-specific term referring to change in cognitive function, behaviour, or attentiveness, including:
  - delirium (see Psychiatry, PS19)
  - dementia (see Psychiatry, PS20)
  - lethargy: state of decreased awareness and alertness (patient may appear wakeful)
  - stupor: unresponsiveness but rousable
  - coma: a sleep-like state, not rousable to consciousness
MANAGEMENT OF ALTERED LOC

History
- obtain collateral from family, friends, police, paramedics, old chart, MedicAlert\textsuperscript{t} bracelet, etc.
- onset and progression
  - antecedent trauma, seizure activity, fever
  - abrupt onset suggests CNS hemorrhage/ischemia or cardiac cause
  - progression over hours to days suggests progressive CNS lesion or toxic/metabolic cause
- determine patient's baseline LOC
- past medical history (e.g. similar episode, depression, overdose)

Physical Exam
- ABCs, vitals including temperature, cardiac, respiratory, abdominal exams
- complete neurological exam; in particular, examination of the eyes ("PEARL" pupils equal and reactive to light)
  - use the GCS to evaluate LOC (see Initial Patient Assessment/Management, ER2)

Investigations
- blood work
  - rapid blood sugar, CBC, electrolytes, Cr, BUN, LFTs, glucose, serum osmolality, VBG, PT/PTT/INR, troponins
  - serum EtOH, acetaminophen, and salicylate levels
- imaging
  - CXR, CT head
- other tests
  - ECG, U/A, UTox

Diagnosis
- administer appropriate universal antidotes
  - thiamine 100 mg IV if history of EtOH or patient looks malnourished
  - one ampule D50W IV if low blood sugar on finger-prick
  - naloxone 0.4-2 mg IV or IM if opiate overdose suspected
- distinguish between structural and toxic/metabolic coma
  - structural coma
    - pupils, extraocular movements, and motor findings, if present, are usually asymmetric
    - look for focal or lateralizing abnormalities
  - toxic/metabolic coma
    - dysfunction at lower levels of the brainstem (e.g. caloric unresponsiveness)
    - respiratory depression in association with an intact upper brainstem (e.g. equal and reactive pupils; see exceptions in Table 13)
    - extraocular movements and motor findings are symmetric or absent
- essential to re-examine frequently because status can change rapidly
- diagnosis may become apparent only with the passage of time
  - delayed deficit after head trauma suggestive of epidural hematoma (characteristic "lucid interval")
Table 13. Toxic-Metabolic Causes of Fixed Pupils

<table>
<thead>
<tr>
<th>Dilated</th>
<th>Dilated to Normal</th>
<th>Constricted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anoxia</td>
<td>Hypothermia</td>
<td>Cholinergic agents (e.g. organophosphates)</td>
</tr>
<tr>
<td>Anticholinergic agents (e.g. atropine, TCAs)</td>
<td>Barbiturates</td>
<td>Opiates (e.g. heroin), except meperidine</td>
</tr>
<tr>
<td>Methanol (rare)</td>
<td>Antipsychotics</td>
<td></td>
</tr>
<tr>
<td>Cocaine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opioid withdrawal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphetamines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hallucinogens</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Disposition
- admission: if ongoing decreased LOC, admit to service based on tentative diagnosis, or transfer patient if appropriate level of care not available
- discharge: readily reversible alteration of LOC; ensure adequate follow-up care available

Chest Pain

Table 14. Differential Diagnosis for Chest Pain

<table>
<thead>
<tr>
<th>Emergent</th>
<th>Usually Less Emergent</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>MI, unstable angina, aortic dissection, cardiac tamponade, arrhythmia</td>
</tr>
<tr>
<td>Respirology</td>
<td>PE, pneumothorax</td>
</tr>
<tr>
<td>GI</td>
<td>Esophageal rupture, pneumomediastinum</td>
</tr>
<tr>
<td>MSK</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

History and Physical Exam
- OPQRST, previous episodes and change in pattern
- cardiac risk factors (HTN, DM, dyslipidemia, smoking, FHx)
- vitals, cardiac, respiratory, peripheral vascular, abdominal exams

Investigations
- CBC, electrolytes, Cr, BUN, glucose, PTT/INR
- ECG: always compare with previous; may be normal in up to 50% of PE and acute MI
- CXR: compare with previous

Management and Disposition
- ABCs, O2, cardiac monitors, IV access
- treat underlying cause and involve consultants as necessary
- consider further observation/monitoring if unclear diagnosis or risk of dysrhythmia
- discharge: patients with a low probability of life-threatening illness due to resolving symptoms and negative workup; arrange follow-up and instruct to return if SOB or increased chest pain develops

Life-Threatening Causes of Chest Pain
- PET MAP
  - PE
  - Esophageal rupture
  - Tamponade
  - MI/angina
  - Aortic dissection
  - Pneumothorax

Imaging is necessary for all suspected aortic dissections, regardless of BP

Angina Characteristics
1. Retrosternal location
2. Provoked by exertion
3. Relieved by rest or nitroglycerin

Risk for CAD
- 3/3 = “typical angina” - high risk
- 2/3 = intermediate risk for women >50 yr, all men
- 1/3 = Intermediate risk in men >40 yr, women >60 yr
<table>
<thead>
<tr>
<th>Chest Pain Diagnoses</th>
<th>Classic History</th>
<th>Classic Findings</th>
<th>Diagnostic Investigations</th>
<th>Management and Disposition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute Coronary Syndrome</strong></td>
<td>New or worsening pattern of retrosternal squeezing/pain,</td>
<td>Nyne or worsened murmur, hypotension, diaphoresis, pulmonary edema</td>
<td>ECG: ischemia (15-lead if hypotensive, AV node involvement or inferior MI), serial troponin I (sensitive 6-8 hr after onset), CK-MB, CK</td>
<td>ABCs, aspirin, anticoagulation and emergent cardiology consult to consider percutaneous intervention or thrombolytic</td>
</tr>
<tr>
<td><strong>Pulmonary Embolism</strong></td>
<td>Pleuritic chest pain (75%), dyspnea; risk factors for venous thromboembolism</td>
<td>Tachycardia, hypoxemia; evidence of DVT</td>
<td>Wells’ criteria: D-dimer, CT pulmonary angiograms®, V/Q scan; leg Doppler, CXR</td>
<td>ABCs, anticoagulation; consider airway management and thrombolysis if respiratory failure</td>
</tr>
<tr>
<td><strong>Acute Pericarditis</strong></td>
<td>Viral prodrome, anterior precordial pain, pleuritic, relieved by sitting up and leaning forward</td>
<td>Trichaphic friction rub</td>
<td>ECG: sinus tachycardia, diffuse ST elevation, PR depression in II, III, AVF and V4-V6; reciprocal PR elevation and ST depression in aVR &gt; V1; echocardiography</td>
<td>ABCs, rule out MI, high dose NSAIDs +/- colchicine; consult if chronic/recurrent or non-viral cause (e.g. SLE, renal failure, requires surgery)</td>
</tr>
<tr>
<td><strong>Pneumothorax</strong></td>
<td>Trauma or spontaneous pleuritic chest pain often in tall, thin, young male athlete</td>
<td>Hemithorax with decreased/absent breath sounds, hyper-resonance; deviated trachea and hemodynamic compromise</td>
<td>Clinical diagnosis CXR: PA, lateral, inspiratory views — lung edge, loss of lung markings, tracheal shift; deep sulcus sign on supine view</td>
<td>ABCs, if unstable, needle to 2nd ICS at MCL; urgent surgical consult / thoracostomy 4th ICS and chest tube</td>
</tr>
<tr>
<td><strong>Aortic Dissection</strong></td>
<td>Sudden severe tearing retrosternal or midscapular pain ± focal pain/neurologic loss in extremities in context of HTN</td>
<td>HTN: systolic BP difference &gt; 20 mmHg or pulse deficit between arms; aortic regurgitant murmur</td>
<td>CT angiography; Beck’s triad - hypotension, elevated JVP, muffled heart sounds; tachycardia, pulsus paradoxus &gt; 10 mmHg</td>
<td>ABCs, reduce BP and HR; classify type A (ascending aorta, urgent surgery) vs. B (not ascending aorta, medical) on CT angiography and urgent cardiology consult</td>
</tr>
<tr>
<td><strong>Cardiac Tamponade</strong></td>
<td>Dyspnea, cold extremities, ± chest pain; often a recent cardiac intervention or symptoms of malignancy, connective tissue disease</td>
<td>Beck’s triad - hypotension, elevated JVP, muffled heart sounds; tachycardia, pulsus paradoxus &gt; 10 mmHg</td>
<td>Clinical diagnosis CXR: may show cardiomegaly, evidence of trauma</td>
<td>ABCs, cardiac surgery or cardiology consult, pericardiocentesis if unstable, treat underlying cause</td>
</tr>
<tr>
<td><strong>Esophageal Rupture</strong></td>
<td>Sudden onset severe pain after endoscopy, forcible vomiting, labour, or convulsion, or in context of corrosive injury or cancer</td>
<td>Subacute or chronic esophagitis, compatible with sepsis</td>
<td>CXR: pleural effusion (75%), pneumomediastinum; CT or water soluble contrast esophagogram</td>
<td>ABCs, early antibiotics, resuscitation, thoracics consult, NPO, consider chest tube</td>
</tr>
<tr>
<td><strong>Esophagitis or GERD</strong></td>
<td>Frequent heartburn, acid reflux, dysphagia, relief with antacids</td>
<td>Oral thrush or ulcers (rare)</td>
<td>None acutely</td>
<td>ABCs, PPI, avoid ESH®, tobacco, trigger foods</td>
</tr>
<tr>
<td><strong>Herpes Zoster</strong></td>
<td>Abnormal skin sensation – itching/tingling/pain – preceding rash by 1-5 d</td>
<td>None if early; maculopapular rash developing into vesicles and pustules that crust</td>
<td>Clinical diagnosis; direct immunofluorescence assay</td>
<td>ABCs, anti-virals, analgesia ± steroids, dressing; 1/0 oculomotor involvement/refer if necessary</td>
</tr>
<tr>
<td><strong>MSK</strong></td>
<td>History of injury</td>
<td>Reproduction of symptoms with movement or palpation (not specific – present in 25% of MI)</td>
<td>MSK injury or fracture on X-rays</td>
<td>ABCs, NSAIDs, rest, orthopedics consultation for fractures</td>
</tr>
<tr>
<td><strong>Anxiety</strong></td>
<td>Symptoms of anxiety, depression, history of psychiatric disorder; may coexist with physical disease</td>
<td>Tachycardia, diaphoresis, tremor</td>
<td>Diagnosis of exclusion</td>
<td>ABCs, arrange social supports, rule out suicidality and consider psychiatry consult</td>
</tr>
</tbody>
</table>

**Table 15. Comparison of Chest Pain Diagnoses**

- **ACLS** more likely to be atypical in females, diabetics, and > 80 yr. Anginal equivalents include dyspnea, diaphoresis, fatigue, non-retrosternal pain
- **Signs of PE on CXR**
  
  - Westermark’s sign: abrupt tapering of a vessel on chest film
  - Hampton’s hump: a wedge-shaped infiltrate that abuts the pleura
  - Effusion, pleural effusion, or infiltrates 50% normal

- **It is important to look for reciprocal changes in STEMI in order to differentiate from pericarditis (diffuse elevations)**

- **Tracheal deviation is away from tension or towards non-tension pneumothorax**

**Addition of Clopidogrel to Aspirin® and fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation**

*NEJM 2005;352:1179-1191*

**Purpose**: To assess the benefit of adding clopidogrel to Aspirin® and fibrinolytic therapy in ST-elevation MI.

**Study Characteristics**: Double-blind, RCT following intention-to-treat analysis, with 3,491 patients and clinical follow-up at 30 d.

**Participants**: Individuals presenting within 12 h of onset of ST-elevation MI (mean age 57, 80.3% male, 50.3% smokers, 9.1% previous MI). Those presenting after 12 h, age > 75, or with previous CABG, were excluded.

**Intervention**: Clopidogrel (300 mg loading dose followed by 75 mg OD until day of angiogram) or placebo, in addition to Aspirin®, a fibrinolytic agent, and heparin when appropriate.

**Primary Outcome**: Composite of occluded infarct-related artery on angiography (thrombolysis in MI flow grade 0 or 1), or death or recurrent MI prior to angiography.

**Results**: Ratio of primary end point was 21.1% in the placebo group and 15.0% in the clopidogrel group (95% CI 24-47%). Among the individual components of the primary end point, clopidogrel had a significant effect on the rate of an occluded infarct-related artery and the rate of recurrent MI, but no effect on the rate of death from any cause. At 30 d clinical follow-up, there was no difference in rate of death from cardiovascular causes, a significant reduction in the odds of recurrent MI, and a non-significant reduction in recurrent ischemia with need for urgent revascularization. The rates of major bleeding and intracranial hemorrhage were similar between the two groups.

**Conclusion**: Addition of clopidogrel improves the patency rate of infarct-related arteries and reduces ischemic complications, both of which are associated with improved long-term survival after MI. The trial was not powered to detect a survival benefit, and none was seen.
Table 16. Common Life-Threatening ECG Changes

<table>
<thead>
<tr>
<th>Pathology</th>
<th>ECG Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dysrhythmia</strong></td>
<td></td>
</tr>
<tr>
<td>a) Torsades de pointes</td>
<td>Ventricular complexes in upward-pointing and downward-pointing continuum (250-350 bpm)</td>
</tr>
<tr>
<td>b) Ventricular tachycardia</td>
<td>6 or more consecutive premature ventricular beats (150-250 bpm)</td>
</tr>
<tr>
<td>c) Ventricular flutter</td>
<td>Smooth sine wave pattern of similar amplitude (250-350 bpm)</td>
</tr>
<tr>
<td>d) Ventricular fibrillation</td>
<td>Erratic ECG tracing, no identifiable waves</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conduction</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>a) 2nd degree heart block (Mobitz Type II)</td>
<td>PR interval stable, some QRSs dropped</td>
</tr>
<tr>
<td>b) 3rd degree heart block</td>
<td>Total AV dissociation, but stable P-P and R-R intervals</td>
</tr>
<tr>
<td>c) Left bundle branch block</td>
<td>Prolonged QRS complex (&gt;0.12 s)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ischemia</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>a) STEMI</td>
<td>ST elevation in leads associated with injured area of heart and reciprocal lead changes (depression)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Metabolic</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>a) Hyperkalemia</td>
<td>Tall T waves</td>
</tr>
<tr>
<td>b) Hypokalemia</td>
<td>P wave flattening</td>
</tr>
<tr>
<td></td>
<td>QRS complex widening and flattening</td>
</tr>
<tr>
<td></td>
<td>U waves appear</td>
</tr>
<tr>
<td></td>
<td>Flattened T waves</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Digitalis Toxicity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>a) Brugada</td>
<td>RBBB with ST elevation in V1, V2, and V3</td>
</tr>
<tr>
<td>b) Wellsens</td>
<td>Susceptible to deadly dysrhythmias, including VFib</td>
</tr>
<tr>
<td>c) Long QT syndrome</td>
<td>QT interval longer than ½ of cardiac cycle</td>
</tr>
</tbody>
</table>

**Syndromes**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>a) Subarachnoid hemorrhage (SAH) (see Neurosurgery, NS17)</td>
<td>Sudden onset, “worst headache of life” maximum intensity within minutes</td>
</tr>
<tr>
<td>b) Increased ICP</td>
<td>Increased ICP</td>
</tr>
<tr>
<td>c) Difficult to interpret, new LBBB is considered STEMI equivalent</td>
<td></td>
</tr>
</tbody>
</table>

**Immediate Treatment of Acute M**

- **BEMOAN**
  - β-blocker
  - Enoxaparin
  - Morphine
  - Oxygen
  - ASA
  - Nitroglycerin

**Headache**

- **See Neurology, N44**

**Etiology**

- **The common**
  - Common migraine (without aura)/classic migraine (with aura)
    - Common: unilateral, throbbing, aggravated by activity, moderate/severe, N/V, photo-/ phonophobia
    - Classic: varied aura symptoms, e.g. flashing lights, pins and needles (paresthesia), loss of vision, dysarthria
    - Abortive treatment: fluids, NSAIDs, antiemetics, antiepileptic drugs, vasoactive medications
    - Family doctor to consider prophylactic treatment
  - Tension/muscular headache
    - Mild-moderate headache with gradual onset lasting minutes to days
    - Bilateral-frontal or nuchal-occipital
    - Increased with stress, sleep deprivation
    - Treatment: modify stressor(s), local measures, NSAIDs, tricyclic antidepressants

- **The deadly**
  - Subarachnoid hemorrhage (SAH) (see Neurosurgery, NS17)
  - Sudden onset, “worst headache of life” maximum intensity within minutes
  - Increased pain with exertion, N/V, meningeal signs
  - Diagnosis
    - New generation CT 100% sensitive within 6h of onset (hyperattenuating signal around Circle of Willis)
    - LP if suspected SAH and normal CT after 6h
    - Management: urgent neurosurgery consult
  - Increased ICP
    - Worse in morning, when supine or bending down, with cough or valsalva
    - Physical exam: neurological deficits, cranial nerve palsies, papilledema
  - Diagnosis: CT head
  - Management: consult neurosurgery

**Common Therapeutic Approach to Severe Migraine**

- **1L bolus of NS**
- **Prochlorperazine 10 mg IV**
- **Diphenhydramine 25 mg IV**
- **Ketorolac 30 mg IV**
- **Dexamethasone 10 mg IV**
- Other options include haloperidol, metoclopramide, ergotamine, sumatriptan, analgesics

**Ottawa SAH Rule**

- **1L bolus of NS**
- **2 episodes over 6h**
- **Larger than 0.5 cm**
- **Cranial nerve palsies**
- **Increased ICP**
- **Worsened by neck flexion**
- **History of recurrent headaches**

- Use for alert patients older than 15 yr with new severe non-traumatic headache reaching maximum intensity within 1 h
- Not for patients with new neurologic deficits, previous aneurysms, SAH, brain tumours, or history of recurrent headaches (>3 episodes over the course of ≥6 mo)
- Investigate if ≥2 high-risk variables present:
  - Age ≥60 yr
  - Neck pain or stiffness
  - Witnessed loss of consciousness
  - Onset during exertion
  - Thunderclap headache (instantly peaking pain)
  - Limited neck flexion on examination
- Subarachnoid hemorrhage can be predicted with 100% sensitivity using this rule.
Disposition
- admission: if underlying condition is critical or emergent, if there are abnormal neurological findings, if patient is elderly or immunocompromised (atypical presentation), or if pain is refractory to oral medications
- discharge: assess for risk of narcotic misuse; most patients can be discharged with appropriate analgesia and follow-up with their family physician; instruct patients to return for fever, vomiting, neurologic changes, or increasing pain

**Joint and Back Pain**

**JOINT PAIN** (see **Rheumatology, RH3**)
- rule out life threatening causes: septic joint (see **Orthopedics, OR10**)  

**History and Physical Exam**
- associated symptoms: fever, constitutional symptoms, skin lesions, conjunctivitis, urethritis
- patterns of joint involvement: polyarticular vs. monoarticular, symmetric vs. asymmetric
- inflammatory symptoms: prolonged morning stiffness, stiffness and pain ease through the day, mid-day fatigue, soft tissue swelling
- non-inflammatory symptoms: stiffness short lived after inactivity, short duration stiffness in the morning, pain increases with activity
- assess ROM, presence of joint effusion, warmth
- assess for localized joint pain, erythema, warmth, swelling with pain on active ROM, inability to bear weight, fever; may indicate presence of septic joint

**Investigations**
- blood work: CBC, ESR, CRP, WBC, INR/PTT, blood cultures, urate
- joint x-ray ± contralateral joint for comparison
- bedside U/S to identify effusion
- test joint aspirate for: WBC, protein, glucose, Gram stain, crystals

**Management**
- septic joint: IV antibiotics ± joint decompensation and drainage
- antibiotics can be started empirically if septic arthritis cannot be ruled out
- crystalline synovitis: NSAIDs at high dose, colchicine within first 24 h, corticosteroids
- do not use allopurinol, as it may worsen acute attack
- acute polyarthritides: NSAIDs, analgesics (acetaminophen ± opioids), local or systemic corticosteroids
- osteoarthritides: NSAIDs, acetaminophen
- soft tissue pain: allow healing with enforced rest ± immobilization
- non-pharmacologic treatment: local heat or cold, electrical stimulation, massage
- pharmacologic: oral analgesics, NSAIDs, muscle relaxants, corticosteroid injections, topical agents

**BACK PAIN** (see **Family Medicine, FM38**)
- rule out vascular emergencies: aortic dissection, AAA, PE, MI, retroperitoneal bleed
- rule out spinal emergencies using red flags (see sidebar): osteomyelitis, cauda equina, epidural abscess or hematoma
- evaluate risk for fracture (osteoporosis, age), infection (IV drug user, recent spinal intervention, immunosuppression), cancer, vascular causes (cardiac risk factors)
- typical benign back pain is moderate, dull, aching, worse with movement or cough
- palpate spine for bony tenderness; precordial, respiratory, abdominal and neurological exams guided by history
- reserve imaging for suspicion of emergencies, metastases, and patients at high risk of fracture, infection, cancer, or vascular causes

---

**ER24 Emergency Medicine Toronto Notes 2017**

- meningitis (see **Infectious Diseases, ID18**)
  - flu-like symptoms (fever, N/V, malaise), meningeal signs, petechial rash
  - altered LOC and confusion
  - rule out increased ICP: if CT head or normal mental status, no neurological signs and no papilledema, then do LP for diagnosis
  - treatment: early empiric antibiotics ± acyclovir, steroid therapy
- temporal arteritis (causes significant morbidity, blindness) (see **Ophthalmology, OP35**)
  - vasculitis of large and mid-sized arteries, gender 3:1 F:M, most commonly age >70 yr
  - headache, scalp tenderness, jaw claudication, arthralgia, myalgia, fever, malaise or weight loss
  - temporal artery tender on palpation, relative afferent pupillary defect (RAPD), optic disc edema on fundoscopy
  - labs: elevated ESR, CRP
- temporal artery biopsy is gold standard for diagnosis
- associated with polymyalgia rheumatica
- treatment: high-dose steroids immediately if suspected, no need to hold treatment until pathology results

---

**Joint Pain**

**Which Patients can Safely Undergo Lumbar Puncture Without Screening CT?**

Arch Intern Med 1999; 159(22):2681-2685

**Study:** a prospective study to identify patients who can safely undergo LP without CT

**Population:** 113 patients, age >10 yr, needing urgent LP as determined by ED physician

**Intervention:** all patients were examined before CT by staff physicians. Physician examiners involved in the study then recorded the presence or absence of 10 clinical findings and answered 6 questions regarding the patient’s past medical history and recorded then perceived likelihood that LP would be contraindicated

**Main Outcome Measure:** results of non-contrast CTs interpreted by staff radiologist

**Results:** 2.7% of patients had lesions on CT that contraindicated LP. Overall, clinical impression had the highest predictive value in identifying patients with contraindications to LP (+LR 14.0, -LR 0.05). When used in aggregate—alternating mental, local neurologic examination and papilledema were three statistically significant identified predictors of new intracranial lesions (+LR 2.7, -LR 1.0). When used alone these predictors were inadequate

**Conclusion:** given the low prevalence of lesions that contraindicate LP, screening CT safely to establish the safety of LP provides minimal extra information. Physicians can rely on their clinical judgement and the three predictors.

---

**Meningitis**

- Do not delay IV antibiotics for LP
- Deliver first dose of dexamethasone within 0 hr or before first dose of antibiotic therapy

---

**CT Head within 6 h is 100% Sensitive for Diagnosis of Subarachnoid Hemorrhage (SAH)**

BMJ 2012;344(34427)

**Study:** a prospective multicentre cohort study was conducted in 11 tertiary care emergency departments across Canada to measure the sensitivity of CT head in the evaluation of ED patients for SAH

**Population:** neurologically intact adults who presented neurologically intact adults who presented

**Design:** patients were deemed positive for SAH if there was subarachnoid blood on CT, xanthochromia in the CSF, or evidence of SAH in the subarachnoid space on fundoscopy or if there was an abnormality on CT that was subarachnoid hemorrhage

**Results:** of 919 patients with non-contrast CT performed, 877 patients had CT performed within 6 h of headache. Of these patients, 125 had SAH and 557 had no other evidence of SAH

**Main Outcome Measure:** results of CT interpreted by staff radiologist

**Results:** sensitivity of SAH detection was 93.5% with specificity 99.9% and positive predictive value 93.5%

**Conclusion:** CT is extremely sensitive in identifying subarachnoid hemorrhage when it is carried out within 6 h of headache onset
Management
• treat underlying cause
• lumbosacral strain and disc herniation: analgesia and continue daily activities as much as tolerated; discuss red flags and organize follow-up
• spinal infection: early IV antibiotics and ID consultation
• cauda equina: dexamethasone, early neurosurgical consultation

Seizures
• see Neurology, N18

Definition
• paroxysmal alteration of behaviour and/or EEG changes resulting from abnormal, excessive activity of neurons
• status epilepticus: continuous or intermittent seizure activity for greater than 5 min without regaining consciousness (life threatening)

Categories
• generalized seizure (consciousness always lost): tonic/clonic, absence, myoclonic, atonic
• partial seizure (focal): simple partial, complex partial
• causes: primary seizure disorder, structural (trauma, intracranial hemorrhage, infection, increased ICP), metabolic disturbance (hyper-/hypoglycemia, hypo-/hypernatremia, hypocalcemia, hypomagnesemia, toxins/drugs)
• differential diagnosis: syncope, pseudoseizures, migraines, movement disorders, narcolepsy/cataplexy, myoclonus

History
• from patient and bystander: flaccid and unconscious, often with deep rapid breathing
• preceding aura, rapid onset, loss of bladder/bowel control, tongue-biting (sides of the tongue)
• length of seizure and post-ictal symptoms

Physical Exam
• injuries to head and spine and bony prominences (e.g. elbows), tongue laceration, aspiration, urinary incontinence

Table 17. Concurrent Investigation and Management of Status Epilepticus

<table>
<thead>
<tr>
<th>Timing</th>
<th>Steps</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immediate</td>
<td>Protect airway with positioning; intubate if airway compromised or elevated ICP. Monitor: vital signs, ECG, oximetry; bedside blood glucose. Establish IV access. Benzodiazepine - IV lorazepam 0.1 mg/kg up to 4 mg/dose at 2 mg/min preferred over IV diazepam 0.15 mg/kg up to 10 mg/dose at 5 mg/min; repeat at 5 min if ineffective. Fluid resuscitation. Give 50 ml 50% glucose (preceded by thiamine 100 mg IM in adults). Obtain blood samples for glucose, CBC, electrolytes, Ca++, Mg++, toxins, and antiepileptic drug levels; consider prolactin, β-hCG. Vasopressor support if sBP &lt;90 or MAP &lt;70 mmHg.</td>
</tr>
<tr>
<td>Urgent</td>
<td>Establish second IV line, urinary catheter. If status persists, phenytoin 20 mg/kg IV at 25-50 mg/min in adults; may give additional 10 mg/kg IV 10 minutes after loading infusion. If seizure resolves, antiepileptic drug still required to prevent recurrence. EEG monitoring to evaluate for non-convulsive status epilepticus.</td>
</tr>
<tr>
<td>Refractory</td>
<td>If status persists after maximum doses above, consult ICU and start one or more of: Phenobarbital 20 mg/kg IV at 50 mg/min. Midazolam 0.2 mg/kg IV loading dose and 0.05-0.5 mg/kg/h. Propofol 2-5 mg/kg IV loading dose then 2-10 mg/kg/h.</td>
</tr>
<tr>
<td>Post-Seizure</td>
<td>Investigate underlying cause: consider CT, LP, MRI, intracranial pressure monitoring.</td>
</tr>
</tbody>
</table>

Disposition
• decision to admit or discharge should be based on the underlying disease process identified
  • if a patient has returned to baseline function and is neurologically intact, then consider discharge with outpatient follow-up
  • first-time seizure patients being discharged should be referred to a neurologist for follow-up
  • admitted patients should generally have a neurology consult
  • patient should not drive until medically cleared (local regulations vary)
  • complete notification form to appropriate authority regarding ability to drive
  • warn regarding other safety concerns (e.g. no swimming, bathing children alone, etc.)
Shortness of Breath

- see Respirology, R3 and Cardiology and Cardiac Surgery, C5

<table>
<thead>
<tr>
<th>Table 18. Differential Diagnosis for Dyspnea</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>High Mortality/Morbidity</strong></td>
</tr>
<tr>
<td>Respiratory</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Cardiac</td>
</tr>
<tr>
<td>Metabolic</td>
</tr>
<tr>
<td>Neuromuscular</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

History and Physical Exam
- acute SOB is often due to a relatively limited number of conditions; associated symptoms and signs are key to the appropriate diagnosis
  - substernal chest pain with cardiac ischemia
  - fever, cough, and sputum with respiratory infections
  - urticaria with anaphylaxis
  - wheezing with acute bronchospasm
  - environmental or occupational exposures
- dyspnea may be the sole complaint and the physical exam may reveal few abnormalities (e.g. PE, pneumothorax)
- vitals including pulse oximetry
  - wheeze and stridor (airway) vs. crackles (parenchymal), JVP, and murmurs

Investigations
- blood work
  - CBC and differential (hematocrit to exclude anemia), electrolytes, consider VBG
  - serial cardiac enzymes and ECG if considering cardiac source
  - Wells scores to consider appropriateness of d-dimer
- imaging
  - CXR (hyperinflation and bullous disease suggestive of obstructive lung disease, or changes in interstitial markings consistent with inflammation, infection, or interstitial fluid)
  - CT chest usually is not indicated in the initial evaluation of patients with dyspnea, but can be valuable in patients with interstitial lung disease, occult emphysema, or chronic thromboembolic disease (i.e. PE)

Management of Life-Threatening Dyspnea NYD
- see Primary and Secondary Surveys, ER2-3
- treat underlying cause

Disposition
- the history and physical exam lead to accurate diagnoses in patients with dyspnea in approximately two-thirds of cases; the decision to admit or discharge should be based on the underlying disease process identified
  - consider intubation in CO₂ retainer (e.g. COPD)
- if discharging, organize follow-up and educate regarding signs to return to hospital

Syncope

Definition
- sudden, transient loss of consciousness and postural tone with spontaneous recovery
- usually caused by generalized cerebral or reticular activating system hypoperfusion

Etiology
- cardiogenic: dysrhythmia, outflow obstruction (e.g. PE, pulmonary HTN), MI, valvular disease
- non-cardiogenic: peripheral vascular (hypovolemia), vasovagal, cerebrovascular disorders, CNS, metabolic disturbances (e.g. EtOH intoxication)
History
- gather details from witnesses, and clarify patient's experience (e.g. dizziness, ataxia, or true syncope)
  - two key historical features: prodrome and situation
- distinguish between syncope and seizure (see Neurology, N19)
  - some patients may have myoclonic jerks with syncope – NOT a seizure
    - signs and symptoms during presyncope, syncope, and postsyncope
    - past medical history, drugs
    - think anatomically in differential; pump (heart), blood, vessels, brain
- syncope is cardiogenic until proven otherwise if
  - there is sudden loss of consciousness with no warning or prodrome
  - syncope is accompanied by chest pain

Physical Exam
- postural BP and HR
- cardiovascular, respiratory, and neurological exam
- examine for signs of trauma caused by syncopal episode

Investigations
- ECG (tachycardia, bradycardia, blocks, Wolff-Parkinson White, long QT interval, Brugada Syndrome, RV strain), bedside glucose
- blood work: CBC, electrolytes, BUN/Cr, ABGs, troponin, Ca²⁺, Mg²⁺, β-hCG, D-dimer
- consider toxicology screen

Management
- ABCs, IV, O₂, monitor
- cardiogenic syncope: admit to medicine/cardiology
- low risk syncope: discharge with follow-up as indicated by cause (non-cardiogenic syncope may still be admitted)

Disposition
- decision to admit is based on etiology
- most patients will be discharged
- on discharge, instruct patient to follow up with family physician
  - educate about avoiding orthostatic or situational syncope
  - evaluate the patient for fitness to drive or work
  - patients with recurrent syncope should avoid high-risk activities (e.g. driving)

Epidemiology
- 1 in 4 women and 1 in 10 men will be sexually assaulted in their lifetime; only 7% are reported

General Approach
- ABCs, treat acute, serious injuries; physician priority is to treat medical issues and provide clearance
- ensure patient is not left alone and provide ongoing emotional support
- obtain consent for medical exam and treatment, collection of evidence, disclosure to police (notify police as soon as consent obtained)
- Sexual Assault Kit (document injuries, collect evidence) if <72 h since assault
- label samples immediately and pass directly to police
- offer community crisis resources (e.g. shelter, hotline)
- do not report unless victim requests or if <16 yr old (legally required)

History
- ensure privacy for the patient – others should be asked to leave
- questions to ask: who, when, where did penetration occur, what happened, any weapons, or physical assault?
- post-assault activities (urination, defecation, change of clothes, shower, douche, etc.)
- gynecologic history
  - gravidity, parity, last menstrual period
  - contraception use
  - last voluntary intercourse (sperm motile 6-12 h in vagina, 5 d in cervix)
  - medical history: acute injury/illness, chronic diseases, psychiatric history, medications, allergies, etc.

Physical Exam
- never re-traumatize a patient with the examination
- general examination
  - mental status
  - sexual maturity
  - patient should remove clothes and place in paper bag
  - document abrasions, bruises, lacerations, torn frenulum/broken teeth (indicates oral penetration)
• pelvic exam and specimen collection
  ■ ideally before urination or defecation
  ■ examine for seminal stains, hymen, signs of trauma
  ■ collect moistened swabs of dried seminal stains
  ■ pubic hair combings and cuttings
  ■ speculum exam
  ■ lubricate with water only
  ■ vaginal lacerations, foreign bodies
  ■ Pap smear, oral/cervical/rectal culture for gonorrhea and chlamydia
  ■ posterior fornix secretions if present or aspiration of saline irrigation
  ■ immediate wet smear for motile sperm
  ■ air-dried slides for immotile sperm, acid phosphatase, ABO group
  ■ fingernail scrapings and saliva sample from victim

**Investigations**
- VDRL: repeat in 3 mo if negative
- serum β-hCG
- blood for ABO group, Rh type, baseline serology (e.g. hepatitis, HIV)

**Management**
- involve local/regional sexual assault team
- medical
  ■ suture lacerations, tetanus prophylaxis
  ■ gynecology consult for foreign body, complex lacerations
  ■ assumed positive for gonorrhea and chlamydia
  ■ management: azithromycin 1 g PO x 1 dose (alt: doxycycline 100 mg PO bid x 7 d) and cefixime 800 mg PO x 1 dose (alt: ceftriaxone 250 mg IM x 1 dose)
  ■ may start prophylaxis for hepatitis B and HIV
  ■ pre and post counselling for HIV testing
  ■ pregnancy prophylaxis offered
    ■ levonorgestrel 0.75 mg PO STAT, repeat within 12 h (Plan B’)
- psychological
  ■ high incidence of psychological sequelae
  ■ have victim change and shower after exam completed

**Disposition**
- discharge if injuries/social situation permit
- follow-up with physician in rape crisis centre within 24 h
- best if patient does not leave ED alone

**DOMESTIC VIOLENCE**
- women are usually the victims, but male victimization also occurs
- identify the problem (need high index of suspicion)
- suggestive injuries (bruises, sprains, abrasions, occasionally fractures, burns, or other injuries; often inconsistent with history provided)
- somatic symptoms (chronic and vague complaints)
- psychosocial symptoms
  ■ clinician impression (your ‘gut feeling’, e.g. overbearing partner that won’t leave patient’s side)
- if disclosed, be supportive and assess danger
- patient must consent to follow-up investigation/reporting (unless for children)

**Management**
- treat injuries and document findings
- ask about sexual assault and children at home (encourage notification of police)
- safety plan with good follow-up with family doctor/social worker

---

**Medical Emergencies**

**Anaphylaxis and Allergic Reactions**

**Etiology**
- anaphylaxis is an exaggerated immune mediated hypersensitivity reaction that leads to systemic histamine release, increased vascular permeability, and vasodilation; regardless of the etiology, the presentation and management of anaphylactic reactions are the same
- allergic (re-exposure to allergen)
- non-allergic (e.g. exercise induced)
Diagnostic Criteria
- anaphylaxis is highly likely with any of
  1. acute onset of an illness (min to hrs) with involvement of the skin, mucosal tissue and at least one of
     • respiratory compromise (e.g. dyspnea, wheeze, stridor, hypoxemia)
     • hypotension/end-organ dysfunction (e.g. hypotonia, collapse, syncope, incontinence)
  2. two or more of the following after exposure to a LIKELY allergen for that patient (min to hrs)
     • involvement of the skin-mucosal tissue
     • respiratory compromise
     • hypotension or associated symptoms
     • persistent gastrointestinal symptoms (e.g. crampy abdominal pain, vomiting)
  3. hypotension after exposure to a KNOWN allergen for that patient (min to hrs)
     • management is also appropriate in cases which do not fulfill criteria, but who have had previous episodes of anaphylaxis
     • life-threatening differentials for anaphylaxis include asthma and septic shock
     • angioedema may mimic anaphylaxis but tends not to improve with standard anaphylaxis treatment

Management
- moderate reaction: generalized urticaria, angioedema, wheezing, tachycardia
  • epinephrine (1:1000) 0.3-0.5 mg IM
  • antihistamines: diphenhydramine (Benadryl®) 25-50 mg IM
  • salbutamol (Ventolin®) 1 cc via MDI
- severe reaction/evolution: severe wheezing, laryngeal/pulmonary edema, shock
  • –ABCs, may need ETT due to airway edema
  • epinephrine (1:1000) 0.1-0.3 mg IV (or via ETT if no IV access) to start, repeat as needed
  • antihistamines: diphenhydramine (Benadryl®) 50 mg IV (~1 mg/kg)
  • steroids: hydrocortisone (Solucortef®) 100 mg IV (~1.5 mg/kg) or methylprednisolone (Solumedrol®) 1 mg/kg IV q6h x 24 h
  • large volumes of crystalloid may be required

Disposition
- monitor for 4-6 h in ED (minimum) and arrange follow-up with family physician in 24-48 h
- can have second phase (biphasic) reaction up to 48 h later, patient may need to be supervised
- educate patient on avoidance of allergens
- medications
  • H2 antagonist (cetirizine 10 mg PO OD or Benadryl® 50 mg PO q4-6h x3d)
  • H2 antagonist (ranitidine 150 mg PO OD x3d)
  • corticosteroid (prednisone 50 mg PO OD) x5d to prevent secondary reaction

Asthma
- see Respirology R7
- chronic inflammatory airway disease with episodes of bronchospasm and inflammation resulting in reversible airflow obstruction

History and Physical
- find cause of asthma exacerbation (viral, environmental, etc.)
- history of asthma control; severity of exacerbations (ICU, intubation history)
- signs of respiratory distress
- vitals, specifically O2

Investigations
- peak flow meter
- ± ABG if in severe respiratory distress
- CXR if diagnosis in doubt to rule out pneumonia, pneumothorax, etc.
Table 19. Asthma Assessment and Management

<table>
<thead>
<tr>
<th>Classifications</th>
<th>History and Physical Exam</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Respiratory Arrest</strong></td>
<td>Exhausted, confused, diaphoretic, cyanotic</td>
<td>100% O₂, cardiac monitor, IV access</td>
</tr>
<tr>
<td>Imminent</td>
<td>Silent chest, ineffective respiratory effort, D. sat &lt;90% despite supplemental O₂</td>
<td>Intubate (consider induction with ketamine)</td>
</tr>
<tr>
<td></td>
<td>Decreased HR, RR 30, pCO₂ 35 mmHg</td>
<td>Short acting β-agonist (Ventolin): nebulizer 5 mg continually</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Short-acting Anticholinergic (Atrovent): nebulizer 0.5 mg x 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IV steroids: methylprednisolone 125 mg</td>
</tr>
<tr>
<td><strong>Severe Asthma</strong></td>
<td>Agitated, diaphoretic, laboured respiration</td>
<td>Anticipate need for intubation</td>
</tr>
<tr>
<td></td>
<td>Speaking in words</td>
<td>Similar to above management</td>
</tr>
<tr>
<td></td>
<td>No relief from β-agonist</td>
<td>Magnesium sulphate 2 g IV</td>
</tr>
<tr>
<td></td>
<td>D. sat &lt;90%, FEV₁ &lt;50%</td>
<td>O₂ to achieve: D. sat &gt;92%</td>
</tr>
<tr>
<td><strong>Moderate Asthma</strong></td>
<td>SOB at rest, cough, congestion, chest tightness</td>
<td>O₂ to achieve: D. sat &gt;92%</td>
</tr>
<tr>
<td></td>
<td>Speaking in phrases</td>
<td>Short-acting β-agonist (Ventolin): MDI or nebulizer q5min</td>
</tr>
<tr>
<td></td>
<td>Inadequate relief from β-agonist</td>
<td>Short-acting Anticholinergic (Atrovent): MDI or nebs x 3</td>
</tr>
<tr>
<td></td>
<td>FEV₁ 50-80%</td>
<td>Steroids: prednisone 40-60 mg PO</td>
</tr>
<tr>
<td><strong>Mild Asthma</strong></td>
<td>Exertional SOB/cough with some nocturnal symptoms</td>
<td>β-agonist</td>
</tr>
<tr>
<td></td>
<td>Difficulty finishing sentences</td>
<td>Monitor FEV₁</td>
</tr>
<tr>
<td></td>
<td>FEV₁ &gt;80%</td>
<td>Consider steroids (MDI or PO)</td>
</tr>
</tbody>
</table>

Disposition
- discharge safe in patients with FEV₁ or PEF > 60% predicted, and may be safe if FEV₁ or PEF 40-60% predicted based on patient’s risk factors for recurrence of severe attack
- risk factors for recurrence: frequent ED visits, frequent hospitalizations, recent steroid use, recent exacerbation, poor medication compliance, prolonged use of high dose β-agonists
- β-agonist MDI with aerochamber 2-4 puffs q2-4h until symptoms controlled, then prn
- initiate inhaled corticosteroids with aerochamber if not already prescribed
- if moderate to severe attack, administer prednisone 30-60 mg/d for 7 d with no taper
- counsel on medication adherence and educate on use of aerochamber
- follow-up with primary care physician or asthma specialist

Cardiac Dysrhythmias

- see Cardiology and Cardiac Surgery, C16

Bradydysrhythmias and AV Conduction Blocks
- AV conduction blocks
  - 1st degree: prolonged PR interval (>200 msec), no treatment required
  - 2nd degree
    - Mobitz I: gradual prolongation of PR interval then dropped QRS complex, usually benign
    - Mobitz II: PR interval constant with dropped QRS complex, can progress to 3rd degree AV block
  - 3rd degree: P wave unrelated to QRS complex, PP and RR intervals constant
  - atropine and transcutaneous pacemaker (atropine with caution)
  - if transcutaneous pacemaker fails consider dopamine, epinephrine IV
  - long-term treatment for Mobitz II and 3rd degree block – internal pacemaker
- sinus bradycardia (rate <60 bpm)
  - can be normal (especially in athletes)
  - causes: vagal stimulation, vomiting, myocardial infarction/ischemia, increased ICP, sick sinus node, hypothyroidism, drugs (e.g. β-blockers, CCBs)
  - treat if symptomatic (hypotension, chest pain)
    - acute: atropine ± transcutaneous pacing
    - sick sinus: transcutaneous pacing
    - drug induced: discontinue/reduce offending drug, consider antidotes

Supraventricular Tachydysrhythmias (narrow QRS)
- sinus tachycardia (rate >100 bpm)
  - causes: increased sympathetic tone, drugs, fever, hypotension, anemia, thyrotoxicosis, MI, PE, emotional, pain, etc.
  - search for and treat underlying cause, consider β-blocker if symptomatic
- regular rhythm (i.e. not sinus tachycardia)
  - vagal maneuvers (carotid massage, Valsalva), adenosine 6 mg IV push, if no conversion give 12 mg, can repeat 12 mg dose once
  - rhythm converts: probable re-entry tachycardia (AVNRT more common than AVRT)
    - monitor for recurrence
    - treat recurrence with adenosine or longer acting medications

If the patient with tachydysrhythmia is unstable, perform immediate synchronized cardioversion
• rhythm does not convert: atrial flutter, ectopic atrial tachycardia, junctional tachycardia
  • rate control (diltiazem, β-blockers) and consult cardiology
• irregular rhythm
  • probable Afib, atrial flutter, or multifocal atrial tachycardia
  • rate control (diltiazem, β-blockers)

**Atrial Fibrillation**
• most common sustained dysrhythmia; no organized P waves (atrial rate >300/min), irregularly irregular heart rate, narrow QRS (typically)
• etiology: HTN, CAD, thyrotoxicosis, EtOH (holiday heart), valvular disease, pericarditis, cardiomyopathy, sick sinus syndrome
• treatment principles: stroke prevention, treat symptoms, identify/treat underlying cause
• decreases cardiac output by 20-30% (due to loss of organized atrial contractions)
• acute management
  • if unstable: immediate synchronized cardioversion
  • if onset of Afib is >48 h: rate control, anticoagulate 3 wk prior to and 4 wk after cardioversion, or do transesophageal echocardiogram to rule out clot
  • if onset <48 h or already anticoagulated: mayo cardiover, electrical cardioversion: synchronized direct current (DC) cardioversion
  • chemical cardioversion: procainamide, flecainide, propafenone
• long-term management: rate or rhythm control, consider anticoagulation (CHADS2 score, see Cardiology and Cardiac Surgery, C20)

**Ventricular Tachydysrhythmias (wide QRS)**
• VTach (rate usually 140-200 bpm)
  • definition: 3 or more consecutive ventricular beats at >100 bpm
  • etiology: CAD with MI is most common cause
  • treatment: sustained VTach (>30 s) is an emergency
    • hemodynamic compromise: synchronized DC cardioversion
    • no hemodynamic compromise: synchronized DC cardioversion, amiodarone, procainamide
• VFib: call a code blue, follow ACLS for pulseless arrest
• Torsades de pointes
  • looks like VTach but QRS ‘rotates around baseline’ with changing axis and amplitude (twisted ribbon)
  • etiology: prolonged QT due to drugs (e.g. quinidine, TCAs, erythromycin, quinolones), electrolyte imbalance (hypokalemia, hypomagnesemia), congenital
  • treatment
    • IV Mg₂⁺, temporary overdrive pacing, isoproterenol
    • correct cause of prolonged QT

**Acute Exacerbation of COPD (AECOPD)**
• for chronic management of COPD see Respirology, R9
• progressive development of irreversible airway obstruction, typically caused by smoking

**History and Physical Exam**
• cardinal symptoms of AECOPD: increased dyspnea, increased coughing frequency or severity, increased sputum volume or purulence
• triggers: virus, pneumonia, urinary tract infection, PE, CHF, MI, drugs
• characterize previous episodes and hospitalizations, smoking history
• vital signs, level of consciousness, signs of respiratory distress, respiratory exam

**Investigations**
• CBC, electrolytes, ABG, CXR, ECG
• PFTs are NOT useful in managing acute exacerbations

**Management**
• oxygen: keep O₂ sat 88-92% (be aware when giving O₂ to chronic hypercapnic/C0₂: retainers but do not withhold O₂ if hypoxic)
• bronchodilators: short-acting β-agonist (Salbutamol 4-8 puffs via MDI with spacer q15min x3 prn) ± short-acting anticholinergic (Ipratropium 4-8 puffs via MDI q15min x3 prn)
• steroids: prednisone 40-60 mg PO for 7-14 d, or methylprednisolone 125 mg IV bid-qid if severe exacerbation, or unable to take PO
• antibiotics: TMP-SMX, cephalosporins, respiratory quinolones (given if all 3 cardinal symptoms present or 2 cardinal symptoms with increased sputum purulence or mechanical ventilation)
• ventilation: apply NIPPV (CPAP or BiPAP) if severe distress or signs of fatigue, arterial pH <7.35, or hypercapnic
• if life-threatening, ICU admission for intubation and ventilation (chance of ventilation dependency)

**Disposition**
• no guidelines for admission - based on clinical judgement and comorbidities
• lower threshold to admit if comorbid illness (diabetes, CHF, CAD, alcohol abuse)
• if discharging, use antibiotics, tapering steroids, up to 4-6 puffs qid of Ipratropium and salbutamol and organize follow-up

**Causes of Atrial Fibrillation**
- C (“sea”) PIRATES
  - CHF, Cardiomyopathy
  - Pulmonary embolism
  - Ischemic heart disease
  - Rheumatic or valvular disease
  - Anemia
  - Thyroid
  - EtOH
  - Hypertension
  - Sick Sinus, Stress - surgery, sepsis

**Physical Exam Findings in COPD**
- Wheeze
- Maximum laryngeal height ≤4 cm
- Forced expiratory time ≤6 s
- Decreased breath sounds
- Decreased cardiac dullness

**Need to Rule Out with COPD Exacerbation**
- Pneumothorax
- CHF exacerbation
- Acute MI
- Pneumonia and other infectious causes
- PE
# Acute Decompensated Heart Failure (ADHF)

- for chronic management of CHF see Cardiology and Cardiac Surgery, C36

## Etiology
- Causes of CHF: decreased myocardial contractility (ischemia, infarction, cardiomyopathy, myocarditis), pressure overload states (HTN, valve abnormalities, congenital heart disease), restricted cardiac output (myocardial infiltrative disease, cardiac tamponade)
- Precipitants of acute decompensation of CHF
  - cardiac (ischemia, infarction, arrhythmia - Afib)
  - medications (beta-blockers, CCBs, NSAIDs, steroids, non-compliance)
  - dietary (increased sodium and/or water intake)
  - high output (anemia, infection, pregnancy, hyperthyroid)
  - other (renal failure, hypertensive crisis, iatrogenic fluid overload - blood transfusions or IV fluids)

## Presentation
- left-sided heart failure
  - dyspnea, SOB, orthopnea, PND, nocturia, fatigue, altered mental status, presyncope/syncope, anemia, systemic hypotension
  - hypoxia, decreased air entry to lungs, crackles, S3 or S4, pulmonary edema (on CXR), pleural effusion (usually right-sided)
- right-sided heart failure
  - dependent bilateral pitting edema, JVP elevation and positive AJR, ascites, hepatomegaly
- patients often present with a combination of right-sided and left-sided symptoms

## Investigations
- blood work: CBC, electrolytes, AST, ALT, bilirubin, Cr, BUN, cardiac enzymes, brain natriuretic peptide (BNP/NT-proBNP/Brain natriuretic peptide (BNP/NT-proBNP))
- CXR: most useful test (see sidebar)
- ECG: look for MI, ischemia (ST elevation/depression, T-wave inversion), LVH, atrial enlargement, conduction abnormalities
- ABG: if severe or refractory to treatment
  - hypoxemia, hypercapnia and acidosis are signs of severe CHF
- echocardiogram: not usually used in emergency evaluation, previous results may aid in diagnosis
- rule out serious differentials such as PE, pneumothorax, pneumonia/empyema, AECOPD

## Management
- ABCs, may require intubation if severe hypoxia
- sit upright, cardiac monitoring, and continuous pulse oximetry
- saline lock IV, Foley catheter (to follow effectiveness of diuresis)
- 100% O₂: by mask
- if poor response, may require BiPAP or intubation
- drugs
  - diuretic (if volume overloaded): Furosemide 40–80 mg IV
  - vasodilators (if sBP > 100): Nitroglycerin 0.3 mg SL q30min prn ± topical Nitrodur patch (0.4-0.8 mg/h)
  - if not responding or signs of ischemia (angina): Nitroglycerine 10–20 µg/min IV, titrate to response
  - if severe or refractory hypertension: Nitroprusside 0.5 µg/kg/min, titrate to response
  - inotropes/vasopressors (if sBP < 90)
    - without signs of shock: Dobutamine 2.5 µg/kg/minute IV, titrate up to sBP > 90 mmHg
    - with signs of shock: Dopamine 5–10 µg/kg/minute IV, titrate up to sBP > 90 mmHg
  - treat precipitating factor - e.g. rate control (beta-blocker, CCB) or rhythm-control (electrical or chemical cardioversion) if new Afib
  - cardiology or medicine consult

### Venous Thromboembolism (VTE)

- see Respirology, R20

## Risk Factors
- Virchow's triad: alterations in blood flow (venous stasis), injury to endothelium, hypercoagulable state (including pregnancy, use of OCP, malignancy)
- clinical risk factors (see sidebar)

## Deep Vein Thrombosis (DVT)

### Presentation
- calf pain, unilateral leg swelling/erythema/edema, palpable cord along the deep venous system on exam; can be asymptomatic
- clinical signs/symptoms are unreliable for diagnosis and exclusion of DVT; investigation often needed
**Investigations**
- use Wells’ criteria for DVT to guide investigations (Figure 12)
- D-dimer is only useful at ruling out a DVT if it is negative in low to moderate risk patients (highly sensitive)
  - high risk of false positives in: elderly, infection, recent surgery, trauma, hemorrhage, late in pregnancy, liver disease, cancer
- U/S has high sensitivity & specificity for proximal clot but only 73% sensitivity for calf DVT (may need to repeat in 1 wk)
  - if positive – treat for DVT regardless of risk
  - if negative and low risk – rule out DVT
  - if negative and moderate to high risk – repeat U/S in 5-7 days to rule out DVT

**Management**
- LMWH unless patient also has renal failure
  - dalteparin 200 IU/kg SC q24h or enoxaparin 1.5 mg/kg SC q24h
  - warfarin started at same time as LMWH (5 mg PO OD initially followed by dosing based on INR)
  - LMWH discontinued when INR has been therapeutic (2-3) for 2 consecutive days
  - rivaroxaban can be used in acute management of symptomatic DVT
    - 15 mg PO bid for first 21 d; 20 mg PO daily for remaining treatment (taken with food at approximately the same time each day)
  - consider thrombolysis if extensive DVT causing limb compromise
  - IVC filter or surgical thrombectomy considered if anticoagulation is contraindicated
  - duration of anticoagulation: 3 months if transient coagulopathy; 6 months if unprovoked DVT; life-long if ongoing coagulopathy

**PULMONARY EMBOLISM (PE)**

**Presentation**
- dyspnea, pleuritic chest pain, hemoptysis, tachypnea, cyanosis, hypoxia, fever
- clinical signs/symptoms are unreliable for diagnosis and exclusion of DVT; investigation often needed

**Investigations**
- use Wells’ criteria for PE to guide investigations (Figures 13-14)
- PERC score alone can rule out PE in low risk patients (as determined by Wells’ criteria) unless patient is pregnant
- ECG and CXR are useful to rule out other causes (e.g. ACS, pneumonia, pericarditis) or to support diagnosis of PE
  - ECG changes in PE: sinus tachycardia, right ventricular strain (S1Q3T3), T wave inversions in anterior and inferior leads
  - CXR findings in PE: Hampton's hump (triangular density extending from pleura) or Westermark's sign
- D-dimer is only useful at ruling out a PE if it is negative in low to moderate risk patients (highly sensitive)
  - if positive D-dimer or high-probability patient, then pursue CT angiography or V/Q scan
  - CT angiography has high sensitivity and specificity for PE, may also suggest other etiology
  - V/Q scan useful in pregnancy, when CT angiography not available, or IV contrast contraindicated

**Management of PE**
- treatment of PE with anticoagulation and duration of treatment is the same as for DVT (see above)
- consider thrombolysis if extensive PE causing hemodynamic compromise or cardiogenic shock
- catheter-directed thrombolysis or surgical thrombectomy rarely considered in massive PE or contraindication to anticoagulation
- often can be treated as outpatient, may require analgesia for chest pain (narcotic or NSAID)
- admit if hemodynamically unstable, require supplemental O2, major comorbidities, lack of sufficient social supports, unable to ambulate, need invasive therapy
- referral to medicine for coagulopathy and malignancy workup

---

**Figure 12. Approach to suspected DVT**

---
Diabetic Emergencies

- see Endocrinology, E11

Diabetic Ketoacidosis

- triad of hyperglycemia, ketosis, and acidosis due to severe insulin deficiency and counter-regulatory hormone excess
- clinical presentation
  - often young, Type 1 DM patients, (may rarely be first presentation of undiagnosed Type 2 DM) with symptoms evolving within a day
  - early signs and symptoms: polyuria, polydipsia, malaise, nocturia, weight loss
  - late signs and symptoms
    - GI: anorexia, nausea, vomiting, abdominal pain
    - neurological: fatigue, drowsiness, stupor, coma
    - respiratory: Kussmaul’s respiration, dyspnea (often due to acidosis), fruity ketotic breath
- investigations
  - blood work: CBC, electrolytes, Ca++, Mg++, PO4-, Cr, BUN, glucose, ketones, osmolality, AST/ALT/ALP, amylase, troponin
  - urine: glucose and ketones
  - ABG
  - ECG (MI is possible precipitant; electrolyte disturbances may predispose to dysrhythmia)
- management
  - rehydration
    - bolus of NS, then high rate NS infusion (be aware of overhydration and cerebral edema, especially in pediatric patients)
  - beware of a pseudohyponatremia due to hyperglycemia (add 3 NaCl to the formula)
  - potassium
    - essential to avoid hypokalemia: replace KCl (20 mEq/L if adequate renal function and initial K+ <5.5 mmol/L)
    - use cardiac monitoring if potassium levels normal or low

Clinical Criteria to Prevent Unnecessary Diagnostic Testing in Emergency Department Patients with Suspected Pulmonary Embolism


Purpose: To develop PE rule-out criteria (PERC) that can be used at the bedside, and prevents overtreatment for PE, which includes the D-dimer test that frequently results in false positives.

Study: 21 variables were collected prospectively from 3,148 ER patients evaluated for possible PE to develop rule-out criteria. The application of the developed rules was investigated in 1,427 low-risk patients and 382 very low-risk patients.

Results: Eight variables were included in a block rule (age > 50 y, pulse < 100 bpm, SaO2 > 94%, no unilateral leg swelling, no hemoptysis, no recent trauma or surgery, no prior PE or DVT, no hormone use) and a negative score was used to rule-out PE.

In low-risk and very-low-risk patients, the rule had a sensitivity of 98 and 100%, respectively and a specificity of 27 and 15%, respectively.

Summary: D-dimer testing for PE may not be favourable if all eight factors in the PERC are negative.

Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism

NEJM 2012;366:1297-1297

Background: Evidence supporting rivaroxaban as effective therapy in DVT may also apply to simplify treatment of PE.

Methods: A randomized, open-label, event-driven, non-inferiority trial involving 4,832 patients with acute symptomatic PE with or without DVT, was undertaken to compare rivaroxaban (15 mg twice daily for 3 wk, followed by 20 mg once daily) with standard therapy of enoxaparin followed by an adjusted-dose vitamin K antagonist.

Results: Rivaroxaban was non-inferior to standard therapy (non-inferiority margin, 2.0; p = 0.003) for preventing recurrent VTE (HR: 1.12; 95% CI 0.75-1.68). Major bleeding occurred less in the rivaroxaban group (hazard ratio, 0.49; 95% CI 0.31-0.78; p = 0.003). Rates of other adverse events were similar in the two groups.

Conclusions: A fixed-dose regimen of rivaroxaban alone was non-inferior to standard therapy for the initial and long-term treatment of PE.

Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

NEJM 2010;363:2499-2510

Background: Rivaroxaban, an oral factor Xa inhibitor, hypothesized to provide a simple, fixed-dose regimen for treating acute DVT and for continued treatment, without the need for laboratory monitoring.

Methods: An open-label, randomized, event-driven, non-inferiority study compared oral rivaroxaban alone (15 mg twice daily for 3 wk, followed by 20 mg once daily) with standard therapy of subcutaneous enoxaparin followed by vitamin K antagonist in patients with acute, symptomatic DVT (sample size: 3,449 patients). In parallel, a double-blind, randomized, event-driven superiority study was conducted to compare rivaroxaban alone (20 mg once daily) versus placebo in patients who had received treatment for VTE (sample size: 602 patients in intervention vs 594 in placebo group).

Results: Rivaroxaban had non-inferior efficacy with respect to recurrent VTE (HR: 0.69; 95% CI 0.44-1.04). Similar bleeding prevalence were reported in each group. In the parallel continued-treatment study, rivaroxaban had superior efficacy with respect to preventing VTE (HR: 0.18; 95% CI 0.09-0.39). Four patients in the rivaroxaban group had fatal major bleeding vs. none in the placebo group (p = 0.11).

Conclusions: Rivaroxaban offers a single-dose approach to treatment of VTE that may improve the benefit-to-risk profile of anticoagulation.
• insulin
  • critical, as this is the only way to turn off gluconeogenesis/ketosis
  • do not give insulin if K+ <3.3 mmol/L
  • initial bolus of 5-10 U short-acting/regular insulin (or 0.2 U/kg) IV in adults (controversial – may just start with infusion)
  • followed by continuous infusion at 5-10 U (or 0.1 U/kg) per hour
  • once the blood glucose <14 mmol/L, patient should receive their regular insulin SC injection and the infusion stopped in 1 hour
  • add D5W to IV fluids when blood glucose <15 mmol/L to prevent hypoglycemia
  • bicarbonate is not given unless patient is at risk of death or shock (typically pH <7.0)

Hyperosmolar Hyperglycemic State
• state of extreme hyperglycemia (44-133.2 mmol/L) due to relative insulin deficiency, counter-regulatory hormones excess, gluconeogenesis, and dehydration (due to osmotic diuresis)
• clinical presentation
  • often older, Type 2 DM patients with more co-morbid illnesses and larger fluid losses with symptoms evolving over days to weeks, less GI symptoms and more neurological deficits than DKA including: mental disturbances, coma, delirium, seizures
  • polyuria, N/V
• investigations
  • blood work: CBC, electrolytes, Ca++, Mg++, PO4, Cr, BUN, glucose, ketones, osmolality
  • urine: glucose and ketones
  • ABG
  • find underlying cause: ECG, CXR, blood and urine C&S
• management
  • rehydration with IV NS (total water deficit estimated at average 100 cc/kg body weight)
  • O2: and cardiac monitoring, frequent electrolyte and glucose monitoring
  • insulin is controversial
  • identify and treat precipitant if present (the 5 Is)

Hypoglycemia
• characterized by Whipple’s triad: low plasma glucose, symptoms suggestive of hypoglycemia, prompt resolution of symptoms with glucose
• clinical presentation
  • autonomic symptoms: headaches, confusion, seizures, coma
  • neuroglycopenic symptoms: diaphoresis, nausea, hunger, tachycardia, palpitations
• history and physical exam
  • last meal, known DM, prior similar episodes, drug therapy, and compliance
  • liver/renal/endocrine/neoplastic disease
  • depression, alcohol or drug use
• management
  • IV access and rapid blood glucose measurement
  • D50W 50 mL IV push, glucose PO if mental status permits
  • if IV access not possible, glucagon 1-2 mg IM, repeat x 1 in 10-20 min
  • O2, cardiac, frequent blood glucose monitoring
  • thiamine 100 mg IM
  • full meal as soon as mental status permits
  • if episode due to long-acting insulin, or sulfonylureas, watch for prolonged hypoglycemia due to long t1/2 (may require admission for monitoring)
  • search for cause (most often due to exogenous insulin, alcohol, or sulfonylureas)
Electrolyte Disturbances

- see Nephrology, NP7 and Endocrinology, E36

### Table 20. Electrolyte Disturbances

<table>
<thead>
<tr>
<th>Electrolyte Disturbance</th>
<th>Common Causes</th>
<th>Symptoms</th>
<th>Treatment</th>
<th>Special Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypokalemia</td>
<td>Metabolic alkalosis (e.g. diarhea), insulin, diuretics, anorexia, salbutamol</td>
<td>N/V, fatigue, muscle cramps, constipation</td>
<td>K-Dur®; K+ sparing diuretics, IV solutions with 20-40 mEq/L KCl over 3-4 h</td>
<td>ECG: U waves most important, flattened/inverted T waves, prolonged QT, depressed ST. May need to restore Mg²⁺.</td>
</tr>
<tr>
<td>Hypokalemia</td>
<td>Metabolic alkalosis (e.g. diarhea), insulin, diuretics, anorexia, salbutamol</td>
<td>N/V, fatigue, muscle cramps, constipation</td>
<td>K-Dur®; K+ sparing diuretics, IV solutions with 20-40 mEq/L KCl over 3-4 h</td>
<td>ECG: U waves most important, flattened/inverted T waves, prolonged QT, depressed ST. May need to restore Mg²⁺.</td>
</tr>
<tr>
<td>Hyperkalemia</td>
<td>Rhabdomyolysis, insulin deficiency, metabolic acidosis (e.g. acute renal failure, missed dialysis)</td>
<td>Nausea, palpitations, muscle stiffness, anorexia</td>
<td>Protect heart: calcium gluconate Shift K⁺ into cells: D50W + Insulin, NaHCO₃, salbutamol Remove K⁺: Fluids + furosemide, dialysis</td>
<td>High risk of dysrhythmia - ECG: peaked/narrow T wave, decreased P wave, prolonged PR interval, widening of QRS, AV block, VFib.</td>
</tr>
<tr>
<td>Hyperkalemia</td>
<td>Rhabdomyolysis, insulin deficiency, metabolic acidosis (e.g. acute renal failure, missed dialysis)</td>
<td>Nausea, palpitations, muscle stiffness, anorexia</td>
<td>Protect heart: calcium gluconate Shift K⁺ into cells: D50W + Insulin, NaHCO₃, salbutamol Remove K⁺: Fluids + furosemide, dialysis</td>
<td>High risk of dysrhythmia - ECG: peaked/narrow T wave, decreased P wave, prolonged PR interval, widening of QRS, AV block, VFib.</td>
</tr>
<tr>
<td>Hyperkalemia</td>
<td>Rhabdomyolysis, insulin deficiency, metabolic acidosis (e.g. acute renal failure, missed dialysis)</td>
<td>Nausea, palpitations, muscle stiffness, anorexia</td>
<td>Protect heart: calcium gluconate Shift K⁺ into cells: D50W + Insulin, NaHCO₃, salbutamol Remove K⁺: Fluids + furosemide, dialysis</td>
<td>High risk of dysrhythmia - ECG: peaked/narrow T wave, decreased P wave, prolonged PR interval, widening of QRS, AV block, VFib.</td>
</tr>
<tr>
<td>Hyperkalemia</td>
<td>Rhabdomyolysis, insulin deficiency, metabolic acidosis (e.g. acute renal failure, missed dialysis)</td>
<td>Nausea, palpitations, muscle stiffness, anorexia</td>
<td>Protect heart: calcium gluconate Shift K⁺ into cells: D50W + Insulin, NaHCO₃, salbutamol Remove K⁺: Fluids + furosemide, dialysis</td>
<td>High risk of dysrhythmia - ECG: peaked/narrow T wave, decreased P wave, prolonged PR interval, widening of QRS, AV block, VFib.</td>
</tr>
<tr>
<td>Hypoaldosteronism</td>
<td>Excessive diuretics, diuretics, anorexia, salbutamol</td>
<td>N/V, fatigue, muscle cramps, constipation</td>
<td>K-Dur®; K+ sparing diuretics, IV solutions with 20-40 mEq/L KCl over 3-4 h</td>
<td>ECG: U waves most important, flattened/inverted T waves, prolonged QT, depressed ST. May need to restore Mg²⁺.</td>
</tr>
<tr>
<td>Hypoaldosteronism</td>
<td>Excessive diuretics, diuretics, anorexia, salbutamol</td>
<td>N/V, fatigue, muscle cramps, constipation</td>
<td>K-Dur®; K+ sparing diuretics, IV solutions with 20-40 mEq/L KCl over 3-4 h</td>
<td>ECG: U waves most important, flattened/inverted T waves, prolonged QT, depressed ST. May need to restore Mg²⁺.</td>
</tr>
<tr>
<td>Hypoaldosteronism</td>
<td>Excessive diuretics, diuretics, anorexia, salbutamol</td>
<td>N/V, fatigue, muscle cramps, constipation</td>
<td>K-Dur®; K+ sparing diuretics, IV solutions with 20-40 mEq/L KCl over 3-4 h</td>
<td>ECG: U waves most important, flattened/inverted T waves, prolonged QT, depressed ST. May need to restore Mg²⁺.</td>
</tr>
<tr>
<td>Hypoaldosteronism</td>
<td>Excessive diuretics, diuretics, anorexia, salbutamol</td>
<td>N/V, fatigue, muscle cramps, constipation</td>
<td>K-Dur®; K+ sparing diuretics, IV solutions with 20-40 mEq/L KCl over 3-4 h</td>
<td>ECG: U waves most important, flattened/inverted T waves, prolonged QT, depressed ST. May need to restore Mg²⁺.</td>
</tr>
<tr>
<td>Hypoaldosteronism</td>
<td>Excessive diuretics, diuretics, anorexia, salbutamol</td>
<td>N/V, fatigue, muscle cramps, constipation</td>
<td>K-Dur®; K+ sparing diuretics, IV solutions with 20-40 mEq/L KCl over 3-4 h</td>
<td>ECG: U waves most important, flattened/inverted T waves, prolonged QT, depressed ST. May need to restore Mg²⁺.</td>
</tr>
<tr>
<td>Hypoaldosteronism</td>
<td>Excessive diuretics, diuretics, anorexia, salbutamol</td>
<td>N/V, fatigue, muscle cramps, constipation</td>
<td>K-Dur®; K+ sparing diuretics, IV solutions with 20-40 mEq/L KCl over 3-4 h</td>
<td>ECG: U waves most important, flattened/inverted T waves, prolonged QT, depressed ST. May need to restore Mg²⁺.</td>
</tr>
</tbody>
</table>

Hypertensive Emergencies

### Hypertensive Emergency (Hypertensive Crisis)

- Definition: severe elevation of BP with evidence of end-organ damage (CNS, retinal, CVS, renal, GI)
- Etiology
  - Essential HTN, emotional exertion, pain, use of sympathomimetic drugs (cocaine, amphetamine, etc.), MAOI use with ingestion of tyramine-containing food (cheese, red wine, etc.), pheochromocytoma, pregnancy
- Clinical presentation

#### Table 21. Signs and Symptoms of Hypertensive Emergencies

<table>
<thead>
<tr>
<th>CNS</th>
<th>Retinal</th>
<th>Renal</th>
<th>Cardiovascular</th>
<th>Gastrointestinal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke/TIA, headache, altered mental status, seizures, hemorrhage</td>
<td>Vision change, hemorrhage, exudates, papilledema</td>
<td>Nocturia, elevated Cr, proteinuria, hematuria, oliguria</td>
<td>Ischemia/angina, infarction, dissection (back pain), CHF</td>
<td>N/V, abdominal pain, increased liver enzymes</td>
</tr>
</tbody>
</table>

- Investigations
  - Blood work: CBC, electrolytes, BUN, Cr
  - Urinalysis
  - Peripheral blood smear: to detect microangiopathic hemolytic anemia
  - CXR: if SOB or chest pain
  - ECG, troponins, CK: if chest pain
  - CT head: if neurological findings or severe headache
  - Toxicology screen if sympathomimetic overdose suspected

- Management
  - In general, the strategy for management is to gradually and progressively reduce BP in 24-48 h
  - Lower BP by 25% over the initial 60 min by initiating antihypertensive therapy (usually nitroprusside and labetalol)
  - If preeclampsia, immediately consult OB/GYN (see Obstetrics, OR24)
  - Establish arterial line; transfer to ICU for further reduction in BP under monitored setting
  - In case of ischemic stroke: do not rapidly reduce BP; maintain BP > 150/100 for 5 d
  - In case of aortic dissection: rapid reduction of sBP to 110-120 STAT (do not resuscitate with IV fluids)
  - In case of excessive catecholamines: avoid β-blockers (except labetalol)
  - In case of ACS: address ischemia initially, then BP

- Catecholamine-Induced Hypertensive Emergencies
  - Avoid use of non-selective β-blockers as they inhibit β-mediated vasodilation and leave α-adrenergic vasoconstriction unopposed
Hypertensive Urgency

- definition: severely elevated BP (usually sBP >180, dBP >110) with no evidence of end-organ damage
- most commonly due to non-adherence with medications
- treatment: initiate/adjust antihypertensive therapy, monitor in ED (up to 6 h) and discharge with follow up for 48-72 h
- goal: differentiate hypertensive emergencies from hypertensive urgencies

Table 22. Commonly Used Agents for the Treatment of Hypertensive Crisis

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Onset of Action</th>
<th>Duration of Action</th>
<th>Adverse Effects*</th>
<th>Special Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium Nitroprusside</td>
<td>0.25-10 µg/kg/min</td>
<td>Immediate</td>
<td>3-5 min</td>
<td>N/V, muscle twitching, sweating, cyanide intoxication, coronary steal syndrome</td>
<td>Most hypertensive emergencies, especially CHF, aortic dissection. Use in combination with β-blockers (e.g. esmolol) in aortic dissection. Caution with high ICP and azotemia.</td>
</tr>
<tr>
<td>Labetalol</td>
<td>5-10 mg IV bolus, then 4 mg/kg/h IV</td>
<td>5-10 min</td>
<td>2-6 h</td>
<td>Dizziness, drowsiness, headache, tachycardia, Na+ retention</td>
<td>Eclampsia</td>
</tr>
<tr>
<td>Nicardipine (CCB)</td>
<td>2 mg IV bolus, then 4 mg/kg/h IV</td>
<td>15-30 min</td>
<td>40 min</td>
<td>Tachycardia, headache, flushing, local phlebitis (e.g. encephalopathy, RF, eclampsia, sympathetic crisis)</td>
<td>Most hypertensive emergencies, Caution with acute CHF</td>
</tr>
<tr>
<td>Fenoldopam Mesylate (dopamine receptor antagonist)</td>
<td>0.05-0.1 µm/kg/min IV</td>
<td>&lt;5 min</td>
<td>8-10 min</td>
<td>Tachycardia, headache, nausea, flushing (e.g. acute RF)</td>
<td>Most hypertensive emergencies, Caution with glaucoma</td>
</tr>
<tr>
<td>Enalapril (ACEI)</td>
<td>0.625-1.25 mg q6h</td>
<td>15-30 min</td>
<td>12-24 h</td>
<td>Theoretical fall in pressure in high renin states not seen in studies</td>
<td>Acute LV failure, Avoid in acute MI, pregnancy, acute RF</td>
</tr>
<tr>
<td>Nitroglycerin</td>
<td>5-20 µg/min IV</td>
<td>1-2 min</td>
<td>3-5 min</td>
<td>Hypotension, bradycardia, headache, lightheadedness, dizziness</td>
<td>MI/pulmonary edema</td>
</tr>
<tr>
<td>Hydralazine</td>
<td>5-10 mg IV/IM q20min (max 20 mg)</td>
<td>5-20 min</td>
<td>2-6 h</td>
<td>Dizziness, drowsiness, headache, tachycardia, Na+ retention</td>
<td>Eclampsia</td>
</tr>
</tbody>
</table>

ADRENERGIC INHIBITORS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Onset of Action</th>
<th>Duration of Action</th>
<th>Adverse Effects*</th>
<th>Special Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labetalol</td>
<td>20 mg IV bolus q10min or 0.5-2 mg/min</td>
<td>5-10 min</td>
<td>3-6 h</td>
<td>Vomiting, scalp tingling, burning in throat, dizziness, nausea, heart block, orthostatic hypotension</td>
<td>Most hypertensive emergencies (especially eclampsia), Avoid in acute CHF, heart block &gt;1st degree</td>
</tr>
<tr>
<td>Esmolol</td>
<td>250-500 µg/kg/min 1 min, then 50 µg/kg/min for 4 min; repeat</td>
<td>1-2 min</td>
<td>10-20 min</td>
<td>Hypotension, nausea, bronchospasm</td>
<td>Aortic dissection, acute MI, SVT dysrhythmias, perioperative HTN, Avoid in acute CHF, heart block &gt;1st degree</td>
</tr>
<tr>
<td>Phentolamine</td>
<td>5-15 mg q5-15min</td>
<td>1-2 min</td>
<td>3-10 min</td>
<td>Tachycardia, headache, flushing</td>
<td>Catecholamine excess (e.g. pheochromocytoma)</td>
</tr>
</tbody>
</table>

*Hypotension may occur with all of these agents

Acute Coronary Syndrome

- see Cardiology and Cardiac Surgery, C27
- definition: new onset of chest pain, or acute worsening of previous chest pain, or chest pain at rest with:
  - negative cardiac biomarkers and no ECG changes = Unstable angina (UA)
  - positive cardiac biomarkers (elevated troponin) and no ECG changes = NSTEMI
  - positive cardiac biomarkers (elevated troponin) and ST segment elevation on ECG = STEMI
- investigations
  - ECG STAT (as soon as ACS is suspected on history), troponin (2-6 hours after symptom onset), CXR (to rule out other causes)
- management
  - stabilize: ABCs, oxygen, IV access, cardiac monitors, oximetry
  - ASA 162-325 mg chewed and swallowed
  - nitroglycerin 0.3 mg SL q5min x 3; IV only if persistent pain, CHF, or hypertensive
- contraindications: hypotension, phosphodiesterase inhibitor use, right ventricular infarctions (½ of all inferior MIs)
anticoagulation: choice of anticoagulation (unfractionated heparin, LMWH, or fondaparinux) and additional antiplatelet therapy (clopidogrel, ticagrelor, or prasugrel) depends on STEMI vs. NSTEMI and reperfusion strategy

early cardiology consult for reperfusion therapy
  • UA/NSTEMI: early coronary angiography recommended if high TIMI risk score
  • STEMI: primary percutaneous coronary intervention (within 90 min) preferred; thrombolytics if unavailable within 120 min of medical contact, symptoms <12 hr and no contraindications
• atorvastatin 80 mg to stabilize plaques
• β-blocker if no signs of CHF, hemodynamic compromise, bradycardia or severe reactive airway disease
• ACEI initiated within 24 hours

Sepsis

• see Infectious Diseases, ID21 and Respiratory, R33
• definitions
  • SIRS: Two or more of: 1) T < 36 or > 38; 2) Pulse > 90 bpm; 3) RR > 20 breaths per min (or PaCO₂ < 30 mmHg); 4) WBC > 12 x 10³ cells/L, or < 4 x 10³ cells/L, or > 10% bands
• sepsis: SIRS in response to infection
  • severe sepsis: sepsis and signs of organ dysfunction (altered mental status, lung injury, renal failure, coagulopathy, decreased urine output, lactic acidosis, liver failure)
  • septic shock: severe sepsis and hypotension (sBP <90) unresponsive to IV crystalloid
• management
  • early recognition of sepsis and investigations to locate source of infection
  • identify severe sepsis with lactate or evidence of tissue hypoperfusion
  • treatment priorities
    • ABCs, monitors, lines
    • aggressive fluid resuscitation; consider ventilatory and inotropic support
    • cultures, then early empiric appropriate antibiotics - consider broad spectrum and atypical coverage
    • source control - e.g. remove infected Foley or surgery for ischemic gut
  • monitor adequate resuscitation with vital signs, inferior vena cava on U/S, and serial lactates

Stroke and TIA

• see Neurology, N48
• definitions
  • stroke: sudden loss of brain function due to ischemia (80%) or hemorrhage (20%) with persistence of symptoms >24 hr or neuroimaging evidence
  • TIA: transient episode of neurologic dysfunction from focal ischemia without acute infarction typically lasting <1 h, but defined as <24 h
• clinical presentation

Table 23. Signs and Symptoms of Stroke

<table>
<thead>
<tr>
<th>Signs/ Symptoms</th>
<th>General</th>
<th>Language/ Threat</th>
<th>Vision</th>
<th>Coordination</th>
<th>Motor</th>
<th>Sensation</th>
<th>Reflex</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decreased LOC, changed mental status, confusion, neglect</td>
<td>Dysarthria, aphasia, swallowing difficulty</td>
<td>Diplopia, eye deviation, asymmetric pupils, visual field defect</td>
<td>Ataxia, intention tremor, lack of coordination</td>
<td>Increased tone, loss of power, spasticity</td>
<td>Loss of sensation</td>
<td>Hyper-reflexia, clonus</td>
<td></td>
</tr>
</tbody>
</table>

patients with hemorrhagic stroke can present with sudden onset thunderclap headache that is usually described as “worst headache of life”

stroke mimics: seizure, migraine, hypoglycemia, Todd’s paresis, peripheral nerve injury, Bell’s palsy, tumour, syncope

Table 24. Stroke Syndromes

<table>
<thead>
<tr>
<th>Region of Stroke</th>
<th>Stroke Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anterior Cerebral Artery</td>
<td>Primarily frontal lobe function affected</td>
</tr>
<tr>
<td>Middle Cerebral Artery</td>
<td>Contralateral hemiparesis (arm and face weakness &gt; leg weakness) and hypoesthesia, ipsilateral hemianopsia, gaze preference to side of lesion ± agnosia, receptive/expressive aphasia</td>
</tr>
<tr>
<td>Posterior Cerebral Artery</td>
<td>Affects vision and thought</td>
</tr>
<tr>
<td>Verteobasilar Artery</td>
<td>Wide variety of cranial nerve, cerebellar, and brainstem deficits: vertigo, nystagmus, diplopia, visual field deficits, dysphagia, dysarthria, facial hypoesthesia, syncope, ataxia</td>
</tr>
</tbody>
</table>

Loss of pain and temperature sensation in ipsilateral face and contralateral body

7 Causes of Emboli from the Heart

- AFib
- MI
- Endocarditis
- Valvular disease
- Dilated cardiomyopathy
- Left heart myxoma
- Prosthetic valves

Differentiation of UMN Disease vs. LMN Disease

<table>
<thead>
<tr>
<th>Category</th>
<th>UMN Disease</th>
<th>LMN Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muscular</td>
<td>Muscle groups</td>
<td>Increased</td>
</tr>
<tr>
<td>Deficit</td>
<td>Absent</td>
<td>Decreased</td>
</tr>
<tr>
<td>Reflexes</td>
<td>Increased</td>
<td>Absent</td>
</tr>
<tr>
<td>Tone</td>
<td>Absent/minimal</td>
<td>Present</td>
</tr>
<tr>
<td>Fasciculations</td>
<td>Absent</td>
<td>Present</td>
</tr>
<tr>
<td>Atrophy</td>
<td>Absent</td>
<td>Present</td>
</tr>
<tr>
<td>Babinski</td>
<td>Upgoing</td>
<td>Downgoing</td>
</tr>
</tbody>
</table>
Otolaryngological Presentations and Emergencies

Investigations
• CBC, electrolytes, blood glucose, coagulation studies ± cardiac biomarkers ± toxicology screen
• non-contrast CT head: look for hemorrhage, ischemia
• ECG ± echocardiogram: rule out AFib, acute MI as source of emboli
• other imaging: carotid Dopplers, CTA, MRA as appropriate

Management
• ABCs; intubation with RSI if GCS ≤ 8, rapidly decreasing GCS, or inadequate airway protection reflexes
• thrombolysis: immediate assessment for eligibility; need acute onset, <4.5 h from drug administration time AND compatible physical findings AND normal CT with no bleed
• elevating head of bed if risk of elevated ICP, aspiration, or worsening cardiopulmonary status
• NPO, IV ± cardiac monitoring
  ▪ judge fluid rate carefully to avoid overhydration (cerebral edema) as well as underhydration (underperfusion of the ischemic penumbra)
• BP control: only treat severe HTN (sBP > 200, dBP > 120, mean arterial BP > 140) or HTN associated with hemorrhagic stroke transformation, cardiac ischemia, aortic dissection, or renal damage; use IV nitroprusside or labetalol
• glycemic control: keep fasting glucose < 6.5 in acute phase (5 d)
• cerebral edema control: hyperventilation, mannitol to decrease ICP if necessary
• consult neurosurgery, neurology, medicine as indicated

Medications
• acute ischemic stroke: thrombolytics (rt-PA, e.g. alteplase) if within 4.5 h of symptom onset with no evidence of hemorrhage on CT scan
• antiplatelet agents: prevent recurrent stroke or stroke after TIs, e.g. Aspirin® (1st line); clopidogrel, Aggrenox® (2nd line)
• anticoagulation: DVT prophylaxis if immobile; treat AFib if present
• follow-up for consideration of carotid endarterectomy, cardiovascular risk optimization

Otolaryngological Presentations and Emergencies

• see Otolaryngology, OT6
• ear associated symptoms: otalgia, aural fullness, otorrhea, hearing loss, tinnitus, vertigo, pruritis, fever
• risk factors: Q-tip use, hearing aids, headphones, occupational noise exposure

Dizziness and Vertigo
• distinguish four types of dizziness: vertigo (“room spinning”), lightheadedness (“disconnected from environment”), presyncope (“almost blacking out”), dysequilibrium (“unstable, off-balance”)
• broad differential and diverse management (see Family Medicine, FM25; Otolaryngology, OT6)
• consider medication adverse effects

Otalgia (see Otolaryngology, OT6)
• differential diagnosis
  ▪ infections: acute otitis externa, acute otitis media, otitis media with effusion, mastoiditis, myringitis, malignant otitis in diabetics, herpes simplex/zoster, auricular cellulitis, external canal abscess, dental disease
  ▪ others: trauma, temporomandibular joint dysfunction, neoplasm, foreign body, cerumen impactions, trigeminal neuralgia, granulomatosis with polyangiitis
• observe for otorrhea, palpation of outer ear/mastoid, otoscope to see bulging erythematous tympanic membrane, perforation
• C&S of ear canal discharge, if present
• CT head if suspicion of mastoiditis, malignant otitis externa
• antibiotics/antifungals/antivirals for respective infections

Hearing Loss (see Otolaryngology, OT7)
• differentiate conductive versus sensorineural hearing loss
• rule out sudden sensorineural hearing loss (SNHL), a medical emergency requiring high dose steroids and urgent referral
• in elderly, unilateral tinnitus or SNHL is acoustic neuroma until proven otherwise
• consider audiogram and referral or follow-up with family physician

Epistaxis

• see Otolaryngology, OT26
• 90% of nosebleeds stem from the anterior nasal septum (at Kiesselbach’s plexus located in Little’s area)
• can be life-threatening
Etiology
- most commonly caused by trauma (digital, blunt, foreign bodies)
- other causes: barometric changes, nasal dryness, chemicals (cocaine, Otrivin®), or systemic disease (coagulopathies, HTN, etc.)

Investigations
- blood work: CBC, PT/PTT (as indicated)
- imaging: X-ray, CT as needed

Treatment
- aim is to localize bleeding and achieve hemostasis
- first-aid: ABCs, clear clots by blowing nose or suctioning, lean forward, pinch cartilaginous portion of nose for 20 min twice
- assess blood loss: vitals, IV NS, cross match 2 units pRBC if significant
- if first aid measures fail twice, proceed to packing
- apply an anterior pack
  - clear nose of any clots
  - apply topical anesthesia/vasoconstrictors (lidocaine with epinephrine, cocaine, or soaked pledgets)
  - insert either a traditional Vaseline® gauze pack or a commercial nasal tampon or balloon
  - if bleeding stops, arrange follow-up in 48-72 h for reassessment and pack removal
  - if packing both nares, prophylactic anti-staphylococcal antibiotics to prevent sinusitis or toxic shock syndrome
  - if bleeding is controlled with anterior pressure, cautery with silver nitrate can be performed if the site of bleeding is identified (one side of septum only because if both are cauterized this can lead to septal perforation)
- if suspect posterior bleed or anterior packing does not provide hemostasis, consult ENT for posterior packing and further evaluation
- posterior packing requires monitoring because can cause significant vagal response and posterior bleeding source can lead to significant blood loss, therefore usually requires admission

Disposition
- discharge: discharged upon stabilization and appropriate follow-up; educate patients about prevention (e.g. humidifiers, saline spray, topical ointments, avoiding irritants, managing HTN)
- admission: severe cases of refractory bleeding, and most cases of posterior packing

Gynecologic/Urologic Emergencies

Vaginal Bleeding

- see Gynecology, GY10 and Obstetrics, OB13

Etiology
- pregnant patient
  - 1st/2nd trimester pregnancy: ectopic pregnancy, abortion (threatened, incomplete, complete, missed, inevitable, septic), molar pregnancy, implantation bleeding, friable cervix (most common cause)
  - 2nd/3rd trimester pregnancy: placenta previa, placental abruption, premature rupture of membranes, preterm labour
  - other: trauma, bleeding cervical polyp, passing of mucous plug
- postpartum
  - postpartum hemorrhage, uterine inversion, retained placental tissue, endometritis
- non-pregnant patients
  - dysfunctional uterine bleeding, uterine fibroids, pelvic tumours, trauma, endometriosis, PID, exogenous hormones

History
- characterize bleeding (frequency, duration, number of pads/tampons, cyclicity)
- pain, if present (OPQRSTU)
- menstrual history, sexual history, STI history, syncope/pre-syncope
- details of pregnancy, including gush of fluid and fetal movement (>20 wk)

Physical Exam
- ABC (especially noting postural BP/HR and mucous membrane)
- abdominal examination (peritoneal signs, tenderness, distension, mass)
- speculum examination (NOT IF 2nd/3rd trimester bleeding; perform only when placenta previa is ruled out with U/S)
  - look for active bleeding, trauma/anomaly, and cervical dilatation
  - use sterile speculum if pregnant
- bimanual examination (cervical tenderness, size of uterus, cervical length/dilatation)
- sterile gloves if pregnant

Complications of Nasal Packing
- Thrombocytopenic patients – use resorbable packs to avoid risk of re-bleeding caused by pulling out the removable pack
- Complications of Nasal Packing
  - Hypoxemia
  - Toxic-shock syndrome
  - Aspiration
  - Pharyngeal fibrosis/stenosis
  - Alar/septal necrosis

Gynaecology can be life-threatening
Always start with ABCs and ensure your patient is stable
Investigations
- β-hCG test for all patients with childbearing potential
- CBC, blood and Rh type, quantitative β-hCG, PT, INR
- type and cross if significant blood loss
- transvaginal U/S (rule out ectopic pregnancy and spontaneous abortion)
- abdominal U/S (rule out placenta previa and fetal demise)
- postpartum
  - U/S for retained products
  - β-hCG if concerned about retained tissue

Management
- ABCs
- pulse oximeter and cardiac monitors if unstable
- Rh immune globulin (Rhogam®) for vaginal bleeding in pregnancy and Rh-negative mother
- 1st/2nd trimester pregnancy
  - ectopic pregnancy: definitive treatment with surgery or methotrexate
  - intrauterine pregnancy, no concerns of coexistent ectopic; discharge patient with obstetrics follow-up
  - U/S indeterminate or β-hCG >1,000-2,000 IU: further workup and/or gynecology consult
- abortions: if complete, discharge if stable; for all others, acquire gynecology consult
- 2nd/3rd trimester pregnancy
  - placenta previa or placental abruption: obstetrics consult for possible admission
- postpartum
  - manage ABCs: start 2 large bore IV rapid infusion, type and cross 4 units of blood, consult OB/GYN immediately
- non-pregnant
  - dysfunctional uterine bleeding (prolonged or heavy flow ± breakthrough bleeding and without ovulation, a diagnosis of exclusion)
    - <35-40 yr of age: Provera® 10 mg PO OD x 10 d, warn patient of a withdrawal bleed, discharge if stable
    - if unstable, admit for IV hormonal therapy, possible D&C
  - >35-40 yr of age: uterine sampling necessary prior to initiation of hormonal treatment to rule out endometrial cancer, U/S for any masses felt on exam
  - tranexamic acid (Cyklokapron®) to stabilize clots
  - structural abnormalities: fibroids or uterine tumours may require excision for diagnosis/treatment, U/S for workup of other pelvic masses, Pap smear/biopsy for cervical lesions

Disposition
- decision to admit or discharge should be based on the stability of the patient, as well as the nature of the underlying cause; consult gynecology for admitted patients
- if patient can be safely discharged, ensure follow-up with family physician or gynecologist
- instruct patient to return to ED for increased bleeding, presyncope

Pregnant Patient in the ED

Table 25. Complications of Pregnancy

<table>
<thead>
<tr>
<th>Trimester</th>
<th>Fetal</th>
<th>Maternal</th>
</tr>
</thead>
<tbody>
<tr>
<td>First</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-12 wk</td>
<td>Pregnancy failure</td>
<td>Ectopic pregnancy</td>
</tr>
<tr>
<td></td>
<td>Spontaneous abortion</td>
<td>Anemia</td>
</tr>
<tr>
<td></td>
<td>Fetal demise</td>
<td>Hyperemesis gravidarum</td>
</tr>
<tr>
<td></td>
<td>Gestational trophoblastic disease</td>
<td>UTI/pyelonephritis</td>
</tr>
<tr>
<td>Second</td>
<td>Disorders of fetal growth</td>
<td>Gestational DM</td>
</tr>
<tr>
<td>13-27 wk</td>
<td>IUGR</td>
<td>Rh incompatibility</td>
</tr>
<tr>
<td></td>
<td>Oligo/polyhydramnios</td>
<td>UTI/pyelonephritis</td>
</tr>
<tr>
<td>Third</td>
<td>Vasa previa</td>
<td>Preterm labour/PPROM</td>
</tr>
<tr>
<td>28-41 wk</td>
<td></td>
<td>Preeclampsia/eclampsia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placenta previa</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placental abruption</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Uterine rupture</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DVT</td>
</tr>
</tbody>
</table>
Nephrolithiasis (Renal Colic)

- see Urology, U17

Epidemiology and Risk Factors
- 10% of population (twice as common in males)
- recurrence 50% at 5 yr
- peak incidence 30-50 yr of age
- 75% of stones <5 mm pass spontaneously within 2 wk, larger stones may require consultation

Clinical Features
- urinary obstruction → upstream distention of ureter or collecting system → severe colicky pain
- may complain of pain at flank, groin, testes, or tip of penis
- writhing, never comfortable, N/V, hematuria (90% microscopic), diaphoresis, tachycardia, tachypnea
- occasionally symptoms of trigonal irritation (frequency, urgency)
- fever, chills, rigors in secondary pyelonephritis
- peritoneal findings/anterior abdominal tenderness usually absent

Differential Diagnosis of Renal Colic
- acute ureteric obstruction
- acute abdomen: biliary, bowel, pancreas, AAA
- urogynecological: ectopic pregnancy, torsion/rupture of ovarian cyst, testicular torsion
- pyelonephritis (fever, chills, pyuria, vomiting)
- radiculitis (L1): herpes zoster, nerve root compression

Investigations
- screening
- CBC: elevated WBC in presence of fever suggests infection
- electrolytes, Cr, BUN to assess renal function
- UA: R&M (WBCs, RBCs, crystals), C&S
- imaging
- non-contrast spiral CT is the study of choice
- abdominal U/S may demonstrate stone or hydronephrosis (consider in females of childbearing age)
- AXR will identify large radioopaque stones (calcium, struvite, and cystine stones) but may miss smaller stones, uric acid stones, or stones overlying bony structures; consider as an initial investigation in patients who have a history of radioopaque stones and similar episodes of acute flank pain (CT necessary if film is negative)
- strain all urine stone analysis

Management
- analgesics: NSAIDs (usually ketorolac [Toradol™], preferable over opioids), antiemetics, IV fluids
- urology consult may be indicated, especially if stone >5 mm, or if patient has signs of obstruction or infection
- α-blocker (e.g. tamsulosin) may be helpful to increase stone passage in select cases

Disposition
- most patients can be discharged
- ensure patient is stable, has adequate analgesia, and is able to tolerate oral medications
- may advise hydration and limitation of protein, sodium, oxalate, and alcohol intake

Ophthalmologic Emergencies

- see Ophthalmology, OP5

History and Physical Exam
- patient may complain of pain, tearing, itching, redness, photophobia, foreign body sensation, trauma
- mechanism of foreign body insertion → if high velocity injury suspected (welding, metal grinding, metal striking metal), must obtain orbital X-rays, U/S, or CT scan to exclude presence of intraocular metallic foreign body
- visual acuity in both eyes, pupils, extraocular structures, fundoscopy, tonometry, slit lamp exam

Management of Ophthalmologic Foreign Body
- copious irrigation with saline for any foreign body
- remove foreign body under slit lamp exam with cotton swab or sterile needle
- antibiotic drops qid until healed
- patching may not improve healing or comfort – do not patch contact lens wearers
- limit use of topical anesthetic to examination only
- consider tetanus prophylaxis
- ophthalmology consult if globe penetration suspected

Visual acuity is the “vital sign” of the eyes and should ALWAYS be assessed and documented in both eyes when a patient presents to the ER with an ophthalmologic complaint.
Table 26. Differential Diagnosis of Red Eye in the Emergency Department

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Possible Serious Etiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Light sensitivity</td>
<td>Iritis, keratitis, abrasion, ulcer</td>
</tr>
<tr>
<td>Unilateral</td>
<td>Above + herpes simplex, acute angle closure glaucoma</td>
</tr>
<tr>
<td>Significant pain</td>
<td>Above + scleritis</td>
</tr>
<tr>
<td>White spot on cornea</td>
<td>Corneal ulcer</td>
</tr>
<tr>
<td>Non-reactive pupil</td>
<td>Acute glaucoma, iritis</td>
</tr>
<tr>
<td>Copious discharge</td>
<td>Gonococcal conjunctivitis</td>
</tr>
<tr>
<td>Blurred vision</td>
<td>All of the above</td>
</tr>
</tbody>
</table>

Painless vision loss: Central retinal vein occlusion, amaurosis fugax, occipital stroke

Table 27. Select Ophthalmologic Emergencies

<table>
<thead>
<tr>
<th>Condition</th>
<th>Signs and Symptoms</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute Angle Closure Glaucoma</td>
<td>Unilateral red, painful eye</td>
<td>Ophthalmology consult for laser iridotomy</td>
</tr>
<tr>
<td></td>
<td>Decreased visual acuity, halos around lights</td>
<td>Topical β-blockers, adrenergics, and cholinergics</td>
</tr>
<tr>
<td></td>
<td>Fixed, mid-dilated pupil</td>
<td>Systemic carbonic anhydrase inhibitors and</td>
</tr>
<tr>
<td></td>
<td>N/V</td>
<td>hyperosmotic agents</td>
</tr>
<tr>
<td></td>
<td>Marked increase in IOP (&gt; 40 mmHg)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Shallow anterior chamber ± cells</td>
<td></td>
</tr>
<tr>
<td>Chemical Burn</td>
<td>Known exposure to acids or alkali (reverse)</td>
<td>Irrigate at site of accident</td>
</tr>
<tr>
<td></td>
<td>Pain, decreased visual acuity</td>
<td>IV NS drip in ED with eyelid retracted</td>
</tr>
<tr>
<td></td>
<td>Vascularization or defects of cornea</td>
<td>Swab fomices</td>
</tr>
<tr>
<td></td>
<td>Iris and lens damage</td>
<td>Cycloplegic drops</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Topical antibiotics and patching</td>
</tr>
<tr>
<td>Orbital Cellulitis</td>
<td>Red, painful eye, decreased visual acuity</td>
<td>Admission, ophthalmology consult</td>
</tr>
<tr>
<td></td>
<td>Headache, fever</td>
<td>Blood cultures, orbital CT</td>
</tr>
<tr>
<td></td>
<td>Lid erythema, edema, and difficulty opening eye</td>
<td>IV antibiotics (ceftiraxone+ vancomycin)</td>
</tr>
<tr>
<td></td>
<td>Conjunctival injection and chemosis</td>
<td>Drainage of abscess</td>
</tr>
<tr>
<td></td>
<td>Proptosis, ophthalmoplegia ± RAPD</td>
<td></td>
</tr>
<tr>
<td>Retinal Artery Occlusion</td>
<td>Sudden, painless, monocular vision loss</td>
<td>Restore blood flow &lt;2 h</td>
</tr>
<tr>
<td></td>
<td>RAPD</td>
<td>Massage globe</td>
</tr>
<tr>
<td></td>
<td>Cherry red spot and retinal pallor on fundoscopy</td>
<td>Decrease IOP (topical β-blockers, inhaled O2/CO2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>mix, IV Diamox™, IV mannitol, drain aqueous fluid</td>
</tr>
<tr>
<td>Retinal Detachment</td>
<td>Flashes of light, floaters, and curtains of blackness/</td>
<td>Ophthalmology consult for scleral buckle/</td>
</tr>
<tr>
<td></td>
<td>peripheral vision loss</td>
<td>pneumatic retinopexy</td>
</tr>
<tr>
<td></td>
<td>Painless</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Loss of red reflex, decreased IOP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Detached areas are grey ± RAPD</td>
<td></td>
</tr>
</tbody>
</table>

**Contraindications to Pupil Dilation**
- Shallow anterior chamber
- Iris-supported lens implant
- Potential neurological abnormality requiring pupillary evaluation
- Cautions with CV disease — mydriatics can cause tachycardia

**Other Ophthalmologic Emergencies**
- **Infectious:** Red eye, endophthalmitis, hypopyon
- **Trauma:** Globe rupture, orbital blow-out fractures, corneal injuries, eyelid laceration, hyphaema, lens dislocation, retrobulbar hemorrhage
- **Painful vision loss:** Acute iritis, corneal abrasion, globe rupture, lens dislocation, retrobulbar hemorrhage, optic neuritis, temporal arteritis, endophthalmitis, keratitis
- **Painless vision loss:** Central retinal vein occlusion, amaurosis fugax, occipital stroke

**Dermatologic Emergencies**

**Rash Characteristics**

**A. Diffuse Rashes**

- **Staphylococcal Scalded Skin Syndrome (SSSS)**
  - caused by an exotoxin from infecting strain of coagulase-positive *S. aureus*
  - mostly occurs in children
  - prodrome: fever, irritability, malaise, and skin tenderness
  - sudden onset of diffuse erythema: skin is red, warm, and very tender
  - flaccid bullae that are difficult to see, then desquamate in large sheets
  - Nikolsky’s sign: gentle lateral stroking of skin causes epidermis to separate

- **Toxic Epidermal Necrolysis (TEN): >30% of BSA**
  - see Dermatology, D22
  - caused by drugs (e.g. phenytoin, sulfas, penicillins, and NSAIDs), bone marrow transplantation, and blood product transfusions
  - usually occurs in adults
  - diffuse erythema followed by necrosis
  - severe mucous membrane blistering
  - entire epidermis desquamation
  - high mortality (>50%)

- **Toxic Shock Syndrome (TSS)**
  - see Infectious Diseases, ID23
  - caused by superantigen from *S. aureus* or GAS activating T-cell and cytokines
  - patient often presents with onset of shock and multi-organ failure, fever
  - diffuse erythematous macular rash
  - at least 3 organ systems involved: CNS, respiratory, GI, muscular, mucous membranes, renal, liver, hematologic, and skin (necrotizing fasciitis, gangrene)
Dermatologic Emergencies

- vesicobullous lesions
- Erythema Multiforme (EM)
  - see Dermatology, D29
  - immunologic reaction to herpes simplex
  - viral prodrome 1-14 d before rash
  - "target lesion": central grey bulla or wheal surrounded by concentric rings of erythema and normal skin
- Stevens-Johnson Syndrome (SJS): <10% of BSA
  - see Dermatology, D22
  - related to drugs such as antiepileptics and biologic agents (e.g. infliximab)
  - EM with constitutional symptoms and mucous membrane involvement (milder mucous membrane involvement than TEN)

B. Discrete Lesions
- pyoderma gangrenosum
  - often associated with immunocompromised patients (HIV, leukemia, or lymphoma) with Gram-negative sepsis
  - often occurs in arms, hands, feet, or perineal region
  - usually begins as painless macule/vesicle pustule/bulla on red/blue base sloughing, leaving a gangrenous ulcer
- disseminated gonococcal infection
  - see Dermatology, D32
  - fever, skin lesions (pustules/vesicles on erythematous base ~5 mm in diameter), arthritis (joint swelling and tenderness), and septic arthritis (in larger joints, such as knees, ankles, and elbows)
  - most commonly in gonococcus positive women during menstruation or pregnancy
  - skin lesions usually appear in extremities and resolve quickly (<7 d)
- meningococcemia
  - flu-like symptoms of headache, myalgia, N/V
  - petechial, macular, or maculopapular lesions with grey vesicular centres
  - usually a few millimeters in size, but may become confluent and hemorrhagic
  - usually appear in extremities, but may appear anywhere
  - look for signs of meningeal irritation: Brudzinski, Kernig, nuchal rigidity, jolt accentuation

**History and Physical Exam**
- determine onset, course, and location of skin lesions
- fever, joint pain
- associated symptoms: CNS, respiratory, GU, GI, renal, liver, mucous membranes
- medication history
- vitals

**Investigations**
- immediate consultation if patient unstable
- CBC, electrolytes, Cr, AST, ALT, ALP, blood culture, skin biopsy, serum immunoglobulin levels (serum IgE)

**Management**
- general: judicious IV fluids and electrolyte control, consider vasopressors if hypotensive, prevention of infection
- determine if admission and consult needed: dermatology or infectious diseases
- specific management is determined by etiology
  - SSSS, TSS, DGI, and meningococcemia
  - IV antibiotics
  - EM, SJS, and TEN
    - stop precipitating medication
    - fluids
    - symptomatic treatment: antihistamines, antacids, topical corticosteroids, systemic corticosteroids (controversial), prophylactic oral acyclovir, consider IVIG
    - TEN: debride necrotic tissue

**Disposition**
- most cases will require urgent care and hospitalization
- TEN: early transfer to burn centre improves outcome
Environmental Injuries

Heat Exhaustion and Heat Stroke

- Predisposing factors: young persons who overexert themselves, older adults who cannot dissipate heat at rest (e.g. using anticholinergic drugs such as antihistamines or TCAs), and patients with schizophrenia who are using anticholinergic or antiepileptic medications

Heat Exhaustion
- Clinical features relate to loss of circulating volume caused by exposure to heat stress
- "Water depletion": heat exhaustion occurs if lost fluid not adequately replaced
- "Salt depletion": heat exhaustion occurs when losses replaced with hypotonic fluid

Heat Stroke
- Life-threatening emergency resulting from failure of normal compensatory heat-shedding mechanisms
- Divided into classical and exertional subtypes
- If patient does not respond relatively quickly to cooling treatments, consider other possible etiologies of hyperpyrexia (e.g. meningitis, thyroid storm, anticholinergic poisoning, delirium tremens, other infections)

Table 28. Heat Exhaustion vs. Heat Stroke

<table>
<thead>
<tr>
<th>Clinical Features</th>
<th>Heat Exhaustion</th>
<th>Classical Heat Stroke</th>
<th>Exertional Heat Stroke</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body temp &lt; 32°C</td>
<td>Non-specific malaise, headache, fatigue</td>
<td>Occurs in setting of high ambient temperatures (e.g. heat wave, poor ventilation)</td>
<td>Occurs with high endogenous heat production (e.g. exercise) that overwhelms homeostatic mechanisms</td>
</tr>
<tr>
<td>No coma or seizures</td>
<td>Dehydration (HR, orthostatic hypotension)</td>
<td>Often patients are older, poor, and sedentary or immobile</td>
<td>Patients often younger, more active</td>
</tr>
<tr>
<td>Temp usually &gt; 40.5°C</td>
<td>Altered mental status, seizures, delirium, or coma</td>
<td>May have elevated AST, ALT</td>
<td>Skin often diaphoretic</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Rest in a cool environment IV NS if orthostatic hypotension; otherwise replace losses slowly PO</th>
<th>Cool body temperature with water mist (e.g. spray bottle) and standing fans</th>
<th>Ice water immersion also effective; monitor body temperature closely to avoid hypothermic overshoot</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Secure airway because of seizure and aspiration risk</td>
<td>Give fluid resuscitation if still hypotensive after above therapy</td>
<td>Avoid β-agonists (e.g. epinephrine), peripheral vasconstriction, and antipyretics (e.g. ASA)</td>
</tr>
</tbody>
</table>

Hypothermia and Cold Injuries

HYPOTHERMIA
- Predisposing factors: extremes of age, lack of housing, drug overdose, EtOH ingestion, trauma (incapacitating), cold water immersion, outdoor sports
- Treatment based on re-warming and supporting cardiorespiratory function
- Complications: coagulopathy, acidosis, ventricular dysrhythmias (VFib), asystole, volume and electrolyte depletion
- Labs: CBC, electrolytes, ABG, serum glucose, Cr/BUN, Mg++, Ca++, amylase, coagulation profile
- Imaging: CXR (aspiration pneumonia, pulmonary edema are common)
- Monitors: ECG, rectal thermometer, Foley catheter, NG tube, monitor metabolic status frequently

Table 29. Classification of Hypothermia

<table>
<thead>
<tr>
<th>Class</th>
<th>Temp</th>
<th>Symptoms/Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>32-34.9°C</td>
<td>Tachypnea, tachycardia, ataxia, dysarthria, shivering</td>
</tr>
<tr>
<td>Moderate</td>
<td>28-31.9°C</td>
<td>Loss of shivering, dysrhythmias, Osborne (J) waves on ECG, decreased LOC, combative behaviour, muscle rigidity, dilated pupils</td>
</tr>
<tr>
<td>Severe</td>
<td>&lt; 28°C</td>
<td>Coma, hypotension, acidemia, VFib, asystole, flaccidity, apnea</td>
</tr>
</tbody>
</table>

Re-warming Options
- Gentle fluid and electrolyte replacement in all (due to cold diuresis)
- Passive external re-warming
  - Suitable for most stable patients with core temperature >32.2°C
  - Involves covering patient with insulating blanket; body generates heat and re-warms through metabolic process, shivering
Environmental Injuries

• active external re-warming
  ■ involves use of warming blankets
  ■ beware of "afterdrop" phenomenon
  ■ safer when done in conjunction with active core re-warming

• active core re-warming
  ■ generally for patients with core temperature <32.2°C, and/or with cardiovascular instability
  ■ avoids "afterdrop" seen with AER alone
  ■ re-warm core by using
    ◆ warmed humidified oxygen, IV fluids
    ◆ peritoneal dialysis with warm fluids
    ◆ stric/colonic/pleural irrigation with warm fluids
    ◆ external circulation (cardiopulmonary bypass machine) is most effective and fastest

Approach to Cardiac Arrest in the Hypothermic Patient
• do all procedures gently or may precipitate VFib
• check pulse and rhythm for at least 1 min; may have profound bradycardia
• if any pulse at all (even very slow) do NOT do CPR
• if in VFib try to defibrillate up to maximum 3 shocks if core temperature <30°C
• intubate if required, ventilate with warmed, humidified O₂
• medications (vasopressors, antidysrhythmics) may not be effective at low temperatures
  ◆ controversial; may try one dose
• focus of treatment is re-warming

FROSTBITE

Classification
• ice crystals form between cells
• classified according to depth – similar to burns (1st to 3rd degree)
• 1st degree
  ■ symptoms: initial paresthesia, pruritus
  ■ signs: erythema, edema, hyperemia, no blisters
• 2nd degree
  ■ symptoms: numbness
  ■ signs: blistering (clear), erythema, edema
• 3rd degree
  ■ symptoms: pain, burning, throbbing (on thawing); may be painless if severe
  ■ signs: hemorrhagic blisters, skin necrosis, edema, no movement

Management
• treat for hypothermia: O₂, IV fluids, maintenance of body warmth
• remove wet and constrictive clothing
• immerse in 40-42°C agitated water for 10-30 min (very painful; administer adequate analgesia)
• clean injured area and leave it open to air
• consider aspiration/debridement of blisters (controversial)
• debride skin
• tetanus prophylaxis
• consider penicillin G as frost bite injury has high risk of infection
• surgical intervention may be required to release restrictive eschars
• never allow a thawed area to re-chill/freeze

Burns

• see Plastic Surgery, PL17

Clinical Presentation/Physical Exam Findings
• burn size
  ■ rule of nines; does not include 1st degree burns
• burn depth
  ■ superficial (1st degree): epidermis only (e.g. sunburn), painful and tender to palpation
  ■ superficial partial thickness (2nd degree): extends to epidermis and superficial dermis, blister formation occurs, very painful
  ■ deep partial thickness (2nd degree): involves hair follicles, sebaceous glands; skin is blistered, exposed dermis is white to yellow, absent sensation
  ■ full thickness (3rd degree): epidermis and all dermal layers; skin is pale, insensitive, and charred or leathery
  ■ deep (4th degree): involvement of fat, muscle, even bone

Management
• remove noxious agent/stop burning process
• establish airway if needed (indicated with burns >40% BSA or smoke inhalation injury)
• resuscitation for 2nd and 3rd degree burns (after initiation of 2 large bore IVs)
• Fluid boluses if unstable
  ■ Parkland Formula: Ringer's lactate 4 cc/kg/%BSA burned; give half in first 8 h, half in next 16 h; maintenance fluids are also required if patient cannot tolerate PO hydration
  ■ Urine output is best measure of resuscitation, should be 40-50 cc/h or 0.5 cc/kg/h; avoid diuretics
  • Pain relief: continuous morphine infusion with breakthrough bolus
  • Investigations: CBC, electrolytes, U/A, CXR, ECG, ABG, carboxyhemoglobin
  • Burn wound care: prevent infection, clean/debride with mild soap and water, sterile dressings
  • Escharotomy or fasciotomy for circumferential burns (chest, extremities)
  • Topical antibiotics, systemic antibiotics infrequently indicated
  • Tetanus prophylaxis if burn is deeper than superficial dermis

Disposition
• Admit
  ■ 2nd degree burns >10% BSA, or any significant 3rd degree burns
  ■ 2nd degree burns on face, hands, feet, perineum, or across major joints
  ■ Electrical, chemical burns, and inhalation injury
  ■ Burn victims with underlying medical problems or immunosuppressed patients

Inhalation Injury

Etiology
• CO or cyanide poisoning
• Direct thermal injury: limited to upper airway
• Smoke causes bronchospasm and edema from particulate matter and toxic inhalants (tissue asphyxiates, pulmonary irritants, systemic toxins)

History and Physical Exam
• Risk factors: closed space fires, period of unconsciousness, noxious chemicals involved
• Cherry red skin (unreliable, usually post-mortem finding)
• Singed nasal hairs, soot on oral/nasal membranes, sooty sputum
• Hoarseness, stridor, dyspnea
• Decreased LOC, confusion
• PO2 normal but O2 saturation low suggests CO poisoning

Investigations
• Measure carboxyhemoglobin levels, co-oximetry
• ABG
• CXR ± Bronchoscopy

Management
• CO poisoning: 100% O2 ± hyperbaric O2 (controversial)
• Direct thermal injury: humidified oxygen, early intubation, pulmonary toilet, bronchodilators, and mucolytics (N-acetylcysteine)

Bites

Mammalian Bites
• See Plastic Surgery, PI.10

History
• Time and circumstances of bite, symptoms, allergies, tetanus immunization status, comorbid conditions, rabies risks, HIV/hepatitis risk (human bite)
• High morbidity associated with clenched fist injuries, "fight bites"

Physical Exam
• Assess type of wound: abrasion, laceration, puncture, crush injury
• Assess for direct tissue damage: skin, bone, tendon, neurovascular status

Investigations
• If bony injury or infection suspected, check for fracture and gas in tissue with x-rays
• Get skull films in children with scalp bite wounds ± CT to rule out cranial perforation
• Ultrasound may be helpful for identifying abscess formation as well as locating radiolucent foreign bodies in infected wounds

Initial Management
• Wound cleansing and copious irrigation as soon as possible
• Irrigate/debride puncture wounds if feasible, but not if sealed or very small openings; avoid hydrodissection along tissue planes
• Debridement is important in crush injuries to reduce infection and optimize cosmetic and functional repair
• culture wound if signs of infection (erythema, necrosis, or pus); obtain anaerobic cultures if wound foul smelling, necrotizing, or abscess; notify lab that sample is from bite wound
• suturing
  - vascular structures (i.e. face and scalp) are less likely to become infected, therefore consider suturing
  - allow avascular structures (i.e. pretibial regions, hands, and feet) to heal by secondary intention
• tetanus immunization if >10 yr or incomplete primary series

Prophylactic Antibiotics
• types of infections resulting from bites: cellulitis, lymphangitis, abscesses, tenosynovitis, osteomyelitis, septic arthritis, sepsis, endocarditis, meningitis
• a 3-5 d course of antibiotics is recommended for all bite wounds to the hand and should be considered in other bites if any high-risk factors present (efficacy not proven)
• dog and cat bites (pathogens: Pasteurella multocida, S. aureus, S. viridans)
  - 10-50% of cat bites, 5% of dog bites become infected
  - 1st line: amoxicillin + clavulanic acid
• human bites (pathogens: Eikenella corrodens, S. aureus, S. viridans, oral anaerobes)
  - 1st line: amoxicillin + clavulanic acid
• rabies (see Infectious Diseases, ID20)
  - reservoirs: warm-blooded animals except rodents, lagomorphs (e.g. rabbits)
  - post-exposure vaccine is effective; treatment depends on local prevalence

INSECT BITES
• bee stings
  - 5 types of reactions to stings (local, large local, systemic, toxic, unusual)
  - history and physical exam key to diagnosis; no lab test will confirm
• investigations: CBC, electrolytes, BUN, Cr, glucose, ABGs, ECG
• ABC management, epinephrine 0.1 mg IV over 5 min if shock, antihistamines, cimetidine 300 mg IV/IM/PO, steroids, β-agonists for SOB/wheezing 3 mg in 5 mL NS via nebulizer, local site management
• West Nile virus (see Infectious Diseases, ID24)

Near Drowning
• most common in children <4 yr and teenagers
• causes lung damage, hypoxemia, and may lead to hypoxic encephalopathy
• must also assess for shock, C-spine injuries, hypothermia, and scuba-related injuries (barotrauma, air emboli, lung re-expansion injury)
• complications: volume shifts, electrolyte abnormalities, hemolysis, rhabdomyolysis, renal, DIC

Physical Exam
• ABCs, vitals: watch closely for hypotension
• respiratory: rales (ARDS, pulmonary edema), decreased breath sounds (pneumothorax)
• CVS: murmurs, dysrhythmias, JVP (CHF, pneumothorax)
• H&N: assess for C-spine injuries
• neurological: GCS or AVPU, pupils, focal deficits

Investigations
• labs: CBC, electrolytes, ABGs, Cr, BUN, INR, PTT, U/A (drug screen, myoglobin)
• imaging: CXR (pulmonary edema, pneumothorax) ± C-spine imaging
• ECG

Management
• ABCs, treat for trauma, shock, hypothermia
• cardiac and O2: monitors, IV access
• intensive respiratory care
  - ventilator assistance if decreased respirations, pCO2 >50 mmHg, or pO2 <60 mmHg on maximum O2
  - may require intubation for airway protection, ventilation, pulmonary toilet
  - high flow O2/CPAP/BiPAP may be adequate but some may need mechanical ventilation with positive end-expiratory pressure
  - dysrhythmias: usually respond to corrections of hypoxemia, hypothermia, and acidosis
  - vomiting: very common, NG suction to avoid aspiration
  - convulsions: usually respond to O2; if not, diazepam 5-10 mg IV slowly
  - bronchospasm: bronchodilators
  - bacterial pneumonia: prophylactic antibiotics not necessary unless contaminated water or hot tub (Pseudomonas)
• always initiate CPR in drowning-induced cardiac arrest even if patient hypothermic; continue CPR until patient is fully rewarmed
Disposition
- non-significant submersion: discharge after short observation
- significant submersion (even if asymptomatic): long period of observation (24 h) as pulmonary edema may appear late
- CNS symptoms or hypoxemia: admit
- severe hypoxemia, decreased LOC: ICU

Toxicology

“ABCD3EFG” of Toxicology

- basic axiom of care is symptomatic and supportive treatment
- address underlying problem only once patient is stable

A  Airway (consider stabilizing the C-spine)
B  Breathing
C  Circulation
D1  Drugs
    ▪ ACLS as necessary to resuscitate the patient
    ▪ universal antidotes
D2  Draw bloods
D3  Decontamination (decrease absorption)
E  Expose (look for specific toxidromes)/Examine the patient
F  Full vitals, ECG monitor, Foley, X-rays
G  Give specific antidotes and treatments

- reassess
- call Poison Information Centre
- obtain corroborative history from family, bystanders

D1 – Universal Antidotes

- treatments that will not harm patients and may be essential

Dextrose (glucose)
- give to any patient presenting with altered LOC
- measure blood glucose prior to glucose administration if possible
- adults: 0.5–1.0 g/kg (1–2 mL/kg) IV of D50W
- children: 0.25 g/kg (2–4 mL/kg) IV of D25W

Oxygen
- do not deprive a hypoxic patient of oxygen no matter what the antecedent medical history (i.e. even COPD with CO₂ retention)
- if depression of hypoxic drive, intubate and ventilate
- exception: paraquat or diquat (herbicides) inhalation or ingestion (oxygen radicals increase morbidity)

Naloxone (central μ-receptor competitive antagonist, shorter t1/2 than naltrexone)
- antidote for opioids: administration is both diagnostic and therapeutic (1 min onset of action)
- used for the undifferentiated comatose patient
- loading dose
  ▪ adults
    ▪ response to naloxone can be drastic, so stepwise delivery of initial 2 mg bolus is recommended
    ▪ draw up 2 mg to deliver IV/IM/SL/SC or via ETT (ETT dose = 2–2.5x IV dose)
      – 1st dose 0.4 mg
      – if no response, deliver second dose 0.6 mg
      – if still no response, deliver remaining 1 mg
  ▪ child
    ▪ 0.01 mg/kg initial bolus IV/IO/ETT
    ▪ 0.1 mg/kg if no response and opioid still suspected to max of 10 mg
- maintenance dose
  ▪ may be required because half-life of naloxone (30–80 min) is much shorter than many opioids
  ▪ hourly infusion rate at 2/3 of initial dose that allowed patient to be roused

Thiamine (Vitamin B1)
- 100 mg IV/IM with IV/PO glucose to all patients
- given to prevent/treat Wernicke’s encephalopathy
- a necessary cofactor for glucose metabolism (may worsen Wernicke’s encephalopathy if glucose given before thiamine), but do not delay glucose if thiamine unavailable
- must assume all undifferentiated comatose patients are at risk

Populations at Risk for Thiamine Deficiency
- Alcoholics
- Anorexics
- Hyperemesis of pregnancy
- Malnutrition states
D2 – Draw Bloods

- essential tests
  - CBC, electrolytes, BUN/Cr, glucose, INR/PTT, osmolality
  - ABGs, measure O₂ sat
  - ASA, acetaminophen, EtOH levels
- potentially useful tests
  - drug levels – this is NOT a serum drug screen
  - Ca²⁺, Mg²⁺, PO₄³⁻
  - protein, albumin, lactate, ketones, liver enzymes, CK – depending on drug and clinical presentation

Serum Drug Levels
- treat the patient, not the drug level
- negative toxicology screen does not rule out a toxic ingestion – signifies only that the specific drugs tested were not detectable in the specimen
- specific drugs available on general screen vary by institution; check before ordering
- urine screens also available (qualitative only)

<table>
<thead>
<tr>
<th>Table 30. Toxic Gaps (see Nephrology, NP16)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>METABOLIC ACIDOSIS</strong></td>
</tr>
<tr>
<td>Increased AG: ”MUDPILES CAT“ (* = toxic)</td>
</tr>
<tr>
<td>Methanol*</td>
</tr>
<tr>
<td>Uremia</td>
</tr>
<tr>
<td>Diabetic ketoacidosis/Starvation ketoacidosis</td>
</tr>
<tr>
<td>Phenformin*/Paraldehyde*</td>
</tr>
<tr>
<td>Isoniazid, iron, ibuprofen</td>
</tr>
<tr>
<td>Lactate (anything that causes seizures or shock)</td>
</tr>
<tr>
<td>Ethylene glycol</td>
</tr>
<tr>
<td>Salicylates*</td>
</tr>
<tr>
<td>Cyanide, CO*</td>
</tr>
<tr>
<td>Alcoholic ketoacidosis</td>
</tr>
<tr>
<td>Toluene, theophylline*</td>
</tr>
<tr>
<td>Increased POG: ”MAE DIE“ (if it ends in “-ol”, it will likely increase the POG)</td>
</tr>
<tr>
<td>Methanol</td>
</tr>
<tr>
<td>Acetone</td>
</tr>
<tr>
<td>Ethanol</td>
</tr>
<tr>
<td>Diuretics (glycerol, mannitol, sorbitol)</td>
</tr>
<tr>
<td>Isopropanol</td>
</tr>
<tr>
<td>Ethylene glycol</td>
</tr>
<tr>
<td>Note: normal POG does not rule out toxic alcohol; only an elevated gap is helpful</td>
</tr>
</tbody>
</table>

- Decreased AG
  - Electrolyte imbalance (increased Na⁺/K⁺/Mg²⁺)
  - Hypoalbuminemia (50% fall in albumin ~5.5 mmol/L decrease in the AG)
  - Lithium, bromine elevation
  - Paraproteins (multiple myeloma)

- Normal AG
  - High K⁺: pyelonephritis, obstructive nephropathy, renal tubular acidosis IV, TPN
  - Low K⁺: small bowel losses, acetazolamide, renal tubular acidosis I, II

| Table 31. Use of the Clinical Laboratory in the Initial Diagnosis of Poisoning |
|-------------------------------|-------------------------------|
| Test                          | Finding                      | Selected Causes                           |
| ABG                           | Hypoventilation (pCO₂)       | CNS depressants (opioids, sedative-hypnotic agents, phenothiazines, EtOH) |
|                               | Hyperventilation (pCO₂)      | Salicylates, CO, other asphyxiants         |
| Electrolytes                  | AG metabolic acidosis        | ”MUDPILES CAT“: see Table 30               |
|                               | Hyperkalemia                 | Digitalis glycosides, fluoride, potassium |
|                               | Hypokalemia                  | Theophylline, caffeine, β-adrenergic agents, soluble barium salts, diuretics, insulin |
| Glucose                       | Hypoglycemia                 | Oral hypoglycemic agents, insulin, EtOH, ASA |
| Osmolality and Osmolar Gap    | Elevated osmolar gap         | ”MAE DIE“: see Table 30                    |
| ECG                           | Wide QRS complex             | TCAs, quinidine, other class la and lc antidysrhythmic agents |
|                               | Prolonged QT interval        | Terfenadine, astemizole, antipsychotics    |
|                               | Atroventricular block        | Ca²⁺ antagonists, digitalis glycosides, phenylpropanolamine |
| Abdominal X-Ray               | Radioopaque pills or objects | ”CHIPS“: Calcium, Chloral hydrate, CO₂, Heavy metals, Iron, Potassium, Enteric coated Salicylates, and some foreign bodies |
| Serum Acetaminophen           | Elevated level (>140 mg/L or 1,000 μmol/L 4 h after ingestion) | May be only sign of acetaminophen poisoning |
D3 – Decontamination and Enhanced Elimination

Ocular Decontamination
• saline irrigation to neutralize pH; alkali exposure requires ophthalmology consult

Dermal Decontamination (Wear Protective Gear)
• remove clothing, brush off toxic agents, irrigate all external surfaces

Gastrointestinal Decontamination
• single dose activated charcoal
  ▪ adsorption of drug/toxin to activated charcoal prevents availability
  ▪ contraindications: caustics, small bowel obstruction, perforation
  ▪ dose: 10 g/g drug ingested or 1g/kg body weight
  ▪ odourless, tasteless, prepared as slurry with H_2O
• whole bowel irrigation
  ▪ 500 mL/h (child) to 2,000 mL/h (adult) of polyethylene glycol solution by mouth until clear effluent per rectum
  ▪ start slow (500 mL in an adult) and aim to increase rate hourly as tolerated
• indications
  ▪ awake, alert, can be nursed upright OR intubated and airway protected
  ▪ delayed release product
  ▪ drug/toxin not bound to charcoal
  ▪ drug packages (if any evidence of breakage emergency surgery)
  ▪ recent toxin ingestion
• contraindications
  ▪ evidence of ileus, perforation, or obstruction
• surgical removal in extreme cases
  ▪ indicated for drugs that are toxic, form concretions, or cannot be removed by conventional means
  ▪ no evidence for the routine use of cathartics (i.e. ipecac)

Urine Alkalinization
• may be used for: ASA, methotrexate, phenobarbital, chlorpropamide
• weakly acidic substances can be trapped in alkali urine (pH >7.5) to increase elimination

Multidose Activated Charcoal
• may be used for: carbamazepine, phenobarbital, quinine, theophylline
• for toxins which undergo enterohepatic recirculation
• removes drug that has already been absorbed by drawing it back into GI tract
• various regimens: 12.5 g (1/4 bottle) PO q1h or 25 g (1/2 bottle) PO q2h until non-toxic

Hemodialysis
• indications/criteria for hemodialysis
  ▪ toxins that have high water solubility, low protein binding, low molecular weight, adequate concentration gradient, small volume of distribution, or rapid plasma equilibration
  ▪ removal of toxin will lead to clinical improvement
  ▪ advantage is shown over other modes of therapy
  ▪ predicted that drug or metabolite will have toxic effects
  ▪ impairment of normal routes of elimination (cardiac, renal, or hepatic)
  ▪ clinical deterioration despite maximal medical support
• useful for the following toxins
  ▪ methanol
  ▪ ethylene glycol
  ▪ salicylates
  ▪ lithium
  ▪ phenobarbital
  ▪ chloral hydrate (trichloroethanol)
• others include theophylline, carbamazepine, valproate, methotrexate

E – Expose and Examine the Patient
• vital signs (including temperature), skin (needle tracks, colour), mucous membranes, pupils, odours, and CNS
• head-to-toe survey including
  ▪ C-spine
  ▪ signs of trauma, seizures (incontinence, "tongue biting", etc.), infection (meningismus), or chronic alcohol/drug abuse (track marks, nasal septum erosion)
• mental status
# Table 32. Specific Toxidromes

<table>
<thead>
<tr>
<th>Toxidrome</th>
<th>Overdose Signs and Symptoms</th>
<th>Examples of Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anticholinergic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperthermia</td>
<td>“Hot as a hare”</td>
<td>Antidepressants (e.g. TCAs)</td>
</tr>
<tr>
<td>Dilated pupils</td>
<td>“Blind as a bat”</td>
<td>Cyclobenzaprine (Flexeril®)</td>
</tr>
<tr>
<td>Dry skin</td>
<td>“Dry as a bone”</td>
<td>Carbamazepine</td>
</tr>
<tr>
<td>Vasodilation</td>
<td>“Red as a beet”</td>
<td>Antihistamines (e.g. diphenhydramine)</td>
</tr>
<tr>
<td>Agitation/hallucinations</td>
<td>“Mad as a hatter”</td>
<td>Antiparkinsonians</td>
</tr>
<tr>
<td>Ileus</td>
<td>“The bowel and bladder”</td>
<td>Antipsychotics</td>
</tr>
<tr>
<td>Urinary retention</td>
<td>lose their tone and the</td>
<td>Antispasmodics</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>heart goes on alone”</td>
<td>Belladonna alkaloids (e.g. atropine)</td>
</tr>
<tr>
<td><strong>Cholinergic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>“DUMBELS”</td>
<td></td>
<td>Natural plants: mushrooms, trumpet flower</td>
</tr>
<tr>
<td>Diaphoresis, Diarrhea</td>
<td>Decreased BP</td>
<td>Anticholinesterases: physostigmine</td>
</tr>
<tr>
<td>Urination</td>
<td></td>
<td>Insecticides (organophosphates, carbamates)</td>
</tr>
<tr>
<td>Miosis</td>
<td></td>
<td>Nerve gases</td>
</tr>
<tr>
<td>Bronchospasm, Bronchorrhoea, Bradycardia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emesis, Excitation of skeletal muscle</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lacrimation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salivation, Seizures</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Extrapyramidal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyphonia, dysphagia</td>
<td></td>
<td>Major tranquilizers</td>
</tr>
<tr>
<td>Rigidity and tremor</td>
<td></td>
<td>Antipsychotics</td>
</tr>
<tr>
<td>Motor restlessness, crawling sensation (akathisia)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constant movements (dyskinesia)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dystonia (muscle spasms, laryngospasm, triamus, eclamptic crisis, toxicis)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hemoglobin Derangements</strong></td>
<td>Increased respiratory rate</td>
<td>CD poisoning (carboxyhemoglobin)</td>
</tr>
<tr>
<td></td>
<td>Decreased LOC</td>
<td>Drug ingestion (methemoglobin, sulfmethemoglobin)</td>
</tr>
<tr>
<td></td>
<td>Seizures</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cyanosis unresponsive to O₂</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lactic acidosis</td>
<td></td>
</tr>
<tr>
<td><strong>Opioid, Sedative/ Hypnotic, EtOH</strong></td>
<td>Hypothermia</td>
<td>EtOH</td>
</tr>
<tr>
<td></td>
<td>Hypotension</td>
<td>Benzodiazepines</td>
</tr>
<tr>
<td></td>
<td>Respiratory depression</td>
<td>Opioids (morphine, heroin, fentanyl, etc.)</td>
</tr>
<tr>
<td></td>
<td>Dilated or constricted pupils (pinpoint in opioid)</td>
<td>Barbiturates</td>
</tr>
<tr>
<td></td>
<td>CNS depression</td>
<td>Gamma hydroxybutyrate</td>
</tr>
<tr>
<td><strong>Sympathomimetic</strong></td>
<td>Increased temperature</td>
<td>Amphetamines, caffeine, cocaine, LSD, phencyclidine</td>
</tr>
<tr>
<td></td>
<td>CNS excitation (including seizures)</td>
<td>Ephedrine and other decongestants</td>
</tr>
<tr>
<td></td>
<td>Tachycardia, HTN</td>
<td>Thyroid hormone</td>
</tr>
<tr>
<td></td>
<td>N/V</td>
<td>Sedative or EtOH withdrawal</td>
</tr>
<tr>
<td></td>
<td>Diaphoresis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dilated pupils</td>
<td></td>
</tr>
<tr>
<td><strong>Serotonin Syndrome</strong></td>
<td>Mental status changes, autonomic hyperactivity, neuromuscular abnormalities, hyperthermia, diarhea, HTN</td>
<td>MAOI, TCA, SSRI, opiate analoges</td>
</tr>
</tbody>
</table>

Note: ASA poisoning and hypoglycemia mimic sympathomimetic toxidrome

## F – Full Vitals, ECG Monitor, Foley, X-Rays

## G – Give Specific Antidotes and Treatments

### Urine Alkalization Treatment for ASA Overdose

- **urine pH > 7.5**
- fluid resuscitate first, then 3 amps NaHCO₃/L of D5W at 1.5x maintenance
- add 20–40 mEq/L KCl if patient is able to urinate

### Table 33. Protocol for Warfarin Overdose

<table>
<thead>
<tr>
<th>INR</th>
<th>Management: Consider Prothrombin Complex Concentrate (Octaplex®, Beriplex®) for any elevated INR, AND either life-threatening bleeding, or a plan for the patient to undergo a surgical procedure within the next 6 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;5.0</td>
<td>Cessation of warfarin administration, observation, serial INR/PT</td>
</tr>
<tr>
<td>5.1–9.0</td>
<td>If no risk factors for bleeding, hold warfarin x 1-2 d and reduce maintenance dose OR Vitamin K 1-2 mg PO if patient at increased risk of bleeding</td>
</tr>
<tr>
<td>9.1–20.0</td>
<td>Hold warfarin, vitamin K 2-4 mg PO, serial INR/PT, additional vitamin K if necessary</td>
</tr>
<tr>
<td>&gt;20.0</td>
<td>Hold warfarin, vitamin K 10 mg IV over 10 min, increase vitamin K dosing (q4h) if needed</td>
</tr>
</tbody>
</table>
Table 34. Specific Antidotes and Treatments for Common Toxins*

<table>
<thead>
<tr>
<th>Toxin</th>
<th>Treatment</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen</td>
<td>Decontaminate (activated charcoal)</td>
<td>Often clinically silent; evidence of liver/renal damage delayed &gt;24 h</td>
</tr>
<tr>
<td></td>
<td>N-acetylcysteine</td>
<td>Toxic dose &gt;200 mg/kg (&gt;7.5 g adult)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monitor drug level 4 h post-ingestion; also liver enzymes, INR, PTT, BUN, Cr</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypoglycaemia, metabolic acidosis, encelophalopathy poor prognosis</td>
</tr>
<tr>
<td>Acute Dystonic</td>
<td>Benztropine: 1-2 mg IM/IV then 2 mg PO x 3 d</td>
<td>Berotropine (Cogentin®) has euphoric effect and potential for abuse</td>
</tr>
<tr>
<td>Reaction</td>
<td>OR Diphenhydramine 1-2 mg/kg IV, then 25 mg PO</td>
<td></td>
</tr>
<tr>
<td></td>
<td>qid x 3 d</td>
<td>Special antidotes available; consult Poison Information Centre</td>
</tr>
<tr>
<td>Anticholinergics</td>
<td>Decontaminate (activated charcoal)</td>
<td>Monitor serum pH and drug levels closely</td>
</tr>
<tr>
<td>ASA</td>
<td>Decontaminate (activated charcoal)</td>
<td>Monitor K⁺ level; may require supplement for urine alkalinization</td>
</tr>
<tr>
<td></td>
<td>Alkalinize urine; want urine pH &gt;7.5</td>
<td>Hemodialysis may be needed if intractable metabolic acidosis, very high levels,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>or end-organ damage (i.e. unable to diurease)</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>Decontaminate (activated charcoal)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Flumazenil</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Supportive care</td>
<td></td>
</tr>
<tr>
<td>β-blockers</td>
<td>Decontaminate (activated charcoal)</td>
<td>Consult Poison Information Centre</td>
</tr>
<tr>
<td></td>
<td>Consider high dose insulin euglycemia therapy</td>
<td></td>
</tr>
<tr>
<td>Calcium Channel</td>
<td>Decontaminate (activated charcoal)</td>
<td>Order ECG, electrolytes (especially Ca²⁺, Mg²⁺, Na⁺, K⁺)</td>
</tr>
<tr>
<td>Phosphodiesterase</td>
<td>CaCl₂ 1-4 g of 10% solution IV if hypotensive</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other: high dose insulin euglycemia inotropes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>or intralipids</td>
<td></td>
</tr>
<tr>
<td>Cocaine</td>
<td>Decontaminate (activated charcoal)</td>
<td>Beta-blockers are contraindicated in acute cocaine toxicity</td>
</tr>
<tr>
<td></td>
<td>if oral</td>
<td>Intralipid for life-threatening symptoms</td>
</tr>
<tr>
<td></td>
<td>Aggressive supportive care</td>
<td></td>
</tr>
<tr>
<td>CO Poisoning</td>
<td>See Inhalation Injury, ER47</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Supportive care</td>
<td></td>
</tr>
<tr>
<td></td>
<td>100% O₂</td>
<td></td>
</tr>
<tr>
<td>Cyanide</td>
<td>Hydroxocobalamin</td>
<td></td>
</tr>
<tr>
<td>Digoxin</td>
<td>Decontaminate (activated charcoal)</td>
<td>Use for life-threatening dysrhythmias unresponsive to conventional therapy, 6</td>
</tr>
<tr>
<td></td>
<td>Digoxin-specific Ab fragments</td>
<td>h serum digoxin &gt;12 mmol/L, initial K⁺ &gt;5 mmol/L, ingestion &gt;10 mg (adult)/4 mg (child)</td>
</tr>
<tr>
<td></td>
<td>10-20 vials IV if acute; 3-6 if chronic</td>
<td>Common dysrhythmias include VFib, VTach, and conduction blocks</td>
</tr>
<tr>
<td></td>
<td>1 vial (40 mg) neutralizes 0.5 mg of toxin</td>
<td></td>
</tr>
<tr>
<td>Ethanol</td>
<td>Thiamine 100 mg IM/IV</td>
<td>Hypoglycaemia very common in children</td>
</tr>
<tr>
<td></td>
<td>Manage airway and circulatory support</td>
<td>Mouthwash = 70% EtOH; perfumes and colognes =</td>
</tr>
<tr>
<td></td>
<td></td>
<td>40-60% EtOH; order serum EtOH level and glucose level; treat glucose level</td>
</tr>
<tr>
<td></td>
<td></td>
<td>appropriately</td>
</tr>
<tr>
<td>Ethylene Glycol/</td>
<td>Fomepizole (4-methylpyrazole)</td>
<td>CBC, electrolytes, glucose, ethanol level</td>
</tr>
<tr>
<td>Methanol</td>
<td>15 mg/kg IV load over 30 min, then 10 mg/kg q</td>
<td>Consider hemodialysis</td>
</tr>
<tr>
<td></td>
<td>2h OR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ethanol (10%) 10 mL/kg over 30 min, then 1.5 mL/h</td>
<td></td>
</tr>
<tr>
<td>Heparin</td>
<td>Protamine sulfate 25-50 mg IV</td>
<td>For unfractionated heparin overdose only</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heparin</td>
<td>Protamine sulfate 25-50 mg IV</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heparin</td>
<td>Protamine sulfate 25-50 mg IV</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heparin</td>
<td>Protamine sulfate 25-50 mg IV</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heparin</td>
<td>Protamine sulfate 25-50 mg IV</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heparin</td>
<td>Protamine sulfate 25-50 mg IV</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heparin</td>
<td>Protamine sulfate 25-50 mg IV</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heparin</td>
<td>Protamine sulfate 25-50 mg IV</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heparin</td>
<td>Protamine sulfate 25-50 mg IV</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin IM/SC/</td>
<td>Glucose IV/PO/NG tube</td>
<td>Glyburide carries highest risk of hypoglycaemia among oral agents</td>
</tr>
<tr>
<td>Oral Hypoglycemic</td>
<td>Glucagon: 1-2 mg IM (if no access to glucose)</td>
<td>Consider octreotide for oral hypoglycemics (50-100 µg SC q8h) in these cases; consult local Poison Information Centre</td>
</tr>
<tr>
<td>MDMA</td>
<td>Decontaminate (activated charcoal), supportive care</td>
<td>Monitor CK; treat rhabdomyolysis with high flow fluids: aggressive external cooling for hyperthermia</td>
</tr>
<tr>
<td>Opioids</td>
<td>See Universal Antidotes, ER49</td>
<td></td>
</tr>
<tr>
<td>TCAs</td>
<td>Decontaminate (activated charcoal)</td>
<td>Flumazenil antidote contraindicated in combined TCA and benzodiazepine overdose</td>
</tr>
<tr>
<td></td>
<td>Aggressive supportive care</td>
<td>Also consider cardiac and hypotension support, seizure control</td>
</tr>
<tr>
<td></td>
<td>NaHCO₃ bolus for wide QRS/seizures</td>
<td>Intralipid therapy (consult local Poison Information Centre)</td>
</tr>
</tbody>
</table>

* Call local Poison Information Centre for specific doses and treatment recommendations.
Alcohol Related Emergencies

- see Psychiatry, PS23

Acute Intoxication
- slurred speech, CNS depression, disinhibition, lack of coordination
- nystagmus, diplopia, dysarthria, ataxia may progress to coma
- hypotension (peripheral vasodilation)
- if obtunded, rule out
  - head trauma/intracranial hemorrhage
  - associated depressants/street drugs, toxic alcohols
    - may also contribute to respiratory/cardiac depression
  - hypoglycemia (screen with bedside glucometer)
  - hepatic encephalopathy: confusion, altered LOC, coma
    - precipitating factors: GI bleed, infection, sedation, electrolyte abnormalities, protein meal
  - Wernick's encephalopathy (ataxia, ophthalmoplegia, delirium)
  - post-ictal state, basilar stroke

Withdrawal
- beware of withdrawal signs
- treatment
  - diazepam 10-20 mg IV/PO or lorazepam 2-4 mg IV/PO q1h until calm
    - frequency of dosing may have to be increased depending on clinical response
  - may use CIWA protocol and give benzodiazepines as above until CIWA <10
  - thiamine 100 mg IM/IV then 50-100 mg/d
  - magnesium sulfate 4 g IV over 1-2 h (if hypomagnesemic)
  - admit patients with DT or multiple seizures

Table 35. Alcohol Withdrawal Signs

<table>
<thead>
<tr>
<th>Time Since Last Drink</th>
<th>Syndrome</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-8 h</td>
<td>Mild withdrawal</td>
<td>Generalized tremor, anxiety, agitation, but no delirium</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Autonomic hyperactivity (sinus tachycardia), insomnia, N/V</td>
</tr>
<tr>
<td>1-2 d</td>
<td>Alcoholic hallucinations</td>
<td>Visual (most common), auditory, and tactile hallucinations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vitals often normal</td>
</tr>
<tr>
<td>8 h-2 d</td>
<td>Withdrawal seizures</td>
<td>Typically brief generalized tonic-clonic seizures</td>
</tr>
<tr>
<td></td>
<td></td>
<td>May have several within a few hours</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CT head if focal seizures have occurred</td>
</tr>
<tr>
<td>3-5 d</td>
<td>DT</td>
<td>5% of untreated withdrawal patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Severely confused state, fluctuating LOC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Agitation, insomnia, hallucinations/delusions, tremor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tachycardia, hyperpyrexia, diaphoresis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>High mortality rate</td>
</tr>
</tbody>
</table>

Cardiovascular Complications
- HTN
- cardiomyopathy: SOB, edema
- dysrhythmias (“holiday heart”)
- AFib (most common), atrial flutter, SVT, VTach (especially Torsades if hypomagnesemic/hypokalemic)

Metabolic Abnormalities
- alcoholic ketoacidosis
  - AG metabolic acidosis, urine ketones, low glucose, and normal osmolality
  - history of chronic alcohol intake with abrupt decrease/cessation
  - malnourished, abdominal pain with N/V
  - treatment: dextrose, thiamine (100 mg IM/IV prior to dextrose), volume repletion (with NS)
  - generally resolves in 12-24 h
- other alcohols
  - ethylene glycol CNS, CVS, renal findings
  - methanol
    - early: lethargy, confusion
    - late: headache, visual changes, N/V, abdominal pain, tachypnea
  - both ethylene glycol and methanol produce severe metabolic acidosis with anion gap (as the alcohol is metabolized) and osmolar gap (initially after ingestion but before metabolism)
- EtOH co-ingestion is protective
treatment
- urgent hemodialysis required
- fomepizole 15 mg/kg IV bolus OR EtOH 10% IV bolus and infusion to achieve blood level of 22 mmol/L (EtOH loading may be done PO)
- consider folic acid for methanol, and pyridoxine and thiamine for ethylene glycol – both help reduce conversion to active metabolites
- other abnormalities associated with alcohol: hypomagnesemia, hypophosphatemia, hypocalcemia, hypoglycemia, hypokalemia

Gastrointestinal Abnormalities
- gastritis
  - common cause of abdominal pain and GI bleed in chronic alcohol users
- pancreatitis
  - serum amylase very unreliable in patients with chronic pancreatitis, may need serum lipase
  - hemorrhagic form (15%) associated with increased mortality
- fluid resuscitation very important
- hepatitis
  - AST/ALT ratio >2 suggests alcohol as the cause as well as elevated GGT with acute ingestion
- peritonitis/spontaneous bacterial peritonitis
  - leukocytosis, fever, generalized abdominal pain/tenderness
  - occasionally accompanies cirrhosis
  - paracentesis for diagnosis (common pathogens: E. coli, Klebsiella, Streptococcus)
- GI bleeds
  - most commonly gastritis or ulcers, even if patient known to have varices
  - consider Mallory-Weiss tear secondary to retching
  - often complicated by underlying coagulopathies
  - minor: treat with antacids
  - severe or recurrent: endoscopy

Disposition
- before patient leaves ED ensure stable vital signs, can walk unassisted, and fully oriented
- offer social services to find shelter or detox program
- ensure patient can obtain any medications prescribed and can complete any necessary follow-up

Approach to the Overdose Patient

History
- age, weight, underlying medical problems, medications
- substance and how much
- time and symptoms since exposure determines prognosis and need for decontamination
- route
- intention, suicidality

Physical Exam
- focus on: ABCs, LOC/GCS, vitals, pupils

Disposition from the Emergency Department
- methanol, ethylene glycol
  - delayed onset, admit and watch clinical and biochemical markers
- TCAs
  - prolonged/delayed cardiotoxicity warrants admission to monitored (ICU) bed
  - if asymptomatic and no clinical signs of intoxication: 6 h ED observation adequate with proper decontamination and no ECG abnormalities
  - sinus tachycardia alone (most common finding) with history of overdose warrants observation in ED
- hydrocarbons/smoke inhalation
  - pneumonitis may lag 6-8 h
  - consider observation for repeated clinical and radiographic examination
- ASA, acetaminophen
  - if borderline level, get second level 2-4 h after first
  - for ASA, must have at least 2 levels going down before discharge (3 levels minimum)
- oral hypoglycemics
  - admit all patients for minimum 24 h if hypoglycemic and 12 h after last octreotide dose
  - observe asymptomatic patient for at least 8 h

Psychiatric Consultation
- once patient medically cleared, arrange psychiatric intervention if required
- beware – suicidal ideation may not be expressed
Psychiatric Emergencies

Approach to Common Psychiatric Presentations

- see Psychiatry, PS4
- before seeing patient, ensure your own safety; have security/police available if necessary

**History**
- safety
  - assess suicidality: suicidal ideation (SI), intent, plan, lethal means, and past attempts
  - assess homicidality: homicidal ideation (HI), access to weapons, intended victim, and history of violence
  - driving and children
  - command hallucinations
  - identify current stressors and coping strategies
  - mood symptoms: manic, depressive
  - anxiety: panic attacks, generalized anxiety, phobias, obsessive-compulsive disorder, post-traumatic stress disorder
  - psychotic symptoms: delusions, hallucinations, disorganized speech, disorganized or catatonic behaviour, negative symptoms (affective flattening, alogia, avolition)
  - substance use history: most recent use, amount, previous withdrawal reactions
  - past psychiatric history, medications, adherence with medications
  - medical history: obtain collateral if available

**Physical Exam**
- complete physical exam focusing on: vitals, neurological exam, signs of head trauma, signs of drug toxicity, signs of metabolic disorder
- mental status exam: general appearance, behaviour, cooperation, speech, mood and affect, thought content and form, perceptual disturbances, cognition (including MMSE if indicated), judgment, insight, reliability

**Investigations**
- investigations vary with age, established psychiatric diagnosis vs. first presentation, history and physical suggestive of organic cause
- as indicated: blood glucose, urine and serum toxicology screen, pregnancy test, electrolytes, TSH, AST/ALT, bilirubin, serum Cr, BUN, and osmolality
- blood levels of psychiatric medications
- CT head if suspect neurological etiology
- LP if indicated

**Acute Psychosis**

**Differential Diagnosis**
- primary psychotic disorder (e.g. schizophrenia)
- secondary to medical condition (e.g. delirium)
- drugs: substance intoxication or withdrawal, medications (e.g. steroids, anticholinergics)
- infectious (CNS)
- metabolic (hypoglycemic, hepatic, renal, thyroid)
- structural (hemorrhage, neoplasm)

**Management**
- violence prevention
  - remain calm, empathic, and reassuring
  - ensure safety of staff and patients, have extra staff and/or security on hand
  - patients demonstrating escalating agitation or overt violent behaviour may require physical restraint and/or chemical tranquilization
- treat agitation: whenever possible, offer medication to patients as opposed to administering with force (helps calm and engage patient)
  - benzodiazepines: lorazepam 2 mg PO/IM/SL
  - antipsychotics: olanzapine 5 mg PO, haloperidol 5 mg PO/IM
- treat underlying medical condition
- psychiatry or Crisis Intervention Team consult
**Suicidal Patient**

**Epidemiology**
- attempted suicide F>M, completed suicide M>F
- second leading cause of death in people <24 yr

**Management**
- ensure patient safety: close observation, remove potentially dangerous objects from person and room
- assess thoughts (ideation), means, action (preparatory, practice attempts), previous attempts
- admit if there is evidence of intent and organized plan, access to lethal means, psychiatric disorder, intoxication (suicidal ideation may resolve with few days of abstinence)
- patient may require certification if unwilling to stay voluntarily
- do not start long-term medications in the ED
- psychiatry or Crisis Intervention Team consult

### Common Pediatric ED Presentations

#### Modified Glasgow Coma Score

**Table 36. Modified GCS**

<table>
<thead>
<tr>
<th>Eye Opening</th>
<th>Verbal Response</th>
<th>Motor Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 – spontaneously</td>
<td>5 – coos, babbles</td>
<td>6 – normal, spontaneous movement</td>
</tr>
<tr>
<td>3 – to speech</td>
<td>4 – irritable cry</td>
<td>5 – withdraws to touch</td>
</tr>
<tr>
<td>2 – to pain</td>
<td>3 – cries to pain</td>
<td>4 – withdraws to pain</td>
</tr>
<tr>
<td>1 – no response</td>
<td>2 – moans to pain</td>
<td>3 – decorticate flexion</td>
</tr>
</tbody>
</table>

**Modified GCS for Infants**

- **Eye Opening**
  - 4 – spontaneously
  - 3 – to speech
  - 2 – to pain
  - 1 – no response
- **Verbal Response**
  - 5 – coos, babbles
  - 4 – irritable cry
  - 3 – cries to pain
  - 2 – moans to pain
  - 1 – no response
- **Motor Response**
  - 6 – normal, spontaneous movement
  - 5 – withdraws to touch
  - 4 – withdraws to pain
  - 3 – decorticate flexion
  - 2 – decerebrate extension
  - 1 – no response

**Modified GCS for Children <4 years**

- **Eye Opening**
  - 4 – spontaneously
  - 3 – to speech
  - 2 – to pain
  - 1 – no response
- **Verbal Response**
  - 5 – oriented, social, speaks, interacts
  - 4 – confused speech, disoriented, consolable
  - 3 – inappropriate words, not consolable/aware
  - 2 – incomprehensible, agitated, restless, not aware
  - 1 – no response
- **Motor Response**
  - 6 – normal, spontaneous movement
  - 5 – localizes to pain
  - 4 – withdraws to pain
  - 3 – decorticate flexion
  - 2 – decerebrate extension
  - 1 – no response

#### Respiratory Distress

- see Pediatrics, P84

**History and Physical Exam**
- infants not able to feed, older children not able to speak in full sentences
- anxious, irritable, lethargic – may indicate hypoxia
- tachypnea >60 (>40 if preschool age, >30 if school age), retractions, tracheal tug
  - see Pediatrics, P3 for age specific vital signs
- pulsus paradoxus
- wheezing, grunting, vomiting

**Table 37. Stridorous Upper Airway Diseases: Diagnosis**

<table>
<thead>
<tr>
<th>Feature</th>
<th>Group</th>
<th>Bacterial Tracheitis</th>
<th>Epiglottitis¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age Range (yr)</td>
<td>0.5-4</td>
<td>5-10</td>
<td>2-8</td>
</tr>
<tr>
<td>Prodrome</td>
<td>Days</td>
<td>Hours to days</td>
<td>Minutes to hours</td>
</tr>
<tr>
<td>Temperature</td>
<td>Low grade</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Radiography</td>
<td>Steeple sign</td>
<td>Exudates in trachea</td>
<td>Thumb sign</td>
</tr>
<tr>
<td>Etiology</td>
<td>Parainfluenza</td>
<td>S. aureus/GAS</td>
<td>H. influenzae type b</td>
</tr>
<tr>
<td>Barky Cough</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Drooling</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Appear Toxic</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Intubation/ICU</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Antibiotics</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>NOTE</td>
<td>Oral exam</td>
<td>Oral exam</td>
<td>No oral exam, consult ENT</td>
</tr>
</tbody>
</table>

¹Now rare with Hib vaccine in common use
Management
• croup (usually laryngotracheitis caused by parainfluenza viruses)
  - humidified O₂ should not be given (no evidence for efficacy)
  - racemic epinephrine q1h x 3 doses, observe for ‘rebound effects’
  - nebulized 1:1000 epinephrine (racemic has limited availability)
  - dexamethasone x 1 dose
  - consider bacterial tracheitis/epiglottitis if unresponsive to croup therapy
• bacterial tracheitis
  - start croup therapy, but may have poor response
  - usually require intubation, ENT consult, ICU
  - start antibiotics (e.g. cloxacillin), pending C&S
• epiglottitis
  - 4 D’s: drooling, dyspnea, dysphagia, dysphonia + tripod sitting
  - do not examine oropharynx or agitate patient
  - immediate anesthesia, ENT call – intubate
  - then IV fluids, antibiotics, blood cultures
• asthma
  - supplemental O₂ if saturation <90% or PaO₂ <60%
  - bronchodilator therapy: salbutamol (Ventolin®) 0.15 mg/kg by masks q20min x 3
  - add 250-500 µg ipratropium (Atrovent®) to first 3 doses salbutamol
  - give corticosteroid therapy as soon as possible after arrival (prednisolone 2 mg/kg, dexamethasone 0.3 mg/kg)
  - if critically ill, not responding to inhaled bronchodilators or steroids: give IV bolus, then infusion of MgSO₄
  - IV β₂-agonists if critically ill and not responding to above

Febrile Infant and Febrile Seizures

FEBRILE INFANT
• see Pediatrics, P51
• for fever >38°C without obvious focus
  - <28 d
    - admit
    - full septic workup (CBC and differential, blood C&S, urine C&S, LP ± stool C&S, CXR if indicated)
    - treat empirically with broad spectrum IV antibiotics
  - 28-90 d
    - as above unless infant meets Rochester criteria, investigate as indicated by history and physical
  - >90 d
    - toxic admit, treat, full septic workup
    - non-toxic and no focus: investigate as indicated by history and physical

FEBRILE SEIZURES
• see Pediatrics, P82

Etiology
• children aged 6 mo-6 yr with fever or history of recent fever
• typical vs. atypical febrile seizures
• normal neurological exam afterward
• no evidence of intracranial infection or history of previous non-febrile seizures
• often positive family history of febrile seizures
• relatively well- looking after seizure

Investigations and Management
• if it is a febrile seizure: treat fever and look for source of fever
• if not a febrile seizure: treat seizure and look for source of seizure
  - note: may also have fever but may not meet criteria for febrile seizure
• ± EEG (especially if first seizure), head U/S (if fontanelle open)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Typical</th>
<th>Atypical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration</td>
<td>&lt;15 min</td>
<td>&gt;15 min</td>
</tr>
<tr>
<td>Type of Seizure</td>
<td>Generalized</td>
<td>Focal features</td>
</tr>
<tr>
<td>Frequency</td>
<td>1 in 24 h</td>
<td>&gt;1 in 24 h</td>
</tr>
</tbody>
</table>
Abdominal Pain

- see Pediatrics, P37

History
- nature of pain, associated fever
- associated GI, GU symptoms
- anorexia, decreased fluid intake

Physical Exam
- HEENT, respiratory, abdominal exam including DRE, testicular/genital exam

Table 39. Differential Diagnosis of Abdominal Pain in Infants/Children/Adolescents

<table>
<thead>
<tr>
<th>Medical</th>
<th>Surgical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colic</td>
<td>Malrotation with volvulus</td>
</tr>
<tr>
<td>UTI</td>
<td>Hirschsprung’s disease</td>
</tr>
<tr>
<td>Constipation</td>
<td>Necrotizing enterocolitis</td>
</tr>
<tr>
<td>Gastroenteritis</td>
<td>Incarcerated hernia</td>
</tr>
<tr>
<td>Sepsis</td>
<td>Intussusception</td>
</tr>
<tr>
<td>Henoch-Schönlein purpura</td>
<td>Duodenal atresia</td>
</tr>
<tr>
<td>IBD</td>
<td>Appendicitis</td>
</tr>
<tr>
<td>Hemolytic uremic syndrome</td>
<td>Cholecystitis</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>Pancreatitis</td>
</tr>
<tr>
<td>Strep throat</td>
<td>Testicular torsion</td>
</tr>
<tr>
<td>Sickle cell disease crisis</td>
<td>Trauma</td>
</tr>
<tr>
<td>DKA</td>
<td>Pyloric stenosis</td>
</tr>
</tbody>
</table>

*Remember to keep an index of suspicion for child abuse

Common Infections

- see Pediatrics, P51

Table 40. Antibiotic Treatment of Pediatric Bacterial Infections

<table>
<thead>
<tr>
<th>Infection</th>
<th>Pathogens</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MENINGITIS SEPSIS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neonatal</td>
<td>GBS, E. coli, Listeria, Gram-negative bacilli</td>
<td>ampicillin + cefotaxime</td>
</tr>
<tr>
<td>1-3 mo</td>
<td>Same pathogens as above and below</td>
<td>ampicillin + cefotaxime + vancomycin</td>
</tr>
<tr>
<td>&gt;3 mo</td>
<td>S. pneumoniae, H. influenzae type b (&gt;5 yr), meningococcus</td>
<td>ceftriazone + vancomycin</td>
</tr>
<tr>
<td><strong>OTITIS MEDIA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1st line</td>
<td>S. pneumoniae, H. influenzae type b, M. catarrhalis</td>
<td>amoxicillin 80-90 mg/kg per day</td>
</tr>
<tr>
<td>2nd line</td>
<td></td>
<td>clarithromycin 15 mg/kg/d bid (for penicillin allergy)</td>
</tr>
<tr>
<td>Treatment failure</td>
<td></td>
<td>90 mg/kg/d amoxicillin and 6.4 mg/kg/d clavulanate divided into bid dosage</td>
</tr>
<tr>
<td><strong>STREP PHARYNGITIS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Group A β-hemolytic Streptococcus</td>
<td>penicillin/amoxicillin or erythromycin (penicillin allergy)</td>
</tr>
<tr>
<td><strong>UTI</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>E. coli, Proteus, H. influenzae, Pseudomonas, S. saprophyticus, Enterococcus, GBS</td>
<td>Oral: cephalexin (older children) IV: ampicillin and aminoglycoside</td>
</tr>
<tr>
<td><strong>PNEUMONIA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-3 mo</td>
<td>Viral, S. pneumoniae, C. trachomatis, B. pertussis, S. aureus, H. influenzae</td>
<td>cefuroxime ± macrolide (erythromycin)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OR ampicillin ± macrolide</td>
</tr>
<tr>
<td>3 mo-5 yr</td>
<td>Viral, S. pneumoniae, S. aureus, H. influenzae, Mycoplasma pneumoniae</td>
<td>amoxicillin/amoxicillin or cefuroxime</td>
</tr>
<tr>
<td>&gt;5 yr</td>
<td>As above</td>
<td>amoxicillin/amoxicillin + macrolide or cefuroxime + macrolide</td>
</tr>
</tbody>
</table>
Child Abuse and Neglect

- see Pediatrics, P14
- obligation to report any suspected/known case of child abuse or neglect to CAS yourself (do not delegate)
- document injuries
- consider skeletal survey x-rays (especially in non-ambulatory child), ophthalmology consult, CT head
- injury patterns associated with child abuse
  - HI: torn frenulum, dental injuries, bilateral black eyes, traumatic hair loss, diffuse severe CNS injury, retinal hemorrhage
  - Shaken Baby Syndrome: diffuse brain injury, subdural/SAH, retinal hemorrhage, minimal/no evidence of external trauma, associated bony fractures
  - skin injuries: bites, bruises/burns in shape of an object, glove/stocking distribution of burns, bruises of various ages, bruises in protected areas
  - bone injuries: rib fractures without major trauma, femur fractures age <1 yr, spiral fractures of long bones in non-ambulatory children, metaphyseal fractures in infants, multiple fractures of various ages, complex/multiple fractures
  - GU/GI injuries: chronic abdominal/perineal pain, injury to genitals/rectum, STI/pregnancy, recurrent vomiting or diarrhea

Common Medications

### Table 41. Commonly Used Medications

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosing Schedule</th>
<th>Indications</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen</td>
<td>25-650 mg PO q4-6h pm</td>
<td>Pain control</td>
<td>Max 4 g daily</td>
</tr>
<tr>
<td>Activated charcoal</td>
<td>30-100 g PO in 250 mL H2O</td>
<td>Poisoning/overdose</td>
<td></td>
</tr>
<tr>
<td>ASA</td>
<td>325-650 mg PO q4h max 4g/d stroke/MI risk: 81-325 mg PO OD 160 mg chewed</td>
<td>Pain control, Cardiac prevention ACS</td>
<td></td>
</tr>
<tr>
<td>β-blockers (metoprolol)</td>
<td>5 mg slow IV q5min x 3 if no contraindications</td>
<td>Acute MI</td>
<td></td>
</tr>
<tr>
<td>Diazepam</td>
<td>anxiety: 2-10 mg PO tid/qid alcohol withdrawal: 10-20 mg PO q1h titrated to signs/symptoms</td>
<td>Anxiety Alcohol withdrawal</td>
<td></td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>1 mg/kg SC bid</td>
<td>Acute MI</td>
<td></td>
</tr>
<tr>
<td>Epinephrine</td>
<td>anaphylaxis: 0.1-0.5 mg IM; can repeat q10-15min</td>
<td>Anaphylaxis</td>
<td>Max 1 mg/dose</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>0.5-1.0 μg/kg IV</td>
<td>Procedural sedation</td>
<td>Very short acting narcotic (complication = apnea)</td>
</tr>
<tr>
<td>Flumazenil</td>
<td>0.3 mg IV bolus q5min x 3 doses</td>
<td>Reversal of procedural sedation</td>
<td>Benzodiazepine antagonist Can cause seizures/status epilepticus in chronic benzodiazepine users</td>
</tr>
<tr>
<td>Furosemide (Lasix®)</td>
<td>CHF: 40-80 mg IV HTN: 10-40 mg PO bid</td>
<td>CHF HTN</td>
<td>Monitor for electrolyte imbalances</td>
</tr>
<tr>
<td>Glucose</td>
<td>0.5-1.0 g/kg (1-2 mL/kg) IV of D50W</td>
<td>Hypoglycemia/DKA</td>
<td></td>
</tr>
<tr>
<td>Haloperidol</td>
<td>2.5-5.0 mg PO/IM initial effective dose 6-20 mg/d</td>
<td>Psychosis</td>
<td>Monitor with Parkinson’s results in CNS depression</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>200-800 mg PO tid pm max 1,200 mg/d</td>
<td>Mild to moderate acute pain</td>
<td></td>
</tr>
<tr>
<td>Insulin</td>
<td>bolus 5-10 U (0.2 U/kg) then 5-10 U (0.1 U/kg) per h</td>
<td>Hyperglycemia</td>
<td>Monitor blood glucose levels Consider K+ replacement, also measure blood glucose levels before administration</td>
</tr>
<tr>
<td>Ipratropium bromide</td>
<td>2-3 puffs inhaled tid-qid, max 12 puffs/d</td>
<td>Asthma</td>
<td>Contraindicated with peanut/soy allergy Caution with narrow-angle glaucoma</td>
</tr>
<tr>
<td>Lidocaine with epi</td>
<td>max 7 mg/kg SC</td>
<td>Local anesthetic</td>
<td>Not to be used in fingers, nose, toes, penis, ears</td>
</tr>
<tr>
<td>Lidocaine w/o epi</td>
<td>max 5 mg/kg SC</td>
<td>Local anesthetic</td>
<td></td>
</tr>
<tr>
<td>Lorazepam</td>
<td>anxiety: 0.5-2 mg PO/IM/IV q6-8h status epilepticus: 4 mg IV repeat up to q5min</td>
<td>Anxiety Status epilepticus</td>
<td></td>
</tr>
<tr>
<td>Midazolam</td>
<td>50 μg/kg IV</td>
<td>Procedural sedation</td>
<td>Short acting benzodiazepine (complication = apnea when used with narcotic) Fentanyl and midazolam often used together for procedural sedation</td>
</tr>
</tbody>
</table>

Presentation of Neglect

- Failure to thrive, developmental delay
- Inadequate or dirty clothing, poor hygiene
- Child exhibits poor attachment to parents

Procedures that may Require Sedation

- Setting fractures
- Reducing dislocations
- Draining abscesses
- Exploring wounds/ulcers/superficial infections
- Endoscopic examination
- Reduce patient anxiety/ agitation for imaging/procedures
## Table 41. Commonly Used Medications (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosing Schedule</th>
<th>Indications</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine</td>
<td>15-30 mg PO q8-12h 0.1-0.2 mg/kg max 15 mg IV q4h</td>
<td>Mild to moderate acute/chronic pain</td>
<td>GI and constipation side effects  DO NOT CRUSH, CUT, or CHEW</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prescribed in combination with NSAIDs or acetaminophen</td>
<td></td>
</tr>
<tr>
<td>Naloxone</td>
<td>0.5-2 mg or 0.01-0.02 mg/kg initial bolus IV/IM/SL/SC or via ETT (2-2.5x IV dose), increase dose by 2 mg until response/max 10 mg</td>
<td>Comatose patient Opioid overdose Reversal in procedural sedation</td>
<td></td>
</tr>
<tr>
<td>Nitroglycerin</td>
<td>acute angina: 0.3-0.6 mg SL q5min, OR 5 µg/min IV increasing by 5-20 µg/min q3-5min</td>
<td>Angina Acute MI</td>
<td>Not to be used with other antihypertensives Not in right ventricular MI</td>
</tr>
<tr>
<td>Perocet 10/325®</td>
<td>1-2 tabs PO q6h pm</td>
<td>Moderate pain control</td>
<td>Oxycodone + acetaminophen Max 4 g acetaminophen daily</td>
</tr>
<tr>
<td>Phenytin</td>
<td>Status epilepticus: see Table 17</td>
<td>Status epilepticus</td>
<td>Begin maintenance dose 12 h after loading dose Continuous ECG, BP monitoring mandatory</td>
</tr>
<tr>
<td>Polysporin®</td>
<td>Apply to affected area bid-tid</td>
<td>Superficial infections</td>
<td></td>
</tr>
<tr>
<td>Propofol</td>
<td>0.25-1 mg/kg IV</td>
<td>Procedural sedation</td>
<td>Short acting Anesthetic/sedative (complication = apnea, decreased BP)</td>
</tr>
<tr>
<td>Salbutamol</td>
<td>2 puffs inhaled q4-6h max 12 puffs/d</td>
<td>Asthma</td>
<td>Caution with cardiac abnormalities</td>
</tr>
<tr>
<td>Thiamine</td>
<td>100 mg IV/IM initially, then 50-100 mg IM/IV/PO OD x 3d</td>
<td>To treat/prevent Wernicke’s encephalopathy</td>
<td>Caution use in pregnancy</td>
</tr>
<tr>
<td>TYLENOL #3®</td>
<td>1-2 tabs PO q4-6h pm</td>
<td>Pain control</td>
<td>Max 4 g acetaminophen daily</td>
</tr>
</tbody>
</table>
References


Acronyms ........................................ 2

Basic Anatomy Review .......................... 2
Major Endocrine Organs

Dyslipidemias ...................................... 2
Overview of Lipid Transport
Hypertriglyceridemia (Elevated Triglycerides)
Hypercholesterolemia
Low High-Density Lipoprotein
Dyslipidemia and the Risk for Coronary Artery Disease
Treatment of Dyslipidemias

Disorders of Glucose Metabolism ............. 6
Overview of Glucose Regulation
Pre-Diabetes (Impaired Glucose Tolerance/Impaired Fasting Glucose)
Diabetes Mellitus
Treatment of Diabetes
Acute Complications
Macrovacular Complications
Microvascular Complications
Other Complications
Hypoglycemia (BG <4.0 mmol/L or 72 mg/dL)
Metabolic Syndrome

Obesity ............................................. FM7

Pituitary Gland .................................... 15
Pituitary Hormones
Growth Hormone
Prolactin
Thyroid Stimulating Hormone
Adrenocorticotropic Hormone
Luteinizing Hormone and Follicle Stimulating Hormone
Antidiuretic Hormone
Pituitary Pathology

Thyroid ........................................... 20
Thyroid Hormones
Tests of Thyroid Function and Structure
Thyrotoxicosis
Graves’ Disease
Subacute Thyroiditis (Thyrotoxic Phase)
Toxic Adenoma/Toxic Multinodular Goitre
Thyrotoxic Crisis/Thyrotoxic Storm
Hypothyroidism
Hashimoto’s Thyroiditis
Myxedema Coma
Sick Euthyroid Syndrome
Non-Toxic Goitre
Thyroid Nodules
Thyroid Malignancies

Adrenal Cortex .................................... 29
Adrenocorticotropic Hormone
Adrenocortical Hormones
Adrenocortical Functional Workup
Mineralocorticoid Excess Syndromes
Cushing’s Syndrome
Congenital Adrenal Hyperplasia
Hyperandrogenism
Adrenocortical Insufficiency

Adrenal Medulla .................................. 34
Catecholamine Metabolism
Pheochromocytoma

Disorders of Multiple Endocrine Glands ...... 35
Multiple Endocrine Neoplasms

Calcium Homeostasis ............................ 36
Hypercalcemia
Hypocalcemia

Metabolic Bone Disease ....................... 40
Osteoporosis
Osteomalacia and Rickets
Renal Osteodystrophy
Paget’s Disease of Bone

Male Reproductive Endocrinology .......... 45
Androgen Regulation
Tests of Testicular Function
Hypogonadism and Infertility
Erectile Dysfunction
Gynecomastia

Female Reproductive Endocrinology ...... 48

Paraneoplastic Syndrome ..................... 48

Common Medications ........................... 49
Diabetes Medications
Dyslipidemia Medications
Thyroid Medications
Metabolic Bone Disease Medications
Adrenal Medications

Landmark Endocrinology Trials ............. 53

References ..................................... 54
**Acronyms**

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>DM</td>
<td>diabetes mellitus</td>
</tr>
<tr>
<td>ACR</td>
<td>albumin-creatinine ratio</td>
</tr>
<tr>
<td>ACRH</td>
<td>adenocorticotrophic hormone</td>
</tr>
<tr>
<td>ADH</td>
<td>antidiuretic hormone</td>
</tr>
<tr>
<td>AG</td>
<td>anion gap</td>
</tr>
<tr>
<td>AVP</td>
<td>arginine vasopressin</td>
</tr>
<tr>
<td>BMD</td>
<td>bone mineral density</td>
</tr>
<tr>
<td>BMI</td>
<td>body mass index</td>
</tr>
<tr>
<td>CAD</td>
<td>coronary artery disease</td>
</tr>
<tr>
<td>CAH</td>
<td>congenital adrenal hyperplasia</td>
</tr>
<tr>
<td>CHO</td>
<td>carbohydrates</td>
</tr>
<tr>
<td>CK</td>
<td>creatine kinase</td>
</tr>
<tr>
<td>CMV</td>
<td>cytomegaloovirus</td>
</tr>
<tr>
<td>CrCl</td>
<td>creatinine clearance</td>
</tr>
<tr>
<td>CRH</td>
<td>corticotropin releasing hormone</td>
</tr>
<tr>
<td>CVD</td>
<td>cardiovascular disease</td>
</tr>
<tr>
<td>DDAP</td>
<td>desmopressin (1-deamino-8-D-arginine vasopressin)</td>
</tr>
<tr>
<td>DHEA</td>
<td>dehydroepiandrosterone</td>
</tr>
</tbody>
</table>

**Basic Anatomy Organs**

**HYPOTHALAMUS**
- Corticotropin-RH (CRH)
- Gonadotropin-RH (GnRH)
- Thyrotropin-RH (TRH)
- Growth hormone-RH (GH-RH)
- Antidiuretic hormone (ADH)*
- Oxytocin*

**THYROID GLAND**
- Triiodothyronine (T3)
- Thyroxine (T4)

**ADRENAL GLAND**
- Cortex
  - Aldosterone
  - Cortisol
  - Androgens
  - Medulla
  - Catecholamines
- TESTES
  - Testosterone

**PARATHYROID GLANDS**
- Parathyroid hormone (PTH)

**PITUITARY GLAND**
- Anterior pituitary
  - Growth hormone (GH)
  - Prolactin (PRL)
  - Thyroid-stimulating hormone (TSH)
  - Luteinizing hormone (LH)
  - Follicle-stimulating hormone (FSH)
- Adrenocorticotrophic hormone (ACTH)
- Posterior pituitary
  - Antidiuretic hormone (ADH)*
  - Oxytocin*

**PARATHYROID GLANDS**
- Parathyroid hormone (PTH)

**PANCREAS**
- Insulin
- Glucagon

**OVARIAS**
- Estrogen
- Progesterone

**Dyslipidemias**

**Definition**
- metabolic disorders characterized by elevations of fasting plasma LDL-cholesterol, and/or triglycerides (TG), and/or low HDL-cholesterol

**Overview of Lipid Transport**
- lipoproteins are spherical complexes that consist of a lipid core surrounded by a shell of water-soluble cholesterol, apoproteins, and phospholipids
- lipoproteins transport lipids within the body
- apolipoproteins serve as enzyme co-factors, promote clearance of the particle by interacting with cellular receptors, and stabilize the lipoprotein micelle
Table 1. Lipoproteins

<table>
<thead>
<tr>
<th>Lipoprotein Pathway</th>
<th>Apolipoproteins</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exogenous Pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chylomicron</td>
<td>B-48, C, E, A-I, A-II, A-IV</td>
<td>Transports dietary TG from gut to adipose tissue and muscle</td>
</tr>
<tr>
<td>Endogenous Pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VLDL</td>
<td>B-100, C, E</td>
<td>Transports hepatic synthesized TG from liver to adipose tissue and muscle</td>
</tr>
<tr>
<td>IDL</td>
<td>B-100, E</td>
<td>Product of hydrolysis of TG in VLDL by lipoprotein lipase resulting in depletion of TG core</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Enriched in cholesterol esters</td>
</tr>
<tr>
<td>LDL</td>
<td>B-100</td>
<td>Formed by further removal of residual TG from IDL core by hepatic lipase resulting in greater enriched particles with cholesterol esters</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Transports cholesterol from liver to peripheral tissues (gonads, adrenals)</td>
</tr>
<tr>
<td>HDL</td>
<td>A-I, A-II, C, E</td>
<td>Transports cholesterol from peripheral tissues to liver</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Acts as a reservoir for apolipoproteins</td>
</tr>
</tbody>
</table>

Table 2. Primary Hypertriglyceridemias

<table>
<thead>
<tr>
<th>Hypertriglyceridemia</th>
<th>Etiology/Pathophysiology</th>
<th>Labs</th>
<th>Clinical Presentation</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Familial Lipoprotein Lipase Deficiency</td>
<td>Autosomal recessive deficiency of lipoprotein lipase or its cofactor</td>
<td>↑ TG</td>
<td>Presents at infancy</td>
<td>Decrease dietary fat intake to &lt;10% of total calories</td>
</tr>
<tr>
<td></td>
<td></td>
<td>↑ Chylomicrons</td>
<td>Recurrent abdominal pain</td>
<td>Decrease dietary simple carbohydrates</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderate ↑ in VLDL</td>
<td>Hepatosplenomegaly</td>
<td>Cook with medium chain fatty acids</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Splenic infarct</td>
<td>Abstain from EtOH</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Anemia, granulocytopenia</td>
<td>Gene therapy (Glybera)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>thrombocytopenia 2° to hypersplenism</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pancreatitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lipemia retiniana</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Eruptive xanthomata</td>
<td></td>
</tr>
<tr>
<td>Familial Hypertriglyceridemia</td>
<td>Autosomal dominant for inactivating mutations of the LP lipase gene</td>
<td>↑ TG</td>
<td>Possible premature CAD</td>
<td>Decrease dietary simple carbohydrates and fat intake</td>
</tr>
<tr>
<td></td>
<td>Several genetic defects resulting in ↑ hepatic VLDL synthesis or ↓ removal of VLDL</td>
<td>↑ VLDL</td>
<td>Develop syndrome of obesity, hypertriglyceridemia, hyperinsulinemia, and hyperuricemia in early adulthood</td>
<td>Abstain from EtOH</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fibrates or niacin</td>
</tr>
</tbody>
</table>
SECONDARY HYPERTRIGLYCERIDEMIA

Etiology
- endocrine: obesity/metabolic syndrome, hypothyroidism (more for high LDL, not TG), acromegaly, Cushings syndrome, DM
- renal: chronic renal failure, polycystic and monoclonal hypergammaglobulinemia
- hepatic: chronic liver disease, hepatitis, glycogen storage disease
- drugs: alcohol, corticosteroids, estrogen, hydrochlorothiazide, retinoic acid, beta-blockers without intrinsic sympathomimetic action (ISA), anti-retroviral drugs, atypical antipsychotics, oral contraceptive pills
- other: pregnancy

Hypercholesterolemia

Table 3. Primary Hypercholesterolemias

<table>
<thead>
<tr>
<th>Hypercholesterolemia</th>
<th>Etiology/Pathophysiology</th>
<th>Labs</th>
<th>Clinical Presentation</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Familial Hypercholesterolemia</td>
<td>1/500 in U.S. population Autosomal codominant with high penetrance More prevalent in French Canadian, Dutch Afrikaner, Christian Lebanese populations Most commonly due to defects in the normal LDL receptor on cell membranes</td>
<td>↑ LDL ↑ TC</td>
<td>Tendinous xanthomatosis (Achilles, patellar, and extensor tendons of hand) Arcus cornealis Xanthelasma Heterozygotes: premature CAD, 50% risk of MI in men by age 30 Homozygotes: manifest CAD and other vascular disease early in childhood and can be fatal (&lt;20 yr) if untreated</td>
<td>Heterozygotes: improvement of LDL with statins, often in combination with ezetimibe or bile acid sequestrants or PCSK9 inhibitor Homozygotes: partial control with portacaval shunt or LDL apheresis in conjunction with niacin; large dose statin is modestly effective; potential liver transplant; consider lomitapide (inhibitor of the microsomal TG transfer protein) and mipomersen (inhibits AzoB gene)</td>
</tr>
<tr>
<td>Polygenic Hypercholesterolemia</td>
<td>Most common Few mild inherited defects in cholesterol metabolism</td>
<td>↑ TC</td>
<td>Asymptomatic until vascular disease develops No xanthoma</td>
<td>Statins, ezetimibe, niacin, bile acid sequestrant, PCSK9 inhibitor</td>
</tr>
<tr>
<td>Familial Combined Hyperlipidemia</td>
<td>In many cases, over-population of VLDL and associated ↑ LDL 2 to excess hepatic synthesis of apolipoprotein B Autosomal dominant</td>
<td>↑ TC + G ↑ VLDL ↑ LDL</td>
<td>Xanthelasma CAD and other vascular disease</td>
<td>Weight reduction Decrease simple carbohydrates, fat, cholesterol, and E10H in diet Statins Niacin, fibrates, ezetimibe, PCSK9 inhibitor</td>
</tr>
</tbody>
</table>

SECONDARY HYPERCHOLESTEROLEMIA

Etiology
- endocrine: hypothyroidism
- renal: nephrotic syndrome
- immunologic: monoclonal gammopathy
- hepatic: cholestatic liver disease (e.g. primary biliary cirrhosis)
- nutritional: diet, anorexia nervosa
- drugs: cyclosporin, anabolic steroids, carbamazepine

Low-Density Lipoprotein

PRIMARY CAUSES

Table 4. Primary Low HDL Cholesterol Levels

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Etiology/Pathophysiology</th>
<th>Clinical Presentation</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Familial Hypercholesterolemia or Familial HDL Deficiency</td>
<td>Autosomal dominant inheritance of a mutation in the ABCA1 or the APOA1 gene</td>
<td>Premature atherosclerosis Cerebrovascular disease Premature atherosclerosis Xanthomas</td>
<td>Reduce the risk of atherosclerosis with lifestyle changes, management of concomitant hypercholesterolemia, hypertriglyceridemia, and metabolic syndrome if present</td>
</tr>
<tr>
<td>Tangier Disease</td>
<td>Autosomal recessive inheritance of mutations in the ABCA1 gene Impaired HDL-mediated cholesterol efflux from macrophages and impaired intracellular lipid trafficking</td>
<td>Mild hypertriglyceridemia Neuropathy Enlarged, orange-coloured tonsils Premature atherosclerosis Splenomegaly Hepatomegaly Corneal clouding Type 2 DM</td>
<td>Reduce the risk of atherosclerosis with lifestyle changes, management of concomitant hypercholesterolemia, hypertriglyceridemia, and metabolic syndrome if present</td>
</tr>
</tbody>
</table>
SECONDARY CAUSES

Etiology
• endocrine: obesity/metabolic syndrome, DM
• drugs: β-blockers, benzodiazepines, anabolic steroids
• other: acute infections, inflammatory conditions

Dyslipidemia and the Risk for Coronary Artery Disease

• increased LDL is a major risk factor for atherosclerosis and CAD as LDL is the major atherogenic lipid particle
• increased HDL is associated with decreased cardiovascular disease and mortality
• moderate hypertriglyceridemia (triglyceride level 2.3-9 mmol/L) is an independent risk factor for CAD, especially in people with DM and in post-menopausal women
• treatment of hypertriglyceridemia has not been shown to reduce CAD risk

Screening
• screen men over age 40, women over age 50 or post-menopausal
• if following risk factors present, screen at any age
  • DM
  • current cigarette smoking or COPD
  • HTN (sBP >140, dBP >90)
  • obesity (BMI >27 kg/m²)
  • family history of premature CAD
  • clinical signs of hyperlipidemia (xanthelasma, xanthoma, arcus cornealis)
  • evidence of atherosclerosis
  • inflammatory disease (rheumatoid arthritis, SLE, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease)
  • HIV infection on highly active anti-retroviral therapy (HAART)
  • chronic kidney disease (estimated GFR <60 mL/min/1.73 m²)
  • erectile dysfunction
  • screen children with a family history of hypercholesterolemia or chylomicronemia

Factors Affecting Risk Assessment
• metabolic syndrome
• apolipoprotein B (apo B)
  • each atherogenic particle (VLDL, IDL, LDL, and lipoprotein A) contains one molecule of apo B
  • serum [apo B] reflects the total number of particles and may be useful in assessing cardiovascular risk and adequacy of treatment in high risk patients and those with metabolic syndrome
• C-reactive protein (hs-CRP) levels
• highly sensitive acute phase reactant
• may be clinically useful in identifying those at a higher risk of cardiovascular disease than predicted by the global risk assessment

Treatment of Dyslipidemias

Approach to Treatment
For clinical guidelines see Can J Cardiol 2012;28:101-167
• estimate 10 yr risk of CAD using Framingham model
• establish treatment targets according to level of risk

Table 5. Target Lipids by Risk Group

<table>
<thead>
<tr>
<th>Level of Risk</th>
<th>Definition (10 Yr Risk of CAD)</th>
<th>Initiate Treatment if:</th>
<th>Primary Target LDL-C</th>
<th>Alternate</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>Risk ≥20%, or Clinical atherosclerosis, Abdominal aortic aneurysm, DM &gt;15 yr duration or age older than 30 yr, DM with age ≥40 yr, Microvascular disease, High risk kidney disease, High risk HTN</td>
<td>Consider treatment in all patients</td>
<td>≤2 mmol/L or ≤50% ↓ in LDL</td>
<td>apo B ≤0.80 g/L or non-HDL-C ≤2.6 mmol/L</td>
</tr>
<tr>
<td>Moderate</td>
<td>Risk 10-19%</td>
<td>LDL &gt;3.5 mmol/L For LDL-C &lt;3.5 consider if: apo B ≥1.2 g/L or non-HDL-C ≥4.3 mmol/L</td>
<td>≤2 mmol/L or ≤50% ↓ in LDL</td>
<td>apo B &lt;0.80 g/L or non-HDL-C ≤2.6 mmol/L</td>
</tr>
<tr>
<td>Low</td>
<td>Risk &lt;10%</td>
<td>LDL ≤5.0 mmol/L Familial hypercholesterolemia</td>
<td>≤50% ↓ in LDL</td>
<td></td>
</tr>
</tbody>
</table>

Simvastatin to Lower CAD Risk – The Heart Protection Study (HPS) 
Lancet 2002;360:797-82

Study: Randomized, double-blind, placebo-controlled trial (median follow-up 5.0 yr).
Patients: 20,536 patients with coronary disease, other occlusive arterial disease or DM aged 40-80 yrs who had a total cholesterol level of ≥3.5 mmol/L.
Intervention: Simvastatin 40 mg/d or placebo.
Main Outcome: Mortality, fatal or non-fatal vascular events.
Results: The use of simvastatin significantly decreased total mortality (12.9 vs. 14.1, p=0.0003) and the first event rate of any cardiovascular event by 25% (p=0.0001).
Conclusion: Treatment with simvastatin improved survival and cardiovascular outcomes in high-risk CAD patients.
Disorders of Glucose Metabolism

Overview of Glucose Regulation

Figure 3. Blood glucose regulation

Pre-Diabetes (Impaired Glucose Tolerance/Impaired Fasting Glucose)

- 1-5% per yr go on to develop DM
- 50-80% revert to normal glucose tolerance
- weight loss may improve glucose tolerance
- increased risk of developing macrovascular complications (IGT >IFG)
- lifestyle modifications decrease progression to DM by 58%

Diagnostic Criteria (CDA Guidelines)

- impaired fasting glucose (IFG): fasting plasma glucose (FPG) 6.1-6.9 mmol/L
- impaired glucose tolerance (IGT): 2h 75 g oral glucose tolerance test (OGTT) 7.8-11.0 mmol/L
- HbA1c: 6.0-6.4%

Three Year Efficacy of Complex Insulin Regimens in Type 2 DM: 4T Trial

Study: Randomized unblinded trial with 3 yr of follow-up.
Population: 708 patients with type 2 DM, not on insulin or thiazolidinedione therapy on maximal metformin and sulfonylurea therapy.
Intervention: Twice-daily prandial insulin aspart, versus twice-daily bolus insulin aspart, versus once-daily basal insulin detemir. Sulfonylurea therapy was replaced with a secondary insulin regimen specific to each arm if there was persistent hyperglycemia.
Primary Outcome: Three yr hemoglobin HbA1c.
Results: Significant difference in rates of patient withdrawal from the study: 5.1% bippionic, 11.7% prandial, 8.5% basal regimens (p=0.04). There were no significant differences in median HbA1c levels between all three arms from yr 1-3. A smaller proportion of patients reached HbA1c < 6.5% or < 7.0% in the biphasic arm. The basal arm had least weight gain and least weight circumference increase, but highest rate of secondary insulin requirement. The basal arm had lowest severe hypoglycemic events per patient yr, while the biphasic arm had the most serious adverse effects.
Conclusion: Basal insulin regimen provides the best glycemic control over a 3 yr study; with better HbA1c control, fewer hypoglycemic events, and less weight gain.
Disorders of Glucose Metabolism

Diabetes Mellitus

Definition
- syndrome of disordered metabolism and inappropriate hyperglycemia secondary to an absolute/relative deficiency of insulin, or a reduction in biological effectiveness of insulin, or both

Diagnostic Criteria (CDA Guidelines)
- any one of the following is diagnostic
  - FPG ≥7.0 mmol/L (fasting = no caloric intake for at least 8 h) OR
  - 2h 75 g OGTT ≥11.1 mmol/L OR
  - random PG ≥11.1 mmol/L OR
  - HbA1c ≥6.5% (not for diagnosis of suspected Type 1 DM, children, adolescents, or pregnant women)
- in the presence of hyperglycemia symptoms (polyuria, polydipsia, polyphagia, weight loss, blurry vision.), a confirmatory test is not required
- in the absence of hyperglycemic symptoms, a repeat confirmatory test is required to make the diagnosis of diabetes

Etiology and Pathophysiology

Table 7. Etiologic Classification of Diabetes Mellitus

<table>
<thead>
<tr>
<th>I. Type 1 DM</th>
<th>Immune-mediated β cell destruction, usually leading to absolute insulin deficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>II. Type 2 DM</td>
<td>Ranges from predominantly insulin resistance with relative insulin deficiency to a predominantly insulin secretory defect with insulin resistance 2o to β cell dysfunction</td>
</tr>
<tr>
<td>III. Other Specific Causes of DM</td>
<td></td>
</tr>
</tbody>
</table>
  a. Genetic defects of β cell function (e.g. MODY – Maturity-Onset Diabetes of the Young) or insulin action |
  b. Diseases of the exocrine pancreas: Pancreatitis, pancreactectomy, neoplasia, cystic fibrosis, hemochromatosis (“bronze diabetes”) |
  c. Endocrinopathies: Acromegaly, Cushing’s syndrome, glucagonoma, pheochromocytoma, hyperthyroidism |
  d. Drug-induced: Glucocorticoids, thyroid hormone, β-adrenergic agonists, thiazides, phenytoin, clozapine |
  e. Infections: Congenital rubella, CMV, coxsackie |
  f. Genetic syndromes associated with DM: Down’s syndrome, Klinefelter’s syndrome, Turner’s syndrome |

Table 8. Comparison of Type 1 and Type 2 Diabetes Mellitus

<table>
<thead>
<tr>
<th>Type 1</th>
<th>Type 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset</td>
<td>Usually &lt;30 yr of age</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>More common in Caucasians</td>
</tr>
<tr>
<td></td>
<td>Less common in Asians, Hispanics, Aboriginals, and Blacks</td>
</tr>
<tr>
<td>Etiology</td>
<td>Autoimmune</td>
</tr>
<tr>
<td>Genetics</td>
<td>Monogenic twin concordance is 30-40% Associated with HLA class II DR3 and DR4, with either allele present in up to 95% of type 1 DM Certain DG alleles also confer a risk</td>
</tr>
<tr>
<td>Pathophysiology</td>
<td>Synergistic effects of genetic, immune, and environmental factors that cause β cell destruction resulting in impaired insulin secretion Autoimmune process is believed to be triggered by environmental factors (e.g. viruses, bovine milk, protein, urea compounds) Pancreatic cells are infiltrated with lymphocytes resulting in islet cell destruction 80% of β cell mass is destroyed before features of DM present</td>
</tr>
</tbody>
</table>

Blood Glucose Control in Type 2 DM – UKPDS 33

Lancet 1998;352:837-853

Study: RCT (mean follow-up 10 yr).

Patients: 3,887 patients with newly diagnosed type 2 DM (mean age 53 yr, 67% men, 81% white, mean fasting plasma glucose (FPG) 6.1-15.0 mmol/L).

Exclusions included severe cardiovascular disease, renal disease, retinopathy, and others.

Intervention: Intensive treatment with a sulfonylurea or insulin (target FPG <6 mmol/L) vs. conventional treatment with diet alone (target FPG <15 mmol/L without hyperglycemic symptoms).

Main Outcomes: DM-related endpoints (MI, angina, heart failure, stroke, renal failure, amputation, retinopathy, blindness, death from hyperglycemia or hypoglycemia), DM-related death, and all-cause mortality.

Results: Patients allocated to intensive treatment had lower median HbA1c levels (p<0.001).

Outcome RRR % (p value)

DM-related endpoint 12 (0.029)
DM-related death 10 (0.34)
All-cause mortality 6 (0.44)

Patients allocated to intensive therapy had more hypoglycemic episodes and greater weight gain.

Conclusions: Intensive blood glucose control reduces microvascular, but not macrovascular complications in type 2 DM.

Table 8. Comparison of Type 1 and Type 2 Diabetes Mellitus
Table 8. Comparison of Type 1 and Type 2 Diabetes Mellitus (continued)

<table>
<thead>
<tr>
<th></th>
<th>Type 1</th>
<th>Type 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Natural History</td>
<td>4-7 mmol/L (72-126 mg/dL)</td>
<td>&lt;7.0%</td>
</tr>
<tr>
<td></td>
<td>After initial presentation, honeymoon period often occurs where glycemic control can be achieved with less or no insulin treatment as residual cells are still able to produce insulin. Once these cells are destroyed, there is complete insulin deficiency.</td>
<td>Early on, glucose tolerance remains normal despite insulin resistance as β cells compensate with increased insulin production. As insulin resistance and compensatory hyperinsulinism continue, the β cells are unable to maintain the hyperinsulinaemic state which results in glucose intolerance and DM.</td>
</tr>
<tr>
<td>Lipids</td>
<td>Lipids As per high risk group if age &gt;40 or age &gt;30 if DM duration &gt;15 yr. Blood pressure &lt;130/80.</td>
<td></td>
</tr>
<tr>
<td>Circulating</td>
<td>Islet cell Ab present in up to 60-85% Most common islet cell Ab is against glutamic acid decarboxylase (GAD) Up to 60% have Ab against insulin.</td>
<td>&lt;10%</td>
</tr>
<tr>
<td>Autoantibodies</td>
<td>Personal history of other autoimmune diseases including Graves’, myasthenia gravis, autoimmune thyroid disease, celiac disease, and pernicious anemia. Family history of autoimmune diseases.</td>
<td></td>
</tr>
<tr>
<td>Risk Factors</td>
<td>Age &gt;40 yr Schizophrenia Abdominal obesity/overweight Fatty liver First-degree relative with DM Hyperuricemia Race/ethnicity (Black, Aboriginal, Hispanic, Asian-American, Pacific Islander) Hx of IGT or IFG HTN Dyslipidemia Medications e.g. 2nd generation antipsychotics PCSO Hx of gestational DM or macrosomic baby (&gt;9 lb or 4 kg).</td>
<td></td>
</tr>
<tr>
<td>Body Habits</td>
<td>Normal to thin. Typically overweight with increased central obesity.</td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td>Insulin Lifestyle modification Non-insulin antihyperglycemic agents - unless contraindicated, metformin should be the initial antihyperglycemic agent of choice. Additional agents to be selected on the basis of clinically relevant issues, such as glucose lowering effectiveness, risk of hypoglycemia, and effect on body weight. Insulin therapy.</td>
<td></td>
</tr>
<tr>
<td>Acute Complication</td>
<td>Diabetic ketoacidosis (DKA) in severe cases. Hyperosmolar hyperglycemic state (HHS) DKA in severe cases.</td>
<td></td>
</tr>
<tr>
<td>Screening</td>
<td>Subclinical prodrome can be detected in first and second-degree relatives of those with type 1 DM by the presence of pancreatic islet autoantibodies. Screen individuals with risk factors.</td>
<td></td>
</tr>
</tbody>
</table>

**Treatment of Diabetes**

**Glycemic Targets**
- HbA1c reflects glycemic control over 3 mo and is a measure of patient’s long-term glycemic control.
- Therapy in most individuals with type 1 or type 2 DM (especially younger patients) should be targeted to achieve a HbA1c <7.0% in order to reduce the risk of microvascular and if implemented early in the course of disease, macrovascular complications.
- More intensive glucose control, HbA1c <6.5%, may be targeted in type 2 DM in patients with a shorter duration of DM with no evidence of significant CVD and longer life expectancy, to further reduce risk of nephropathy and retinopathy, provided this does not result in a significant increase in hypoglycemia.
- Less stringent HbA1c targets (7.1-8.5%) may be more appropriate in type 1 and type 2 patients with limited life expectancy, higher level of functional dependency, a history of recurrent severe hypoglycemia, multiple comorbidities, extensive CAD, or a failure to attain HbA1c <7.0% despite intensified basal and bolus insulin therapy.
- There may be harm associated with strategy to target HbA1c <6.0% (see ACCORD trial, E9).

**Diet**
- Daily carbohydrate intake 45-60% of energy, protein 15-20% of energy, and fat <35% of energy.
- Intake of saturated fats <7% and polyunsaturated fats <10% of total calories each.
- Limit sodium, alcohol, and caffeine intake.
- Type 1: carbohydrate counting is used to titrate insulin regimen.
- Type 2: weight reduction.

**Canadian Diabetes Guidelines 2013**

<table>
<thead>
<tr>
<th>Target</th>
<th>HbA1c</th>
<th>Fasting plasma glucose</th>
<th>2h post-prandial glucose</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c</td>
<td>&lt;7.0%</td>
<td>(72-126 mg/dL)</td>
<td>(90-180 mg/dL)</td>
</tr>
<tr>
<td>Fasting plasma glucose</td>
<td>4-7 mmol/L</td>
<td>(72-126 mg/dL)</td>
<td>5-10 mmol/L</td>
</tr>
<tr>
<td>2h post-prandial glucose</td>
<td>5-10 mmol/L</td>
<td>(90-180 mg/dL)</td>
<td>5-8 mmol/L</td>
</tr>
<tr>
<td>Lipids</td>
<td>As per high risk group if age &gt;40 or age &gt;30 if DM duration &gt;15 yr. Blood pressure &lt;130/80.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 DM: The Look AHEAD Trial**

- **Study:** RCT, with 8.6 yr of median follow-up.
- **Population:** 5,145 overweight or obese patients with type 2 DM.
- **Intervention:** Intensive lifestyle intervention promoting weight loss through decreased caloric intake and increased physical activity (intervention) or DM support and education (control).
- **Primary Outcome:** First occurrence of death from cardiovascular (CV) causes, non-fatal MI, non-fatal stroke, or hospitalization for angina.
- **Results:** Although the intensive lifestyle intervention produced greater weight loss and reductions in glycated hemoglobin, the intervention did not significantly reduce the risk of CV morbidity or mortality.
- **Conclusions:** An intensive lifestyle intervention focusing on weight loss did not significantly reduce the risk of cardiovascular events in overweight or obese adults with type 2 DM.
Lifestyle
• regular physical exercise to improve insulin sensitivity, lower lipid concentrations and control blood pressure
• smoking cessation

Medical Treatment: Non-insulin Antihyperglycemic Agents (Type 2 DM)
• initiate non-insulin antihyperglycemic therapy within 2-3 mo if lifestyle management does not result in glycemic control
• if initial HbA1c >8.5% at the time of diagnosis, initiate pharmacologic therapy with metformin immediately and consider combination of therapies or insulin immediately
• continue to add additional pharmacologic therapy in a timely fashion to achieve target HbA1C within 3-6 months of diagnosis
• see Common Medications, E49 for details on antihyperglycemic agents

Medical Treatment: Insulin (Figure 5)
• used for type 1 DM at onset, may be used in type 2 DM at any point in treatment
• routes of administration: subcutaneous injections, continuous subcutaneous insulin infusion pump, IV infusion (regular insulin only)
• bolus insulins: short-acting (Insulin regular), rapid-acting analogue (Insulin aspart, Insulin glulisine, Insulin lispro)
• basal insulins: intermediate-acting (Insulin NPH), long-acting analogue (Insulin detemir, glargine)
• premixed insulins (combination of basal and bolus insulins) available but not used regularly
• estimated total daily insulin requirement: 0.5-0.7 units/kg (often start with 0.3-0.5 units/kg/d)

Effects of Intensive Glucose Lowering in Type 2 DM: The ACCORD Trial
- NEJM 2009;360:2183-2201
Study: Multicenter RCT.
Population: 7,833 patients (mean age 63.2) with type 2 DM, and cardiovascular risk factors.
Intervention: Intensive therapy targeting a HbA1c level of less than 6.0% or standard therapy targeting 7.0-7.9%.
Outcomes: First occurrence of nonfatal MI, nonfatal stroke, or death from CV causes.
Results: The intensive therapy arm was stopped early (7.5 yr vs. 5.5 yr planned) due to evidence of increased mortality. There was no difference in primary outcome for either study arm. There was a significant increase in all-cause mortality, CV mortality, nonfatal MI, and CHF in the intensive therapy group. There were increased rates of all hypoglycemic events, any nonhypoglycemic serious adverse events, fluid retention, and weight gain >10 kg, but lower systolic and diastolic blood pressure in the intensive therapy group. There was an increased incidence of elevated ALT (>3x upper limit) and ACE drug use in the standard therapy group.
Conclusions: Intensive glucose lowering therapy in type 2 DM does not improve clinical outcomes and actually increases the risk of mortality with more adverse events compared to standard therapy. Additional research is required to discern the cause.

Effects of Intensive Blood Pressure Control in Type 2 DM: The ACCORD Trial
- NEJM 2010;362:1575-1585
Study: RCT, unblinded by 4 yr of mean follow-up.
Population: 4,733 patients with type 2 DM, risk factors for cardiovascular (CV) disease, systolic blood pressure (SBP) between 130-180 mmHg.
Intervention: SBP control less than 120 mmHg (intensive) or 140 mmHg (standard).
Primary Outcomes: Major CV event (composite nonfatal MI, nonfatal stroke, or CV-related death).
Results: Mean number of medications at 1 yr for intensive therapy was 3.4 (95% CI 3.2-3.6) versus 2.1 (95% CI 2.1-2.2) for standard therapy. There was a significant increase in all serious adverse events in the intensive treatment arm (3.2% vs. 1.7%, p < 0.001); especially atrial fibrillation or atrial tachycardia (0.5% vs. 0.3%, p = 0.02) and hyperkalemia (0.4% vs. 0.0%, p = 0.01). There was no significant difference in primary outcomes in the two study arms, all-cause mortality. There was a significant reduction in any stroke (0.32% vs. 0.33%, p = 0.01) and nonfatal stroke (1.5% vs. 0.4%, p = 0.04) and nonfatal MI (3.4% vs. 3.5%, p = 0.04). There was no significant difference in primary outcomes in the two study arms, all-cause mortality.
Conclusions: Intensive BP lowering to less than 120 mmHg vs. 140 mmHg in patients with type 2 DM and CV risk factors does not reduce major CV event risk reduction except for stroke events.
Table 9. Available Insulin Formulations (continued)

<table>
<thead>
<tr>
<th>Insulin Type (trade name)</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRE-MIXED INSULINS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Premixed regular insulin – NPH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Humulin 30/70®</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Novolin 30/70®</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Premixed insulin analogues</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biphasic insulin aspart (NovoMix 30®)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin lispro/lispro protamine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Humalog Mix25® and Mix50®)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A single vial or cartridge contains a fixed ratio of insulin (% of rapid acting or short-acting insulin to % of intermediate-acting insulin).

Table 10. Insulin Regimens for Type 2 DM and Type 1 DM

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 2 DM</td>
<td>Non-insulin antihyperglycemic agent + basal insulin</td>
</tr>
<tr>
<td></td>
<td>Start with 10 units of basal insulin at bedtime</td>
</tr>
<tr>
<td></td>
<td>Trat with 1 unit if FPG &lt; 7.0 mmol/L</td>
</tr>
<tr>
<td>Type 1 DM</td>
<td>Basal-bolus (multiple daily injections (MDI))</td>
</tr>
<tr>
<td></td>
<td>Estimated total insulin requirement is 0.5-0.7 U/kg</td>
</tr>
<tr>
<td></td>
<td>20% is given as bolus insulin before breakfast, lunch, and dinner</td>
</tr>
<tr>
<td></td>
<td>Coninue metformin but discontinue secretagogue</td>
</tr>
<tr>
<td>Premixed</td>
<td>Estimated total insulin requirement is 0.5-0.7 U/kg</td>
</tr>
<tr>
<td></td>
<td>2/3 dose is given as pre-mixed insulin before breakfast</td>
</tr>
<tr>
<td></td>
<td>1/3 dose is given as pre-mixed insulin before dinner</td>
</tr>
<tr>
<td></td>
<td>Continue metformin but discontinue secretagogue</td>
</tr>
</tbody>
</table>

*Bolus insulin: Aspart, Glulisine, Lispro; *Basal insulin: Garginle, Detemir; NPH; *Pre-mixed insulin: Humulin 30/70, Novolin 30/70, Novomix 30, Humalog Mix25, Humalog Mix50

Table 11. Titrating Insulin Doses

<table>
<thead>
<tr>
<th>Hyperglycemic Reading</th>
<th>Insulin Correction</th>
</tr>
</thead>
<tbody>
<tr>
<td>High AM sugar</td>
<td>Increase bedtime basal insulin</td>
</tr>
<tr>
<td>High lunch sugar</td>
<td>Increase AM rapid/regular insulin</td>
</tr>
<tr>
<td>High supper sugar</td>
<td>Increase lunch rapid/regular insulin, or increase AM basal insulin</td>
</tr>
<tr>
<td>High bedtime sugar</td>
<td>Increase supper rapid/regular insulin</td>
</tr>
</tbody>
</table>

Variable Insulin Dose Schedule (“Supplemental/Correction Scale”)
- for patients on Basal-Bolus regimen: patient takes usual doses of basal insulin but varies doses of bolus insulin based on BG reading at time of dose
- use baseline bolus insulin dose when within BG target range; add or subtract units when above or below target
- when used in hospital (including perioperative management of DM), patient should also receive basal insulin to prevent fluctuations in blood sugar levels or long periods of hyperglycemia
- construction of a supplemental sliding scale for a patient on anti-hyperglycemics
- Correction Factor (CF) = 100/Total Daily Dose of insulin (TDD)
  - BG <4: call MD and give 15 g carbohydrates
  - BG between 4 to 8: no additional insulin
  - BG between 8 to (8 + CF): give one additional unit
  - BG between (8 + CF) to (8 + 2CF): give two additional units
  - BG between (8 + 2CF) to (8 + 3CF): give three additional units

Insulin Pump Therapy: Continuous Subcutaneous Insulin Infusion (CSII)
- external battery-operated device provides continuous basal dose of rapid-acting insulin analogue (aspart, glulisine, or lispro) through small subcutaneous catheter
- at meals, patient programs pump to deliver insulin bolus
- provides improved quality of life and flexibility
- risk of DKA if pump is inadvertently disconnected
- coverage available for insulin pumps for individuals with Type 1 DM varies by province

Figure 5. Duration of activity of different insulins

Insulin Regimens

Table 10. Insulin Regimens for Type 2 DM and Type 1 DM

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 2 DM</td>
<td>Non-insulin antihyperglycemic agent + basal insulin</td>
</tr>
<tr>
<td></td>
<td>Start with 10 units of basal insulin at bedtime</td>
</tr>
<tr>
<td></td>
<td>Trat with 1 unit if FPG &lt; 7.0 mmol/L</td>
</tr>
<tr>
<td>Type 1 DM</td>
<td>Basal-bolus (multiple daily injections (MDI))</td>
</tr>
<tr>
<td></td>
<td>Estimated total insulin requirement is 0.5-0.7 U/kg</td>
</tr>
<tr>
<td></td>
<td>20% is given as bolus insulin before breakfast, lunch, and dinner</td>
</tr>
<tr>
<td></td>
<td>Coninue metformin but discontinue secretagogue</td>
</tr>
<tr>
<td>Premixed</td>
<td>Estimated total insulin requirement is 0.5-0.7 U/kg</td>
</tr>
<tr>
<td></td>
<td>2/3 dose is given as pre-mixed insulin before breakfast</td>
</tr>
<tr>
<td></td>
<td>1/3 dose is given as pre-mixed insulin before dinner</td>
</tr>
<tr>
<td></td>
<td>Continue metformin but discontinue secretagogue</td>
</tr>
</tbody>
</table>

*Bolus insulin: Aspart, Glulisine, Lispro; *Basal insulin: Garginle, Detemir; NPH; *Pre-mixed insulin: Humulin 30/70, Novolin 30/70, Novomix 30, Humalog Mix25, Humalog Mix50

Table 11. Titrating Insulin Doses

<table>
<thead>
<tr>
<th>Hyperglycemic Reading</th>
<th>Insulin Correction</th>
</tr>
</thead>
<tbody>
<tr>
<td>High AM sugar</td>
<td>Increase bedtime basal insulin</td>
</tr>
<tr>
<td>High lunch sugar</td>
<td>Increase AM rapid/regular insulin</td>
</tr>
<tr>
<td>High supper sugar</td>
<td>Increase lunch rapid/regular insulin, or increase AM basal insulin</td>
</tr>
<tr>
<td>High bedtime sugar</td>
<td>Increase supper rapid/regular insulin</td>
</tr>
</tbody>
</table>

Variable Insulin Dose Schedule (“Supplemental/Correction Scale”)
- for patients on Basal-Bolus regimen: patient takes usual doses of basal insulin but varies doses of bolus insulin based on BG reading at time of dose
- use baseline bolus insulin dose when within BG target range; add or subtract units when above or below target
- when used in hospital (including perioperative management of DM), patient should also receive basal insulin to prevent fluctuations in blood sugar levels or long periods of hyperglycemia
- construction of a supplemental sliding scale for a patient on anti-hyperglycemics
- Correction Factor (CF) = 100/Total Daily Dose of insulin (TDD)
  - BG <4: call MD and give 15 g carbohydrates
  - BG between 4 to 8: no additional insulin
  - BG between 8 to (8 + CF): give one additional unit
  - BG between (8 + CF) to (8 + 2CF): give two additional units
  - BG between (8 + 2CF) to (8 + 3CF): give three additional units

Insulin Pump Therapy: Continuous Subcutaneous Insulin Infusion (CSII)
- external battery-operated device provides continuous basal dose of rapid-acting insulin analogue (aspart, glulisine, or lispro) through small subcutaneous catheter
- at meals, patient programs pump to deliver insulin bolus
- provides improved quality of life and flexibility
- risk of DKA if pump is inadvertently disconnected
- coverage available for insulin pumps for individuals with Type 1 DM varies by province
## Acute Complications

### Table 12. Acute Complications of Diabetes Mellitus: Hyperglycemic Comatose States

<table>
<thead>
<tr>
<th>Diabetic Ketonacidosis (DKA)</th>
<th>Hyperosmolar Hyperglycemic State (HHS)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathophysiology</strong></td>
<td><strong>Prognosis</strong></td>
</tr>
<tr>
<td>• Usually occurs in type 1 DM</td>
<td>• 2-5% mortality in developed countries</td>
</tr>
<tr>
<td>• Insulin deficiency with ↑ counterregulatory hormones (glucagon, cortisol, catecholamines, GH)</td>
<td>• Serious morbidity from sepsis, hypokalemia, respiratory complications, thromboembolic complications, and cerebral edema (the latter in children)</td>
</tr>
<tr>
<td>• Can occur with lack of insulin (non-adherence, inadequate dosage, 1st presentation) or increased stress (surgery, infection, exercise)</td>
<td>• Overall mortality approaches 50% primarily because of the older patient population and underlying etiology/precipitant</td>
</tr>
<tr>
<td>• Unopposed hepatic glucose production → hyperglycemia → osmotic diuresis → dehydration and electrolyte disturbance → ↓ Na⁺ (water shift to ECF causing pseudohyponatremia)</td>
<td><strong>Clinical Features</strong></td>
</tr>
<tr>
<td>• Fat mobilization → ↑ FFAs → ketoadsorption → metabolic acidosis</td>
<td>• Polysomnia, polydipsia, polyphagia with marked fatigue, N/V</td>
</tr>
<tr>
<td>• Severe hyperglycemia exceeds the renal threshold for glucose and ketone reabsorption → glucosuria and ketonuria</td>
<td>• Onset is insidious → preceded by weakness, polyuria, polydipsia</td>
</tr>
<tr>
<td>• Total body K⁺ depletion but serum K⁺ may be normal or elevated, ↑ in 2° to shift from ICF to ECF due to lack of insulin, ↑ plasma osmolality</td>
<td>• History of decreased fluid intake</td>
</tr>
<tr>
<td><strong>Clinical Features</strong></td>
<td>• Severe hyperglycemia, hyperosmolality, and dehydration without ketosis</td>
</tr>
<tr>
<td>• Polyuria, polydipsia, polyphagia with marked fatigue, N/V</td>
<td>• History of decreased fluid intake</td>
</tr>
<tr>
<td>• Dehydration (orthostatic changes)</td>
<td>• Severe dehydration compared to DKA due to more gradual onset and ↑ duration of metabolic compensation plus impaired fluid intake which is common in bedridden or elderly</td>
</tr>
<tr>
<td>• LOC may be ↓ with ketoadsorption or with high serum osmolality (osm &gt;330 mmol/L)</td>
<td>• Volume contraction → renal insufficiency → ↑ hyperglycemia, ↑ osmolality → shift of fluid from neurons to ECF → mental obtundation and coma</td>
</tr>
<tr>
<td>• Abdominal pain</td>
<td><strong>Serum</strong></td>
</tr>
<tr>
<td>• Fruity smelling breath</td>
<td>• ↑ BG (typically 11-55 mmol/L, ↓ Na⁺ (2° to hyperglycemia → for every ↑ in BG by 10 mmol/L there is a ↓ in Na⁺ by 3 mmol/L)</td>
</tr>
<tr>
<td>• Kussmaul’s respiration</td>
<td>• Normal or ↑ K⁺, ↑ HCO⁻, ↑ BUN, ↑ Cr, ketonemia, ↓ PO₂</td>
</tr>
<tr>
<td><strong>ABG</strong></td>
<td>• ↑ osmolality</td>
</tr>
<tr>
<td>• ↑ AG, possible 2° respiratory alkalosis</td>
<td>• ↑ osmolality</td>
</tr>
<tr>
<td>• If severe vomiting/dehydration there may be a metabolic alkalosis</td>
<td><strong>Urine</strong></td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>• Metabolic acidosis absent unless underlying precipitant leads to acidosis (e.g. lactic acidosis in MI)</td>
</tr>
<tr>
<td>• ABCs are first priority</td>
<td>• -ve for ketones unless there is starvation ketosis</td>
</tr>
<tr>
<td>• Monitor degree of ketoadsorption with AG, not BG or serum ketone level</td>
<td>• Glycosuria</td>
</tr>
<tr>
<td>• Rehydration</td>
<td><strong>Prognosis</strong></td>
</tr>
<tr>
<td>– 1 L/h NS in first 2 h</td>
<td>• 2-5% mortality in developed countries</td>
</tr>
<tr>
<td>– after 1st 2 L, 300-400 mL/h NS. Switch to 0.45% NaCl once euvoletic (continue NS if corrected sodium is falling faster than 3 mosm/kg water/h)</td>
<td>• Serious morbidity from sepsis, hypokalemia, respiratory complications, thromboembolic complications, and cerebral edema (the latter in children)</td>
</tr>
<tr>
<td>– once BG reaches 13.9 mmol/L then switch to D5W to maintain BG in the range of 12-14 mmol/L</td>
<td><strong>Endocrinology</strong></td>
</tr>
<tr>
<td>• Insulin therapy</td>
<td><strong>Toronto Notes 2017</strong></td>
</tr>
<tr>
<td>– critical to resolve acidosis, not hyperglycemia</td>
<td>• Consider starvation or alcohol ketosis</td>
</tr>
<tr>
<td>– do not use with hypokalemia (see below), until serum K⁺ is corrected to &gt;3.3 mmol/L</td>
<td><strong>Table 12. Acute Complications</strong></td>
</tr>
<tr>
<td>– use only regular insulin (R)</td>
<td>• All Ketonemia is not DKA</td>
</tr>
<tr>
<td>– maintain on 0.1 U/kg/h insulin R infusion</td>
<td><strong>Consider starvation or alcohol ketosis</strong></td>
</tr>
<tr>
<td>– check serum glucose hourly</td>
<td><strong>Table 12. Acute Complications</strong></td>
</tr>
<tr>
<td>• K⁺ replacement</td>
<td>• Consider starvation or alcohol ketosis</td>
</tr>
<tr>
<td>– with insulin administration, hypokalemia may develop</td>
<td><strong>Consider starvation or alcohol ketosis</strong></td>
</tr>
<tr>
<td>– if serum K⁺ &lt;3.3 mmol/L, hold insulin and give 40 mg Eq/L K⁺ replacement</td>
<td><strong>Consider starvation or alcohol ketosis</strong></td>
</tr>
<tr>
<td>– when K⁺ 3.5-5.0 mmol/L add KCl 20-40 mg Eq/L IV fluid to keep K⁺ in the range of 3.5-5 mg Eq/L</td>
<td><strong>Consider starvation or alcohol ketosis</strong></td>
</tr>
<tr>
<td><strong>HCO⁻</strong></td>
<td><strong>Consider starvation or alcohol ketosis</strong></td>
</tr>
<tr>
<td>– if pH &lt;7.0 or if hypotension, arrhythmia, or coma is present with a pH of &lt;7.1 give HCO⁻ in 0.45% NaCl</td>
<td><strong>Consider starvation or alcohol ketosis</strong></td>
</tr>
<tr>
<td>– do not give if pH &gt;7.1 (risk of metabolic alkalosis)</td>
<td><strong>Consider starvation or alcohol ketosis</strong></td>
</tr>
<tr>
<td>– can give in case of life-threatening hyperkalemia</td>
<td><strong>Consider starvation or alcohol ketosis</strong></td>
</tr>
<tr>
<td>– ± mannitol (for cerebral edema)</td>
<td><strong>Consider starvation or alcohol ketosis</strong></td>
</tr>
</tbody>
</table>

**All Ketonemia is not DKA**
Macrovascular Complications

- increased risk of CAD, ischemic stroke, and peripheral arterial disease secondary to accelerated atherosclerosis
- CAD (see Cardiology and Cardiac Surgery, C32)
  - risk of MI is 3-5x higher in those with DM compared to age-matched controls
  - CAD is the leading cause of death in type 2 DM
- most patients with DM are considered “high risk” under the risk stratification for CAD (see Dyslipidemias, E5)
- ischemic stroke (see Neurology, N50)
  - risk of stroke is approximately 2.5x higher in those with DM
  - level of glycemia is both a risk factor for stroke and a predictor of a poorer outcome in patients who suffer a stroke
  - HbA1c level is a significant and independent predictor of the risk of stroke
- peripheral arterial disease (see Vascular Surgery, VS2)
  - manifested by intermittent claudication in lower extremities, intestinal angina, foot ulceration
  - risk of foot gangrene is 30x higher in those with DM compared to age-matched controls
  - risk of lower extremity amputation is 15x higher in those with DM
- treatment
  - tight blood pressure control (<130/80 mmHg); especially for stroke prevention
  - tight glycemic control in early DM without established CVD (refer to ACCORD, VADT, ADVANCE, DCCT, EDIC, UKPDS extension studies)
  - tight low density lipoprotein (LDL) cholesterol control (LDL ≤2.0 mmol/L)
  - ACEI or angiotensin receptor blocker in high-risk patients
  - smoking cessation

Microvascular Complications

DIABETIC RETINOPATHY (see Ophthalmology, OP33 for a more detailed description)

Epidemiology
- type 1 DM: 25% affected at 5 yr, 100% at 20 yr
- type 2 DM: 25% affected at diagnosis, 60% at 20 yr
- leading cause of blindness in North America between the ages of 20-74
- most important factor is disease duration

Clinical Features
- nonproliferative
- preproliferative
- proliferative

Treatment and Prevention
- tight glycemic control (delays onset, decreases progression), tight lipid control, manage HTN, smoking cessation
- ophthalmological treatments available – see Ophthalmology, OP33 for more details
- annual follow-up visits with an optometrist or ophthalmologist examination through dilated pupils whether symptomatic or not (immediate referral after diagnosis of type 2 DM; 5 yr after diagnosis of type 1 DM)
- interval for follow-up should be tailored to severity of retinopathy

DIABETIC NEPHROPATHY (see Nephrology, NP31 for a more detailed description)

Epidemiology
- DM-induced renal failure is the most common cause of renal failure in North America
- 20-40% of persons with type 1 DM (after 5-10 yr) and 4-20% with type 2 DM have progressive nephropathy

Screening
- serum creatinine
- random urine test for albumin to creatinine ratio (ACR) plus urine dipstick test for all type 2 DM patients at diagnosis, then annually, and for postpubertal type 1 DM patients with ≥5yr duration of DM

Treatment and Prevention
- appropriate glycemic control
- appropriate blood pressure control (<130/80 mmHg)
- use either ACEI or ARB (often used first line for their CVD protection)
- limit use of nephrotoxic drugs and dyes

Average fluid loss runs at 3-6 L in DKA, and 8-10 L in HHS

Laboratory Testing: Ketones
The nitroprusside test for ketones identifies acetone and acetoacetate but does NOT detect β-hydroxybutyrate (BHB), the ketone most frequently in excess. This has two clinical consequences:

- Be wary of a patient with a clinical picture of DKA but negative serum or urinary ketones. These could be false negatives because of the presence of BHB
- As DKA is treated, BHB is converted to acetone and acetoacetate. Serum or urinary ketones may therefore rise, falsely suggesting that the patient is worsening when in fact they are improving

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

NEJM 2015;373:2117-2128

Purpose: To examine whether Empagliflozin (an SGLT2 inhibitor) has any effect on cardiovascular risk in patients with Type 2 DM.

Study: Multi-centre RCT comparing Empagliflozin to placebo control; 7020 patients (test N=4687, placebo N=2333), median observation 3.1 yr.

Outcome: Death from cardiovascular causes, nonfatal MI, or nonfatal stroke.

Results:
- Both groups concurrently received the standard treatment for T2 DM. The Empagliflozin group had significantly lower rates of death from cardiovascular causes than control (3.7%, vs. 5.9%; 30% decreased relative risk). The test group also had lower all-cause mortality (5.7% vs. 8.3%, respectively; 32% decreased relative risk).

Conclusion: Adding Empagliflozin to standard treatment for Type 2 DM reduced death from macrovascular complications and all-cause mortality when compared to placebo.
DIABETIC NEUROPATHY

Epidemiology
- approximately 50% of patients within 10 yr of onset of type 1 DM and type 2 DM

Pathophysiology
- can have peripheral sensory neuropathy, motor neuropathy, or autonomic neuropathy
- mechanism poorly understood
- acute cranial nerve palsies and diabetic amyotrophy are thought to be due to ischemic infarction of peripheral nerve
- the more common motor and sensory neuropathies are thought to be related to metabolic or osmotic toxicity secondary to increased sorbitol and/or decreased myoinositol (possible mechanisms include accumulation of advanced glycation endproducts [AGE], oxidative stress, protein kinase C, nerve growth factor deficiency)

Screening
- 128 Hz tuning fork or 10 g monofilament at diagnosis and annually in people with type 2 DM and after 5 yr duration of type 1 DM

Clinical Features

Table 13. Clinical Presentation of Diabetic Neuropathies

<table>
<thead>
<tr>
<th>Peripheral Sensory Neuropathy</th>
<th>Motor Neuropathy</th>
<th>Autonomic Neuropathy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parasthesias (tingling, itching), neuropathic pain, radicular pain, numbness, decreased tactile sensation</td>
<td>Less common than sensory neuropathy</td>
<td>Postural hypotension, tachycardia, decreased cardiovascular response to Valsalva maneuver</td>
</tr>
<tr>
<td>Bilateral and symmetric with decreased perception of vibration and pain/temperature; especially true in the lower extremities but may also be present in the hands</td>
<td>Delayed motor nerve conduction and muscle weakness/atrophy</td>
<td>Gastroparesis and alternating diarrhea and constipation</td>
</tr>
<tr>
<td>Decreased ankle reflex</td>
<td>May involve one nerve trunk (mononeuropathy) or more (mononeuritis multiplex)</td>
<td>Urinary retention and erectile dysfunction</td>
</tr>
<tr>
<td>Symptoms may first occur in entrapment syndromes e.g. carpal tunnel</td>
<td>Some of the motor neuropathies spontaneously resolve after 6-8 wk</td>
<td></td>
</tr>
<tr>
<td>May result in neuropathic ulceration of foot</td>
<td>Reversible CN palsies: III (ptosis/ophthalmoplegia, pupil sparing), VI (inability to laterally deviate eye), and VII (Bell’s palsy)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diabetic amyotrophy: refers to pain, weakness, and wasting of hip flexors or extensors</td>
<td></td>
</tr>
</tbody>
</table>

Treatment and Management
- tight glycemic control
- for neuropathic pain syndromes: tricyclic antidepressants (e.g. amitriptyline), pregabalin, duloxetine, anti-epileptics (e.g. carbamazepine, gabapentin), and capsaicin
- foot care education
- Jobst™ fitted stocking and tilting of bed of bed may decrease symptoms of orthostatic hypotension
- treat gastroparesis with domperidone and/or metoclopramide (dopamine antagonists), erythromycin (stimulates motilin receptors)
- medical, mechanical, and surgical treatment for erectile dysfunction (see Urology, U30)

Other Complications

Dermatologic
- diabetic dermopathy: atrophic brown spots commonly in pretilial region known as “skin spots”, secondary to increased glycosylation of tissue proteins or vasculopathy
- eruptive xanthomas secondary to increased triglycerides
- necrobiosis lipoidica diabeticorum: rare complication characterized by thinning skin over the shins allowing visualization of subcutaneous vessels

Bone and Joint Disease
- juvenile cheiroarthropathy: chronic stiffness of hand caused by contracture of skin over joints secondary to glycosylated collagen and other connective tissue proteins
- Dupuytren’s contracture
- bone demineralization: bone density 10-20% below normal
- adhesive capsulitis (“frozen shoulder”)

Cataracts
- subcapsular and senile cataracts secondary to glycosylated lens protein or increased sorbitol causing osmotic change and fibrosis

Infections
- see Infectious Diseases, ID15
Hypoglycemia (BG <4.0 mmol/L or 72 mg/dL)

Etiology and Pathophysiology
- Hypoglycemia occurs most frequently in people with DM receiving insulin or certain antihyperglycemic therapies (insulin secretagogues)
- In people without DM, care must be taken to distinguish fasting from post-prandial hypoglycemia as each invokes separate differential diagnoses

<table>
<thead>
<tr>
<th>Etiology and Pathophysiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exogenous insulin</td>
</tr>
<tr>
<td>Sulfonylurea or meglitinide reaction</td>
</tr>
<tr>
<td>Autoimmune hypoglycemia (autoantibodies to insulin or insulin receptor)</td>
</tr>
<tr>
<td>Pentamidine</td>
</tr>
<tr>
<td>Pancreatic β cell tumour – insulinoma</td>
</tr>
</tbody>
</table>

Clinical Features
- Whipple’s triad
  1. Serum glucose <2.5 mmol/L in males and <2.2 mmol/L in females
  2. Neuroglycopenic symptoms
  3. Rapid relief provided by administration of glucose
- Adrenergic symptoms (typically occur first; caused by autonomic nervous system activity)
  - Palpitations, sweating, anxiety, tremor, tachycardia
- Neuroglycopenic symptoms (caused by decreased activity of CNS)
  - Dizziness, headache, clouding of vision, mental dullness, fatigue, confusion, seizures, coma

Investigations
- Electrolytes, creatinine, LFTs, drugs/toxins, cortisol
- If concerned about possible insulinoma:
  - Blood work to be drawn when patient is hypoglycemic (e.g. during hospitalized 72-h fast) for glucose, serum ketones, insulin, pro-insulin, C-peptide, insulin antibodies

Treatment
- For fasting hypoglycemia, must treat underlying cause
- For post-prandial (reactive) hypoglycemia, frequent small feeds
- See Emergency Medicine, ER35
- Treatment of hypoglycemic episode in the unconscious patient or patient NPO
  - D50W 50 mL (1 ampule) IV or 1 mg glucagon SC (if no IV available)
  - Blood work to be drawn when patient is hypoglycemic (e.g. during hospitalized 72-h fast) for glucose, serum ketones, insulin, pro-insulin, C-peptide, insulin antibodies

Table 14. Common Causes of Hypoglycemia

<table>
<thead>
<tr>
<th>Fasting</th>
<th>Without Hyperinsulinism</th>
<th>Post-Prandial (Nonfasting, Reactive)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exogenous insulin</td>
<td>Severe hepatic dysfunction</td>
<td>Alimentary</td>
</tr>
<tr>
<td>Sulfonylurea or meglitinide reaction</td>
<td>Chronic renal insufficiency</td>
<td>Functional</td>
</tr>
<tr>
<td>Autoimmune hypoglycemia</td>
<td>Hypoglycemia</td>
<td>Noninsulinoma pancreatogenous</td>
</tr>
<tr>
<td>(autoantibodies to insulin or insulin receptor)</td>
<td>Alcohol use</td>
<td>hypoglycemic syndrome</td>
</tr>
<tr>
<td>Pentamidine</td>
<td>Non-pancreatic tumours</td>
<td>Occult DM</td>
</tr>
<tr>
<td>Pancreatic β cell tumour – insulinoma</td>
<td>Inborn error of carbohydrate metabolism,</td>
<td>Leucine sensitivity</td>
</tr>
<tr>
<td></td>
<td>glycogen storage disease, gluconeogenic</td>
<td>Hereditary fructose intolerance</td>
</tr>
<tr>
<td></td>
<td>enzyme deficiency</td>
<td>Galactosemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Newborn infant of diabetic mother</td>
</tr>
</tbody>
</table>

Metabolic Syndrome
- Several definitions exist
- Postulated syndrome related to insulin resistance associated with hyperglycemia, hyperinsulinemia, HTN, central obesity, and dyslipidemia
- Obesity aggravates extent of insulin resistance
- Complications include DM, atherosclerosis, CAD, MI, and stroke
- Women with PCOS are at increased risk for developing insulin resistance, hyperlipidemia, and metabolic syndrome
- Not to be confused with syndrome X related to angina pectoris with normal coronary arteries (Prinzmetal angina)

Obesity
- See Family Medicine, FM7
**Pituitary Gland**

**Pituitary Hormones**

![Diagram of Pituitary Gland and Hormones]

**Hypothalamic Control of Pituitary**
- Trophic and inhibitory factors control the release of pituitary hormones.
- Most hormones are primarily under trophic stimulation except prolactin which is primarily under inhibitory control by dopamine, as well as GH and TSH which are inhibited by somatostatin.
- Transection of the pituitary stalk (i.e. dissociation of hypothalamus and pituitary) leads to pituitary hypersecretion of prolactin and hyposecretion of all remaining hormones.

**Anterior Pituitary Hormones**
- Growth hormone (GH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), adrenocorticotropic hormone (ACTH), and prolactin (PRL).

**Posterior Pituitary (Hypothalamic) Hormones**
- Antidiuretic hormone (ADH) and oxytocin.
- Peptides synthesized in the supraoptic and paraventricular nuclei of the hypothalamus.
- Although ADH and oxytocin are produced in the hypothalamus, these hormones are stored and released from the posterior pituitary.

**Table 15. The Physiology and Action of Pituitary Hormones**

<table>
<thead>
<tr>
<th>Hormone</th>
<th>Function</th>
<th>Physiology</th>
<th>Inhibitory Stimulus</th>
<th>Secretory Stimulus</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTH</td>
<td>Stimulates growth of adrenal cortex and secretion of its hormones</td>
<td>Polypeptide</td>
<td>Dexamethasone</td>
<td>CRH, Metyrapone, Insulin-induced hypoglycemia, Vasopressin, Fever, pain, stress</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pulsatile and diurnal variation (highest in AM, lowest at midnight)</td>
<td>Cortisol</td>
<td></td>
</tr>
<tr>
<td>GH</td>
<td>Needed for linear growth IGF-1 stimulates growth of bone and cartilage</td>
<td>Polypeptide</td>
<td>Glucose challenge, Glucocorticoids, Hypothyroidism, Somatostatin, Dopamine D2 receptor agonists, IGF-1 (long-loop)</td>
<td>GHRRH, Insulin-induced hypoglycemia, Exercise, REM sleep, Arginine, chloridene, propranolol, L-dopa</td>
</tr>
<tr>
<td></td>
<td>Acts indirectly through serum factors synthesized in the liver: IGF-1 (somatomedin-C) Serum GH detectable for most of the day and suppressed after meals high in glucose Sustained rise during sleep</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Features of Metabolic Syndrome**

- Level of 3 measures to make a Dx:
  - Abdominal Obesity (Elevated Waist Circumference): Men ≥ 102 cm (40 inches); Women ≥ 88 cm (35 inches)
  - HDL C Level: Men < 1.0 mmol/L (<40 mg/dL); Women < 1.3 mmol/L (<50 mg/dL)
  - Blood Pressure: ≥ 130/85 mmHg
  - Fasting Glucose Level: Men ≥ 5.6 mmol/L (>100 mg/dL)

Drugs treatment for any elevated marker is an alternate indicator.
Table 15. The Physiology and Action of Pituitary Hormones (continued)

<table>
<thead>
<tr>
<th>Hormone</th>
<th>Function</th>
<th>Physiology</th>
<th>Inhibitory Stimulus</th>
<th>Secretory Stimulus</th>
</tr>
</thead>
<tbody>
<tr>
<td>LH/FSH</td>
<td>Stimulate gonads via cAMP</td>
<td>Polypeptide Glycoproteins (similar α subunit as TSH and hCG) Secreted in pulsatile fashion</td>
<td>Estrogen Progesterone Testosterone Inhibin Continuous (i.e. non-pulsatile) GnRH infusion</td>
<td>Pulsatile GnRH</td>
</tr>
<tr>
<td>Prolactin</td>
<td>Promotes milk production Inhibits GnRH secretion</td>
<td>Polypeptide Episodic secretion</td>
<td>Dopamine</td>
<td>Sleep Stress, hypoglycemia Pregnancy, breastfeeding Mid-menstrual cycle Sexual activity TRH Drugs: psychotropics, antihypertensives, dopamine antagonists, opiates, high dose estrogen</td>
</tr>
<tr>
<td>TSH</td>
<td>Stimulates growth of thyroid and secretion of T₃ and T₄ via cAMP</td>
<td>Glycoprotein</td>
<td>Circulating thyroid hormones (T₃, T₄) Opiates, dopamine</td>
<td>TRH Epinephrine Prostaglandins</td>
</tr>
<tr>
<td>ADH</td>
<td>Acts at renal collecting ducts on V2 receptors to cause insertion of aquaporin channels and increases water reabsorption thereby concentrating urine</td>
<td>Octapeptide Secreted by posterior pituitary Osmoreceptors in hypothalamus detect serum osmolality Contracted plasma volume detected by baroreceptors is a more potent stimulus than ↑ osmolality</td>
<td>↓ serum osmolality</td>
<td>Hypovolemia or ↓ effective circulatory volume ↑ serum osmolality Stress, pain, fever, paraneoplastic Lung or brain pathology</td>
</tr>
<tr>
<td>Oxytocin</td>
<td>Causes uterine contraction Breast milk secretion</td>
<td>Nonapeptide Secreted by posterior pituitary</td>
<td>EtOH</td>
<td>Suckling Distention of female genital tract during labour via stretch receptors</td>
</tr>
</tbody>
</table>

**Growth Hormone**

**GH DEFICIENCY**
- cause of short stature in children (see *Pediatrics*, P26)
- controversial significance in adults; often not clinically apparent, may present as fatigue

**GH EXCESS**

**Etiology**
- GH secreting pituitary adenoma, carcinoid or pancreatic islet tumours secreting ectopic GHRH resulting in excess GH

**Pathophysiology**
- normally GH is a catabolic hormone that acts to increase blood glucose levels
- in growth hormone excess states, secretion remains pulsatile but there is loss of hypoglycemic stimulation, glucose suppression, and the nocturnal surge
- proliferation of bone, cartilage, soft tissues, organomegaly
- insulin resistance and IGT

**Clinical Features**
- in children (before epiphyseal fusion) leads to gigantism
- in adults (after epiphyseal fusion) leads to acromegaly
- enlargement of hands and feet, coarsening of facial features, thickening of calvarium, prognathism, thickening of skin, increased sebum production, sweating, acne, sebaceous cysts, fibromata mollusca, acanthosis nigricans, arthralgia, carpal tunnel syndrome, degenerative osteoarthritis, barrel chest, thyromegaly, renal calculi, HTN, cardiomyopathy, obstructive sleep apnea, colonic polyps, erectile dysfunction, menstrual irregularities, and DM

**Risks Associated with GH Excess**
- Cardiac disease (e.g. CAD, cardiomegaly, cardiomyopathy) in 1/3 of patients, with a doubling of risk of death from cardiac disease
- HTN in 1/3 of patients
- Risk of cancer (particularly GI) increased 2-fold to 3-fold
Investigations
- elevated serum insulin-like growth factor-1 (IGF-1) is usually the first line diagnostic test
- glucose suppression test is the most specific test (75 g of glucose PO suppresses GH levels in healthy individuals but not in patients with acromegaly)
- CT, MRI, or skull x-rays may show cortical thickening, enlargement of the frontal sinuses, and enlargement and erosion of the sella turcica
- MRI of the sella turcica is needed to look for a tumour

Treatment
- surgery, octreotide (somatostatin analogue), dopamine agonist (bromocriptine/cabergoline), growth hormone receptor antagonist (pegvisomant), radiation

Prolactin

HYPERPROLACTINEMIA

Etiology
- pregnancy and breastfeeding
- prolactinoma: most common pituitary adenoma (prolactin-secreting tumours may be induced by estrogens and grow during pregnancy)
- pituitary masses with pituitary stalk compression causing reduced dopamine inhibition of prolactin release
- primary hypothyroidism (increased TRH)
- decreased clearance due to chronic renal failure or severe liver disease (prolactin is metabolized by both the kidney and liver)
- medications with anti-dopaminergic properties are a common cause of high prolactin levels: antipsychotics (common), antidepressants, anti-hypertensives, anti-migraine agents (triptans/ergotamines), bowel motility agents (metoclopramide/domperidone), H₂-blockers (ranitidine)
- macroprolactinemia (high molecular weight prolactin also known as big big prolactin)

Clinical Features
- galactorrhea (secretion of breast milk in women and, in rare cases, men), infertility, hypogonadism, amenorrhea, erectile dysfunction

Investigations
- serum PRL, TSH, liver enzyme tests, creatinine, macroprolactin level in select cases
- MRI of the sella turcica in select cases

Treatment
- long-acting dopamine agonist: bromocriptine, cabergoline, or quinagolide
- surgery ± radiation (rare)
- prolactin-secreting tumours are often slow-growing and sometimes require no treatment
- if medication-induced, consider stopping medication if possible
- in certain cases if microprolactinoma and not planning on becoming pregnant, may consider OCP

Thyroid Stimulating Hormone
- see Thyroid, E20

Adrenocorticotropic Hormone
- see Adrenal Cortex, E29

Luteinizing Hormone and Follicle Stimulating Hormone

HYPOGONADOTROPIC HYPOGONADISM

Etiology
- primary/congenital: Kallmann syndrome, CHARGE syndrome, GnRH insensitivity
- secondary: CNS or pituitary tumours, pituitary apoplexy, brain/pituitary radiation, drugs (GnRH agonists/antagonists, glucocorticoids, narcotics, chemotherapy, drugs causing hyperprolactinemia), functional deficiency due to another cause (hyperprolactinemia, chronic systemic illnesses, eating disorders, hypothyroidism, DM, Cushing's disease), systemic diseases (hemochromatosis, sarcoidosis, histiocytosis)

Approach to Nipple Discharge
- Differentiate between galactorrhea (fat droplets present) versus breast discharge (usually unilateral, may be bloody or serous)
- If galactorrhea, determine if physiologic (e.g. pregnancy, lactation, stress) versus pathologic
- If abnormal breast discharge, must rule out a breast malignancy
Clinical Features
• hypogonadism, amenorrhea, erectile dysfunction (see Urology, U30), loss of body hair, fine skin, testicular atrophy, failure of pubertal development

Treatment
• combined FSH/LH hormone therapy, hCG, rFSH, or pulsatile GnRH analogue if fertility desired
• symptomatic treatment with estrogen/testosterone

HYPERGONADOTROPIC HYPOGONADISM
• hypogonadism due to impaired response of the gonads to FSH and LH

Etiology
• congenital:
  ■ chromosomal abnormalities (Turner’s syndrome, Klinefelter syndrome, XX gonadal dysgenesis)
  ■ enzyme defects (17α-hydroxylase deficiency, 17, 20-lyase deficiency)
  ■ gonadotropin resistance (Leydig cell hypoplasia, FSH Insensitivity, pseudohypoparathyroidism type 1A)
• acquired:
  ■ gonadal toxins (chemotherapy, radiation)
  ■ drugs (glucocorticoids, antiandrogens, opioids, alcohol)
  ■ infections (STIs, Mumps)
  ■ gonadal failure in adults (androgen decline and testicular failure in men, premature ovarian failure and menopause in women)

Clinical Features
• hypogonadism, amenorrhea, erectile dysfunction (see Urology, U30), loss of body hair, fine skin, testicular atrophy, failure of pubertal development, low libido, infertility

Treatment
• hormone replacement therapy consisting of androgen (for males) and estrogen (for females) administration

**Antidiuretic Hormone**

**DIABETES INSIPIDUS**

**Definition**
• disorder of ineffective ADH (decreased production or peripheral resistance) resulting in passage of large volumes of dilute urine

**Etiology and Pathophysiology**
• central DI: insufficient ADH due to pituitary surgery, tumours, idiopathic/autoimmune, stalk lesion, hydrocephalus, histiocytes X, trauma, familial central DI
• nephrogenic DI: collecting tubules in kidneys resistant to ADH due to drugs (e.g. lithium), hypercalcemia, hypokalemia, chronic renal disease, hereditary nephrogenic DI
• psychogenic polydipsia and osmotic diuresis must be ruled out

**Clinical Features**
• passage of large volumes of dilute urine, polydipsia, and dehydration; hypernatremia can develop with inadequate water consumption or secondary to an impaired thirst mechanism

**Diagnostic Criteria**
• fluid deprivation will differentiate true DI (high urine output persists, urine osmolality < plasma osmolality) from psychogenic DI (psychogenic polydipsia)
• response to exogenous ADH (DDAVP) will distinguish central from nephrogenic DI

**Treatment**
• DDAVP/vasopressin for central DI
• chlorpropamide, clofibrate, thiazides, NSAIDs, or carbamazepine as second line or for partial DI
• nephrogenic DI treated with solute restriction NSAIDs and thiazide diuretics; DDAVP (if partial)

**SYNDROME OF INAPPROPRIATE ADH SECRETION**

**Diagnostic Criteria**
• hyponatremia with corresponding plasma hypo-osmolality, urine sodium concentration above 40 mEq/L, urine less than maximally diluted (>100 mOsml/kg), euvoemia (edema absent), and absence of adrenal, renal, or thyroid insufficiency
Etiology and Pathophysiology
- stress (pain, nausea, post-surgical)
- malignancy (lung, pancreas, lymphoma)
- CNS disease (inflammatory, hemorrhage, tumour, Guillain-Barré syndrome)
- respiratory disease (TB, pneumonia, empyema)
- drugs (SSRIs, vincristine, chlorpropamide, cyclophosphamide, carbamazepine, nicotine, morphine, DDAVP, oxytocin)

Clinical Features
- symptoms of hyponatremia: headaches, nausea, vomiting, muscle cramps, tremors, cerebral edema If severe (confusion, mood swings, hallucinations, seizures, coma)

Treatment
- treat underlying cause, fluid restriction (800-1000 mL/day), vasopressin receptor antagonists (e.g. tolvaptan, conivaptan), and demeclocycline (antibiotic with anti-ADH properties, rarely-used) fluoroisotone, furosemide

Pituitary Pathology

PITUITARY ADENOMA (see Neurosurgery, NS13)

Clinical Features
- local mass effects
  - visual field defects (bitemporal hemianopsia due to compression of the optic chiasm), diplopia (due to oculomotor nerve palsies), headaches; increased ICP is rare
  - hypofunction
    - hypopituitarism
    - hyperfunction
      - PRL (galactorrhea), GH (acromegaly in adults, gigantism in children), ACTH (Cushing’s disease = Cushing’s syndrome caused by a pituitary tumour)
      - tumours secreting LH, FSH, and TSH are rare

Investigations
- radiological evaluation (MRI is imaging procedure of choice)
- formal visual field testing
- hypothalamic-pituitary hormonal function

HYPOPITUITARISM

Etiology (The Eight Is)
- Invasive
  - pituitary tumours, craniopharyngioma, cysts (Rathke’s cleft, arachnoid, or dermoid), metastases
- Infarction/hemorrhage
  - Sheehan’s syndrome (pituitary infarction due to excessive post-partum blood loss and hypovolemic shock)
  - pituitary apoplexy (acute hemorrhage/infarction of a pituitary tumour; presents with sudden loss of pituitary hormones, severe headache, and altered level of consciousness; can be fatal if not recognized and treated early)
- Infiltrative/inflammatory
  - sarcoidosis, hemochromatosis, histiocytosis
- Infectious
  - syphilis, TB, fungal (histoplasmosis), parasitic (toxoplasmosis)
- Injury
  - severe head trauma
- Immunologic
  - autoimmune destruction
- Iatrogenic
  - following surgery or radiation
- Idiopathic
  - familial forms, congenital midline defects

Clinical Features
- symptoms depend on which hormone is deficient:
  - ACTH: fatigue, weight loss, hypoglycemia, anemia, hyponatremia, failure to thrive and delayed puberty in children
  - GH: short stature in children
  - TSH: tiredness, cold intolerance, constipation, weight gain, hair loss
  - LH and FSH: oligo- or amenorrhea, infertility, decreased facial/body hair and muscle mass in men, delayed puberty
  - Prolactin: inability to breastfeed
  - ADH: symptoms of diabetes insipidus (extreme thirst, polydipsia, hypernatremia)
  - Oxytocin: usually asymptomatic - only needed during labour and breastfeeding

SIADH vs. Cerebral Salt Wasting (CSW)
CSW can occur in cases of subarachnoid hemorrhage. Na⁺ is excreted by malfunctioning renal tubules, mimicking findings of SIADH; hallmark is hypovolemia

Presentations of Pituitary Lesions
- Mass effect (visual field deficits, diplopia, ptosis, headaches, CSF leak)
- Hyperfunction
- Hypofunction

Important Deficiencies to Recognize are:
- Adrenal insufficiency
- Hypothyroidism
- Concurrent adrenal insufficiency and hypothyroidism should be treated with glucocorticoids first and then with thyroid hormone to avoid adrenal crisis

The Pituitary Hormones
Order they are usually lost with compression by a mass:
“Go Look For The Adenoma Phrase”
GH, LH, FSH, TSH, ACTH, PRL + posterior pituitary hormones: ADH and oxytocin
**Investigations**
- triple bolus test
  - stimulates release of all anterior pituitary hormones in normal individuals
  - rapid sequence of IV infusion of insulin, GnRH, and TRH
  - insulin (usual dose 0.1 unit/kg of human regular insulin) → hypoglycemia → increased GH and ACTH/cortisol
  - GnRH (100 µg IV push) → increased LH and FSH
  - TRH (200 µg IV push over 120 s) → increased TSH and PRL (no longer available in Canada)
  - GnRH and TRH stimulation tests are very limited in their utility; the insulin tolerance test is the only truly useful test in the triple bolus assessment

---

**Thyroid Hormones**

**Synthetic Function of Thyroid Gland**
- the synthesis of thyroid hormones $T_3$ (thyroxine) and $T_4$ (triiodothyronine) by the thyroid gland involves trapping and oxidation of iodide, iodination of thyroglobulin, digestion of thyroglobulin, and release of $T_3$ and $T_4$
- free $T_3$ (0.03%) and free $T_4$ (0.3%) represent the hormonally active fraction of thyroid hormones
  - the remaining fraction is bound to thyroxine binding globulin (TBG) and albumin and is biologically inactive
- $T_3$ is more biologically active (3-8x more potent), but $T_4$ has a longer half-life
- 85% of $T_4$ is converted to $T_3$ or reverse $T_3$ (RT3) in the periphery by deiodinases
- RT3 is metabolically inactive but produced in times of stress to decrease metabolic activity
- most of the plasma $T_3$ pool is derived from the peripheral conversion of $T_4$
- calcitonin, a peptide hormone, is also produced in the thyroid, by the parafollicular cells or C cells
  - it functions by inhibiting osteoclast activity and increasing renal calcium excretion

**Role of Thyroid Hormones**
- thyroid hormones act primarily through modifying gene transcription by binding to nuclear receptors
- action of these hormones is diffuse, effecting nearly every organ system
- they increase the basal metabolic rate including: increased Na⁺/K⁺-ATPase activity, increased $O_2$ consumption, increased respiration, heat generation, and increased cardiovascular activity
- also play crucial role during fetal life in both neurological and somatic development

---

<table>
<thead>
<tr>
<th>Patterns of Hormone Levels</th>
<th>TSH</th>
<th>$T_3$, $T_4$</th>
</tr>
</thead>
<tbody>
<tr>
<td>1° Hyper</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>2° Hyper</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>1° Hypo</td>
<td>↑</td>
<td>↓</td>
</tr>
<tr>
<td>2° Hypo</td>
<td>↓</td>
<td>↓</td>
</tr>
</tbody>
</table>
Regulation of Thyroid Function
- extrathyroid
  - stimulation of thyroid by TSH, epinephrine, prostaglandins (cAMP stimulators)
  - T3 negatively feeds back on anterior pituitary to inhibit TSH and on hypothalamus to inhibit TRH
- intrathyroid (autoregulation)
  - synthesis (Wolf-Chaikoff effect, Jod-Basedow effect)
  - there is varying thyroid sensitivity to TSH in response to iodide availability
  - increased ratio of T3 to T4 in iodide deficiency
  - increased activity of peripheral 5’ deiodinase in hypothyroidism increases T3 production despite low T4 levels

Tests of Thyroid Function and Structure

TSH
- sensitive TSH (sTSH) is the best test for assessing thyroid function
- hyperthyroidism
  - primary: TSH is low because of negative feedback from increased levels of circulating T3 and T4
  - secondary: increased TSH results in increased T3 and T4
- hypothyroidism
  - primary: increased TSH (most sensitive test) because of less negative feedback from T3 and T4
  - secondary: TSH is low or normal with variable response to TRH depending on the site of the lesion (pituitary or hypothalamic)

Free T3 and Free T4
- standard assessment of thyroid function measures TSH and if necessary free T4. Free T3 should only be measured in the small subset of patients with hyperthyroidism and suspected T3 toxicity. TSH would be suppressed, free T4 normal, and free T3 elevated

Thyroid Autoantibodies
- thyroglobulin antibodies (TgAb), anti-thyroid peroxidase antibodies (TPOAb), and TSH receptor antibodies (TRAb) of the blocking variety are increased in Hashimoto’s disease; normal variant in 10-20% of individuals
- TRAb of the stimulating variety are also referred to as thyroid stimulating immunoglobulins (TSI) and cause Graves’ disease. However, both TRAb receptor blocking and stimulating antibodies are seen in patients with Graves’ disease

Plasma Thyroglobulin
- used to monitor for residual thyroid tissue post-thyroidectomy, e.g. tumour marker for thyroid cancer recurrence
- normal or elevated levels may suggest persistent, recurrent, or metastatic disease

Serum Calcitonin
- not routinely done to investigate thyroid nodules
- ordered if suspicion of medullary thyroid carcinoma or family history of MEN IIa or IIb syndromes
  - used to monitor for residual or recurrent medullary thyroid cancer

Thyroid Imaging/Scans
- normal gland size 15-20 g (estimated by palpation)
- thyroid U/S
  - to measure size of gland, solid vs. cystic nodule, facilitate fine needle aspirate biopsy (FNAB)
  - radioisotope thyroid scan (Technetium-99)
- test of structure: order if there is a thyroid nodule and patient is hyperthyroid with low TSH
  - differentiates between hot (functioning → excess thyroid hormone production) and cold (non-functioning) nodules
    - hot nodule → very low chance malignancy; treat hyperthyroidism
    - cold nodule → ~5% chance malignancy; further workup required (U/S and FNAB)
- radioactive iodine uptake (RAIU)
  - test of function: order if patient is thyrotoxic
  - RAIU measures the turnover of iodine by thyroid gland in vivo
  - if uptake (i.e. incorporated), gland is overactive (hyperthyroid)
  - if 1 uptake (i.e. not incorporated), gland is leaking thyroid hormone (e.g. thyroiditis), exogenous thyroid hormone use, or excess iodine intake (e.g. amiodarone or contrast dye, which has high iodine content)
  - see Figure 9, Approach to the Evaluation of a Thyroid Nodule, E28 for further information regarding the utility of these scans

Thyroid Biopsy
- fine needle aspiration (FNA) for cytology
  - differentiates between benign and malignant disease
  - best done under U/S guidance
  - accuracy decreased if nodule is greater than 50% cystic, or if nodule located posteriorly in the gland
Table 16. Summary of Diagnostic Testing in Hyperthyroidism and Hypothyroidism

<table>
<thead>
<tr>
<th></th>
<th>Hyperthyroidism</th>
<th>Hypothyroidism</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSH</td>
<td>Decreased in 1° hyperthyroidism</td>
<td>Increased in 1° hypothyroidism</td>
</tr>
<tr>
<td>Free T4</td>
<td>Increased in 1° hyperthyroidism</td>
<td>Decreased in 1° hypothyroidism</td>
</tr>
<tr>
<td>Antibodies</td>
<td>Graves': thyroid stimulating Ig (TSI)</td>
<td>Hashimoto’s: antithyroid peroxidase (TPOAb, TgAb)</td>
</tr>
<tr>
<td>RAIU</td>
<td>Increased uptake</td>
<td>Decreased uptake</td>
</tr>
<tr>
<td></td>
<td>Graves'</td>
<td>Subacute thyroiditis</td>
</tr>
<tr>
<td></td>
<td>Toxic multinodular goitre</td>
<td>Recent iodine load</td>
</tr>
<tr>
<td></td>
<td>Toxic adenoma</td>
<td>Exogenous thyroid hormone</td>
</tr>
<tr>
<td>Radiosotope</td>
<td>Graves': homogenous diffuse uptake</td>
<td></td>
</tr>
<tr>
<td>Thyroid Scan</td>
<td>Multinodular goitre: heterogeneous uptake</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Toxic adenoma: single intense area of uptake with</td>
<td></td>
</tr>
<tr>
<td></td>
<td>suppression elsewhere</td>
<td></td>
</tr>
</tbody>
</table>

**Thyrotoxicosis**

**Definition**
- clinical, physiological, and biochemical findings in response to elevated thyroid hormone

**Epidemiology**
- 1% of general population have hyperthyroidism
- F:M = 5:1

**Etiology and Pathophysiology**

Table 17. Differential Diagnosis of Thyrotoxicosis

<table>
<thead>
<tr>
<th>Disorder</th>
<th>TSH</th>
<th>Free T$_4$/T$_3$</th>
<th>Thyroid Antibodies</th>
<th>RAIU</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HYPERTHYROIDISM</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Graves' Disease</td>
<td>Decreased</td>
<td>Increased</td>
<td>TSI</td>
<td>Increased</td>
<td>Homogenous uptake on scan</td>
</tr>
<tr>
<td>Toxic Nodular Goitre</td>
<td>Decreased</td>
<td>Increased</td>
<td>None</td>
<td>Increased</td>
<td>Heterogeneous uptake on scan</td>
</tr>
<tr>
<td>Toxic Nodule</td>
<td>Decreased</td>
<td>Increased</td>
<td>None</td>
<td>Increased</td>
<td>Intense uptake in hot nodule on scan with</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>no uptake in the rest of the gland</td>
</tr>
<tr>
<td><strong>THYROIDITIS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subacute, Silent, Postpartum</td>
<td>Decreased</td>
<td>Increased</td>
<td>Up to 50% of cases</td>
<td>Decreased (increases</td>
<td>In classical subacute painful thyroiditis,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>once entering</td>
<td>ESR increased</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>hypothyroid phase,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>when TSH rises)</td>
<td></td>
</tr>
<tr>
<td><strong>EXTRATHYROIDAL SOURCES OF THYROID HORMONE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endogenous (struma</td>
<td>Decreased</td>
<td>Increased</td>
<td>None</td>
<td>Decreased</td>
<td></td>
</tr>
<tr>
<td>ovaria, ovarian teratoma, metastatic follicular carcinoma)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exogenous (drugs)</td>
<td>Decreased</td>
<td>Increased</td>
<td>None</td>
<td>Decreased</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EXCESSIVE THYROID STIMULATION</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pituitary thyrotrophoma</td>
<td>Increased</td>
<td>Increased</td>
<td>None</td>
<td>Increased</td>
<td></td>
</tr>
<tr>
<td>Pituitary thyroid hormone receptor resistance</td>
<td>Increased</td>
<td>Increased</td>
<td>None</td>
<td>Increased</td>
<td></td>
</tr>
<tr>
<td>Increased hCG (e.g. pregnancy)</td>
<td>Decreased</td>
<td>Increased</td>
<td>None</td>
<td>Increased</td>
<td>DO NOT DO THIS TEST IN PREGNANCY</td>
</tr>
</tbody>
</table>

**Caution with Amiodarone**

Amiodarone-Induced Hypothyroidism (AIIH):
- AIIH occurs more often in iodine-sufficient areas, and is more common in populations with a higher prevalence of autoimmune thyroid disease, such as women and the elderly. AIIH can also occur in patients without pre-existing thyroid dysfunction.

Amiodarone-Induced Thyrotoxicosis (AIT):
- AIT occurs more often in iodine-deficient areas. It may occur in patients with pre-existing thyroid deficiencies, as an iodine load on an already dysfunctional thyroid may result in excessive thyroid hormone synthesis and release. AIT may also occur in patients without thyroid abnormalities through a cytotoxic mechanism that results in leakage of thyroid hormone into the systemic circulation.

**Signs and Symptoms of HYPERthyroidism**

Tremor  
Heart rate up  
Yawning (fatigued)  
Restlessness  
Oligomenorrhea/amenorrhea  
Intolerance to heat  
Diarrhea  
Irritability  
Sweating  
Muscle wasting/weight loss

**Common Etiologies**

<table>
<thead>
<tr>
<th>Thyrotoxicosis</th>
<th>Hypothyroidism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graves’ Disease</td>
<td>Hashimoto’s</td>
</tr>
<tr>
<td>Toxic Nodular Goitre</td>
<td>Congenital</td>
</tr>
<tr>
<td>Toxic Nodule</td>
<td>Iatrogenic (thionamides, radioactive iodine, or surgery)</td>
</tr>
<tr>
<td>Thyroiditis</td>
<td>Hypothyroid phase of thyroiditis</td>
</tr>
</tbody>
</table>
Clinical Features

Table 18. Clinical Features of Thyrotoxicosis

<table>
<thead>
<tr>
<th>General</th>
<th>Fatigue, heat intolerance, irritability, fine tremor</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>Tachycardia, atrial fibrillation, palpitations</td>
</tr>
<tr>
<td></td>
<td>Elderly patients may have only cardiovascular symptoms, commonly new onset atrial fibrillation</td>
</tr>
<tr>
<td>GI</td>
<td>Weight loss with increased appetite, thirst, increased frequency of bowel movements (hyperdefecation)</td>
</tr>
<tr>
<td>Neurology</td>
<td>Proximal muscle weakness, hypokalemic periodic paralysis (more common in Asians)</td>
</tr>
<tr>
<td>GU</td>
<td>Oligomenorrhea, amenorrhea, decreased fertility</td>
</tr>
<tr>
<td>Dermatology</td>
<td>Fine hair, skin moist and warm, vitiligo, soft nails with onycholysis (Plummer’s nails), palmar erythema, pruritis</td>
</tr>
<tr>
<td></td>
<td>Graves’ disease: clubbing (acropachy), pretibial myxedema (rare)</td>
</tr>
<tr>
<td>MSK</td>
<td>Decreased bone mass, proximal muscle weakness</td>
</tr>
<tr>
<td>Hematology</td>
<td>Graves’ disease: leukopenia, lymphocytosis, splenomegaly, lymphadenopathy (occasionally)</td>
</tr>
<tr>
<td>Eye</td>
<td>Graves’ disease: lid lag, retraction, proptosis, diplopia, decreased acuity, puffiness, conjunctival injection</td>
</tr>
</tbody>
</table>

Treatment
- thionamides: propylthiouracil (PTU) or methimazole (MMI); MMI recommended (except in first trimester pregnancy)
- β-blockers for symptom control
- radioactive iodine thyroid ablation for Graves’ disease
- surgery in the form of hemi, sub-total, or complete thyroidectomy

Graves’ Disease

Definition
- an autoimmune disorder characterized by autoantibodies to the TSH receptor that leads to hyperthyroidism

Epidemiology
- most common cause of thyrotoxicosis
- occurs at any age with peak in 3rd and 4th decade
- F:M = 7:1, 1.5-2% of U.S. women
- familial predisposition: 15% of patients have a close family member with Graves’ disease and 50% have family members with positive circulating antibodies
- association with HLA B8 and DR3
- may be associated with other inherited autoimmune disorders (e.g. pernicious anemia, Hashimoto’s disease)

Etiology and Pathophysiology
- autoimmune disorder due to a defect in T-suppressor cells
- B lymphocytes produce TSI that binds and stimulates the TSH receptor and stimulates the thyroid gland
- immune response can be triggered by postpartum state, iodine excess, lithium therapy, viral or bacterial infections, glucocorticoid withdrawal
- ophthalmopathy (thyroid associated orbitopathy) is a result of increased tissue volume due to inflammation and accumulation of glycosaminoglycans, stimulated by TSI, that increase osmotic pressure within the orbit; this leads to fluid accumulation and displacement of the eyeball forward
- dermopathy may be related to cutaneous glycosaminoglycan deposition

Clinical Features
- signs and symptoms of thyrotoxicosis
- diffuse thyroid goitre ± thyroid bruit secondary to increased blood flow through the gland
- ophthalmopathy: proptosis, diplopia, conjunctival injection, corneal abrasions, periocular puffiness, lid lag, decreased visual acuity (plus signs of hyperthyroidism: lid retraction, characteristic stare)
- dermopathy (rare): pretibial myxedema (thickening of dermis that manifests as non-pitting edema)
- acropachy: clubbing and thickening of distal phalanges

Investigations
- low TSH
- increased free T4 (and/or increased T3)
- positive for TSI (specific but not sensitive for Graves’ disease)
- increased radioactive iodine (I-131) uptake
- homogeneous uptake on thyroid scan (only do this test in the presence of nodule)
Treatment
- thionamides: propylthiouracil (PTU) or methimazole (MMI)
  - PTU and MMI inhibit thyroid hormone synthesis by inhibiting peroxidase-catalyzed reactions, thereby inhibiting organization of iodide, blocking the coupling of iodotyrosines
  - PTU also inhibits peripheral deiodination of T4 to T3
  - continue treatment until remission occurs (20-40% of patients achieve spontaneous remission at 6-18 mo of treatment)
- small goitre and recent onset are good indicators for long-term remission with medical therapy
- major side effects: hepatitis, agranulocytosis, and fever/arthritis
- minor side effects: rash
- iotinated contrast agents: sodium ipodate and iopanoic acid can inhibit conversion of T4 to T3 and are especially effective in combination with MMI
- MMI preferred vs. PTU due to longer duration of action (once daily for most), more rapid efficacy, and lower incidence of side effects
- in pregnancy: use PTU during first trimester and MMI during second and third trimester. MMI is contraindicated in the first trimester due to risk of aplasia cutis; MMI is preferred in the second and third trimester due to the potential risk of hepatotoxicity with PTU in the second and third trimesters
- symptomatic treatment with β-blockers
- thyroid ablation with radioactive 131I if PTU or MMI trial does not produce disease remission
- high incidence of hypothyroidism after 131I requiring lifelong thyroid hormone replacement
- contraindicated in pregnancy
- may worsen ophthalmopathy
- subtotal or total thyroidectomy (indicated for large goitres, suspicious nodule for Ca, if patient is intolerant to thionamides and refusing RAI ablation)
- risks include hypoparathyroidism and vocal cord palsy
- ophthalmopathy/orbitopathy
- smoking cessation is important
- prevent drying of eyes
- high dose prednisone in severe cases
- orbital radiation, surgical decompression

Prognosis
- course involves remission and exacerbation unless gland is destroyed by radioactive iodine or surgery
- lifetime follow-up needed
- risk of relapse is 37%, 21%, 6% in thionamides, radioiodine ablation, and surgery groups, respectively

Subacute Thyroiditis (Thyrotoxic Phase)

Definition
- acute inflammatory disorder of the thyroid gland characterized by an initial thyrotoxic state followed by hypothyroidism eventually followed by euthyroidism in most cases
- two subtypes: painful (“De Quervain’s”) and painless (“Silent”)

Etiology and Pathophysiology
- acute inflammation of the thyroid gland characterized by giant cells and lymphocytes
- disruption of thyroid follicles by inflammatory process results in the release of stored hormone rather than excessive production of new thyroid hormone
- painful = viral (usually preceded by URTI), De Quervain’s (granulomatous thyroiditis)
- painless = postpartum, auto-immune, lymphocytic
  - occurs in 5-10% of postpartum mothers and is symptomatic in 1/3 of patients

Clinical Features
- painful (thyroid, ears, jaw, and occiput) or painless
- fever and malaise may be present, especially in De Quervain’s
- postpartum: thyrotoxicosis 2-3 mo postpartum with a subsequent hypothyroid phase at 4-8 mo postpartum
- may be mistakenly diagnosed as postpartum depression

Laboratory Investigations
- initial elevated free T4, T3, low TSH, RAIU markedly reduced
- marked elevation of ESR in painful variety only
- as disease progresses values consistent with hypothyroidism may appear

Treatment
- painful – high dose NSAIDs, prednisone may be required for severe pain, fever, or malaise
- iotinated contrast agents (e.g. iopanoic acid, ipodate) to inhibit peripheral conversion of T4 to T3
- β-adrenergic blockade is usually effective in reversing most of the hypermetabolic and cardiac symptoms in both subtypes
- if symptomatically hypothyroid, may treat short-term with thyroxine

Prognosis
- full recovery in most cases, but permanent hypothyroidism in 10% of painless thyroiditis
- postpartum: most resolve spontaneously without need for supplementation, however may recur with subsequent pregnancies
**Toxic Adenoma/Toxic Multinodular Goitre**

**Etiology and Pathophysiology**
- autonomous thyroid hormone production from a functioning adenoma that is hypersecreting T₃ and T₄
- may be singular (toxic adenoma) or multiple (toxic multinodular goitre [Plummer's disease])

**Clinical Features**
- goitre with adenomatous changes
- tachycardia, heart failure, arrhythmia, weight loss, nervousness, weakness, tremor, and sweats
- seen most frequently in elderly people, often with presentation of atrial fibrillation

**Investigations**
- low TSH, high T₃ and T₄
- thyroid scan with increased RAIU in nodule(s) and suppression of the remainder of the gland

**Treatment**
- initiate therapy with PTU or MMI to attain euthyroid state
- use high dose radioactive iodine (I-131) to ablate hyperfunctioning nodules
- β-blockers often necessary for symptomatic treatment prior to definitive therapy
- surgical excision may also be used as 1st line treatment

**Thyrotoxic Crisis/Thyroid Storm**

**Definition**
- acute exacerbation of all of the symptoms of thyrotoxicosis presenting in a life-threatening state secondary to uncontrolled hyperthyroidism – medical emergency!
- rare, but serious with mortality rate between 10-30%

**Etiology and Pathophysiology**
- often precipitated by infection, trauma, or surgery in a hyperthyroid patient

**Differential Diagnosis**
- sepsis, pheochromocytoma, malignant hyperthermia, drug overdose, neuroleptic malignant syndrome

**Clinical Features**
- hyperthyroidism
- extreme hyperthermia (≥40°C), tachycardia, vomiting, diarrhea, vascular collapse, hepatic failure with jaundice, and confusion
- tachyarrhythmia, CHF, shock
- mental status changes ranging from delirium to coma

**Laboratory Investigations**
- increased free T₃ and T₄, undetectable TSH
- ± anemia, leukocytosis, hyperglycemia, hypercalcemia, elevated LFTs

**General Measures**
- fluids, electrolytes, and vasopressor agents should be used as indicated
- a cooling blanket and acetaminophen can be used to treat the pyrexia
- propranolol or other β-blockers that additionally decrease peripheral conversion of T₃ → T₄ can be used, but should be used with caution in CHF patients as it may worsen condition

**Specific Measures**
- PTU is the anti-thyroid drug of choice and is used in high doses
- Give iodide, which acutely inhibits the release of thyroid hormone, one hour after the first dose of PTU is given
  - Sodium iodide 1 g IV drip over 12h q12h
  - Lugol's solution 2-3 drops q8h
  - Potassium iodide (SSKI) 5 drops q8h
- dexamethasone 2-4 mg IV q6h for the first 24-48 hours lowers body temperature and inhibits peripheral conversion of T₃ → T₄

**Prognosis**
- probably <20% mortality rate if rapidly recognized and treated
Hypothyroidism

Definition
- clinical syndrome caused by cellular responses to insufficient thyroid hormone production

Epidemiology
- 2-3% of general population
- F:M = 10:1
- 10-20% of women over age 50 have subclinical hypothyroidism (normal T4, TSH mildly elevated)
- iodine deficiency most common cause worldwide, but not in North America

Etiology and Pathophysiology
- primary hypothyroidism (90%)
  - inadequate thyroid hormone production secondary to intrinsic thyroid defect
  - iatrogenic: post-ablative (¹³¹I or surgical thyroidectomy)
  - autoimmune: Hashimoto’s thyroiditis, chronic thyroiditis, idiopathic, burnt out Graves’
  - hypothyroid phase of subacute thyroiditis
  - drugs: goitrogens (iodine), PTU, MMI, lithium
  - infiltrative disease (progressive systemic sclerosis, amyloid)
  - iodine deficiency
  - congenital (1/4,000 births)
- secondary hypothyroidism: pituitary hypothyroidism
  - insufficiency of pituitary TSH
- tertiary hypothyroidism: hypothalamic hypothyroidism
  - decreased TRH from hypothalamus (rare)
- peripheral tissue resistance to thyroid hormone (Refetoff syndrome)

Table 19. Interpretation of Serum TSH and Free T4 in Hypothyroidism

<table>
<thead>
<tr>
<th></th>
<th>Serum TSH</th>
<th>Free T4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overt Primary Hypothyroidism</td>
<td>Increased</td>
<td>Decreased</td>
</tr>
<tr>
<td>Subclinical Primary Hypothyroidism</td>
<td>Increased</td>
<td>Normal</td>
</tr>
<tr>
<td>Secondary Hypothyroidism</td>
<td>Decreased or not appropriately elevated</td>
<td>Decreased</td>
</tr>
</tbody>
</table>

Clinical Features

Table 20. Clinical Features of Hypothyroidism

<table>
<thead>
<tr>
<th></th>
<th>General</th>
<th>CVS</th>
<th>Respiratory</th>
<th>GI</th>
<th>Neurology</th>
<th>GU</th>
<th>Dermatology</th>
<th>Hematology</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fatigue, cold intolerance, slowing of mental and physical performance, hoarseness, macroGLOSSIA</td>
<td>Pericardial effusion, bradycardia, hypotension, worsening CHF + angina, hypercholesterolemia, hyperhomocysteinemia, myxedema heart</td>
<td>Decreased exercise capacity, hypoventilation secondary to weak muscles, decreased pulmonary responses to hypoxia, sleep apnea due to macroGLOSSIA</td>
<td>Weight gain despite poor appetite, constipation</td>
<td>Paresthesia, slow speech, muscle cramps, delay in relaxation phase of deep tendon reflexes (“hung reflexes”), carpal tunnel syndrome, asymptomatic increase in CK, seizures</td>
<td>Menorrhagia, amenorrhea, impotence</td>
<td>Puffiness of face, peri-orbital edema, cool and pale, dry and rough skin, hair dry and coarse, eyebrows thinned (lateral 1/3), discoloration (carotenemia)</td>
<td>Anemia: 10% pernicious due to presence of anti-parietal cell antibodies with Hashimoto’s thyroiditis</td>
</tr>
</tbody>
</table>

Treatment
- L-thyroxine (dose range: 0.05-0.2 mg PO OD ~1.6 µg/kg/d)
- elderly patients and those with CAD: start at 0.025 mg daily and increase gradually every 6 wk (start low, go slow)
- after initiating L-thyroxine, TSH needs to be evaluated in 6 wk; dose is adjusted until TSH returns to normal reference range
- once maintenance dose achieved, follow-up TSH with patient annually
- secondary/tertiary hypothyroidism
  - monitor via measurement of free T4 (TSH is unreliable in this setting)

CONGENITAL HYPOTHYROIDISM
- see Pediatrics, P28
Hashimoto’s Thyroiditis

• most common form of primary hypothyroidism in North America
• chronic autoimmune thyroiditis characterized by both cellular and humoral factors in the destruction of thyroid tissue
• two major forms: goitrous and atrophic; both forms share same pathophysiology but differ in the extent of lymphocytic infiltration, fibrosis, and thyroid follicular cell hyperplasia
• goitrous variant usually presents with a rubbery goitre and euthyroidism, then hypothyroidism becomes evident
  • associated with fibrosis
• atrophic variant patients are hypothyroid from the start
  • associated with thyroid lymphoma

Etiology and Pathophysiology
• defect in clone of T-suppressors leads to cell-mediated destruction of thyroid follicles
• B lymphocytes produce antibodies against thyroid components including thyroglobulin, thyroid peroxidase, TSH receptor, Na+/I– symporter

Risk Factors
• female gender (F:M = 7:1)
• genetic susceptibility: increased frequency in patients with Down’s syndrome, Turner’s syndrome, certain HLA alleles, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
• family Hx or personal Hx of other autoimmune diseases
• cigarette smoking
• high iodine intake
• stress and infection

Investigations
• high TSH, low T₄ (not necessary to measure T₃ as it will be low as well)
• presence of anti-thyroid peroxidase (TPOAb) and thyroglobulin antibodies (TgAb) in serum

Treatment
• if hypothyroid, replace with L-thyroxine (analog of T₄)

Myxedema Coma

Definition
• severe hypothyroidism complicated by trauma, sepsis, cold exposure, MI, inadvertent administration of hypnotics or narcotics, and other stressful events – medical emergency!
• rare, high level of mortality when it occurs (up to 40%, despite therapy)

Clinical Features
• hallmark symptoms of decreased mental status and hypothermia; hyponatremia, hypotension, hypoglycemia, bradycardia, hypoventilation, and generalized edema often present

Investigations
• decreased T₄, increased TSH, decreased glucose
• check ACTH and cortisol for evidence of adrenal insufficiency

Treatment
• aggressive treatment required
• ABCs: ICU admission
• corticosteroids (for risk of concomitant adrenal insufficiency): hydrocortisone 100 mg q8h
• L-thyroxine 0.2-0.5 mg IV loading dose, then 0.1 mg IV OD until oral therapy tolerated; also consider T₃ therapy
• supportive measures: mechanical ventilation, vasopressor drugs, passive rewarming, IV dextrose, fluids if necessary (risk of overload)
• monitor for arrhythmia

Sick Euthyroid Syndrome

Definition
• changes in circulating thyroid hormones amongst patients with serious illness, trauma, or stress
• not due to intrinsic thyroid or pituitary disease
• initially low free T₃ may be followed by low TSH and if severe illness low free T₄
• with recovery of illness, TSH may overshoot and become transiently high
Pathophysiology
- abnormalities include alterations in
  - peripheral transport and metabolism of thyroid hormone
  - regulation of TSH secretion
  - thyroid function itself
- may be protective during illness by reducing tissue catabolism

Labs
- initially decreased free T₃ followed by decreased TSH and finally decreased free T₄

Treatment
- treat the underlying disease; thyroid hormone replacement worsens outcomes
- thyroid function tests normalize once patient is well (initially with a transient increase in TSH)

Non-Toxic Goitre

Definition
- generalized enlargement of the thyroid gland in a euthyroid individual that does not result from inflammatory or neoplastic processes

Pathophysiology
- the appearance of a goitre is more likely during adolescence, pregnancy, and lactation because of increased thyroid hormone requirements
  - early stages: goitre is usually diffuse
  - later stages: multinodular non-toxic goitre with nodule, cyst formation and areas of ischemia, hemorrhage, and fibrosis

Etiology
- iodine deficiency or excess
- goitrogens: brassica vegetables (e.g. turnip, cassava)
- drugs: iodine, lithium, para-aminosalicylic acid
- any disorder of hormone synthesis with compensatory growth
- peripheral resistance to thyroid hormone

Treatment
- remove goitrogens
- radiiodine therapy (need very high doses given low iodine uptake, used as last resort)
- suppression with L-thyroxine (rarely done)
- surgery may be necessary for severe compressive symptoms

Complications
- compression of neck structures causing stridor, dysphagia, pain, and hoarseness
- multinodular goitre may become autonomous leading to toxic multinodular goitre and hyperthyroidism

Thyroid Nodules

Definition
- clearly defined discrete mass, separated from the thyroid parenchyma
- palpable nodules are found in approximately 5% of women and 1% of men

Etiology
- benign tumours (e.g. colloid nodule, follicular adenoma)
- thyroid malignancy
- hyperplastic area in a multinodular goitre
- cyst: true thyroid cyst, area of cystic degeneration in a multinodular goitre

Investigations

---

Figure 9. Approach to the evaluation of a thyroid nodule
Adapted from Dr. J Goguen, University of Toronto, MINMD 2013
Thyroid Malignancies

- see Otolaryngology, OT34

Adrenal Cortex

Adrenocorticotropic Hormone

- a polypeptide (cleaved from prohormone POMC), secreted in a pulsatile fashion from the anterior pituitary with diurnal variability (peak: 0200-0400; trough: 1800-2400)
- secretion regulated by corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP)
- stimulates growth of adrenal cortex and release of glucocorticoids, androgens and, to a limited extent, mineralocorticoids
- some melanocyte stimulating activity

Adrenocortical Hormones

Aldosterone
- a mineralocorticoid which regulates extracellular fluid (ECF) volume through Na⁺ (and Cl⁻) retention and K⁺ (and H⁺) excretion (stimulates distal tubule Na⁺/K⁺ ATPase)
- regulated by the renin-angiotensin-aldosterone system (Figure 12)
- negative feedback to juxtaglomerular apparatus (JGA) by long loop (aldosterone ↑ volume expansion) and short loop (angiotensin II ↑ peripheral vasoconstriction)

Mineralocorticoids
- zona glomerulosa

Glucocorticoids
- zona fasciculata

Sex Steroids
- zona reticularis

Figure 11. Pathways of major steroid synthesis in the adrenal gland and their enzymes

Layers of the Adrenal Cortex
- OUTSIDE
  - Zona Glomerulosa produces mineralocorticoids (aldosterone)
  - Zona Fasciculata produces glucocorticoids (cortisol)
- INSIDE
  - Zona Reticularis produces androgens (DHEA, androstenedione)

Figure 12. Renin-angiotensin-aldosterone axis (see Nephrology, NP4)
Cortisol
- a glucocorticoid, regulated by the HPA axis
- involved in regulation of metabolism; counteracts the effects of insulin
- support blood pressure, vasomotor tone
- also involved in regulation of behaviour and immunosuppression

Table 21. Physiological Effects of Glucocorticoids

<table>
<thead>
<tr>
<th>Stimulatory Effects</th>
<th>Inhibitory Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stimulate hepatic glucose production (gluconeogenesis)</td>
<td>Inhibit bone formation; stimulate bone resorption</td>
</tr>
<tr>
<td>Increase insulin resistance in peripheral tissues</td>
<td>Inhibit fibroblasts, causing collagen and connective tissue loss</td>
</tr>
<tr>
<td>Increase protein catabolism</td>
<td>Suppress inflammation; impair cell-mediated immunity</td>
</tr>
<tr>
<td>Stimulate leukocytosis and lymphopenia</td>
<td>Inhibit growth hormone axis</td>
</tr>
<tr>
<td>Increase cardiac output, vascular tone, Na⁺ retention</td>
<td>Inhibit reproductive axis</td>
</tr>
<tr>
<td>Increase PTH release, urine calcium excretion</td>
<td>Inhibit vitamin D3 and inhibit calcium uptake</td>
</tr>
</tbody>
</table>

Androgens
- sex steroids regulated by ACTH; primarily responsible for adrenarche (growth of axillary and pubic hair)
- principal adrenal androgens are dihydroepiandrosterone (DHEA), androstenedione, and 11-hydroxyandrostenedione
- proportion of total androgens (adrenal to gonadal) increases in old age

Adrenocortical Functional Workup

STIMULATION TEST
- purpose: diagnosis of hormone deficiencies
- method: measure target hormone after stimulation with tropic (pituitary) hormone

1. Tests of Glucocorticoid Reserve
- Cosyntropin (ACTH analogue) Stimulation Test
  - give 1 µg or 250 µg cosyntropin IV, then measure plasma cortisol levels at time 0, 30, and 60 min
  - physiologic response: stimulated plasma cortisol of >500 nmol/L
  - inappropriate response: inability to stimulate increased plasma cortisol
- insulin tolerance is the gold standard test used to diagnose adrenal insufficiency (see Pituitary Gland, E15)

SUPPRESSION TESTS
- purpose: diagnosis of hormone hypersecretion
- method: measure target hormone after suppression of its tropic (pituitary) hormone

1. Tests of Pituitary-Adrenal Suppressibility
- Dexamethasone (DXM) Suppression Test
  - principle: DXM suppresses pituitary ACTH, plasma cortisol should be lowered if HPA axis is normal
  - Screening Test: Overnight DXM Suppression Test
    - oral administration of 1 mg DXM at midnight measure plasma cortisol levels the following day at 8 am
    - physiologic response: plasma cortisol <50 nmol/L, with 50-140 nmol/L being a "grey zone" (cannot be certain if normal or not)
    - inappropriate response: failure to suppress plasma cortisol
  - Confirmatory Test: Other testing is used to confirm the diagnosis, such as:
    - 24 h urine free cortisol (shows overproduction of cortisol)
    - midnight salivary cortisol (if available), shows lack of diurnal variation
      - inappropriate response: remains high (normally will be low at midnight)

2. Tests of Mineralocorticoid Suppressibility
- principle: expansion of extracellular fluid volume (ECFV); plasma aldosterone should be lowered if HPA axis is normal
- ECFV Expansion with Normal Saline (NS)
  - IV infusion of 500 mL/h of NS for 4 h, then measure plasma aldosterone levels
  - plasma aldosterone >277 pmol/L is consistent with primary hyperaldosteronism, <140 pmol/L is normal
  - inappropriate response: failure to suppress plasma aldosterone
**Mineralocorticoid Excess Syndromes**

**Figure 13. Approach to mineralocorticoid excess syndromes**

**Definition**
- Primary hyperaldosteronism (PH): excess aldosterone production (intra-adrenal cause)
- Secondary hyperaldosteronism (SH): aldosterone production in response to excess RAAS (extra-adrenal cause)

**Etiology**
- **Primary hyperaldosteronism**
  - Aldosterone-producing adrenal adenoma (Conn’s syndrome)
  - Bilateral or idiopathic adrenal hyperplasia
  - Glucocorticoid-remediable aldosteronism
  - Aldosterone-producing adrenocortical carcinoma
  - Unilateral adrenal hyperplasia
- Secondary hyperaldosteronism

**Clinical Features**
- HTN
- Hypokalemia (may have mild hypernatremia), metabolic alkalosis
- Normal K⁺, low Na⁺ in SH (low effective circulating volume leads to ADH release) edema
- Increased cardiovascular risk: LV hypertrophy, atrial fibrillation, stroke, MI
- Fatigue, weakness, paresthesia, headache; severe cases with tetany, intermittent paralysis

**Diagnosis**
- Investigate plasma aldosterone to renin ratio in patients with HTN and hypokalemia
- Confirmatory testing for PH: aldosterone suppression test (demonstrate inappropriate aldosterone secretion with ECF volume expansion)
- Imaging: CT adrenal glands

**Table 22. Diagnostic Tests in Hyperaldosteronism**

<table>
<thead>
<tr>
<th>Test</th>
<th>Primary Hyperaldosteronism</th>
<th>Secondary Hyperaldosteronism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma aldosterone to renin ratio (PAC/PRA)</td>
<td>Elevated (↑ ald, ↓ renin)</td>
<td>Normal (↑ ald, ↑ renin)</td>
</tr>
<tr>
<td>Salt loading test</td>
<td>↑ urine aldosterone</td>
<td>Not performed if normal PAC/PRA</td>
</tr>
<tr>
<td>A) Oral test</td>
<td>↑ plasma aldosterone</td>
<td></td>
</tr>
<tr>
<td>B) IV saline test</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Treatment**
- Inhibit action of aldosterone: spironolactone, eplerenone, triamterene, amiloride (act on sodium channels)
- Surgical excision of adrenal adenoma
- Secondary hyperaldosteronism: treat underlying cause
Cushing’s Syndrome

Definition
• results from chronic glucocorticoid excess (endogenous or exogenous sources)

Etiology
• ACTH-dependent (85%) – bilateral adrenal hyperplasia and hypersecretion due to:
  ■ ACTH-secreting pituitary adenoma (Cushing’s disease; 80% of ACTH-dependent)
  ■ ectopic ACTH-secreting tumour (e.g. small cell lung carcinoma, bronchial, carcinoid, pancreatic islet cell, pheochromocytoma, or medullary thyroid tumours)
• ACTH-independent (15%)
  ■ long-term use of exogenous glucocorticoids
  ■ primary adrenocortical tumours: adenoma and carcinoma (uncommon)
  ■ bilateral adrenal nodular hyperplasia

Clinical Features
• symptoms: weakness, insomnia, mood disorders, impaired cognition, easy bruising, oligo-/amenorrhea, hirsutism, and acne (ACTH dependent)
• signs: central obesity, round face, supraclavicular and dorsal fat pads, facial plethora, proximal muscle wasting, purple abdominal striae, skin atrophy, acanthosis nigricans, HTN, hyperglycemia, osteoporosis, pathologic fractures, hyperpigmentation, hyperandrogenism if ACTH-dependent

Diagnosis
• complete a drug history to exclude iatrogenic Cushing’s
• perform one of: 1) 24 h urine free cortisol, 2) dexamethasone suppression test, or 3) late night salivary cortisol
• consider reasons for a false positive (e.g. pregnancy, depression, alcoholism, morbid obesity, poorly controlled DM)
• confirm with one of the remaining tests if necessary (do not rely on random cortisol, insulin tolerance, loperamide, or urinary 17-ketosteroid tests)

Treatment
• adrenal
  ■ adenoma: unilateral adrenalectomy (curative) with glucocorticoid supplementation post-operatively
  ■ carcinoma: adjunctive chemotherapy often not useful (frequent metastases, poor prognosis)
  ■ medical treatment: mitotane, ketoconazole to reduce cortisol
• pituitary
  ■ trans-sphenoidal resection, with glucocorticoid supplement post-operatively
  ■ ectopic ACTH tumour (paraneoplastic syndrome): usually bronchogenic cancer (poor prognosis)
    ■ surgical resection, if possible; chemotherapy/radiation for primary tumour
    ■ medical treatment with mitotane or ketoconazole to reduce cortisol synthesis. Often required when surgery is delayed, contraindicated, or unsuccessful

Congenital Adrenal Hyperplasia
• see Pediatrics, P29

Hyperandrogenism

Definition
• state of having excessive secretion of androgens (DHEA, DHEA sulfate, testosterone)

Etiology and Pathophysiology

Table 23. Etiology of Hyperandrogenism

<table>
<thead>
<tr>
<th>Category</th>
<th>Etiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constitutional/Familial</td>
<td>Family history, predisposing ethnic background</td>
</tr>
<tr>
<td></td>
<td>Premature adrenarche</td>
</tr>
<tr>
<td>Medications Androgen-Mediated</td>
<td>Anabolic steroids, ACTH, androgens, progestational agents</td>
</tr>
<tr>
<td>Ovarian</td>
<td>PCOS</td>
</tr>
<tr>
<td></td>
<td>Ovarian hyperthecosis</td>
</tr>
<tr>
<td></td>
<td>Theca cell tumours</td>
</tr>
<tr>
<td></td>
<td>Pregnancy: placental sulfatase/aromatase deficiency</td>
</tr>
<tr>
<td>Adrenal</td>
<td>Congenital adrenal hyperplasia (CAH, late-onset CAH)</td>
</tr>
<tr>
<td></td>
<td>Tumours (adenoma, carcinoma)</td>
</tr>
<tr>
<td>Pituitary</td>
<td>Cushing’s disease – high ACTH</td>
</tr>
<tr>
<td></td>
<td>Hyperprolactinemia</td>
</tr>
</tbody>
</table>
Clinical Features
Females
- hirsutism
  - male pattern growth of androgen-dependent terminal body hair in women: back, chest, upper abdomen, face, linea alba
  - Ferriman-Gallwey scoring system is used to quantify severity of hirsutism
- virilization
  - masculinization: hirsutism, temporal balding, clitoral enlargement, deepening of voice, acne
  - increase in musculature
- defeminization
  - loss of female secondary sex characteristics (i.e. amenorrhea, ↓ breast size, infertility)

Males
- minimal effects on hair, muscle mass, etc.
- inhibition of gonadotropin secretion may cause reduction in: testicular size, testicular testosterone production, and spermatogenesis

Investigations
- testosterone, DHEA-S as a measure of adrenal androgen production
- LH/FSH (commonly in PCOS >2.5)
- 17-OH progesterone, elevated in CAH due to 21-OH deficiency; check on day 3 of menstrual cycle with a progesterone level
- for virilization: CT/MRI of adrenals and ovaries (identify tumours)
- if PCOS, check blood glucose, lipids, 75 g OGTT

Treatment
- discontinue causative medications
- antiandrogens, e.g. spironolactone
- oral contraceptives (increase sex hormone binding globulin, which binds androgens>estrogens; reduce ovarian production of androgens)
- surgical resection of tumour
- low dose glucocorticoid ± mineralocorticoid if CAH suspected
- treat specific causative disorders, e.g. tumours, Cushing’s, etc.
- cosmetic therapy (laser, electrolysis)

Adrenocortical Insufficiency

Definition
- state of inadequate cortisol and/or aldosterone production by the adrenal glands

Etiology

PRIMARY (ADDISON’S DISEASE)

Table 24. Etiology of Primary Adrenocortical Insufficiency

<table>
<thead>
<tr>
<th>Category</th>
<th>Cause</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autoimmune (70-90%)</td>
<td>Isolated adrenal insufficiency</td>
<td>Polyglandular autoimmune syndrome type I and II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Antibodies often directed against adrenal enzymes and 3 cortical zones</td>
</tr>
<tr>
<td>Infection</td>
<td>TB (7-20%) (most common in developing world)</td>
<td>Fungal: histoplasmosis, paracoccidioidomycosis</td>
</tr>
<tr>
<td></td>
<td>HIV, CMV</td>
<td>Syphilis</td>
</tr>
<tr>
<td></td>
<td>African trypanosomiasis</td>
<td></td>
</tr>
<tr>
<td>Infiltrative</td>
<td>Metastatic cancer (lung, stomach, esophagus, colon, breast); lymphoma</td>
<td>Sarcoïdosis, amyloidosis, hemochromatosis</td>
</tr>
<tr>
<td>Vascular</td>
<td>Bilateral adrenal hemorrhage (risk increased by heparin and warfarin)</td>
<td>Sepsis (meningococcal, Pseudomonas)</td>
</tr>
<tr>
<td></td>
<td>Coagulopathy in adults or Waterhouse-Friderichsen syndrome in children</td>
<td>Thrombosis, embolism, adrenal infarction</td>
</tr>
<tr>
<td>Drugs</td>
<td>Inhibit cortisol: ketoconazole, etomidate, megestrol acetate</td>
<td>Increase cortisol metabolism: rifampin, phenytoin, barbiturates</td>
</tr>
<tr>
<td>Others</td>
<td>Adrenoleukodystrophy</td>
<td>Congenital adrenal hypoplasia (impaired steroidogenesis)</td>
</tr>
<tr>
<td></td>
<td>Familial glucocorticoid deficiency or resistance</td>
<td></td>
</tr>
</tbody>
</table>
SECONDARY ADRENOCORTICAL INSUFFICIENCY
• inadequate pituitary ACTH secretion
• multiple etiologies (see Hypopituitarism, E19), including withdrawal of exogenous steroids

Clinical Features
Table 25. Clinical Features of Primary and Secondary Adrenal Insufficiency (AI)

<table>
<thead>
<tr>
<th></th>
<th>Primary AI (Addison’s or Acute AI)</th>
<th>Secondary AI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin and Mucosa</td>
<td>Dark (palmar crease, extensor surface)</td>
<td>Pale</td>
</tr>
<tr>
<td>Potassium</td>
<td>High</td>
<td>Normal</td>
</tr>
<tr>
<td>Sodium</td>
<td>Low</td>
<td>Normal or Low</td>
</tr>
<tr>
<td>Metabolic Acidosis</td>
<td>Present</td>
<td>Absent</td>
</tr>
<tr>
<td>Associated Diseases</td>
<td>Primary hypothyroidism, type 1 DM, vitiligo, neurological deficits</td>
<td>Central hypogonadism or hypothyroidism, growth hormone deficiency, DI, headaches, visual abnormalities</td>
</tr>
<tr>
<td>Associated Symptoms</td>
<td>Weakness, fatigue, weight loss, hypotension, salt craving, postural dizziness, myalgia, arthralgia, GI: N/V, abdominal pain, diarrhea</td>
<td>Same except: No salt craving GI less common</td>
</tr>
<tr>
<td>Diagnostic Test</td>
<td>Insulin tolerance test Cosyntropin Stimulation Test High morning plasma ACTH</td>
<td>Insulin tolerance test Cosyntropin Stimulation Test Low morning plasma ACTH</td>
</tr>
</tbody>
</table>

Adapted from: Salvatori R. JAMA 2005;294:2481-2488

Treatment
• acute condition – can be life-threatening
  ▪ IV NS in large volumes (2-3 L); add D5W if hypoglycemic from adrenal insufficiency
  ▪ hydrocortisone 50-100 mg IV q6-8h for 24h, then gradual tapering
  ▪ identify and correct precipitating factors
• maintenance
  ▪ hydrocortisone 15-20 mg total daily dose, in 2-3 divided doses, highest dose in the AM
  ▪ Florinef® (fludrocortisone, synthetic mineralocorticoid) 0.05-0.2 mg PO daily if mineralocorticoid deficient increase dose of steroids 2-3 fold for a few days during moderate-severe illness (e.g. with vomiting, fever)
  ▪ major stress (e.g. surgery, trauma) requires 150-300 hydrocortisone IV daily divided into 3 doses
  ▪ medical alert bracelet and instructions for emergency hydrocortisone/dexamethasone IM/SC injection

Adrenal Medulla

Catecholamine Metabolism
• catecholamines are synthesized from tyrosine in postganglionic sympathetic nerves (norepinephrine) and chromaffin cells of adrenal medulla (epinephrine)
• broken down into metanephrines and other metabolites (VMA, HVA) and excreted in urine

Pheochromocytoma

Definition
• rare catecholamine secreting tumour derived from chromaffin cells of the sympathetic system

Epidemiology
• most commonly a single tumour of adrenal medulla
• rare cause of HTN (<0.2% of all hypertensives)

Etiology and Pathophysiology
• most cases sporadic (80%)
  ▪ familial: associated with multiple endocrine neoplasia II (MEN IIA and IIB) (50% penetrance; i.e.
  50% of people with the mutation get pheochromocytoma), von Hippel-Lindau (10-20% penetrance),
  paragangioma (20% penetrance), or neurofibromatosis type 1 (0.1-5.7% penetrance)
• tumours, via unknown mechanism, able to synthesize and release excessive catecholamines
Clinical Features
- 50% suffer from paroxysmal HTN; the rest have sustained HTN
- classic triad (not found in most patients): episodic “pounding” headache, palpitations/tachycardia, diaphoresis
- other symptoms: tremor, anxiety, chest or abdominal pain, N/V, visual blurring, weight loss, polyuria, polydipsia
- other signs: orthostatic hypotension, papilledema, hyperglycemia, dilated cardiomyopathy
- symptoms may be triggered by stress, exertion, anesthesia, abdominal pressure, certain foods (especially tyramine containing foods)

Investigations
- urine catecholamines
  - increased catecholamine metabolites (metanephrines) and free catecholamines
  - plasma metanephrines if available (most sensitive)
- CT abdomen
  - if negative, whole body CT and meta-iodo-benzoguanidine (MIBG) scintigraphy, Octreoscan, or MRI

Treatment
- surgical removal of tumour (curative) with careful pre- and post-operative ICU monitoring
- adequate pre-operative preparation
  - α-blockade for BP control: doxazosin or calcium channel blockers (10-21 d pre-operative), IV phentolamine (perioperative, if required)
  - β-blockade for HR control once a blocked for a few days
- metyrosine (catecholamine synthesis inhibitor) + phenoxybenzamine or prazosin
- volume restoration with vigorous salt-loading and fluids
- rescreen urine 1-3 mo post-operatively
- screen urine in first degree relatives; genetic testing in patients <50 yr old

Disorders of Multiple Endocrine Glands

Multiple Endocrine Neoplasm

- neoplastic syndromes involving multiple endocrine glands
- tumours of neuroectodermal origin
- autosomal dominant inheritance with variable penetrance
- genetic screening for RET proto-oncogene on chromosome 10 has long-term benefit in MEN II
  - early cure and prevention of medullary thyroid cancer

Table 26. MEN Classification

<table>
<thead>
<tr>
<th>Type</th>
<th>Tissues Involved</th>
<th>Clinical Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEN I (chromosome 11)</td>
<td>Pituitary (15-42%)&lt;br&gt;Anterior pituitary adenoma&lt;br&gt;Parathyroid (&gt;95%)&lt;br&gt;Primary hyperparathyroidism from hyperplasia&lt;br&gt;Entero-pancreatic endocrine (30-80%)&lt;br&gt;Pancreatic islet cell tumours&lt;br&gt;Gastrinoma&lt;br&gt;Insulinomas&lt;br&gt;Vasoactive intestinal peptide (VIP)-omas&lt;br&gt;Glucagonoma&lt;br&gt;Carcinoid syndrome</td>
<td>Headache, visual field defects, often non-secreting but may secrete GH (acromegaly) and PRL (galactorrhea, erectile dysfunction, decreased libido, amenorrhea)&lt;br&gt;Nephrolithiasis, bone abnormalities, MSK complaints, symptoms of hypercalcemia&lt;br&gt;Epigastric pain (peptic ulcers and esophagitis)&lt;br&gt;Hypoglycemia&lt;br&gt;Secretory diarrhea&lt;br&gt;Rash, anorexia, anemia, diarrhea, glossitis&lt;br&gt;Flushing, diarrhea, bronchospasm</td>
</tr>
<tr>
<td>1a Sipple’s Syndrome</td>
<td>Thyroid (&gt;90%)&lt;br&gt;Medullary thyroid cancer (MTC)&lt;br&gt;Adrenal medulla (40-50%)&lt;br&gt;Pheochromocytoma (40-50%)&lt;br&gt;Parathyroid (10-20%)&lt;br&gt;Parathyroid hyperplasia&lt;br&gt;Skin&lt;br&gt;Cutaneous lichen amyloidosis</td>
<td>Physical signs are variable and often subtle&lt;br&gt;Neck mass or thyroid nodule; non-tender, anterior lymph nodes&lt;br&gt;HTN, palpitations, headache, sweating&lt;br&gt;Symptoms of hypercalcemia&lt;br&gt;Scaly skin rash</td>
</tr>
<tr>
<td>MEN II (chromosome 10)</td>
<td>Thyroid (&gt;90%)&lt;br&gt;Medullary thyroid cancer (MTC)&lt;br&gt;Adrenal medulla (40-50%)&lt;br&gt;Pheochromocytoma (40-50%)&lt;br&gt;Parathyroid (10-20%)&lt;br&gt;Parathyroid hyperplasia&lt;br&gt;Skin&lt;br&gt;Cutaneous lichen amyloidosis</td>
<td>Physical signs are variable and often subtle&lt;br&gt;Neck mass or thyroid nodule; non-tender, anterior lymph nodes&lt;br&gt;HTN, palpitations, headache, sweating&lt;br&gt;Symptoms of hypercalcemia&lt;br&gt;Scaly skin rash</td>
</tr>
</tbody>
</table>
Table 26. MEN Classification (continued)

<table>
<thead>
<tr>
<th>Type</th>
<th>Tissues Involved</th>
<th>Clinical Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Familial Medullary Thyroid Ca (a variant of IIa)</td>
<td>Thyroid MTC (95%)</td>
<td>MTC without other clinical manifestations of MEN IIa or IIb</td>
</tr>
<tr>
<td>3. IIb</td>
<td>Thyroid MTC Adrenal medulla Pheochromocytoma (50%) Neurons Mucosal neuroma, intestinal ganglioneuromas (100%) MSK (100%)</td>
<td>MTC: most common component, more aggressive and earlier onset than MEN IIa HTN, palpitations, headache, sweating Chronic constipation; megacolon Marfanoid habitus (no aortic abnormalities)</td>
</tr>
</tbody>
</table>

Investigations
- MEN I
  - laboratory
    - may consider genetic screening for MEN-1 mutation in index patients
      - if a mutation is identified, screen family members who are at risk
    - gastrinoma: elevated serum gastrin level (>280 ng/mL) after IV injection of secretin
    - insulinoma: reduced fasting blood glucose (hypoglycemia) with elevated insulin and C-peptide levels
    - glucagonoma: elevated blood glucose and glucagon levels
    - pituitary tumours: assess GH, IGF-1, and prolactin levels (for over-production), TSH, free T4, 8 AM cortisol, LH, FSH, bioavailable testosterone or estradiol (for underproduction due to mass effect of tumour)
      - hyperparathyroidism: serum Ca²⁺ and albumin, PTH levels; bone density scan (DEXA)
  - imaging
    - MRI for pituitary tumours, gastrinoma, insulinoma
- MEN II
  - laboratory
    - genetic screening for RET mutations in all index patients
      - if a mutation is identified screen family members who are at risk
    - calcitonin levels (MTC); urine catecholamines and metanephrines (pheochromocytoma); serum Ca²⁺, albumin, and PTH levels (hyperparathyroidism)
    - pentagastrin ± calcium stimulation test if calcitonin level is within reference range
    - FNA for thyroid nodules-cytology
  - imaging
    - CT or MRI of adrenal glands, metaiodobenzylguanidine (MIBG) scan for pheochromocytoma
    - octreoscan and/or radionuclide scanning for determining the extent of metastasis

Treatment
- MEN I
  - medical
    - proton pump inhibitor (PPI) for acid hypersecretion in gastrinoma
    - cabergoline or other dopamine agonists to suppress prolactin secretion
    - somatostatin for symptomatic carcinoid tumours
  - surgery for hyperparathyroidism, insulinoma, glucagonoma, pituitary tumours (if medical treatment fails for the latter)
    - trans-sphenoidal approach with prn external radiation
- MEN II
  - surgery for MEN IIa with pre-operative medical therapy
    - prostaglandin inhibitors to alleviate diarrhea associated with thyroid cancer
    - α-blocker for at least 10-21 d for pheochromocytoma pre-operatively
    - hydration, calcitonin, IV bisphosphonates for hypercalcemia

Calcium Homeostasis
- normal total serum Ca²⁺: 2.2-2.6 mmol/L
- ionic/free Ca²⁺ levels: 1.15-1.31 mmol/L
- serum Ca²⁺ is about 40% protein bound (mostly albumin), 50% ionized, and 10% complexed with PO₄³⁻ and citrate
- regulated mainly by two factors: parathyroid hormone (PTH) and vitamin D
- actions mainly on three organs: GI tract, bone, and kidney
**Hypercalcemia**

**Definition**
- total corrected serum Ca\(^{2+}\) >2.6 mmol/L OR ionized Ca\(^{2+}\) >1.35 mmol/L

**Approach to Hypercalcemia**
1. Is the patient hypercalcemic? (correct for albumin – see sidebar)
2. Is the PTH high/normal or low?
3. If PTH is low, is phosphate high/normal or low? If phosphate is high/normal is the level of vitamin D metabolites high or low?
Clinical Features

• symptoms depend on the absolute Ca\(^{2+}\) value and the rate of its rise (may be asymptomatic)

Table 28. Symptoms of Hypercalcemia

<table>
<thead>
<tr>
<th>Cardiovascular</th>
<th>GI</th>
<th>Renal</th>
<th>Rheumatological</th>
<th>MSK</th>
<th>Psychiatric</th>
<th>Neurologic</th>
</tr>
</thead>
<tbody>
<tr>
<td>HTN Arthritia</td>
<td>Anorexia</td>
<td>Polyuria</td>
<td>Gout</td>
<td>Weakness</td>
<td>Hypertonia</td>
<td></td>
</tr>
<tr>
<td>Short QT</td>
<td>Nausea</td>
<td>Polydipsia</td>
<td>Pseudogout</td>
<td>Bone pain</td>
<td>Hyporeflexia</td>
<td></td>
</tr>
<tr>
<td>Deposition of Ca(^{2+})</td>
<td>Vomiting</td>
<td>Renal failure (stones)</td>
<td>Chondrocalcinosis</td>
<td>&gt;3 mmol/L (12 mg/dL)</td>
<td>Myopathy</td>
<td></td>
</tr>
<tr>
<td>on valves, coronary arteries, myocardial fibres</td>
<td>PUD</td>
<td>Renal failure (irreversible)</td>
<td>Dehydration</td>
<td>Increased alertness</td>
<td>Muscle cramps</td>
<td></td>
</tr>
</tbody>
</table>

| **Hypercalcemic crisis (usually >4 mmol/L or 16 mg/dL): primary symptoms include oliguria/anuria and mental status changes including somnolence and eventually coma → this is a medical emergency and should be treated immediately!** |

Treatment

• treatment depends on the Ca\(^{2+}\) level and the symptoms
• treat acute, symptomatic hypercalcemia aggressively
• treat the underlying cause of the hypercalcemia
Table 29. Treatment of Acute Hypercalcemia/Hypercalcemic Crisis

| Increase Urinary Ca²⁺ Excretion | Isotonic saline (4-5 L) over 24 h ± loop diuretic (e.g. furosemide) but only if hypervolemic (urine output >200mL/h)
Calcitonin:
4 IU/kg IM/SC q12h
8 IU/kg IM/SC q6h
Only works for 48 h
Rapid onset within 4-6 h |
|---|---|
| Diminish Bone Resorption | Bisphosphonates (treatment of choice)
Inhibits osteoclastic bone resorption and promotes renal excretion of calcium
Acts rapidly but often transient response (decreased by 0.3-0.5 mmol/L beginning within 4-6 h) max effect usually in 7 d
Combination of calcitonin and steroids may prolong reduction in calcium
Tachyphylaxis may occur
Indicated in malignancy-related hypercalcemia (IV pamidronate or zoledronic acid used)
Mithramycin (rarely used) – effective when patient cannot tolerate large fluid load
Dangerous – hematotoxic and hepatotoxic |
| Decrease GI Ca²⁺ Absorption | Corticosteroids in hypervitaminosis D and hematologic malignancies
Anti-tumour effects → decreased calcitriol production by the activated mononuclear cells in lung and lymph node
Slow to act (5-10 d); need high dose |
| Dialysis | Treatment of last resort
Indication: severe malignancy-associated hypercalcemia and renal insufficiency or heart failure |

### Hypocalcemia

**Definition**
- total corrected serum Ca²⁺ <2.2 mmol/L

**Table 30. Clinical Features of Hypocalcemia**

<table>
<thead>
<tr>
<th>Acute Hypocalcemia</th>
<th>Chronic Hypocalcemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paresthesia</td>
<td>CNS: lethargy, seizures, psychosis, basal ganglia calcification, Parkinson’s, dystonia, hemiballismus, papiledema, pseudotumour cerebri</td>
</tr>
<tr>
<td>Laryngospasm (with stridor)</td>
<td>CVS: prolonged QT interval → Torsades de pointes (ventricular tachycardia)</td>
</tr>
<tr>
<td>Hyperreflexia</td>
<td>GI: steatorrhea</td>
</tr>
<tr>
<td>Tetany</td>
<td>ENDO: impaired insulin release</td>
</tr>
<tr>
<td>Chvostek’s sign (tap CN VII)</td>
<td>SNH: dry, scaling, alopecia, brittle and transversely fissured nails, candidiasis, abnormal dentition</td>
</tr>
<tr>
<td>Trouseau’s sign (carpal spasm)</td>
<td>OCULAR: cataracts</td>
</tr>
<tr>
<td>ECG changes</td>
<td>MSK: generalized muscle weakness and wasting</td>
</tr>
<tr>
<td>Delirium</td>
<td>Psychiatric Sx: emotional instability, anxiety, and depression</td>
</tr>
</tbody>
</table>

**Approach to Hypocalcemia**
1. Is the patient hypocalcemic?
2. Is the PTH high or low?
3. If PTH is high, is phosphate low or normal?
4. Is the Mg²⁺ level low?

**Approach to Treatment**
- correct underlying disorder
- mild/asymptomatic (ionized Ca²⁺ >0.8 mmol/L)
  - treat by increasing dietary Ca²⁺ by 1000 mg/d
  - calcitriol 0.25 µg/d (especially in renal failure)
- acute/symptomatic hypocalcemia (ionized Ca²⁺ <0.7 mmol/L)
  - immediate treatment required
  - IV calcium gluconate 1-2 g over 10-20 min followed by slow infusion if necessary
  - goal is to raise Ca²⁺ to low normal range (2.0-2.1 mmol/L) to prevent symptoms but allow maximum stimulation of PTH secretion
  - if PTH recovery not expected, requires long-term therapy with calcitriol and calcium
  - do not correct hypocalcemia if asymptomatic and suspected to be transient

**Differential Diagnosis of Hypocalcemia**
- Primary hyperparathyroidism
- Malignancy: hematologic, humoral, skeletal metastases (>90% from 1 or 2)
- Renal disease: tertiary hyperparathyroidism
- Drugs: calcium carbonate, milk alkali syndrome, thiazide, lithium, theophylline, vitamin A/D intoxication
- Familial hypocalciuric hypercalcemia
- Granulomatous disease: sarcoidosis, TB, Hodgkin’s lymphoma
- Thyroid disease: thyrotoxicosis
- Adrenal disease: adrenal insufficiency, pheochromocytoma
- Immobilization

**Acute Management of Hypercalcemia/ Hypercalcemic Crisis**
- Volume expansion (e.g. NS IV 300-500 cc/h); initial therapy
- Calcitriol: transient, partial response
- Bisphosphonate: treatment of choice
- Corticosteroid: most useful in vitamin D toxicity, granulomatous disease, some malignancies
- Saline diuresis → loop diuretic (for volume overload): temporary measure

**Hypomagnesemia can impair PTH secretion and action**

**Differential Diagnosis of Tetany**
- Hypocalcemia
- Metabolic alkalosis (with hyperventilation)
- Hypokalemia
- Hypomagnesemia

**Signs and Symptoms of Acute Hypocalcemia**
- Paresthesias: perioral, hands, and feet
- Chvostek’s sign: percussion of the facial nerve just anterior to the external auditory meatus elicits glistening spasm of the orbicularis oculi or orbicularis oris muscles
- Trouseau’s sign: inflation of a blood pressure cuff above systolic pressure for 3 min elicits carpal spasm and paresthesia

**Transient hyperparathyroidism (resulting in hypocalcemia) common after subtotal thyroidectomy (permanent in <3% of surgeries)**
Metabolic Bone Disease

Osteoporosis

Definition
- a condition characterized by decreased bone mass and microarchitectural deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to fracture
- bone mineral density (BMD) ≥2.5 standard deviations below the peak bone mass for young adults (i.e. T-score ≤ -2.5)
- osteopenia: BMD with T-score between -1.0 and -2.5

Etiology and Pathophysiology

Primary Osteoporosis (95% of osteoporosis in women and 80% in men)
- primary type 1: most common in post-menopausal women, due to decline in estrogen, worsens with age
- primary type 2: occurs after age 75, seen in females and males at 2.1 ratio, possibly due to zinc deficiency

Secondary Osteoporosis
- gastrointestinal diseases
  - gastrectomy
  - malabsorption (e.g. celiac disease)
  - chronic liver disease
- bone marrow disorders
  - multiple myeloma
  - lymphoma
  - leukemia
- endocrinopathies
  - Cushing’s syndrome
  - hyperparathyroidism
  - hyperthyroidism
  - premature menopause
  - DM
  - hypogonadism
- malignancy
  - secondary to chemotherapy
  - myeloma
- drugs
  - corticosteroid therapy
  - phenytoin
  - chronic heparin therapy
  - androgen deprivation therapy
  - aromatase inhibitors
- other
  - rheumatologic disorders
  - rheumatoid arthritis
  - SLE
  - ankylosing spondylitis
  - renal disease
  - poor nutrition
  - immobilization
  - COPD (due to disease, tobacco, and glucocorticoid use)

Figure 17. Etiology and clinical approach to hypocalcemia

Online Clinical Tools
CAROC
www.osteoporosis.ca/multimedia/pdf/CAROC.pdf
FRAX
www.shef.ac.uk/FRAX/tool.aspx
Clinical Features
- commonly asymptomatic
- height loss due to collapsed vertebrae
- fractures: most commonly in hip, vertebrae, humerus, and wrist
  - fragility fractures: fracture with fall from standing height
  - Dowager's hump: collapse fracture of vertebral bodies in mid-dorsal region
- x-ray: vertebral compression and crush fractures, wedge fractures, "codfishing" sign (weakening of subchondral plates and expansion of intervertebral discs)
- pain, especially backache, associated with fractures

Approach to Osteoporosis
1. assess risk factors for osteoporosis on history and physical
2. decide if patient requires BMD testing with dual-energy x-ray absorptiometry (DEXA): men and women ≥65 yr or younger if presence of risk factors
3. Initial investigations
   - all patients with osteoporosis: calcium corrected for albumin, CBC, creatinine, ALP, TSH
   - also consider serum and urine protein electrophoresis, celiac workup, and 24 h urinary Ca excretion to rule out additional secondary causes
- 25-OH-Vitamin D level should only be measured after 3-4 mo of adequate supplementation and should not be repeated if an optimal level ≥75 nmol/L is achieved
- lateral thoracic and lumbar x-ray if clinical evidence of vertebral fracture
4. Assess 10-yr fracture risk by combining BMD result and risk factors (only if ≥50 yr)
   1) WHO Fracture Risk Assessment Tool (FRAX)
   2) Canadian Association of Radiologists and Osteoporosis Canada Risk Assessment Tool (CAROC)
5. For all patients being assessed for osteoporosis, encourage appropriate lifestyle changes (see Table 33)

Table 31. Indications for BMD Testing

<table>
<thead>
<tr>
<th>Older Adults (age ≥50 yr)</th>
<th>Younger Adults (age &lt; 50 yr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All women and men age ≥65 yr</td>
<td>Fragility fracture</td>
</tr>
<tr>
<td>Menopausal women, and men aged 50-64 yr with clinical risk factors for fracture:</td>
<td>Prolonged use of glucocorticoids</td>
</tr>
<tr>
<td>- Prolonged glucocorticoid use</td>
<td>Use of other high-risk medications</td>
</tr>
<tr>
<td>- Other high-risk medication use (aromatase inhibitors, androgen deprivation therapy)</td>
<td>(aromatase inhibitors, androgen deprivation therapy, antiestrogens)</td>
</tr>
<tr>
<td>- Parental hip fracture</td>
<td>Hypogonadism or premature menopause</td>
</tr>
<tr>
<td>- Vertebral fracture or osteopenia identified on x-ray</td>
<td>Malabsorption syndrome</td>
</tr>
<tr>
<td>- Current smoking</td>
<td>Primary hyperparathyroidism</td>
</tr>
<tr>
<td>- High alcohol intake</td>
<td>Other disorders strongly associated with rapid bone loss and/or fracture</td>
</tr>
<tr>
<td>- Low body weight (&lt;60 kg) or major weight loss (&gt;10% of weight at age 25 yr)</td>
<td></td>
</tr>
<tr>
<td>- Rheumatoid arthritis</td>
<td></td>
</tr>
<tr>
<td>- Other disorders strongly associated with osteoporosis: primary hyperparathyroidism, type 1 DM, osteogenesis imperfecta, uncontrolled hyperthyroidism, hypogonadism or premature menopause (&lt;45 yr), Cushing’s disease, chronic malnutrition or malabsorption, chronic liver disease, COPD and chronic inflammatory conditions (e.g. inflammatory bowel disease)</td>
<td></td>
</tr>
</tbody>
</table>

Table 32. Osteoporosis Risk Stratification

<table>
<thead>
<tr>
<th>Low Risk</th>
<th>Medium Risk</th>
<th>High Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-yr fracture risk &lt; 10%</td>
<td>Discuss patient preference for management and consider additional risk factors Factors that warrant consideration for pharmacological therapy: Additional vertebral fracture(s) identified on vertebral fracture assessment (VFA) or lateral spine x-ray Previous wrist fracture in individuals ≥65 or with T-score ≤-2.5 Lumbar spine T-score much lower than femoral neck T-score Men receiving androgen-deprivation therapy for prostate cancer</td>
<td>10-yr fracture risk &gt; 20%; OR Prior fragility fracture of hip or spine; OR More than one fragility fracture</td>
</tr>
<tr>
<td>Unlikely to benefit from pharmacotherapy; encourage lifestyle changes</td>
<td>Repeat BMD and reassess risk every 1-3 yr initially</td>
<td>Start pharmacotherapy</td>
</tr>
<tr>
<td>Reassess risk in 5 yr</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Calcium Plus Vitamin D Supplementation and Risk of Fractures, Osteoporosis

Purpose: To review trials of Vitamin D and Calcium therapy for reducing fracture risk in osteoporosis.

Study: Systematic review searching 2011-2015, inclusive, identified 8 RCTs totaling 30,970 participants. RCTs reviewed included healthy adults and ambulatory older adults with medical conditions (excluding cancer). Vitamin D and Calcium combination therapy was compared to placebo.

Results: Analysis of RCT data revealed that calcium plus vitamin D supplementation produced a statistically significant reduction in risk of total fractures (0.65; CI:0.55-0.79) and in hip fractures (0.70; CI:0.56-0.87). Subgroup analysis was significant for community dwelling or institutionalized patients.

Conclusions: Systematic analysis suggests that Vitamin D and Calcium therapy significantly decreases fracture risk. This study did not specifically look at individuals with osteoporosis. However, it still supports that Vitamin D and Calcium should continue to be used as preventative treatment for individuals at increased risk of fractures.

Clinical Signs of Fractures or Osteoporosis
- Height loss ≥3 cm (Sn 92%)
- Weight <51 kg
- Kyphosis (Sp 92%)
- Tooth count <20 (Sp 92%)
- Grip strength
- Arm-spine-height difference ≥5 cm (Sp 78%)
- V-AI-occiput distance >0 cm (Sp 87%)
- Rib-pelvis distance ≥2 finger breadths (Sn 88%)
Treatment of Osteoporosis

Table 33. Treatment of Osteoporosis in Women and Men

<table>
<thead>
<tr>
<th>Treatment for Both Men and Women</th>
<th>Diet: Elemental calcium 1000-1200 mg/d; Vit D 1000 IU/d</th>
<th>Exercise: 3x30 min weight-bearing exercises/wk</th>
<th>Cessation of smoking, reduce caffeine intake</th>
<th>Stop/avoid osteoporosis-inducing medications</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Drug Therapy</th>
<th>Bisphosphonate: inhibitors of osteoclast binding</th>
<th>1st line in prevention of hip, nonvertebral, and vertebral # (Grade A): alendronate, risedronate, zoledronic acid</th>
<th>2nd line (Grade B): etidronate</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Parathyroid Hormone</th>
<th>Denosumab: 1st line in prevention of hip, nonvertebral, vertebral # (Grade A)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Calcitonin (2nd line) osteoclast receptor binding</th>
<th>YES fragility #: 18-24 mo duration</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Treatment Specific to Post-Menopausal Women</th>
<th>SERM (selective estrogen-receptor modulator): agonistic effect on bone but antagonistic effect on uterus and breast</th>
<th>Raloxifene: 1st line in prevention of vertebral # (Grade A)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>HRT: combined estrogen + progestogen</th>
<th>For most women, risks &gt; benefits</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(see Gynecology, GY34)</th>
<th>Combined estrogen/progestin prevents hip, vertebral, total #</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Drug Therapy</th>
<th>Treatment for Both Men and Women</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>lifestyle</th>
<th>ADEA / EDF Endocrynology Toronto Notes 2017</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Wall-Occiput Test for Thoracic Fracture</th>
<th>Rib-Pelvis Distance Test for Lumbar Fracture</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Wall-Occiput Distance ≥0 cm</th>
<th>Rib-Pelvis Distance ≤2 Fingerbreadths</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Osteomalacia and Rickets</th>
<th>osteomalacia: osteopenia with disordered calcification leading to a higher proportion of osteoid (unmineralized) tissue prior to epiphyseal closure (in adulthood)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Osteomalacia and Rickets</th>
<th>rickets: osteopenia with disordered calcification leading to a higher proportion of osteoid (unmineralized) tissue prior to epiphyseal closure (in childhood)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Etiology and Pathophysiology</th>
<th>Vitamin D Deficiency</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Vitamin D Deficiency</th>
<th>deficient uptake or absorption</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Vitamin D Deficiency</th>
<th>malabsorption: post-gastrectomy, small bowel disease (e.g. Celiac sprue), pancreatic insufficiency</th>
</tr>
</thead>
</table>
- defective 25-hydroxylation
  - liver disease
  - anticonvulsant therapy (phenytoin, carbamazepine, phenobarbital)
- loss of vitamin D binding protein
  - nephrotic syndrome
- defective 1α,25 hydroxylation
  - hypoparathyroidism
- renal failure
- pathophysiology: leads to secondary hyperparathyroidism and hypophosphatemia

**Mineralization Defect**
- abnormal matrix
  - osteogenesis imperfecta
  - fibrogenesis imperfecta
  - axial osteomalacia
- enzyme deficiency
  - hypophosphatasia (inadequate ALP bioactivity)
- presence of calcification inhibitors
  - bisphosphonates, aluminum, high dose fluoride, anticonvulsants

**Table 34. Clinical Presentations of Rickets and Osteomalacia**

<table>
<thead>
<tr>
<th>Rickets</th>
<th>Osteomalacia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skeletal pain and deformities, bow legged</td>
<td>Not as dramatic</td>
</tr>
<tr>
<td>Fracture susceptibility</td>
<td>Diffuse skeletal pain</td>
</tr>
<tr>
<td>Weakness and hypotonia</td>
<td>Bone tenderness</td>
</tr>
<tr>
<td>Disturbed growth</td>
<td>Fractures</td>
</tr>
<tr>
<td>Rickets rosary (prominent costochondral junctions)</td>
<td>Gait disturbances (waddling)</td>
</tr>
<tr>
<td>Harrison’s groove (indentation of lower ribs)</td>
<td>Proximal muscle weakness</td>
</tr>
<tr>
<td>Hypocalcemia</td>
<td>Hypotonia</td>
</tr>
</tbody>
</table>

**Investigations**

**Table 35. Laboratory Findings in Osteomalacia and Rickets**

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Serum Phosphate</th>
<th>Serum Calcium</th>
<th>Serum ALP</th>
<th>Other Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin D deficiency</td>
<td>Decreased</td>
<td>Decreased to normal</td>
<td>Increased</td>
<td>Decreased calcitriol</td>
</tr>
<tr>
<td>Hypophosphatemia</td>
<td>Decreased</td>
<td>Normal</td>
<td>Normal</td>
<td>Associated with hyperchloremic metabolic acidosis</td>
</tr>
<tr>
<td>Proximal RTA</td>
<td>Decreased</td>
<td>Normal</td>
<td>Decreased to normal</td>
<td></td>
</tr>
</tbody>
</table>

| Conditions associated with abnormal matrix formation | Normal | Normal | Normal |

- radiologic findings
  - pseudofractures, fissures, narrow radiolucent lines – thought to be healed stress fractures or the result of erosion by arterial pulsation
  - loss of distinctness of vertebral body trabeculae; concavity of the vertebral bodies
  - changes due to secondary hyperparathyroidism: subperiosteal resorption of the phalanges, bone cysts, resorption of the distal ends of long bones
  - others: bowing of tibia, coxa profunda hip deformity
  - bone biopsy: usually not necessary but considered the gold standard for diagnosis

**Treatment**
- definitive treatment depends on the underlying cause
- vitamin D supplementation
- PO₄³⁻ supplements if low serum PO₄³⁻, Ca²⁺ supplements for isolated calcium deficiency
- bicarbonate if chronic metabolic acidosis

**Renal Osteodystrophy**

- changes to mineral metabolism and bone structure secondary to chronic kidney disease
- represents a mixture of four types of bone disease:
  - osteomalacia: low bone turnover combined with increased unmineralized bone (osteoid)
  - adynamic bone disease: low bone turnover due to excessive suppression of parathyroid gland
  - osteitis fibrosa cystica: increased bone turnover due to secondary hyperparathyroidism
  - mixed uremic osteodystrophy: both high and low bone turnover, characterized by marrow fibrosis and increased osteoid
- metastatic calcification secondary to hyperphosphatemia may occur

**Pathophysiology**
- metabolic bone disease secondary to chronic renal failure
- combination of hyperphosphatemia (inhibits 1,25(OH)₂-Vit D synthesis) and loss of renal mass (reduced 1α-hydroxylase)
Clinical Features
- soft tissue calcifications, necrotic skin lesions if vessels involved
- osteodystrophy, generalized bone pain and fractures
- pruritus
- neuromuscular irritability and tetany may occur
- radiologic features of osteitis fibrosa cystica, osteomalacia, osteosclerosis, osteoporosis

Investigations
- serum Ca\(^{2+}\)-corrected for albumin, PO\(_4\), PTH, ALP, ± imaging (x-ray, BMD), ± bone biopsy

Treatment
- prevention
- maintenance of normal serum Ca\(^{2+}\) and PO\(_4\) by restricting PO\(_4\) intake to 1 g OD
- Ca\(^{2+}\) supplements; PO\(_4\) binding agents (calcium carbonate, aluminum hydroxide)
- vitamin D with close monitoring to avoid hypercalcemia and metastatic calcification

Paget’s Disease of Bone

Definition
- a metabolic disease characterized by excessive bone destruction and repair

Epidemiology
- a common disease: 5% of the population, 10% of population >80 yr old
- consider Paget’s disease of bone in older adults with ↑ ALP but normal GGT

Etiology and Pathophysiology
- postulated to be related to a slowly progressing viral infection of osteoclasts, possibly paramyxovirus
- strong familial incidence
- initiated by increased osteoclastic activity leading to increased bone resorption; osteoblastic activity increases in response to produce new bone that is structurally abnormal and fragile

Differential Diagnosis
- primary bone lesions
  - osteogenic sarcoma
  - multiple myeloma
  - fibrous dysplasia
- secondary bone lesions
  - osteitis fibrosa cystica
  - metastases

Clinical Features
- usually asymptomatic (routine x-ray finding or elevated ALP)
- severe bone pain (e.g. pelvis, femur, tibia) is often the presenting complaint
- skeletal deformities: bowed tibia, kyphosis, frequent fractures
- skull involvement: headaches, increased hat size, deafness
- increased warmth over involved bones due to increased vascularity
- high output CHF
- hypercalcemia with immobilization
- osteosarcoma

Investigations
- laboratory
  - ↑↑ serum ALP (unless burnt out), Ca\(^{2+}\) normal or ↑, PO\(_4\) normal
  - urinary hydroxyproline ↑ (indicates resorption)
- imaging
  - bone scan to evaluate the extent of disease
  - confirmation on x-ray required to establish the diagnosis
  - skeletal survey: involved bones are denser and expanded with cortical thickening
    - initial lesion may be destructive and radiolucent
    - multiple fissure fractures in long bones

Complications
- local
  - fractures; osteoarthritis
  - cranial nerve compression and palsies (e.g. deafness), spinal cord compression
  - osteosarcoma/sarcomatous change in 1-3%
    - indicated by marked bone pain, new lytic lesions and suddenly increased ALP
- systemic
  - hypercalcemia and nephrolithiasis
  - high output CHF due to increased vascularity
Male Reproductive Endocrinology

Androgen Regulation

- negative feedback may occur by androgens directly or after conversion to estrogen
- testosterone (from Leydig cells) primarily involved in negative feedback on LH and GnRH, whereas inhibin (from Sertoli cells) suppresses FSH secretion

Tests of Testicular Function

- testicular size (lower limit = 4 cm x 2.5 cm)
- LH, FSH, total, bioavailable, and/or free testosterone
- human chorionic gonadotropin (hCG) stimulation test
  - assesses ability of Leydig cell to respond to gonadotropin
  - semen analysis
  - semen volume, sperm concentration, morphology, and motility are the most commonly used parameters
- testicular biopsy
  - indicated with normal FSH and azoospermia/oligospermia

Hypogonadism and Infertility

- see Urology: U34
- deficiency in gametogenesis or testosterone production

Etiology

- causes include primary (testicular failure), secondary (hypothalamic-pituitary failure), and idiopathic
- primary hypogonadism is more common than secondary

Table 36. Classification and Features of Hypogonadism

<table>
<thead>
<tr>
<th>Hypergonadotropic Hypogonadism (Primary Hypogonadism)</th>
<th>Hypogonadotropic Hypogonadism (Secondary Hypogonadism)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definition</strong></td>
<td>Hypothalamo-pituitary axis failure</td>
</tr>
<tr>
<td>Primary testicular failure</td>
<td>↓ LH and FSH (LH sometimes inappropriately normal)</td>
</tr>
<tr>
<td>↑↓ LH and FSH-LH ratio</td>
<td>↓ testosterone and sperm count</td>
</tr>
<tr>
<td><strong>Etiology</strong></td>
<td>Similar to primary</td>
</tr>
<tr>
<td>Congenital</td>
<td></td>
</tr>
<tr>
<td>Chromosomal defects (Klinefelter’s, Noonan)</td>
<td></td>
</tr>
<tr>
<td>Cryptorchidism</td>
<td></td>
</tr>
<tr>
<td>Disorders of sexual development (DSD)</td>
<td></td>
</tr>
<tr>
<td>Bilateral anorchia (vanishing testicle syndrome)</td>
<td></td>
</tr>
<tr>
<td>Myotonic dystrophy</td>
<td></td>
</tr>
<tr>
<td>Mutation of FSH or LH receptor gene</td>
<td></td>
</tr>
<tr>
<td>Disorders of androgen synthesis</td>
<td></td>
</tr>
<tr>
<td>Germ cell defects</td>
<td></td>
</tr>
<tr>
<td>Sertoli cell only syndrome</td>
<td></td>
</tr>
<tr>
<td>Leydig cell aplasia/failure</td>
<td></td>
</tr>
<tr>
<td>Infection/Inflammation</td>
<td></td>
</tr>
<tr>
<td>Orchitis – TB, lymphoma, mumps, leprosy</td>
<td></td>
</tr>
<tr>
<td>Genital tract infection</td>
<td></td>
</tr>
<tr>
<td>Physical factors</td>
<td></td>
</tr>
<tr>
<td>Trauma, heat, irradiation, testicular torsion, varicocele</td>
<td></td>
</tr>
<tr>
<td>Drugs</td>
<td></td>
</tr>
<tr>
<td>Marijuana, alcohol, chemotherapy, ketaconazole, glucocorticoid, spironolactone</td>
<td></td>
</tr>
<tr>
<td><strong>Diagnosis</strong></td>
<td></td>
</tr>
<tr>
<td>Testicular size and consistency (soft/firm)</td>
<td></td>
</tr>
<tr>
<td>Sperm count</td>
<td></td>
</tr>
<tr>
<td>LH, FSH, total, and/or bioavailable testosterone</td>
<td></td>
</tr>
<tr>
<td>hCG stimulation (mainly used in pediatrics)</td>
<td></td>
</tr>
<tr>
<td>Karyotype</td>
<td></td>
</tr>
</tbody>
</table>

Figure 19. Hypothalamo-pituitary-gonadal axis

Two Distinct Features of Primary Hypogonadism

- Associated with an equivalent decrease in sperm count and serum testosterone
- Likely to be associated with gynecomastia

Two Features of Secondary Hypogonadism

- Associated with an equivalent decrease in serum testosterone
- Less likely to be associated with gynecomastia

Testes

- Sertoli cell
- Leydig cell
- Testosterone

- Figure 19. Hypothalamo-pituitary-gonadal axis

- E45 Endocrinology
- Male Reproductive Endocrinology
- Toronto Notes 2017

Treatments

- symptomatic therapy (pain management)
- weight-bearing exercise
- adequate calcium and vitamin D intake to prevent development of secondary hyperparathyroidism
- treat medically if ALP >3x normal
  - bisphosphonates, e.g. alendronate 40 mg PO OD x 6 mo or risedronate 30 mg PO OD x 3 mo OR zoledronic acid 5 mg IV per yr
  - calcitomin 50-100 U/d SC
- surgery for fractures, deformity, degenerative changes
Treatment
- Testosterone replacement (improve libido, muscle mass, strength, body hair growth, bone mass)
  - IM injection, transdermal testosterone patch/gel, oral
  - Side effects: acne, fluid retention, erythrocytosis, sleep apnea, benign prostatic hypertrophy, uncertain effects on cardiac events/mortality in older men
  - Contraindicated if history of metastatic prostate cancer, breast cancer, severe LUTS associated with BPH, uncontrolled or poorly controlled CHF, PSA>4, hematocrit >50%
- GnRH agonist to restore fertility, if hypotalamic dysfunction with intact pituitary
  - Administered SC in pulsatile fashion using an external pump
- hCG ± recombinant follicular stimulating hormone (rFSH) can be used to restore fertility in cases of either hypotalamic or pituitary lesions
- Testicular sperm extraction (TESE) or microscopic sperm extraction (MICROTESE) – only if testicular tissues are not functioning

Other Causes of Male Infertility
- Hereditary disorders: Kartagener syndrome (primary ciliary dyskinesia), cystic fibrosis
- Anatomy: hypospadias, retrograde ejaculation
- Obstruction: vasal occlusion, vasal aplasia, vasectomy, seminal vesicle disease
- Sexual dysfunction: erectile dysfunction, premature ejaculation, infrequent coitus
- Surgery: TURP, radical prostatectomy, orchietomy

DEFECTS IN ANDROGEN ACTION

Etiology
- Complete androgen insensitivity (CAIS)
- Partial androgen insensitivity (PAIS)
- 5-a-reductase deficiency
- Mixed gonadal dysgenesis
- Defects in testosterone synthesis
- Infertile male syndrome
- Undervirilized fertile male syndrome

Clinical Features
- Depends on age of onset

Table 37. Effects of Testosterone Deficiency

<table>
<thead>
<tr>
<th>First Trimester in utero</th>
<th>Incomplete virilization of external genitalia (ambiguous genitalia)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Incomplete development of Wolffian ducts to form male internal genitalia (male pseudohermaphroditism)</td>
</tr>
<tr>
<td>Third Trimester in utero</td>
<td>Micropenis</td>
</tr>
<tr>
<td></td>
<td>Cryptorchidism (failure of normal testicular descent)</td>
</tr>
<tr>
<td>Prepuperty</td>
<td>Incomplete pubertal maturation (high pitch voice, sparse pubic + axillary hair, absence of facial hair)</td>
</tr>
<tr>
<td></td>
<td>Eunuchoid body habitus (greater growth of extremity long bones relative to axial bones)</td>
</tr>
<tr>
<td></td>
<td>Poor muscle development, reduced peak bone mass</td>
</tr>
<tr>
<td>Postpuberty</td>
<td>Decrease in energy, mood, and libido</td>
</tr>
<tr>
<td></td>
<td>Fine wrinkles in corners of mouth and eyes</td>
</tr>
<tr>
<td></td>
<td>Decrease in pubic/axillary hair, hematocrit, muscle mass, strength, and BMD</td>
</tr>
</tbody>
</table>

Adapted from: UpToDate, 2010; Cecil’s Essentials of Medicine

Treatment
- Appropriate gender assignment in the newborn
- Hormone replacement or supplementation
- Psychological support
- Gonadectomy for cryptorchidism (due to increased risk for testicular cancer)
- Reduction mammoplasty for gynecomastia

Erectile Dysfunction

- See Urology, U30
Gynecomastia

Definition
• true gynecomastia refers to benign proliferation of the glandular component of the male breast, resulting in the formation of a concentric, rubbery, firm mass extending from the nipple(s)
• pseudogynecomastia or lipomastia refers to enlargement of soft adipose tissue, especially seen in obese individuals

Etiology

Physiologic
• puberty
• elderly (involutional)
• neonatal (maternal hormone)

Pathologic
• endocrinopathies: primary or secondary hypogonadism, hyperthyroidism, extreme hyperprolactinemia, adrenal disease
• tumours: pituitary, adrenal, testicular, breast, ectopic production of hCG
• chronic diseases: cirrhosis, renal, malnutrition (with refeeding)
• drugs: estrogens and estrogen agonists, spironolactone, ketoconazole, cimetidine, digoxin, chemotherapy, marijuana, alcohol
• congenital/genetic: Klinefelter's syndrome, androgen insensitivity
• other: idiopathic (majority of gynecomastia is classified as idiopathic), familial

Pathophysiology
• hormonal imbalance due to increased estrogen activity (increased production, or increased availability of estrogen precursors for peripheral conversion to estrogen) or decreased androgen activity (decreased androgen production, binding of androgen to sex hormone binding globulin (SHBG), or androgen receptor blockage)

History
• recent change in breast characteristics
• trauma to testicles
• mumps
• alcohol and/or drug use
• FHx
• sexual dysfunction

Physical Exam
• signs of feminization
• breast
  • rule out red flags suggesting breast cancer: unilateral, eccentric, hard or fixed mass, skin dimpling or retraction, and nipple discharge or crusting
  • gynecomastia occurs concentrically around nipple, is not fixed to underlying tissue
• genito-urinary exam
• stigmata of liver or thyroid disease

Investigations
• laboratory: serum TSH, PRL, LH, FSH, testosterone, estradiol, LFTs, creatinine, hCG (if hCG is elevated need to locate the primary tumour)
• CXR and CT of chest/abdomen/pelvis (to locate neoplasm)
• testicular U/S to rule out testicular mass
• MRI of hypothalamic-pituitary region if pituitary adenoma suspected

Treatment
• initial observation for most men with gynecomastia
• medical
  • correct the underlying disorder, discontinue responsible drug
  • androgens for hypogonadism
  • anti-estrogens: tamoxifen has most evidence for benefit
  • aromatase inhibitors: less evidence of benefit as compared to anti-estrogens
• surgical
  • usually required for macromastia, gynecomastia present for >1 yr (fibrosis is unresponsive to medication), or failed medical treatment and for cosmetic purposes

Pubertal Gynecomastia
• This benign condition peaks between 13-14 years of age and spontaneously regresses in 90% of cases within 2yr
• Waiting is often the best approach

Causes of Gynecomastia
DOC TECH
Drugs
Other
Congenital
Tumour
Endocrine
Chronic disease

Occurrence of Gynecomastia

<table>
<thead>
<tr>
<th>Occurrence</th>
<th>% Affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infancy</td>
<td>60-90</td>
</tr>
<tr>
<td>Puberty</td>
<td>4-69</td>
</tr>
<tr>
<td>Ages 50-80</td>
<td>24-65</td>
</tr>
</tbody>
</table>

Female Reproductive Endocrinology

• see Gynecology, GY23
Paraneoplastic Syndrome

- clinical syndromes involving non-metastatic systemic effects that accompany malignant disease
- triggered by antibodies against neoplasm cross-reacting with normal tissue or by production of a physiologically active substance by the neoplasm
- commonly present with cancers of lung, breast, ovaries, or lymphatic system

**Table 38. Clinical Presentation**

<table>
<thead>
<tr>
<th>Syndrome Class</th>
<th>Symptoms/Syndrome</th>
<th>Associated Malignancies</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endocrine</td>
<td>Cushing’s syndrome</td>
<td>Small-cell lung cancer</td>
<td>Ectopic ACTH and ACTH-like substance secretion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pancreatic carcinoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neural tumours</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thymoma</td>
<td></td>
</tr>
<tr>
<td>SIADH</td>
<td></td>
<td>Small-cell lung cancer</td>
<td>Antidiuretic hormone secretion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CNS malignancies</td>
<td></td>
</tr>
<tr>
<td>Hypercalcemia</td>
<td></td>
<td>Lung cancer</td>
<td>PTH-related protein, TGF-α, TNF secretion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Breast carcinoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Renal cell carcinoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Multiple myeloma</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ovarian carcinoma</td>
<td></td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td></td>
<td>Hepatocellular</td>
<td>Insulin or insulin-like substance secretion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>carcinoma/fibrosarcoma</td>
<td></td>
</tr>
<tr>
<td>Carcinoid</td>
<td></td>
<td>Pancreatic carcinoma</td>
<td>Serotonin, bradykinin secretion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gastric carcinoma</td>
<td></td>
</tr>
<tr>
<td>Neurologic</td>
<td>Lambert-Eaton myasthenic syndrome (LEMS)</td>
<td>Small-cell lung cancer</td>
<td>Ab interferes with ACH release</td>
</tr>
<tr>
<td></td>
<td>Muscle weakness in limbs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myasthenia gravis</td>
<td></td>
<td>Thymoma</td>
<td>Ab interferes with ACH release</td>
</tr>
<tr>
<td></td>
<td>Fluctuating muscle weakness and fatiguability</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paraneoplastic limbic encephalitis</td>
<td>Small-cell lung cancer</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>Renal</td>
<td>Hypokalemic nephropathy</td>
<td>Small-cell lung cancer</td>
<td>Ectopic ACTH and ACTH-like substance secretion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ectopic ACTH and ACTH-like substance secretion</td>
<td></td>
</tr>
<tr>
<td>Nephrotic syndrome</td>
<td>Lymphoma</td>
<td>Lymphoma</td>
<td>Immune complex sedimentation in nephrons</td>
</tr>
<tr>
<td>Hematologic</td>
<td>Erythrocytosis</td>
<td>Renal cell carcinoma</td>
<td>EPO production</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hepatocellular carcinoma</td>
<td></td>
</tr>
<tr>
<td>Rheumatologic</td>
<td>SLE</td>
<td>Lymphomas</td>
<td>Anti-nuclear Ab production</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lung cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Breast carcinoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gonadal carcinoma</td>
<td></td>
</tr>
<tr>
<td>Scleroderma</td>
<td></td>
<td>Breast carcinoma</td>
<td>Anti-nuclear Ab production</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lung cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Uterine cancer</td>
<td></td>
</tr>
</tbody>
</table>

**Investigations**
- CBC, electrolytes, creatinine, LFTs, ALP, ESR, CRP, serum/urine electrophoresis
- serum autoantibodies, lumbar puncture
- imaging: skeletal survey, CT, MRI, PET scan
- ± endoscopy

**Treatment**
- treat underlying tumour: surgery, radiation, chemotherapy
- treat immune-mediated disorder: IVlg, steroids, immunosuppressive drugs, plasmapheresis (reserved for patients with identifiable antibodies in serum)
## Diabetes Medications

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Mechanism of Action</th>
<th>Generic Drug Name</th>
<th>Canada Name</th>
<th>US Name (if different)</th>
<th>Dosing</th>
<th>Indications</th>
<th>Contraindications</th>
<th>Side Effects</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Biguanide</strong></td>
<td>Sensitizes peripheral tissues to insulin → increases glucose uptake Decreases hepatic glucose production by simulation of hepatic AMP-activated protein kinase (AMPK)</td>
<td>metformin</td>
<td>Glucophage®</td>
<td>Glumetza®</td>
<td>500 mg OD titrated to 2000 mg/d maximum</td>
<td>Useful in obese type 2 DM Improves both fasting and postprandial hyperglycemia Also ↓ TG</td>
<td>ABSOLUTE: GI upset (abdo discomfort, bloating, diarrhea)</td>
<td>↓ HbA1c 1.0-1.5% Weight neutral</td>
<td></td>
</tr>
<tr>
<td><strong>Insulin Secretagogues</strong></td>
<td>Stimulates insulin release from β cells by causing K⁺ channel closure → depolarization → Ca²⁺ mediated insulin release Use in nonobese type 2 DM</td>
<td>sulfonylureas:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>glyburide</td>
<td>Diabeta®</td>
<td></td>
<td>Micronase®</td>
<td>Glynase PreTab®</td>
<td>2.5-5.0 mg/d titrated to &gt; 5 mg bid</td>
<td>AbsOLUTE: Moderate to severe liver dysfunction RELATIVE (glyburide and glimepiride): Adjust dose in mild to moderate kidney dysfunction and avoid in severe kidney dysfunction Avoid glyburide in the elderly</td>
<td>Hypoglycemia Weight gain</td>
<td>↓ HbA1c 0.8% Gliclazide lowest incidence of hypoglycemia</td>
</tr>
<tr>
<td></td>
<td>gliclazide</td>
<td>Diamicron®</td>
<td>Diamicron® MR</td>
<td></td>
<td>40-160 mg bid 30-120 mg OD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>glimepiride</td>
<td>Amaryl®</td>
<td></td>
<td></td>
<td>1-8 mg OD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>non-sulfonylureas:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>repaglinide</td>
<td>Gliclazide lowest incidence of hypoglycemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>nateglinide</td>
<td>Starlix®</td>
<td></td>
<td></td>
<td>0.5-4 mg tid</td>
<td>Short t½ of 1 h causes brief but rapid ↓ in insulin, therefore effective for post-prandial control</td>
<td>ABSOLUTE: Peripheral edema CHF Anemia Fluid retention and CHF Increased risk of cardiac events with rosiglitazone (requires written informed consent when prescribing) Increased risk of bladder cancer with pioglitazone Fractures</td>
<td>Hypoglycemia Weight gain</td>
<td>↓ HbA1c 0.7% for repaglinide and 0.5-1.0% for nateglinide</td>
</tr>
<tr>
<td><strong>Insulin Sensitizers (thiazolidinedione)</strong></td>
<td>Sensitizes peripheral tissues to insulin → increases glucose uptake Decreases FFA release from adipose Binds to nuclear receptor PPAR-γ</td>
<td>rosiglitazone</td>
<td>Avandia®</td>
<td></td>
<td>2-8 mg OD</td>
<td>Rosiglitazone – indicated only in patients with type 2 DM for whom all other oral antidiabetic agents, in monotherapy or in combination, do not result in adequate glycemic control or are inappropriate due to contraindications or intolerance</td>
<td>ABSOLUTE: NYHA &gt; class II CHF INTERACTIONS: Do not combine with a non-sulfonylurea insulin secretagogue or preprandial insulin</td>
<td>Hypoglycemia Weight gain</td>
<td>↓ HbA1c 0.8%</td>
</tr>
<tr>
<td></td>
<td>pioglitazone</td>
<td>Actos®</td>
<td></td>
<td></td>
<td>15-45 mg OD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>α-Glucosidase Inhibitor</strong></td>
<td>↓ carbohydrate GI absorption by inhibiting brush border α-glucosidase</td>
<td>acarbose</td>
<td>Glucobay®</td>
<td></td>
<td>25 mg OD titrated to 100 mg tid</td>
<td>↓ postprandial hyperglycemia</td>
<td>ABSOLUTE: Inflammatory bowel disease Severe liver dysfunction</td>
<td>Flatulence Abdominal cramps Diarrhea</td>
<td>↓ HbA1c 0.8% Not recommended as initial therapy in patients with A1c &gt; 8.5%</td>
</tr>
<tr>
<td><strong>Dipeptidyl Peptidase-IV (DPP-IV) Inhibitor</strong></td>
<td>Inhibits degradation of endogenous antihyperglycemic incretin hormones Incretin hormones stimulate insulin secretion, inhibit glucagon release, and delay gastric emptying</td>
<td>sitagliptin</td>
<td>Januvia®</td>
<td></td>
<td>100 mg OD</td>
<td></td>
<td></td>
<td></td>
<td>↓ HbA1c 0.7%</td>
</tr>
<tr>
<td></td>
<td>saxagliptin</td>
<td>Onglyza™</td>
<td></td>
<td></td>
<td>2.5-5 mg OD</td>
<td></td>
<td></td>
<td></td>
<td>Weight neutral</td>
</tr>
<tr>
<td></td>
<td>linagliptin</td>
<td>Trajenta®</td>
<td></td>
<td></td>
<td>5 mg OD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Drug Class**
- **Biguanide**
- **Insulin Secretagogues**
- **Insulin Sensitizers (thiazolidinedione)**
- **α-Glucosidase Inhibitor**
- **Dipeptidyl Peptidase-IV (DPP-IV) Inhibitor**

**Mechanism of Action**
- Sensitizes peripheral tissues to insulin
- Increases glucose uptake
- Decreases hepatic glucose production
- Sensitizes peripheral tissues to insulin
- Increases glucose uptake
- Decreases FFA release from adipose
- Sensitizes peripheral tissues to insulin
- Increases glucose uptake
- Decreases FFA release from adipose
- Carbohydrate GI absorption by inhibiting brush border α-glucosidase
- Inhibits degradation of endogenous antihyperglycemic incretin hormones
- Incretin hormones stimulate insulin secretion, inhibit glucagon release, and delay gastric emptying

**Generic Drug Name**
- metformin
- repaglinide
- nateglinide
- rosiglitazone
- pioglitazone
- acarbose
- sitagliptin
- saxagliptin
- linagliptin

**Canada Name**
- Glucophage®
- Glumetza®
- Glucobay®
- Januvia®
- Onglyza™
- Trajenta®

**US Name (if different)**
- Glucophage®
- Glumetza®
- Micronase®
- Glynase PreTab®
- Diamicron®
- Glynase PreTab®
- Amaryl®
- Gliclazide®
- Starlix®
- Avandia®
- Actos®
- Glucobay®
- Januvia®
- Onglyza™
- Trajenta®

**Dosing**
- 500 mg OD titrated to 2000 mg/d maximum
- 2.5-5.0 mg/d titrated to > 5 mg bid
- 40-160 mg bid 30-120 mg OD
- 1-8 mg OD
- 0.5-4 mg tid
- 60-120 mg tid
- 2-8 mg OD
- 15-45 mg OD
- 25 mg OD titrated to 100 mg tid
- 100 mg OD
- 2.5-5 mg OD
- 5 mg OD

**Indications**
- Useful in obese type 2 DM
- Improves both fasting and postprandial hyperglycemia
- Also ↓ TG
- AbsOLUTE: GI upset (abdo discomfort, bloating, diarrhea)
- ↓ HbA1c 1.0-1.5%
- Weight neutral

**Contraindications**
- ABSOLUTE: Moderate to severe liver dysfunction
- RELATIVE: Adjust dose in mild to moderate kidney dysfunction and avoid in severe kidney dysfunction
- Avoid glyburide in the elderly
- INTERACTIONS: Do not combine with a non-sulfonylurea insulin secretagogue or preprandial insulin
- Peripheral edema
- CHF
- Anemia
- Fluid retention and CHF
- Increased risk of cardiac events with rosiglitazone (requires written informed consent when prescribing)
- Increased risk of bladder cancer with pioglitazone
- Fractures

**Side Effects**
- GI upset (abdo discomfort, bloating, diarrhea)
- Lactic acidosis
- Anorexia
- ↓ HbA1c 1.0-1.5%
- Weight neutral

**Comments**
- ↓ HbA1c 0.8%
- Gliclazide lowest incidence of hypoglycemia
- ↓ HbA1c 0.7% for repaglinide and 0.5-1.0% for nateglinide
- ↓ HbA1c 0.8%
## Diabetes Medications (continued)

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Mechanism of Action</th>
<th>Generic Drug Name</th>
<th>Canada Name</th>
<th>US Name (if different)</th>
<th>Dosing</th>
<th>Indications</th>
<th>Contraindications</th>
<th>Side Effects</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucagon-Like Peptide (GLP-1 Analogue)</td>
<td>Enhances insulinotropic effect by stimulating insulin release</td>
<td>Exenatide</td>
<td>Byetta®</td>
<td>5-10 µg SC bid 1 h before meals</td>
<td>1st line monotherapy</td>
<td>Active liver disease</td>
<td>N/V, diarrhea, Dizziness, headache, Muscle weakness</td>
<td>Δ HbA1c 0.7-1.2%</td>
<td></td>
</tr>
<tr>
<td>Sodium-glucose linked transporter 2 (SGLT2) Inhibitor</td>
<td>Enhances urinary glucose excretion by inhibiting glucose reabsorption in the proximal renal tubule</td>
<td>Canagliflozin</td>
<td>Invokana®</td>
<td>100 mg OD before first meal of the day</td>
<td>1st line monotherapy</td>
<td>Uti, genital infections</td>
<td>Hypotension caution with concomitant loop diuretic use</td>
<td>Δ HbA1c 0.7-1.2%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dapagliflozin</td>
<td>Fonaric®</td>
<td>5 mg OD in the morning with or without food</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Empagliflozin</td>
<td>Jardiance®</td>
<td>10 mg OD in the morning with or without food</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For insulin formulations see Table 9, E9

---

## Dyslipidemia Medications

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Mechanism of Action</th>
<th>Generic Drug Name</th>
<th>Canada Name</th>
<th>US Name (if different)</th>
<th>Dosing</th>
<th>Indications</th>
<th>Contraindications</th>
<th>Side Effects</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>HMG-CoA Reductase Inhibitor (statins)</td>
<td>Inhibits cholesterol biosynthesis, ↓ LDL, synthesize, ↓ LDL clearance, modest ↓ HDL, limited ↓ VLDL</td>
<td>atorvastatin</td>
<td>Lipitor®</td>
<td>10-80 mg/d</td>
<td>1st line monotherapy</td>
<td>Active liver disease</td>
<td>G1 symptoms</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>fluvastatin</td>
<td>Lescol®</td>
<td>20-80 mg/d</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>pravastatin</td>
<td>Pravachol®</td>
<td>10-40 mg/d</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>simvastatin</td>
<td>Zocor®</td>
<td>5-40 mg/d</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>lovastatin</td>
<td>Mevacor®</td>
<td>10-80 mg/d</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>fluvastatin</td>
<td>Lescol®</td>
<td>10-80 mg/d</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibrates</td>
<td>Upregulate lipoprotein lipase = apo A1, ↓ VLDL, ↓ TG, modest ↓ LDL, modest ↑ HDL</td>
<td>bezafibrate</td>
<td>Bezalip®</td>
<td>400 mg/d</td>
<td>Used for ↑ TG, hyperchylomicronemia</td>
<td>Hepatic disease</td>
<td>GI upset</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>fenofibrate</td>
<td>Lipidil®</td>
<td>600-1200 mg/d</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>gemfibrozil</td>
<td>Lipid®</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicotinic Acid</td>
<td>Inhibits secretion of hepatic VLDL via lipoprotein lipase (LPL) pathway → decreased VLDL, and LDL; decreased clearance of HDL</td>
<td>nicotinic acid</td>
<td>Niaspan®</td>
<td>60-2 g/d</td>
<td>Used for ↑ LDL, ↑ VLDL</td>
<td>Hyperammonemia</td>
<td>Generalized flushing</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>generic niacin</td>
<td>Niasin®</td>
<td>1-3 g/d</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bile Acid Sequestrants</td>
<td>Resins that bind bile acids in intestinal lumen and prevent absorption thereby ↓ LDL</td>
<td>cholestyramine</td>
<td>Questran®</td>
<td>2-4 g/d</td>
<td>Used for ↑ LDL</td>
<td>Complete biliary obstruction</td>
<td>Constipation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>colestipol</td>
<td>Colestril®</td>
<td>5-30 g/d</td>
<td>Use as adjunct with statins or fibrates</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholesterol Absorption Inhibitors</td>
<td>Inhibits cholesterol absorption at the small intestine brush border</td>
<td>ezetimibe</td>
<td>Niaspan</td>
<td>10 mg/d</td>
<td>Used for ↑ LDL, apo B</td>
<td>Hyperammonemia</td>
<td>Fatigue</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>generic niacin</td>
<td>Epamar®</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zetia®</td>
<td>Ezetrol®</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Thyroid Medications

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Mechanism of Action</th>
<th>Generic Drug Name</th>
<th>Canada Name</th>
<th>US Name (if different)</th>
<th>Dosing</th>
<th>Indications</th>
<th>Contraindications</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antithyroid Agent</td>
<td>Decreases thyroid hormone production by inhibiting iodine and peroxidase from interacting with thyroglobulin to form T4 and T3. PTU also interferes with conversion of T4 to T3.</td>
<td>propylthiouracil (PTU)</td>
<td>Propyl-Thyracil®</td>
<td>Propyl-Thyracil®</td>
<td>Start 100 mg PO tid, then adjust accordingly</td>
<td>Hyperthyroidism</td>
<td>Hypersensitivity, Relative: renal failure, liver disease, PTU recommended in 1st trimester, MMI during 2nd and 3rd trimester, Lactation: safe with PTU &lt;300 mg/day and MMI &lt;20-30 mg/d</td>
<td>N/V, Rash, Drug-induced hepatitis, Agranulocytosis, Hepatitis with PTU, Cholestasis with MMI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>methimazole (MMI)</td>
<td>Tapazole®</td>
<td>Tapazole®</td>
<td>Start 5-20 mg PO QD, then adjust accordingly</td>
<td>Up to 60 mg QD may be required</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Thyroid Hormone

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Mechanism of Action</th>
<th>Generic Drug Name</th>
<th>Canada Name</th>
<th>US Name (if different)</th>
<th>Dosing</th>
<th>Indications</th>
<th>Contraindications</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Synthetic form of thyroxine (T4)</td>
<td>levothyroxine I-thyroxine</td>
<td>Synthroid®</td>
<td>Eltron®</td>
<td>0.05-2.0 mg/d, usually 1.5x weight (kg) is dose in micrograms In elderly patients start at 0.025 mg/d</td>
<td>Hyperthyroidism</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Antithyroid Agent

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Mechanism of Action</th>
<th>Generic Drug Name</th>
<th>Canada Name</th>
<th>US Name (if different)</th>
<th>Dosing</th>
<th>Indications</th>
<th>Contraindications</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiopharmaceutical</td>
<td>radioactive iodine that is incorporated into the thyroid gland irradiating the area and destroying local glandular tissue</td>
<td>sodium iodide I-131</td>
<td>Iodotope®</td>
<td>Iodotope®</td>
<td>Dose corrected for 24 h radioactive iodine uptake</td>
<td>Hyperthyroidism</td>
<td>Thyroid malignancy, Concurrent antithyroid medication, Pregnancy, lactation</td>
<td>N/V, Bone marrow suppression, Sialadenitis, Thyroiditis</td>
</tr>
</tbody>
</table>

## Metabolic Bone Disease Medications

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Mechanism of Action</th>
<th>Generic Drug Name</th>
<th>Canada Name</th>
<th>US Name (if different)</th>
<th>Dosing</th>
<th>Indications</th>
<th>Contraindications</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bisphosphonates</td>
<td>Inhibits osteoclast-mediated bone resorption</td>
<td>alendronate</td>
<td>Fosamax®</td>
<td>Fosamax®</td>
<td>Osteoporosis: 5-10 mg OD or 70 mg once weekly Pagets: 40 mg OD for 6 mo</td>
<td>Prevention of postmenopausal osteoporosis Treatment of osteoporosis Glucocorticoid-induced osteoporosis Paget’s disease</td>
<td>Esophageal strictures or ulceration (oral) Unable to stand or sit upright for &gt;30 min (oral) Hypersensitivity Hypocalcemia Renal insufficiency</td>
<td>GI, MSK pain, Headache, Osteonecrosis of the jaw</td>
</tr>
<tr>
<td></td>
<td></td>
<td>nisedronate</td>
<td>Actonel®</td>
<td>Actonel®</td>
<td>Osteoporosis: 5 mg OD or 55 mg once monthly Pagets: 35 mg OD for 2 mo</td>
<td>Treatment and prevention of postmenopausal osteoporosis Treatment and prevention of glucocorticoid-induced osteoporosis Paget’s disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>etidronate</td>
<td>Didronel®</td>
<td>Didronel®</td>
<td>Pagets: 5-10 mg, 10 mg OD or 5 mg</td>
<td>Symptomatic Paget’s disease Prevention and treatment of heterotopic ossification after total hip replacement or spinal cord injury</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ibandronate</td>
<td>Boniva®</td>
<td>Boniva®</td>
<td>2.5 mg OD or 150 mg once monthly</td>
<td>Treatment and prevention of postmenopausal osteoporosis (US only)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>pamidronate</td>
<td>Aredia®</td>
<td>Aredia®</td>
<td>Hypercalciemia of malignancy 60-90 mg IV over 2-4 h Wait at least 7 d before considering retreatment</td>
<td>Hypercalciemia of malignancy Paget’s disease Osteolytic bone metastases of breast cancer Osteolytic lesions of multiple myeloma</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>zoledronate</td>
<td>Zometa®</td>
<td>Aclasta®</td>
<td>5 mg IV once yearly IV</td>
<td>Treatment of osteoporosis Hypercalciemia of malignancy Treatment and prevention of skeletal complications related to cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Class</td>
<td>Mechanism of Action</td>
<td>Generic Drug Name</td>
<td>Canada Name</td>
<td>US Name (if different)</td>
<td>Dosing</td>
<td>Indications</td>
<td>Contraindications</td>
<td>Side Effects</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>-------------------</td>
<td>-------------</td>
<td>------------------------</td>
<td>--------</td>
<td>----------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>Selective Estrogen Receptor Modulators</td>
<td>Decreases resorption of bone through binding to estrogen receptors</td>
<td>raloxifene</td>
<td>Evista®</td>
<td></td>
<td>60 mg OD</td>
<td>Treatment and prevention of postmenopausal osteoporosis (2nd line)</td>
<td>Lactation, Pregnancy, Active or past history of DVT, PE, or retinal vein thrombosis</td>
<td>Hot flashes, Leg cramps, Increased risk of fatal stroke, venous thromboembolism</td>
</tr>
<tr>
<td>Calcium</td>
<td>Inhibits osteoclast-mediated bone resorption</td>
<td>calcitonin</td>
<td>Micalcin®</td>
<td></td>
<td>One spray (200 IU) per d, alternating nostrils</td>
<td>Treatment of postmenopausal osteoporosis, greater than 5 yr postmenopause</td>
<td>Clinical allergy to salmon-calcitonin, Hot flashes, Leg cramps, Increased risk of fatal stroke, venous thromboembolism</td>
<td></td>
</tr>
<tr>
<td>Anti-RANKL Monoclonal Ab</td>
<td>Inhibits RANKL (osteoclast differentiating factor) == inhibits osteoclast formation and decreases bone resorption</td>
<td>denosumab</td>
<td>Prolia™</td>
<td>Xgeva™</td>
<td>60 mg SC q6mo</td>
<td>Treatment of postmenopausal women at high risk of fracture, Prevent skeletal-related events in patients with bone metastasis from solid tumours</td>
<td>Hypocalcemia, Fatigue/headache, Dermatitis/rash, Hypophosphatemia, Hypercalcemia, Hypercholesterolemia, GI discomfort</td>
<td></td>
</tr>
<tr>
<td>PTH</td>
<td>Stimulates new bone formation by preferential stimulation of osteoclastic activity over osteoclastic activity</td>
<td>teriparatide</td>
<td>Forsteo®</td>
<td></td>
<td>20 µg SC OD x 18-24 mo</td>
<td>Treatment of postmenopausal women with osteoporosis who are at high risk for fracture, Treatment of men with primary or hyperparathyroid osteoporosis who are at high risk for fracture</td>
<td>Paget’s disease, Prior external beam or implant radiation therapy involving the skeleton, Bone metastases, Metabolic bone diseases other than osteoporosis, Orthostatic hypotension, Hypercalcemia, Dizziness, Leg cramps</td>
<td></td>
</tr>
<tr>
<td>Calcium</td>
<td>Inhibits PTH secretion</td>
<td></td>
<td></td>
<td></td>
<td>1200 mg/d (including diet) Divided in 3 doses</td>
<td>Osteopenia, Osteoporosis, Prevention of metabolic bone disease</td>
<td>Caution with renal stones, Vomiting, Constipation, Dry mouth</td>
<td></td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Regulation of calcium and phosphate homeostasis</td>
<td>calcitriol (1,25(DH)2-D)</td>
<td>Rocaltrol®</td>
<td></td>
<td>Start 0.25 µg/d, Titrate up by 0.25 µg/d at 4-8 wk intervals to 0.5-1 µg/d</td>
<td>Hypercalcemia and osteodystrophy in patients with chronic renal failure on dialysis</td>
<td>Hyperparathyroidism, Vitamin B toxicity</td>
<td></td>
</tr>
<tr>
<td>Calcium</td>
<td>Inhibits PTH secretion</td>
<td></td>
<td></td>
<td></td>
<td>Start 0.25 µg/d, Titrate up by 0.25 µg/d at 2-4 wk intervals to 0.5-2 µg/d</td>
<td>Hypocalcemia and osteodystrophy in patients with chronic renal failure on dialysis</td>
<td>Hyperparathyroidism</td>
<td></td>
</tr>
</tbody>
</table>

### Adrenal Medications

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Mineralocorticoid Activity</th>
<th>Generic Drug Name</th>
<th>Potency Relative to Cortisone</th>
<th>Equivalent Dose (mg)</th>
<th>Duration of Action (h x in h)</th>
<th>Dosing</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrocortisone</td>
<td>Yes</td>
<td>Cortef, Solu-Cortef</td>
<td>1.0</td>
<td>20</td>
<td>8</td>
<td>Hydrocortisone: 50-100 mg IV bolus, then 50-100 mg q6h (continuous infusion x 24-48 h) PO once stable (50 mg q6h x 48 h, then taper every 14 d) Chronic AI: 15-20 mg PO OD (0:3 AM, 1:3 PM)</td>
<td>In high doses, mineralocorticoid side effects may emerge (sodium + water retention, ECF volume expansion, HTN, low K+, metabolic alkalosis)</td>
</tr>
<tr>
<td>Cortisone Acetate</td>
<td>Yes</td>
<td>Cortisone Acetate</td>
<td>0.8</td>
<td>25</td>
<td>oral = 9 IM = 18</td>
<td>Hydrocortisone: 75-300 mg/d PO/IM divided q2-4h Chronic AI: 25-75 mg/d</td>
<td>Pre-drug which is converted to active form as hydrocortisone, High doses can result in mineralocorticoid side effects (see above)</td>
</tr>
<tr>
<td>Prednisone</td>
<td>No</td>
<td>Prednisone</td>
<td>4</td>
<td>5</td>
<td>16-36</td>
<td>Hydrocortisone: 15-60 mg/d PO qd or divided bid/pd Chronic AI: 5 mg daily</td>
<td>Pre-drug which is converted to active form as prednisolone</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>No</td>
<td>Dexamethasone</td>
<td>30</td>
<td>0.7</td>
<td>16-54</td>
<td>Hydrocortisone: 4 mg IV, repeat q2-4h if necessary</td>
<td>Used for undiagnosed adrenal insufficiency (does not interfere with measurement of serum cortisol levels)</td>
</tr>
</tbody>
</table>
## Landmark Endocrinology Trials

<table>
<thead>
<tr>
<th>Trial</th>
<th>Reference</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DIABETES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACCORD</td>
<td>NEJM 2008; 358:2560-72</td>
<td>Compared with standard therapy the use of intensive therapy to target normal HbA1c levels (&lt;6%) for 3.5 yr increased mortality and did not significantly reduce major cardiovascular events</td>
</tr>
<tr>
<td>ADVANCE</td>
<td>NEJM 2008; 358:2545-59</td>
<td>Intensive glucose control that lowered the HbA1c value to 6.5% reduced the incidence of nephropathy but did not significantly reduce major macrovascular events, death from cardiovascular events, or death from any cause; hypoglycemia was more common in the intensive control group</td>
</tr>
<tr>
<td>BARI-2D</td>
<td>NEJM 2009; 360:2503-15</td>
<td>In patients with both type 2 DM and CAD no significant difference was found in the rates of death and major cardiovascular events in patients undergoing prompt revascularization and those undergoing medical therapy or between strategies of insulin sensitization and insulin</td>
</tr>
<tr>
<td>DCCT</td>
<td>NEJM 1993; 329:977-86</td>
<td>Intensive blood glucose control delayed the onset and reduced the progression of microvascular complications (retinopathy, nephropathy, and neuropathy) in type 1 DM</td>
</tr>
<tr>
<td>EDIC</td>
<td>NEJM 2005; 353:2644-53</td>
<td>Compared with conventional therapy intensive DM therapy early on without macrovascular disease (goal HbA1c &lt;6.05%) has long-term beneficial effects on the risk of cardiovascular disease in patients with type 1 DM</td>
</tr>
<tr>
<td>Look AHEAD</td>
<td>NEJM 2013; 369:145-54</td>
<td>Moderate weight loss (&lt;7% BW) and increased exercise are not associated with reduction in CVD and its complications among overweight or obese patients with type 2 DM</td>
</tr>
<tr>
<td>NAVIGATOR</td>
<td>NEJM 2010; 362:1463-90</td>
<td>In patients with impaired glucose tolerance, nateglinide did not reduce progression to DM or risk of cardiovascular events while valsartan only reduced progression to DM</td>
</tr>
<tr>
<td>PREDIMED</td>
<td>NEJM 2013; 368:1279-90</td>
<td>A Mediterranean diet with extra-virgin olive oil or nuts reduces rates of MI, CVA, or CV death in those at high risk for CV disease (outcome was driven by reduction in rates of CVA)</td>
</tr>
<tr>
<td>Steno-2</td>
<td>NEJM 2008; 358:580-91</td>
<td>In at-risk patients with type 2 DM intensive intervention with multiple drug combinations and behaviour modification had sustained significant beneficial effects with respect to vascular complications and mortality; multifactorial intervention is critical in the management of type 2 DM</td>
</tr>
<tr>
<td>UKPDS Extension</td>
<td>NEJM 2008; 359:1577-89</td>
<td>Continued risk reduction in microvascular risk and emergent risk reductions for MI and death from any cause 10 yr post UKPDS trial follow up in type 2 DM</td>
</tr>
<tr>
<td>VADT</td>
<td>NEJM 2009; 360:1-11</td>
<td>In patients with longstanding poorly controlled type 2 DM intensive glucose control had no significant effect on the rates of major cardiovascular events, death, or microvascular complications; adverse events, predominantly hypoglycemia, were more common in the intensive control group</td>
</tr>
<tr>
<td><strong>LIPIDS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4S</td>
<td>Lancet 1994; 344:1383-89</td>
<td>In patients with angina or previous MI and high total cholesterol simvastatin reduced: all-cause mortality, fatal and nonfatal coronary events, and need for coronary artery bypass surgery or angioplasty</td>
</tr>
<tr>
<td>FIELD</td>
<td>Lancet 2005; 366:1849-61</td>
<td>In patients with type 2 DM not previously on statin therapy fenofibrate did not significantly reduce the risk of the primary outcome of coronary events; it did reduce non-fatal MI and revascularizations</td>
</tr>
<tr>
<td>HPS</td>
<td>Lancet 2002; 360:7-22</td>
<td>In high-risk patients with various cholesterol values simvastatin reduced all-cause mortality, coronary deaths, and major vascular events</td>
</tr>
<tr>
<td>Jupiter</td>
<td>NEJM 2008; 359:2195-207</td>
<td>Rosuvastatin significantly reduced the incidence of major cardiovascular events in patients with elevated high-sensitivity CRP levels and no hyperlipidemia</td>
</tr>
<tr>
<td>TNT</td>
<td>NEJM 2005; 352:1425-35</td>
<td>Lipid-lowering therapy with atorvastatin 80 mg/d in patients with stable CHD provides clinical benefit beyond atorvastatin 10 mg/d</td>
</tr>
</tbody>
</table>
References

## Acronyms

- FM

## Four Principles of Family Medicine

### Periodic Health Examination

**Purpose of the Periodic Health Examination**

- Classification of Recommendations
- Breast Cancer Screening Guidelines
- Lung Cancer Screening Guidelines
- Colorectal Cancer Screening Guidelines
- Cervical Cancer Screening
- Prostate Cancer Screening

### Health Promotion and Counselling

- Motivational Strategies for Behavioural Change
- Nutrition
- Obesity
- Dyslipidemia
- Exercise
- Smoking Cessation
- Alcohol

### Common Presenting Problems

- Abdominal Pain
- Allergic Rhinitis
- Amenorrhea
- Anxiety
- Asthma/COPD
- Benign Prostatic Hyperplasia
- Bronchitis (Acute)
- Chest Pain
- Common Cold (Acute Rhinitis)
- Concussion/Mild Traumatic Brain Injury
- Contraception
- Cough
- Dementia (Major Neurocognitive Disorder)
- Depression
- Diabetes Mellitus
- Dizziness
- Domestic Violence/Elder Abuse
- Dyspepsia
- Dyspnea
- Dysuria
- Epistaxis
- Erectile Dysfunction
- Fatigue
- Fever
- Headache
- Hearing Impairment
- Hypertension
- Joint Pain
- Low Back Pain
- Menopause/Hormone Replacement Therapy
- Osteoarthritis
- Osteoporosis
- Palliative and End-of-Life Care
- Rash
- Sexually Transmitted Infections
- Sinusitis
- Sleep Disorders
- Sore Throat (Pharyngitis)

### Complementary and Alternative Medicine

- Toronto Notes 2017

### Primary Care Models

- Antimicrobial Quick Reference

### References
Four Principles of Family Medicine

1. The family physician is a skilled clinician
   - diagnoses and manages diseases common to the population served
   - recognizes importance of early diagnosis of serious life-threatening illnesses

2. Family medicine is a community-based discipline
   - provides information and access to community services
   - responds/adapts to changing needs and circumstances of the community

3. The family physician is a resource to a defined practice population
   - serves as a health resource
   - advocates for public policy to promote health

4. The patient-physician relationship is central to the role of the family physician
   - commits to the person, not just the disease
   - promotes continuity of patient care

Periodic Health Examination

- Canadian Task Force on Preventive Health Care established in 1976, first published in 1979
- mandate: to develop and disseminate clinical practice guidelines for primary and preventive care
- recommendations are based on systematic analysis of scientific evidence
  - most notable recommendation is the abolition of the annual physical exam; replaced by the PHE

Purpose of the Periodic Health Examination

- primary prevention: identify risk factors for common diseases; counsel patients to promote healthy behaviour
- secondary prevention: presymptomatic detection of disease to allow early treatment and to prevent disease progression
- update clinical data
- enhance patient-physician relationship

Classification of Recommendations (GRADE, 2011)

Strength of Recommendation
- strong: high level of confidence that desirable effects outweigh undesirable effects (strong recommendation for an intervention) or that the undesirable effects outweigh desirable effects (strong recommendation against an intervention)
  - implies that most individuals will be best served by the recommended course of action
Periodic Health Examination

**Quality of Evidence**
- **weak**: desirable effects probably outweigh the undesirable effects (weak recommendation for an intervention) or undesirable effects probably outweigh the desirable effects (weak recommendation against an intervention); uncertainty exists
- implies that most people would want the recommended course of action but that many would not
- different choices will be appropriate for different individuals, patients require support in reaching a management decision consistent with his/her values and preferences

**Table 1. Periodic Health Exam**

<table>
<thead>
<tr>
<th>DISCUSSION</th>
<th>General Population</th>
<th>Special Population</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dental hygiene</strong> (community fluoridation, brushing, flossing) (A)</td>
<td></td>
<td><strong>Pediatrics</strong>: Home visits for high risk families (A), Inquiry into developmental milestones (B)</td>
</tr>
<tr>
<td><strong>Noise control and hearing protection</strong> (A)</td>
<td></td>
<td><strong>Adolescents</strong>: Counsel on sexual activity and contraceptive practices (B), Counsel to prevent smoking initiation (B)</td>
</tr>
<tr>
<td><strong>Screen for poverty</strong></td>
<td></td>
<td><strong>Perimenopausal Women</strong> (&gt;50): Assess for risk factors for: osteoporosis and fracture (A), Counsel on osteoporosis, Counsel on risks/benefits of hormone replacement therapy (B)</td>
</tr>
<tr>
<td><strong>Smokers: counsel on smoking cessation, provide:</strong> Nicotine replacement therapy (A)</td>
<td></td>
<td><strong>Adults &gt;65</strong>: Follow-up on caregiver concern of cognitive impairment (A), Multidisciplinary post-fall assessment (A)</td>
</tr>
<tr>
<td><strong>Referral to smoking cessation program</strong> (B)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dietary advice on leafy green vegetables and fruits</strong> (B)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Seat belt use</strong> (B)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Injury prevention (bicycle helmets, smoke detectors)</strong> (B)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Avoid sun exposure and wear protective clothing</strong> (B)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Problem drinking screening and counselling</strong> (B)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Counselling to protect against STIs</strong> (B)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nutritional counselling and dietary advice on fat and cholesterol</strong> (B)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dietary advice on calcium and vitamin D requirements</strong> (B)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**PHYSICAL**

- Blood pressure measurement, using techniques described in CHEP guidelines (strong recommendation; moderate quality evidence)
- BMI measurement in obese adults (B)
- **Pediatrics**: Repeated examinations of hips, eyes and hearing (especially in first year of life) (A), Serial height, weight and head circumference (B), Visual acuity testing after age 2 (B)
- **Adults >65**: Visual acuity (Snellen sight chart) (B), Hearing impairment (inquiry, whispered voice test, audiocope) (B)
- **First-Degree Relative with Melanoma**: Full body skin exam (B)

**TESTS**

- See recommendations below for age and gender specific screening for diabetes, dyslipidemia, hypertension and cancer screening (colon, prostate, cervical, lung, and breast)
- **Pediatrics**: Routine hemoglobin for high risk infants (B), Blood lead screening of high risk infants (B)
- **TB High Risk Groups**: Mantoux skin testing (A)
- **STI High Risk Groups**: Viral HSV antibody screening (A) Gonorrhea screening (A) Chlamydia screening in women (B) Syphilis screen (A)
- **Syphilis Risk Group**: VDRL test (A)

**THERAPY**

- Folic acid supplementation to women of child-bearing age (A)
- Pharmacologic treatment of HTN (Refer to CHEP Guidelines) (A)
- Varicella vaccine for children age 1-12 and susceptible adolescents/adults (A)
- Rubella vaccine for all non-pregnant women of child-bearing age unless there is proof of immunity via immunization records or serology (B)
- Tetanus vaccine: routine booster q10y or if 1st series (A)
- Pertussis vaccine: adults <65 should receive one booster given as Tdap—Adacel® or Boostrix® (A)
- Herpes zoster vaccine for adults ≥60
- **Pediatrics**: Routine immunizations (A), Hepatitis B, HPV and Meningococcal immunizations are offered in schools in most Canadian provinces
- **Influenza High Risk Groups**: Outreach strategies for vaccination (A), annual immunization (B), now recommended for all
- **TB High Risk Groups** (INH prophylaxis for household contacts or skin test converters (B) INH prophylaxis for high risk sub-groups (B)
- **Immunocompromised/Age<65/COPD/Asthma/CHF/Anemia/Liver Disease/Renal Failure/DM**: Pneumococcal Vaccine (Pneumovax®) (A)

Classification of recommendation in brackets. See sidebar on FM2 for classification details. See www.canadiantaskforce.ca – for up-to-date guidelines

Reference: Canadian Task Force on Preventive Health Care, 2014

Breast Cancer Screening Guidelines

**2011 Recommendations on Screening for Breast Cancer in Average-Risk Women** (The Canadian Task Force on Preventive Health Care)
- average-risk women: women age 40-74 with no personal history of breast cancer, history of breast cancer in 1st degree relatives, known mutations of the BRCA1/BRCA2 genes or previous exposures of the chest wall to radiation
Mammography
- age 40-49: routine screening with mammography not recommended (weak recommendation - moderate quality evidence)
- age 50-74: routine screening q2-3yr (age 50-69: weak recommendation; moderate quality evidence, age 70-74: weak recommendation; low quality evidence)
- age 75+: screen if benefits outweigh harm, must take overall health into account

Magnetic Resonance Imaging
- no routine screening with MRI scans (weak recommendation - low quality evidence)

Clinical Breast Examination
- no routine CBE alone or in conjunction with mammography to screen for breast cancer (weak recommendation - low quality evidence)

Breast Self-Examination
- recommend not advising women to routinely practice breast self-examination
- for more information on benign breast lesions and breast cancer, see General Surgery, GS55

Lung Cancer Screening Guidelines
2016 Canadian Task Force on Preventative Health Care
- apply to adults aged 18 and older who are not suspected of having lung cancer
- annual screening with low dose CT for adults aged 55-74 with at least a 30 pack-year smoking history who currently smoke or quit less than 15 years ago, up to three consecutive times

Colorectal Cancer Screening Guidelines
- recommendations for average risk individuals (asymptomatic, no family history of UC, polyps, or CRC)
- average risk testing should begin at age 50, but assessment for risk factors should begin earlier to identify high-risk individuals
  - Canadian Task Force on Preventative Health Care (2016)
    - FOBT (either high sensitivity FOBT or FIT - fecal immunochemical testing) q2yr OR flexible sigmoidoscopy q10yr
    - no colonoscopy as a screening test
    - no screening after age 75 is recommended for average risk patients, but it may be assessed on an individual basis for ages 76-85
- for more information on colorectal neoplasms, see General Surgery, GS33

![Figure 1. Approach to higher risk screening](http://www.bcguidelines.ca/pdf/colorectal_screening.pdf)

AAPC = attenuated adenomatous polyposis; FAP = familial adenomatous polyposis; HNPCC = hereditary nonpolyposis colorectal cancer; 1st degree relatives: parents, siblings, children; 2nd degree relatives: grandparents, aunts, uncles; 3rd degree relatives: great-grandparents or cousins. Figure printed with permission from Can J Gastroenterol 2004:18:3:98.
### Cervical Cancer Screening

- either conventional Papanicolaou (Pap) smear or liquid based cytology testing
- endocervical and exocervical cell sampling (aim is to sample the transitional zone)
- best identifies squamous cell abnormalities, less reliable for glandular abnormalities
  - false positives 5-10%, false negatives 10-40% (for single test)
  - false negative rate 50% for existing cervical cancer
- cervical cancer screening guidelines differ by provincial jurisdiction (see The Society of Obstetricians and Gynaecologists of Canada guidelines)

- Canadian Task Force for Preventative Care Guidelines
  - screen all women age ≥25 q3yr (age 25-29: weak recommendation; moderate quality evidence, age 30-69: strong recommendation; high quality evidence)
  - women age ≥70: if 3 normal tests in a row and no abnormal tests in last 10 yr, can discontinue screening (weak recommendation; low quality evidence)

- Ontario guidelines
  - screen all women age ≥21 who are or have ever been sexually active (includes intercourse or digital/oral activity with partner of either gender)
  - if cytology is normal, can screen every 3 yr
  - women age ≥70: if 3 successive negative Pap tests in last 10 yr, can discontinue screening
  - women who are not sexually active by age 21 should delay cervical cancer screening until sexually active
  - pregnant women and women who have sex with women should follow the routine cervical screening regimen
  - women who have had a hysterectomy
    - total: discontinue screening if hysterectomy was for benign disease and no history of cervical dysplasia or HPV infection, continue to swab vaginal vault if history of uterine malignancy/dysplasia
    - subtotal: continue screening according to guidelines
  - exceptions to guidelines
    - immunocompromised (transplant, steroids, diethylstilbestrol exposure, HIV)
    - previously unscreened patients
  - for more information on cervical cancer (see Gynecology, GY43)

### Prostate Cancer Screening

- Canadian Task Force for Preventative Care Guidelines
  - screening for prostate cancer with the prostate specific antigen test is not recommended for any age group (age <55: strong recommendation; low quality evidence, age 55-69: weak recommendation; moderate quality evidence, age >70: strong recommendation; low quality evidence)

---

**Figure 2. Decision making chart for cervical cancer screening (not applicable for adolescents)**

AGUS = atypical glandular cells of unknown significance; ASCUS = abnormal squamous cells of unknown significance; ASC-H = abnormal squamous cells cannot rule out HSIL; LSIL = high grade squamous intraepithelial lesion; LSIL = low grade squamous intraepithelial lesion; TZ = transitional zone

Adapted from: Ontario Cervical Screening Cytology Guidelines. May 2012

---

**Prostate Cancer Mortality at 11 Years of Follow-Up**


Study: Updated “ERSPC” study – multicentre randomized trial of screening for prostate cancer using PSA.

Patients: 162,388 men, ages 55-69 from 8 different European countries.

Intervention: PSA-based screening.

Main Outcome: Mortality from prostate cancer.

Results: After median follow up of 11 yr, the ARR of death from prostate cancer was 21%. The ARR was 1.07 deaths/1,000 men. NNT = 1,055 – therefore to prevent one death from prostate cancer at 11 yr follow up, 1,055 men would need to be screened.
Health Promotion and Counselling

- health promotion is the most effective preventive strategy
- there are several effective ways to promote healthy behavioural change, such as discussions appropriate to a patient’s present stage of change
- for more information about motivational interviewing, see www.motivationalinterviewing.org

Motivational Strategies for Behavioural Change

<table>
<thead>
<tr>
<th>Patient’s Stage of Change</th>
<th>Physician’s Aim</th>
<th>Physician’s Plan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Contemplation</td>
<td>Encourage patient to consider the possibility of change</td>
<td>Raise issue in a sensitive manner</td>
</tr>
<tr>
<td></td>
<td>Assess readiness for change</td>
<td>Offer (not impose) a neutral exchange of information to avoid resistance</td>
</tr>
<tr>
<td></td>
<td>Increase patient’s awareness of the problem and its risks</td>
<td></td>
</tr>
<tr>
<td>Contemplation</td>
<td>Understand patient’s ambivalence and encourage change</td>
<td>Offer opportunity to discuss pros and cons of change using reflective listening</td>
</tr>
<tr>
<td></td>
<td>Build confidence and gain commitment to change</td>
<td></td>
</tr>
<tr>
<td>Preparation</td>
<td>Explore options and choose course most appropriate to patient</td>
<td>Offer realistic options for change and opportunity to discuss inevitable difficulties</td>
</tr>
<tr>
<td></td>
<td>Identify high-risk situations and develop strategies to prevent relapse</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Continue to strengthen confidence and commitment</td>
<td></td>
</tr>
<tr>
<td>Action</td>
<td>Help patients design rewards for success</td>
<td>Offer positive reinforcement and explore ways of coping with obstacles</td>
</tr>
<tr>
<td></td>
<td>Develop strategies to prevent relapse</td>
<td>Encourage self-rewards to positively reinforce change</td>
</tr>
<tr>
<td></td>
<td>Support and reinforce convictions towards long-term change</td>
<td></td>
</tr>
<tr>
<td>Maintenance</td>
<td>Help patient maintain motivation</td>
<td>Discuss progress and signs of impending relapse</td>
</tr>
<tr>
<td></td>
<td>Review identified high-risk situations and strategies for preventing relapse</td>
<td></td>
</tr>
<tr>
<td>Relapse</td>
<td>Help patient view relapse as a learning experience</td>
<td>Offer a non-judgmental discussion about circumstances surrounding relapse and how to avoid relapse in the future</td>
</tr>
<tr>
<td></td>
<td>Provide support appropriate to present level of readiness post-relapse</td>
<td>Reassess patient’s readiness to change</td>
</tr>
</tbody>
</table>


Nutrition

General Population
- Canada’s Food Guide is appropriate for individuals age ≥2
- counsel on variety, portion size, and plate layout

Table 3. Canada’s Food Guide 2011 Recommendations for Children >2 and Adults (# of servings/d)

<table>
<thead>
<tr>
<th>Age in Years</th>
<th>Children</th>
<th>Teens</th>
<th>Adults</th>
<th>Choose More From</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Whole grain and enriched grain products</td>
</tr>
<tr>
<td>Grain Products</td>
<td>2-3</td>
<td>4-8</td>
<td>9-13</td>
<td>14-18</td>
</tr>
<tr>
<td>Milk and Alternatives</td>
<td>2</td>
<td>2</td>
<td>3-4</td>
<td>F:3-4</td>
</tr>
<tr>
<td>Meat and Alternatives</td>
<td>1</td>
<td>1</td>
<td>1-2</td>
<td>F:2</td>
</tr>
</tbody>
</table>

Table 3. Recommendations for Vitamin D Use
- Based on CCS research on Vitamin D and the prevention of colorectal, breast and prostate cancer
- In consultation with their healthcare provider, the Society is recommending that:
  - Adults living in Canada should consider Vitamin D supplementation of 1,000 international units (IU) a day during the fall and winter
  - Adults at higher risk of having lower Vitamin D levels should consider taking Vitamin D supplementation of 1,000 IU/d all year round. This includes people who are older, with dark skin, who do not go outside often, and who wear clothing that covers most of their skin
  - Babies who are exclusively breast-fed: 400 IU/d
Cardiovascular Disease Prevention

### Table 4. Dietary Guidelines for Reducing Risk of Cardiovascular Disease

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fat, Carbohydrates, Protein</strong></td>
<td>Lower LDL</td>
</tr>
<tr>
<td>Overall fat intake: 26-27% of total energy</td>
<td></td>
</tr>
<tr>
<td>Saturated fat: 5-6% of total energy</td>
<td></td>
</tr>
<tr>
<td>Trans fat: reduce intake, replace with MUFAs or PUFA</td>
<td></td>
</tr>
<tr>
<td>Carbohydrates: 55-59% of total energy</td>
<td></td>
</tr>
<tr>
<td>Protein: 15-18% of total energy</td>
<td></td>
</tr>
<tr>
<td><strong>Omega-3 Fatty Acid Rich Foods</strong></td>
<td>Decreased sudden death, death from CAD</td>
</tr>
<tr>
<td>≥2 servings/wk of fish (especially oily fish like salmon)</td>
<td>Lower TG</td>
</tr>
<tr>
<td><strong>Salt</strong></td>
<td>Combined decreased sodium intake with the DASH diet (see below) achieves even greater BP-lowering effects</td>
</tr>
<tr>
<td>≤2,400 mg/d</td>
<td></td>
</tr>
<tr>
<td><strong>Alcohol</strong></td>
<td>Decreased risk of hypertiglyceridemia, HTN, osteoporosis, certain cancers</td>
</tr>
<tr>
<td>≤3 drinks/day for men, max 15/wk</td>
<td></td>
</tr>
<tr>
<td>≤2 drink/day for women, max 10/wk</td>
<td></td>
</tr>
<tr>
<td><strong>Dietary Approaches</strong></td>
<td>Lower BP, lower LDL</td>
</tr>
<tr>
<td>DASH diet (Dietary Approaches to Stop Hypertension), recommended by the American Heart Association (AHA)</td>
<td></td>
</tr>
<tr>
<td>Diet: high in vegetables/fruits, low-fat dairy, whole grains, poultry, fish, and nuts; Low in sweets, sugar-sweetened beverages, red meats</td>
<td></td>
</tr>
<tr>
<td>Macronutrients: low in saturated/total fat and cholesterol; high in potassium, magnesium, calcium, protein, and fibre</td>
<td></td>
</tr>
<tr>
<td>Mediterranean diet (fruits, vegetables, whole grains, legumes, nuts, olive oil, and herbs)</td>
<td></td>
</tr>
</tbody>
</table>

MUFAs = monounsaturated fatty acids; PUFAs = polyunsaturated fatty acids


### Obesity

- see Canadian Task force on Preventive Health Care recommendations (CMAJ February 2015) at: [canadiantaskforce.ca/ca/ctfphc-guidelines/2015-obesity-adults/](canadiantaskforce.ca/ca/ctfphc-guidelines/2015-obesity-adults/)
- body mass index (BMI) = weight (kg)/height (m)² = weight (lbs)/height (in)² x 703; BMI is a poor predictor of obesity
- waist circumference (WC) = flexible tape placed on horizontal plane at iliac crest, normal depends on ethnic background
- increased WC for BMI 25-35 increases the risk of cardiovascular disease and type 2 diabetes

### Table 5. Classification of Weight by BMI, Waist Circumference, and Associated Disease Risks in Adults

<table>
<thead>
<tr>
<th>BMI (kg/m²)</th>
<th>Obesity Class</th>
<th>Men ≤102 cm (40 in) Women ≤88 cm (35 in)</th>
<th>Men &gt;102 cm (40 in) Women &gt;88 cm (35 in)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;18.5</td>
<td>Underweight</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.5-24.9</td>
<td>Normal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25.0-29.9</td>
<td>Overweight</td>
<td>Increased</td>
<td>High</td>
</tr>
<tr>
<td>30.0-34.9</td>
<td>Obesity Class I</td>
<td>High</td>
<td>Very High</td>
</tr>
<tr>
<td>35.0-39.9</td>
<td>Obesity Class II</td>
<td>Very High</td>
<td>Very High</td>
</tr>
<tr>
<td>40.0 -</td>
<td>Obesity Class III</td>
<td>Extremely High</td>
<td>Extremely High</td>
</tr>
</tbody>
</table>


### Epidemiology

- 16% (4 million) of people ≥18 yr old are obese, 32% (8 million) are overweight in Canada, according to StatsCan (2007)
- obesity rate in people of Aboriginal origin is 1.6 times higher than the national average
- proportion of children aged 6-11 who are overweight has more than doubled in the last 25 yr; percentage of overweight adolescents has tripled
- overweight and obesity rates in children are directly proportional to screen time (see Exercise, FM10)
- only 10-15% of population consume <30% fat daily
- obese persons generally consume more energy-dense food which tends to be highly processed, micronutrient poor, and high in fats, sugars, or starch

### Adverse Medical Consequences of Obesity

- Type 2 DM
- CAD
- Stroke
- HTN
- Gallbladder disease
- Non-alcoholic steatohepatitis
- Complications of pregnancy

- Dyslipidemia
- Osteoarthritis
- Stroke
- Heart failure
- Certain cancers
- CHF
- Low back pain
- Increased mortality
Screening Recommendations
- the CANRISK or FINRISC scores can be used to assess the risk for type 2 diabetes in overweight and obese patients
- BMI risk assessment should be done every 3-5 yr in people at high risk of developing diabetes within 10 yr

Management

**Behavioural/Lifestyle**
- weight loss of >5% is clinically significant for reducing many cardiovascular risk factors (e.g. elevated blood pressure, glucose and lipids)
- efficacious behavioural interventions are greater than 12 months duration, include diet and/or exercise and/or lifestyle components, and include group and individual sessions
- structured behavioural and lifestyle interventions should be offered or arranged for overweight individuals BMI >25
- strong recommendation for those with increased risk of Type 2 DM
- BMI >35 + risk factors or BMI >40 are candidates for bariatric surgery failing behavioural modification

Pharmacologic
- the task force recommends against pharmacologic intervention to manage patients who are overweight and obese, although some patients may prefer medications and be good candidates for pharmacologic treatment
- high benefit of behavioural modification alone, NNH (number needed to harm) 10 (mostly GI side effects) for pharmacotherapy

**Figure 4. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children (summary)**
Adapted from: CMAJ 2007;176:S1-S13
Dyslipidemia

- see Endocrinology, E2
- defined as abnormal elevation of plasma cholesterol or triglyceride levels

Assessment
- measure fasting serum TC, LDL-C, HDL-C, and TG
- screen with full fasting lipid profile q1-3yr in males >40 yr and females >50 yr or who are menopausal, or at any age for adults with additional dyslipidemia risk factors (see sidebar)
- screen for secondary causes: hypothyroidism, chronic kidney disease, DM, nephrotic syndrome, liver disease

risk category
- estimate using the model for 10 yr CAD risk developed from the Framingham data (Framingham Risk Score – FRS)
  - FRS calculated based on the following factors: gender, age, HDL-C, total cholesterol, sBP, smoking, DM
  - family history of CVD <55 male relative or <65 in female relative doubles FRS
- to be completed for men age 40-75, and women age 50-75 q3-5yr
- cardiovascular age calculated as patient’s age ± the difference between his or her estimated remaining life expectancy
  - used to increase adherence to therapy and reaffirm positive effect of following therapy
- treatment decisions focus on LDL-C level and/or FRS risk; the alternate primary targets are apolipoprotein B (apo B) and non-HDL-C (not used widely yet)
  - if moderate risk and LDL-C <3.5, treatment decision thresholds shifted to apo B >1.2g/L or non-HDL-C >4.3 mmol/L
  - other targets include: TC:HDLC ratio, apo B:Apo AI ratio, hs-CRP (used more for risk stratification of CAD), non-HDL-C, and serum TG levels

Table 6. Target Lipid Values for Primary Prevention of CAD (2012 Canadian Cholesterol Guidelines)

<table>
<thead>
<tr>
<th>Risk Category</th>
<th>Initiate Treatment if</th>
<th>Primary Targets</th>
<th>Alternate</th>
</tr>
</thead>
<tbody>
<tr>
<td>High (FRS ≥20%)</td>
<td>Consider treatment in all patients</td>
<td>≤2 mmol/L, or ≥50% decrease in LDL-C</td>
<td>apo B &lt;0.80 g/L non HDL-C ≤2.6mmol/L</td>
</tr>
<tr>
<td>Also: AAA, history of DM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For LDL-C ≥3.5 consider if: apo B ≥1.2 g/L or non-HDL-C ≥4.3 mmol/L</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate (FRS 10-19%)</td>
<td>LDL-C ≥3.5 mmol/L</td>
<td>≤2 mmol/L, or ≥50% decrease in LDL-C</td>
<td>apo B ≤0.80 g/L non HDL-C ≤2.6mmol/L</td>
</tr>
<tr>
<td></td>
<td>For LDL-C &lt;3.5 consider if:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low (FRS &lt;10%)</td>
<td>LDL-C ≥5.0 mmol/L</td>
<td>≥50% decrease in LDL-C</td>
<td>Familial hypercholesterolemia LDL-C</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Management

- intensity and type of treatment is guided by “risk category” assigned (see Table 6)

1. health behaviours (can decrease LDL-C by up to 10%)
  - smoking cessation: probably the most important for preventing CAD
  - dietary modification: reduce saturated fat, red meat, refined sugar, alcohol; consume nuts, fruits/vegetables, poultry, fish
  - physical activity: at least 150 min of moderate to vigorous intensity aerobic exercise per wk
  - employ consistent lifestyle modifications for at least 3 mo before considering drug therapy; high risk patients should start treatment immediately with concurrent health behaviour interventions

2. pharmacologic therapy (can decrease LDL-C by up to 40%)
  - for a comparison of dyslipidemia medications, see Endocrinology, E50
  - 1st line monotherapy: statins (HMG-CoA reductase inhibitors)
    - risks: myopathy and hepatotoxicity
    - if severe side effects: ezetimibe (cholesterol absorption inhibitor) can be used for 19% reduction in LDL-C
    - post-ACS, cholesterol absorption inhibitors (e.g. ezetimibe) in addition to simvastatin reduced mortality, attained lipid targets <1.8, and improved outcomes in high risk individuals
    - lower evidence for other agents: bile acid sequestrants, nicotinic acid, fibrates, psyllium
  - monitoring
    - ALT, CK, Cr at baseline then 6 wk later for signs of transaminits or myositis; tolerance rise in CK up to 10 times upper limit of normal vs. 2-3 times if symptomatic, or serum creatinine rise of ≤25%
    - no routine repeated measures of ALT and CK necessary in asymptomatic patients using statin therapy
    - if adequate response is achieved, evaluate fasting lipids q6-12mo

To calculate Framingham Risk Score, go to http://www.framinghamheartstudy.org/riskfunctions/cardiovascular-disease/10-year-risk.php#
Isolated Hypertriglyceridemia
- does not increase your cardiovascular risk
- normal HDL-C and TC, elevated TG
- mild ≥2.2 mmol/L (≥200 mg/dL); marked ≥5.6 mmol/L (≥500 mg/dL)
- principal therapy is lifestyle modification
  - weight loss, exercise, avoidance of smoking and alcohol, effective blood glucose control in diabetics,
    increased omega-3 fatty acid intake
  - severe hypertriglyceridemia (typically >10 mmol/L) is associated with an increased risk of acute
    pancreatitis
- drug therapy (used to prevent pancreatitis, NOT cardiovascular disease!)
  - nicotinic acid
  - fibrates

Exercise

Epidemiology
- 25% of the population exercises regularly, 50% occasionally, 25% are sedentary

Management
- assess current level of fitness, motivation, and access to exercise
- encourage warm up and cool down periods to allow transition between rest and activity and to avoid
  injuries
- exercise with caution for patients with CAD, DM (risk of hypoglycemia), exercise-induced asthma
- patients with known CAD should have cardiac assessment prior to commencing exercise
- benefits of exercise
  - reduces risk of premature death, heart disease, stroke, HTN, certain types of cancer, type 2 DM,
    osteoporosis, and overweight/obesity
  - leads to improved fitness, strength, and mental health (morale and self-esteem)

Table 7. Canadian Physical Activity and Sedentary Behaviour Guidelines (2012 CSEP Guidelines)

<table>
<thead>
<tr>
<th>Age Category</th>
<th>Physical Activity Guidelines</th>
<th>Example Activities</th>
<th>Sedentary Behaviour Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infant (&lt;1y)</td>
<td>Active several times daily</td>
<td>Interactive floor-based play including tummy time, reaching for toys, crawling</td>
<td>Minimize time spent sedentary, including sitting and being restrained (stroller, etc.) Screen time not recommended for infants &lt;1y, limit to &lt;1h/d ages 2-4 apo B &lt;0.80 g/L non HDL-C ≥2.6mmol/L</td>
</tr>
<tr>
<td>Toddler (1-2)</td>
<td>Accumulate 180 min of physical activity at any intensity spread throughout the day</td>
<td>Moving around the home Climbing stairs Exploring environment Brisk walking, running Dancing</td>
<td>apo B &lt;0.80 g/L non HDL-C ≥2.6mmol/L</td>
</tr>
<tr>
<td>Preschool (2-4)</td>
<td>Accumulate 60 min of moderate to vigorous intensity physical activity daily</td>
<td>Vigorous intensity activities at least 3 d per wk Activities that strengthen muscle and bone at least 3 d per wk</td>
<td>Minimize time spent being sedentary Limited recreational screen time no more than 2 h per day   Limit sedentary (motorized) transport, sitting, and time spent indoors</td>
</tr>
<tr>
<td>Children (5-11)</td>
<td>Accumulate 60 min of moderate to vigorous intensity physical activity daily</td>
<td>Moderate: bike riding, playground Vigorous: running, swimming</td>
<td>Minimize time spent being sedentary Limited recreational screen time no more than 2 h per day   Limit sedentary (motorized) transport, sitting, and time spent indoors</td>
</tr>
<tr>
<td>Youth (12-17)</td>
<td>Accumulate 60 min of moderate to vigorous intensity physical activity daily</td>
<td>Vigorous: running, roller blading</td>
<td>Minimize time spent being sedentary Limited recreational screen time no more than 2 h per day   Limit sedentary (motorized) transport, sitting, and time spent indoors</td>
</tr>
<tr>
<td>Adults (18-64)</td>
<td>Accumulate 150 min of moderate to vigorous intensity aerobic physical activity per wk, in bouts of 10 m or more. It is beneficial to add muscle and bone strengthening activities using major muscle groups, at least 2 d per wk</td>
<td>Moderate: brisk walking, bike riding Vigorous: jogging, cross country skiing</td>
<td>No specific guidelines</td>
</tr>
<tr>
<td>Older Adults (65 and older)</td>
<td>Accumulate 150 min of moderate to vigorous intensity aerobic physical activity per wk, in bouts of 10 m or more. It is beneficial to add muscle and bone strengthening activities using major muscle groups, at least 2 d per wk</td>
<td>Moderate: brisk walking, bike riding Vigorous: cross country skiing, swimming Those with poor mobility should perform physical activities to enhance balance and prevent falls</td>
<td>No specific guidelines</td>
</tr>
</tbody>
</table>

Clinical Definition of Metabolic Syndrome
- Central obesity
  - Men – waist circumference ≥94 cm
  - Women – waist circumference ≥80 cm
- Plus any TWO of the following four factors

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Defining Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>TG level</td>
<td>≥1.7 mmol/L (150 mg/dL)</td>
</tr>
<tr>
<td>HDL-C level</td>
<td>Men &lt;1.0 mmol/L (40 mg/dL) Women &lt;1.3 mmol/L (50 mg/dL)</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>≥130/85 mmHg</td>
</tr>
<tr>
<td>Fasting glucose level</td>
<td>≥5.6 mmol/L (100 mg/dL)</td>
</tr>
</tbody>
</table>

Statin-Related Adverse Events: A Meta-Analysis
- Clin Ther 2008;20:26-35
- Study: Meta-analysis of 18 RCTs (N = 71,108) focused on adverse effects of statins
- Patients: Those taking statin monotherapy for primary or secondary prevention of CVD
- Main Outcome: Adverse events (AE) including elevated liver enzymes or myopathy (myalgias, elevated CK, rhabdomyolysis).
- Results: Statin therapy increased the risk of any AE by 39% (OR 1.39, 95% CI 1.09-1.79, p=0.004) compared with placebo. Treating 1,000 patients with a statin would cause 9 AE. Serious events (CK >10 times the upper limit of normal or rhabdomyolysis) are infrequent (NNH 1,400) and rhabdomyolysis, although serious, is rare (NNH 7,428).
- Conclusion: Statin therapy was associated with greater odds of AEs compared with placebo but with substantial clinical benefit. Similar rates of serious AEs were observed between statin and placebo.
Smoking Cessation

Epidemiology
• smoking is the single most preventable cause of premature illness and death
• 70% of smokers see a physician each year
• 2012 Canadian data from the Canadian Tobacco Use Monitoring Survey (CTUMS) on population age ≥15
  ▪ 16% are current smokers (lowest since 1965)
  ▪ highest prevalence in age group 20-24 (20%)
  ▪ 11% of youth age 15-19 smoke (decreased from 25% in 2000): more males smoke than females; number of cigarettes consumed per day also decreasing

Management
• general approach
  ▪ identify tobacco users; elicit smoking habits, previous quit attempts and results
  ▪ CAN-ADAPTT 2012 guidelines
    • tobacco use status should be updated for all patients regularly (Grade 1A)
    • health care providers should clearly advise patients to quit (Grade 1C)
    • health care providers should also monitor the patient’s mental health status/other addictions while quitting smoking. Medication dosage should be monitored and adjusted as necessary (Grade 1A)
  ▪ every smoker should be offered treatment
    • combining counselling and smoking cessation medication is more effective than either alone (Grade 1A)
    • make patient aware of withdrawal symptoms
      • low mood, insomnia, irritability, anxiety, difficulty concentrating, restlessness, decreased heart rate, increased appetite
    • ≥4 counselling sessions >10 min each with 6-12 mo follow-up yields better results
    • 14% abstinent with counselling vs. 10% without counselling
    • approach depends on patient’s stage of change (see Motivational Strategies for Behavioural Change, FM6)
• willing to quit
  ▪ provision of social support, community resources (self-help, group, helpline, web-based strategies)
  ▪ pregnant patients: counselling is recommended as 1st line treatment (Grade 1A). Nicotine replacement therapy (NRT) should be made available to pregnant women who are unable to quit using non-pharmacologic methods; intermittent NRT use (lozenges, gum) is preferred over continuous dosing of the patch (Grade 1C). Use bupropion (no evidence of fetal or reproductive harm) only if benefits > risks; consult Motherisk. Varenicline has not been studied in pregnancy and should not be used in pregnant women
• pharmacologic therapy
  1. Nicotine Replacement Therapy
    • 19.7% abstinent at 12 mo with NRT vs. 11.5% for placebo
    • no difference in achieving abstinence for different forms of NRT
    • reduces cravings and withdrawal symptoms without other harmful substances that are contained in cigarettes
    • use with caution: immediately post-MI, serious/worsening angina, serious arrhythmia
    • advise NO smoking while using NRT
  2. Antidepressants (note: mode of action appears to be independent of antidepressant effect)
    • Bupropion SR (Zyban®)
      • 21% abstinent at 12 mo vs. 8% for placebo
      • no advantage for NRT vs. bupropion (similarly effective)
    3. Varenicline (Champix®)
      • partial nicotinic receptor agonist (to reduce cravings) and partial competitive nicotinic receptor antagonist (to reduce the response to smoked nicotine)
      • more effective than bupropion (23% abstinent from 9-52 wk with varenicline vs. 16% for bupropion vs. 9% with placebo)
      • significant side effects may lower patient compliance

Table 8. Types of Nicotine Replacement Therapy

<table>
<thead>
<tr>
<th>Type</th>
<th>Dosage</th>
<th>Comment</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicotine Gum (OTC)</td>
<td>2 mg if &lt; 25 cig/d</td>
<td>Chew until “peppery” taste than “park”</td>
<td>Mouth soreness</td>
</tr>
<tr>
<td></td>
<td>4 mg if ≥25 cig/d</td>
<td>between gum and cheek to facilitate absorption</td>
<td>Hiccups</td>
</tr>
<tr>
<td></td>
<td>1 piece q1-2h for 1-3 mo</td>
<td>Continue to chew-park intermittently</td>
<td>Dysepsia</td>
</tr>
<tr>
<td></td>
<td>(max 24 pieces/d)</td>
<td>for 30 min</td>
<td>Jaw ache</td>
</tr>
<tr>
<td>Nicotine Patch (OTC)</td>
<td>Use for 8 wk</td>
<td>Start with lower dose if &lt; 10 cig/d</td>
<td>Most are transient</td>
</tr>
<tr>
<td></td>
<td>21 mg/d x 4 wk</td>
<td>Change patch q2h and alternate sides</td>
<td>Skin irritation</td>
</tr>
<tr>
<td></td>
<td>14 mg/d x 2 wk</td>
<td></td>
<td>Insomnia</td>
</tr>
<tr>
<td></td>
<td>7 mg/d x 2 wk</td>
<td></td>
<td>Palpitations</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Anxiety</td>
</tr>
<tr>
<td>Nicotine Inhaler (OTC)</td>
<td>6-16 cartridges/d</td>
<td>Nicotine inhaled through mouth, absorbed in</td>
<td>Local irritation</td>
</tr>
<tr>
<td></td>
<td>for up to 12 wk</td>
<td>mouth and throat not in lungs</td>
<td>Coughing</td>
</tr>
<tr>
<td>Nicotine Nasal Spray (Rx)</td>
<td>Newer form of NRT</td>
<td></td>
<td>Local irritation, coughing</td>
</tr>
</tbody>
</table>

Physician Advice for Smoking Cessation
Cochrane DB Syst Rev 2013;5:CD0000185
This systematic review of 17 trials compared brief advice by the physician versus no advice.
Conclusions: Simple advice can increase cessation rates by 1%. More intensive advice and providing follow-up support may further increase the quit rates.

The 5 A’s for Patients Willing to Quit
Ask if the patient smokes
 Advise patients to quit
 Assess willingness to quit
 Assist in quit attempt
 Arrange follow-up

The 2-3 Pattern of Smoking Cessation
- Onset of withdrawal is 2-3 h after last cigarette
- Peak withdrawal is at 2-3 d
- Expect improvement of withdrawal symptoms at 2-3 wk
- Resolution of withdrawal at 2-3 mo
- Highest relapse rate within 2-3 mo

Assist Patient in Developing Quit Plan
STAR
Set quit date
Tell family and friends (for support)
Anticipate challenges (e.g. withdrawal)
Remove tobacco-related products (e.g. ashtrays/lighters)

Antidepressants for Smoking Cessation
Cochrane DB Syst Rev 2014;1:CD0000031
This systematic review of 90 randomized trials compared antidepressant medication to placebo or alternative pharmacotherapy for smoking cessation and where follow-up was longer than 6 mo.
Conclusions: The antidepressants bupropion and nortriptyline can aid smoking cessation and have a similar efficacy to NRT. Bupropion is less effective than varenicline. Neither SSRIs (e.g. fluoxetine) nor MAOIs aid smoking cessation.

Nicotine Replacement Therapy for Smoking Cessation
Cochrane DB Syst Rev 2012;11:CD0000146
This systematic review of 132 randomized trials compared NRT to placebo or no treatment or compared different NRT doses.
Conclusions: All commercially available forms of NRT (gum, transdermal patch, nasal spray, inhaler, and sublingual tablets/lozenges) are effective as part of a strategy to promote smoking cessation. They increase the rate of quitting by 50-70% regardless of setting and independent on the level of additional support provided to the smoker. Compared to a single form of NRT, combining a nicotine patch with a rapid delivery form of NRT may be more effective.
### Table 9. Pharmacologic Treatments for Smoking Cessation

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mechanism</th>
<th>Dosage</th>
<th>Prescribing*</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bupropion</td>
<td>Inhibits re-uptake of dopamine and/or norepinephrine, competitive antagonist</td>
<td>1. 150 mg qAM x 3 d 2. Then 150 mg bid x 7-12 wk 3. For maintenance consider 150 mg bid for up to 6 mo</td>
<td>1. Decide on a quit date 2. Continue to smoke for first 1-2 wk of treatment and then completely stop (therapeutic levels reached in 1 wk)</td>
<td>Seizure disorder  Eating disorder  MAOI use in past 14 d  Simultaneous use of bupropion (Wellbutrin®) for depression</td>
</tr>
<tr>
<td>Varenicline</td>
<td>Partial nicotinic receptor agonist, and partial nicotinic receptor antagonist</td>
<td>1. 0.5 mg qAM x 3 d 2. Then 0.5 mg bid x 4 d 3. Continue 1 mg bid x 12 wk ± additional 12 wk as maintenance</td>
<td>1. Decide on a quit date 2. Continue to smoke for first wk of treatment and then completely stop</td>
<td>Caution with pre-existing psychiatric condition</td>
</tr>
</tbody>
</table>

*Bupropion and Varenicline may be used in combination with nicotine replacement therapy

- unwilling to quit
  - motivational intervention (5 Rs)
    1. Relevance to patient
      - relevant to patient's disease status or risk, family or social situation (e.g. having children in the home), health concerns, age, gender
    2. Risks of smoking
      - short-term: SOB, asthma exacerbation, impotence, infertility, pregnancy complications, heartburn, URTI
      - long-term: MI, stroke, COPD, lung CA, other cancers
      - environmental: higher risk in spouse/children for lung CA, SIDS, asthma, respiratory infections
    3. Rewards: benefits
      - improved health, save money, food tastes better, good example to children
    4. Roadblocks: obstacles
      - fear of withdrawal, weight gain, failure, lack of support
    5. Repetition
      - reassure unsuccessful patients that most people try many times before successfully quitting (average number of attempts before success is 7)

- recent quitter
  - highest relapse rate within 3 mo of quitting
  - minimal practice: congratulate on success, encourage ongoing abstinence, review benefits and problems
  - prescriptive interventions: address problem of weight gain, negative mood, withdrawal, lack of support

### Alcohol

- see Psychiatry, PS23

#### Definition
- diagnostic categories occur along a continuum

#### Epidemiology
- 10-15% of patients in family practice are problem drinkers
- 20-50% of hospital admissions, 10% of premature deaths, 30% of suicides, and 50% of fatal traffic accidents in Canada are alcohol-related
- more likely to miss diagnosis in women or elderly, patients with high socioeconomic status

#### Assessment
- screen for alcohol dependence with CAGE questionnaire
  - if CAGE positive, explore with further questions for alcohol abuse/dependence
  - assess drinking profile
    - setting, time, place, occasion, with whom
    - impact on: family, work, social
    - quantity-frequency history
      - how many drinks per day?
      - how many days per week?
      - maximum number of drinks on any one day in the past month

**Standard Drink Equivalents**
- One standard drink = 14 g of pure alcohol
  - Beer (5% alcohol) = 12 oz
  - Wine (12-17% alcohol) = 5 oz
  - Fortified wine = 3 oz
  - Hard liquor (40%) = 1.5 oz

**CAGE Questionnaire**
- Have you ever felt the need to CUT down on your drinking?
- Have you ever felt ANNOYED at criticism of your drinking?
- Have you ever felt GUILTY about your drinking?
- Have you ever had a drink first thing in the morning to steady your nerves or get rid of a hangover? (EYE OPENER)
- A cut-off of 2 for men or 1 for women suggests possibility of problem drinking (sensitivity 85%, specificity 89%)
• if identified positive for alcohol problem
  ■ screen for other drug use
  ■ identify medical/psychiatric complications
  ■ ask about drinking and driving
  ■ ask about past recovery attempts and current readiness for change

Investigations
• GGT and MCV for baseline and follow-up monitoring
• AST, ALT (usually AST:ALT approaches 2:1 in an alcoholic)
• CBC (anemia, thrombocytopenia), INR (decreased clotting factor production by liver)

Management
• intervention should be consistent with patient's motivation for change
• individualized counselling and regular follow-up is crucial
• 10% of patients in alcohol withdrawal will have seizures or delirium tremens
• Alcoholics Anonymous/12-step program
  ■ outpatient/day programs for those with chronic, resistant problems
  ■ family treatment (Al-Anon, Alateen, screen for spouse/child abuse)
• in-patient program if
  ■ dangerous or highly unstable home environment
  ■ severe medical/psychiatric problem
  ■ addiction to drug that may require in-patient detoxification
  ■ refractory to other treatment programs
• pharmacologic
  ■ diazepam for withdrawal
  ■ disulfiram (Antabuse®): impairs metabolism of alcohol by blocking conversion of acetaldehyde to acetic acid, leading to flushing, headache, N/V, hypotension if alcohol is ingested (available in U.S., but no longer available in Canada)
  ■ naltrexone: competitive opioid antagonist that reduces cravings and pleasurable effects of drinking
  ■ may trigger withdrawal in opioid-dependent patients
  ■ acamprosate: glutamate receptor modulator that also reduces craving
• see Psychiatry, PS23

Prognosis
• relapse is common and should not be viewed as failure
• monitor regularly for signs of relapse
• 25-30% of abusers exhibit spontaneous improvement over 1 yr
• 60-70% of individuals with jobs and families have an improved quality of life 1 yr post-treatment

Common Presenting Problems

Abdominal Pain

• see Gastroenterology, G11 and General Surgery, GS4

Epidemiology
• 20% of individuals have experienced abdominal pain within the last 6-12 mo
• 90% resolve in 2-3 wk
• only 10% are referred to specialists, of those <10% admitted to hospital

Etiology
• most common diagnosis in family medicine at 28% is "nonspecific abdominal pain," which has no identifiable cause and is usually self-limited
• GI disorders (e.g. PUD, pancreatitis, IBD, appendicitis, gastroenteritis, IBS, diverticular disease, biliary tract disease)
• urinary tract disorders (e.g. UTI, renal calculi)
• gynecological disorders (e.g. PID, ectopic pregnancy, endometriosis)
• cardiovascular disorders (e.g. CAD, AAA, ischemic bowel)
• other: DKA, porphyria, hypercalcemia, medications (e.g. NSAIDs), alcohol, toxic ingestion, foreign body, psychogenic

Some Adverse Medical Consequences of Problem Drinking
• GI: gastritis, dyspepsia, pancreatitis, liver disease, bleeds, diarrhea, oral esophageal cancer
• Cardiac: HTN, alcoholic cardiomyopathy
• Neurologic: Wernicke-Korsakoff syndrome, peripheral neuropathy
• Hematologic: anemia, coagulopathies
• Other: trauma, insomnia, family violence, anxiety/depression, social/family dysfunction, sexual dysfunction, fetal damage

Abstinence

Low Risk Drinking
<2 drinks/d
<10 drinks/wk for women
<15 drinks/wk for men

At Risk Drinking
Consumption above low-risk level but no alcohol-related physical or social problems

Alcohol Use Disorder
Physical or social problems
Continued use despite consequences
Inability to fulfill life roles
Legal problems
No evidence of dependence

Alcohol Use Disorder

Figure 5. Continuum of alcohol use

If pain precedes nausea/vomiting, cause of abdominal pain is more likely to be surgical
Pathophysiology
- Type of pain
  - Somatic pain: sharp, localized pain
  - Visceral pain: dull, generalized pain
- Location of pain
  - Epigastric (foregut): distal esophagus, stomach, proximal duodenum, biliary tree, pancreas, liver
  - RUQ: biliary, hepatic, colonic, pulmonary, renal
  - LIQ: cardiac, gastric, pancreatic, renal, vascular
  - Periumbilical (midgut): distal duodenum to proximal 2/3 of transverse colon
  - Hypogastric (hindgut): distal 1/3 of transverse colon to rectosigmoid region
  - RLQ: colonic, appendix, gynecologic, renal
  - LLQ: colonic, gynecologic, renal
  - Any location: aneurysm, dissection, ischemia, zoster, muscle strain, hernia, bowel obstruction, ischemia, peritonitis, porphyria, DKA

Investigations
- Guided by findings on history and physical
- Possible blood work: CBC, electrolytes, BUN, Cr, amylase, lipase, AST, ALT, ALP, bilirubin, glucose, INR/PTT, tox screen, β-hCG
- Imaging
  - CXR (for free air under the diaphragm) in setting of perforation in surgical abdomen
  - Abdominal x-ray, KUB (consider: gas pattern, free air, kidney stones, constipation)
  - Ultrasound (renal stones, gallbladder disease, gynecological problems, liver disease, pancreatitis, diverticular disease, appendicitis)
  - CT scan (AAA, appendicitis), non-contrast helical CT-Scan (first choice for renal stones)
- Other tests
  - Urinalysis
  - Endoscopy (for peptic ulcers, gastritis, tumours, etc.)
  - H. pylori testing (urea breath test, serology, biopsy)

Allergic Rhinitis
- See Otolaryngology, OT23

Definition
- Inflammation of the nasal mucosa that is triggered by an allergic reaction
- Classification
  - Seasonal
    - Symptoms during a specific time of the year
    - Common allergens: trees, grass and weed pollens, airborne moulds
  - Perennial
    - Symptoms throughout the year with variation in severity
    - Common allergens: dust mites, animal dander, moulds
- Persistent allergic rhinitis may lead to chronic rhinosinusitis

Etiology
- Increased IgE levels to certain allergens → excessive degranulation of mast cells → release of inflammatory mediators (e.g. histamine) and cytokines → local inflammatory reaction

Epidemiology
- Affects approximately 40% of children and 20-30% of adults
- Prevalence has increased in developed countries, particularly in the past two decades
- Associated with asthma, eczema, sinusitis, and otitis media

Assessment
- Identify allergens
- Take an environmental/occupational history
- Ask about related conditions (e.g. atopic dermatitis, asthma, sinusitis, and family history)

Management
- Conservative
  - Minimize exposure to allergens
  - Most important aspect of management, often sufficient (may take months)
  - Maintain hygiene, saline nasal rinses
- Pharmacologic agents
  - Oral antihistamines → first line therapy for mild symptoms
    - E.g. cetirizine (Reactine®), fexofenadine (Allegra®), loratadine (Claritin®)
  - Intranasal corticosteroids for moderate/severe or persistent symptoms (>1 mo of consistent use to see results)
  - Intranasal decongestants (use must be limited to <5 d to avoid rhinitis medicamentosa)
- allergy skin testing
  - for patients with chronic rhinitis
  - symptoms not controlled by allergen avoidance, pharmacological therapy
  - may identify allergens to include in immunotherapy treatment
- immunotherapy (allergy shots)
  - reserved for severe cases unresponsive to pharmacologic agents
  - consists of periodic (usually weekly) subcutaneous injections of custom prepared solutions of one or more antigens to which the patient is allergic

**Amenorrhea**

- see Gynecology, GY10

**Anxiety**

- see Psychiatry, PS13

**Epidemiology**

- 25-30% of patients in primary care settings have psychiatric disorders
- many are undiagnosed or untreated; hence the need for good screening
- high rate of coexistence of anxiety disorders and depression

**Screening**

- screening tools such as the GAD-7 tool
- screening questions
  - Do you tend to be an anxious or nervous person?
  - Have you felt unusually worried about things recently?
  - Has this worrying affected your life? How?

**Assessment**

- associated symptoms
- risk factors
  - family history of anxiety or depression, past history of anxiety, stressful life event, social isolation, female, comorbid psychiatric diagnosis (e.g. depression)
  - assess substance abuse, comorbid depression, stressful life events, trauma, suicidal ideation/self-harm
- to differentiate anxiety disorders, consider symptoms (panic attacks, specific situations/stressors, excessive worry about common concerns, repetitive thoughts and/or behaviours to neutralize the anxiety) and their duration
- Generalized Anxiety Disorder 7-item (GAD – 7) scale to assess level of anxiety

**Symptoms of GAD**

- ANXIOUS, NERVOUS, OR WORRIED
- NO CONTROL OVER THE WORRY
- DURATION > 6 MONTHS
- INABILITY
- CONCENTRATION IMPAIRMENT
- RESTLESSNESS
- ENERGY DECREASED
- SLEEP IMPAIRMENT

**Differential Diagnosis of Anxiety Disorders**

- Panic disorder
- GAD
- Social Anxiety Disorder (previously Social Phobia)
- Agoraphobia
- Specific phobia
- Selective Mutism
- Separation Anxiety Disorder
- Other: GMC, AMC, mood disorder, psychotic disorder, OCD, PTSD

**Rule Out**

- Cardiac (post MI, arrhythmias)
- Endocrine (hyperthyroidism, diabetes, pheochromocytoma)
- Respiratory (asthma, COPD)
- Somatoform disorders
- Psychotic disorders
- Mood disorders (depression, bipolar)
- Personality disorder (COPD)
- Drugs (amphetamine, thyroid preparations, caffeine, OTC for colds/decongestants, alcohol/benzodiazepine withdrawal)

---

**Figure 6. Differentiating anxiety disorders**
Management
• patient education: emphasize prevalence, good recovery rate of anxiety conditions
• lifestyle advice: decrease caffeine and alcohol intake, exercise, relaxation techniques, mindfulness strategies
• self-help materials, community resources (e.g. support groups)
• CBT: cognitive interventions, exposure therapy, etc.
• treat any underlying medical and/or comorbid conditions
• provide support to family and caregivers
• for pharmacotherapy, see Psychiatry, PS48

Asthma/COPD

Definition
• asthma
  ▪ chronic, reversible airway inflammation characterized by periodic attacks of wheezing, SOB, chest tightness, and coughing
  ▪ airways hyper-responsive to triggers/antigens leading to acute obstructive symptoms by bronchoconstriction, mucus plugs and increased inflammation
  ▪ cannot be diagnosed at first presentation; called reactive airway disease until recurrent presentations
  ▪ pulmonary function tests (PFTs) can be done from age 6 or when child able to follow instructions to do PFTs
  ▪ peak flow meters are useful in the office and at home for monitoring
• chronic obstructive pulmonary disease (COPD)
  ▪ group of chronic, progressive, non-reversible lung diseases characterized by limited airflow with variable degrees of air sac enlargement and lung tissue destruction
  ▪ emphysema and chronic bronchitis are the most common forms

Table 10. Differentiating COPD from Asthma

<table>
<thead>
<tr>
<th>COPD</th>
<th>Asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age of Onset</strong></td>
<td>Usually in 6th decade</td>
</tr>
<tr>
<td><strong>Role of Smoking</strong></td>
<td>&gt;10 pack yr</td>
</tr>
<tr>
<td><strong>Reversibility of Airflow Obstruction</strong></td>
<td>Airflow obstruction is chronic and persistent</td>
</tr>
<tr>
<td><strong>Evolution</strong></td>
<td>Slow, progressive worsening (with periodic exacerbations)</td>
</tr>
<tr>
<td><strong>History of Allergy</strong></td>
<td>Infrequent</td>
</tr>
<tr>
<td><strong>Precipitators</strong></td>
<td>Environmental irritants (air pollution), cigarette smoking, a-1 antitrypsin deficiency, viral infection, occupational exposure (firefighters, dusty jobs)</td>
</tr>
<tr>
<td><strong>Symptoms/Signs</strong></td>
<td>Chronic cough, sputum, and/or dyspnea</td>
</tr>
<tr>
<td><strong>Diffusion Capacity</strong></td>
<td>Decreased (more so in pure emphysema)</td>
</tr>
<tr>
<td><strong>Hypoxemia</strong></td>
<td>Chronic in advanced stages</td>
</tr>
<tr>
<td><strong>Spirometry</strong></td>
<td>May have improvement with bronchodilators but not universally seen</td>
</tr>
<tr>
<td><strong>Chest X-Ray</strong></td>
<td>Often normal</td>
</tr>
<tr>
<td></td>
<td>Increased bronchial markings (chronic bronchitis) and chronic hyperinflation (emphysema) often co-exist, bullae</td>
</tr>
</tbody>
</table>

Management
• Mild
  • Step 1: SABA prn (salbutamol)
  • Step 2: SABA prn + LAAC (i.e. tiotropium) or LABA (e.g. salmeterol)
• Moderate
  • Step 3: SABA prn + LAAC + low-dose combined ICS/LABA; consider inhaled vs. oral steroids
• Severe
  • Step 4: ± theophylline

Pneumococcal vaccination, annual influenza immunization

Ongoing patient education, and environmental control SABA taken prn as rescue medication + maintenance meds

Maintenance medications

Step 1: Low-dose ICS

Step 2: Medium/high-dose ICS or low-dose ICS plus either LABA, LT modifier, or long-acting theophylline

Step 3: Medium/high-dose ICS plus either LABA, LT modifier, or long-acting theophylline

As above plus immunotherapy ± oral glucocorticosteroids + pneumococcal vaccination, annual influenza immunization

ICS = inhaled corticosteroids; LAAC = long-acting anticholinergic; LABA = long-acting β-agonist; LT modifier = leukotriene modifier; SABA = short-acting β-agonist

---

**Figure 7. Expiratory flow volume curves (obstructive, normal, and restrictive disease)**

See Respirology, R7 Adapted from: Weinberger SE. Principles of pulmonary medicine, 5th ed. With permission from Elsevier. ©2008

**Signs of Poorly Controlled Asthma**
• S2 agonist use >4x/wk
• Asthma-related absence from work/school
• Exercise induced asthma
• Night-time symptoms >1x/wk

**What Colour is Your Inhaler?**

<table>
<thead>
<tr>
<th>Name</th>
<th>Body/Cap Colour</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-agonists</td>
<td></td>
</tr>
<tr>
<td>Salbutamol − Ventolin®</td>
<td>light blue/navy</td>
</tr>
<tr>
<td>Salmeterol − Serenvent®</td>
<td>teal/light teal</td>
</tr>
<tr>
<td>Terbutaline − Brinycyl®</td>
<td>blue/white</td>
</tr>
<tr>
<td>β-Agonists</td>
<td></td>
</tr>
<tr>
<td>Fluticasone − Flovent®</td>
<td>orange/peach</td>
</tr>
<tr>
<td>Budesonide − Pulmicort®</td>
<td>white/brown</td>
</tr>
<tr>
<td>Combined Long-Acting β-Agonist + ICS</td>
<td>purple discus</td>
</tr>
<tr>
<td>Fluticasone/Salmeterol − Advair®</td>
<td></td>
</tr>
<tr>
<td>Budesonide/Formoterol − Symbricort®</td>
<td>red/white</td>
</tr>
<tr>
<td>Ipratropium/Albuterol − Combivent®</td>
<td>clear/orange</td>
</tr>
<tr>
<td>Anticholinergics</td>
<td></td>
</tr>
<tr>
<td>Ipratropium − Atrovent®</td>
<td>clear/green</td>
</tr>
<tr>
<td>Tiotropium − Spiriva®</td>
<td>white/turquoise</td>
</tr>
</tbody>
</table>

**More About Inhalers**
• Aerosols (puffers=MDI,MDI + spacer) MDIs should be used with spacers to:
  • Reduce side effects
  • Improve amount inhaled
  • Increase efficiency of use
• Dry Powder Inhalers (discus, turbuhaler, and diskhaler) require deep and fast breathing (may not be ideal for children)
• Nebulizers can be used to convert liquid medications into a fine mist: recommended for use if contraindications to MDIs

**Differential Diagnosis of Wheezing**
• Allergies, anaphylaxis
• Asthma, reactive airway disease
• GERD
• Infections (bronchitis, pneumonia)
• Obstructive Sleep Apnea
• COPD
• Less common: congestive heart disease, foreign body, malignancy, cystic fibrosis, vocal cord dysfunction

When prescribing salbutamol, watch out for signs of hypokalemia: lethargy, irritability, paresthesias, myalgias, weakness, palpitations, NV, polyuria
Benign Prostatic Hyperplasia

- see Urology, U7

Definition
- hyperplasia of the stroma and epithelium in the periurethral transition zone

History and Physical
- include current/past health, surgeries, trauma, current and OTC meds
- specific urinary symptoms
- physical exam must include DRE for size, symmetry, nodularity, and texture of prostate (prostate is symmetrically enlarged, smooth, and rubbery in BPH)

Investigations
- urinalysis to exclude UTI and for microscopic hematuria (common sign)
- serum PSA: protein produced by prostatic tissue
  - values
    - <4.0 ng/mL: normal, but must take into account patient's age and velocity of PSA increase
    - 4-10 ng/mL: consider measuring free/total PSA
    - >10 ng/mL: high likelihood of prostate pathology
- PSA testing is inappropriate in men with a life expectancy less than 10 yr or patients with prostatitis, UTI
- increased PSA in a younger man is more often due to cancer than other causes
- abnormal DRE or PSA should trigger further assessment
- discuss test with men at increased risk of prostate cancer (FHx, African ancestry) or who are concerned about development of prostate cancer
- decision to test PSA in an asymptomatic man should involve discussion about the risks and possible benefits
- other tests
  - Cr, BUN
  - post-void residual volume by ultrasound
  - urodynamic studies, renal ultrasound
  - patient voiding diary
- tests NOT recommended as part of routine initial evaluation include:
  - cystoscopy
  - cytology
  - prostate ultrasound or biopsy
  - IVP
  - urodynamic studies

Table 11. Symptoms and Complications of BPH

<table>
<thead>
<tr>
<th>Obstructive Symptoms</th>
<th>Irritative Symptoms</th>
<th>Late Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hesitancy (difficulty starting urine flow)</td>
<td>Urgency</td>
<td>Hydronephrosis</td>
</tr>
<tr>
<td>Diminution in size and force of urinary stream</td>
<td>Frequency</td>
<td>Loss of renal concentrating ability</td>
</tr>
<tr>
<td>Stream interruption (double voiding)</td>
<td>Nocturia</td>
<td>Systemic acidosis</td>
</tr>
<tr>
<td>Urinary retention (bladder does not feel completely empty)</td>
<td>Urge incontinence</td>
<td>Renal failure</td>
</tr>
<tr>
<td>Post-void dribbling</td>
<td>Dysuria</td>
<td></td>
</tr>
<tr>
<td>Overflow incontinence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nocturia</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Management
- referral to urologist if moderate/severe symptoms
  - conservative: for patients with mild symptoms or moderate/severe symptoms considered by the patient to be non-bothersome
    - fluid restriction (avoid alcohol and caffeine)
    - avoidance/monitoring of certain medications (e.g. antihistamines, diuretics, antidepressants, decongestants)
    - pelvic floor/Kegel exercises
    - bladder retraining (scheduled voiding)
- pharmacological: for moderate/severe symptoms
  - α-receptor antagonists (e.g. terazosin [Hytrin®], doxazosin [Cardura®], tamsulosin [Flomax®], alfuzosin [Xatral®])
  - relaxation of smooth muscle around the prostate and bladder neck
  - 5-α reductase inhibitor (e.g. finasteride [Proscar®])
  - only for patients with demonstrated prostatic enlargement due to BPH
  - inhibits enzyme responsible for conversion of testosterone into dihydrotestosterone (DHT) thus reducing growth of prostate
  - phytotherapy (e.g. saw palmetto berry extract, Pygeum africanum)
- more studies required before this can be recommended as standard therapy
  - considered safe
• surgical
  ■ TURP (transurethral resection of the prostate), TUIP (transurethral incision of the prostate, for prostates <30 g)
  ■ absolute indications: failed medical therapy, intractable urinary retention, benign prostatic obstruction leading to renal insufficiency
  ■ complications: impotence, incontinence, ejaculatory difficulties (retrograde ejaculation), decreased libido

### Bronchitis (Acute)

**Definition**
- acute infection of the tracheobronchial tree causing inflammation leading to bronchial edema and mucus formation

**Epidemiology**
- 5th most common diagnosis in family medicine, most common is URTI

**Etiology**
- 80% viral: rhinovirus, coronavirus, adenovirus, influenza, parainfluenza, respiratory syncytial virus (RSV)
- 20% bacterial: *M. pneumoniae, C. pneumoniae, S. pneumoniae*

**Investigations**
- sputum culture/gram stain is not useful
- CXR if suspect pneumonia (cough > 3 wk, abnormal vital signs, localized chest findings) or CHF
- PFT with methacholine challenge if suspect asthma

**Management**
- primary prevention: frequent hand washing, smoking cessation, avoid irritant exposure
- symptomatic relief: rest, fluids (3-4 L/d when febrile), humidity, analgesics and antitussives as required
- bronchodilators may offer improvement of symptoms (e.g. salbutamol)
- current literature does not support routine antibiotic treatment for the management of acute bronchitis because it is most likely to be caused by a viral infection
  - antibiotics may be useful if elderly, comorbidities, suspected pneumonia, or if the patient is toxic (see [Antimicrobial Quick Reference, FM49](#))
  - antibiotics in children show no benefit

### Chest Pain

- see [Cardiology and Cardiac Surgery, C4 and Emergency Medicine, ER21](#)

**Differential Diagnosis**

<table>
<thead>
<tr>
<th>Cardiac</th>
<th>Pulmonary</th>
<th>GI</th>
<th>MSK/Neuro</th>
<th>Psychologic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angina*</td>
<td>Hemorrhax*</td>
<td>Cholezystitis</td>
<td>Arthritis</td>
<td>Anxiety</td>
</tr>
<tr>
<td>Aortic dissection*</td>
<td>Lung CA</td>
<td>Esophageal spasm</td>
<td>Costochondritis</td>
<td>Depression</td>
</tr>
<tr>
<td>Endocarditis</td>
<td>PE*</td>
<td>GERD</td>
<td>Herpes zoster</td>
<td>Panic</td>
</tr>
<tr>
<td>MI*</td>
<td>Pneumonia*</td>
<td>Hepatitis</td>
<td>Intercostal strain</td>
<td></td>
</tr>
<tr>
<td>Myocarditis</td>
<td>Perforated viscus*</td>
<td>PUD</td>
<td>Rib fractures</td>
<td></td>
</tr>
<tr>
<td>Pericarditis*</td>
<td>Pulmonary HTN</td>
<td>]</td>
<td>Trauma</td>
<td></td>
</tr>
</tbody>
</table>

**Investigations**
- ECG, CXR, and others if indicated (cardiac enzymes, d-dimers, liver function tests [LFTs], etc.)
- refer to ED if suspect serious etiology (e.g. aortic dissection, MI)

**Management of Common Causes of Chest Pain**
- angina/ischemic heart disease
  - nitroglycerin (NTG): wait 5 min between sprays and if no effect after 3 sprays, send to ED
  - myocardial infarction
    - ASA (160-325 mg, chewed stat), clopidogrel (Plavix*), LMWH (enoxaparin), morphine, oxygen, NTG
    - ± reperfusion therapy with fibrinolitics (e.g. tPA, RPA, TNK, or SK) if within 12h (ideally <30 min) or percutaneous intervention (cath lab) if <90 min
    - start β-blocker (e.g. metoprolol starting dose 25 mg PO q6h or bid, titrating to HR goal of 55-60 bpm)
  - endocarditis: antibiotic choice is based on whether patient has a native or prosthetic heart valve as well as culture and sensitivity results
  - GERD: antacids, H₂-blockers, PPIs, patient education
  - costochondritis: NSAIDs

**Treatment of Stable Ischemic Heart Disease**
- see [Cardiology and Cardiac Surgery, C27](#)

**Risk Factors for CAD**
- Major
  - Smoking
  - Diabetes
  - HTN
  - Hyperlipidemia
  - Family history of early CAD in first degree relative (males <55 yr, females <65 yr)
  - Untreated obstructive sleep apnea
  - Chronic kidney disease
- Minor
  - Obesity
  - Sedentary lifestyle
  - Age
**Common Cold (Acute Rhinitis)**

- **Definition**
  - viral URTI with inflammation

- **Epidemiology**
  - most common diagnosis in family medicine, peaks in winter months
  - incidence: adults = 2-4/yr, children = 6-10/yr
  - organisms
    - mainly rhinoviruses (30-35% of all colds)
    - others: coronavirus, adenovirus, RSV, influenza, parainfluenza, coxsackie virus
  - incubation: 1-5 d
  - transmission: person-person contact via secretions on skin/objects and by aerosol droplets

- **Risk Factors**
  - psychological stress, excessive fatigue, allergic nasal/oropharyngeal disorders, smoking, sick contacts

- **Clinical Features**
  - symptoms
    - local: nasal congestion, clear to mucopurulent secretions, sneezing, sore throat, conjunctivitis, cough
    - general: malaise, headache, myalgias, mild fever
  - signs
    - erythematous nasal/oropharyngeal mucosa, enlarged lymph nodes
  - complications
    - secondary bacterial infection: otitis media, sinusitis, bronchitis, pneumonia
    - asthma/COPD exacerbation

- **Differential Diagnosis**
  - allergic rhinitis, pharyngitis, influenza, laryngitis, croup, sinusitis, bacterial infections

- **Management**
  - patient education
    - symptoms peak at 1-3 d and usually subside within 1 wk
    - cough may persist for days to weeks after other symptoms disappear
    - no antibiotics indicated because of viral etiology
    - secondary bacterial infection can present within 3-10 d after onset of cold symptoms
  - prevention
    - frequent hand washing, avoidance of hand to mucous membrane contact, use of surface disinfectant
    - yearly influenza vaccination
  - symptomatic relief
    - rest, hydration, gargling warm salt water, steam, nasal irrigation (spray/pot)
    - analgesics and antipyretics: acetaminophen, ASA (not in children because risk of Reye’s syndrome)
    - cough suppression: dextromethorphan or codeine if necessary (children under 6 yr of age should not use any cough/cold medications)
    - decongestants, antihistamines
  - patients with reactive airway disease will require increased use of bronchodilators and inhaled steroids

**Concussion/Mild Traumatic Brain Injury**

- **Definition**
  - a useful tool for the assessment of individuals and athletes with concussion is the Sport Concussion Assessment Tool, 3rd edition (SCAT3), Br J Sports Med 2013 47: 259

**Contraception**

- **Definition**
  - see Gynecology, FY16

- **Emergency Contraception**
  - hormonal EC (Yuzpe® or Plan B®, usually 2 doses taken 12 h apart) or post-coital copper IUD insertion
  - hormonal EC is effective if taken within 72 h of unprotected intercourse (reduces chance of pregnancy by 75-85%), most effective if taken within 24 h, does not affect an established pregnancy
  - copper IUDs inserted within 5 d of unprotected intercourse are significantly more effective than hormonal EC (reduces chance of pregnancy by ~99%)
  - pregnancy test should be performed if no menstrual bleeding within 21 d of either treatment
  - advance provision of hormonal EC increases the use of EC without decreasing the use of regular contraception
  - pharmacists across Canada can dispense Plan B® OTC
Cough

History and Physical
- duration (chronic - 8 wk), onset, frequency, quality (dry vs. productive), sputum characteristics, provoking/relieving factors, recent changes
- associated symptoms: fever, dyspnea, hemoptysis, wheezing, chest pain, orthopnea, PND, rhinitis, reflux, post-nasal drip
- constitutional symptoms: fever, chills, fatigue, night sweats
- risk factors: smoking, occupation, exposure, family history of lung CA or other CA, TB status, recent travel
- medications (e.g. ACEI, β-blockers), allergies
- PMH: lung (asthma, COPD, CF), heart (CHF, MI, arrhythmias), chronic illness, GI (reflux)
- vitals including O₂ saturation, respiratory exam, HEENT and precordial exam

Investigations
- guided by findings on history and physical
  - consider throat swab, CXR, PFTs, upper GI series, sputum culture test for acid-fast bacilli (if TB is suspected)
Assessment
- risk factors: see Psychiatry, PS10
- personal or family history of depression
- medications and potential substance abuse problems
- high risk for suicide/homicide
  - fill out Form 1 (in Ontario): application by physician to hospitalize a patient against his/her will for psychiatric assessment (up to 72 h)
  - functional impairment (e.g. work, relationships)
- at least 5 out of 9 criteria including at least one of anhedonia or depressed mood ≥2 wk for actual diagnosis to be met (see sidebar)
- validated depression rating scales: Beck's depression inventory, Zung's self-rating depression scale, Children's depression inventory, Geriatric Depression Scale, Personal Health Questionnaire Depression Scale (PHQ-9)
- routine medical workup (physical exam, CBC, TSH, ferritin, folate, B12, electrolytes, urinalysis, glucose, etc.)

Treatment
- goal: full remission of symptoms and return to baseline psychosocial function
- phases of treatment
  - acute phase (8-12 wk): relieve symptoms and improve quality of life
  - maintenance phase (6-12 mo after symptom resolution): prevent relapse/recurrence, must stress importance of continuing medication treatment for full duration to patients
- treatment options are pharmacotherapy psychotherapy, or a combination of both
- combination therapy is synergistic and most effective
- treatment of youth (age 10-21)
  - for mild depression, a period of active support and monitoring before initiating treatment is recommended
  - fluoxetine is first line among SSRIs (most evidence)
    - monitor closely for adverse effects such as suicidal ideation and behaviour
    - psychotherapy
    - CBT or interpersonal therapy (IPT) alone can be used for mild depression
    - psychotherapy plus medication is recommended for moderate to severe depression
    - treatment should continue for at least 6 months
    - ongoing management should include assessment in key domains (school, home, social setting)
    - reassessment and referral recommended if no improvement after 6-8 wk of treatment
  - for adolescents with moderate/severe depression and coexisting psychosis and/or substance abuse, consider referral

Table 13. Common Medications

<table>
<thead>
<tr>
<th>Class</th>
<th>Examples</th>
<th>Action</th>
<th>Side Effects</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSRI</td>
<td>prozac (Fluoxetine)</td>
<td></td>
<td>Sexual dysfunction (impotence, decreased libido, delayed ejaculation, anorgasmia), headache, GI upset, weight loss, tremors, insomnia, fatigue, increase QT interval (baseline ECG is suggested)</td>
<td>First line therapy for youth is fluoxetine; paroxetine is not recommended for youth (controversial)</td>
</tr>
<tr>
<td>SNRI</td>
<td>venlafaxine (Effexor®)</td>
<td></td>
<td>Insomnia, tremors, tachycardia, sweating</td>
<td></td>
</tr>
<tr>
<td>SDRI</td>
<td>bupropion (Wellbutrin®)</td>
<td></td>
<td>Headache, insomnia, nightmares, seizures, less sexual dysfunction than SSRIs</td>
<td>Often chosen for lack of sexual side effects, can be used for augmentation of anti-depressant effects with other classes of medication</td>
</tr>
<tr>
<td>TCA</td>
<td>amitriptyline (Elavil®)</td>
<td></td>
<td>Sexual dysfunction, weight gain, tremors, tachycardia, sweating</td>
<td>Narrow therapeutic window, lethal in overdose</td>
</tr>
</tbody>
</table>

Prognosis
- up to 40% resolve spontaneously within 6-12 mo
- risks of recurrence: 50% after 1 episode; 70% after 2 episodes; 90% after 3 episodes

Diabetes Mellitus
- see Endocrinology, E7

Definition
- metabolic disorder characterized by the presence of hyperglycemia due to deficiency insulin secretion, defective insulin action or both
Classification
- type 1: primarily a result of pancreatic β-cell destruction
- type 2: characterized by insulin resistance
- GDM: glucose intolerance with onset or first recognition during pregnancy

Epidemiology
- major health concern, affecting up to 10% of Canadians
- incidence of type 2 DM is rising due to increasing obesity, sedentary lifestyle, and age of the population
- leading cause of new-onset blindness and renal dysfunction
- Canadian adults with DM are twice as likely to die prematurely, compared to persons without DM

Risk Factors
- type 1 DM
  - personal or family history of autoimmune disease
- type 2 DM
  - first degree relative with DM
  - age ≥40 yr
  - obesity (especially abdominal), HTN, hyperlipidemia, CAD, vascular disease
  - prior GDM, macrosomic baby (≥4 kg)
  - PCOS
  - history of IGT or IFG
  - presence of complications associated with DM
  - presence of associated diseases: PCOS, acanthosis nigricans, psychiatric disorders, HIV
  - medications: glucocorticoids, atypical antipsychotics, HAART
  - both
    - member of a high risk population (e.g. Aboriginal, Hispanic, Asian, or African descent)

Diagnosis
- persistent hyperglycemia is the hallmark of all forms of DM

Table 14. Diagnosis of Prediabetes and Diabetes

<table>
<thead>
<tr>
<th>Condition</th>
<th>Diagnostic Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>DM</td>
<td>One of the following on 2 occasions:</td>
</tr>
<tr>
<td></td>
<td>Random BG ≥11.1 mmol/L (200 mg/dL) with symptoms of DM (fatigue, polyuria,</td>
</tr>
<tr>
<td></td>
<td>polydipsia, unexplained weight loss) OR</td>
</tr>
<tr>
<td></td>
<td>Fasting BG ≥7.0 mmol/L (126 mg/dL) OR</td>
</tr>
<tr>
<td></td>
<td>**If asymptomatic (and meet any of the above criteria) a repeat test must be done to</td>
</tr>
<tr>
<td></td>
<td>confirm the diagnosis. If symptomatic (fatigue, polyuria, polydipsia, unexplained</td>
</tr>
<tr>
<td></td>
<td>weight loss), the diagnosis is made with one test.</td>
</tr>
<tr>
<td>Impaired Fasting Glucose</td>
<td>Fasting BG = 6.1-6.9 mmol/L (110-124 mg/dL)</td>
</tr>
<tr>
<td>(IFG)</td>
<td></td>
</tr>
<tr>
<td>Impaired Glucose Tolerance</td>
<td>BG 2 h post 75 g OGTT ≥7.8-11.0 mmol/L (141-198 mg/dL)</td>
</tr>
<tr>
<td>(IGT)</td>
<td></td>
</tr>
<tr>
<td>Prediabetes</td>
<td>HbA1C = 6.0-6.4%</td>
</tr>
</tbody>
</table>

Screening
- type 2 DM
  - FBG in everyone ≥40 q3yr, or at high risk using the CANRISK calculator
  - more frequent and/or earlier testing if presence of ≥1 risk factor (see above)
  - GDM (see Obstetrics, OB26)
    - all pregnant women between 24-28 wk gestation

Goals of Therapy

Table 15. Goals of Therapy in Diabetes

| General                      | Avoid complications (e.g. ketoacidosis, hyperglycemia, infection)                  |
|                             | Prevent long-term complications (microvascular and macrovascular)              |
|                             | Minimize negative sequelae associated with therapies (e.g. hypoglycemia, weight gain) |

| Fasting or Preprandial BG   | Ideal: 4.7 mmol/L (72-126 mg/dL)                                                |
|                             | Suboptimal: 7.1-10 mmol/L (128-180 mg/dL); action may be required                |
|                             | Inadequate: >10.0 mmol/L (180 mg/dL); action required                            |
| HbA1c                       | ≤7% or ≤6.5% in some type 2 DM patients at risk for nephropathy                   |
| Suboptimal: 7.8-4%          | Inadequate: >8.4%                                                               |
| Frail elderly: target is 5-12 mmol/L |                                      |

| 2 h Postprandial BG         | 5-10 mmol/L (90-180 mg/dL) if HbA1c target met                                 |
|                           | 5-8 mmol/L (90-144 mg/dL) if HbA1c target not met                             |
| Frail elderly: use clinical judgment |                                      |

Blood Pressure
- <130/80 in adults (DM and HTN guidelines)

Lipids
- LDL < 2.0 mmol/L (36 mg/dL)
Assessment and Monitoring

Table 16. Assessment and Monitoring

<table>
<thead>
<tr>
<th></th>
<th>Initial Assessment</th>
<th>q2-4mo</th>
<th>Annually</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>History</strong></td>
<td>Symptoms of hyperglycemia, ketoacidosis, hypoglycemia</td>
<td>DM-directed history</td>
<td>DM-directed history</td>
</tr>
<tr>
<td></td>
<td>Past medical history</td>
<td>Screen for awareness</td>
<td>Screen for awareness</td>
</tr>
<tr>
<td></td>
<td>Functional inquiry</td>
<td>and frequency of</td>
<td>and frequency of</td>
</tr>
<tr>
<td></td>
<td>Family history</td>
<td>hypoglycemia and</td>
<td>hypoglycemia and</td>
</tr>
<tr>
<td></td>
<td>Risk factors</td>
<td>DKA</td>
<td>DKA</td>
</tr>
<tr>
<td></td>
<td>Medication</td>
<td>Use of insulin and oral</td>
<td>Glucose monitoring</td>
</tr>
<tr>
<td></td>
<td>Sexual function</td>
<td>agents</td>
<td>Use of insulin and oral</td>
</tr>
<tr>
<td></td>
<td>Lifestyle</td>
<td>Smoking cessation</td>
<td>agents</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lifestyle counselling</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Screen for depression</td>
</tr>
<tr>
<td><strong>Physical Exam</strong></td>
<td>General: Ht, Wt, BMI, BP, WC</td>
<td>Wt, BP, BMI, WC</td>
<td>Foot exam for sensation (using a 10 g monofilament), ulcers or infection</td>
</tr>
<tr>
<td></td>
<td>Head and neck: fundoscopy, thyroid exam</td>
<td>FBG as needed</td>
<td>Remainder of exam as per PHE</td>
</tr>
<tr>
<td></td>
<td>Cardiovascular exam: signs of PVD, pulses, bruits</td>
<td>Fasting lipid profile</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Abdominal exam (e.g. for organomegaly)</td>
<td>Annual random ACR and eGFR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hand/foot/skin exam</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neurological exam</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td>FBG, HbA1c, fasting lipids, Cr, microalbumin:creatinine</td>
<td>HbA1c q3mo</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ratio</td>
<td>FBG as needed</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Baseline ECG; repeat testing q2yrs for those at high risk</td>
<td>Fasting lipid profile</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Annual random ACR and eGFR</td>
<td></td>
</tr>
<tr>
<td><strong>Management</strong></td>
<td>Nutritional and physical education</td>
<td>Assess progress towards long-term complications</td>
<td>Calibrate home glucose monitor</td>
</tr>
<tr>
<td></td>
<td>Consider referral to DM</td>
<td>Adjust treatment plan if necessary</td>
<td>Arrange retinopathy screening</td>
</tr>
<tr>
<td></td>
<td>education program if available</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Monitoring BG: explain methods and frequency</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medication counselling: oral</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>hypoglycemics and/or insulin, method of</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>administration, dosage adjustments</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pneumococcal vaccination</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ophthalmology consult</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>type 1 DM within 5 yr</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>type 2 DM at diagnosis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Nonpharmacologic Management

- **diet**
  - all diabetics should see a registered dietician for nutrition counselling
  - can reduce HbA1c by 1-2%
  - moderate weight loss (5%) improves glycemic control and CVD risk factors
  - decrease combined saturated fats and trans-fatty acids to <10% of calories
  - avoid simple sugars, choose low glycemic-index foods, ensure regularity in timing and spacing of meals
- physical activity and exercise
  - at least 150 min of aerobic exercise per wk, plus 2 sessions per wk of resistance exercise is recommended
  - encourage 30-45 min of moderate exercise 4-7 d/wk
  - promote cardiovascular fitness: increases insulin sensitivity, lowers BP, and improves lipid profile
  - if insulin treated, may require alterations of diet, insulin regimen, injection sites, and self-monitoring

Self-Monitoring of Blood Glucose

- **type 1 DM:** 3 or more self-tests/d is associated with a 1% reduction in HbA1c
- **type 2 DM:** recommendations vary based on treatment regimen (e.g. insulin dependent requires more frequent monitoring – refer to 2013 Canadian Practice Guidelines)
- if FBG >14 mmol/L, perform ketone testing to rule out DKA
- if bedtime level is <7 mmol/L, have bedtime snack to reduce risk of nocturnal hypoglycemia
Common Presenting Problems

FM24  Family Medicine

Family Medicine
Toronto Notes 2017

Figure 8. Types of insulin preparation

Figure 9. Management of hyperglycemia in type 2 diabetes

At diagnosis of Type 2 DM
Start lifestyle intervention (nutrition therapy and physical activity) ± Metformin

<table>
<thead>
<tr>
<th>A1C &lt; 8.5%</th>
<th>A1C ≥ 8.5%</th>
<th>Symptomatic hyperglycemia with metabolic decompensation</th>
</tr>
</thead>
<tbody>
<tr>
<td>If not at glycemic target (2-3 mo)</td>
<td>Start metformin immediately</td>
<td>Consider initial combination with another antihyperglycemic agent</td>
</tr>
<tr>
<td>Start or increase metformin</td>
<td>If not at glycemic targets</td>
<td></td>
</tr>
</tbody>
</table>

Add another agent best suited to the individual by prioritizing patient characteristics:

**PATIENT CHARACTERISTIC**

- Degree of hyperglycemia
- Risk of hypoglycemia
- Overweight or obesity
- Cardiovascular disease
- Comorbidities (renal, CHF, hepatic)
- Preferences and access to treatment

**CHOICE OF AGENT**

- SGLT2 inhibitor with demonstrated CV outcome benefit
- Consider relative A1C lowering
- Rare hypoglycemia
- Weight loss or weight neutral
- Effect on cardiovascular outcome
- See therapeutic considerations, consider eGFR
- See cost column; consider access

Add another class of agent best suited to the individual (classes listed in alphabetical order):

<table>
<thead>
<tr>
<th>Class</th>
<th>Relative A1C Lowering</th>
<th>Hypoglycemia</th>
<th>Weight</th>
<th>Effect in Cardiovascular Outcome Trial</th>
<th>Other Therapeutic Considerations</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-Glucosidase inhibitor (acarbose)</td>
<td>↓</td>
<td>Rare</td>
<td>Neutral to ↓</td>
<td>Improved postprandial control, GI side-effects</td>
<td>$</td>
<td></td>
</tr>
<tr>
<td>Incretin agents: DPP-4 inhibitors</td>
<td>↓↓</td>
<td>Rare</td>
<td>Neutral to ↓</td>
<td>Neutral (alet, saxa, sita)</td>
<td>Cautions with saxagliptin in heart failure</td>
<td>$$$</td>
</tr>
<tr>
<td>GLP-1R agonists</td>
<td>↓↓↓</td>
<td>Rare</td>
<td>↓</td>
<td>Neutral (liva)</td>
<td>GI side-effects</td>
<td>$$$</td>
</tr>
<tr>
<td>Insulin secretagogue; Meglitinide</td>
<td>↓↓</td>
<td>Yes</td>
<td>↑↑</td>
<td>Neutral (sita)</td>
<td>No dose ceiling, flexible regimens</td>
<td>$-$$-$$</td>
</tr>
<tr>
<td>Sulfonylurea</td>
<td>↓↓</td>
<td>Yes</td>
<td>↑</td>
<td>Less hypoglycemia in context of missed meals, but usually requires TID to QID dosing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SGLT2 inhibitors</td>
<td>↓↓↓</td>
<td>Rare</td>
<td>↓</td>
<td>Superior (empa in T2DM patients with clinical CVD)</td>
<td></td>
<td>$$$</td>
</tr>
<tr>
<td>Thiazolidinediones</td>
<td>↓↓</td>
<td>Rare</td>
<td>↑↑</td>
<td>Neutral</td>
<td>CHF, edema, fractures, rare bladder cancer (pioglitazone), cardiovascular controversy (rosiglitazone), 6-12 wk required for max effect</td>
<td>$$$</td>
</tr>
<tr>
<td>Weight loss agent (orlistat)</td>
<td>↓</td>
<td>None</td>
<td>↓</td>
<td></td>
<td>GI side-effects</td>
<td>$</td>
</tr>
</tbody>
</table>

**Note:** Physicians should refer to the most recent edition of the *Compendium of Pharmaceuticals and Specialties* (Pharmacists’ and Specialists’ Evaluation Pharmacists’ Association, Ottawa, Ontario, Canada) for product monographs and for detailed prescribing information.

A1C = glycated hemoglobin  emp = empagliflozin  lixiv = lixisenatide
alo = alogluptin  GI = gastrointestinal  saxa = saxagliptin
CHF = congestive heart failure  sita = sitagliptin
DPP-4 = dipeptidyl peptidase 4  GLP-1 = glucagon-like peptide 1  TZD = thiazolidinediones

If not at glycemic targets

Add another agent from a different class; add or intensify insulin regimen

Make timely adjustments to attain target A1C within 3-6 mo

Figure 8. Types of insulin preparation

Figure 9. Management of hyperglycemia in type 2 diabetes

Hypoglycemic Agents (Type 2 DM)
- oral
  ■ biguanide: metformin (Glucophage®)
  ■ thiazolidinediones: troglitazone (Rezulin®), rosiglitazone (Avandia®)
  ■ α-glucosidase inhibitor: acarbose (Precose®)
  ■ nonsulfonylureas: nateglinide (Starlix®), repaglinide (Glucotrol®)
  ■ sulfonylureas: glyburide (Diabeta®), glimepiride (Amaryl®), gliclazide (Diamicron®)
  ■ DPP-4 inhibitor: sitagliptin (Januvia®)
- injectable
  ■ GLP-1 analogue: liraglutide (Victoza®)

Other Medications Used in DM
- ACEI or ARB in those with any of
  ■ clinical macrovascular disease
  ■ age ≥55 years
  ■ age <55 and microvascular complications
- statin in those with any of
  ■ clinical macrovascular disease
  ■ age ≥40 years
  ■ age <40 and any of the following:
    ■ diabetes duration >15 years and age >30 years
    ■ microvascular complications
    ■ other cardiovascular risk factors
- low dose ASA (81-325 mg)
  ■ for secondary prevention in people with established CVD (NOT to be used routinely for primary prevention)

Dizziness
- see Otolaryngology OT6

Epidemiology
- 70% see general practitioners initially; 4% referred to specialists
- frequency proportional to age; commonest complaint of ambulatory patients age >75

Differential Diagnosis

Figure 10. Differential diagnosis of dizziness

History
- clarify type of dizziness: vertigo, pre-syncope, disequilibrium, light-headedness
- duration
- exacerbations
  ■ worse with head movement or eye closure (vestibular)
  ■ no change with head movement and eye closure (nonvestibular)
  ■ worse with exercise (cardiac/pulmonary causes)
Associated Symptoms
- Neurologic (central)
  - Transient diplopia, dysphagia, dysarthria, ataxia (TIA, VBI, migraine)
- Persistent headache, alterations in level of consciousness, sensory and/or motor deficits (CNS)
- Audioligic (peripheral)
  - Hearing loss, tinnitus, otalgia, aural fullness
- Others
  - N/V (peripheral vestibular disorders)
  - SOB, palpitations (hyperventilation, cardiac problem)
- General medical history
  - HTN, DM, heart disease, fainting spells, seizures, cerebrovascular disease, migraines
  - Ototoxic drugs: aminoglycosides (gentamicin, streptomycin, tobramycin), erythromycin, ASA, antimalarials
  - Hypotension (secondary to diuresis): furosemide, caffeine, alcohol
  - Depression/anxiety: can present with light-headedness

Physical Exam/Investigations
- Syncopal
  - Cardiac (orthostatic changes in vials), peripheral vascular, and neurologic exams
  - Blood work, ECG, 24 h Holter, treadmill stress test, loop ECG, tilt table testing, carotid, and vertebral doppler, EEG
- Vertiginous
  - ENT and neurologic exams
  - Dix-Hallpike, consider audiometry and MRI if indicated
- Non-syncopal, non-vertiginous
  - Assess gait, vision and test for neuropathy
  - Cardiac and neurologic exams
  - 3-min hyperventilation trial (patient is coached to hyperventilate until patient becomes dizzy to identify if symptoms are reproducible and confirm that hyperventilation is the etiology of the symptoms), ECG, EEG
  - Romberg test: test for disequilibrium (patient sways towards the side of vestibular dysfunction)

Treatment
- Guided by history, physical exam, and investigations
- Include education, lifestyle modification, physical maneuvers (e.g. Epley for BPPV), symptomatic management (e.g. antiemetics), pharmacotherapy, and surgery
- Refer when significant central disease is suspected, when vertigo of peripheral origin is persistent (lasting >2-4 wk), or if atypical presentation

Domestic Violence/Elder Abuse

Intimate Partner Violence

Definition
- Includes physical, sexual, emotional, psychological, and financial abuse (see Emergency Medicine, ER28)

Epidemiology
- Lifetime prevalence of intimate partner violence against women is between 25-30%.
- Women who experience abuse have increased rates of injury, death, and health consequences including 50-70% increase in gynecological, central nervous system, stress-related problems.
- Occurs in all socioeconomic, educational, and cultural groups with increased incidence in pregnancy, disabled women, and 18-24 age group.
- 25-50% chance of child abuse or neglect in families where partner abuse occurs.
- Physician recognition rates as low as 5%.

Presentation
- Multiple visits with vague, ill-defined complaints such as: headaches, gastrointestinal symptoms, insomnia, chronic pain, hyperventilation.
- May also present with injuries inconsistent with history.

Management
- Screen ALL patients
  - Always have a high index of suspicion.
  - Asking about abuse is the strongest predictor of disclosure.
  - Several screening tools (see sidebar) exist to identify victims of partner violence.
  - Make sure to determine the victim’s level of immediate and long-term danger and ask if there are weapons in the house.
  - Ensure patient safety.
  - Victim most at risk for homicide when attempting to leave home or following separation.

Screening Instruments for Domestic Violence

A) Woman Abuse Screening Tool (WAST)-SHORT
1. In general how would you describe your relationship?
   a. A lot of tension
   b. Some tension
   c. No tension
2. Do you and your partner work out arguments with...
   a. Great difficulty
   b. Some difficulty
   c. No difficulty

Endorsing either question 1 ("a lot of tension") or question 2 ("great difficulty") makes intimate partner violence exposure likely.

B) HITS
How often does your partner:
1. Physically hurt you?
2. Insult you?
3. Threaten you with harm?
4. Scream or curse at you?

Each question on HITS to be answered on a 5 point scale ranging from 1 (= never) to 5 (= frequently)
A total score of 10.5 is significant.
• provide community resources
  ▪ safety planning includes ensuring that there is access to an exit in the home, establishing a safe place
to go and having money, clothes, keys, medications, important documents, and other emergency
  items prepared should the patient need to leave quickly
  ▪ shelter or helpline number with legal advocacy and counselling services
  ▪ involve social workers or domestic violence advocates
  ▪ appointment for follow-up to assess whether condition is better or worse
  ▪ reassure patient she/he is not to blame and that the assault is a crime
  ▪ goal is to convey the message that “As your doctor, I am concerned for your safety” and “Your
    partner has a problem that he/she needs help with” and “I want to help you”
  ▪ reporting suspected or known child abuse is mandatory
  ▪ spousal abuse is a criminal act, but not reportable without the woman’s/man’s permission
  ▪ DOCUMENT all evidence of abuse-related visits for medico-legal purposes

ELDER ABUSE

• see Geriatric Medicine, GM4

Dyspepsia

• see Gastroenterology, G10

Definition and Clinical Features

• defined as epigastric pain or discomfort
• can be associated with fullness, belching, bloating, heartburn, food intolerance, N/V

Epidemiology

• annual incidence 1-2%, prevalence 20-40%

Etiology

• common: functional, PUD, GERD, gastritis
• others: cholelithiasis, irritable bowel syndrome, esophageal or gastric cancer, pancreatitis, pancreatic
cancer, Zollinger-Ellison syndrome, and abdominal angina

History

• symptoms may not be useful in finding cause
• associated with eating, anorexia, N/V, alcohol, NSAID use
• red flags: vomiting, bleeding/ anemia, abdominal mass, dysphagia (VBAD)

Investigations and Management

• for new onset dyspepsia, test for H. pylori using the urea breath test or serology
• upper endoscopy (preferred), upper GI series (not in patients with alarm symptoms)
• lifestyle modifications: decreased caffeine and alcohol intake, avoid citrus food , avoid supine position
  right after meals, smoking cessation
• pharmacologic treatment
• gastric acid suppression: H2 blockers, PPIs; both are effective for PUD and GERD
• prokinetics: e.g. Metoclopramide; effective for functional dyspepsia
• H. pylori eradication
• do not keep patients on PPI without at least 1 trial off the medication per year
  (http://www.choosingwiselycanada.org/in-action/toolkits/buye-bye-ppi/)
• for non-responders, gastroscopy should be considered

Dyspepsia Red Flags

• Weight Loss
• Dysphagia
• Persistent vomiting
• GI bleeding (hematemesis, hematochezia, melena)
• Onset age >50

H. pylori Eradication

Take the following 10 day treatment

1) PPI 1 tablet 2x/d for 10 d and
2) Amoxicillin 1 g twice a day for 5 d (day 1-5)
Followed by
3) Clarithromycin 500 mg 2x/d (day 6-10) and
4) Metronidazole 500 mg 2x/d (day 6-10)

DDx of Dyspepsia

Pulmonary
• COPD
• Asthma
• Restrictive lung disease
• Pneumothorax
• Congenital lung disease
• PE

Cardiac
• CHF
• CAD
• MI (recent or past)
• Cardiomyopathy
• Valve dysfunction
• Pericarditis
• Arrhythmia
• Hypertrophy

Mixed/Other
• Deconditioning
• Trauma
• Pain
• Neuromuscular
• Metabolic condition
• Functional: anxiety, panic attack, hyperventilation

Dyspnea

• see Respirology, R3 and Emergency Medicine, ER26

Definition

• uncomfortable, abnormal awareness of breathing

History and Physical Exam

• history
  ▪ cough, sputum, hemoptysis, wheezing, chest pain, palpitations, dizziness, edema, SOB
  ▪ asthma, allergy, eczema, ASA/NSAID sensitivity, nasal polyps
  ▪ constitutional symptoms
  ▪ smoking, recreational drugs, medications
  ▪ occupational exposure, environmental exposure (e.g. pets, allergens, smoke)
  ▪ travel and birth place
  ▪ FHx of atopy
  ▪ previous CXR or PFTs
• physical exam: vitals, respiratory, precordial, HEENT, signs of anemia/liver failure/heart failure
Common Presenting Problems

Investigations
- CXR, ECG
- PFTs, ABG acutely if indicated

Management
- ABCs: send to ED if in severe respiratory distress
- depends on cause

Dysuria
- see Urology, U10

Definition
- the sensation of pain, burning, or discomfort on urination

Epidemiology
- in adulthood, more common in women than men
- approximately 25% of women report one episode of acute dysuria per year
- most common in women age 25-54 and in those who are sexually active
- in men, dysuria becomes more prevalent with increasing age

Etiology
- infectious
  - most common cause
  - presents as cystitis, urethritis, pyelonephritis, vaginitis, cervicitis, epididymo-orchitis, or prostatitis
- non-infectious
  - hormonal conditions (hypostrogenism), obstruction (BPH, urethral strictures), allergic reactions, radiation, drugs/chemicals, foreign bodies, trauma, neoplasm, kidney stones, inflammatory diseases, endometriosis, psychogenic

Table 17. Etiology, Signs and Symptoms of Common Causes of Dysuria

<table>
<thead>
<tr>
<th>Infection</th>
<th>Etiology</th>
<th>Signs and Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>UTI/Cystitis</td>
<td>K. pneumonia, E. coli, Enterobacter, P. mirabilis, S. saprophyticus</td>
<td>Internal dysuria throughout micturition, frequency, urgency, incontinence, hematuria, nocturia, back pain, suprapubic discomfort, low grade fever (rare)</td>
</tr>
<tr>
<td>Urethritis</td>
<td>C. trachomatis, N. gonorrhoeae, T. vaginalis, Candida, herpes</td>
<td>Initial dysuria, urethral/vaginal discharge, history of STI</td>
</tr>
<tr>
<td>Vaginitis</td>
<td>Candida, Gardnerella, T. vaginalis, C. trachomatis, atrophic, herpes, lichen sclerosis</td>
<td>External dysuria/pain, vaginal discharge, irritation, dyspareunia, abnormal vaginal bleeding</td>
</tr>
<tr>
<td>Prostatitis</td>
<td>E. coli, C. trachomatis, S. saprophyticus, P. mirabilis, Enterobacter, K. pneumonia, P. saprophyticus</td>
<td>Dysuria, fever, chills, urgency, frequency, tender prostate, rectal pain</td>
</tr>
<tr>
<td>Pyelonephritis</td>
<td>E. coli, S. saprophyticus, P. mirabilis, Enterobacter, K. pneumonia, P. saprophyticus</td>
<td>Internal dysuria, fever, chills, flank pain radiating to groin, CVA tenderness, N/V</td>
</tr>
</tbody>
</table>

Investigations
- no investigations necessary when history and physical consistent with uncomplicated UTI – treat empirically (urinalysis can be performed when indicated by dipstick or microscopy)
- urinalysis/dipstick: positive for nitrites and leukocytes
- urine R&: pyuria, bacteriuria, hematuria
- urine C&S
- CBC and differential if suspecting pyelonephritis
- if vaginal/urethral discharge present: wet mount, Gram stain, KOH test, vaginal pH, culture for yeast and trichomonas, endocervical/urethral swab or urine PCR for N. gonorrhoeae and C. trachomatis
- radiologic studies and other diagnostic tests if atypical presentation
- see Pediatrics, P62 for UTI in children

Management
- UTI/cystitis
  - pregnant women with bacteriuria (2-7%) must be treated even if asymptomatic, due to increased risk of pyelonephritis, preterm labour, low birth weight and perinatal mortality; need to follow with monthly urine cultures and retreat if still infected
  - patients with recurrent UTIs (>3/yr) should be considered for prophylactic antibiotics
  - if complicated UTI, patients require longer courses of broader spectrum antibiotics
  - urethritis
    - when swab or PCR is positive for chlamydia or gonorrhea must report to Public Health
  - all patients should return 4-7 d after completion of therapy for clinical evaluation
Epistaxis

• see Otolaryngology, OT26

Erectile Dysfunction

• see Urology, U30

Definition
• consistent or recurrent inability to attain and/or maintain penile erection sufficient for sexual performance of ≥3 mo duration

Epidemiology
• ~20% of men age 40; ~50% of men age 70

Etiology
• organic: vascular (90%) (arterial insufficiency, atherosclerosis), endocrine (low testosterone, DM), anatomic (structural abnormality, e.g. Peyronie’s), neurologic (post-operative, DM), medications (clonidine, antihypertensives, psychotropics)
• psychogenic (10%)

Table 18. Differentiation Between Organic and Psychogenic ED

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Organic</th>
<th>Psychogenic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset</td>
<td>Gradual</td>
<td>Acute</td>
</tr>
<tr>
<td>Circumstances</td>
<td>Global</td>
<td>Situational</td>
</tr>
<tr>
<td>Course</td>
<td>Constant</td>
<td>Varying</td>
</tr>
<tr>
<td>Non-Coital Erection</td>
<td>Poor</td>
<td>Rigid</td>
</tr>
<tr>
<td>Morning Erection</td>
<td>Absent</td>
<td>Present</td>
</tr>
<tr>
<td>Psychosexual Problem</td>
<td>Secondary</td>
<td>Long history</td>
</tr>
<tr>
<td>Partner Problem</td>
<td>Secondary</td>
<td>At onset</td>
</tr>
<tr>
<td>Anxiety and Fear</td>
<td>Secondary</td>
<td>Primary</td>
</tr>
</tbody>
</table>

Walsh: Campbell’s Urology, 8th ed. Table 46-4

History
• comprehensive sexual, medical, and psychosocial history
• time course
  • last satisfactory erection
  • gradual or sudden onset
  • attempts at sexual activity
• quantify
  • presence of morning or night time erections
  • stiffness (scale of 1-10)
  • ability to initiate and maintain an erection with sexual stimulation
  • erection stiffness during sex (scale of 1-10)
• qualify
  • partner or situation specific
  • loss of erection before penetration or climax
  • degree of concentration required to maintain an erection
  • percentage of sexual attempts satisfactory to patient and/or his partner
  • significant bends in penis or pain with erection
  • difficulty with specific positions
  • impact on quality of life and relationship

Investigations
• hypothalamic-pituitary-gonadal axis evaluation: testosterone (free + total), prolactin, LH
• risk factor evaluation: fasting glucose, HbA1c, lipid profile
• others: TSH, CBC, urinalysis
• specialized testing
  • psychological and/or psychiatric consultation
  • in-depth psychosexual and relationship evaluation
  • nocturnal penile tumescence and rigidity (NPTR) assessment
  • vascular diagnostics (e.g. doppler studies, angiography)

DDx of Erectile Dysfunction

PENIS
Psychogenic
Endocrine (type 2 DM, testosterone)
Neurogenic (type 2 DM, post-operative)
Insufficiency of blood (atherosclerosis)

Reasons for Referral to Urology
• Significant penile anatomic disease
• Younger patient with a history of pelvic or perineal trauma
• Cases requiring vascular or neuro-surgical intervention
• Complicated endocrinopathies
• Complicated psychiatric or psychosocial problems
• Patient or physician desire for further evaluation

The Effect of Lifestyle Modification and Cardiovascular Risk Factor Reduction on Erectile Dysfunction

Arch Intern Med 2011;171:1797-1803
Study: Meta-analysis of 6 RCTs.
Population: 740 male participants.
Intervention: Lifestyle modification and pharmacotherapy targeting CAD risk factors.
Main Outcome Measure: International Index of Erectile Dysfunction (IIEF-5) score.
Results: Lifestyle modifications and pharmacotherapy for cardiovascular risk factors had a statistically significant association with improved sexual function (weighted mean difference 2.66; 95% CI 1.19-3.61). Lifestyle modification without use of statins was also statistically significantly associated with improved sexual function (weighted mean difference 2.40; 95% CI 1.19-3.61).
Conclusion: Lifestyle modification alone or combined with pharmacotherapy can improve sexual function.
Management

Table 19. Management of Erectile Dysfunction

<table>
<thead>
<tr>
<th>Nonpharmacologic</th>
<th>Pharmacologic</th>
<th>Surgical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lifestyle changes (alcohol, smoking, exercise)</td>
<td>Oral agents</td>
<td>Implants</td>
</tr>
<tr>
<td>Relationship/sexual counseling</td>
<td>Suppository</td>
<td>Vascular repair</td>
</tr>
<tr>
<td>Vacuum devices</td>
<td>Male urethral suppository for erection (MUSE)</td>
<td>Realignment</td>
</tr>
</tbody>
</table>

- pharmacologic treatment
  - phosphodiesterase type 5 inhibitors
  - α-adrenergic blockers (e.g. yohimbine)
  - serotonin antagonist and reuptake inhibitor (e.g. trazodone)
  - testosterone – currently only indicated in patients presenting with hypogonadism and testosterone deficiency (note: breast/prostate cancer are absolute contraindications)

Table 20. Phosphodiesterase Type 5 Inhibitors

<table>
<thead>
<tr>
<th>Examples</th>
<th>Dosing (1 dose/d)</th>
<th>Specifics</th>
<th>Side Effects</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>sildenafil (Viagra®)</td>
<td>25-100 mg/dose</td>
<td>Take 0.5-4 h prior to intercourse</td>
<td>Flushing, headache, indigestion</td>
<td>Not to be used in patients taking nitrates</td>
</tr>
<tr>
<td>tadalafil (Cialis®)</td>
<td>5-20 mg/dose</td>
<td>Effects may last 36 h</td>
<td>As above</td>
<td>As above</td>
</tr>
<tr>
<td>vardenafil (Levitra®)</td>
<td>2.5-20 mg/dose</td>
<td>Take 1 h prior to intercourse</td>
<td>As above</td>
<td>As above</td>
</tr>
</tbody>
</table>

Fatigue

Epidemiology

- 25% of office visits to family physicians
  - peaks in ages 20-40
  - F:M = 3:4:1
- 50% have associated psychological complaints/problems, especially if <6 mo duration

Differential Diagnosis

Table 21. Differential Diagnosis of Fatigue: PS VINDICATE

| P | Psychogenic | Depression, life stresses, anxiety disorder, chronic fatigue syndrome, fibromyalgia |
|   | Physiologic | Pregnancy, caregiving demands (young children, elderly) |
| S | Sleep disturbance | Obstructive sleep apnea, sleep disorder, poor sleep hygiene, BPH, shift work, pain |
|   | Sedentary | Unhealthy/sedentary lifestyle |
| V | Vascular | Stroke |
| I | Infectious | Viral (e.g. mononucleosis, hepatitis, HIV), bacterial (e.g. TB), fungal, parasitic |
| N | Neoplastic | Any malignancy |
|   | Nutrition | Anemia (Fe²⁺ deficiency, B₁₂ deficiency) |
|   | Neurogenic | Myasthenia gravis, multiple sclerosis, Parkinson’s disease |
| D | Drugs | β-blockers, antihistamines, anticholinergics, benzodiazepines, antiepileptics, antidepressants |
| I | Idiopathic |
| C | Chronic illnesses | CHF, lung diseases (e.g. COPD, sarcoidosis), renal failure, chronic liver disease |
| A | Autoimmune | SLE, RA, mixed connective tissue disease, polymyalgia rheumatica |
| T | Toxin | Substance abuse (e.g. alcohol), heavy metal |
| E | Endocrine | Hypothyroidism, DM, Cushing’s syndrome, adrenal insufficiency, pregnancy |

Common causes are in bold

Investigations

- psychosocial causes are common, so usually minimal investigation is warranted
- physical causes of fatigue usually have associated symptoms/signs that can be elicited from a focused history and physical exam
- investigations should be guided by history and physical exam and may include
  - CBC and differential, electrolytes, BUN, Cr, ESR, glucose, TSH, ferritin, vitamin B₁₂, serum protein electrophoresis, Bence-Jones protein, albumin, AST, ALT, ALP, bilirubin, calcium, phosphate, ANA, β-hCG
  - urinalysis, CXR, ECG
- additional tests: serologies (Lyme disease, hepatitis B and C screen, HIV, ANA) and Mantoux skin tests
Treatment
- treat underlying cause
- if etiology cannot be identified (1/3 of patients)
  - reassurance and follow-up, especially with fatigue of psychogenic etiology
  - quick follow-up for reassurance
  - supportive counselling, behavioural, or group therapy
  - encourage patient to stay physically active to maximize function
  - review all medications, OTC, and herbal remedies for drug-drug interactions and side effects
  - prognosis: after 1 yr, 40% are no longer fatigued

CHRONIC FATIGUE SYNDROME

Definition (CDC 2006) – must meet both criteria
1. new or definite onset of unexplained, clinically evaluated, persistent or relapsing chronic fatigue, not relieved by rest, which results in occupational, educational, social, or personal dysfunction
2. concurrent presence of ≥4 of the following symptoms for a minimum of 6 mo
  - impairment of short-term memory or concentration, severe enough to cause significant decline in function
  - sore throat
  - tender cervical or axillary lymph nodes
  - muscle pain
  - multi-joint pain with no swelling or redness
  - new headache
  - unrefreshing sleep
  - post-exertion malaise lasting >24 h
  - exclusion criteria: medical conditions that may explain the fatigue, certain psychiatric disorders (depression with psychotic or melancholic features, schizophrenia, eating disorders), substance abuse, severe obesity (BMI >45)

Epidemiology
- F>M, Caucasians > other groups, majority in their 30s
- found in <5% of patients presenting with fatigue

Etiology
- unknown, likely multifactorial
- may include infectious agents, immunological factors, neurohormonal factors, and/or nutritional deficiency

Investigations
- no specific diagnostic laboratory tests

Treatment
- promote sleep hygiene
- provide support and reassurance that most patients improve over time
- non-pharmacological
  - regular physical activity, optimal diet, psychotherapy (e.g. CBT), family therapy, support groups
- pharmacological
  - to relieve symptoms: e.g. antidepressants, anxiolytics, NSAIDs, antimicrobials, antiallergy therapy,
  - antihypotensive therapy

Fever
- see Pediatrics, P51

Definition
- oral temperature >37.2°C (AM), 37.7°C (PM)
- fever in children under 2 must be a rectal temperature for accuracy
- TM not accurate for measurement until child is >5 yr

Table 22. Differential Diagnosis of Fever

<table>
<thead>
<tr>
<th>Infection</th>
<th>Cancer</th>
<th>Medications</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial</td>
<td>Leukemia</td>
<td>Allopurinol</td>
<td>Irritable Bowel Syndrome</td>
</tr>
<tr>
<td>Viral</td>
<td>Lymphoma</td>
<td>Captopril</td>
<td>Collagen Vascular Disease</td>
</tr>
<tr>
<td>TB</td>
<td>Other Malignancies</td>
<td>Cimetidine</td>
<td>DVT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Heparin</td>
<td></td>
</tr>
</tbody>
</table>
**History**
- fever
  - peak temperature, thermometer, route, duration
  - time of day
  - response to antipyretics
- systemic symptoms
- weight loss, fatigue, rash, arthralgia, night sweats
- symptoms of possible source
  - UTI/pyelonephritis: dysuria, foul-smelling urine, incontinence, frequency, hematuria, flank pain
  - pneumonia: cough, pleuritic chest pain
  - URTI: cough, coryza, ear pain
  - meningitis: headache, confusion, stiff neck, rash
  - osteomyelitis: bone pain
  - skin: purulent discharge
  - PID: discharge, dyspareunia, lower abdominal pain
  - gastroenteritis: abdominal pain, diarrhea, blood per rectum, vomit
  - medications
  - PE/DVT: swollen legs, pain in calf, SOB, pleuritic chest pain
  - history of cancer/family history of cancer
- infectious contacts
  - travel history, camping, day care, contact with TB, foodborne, animals

**Possible Investigations**
- CBC and differential, blood culture, urine culture, urinalysis
- stool O&P, Gram stain, culture
- CXR, Mantoux skin test, sputum culture
- LP

**Management**
- increase fluid intake
- general: sponge bath, light clothing
- acetaminophen/ibuprofen as needed
- treat underlying cause

**Headache**

- see Neurology, N44

**Primary Headaches**

<table>
<thead>
<tr>
<th>Table 23. Primary Headaches</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Migraine</strong></td>
</tr>
<tr>
<td>Epidemiology</td>
</tr>
<tr>
<td>Duration</td>
</tr>
<tr>
<td>Pain</td>
</tr>
<tr>
<td>Triggers</td>
</tr>
</tbody>
</table>

**Secondary Headaches**
- caused by underlying organic disease
- account for <10% of all headaches, may be life-threatening
Etiology
- aneurysm
- medication overuse headache
- space-occupying lesion
- systemic infection (meningitis, encephalitis)
- stroke
- subarachnoid hemorrhage
- systemic disorders (thyroid disease, HTN, pheochromocytoma, etc.)
- temporal arteritis
- traumatic head injuries
- TMJ or C-spine pathology
- serious ophthalmological and otolaryngological causes of headache

Investigations
- indicated only when red flags are present and may include:
  - CBC for suspected systemic or intracranial infection
  - ESR for suspected temporal arteritis
  - neuroimaging (CT or MRI) to rule out intracranial pathology
  - CSF analysis for suspected intracranial hemorrhage, infection

Management
- based on underlying disorder
- analgesics may provide symptomatic relief

Hearing Impairment

Definition
- hearing impairment: a raised hearing threshold measured as decibels of hearing loss relative to the normal population at specific frequencies
- hearing disability: hearing impairment that interferes with performing daily tasks

Epidemiology
- prevalence increases with age (6% of 35-44 yr old, 43% of 65-84 yr old)
- 90% of age-related hearing loss (presbycusis) is sensorineural
- hearing loss detectable by audiology is present in greater than 1/3 of people >65 yr
- associated with significant physical, functional, and mental health consequences

Classification
- conductive (external sound does not reach the middle ear)
- sensorineural involving the inner ear, cochlea, or auditory nerve
- mixed

Assessment
- infants
  - universal newborn hearing screening program
- elderly
  - presbycusis is characterized by the progressive, symmetric loss of high-frequency hearing
  - tinnitus, vertigo, and disequilibrium may be present
  - can cause low self-esteem, isolation, and depression
  - whispered-voice test
  - whisper 6 test words 6 in-2.
  - tuning fork test (to distinguish conductive from sensorineural hearing loss)
  - Rinne and Weber (not for general screening)
  - formal audiologic assessment
  - pure tone, air, and bone conduction testing
  - speech audiometry
  - impedance audiometry

Management
- counsel about noise control and hearing protection programs (Grade A evidence)
- investigations in patients with unexplained sensorineural hearing loss
  - blood sugar, CBC+ differential, TSH, syphilis testing
- referral
  - refer patients with hearing loss for a complete audiological examination
  - unclear etiology of hearing loss: referral to ENT
  - sudden hearing loss: urgent referral as treatment success is related to early treatment
  - patients with progressive asymmetric sensorineural hearing loss should have an MRI/CT scan to exclude vestibular schwannoma (acoustic neuroma)
  - hearing amplification (e.g. hearing aids), assistive listening devices, and cochlear implants can dramatically improve quality of life.
Hypertension

Hypertension Guidelines are reviewed and updated annually, for up-to-date recommendations, please see www.hypertension.ca/chep

Epidemiology
- 22% of Canadian adults suffer from HTN (prevalence is 52% in the 60-70 age group)
- lifetime risk of developing hypertension is approximately 90%
- 64% of Canadians who have HTN are treated and controlled, while 17% are unaware that they have HTN
- 3rd leading risk factor associated with death
  - risk factor for CAD, CFE, cerebrovascular disease, renal failure, peripheral vascular disease

Definitions
- HTN
  - BP ≥140/90 mmHg, unless DM (≥130/80 mmHg), or age ≥80 yr (≥150/90 mmHg)
- isolated systolic HTN
  - sBP ≥140 and dBP <90
  - associated with progressive reduction in vascular compliance
  - usually begins in 5th decade
- hypertensive urgency
  - sBP >210 or dBP ≥120 with minimal or no target-organ damage
- hypertensive emergency
  - severe HTN + acute target-organ damage
  - accelerated HTN
    - significant recent increase in BP over previous hypertensive levels associated with evidence of vascular damage on fundoscopy, but without papilledema
    - malignant HTN
      - sufficient elevation in BP to cause papilledema and other manifestations of vascular damage (retinal hemorrhages, bulging discs, mental status changes, increasing creatinine)
- white coat hypertension
  - high clinic BP with normal home BP and 24 ambulatory BP, caused by anxiety in clinic
- masked hypertension
  - normal clinic BP with high BP in home and/or ambulatory setting, often provoked by anxiety, job stress, exercise

Etiology
- essential (primary) HTN (>90%)
  - undetermined cause
  - secondary HTN (10%)

Predisposing Factors
- family history
- obesity (especially abdominal)
- alcohol consumption
- stress
- sedentary lifestyle
- smoking
- male
- age >30
- excessive salt intake/fatty diet
- African American ancestry
- dyslipidemia

Table 24. Causes of Secondary HTN

<table>
<thead>
<tr>
<th>Common Cause</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal</td>
</tr>
<tr>
<td>Renovascular HTN</td>
</tr>
<tr>
<td>Renal parenchymal disease, glomerulonephritis, pyelonephritis, polycystic kidney</td>
</tr>
<tr>
<td>Endocrine</td>
</tr>
<tr>
<td>1st hyperaldosteronism</td>
</tr>
<tr>
<td>Pheochromocytoma</td>
</tr>
<tr>
<td>Cushing’s syndrome</td>
</tr>
<tr>
<td>Hyperthyroidism/hyperparathyroidism</td>
</tr>
<tr>
<td>Hypercalcemia of any cause</td>
</tr>
<tr>
<td>Vascular</td>
</tr>
<tr>
<td>Coarctation of the aorta</td>
</tr>
<tr>
<td>Renal artery stenosis</td>
</tr>
<tr>
<td>Drug-Induced</td>
</tr>
<tr>
<td>Estrogens/OCP</td>
</tr>
<tr>
<td>MAOIs</td>
</tr>
<tr>
<td>Cocaine</td>
</tr>
<tr>
<td>Steroids</td>
</tr>
<tr>
<td>Lithium</td>
</tr>
<tr>
<td>Amphetamines</td>
</tr>
<tr>
<td>NSAIDs</td>
</tr>
<tr>
<td>Decongestants</td>
</tr>
</tbody>
</table>

Investigations
- for all patients with HTN
  - electrolytes, Cr, fasting glucose and/or HbA1c, lipid profile, 12-lead ECG, urinalysis
- self-measurement of BP at home is encouraged (recommended devices listed at www.hypertension.ca)
- for specific patient subgroups
  - DM or chronic kidney disease; urinary protein excretion
  - if suspected renovascular HTN: renal ultrasound, captopril renal scan (if GFR >60 mL/min), MRA/CTA (if normal renal function)
Diagnosis
- all Canadian adults should have BP assessed at all appropriate clinical visits, oscillometric preferred to manual

Treatment
- treat to target BP: <140/90 mmHg, <130/80 mmHg if DM, sBP<150 in very elderly (>80 yrs)
- optimum management of hypertension requires assessment of overall cardiac risk
- lifestyle modification (in all HTN patients)
  - may be sufficient in patients with stage 1 HTN (140-159/90-99)
  - diet
    - follow Canada’s Guide to Healthy Eating (see Nutrition, FM6) and Dietary Approaches to Stop Hypertension (DASH) (reduced cholesterol and saturated fats)
    - limit daily sodium intake to 65-100 mmol (1.5-2.3 g)
    - potassium/magnesium/calcium supplementations are NOT recommended for HTN
  - moderate intensity dynamic exercise: 30-60 min, 4-7 x/wk; higher intensity exercise is no more effective
  - smoking cessation
  - stress management
  - low-risk alcohol consumption (see Alcohol, FM12)
  - achieve and maintain a healthy BMI (18.5-24.9 kg/m²) and waist circumference (<102 cm for men, <88 cm for women); use multidisciplinary approach to weight loss
  - individualized cognitive behavioural interventions for stress management
- pharmacological
  - indications regardless of age (caution with elderly patients)
    - dBP ≥90 mmHg with target organ damage or independent cardiovascular risk factors
    - dBP ≥100 mmHg or sBP ≥160 mmHg without target organ damage or cardiovascular risk factors
    - sBP ≥140 with target organ damage
    - first line antihypertensives: thiazide/thiazide-like diuretic, ACEI (for non-African patients), ARB, long-acting CCB, β-blockers (if age <60)
    - if partial response to standard dose monotherapy, add another first-line drug
    - caution with combination of non-DHP CCB and β-blocker
    - combination of ACEI and ARB is not recommended
    - be cautious of hypokalemia in patients treated with thiazide/thiazide-like diuretic monotherapy
    - if still not controlled or adverse effects, can add other classes of anti-hypertensives
    - focus on adherence to health behaviour modification and pharmacotherapy; should be assessed at each visit

Figure 11. Assessment of patients with hypertension  Adapted from: CHEP 2015 Guidelines

Impact of Health Behaviour on Blood Pressure

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Systolic BP (mmHg)</th>
<th>Diastolic BP (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diet and weight control</td>
<td>-6.0</td>
<td>-4.8</td>
</tr>
<tr>
<td>Reduced salt/ sodium intake</td>
<td>-5.4</td>
<td>-2.8</td>
</tr>
<tr>
<td>Reduced alcohol intake (heavy drinkers)</td>
<td>-3.4</td>
<td>-3.4</td>
</tr>
<tr>
<td>DASH diet</td>
<td>-11.4</td>
<td>-5.5</td>
</tr>
<tr>
<td>Physical activity</td>
<td>-3.1</td>
<td>-1.8</td>
</tr>
<tr>
<td>Relaxation therapies</td>
<td>-3.7</td>
<td>-3.5</td>
</tr>
</tbody>
</table>


ACEI
Not recommended as monotherapy in people of African descent

β-blocker
Not recommended as first line for patients of age ≥60
Table 25. Pharmacologic Treatment of Hypertension in Patients with Unique Conditions

<table>
<thead>
<tr>
<th>Condition or Risk Factor</th>
<th>Recommended Drugs</th>
<th>Alternative Drugs</th>
<th>Not Recommended/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Isolated Diastolic HTN</strong></td>
<td>Thiazide diuretic, β-blocker, ACEI, ARB, or long-acting CCB (consider ASA and statin in select patients)</td>
<td>Combinations of first-line drugs</td>
<td>β-blocker monotherapy (age &gt;60) or combination of ACEI with an ARB</td>
</tr>
<tr>
<td><strong>Isolated Systolic HTN</strong></td>
<td>Thiazide diuretic, ARB, or long acting dihydropyridine CCB</td>
<td>Combinations of first-line drugs</td>
<td>Same as above</td>
</tr>
<tr>
<td><strong>CAD</strong></td>
<td>ACEI or ARB; β-blocker for patients with stable angina Long acting CCB, when combination therapy for high risk patients, ACEI/OHP CCB is preferred</td>
<td>Short-acting CCB (nifedipine) or ACEI + ARB is not recommended dBP 60 mmHg may exacerbate MI</td>
<td></td>
</tr>
<tr>
<td><strong>Prior MI</strong></td>
<td>β-blocker + ACEI (ARB if cannot tolerate ACEI) Long-acting CCB</td>
<td>ACEI + ARB combination is not recommended</td>
<td></td>
</tr>
<tr>
<td><strong>Left Ventricular Hypertrophy</strong></td>
<td>ACEI, ARB, thiazide, or long-acting CCB</td>
<td>Combination of additional agents</td>
<td>Hydralazine and minoxidil can increase LHV, thus not recommended</td>
</tr>
<tr>
<td><strong>Cerebrovascular Disease</strong> (stroke/TIA)</td>
<td>ACEI + diuretic</td>
<td>Combination of additional agents</td>
<td>ACEI + ARB combination after a stroke is not recommended</td>
</tr>
<tr>
<td><strong>Heart Failure</strong></td>
<td>ACEI (ARB if ACEI intolerant) and β-blocker Spironolactone in patients with NYHA class II-IV</td>
<td>ARB in addition to ACEI Hydralazine/soroside dinitrate combination if ARB or ACEI not tolerated/contraindicated</td>
<td>Non-DHP CCB not recommended Carefully monitor for side effects if using ACEI + ARB</td>
</tr>
<tr>
<td><strong>Dyslipidemias</strong></td>
<td>Does not affect initial treatment recommendations</td>
<td>Combination of additional agents</td>
<td></td>
</tr>
<tr>
<td><strong>DM with Albuminuria</strong> (ACR &gt;2.0 mg/mmol in men and &gt;2.8 mg/mmol in women)</td>
<td>ACEI or ARB (DHP CCB = HCTZ for combination therapy with ACEI) Add thiazide diuretic, cardioselective β-blocker, long acting CCB</td>
<td>If serum Cr &gt;150 µmol/L, a loop diuretic should be considered instead of low-dose thiazide diuretic</td>
<td></td>
</tr>
<tr>
<td><strong>DM without Albuminuria</strong> (criteria listed above)</td>
<td>ACEI, ARB, DHP CCB, or thiazide diuretic</td>
<td>Combination of first-line drugs or, first-line agents not tolerated, cardioselective β-blocker or non-DHP CCB</td>
<td>ACEI + ARB combination not recommended</td>
</tr>
<tr>
<td><strong>Non-Diabetic Chronic Kidney Disease with Proteinuria</strong> (urinary protein &gt;500 mg/24 h or ACR &gt;30 mg/mmol)</td>
<td>ACEI (ARB if ACEI intolerant), diuretic as additive therapy</td>
<td>Thiazide for additive antihypertensive therapy, loop diuretic for volume overload</td>
<td>ACEI + ARB combination is not recommended</td>
</tr>
<tr>
<td><strong>Renovascular Disease</strong></td>
<td>Same as HTN without other indications</td>
<td>Caution in using ACEI or ARB – monitor for AKI Renal angioplasty and stenting offer no benefits over optimal medical therapy alone</td>
<td></td>
</tr>
<tr>
<td><strong>Asthma</strong></td>
<td>K+-sparing + thiazide diuretic for patients on salbutamol</td>
<td>β-blocker, unless specific indications like angina or post-MI</td>
<td></td>
</tr>
<tr>
<td><strong>Gout</strong></td>
<td>Low dose thiazide ACEI</td>
<td>Thiazide, but asymptomatic hyperuricemia is not a contraindication</td>
<td></td>
</tr>
<tr>
<td><strong>Pregnancy</strong></td>
<td>Methylodon Hydralazine Labetolol Nifedipine</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Elderly (&gt;60 yr)</strong></td>
<td>As for uncomplicated isolated diastolic HTN, except for use of β-blocker</td>
<td>β-blocker not recommended as first line treatment</td>
<td></td>
</tr>
<tr>
<td><strong>Emergency</strong></td>
<td>BP &gt;169/90 = labetolol, nifedipine</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>If &gt;3 Cardiovascular Risk Factors or Established Atherosclerotic Disease</strong></td>
<td>Statin (age &gt;40), low-dose ASA (age &gt;50)</td>
<td>Caution with use of ASA in patients with uncontrolled BP</td>
<td></td>
</tr>
</tbody>
</table>

Follow-Up
• assess and encourage adherence to pharmacological and non-pharmacological therapy at every visit
• lifestyle modification q3-6mo
• pharmacological
  • q1-2mo until BP under target for 2 consecutive visits
  • more often for symptomatic HTN, severe HTN, antihypertensive drug intolerance, target organ damage
  • q3-6mo once at target BP
• referral is indicated for cases of refractory HTN, suspected secondary cause or worsening renal failure
• hospitalization is indicated for malignant HTN

Joint Pain

• see Rheumatology, RH3

Table 26. Differential Diagnosis of Joint Pain

<table>
<thead>
<tr>
<th>Localized Non-Articular</th>
<th>Generalized</th>
<th>Inflammatory</th>
<th>Articular</th>
<th>Degenerative</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bursitis</td>
<td>Fibromyalgia</td>
<td>Seropositive</td>
<td>Primary</td>
<td>Neoplastic</td>
<td></td>
</tr>
<tr>
<td>Tendonitis</td>
<td>Polymyalgia rheumatica</td>
<td>RA</td>
<td>Familial Heberden’s node</td>
<td>Drug-induced</td>
<td></td>
</tr>
<tr>
<td>Capsulitis</td>
<td>Myofascial pain syndrome</td>
<td>Systemic lupus erythematosus</td>
<td>Osteoarthritis</td>
<td>Endocrine (hyperthyroid, hypothyroid, hyperparathyroid)</td>
<td></td>
</tr>
</tbody>
</table>

History
• number of joints involved: monoarticular, oligoarticular, polyarticular
• pattern of joints involved: symmetrical vs. asymmetrical, large vs. small joints, axial skeleton
• onset: acute vs. chronic (>6 wk)
• trauma, infection, medications (steroids, diuretics)
• morning stiffness (duration) vs. worse at end of day
• FHx of arthritis
• comorbidities: DM (carpal tunnel syndrome), renal insufficiency (gout), psoriasis (psoriatic arthritis), myeloma (low back pain), osteoporosis (fracture), obesity (OA)
• constitutional symptoms (neoplasm)

Physical Exam
• vitals
• specific joint exams
• systemic features (skin, nails, eyes, hands)

Investigations (Guided by the History and Physical Exam)
• general: CBC and differential, electrolytes, Cr
• acute phase reactants: ESR, CRP, ferritin, albumin, fibrinogen
• complement (C3, C4)
• urine analysis to detect disease complications (proteinuria, active sediment)
• serology (ANA, anti-dsDNA, HLA-B27, anti-jo-1, anti-Sm, anti-Ro, RHF, and anti-CCP, etc.)
• synovial fluid analysis (cell count + differential, culture, Gram stain, microscopy)
• tissue cultures
• radiology (plain film, CT, MRI, U/S, bone densitometry, angiography, bone scan)

Treatment
• patient education including lifestyle modifications
• physiotherapy, occupational therapy
• manage pain (acetaminophen, NSAIDs)
• treat specific causes (e.g. antibiotics, DMARDs etc., see Rheumatology, RH26)

Signs and Symptoms of Inflammatory Arthritis

WARM(S) Joints
Worse with rest, better with activity
Awakening in the latter half of the night
Morning stiffness (>30 min)
Soft tissue swelling, erythema

Systemic Features
• Fever (SLE, infection)
• Rash (SLE, psoriatic arthritis)
• Nail abnormalities (psoriatic, reactive arthritis)
• Uveitis (psoriatic, reactive arthritis, ankylosing spondylitis)
• Myalgias (fibromyalgia, myopathy)
• Weakness (polymyositis, neuropathy)
• GI symptoms (scleroderma, IBD)
• GU symptoms (reactive arthritis, gonococcal)
Low Back Pain

- see Orthopedics, OR25

**Definition**
- acute: <6 wk
- subacute: 6-12 wk
- chronic: >12 wk

**Epidemiology**
- 5th most common reason for visiting a physician
- lifetime prevalence: 90%
- peak prevalence: age 45-60
- largest WSIB category
- most common cause of chronic disability for individuals <45 yr old
- 90% resolve in 6 wk, <5% become chronic

**Etiology**
- source of pain can be local, radicular, referred, or related to a psychiatric illness
- 98% are mechanical causes
  - pain is worse with movement, better with rest
  - sprain (ligament), strain (muscle), facet joint degeneration, disc degeneration/herniation, spinal stenosis (e.g. spondylosis), spondylolisthesis, compression fracture, pregnancy
- 2% are non-mechanical causes
  - surgical emergencies
    - cauda equina syndrome (areflexia, lower extremity weakness, decreased anal tone, saddle anesthesia, fecal incontinence, urinary retention), AAA (pulsatile abdominal mass)
  - medical conditions
    - neoplastic (primary, metastatic, multiple myeloma)
    - infectious (osteomyelitis, TB)
    - metabolic (osteoporosis, osteomalacia, Paget's disease)
    - rheumatologic (ankylosing spondylitis, polymyalgia rheumatica)
  - referred pain (perforated ulcer, pancreatitis, pyelonephritis, ectopic pregnancy, herpes zoster)

**Physical Exam**
- inspection: curvature, posture, gait
- palpation: bony deformities/tenderness, paraspinal muscle bulk/tenderness, trigger points
  - percussion of spine to elicit pain due to fracture or infection
- ROM and peripheral pulses
- neurologic exam for L4/L5/S1 helps determine level of spinal involvement (power, reflexes, sensation)
- special tests
  - straight leg raise (positive if pain at <70 degrees and aggravated by ankle dorsiflexion), positive test is indicative of sciatica
  - crossed straight leg raise (raising of uninvolved leg elicits pain in leg with sciatica), more specific than straight leg raise
  - femoral stretch test (patient prone, knee flexed, examiner extends hip) to diagnose L4 radiculopathy

**Investigations**
- plain films not recommended in initial evaluation
- if infection/cancer suspected: CBC, ESR
- if neurologic deficits worsening or infection/cancer suspected: consider CT or MRI
A Summary of the Guideline for the Evidence-Informed Primary Care Management of Low Back Pain

This evidence-informed guidelines is for non-specific, non-malignant low back pain in adults only.

Conduct a full assessment including:
- History taking
- Physical and neurological exam
- Evaluation of Red Flags
- Psychosocial risk factors/ Yellow Flags

Red Flags help identify rare, but potentially serious conditions. They include:
- Features of Cauda Equina Syndrome including sudden onset of loss of bladder/bowel control, saddle anesthesia (EMERGENCY)
- Severe worsening pain, especially at night or when lying down (URGENT)
- Significant trauma (URGENT)
- Weight loss, history of cancer, fever (URGENT)
- Use of steroids or intravenous drugs (URGENT)
- Patient with first episode over 50 years old, especially over 85 (SOON)
- Widespread neurological signs (SOON)

EMERGENCY — refer within hours
URGENT — refer within 24 – 48 hours
SOON — refer within weeks

Consider referring for evaluation and treatment (e.g., emergency room, surgical evaluation, relevant specialist)

ACUTE and SUBACUTE (within 12 weeks of pain onset)

1 – 6 WEEKS

Red flags (including Red Flags): if patient is not returning to normal function or symptoms are worrisome

Consider referral
- Physical therapist
- Chiropractor
- Osteopathic physician
- Physician specializing in musculoskeletal medicine
- Spinal surgeon (for unresolved radicular symptoms)
- Multidisciplinary pain program (if not returning to work)

Yellow Flags indicate psychosocial barriers to recovery. They include:
- Belief that pain and activity are harmful
- Stiffness behaviors (like extended rest
- Low or negative mood, social withdrawal
- Treatment expectations that do not fit best practice
- Problems with claim and compensation
- History of back pain, time-off, other claims
- Problems at work, poor job satisfaction
- Heavy work, unsociable hours (shift work)
- Disengaged family or lack of support

MODERATE TO SEVERE PAIN

Opioids (for appropriate patients: refer to the Canadian National Opioid Guideline endorsed by the College of Physicians and Surgeons of Alberta) (http://nationalpaincentre.mcmaster.ca/opioids)

Referral Options
- Community-based active rehabilitation program
- Community-based self-management/cognitive behavioral therapy program

Additional Options
- Progressive muscle relaxation
- Acupuncture
- Massage therapy, TENS as adjunct to active therapy
- Aqua therapy and yoga

Massage for Low Back Pain
Cochrane Syst Rev 2008;4:CD001192
This meta-analysis of 13 randomized trials assessed the use of massage therapy for non-specific low back pain compared to other active or sham treatments.

Conclusions: For some patients with subacute or chronic non-specific low back pain, massage may be beneficial, especially with education and exercises. Some evidence suggests that acupuncture massage may be more effective than classic massage but more studies are required to confirm these results.

Spinal Manipulative Therapy (SMT) for Acute Low-Back Pain
Cochrane Syst Rev 2012;9:CD008880
Conclusions: SMT is no more effective in participants with acute low-back pain than inert interventions, sham SMT, or when added to another intervention. SMT also appears to be no better than other recommended therapies.

Table 27. Approach to Non-Trueamatic Low Back Pain

<table>
<thead>
<tr>
<th>Back Dominant (Pain greatest above gluteal fold)</th>
<th>Leg Dominant (Pain greatest below gluteal fold)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>History</strong></td>
<td><strong>Pattern 1</strong></td>
</tr>
<tr>
<td>Worse with flexion</td>
<td>Constant/intermittent</td>
</tr>
<tr>
<td>Constant/intermittent</td>
<td></td>
</tr>
<tr>
<td><strong>Physical Exam</strong></td>
<td><strong>Pattern 2</strong></td>
</tr>
<tr>
<td>Normal neuro exam</td>
<td>Fast responder</td>
</tr>
<tr>
<td>Fast responder</td>
<td></td>
</tr>
<tr>
<td>Improves with extension</td>
<td>Worse with extension</td>
</tr>
<tr>
<td>Slow responder</td>
<td>No change or worsens with extension</td>
</tr>
<tr>
<td><strong>Likely Pathology</strong></td>
<td><strong>Sciatica</strong></td>
</tr>
<tr>
<td>Arising from intervertebral discs or adjacent ligaments</td>
<td></td>
</tr>
<tr>
<td><strong>Initial Management</strong></td>
<td><strong>Scheduled extension</strong></td>
</tr>
<tr>
<td>Lumbar roll</td>
<td>Limited extension</td>
</tr>
<tr>
<td>Night lumbar roll</td>
<td>Night lumbar roll</td>
</tr>
<tr>
<td>Medication as required</td>
<td>Medication as required</td>
</tr>
</tbody>
</table>

Menopause/Hormone Replacement Therapy

- see Gynecology, GY34

Epidemiology
- mean age of menopause = 51.4 yr

Clinical Features
- associated with estrogen deprivation
- urogenital tract: atrophy, vaginal dryness/itching, urinary frequency/urgency/incontinence, bleeding
- blood vessels and heart: vasomotor instability (e.g. hot flashes), increased risk of heart disease
- bones: bone loss, joint/muscle/back pain, fractures, loss of height
- brain: depression, irritability, mood swings, memory loss

Management
- encourage physical exercise, smoking cessation, and a balanced diet with adequate intake/supplementation of calcium (1,200-1,500 mg/d) and vitamin D (800-2,000 IU/d)
- hormone replacement therapy (HRT)
  - prescribe for moderate to severe symptoms for no longer than 5 yr; routine use is not recommended
  - regimens: cyclic estrogen-progesterin, continuous estrogen-progesterin, estrogen only (if no uterus), estrogen patch/gel/cream/ring/vaginal tablet
  - decreases risk of osteoporotic fractures, colorectal cancer
  - increases risk of breast cancer, coronary heart disease, stroke, DVT, and PE
  - initiation of HRT requires a thorough discussion of short- and long-term benefits and risks
- consider venlafaxine, SSRI, or gabapentin to ease vasomotor instability

Osteoarthritis

- see Rheumatology, RH5

Epidemiology
- most common form of arthritis seen in primary care
- prevalence is 10-12% and increases with age
- results in long-term disability in 2-3% of patients with OA
- almost everyone over the age of 65 shows signs of OA on x-ray, but only 33% of these individuals will be symptomatic

Clinical Features
- joint pain with activity, improved with rest, morning stiffness or gelling <30 min
- deformity, bony enlargement, crepitus, limitation of movement, peri-articular muscle atrophy
- usually affects distal joints of hands, spine, hips, and knees

Investigations
- no laboratory tests for the diagnosis of OA
- hallmark radiographic features: joint space narrowing, subchondral sclerosis, subchondral cysts, osteophytes

Management
- goals: relieve pain, preserve joint motion and function, prevent further injury
- conservative
  - patient education, weight loss, low-impact exercise (OT/PT), assistive devices (e.g. canes, orthotics, raised toilet seats)
- pharmacological
  - consider comorbidities such as PUD, HTN, IHD, hepatic disease, and renal disease
  - medications do not alter natural course of OA
  - 1st line: acetaminophen up to 4 g/d (OA is not an inflammatory disorder)
  - 2nd line NSAIDs in the lowest effective dose for the shortest duration of time, along with gastroprotection; COX-2 selective inhibitors (celecoxib/Celebrex®, Meloxicam/Mobicox®) are recommended if long-term treatment or if high risk for serious GI problems
  - combination analgesics (e.g. acetaminophen and codeine)
  - intra-articular hyaluronic acid injections
  - intra-articular corticosteroid injections (no more than 3-4x/yr) may be helpful in acute flares (benefits last 4-6 wk, can be up to 6 mo)
  - topical NSAIDs (diclofenac/Pennsaid®)
  - capsacin cream (Zostrix®)
  - oral glucosamine
  - surgery
- consider if persistent significant pain and functional impairment despite optimal pharmacotherapy (e.g. debridement, osteotomy, total joint arthroplasty)

Glucosamine Therapy for Treating Osteoarthritis

This meta-analysis of 25 single- and double-blinded randomized controlled trials with 4,963 patients compared glucosamine treatment, administered by any route, against placebo or another treatment.
Conclusions: Glucosamine can decrease pain and functional impairment resulting from OA and is not associated with any side effects compared to placebo. Differences in the effectiveness of Rotta and non-Rotta preparations highlight variability between glucosamine preparations and patients should be made aware of this.
Osteoporosis

- see Endocrinology, E40
- for current guidelines and tools see www.osteoporosis.ca
- age-related disease characterized by decreased bone mass and increased susceptibility to fractures
- affects 1 in 4 Canadian women and 1 in 8 Canadian men

**Management**
- see Endocrinology, E40

**Palliative and End-of-Life Care**
- see Geriatric Medicine, GM12

**Rash**

**ATOPIC DERMATITIS**
- affects all ages but is more common in children
- pruritus is the most common symptom; scratching worsens the rash creating a vicious cycle

**treatment**
- goals: limit itching, repair skin
- moisturizers, emollients, topical corticosteroids; oral corticosteroids and topical calcineurin inhibitors may be used
SEBORRHEIC DERMATITIS

- clinical features
  - affects all ages but is most common in infants within the first 3 mo of life (e.g. pityriasis capitis or “cradle cap”) and adults age 30-60 yr
  - affects the scalp, central face, and anterior chest; often presents as scalp scaling (dandruff) in adolescents and adults
  - may cause mild to marked erythema of the nasolabial fold, often with greasy scaling
- treatment
  - topical antifungals, topical low-potency steroids; topical calcineurin inhibitors may be used

ROSacea

- clinical features
  - stages: (1) facial flushing, (2) erythema and/or edema and ocular symptoms, (3) papules and pustules, (4) rhinophyma
- treatment
  - topical or oral antibiotics, oral retinoids
  - laser treatment may be an option for progressive telangiectasias or rhinophyma
  - referral may be required to manage rhinophyma, ocular complications, or severe disease

ACNE Vulgaris

- clinical features
  - types: (I) comedonal, (II) papular, (III) pustular, (IV) nodulocystic
  - predilection for the face, neck, upper chest, and back
- treatment
  - mild acne: topical treatments (antibiotics, benzoyl peroxide, retinoids)
  - moderate acne: after topical treatments have failed, add oral antibiotics and consider hormonal therapy
  - severe acne: consider systemic retinoids

ONYCHOMYCOSIS (Tinea Unguium)

- definition: fungal infection of the nail bed, matrix, or plate
- clinical features
  - occurs primarily in adults, most commonly after age 60
  - crumbling, distally dystrophic nails; yellowish, opaque with subungual hyperkeratotic debris
  - toenails are affected more often than fingernails
- investigations
  - microscopy of subungual scrapings under KOH preparation, culture
- treatment
  - oral antifungals (terbinafine/Lamisil™, itraconazole/Sporanox™), topical antifungals (ciclopirox/ Loprox™) are less effective

Sexually Transmitted Infections

- see Gynecology, GY27

Definition

- diverse group of infections caused by multiple microbial pathogens
- transmitted by either secretions or fluids from mucosal surfaces

Epidemiology

- high incidence rates worldwide
- Canadian prevalence in clinical practice
  - common: chlamydia (most common), gonorrhea (2nd most common), HPV, genital herpes (increasing incidence of chlamydia and gonorrhea)
  - less common: hepatitis B, HIV, and syphilis (increasing in incidence), trichomoniasis
  - rare: chancre, granuloma inguinale, lymphogranuloma venereum
- non-sexually transmitted genital tract infections: vulvovaginal candidiasis (VVC), bacterial vaginosis (BV)
- three most common infections associated with vaginal discharge in adult women are BV, VVC, and trichomoniasis

History

- sexual history
  - age of first intercourse, sexual orientation, sexual activity (oral, anal, and/or vaginal intercourse), sexual activity during travel
  - total number of partners in the past year/month/week and duration of involvement with each
- STI history
  - STI awareness, contraception, previous STIs and testing (including Pap tests), partner communication regarding STIs
  - local symptoms such as burning, itching, discharge, sores, vesicles, testicular pain, dysuria, abdominal pain
  - systemic symptoms such as fever, lymphadenopathy, arthralgia

STI Risk Factors

- Sexually active males and females < 25 yr old
- Unprotected sex, sexual contact with a known case of STI, previous STI
- New sexual partner or > 2 sexual partners in the past 12 mo
- Street involved, homeless, and/or substance abuse

Sexual History

S P’s
- Partners (numbers, gender)
- Practices (vaginal, oral, anal insertive/receptive)
- Protection
- Past history of STIs
- Pregnancy prevention
Investigations/Screening
- individuals at increased risk, even those who are asymptomatic, should be screened for chlamydia, gonorrhea, hepatitis B, HIV, and syphilis
- Pap test if none performed in the preceding 12 mo

Management
- primary prevention is vastly more effective than treating STIs and their sequelae
- offer hepatitis B vaccine if not immune
- offer Gardasil® to women over 9 years of age (can be offered to men as well but not covered by OHIP)
- discuss STI risk factors (e.g. decreasing the number of sexual partners)
- direct advice to ALWAYS use condoms or to abstain from intercourse
- condoms are not 100% effective against HIV or HSV
- an STI patient is not considered treated until the management of his/her partner(s) is ensured (contact tracing by Public Health)
- patients diagnosed with bacterial STI or trichomonal infection should abstain from sexual activity until treatment completion and for 7 d after treatment for both partners, or until test of cure completed
- mandatory reporting: chlamydia, gonorrhea, hepatitis B, HIV, syphilis

Table 28. Diagnosis and Treatment of Common STIs

<table>
<thead>
<tr>
<th>Signs and Symptoms</th>
<th>Investigations</th>
<th>Treatment</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gonococcal Urethritis/ Cervicitis</strong> (Neisseria gonorrhoeae)</td>
<td>M: urethral discharge, unexplained pyuria, dysuria, irritation, testicular swelling, SX of epididymitis F: mucopurulent endocervical discharge, vaginal bleeding, dysuria, pelvic pain, dyspareunia M and F: often asymptomatic, can involve rectal symptoms in cases of unprotected anal sex</td>
<td>M: urine swab for Gram stain and culture F: urine PCR, endocervical swab for Gram stain and culture, vaginal swab for wet mount (to rule out trichomons) M and F: urine PCR, rectal/ pharyngeal swabs if indicated</td>
<td>Ceftriaxone 250 mg IM single dose* If risk factors for treatment failure (e.g. pregnancy, pharyngeal/rectal infection, potentially reduced susceptibility) Test of cure: culture 4 d post-treatment (preferred) or urine PCR 2 wk post treatment (alternative) If no risk factors, rescreen 6-12 months post treatment</td>
</tr>
<tr>
<td><strong>Non-Gonococcal Urethritis/Cervicitis</strong> (Usually Chlamydia trachomatis**)</td>
<td>~ 70% asymptomatic If symptoms appear (usually 2-6 wk after infection) then similar to gonococcal symptoms (see above)</td>
<td>Same as above</td>
<td>Same as above</td>
</tr>
<tr>
<td><strong>Human Papillomavirus</strong> (genital warts, cervical dysplasia)</td>
<td>Most are asymptomatic M: cauliflower lesions (condyloma acuminata) on skin/mucosa of penile or anal area F: cauliflower lesions and/or pre-neoplastic/neoplastic lesions on cervix/vagina/vulva</td>
<td>None needed if simple condyloma Potential biopsy of suspicious lesions F: screening for cervical dysplasia through regular Pap smears</td>
<td>For condylomata: cryotherapy, electrocautery, laser excision, topical therapy (patient-applied or office-based) For cervical dysplasia: colposcopy and possible excision, dependent on grade of lesion</td>
</tr>
<tr>
<td><strong>Genital Herpes</strong> (HSV-1 and -2)</td>
<td>1° episode: painful vesiculocurative genital lesions = fever, tender lymphadenopathy, protracted course Recurrent episodes: less extensive lesions, shorter course may have “trigger factors”</td>
<td>Swab of vesicular content for culture, type-specific serologic testing for HSV-1 vs. HSV-2 antibodies and to determine 1° vs. recurrent episode</td>
<td>1° Episode Acyclovir 200 mg PO 5x/day x 5-10 d or Valacyclovir 1,000 mg PO bid x 10 d Recurrent Episode Acyclovir 200 mg PO 5x/day x 5d or 800 mg PO tid x 2 d or Famiciclovir 125 mg PO bid x 5 d or Valacyclovir 500 mg PO bid x 3 d or 1,000 mg PO OD x 3 d</td>
</tr>
<tr>
<td><strong>Infectious Syphilis</strong> (Treponema pallidum)</td>
<td>1°: chancre (painless sore), regional lymphadenopathy 2°: rash and flu-like symptoms, meningitis, H/A, urethritis, reitinitis, condyloma lata, mucus lesions, alopecia Late Phase: asymptomatic 3°: neurologic, cardiovascular, and tissue complications</td>
<td>Specimen collection from 1° and 2° lesions, screen high risk individuals with serologic syphilis testing (VGRIL), universal screening of pregnant women</td>
<td>Benzathine penicillin G IM (dose depends on stage and patient population. Check Public Health Canada guidelines) Notify partners (last 3-12 mo) Continuous follow-up and testing until patients are seronegative</td>
</tr>
</tbody>
</table>
Sinusitis

- see Otolaryngology, OT24

Etiology
- viral etiology is more common
- viral: rhinovirus, influenza, parainfluenza
- bacterial: S. pneumoniae, H. influenzae, M. catarrhalis

Management of Acute Sinusitis
- may provide symptom relief: oral analgesics (acetaminophen, NSAIDs), nasal saline rinse, short-term use of topical or oral decongestants
- do not prescribe antihistamines
- intra-nasal corticosteroids if diagnosed with mild to moderate acute bacterial sinusitis
- antibiotics and intra-nasal corticosteroids if diagnosed with severe acute bacterial sinusitis
- ENT referral if: anatomic defect (e.g. deviated septum, polyp, adenoid hypertrophy), failure of second-line therapy, ≥4 episodes/yr, development of complications (e.g. mucocele, orbital extension, meningitis, intra-cranial abscess, venous sinus thrombosis)

Figure 15. Diagnosis and management of sinusitis

ABRS = acute bacterial rhinosinusitis
Sleep Disorders

• see Respirology, R31 and Neurology, N46

Definition
• most often characterized by one of three complaints
  ■ insomnia
    • difficulty falling asleep, difficulty maintaining sleep, early-morning wakening, non-refreshing sleep
  ■ parasomnias
    • night terrors, nightmares, restless leg syndrome, somnambulism (performing complex behaviour during sleep with eyes open but without memory of event)
    • excessive daytime sleepiness

Epidemiology
• 1/3 of patients in primary care setting have occasional sleep problems, 10% have chronic sleep problems

Etiology
• primary sleep disorders
  ■ primary insomnia, narcolepsy, obstructive sleep apnea, restless leg syndrome, periodic limb movements of sleep
• secondary causes
  ■ medical: COPD, asthma, CHF, hyperthyroidism, chronic pain, BPH, menopause, GERD, PUD, pregnancy, neurological disorders
  ■ drugs: alcohol, caffeine, nicotine, nicotine replacement therapy, β-agonists, antidepressants, steroids
  ■ psychiatric: mood and anxiety disorders
  ■ lifestyle factors: shift work, jet-lag

Investigations
• complete sleep diary every morning for 1-2 wk
  ■ record bedtime, sleep latency, total sleep time, awakenings, quality of sleep
• rule out specific medical problems (e.g. CBC and differential, TSH)
• refer for sleep study, nocturnal polysomnogram, or daytime multiple sleep latency test if suspicion of sleep apnea or periodic limb movements of sleep

Treatment of Specific Problems
• Primary insomnia
  ■ majority of cases
  ■ person reacts to insomnia with fear or anxiety around bedtime or with a change in sleep hygiene, which can progress to a chronic disorder (psychophysiological insomnia)
  ■ treat any suspected medical or psychiatric cause
  ■ behaviour-based treatment
    ■ sleep hygiene: avoid alcohol, caffeine, nicotine; comfortable sleep environment; regular sleep schedule; no napping
    ■ exercise regularly, avoid heavy exercise within 3 h of bedtime
    ■ relaxation therapy: deep breathing, meditation, biofeedback
    ■ stimulus control therapy: re-association of bed/bedroom with sleep, re-establishment of a consistent sleep-wake schedule, reduce activities that cue staying awake
    ■ sleep restriction therapy: total time in bed should closely match the total sleep time of the patient (improves sleep efficacy)
    ■ CBT: address inappropriate beliefs and attitudes that perpetuate dysfunctional sleep
  ■ pharmacologic treatment
    ■ short-acting benzodiazepines (e.g. lorazepam, oxazepam, temazepam) at the lowest effective dose should be used <7 consecutive nights to break cycle of chronic insomnia or to manage an exacerbation of previously controlled primary insomnia
    ■ non-benzodiazepines: zopiclone (Imovane®), zolpidem (Sublinox®), melatonin, low dose antidepressants with sedating properties (amitriptyline, trazadone, mirtazapine)
    ■ follow-up every 2-4 wk initially (to reinforce behavioural interventions and renew/consider pharmacotherapy) then every 3 mo; if no progress or limited improvement, consider referral to sleep medicine program

• Snoring
  ■ results from soft tissue vibration at the back of the nose and throat due to turbulent airflow through narrowed air passages
  ■ physical exam: obesity, nasal polyps, septal deviation, hypertrophy of the nasal turbinates, enlarged uvula and tonsils
  ■ investigations (only if severely symptomatic): nocturnal polysomnography and airway assessment (CT/MRI)
  ■ treatment
    ■ sleep on side (position therapy), weight loss
    ■ nasal dilators (noninvasive external dilator made with elastic adhesive backing applied over nasal bridge), tongue-retaining devices, mandibular advancement devices
    ■ at risk of developing obstructive sleep apnea
• **Obstructive Sleep Apnea (OSA)**
  - apnea (no breathing for ≥10 s) resulting from upper airway obstruction due to collapse of the base of the tongue, soft palate with uvula, and epiglottis; respiratory effort is present
  - leads to a distinctive snorting, choking, awakening type pattern as the body rouses itself to open the airway (resuscitative breath)
  - apneic episodes can last from 20 s-3 min and occur 100-600 episodes/night
  - diagnosis is based on nocturnal polysomnography: >15 apneic/hypopneic episodes per hour of sleep with arousal recorded
  - consequences
    - daytime somnolence, non-restorative sleep
    - poor social and work performance
    - mood changes: anxiety, irritability, depression
    - sexual dysfunction: libido, impotence
    - morning headache (due to hypercapnia)
    - HTN (2x increased risk), CAD (3x increased risk), stroke (4x increased risk), arrhythmias
  - OSA is an independent risk factor for CAD
  - pulmonary HTN, right ventricular dysfunction, cor pulmonale (due to chronic hypoxemia)
  - memory loss, decreased concentration, confusion
  - investigations
    - valuate BP, inspect nose and oropharynx (enlarged adenoids or tonsils)
    - blood gas not helpful, TSH if clinically indicated
    - nocturnal polysomnography
  - treatment
    - modifiable factors: avoid sleeping supine; weight loss; avoid alcohol, sedatives, opioids; inhaled steroids if nasal swelling present; dental appliances to modify mandibular position
    - primary treatment of OSA is CPAP: maintains patent airway in 95% of OSA cases
    - surgery: somnoplasty, uvulopalatopharyngoplasty (UPPP), tonsillectomy, and adenoidectomy (in children)
    - report patient to Ministry of Transportation if OSA is not controlled by CPAP

---

**Sore Throat (Pharyngitis)**

**Definition**
- inflammation of the oropharynx
- may be caused by a wide range of infectious organisms, most of which produce a self-limited infection with no significant sequelae

**Etiology**
- viral: adenovirus, rhinovirus, influenza virus, RSV, EBV, coxsackie virus, herpes simplex virus, CMV, HIV
- bacterial: Group A β-Hemolytic Streptococcus (GABHS), Group C and Group β-Hemolytic Streptococcus, Neisseria gonorrhoeae, Chlamydia pneumoniae, Mycoplasma pneumoniae, Corynebacterium diphtheriae

**Epidemiology**
- viral
  - most common cause (90% in adults is viral), occurs year round
- bacterial
  - GABHS (Group A β-Hemolytic Streptococcal Infections)
    - most common bacterial cause
    - occurs most often in winter months
    - 5-15% of adult cases and up to 50% of all pediatric cases of acute pharyngitis
    - most prevalent between 5-17 yr old

**Clinical Features**
- viral
  - pharyngitis, conjunctivitis, rhinorrhea, hoarseness, cough
  - nonspecific flu-like symptoms such as fever, malaise, and myalgia
  - often mimics bacterial infection
- common viral infections
  - EBV (infectious mononucleosis)
    - pharyngitis, tonsillar exudate, fever, lymphadenopathy, fatigue, rash
  - coxsackie virus (hand, foot, and mouth disease)
    - primarily late summer, early fall
    - sudden onset of fever, pharyngitis, headache, abdominal pain, and vomiting
    - appearance of small vesicles that rupture and ulcerate on soft palate, tonsils, pharynx
      - ulcers are pale grey and several mm in diameter, have surrounding erythema, and may appear on hands and feet
  - herpes simplex virus
    - like coxsackie virus but ulcers are fewer and larger
      - pharyngitis, tonsillar exudate, fever, lymphadenopathy, fatigue, rash
• bacterial
  ■ symptoms: pharyngitis, fever, malaise, headache, abdominal pain, absence of cough
  ■ signs: fever, tonsillar or pharyngeal erythema/exudate, swollen/tender anterior cervical nodes, halitosis
  ■ complications: rheumatic fever, glomerulonephritis, suppurrative complications (abscess, sinusitis, otitis media, cervical adenitis, pneumonia), meningitis, impetigo

Investigations
• suspected GABHS
  ■ see Table 29 for approach to diagnosis and management of GABHS
  ■ gold standard for diagnosis is throat culture
  ■ rapid test for streptococcal antigen: high specificity (95%) but low sensitivity (50-90%)
  ■ suspected EBV (infectious mononucleosis)
    ● peripheral blood smear, heterophile antibody test (i.e. the latex agglutination assay or “monospot”)

Table 29. Modified Centor Score: Approach to Diagnosis and Management of GABHS

<table>
<thead>
<tr>
<th>POINTS</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4 or more</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cough absent?</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>History of fever &gt;38ºC?</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tonsillar exudate?</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Swollen, tender anterior nodes?</td>
<td></td>
<td></td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age 3-14</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Age 15-44</td>
<td></td>
<td></td>
<td></td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Age &gt;45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>–1</td>
</tr>
</tbody>
</table>

In communities with moderate levels of strep infection (10-20% of sore throats):

<table>
<thead>
<tr>
<th>Score</th>
<th>1-2.5%</th>
<th>5-10%</th>
<th>11-17%</th>
<th>28-35%</th>
<th>51-53%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suggested action</td>
<td>NO culture or antibiotic</td>
<td>Culture all, treat with antibiotics only if culture is positive</td>
<td>Culture all, treat with antibiotics on clinical grounds, discontinue antibiotics if culture comes back negative</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Management
• viral pharyngitis
  ■ antibiotics not indicated
  ■ symptomatic therapy: acetaminophen/NSAIDs for fever and muscle aches, decongestants
• GABHS
  ■ antibiotic treatment decreases severity and duration of symptoms, risk of transmission (after 24 h of treatment), and risk of rheumatic fever and suppurrative complications
  ■ incidence of glomerulonephritis is not decreased with antibiotic treatment
  ■ no increased incidence of rheumatic fever with 48 h delay in antibiotic treatment; if possible, delay antibiotic treatment until culture confirms diagnosis
  ■ routine F/U and/or post-treatment throat cultures are not required for most patients
  ■ F/U throat culture only recommended for: patients with history of rheumatic fever, patients of family member(s) with history of acute rheumatic fever, suspected streptococcal carrier
• infectious mononucleosis (EBV)
  ■ self-limiting course; antibiotics are not indicated
  ■ symptomatic treatment: acetaminophen/NSAIDs for fever, pharyngitis, malaise
  ■ avoid heavy physical activity and contact sports for at least one month or until splenomegaly resolves because of risk of splenic rupture
  ■ if acute airway obstruction, give corticosteroids and consult ENT
Complementary and Alternative Medicine

**Epidemiology**
- 50-75% of Canadians report some use of CAM over their lifetime, and only half will disclose this use to their physician
- use is highest in Western provinces and lowest in Atlantic provinces
- more likely to be used by younger patients and those with higher education and income
- examples: chiropractic, acupuncture, massage, naturopathy, homeopathy, traditional Chinese medicine, craniosacral therapy, osteopathy

**Herbal Products**
- over 50% of Canadians use natural health products (NHPs)
- most commonly used include echinacea, ginseng, ginkgo, garlic, St. John’s wort, and soy
- relatively few herbal products have been shown to be effective in clinical trials
- many patients believe herbal products are inherently safe and are unaware of potential side effects and interactions with conventional medicines
- all NHPs must be regulated under The Natural Health Products Regulations as of January 1, 2004, including herbal remedies, homeopathic medicines, vitamins, minerals, traditional medicines, probiotics, amino acids, and essential fatty acids (e.g. omega-3)
- always ask patients whether they are taking any herbal product, herbal supplement, or other natural remedy. Further questions may include:
  - Are you taking any prescription or non-prescription medications for the same purpose as the herbal product?
  - Are you allergic to any plant products?
  - Are you pregnant or breastfeeding?
- information resources: National Center for CAM (www.nccam.nih.gov), Health Canada website

**Table 30. Common Herbal Products**

<table>
<thead>
<tr>
<th>Common Name</th>
<th>Reported Uses</th>
<th>Possible Adverse Effects</th>
<th>Possible Drug Interactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Black Cohosh</td>
<td>Menopausal symptoms, PMS, labour induction, arthritis</td>
<td>Hepatitis, liver failure, headaches, GI discomfort, heaviness in legs, weight problems</td>
<td>None reported</td>
</tr>
<tr>
<td>Chamomile</td>
<td>Mild sedative, anxiolytic, GI complaints, common cold</td>
<td>Allergic/contact dermatitis, anaphylaxis</td>
<td>Anxiolytics, sedatives</td>
</tr>
<tr>
<td>Echinacea</td>
<td>Common cold, flu, wound treatment, UTI, cancer</td>
<td>Hypersensitivity, hepatotoxicity with prolonged use, avoid use if immunosuppressed</td>
<td>Potentiates warfarin</td>
</tr>
<tr>
<td>Evening Primrose</td>
<td>Dysmenorrhoea, menopausal sx, inflammation, allergies, eczema, arthritis, MS</td>
<td>Headache, restlessness, nausea, diarrhea, may decrease seizure threshold</td>
<td>Anticoagulants, antiplatelets</td>
</tr>
<tr>
<td>Feverfew</td>
<td>Migraine prevention, RA, anti-inflammatory</td>
<td>Anxiety, upset stomach, skin rash, miscarriage</td>
<td>Anticoagulants, antiplatelets</td>
</tr>
<tr>
<td>Flaxseed Oil</td>
<td>Laxative, menopausal symptoms, source of omega-3 fatty acids</td>
<td>Diarrhea</td>
<td>Do not take with other medications as fibre content can bind drugs</td>
</tr>
<tr>
<td>Garlic</td>
<td>Elevated lipids, HTN, hyperglycemia, antimicrobial</td>
<td>GI irritation, contact dermatitis, may increase post-operative bleeding</td>
<td>Anticoagulants, potentiates antihypertensives</td>
</tr>
<tr>
<td>Ginger</td>
<td>Nausea, motion sickness, dyspepsia, anti-inflammatory</td>
<td>Heartburn, not to be used for morning sickness</td>
<td>None known</td>
</tr>
<tr>
<td>Ginkgo Biloba</td>
<td>Increases peripheral circulation (AD, dementia, intermittent claudication), premenstrual syndrome, vertigo</td>
<td>Headache, cramping, bleeding, mild digestive problems; reports of intracranial hemorrhage</td>
<td>Anticoagulants, thiazide diuretics, MAO inhibitors</td>
</tr>
<tr>
<td>Ginseng</td>
<td>Energy enhancer, decreases stress, adjunct support for chemotherapy/ radiation</td>
<td>HTN, nervousness, insomnia, breakthrough bleeding, palpitations</td>
<td>Stimulant medications, antihypertensives, hormonal therapies</td>
</tr>
<tr>
<td>Glucosamine</td>
<td>Osteoarthritis</td>
<td>GI distress, headache, drowsiness, palpitations</td>
<td>Caution if shellfish allergy</td>
</tr>
<tr>
<td>Glucosamine (Chondroitin)</td>
<td>Osteoarthritis</td>
<td>GI distress, headache, drowsiness, palpitations</td>
<td>Caution if shellfish allergy</td>
</tr>
<tr>
<td>Saw Palmetto</td>
<td>BPH, adjunct to finasteride</td>
<td>Mild GI distress</td>
<td>α-adrenergics, finasteride</td>
</tr>
<tr>
<td>St. John’s Wort</td>
<td>Mild to moderate depression</td>
<td>Photosensitivity, increased liver enzymes, drowsiness, diziness, nausea, headache</td>
<td>CNS depressants, contraindicated with indinavir</td>
</tr>
<tr>
<td>Valerian Root</td>
<td>Sedative, anxiolytic, muscle relaxant, PMS</td>
<td>Drowsiness, headache, digestive problems, paradoxical insomnia</td>
<td>CNS depressants, antihistamines</td>
</tr>
</tbody>
</table>
# Primary Care Models

## Table 31. Primary Care Models (Adapted from www.healthforceontario.ca)

<table>
<thead>
<tr>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Comprehensive Care Model</strong></td>
</tr>
<tr>
<td>Payment model: fee-for-service</td>
</tr>
<tr>
<td><strong>Family Health Team</strong></td>
</tr>
<tr>
<td>Wider range of services (e.g. rehabilitation, palliative care), with increased after-hours availability</td>
</tr>
<tr>
<td>Receives provincial funding for allied health</td>
</tr>
<tr>
<td>Patient enrolment is strongly encouraged</td>
</tr>
<tr>
<td>Payment model: paid annually per patient rostered depending on demographic category (blended capitation model)</td>
</tr>
<tr>
<td><strong>Family Health Group</strong></td>
</tr>
<tr>
<td>Physicians commit to enroll patients</td>
</tr>
<tr>
<td>Payment model: blended capitation model i.e. age- and sex-adjusted base rate remuneration plus bonuses and incentives</td>
</tr>
<tr>
<td><strong>Family Health Network</strong></td>
</tr>
<tr>
<td><strong>Family Health Organization</strong></td>
</tr>
<tr>
<td>Physicians commit to enrol patients</td>
</tr>
<tr>
<td>Must sign governance and Family Health Organization agreements to join</td>
</tr>
<tr>
<td>Payment model: blended capitation model i.e. age- and sex-adjusted base rate remuneration plus bonuses and incentives</td>
</tr>
</tbody>
</table>

## Antimicrobial Quick Reference

### RESPIRATORY/ENT

#### Acute Rhinitis
(common cold)

- Rhinovirus, coronavirus, influenza, RSV, parainfluenza, adenovirus
- None

#### Pharyngitis
(sore throat)

- Rhinovirus, adenovirus, influenza, parainfluenza, coxsackievirus, coronavirus
- None

#### Strep Pharyngitis

- Group A β-Hemolytic Streptococcus
- Children: 1st line: penicillin V 40 mg/kg/d PO div bid-tid (max 750 mg/d) x 10 d (use adult dose if >27 kg) amoxicillin 40 mg/kg/d PO div bid-tid x 10 d 2nd line: erythromycin estolate 40 mg/kg/d PO div bid-tid x 10 d 3rd line: cephalaxin 25-50 mg/kg/d PO div qid x 10 d cefprozil 15 mg/kg/d PO div bid x 10 d Adults: 1st line: penicillin V 300 mg PO tid or 600 mg bid x 10 d 2nd line: erythromycin 250 mg PO qid x 10 d 3rd line: cephalexin 250 mg PO qid x 10 d cefadroxil 500 mg PO bid x 10 d

#### Sinusitis

- S. pneumoniae
- H. influenzae
- M. catarrhalis
- S. aureus
- Children: 1st line: amoxicillin 80 mg/kg/d PO div bid-tid x 5-10 d (max 3 g/d) x 10-14 d 2nd line: amoxicillin/clavulanate 40-80 mg/kg/d PO div bid (max 3 g/d) x 10-14 d cefprozil 30 mg/kg/d PO div bid x 10-14 d 3rd line: cefuroxime-AX 30-40 mg/kg/d PO div bid x 10-14 d clarithromycin 15 mg/kg/d PO div bid x 10-14 d Adults: 1st line: amoxicillin 500 mg PO tid x 5-10 d 2nd line: amoxicillin/clavulanate 500 or 875 mg PO bid x 5-10 d cefuroxime-AX 250-500 mg PO bid x 5-10 d 3rd line: levofloxacin 500 mg PO OD x 5-10 d moxifloxacin 400 mg PO OD x 5-10 d
<table>
<thead>
<tr>
<th>Condition</th>
<th>Microorganisms</th>
<th>Antimicrobial</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute Otitis Media</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common Cold (WBC &gt; 5 x 10^9/L)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic TM perforation or ventilation tubes:</td>
<td>Ciprodex® otic suspension 4 drops bid x 5 d</td>
<td></td>
</tr>
<tr>
<td>Adults:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1st line:</td>
<td></td>
<td>amoxicillin 500 mg PO tid x 7-10 d</td>
</tr>
<tr>
<td>2nd line:</td>
<td></td>
<td>clarithromycin 500 mg PO bid or 1,000 mg (ER) PO OD x 7-14 d</td>
</tr>
<tr>
<td><strong>Community Acquired Pneumonia:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Community Acquired Pneumonia:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;3 BM/d, no blood, no fever:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate to severe:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;3 BM/d, blood, fever:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multilocular fluctuant:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Penicillin V potassium 500 mg PO qid x 7-10 d</td>
<td>clindamycin 300 mg PO qid or 600 mg bid x 7-10 d</td>
<td></td>
</tr>
<tr>
<td><strong>Gastroenterology</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Diarrhea – Enteritis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enterotoxigenic E. coli (ETEC)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Campylobacter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salmonella</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shigella</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viruses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protozoa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Flora</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gastroenterology</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Diarrhea – Post Abx</strong> (common with clindamycin)</td>
<td>C. difficile</td>
<td>Mild to moderate (WBC &lt; 5 x 10^9/L and Cr &lt; 1.5 x baseline): metronidazole 500 mg PO tid or 250 mg PO qid x 10 d (children: 15-30 mg/kg/d PO div tid-qid max 4 g/d)</td>
</tr>
<tr>
<td><strong>Peptic Ulcer Disease</strong> (non-NSAID related)</td>
<td>H. pylori</td>
<td>1st line: (PPI PO bid + amoxicillin 1,000 mg PO bid + clarithromycin 500 mg PO bid) x 7 d (e.g. HP-PAC: lansoprazole 30 mg PO bid + amoxicillin 1,000 mg PO bid + clarithromycin 500 mg PO bid) x 7 d)</td>
</tr>
<tr>
<td>Condition</td>
<td>Microorganisms</td>
<td>Antimicrobial</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-----------------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>DERMATOLOGIC</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Head and Pubic Lice (crabs)</td>
<td>Pediculosis humanus capitis Phthirius pubis</td>
<td>permethrin cream 1%: apply as liquid onto washed hair for 10 min, then rinse; repeat in 1 wk</td>
</tr>
<tr>
<td>Vulvovaginal Candidiasis</td>
<td>Candida</td>
<td>Treat only if patient is symptomatic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>fluconazole 150 mg PO single dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td>miconazole 2% cream (Monistat 7®): one applicator (5 g) intravaginally qhs x 7 d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>multiple other OTC azole treatments</td>
</tr>
<tr>
<td>Bacterial Vaginosis</td>
<td>Overgrowth of: G. vaginalis M. hominis Anaerobes</td>
<td>If patient is asymptomatic, treatment is unnecessary unless high-risk pregnancy, prior IUD insertion, gynecologic surgery, induced abortion, or upper tract instrumentation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1st line: metronidazole 500 mg PO bid x 7 d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>metronidazole 0.75% gel: one applicator (5 g) intravaginally qhs x 7 d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>clindamycin 2% cream: one applicator (5 g) intravaginally qhs x 7 d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2nd line: metronidazole 2 g PO single dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td>clindamycin 300 mg PO bid x 7 d</td>
</tr>
<tr>
<td>Herpes</td>
<td>Herpes simplex virus</td>
<td>1° episode: acyclovir 400 mg PO tid x 5-7 d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>famciclovir 250 mg PO tid x 5-7 d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>valacyclovir 500-1,000 mg PO bid x 5-7 d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Recurrent Episode: acyclovir 400 mg PO tid x 5 d or 800 mg PO bid x 5 d 800 mg PO tid x 2 d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>famciclovir 125 mg PO bid x 5 d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>valacyclovir 500 mg PO bid x 3 d or 1,000 mg PO OD x 3 d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pregnancy:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1° episode: acyclovir 200 mg PO 5x/d x 5-10 d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prior infection within previous yr: acyclovir 200 mg PO qid at 36 wk</td>
</tr>
<tr>
<td></td>
<td></td>
<td>valacyclovir 500 mg PO bid at 36 wk</td>
</tr>
<tr>
<td>Gonorrhea/Chlamydia</td>
<td>N. gonorrhoeae C. trachomatis</td>
<td>ceftriaxone 250 mg IM x 1 dose + azithromycin 1 g PO</td>
</tr>
<tr>
<td>Mastitis</td>
<td>S. aureus</td>
<td>cloxacillin 500 mg PO qid x 7 d</td>
</tr>
<tr>
<td></td>
<td>S. pyogenes</td>
<td>cephalaxin 500 mg PO qid x 7 d</td>
</tr>
<tr>
<td>Tinea Cruris/Pedis (jock itch/athlete’s foot)</td>
<td>Trichophyton</td>
<td>clotrimazole 1% cream bid</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ketoconazole 2% cream bid</td>
</tr>
<tr>
<td>Uncomplicated Cellulitis</td>
<td>S. aureus</td>
<td>Children:</td>
</tr>
<tr>
<td></td>
<td>Group A Streptococcus</td>
<td>1st line: cephalaxin 50-100 mg/kg/d div qid x 10-14 d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2nd line: cloxacillin 50 mg/kg/d div qid x 10-14 d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>clindamycin 25 mg/kg/d x 10-14 d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adults:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1st line: cephalaxin 500 mg PO qid x 10-14 d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2nd line: cloxacillin 500 mg PO qid x 10-14 d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>clindamycin 300 mg PO x 10-14 d</td>
</tr>
</tbody>
</table>
Gastroenterology

Rory Blackler, Michael Tjong, and Gary Tran, chapter editors
Claudia Frankfurter and Inna Gong, associate editors
Brittany Prevost and Robert Vanner, EBM editors
Dr. Maria Cino, Dr. Gabor Kandel, and Dr. Piero Tartaro, staff editors

Acronyms ........................................ 2

Anatomy Review ................................. 2
Overview of Gastrointestinal Tract
Visualizing the GI Tract

Differential Diagnosis of Common Complaints . . . 4

Esophagus ........................................ 6
Gastroesophageal Reflux Disease
Barrett’s Esophagus
Dysphagia
Esophageal Motor Disorders
Esophageal Diverticula
Peptic Stricture (from Esophagitis)
Esophageal Carcinoma
Webs and Rings
Infectious Esophagitis

Stomach and Duodenum ....................... 10
Dyspepsia
Stomach
Gastritis
Peptic Ulcer Disease
H. pylori-Induced Peptic Ulceration
NSAID-Induced Ulceration
Stress-Induced Ulceration
Gastric Carcinoma

Small and Large Bowel ....................... 14
Classification of Diarrhea
Acute Diarrhea
Traveller’s Diarrhea
Chronic Diarrhea
Maldigestion and Malabsorption
Celiac Disease (Gluten Enteropathy/Sprue)
Inflammatory Bowel Disease
Crohn’s Disease
Ulcerative Colitis
Irritable Bowel Syndrome
Constipation
Upper Gastrointestinal Bleeding
Esophageal Varices
Mallory-Weiss Tear
Lower Gastrointestinal Bleeding
Colorectal Carcinoma
Colorectal Polyps
Familial Colon Cancer Syndromes
Benign Anorectal Disease

Liver .............................................. 28
Investigations of Hepatobiliary Disease
Acute Viral Hepatitis (General)
Hepatitis A Virus
Hepatitis B Virus
Hepatitis D
Hepatitis C Virus
Autoimmune Chronic Active Hepatitis
Drug-Induced Liver Disease
Wilson’s Disease

Biliary Tract ................................. 40
Jaundice
Gilbert’s Syndrome
Primary Sclerosing Cholangitis
Primary Biliary Cholangitis (formerly cirrhosis)
Secondary Biliary Cirrhosis
Biliary Colic, Cholecystitis
Ascending Cholangitis

Pancreas ........................................ 43
Pancreatic Enzyme Abnormalities
Acute Pancreatitis
Chronic Pancreatitis
Autoimmune Pancreatitis

Clinical Nutrition ......................... 47
Determination of Nutritional Status
Enteral Nutrition
Parenteral Nutrition

Common Medications ....................... 49

Landmark Gastroenterology Trials .......... 51

References ...................................... 51
### Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALF</td>
<td>acute liver failure</td>
</tr>
<tr>
<td>BE</td>
<td>Barrett’s esophagus</td>
</tr>
<tr>
<td>BT</td>
<td>bethologic therapy</td>
</tr>
<tr>
<td>CCK</td>
<td>cholecystokinin</td>
</tr>
<tr>
<td>CD</td>
<td>Crohn’s disease</td>
</tr>
<tr>
<td>DM</td>
<td>diabetes mellitus</td>
</tr>
<tr>
<td>DPG</td>
<td>deamidated gliadin peptides</td>
</tr>
<tr>
<td>DES</td>
<td>diffuse esophageal spasm</td>
</tr>
<tr>
<td>EIM</td>
<td>extraintestinal manifestation</td>
</tr>
<tr>
<td>EN</td>
<td>enteral nutrition</td>
</tr>
<tr>
<td>ERCP</td>
<td>endoscopic retrograde cholesgiopancreatography</td>
</tr>
<tr>
<td>EUS</td>
<td>endoscopic ultrasound</td>
</tr>
<tr>
<td>EVL</td>
<td>endoscopic variceal ligation</td>
</tr>
<tr>
<td>FAP</td>
<td>familial adenomatous polyposis</td>
</tr>
<tr>
<td>GE</td>
<td>gastroesophageal</td>
</tr>
<tr>
<td>GERD</td>
<td>gastroesophageal reflex disease</td>
</tr>
<tr>
<td>GI</td>
<td>gastrointestinal</td>
</tr>
<tr>
<td>HAV</td>
<td>hepatitis A virus</td>
</tr>
<tr>
<td>HBV</td>
<td>hepatitis B virus</td>
</tr>
<tr>
<td>HCC</td>
<td>hepatocellular carcinoma</td>
</tr>
<tr>
<td>HCV</td>
<td>hepatitis C virus</td>
</tr>
<tr>
<td>HRPCC</td>
<td>hereditary non-polyposis colorectal cancer</td>
</tr>
<tr>
<td>HRS</td>
<td>hepatorenal syndrome</td>
</tr>
<tr>
<td>HVPG</td>
<td>hepatic venous pressure gradient</td>
</tr>
<tr>
<td>IBD</td>
<td>inflammatory bowel disease</td>
</tr>
<tr>
<td>IBS</td>
<td>irritable bowel syndrome</td>
</tr>
<tr>
<td>ICP</td>
<td>intracranial pressure</td>
</tr>
<tr>
<td>INH</td>
<td>isoniazid</td>
</tr>
<tr>
<td>LES</td>
<td>lower esophageal sphincter</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>MS</td>
<td>multiple sclerosis</td>
</tr>
<tr>
<td>NAC</td>
<td>N-acetyl cysteine</td>
</tr>
<tr>
<td>NAPLD</td>
<td>non-alcoholic fatty liver disease</td>
</tr>
<tr>
<td>NERD</td>
<td>non-erosive reflux disease</td>
</tr>
<tr>
<td>NMS</td>
<td>neuroleptic malignant syndrome</td>
</tr>
<tr>
<td>OGD</td>
<td>oesophagogastrroduodenoscopy</td>
</tr>
<tr>
<td>PBC</td>
<td>primary biliary cirrhosis</td>
</tr>
<tr>
<td>PN</td>
<td>parenteral nutrition</td>
</tr>
<tr>
<td>PPI</td>
<td>proton pump inhibitor</td>
</tr>
<tr>
<td>PSC</td>
<td>primary sclerosing cholangitis</td>
</tr>
<tr>
<td>PTC</td>
<td>percutaneous transhepatic cholangiography</td>
</tr>
<tr>
<td>PUD</td>
<td>peptic ulcer disease</td>
</tr>
<tr>
<td>SBP</td>
<td>spontaneous bacterial peritonitis</td>
</tr>
<tr>
<td>TIPS</td>
<td>transjugular intrahepatic portosystemic shunt</td>
</tr>
<tr>
<td>TPN</td>
<td>total parenteral nutrition</td>
</tr>
<tr>
<td>TTG</td>
<td>tissue transglaminase</td>
</tr>
<tr>
<td>UC</td>
<td>ulcerative colitis</td>
</tr>
</tbody>
</table>

### Anatomy Review

**Overview of Gastrointestinal Tract**

- the gastrointestinal tract runs from mouth to anus (“gum to bum”)
Table 1. Summary of Gastrointestinal Tract Structure and Function

<table>
<thead>
<tr>
<th>Organ</th>
<th>Function</th>
<th>Blood Supply</th>
<th>Innervation</th>
<th>Histology and Structural Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Esophagus</td>
<td>Muscular tube approximately 25 cm long with a diameter of 2 cm</td>
<td>Arterial: left gastric artery and left inferior phrenic artery</td>
<td>Parasympathetic innervation via anterior and posterior gastric nerves (vagal trunks)</td>
<td>Mucous: stratified squamous epithelium</td>
</tr>
<tr>
<td></td>
<td>Extends from pharynx to the stomach</td>
<td>Venous: Left gastric vein → portal venous system</td>
<td>Sympathetic innervation via thoracic trunks of the greater splanchnic nerves</td>
<td>Submucosa: connective tissue, lymphocytes, plasma cells, nerve cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Esophageal veins → aygos vein → IVC (systemic)</td>
<td></td>
<td>Muscularis propria (muscularis externa): inner circular, outer longitudinal muscle</td>
</tr>
<tr>
<td>Stomach</td>
<td>Delivers food to intestine for digestion and absorption</td>
<td>Lesser curvature</td>
<td>Parasympathetic innervation via vagus nerve</td>
<td>Upper 1/3: stratified muscle</td>
</tr>
<tr>
<td></td>
<td>Secrectes acid, probably to reduce enteric infections/pneumonia; facilitate digestion of protein/iron/B12</td>
<td>Right and left gastric arteries (from celiac trunk)</td>
<td>Sympathetic innervation via greater and lesser splanchnic nerves</td>
<td>Middle 1/2: transition zone</td>
</tr>
<tr>
<td></td>
<td>Secrectes intrinsic factor to facilitate B12 absorption</td>
<td>Greater curvature</td>
<td></td>
<td>Lower 1/3: smooth muscle</td>
</tr>
<tr>
<td></td>
<td>Minor contribution to initial protein digestion via pepsin</td>
<td>Right and left gastro-omental (gastronemial) arteries</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(from gastroduodenal and splenic arteries respectively)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fundus: short and posterior gastric arteries (from the splenic artery)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duodenum</td>
<td>Modulates enteral pH via secretin → decreased gastric acid secretion; increased bicarbonate secretion</td>
<td>Branches of celiac artery and superior mesenteric artery</td>
<td>Parasympathetic innervation via vagus nerve</td>
<td>5 parts</td>
</tr>
<tr>
<td></td>
<td>Secretes CCK to stimulate bile secretion</td>
<td>Superior mesenteric artery</td>
<td>Sympathetic innervation via greater and lesser splanchnic nerves</td>
<td>Superior (5 cm)</td>
</tr>
<tr>
<td></td>
<td>Site of iron absorption</td>
<td></td>
<td></td>
<td>Descending (7-10 cm)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ascending (9 cm)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1st part is intraperitoneal; rest is retroperitoneal</td>
<td></td>
</tr>
<tr>
<td>Jejunum</td>
<td>Absorption of sodium, water, and nutrients</td>
<td>Superior mesenteric artery</td>
<td>Parasympathetic innervation via fibres of the posterior vagal trunk</td>
<td>Deep red colour</td>
</tr>
<tr>
<td></td>
<td>(protein, carbohydrates, fat, folic acid, and vitamin A, B, C, D, E, K)</td>
<td></td>
<td>Sympathetic innervation via fibres of T8-T10</td>
<td>2-4 cm in thickness</td>
</tr>
<tr>
<td>Illeum</td>
<td>Absorption of sodium, water, nutrients, soluble vitamins (only site of vitamin B12 absorption), and bile salts (entero-hepatic circulation)</td>
<td>Superior mesenteric artery</td>
<td>Same as jejunum</td>
<td>Thick and heavy wall</td>
</tr>
<tr>
<td>Large Bowel</td>
<td>Absorption of water (5-10% of total water)</td>
<td>Branches of superior and inferior mesenteric arteries</td>
<td>When compared to jejunum</td>
<td>Plicae circulares are large, tall, and closely packed</td>
</tr>
<tr>
<td></td>
<td>Bacteria: further digestion of chyme and metabolism of undigested CHO</td>
<td>Rectal blood supply: sigmoid, right pudendal, and rectal arteries</td>
<td>Paler pink colour</td>
<td>Has long vasa recta</td>
</tr>
<tr>
<td></td>
<td>to short chain fatty acids</td>
<td></td>
<td>Scant fat in mesentery</td>
<td>Szent Peyer’s patches</td>
</tr>
<tr>
<td></td>
<td>Formation and storage of feces</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>Glucose homeostasis</td>
<td>2 sources</td>
<td>Largest internal organ</td>
<td>Consists of cecum, colon (ascending, transverse, descending, and sigmoid), rectum and anal canal</td>
</tr>
<tr>
<td></td>
<td>Plasma protein synthesis</td>
<td>Portal vein (75-80%)</td>
<td>Composed of 4 lobes (left, right, caudate, quadrato), and divided into 8 segments</td>
<td>Features include teniae cell, haustra, and omental appendices</td>
</tr>
<tr>
<td></td>
<td>Lipid and lipoprotein synthesis</td>
<td>Hepatic artery (20-25%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biliary Tract</td>
<td>Gallbladder functions to store and release bile that is produced in the liver</td>
<td>Cystic artery</td>
<td>Parasympathetic innervation via vagus nerve</td>
<td>Consists of the hepatic ducts (intrahepatic, left, right and common), gallbladder, cystic duct, common bile duct, and ampulla of Vater</td>
</tr>
<tr>
<td></td>
<td>Bile is used to emulsify fat and is composed of cholesterol, lecithin, bile acids, and bilinilin</td>
<td></td>
<td>Sympathetic and visceral innervation via celiac plexus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CCK stimulates gallbladder emptying while trypsin and chymotrypsin inhibit bile release</td>
<td></td>
<td>Somatic afferent fibres via right phrenic nerve</td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td>Endocrine function: islets of Langerhans produce glucagon, insulin, and somatostatin</td>
<td>Anterior superior pancreaticoduodenal artery (from the celiac trunk)</td>
<td>Parasympathetic innervation via vagus nerve</td>
<td>4 parts of pancreas: head (includes uncinate process), neck, body, and tail (Major) pancreatic duct connecting to common bile duct prior to ampulla of Vater</td>
</tr>
<tr>
<td></td>
<td>Exocrine function: digestive enzymes are produced including amylase, lipase, trypsin, chymotrypsin, and carboxypeptidase</td>
<td>Anterior inferior pancreaticoduodenal artery (from the superior mesenteric artery)</td>
<td>Sympathetic innervation via abdominopelvic splanchnic nerves</td>
<td>Accessory pancreatic duct connected directly to duodenum</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dorsal pancreatic artery (from the splenic artery)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pancreatic veins drain into the portal, splenic, and superior mesenteric veins</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Visualizing the GI Tract

- see Medical Imaging, MI15

Esophagus, Stomach, Duodenum
- OGD: best visualization of mucosa; also allows for therapeutic intervention (e.g. banding varices, thermal therapy/clipping/injecting bleeding ulcers, and dilatation e.g. treatment of esophageal strictures)
  - consider barium swallow first if dysphagia, decreased level of consciousness (increases risk of aspiration), inability to cooperate (increases risk of pharyngeal trauma during intubation), possibility of fistulas
  - endotracheal intubation first if massive upper GI bleed, acidemia, or inability to protect airway

Small Bowel
- most difficult to visualize, especially if mucosal detail is needed
- CT enterography more accurate than small bowel follow through, but both have low sensitivity
- MRI small bowel imaging increasingly available, especially useful if radiation exposure is an issue (e.g. young patient, multiple radiological images already done)
  - note: MRI enteroclysis: luminal contrast administered by nasojejunal tube to dilate the small bowel – disliked by both radiologist and patient, but may improve sensitivity
  - “double balloon” enteroscopy (enteroscope with proximal and distal balloons to propel endoscope into jejunum from mouth or into jejunum/ileum or into ileus from anus) may be most sensitive but currently available only in selected centres; technically demanding
  - wireless endoscopy capsule (26 x 11 mm capsule is swallowed, transmits images to a computer; contraindicated in bowel obstruction) is also accurate in diagnosis but unable to provide any therapeutic intervention

Colon and Terminal ileum
- colonoscopy, with biopsy if required; contraindicated in perforation, acute diverticulitis, and severe colitis (increased risk of perforation)
- CT colonography (“virtual colonoscopy”) more accurate in diagnosing diverticulosis, extrinsic pressure on colon (e.g. ovarian cancer compressing sigmoid colon), and fistulae; increasing evidence for use in colorectal cancer screening, especially for assessment of right side of colon in cases where colonoscopy is less sensitive. Most often used when optical endoscopic colonoscopy is a risk (e.g. frail elderly) or unsuccessful (e.g. stricture).
  - most often used when optical endoscopic colonoscopy is a risk (e.g. frail elderly) or unsuccessful (e.g. stricture)

Pancreatic/Biliary Duct
- MRCP almost as sensitive as ERCP in determining if bile duct obstruction present, but less accurate in determining cause of obstruction (tumour, stone, stricture)
- ERCP if therapeutic intervention likely to be required: strong suspicion of stone, obstruction requiring stenting, or if tissue sampling required

Differential Diagnosis of Common Complaints

- see General Surgery, Acute Abdominal Pain, GS4

Table 2. Differential Diagnosis of Common Presenting Complaints

<table>
<thead>
<tr>
<th>CHRONIC/RECURRENT ABDOMINAL PAIN</th>
<th>Inflammatory</th>
<th>Neoplastic/Vascular</th>
<th>Toxic</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>PUD</td>
<td>Recurrent bowel obstruction</td>
<td>Meckel’s diverticulum</td>
<td>Sickle cell anemia</td>
<td>Mittelschmerz</td>
</tr>
<tr>
<td>Bilary colic</td>
<td>Lead poisoning</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IBD</td>
<td></td>
<td>Mesenteric ischemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic pancreatitis</td>
<td></td>
<td>Sideo aneurysm</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ACUTE DIARRHEA

<table>
<thead>
<tr>
<th>Causes of bloody diarrhea</th>
<th>Inflammatory</th>
<th>Non-Inflammatory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial</td>
<td>Protozoal</td>
<td></td>
</tr>
<tr>
<td><em>Staphylococcus</em></td>
<td><em>E. histolytica</em></td>
<td><em>Giardia lamblia</em></td>
</tr>
<tr>
<td><em>Salmonella</em></td>
<td>Strongyloides</td>
<td><em>Rotavirus</em></td>
</tr>
<tr>
<td><em>Campylobacter</em></td>
<td></td>
<td><em>Norwalk</em></td>
</tr>
<tr>
<td><em>Yersinia</em></td>
<td></td>
<td><em>CMV</em></td>
</tr>
<tr>
<td><em>Entamoeba histolytica</em></td>
<td></td>
<td><strong>Antacids</strong> (magnesium)</td>
</tr>
<tr>
<td><em>Anaerobes</em></td>
<td></td>
<td><em>Antacids</em> (magnesium)</td>
</tr>
<tr>
<td><em>Vibrio cholera</em></td>
<td></td>
<td><em>Antacids</em> (magnesium)</td>
</tr>
<tr>
<td><em>Protozoa</em></td>
<td></td>
<td><em>Antacids</em> (magnesium)</td>
</tr>
<tr>
<td><em>Giardia lamblia</em></td>
<td></td>
<td><em>Antacids</em> (magnesium)</td>
</tr>
</tbody>
</table>

Inflammatory Diarrhea: Occurs when there is damage to the mucosal lining or brush border, which leads to a passive loss of protein-rich fluids and a decreased ability to absorb these lost fluids. Diarrhea may be profuse or very small in volume. Often associated with abdominal pain, fever and cramps.

Non-Inflammatory Diarrhea: No damage to the mucosal lining. N/V may be present. Fever, chills, blood in the stool, severe abdominal pain or tenderness are not present.
Table 2. Differential Diagnosis of Common Presenting Complaints (continued)

<table>
<thead>
<tr>
<th>CHRONIC DIARRHEA</th>
<th>Inflammatory</th>
<th>Secretory</th>
<th>Steatorrhea</th>
<th>Osmotic</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Causes of bloody diarrhea</em></td>
<td>BD*&lt;br&gt;(TB, CMV, HSV)&lt;br&gt;Ishemic bowel&lt;br&gt;Radiation colitis&lt;br&gt;Neoplasia&lt;br&gt;C. difficile rarely causes bleeding</td>
<td>Stimulant laxatives&lt;br&gt;Post-ulcer resection/cholecystectomy (bile salts)&lt;br&gt;Bacterial toxins&lt;br&gt;Vancomycin&lt;br&gt;Neoplasia <em>(colon ca, carcinoma, VIPoma)</em>&lt;br&gt;Addison’s disease</td>
<td>Giardia lamblia&lt;br&gt;Celiac sprue&lt;br&gt;Chronic pancreatitis&lt;br&gt;Radioabortion&lt;br&gt;Chronic cholelithiasis</td>
<td>Omotic laxatives&lt;br&gt;Lactose intolerance&lt;br&gt;Chewing gum (sorbitol, mannitol)</td>
</tr>
</tbody>
</table>

**CONSTITUTION:** if no associated rectal bleeding/weight loss, etc., usually no cause found (and dysmotility assumed)

<table>
<thead>
<tr>
<th>UPPER GI BLEED</th>
<th>Common</th>
<th>Uncommon</th>
<th>Rare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastric outlet obstruction</td>
<td>Gastric outlet obstruction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Small bowel obstruction</td>
<td>Small bowel obstruction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GERD (regurgitation more common)</td>
<td>GERD (regurgitation more common)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Functional dyspepsia</td>
<td>Functional dyspepsia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug side effect</td>
<td>Drug side effect</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peptic ulcer</td>
<td>Peptic ulcer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GERD (esophagitis)</td>
<td>GERD (esophagitis)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lower GI Bleed</td>
<td>Lower GI Bleed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diverticulosis</td>
<td>Diverticulosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ischemia</td>
<td>Ischemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angiodysplasia (elderly/infected)</td>
<td>Angiodysplasia (elderly/infected)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infectious</td>
<td>Infectious</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anorectal (hemorrhoids, fissure, ulcer)</td>
<td>Anorectal (hemorrhoids, fissure, ulcer)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>Dyspepsia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanical (Solids)</td>
<td>Mechanical (Solids)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Motility (Solids and Liquids)</td>
<td>Motility (Solids and Liquids)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanical stricture/cancer</td>
<td>Mechanical stricture/cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Esophageal varices</td>
<td>Esophageal varices</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mallory-Weiss tears</td>
<td>Mallory-Weiss tears</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erosive esophagitis</td>
<td>Erosive esophagitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erosive gastritis</td>
<td>Erosive gastritis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dysphagia</td>
<td>Dysphagia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Odynophagia</td>
<td>Odynophagia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>Osteoporosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herpes</td>
<td>Herpes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CMV (common in those who are immunosuppressed)</td>
<td>CMV (common in those who are immunosuppressed)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABDOMINAL DISTENTION</td>
<td>Fluid (Ascites)</td>
<td>Flatulence</td>
<td>Feces</td>
</tr>
<tr>
<td>Portal HTN</td>
<td>Portal HTN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal Portal Pressure</td>
<td>Normal Portal Pressure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cirrhosis</td>
<td>Cirrhosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac failure</td>
<td>Cardiac failure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatic vein thrombosis</td>
<td>Hepatic vein thrombosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fat</td>
<td>Fat</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feces</td>
<td>Feces</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy (fetus)</td>
<td>Pregnancy (fetus)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td>Constipation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colonic obstruction</td>
<td>Colonic obstruction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dysmotility</td>
<td>Dysmotility</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>Death</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large tumours (fatal growth)</td>
<td>Large tumours (fatal growth)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Commonly Forgotten Causes of Vomiting**
- Drugs
- Uremia
- CNS Disease
- Pregnancy
- Marijuana (cannabinoid hyperemesis)

**Difference Between Dysphagia and Odynophagia**
- Dysphagia: Difficulty swallowing due to mechanical obstruction or dysmotility of the esophagus or pharynx
- Odynophagia: Pain when swallowing due to ulceration or inflammation (e.g. eosinophilic esophagitis) in the esophagus or pharynx

**Differential Diagnosis Abdominal Distention**
- 6 Fs
- Fat
- Feces
- Pregnancy
- Fluid
- Fetal Growth
Table 2. Differential Diagnosis of Common Presenting Complaints (continued)

<table>
<thead>
<tr>
<th>JAUNDICE (UNCONJUGATED BILIRUBIN)</th>
<th>Overproduction</th>
<th>Decreased Hepatic Intake</th>
<th>Decreased Conjugation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemydys</td>
<td>Gilbert’s syndrome</td>
<td>Drug inhibition (e.g. chloramphenicol)</td>
<td></td>
</tr>
<tr>
<td>ineffective erythropoiesis</td>
<td>Drugs (e.g. rifampin)</td>
<td>Crigier-Najjar syndromes type I and II</td>
<td></td>
</tr>
<tr>
<td>(e.g. megaloblastic anemias)</td>
<td></td>
<td>Gilbert’s syndrome</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neonatal jaundice</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>JAUNDICE (CONJUGATED BILIRUBIN)</th>
<th>Common</th>
<th>Uncommon</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatocellular disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cirrhosis (any cause)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammation (hepatitis, any cause)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infective (e.g. hemochromatosis)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Familial disorders (e.g. Rotor syndrome, Dubin-Johnson syndrome, cholestasis of pregnancy)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PBC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sepris</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-operative/TPN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intraductal obstruction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gallstones</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biliary stricture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parasites</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignancy (cholangiocarcinoma)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sclerosing cholangitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extra ductal obstruction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignancy (e.g. pancreatic cancer, lymphoma)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metastases in peri-portal nodes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammation (e.g. pancreatitis)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Esophagus

Gastroesophageal Reflux Disease

Definition
- condition in which the stomach contents (most characteristically acid) moves backwards from the stomach into the esophagus

Etiology
- inappropriate transient relaxations of LES – most common cause
- low basal LES tone (especially in scleroderma)
- contributing factors include: delayed esophageal clearance, delayed gastric emptying, obesity, pregnancy, acid hypersecretion (rare) from Zollinger-Ellison syndrome (gastrin-secreting tumour)
- hiatus hernia worsens reflux, does not cause it (see General Surgery, GS13)

Clinical Features
- "heartburn" (pyrosis) and acid regurgitation (together are 80% sensitive and specific for reflux) ± sour regurgitation; less sensitive and less specific: water brash, sensation of a lump in the throat (globus sensation), and frequent belching
- non-esophageal symptoms are increasingly recognized of being poor predictors of reflux

Investigations
- usually, a clinical diagnosis is sufficient based on symptom history and relief following a trial of pharmacotherapy (PPI: symptom relief 80% sensitive for reflux)
  - absolute indications
    - heartburn accompanied by red-flags (bleeding, weight loss, etc.)
    - persistent reflux symptoms or prior severe erosive esophagitis after therapeutic trial of 4-8 wk of PPI 2x daily
    - history suggests esophageal stricture especially dysphagia
    - high risk for Barrett’s (male, age >50, obese, white, tobacco use, long history of symptoms)
    - repeat endoscopy after 6-8 wks of PPI therapy indicated if: severe esophagitis because it can mask Barrett’s esophagus or symptoms
    - esophageal manometry (study of esophageal motility)
    - done to diagnose abnormal peristalsis and/or decreased LES tone, but cannot detect presence of reflux; indicated before surgical fundoplication to ensure intact esophageal function

Figure 2. Signs and symptoms of GERD

Gastroesophageal Reflux Disease

Gastroscopy

Non-erosive reflux disease (NERD)
Normal esophagus
Aim for symptom relief only; proton pump inhibitor PRN

Esophagitis
Esophageal inflammation
Aim to heal inflammation; proton pump inhibitor indefinitely or surgical fundoplication

Figure 3. Classification and gastroscopic findings of GERD

Bowel Ischemia
The splenic flexure and rectosigmoid junction are watershed areas and are susceptible to ischemia. History and symptoms include acute onset crampy left abdominal pain, absence of abdominal tenderness on exam, rectal bleeding, and risk factors for embolization, atherosclerosis and atrial fibrillation

Dyspepsia = postprandial fullness, early satiety, epigastric pain, or burning

Foods/Substances that Aggravate GERD
- EOH
- Caffeine
- Tobacco
- Fatty/fried foods
- Chocolate
- Peppermint
- Spicy foods
- Citrus fruit juices
• surgical fundoplication (wrapping of gastric fundus around the lower end of the esophagus) more likely to alleviate symptoms if lower esophageal pressure is diminished; less likely to be successful if abnormal peristalsis
• 24 h pH monitoring: most accurate test for reflux, but not required or performed in most cases
• most useful if PPIs do not improve symptoms

Treatment
• PPIs are the most effective therapy and usually need to be continued as maintenance therapy
• on-demand: antacids (Mg(OH)₂, Al(OH)₃, alginate), H₂-blockers, or PPIs can be used for NERD
• diet helps symptoms, not the disease; avoid alcohol, coffee, spices, tomatoes, and citrus juices
• only beneficial lifestyle changes are weight loss (if obese) and elevating the head of bed (if nocturnal symptoms)
• symptoms may recur if therapy is discontinued

Complications
• esophageal stricture disease – scarring can lead to dysphagia (solids)
• ulcer
• bleeding
• Barrett’s esophagus and esophageal adenocarcinoma – gastroscopy is recommended for patients with chronic GERD or symptoms suggestive of complicated disease (e.g. anorexia, weight loss, bleeding, dysphagia)

Barrett’s Esophagus

Definition
• metaplasia of normal squamous esophageal epithelium to abnormal columnar epithelium containing-type intestinal mucosa (intestinal metaplasia)

Etiology
• thought to be acquired via long-standing GERD and consequent damage to squamous epithelium

Epidemiology
• in North America and Western Europe, 0.5-2.0% of adults are thought to have Barrett’s esophagus
• up to 10% of GERD patients will have already developed BE by the time they seek medical attention
• more common in males, age >50, Caucasians, smokers, overweight, hiatus hernia, and long history of reflux symptoms

Pathophysiology
• endoscopy shows erythematous epithelium in distal esophagus; diagnosis of BE relies on biopsy demonstrating the presence of specialized intestinal epithelium of any length within the esophagus
• BE predisposes first to premalignant changes characterized as low or high-grade dysplasia, which then progresses to adenocarcinoma

Significance
• rate of malignant transformation is approximately 0.12% per yr for all BE patients prior to dysplasia
• risk of malignant transformation in high-grade dysplasia is significantly higher; studies have reported a 32-59% transformation rate over 5-8 yr of surveillance
• increased gastric acid secretion is more frequently associated with Barrett’s esophagus as opposed to reflux alone

Treatment
• acid suppressive therapy with high-dose PPI indefinitely (or surgical fundoplication)
• endoscopy every 3 yr if no dysplasia
• high grade dysplasia: regular and frequent surveillance with intensive biopsy, endoscopic ablation/resection, or esophagectomy produce similar outcomes; however, evidence increasingly favouring endoscopic ablation with mucosal resection or radiofrequency ablation
• if low grade dysplasia, both surveillance and endoscopic ablation/resection are satisfactory options
# Dysphagia

**Definition**
- difficulty swallowing

**Figure 4. Approach to dysphagia (eosinophilic esophagitis omitted)**

### Esophageal Motor Disorders

**Clinical Features**
- dysphagia with solids and liquids
- chest pain (in some disorders)

**Diagnosis**
- motility study (esophageal manometry)
- barium swallow sometimes helpful

**Causes**
- idiopathic
- achalasia (painless)
- scleroderma (painless)
- DM
- DES: rare and can be difficult to diagnose due to intermittent presentation

**Table 3. Esophageal Motor Disorders**

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Achalasia</th>
<th>Scleroderma</th>
<th>Diffuse Esophageal Spasm</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definition</strong></td>
<td>Failure of smooth muscle relaxation at LES&lt;br&gt;Progressive loss of peristaltic function</td>
<td>See Rheumatology, RH13&lt;br&gt;Systemic disease characterized by vasculopathy and tissue fibrosis (especially skin thickening)</td>
<td>Normal peristalsis interspersed with frequent, repetitive, spontaneous, high pressure, non-peristaltic waves (tertiary peristalsis)</td>
</tr>
<tr>
<td><strong>Etiology</strong></td>
<td>Usually idiopathic&lt;br&gt;2º or pseudo-achalasia: e.g. malignancy, Chagas disease (Trypanosoma cruzi)</td>
<td>Involves autoimmune, genetic, hormonal, and environmental factors&lt;br&gt;Idiopathic</td>
<td>Idiopathic</td>
</tr>
<tr>
<td><strong>Pathophysiology</strong></td>
<td>Inflammatory degeneration of Auerbach’s plexus → increase in LES pressure, incomplete relaxation of LES with swallowing, aperistalsis</td>
<td>Blood vessel damage → intramural neuronal dysfunction → distal esophageal muscle weakening → aperistalsis and loss of LES tone → reflux → stricture → dysphagia</td>
<td>Potential mechanisms include impaired inhibitory innervation to esophageal body, malfunction in endogenous nitric oxide synthesis</td>
</tr>
<tr>
<td><strong>Diagnosis</strong></td>
<td>CXR: no air in stomach, dilated esophagus&lt;br&gt;Barium studies: esophagus terminates in narrowing at LES (“bird’s beak”)&lt;br&gt;Endoscopy: normal mucosa&lt;br&gt;Manometry: definitive diagnosis (signs listed above)</td>
<td>Clinical features of scleroderma&lt;br&gt;Manometry: decreased pressure in LES, decreased peristalsis in body of esophagus</td>
<td>Barium x-ray: “Corkscrew pattern”&lt;br&gt;Manometry: &gt;30% (but &lt;100%) of esophageal contractions are aperistaltic&lt;br&gt;Endoscopy: normal mucosa</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>Dilatation of LES with balloon, = GERD prophylaxis, 50% good response, can repeat, risk of perforation (5%)&lt;br&gt;Injection of botulinum toxin into LES (temporary)&lt;br&gt;POEM (peroral endoscopic myotomy)</td>
<td>Medical: aggressive GERD therapy&lt;br&gt;PPis bid&lt;br&gt;Surgery: anti-reflux surgery (gastropasty, last resort)</td>
<td>Reassurance not cardiac pain&lt;br&gt;Medical: nitrates, calcium channel blockers, anticoagulants have variable benefit&lt;br&gt;Surgical: long esophageal myotomy if unresponsive to above treatment (rarely helpful); balloon dilatation</td>
</tr>
</tbody>
</table>
Esophageal Diverticula

Definition
• outpouchings of one or more layers of the esophageal tract

Clinical Features
• commonly associated with motility disorders
• dysphagia, regurgitation, retrosternal pain, intermittent vomiting, may be asymptomatic

Classification
• classified according to location
  • pharyngoesophageal (Zenker’s) diverticulum
    • most frequent form of esophageal diverticulum
  • posterior pharyngeal outpouching most often on the left side, above cricopharyngeal muscle and below the inferior pharyngeal constrictor muscle
  • symptoms: dysphagia, regurgitation of undigested food, halitosis
  • treatment: endoscopic or surgical myotomy of cricopharyngeal muscle or surgical excision of sac
  • mid-esophageal diverticulum
    • secondary to mediastinal inflammation (“traction” diverticulae), motor disorders
    • usually asymptomatic; no treatment required
  • just proximal to LES (pulsatile type)
    • usually associated with motor disorders
    • usually asymptomatic, no treatment required

Peptic Stricture (from Esophagitis)
• presents as dysphagia alongside a long history of reflux symptoms, but reflux symptoms may disappear as stricture develops
• diagnosed with endoscopy or barium study if endoscopy contraindicated or unavailable

Treatment
• endoscopic dilatation and indefinite PPI

Esophageal Carcinoma
• see General Surgery, GS15

Webs and Rings
• web = partial occlusion (upper esophagus)
• ring = circumferential narrowing (lower esophagus)

Clinical Features
• asymptomatic with lumen diameter >12 mm, provided peristalsis is normal
• dysphagia with large food boluses
• Schatzki ring
  • mucosal ring at squamo-columnar junction above a hiatus hernia
  • causes intermittent dysphagia with solids
  • treatment involves disrupting ring with endoscopic bougie

Infectious Esophagitis

Definition
• severe mucosal inflammation and ulceration as a result of a viral or a fungal infection

Risk Factors
• DM
• chemotherapeutic agents
• immunocompromised states

Clinical Features
• characteristically odynophagia, less often dysphagia
• diagnosis is via endoscopic visualization and biopsy

Appearance
• Candida (most common): whitish-yellow plaques without visible ulceration or inflammation
• Herpes (second most common), CMV: focal ulcers

Plummer-Vinson Syndrome Triad
• Iron deficiency anemia
• Dysphagia
• Esophageal webs
* rare (prevalence <1 in 1,000,000) but good prognosis when treated with iron and esophageal dilatation

Eosinophilic Esophagitis
• Eosinophils infiltrate the epithelium of the esophagus
• Causes odynophagia, dysphagia, common cause of bolus food impaction
• Usually primary, but can be part of the spectrum of eosinophilic gastroenteritis, secondary to drugs, parasites etc.
• Often associated with allergies
• Most characteristically occurs in young men
• Diagnosis established by endoscopic biopsy, suggested by mucosal rings seen in the esophageal mucosa at endoscopy
• Treatment: (a)diet, (b)swallow corticosteroid nasal spray (fluticasone), (c)swallow viscous corticosteroid (budesonide mixed with sucralose
Investigations
- diagnosis via endoscopic visualization and biopsy

Treatment
- Candida: nystatin swish and swallow, ketoconazole, fluconazole
- Herpes: often self-limiting; acyclovir, valacyclovir, famciclovir
- CMV: IV gancyclovir, famciclovir, or oral valganciclovir

Stomach and Duodenum

Dyspepsia

Definition
- one or more of the following symptoms: postprandial fullness, early satiation, epigastric pain or burning (Rome III criteria)
- multiple causes: esophagitis, GERD, peptic ulcer, stomach cancer, drugs, but overall functional disease is most common

History and Physical Exam
- history: most important are age, associated symptoms (such as weight loss and vomiting), and drugs (especially NSAIDs)
- physical exam: adenopathy, abdominal mass/organomegaly, Carnett’s sign (if pain is due to abdominal wall muscle problem then the pain will increase during muscle contraction, such as during a sit-up)

Investigations
- laboratory: usual (CBC, liver enzymes, glucose, Cr, etc.), amylase, albumin, calcium, protein electrophoresis, TSH, H. pylori serology
- consider trial of empiric anti-secretory drug therapy, non-invasive testing for H. pylori infection, endoscopy; barium radiography is outdated

Stomach

Table 4. Cells of the Gastric Mucosa

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>Secretory Product</th>
<th>Important Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parietal Cells</td>
<td>Gastric acid (HCl)</td>
<td></td>
</tr>
<tr>
<td>Intrinsic Factor</td>
<td>Stimulated by histamine, ACh, gastrin</td>
<td></td>
</tr>
<tr>
<td>Chief Cells</td>
<td>Pepsinogen</td>
<td>Stimulated by vagal input and local acid</td>
</tr>
<tr>
<td>G-Cells</td>
<td>Gastrin</td>
<td>Stimulates H+ production from parietal cells</td>
</tr>
<tr>
<td>Superficial Epithelial Cells</td>
<td>Mucus, HCO$_3^-$</td>
<td>Protect gastric mucosa</td>
</tr>
<tr>
<td>Neuroendocrine Cells</td>
<td>Multiple (e.g. somatostatin, inhibits cell secretion)</td>
<td>Involved in neural, hormonal, and paracrine pathways</td>
</tr>
</tbody>
</table>

Figure 5. Stimulation of H+ secretion from the parietal cell
Gastritis

Definition
- defined histologically: inflammation of the stomach mucosa

Etiology
- some causative agents may play a role in more than one type of gastritis and an individual patient may have histopathological evidence of more than one type of gastritis

Table 5. Updated Sydney Classification of Gastritis

<table>
<thead>
<tr>
<th>Type</th>
<th>Common Etiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute Gastritis</td>
<td>Alcohol, Aspirin®/NSAID, shock/physiological stress (seen in ICU patients)</td>
</tr>
<tr>
<td>Hemorrhagic/erosive gastritis</td>
<td>Alcohol, Aspirin®/NSAID, shock/physiological stress (seen in ICU patients)</td>
</tr>
<tr>
<td>Helicobacter gastritis</td>
<td>H. pylori*</td>
</tr>
</tbody>
</table>

Chronic Gastritis
- Non-atrophic
- Atrophic
- Chemical
- Radiation
- Lymphocytic
- Eosinophilic
- Non-infectious granulomatous
- Other infectious gastritides

Clinical Features
- non-erosive gastritis is asymptomatic (except in certain rare causes like Crohn’s disease), does not cause pain; difficult to diagnose clinically or endoscopically – requires biopsy for diagnosis
- erosive gastritis can cause bleeding (pain only if progresses to ulcers – rare); can be seen endoscopically

Treatment
- determined by etiology (see H. pylori, G13, NSAID, G13 and Stress-Induced Ulceration, G14)
- non-pharmacological: avoidance of mucosal irritants such as alcohol, NSAIDs, and foods that trigger symptoms

Peptic Ulcer Disease

Definition
- focal defects in the mucosa that penetrate the muscularis mucosal layer results in scarring (defects superficial to the muscularis mucosa are erosions and do not cause scarring)
- peptic ulcer disease includes defects located in the stomach (gastric ulcers) and duodenum (duodenal ulcers)

Etiology

Table 6. Etiology of Peptic Ulcer Disease

<table>
<thead>
<tr>
<th></th>
<th>Duodenal</th>
<th>Gastric</th>
</tr>
</thead>
<tbody>
<tr>
<td>H. pylori Infection</td>
<td>90%</td>
<td>60%</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>7%</td>
<td>35%</td>
</tr>
<tr>
<td>Physiologic Stress-Induced</td>
<td>&lt;3%</td>
<td>&lt;5%</td>
</tr>
<tr>
<td>Zollinger-Ellison Syndrome</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Idiopathic</td>
<td>15%</td>
<td>10%</td>
</tr>
</tbody>
</table>

- NSAID negative, H. pylori negative ulcers becoming more commonly recognized
- others: CMV, ischemic, idiopathic
- alcohol: damages gastric mucosa but rarely causes ulcers
- peptic ulcer associated with cigarette smoking, cirrhosis of liver, COPD, and chronic renal failure

Clinical Features
- dyspepsia: most common presenting symptom
  - only 5% of patients with dyspepsia have ulcers, while most have functional disease
- may present with complications
  - bleeding 10% (severe if from gastroduodenal artery), perforation 2% (usually anterior ulcers), gastric outlet obstruction 2%
  - posterior inflammation (penetration) 2%; may also cause pancreatitis
• duodenal ulcers: 6 classical features, but history alone cannot distinguish from functional dyspepsia
  • epigastric pain; may localize to tip of xiphoid
  • burning
  • develops 1-3 h after meals
  • relieved by eating and antacids
  • interrupts sleep
  • periodicity (tends to occur in clusters over wk with subsequent periods of remission)
• gastric ulcers: more atypical symptoms; a biopsy is necessary to exclude malignancy

Investigations
• endoscopy (most accurate)
• upper GI series
• H. pylori tests (see Table 7)
• fasting serum gastrin measurement if Zollinger-Ellison syndrome suspected (but most common cause of elevated serum gastrin level is atrophic gastritis)

Treatment
• specific management depends on etiology; (see H. pylori, GI3, NSAID-Induced Ulceration, GI3 and Stress-Induced Ulceration, G14)
• eradicate H. pylori if present; chief advantage of triple therapy over PPI is to lower ulcer recurrence rate
• stop NSAIDs if possible
• start PPI: inhibits parietal cell H+K+ ATPase pump which secretes acid
• heals most ulcers, even if NSAIDs are continued
• other medications (e.g. histamine H2-antagonists) less effective
• discontinue cigarette smoking
• no diet modifications required but some people have fewer symptoms if they avoid caffeine, alcohol, and spices

Management of Bleeding Peptic Ulcers
• OGD to explore upper GI tract
• IV pantoprazole continuous drip
• establish risk of rebleeding/continuous bleed (since most ulcers stop bleeding spontaneously)
  • clinical risk factors: increased age (>60), bleeding diathesis, history of PUD, comorbid disease, hemodynamically unstable
• endoscopic signs of recurrent bleeding (active bleeding, visible vessel, clot, red spot) more predictive than clinical risk factors
  • if high risk, consider ICU admission

Suspected Bleeding Peptic Ulcer
ABCs: assess vitals (BP and HR, orthostatic changes)
CBC, lytes, BUN, Cr, INR, blood type, cross and type
Resuscitate: crystalloids and blood products if indicated

Consider
NG tube placement + aspiration: confirm upper GI source
IV pantoprazole: 80 mg starting dose + 8 mg/h continuous infusion
Erythromycin 250 mg 30 min before endoscopy

Endoscopy
Active bleeding or visible vessel
High Risk:
Hemostasis: clips, thermal coagulation, epinephrine injection
Continue (or start) IV PPI
Monitor for re-bleeding in hospital
If adherent clot: consider removal
Low Risk:
No hemostasis necessary
Continue (or start) oral PPI
Decreased need for in-hospital monitoring

Post-Endoscopy
Resume clear fluids 6 hours post-endoscopy
Test for H. pylori
Counsel re: most likely causes (NSAIDs, anti-platelet agents)
If re-bleeding: repeat endoscopy with aim of hemostasis
Consult interventional radiology or surgery if needed

Figure 6. Approach to management of suspected bleeding peptic ulcer
Adapted from: Graheik J, Barkun A, Barkou M. Management of acute bleeding from a peptic ulcer. NEJM 2008;359:928-937

Gastric vs. Duodenal Ulcers
Gastric ulcers must always be biopsied to rule out malignancies; duodenal ulcers are rarely malignant

Approach to PUD
• Stop NSAIDs
• Acid neutralization
• H. pylori eradication
• Quit smoking

Bleeding Peptic Ulcers
Risk Factors for Increased Mortality
• Co-existent illness
• Hemodynamic instability
• Age > 60 yr
• Transfusion required
**H. pylori-Induced Peptic Ulceration**

**Pathophysiology**
- *H. pylori*: Gram-negative flagellated rod that resides within the gastric mucosa, causing persistent infection and inflammation
- acid secreted by parietal cells (stimulated by vagal acetylcholine, gastrin, histamine) necessary for most ulcers
- theories of how *H. pylori* causes ulcers: none satisfactory, but pattern of colonization correlates with outcome
- gastritis only in antrum (15% of patients), high gastric acid, associated with duodenal ulcer, may progress to gastric metaplasia of duodenum where ulcer forms
- gastritis throughout stomach (“pangastritis” – 85% of patients), low gastric acid, associated with stomach ulcer and cancer

**Epidemiology**
- *H. pylori* is found in about 20% of all Canadians
- highest prevalence in those raised during 1930s
- infection most commonly acquired in childhood, presumably by fecal-oral route
- high prevalence in developing countries, low socioeconomic status (poor sanitation and overcrowding)

**Outcome**
- gastritis (non-erosive) in 100% of patients but asymptomatic
- peptic ulcer in 15% of patients
- gastric carcinoma and mucosal associated lymphomatous tissue [MALT] lymphoma in 0.5% of patients
- most are asymptomatic but still worthwhile eradicating to lower future risk of peptic ulcer/gastric malignancy and prevent spread to others (mostly children <5 yr of age)

**Diagnosis**

<table>
<thead>
<tr>
<th>Test</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-invasive Tests</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urea breath test</td>
<td>90-100%</td>
<td>89-100%</td>
<td>Affected by PPI therapy (false negatives)</td>
</tr>
<tr>
<td>Serology</td>
<td>88-99%</td>
<td>89-95%</td>
<td>Can remain positive after treatment</td>
</tr>
<tr>
<td>Invasive Tests (require endoscopy)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histology</td>
<td>93-99%</td>
<td>95-99%</td>
<td>Gold standard; affected by PPI therapy (false negatives)</td>
</tr>
<tr>
<td>Rapid urease test (on biopsy)</td>
<td>89-98%</td>
<td>93-100%</td>
<td>Rapid</td>
</tr>
<tr>
<td>Microbiology culture</td>
<td>98%</td>
<td>95-100%</td>
<td>Research only</td>
</tr>
</tbody>
</table>

**Treatment: H. pylori Eradication**
- triple therapy for 7-14 d (Hp-Pac®): PPI bid (e.g. lansoprazole 30 mg bid) + amoxicillin 1 g bid + clarithromycin 500 mg bid
- becoming less successful as prevalence of *H. pylori* clarithromycin-resistance increases
- quadruple therapy for 10-14 d now recommended: PPI bid + bismuth 525 mg qid + tetracycline 500 mg qid + metronidazole 250 mg qid
- levofloxacin can replace metronidazole or tetracycline
- sequential therapy
- days 1-5: PPI bid + amoxicillin 1 g bid
- days 6-10: PPI bid + clarithromycin 500 mg bid + tinidazole (generally substitute with metronidazole as tinidazole not available in Canada) 500 mg bid
- 5-15% of cases are resistant to all known therapies

**NSAID-Induced Ulceration**
- NSAID use causes gastric mucosal petechiae in virtually all, erosions in most, ulcers in some (25%)
- erosions bleed, but usually only ulcers cause significant clinical problems
- most NSAID ulcers are clinically silent: dyspepsia is as common in patients with ulcers as in patients without ulcers; NSAID-induced ulcers characteristically present with complications (bleeding, perforation, obstruction)
- NSAIDs more commonly cause gastric ulcers than duodenal ulcers
- may exacerbate underlying duodenal ulcer disease

**Pathophysiology**
- direct: erosions/petechiae – are due to local (direct) effect of drug on gastric mucosa
- indirect: systemic NSAID effect (intravenous NSAID causes ulcers, but not erosions), inhibits mucosal cyclooxygenase, leading to decreased synthesis of protective prostaglandins, thus leading to ulcers
Risk Factors for NSAID-induced Peptic Ulcer
- previous peptic ulcers/UGIB
- age (≥65 yr)
- high dose of NSAID/multiple NSAIDs being taken
- concomitant corticosteroid use
- concomitant cardiovascular disease/other significant diseases

Treatment
- prophylactic cytoprotective therapy with a PPI is recommended if any of the above risk factors exist concomitantly with ASA/NSAID use
- lower NSAID dose or stop all together and replace with acetaminophen
- combine NSAID with PPI or misoprostol (less effective) in one tablet
- enteric coating of Aspirin® (ECASA) provides minor benefit since this decreases incidence of erosion, not incidence of ulceration

Stress-Induced Ulceration

Definition
- ulceration or erosion in the upper GI tract of ill patients, usually in ICU (stress is physiological, not psychiatric)
- lesions most commonly in fundus of stomach

Pathophysiology
- unclear: likely involves ischemia; may be caused by CNS disease, acid hypersecretion, Cushing ulcers
- mechanical ventilation is the most important risk factor

Risk Factors
- mechanical ventilation
- anti-coagulation
- multi-organ failure
- septicemia
- severe surgery/trauma
- CNS injury ("Cushing's ulcers")
- burns involving more than 35% of body surface

Clinical Features
- UGIB (see Upper Gastrointestinal Bleeding, G25)
- painless

Treatment
- prophylaxis with gastric acid suppressants decreases risk of UGIB; PPI most potent but may increase risk of pneumonia; H2 blockers less potent but less likely to cause pneumonia
- treatment same as for bleeding peptic ulcer but often less successful

Gastric Carcinoma

- see General Surgery, GS19

Small and Large Bowel

Classification of Diarrhea

Definition
- clinically: diarrhea defined as stools that are looser and/or more frequent than normal (i.e. ≥3x per day); physiologically: 24 h stool weight >200 g (less useful clinically)

Classification
- acute vs. chronic
- small volume (tablespoons of stool; typical of colonic diseases) vs. large volume (>1/2 cup stool; typical of small bowel diseases)
- watery: secretory (diarrhea persists with fasting) vs. osmotic (diarrhea stops with fasting)
- steatorrhea
- inflammatory
- functional
**Acute Diarrhea**

**Definition**
- passage of frequent unformed stools for <14 d

**Etiology**
- most commonly due to infections
- most infections are self-limiting and resolve within 7 d

**Risk Factors**
- food (seafood, chicken, turkey, eggs, beef)
- medications: antibiotics, laxatives
- others: high risk sexual activity, infectious outbreaks, family history (IBD)

**Table 8. Classification of Acute Diarrhea**

<table>
<thead>
<tr>
<th></th>
<th>Inflammatory</th>
<th>Non-Inflammatory</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definition</strong></td>
<td>Disruption of intestinal mucosa</td>
<td>Intestinal mucosa intact</td>
</tr>
<tr>
<td><strong>Site</strong></td>
<td>Usually colon</td>
<td>Usually small intestine</td>
</tr>
<tr>
<td><strong>Mechanism</strong></td>
<td>Organisms and cytotoxins invade mucosa, killing mucosal cells, and further perpetuating the diarrhea</td>
<td>Stimulation of intestinal water secretion and inhibition of water absorption (i.e. secretory problem)</td>
</tr>
<tr>
<td><strong>Sigmoidoscopy</strong></td>
<td>Usually abnormal mucosa seen</td>
<td>Usually normal</td>
</tr>
<tr>
<td><strong>Symptoms</strong></td>
<td>Bloody (not always)</td>
<td>Watery, little or no blood</td>
</tr>
<tr>
<td></td>
<td>Small volume, high frequency</td>
<td>Large volume</td>
</tr>
<tr>
<td></td>
<td>Often lower abdominal cramping with urgency ± tenesmus</td>
<td>Upper/perianal pain/cramp ± shock</td>
</tr>
<tr>
<td></td>
<td>May have fever ± shock</td>
<td></td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td>Fecal WBC and RBC positive</td>
<td>Fecal WBC negative</td>
</tr>
<tr>
<td><strong>Etiology</strong></td>
<td>See Differential Diagnosis of Presenting Complaints, G4</td>
<td>See Differential Diagnosis of Presenting Complaints, G4</td>
</tr>
<tr>
<td><strong>Differential Diagnosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Significance</strong></td>
<td>Higher yield with stool C&amp;S</td>
<td>Lower yield with stool C&amp;S</td>
</tr>
<tr>
<td></td>
<td>Can progress to life-threatening megacolon, perforation, hemorrhage</td>
<td>Chief life-threatening problem is electrolyte disturbances/ fluid depletion</td>
</tr>
<tr>
<td></td>
<td>Antibiotics may benefit</td>
<td>Antibiotics unlikely to be helpful</td>
</tr>
</tbody>
</table>

**Infections**
- stool cultures/microscopy (C&S/O&P) are required only if diarrhea is inflammatory, severe, or for epidemiological purposes (day care worker, nursing home resident, community outbreaks, e.g. Walkerton, etc.)
- C&S only tests Campylobacter, Salmonella, Shigella, E. coli
- other organisms must be ordered separately
- flexible sigmoidoscopy (without bowel preparation); useful if inflammatory diarrhea suspected
- biopsies are the most useful method of distinguishing idiopathic IBD (Crohn’s disease and ulcerative colitis) from infectious colitis or acute self-limited colitis
- C. difficile toxin: indicated when recent/remote antibiotic use, hospitalization, nursing home, or recent chemotherapy

**Treatment**
- fluid and electrolyte replacement orally in most cases, intravenously if severe extremes of age/coma
- anti-diarrheals
  - antimotility agents: diphenoxylate, loperamide (Imodium®); contraindicated in mucosal inflammation
    - side effects: abdominal cramps, toxic megacolon
- absorbants: kaolin/pectin (Kapectate®), methylcellulose, activated attapulgite
  - act by absorbing intestinal toxins/micro-organisms, or by coating intestinal mucosa
  - much less effective than antimotility agents
- modifiers of fluid transport: bismuth subsalicylate (Pepto-Bismol®) may be helpful (but should not be used in the presence of bloody diarrhea or fever
- antibiotics: rarely indicated
  - risks
    - prolonged excretion of enteric pathogen (especially Salmonella)
    - drug side effects (including C. difficile infection)
    - development of resistant strains
    - renal failure/hemolysis (enterohemorrhagic E. coli O157:H7)

**Useful Questions in Acute Diarrhea**
- Those Fads Wilt
  - Travel
  - Homosexual contacts
  - Outbreaks
  - Seafood
  - Extra-intestinal signs of IBD
  - Family history
  - Antibiotics
  - Diet
  - Straitmote
  - Weight loss
  - Immunosuppressed
  - Laxatives
  - Tumour history

**Infectious Causes of Inflammatory Diarrhea**
- Your Stool Smells Extremely Crappy
  - Yersinia
  - Shigella
  - Salmonella
  - E. coli (EHEC O157:H7), E. histolytica
  - Campylobacter, C. difficile

**Finally: A Role for Bacteriotherapy**
- Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
- NEJM 2013; 368:407-15
- For centuries, out-of-the-box thinkers have speculated that the colonic bacteria all of us have, but which differs among individuals, play a role in disease. More recently, the colonic microbiome has become the hottest area of research in gastroenterology. The best documented medical indication for manipulating the colonic bacteria is recurrent C. difficile infection. In this randomized study of this disease, infusion of donor feces via a nasojejunal tube resolved diarrhea in 81% of patients, without side-effects, compared to 31% given the standard treatment of oral vancomycin, and 27% of patients given oral vancomycin plus bowel/usage. It takes little prescience to predict an onslaught of future studies investigating the therapeutic potential of altering the human microbiome.
- indications for antimicrobial agents in acute diarrhea
  - sepsisemia
  - prolonged fever with fecal blood or leukocytes
  - clearly indicated: *Shigella*, *V. cholerae*, *C. difficile*, traveller's diarrhea (enterotoxigenic *E. coli* [ETEC]), *Giardia, Entamoeba histolytica*, *Cyclospora*
  - situational: *Salmonella*, *Campylobacter*, *Yersinia*, non-enterotoxigenic *E. coli*
  - *Salmonella* always treat *Salmonella typhi* (typhoid or enteric fever); treat other *Salmonella* only if there is underlying immunodeficiency, hemolytic anemia, extremes of age, aneurysms, prosthetic valve grafts/joints, sickle cell disease

### Traveller’s Diarrhea

- see Infectious Diseases, ID13

### Chronic Diarrhea

**Definition**
- passage of frequent unformed stool for >4 wk (persistent diarrhea as 14-30 d)
- approach is similar to that of acute diarrhea except that the majority of cases are non-infectious

**Etiology/Classification**
- see Differential Diagnosis of Common Presenting Complaints, G4

**Investigations**
- guided by history
- stool analysis for: *C. difficile* toxin, C&S, O&P ± fecal fat, WBC
- blood for: CBC, electrolytes, CRP, TSH, celiac serology (IgA anti-tTG; ask for serum protein electrophoresis or immunoglobulin quantitation to rule out IgA deficiency which has an increased frequency in celiac disease)
- colonoscopy and ileoscopy with biopsy
- upper GI endoscopy with duodenal biopsy
- wireless small bowel endoscopy capsule (low yield)
- trial of lactose free diet
  - caveat: may delay diagnosis of IBD and celiac disease

### Malabsorption and Maldigestion

**Definition**
- maldigestion: inability to break down large molecules in the lumen of the intestine into their component small molecules
- malabsorption: inability to transport molecules across the intestinal mucosa into circulation
- malassimilation: encompasses both maldigestion and malabsorption

**Etiology**
- maldigestion
  - inadequate mixing of food with enzymes (e.g. post-gastrectomy)
  - pancreatic exocrine deficiency
  - primary diseases of the pancreas (e.g. cystic fibrosis, pancreatitis, cancer)
  - bile salt deficiency
    - terminal ileal disease (impaired recycling), bacterial overgrowth (deconjugation of bile salts), rarely liver disease (cholestatic, e.g. primary biliary cirrhosis)
  - specific enzyme deficiencies (e.g. lactase)
- malabsorption
  - inadequate absorptive surface
  - infections/infestations (e.g. Whipple's disease, *Giardia*)
  - immunologic or allergic injury (e.g. celiac disease)
  - infiltration (e.g. lymphoma, amyloidosis)
  - fibrosis (e.g. systemic sclerosis, radiation enteritis)
  - bowel resection (length, site, location, presence/absence of ileocecal valve are important)
  - extensive ileal *Crohn's* disease
  - drug-induced
    - *cholestyramine*, ethanol, neomycin, tetracycline, and other antibiotics
    - endocrine
      - DM (complex pathogenesis)

**Clinical Features**
- symptoms usually vague unless disease is severe
- weight loss, diarrhea, steatorrhea, weakness, fatigue
- manifestations of malabsorption/deficiency
Table 9. Absorption of Nutrients and Fat Soluble Vitamins

<table>
<thead>
<tr>
<th>Deficiency</th>
<th>Absorption</th>
<th>Clinical Disease and/or Features</th>
<th>Investigations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iron</td>
<td>Duodenum, upper jejunum</td>
<td>Hypochromic, microcytic anemia, glossitis, kolonchytia (spoon nails), pica</td>
<td>↓ Hb, ↓ serum Fe, ↓ serum ferritin</td>
</tr>
<tr>
<td>Calcium</td>
<td>Duodenum, upper jejunum (binds to Ca^{2+}-binding protein in cells; levels increased by Vit D)</td>
<td>Metabolic bone disease, may get tetany and paresthesias if serum calcium falls (see Endocrinology, E36)</td>
<td>↓ serum Ca^{2+}, ↓ serum Mg^{2+}, and ↑ ALP. Evaluate for ↓ bone mineralization radiographically (DEXA)</td>
</tr>
<tr>
<td>Folic Acid</td>
<td>Jejunum</td>
<td>Megaloblastic anemia, glossitis, ↓ red cell folate (may see ↑ folic acid with bacterial overgrowth)</td>
<td>↓ serum folic acid</td>
</tr>
<tr>
<td>Vitamin B_{12}</td>
<td>B_{12} ingested and bound to R proteins mainly from salivary glands; stomach secretes intrinsic factor (IF) in acidic medium; in basic medium, proteases from the pancreas cleave R protein and B_{12}-IF complex forms, protecting B_{12} from further protease attack; B_{12} absorbed in ileum and binds to transcobalamin (TC)</td>
<td>Subacute combined degeneration of the spinal cord, peripheral/ optic neuropathy, dementia, megaloblastic anemia, glossitis</td>
<td>Differentiate causes by nuclear Schilling test (when available). Positive anti-intrinsic factor antibodies and atrophic gastritis point toward pernicious anemia (see Hematology, H24)</td>
</tr>
<tr>
<td>Protein</td>
<td>Digestion at stomach, brush border, and inside cell. Absorption occurs primarily in the jejunum</td>
<td>General malnutrition and weight loss, amenorrhea, and ↓ libido if severe</td>
<td>↓ serum albumin (low sensitivity)</td>
</tr>
<tr>
<td>Fat</td>
<td>Lipase, colipase, phospholipase A (pancreatic enzymes), and bile salts needed for digestion. Products of lipolysis form micelles which solublize fat and aid in absorption. Fatty acids diffuse into cell cytoplasm</td>
<td>Generalized malnutrition, weight loss, and diarrhea. Foul-smelling feces + gas. Steatorrhea</td>
<td>Small bowel biopsy. MRC, ERCP, pancreatic function tests (not routinely available). Quantitative stool fat test (72 h). May start with qualitative stool fat test (Sudan stain of stool). C-tropein breath test (not routinely available)</td>
</tr>
<tr>
<td>Vitamin A</td>
<td>Dietary sources (e.g. milk, eggs, liver, carrots, sweet potatoes)</td>
<td>Night blindness. Dry skin. Keratomalacia</td>
<td></td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Skin (via UV light) or diet (e.g. eggs, fish oil, fortified milk)</td>
<td>Osteomalacia in adults. Rickets in children</td>
<td></td>
</tr>
<tr>
<td>Vitamin E</td>
<td>Dietary sources (e.g. vegetable oils, nuts, leafy green vegetables)</td>
<td>Retinopathy, neurological problems</td>
<td></td>
</tr>
<tr>
<td>Vitamin K</td>
<td>Synthesized by intestinal flora. ↑ risk of deficiency after prolonged use of broad spectrum antibiotics and/or starvation</td>
<td>Prolonged INR may cause bleeding</td>
<td></td>
</tr>
</tbody>
</table>

* Calcium malabsorption more commonly causes decreased bone density rather than hypocalcemia because serum calcium levels are protected by leaching calcium from the bone.

**Investigations**
- transglutaminase (tTG) antibody serology/imunoglobulin quantitation and abdominal imaging are most useful because celiac disease and chronic pancreatitis are the two most common causes of steatorrhea
- 72 h stool collection (weight, fat content) documents steatorrhea (gold standard)
- fecal elastase (not routinely available) to screen for pancreatic insufficienty and/or consider empiric trial of pancreatic enzymes based on clinical context
- serum carotene (precursor to vitamin A), folate, Ca^{2+}, Mg^{2+}, vitamin B_{12}, albumin, ferritin, serum iron solution, INR/PTT
- stool fat globules on fecal smear stained with Sudan (rarely used)
- other tests specific for etiology (e.g. CT scan/MRI to visualize pancreas)

**Treatment**
- dependent on underlying etiology
Celiac Disease (Gluten Enteropathy/Sprue)

Definition
• abnormal small intestine mucosa due to intestinal reaction to gluten, a protein found in cereal grains

Etiology
• only autoimmune disease in which antigen (various gliadin peptides) is recognized
• associated with other autoimmune diseases, especially Sjögren’s, thyroid disease
• gluten, a protein in cereal grains, is broken down to gliadin, which is the toxic factor
• HLA-DQ2 (chromosome 6) found in 80-90% of patients compared with 20% in general population; celiac also associated with HLA-DQ8 (note: up to 40% of Caucasians carry the HLA alleles, but will never develop celiac disease)

Epidemiology
• more common in women
• family history: 10-15% of first-degree relatives
• may present any time from infancy (when cereals introduced) to elderly
• peak presentation in infancy

Clinical Features
• classic presentation: diarrhea, weight loss, anemia, symptoms of vitamin/mineral deficiency, failure to thrive; more common current presentation: bloating, gas, iron deficiency
• improves with gluten-free diet, deteriorates when gluten reintroduced
• disease is usually most severe in proximal bowel
  • thus iron, calcium, and folic acid deficiency (proximal absorption) more common than vitamin B12 deficiency (absorbed in ileum)
• gluten enteropathy may be associated with dermatitis herpetiformis skin eruption, epilepsy, myopathy, depression, paraonia, infertility, bone fractures/metabolic bone disease

Investigations
• serological tests
  • serum anti-tTG antibody, IgA, is 90-98% sensitive, 94-97% specific
  • IgA deficient patients have false-negative anti-tTG
  • therefore, measure serum IgA concomitantly (via serum quantitative protein electrophoresis)
  • incorporate serum testing tTG and/or DGP IgG in IgA deficiencies
• small bowel mucosal biopsy (usually duodenum) is diagnostic with increased intraepithelial lymphocytes (earliest pathologic finding)
  • crypt hyperplasia
  • villous atrophy
  • note: villous atrophy also seen in small bowel overgrowth, Crohn’s, lymphoma, Giardia, HIV
• improvement with a gluten-free diet, but should not be started before serological tests and biopsy
• consider CT enterography to visualize small bowel to rule out lymphoma
• evidence of malabsorption (localized or generalized)
  • steatorrhea
  • low levels of ferritin/iron saturation, Ca++, Fe, albumin, cholesterol, carotene, B12 absorption
• fecal fat >7%

Treatment
• dietary counselling
  • gluten free diet; avoid barley, rye, wheat (as these grains are related and also have toxic factor, similar to gliadin)
  • oats allowed if not contaminated by other grains (grown in soil without cross-contamination)
  • rice and corn flour are acceptable
  • iron, folate supplementation (with supplementation of other vitamins as needed)
• if poor response to diet change, consider
  • alternate diagnosis
  • non-adherence to gluten-free diet
  • concurrent disease (e.g. microscopic colitis, pancreatic insufficiency)
  • development of intestinal (enteropathy-associated T-cell) lymphoma (abdominal pain, weight loss, palpable mass)
  • development of diffuse intestinal ulceration, characterized by aberrant intraepithelial T-cell population (precursor to lymphoma)

Prognosis
• associated with increased risk of lymphoma, carcinoma (e.g. small bowel and colon; slight increase compared with general population), autoimmune diseases
• risk of lymphoma may be lowered by dietary gluten restriction
Inflammatory Bowel Disease

Definition
- Crohn’s disease (CD), ulcerative colitis (UC), indeterminate colitis or IBD-unclassified (IBDU)

Pathophysiology
- poorly understood
- most likely a sustained response of the immune system, perhaps to enteric flora
- lack of appropriate down-regulation of immune responsiveness after an infection in a genetically predisposed individual

Genetics
- increased risk of both UC and CD in relatives of patients with either disease, especially siblings, early onset disease
  - familial risk greater if proband has CD rather than UC
- likely polygenomic pattern: 9 gene loci are associated
- CARD15/NOD2 gene mutation associated with CD (relative risk in heterozygote is 3, in homozygote is 40), especially Ashkenazi Jews, early onset disease, ileal involvement, fistulizing and stenotic disease
  - CARD15 gene product modulates NFκB, which is required for the innate immune response to microbial pathogens, best expressed in monocytes-macrophages

Clinical Features

<table>
<thead>
<tr>
<th></th>
<th>Crohn’s Disease</th>
<th>Ulcerative Colitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location</td>
<td>Any part of GI tract</td>
<td>Isolated to large bowel</td>
</tr>
<tr>
<td></td>
<td>Small bowel + colon: 50%</td>
<td>Always involves rectum, may progress proximally</td>
</tr>
<tr>
<td></td>
<td>Small bowel only: 30%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Colon only: 20%</td>
<td></td>
</tr>
<tr>
<td>Rectal Bleeding</td>
<td>Uncommon</td>
<td>Very common (90%)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>Less prevalent, non-bloody</td>
<td>Frequent, mucous, bloody, small volume stools</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>Post-prandial/colicky</td>
<td>Less common</td>
</tr>
<tr>
<td>Fever</td>
<td>Common</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Urgency/Tenesmus</td>
<td>Uncommon (unless rectum involved)</td>
<td>Common</td>
</tr>
<tr>
<td>Palpable Mass</td>
<td><strong>Frequent (25%), RLQ</strong></td>
<td>Rare (if present, often related to cecum full of stool)</td>
</tr>
<tr>
<td>Recurrence After Surgery</td>
<td>Common</td>
<td>None post-colectomy</td>
</tr>
<tr>
<td>Endoscopic Features</td>
<td>Ulcers (aphthous, stellate, linear), patchy lesions, pseudopolyps, cobblestoning</td>
<td>Continuous diffuse inflammation, erythema, friability, loss of normal vascular pattern, pseudopolyps</td>
</tr>
<tr>
<td>Histologic Features</td>
<td>Transmural distribution with skip lesions</td>
<td>Mucosal distribution, continuous disease (no skip lesions)</td>
</tr>
<tr>
<td></td>
<td>Focal inflammation</td>
<td>Architectural distortion, gland disruption, crypt abscess</td>
</tr>
<tr>
<td></td>
<td>± noncaseating granulomas, deep fissuring + aphthous ulcerations, strictures</td>
<td>Granulomas absent</td>
</tr>
<tr>
<td></td>
<td>Glands intact</td>
<td></td>
</tr>
<tr>
<td>Radiologic Features</td>
<td>Cobblestone mucosa</td>
<td>Lack of haustra</td>
</tr>
<tr>
<td></td>
<td>Frequent strictures and fistulae</td>
<td>Strictures rare; need to rule out complicating cancer</td>
</tr>
<tr>
<td></td>
<td>AXR: bowel wall thickening “string sign”</td>
<td></td>
</tr>
<tr>
<td>Complications</td>
<td>Strictures, fistulae, perianal disease</td>
<td>Toxic megacolon</td>
</tr>
<tr>
<td>Colon Cancer Risk</td>
<td>Increased if &gt; 30% of colon involved</td>
<td>Increased except in proctitis</td>
</tr>
</tbody>
</table>
Table 11. Extraintestinal Manifestations (EIM) of IBD

<table>
<thead>
<tr>
<th>System</th>
<th>Crohn’s Disease</th>
<th>Ulcerative Colitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dermatologic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythema nodosum</td>
<td>15%</td>
<td>10%</td>
</tr>
<tr>
<td>Pyoderma gangrenosum</td>
<td>10%</td>
<td>Less common</td>
</tr>
<tr>
<td>Perianal skin tags</td>
<td>75-80%</td>
<td>Rare</td>
</tr>
<tr>
<td>Oral mucosal lesions</td>
<td>Common</td>
<td>Rare</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>Statistically associated in 5-10% of those with IBD but not an EIM</td>
<td></td>
</tr>
<tr>
<td>Stomatitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatologic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral arthritis</td>
<td>15-20% of those with IBD (CD&gt;UC)</td>
<td></td>
</tr>
<tr>
<td>Ankylosing spondylitis</td>
<td>10% of those with IBD (CD&gt;UC)</td>
<td></td>
</tr>
<tr>
<td>Sacroiliitis</td>
<td>Occurs equally in CD and UC</td>
<td></td>
</tr>
<tr>
<td>Ocular (~10% of IBD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uveitis (vision threatening)</td>
<td>3-4% of IBD patients (CD&gt;UC)</td>
<td></td>
</tr>
<tr>
<td>Episcleritis (benign)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatobiliary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholelithiasis</td>
<td>15-35% of patients with ileal Crohn’s</td>
<td></td>
</tr>
<tr>
<td>PSC</td>
<td>1-5% of IBD cases involving colon</td>
<td></td>
</tr>
<tr>
<td>Fatty liver</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gallstones</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urologic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calculi</td>
<td>Most common in CD, especially following ileal resection</td>
<td></td>
</tr>
<tr>
<td>Ureteric obstruction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fistulae</td>
<td>Characteristic of Crohn’s</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thromboembolism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vasculitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osteoporosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin deficiencies (B12, Vit ADEK)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiopulmonary disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreatitis (rare)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thromboembolism</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Crohn’s Disease**

**Definition**
- chronic transmural inflammatory disorder potentially affecting the entire gut from mouth to perianal region (“gum to bum”)

**Epidemiology**
- incidence 1-6/100,000; prevalence 10-100/100,000
- bimodal: onset before 30 yr, second smaller peak age 60; M=F
- incidence of Crohn’s increasing (relative to UC) especially in young females
- more common in Caucasians, Ashkenazi Jews
  - risk in Asians increases with move to Western countries
- smoking incidence in Crohn’s patients is higher than general population

**Pathology**
- most common location: ileum + ascending colon
- linear ulcers leading to mucosal islands and “cobblestone” appearance
- granulomas are found in 50% of surgical specimens, 15% of mucosal biopsies

**Clinical Features**
- natural history unpredictable; young age, perianal disease, and need for corticosteroids have been associated with poor prognosis, but associations are not strong enough to guide clinical decisions
- most often presents as recurrent episodes of abdominal cramps, non-bloody diarrhea, and weight loss
- ileitis may present with post-prandial pain, vomiting, RLQ mass; mimics acute appendicitis
- extra-intestinal manifestations are more common with colonic involvement
- fistulae, fissures, abscesses are common
- deep fissures with risk of perforation into contiguous viscera (leads to fistulae and abscesses)
- enteric fistulae may communicate with skin, bladder, vagina, and other parts of bowel

**Investigations**
- colonoscopy with biopsy to visualize (less often gastroscopy)
- CT/MR enterography to visualize small bowel
- CRP elevated in most new cases, useful to monitor treatment response (especially acutely in UC)
- bacterial cultures, O&P, C. difficile toxin to exclude other causes of inflammatory diarrhea
Management (see Figure 7)

Table 12. Management of Crohn’s Disease

<table>
<thead>
<tr>
<th>Management/Diet</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lifestyle/Diet</td>
<td>Smoking cessation</td>
</tr>
<tr>
<td></td>
<td>Fluids only during acute exacerbation</td>
</tr>
<tr>
<td></td>
<td>Enteral diets may aid in remission only for Crohn’s ileitis, not colitis</td>
</tr>
<tr>
<td></td>
<td>No evidence for any non-enteral diet changing the natural history of Crohn’s disease, but may affect symptoms</td>
</tr>
<tr>
<td></td>
<td>Those with extensive small bowel involvement or extensive resection require electrolyte, mineral, and vitamin supplements (vit D, Ca++, Mg++, zine, Fe, B12)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Antidiarrheal Agents*</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Loperamide (Imodium®) &gt; diphenoxylate (Lomotil®) &gt; codeine (cheap but addictive)</td>
<td></td>
</tr>
<tr>
<td>All work by decreasing small bowel motility, used only for symptom relief</td>
<td></td>
</tr>
<tr>
<td>CAUTION if colitis is severe (risk of precipitating toxic megacolon), therefore avoid during flares-ups</td>
<td></td>
</tr>
</tbody>
</table>

5-ASA**
- Efficacy controversial: Is currently used for mild ileitis |
- Sulfasalazine (Salazopyrin®): 5-ASA bound to sulfapyridine |
- Hydrolysis by intestinal bacteria releases 5-ASA (active component) |
- Dose-dependent efficacy |
- Mesalamine (Pentasa®): coated 5-ASA releases 5-ASA in the ileum and colon when inflammation is mild |

Antibiotics
e.g. metronidazole (20 mg/kg/d, bid or tid dosing) or ciprofloxacin |
- Best described for perianal Crohn’s, although characteristic relapse when discontinued |

Corticosteroids
- Prednisone: starting dose 40 mg OD for acute exacerbations; IV methylprednisolone if severe |
- No proven role for steroids in maintaining remissions; masks intra-abdominal sepsis |

Immunosuppressives
- 6-mercaptopurine (6-MP), azathioprine (Imuran®); methotrexate (used less often) |
- More often used to maintain remission than to treat active inflammation |
- Most commonly used as steroid-sparing agents |
- i.e. to lower risk of relapse as corticosteroids are withdrawn |
- May require > 3 mo to have beneficial effect; usually continued for several years |
- May help to heal fistulae, decrease disease activity |
- Increases efficacy of biologicals plus lowers chances of biological dosing efficacy (tolerance) so often given in combination with biologics |
- Side effects: vomiting, pancreatitis, bone marrow suppression, increased risk of malignancy (i.e. lymphoma) |

Biologics
- Infliximab IV (Remicade®) or adalimumab SC (Humira®): both = antibody to TNF-α |
- Proven effective for treatment of fistulae and patients with medically refractory CD |
- First-line immunosuppressive therapy with infliximab = azathioprine more effective than using either alone |

Surgical/Experimental
- Surgical treatment (see General Surgery, GS28) |
- Surgery generally reserved for complications such as fistulae, obstruction, abscess, perforation, bleeding, and for medically refractory disease |
- If < 50% or < 200 cm of functional small intestine, risk of short bowel syndrome |
- At least 50% cumulative recurrence within 5 yr; 85% within 15 yr; endoscopic recurrence rate even higher |
- 40% likelihood of second bowel resection, 30% likelihood of third bowel resection |
- Complications of ileal resection |
  - < 100 cm resected → watery diarrhea or cholorrhea (impaired bile salt absorption) |
  - Treatment: cholestyramine or anti-diarrheals e.g. loperamide |
  - > 100 cm resected → steatorrhea (reduced mucosal surface area, bile salt deficiency) |
  - Treatment: fat restriction, medium chain triglycerides |

Prognosis
- Highly variable course |
- 10% disabled by the disease eventually, spontaneous remission also described |
- Increased mortality, especially with more proximal disease, greatest in the first 4-5 yr |
- Complications include |
  - Intestinal obstruction/perforation |
  - Fistula formation |
  - Malignancy (lower risk compared to UC) |
- Surveillance colonoscopy same as ulcerative colitis (see Ulcerative Colitis) if more than 1/3 of colon involved |

Ulcerative Colitis

Definition
- Inflammatory disease affecting colonic mucosa anywhere from rectum (always involved) to cecum |

Epidemiology
- Incidence 2-10/100,000; prevalence 35-100/100,000 (more common than Crohn’s) |
- 2/3 onset by age 30 (with second peak after 50); M=F |
- Small hereditary contribution (15% of cases have 1st degree relative with disease) |
- Risk is less in smokers |
- Inflammation limited to rectum or left colon is more common than pancolitis
Pathology
• disease can involve any portion of lower bowel ranging from rectum only (proctitis) to entire colon (pancolitis)
• inflammation is diffuse, continuous and confined to mucosa

Clinical Features
• rectal bleeding is the hallmark feature; diarrhea present if more than the rectum is involved
  • can also have abdominal cramps/pain, especially with defecation
• severity of colonic inflammation correlates with symptoms (stool volume, amount of blood in stool)
• tenesmus, urgency, incontinence
• systemic symptoms: fever, anorexia, weight loss, fatigue in severe cases
• extra-intestinal manifestations (see Table 11)
• characteristic exacerbations and remissions; 5% of cases are fulminant

Investigations
• sigmoidoscopy with mucosal biopsy (to exclude self-limited colitis) without bowel prep often sufficient for diagnosis
• colonoscopy helpful to determine extent of disease; contraindicated in severe exacerbation
• CT colonography (formerly barium enema) if colonoscopy cannot be done; contraindicated in severe disease
• stool culture, microscopy, C. difficile toxin assay necessary to exclude infection
• no single confirmatory test

Treatment
• mainstays of treatment: 5-ASA (mesalamine) derivatives (only in mild to moderate disease) and corticosteroids, with azathioprine used in steroid-dependent or resistant cases
• diet of little value in decreasing inflammation but may alleviate symptoms
• anti-diarrheal medications generally not indicated in UC
  • 5-ASA
    • topical (suppository or enema): effective for distal disease (rectum to splenic flexure) if inflammation is mild, preferable to corticosteroids
    • oral: effective for mild to moderate, but not severe colitis (e.g. sulfasalazine 3-4 g/d, mesalamine 4 g/d)
    • commonly used in maintaining remission (decreases yearly relapse rate from 60% to 15%)
  • may decrease rate of colorectal cancer
  • corticosteroids
    • to remit acute disease, especially if severe or first attack; may need maximum dose IV steroids initially (e.g. methylprednisolone 30 mg IV q12h)
    • limited role as maintenance therapy for mild to moderate disease
    • use suppositories for proctitis
    • use enemas and topical steroids (e.g. hydrocortisone foam, budesonide enemas) for inflammation distal to splenic flexure
  • immunosuppressants (steroid-sparing)
    • in hospitalized patients with severe UC – add IV infliximab if no response to IV methylprednisolone within 3 days; then colectomy if inadequate response
    • biologics (infliximab, adalimumab, golimumab, vedolizumab) can also be used for outpatients with moderate-severe disease, particularly those that are steroid-unresponsive or steroid-dependent
    • azathioprine and 6-mercaptopurine: too slow to rapidly resolve acute relapse
    • most commonly used to maintain remission as corticosteroids withdrawn
    • given with biologics: increase efficacy of biologics and decrease likelihood of tolerance to biologics (~ 10% chance/yr)
• surgical treatment curative
  • aim for cure with colectomy; bowel continuity can be restored with ileal pouch-anal anastomosis (IPAA)
  • indications: failure of adequate medical therapy; toxic megacolon, uncontrollable bleeding, pre-cancerous changes detected either by endoscopy or endoscopic biopsies (dysplasia), inability to taper corticosteroids, overt malignancy

Complications
• similar to CD, except
  • more liver problems (especially PSC in men)
  • greater risk of colorectal cancer
    • risk increases with duration and extent of disease (5% at 10 yr, 15% at 20 yr for pancolitis; overall relative risk is 8%)
    • risk also increases with active mucosal inflammation and sclerosing cholangitis
  • thus, regular colonoscopy and biopsy in pancolitis of ≥8 yr is indicated
  • toxic megacolon (transverse colon diameter >6 cm on abdominal x-ray) with immediate danger of perforation (see General Surgery, GS37)

Medical Management of Ulcerative Colitis

<table>
<thead>
<tr>
<th>Treatment/Induction</th>
<th>Remission</th>
<th>Maintenance</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-ASA</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Steroids</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Immunosuppressant</td>
<td>+</td>
<td></td>
</tr>
</tbody>
</table>

When Considering Complications of IBD, Think:

ULCERATIVE COLITIS
Urinary calculi
Liver problems
Cholelithiasis
Epithelial problems
Retardation of growth/sexual maturation
Arthralgias
Thrombophlebitis
Iatrogenic complications
Vitamin deficiencies
Eyes
Colorectal cancer
Obstruction
Leakage (perforation)
Iron deficiency
Toxic megacolon
Inanition (wasting)
Strictures
Prognosis
• chronic relapsing pattern in most patients
• 10-15% chronic continuous pattern
• >1 attack in almost all patients
• more colonic involvement in the 1st yr correlates with increased severity of attacks and increased colectomy rate
• colectomy rate = 1% for all patients after the 1st yr; 20-25% eventually undergo colectomy
• normal life expectancy
• if proctitis only, usually benign course
• stool calprotectin increasingly recognized as a marker of bowel mucosal inflammation, reported especially to be useful in monitoring the activity of inflammatory bowel disease, but still accuracy is still controversial

Irritable Bowel Syndrome

Definition
• a form of functional bowel disease; more than just a label for GI symptoms unexplained after normal investigations

Epidemiology
• 20% of North Americans
• onset of symptoms usually in young adulthood
• F>M

Pathophysiology
• associated with either abnormal perception of intestinal activity or abnormal intestinal motility
• abnormal motility: multiple abnormalities described; unclear if associations or if causative
• psychological: stress may increase IBS symptoms but probably does not cause IBS
• types of IBS: IBS with diarrhea, IBS with constipation, IBS-mixed type (both diarrhea and constipation), and IBS untyped (insufficient abnormality in stool consistency to meet other types)

Diagnosis

Table 13. Rome III Criteria for Diagnosing Irritable Bowel Syndrome

<table>
<thead>
<tr>
<th>IBS Rome III Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥12 wk in the past 12 mo of abdominal discomfort plus pain that has 2 out of 3 features</td>
</tr>
<tr>
<td>Relieved with defecation</td>
</tr>
<tr>
<td>Associated with a change in frequency of stool</td>
</tr>
<tr>
<td>Associated with a change in consistency of stool</td>
</tr>
</tbody>
</table>

The following are supportive, but not essential to the diagnosis:
- Abnormal stool frequency (>3/d or <3/wk)
- Abnormal stool form (lumpy/hard/loose/watery) >1/4 of defecations
- Abnormal stool passage (straining, urgency, feeling of incomplete evacuation) >1/4 of defecations
- Passage of mucus >1/4 of defecations
- Bloating

Diagnosis of IBS Less Likely in Presence of "Red Flag" Features

<table>
<thead>
<tr>
<th>Weight loss</th>
<th>Anemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>Blood or pus in stool</td>
</tr>
<tr>
<td>Nocturnal defecation</td>
<td>Abnormal gross findings on flexible sigmoidoscopy</td>
</tr>
</tbody>
</table>

Normal Physical Exam

Investigations
• if history consistent with Rome III criteria, no alarm symptoms, and no family history of IBD or colorectal cancer, limited investigations required
• aim is to rule out diseases which mimic IBS, particularly celiac disease and IBD
• investigations can be limited to CBC, inflammatory markers (ESR, CRP) and celiac serology
• if available, fecal calprotectin is likely more reliable test to rule out IBD
• consider TSH, stool cultures depending on clinical circumstances
• consider colonoscopy (e.g. if alarming features present, family history of IBD or age > 50)

Treatment
• reassurance, explanation, support, aim for realistic goals
• relaxation therapy, biofeedback, hypnosis, stress reduction, probably exercise
• low FODMAP diet for pain, bloating gas, irregular bowel movements
• no therapeutic agent consistently effective, pain most difficult to control, no drug changes natural history so the drug should be “wanted, since it is not needed”
• symptom-guided treatment
  ■ pain predominant
    ▪ antispasmodic medication before meals (e.g. hyoscine, pinaverium, trimebutine - low level evidence)
    ▪ increase dietary fibre (bran or psyllium)
    ▪ tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI - moderate level of evidence)
  ■ IBS with diarrhea (IBS-D)
    ▪ increase dietary fibre (bran or psyllium) to increase stool consistency but worsens abdominal gas
    ▪ loperamide (Imodium®)
    ▪ diphenoxylate (Lomotil®)
    ▪ cholestyramine
  ■ IBS with constipation (IBS-C)
    ▪ increase fibre in diet
    ▪ linaclootide
    ▪ osmotic or other laxatives (help more with the constipation than the pain)
    ▪ mixed (alternating constipation and diarrhea) (IBS-M)

Prognosis
• 80% improve over time
• most have intermittent episodes
• normal life expectancy

**Constipation**

**Definition**
• passage of infrequent or hard stools with straining (stool water <50 mL/d); bowel frequency <3x/wk

**Epidemiology**
• increasing prevalence with age; F>M
• rare in Africa and India where stool weight is 3-4x greater than in Western countries

**Etiology**
• most common: idiopathic attributed to colon dysmotility but this is difficult to measure
• organic causes
  ▪ medication side effects (narcotics, antidepressants) are the most common
  ▪ intestinal obstruction, left sided colon cancer (consider in older patients), and fecal impaction
• metabolic
  ▪ DM
  ▪ hypothyroidism
  ▪ hypercalcemia, hypokalemia, uremia
• neurological
  ▪ intestinal pseudo-obstruction
  ▪ Parkinson’s disease
  ▪ MS
• collagen vascular disease (e.g. scleroderma)
• painful anal conditions (e.g. fissures)

**Clinical Presentation**
• overlaps with IBS
• stool firm, difficult to expel, passed with straining, abdominal pain relieved by defecation, flatulence, overflow diarrhea, tenesmus, abdominal distension, infrequent BMs (<3x/wk)

**Investigations**
• underlying disease rarely found if constipation is the only presenting symptom
  ▪ only test indicated in this situation is a CBC (2013 recommendation of American Gastroenterology Association), but also consider TSH, calcium, and glucose, X-ray of abdomen
  ▪ colon visualization if concomitant symptoms such as rectal bleeding, weight loss, or anemia (colonoscopy, CT colonography)
• if refractory to treatment, consider classification based on colon transit time; can measure colonic transit time with radio-opaque markers that are ingested and followed with a series of plain film abdominal x-rays (normal: 70 h)
  1. normal = misperception of normal defecation (IBS)
  2. prolonged throughout = “colonic inertia” (infrequent bowel movements with gas/bloating, tends to occur in youth)
  3. outlet obstruction = inability to coordinate pelvic floor muscles to empty rectum, straining, stool in rectum on digital exam, tends to occur in old age
• combination of 1 and 3 common
Treatment (in order of Increasing Potency)

- dietary fibre
  - useful if mild or moderate constipation, but not if severe
  - aim for 30 g daily, increase dose slowly
- surface-acting (soften and lubricate)
  - docusate salts, mineral oils
- osmotic agents (effective in 2-3 d)
  - lactulose, sorbitol, magnesium salts (e.g. magnesium hydroxide, i.e. milk of magnesia), lactitol
  - (β-galactosido-sorbitol), polyethylene glycol 3350
- cathartics/stimulants (effective in 24 h)
  - castor oil, senna (avoid prolonged use to prevent melanosis coli), bisacodyl
- enemas and suppositories (e.g. saline enema, phosphate enema, glycerin suppository, bisacodyl suppository)
- prokinetic agents (prucalopride)
- linaclotide (increases water secretion into the intestinal lumen)

Upper Gastrointestinal Bleeding

Definition

- bleeding proximal to the ligament of Treitz, see Gastrointestinal Tract, G2 (75% of GI bleeds)
  - ligament of Treitz: suspensory ligament where fourth portion of the duodenum transitions to jejunum

Etiology

- above the GE junction
  - epistaxis
  - esophageal varices (10-30%)
  - esophagitis
  - esophageal cancer
  - Mallory-Weiss tear (10%)
- stomach
  - gastric ulcer (20%) (see Peptic Ulcer Disease, G11)
  - erosive gastritis (e.g. from EtOH or post-surgery) (20%)
  - gastric cancer
  - gastric antral vascular ectasia (rare, associated with cirrhosis and CTD)
  - Dieulafoy’s lesion (very rare)
- duodenum
  - ulcer in bulb (25%)
  - aortoenteric fistula: usually only if previous aortic graft (see sidebar)
  - coagulopathy (drugs, renal disease, liver disease)
  - vascular malformation (Dieulafoy’s lesion, AVM)

Clinical Features

- in order of decreasing severity of the bleed: hematochezia (brisk upper GI bleed) > hematemesis > coffee ground emesis > melena > occult blood in stool

Treatment

- stabilize patient (1-2 large bore IVs, IV fluids, monitor)
- send blood for CBC, cross and type, platelets, PT, PTT, electrolytes, BUN, Cr, LFTs
- keep NPO
- consider NG tube to determine upper vs. lower GI bleeding in some cases
- IV PPI: decrease risk of rebleed if endoscopic predictors of rebleeding seen (see prognosis section)
  - given to stabilize clot, not to accelerate ulcer healing
  - if given before endoscopy, decreases need for endoscopic therapeutic intervention
- for variceal bleeds, octrreotide 50 µg loading dose followed by constant infusion of 30 µg/h
- consider IV erythromycin (or metoclopramide) to accelerate gastric emptying prior to gastroscopy to remove clots from stomach
- endoscopy (OGD): establish bleeding site + treat lesion
  - if bleeding peptic ulcer: most commonly used method of controlling bleeding is injection of epinephrine around bleeding point + thermal hemostasis (bipolar electrocoagulation or heater probe); less often thermal hemostasis may be used alone, but injection alone not recommended
  - endoclips
  - hemoarset

Prognosis

- 80% stop spontaneously
- peptic ulcer bleeding: low mortality (2%) unless rebleeding occurs (25% of patients, 10% mortality)
- endoscopic predictors of rebleeding (Forrest classification): spur or ooze, visible vessel, fibrin clot
- can send home if clinically stable, bleed is minor, no comorbidities, endoscopy shows clean ulcer with no high risk predictors of rebleeding
- H2-antagonists should not be used since they impact minimally on rebleeding rates and need for surgery
- esophageal varices have a high rebleeding rate (55%) and mortality (25%)

Forrest Prognostic Classification of Bleeding Peptic Ulcers

<table>
<thead>
<tr>
<th>Forrest Class</th>
<th>Type of Lesion</th>
<th>Risk of Rebleed (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Arterial bleeding (oozing/spurting)</td>
<td>55-100</td>
</tr>
<tr>
<td>IIa</td>
<td>Visible vessel</td>
<td>43</td>
</tr>
<tr>
<td>IIb</td>
<td>Sentinel clot</td>
<td>22</td>
</tr>
<tr>
<td>IIc</td>
<td>Hematin covered</td>
<td>10</td>
</tr>
<tr>
<td>III</td>
<td>No stigma of hemorrhage</td>
<td>5</td>
</tr>
</tbody>
</table>

Lancet 1974;2:394-397
Esophageal Varices

**Etiology**
- almost always due to portal hypertension

**Clinical Features**
- characteristically massive upper GI bleeding

**Prognosis**
- risk of bleeding: 30% in 1st yr
- risk of rebleeding: 50-70% (20% mortality at 6 wk)

**Investigations**
- endoscopy

**Management**

1. Assess hemodynamic stability and resuscitate*
2. IV octreotide
   - Causes splanchnic vasoconstriction
   - Decreases portal collateral circulation and pressure
3. Endoscopic therapy: variceal ligation (EVL) or sclerotherapy

*IV ceftriaxone lowers risk of sepsis, especially spontaneous bacterial peritonitis

If varices isolated to stomach, think of splenic vein thrombosis

Gastric varices best treated by endoscopic injection of cyanoacetate (“crazy glue”)

Mallory-Weiss Tear

**Definition**
- longitudinal laceration in gastric mucosa on lesser curvature near GE junction (20% straddle junction, 5% in distal esophagus)

**Etiology**
- due to rapid increases in gastric pressure from retching/vomiting against a closed glottis
- hiatus hernia usually present

**Clinical Features**
- hematemesis ± melena, classically following an episode of retching without blood
- can lead to fatal hematemesis

**Management**
- 90% stop spontaneously
- if persistent: endoscopy with epinephrine injection ± clips or surgical repair
Lower Gastrointestinal Bleeding

**Definition**
- bleed distal to ligament of Treitz

**Etiology**
- if blood per rectum with hemodynamic instability, rule out upper GI source
- diverticular (60% from right colon)
- vascular
  - angiodysplasia (small vascular malformations of the gut)
  - anorectal (hemorrhoids, fissures)
- neoplasm
  - cancer
  - polyps
- inflammation
  - colitis (ulcerative, infectious, radiation, ischemic)
  - post-polypectomy

**Clinical Features**
- hematochezia (see Figure 10)
- anemia
- occult blood in stool
- rarely melena

**Treatment**
- treat underlying cause

![Figure 10. Approach to hematochezia](image)

**Colorectal Carcinoma**
- see General Surgery, GS34

**Colorectal Polyps**
- see General Surgery, GS33

**Familial Colon Cancer Syndromes**
- see General Surgery, GS33

**Benign Anorectal Disease**
- see General Surgery, GS38
Liver

Investigations of Hepatobiliary Disease

A. Tests of Liver Function

Table 14. Liver Function Tests

<table>
<thead>
<tr>
<th>Test</th>
<th>What Do Levels Correlate With?</th>
<th>Increased by</th>
<th>How to Interpret</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prothrombin Time (PT or INR)</td>
<td>Hepatic protein synthesis All coagulation factors except VIII</td>
<td>Hepatocellular dysfunction Vitamin K deficiency (due to malnutrition, malabsorption, etc.)</td>
<td>PT/INR will promptly correct if vitamin K is administered, so increased PT/INR in absence of vitamin K deficiency is a reliable marker of hepatocellular dysfunction</td>
</tr>
<tr>
<td>Serum Albumin</td>
<td>Hepatic protein synthesis (and other causes listed in next column)</td>
<td>Hepatocellular dysfunction Malnutrition Renal or GI losses Significant inflammation Malignancy</td>
<td>Rule out potential causes other than hepatocellular dysfunction</td>
</tr>
<tr>
<td>Serum Direct Bilirubin*</td>
<td>Hepatic excretion from hepatocyte to biliary system</td>
<td>Liver dysfunction</td>
<td>Conjugation is preserved even in end stage liver failure, thus increased direct bilirubin indicates liver dysfunction</td>
</tr>
</tbody>
</table>

*Serum Bilirubin
*canaliculus breakdown product of hemoglobin; metabolized in the reticuloendothelial system of liver, transported through biliary system, excreted via gut
*direct bilirubin = conjugated; indirect = unconjugated bilirubin

B. Tests of Liver Injury

- disproportionately increased AST or ALT = hepatocellular damage
  - ALT more specific to liver; AST from multiple sources (especially muscle)
  - elevation of both highly suggestive of liver injury
  - most common cause of elevated ALT is fatty liver
- disproportionately increased ALP (and GGT) = cholestasis (stasis of bile flow)
  - if ALP is elevated alone, rule out bone disease by fractionating ALP and/or checking GGT
  - if ALP elevation out of proportion to ALT/AST elevation, consider
    1. obstruction of common bile duct (e.g. extraluminal = pancreatic Ca, lymphoma; intraluminal = stones, cholangiocarcinoma, sclerosing cholangitis, helminths)
    2. destruction of microscopic ducts (e.g. PBC)
    3. bile acid transporter defects (e.g. drugs, intrahepatic cholestasis of pregnancy)
    4. infiltration of the liver (e.g. liver metastases, lymphoma, granulomas, amyloid)

Acute Viral Hepatitis (General)

Definition
- viral hepatitis lasting <6 mo

Clinical Features
- most are subclinical
- flu-like prodrome may precede jaundice by 1-2 wk
  - nausea/vomiting, anorexia, headaches, fatigue, myalgia, low-grade fever, arthralgia and urticaria (especially HBV)
- only some progress to icteric (clinical jaundice) phase, lasting days to weeks
  - pale stools and dark urine 1-5 d prior to icteric phase
  - hepatomegaly and RUQ pain
  - splenomegaly and cervical lymphadenopathy (10-20% of cases)

Investigations
- AST and ALT (>10-20x normal in hepatocellular necrosis)
- ALP minimally elevated
- viral serology, particularly the IgM antibody directed to the virus

Treatment
- supportive (hydration, diet)
- usually resolves spontaneously, but if severe HBV infection, treatment with entecavir should be considered; in anicteric hepatitis C, anti-viral treatment should be considered (see hepatitis C)
- indications for hospitalization: encephalopathy, coagulopathy, severe vomiting, hypoglycemia

Prognosis
- poor prognostic indicators: comorbidities, persistently high bilirubin (>340 mmol; 20 mg/dL), increased INR, decreased albumin, hypoglycemia
Complications
- cholestasis (most commonly associated with HAV infection)
- hepatocellular necrosis: AST, ALT >10-20x normal, ALP and bilirubin minimally increased, increased cholestasis

**Hepatitis A Virus**

- RNA virus
- fecal-oral transmission; incubation period 4-6 wk
- diagnosed by elevated transaminases, positive anti-HAV IgM
- in children: characteristically asymptomatic
- in adults: fatigue, nausea, arthralgia, fever, jaundice
- can cause acute liver failure and subsequent death (<1-5%)
- can relapse (rarely), but never becomes chronic

**Hepatitis B Virus**

<table>
<thead>
<tr>
<th>Table 15. Hepatitis B Serology</th>
<th>HBsAg</th>
<th>Anti-HBs</th>
<th>HBeAg</th>
<th>Anti-HBe</th>
<th>Anti-HBc</th>
<th>Liver Enzymes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute HBV</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>IgM</td>
</tr>
<tr>
<td>Chronic (e-Ag positive) HBV (generally high HBV DNA)</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>IgG, ALT, AST elevated</td>
</tr>
<tr>
<td>Chronic (e-Ag negative) HBV (generally low HBV DNA)</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>IgG, ALT, AST normal</td>
</tr>
<tr>
<td>Resolved infection</td>
<td>–</td>
<td>±</td>
<td>–</td>
<td>±</td>
<td>–</td>
<td>IgG</td>
</tr>
<tr>
<td>Immunization</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Figure 11. Time course of acute hepatitis B infection

**Epidemiology**
- 4 phases of chronic hepatitis B: not all carriers will go through all 4 phases, but all carriers will have positive HBsAg
  1. **immune tolerance**: extremely high HBV-DNA (>20,000 IU/mL), HBeAg positive, but normal ALT/AST; due to little immune control and minimal immune-mediated liver damage; characteristic of perinatal infection (or ‘incubation period’ in adult with newly-acquired HBV)
  2. **immune clearance** (or immunoactive): HBV-DNA levels (>20,000 IU/mL), HBeAg positive; due to immune attack on the virus and immune-mediated liver damage; characterized by progressive disease without treatment and increasing liver fibrosis (sometimes progressing to cirrhosis and/or hepatocellular carcinoma); likely to benefit from treatment
  3. **immune control**: lower HBV-DNA (<20,000 IU/mL), HBeAg negative, anti-HBe positive, ALT/AST normal; due to immune control without immune-mediated liver damage; risk of reactivation to phase 2 (clinically resembles acute hepatitis B), especially with immunosuppression e.g. corticosteroids or chemotherapy
  4. **immune escape** ("core or precore mutant"): elevated HBV-DNA (>2,000 IU/mL), HBeAg negative because of pre-core or core promoter gene mutation, anti-HBe positive, ALT/AST high; characterized by progressive disease without treatment and increasing liver fibrosis (sometimes progressing to cirrhosis and/or hepatocellular carcinoma); likely to benefit from treatment

**DDx for Hepatitis**
- Viral infection
- Alcohol
- Drugs
- Immune-mediated
- Toxins

**Causes of Elevated Serum Transaminases in Chronic Hepatitis B**
- Ongoing immune-mediated liver injury without immune control of HBV (HBsAg positive)
- Immune escape (anti-HBe positive)
- Reactivation, seroconversion (conversion from anti-HBe to HBeAg)
- Hepatitis D
- Hepatocellular carcinoma
- Other liver insult (lathy liver, alcohol, drugs, hepatitis A)

**Risk Factors for Progression**
- EtOH
- HIV coinfection
- Old age at diagnosis

In acute hepatitis B, HDV coinfection increases severity of hepatitis but does not increase risk of progression to chronic hepatitis. However in the context of chronic hepatitis B, superinfection with HDV increases progression to cirrhosis

Without treatment, 8-20% of those with ongoing immunooactive chronic hepatitis can develop cirrhosis within 5 yr. In contrast, those in the immune tolerant phase (with extremely high HBV-DNA levels) are at minimal risk for liver fibrosis as they do not have immune-mediated liver injury

Risk of hepatocellular carcinoma in HBV increases with increasing age, which is likely a surrogate for increasing liver fibrosis/cirrhosis, and serum HBV-DNA

Risk of hepatocellular carcinoma in HCV increases only after cirrhosis develops

HCV (and HBV) treatment lowers the risk of hepatocellular carcinoma
**Hepatitis D**
- Defective RNA virus requiring HBsAg for entry into hepatocyte, therefore infects only patients with HBV; causes more aggressive disease than hepatitis B virus alone
- Coinfection: acquire HDV and HBV at the same time
- HDV can present as ALF and/or accelerate progression to cirrhosis
- Treatment: low-dose interferon (20% response) and liver transplant for end-stage disease

**Hepatitis C Virus**
- RNA virus (7 genotypes; genotype 1 is most common in North America)
- Blood-borne transmission; sexual transmission is “inefficient”
- Major risk factor: injection drug use
- Other risk factors: blood transfusion received before 1992 (or received in developing world), tattoos, intranasal cocaine use
- Clinical manifestation develops 6-8 wk after exposure
  - Symptoms mild and vague (fatigue, malaise, nausea) therefore not commonly diagnosed in acute stage

**Diagnosis**
- Suspected on basis of elevated ALT/AST and positive serum anti-HCV
- Diagnosis established by detectable HCV-RNA in serum
- Virus genotype correlates with response to treatment but not prognosis
  - Serum HCV-RNA inversely correlates with response to treatment
- Normal transaminases can have underlying cirrhosis on biopsy, but otherwise excellent prognosis

**Treatment**
- Blood-borne precautions; vaccinate for hepatitis A and B if serology negative; avoid alcohol
- Clearest indication for treatment is in subgroup likely to develop clinically significant liver disease
- Persistently elevated transaminases, liver biopsy shows fibrosis/cirrhosis and at least moderately severe necrosis/inflammation
- Treatment depends on genotype
- Oral interferon-free regimens (e.g. sofosbuvir/ledipasvir, ombitasvir/paritaprevir/ritonavir+dasabuvir, or elbasvir/grazoprevir) are now becoming the standard of care with >90% success rate without significant side-effects including those who failed previous interferon-based treatment

**Prognosis**
- 80% of acute hepatitis C become chronic (of these 20% evolve to cirrhosis)
- Risk of hepatocellular carcinoma increases if cirrhotic
- Can cause cryoglobulinemia; associated with membranoproliferative glomerulonephritis, lymphoma
Table 16. Characteristics of the Viral Hepatitides

<table>
<thead>
<tr>
<th>Virus Family</th>
<th>HBV</th>
<th>HCV</th>
<th>HDV</th>
<th>HEV</th>
<th>CMV</th>
<th>EBV</th>
<th>Yellow Fever</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA</td>
<td>DNA</td>
<td>RNA</td>
<td>DNA</td>
<td>RNA</td>
<td>DNA</td>
<td>RNA</td>
<td>RNA</td>
</tr>
<tr>
<td>Envelope</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Transmission</td>
<td>Fecal/oral</td>
<td>Parenteral/sexual or equivalent Vertical</td>
<td>Parenteral/sexual (transfusion, IVDU, sexual [-HIV])</td>
<td>Non-parenteral (close contact in endemic areas)</td>
<td>Fecal/oral (endemic: Africa, Asia, central America, India, Pakistan)</td>
<td>Close contacts, most body fluids</td>
<td>Saliva/oral</td>
</tr>
<tr>
<td>Incubation</td>
<td>4-6 wk</td>
<td>6 wk-6 mo</td>
<td>2-26 wk</td>
<td>3-13 wk</td>
<td>2-6 wk</td>
<td>20-60 d</td>
<td>30-50 d</td>
</tr>
<tr>
<td>Onset</td>
<td>Usually abrupt</td>
<td>Usually insidious</td>
<td>Insidious</td>
<td>Usually abrupt</td>
<td>Usually abrupt</td>
<td>Variable</td>
<td>Variable</td>
</tr>
<tr>
<td>Communicability</td>
<td>2-3 wk in late incubation to early clinical phase</td>
<td>Acute hepatitis in most adults, 10% of children</td>
<td>Communicable prior to overt symptoms and throughout chronic illness</td>
<td>Infectious only in presence of HBV (HBsAg required for replication)</td>
<td>Unknown</td>
<td>Variable – dormant or persistent</td>
<td>Communicable highest during year after primary infection but never zero</td>
</tr>
<tr>
<td>Chronicity</td>
<td>None, although can relapse</td>
<td>5% adults, 80% infants</td>
<td>80%, 20% of which develop cirrhosis</td>
<td>9%</td>
<td>None</td>
<td>Common; latent</td>
<td>Common; latent</td>
</tr>
<tr>
<td>Serology</td>
<td>Anti-HAV (IgM)</td>
<td>See Table 15</td>
<td>HCV-RNA</td>
<td>Anti-HCV (IgG/IgM)</td>
<td>HBsAg</td>
<td>Anti-HBV (IgG/IgM)</td>
<td>Anti-CMV (IgM/IgG)</td>
</tr>
<tr>
<td>Immunity</td>
<td>Yes</td>
<td>Yes</td>
<td>?</td>
<td>Yes</td>
<td>?</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>Vaccine</td>
<td>HAV, 2 doses at 0, 7, and 21 d</td>
<td>Recombivac HVTM, age 11-15, 2 doses q5mo</td>
<td>Prevention: no vaccine Rx: IFN + ribavirin; although all oral anti-viral (IFN-free) therapy now available is highly efficacious</td>
<td>Prevention: HBV vaccine</td>
<td>Prevention: general hygiene, no vaccine</td>
<td>In high risk transplant patients: CMV Ig and anti-virals (ganciclovir; valganciclovir)</td>
<td>Supportive treatment post infection</td>
</tr>
<tr>
<td>Management</td>
<td>General hygiene (anti-HAV Ig)</td>
<td>Prophylaxis for high-risk groups (HAV vaccine = HAV Ig) unless immune</td>
<td>Prevention: HBV vaccine and/or hepatitis B Ig (HBIG) for needlestick, sexual contact, infants of infected mothers unless already immune Rx: oral antivirals vs interferon if indications met</td>
<td>Prevention: no vaccine Rx: IFN + ribavirin; although all oral anti-viral (IFN-free) therapy now available is highly efficacious</td>
<td>Prevention: HBV vaccine</td>
<td>Prevention: general hygiene, no vaccine</td>
<td>In high risk transplant patients: CMV Ig and anti-virals (ganciclovir; valganciclovir)</td>
</tr>
<tr>
<td>Acute Mortality</td>
<td>0.1-0.3%</td>
<td>0.5-2%</td>
<td>1%</td>
<td>2-20% co-infection with HCV, 30% superinfection Predisposes HBV carriers to more severe hepatitis and faster progression to cirrhosis</td>
<td>1-2% overall, 10-20% in pregnancy</td>
<td>Rare in immunocompetent adults</td>
<td>Rare</td>
</tr>
<tr>
<td>Oncopatency</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>?</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Complications</td>
<td>Can cause acute liver failure and subsequent death (&lt;1.5%)</td>
<td>Hepatocellular carcinoma secondary to cirrhosis, serum sickness-like syndrome, gianomulonephritis, polyarteritis nodosa, porphyria cutanea tarda</td>
<td>Hepatocellular carcinoma in 2-5% of cirrhosis per year</td>
<td>Leukocytoclastic vasculitis, membranous glomerulonephropathy</td>
<td>MIA, except in third trimester</td>
<td>5% of neonates born to multiple handicaps</td>
<td>Associated with Burkitt’s lymphoma and nasopharyngal carcinoma (rare in Western world)</td>
</tr>
</tbody>
</table>

Autoimmune Chronic Active Hepatitis

- diagnosis of exclusion: rule out viruses, drugs, metabolic, or genetic causes
- can be severe: 40% mortality at 6 mo without treatment
- extrahepatic manifestations
  - sicca, Raynaud’s, thyroiditis, Sjögren’s, arthralgias
  - hypergammaglobulinemia
    - anti-smooth muscle antibody elevation is most characteristic; also elevations in anti-LKM elevation (liver kidney microsome), especially in children
    - less specific: elevated ANA, RF
  - can have false positive viral serology (especially anti-HCV)
  - biopsy – perportal (zone 1) and interface inflammation and necrosis
- treatment: corticosteroids (80% respond) ± azathioprine (without this, most will relapse as corticosteroids are withdrawn)
**Drug-Induced Liver Disease**

### Table 17. Classification of Hepatotoxins

<table>
<thead>
<tr>
<th></th>
<th>Direct</th>
<th>Indirect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Example</td>
<td>Acetaminophen, CCl4</td>
<td>Phenytoin, INH</td>
</tr>
<tr>
<td>Dose-Dependence</td>
<td>Usual</td>
<td>Unusual</td>
</tr>
<tr>
<td>Latent Period</td>
<td>Hours-days</td>
<td>Weeks-months</td>
</tr>
<tr>
<td>Host Factors</td>
<td>Not important</td>
<td>Very important</td>
</tr>
<tr>
<td>Predictable</td>
<td>Yes</td>
<td>No (idiosyncratic)</td>
</tr>
</tbody>
</table>

### Specific Drugs
- aceterminophen
  - metabolized by hepatic cytochrome P450 system
  - can cause ALF (transaminases >1,000 U/L followed by jaundice and encephalopathy)
  - requires 10-15 g in healthy, 4-6 g in alcoholics/anticonvulsant users
  - mechanism: high aceterminophen dose saturates glucuronidation and sulfation elimination pathways → reactive metabolite is formed → covalently binds to hepatocyte membrane
  - presentation
    - first 24 h: N/V (usually within 4-12 h of overdose)
    - 24-48 h: asymptomatic, but ongoing hepatic necrosis resulting in increased transaminases
    - >48 h: continued hepatic necrosis possibly complicated with ALF or resolution
    - note: potential delay in presentation in sustained-release products
  - blood levels of aceterminophen correlate with the severity of hepatic injury, particularly if time of ingestion known
  - therapy
    - gastric lavage/emasition (if <2 h after ingestion)
    - oral activated charcoal
    - N-acetylcysteine (NAC, Mucomyst*) can be given PO or IV (most effective within 8-10 h of ingestion, but should be given no matter when time of ingestion)
      - promotes hepatic glutathione regeneration
      - no recorded fatal outcomes if NAC given before increase in transaminases
    - chlorpromazine: cholestasis in 1% after 4 wk; often with fever, rash, jaundice, pruritus, and eosinophilia
    - INH (isoniazid)
      - 20% develop elevated transaminases but <1% develop clinically significant disease
      - susceptibility to injury increases with age
    - methotrexate
      - causes fibrosis/cirrhosis; increased risk in the presence of obesity, DM, alcoholism (i.e. with underlying risk for pre-existing fatty liver)
      - scarring develops without symptoms or changes in liver enzymes, therefore biopsy may be needed in long-term treatment
    - amiodarone: can cause same histology and clinical outcome as alcoholic hepatitis
    - others: azoles, statins, methylprednisolone, phenytoin, propylthiouracil (PTU), rifampin, sulfonamides, tetracyclines
    - herbs: chaparrel, Chinese herbs (e.g. germander, comfrey, bush tea)

### Wilson’s Disease

**Definition**
- autosomal recessive defect in copper metabolism (gene ATP7B)

**Etiology**
- decreased biliary excretion of copper plus decreased incorporation of copper into ceruloplasmin

**Clinical Features**
- liver: acute hepatitis, acute liver failure, chronic active hepatitis, cirrhosis, low risk of hepatocellular carcinoma
- eyes: Kayser-Fleischer rings (copper deposits in Descemet’s membrane); more common in patients with CNS involvement, present in 50% if only liver involvement
- CNS: basal ganglia (wing flapping tremor, Parkinsonism), cerebellum (dysarthria, dysphagia, incoordination, ataxia), cerebrum (psychosis, affective disorder)
- kidneys: Fanconi’s syndrome (proximal tubule transport defects) and stones
- blood: intravascular hemolysis; may be initial presentation in fulminant hepatitis
- joints: arthritis, bone demineralization, calcifications

**Investigations**
- suspect if increased liver enzymes with clinical manifestations at young age (<30); especially combination of liver disease with dystonia, psychiatric symptoms
Hemochromatosis

Definition
- Excessive iron storage causing multiorgan system dysfunction (liver, in particular) with total body stores of iron increased to 20–40 g (normal 1 g).

Etiology
- Primary (hereditary) hemochromatosis
  - Hepcidin deficiency results in ongoing gut absorption of iron despite adequate iron stores.
- Secondary hemochromatosis
  - Parenteral iron overload (e.g., transfusions).
  - Chronic hemolytic anemia: thalassemia, pyruvate kinase deficiency.
  - Excessive iron intake.

Epidemiology
- Hereditary hemochromatosis most common in Northern European descent.
- Primarily due to common recessive gene (HFE, 5%); 1/400 patients are homozygotes.

Clinical Features
- Usually presents with trivial elevation in serum transaminases.
- Liver: cirrhosis (30%), HCC (200x increased risk) – most common cause of death (1/3 of patients).
- Pancreas: DM, chronic pancreatitis.
- Skin: bronze or grey (due to melanin, not iron).
- Joint: arthralgia (any joint, but especially MCP joints), chondrocalcinosis.

Investigations
- Screening for individuals with clinical features and/or family history (1/4 chance of sibling having the disease).
  - Transferrin saturation (free Fe²⁺/TIBC) >45%.
  - Serum ferritin >400 ng/mL.
  - HFE gene analysis: 90% of primary hemochromatosis involves C282Y allele, while H63D and S65C alleles also commonly involved and screened.
- Liver biopsy (generally used to detect cirrhosis or if potential for other causes of liver disease).
  - Markers of advanced fibrosis: if any of the following are present at the time of diagnosis – age >40, elevated liver enzymes, or ferritin >1000.
  - Considered if compound heterozygote and potential other cause of liver injury (e.g., fatty liver, etc.).
  - If C282Y/C282Y and no markers of advanced fibrosis, then biopsy generally not needed.
- HCC screening if cirrhosis.

Treatment
- Phlebotomy: weekly or q2wk then lifelong maintenance phlebotomies q2-6mo.
- Detreraxamines if phlebotomy contraindicated (e.g., cardiomyopathy, anemia).
- Primary hemochromatosis responds well to phlebotomy.
- Secondary hemochromatosis usually requires chelation therapy (administration of agents that bind and sequester iron, and then excreted).

Prognosis
- Normal life expectancy if treated before the development of cirrhosis or DM.
Alcoholic Liver Disease

Definition
- fatty liver (all alcoholics): always reversible if alcohol stopped
- alcoholic hepatitis (35% of alcoholics): usually reversible if alcohol stopped
- cirrhosis (10-15% of alcoholics): potentially irreversible

Pathophysiology
- several mechanisms, poorly understood
- ethanol oxidation to acetaldehyde
  - reduces NAD to NADH; increased NADH decreases ATP supply to liver, impairing lipolysis so fatty acids and triglycerides accumulate in liver
- binds to hepatocytes evoking an immune reaction
- ethanol increases gut permeability leading to increased bacterial translocation
- alcohol metabolism causes
  - relative hypoxia in liver zone III (near central veins; poorly oxygenated) > zone I (around portal tracts, where oxygenated blood enters)
  - necrosis and hepatic vein sclerosis
- histology of alcoholic hepatitis
  - ballooned (swollen) hepatocytes often containing Mallory bodies, characteristically surrounded by neutrophils
  - large fat globules
  - fibrosis: space of Disse and perivenular

Clinical Features
- >2-3 standard drinks/d in females and >3-6 standard drinks/d in men for >10 yr leads to cirrhosis, but only in about 10-20% of those who consume this amount daily on a continuous basis; cirrhosis risk increases with amount of alcohol consumed above threshold
- clinical findings do not accurately predict type of liver involvement
- fatty liver
  - mildly tender hepatomegaly; jaundice rare
  - mildly increased transaminases <5x normal
- alcoholic hepatitis
  - variable severity: mild to fatal liver failure
  - mild: stops drinking because feels unwell, resumes when feeling better (if assessed, findings of hepatitis, potentially mildly jaundice, and mildly elevated INR)
  - severe: stops drinking but feels unwell, low grade fever, RUQ discomfort, increased white blood cell count – mimics RLL pneumonia and cholecystitis

Investigations
- blood tests are non-specific, but in general
  - AST/ALT >2:1 (both usually <300)
  - if ALT>AST, usually cirrhosis has developed (assuming alcohol in the cause of the liver disease)
  - CBC: increased MCV, increased WBC

Treatment
- alcohol cessation (see Psychiatry, PS23)
  - Alcohols Anonymous, disulfiram, naltrexone, acamprosate
  - multivitamin supplements (especially thiamine)
  - caution with drugs metabolized by the liver
  - prednisone and pentoxifylline less used since most definitive trial did not show efficacy

Prognosis
- Maddrey's discriminant function (based on PT and bilirubin) and MELD predict mortality and guide treatment
- fatty liver: complete resolution with cessation of alcohol intake
- alcoholic hepatitis mortality
  - immediate: 30%-60% in the first 6 mo if severe
  - with continued alcohol: 70% in 5 yr
  - with cessation: 30% in 5 yr

Non-Alcoholic Fatty Liver Disease

Definition
- spectrum of disorders characterized by macrovesicular hepatic steatosis, sometimes with inflammation and/or fibrosis
- most common cause of liver disease in North America
Etiology
• pathogenesis not well elucidated; insulin resistance implicated as key mechanism, leading to hepatic steatosis
• histological changes indistinguishable from those of alcoholic hepatitis despite negligible history of alcohol consumption

Risk Factors
• likely a component of the metabolic syndrome along with type 2 DM, HTN, hypertriglyceridemia
• rapid weight loss or weight gain

Clinical Features
• often asymptomatic
• may present with fatigue, malaise, and vague RUQ discomfort
• elevated serum triglyceride/cholesterol levels and insulin resistance

Investigations
• elevated serum AST, ALT ± ALP; AST/ALT <1
• presents as echogenic liver texture on ultrasound
• liver biopsy diagnostic, but often necessary only for prognosis

Treatment
• mainstay is gradual weight loss (0.5-1 kg/wk) as rapid weight loss can worsen liver disease
  • ideally, aim to lose at least 7-10% of body weight
• some evidence for vitamin E (800 U daily) if there is hepatic inflammation
• some evidence for benefits of coffee drinking (3 cups per day) and vitamin D

Prognosis
• most die from cardiovascular or cerebrovascular disease
• better prognosis than alcoholic hepatitis
  • <25% progress to cirrhosis over a 7-10 yr period
• risk of progression increases if inflammation or scarring occurs alongside fat infiltration (non-alcoholic steatohepatitis)
• other clinical indicators of unfavourable prognosis: DM, age, metabolic syndrome

Acute Liver Failure (formerly Fulminant Hepatic Failure)

Definition
• severe decline in liver function characterized by coagulation abnormality (INR>1.5) and encephalopathy
• in setting of previously normal liver
• rapid (<26 wk duration)

Etiology
• drugs (especially acetaminophen), hepatitis B (measure anti-HBc, IgM fraction because sometimes HBV-DNA and even HBsAg rapidly becomes negative), hepatitis A, hepatitis C (rare), ischemic, idiopathic

Treatment
• correct hypoglycemia, monitor level of consciousness, prevent GI bleeding with PPI, monitor for infection and multiorgan failure (usually requires ICU)
• consider liver biopsy before INR becomes too high
• chief value of biopsy is to exclude chronic disease, less helpful for prognosis
• liver transplant (King’s College criteria can be used as prognostic indicator): consider early, especially if time from jaundice to encephalopathy >7 d (e.g. not extremely rapid), age <10 or >40, cause is drug or unknown, bilirubin >300 µmol/L, INR >3.5, creatinine >200 µmol/L

Cirrhosis

Definition
• liver damage characterized by diffuse distortion of the basic architecture and replacement with scar tissue and formation of regenerative nodules
• Stage 1 cirrhosis is compensated and asymptomatic, can last for 10-20 yr with almost normal life expectancy
• Stage 2 cirrhosis is decompensation, typically development of ascites (most common), variceal bleeding, encephalopathy, characteristically presents abruptly even though histologically the liver fibrosis is gradually progressive

Etiology
• fatty liver (alcoholic or non-alcoholic fatty liver disease)
• chronic viral hepatitis (B, B+D, C; not A or E)
- autoimmune hepatitis
- hemochromatosis
- primary biliary cirrhosis
- chronic hepatic congestion
  - cardiac cirrhosis (chronic right heart failure, constrictive pericarditis)
  - hepatic vein thrombosis (Budd-Chiari)
  - cryptogenic (i.e., no identifiable cause, although many of these patients may represent “burnt-out NASH”)
- rare: Wilson’s disease, Gaucher’s disease, α1-antitrypsin deficiency

**Investigations**
- definitive diagnosis is histologic (liver biopsy)
- other tests may be suggestive
  - blood work: fall in platelet count <150 is the earliest finding, followed many years later with rise in INR, fall in albumin, rise in bilirubin, fall in glucose level (pre-terminal event)
  - FibroTest: combination of various clinical and biochemical markers that can predict degree of fibrosis
  - imaging
    - U/S is the primary imaging modality but only finds advanced cirrhosis
    - CT to look for varices, nodular liver texture, splenomegaly, ascites
    - Ultrasound elastography (FibroScan): non-invasive tool using elastography (variable availability)
  - gastroscopy: varices or portal gastropathy

**Treatment**
- treat underlying disorder
- decrease insults (e.g., alcohol cessation, hepatotoxic drugs, immunize for Hep A and B if non-immune)
- follow patient for complications (esophageal varices, ascites, HCC defines stage 2 cirrhosis)
- prognosis: Child-Pugh score and MELD score
- liver transplantation for end-stage disease if no alcohol for >6 mo; use MELD score

**Table 18. Child-Pugh Score and Interpretation**

<table>
<thead>
<tr>
<th>Classification</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum bilirubin (µmol/L)</td>
<td>&lt;34</td>
<td>34-51</td>
<td>&gt;51</td>
</tr>
<tr>
<td>Serum albumin (g/L)</td>
<td>&gt;35</td>
<td>28-35</td>
<td>&lt;28</td>
</tr>
<tr>
<td>INR</td>
<td>&lt;1.7</td>
<td>1.7-2.3</td>
<td>&gt;2.3</td>
</tr>
<tr>
<td>Presence of ascites</td>
<td>Absent</td>
<td>Controllable</td>
<td>Refractory</td>
</tr>
<tr>
<td>Encephalopathy</td>
<td>Absent</td>
<td>Minimal</td>
<td>Severe</td>
</tr>
</tbody>
</table>

**Interpretation**

<table>
<thead>
<tr>
<th>Points</th>
<th>Class</th>
<th>Life Expectancy</th>
<th>Perioperative Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-6</td>
<td>A</td>
<td>15-50 yr</td>
<td>10%</td>
</tr>
<tr>
<td>7-9</td>
<td>B</td>
<td>Candidate for transplant</td>
<td>30%</td>
</tr>
<tr>
<td>10-15</td>
<td>C</td>
<td>1-3 mo</td>
<td>82%</td>
</tr>
</tbody>
</table>

Score: 5-6 (Child’s A), 7-9 (Child’s B), 10-15 (Child’s C)

*Note: Child’s classification is rarely used for shunting (TIPS or other surgical shunts), but is still useful to quantitate the severity of cirrhosis

**Complications**
- hematologic changes in cirrhosis
  - pancytopenia from hypersplenism: platelets first, then WBC, then hemoglobin
  - decreased clotting factors resulting in elevated INR
  - relationship of INR to bleeding tendency is controversial; some patients may be hypocoagulable, others may be hypercoagulable
- variceal bleeds
  - half of patients with cirrhosis have gastroesophageal varices and one-third of these develop hemorrhage with an overall mortality of >30%
  - hepatic venous pressure gradient (HVPG) ≥10 mmHg is the strongest predictor of variceal development
  - treatment: resuscitation, antibiotic prophylaxis, vasoactive drugs (e.g., octreotide IV) combined with endoscopic band ligation or sclerotherapy, TIPS
- renal failure in cirrhosis
  - classifications
    - pre-renal (usually due to over-diuresis)
    - acute tubular necrosis
    - HRS
      - Type I: sudden and acute renal failure (rapid doubling of creatinine over 2 wk)
      - Type II: gradual increase in creatinine with worsening liver function (creatine doubling over years)

**MELD-Na (Model for End Stage Liver Disease)**
- Predicts 3 mo survival and used to stratify patients on transplant list
- Based on creatinine, INR, total bilirubin, and serum sodium concentration

**Liver Transplantation**
- Candidate for transplant
- Priorities: MELD score
- Liver allocation based on MELD score and transplant waiting time

**Liver Transplant**
- Operative mortality: 10%
- 1-3 mo: 30%
- 15-50 yr: 10%

**Cirrhosis Complications**

- **Varices**
  - Acute Hemorrhage
  - Portal Hypertension
- **Ascites/Anemia**
- **Renal Failure** (hepatorenal syndrome)
- **Coagulopathy**
- **Encephalopathy**
- **Sepsis**

**Usual causes of death in cirrhosis:**
- Renal failure (hepatorenal syndrome), sepsis, GI bleed, or HCC

**Hepatorenal Syndrome vs. Pre-Renal Failure – Difficult to Differentiate**
- Similar blood and urine findings
- Urine sodium: very low in hepatorenal; low in pre-renal
- Intravenous fluid challenge: giving volume expanders improves pre-renal failure, but not hepatorenal syndrome
HRS can occur at any time in severe liver disease, especially after
- overdiuresis or dehydration, such as diarrhea, vomiting, etc.
- GI bleed
- sepsis
- treatment for hepatorenal syndrome (generally unsuccessful at improving long-term survival)
  - for type I HRS: octreotide + midodrine + albumin (increases renal blood flow by increasing systemic vascular resistance)
  - definitive treatment is liver transplant

hepatopulmonary syndrome
- majority of cases due to cirrhosis, though can be due to other chronic liver diseases, such as non-cirrhotic portal HTN
- thought to arise from ventilation-perfusion mismatch, intrapulmonary shunting and limitation of oxygen diffusion, failure of damaged liver to clear circulating pulmonary vasodilators vs. production of a vasodilating substance by the liver
- clinical features
  - hyperdynamic circulation with cardiac output >7 L/min at rest and decreased pulmonary + systemic resistance (intrapulmonary shunting)
  - dyspnea, platypnea (increase in dyspnea in upright position, improved by recumbency), and orthodeoxia (desaturation in the upright position, improved by recumbency)
  - diagnosis via contrast-enhanced echocardiography: inject air bubbles into peripheral vein; air bubbles appear in left ventricle after third heartbeat (normal = no air bubbles; in ventricular septal defect, air bubbles seen <3 heart beats)
  - only proven treatment is liver transplantation

Effects of Liver Failure
- Encephalopathy (coma)
- Xanthelasma
- Scleral icterus
- jaundice
- Fétor hepaticus
- Spider angioma
- Gynecomastia
- Muscle wasting
- Bleeding tendency (bruising)
- Loss of sexual hair, testicular atrophy
- Ankle edema
- Palmar erythema
- Dupuytren’s contracture, asterixis anemia
- Leukonychia, Terry’s nails, clubbing

Figure 13. Clinical features of liver disease

Hepatocellular Carcinoma
- see General Surgery, GS44

Liver Transplantation
- see General Surgery, GS45

Portal Hypertension

Definition
- pressure gradient between hepatic vein pressure and wedged hepatic vein pressure (corrected sinusoidal pressure) >5 mmHg

Pathophysiology
- 3 sites of increased resistance (remember pressure = flow x resistance)
  - pre-sinusoidal (e.g. portal vein thrombosis, schistosomiasis, sarcoidosis)
  - sinusoidal (e.g. cirrhosis, alcoholic hepatitis)
  - post-sinusoidal (e.g. right-sided heart failure, hepatic vein thrombosis, veno-occlusive disease, constrictive pericarditis)

Complications
- GI bleeding from varices in esophagus, less commonly in stomach, even less frequently from portal hypertensive gastropathy
- ascites
- hepatic encephalopathy
- thrombocytopenia
- renal dysfunction
- sepsis
- arterial hypoxemia

Fibrosis may regress and disappear if cause of liver injury is treated or resolves

Hepatopulmonary Syndrome
- Clinical Triad
  - Liver disease
  - Increased alveolar-arterial gradient while breathing room air
  - Evidence for intrapulmonary vascular abnormalities

© Jason Sharpe 2003
Treatment
- non-selective β-blockers (propanolol, nadolol) decrease risk of bleeding from varices
- TIPS: to decrease portal venous pressure
  - radiologically inserted stent between portal and hepatic vein via transjugular vein catheterization and percutaneous puncture of portal vein
  - can be used to stop acute bleeding or prevent rebleeding or treat ascites
- shunt usually remains open for <1 yr
- complications: hepatic encephalopathy, deterioration of hepatic function
- contraindicated with severe liver dysfunction
- most commonly used as a “bridge” to liver transplant
- other surgically created shunts: portacaval, distal spleno-renal (Warren shunt) - all used only rarely in the modern era

**Hepatic Encephalopathy**

Definition
- spectrum of potentially reversible neuropsychiatric syndromes secondary to liver disease diagnosed after ruling out other causes for symptoms (e.g. structural/metabolic)

Pathophysiology
- portosystemic shunt around hepatocytes and decreased hepatocellular function increase level of systemic toxins (believed to be ammonia from gut, mercaptans, fatty acids, amino acids) which go to the brain

Precipitating Factors
- nitrogen load (GI bleed, protein load from food intake, renal failure, constipation)
- drugs (narcotics, CNS depressants)
- electrolyte disturbance (hypokalemia, alkalosis, hypoxia, hypovolemia)
- infection (spontaneous bacterial peritonitis)
- deterioration in hepatic function or superimposed liver disease

Stages
- I: apathy, restlessness, reversal of sleep-wake cycle, slowed intellect, impaired computational abilities, impaired handwriting
- II: asterixis, lethargy, drowsiness, disorientation
- III: stupor (rousable), hyperactive reflexes, extensor plantar response (upgoing Babinski)
- IV: coma (response to painful stimuli only)

Investigations
- clinical diagnosis: supported by laboratory findings and exclusion of other neuropsychiatric diseases
- rule out
  - non-liver-related neuropsychiatric disease in a patient with liver problems (e.g. alcohol withdrawal or intoxication, sedatives, subdural hematoma, metabolic encephalopathy)
  - causes of metabolic encephalopathy (e.g. renal failure, respiratory failure, severe hyponatremia, hypoglycemia)
- characteristic EEG findings: diffuse (non-focal), slow, high amplitude waves
- serum ammonia levels increased, but not often necessary to measure in routine clinical use

Treatment
- treat underlying precipitating factors
- decrease generation of nitrogenous compounds
  - routine protein restriction is no longer recommended given patients generally have concurrent malnutrition and muscle wasting; however, vegetable protein is better tolerated than animal protein
  - lactulose: titrated to achieve 2-3 soft stools/d
    - prevents diffusion of NH3 (ammonia) from the colon into blood by lowering pH and forming non-diffusible NH4 ( ammonium)
    - serves as a substrate for incorporation of ammonia by bacteria, promotes growth in bowel lumen of bacteria which produce minimal ammonia
    - also acts as a laxative to eliminate nitrogen-producing bacteria from colon
- oral rifaximin for both acute treatment and maintenance therapy has high level evidence for efficacy
- best acute treatment in comatose patient is lactulose enemas
- other antibiotics that may be used include metronidazole and vancomycin
Ascites

Definition
• accumulation of excess fluid in the peritoneal cavity

Etiology
Table 19. Serum-Ascites Albumin Gradient as an Indicator of the Causes of Ascites

<table>
<thead>
<tr>
<th>Serum [Alb] – Ascitic [Alb] &gt;11 g/L (1.1 g/dL)</th>
<th>Serum [Alb] – Ascitic [Alb] &lt;11 g/L (1.1 g/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Portal Hypertension Related</td>
<td>Non-Portal Hypertension Related</td>
</tr>
<tr>
<td>Cirrhosis/severe hepatitis</td>
<td>Peritoneal carcinomatosis</td>
</tr>
<tr>
<td>Chronic hepatic congestion (right heart failure, Budd-Chiari)</td>
<td>TB</td>
</tr>
<tr>
<td>Massive liver metastases</td>
<td>Pancreatic disease</td>
</tr>
<tr>
<td>Myxedema</td>
<td>Serositis</td>
</tr>
<tr>
<td>* In nephrotic syndrome: decreased serum [Alb] to begin with therefore gradient not helpful</td>
<td></td>
</tr>
</tbody>
</table>

Pathophysiology
• key factor in pathogenesis is increased sodium (and water) retention by the kidney for reasons not fully understood. Theories include:
  ■ underfill hypothesis: first step in ascites formation is increased portal pressure and low oncotic pressure (e.g. low serum albumin) driving water out of the splanchnic portal circulation into abdominal cavity; the resulting decreased circulating volume causes secondary sodium retention by the kidney
  ■ overfill hypothesis: cirrhosis directly causes increased sodium retention by the kidney in the absence of hypovolemia and ascites arises secondarily
  ■ peripheral arterial vasodilation theory (most popular): as portal HTN develops in cirrhosis, production of local mediators such as nitric oxide lead to splanchnic arterial vasodilation which ultimately results in reduction of effective arterial volume and compensatory sodium and fluid retention by the kidneys (i.e. circulation volume is increased, as per overfill hypothesis, but relatively underfilled, as per underfill hypothesis)

Diagnosis
• abdominal ultrasound
• physical exam (clinically detectable when >500 mL)
  ■ bulging flanks, shifting dullness, fluid-wave test positive
  ■ most sensitive symptom: ankle swelling

Investigations
• diagnostic paracentesis
  ■ 1st aliquot: cell count and differential
  ■ 2nd aliquot: chemistry (especially albumin, but also total protein; amylase if pancreatitis; TG and chylomicrons if turbid and suspect chyloous ascites)
  ■ 3rd aliquot: C&S, Gram stain
  ■ 4th aliquot: cytology (usually positive in peritoneal carcinomatosis)

Treatment
• non-refractory ascites
  ■ Na⁺ restriction (daily sodium intake <2 g)
  ■ diuretics: spironolactone, furosemide
  ■ aim for weight loss 0.5-1 kg/d, more if concomitant peripheral edema (which is mobilized quicker than ascitic fluid); overly rapid weight loss increases risk of renal failure
  ■ if target weight loss is not achieved and there are no complications, increase dose to achieve target while monitoring for complications

• refractory ascites (diuretics are inadequate or not tolerated)
  ■ therapeutic paracentesis with intravenous albumin
  ■ TIPS in an appropriate patient (no contraindications) with potential transplant-free survival advantage
  ■ liver transplantation should be considered in every case, since development of ascites in patients with cirrhosis is associated with 50% 2 yr mortality
Complication: Primary/Spontaneous Bacterial Peritonitis

- primary/spontaneous bacterial peritonitis (SBP)
  - complications: ascites, but does not cause it (occurs in 10% of cirrhotic ascites); higher risk in patients with GI bleed
  - 1/3 of patients are asymptomatic, thus do not hesitate to do a diagnostic paracentesis in ascites even if no clinical indication of infection
  - fever, chills, abdominal pain, ileus, hypotension, worsening encephalopathy, acute kidney injury
  - Gram-negatives compose 70% of pathogens: E. coli (most common), Streptococcus, Klebsiella

- diagnosis
  - absolute neutrophil count in peritoneal fluid >0.25x10^9 cells/L (250 cells/mm^3)
  - Gram stain positive in only 10-50% of patients (not needed for diagnosis)
  - culture positive in <80% of patients

- prophylaxis: consider in patients with
  - cirrhosis or GI bleed: ceftriaxone IV daily or norfloxacine bid x 7 d
  - previous episode of SBP: long-term prophylaxis with daily norfloxacine or TMP-SMX

- treatment
  - IV antibiotics (cefotaxime 2 g IV q8h or ceftriaxone 2g IV daily is the treatment of choice for 5 d; modify if response inadequate or culture shows resistant organisms)
  - IV albumin (1.5 g/kg at time of diagnosis and 1 g/kg on day 3) decreases mortality by lowering risk of acute renal failure

Biliary Tract

Jaundice

- see Table 2 and Figures 15 and 16

Signs and Symptoms

- dark urine, pale stools: suggests that bilirubin elevation is from direct fraction
- pruritus: suggests chronic disease, cholestasis
- abdominal pain: suggests biliary tract obstruction from stone or pancreatic tumour (obstructive jaundice)
- painless jaundice in the elderly: think of pancreatic cancer, although most patients with pancreatic cancer have pain
- keratitis: rarely seen in adults due to maturation of blood brain barrier

Investigations

- blood work: CBC, bilirubin (direct and total), liver enzymes (AST, ALT, ALP, GGT), liver function tests (INR/PT, PTT, albumin), amylase
- U/S or CT for evidence of bile duct obstruction (e.g. bile duct dilation)
- direct bile duct visualization
- magnetic resonance cholangiopancreatography (MRCP): non-invasive
- endoscopic ultrasound (EUS): sensitive for stones and pancreatic tumours
- endoscopic retrograde cholangiopancreatography (ERCP): invasive, most accurate, allows for therapeutic intervention
- percutaneous transhepatic cholangiography (PTC): if ERCP fails (endoscopic access not possible)
**Gilbert’s Syndrome**

**Definition**
- mild decrease in glucuronyltransferase activity leading to defective conjugation of bilirubin
- an abnormality of bilirubin metabolism with no clinical relevance

**Etiology/Epidemiology**
- some patients have decreased hepatobiliary uptake
- affects 7% of population, especially males
- autosomal dominant, 70% due to a mutation in the UGT gene

**Clinical Features**
- presents in teens-20s, often an incidental finding
- only manifestation is intermittent jaundice with increased serum unconjugated bilirubin developing most characteristically while fasting, or at times of acute illness; no other clinical implications

**Treatment**
- none indicated (entirely benign)

---

**Primary Sclerosing Cholangitis**

**Definition**
- narrowing of biliary tree (intra and/or extrahepatic bile ducts) from scarring

**Etiology**
- primary/idiopathic (most common)
  - associated with IBD, more commonly UC, in up to 70% of patients (usually male)
  - one of the most common indications for liver transplant
- secondary (less common)
  - long-term cholelithiasis
  - cholangiocarcinoma
  - surgical/traumatic injury (iatrogenic)
  - contiguous inflammatory process
  - post-ERCP
  - associated with HIV/AIDS (“HIV cholangiopathy”)
  - IgG4-related disease

**Signs and Symptoms**
- often insidious, may present with fatigue and pruritus
- may present with signs of episodic bacterial cholangitis secondary to biliary obstruction

**Investigations**
- increased ALP (hallmark), less often increased bilirubin
- mildly increased AST, usually <300 U/L
- p-ANCA (30-80%), elevated IgM (40-50%)
- MRCP and ERCP shows narrowing and dilatations of bile ducts that may result in “beading”, both intrahepatic and extrahepatic bile ducts
  - if intrahepatic narrowing only, do anti-mitochondrial antibody to rule out PBC

**Complications**
- repeated bouts of cholangitis may lead to complete biliary obstruction with resultant secondary biliary cirrhosis and hepatic failure
- increased incidence of cholangiocarcinoma (10-15%): difficult to diagnose and treat

**Treatment**
- image bile duct (MRCP) at least annually for early detection of cholangiocarcinoma (controversial)
- endoscopic sphincterotomy; biliary stent in selected cases of dominant CBD stricture
- antibiotics for cholangitis
- suppurrative cholangitis requires emergency drainage of pus in CBD
- liver transplantation appears to be the best treatment for advanced sclerosing cholangitis (nearly 90% 1-yr survival; mean follow-up from time of diagnosis to need for transplant is 10 yr)
- ursodiol: previously recommended, but studies suggest that at least in high doses it increases mortality

**Prognosis**
- unfavourable regardless of treatment
- mean survival after diagnosis remains 4-10 yr
Primary Biliary Cholangitis (formerly cirrhosis)

Definition
• chronic inflammation and fibrous obliteration of intrahepatic bile ductules

Etiology/Epidemiology
• likely autoimmune (associated with Sjögren’s syndrome, scleroderma, CREST syndrome, RA, thyroiditis)
• affects mainly middle-aged women (M:F = 1:9)

Signs and Symptoms
• often asymptomatic
• initial symptoms: pruritus, fatigue
• chronic: jaundice and melanosis (darkening skin) and other signs of cholestasis
• end-stage: hepatocellular failure, portal HTN, ascites
• high incidence of osteoporosis

Investigations
• increased ALP, GGT; bilirubin rises in later stage
• positive anti-mitochondrial antibodies (AMA; 95% specificity and sensitivity)
• increased serum cholesterol (mild increase in LDL, larger increase in HDL)
  • may have: xanthelasmas, xanthomas
• liver biopsy confirms diagnosis and stages severity
• normal bile duct on MRCP rules out bile duct obstruction which can mimic PBC
• recently described “overlap” syndromes with autoimmune cholangitis, autoimmune hepatitis, sclerosing cholangitis

Treatment
• treat with ursodiol (less frequently colchicine, methotrexate)
• cholestyramine (for pruritus and hypercholesterolemia)
• calcium and vitamin D for low bone density; bisphosphonates if osteoporosis severe
• monitor for thyroid disease
• liver transplant if disease severe, progressive

Prognosis
• can be fatal, although not all asymptomatic patients show progression

Secondary Biliary Cirrhosis

Definition
• cirrhosis from prolonged partial or total obstruction of major bile ducts

Etiology
• acquired: post-operative strictures, chronic pancreatitis, sclerosing cholangitis, stone in bile duct
• congenital: CF, congenital biliary atresia, choledochal cysts

Investigations
• cholangiography and liver biopsy

Treatment
• treat obstruction, give antibiotics for cholangitis prophylaxis

Biliary Colic, Cholecystitis

• see General Surgery, GS47
Ascending Cholangitis

• see General Surgery, GS49

Definition
• infection of the biliary tree

Etiology
• stasis in the biliary tract due to obstruction or stricture (usually from previous cholecystectomy)
• infection originates in the duodenum or spreads hematogenously from the portal vein
• bacteria
  ▪ E. coli, Klebsiella, Enterobacter, Enterococcus
  ▪ co-infection with Bacteroides and Clostridia can occur

Signs and Symptoms
• Charcot's triad: fever, RUQ pain, jaundice (50-70%)
• Reynolds' Pentad in patients with suppurative cholangitis: fever, RUQ pain, jaundice, hypotension, altered mental status

Investigations
• increased WBC
• usually increased ALP and bilirubin, ALT variably elevated
• blood culture
• abdominal U/S: CBD dilation, stones

Treatment
• most important is drainage, ideally via ERCP, but if not possible technically by percutaneous biliary or least often by surgical routes
• antibiotic therapy: broad spectrum to cover Gram-negatives, Enterococcus, and anaerobes (especially if CBD manipulation); no clear consensus on antibiotic choice but consider:
  ▪ ampicillin + sulbactam or piperacillin/tazobactam
  ▪ metronidazole + 3rd generation cephalosporin (e.g. ceftriaxone) or fluoroquinolone (e.g. ciprofloxacin or levofloxacin)
  ▪ carbapenem monotherapy (e.g. imipenem or meropenem)

Prognosis
• good with effective drainage and antibiotics in mild to moderate cases
• high mortality (~50%) in patients with Reynolds Pentad

Pancreas

Pancreatic Enzyme Abnormalities

Causes of Increased Serum Amylase
• pancreatic disease
  ▪ pancreatitis, pancreatic duct obstruction (e.g. ampullary cancer), pseudocyst, abscess, ascites, trauma, cancer
• non-pancreatic abdominal disease
  ▪ biliary tract disease, bowel obstruction/ischemia, perforated or penetrating ulcer, ruptured ectopic pregnancy, aneurysm, chronic liver disease, peritonitis
• non-abdominal disease
  ▪ cancer (lung, ovary, esophagus, etc.), salivary gland lesions, bulimia, renal transplant/insufficiency, burns, ketoacidosis
  ▪ macroamylasemia

Causes of Increased Serum Lipase
• pancreatic disease: same as above
• non-pancreatic abdominal disease (mild elevations only): same as above
• non-abdominal disease
  ▪ macrolipasemia
  ▪ renal failure
**Acute Pancreatitis**

**Etiology** (most common are alcohol and gallstones)

- **Idiopathic:** thought to be hypertensive sphincter or microlithiasis
- **Gallstones** (45%)
- **Ethanol** (35%)
- **Tumours:** pancreas, ampulla, choledochocoele
- **Scorpion stings**

**Microbiological**
- **bacterial:** Mycoplasma, Campylobacter, TB, M. avium intracellulare, Legionella, leptospirosis
- **viral:** mumps, rubella, varicella, viral hepatitis, CMV, EBV, HIV, Coxsackie virus, echovirus, adenovirus
- **parasites:** ascaris, clonorchiasis, echinococcus

**Autoimmune:** SLE, polyarteritis nodosa (PAN), Crohn’s disease

**Surgery/trauma**
- manipulation of sphincter of Oddi (e.g. ERCP), post-cardiac surgery, blunt trauma to abdomen, penetrating peptic ulcer

**Hyperlipidemia** (TG >11.3 mmol/L; >1000 mg/dL), **Hypercalcemia, Hypothermia**

**Emboli or ischemia**

**Drugs/toxins**
- azathioprine, mercaptopurine, furosemide, estrogens, methyl dopa, H₂-blockers, valproic acid, antibiotics, acetaminophen, salicylates, methanol, organophosphates, steroids (controversial)

**Pathophysiology**

- activation of proteolytic enzymes within pancreatic cells, starting with trypsin, leading to local and systemic inflammatory response
- in gallstone pancreatitis, this is due to mechanical obstruction of the pancreatic duct by stones
- in ethanol-related pancreatitis, pathogenesis is unknown
- in rare genetic diseases, mutations prevent the physiological breakdown of trypsin required normally to stop proteolysis (e.g. mutant trypsin in hereditary pancreatitis or mutation in SPINK 1 gene which normally inhibits activated trypsin); may be model for ethanol-related pancreatitis

**Pathology**

- mild (interstitial)
  - peri-pancreatic fat necrosis
  - interstitial edema
- severe (necrotic)
  - extensive peri-pancreatic and intra-pancreatic fat necrosis
  - parenchymal necrosis and hemorrhage → infection in 60%
  - release of toxic factors into systemic circulation and peritoneal space (causes multi-organ failure)
  - severity of clinical features may not always correlate with pathology
- 3 phases
  - local inflammation + necrosis → hypovolemia
  - systemic inflammation in multiple organs, especially in lungs, usually after IV fluids given → pulmonary edema
  - local complications 2 wk after presentation → pancreatic sepsis/abscess

**Signs and Symptoms**

- pain: epigastric, noncolicky, constant
- can radiate to back
- may improve when leaning forward (Inglefinger’s sign)
- tender rigid abdomen; guarding
- N/V
- abdominal distention from paralytic ileus
- fever: chemical, not due to infection
- jaundice: compression or obstruction of bile duct
- Cullen’s/Grey-Turner’s signs
- tetany: transient hypocalcemia
- hypovolemic shock: can lead to renal failure
- acute respiratory distress syndrome
- coma

**Investigations**

- increased serum pancreatic enzymes: amylase, lipase (more specific)
- ALT >150 specific for biliary cause
- increased WBC, glucose, low calcium
- imaging: CT most useful for diagnosis and prognosis
  - x-ray: “sentinel loop” (dilated proximal jejunum), calcification, and “colon cut-off sign” (colonic spasm)
  - U/S: useful for evaluating biliary tree (67% sensitivity, 100% specificity)
  - CT scan with IV contrast (67% sensitivity, 100% specificity)
  - CT scan with IV contrast: useful for diagnosis and prognosis because contrast seen only in viable pancreatic tissue, non-viable areas can be biopsied percutaneously to differentiate sterile from infected necrosis
  - ERCP or MRCP if cause uncertain, assess for duct stone, pancreatic or ampullary tumour, pancreas divisum
Classification
- interstitial edematous vs. necrotizing
- mild, moderate, severe

Prognosis
- usually a benign, self-limiting course, single or recurrent
- occasionally severe leading to
  - shock
  - pulmonary edema
  - multi-organ dysfunction syndrome
  - GI ulceration due to stress
  - death
- numerous scales to describe severity; probably most useful is proportion of pancreas not taking up contrast on CT done 48 hours after presentation (necrotic pancreas does not take up the contrast dye)
- presence of organ failure, particularly organ failure that persists > 48 hours, is associated with worse outcomes

Table 21. Collections in pancreatitis (Revised 2012 Atlanta Classification)

<table>
<thead>
<tr>
<th></th>
<th>Liquid</th>
<th>Solid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute</td>
<td>Acute peripancreatic fluid collection (APFC)</td>
<td>Acute necrotic collection (ANC)</td>
</tr>
<tr>
<td>Chronic</td>
<td>Pancreatic pseudocyst</td>
<td>Walled-off necrosis (WON)</td>
</tr>
</tbody>
</table>

All of these collections are classified as infected or not infected

Treatment
- goals (only supportive therapy available)
  1. hemodynamic stability
  2. analgesia
  3. oxygen
  4. stop progression of damage (difficult)
  5. treat local and systemic complications
- antibiotics controversial except in documented infection (use cephalosporins, imipenem)
- aspirate necrotic areas of pancreas to diagnose infection; drain if infected
- IV fluids (crystalloid or colloid)
  - beware third spacing of fluid, monitor urine output carefully
- NG suction (lets pancreas rest) if vomiting, stomach very dilated
- endoscopic sphincterotomy if severe gallstone pancreatitis (i.e. cholangitis or ongoing obstruction)
- nutritional support: nasojejunal feeding tube or TPN if cannot tolerate enteric feeds
  - recent evidence supports nasogastric enteral (or oral if feasible) feeds
- no benefit: glucagon, atropine, aprotinin, H2–blockers, peritoneal lavage
- follow clinically and CT/ultrasound to exclude complications
- chief role of invasive intervention is to excise necrotic tissue (necrosectomy) in the case of infected pancreatic necrosis (try to delay for >2 wk to allow demarcation between viable and necrotic tissue), better done endoscopically or radiologically than surgically if technically possible

Late Complications
- pseudocysts: follow if asymptomatic, drain if symptomatic or growing
  - drain: choice of endoscopic, percutaneous under radiological guidance, or surgical
  - bleeding: (1) gastric varices if splenic vein thrombosis, (2) pseudoaneurysm of vessels in areas of necrosis, especially splenic artery, (3) duodenal ulcer related to compression of duodenum by enlarged pancreas
- splenic and portal vein thrombosis: no effective therapy described, anticoagulation not proven, hazardous
- rare: DM, pancreatic duct damage

Chronic Pancreatitis

Definition
- irreversible damage to pancreas characterized by
  1. pancreatic cell loss (from necrosis)
  2. inflammation
  3. fibrosis

Etiology/Pathophysiology
- alcohol (most common)
  - causes a larger proportion (>90%) of chronic pancreatitis than acute pancreatitis
  - changes composition of pancreatic juice (e.g. increases viscosity)

Etiology
- alcohol abstinence
- Pancreatic enzyme replacement
- Analgesics
- Pancreatic resection if ductular blockage

Etiology = Almost Always Alcohol
• decreases pancreatic secretion of pancreatic stone protein (lithostathine) which normally solubilizes calcium salts
  • precipitation of calcium within pancreatic duct results in duct and gland destruction
• toxic effect on acinar and duct cells – directly or via increasing free radicals
• acinar cell injury leads to cytokine release, which stimulates pancreatic stellate cells to form collagen (leading to fibrosis)
• varying degrees of ductular dilatation, strictures, protein plugs, calcification
• no satisfactory theory to explain why only a minority of alcoholics develop pancreatitis
• unusual causes
  • CF
    • severe protein-calorie malnutrition
    • hereditary
    • idiopathic

**Signs and Symptoms**

• early stages
  • recurrent attacks of severe abdominal pain (upper abdomen and back)
  • chronic painless pancreatitis: 10%
• late stages: occurs in 15% of patients
  • malabsorption syndrome when >90% of function is lost, steatorrhea
  • diabetes, calcification, jaundice, weight loss, pseudocyst, ascites, GI bleed

**Investigations**

• laboratory
  • increase in serum glucose
  • increase in serum ALP, less commonly bilirubin (jaundice)
  • serum amylase and lipase usually normal
  • stool elastase is low in steatorrhea
• AXR: pancreatic calcifications
• U/S or CT: calcifications, dilated pancreatic ducts, pseudocyst
• MRCP or ERCP: abnormalities of pancreatic ducts-narrowing and dilatation
• EUS: abnormalities of pancreatic parenchyma and pancreatic ducts, most sensitive test
• 72-h fecal fat test: measures exocrine function
• secretin test: gold standard, measures exocrine function but difficult to perform, unpleasant for patient, expensive
• fecal pancreatic enzyme measurement (elastase-1, chymotrypsin): available only in selected centres

**Treatment**

• most common problem is pain, difficult to control
• general management
  • total abstinence from alcohol
  • enzyme replacement may help pain by resting pancreas via negative feedback
  • analgesics
  • celiac ganglion blocks
  • time: pain decreases with time as pancreas “burns out”
• endoscopy: sphincterotomy, stent if duct dilated, remove stones from pancreatic duct
• surgery: drain pancreatic duct (pancreaticojejunostomy) if duct dilated (more effective than endoscopy); resect pancreas if duct contracted
• steatorrhea
  • pancreatic enzyme replacement
  • restrict fat, increase carbohydrate and protein (may also decrease pain)
  • neither endoscopy nor surgery can improve pancreatic function

**Autoimmune Pancreatitis**

• most commonly presents as a mimicker of pancreatic cancer (pancreatic mass detected because of jaundice ± abdominal pain)

**Investigations**

• histology: lymphocyte and plasma cell infiltration of pancreas
• imaging: focal or diffuse enlargement of pancreas on CT or MRI, sausage shaped, low density rim around pancreas
• serology: increased serum IgG4
• other organ involvement: sialadenitis, retroperitoneal fibrosis, biliary duct narrowing, nephritis

**Treatment**

• responds to prednisone
Clinical Nutrition

Determination of Nutritional Status

- Corrected weight loss (expressed as body mass index [kg/m²]) is the most important parameter in assessing need for nutritional support.
- Subjective Global Assessment: a simple bedside tool to assess nutritional status, to help identify those who will benefit from nutritional support.

Investigations

- Plasma proteins: albumin, pre-albumin (shorter half-life than albumin), transferrin.
- Decrease may indicate decreased nutritional status or disease state.
- Thyroid-binding globulin, retinol-binding protein (may be too sensitive).
- Anthropometry (e.g., triceps skinfold thickness, grip strength) less often used.

Table 22. Areas of Absorption of Nutrients

<table>
<thead>
<tr>
<th></th>
<th>Fe</th>
<th>CHO</th>
<th>Proteins, Lipids</th>
<th>Na⁺, H₂O</th>
<th>Bile Acids</th>
<th>Vit B₁₂</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duodenum</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jejunum</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ileum</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>++</td>
<td>+++</td>
</tr>
</tbody>
</table>

Enteral Nutrition

Definition

- Enteral nutrition (tube feeding) is a way of providing food through a tube placed in the stomach or the small intestine.
- Choice of tubes: nasogastric (NG), nasojejunal (NJ), percutaneous endoscopic gastrostomy ("G-tube" or "PEG tube"), percutaneous endoscopic jejunostomy (J-tube) or tubes can be placed radiologically, surgically.

Indications

- Oral feeding inadequate or contraindicated.

Feeds

- Polymeric feeds contain whole protein, carbohydrate, fat as a liquid, with or without fibre.
- Elemental feeds contain protein as amino acids, carbohydrate as simple sugars, fat content low (therefore high osmolarity).
- Specific diets: low carbohydrate/high fat solution for ventilated patients (carbohydrate has a high respiratory quotient so minimizes carbon dioxide production), high energy, low electrolyte solutions for dialysis patients.

Relative Contraindications

- Non-functioning gut (e.g., intestinal obstruction, enterointestinal or enterocutaneous fistulae).
- Uncontrolled diarrhea.
- GI bleeding.

Complications

- Aspiration.
- Diarrhea.
- Refeeding syndrome (rare): carbohydrate can stimulate excessive insulin release, leading to cellular uptake and low serum levels of phosphate, magnesium, potassium.
- Overfeeding syndrome (rare): hypertonic dehydration, hyperglycemia, hypercapnea, azotemia (from excess protein).

Enteral Nutrition Advantages over Parenteral Nutrition

- Fewer serious complications (especially sepsis).
- Nutritional requirements for enteral administration better understood.
- Can supply gut-specific fuels such as glutamine and short chain fatty acids.
- Nutrients in the intestinal lumen prevent atrophy of the gut and pancreas.
- Prevents gallstones by stimulating gallbladder motility.
- Much less expensive.
Parenteral Nutrition

**Definition**
- Parenteral nutrition (PN) is the practice of feeding a person intravenously, bypassing the usual process of eating and digestion.

**Indications**
- Short-term (<1 mo)
  - Whenever GI tract not functioning
  - Only situations where PN has been well shown to increase survival are after bone marrow transplant and in short bowel syndrome, some evidence for benefit in gastric cancer, but often used in ICU, perioperatively, and in difficult to control sepsis.
  - Pre-operative: only useful in severely malnourished (e.g., loss of >15% of pre-morbid weight, serum albumin <28 g/L or <2.8 g/dL), and only if given for ≥2 wk.
  - Renal failure: PN shown to increase rate of recovery; no increase in survival.
  - Liver disease: branched chain amino acids may shorten duration of encephalopathy; no increase in survival.
  - IBD: PN closes fistulae and heals acute exacerbations of mucosal inflammation, but effect is transient (EN is equally effective).
  - Some evidence for efficacy, but convincing data not available for:
    - Radiation/chemotherapy-induced enteritis
    - AIDS with wasting diarrhea
    - Severe acute pancreatitis
- Long-term (>1 mo): can be given at home
  - Severe untreatable small bowel disease (e.g., radiation enteritis, extensive CD, high output fistulae)
  - Following surgical resection of >70% of small bowel (e.g., small bowel infarction)
  - Severe motility diseases (e.g., scleroderma affecting bowel)

**Relative Contraindications**
- Functional GI tract for enteral nutrition
- Active infection; at least until appropriate antibiotic coverage
- Inadequate venous access; triple-lumen central venous lines usually prevent this problem
- Unreliable patient or clinical setting

**Complications of PN**
- Sepsis: Most serious of the common complications
- Mechanical pneumothorax from insertion of central line, catheter migration and thrombosis, air embolus
- Metabolic: CHF, hyperglycemia, gallstones, cholestasis

Enteral vs. Parenteral Nutrition for Acute Pancreatitis
Cochrane DB of Syst Rev 2010;1:CD002837

**Purpose:** Compare EN vs. TPN on mortality, morbidity, and hospital stay in patients with pancreatitis.

**Study Selection:** RCTs of TPN vs. EN in pancreatitis.

**Results:** Eight trials (n=348) were included. Enteral nutrition decreases RR of death (0.50); multiple organ failure (0.55), infection (0.39), and other local complications (0.70). It also decreased hospital stay by 2.37 d.

**Conclusion:** EN reduces mortality, organ failure, infections, and length of hospital stay in patients with pancreatitis.
## Common Medications

### Table 23. Common Drugs Prescribed in Gastroenterology

<table>
<thead>
<tr>
<th>Class</th>
<th>Generic Drug Name</th>
<th>Trade Name</th>
<th>Dosing</th>
<th>Mechanism of Action</th>
<th>Indications</th>
<th>Contraindications</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Proton Pump Inhibitors</strong></td>
<td><em>omeprazole</em></td>
<td>Losec®/</td>
<td>20 mg PO OD</td>
<td>Inhibits gastric enzymes H+/K+-ATPase (proton pump)</td>
<td>Duodenal ulcer, gastric ulcer, NSAID-associated gastric and duodenal ulcers, reflux esophagitis, symptomatic GERD, dyspepsia, Zollinger-Ellison syndrome, eradication of H. pylori (combined with antibiotics)</td>
<td>Hypersensitivity to drug</td>
<td>Distress, headache, flatulence, abdominal pain, nausea, rash, increased risk of osteoporotic fracture (secondary to impaired calcium absorption)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prilosec®</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Laxatives</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Bulk Stimulant</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Laxatives</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Stool Softener</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Histamine H2-Receptor Antagonists</strong></td>
<td><em>ranitidine</em></td>
<td>Zantac®</td>
<td>300 mg PO OD or 150 mg bid IV therapy: 50 mg qid (does not need to be taken before breakfast)</td>
<td>Inhibits histamine H2-receptors</td>
<td>Duodenal ulcer, gastric ulcer, NSAID-associated gastric and duodenal ulcers, reflux esophagitis, symptomatic GERD; not useful for acute GI bleeds</td>
<td>Hypersensitivity to drug</td>
<td>Confusion, dizziness, headache, anhydrosis, constipation, nausea, agranulocytosis, pancytopenia, depression</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Osmotic Laxatives</strong></td>
<td><em>lactulose</em></td>
<td>Lactulose/ Constulose®</td>
<td>Constriction: 15-30 mL PO OD to bid</td>
<td>Osmotic agent causes water retention in stool and promotes frequency of stool</td>
<td>Osmotic constipation, prevention, and treatment of portal-systemic encephalopathy</td>
<td>Patients who require a low galactose diet</td>
<td>Fatigue, intestinal cramps, nausea, diarrhea if excessive dosage</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>15-30 mL bid to qd</td>
<td>Poorly absorbed in GI tract and is broken down by colonic bacteria into lactic acid in the colon, increases osmotic colonic contents, increases stool volume</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PEG3350</strong></td>
<td>Lax-a-day®/Golytely®</td>
<td>17 g powder dissolved in 4-8 oz liquid PO OD</td>
<td>Osmotic agent causes water retention in stool and promotes frequency of stool</td>
<td>Relief of constipation</td>
<td>Colonscopy prep</td>
<td>Hypersensitivity to drug</td>
<td>Abdominal distension, pain, oral pain, thirst, nausea, rigor, tonic-clonic seizures (rare)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Magnesium Hydroxide</strong></td>
<td>Milk of Magnesia/ Pedi-Lax®</td>
<td>400 mg/5 mL 30-60 mL PO qhs</td>
<td>Osmotic retention of fluid which distends the colon and increases peristaltic activity</td>
<td>Relief of constipation</td>
<td>Patients with myasthenia gravis or other neuromuscular disease</td>
<td>Renal impairment</td>
<td>Abdominal pain, vomiting, diarrhea</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Stimulant Laxatives</strong></td>
<td><em>senna</em></td>
<td>Senokot®</td>
<td>Tablets: 1-4 PO qhs; Syrup: 10-15 mL PO qhs</td>
<td>Induce peristalsis in lower colon</td>
<td>Constipation</td>
<td>Patients with acute abdomen</td>
<td>Abdominal cramps, discoloration of breast milk, urine, feces, melanosis col and atonic colon from prolonged use (controversial)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bisacodyl</strong></td>
<td><em>bisacodyl</em></td>
<td></td>
<td>5-30 mg PO OD (start at 10 mg for bowel preparation)</td>
<td>Enteric nerve stimulation and local contact-induced secretory effects Colonic movements</td>
<td>Constipation</td>
<td>GI obstruction</td>
<td>Abdominal colic, abdominal discomfort, pruritus (with suppressory use), diarrhea</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Metoclopramide</strong></td>
<td><em>metoclopramide</em></td>
<td>Maxeran®</td>
<td></td>
<td>See anti-emetics</td>
<td>See anti-emetics</td>
<td>See anti-emetics</td>
<td>See anti-emetics</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Psyllium</strong></td>
<td><em>psyllium</em></td>
<td>Metamucil®</td>
<td>2-6 tabs (1 tab = 0.52 g PO)</td>
<td>Increases stool bulk → water retention in stool</td>
<td>Constipation</td>
<td>GI obstruction</td>
<td>GI obstruction, diarrhea, constipation, abdominal cramps</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antidiarrheal Agents</strong></td>
<td><em>loperamide</em></td>
<td>Imodium®</td>
<td>Acute diarrhea: 4 mg PO initially, followed by 2 mg after each unformed stool</td>
<td>Adjunctive therapy for acute non-specific diarrhea, chronic diarrhea associated with IBD and for reducing the volume of discharge for ileostomies, colostomies, and other intestinal resections</td>
<td>Children &lt; 2 y; known hypersensitivity to drug, acute diarrhea characterized by blood in stools and fever, acute ulcerative colitis or pseudomembranous colitis associated with broad-spectrum antibiotics</td>
<td>Lack of effective therapy for acute non-specific diarrhea, chronic diarrhea associated with IBD and for reducing the volume of discharge for ileostomies, colostomies, and other intestinal resections</td>
<td>Abdominal pain or discomfort, diarrheousness or diarrhea, tenderness, dry mouth, nausea and vomiting, hypersensitivity reaction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dihydroxyalane/ Atropine</strong></td>
<td><em>lomotil®</em></td>
<td>Lomotil®</td>
<td>5 mg PO tid to qid</td>
<td>Inhibits GI propulsion via direct action on smooth muscle, resulting in a decrease in peristaltic action and increase in transit time</td>
<td>Adjunctive therapy for diarrhea, as above</td>
<td>Hypersensitivity to dihydroxyalane or atropine, jaundice, pseudomembranous enterocolitis, diarrhea caused by enterotoxin producing bacteria</td>
<td>Diarrhea, diarrheousness, tenesmus, headache, N/V, cramps, allergic reaction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Note: PO = Per os (by mouth); IV = Intravenous; OD = Once daily; qHs = QHS (at bedtime); bid = Twice daily; tid = Three times daily; qid = Four times daily; prn = As needed; OD = Once daily; bid = Twice daily; tid = Three times daily; qid = Four times daily; prn = As needed; PO = Per os (by mouth); IV = Intravenous*
### Table 23. Common Drugs Prescribed in Gastroenterology (continued)

<table>
<thead>
<tr>
<th>Class</th>
<th>Generic Drug Name</th>
<th>Trade Name</th>
<th>Dosing</th>
<th>Mechanism of Action</th>
<th>Indications</th>
<th>Contraindications</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anti-Emetics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dicyclomine</td>
<td>Gravol®</td>
<td></td>
<td>25-50 mg PO/IM q6h pm</td>
<td>Competitive H1 receptor antagonist in GI tract, blood vessels, and respiratory tract. Blocks cholinergic and anti-cholinergic effects.</td>
<td>D1, D2 receptor antagonist in cholinergic and anti-cholinergic effects. Blocks cholinergic and anti-cholinergic effects.</td>
<td>Post-operative N/V, antipsychotic, anxiety</td>
<td>Hypersensitivity to drug</td>
</tr>
<tr>
<td>metoclopramide</td>
<td>Mavante®</td>
<td></td>
<td>10 mg IV/IM q2-3 h pm, 10-15 mg PO qd (30 min before meals and quix)</td>
<td>D1, D2 receptor antagonist in cholinergic and anti-cholinergic effects. Blocks cholinergic and anti-cholinergic effects.</td>
<td>D1, D2 receptor antagonist in cholinergic and anti-cholinergic effects. Blocks cholinergic and anti-cholinergic effects.</td>
<td>Post-operative N/V, antipsychotic, anxiety</td>
<td>Hypersensitivity to drug</td>
</tr>
<tr>
<td>ondansetron</td>
<td>Zofran®</td>
<td></td>
<td>Depends on procedure, generally 8-16 mg PO</td>
<td>Selective 5HT3 receptor antagonist in central and peripheral nervous system</td>
<td>N/V caused by cancer chemotherapy and radiation therapy</td>
<td>Morphotropism, hypersensitivity to drug</td>
<td>Constipation, diarrhea, increased liver enzymes, headache, fatigue, malaise, cardiac dysrhythmias</td>
</tr>
<tr>
<td>granisetron</td>
<td>Kytril®</td>
<td></td>
<td>1 mg PO bid (for nausea from chemotherapy/radiation)</td>
<td>Same as above</td>
<td>N/V caused by cancer chemotherapy and radiation therapy</td>
<td>Same as above</td>
<td>Constipation, prolonged QT interval (rarely)</td>
</tr>
<tr>
<td>IBD Agents</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mesalamine</td>
<td>Pentasa®</td>
<td>Salsalate®</td>
<td>Maintenance UC: 1.6-3.2 g PO divided doses daily as suppositories and enemas</td>
<td>5-ASA: Blocks arachidonic acid metabolism to prostanoids and leukotrienes</td>
<td>BID</td>
<td>Hypersensitivity to mesalamine salicylates; Asacol contains phthalate, potential urogenital teratogenicity for male fetus</td>
<td>Abdominal pain, constipation, arthritis, headache</td>
</tr>
<tr>
<td>sulfasalazine</td>
<td>Salazopyrin®</td>
<td></td>
<td>3-4 g PO in divided doses</td>
<td>Compound composed of 5-ASA bound to sulfapyridine, hydrolysis by intestinal bacteria releases 5-ASA, the active component</td>
<td>Colonic disease</td>
<td>Hypersensitivity to sulfasalazine, sulfa drugs, salicylates; intestinal or urinary obstruction, periphary</td>
<td>Rash, loss of appetite, N/V, headache, oligosperma (reversible)</td>
</tr>
<tr>
<td>prednisone</td>
<td></td>
<td></td>
<td>20-40 mg PO OD for acute exacerbation</td>
<td>Anti-inflammatory</td>
<td>BID</td>
<td>Same as above</td>
<td>Complications of steroid therapy</td>
</tr>
<tr>
<td>Immuno-suppressive Agents</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6-mercaptopurine (6-MP)</td>
<td>Pentostatin®</td>
<td></td>
<td>CD: 1.5 mg/kg/d PO</td>
<td>Immunosuppressive</td>
<td>BID: active inflammation and to maintain remission</td>
<td>Hypersensitivity to 6-mercaptopurine, prior resistance to mercaptopurine or thioguanine, history of treatment with alkylating agents, hypersensitivity to azathioprine, pregnancy</td>
<td>Pancreatitis, bone marrow suppression, increased risk of cancer</td>
</tr>
<tr>
<td>azathioprine</td>
<td>Azasan®/Imuran®</td>
<td></td>
<td>IBD: 2-3 mg/kg/d PO</td>
<td>Same as above</td>
<td>Same as above</td>
<td>Same as above</td>
<td>Same as above</td>
</tr>
<tr>
<td>Biologics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>infliximab</td>
<td>Remicade®</td>
<td></td>
<td>5-10 mg IV over 2 h</td>
<td>Monoclonal antibody to TNF-α</td>
<td>Medically refractory CD</td>
<td>Heart failure, moderate to severe, doses &gt;5 mg/kg</td>
<td>Reported cases of reactivated TBC, COPD, lymphoma, other infections (Other TNF-α share similar serious side-effects)</td>
</tr>
<tr>
<td>adalimumab</td>
<td>Humira®</td>
<td></td>
<td>CD induction: 40 mg SC on day 1, then 80 mg 2 wks later (day 19)</td>
<td>Monoclonal antibody to TNF-α</td>
<td>Medically refractory CD or poor response to infliximab</td>
<td>Hypersensitivity to adalimumab</td>
<td>Headaches, skin rash, upper respiratory tract infection</td>
</tr>
<tr>
<td>golimumab</td>
<td>Simponi®</td>
<td></td>
<td>RA: 2 mg/kg at wk 0, 4 and then every 8 wks thereafter (use with methotrexate); UC induction: 200 mg SC at wk 0, then 100 mg at wk 2, UC maintenance: 50 mg every 4 wk</td>
<td>Monoclonal antibody to TNF-α</td>
<td>Active ankylosing spondylitis, Psoriatic arthritis, Moderate-to-severe active RA (combined with methotrexate); UC: medically refractory UC</td>
<td>Hypersensitivity to golimumab or latex; Severe infection</td>
<td>Moderate-to-severe heart failure</td>
</tr>
<tr>
<td>vedolizumab</td>
<td>Entyvio®</td>
<td></td>
<td>CD:UC: 200 mg at 0, 2, 6 wks and then every 8 wks thereafter</td>
<td>Monoclonal antibody to α4β7 integrin</td>
<td>Medically refractory CD/UC, including other TNF-α inhibitors and corticosteroids</td>
<td>Hypersensitivity to vedolizumab</td>
<td>Infections, liver injury, and progressive multifocal leukoencephalopathy</td>
</tr>
</tbody>
</table>
Landmark Gastroenterology Trials

Table

<table>
<thead>
<tr>
<th>Trial</th>
<th>Reference</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>MELD score as a predictor of death in chronic liver disease</td>
<td>Gastroenterology 2003;124:91-6</td>
<td>MELD score can be applied for allocation of donor livers as it accurately predicts 3 mo mortality in patients with chronic liver failure</td>
</tr>
<tr>
<td>Infliximab, azathioprine, or combination for Crohn's disease</td>
<td>NEJM 2010; 362:1383-95</td>
<td>In moderate-severe Crohn's disease, infliximab + azathioprine was more likely to result in corticosteroid-free remission than infliximab monotherapy. Infliximab monotherapy was more effective than azathioprine monotherapy. Similar results have been reported for ulcerative colitis (Gastroenterology 2014; 146:392-400)</td>
</tr>
<tr>
<td>Enteral versus parenteral nutrition for acute pancreatitis</td>
<td>Cochrane DB Syt Rev 2010; 1: CD002837</td>
<td>For acute pancreatitis, no trial was convincing alone, but in aggregate, enteral feeds via nasogastric tube is preferable to either no feeding or parenteral nutrition</td>
</tr>
<tr>
<td>Rifaximin treatment in hepatic encephalopathy</td>
<td>NEJM 2010; 362:1071-81</td>
<td>The most convincing of several articles establishing this non-absorbable antibiotic as the treatment of choice for hepatic encephalopathy for maintaining remission from hepatic encephalopathy and reducing hospitalization associated with the disease</td>
</tr>
<tr>
<td>Adenoma detection rate and risk of colorectal cancer and death</td>
<td>NEJM 2014; 370:1298-1306</td>
<td>A high miss rate for colorectal cancers has been suggested, chiefly in the right colon. This study demonstrates a method of assessing the competence of endoscopists in detecting cancers using adenoma detection rate (the proportion of colposcopic exams in which a physician detects one or more adenomas) as a surrogate marker. Adenoma detection rate was associated with lower risk of interval colorectal cancer and has launched quality assurance programs for screening colonoscopies</td>
</tr>
<tr>
<td>Prednisolone or pentoxifylline for alcoholic hepatitis</td>
<td>NEJM 2015; 372:1619-28</td>
<td>For alcoholic hepatitis, prednisolone improved survival when the Maddrey's discriminant function &gt; 32, but the benefit did not reach statistical significance and pentoxifylline was of no advantage at all. Other studies had shown some benefit with pentoxifylline, but this study was the most definitive</td>
</tr>
</tbody>
</table>

References

Adas
Kandel C. Division of Gastroenterology, St. Michael’s Hospital, Toronto.
Olscarg G. Division of Gastroenterology, St. Michael’s Hospital, Toronto.
Sahbi F. Division of Gastroenterology, Sunnybrook and Women’s College Health Sciences Centre, Toronto.
Haber G. Division of Gastroenterology, Lennox Hall Hospital, New York.

Esophageal and Gastric Disease

Stomach and Duodenum

Liver and Biliary Tract
Williams JW, Snel MD. Does this patient have ascites? JAMA 1992;262:2645-2647.

Pancreas
Steele ML. Chronic pancreatitis. NEJM 1995;332:1482-1490.

Rational Clinical Examination
Groover SA, Barkun AN, Sackett DL. Does this patient have splenomegaly? JAMA 1993;270:2218-2221.
Williams JW, Snel MD. Does this patient have ascites? How to divide fluid in the abdomen. JAMA 1992;267:2645-2647.

Small and Large Bowel
Hattatiere TF, Fanin D. Infections: when to test and when to treat. CMAJ 2011;183:339-344.

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acronyms</td>
<td>2</td>
</tr>
<tr>
<td>Basic Anatomy Review</td>
<td>2</td>
</tr>
<tr>
<td>Differential Diagnoses of Common Presentations</td>
<td>4</td>
</tr>
<tr>
<td>Acute Abdominal Pain</td>
<td></td>
</tr>
<tr>
<td>Abdominal Mass</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal Bleeding</td>
<td></td>
</tr>
<tr>
<td>Jaundice</td>
<td></td>
</tr>
<tr>
<td>Pre-Operative Preparations</td>
<td>7</td>
</tr>
<tr>
<td>Surgical Complications</td>
<td>7</td>
</tr>
<tr>
<td>Post-Operative Fever</td>
<td></td>
</tr>
<tr>
<td>Wound/Incisional Complications</td>
<td></td>
</tr>
<tr>
<td>Urinary and Renal Complications</td>
<td></td>
</tr>
<tr>
<td>Post-Operative Dyspnea</td>
<td></td>
</tr>
<tr>
<td>Respiratory Complications</td>
<td></td>
</tr>
<tr>
<td>Cardiac Complications</td>
<td></td>
</tr>
<tr>
<td>Intra-Abdominal Abscess</td>
<td></td>
</tr>
<tr>
<td>Paralytic Ileus</td>
<td></td>
</tr>
<tr>
<td>Delirium</td>
<td></td>
</tr>
<tr>
<td>Thoracic Surgery</td>
<td>13</td>
</tr>
<tr>
<td>Hiatus Hernia</td>
<td></td>
</tr>
<tr>
<td>Esophageal Perforation</td>
<td></td>
</tr>
<tr>
<td>Esophageal Carcinoma</td>
<td></td>
</tr>
<tr>
<td>Thymoma</td>
<td></td>
</tr>
<tr>
<td>Pleura, Lung, and Mediastinum</td>
<td></td>
</tr>
<tr>
<td>Tube Thoracostomy</td>
<td></td>
</tr>
<tr>
<td>Lung Transplantiation</td>
<td></td>
</tr>
<tr>
<td>Chronic Obstructive Pulmonary Disease</td>
<td></td>
</tr>
<tr>
<td>Stomach and Duodenum</td>
<td>18</td>
</tr>
<tr>
<td>Peptic Ulcer Disease</td>
<td></td>
</tr>
<tr>
<td>Gastric Carcinoma</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal Stromal Tumour</td>
<td></td>
</tr>
<tr>
<td>Bariatric Surgery</td>
<td></td>
</tr>
<tr>
<td>Complications of Gastric Surgery</td>
<td></td>
</tr>
<tr>
<td>SMALL INTESTINE</td>
<td>22</td>
</tr>
<tr>
<td>Small Bowel Obstruction</td>
<td></td>
</tr>
<tr>
<td>Mechanical Small Bowel Obstruction</td>
<td></td>
</tr>
<tr>
<td>Paralytic Ileus</td>
<td></td>
</tr>
<tr>
<td>Intestinal Ischemia</td>
<td></td>
</tr>
<tr>
<td>Tumours of Small Intestine</td>
<td></td>
</tr>
<tr>
<td>Short Gut Syndrome</td>
<td></td>
</tr>
<tr>
<td>Abdominal Hernia</td>
<td>25</td>
</tr>
<tr>
<td>Groin Hernias</td>
<td></td>
</tr>
<tr>
<td>Appendix</td>
<td>27</td>
</tr>
<tr>
<td>Appendicitis</td>
<td></td>
</tr>
<tr>
<td>Inflammatory Bowel Disease</td>
<td>28</td>
</tr>
<tr>
<td>Crohn’s Disease</td>
<td></td>
</tr>
<tr>
<td>Ulcerative Colitis</td>
<td></td>
</tr>
<tr>
<td>LARGE INTESTINE</td>
<td>29</td>
</tr>
<tr>
<td>Large Bowel Obstruction</td>
<td></td>
</tr>
<tr>
<td>Mechanical Large Bowel Obstruction</td>
<td></td>
</tr>
<tr>
<td>Functional LBO: Colonic Pseudo-Obstruction</td>
<td></td>
</tr>
<tr>
<td>(Ogilvie’s Syndrome)</td>
<td></td>
</tr>
<tr>
<td>Diverticular Disease</td>
<td>31</td>
</tr>
<tr>
<td>Diverticulosis</td>
<td></td>
</tr>
<tr>
<td>Diverticulitis</td>
<td></td>
</tr>
<tr>
<td>Colorectal Neoplasms</td>
<td>33</td>
</tr>
<tr>
<td>Colorectal Polyps</td>
<td></td>
</tr>
<tr>
<td>Familial Colon Cancer Syndromes</td>
<td></td>
</tr>
<tr>
<td>Colorectal Carcinoma</td>
<td></td>
</tr>
<tr>
<td>Other Conditions of the Large Intestine</td>
<td>36</td>
</tr>
<tr>
<td>Angiodysplasia</td>
<td></td>
</tr>
<tr>
<td>Volvulus</td>
<td></td>
</tr>
<tr>
<td>Toxic Megacolon</td>
<td></td>
</tr>
<tr>
<td>Fistula</td>
<td></td>
</tr>
<tr>
<td>Stomas</td>
<td></td>
</tr>
<tr>
<td>Anorectum</td>
<td>38</td>
</tr>
<tr>
<td>Hemorrhoids</td>
<td></td>
</tr>
<tr>
<td>Anal Fissures</td>
<td></td>
</tr>
<tr>
<td>Anorectal Abscess</td>
<td></td>
</tr>
<tr>
<td>Fistula-In-Ano</td>
<td></td>
</tr>
<tr>
<td>Pilonidal Disease</td>
<td></td>
</tr>
<tr>
<td>Rectal Prolapse</td>
<td></td>
</tr>
<tr>
<td>Anal Neoplasms</td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>42</td>
</tr>
<tr>
<td>Liver Cysts</td>
<td></td>
</tr>
<tr>
<td>Liver Abscesses</td>
<td></td>
</tr>
<tr>
<td>Neoplasms</td>
<td></td>
</tr>
<tr>
<td>Liver Transplantation</td>
<td></td>
</tr>
<tr>
<td>Biliary Tract</td>
<td>46</td>
</tr>
<tr>
<td>Cholelithiasli</td>
<td></td>
</tr>
<tr>
<td>Biliary Colic</td>
<td></td>
</tr>
<tr>
<td>Acute Cholecystitis</td>
<td></td>
</tr>
<tr>
<td>Acalculous Cholecystitis</td>
<td></td>
</tr>
<tr>
<td>Choledocholithiasis</td>
<td></td>
</tr>
<tr>
<td>Acute Cholangitis</td>
<td></td>
</tr>
<tr>
<td>Gallstone Ileus</td>
<td></td>
</tr>
<tr>
<td>Carcinoma of the Gallbladder</td>
<td></td>
</tr>
<tr>
<td>Cholangiocarcinoma</td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td>51</td>
</tr>
<tr>
<td>Acute Pancreatitis</td>
<td></td>
</tr>
<tr>
<td>Chronic Pancreatitis</td>
<td></td>
</tr>
<tr>
<td>Pancreatic Cancer</td>
<td></td>
</tr>
<tr>
<td>Spleen</td>
<td>54</td>
</tr>
<tr>
<td>Splenic Trauma</td>
<td></td>
</tr>
<tr>
<td>Splenectomy</td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>55</td>
</tr>
<tr>
<td>Benign Breast Lesions</td>
<td></td>
</tr>
<tr>
<td>Breast Cancer</td>
<td></td>
</tr>
<tr>
<td>Surgical Endocrinology</td>
<td>60</td>
</tr>
<tr>
<td>Thyroid and Parathyroid</td>
<td></td>
</tr>
<tr>
<td>Adrenal Gland</td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td></td>
</tr>
<tr>
<td>Pediatric Surgery</td>
<td>62</td>
</tr>
<tr>
<td>Skin Lesions</td>
<td>65</td>
</tr>
<tr>
<td>Common Medications</td>
<td>65</td>
</tr>
<tr>
<td>References</td>
<td>66</td>
</tr>
</tbody>
</table>
**Acronyms**

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-FU</td>
<td>5-fluorouracil</td>
</tr>
<tr>
<td>AAA</td>
<td>abdominal aortic aneurysm</td>
</tr>
<tr>
<td>ABG</td>
<td>arterial blood gas</td>
</tr>
<tr>
<td>ABI</td>
<td>ankle brachial index</td>
</tr>
<tr>
<td>ALND</td>
<td>axillary lymph node dissection</td>
</tr>
<tr>
<td>APR</td>
<td>abdominoperineal resection</td>
</tr>
<tr>
<td>ARDS</td>
<td>acute respiratory distress syndrome</td>
</tr>
<tr>
<td>ATN</td>
<td>acute tubular necrosis</td>
</tr>
<tr>
<td>BRBP</td>
<td>bright red blood per rectum</td>
</tr>
<tr>
<td>BCS</td>
<td>breast conserving surgery</td>
</tr>
<tr>
<td>CBD</td>
<td>common bile duct</td>
</tr>
<tr>
<td>CF</td>
<td>cystic fibrosis</td>
</tr>
<tr>
<td>CHF</td>
<td>congestive heart failure</td>
</tr>
<tr>
<td>CRC</td>
<td>colorectal cancer</td>
</tr>
<tr>
<td>CVA</td>
<td>costovertebral angle</td>
</tr>
<tr>
<td>MVP</td>
<td>central venous pressure</td>
</tr>
<tr>
<td>DCIS</td>
<td>disseminated intravascular coagulation</td>
</tr>
<tr>
<td>DPL</td>
<td>diagnostic peritoneal lavage</td>
</tr>
<tr>
<td>DRE</td>
<td>digital rectal exam</td>
</tr>
<tr>
<td>EBL</td>
<td>estimated blood loss</td>
</tr>
<tr>
<td>ERCP</td>
<td>endoscopic retrograde cholangiopancreatography</td>
</tr>
<tr>
<td>EUS</td>
<td>endoscopic ultrasound</td>
</tr>
<tr>
<td>FAP</td>
<td>familial adenomatous polyposis</td>
</tr>
<tr>
<td>FAST</td>
<td>focused abdominal sonography for trauma</td>
</tr>
<tr>
<td>FC</td>
<td>fine needle aspiration</td>
</tr>
<tr>
<td>GI</td>
<td>gastrointestinal</td>
</tr>
<tr>
<td>GIST</td>
<td>gastrointestinal stromal tumour</td>
</tr>
<tr>
<td>GM</td>
<td>genitourinary</td>
</tr>
<tr>
<td>HDG</td>
<td>hepatodigastrocolic cancer</td>
</tr>
<tr>
<td>HWPPP</td>
<td>hepatobiliary imino-diatic acid</td>
</tr>
<tr>
<td>I&amp;D</td>
<td>incision and drainage</td>
</tr>
<tr>
<td>IPH</td>
<td>idiopathic pulmonary arterial hypertension</td>
</tr>
<tr>
<td>IPF</td>
<td>idiopathic pulmonary fibrosis</td>
</tr>
<tr>
<td>LAR</td>
<td>low anterior resection</td>
</tr>
<tr>
<td>LBD</td>
<td>large bowel obstruction</td>
</tr>
<tr>
<td>LCIS</td>
<td>lobular carcinoma in situ</td>
</tr>
<tr>
<td>LES</td>
<td>lower esophageal sphincter</td>
</tr>
<tr>
<td>LGB</td>
<td>lower gastrointestinal bleeding</td>
</tr>
<tr>
<td>LVRS</td>
<td>lung volume reduction surgery</td>
</tr>
<tr>
<td>MALT</td>
<td>mucosa-associated lymphoid tissue</td>
</tr>
<tr>
<td>MEN</td>
<td>multiple endocrine neoplasia</td>
</tr>
<tr>
<td>MBG</td>
<td>metastadobenzoyguanidine</td>
</tr>
<tr>
<td>MIS</td>
<td>minimally invasive surgery</td>
</tr>
<tr>
<td>MRCP</td>
<td>magnetic resonance cholangiopancreatography</td>
</tr>
<tr>
<td>NCT</td>
<td>nasogastric tube</td>
</tr>
<tr>
<td>OGD</td>
<td>oesophagogastroduodenoscopy</td>
</tr>
<tr>
<td>POD</td>
<td>post-operative day</td>
</tr>
<tr>
<td>POD</td>
<td>percutaneous dilatational</td>
</tr>
<tr>
<td>PPI</td>
<td>proton pump inhibitor</td>
</tr>
<tr>
<td>PTC</td>
<td>percutaneous transhepatic cholangiography</td>
</tr>
<tr>
<td>PUD</td>
<td>peptic ulcer disease</td>
</tr>
<tr>
<td>SBO</td>
<td>small bowel obstruction</td>
</tr>
<tr>
<td>SCC</td>
<td>squamous cell carcinoma</td>
</tr>
<tr>
<td>SIADH</td>
<td>syndrome of inappropriate anti-diuretic hormone</td>
</tr>
<tr>
<td>SMA</td>
<td>superior mesenteric artery</td>
</tr>
<tr>
<td>SMV</td>
<td>superior mesenteric vein</td>
</tr>
<tr>
<td>SNLB</td>
<td>sentinel lymph node biopsy</td>
</tr>
<tr>
<td>TEE</td>
<td>transesophageal echocardiogram</td>
</tr>
<tr>
<td>TTE</td>
<td>thoracoscopic echocardiogram</td>
</tr>
<tr>
<td>UGB</td>
<td>upper gastrointestinal bleed</td>
</tr>
<tr>
<td>VATS</td>
<td>video-assisted thoracoscopic surgery</td>
</tr>
<tr>
<td>VIP</td>
<td>vasoactive intestinal peptide</td>
</tr>
</tbody>
</table>

**Basic Anatomy Review**

**Figure 1. Abdominal incisions**

**Lateral Abdominal Wall Layers and their Continuous Spermatic and Scrotal Structures (superficial to deep)**

1. skin (epidermis, dermis, subcutaneous fat)
2. superficial fascia
   - Camper’s fascia (fatty) → Dartos fascia
   - Scarpa’s fascia (membranous) → Colles’ superficial perineal fascia
3. muscle (see Figure 2 and Figure 3)
   - external oblique → inguinal ligament → external spermatic fascia and fascia lata
   - internal oblique → cremasteric muscle/fascia
   - transversus abdominis → posterior inguinal wall
4. transversalis fascia → internal spermatic fascia
5. preperitoneal fat
6. peritoneum → tunica vaginalis

**Midline Abdominal Wall Layers (superficial to deep)**

1. skin
2. superficial fascia
3. rectus abdominis muscle: in rectus sheath, divided by linea alba
   - above arcuate line (midway between symphysis pubis and umbilicus)
     - anterior rectus sheath = external oblique aponeurosis and anterior leaf of internal oblique aponeurosis
     - posterior rectus sheath = posterior leaf of internal oblique aponeurosis and transversus abdominis aponeurosis
   - below arcuate line
     - aponeuroses of external oblique, internal oblique, transversus abdominis all pass in front of rectus abdominis
4. arteries: superior epigastric (branch of internal thoracic), inferior epigastric (branch of external iliac); both arteries anastomose and lie behind the rectus muscle (superficial to posterior rectus sheath above arcuate line)
5. transversalis fascia
6. peritoneum
Figure 2. Continuity of the abdominal wall with layers of the scrotum and spermatic cord

Figure 3. Midline cross-section of abdominal wall

Figure 4. Blood supply to the GI tract

Celiac trunk (1)
  i) Common hepatic artery (2)
     • Hepatic proper (3)
       – Left hepatic artery (4)
       – Right hepatic artery (5)
     • Right gastric artery (7)
   ii) Gastro-duodenal artery (8)
  iii) Splenic artery (9)

Superior mesenteric artery (10)
  i) Right colic artery (12)
  ii) Middle colic artery (11)
  iii) Ileocolic artery (13)
  iv) Ileal and jejunal branches (14)

Inferior mesenteric artery (15)
  i) Left colic artery (16)
  ii) Sigmoid arteries (17)
  ii) Superior rectal artery (18)
Venous Flow

![Venous drainage of the GI tract](image)

**Figure 5. Venous drainage of the GI tract**

---

## Differential Diagnoses of Common Presentations

### Acute Abdominal Pain

- acute abdomen = severe abdominal pain of acute onset and requires urgent medical attention
- in patients with acute abdominal pain, the first diagnoses that you should consider are those requiring potential urgent surgical intervention
- two main patterns constituting urgent general surgery referrals are peritonitis and obstruction

<table>
<thead>
<tr>
<th>RUQ</th>
<th>RLQ</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hepatobiliary</strong></td>
<td></td>
</tr>
<tr>
<td>Biliary colic</td>
<td></td>
</tr>
<tr>
<td>Cholecystitis</td>
<td></td>
</tr>
<tr>
<td>Cholangitis</td>
<td></td>
</tr>
<tr>
<td>CRD obstruction (stone, tumour)</td>
<td></td>
</tr>
<tr>
<td>Hepatitis</td>
<td></td>
</tr>
<tr>
<td>Budd-Chiari</td>
<td></td>
</tr>
<tr>
<td>Hepatic abscess/mass</td>
<td></td>
</tr>
<tr>
<td>Right subhepatic abscess</td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td></td>
</tr>
<tr>
<td>Pancreatitis</td>
<td></td>
</tr>
<tr>
<td>Presentation of gastric, duodenal, or pancreatic pathology</td>
<td></td>
</tr>
<tr>
<td>Hepatic flexure pathology (CRC, subcostal incisional hernia)</td>
<td></td>
</tr>
<tr>
<td>Genitourinary</td>
<td></td>
</tr>
<tr>
<td>Nephrolithiasis</td>
<td></td>
</tr>
<tr>
<td>Pyelonephritis</td>
<td></td>
</tr>
<tr>
<td>Renal: mass, ischemia, trauma</td>
<td></td>
</tr>
<tr>
<td><strong>Cardiopulmonary</strong></td>
<td></td>
</tr>
<tr>
<td>RLL pneumonia</td>
<td></td>
</tr>
<tr>
<td>Effusion/empyema</td>
<td></td>
</tr>
<tr>
<td>CHF (causing hepatic congestion and R pleural effusion)</td>
<td></td>
</tr>
<tr>
<td>MI</td>
<td></td>
</tr>
<tr>
<td>Pericarditis</td>
<td></td>
</tr>
<tr>
<td>Pleuritis</td>
<td></td>
</tr>
<tr>
<td><strong>Miscellaneous</strong></td>
<td></td>
</tr>
<tr>
<td>Herpes zoster</td>
<td></td>
</tr>
<tr>
<td>Trauma</td>
<td></td>
</tr>
<tr>
<td>Costochondritis</td>
<td></td>
</tr>
</tbody>
</table>

### Portal vein (1)
- Superior mesenteric vein (7)
  - i) ileal and jejunal veins (13)
  - ii) ileocecal vein (14)
  - iii) Right colic vein (12)
  - iv) Middle colic vein (11)
  - v) Pancreaticoduodenal vein (8)
  - vi) Right gastroepiploic vein (9)
- Splenic vein (5)
  - i) Inferior mesenteric vein (10)
    - Superior rectal vein (15)
    - Sigmoid veins (16)
    - Superior rectal veins (17)
  - ii) Pancreatic veins |
  - iii) Left gastroepiploic vein |
  - iv) Short gastric veins (6)
- Left gastric (coronary) vein (2)
- Right gastric vein (3)
- Cystic vein (4)
- Paraumbilical vein

### Key Tests for Specific Diagnosis

- ALP, ALT, AST, bilirubin
- Lipase/amylase
- Urease
- β-hCG (in women of childbearing age)
- Troponins
- Lactate

### Key Tests for or Preparation

- CBC, electrolytes, creatinine, glucose
- INR/PTT
- CXR (if history of cardiac or pulmonary disease)
- ECG if clinically indicated by history or if >69 years and no risk factors

### Types of Peritonitis

- Primary peritonitis: spontaneous without clear etiology
- Secondary peritonitis: due to a perforated viscus
- Tertiary peritonitis: recurrent secondary peritonitis more often with resistant organisms

### Localization of Pain

Most digestive tract pain is perceived in the midline because of bilaterally symmetric innervation; kidney, ureter, ovary, or somatotopically innervated structures are more likely to cause referred lateralized pain

### Referred Pain

- Biliary colic: to right shoulder or scapula
- Renal colic: to groin
- Appendicitis: periumbilical to right lower quadrant (RLQ)
- Pancreatitis: to back
- Ruptured aortic aneurysm: to back or flank
- Perforated ulcer: to RLQ (right paracolic gutter)
- Hip pain: to groin

---

© Carly Vanderlee 2011
Table 1. Differential Diagnosis of Acute Abdominal Pain (continued)

<table>
<thead>
<tr>
<th>RLQ</th>
<th>LLQ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pancreatic</td>
<td>Gastrointestinal</td>
</tr>
<tr>
<td>Pancreatitis (acute vs. chronic)</td>
<td>Diverticulitis</td>
</tr>
<tr>
<td>Pancreatic pseudocyst</td>
<td>Diverticulosis</td>
</tr>
<tr>
<td>Pancreatic tumours</td>
<td>Colon/rectal cancer</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Fecal impaction</td>
</tr>
<tr>
<td>Gastritis</td>
<td>Proctitis (ulcerative colitis, infectious; i.e. pseudomembranous colitis</td>
</tr>
<tr>
<td>PUD</td>
<td>Sigmoid volvulus</td>
</tr>
<tr>
<td>Splenic flexure pathology</td>
<td>Hemia</td>
</tr>
<tr>
<td>(e.g. CRC, ischemia)</td>
<td>Gynecological</td>
</tr>
<tr>
<td>Splenic</td>
<td>See ‘suprapubic’</td>
</tr>
<tr>
<td>Splenic infarct/abscess</td>
<td>Genitourinary</td>
</tr>
<tr>
<td>Splenomegaly</td>
<td>See ‘suprapubic’</td>
</tr>
<tr>
<td>Splenic rupture</td>
<td>Extraperitoneal</td>
</tr>
<tr>
<td>Splenic artery aneurysm</td>
<td>Abdominal wall hematoma/abscess</td>
</tr>
<tr>
<td>Cardiopulmonary (see RUQ and Epigastric)</td>
<td>Psoas abscess</td>
</tr>
<tr>
<td>Genitourinary (see RUQ)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>See Gynecology, Urology, and Respiratory for further details regarding respective RLQ and suprapubic pain</td>
</tr>
</tbody>
</table>

Table 2. Differential Diagnosis of Abdominal Mass

<table>
<thead>
<tr>
<th>Right Upper Quadrant (RUQ)</th>
<th>Upper Midline</th>
<th>Left Upper Quadrant (LUQ)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gallbladder: cholecystitis, cholangiocarcinoma, peri-ampullary malignancy, cholelithiasis</td>
<td>Pancreas: pancreatic adenocarcinoma, other pancreatic neoplasm, pseudocyst</td>
<td>Spleen: splenomegaly, tumour, abscess, subcapsular splenic hematoma, can also present as RLQ mass if extreme splenomegaly</td>
</tr>
<tr>
<td>Biliary tract: Klatskin tumour</td>
<td>Abdominal aorta: AAA (pseudotumour)</td>
<td>Stomach: tumour</td>
</tr>
<tr>
<td>Liver: hepatomegaly, hepatitis, abscess, tumour (hepatocellular carcinoma, metastatic tumour, etc.)</td>
<td>GI: gastric tumour (adenocarcinoma, gastrointestinal stromal tumour, carcinoid tumour), MALT lymphoma</td>
<td></td>
</tr>
<tr>
<td>Right Lower Quadrant (RLQ)</td>
<td>Lower Midline</td>
<td>Left Lower Quadrant (LLQ)</td>
</tr>
<tr>
<td>Intestine: stool, tumour (CRC), mesenteric adenitis, appendicitis, appendiceal phlebitis or other abscess, typhilitis, intussusception, Crohn’s inflammation</td>
<td>Uterus: pregnancy, leiomyoma (fibroid), uterine cancer, pyometra, hematometra</td>
<td>Intestine: stool, tumour, abscess (see RLQ)</td>
</tr>
<tr>
<td>Ovary: ectopic pregnancy, cyst (pathological vs. pathological), tumour (serous, mucinous, struma ovari, germ cell, Krukenberg)</td>
<td>GU: bladder distention, tumour</td>
<td>Ovary: see RLQ</td>
</tr>
<tr>
<td>Fallopian tube: ectopic pregnancy, tubo-ovarian abscess, hydrosalpinx, tumour</td>
<td></td>
<td>Fallopian tube: see RLQ</td>
</tr>
</tbody>
</table>

**Abdominal Mass**

**Most Common Presentations of Surgical Pain**
- Sudden onset with rigid abdomen = perforated viscus
- Pain out of proportion to physical findings = ischemic bowel
- Vague pain that subsequently localizes = appendicitis or other intra-abdominal process that irritates the parietal peritoneum
- Waves of colicky pain = bowel obstruction

Pancreatitis can look like a surgical abdomen, but is rarely an indication for immediate surgical intervention.
### Gastrointestinal Bleeding

- see Gastroenterology, G25 and G27

#### Indications for Surgery
- failure of medical management
- exsanguinating hemorrhage: hemodynamic instability despite vigorous resuscitation
- recurrent hemorrhage after initial stabilization procedures with up to two attempts of endoscopic hemostasis
- prolonged bleeding with transfusion requirement >3 units
- bleeding at rate >1 unit/8 h

#### Surgical Management of GI Bleeding

**UGIB**
- bleeding from a source proximal to the ligament of Treitz
- often presents with hematemesis and melena unless very brisk (then can present with hematochezia)
- initial management with endoscopy; if fails, then consider surgery
- PUD accounts for approximately 55% of severe UGIB

**LGIB**
- bleeding from a source distal to the ligament of Treitz
- often presents with BRBPR unless proximal to transverse colon
  - may occasionally present with melena
- initial management with colonoscopy to detect and potentially stop source of bleeding
- 75% of patients will spontaneously stop bleeding, however if bleeding continues barium enema should not be performed
- angiography or RBC scan to determine source as indicated
- surgery indicated if bleeding is persistent - aimed at resection of area containing source of bleeding
- obscure bleed may require blind total colectomy if the source is not found

#### Table 3. Differential Diagnosis of GI Bleeding

<table>
<thead>
<tr>
<th>Anatomical Source</th>
<th>Etiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematological</td>
<td>Excess anticoagulation (coumadin, heparin, etc.)</td>
</tr>
<tr>
<td></td>
<td>Excess antplatelet (clopidogrel, ASA)</td>
</tr>
<tr>
<td></td>
<td>DIC</td>
</tr>
<tr>
<td></td>
<td>Congenital bleeding disorders</td>
</tr>
<tr>
<td>Nose</td>
<td>Epistaxis</td>
</tr>
<tr>
<td>Esophagus</td>
<td>Esophageal varices</td>
</tr>
<tr>
<td></td>
<td>Malory-Weiss tear</td>
</tr>
<tr>
<td></td>
<td>Esophagitis</td>
</tr>
<tr>
<td>Stomach</td>
<td>Gastritis</td>
</tr>
<tr>
<td></td>
<td>Gastric varices</td>
</tr>
<tr>
<td></td>
<td>Dieulafoy’s lesion</td>
</tr>
<tr>
<td>Duodenum</td>
<td>Duodenal ulcer</td>
</tr>
<tr>
<td></td>
<td>Perforated duodenal ulcer*</td>
</tr>
<tr>
<td>Jejunum</td>
<td>Tumours*</td>
</tr>
<tr>
<td></td>
<td>Polyps</td>
</tr>
<tr>
<td></td>
<td>Ulcers</td>
</tr>
<tr>
<td>Ileum and Ileocecal Junction</td>
<td>Meckel’s diverticulum (rare surgical management)</td>
</tr>
<tr>
<td></td>
<td>Small bowel obstruction</td>
</tr>
<tr>
<td>Large Intestine</td>
<td>Colorectal cancer*</td>
</tr>
<tr>
<td></td>
<td>Mesenteric thrombosis/ischemic bowel*</td>
</tr>
<tr>
<td></td>
<td>Ulcerative colitis*</td>
</tr>
<tr>
<td></td>
<td>Subtotal colectomy if failure of medical management</td>
</tr>
<tr>
<td></td>
<td>Angiodysplasia</td>
</tr>
<tr>
<td></td>
<td>Diverticulosis (*if bleeding is persistent)</td>
</tr>
<tr>
<td>Sigmoid</td>
<td>Diverticulosis (*if bleeding is persistent)</td>
</tr>
<tr>
<td></td>
<td>Sigmoid cancer*</td>
</tr>
<tr>
<td></td>
<td>Bleeding post-polypectomy</td>
</tr>
<tr>
<td>Rectum and Anus</td>
<td>Hemorrhoids</td>
</tr>
<tr>
<td></td>
<td>Fissures</td>
</tr>
<tr>
<td></td>
<td>Rectal cancer*</td>
</tr>
<tr>
<td></td>
<td>Anal vancies</td>
</tr>
<tr>
<td></td>
<td>Polyps (*if not amenable to colonoscopic polypectomy)</td>
</tr>
<tr>
<td></td>
<td>Crohn’s or ulcerative colitis*</td>
</tr>
<tr>
<td></td>
<td>Solitary rectal ulcer syndrome</td>
</tr>
</tbody>
</table>

*Managed surgically in most cases

#### Jaundice

- see Gastroenterology, G40

#### Indications for Urgent Operation

- IHOP
- Ischemia
- Hemorrhage
- Obstruction
- Perforation

#### Overt bleeding: obvious hemorrhage or melena per rectum visible to naked eye

#### Occult bleeding: bleeding per rectum is not obvious to naked eye (e.g. positive guaiac test)

#### Obusc bleeding: overt bleeding with no identifiable source after colonoscopy and endoscopy

#### Transfusion Strategies for Acute Upper Gastrointestinal Bleeding

Recent study by Vilaume et al., demonstrates that a restrictive transfusion strategy (transfusion with hemoglobin below 70 g/L) significantly improves outcomes in patients with acute UGB, compared to a liberal transfusion strategy (transfusion with hemoglobin below 90 g/L). Refer to study for details.

#### Biochemical Signs for Differentiating Jaundice

- Hepatocellular: Elevated bilirubin + elevated ALP/AST
- Cholestatic: Elevated bilirubin + elevated ALP/GGT ± duct dilatation upon biliary U/S
- Hemolysis: ↓ haptoglobin ↑ LDH

Note: cholestatic jaundice is often surgical
Pre-Operative Preparations

Considerations
- informed consent (see Ethical, Legal, and Organizational Medicine, ELOM6)
- screening questionnaire to determine risk factors e.g. age, exercise capacity, medication use, allergies
- consider pre-operative anesthesia, medicine consult as indicated to optimize patient status
- NPO according to guidelines (see Anesthesia and Perioperative Medicine, A4)
- IV – balanced crystalloid at maintenance rate (4:2:1 rule → roughly 100-125 cc/h): normal saline or Ringer’s lactate; bolus to catch up on estimated losses including losses from bowel prep
- appropriate use of fluids perioperatively decreases risk of cardiorespiratory complications
- patient’s regular medications included with the exception of hypoglycemic agents, diuretics and ACEI
- patients on steroids may require stress dose coverage, anticoagulation/antiplatelet medication must be managed to decrease surgical bleeding but not put patient at risk for increased thrombotic events (e.g. switching from warfarin to LMWH)
- prophylactic antibiotics depending on wound class (within 1 h prior to incision): usually cefazolin (Ancef®) ± metronidazole (Flagyl®)
- consider bowel prep: cleans out bowel and decreases bacterial population
  - oral cathartic (e.g. fleet Phosphosoda®) starting previous day
  - in selected cases, current evidence does not support routine use
- consider VTE prophylaxis for all inpatient surgery (LMWH or heparin)
- do not hold anticoagulation prior to surgery unless epidural is expected
- smoking cessation and weight loss pre-operative can significantly decrease post-operative complications
- infection: delay elective surgery until infection controlled including respiratory infection particularly in asthma patients

Investigations
- see Anesthesia and Perioperative Medicine, A4
- routine pre-operative laboratory investigations for elective procedures should be selective
  - only ASA class and surgical risk have been found to independently predict post-operative adverse effects
- blood components: group and screen or cross and type depending on procedure
- CBC, electrolytes, creatinine
- INR/PT, PTT
- CXR (PA and lateral) for patients with history of cardiac or pulmonary disease
- ECG as indicated by history or if >69 yr and no risk factors
- β-hCG testing in all women of reproductive age

Drains
- NGT
  - indications: gastric decompression, analysis of gastric contents, irrigation/dilution of gastric contents, feeding, if necessary
  - contraindications: suspected basal skull fracture, obstruction of nasal passages due to trauma
- Foley catheter with urometer
  - indications: to accurately monitor urine output, decompression of bladder, relieve obstruction, rapidly expanding suprapubic mass
  - contraindications: suspected urethral injury, difficult insertion of catheter

Surgical Complications
- general principles in preventing complications during the post-operative period include
  - frequent examination of the patient (daily or more) and their wound
  - removal of surgical tubes as soon as possible (e.g. Foley catheters and surgical drains)
  - early ambulation
  - monitor fluid balance and electrolytes
  - analgesia - enough to adequately address pain, but not excessive
  - skillful nursing care

Post-Operative Fever
- fever does not necessarily imply infection particularly in the first 24-48 h post-operative
- fever may not be present or is blunted if patient is receiving chemotherapy, glucocorticoids, or immunosuppression
- timing of fever may help identify cause
  - hours after surgery - POD #1 (immediate)
    - inflammatory reaction in response to trauma from surgery; unlikely to be infectious
    - reaction to blood products received during surgery
    - malignant hyperthermia
- POD #5-8 (wound infection - if earlier think streptococcal or clostridial infection)
- POD #8+ (thrombosis – DVT/PE)
- Wonder drugs POD #1+ (drug)

Bilirubin Levels

<table>
<thead>
<tr>
<th>Source Bilirubin</th>
<th>Prehepatic</th>
<th>Intrahepatic</th>
<th>Posthepatic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indirect</td>
<td>↑</td>
<td>↑</td>
<td>N</td>
</tr>
<tr>
<td>Direct</td>
<td>N</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Urobilogen</td>
<td>↑</td>
<td>↑</td>
<td>–</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

In patients with liver disease and an acute abdomen, spontaneous bacterial peritonitis must be ruled out

Surgical Emergencies: Take an AMPLE History

- Allergies
- Medications
- Past medical/surgical history (including anesthesia and bleeding disorders)
- Last meal
- Events (HPI)

Best Practice in General Surgery (BPGS)

http://www.bpgs.ca/
BPGS is a University of Toronto initiative with the goal of standardizing care in general surgery. This link contains BSM-based guidelines which have been implemented by consensus within all Toronto teaching hospitals. This is a highly recommended source for the most up-to-date pre-operative and general treatment guidelines

Drain Size

Measured by the unit French:
French = diameter (mm) x 3

Pre and Post-Operative Orders

ADDAVIFS
Admit to ward X under Dr. Y
Diagnosis
Diet
Activity
Vitals (q8h from ED and post-operative is standard)
IV, Investigations, Ins and Outs
Drugs, Dressings, Drains
Special procedures

5 Vs of Post-Operative Fever

Word POD #1-2 (pulmonary – atelectasis, pneumonia)
Water POD #3-5 (urine – UTI)
Wound POD #5-8 (wound infection - if earlier think streptococcal or clostridial infection)
Walk POD #8+ (thrombosis – DVT/PE)
Wonder drugs POD #1+ (drug)
- POD #1-2 (acute)
  ◆ atelectasis (most common cause of fever on POD #1)
  ◆ early wound infection (especially *Clostridium*, Group A *Streptococcus* – feel for crepitus and look for "dishwater" drainage)
  ◆ aspiration pneumonitis
  ◆ other: Addisonian crisis, thyroid storm, transfusion reaction
- POD #3-7 (subacute): likely infectious
  ◆ UTI, surgical site infection, IV site/line infection, septic thrombophlebitis, leakage at bowel anastomosis (tachycardia, hypotension, oliguria, abdominal pain)
- POD #8+ (delayed)
  ◆ intra-abdominal abscess, DVT/PE (can be anytime post-operative, most commonly POD #8-10), drug fever
  ◆ other: cholecystitis, peri-rectal abscess, URTI, infected seroma/biloma/hematoma, parotitis, *C. difficile* colitis, endocarditis

### Treatment
- treat primary cause
- antipyrexia (e.g. acetaminophen)

## Wound/Incisional Complications

**WOUND CARE** (see *Plastic Surgery*, PL8)
- can shower POD #2-3 after epithelialization of wound
- dressings can be removed POD #2 and left uncovered if dry
- examine wound if wet dressing, signs of infection (fever, tachycardia, pain)
- skin sutures and staples can be removed POD #7-10
  ◆ exceptions: incision crosses crease (groin), closed under tension, in extremities (hand) or patient factors (elderly, corticosteroid use, immunosuppressed) removed POD #14, earlier if signs of infection
- negative pressure dressings consist of foam and suction, promote granulation
  ◆ ideal for large (grafted sites) or non-healing wounds (irradiated skin, ulcer)

**DRAINS**
- drains may be placed selectively at the time of surgery to prevent fluid accumulation (blood, pus, serum, bile, urine)
  ◆ can be used to assess quantity of third space fluid accumulation post-operatively
- potential route of infection; to decrease risk of wound infection bring out through separate incision (vs. operative wound) and remove as soon as possible
- types of drains
  ◆ open (e.g. Penrose), higher risk of infection
  ◆ closed: 1) Gravity drainage (e.g. Foley catheter); 2) Underwater-seal drainage system (e.g. chest tube); 3) Suction drainage (e.g. Jackson-Pratt)
  ◆ sump (e.g. NGT)
- monitor drain outputs daily
- drains should be removed once drainage is minimal (usually <30-50 cc/24 h)
- drains do not guarantee that the patient will not form a collection of fluid
- ridged drains can erode through internal structures, and excessive suction can cause necrosis
- evidence does not support routine post-operative drainage of abdominal cavity

## SURGICAL SITE INFECTION

### Etiology
- *S. aureus*, *E. coli*, *Enterococcus*, *Streptococcus* spp., *Clostridium* spp.

### Risk Factors

#### Table 4. Procedures and Their Impact on Surgical Site Infection

<table>
<thead>
<tr>
<th>Classification</th>
<th>Clean</th>
<th>Clean-Contaminated</th>
<th>Contaminated</th>
<th>Dirty/Infected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definition</td>
<td>Incision under sterile conditions; nontraumatic; no entrance of hollow organ</td>
<td>Incision under sterile conditions; ENTRANCE of hollow viscus; no evidence of active infection; minimal contamination</td>
<td>Incision under sterile conditions; MAJOR contamination of wound during procedure (i.e. gross spillage of stool, infection in biliary, respiratory, or GU systems)</td>
<td>Established infection present before wound is made in skin</td>
</tr>
<tr>
<td>Example</td>
<td>Wound created to repair hernia</td>
<td>Routine cholecystectomy; colon resection</td>
<td>Bowel obstruction with enterotomy and spillage of contents; necrotic bowel resection; fresh traumatic wounds</td>
<td>Appendiceal abscess; traumatic wound with contaminated devitalized tissue; perforated vescus</td>
</tr>
<tr>
<td>Infection Rate</td>
<td>&lt;2%</td>
<td>3-4%</td>
<td>7-10%</td>
<td>30-40%</td>
</tr>
<tr>
<td>Wound Closure</td>
<td>Primary closure</td>
<td>Primary closure</td>
<td>Often secondary closure</td>
<td>Secondary closure</td>
</tr>
</tbody>
</table>
• patient characteristics
  ■ age, DM, steroids, immunosuppression, obesity, burn, malnutrition, patient with other infections, traumatic wound, radiation, chemotherapy
• other factors
  ■ prolonged pre-operative hospitalization, reduced blood flow, break in sterile technique, multi-antibiotics, hematoma, seroma, foreign bodies (drains, sutures, grafts), skin preparation, hypoxemia, hypothermia

Prophylaxis
• pre-operative antibiotics for most surgeries (cefazolin ± metronidazole or if β-lactam allergy, clindamycin ± gentamicin)
  ■ within 1 h pre-incision; can redose at 1-2 half-lives (~q4-8h) in the OR
  ■ not required for low risk elective cholecystectomy, hemorrhoidectomy, fistulotomy, sphincterotomy for fissure
• some evidence suggests role in breast surgery
  ■ reserve post-operative antibiotics for treatment of suspected or documented intra-abdominal infection, hair removal should not be performed unless necessary; if so, clipping superior to shaving chlorhexidine-alcohol wash of surgical site
• normothermia (maintain patient temperature 36-38°C during OR)
• hyperoxygenation (consider FiO2 of 80% in OR)
• consider delayed primary closure of incision for contaminated wounds

Clinical Presentation
• typically fever POD #5-8 (Streptococcus and Clostridium can present in 24 h)
• pain, blanchable wound erythema, induration, purulent discharge, warmth
• complications: fistula, sinus tracts, sepsis, abscess, suppressed wound healing, superinfection, spreading infection to myonecrosis or fascial necrosis (necrotizing fasciitis), wound dehiscence, evisceration, hernia

Treatment
• examination of the wound: inspect, compress adjacent areas, swab drainage for C&S and Gram stain
• re-open affected part of incision, drain, pack, heal by secondary intention in most cases
• for deeper infections, debride necrotic and non-viable tissue
• antibiotics and dermabration of erythema only if cellulitis or immunodeficiency

Wound Hemorrhage/Hematoma
• secondary to inadequate surgical control of hemostasis

Risk Factors
• anticoagulant therapy, coagulopathies, thrombocytopenia, DIC, severe liver disease, myeloproliferative disorders, severe arterial HTN, severe cough
• more common with transverse incisions through muscle, due to cutting of muscle

Clinical Features
• pain, swelling, discolouration of wound edges, leakage
• rapidly expanding neck hematoma can compromise airway and is a surgical emergency; consider having a suture kit at bedside in all neck surgery in the event of having to open the wound urgently

Treatment
• pressure dressing
• open drainage ± wound packing (large hematoma only)
• if significant bleeding, may need to re-operate to find source (often do not find a discrete source)

Seroma
• fluid collection other than pus or blood
• secondary to transection of lymph vessels
• delays healing
• increased infection risk

Treatment
• consider pressure dressing ± needle drainage
• if significant may need to re-operate

Wound Dehiscence
• disruption of fascial layer, abdominal contents contained by skin only
• 95% caused by intact suture tearing through fascia

Clinical Features
• typically POD #1-3; most common presentation sign is serosanguinous drainage from wound ± evisceration
• palpaton of wound edge: should normally feel a “healing ridge” from abdominal wall closure (raised area of tissue under incision)
Risk Factors
- local: technical failure of closure, increased intra-abdominal pressure (e.g. COPD, ileus, bowel obstruction), hematoma, infection, poor blood supply, radiation, patient not fully paralyzed while closing, transverse incision
- systemic: smoking, malnutrition (hypoproteinemia, vitamin C deficiency), connective tissue diseases, immunosuppression, pulmonary disease, ascites, poor nutrition, steroids, chemotherapy, obesity, other (e.g. age, sepsis, uremia)
- DM alone is not a risk factor

Treatment
- place moist dressing over wound with binder around abdomen and transfer to OR
- may consider conservative management with debridement of fascial and/or skin margins
- evisceration, also known as 'burst abdomen', is a surgical emergency: take patient for operative reclusion.

Urinary and Renal Complications

Urinary Retention
- may occur after any operation with general anesthesia or spinal anesthesia
- more likely in older males with history of benign prostatic hyperplasia, patients on anticholinergics

Clinical Presentation
- abdominal discomfort, palpable bladder, overflow incontinence, post-void residual urine volume >100 mL

Treatment
- Foley catheter to rest bladder, then trial of voiding

Oliguria/Anuria (see Nephrology, NP18)

Etiology
- prerenal vs. renal vs. postrenal
- most common post-operative cause is prerenal ± ischemic ATN
  - external fluid loss: hemorrhage, dehydration, diarrhea
  - internal fluid loss: third-spacing due to bowel obstruction, pancreatitis

Clinical Presentation
- urine output <0.5 cc/kg/h, increasing Cr, increasing BUN

Treatment
- according to underlying cause; fluid deficit is treated with crystalloid (NS or RL)

Post-Operative Dyspnea
- see Respiratory Complications next and Cardiac Complications, GS12

Etiology
- respiratory: atelectasis, pneumonia, pulmonary embolus (PE), ARDS, asthma, pleural effusion
- cardiac: MI, arrhythmia, CHF
- inadequate pain control

Respiratory Complications

Atelectasis
- comprises 90% of post-operative pulmonary complications

Clinical Features
- low-grade fever on POD #1, tachycardia, crackles, decreased breath sounds, bronchial breathing, tachypnea

Risk Factors
- COPD, smoking, obesity, elderly persons
- upper abdominal/thoracic surgery, oversedation, significant post-operative pain, poor inspiratory effort
Treatment
- pre-operative prophylaxis
  - smoking cessation (best if >8 wk pre-operative)
- post-operative prophylaxis
  - incentive spirometry, deep breathing exercise, chest physiotherapy, intermittent positive-pressure breathing
  - selective NGT decompression after abdominal surgery
  - short-acting neuromuscular blocking agents
  - minimize use of respiratory depressant drugs, appropriate pain control, early ambulation

PNEUMONIA/PNEUMONITIS
- may be secondary to aspiration of gastric contents during anesthetic induction or extubation, causing a chemical pneumonitis

Risk Factors
- aspiration: general anesthetic, decreased LOC, GERD, full stomach, bowel/gastric outlet obstruction + non-functioning NGT, pregnancy, seizure disorder
- non-aspiration: atelectasis, immobility, pre-existing respiratory disease

Clinical Features
- productive cough, fever
- tachycardia, cyanosis, respiratory failure, decreased LOC
- CXR: pulmonary infiltrate

Treatment
- prophylaxis: see atelectasis prophylaxis, pre-operative NPO/NGT, rapid sequence anesthetic induction
- immediate removal of debris and fluid from airway
- consider endotracheal intubation and flexible bronchoscopic aspiration
- IV antibiotics to cover oral nosocomial aerobes and anaerobes (e.g. ceftriaxone, metronidazole)

PULMONARY EMBOLUS (See Respirology, R18)

Clinical Features
- unilateral leg swelling and pain (DVT as a source of PE), sudden onset shortness of breath, tachycardia, fever
- most commonly POD #8-10, but can occur anytime post-operatively, even after discharge
- diagnosis made by Chest CT scan usually

Treatment
- initial treatment IV heparin or therapeutic- dose LMWH, bridging to therapeutic anticoagulation is required for a minimum of 3 months; for patients with cancer, or other risk factors for hypercoagulability, the duration of anticoagulation may be longer
- Greenfield (IVC) filter if contraindications to anticoagulation
- prophylaxis: subcutaneous heparin (5,000 U bid) or LMWH, compression stockings (TED™ Hose), sequential compression devices

PULMONARY EDEMA

Etiology
- cardiogenic vs. noncardiogenic
- circulatory overload: excess volume replacement, LV failure, shift of fluid from peripheral to pulmonary vascular bed, negative airway pressure, alveolar injury due to toxins (e.g. ARDS)
- more common with pre-existing cardiac disease
- negative pressure pulmonary edema due to inspiratory efforts against a closed glottis upon awakening from general anesthesia

Clinical Features
- shortness of breath, crackles at lung bases, CXR abnormal

Treatment (LMNOP)
- Lasix
- Morphine (decreases symptoms of dyspnea, venodilator and afterload reduction)
- Nitrates (venodilator)
- Oxygen + non-invasive ventilation
- Position (sit patient up)

New onset “asthma” and wheezing in the elderly is cardiogenic until proven otherwise
RESPIRATORY FAILURE

Clinical Features
- dyspnea, cyanosis, evidence of obstructive lung disease
- earliest manifestations – tachypnea and hypoxemia (RR >25, pO\textsubscript{2} <60)
- pulmonary edema, unexplained decrease in SaO\textsubscript{2}

Treatment
- ABCs, O\textsubscript{2}, ± positive pressure ventilation, intubation
- bronchodilators, diuretics to treat CHF
- adequate blood pressure to maintain pulmonary perfusion
- if these measures fail to keep PaO\textsubscript{2} >60, consider ARDS

Cardiac Complications
- abnormal ECGs common in post-operative period (compare to pre-operative ECG)
- common arrhythmias: supraventricular tachycardia, atrial fibrillation (secondary to fluid overload, PE, MI)

MYOCARDIAL INFARCTION
- see Cardiology and Cardiac Surgery, C27
- surgery increases risk of MI
- incidence
- 0.5% in previously asymptomatic men >50 yr old
- 40-fold increase in men >50 yr old with previous MI

Risk Factors
- pre-operative HTN, CHF
- previous MI (highest risk ≤6 mo, but risk never returns to baseline)
- increased age
- intra-operative hypotension
- operations >3 h
- angina

Clinical Features
- majority of cases on day of operation or POD #3-4 (shifting of third space fluid back into intravascular compartment)
- often silent without chest pain, may only present with new-onset CHF (dyspnea), arrhythmias, hypotension

Intra-Abdominal Abscess

Definition
- collection of pus walled-off from rest of peritoneal cavity by inflammatory adhesions and viscera

Etiology
- usually polymicrobial: Gram-negative bacteria, anaerobes
- consider Gram-positives if coexisting cellulitis

Risk Factors
- emergency surgery, contaminated OR
- GI surgery with anastomoses
- poor healing risk factors (DM, poor nutrition, etc.)
- may occur POD #3 after laparotomy when third space fluid re-distribution occurs

Clinical Features
- persistent spiking fever, dull pain, weight loss
- mass difficult to palpate
- peritoneal signs if abscess perforation and secondary peritonitis
- leukocytosis or leukopenia (immunocompromised, elderly)
- co-existing effusion (pleural effusion with subphrenic abscess)
- common sites: pelvis, Morrison’s pouch (space between kidney and liver), subphrenic, paracolic gutters, lesser sac, peri-appendiceal, post-surgical anastomosis, diverticular, psoas

Investigations
- CBC, blood cultures x2
- CT ± IV and water-soluble contrast
- DRE (pelvic abscess)
Treatment
- drain placement by interventional radiology (preferred), laparoscopy, open drainage
- subsequent antibiotic coverage; ceftriaxone + metronidazole or piperacillin-tazobactam (PepTazo)

Paralytic Ileus
- see Bowel Obstruction, GS23

Delirium
- see Psychiatry, PS19 and Neurology, N20

Thoracic Surgery

Hiatus Hernia

Figure 6. Types of hiatus hernia

SLIDING HIATUS HERNIA (TYPE I)
- see Figure 6
- herniation of both the stomach and the gastroesophageal (GE) junction into thorax
- 90% of esophageal hernias

Risk Factors
- age
- increased intra-abdominal pressure (e.g. obesity, pregnancy, coughing, heavy lifting)
- smoking

Clinical Features
- majority are asymptomatic
- hernias frequently associated with GERD due to decreased competence of LES

Complications
- most common complication is GERD
- other complications are rare and are related to reflux
- esophagitis (dysphagia, heartburn)
- consequences of esophagitis (peptic stricture, Barrett’s esophagus, esophageal carcinoma)
- extra-esophageal complications (aspiration pneumonitis/pneumonia, asthma type bronchospasm, cough, laryngitis)

Investigations
- barium swallow, endoscopy (esophago-gastroscopy), or esophageal manometry (technique for measuring LES pressure)
- 24 h esophageal pH monitoring to quantify reflux
- endoscopy with biopsy to document type and extent of tissue damage and rule out esophagitis, Barrett’s esophagus, and cancer
Treatment
- lifestyle modification
  - stop smoking, weight loss, elevate head of bed, no meals <3 h prior to sleeping, smaller and more frequent meals, avoid alcohol, coffee, mint, and fat
- medical
  - antacid, H₂-antagonist, PPI, prokinetic agent
- surgical (<15%)
  - if failure of medical therapy, complications of GERD such as esophageal stricture, severe nocturnal aspiration, Barrett's esophagus
  - anti-reflux procedure (usually laparoscopic) e.g. Nissen fundoplication
    - fundus of stomach is wrapped around the lower esophagus and sutured in place
    - 90% success rate

PARAESOPHAGEAL HIATUS HERNIA (TYPE II)
- see Figure 6
- herniation of all or part of the stomach through the esophageal hiatus into the thorax with an undisplaced GE junction
- least common esophageal hernia (<10%)

Clinical Features
- usually asymptomatic due to normal GE junction
- pressure sensation in lower chest, dysphagia

Complications
- hemorrhage, incarceration, strangulation (gastric volvulus), obstruction, gastric stasis ulcer (Cameron's lesion – causes Fe-deficiency anemia)

Treatment
- surgery to address symptoms or treat/prevent complications
- reduce hernia and excise hernia sac, repair defect at hiatus, and anti-reflux procedure (e.g. Nissen fundoplication)
- may consider suturing stomach to anterior abdominal wall (gastropexy)
- in very elderly patients at high surgical risk consider PEG (percutaneous endoscopic gastrostomy) to anchor the stomach in the abdomen

MIXED HIATUS HERNIA (TYPE III)
- see Figure 6
- combination of Types I and II

TYPE IV HERNIA
- herniation of stomach and other abdominal organs into thorax: colon, spleen, small bowel
- Fe-deficiency anemia is common

Esophageal Perforation

Etiology
- iatrogenic (most common)
  - endoscopic, dilatation, biopsy, intubation, operative, NGT placement (rare)
- barogenic
  - trauma
  - repeated, forceful vomiting (Boerhaave's syndrome)
- other: convulsions, defecation, labour (rare)
- ingestion injury
  - foreign body, corrosive substance
- carcinoma

Clinical Features
- neck or chest pain
- fever, tachycardia, hypotension, dyspnea, respiratory compromise
- subcutaneous emphysema, pneumothorax, pleural effusion, and hematemesis,

Investigations
- CXR: pneumothorax, pneumomediastinum, pleural effusion, subdiaphragmatic air, widened mediastinum
- CT chest: pneumomediastinum, pleural effusion, pneumothorax, contrast in the chest, subq emphysema
- Upper GI swallow study with water soluble contrast. If negative then perform with diluted barium: contrast extravasation
Treatment
• supportive if rupture is contained
  • NPO, fluid resuscitation, broad-spectrum antibiotics, possible percutaneous drainage of mediastinum or pleura
• surgical
  • <24 h: primary closure of a healthy esophagus or resection of diseased esophagus
  • >24 h or non-viable wound edges
    • diversion and exclusion followed by delayed reconstruction (i.e. esophagostomy proximally, close esophagus distally, gastrostomy/jejunostomy for decompression/feeding)

Complications
• sepsis, abscess, fistula, empyema, mediastinitis, death
• post-operative esophageal leak
• mortality 10-50% dependent on timing of diagnosis

Esophageal Carcinoma

Epidemiology
• M:F = 3:1
• onset 50-60 yr of age
• upper (20-33%), middle (33%), lower (33-50%)
• main types
  • most common worldwide: SCC in upper 2/3 of esophagus
  • most common in Western countries: adenocarcinoma in distal 1/3 of esophagus

Risk Factors
• geographic variation in incidence
• SCC
  • underlying esophageal disease such as strictures, diverticula, achalasia
  • smoking, alcohol, hot liquids
  • more common in patients from Asia
• adenocarcinoma
  • Barrett’s esophagus (most important), smoking, obesity (increased reflux), GERD

Clinical Features
• progressive dysphagia (mechanical): first solids then liquids
• odynophagia then constant pain
• constitutional symptoms
• regurgitation and aspiration (aspiration pneumonia)
• hematemesis, anemia
• direct, hematogenous, or lymphatic spread
  • trachea (coughing), recurrent laryngeal nerves (hoarseness, vocal paralysis), aortic, liver, lung, bone, celiac and mediastinal nodes

Investigations and Staging
• barium swallow: shows narrowing – suggestive but not diagnostic
• endoscopic biopsy and assess resectability
• both SCC and adenocarcinoma use TNM staging system but have separate stage groupings according to histology
• endoscopic U/S (EUS)
  • visualize local disease
  • regional nodal involvement (number of nodes may be more important than location)
• bronchoscopy + thoracoscopy
  • rule out airway invasion in tumours of the upper and mid esophagus
• full metastatic workup (CXR, bone scan, CT head, CT chest/abdomen/pelvis, LFTs, etc.)
• PET scan more sensitive than CT in detecting metastatic disease

Treatment
• if present with distant metastatic disease
  • treat with systemic therapy and treat symptoms (esophageal stent)
• if locally advanced (locally invasive disease or nodal disease on CT or EUS)
  • multimodal therapy
    • concurrent external beam radiation and chemotherapy (cisplatin and 5-FU)
    • possibility of curative esophagectomy after chemoradiation if disease responds well
  • if unable to tolerate multimodal therapy or if highly advanced disease, consider palliative resection, brachytherapy, or endoscopic dilatation/stenting/laser ablation for palliation

Esophageal Carcinoma

Epidemiology
• M:F = 3:1
• onset 50-60 yr of age
• upper (20-33%), middle (33%), lower (33-50%)
• main types
  • most common worldwide: SCC in upper 2/3 of esophagus
  • most common in Western countries: adenocarcinoma in distal 1/3 of esophagus

Risk Factors
• geographic variation in incidence
• SCC
  • underlying esophageal disease such as strictures, diverticula, achalasia
  • smoking, alcohol, hot liquids
  • more common in patients from Asia
• adenocarcinoma
  • Barrett’s esophagus (most important), smoking, obesity (increased reflux), GERD

Clinical Features
• progressive dysphagia (mechanical): first solids then liquids
• odynophagia then constant pain
• constitutional symptoms
• regurgitation and aspiration (aspiration pneumonia)
• hematemesis, anemia
• direct, hematogenous, or lymphatic spread
  • trachea (coughing), recurrent laryngeal nerves (hoarseness, vocal paralysis), aortic, liver, lung, bone, celiac and mediastinal nodes

Investigations and Staging
• barium swallow: shows narrowing – suggestive but not diagnostic
• endoscopic biopsy and assess resectability
• both SCC and adenocarcinoma use TNM staging system but have separate stage groupings according to histology
• endoscopic U/S (EUS)
  • visualize local disease
  • regional nodal involvement (number of nodes may be more important than location)
• bronchoscopy + thoracoscopy
  • rule out airway invasion in tumours of the upper and mid esophagus
• full metastatic workup (CXR, bone scan, CT head, CT chest/abdomen/pelvis, LFTs, etc.)
• PET scan more sensitive than CT in detecting metastatic disease

Treatment
• if present with distant metastatic disease
  • treat with systemic therapy and treat symptoms (esophageal stent)
• if locally advanced (locally invasive disease or nodal disease on CT or EUS)
  • multimodal therapy
    • concurrent external beam radiation and chemotherapy (cisplatin and 5-FU)
    • possibility of curative esophagectomy after chemoradiation if disease responds well
  • if unable to tolerate multimodal therapy or if highly advanced disease, consider palliative resection, brachytherapy, or endoscopic dilatation/stenting/laser ablation for palliation
• if early stage (non-transmural and without evidence of nodal disease)
  ■ endoscopic mucosal resection can be considered for early mucosal cancer or high grade dysplasia
  ■ esophagectomy (transthoracic or trans-hiatal approach) and lymphadenectomy
    ■ anastomosis in chest or neck
    ■ stomach most often used for reconstruction; may also use colon
  ■ neoadjuvant chemotherapy and radiation are controversial
  ■ adjuvant chemotherapy ± radiation usually recommended for post-operative node-positive disease

**Prognosis**
• TNM status - usually poor because presentation is usually at advanced stage.

**OTHER DISORDERS**
• esophageal motor disorders (see Gastroenterology, G8)
• esophageal varices (see Gastroenterology, G26)
• Mallory-Weiss tear (see Gastroenterology, G26)

---

**Thymoma**

**Epidemiology**
• most common neoplasms in thymus including both thymoma and thymic carcinoma
• patients between 40 and 60 yr
• M > F

**Risk Factors**
• no known risk factors, strong association with myasthenia gravis and other paraneoplastic syndromes

**Clinical Presentation**
• frequently asymptomatic: incidental finding on imaging
• symptoms related to tumour size and location or myasthenia gravis: chest pain, SOB, cough, phrenic nerve palsy
• ddx includes lymphoma, other anterior mediastinal tumours (see Respirology, R21)

**Investigations**
• CT chest (and/or MRI)
• Germ cell tumour markers (β-hCG, alpha fetoprotein), thyroid function, PFTs

**Treatment**
• for patients with resectable disease
• surgical resection of thymus via median sternotomy or VATS depending on the size
• ± post-operative radiation based on Masaoka staging
• for non-surgical patients
• multimodal therapy including neoadjuvant or palliative chemotherapy and post-operative chemoradiotherapy if de-bulking procedure feasible

**Prognosis**
• depends upon stage of disease and resectability
• generally slow growing tumours and have good prognosis

---

**Pleura, Lung, and Mediastinum**

• see Respirology, R21

---

**Tube Thoracostomy**

**Indications**
• to drain abnormal large-volume air or fluid collections in the pleural space
  ■ hemothorax, pleural effusion, chylothorax, empyema
  ■ pneumothorax, if
    ■ large or progressive
    ■ patient is on mechanical ventilation
    ■ bronchopleural fistula
    ■ tension pneumothorax
• to treat symptomatic and/or recurrent pleural effusion
  ■ see Respirology, R22
• for long-term drainage of malignant effusions use: 1. Tunneled pleural catheter; 2. Pleural drainage and chemical pleurodesis
• via facilitation of pleurodesis (obliteration of the pleural space by instilling talc or doxycycline to cause fibrosis and adherence of parietal and visceral pleura)
Complications
• overall complications are rare (1-3%)
• malposition (most common complication), especially by inexperienced operators
  - tubes may dissect along the external chest wall, or may be placed below the diaphragm
• bleeding (anticoagulation is a relative contraindication)
• local infection, empyema
• perforation of lung parenchyma or vasculature
• risk of re-expansion pulmonary edema when large volumes of air or fluid are drawn off quickly (>1.0-1.5 L)

Lung Transplantation

Conditions Leading to Transplantation
• chronic acquired lung disease: COPD
• genetic: CF, emphysema due to α-1 antitrypsin deficiency
• idiopathic interstitial pneumonias: IPF, nonspecific interstitial pneumonitis
• HTN-related: IPAH, secondary pulmonary HTN, Eisenmenger’s syndrome
• other: sarcoidosis, lymphangioleiomyomatosis, pulmonary Langerhans cell histiocytosis

Clinical Indications
• transplantation should be considered for patients with advanced lung disease refractory to maximal medical or surgical therapy
• patients who are symptomatic during activities of daily living and have limited expected survival over the next 2 yr

Criteria for Transplantation
• lung allocation score based on: 1) post-transplant survival measure, and 2) waiting list urgency measure
• transplant benefit = post-transplant survival (days) – waitlist survival (days)

Contraindications
• uncontrolled or untreatable pulmonary or extrapulmonary infection
• malignancy in the last 2 yr
• advanced cardiopulmonary disease
• significant chest wall/spinal deformity
• active cigarette smoking
• HIV infection, ongoing HBV or HCV infections

Post-Operative Complications
• primary graft dysfunction: main cause is ischemia-reperfusion injury, graded by PaO₂/FiO₂ ratio and CXR findings
• airway anastomotic complications (focal infection, bronchial necrosis and dehiscence, excess granulation tissue, tracheobronchomalacia, stenosis, fistula)
• chronic graft dysfunction: bronchiolitis obliterans syndrome
• infectious complications (bacterial, fungal, CMV, community-acquired respiratory viruses, mycobacteria)
• malignancy (non-melanoma skin cancer, post-transplant lymphoproliferative disease, colon, breast, Kaposi’s sarcoma, bladder)

Prognosis
• median survival for all adult recipients: 5.4 yr
• 1 yr survival: COPD > IPF > IPAH
• 10 yr survival: CF, α-1 antitrypsin deficiency > IPAH > COPD, IPF

Chronic Obstructive Pulmonary Disease

Treatment
• indications for surgical management
  • dyspnea despite maximal medical therapy and pulmonary rehabilitation
  • CT showing hyperinflation and heterogeneously distributed emphysema predominant in the upper lung zone
  • may be used as a bridging procedure to lung transplantation
• contraindications
  • age >75, cigarette smoking within the prior 6 mo, higher risk of surgical mortality
  • homogeneously distributed emphysematous changes with areas of preserved lung tissue
  • diffusing capacity of lung for carbon monoxide <20% of predicted, PaCO₂ >60 mmHg, PaO₂ <45 mmHg
• surgical procedures
  • lung volume reduction surgery: wedge excision of emphysematous tissue
  • bilateral or unilateral, thoracotomy or VATS
Complications of Treatment
- air leak: may require reintubation and mechanical ventilation
- arrhythmias, pneumonia

Prognosis
- total mortality at 2 yr same as with maximal medical therapy, but better exercise capacity and quality of life with LVRS

Stomach and Duodenum

Peptic Ulcer Disease

GASTRIC ULCERS
- see Gastroenterology, G11

Indications for Surgery
- refractory to medical management
- suspicion of malignancy (even if biopsy benign)
- complications of PUD: obstruction, perforation, bleeding (3x greater risk compared to duodenal ulcers)
- surgical treatment is increasingly rare due to H. pylori eradication and medical treatment

Procedures
- ligation of bleeding vessels
- distal gastrectomy with ulcer excision: Billroth II, Roux-en-Y gastrojejunostomy or Billroth I (rarely) reconstruction
- vagotomy and pyloroplasty only if acid hypersecretion (rare)
- wedge resection if possible or biopsy with primary repair

DUODENAL ULCERS
- see Gastroenterology, Bleeding Peptic Ulcer, G12, and Peptic Ulcer Disease, G11
- most within 2 cm of pylorus (duodenal bulb)

Indications for Surgery
- hemorrhage, rebleed in hospital, perforation, gastric outlet obstruction
- refractory to medical and endoscopic management

Procedures
- omental (Graham) patch: plication of ulcer supported by overlying omental patch
- oversewing of bleeding ulcer + pyloroplasty
- treat with H. pylori eradication protocol post operatively.

Complications of Gastric Surgery
- retained antrum
- fistula (gastrocolic/gastrojejunal)
- dumping syndrome, postvagotomy diarrhea, afferent loop syndrome (see Complications of Gastric Surgery, G11)

Table 5. Complications of Duodenal Ulceration

<table>
<thead>
<tr>
<th>Complication</th>
<th>Clinical Features</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perforated Ulcer (typically on anterior surface)</td>
<td>Sudden onset of pain (possibly in RLQ due to track down right paracolic gutter) Acute abdomen: rigid, diffuse guarding R厌恶 Initial chemical peritonitis followed by bacterial peritonitis</td>
<td>Investigation CXR – free air under diaphragm (70% of patients) Treatment Oversew ulcer (plication) and omental (Graham) patch – most common treatment</td>
</tr>
<tr>
<td>Posterior Penetration</td>
<td>Elevated amylase/lipase if penetration into pancreas Constant mid-epigastric pain burrowing into back, unrelated to meals</td>
<td>Resuscitation initially with crystalloids; blood transfusion if necessary Diagnostic and/or therapeutic endoscopy (laser, cautery, or injection); if recurs, may have second scope Consider interventional radiology: angiography with embolization/ coiling Surgery if severe or recurrent bleeding, hemodynamically unstable, or failure of endoscopy and IR: oversewing of ulcer, pyloroplasty</td>
</tr>
<tr>
<td>Hemorrhage (typically on posterior surface)</td>
<td>Gastroduodenal artery involvement</td>
<td>Resuscitation initially with crystalloids; blood transfusion if necessary Diagnostic and/or therapeutic endoscopy (laser, cautery, or injection); if recurs, may have second scope Consider interventional radiology: angiography with embolization/ coiling Surgery if severe or recurrent bleeding, hemodynamically unstable, or failure of endoscopy and IR: oversewing of ulcer, pyloroplasty</td>
</tr>
<tr>
<td>Gastric Outlet Obstruction</td>
<td>Ulcer can lead to edema, fibrosis of pyloric channel, neoplasia N/V (undigested food, non-bilious), dilated stomach, crampy abdominal pain Succussion splash (splashing noise heard with stethoscope over the stomach when patient is shaken) Auscultate gas and fluid movement in obstructed organ</td>
<td>NGT decompression and correction of hypochloremic, hypokalemic metabolic alkalosis Medical management initially: high dose PPI therapy Surgical resection if obstruction does not resolve: either Billroth I, pyloroplasty, or gastrojejunostomy</td>
</tr>
</tbody>
</table>

Figure 9. Billroth I and Billroth II with Roux-en-Y reconstruction (gastrojejunostomy)
Gastric Carcinoma

Epidemiology
- 5th most common cancer in the world
- M:F = 3:2
- most common age group = 50-59 yr
- incidence has decreased by 2/3 in past 50 yr
- incidence of adenocarcinoma <10 (US) vs. 40 (Japan, Korea) per 100,000 (incidence highest in Asia, Latin America, and Caribbean)

Risk Factors
- compensatory epithelial cell proliferation via gastric atrophy from:
  - *H. pylori*, causing chronic atrophic gastritis
  - pernicious anemia associated with achlorhydria and chronic atrophic gastritis
  - previous partial gastrectomy (>10 yr post-gastrectomy)
- host-related factors
  - blood type A
  - hereditary nonpolyposis colorectal cancer (HNPPC), hereditary diffuse gastric carcinoma (HDGC)
  - gastric adenomatous polyps
  - hypertrophic gastropathy
- genetic syndromes: hereditary diffuse gastric cancer E-cahedrin (CDH-1) gene
- environmental factors: smoking, alcohol, smoked food, nitrosoamines

Clinical Features
- clinical suspicion
  - ulcer fails to heal
  - lesion on greater curvature of stomach or cardia
- asymptomatic, insidious, or late onset of symptoms
  - postprandial abdominal fullness, vague epigastric pain
  - anorexia, weight loss
  - burping, N/V, dyspepsia, dysphagia
  - hepatomegaly, epigastric mass (25%)
  - hematemesis, fecal occult blood, melena, iron-deficiency anemia
- metastasis
  - peritoneum, ovarian, liver, lung, brain

Investigations
- OGD and biopsy; consider EUS to assess pre-operative T-stage and N-stage
- CT chest/abdomen/pelvis (for metastatic workup see Table 7)

Table 6. TNM Classification System for Staging of Gastric Carcinoma (AJCC/UICC 2010)

<table>
<thead>
<tr>
<th>Primary Tumour (T)</th>
<th>Regional Lymph Nodes (N)</th>
<th>Distant Metastasis (M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>T0</td>
<td>NX</td>
<td>MO</td>
</tr>
<tr>
<td>Ts</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>T1a</td>
<td>N1</td>
<td>M1</td>
</tr>
<tr>
<td>T1b</td>
<td>N2</td>
<td>M1</td>
</tr>
<tr>
<td>T2</td>
<td>N3a</td>
<td>M1</td>
</tr>
<tr>
<td>T3</td>
<td>N3b</td>
<td>M1</td>
</tr>
<tr>
<td>T4a</td>
<td>N1</td>
<td>M1</td>
</tr>
<tr>
<td>T4b</td>
<td>N2</td>
<td>M1</td>
</tr>
<tr>
<td>N0</td>
<td>M0</td>
<td>M1</td>
</tr>
<tr>
<td>N1</td>
<td>M0</td>
<td>M1</td>
</tr>
<tr>
<td>N2</td>
<td>M0</td>
<td>M1</td>
</tr>
<tr>
<td>N3a</td>
<td>M0</td>
<td>M1</td>
</tr>
<tr>
<td>N3b</td>
<td>M0</td>
<td>M1</td>
</tr>
</tbody>
</table>

Treatment
- adenocarcinoma
  - proximal lesions
    - total gastrectomy and Roux-en-Y esophagejunostomy
  - distal lesions
    - distal gastrectomy: wide margins, en bloc removal of omentum and lymph nodes with Roux-en-Y or Billroth II reconstruction
  - palliation
    - limited gastric resection or endoscopic stenting to decrease bleeding and relieve obstruction, enables the patient to eat
    - radiation therapy
    - studies are showing larger role for adjuvant/ neoadjuvant and palliative chemotherapy

Staging and 5 Yr Survival Rates for Gastric Cancer

<table>
<thead>
<tr>
<th>Stage</th>
<th>TNM</th>
<th>5-Yr Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>T1N0M0</td>
<td>71%</td>
</tr>
<tr>
<td>IB</td>
<td>T2N0M0</td>
<td>57%</td>
</tr>
<tr>
<td>IIA</td>
<td>T3N0M0</td>
<td>45%</td>
</tr>
<tr>
<td>IIB</td>
<td>T4N0M0</td>
<td>33%</td>
</tr>
<tr>
<td>IIIA</td>
<td>T4N1M0</td>
<td>20%</td>
</tr>
<tr>
<td>IIIB</td>
<td>T4N2M0</td>
<td>14%</td>
</tr>
<tr>
<td>IIC</td>
<td>T4N3M0</td>
<td>9%</td>
</tr>
<tr>
<td>IV</td>
<td>T4N0M1</td>
<td>4%</td>
</tr>
</tbody>
</table>

Signs of Metastatic Gastric Carcinoma
- Virchow’s node: left supraclavicular node
- Blumer’s shelf: mass in pouch of Douglas
- Sister Mary Joseph node: umbilical metastases
- Irish’s node: left axillary nodes
• lymphoma
  ■ H. pylori eradication, chemotherapy ± radiation, surgery in limited cases (perforation, bleeding, obstruction)

Gastrointestinal Stromal Tumour

Epidemiology
• most common mesenchymal neoplasm of GI tract
• derived from interstitial cells of Cajal (cells associated with Auerbach's plexus that have autonomous pacemaker function which coordinate peristalsis throughout the GI tract)
• 75-80% associated with tyrosine kinase (c-KIT) mutations
• most common in stomach (50%) and proximal small intestine (25%), but can occur anywhere along GI tract
  typically present with vague abdominal mass, feeling of abdominal fullness, or with secondary symptoms of bleeding and anemia
  often discovered incidentally on CT, laparotomy, or endoscopy

Risk Factors
• Carney's triad: GISTs, paraganglioma, and pulmonary chondroma
• Type IA neurofibromatosis

Investigations
• pre-operative biopsy (endoscopic ultrasound): controversial, but useful for indeterminate lesions
  ■ not recommended if index of suspicion for GIST is high
  ■ percutaneous biopsy is NOT recommended due to high friability and risk of peritoneal spread

Treatment
• surgical resection if >2 cm; follow with serial endoscopy if <2 cm and resect if growing or symptomatic
• localized GIST
  ■ surgical resection with preservation of intact pseudocapsule
  ■ lymphadenectomy NOT required, as GISTs rarely metastasize to lymph nodes
  ■ consider adjuvant treatment with imatinib (Gleeve) or high-risk GIST (large, >4 cm with significant mitotic activity)
  ■ advanced disease (i.e. metastases to liver and/or peritoneal cavity)
    ■ palliative intent chemotherapy with imatinib
    ■ metastectomy may be considered for liver limited disease

Prognosis
• risk of metastatic potential depends on
  ■ tumour size (worse if >10 cm)
  ■ mitotic activity (worse if >5 mitotic figures or 50/hpf)
  ■ degree of nuclear pleomorphism
  ■ location: with identical sizes, extra-gastric location has a higher risk of progression than GISTs in the stomach
  ■ metastases to liver, omentum, peritoneum; nodal metastases rare

Bariatric Surgery

• weight reduction surgery for morbid obesity
  • indications: BMI ≥40 without illness or BMI ≥35 with 1+ serious comorbidity (e.g. DM, CAD, sleep apnea, severe joint disease)

Surgical Options
• malabsorptive/restrictive
  ■ laparoscopic Roux-en-Y gastric bypass (most common – see Figure 9)
  ■ staple off small gastric pouch (restrictive) with Roux-en-Y limb to pouch (malabsorptive) with dumping syndrome physiology
  ■ most effective, higher complication rates
• restrictive
  ■ laparoscopic adjustable gastric banding
  ■ silicone band around fundus creates pouch, adjustable through port under skin
  ■ laparoscopic vertical sleeve gastrectomy
  ■ vertical stapled small gastric pouch
• malabsorptive
  ■ biliopancreatic diversion with duodenal switch
  ■ gastrectomy, enterostomy, duodenal division closure and duodenoenterostomy

Bariatric (Weight Loss) Surgery for Obesity is Considered when Other Treatments have Failed
Cochrane GB Syn Rev 2009:2:CD003641

Benefits
• Greater weight loss in patients with BMI >30 at 2 yr.
• Reduction in comorbidities (type 2 DM, HTN, and medication use).
• Improvement in quality of life at 2 yr (physical function, physical role, general health, vitality, and emotional role).

Risks
• Complications: leaks, hernias, infection, pulmonary embolism, post-operative mortality.
• Side effects specific to type of procedure (i.e. vomiting, dumping syndrome, food intolerance).
• Cholecystitis occurs as a result of rapid weight loss.
Complications
- perioperative mortality ~1% (anastomotic leak with peritoneal signs, PE)
- obstruction at enteroenterostomy (see Complications of Gastric Surgery)
- staple line dehiscence
- dumping syndrome
- cholelithiasis due to rapid weight loss (20-30%)
- band abscess (if long-term)

Complications of Gastric Surgery
- most resolve within 1 yr

Alkaline Reflux Gastritis (see Figure 10A)
- duodenal contents (bilious) reflux into stomach causing gastritis ± esophagitis
- treatment
  - medical: H₂-blocker, metoclopramide, cholestyramine (bile acid sequestrant)
  - surgical: conversion of Billroth I or II to Roux-en-Y

Afferent Loop Syndrome (see Figure 10B)
- accumulation of bile and pancreatic secretions causes intermittent mechanical obstruction and distention of afferent limb
- clinical features
  - early postprandial distention, RUQ pain, nausea, bilious vomiting, anemia
- treatment: surgery (conversion to Roux-en-Y increases afferent loop drainage)

Dumping Syndrome (see Figure 10C)
- early – 15 min post-prandial
  - etiology
    - hyperosmotic chyme released into small bowel (fluid accumulation and jejunal distention)
  - clinical features
    - post-prandial symptoms
    - epigastric fullness or pain, emesis, nausea, diarrhea, palpitations, dizziness, tachycardia, diaphoresis
  - treatment
    - small multiple low carbohydrate, low fat, and high protein meals and avoidance of liquids with meals
    - last resort is interposition of antiperistaltic jejunal loop between stomach and small bowel to delay gastric emptying
- late – 3 h post-prandial
  - etiology: large glucose load leads to large insulin release and hypoglycemia
  - treatment: small snack 2 h after meals

Blind-Loop Syndrome (see Figure 10D)
- bacterial overgrowth of colonic Gram-negative bacteria in afferent limb
- clinical features
  - anemia/weakness, diarrhea, malnutrition, abdominal pain, and hypocalcemia
- treatment: broad-spectrum antibiotics, surgery (conversion to Billroth I)

Postvagotomy Diarrhea (see Figure 10E)
- up to 25%
- bile salts in colon inhibit water resorption
- treatment: medical (cholestyramine), surgical (reversed interposition jejunal segment)
SMALL INTESTINE

Small Bowel Obstruction

Mechanical Small Bowel Obstruction

Etiology

Table 7. Common Causes of SBO

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Intraluminal</th>
<th>Intramural</th>
<th>Extramural</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intussusception</td>
<td>Crohn’s</td>
<td>Adhesions from previous surgeries (75% SBO)</td>
<td></td>
</tr>
<tr>
<td>Gallstones</td>
<td>Radiation stricture</td>
<td>Incarcerated hernia</td>
<td></td>
</tr>
<tr>
<td>Bezoars</td>
<td>Adenocarcinoma</td>
<td>Peritoneal carcinomatosis</td>
<td></td>
</tr>
</tbody>
</table>

Pathophysiology

- obstruction → gas & fluid (swallowed or GI secretions) accumulate proximal to site of obstruction and distal decompression → intestinal activity increases to overcome obstruction → colicky pain and diarrhea (initially)
- bowel wall edema and disruption of normal bowel absorptive function can lead to increased intraluminal fluid and transudative fluid loss into peritoneal cavity, electrolyte disturbances
- increase intramural pressure can lead to impaired microvascular perfusion leading to intestinal ischemia and necrosis (strangulated bowel obstruction)
- three types
  - partial SBO: only a portion of intestinal lumen is occluded, allows passage of some gas & fluid, low risk of strangulation
  - complete SBO: the lumen of the intestine is occluded, no passage of gas or stool, at higher risk of strangulation
  - closed-loop obstruction: segment of intestine is obstructed both proximally and distally (e.g. volvulus), leading to rapid rise in intraluminal pressure from gas and fluid that cannot escape, high risk of strangulation due to bowel wall ischemia

Risk Factors

- prior abdominal or pelvic surgery, abdominal wall or groin hernia, history of malignancy, prior radiation

Clinical Features

- 1) distinguish mechanical obstruction from ileus; 2) determine etiology of obstruction; 3) recognize partial from complete SBO; 4) differentiate simple from complicated (e.g. strangulated) obstruction
- symptoms: colicky abdominal pain, nausea/vomiting, obstipation
  - vomiting is more prominent with proximal than distal
  - more feculent vomitus suggest more established obstruction because of bacterial overgrowth
  - continue passage of gas and/or stool 6-12 h after onset of symptoms suggest partial than complete obstruction
- signs: abdominal distention (most prominent if obstruction at distal ileum), hyperactive proceeding to minimal bowel sound
- strangulated obstruction: abdominal pain disproportionate to physical exam findings suggest intestinal ischemia
  - may have tachycardia, localized abdominal tenderness, fever, marked leukocytosis, lactate acidosis

Investigations

- radiological
  - abdominal x-ray (3 views): triad of dilated small bowel (>3 cm in diameter), air-fluid levels on upright film, paucity of air in colon (high sensitivity, low specificity as ileus and LBO can present similarly)
  - CT: discrete transition zone with proximal bowel dilation, distal bowel decompression, and intraluminal contrast does not pass the transition zone
  - most importantly to r/o ischemic bowel/strangulation: pneumatosis intestinalis (free air in bowel wall) & thickened bowel wall, air in portal vein, free intraperitoneal liquids, differential wall enhancements (poor uptake of IV contrast into the wall of the affected bowel)
- other
  - less used: upper GI series/small bowel series (if no cause apparent, i.e. no hernias, no previous surgeries)
  - may consider U/S or MRI in pregnant patients

- laboratory
  - may be normal early in disease course
  - creatinine, hematocrit to assess degree of dehydration
  - fluid, electrolyte abnormalities; metabolic alkalosis due to frequent emesis; amylase elevated
  - if strangulation: leukocytosis with left shift, elevated lactate (late signs)
Small Bowel Obstruction

Treatment
- IV isotonic fluid resuscitation + urine output monitoring with catheter
  - SBO related vomiting and decrease PO intake leads to volume depletion
- NG tube in the stomach for gastric decompression; decrease nausea, distention, and risk of aspiration from vomiting
- Partial SBO/Crohn's/Carcinomatosis: conservative management with fluid resuscitation and NG tube decompression
  - 48 h of watchful waiting; if no improvement or develops complications, surgery
- Complete SBO, if no clinical features of strangulation, short course of conservative management with fluid resuscitation and NG tube decompression with frequent re-examination by surgical team
  - duration of observation varies from hours to a few days
  - if SBO fails to resolve, or if symptoms of strangulation develop then surgery

High risk for strangulation based on clinical symptoms: urgent surgery to prevent irreversible ischemia
- early post-operative SBO: if bowel function do not return within 3-5 d after surgery; usually partial, extended conservative therapy (2-3 wk) with bowel rest, fluids, and TPN is appropriate
  - surgery if presence of peritonitis or complete SBO demonstrated

Prognosis
- related to etiology; mortality: non-strangulating <1%, strangulating 8% (25% if >36 h), ischemic = up to 50%

Prevention
- open surgery has four fold increase in risk of SBO in 5 yr compared to laparoscopic surgery

Paralytic Ileus

Pathogenesis
- temporary, reversible impairment of intestinal motility; mostly frequently caused by:
  - abdominal operations, infections & inflammation, medications (opiates, anesthetics, psychotropics), and electrolyte abnormalities
  - passing gas is the most useful indicator
- NOT the same as intestinal pseudo-obstruction
  - chronic pseudo-obstruction refers to specific disorders that affect the smooth muscle and myenteric plexus, leading to irreversible intestinal dysmotility

Clinical Features
- symptoms and signs of intestinal obstruction without mechanical obstruction
  - bowel sounds are diminished or absent (in contrast to initial hyperactive bowel sounds in SBO)

Investigations
- routine post-operative ileus: expected, no investigation needed
- if ileus persists or occurs without abdominal surgery
  - review patient medications (especially opiates)
  - measure serum electrolyte to monitor for electrolyte abnormalities (including extended lytes like Mg, Ca\(^{2+}\), PO\(_4\))
  - CT scan to rule out abscess or peritoneal sepsis, or to exclude complete mechanical obstruction

Treatment
- most important: NPO + fluid resuscitation
- NGT decompression, correct causative abnormalities (e.g. sepsis, medications, electrolytes), consider TPN for prolonged ileus
- post-operative: gastric and small bowel motility returns by 24-48 h, colonic motility by 3-5 d
- current interest in novel therapies such as gum chewing and pharmacologic therapy (e.g. alvimopan, an opioid antagonists)

Intestinal Ischemia

Etiology
- acute
  - arterio-occlusive mesenteric ischemia (AOMI)
    - thrombotic, embolic, extrinsic compression (e.g. strangulating hernia)
  - non-occlusive mesenteric ischemia (NOMI)
    - mesenteric vasoconstriction secondary to systemic hypoperfusion (preserves supply to vital organs)
    - mesenteric venous thrombosis (MVT)
      - consider hypercoagulable state (i.e. rule out malignancy), DVT (prevents venous outflow)
  - chronic: usually due to atherosclerotic disease – look for CVD risk factors
  - can lead to occlusion in vessels that supplies the small intestine and the large intestine

Figure 11. Appendix anatomy
Clinical Features
- acute: severe abdominal pain out of proportion to physical findings, vomiting, bloody diarrhea, bloating, minimal peritoneal signs early in course, hypotension, shock, sepsis
- chronic: postprandial pain (from mesenteric angina), fear of eating, weight loss
- common sites: SMA supplied territory, “watershed” areas of colon – splenic flexure, left colon, sigmoid colon

Investigations
- laboratory: leukocytosis (non-specific), lactic acidosis (late finding)
  - amylase, lactate, CK, ALP can be used to observe progress
  - hypercoagulability workup if suspect venous thrombosis
- AXR: portal venous gas, intestinal pneumatosis, free air if perforation
- contrast CT: thickened bowel wall, luminal dilatation, SMA or SMV thrombus, mesenteric/portal venous gas, pneumatosis
- CT angiography is the gold standard for acute arterial ischemia

Treatment
- fluid resuscitation, correct metabolic acidosis, NPO, NGT decompression of stomach, prophylactic broad-spectrum antibiotics, avoid vasoconstrictors and digitalis
- exploratory laparotomy
- angiogram, embolectomy/thrombectomy, bypass/graft, mesenteric endarterectomy, anticoagulation therapy, percutaneous transluminal angioplasty ± stent
- segmental resection of necrotic intestine
- assess extent of viability; if extent of bowel viability is uncertain, a second look laparotomy 12-24 h later is mandatory

Tumours of Small Intestine

BENIGN TUMOURS
- 10x more common than malignant
- usually asymptomatic until large
- most common sites: terminal ileum, proximal jejunum
- polyps
  - adenomas
  - hamartomas
- FAP (see Familial Colon Cancer Syndromes, GS33)
- juvenile polyps
- other: leiomyomas, lipomas, hemangiomas

Table 8. Malignant Tumours of the Small Intestine

<table>
<thead>
<tr>
<th>Tumour Type</th>
<th>Epidemiology</th>
<th>Risk Factors</th>
<th>Clinical Features</th>
<th>Investigations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenocarcinoma</td>
<td>Usually 50-70 yr M&gt;F</td>
<td>Crohn’s, FAP, history of CRC, HNPCC</td>
<td>Early metastasis to lymph nodes 80% metastatic at time of operation Abdominal pain (common)</td>
<td>CT abdomen/pelvis Endoscopy</td>
</tr>
<tr>
<td>Carcinoid</td>
<td>Increased incidence 50-60 yr M&gt;F</td>
<td>Crohn’s, celiac disease, autoimmune disease, immunosuppression, radiation therapy, nodular lymphoid hyperplasia</td>
<td>Obstruction, bleeding, crampy abdominal pain, intussusception Carcinoid syndrome (&lt;10%) Hot flushes, hypotension, diarrhea, bronchoconstriction, right heart failure Requires liver involvement: lesion secretes serotonin, kinins, and vasoactive peptides directly to systemic circulation (normally inactivated by liver)</td>
<td>Most found incidentally at surgery for obstruction or appendectomy Chest thorax/abdomen/pelvis Consider small bowel enteroclysis to look for primary Serum chromogranin A as a tumour marker Elevated 5-HIAA (breakdown product of serotonin) in urine or increased 5-HT in blood Radiolabelled octreotide or MIBG scans to search for metastases and locate tumour</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>Highest incidence in 70s M&gt;F Usually non-Hodgkin’s lymphoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metastatic</td>
<td>Most common site of GI metastases in patients with metastatic melanoma</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Carcinoid Syndrome Symptoms
- flushing
- diarrhea
- right-sided heart failure

FDR
Table 8. Malignant Tumours of the Small Intestine (continued)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Adenocarcinoma</th>
<th>Carcinoid</th>
<th>Lymphoma</th>
<th>Metastatic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical resection ± chemotherapy</td>
<td>Surgical resection ± chemotherapy</td>
<td>Carcinoid syndrome treated with steroids, histamine, octreotide</td>
<td>Low grade: chemotherapy with cyclophosphamide</td>
<td>Palliation</td>
</tr>
<tr>
<td>Metastatic: risk 2% if size ≤ 1 cm, 90% if &gt; 2 cm</td>
<td>Metastatic: risk 2% if size ≤ 1 cm, 90% if &gt; 2 cm</td>
<td>Metastatic: risk 2% if size ≤ 1 cm, 90% if &gt; 2 cm</td>
<td>Metastatic: risk 2% if size ≤ 1 cm, 90% if &gt; 2 cm</td>
<td>Metastatic: risk 2% if size ≤ 1 cm, 90% if &gt; 2 cm</td>
</tr>
</tbody>
</table>

| Prognosis | 5 yr survival 25% (if node positive) | 5 yr survival 70%; 20% with liver metastases | 5 yr survival 40% | Poor |

<table>
<thead>
<tr>
<th>Origin/Location</th>
<th>Usually in proximal small bowel, incidence decreases distally</th>
<th>Classified based on embryological origin (foregut, midgut, hindgut)</th>
<th>Oftentimes in patients with celiac disease</th>
<th>Hematogenous spread from breast, lung, kidney</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(often not visible)</td>
<td>Appendix 46%, distal ileum 28%, rectum 17%</td>
<td>Usually distal ileum</td>
<td>Direct extension from cervix, ovaries, colon</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Staging System</th>
<th>TNM</th>
<th>TNM</th>
<th>Ann Arbor</th>
</tr>
</thead>
</table>

### Short Gut Syndrome

**Definition**
- reduced surface area (length) of small bowel causing insufficient intestinal absorption leading to diarrhea, malnutrition, and dehydration

**Risk Factors**
- acute mesenteric ischemia: resection of large amount of bowel at once
- Crohn’s disease: cumulative resections
- malignancies

**Prognostic Factors**
- residual small bowel length, residual colon length (reabsorption of water and electrolytes and some reabsorption of nutrients), condition of the remnant small bowel (healthier bowel facilitate better reabsorption), presence of ileoceleal valve (delay transition into colon leading to more reabsorption)
- resection of ileum is less tolerated than resection of jejunum (ileum reabsorbs bile salt and vitamin B12)

**Therapy**
- medical
  - TPN: replenish lost fluid and electrolytes in diarrhea
  - HT2R antagonist or PPI to prevent gastric acid secretion
  - antimotility agent to prolong transit time in the small intestine
  - consider octreotide to decrease GI secretion & cholystryramine for bile acid absorption
- surgical: non-transplant
  - to slow transit time: small bowel segmental reversal, intestinal valve construction, or electrical pacing of small bowel
  - to increase intestinal length:
    - LIIT (longitudinal intestinal lengthening and tailoring) procedure
    - STEP (serial transverse enteroplasty procedure) in dilated small bowels
- surgical: transplant
  - indication: life-threatening complication from intestinal failure or long-term TPN
  - liver failure, thrombosis of major central veins, recurrent catheter-related sepsis, recurrent severe dehydration

### Abdominal Hernia

- see Hiatus Hernia, GS13

**Definition**
- defect in abdominal wall causing abnormal protrusion of intra-abdominal contents

**Epidemiology**
- M:F = 9:1
- lifetime risk of developing a hernia: males 20-25%, females 2%
- frequency of occurrence: 50% indirect inguinal, 25% direct inguinal, 8-10% incisional (ventral), 5% femoral, 3-8% umbilical
- most common surgical disease of males

**Risk Factors**
- activities which increase intra-abdominal pressure
  - obesity, chronic cough, asthma, COPD, pregnancy, constipation, bladder outlet obstruction, ascites, heavy lifting
- congenital abnormality (e.g. patent processus vaginalis, indirect inguinal hernia)
- previous hernia repair, especially if complicated by wound infection
- loss of tissue strength and elasticity (e.g. hiatus hernia, aging, repetitive stress)
Clinical Features
• mass of variable size
• tenderness worse at end of day, relieved with supine position or with reduction
• abdominal fullness, vomiting, constipation
• transmits palpable impulse with coughing or straining

Investigations
• physical examination usually sufficient
• US ± CT (CT required for obturator hernias, internal abdominal hernias, and Spigelian and/or femoral hernias in obese patients)

Classification
• complete: hernia sac and contents protrude through defect
• incomplete: partial protrusion through the defect
• internal hernia: sac herniating into or involving intra-abdominal structure
• external hernia: sac protrudes completely through abdominal wall
• strangulated hernia: vascular supply of protruded viscus is compromised (ischemia)
  • requires emergency repair
• incarcerated hernia: irreducible hernia, not necessarily strangulated
• Richter’s hernia: only part of bowel circumference (usually anti-mesenteric border) is incarcerated or strangulated so may not be obstructed
• a strangulated Richter’s hernia may self-reduce and thus be overlooked, leaving a gangrenous segment at risk of perforation in the absence of obstructive symptoms
• sliding hernia: part of wall of hernia sac formed by retroperitoneal structure (usually colon)

Anatomical Types
• groin
  • indirect and direct inguinal, femoral
  • pantaloon: combined direct and indirect hernias, peritoneum draped over inferior epigastric vessels
• epigastric: defect in linea alba above umbilicus
• incisional: ventral hernia at site of wound closure, may be secondary to wound infection
• other: Littre’s (involving Meckel’s), Amyand’s (containing appendix), lumbar, obturator, peristomal, umbilical, Spigelian (ventral hernia through linea semilunaris)

Complications
• incarceration
• strangulation
• small, new hernias more likely to strangulate
• femoral >> indirect inguinal > direct inguinal
• intense pain followed by tenderness
• intestinal obstruction, gangrenous bowel, sepsis
• surgical emergency
• DO NOT attempt to manually reduce hernia if septic or if contents of hernial sac gangrenous
• will cause closed loop SBO – and EMERGENCY

Treatment
• surgical treatment (herniorrhaphy) is only to prevent strangulation and evisceration, for symptomatic relief, for cosmesis; if asymptomatic can delay surgery
• repair may be done open or laparoscopic and may use mesh for tension-free closure
• most repairs are now done using tension free techniques – a plug in the hernial defect and a patch over it or patch alone
• observation is acceptable for small asymptomatic inguinal hernias

Post-Operative Complications
• recurrence (15-20%)
  • risk factors: recurrent hernia, age >50, smoking, BMI >25, poor pre-operative functional status (ASA ≥ 3 – see Anesthesia and Perioperative Medicine, A4), associated medical conditions: type 2 DM, hyperlipidemia, immunosuppression, any comorbid conditions increasing intra-abdominal pressure
  • less common with mesh/”tension-free” repair
• scrotal hematoma (3%)
• painful scrotal swelling from compromised venous return of testes
• deep bleeding: may enter retroperitoneal space and not be initially apparent
• difficulty voiding
• nerve entrapment
• ilioinguinal (causes numbness of inner thigh or lateral scrotum)
• genital branch of genitofemoral (in spermatic cord)
• stenosis/occlusion of femoral vein
• acute leg swelling
• ischemic colitis

Outcomes of Laparoscopic vs. Open Repair of Primary Ventral Hernias
Purpose: To compare outcomes (surgical site infection (SSI), hernia recurrence and bulging) of patients undergoing laparoscopic ventral hernia repair (LVRH) versus open ventral hernia repair (OVHR).
Results/Conclusions: 79 patients with LVRH matched to 79 patients with OVHR with mesh with a median follow-up of 56 mo. UHRH was associated with fewer SSIs (7.6% vs. 34.1%) but more cases of bulging (21.5% vs. 1.2%) and port-site hernia (2.5% vs. 0.0%). No differences in recurrence were observed.
Groin Hernias

Table 9. Groin Hernias

<table>
<thead>
<tr>
<th>Direct Inguinal</th>
<th>Indirect Inguinal</th>
<th>Femoral</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidemiology</td>
<td>1% of all men</td>
<td>Most common hernia in men and women M&gt;F</td>
</tr>
<tr>
<td>Etiology</td>
<td>Acquired weakness of transversalis fascia “Wear and tear”</td>
<td>Congential persistence of processus vaginalis in 20% of adults</td>
</tr>
<tr>
<td>Treatment</td>
<td>Surgical repair</td>
<td>Surgical repair</td>
</tr>
<tr>
<td>Prognosis</td>
<td>3-4% risk of recurrence</td>
<td>&lt;1% risk of recurrence</td>
</tr>
</tbody>
</table>

McBurney’s Sign
Tenderness 1/3 the distance from the ASIS to the umbilicus on the right side

Appendix

Appendicitis

Epidemiology
• 6% of population, M>F
• 80% between 5-35 yr of age

Pathogenesis
• luminal obstruction → bacterial overgrowth → inflammation/swelling → increased pressure → localized ischemia → gangrene/perforation → localized abscess (walled off by omentum) or peritonitis
• etiology
  ▪ children or young adult: hyperplasia of lymphoid follicles, initiated by infection
  ▪ adult: fibrosis/stricture, fecolith, obstructing neoplasm
  ▪ other causes: parasites, foreign body

Clinical Features
• most reliable feature is progression of signs and symptoms
• low grade fever (38°C), rises if perforation
• abdominal pain then anorexia, N/V
• classic pattern: pain initially periumbilical; constant, dull, poorly localized, then well localized pain over McBurney’s point
  ▪ due to progression of disease from visceral irritation (causing referred pain from structures of the embryonic midgut, including the appendix) to irritation of parietal structures
  ▪ McBurney’s sign
• signs
  ▪ inferior appendix: McBurney’s sign (see sidebar), Rovsing’s sign (palpation pressure to left abdomen causes McBurney’s point tenderness).
  ▪ McBurney’s sign is present whenever the opening of the appendix at the cecum is directly under McBurney’s point; therefore McBurney’s sign is present even when the appendix is in different locations
  ▪ retrocecal appendix: psoas sign (pain on flexion of hip against resistance or passive hyperextension of hip)
  ▪ pelvic appendix: obturator sign (flexion then external or internal rotation about right hip causes pain)
• complications
  ▪ perforation (especially if >24 h duration)
  ▪ abscess, phlegmon
  ▪ sepsis

*see Basic Anatomy Review, Figure 2, GS3

Table 10. Superficial Inguinal Ring vs. Deep Inguinal Ring*

<table>
<thead>
<tr>
<th>Superficial Inguinal Ring</th>
<th>Deep Inguinal Ring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening in external abdominal aponeurosis: palpable superior and lateral to pubic tubercle</td>
<td>Opening in transversalis fascia: palpable superior to mid-inguinal ligament</td>
</tr>
<tr>
<td>Medial border: medial crus of external abdominal aponeurosis</td>
<td>Medial border: inferior epigastric vessels</td>
</tr>
<tr>
<td>Lateral border: lateral crus of external oblique aponeurosis</td>
<td>Superior-lateral border: internal oblique and transversus abdominis muscles</td>
</tr>
<tr>
<td>Roof: intercrural fibres</td>
<td>Inferior border: inguinal ligament</td>
</tr>
</tbody>
</table>

*see Basic Anatomy Review, Figure 2, GS3

Epidemiology
• 80% between 5-35 yr of age
Investigations
- laboratory
  - mild leukocytosis with left shift (may have normal WBC counts)
  - higher leukocyte count with perforation
  - β-hCG to rule out ectopic pregnancy
  - urinalysis
- imaging
  - U/S may visualize appendix, but also helps rule out gynecological causes – overall accuracy 90-94%, can rule in but CANNOT rule out appendicitis (if >6 mm, SENS/SPEC/PPV/PNP 98%)
  - =CT scan: thick wall, appendicolith, inflammatory changes – overall accuracy 94-100%, optimal investigation

Treatment
- hydrate, correct electrolyte abnormalities
- appendectomy (gold standard)
  - laparoscopic vs. open (see sidebar)
- complications: intra-abdominal abscess, appendiceal stump leak
- perioperative antibiotics:
  - cefazolin + metronidazole if uncomplicated peri-operative dose is adequate
  - consider treatment with post-operative antibiotics for perforated appendicitis
- for patients who present with an abscess (palpable mass or phlegmon on imaging and often delayed diagnosis with symptoms for >4-5 d), consider radiologic drainage + antibiotics x 14 d ± interval appendectomy once inflammation has resolved = (controversial)
- recent research supports antibiotic only treatment as reasonable for uncomplicated appendicitis, with 10-20% recurrence rates
- colonoscopy in the elderly to rule out other etiology (neoplasm)

Prognosis
- mortality rate: 0.08% (non-perforated), 0.5% (perforated appendicitis)

Inflammatory Bowel Disease

- see Gastroenterology, G19

Principles of Surgical Management
- can alleviate symptoms, address complications, improve quality of life
- conserve bowel: resect as little as possible to avoid short gut syndrome
- perioperative management
  - optimize medical status: may require TPN (especially if >7 d NPO) and bowel rest
  - hold immunosuppressive therapy pre-operative, provide pre-operative stress dose of corticosteroid if patient had recent steroid therapy, taper steroids post-operative
  - VTE prophylaxis: LMWH or heparin (IBD patients at increased risk of thromboembolic events)

Crohn’s Disease

- see Gastroenterology, G20

Treatment
- surgery is for symptom management, it is NOT curative, but over lifetime ~70% of Crohn’s patients will have surgery
- indications for surgical management
  - failure of medical management
  - SBO (due to stricture/inflammation): indication in 50% of surgical cases
  - abscess, fistula (enterocolic, vesicular, vaginal, cutaneous abscess), quality of life, perforation, hemorrhage, chronic disability, failure to thrive (children), perianal disease
- surgical procedures
  - resection and anastomosis/stoma if active or subacute inflammation, perforation, fistula
  - resection margin only has to be free of gross disease (microscopic disease irrelevant to prognosis)
  - stricturoplasty – widens lumen in chronically scarred bowel: relieves obstruction without resecting bowel (contraindicated in acute inflammation)

Complications of Treatment
- short gut syndrome (diarrhea, steatorrhea, malnutrition)
- fistulas
- gallstones (if terminal ileum resected, decreased bile salt resorption → increased cholesterol precipitation)
- kidney stones (loss of calcium in diarrhea → increased oxalate absorption and hyperoxaluria → stones)
Prognosis
- recurrence rate at 10 yr: ileocolic (25-50%), small bowel (50%), colonic (40-50%)
- re-operation at 5 yr: primary resection (20%), bypass (50%), stricturoplasty (10% at 1 yr)
- 80-85% of patients who need surgery lead normal lives
- mortality: 15% at 30 yr

Ulcerative Colitis
- see Gastroenterology, G21

Treatment
- indications for surgical management
  - failure of medical management (including inability to taper steroids)
  - complications: hemorrhage, obstruction, perforation, toxic megacolon (emergency), failure to thrive (children)
  - reduce cancer risk (1-2% risk per yr after 10 yr of disease)
- surgical procedures
  - proctocolectomy and ileal pouch-anal anastomosis (IPAA) ± rectal mucosectomy (operation of choice)
  - proctocolectomy with permanent end ileostomy (if not a candidate for ileoanal procedures)
  - colectomy and IPAA ± rectal mucosectomy
  - in emergency: total colectomy and ileostomy with Hartmann closure of the rectum, rectal preservation

Complications of Treatment
- early: bowel obstruction, transient urinary dysfunction, dehydration (high stoma output), anastomotic leak
- late: stricture, anal fistula/abscess, pouchnitis, poor anorectal function, reduced fertility

Prognosis
- mortality: 5% over 10 yr
- total proctocolectomy will eliminate risk of cancer
- perforation of the colon is the leading cause of death from ulcerative colitis

LARGE INTESTINE

Large Bowel Obstruction

Mechanical Large Bowel Obstruction

Etiology

Table 11. Common Causes of LBO

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Intraluminal</th>
<th>Intramural</th>
<th>Extramural</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constipation</td>
<td>Adenocarcinoma</td>
<td>Volvulus</td>
<td>Hernias (sigmoid colon in a large groin hernia)</td>
</tr>
<tr>
<td>Foreign bodies</td>
<td>Diverticulitis</td>
<td>Adhesions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IBD stricture</td>
<td>Hernias</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Radiation stricture</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Clinical Features (unique to LBO)
- open loop (10-20%)
  - incompetent ileocecal valve allows relief of colonic pressure as contents reflux into ileum, therefore clinical presentation similar to SBO
- closed loop (80-90%) (dangerous)
  - competent ileocecal valve, resulting in proximal and distal occlusions
  - massive colonic distention → increased pressure in cecum → bowel wall ischemia → necrosis → perforation

Treatment
- surgical correction of obstruction (usually requires resection + temporary diverting colostomy)
- volvulus requires sigmoidoscopic or endoscopic decompression followed by operative reduction if unsuccessful
  - if successful, consider interval sigmoid resection on same admission
- cecal volvulus can be a true volvulus or a cecal 'bascule' (cecum folds anteriorly to the ascending colon producing a flap valve occlusion to cecal emptying) – both need surgical treatment
Prognosis
- overall mortality: 10%
- cecal perforation + feculent peritonitis: 20% mortality

Table 12. Bowel Obstruction vs. Paralytic Ileus

<table>
<thead>
<tr>
<th></th>
<th>SBO</th>
<th>LBO</th>
<th>Paralytic Ileus</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/V</td>
<td>Early, may be bilious</td>
<td>Late, may be feculent</td>
<td>Present</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>Colicky</td>
<td>Colicky</td>
<td>Minimal or absent</td>
</tr>
<tr>
<td>Abdominal Distention</td>
<td>+ (prox SBO), + (distal SBO)</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Constipation</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Bowel Sounds</td>
<td>Normal, increased Absent if secondary ileus (delayed presentation)</td>
<td>Normal, increased (borborygmi) Absent if secondary ileus (delayed presentation)</td>
<td>Decreased, absent</td>
</tr>
<tr>
<td>AXR Findings</td>
<td>Air-fluid levels &quot;Ladder&quot; pattern (plicae circularis) Proximal distention (&gt;3 cm) + no colonic gas</td>
<td>Air-fluid levels &quot;Picture frame&quot; appearance Proximal distention + distal decompression No small bowel air if competent ileocecal valve Coffee bean sign (sigmoid volvulus)</td>
<td>Air throughout small bowel and colon</td>
</tr>
</tbody>
</table>

Functional LBO: Colonic Pseudo-Obstruction (Ogilvie’s Syndrome)

Definition
- acute pseudo-obstruction
- distention of colon without mechanical obstruction in distal colon
- exact mechanism unknown, likely autonomic motor dysregulation → possibly sympathetic deprivation to colon, unopposed parasympathetic tone, and interruption of sacral parasympathetic tone to distal bowel

Associations
- most common: trauma, infection, cardiac (MI, CHF)
- disability (long-term debilitation, chronic disease, bed-bound nursing home patients, paraplegia), drugs (narcotic use, laxative abuse, polypharmacy), other (recent orthopedic or neurosurgery, post-partum, electrolyte abnormalities including hypokalemia, retroperitoneal hematoma, diffuse carcinomatosis)

Clinical Features
- most prominent is abdominal distention (acute or graduate over 3-7 days)
- abdominal pain, nausea and vomiting, constipation/diarrhea
- watch out for fever, leukocytosis, and presence of peritoneal signs

Investigations
- AXR: cecal dilatation – if diameter ≥12 cm, increased risk of perforation

Treatment
- treat underlying cause
- NPO, NGT
- decompression: rectal tube, colonoscopy, neostigmine (cholinergic drug), surgical decompression (ostomy/resection) uncommon
- surgery (extremely rare): if perforation, ischemia, or failure of conservative management

Prognosis
- most resolve with conservative management
Diverticular Disease

Definitions
- diverticulum: abnormal sac-like protrusion from the wall of a hollow organ
- diverticulosis: presence of multiple diverticula
- diverticulitis: inflammation of diverticula
- true (congenital) diverticuli: contain all layers of colonic wall, often right-sided
- false (acquired) diverticuli: contain mucosa and submucosa, often left-sided

![TRUE DIVERTICULUM (full wall thickness)](mucosa)
![FALSE DIVERTICULUM (mucosal herniations)](circular muscle)

Figure 13. Diverticular disease – cross-sections of true and false diverticuli

Diverticulosis

Epidemiology
- 5-50% of Western population, lower incidence in non-Western countries, M=F
- prevalence is age dependent: <5% by age 40, 30% by age 60, 65% by age 85
- 95% involve sigmoid colon (site of highest pressure)

Pathogenesis
- risk factors
  - lifestyle: low-fibre diet (predispose to motility abnormalities and higher intraluminal pressure), inactivity, obesity
  - muscle wall weakness from aging and illness (e.g. Ehler-Danlos, Marfan’s)
- high intraluminal pressures cause outpouching to occur at point of greatest weakness, most commonly where vasa recta penetrate the circular muscle layer, therefore increased risk of hemorrhage

Clinical Features
- uncomplicated diverticulosis: asymptomatic (70-80%)
- episodic abdominal pain (often LLQ), bloating, flatulence, constipation, diarrhea
- absence of fever/leukocytosis
- no physical exam findings or poorly localized LLQ tenderness
- complications
  - diverticulitis (15-25%): 25% of which are complicated (i.e. abscess, obstruction, perforation, fistula)
  - bleeding (5-15%): PAINLESS rectal bleeding, 30-50% of massive LGIB
  - diverticular colitis (rare): diarrhea, hematochezia, tenesmus, abdominal pain

Treatment
- uncomplicated diverticulosis: high fibre, education
- diverticular bleed
  - initially workup and treat as any LGIB
  - if hemorrhage does not stop, resect involved region

Diverticulitis

Epidemiology
- 95% left-sided in patients of Western countries, 75% right-sided in Asian populations

Pathogenesis
- erosion of the wall by increased intraluminal pressure or inspissated food particles → inflammation and focal necrosis → micro or macroscopic perforation
- usually mild inflammation with perforation walled off by pericolic fat and mesentery; abscess, fistula, or obstruction can ensue
- poor containment results in free perforation and peritonitis
Clinical Features
- depend on severity of inflammation and whether or not complications are present; hence ranges from asymptomatic to generalized peritonitis
- LLQ pain/tenderness (2/3 of patients) often for several days before admission
- constipation, diarrhea, N/V, urinary symptoms (with adjacent inflammation)
- complications (25% of cases)
  - abscess: palpable tender abdominal mass
  - fistula: colovesical (most common), coloenteric, colovaginal, colocutaneous
  - colonic obstruction: due to scarring from repeated inflammation
  - perforation: generalized peritonitis (feculent vs. purulent)
    - recurrent attacks rarely lead to peritonitis
- low-grade fever, mild leukocytosis common, occult or gross blood in stool rarely coexist with acute diverticulitis

Investigations
- AXR, upright CXR
  - localized diverticulitis (ileus, thickened wall, SBO, partial colonic obstruction)
  - free air may be seen in 30% with perforation and generalized peritonitis
- CT scan (test of choice): very useful for assessment of severity and prognosis; usually done with rectal contrast
  - 97% sensitive, 99% specific
  - increased soft tissue density within pericolic fat secondary to inflammation, diverticula secondary to inflammation, bowel wall thickening, soft tissue mass (pericolic fluid, abscesses), fistula
  - 10% of diverticulitis cannot be distinguished from carcinoma
- elective evaluation: establish extent of disease and rule out other diagnoses (polyps, malignancy)
  - colonoscopy or barium enema and flexible sigmoidoscopy

Treatment
- uncomplicated: conservative management
- outpatient: clear fluids only until improvement and antibiotics (e.g. cefazolin and metronidazole) 7-10 d to cover gram negative rods and anaerobes (e.g. B. fragilis)
- hospitalize: if severe presentation, inability to tolerate oral intake, significant comorbidities, fail to improve outpatient management
- treat with NPO, IV, IV antibiotics (e.g. IV ceftriaxone + metronidazole)
- indications for surgery
  - unstable patient with peritonitis
  - Hinchey stage 3-4
  - after 1 attack if immunosuppressed
- consider if recurrent episodes of diverticulitis (3 or more), recent trend is toward conservative management of recurrent mild/moderate attacks
- complications: perforation, abscess, fistula, obstruction, hemorrhage, inability to rule out colon cancer on endoscopy, or failure of medical management
- surgical procedures
  - for unstable patient or complex cases: Hartmann procedure
    - colon resection + colostomy and rectal stump → colostomy reversal in 3-6 mo
  - for more stable patients with Hinchey stage III and IV acute diverticulitis, colonic resection, primary anastomosis + diverting loop ileostomy is becoming more common, with benefits for mortality and morbidity
- laparoscopic peritoneal lavage with drain placement near the affected colon, in addition to IV antibiotics (NO resection) has been proposed for Hinchey stage III

Prognosis
- mortality rates: 6% for purulent peritonitis, 35% for feculent peritonitis
- recurrence rates: 13-30% after first attack, 30-50% after second attack

Table 13. Hinchey Staging and Treatment for Diverticulitis

<table>
<thead>
<tr>
<th>Hinchey Stage</th>
<th>Description</th>
<th>Acute Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Phlegmon/small pericolic abscess</td>
<td>Medical</td>
</tr>
<tr>
<td>2</td>
<td>Large abscess/fistula</td>
<td>Medical, abscess drainage ± resection with primary anastomosis</td>
</tr>
<tr>
<td>3</td>
<td>Purulent peritonitis (ruptured abscess)</td>
<td>Resection or Hartmann procedure</td>
</tr>
<tr>
<td>4</td>
<td>Feculent peritonitis</td>
<td>Hartmann procedure</td>
</tr>
</tbody>
</table>
Colorectal Neoplasms

Colorectal Polyps

Definition
- polyp: protuberance into the lumen of normally flat colonic mucosa
- sessile (flat) or pedunculated (on a stalk)

Epidemiology
- 30% of the population have polyps by age 50, 40% by age 60, 50% by age 70

Clinical Features
- 50% in the rectosigmoid region, 50% are multiple
- usually asymptomatic, do not typically bleed, tenesmus, intestinal obstruction, mucus
- usually detected during routine endoscopy or familial/high risk screening

Pathology
- non-neoplastic
  - hyperplastic: most common non-neoplastic polyp
  - mucosal polyps: small <5 mm, no clinical significance
  - inflammatory pseudopolyps: associated with IBD, no malignant potential
  - submucosal polyps: lymphoid aggregates, lipomas, leiomyomas, carcinoids
- neoplastic
  - lipomas, leiomyomas, carcinoids
  - hamartomas: juvenile polyps (large bowel), Peutz-Jegher syndrome (small bowel)
    - malignant risk due to associated adenomas (large bowel)
  - low malignant potential → most spontaneously regress or autoamputate
  - adenomas: premalignant, considered carcinoma in situ IF high grade dysplasia
    - some may contain invasive carcinoma ("malignant polyp" – 3-9%): invasion into submucosa
      - malignant potential: villous > tubulovillous > tubular

Table 14. Characteristics of Tubular vs. Villous Polyps

<table>
<thead>
<tr>
<th></th>
<th>Tubular</th>
<th>Villous</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence</td>
<td>Common (60-80%)</td>
<td>Less common (10%)</td>
</tr>
<tr>
<td>Size</td>
<td>Small (&lt;2 cm)</td>
<td>Large (usually &gt;2 cm)</td>
</tr>
<tr>
<td>Attachment</td>
<td>Pedunculated</td>
<td>Sessile</td>
</tr>
<tr>
<td>Malignant Potential</td>
<td>Lower</td>
<td>Higher</td>
</tr>
<tr>
<td>Distribution</td>
<td>Even</td>
<td>Left-sided predominance</td>
</tr>
</tbody>
</table>

Investigations
- colonoscopy is the gold standard for diagnosis and treatment of colonic polyps
- CT colonography: increasing in availability; patients still require bowel prep and will require colonoscopy if polyps are identified
- other: flexible sigmoidoscopy if polyps are detected, proceed to colonoscopy for examination of entire bowel and biopsy

Treatment
- indications: symptoms, malignancy or risk of malignancy (i.e. adenomatous polyps)
- endoscopic removal of entire growth
- indications for segmental resection for malignant polyps: 1) lymphovascular invasion; 2) tumour budding; 3) positive resection margin; 4) poorly differentiated cells; 5) evidence of regional or distant metastases on staging. Most of these cases are usually discussed at multi-disciplinary tumour boards
- follow-up endoscopy 1 yr later, then every 3-5 yr

Familial Colon Cancer Syndromes

FAMILIAL ADENOMATOUS POLYPOSIS

Pathogenesis
- autosomal dominant inheritance, mutation in adenomatous polyposis coli (APC) gene on chromosome 5q21
Clinical Features

- hundreds to thousands of colorectal adenomas usually by age 20 (by 40s in attenuated FAP)
- extracolonic manifestations
  - carcinoma of small bowel (i.e. polyps in colon), bile duct, pancreas, stomach, thyroid, adrenal, small bowel
  - congenital hypertrophy of retinal pigment epithelium presents early in life in 2/3 of patients; 97% sensitivity
  - virtually 100% lifetime risk of colon cancer (because of number of polyps)
- variants
  - Gardner’s syndrome: FAP + extra-intestinal lesions (sebaceous cysts, osteomas, desmoid tumours)
  - Turcot syndrome: FAP + CNS tumours (childhood cerebellar medulloblastoma)

Investigations

- genetic testing (80-95% sensitive, 99-100% specific)
- if no polyposis found: annual flexible sigmoidoscopy from puberty to age 50, then routine screening
- if polyposis or APC gene mutation found: annual colonoscopy and consider surgery (see Figure 14); consider upper endoscopy to evaluate for periampullary tumours

Treatment

- surgery indicated by age 17-20
- total proctocolectomy with ileostomy or total colectomy with ileorectal anastomosis
- doxorubicin-based chemotherapy
- NSAIDs for intra-abdominal desmoids

HEREDITARY NON-POLYPOSIS COLORECTAL CANCER – LYNCH SYNDROME

Pathogenesis

- autosomal dominant inheritance, mutation in a DNA mismatch repair gene (MSH2, MSH6, MLH1) resulting in microsatellite genomic instability and subsequent mutations
- microsatellite instability account for approximately 15% of all colorectal cancers

Clinical Features

- early age of onset, right > left colon, synchronous and metachronous lesions
- mean age of cancer presentation is 44 yr, lifetime risk 70-80% (M>F)
- HNPCC I: hereditary site-specific colon cancer
- HNPCC II: cancer family syndrome – high rates of extracolonic tumours (endometrial, ovarian, hepatobiliary, small bowel)

Diagnosis

- Amsterdam Criteria
  - 3 or more relatives with verified Lynch syndrome associated cancers, and 1 must be 1st degree relative of the other 2
  - 2 or more generations involved
  - 1 case must be diagnosed before 50 yr old
  - FAP is excluded
- genetic testing (80% sensitive) – colonoscopy mandatory even if negative
  - refer for genetic screening individuals who fulfill EITHER the Amsterdam Criteria OR the revised Bethesda Criteria
- colonoscopy (starting age 20) annually
- surveillance for extracolonic lesions

Treatment

- total colectomy and ileorectal anastomosis with annual proctoscopy

Colorectal Carcinoma

Epidemiology

- 4th most common cancer (after lung, prostate, and breast), 2nd most common cause of cancer death

Risk Factors

- most patients have no specific risk factors
- age >50 (dominant risk factor in sporadic cases), mean age is 70
- genetic: FAP, HNPCC, family history of CRC
- colonic conditions
  - adenomatous polyps (especially if >1 cm, villous, multiple)
  - IBD (especially UC: risk is 1-2%/yr if UC >10 yr)
  - previous colorectal cancer (also gonadal or breast)
  - diet (increased fat, red meat, decreased fibre) and smoking
  - DM and acromegaly (insulin and IGF-1 are growth factors for colonic mucosal cells)
Pathogenesis
- adenoma-carcinoma sequence; rarely arise de novo

Clinical Features
- often asymptomatic
- hematochezia/melena, abdominal pain, change in bowel habits
- others: weakness, anemia, weight loss, palpable mass, obstruction
- 20% patients have distant metastatic disease at time of presentation
- spread
  - direct extension, lymphatic, hematogenous (liver most common, lung, bone, brain; tumour of distal rectum → IVC → lungs)
  - peritoneal seeding: ovary, Blumer's shelf (pelvic cul-de-sac)

### Table 15. Clinical Presentation of CRC

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Pathology</th>
<th>Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td>25%</td>
<td>Exophytic lesions with occult bleeding</td>
<td>Weight loss, weakness, rarely obstruction</td>
</tr>
<tr>
<td>35%</td>
<td>Annular, invasive lesions</td>
<td>Constipation → overflow (alternating bowel patterns), abdominal pain, decreased stool calibre, rectal bleeding</td>
</tr>
<tr>
<td>30%</td>
<td>Ulcerating</td>
<td>Obstruction, tenesmus, rectal bleeding</td>
</tr>
</tbody>
</table>

Investigations
- colonoscopy (best), look for synchronous lesions (3-5% of patients); alternative: air contrast barium enema (“apple core” lesion) + sigmoidoscopy
- laboratory: CBC, urinalysis, liver enzymes, liver function tests, carcinogenic embryonic antigen (CEA)
  - (pre-operative for baseline, >5 ng/mL have worse prognosis)
- staging: CT chest/abdomen/pelvis; bone scan, CT head only if lesions suspected
- rectal cancer: pelvic MRI or endorectal U/S to determine T and N stage
- other: weakness, anemia, weight loss, palpable mass, obstruction

### Table 16. TNM Classification System for Staging of Colorectal Carcinoma (AJCC/UICC 2010)

<table>
<thead>
<tr>
<th>Primary Tumour (T)</th>
<th>Regional Lymph Nodes (N)</th>
<th>Distant Metastasis (M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>T0</td>
<td>N0</td>
<td>M0 No distant metastasis</td>
</tr>
<tr>
<td>T1</td>
<td>N1</td>
<td>M1 Distinct metastasis</td>
</tr>
<tr>
<td>T2</td>
<td>N2</td>
<td>M0 No distant metastasis</td>
</tr>
<tr>
<td>T3</td>
<td>N3</td>
<td>M1 Distinct metastasis</td>
</tr>
<tr>
<td>T4</td>
<td>N4</td>
<td>M0 No distant metastasis</td>
</tr>
</tbody>
</table>

### Treatment

- colon cancer
  - wide surgical resection of lesion and regional lymphatic drainage; usually colectomy with primary anastomosis
  - curative: wide resection of lesion (5 cm margins) with nodes (>12) and mesentery
  - metastatic lesions confined to the liver can be resected with curative intent
  - palliative: if distant spread, local control for hemorrhage or obstruction
  - care is taken to not spread tumour by unnecessary palpation
  - cancer-bearing portion of colon is removed according to vascular distribution of segment
  - adjuvant chemotherapy (5-FU or oral capcitabine with oxaliplatin) for stage III and is considered in select stage II patients
- rectal cancer
  - choice of operation depends on individual case; types of operations
  - low anterior resection of rectum (LAR): curative procedure of choice if adequate distal margins (~2cm); uses technique of total mesorectal excision
  - abdominoperineal resection of rectum (APR): if adequate distal margins cannot be obtained; involves the removal of distal sigmoid colon, rectum, and anus – permanent end colostomy required
  - transanal minimally invasive surgery (TAMIS)- local excision for select T1 lesions only
  - palliative procedures involve proximal diversion with an ostomy for obstruction and radiation for bleeding or pain
  - adjuvant therapy
  - combined neoadjuvant chemoradiation therapy followed by post-operative adjuvant chemotherapy for stages II and III

---

**Figure 16. APR vs. LAR**

5-yr Survival Rates for CRC
- Colon
- Rectum
- Stage I: 74% vs. 74%
- Stage II: 67% vs. 64%
- Stage III: 59% vs. 52%
- Stage IV: 37% vs. 32%
- Stage IIIA: 73% vs. 74%
- Stage IIIB: 46% vs. 45%
- Stage IIIC: 28% vs. 33%
- Stage IV: 6% vs. 6%

**Conclusion:**
- There is long-term reduction in local recurrence of stage II rectal cancer with pre-operative chemotherapy, but no improvement in overall survival or distant recurrence of disease.

**Methods:**
- Patients with stage II to III rectal cancer (n = 799) were randomly assigned to pre-operative (n = 400) or post-operative CRT (n = 399) with fluorouracil (5-FU), radiation, and adjuvant FU chemotherapy, in addition to total mesorectal excision surgery. Follow-up was designed to assess long-term overall survival as the primary end point, and cumulative incidence of local and distant relapses and disease-free survival as secondary end points.

**Results:**
- 10-yr incidence of local relapse was significantly lower in the pre-operative CRT group than in the post-operative group (7.1% vs. 10.1%, p = 0.0048).
- Overall survival at 10 yr was similar at ~60% for patients treated with pre-operative or post-operative CRT (p = 0.08). Disease-free survival rates at 10 yr were similar at ~88% for patients treated with pre-operative or post-operative CRT (p = 0.56). No significant difference was detected for 10-yr incidence of distant metastases (pre-operative CRT 28.9% vs. post-operative CRT 25.6%, p = 0.18).
- Conclusion: There is long-term reduction in local recurrence of stage II to III rectal cancer with pre-operative chemotherapy, but no improvement in overall survival or distant recurrence of disease.
Follow-Up
• currently there are no data suggesting optimal follow-up
• combination of periodic CT chest/abdomen/pelvis, CEA, and colonoscopy is recommended
• CEA to monitor for initial response to treatment, and for surveillance (q6months)

Other Conditions of the Large Intestine

Angiodysplasia

Definition
• vascular anomaly: focal submucosal venous dilatation and tortuosity

Clinical Features
• most frequently in right colon of patients >60 yr old
• bleeding typically intermittent, rarely massive, not usually hypotensive (melena, anemia, guaiac positive stools)

Investigations
• colonoscopy: cherry red spots, branching pattern from central vessel
• angiography: early-filling vein, vascular tuft, delayed emptying vein; rarely active bleeding
• RBC technetium-99 scan
• barium enema is contraindicated (obscures other x-rays, i.e. angiogram)

Treatment
• none if asymptomatic
• cautery, right hemicolectomy, embolization, vasopressin infusion, sclerotherapy, band ligation, laser, octreotide, and rarely segmental resection if other treatments fail

Volvulus

Definition
• rotation of segment of bowel about its mesenteric axis
• sigmoid (65%), cecum (30%), transverse colon (3%), splenic flexure (2%)
• 5-10% of large bowel obstruction; 25% of intestinal obstruction during pregnancy

Risk Factors
• age (30% of patients >70 yr: stretching/elongation of bowel with age is a predisposing factor)
• high fibre diet (can cause elongated/redundant colon), chronic constipation, laxative abuse, pregnancy, bedridden, institutionalization (less frequent evacuation of bowels)
• congenital hypermobile cecum

Clinical Features
• symptoms due to bowel obstruction (see Large Bowel Obstruction, GS29) or intestinal ischemia (see Intestinal Ischemia, GS23)
• colicky abdominal pain, persistence of pain between spasms, abdominal distention, vomiting

Investigations
• AXR (classic findings): “omega”, “bent inner-tube”, “coffee-bean” signs
• barium/Gastrografin enema: “ace of spades” or “bird’s beak” appearance due to funnel-like luminal tapering of lower segment towards volvulus
• sigmoidoscopy or colonoscopy as appropriate
• CT

Treatment
• initial supportive management (same as initial management for bowel obstruction (see Large Bowel Obstruction, GS29)
• cecum
  • nonsurgical
    • may attempt colonoscopic detorsion and decompression
  • surgical
    • right colectomy + ileotransverse colonic anastomosis
• sigmoid
  • nonsurgical
    • decompression by flexible sigmoidoscopy and insertion of rectal tube past obstruction
    • subsequent elective surgery recommended (50-70% recurrence)
  • surgical: Hartmann procedure (if urgent)
    • indications: strangulation, perforation, or unsuccessful endoscopic decompression
Toxic Megacolon

Pathogenesis
- extension of inflammation into smooth muscle layer causing paralysis
- damage to myenteric plexus and electrolyte abnormalities are not consistently found

Etiology
- inflammatory bowel disease (ulcerative colitis > Crohn's disease)
- infectious colitis: bacterial (C. difficile, Salmonella, Shigella, Campylobacter), viral (cytomegalovirus), parasitic (E. histolytica)

Clinical Features
- infectious colitis usually presents for >1 wk before colonic dilatation
- diarrhea ± blood (but improvement of diarrhea may portend onset of megacolon)
- abdominal distention, tenderness, ± local/general peritoneal signs (suggest perforation)
- triggers: hypokalemia, constipating agents (opioids, antidepressants, loperamide, anticholinergics), barium enema, colonoscopy

Diagnostic Criteria
- must have both colitis and systemic manifestations for diagnosis
- radiologic evidence of dilated colon
- three of: fever, HR >120, WBC >10.5, anemia
- one of: fluid and electrolyte disturbances, hypotension, altered LOC

Investigations
- CBC (leukocytosis with left shift, anemia from bloody diarrhea), electrolytes, elevated CRP, ESR
- metabolic alkalosis (volume contraction and hypokalemia) and hypoalbuminemia are late findings
- AXR: dilated colon >6 cm (right > transverse > left), loss of haustra
- CT: useful to assess underlying disease

Treatment
- NPO, NGT, stop constipating agents, correct fluid and electrolyte abnormalities, transfusion
- serial AXRs
- broad-spectrum antibiotics (reduce sepsis, anticipate perforation)
- aggressive treatment of underlying disease (e.g. steroids in IBD, metronidazole for C. difficile)
- indications for surgery (50% improve on medical management)
- worsen in other toxicity or dilation after 48-72 h
- severe hemorrhage, perforation
- high lactate and WBC especially for C. difficile
- procedure: subtotal colectomy + end ileostomy (may be temporary, with second operation for re-anastomosis later)

Prognosis
- average 25-30% mortality

Fistula

Definition
- abnormal communication between two epithelialized surfaces (e.g. enterocutaneous, colovesical, aortoenteric, entero-enteric)

Etiology
- foreign body erosion (e.g. gallstone, graft)
- inflammatory states (e.g. infection, IBD [especially Crohn's], diverticular disease)
- iatrogenic/surgery (e.g. post-operative anastomotic leak, radiation)
- congenital, trauma
- neoplastic

Investigations
- U/S, CT scan, fistulogram
- measure amount of drainage from fistula

Treatment
- decrease secretion: octreotide/somatostatin/omeprazole
- surgical intervention: dependent upon etiology (for non-closing fistulas); uncertainty of diagnosis
Stomas

Definition
• an opening of the GI tract onto the surface of the abdomen wall
  • stomas can be constructed as either end stomas: the proximal end of the GI tract forms the stoma and the distal end of the GI tract is not part of the stoma, or loop stomas: a loop of the GI tract is brought up to the skin and the anti-mesenteric surface of the bowel is matured as a stoma. The proximal and distal GI tract remain in continuity

Ileostomy
• usually positioned in RLQ; ileum is brought through rectus abdominus muscles
• indications: after protocolectomy for ulcerative colitis, in some cases of Crohn’s disease or familial polyposis
• conventional ileostomy: discharges small quantities of liquid material continuously, appliance (plastic bag attached to a sheet of protective material) required at all times
• continent ileostomy: reservoir is constructed from distal ileum, emptied by inserting catheter into stoma several times a day; rarely used, has mostly been replaced by ileal pouch anal anastomosis

Colostomy
• indications: to decompress an obstructed colon, to protect a distal anastomosis after resection, or to evacuate stool after distal colon or rectum is removed
• colostomies can be done by making an opening in a loop of colon (loop colostomy) or by dividing the colon and bringing out one end (end colostomy)
• most common permanent colostomy is a sigmoid colostomy – expels stool once per day, no appliance required
• chronic paracolostomy hernia is a common complication

Complications (10%)
• obstruction: herniation, stenosis (skin and abdominal wall), adhesive bands, volvulus
• peri-ileostomy abscess and fistula
• skin irritation
• prolapse or retraction
• diarrhea (excessive output)

Figure 17. Ostomies

Hemorrhoids

Etiology
• vascular and connective tissue complexes form a plexus of dilated veins (cushion)
• internal: superior hemorrhoidal veins, above dentate line, portal circulation
• external: inferior hemorrhoidal veins, below dentate line, systemic circulation

Risk Factors
• increased intra-abdominal pressure: chronic constipation, pregnancy, obesity, portal HTN, heavy lifting

Figure 19. Hemorrhoids
**Clinical Features and Treatment**

- **internal hemorrhoids**
  - engorged vascular cushions usually at 3, 7, 11 o’clock positions (patient in lithotomy position)
  - **PAINLESS** rectal bleeding, anemia, prolapse, mucus discharge, pruritus, burning pain, rectal fullness
    - 1st degree: bleed but do not prolapse through the anus
      - treatment: high fibre/bulk diet, sitz baths, steroid cream, paroxine (Anusol™), rubber band ligation, sclerotherapy, photocoagulation
    - 2nd degree: bleed, prolapse with straining, spontaneous reduction
      - treatment: rubber band ligation, photocoagulation
    - 3rd degree: bleed, prolapse, requires manual reduction
      - treatment: same as 2nd degree, but may require closed hemorrhoidectomy
    - 4th degree: bleed, permanently prolapsed, cannot be manually reduced
      - treatment: closed hemorrhoidectomy
  - **external hemorrhoids**
    - dilated venules usually mildly symptomatic
    - **PAIN** after bowel movement, associated with poor hygiene
    - medical treatment: dietary fibre, stool softeners, steroid cream (short course), paroxine (Anusol™), avoid prolonged straining
    - thrombosed hemorrhoids are very painful
    - resolve within 2 wk, may leave excess skin = perianal skin tag
    - treatment: consider surgical decompression within first 48 h of thrombosis, otherwise medical treatment

<table>
<thead>
<tr>
<th>Internal Hemorrhoids</th>
<th>External Hemorrhoids</th>
</tr>
</thead>
<tbody>
<tr>
<td>Painless BRBPR</td>
<td>Sudden severe perianal pain</td>
</tr>
<tr>
<td>Rectal fullness or discomfort</td>
<td>Perianal mass</td>
</tr>
<tr>
<td>Mucus discharge</td>
<td></td>
</tr>
</tbody>
</table>

**Table 17. Signs and Symptoms of Internal vs. External Hemorrhoids**

**Anal Fissures**

**Definition**
- tear of anal canal below dentate line (very sensitive squamous epithelium)
- 90% posterior midline, 10% anterior midline
- if off midline: consider other possible causes such as IBD, STIs, TB, leukemia, or anal carcinoma
- repetitive injury cycle after first tear
  - sphincter spasm occurs preventing edges from healing and leads to further tearing
  - ischemia may ensue and contribute to chronicity

**Etiology**
- forceful dilation of anal canal: large, hard stools and irritant diarrheal stools
- tightening of anal canal secondary to nervousness/pain leads to further tearing
- others: habitual use of cathartics, childbirth

**Clinical Features**
- **acute fissure**
  - very painful bright red bleeding especially after bowel movement, sphincter spasm on limited DRE
  - treatment is conservative: stool softeners, bulking agent, sitz baths (heals 90%)
  - triad: fissure, sentinel skin tags, hypertrophied papillae
  - treatment
    - stool softeners, bulking agents, sitz baths
    - topical nitroglycerin or nifedipine: increases local blood flow, promoting healing and relieves sphincter spasm
    - lateral internal anal sphincterotomy (most effective): objective is to relieve sphincter spasm → increases blood flow and promotes healing; but 5% chance of fecal incontinence therefore not commonly done
    - alternative treatment
      - botulinum toxin: inhibits release of acetylcholine (ACh), reducing sphincter spasm
### Anorectal Abscess

**Definition**
- infection in one or more of the anal spaces
- usually bacterial infection of blocked anal gland at the dentate line
- *E. coli, Proteus, Streptococci, Staphylococci, Bacteroides, anaerobes*

**Clinical Features**
- throbbing pain that may worsen with straining and ambulation
- abscess can spread vertically downward (perianal), vertically upward (supralevator), or horizontally (ischiorectal)
- tender perianal/rectal mass on exam

**Treatment**
- I&D
  - curative in 50% of cases
  - 50% develop anorectal fistulas
  - may require antibiotics if diabetic, heart murmur, or cellulitis

### Fistula-In-Ano

**Definition**
- anal fistula from rectum to perianal skin
- an inflammatory tract with internal os at dentate line, external os on skin

**Etiology**
- see Fistula, GS37
- same perirectal process as an anal abscess, therefore usually associated with an abscess
- other causes: post-operative, trauma, anal fissure, malignancy, radiation proctitis

**Clinical Features**
- intermittent or constant purulent discharge from perianal opening
- pain
- palpable cord-like tract

**Treatment**
- identification
  - internal opening
    - Goodsall’s rule
      - fistulas originating anterior to a transverse line through the anus will have a straight course and exit anteriorly, whereas those originating posterior to the transverse line will begin in the midline and have a curved tract
  - fistulous tract
    - probing or fistulography under anesthesia

---

Recurrent perianal abscesses is associated with Crohn’s disease

Antibiotics are not typically helpful in the treatment of perianal abscesses
• surgery
  ■ fistulotomy: unroof tract from external to internal opening, allow drainage, heals by secondary intention
  ■ low lying fistula (does not involve external sphincter) → primary fistulotomy
  ■ high lying fistula (involves external sphincter) → staged fistulotomy with Seton suture placed through tract
    • promotes drainage
    • promotes fibrosis and decreases incidence of incontinence
    • delineates anatomy
    • usually done to spare muscle cutting

Post-Operative
• sitz baths, irrigation, and packing to ensure healing proceeds from inside to outside

Complications
• recurrence
• rarely fecal incontinence

**Pilonidal Disease**

**Definition**
• chronic recurring abscess or chronic draining sinus in sacrococcygeal area

**Epidemiology**
• occurs most frequently in young men age 15-40 yr; rare in >50 yr

**Etiology**
• obstruction of the hair follicles in this area → formation of cysts, sinuses, or abscesses

**Clinical Features**
• asymptomatic until acutely infected, then pain/tenderness, purulent discharge, inspissated hair

**Treatment**
• acute abscess
  ■ I&D (often performed by primary care doctors)
  ■ wound packed open
  ■ 40% develop chronic pilonidal sinuses
• surgery
  ■ indication: failure of healing after I&D, recurrent disease, complex disease
  ■ pilonidal cystotomy: excision of sinus tract and cyst; wound closed by secondary intention, primary closure with tissue flap, or marsupialization (cyst edge sewn to surrounding tissue to leave sinus tract open)

**Rectal Prolapse**

**Definition**
• protrusion of some or all of rectal mucosa through external anal sphincter

**Epidemiology**
• extremes of ages: <5 yr old and >5th decade
  ■ 85% women

**Etiology**
• lengthened attachment of rectum secondary to constant straining
  • 2 types
  1. false/partial/mucosal: protrusion of mucosa only, radial furrows at junction with anal skin; most common type of rectal prolapse in childhood
  2. true/complete (most common): full thickness extrusion of rectal wall, concentric folds in:
    • first degree: prolapse includes mucocutaneous junction
    • second degree: without involvement of mucocutaneous junction
    • third degree (internal intussusception): prolapse is internal, concealed, or occult

**Risk Factors**
• gynecological surgery
• chronic neurologic/psychiatric disorders affecting motility
Clinical Features
- extrusion of mass with increased intra-abdominal pressure
  - straining, coughing, laughing, Valsalva
- difficulty in bowel regulation
  - tenesmus, constipation, fecal incontinence
- permanently extruded rectum with excoriation, ulceration, and constant soiling
- may be associated with urinary incontinence or uterine prolapse

Treatment
- Type I
  - conservative: gentle manual reduction of prolapsed area, especially in children
  - mucosectomy with excision of redundant mucosa, mostly in adults
- Type II
  - conservative: reduce if possible
  - surgery: abdominal, perineal, transsacral approaches

Anal Neoplasms

ANAL CANAL

Squamous Cell Carcinoma of Anal Canal (Above Dentate Line)
- most common tumour of anal canal (75%)
- anus prone to human papillomavirus (HPV) infection, therefore at risk for anal squamous intra-epithelial lesions (ASIL)
  - high grade squamous intra-epithelial lesion (HSIL) and low grade squamous intra-epithelial lesion (LSIL) terminology used
- clinical features: anal bleeding, pain, mass, ulceration, pruritus; 25% asymptomatic
- treatment: chemotherapy ± radiation ± surgery
- prognosis: 80% 5-yr survival

Malignant Melanoma of Anal Canal
- 3rd most common site for primary malignant melanoma after skin, eyes
- aggressive, distant metastases common at time of diagnosis
- treatment: wide excision or APR ± chemoradiation
- prognosis: <5% 5 yr survival

ANAL MARGIN
- clinical features and treatment as for skin tumours elsewhere
- squamous and basal cell carcinoma, Bowen’s disease (SCC in situ), and Paget’s disease
Liver Cysts

Table 18. Characteristics of Liver Cysts

<table>
<thead>
<tr>
<th>Description</th>
<th>Simple Cysts</th>
<th>Polycystic Liver Disease</th>
<th>Choledochal Cysts</th>
<th>Hydatid (Cystic Echinococcosis)</th>
<th>Cystadenoma (Premalignant)/Cystadenocarcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description</td>
<td>Contain clear fluid that do not communicate with the intrahepatic biliary tree</td>
<td>Several cysts that replace much of the liver</td>
<td>Congenital malformations of pancreaticobiliary tree high risk of malignancy majority present before age 10</td>
<td>Infection with parasite Echinococcus granulosus associated with exposure to dogs, sheep, and cattle in Southern Europe, Middle East, Australasia, South America</td>
<td>Rare cystic tumours that occur in the liver parenchyma or the extrahepatic bile ducts Cystadenocarcinoma is an invasive carcinoma</td>
</tr>
<tr>
<td>Clinical Features</td>
<td>Usually asymptomatic may have multiple simple cysts</td>
<td>Progressive 50% associated with polycystic kidney disease</td>
<td>Recurrent abdominal pain Intermittent jaundice RUG mass Cholangitis Panreatitis</td>
<td>Asymptomatic mass chronic pain Hepatomegaly</td>
<td>Upper abdominal mass Abdominal pain Anorexia</td>
</tr>
<tr>
<td>Investigations</td>
<td>U/S: Used for diagnosis and follow-up CT: well demarcated lesion that does not enhance with contrast</td>
<td>U/S CT Transhepatic cholangiography LFTs</td>
<td>Anti-Echinococcus Ab (IgG) U/S CT: calcified mass Needle biopsy</td>
<td></td>
<td>Appearance as complex cysts: internal septae, papillary projections, irregular lining Need histology for definite diagnosis</td>
</tr>
<tr>
<td>Treatment</td>
<td>Not required unless very large Monitor if &gt;4 cm</td>
<td>Only if symptomatic partial liver resection drainage</td>
<td>Complete excision of cysts liver transplant if cyst involves intrahepatic bile ducts (Caroll’s disease)</td>
<td>Albendazole (anti-helminthic) – cure up to 30% Surgical (risk of spillage into abdomen): Conservative: open endocystectomy or PAIR (Percutaneous Aspiration, Injection of protoscolicidal agent, Re-aspiration) Radical: partial heptectomy or total pericystectomy</td>
<td>All complex, multiloculated cysts (except echinococcal) should be excised because of malignancy risk</td>
</tr>
<tr>
<td>Complications</td>
<td>Intracytic hemorrhage</td>
<td>Bilary cirrhosis, portal HTN, rupture, cholangiocarcinoma Abnormal pancreatobiliary junction is associated with increased risk of malignancy</td>
<td>Inferior vena cava compression rupture can cause biliary colic, jaundice, cholangitis, pancreatitis, or anaphylactic reaction</td>
<td>Cystadenocarcinoma can invade adjacent tissues and metastasize</td>
<td></td>
</tr>
</tbody>
</table>

Liver Abscesses

Etiology
- types
- pyogenic (bacterial): most common etiology; most often polymicrobial – E. coli, Klebsiella, Proteus, Strep. milleri
- parasitic (amoebic): Entamoeba histolytica, Echinococcal cyst
- fungal: Candida
- sources: direct spread from biliary tract infection, portal spread from GI infection, systemic infection (e.g. endocarditis)

Clinical Features
- fever, malaise, chills, anorexia, weight loss, abdominal pain, nausea
- RUQ tenderness, hepatomegaly, jaundice

Investigations
- leukocytosis, anemia, elevated liver enzymes, echinococcal serology
- U/S, CXR (right basilar atelectasis/effusion), CT, cyst aspiration with C&S, MRI

Treatment
- treat underlying cause
- bacterial abscesses generally will treat initially with antibiotics, and add surgical or percutaneous drainage and IV antibiotics for larger abscesses (initially ceftriaxone + metronidazole or piperacillin/tazobactam)
- consider potential source of sepsis (e.g. biliary source, infected tumour)

Prognosis
- overall mortality 15% – higher rate if delay in diagnosis, multiple abscesses, malnutrition
Neoplasms

BENIGN LIVER NEOPLASMS

Hemangioma (cavernous)
- pathogenesis: most common benign hepatic tumour; results from malformation of angioblastic fetal tissue
- risk factors: F:M = 3:1
- clinical features
  - usually small and asymptomatic
  - consumptive coagulopathy if giant (in children)
- investigations
  - contrast CT (well-demarcated hypodense mass with peripheral enhancement on arterial phase with centripetal filling on delayed phases), U/S (homogenous hyperchoic mass), MRI
  - avoid biopsy: may result in hemorrhage
- treatment
  - usually none

Focal Nodular Hyperplasia
- pathogenesis: unclear, may be regenerative response to hyperperfusion from anomalous arteries at centre of nodule
- risk factors: female, age 20-50
- clinical features: asymptomatic, rarely grows or bleeds, no malignant potential
- investigations: central stellate scar on CT scan; MRI, biopsy may be required
- treatment: may be difficult to distinguish from adenoma/fibrolamellar HCC (malignant potential)
  - if confirmed to be FNH → no treatment required

Adenoma
- definition: benign glandular epithelial tumour
- risk factors: female, age 20-50, estrogen (OCP pregnancy)
- clinical features: asymptomatic, 25% present with RUQ pain or mass, may present with bleeding
- investigations: CT (well-demarcated masses, often heterogeneous enhancement on arterial phase, isodense on venous phase without washout of contrast), U/S, MRI, biopsy often needed
- treatment
  - stop anabolic steroids or OCP
  - excise, especially if large (>5 cm), due to risk of transformation to hepatocellular carcinoma and spontaneous rupture/hemorrhage

MALIGNANT LIVER NEOPLASMS

Primary
- most commonly hepatocellular carcinoma (HCC) and cholangiocarcinomas
- others include angiosarcoma, hepatoblastoma, hemangiendothelioma, HCC
- epidemiology: 3rd leading cause of cancer death worldwide, 9th in United States; highest in Africa, China, Taiwan
- risk factors
  - chronic liver inflammation: cirrhosis from any cause, chronic hepatitis B (inherently oncogenic) and hepatitis C, hemochromatosis, α1-antitrypsin deficiency
  - medications: OCPS (3x increased risk), steroids
  - smoking, alcohol, Betel nuts
  - chemical carcinogens (aflatoxin, microcystin, vinyl chloride – associated with angiosarcoma)
- clinical features
  - RUQ discomfort, right shoulder pain
  - jaundice, weakness, weight loss, ± fever (if central tumour necrosis)
  - hepatomegaly, bruit, hepatic friction rub
  - ascites with blood (sudden intra-abdominal hemorrhage)
  - paraneoplastic syndromes – hypoglycemia, hypercalcemia, erythrocytosis, watery diarrhea
  - metastasis: lung, bone, brain, peritoneal seeding
- investigations
  - elevated ALP, bilirubin, and α-fetoprotein (80% of patients)
  - U/S (poorly-defined margins with internal echoes), triphasic CT (enhancement on arterial phase and washout on portal venous phase), MRI
  - liver enzyme and liver function tests: AST, ALT, ALP, bilirubin, albumin, INR
- treatment
  - cirrhosis is a relative contraindication to tumour resection due to decreased hepatic reserve
  - surgical: resection (10% of patients have resectable tumours)
  - liver transplant; may use bridging therapy while awaiting transplant
    - absolute contraindications: extrahepatic disease, vascular invasion
    - relative contraindications: dependent on liver transplant protocol based on staging criteria followed by transplant centre

Child-Turcotte-Pugh Score (Prognosis of Chronic Liver Disease/Cirrhosis, Including Post-Operatively)

<table>
<thead>
<tr>
<th>Points</th>
<th>Class</th>
<th>One Yr Survival</th>
<th>Two Yr Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-6</td>
<td>A</td>
<td>100%</td>
<td>85%</td>
</tr>
<tr>
<td>7-9</td>
<td>B</td>
<td>81%</td>
<td>57%</td>
</tr>
<tr>
<td>10-15</td>
<td>C</td>
<td>45%</td>
<td>35%</td>
</tr>
</tbody>
</table>

Differential Diagnosis of Metastatic Liver Mass

<table>
<thead>
<tr>
<th>Mass Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Some GU Cancers Produce Bumpy Lumps</td>
<td></td>
</tr>
<tr>
<td>Stomach</td>
<td></td>
</tr>
<tr>
<td>Genito Urinary cancers (kidney, ovary, uterus)</td>
<td></td>
</tr>
<tr>
<td>Colon</td>
<td></td>
</tr>
<tr>
<td>Pancreas</td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td></td>
</tr>
</tbody>
</table>
non-surgical: radiofrequency ablation, percutaneous ethanol injection, transcatheter arterial chemoembolization (TACE), chemotherapy (consider sorafenib for HCC; pre-operative chemotherapy for hepatoblastoma is standard of care), radiotherapy

prognosis
- median survival: 6-20 mo
- 5 yr survival: all patients – 5%; patients undergoing complete resection – 11-40%

Secondary
- metastases to the liver are the most common malignant tumors found in the liver
- etiology
  - GI (colorectal most common), lung, breast, pancreas, ovary, uterus, kidney, gallbladder, prostate
- treatment
  - depends on the primary cancer site and prognosis. Often liver metastases are a manifestation of Stage IV disease, and chemotherapy is indicated
  - metastasectomy may be appropriate for some cancers
  - hepatic resection: metastatic colorectal liver metastases is standard of care as part of multi-modality treatment that includes chemotherapy if complete resection of the primary cancer and metastases is possible
  - prognosis following liver resection for colorectal metastases is an overall survival of 30-60% at 5 yr

Liver Transplantation

<table>
<thead>
<tr>
<th>Parenchymal Disease</th>
<th>Cholestatic Disease</th>
<th>Inborn Errors</th>
<th>Tumours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic hepatitis B or C*</td>
<td>Biliary atresia**</td>
<td>a1-antitrypsin deficiency</td>
<td>Hepatocellular carcinoma</td>
</tr>
<tr>
<td>Alcoholic cirrhosis</td>
<td>Primary biliary cirrhosis</td>
<td>Wilson’s disease</td>
<td>Homochromatosis</td>
</tr>
<tr>
<td>Acute liver failure</td>
<td>Sclerosing cholangitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Budd-Chiari syndrome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congenital hepatic fibrosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autoimmune hepatitis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cryptogenic cirrhosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug induced hepatotoxicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-alcoholic steatohepatitis</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*leading cause in adults; **leading cause in children

Clinical Indications
- early referral for transplant should be considered for all patients with progressive liver disease not responsive to medical therapy, especially:
  - decompensated cirrhosis (ascites, esophageal variceal hemorrhage, spontaneous hepatic encephalopathy, coagulopathy, progressive jaundice, severe fatigue)
  - unresetable primary liver cancers
  - fulminant hepatic failure
  - end-stage liver disease with life expectancy <1 yr and if no other therapy is appropriate
  - suitable HCC not amenable to liver resection

Criteria for Transplantation
- Model for End-Stage Liver Disease (MELD): prognostic model to estimate 3 mo survival and disease severity if patient does not receive transplant; based on creatinine, bilirubin, INR; MELD scores from 6-40 used to prioritize liver allocation
- Child-Turcotte-Pugh Score: classification system to assess the prognosis and mortality of liver disease; patient must have ≥7 points (Class B)

Contraindications
- active alcohol/substance abuse
- extrahepatic malignancy within 5 yr
- advanced cardiopulmonary disease
- active uncontrolled infection

Post-Operative Complications
- primary non-function (graft failure): urgent re-transplantation is indicated
- acute and chronic rejection, ischemia-reperfusion injury
- vascular: hepatic artery or portal vein thrombosis, IVC obstruction
- biliary complications: fever, increasing bilirubin and ALP
- complications related to immunosuppression: HTN, renal disease, DM, obesity, hyperlipidemia, osteoporosis, malignancy, neurologic complications, infection (leading cause of mortality following transplant)

Prognosis
- patient survival at 1 yr: 85%
- graft survival at 1 yr: >80%, at 5 yr: 60-70%

Liver Toronto Notes 2017

Secondary liver metastases are common in many cancers, with some studies showing a prevalence of 40-50% amongst patients with extrahepatic cancers. They commonly arise from breast, lung, and colorectal cancers. For metastases secondary to colorectal cancer, surgical resection offers the greatest likelihood of cure.

Living Liver Donors vs. Deceased Liver Donors
The right lobe of a living donor liver is transplanted into the recipient, whereas whole livers from deceased donors are transplanted orthotopically into the recipient.

Which Matters Most: Number of Tumours, Size of the Largest Tumour, or Total Tumour Volume?
Liver Transplant 2011;17:508-46
Purpose: To determine if the size and/or number of hepatocellular carcinoma (HCC) nodules predict disease recurrence and survival after liver transplantation.
Methods: Systematic review and meta-analysis.
Results: 74 studies were included for analysis. Patients beyond the Milan criteria had reduced overall and disease-free survivals and higher recurrence. Patients outside the UCSF criteria had reduced overall and disease-free survivals and higher recurrence. Patients outside the Milan criteria but within the UCSF criteria had reduced overall and disease-free survivals. Overall and disease-free survivals were reduced for patients with larger total tumour diameter, ≥10 cm vs. <10 cm and ≥8 cm vs. <8 cm, respectively. Similarly, patients with higher diameter of largest tumour nodule ≥3 cm vs. <3 cm had reduced overall survival and higher recurrence. Overall and disease-free survivals were reduced and recurrence higher for patients with tumour size ≥5 cm vs. <5 cm. Mixed results were found regarding number of tumour nodules.
Conclusion: Tumour size and volume are important factors in survival after liver transplantation.

Living Donor Liver Transplantation vs. Deceased Donor Liver Transplantation for Hepatocellular Carcinoma: Comparable Survival and Recurrence
Liver Transplant 2012;18:315-322
Purpose: To compare the overall survival and hepatocellular carcinoma (HCC) recurrence rates after living donor liver transplantation (LLT) versus deceased donor liver transplantation (DDLT) in a series of patients with HCC.
Methods: Study conducted between 1996 and 2009 at a single center. 345 patients with HCC undergoing liver transplantation included.
Results: The overall survival rates at 1, 3, and 5 yr did not significantly differ between the DDLT and DDLT (p=0.62). Disease-free survival at 1, 5, and 5 yr did not differ between the groups (p=0.62). The recurrence rates at 1, 3, and 5 yr also did not differ between the two groups (p=0.59).
Conclusion: LLT and DDLT lead to similar survival and recurrence rates.
Biliary Tract

Cholelithiasis

Definition
• the presence of gallstones

Pathogenesis
• imbalance of cholesterol and its solubilizing agents (bile salts and lecithin)
• excessive hepatic cholesterol secretion → bile salts and lecithin are “overloaded” → supersaturated cholesterol can precipitate and form gallstones
• North America: cholesterol stones (80%), pigment stones (20%)

Risk Factors
• cholesterol stones
  ■ obesity, age <50
  ■ estrogens: female, multiparity, OCPs
  ■ ethnicity: First Nations heritage (especially Pima Indians) > Caucasian > Black
  ■ terminal ileal resection or disease (e.g. Crohn’s disease)
  ■ impaired gallbladder emptying: starvation, TPN, DM
  ■ rapid weight loss: rapid cholesterol mobilization and biliary stasis
• pigment stones (contain calcium bilirubinate)
  ■ cirrhosis
  ■ chronic hemolysis
  ■ biliary stasis (strictures, dilation, biliary infection)
  ■ protective factors: statins, vitamin C, coffee, exercise

Risk Factors for Cholesterol Stones
4Fs
Fat
Female
Fertile
Forties

Clinical Presentation
• asymptomatic (80%)
  ■ most do NOT require treatment
  ■ consider cholecystectomy if: increased risk of malignancy (choledochal cysts, Caroli’s disease, porcelain or calcified gallbladder), sickle cell disease, pediatric patient, bariatric surgery, immunosuppression
• biliary colic (10-25%)
• cholecystitis
• choledocholithiasis (8-15%)
• cholangitis
• gallstone pancreatitis (see Acute Pancreatitis, GS51)
• gallstone ileus (0.3-0.5%)
• other: empyema of the gallbladder, liver abscess, gallbladder perforation with bile peritonitis

Figure 25. Gallstone disease

© Merry Shiyu Wang 2012

Summary of Biliary Tract Conditions

<table>
<thead>
<tr>
<th>Condition</th>
<th>Asymptomatic</th>
<th>Pain Only</th>
<th>Infection + Pain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholelithiasis</td>
<td>✓ (majority)</td>
<td>✓ (majority)</td>
<td>✓ (majority)</td>
</tr>
<tr>
<td>Cholecystitis</td>
<td>✓ (majority)</td>
<td>✓ (majority)</td>
<td>✓ (majority)</td>
</tr>
<tr>
<td>Common Bile Duct</td>
<td>✓ (majority)</td>
<td>✓ (majority)</td>
<td>✓ (majority)</td>
</tr>
<tr>
<td>Choledocholithiasis</td>
<td>✓ (majority)</td>
<td>✓ (majority)</td>
<td>✓ (majority)</td>
</tr>
<tr>
<td>Cholangitis</td>
<td>✓ (majority)</td>
<td>✓ (majority)</td>
<td>✓ (majority)</td>
</tr>
</tbody>
</table>
Investigations
- Labs
  - CBC, LFTs, amylase, and lipase
- U/S: diagnostic procedure of choice
  - image for signs of inflammation, obstruction, localization of stones
  - 95% specific for detecting stones
  - signs: gallbladder wall thickening > 4 mm, edema (double-wall sign), gallbladder sludge, pericholecystic fluid, sonographic Murphy's sign
- HIDA scan
  - used less commonly
  - radiisotope technetium-99 injected into a vein is excreted in high concentrations into bile, allowing visualization of the biliary tree
  - does not visualize stones; diagnosis by seeing occluded cystic duct or CBD

Choledocholithiasis (suspected or confirmed)
- MRCP
  - visualization of ampullary region, biliary and pancreatic anatomy
- ERCP
  - CBD stones in periampullary region
  - complications: retained stones, ERCP pancreatitis (1-2%), pancreatic or biliary sepsis

Percutaneous Transhepatic Cholangiography
- percutaneous approach to the proximal biliary tree (i.e. intra-hepatic biliary system) via the hepatic parenchyma
- useful for proximal bile duct obstruction or when ERCP fails or not available
- requires prophylactic antibiotics
- contraindications: coagulopathy, ascites, peri/intrahepatic sepsis, disease of right lower lung or pleura
- complications: bile peritonitis, chylothorax, pneumothorax, biliary sepsis, hemobilia

Biliary Colic

Pathogenesis
- gallstone transiently impacted in cystic duct, no infection

Clinical Features
- steady, severe dull pain in epigastrium or RUQ for minutes to hours (<6 h), crescendo-decrescendo pattern
- may present with chest pain
- N/V
- frequently occurs at night or after fatty meal, not after fasting
- can radiate to right shoulder or scapula
- no peritoneal findings, no systemic signs

Investigations
- normal blood work: CBC, electrolytes, LFTs, bilirubin, amylase
- U/S shows choledolithiasis, may show stone in cystic duct

Treatment
- analgesia, rehydration during colic episode
- elective cholecystectomy (95% success)
- complications: CBD injury (0.3-0.5%), hollow viscus injury, bile peritonitis, vessel injury
- laparoscopic cholecystectomy is the standard of care, no benefit to delaying surgery
- risk of open cholecystectomy higher in emergency situations

Acute Cholecystitis

Pathogenesis
- inflammation of gallbladder resulting from sustained gallstone impaction in cystic duct or Hartmann's pouch
- no choledolithiasis in 5-10% (see Acalculous Cholecystitis, GS48)

Clinical Features
- often have history of biliary colic
- severe constant (<6hr) epigastric or RUQ pain, anorexia, N/V, low grade fever (<38.5°C)
- focal peritoneal findings: Murphy's sign, palpable, tender gallbladder (in 33%)
- Boas' sign: right subscapular pain

Early vs. Delayed Laparoscopic Cholecystectomy for Uncomplicated Biliary Colic
(Cochrane DB Syst Rev 2013;6:CD007196)
Study: To assess the benefits and harms of early vs. delayed laparoscopic cholecystectomy for patients with uncomplicated biliary colic due to gallstones.
Results: One trial with 75 participants, average age 43 yr. Early laparoscopic cholecystectomy (<24 h) vs. delayed (mean wait period 4.6 mo). The proportion of serious adverse events was lower in the early vs. delayed group (0% vs. 22.5%, respectively). There was a shorter hospital stay in the early group (MD -1.25 d, 95% CI -2.05 to -0.45) and a shorter operating time in the early group (MD -14.80 min, 95% CI -18.02 to -11.58). There was no difference in the proportion of patients requiring conversion to open cholecystectomy in the two groups.
Conclusion: Early laparoscopic cholecystectomy (<24 h of diagnosis of biliary colic) decreased morbidity during the waiting period for elective laparoscopic cholecystectomy, hospital stay, and operating time.
Investigations
- blood work: elevated WBC and left shift, mildly elevated bilirubin, AST, ALT, and ALP
- U/S: 98% sensitive, consider HIDA scan if U/S negative

Complications
- Mirizzi syndrome: extra-luminal compression of CBD/CHD due to large stone in cystic duct
- empyema of gallbladder: suppurative cholecystitis, pus in gallbladder + sick patient
- emphysematous cholecystitis: bacterial gas present in gallbladder lumen, wall, or pericholecystic space (risk in diabetic patient); organisms involved in secondary infection: E. coli, Klebsiella, Enterococcus
- gangrenous gallbladder (20%), perforation (2%): result in abscess formation or peritonitis
- cholecystoenteric fistula, from repeated attacks of cholecystitis, can lead to gallstone ileus

Treatment
- admit, hydrate, NPO, NGT (if persistent vomiting from associated ileus), analgesics once diagnosis is made
- antibiotics
  - cefazolin if uncomplicated cholecystitis
- ERCP prior to surgery if US if CBD stones are present
  - MRCP ± ERCP if CBD is markedly dilated or CBD stones suspected
- cholecystectomy
  - early (within 72 h) vs. delayed (after 6 wk)
    - equal morbidity and mortality
    - early cholecystectomy preferred: shorter hospitalization and recovery time, no benefit to delaying surgery
    - emergent OR indicated if high risk, e.g. emphysematous
  - laparoscopic: reduced risk of wound infections, shorter hospital stay, reduced post-operative pain, increased risk of bile duct injury
  - intra-operative cholangiography (IOC)
    - indications: clarify bile duct anatomy, history of biliary pancreatitis, small stones in gallbladder with a wide cystic duct (>15 mm), jaundice
  - percutaneous cholecystostomy tube: critically ill or if general anesthetic contraindicated

Acalculous Cholecystitis

Definition
- acute or chronic cholecystitis in the absence of stones

Pathogenesis
- typically due to gallbladder ischemia, stasis

Risk Factors
- DM, immunosuppression, ICU admission, trauma patient, TPN, sepsis

Clinical Features
- see Acute Cholecystitis, GS47
- occurs in 20% of cases of acute cholecystitis

Investigations
- U/S: shows sludge in gallbladder, other U/S features of cholecystitis (see Acute Cholecystitis)
- CT or HIDA scan

Treatment
- broad-spectrum antibiotics, cholecystectomy
- if patient unstable → cholecystostomy

Choledocholithiasis

Definition
- stones in CBD

Clinical Features
- 50% asymptomatic
- often have history of biliary colic
- tenderness in RUQ or epigastrium
- acholic stool, dark urine, fluctuating jaundice
- primary vs. secondary stones
  - primary: formed in bile duct, indicates bile duct pathology (e.g. benign biliary stricture, sclerosing cholangitis, choledochal cyst, CF)
  - secondary: formed in gallbladder (85% of cases in U.S.)
Investigations
• CBC: usually normal; leukocytosis suggests cholangitis
• LFTs: increased AST, ALT early in disease, increased bilirubin (more sensitive), ALP, GGT later
• amylase/lipase: to rule out gallstone pancreatitis
• U/S: intra-/extra-hepatic duct dilatation; differential diagnosis is choledochal cyst
• MRCP (90% sensitive)

Complications
• cholangitis, pancreatitis, biliary stricture, and biliary cirrhosis

Treatment
• treat with ERCP for CBD stone extraction possibly followed by elective cholecystectomy in 25% of patients

Acute Cholangitis

Pathogenesis
• obstruction of CBD leading to biliary stasis, bacterial overgrowth, suppuration and biliary sepsis – may be life-threatening, especially in elderly

Etiology
• choledocholithiasis (60%), stricture, neoplasm (pancreatic or biliary), extrinsic compression (pancreatic pseudocyst or pancreatitis), instrumentation of bile ducts (PTC, ERCP), biliary stent
• organisms: E. coli, Klebsiella, Pseudomonas, Enterococcus, B. fragilis, Proteus

Clinical Features
• Charcot's triad: fever, RUQ pain, jaundice
• Reynold's pentad: fever, RUQ pain, jaundice, shock, confusion
• may have N/V, abdominal distention, ileus, acholic stools, tea-coloured urine (elevated direct bilirubin)

Investigations
• CBC; elevated WBC + left shift
• may have positive blood cultures
• LFTs: obstructive picture (elevated ALP, GGT, and conjugated bilirubin, mild increase in AST, ALT)
• amylase/lipase: rule out pancreatitis
• U/S: intra-/extra-hepatic duct dilatation

Treatment
• initial: NPO, fluid and electrolyte resuscitation, ± NGT, IV antibiotics (treats 80%)
• biliary decompression
  • ERCP + sphincterotomy: diagnostic and therapeutic
  • PTC with catheter drainage: if ERCP not available or unsuccessful
  • laparotomy with CBD exploration and T-tube placement if above fails
• all patients should also have a cholecystectomy, unless contraindicated

Prognosis
• suppurative cholangitis mortality rate: 50%

Gallstone Ileus

Pathogenesis
• repeated inflammation causing a cholecystoenteric fistula (usually duodenal) → large gallstone enters the gut and impacts near the ileocecal valve, causing a true bowel obstruction (note: ileus is a misnomer in this context)

Clinical Features
• crampy abdominal pain, N/V (see Large Bowel Obstruction, GS29)

Investigations
• AXR: dilated small intestine, air fluid levels, may reveal radiopaque gallstone, air in biliary tree (pneumobilia) (40%)
• CT: biliary tract air, obstruction, gallstone in intestine
• Rigler's triad: pneumobilia (air in biliary tree), small bowel obstruction (partial or complete), gallstone (usually in right iliac fossa)

Treatment
• fluid resuscitation, NGT decompression
• surgery: enterolithotomy and removal of stone, inspect small and large bowel for additional proximal stones
• may close fistula surgically or manage expectantly (can resolve spontaneously)
• cholecystectomy is generally not performed
Carcinoma of the Gallbladder

Risk Factors
- chronic symptomatic gallstones (70% of cases), old age, female, gallbladder polyps, porcelain gallbladder, chronic infection (*Salmonella, Helicobacter*), abnormal pancreaticobiliary duct junction

Clinical Features
- majority are adenocarcinoma
- may be incidental finding on elective cholecystectomy (~1% of open cholecystectomies 0.1% in laparoscopic cholecystectomies)
- many patients are asymptomatic until late
- local: non-specific RUQ pain, ± palpable RUQ mass
- Courvoisier’s gallbladder: an enlarged, often palpable gallbladder in a patient with carcinoma of the head of the pancreas; associated with jaundice due to obstruction of the CBD
- systemic: jaundice (50%) due to invasion of CBD or compression of CBD by pericholedochal nodes, weight loss, malaise, anorexia
- early local extension to liver, may extend to stomach, duodenum
- early metastasis common to liver, lung, bone

Investigations
- U/S: mural thickening, calcification, loss of interface between gallbladder and liver, fixed mass
- endoscopic U/S (EUS): good for distinguishing carcinomas from other diagnoses such as polyps, good for staging, allows sampling of bile for cytology
- abdominal CT: polyloid mass, mural thickening, liver invasion, nodal involvement, distant metastases
- MRI/MRCP: good for distinguishing benign and malignant polyps

Treatment
- if carcinoma of the gallbladder is suspected pre-operatively, an open cholecystectomy should be considered to avoid tumour seeding of the peritoneal cavity
- confined to mucosa (rare): cholecystectomy
- beyond mucosa: cholecystectomy, en bloc wedge resection of 3-5 cm underlying liver, dissection of hepatoduodenal lymph nodes

Prognosis
- poor 5 yr survival (10%) as gallbladder carcinoma is often detected late
- better outcomes when detected incidentally following cholecystectomy

Cholangiocarcinoma

Definition
- malignancy of extra- or infrahepatic bile ducts

Risk Factors
- age 50-70, gallstones, ulcerative colitis, primary sclerosing cholangitis, choledochal cyst, *Clonorchis sinensis* infection (liver fluke), chronic intrahepatic stones (hepatolithiasis)

Clinical Features
- majority are adenocarcinomas
- gradual signs of biliary obstruction: jaundice, pruritus, dark urine, pale stools
- anorexia, weight loss, RUQ pain, Courvoisier’s sign (if CBD obstructed), hepatomegaly
- early metastases are uncommon, but commonly tumour grows into portal vein or hepatic artery
- Klatskin tumour: cholangiocarcinoma located at bifurcation of common hepatic duct

Investigations
- LFTs show obstructive picture
- U/S, CT: bile ducts usually dilated, but not necessarily
- ERCP or PTC: to determine resectability, for biopsies
- CXR, bone scan: for metastatic workup

Treatment
- if resectable biliary drainage and wide excision margin
- intra-hepatic lesions: liver resection
  - upper third lesions: duct resection + Roux-en-Y hepaticojejunostomy, ± liver resection
  - middle third lesions (uncommon): duct resection + Roux-en-Y hepaticojejunostomy
  - lower third lesions: Whipple procedure
- unresectable lesions: stent or choledochojejunostomy (surgical bypass)
- chemotherapy ± radiotherapy
- role for transplantation in selected patients with Klatskins tumours

Prognosis
- overall 5 yr survival: 15%

### Ranson’s Criteria

**A. At admission**
1. Age > 55 yr
2. WBC > 16 x 10^9/L
3. Glucose > 11 mmol/L
4. LDH > 350 IU/L
5. AST > 250 IU/L

**B. During initial 48 h**
1. Hct drop > 10%
2. BUN rise > 1.8 mmol/L
3. Arterial PO2 < 60 mmHg
4. Base deficit > -4 mmol/L
5. Calcium < 2 mmol/L
6. Fluid sequestration > 6 L

**C. Interpretation**
- 2 = difficult course
- 3 = high mortality (≥15%)

---

**Courvoisier’s Sign**
Palpable, nontender distended gallbladder due to CBD obstruction. Present in 33% of patients with pancreatic carcinoma. The distended gallbladder could not be due to acute cholecystitis or stone disease because the gallbladder would actually be scarred and smaller, not larger.
Pancreas

Acute Pancreatitis

- see Gastroenterology, G44

GALLSTONE PANCREATITIS (35% of Acute Pancreatitis)

Pathogenesis
- obstruction of pancreatic duct by large or small gallstones and biliary sludge
- backup of pancreatic enzymes can cause autodigestion of the pancreas

Clinical Features (Pancreatitis of Any Etiology)
- pain (epigastric pain radiating to back), N/V, ileus, peritoneal signs, jaundice, fever
- Inglefinger’s sign: pain worse when supine, better when sitting forward
- may have coexistent cholangitis or pancreatic necrosis
- Ranson’s criteria for determining prognosis of acute pancreatitis (see sidebar)
- physical exam may show: tachypnea, tachycardia, hypotension, abdominal distention and tenderness, Cullen’s sign, Grey Turner’s sign

Investigations
- elevated amylase (higher than alcoholic pancreatitis), lipase, leukocytosis
- elevated ALT (>150 IU/L), AST strongly suggest gallstone etiology of pancreatitis
- U/S may show multiple stones (may have passed spontaneously), edematous pancreas
- CXR, AXR, CT (if severe to evaluate for complications)

Treatment
- supportive: e.g. NPO, hydration, analgesia, early enteric nutrition
- antibiotics for severe cases of necrotizing pancreatitis or signs of sepsis
- stone often passes spontaneously (~90%); usually no surgical management in uncomplicated acute pancreatitis
- cholecystectomy during same admission (25-60% recurrence if no surgery)
- may need urgent ERCP + sphincterotomy if CBD stone impacted or cholangitis
- surgical indications in acute pancreatitis (rare):
  - drain placement and debridement for necrotizing pancreatitis if refractory to medical management, if septic or in ICU without other sources of sepsis

Complications
- acute fluid collections
- pseudocyst (collection of pancreatic secretions >4 wk old surrounded by a defined wall of granulation tissue)
- abscess/infection, necrosis
- splenic/mesenteric/portal vessel thrombosis
- pancreatic ascites/pancreatic pleural effusion
- DM
- ARDS/sepsis/multiorgan failure
- coagulopathy/DIC
- severe hypocalcemia

Chronic Pancreatitis

- see Gastroenterology, G45

Surgical Treatment
- treatment is generally medical
- indications for surgery
  - failure of medical treatment
  - debilitating abdominal pain
  - pseudocyst complications: persistence, hemorrhage, infection, rupture
  - CBD obstruction (e.g. strictures), duodenal obstruction
  - pancreatic fistula, variceal hemorrhage secondary to splenic vein obstruction
  - rule out pancreatic cancer (present in 15% of chronic pancreatitis treated surgically)
  - anatomical abnormality causing recurrent pancreatitis
- pre-operative CT and/or ERCP are mandatory to delineate anatomy
- minimally invasive options
  - endoscopic pancreatic duct decompression: less effective than surgery
  - extracorporeal shockwave lithotripsy: if pancreatic duct stones
  - celiac plexus block: lasting benefit in 30% patients, less effective in those <45 yr or with prior pancreatic surgery
surgical options
- drainage procedures: only effective if ductal system is dilated
  - Puestow procedure (lateral pancreaticojejunostomy): improves pain in 80% of patients
- pancreatoduodenectomy: best option in absence of dilated duct
  - proximal disease: Whipple procedure (pancreaticoduodenectomy) – pain relief in 80%
  - distal disease: distal pancreatoduodenectomy ± Roux-en-Y pancreaticojejunostomy
- total pancreatoduodenectomy: refractory disease
- denervation of celiac ganglion and splanchnic nerves

PSEUDOCYST
- localized fluid collections rich in pancreatic enzymes, with a non-epithelialized wall consisting of fibrous and granulation tissue
- complication of chronic and/or acute pancreatitis
- often resolve spontaneously
- cyst wall must be mature prior to drainage (4-6 wk)
- pseudoaneurysm an absolute contraindication to endoscopic drainage, must embolize first

Treatment
- expectant management if asymptomatic
- endoscopic drainage
  - cystgastrostomy
  - cystduodenostomy
- percutaneous catheter drainage
- surgical drainage (gold standard)
  - cystgastrostomy
  - cystenterostomy
- resection
  - consider biopsy of cyst wall to rule out cystadenocarcinoma

Pancreatic Cancer

Epidemiology
- fourth most common cause of cancer-related mortality in both men and women in Canada
- M:F = 1.3:1, average age: 50-70

Risk Factors
- increased age
- smoking: 2-5x increased risk, most clearly established risk factor
- high fat/low fibre diets, heavy alcohol use
- obesity
- DM, chronic pancreatitis
- partial gastrectomy, cholecystectomy
- chemicals: betanaphthylamine, benzidine
- African descent

Clinical Features
- head of the pancreas (70%)  
  - weight loss, obstructive jaundice, steatorrhea, vague constant mid-epigastric pain (often worse at night, may radiate to back)
  - painless jaundice, Courvoisier’s sign
- body or tail of pancreas (30%)
  - tends to present later and usually inoperable
  - weight loss, vague mid-epigastric pain
  - <10% jaundiced
  - sudden onset DM

Investigations
- serum chemistry is non-specific, can have elevated ALP and high bilirubin
- CA 19-9 (most useful serum marker of pancreatic cancer)
- U/S, CT (also evaluates metastasis and resectability) ± ERCP, MRI, EUS

Pathology
- ductal adenocarcinoma: most common type (75-80%); exocrine pancreas
- intraductal papillary mucinous neoplasm (IPMN)
- other: pancreatic neuroendocrine tumours (non-functional, insulinoma, gastrinoma, VIPoma, glucagonoma, somatostatinoma), mucinous cystic neoplasm (MCN), acinar cell carcinoma
  - see Surgical Endocrinology, GS60 for functional pancreatic neuroendocrine tumours
Treatment
• resectable (10-20% of pancreatic cancer)
  ■ no involvement of liver, peritoneum, or vasculature (hepatic artery, SMA, SMV, portal vein, IVC, aorta), no distant metastasis
  ■ Whipple procedure (pancreaticoduodenectomy) for cure <5% mortality
  ■ distal pancreatectomy ± splenectomy, lymphadenectomy if carcinoma of midbody and tail of pancreas
  ■ locally advanced, borderline resectable
  ■ tumours that abut the SMA, SMV, portal vein, hepatic artery, or celiac artery
  ■ locally advanced, non-resectable (palliative -→ relieve pain, obstruction)
  ■ encasement of major vascular structures including artery
  ■ most body/tail tumours are not resectable (due to late presentation)
  ■ relieve biliary/duodenal obstruction with endoscopic stenting or double bypass procedure
    (choledochoenterostomy + gastroenterostomy)
  ■ palliative chemotherapy (gemcitabine + nab-paclitaxel, FOLIRINOX) ± radiotherapy

Prognosis
• most important prognostic indicators are lymph node status, margin status, size >3 cm, perineural invasion (invasion of tumour into microscopic nerves of pancreas)
• overall 5 yr survival for all patients with pancreas cancer is 1%; following surgical resection 5 yr survival is 20%
• median survival for unresectable disease: 3-6 mo if metastatic, 8-12 mo if locally advanced at presentation

<table>
<thead>
<tr>
<th>Primary Tumour (T)</th>
<th>Regional Lymph Nodes (N)</th>
<th>Distant Metastasis (M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>NX</td>
<td>M0 No distant metastasis</td>
</tr>
<tr>
<td>T0</td>
<td>N0</td>
<td>M1 Distant metastasis</td>
</tr>
<tr>
<td>Tis</td>
<td>N1</td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>Tumour limited to pancreas, &lt;2 cm in greatest dimension</td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>Tumour limited to pancreas, &gt;2 cm in greatest dimension</td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>Tumour extends beyond pancreas, no involvement of celiac axis or SMA</td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>Tumour involves celiac axis or SMA (unresectable)</td>
<td></td>
</tr>
</tbody>
</table>

Table 21. Staging and Treatment of Pancreatic Cancer

<table>
<thead>
<tr>
<th>Stage</th>
<th>Classification</th>
<th>5 Yr Survival</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Tis, N0, M0</td>
<td>14%</td>
<td>Surgical resection ± chemotherapy</td>
</tr>
<tr>
<td>IA</td>
<td>T1, N0, M0</td>
<td>12%</td>
<td>Same as above</td>
</tr>
<tr>
<td>IB</td>
<td>T2, N0, M0</td>
<td>7%</td>
<td>Same as above</td>
</tr>
<tr>
<td>IIA</td>
<td>T3, N0, M0</td>
<td>5%</td>
<td>Same as above</td>
</tr>
<tr>
<td>IIB</td>
<td>T1-3, N1, M0</td>
<td>3%</td>
<td>Borderline resectable, trial of chemotherapy and radiation</td>
</tr>
<tr>
<td>III</td>
<td>T4, any N, M0</td>
<td>1%</td>
<td>Non-resectable, palliative treatments</td>
</tr>
<tr>
<td>IV</td>
<td>any T, any N, M1</td>
<td>1%</td>
<td></td>
</tr>
</tbody>
</table>

Steps of a Whipple Resection (Pancreatoduodenectomy)
1. Assessment of metastatic disease (all peritoneal surfaces)
2. Mobilization of the duodenum and head of the pancreas
3. Identification of the superior mesenteric vein and mobilization of the pancreatic neck
4. Mobilization of the stomach; dissection of the hepatoduodenal ligament and choledochojejunostomy
5. Division of the stomach, proximal jejunum, and CBD
6. Transection of the pancreatic neck and dissection of the unciate process from the retroperitoneum
7. Restoration of gastrointestinal continuity: construction of a pancreaticojejunostomy, hepaticojejunostomy, gastrojejunostomy using a neoduodenum

Removed
• CBD
• Gallbladder
• Duodenum
• Pancreatic head
• Distal stomach (sometimes)

Diagnostic Value of Serum Carbohydrate Antigen 19-9 in Pancreatic Cancer: A Meta-Analysis

Summary: 11 studies with 2,316 patients were included in the analysis. The sensitivity of CA19-9 in the diagnosis of pancreatic cancer was found to be 0.9 (95% CI 0.77-0.92) and the specificity also 80% (95% CI 0.77-0.82) with a diagnostic odds ratio of 14.79 (95% CI 8.55-25.59). Overall, CA19-9 plays an important role in the diagnosis of pancreatic cancer.

Figure 26. Schematic of Whipple resection, showing the resected components
Spleen

Splenic Trauma

- typically from blunt trauma (especially in people with splenomegaly)
- most common intra-abdominal organ injury in blunt trauma
- may have Kehr's sign

Treatment

- non-operative
  - in stable patients: extended bed rest with serial hematocrit levels, close monitoring for 3-5 d; pediatric guidelines for days of bed rest is grade plus 1 (i.e. grade 3 splenic laceration requires 4 d of bed rest)
  - hemostatic control
  - splenic artery embolization if patient stable and one of: active contrast extravasation, splenic pseudoaneurysm, hemoperitoneum
- operative
  - splenorrhaphy (suture of spleen) ± splenic wrapping with hemostatic mesh – if patient hemodynamically stable, patient has stopped bleeding and laceration does not involve hilum
  - partial splenectomy, rarely performed due to risk of recurrent hemorrhage
  - total splenectomy if patient unstable or high-grade injury

Splenectomy

Indications

- splenic trauma (most common reason for splenectomy), hereditary spherocytosis, primary hypersplenism, chronic immune thrombocytopenic purpura (ITP), splenic vein thrombosis causing esophageal varices, splenic abscess, thrombotic thrombocytopenic purpura (TTP), sickle cell disease
- does not benefit all thrombocytopenic states (e.g. infection, most malignancies involving the bone marrow, drugs/toxins)
- probability of cure of ITP by splenectomy is 60-70%, may be predicted by response to IVIg

Complications

- short-term
  - injury to surrounding structures (e.g. gastric wall, tail of pancreas)
  - post-operative thrombocytosis, leukocytosis
  - thrombosis of portal, splenic, or mesenteric veins
  - subphrenic abscess
- long-term
  - post-splenectomy sepsis (encapsulated organisms): 4% of splenectomized patients (highest risk in those <16 yr old)
    - 50% mortality
    - prophylaxis with vaccinations, ideally 2 wk pre- or post-operative (pneumococcal, *H. influenzae*, and meningococcus)
    - liberal use of penicillin especially in children <6 yr old
  - splenosis: intra-abdominal "seeding" of splenic tissue during removal
Benign Breast Lesions

Three Categories
1. nonproliferative
2. proliferative without atypia
3. atypical hyperplasia

NONPROLIFERATIVE LESIONS
- benign breast condition characterized by fibrous and cystic changes in the breast
- most common: breast cysts
- other lesions include papillary apocrine change, epithelial-related calcifications and mild hyperplasia of the usual type
- no increased risk of breast cancer
- age 30 to menopause (and after if HRT used)
- clinical features
  - breast pain, focal areas of nodularity or cysts often in the upper outer quadrant, frequently bilateral, mobile, varies with menstrual cycle, nipple discharge (straw-like, brown, or green)
- treatment
  - evaluation of breast mass (U/S, mammography as indicated) and reassurance
  - no strong evidence for avoidance of xanthine-containing products (coffee, tea, chocolate, cola)
  - analgesia (ibuprofen, ASA)
  - no atypia or DCIS

PROLIFERATIVE LESIONS – WITHOUT ATYPIA

<table>
<thead>
<tr>
<th>Clinical Features</th>
<th>Diagnosis</th>
<th>Treatment</th>
<th>Risk of Breast Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibroadenoma</td>
<td>Most common breast tumour in women &lt;30 yr</td>
<td>Nodules: firm, rubbery, discrete, well-circumscribed, non-tender, mobile, hormone-dependent (unlike cysts), needle aspiration yields no fluid</td>
<td>Core or excisional biopsy sometimes required if concerned about malignancy US and FNA alone cannot differentiate fibroadenoma from Phyllodes tumour</td>
</tr>
<tr>
<td>Intraductal Papilloma</td>
<td>Solitary intraductal benign polyp</td>
<td>Can present as nipple discharge (most common cause of spontaneous, unilateral, bloody nipple discharge = pathologic nipple discharge), breast mass, nodule on US</td>
<td>Surgical excision of involved duct to ensure no atypia</td>
</tr>
<tr>
<td>Usual Ductal Hyperplasia</td>
<td>Increased number of cells within the ductal space</td>
<td>Incidental finding on biopsy of mammographic abnormalities or breast masses</td>
<td>None required</td>
</tr>
<tr>
<td>Sclerosing Adenosis</td>
<td>Lobular lesion with increased fibrous tissue and glandular cells</td>
<td>Mass or mammographic abnormality</td>
<td>None required</td>
</tr>
</tbody>
</table>
ATYPICAL HYPERPLASIA
- can involve ducts (ductal hyperplasia with atypia) or lobules (lobular hyperplasia with atypia)
- cells lose apical-basal orientation
- increased risk of breast cancer
- diagnosis: core or excisional biopsy
- treatment: complete resection, risk modification (avoid exogenous hormones), close follow-up

OTHER LESIONS

Fat Necrosis
- uncommon, result of trauma (may be minor, positive history in only 50%), after breast surgery (i.e. reduction)
- firm, ill-defined mass with skin or nipple retraction, ± tenderness
- regress spontaneously, but complete imaging ± biopsy to rule out carcinoma

Mammary Duct Ectasia
- obstruction of a subareolar duct leading to duct dilation, inflammation, and fibrosis
- may present with nipple discharge, bluish mass under nipple, local pain
- risk of secondary infection (abscess, mastitis)
- resolves spontaneously

Montgomery Tubercle
- Montgomery tubercles (or Morgagni tubercles) are papular projections at the edge of the areola
- obstruction of these glands can lead to inflammation or cystic collections (cyst of Montgomery i.e. retroareolar cyst)
- if signs of secondary infection, start treatment for mastitis
- resolves spontaneously in weeks to years

Abscess
- lactational (see Obstetrics, OB45) vs. periductal/subareolar
- unilateral localized pain, tenderness, erythema, subareolar mass, nipple discharge, nipple inversion
- rule out inflammatory carcinoma, as indicated
- treatment: initially broad-spectrum antibiotics and I&D, if persistent total duct excision (definitive)
- if mass does not resolve: U/S to assess for presence of abscess, core biopsy to exclude cancer, consider MRI

Breast Cancer

Epidemiology
- leading cancer diagnosis in women in NA, 2nd leading cause of cancer mortality in women
- 1 in 8 (12.9% life time risk) women in Canada will be diagnosed with breast cancer in their lifetime
- 1 in 30 women in Canada will die from breast cancer
- all age relative survival is 88%

Risk Factors
- gender (99% female)
- age (80% >40 yr old)
- personal history of breast cancer and/or prior breast biopsy (regardless of pathology)
- family history of breast cancer (greater risk if relative was first degree and premenopausal)
- high breast density, nulliparity, first pregnancy >30 yr, menarche <12 yr, menopause >55 yr
- decreased risk with lactation, early menopause, early childbirth
- radiation exposure (e.g. mantle radiation for Hodgkin's disease)
- >5 yr HRT use, >10 yr OCP use
- BRCA1 and BRCA2 gene mutations
- alcohol use, obesity, sedentary lifestyle

Male breast cancer (<1%)
- most commonly invasive ductal carcinoma
- often diagnosed at later stages
- stage-for-stage similar prognosis to breast cancer in females
- consider genetic testing: most often hormone receptor positive

Investigations
- mammography
  - indications
    - screening guidelines (see Family Medicine, FM4)
    - findings indicative of higher risk of malignancy
      - mass that is poorly defined, spiculated border
      - microcalcifications
      - architectural distortion
      - interval mammographic changes
    - normal mammogram does not rule out suspicion of cancer based on clinical findings
• other radiographic studies
  ■ U/S: differentiate between cystic and solid
  ■ MRI: high sensitivity, low specificity
  ■ galactogram/ductogram: for nipple discharge; identifies lesions in ducts
  ■ metastatic workup indicated in Stage II-IV disease: bone scan, abdominal U/S, CXR (or CT chest/abdomen/pelvis), CT head (if specific neurological symptoms)

Diagnostic Procedures
• needle aspiration: for palpable cystic lesions; send fluid for cytology if blood or cyst does not completely resolve
• U/S or mammography guided core needle biopsy (most common)
• FNA: for palpable solid masses; need experienced practitioner for adequate sampling
• excisional biopsy: only performed as second choice to core needle biopsy; should not be done for diagnosis if possible

Genetic Screening
• consider testing for BRCA1/2 if
  ■ patient diagnosed with breast AND ovarian cancer
  ■ strong family history of breast/ovarian cancer
  ■ family history of male breast cancer
  ■ young patient (<35 yr)
  ■ bilateral breast cancer in patients <50 yr

Staging
• patients are assigned a clinical stage pre-operatively (cTNM); following surgery the pathologic stage is determined (pTNM)

  • clinical
  ■ tumour size by palpation, mammogram, U/S and/or MRI
  ■ nodal involvement by palpation, imaging
  ■ metastasis by physical exam, CXR, and abdominal U/S (or CT chest/abdomen/pelvis), bone scan (usually done post-operative if node-positive disease)

  • pathological
  ■ tumour size and type (see Pathology)
  ■ grade: modified Bloom and Richardson score (I to III) – histologic, nuclear, and mitotic grade
  ■ number of axillary nodes positive for malignancy out of total nodes resected, extranodal extension, sentinel lymph node biopsy (SLNB) positive/negative
  ■ tumour biology: estrogen receptor (ER), progesterone receptor (PR) and HER2/neu oncogene status
  ■ margins: for invasive breast cancer negative margin is sufficient, for DCIS prefer 2mm margin
  ■ lymphovascular invasion (LVI)
  ■ extensive in situ component (EIC): DCIS in surrounding tissue
  ■ involvement of dermal lymphatics (inflammatory) – automatically Stage IIIb

Table 23. Staging of Breast Cancer (American Joint Committee on Cancer)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Tumour</th>
<th>Nodes (regional)</th>
<th>Metastasis</th>
<th>Survival (5 yr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>in situ</td>
<td>None</td>
<td>None</td>
<td>99%</td>
</tr>
<tr>
<td>I</td>
<td>&lt;2 cm</td>
<td>None</td>
<td>None</td>
<td>94%</td>
</tr>
<tr>
<td>II A</td>
<td>&lt;2 cm</td>
<td>Mobile ipsilateral</td>
<td>None</td>
<td>85%</td>
</tr>
<tr>
<td>II B</td>
<td>2-5 cm</td>
<td>None or mobile ipsilateral</td>
<td>None</td>
<td>70%</td>
</tr>
<tr>
<td>or &gt;5 cm</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>III A</td>
<td>Any size</td>
<td>Fixed ipsilateral or internal mammary</td>
<td>None</td>
<td>52%</td>
</tr>
<tr>
<td>III B</td>
<td>Skin/pectoral wall</td>
<td>Any</td>
<td>None</td>
<td>48%</td>
</tr>
<tr>
<td>III C</td>
<td>Any size</td>
<td>Ipsilateral infraclavicular/internal mammary plus axillary nodes; ipsilateral supradiaphragmatic node(s) + axillary nodes</td>
<td>None</td>
<td>33%</td>
</tr>
<tr>
<td>IV</td>
<td>Any</td>
<td>Any</td>
<td>Distant</td>
<td>18%</td>
</tr>
</tbody>
</table>

Pathology

NON-INVASIVE

Ductal Carcinoma in situ (DCIS)
• proliferation of malignant ductal epithelial cells completely contained within breast ducts, often multifocal
• 80% non-palpable, detected by screening mammogram
• risk of invasive ductal carcinoma in same breast up to 35% in 10 yr
• treatment
  ■ lumpectomy with wide excision margins + radiation (5-10% risk of invasive cancer)
  ■ mastectomy if large area of disease, high grade, or multifocal (risk of invasive cancer reduced to 1%)
  ■ possibly tamoxifen as an adjuvant treatment
  ■ 99% 5 yr survival

Lobular Carcinoma in situ (LCIS)
  ■ neoplastic cells completely contained within breast lobule
  ■ no palpable mass, no mammographic findings, usually incidental finding on breast biopsy for another indication
  ■ LCIS is a risk factor for invasive carcinoma (approximately 1%/yr)
  ■ treatment
    • if diagnosed on core biopsy, excisional biopsy necessary to rule out malignancy
    • if diagnosed on excisional biopsy, wide excision not needed since LCIS if often multicentric and not managed as precursor lesion
    • clinical follow-up and surveillance
    • consider chemoprevention (e.g. tamoxifen)

INVASIVE

Invasive Ductal Carcinoma (most common 80%)
  ■ originates from ductal epithelium and infiltrates supporting stroma
  ■ characteristics: hard, scirrhous, infiltrating tentacles, gritty on cross-section

Invasive Lobular Carcinoma (8-15%)
  ■ originates from lobular epithelium
  ■ 20% bilateral (i.e. more often than infiltrating ductal carcinoma)
  ■ does not form microcalcifications, harder to detect mammographically (may benefit from MRI)

Paget’s Disease (1-3%)
  ■ ductal carcinoma that invades nipple with scaling, eczematoid lesion

Inflammatory Carcinoma (1-4%)
  ■ ductal carcinoma that invades dermal lymphatics
  ■ most aggressive form of breast cancer
  ■ clinical features: erythema, skin edema, warm, swollen, and tender breast ± lump
  ■ peau d’orange indicates advanced disease (IIIb-IV)

Sarcomas: rare
  ■ most commonly Phyllodes tumour, a variant of fibroadenoma with potential for malignancy
  ■ can also be angiosarcomas – after previous radiation

Lymphoma: rare

Other
  ■ papillary, medullary, mucinous, tubular cancers
  ■ generally better prognosis

Treatment

Table 24. Breast Cancer Treatment by Stage

<table>
<thead>
<tr>
<th>Stage</th>
<th>Primary Treatment Options</th>
<th>Adjuvant Systemic Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 (in situ)</td>
<td>BCS + radiotherapy BCS alone if margins &gt;1 cm and low nuclear grade Mastectomy* + SLNB</td>
<td>Consider post-operative tamoxifen for ER+, trastuzumab for HER2+</td>
</tr>
<tr>
<td>I</td>
<td>BCS + axillary node dissection + radiotherapy Mastectomy* + axillary node dissection/SLNB</td>
<td>May not be needed; discuss risks/benefits of chemotherapy and tamoxifen</td>
</tr>
<tr>
<td>II</td>
<td>BCS + axillary node dissection + radiotherapy Mastectomy* + axillary node dissection/SLNB</td>
<td>Chemotherapy for premenopausal women or postmenopausal and ER negative, followed by tamoxifen if ER+</td>
</tr>
<tr>
<td>III</td>
<td>Likely mastectomy + axillary node dissection + radiotherapy after chemotherapy (neoadjuvant)</td>
<td>Neoadjuvant therapy should be considered i.e. pre-operative especially if not resectable chemotherapy and/or hormone therapy. Adjuvant radiation and chemotherapy may also be appropriate (i.e. post-operative)</td>
</tr>
<tr>
<td>Inflammatory</td>
<td>Mastectomy + axillary node dissection + radiotherapy</td>
<td>Neoadjuvant therapy</td>
</tr>
<tr>
<td>IV</td>
<td>Surgery as appropriate for local control</td>
<td>Primary treatment is systemic therapy i.e. chemotherapy and/or hormone therapy</td>
</tr>
</tbody>
</table>

BCS = breast conserving surgery; SLNB = sentinel lymph node biopsy

*If no reason to select mastectomy, the choice between BCS + radiotherapy and mastectomy can be made according to patient’s preference since choice of local treatment does not significantly affect survival if local control is achieved.
PRIMARY SURGICAL TREATMENT

Breast Conservation Surgery (BCS)
- lumpectomy must be combined with radiation for survival equivalent to mastectomy
- contraindications include
  - high risk of local recurrence e.g. extensive malignant-type calcifications on mammogram, multifocal primary tumours
  - failure to obtain tumour-free margins after re-excision
  - not suitable for radiation therapy (pregnancy, previous radiation, collagen vascular disease)
  - large tumour size relative to breast

Mastectomy
- radical mastectomy (rarely): removes all breast tissue, skin, pectoralis muscle, axillary nodes
- modified radical mastectomy (MRM): removes all breast tissue, skin, and axillary nodes
- simple mastectomy: removes all breast tissue and skin
- see Plastic Surgery, PL34 for breast reconstruction

Sentinel Lymph Node Biopsy (SLNB)
- perform in women with clinically node-negative invasive breast cancer and those with extensive DCIS who are undergoing mastectomy
- patients with clinically suspicious nodes should U/S + FNA prior to decision to proceed with SLNB
- technetium-99 ± blue dye injected at tumour site prior to surgery to identify sentinel node(s)
- intra-operative frozen section evaluated can be considered
- proceed with ALND if >3 positive nodes, with 1-3 nodes whole breast radiation therapy may be alternative
- 5% false negative rate

Axillary Lymph Node Dissection (ALND)
- perform in all patients with pathologic confirmation of nodal involvement (including positive SLNB as above)
- risk of arm lymphedema (10-15%) especially if getting radiation therapy, decreased arm sensation, shoulder pain

ADJUVANT/NEOADJUVANT

Radiation
- indications
  - decrease risk of local recurrence; almost always used after BCS, sometimes after mastectomy
  - inoperable locally advanced cancer
  - axillary nodal radiation may be added if nodal involvement

Hormonal
- indications
  - ER positive plus node-positive or high-risk node-negative
  - SERM if premenopausal (e.g. tamoxifen) or aromatase inhibitors if postmenopausal (e.g. anastrozole); optimal duration 5-10 yr
  - ovarian ablation (e.g. goserelin/GnRH agonist, oophorectomy), progestins (e.g. megestrol acetate), androgens (e.g. fluoxymesterone) are other options
  - palliation for metastatic disease

Chemotherapy
- indications
  - ER negative plus node-positive or high-risk node-negative
  - ER positive and young age
  - stage I disease at high risk of recurrence (high grade, lymphovascular invasion)
  - palliation for metastatic disease
  - can consider oncoype DX (21 gene analysis) to provide recurrence score (low, intermediate, high)

FOLLOW-UP

Post-Treatment Follow-Up
- assessment and physical exam q3-6mo x 3 yr, q6-12mo x 2yr, and annually thereafter
- following BCS mammography q6-12mo; can reduce to annual once stable, no other routine imaging unless clinically indicated
- women who receive tamoxifen should have regular gynecologic follow-up (increased risk of endometrial cancer)
- psychosocial support and counselling
- delayed breast reconstruction if underwent a mastectomy
Local/Regional Recurrence
• recurrence in treated breast or ipsilateral axilla
• 1% per yr up to maximum of 15% risk of developing contralateral malignancy
• 5x increased risk of developing metastases

Metastasis
• bone > lungs > pleura > liver > brain
• treatment is palliative: hormone therapy, chemotherapy, radiation
• overall survival of metastatic breast cancer is 36-60 mo

Thyroid and Parathyroid

Thyroidectomy
• indications: thyroid cancer, symptomatic thyroid mass or goitre, medically refractory Graves’ or hyperthyroidism
• contraindications: uncontrolled severe hyperthyroidism (i.e. Graves’) due to risk of intra-operative or post-operative thyroid storm
• pre-operative workup: thyroid U/S for thyroid nodules, FNA for large nodules, U/S of the neck for lesions suspicious for papillary or medullary thyroid cancer, CT neck useful to rule out extension, vocal cord function
• complications: hypocalcemia secondary to hypoparathyroidism, recurrent/superior laryngeal nerve injury, neck hematoma, infection, thyrotoxic storm

Parathyroidectomy
• indications: symptomatic primary hyperparathyroidism due to effects of PTH on bone or kidneys, asymptomatic primary hyperparathyroidism with specific laboratory criteria (elevated serum Ca, marked hypercalcuria, Cr clearance <30% normal, bone density reduction with T score <2.5, <50 yr)
• contraindications: familial hypocalciuric hypercalcemia
• pre-operative workup: 99mTc sestamibi scanning, ± SPECT or CT, U/S
• complications: recurrent/superior laryngeal nerve injury, post-operative hypocalcemia, infection, bleeding

Adrenal Gland

see Endocrinology, E29

functional anatomy
• cortex: glomerulosa (mineralocorticoids), fasciculata (glucocorticoids), reticularis (sex steroids)
• medulla: catecholamines (epinephrine, norepinephrine)
• types of adrenal tumours: functional (e.g. Cushing's syndrome, Conn's syndrome) or non-functional

INCIDENTALOMA
• adrenal mass discovered by investigation of unrelated symptoms

Epidemiology
• benign adenoma (38%) > metastases to adrenal (22%) >> cyst, carcinoma, pheochromocytoma, neuroblastoma
• metastasis to adrenal gland from: lung > breast, colon, lymphoma, melanoma, kidney
• peak incidence of carcinoma: females age 50-60, risk decreases with increasing age and male gender

Investigations
• MRI, CT: size >6 cm is best predictor of primary adrenal carcinoma (92% are >6 cm)
• functional studies
  • pheochromocytoma: 24 h urine epinephrine, norepinephrine, metanephrine, normetanephrine, VMA (vanillylmandelic acid)
  • Cushing’s: 24 h urine cortisol or 1 mg overnight dexamethasone suppression test
  • aldosteronoma: electrolytes, aldosterone-renin level, saline suppression test if appropriate
  • adrenal androgens: 17-OH progesterone, DHEAS
• FNA biopsy: if suspect metastasis to adrenal (must exclude pheochromocytoma first to prevent a hypertensive crisis)
  • indicated if history of cancer or patient is smoker
• iodocholesterol scintigraphy: may distinguish benign vs. malignant disease
Treatment
• functional tumour: resect
• non-functional tumour
  ■ >4 cm: resect
  ■ <4 cm: follow-up imaging in 6-12 mo, resect if >1 cm enlargement

Pancreas

INSULINOMA
• tumour that secretes insulin
• most common pancreatic endocrine neoplasm; 10% associated with MEN1 syndrome

Clinical Features
• Whipple's triad
  palpitations, trembling, diaphoresis, confusion, seizure, personality changes

Investigations
• blood work: decreased serum glucose and increased serum insulin and C-peptide
• U/S, CT: insulinomas evenly distributed throughout head, body, tail of pancreas

Treatment
• only 10% are malignant
• enucleation of solitary insulinomas may be done endoscopically
• tumours >2 cm located close to the pancreatic duct may require pancreatectomy or
pancreaticoduodenectomy

GASTRINOMA
• tumour secreting gastrin; cause of Zollinger-Ellison syndrome

Clinical Features
• abdominal pain, PUD, severe esophagitis
• multiple ulcers in atypical locations refractory of antacid therapy

Investigations
• blood work: serum gastrin levels (usually >1,000 pg/mL), secretin stimulation test
• U/S, CT: 70-90% found in Passaro's triangle (head of pancreas medially, 2nd portion of duodenum
  inferiorly, and the confluence of the cystic and CBD superiorly)
• octreotide scintigraphy scan

Treatment
• 50% are malignant
• surgical resection of tumour dependent on location
• non-surgical treatment: chemotherapy, somatostatin analogues, interferon, chemoembolization
• if inoperable, vagotomy can be performed for symptomatic control

VASOACTIVE INTESTINAL PEPTIDE-SECRETING TUMOUR
• tumour secreting VIP; commonly located in the distal pancreas and most are malignant when
diagnosed

Clinical Features
• severe watery diarrhea causing dehydration, weakness, electrolyte imbalance

Investigations
• blood work: serum VIP levels
• U/S, CT

Treatment
• somatostatin analogues
• surgical resection/palliative debulking

Whipple’s Triad
• Symptomatic fasting hypoglycemia
• Serum glucose <50 mg/dL
• Relief of symptoms when glucose is administered

Rule of 2s for Meckel’s Diverticulum
• 2% of the population
• 2:1 male-to-female ratio
• Symptomatic in 2% of cases
• Found within 2 feet (10-90 cm) of the ileocecal (IC) valve
• 2 inches in length
• 2 inches in diameter
• 2 types of tissue (gastric, pancreatic)
• Often present by 2 yr of age
### Pediatric Surgery

<table>
<thead>
<tr>
<th>Condition</th>
<th>Epidemiology and Risk Factors</th>
<th>Pathophysiology</th>
<th>Clinical Features and History</th>
<th>Physical Exam</th>
<th>Investigations</th>
<th>Treatment</th>
<th>Prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hydrocolic (see Urology U29)</strong></td>
<td>1-2% of live births Present at birth, majority close spontaneous by 1 yr M:F = 4:1 Prematurity</td>
<td>Communicating hydrocolic: processus vaginalis fails to close with small opening for fluid to move freely between peritoneal cavity through patent processus (risk opening progresses to allow passage of intestine, it is a hernia) Noncommunicating hydrocolic: fluid trapped in tunica vaginalis; in older children, may be secondary to testicular pathology (reactive hydrocolic)</td>
<td>Painless scrotal mass Communicating hydrocolic increases in size with standing or valsalva, may be absent in the morning and large in the evening Transillumination suggests hydrocolic SkQ glove sign gently palpating hydrocolic sac over pubic tubercle feels like rubbing silk on silk</td>
<td>US if suspect pathology hydrocolic SkQ shows pyloric length &gt; 14 mm, muscle thickness &gt; 4 mm Upper GI series necessary only when US unanswerable or cannot diagnose shows “string sign”</td>
<td>Most resolve spontaneously by 1 yr Surgical repair if Persistent &gt; 2 yr Pain Fluctuating in size which suggests communication Cosmetic reasons Infection</td>
<td>&lt;2% recurrence</td>
<td></td>
</tr>
</tbody>
</table>

| **Hypertrophic Pyloric Stenosis** | 0.03-1.0% of live births Can present at 1-30 wk, most commonly at 6-8 wk M:F = 4:1 Early erythromycin exposure (<13 d old) | Acquired pyloric circular muscle hypertrophy results in gastric outlet obstruction Hypovolemia caused by emesis of gastric contents causes hyperchloremic metabolic alkalosis Electrolyte exchange based volume retention in kidneys results in paradoxical ascites | Projectile non-bilious vomiting Vomiting 10-60 min after feeds Hungry after vomiting Dehydration (variable severity) Smooth distending 1-2 cm mass palpable above umbilicus, “slive” visible left-to-right gastric contraction “waves” after feeding Electrolytes (assesses hypochloremia, dehydration) US shows pyloric length > 14 mm, muscle thickness > 4 mm Upper GI series necessary only when US unanswerable or non-diagnostic will show “string sign” | Fluid resuscitate with normal saline, correct electrolyte and acid base abnormalities with DS, 1/2NS + 20 mEq/L KCl at maintenance rate NGT decompression unnecessary Pyelotomy, open (Ramstedt vs. transumbilical or laparoscopic approach) Alternatives therapies such as TPN/Waist or atropine impractical due to long time course of effect | Pyloromyotomy curative |

| **Congenital Diaphragmatic Hernias** | 1 in 2,000 to 5,000 live births Presents within hours of life although some cases of delayed presentation M:F = 4:1 >10% are associated with other congenital anomalies Prenatal diagnosis common | Left-sided: small bowel, large bowel, stomach, and solid viscera (spine, left lobe of liver) herniate into thorax Right-sided: liver, large bowel herniate into thorax Pulmonary hypoplasia Pulmonary HTN | Early respiratory distress Cyanosis Scaphoid abdomen Prenatal diagnosis Decreased air entry ± bowel sounds in the chest Displaced heart sounds | Prenatal US/MRI ABG CR (bowel loops in herniated, shifted heart) Echocardiography Genetic consultation if warranted Intubate Diaphragmatic suction Period of respiratory stabilization due to associated pulmonary hypoplasia (may require ECMO) Surgical repair after stable by hemicorrision and closure of diaphragmatic defect – open vs. thorascoposcopic vs. laparoscopic with or without prosthetic or muscular patch depending on size of defect | Better outcomes in later presentations Hearing deficit (40%) Associated GERD MSK defects – chest wall and scoliotic defects a potential complication of thoracotomy Long-term surveillance for potential recurrence Failure to thrive Chronic lung disease if severe hypoplasia |

| **Meckel’s Diverticulum** | Most common remnant of vitelline duct that connects yolk sac with primitive midgut | Failure of vitelline duct to regress 5-7 wk in utero; 50% contain heterotopic tissue (e.g. gastric mucosa, ectopic pancreas); other associated anomalies include omphaloenteric fistula, umbilical sinus, umbilical cyst, fibrous band | BRBPR (Heterotopic gastric mucosa in Meckel’s causing mucosal ulceration and bleeding in adjacent small bowel mucosa) Abdominal ascites (Meckel’s diverticulitis = perforation) Small bowel volvulus around fibrous band Tenderness (lower abdomen) near umbilicus | ANR: Meckel scan: scan for ectopic gastric mucosa with technetium Tc99m pertechnetate IV (sensitivity 85%, specificity 85%) | Stable, reaction to laparotomy or laparoscopy ± incidental appendectomy Resection curative |
## Malrotation

<table>
<thead>
<tr>
<th>Condition</th>
<th>Epidemiology and Risk Factors</th>
<th>Pathophysiology</th>
<th>Clinical Features and History</th>
<th>Physical Exam</th>
<th>Investigations</th>
<th>Treatment</th>
<th>Prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malrotation</td>
<td>1,500 live births 1/3 present by 1 wk of age, 3/4 by 1 mo of age, 90% by 1 yr of age M:F = 1:1; higher incidence among patients with cardiac anomalies, heterotaxy syndromes</td>
<td>Failure of gut to normally rotate around SMA with associated abnormal intestinal attachments and anatomic positions</td>
<td>Biloikus exclusion is THE cardinal sign, especially if abdomen nondistended If bilious exclusion in W child with distended abdomen, consider surgical exploration to rule out volvulus Rectal bled (lots/omnius signs)</td>
<td>Intestinal tenderness</td>
<td>AXR: obstruction of proximal SBD, double-bubble sign, intestinal wall thickened Immediate UGI: dilated duodenum, duodenjejunal segment (ligament of Trietz) Right of midline and not fixed posteriorly over spinal column, &quot;corkscrew&quot; sign indicating volvulus U/S: &quot;whirlpool&quot; sign, abnormal SMA/SMV relationship indicates UGI to rule out rotational anomalies</td>
<td>IV antibiotics Fluid resuscitation EMERGENT LAPAROTOMY Ladd procedure counter clockwise reduction of mid gut volvulus, division of Ladd's bands, division of peritoneal attachments between cecum and abdominal wall that disrupt duodenum, broadening of the mesentry (open divided mesentry like a book)</td>
<td>Mortality related to length of bowel loss: 10% necrosis – 100% survival rate, 75% necrosis – 35% survival rate Recurrence 2-6%</td>
</tr>
</tbody>
</table>

## Gastroesophageal Reflux Disease

<table>
<thead>
<tr>
<th>Condition</th>
<th>Epidemiology and Risk Factors</th>
<th>Pathophysiology</th>
<th>Clinical Features and History</th>
<th>Physical Exam</th>
<th>Investigations</th>
<th>Treatment</th>
<th>Prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastroesophageal Reflux Disease</td>
<td>1,200 live births Antenatal diagnosis common Increases with younger maternal age and associated with IUGR M:F = 1:1</td>
<td>Defect of abdominal wall, with free extrusion of intestine into amniotic cavity No specific environmental factor identified Defect in embryogenesis unclear</td>
<td>Not associated with genetic syndromes 10% with intestinal atresia Some cases associated with short bowel syndrome due to antenatal volvulus and necrosis of herniated bowel</td>
<td>Hollow visceras (stomach, small and large bowells) Defect lateral to cord (usually right) Bowel may be inflamed, thickened, matted, foreshortened</td>
<td>Prenatal U/S Elevated MS-AFP</td>
<td>NGT decompression IV fluids IV antibiotics</td>
<td>&gt;90% survival rate</td>
</tr>
</tbody>
</table>

## Omphalocele

<table>
<thead>
<tr>
<th>Condition</th>
<th>Epidemiology and Risk Factors</th>
<th>Pathophysiology</th>
<th>Clinical Features and History</th>
<th>Physical Exam</th>
<th>Investigations</th>
<th>Treatment</th>
<th>Prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omphalocele</td>
<td>1,500 live birth Antenatal diagnosis common Lower gestational age Increased maternal age M:F = 1.5:1</td>
<td>Defect of abdominal wall, with extrusion of sac covered visceras (amnion, Wharton's jelly, peritoneum) Dahamal theory – failure of body wall morphogenesis</td>
<td>Associated with genetic syndromes 30-70% (e.g. Pentalogy of Cantrell, congenital heart disease, Beckwith-Wiedemann syndrome) Associated pulmonary hypoplasia</td>
<td>Hollow visceras (stomach, small and large bowells, often liver) Cord on the sac</td>
<td>Preanatal U/S Elevated MS-AFP</td>
<td>NGT decompression IV fluids, IV antibiotics Small defect (&lt;2 cm): Primary closure Medium (2-4 cm) and large (&gt;4 cm) defects: silver sulfadiazine coupled with compression dressing to allow epithelialization and gradual reduction, followed by future repair ± mesh</td>
<td>40-70% survival rate Higher survival rates most likely related to antenatal mortality of fetuses with giant omphaloceles</td>
</tr>
</tbody>
</table>

## Umbilical Hernias

<table>
<thead>
<tr>
<th>Condition</th>
<th>Epidemiology and Risk Factors</th>
<th>Pathophysiology</th>
<th>Clinical Features and History</th>
<th>Physical Exam</th>
<th>Investigations</th>
<th>Treatment</th>
<th>Prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Umbilical Hernias</td>
<td>Incidence 2-14% Increases with prematurity Decreases with increasing age</td>
<td>Incomplete closure of peritoneal and fascial layers within umbilicus by 5 yr</td>
<td>Majority asymptomatic Majority spontaneously resolve by age 5 Incarceration prior to age 5 very rare Most symptoms occur in late adolescence or adulthood</td>
<td>Potrusion from umbilicus Different from less common abdominal wall hernias that do not spontaneously resolve (e.g. epigastric hernias) Most defects &gt;1.5 cm in infancy will not close spontaneously</td>
<td>None if uncomplicated</td>
<td>Repair if not spontaneously closed by age 5 Earlier repair of large &quot;protruded&quot; hernias with extensive skin stretching may be warranted for cosmetic reasons Simple primary closure of fascial defect</td>
<td>Low risk of recurrence</td>
</tr>
</tbody>
</table>

## Intestinal Atresia

<table>
<thead>
<tr>
<th>Condition</th>
<th>Epidemiology and Risk Factors</th>
<th>Pathophysiology</th>
<th>Clinical Features and History</th>
<th>Physical Exam</th>
<th>Investigations</th>
<th>Treatment</th>
<th>Prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intestinal Atresia</td>
<td>Incidence 2-14% May be antenatally diagnosed by dilated bowel loops or &quot;double bubble&quot; sign on x-ray for duodenal atresia Decreased with increasing age</td>
<td>Duodenal – failure of bowel to recognize after endodermal epithelium proliferation (wk 8-10) Jejunum/ileum – acquired as a result of vascular disruption – ischemic necrosis – resection of necrotic tissue → blind distal and proximal ends Colonic – mechanism unknown, thought to be similar to small bowel atresia</td>
<td>Gastric distension and vomiting (usually bilious) Duodenal – may be associated with other anomalies (tracheoesophageal fistula, cardiac, renal, and ventral anomalies), 24-18% have Down syndrome Jejunum/ileum – within 2 d of birth, may be associated with CF Colon – within 3 d of birth</td>
<td>Complete physical Special attention to abdominal exam Peritoneum and assay Include evaluation of respiratory distress and signs of volume depletion Congenital anomalies Jeunice</td>
<td>Contrast enema ± UGI with small bowel follow through (SBFT) Group and screen INR and PTT if for surgery</td>
<td>NPD NGT decompression Fluid resuscitate TPN Broad spectrum antibiotics Duodenal – duodenoduodenostomy or duodenoejunojejunostomy Jejunum/Ileal – primary anastomosis; or if ileus associated with short bowel then may create end stoma or defer surgery for bowel lengthening procedures Colon – primary anastomosis</td>
<td>Long-term survival Duodenal – 86% Jejunum/Ileal – 84% Colon – 100%</td>
</tr>
<tr>
<td>Condition</td>
<td>Epidemiology and Risk Factors</td>
<td>Pathophysiology</td>
<td>Clinical Features and History</td>
<td>Physical Exam</td>
<td>Investigations</td>
<td>Treatment</td>
<td>Prognosis</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------</td>
<td>-----------------</td>
<td>------------------------------</td>
<td>---------------</td>
<td>--------------</td>
<td>----------</td>
<td>----------</td>
</tr>
<tr>
<td>Hirschsprung’s Disease</td>
<td>1:5,000 births M:F = 3:1 to 4:1, approaches 1:1 when whole colon involved Can have aganglionosis of small bowel as well Familial Hirschsprung’s in &lt;5% of cases</td>
<td>Defect in migration of neurocryst cells to intestine resulting in aganglionic bowel that fails to peristalsis and internal sphincter that fails to relax (internal anal sphincter achalasia) causing functional and partial mechanical obstruction, respectively always starts in the rectum and variable involvement proximally; RET mutation</td>
<td>Failure to pass meconium spontaneously within 6h of life is the classic history (95% pass meconium within 24h, 5% within 48h) Symptoms of bowel obstruction: constipation, bilious emesis Enterocolitis/vomiting Failure to thrive</td>
<td>Rectal biopsy (gold standard) – look for aganglionosis and neural hypothyrosis AUR Contrast enema to find narrow rectum and transition zone Anal manometry unreliable in infants – classic finding is absence of rectoanal inhibitory reflex</td>
<td>Surgical resection of aganglionic intestinal segment and anastomosis of remaining intestine to anus Either in newborn period or staged if extensive aganglionosis</td>
<td>Most have normal near-normal anorectal function Complications: Fecal incontinence and constipation, post-operative enterocolitis (medical emergency if progresses to sepsis)</td>
<td></td>
</tr>
<tr>
<td>Cryptorchidism</td>
<td>2-3% of term males – most of these descend spontaneously by time of age 1% of males do not spontaneously descend</td>
<td>Idiopathic Descent is mediated by descendin which is created in response to testosterone. Descent usually begins at 28 weeks</td>
<td>Palpable testicle within inguinal canal or testicle which can be milked down into scrotum (called retrograde testicle) Occasionally no-palpable testis as it is intra-abdominal Consider other congenital abnormalities</td>
<td>Bi-annual testicular exam with palpation Distinguish truly undescended testes from retrograde testes (which is “high” testis due to hyperactive cremasteric muscles)</td>
<td>Depends on age of presentation USS or MRI if no palpable testes Older child: LH, FSH, MS, HCG stimulation test for gonadotropin production Infant: USS, FSH, LH, karyotyping, 17-hydroxy-progesterone</td>
<td>HCG to stimulate testosterone production and descent Orchidopexy – especially if undescended by age 6 mo-2 yr Orchidopexy Decreased risk of torsion and blunt trauma to testicle No effect on malignant potential of testicle Descent can preserve spermatogenesis if performed by 1 yr of age</td>
<td></td>
</tr>
<tr>
<td>Intussusception</td>
<td>Most common cause of bowel obstruction between 6-36 mo 26:100,000 newborns M:F = 1.2 Pathologic lead points: enlarged Peyer’s patches due to viral infections of the Gl tract, polyps, Meckel’s diverticulum CF lymphoma, IBD may increase risk</td>
<td>Idiopathic is most common Usually starts at ileocecal junction Telescopy of bowel into itself causing an obstruction and vascular compromise</td>
<td>Acute onset of abdominal pain which is classic episodic “cyclic” pain Vomiting: ± bilious Abdominal mass Current-jelly stool suggests mucosal necrosis and sloughing</td>
<td>Abdominal exam Palpate for masses (especially sausage shaped upper abdominal mass) and tenderness Signs of bowel obstruction: distended abdomen Look for localized peritonitis which suggests transmural ischemia</td>
<td>AUR for signs of bowel obstruction or perforation USS if suspect pathology</td>
<td>If perforation, then consider operative management Non-operative management involves reduction via air contrast enema Operative reduction can be done open or laparoscopically Resection of involved colon if failure to reduce or bowel appears compromised</td>
<td>10% recurrence rate If recurrent = more likely non-dispatiche If successfully reduced by enema in older children allow 2wk resolution of edema then perform SBFT to rule out pathologic lead points</td>
</tr>
<tr>
<td>Tracheoesophageal Fistula (TEF)</td>
<td>1:3,000-1:4,500 Associated anomalies in 50% VACTERL association (see Pediatrics, P40)</td>
<td>Varies with type of fistula May have history of maternal polyhydramnios May present after several months (if no associated esophageal atresia) of non-bilious vomiting, coughing, cyanosis with feeds, respiratory distress, recurrent pneumonia, frothy bubbles of mucus in mouth and nose that return after suctioning</td>
<td>X-ray: anatomic abnormalities, NGT curled in pouch</td>
<td>Investigate for other congenital anomalies, early repair by surgical ligation to prevent lung damage and maintain nutrition and growth</td>
<td>Complications: pneumonia, sepsis, reactive airways disease Following repair: esophageal stenosis and strictures at repair site, GERD and poor swallowing (i.e. dysphagia, regurgitation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inguinal Hernias</td>
<td>5% of all term newborns 2x risk and more likely bilateral if pre-term M:F = 4:1 Low birth weight increases risk 1/5 inguinal hernias will become incarcerated if patient is &lt;1 yr old Incarceration is more common in females Associated with other conditions: androgen insensitivity, connective tissue diseases</td>
<td>All infant hernias are indirect: descent of intra-abdominal contents through the internal inguinal ring through a patent tunica vaginalis</td>
<td>Most common presentation: painless intermittent mass in groin, may also note extension into scrotum (scrotal mass in absence of inguinal mass is a hydrocele) If incarcerated: tender, vomiting, firm mass, erythema then cyanosis of mass may be noted</td>
<td>Palpate for “bag of worms” suggests possible testicular varicocele Biannual testicular exam + palpation along inguinal canal to evaluate for any masses “Silk sign” – palpable thickening of cord Mass palpated at external inguinal ring and reducible through inguinal canal into abdomen Must always try reduction to confirm that hernia is not incarcerated</td>
<td>Physical exam is gold standard U/S only if physical exam uncertain (e.g. in small infants where exam can be difficult)</td>
<td>Manual reduction – to relieve acute symptoms Herniomy – definitive treatment by reduction of herniated contents and high ligation of sac for indirect hernias Laparoscopic or open techniques</td>
<td>Risk of recurrence after surgical reduction &lt;3% but higher if repair done in premature infants or if hernia was incarcerated/strangled at repair</td>
</tr>
</tbody>
</table>

**Notes:**
- **Cryptorchidism**
  - Most common cause of bowel obstruction between 6-36 mo
  - 26:100,000 newborns
  - M:F = 1.2
  - Pathologic lead points: enlarged Peyer’s patches due to viral infections of the Gl tract, polyps, Meckel’s diverticulum, CF, lymphoma, IBD may increase risk

- **Intussusception**
  - Most common cause of bowel obstruction
  - Usually starts at ileocecal junction
  - Telescopy of bowel into itself causing an obstruction and vascular compromise

- **Tracheoesophageal Fistula (TEF)**
  - Associated anomalies in 50% VACTERL association
  - Varies with type of fistula
  - May have history of maternal polyhydramnios
  - May present after several months (if no associated esophageal atresia) of non-bilious vomiting, coughing, cyanosis with feeds, respiratory distress, recurrent pneumonia, frothy bubbles of mucus in mouth and nose that return after suctioning

- **Inguinal Hernias**
  - 5% of all term newborns
  - 2x risk and more likely bilateral if pre-term
  - M:F = 4:1
  - Low birth weight increases risk
  - 1/5 inguinal hernias will become incarcerated if patient is <1 yr old
  - Incarceration is more common in females
  - Associated with other conditions: androgen insensitivity, connective tissue diseases
Skin Lesions

- see Dermatology, D5; Emergency Medicine, ER17; Plastic Surgery, PL5

### Common Medications

#### Antiemetics
- dimenhydrinate (Gravol®) 25-50 mg PO/IM q4-8h
- prochlorperazine (Stemetil®) 5-10 mg PO/IM bid-tid
- metoclopramide (Maxeran®) 10 mg IV/IM q2-3h
- ondansetron (Zofran®) 4-8 mg PO q6h
- granisetron (Kytril®) 1 mg PO bid (for nausea from chemotherapy/radiation)

#### Analgesics
- acetaminophen + codeine (Tylenol® #3/gan) 1-2 tabs q4-6h PO/PR bid
- hydromorphone i-tabs PO q4h
- ibuprofen 200-400 mg PO q4-6h
- morphine 2.5-10 mg IM/SC q4-6h
- ketorolac (Toradol®) 30-60 mg IM/IV q6h
- Percocet® (acetaminophen/oxycodone, 325/5 mg) 1-2 tabs PO q4-6h

#### DVT Prophylaxis
- heparin 5,000 units SC bid
- enoxaparin (Lovenox®) 40 mg SC daily
- dalteparin (Fragmin®) 5,000 units SC daily

#### Antidiarrheals
- loperamide (Imodium®) 4 mg PO initially, then 2 mg PO after each loose stool up to 16 mg/d
- diphenoxylate + atropine (Lomotil®) 2 tabs/10 mL PO qid

#### Laxatives
- sennosides (Senokot®) 1-2 tabs qhs
- docusate sodium (Colace®) 100 mg PO bid
- glycerine suppository 1 tab PR bid
- lactulose 15-30 mL PO qid
- milk of magnesia (MOM) 30-60 mL PO qid
- bisacodyl (Dulcolax®) 10-15 mg PO qm

#### Sedatives
- zopiclone (Imovane®) 5-7.5 mg PO qhs
- lorazepam (Ativan®) 0.5-2 mg PO/SL qhs

#### Antibiotics
- cefazolin (Ancef®) 1 g IV/IM on call to OR or q6h – GP except Enterococcus, GN only. E. coli, Klebsiella, and Proteus
- cefalexin (Keflex®) 250-500 mg PO qid – Staphylococci, GN only. E. coli, Klebsiella, and Proteus
- ceftriaxone 1-2 g IM/IV q24h – broad coverage including Pseudomonas
- ampicillin 1-2 g IV q4-6h – Staphylococci except Enterococcus and E. coli, oral anaerobes except Bacteroides
- gentamicin 3-5 mg/kg IM/IV divided q8h – monitor creatinine, gentamicin levels – GN including Pseudomonas
- ciprofloxacin 400 mg IV q12h, 500 mg PO bid – GN including Pseudomonas
- metronidazole (Flagyl®) 500 mg PO/IV bid (500 mg PO tid for C. difficile) – anaerobes
- clindamycin 600-900 mg IV q6h, 150-400 mg PO qid – GP except Enterococcus, anaerobes
- piperacillin/tazobactam 4.5 mg IV q6h – GP, GN, and anaerobes
- vancomycin 1g IV q12h – GP and MRSA
- sulfa (Bactrim®/Septra®) PO bid – GP, GN including Nocardia

#### Over-the-Counter Medications
- Pepto-Bismol® (bismuth subsalicylate) 2 tabs or 30 mL PO q30min-1h up to 8 doses/d side effects: black stools, risk of Reye’s syndrome in children
- Alka-Seltzer® (ASA + citrate + bicarbonate) 2 tabs in 4 oz water PO q6h pm, max 8 tabs
- Maalox® (aluminum hydroxide + magnesium hydroxide) 10-20 mL or 1-4 tabs PO q6h
- Tums® (calcium carbonate) 1-3 g PO q6h
- Rolaid® (calcium carbonate and magnesium hydroxide) 2-4 tabs PO q1h pm, max 12 tabs/d
Acronyms .................................................. 2

Seniors in Canada and the U.S. .............. 2
Health Status

Physiology and Pathology of Aging .......... 2

Differential Diagnoses of Common Presentations . . 3
Constipation
Delirium, Dementia, and Depression
Elder Abuse
Falls
Frailty (Functional Decline/Failure to Thrive)
Incontinence
Gait Disorders
Hazards of Hospitalization
Hypertension
Immobility
Immunizations
Malnutrition
Osteoporosis
Presbycusis
Pressure Ulcers

Driving Competency ............................... 11
Reporting Requirements
Conditions that may Impair Driving

Health Care Institutions ......................... 12

Palliative and End-of-Life Care ............... 12
Principles and Quality of Life
End-of-Life Care Discussions
Power of Attorney
Instructional Advance Directives
Symptom Management

Geriatric Pharmacology .......................... 14
Pharmacokinetics
Pharmacodynamics
Polypharmacy
Inappropriate Prescribing in the Elderly

Common Medications ............................ 15

Landmark Geriatric Trials ........................ 16

References .......................................... 16
Table 1. Causes of Mortality and Morbidity in Canadian and American Seniors

<table>
<thead>
<tr>
<th>Mortality (Can¹/U.S.²)</th>
<th>Morbidity³,⁴</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Diseases of the heart and circulatory system (19.7/27.0%)</td>
<td>1. Hypertension 5. Ulcers</td>
</tr>
<tr>
<td>3. Cerebrovascular disease (5.5/6.0%)</td>
<td>3. Heart disease 7. Asthma</td>
</tr>
<tr>
<td>4. Chronic lower respiratory disease (4.6/7.0%)</td>
<td>4. Diabetes 8. Allergies</td>
</tr>
<tr>
<td>5. Accidents (4.4%)</td>
<td>6. Alzheimer's (2.6/5.0%)</td>
</tr>
</tbody>
</table>

¹Statistics Canada, 2011  ²Minino AM, 2009

Definition
- major categories of impairment that appear with age and affect the physical, mental, and social domains of the elderly, usually due to many predisposing and precipitating factors, rather than a single cause

Table 2. Changes Occurring Frequently with Aging

<table>
<thead>
<tr>
<th>System</th>
<th>Physiological Changes</th>
<th>Pathological Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurologic</td>
<td>Decreased wakefulness, brain mass, cerebral blood flow, increased white matter changes</td>
<td>Increased insomnia, neurodegenerative disease, stroke, decreased reflex response</td>
</tr>
<tr>
<td>Special Senses</td>
<td>Decreased lacrimal gland secretion, lens transparency, dark adaptation, decreased sense of smell and taste</td>
<td>Increased glaucoma, cataracts, macular degeneration, presbycusis, presbyopia, tinnitus, vertigo, oral dryness</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Increased sBP, dBP, decreased HR, CO Decreased vessel elasticity, cardiac myocyte size and number, β-adrenergic responsiveness</td>
<td>Increased atherosclerosis, CAD, MI, CHF; hypertension, arrhythmias, orthostatic hypotension</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Increased tracheal cartilage calcification, mucous gland hypertrophy Decreased elastic recoil, mucociliary clearance, pulmonary function reserve</td>
<td>Increased COPD, pneumonia, pulmonary embolism</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Increased intestinal villos atrophy Decreased esophageal peristalsis, gastric acid secretion, liver mass, hepatic blood flow, calcium and iron absorption</td>
<td>Increased cancer, diverticulitis, constipation, fecal incontinence, hemorrhoids, intestinal obstruction, malnutrition, weight loss</td>
</tr>
<tr>
<td>Renal and Urologic</td>
<td>Increased proteinuria, urinary frequency Decreased renal mass, creatinine clearance, urine acidification, hydroxylation of vitamin D, bladder capacity</td>
<td>Increased urinary incontinence, nocturia, BPH, prostate cancer, pylonephritis, nephrolithiasis, UTI</td>
</tr>
<tr>
<td>Reproductive</td>
<td>Decreased androgen, estrogen, sperm count, vaginal secretion Decreased ovary, uterus, vagina, breast size</td>
<td>Increased breast and endometrial cancer, cystocele, rectocele, atrophic vaginitis</td>
</tr>
<tr>
<td>Endocrine</td>
<td>Increased NE, PTH, insulin, vasopressin Decreased thyroid and adrenal corticosteroid secretion</td>
<td>Increased DM, hypothyroidism, stress response</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>Increased calcium loss from bone Decreased muscle mass, cartilage</td>
<td>Increased arthritis, bursts, osteoporosis, muscle weakness with gait abnormalities, polymyalgia rheumatica</td>
</tr>
<tr>
<td>Integumentary</td>
<td>Atrophy of sebaceous and sweat glands Decreased epidermal and dermal thickness, dermal vascularity, melanocytes, collagen synthesis</td>
<td>Increased lentigo, cherry hemangiomas, pruritus, seborrheic keratosis, herpes zoster, decubitus ulcers, skin cancer, easy bruising</td>
</tr>
<tr>
<td>Psychiatric</td>
<td>None</td>
<td>Increased depression, dementia, delirium, suicidality, anxiety, sleep disruption</td>
</tr>
</tbody>
</table>
Differential Diagnoses of Common Presentations

Constipation

- see Gastroenterology, G24

Definition
- less than 3 bowel movements in one wk and/or hard stools, straining, sense of blockade, needing manual maneuvers or incomplete evacuation on more than 25% of occasions for at least 12 wk (does not need to be consecutive)

Epidemiology
- chronic constipation increases with age (up to 1/3 of patients >65 yr experience constipation and 1/2 of patients >80)
- in the elderly, chronic constipation may present as fecal impaction

Pathophysiology
- impaired rectal sensation (increased rectal distention required to stimulate the urge to defecate)
- colorectal dysmotility

Treatment
- non-pharmacological
- increase fibre intake
- ensure adequate fluid intake
- discourage chronic laxative use
- engage in regular exercise
- review medication regime, reduce dosages or substitute
- pharmacologic
- see Common Medications, GM11

Figure 1. Treatment algorithm for the management of chronic constipation in the elderly

Adapted from: Clin Interv Aging 2010;5:163-171

Common Causes of Constipation Include:
- Electrolyte abnormalities (hypokalemia, hypercalcemia)
- Endocrine (hypothyroidism, DM)
- GI (IBS, colon cancer)
- Neurologic (multiple sclerosis, Parkinson’s disease)
- Psychiatric (depression, dementia)
- Other (dehydration, immobility)

Drugs Associated with Constipation Include:
- Analgesics (narcotics, NSAIDs)
- Anticholinergics
- Calcium channel blockers
- Diuretics
- Supplements (iron or calcium)

Treatment of Constipation in Older Adults

CMAJ 2013;185(8):663-70

Objectives: To discuss management of constipation in older adults.

Results/Conclusions: In older adults, the predominant symptom of constipation is more frequently straining than decreased stool frequency. RCTs support the use of osmotic agents to treat symptoms of constipation in older adults. In contrast, evidence supporting the use of bulk agents, stool softeners, stimulants, and prokinetic agents is lacking, limited and inconsistent.
Delirium, Dementia, and Depression

- see Psychiatry, PS19, PS20, PS10 and Neurology, N20

Definition
- all of the above may present with pathologic decrease in memory, language, or executive function

Differential Diagnosis
- delirium, dementia, or pseudodementia of depression (see Psychiatry)

Delirium Prevention in Elderly
- ensure optimal vision and hearing to support orientation (e.g. appropriate eye wear and hearing aids)
- provide adequate nutrition and hydration (up in chair to eat and drink whenever feasible)
- encourage regular mobilization to build and maintain strength, balance, and endurance
- avoid unnecessary medications and monitor for drug interactions
- avoid bladder catheterization if possible
- ensure adequate sleep

Elder Abuse

Definition
- includes physical abuse, sexual abuse, emotional/psychological abuse, financial abuse, abandonment, and neglect
- elder abuse is a criminal offence under the Criminal Code of Canada
- in the U.S., most states have criminal penalties for elder abuse

Epidemiology
- in Canada in 2013, almost 3000 seniors were victims of family violence. The perpetrators of family violence against seniors were identified to be their grown child (43% of cases) and their spouses (28% of the cases)
- in Canada in 2013, the rate of family-related homicides against seniors was 3.2 for every 1 million seniors
- in the U.S., estimates of the frequency of elder abuse range from 3-8%
- physician reporting is mandatory only in Newfoundland, Nova Scotia, and Prince Edward Island; in Canada in 2013, almost 3000 seniors were victims of family violence. The perpetrators of family violence against seniors were identified to be their grown child (43% of cases) and their spouses (28% of the cases)
- in Canada in 2013, almost 3000 seniors were victims of family violence. The perpetrators of family violence against seniors were identified to be their grown child (43% of cases) and their spouses (28% of the cases)

Risk Factors

Table 3. Risk Factors for Elder Abuse

<table>
<thead>
<tr>
<th>Situational Factors</th>
<th>Isolation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unstable or unsafe living arrangements</td>
</tr>
<tr>
<td></td>
<td>Lack of family, community or living facility resources for additional care</td>
</tr>
</tbody>
</table>

Victim Characteristics
- Physical or emotional dependence on caregiver
- Lack of close family ties
- History of family violence
- Dementia or recent deterioration in health

Perpetrator Characteristics
- Related to victim
- Living with victim
- Long duration of care for victim (mean 9.5 yr)
- Financial, marital, occupational or other stressors

Caregiver Abuse Screen (CASE)

- instructions
  - to be answered by caregivers, if answer "yes" to a question, further explore issue
  - the more "yes" responses, the more likely the presence of abuse
  - screening tool
  - please answer the following questions as a helper/caregiver:
  1. Do you sometimes have trouble making ______ control his/her temper or aggression?
  2. Do you often feel you are being forced to act out of character/do things you feel badly about?
  3. Do you find it difficult to manage ______’s behaviour?
  4. Do you sometimes feel that you are forced to be rough with ______?
  5. Do you sometimes feel that you can’t do what is really necessary or what should be done for ______?
  6. Do you often feel you have to reject/ignore ______?
  7. Do you often feel so tired and exhausted that you cannot meet ______’s needs?
  8. Do you often feel you have to yell at ______?

From: NICE. Case: Caregiver Abuse Screen. 2010. Reproduced with permission from NICE.
Management
- assess safety and determine capacity to make decisions about living arrangements
- establish need for hospitalization or alternate accommodation (e.g. immediate risk of physical harm by self or caregiver)
- involve multidisciplinary team (e.g. nurse, social worker, family members, and physicians including geriatrician, psychiatrist or family physician)
- educate and assist caregiver, contact local resources (e.g. legal aid, crisis support, PSW, caregiver support groups)
- interpret critical and lab findings that are key in exclusion, differentiation and diagnosis

Falls

Definition
- an event which results in a person coming to rest inadvertently on the ground or floor or other lower level

Epidemiology
- 30-40% of people >65 yr old and ~50% of people >80 yr old fall each year
  - equally common between men and women, but more likely to result in injury in women and death in men
  - 5% of falls lead to hospitalization
  - falls are the leading cause of death from injury in persons older than 65 yr
  - 25% associated with serious injuries (e.g. hip fracture, head injury, bruises, laceration)
  - between 25-75% do not recover to previous level of ADL function
  - mortality increases with age (171/100,000 in men >85 yr old) and type of injury (25% with hip fracture die within 6 mo)

Etiology
- multifactorial
  - extrinsic
    - environmental (e.g. home layout, lighting, stairs, overcrowding)
    - accidental, abuse
    - side effects of medications and substance abuse (e.g. alcohol)
  - ace illness, exacerbation of chronic illness
- intrinsic
  - orthostatic/syncopal
  - age-related changes and diseases associated with aging: musculoskeletal (arthritis, muscle weakness), sensory (visual, proprioceptive, vestibular), cognitive (depression, dementia, delirium, anxiety), cardiovascular (CAD, arrhythmia, MI, low BP), neurologic (stroke, decreased LOC, gait disturbances/ataxia), metabolic (glucose, electrolytes)

Investigations
- directed by history and physical
- comprehensive geriatric assessment to identify all potential causes
- CBC, electrolytes, BUN, creatinine, glucose, Ca\(^{++}\), TSH, B12, urinalysis, cardiac enzymes, ECG, CT head

Prevention
- multidisciplinary, multifactorial, health, and environmental risk factor screening and intervention programs in the community
- muscle strengthening, balance retraining, and group exercise programs (e.g. Tai Chi)
- home hazard assessment and modification (e.g. remove rugs, add shower bars, etc.)
- prescription of vitamin D 1000 IU daily
- tapering or gradually discontinuation of psychotropic medication
- postural hypotension, heart rate, and rhythm abnormalities management
- eyesight and footwear optimization

Red Flags for Elder Abuse
- Delay in seeking medical attention
- Disparity in histories
- Implausible or vague explanations
- Frequent emergency room visits for exacerbations of chronic disease despite plan for medical care and adequate resources
- Presentation of functionally impaired patient without designated caregiver
- Lab findings inconsistent with history

Key Physical Findings in the Elderly Patient

Who Falls or Nearly Falls
I HATE FALLING
Inflammation of joints
Hypotension (orthostatic changes)
Auditory and visual abnormalities
Tremor
Equilibrium (balance) problem
Foot Problems
Arrhythmia, heart block or valvular disease
Leg-length discrepancy
Lack of conditioning (generalized weakness)
Illness
Nutrition
Gait disturbance
Am Fam Phy 2001;61:2159-2172

A history of falls within the past 1-2 yr is a predictor of motor vehicle crashes in the older population. These patients should be evaluated on their ability to drive and counseled about driving

Drugs That May Increase the Risk of Falling
- Sedative-hypnotic and anxiolytic drugs (especially long-acting benzodiazepines)
- Antidepressants (including MAOIs, SSRIs, TCAs)
- Antipsychotics and tranquilizers (phenothiazines and butyrophenones)
- Antihypertensive drugs
- Antihypertensive drugs (Class IA)
- Diuretics
- Systemic corticosteroids
- NSAIDs
- Anticholinergic drugs
- Hypoglycemic agents
- Alcohol
Adapted from: Am Fam Phy 2001;61:2159-2172

Fall Prevention Tips
- Improve lighting, especially on stairs
- Caution while adjusting to new bifocal prescription (poor depth perception)
- Side rails in bathtubs
- Railings on steps
- Connect patient to lifeline button signaling systems
- Remove loose mats or carpets, telephone cords and other tripping hazards
- Recommend support hose for varicose veins and swelling of ankles
Essential Geriatrics: Managing 6 Conditions. Patient Care Canada 1987;8
**Frailty (Functional Decline/Failure to Thrive)**

**Definition**
- frailty - clinical state of older adults with increased vulnerability to acute stressors resulted from functional decline
- functional decline - progressive limitation in the ability to carry out basic functional activities
- failure to thrive - a state of decline that may be characterized by weight loss, decreased appetite, poor nutrition, and inactivity

**Etiology**
- multifactorial - malnutrition, functional impairment, cognitive impairment, and depression

**Table 4. Common Medical Conditions Associated with Failure to Thrive**

<table>
<thead>
<tr>
<th>Medical Condition</th>
<th>Cause of Failure to Thrive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer</td>
<td>Metastases, malnutrition, cachexia</td>
</tr>
<tr>
<td>Chronic lung disease</td>
<td>Respiratory failure</td>
</tr>
<tr>
<td>Chronic renal insufficiency</td>
<td>Renal failure</td>
</tr>
<tr>
<td>Chronic steroid use</td>
<td>Steroid myopathy, diabetes, osteoporosis, vision loss</td>
</tr>
<tr>
<td>Cirrhosis, hepatitis</td>
<td>Hepatic failure</td>
</tr>
<tr>
<td>Depression, other psychiatric disorders</td>
<td>Major depression, psychosis, poor functional status, cognitive loss</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Malabsorption, poor glucose homeostasis, end-organ damage</td>
</tr>
<tr>
<td>Gastrointestinal surgery</td>
<td>Malabsorption, malnutrition</td>
</tr>
<tr>
<td>Hip, long bone fracture</td>
<td>Functional impairment</td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>Malabsorption, malnutrition</td>
</tr>
<tr>
<td>Myocardial infarction, congestive heart failure</td>
<td>Cardiac failure</td>
</tr>
<tr>
<td>Recurrent UTI, pneumonia</td>
<td>Chronic infection, functional impairment</td>
</tr>
<tr>
<td>Rheumatologic disease (GCA, RA, SLE)</td>
<td>Chronic inflammation</td>
</tr>
<tr>
<td>Stroke</td>
<td>Dysphagia, depression, cognitive loss, functional impairment</td>
</tr>
<tr>
<td>Tuberculosis, other systemic infections</td>
<td>Chronic infection</td>
</tr>
</tbody>
</table>

Adapted from: Côté-Genier MD 1997:13:769-770

**Figure 2. Approach to falls in the elderly**

Adapted from: Davuluri S, Dharanraj T. Clinical Geriatrics 2013;21(10)

**Will My Patient Fall?**

*JAMA* 2007;297:77-86

**Purpose:** To identify the prognostic value of risk factors for future falls among older patients.

**Study Selection:** Meta-analysis of prospective cohort studies of risk factors for falls.

**Results:** 18 studies were included. Clinically identifiable risk factors were identified across 6 domains: orthostatic hypotension, visual impairment, impairment of gait or balance, medication use, limitations in basic or instrumental activities of daily living, and cognitive impairment. The estimated prettest probability of falling at least once in any given yr for individuals 65 yr and older was 27% (95% CI 19-36%). Patients who have fallen in the past yr are more likely to fall again (LR2.3-2.8). Best predictors of future falls were disturbances in gait of balance (LR 1.7-2.4), while visual impairment, impaired cognition, and medication were not reliable predictors.

**Conclusions:** Screening for risk of falling during the clinical examination begins with determining if the patient has fallen in the past yr. For patients who have not previously fallen, screening consists of an assessment of gait and balance. Patients who have fallen or who have a gait or balance problem are at higher risk of future falls.
Fecal Incontinence

Definition
- Involuntary passage or the inability to control the discharge of fecal matter through the rectum.
- Severity can range from unintentional flatus to the complete evacuation of bowel contents.
- There are three subtypes:
  1. Passive incontinence: involuntary discharge of stool or gas without awareness.
  2. Urgency incontinence: discharge of fecal matter in spite of active attempts to retain bowel contents.
  3. Fecal: leakage of stool following otherwise normal evacuation.

Epidemiology
- Second leading cause of nursing home placement.
- US estimates show that 10-25% of hospitalized geriatric patients suffer from fecal incontinence.

Etiology
- Commonly multifactorial
  - Structural abnormalities
  - Trauma (e.g., prior vaginal delivery, surgery).
  - Prolapse
  - Tumour/trauma (e.g., brain, spinal cord, cauda equina).
  - Overflow (e.g., encopresis, impaction).
- Functional abnormalities
  - Neuropathic conditions – neuropathy, multiple sclerosis, stroke, dementia.
- Others
  - Constipation with overflow may be a factor.
  - Psychosis (willful soiling).
  - Age >80 yr: decreased external sphincter strength and weak anal squeeze, increased rectal compliance, decreased resting tone and internal sphincter, impaired anal sensation.
  - Medications (e.g., laxatives, anticholinergics, antidepressants, caffeine, muscle relaxants).

Differential Diagnoses of Common Presentations Toronto Notes 2017GM7   Geriatric Medicine

Figure 3. Failure to thrive in elderly patients
Adapted from: American Family Physician 2004;70:343-350
Investigations (if cause not apparent from history and physical)
- differentiate true incontinence from frequency and urgency (i.e. IBS, IBD)
- stool studies
- endorectal ultrasound
- colonoscopy, sigmoidoscopy, anoscopy
- anorectal manometry/functional testing

Management
- diet/bulking agent if stool is liquid or loose
- disimpaction, prevent impaction
- anti-diarrheal agents (e.g. loperamide)
- regular defecation program in patients with dementia
- counsel about biofeedback therapy (retraining of pelvic floor muscles)

URINARY INCONTINENCE
- see Urology, U5

Definition
- complaint of any involuntary loss of urine
- can be further classified according to patients symptoms as urgency urinary incontinence, stress urinary continence, mixed urinary incontinence, nocturnal enuresis, post-micturition dribble, and continuous urinary leakage

Epidemiology
- 15-30% prevalence dwelling in community and at least 50% of institutionalized seniors
- morbidity: cellulitis, pressure ulcers, urinary tract infections, falls with fractures, sleep deprivation, social withdrawal, depression, sexual dysfunction
- not associated with increased mortality

Pathophysiology
- not a normal part of aging, urinary incontinence is a loss of control due to a combination of:
  - genitourinary pathology: increased post-void residual volume, increased involuntary bladder contractions (urge incontinence)
  - age-related changes: decreased bladder capacity
  - comorbid conditions and medications
  - functional impairment
- in elderly women: decline in bladder outlet and urethral resistance pressure promoting stress incontinence
- in elderly men: prostatic enlargement can cause overflow and urge incontinence

Gait Disorders
- see Neurology, N10

Hazards of Hospitalization

Table 5. Recommendations for Sequelae of Hospitalization in Older Patients

<table>
<thead>
<tr>
<th>Sequelae</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malnutrition</td>
<td>No dietary restrictions (except diabetes), assistance, dentures if necessary, sitting in a chair to eat</td>
</tr>
<tr>
<td>Urinary incontinence</td>
<td>Medication review, remove environmental barriers, discontinue use of catheter</td>
</tr>
<tr>
<td>Depression</td>
<td>Routine screening</td>
</tr>
<tr>
<td>Adverse drug event</td>
<td>Medication review</td>
</tr>
<tr>
<td>Confusion/delirium</td>
<td>Orientation, visual and hearing aids, volume repletion, noise reduction, early mobilization, medication review, remove restraints</td>
</tr>
<tr>
<td>Pressure ulcers</td>
<td>Low-resistance mattress, daily inspection, repositioning every 2 h</td>
</tr>
<tr>
<td>Infection</td>
<td>Early mobilization, remove unnecessary IV lines, catheters, NG tubes</td>
</tr>
<tr>
<td>Falls</td>
<td>Appropriate footwear, assistive devices, early mobilization, remove restraints, medication review</td>
</tr>
<tr>
<td>Hypotension/dehydration</td>
<td>Early recognition and repletion</td>
</tr>
<tr>
<td>Diminished aerobic capacity/loss of muscle strength/contractures</td>
<td>Early mobilization</td>
</tr>
<tr>
<td>Decreased respiratory function</td>
<td>Incentive spirometry, physiotherapy</td>
</tr>
</tbody>
</table>

Hypertension

- see Family Medicine, FM34

Definition
- blood pressure at which an otherwise healthy person would have increased risk of cardiovascular disease
- definition of high blood pressure has changed over time and differs between guidelines proposed by expert bodies
- target: <140/90 mm Hg for adults younger than 80, <130/80 mm Hg for individuals with DM, <150/90 mm Hg for adults aged 80 or older

Epidemiology
- 60%-80% of elderly (>65 yr old) have hypertension
  - 60% of these have isolated systolic HTN
  - the benefit of treating hypertension in the elderly is 2-4 times greater than that achieved in the treatment of younger patients with primary hypertension
  - systolic and pulse pressure are major predictors of outcome in the elderly patient
  - in older adults, base treatment on sBP

Management
- non-pharmacologic treatments are first-line, then thiazide or thiazide-like diuretic monotherapy is recommended in patients without comorbidities
- add ACEI/ARB if also atherosclerosis, DM, CHF or chronic kidney disease
- add β-blockers if also angina or CHF

Immobility

Complications
- cardiovascular: orthostatic hypotension, venous thrombosis, embolism
- respiratory: decreased ventilation, atelectasis, pneumonia
- gastrointestinal: anorexia, constipation, incontinence, dehydration, malnutrition
- genitourinary: infection, urinary retention, bladder calculi, incontinence
- musculoskeletal: atrophy, contractures, bone loss
- skin: pressure ulcers
- psychological: sensory deprivation, delirium, depression

Immunizations

- the following immunizations are recommended for people 65 yr of age and older
  - tetanus: every 10 yr
  - pneumococcus: every 5 yr
  - influenza: every autumn
  - herpes zoster: Zostivax

Malnutrition

Definition
- involuntary weight loss of ≥5% baseline body weight or ≥5 kg
- hypoalbuminemia, hypocholesterolemia

Etiology
- nutritional
  - decreased assimilation: impaired transit, maldigestion, malabsorption
  - decreased intake: financial, psychiatric (depression), cognitive deficits, anorexia associated with chronic disease, functional deficits (e.g. difficulty shopping, preparing meals or feeding oneself due to functional impairment)
  - stress: acute or chronic illness/infection, chronic inflammation, abdominal pain
  - mechanical: dental problems, dysphagia
  - age-related changes: appetite dysregulation, decreased thirst
  - mixed: increased energy demands (e.g. hyperthyroidism), abnormal metabolism, protein-losing enteropathy

Clinical Features
- history
  - recent or chronic illness
    - depression, GI symptoms

Etiology of Malnutrition in the Elderly

MEALS ON WHEELS
- Medications
- Emotional problems
- Anorexia
- Late-life paranoia
- Swallowing disorders
- Oral problems
- Neocarcinomatous infections
- Wandering/dementia related activity
- Hyperthyroidism/Hypercorticism/Hypoadrenalism
- Emetic disorders
- Eating problems
- Low-salt/Low-fat diet
- Stones

Remember to Calculate BMI
- BMI outside 22-27 kg/m² is a health risk
• functional disability: impaired ADLs and IADLs
• social factors: economic barriers, dental problems and living situation (e.g. living alone)
• constitutional symptoms (e.g. recent weight loss)
• physical exam
  • BMI <23.5 in males, <22 in females should raise concern
  • temporal wasting, muscle wasting, presence of triceps skin fold
  • assess cognition

Investigations
• CBC, electrolytes, Ca++, Mg++, PO4-, creatinine, LFTs (albumin, INR, bilirubin), B12, folate, TSH, transferrin, lipid profile, urinalysis, ESR, CXR

Treatment
• direct treatment at underlying causes
• dietary modification: high calorie foods, oral nutritional supplementation

Osteoporosis
• see Endocrinology, E40

Presbycusis
• see Otolaryngology, OT19

Pressure Ulcers
• see Plastic Surgery, PL16

Risk Factors
• extrinsic factors: friction, pressure, shear force
• intrinsic factors: immobility, malnutrition, moisture, sensory loss

Table 6. Classification of Pressure Ulcers

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Changes include skin temperature, tissue consistency or sensation. An area of persistent erythema in lightly pigmented, intact skin; in darker skin, it may appear red, blue or purple.</td>
</tr>
<tr>
<td>II</td>
<td>Partial thickness skin loss involving the epidermis, dermis or both. The ulcer is superficial and presents as an abrasion, blister or shallow crater.</td>
</tr>
<tr>
<td>III</td>
<td>Full thickness skin loss involving damage or necrosis of subcutaneous tissue which may extend down to, but not through, underlying fascia. Presents as a deep crater with or without undermining of adjacent tissue.</td>
</tr>
<tr>
<td>IV</td>
<td>Full thickness skin loss with extensive destruction, tissue necrosis or damage to muscle, bone or supporting structures. May have associated undermining and/or sinus tracts.</td>
</tr>
</tbody>
</table>

Prevention
• pressure reduction
  • frequent repositioning
  • pressure-reducing devices (static, dynamic)
  • maintaining nutrition, encouraging mobility and managing incontinence

Treatment
• optimize nutritional status
• minimize pressure on wound
• analgesia
• wound debridement (mechanical, enzymatic, autolytic) and dressing application
• maintain moist wound environment to enable re-epithelialization
• treatment of wound infections (topical gentamicin, silver sulfadiazine, mupirocin)
• swab wounds not demonstrating clinical improvement for C&S; biopsy chronic wounds to rule out malignancy
• stage IV ulcers typically warrant surgical debridement
• consider other treatment options
  • negative pressure wound therapy/vacuum-assisted closure (VAC)
  • biological agents: application of fibroblast growth factor, platelet-derived growth factor to wound
  • non-contact normothermic wound therapy
  • electrotherapy

Calculating Basic Caloric and Fluid Requirements

**WHO daily energy estimates for adults**

**Male:**

\[ 13.5 \times (weight \text{ in kg}) + 487 \]

**Female:**

\[ 10.5 \times (weight \text{ in kg}) + 596 \]

Maintenance fluid requirements for the elderly without cardiac or renal disease: 1500-2500 cc/24 h
Driving Competency

Reporting Requirements

- physician-reporting to the Ministry of Transportation is mandatory in all provinces and territories except in Quebec, Nova Scotia, and Alberta, where it is discretionary
- not an issue unique to geriatrics – any patient may suffer from a medical condition that impairs their ability to drive should be reported
- in the U.S., varies by state

Conditions that may Impair Driving

**Table 7. Conditions that Impair Driving**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Impairment Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol</td>
<td>Patients with history of impaired driving and those with high probability of future impaired driving should not drive until further assessed. Alcohol dependence or abuse: if suspected, should be advised not to drive. Alcohol withdrawal seizure: must complete a rehabilitation program and remain abstinent and seizure-free for 6 mo before driving.</td>
</tr>
<tr>
<td>Blood Pressure Abnormalities</td>
<td>Hypertension: sustained BP &gt;170/110 should be evaluated carefully. Hypotension: if syncopal, discontinue until attacks are treated and preventable.</td>
</tr>
<tr>
<td>Cardiovascular Disease</td>
<td>Suspected asymptomatic CAD or stable angina: no restrictions. STEMI, NSTEMI with significant LV damage, coronary artery bypass surgery: no driving for one mo following hospital discharge. NSTEMI with minor LV damage, unstable angina: no driving for 48 h if percutaneous coronary intervention (PCI) performed or 7 d if no PCI performed.</td>
</tr>
<tr>
<td>Cerebrovascular Conditions</td>
<td>TIA: should not be allowed to drive until a medical assessment is completed. Stroke: should not drive for at least one mo; may resume driving if functionally able, no clinically significant motor, cognitive, perceptual or vision deficits; no obvious risk of sudden recurrence; underlying cause appropriately treated; no post-stroke seizure.</td>
</tr>
<tr>
<td>COPD</td>
<td>Mild/moderate impairment: no restrictions. Moderate or severe impairment requiring supplemental oxygen: road test with supplemental oxygen.</td>
</tr>
<tr>
<td>Cognitive Impairment/Dementia</td>
<td>Moderate to severe dementia is a contraindication to driving: defined as the “inability to independently perform 2 or more IADLs or any basic ADL.” Patients with mild dementia should be assessed, if indicated, refer to specialized driving testing centre; if deemed fit to drive, re-evaluate patient every 6-12 mo. Poor performance on MMSE, clock drawing or Trails B suggests a need to investigate driving ability further. MMSE score alone (whether normal or low) is insufficient to determine fitness to drive.</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Diet controlled or oral hypoglycemic agents: no restrictions in absence of diabetes complications that may impair ability to drive (e.g. retinopathy, nephropathy, neuropathy, cardiovascular or cerebrovascular disease). Insulin use: may drive if no complications (as above) and no severe hypoglycemic episode in the last 6 mo.</td>
</tr>
<tr>
<td>Drugs</td>
<td>Be aware of: analgesics, anticholinergics, anticonvulsants, antidepressants, antipsychotics, opiates, sedatives, stimulants. Degree of impairment varies: patients should be warned of the medication/withdrawal effect on driving.</td>
</tr>
<tr>
<td>Hearing Loss</td>
<td>Effect of impaired hearing on ability to drive safely is controversial. Acute labyrinthitis, positional vertigo with horizontal head movement, recurrent vertigo: advise not to drive until condition resolves.</td>
</tr>
<tr>
<td>Musculoskeletal Disorders</td>
<td>Physician’s role is to report etiology, prognosis and extent of disability (pain, range of motion, coordination, muscle strength)</td>
</tr>
<tr>
<td>Post-Operative</td>
<td>Outpatient, conscious sedation: no driving for 24 h. Outpatient, general anesthesia: no driving for &gt;24 h.</td>
</tr>
<tr>
<td>Seizures</td>
<td>First, single, unprovoked: no driving for 3 mo until complete neurologic assessment, EEG, CT head. Epilepsy: can drive if seizure-free on medication and physician has insight into patient compliance.</td>
</tr>
<tr>
<td>Sleep Disorders</td>
<td>If patient is believed to be at risk due to a symptomatic sleep disorder but refuses investigation with a sleep study or refuses appropriate treatment, the patient should not drive.</td>
</tr>
<tr>
<td>Visual Impairment</td>
<td>Visual acuity: contraindicated to drive if &lt;20/50 with both eyes examined simultaneously. Visual field: contraindicated to drive if &lt;120° along horizontal meridian and 15° continuous above and below fixation with both eyes examined simultaneously.</td>
</tr>
</tbody>
</table>

N.B. guidelines included refer specifically to private driving; please see CMA guidelines for commercial driving.

Key Factors to Consider in Older Drivers

- SAFEDRIVE
  1. Unpaired vision
  2. Adequate cognition
  3. Ability to maintain consciousness
  4. Physical mobility (e.g. mobility of arms/legs/neck)

Simplified Functional Approach to Driving Assessment

- Visual acuity: contraindicated to drive if <20/50 with both eyes examined simultaneously
- Visual field: contraindicated to drive if <120° along horizontal meridian and 15° continuous above and below fixation with both eyes examined simultaneously

Systematic Review of Driving Risk and the Efficacy of Compensatory Strategies in Persons with Dementia


**Purpose:** To determine whether persons with dementia are at greater driving risk and, if so, to estimate the magnitude of this risk and determine whether there are efficacious methods to compensate for or accommodate it.

**Study Selection:** Systematic review of the case-control studies of drivers with a diagnosis of dementia.

**Results:** Drivers with dementia universally exhibited poorer performance on road tests and simulator evaluations. The one study that used an objective measure of motor vehicle crashes found that the crash risk in persons with dementia was 2-2.5 times greater than matched controls. No studies were found that examined the efficacy of methods to compensate for or accommodate the decreased driving performance.

**Conclusions:** Drivers with dementia are poorer drivers than cognitively normal drivers, but studies have not consistently demonstrated higher crash rates. Clinicians and policy makers must take these findings into account when addressing issues pertinent to drivers with a diagnosis of dementia.
Health Care Institutions

Table 8. Classification of Health Care Services and Institutions

<table>
<thead>
<tr>
<th>Institution/Service</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Community Support Services</td>
<td>Health care services offered at home for those who can live independently at home or under the care of family members including professional health care services, personal care and support (ADL assistance), homemaking (IADL assistance), community support services (e.g. transportation, meal delivery, day programs, caregiver relief, security checks, etc.)</td>
</tr>
<tr>
<td>Rehabilitation</td>
<td>Health care services offered in an institution to optimize patients’ function, independence and quality of life</td>
</tr>
<tr>
<td>Residential</td>
<td></td>
</tr>
<tr>
<td>a) Seniors Affordable Housing</td>
<td>Seniors who live independently and manage their own care but prefer to live near other seniors; usually has accessibility features and rent is adjusted based on income</td>
</tr>
<tr>
<td>b) Retirement/Nursing Home</td>
<td>Residents are fairly independent and require minimal support with ADLs and IADLs; often privately owned</td>
</tr>
<tr>
<td>c) Supportive Housing</td>
<td>Residents require minimal to moderate assistance with daily activities while living independently; often rental units in an apartment and may offer some physiotherapy and rehabilitation services</td>
</tr>
<tr>
<td>d) Long-term Care/Skilled Nursing Facility</td>
<td>Around the clock nursing care and on-call physician coverage; often offers occupational therapy, physiotherapy, respiratory therapy, and rehabilitation services; may be used short-term for caregiver respite or for supportive patient care to regain strength and confidence after leaving the hospital</td>
</tr>
<tr>
<td>e) Hospice</td>
<td>Free-standing facility or designated floor in a hospital or nursing home for care of terminally ill patients and their families; focus is on quality of life and often requires prognosis ≤3 mo</td>
</tr>
</tbody>
</table>

- names of community health care institutions, types of facilities, and services offered vary between geographical locations
- factors to consider when seeking services/institutions include level of care required, support networks, duration of stay, and cost

Palliative and End-of-Life Care

Principles and Quality of Life

- support, educate, and treat both patient and family
- address physical, psychological, social and spiritual needs
- focus on symptom management and comfort measures
- offer therapeutic environment and bereavement support
- ensure maintenance of human dignity

End-of-Life Care Discussions

When to Initiate End-of-Life Care Discussions

- recent hospitalization for serious illness
- severe progressive medical condition(s)
- death expected within 6-12 mo
- patient inquires about end-of-life care

Suggested Topics for Discussion

- goals of care (disease vs. symptom management)
- advance directives, power of attorney, public guardian and trustee
- treatment options and likelihood of success
- common medical interventions
  - mechanical ventilation
  - antibiotic therapy
  - feeding tubes
- resuscitation options and likelihood of success (Full Code vs. DNR status including preferences for CPR, intubation, ICU admission, artificial hydration)

Power of Attorney

- see Ethical, Legal, and Organizational Medicine, ELOM9
### Instructional Advance Directives

- see *Ethical, Legal, and Organizational Medicine, ELOM9*

### Symptom Management

#### Assessment Tools

- **Edmonton Symptom Assessment System (ESAS):** a tool that asks patients to rate the intensity of symptoms from 0 to 10 and allows for tracking of the efficacy of interventions. Assesses: pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, shortness of breath, and “other problems”
- **Palliative Performance Scale (PPS):** a tool that uses functional status to predict survival in terminally ill patients. Assesses 5 components: ambulation, activity and evidence of disease, self-care, intake and conscious level

*Source: J Palliat Care 1991;7:6-9 and Victoria Hospice Society 2006;120-121*

#### Table 9. Management of Common End-of-Life Symptoms

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Non-Pharmacologic Management</th>
<th>Pharmacologic Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constipation</td>
<td>Rule out obstruction, impaction, anorectal disease; hydration and high fibre intake; increase mobility</td>
<td>Stop unnecessary opioids and medications with anticholinergic side effects; provide stool softener (e.g. docusate sodium), increase peristalsis (e.g. senna), alter water and electrolyte secretion (e.g. magnesium hydroxide, lactulose, peg3350) Multiply by 0.85 for females</td>
</tr>
</tbody>
</table>
| Death Rattle/Increased Pulmonary Secretions | Oral suctioning  
Discontinue unnecessary IV solutions | Scopolamine SC or transdermal octreotide |
| Dry mouth              | Oral hygiene q2h, ice cubes, sugarless gum  
Artificial saliva substitutes, bethanechol, pilocarpine 1% solution as mouth rinse | |
| Dysphagia              | Frequent small feeds, ideally seated, keep head of bed elevated for 30 min after eating, suction as necessary | Treat painful mucositis (diphenhydramine: lidocaine: Maalox® in a 1:2:8 mixture), candidiasis (fluconazole) |
| Dyspnea                | Elevate head of bed, eliminate allergens, open window/use fan | Oxygen, bronchodilators, opioids (e.g. morphine, hydromorphone) |
| Hiccups                | Dry sugar, breathing in paper bag | Chlorpromazine, haloperidol, metoclopramide, baclofen, marijuana |
| Nausea and Vomiting    | Frequent and small meals, avoid offensive strong odours, treat constipation if present | Raised ICP: dexamethasone  
Anticipatory nausea, anxiety: lorazepam  
Vestibular disease, vertigo: dimenhydrinate  
Drug induced, hepatic or renal failure: prochlorperazine, haloperidol  
GERD: PPI or H2 antagonist  
Gastric stasis: metoclopramide  
Bowel obstruction: metoclopramide, dexamethasone, octreotide |
| Pain                   | Hot and cold compresses, music therapy, relaxation techniques, individualized program of physical activity designed to improve flexibility, strength and endurance, and cognitive behavioural therapy (CBT) | Nociceptive pain: non-opioids (NSAIDs, acetaminophen), weak opioids (codeine, hydrocodone, oxycodone), strong opioids (morphine, hydromorphone, oxycodone, fentanyl)  
Neuropathic pain: anticonvulsants (gabapentin, pregabalin), antidepressants (TCAs, SSRIs), steroids (dexamethasone)  
Bony pain: non-opioids, weak opioids, bisphosphonates, radiation therapy |
| Pruritus                | Bathing with tepid water, avoid soap, bath oils; sodium bicarbonate for jaundice  
Antihistamines, phenothiazines, topical corticosteroids, calamine lotion | |
| Weakness               | Modify environment and activities to decrease energy expenditure | Treat insomnia, anemia, depression; consider psychostimulants |

**Geriatric Pharmacology**

### Pharmacokinetics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Age Effect</th>
<th>Implications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absorption</td>
<td>Increased gastric pH</td>
<td>Drug-drug and drug-food interactions are more likely to affect absorption</td>
</tr>
<tr>
<td></td>
<td>(less significant)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Decreased splanchnic blood flow, GI absorptive surface and dermal vascularity; delayed gastric emptying</td>
<td></td>
</tr>
<tr>
<td>Distribution</td>
<td>Increased total body fat and α1-glycoprotein</td>
<td>Lipophilic drugs have a larger volume of distribution</td>
</tr>
<tr>
<td></td>
<td>Decreased lean body mass, total body water, and albumin</td>
<td>Lower doses may be therapeutic</td>
</tr>
<tr>
<td></td>
<td>(less significant)</td>
<td></td>
</tr>
<tr>
<td>Metabolism</td>
<td>Decreased hepatic mass and hepatic blood flow; impaired phase I reactions (oxidative system)</td>
<td>For every x% reduction in clearance, decrease the dose by x% and increase the interval by x%</td>
</tr>
<tr>
<td>Elimination</td>
<td>Decreased renal blood flow, GFR, tubular secretion and renal mass</td>
<td></td>
</tr>
</tbody>
</table>

**Pharmacodynamics**

**Drug Sensitivity**
- changes in pharmacokinetics as well as intrinsic sensitivity lead to altered drug responses
- increased sensitivity to warfarin, sedatives, antipsychotics, digoxin and narcotics
- decreased sensitivity to β-blockers in majority of elderly patients, though some may have increased sensitivity

**Decreased Homeostasis**
- poorer compensatory mechanisms leading to more adverse reactions (e.g. bleeding with NSAIDs/anticoagulants, altered mental status with anticholinergic/sympathomimetic/anti-Parkinsonian drugs)

**Polypharmacy**

**Definition**
- prescription, administration or use of five or more medications at the same time

**Epidemiology**
- in Canada, > 60% of elderly individuals reported using ≥5 medications
- hospitalized elderly are given an average of 10 medications during admission

**Risk Factors for Non-Compliance**
- risk of non-compliance correlates with medication factors, not age
  - number of medications: compliance with 1 medication is 80%, but drops to 25% with ≥6 medications
  - increased dosing frequency, complicated container design, financial constraints, and cognitive impairment

**Adverse Drug Reactions (ADRs)**
- any noxious or unintended response to a drug that occurs at doses used for prophylaxis or therapy
- risk factors in the elderly
  - intrinsic: comorbidities, age-related changes in pharmacokinetics and pharmacodynamics
  - extrinsic: number of medications, multiple prescribers, unreliable drug history
- 90% of ADRs are from: ASA, analgesics, anticoagulants, antimicrobials, antineoplastics, digoxin, diuretics, hypoglycemics, and steroids

**Preventing Polypharmacy**
- consider drug: safer side effect profiles, convenient dosing schedules, convenient route, efficacy
- consider patient: other medications, clinical indications, medical comorbidities
- consider patient-drug interaction risk factors for ADRs
- review drug list regularly to eliminate medications with no clinical indication or with evidence of toxicity
- avoid treating an ADR with another medication
# Inappropriate Prescribing in the Elderly

## Epidemiology
- the estimated prevalence of potentially inappropriate prescribing ranges from 12–40%

## Beers Criteria
- a list of medications to avoid in adults 65 yr and older due to safety concerns
- examples include long-acting benzodiazepines, strong anticholinergics, high-dose sedatives
- the elderly are also under-treated (ACEI, ASA, β-blockers, thrombolytics, warfarin)

## Table 1. Common Medications

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Brand Name</th>
<th>Dosing Schedule</th>
<th>Indications</th>
<th>Contraindications</th>
<th>Side Effects</th>
<th>Mechanism of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>donepezil</td>
<td>Aricept®</td>
<td>5-10 mg PO daily</td>
<td>Moderate to severe dementia of Alzheimer’s type</td>
<td>Known hypersensitivity, caution in pulmonary disease, sick sinus syndrome, seizure disorder</td>
<td>N/V, diarrhea, anorexia, falls, hip fracture, increase need for pacemaker insertion</td>
<td>Reversible inhibition of acetylcholinesterase</td>
</tr>
<tr>
<td>galantamine</td>
<td>Reminyl®</td>
<td>8-12 mg PO bid</td>
<td>Mild to moderate dementia of Alzheimer’s type</td>
<td>Known hypersensitivity, caution in sick sinus syndrome, seizure disorder, pulmonary disease, low body weight</td>
<td>N/V, diarrhea, anorexia, falls, hip fracture, increase need for pacemaker insertion</td>
<td>Reversible inhibition of acetylcholinesterase</td>
</tr>
<tr>
<td>rivastigmine</td>
<td>Exelon®</td>
<td>1.5 mg PO daily (starting) up to 6 mg PO bid</td>
<td>Mild to moderate dementia of Alzheimer’s type</td>
<td>Known hypersensitivity, severe hepatic disease, caution in sick sinus syndrome, pulmonary disease, seizure disorder</td>
<td>N/V, diarrhea, anorexia, falls, hip fracture, increase need for pacemaker insertion</td>
<td>Acetylcholinesterase inhibition (reversible but very slow)</td>
</tr>
<tr>
<td>memantine</td>
<td>Ebixa®/Namenda® (Can)(U.S.)</td>
<td>5 mg PO daily (starting) up to 10 mg PO bid</td>
<td>Mild to moderate dementia of Alzheimer’s type</td>
<td>Known hypersensitivity, conditions that alkalize urine, caution in cardiovascular conditions</td>
<td>Agitation, fatigue, dizziness, headache, hypertension, constipation</td>
<td>NMDA-receptor antagonist</td>
</tr>
</tbody>
</table>

## Laxatives

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Brand Name</th>
<th>Dosing Schedule</th>
<th>Indications</th>
<th>Contraindications</th>
<th>Side Effects</th>
<th>Mechanism of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>bran</td>
<td>All-Bran®</td>
<td>1 cup/d</td>
<td>Constipation</td>
<td></td>
<td>Bloating, flatulence</td>
<td>Bulk-forming laxative</td>
</tr>
<tr>
<td>psyllium</td>
<td>Metamucil® Prodiem Plan®</td>
<td>1 tsp PO tid</td>
<td>Constipation, hypercholesterolemia</td>
<td>N/V, abdominal pain, obstruction</td>
<td>Bloating, flatulence</td>
<td>Bulk-forming laxative</td>
</tr>
<tr>
<td>lactulose</td>
<td>Chronulac® Cephulac® Kristalose®</td>
<td>15-30 cc PO daily/bid</td>
<td>Constipation, hepatic encephalopathy, bowel evacuation following barium exam</td>
<td>Patients on low galactose diets</td>
<td>Flatus, cramps, nausea, diarrhea</td>
<td>Hypersmolar agent, lowers pH of colon to decrease blood ammonia levels</td>
</tr>
<tr>
<td>senna</td>
<td>Senokot®/Ex-lax® Glysmend®</td>
<td>1-2 tabs PO daily or 10-15 cc syrup PO daily</td>
<td>Constipation</td>
<td>Abdominal pain, N/V</td>
<td>Cramps, griping, dependence</td>
<td>Stimulant laxative</td>
</tr>
<tr>
<td>bisacodyl</td>
<td>Dulcolax®</td>
<td>5-15 mg PO (10 mg PR)</td>
<td>Constipation</td>
<td>Ileus, obstruction, abdominal pain, N/V, severe dehydration</td>
<td>Cramps, pain, diarrhea</td>
<td>Stimulant laxative</td>
</tr>
</tbody>
</table>

## Parkinsonian Agents – see Neurology, N32

## Sleeping Medications

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Brand Name</th>
<th>Dosing Schedule</th>
<th>Indications</th>
<th>Contraindications</th>
<th>Side Effects</th>
<th>Mechanism of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>zopiclone</td>
<td>Imovane®</td>
<td>3.75 mg PO qhs (initially)</td>
<td>Insomnia</td>
<td>Known hypersensitivity, caution in myasthenia gravis, severe hepatic disease</td>
<td>Bitter taste, palpitations, vomiting, anorexia, sialorrhea, confusion, agitation, anxiety, tremor, sweating, cognitive impairment, falls</td>
<td>Short-acting hypnotic (no tolerance effects)</td>
</tr>
<tr>
<td>temazepam</td>
<td>Restoril®</td>
<td>15 mg PO qhs</td>
<td>Short-term management of insomnia</td>
<td>Known hypersensitivity, myasthenia gravis, steep aplea</td>
<td>Drowsiness, dizziness, impaired coordination, hangover, lethargy, dependence, cognitive impairment, falls</td>
<td>Benzoazopine: generalized CNS depression mediated by GABA</td>
</tr>
<tr>
<td>lorazepam</td>
<td>Ativan®</td>
<td>0.5 mg PO qhs (initially)</td>
<td>Anxiety, insomnia</td>
<td>Known hypersensitivity, myasthenia gravis, narrow-angle glaucoma</td>
<td>Dizziness, drowsiness, lethargy, dependence, cognitive impairment, falls</td>
<td>Benzodiazepine: generalized CNS depression mediated by GABA</td>
</tr>
<tr>
<td>melatonin</td>
<td>Good Neighbor Pharmacy Melatonin, Nature’s Blend Melatonin</td>
<td>Immediate release 5mg PO qhs (initially), or extended release 2mg PO qhs</td>
<td>Insomnia</td>
<td>Known hypersensitivity, concurrent immunosuppressive treatment</td>
<td>Hypothermia, sedation, somnolence, fatigue</td>
<td>Mimics hormone produced by pineal gland, regulates sleep cycle</td>
</tr>
</tbody>
</table>

Note: Docusate has been shown to be ineffective for the prevention/treatment of constipation in the elderly
**Landmark Geriatric Trials**

<table>
<thead>
<tr>
<th>Trial</th>
<th>Reference</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Optimal management of urinary tract infections in older people</td>
<td>Clin Interv Aging 2011; 6:173-180</td>
<td>UTIs are over diagnosed and over treated in older people. Asymptomatic bacteriuria is very common in later life and should not be screened for or treated</td>
</tr>
<tr>
<td>Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study</td>
<td>Brain 2012; 135(9): 2809-16</td>
<td>First population study to show that delirium is a strong risk factor for dementia and cognitive decline in elderly patients</td>
</tr>
<tr>
<td>Donepezil and Memantine for Moderate-to-Severe Alzheimer’s Disease</td>
<td>NEJM 2012; 366:893-903</td>
<td>Continued treatment with donepezil was associated with cognitive benefits over the course of 12 mo in patients with moderate or severe Alzheimer’s disease</td>
</tr>
<tr>
<td>Early palliative care for metastatic lung cancer</td>
<td>NEJM 2010; 363:733-742</td>
<td>Among patients with metastatic non-small-cell lung cancer, early palliative care led to significant improvements in both quality of life and mood. As compared with patients receiving standard care, patients receiving early palliative care had less aggressive care at the end-of-life but longer survival</td>
</tr>
<tr>
<td>Hip protectors for fracture prevention</td>
<td>NEJM 2000; 343:1506-1513</td>
<td>The risk of hip fracture can be reduced in frail elderly adults by the use of an anatomically designed external hip protector</td>
</tr>
<tr>
<td>HVET</td>
<td>NEJM 2008; 358:1887-1898</td>
<td>Antihypertensive treatment with indapamide (sustained release), with or without perindopril, in adults 80 yr or older is beneficial</td>
</tr>
<tr>
<td>PROFET</td>
<td>Lancet 1999; 353:93-97</td>
<td>Demonstrates that an interdisciplinary approach to elderly adults with a previous history of falls can significantly decrease the risk of further falls and limit functional impairment</td>
</tr>
<tr>
<td>Yale Delirium Prevention Trial</td>
<td>NEJM 1999; 340:669-676</td>
<td>A risk-factor intervention strategy can result in significant reductions in the number and duration of episodes of delirium in hospitalized older patients</td>
</tr>
</tbody>
</table>

**References**

Constitution

Delirium, Dementia, and Depression

Driving Competency
CMA. CMA Drive’s guide: determining medical fitness to operate motor vehicles. Ottawa, 2012

Delirium is a strong risk factor for dementia and cognitive decline in elderly patients

Fall

Elder Abuse

Optimal management of urinary tract infections in older people


Falls

Optimal management of urinary tract infections in older people


Falls

Optimal management of urinary tract infections in older people


Falls

Optimal management of urinary tract infections in older people


Gynecology

Katie Bies, Tahrin Mahmood, and Tammy Ryan, chapter editors
Dhruvin Hirpara and Sneha Raju, associate editors
Valerie Lemieux and Simran Mundi, EBM editors
Dr. Sari L. Kives, Dr. Ally Murji, and Dr. Fay Weisberg, staff editors

Acronyms ................................................. 2
Basic Anatomy Review ................................. 2
Menstruation ............................................. 4
Menstrual Cycle
Stages of Puberty
Premenstrual Syndrome
Premenstrual Dysphoric Disorder

Differential Diagnoses of Common Presentations ............................. 6
Abnormal Uterine Bleeding
Dysmenorrhea
Pruritus
Pelvic Pain
Pelvic Mass
Dyspareunia
First and Second Trimester Bleeding

Common Investigations and Procedures .................................. 8
Imaging
Endometrial Biopsy
Hysterectomy

Disorders of Menstruation ........................................... 10
Amenorrhea
Abnormal Uterine Bleeding
Dysmenorrhea

Endometriosis ................................................. 13
Adenomyosis ................................................. 15

Fibroids ......................................................... 15

Contraception .................................................. 16
Hormonal Methods
Intrauterine Device
Emergency Postcoital Contraception

Termination of Pregnancy ........................................ 20

Pregnancy-Related Complications ................................ 21
Spontaneous Abortions

Ectopic Pregnancy .......................................... 21

Infertility ......................................................... 23
Female Factors
Male Factors

Polycystic Ovarian Syndrome ...................................... 24

Gynecological Infections ......................................... 25
Physiologic Discharge
Vulvovaginitis
Sexually Transmitted Infections
Bartholin Gland Abscess
Pelvic Inflammatory Disease
Toxic Shock Syndrome
Surgical Infections

Sexual Abuse .................................................. 33

Sexuality and Sexual Dysfunction .................................. 33

Menopause ....................................................... 34
Hormone Replacement Therapy

Urogynecology .................................................. 36
Prolapse
Urinary Incontinence

Gynecological Oncology ............................................ 38
Uterus
Ovary
Cervix
Vulva
Vagina
Fallopian Tube
Gestational Trophoblastic Disease/Neoplasia

Common Medications ............................................ 50

References ....................................................... 52
A. EXTERNAL GENITALIA
- referred to collectively as the vulva
- blood supply: internal pudendal artery
- sensory innervation: pudendal nerve
- lymphatic drainage: inguinal nodes

B. VAGINA
- muscular canal extending from cervix to vulva, anterior to rectum and posterior to bladder
- lined by rugated, stratified-squamous epithelium
- upper vagina separated by cervix into anterior, posterior, and lateral fornices
- blood supply: vaginal branch of internal pudendal artery with anastomoses from uterine, inferior vesical, and middle rectal arteries

C. UTERUS
- thick walled, muscular organ between bladder and rectum, consisting of two major parts:
  - uterine corpus
  - cervix
- blood supply: cervical branch of uterine artery
- supported by the pelvic diaphragm, the pelvic organs, and 4 paired sets of ligaments
  - round ligaments: travel from anterior surface of uterus, through broad ligaments, and inguinal canals then terminate in the labia majora
    - function: anteversion
  - blood supply: Sampson's artery (branch of uterine artery running through round ligament)
  - uterosacral ligaments: arise from sacral fascia and insert into posterior inferior uterus
    - function: mechanical support for uterus and contain autonomic nerve fibres
  - cardinal ligaments: extend from lateral pelvic wall to insert into lateral cervix and vagina
    - function: mechanical support, prevent prolapse
  - broad ligaments: pass from lateral pelvic wall to the bladder
    - function: maintain position of uterus
  - infundibulopelvic ligament: continuous tissue that connects ovary to pelvic wall
    - contains the ovarian artery, ovarian vein, ovarian plexus, and lymphatic vessels
- position of the uterus
  - anteverted (majority), retroverted, neutral
D. FALLOPIAN TUBES
- 8-14 cm muscular tubes extending laterally from the uterus to ovary
- interstitial, isthmic, ampullary, and infundibular segments; terminates at fimbriae
- mesosalpinx: peritoneal fold that attaches fallopian tube to broad ligament
- blood supply: uterine and ovarian arteries

E. OVARIIES
- consist of cortex with ova and medulla with blood supply
- supported by infundibulopelvic ligament (suspensory ligament of ovary)
- mesovarium: peritoneal fold that attaches ovary to broad ligament
- blood supply: ovarian arteries (branches off aorta), left ovarian vein (drains into left renal vein), right ovarian vein (drains into inferior vena cava)
**Menstrual Cycle**

<table>
<thead>
<tr>
<th>Hormone levels</th>
<th>Menstrual</th>
<th>Proliferative</th>
<th>Secretory</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOLLICULAR/PROLIFERATIVE PHASE (Variable Duration)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early</td>
<td>Mid</td>
<td>Late</td>
<td>OVARIES</td>
</tr>
<tr>
<td>Initiating Events</td>
<td>$E$ and $P$ (from end of previous cycle)</td>
<td>Growing follicles continue to secrete $E$</td>
<td>Switch from negative to positive feedback ($E$ and $P$ now $FSH$ &amp; $LH$)</td>
</tr>
<tr>
<td>HPO Axis</td>
<td>$FSH$ pulse frequency</td>
<td>$E$ from follicles (ovary)</td>
<td>$LH$ pulse frequency</td>
</tr>
<tr>
<td>Hormones</td>
<td>$E$ and $P$</td>
<td>$E$ from follicles, especially from dominant follicle</td>
<td>$P$ from corpus luteum</td>
</tr>
<tr>
<td>Feedback on HPO Axis</td>
<td>Negative feedback $E$</td>
<td>$FSH$, $LH$</td>
<td>Positive feedback: $E$ and $P$</td>
</tr>
<tr>
<td>Ovaries</td>
<td>$FSH$ follicular growth in 3-30 follicles</td>
<td>Dominant follicle persists, remainder undergo atresia</td>
<td>$E$ peaks → LH surge → ovulation</td>
</tr>
<tr>
<td>Endometrium</td>
<td>Menses from P withdrawal (from end of previous cycle)</td>
<td>$E$ builds up endometrium</td>
<td>$P$ stabilizes endometrium</td>
</tr>
<tr>
<td>Cervical Mucus</td>
<td>Cervical mucus: Clear, ↑ amount, Spinnbarkeit 8-10 cm, more stringy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**CHARACTERISTICS**
- Menarche 10-15 yr
- Average 12.2 yr
- Entire cycle 28 ± 7 d with bleeding for 1-6 d
- 25-80 mL blood loss per cycle

**ESTROGEN**
- Estrogen is the main hormone in the follicular/proliferative phase and is stimulated by $FSH$. As the level increases it acts negatively on $FSH$. The majority of estrogen is secreted by the dominant follicle.
- Effects:
  - On the follicles in the ovaries
  - On the endometrium
  - Proliferation of glandular and stromal tissue
  - On all target tissues
  - Decreases $E$ receptors

**PROGESTERONE**
- Progesterone is the main hormone in the luteal/secretory phase and is stimulated by $LH$. Increased progesterone acts negatively on $LH$ and is secreted by the corpus luteum (remnant of dominant follicle).
- Effects:
  - On the endometrium:
    - Cessation of mitoses (stops building endometrium up)
    - "Organization" of glands (initiates secretions from glands)
    - Inhibits macrophages, interleukin-8, and enzymes from degrading endometrium
  - On all target tissues:
    - Decrease $E$ receptors (the "anti-estrogen" effect)
    - Decrease $P$ receptors

**ESTROGEN**
- $E$ and $P$ (from end of previous cycle)
- $FSH$ acts on ovarian granulosa cells
- $E$ from follicles (ovary)

**PROGESTERONE**
- $LH$ pulse frequency
- $E$ from follicles, especially from dominant follicle
- $P$ from corpus luteum

**OVULATION**
- Sudden switch from negative to positive feedback ($E$ and $P$ now $FSH$ & $LH$)
- $LH$ pulse amplitude (LH surge)
- $P$ from corpus luteum
- $P$ secondary to degeneration of corpus luteum
Stages of Puberty

- see Pediatrics, P30
- adrenarche: increase in secretion of adrenal androgens; usually precedes gonadarche by 2 yr
- gonadarche: increased secretion of gonadal sex steroids; –age 8 yr
- thelarche: breast development
- pubarche: pubic and axillary hair development
- menarche: onset of menses, usually following peak height velocity and/or 2 yr following breast budding

Premenstrual Syndrome

- synonyms: “ovarian cycle syndrome,” “menstrual molimina” (moodiness)

Etiology

- multifactorial: not completely understood; genetics likely play a role
- CNS-mediated neurotransmitter interactions with sex steroids (progesterone, estrogen, and testosterone)
- serotonergic dysregulation – currently most plausible theory

Diagnostic Criteria for Premenstrual Syndrome

- at least one affective and one somatic symptom during the 5 days before menses in each of the three prior menstrual cycles
  - affective: depression, angry outbursts, irritability, anxiety, confusion, social withdrawal
  - somatic: breast tenderness, abdominal bloating, headache, swelling of extremities
- symptoms relieved within 4 d of onset of menses
- symptoms present in the absence of any pharmacologic therapy, drug or alcohol use
- symptoms occur reproducibly during 2 cycles of prospective recording
- patient suffers from identifiable dysfunction in social or economic performance

Treatment

- goal: symptom relief
- psychological support
- medications
  - NSAIDs for discomfort and pain
  - spironolactone for fluid retention: used during luteal phase
  - SSRIs: used during luteal phase x 14 d or continuously
  - OCP: primarily beneficial for physical/somatic symptoms
  - danazol: an androgen that inhibits the pituitary-ovarian axis
  - GnRH agonists if PMS is severe and unresponsive to treatment (may use prior to considering definitive treatment with BSO)
- mind/body approaches
  - regular aerobic exercise
  - cognitive behavioural therapy
  - relaxation, light therapy biofeedback, and guided imagery
- herbal remedies (variable evidence)
  - black cohosh, kava, ginkgo, agnus castus fruit extract
- BSO if symptoms severe

Premenstrual Dysphoric Disorder

Clinical Presentation

- irritability, depressed mood
- breast pain and bloating

Diagnostic Criteria for Premenstrual Dysphoric Disorder

- at least 5 of the following 11 symptoms during most menstrual cycles of the last year (with at least 1 of the first 4)
  - depressed mood or hopelessness
  - anxiety or tension
  - affective symptoms
  - anger or irritability
  - decreased interest in activities
  - difficulty concentrating
  - lethargy
  - change in appetite
  - hypersomnia or insomnia
  - feeling overwhelmed
  - physical symptoms: breast tenderness/swelling, headaches, joint/muscle pain, bloating, or weight gain
- symptoms interfere with social or occupational functioning
- symptoms must be discretely related to the menstrual cycle
- 1, 2 and 3 must be confirmed during at least 2 consecutive symptomatic menstrual cycles
Abnormal Uterine Bleeding

Abnormal Uterine Bleeding (AUB)
- Heavy Menstrual Bleeding (AUB-HMB)
- Intermenstrual Bleeding (AUB-IMB)

Structural Causes (PALM)
- Polyp (AUB-P)
- Adenomyosis (AUB-A)
- Leiomyoma (AUB-L)
  - Submucosal (AUB-LSM)
  - Other (AUB-LO)
- Malignancy and hyperplasia (AUB-M)

Non-Structural Causes (COEIN)
- Coagulopathy (AUB-C)
- Ovulatory dysfunction (AUB-O)
- Endometrial (AUB-E)
- Iatrogenic (AUB-I)
- Not yet classified (AUB-N)

Dysmenorrhea

- see Disorders of Menstruation, GY10
- primary/idiopathic
- secondary (acquired)
  - endometriosis
  - adenomyosis
  - uterine polyps
  - uterine anomalies (e.g. non-communicating uterine horn)
  - leiomyoma
  - intrauterine synechiae
  - ovarian cysts
  - cervical stenosis
  - imperforate hymen, transverse vaginal septum
  - pelvic inflammatory disease
  - IUD (copper)
  - foreign body

Pruritus

- see Gynecological Infections, GY25
- physiologic discharge and cervical mucus production
- non-physiologic
  - genital tract infection
  - vulvovaginitis: candidiasis, trichomoniasis, BV, polymicrobial superficial infection
  - chlamydia, gonorrhea
  - pyosalpinx, salpingitis
  - genital tract inflammation (non-infectious)
  - local: chemical irritants, douches, sprays, foreign body, trauma, atrophic vaginitis, desquamative inflammatory vaginitis, focal vulvitis
  - neoplasia: vulvar, vaginal, cervical, endometrial
  - systemic: toxic shock syndrome, Crohn’s disease, collagen disease, dermatologic (e.g. lichen sclerosis)
  - IUD, OCP (secondary to progesterone)
Pelvic Pain

Figure 7. Approach to pelvic pain

20% of chronic pelvic pain patients have a history of previous sexual abuse/assault; remember to ask about it

Pelvic Mass

Figure 8. Differential diagnosis of pelvic mass

Pyometra
Pus within the uterine cavity
Hematometra
Blood within the uterine cavity
Hydrometra
Fluid within the uterine cavity
Hematocolpos
Blood within the vagina
Dyspareunia

First and Second Trimester Bleeding

Approach to the Patient with Bleeding in T1/T2

History
- risk factors for ectopic pregnancy (see Ectopic Pregnancy, GY21)
- previous spontaneous abortion
- recent trauma
- characteristics of the bleeding (including any tissue passed)
- characteristics of the pain (cramping pain suggests spontaneous abortion)
- history of coagulopathy
- gynecological/obstetric history
- fatigue, dizziness, syncopal episodes due to hypovolemia, fever (may be associated with septic abortion)

Physical
- vitals (including orthostatic changes)
- abdomen (symphysis fundal height, tenderness, presence of contractions)
- perineum (signs of trauma, genital lesions)
- speculum exam (cervical os open or closed, presence of active bleeding/clots/tissue)
- pelvic exam (uterine size, adnexal mass, uterine/adnexal tenderness)

Investigations
- β-hCG (lower than expected for GA in spontaneous abortion, ectopic pregnancy)
- U/S (confirm intrauterine pregnancy and fetal viability)
- CBC
- group and screen

Treatment
- IV resuscitation for hemorrhagic shock
- treat the underlying cause

Common Investigations and Procedures

Imaging

Ultrasound (U/S)
- transabdominal or transvaginal U/S is the imaging modality of choice for pelvic structures
- transvaginal U/S provides better resolution of uterus and adnexal structures
- detects early pregnancy if β-hCG ≥1,500 (β-hCG must be ≥6,500 for transabdominal U/S)
- may be used to identify pelvic pathology
- identify ectopic pregnancy, intrauterine pregnancy
- assess uterine, adnexal, cul-de-sac, ovarian masses (e.g. solid or cystic)
- determine endometrial thickness, locate/characterize fibroids
- monitor follicles during assisted reproduction
- assess endometrial lining in postmenopausal women
Endometrial Biopsy

- performed in the office using an endometrial suction curette (pipelle) guided through the cervix to aspirate fragments of endometrium
  - pre-treatment with misoprostol (Cytotec®) if nulliparous or postmenopausal
- more invasive procedure (D&C) may be done in the office or operating room ± hysteroscopy. This may be required if endometrial biopsy is not possible in the office setting
- indications
  - AUB/PMB
    - age > 40
    - risk factors for endometrial cancer
    - failure of medical treatment
    - significant intermenstrual bleeding
    - consider in women with infrequent menses suggesting anovulatory cycles

Hysterectomy

Indications
- uterine fibroids
- endometriosis, adenomyosis
- uterine prolapse
- pelvic pain
- AUB
- cancer (endometrium, ovaries, fallopian tubes, cervix)

Complications
- general anesthetic
- bleeding
- infection
- injury to other organs (ureter, bladder, rectum)
- loss of ovarian function (if ovaries removed, iatrogenic menopause)

Approaches
1. open (abdominal approach): uterus removed via transverse (pfannenstiel) or midline laparotomy
2. minimally Invasive Approaches
  - vaginal: uterus removed via vagina; uterus is separated from surrounding structures by vaginal route, no abdominal incisions
  - indications: mobile uterus, uterine size <12 wk
  - advantages: less pain, faster recovery time, allows for simultaneous repair of rectocele/cystocele/enterocele, improved aesthetics. This is the gold standard of the minimally invasive routes.
3. Robotic
  - similar advantages to laparoscopy
  - may be advantageous in high BMI patients
  - more costly

Table 1. Classification of Hysterectomy

<table>
<thead>
<tr>
<th>Classification</th>
<th>Tissues Removed</th>
<th>Indications</th>
</tr>
</thead>
</table>
| Subtotal Hysterectomy | Uterus | Inaccessible cervix (e.g. adhesions)  
Patient choice/preference  
Severe endometriosis |
| Total Hysterectomy (extrafascial simple hysterectomy/type 1) | Uterus, cervix, uterine artery ligated at uterus | Uterine fibroids  
Endometriosis  
Adenomyosis  
Menorrhagia  
DUB |
| Total Hysterectomy (extrafascial simple hysterectomy/type 1) + Bilateral Salpingo-Oophorectomy | Uterus, cervix, uterine artery ligated at uterus, fallopian tubes, ovaries | Endometrial cancer  
Malignant adrenal masses  
Consider for endometriosis |
| Modified Radical Hysterectomy (type 2) | Uterus, cervix, proximal 1/3 parametria, uterine artery ligated medial to the ureter, mid point of uterosacral ligaments and upper 1-2 cm vagina | Cervical cancer [up to stage IB1] |
| Radical Hysterectomy (type 3) | Uterus, cervix, upper 1/3-1/2 vagina, entire parametria, uterine artery ligated at its origin from internal iliac artery, uterosacral ligament at most distal attachment (rectum) | Cervical cancer |
Disorders of Menstruation

Amenorrhea

Differential Diagnosis of Amenorrhea

Table 2. Differential Diagnosis of Primary Amenorrhea

<table>
<thead>
<tr>
<th>With Secondary Sexual Development</th>
<th>Without Secondary Sexual Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal breast and pelvic development</td>
<td>Normal breast, abnormal uterine development</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>Hypertension</td>
</tr>
<tr>
<td>Hyperprolactinemia</td>
<td>PCOS</td>
</tr>
<tr>
<td>Hypothalamic dysfunction</td>
<td>Anatomic abnormalities</td>
</tr>
<tr>
<td>Müllerian agenesis</td>
<td>Uterovaginal septum, imperforate hymen</td>
</tr>
<tr>
<td>Gonadal dysgenesis</td>
<td>Abnormal sex chromosome</td>
</tr>
<tr>
<td>(Tanner’s X0)</td>
<td>Normal sex chromosome</td>
</tr>
<tr>
<td>High FSH (hypergonadotropic hypogonadism)</td>
<td>Low FSH (hypogonadotropic hypogonadism)</td>
</tr>
<tr>
<td>Constitutional delay (most common)</td>
<td>Congenital abnormalities</td>
</tr>
<tr>
<td>Isolated GnRH deficiency</td>
<td>Pituitary failure (Kallman syndrome, head injury, pituitary adenoma, etc.)</td>
</tr>
<tr>
<td>Acquired</td>
<td>Endocrine disorders (type 1 DM)</td>
</tr>
<tr>
<td>Endocrine disorders (type 1 DM)</td>
<td>Pituitary tumours</td>
</tr>
<tr>
<td>Systemic disorders (IBD, JRA, chronic infections, etc.)</td>
<td></td>
</tr>
</tbody>
</table>

Table 3. Differential Diagnosis of Secondary Amenorrhea

<table>
<thead>
<tr>
<th>With Hyperandrogenism</th>
<th>Without Hyperandrogenism</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCOS</td>
<td>Hypergonadotropic hypogonadism (i.e. premature ovarian failure: high FSH, low estradiol)</td>
</tr>
<tr>
<td>Autonomous hyperandrogenism (androgen secretion independent of the HP axis)</td>
<td>Idiopathic</td>
</tr>
<tr>
<td>Ovarian: tumour, hyperthecosis</td>
<td>Autoimmune: type 1 DM, autoimmune thyroid disease, Addison’s disease</td>
</tr>
<tr>
<td>Adrenal androgen-secreting tumour</td>
<td>Autoimmune: cyclosporine, drugs, radiation</td>
</tr>
<tr>
<td>Late onset or mild congenital adrenal hyperplasia (rare)</td>
<td>Functional hypothalamic amenorrhea (often related to stress and/or anorexia)</td>
</tr>
<tr>
<td>Hypothalamic dysfunction</td>
<td>Endocrineopathies: most commonly hyper or hypothyroidism</td>
</tr>
<tr>
<td>Endocrinopathies: most commonly hyper or hypothyroidism (low FSH): Pituitary compression or destruction: pituitary adenoma, craniopharyngioma, lymphocytic hypophysitis, infiltration (sarcoidosis), head injury, Sheehan’s syndrome</td>
<td></td>
</tr>
<tr>
<td>Functional hypothalamic amenorrhea</td>
<td>Premature ovarian failure</td>
</tr>
<tr>
<td>PCOS – hyperandrogenism</td>
<td>Hypogonadotropic hypogonadism</td>
</tr>
<tr>
<td>• Constitutional delay</td>
<td>• HP axis dysfunction</td>
</tr>
<tr>
<td>• Hypothalamic dysfunction</td>
<td></td>
</tr>
<tr>
<td>• MRI hypothalamus, pituitary</td>
<td></td>
</tr>
<tr>
<td>• Measure other pituitary hormones</td>
<td></td>
</tr>
<tr>
<td>• Common etiology:</td>
<td></td>
</tr>
<tr>
<td>• Weight loss</td>
<td></td>
</tr>
<tr>
<td>• Excessive exercise</td>
<td></td>
</tr>
<tr>
<td>• Systemic diseases</td>
<td></td>
</tr>
</tbody>
</table>

Investigations

**Amenorrhea**

1. **Amenorrhea**
2. **Amenorrhea**
3. **Amenorrhea**

**Investigations**

- **1st Amenorrhea**
  - History and Physical Exam
  - Yes
  - Karotype
  - XX
  - Transverse vaginal septum
  - Imperforate hymen
  - Cervical agenesis
  - Müllerian agenesis
  - XY
  - Normal
  - FSH/LH
  - Low
  - Hypergonadotropic
  - Hypogonadotropic
  - Constitutional delay
  - HP axis abnormality
  - W/D bleed
  - Progesterin challenge
  - Normal
  - Progesterin challenge
  - Positive
  - Prolactin
  - Abnormal
  - Pregnancy
  - Negative
  - Prolactin
  - Normal
  - Progesterin challenge
  - No W/D bleed
  - Uterine defect
  - Asherman’s syndrome
  - HP axis dysfunction
  - Abnormal
  - Prolactin
  - Normal/Low
  - FSH/LH
  - High
  - Premature ovarian failure
  - PCOS – hyperandrogenism
  - CT head if >100 ng/dL
  - TSH for hypothyroidism

**Figure 10. Diagnostic approach to amenorrhea**
Disorders of Menstruation

- β-hCG, hormonal workup (TSH, prolactin, FSH, LH, androgens, estradiol)
- progesterone challenge to assess estrogen status
  - medroxyprogesterone acetate (Provera™) 10 mg PO OD for 10-14 d
  - any uterine bleed within 2-7 d after completion of Provera™ is considered to be a positive test/withdrawal bleed
    - withdrawal bleed suggests presence of adequate estrogen to thicken the endometrium; thus withdrawal of progesterone results in bleeding
    - if no bleeding occurs, there may be inadequate estrogen (hypoestrogenism), excessive androgens, or progesterones (decidualization)
- karyotype: indicated if premature ovarian failure or absent puberty
- U/S to confirm normal anatomy, identify PCOS

Treatment

**Table 4. Management of Amenorrhea**

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1º AMENORRHEA</strong></td>
<td></td>
</tr>
<tr>
<td>Androgen insensitivity syndrome</td>
<td>Gonadal resection after puberty, Psychological counselling, Creation of neo-vagina</td>
</tr>
<tr>
<td>Anatomical</td>
<td>Surgical management</td>
</tr>
<tr>
<td>Imperforate hymen</td>
<td></td>
</tr>
<tr>
<td>Transverse vaginal septum</td>
<td></td>
</tr>
<tr>
<td>Cervical agenesis</td>
<td></td>
</tr>
<tr>
<td>Mülllerian dysgenesis (MRKH syndrome)</td>
<td>Psychological counselling, Creation of neo-vagina with dilatation, Diagnostic study to confirm normal urinary system and spine</td>
</tr>
<tr>
<td><strong>2º AMENORRHEA</strong></td>
<td></td>
</tr>
<tr>
<td>Uterine defect</td>
<td>Evaluation with hysterosalpingography or sonohysterography</td>
</tr>
<tr>
<td>Asherman’s syndrome</td>
<td>Hysteroscopy: excision of synchieae</td>
</tr>
<tr>
<td>HP-axis dysfunction</td>
<td>Identify modifiable underlying cause</td>
</tr>
<tr>
<td>Premature ovarian failure</td>
<td>Combined OCP to decrease risk of osteoporosis, maintain normal vaginal and breast development (NOT proven to work)</td>
</tr>
<tr>
<td>Hyperprolactinemia</td>
<td>Screen for DM, hypothyroidism, hypoparathyroidism, hypoprolactinemia</td>
</tr>
<tr>
<td>Hormonal therapy with estrogen + progestin to decrease risk of osteoporosis; can use OCP</td>
<td></td>
</tr>
<tr>
<td>Polycystic ovarian syndrome</td>
<td>MR/CT head to rule out lesion, If no demonstrable lesions by MRI, Bromocriptine, cabergoline if fertility desired, Combined OCps if no fertility desired, Demonstrable lesions by MRI; surgical management</td>
</tr>
</tbody>
</table>

**Prolactinoma Symptoms**

- Galactorrhea, visual changes, headache

**Primary Amenorrhea**

- No menses by age 13 in absence of 2º sexual characteristics or no menses by age 15 with 2º sexual characteristics or no menses 2 yr after thelarche

**Secondary Amenorrhea**

- No menses for > 6 mo or 3 cycles after documented menarche

**Oligomenorrhea**

- Episodic vaginal bleeding occurring at intervals > 35 d

**2º amenorrhea is pregnancy until proven otherwise**

**Abnormal Uterine Bleeding**

- Regular (predictable cycle)
  - Heavy
    - AUB-A
    - AUB-LSM
    - AUB-C
    - AUB-E
  - Intermenstrual Bleeding
  - AUB-P

- Irregular (unpredictable cycle)
  - AUB and/or unpredictable AUB
    - AUB-O
    - AUB-M

Figure 11. Diagnostic approach to abnormal uterine bleeding
Approach
- is it regular?
  - regular: cycle to cycle variability of <20 d – “Can you predict your menses within 20 days?”
  - irregular: cycle to cycle variability of ≥20 d
- is it heavy
  - ≥80 cc of blood loss per cycle or
  - ≥8 d of bleeding per cycle or
  - bleeding that significantly affects quality of life
- is it structural?
  - PALM
- is it non-structural?
  - COEIN

Table 5. AUB – Etiologies, Investigations, and Management

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Investigations</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyps (AUB-P)</td>
<td>Transvaginal Sonography</td>
<td>Polypectomy (triage based on symptomatic, polyp size, histopathology and patient age)</td>
</tr>
<tr>
<td>Adenomyosis (AUB-A)</td>
<td>Transvaginal Sonography</td>
<td>See Adenomyosis, GY15</td>
</tr>
<tr>
<td>Leiomyoma (AUB-L)</td>
<td>Transvaginal Sonography</td>
<td>See Fibroids (Leiomyomata), GY15</td>
</tr>
<tr>
<td>Submucosal (AUB-Lsm)</td>
<td>Transvaginal Sonography</td>
<td></td>
</tr>
<tr>
<td>Other (AUB-Lo)</td>
<td>Transvaginal Sonography</td>
<td></td>
</tr>
<tr>
<td>Malignancy and Hyperplasia (AUB-M)</td>
<td>Transvaginal Sonography</td>
<td>Endometrial Biopsy - consider biopsy in women &gt;40 yr to exclude endometrial cancer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Non-Structural</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Coagulopathy (AUB-C)</td>
<td>CBC, coagulation profile (especially in adolescents), von Willebrand Factor, Ristocetin Cofactor, Factor VIII</td>
<td>Dependent on diagnosis (Hormonal modulation (e.g. OCP), Mirena IUD, endometrial ablation)</td>
</tr>
<tr>
<td>Ovulatory dysfunction (AUB-O)</td>
<td>Bloodwork: β-hCG, feritin, prolactin, FSH, LH, serum androgens (free testosterone, DHEA), progesterone, 17-hydroxy progesterone, TSH, fT4, pelvic ultrasound</td>
<td>See Infertility, GY23</td>
</tr>
<tr>
<td>Endometrial (AUB-E)</td>
<td>Endometrial Biopsy</td>
<td>Tranexamic acid Hormonal modulation (eg. OCP), Mirena IUD endometrial ablation</td>
</tr>
<tr>
<td>Iatrogenic (AUB-I)</td>
<td>Transvaginal Sonography (rule out forgotten IUD)</td>
<td>Remove offending agent</td>
</tr>
<tr>
<td>Not yet classified (AUB-N)</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

*Ferrous gluconate 300 mg PO TID will raise Hb 10 points per wk

Treatment
- resuscitate patient if hemodynamically unstable
- treat underlying disorders
  - if anatomic lesions and systemic disease have been ruled out, consider AUB
- medical
  - mild AUB
    - NSAIDs
    - anti-fibrinolytic (e.g. Cyklokapron®) at time of menses
    - combined OCP
    - progestins (Provera®) on first 10-14 d of each month or every 3 mo if AUB-O
    - Mirena® IUD
    - danazol
  - acute, severe AUB
    - replace fluid losses, consider admission
      - a) estrogen (Premarin®) 25 mg IV q4h x 24 h with Gravol® 50 mg IV/PO q4h or anti-fibrinolytic (e.g. Cyklokapron®) 10 mg/kg IV q8h
      - b) Tapering OCP regimen, 35µg pill TID x7d then taper to 1 pill/d for 3w with Gravol® 50 mg IV/PO q4h
      - taper to 1 tab tid x 2 d → bid x 2 d → OD
      - after (a) or (b), maintain patient on monophasic OCP for next several months or consider alternative treatments

Abnormal Uterine Bleeding
Change in frequency, duration, or amount of menstrual flow

AUB in women >40 yr requires an endometrial biopsy to rule out cancer even if known to have fibroids

Determine if patient is hemodynamically stable prior to any other task
Endometriosis

- surgical
  - endometrial ablation
    - if finished childbearing
    - repeat procedure may be required if symptom reoccur especially if <40 yr
  - hysterectomy: definitive treatment

Dysmenorrhea

Etiology
- see Differential Diagnoses of Common Presentations, GY6

Table 6. Comparison of Primary and Secondary Dysmenorrhea

<table>
<thead>
<tr>
<th>Features</th>
<th>Primary Dysmenorrhea</th>
<th>Secondary Dysmenorrhea</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Menstrual pain in absence of organic disease Begins 6 mo-2 yr after menarche (once ovulatory cycles established)</td>
<td>Menstrual pain due to organic disease Usually begins in women who are in their 20s, worsens with age May improve temporarily after childbirth</td>
</tr>
<tr>
<td>Signs and Symptoms</td>
<td>Colicky pain in abdomen, radiating to the lower back, labia, and inner thighs beginning hours before onset of bleeding and persisting for hours or days (48-72 h) Associated symptoms: N/V, altered bowel habits, headaches, fatigue (prostaglandin-associated)</td>
<td>Associated dyspareunia, abnormal bleeding, infertility</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Associated dyspareunia, abnormal bleeding, infertility Rule out underlying pelvic patholgy and confirm cyclic nature of pain</td>
<td>Bimanual exam: uterine or adnexal tenderness, fixed uterine retroflexion, uterosacral nodularity, pelvic mass, or enlarged irregular uterus (findings are rare in women &lt;20 yr) U/S, laparoscopy and hysteroscopy may be necessary to establish the diagnosis Screening for infections (vaginal and cervical cultures) may be required</td>
</tr>
<tr>
<td>Treatment</td>
<td>PG synthetase inhibitors (e.g. Anaprox®): should be started before onset of pain OCP: suppress ovulation/reduce menstrual flow</td>
<td>Treat underlying cause</td>
</tr>
</tbody>
</table>

Endometriosis

Etiology
- not fully understood
- proposed mechanisms (combination likely involved)
  - retrograde menstruation (Sampson's theory)
  - immunologic theory: altered immunity may limit clearance of transplanted endometrial cells from pelvic cavity (may be due to decreased NK cell activity)
  - metaplasia of coelomic epithelium
  - extrapelvic disease may be due to aberrant vascular or lymphatic dissemination of cells
    - e.g. ovarian endometriosis may be due to direct lymphatic flow from uterus to ovaries

Epidemiology
- incidence: 15-30% of pre-menopausal women
- mean age at presentation: 25-30 yr
- regresses after menopause

Risk Factors
- family history (7-10x increased risk if affected 1st degree relative)
- obstructive anomalies of the genital tract (earlier onset) – resolve with treatment of anomaly
- nulliparity
- age >25 yr

Sites of Occurrence
- ovaries: 60% patients have ovarian involvement
- broad ligament, vesicoperitoneal fold
- peritoneal surface of the cul-de-sac, uterosacral ligaments
- rectosigmoid colon, appendix
- rarely may occur in sites outside abdomen/pelvis, including lungs

A sharp, firm, and exquisitely tender “barb” on the uterosacral ligament is a classic feature of endometriosis
Clinical Features

- may be asymptomatic and can occur with one of 3 presentations

1. pain
   - menstrual symptoms
   - cyclic symptoms due to growth and bleeding of ectopic endometrium, usually precede menses (24-48 h) and continue throughout and after flow
   - secondary dysmenorrhea
   - sacral backache with menses
   - pain may eventually become chronic, worsening perimenstrually
   - deep dyspareunia
   - bowel and bladder symptoms
   - frequency, dysuria, hematuria
   - cyclic diarrhea/constipation, hematochezia, dyschezia (suggestive of deeply infiltrating disease)

2. infertility
   - 30-40% of patients with endometriosis will be infertile
   - 15-30% of those who are infertile will have endometriosis

3. mass (endometrioma)
   - ovarian mass can present with any of above symptoms or be asymptomatic
   - physical
     - tender nodularity of uterine ligaments and cul-de-sac felt on rectovaginal exam
     - fixed retroversion of uterus
     - firm, fixed adnexal mass (endometrioma)
   - physical findings not present in adolescent population

Investigations

- definitive diagnosis requires
  - direct visualization of lesions typical of endometriosis at laparoscopy
  - biopsy and histologic exam of specimens (2 or more of: endometrial epithelium, glands, stroma, hemosiderin-laden macrophages)

- laparoscopy
  - mulberry spots: dark blue or brownish-black implants on the uterosacral ligaments, cul-de-sac, or anywhere in the pelvis
  - endometrioma: “chocolate” cysts on the ovaries
  - “powder-burn” lesions on the peritoneal surface
  - early white lesions and clear blebs
  - peritoneal “pockets”

- CA-125
  - may be elevated in patients with endometriosis but should NOT be used as a diagnostic test

Figure 12. SOGC guidelines for treatment of endometriosis

Treatment

- surgical confirmation of disease is NOT required prior to starting medical management.
- Asymptomatic endometriosis does not require treatment. Management depends on certainty of the diagnosis, severity of symptoms, extent of disease, desire for future fertility, and impact to GI/GU systems (e.g. intestinal obstruction)

- medical
  - NSAIDs (e.g. naproxen sodium – Anaprox®)
  - 1st line
    - cyclic/continuous estrogen-progestin (OCP)
    - progestin (IM medroxyprogesterone (Depo-Provera®) or oral dienogest (Visanne®)
    - Mirena® IUS

Endometriosis – Take Home Points

- Suggestive history even with a negative exam should be considered adequate for a presumptive diagnosis
- Pelvic pain that is not primary dysmenorrhea should be considered endometriosis until proven otherwise
- Medical management is the mainstay of endometriosis
Adenomyosis

• synonym: “endometriosis interna” (uterine wall may be diffusely involved)

Epidemiology
• 15% of females >35 yr old; found in 20-40% of hysterectomy specimens
• mean age at presentation: 40-50 yr old (older age group than seen in endometriosis)
• adenomyosis is a common histologic finding in asymptomatic patients

Clinical Features
• often asymptomatic
• menorrhagia, secondary dysmenorrhea, pelvic discomfort
• dyspareunia, dyschezia
• uterus symmetrically bulky, usually <14 cm, mobility not restricted, no associated adnexal pathology
• Halban sign: tender, softened uterus on premenstrual bimanual exam

Investigations
• clinical diagnosis
• U/S or MRI can be helpful
• endometrial sampling to rule out other pathology

Treatment
• iron supplements as necessary
• analgesics, NSAIDs
• OCP, medroxyprogesterone (Depo-Provera™)
• GnRH agonists (e.g. leuprolide)
• Mirena™ IUS
• low dose danazol 100-200 mg PO OD (trial x 4 mo)
• definitive: hysterectomy (no conservative surgical treatment)

Fibroids

Epidemiology
• diagnosed in approximately 40-50% of pre-menopausal women >35 yr
• more common in African Americans, where they are also larger and occur at earlier age
• common indication for major surgery in females
• minimal malignant potential (1:1,000)
• typically regress after menopause; enlarging fibroids in a postmenopausal woman should prompt consideration of malignancy

Pathogenesis
• estrogen stimulates monoclonal smooth muscle proliferation
• progestrone stimulates production of proteins that inhibit apoptosis
• degenerative changes (occur when tumour outgrows blood supply)
• fibroids can degenerate, become calcified, have sarcomatous component or obtain parasitic blood supply

Clinical Features
• majority asymptomatic (60%), often discovered as incidental finding on pelvic exam or U/S
• abnormal uterine bleeding (30%): dysmenorrhea, menorrhagia
• pressure/bulk symptoms (20-50%)
  • pelvic pressure/heaviness
  • increased abdominal girth
  • urinary frequency and urgency
  • acute urinary retention (extremely rare but surgical emergency?)
  • constipation, bloating (rare)
• acute pelvic pain
  ■ fibroid degeneration
  ■ fibroid torsion (pedunculated subserosal)
• infertility, recurrent pregnancy loss
• pregnancy complications (potential enlargement and increased pain, obstructed labour, difficult C-section)

Investigations
• bimanual exam: uterus asymmetrically enlarged, usually mobile
• CBC: anemia
• U/S: to confirm diagnosis and assess location of fibroids
• sonohysterogram: useful for differentiating endometrial polyps from submucosal fibroids, or if intracavitary growth
• endometrial biopsy to rule out uterine cancer (especially if age >40 yr)
• occasionally MRI is used for pre-operative planning (e.g. before myomectomy)

Treatment
• only if symptomatic, rapidly enlarging, menorrhagia, menometrorrhagia, or intracavitary
• treat anemia if present
• conservative approach (watch and wait) if
  ■ symptoms absent or minimal
  ■ fibroids <6-8 cm or stable in size
  ■ not submucosal (submucosal fibroids are more likely to be symptomatic)
  ■ currently pregnant due to increased risk of bleeding (follow-up U/S if symptoms progress)
• medical approach to treat AUB-L
  ■ antiprostaglandins (ibuprofen, other NSAIDs)
  ■ tranexamic acid (Cyklokapron®)
  ■ GnRH agonist: leuprolide (Lupron®), danazol (Danocrine®)
    ■ short-term use only (6 mo)
    ■ often used pre-myomectomy or pre-hysterectomy to reduce fibroid size
    ■ reduced bleeding
  ■ ulipristal acetate: a partial progesterone receptor agonist
• interventional radiology approach
  ■ uterine artery embolization (occludes both uterine arteries) → shrinks fibroids by 50% at 6 mo; improves heavy bleeding in 90% of patients within 1-2 mo; not an option in women considering childbearing
• surgical approach
  ■ myomectomy (hysteroscopic, transabdominal, or laparoscopic): preserves fertility
  ■ hysteroscopic resection of fibroid and endometrial ablation for AUB-Lsm
  ■ hysterectomy (see Hysterectomy, GY9)
  ■ note: avoid operating on fibroids during pregnancy (due to vessel activity and potential pregnancy loss); expectant management usually best

---

Table 7. Classification of Contraceptive Methods

<table>
<thead>
<tr>
<th>Type</th>
<th>Effectiveness (Perfect Use, Typical Use)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Physiological</strong></td>
<td></td>
</tr>
<tr>
<td>Withdrawal/coitus interruptus</td>
<td>77%</td>
</tr>
<tr>
<td>Rhythm method/calendar/mucus/symptothermal</td>
<td>98%, 76%</td>
</tr>
<tr>
<td>Lactational amenorrhea</td>
<td>98% (first 6 mo postpartum)</td>
</tr>
<tr>
<td>Chance – no method used</td>
<td>10%</td>
</tr>
<tr>
<td>Abstinence of all sexual activity</td>
<td>100%</td>
</tr>
<tr>
<td><strong>Barrier Methods</strong></td>
<td></td>
</tr>
<tr>
<td>Condom alone</td>
<td>98%, 85%</td>
</tr>
<tr>
<td>Spermicide alone</td>
<td>82%, 71%</td>
</tr>
<tr>
<td>Sponge – Parous</td>
<td>80%, 68%</td>
</tr>
<tr>
<td>– Nulliparous</td>
<td>91%, 84%</td>
</tr>
<tr>
<td>Diaphragm with spermicide</td>
<td>94%, 84%</td>
</tr>
<tr>
<td>Female condom</td>
<td>95%, 79%</td>
</tr>
<tr>
<td>Cervical cap – Parous</td>
<td>74%, 68%</td>
</tr>
<tr>
<td>– Nulliparous</td>
<td>91%, 84%</td>
</tr>
</tbody>
</table>

---

Contraception

see Family Medicine, FM19

---

The effect of pregnancy on fibroid size is variable

Submucosal leiomyomata are most symptomatic (bleeding, infertility)

Ulipristal Acetate vs. Leuprolide Acetate for Uterine Fibroids

NEJM 2012;366:421-432

Study: Phase II, double-blind RCT of the efficacy and side-effect profile of ulipristal acetate versus those of leuprolide acetate for the treatment of symptomatic uterine fibroids before surgery.

Outcomes: Control of uterine bleeding at week 13 was the primary outcome. Secondary outcomes included bleeding pattern, amenorrhea, changes in fibroid/uterine volume, and global pain score.

Patients: 307 premenopausal women with symptomatic fibroids and excessive uterine bleeding were randomly assigned to oral ulipristal acetate (5 mg or 10 mg) or intramuscular injections of leuprolide acetate.

Results: Control of bleeding at week 13 was not significantly different between the treatment groups. All three treatments reduced uterine volume, although this decrease was significantly greater in the leuprolide group (47% reduction) than in the ulipristal groups (30-22%). 40% of the leuprolide group reported moderate-to-severe hot flashes, but only 11% (5 mg) and 10% (10 mg) of the ulipristal groups did.

Conclusions: Oral ulipristal acetate (5 mg or 10 mg) is noninferior to intramuscular leuprolide acetate for control of uterine bleeding due to fibroids, and it had a better side-effect profile.

Counselling the Adolescent about Contraception

More than 90% of adolescent pregnancies are unintended, and ~50% of all pregnancies occur within the first 6 mo of initiating sexual activity; in addition, 85% of sexually active women become pregnant within 1 yr if no contraception is used and even some of the least effective contraceptive methods markedly decrease the risk of pregnancy.
Table 7. Classification of Contraceptive Methods (continued)

<table>
<thead>
<tr>
<th>Type</th>
<th>Effectiveness (Perfect Use, Typical Use)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hormonal</strong></td>
<td></td>
</tr>
<tr>
<td>OCP</td>
<td>99.7%, 92%</td>
</tr>
<tr>
<td>NuvaRing®</td>
<td>99.7%, 92%</td>
</tr>
<tr>
<td>Transdermal (Ortho Evra®)</td>
<td>99.7%, 92%</td>
</tr>
<tr>
<td>Depo-Provera®</td>
<td>99.7%, 97%</td>
</tr>
<tr>
<td>Progestin-only pill (Micronor®)</td>
<td>90-99%</td>
</tr>
<tr>
<td>Mirena® IUS</td>
<td>99.9%</td>
</tr>
<tr>
<td>Jaydess® IUS</td>
<td>99.9%</td>
</tr>
<tr>
<td>Copper IUD</td>
<td>99.3%</td>
</tr>
<tr>
<td>Surgical</td>
<td></td>
</tr>
<tr>
<td>Tubal ligation</td>
<td>99.65%</td>
</tr>
<tr>
<td>Vasectomy</td>
<td>99.9%</td>
</tr>
<tr>
<td><strong>Emergency Postcoital Contraception (EPC)</strong></td>
<td></td>
</tr>
<tr>
<td>Yuzpe® method</td>
<td>98% (within 24 h), decreases by 30% at 72 h</td>
</tr>
<tr>
<td>“Plan B” levonorgestrel only</td>
<td>98% (within 24 h), decreases by 70% at 72 h</td>
</tr>
<tr>
<td>Postcoital IUD</td>
<td>99.9%</td>
</tr>
<tr>
<td>Ella</td>
<td>98% (within 120 h)</td>
</tr>
</tbody>
</table>

Effectiveness: percentage of women reporting no pregnancy after 1 yr of use

**Hormonal Methods**

**Combined Oral Contraceptive Pills**
- most contain low dose ethinyl estradiol (20-35 µg) plus progestin (norethindrone, norgestrel, levonorgestrel, desogestrel, norgestimate, drospirenone)
- failure rate (0.3% to 8%) depending on compliance
- monophasic or triphasic formulations (varying amount of progestin throughout cycle)

**Transdermal (Ortho Evra®)**
- continuous release of 6 mg norgestimate and 0.60 mg ethinyl estradiol into bloodstream
- applied to lower abdomen, back, upper arm, buttocks, NOT breast
- worn for 3 consecutive weeks (changed every wk) with 1 wk off to allow for menstruation
- as effective as OCP in preventing pregnancy (>99% with perfect use)
- may be less effective in women >90 kg
- may not be covered by drug plans

**Contraceptive Ring (Nuva Ring®)**
- thin flexible plastic ring; releases etonogestrel 120 µg/d and estradiol 15 µg/d
- works for 3 wk then removed for 1 wk to allow for menstruation
- as effective as OCP in preventing pregnancy (98%)
- side effects: vaginal infections/irritation, vaginal discharge
- may have better cycle control; i.e. decreased breakthrough bleeding

**Starting Hormonal Contraceptives**
- thorough history and physical exam, including blood pressure and breast exam
- can start at any time during cycle but ideal if within 5 d of LMP
- follow-up visit 6 wk after hormonal contraceptives prescribed
- pelvic exam not required as STI screening can be done by urine and pap smear screening does not start until >21 yr

**Effect of Ethinyl Estradiol Dose**
- ALL OCPs with ≤35 µg ethinyl estradiol carry a lower risk of VTE compared with oral contraceptives with ≥50 µg.

**Effect of Progestin Type**
- Drospirenone: third generation progestin, e.g. Tesirone and Femulen®
- Levonorgestrel: first generation progestin, e.g. Alesse®
- Two high quality research studies found comparable VTE rates with drospirenone-containing OCPs and other approved products.

**Results**
- Total of 1,686,158 women, thrombotic VTE rates with drospirenone-containing OCPs and other approved products.
- Two reports with significant methodological flaws found increased VTE risk. Results and conclusions may have been distorted by residual confounding.
- Lidegaard et al., NEJM 2009;339:b2921
- Seeger et al., Obstet Gynecol 2007;110:587-593
- One quality research study found the VTE rates with drospirenone-containing OCPs and other approved products.
- Dinger et al., Contraception 2007;75:344-354
- VTE rates with drospirenone-containing OCPs and other approved products.

**Conclusion**
- Occurrence of serious risks, such as VTE, is rare with all contemporary OCPs.
- Individualized risk assessment is mandatory.
- For most healthy women of reproductive age, the benefits of OCP will outweigh the risks.

**Oral Contraceptives and the Risk of Venous Thromboembolism: An Update (2010)**
- Rates of Venous Thromboembolism (VTE: DVT and PE) expressed in per year.
- Hormones of reproductive age: 4-5/10,000
- OCP users: 9-10/10,000
- Pregnancy: 29/10,000
- Immediate post-partum: 300-400/10,000
- Risk is highest in the first months of use and in medication switch and if stop and restart.

**Conclusions**
- Although the absolute risk of thrombotic stroke and MI with hormonal contraception is low, it is increased by a factor of 0.9-1.7 with oral contraceptives that contain ethinyl estradiol at a dose of 20 µg and by a factor of 1.2-2.3 with ethinyl estradiol doses of 30-40 µg, with relatively small differences in risk according to progestin type.
### Table 8. Combined Estrogen and Progestin Contraceptive Methods

<table>
<thead>
<tr>
<th>Mechanism of Action</th>
<th>Advantages</th>
<th>Side Effects</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovulatory suppression through inhibition of LH and FSH</td>
<td>Highly effective</td>
<td>Estrogen-related</td>
<td>Absolute</td>
</tr>
<tr>
<td>Decidualization of endometrium</td>
<td>Reversible</td>
<td>Nausea</td>
<td>Known/suspected pregnancy</td>
</tr>
<tr>
<td>Thickening of cervical mucus resulting in decreased sperm penetration</td>
<td>Cycle regulation</td>
<td>Breast changes (tenderness, enlargement)</td>
<td>Undiagnosed abnormal vaginal bleeding</td>
</tr>
<tr>
<td></td>
<td>Decreased dysmenorrhea and menorrhagia (less anemia)</td>
<td>Fluid retention/bloating/edema</td>
<td>Prior thromboembolic events, thromboembolic disorders (Factor V Leiden mutation; protein C or S, or antithrombin III deficiency), active thrombophlebitis</td>
</tr>
<tr>
<td></td>
<td>Decreased benign breast disease and ovarian cyst development</td>
<td>Weight gain (rare)</td>
<td>Cerebrovascular or coronary artery disease</td>
</tr>
<tr>
<td></td>
<td>Decreased risk of ovarian and endometrial cancer</td>
<td>Migraine, headaches</td>
<td>Estrogen-dependent tumours (breast, uterus)</td>
</tr>
<tr>
<td></td>
<td>Increased cervical mucus which may lower risk of STIs</td>
<td>Thromboembolic events</td>
<td>Impaired liver function associated with acute liver disease</td>
</tr>
<tr>
<td></td>
<td>Decreased PMS symptoms</td>
<td>Liver adenoma (rare)</td>
<td>Congenital hyperthryoidism</td>
</tr>
<tr>
<td></td>
<td>Improved acne</td>
<td>Breakthrough bleeding (low estradiol levels)</td>
<td>Smoker age &gt;35 yr</td>
</tr>
<tr>
<td></td>
<td>Osteoporosis protection (possibly)</td>
<td>Progestin-related</td>
<td>Migraines with focal neurological symptoms (excluding aura)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Amenorrhea/breakthrough bleeding</td>
<td>Uncontrolled HTN</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Headaches</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Breast tenderness</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Increased appetite</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Decreased libido</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mood changes</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>HTN</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Acne/oily skin*</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hirsutism*</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>* Androgenic side effects may be minimized by prescribing formulations containing desogestrel, norgestimate, drospirenone, or cyproterone acetate</td>
<td></td>
</tr>
</tbody>
</table>

### Table 9. Selected Examples of OCPs

<table>
<thead>
<tr>
<th>Type</th>
<th>Active Compounds (estradiol and progestin derivative)</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alesse®</td>
<td>20 µg ethinyl estradiol and 0.5 mg levonorgestrel</td>
<td>Low dose (20 µg) OCP</td>
<td>Low-dose pills can often result in breakthrough bleeding If this persists for longer than 3 mo, patient should be switched to an OCP with higher estrogen content</td>
</tr>
<tr>
<td>Tri-cyclen®</td>
<td>35 µg ethinyl estradiol and 0.180/0.215/0.250 mg norgestimate</td>
<td>Low androgenic activity can help with acne</td>
<td>Triphasic OCPs not ideal for continuous use &gt;3 weeks in a row (unlike monophasic formulation)</td>
</tr>
<tr>
<td>Yasmin® and Yaz®</td>
<td>30 µg ethinyl estradiol + 3 mg drospirenone (a new progestin)</td>
<td>Decreased perception of cyclic weight gain/bloating Fewer PMS symptoms Improved acne</td>
<td>Hyperkalemia (rare, contraindicated in renal and adrenal insufficiency) Check potassium if patient also on ACEI, ARB, K⁺-sparking diuretic, heparin Continue use of spironolactone</td>
</tr>
</tbody>
</table>

**PROGESTIN-ONLY METHOD**

### Table 10. Progestin Only Contraceptive Methods

<table>
<thead>
<tr>
<th>Indications</th>
<th>Mechanism of Action</th>
<th>Side Effects</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suitable for postpartum women (does not affect breast milk supply)</td>
<td>Progestin prevents LH surge Thickenening of cervical mucus Decrease tubal motility Endometrial decidualization Ovulation suppression – oral progestins (not IM) do not consistently suppress compared to combined OCPs</td>
<td>Irregular menstrual bleeding Weight gain Headache Breast tenderness Mood changes Functional ovarian cysts Acne/oily skin Hirsutism</td>
<td>Absolute None</td>
</tr>
<tr>
<td>Women with contraindications to combined OCP (e.g. thromboembolic or myocardial disease)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women intolerant of estrogenic side effects of combined OCPs</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Reference: World Health Organization Guidelines for Oral Contraceptive Pill Use
SELECTED EXAMPLES OF PROGESTIN-ONLY METHODS

Progestin-Only Pill ("minipill")
- Micronor® 0.35 mg norethindrone
- taken daily at same time of day to ensure reliable effect; no pill free interval
- higher failure rate (1.1-13% with typical use, 0.5-1% with perfect use) than other hormonal methods
- ovulation inhibited only in 60% of women; most have regular cycles (but may cause oligo/amenorrhea)
- highly effective if also post-partum breastfeeding, or if >35 yr
- relies on the progestin effects on the cervical mucous and endometrial lining

Depo-Provera®
- injectable depot medroxyprogesterone acetate
- dose 150 mg IM q12-14wk (convenient dosing)
- initiate ideally within 5 d of beginning of normal menses, immediately postpartum in breastfeeding and non-breastfeeding women. Can consider quick start
- irregular spotting progresses to complete amenorrhea in 70% of women (after 1-2 yr of use)
- highly effective 99%; failure rate 0.3%
- suppresses ovulation very effectively
- side effect: decreased bone density (may be reversible)
- disadvantage: restoration of fertility may take up to 1-2 yr

*Cervical swabs for gonorrhea and chlamydia should be done prior to insertion

Table 11. IUS/IUD Contraceptive Methods

<table>
<thead>
<tr>
<th>Mechanism of Action</th>
<th>Side Effects</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Copper-Containing IUD</td>
<td>Both Copper and Progestrone IUD</td>
<td>Absolute</td>
</tr>
<tr>
<td>(NovaT®): mild foreign body reaction to endometrium toxic to sperm and alters sperm motility</td>
<td>Breakthrough bleeding</td>
<td>Both Copper and Progestrone IUD</td>
</tr>
<tr>
<td></td>
<td>Expulsion (5% in the 1st yr, greatest in 1st mo and in nulliparous women)</td>
<td>Known or suspected pregnancy</td>
</tr>
<tr>
<td></td>
<td>Uterine wall perforation (1/1,000) on insertion</td>
<td>Undiagnosed genital tract bleeding</td>
</tr>
<tr>
<td></td>
<td>If pregnancy occurs with an IUD, increased risk of ectopic pregnancy</td>
<td>Acute or chronic PID</td>
</tr>
<tr>
<td></td>
<td>Increased risk of PID (within first 10 of insertion only)</td>
<td>Lifestyle risk for SIH*</td>
</tr>
<tr>
<td>Progestrone-Releasing IUS</td>
<td>Copper IUD</td>
<td>Copper IUD</td>
</tr>
<tr>
<td>(Mirena®, Jaydess®):</td>
<td>Increased blood loss and duration of menses, dysmenorrhea</td>
<td>Known allergy to copper</td>
</tr>
<tr>
<td>decidualization of endometrium and thickening of cervical mucus; minimal effect on ovulation</td>
<td>Valvular heart disease</td>
<td>Wilson’s disease</td>
</tr>
<tr>
<td></td>
<td>Copper IUD: bloating, headache</td>
<td>Relative</td>
</tr>
<tr>
<td></td>
<td>Progestrone IUD: bloating, headache</td>
<td>Both Copper and Progestrone IUD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Valvular heart disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Past history of PID or ectopic pregnancy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Presence of prosthesis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormalities of uterine cavity, intracavitary fibroids</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cervical stenosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Immunossuppressed individuals (e.g. HIV)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Copper IUD: severe dysmenorrhea or menorrhagia</td>
</tr>
</tbody>
</table>

*Cervical swabs for gonorrhea and chlamydia should be done prior to insertion

Intrauterine Device

Table 11. IUS/IUD Contraceptive Methods

<table>
<thead>
<tr>
<th>Mechanism of Action</th>
<th>Side Effects</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Copper-Containing IUD</td>
<td>Both Copper and Progestrone IUD</td>
<td>Absolute</td>
</tr>
<tr>
<td>(NovaT®): mild foreign body reaction to endometrium toxic to sperm and alters sperm motility</td>
<td>Breakthrough bleeding</td>
<td>Both Copper and Progestrone IUD</td>
</tr>
<tr>
<td></td>
<td>Expulsion (5% in the 1st yr, greatest in 1st mo and in nulliparous women)</td>
<td>Known or suspected pregnancy</td>
</tr>
<tr>
<td></td>
<td>Uterine wall perforation (1/1,000) on insertion</td>
<td>Undiagnosed genital tract bleeding</td>
</tr>
<tr>
<td></td>
<td>If pregnancy occurs with an IUD, increased risk of ectopic pregnancy</td>
<td>Acute or chronic PID</td>
</tr>
<tr>
<td></td>
<td>Increased risk of PID (within first 10 of insertion only)</td>
<td>Lifestyle risk for SIH*</td>
</tr>
<tr>
<td>Progestrone-Releasing IUS</td>
<td>Copper IUD</td>
<td>Copper IUD</td>
</tr>
<tr>
<td>(Mirena®, Jaydess®):</td>
<td>Increased blood loss and duration of menses, dysmenorrhea</td>
<td>Known allergy to copper</td>
</tr>
<tr>
<td>decidualization of endometrium and thickening of cervical mucus; minimal effect on ovulation</td>
<td>Valvular heart disease</td>
<td>Wilson’s disease</td>
</tr>
<tr>
<td></td>
<td>Copper IUD: bloating, headache</td>
<td>Relative</td>
</tr>
<tr>
<td></td>
<td>Progestrone IUD: bloating, headache</td>
<td>Both Copper and Progestrone IUD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Valvular heart disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Past history of PID or ectopic pregnancy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Presence of prosthesis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormalities of uterine cavity, intracavitary fibroids</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cervical stenosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Immunossuppressed individuals (e.g. HIV)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Copper IUD: severe dysmenorrhea or menorrhagia</td>
</tr>
</tbody>
</table>

*Cervical swabs for gonorrhea and chlamydia should be done prior to insertion
Emergency Postcoital Contraception

Table 12. Emergency Contraceptive Methods

<table>
<thead>
<tr>
<th>Method</th>
<th>Mechanism of Action</th>
<th>Side Effects</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HORMONAL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Yuzpe Method</strong></td>
<td>Unknown; theories include: Supresses ovulation or causes deficient luteal phase</td>
<td>Nausea (due to estrogen; treat with Gravol®)</td>
<td>Pre-existing pregnancy (although not teratogenic)</td>
</tr>
<tr>
<td></td>
<td>Alters endometrium to prevent implantation</td>
<td>Irregular spotting</td>
<td>Caution in women with contraindications to OCP (although NO absolute contraindications)</td>
</tr>
<tr>
<td></td>
<td>Affects sperm/ova transport</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Efficacy decreased with time (e.g. less effective at 72 h than 24 h)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>% overall risk of pregnancy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Can substitute with any OCP as long as same dose of estrogen used</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2% overall risk of pregnancy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Terminations are generally done until the stage of viability (~23.5 wk), although this varies depending on the provider</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>“Plan B”</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Consists of levonorgestrel 750 µg q12h for 2 doses (can also take 2 doses together); taken within 72 h of intercourse. Can be taken up to 5 d Greater efficacy (75-95% if used within 24 h) and better side effect profile than Yuzpe method but efficacy decreases with time; 1st line if &gt;24 h No estrogen thus very few contraindications/side effects (less nausea) Less effective in overweight individuals (&gt;75 kg less effective, &gt;80 kg not recommended)</td>
<td>Same as above</td>
<td>Same as above</td>
</tr>
<tr>
<td></td>
<td>Selective Progesterone Receptor Modulator (SPERM) with primarily antiprogestin activity: may delay ovulation by up to 5 d</td>
<td>Headache, hot flashes, constipation, vertigo, endometrial thickening</td>
<td>Same as above</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ulipristal</strong></td>
<td>30 mg PO within 5 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Selective Progesterone Receptor Modulator (SPERM) with primarily antiprogestin activity: may delay ovulation by up to 5 d</td>
<td>Headache, hot flashes, constipation, vertigo, endometrial thickening</td>
<td>Same as above</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NON-HORMONAL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Postcoital IUD (Copper)</strong></td>
<td>Insert up to 7 d postcoitus Prevents implantation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1% failure rate</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Can use for short duration in higher risk individuals</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Minora® IUS cannot be used as EPC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Follow-up
- 3–4 wk post treatment to confirm efficacy (confirmed by spontaneous menses or pregnancy test)
- contraception counselling

Termination of Pregnancy

Definition
- active termination of a pregnancy before fetal viability (usually <500 g or <20 wk GA)

Indications
- inability to carry a pregnancy to term due to medical or social reasons (including patient preference)

Management
- medical
  - <9 wk: methotrexate + misoprostol
  - >12 wk: prostaglandins (intra- or extra-amniotically or IM) or misoprostol
- surgical
  - <12 wk: dilatation + vacuum aspiration ± curettage
  - >12 wk: dilatation and evacuation, early induction of labour
  - common complications: pain or discomfort
  - less common complications: hemorrhage, perforation of uterus, laceration of cervix, risk of infertility, infection/endometritis, Asherman’s syndrome (adhesions within the endometrial cavity causing amenorrhea/infertility), retained products of conception
- counselling
  - supportive and counselling services
  - future contraception and family planning services
  - ensure follow-up

Any OCP can be used as EPC; 100 µg ethinyl estradiol PO q12h x 2 doses
- Levonorgestrel emergency contraception regimens are more effective and cause fewer side effects than the Yuzpe regimen
- Levonorgestrel emergency contraception single dose (1.5 mg) and the 2-dose levonorgestrel regimen (0.75 mg 12 h apart) have similar efficacy with no difference in side effects

CMA Policy (1988)
- “Induced abortion should be uniformly available to all women in Canada” and “there should be no delay in the provision of abortion services”

Terminations are generally done until the stage of viability (~23.5 wk), although this varies depending on the provider
Pregnancy-Related Complications

Spontaneous Abortions

- see Termination of Pregnancy for therapeutic abortions

Table 13. Classification of Spontaneous Abortions

<table>
<thead>
<tr>
<th>Type</th>
<th>History</th>
<th>Clinical</th>
<th>Management (+ Rhogam*)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Threatened</td>
<td>Vaginal bleeding ± cramping</td>
<td>Cervix closed and soft</td>
<td>Watch and wait &lt;5% go on to abort</td>
</tr>
</tbody>
</table>
| Inevitable    | Increasing bleeding and cramps ± rupture of membranes | Cervix closed until products start to expel, then external os opens | a) Watch and wait  
|               |                            |                           | b) Misoprostol 400-800 µg PQ/PV  
|               |                            |                           | c) DBC ± oxytocin                     |
| Incomplete    | Extremely heavy bleeding and cramps ± passage of tissue noticed | Cervix open                | a) Watch and wait  
|               |                            |                           | b) Misoprostol 400-800 µg PQ/PV  
|               |                            |                           | c) DBC ± oxytocin                     |
| Complete      | Bleeding and complete passage of sac and placenta | Cervix open                | No DB + – expectant management       |
| Missed        | No bleeding (fetal death in utero) | Cervix closed             | a) Watch and wait  
|               |                            |                           | b) Misoprostol 400-800 µg PQ/PV  
|               |                            |                           | c) DBC ± oxytocin                     |
| Recurrent     | ≥3 consecutive spontaneous abortions | Cervix closed             | Evaluate mechanical, genetic, environmental, and other risk factors |
| Septic        | Contents of uterus infected – infrequent |                           | DB & IV broad spectrum antibiotics    |

Ectopic Pregnancy

Definition
- embryo implants outside of the endometrial cavity

Figure 14. Sites of ectopic pregnancy implantation

- Ampullary (70%) >> isthmal (12%) > fimbrial (11%) > ovarian (3%) > interstitial (2%) > abdominal (1%)

Epidemiology
- 1/100 pregnancies
- fourth leading cause of maternal mortality, leading cause of death in first trimester
- increase in incidence over the last 3 decades
- three commonest locations for ectopic pregnancy: ampullary (70%), isthmic (12%), fimbrial (11%)
Ectopic Pregnancy

**Etiology**
- 50% due to damage of fallopian tube cilia following PID
- intrinsic abnormality of the fertilized ovum
- conception late in cycle
- transmigration of fertilized ovum to contralateral tube

**Risk Factors**
- previous ectopic pregnancy
- gynecologic
  - current IUD use – increased risk of ectopic if pregnancy occurs
  - history of PID (especially infection with *C. trachomatis*), salpingitis
  - infertility
  - infertility treatment (IVF pregnancies following ovulation induction [7% ectopic rate])
  - previous procedures
    - any surgery on fallopian tube (for previous ectopic, tubal ligation, etc.)
    - abdominal surgery for ruptured appendix, etc.
  - smoking
  - structural
    - uterine leiomyomas
    - adhesions
    - abnormal uterine anatomy (e.g. T-shaped uterus)

**Investigations**
- serial β-hCG levels; normal doubling time with intrauterine pregnancy is 1.6-2.4 d in early pregnancy
  - rise of <20% of β-hCG is 100% predictive of a non-viable pregnancy
  - prolonged doubling time, plateau, or decreasing levels before 8 wk implies nonviable gestation but does not provide information on location of implantation
  - 85% of ectopic pregnancies demonstrate abnormal β-hCG doubling
- ultrasound
  - U/S is only definitive if fetal cardiac activity is detected in the tube or uterus
  - specific finding on transvaginal U/S is a tubal ring
  - suspect ectopic in case of empty uterus with β-hCG >5000 and no bleeding
  - laparoscopy (sometimes used for definitive diagnosis)

**Treatment**
- goals of treatment: conservative (preserve tube if possible), maintain hemodynamic stability
- surgical = laparoscopy
  - linear salpingostomy an option if tube salvageable
  - salpingectomy if tube damaged or ectopic is ipsilateral recurrence
  - 15% risk of persistent trophoblast; must monitor β-hCG titre weekly until they reach non-detectable levels
  - consider Rhogam® if Rh negative
  - may require laparotomy if patient is unstable, extensive abdominal surgical history, etc.

---

**DDx of Lower Abdominal Pain**
- Urinary tract: UTI, kidney stones
- GI: diverticulitis, appendicitis
- Gyne: endometriosis, PID, fibroid (degenerating, infarcted, torsion), ovarian torsion, ovarian neoplasm, ovarian cyst, pregnancy-related

**Clinical Features of Ectopic Pregnancy**
- 4Ts and 1S
  - Temperature >38°C (20%)
  - Tenderness: abdominal (90%) = rebound (45%)
  - Tenderness on bimanual examination, cervical motion tenderness
  - Tissue: palpable adnexal mass (50%) (half have contralateral mass due to lutein cyst)
  - Signs of pregnancy (e.g. Chadwick’s sign, Hegar’s sign)

**Figure 15. Algorithm for suspected ectopic pregnancy**

**Suspected Ectopic Pregnancy**
1. Positive urine β-hCG
2. Abdominal pain
3. Vaginal bleeding

**Procedures**
- Vital signs stable
  - Transvaginal U/S
  - Serum β-hCG
- Vital signs unstable
  - U/S is only definitive if fetal cardiac activity is detected in the tube or uterus
  - Methotrexate
  - Consider surgical management; if using methotrexate, follow-up is more frequent

**If Ectopic Pregnancy Ruptures**
- Acute abdomen with increasing pain
- Shock
- Management of Abortions
  - Always rule out an ectopic
  - Always check Rh; if negative, give Rhogam®
  - Always ensure patient is hemodynamically stable
• medical = methotrexate (for indications see Figure 4)
  ■ use 50 mg/m² body surface area; given in a single IM dose
  ■ this is 1/5 to 1/6 chemotherapy dose, therefore minimal side effects (reversible hepatic dysfunction, diarrhea, gastritis, dermatitis)
  ■ follow β-hCG levels weekly until β-hCG is non-detectable
    • plateau or rising levels suggest persisting trophoblastic tissue (requires further treatment)
  ■ 82-95% success rate, but up to 25% will require a second dose
  ■ tubal patency following methotrexate treatment approaches 80%

Prognosis
• 9% of maternal deaths during pregnancy
• 40-60% of patients will become pregnant again after surgery
• 10-20% will have subsequent ectopic pregnancy

Infertility

Epidemiology
• 10-15% of couples, must investigate both members of the couple

Female Factors

Etiology
• ovulatory dysfunction (15-20%)
  ■ hypothalamic (hypothalamic amenorrhea)
    • stress, poor nutrition, excessive exercise (even with presence of menstruation)
  ■ pituitary (prolactinoma, hypopituitarism)
  ■ PCOS
  ■ ovarian
    • premature ovarian failure
    • luteal phase defect (poor follicle production, premature corpus luteum failure, failed uterine lining response to progesterone), poorly understood
  ■ systemic diseases (thyroid, Cushing’s syndrome, renal/hepatic failure)
    • congenital (Turner’s syndrome, gonadal dysgenesis or gonadotropin deficiency)
  ■ outflow tract abnormality (15-20%)
    • tubal factors (20-30%)
      • PID
      • adhesions (previous surgery, peritonitis, endometriosis)
      • ligation/occlusion (e.g. previous ectopic pregnancy)
    • uterine factors (<5%)
      • congenital anomalies, bicornuate uterus, septate uterus, prenatal DES exposure, intrauterine adhesions (e.g. Asherman’s syndrome), fibroids/polyps (particularly intrauterine)
      • infection (endometritis, pelvic TB)
      • endometrial ablation
    • cervical factors (5%)
      • hostile or acidic cervical mucus, anti-sperm antibodies
      • structural defects (cone biopsies, laser or cryotherapy)
  ■ endometriosis (15-30%)
  ■ multiple factors (30%)
  ■ unknown factors (10-15%)

Investigations
• ovulatory
  ■ day 3: FSH, LH, TSH, prolactin ± DHEA, free testosterone (if hirsute) add estradiol for proper FSH interpretation
  ■ day 21-23: serum progesterone to confirm ovulation
  ■ initiate basal body temperature monitoring (biphasic pattern)
  ■ postcoital test: evaluate mucus for clarity, pH, spininbarkeit/fibrosity (rarely done)
• tubal factors
  • HSG (can be therapeutic – opens fallopian tube)
  • SHG (can be therapeutic; likely less – opens fallopian tube)
  • laparoscopy with dye insufflation (or tubal dye test)
• peritoneal/uterine factors
  • HSG/SHG, hysteroscopy
  • other
    • karyotype

Controversial and Evolving Ethical Issues
• infertility demands non-judgmental discussion
• Ethical issues surrounding therapeutic donor insemination in same sex couples, surrogacy, donor gametes, and other advanced reproductive technologies are still evolving and remain controversial
• If the doctor finds that certain treatment options lie outside of their moral boundaries, the infertile couple should be referred to another physician

Interventions for Tubal Ectopic Pregnancy
Cochrane Review of randomized controlled trials comparing treatments in women with tubal ectopic pregnancy.

Patients: Women with a diagnosis of tubal ectopic pregnancy.

Intervention: Surgery (salpingectomy/ salpingostomy by open surgery or by laparoscopy), medical treatment, and expectant management.

Main Outcome: Primary treatment success, defined as an uneventful decline in serum β-hCG to undetectable levels by the initial treatment.

Results: Intramuscular MTX therapy and salpingostomy yielded similar treatment success rates (82-95% for MTX therapy vs. 80-92% for salpingostomy).
Polycystic Ovarian Syndrome

**Treatment**
- education: timing intercourse relative to ovulation (from 2 d prior to 2 d following presumed ovulation), every other day
- medical
  - ovulation induction
    - clomiphene citrate (Clomid\(^\text{TM}\)): estrogen antagonist causing a perceived decreased estrogen state, resulting in increased pituitary gonadotropins; which increases FSH and LH and induces ovulation (better results if anovulatory)
    - followed by β-hCG for stimulation of ovum release
  - may add
    - bromocriptine (dopamine agonist) if elevated prolactin
    - dexamethasone for hyperandrogenism (adult onset congenital adrenal hyperplasia)
    - metformin (for PCOS)
  - luteal phase progesterone supplementation for luteal phase defect (mechanism not completely understood)
  - antigestagen and ASA (81 mg PO OD) for women with a history of recurrent spontaneous abortions (for antiphospholipid antibody syndrome)
  - thyroid replacement to keep TSH < 2.5
- surgical/procedural
  - tubuloplasty
  - lysis of adhesions
  - artificial insemination: intracervical insemination (ICI), intrauterine insemination (IUI), intratubal insemination (ITI)
  - sperm washing
  - IVF (in vitro fertilization)
  - IFT (intrafallopian transfer)
  - GIFT\(^*\) (gamete intrafallopian transfer): immediate transfer with sperm after oocyte retrieval
  - ZIFT\(^*\) (zygote intrafallopian transfer): transfer after 24 h culture of oocyte and sperm
  - TET\(^*\) (tubal embryo transfer): transfer after >24 h culture
  - ICSI (intracytoplasmic sperm injection)
  - IVM (in vitro maturation)
  - ± oocyte or sperm donors
  - ± pre-genetic screening for single gene defects in karyotype of zygote
  - not performed in Canada

**Male Factors**

- see Urology, U34

**Etiology**
- varicocele (>40%)
- idiopathic (>20%)
- obstruction (<15%)
- cryptorchidism (<8%)
- immunologic (<3%)

**Investigations**
- semen analysis and culture
- postcoital (Hühner) test: rarely done

**Polycystic Ovarian Syndrome**

- also called chronic ovarian androgenism

**Etiology**

![Pathophysiology of polycystic ovarian syndrome]

- Obesity
- ↑ peripheral conversion to estrogen
- ↑ estrogen
- ↓ FSH secretion + ↑ LH secretion
- Anovulation
- ↑ ovarian secretion of androgens
- Hirsutism
- Infertility
- Oligomenorrhea
- Insulin
- ↑ peripheral conversion to estrogen
- ↑ estrogen
Diagnosis
- Rotterdam diagnostic criteria: 2 of 3 required
  - oligoamenorrhea/irregular menses for 6 mo
  - hyperandrogenism
    - clinical evidence - hirsutism or male pattern alopecia or
    - biochemical evidence - raised free testosterone
  - polycystic ovaries on U/S

Clinical Features
- average age 15-35 yr at presentation
- in adolescents, wait at least 1-2 yr to make diagnosis
- abnormal/irregular uterine bleeding, hirsutism, infertility, obesity, virilization
- anacistic nigrians: browning of skin folds in intertriginous zones (indicative of insulin resistance)
- insulin resistance occurs in both lean and obese patients, family history of DM

Investigations
- goal: identify hyperandrogenism or chronic anovulation; and rule out specific pituitary or adrenal disease as the cause
- laboratory
  - prolactin, 17-hydroxyprogesterone, free testosterone, DHEA-S, TSH, free T4, androstenedione, SHBG
  - LH:FSH >2:1; LH is chronically high with FSH mid-range or low (low sensitivity and specificity)
  - increased DHEA-S, androstenedione and free testosterone (most sensitive), decreased SHBG
- transvaginal or transabdominal U/S: polycystic-appearing ovaries (“string of pearls” – 12 or more small follicles 2-9 mm, or increased ovarian volume)
- tests for insulin resistance or glucose tolerance
  - fasting glucose/insulin ratio <4.5 is consistent with insulin resistance (U.S. units)
  - 75 g OGTT yearly (particularly if obese)
- laparoscopy
  - not required for diagnosis
  - most common to see white, smooth, sclerotic ovaries with a thick capsule; multiple follicular cysts in various stages of atresia; hyperplastic theca and stroma
- rule out other causes of abnormal bleeding

Treatment
- lifestyle modification (decrease BMI, increase exercise) to decrease peripheral estrone formation
- OCP monthly or cyclic Provera® to prevent endometrial hyperplasia due to unopposed estrogen
- oral hypoglycemic (e.g. metformin) if type 2 diabetic or if trying to become pregnant
- tranexamic acid (Cyklokapron®) for menorrhagia only
- infertility
  - medical induction of ovulation: clomiphene citrate, human menopausal gonadotropins (HMG [Pergonal®]), LHHR, recombinant FSH, and metformin
  - metformin may be used alone or in conjunction with clomiphene citrate for ovulation induction
  - ovarian drilling (perforate the stroma), wedge resection of the ovary
- bromocriptine (if hyperprolactinemia)
- hyperandrogenism
  - any OCP can be used
    - Diane 35® (cyproterone acetate): antiandrogenic
    - Yasmin® (drospirenone and ethinyl estradiol): spironolactone analogue (inhibits steroid receptors)
  - mechanical removal of hair
  - finasteride (3-a reductase inhibitor)
  - flutamide (androgen reuptake inhibitor)
  - spironolactone: androgen receptor inhibitor

Use of Metformin in Polycystic Ovary Syndrome: A Meta-Analysis
Study: This meta-analysis of 17 RCTs assessed the efficacy of metformin or metformin in combination with clomiphene citrate in women with PCOS who were seeking pregnancy.
Main Outcomes: Ovulation, pregnancy, and live birth. Patients: 1,639 patients with PCOS were followed up for up to 12 mo.
Results: Compared to placebo, metformin increased the odds of ovulation (OR 2.94, 95% CI 1.43-6.02). However, when used alone, metformin did not significantly increase the odds of achieving pregnancy (OR 1.56, 95% CI 0.74-3.33). When compared to clomiphene alone, the combination of metformine and clomiphene increased the likelihood of ovulation (OR 4.39, 95% CI 1.94-9.96) and pregnancy (OR 2.87, 95% CI 1.45-4.94). The effect of combination therapy was most prominent in clomiphene-resistant and obese women with PCOS. Furthermore, the combination therapy had a higher likelihood of having a live birth compared to clomiphene alone, but this did not reach significance (OR 1.7, 95% CI 0.79-3.86).
Conclusions: Metformin increases the likelihood of ovulation. When used together with clomiphene, metformin increases the likelihood of both ovulation and pregnancy, especially in clomiphene-resistant and obese women.

Gynecological Infections
Physiologic Discharge
- clear, white, flocculent, odourless discharge; pH 3.8-4.2
- smear contains epithelial cells, Lactobacilli
- increases with increased estrogen states: pregnancy, OCP mid-cycle, PCOS, or premenarchal
- if increased in perimenopausal/postmenopausal woman, consider investigation for other effects of excess estrogen (e.g. endometrial cancer)
**Vulvovaginitis**

**PREPUBERTAL VULVOVAGINITIS**

- **clinical features**
  - irritation, pruritus
  - discharge
  - vulvar erythema
  - vaginal bleeding (specifically due to Group A Streptococci and *Shigella*).

- **differential diagnosis**
  - non-specific vulvovaginitis (25-75%)
  - infections (respiratory, enteric, systemic, sexually acquired)
  - foreign body (toilet paper most common)
  - *Candida* (if using diapers or chronic antibiotics)
  - pinworms
  - polyps, tumour (ovarian malignancy)
  - vulvar skin disease (*lichen sclerosis, condyloma acuminata*)
  - trauma (accidental straddle injury, sexual abuse)
  - psychosomatic vaginal complaints (specific to vaginal discharge)
  - endocrine abnormalities (specific to vaginal bleeding)
  - blood dyscrasia (specific to vaginal bleeding).

- **etiology**
  - infectious
    - poor hygiene, proximity of vagina to anus
    - recent infection (respiratory, enteric, systemic)
    - STI: investigate sexual abuse
  - non-specific
    - lack of protective hair and labial fat pads
    - lack of estrogenization
    - susceptible to chemicals, soaps (bubble baths), medications, and clothing
    - enuresis

- **investigations**
  - vaginal swab for culture (specifically state that it is a pre-pubertal specimen), pH, wet-mount, and KOH smear in adults only.

- **treatment**
  - enhanced hygiene and local measures (handwashing, white cotton underwear, no nylon tights, no tight fitting clothes, no sleeper pajamas, sitz baths, avoid bubble baths, use mild detergent, eliminate fabric softener, avoid prolonged exposure to wet bathing suits, urination with legs spread apart)
  - A&D® dermatological ointment (vitamin A/D) to protect vulvar skin
  - infectious: treat with antibiotics for organism identified

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Pinworms</th>
<th>Lichen Sclerosis</th>
<th>Foreign Body</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
<td>Empirical treatment with mebendazole</td>
<td>Area of white patches and thinning of skin</td>
<td>Irrigation of vagina with saline, may require local anesthesia or an exam under anesthesia</td>
</tr>
</tbody>
</table>

**VAGINITISROPHIC / VAGINITIS**

- **clinical features**
  - dyspareunia, postcoital spotting, mild pruritus

- **investigations**
  - atrophy is usually a visual diagnosis: thinning of tissues, erythema, petechiae, bleeding points, dryness on speculum exam
  - rule out malignancy, especially endometrial cancer

- **treatment**
  - local estrogen replacement (ideal): Premarin® cream, VagiFem® tablets, or Estring®
  - oral or transdermal hormone replacement therapy (if treatment for systemic symptoms is desired)
  - good hygiene
### Infectious Vulvovaginitis

#### Table 15. Infectious Vulvovaginitis

<table>
<thead>
<tr>
<th>Pathophysiology or Transmission</th>
<th>Organisms</th>
<th>Pathogenesis</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Predispelling factors include:</td>
<td>Candida albicans (80%)</td>
<td>Replacement of vaginal Lactobacillus with organisms above</td>
<td>Metronidazole 2 g PO single dose or 500 mg bid x 7 d (alternative)</td>
</tr>
<tr>
<td>Immunocompromised host (DM, AIDS, etc.)</td>
<td>Candida glabrata (&lt;5%)</td>
<td></td>
<td>Symptomatic pregnant women should be treated with 2 g metronidazole once</td>
</tr>
<tr>
<td>Recent antibiotic use</td>
<td>Candida tropicalis (&lt;5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased estrogen levels (e.g., pregnancy, OCP)</td>
<td><strong>HIV</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Speculum Exam</strong></td>
<td><strong>Figure 17. Speculum exam</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Chlamydia</strong></td>
<td><strong>Candidiasis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gonococcal Infection</strong></td>
<td><strong>Trichomoniasis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bacterial Vaginosis (BV)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Trichomoniasis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Other

- **Discharge**
  - Whitish, “cottage cheese,” minimal
  - Grey, thin, diffuse
  - Yellow-green, malodorous, diffuse, frothy
- **Other**
  - 20% asymptomatic
  - 50-75% asymptomatic
  - 25% asymptomatic
- **Signs/Symptoms**
  - Intense pruritus
  - Swollen, inflamed genitals
  - Vulvar burning, dysuria, dyspareunia
  - Fishy odour, especially after coitus
  - Absence of vulvar/vaginal irritation
  - Petechiae on vagina and cervix
  - Occasionally irritated tender vulva
  - Dysuria, frequency
- **pH**
  - ≤4.5
  - ≥4.5
- **Saline Wetmount**
  - KOH wetmount reveals hyphae and spores
  - >20% clue cells = squamous epithelial cells dotted with coccobacilli (Gardnerella)
  - Paucity of WBC
  - Paucity of Lactobacilli
  - Positive whiff test: fishy odour with addition of KOH to slide (due to formation of amines)

#### Treatment

- **Clotrimazole**, butoconazole, miconazole, terconazole suppositories, and/or creams for 1, 3, or 7 d treatments
- **Metronidazole 150 mg PO in single dose (can be used in pregnancy)**
- **Clindamycin 2% 5 g intravaginally at bedtime for 7 d**
- **Fluconazole 150 mg PO in single dose**
- **Lactobacillus**
- **Probiotics (lactobacillus sp.): oral or topical  alone or in combination**
- **Fluconazole 200 mg PO once**
- **Symptomatic pregnant women should be treated with 2 g metronidazole once**

#### Other

- **Prophylaxis for recurrent infection includes**
  - Boric acid, vaginal suppositories, luteal phase
  - Metronidazole
  - Fluconazole
  - Clindamycin
  - Flunisolide
  - Probiotics (lactobacillus sp.): oral or topical alone or as adjuvant
  - **Inflammation of cervix**

** warnings accompanying metronidazole use**

Treat even if asymptomatic

- **Metronidazole 2 g PO single dose or 500 mg bid x 7 d (alternative)**
- **Symptomatic pregnant women should be treated with 2 g metronidazole once**

---

**CDC Notifiable Diseases**

- Chancroid
- Chlamydia
- Gonorrhea
- Hepatitis A, B, C
- HIV
- Syphilis

**Risk Factors for STIs**

- History of previous STI
- Contact with infected person
- Sexually active individual <25 yr
- Multiple partners
- New partner in last 3 mo
- Lack of barrier protection use
- Street involvement (homelessness, drug use)

---

**Sexually Transmitted Infections**

- see Family Medicine, FM42
TRICHOMONIASIS
• see Infectious Vulvovaginitis, Table 15

CHLAMYDIA

Etiology
• Chlamydia trachomatis

Epidemiology
• most common bacterial STI in Canada
• often associated with N. gonorrhoeae

Clinical Features
• asymptomatic (80% of women)
• muco-purulent endocervical discharge
• urethral syndrome: dysuria, frequency, pyuria, no bacteria on culture
• pelvic pain
• postcoital bleeding or intermenstrual bleeding (particularly if on OCP and prior history of good cycle control)
• symptomatic sexual partner

Investigations
• cervical culture or nucleic acid amplification test
• obligate intracellular parasite: tissue culture is the definitive standard
• urine and self vaginal tests now available, which are equally or more effective than cervical culture

Treatment
• doxycycline 100 mg PO bid for 7 d or azithromycin 1 g PO in a single dose (may use in pregnancy)
• also treat gonorrhea because of high rate of co-infection
• treat partners
• reportable disease
• test of cure for chlamydia required in pregnancy (cure rates lower in pregnant patients) → retest 3-4 wk after initiation of therapy

Screening
• high risk groups
• during pregnancy
• when initiating OCP if sexually active (independent risk factor)

Complications
• acute salpingitis, PID
• Fitz-Hugh-Curtis syndrome (liver capsule inflammation)
• reactive arthritis (male predominance, HLA-B27 associated), conjunctivitis, urethritis
• infertility: tubal obstruction from low grade salpingitis
• ectopic pregnancy
• chronic pelvic pain
• perinatal infection: conjunctivitis, pneumonia

Etiology
• Neisseria gonorrhoeae
• symptoms and risk factors same as with chlamydia

Investigations
• Gram stain shows Gram-negative intracellular diplococci
• cervical, rectal, and throat culture (if clinically indicated)

Treatment
• single dose of ceftriaxone 250 mg IM plus azithromycin 1 g PO
  • if pregnant: above regimen or 2 g spectinomycin IM plus azithromycin 1 g PO (avoid quinolones)
  • also treat chlamydia, because of high rate of co-infection
• treat partners
  • reportable disease
  • screening as with chlamydia
HUMAN PAPILLOMAVIRUS

Etiology
- most common viral STI in Canada
- >200 subtypes, of which >30 are genital subtypes
- HPV types 6 and 11 are classically associated with anogenital warts/condylomata acuminata
- HPV types 16 and 18 are the most oncogenic (classically associated with cervical HSIL)
- types 16, 18, 31, 33, 35, 36, 45 (and others) associated with increased incidence of cervical and vulvar intraepithelial hyperplasia and carcinoma

Clinical Features
- latent infection
  - no visible lesions, asymptomatic
- subclinical infection
  - only detected by DNA hybridization tests
- clinical infection
  - visible lesion found during colposcopy or on Pap test
- visible wart-like lesion without magnification
  - hyperkeratotic, verrucous or flat, macular lesions
- vulvar edema

Investigations
- cytology
- koilocytosis: nuclear enlargement and atypia with perinuclear halo
- biopsy of lesions at colposcopy
- detection of HPV DNA subtype using nucleic acid probes (not routinely done but can be done in presence of abnormal Pap test to guide treatment)

Treatment
- patient administered
  - podofilox 0.5% solution or gel bid x 3 d in a row (4 d off) then repeat x 4 wk
  - imiquimod (Aldara*) 5% cream 3x/wk qhs x 16 wk
- provider administered
  - cryotherapy with liquid nitrogen: repeat q1-2wk
  - podophyllin resin in tincture of benzoin: weekly
  - trichloroacetic acid (TCA) or bichloroacetic acid weekly (80-90%); safe in pregnancy
  - surgical removal/laser
  - intralesional interferon

Prevention
- vaccination: Gardasil*, Cervarix* see Table 25, GY43
- condoms may not fully protect (areas not covered, must be used every time throughout entire sexual act)

HERPES SIMPLEX VIRUS OF VULVA

Etiology
- 90% are HSV-2, 10% are HSV-1

Clinical Features
- may be asymptomatic
- initial symptoms: present 2-21 d after contact
- prodromal symptoms: tingling, burning, pruritus
- multiple, painful, shallow ulcerations with small vesicles appear 7-10 d after initial infection (absent in many infected persons); lesions are infectious
- inguinal lymphadenopathy, malaise, and fever often with first infection
- dysuria and urinary retention if urethral mucosa affected
- recurrent infections: less severe, less frequent, and shorter in duration (usually only HSV-2)

Investigations
- viral culture preferred in patients with ulcer present, however decreased sensitivity as lesions heal
- cytologic smear (Tzanck smear) shows multinucleated giant cells, acidophilic intranuclear inclusion bodies
- HSV DNA PCR
- type specific serologic tests for antibodies to HSV-1 and HSV-2 (not available routinely in Canada)

Genital Warts During Pregnancy
- Condyloma tend to get larger in pregnancy and should be treated early (consider excision)
- C-section only if obstructing birth canal or risk of extensive bleeding
- Do not use imiquimod, podophyllin, or podofilox

Human Rights in Health Equity: Cervical Cancer and HPV Vaccines
- While cervical cancer rates have drastically fallen in developed countries due to effective prevention and treatment, socially disadvantaged women within these countries remain disproportionately more likely to develop and die of cervical cancer.
- In most developing countries cervical cancer rates have risen or remained unchanged.
- Must recognize that cervical cancer disparities between race, urban and rural residence, and high and low socioeconomic status are attributed to disparate screening and vaccination coverage.
- Programs are implemented without sufficient attention to conditions that render screening less effective or inaccessible to disadvantaged social groups including: lack of information, undervaluing of preventive care, opportunistic delivery in limited health care settings, sexual health stigma, and related privacy concerns.

A 9-Valent HPV Vaccine Against Infection and Intraepithelial Neoplasia in Women

Method: International randomized, double-blinded phase 2B-3 study of 9 HPV vaccine in 14,215 women between ages of 16-26. Participants were randomized to the 9vHPV vaccine group or the qHPV vaccine group and each received a series of three IM injections (day 1, 2 and 6 months). Swabs of labial, vulvar, perineal, perianal, endocervical, and ectocervical tissue was obtained and used for HPV DNA testing/Pap smear.

Results: Rate of high-grade cervical, vulvar, or vaginal disease was 14.0 per 1,000 person-years in both vaccine groups. The rate of high-grade cervical, vulvar, or vaginal disease related to HPV-31, 33, 45, 52, and 58 was 0.1 per 1,000 person-years in the qHPV group and 1.6 per 1,000 person-years in the 9vHPV group (85% CI = 80.9-99.0). Antibody responses to HPV 6, 11, 16, and 18 were not significantly different between the two vaccine groups although adverse events related to injection sites were more common in the qHPV group.

Conclusions: The 9vHPV vaccine was non-inferior to qHPV vaccine in preventing infection and disease related to HPV-6, 11, 16, and 18 and also covered additional oncogenic types HPV-31, 33, 45, 52, and 58 in a susceptible population.
Treatment
• first episode
  ■ acyclovir 200 mg PO five times daily x 5-10 d, or famciclovir 250 mg PO tid x 7-10 5 d, or valacyclovir 1 g PO bid x 10 d
• recurrent episode
  ■ acyclovir 200 mg PO five times daily x 5 d, or famciclovir 125 mg PO bid x 5 d, or valacyclovir 500 mg PO bid OR 1 g PO OD x 3 d
• daily suppressive therapy
  ■ consider for > 6 recurrences per yr or one every 2 mo
  ■ acyclovir 400 mg PO bid, or famciclovir 250 mg bid, or valacyclovir 0.5-1 g PO OD
• severe disease: consider IV therapy: acyclovir 55 mg/kg IV over 60 min q8h
• education regarding transmission
• avoid contact from onset of prodrome until lesions have cleared
• use barrier contraception

SYPHILIS

Etiology
• Treponema pallidum

Classifications
• primary syphilis
  ■ 3-4 wk after exposure
  ■ painless chancre on vulva, vagina, or cervix
  ■ painless inguinal lymphadenopathy
  ■ serological tests usually negative, local infection only
• secondary syphilis (can resolve spontaneously)
  ■ 2-6 mo after initial infection
  ■ nonspecific symptoms: malaise, anorexia, headache, diffuse lymphadenopathy
  ■ generalized maculopapular rash: palms, soles, trunk, limbs
  ■ condylomata lata: anogenital, broad-based fleshy grey lesions
  ■ serological tests usually positive
• latent syphilis
  ■ no clinical manifestations; detected by serology only
• tertiary syphilis
  ■ may involve any organ system
  ■ neurological: tabes dorsalis, general paresis
  ■ cardiovascular: aortic aneurysm, dilated aortic root
  ■ vulvar gumma: nodules that enlarge, ulcerate and become necrotic (rare)
• congenital syphilis
  ■ may cause fetal anomalies, stillbirths, or neonatal death

Investigations
• aspiration of ulcer serum or node
• darkfield microscopy (most sensitive and specific diagnostic test for syphilis)
  ■ spirochetes
• non-treponemal screening tests (VDRL, RPR); nonreactive after adequate treatment
• specific anti-treponemal antibody tests (FTA-ABS, MHA-TP, TP-PA)
  ■ confirmatory tests; remain reactive for life (even after adequate treatment)

Treatment
• treatment of primary, secondary, latent syphilis of <1 yr duration
  ■ benzathine penicillin G 2.4 million units IM single dose
  ■ treat partners, reportable disease
• treatment of latent syphilis of >1 yr duration
  ■ benzathine penicillin G 2.4 million units IM q1wk x 3 wk
• treatment of neurosyphilis
  ■ IV aqueous penicillin G 3-4 million units IM q12h x 10-14 d
• screening
  ■ high risk groups
  ■ in pregnancy (see Obstetrics, Table Infections During Pregnancy, OB29)

Complications
• if untreated, 1/3 will experience late complications

HIV
• see Infectious Diseases, ID27
Bartholin Gland Abscess

Etiology
- often anaerobic and polymicrobial
- \textit{U. urealyticum, N. gonorrhoeae, C. trachomatis, E. coli, P. mirabilis, Streptococcus spp., S. aureus} (rare)
- blockage of duct

Clinical Features
- unilateral swelling and pain in inferior lateral opening of vagina
- sitting and walking may become difficult and/or painful

Treatment
- sitz baths, warm compresses
- antibiotics: cephalexin x 1 wk
- incision and drainage using local anesthesia with placement of Word catheter (10 French latex catheter) for 2-3 wk (or as long as stays insitu)
- marsupialization under general anesthetic – more definitive treatment
- rarely treated by removing gland

Pelvic Inflammatory Disease

- up to 20% of all gynecology-related hospital admissions

Etiology
- causative organisms (in order of frequency)
  - \textit{C. trachomatis}
  - \textit{N. gonorrhoeae}
    - gonorrhea and chlamydia often co-exist
  - endogenous flora: anaerobic, aerobic, or both
    - \textit{E. coli, Staphylococcus, Streptococcus, Enterococcus, Bacteroides, Peptostreptococcus, H. influenzae, G. vaginalis}
    - cause of recurrent PID
    - associated with instrumentation
  - \textit{Actinomyces israelii} (Gram-positive, non acid-fast anaerobe)
    - 1-4% of PID cases associated with IUDs
    - others (TB, Gram-negatives, CMV, U. urealyticum, etc.)

Risk Factors
- age <30 yr
- risk factors as for chlamydia and gonorrhea
- vaginal douching
- IUD (within first 10 d after insertion)
- invasive gynecologic procedures (D&C, endometrial biopsy)

Clinical Presentation
- up to 2/3 asymptomatic: many subtle or mild symptoms
- common: fever >38.3º C, lower abdominal pain and tenderness, abnormal discharge: cervical or vaginal
- uncommon: N/V, dysuria, AUB
- chronic disease (often due to chlamydia)
  - constant pelvic pain
  - dyspareunia
  - palpable mass
  - very difficult to treat, may require surgery

Investigations
- blood work
  - β-hCG (must rule out ectopic pregnancy), CBC, blood cultures if suspect septicemia
- urine R&M
- speculum exam, bimanual exam
  - vaginal swab for Gram stain, C&S
  - cervical cultures for \textit{N. gonorrhoeae, C. trachomatis}
  - endometrial biopsy will give definitive diagnosis (rarely done)
- ultrasound
  - may be normal
  - free fluid in cul-de-sac
  - pelvic or tubo-ovarian abscess
  - hydrosalpinx (dilated fallopian tube)
- laparoscopy (gold standard)
  - for definitive diagnosis: may miss subtle inflammation of tubes or endometritis

PID accounts for up to 20% of all gynecological hospital admissions

PID Inflammation of the upper genital tract (above cervix) including endometrium, fallopian tubes, ovaries, pelvic peritoneum, ± contiguous structures

PID Diagnosis
- Must have
  - Lower abdominal pain
- Plus one of
  - Cervical motion tenderness
  - Adnexal tenderness
  - Plus one or more of
    - High risk partner
    - Temperature >38º C
    - Mucopurulent cervical discharge
    - Positive culture for \textit{N. gonorrhoeae, C. trachomatis, E. coli}, or other vaginal flora
    - Cul-de-sac fluid, pelvic abscess or inflammatory mass on U/S or bimanual
    - Leukocytosis
    - Elevated ESR or CRP (not commonly used)
Treatment
- must treat with polymicrobial coverage
- inpatient if
  - moderate to severe illness
  - atypical infection
  - adnexal mass, tubo-ovarian mass, or pelvic abscess
  - unable to tolerate oral antibiotics or failed oral therapy
  - immunocompromised
  - pregnant
  - adolescent – first episode
  - surgical emergency cannot be excluded (e.g. ovarian torsion)
- PID is secondary to instrumentation
- recommended treatment
  - cefoxitin 2 g IV q6h (no longer available in U.S.A.) + doxycycline 100 mg IV/PO q12h or clindamycin 900 mg IV q6h + gentamicin 2 mg/kg IV/IM loading dose then gentamicin 1.5 mg/kg IV q8h maintenance dose
  - continue IV antibiotics for 24 h after symptoms have improved then doxycycline 100 mg PO bid to complete 14 d
  - percutaneous drainage of abscess under U/S guidance
  - when no response to treatment, laparoscopic drainage
  - if failure, treatment is surgical (salpingectomy, TAH/BSO)
- outpatient if
  - typical findings
  - mild to moderate illness
  - oral antibiotics tolerated
  - compliance ensured
  - follow-up within 48-72 h (to ensure symptoms not worsening)
- recommended treatment
  - ceftriaxone 250 mg IM x 1 + doxycycline 100 mg PO bid x 14 d or cefoxitin 2 g IM x 1 + probenecid 1 g PO + doxycycline 100 mg PO bid ± metronidazole 500 mg PO bid x 14 d
  - ofloxacin 400 mg PO bid x 14 d or levofloxacin 500 mg PO OD x 14 d ± metronidazole 500 mg PO bid x 14 d
  - consider removing IUD after a minimum of 24 h of treatment
  - reportable disease
  - treat partners
  - consider re-testing for C. trachomatis and N. gonorrhoeae 4-6 wk after treatment if documented infection

Complications of Untreated PID
- chronic pelvic pain
- abscess, peritonitis
- adhesion formation
- ectopic pregnancy
- infertility
  - 1 episode of PID \(\rightarrow\) 13% infertility
  - 2 episodes of PID \(\rightarrow\) 36% infertility
- bacteremia
- septic arthritis, endocarditis

Toxic Shock Syndrome
- see Infectious Diseases, ID23

Risk Factors
- tampon use
- diaphragm, cervical cap, or sponge use (prolonged use, i.e. >24 h)
- wound infections
- post-partum infections
- early recognition and treatment of syndrome is imperative as incorrect diagnosis can be fatal

Clinical Presentation
- sudden high fever
- sore throat, headache, diarrhea
- erythoderma
- signs of multisystem organ failure
- refractory hypotension
- exfoliation of palmar and plantar surfaces of the hands and feet 1-2 wk after onset of illness
Treatment
- remove potential sources of infection (foreign objects and wound debris)
- debride necrotic tissues
- adequate hydration
- penicillinase-resistant antibiotics, e.g. cloxacillin
- steroid use controversial but if started within 72 h, may reduce severity of symptoms and duration of fever

Surgical Infections
Post-Operative Infections in Gynecological Surgery
- pelvic cellulitis
  - common post hysterectomy, affects vaginal vault
  - erythema, induration, tenderness, discharge involving vaginal cuff
  - treat if fever and leukocytosis with broad spectrum antibiotics, i.e. clindamycin and gentamicin
  - drain if excessive purulence or large mass
  - can result in intra-abdominal and pelvic abscess
- see General Surgery, Post-Operative Fever, GS7

Sexual Abuse
- see Family Medicine, FM26, Emergency Medicine, ER27

Sexuality and Sexual Dysfunction

SEXUAL RESPONSE
1. desire: energy that allows an individual to initiate or respond to sexual stimulation
2. arousal: physical and emotional stimulation leading to breast and genital vasodilation and clitoral engorgement
3. orgasm: physical and emotional stimulation is maximized, allowing the individual to relinquish their sense of control
4. resolution: most of the congestion and tension resolves within seconds, complete resolution may take up to 60 min

SEXUAL DYSFUNCTION

Etiology
- psychological or emotional: depression, abuse
- hormonal: menopause
- neurologic dysfunction: spinal cord injury
- vascular insufficiency: DM
- drug side effects: β-blockers
- trauma: episiotomy

Classification
- lack of desire (60-70% of women)
- lack of arousal
- anorgasmia (5-10%)
  - primary anorgasmia: never before achieved orgasm under any circumstances
  - secondary anorgasmia: was able to achieve orgasm before but now unable to
- dyspareunia (3-6%): painful intercourse, superficial or deep
  - vaginismus (15%)
  - vulvodynia
  - vaginal atrophy
  - vulvar vestibulitis: associated with history of frequent yeast infections
  - PID

Treatment
- lack of desire: assess factors, rule out organic causes, relationship therapy, sensate focus exercises
- anorgasmia: self-exploration/pleasuring, relationship therapy if needed, bridging techniques (different sexual positions, clitoral stimulation during intercourse)
- dyspareunia
  - Kegel and reverse Kegel exercises
  - dilator treatment
  - comfort with self-exam
  - psychotherapy, other behavioural techniques
  - female on top position: allows for control of speed and duration
  - vestibulitis: remove local irritants, change in contraceptive methods, dietary changes (increased citrate, decreased oxalate), and vestibulectomy (rare)
  - vulvodynia: local moisturization, cold compresses, systemic nerve blocking therapy (amitriptyline, gabapentin) orally or topically, topical anesthetics, estrogen cream
  - pain clinic

Dyspareunia Cycle
- Painful intercourse (initially due to organic etiology)
- 2nd vaginismus
- Fear of pain with intercourse
- Anxiety with or without sexual response

Figure 20. Dyspareunia Cycle

Kegel Exercises
- Regular contraction and relaxation to strengthen pelvic floor muscles

Reverse Kegel Exercises
- 1 s contraction then 5 s of relaxation

Figure 20. Dyspareunia Cycle
Menopause

• see Family Medicine, FM40

Definitions
• lack of menses for 1 yr
• types of menopause
  ▪ physiological; average age 51 yr (follicular atresia)
  ▪ premature ovarian failure; before age 40 (autoimmune disorder, infection, Turner’s syndrome)
  ▪ iatrogenic (surgical/radiation/chemotherapy)

Clinical Features
• associated with estrogen deficiency
  ▪ vasomotor instability (tends to dissipate with time)
  ▪ hot flushes/flushes, night sweats, sleep disturbances, formication, nausea, palpitations
  ▪ urogenital atrophy involving vagina, urethra, bladder
  ▪ dyspareunia, pruritus, vaginal dryness, bleeding, urinary frequency, urgency, incontinence
  ▪ skeletal
  ▪ osteoporosis, joint and muscle pain, back pain
  ▪ skin and soft tissue
  ▪ decreased breast size, skin thinning/loss of elasticity
  ▪ psychological
  ▪ mood disturbance, irritability, fatigue, decreased libido, memory loss

Investigations
• increased levels of FSH (>35 IU/L) on day 3 of cycle (if still cycling) and LH (FSH>LH)
• FSH level not always predictive due to monthly variation; use absence of menses for 1 yr to diagnose
• decreased levels of estradiol (later)

Treatment
• goal is for individual symptom management
  ▪ vasomotor instability
    ▪ HRT (first line), SSRIs, venlafaxine, gabapentin, propranolol, clonidine
    ▪ acupuncture
  ▪ vaginal atrophy
    ▪ local estrogen: cream (Premarin®), vaginal suppository (VagiFem®), ring (Estring®)
    ▪ lubricants (Replens®)
  ▪ urogenital health
  ▪ lifestyle changes (weight loss, bladder re-training), local estrogen replacement, surgery
  ▪ osteoporosis
    ▪ 1,000-1,500 mg calcium OD, 800-1,000 IU vitamin D, weight-bearing exercise, smoking cessation
    ▪ bisphosphonates (e.g. alendronate)
    ▪ selective estrogen receptor modifiers (SERMs): raloxifene (Evista®) – mimics estrogen effects on bone, avoids estrogen-like action on breast and uterine cancer; does not help hot flashes
    ▪ HRT: second-line treatment (unless for vasomotor instability as well)
    ▪ decreased libido
    ▪ vaginal lubrication, counselling, androgen replacement (testosterone cream or the oral form Andriol®)
  ▪ cardiovascular disease
    ▪ management of cardiovascular risk factors
  ▪ mood and memory
    ▪ antidepressants (first line), HRT (augments effect)
    ▪ alternative choices (not evidence-based, safety not established)
      ▪ black cohosh, phytoestrogens, St. John’s wort, ginkgo biloba, valerian, evening primrose oil, ginseng, Don Quai

Hormone Replacement Therapy
• see Family Medicine, FM40
• primary indication is treatment of menopausal symptoms (vasomotor instability)
• keep doses low (e.g. 0.3 mg Premarin®) and duration of treatment short (<5 yr)

HRT Components
• estrogen
• oral or transdermal (e.g. patch, gel)
• transdermal preferred for women with hypertriglyceridemia or impaired hepatic function, smokers, and women who suffer from headaches associated with oral HRT

Menopause
Occurrence of last spontaneous menstrual period, resulting from loss of ovarian function (loss of oocyte response to gonadotropins)

“Being in menopause”
Lack of menses for 1 yr

Perimenopause
Period of time surrounding menopause (2-8 yr preceding + 1 yr after last menses) characterized by fluctuating hormone levels, irregular menstrual cycles, and symptom onset

• 85% of women experience hot flashes
• 20-30% seek medical attention
• 10% are unable to work

Menopause Pathophysiology
Degenerating theca cells fail to react to endogenous gonadotropins (FSH, LH)
  ▪ Less estrogen is produced
  ▪ Decreased negative feedback on hypothalamic-pituitary-adrenal axis
  ▪ Increased FSH and LH
  ▪ Stromal cells continue to produce androgens as a result of increased LH stimulation

Figure 21. Menopause pathophysiology

• Osteoporosis is the single most important health hazard associated with menopause
• Cardiovascular disease is the leading cause of death post-menopause
• Increased risk of breast cancer (RR 1.3) is associated with estrogen + progesterone HRT, but not with estrogen-only HRT
• All women taking HRT should have periodic surveillance and counselling regarding its benefits and risks
- low-dose (preferred dose: 0.3 mg Premarin®/25 µg Estradot® patch, can increase if necessary)
- progestin
- given in combination with estrogen for women with an intact uterus to prevent development of endometrial hyperplasia/cancer

### Table 16. Examples of HRT Regimens

<table>
<thead>
<tr>
<th>HRT Regimen</th>
<th>Estrogen Dose</th>
<th>Progestin Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unopposed</td>
<td>CEE 0.625 mg PO OD</td>
<td>None</td>
<td>If no intact uterus</td>
</tr>
<tr>
<td>Standard-dose</td>
<td>CEE 0.625 mg PO OD</td>
<td>MPA 2.5 mg PO OD, or micronized progesterone 100 mg PO OD</td>
<td>Withdrawal bleeding may occur in a spotty, unpredictable manner Usually abates after 6-8 mo due to endometrial atrophy Once patient has become amenorrheic on HRT, significant subsequent bleeding episodes require evaluation (endometrial biopsy)</td>
</tr>
<tr>
<td>Standard-dose Cyclic</td>
<td>CEE 0.625 mg PO OD</td>
<td>MPA 5-10 mg PO days 1-14 only, or micronized progesterone 200 mg PO OD days 1-14 only</td>
<td>Bleeding occurs monthly after day 14 of progestin (can continue for years) PMS-like symptoms (breast tenderness, fluid retention, headache, nausea) are more prominent with cyclic HRT</td>
</tr>
<tr>
<td>Pulsatile</td>
<td>CEE 0.625 mg PO OD</td>
<td>MPA low-dose</td>
<td>3 d on, 3 d off</td>
</tr>
</tbody>
</table>
| Transdermal       | Estraderm®-Estradiol 0.05 mg/d or 0.1 mg/d Estralis®-Estradiol 140 µg/d or 250 µg/d | Estrodex®-MPA 2.5 mg PO OD Estralis®-NEA 50 µg/d | Use patch twice weekly
Use patch twice weekly
Can use oral progestins (Estrodex®)
Combined patches available (Estralis®) |
| Topical           | Estrace® 2.4 g/d x 1-2 wk, 1 g/d maintenance Premarin® 0.5-2 g/d for 21 d then off 7 d for vaginal atrophy, 0.5 g/d for 21 d then off 7 d or twice/wk for dyspareunia Estragyn® 2-4 g/d | Crinone® 4% or 8% (45 or 90 mg applicator) | If simultaneously taking oral estrogen tablet, may need to adjust dosing
If intact uterus, also take progestosterone |

CEE = conjugated equine estrogen (e.g. Premarin®); MPA = medroxyprogesterone acetate (e.g. Provera®); NEA = norethindrone acetate
Consider lower dose regimens; PREMPRO® 0.4/1.5 (Premarin® 0.45 mg and Provera® 1.5 mg); Estrace® (topical 17β-estradiol) = 0.1 mg active ingredient/g; Premarin® (topical CEE) = 0.625 mg active ingredient/g; Estragyn® (topical estrone) = 1 mg active ingredient/g

### Side Effects of HRT
- abnormal uterine bleeding
- mastodynia – breast tenderness
- edema, bloating, heartburn, nausea
- mood changes (progestosterone)
- may be worse in progesterone phase of combined therapy

### Contraindications to HRT
- absolute
  - acute liver disease
  - undiagnosed vaginal bleeding
  - known or suspected uterine cancer/breast cancer
  - acute vascular thrombosis or history of severe thrombophlebitis or thromboembolic disease
  - cardiovascular disease
- relative
  - pre-existing uncontrolled HTN
  - uterine fibroids and endometriosis
  - familial hyperlipidemias
  - migraine headaches
  - family history of estrogen-dependent cancer
  - chronic thrombophlebitis
  - DM (with vascular disease)
  - gallbladder disease, hypertriglyceridemia, impaired liver function (consider transdermal estrogen)
  - fibrocystic disease of the breasts
WOMEN’S HEALTH INITIATIVE (launched in 1991)
- two non-randomized studies investigating health risks and benefits of HRT in healthy postmenopausal women 50-79 yr old
  - continuous combined HRT (CEE 0.625 mg + MPA 2.5 mg OD) in 16,608 women with an intact uterus
  - estrogen-alone (CEE 0.625 mg) in 10,739 women with a previous hysterectomy
- both arms of the trial were stopped early because of evidence of increased risk of breast cancer, stroke, PE, and CHD in the combined HRT arm, and increased risk of stroke with no CHD benefits in the estrogen-alone arm
- the apparent increase in CHD was in disagreement with results of previous observational trial
- results of the WHI study have since been challenged and revision of how CHD was diagnosed led to loss of statistical significance of the results
- benefits and risks reported as number of cases per 10,000 women each year

### Table 17. HRT Benefits vs. Risks

<table>
<thead>
<tr>
<th>Benefits</th>
<th>Risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vasomotor Symptoms: less frequent and severe with use of either combined or estrogen-alone HRT</td>
<td>Stroke: 8 additional cases with combined HRT, and 12 additional cases for estrogen alone (WHI)</td>
</tr>
<tr>
<td>Osteoporosis: 5 fewer cases of hip fractures and 47 fewer cases of all fractures with combined HRT, 6 fewer cases of hip fractures with estrogen alone</td>
<td>DVT/PE: 18 additional cases with combined HRT, and 9 additional cases for estrogen-alone (WHI)</td>
</tr>
<tr>
<td>Colon Cancer: 6 fewer cases with combined HRT (WHI) One additional case with estrogen-alone</td>
<td>CHD: 7 additional MIs with combined HRT (WHI); secondary analysis suggests greater absolute risk for women aged &gt;70 yr and for women who start HRT &gt;10 yr post-menopause</td>
</tr>
<tr>
<td>Breast Cancer: 8 additional cases with combined HRT (WHI) Risk only increased after &gt;5 yr of combined HRT use; no increased risk for estrogen-alone</td>
<td>Breast Cancer: additional cases with combined HRT (WHI)</td>
</tr>
<tr>
<td>Dementia and Mild Cognitive Impairment: 50% greater risk of developing dementia in women taking estrogen-alone after age 65; risk is greater for women taking combined HRT, risk of developing dementia was reduced for women taking HRT before age 65</td>
<td></td>
</tr>
</tbody>
</table>

### Conclusions
- HRT is not indicated for primary or secondary prevention of cardiovascular disease or dementia. Although HRT is considered effective for the prevention of postmenopausal osteoporosis, it is generally recommended as an option only for women at significant risk, for whom non-estrogen therapies are unsuitable.
### Prolapse

**Etiology**
- relaxation, weakness, or defect in the cardinal and uterosacral ligaments which normally maintain the uterus in an anteflexed position and prevent it from descending through the urogenital diaphragm (i.e. levator ani muscles)
- related to
  - vaginal childbirth
  - aging
  - decreased estrogen (post-menopause)
  - following pelvic surgery
  - increased intra-abdominal pressure (obesity, chronic cough, constipation, ascites, heavy lifting)
  - congenital (rarely)
  - ethnicity (Caucasian women > Asian or African women)
  - collagen disorders

**GENERAL CONSERVATIVE TREATMENT**
(for pelvic relaxation/prolapse and urinary incontinence)
- Kegel exercises
- local vaginal estrogen therapy
- vaginal pessary (intravaginal suspension disc)

<table>
<thead>
<tr>
<th>Table 18. Pelvic Prolapse</th>
<th>Clinical Features</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cystocele (protrusion of bladder into the anterior vaginal wall)</td>
<td>Frequency, urgency, nocturia Stress incontinence Incomplete bladder emptying ± associated increased incidence of UTIs – may lead to renal impairment</td>
<td>See above Anterior colporrhaphy (“anterior repair”) Consider additional/alternative surgical procedure if documented urinary stress incontinence</td>
</tr>
<tr>
<td>Enterocele (protrusion of small bowel in upper posterior vaginal wall)</td>
<td>Straining/digitation to evacuate stool Constipation</td>
<td>Similar to herna repair Contents reduced, neck of peritoneal sac ligated, uterosacral ligaments, and levator ani muscles approximated</td>
</tr>
<tr>
<td>Rectocele (protrusion of rectum into posterior vaginal wall)</td>
<td>Grind/back pain (stretching of uterosacral ligaments) Feeling of heaviness/pressure in the pelvis Worse with standing, lifting Worse at the end of the day Relieved by lying down Ulceration/bleeding (particularly if hypoestrogenic) ± urinary incontinence</td>
<td>See above Vaginal hysterectomy ± surgical prevention of vault prolapse Consider additional surgical procedures if urinary incontinence, cystocele, rectocele, and/or enterocele are present</td>
</tr>
<tr>
<td>Uterine Prolapse (protrusion of cervix and uterus into vagina)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vault Prolapse (protrusion of apex of vaginal vault into vagina, post-hysterectomy)</td>
<td></td>
<td>See above Sacralcolpopexy (vaginal vault suspension), sacrospinous fixation, or uterosacral ligament suspension</td>
</tr>
</tbody>
</table>

### Urinary Incontinence

- see Urology, U5

#### STRESS INCONTINENCE

**Definition**
- involuntary loss of urine with increased intra-abdominal pressure (coughing, laughing, sneezing, walking, running)

**Risk Factors for Stress Incontinence in Women**
- pelvic prolapse
- pelvic surgery
- vaginal delivery
- hypoestrogenic state (post-menopause)
- age
- smoking
- neurological/pulmonary disease
Treatment
- see Prolapse, General Conservative Treatment, GY37
- surgical
  - tension-free vaginal tape (TVT), tension-free obturator tape (TOT), prosthetic/fascial slings or retropubic bladder suspension (Burch or Marshall-Marchetti-Krantz procedures)

URGE INCONTINENCE

Definition
- urine loss associated with an abrupt, sudden urge to void
- “overactive bladder”
- diagnosed based on symptoms

Etiology
- idiopathic (90%)
- detrusor muscle overactivity (“detrusor instability”)

Associated Symptoms
- frequency, urgency, nocturia, leakage

Treatment
- behaviour modification (reduce caffeine/liquid, smoking cessation, regular voiding schedule)
- Kegel exercises
- medications
  - anticholinergics: oxybutinin (Ditropan®), tolterodine (Detrol®), solifenacin (VESIcare®)
  - tricyclic antidepressants: imipramine

ENDOMETRIAL CARCINOMA

Epidemiology
- most common gynecological malignancy in North America (40%); 4th most common cancer in women
- 2-3% of women develop endometrial carcinoma during lifetime
- mean age is 60 yr
- majority are diagnosed in early stage due to detection of symptoms
- 85-90% 5 yr survival for stage I disease
- 70-80% overall 5 yr survival for all stages

Risk Factors
- General: increasing age and FHx
- Type I: excess estrogen (estrogen unopposed by progesterone)
  - obesity
  - PCOS
  - unbalanced HRT (balanced HRT is protective)
  - nulliparity
  - late menopause (> 55 yr), early menarche
  - estrogen-producing ovarian tumours (e.g. granulosa cell tumours)
  - HNPCC (hereditary non-polyposis colorectal cancer)/Lynch II syndrome
  - tamoxifen
- Type II: not estrogen-related
  - possibly tamoxifen

Classification and Clinical Features
- Type I (well-differentiated endometrioid adenocarcinoma) ~80% of cases
  - postmenopausal bleeding in majority, abnormal uterine bleeding in majority of affected pre-menopausal women (menorrhagia, intermenstrual bleeding)
- Type II (serous, clear cell carcinoma, grade 3 endometrioid, undifferentiated, carcinosarcoma) ~15% of cases
  - may not present with bleeding in early stage, more likely to present with advanced stage disease with symptoms like ovarian cancer (i.e. bloating, bowel dysfunction, pelvic pressure)

Investigations
- endometrial sampling
  - office endometrial biopsy
  - D&C ± hysteroscopy
- ± pelvic ultrasound (in women where adequate endometrial sampling not feasible without invasive methods)
- not acceptable as alternative to pelvic exam or endometrial sampling to rule out cancer

Incidence of Malignant Gynecological Lesions in North America
endometrium > ovary > cervix > vulva > vagina > fallopian tube

Risk Factors for Endometrial Cancer
COLD NUT
- Cancer (ovarian, breast, colon)
- Obesity
- Late menopause
- Diabetes mellitus
- Nulliparity
- Unopposed estrogen: PCOS, anovulation, HRT
- Tamoxifen: chronic use

Postmenopausal bleeding = endometrial cancer until proven otherwise (95% present with vaginal bleeding)

An endometrial thickness of 5 mm or more is considered abnormal in a postmenopausal woman with vaginal bleeding
Table 19. FIGO Staging of Endometrial Cancer (2009)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Confined to corpus</td>
<td>IIIC</td>
<td>Metastasis to pelvic ± para-aortic LNs</td>
</tr>
<tr>
<td>IA</td>
<td>No or less than half myometrial invasion</td>
<td>IIIC1</td>
<td>Positive pelvic LN</td>
</tr>
<tr>
<td>IB</td>
<td>Invades through ≥1/2 of myometrium</td>
<td>IIIC2</td>
<td>Positive para-aortic LN ± positive pelvic LNs</td>
</tr>
<tr>
<td>II</td>
<td>Tumour invades cervical stroma, but does not extend beyond uterus*</td>
<td>IV</td>
<td>Invasion of bladder ± bowel mucosa ± distant metastases</td>
</tr>
<tr>
<td>III</td>
<td>Local and/or regional spread of tumour</td>
<td>IVA</td>
<td>Invasion of bladder ± bowel mucosa</td>
</tr>
<tr>
<td>IIIA</td>
<td>Invasion of serosa, corpus uteri ± adenexae</td>
<td>IVB</td>
<td>Distal mets, including intra-abdominal mets ± inguinal LNs</td>
</tr>
<tr>
<td>IIIB</td>
<td>Vaginal ± parametrical involvement</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Note: endocervical glandular involvement is now considered as Stage I (previously Stage II)

**FIGO:** International Federation of Gynecology and Obstetrics

**BAD-P:**
- Bleeding
- Abdominal distention
- Foul smelling vaginal discharge
- Pelvic Pressure

**Treatment**
- Surgical: hysterectomy/bilateral salpingo-oophorectomy (BSO) and pelvic washings ± pelvic and para-aortic node dissection ± omentectomy.
- Goals: diagnosis, staging, treatment, defining optimal adjuvant treatment.
- Laparoscopic approach associated with improved quality of life (optimal for most patients).
- Adjuvant radiotherapy (for improved local control in patients at risk for local recurrence) and adjuvant chemotherapy (in patients at risk for distant recurrence or with metastatic disease).
- Presence of poor prognostic factors in definitive pathology.
- Chemotherapy: often used for recurrent disease (especially if high grade or aggressive histology).
- Hormonal therapy: progestins can be used for recurrent disease (especially if low grade).

**UTERINE SARCOMA**
- Rare; 2-6% of all uterine malignancies.
- Arise from stromal components (endometrial stroma, mesenchymal or myometrial tissues).
- Behave more aggressively and are associated with worse prognosis than endometrial carcinoma; 5-yr survival is 35%.
- Vaginal bleeding is most common presenting symptom.

**Table 20. Summary of Uterine Sarcoma Subtypes and Features**

<table>
<thead>
<tr>
<th>Type</th>
<th>Epidemiology</th>
<th>Features</th>
<th>Diagnosis</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PURE TYPE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Leiomyosarcoma</td>
<td>Accounts for 40%</td>
<td>Histologic distinction from leiomyoma 1. Increased mitotic count (&gt;10 mitoses/10 high power fields) 2. Tumour necrosis 3. Cellular atypia</td>
<td>Often post-operatively after uterus removed for presumed fibroids Stage using FIGO 2009 staging for leiomyosarcomas and ECC</td>
<td>Hysterectomy/BSO usually No routine pelvic lymphadenectomy Adjuvant chemotherapy may be used if tumour has spread beyond uterus Radiation therapy does not improve local control or survival Poor outcomes overall, even for early stage disease</td>
</tr>
<tr>
<td>2. Endometrial Stromal Sarcoma (ESS)</td>
<td>Accounts for 10-15%</td>
<td>Abnormal uterine bleeding Good prognosis</td>
<td>Diagnosed by histology of endometrial biopsy or D&amp;C Stage using FIGO 2009 staging for leiomyosarcomas and ECC</td>
<td>Hysterectomy &amp; BSO (remove ovaries as ovarian hormones may stimulate growth) No routine pelvic lymphadenectomy Adjuvant therapy based on stage and histologic features (hormones and/or radiation) Hormonal therapy (progestins) may be used for metastatic disease</td>
</tr>
<tr>
<td>3. Undifferentiated Sarcoma</td>
<td>Accounts for 5-10%</td>
<td>Severe nuclear pleomorphism, high mitotic activity, tumour cell necrosis, and lack smooth muscle or endometrial stromal differentiation Poor prognosis</td>
<td>Often found incidentally post-operatively for abnormal bleeding</td>
<td>Treatment primarily surgical Radiation and/or chemotherapy for advanced disease or unresectable disease</td>
</tr>
</tbody>
</table>

**MIXED TYPE**

| 4. Adenosarcoma | The rarest of the uterine sarcoma Mixed tumour of low malignant potential | Present with abnormal vaginal bleeding Polypoid mass in uterine cavity | Mixture of benign epithelium with malignant low-grade sarcoma Often found incidentally at time of hysterectomy for PMB Stage using FIGO 2009 staging for adenosarcoma | Treatment is surgical with hysterectomy and BSO |

**RECLASSIFIED**

| 5. Carcinosarcoma | Most common (43%) Recently reclassified as high grade endometroid carcinoma with associated metaplasia of the mesenchyme, rather than arising separately from stroma | Both epithelial and stromal malignant elements present Tend to form bulky polypoid masses that often fill uterine cavity and extend into or through the endocervical canal – often have exetraterine disease at presentation | Diagnosed by histology of endometrial biopsy or D&C Stage using FIGO 2009 staging for endometrial cancer | Usually treated as “high grade endometrial carcinoma” since behaviour and treatment similar (i.e. surgical staging and resection of any gross metastatic disease, adjuvant chemotherapy and radiation) |

**Prognostic Factors**
- Most important is FIGO stage
- Other Prognostic Factors:
  - Age
  - Grade
  - Histologic subtype
  - Depth of myometrial invasion
  - Presence of lymphovascular space involvement (LVS)
  - Hormone receptor status

**Complications of Therapy**
- Surgical site infection
- Lymphedema
- Radiation fibrosis
- Cystitis
- Proctitis

**Uterine Sarcoma – Symptoms**
- BAD-P
- Bleeding
- Abdominal distention
- Foul smelling vaginal discharge
- Pelvic Pressure

A rapidly enlarging uterus, especially in a postmenopausal woman, should prompt consideration of leiomyosarcoma.
Table 21. FIGO Staging of Uterine Sarcoma (2009)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Tumour limited to uterus</td>
<td>III</td>
<td>Tumour invades abdominal tissues, one site</td>
</tr>
<tr>
<td>IA</td>
<td>&lt;5 cm</td>
<td>IIA</td>
<td>Tumour invades bladder and/or rectum</td>
</tr>
<tr>
<td>IB</td>
<td>&gt;5 cm</td>
<td>IIIB</td>
<td>Metastasis to pelvic and/or para-aortic lymph nodes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IIIC</td>
<td>Tumour invades bladder and/or rectum</td>
</tr>
<tr>
<td>II</td>
<td>Tumour extends beyond uterus</td>
<td>IV</td>
<td></td>
</tr>
<tr>
<td>IIA</td>
<td>To the pelvis, adnexal involvement</td>
<td>IVA</td>
<td>Tumour invades bladder and/or rectum</td>
</tr>
<tr>
<td>IIB</td>
<td>To extra-uterine pelvic tissue</td>
<td>IVB</td>
<td>Distant metastasis</td>
</tr>
</tbody>
</table>

Ovary

BENIGN OVARIAN TUMOURS
- see Table 22
- many are asymptomatic
- usually enlarge slowly, if at all
- may rupture or undergo torsion, causing pain
  - pain associated with torsion of an adnexal mass usually originates in the iliac fossa and radiates to the flank
  - peritoneal irritation may result from an infarcted tumour – rare

MALIGNANT OVARIAN TUMOURS
- see Table 22

Epidemiology
- lifetime risk 1.4%
- in women >50 yr, more than 50% of ovarian tumours are malignant
- causes more deaths in North America than all other gynecologic malignancies combined
- 4th leading cause of cancer death in women
- 65% epithelial; 35% non-epithelial
- 5-10% of epithelial ovarian cancers are related to hereditary predisposition

Risk Factors (for epithelial ovarian cancers)
- excess estrogen
  - nulliparity
  - early menarche/late menopause
- age
- family history of breast, colon, endometrial, ovarian cancer
- race: Caucasian

Protective Factors (for epithelial ovarian cancers)
- OCP: likely due to ovulation suppression (significant reduction in risk even after 1 yr of use)
- pregnancy/breastfeeding
- salpingectomy (prophylactic)
- BSO (prophylactic surgery performed for this reason in high risk women – i.e. BRCA mutation carriers)

Screening
- no effective method of mass screening
- routine CA-125 level measurements or U/S not recommended
- high false positive rates
- controversial in high risk groups: transvaginal U/S and CA-125, starting age 30 (no consensus on interval)
  - familial ovarian cancer (>1 first degree relative affected, BRCA-1 mutation)
  - other cancers (e.g. endometrial, breast, colon)
  - BRCA-1 or BRCA-2 mutation: may recommend prophylactic bilateral oophorectomy after age 35 or when child-bearing is completed

Clinical Features
- most women with epithelial ovarian cancer present with advanced stage disease since often “asymptomatic” until disseminated disease (symptoms with early stage disease are vague and non-specific)
- when present, symptoms may include
  - abdominal symptoms (nausea, bloating, dyspepsia, anorexia, early satiety)
  - symptoms of mass effect
    - increased abdominal girth – from ascites or tumour itself
    - urinary frequency
    - constipation
  - postmenopausal bleeding; irregular menses if pre-menopausal (rare)

Ovarian Tumour Markers
- Epithelial cell – CA-125
- Stromal
- Granulosa cell – inhibin
- Sertoli-Leydig – androgens
- Germ cell
- Dysgerminoma – LDH
- Yolk sac – AFP
- Choriocarcinoma – β-hCG
- Immature Teratoma – none
- Embryonal cell – AFP + β-hCG

Diagnosis of ovarian tumours requires surgical pathology
- Any adnexal mass in postmenopausal women should be considered malignant until proven otherwise

Omental Cake: a term for ascites plus a fixed upper abdominal and pelvic mass; almost always signifies ovarian cancer
Low Malignant Potential (also called “Borderline”) Tumours
- pregnancy, OCP, and breastfeeding are protective factors
- ~15% of all epithelial ovarian tumours
- tumour cells display malignant characteristics histologically, but no invasion is identified
- able to metastasize, but not commonly
- treated primarily with surgery (BSO/omental biopsy ± hysterectomy)
- NO proven benefit of chemotherapy
- generally slow growing, excellent prognosis
  - 5 yr survival >99%
  - recurrences tend to occur late, may be associated with low grade serous carcinoma

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
<th>Presentation</th>
<th>Ultrasound/Cytology</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Follicular Cyst</td>
<td>Follicle fails to rupture during ovulation</td>
<td>Usually asymptomatic May rupture, bleed, tort, infarct causing pain ± signs of peritoneal irritation</td>
<td>4-8 cm mass, unilocular, lined with granulosa cells</td>
<td>Symptomatic or suspicious masses warrant surgical exploration Otherwise if &lt;8 cm, wait 6 wk then re-examine as cyst usually regresses with next cycle OCP (ovarian suppression) – will prevent development of new cysts Treatment usually laparoscopic (cystectomy vs. oophorectomy, based on fertility choice)</td>
</tr>
<tr>
<td>Corpus Luteum Cyst</td>
<td>Corpus luteum fails to regress after 14 d, becoming cystic or hemorrhagic</td>
<td>More likely to cause pain than follicular cyst May delay onset of next period</td>
<td>Larger (10-15 cm) and firmer than follicular cysts</td>
<td>Same as for follicular cysts</td>
</tr>
<tr>
<td>Theca-Lutein Cyst</td>
<td>Due to atretic follicles stimulated by abnormal β-hCG levels</td>
<td>Associated with molar pregnancy, ovulation induction with clomiphene</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometrioma</td>
<td>See Endometriosis, GY13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polycystic Ovaries</td>
<td>See Polycystic Ovarian Syndrome, GY24</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Benign Cystic Ovaries

Malignant Germ-Cell Tumours

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
<th>Presentation</th>
<th>Ultrasound/Cytology</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dysgerminoma</td>
<td>Produces LDH</td>
<td>10% bilateral</td>
<td></td>
<td>Usually very responsive to chemotherapy, therefore complete resection is not necessary for cure</td>
</tr>
<tr>
<td>Immobile Teratoma</td>
<td>No tumour marker identified</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gonadoblastoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Epithelial Ovarian Tumours (malignant or borderline)

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
<th>Presentation</th>
<th>Ultrasound/Cytology</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serous</td>
<td>Most common ovarian tumour 50% of all ovarian cancers 75% of epithelial tumours 70% benign</td>
<td>20-30% bilateral</td>
<td>Lining similar to fallopian tube epithelium Often multilocular Histologically contain Psamomma bodies (calcified concentric concretions)</td>
<td>Borderline Cystectomy vs. unilateral salpingo-oophorectomy Malignant 1. Early stage (stage I): Hysterectomy/BSO/staging (omentumectomy, peritoneal biopsies, washings, pelvic and para-aortic lymphadenectomy) 2. Advanced stage: Upfront cytoreductive (debulking) followed by adjuvant chemotherapy consisting of IV carboplatin/paclitaxel vs. intraperitoneal chemotherapy (stage III) neoadjuvant chemotherapy with IV carboplatin/paclitaxel, followed by delayed debulking with further adjuvant IV chemotherapy</td>
</tr>
</tbody>
</table>

Malignant Ovarian Tumour Prognosis

<table>
<thead>
<tr>
<th>Stage</th>
<th>5 Year Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>75-95%</td>
</tr>
<tr>
<td>II</td>
<td>60-75%</td>
</tr>
<tr>
<td>III</td>
<td>23-41%</td>
</tr>
<tr>
<td>IV</td>
<td>11%</td>
</tr>
</tbody>
</table>
Table 22. Ovarian Tumours (continued)

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
<th>Presentation</th>
<th>Ultrasound/Cytology</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPITHELIAL OVARIAN TUMOURS (malignant or borderline)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mucinous</td>
<td>20% of epithelial tumours 85% benign</td>
<td>Rarely complicated by Pseudomyxoma peritonei: implants seed abdominal cavity and produce large quantities of mucin</td>
<td>Resembles endocervical epithelium: Often multilocular: May reach enormous size</td>
<td>Poor response to chemotherapy: If mucinous, remove appendix as well to rule out possible source of primary disease</td>
</tr>
<tr>
<td><strong>SEX CORD STROMAL OVARIAN TUMOURS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General Information</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibroma/Thecoma (benign)</td>
<td>From mature fibroblasts in ovarian stroma</td>
<td>Non-functioning: Occasionally associated with Meig’s syndrome: (benign ovarian tumour and ascites and pleural effusion)</td>
<td>Firm, smooth rounded tumour with interlacing fibrocytes</td>
<td></td>
</tr>
<tr>
<td>Granulosa-Theca Cell Tumours (benign or malignant)</td>
<td>Can be associated with endometrial cancer inhibin is tumour marker</td>
<td>Estrogen-producing → feminizing effects: precocious puberty, menorrhagia, postmenopausal bleeding</td>
<td>Histologic hallmark of cancer is small groups of cells known as Cal-Esker bodies</td>
<td></td>
</tr>
<tr>
<td>Sertoli-Leydig Cell Tumour (benign or malignant)</td>
<td>Can measure elevated androgens as tumour markers</td>
<td>Androgen-producing → virilizing effects: (hirsutism, deep voice, recession of front hairline)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>METASTATIC OVARIAN TUMOURS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>From GI Tract, Breast, Endometrium, Lymphoma</td>
<td>From GI tract, commonly stomach or colon, breast with “signet-ring” cells</td>
<td>4-8% of ovarian malignancies: Krukenberg tumour – metastatic ovarian tumour (usually GI tract, commonly stomach or colon, breast)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Investigation of Suspicious Ovarian Mass

- women with suspected ovarian cancer based on history, physical, or investigations should be referred to a gynecologic oncologist
  - bimanual examination
  - RMI (Risk of Malignancy Index) is best tool available to assess likelihood of ovarian malignancy and need for pre-operative gynecologic oncology referral (see sidebar, GY43)
  - blood work: CA-125 for baseline, CBC, liver function tests, electrolytes, creatinine
  - radiology
  - bone scan or PET scan not indicated
  - transvaginal ultrasound best to visualize ovaries
  - CT scan abdomen and pelvis to look for metastatic disease
  - try to rule out other primary source if suspected, based on
    - occult blood per rectum: endoscopy ≠ barium enema
    - gastric symptoms, gastroscopy ≠ upper GI series
    - abnormal vaginal bleeding, endometrial biopsy to rule out concurrent endometrial cancer, colposcopy ≠ endocervical curettage to rule out cervical cancer if abnormal cervix
    - breast lesion identified or risk factors present: mammogram

Table 23. FIGO Staging for Primary Carcinoma of the Ovary (Surgical Staging) (2014)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Growth limited to the ovaries</td>
</tr>
<tr>
<td>IA</td>
<td>1 ovary, no ascites, no tumour on external surface, capsule intact, negative washings</td>
</tr>
<tr>
<td>IB</td>
<td>2 ovaries, no ascites, no tumour on external surface, capsule intact, negative washings</td>
</tr>
<tr>
<td>IC</td>
<td>1 or 2 ovaries with any of the following: surgical spill (IC1), capsule ruptured (IC2), tumour on ovarian surface (IC2), or malignant cells in ascites (IC3)</td>
</tr>
<tr>
<td>II</td>
<td>Growth involving one or both ovaries with pelvic extension or primary peritoneal cancer</td>
</tr>
<tr>
<td>IIA</td>
<td>Extension ± implants to uterus/tubes</td>
</tr>
<tr>
<td>IIB</td>
<td>Extension to other pelvic structures</td>
</tr>
<tr>
<td>III</td>
<td>Tumour involving one or both ovaries with peritoneal implants outside the pelvis and/or positive retroperitoneal nodes</td>
</tr>
<tr>
<td>IIIA</td>
<td>Positive retroperitoneal LN and/or microscopic metastasis beyond pelvis</td>
</tr>
<tr>
<td>IIIA1</td>
<td>Positive retroperitoneal LN</td>
</tr>
<tr>
<td>IIIA2</td>
<td>Microscopic, extrapelvic peritoneal involvement ± positive retroperitoneal LN</td>
</tr>
<tr>
<td>IIIB</td>
<td>Microscopic peritoneal metastasis beyond pelvis ≥ 2 cm, ≥ positive retroperitoneal LN. Includes extension to capsule of liver/spleen</td>
</tr>
<tr>
<td>IIIC</td>
<td>Same as above but peritoneal metastasis &gt; 2 cm</td>
</tr>
<tr>
<td>IV</td>
<td>Distant metastasis beyond peritoneal cavity</td>
</tr>
<tr>
<td>IVA</td>
<td>Pleural effusion with positive cytology</td>
</tr>
<tr>
<td>IVB</td>
<td>Hepatic and/or splenic parenchymal metastasis or metastasis to extra-abdominal organs (inguinal LNs and LNs outside of abdominal cavity included)</td>
</tr>
</tbody>
</table>

**FIGO** = International Federation of Gynecology and Obstetrics
Cervix

BENIGN CERVICAL LESIONS
• Nabothian cyst/inclusion cyst
• no treatment required
• endocervical polyps
• treatment is polypectomy (office procedure)

MALIGNANT CERVICAL LESIONS

Epidemiology
• majority are SCC (95%); adenocarcinomas increasing (3%); rare subtypes include small cell, adenosquamous
• 8,000 deaths annually in North America
• annual Pap test reduces a woman’s chance of dying from cervical cancer from 0.4% to 0.05%
• average age at presentation: 52 yr old

Etiology
• at birth, vagina is lined with squamous epithelium; columnar epithelium lines only the endocervix and the central area of the ectocervix (original squamocolumnar junction)
• during puberty, estrogen stimulates eversion of a single columnar layer (ectopy), thus exposing it to the acidic pH of the vagina, leading to metaplasia (change of exposed epithelium from columnar to squamous)
  • a new squamocolumnar junction forms as a result
  • the transformation zone (TZ) is the area located between the original and the current squamocolumnar junction
  • the majority of dysplasias and cancers arise in the TZ of the cervix
• must have active metaplasia in presence of inducing agent (HPV) to get dysplasia
  • dysplasia → carcinoma in situ (CIS) → invasion
• slow process (~10 yr on average)
• growth is by local extension
• metastasis occurs late

Risk Factors
• HPV infection
  • see Sexually Transmitted Infections, GY27
  • high risk of neoplasia associated with types 16, 18
  • low risk of neoplasia associated with types 6, 11
  • >99% of cervical cancers contain one of the high risk HPV types
• high risk behaviours (risk factors for HPV infection)
  • multiple partners
  • other STIs (HSV, trichomonas)
• early age at first intercourse
• high risk male partner
• smoking
• poor screening uptake is the most important risk factor for cervical cancer in Canada
• at-risk groups include
  • immigrant Canadians
  • First Nations Canadians
  • geographically isolated Canadians
  • sex-trade workers
  • low socioeconomic status

Cervical Cancer Screening Guidelines (Pap Test)
• see Family Medicine, FM5

Clinical Features
• SCC: exophytic, fungating tumour
• adenocarcinoma: endophytic, with barrel-shaped cervix
• early
  • asymptomatic
  • discharge: initially watery, becoming brown or red
  • postcoital bleeding
• late
  • 80-90% present with bleeding: either postcoital, postmenopausal or irregular bleeding
  • pelvic or back pain (extension of tumour to pelvic walls)
  • bladder/bowel symptoms
• signs
  • friable, raised, reddened, or ulcerated area visible on cervix

A Risk of Malignancy Incorporating CA125, Ultrasound, and Menopausal Status for the Accurate Pre-Operative Diagnosis of Ovarian Cancer
BJOG 1990;97:922-929
RMI = U x M x CA-125
Ultrasound Findings (1 pt for each)
• Multicystic cyst
• Evidence of solid areas
• Evidence of metastases
• Presence of ascites
• Bilateral lesions
U = 1 (for U/S scores of 0 or 1)
U = 4 (for U/S scores of 2-6)
Menopausal Status
• Postmenopausal: M = 4
• Premenopausal: M = 1
Absolute Value of CA-125 Serum Level
• For RMI>200: Gynecologic oncology referral is recommended

Cervical cancer is most prevalent in developing countries and therefore is the only gynecologic cancer that uses clinical staging; this facilitates consistent international staging with countries that do not have technologies, such as CT and MRI.
Diagnosis
- apply acetic acid and identify acetowhite lesions, punctuation, mosaicism, and abnormal blood vessels to guide cervical biopsy
- endocervical curettage (ECC) if entire lesion is not visible or no lesion visible
- diagnostic excision (LEEP) if
  - lesion extends into endocervical canal
  - positive ECC
  - discrepancy between Pap test results and colposcopy
- microinvasive carcinoma
- consider cold knife conization (in OR) if glandular abnormality suspected based on cytology or colposcopic findings due to concern for margin interpretation
- tests permitted for FIGO clinical staging include: physical exam (including examination under anesthesia), cervical biopsy (including cone biopsy), proctoscopy/cystoscopy, IVP, ultrasound liver/kidneys, CXR, LFTs
- MRI and/or CT and/or PET scan can often done to facilitate planning of radiation therapy, results do not influence clinical stage

Table 24. FIGO Staging Classification of Cervical Cancer (Clinical Staging) (2009)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Confined to cervix&lt;br&gt;IA  Microinvasive (diagnosed only by microscopy)&lt;br&gt;IA1 Stromal invasion not &gt;3 mm deep, not &gt;7 mm wide&lt;br&gt;IA2 3-5 mm deep; not &gt;7 mm wide&lt;br&gt;IB Clinically visible lesion confined to cervix, or microscopic lesion &gt;IA&lt;br&gt;IB1 Clinically visible lesion &lt;4 mm in greatest dimension&lt;br&gt;IB2 Clinically visible lesion &gt;4 mm in greatest dimension</td>
</tr>
<tr>
<td>II</td>
<td>Beyond uterus but not to the pelvic wall or lower 1/3 of vagina&lt;br&gt;IIA No obvious parametral involvement&lt;br&gt;IIA1 Clinically visible lesion &lt;4 mm in greatest dimension&lt;br&gt;IIA2 Clinically visible lesion &gt;4 mm in greatest dimension&lt;br&gt;IIIB Obvious parametral involvement</td>
</tr>
<tr>
<td>III</td>
<td>Extends to pelvic wall, and/or involves lower 1/3 of vagina and/or causes hydronephrosis or non-functioning kidney&lt;br&gt;IIIA Involves lower 1/3 vagina but no extension into pelvic side wall&lt;br&gt;IIIB Extension into pelvic side wall and/or hydronephrosis or non-functioning kidney</td>
</tr>
<tr>
<td>IV</td>
<td>Carcinoma has extended beyond true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum&lt;br&gt;IVA Spread of the growth to adjacent organs (bladder or rectum)&lt;br&gt;IVB Distant metastases</td>
</tr>
</tbody>
</table>

Treatment: Prevention and Management

Prevention: HPV Vaccine
- two vaccines currently approved (Gardasil®, Cervarix®)
Table 25. Comparison of Two Vaccines against Human Papillomavirus (HPV)

<table>
<thead>
<tr>
<th></th>
<th>Gardasil® 8</th>
<th>Cervarix®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viral Strains Covered</td>
<td>6, 11, 16, 18</td>
<td>16, 18</td>
</tr>
<tr>
<td>Route of Administration</td>
<td>IM</td>
<td>IM</td>
</tr>
<tr>
<td>Schedule of Dosing</td>
<td>0, 2, 6 mo</td>
<td>0, 1, 6 mo</td>
</tr>
<tr>
<td>Side Effects</td>
<td>Local: redness, pain, swelling</td>
<td>Local: redness, pain, swelling</td>
</tr>
<tr>
<td></td>
<td>General: headache, low grade fever, GI upset</td>
<td>General: headache, low grade fever, GI upset</td>
</tr>
<tr>
<td>Approved Age</td>
<td>Females age 9-45, males age 9-26</td>
<td>Females age 10-25</td>
</tr>
<tr>
<td>Contraindications</td>
<td>Pregnant women and women who are nursing (limited data)</td>
<td></td>
</tr>
</tbody>
</table>

*Gardasil-9 also covers types 31, 33, 45, 52, and 58; also used to prevent genital warts.

Abnormal Pap Tests in Pregnancy
- should be administered before onset of sexual activity (i.e. before exposure to virus) for optimal benefit of vaccination
- may be given at the same time as hepatitis B or other vaccines using a different injection site
- not for treatment of active infections
- most women will not be infected with all four types of the virus at the same time, therefore vaccine is still indicated for sexually active females or those with a history of previous HPV infection or HPV-related disease
- conception should be avoided until 30 d after last dose of vaccination

Table 26. Management of Patients Abnormal Cervical Histology and Cervical Cancer

<table>
<thead>
<tr>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CIN I</strong></td>
</tr>
<tr>
<td>Preferred option for biopsy-proven CIN I is observation</td>
</tr>
<tr>
<td>Repeat assessment and cytology in 12 mo</td>
</tr>
<tr>
<td>Management according to cytology results</td>
</tr>
<tr>
<td>If after HSIL, or AGC:</td>
</tr>
<tr>
<td>Cytology and histology should be reviewed</td>
</tr>
<tr>
<td>If discrepancy remains, excisional biopsy may be considered</td>
</tr>
</tbody>
</table>

| **CIN II and CIN III** |
| Women ≤25 y: |
| CIN II or III should be treated |
| Excisional procedures preferred for CIN III |
| Those with positive margins should have follow-up with colposcopy and directed biopsies and/or endocervical curettage |
| Treatment for recurrent CIN II or III should be by excision |
| Women <25 y: |
| Pathologist should be asked to clarify whether lesion is CIN II or CIN III |
| CIN II: observe with colposcopy at 6-mo intervals for up to 24 mo before treatment considered |
| CIN III: should be treated |
| During pregnancy: |
| CIN II or III suspected or diagnosed during pregnancy, repeat colposcopy and treatment delayed until 8-12 wk after delivery |

| **Stage IA1 (no LVI)** |
| Trachelectomy (removal of only the cervix) if future fertility desired (and lesion ≤2 cm) |
| Simple hysterectomy if future fertility is not desired |

| **Stage IA2, IB1** |
| Typically treated with radical hysterectomy and pelvic lymphadenectomy (sentinel nodes under study) |
| Equal cure rates may be obtained with primary radiation therapy; advantage of surgery: may accurately stage and grade and more targeted adjuvant therapy |
| Advantage is that ovaries can be spared if pre-menopausal |
| For fertility preservation, may have radical trachelectomy (removal of cervix and parametria) and nodes instead of radical hysterectomy for early-stage disease |
| Concurrent chemoradiation therapy if adverse high risk prognostic factors on radical surgical specimen, such as: positive pelvic lymph nodes, positive parametria, and/or positive margins |

| **Stages IB2 (>4 cm), II, III, IV** |
| Primary chemoradiation therapy |
| PET/CT to grade: evaluate pelvic and para-aortic nodes |
| For positive nodes on PET: primary chemoradiation with extended field RT |
| Hysterectomy generally not suggested following primary treatment with curative intent |

Selected Outcomes: Development of HPV-16/18 associated CIN II+ was the primary outcome. Secondary to this were persistence of infections with HPV-16, HPV-18, or other oncogenic HPV types.

**Conclusions:** The HPV-16/18 AS04-adjuvanted vaccine protected against HPV-16/18 associated CIN II+ lesions and lesions associated with HPV-31, HPV-33, and HPV-45.
**Vulva**

**BENIGN VULVAR LESIONS**

**Non-Neoplastic Disorders of Vulvar Epithelium**
- biopsy is necessary to make diagnosis and/or rule out malignancy
- hyperplastic dystrophy (squamous cell hyperplasia)
  - surface thickened and hyperkeratotic
  - pruritus most common symptom
  - typically postmenopausal women
  - treatment: 1% fluorinated corticosteroid ointment bid for 6 wk
- lichen sclerosis
  - subepithelial fat becomes diminished; labia become thin, atrophic, with membrane-like epithelium and labial fusion
  - pruritus, dyspareunia, burning
  - ‘figure of 8’ distribution
  - most common in postmenopausal women but can occur at any age
  - treatment: ultrapotent topical steroid 0.05% clobetasol x 2-4 wk then taper down, can consider long term suppression twice a week
- mixed dystrophy (lichen sclerosis with epithelial hyperplasia)
  - hyperkeratotic areas with areas of thin, shiny epithelium
  - treatment: fluorinated corticosteroid ointment

**Tumours**
- papillary hidradenoma, nevus, fibroma, hemangioma

**MALIGNANT VULVAR LESIONS**

**Epidemiology**
- 5% of genital tract malignancies
- 90% SCC, remainder melanomas, basal cell carcinoma, Paget’s disease, Bartholin’s gland carcinoma
  - Type I disease: HPV-related (50-70%)
    - more likely in younger women
  - 90% of VIN contain HPV DNA (usually types 16, 18)
  - Type II disease: not HPV-related, associated with current or previous vulvar dystrophy
    - usually postmenopausal women

**Risk Factors**
- HPV infection
- vulvar intraepithelial neoplasia (VIN): precancerous change which presents as multicentric white or pigmented plaques on vulva (may only be visible at colposcopy)
  - progression to cancer rarely occurs with appropriate management
- treatment: local excision (i.e. superficial vulvectomy ± split thickness skin grafting to cover defects if required) vs. ablative therapy (i.e. laser, cauterization) vs. local immunotherapy (imiquimod)

**Clinical Features**
- many patients asymptomatic at diagnosis (many also deny or minimize symptoms)
- most lesions occur on the labia majora, followed by the labia minora (less commonly on the clitoris or perineum)
  - localized pruritus or lesion most common
- less common: raised red, white or pigmented plaque, ulcer, bleeding, discharge, pain, dysuria
- patterns of spread
  - local
  - groin lymph nodes (usually inguinal → pelvic nodes)
  - hematogenous

**Investigations**
- ± colposcopy
  - ALWAYS biopsy any suspicious lesion

**Prognosis**
- depends on stage – particularly nodal involvement (single most important predictor followed by tumour size)
- lesions >4 cm associated with poorer prognosis
- overall 5 yr survival rate: 79%
BENIGN VAGINAL LESIONS

- inclusion cysts
  - cysts form at site of abnormal healing of laceration (e.g. episiotomy)
  - no treatment required
- endometriosis
  - dark lesions that tend to bleed at time of menses
  - treatment: excision
- Gartner's duct cysts
  - remnants of Wolffian duct, seen along side of cervix
  - treatment: conservative unless symptomatic
- urethral diverticulum
  - can lead to recurrent urethral infection, dyspareunia
  - treatment: surgical correction if symptomatic

MALIGNANT VAGINAL LESIONS

Epidemiology

- primary carcinomas of the vagina represent 2-3% of malignant neoplasms of the female genital tract
- 80-90% are SCC
- more than 50% diagnosed between 70-90 yr old

Risk Factors

- associated with HPV infection (analogous to cervical cancer)
- increased incidence in patients with prior history of cervical and vulvar cancer

Investigations

- cytology
  - significant false negative rate for existing malignancy (i.e. if gross lesion present, biopsy!)
- colposcopy
- Schiller test (normal squamous epithelium takes up Lugol's iodine)
- biopsy, partial vaginectomy (wide local excision for diagnosis)
- rule out disease on cervix, vulva, or anus (most vaginal cancers are actually metastatic from one of these sites)
- staging

Clinical Features

<table>
<thead>
<tr>
<th>Type</th>
<th>Clinical Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaginal Intra-Epithelial Neoplasia (VAIN)</td>
<td>Grades: analogous to cervical dysplasia</td>
</tr>
<tr>
<td>Squamous Cell Carcinoma (SCC)</td>
<td>Most common site is upper 1/3 of posterior wall of vagina</td>
</tr>
<tr>
<td></td>
<td>Asymptomatic</td>
</tr>
<tr>
<td></td>
<td>Painless discharge and bleeding</td>
</tr>
<tr>
<td></td>
<td>Vaginal discharge (often foul-smelling)</td>
</tr>
<tr>
<td></td>
<td>Vaginal bleeding especially during/post-coitus</td>
</tr>
<tr>
<td></td>
<td>Urinary and/or rectal symptom 2° to compression</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>Most are metastatic, usually from cervix, endometrium, ovary, or colon</td>
</tr>
<tr>
<td></td>
<td>Most primaries are clear cell adenocarcinomas</td>
</tr>
<tr>
<td></td>
<td>2 types: non-DES and DES syndrome</td>
</tr>
</tbody>
</table>

Fallopian Tube

- least common site for carcinoma of female reproductive system (0.3%)
- usually serous epithelial carcinoma
- recently considered to be origin of serous ovarian cancer
- more common in fifth and sixth decade

Clinical Features

- classic triad present in minority of cases, but very specific
  - watery discharge (most specific) = “hydrops tubae profluens”
  - vaginal bleeding or discharge in 50% of patients
  - crampy lower abdominal/pelvic pain
  - most patients present with a pelvic mass (see Ovarian Tumours, GY40 for guidelines regarding diagnosis/investigation)

Treatment

- as for malignant epithelial ovarian tumours
Gestational Trophoblastic Disease/Neoplasia

• refers to a spectrum of proliferative abnormalities of the trophoblast

Epidemiology
• 1/1,000 pregnancies
• marked geographic variation – as high as 1/125 in Taiwan
• 80% benign, 15% locally invasive, 5% metastatic
• cure rate >95%

HYDATIDIFORM MOLE (Benign GTD)

Complete Mole
• most common type of hydatidiform mole
• diffuse trophoblastic hyperplasia, hydropic swelling of chorionic villi, no fetal tissues, or membranes present
• 46XX or 46XY, chromosomes completely of paternal origin (90%)
• 2 sperm fertilize empty egg or 1 sperm with reduplication
• 15-20% risk of progression to malignant sequelae
• risk factors
  ■ geographic (South East Asia most common)
  ■ others (maternal age >40 yr, β-carotene deficiency, vitamin A deficiency) – not proven
• clinical features
  • often present during apparent pregnancy with abnormal symptoms/findings
    • vaginal bleeding (97%)
    • excessive uterine size for LMP (51%)
    • theca-lutein cysts >6 cm (50%)
    • preeclampsia (27%)

Partial (or Incomplete) Mole
• focal trophoblastic hyperplasia and hydropic villi are associated with fetus or fetal parts
• often triploid (XXX, XYY, XXX) with chromosome complement from both parents
  ■ usually related to single ovum fertilized by two sperm
• low risk of progression to malignant sequelae (<4%)
• associated with fetus, which may be growth-restricted, and/or have multiple congenital malformations
• clinical features
  ■ typically present similar to threatened/spontaneous/missed abortion
  ■ pathological diagnosis often made after D&C

Investigations
• quantitative β-hCG levels (tumour marker) abnormally high for gestational age
• U/S findings
  ■ if complete: no fetus (classic "snow storm" due to swelling of villi)
  ■ if partial: molar degeneration of placenta ± fetal anomalies, multiple echogenic regions corresponding to hydropic villi, and focal intrauterine hemorrhage
• CXR (may show metastatic lesions)
• features of molar pregnancies at high risk of developing persistent GTN post-evacuation
  ■ local uterine invasion as high as 31%
  ■ β-hCG >100,000 IU/L
  ■ excessive uterine size
  ■ prominent theca-lutein cysts

Treatment
• suction D&C with sharp curettage and oxytocin
• Rhogam® if Rh negative
• consider hysterectomy (if patient no longer desires fertility)
• prophylactic chemotherapy of no proven benefit
• chemotherapy for GTN if develops after evacuation

Follow-Up
• contraception required to avoid pregnancy during entire follow-up period
• serial β-hCGs (as tumour marker) every week until negative x 3 (usually takes several wk), then monthly for 6-12 mo prior to trying to conceive again
• increase or plateau of β-hCG indicates GTN → patient needs chemotherapy

With development of hypertension early in pregnancy (i.e. <20 wk), think gestational trophoblastic disease
GTN (MALIGNANT GTD)

Invasive Mole or Persistent GTN
- diagnosis made by rising or plateau in β-hCG, development of metastases following treatment of documented molar pregnancy
- histology: molar tissue from D&C
- metastases are rare (4%)

Choriocarcinoma
- often present with symptoms from metastases
- highly anaplastic, highly vascular
- no choriocarcinoma, elements of syncytiotrophoblast and cytotrophoblast
- may follow molar pregnancy, abortion, ectopic, or normal pregnancy

Placental-Site Trophoblastic Tumour
- rare aggressive form of GTN
- abnormal growth of intermediate trophoblastic cells
- low β-hCG, production of human placental lactogen (hPL), relatively insensitive to chemotherapy

CLASSIFICATION OF GTN
- non-metastatic
  - ~15% of patients after molar evacuation
  - may present with abnormal bleeding
  - all have rising or plateau of β-hCG
  - negative metastases on staging investigations
- metastatic
  - 4% patients after treatment of complete molar pregnancy
  - metastasis more common with choriocarcinoma which tends toward early vascular invasion and widespread dissemination
  - if signs or symptoms suggest hematogenous spread, do not biopsy (they bleed)
    - lungs (80%): cough, hemoptysis, CXR lesion(s)
    - vagina (30%): vaginal bleeding, “blue lesions” on speculum exam
    - pelvis (20%): rectal bleeding (if invades bowel), U/S lesion(s)
    - liver (10%): elevated LFTs, U/S or CT findings
    - brain (10%): headaches, dizziness, seizure (symptoms of space-occupying lesion), CT/MRI findings
  - highly vascular tumour → bleeding → anemia
  - all have rising or plateau of β-hCG
- classification of metastatic GTN
  - divided into good prognosis and bad prognosis
  - features of bad prognosis
    - long duration (>4 mo from antecedent pregnancy)
    - high pre-treatment β-hCG titre: >100,000 IU/24 h urine or >40,000 IU/L of blood
    - brain or liver metastases
    - prior chemotherapy
  - metastatic disease following term pregnancy
  - good prognosis characterized by the absence of each of these features

Investigations – For Staging
- blood work: CBC, electrolytes, creatinine, β-hCG, TSH, LFTs
- imaging: CXR, U/S pelvis, CT abdo/pelvis, CT brain
- if suspect brain metastasis but CT brain negative, consider lumbar puncture for CSF β-hCG
- ratio of plasma β-hCG:CSF β-hCG <60 indicates metastases

Table 28. FIGO Staging and Management of Malignant GTN

<table>
<thead>
<tr>
<th>Stage</th>
<th>Findings</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Disease confined to uterine corpus</td>
<td>Single agent chemotherapy for low risk disease (WHO score ≤5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1st line: actinomycin D (Act-D) IV q2wk</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alternatives: MTX-based regimen</td>
</tr>
<tr>
<td></td>
<td></td>
<td>20% of patients need to switch to alternate single-agent regimen due to failure of β-hCG to return to normal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Combination chemotherapy (EMA-CO: etoposide, MTX, ACT-D, cyclophosphamide, vincristine) if high risk (WHO score ≥7) or if resistant to single agent chemotherapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Can consider hysterectomy if fertility not desired or placental-site trophoblastic tumour</td>
</tr>
<tr>
<td>II</td>
<td>Metastatic disease to genital structures</td>
<td>As above</td>
</tr>
<tr>
<td>III</td>
<td>Metastatic disease to lungs with or without genital tract involvement</td>
<td>As above</td>
</tr>
<tr>
<td>IV</td>
<td>Distant metastatic sites including brain, liver, kidney, GI tract</td>
<td>Usually high risk (EMA-CO) with surgical resection of sites of disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Persistence/resistance to chemotherapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Consider radiation for brain mets</td>
</tr>
</tbody>
</table>
### Table 29. WHO Prognostic Score for GTD (2011)

<table>
<thead>
<tr>
<th>Prognostic Factor</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal Age</td>
<td>0</td>
</tr>
<tr>
<td>&gt;40</td>
<td>1</td>
</tr>
<tr>
<td>Antecedent Pregnancy</td>
<td>2</td>
</tr>
<tr>
<td>Mole</td>
<td>4</td>
</tr>
<tr>
<td>Interval (end of Antecedent Pregnancy to chemotherapy in months)</td>
<td>4-6</td>
</tr>
<tr>
<td>HCG IU/l</td>
<td>&lt;103</td>
</tr>
<tr>
<td>Number of Metastases</td>
<td>0</td>
</tr>
<tr>
<td>1-4</td>
<td>5-8</td>
</tr>
<tr>
<td>Site of Metastases</td>
<td>Lung</td>
</tr>
<tr>
<td>Spleen, kidney</td>
<td>GI tract</td>
</tr>
<tr>
<td>Brain, liver</td>
<td></td>
</tr>
<tr>
<td>Largest Tumour Mass</td>
<td>3-5 cm</td>
</tr>
<tr>
<td>Prior Chemotherapy</td>
<td>Single drug</td>
</tr>
</tbody>
</table>

**Follow-up (for GTN)**
- contraception for all stages to avoid pregnancy during entire follow-up period
- stage I, II, III
  - weekly β-hCG until 3 consecutive normal results
  - then monthly x 12 mo
- stage IV
  - weekly β-hCG until 3 consecutive normal results
  - then monthly x 24 mo

**GTN Diagnosis**
- β-hCG plateau: <10% drop in β-hCG over four values in 3 wk (e.g., days 1, 7, 14, and 21) OR
- β-hCG rise >20% in any two values over two wk or longer (e.g., measure at days 1, 7, 14) OR
- β-hCG persistently elevated >6 mo OR
- metastases on workup

### Common Medications

<table>
<thead>
<tr>
<th>Drug Name (Brand Name)</th>
<th>Action</th>
<th>Dosing Schedule</th>
<th>Indications</th>
<th>Side Effects (S/E), Contraindications (C/I), Drug Interactions (D/I)</th>
</tr>
</thead>
<tbody>
<tr>
<td>acyclovir (Zovirax®)</td>
<td>Antiviral; inhibits DNA synthesis and viral replication</td>
<td>First Episode: 400 mg PO tid x 7-10 d Recurrence: 400 mg PO tid x 5 d</td>
<td>Genital herpes</td>
<td>S/E: headache, GI upset D/I: zidovudine, probenecid</td>
</tr>
<tr>
<td>bromocriptine (Parlodel®)</td>
<td>Dopaminomimetic Agonist at D2R Antagonist at D1R</td>
<td>Initial: 1.25-2.5 mg PO qhs with food Then: increase by 2.5 mg every 2-7 d as needed until optimal therapeutic response Usual Range: 1.5-15 mg OD</td>
<td>Galactorrhea + amenorrhea 2° to hyperprolactinemia Prolactin-dependent menstrual disorders and infertility Prolactin-secreting adenomas (microadenomas, prior to surgery of macroadenomas)</td>
<td>S/E: N/V, headache, postural hypotension, somnolence C/I: uncontrolled HTN, pregnancy-induced HTN, CAD, breastfeeding D/I: domperidone, macrolides, octreotide</td>
</tr>
<tr>
<td>clomiphene citrate (Clomid®)</td>
<td>Increases output of pituitary gonadotropins which induces ovulation</td>
<td>50 mg OD x 5 d Try 100 mg or 160 mg OD if ineffective 3 courses = adequate trial</td>
<td>Patients with persistent ovulatory dysfunction (e.g., amenorrhea, PCOS) who desire pregnancy</td>
<td>S/E: Common – hot flashes, abdominal discomfort, exaggerated cyclic ovarian enlargement, accentuation of Mittelschmerz Rare – ovarian hyperstimulation syndrome, multiple pregnancy, visual blurring, birth defects CA: pregnancy, liver disease, hormone-dependent tumours, ovarian cyst, undiagnosed vaginal bleeding</td>
</tr>
<tr>
<td>clotrimazole (Canesten®)</td>
<td>Antifungal; disrupt fungal cell membrane</td>
<td>Tablet: 100 mg/d intravaginally x 7 d or 200 mg/d x 3 d or 500 mg x 1 dose Cream (1 or 2%): 1 applicator intravaginally qhs x 3-7 d Topical: apply bid x 7 d</td>
<td>Vulvovaginal candidiasis</td>
<td>S/E: vulvar/vaginal burning</td>
</tr>
<tr>
<td>danazol (Cyclomen® – CAN) (Danocrine® – US)</td>
<td>Synthetic steroid that inhibits pituitary gonadotropin output and ovarian steroid synthesis Has mild androgenic properties</td>
<td>200-800 mg in 2-3 divided doses Used for 3-6 mo Biannual hepatic U/S required if &gt;6 mo use</td>
<td>Endometriosis 1° menorrhagia/DUB</td>
<td>S/E: weight gain, acne, mild hirsutism, hepatic dysfunction CA: pregnancy, undiagnosed vaginal bleeding, breastfeeding, severely impaired renal/hepatic/cardiac function, porphyria, genital neoplasia, thromboembolic disease D/I: warfarin, carbamazepine, cyclosporine, tacrolimus, anti-hypertensives</td>
</tr>
<tr>
<td>Drug Name (Brand Name)</td>
<td>Action</td>
<td>Dosing Schedule</td>
<td>Indications</td>
<td>Side Effects (S/E), Contraindications (C/I), Drug Interactions (D/I)</td>
</tr>
<tr>
<td>------------------------</td>
<td>--------</td>
<td>----------------</td>
<td>-------------</td>
<td>-----------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| doxycycline            | Tetracycline derivative; inhibit protein synthesis | 100 mg PO bid x 7 d | Chlamydia, gonococcal infection, syphilis | S/E: GI upset, hepatotoxicity  
 C/I: pregnancy, severe hepatic dysfunction  
 D/I: warfarin, digoxin |
| fluconazole (Diflucan®) | Antifungal, disrupt fungal cell membrane | 150 mg PO x 1 dose | Vulvovaginal candidiasis unresponsive to clotrimazole | S/E: headache, rash, N/V, abdominal pain, diarrhea  
 C/I: terfenadine, cisapride, astemizole, hydrochlorothiazide, phenytoin, warfarin, rifampin |
| leuprolide (Lupron®)   | Synthetic GnRH analog Induces reversible hypoestrogenic state | 3.75 mg IM q1mo or 11.25 mg IM q3mo Usually x8 mo, check bone density if > 6 mo  
 Treatment with Lupron® alone not recommended because of effects on bone density | Endometriosis Leiomymoma DUB Precocious puberty | S/E: hot flashes, sweats, headache, vaginitis, reduction in bone density, acne, GI upset  
 C/I: pregnancy, undiagnosed vaginal bleeding, breastfeeding |
| metronidazole (Flagyl®) | Bactericidal; forms toxic metabolites which damage bacterial DNA | 2 g PO x 1 dose or 500 mg PO bid x 7 d | Bacterial vaginosis, trichomonas vaginitis | S/E: headache, dizziness, N/V, diarrhea, disulfiram-like reaction (flushing, tachycardia, N/V)  
 C/I: pregnancy (1st trimester)  
 D/I: cisapride, warfarin, cimetidine, lithium, alcohol, amiodarone, milk thistle, carbamazepine |
| oxybutinin (Ditropan®) | Anticholinergic – relaxes bladder smooth muscle, inhibits involuntary detrusor contraction | 5-10 mg/d PO  
 May increase doses by 5 mg weekly to a max of 30 mg/d | Overactive bladder (urge incontinence) | S/E: dry mouth/eyes, constipation, palpitations, urinary retention, dizziness, headache  
 C/I: glaucoma, GI ulcers, severe colitis, obstructive uropathy, use with caution if impaired hepatic/renal function |
| tolterodine (Detrol®)  | Anticholinergic | 1-2 mg PO bid | Overactive bladder (urge incontinence) | S/E: anaphylaxis, psychosis, tachycardia, dry mouth/eyes, headache, constipation, urinary retention, chest pain, abdominal pain  
 C/I: glaucoma, gastric/urinary retention, use with caution if impaired hepatic/renal function |
| tranexamic acid (Cyklokapron®) | Anti-BHnanalytic, reversibly inhibits plasminogen activation | 1-1.5 g tid-qid for first 4 d of cycle  
 Ophthalmic check if used for several wk | Menorrhagia | S/E: N/V, diarrhea, dizziness, rare cases of thrombosis, abdominal pain, NSX pain  
 C/I: thromboembolic disease, acquired disturbances of colour vision, subarachnoid hemorrhage, age < 15 yr |
| ulipristal acetate (Fibristal®) | Selective progesterone receptor modulator (SPRM) | 5 mg PO OD for max 3 mc; first tablet taken anytime during first 7 days of menstruation | Leiomyoma (pre-operative) | S/E: headache, hot flushes, constipation, vertigo, endometrial thickening  
 C/I: pregnancy, undiagnosed vaginal bleeding, any gyna cancer |
| urofollitropin (Metrodin®) | FSH | 75 IU SC x 7-12d | Ovulation induction in PCOS | S/E: ovarian enlargement or cysts, edema and pain at injection site, arterial thromboembolism, fever, abdominal pain, headache, multiple pregnancy  
 C/I: primary ovarian failure, intracranial lesion (e.g. pituitary tumour), uncontrolled thyroid/adrenal dysfunction, ovarian cyst (not PCOS), pregnancy, undiagnosed uterine bleeding |
| combined oral contraceptive pill (OCP) | Ovulatory suppression by inhibiting LH and FSH  
 Decidualization of endometrium  
 Thickening of cervical mucus to prevent sperm penetration | | Contraception Disorders of menstruation | See Tables 8-12 |
| intrauterine device (IUD) | Copper IUD; mild foreign body reaction in endometrium which is toxic to sperm and alters sperm motility  
 Progesterone-releasing IUD: decidualization of endometrium and thickening of cervical mucus, may suppress ovulation | | Contraceptive effects last 3 yrs (Jaydess); up to 5 yr (Copper IUD, Mirena) | Same as above See Table 8-12 |
Hematology

Ryan Chan, Tejas Desai, and Brent Parker, chapter editors
Claudia Frankfurter and Inna Gong, associate editors
Brittany Prevost and Robert Vanner, EBM editors
Dr. Michelle Sholzberg and Dr. Martina Trinkaus, staff editors

Acronyms ............................................. 2
Basics of Hematology ................................. 2
Complete Blood Count
Blood Film Interpretation
Bone Marrow Aspiration and Biopsy
Common Presenting Problems............... 6
Anemia
Erythrocytosis
Thrombocytopenia
Thrombocytosis
Pancytopenia
Neutropenia
Neutrophilia
Lymphocytosis
Lymphopenia
Eosinophilia
Agranulocytosis
Leukemoid Reaction

Approach to Lymphadenopathy ............... 12
Approach to Splenomegaly ....................... 13

Microcytic Anemia ................................. 13
Iron Metabolism
Iron Deficiency Anemia
Anemia of Chronic Inflammation
Sideroblastic Anemia
Lead Poisoning

Normocytic Anemia ................................. 17
Aplastic Anemia

Hemolytic Anemia ................................. 18
Thalassemia
β-Thalassemia Minor (Thalassemia Trait)
β-Thalassemia Major
β-Thalassemia Intermedia
α-Thalassemia
Sickle Cell Disease
Autoimmune Hemolytic Anemia
Microangiopathic Hemolytic Anemia/
    Thrombotic Microangiopathy
Hereditary Spherocytosis
Hereditary Elliptocytosis
Glucose-6-Phosphate Dehydrogenase Deficiency

Macrocytic Anemia ................................. 23
Vitamin B₁₂ Deficiency
Folate Deficiency

Hemostasis ......................................... 25
Stages of Hemostasis

Disorders of Primary Hemostasis ............ 27
Immune Thrombocytopenia
Thrombotic Thrombocytopenic Purpura
    and Hemolytic Uremic Syndrome
Von Willebrand Disease

Disorders of Secondary Hemostasis .......... 31
Hemophilia A (Factor VIII Deficiency)
Hemophilia B (Factor IX Deficiency)
Factor XI Deficiency
Liver Disease
Vitamin K Deficiency
Disseminated Intravascular Coagulation

Hypercoagulable Disorders ................. 33

Venous Thromboembolism ....................... 35
Approach to Treatment of Venous
    Thromboembolism

Hematologic Malignancies and
    Related Disorders ............................. 37

Myeloid Malignancies ............................. 37
Acute Myeloid Leukemia
Myelodysplastic Syndromes

Myeloproliferative Neoplasms ............... 40
Chronic Myeloid Leukemia
Polycythemia Vera
Idiopathic Myelofibrosis
Essential Thrombocythemia

Lymphoid Malignancies ........................... 43
Acute Lymphoblastic Leukemia

Lymphomas ......................................... 45
Hodgkin Lymphoma
Non-Hodgkin Lymphoma

Malignant Clonal Proliferations of
    Mature B-Cells. ............................... 48
Chronic Lymphocytic Leukemia
Multiple Myeloma
Monoclonal Gammapathy of Unknown
    Significance
Lymphoplasmacytic Lymphoma
    (Waldenstrom's Macroglobulinemia)

Complications of Hematologic Malignancies .. 51
Hyperviscosity Syndrome
Tumour Lysis Syndrome

Blood Products and Transfusions ............ 52
Red Blood Cells
Platelets
Coagulation Factors
Acute Blood Transfusion Reactions
Delayed Blood Transfusion Reactions

Common Medications ............................. 56
Antiplatelet Therapy
Anticoagulant Therapy
Chemotherapeutic and Biologic Agents Used
    in Oncology

Landmark Hematology Trials .................. 59

References ........................................ 60
**Acronyms**

AFib - atrial fibrillation  
AFLP - acute fatty liver of pregnancy  
AHA - autoimmune hemolytic anemia  
ALL - acute lymphoblastic leukemia  
AML - acute myeloid leukemia  
ANC - absolute neutrophil count  
APC - activated protein C  
APCR - activated protein C resistance  
APS - antiphospholipid antibody syndrome  
BM - bone marrow  
CBC - complete blood count  
CLL - chronic lymphocytic leukemia  
CML - chronic myeloid leukemia  
DIC - disseminated intravascular coagulation  
EPO - erythropoietin  
ERG - erythrocyte sedimentation rate  
ET - essential thrombocythemia  
FNA - fine needle aspiration  
G-CSF - granulocyte-colony stimulating factor  
GSH - glutathione  
HA - hemolytic anemia  
HB - hemoglobin  
Hct - hematocrit  
H2 - Hematology Toronto Notes 2017

**Basics of Hematology**

- Over $10^{11}$ blood cells are produced daily.  
- Sites of hematopoiesis in adults: pelvis, sternum, vertebral bodies, cranium.  
- Lifespan of mature cells in blood:  
  - Erythrocytes (90-120 d), neutrophils (~1 d), platelets (7-10 d), lymphocytes (varies – memory cells persist for years).  
- Role of lymphoid organs:  
  - Spleen: part of reticuloendothelial system, sequesters aged RBCs, removes opsonized cells, site of antibody production.  
  - Thymus: site of T-cell maturation, involutes with age.  
  - Lymph nodes: sites of B and T-cell activation (adaptive immune response).
### Complete Blood Count

#### Table 1. Common Terms Found in the CBC

<table>
<thead>
<tr>
<th>Test</th>
<th>Definition</th>
<th>Normal Values*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Red Blood Cell (RBC) Count</td>
<td>The number of RBCs per volume of blood</td>
<td>4.2-6.9 x 10⁶/mm³</td>
</tr>
<tr>
<td>Hemoglobin (Hb)</td>
<td>Amount of oxygen-carrying protein in the blood</td>
<td>130-180 g/L (male)</td>
</tr>
<tr>
<td>Hematocrit (Hct)</td>
<td>Percentage of a given volume of whole blood occupied by packed RBCs</td>
<td>45%-62% (male)</td>
</tr>
<tr>
<td>Mean Corpuscular Volume (MCV)</td>
<td>Measurement of RBC size</td>
<td>60-100 µm³</td>
</tr>
<tr>
<td>Mean Corpuscular Hb (MCH)</td>
<td>Amount of oxygen-carrying Hb inside RBCs</td>
<td>27-32 pg/cell</td>
</tr>
<tr>
<td>White Blood Cell (WBC) Count</td>
<td>The number of WBCs per volume of blood</td>
<td>4.3-10.8 x 10⁹/mm³</td>
</tr>
<tr>
<td>WBC Differential</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Neutrophils</td>
<td></td>
<td>1.8-3.8 x 10⁹/mm³</td>
</tr>
<tr>
<td>- Lymphocytes</td>
<td></td>
<td>0.7-4.5 x 10⁹/mm³</td>
</tr>
<tr>
<td>- Monocytes</td>
<td></td>
<td>0.1-1.0 x 10⁹/mm³</td>
</tr>
<tr>
<td>- Eosinophils</td>
<td></td>
<td>0.0-0.4 x 10⁹/mm³</td>
</tr>
<tr>
<td>- Basophils</td>
<td></td>
<td>0.0-0.2 x 10⁹/mm³</td>
</tr>
<tr>
<td>Platelet Count</td>
<td>The number of platelets per volume of blood</td>
<td>150-400 x 10³/mm³</td>
</tr>
<tr>
<td>Mean Platelet Volume (MPV)</td>
<td>Measurement of platelet size</td>
<td></td>
</tr>
<tr>
<td>Reticulocytes</td>
<td>Immature RBCs that contain no nucleus but have residual RNA</td>
<td>Normally make up 1% of total RBC count</td>
</tr>
</tbody>
</table>

*I-normal values may vary depending on site and age

---

### Approach to Interpreting a CBC

1. consider values in the context of individual's baseline
2. is one cell line affected or are several?
   - if all lines are low: pancytopenia (see Pancytopenia, H8)
   - if RBCs and platelets are low: consider a MAHA/TMA (see Microangiopathic Hemolytic Anemia/Thrombotic Microangiopathy, H22)
   - if single cell line affected: see Common Presenting Problems, H6

---

### Blood Film Interpretation

#### RED BLOOD CELLS

**Size**
- microcytic (MCV <80 µm³), normocytic (MCV = 80-100 µm³), macrocytic (MCV >100 µm³)
- anisocytosis: RBCs with increased variability in size (increased RDW)
  - iron deficiency anemia, hemolytic anemias, myelofibrosis, blood transfusion, MDS

**Colour**
- hypochromic: increase in size of central pallor (normal = less than 1/3 of RBC diameter)
  - iron deficiency anemia, anemia of chronic disease, sideroblastic anemia
- polychromasia: increased reticulocytes (pinkish-blue cells)
  - increased RBC production by bone marrow

**Shape**
- poikilocytosis: increased proportion of RBCs of abnormal shape
  - iron deficiency anemia, myelofibrosis, severe B12 deficiency, MDS, burns
### Table 2. Common Erythrocyte Shapes

<table>
<thead>
<tr>
<th>Shape</th>
<th>Definition</th>
<th>Associated Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discocyte</td>
<td>Biconcave disc</td>
<td>Normal RBC</td>
</tr>
<tr>
<td>Spherocyte</td>
<td>Spherical RBC (due to loss of membrane)</td>
<td>Hereditary spherocytosis, immune hemolytic anemia, post-transfusion</td>
</tr>
<tr>
<td>Elliptocyte/Ovalocyte</td>
<td>Oval-shaped, elongated RBCs</td>
<td>Hereditary elliptocytosis, megaloblastic anemia, myelofibrosis, iron-deficiency, MDS (myelodysplastic syndrome)</td>
</tr>
<tr>
<td>Schistocyte (helmet cell, fragment)</td>
<td>Fragmented cells (due to traumatic disruption of membrane)</td>
<td>Microangiopathic hemolytic anemia (HUS, aHUS, TTP, DIC, preeclampsia, HELLP, malignant HTN, vasculitis, glomerulonephritis, prosthetic heart valve)</td>
</tr>
<tr>
<td>Sickle Cell</td>
<td>Sickle-shaped RBC (due to polymerization of hemoglobin)</td>
<td>Sickle cell disorders: HbSC, HbSS</td>
</tr>
<tr>
<td>Codocyte (target cell)</td>
<td>“Bul’s eye” on dried film</td>
<td>Liver disease, hemoglobin SC, thalassemia, iron deficiency, asplenia</td>
</tr>
<tr>
<td>Dacrocyte (teardrop cell)</td>
<td>Single pointed end, looks like a teardrop</td>
<td>Myelofibrosis, thalassemia major, megaloblastic anemia, bone marrow infiltration</td>
</tr>
<tr>
<td>Acanthocyte (spur cell)</td>
<td>Distorted RBC with irregularly distributed thorn-like projections (due to abnormal membrane lipids)</td>
<td>Severe liver disease (spur cell anemia), starvation/anorexia, post-splenectomy</td>
</tr>
<tr>
<td>Echinocyte (burr cell)</td>
<td>RBC with numerous regularly spaced, small spiny projections</td>
<td>Uremia, HUS, burns, cardiopulmonary bypass, post-transfusion, storage artifact</td>
</tr>
<tr>
<td>Rouleaux Formation</td>
<td>Aggregates of RBC resembling stacks of coins (due to increased plasma concentration of high molecular weight proteins)</td>
<td>Pregnancy is most common cause (due to physiological increase in fibrinogen) Inflammatory conditions (due to polyclonal immunoglobulins) Plasma cell dyscrasias (due to monoclonal paraproteinemia, e.g. multiple myeloma, macroglobulinemia) Storage artifact</td>
</tr>
</tbody>
</table>

DIC = disseminated intravascular coagulation; HUS = hemolytic uremic syndrome; aHUS = atypical HUS; TTP = thrombotic thrombocytopenic purpura
Illustrations: Ayalah Hutchins and Merry Shiyu Wang 2012

### Table 3. RBC Inclusions

<table>
<thead>
<tr>
<th>Inclusions</th>
<th>Definition</th>
<th>Associated Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nucleus</td>
<td>Present in erythroblasts (immature RBCs)</td>
<td>Hyperplastic erythropoiesis (seen in hypoxia, hemolytic anemia), BM infiltration disorders, MPPs (MF)</td>
</tr>
<tr>
<td>Heinz Bodies</td>
<td>Denatured and precipitated hemoglobin</td>
<td>G6PD deficiency (post-exposure to oxidant), thalassemia, unstable hemoglobins</td>
</tr>
<tr>
<td>Howell-Jolly Bodies</td>
<td>Small nuclear remnant resembling a pyknotic nucleus</td>
<td>Post-splenectomy, hyposplenism (sickle cell disease), neonates, megaloblastic anemia</td>
</tr>
<tr>
<td>Basophilic Stippling</td>
<td>Deep blue granulations indicating ribosome aggregation</td>
<td>Thalassemia, heavy metal (Pb, Zn, Ag, Hg) poisoning, megaloblastic anemia, hereditary (pyrimidine 5’nucleotidase deficiency)</td>
</tr>
<tr>
<td>Sideroblasts</td>
<td>Erythrocytes with Fe containing granules in the cytoplasm</td>
<td>Hereditary, idiopathic, drugs, hypothyroidism (see Sideroblastic Anemia, H16), myelodysplastic syndrome, toxins (lead)</td>
</tr>
</tbody>
</table>

BM = bone marrow; MF = myelofibrosis; MPP = myeloproliferative neoplasm
Illustrations: Ayalah Hutchins and Merry Shiyu Wang 2012
**WHITE BLOOD CELLS**
- lymphocytes: comprise 30–40% of WBCs; great variation in "normal" lymphocyte morphology
- neutrophils
  - normally, only mature neutrophils (with 3–4 lobed nucleus) and band neutrophils (immediate precursor with horseshoe-shaped nucleus) are found in circulation
  - hypersegmented neutrophil: >5 lobes suggests megaloblastic process (B12 or folate deficiency)
- left shift (increased granulocyte precursors)
  - seen in leukemoid reactions: acute infections, pregnancy, neonates, hypoxia, shock, myeloproliferative neoplasms (CML, MF)
- blasts
  - immature, undifferentiated precursors; associated with acute leukemia, MDS, G-CSF (growth factor that stimulates neutrophil production) use

This is a MEDICAL EMERGENCY

**Table 4. Abnormal White Blood Cells on Film**

<table>
<thead>
<tr>
<th>Appearance</th>
<th>Definition</th>
<th>Associated Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reed-Sternberg Cell</td>
<td>Giant, multinucleated B-lymphocyte, (classic ‘owl-eye’ morphology)</td>
<td>Primarily Hodgkin lymphoma, also seen in some non-Hodgkin lymphoma, CLL, and EBV infection</td>
</tr>
<tr>
<td>Smudge Cell</td>
<td>Lymphocytes damaged during blood film preparation indicating cell fragility</td>
<td>CLL and other lymphoproliferative disorders Pathognomonic in EBV infection</td>
</tr>
<tr>
<td>Auer Rod</td>
<td>Cytoplasmic inclusions that form long needles in the cytoplasm of myeloblasts</td>
<td>Pathognomonic for acute myeloid leukemia (AML)</td>
</tr>
<tr>
<td>Atypical Lymphocyte</td>
<td>Pale blue cytoplasm following RBC edges with pink granules</td>
<td>Viruses (particularly EBV) T-cell large granular lymphocyte leukemia (T-LGL)</td>
</tr>
</tbody>
</table>

EBV = Epstein-Barr virus , CLL = chronic lymphocytic leukemia
Illustrations: Ayalah Hutchins and Merry Shiyu Wang 2012

**PLATELETS**
- small, purple, anuclear cell fragments

**Bone Marrow Aspiration and Biopsy**
- sites: posterior iliac crest, sternum
- analyses: most often done together
  - aspiration: takes a fluid marrow sample for cellular morphology, flow cytometry, cytogenetics, molecular studies, microbiology (C&S, acid-fast bacilli, PCR)
  - note: differential diagnosis for a “dry tap”: MF, hairy cell leukemia, bone marrow infiltration
  - biopsy: takes a sample of intact bone marrow to assess histology (architecture) and immunohistochemistry

**Indications**
- unexplained CBC abnormalities
- diagnosis and evaluation of infiltrating cancers: plasma cell disorders, leukemias, solid tumours
- diagnosis and staging of lymphoma or solid tumours
- evaluate iron metabolism and stores (gold standard, but rarely done)
- evaluate suspected deposition and storage disease (e.g. amyloidosis, Gaucher’s disease)
- evaluate fever of unknown origin, suspected mycobacterial, fungal/parasitic infections, or granulomatous disease
- evaluate unexplained splenomegaly
- confirm normal bone marrow in potential allogenic hematopoietic cell donor

**Important Considerations:**
- consult a hematologist prior to conducting a bone marrow biopsy on a patient with an inherited (e.g. hemophilia, VWF disease) or acquired (e.g. DIC, anticoagulant therapy, coagulopathy of liver disease, severe thrombocytopenia) bleeding diathesis to determine if pro-hemostatic therapy is indicated pre-procedure
- do not perform a bone marrow biopsy if there is evidence of infection over the targeted skin site
Common Presenting Problems

Anemia

Definition
- a decrease in red blood cell (RBC) mass that can be detected by hemoglobin (Hb) concentration, hematocrit (Hct), and RBC count
  - adult males: Hb <130 g/L or Hct <0.41
  - adult females: Hb <120 g/L or Hct <0.36 (changes with pregnancy and trimester)

Clinical Features
- symptoms of anemia: fatigue, headache, light-headedness, malaise, weakness, decreased exercise tolerance, dyspnea, palpitations, dizziness, tinnitus, syncope
- acute vs. chronic, bleeding, systemic illness, diet (Fe, B12 sources), alcohol, family history
- menstrual history: menorrhagia, menometrorrhagia
- rule out pancytopenia (recurrent infection, mucosal bleeding, easy bruising)
- physical signs
  - HEENT: pallor in mucous membranes and conjunctiva at Hb <90 g/L (<9 g/dL), ocular bruits at Hb <35 g/L (<5.5 g/dL), angular chelosis, jaundice
  - cardiac: tachycardia, orthostatic hypotension, systolic flow murmur, wide pulse pressure, signs of CHF
dermatologic: ecchymosis, petechiae, pallor in palmar skin creases at Hb <75 g/L, jaundice (if due to hemolysis), nail changes (spooning), glossitis
  - splenomegaly, lymphadenopathy

Investigations
- rule out dilutional anemia (low Hb due to increased effective circulating volume)
- CBC with differential
- reticulocyte count and blood smear/film
- rule out nutritional deficit, gastrointestinal and genitourinary disease in iron deficiency anemia
- additional laboratory investigations as indicated (see Microcytic Anemia, H13, Normocytic Anemia, H17, Hemolytic Anemia, H18, and Macrocytic Anemia, H23)
- N.B. may have a mixed picture with multiple concomitant nutritional deficiencies

Erythrocytosis

Definition
- an increase in the number of RBCs: Hb >185 g/L or Hct >52% (males); Hb >165 or Hct >47% (females and African males)

Etiology
- relative/spurious erythrocytosis (decreased plasma volume): diuretics, severe dehydration, burns, “stress” (Gaisböck’s syndrome)
- absolute erythrocytosis
### Table 5. Etiology of Erythrocytosis

<table>
<thead>
<tr>
<th>Primary</th>
<th>Secondary</th>
<th>Inappropriate Production of Erythropoietin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polycythemia Vera (PV)</td>
<td>Physiologic (poor tissue oxygenation/hypoxia)</td>
<td>Tumours</td>
</tr>
<tr>
<td>(see Polycythemia Vera, H41)</td>
<td>Carbon monoxide poisoning</td>
<td>Hepatocellular carcinoma</td>
</tr>
<tr>
<td></td>
<td>Heavy smoking</td>
<td>Renal cell carcinoma</td>
</tr>
<tr>
<td></td>
<td>High altitude</td>
<td>Cerebellar hemangiblastoma</td>
</tr>
<tr>
<td>Pulmonary Disease</td>
<td>COPD</td>
<td>Pheochromocytoma</td>
</tr>
<tr>
<td></td>
<td>Sleep apnea</td>
<td>Uterine leiomyoma</td>
</tr>
<tr>
<td></td>
<td>Pulmonary hypertension</td>
<td>Ovarian tumour</td>
</tr>
<tr>
<td>Cardiovascular Disease</td>
<td>R to L shunt (Eisenmenger syndrome)</td>
<td>Other</td>
</tr>
<tr>
<td></td>
<td>RBC defects (Hb with increased O₂ affinity, methemoglobinemia)</td>
<td>Polycystic kidney disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Post-kidney transplant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hydrenephrosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Androgens</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exogenous erythropoietin</td>
</tr>
</tbody>
</table>

#### Clinical Features
- secondary to high red cell mass and hyperviscosity
  - headache, dyspnea, dizziness, tinnitus, visual disturbances, hypertensive symptoms, numbness/tingling
  - symptoms of angina, congestive heart failure, aquagenic pruritus (only in MPNs)
- thrombosis (venous or arterial) or bleeding (seen with acquired vWD or acquired platelet dysfunction in MPNs)
- physical findings
  - splenomegaly ± hepatomegaly, facial plethora/ruddy complexion (70%) and/or palms, gout

#### Investigations
- serum erythropoietin (EPO): differentiates primary (low/normal) from other etiologies (elevated)
  - search for tumour as source of EPO as indicated (e.g. abdominal U/S, CT head)
  - JAK-2 mutation analysis: positive in >96% of cases of PV
  - only send if low/normal EPO level
- ferritin (iron deficiency can mask the diagnosis; if iron deficient with reticulocytosis, suggestive of PV)

#### Treatment
- if primary: see Polycythemia Vera, H41
- if secondary: treat underlying cause
  - O₂ for hypoxemia, CPAP for sleep apnea, surgery for EPO-secreting tumours
  - often cardiologists will be hesitant to treat high Hct in cyanotic patients

---

### Thrombocytopenia

#### Definition
- platelet count <150 x10⁹/L

#### Clinical Features
- history: mucocutaneous bleeding (easy bruising, gingival bleeding), epistaxis, peri-operative bleeding (including dental procedures), heavy menstrual bleeding, peripartum bleeding
  - physical exam: bruising, petechiae, ecchymoses, non-palpable purpura, wet purpura
  - see Disorders of Primary Hemostasis, H27 for complications

#### Investigations
- CBC and differential
- blood film
  - rule out pseudo-thrombocytopenia (platelet clumping or platelet satellitism)
  - decreased production: other cell line abnormalities, blasts, hypersegmented PMNs, leukoerythroblastic changes
  - increased destruction: large platelets (often seen in ITP), schistocytes (seen in MAHA/TMA)
  - workup for nutritional deficiencies: B₁₂, RBC folate
  - PT/INR, aPTT and fibrinogen if DIC suspected
  - LFTs

#### Treatments
- life threatening bleeding: platelet transfusion (repeat CBC 1 h post-transfusion to confirm an appropriate rise in counts)
- if secondary: treat underlying cause
  - ITP: see Immune Thrombocytopenic Purpura, H27
**Thrombocytopenia**

**Definition**
- platelet count >400 x10^9/L
- primary thrombocytosis (uncommon): due to myeloproliferative neoplasms (e.g. CML, polycythemia vera, primary myelofibrosis, essential thrombocytosis; rarely associated with MDS)
- reactive/secondary thrombocytosis (common): acute phase reactant (e.g. surgery, inflammation, infection, trauma, bleeding, iron deficiency, neoplasms, ischemic injury)

**Clinical Features**
- history: trauma, surgery, splenectomy, infection, inflammation, bleeding, iron deficiency, prior diagnosis of chronic hemolytic disorder, constitutional symptoms (malignancy)
- vasomotor symptoms: headache, visual disturbances, lightheadedness, atypical chest pain, acral dysesthesia, erythromelalgia, livedo reticularis, aquagenic pruritus
- clotting risk, bleeding risk (rare)
- physical exam: splenomegaly can be seen in myeloproliferative neoplasms (MPNs)

**Investigations**
- CBC, peripheral blood film, serum ferritin concentration
- non-specific markers of infection or inflammation (e.g. CRP, ESR, ferritin)
- if reactive process has been ruled out, bone marrow biopsy may be required to rule out MPN/MDS

**Treatment**
- primary: ASA ± cytoreductive agents (e.g. hydroxyurea, anagrelide, interferon-α)
- secondary: treat underlying cause

---

**Pancytopenia**

**Definition**
- a decrease in all hematopoietic cell lines

**Clinical Features**
- anemia: fatigue (see Anemia, H6)
- leukopenia: recurrent infections (see Neutropenia, H9)
- thrombocytopenia: mucosal bleeding (see Thrombocytopenia, H7)

**Investigations**
- CBC, peripheral blood film, serum ferritin concentration, B12, folate
- non-specific markers of infection or inflammation (e.g. CRP, ESR, ferritin)
- work up as per Figure 4 and presenting symptoms/physical exam
- if reactive process has been ruled out, bone marrow biopsy may be required

*In hospitalized patients most common causes of thrombocytopenia are drugs and infection*

**Figure 3. Approach to thrombocytopenia**

ADAPTED FROM: Cecil Essentials of Medicine

---

**References**
- APS: see Hematology, H34
- Aplastic Anemia: see Hematology, H17
- B12-Folate Deficiency: see Hematology, H24/H25
- DIC: see Hematology, H27
- H1: see Hematology, H29
- HIV: see Infectious Diseases, H27
- ITP: see Hematology, H27
- Myelodysplasia: see Hematology, H39
- Preeclampsia: see Obstetrics, OB24
- SLE: see Rheumatology, RH11
Neutrophilia

Definition
- variable definition, but generally an absolute neutrophil count (ANC) $>7.7 \times 10^9/L$ (WHO definition)

Etiology
- primary neutrophilia
  - chronic myeloid leukemia (CML)
  - other myeloproliferative disorders: PV, ET, myelofibrosis
  - hereditary neutrophilia (autosomal dominant)
  - chronic idiopathic neutrophilia in otherwise healthy patients
  - leukocyte adhesion deficiency
- secondary neutrophilia
  - stress/exercise/epinephrine: movement of neutrophils from marginated pool into circulating pool
  - obesity
  - infection: leukocytosis with left shift ± toxic granulation, Döhle bodies (intra-cytoplasmic structures composed of agglutinated ribosomes)
  - inflammation: e.g. rheumatoid arthritis (RA), IBD, chronic hepatitis, MI, PE, burns
  - malignancy: hematologic (i.e. marrow invasion by tumour) and non-hematologic (especially large cell lung cancer)
  - medications: glucocorticoids, β-agonists, lithium, G-CSF

Clinical Features
- look for signs and symptoms of fever, inflammation, malignancy to determine appropriate further investigations
  - including lymphadenopathy and organomegaly
- examine oral cavity, teeth, peri-rectal area, genitals, and skin for signs of infection

Investigations
- CBC and differential: mature neutrophils or bands $>20\%$ of total WBC suggests infection/inflammation
- blood film: Döhle bodies, toxic granulation, cytoplasmic vacuoles in infection
- may require bone marrow biopsy if MPN suspected

Treatment
- directed at underlying cause

Neutropenia

Definition
- mild: ANC $1.0-1.5 \times 10^9/L$
- moderate: ANC $0.5-1.0 \times 10^9/L$ (risk of infection starts to increase)
- severe: ANC $<0.5 \times 10^9/L$
- profound: ANC $<0.1 \times 10^9/L$ for $>7$ d

Absolute Neutrophil Count (ANC) = WBC count x (%PMNs + %bands)
Beware of fever + ANC $<0.5 \times 10^9/L = \text{FEBRILE NEUTROPENIA}$
Etiology

Table 6. Etiology of Neutropenia

<table>
<thead>
<tr>
<th>Decreased Production</th>
<th>Peripheral Destruction/Sequestration</th>
<th>Excessive Margination (Transient Neutropenia)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infection</strong></td>
<td>Anti-neutrophil antibodies</td>
<td>Idiopathic (most common)</td>
</tr>
<tr>
<td>Viral hepatitis, EBV, HIV, TB, typhoid, malaria</td>
<td>Spleen or lung trapping</td>
<td>Overwhelming bacterial infection</td>
</tr>
<tr>
<td><strong>Hematological Diseases</strong></td>
<td>Autoimmune disorders: RA (Felty’s syndrome), SLE</td>
<td>Hemodialysis</td>
</tr>
<tr>
<td>Idiopathic, aplastic anemia, myelofibrosis, BM infiltration, cyclic, PNH, MDS, immune-mediated</td>
<td>Granulomatosis with polyangitis (formerly Wegener’s)</td>
<td>Cardiopulmonary bypass</td>
</tr>
<tr>
<td><strong>Drug-Induced</strong></td>
<td>Drugs: haptens (e.g. α-methyl dopa)</td>
<td>Racial variation (e.g. African or Ashkenazi Jewish descent)</td>
</tr>
<tr>
<td>Alkylating agents, antimetabolites, anticancer drugs, anti-inflammatory agents, anti-thyroid drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Toxins/Chemicals</strong></td>
<td>High dose radiation, benzene, DDT</td>
<td></td>
</tr>
<tr>
<td><strong>Nutritional Deficiency</strong></td>
<td>B₁, folate</td>
<td></td>
</tr>
<tr>
<td><strong>Idiopathic</strong></td>
<td>Constitutional neutropenia, benign cyclic neutropenia</td>
<td></td>
</tr>
</tbody>
</table>

Clinical Features

- fever, chills (only if infection present)
- infection by endogenous bacteria (e.g. S. aureus, gram negatives from GI and GU tract)
- painful ulceration on skin, anus, mouth, and throat following colonization by opportunistic organisms
- avoid digital rectal exam

Investigations

- dependent on degree of neutropenia, history, and symptoms
- ranges from observation with frequent CBCs to bone marrow aspiration and biopsy

Treatment

- regular dental care: chronic gingivitis and recurrent stomatitis major sources of morbidity
- treatment of febrile neutropenia (see Infectious Diseases, ID45)
- in severe immune-mediated neutropenia, G-CSF may increase neutrophil counts
- if no response to G-CSF, consider immunosuppression (e.g. steroids, cyclosporine, methotrexate)

**Lymphocytosis**

Definition

- absolute lymphocyte count >4.0 x 10⁹/L

Etiology

- infection (reactive lymphocytosis)
  - viral infections (majority); particularly mononucleosis
  - TB, pertussis, brucellosis, toxoplasmosis
  - smoking
  - physiologic response to stress (e.g. trauma, status epilepticus)
  - hypersensitivity (e.g. drugs, serum sickness)
  - autoimmune (e.g. rheumatoid arthritis)
  - neoplasm (e.g. ALL if blasts present, CLL, B cell lymphocytosis of undetermined significance)

Investigations

- CBC, peripheral smear assessing lymphocyte morphology

Treatment

- treat underlying cause
**Lymphopenia**

**Definition**
- absolute lymphocyte count <1.0 x 10^9/L

**Etiology**
- idiopathic CD4+ lymphocytopenia
- radiation
- HIV/AIDS, hepatitis B, hepatitis C
- malignancy/chemotherapeutic agents
- malnutrition, alcoholism
- autoimmune disease (e.g. SLE)

**Clinical Features**
- opportunistic infections (see Infectious Diseases, ID34)

**Treatment**
- treat underlying cause
- treat opportunistic infections aggressively and consider antimicrobial prophylaxis (see Infectious Diseases, ID30)

---

**Eosinophilia**

**Definition**
- absolute eosinophil count >0.5 x 10^9/L

**Etiology**
- primary: due to clonal bone marrow disorder
  - if no primary etiology identified, classified as hypereosinophilic syndrome
    - 6 mo of eosinophilia (count >1.5 x 10^9/L) with no other detectable causes and end organ damage
    - can involve heart, bone marrow, CNS
- secondary
  - most common causes are parasitic (usually helminth) infections and allergic reactions
  - less common causes
    - collagen vascular diseases (e.g. RA, polyarteritis nodosa, see Rheumatology, RH19)
    - respiratory causes (asthma, eosinophilic pneumonia, Churg-Strauss)
    - cholesterol emboli
    - hematologic malignancy: see Chronic Myeloid Leukemia, H40 and Hodgkin Lymphoma, H45
    - adrenal insufficiency, see Endocrinology, E33
    - medications (penicillins)
    - atopic dermatitis

**Treatment**
- treat underlying cause
- ensure strongyloides serology is collected to rule out infection before initiating steroids for patients at risk

---

**Agranulocytosis**

**Definition**
- severe depletion of granulocytes (neutrophils, eosinophils, basophils) from the blood and granulocyte precursors from bone marrow

**Etiology**
- associated with medications in 70% of cases: e.g. chemotherapy, clozapine, thionamides (antithyroid drugs), sulfasalazine, and ticlopidine
  - immune-mediated destruction of circulating granulocytes by drug-induced antibodies or direct toxic effects upon marrow granulocytic precursors

**Clinical Features**
- abrupt onset of fever, chills, weakness, and oropharyngeal ulcers

**Prognosis**
- high fatality without vigorous treatment

**Investigations/Treatment**
- discontinue offending drug
- pan-culture and screen for infection if patient is febrile (blood cultures x2, urine culture, and chest x-ray as minimum, initiate broad-spectrum antibiotics)
- consider bone marrow aspirate and biopsy if cause unclear
- consider G-CSF
Leukemoid Reaction

- blood findings resembling those seen in certain types of leukemia which reflect the response of healthy BM to cytokines released due to infection or trauma
- leukocytosis >50 x 10^9/L, marked left shift (myelocytes, metamyelocytes, bands in peripheral blood smear)

Approach to Lymphadenopathy

History

- constitutional/B-symptoms: seen in TB, lymphoma, other malignancies
- growth pattern: acute vs. chronic
- exposures: cats (cat scratch – Bartonella henselae), ticks (Lyme disease – Borrelia burgdorferi), high risk behaviours (HIV)
- joint pain/swelling, rashes (connective tissue disorder)
- pruriitus (seen in Hodgkin lymphoma)
- medications (can cause serum sickness – lymphadenopathy)

Clinical Features

- determine if lymphadenopathy is localized or generalized
- localized: typically reactive or neoplastic
  - cervical (bacterial/mycobacterial infections, ENT malignancies, metastatic cancer)
  - supravacular
    - right (mediastinal, bronchogenic, esophageal cancer)
    - left (gastric, gall bladder, pancreas, renal, testicular/orvian cancer)
  - axillary (cat scratch fever, breast cancer, metastatic cancer)
  - epitrochlear (infections, sarcoidosis, lymphoma)
- check for splenomegalgy, constitutional symptoms

Investigations

- CBC and differential, blood film
- if generalized, consider tuberculin test, HIV RNA, VDRL, Monospot®/EBV serology, ANA, imaging
- if localized and no symptoms suggestive of malignancy, can observe 3-4 wk (if no resolution – biopsy)
- excisional biopsy is preferred as it preserves node architecture (essential for diagnosing lymphoma)
- in areas difficult to access (retroperitoneal, mediastinal/hilar) multiple core biopsies may be more practical/feasible
- FNA should NOT be used for diagnostic purposes in lymphoproliferative disease (use excisional biopsy instead)
  - FNA is helpful for recurrence of solid tumour malignancy
  - imaging such as U/S or CT can provide more info, but generally adds little to diagnosis

Table 7. Inflammatory vs. Neoplastic Lymph Nodes

<table>
<thead>
<tr>
<th>Feature</th>
<th>Inflammatory</th>
<th>Neoplastic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consistency</td>
<td>Rubbery</td>
<td>Firm/hard</td>
</tr>
<tr>
<td>Mobility</td>
<td>Mobile</td>
<td>Matted/immobile</td>
</tr>
<tr>
<td>Tenderness</td>
<td>Tender</td>
<td>Non-tender</td>
</tr>
<tr>
<td>Size</td>
<td>&lt; 2 cm</td>
<td>&gt; 2 cm</td>
</tr>
</tbody>
</table>

*Note: these classifications are not absolute; lymphomas and CLL nodes can feel rubbery and are frequently mobile, non-tender

Table 8. Differential Diagnosis of Generalized Lymphadenopathy

<table>
<thead>
<tr>
<th>Reactive</th>
<th>Inflammatory</th>
<th>Neoplastic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial (TB, Lyme, brucellosis, cat scratch disease, syphilis)</td>
<td>Collagen disease (RA, dermatomyositis, SLE, vasculitis, Sjögren’s)</td>
<td>Lymphoproliferative disorder/lymphoma</td>
</tr>
<tr>
<td>Viral (EBV, CMV, HIV)</td>
<td>Drug hypersensitivity</td>
<td>Metastatic cancer</td>
</tr>
<tr>
<td>Parasitic (toxoplasmosis)</td>
<td>Sarcoïdosis, amyloidosis</td>
<td>Histocytosis X</td>
</tr>
<tr>
<td>Fungal (histoplasmosis)</td>
<td>Serum sickness</td>
<td></td>
</tr>
</tbody>
</table>
Approach to Splenomegaly

Table 9. Differential Diagnosis of Splenomegaly

<table>
<thead>
<tr>
<th>Increased Demand for Splenic Function</th>
<th>Congestive</th>
<th>Infiltrative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematological</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nutritional anemias</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobinopathies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemolytic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spherocytosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sequestration crisis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elliptocytosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infections</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viral e.g. EBV, HIV/AIDS, CMV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacterial e.g. Bacterial endocarditis, TB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parasitic e.g. Malaria, Histoplasmosis, Leishmaniais, Fungal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammatory</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarcoïdosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Felty syndrome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Still’s disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cirrhosis</td>
<td>Portal HTN</td>
<td></td>
</tr>
<tr>
<td>Portal vein obstruction</td>
<td>(including right heart failure)</td>
<td></td>
</tr>
<tr>
<td>Splenic vein thrombosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Malignant</td>
<td>Benign metaplasia</td>
<td></td>
</tr>
<tr>
<td>Cysts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amyloidosis, Sarcoïdosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hamartomas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vascular abnormalities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lysosomal storage diseases (Gaucher’s, Niemann-Pick)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glycogen storage diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignant</td>
<td>Leukemia (CML, CLL), Lymphoproliferative disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hodgkin lymphoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Myeloproliferative disorders</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metastatic tumour</td>
<td></td>
</tr>
</tbody>
</table>

The underlined conditions cause massive splenomegaly (spleen crosses midline or reaches pelvis).

History
- constitutional symptoms, feeling of fullness in LUQ, early satiety
- signs or symptoms of infection (e.g. mononucleosis) or malignancy
- history of liver disease, hemolytic anemia, or high-risk exposures

Clinical Features
- jaundice, petechiae
- signs of chronic liver disease
- percussion (Castell's sign, Traube's space, Nixon's method) and palpation
- associated lymphadenopathy or hepatomegaly
- signs of CHF

Investigations
- CBC and differential, blood film
- as indicated: liver enzymes (AST, ALT, ALP, GGT) and/or LFTs (platelet, INR, albumin, bilirubin), reticulocyte count, Monospot®/EBV, haptoglobin, LDH, infectious, and autoimmune workup
- imaging
  - ultrasound of abdomen/liver to assess for cirrhosis and portal vein thrombosis (if positive, refer to hepatology for evaluation)
  - echo for cardiac function
  - CT to rule out lymphoma and assess splenic lesions

Microcytic Anemia

- MCV <80 fl
- see Figure 2, Approach to Anemia, H6

Table 10. Iron Indices and Blood Film in Microcytic Anemia

<table>
<thead>
<tr>
<th>Lab Tests</th>
<th>Blood Film</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferritin</td>
<td>Serum Iron</td>
</tr>
<tr>
<td>Iron Deficiency Anemia</td>
<td>↓↓</td>
</tr>
<tr>
<td>Anemia of Chronic Disease</td>
<td>N/↑</td>
</tr>
<tr>
<td>Sideroblastic Anemia</td>
<td>N/↑</td>
</tr>
<tr>
<td>Thalassemia</td>
<td>N/↑</td>
</tr>
</tbody>
</table>

Iron Metabolism

Iron Intake (Dietary)
- average North American adult diet = 10-20 mg iron (Fe) daily
- steady state absorption is 5-10% (0.5-2 mg/d); enhanced by citric acid, ascorbic acid (vitamin C) and reduced by polyphenols (e.g. in tea), phytate (e.g. in bran), dietary calcium, and soy protein
- males have positive Fe balance; up to 20% of menstruating females have negative Fe balance
Iron Absorption and Transport
- Dietary iron is absorbed in the duodenum (e.g., absorption impaired in IBD and Celiac disease)
- In circulation, the majority of non-heme iron is bound to transferrin, which transfers iron from enterocytes and storage pool sites (macrophages of the reticuloendothelial system and hepatocytes) to RBC precursors in the bone marrow.

Iron Levels
- Hepcidin is a hormone produced by hepatocytes that regulates systemic iron levels.
  - Binds to iron exporter ferroportin (on duodenal enterocytes and reticuloendothelial cells) and induces its degradation, thereby inhibiting iron export into circulation (diminished absorption of iron and iron trapping in reticuloendothelial system cells).
  - Hepcidin production is:
    ■ Increased in states of iron overload (inhibiting additional iron absorption) and inflammation (mediating anemia of chronic inflammation through iron trapping).
    ■ Decreased in states where erythropoiesis is increased (e.g., hemolysis) or oxygen tension is low.

Iron Storage
- Ferritin
  ■ Ferric iron (Fe$^{3+}$) complexed to a protein called apoferritin (hepatocytes are main ferritin storage site).
  ■ Small quantities are present in plasma in equilibrium with intracellular ferritin.
  ■ Also an acute phase reactant – can be spuriously elevated despite low Fe stores in response to a stressor.
- Hemosiderin
  ■ Aggregates or crystals of ferritin with the apoferritin partially removed.
  ■ Macrophage-monocyte system is main source of hemosiderin storage.

Iron Indices
- Bone marrow aspirate: Gold standard test for assessment of iron stores (rarely done).
- Serum ferritin: Most important blood test for iron stores.
  ■ Decreased in iron deficiency anemia.
  ■ Elevated in infection, inflammation, malignancy, liver disease, hyperthyroidism, and iron overload.
- Serum iron: Measure of all non-heme iron present in blood.
  ■ Varies significantly daily.
  ■ Virtually all serum iron is bound to transferrin, only a trace is free or complexed in ferritin.
- Total iron binding capacity (TIBC): Total amount of transferrin present in blood.
  ■ Normally, one third of TIBC is saturated with iron.
  ■ High specificity for decreased iron, low sensitivity.
- Saturation
  ■ Serum Fe divided by TIBC, expressed as a proportion or a percentage.
- Soluble transferrin receptor (sTfR)
  ■ Reflects the availability of iron at the tissue level.
  ■ The transferrin receptor is expressed on the surface of erythroblasts and is responsible for iron uptake – some is cleaved off and is present in circulation as sTfR.
  ■ In iron deficient states more transferrin receptor is expressed on erythroblasts leading to an increase in sTfR.
  ■ Low in reduced erythropoiesis and iron overload.
  ■ Useful in determining iron deficiency in the setting of chronic inflammatory disorders (see Iron Deficiency Anemia).
Iron Deficiency Anemia

- see Pediatrics, P45
- most common cause of anemia in North America

Etiology
- increased demand
  - increased physiological need for iron in the body (e.g. pregnancy)
  - decreased supply: dietary deficiencies (rarely the only etiology in the developed world)
  - cow’s milk (infant diet), “tea and toast” diet (elderly), absorption imbalances, post-gastrectomy, malabsorption (IBD of duodenum, celiac disease, autoimmune atrophic gastritis, H. pylori infection)
- increased losses
  - hemorrhage
    - obvious causes: menorrhagia, abnormal uterine bleeding, frank GI bleed
    - occult: peptic ulcer disease, GI cancer
  - hemolysis
    - chronic intravascular hemolysis (e.g. PNH, cardiac valve RBC fragmentation)
- most common cause of anemia in North America

Clinical Features
- iron deficiency may cause fatigue before clinical anemia develops
- signs/symptoms of anemia: see Anemia, H6
- brittle hair, nail changes (brittle, koilonychia)
- pica (appetite for non-food substances e.g. ice, paint, dirt)
- restless leg syndrome

Investigations
- iron indices, including soluble transferrin receptor
  - low ferritin (<18 µg/L) is diagnostic of iron deficiency
  - ferritin is an acute phase reactant and is elevated in the setting of inflammatory conditions and liver disease; serum ferritin <100 µg/L in these settings is suggestive of iron deficiency, necessitating further workup
- peripheral blood film
  - hypochromic microcytosis: RBCs have low Hb levels due to lack of iron
  - pencil forms, anisocytosis
  - target cells
- bone marrow (gold standard but rarely done)
  - iron stain (Prussian blue) shows decreased iron in macrophages and in erythroid precursors (sideroblasts)
  - intermediate and late erythroblasts show micrornormoblastic maturation

Treatment
- treat underlying cause
- supplementation
  - oral (capsules, syrup)
    - ferrous sulphate 325 mg tid (65 mg elemental iron), ferrous gluconate 300 mg tid (35 mg elemental iron), or ferrous fumarate 300 mg tid (100 mg elemental iron)
    - supplement until anemia corrects, then continue for 3+ mo until serum ferritin returns to normal
    - oral iron should be taken with citrus juice (vitamin C) to enhance absorption
  - IV (iron sucrose or dextran) can be used if patient cannot tolerate or absorb oral iron
- monitoring response
  - reticulocyte count will begin to increase after one wk
  - Hb normalizes by 10 g/L per wk (if no blood loss)

Investigations

<table>
<thead>
<tr>
<th>Ferritin ≤45 µg/L</th>
<th>Ferritin 46–99 µg/L</th>
<th>Ferritin ≥100 µg/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assess other iron indices</td>
<td>Any other result: Order sTfR</td>
<td></td>
</tr>
<tr>
<td>↑ TIBC, ↓ serum Fe</td>
<td>↓ TIBC, ↑ serum Fe</td>
<td></td>
</tr>
<tr>
<td>↓ saturation</td>
<td>↑ saturation</td>
<td></td>
</tr>
<tr>
<td>↑ sTfR</td>
<td>↓ sTfR</td>
<td></td>
</tr>
</tbody>
</table>

Figure 6. Approach to interpreting iron indices
Adapted from: Am Fam Physician 2001;74:671-678
**Anemia of Chronic Inflammation**

**Etiology**
- infection, malignancy, inflammatory and rheumatologic disease, chronic renal and liver disease, endocrine disorders (e.g. DM, hypothyroidism, hypogonadism, hypopituitarism)

**Pathophysiology**
- an anemia of underproduction due to impaired iron utilization (hepcidin is a key regulatory peptide)
  - hepatic hepcidin production is increased in inflammatory processes, trapping iron in enterocytes and macrophages (via ferroportin inhibition) (see Figure 5)
  - reduced plasma iron levels make iron relatively unavailable for new hemoglobin synthesis
  - marrow unresponsive to normal or slightly elevated EPO
- mild hemolytic component is often present i.e. RBC survival is modestly decreased

**Investigations**
- diagnosis of exclusion
- associated with elevation in acute phase reactants (ESR, CRP, fibrinogen, platelets)
- peripheral blood
  - mild: usually normocytic and normochromic
  - moderate: may be microcytic and normochromic
  - severe: may be microcytic and hypochromic
  - absolute reticulocyte count is frequently low, reflecting overall decrease in RBC production
- “classic” serum iron indices
  - serum iron and TIBC low, % saturation low
  - serum ferritin is normal or increased
- bone marrow
  - normal or increased iron stores
  - decreased or absent staining for iron in erythroid precursors

**Treatment**
- treat underlying disease
- only treat anemia in patients who can benefit from a higher hemoglobin
- IV iron if no benefit from PO iron (overcomes sequestration in enterocytes)
- erythropoietin indicated in chronic renal failure; not to be used if patient has concomitant curative solid tumour malignancy; ensure Hb target <110 g/L

---

**Sideroblastic Anemia**

**Sideroblasts**
- erythrocytes with iron-containing (basophilic) granules in the cytoplasm
- "normal": in healthy individuals, granules are small and randomly spread in the cytoplasm
- "ring": iron deposits in mitochondria, forming large, abnormal granules that surround the nucleus
  - the hallmark of sideroblastic anemia

**Etiology**
- due to defects in heme biosynthesis in erythroid precursors
- hereditary (rare): X-linked; median survival 10 yr
- idiopathic (acquired)
  - refractory anemia with ringed sideroblasts: a subtype of MDS (see Myelodysplastic Syndromes, H39)
  - may be a preleukemic phenomenon (10% transform to AML)
- reversible
  - drugs (isoniazid, chloramphenicol), alcohol, lead, copper deficiency, zinc toxicity, hypothyroidism

**Clinical Features**
- anemia symptoms (see Anemia, H6)
- hepatosplenomegaly, evidence of iron overload

**Investigations**
- serum iron indices
  - increased serum Fe²⁺, normal TIBC, increased ferritin, increased sTfR
- blood film/bone marrow biopsy
  - ringed sideroblasts (diagnostic hallmark)
  - RBCs are hypochromic; can be micro-, normo-, or macrocytic
  - anisocytosis, poikilocytosis, basophilic stippling
**Normocytic Anemia**

- MCV 80-100 fL
- see Figure 2, *Approach to Anemia*, H6

**Aplastic Anemia**

**Definition**
- destruction of hematopoietic cells of the bone marrow leading to pancytopenia and hypocellular bone marrow

**Etiology**

<table>
<thead>
<tr>
<th>Congenital</th>
<th>Acquired</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fanconi’s anemia</td>
<td>Idiopathic</td>
</tr>
<tr>
<td>Shwachman-Diamond syndrome</td>
<td>Often T-cell mediated</td>
</tr>
<tr>
<td>Drugs</td>
<td>Ionizing Radiation</td>
</tr>
<tr>
<td>Dose-related (i.e. chemotherapeutics)</td>
<td>Post-Viral Infection</td>
</tr>
<tr>
<td>Idiosyncratic (chloramphenicol, anti-malarials, phenylbutazone)</td>
<td>Parvovirus B19, EBV, HDV, HEV, HBV, HHV6, HIV</td>
</tr>
<tr>
<td>Toxins</td>
<td>Autoimmune (rare)</td>
</tr>
<tr>
<td>Benzene/organic solvents</td>
<td>SLE, Graft-versus-host disease</td>
</tr>
<tr>
<td>DDT, insecticides</td>
<td>Others</td>
</tr>
<tr>
<td></td>
<td>PNH, pregnancy, anorexia nervosa, thymoma</td>
</tr>
</tbody>
</table>

**Clinical Features**
- can present acutely or insidiously
- symptoms of anemia (see Anemia, H6), thrombocytopenia (see Thrombocytopenia, H7), and/or infection
- ± splenomegaly and lymphadenopathy (depending on the cause)

**Investigations**
- exclude other causes of pancytopenia (see Figure 4), including PNH (overlap syndrome)
- CBC
  - anemia or neutropenia or thrombocytopenia (any combination) ± pancytopenia
  - decreased reticulocytes (<1% of the total RBC count)
- blood film
  - decreased number of normal RBCs
- bone marrow
  - aplasia or hypoplasia of marrow cells with fat replacement
  - decreased cellularity

**Treatment**
- remove offending agents
- supportive care (red cell and platelet transfusions, antibiotics)
- judicious use so as to not increase the risk of immune sensitization to blood products
- immunosuppression (for idiopathic aplastic anemia)
- anti-thymocyte globulin: 50-60% of patients respond
- cyclosporine
- allogenic bone marrow transplant
- growth factors: e.g. Eltrombopag (TPO receptor agonist), G-CSF and EPO not effective

---

**Lead Poisoning**

**Definition/Etiology**
- blood lead levels greater than 80 µg/dL, possible symptomatology at 50 µg/dL
- identify source: consider occupational history, exposures history, utensil history

**Clinical Features**
- abdominal pain, constipation, irritability, difficulty concentrating

**Treatment**
- chelation therapy: dimercaprol and EDTA are first line agents
Hemolytic Anemia

**Definition**
- anemia due to a shortened survival of circulating RBCs, usually defined as <100 d
- uncommon cause for anemia (<5% of cases) with many etiologies (>200)

**Classification**
- hereditary
  - abnormal membrane (spherocytosis, elliptocytosis)
  - abnormal enzymes (pyruvate kinase deficiency, G6PD deficiency)
  - abnormal hemoglobin synthesis (thalassemias, hemoglobinopathies)
- acquired
  - immune
    - autoimmune: warm vs. cold autoimmune hemolytic anemias (AIHA), see Table 14 Classification of AIHA, H22
    - alloimmune: hemolytic disease of the fetus/newborn, post-transfusion
  - non-immune
    - MAHA/TMA, now known as TMA: thrombus in blood vessel causes RBCs to be sheared
      - associated with DIC, HUS, aHUS, TTP; preeclampsia/HELLP; vasculitides, malignant hypertension
    - other causes: PNH, hypersplenism, march hemoglobinuria (exertional hemolysis), infection (e.g. malaria), snake venoms, mechanical heart valves
- also classified as intravascular or extravascular
  - intravascular: MAHA/TMA (e.g. TTP, DIC), infections (malaria, Clostridium), and PNH
  - extravascular: RBCs are coated with antibodies (AIHA) or have an abnormal membrane structure/shape or inclusions

**Clinical Features Specific to HA**
- jaundice
- dark urine (hemoglobinuria, bilirubin)
- cholelithiasis (pigment stones)
- potential for an aplastic crisis (i.e. BM suppression in overwhelming infection)
- iron overload with extravascular hemolysis
- iron deficiency with intravascular hemolysis

**Investigations**

<table>
<thead>
<tr>
<th>Screening Tests</th>
<th>Tests Specific For Intravascular Hemolysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased LDH</td>
<td>Schistocytes on blood film</td>
</tr>
<tr>
<td>Decreased haptoglobin</td>
<td>Free hemoglobin in serum</td>
</tr>
<tr>
<td>Increased unconjugated bilirubin</td>
<td>Methemalbuminemia (heme + albumin)</td>
</tr>
<tr>
<td>Increased urobilinogen</td>
<td>Hemoglobinuria (immediate)</td>
</tr>
<tr>
<td>Reticulocytosis</td>
<td>Hemosiderinuria (delayed) – most sensitive</td>
</tr>
</tbody>
</table>

**Tests Specific For Extravascular Hemolysis**

**Direct Antiglobulin Test (direct Coombs)**
Detects IgG or complement on the surface of RBCs
Add anti-IgG or anti-complement Ab to patient’s RBCs; positive if agglutination
Indications: hemolytic disease of newborn, AIHA, hemolytic transfusion reaction

**Indirect Antiglobulin Test (indirect Coombs)**
Detects antibodies in serum that can recognize antigens on RBCs
Mix patient’s serum + donor RBCs + Coombs serum (anti-human Ig Ab); positive if agglutination
Indications: cross-matching donor RBCs, atypical blood group, blood group Ab in pregnant women, AIHA

**Thalassemia**

**Definition**
- defects in production of the α or β chains of hemoglobin
  - resulting imbalance in globin chains leads to ineffective erythropoiesis and hemolysis in the spleen or BM
- clinical manifestations and treatment depends on specific gene and number of alleles affected
- common features
  - increasing severity with increasing number of alleles involved
  - hypochromic microcytic anemia
  - basophilic stippling, abnormally shaped RBCs on blood film
  - α-Thal → prevalent in South East Asia (SEA) and Africa (α = Asia, Africa)
  - β-Thal → prevalent in Mediterranean
Pathophysiology
- defect may be in any of the Hb genes
  - normally 4α genes in total; 2 on each copy of chromosome 16
  - normally 2β genes in total; 1 on each copy of chromosome 11
  - fetal hemoglobin, HbF (α2γ2), switches to adult forms HbA (α2β2) and HbA2 (α2δ2) at 3-6 mo of life
  - HbA constitutes 97% of adult hemoglobin
  - HbA2 constitutes 3% of adult hemoglobin

β-Thalassemia Minor (Thalassemia Trait)

Definition
- defect in single allele of β gene (heterozygous for one normal beta globin allele and one beta globin thalassemic allele)
- common in people of Mediterranean and Asian descent

Clinical Features
- usually asymptomatic; a palpable spleen is very rare

Investigations
- Hb (100-140 g/L), MCV(<70), Fe (normal), RBC count (normal)
- peripheral blood film – microcytosis basophilic stippling
- Hb electrophoresis
  - specific: HbA2 increased to 3.5-5% (normal 1.5-3.5%)
  - non-specific: 50% have slight increase in HbF

Treatment
- no treatment required
- genetic counselling for patient and family

β-Thalassemia Major

Definition
- defect in both alleles of β gene ( homozygous, autosomal recessive)

Pathophysiology
- ineffective chain synthesis leading to ineffective erythropoiesis, hemolysis of RBCs, and increase in HbF

Clinical Features
- initial presentation at age 6-12 mo when HbA (α2/β2) normally replaces HbF (α2/γ2)
  - severe anemia, jaundice
- iron overload progressing to hemochromatosis
  - secondary to repeated transfusions and ineffective erythropoiesis
  - leads to iron-induced organ damage (see Gastroenterology, G26)
- stunted growth and development (hypogonadal dwarf)
- gross hepatosplenomegaly (due to extramedullary hematopoiesis)
- radiologic changes (due to expanded marrow cavity) and extramedullary hematopoietic masses (erythroid tissue tumours)
  - skull x-ray has “hair-on-end” appearance
  - pathologic fractures common
- evidence of increased Hb catabolism (e.g. pigmented gallstones)
- death can result from
  - untreated anemia (should transfuse)
  - infection (should identify and treat early)
  - iron overload (common): late complication from repeated transfusions and ineffective erythropoiesis

Investigations
- severe microcytic anemia (Hb <60 g/L)
- peripheral blood film: teardrop, target, hypochromatic, microcytic
- Hb electrophoresis
  - HbA: 0-10% (normal >95%)
  - HbA2 >2.5%
  - HbF: 90-100%

Treatment
- lifelong regular transfusions to suppress endogenous erythropoiesis
- iron chelation (e.g. deferoxamine, deferasirox, deferiprone) to prevent iron overload in organs and the formation of free radicals (which promote tissue damage and fibrosis)
- folic acid supplementation if not transfused
- allogenic bone marrow transplantation (potentially curative) or cord blood transplant
- splenectomy (now performed less frequently)
β-Thalassemia Intermedia

Definition
- clinical diagnosis in patients whose clinical manifestations are too mild to be classified as thalassemia major, but too severe to be classified as thalassemia minor

Clinical Features
- wide variety of clinical phenotypes
- in most cases of TI, both β-globin genes affected
- three main mechanisms account for the milder phenotype compared to thalassemia major: (1) subnormal (vs. absent) beta-chain synthesis, (2) increased number of gamma chains, (3) coinheritance of alpha thalassemia (in some cases)
- complications more commonly seen in TI than thalassemia major include extramedullary hematopoiesis, leg ulcers, gallstones, thrombosis, and pulmonary hypertension, and growth retardation

α-Thalassemia

Definition
- defect(s) in α genes
- similar geographic distribution as β-thalassemia, but higher frequency among Asians and Africans

Clinical Features
- 1 defective α gene (αα/α–): clinically silent; normal Hb, normal MCV
- 2 defective α genes (αα/α–; or trans: αα/α–): decreased MCV, normal Hb
  - N.B. cis 2-gene deletion more common in Asia vs. trans 2-gene deletion more common in Africa – this leads to increased risk of fetal hydrops in offspring of Asian patients vs. African patients
- 3 defective α genes (αα/α–): HbH (β4) disease; presents in adults, decreased MCV, decreased Hb, splenomegaly
- 4 defective α genes (αα/α–): Hb Barts (γ4) disease (hydrops fetalis); usually incompatible with life

Investigations
- peripheral blood film – screen for HbH inclusion bodies with supravital stain
- electrophoresis can be used to identify HgH disease, definitive diagnosis with DNA genotyping

Treatment
- depends on degree of anemia, referral for genetic/prenatal counselling
  - 1 or 2 defective α genes: no treatment required
  - HbH disease: similar to β-thalassemia intermedia
  - HbBarts: no definitive treatment, majority of pregnancies terminated (fetal/maternal mortality risk), intrauterine transfusion, stem cell transplants

Sickle Cell Disease

Definition
- autosomal recessive sickling disorders arise due to a mutant β-globin chain, most commonly caused by a Glu → Val substitution at position 6 (chromosome 11) resulting in HbS variant, rather than HbA (normal adult Hb)
  - increased incidence of HbS allele with African or Mediterranean heritage (thought to be protective against malaria)
  - sickle cell disease occurs when an individual has two HbS genes (homozygous, HbSS) or one HbS gene + another mutant β-globin gene (compound heterozygote) – most commonly HbS-α-thal and HbSβ'

Pathophysiology
- at low pO2, deoxy HbS polymerizes leading to rigid crystal-like rods that distort membranes → ‘sickles’
  - the pO2 level at which sickling occurs is related to the percentage of HbS present
  - sickling aggravated by acidemia, increased CO2, increased 2,3-DPG, fever, and osmolality
  - fragile sickle cells then cause injury in two main ways
    1. fragile sickle cells hemolysise (nitric oxide depletion)
    2. occlusion of small vessels (hypoxia, ischemia-reperfusion injury)

Clinical Features
- HbAS (sickle cell trait): patient will be asymptomatic except during extreme hypoxia or infection
- increased risk of renal medullary carcinoma
- SCD-SS (HbSS)
  - chronic hemolytic anemia
  - jaundice in the first yr of life
  - retarded growth and development ± skeletal changes
  - splenomegaly in childhood; splenic atrophy in adulthood

Functional asplenism: increased susceptibility to infection by encapsulated organisms
- S. pneumoniae
- N. meningitidis
- H. influenzae
- Salmonella (osteomyelitis)
SCD-SS often presents with acute pain episode
1. aplastic crises
   - toxins and infections (especially parvovirus B19) transiently suppress bone marrow
2. splenic sequestration crises
   - usually in children; significant pooling of blood in spleen resulting in acute Hb drop and shock
   - uncommon in adults due to asplenia from repeated infarction
3. vaso-occlusive crises (infarction)
   - may affect various organs causing ischemia-reperfusion injury (especially in back, chest, abdomen, and extremities), fever, and leukocytosis
   - can cause a stroke or a silent myocardial infarction
   - precipitated by infections, dehydration, rapid change in temperature, pregnancy, menses, and alcohol
4. acute chest syndrome (see sidebar)
SCD-SC (most common compound heterozygote)
- 1:333 live births in African-Americans, common in West Africa
- milder anemia than HbSS
- similar complications as HbSS, although typically milder and less frequent (exception is proliferative sickle retinopathy, glomerulonephritis, and avascular necrosis)
- spleen not always atrophic in adults

Investigations
- sickle cell prep (detects sickling of RBCs under the microscope in response to O₂ lowering agent): determines the presence of a Hb SS allele, but does not distinguish HbAS from HbSS
- Hb electrophoresis distinguishes HbAS, HbSS, HbSC, and other variants
- all newborns in developed countries typically screened for SCD

Table 13. Investigations for Sickle Cell Disease

<table>
<thead>
<tr>
<th></th>
<th>HbAS</th>
<th>HbSS</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBC</td>
<td>Normal</td>
<td>Increased reticulocytes, decreased Hb, decreased Hct</td>
</tr>
<tr>
<td>Peripheral Blood</td>
<td>Normal; possibly a few target cells</td>
<td>SICKLED cells</td>
</tr>
<tr>
<td>Hb Electrophoresis</td>
<td>HbA fraction of 0.65 (65%)</td>
<td>No HbA, only HbS and HbF (proportions change with age); normal amount of HbA</td>
</tr>
<tr>
<td></td>
<td>HbS fraction of 0.35 (35%)</td>
<td></td>
</tr>
</tbody>
</table>

Treatment
- genetic counselling
- HbAS: no treatment required
- HbSC: treatment as per HbSS, but is dictated by symptom severity
- HbSS
  1. folic acid to prevent folate deficiency
  2. hydroxyurea to enhance production of HbF
     - mechanism of action: stops repression of Hb-γ chains and/or initiates differentiation of stem cells in which this gene is active
     - presence of HbF in the SS cells decreases polymerization and precipitation of HbS
     - N.B. hydroxyurea is cytotoxic and may cause bone marrow suppression
  3. treatment of vaso-occlusive crisis
     - supportive care: oxygen, hydration (reduces viscosity), correct acidosis, analgesics/opiates
     - indication for exchange transfusion: Hb <50-60 g/L, SCD complications (acute chest syndrome, aplastic crisis, hepatic or splenic sequestration, stroke), prevention of complications, pre-operative
     - less routinely: antimicrobials for suspected infection
  4. prevention of crises
     - establish diagnosis
     - avoid conditions that promote sickling (hypoxia, acidosis, dehydration, fever)
     - vaccination in childhood (pneumococcus, meningococcus, H. influenzae b)
     - prophylactic penicillin (age 3 mo-5 yr)
     - good hygiene, nutrition, and social support
  5. screen for complications
     - regular blood work (CBC, reticulocytes, iron indices, BUN, LFTs, creatinine)
     - urinalysis annually (proteinuria, glomerulopathy)
     - transcranial doppler annually until 16 yr old (stroke prevention)
     - retinal examinations annually from 8 yr old (screen for retinopathy)
     - echocardiography once in late childhood/early adulthood (screen for pulmonary hypertension)

Organs Affected by Vaso-Occlusive Crisis

<table>
<thead>
<tr>
<th>Organ</th>
<th>Problem</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain</td>
<td>Ischemic or hemorrhagic stroke, vasculopathy</td>
</tr>
<tr>
<td>Eye</td>
<td>Hemorrhage, blindness</td>
</tr>
<tr>
<td>Liver</td>
<td>Infarcts, RHD syndrome</td>
</tr>
<tr>
<td>Lung</td>
<td>Chest syndrome, long-term pulmonary hypertension</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>Stones</td>
</tr>
<tr>
<td>Heart</td>
<td>Hyperdynamic flow murmurs</td>
</tr>
<tr>
<td>Spleen</td>
<td>Enlarged (child), atrophic (adult)</td>
</tr>
<tr>
<td>Kidney</td>
<td>Hematuria, loss of renal concentrating ability, proteinuria</td>
</tr>
<tr>
<td>Intestines</td>
<td>Acute abdomen</td>
</tr>
<tr>
<td>Placenta</td>
<td>Stillbirths</td>
</tr>
<tr>
<td>Penis</td>
<td>Priapism</td>
</tr>
<tr>
<td>Digits</td>
<td>Dactylitis</td>
</tr>
<tr>
<td>Femoral and Humeral Head</td>
<td>Avascular necrosis</td>
</tr>
<tr>
<td>Bone</td>
<td>Infarction, infection</td>
</tr>
<tr>
<td>Ankle</td>
<td>Leg ulcers</td>
</tr>
</tbody>
</table>

NIH Consensus Development Conference
Statement: Hydroxyurea Treatment for Sickle Cell Disease
Efficacy: Strong evidence for adolescents and adults and there is emerging data supporting its use in children. In the single RCT, the Hb level was higher in hydroxyurea recipients than placebo recipients after 2 yr (difference, 6 g/L), as was HbF (absolute difference, 3.2%). The median number of painful crises was 44% lower than in the placebo arm. The 12 observational studies that enrolled adults reported a relative increase in HbF of 4-20% and a relative reduction in crisis rates by 40-84%. Hospital admissions declined by 18-32%.
Effectiveness: Data is limited. It seems to be highly effective but is currently underestimated.
Short-Term Harms (within 6 mo): Dose-related leukopenia, thrombocytopenia, anemia, and decreased reticulocyte count. Others include decreased sperm production and dry skin.
Long-Term Harms: Birth defects in offspring of people receiving the drug, growth delays in children receiving the drug, and cancer in both children and adults who receive the drug.
Autoimmune Hemolytic Anemia

Table 14. Classification of AIHA

<table>
<thead>
<tr>
<th>Warm (75-90% cases)</th>
<th>Cold</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibody Allotype</td>
<td>IgG</td>
</tr>
<tr>
<td>Agglutination</td>
<td>37ºC</td>
</tr>
<tr>
<td>Temperature</td>
<td></td>
</tr>
<tr>
<td>Direct Coombs Test</td>
<td>Positive for IgG ± complement</td>
</tr>
<tr>
<td>(direct anti-globulin test)</td>
<td></td>
</tr>
<tr>
<td>Etiology</td>
<td>Idiopathic</td>
</tr>
<tr>
<td></td>
<td>Secondary to lymphoproliferative disorder (e.g. CLL, Hodgkin lymphoma)</td>
</tr>
<tr>
<td>Blood Film</td>
<td>Spherocytes</td>
</tr>
<tr>
<td>Management</td>
<td>Treat underlying cause</td>
</tr>
<tr>
<td></td>
<td>Corticosteroids</td>
</tr>
<tr>
<td></td>
<td>Immunosuppression</td>
</tr>
<tr>
<td></td>
<td>Splenectomy</td>
</tr>
<tr>
<td></td>
<td>Folic acid</td>
</tr>
<tr>
<td></td>
<td>Rituximab (2nd line to steroids)</td>
</tr>
</tbody>
</table>

Microangiopathic Hemolytic Anemia/Thrombotic Microangiopathy

Definition
- hemolytic anemia due to intravascular fragmentation of RBCs

Etiology
- see Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome, H30
- see Disseminated Intravascular Coagulation, H32
- eclampsia, HELLP syndrome, AFLP (see Obstetrics, OB25)
- malignant hypertension
- vasculitis
- malfunctioning heart valves
- metastatic carcinoma
- drugs (calcineurin inhibitors, quinine, simvastatin)
- infections (severe CMV or meningococcus)
- catastrophic antiphospholipid antibody syndrome

Investigations
- blood film: evidence of hemolysis, schistocytes
- hemolytic workup
- urine: hemosiderinuria, hemoglobinuria

Hereditary Spherocytosis

- most common type of hereditary hemolytic anemia
- abnormality in RBC membrane proteins (e.g. spectrin)
  - spleen makes defective RBCs more spherocytotic (and more fragile) by membrane removal; also acts as site of RBC destruction
  - autosomal dominant with variable penetrance

Investigations
- blood film (shows spherocytes), osmotic fragility (increased), molecular analysis for spectrin gene

Treatment
- in severe cases, splenectomy and vaccination against pneumococcus, meningococcus, and H. influenza b (avoid in early childhood)
Hereditary Elliptocytosis

Definition/Etiology
- abnormality in spectrin interaction with other membrane proteins
- autosomal dominant
- 25-75% elliptocytes
- hemolysis is usually mild

Treatment
- immunizations; splenectomy for severe hemolysis

Glucose-6-Phosphate Dehydrogenase Deficiency

Definition
- deficiency in glucose-6-phosphate dehydrogenase (G6PD), corresponding to a lack of reduced glutathione (GSH) and leading to RBC sensitivity due to oxidative stress

Pathophysiology
- X-linked recessive, prevalent in individuals of African, Asian, and Mediterranean descent

Clinical Features
- frequently presents as episodic hemolysis precipitated by:
  - oxidative stress
  - drugs (e.g. sulfonamide, antimalarials, nitrofurantoin)
  - infection
  - food (fava beans)
- in neonates: can present as prolonged, pathologic neonatal jaundice

Investigations
- neonatal screening
- G6PD assay (may not be useful if result is normal)
  - should not be done in acute crisis when reticulocyte count is high (reticulocytes have high G6PD levels)
- blood film
  - Heinz bodies (granules in RBCs due to oxidized Hb); passage through spleen results in the generation of bite cells
  - may have features of intravascular hemolysis (e.g. RBC fragments)

Treatment
- folic acid
- stop offending drugs and avoid triggers
- transfusion in severe cases

Macrocytic Anemia

- MCV >100 fl.
- see Figure 2, Approach to Anemia, H6

Table 15. Comparison Between Megaloblastic and Non-Megaloblastic Macrocytic Anemia

<table>
<thead>
<tr>
<th></th>
<th>Megaloblastic</th>
<th>Non-Megaloblastic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphology</td>
<td>Large, oval, nucleated RBC precursor</td>
<td>Large round RBC</td>
</tr>
<tr>
<td></td>
<td>Hypersegmented neutrophils</td>
<td>Normal neutrophils</td>
</tr>
<tr>
<td>Pathophysiology</td>
<td>Failure of DNA synthesis resulting in asynchronous</td>
<td>Reflects membrane abnormality with abnormal</td>
</tr>
<tr>
<td></td>
<td>maturation of RBC nucleus and cytoplasm</td>
<td>cholesterol metabolism</td>
</tr>
</tbody>
</table>

Causes of Macrocytic Anemia
- ABCDEF
  - Alcoholism (liver disease)
  - B- deficiency
  - Compensatory reticulocytosis
  - Drugs (cytotoxic, AZT)/Dysplasia
  - Endocrine (hypothyroidism)
  - Folate deficiency/Fetus (pregnancy)

Characteristics of Megaloblastic Macrocytic Anemia
- Pancytopenia
- Hypersegmented neutrophils
- Megaloblastic bone marrow
## Vitamin B12 Deficiency

B12 (cobalamin) see *Family Medicine – Nutrition, FM6*
- binds to intrinsic factor (IF) secreted by gastric parietal cells
- absorbed in terminal ileum
- total body stores sufficient for 3-4 yr

### Etiology

**Table 16. Etiology of Vitamin B12 Deficiency**

<table>
<thead>
<tr>
<th>Diet</th>
<th>Gastric</th>
<th>Intestinal Absorption</th>
<th>Genetic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strict vegan</td>
<td>Mucosal atrophy</td>
<td>Malabsorption</td>
<td>Transcobalamin II deficiency</td>
</tr>
<tr>
<td>More likely to present in pediatric population</td>
<td>Gastritis, autoimmune</td>
<td>Crohn's, celiac sprue, pancreatic insufficiency, H. pylori</td>
<td>IF receptor defect</td>
</tr>
<tr>
<td>Vegetarian in pregnancy</td>
<td>Pernicious anemia (see below)</td>
<td>Stagnant bowel</td>
<td></td>
</tr>
<tr>
<td>Malnutrition</td>
<td>Post-gastrectomy</td>
<td>Fish tapeworm</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Resection of ileum</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drugs</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neomycin, biguanides, PPI, N/L anesthesia, metformin</td>
<td></td>
</tr>
</tbody>
</table>

### Pathophysiology of Pernicious Anemia

- auto-antibodies produced against gastric parietal cells leading to achlorhydria and lack of intrinsic factor secretion
- intrinsic factor is required to stabilize B12 as it passes through the bowel
- decreased intrinsic factor leads to decreased ileal absorption of B12
- may be associated with other autoimmune disorders (polyglandular endocrine insufficiency)
- most common in Northern European Caucasians, usually >30 yr old (median age of 60 yr old)

### Clinical Features

- neurological (severity of anemia and neurological sequelae depends on deficiency)
  - peripheral neuropathy (variable reversibility)
  - usually symmetrical, affecting lower limbs more than upper limbs
  - cord (irreversible damage)
- subacute combined degeneration
  - posterior columns: decreased vibration sense, proprioception, and 2-point discrimination, parasthesia
  - pyramidal tracts: spastic weakness, ataxia
- cerebral (common, reversible with B12 therapy)
- confusion, delirium, dementia
- cranial nerves (rare)
- optic atrophy

### Investigations

- CBC, reticulocyte count
  - anemia often severe ± neutropenia ± thrombocytopenia
  - MCV >110 fL
  - low reticulocyte count relative to the degree of anemia (<2%)
- serum B12 and RBC folate
  - caution: low serum B12 leads to low RBC folate because of failure of folate polyglutamate synthesis in the absence of B12
  - alternatively, can measure elevated urine metabolites (methylmalonate, homocysteine)
- blood film
  - oval macrocytes, hypersegmented neutrophils
- bone marrow
  - hypercellularity
  - nuclear-cytoplasmic asynchrony in RBC precursors (less mature nuclei than expected from the development of the cytoplasm)
- bilirubin and LDH
  - elevated unconjugated bilirubin and LDH due to breakdown of cells in BM
- Schilling test (radiolabeled B12 test, rarely done) to distinguish pernicious anemia from other causes
  - anti-intrinsic factor antibody, anti-parietal cell antibody

### Treatment

- vitamin B12 1,000 µg IM or 1,000-2,000 µg PO if intestinal absorption intact, route and duration depends on cause
- less frequent, higher doses may be as effective (e.g. 1,000 µg IM q3mo)
- watch for hypokalemia and rebound thrombocytosis when treating severe megaloblastic anemia

### Oral Vitamin B12 vs. Intramuscular Vitamin B12 for Vitamin B12 Deficiency

**Cochrane DB Syst Rev 2005;2:CD004655**

**Study:** Systematic review; 2 RCTs met inclusion criteria; total 108 patients with follow-up from 90-4 mo.

**Intervention:** One study evaluated 1,000 µg of oral B12 compared to 1,000 µg IM B12 on the same dosing schedule. The other compared 2,000 µg daily oral B12 to 1,000 µg IM B12 on a less frequent dosing schedule. Neurological and hematological endpoint rates were evaluated.

**Results:** Meta-analysis was not attempted due to study heterogeneity. Both studies reported improvements in hematological and neurological end-points in both oral and IM groups. No significant difference was observed between groups in either study.

**Conclusions:** Limited data suggests high dose oral vitamin B12 (1,000-2,000 µg) is equivalent to IM vitamin B12 on the same or less frequent dosing schedule. This data is limited by small sample sizes and short follow-up periods. However, it suggests that a 3 to 4 month trial of oral supplementation is a reasonable first choice for patients with B12 deficiency.

### Schilling Test

**Part 1**

- Tracer dose (1 µg) of radiolabeled B12, given PO
- Flush through dose (1 mg) of unlabeled B12 IM 1 h later to saturate tissue binders of B12 thus allowing radioactive B12 to be excreted in urine
- 24 h urine radiolabeled B12 measured
- Normal ≤ 5% excretion (a normal excretion will only be seen if the low B12 was due to dietary deficiency)

**Part 2**

- Same as part 1, but radiolabeled B12 given with oral intrinsic factor
- Should be done only if first stage shows reduced excretion
- Normal test result (= 5% excretion) = pernicious anemia
- Abnormal test result (< 5% excretion) = intestinal causes (malabsorption)
Folate Deficiency

• uncommon in developed countries due to extensive dietary supplementation (enriched in flour)
• folate stores are depleted in 3-6 mo
• folate commonly found in green, leafy vegetables and fortified cereals

Etiology

Table 17. Etiology of Folate Deficiency

<table>
<thead>
<tr>
<th>Diet/Deficiency</th>
<th>Malabsorption</th>
<th>Drugs</th>
<th>Increased Demand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcoholism</td>
<td>Malabsorption</td>
<td>Anti-folates (methotrexate)</td>
<td>Pregnancy</td>
</tr>
<tr>
<td>Substance abuse</td>
<td>Celiac sprue</td>
<td>Anticonvulsants (phenytoin)</td>
<td>Hemolysis</td>
</tr>
<tr>
<td>Elderly/infants</td>
<td>IBD</td>
<td>Alcohol</td>
<td>Prematurity</td>
</tr>
<tr>
<td>Poor intake</td>
<td>Infiltrative bowel disease</td>
<td>Oral contraceptive</td>
<td>Exfoliative dermatitis/psoriasis</td>
</tr>
<tr>
<td></td>
<td>Short bowel syndrome</td>
<td></td>
<td>Hemodialysis</td>
</tr>
</tbody>
</table>

Clinical Features

• anemia, mild jaundice, glossitis, diarrhea, confusion, pallor
• unlike B₁₂ deficiency, folate deficiency has no neurologic manifestations
• consider social history, alcohol/drug abuse, very poor diet (e.g. elderly, depressed)

Investigations

• similar to B₁₂ deficiency (CBC, reticulocytes, blood film, RBC folate, serum B₁₂)
• if decreased RBC folate, rule out B₁₂ deficiency as cause

Management

• folic acid 1-5 mg PO OD x 1-4 mo; then 1 mg PO OD maintenance if cause is not reversible

Hemostasis

Stages of Hemostasis

1. Primary Hemostasis

• cellular defense – involves the platelet and VWF predominantly
• goal is rapid cessation of bleeding; main effect is on mucocutaneous bleeding
• vessel injury results in collagen/subendothelial matrix exposure and release of vasoconstrictors
• blood flow is impeded and platelets come into contact with damaged vessel wall (Figure 11a)
  • adhesion: platelets adhere to subendothelium via Von Willebrand factor (VWF)
  • activation: platelets are activated resulting in change of shape and release of ADP and thromboxane A₂
  • aggregation: these factors further recruit and aggregate more platelets resulting in formation of localized hemostatic plug

2. Secondary Hemostasis

• platelet plug is reinforced by production of fibrin clot (Figure 11b)
• extrinsic (initiation) pathway: initiation of coagulation in vivo
• intrinsic (amplification) pathway: amplification once coagulation has started via positive feedback
• both intrinsic and extrinsic pathways converge onto the common pathway which results in thrombin generation and fibrin formation

3. Fibrin Stabilization

• conversion from soluble to insoluble and stable clot

4. Fibrinolysis

• once healing initiated, clot dissolution via action of the fibrinolytic system
Table 18. Commonly Used Tests of Hemostasis

<table>
<thead>
<tr>
<th>Type of Hemostasis</th>
<th>Test</th>
<th>Reference Range</th>
<th>Purpose</th>
<th>Examples of Associated Diagnoses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary</td>
<td>Platelet count</td>
<td>150-400 x 10^9/L</td>
<td>To quantitate platelet number</td>
<td>Low in ITP, HUS/ITP, DIC</td>
</tr>
<tr>
<td>Secondary</td>
<td>aPTT</td>
<td>22-35 s</td>
<td>Measures intrinsic pathway (factors VIII, IX, XII) and common pathway</td>
<td>Prolonged in hemophilias A and B (if factor deficiency is below reagent threshold of detection)</td>
</tr>
<tr>
<td></td>
<td>PT</td>
<td>11-24 s</td>
<td>Measures extrinsic pathway (factor VII) and common pathway</td>
<td>Prolonged in vitamin K deficiency, vitamin K antagonist therapy (warfarin), factor VII deficiency</td>
</tr>
<tr>
<td></td>
<td>INR</td>
<td>0.9-1.2</td>
<td>Used to monitor warfarin therapy and for assessment of hepatic function</td>
<td>Normalization of clotting time if deficiency of single clotting factor (normalization may not occur if multiple clotting factors are deficient)</td>
</tr>
<tr>
<td></td>
<td>Mixing studies</td>
<td></td>
<td>May differentiate inhibitors of clotting factor(s) from a deficiency in clotting factors</td>
<td>Lack of normalization if inhibitor presence</td>
</tr>
</tbody>
</table>

**Fibrinolysis**

- **Euglobulin lysis time**
  - N > 90 min
  - Looks for accelerated fibrinolysis
  - May be accelerated in DIC or factor XIII deficiency
  - Decreased in hereditary deficiency of fibrinogen

**Other**

- **Fibrinogen**
- **D-dimer**
- **Specific factor assays (e.g. factor VIII)**
- **Lupus anticoagulant**
- **Thrombophilia tests (e.g. activated protein C resistance)**
- **Von Willebrand tests (VWF antigen, Ristocetin cofactor activity, factor VIII)**

Table 19. General Rules of Thumb: Signs and Symptoms of Disorders of Hemostasis

<table>
<thead>
<tr>
<th>Primary (Platelet, VWF)</th>
<th>Secondary (Coagulation)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Surface Cuts</strong></td>
<td>Excessive, prolonged bleeding</td>
</tr>
<tr>
<td><strong>Onset After Injury</strong></td>
<td>Immediate</td>
</tr>
<tr>
<td><strong>Site of Bleeding</strong></td>
<td>Superficial i.e. mucosal (nasal, gingival, GI tract, vaginal), skin</td>
</tr>
<tr>
<td><strong>Lesions</strong></td>
<td>Petechiae, ecchymoses</td>
</tr>
</tbody>
</table>
Table 20. Lab Values in Disorders of Hemostasis

<table>
<thead>
<tr>
<th></th>
<th>PT</th>
<th>PTT</th>
<th>Platelet Count</th>
<th>Hemoglobin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemophilia A/B</td>
<td>N</td>
<td>↑</td>
<td>N</td>
<td>N*</td>
</tr>
<tr>
<td>VWD</td>
<td>N</td>
<td>±</td>
<td>N/↓</td>
<td>N*</td>
</tr>
<tr>
<td>DIC</td>
<td>↑</td>
<td>↑</td>
<td>N/↑</td>
<td>N/↓</td>
</tr>
<tr>
<td>Liver Failure</td>
<td>↑</td>
<td></td>
<td>N/↑</td>
<td>N</td>
</tr>
<tr>
<td>ITP</td>
<td>N</td>
<td>N</td>
<td>↓</td>
<td>N</td>
</tr>
<tr>
<td>TTP</td>
<td>N</td>
<td>N</td>
<td>↓</td>
<td>L</td>
</tr>
</tbody>
</table>

DIC = disseminated intravascular coagulation; ITP = idiopathic thrombocytopenic purpura; TTP = thrombotic thrombocytopenic purpura; VWD = von Willebrand disease; * = anemia may develop from progressive iron deficiency and/or active bleeding.

Disorders of Primary Hemostasis

Definition

- inability to form an adequate platelet plug due to
  - disorders of blood vessels
  - disorders of platelets: abnormal function/numbers
  - disorders of VWF

Classification

![Figure 13. Approach to disorders of primary hemostasis](image)

Immune Thrombocytopenia

Table 21. Features for Childhood vs. Adult Immune Thrombocytopenia

<table>
<thead>
<tr>
<th>Features</th>
<th>Childhood ITP, see Pediatrics, P66</th>
<th>Adult ITP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peak Age</td>
<td>2-6 yr</td>
<td>20-40 yr</td>
</tr>
<tr>
<td>Gender</td>
<td>None</td>
<td>F &gt; M (3:1)</td>
</tr>
<tr>
<td>History of Recent Infection</td>
<td>Common</td>
<td>Rare</td>
</tr>
<tr>
<td>Onset of Bleed</td>
<td>Abrupt</td>
<td>Insidious</td>
</tr>
<tr>
<td>Duration</td>
<td>Usually wk</td>
<td>Months to yr</td>
</tr>
<tr>
<td>Spontaneous Remissions</td>
<td>80% or more</td>
<td>Uncommon</td>
</tr>
</tbody>
</table>

Terminology of ITP

- primary: isolated thrombocytopenia (platelet count <100x10⁹/L) with no other cause of thrombocytopenia
- secondary: thrombocytopenia associated with another condition (e.g. HIV, HCV, SLE, CLL)
- drug-induced: drug-dependent platelet antibodies causing platelet destruction
Classification of primary ITP
- acute: newly diagnosed (diagnosis to 3 mo)
- persistent: 3-12 mo from diagnosis
- chronic: >12 mo
- refractory: post-splenectomy

Pathophysiology
- primary or secondary ITP
- an acquired immune-mediated disorder (pathophysiology incompletely understood)
  - anti-platelet antibodies bind to platelet surface → increased splenic clearance
  - impaired platelet production
  - helper T-cell and cytotoxic T-cell activation also implicated in platelet destruction
- Direct effect of HIV on marrow
- Immune-mediated platelet destruction
- Some anti-retrovirals reduce platelet production

Clinical Presentation
- variable presentation: asymptomatic, fatigue, minimal bruising, mucocutaneous bleed, intracranial bleed
- assess for symptoms/signs suggesting a secondary cause

Investigations
- CBC and reticulocyte count: thrombocytopenia
- PT and aPTT: normal
- peripheral blood film: decreased platelets, giant platelets (rule out platelet clumping)
- HIV, HCV, H. pylori serology
- vitamin B12, ANA, C3, C4, depending on clinical symptoms
- bone marrow aspirate and biopsy: increased number of megakaryocytes
  - recommended in patients >60 yr of age, pre-splenectomy or have failed traditional ITP therapy, those with systemic symptoms, an abnormal blood film
  - bone marrow aspirate and biopsy should be considered if there is any suspicion of diminished bone marrow function (e.g. myelodysplasia, infiltration)

Treatment
- rarely indicated if platelets >30 x 10^9/L unless active bleeding, trauma, or surgery
- emergency treatment (active bleeding [CNS, GI, or GU] or in need of emergency surgery)
  - general measures: stop drugs that reduce platelet function, control blood pressure, minimize trauma
  - corticosteroids: prednisone (1 mg/kg) or dexamethasone (40 mg PO x 4 d)
  - antifibrinolytic: tranexamic acid (1 g PO tid or 1 g IV q6h) if mucosal bleeding
  - IVlg 1 g/kg/d x 2 doses
  - platelet transfusion: for refractory, major bleeding or need for urgent surgery (expect that platelet recovery will be diminished)
  - emergency splenectomy: may be considered, vaccinations prior if possible (pneumococcus, meningococcus, H. influenzae b)
  - management of intracranial bleeding: IV steroids, IVlg, platelets
- non-urgent treatment (platelet count <20-30 x 10^9/L and no bleeding)
  - 1st line
    - corticosteroids (dexamethasone 40 mg qd x 4 days x 1-4 cycles (not weeks) or prednisone x 3 weeks then taper)
    - IVlg
  - anti-D: appropriate for Rh+ non-splenectomized patients, but can cause hemolysis (avoid if low Hb at baseline or if DAT is positive)
  - 2nd line
    - splenectomy (need vaccinations prior to splenectomy: pneumococcus, meningococcus, H. influenzae b)
    - rituximab
  - 3nd line
    - thrombopoietin (TPO) receptor agonists (romiplostim, eltrombopag) – may be considered for second line therapy if funding available
    - immunomodulating therapy (azathioprine, cyclophosphamide, danazol, vincristine)

Definitions of response to treatment
- complete response: platelet >100
- partial response: platelet 30-100
- no response: platelet <30

Prognosis
- ~20% will not attain a hemostatic platelet count after first and second line therapy
- fluctuating course
- overall relatively benign, life-expectancy similar to general population (however, risk of mortality from bleeding/infection increases with advancing age)
- major concern is spontaneous intracranial hemorrhage if platelet <5 x 10^9/L, more common in the elderly
Table 22. Heparin-Induced Thrombocytopenia (HIT)

Pathophysiology

Immune mediated
Ab recognizes a complex of heparin and platelet factor 4 (PF4) leading to platelet activation via platelet Fc receptor and activation of coagulation system

Diagnosis

Suspected with intermediate or high probability HIT Score (Table 23)
Confirm with ELISA testing and SRA testing

Onset of Decreased Platelets

5-15 d (if previously exposed to heparin within 100 d, HIT can develop in hours due to an anamnestic response)

Risk of Thrombosis

~30% to 50% (25% of events are arterial)

Clinical Features

Bleeding complications uncommon
Venous thrombosis: DVT, PE, limb gangrene, cerebral sinus thrombosis
Arterial thrombosis: MI, stroke, acute limb ischemia, organ infarct (mesentery, kidney)
Heparin-induced skin necrosis (with LMWH)
Acute platelet activation syndromes: acute inflammatory reactions (e.g. fever/chills, flushing, etc.)
Transient global amnesia (rare)

Specific Tests

Re-test clinical scoring models can help rule-out HIT: 4-Ts (see Table 23) and the HIT Expert Probability (HEP) score
14C serotonin release assay (uses donor platelets with 14C serotonin and heparin with patient’s plasma)
ELISA for HIT-Ig (more sensitive, less specific than serotonin assay)
Ultrasound of lower limb veins for DVT

Management

Clinical suspicion of HIT should prompt discontinuation of heparin and LWMH (specific tests take several days)
Initiate anticoagulation with a non-heparin anticoagulant:
e.g. argatroban, danaparoid, fondaparinux, bivalirudin unless there is a strong contraindication
duration of treatment at least 2-3 mo if no thrombotic event, and at least 3-6 mo if thrombotic event has occurred
Warfarin should only be restarted when platelet count >150 x 10^9/L
Allergy band and alert in patient records

Table 23. The 4-T Pre-Test Clinical Scoring Model for HIT

<table>
<thead>
<tr>
<th>Category</th>
<th>2 Points</th>
<th>1 Point</th>
<th>0 Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Thrombocytopenia</td>
<td>Platelet count fall &gt;50% AND platelet nadir &gt;20 x 10^9/L</td>
<td>Platelet count fall 30-50% OR platelet nadir 10-19 x 10^9/L</td>
<td>Platelet count fall &lt;30% OR platelet nadir &lt;10 x 10^9/L</td>
</tr>
<tr>
<td>2. Timing of Platelet Count Fall</td>
<td>Clear onset between 5-10 d of heparin exposure OR platelet count fall at ≤1 d if prior heparin exposure within last 30 d</td>
<td>Consistent with fall in platelet count at 5-10 d but unclear (e.g. missing platelet counts) OR onset after day 10 OR fall ≤1 d with prior heparin exposure within 30-100 d</td>
<td>Platelet count fall after &lt;4 d of heparin exposure, and no recent heparin</td>
</tr>
<tr>
<td>3. Thrombosis or Other Sequelae</td>
<td>Confirmed new thrombosis, skin necrosis, or acute systemic reaction after IV unfractionated heparin bolus</td>
<td>Progressive or recurrent thrombosis, non-necrotizing (erythematous) skin lesions, or suspected thrombosis that has not been proven</td>
<td>None</td>
</tr>
<tr>
<td>4. Other Causes for Thrombocytopenia</td>
<td>None apparent</td>
<td>Possible</td>
<td>Definite</td>
</tr>
</tbody>
</table>

6-8 points = high probability of HIT; 4-5 points = intermediate probability of HIT; 0-3 points = low probability of HIT
J Thromb Haemos 2006;4:759-765
Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome

Table 24. TTP and HUS

<table>
<thead>
<tr>
<th></th>
<th>TTP</th>
<th>HUS (see Pediatrics, P76)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Epidemiology</strong></td>
<td>Predominantly adult</td>
<td>Predominantly children and elderly</td>
</tr>
<tr>
<td><strong>Etiology</strong></td>
<td>Deficiency of metalloproteinase that breaks down ultra-large VWF multimers: ADAMTS13</td>
<td>Shiga toxin (E. coli serotype 0157:H7) in 90% Other bacteria, viruses, genetic causes, drugs</td>
</tr>
<tr>
<td><strong>Clinical Features</strong></td>
<td>1. Thrombocytopenia</td>
<td>1. Severe thrombocytopenia</td>
</tr>
<tr>
<td></td>
<td>2. MAHA/TMA</td>
<td>2. MAHA/TMA</td>
</tr>
<tr>
<td></td>
<td>4. Symptoms can be mild and non-specific</td>
<td>4. Bloody Diarrhea</td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td>CBC and blood film: decreased platelets and schistocytes</td>
<td>5. GI prodrome</td>
</tr>
<tr>
<td></td>
<td>PT, aPTT, fibrinogen: normal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Markers of hemolysis: increased unconjugated bilirubin, increased LDH, decreased haptoglobin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Creatinine, urea, to follow renal function</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ADAMTS-13 gene, activity or inhibitor testing (TTP)</td>
<td></td>
</tr>
<tr>
<td><strong>Management</strong></td>
<td>Medical emergency</td>
<td>Supportive therapy (fluids, RBC transfusion, nutrition, etc.)</td>
</tr>
<tr>
<td></td>
<td>Plasma exchange ± steroids</td>
<td>Some evidence for plasma exchange</td>
</tr>
<tr>
<td></td>
<td>Platelet transfusion avoided unless life-threatening bleed (associated with microvascular thrombosis)</td>
<td>Possible role of Eculizumab (C5 antibody blocks complement activation) for neurologic symptoms</td>
</tr>
<tr>
<td></td>
<td>Plasma infusion if platelets complex with Factor VIII</td>
<td></td>
</tr>
<tr>
<td>Note: atypical HUS is a complex disease with different etiology, treatment depends on genetic abnormalities</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Von Willebrand Disease

Pathophysiology
- most common inherited bleeding disorder (prevalence of 1%)
- usually autosomal dominant (type 3 is autosomal recessive)
- women more commonly diagnosed (heavy menstrual bleeding, peripartum bleeding)
- qualitative defect or quantitative deficiency of VWF depending on type
  - VWF needed for platelet adhesion/aggregation and acts as chaperone for Factor VIII (extending its half-life in circulation), therefore abnormality of VWF can affect both primary and secondary hemostasis
  - VWF exists as a series of multimers ranging in size
    - largest multimers are most active in mediation of platelet adhesion/aggregation
    - both large and small multimers complex with Factor VIII
    - VWF levels vary according to blood group (non-group O patients have higher levels than group O patients)

Classification
- type 1: mild quantitative defect (decreased amount of VWF and proportional decrease in VWF activity) – 80% of cases
- type 2: qualitative defect (VWF activity disproportionally lower than quantity) – 20% of cases
- type 3: severe total quantitative defect (virtually no VWF produced), 1 per million

Clinical Features
- bleeding history is the single most important predictor of an underlying bleeding disorder
- validated, standardized bleeding assessment tools (e.g. ISTH-BAT) to facilitate exploration of the bleeding history
- mucocutaneous bleeding (easy bruising, epistaxis, heavy menstrual bleeding, peripartum bleeding, post-dental extraction bleeding, post-operative bleeding, gastrointestinal bleeding)
  - type 3 VWD patients can experience musculoskeletal bleeding due to significant deficiency in FVIII due to lack of FVIII chaperoning as VWF is absent

Investigations
- CBC, platelet, VWF:Antigen (determine how much VWF is present), VWF:Ristocetin cofactor activity (determine how well VWF bind to platelet), Factor VIII (determine how well VWF chaperon with FVIII), PTT
- tests to further categorize type/subtype of VWD: multimer analysis, ristocetin induced platelet agglutination, genetic studies
Table 25. Investigations in VWD

<table>
<thead>
<tr>
<th>Test</th>
<th>Expected Result</th>
<th>Test</th>
<th>Expected Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTT</td>
<td>N/L</td>
<td>von Willebrand antigen</td>
<td>↓</td>
</tr>
<tr>
<td>Factor VIII</td>
<td>N/L</td>
<td>Blood group</td>
<td>Affects antigen quantification (↓ in group O)</td>
</tr>
<tr>
<td>Plt Count</td>
<td>N/L</td>
<td>vWF multimer analysis</td>
<td>Multimer variants</td>
</tr>
<tr>
<td>Ristocetin Activity</td>
<td>↓ (cofactor for vWF-Plt binding)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Treatment**

- desmopressin (DDAVP®) is effective treatment for 85-90% of patients with type 1 VWD and for some subtypes of type 2 VWD
  - causes release of VWF and Factor VIII from endothelial cells
  - variable efficacy depending on disease type; tachyphylaxis occurs after 4 consecutive doses
  - need to document responsiveness with “DDAVP challenge”
  - caution in children due to hyponatremia
- tranexamic acid (Cyklokapron®, antifibrinolytic) to stabilize clot formation
- VWF:FVIII concentrate (Humate P®, Wilate®) if DDAVP unresponsive/clinically ineffective or for severe bleeding episode
  - need to monitor VWF and factor VIII levels (very high factor VIII level can be prothrombotic)
- gynecologic focused care for heavy menstrual bleeding (NB estrogens have the added benefit of increasing VWF levels)

**Prognosis**

- patients with mild type 1 VWD have auto-correction of VWF deficiency in pregnancy
- patients are best managed by a hematologist, ideally one who works in a Hemophilia Treatment Centre (HTC)

---

**Disorders of Secondary Hemostasis**

**Definition**

- inability to form an adequate fibrin clot
  - disorders of clotting factors or co-factors
  - disorders of proteins associated with fibrinolysis
- characterized by delayed bleeding, deep muscular bleeding, spontaneous hemarthroses

**Table 26. Classification of Secondary Hemostasis Disorders**

<table>
<thead>
<tr>
<th>Hereditary</th>
<th>Acquired</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor VIII: Hemophilia A, VWD</td>
<td>Liver disease</td>
</tr>
<tr>
<td>Factor IX: Hemophilia B (Christmas Disease)</td>
<td>DIC</td>
</tr>
<tr>
<td>Factor XI</td>
<td>Vitamin K deficiency</td>
</tr>
<tr>
<td>Other factor deficiencies are rare</td>
<td>Acquired inhibitors (FVIII most common)</td>
</tr>
</tbody>
</table>

**Hemophilia A (Factor VIII Deficiency)**

**Pathophysiology**

- X-linked recessive, 1/5,000 males
- mild (>5% of normal factor level), moderate (1-5%), severe (<1%)

**Clinical Features**

- see Table 19 – Signs and Symptoms of Disorders of Hemostasis, H26
- older patients may also have HIV or HCV from contaminated blood products

**Investigations**

- prolonged aPTT, normal INR (PT)
- decreased Factor VIII (<40% of normal)

**Treatment**

- desmopressin (DDAVP®) in mild hemophilia A
- Factor VIII concentrate for:
  - prophylaxis
  - on-demand (i.e. to treat a bleed)
- anti-fibrinolytic agents (e.g. tranexamic acid)

**Hemophilia B (Factor IX Deficiency)**

- X-linked recessive, 1/30,000 males; approximately half have severe disease (factor IX activity <1% of normal)
- clinical and laboratory features identical to hemophilia A (except decreased Factor IX)
- treatment: Factor IX concentrate (prophylaxis or on-demand), anti-fibrinolytic agents
**Factor XI Deficiency**

- autosomal recessive; more common in Ashkenazi Jewish population
- usually mild, often diagnosed in adulthood
- Factor XI level does not correlate with bleeding risk – risk of bleeding correlates with a previous history or family history of bleeding
- treatment: antifibrinolytic agents, frozen plasma, Factor XI concentrate

**Liver Disease**

- see Gastroenterology, G32

**Pathophysiology**

- deficient synthesis of all factors except VIII (also made in endothelium)
- aberrant or diminished synthesis of fibrinogen (factor I)
- diminished synthesis of natural anticoagulants and altered regulation of fibrinolysis

**Investigations**

- peripheral blood film: target cells
- primary hemostasis affected
  - thrombocytopenia 2º to hypersplenism, nutritional deficiency, direct bone marrow toxicity related to alcohol, diminished production from chronic viral infections (e.g. HCV), decreased production of thrombopoietin
- secondary hemostasis affected
  - elevated INR (PT), aPTT and TT, low fibrinogen in end-stage liver disease

**Treatment**

- supportive, treat liver disease, blood products if active bleeding (frozen plasma, platelets, cryoprecipitate)

**Vitamin K Deficiency**

**Etiology**

- drugs
  - vitamin K antagonist (e.g. Warfarin) – diminished production of functional Factors II, VII, IX, X, proteins C and S
  - antibiotics eradicating gut flora, altering vitamin K uptake
- poor diet (especially in alcoholics) e.g. prolonged fasting or starvation
- biliary obstruction
- chronic liver disease (decreased stores)
- fat malabsorption (e.g. celiac disease, disorders of bile or pancreatic secretion, intestinal disease, CF)
- hemorrhagic disease of newborn, see Pediatrics, P46

**Investigations**

- INR (PT) is elevated out of proportion to elevation of the aPTT
- decreased Factors II, VII, IX, X (vitamin K-dependent)

**Treatment**

- hold anticoagulant if vitamin K antagonist on board
- vitamin K PO if no active bleeding
- if bleeding, give vitamin K 10 mg IV (reversal may take up to 12 hrs)
- if life-threatening bleeding and vitamin K antagonist used, give prothrombin complex concentrate (PCC) or FP if PCC contraindicated
  - PCCs are contraindicated if there is a previous history of HIT (heparin is within the PCC product)

**Disseminated Intravascular Coagulation**

**Definition**

- excessive, dysregulated release of plasmin and thrombin leading to intravascular coagulation and depletion of platelets, coagulation factors and fibrinogen
- risk of life-threatening hemorrhage or thromboembolism

**Etiology**

- occurs as a complication of many other severe medical, surgical or obstetrical conditions
- widespread endothelial damage and extensive inflammatory cytokine release

**Factor Levels in Acquired Coagulopathies**

<table>
<thead>
<tr>
<th>Factor</th>
<th>Liver Disease</th>
<th>Vitamin K Def</th>
<th>DIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>V</td>
<td>↓</td>
<td>N</td>
<td>↓</td>
</tr>
<tr>
<td>VII</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>VIII</td>
<td>N/↑</td>
<td>N</td>
<td>↓</td>
</tr>
</tbody>
</table>
Table 27. Etiology of DIC

<table>
<thead>
<tr>
<th>Activation of Procoagulant Activity</th>
<th>Endothelial Injury</th>
<th>Reticuloendothelial Injury</th>
<th>Vascular Stasis</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiphospholipid antibody syndrome (APS)</td>
<td>Infections/sepsis</td>
<td>Liver disease</td>
<td>Hypotension</td>
<td>Acute hypoxia/acidosis (check lactate)</td>
</tr>
<tr>
<td>Intravascular hemolysis</td>
<td>Vasculitis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incompatible blood, malaria</td>
<td>Metastatic adenocarcinoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tissue injury</td>
<td>Aortic aneurysm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obstetric complications, trauma, burns, crush injuries</td>
<td>Giant hemangioma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignancy</td>
<td>Snake venom, fat embolism, heat stroke</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solid tumours, hematologic malignancies (especially APML)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Clinical Features
- presence of both hemorrhage and clotting

Table 28. Clinical Features of DIC

<table>
<thead>
<tr>
<th>Signs of Microvascular Thrombosis</th>
<th>Signs of Hemorrhagic Diathesis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurological: multifocal infarcts, delirium, coma, seizures</td>
<td>Bleeding from any site in the body (2&quot; to decreased platelets and clotting factors)</td>
</tr>
<tr>
<td>Skin: focal ischemia, superficial gangrene</td>
<td>Neurologic: intracranial bleeding</td>
</tr>
<tr>
<td>Renal: oliguria, azotemia, cortical necrosis</td>
<td>Skin: petechiae, ecchymosis, oozing from puncture sites</td>
</tr>
<tr>
<td>Pulmonary: ARDS</td>
<td>Renal: hematuria</td>
</tr>
<tr>
<td>GI: acute ulceration</td>
<td>Mucosal: gingival oozing, epistaxis, massive bleeding</td>
</tr>
<tr>
<td>RBC: microangiopathic hemolysis</td>
<td></td>
</tr>
</tbody>
</table>

Investigations
- primary hemostasis: decreased platelets
- secondary hemostasis: prolonged INR (PT), aPTT, TT, decreased fibrinogen and other factors
- fibrinolysis: increased FDPs or D-dimers, short euglobulin lysis time (i.e. accelerated fibrinolysis)
- extent of fibrin deposition: urine output, RBC fragmentation

Treatment
- recognize early and treat underlying disorder - supportive measures: hemodynamic and/or ventilator support, aggressive hydration, RBC transfusion if severe bleed
- in hemorrhage: replacement of hemostatic elements with platelet transfusion, frozen plasma, cryoprecipitate
  - British Hematology Guidelines:
    - maintain platelets >50 x10^9, hemoglobin >80 g/L, calcium between 2.2-2.7 mmol/L, and avoid hypothermia
    - 4-5 units of FP if INR >1.5 or aPTT >38
    - 10 units of cryoprecipitate if fibrinogen <1 g/L
    - 1 adult dose of buffy-coat platelets if <10 x10^9 (<20 if febrile, <50 before invasive procedure)
- in thrombotic phase: UFH or LMWH in critically ill, non-bleeding patients

Table 29. Screening Test Abnormalities in Coagulopathies

<table>
<thead>
<tr>
<th>Increased INR Only</th>
<th>Increased PTT Only</th>
<th>Both Increased</th>
</tr>
</thead>
<tbody>
<tr>
<td>Warfarin</td>
<td>Hemophilia A and B</td>
<td>Prothrombin deficiency</td>
</tr>
<tr>
<td>Vitamin K deficiency</td>
<td>Heparin</td>
<td>Severe fibrinogen deficiency</td>
</tr>
<tr>
<td>Factor VII deficiency</td>
<td>Antiphospholipid Ab</td>
<td>Factor V and X deficiency</td>
</tr>
<tr>
<td>Liver disease</td>
<td>Intrinsic factor inhibitors (e.g. FVIII)</td>
<td>Severe liver disease</td>
</tr>
<tr>
<td>Factor VII inhibitors</td>
<td>Factor XI and XII deficiency</td>
<td>Factor V and X, prothrombin, and fibrinogen inhibitors</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Excessive anticoagulation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Severe vitamin K deficiency</td>
</tr>
</tbody>
</table>

Hypercoagulable Disorders

Hypercoagulability Workup – Venous Thrombosis
- work up for malignancy is suggested in the event of abnormal blood work, constitutional symptoms or physical exam suggestive of cancer
- work up for hypercoagulable state is controversial and should only be done if it will alter treatment decisions
- recommendations for a hypercoagulable work up include:
  - patients with recurrent or multiple thrombosis only if it will change management plans
  - warfarin-induced skin necrosis or neonatal purpura fulminans (protein C or S deficiency)
  - consider for patients with a family history of VTE who are considering OCP use
  - consider for patients who present with thrombosis at an unusual venous site only if it will change management plans
- arterial thrombotic events have only been proven to be associated with APLA, HIT, JAK2 MPNs, and PNH
• work up
  ■ initial
    ◆ CBC, blood smear, coagulation studies, liver/renal function, urinalysis, hemolysis markers (if anemic)
    ◆ malignancy history, age appropriate cancer screening (see sidebar)
    ◆ serology: antiphospholipid antibodies (APLA)
  ■ post-treatment (or ≥6 weeks, as protein levels depleted/consumed by clot)
    ◆ antithrombin (not on heparin)
    ◆ proteins C, S (not on warfarin)
• note: most of these tests do not change management, and a negative test does not rule out a hypercoagulable state
  ◆ thus more focus on the reversible/treatable causes (APLA, cancer, etc.)

SELECTED CAUSES OF HYPERCOAGULABILITY LEADING TO VENOUS THROMBOEMBOLISM

Activated Protein C Resistance (Factor V Leiden)
• most common cause of hereditary thrombophilia
  • 3-7% of European Caucasian population are heterozygotes
  • point mutation in the Factor V gene (R506Q) results in resistance to inactivation of Factor Va by activated protein C

Prothrombin Gene Mutation (PT) G20210A
• 1-3% of European Caucasian population are heterozygotes
  • G to A transposition at nucleotide position 20210 of the prothrombin gene promoter region results in increased levels of prothrombin, thus increased thrombin generation

Protein C and Protein S Deficiency
• protein C inactivates Factor Va and VIIIa using protein S as a cofactor
• protein C deficiency
  ◆ homozygous or compound heterozygous: neonatal purpura fulminans
  ◆ heterozygous
    ■ type I: decreased protein C levels
    ■ type II: decreased protein C activity
  • acquired: liver disease, sepsis, DIC, warfarin, certain chemotherapeutic agents
  • 1/3 of patients with warfarin necrosis have underlying protein C deficiency
• protein S deficiency
  ◆ type I: decreased free and total protein S levels
  ◆ type II: decreased protein S activity
  ◆ type III: decreased free protein S levels
  • acquired: liver disease, DIC, pregnancy, nephrotic syndrome, inflammatory conditions, warfarin

Antithrombin Deficiency
• antithrombin slowly inactivates thrombin in the absence of heparin, rapidly inactivates thrombin in the presence of heparin
• autosomal dominant inheritance, urinary losses in nephrotic syndrome, or reduced synthesis in liver disease
• diagnosis must be made outside window of acute thrombosis and anticoagulation treatment (acute thrombosis, heparin, systemic disease all decrease antithrombin levels)
• deficiency may result in resistance to unfractionated heparin (LMWH may be considered, with monitoring of anti-Xa levels)
  ◆ heparin resistance: suspect if >35,000 units of UFH required during 24 hour use

Elevated Factor VIII Levels
• an independent marker of increased incident and recurrent thrombotic risk, but levels can also be increased in numerous states as an acute phase reactant, therefore its clinical use is controversial

Congenital Dysfibrinogenemia
• may predispose to thromboembolic disease, bleeding or both

Disorders of Fibrinolysis
• includes congenital plasminogen deficiency, tissue plasminogen activator deficiency, although association with VTE risk is not clear

Antiphospholipid Antibody Syndrome (APS)
• definition: ≥1 clinical and ≥1 laboratory criteria
  ◆ clinical: thrombosis, recurrent (>3) early pregnancy losses <10 weeks, one late fetal loss ≥10 weeks (morphologically normal), or premature birth before 34 wk due to (pre)eclampsia or placental insufficiency
  ◆ laboratory (must be confirmed on two occasions, tested ≥12 wks apart): antiphospholipid antibodies, anti-β2 glycoprotein-I antibody, lupus anticoagulant

Common Causes of Hypercoagulability

- Protein C deficiency
- Antithrombin deficiency
- Malignancy
- Antiphospholipid antibodies
- Prothrombin G20210A
- Increased Factor VIII (Eight)
- Protein S deficiency

Causes of Both Venous and Arterial Thrombosis include:
- Antiphospholipid antibodies
- Myeloproliferative neoplasms
- Heparin-induced thrombocytopenia
- Distal venous clot with patent foramen ovale
- Paroxysmal nocturnal hemoglobinuria

Malignancy is a common cause of acquired hypercoagulability

Work up should include:
- Complete history and physical
- Routine blood work
- Urinalysis
- CXR
- Age appropriate screening: mammogram, Pap, PSA, colonoscopy
- Close follow-up
- No benefit with CT imaging

Although lupus anticoagulant prolongs PTT, this is a misnomer, as its main clinical feature is thrombosis
Venous Thromboembolism

Definition
- thrombus formation and subsequent inflammatory response in a superficial or deep vein
- superficial thrombophlebitis, deep vein thrombosis (DVT), and pulmonary embolism (PE)
- thrombi propagate in the direction of blood flow (commonly originating in calf veins)
- more common in lower extremity than upper extremity
- incidence ~1% if age >60 yr
- most important sequelae are pulmonary embolism (~50% chance with proximal DVT) and chronic venous insufficiency

Etiology (Virchow’s Triad)
- endothelial damage
  - exposes endothelium to prompt hemostasis
  - leads to decreased inhibition of coagulation and local fibrinolysis
- venous stasis
  - immobilization (post-MI, CHE, stroke, post-operative) inhibits clearance and dilution of coagulation factors
- hypercoagulability
  - inherited (see Hypercoagulable Disorders, H33)
  - acquired
    - age (risk increases with age)
    - surgery (especially orthopedic, thoracic, GI, and GU)
    - trauma (especially fractures of spine, pelvis, femur or tibia, spinal cord injury)
    - neoplasms (especially lung, pancreas, colon, rectum, kidney, and prostate)
    - blood dyscrasias (myeloproliferative neoplasms, especially PV, ET), PNH, hyperviscosity (multiple myeloma, polycythemia, leukemia, sickle cell disease)
    - prolonged immobilization (CHF, stroke, MI, leg injury)
    - hormone related (pregnancy, OCP, HRT, SERMs)
    - APS
    - heart failure (risk of DVT greatest with right heart failure and peripheral edema)
    - idiopathic (10-20% are later found to have cancer)

Clinical Features of DVT
- absence of physical findings does not rule out disease
- unilateral leg edema, erythema, warmth, and tenderness purple-blue
- palpable cord (thrombosed vein)
- phlegmasia alba dolens (white appearance) and phlegmasia cerula dolens (acute pain and edema) with massive thrombosis
- Homans’ sign (pain with foot dorsiflexion) is unreliable

Differential Diagnosis of DVT
- muscle strain or tear, lymphangitis or lymph obstruction, venous valvular insufficiency, ruptured popliteal cysts, cellulitis, arterial occlusive disease

Investigations for DVT
- D-dimer test only useful to rule out DVT if negative with low clinical suspicion of disease and no other acute medical issues
- doppler ultrasound is most useful diagnostic test for DVT
  - sensitivity and specificity for proximal DVT ~95%
  - sensitivity for calf DVT ~70%
- other non-invasive tests include MRI and impedance plethysmography
- venography is the gold standard, but is expensive, invasive, and higher risk
- CTPA or V/Q scan if PE suspected

Post-Thrombotic Syndrome
- development of chronic venous stasis signs and symptoms secondary to a deep venous thrombosis
- symptoms: pain, venous dilatation, edema, pigmentation, skin changes, venous ulcers
- clinical severity can be estimated based on the Villalta score
- large impact on quality of life following a DVT
- treatment: extremity elevation, exercise, continuous compression stockings, intermittent pneumatic compression therapy, skin/ulcer care
- for clinical features and treatment of PE, see Respiratology, R18

Risk of VTE in Hospitalized Patients Receiving Ineffective Antithrombotic Therapy

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>RR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt;75 yr</td>
<td>1.79 (1.18-2.71)</td>
<td>0.007</td>
</tr>
<tr>
<td>Cancer</td>
<td>1.58 (1.01-2.51)</td>
<td>0.08</td>
</tr>
<tr>
<td>Previous VTE</td>
<td>1.67 (1.01-2.77)</td>
<td>0.08</td>
</tr>
<tr>
<td>Obesity</td>
<td>0.94 (0.59-1.51)</td>
<td>0.91</td>
</tr>
<tr>
<td>Hormone therapy</td>
<td>0.61 (0.08-3.38)</td>
<td>0.70</td>
</tr>
<tr>
<td>Acute infectious disease</td>
<td>1.50 (1.00-2.26)</td>
<td>0.06</td>
</tr>
<tr>
<td>Acute respiratory disease</td>
<td>1.45 (0.04-2.50)</td>
<td>0.27</td>
</tr>
</tbody>
</table>

Source: JAMA 2004;291:963-968

Venous Thromboembolism in Patients with Cancer

Methods: Patients with cancer who had acute, symptomatic proximal DVT, PE, or both were randomly assigned to either dalteparin or coumarin treatment for 6 mo.

Results: 27 of 338 patients in the dalteparin group had recurrent VTE versus 53 of 338 patients in the coumarin group (hazard ratio, 1.48; p = 0.002). The probability of recurrent thromboembolism at 6 mo was 9% and 17% in dalteparin and coumarin groups respectively. There was no significant difference in bleeding rates. The mortality rate was 39% in the dalteparin group and 41% in the coumarin group.

Conclusions: In patients with cancer and acute VTE, dalteparin was more effective than coumarin in decreasing the risk of recurrent thromboembolism without increasing the risk of bleeding.

Wells’ Score for DVT
Criteria (Score)
- Paralysis, paresis, or recent orthopedic casting of lower extremity (1)
- Recently bedridden (>3 d) or major surgery within past 4 wk (1)
- Localized tenderness in deep vein system (1)
- Swelling of entire leg (1)
- Calf swelling >3 cm than other leg (measured 10 cm below the tibial tuberosity) (1)
- Pitting edema greater in the symptomatic leg (1)
- Collateral venous collateral superficial veins (1)
- Active cancer or cancer treated within 6 mo (1)
- Alternative diagnosis more likely than DVT (e.g. Baker’s cyst, cellulitis, muscle damage, superficial venous thrombosis) (-2)

Total Score Interpretation
3-8: High probability, 1-2: Moderate probability, 0-2: Low probability

Low-Molecular-Weight Heparin vs. Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer

Methods: RCT comparing the efficacy of LMWH (dalteparin) with an oral anti-coagulant agent (coumarin) in preventing recurrent thrombosis in patients with cancer.

Results: 27 of 338 patients in the dalteparin group had recurrent VTE versus 53 of 338 patients in the coumarin group (hazard ratio, 1.48; p = 0.002). The probability of recurrent thromboembolism at 6 mo was 9% and 17% in dalteparin and coumarin groups respectively. There was no significant difference in bleeding rates. The mortality rate was 39% in the dalteparin group and 41% in the coumarin group. 

Conclusions: In patients with cancer and acute VTE, dalteparin was more effective than coumarin in decreasing the risk of recurrent thromboembolism without increasing the risk of bleeding.
Approach to Treatment of Venous Thromboembolism

Purpose
- prevent further clot extension (3 mo duration is optimal)
- prevent acute pulmonary embolism (occurs in up to 50% of untreated patients)
- reduce the risk of recurrent thrombosis (duration depends on presence of other risk factors)
- treatment of massive iliofemoral thrombosis with acute lower limb ischemia and/or venous gangrene (phlegmasia cerulea dolens)
- limit development of late complications (e.g. postphlebitic syndrome, chronic venous insufficiency, and chronic thromboembolic pulmonary HTN)

Initial Treatment
- low molecular weight heparin (LMWH)
  - administered SC, at least as effective as UFH with a lower bleeding risk
  - advantages: predictable dose response and fixed dosing schedule; lab monitoring not required; <1% HIT; safe and effective outpatient therapy
  - disadvantages: only partially reversible by protamine, long-term use associated with osteoporosis
  - Costly!
  - relapsed cleared – must adjust dose in patients with renal dysfunction
- unfractionated heparin (UFH)
  - in patient with average risk bleed; use hospital-based nomograms that use bleeding risk and patient weight to determine appropriate dose
  - advantages: rapidly reversible by protamine
  - disadvantages: must monitor aPTT or heparin levels with adjustment of dose to reach therapeutic level (~2x normal value); monitor platelet counts for development of HIT
- alternatives to LMWH and UFH
  - direct thrombin inhibitors (hirudin, lepirudin, argatroban), direct factor Xa inhibitors (apixaban, rivaroxaban)
  - thrombolytic drugs (e.g. streptokinase, tPA) reserved for acute limb/life-threatening thrombosis, and low bleeding risk

Long-Term Treatment
- anticoagulant therapy
  - warfarin
    - standard treatment; should be initiated with heparin overlap; dual therapy for at least 48 hours with INR > 2, due to initial prothrombotic state secondary to warfarin’s inhibition of natural anticoagulants protein C/S, half life of vitamin K factors and risk of warfarin-induced skin necrosis
    - INR: warfarin dosed to maintain INR at 2-3, monitor twice weekly for 1-2wk. Discontinue heparin after INR>2.0 for 2 consecutive days
    - direct oral anticoagulants (DOACs)
      - apixaban or rivaroxaban; with no laboratory monitoring required, patients with CrCl > 50 ml/ min
    - dabigatran (factor IIa inhibitor): LMWH or IV heparin for at least 5-10 days before initiating dabigatran, patients with CrCl >30 ml/min
    - important drug interactions to consider for DOACs (no relevant food interactions however)
  - cancer patients: LMWH more effective than warfarin at preventing recurrence of venous thrombosis in cancer patients
- duration of anticoagulant treatment
  - provoked VTE with transient risk factor: 3 mo
  - provoked VTE with ongoing risk factor: consider indefinite therapy with annual reassessment
  - first unprovoked VTE: at least 3mo, subsequent reassessment
  - unprovoked proximal DVT or PE: consider indefinite therapy with annual reassessment
  - second unprovoked VTE: consider indefinite therapy
  - cancer-associated DVT: at least 3 mo, longer if continued evidence of cancer
- IVC filters
  - temporary filter indicated only if acute DVT (<4 wk) with significant contraindications to anticoagulant therapy (i.e. active bleeding) or if require interruption of anticoagulation (i.e. for urgent surgery)
  - must be retrieved once safe to do so as filter is pro-thrombotic in the long-term (consider anticoagulation if not retrieved)
- special considerations
  - pregnancy: treat with LMWH during pregnancy, then LMWH or warfarin for 6 wk post-partum (minimum total anticoagulation time of 3-6 mo, but must include 6 wks post-partum, as this is a high risk period); avoid warfarin in pregnancy due to teratogenicity
  - surgery: avoid elective surgery in the first three months after a venous thromboembolic event
    - pre-operatively: IV heparin may be used up to 4-6 h pre-operatively
    - perioperatively: warfarin or DOACs discontinued for at least 3-5 d pre-operatively (consider mechanism of drug clearance)
    - surgery safe when INR <1.5 off of warfarin, normal PT/TT on dabigatran, drug-specific Xa level at zero for apixaban/ rivaroxaban/LMWH, normal PT on IV unfractionated heparin

Duration of Treatment with Vitamin K Antagonists in Symptomatic Venous Thromboembolism

Cochrane DB Syst Rev 2009:CD001367
Study: Meta-analysis of 8 RCTs (2,994 patients) comparing different durations of treatment with vitamin K antagonists in patients with symptomatic VTE.
Results: In patients treated with vitamin K antagonists for a prolonged period, the reduction in risk of recurrent VTE remained consistent regardless of the period of time since the index event (OR 0.18; 95% CI 0.13-0.26). In addition, there was no observed excess of VTE recurrences following cessation of prolonged treatment (i.e. rebound phenomenon) (OR 1.24; 95% CI 0.91-1.69). However, patients who received prolonged treatment had a persistent increase in their risk of major bleeding complications (OR 2.61; 95% CI 1.40-4.61).
Conclusion: Prolonged treatment with vitamin K antagonists leads to a consistent reduction in the risk of recurrent VTE for as long as therapy is continued. Therapy should be discontinued when the risk of harm from major bleeding (which remains constant over time) is of greater concern than the absolute risk of recurrent VTE (which decreases over time). No specific recommendation was made regarding optimal duration of treatment.

Common Medications that Interact with Warfarin
- Acetaminophen (interference with vitamin K metabolism)
- Alopurinol
- NSAIDs (GI injury)
- Fluoroquinolones
- Metronidazole
- Sulfamethoxazole
- Tamoxifen

Initiation of Warfarin Therapy Requires Bridging with Heparin Therapy for 4-5 Days
- 10 mg loading dose (for example) of warfarin causes a precipitous decline in protein C levels in first 36 h resulting in a transient hypercoagulable state
- Warfarin decreases Factor VII levels in first 48 h, INR is prolonged (most sensitive to Factor VII levels), however full antithrombotic effect is not achieved until Factor IX, X, and II are sufficiently reduced (occurs after ~4 d)

Low Risk Surgical Patients
- <40 yr, no risk factors for VTE, general anesthetic (GA) <30 min, minor elective, abdominal, or thoracic surgery

Moderate Risk Surgical Patients
- >40 yr, >1 risk factor for VTE, GA >30 min

High Risk Surgical Patients
- >40 yr, surgery for malignancy or lower extremity orthopedic surgery lasting >30 min, inhibitor deficiency, or other risk factor

High Risk Medical Patients
- Heart failure, severe respiratory disease, ischemic stroke and lower limb paralysis, confined to bed and tube
Post-operatively: IV heparin, LMWH, DOAC can be used for anticoagulation (consult with surgeon prior to re-initiation).

For patients at high risk for thromboembolism (VTE <12 wk, recurrent VTE, antiphospholipid antibody syndrome, atrial fibrillation with prior stroke, mechanical heart valve), IV heparin or LMWH (bridging) should be given before and after the procedure while the INR is below 2.0.

**Prophylaxis**
- See sidebar.
- Consider for those with a moderate to high risk of thrombosis without contraindications.
- Non-pharmacological measures include: early ambulation, elastic compression stockings (TEDs), intermittent pneumatic compression (IPC).
- UFH 5,000 IU SC bid, UFH 5,000 IU SC tid or LMWH as per hospital protocol (e.g. enoxaparin 40 mg SC daily, dalteparin 5000 U SC qid), DOACs for orthopedic surgery thromboprophylaxis.

**Contraindications and Adverse Reactions of Anticoagulant Therapy**
- Absolute: active bleeding, severe bleeding diathesis, or platelets <20 x 10^9/L (<20,000/mm³).
- Intracranial bleeding.
- Neurosurgery or ocular surgery within <10 d.
- Relative: mild-moderate neurologic diathesis or thrombocytopenia, brain metastases, recent major trauma, major abdominal surgery within past 2 d, GI/GU bleed within 14 d, endocarditis, severe HTN (sBP >200 or dBP >120), recent stroke.

**Table 30. Contraindications of Anticoagulant Therapy**

<table>
<thead>
<tr>
<th>Absolute Contraindications to Treatment</th>
<th>Relative Contraindications to Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active bleeding</td>
<td>Mild-moderate bleeding diathesis or thrombocytopenia</td>
</tr>
<tr>
<td>Severe bleeding diathesis or platelet count &lt;20 x 10^9/L (&lt;20,000/mm³)</td>
<td>Brain metastases</td>
</tr>
<tr>
<td>Intracranial bleeding</td>
<td>Recent major trauma</td>
</tr>
<tr>
<td>Neurosurgery or ocular surgery within 10 d</td>
<td>Recent stroke</td>
</tr>
<tr>
<td></td>
<td>Major abdominal surgery within past 2 d</td>
</tr>
<tr>
<td></td>
<td>GI/GU bleeding within 1-4 d</td>
</tr>
<tr>
<td></td>
<td>Endocarditis</td>
</tr>
<tr>
<td></td>
<td>Severe hypertension (sBP &gt;200 or dBP &gt;120)</td>
</tr>
</tbody>
</table>

**Treatment of Pulmonary Embolism**
- See Respirology: R18.

---

**Hematologic Malignancies and Related Disorders**

### Leukemia
- ALL
- CLL
- AML
- MDS
- Myelodysplasia

### Lymphoma
- Hodgkin
- Non-Hodgkin
- T Cell
- B Cell
- Other cell origin (e.g. NK)

### Plasma Cell Dyscrasias
- Multiple myeloma
- MGUS
- Waldenstrom’s macroglobulinemia

**Figure 14. Overview of hematologic malignancies and related disorders**

---

**Myeloid Malignancies**

### Acute Myeloid Leukemia

**Definition**
- Rapidly progressive malignancy characterized by failure of myeloid cells to differentiate beyond blast stage.

**Epidemiology**
- Incidence increases with age; median age of onset is 65 yr old; 80% of acute adult leukemias.
- Accounts for 10-15% of childhood leukemias.

---

**2009 WHO Classification of AML and Related Neoplasms**
- AML with recurrent genetic abnormalities.
- AML with myelodysplasia-related changes.
- Therapy-related myeloid neoplasms.
- Myelodysplasia.
- Myeloid proliferations related to Down syndrome.
- Blastic plasmacytoid dendritic cell neoplasm.
- AML, not otherwise specified (equivalent FAB classification).
- Undifferentiated (M1).
- Myeloblastic (M2).
- Promyelocytic (M3).
- Myelomonocytic (M4).
- Monocytic (M5).
- Erythroleukemic (M6).
- Megakaryocytic (M7).
- Acute basophilic leukemia.
- Acute panmyelosis with myelofibrosis.

---

**Acute Leukemia**

**Definition (WHO):** presence of 20% blast cells or greater in bone marrow at presentation.

**Classification:** divided into myeloid (AML) and lymphoid (ALL) depending on whether blasts are myeloblasts or lymphoblasts, respectively.

---

**Typical Age of Presentation of Leukemias**
- ALL: Children and older adults
- CML: 40-60 yr
- AML, CLL: >60 yr

---

**Leukemia:** malignant cells arise in bone marrow and may spread elsewhere (including blood, lymph nodes, and lymphoid tissue).

**Lymphoma:** malignant cells arise in lymph nodes and lymphoid tissues and may spread elsewhere (including blood and bone marrow).

**But** the location where the malignant cells are found does not solely define the type of hematologic malignancy – classified based on the characteristics of the cell (histology, histochemistry, immunophenotyping, cytogenetics, molecular changes).

---

**Myeloid proliferations related to Down syndrome:**
- Blastic plasmacytoid dendritic cell neoplasm.
- AML, not otherwise specified (equivalent FAB classification).
- Undifferentiated (M1).
- Myeloblastic (M2).
- Promyelocytic (M3).
- Myelomonocytic (M4).
- Monocytic (M5).
- Erythroleukemic (M6).
- Megakaryocytic (M7).
- Acute basophilic leukemia.
- Acute panmyelosis with myelofibrosis.

---

**Auer rods are pathognomonic for AML.**
Risk Factors
- myelodysplastic syndromes (MDS), benzene, radiation, Down Syndrome, alkylating agents as treatment for previous malignancy

Pathophysiology
- etiology subdivided into
  - primary: de novo
  - secondary: hematologic malignancies (e.g. myeloproliferative disorders and MDS) or previous chemotherapeutic agents (e.g. alkylating agents)
- uncontrolled growth of blasts in marrow leads to
  - suppression of normal hematopoietic cells
  - appearance of blasts in peripheral blood – risk of leukostasis
  - accumulation of blasts in other sites (e.g. skin, gums)
  - metabolic consequences; tumour lysis syndrome

Clinical Features
- anemia, thrombocytopenia (associated with DIC in promyelocytic leukemia), neutropenia (even with normal WBC), leads to infections, fever
- accumulation of blast cells in marrow
  - skeletal pain, bony tenderness (especially sternum)
  - organ infiltration
  - gingival hypertrophy (particularly myelomonocytic leukemia) – may present to dentist first
  - hepatosplenomegaly (in ALL)
  - lymphadenopathy (not marked in ALL)
  - gonads (in ALL)
  - skin: leukemia cutis or myeloid sarcoma
  - eyes: hemorrhages and/or whitish plaques, Roth spots, cotton wool spots, vision changes (uncommon)
- leukostasis/hyperleukocytosis syndrome (medical emergency)
  - large numbers of blasts interfere with circulation and lead to hypoxia and hemorrhage – can cause diffuse pulmonary infiltrates, CNS bleeding, respiratory distress, altered mental status, priapism
  - associated with AML more than ALL
- metabolic effects; aggravated by treatment (rare)
  - increased uric acid → nephropathy, gout
  - release of phosphate → decreased Ca++, decreased Mg++
  - release of procoagulants → DIC (higher risk in acute promyelocytic leukemia)
- decreased or normal K+ before treatment, increased K+ after treatment (from lysed cells)

Investigations
- blood work
  - CBC: anemia, thrombocytopenia, variable WBC
  - INR, aPTT, fibrin degradation products (FDP), fibrinogen (in case of DIC)
  - increased LDH, increased uric acid, increased PO4- (released by leukemic blasts), decreased Ca++, decreased K+
  - baseline renal and liver function tests
- peripheral blood film – circulating blasts with Auer rods (azurophilic granules) are pathognomonic for AML
- bone marrow aspirate for definitive diagnosis
  - blast count: AML >20% (normal is <5%)
  - morphologic, cytochemical, and/or immunotypic features are used to establish lineage and maturation (see sidebar for WHO classification of AML, H37)
- CXR to rule out pneumonia, ECG, MUGA scan prior to chemotherapy (cardiotoxic)

Treatment
- mainstay of treatment is chemotherapy (rapidly fatal without treatment)
- all AML subtypes are treated similarly, except acute promyelocytic leukemia (APL) with t(15:17) translocation
- all-trans-retinoic acid (ATRA) added to induce differentiation; arsenic trioxide + ATRA combination therapy for APL is non-inferior to traditional chemotherapy
- treatment strategy
  1. Induction: chemotherapy to induce complete remission of AML (see sidebar)
     - several possible regimens (e.g. cytarabine with anthracycline [daunorubicin])
     - patients with poor response to initial induction therapy – worse prognosis
     - must ensure reversal of DIC, platelet transfusions if <10
  2. Consolidation: to prevent recurrence
     - intensive consolidation chemotherapy
     - stem cell transplantation – autologous or allogeneic (younger patients with better performance status)
- consider acceleration with hematopoietic growth factors (e.g. G-CSF) if severe infection develops

Cure: survival that parallels age-matched population
Complete Remission: tumour load below threshold of detectable disease (normal peripheral blood film, normal bone marrow with <5% blasts, normal clinical state)
• supportive care
  ■ screening for infection via regular C&S of urine, stool, sputum, oropharynx, catheter sites, perianal area
  ■ fever: C&S of all orifices, CXR, start antibiotics
  ■ platelet and RBC transfusions (irradiated to prevent transfusion-related GVHD) ± EPO
  ■ prevention and treatment of metabolic abnormalities
  ■ allopurinol, rasburicase for prevention of hyperuricemia

Prognosis
• achievement of first remission
  ■ 70-80% if ≤60 yr old, 50% if >60 yr old
  ■ median survival 12-24 mo
  ■ prognosis is most related to 1) cytogenetics; classified as favourable, intermediate, or adverse and 2) molecular studies (i.e. NPM1+/FLT3- mutations)
• prognosis depends on cytogenetics, age, performance status, prior cytotoxic agents or radiation therapy

Myelodysplastic Syndromes

Definition
• heterogeneous group of malignant stem cell disorders characterized by dysplastic and ineffective blood cell production resulting in peripheral cytopenias, and a variable risk of transformation to acute leukemias
• syndromes defined according to World Health Organization (WHO) classifications (see sidebar)

Pathophysiology
• disordered maturation: ineffective hematopoiesis despite presence of adequate numbers of progenitor cells in bone marrow (usually hypercellular); formed elements sometimes exhibit qualitative functional defects
• intramedullary apoptosis: programmed cell death within bone marrow
• both processes lead to reduced mature cells in periphery
• <30% develop AML

Risk Factors
• elderly, post-chemotherapy, exposures (benzene, tobacco, radiation), inherited genetic abnormalities
• occurs in 4/100,000 patients >60 yr old

Clinical Features
• insidious onset; associated with pancytopenia; most patients asymptomatic at diagnosis
• infections and bleeding out of proportion with peripheral blood counts

Investigations
• diagnosed by
  ■ anemia ± thrombocytopenia ± neutropenia
  ■ CBC and peripheral blood film
  ■ RBC: usually macrocytic with oval shaped red cells (macro-ovalocytes), decreased reticulocyte count
  ■ WBC: decreased granulocytes and abnormal morphology (e.g. bi-lobed or unsegmented nuclei = Pelger abnormality)
  ■ platelets: thrombocytopenia, abnormalities of size and cytoplasm (e.g. giant hypogranular platelets)
• bone marrow aspirate and biopsy with cytogenetic analysis required for definitive diagnosis
• bone marrow: dysplastic and often normocellular/hypercellular
cytogenetics: high risk include partial or total loss of chromosomes 5, 7, and complex (>3 abnormalities)

Treatment
• low risk of transformation to acute leukemia (IPSS-R Very Low or Low)
  ■ erythropoietin stimulating agents weekly is first line in reducing transfusion requirements (EPO level must be <500)
  ■ if 5q deletion based on cytogenetics: lenalidomide PO
  ■ supportive care: RBC and platelet transfusion (consider iron chelation if frequent RBC transfusions)
• high risk of transformation to acute leukemia (IPSS-R Intermediate, High or Very High)
  ■ supportive care
  ■ stem cell transplantation if age <65 yr
  ■ epigenetic therapy: DNA methyltransferase inhibitors (e.g. 5-azacytidine), histone deacetylase inhibitors

Prognosis
• Revised International Prognostic Scoring System (IPSS-R) uses 5 factors to estimate mean survival:
  ■ cytology: % bone marrow blasts, hemoglobin, platelets, absolute neutrophil count
  ■ based on the calculated score, a patient’s MDS prognostic risk is “Very Low”, “Low”, “Intermediate”, “High”, or “Very High” with a mean survival of 8.7, 5.3, 3.0, 1.6, and 0.8 yr, respectively
**Myeloproliferative Neoplasms**

**Definition**
- clonal myeloid stem cell abnormalities leading to overproduction of one or more cell lines (leading to abnormalities in erythrocytes, platelets, and other cells of myeloid lineage)

**Epidemiology**
- mainly middle-aged and older patients (peak 60-80 yr)

**Prognosis**
- may develop marrow fibrosis with time
- all disorders may progress to AML

### Table 31. Chronic Myeloproliferative Disorders

<table>
<thead>
<tr>
<th></th>
<th>CML</th>
<th>PV</th>
<th>IMF</th>
<th>ET</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hct</td>
<td>↓/N</td>
<td>↑↑</td>
<td>↓</td>
<td>N</td>
</tr>
<tr>
<td>WBC</td>
<td>↑↑</td>
<td>↑</td>
<td>↑/↓</td>
<td>N</td>
</tr>
<tr>
<td>Plt</td>
<td>↑/↓</td>
<td>↑</td>
<td>↑/↓</td>
<td>↑↑</td>
</tr>
<tr>
<td>Marrow Fibrosis</td>
<td>±</td>
<td>±</td>
<td>+++</td>
<td>±</td>
</tr>
<tr>
<td>Splenomegaly</td>
<td>+++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Hepatomegaly</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>–</td>
</tr>
<tr>
<td>Genetic Association</td>
<td>bcr-abl mut. (95+%)</td>
<td>JAK2 mut. (96%)</td>
<td>JAK2 mut. (~50%)</td>
<td>CALR mut (~30%)</td>
</tr>
</tbody>
</table>

**Chronic Myeloid Leukemia**

**Definition**
- myeloproliferative disorder characterized by increased proliferation of the granulocytic cell line without the loss of their capacity to differentiate

**Epidemiology**
- occurs in any age group (mostly middle age to elderly) with a median age of 65 yr

**Pathophysiology**
- Philadelphia chromosome (Ph)
  - translocation between chromosomes 9 and 22
  - the c-abl proto-oncogene is translocated from chromosome 9 to “breakpoint cluster region” (bcr) of chromosome 22 to produce bcr-abl fusion gene, an active tyrosine kinase

**Clinical Features**
- 3 clinical phases
  - **chronic phase**: 85% diagnosed here
    - few blasts (<10%) in peripheral film
    - ± slightly elevated eosinophils and basophils
    - no significant symptoms
  - **accelerated phase**: impaired neutrophil differentiation
    - circulating blasts (10-19%) with increasing peripheral basophils (pruritus)
    - CBC: thrombocytopenia <100 x 10^9/L
    - cytogenetic evidence of clonal evolution
    - worsening constitutional symptoms and splenomegaly (extramedullary hematopoiesis)
  - **blast crisis**: more aggressive course, blasts fail to differentiate
    - blasts (>20%) in peripheral blood or bone marrow; reflective of acute leukemia (1/3 ALL, 2/3 AML)
- clinical presentation
  - 20-50% of patients are asymptomatic when diagnosed (incidental lab finding)
  - nonspecific symptoms
    - fatigue, weight loss, malaise, excessive sweating, fever
  - secondary to splenic involvement
    - early satiety, LUQ pain/fullness, shoulder tip pain (referred)
    - splenomegaly (most common physical finding)
  - anemia
  - bleeding: secondary to platelet dysfunction
    - pruritus, PUD: secondary to increased blood histamine
    - leukostasis, priapism, encephalopathy (rare): secondary to very elevated WBC (rare)

**Investigations**
- elevated WBC, decreased/normal RBC, increased/decreased platelets, increased basophils
- WBC differential shows a bimodal distribution, with predominance of myelocytes and neutrophils
• peripheral blood film
  ■ leukoerythroblastic picture (immature red cells and granulocytes present, e.g. myelocytes and normoblasts)
  ■ presence of different mid-stage progenitor cells differentiates it from AML
• bone marrow
  ■ myeloid hyperplasia with left shift, increased megakaryocytes, mild fibrosis
  ■ molecular and cytogenetic studies of bone marrow or peripheral blood for Philadelphia chromosome
• abdominal imaging for spleen size

**Treatment**

- **symptomatic**
  - allopurinol and antihistamines
- **chronic phase**
  - imatinib mesylate inhibits proliferation and induces apoptosis by inhibiting tyrosine kinase activity in cells positive for bcr-abl
  - if loss of response or intolerance (~40%), trial of 2nd generation TKIs: dasatinib or nilotinib
  - dasatinib and nilotinib may also be considered for first line management
  - interferon-a: may improve response to tyrosine kinase inhibitors; typically now only used for pregnant patients
  - hydroxyurea in palliative setting to reduce WBC
- **accelerated phase or blast phase**
  - refer for clinical trial or 2nd/3rd generation TKI and prepare for allogeneic stem cell transplant patients, in blast phase typically get standard AML induction
  - stem cell transplantation may be curative: to be considered in young patients who do not meet therapeutic milestones
  - treatment success is monitored based on therapeutic milestones
    - hematologic: improved WBC and platelet counts, reduced basophils
    - cytogenetic: undetectable Philadelphia-chromosome in the bone marrow
    - molecular: reduction/absence of bcr-abl transcripts in periphery and marrow

**Prognosis**

- survival dependent on response
  - those achieving complete cytogenetic response (CCR) on imatinib by 18 mo of therapy: 6 yr overall survival >90%
  - those who do NOT achieve CCR on imatinib: 6 yr overall survival of 66%
- acute phase (blast crisis – usually within 3-5 yr)
  - 2/3 develop a picture similar to AML
  - unresponsive to remission induction
  - 1/3 develop a picture similar to ALL
  - remission induction (return to chronic phase) achievable

---

**Polycythemia Vera**

**Definition**

- stem cell disorder characterized by elevated RBC mass (erythrocytosis) ± increased white cell and platelet production
- diagnosis (WHO 2008) requires either both major criteria plus one minor criteria OR the first major criterion plus 2 minor criteria
  - **Major Criteria**
    1. hemoglobin >185 g/L in men, >165 g/L in women or other evidence of increased red cell volume
    2. presence of JAK2 V617F or other functionally similar mutation such as JAK2 exon 12 mutation
  - **Minor Criteria**
    1. bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) with prominent erythroid, granulocytic, and megakaryocytic proliferation
    2. serum erythropoietin level below the reference range for normal
    3. endogenous erythroid colony formation in vitro

**Clinical Features**

- symptoms are secondary to high red cell mass and hyperviscosity (see *Erythrocytosis, H6*)
- thrombotic complications: DVT, PE, Budd-Chiari (hepatic vein thrombosis), portal vein thrombosis, thrombopilebitis, increased incidence of stroke, MI
  - due to increased blood viscosity, increased platelet number and/or activity
  - bleeding complications: epistaxis, gingival bleeding, ecchymoses, and GI bleeding
  - if high platelet counts with associated acquired vWD
- erythromelalgia (burning pain in hands and feet and erythema of the skin)
  - associated with platelets >400 x 10^9/L
  - pathognomonic microvascular thrombotic complication in PV and ET
- pruritus, especially after warm bath or shower (40%)
  - due to cutaneous mast cell degranulation and histamine release
- epigastric distress, PUD
  - due to increased histamine from tissue basophils, alterations in gastric mucosal blood flow due to increased blood viscosity

---

**Erythromelalgia** is a pathognomonic microvascular thrombotic complication in PV and ET

**Cardiovascular Events and Intensity of Treatment in Polycythemia Vera**

*NEJM* 2013;369:22-33

**Study:** Prospective, RCT, mean follow-up of 28.9 mo. Blinding not described.

**Population:** 365 patients with JAK2-positive polycythemia vera being treated with phlebotomy, hydroxyurea, or both.

**Intervention:** Patients were randomized to a target hematocrit: <45% (low-hematocrit group) or 45-50% (high-hematocrit group).

**Outcome:** Composite of time until death from cardiovascular causes of major thrombotic events.

**Results:** The hazard ratio (HR) for the primary outcome was 3.91 (95% CI 1.45-10.53, p=0.007), while the HR for the primary outcome plus superificial venous thrombosis was 2.69 (95% CI 1.19-6.12, p=0.02) for the high-hematocrit group vs. low-hematocrit group.

**Conclusions:** The hematocrit target of <45% was associated with a lower incidence of cardiovascular events, major thrombotic events, and superficial venous thrombosis in patients with polycythemia vera.
Myeloproliferative Neoplasms

- gout (hyperuricemia)
  - due to increased cell turnover
- characteristic physical findings
  - plethora (ruddy complexion) of face (70%), palms
  - splenomegaly (70%), hepatomegaly (40%)

Investigations
- see Erythrocytosis, H6
- must rule out secondary polycythemia if high Epo level

Treatment
- phlebotomy to keep hematocrit <45%
- hydroxyurea (prior thrombosis or symptoms, severe coronary artery disease, refractory to phlebotomy)
- low-dose Aspirin® (for antithrombotic prophylaxis, will also treat erythromelalgia)
- allopurinol: as needed
- antihistamines: as needed

Prognosis
- 10-20 yr survival with treatment
- complicated by thrombosis, hemorrhage, leukemic transformation (AML)

Idiopathic Myelofibrosis

Definition
- excessive bone marrow fibrosis leading to marrow failure
- characterized by anemia, extramedullary hematopoiesis, leukoerythroblastosis, teardrop red cells in peripheral blood and hepatosplenomegaly

Epidemiology
- rare; median age at presentation is 65 yr

Pathophysiology
- abnormal myeloid precursor postulated to produce dysplastic megakaryocytes that secrete fibroblast growth factors
- stimulates fibroblasts and stroma to deposit collagen in marrow
- increasing fibrosis causes early release of hematopoietic precursors leading to:
  - leukoerythroblastic blood film (primitive RBCs and WBCs present in blood)
  - migration of precursors to other sites: extramedullary hematopoiesis (leading to hepatosplenomegaly)

Clinical Features
- anemia (severe fatigue is most common presenting complaint, pallor on exam in >60%)
- weight loss, fever, night sweats → secondary to hypermetabolic state
- splenomegaly (90%) → secondary to extramedullary hematopoiesis; may cause early satiety
- hepatomegaly (70%) → may get portal hypertension
- bone and joint pain → secondary to osteosclerosis, gout
- signs of extramedullary hematopoiesis (depends on organ involved)

Investigations
- CBC: anemia, variable platelets, variable WBC
- biochemistry: increased ALP (liver involvement, bone disease), increased LDH (2nd to ineffective hematopoiesis), increased uric acid (increased cell turnover), increased BUN (2nd to increased neutrophil mass)
- blood film: leukoerythroblastosis with teardrop RBCs, nucleated RBCs, variable polychromasia, large platelets, and megakaryocyte fragments
- JAK2 PCR and calreticulin PCR
- bone marrow aspirate: “dry tap” in as many as 50% of patients (no blood cells aspirated)
- bone marrow biopsy (essential for diagnosis): fibrosis, atypical megakaryocytic hyperplasia, thickening and distortion of the bony trabeculae (osteosclerosis)

Treatment
- allogeneic stem cell transplant is potentially curative
- JAK2 inhibitors (Ruxolitinib)
- symptomatic treatment
  - transfusion for anemia
  - erythropoetin: 30–50% of patients respond
  - androgens for anemia (e.g. danazol has shown transient response with response rates of <30%)
  - hydroxyurea for splenomegaly; thrombocytosis, leukocytosis, systemic symptoms
  - interferon-α (as second line therapy)
  - splenectomy (as third line therapy; associated with high mortality and morbidity)
  - radiation therapy for symptomatic extramedullary hematopoiesis, symptomatic splenomegaly

Efficacy and Safety of Low-dose Aspirin® in Polycythemia Vera
NEJM 2004;350:114-124
Study: Double-blind, placebo-controlled, RCT.
Participants: 518 patients with polycythemia vera (PV) with no clear indication for, or contraindication to, ASA therapy.
Intervention: Patients received either low-dose ASA 100 mg daily (n=253) or placebo (n=265) and were followed for up to 5 yr.
Primary Outcome: Cumulative rate of (I) nonfatal MI, nonfatal stroke, or death from cardiovascular causes and the cumulative rate of (II) the previous 3 plus PE and major venous thrombosis.
Results: Primary outcomes (I) and (II) were reduced with treatment compared to placebo (HR 0.41; p=0.09 and RR 0.4; p=0.63, respectively). There were no differences in overall or cardiovascular mortality and major bleeding episodes.
Conclusion: Low-dose ASA can safely prevent thrombotic complications in patients with PV.

Myelofibrosis can be either primary (idiopathic) or occur as a transformation of an antecedent PV or ET

A “leukoerythroblastic” blood film (RBC and granulocyte precursors) implies bone marrow infiltration with malignancy (e.g. leukemias, solid tumour metastases) or fibrosis (e.g. IMF)

IMF typically has a dry BM aspirate and teardrop RBCs (aspiration gives no blood cells)

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
NEJM 2012;366:799-807
Study: Double-blind RCT of 309 patients with myelofibrosis randomized to ruxolitinib or placebo.
Outcome: Primary outcome was reduction in spleen volume of >35% at 24 wk. Secondary outcomes were durability of response, symptom burden, and overall survival.
Results: A greater proportion of patients on ruxolitinib had reduction in spleen volume >35% (41.9% vs. 2.7%) and this was sustained in 67% at 48 wk. Ruxolitinib also led to greater symptom improvement (40% vs. 5.3%) and less mortality (0% vs. 24%). There was no difference in rate of discontinuation due to adverse events (11.0% vs. 10.6%) but anemia and thrombocytopenia were more common with ruxolitinib.
Conclusion: Ruxolitinib reduced spleen size, improved symptoms and improved survival, compared with placebo.
Prognosis
- International Prognostic Scoring System (IPSS) for IMF uses 5 factors to determine mean survival
  - presence of constitutional symptoms; age >65; hemoglobin <100 g/L; leukocyte count >25,000/mm³;
  - circulating blast cells ≥1%
- based on the calculated score, a patient’s IMF is categorized as “low”, “intermediate 1”, “intermediate 2”, or “high” with a mean survival of 135, 95, 48, and 27 mo respectively
- risk of transformation to AML (8-10%)

Essential Thrombocythemia

Definition
- overproduction of platelets in the absence of recognizable stimulus
- must rule out secondary thrombocythemia

Epidemiology
- increases with age; F:M = 2:1, but F=M at older age

Diagnosis (2008 WHO Criteria) requires meeting all four criteria:
1. sustained platelet count >450 x 10⁹/L
2. bone marrow biopsy specimen showing proliferation mainly of the megakaryocytic lineage with increased number of enlarged, mature megakaryocytes; no significant increase or left shift of neutrophil granulopoiesis or erythropoiesis
3. not meeting WHO criteria for PV, primary myelofibrosis, bcr-abl CML, or myelodysplastic syndrome or other myeloid neoplasms
4. demonstration of JAK2 V617F or calreticulin (or in its absence another clonal marker), no evidence for reactive thrombocytosis

Clinical Features
- often asymptomatic
- vasomotor symptoms (40%)
  - headache (common), dizziness, syncope
  - erythromelalgia (burning pain of hands and feet, dusky colour, usually worse with heat, caused by platelet activation → microvascular thrombosis)
- thrombosis (arterial and venous)
- bleeding (often GI; associated with platelets >1,000 x 10⁹/L)
- constitutional symptoms, splenomegaly
- pregnancy complications; increased risk of spontaneous abortion
- risk of transformation to AML (0.6-5%), myelofibrosis

Investigations
- CBC: increased platelets; may have abnormal platelet aggregation studies or VWD studies
- JAK2 PCR assay; if negative, CALR PCR assay
- bone marrow hypercellularity, megakaryocytic hyperplasia, giant megakaryocytes
- increased K⁺, increased PO₂ (2° to release of platelet cytoplasmic contents)
- diagnosis: exclude other myeloproliferative disorders and reactive thrombocytosis

Treatment
- low dose ASA if previous history of thrombotic event, ≥1 cardiovascular risk factors, older, or symptomatic
- cytoreductive therapy if thrombosis or thrombotic symptoms: hydroxyurea (HU) (1st line therapy), anagrelide, interferon-α, or ³²P (age >80 or lifespan <10 yr)

Lymphoid Malignancies

Acute Lymphoblastic Leukemia

Definition
- malignant disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow
- WHO subdivides ALL into two types depending on cell of origin
  1. B-cell: precursor B lymphoblastic leukemia
  2. T-cell: precursor T lymphoblastic leukemia
- the French-American-British (FAB) classification (L1, L2, L3) is no longer encouraged, as morphology is not prognostic

75% of ALL occurs in children < 6 yr old; second peak at age 40
Clinical Features
- see Acute Myeloid Leukemia, H37 for full list of symptoms
- distinguish ALL from AML based on Table 32
- clinical symptoms usually secondary to:
  - **bone marrow failure**: anemia, neutropenia (50% present with fever; also infections of oropharynx, lungs, perianal region), thrombocytopenia
  - **organ infiltration**: tender bones, lymphadenopathy, hepatosplenomegaly, meningeval signs (headache, N/V, visual symptoms; especially in ALL relapse)

Investigations
- CBC: increased leukocytes >10 x 10^9/L (occurs in 50% of patients); neutropenia, anemia, or thrombocytopenia
- may have increased uric acid, K⁺, PO₄⁻, Ca²⁺, LDH
- PT, aPTT, fibrinogen, D-dimers for DIC
- leukemic lymphoblasts lack specific morphological (no granules) or cytochemical features, therefore diagnosis depends on immunophenotyping
- cytogenetics: Philadelphia (Ph) chromosome in ~25% of adult ALL cases
- CXR: patients with ALL may have a mediastinal mass
- LP prior to systemic chemotherapy to assess for CNS involvement (ensure adequate platelet count and PT/PTT)

Treatment
- eliminate abnormal cloned cells
  1. **induction chemotherapy**: to induce complete remission (undetectable leukemic blasts, restore normal hematopoiesis)
  2. **consolidation and/or intensification of chemotherapy**
     - consolidation: continuing same chemotherapy to eliminate subclinical leukemic cells
     - intensification: high doses of different (non-cross-reactive) chemotherapy drugs to eliminate cells with resistance to primary treatment
  3. **maintenance chemotherapy**: low dose intermittent chemotherapy over prolonged period (2-3 yr) to prevent relapse
  4. **prophylaxis**: CNS radiation therapy or methotrexate (intrathecal or systemic)

- hematopoietic stem cell transplantation: potentially curative (due to pre-implant myeloablative chemoradiation and post-implant graft-versus-leukemia effect) but relapse rates and non-relapse mortality high

Prognosis
- depends on response to initial induction or if remission is achieved following relapse
- good prognostic factors: young, WBC <30 x 10^9/L, T-cell phenotype, absence of Ph chromosome, early attainment of complete remission
- achievement of first remission: 60-90%
- childhood ALL: 75% long-term remission (>5 yr)
  - higher cure rates in children because of better chemotherapy tolerance, lower prevalence of bcr-abl fusion gene (associated with chemotherapeutic resistance)
- adult ALL: 30-40% 5-yr survival

<table>
<thead>
<tr>
<th>Table 32. Differentiating AML From ALL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AML</strong></td>
</tr>
<tr>
<td>Big people (adults)</td>
</tr>
<tr>
<td>Big blasts</td>
</tr>
<tr>
<td>Big mortality rate</td>
</tr>
<tr>
<td>Lots of cytoplasm</td>
</tr>
<tr>
<td>Lots of nucleoli (3-5)</td>
</tr>
<tr>
<td>Lots of granules and Auer rods</td>
</tr>
<tr>
<td>Myeloperoxidase, Sudan black stain</td>
</tr>
<tr>
<td>Maturation defect beyond myeloblast or promyelocyte</td>
</tr>
</tbody>
</table>
**Lymphomas**

**Definition**
- collection of lymphoid malignancies in which malignant lymphocytes accumulate at lymph nodes and lymphoid tissues
  - leading to lymphadenopathy, extranodal disease, and constitutional symptoms

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Involvement of a single lymph node region OR extralymphatic organ/site (Stage IE)</td>
</tr>
<tr>
<td>II</td>
<td>Involvement of two or more lymph node regions or an extralymphatic site and one or more lymph node regions on same side of diaphragm</td>
</tr>
<tr>
<td>III</td>
<td>Involvement of lymph node regions on both sides of the diaphragm; may or may not be accompanied by single extra lymphatic site or splenic involvement</td>
</tr>
<tr>
<td>IV</td>
<td>Diffuse involvement of one or more extralymphatic organs including bone marrow</td>
</tr>
</tbody>
</table>

- subtypes
  - A = absence of B-symptoms (see Approach to Lymphadenopathy, H12)
  - B = presence of B-symptoms

**Table 33. Ann Arbor System for Staging Lymphomas**

<table>
<thead>
<tr>
<th>Translocation</th>
<th>Gene Activation</th>
<th>Associated Neoplasm</th>
</tr>
</thead>
<tbody>
<tr>
<td>t(2;5)</td>
<td>ALK1 mutation</td>
<td>Anaplastic large cell lymphoma</td>
</tr>
<tr>
<td>t(8;14)</td>
<td>c-myc activation</td>
<td>Burkitt’s lymphoma</td>
</tr>
<tr>
<td>t(14;18)</td>
<td>bcl-2 activation</td>
<td>Follicular lymphoma</td>
</tr>
<tr>
<td>t(11;14)</td>
<td>Overexpression of cyclin D1 protein</td>
<td>Mantle cell lymphoma</td>
</tr>
<tr>
<td>t(11;18)</td>
<td>MALT1 activation</td>
<td>Mucosa-associated lymphoid tissue (MALT)</td>
</tr>
</tbody>
</table>

**Hodgkin Lymphoma**

**Definition**
- malignant proliferation of lymphoid cells with Reed-Sternberg cells (thought to arise from germinal centre B-cells)

**Epidemiology**
- bimodal distribution with peaks at 20 yr and >50 yr
- association with Epstein-Barr virus in up to 50% of cases, causal role not determined

**Clinical Features**
- asymptomatic lymphadenopathy (70%)
  - non-tender, rubbery consistency
  - cervical supraclavicular (60-80%), axillary (10-20%), inguinal (6-12%)
  - splenomegaly (50%) ± hepatomegaly
  - mediastinal mass
    - found on routine CXR, may be symptomatic (cough)
    - rarely may present with SVC syndrome, pleural effusion
  - systemic symptoms
    - B symptoms (especially in widespread disease; fever in 30%), pruritus
    - non-specific/paraneoplastic
      - alcohol-induced pain in nodes, nephrotic syndrome
    - starts at a single site in lymphatic system (node), spreads first to adjacent nodes
      - disease progresses in contiguity with lymphatic system

**Investigations**
- CBC
  - anemia (chronic disease, rarely hemolytic), eosinophilia, lymphopenia, platelets normal or increased early, decreased in advanced disease
- biochemistry
  - HIV serology
  - liver enzymes and/or LFTs (liver involvement)
  - renal function tests (prior to initiating chemotherapy)
  - ALP, Ca²⁺ (bone involvement)
  - ESR, LDH (monitor disease progression)
- imaging
  - CXR, CT chest (lymph nodes, mediastinal mass), CT abdomen/pelvis (liver or spleen involvement), PET scans have replaced gallium scans
- cardiac function assessment (MUGA scan or echocardiography): for patients at high risk of pre-treatment cardiac disease (age >60, history of HTN, CHF, PUD, CAD, MI, CVA, malnourished), treatment can be cardiotoxic
- PFTs: if history of lung disease (COPD, smoking, previous radiation to lung)
- excisional lymph node or core biopsy confirms diagnosis
- bone marrow biopsy to assess marrow infiltration (only necessary if B-symptoms, stage III or IV, bulky disease or cytopenia)

**Treatment**
- stage I-II: chemotherapy (ABVD) followed by involved field or involved site radiotherapy (XRT)
- stage III-IV: chemotherapy (ABVD) with XRT for bulky disease
- relapse, resistant to therapy: high dose chemotherapy, autologous stem cell transplant
  - PET scan results essential in clarifying disease response

**Complications of Treatment**
- cardiac disease: secondary to XRT, adriamycin is also cardiotoxic
- pulmonary disease: secondary to bleomycin (interstitial pneumonitis)
- infertility: recommend sperm banking
- secondary malignancy in irradiated field
  - <2% risk of MDS, AML (secondary to treatment, usually within 8 yr)
  - solid tumours of lung, breast; >8 yr after treatment
- non-Hodgkin lymphoma
- hypothyroidism: post XRT

**Prognosis**
- Hasenclever adverse prognostic factors:
  1. serum albumin <40 g/L
  2. hemoglobin <105 g/L
  3. male
  4. stage IV disease
  5. age >45 yr
  6. leukocytosis (WBC >1.5 x 10^9/L)
  7. lymphocytopenia (lymphocytes <0.06 x 10^9/L or <8% of WBC count or both)
- prognostic score
  - each additional adverse prognostic factor decreases freedom from progression at 5 yr (FFP)

**Non-Hodgkin Lymphoma**

**Definition**
- malignant proliferation of lymphoid cells of progenitor or mature B- or T-cells

**Classification**
- multiple classification systems exist at present and may be used at different centres
- can originate from both B- (85%) and T- or NK- (15%) cells
  - B-cell NHL: e.g. diffuse large B-cell lymphoma, follicular lymphoma, Burkitt’s lymphoma, mantle cell lymphoma
  - T-cell NHL: e.g. mycosis fungoides (skin), TCL-NOS, anaplastic large cell lymphoma
- WHO/REAL classification system: 3 categories of NHLs based on natural history
  - indolent (35-40% of NHL): e.g. follicular lymphoma, small lymphocytic lymphoma/CLL, mantle cell lymphoma
  - aggressive (~50% of NHL): e.g. diffuse large B-cell lymphoma
  - highly aggressive (~5% of NHL): e.g. Burkitt’s lymphoma

**Clinical Features**
- painless superficial lymphadenopathy, usually >1 lymph node region
- usually presents as widespread disease (exception is aggressive lymphoma)
- constitutional symptoms not as common as in Hodgkin lymphoma
- cytopenia: anemia ± neutropenia ± thrombocytopenia can occur when bone marrow is involved
- abdominal signs
  - hepatosplenomegaly
  - retroperitoneal and mesenteric involvement (second most common site of involvement)
  - oropharyngeal involvement in 5-10% with sore throat and obstructive apnea
- extranodal involvement: most commonly GI tract; also testes, bone, kidney
- CNS involvement in 1% (often with HIV)

**Investigations**
- CBC
  - normocytic normochromic anemia
  - autoimmune hemolytic anemia rare
  - advanced disease: thrombocytopenia, neutropenia, and leukoerythroblastic anemia
- peripheral blood film may show lymphoma cells
• flow cytometry of peripheral blood lymphocytosis is valuable for low-grade NHL
• biochemistry
  ■ increase in uric acid
  ■ abnormal LFTs in liver metastases
  ■ increased LDH (rapidly progressing disease, poor prognostic factor)
• staging: CT neck, chest, abdomen, pelvis and bone marrow biopsy
• PET is useful for monitoring response to treatment and evaluation of residual tumour following therapy in aggressive histological disease
• diagnosed by
  ■ lymph node biopsy: excisional biopsy preferred, FNA unreliable
  ■ bone marrow biopsy: not optimal for diagnosis as BM involved in only 30% of high grade lymphomas

Treatment
• localized disease (e.g. GI, brain, bone, head and neck)
  ■ radiotherapy to primary site and adjacent nodal areas
  ■ adjuvant chemotherapy
  ■ surgery: splenic marginal zone lymphoma
• indolent lymphoma: goal of treatment is symptom management
  ■ watchful waiting
  ■ radiation therapy for localized disease
  ■ bendamustine plus rituximab, an anti-CD20 antibody, is superior to CHOP + rituximab (CHOP-R) for advanced stage disease (StIL trial)
• aggressive lymphoma: goal of treatment is curative
  ■ combination chemotherapy: CHOP is mainstay, plus rituximab if B-cell lymphoma
  ■ radiation for localized/bulky disease
  ■ CNS prophylaxis with high-dose methotrexate if certain sites involved (testicular)
  ■ relapse, resistant to therapy: high dose chemotherapy, autologous SCT
• highly aggressive lymphoma
  ■ Burkitt lymphoma: short bursts of intensive chemotherapy “CODOX-M” chemotherapy regimen also often used ± IVAC with Rituximab
  ■ CNS prophylaxis and tumour lysis syndrome prophylaxis

Complications
• hypersplenism
• infection
• autoimmune hemolytic anemia and thrombocytopenia
• vascular obstruction (from enlarged nodes)
• bowel perforation
• tumour lysis syndrome (particularly in very aggressive lymphoma) see Tumour Lysis Syndrome, H52

Prognosis
• follicular lymphoma: Follicular Lymphoma International Prognostic Index is used (5 adverse prognostic factors): age >60; >4 nodal areas; elevated LDH; Lugano stage III-IV; hemoglobin <120 g/L
  ■ based on calculated risk, mean 5 yr survival ranges from 53-91%
  ■ rarely curative, typically relapsing and remitting course with risk of transformation to aggressive lymphoma such as diffuse large B-cell lymphoma
• diffuse large B-cell lymphoma: The International Prognostic Factor Index is used (5 adverse prognostic factors): age >60; Ann Arbor stage (III-IV); performance status (ECOG/Zubrand 2-4); elevated LDH; >1 extranodal site
  ■ based on calculated risk, mean 5 yr survival ranges from 26-73%
  ■ ~40% rate of cure

Table 35. Characteristics of Select Non-Hodgkin Lymphomas

<table>
<thead>
<tr>
<th>Percentage of NHLs</th>
<th>Follicular Lymphoma</th>
<th>Diffuse Large B-Cell Lymphoma (DLBCL)</th>
<th>Burkitt Lymphoma</th>
<th>Mantle Cell Lymphoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>~2%</td>
<td>22-30%</td>
<td>33%</td>
<td>&lt;1% adult NHLs, 30% childhood NHLs</td>
<td>6%</td>
</tr>
<tr>
<td>Genetic Mutation</td>
<td>Bcl-2 activation</td>
<td>Bcl-2, Bcl-6, MYC rearrangements</td>
<td>c-myc activation</td>
<td>Overexpression of cyclin D1 (Bcl-1 activation)</td>
</tr>
<tr>
<td>Classification</td>
<td>Indolent</td>
<td>Aggressive (high-grade)</td>
<td>Very aggressive</td>
<td>Indolent</td>
</tr>
<tr>
<td>Risk Factors</td>
<td>Middle-age – elderly</td>
<td>Previous CLL (Richter’s transformation: 5% CLL patients progress to DLBCL)</td>
<td>Male (M:F = 4:1)</td>
<td></td>
</tr>
<tr>
<td>Clinical Features</td>
<td>Widespread painless LAD* ± bone marrow involvement</td>
<td>Rapidly progressive LAD and extranodal infiltration</td>
<td>Endemic form: massive jaw LAD</td>
<td>Often presents Stage IV with palpable LAD</td>
</tr>
<tr>
<td></td>
<td>Very responsive to chemotherapy treatment</td>
<td>High risk of tumour lysis syndrome upon treatment</td>
<td>“Starry-sky” histology</td>
<td>Involvement of GI tract (lymphomatosis polyposis), Waldeyer’s Ring</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5 yr survival 25%</td>
<td></td>
</tr>
</tbody>
</table>

* LAD = lymphadenopathy
Malignant Clonal Proliferations of Mature B-Cells

Table 36. Characteristics of B-Cell Malignant Proliferation

<table>
<thead>
<tr>
<th></th>
<th>CLL</th>
<th>Lymphoplasmacytic Lymphoma</th>
<th>Myeloma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell Type</td>
<td>Lymphocyte</td>
<td>Plasmacytoid</td>
<td>Plasma cell</td>
</tr>
<tr>
<td>Protein</td>
<td>IgM if present</td>
<td>IgM</td>
<td>IgG, A, light chain (rarely M, D, or E)</td>
</tr>
<tr>
<td>Lymph Nodes</td>
<td>Very common</td>
<td>Common</td>
<td>Rare</td>
</tr>
<tr>
<td>Hepatosplenomegaly</td>
<td>Common</td>
<td>Common</td>
<td>Rare</td>
</tr>
<tr>
<td>Bone Lesions</td>
<td>Rare</td>
<td>Rare</td>
<td>Common</td>
</tr>
<tr>
<td>Hypercalcemia</td>
<td>Rare</td>
<td>Rare</td>
<td>Common</td>
</tr>
<tr>
<td>Renal Failure</td>
<td>Rare</td>
<td>Rare</td>
<td>Common</td>
</tr>
<tr>
<td>Immunoglobulin Complications</td>
<td>Common</td>
<td>Rare</td>
<td>Rare</td>
</tr>
</tbody>
</table>

Chronic Lymphocytic Leukemia

Definition
- indolent disease characterized by clonal malignancy of mature B-cells

Epidemiology
- most common leukemia in Western world
- mainly older patients; median age 70 yr
- M>F

Pathophysiology
- accumulation of neoplastic lymphocytes in blood, bone marrow, lymph nodes, and spleen

Clinical Features
- 25% asymptomatic (incidental finding)
- 5-10% present with B-symptoms (≥1 of: unintentional weight loss ≥10% of body weight within previous 6 mo, temperature >38°C or night sweats for ≥2 wk without evidence of infection, extreme fatigue)
- lymphadenopathy (50-90%), splenomegaly (25-55%), hepatomegaly (15-25%)
- immune dysregulation: autoimmune hemolytic anemia (Coombs positive), ITP, hypogammaglobulinemia ± neutropenia
- bone marrow failure: late, secondary to marrow involvement by CLL cells

Investigations
- CBC: clonal population of B lymphocytes >5 x 10^9/L
- peripheral blood film
  - lymphocytes are small and mature
  - smudge cells
- flow cytometry (CD5, CD20dim, CD23)
- cytogenetics: FISH (dictates response therapy and prognosis)
- bone marrow aspirate
  - lymphocytes >30% of all nucleated cells
  - infiltration of marrow by lymphocytes in 4 patterns: nodular (10%), interstitial (30%), diffuse (35%, worse prognosis), or mixed (25%)

Natural History and Treatment
- natural history: indolent and incurable; most cases show slow progression
- small minority present with aggressive disease; usually associated with chromosomal abnormalities (e.g. p53 deletion)
- first line therapy is dictated by cytogenetic status and patient co-morbidities
  - observation if early, stable, asymptomatic
  - treatment options vary by region; ideal first line therapy should include a monoclonal CD20 agent (e.g. rituximab, obinutuzumab)
    - commonly fludarabine + cyclophosphamide + rituximab (FCR) in fit patients with normal CrCl;
    - bendamustine + rituximab (BR) in less fit
    - chlorambucil + anti-CD20 obinutuzumab in the elderly
- corticosteroids, IVIg: especially for autoimmune phenomenon
- molecular therapies
  - Idelalisib – PI3K inhibitor
  - Ibrutinib – BTK (Bruton’s tyrosine kinase) inhibitor
Malignant Clonal Proliferations of Mature B-Cells

Prognosis
- 9 yr median survival, but varies greatly
- prognosis predicted by Rai staging and cytogenetic status
- low risk: lymphocytosis in blood and bone marrow only
- intermediate risk: lymphocytosis with enlarged nodes in any site or splenomegaly, hepatomegaly
- high risk: lymphocytosis with disease-related anemia (<110 g/L) or thrombocytopenia (<100 x 10^9/L)

Complications
- bone marrow failure
- immune complications: AIHA, ITP; immune deficiency (hypogammaglobulinemia, impaired T-cell function)
- polyclonal or monoclonal gammapathy (often IgM)
- hyperuricemia with treatment
- 5% undergo Richter’s transformation: aggressive transformation to diffuse large B-cell lymphoma (see Table 35)

Multiple Myeloma

Definition
- neoplastic clonal proliferation of plasma cells producing a monoclonal immunoglobulin resulting in end organ dysfunction
- usually single clone of plasma cells, although biclonal myeloma also occurs; rarely non-secretory

Epidemiology
- incidence 3 per 100,000, most common plasma cell malignancy
- increased frequency with age; median age of diagnosis is 68 yr; M>F

Pathophysiology
- malignant plasma cells secrete monoclonal antibody
  - 95% produce M protein (monoclonal Ig = identical heavy chain + identical light chain, or light chains only)
  - IgG 50%, IgA 20%, IgD 2%, IgM 0.5%
  - 15-20% produce free light chains or light chains alone found in either:
    - serum as an increase in the quantity of either kappa or lambda light chain (with an abnormal kappa:lambda ratio)
    - urine has Bence-Jones protein
  - <5% are non-secretors

Clinical Features and Complications
- bone disease: pain (usually back), bony tenderness, pathologic fractures
- lytic lesions are classical (skull, spine, proximal long bones, ribs)
- increased bone resorption secondary to osteoclast activating factors such as PTHrP
- anemia: weakness, fatigue, pallor
- secondary to bone marrow suppression
- weight loss
- infections
  - usually S. pneumoniae and Gram-negatives
  - secondary to suppression of normal plasma cell function
- hypercalcaemia: N/V, confusion, constipation, polyuria, polydipsia
  - secondary to increased bone turnover
- renal disease/renal failure
  - most frequently causes cast nephropathy (see Nephrology, NP32)
- bleeding
  - secondary to thrombocytopenia, may see petechiae, purpura
  - can also be caused by acquired Von Willebrand disease
- extramedullary plasmacytoma
  - soft tissue mass composed of monoclonal plasma cells, purplish colour
- hyperviscosity: may manifest as headaches, stroke, angina, MI
  - secondary to increased viscosity caused by M protein
- amyloidosis
  - accumulation of insoluble fibrillar protein (Ig light chain) in tissues; can cause infiltration of any organ system: cardiac infiltration – diastolic dysfunction, cardiac arrhythmias, syncope, sudden death; GI involvement – malabsorption, beefy large or laterally scalloped tongue; neurologic involvement – orthostatic hypotension, carpal tunnel syndrome
  - may cause Factor X deficiency if fibrils bind Factor X → bleeding (raccoon eyes)
- neurologic disease: muscle weakness, pain, paresthesias
  - radiculopathy caused by vertebral fracture, extramedullary plasmacytoma
  - spinal cord compression (10-20% of patients) is a medical emergency
Investigations

- CBC
  - normocytic anemia, thrombocytopenia, leukopenia
  - rouleaux formation on peripheral film
- biochemistry
  - increased Ca\(^{2+}\), increased ESR, decreased anion gap, increased Cr, albumin, β2-microglobulin (as part of staging), proteinuria (24 h urine collection)
- monoclonal proteins
  - serum protein electrophoresis (SPEP): demonstrates monoclonal protein spike in serum in 80% (i.e. M protein)
  - urine protein electrophoresis (UPEP): demonstrates light chains in urine = Bence-Jones protein (15% secrete only light chains)
  - immunofixation: demonstrates M protein and identifies Ig type; also identifies light chains
  - serum free light chain quantification: kappa and lambda light chains, calculated ratio
- bone marrow aspirate and biopsy
  - often focal abnormality, greater than 10% plasma cells, abnormal morphology, clonal plasma cells; send for FISH or cytogenetics (prognostic implications)
- skeletal series (x-rays), MRI if symptoms of cord compression.
- presence of lytic lesions and areas at risk of pathologic fracture
- bone scans are not useful since they detect osteoblast activity
- β2-microglobulin, LDH, and CRP are poor prognosticators

Diagnosis

- International Myeloma Working Group Criteria
  1. serum or urinary monoclonal protein
  2. presence of clonal plasma cells in bone marrow (>60% without "CRAB") or a plasmacytoma
  3. presence of end-organ damage related to plasma cell dyscrasia, such as:
    - increased serum Ca\(^{2+}\)
    - lytic bone lesions
    - anemia
    - renal failure
- supportive management
  - melphalan, prednisone, cyclophosphamide and proteasome inhibitor (i.e. bortezomib)
- dexamethasone and bortezomib if ARF; bortezomib ± dexamethasone in light chain amyloidosis
- treatment goals
  - improvement in quality of life (improve anemia, reverse renal failure, bony pain)
  - prevention of progression and complications
  - increase overall survival
- autologous stem cell transplant if <65 yr old
  - usually preceded by 4-6 mo of cytoreductive therapy: steroid based with novel agents (i.e. immunomodulatory drugs or proteasome inhibitors)
  - melphalan, prednisone, cyclophosphamide and proteasome inhibitor (i.e. bortezomib)
  - dexamethasone and bortezomib if ARF; bortezomib ± dexamethasone in light chain amyloidosis

Prognosis

- ISS - International Staging System (β2-microglobulin and albumin) used to stage and estimate prognosis
- revised ISS for risk stratification: combination of original ISS, cytogenetic profile (i.e. p53 mutation associated with poor survival and resistance to chemotherapy) and LDH
- median survival based on stage, usually 3-7 yr

Monoclonal Gammopathy of Unknown Significance

Definition

- presence of M protein in serum in absence of any clinical or laboratory evidence of a plasma cell dyscrasia or lymphoproliferative disorders
- incidence: 0.15% in general population, 5% of people >70 yr of age
- asymptomatic
Diagnosis
- presence of a serum monoclonal protein (M protein) at a concentration <30 g/L
- <10% plasma cells in bone marrow
- absence of hypercalcemia, renal insufficiency, anemia, bone disease related to the plasma cell proliferative process (absence of “CRAB”)
- 0.3-1% of patients develop a hematologic malignancy each yr
  - patients with M protein peak ≥15 g/L or patients with IgA or IgM MGUS are at higher risk of malignant transformation
  - patients with abnormal serum free light chains ratio are at increased risk of malignant transformation
- monitor with annual history, physical, CBC, Cr, calcium, albumin, serum protein electrophoresis (considered pre-malignant)

Lymphoplasmacytic Lymphoma
(Waldenstrom’s Macroglobulinemia)

Definition
- proliferation of lymphoplasmacytoid cells
  - presence of monoclonal IgM paraprotein

Clinical Features
- chronic disorder of elderly patients; median age 64 yr
- symptoms: weakness, fatigue, bleeding (oronasal), weight loss, recurrent infections, dyspnea, CHF (triad of anemia, hyperviscosity, plasma volume expansion), neurological symptoms, peripheral neuropathy, cerebral dysfunction
- signs: pallor, splenomegaly, hepatomegaly, lymphadenopathy, retinal lesions
- key complication to avoid: hyperviscosity syndrome
  - because IgM (unlike IgG) confined largely to intravascular space

Investigations and Diagnosis
- bone marrow shows plasmacytoid lymphocytes
- bone lesions usually not present
- blood work rarely see hypercalcemia
- cold hemagglutinin disease possible: Raynaud’s phenomenon, hemolytic anemia precipitated by cold weather
- normocytic anemia, rouleaux, high ESR if hyperviscosity not present

Treatment
- Bendamustine – R/R-CVP chemotherapy, alkylating agents (chlorambucil), nucleoside analogues (fludarabine), rituximab, or combination therapy
- corticosteroids
- plasmapheresis for hyperviscosity: acute reduction in serum IgM

Complications of Hematologic Malignancies

Hyperviscosity Syndrome

Definition
- refers to clinical sequelae of increased blood viscosity (when relative serum viscosity >5-6 units), resulting from increased circulating serum lgs or from increased cellular blood components in hyperproliferative disorders (e.g. multiple myeloma, leukemia, PV)
- Waldenstrom’s macroglobulinemia accounts for 85% of cases

Clinical Features
- hypervolemia causing: CHF, headache, lethargy, dilutional anemia
- CNS symptoms due to decreased cerebral blood flow: headache, vertigo, ataxia, stroke
- retina shows venous engorgement and hemorrhages
- bleeding diathesis
  - due to impaired platelet function, absorption of soluble coagulation factors (e.g. nasal bleeding, oozing gums)
- ESR usually very low

Treatment
- plasmapheresis, chemotherapy
Tumour Lysis Syndrome

Definition
• group of metabolic complications that result from spontaneous or treatment-related breakdown of cancer cells
• more common in diseases with large tumour burden and high proliferative rate (high grade lymphoma, leukemia)

Clinical Features
• metabolic abnormalities
  - cells lyse, releasing K⁺, uric acid, PO₄³⁻ (increased levels)
  - PO₄³⁻ binds Ca²⁺ (decreased Ca²⁺)
• complications
  - lethal cardiac arrhythmia (increased K⁺)
  - acute kidney injury (formerly known as renal failure, see Nephrology, NP18)

Treatment
• prevention
  - aggressive IV hydration
  - alkalization not recommended due to risk of calcium phosphate or xanthine precipitation in renal tubules
  - allopurinol or rasburicase
  - correction of pre-existing metabolic abnormalities
• dialysis

Blood Products and Transfusions

Blood Products
• RBCs, platelets and coagulation factors (frozen plasma [FP], cryoprecipitate, factor concentrates) are available for transfusion
• donated blood (1 U = 450-500 mL) is fractionated into these various components
  - centrifugation separates whole blood into RBCs and platelet-rich plasma
  - platelet-rich plasma is further fractionated into platelets and plasma
• need to pool together multiple units to obtain therapeutic amounts
• FP (previously known as FFP) is plasma frozen within 24 h of collection
• cryoprecipitate is the high MW precipitate generated when FP is thawed at low temperatures

Specialized Products
• irradiated blood products
  - prevent proliferation of donor T-cells in potential or actual bone marrow transplant recipients
  - used for immunocompromised patients or for patients on purine analogue chemotherapy, first-degree relatives, HLA-matched products and intrauterine transfusions, Hodgkin lymphoma
• CMV-negative blood products
  - potential transplant recipients
  - neonates
  - AIDS patients
  - seronegative pregnant women

Red Blood Cells

Packed Red Blood Cells
• stored at 4°C
• transfuse within 42 d of collection, otherwise cell lysis may result in hyperkalemia
• infuse each unit over 2 h (max of 4 h)

Indications for Packed RBC Transfusion
• Hb <70 g/L; this may change as per patient’s tolerance or symptoms
  - maintain Hb between 70 and 100 g/L during active bleeds
  - consider maintaining a higher Hb for patients with:
    - CAD/unstable coronary syndromes
    - uncontrolled, unpredictable bleeding
    - impaired pulmonary function
    - increased O₂ consumption
Selection of Red Cells for Transfusion
- when anticipating an RBC transfusion, the following should be ordered:
  - group and screen: determines the blood group and Rh status of the recipient as well as the presence of autoantibodies vs. major/minor blood group antigens in the patient’s serum
  - cross-match: involves mixing the recipient’s blood with potential donor blood and looking for agglutination (takes 30-45 min)
- when blood is required, several options are available
  1st line: fully crossmatched blood, electronic crossmatch is becoming more widely used (not always available in emergency situations)
  2nd line: donor blood of the same group and Rh status as the recipient
  3rd line: O- blood for females of reproductive age; O+ blood for all others

Platelets

Table 37. Platelet Products

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random donor (pooled)</td>
<td>Thrombocytopenia with bleeding</td>
</tr>
<tr>
<td>Single donor platelets</td>
<td>Potential BMT recipients</td>
</tr>
<tr>
<td>HLA matched platelets</td>
<td>Refractory to pooled or single donor platelets, presence of HLA antibodies</td>
</tr>
</tbody>
</table>

- stored at 20-24°C
- random donor platelets are transfused from a pool of 4 units; this should increase the platelet count by ≥15 x 10^9/L
- single donor platelets (transfused as single units) should increase the platelet count by 40-60 x 10^9/L
- if an increase in the platelet count is not seen post-transfusion: autoantibodies (i.e. TTP), alloantibodies, consumption (bleeding, sepsis), or hypersplenism may be present

Table 38. Indications for Platelet Transfusion

<table>
<thead>
<tr>
<th>PT (x 10^9/L)</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;10</td>
<td>Non-immune thrombocytopenia</td>
</tr>
<tr>
<td>&lt;20</td>
<td>Procedures not associated with significant blood loss</td>
</tr>
<tr>
<td>&lt;50</td>
<td>Procedures associated with blood loss or major surgery (&gt;500 mL EBL)</td>
</tr>
<tr>
<td>&lt;100</td>
<td>Pre-neurosurgery or head trauma</td>
</tr>
<tr>
<td>Any</td>
<td>Platelet dysfunction (or antiplatelet agents) and marked bleeding</td>
</tr>
</tbody>
</table>

Relative Contraindications of Platelet Transfusion
- TTP, HIT, post-transfusion purpura, HELLP

Coagulation Factors

Table 39. Coagulation Factor Products

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frozen plasma (FP)</td>
<td>Depletion of multiple coagulation factors (e.g. sepsis, DIC, dilution, TTP/HUS, liver disease), emergency reversal of life-threatening bleeding secondary to warfarin overdose</td>
</tr>
<tr>
<td>Cryoprecipitate (enriched fibrinogen, WVF, VIII, XIII)</td>
<td>Hemophilia A (Factor VIII deficiency) – use in emergencies Von Willebrand disease – use in emergencies Hypofibrinogenemia</td>
</tr>
<tr>
<td>Humate P or Wilate</td>
<td>Von Willebrand disease – use in emergencies Hemophilia A</td>
</tr>
<tr>
<td>Factor VIII concentrate</td>
<td>Factor VIII deficiency (Hemophilia A)</td>
</tr>
<tr>
<td>Factor IX concentrate</td>
<td>Factor IX deficiency (Hemophilia B)</td>
</tr>
<tr>
<td>Recombinant factor VIIa</td>
<td>Factor VII deficiency with bleeding/surgery, Hemophilia A or B with inhibitors, Glanzmann thrombasthenia</td>
</tr>
<tr>
<td>Prothrombin complex concentrate; PCC (Octaplex, Beriplex®)</td>
<td>Reversal of warfarin therapy or vitamin K deficiency in bleeding patient or in patient requiring urgent (&lt;6 h) surgical procedure, urgent non-specific &quot;reversal&quot; of direct Xa inhibitors</td>
</tr>
<tr>
<td>Activated prothrombin complex concentrate; aPCC (FEIBA)</td>
<td>Hemophilia A or B with inhibitors, urgent non-specific &quot;reversal&quot; of direct thrombin inhibitors</td>
</tr>
</tbody>
</table>

Multicentre RCT.
Participants: 418 critically ill patients with euolemic after initial treatment and hemoglobin less than 9 g/dL, within 72 h of ICU admission.
Intervention: Patients receiving a transfusion followed either (1) a restrictive strategy (RS; n=418) in which red cells were transfused if hemoglobin was less than 7.0 g/dL, and then maintained at 7 to 9 g/dL or (2) a liberal strategy (LS, n=406) in which transfusions occurred when the hemoglobin was less than 10.0 g/dL, and then maintained at 10 to 12 g/dL.
Primary Outcome: Mortality at 30 d and severity of organ dysfunction.
Results: Mortality rates at 30 d were similar between groups. However, mortality rates were significantly lower with the RS among less acutely ill patients (8.7% and RS group and 16.1% in LS group; p=0.03) and among those <55 yr of age (5.7% RS and 12% LS, p=0.02), but did not differ in a subgroup with clinically significant cardiac disease.
Conclusion: A RS of red cell transfusion is at least as effective as, and possibly superior to, a LS transfusion in critically ill patients.

Liberal or Restrictive Transfusion in High-Risk Patients After Hip Surgery (FOCUS) NEJM 2011;365:2453-2462
Participants: 2,016 patients aged greater than 50 yr with a history of or risk factors for cardiovascular disease and hemoglobin (Hb) level below 10 g/dL after hip-fracture surgery.
Intervention: Patients were randomly assigned to a liberal transfusion strategy (a Hb threshold of 10 g/dL) or a restrictive transfusion strategy (anemia symptoms or at physician discretion for a Hb level less than 8 g/dL).
Primary Outcome: Mortality or inability to walk across a room without human assistance on a 60 day follow-up.
Results: Primary outcome rates were 35.2% in the liberal transfusion strategy group and 34.7% in the restrictive transfusion strategy group. Rates of complications were similar in the two groups.
Conclusion: A liberal transfusion strategy did not reduce mortality rates or the inability to walk independently on 60 d follow-up compared to a restrictive transfusion strategy in elderly patients with high cardiovascular risk factors after hip surgery.
# Acute Blood Transfusion Reactions

## IMMUNE

### Acute Hemolytic Transfusion Reactions
- ABO incompatibility resulting in intravascular hemolysis secondary to complement activation, occurs immediately after transfusion
- most commonly due to incorrect patient identification
- risk per unit of blood is <1 in 40,000
- presentation: fever, chills, hypotension, back or flank pain, dyspnea, hemoglobinuria
- acute renal failure (<24 h) and DIC
- treatment
  - stop transfusion
  - notify blood bank and check for clerical error
  - maintain BP with vigorous IV fluids ± inotropes
  - maintain urine output with diuretics, crystalloids, dopamine

### Febrile Nonhemolytic Transfusion Reactions
- due to alloantibodies to WBC, platelets or other donor plasma antigens, and release of cytokines from blood product cells
- occurs within 0-6 h of transfusion
- risk per unit of blood is 1 in 100 (minor), 1 in 10,000 to 40,000 (severe)
- presents with fever ± rigors, facial flushing, headache, myalgia, hypotension
- treatment
  - rule out hemolytic reaction or infection
  - if temperature <38°C, continue with transfusion but decrease rate and give antipyretics
  - if temperature >38°C, stop transfusion, give antipyretics and anti-histamine

### Allergic Nonhemolytic Transfusion Reactions
- alloantibodies (IgE) to proteins in donor plasma result in mast cell activation and release of histamine
- occurs mainly in those with history of multiple transfusions or multiparous women
- risk per unit of blood is 1 in 100
- presents mainly as urticaria and occasionally with fever
- can present as anaphylactoid reaction with bronchospasm, laryngeal edema, and hypotension, but this occurs mainly in IgA deficient patients that have anti-IgA antibodies
- treatment
  - mild: slow transfusion rate and give diphenhydramine
  - moderate to severe: stop transfusion, give IV diphenhydramine, steroids, epinephrine, IV fluids, and bronchodilators

### Transfusion-Related Acute Lung Injury
- new-onset acute lung injury that occurs during transfusion or within 6 h of transfusion completion
- insidious, acute onset of pulmonary insufficiency
- profound hypoxemia (PaO\textsubscript{2}/FiO\textsubscript{2} <300 mmHg)
- bilateral pulmonary edema on CXR
- pulmonary artery wedge pressure <18 mmHg
- no clinical evidence of left atrial hypertension
- pathogenesis uncertain; perhaps due to binding of donor antibodies to WBC of recipient and release of mediators that increase capillary permeability in the lungs
- typically occurs 2-4 h post transfusion and resolves in 24-72 h
- risk per unit of blood is 1 in 10,000
- is currently the leading cause of transfusion-related morbidity and mortality
- treatment: supportive therapy (oxygen)
- inform blood bank; patient and donor testing will be arranged

## NONIMMUNE

### Transfusion-Associated Circulatory Overload
- due to impaired cardiac function and/or excessive rapid transfusion
- presentation: dyspnea, orthopnea, hypotension, tachycardia, crackles at base of lung, and increased venous pressure
- incidence: 1 in 700 and is becoming more common
- treatment: transfuse at lower rate, give diuretics and oxygen

### Bacterial Infection
- Gram positive: *S. aureus*, *S. epidermidis*, *Bacillus cereus*
- Gram negative: *Klebsiella*, *Serratia*, *Pseudomonas*, *Yersinia*
- overall risk is 1 in 100,000 for RBC and 1 in 10,000 for platelets
- never store blood >4 h after bag has left blood bank
- treatment: stop transfusion, blood cultures, IV antibiotics, fluids
**Hyperkalemia**  
- due to K⁺ release from stored RBC  
- risk increases with storage time and if blood is irradiated and risk decreases if given fresh blood  
- occurs in 5% of massively transfused patients  
- treatment: see Nephrology, NP13

**Citrate Toxicity**  
- occurs with massive transfusion in patients with liver disease – patients are unable to clear citrate from blood  
- citrate binds to Ca²⁺ and causes signs and symptoms of hypocalcemia  
- treatment: IV calcium gluconate (10 mL for every 2 units of blood)

**Dilutional Coagulopathy**  
- occurs with massive transfusion (>10 units)  
- pRBC contains no clotting factors, fibrinogen, cryoprecipitate, or platelets  
- treatment: FP, cryoprecipitate, and platelets

### Delayed Blood Transfusion Reactions

#### IMMUNE

**Delayed Hemolytic**  
- due to alloantibodies to minor antigens such as Rh, Kell, Duffy, and Kidd  
- level of antibody at time of transfusion is too low to cause hemolysis; later the level of antibody increases due to secondary stimulus and causes extravascular hemolysis  
- occurs 5-7 d after transfusion  
- presentation: anemia and mild jaundice  
- treatment: no specific treatment required; important to note for future transfusion  
- N.B. serologic transfusion reactions are the development of alloantibodies in the absence of frank hemolysis

**Transfusion-Associated Graft Versus Host Disease**  
- transfused T-lymphocytes recognize and react against “host” (recipient)  
- occurs 4-30 d following transfusion  
- most patients already have severely impaired immune systems (e.g. Hodgkin lymphoma or leukemia)  
- presentation: fever, diarrhea, liver function abnormalities, and pancytopenia  
- can be prevented by giving irradiated blood products

#### NONIMMUNE

**Iron Overload**  
- due to repeated transfusions over long period of time (e.g. β-thalassemia major)  
- can cause secondary hemochromatosis  
- treatment: iron chelators or phlebotomy if no longer requiring blood transfusion and not anemic

**Viral Infection Risk**  
- HBV 1 in 1.1 to 1.7 million  
- HCV 1 in 5 to 7 million  
- HIV 1 in 8 to 12 million  
- Human T-lymphotropic virus (HTLV) 1 in 1 to 1.3 million  
- other infections include EBV, CMV, WNV (West Nile virus)
Common Medications

Antiplatelet Therapy

- see Figure 11a, Platelet Activation Cascade, H26

![Mechanisms of action of antiplatelet therapy](image.png)

Figure 15. Mechanisms of action of antiplatelet therapy

Table 40. Antiplatelet Therapy

<table>
<thead>
<tr>
<th>Mechanism of Action</th>
<th>Dose/Route of Administration</th>
<th>Onset/Peak/Duration</th>
<th>Specific Side Effects</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin® (ASA)</td>
<td>Irreversibly acetylates COX, inhibiting TXA2 synthesis, thus inhibiting platelet aggregation</td>
<td>Single loading 200-300 mg PO, followed by dose of 75-100 mg PO daily</td>
<td>Onset: 5-30 min Peak: 0.25-3 h Duration: 3-6 h</td>
<td>GI ulcer/bleeding Tinnitus Bronchospasm Angioedema Reye's syndrome in pediatric patients</td>
</tr>
<tr>
<td>Aggrenox® (ASA + Dipyridamole)</td>
<td>Dipyridamole increases intracellular cAMP levels, which inhibits TXA2 synthesis, leading to decreased platelet aggregation</td>
<td>1 capsule PO bid</td>
<td>Peak: 75 min</td>
<td>H/A Dyspepsia N/V Abdominal pain Cardiac failure Hemorrhoids</td>
</tr>
<tr>
<td>Clopidogrel (Plavix®)</td>
<td>Irreversibility inhibit ADP binding to platelets, thus decreased platelet aggregation</td>
<td>75-300 mg PO daily</td>
<td>Onset: 2 h Peak: 1 h</td>
<td>URI Chest pain H/A Flu-like syndrome Depression UTI GI hemorrhage Pancytopenia May cause TTP</td>
</tr>
<tr>
<td>Prasugrel (Effient®)</td>
<td>Same as clopidogrel</td>
<td>5-10 mg PO daily</td>
<td>Onset: 30 min</td>
<td>Dizziness H/A Nervousness Blurry vision</td>
</tr>
</tbody>
</table>
### Table 40. Antiplatelet Therapy (continued)

<table>
<thead>
<tr>
<th>Medication</th>
<th>Mechanism of Action</th>
<th>Dose/Route of Administration</th>
<th>Onset/Peak/Duration</th>
<th>Specific Side Effects</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ticagrelor (<a href="#">Brilinta®</a>)</td>
<td>Reversibly inhibit ADP binding to platelets</td>
<td>90 mg PO daily</td>
<td>Onset: 1.5 h for prodrug, 2.5 h for active metabolite</td>
<td>Difficulty or labored breathing, Shortness of breath, Tightness in chest, Dizziness</td>
<td>Alternative to clopidogrel for prevention of cardiovascular events in high-risk patients, Higher potency compared to clopidogrel (higher bioavailability compared to normal heparin)</td>
</tr>
<tr>
<td>Glycoprotein IIb/IIIa Inhibitors (<a href="#">abciximab</a>, <a href="#">Integrilin® (epti)</a>)</td>
<td>Blocking GP IIb/IIIa receptor, inhibits fibrinogen and vWF binding, leading to decreased platelet aggregation</td>
<td>Variable IV</td>
<td>Variable</td>
<td>Hypotension, Back pain, N/V, Chest pain, Abdominal pain, Thrombocytopenia</td>
<td>Used most commonly in cardiac catheterization monitoring, For patients with renal failure (CrCl &lt;30 mL/min) can accumulate LMWH, therefore must adjust dose, Adverse reactions less common than UFH</td>
</tr>
</tbody>
</table>

### Anticoagulant Therapy

<table>
<thead>
<tr>
<th>Medication</th>
<th>Mechanism of Action</th>
<th>Dose/Route of Administration</th>
<th>Onset/Peak/Duration</th>
<th>Reversing Agent</th>
<th>Monitoring</th>
<th>Specific Side Effects</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heparin</td>
<td>Accelerates inhibitory activity of antithrombin</td>
<td>As per hospital nomogram</td>
<td>Onset: 20-60 min Peak: 2-4 h</td>
<td>Protamine sulfate</td>
<td>aPTT (intrinsic pathway), UFH (anti-Xa) levels</td>
<td>Hemorrhage, HIT, Increased liver enzymes</td>
<td>Pregnancy: safe (does not cross placenta)</td>
</tr>
<tr>
<td>Warfarin</td>
<td>Vitamin K antagonist: inhibits production of II, VII, IX, X, proteins C and S</td>
<td>Individualized dosing by monitoring PT/INR</td>
<td>Onset: 36-48 h Peak: 1.5-3 d</td>
<td>IV vitamin K</td>
<td>PT/INR maintain 2-3 (2.5-3.5 for mechanical valves)</td>
<td>Hemorrhage, Cholesteral embolism syndrome (intracranial hemorrhage)</td>
<td>Pregnancy: not used, can cross placenta (teratogenic)</td>
</tr>
<tr>
<td>LMWH (<a href="#">enoxaparin</a>, <a href="#">dalteparin</a>, <a href="#">tinzaparin</a>)</td>
<td>Inhibits FXa</td>
<td>Variable SC/W</td>
<td>Onset: 3-5 h Peak: 3-5 Duration: 12 h</td>
<td>Partial reversal with protamine sulfate</td>
<td>FXa in pediatrics, pregnancy and weight &gt;150 kg</td>
<td>Hemorrhage, Fever, Increased liver enzymes &lt;1% HIT</td>
<td>Increased bioavailability than heparin, Can accumulate in patients low CrCl (&lt;30 mL/min)</td>
</tr>
<tr>
<td>Fondaparinux</td>
<td>Indirect inhibitor of FXa (through antithrombin)</td>
<td>Variable SC daily</td>
<td>Onset: 2 h Peak: 2-3 h</td>
<td>Not reversible</td>
<td>None</td>
<td>Anemia, Fever, Nausea, Rash</td>
<td>Heparin analogue, Contraindicated in renal failure</td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>Direct FXa inhibitor</td>
<td>PO</td>
<td>Peak: 2-4 h</td>
<td>Not reversible</td>
<td>None</td>
<td>Syncope, GI hemorrhage</td>
<td>Indicated in treatment of acute VTE (non-cancer patients), secondary VTE prevention, thromboprophylaxis in orthopedic patients and stroke prophylaxis in non-valvular AFib; ensure CrCl &gt;30 mL/min</td>
</tr>
<tr>
<td>Apixaban</td>
<td>Direct FXa inhibitor</td>
<td>PO</td>
<td>Onset: 3-4h Peak: 3-4 h</td>
<td>Not reversible</td>
<td>None</td>
<td>Hemorrhage, Anemia</td>
<td>Indicated for stroke prophylaxis in non-valvular AFib; idiopathic VTE; ensure CrCl &gt;30</td>
</tr>
<tr>
<td>Argatroban</td>
<td>Direct thrombin inhibitor</td>
<td>Variable IV</td>
<td>Onset: 5-10 min Duration: 20-40 min</td>
<td>Not reversible</td>
<td>aPTT</td>
<td>Dyspnea, Hypotension, Fever</td>
<td>Indicated for HIT and heparin resistance in the presence renal failure</td>
</tr>
<tr>
<td>Dabigatran</td>
<td>Direct thrombin inhibitor</td>
<td>150 mg PO bid</td>
<td>Peak: 1 h</td>
<td>Not reversible</td>
<td>None (prolonged aPTT can suggest residual drug on board)</td>
<td>GI upset, Dyspepsia</td>
<td>Only indicated for AFib in Canada, Contraindicated in renal failure, cancer patients, mechanical heart valves</td>
</tr>
</tbody>
</table>

### Adverse Reactions of Heparin
- Hemorrhage: depends on dose, age, and concomitant use of antiplatelet agents or thrombolytics
- Heparin-induced thrombocytopenia: associated with venous or arterial thrombosis (see Table 22, H29)
- Osteoporosis: with long-term use

### Low Molecular Weight Heparin ([enoxaparin](#), [dalteparin](#), [tinzaparin](#))
- Increased bioavailability compared to normal heparin
- Increased duration of action
- SC route of administration
- Do not need to monitor aPTT
- Adverse reactions less common than UFH
- Patients with renal failure (CrCl <30 mL/min) can accumulate LMWH, therefore must adjust dose
- Only partially reversible with protamine sulfate
- HIT is less common
Table 42. Recommended Therapeutic INR Ranges of Common Indications for Oral Anticoagulant Therapy

<table>
<thead>
<tr>
<th>Indication</th>
<th>INR Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prophylaxis of venous thrombosis (high-risk surgery)</td>
<td>2.0-3.0</td>
</tr>
<tr>
<td>Treatment of venous thrombosis</td>
<td></td>
</tr>
<tr>
<td>Most cases of thrombosis with antiphospholipid antibody syndrome</td>
<td></td>
</tr>
<tr>
<td>Treatment of pulmonary embolism</td>
<td></td>
</tr>
<tr>
<td>Prevention of systemic embolism</td>
<td></td>
</tr>
<tr>
<td>Tissue heart valves</td>
<td></td>
</tr>
<tr>
<td>AMI (to prevent systemic embolism)</td>
<td></td>
</tr>
<tr>
<td>Valvular heart disease</td>
<td></td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td></td>
</tr>
<tr>
<td>Bileaflet mechanical valve in aortic position</td>
<td></td>
</tr>
<tr>
<td>Mechanical prosthetic mitral valves (high risk)</td>
<td>2.5-3.5</td>
</tr>
</tbody>
</table>

AMI = acute myocardial infarction

Table 43. Recommended Management of a Supratherapeutic INR

<table>
<thead>
<tr>
<th>INR</th>
<th>Bleeding Present</th>
<th>Recommended Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; Therapeutic to 4.5 No</td>
<td>Lower warfarin dose OR Omit a dose and resume warfarin at a lower dose when INR is in therapeutic range OR No dose reduction needed if INR is minimally prolonged</td>
<td></td>
</tr>
<tr>
<td>&gt; 4.5 to 10.0 No</td>
<td>Omit the next 1 to 2 doses of warfarin, monitor INR more frequently and resume treatment at a lower dose when INR is in therapeutic range OR Omit a dose and administer 1 to 2.5 mg oral vit K in patients with increased risk of bleeding</td>
<td></td>
</tr>
<tr>
<td>&gt; 10.0 No</td>
<td>Hold warfarin and administer 5 to 10 mg oral vit K; monitor INR more frequently and administer more vit K as needed; resume warfarin at a lower dose when INR is in therapeutic range</td>
<td></td>
</tr>
</tbody>
</table>

Any | Serious or life threatening | Hold warfarin and administer 10 mg vit K by slow IV infusion; supplement with four-factor prothrombin complex concentrate; monitor and repeat as needed |

Adapted from: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(suppl):e152S

Chemotherapeutic and Biologic Agents Used in Oncology

Table 44. Selected Chemotherapeutic and Biologic Agents

<table>
<thead>
<tr>
<th>Class</th>
<th>Example</th>
<th>Mechanism of Action or Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alkylating Agent</td>
<td>• chlorambucil, cyclophosphamide, melphalan (nitrogen mustards)</td>
<td>Damage DNA via alkylation of base pairs Leads to cross-linking of bases, abnormal base-pairing, DNA breakage</td>
</tr>
<tr>
<td></td>
<td>• carboplatin, cisplatin</td>
<td>Leads to cross-linking of bases, abnormal base-pairing, DNA breakage</td>
</tr>
<tr>
<td></td>
<td>• dacarbazine, procarbazine</td>
<td>Damage DNA via alkylation of base pairs</td>
</tr>
<tr>
<td></td>
<td>• busulfan</td>
<td>Damage DNA via alkylation of base pairs</td>
</tr>
<tr>
<td></td>
<td>• bendamustine</td>
<td>Damage DNA via alkylation of base pairs</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td>• methotrexate (folic acid antagonist)</td>
<td>Inhibit DNA synthesis</td>
</tr>
<tr>
<td></td>
<td>• 6-mercaptopurine, fludarabine (purine antagonist)</td>
<td>Inhibit DNA synthesis</td>
</tr>
<tr>
<td></td>
<td>• 5-fluorouracil (5-FU) (pyrimidine antagonist)</td>
<td>Inhibit DNA synthesis</td>
</tr>
<tr>
<td></td>
<td>• hydroxyurea</td>
<td>Inhibit DNA synthesis</td>
</tr>
<tr>
<td></td>
<td>• cytarabine</td>
<td>Inhibit DNA synthesis</td>
</tr>
<tr>
<td>Antibiotics</td>
<td>• Adriamycin (anthracycline)</td>
<td>Interferes with DNA and RNA synthesis</td>
</tr>
<tr>
<td></td>
<td>• bleomycin</td>
<td>Interferes with DNA and RNA synthesis</td>
</tr>
<tr>
<td></td>
<td>• mitomycin C</td>
<td>Interferes with DNA and RNA synthesis</td>
</tr>
<tr>
<td></td>
<td>• daunorubicin</td>
<td>Interferes with DNA and RNA synthesis</td>
</tr>
<tr>
<td>Taxanes</td>
<td>• Paclitaxel</td>
<td>Stabilize microtubules against breakdown once cell division complete</td>
</tr>
<tr>
<td></td>
<td>• Docetaxel</td>
<td>Stabilize microtubules against breakdown once cell division complete</td>
</tr>
<tr>
<td>Vinca-alkaloids</td>
<td>• Vinblastine</td>
<td>Inhibit microtubule assembly (mitotic spindles, blocking cell division</td>
</tr>
<tr>
<td></td>
<td>• vincristine</td>
<td>Inhibit microtubule assembly (mitotic spindles, blocking cell division</td>
</tr>
<tr>
<td></td>
<td>• vinorelbine</td>
<td>Inhibit microtubule assembly (mitotic spindles, blocking cell division</td>
</tr>
<tr>
<td>Topoisomerase Inhibitors</td>
<td>• irinotecan, topotecan (topo I)</td>
<td>Interferes with DNA unwinding necessary for normal replication and transcription</td>
</tr>
<tr>
<td></td>
<td>• etoposide (topo II)</td>
<td>Interferes with DNA unwinding necessary for normal replication and transcription</td>
</tr>
<tr>
<td>Steroids</td>
<td>• Prednisone</td>
<td>Immunosuppression</td>
</tr>
<tr>
<td></td>
<td>• dexamethasone</td>
<td>Immunosuppression</td>
</tr>
<tr>
<td>Purine Analogue</td>
<td>• Fludarabine</td>
<td>Interferes with DNA synthesis</td>
</tr>
<tr>
<td></td>
<td>• cladribine</td>
<td>Interferes with DNA synthesis</td>
</tr>
<tr>
<td>Monoclonal Antibodies</td>
<td>• trastuzumab (Herceptin®)</td>
<td>HER2 antagonist</td>
</tr>
<tr>
<td></td>
<td>• bevacizumab (Avastin®)</td>
<td>VEGF antagonist</td>
</tr>
<tr>
<td></td>
<td>• rituximab ( Rituxan®), obinutuzumab (Gazyva®), cetuximab (Erbitux®)</td>
<td>CD20 antagonist</td>
</tr>
<tr>
<td></td>
<td>• cetuximab (Erbitux®)</td>
<td>EGFR antagonist</td>
</tr>
<tr>
<td>Small Molecule Inhibitors</td>
<td>• Imatinib mesylate (Gleevec®)</td>
<td>Bcr-Abi inhibitor</td>
</tr>
<tr>
<td></td>
<td>• Dasatinib</td>
<td>Bcr-Abi inhibitor</td>
</tr>
<tr>
<td></td>
<td>• nilotinib</td>
<td>Bcr-Abi inhibitor</td>
</tr>
<tr>
<td></td>
<td>• erlotinib (Tarceva®)</td>
<td>EGFR antagonist</td>
</tr>
<tr>
<td></td>
<td>• gefitinib (Iressa®)</td>
<td>EGFR antagonist</td>
</tr>
<tr>
<td></td>
<td>• Bortezomib (Velcade®)</td>
<td>26S proteasome inhibitor</td>
</tr>
<tr>
<td></td>
<td>• Sorafenib (Sutent®)</td>
<td>VEGFR, PDKFR antagonist</td>
</tr>
<tr>
<td></td>
<td>• Ibrutinib (Imbruvica®)</td>
<td>BTK inhibitor</td>
</tr>
<tr>
<td></td>
<td>• Idealix (Cyvelity®)</td>
<td>P12K inhibitor</td>
</tr>
<tr>
<td></td>
<td>• Nilotinib (Pfizer)</td>
<td>JAK2 inhibitor</td>
</tr>
</tbody>
</table>

Factor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Cerebral or Systemic Embolism in Patients with Atrial Fibrillation

**Purpose:** To review the evidence comparing factor Xa inhibitors with vitamin K antagonists for prevention of embolic events in patients with atrial fibrillation.

**Study:** Systematic review search 1950-2013, inclusive. Results included 10 RCTs, 42,084 patients, follow up for 12 wk to 1.9 yr.

**Outcome:** Stroke (hemorrhagic or ischemic) and non-CNS embolic event

**Results:** Factor Xa inhibitor treatment resulted in significantly fewer embolic events than dose adjusted warfarin treatment (OR 0.81; CI 0.72 to 0.91). There was no significant difference in rate of major bleeds between factor Xa inhibitors and warfarin treatment. Furthermore, factor Xa inhibitors resulted in significantly fewer intracranial bleeds and lower all-cause mortality.

**Conclusions:** Use of factor Xa inhibitor for anti-coagulation in patients with atrial fibrillation offered better protection against embolic events than warfarin. Factor Xa inhibitors also had equal or lower rates of adverse events.

Oral Direct Thrombin Inhibitors or Oral Factor Xa Inhibitors for the Treatment of Deep Vein Thrombosis

**Cochrane OB Sys Rev 2015;6: CD010956**

**Purpose:** To assess whether DTIs or factor Xa inhibitors are effective treatment for DVT.

**Study:** Systematic review search 1950-2013, inclusive. Results included 11 RCTs, 27,945 patients, comparing DTIs or factor Xa inhibitors to standard treatment (heparin, warfarin, and similar)

**Outcome:** Recurrent DVT or PE

**Results:** Separate meta-analyses of DTIs and factor Xa inhibitors showed that each was comparable to standard treatment in terms of DVT recurrence rates. Rates of fatal or non-fatal PE, and all-cause mortality were also not significantly different. Additionally, factor Xa inhibitors had lower rates of bleeding complications than standard treatment (OR 0.57; CI 0.43 to 0.76).

**Conclusions:** New oral treatment options, including direct thrombin inhibitors and factor Xa inhibitors represent reasonable and safe alternatives for acute.
## Landmark Hematology Trials

### Hematologic Malignancies and Related Disorders

<table>
<thead>
<tr>
<th>Trial</th>
<th>Reference</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hodgkin Lymphoma: ABVD vs. MOPP</td>
<td>NEJM 1992; 327:1478-84</td>
<td>In Hodgkin lymphoma, ABVD regimen has equal failure-free and overall survival to MOPP + ABVD, but less myelotoxicity; ABVD is standard chemotherapy for Hodgkin lymphoma</td>
</tr>
<tr>
<td>CHOP</td>
<td>NEJM 1993; 328:1002-6</td>
<td>In NHL, CHOP has lowest incidence of fatal toxic reactions and shows no significant difference from 3 other regimens in response or disease-free/overall survival; CHOP is the standard for advanced NHL</td>
</tr>
<tr>
<td>R-CHOP</td>
<td>NEJM 2002; 346:235-42</td>
<td>Addition of rituximab to CHOP increases complete response rate and prolongs event-free survival and overall survival in elderly with DLBCL</td>
</tr>
<tr>
<td>CML: Imatinib vs. IFN + Cytarabine</td>
<td>NEJM 2003; 348:994-1004</td>
<td>In patients with chronic-phase CML, imatinib was more effective than IFNα + cytarabine in inducing cytogenetic response and freedom from progression to accelerated phase/blast crisis</td>
</tr>
<tr>
<td>AZA-001</td>
<td>Lancet Oncol 2009; 10:223-32</td>
<td>Azacitidine increases overall survival in higher-risk myelodysplastic syndrome than conventional care</td>
</tr>
<tr>
<td>CLL8</td>
<td>Lancet 2010; 376:1164-74</td>
<td>Rituximab plus fludarabine and cyclophosphamide (FCR) improves progression-free and overall survival compared with fludarabine and cyclophosphamide alone (FC) in the treatment of CLL</td>
</tr>
<tr>
<td>VISTA</td>
<td>JCO 2010; 28:2259-66</td>
<td>Bortezomib plus melphalan and prednisone (MPV) is superior to melphalan and prednisone (MP) in overall survival of non-transplant-eligible multiple myeloma patients</td>
</tr>
<tr>
<td>MiN1 Group</td>
<td>Lancet 2011; 12:1013-1022</td>
<td>Rituximab added to CHOP-like chemotherapy improved long-term outcomes for young patients with good-prognosis DLBCL</td>
</tr>
<tr>
<td>StIL</td>
<td>Lancet 2013; 381(9873):1203-10</td>
<td>Bendamustine plus rituximab is superior to R-CHOP in terms of progression-free survival and fewer toxic effects in patients with previously untreated indolent lymphoma</td>
</tr>
<tr>
<td>Ibrutinib vs. Ofatumumab in previously treated CLL</td>
<td>NEJM 2014; 371:213-223</td>
<td>Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL</td>
</tr>
</tbody>
</table>

### Thrombosis

<table>
<thead>
<tr>
<th>Trial</th>
<th>Reference</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL01</td>
<td>NEJM 2003; 349:146-53</td>
<td>In patients with cancer and acute venous thromboembolism, LWMH was more effective than warfarin in reducing the risk of recurrent thromboembolism without increasing the risk of bleeding</td>
</tr>
<tr>
<td>PT1</td>
<td>NEJM 2005; 353:85-6</td>
<td>Hydroxyurea plus low-dose ASA is superior to anagrelide plus low-dose ASA for patients with essential thrombocythemia at high risk for vascular events</td>
</tr>
<tr>
<td>ESPRIT</td>
<td>Lancet 2006; 367:1665-73</td>
<td>ASA plus dipiridamole is recommended over ASA alone as antithrombotic therapy after cerebral ischemia of arterial origin</td>
</tr>
<tr>
<td>Dagabatran vs. Warfarin in VTE</td>
<td>NEJM 2009; 361:2342-52</td>
<td>In the treatment of venous thromboembolism, dabigatran is as effective as warfarin and also has a similar safety profile; note: many problems in the trial, making it less pivotal in having drug approval</td>
</tr>
<tr>
<td>EINSTEIN-PE</td>
<td>NEJM 2012; 366:1287-1297</td>
<td>Among patients with acute PE, rivaroxaban is noninferior to warfarin in preventing recurrent VTE, and is associated with similar bleeding rates</td>
</tr>
<tr>
<td>AMPLIFY</td>
<td>NEJM 2013; 369:799-808</td>
<td>In patients with VTE who have completed 6-12 months of anticoagulation, long-term apixaban treatment reduces recurrent VTE or all-cause mortality without increasing rates of major bleeding.</td>
</tr>
<tr>
<td>RE-VERSE AD</td>
<td>NEJM 2015; 373:511-520</td>
<td>Idarucizumab for dabigatran reversal</td>
</tr>
</tbody>
</table>

### Blood Products and Transfusion

<table>
<thead>
<tr>
<th>Trial</th>
<th>Reference</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platelet Transfusion Threshold</td>
<td>NEJM 1997; 337:1870-5</td>
<td>The risk of major bleeding in patients with AML undergoing induction chemotherapy was similar whether the platelet-transfusion threshold was set at 20 or 10; use of the lower threshold reduced platelet usage by 21.5%</td>
</tr>
<tr>
<td>TRICC BP</td>
<td>NEJM 1999; 340:409-17</td>
<td>A restrictive strategy of red-cell transfusion (when Hb &lt;70) is at least as effective as and possibly superior to a liberal transfusion strategy (when Hb &lt;100) in ICU patients; one possible exception is patients with an acute MI or unstable angina</td>
</tr>
<tr>
<td>Dose of Platelet Transfusion</td>
<td>NEJM 2010; 362:600-13</td>
<td>Low dose prophylactic platelet transfusion decreases total number of platelets transfused but increases number of transfusions but not incidence of bleeding in patients with hypoproliferative thrombocytopenia</td>
</tr>
<tr>
<td>Transfusion in High-Risk Patients after Hip Surgery</td>
<td>NEJM 2011; 365:2453-2462</td>
<td>A liberal transfusion strategy (Hb &lt;100), as compared with a restrictive strategy (anemia symptoms or at physician discretion for Hb &lt;80), did not reduce rates of death or inability to walk independently on 60-day follow-up or reduce in-hospital morbidity in elderly patients at high cardiovascular risk</td>
</tr>
<tr>
<td>Therapeutic Platelet Transfusion</td>
<td>Lancet 2012; 380:1309-16</td>
<td>Therapeutic platelet transfusions (when bleeding occurs) may be used if severe bleeding can be identified early in autologous stem-cell transplant patients; prophylactic transfusion (when platelets &lt;10) should remain standard of care in AML patients</td>
</tr>
<tr>
<td>Transfusion Strategies for Acute Upper GI Bleeding</td>
<td>NEJM 2013; 368:11-21</td>
<td>As compared with a liberal transfusion strategy (Hb &lt;90), a restrictive strategy (Hb &lt;70) significantly improved outcomes in patients with acute upper gastrointestinal bleeding</td>
</tr>
</tbody>
</table>

### Other

<table>
<thead>
<tr>
<th>Trial</th>
<th>Reference</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSH</td>
<td>NEJM 1995; 332:1317-22</td>
<td>Hydroxyurea is effective in reduction of complications and clinical manifestations of sickle cell disease</td>
</tr>
<tr>
<td>ITP: Dexamethasone</td>
<td>NEJM 2003; 349:831-6</td>
<td>A four-day course of high-dose dexamethasone is effective initial therapy for adults with immune thrombocytopenic purpura</td>
</tr>
<tr>
<td>CRASH-2</td>
<td>Health Technol Assess 2013; 17(10):1-79</td>
<td>Early administration of TXA safely reduced the risk of death in bleeding trauma patients and is highly cost-effective. Treatment beyond 3 hours of injury is unlikely to be effective</td>
</tr>
</tbody>
</table>
Acronyms .......................................................... 2
Principles of Microbiology ................................. 2
Bacteriology
Virology
Mycology
Parasitology
Transmission of Infectious Diseases
Nosocomial Infections ................................. 6
Respiratory Infections ................................. 7
Pneumonia
Influenza
Skin and Soft Tissue Infections .............. 10
Cellulitis
Necrotizing Fasciitis ................................. 10
Gastrointestinal Infections ....................... 11
Acute Diarrhea
Traveller’s Diarrhea ................................. 13
Chronic Diarrhea ............................................. G16
Peptic Ulcer Disease (H. pylori) .............. G11
Bone and Joint Infections ........................... 14
Septic Arthritis
Diabetic Foot Infections
Osteomyelitis
Cardiac Infections ................................. 16
Infective Endocarditis
CNS Infections ................................. 18
Meningitis
Encephalitis
Generalized Tetanus
Rabies
Systemic Infections ................................. 21
Sepsis and Septic Shock
Leprosy (Hansen’s Disease)
Lyme Disease
Toxic Shock Syndrome
Cat Scratch Disease
Rocky Mountain Spotted Fever
West Nile Virus
Syphilis
Tuberculosis ................................................. 26
HIV and AIDS ............................................. 27
Epidemiology
Definition and Pathophysiology
Modes of Transmission
Natural History
Management of the HIV-Positive Patient
Antiretroviral Treatment
Prevention of HIV Infection
Types of Testing
HIV Pre- and Post-Test Counselling
Fungal Infections ............................................. 33
Skin and Subcutaneous Infections
Superficial Fungal Infections
Dermatophytes
Subcutaneous Fungal Infection
Endemic Mycoses
Opportunistic Fungi
Pneumocystis jiroveci (formerly P. carinii)
Pneumonia: PJP or PCP
Cryptococcus spp.
Candida albicans
Aspergillus spp.
Parasitic Infections ............................................. 36
Protozoa – Intestinal/Genitourinal Infections
Entamoeba histolytica (Amoebas)
Giardia lamblia
Trichomonas vaginalis
Cryptosporidium spp.
Blood and Tissue Infections ....................... 38
Plasmodium spp. (Malaria)
Trypanosoma cruzi
Toxoplasma gondii
Helminths
Roundworms – Nematodes
Flatworms
Cestodes/Trematodes
Trematodes/Flukes
Schistosoma spp.
Ectoparasites
Travel Medicine ............................................. 42
Fever in the Returned Traveller
Fever of Unknown Origin ......................... 44
Infections in the Immunocompromised Host 45
Febrile Neutropenia
Infections in Solid Organ Transplant Recipients
Immune Reconstitution Syndrome
A Simplified Look at Antibiotics .................. 47
Antimicrobials ............................................. 48
Antibiotics
Antivirals .................................................... 53
Antifungals .................................................. 53
Antiparasitics .............................................. 55
Quick Reference: Common Infections and Their Antibiotic Management ........................ FM49
References ................................................. 56
**Acronyms**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFB</td>
<td>acid-fast bacilli</td>
<td>GBS</td>
<td>group B Streptococcus</td>
</tr>
<tr>
<td>AIDS</td>
<td>acquired immune deficiency syndrome</td>
<td>GC</td>
<td>gonococcus</td>
</tr>
<tr>
<td>ANC</td>
<td>absolute neutrophil count</td>
<td>GNB</td>
<td>Gram negative bacilli</td>
</tr>
<tr>
<td>ADOM</td>
<td>acute otitis media</td>
<td>GP</td>
<td>Gram positive</td>
</tr>
<tr>
<td>ARV</td>
<td>anti-retroviral</td>
<td>H. flu</td>
<td>Haemophilus influenzae</td>
</tr>
<tr>
<td>ART</td>
<td>anti-retroviral therapy</td>
<td>HAART</td>
<td>highly active anti-retroviral treatment</td>
</tr>
<tr>
<td>BAL</td>
<td>bronchoalveolar lavage</td>
<td>HAV</td>
<td>hepatitis A virus</td>
</tr>
<tr>
<td>BCG</td>
<td>Bacille Calmette-Guérin</td>
<td>HBC</td>
<td>HBV core antigen</td>
</tr>
<tr>
<td>CNS</td>
<td>culture and sensitivity</td>
<td>HBVAg</td>
<td>HBV envelope antigen</td>
</tr>
<tr>
<td>CFU</td>
<td>colony forming units</td>
<td>HBsAg</td>
<td>HBV surface antigen</td>
</tr>
<tr>
<td>CMV</td>
<td>cytomegalovirus</td>
<td>HCV</td>
<td>hepatitis C virus</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
<td>HCV-A</td>
<td>hepatitis C virus</td>
</tr>
<tr>
<td>CSF</td>
<td>cerebrospinal fluid</td>
<td>HDV</td>
<td>hepatitis D virus</td>
</tr>
<tr>
<td>DEET</td>
<td>N,N-Diethyl-meta-toluamide</td>
<td>HEV</td>
<td>hepatitis E virus</td>
</tr>
<tr>
<td>DM</td>
<td>diabetes mellitus</td>
<td>HIV</td>
<td>human herpes virus</td>
</tr>
<tr>
<td>DVT</td>
<td>deep vein thrombosis</td>
<td>HIB</td>
<td>Haemophilus influenzae b</td>
</tr>
<tr>
<td>EBV</td>
<td>Epstein-Barr virus</td>
<td>HIV</td>
<td>human immunodeficiency virus</td>
</tr>
<tr>
<td>EHEC</td>
<td>enterohemorrhagic E. coli</td>
<td>HEP</td>
<td>hepatitis E virus</td>
</tr>
<tr>
<td>EIEC</td>
<td>enteroinvasive E. coli</td>
<td>HRF</td>
<td>human rabies immunoglobulin</td>
</tr>
<tr>
<td>EPEC</td>
<td>enteropathogenic E. coli</td>
<td>HSV</td>
<td>herpes simplex virus</td>
</tr>
<tr>
<td>FDP</td>
<td>fibrinogen degradation products</td>
<td>HUS</td>
<td>hemolytic uremic syndrome</td>
</tr>
<tr>
<td>GAS</td>
<td>group A Streptococcus</td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>GAS</td>
<td>group A Streptococcus</td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>Genital tract</td>
<td></td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>Genital tract</td>
<td></td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>Genital tract</td>
<td></td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>Genital tract</td>
<td></td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>Genital tract</td>
<td></td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>Genital tract</td>
<td></td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>Genital tract</td>
<td></td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>Genital tract</td>
<td></td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>Genital tract</td>
<td></td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>Genital tract</td>
<td></td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>Genital tract</td>
<td></td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>Genital tract</td>
<td></td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>Genital tract</td>
<td></td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>Genital tract</td>
<td></td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>Genital tract</td>
<td></td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>Genital tract</td>
<td></td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>Genital tract</td>
<td></td>
<td>ID2</td>
<td>Infectious Diseases</td>
</tr>
</tbody>
</table>

**Principles of Microbiology**

**Bacteriology**

- **Bacteria Basics**
  - bacteria are prokaryotic cells that divide asexually by binary fission
  - Gram stain divides most bacteria into two groups based on their cell wall
  - Gram positive (GP): thick, rigid layer of peptidoglycan
  - Gram negative (GN): thin peptidoglycan layer + thicker outer membrane composed of lipoproteins and lipopolysaccharides
  - clinical significance: GN thick outer membrane makes it resistant to penicillin's mechanism of action
  - acid-fast bacilli (AFB): high mycolic acid content in cell wall, ”acid fast” as washout phase with acid-alcohol
  - “atypical” bacteria: not seen on Gram stain and difficult to culture
    - obligate intracellular bacteria: e.g. *Chlamydia, Chlamydophila*
    - bacteria lacking a cell wall: e.g. *Mycoplasma*
    - spirochetes: e.g. *Treponema pallidum*
    - O2 can be either vital or detrimental to growth
      - obligate aerobes: require O2
      - obligate anaerobes: require environment without O2
      - facultative anaerobes: can survive in environments with or without O2

- **Mechanisms of Bacterial Disease**
  1. adherence to and colonization of skin or mucous membranes
  2. invasion or crossing epithelial barriers
  3. evasion of host defense system through inhibition of
    - phagocytic uptake via polysaccharide capsule (e.g. *S. pneumoniae, N. meningitidis, H. influenzae*) or surface proteins (e.g. *Staphylococcus, Streptococcus*)
  4. toxin production
    - exotoxins are secreted by living pathogenic bacteria and cause disease even if the bacteria is not present (e.g. *Clostridium*)
    - endotoxins are structural components of GN bacterial cell walls, and may be shed by live cells or released during cell lysis
  5. intracellular growth
    - obligate intracellular: *Rickettsia, Chlamydia, Chlamydophila*
    - facultative intracellular: *Salmonella, Neisseria, Brucella, Mycobacteria, Listeria, Legionella*
  6. biofilm
    - an extracellular polysaccharide network forming mesh around the bacteria (e.g. *S. epidermidis*) which can coat prosthetic devices such as IV catheters
Table 1. Common Bacteria

<table>
<thead>
<tr>
<th>Aerobes</th>
<th>Anaerobes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gram-Positive Bacteria</strong></td>
<td><strong>Gram-Negative Bacteria</strong></td>
</tr>
<tr>
<td>Cocci</td>
<td>Bacilli (rods)</td>
</tr>
<tr>
<td>Staphylococcus</td>
<td>Bacillus</td>
</tr>
<tr>
<td>S. aureus</td>
<td>B. anthracis</td>
</tr>
<tr>
<td>S. epidermidis</td>
<td>N. gonorrhoeae</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Moraxella</td>
</tr>
<tr>
<td>S. pneumoniae</td>
<td>M. catarrhalis</td>
</tr>
<tr>
<td>S. pyogenes (GAS)</td>
<td></td>
</tr>
<tr>
<td>S. agalactiae (GBS)</td>
<td></td>
</tr>
<tr>
<td>Enterococcus</td>
<td></td>
</tr>
<tr>
<td>E. faecalis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Acid Fast</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aerobes</th>
<th>Anaerobes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Not Seen on Gram Stain</strong></td>
<td><strong>Others</strong></td>
</tr>
<tr>
<td>Staphylococcus</td>
<td>Bacillus</td>
</tr>
<tr>
<td>S. aureus</td>
<td>Bacillus</td>
</tr>
<tr>
<td>S. epidermidis</td>
<td>N. gonorrhoeae</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>Moraxella</td>
</tr>
<tr>
<td>S. pneumoniae</td>
<td>M. catarrhalis</td>
</tr>
<tr>
<td>S. pyogenes (GAS)</td>
<td></td>
</tr>
<tr>
<td>S. agalactiae (GBS)</td>
<td></td>
</tr>
<tr>
<td>Enterococcus</td>
<td></td>
</tr>
<tr>
<td>E. faecalis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Commensal Flora

<table>
<thead>
<tr>
<th>Site</th>
<th>Organisms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin</td>
<td>Coagulase-negative staphylococci, Corynebacterium, Propionibacterium acnes, Bacillus, S. aureus</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>Viridans group streptococci, Haemophilus, Neisseria, anaerobes (Peptostreptococcus, Bacteroides, Veillonella, Fusobacterium, Actinomyces, Prevotella)</td>
</tr>
<tr>
<td>Small Bowel</td>
<td>E. coli, anaerobes (low numbers)</td>
</tr>
<tr>
<td>Colon</td>
<td>E. coli, Klebsiella, Enterobacter, Enterococcus, anaerobes (Bacteroides, Peptostreptococcus, Clostridium)</td>
</tr>
<tr>
<td>Vagina</td>
<td>Lactobacillus acidophilus, viridans group streptococci, coagulase-negative staphylococci, facultative Gram-negative bacilli, anaerobes</td>
</tr>
</tbody>
</table>

Figure 2. Laboratory identification of bacterial species
Virology

Viral Basics
- viruses are infectious particles consisting of RNA or DNA covered by a protein coat
  - infect cells and use host metabolic machinery to replicate
  - nucleic acid can be double stranded (ds) or single stranded (ss)
  - can be enveloped or naked
- virions are mature virus particles that can be released into the extracellular environment
- host susceptibility is governed by the host cell and virus surface proteins (viral tropism) and cellular immunity

Viral Disease Patterns
1. acute infections (e.g. adenovirus)
   - host cells are lysed in the process of virion release
   - some produce acute infections with late sequelae (e.g. measles virus subacute sclerosing panencephalitis)
2. chronic infections (>6 mo): (e.g. HBV, HIV)
   - host cell machinery is used to produce and chronically release virions
3. latent infections
   - viral genome remains latent in host cell nucleus
   - can reactivate (e.g. HSV, VZV)

Table 3. Common Viruses

<table>
<thead>
<tr>
<th>Nucleic Acid</th>
<th>Enveloped</th>
<th>Virus Family</th>
<th>Major Viruses</th>
<th>Medical Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>dsDNA</td>
<td>N</td>
<td>Adenoviridae</td>
<td>Adenovirus</td>
<td>URTI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Conjunctivitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Gastroenteritis</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>Papillomaviridae</td>
<td>HPV1, 4</td>
<td>Plantar warts</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HPV6,11</td>
<td>Genital warts</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HPV16,18, etc.</td>
<td>Cervical/anal dysplasia and cancer</td>
</tr>
<tr>
<td></td>
<td>Y</td>
<td>Herpesviridae</td>
<td>HHV1 = HSV1</td>
<td>Oral, ocular, and genital herpes; encephalitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HHV2 = HSV2</td>
<td>Genital, oral, and ocular herpes; encephalitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HHV3 = VZV</td>
<td>Chicken pox, shingles</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HHV4 = EBV</td>
<td>Mononucleosis, viral hepatitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HHV5 = CMV</td>
<td>Retinitis, pneumonitis, hepatitis, encephalitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HHV6*</td>
<td>Roseola</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HHV8 = KSHV</td>
<td>Kaposi’s sarcoma, multicentric Castleman’s disease, body cavity lymphoma</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>Polyomaviridae</td>
<td>JC virus</td>
<td>Progressive multifocal leukoencephalopathy</td>
</tr>
<tr>
<td></td>
<td>Y</td>
<td>Hepadnaviridae</td>
<td>Hepatitis B</td>
<td>Hepatitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Vanola</td>
<td>Smallpox</td>
</tr>
<tr>
<td>ssDNA</td>
<td>N</td>
<td>Parvoviridae</td>
<td>Parvovirus B19</td>
<td>Erythema infectosum (Fifth disease)</td>
</tr>
<tr>
<td>(+) ssRNA</td>
<td>N</td>
<td>Caliciviridae</td>
<td>Norwalk</td>
<td>Gastroenteritis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatitis E</td>
<td>Acute hepatitis</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>Picornaviridae</td>
<td>Poliovirus</td>
<td>Poliomyelitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Echovirus</td>
<td>URTIs, viral meningitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Rhinovirus</td>
<td>URTIs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Coxsackie virus</td>
<td>Hand-foot-and-mouth, viral meningitis, myocarditis</td>
</tr>
<tr>
<td></td>
<td>Y</td>
<td>Coronaviridae</td>
<td>Coronavirus</td>
<td>URTIs, SARS, MERS</td>
</tr>
<tr>
<td></td>
<td>Y</td>
<td>Flaviviridae</td>
<td>Yellow fever</td>
<td>Yellow fever</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dengue fever</td>
<td>Dengue fever</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatitis C</td>
<td>Hepatitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>West Nile</td>
<td>Encephalitis, flaccid paralysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Zika</td>
<td>Zika fever</td>
</tr>
<tr>
<td></td>
<td>Y</td>
<td>Togaviridae</td>
<td>Rubella</td>
<td>Rubella (German measles)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chikungunya</td>
<td>Chikungunya</td>
</tr>
<tr>
<td>(+) ssRNA-RT</td>
<td>Y</td>
<td>Arenaviridae</td>
<td>Lassa</td>
<td>Lassa fever</td>
</tr>
<tr>
<td>(+) ssRNA</td>
<td>Y</td>
<td>Filoviridae</td>
<td>Ebola, Marburg</td>
<td>Hemorrhagic fever</td>
</tr>
<tr>
<td>(+) ssRNA</td>
<td>Y</td>
<td>Orthomyxovirida</td>
<td>Influenza A, B, C</td>
<td>Influenza</td>
</tr>
<tr>
<td>(+) ssRNA</td>
<td>Y</td>
<td>Paramyxovirida</td>
<td>Measles</td>
<td>Measles</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mumps</td>
<td>Mumps</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Parainfluenza</td>
<td>URTIs, croup, bronchiolitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>RSV</td>
<td>Bronchiolitis, pneumonia</td>
</tr>
<tr>
<td>(+) ssRNA</td>
<td>Y</td>
<td>Rhadoviridae</td>
<td>Rabies</td>
<td>Rabies</td>
</tr>
</tbody>
</table>

Table Note: ___virus = family, ___ = genus, # = species (e.g. Retroviridae HIV-2)

*Rosedovirus, Herpes lymphotropic virus

Figure 3. Virus morphology
### Mycology

#### Fungal Basics
- fungi are eukaryotic organisms, they can have the following morphologies
  1. yeast (unicellular)
  2. moulds (also known as filamentous fungi) (multicellular with hyphae)
  3. dimorphic fungi (found as mould at room temperature but grow as yeast-like forms at body temperature)

#### Table 4. Membrane and Cell Wall Compositions

<table>
<thead>
<tr>
<th></th>
<th>Membrane Sterol</th>
<th>Cell Wall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacteria</td>
<td>–</td>
<td>Peptidoglycan</td>
</tr>
<tr>
<td>Human Cell</td>
<td>Cholesterol</td>
<td>–</td>
</tr>
<tr>
<td>Fungi</td>
<td>Ergosterol</td>
<td>Chitin (complex glycopolysaccharide)</td>
</tr>
</tbody>
</table>

### Parasitology

#### Parasite Basics
- parasite: an organism that lives in or on another organism (host) and damages the host in the process
- parasites with complex life cycles require more than one host to reproduce
  - reservoir host: maintains a parasite and may be the source for human infection
  - intermediate host: maintains the asexual stage of a parasite or allows development of the parasite to proceed through the larval stages
  - definitive host: allows the parasite to develop to the adult stage where reproduction occurs
- 2 major groups of parasites: protozoa and helminths
- see Tables 26 and 27 for examples of clinically important parasites

#### Table 5. Differences Between Protozoa and Helminths

<table>
<thead>
<tr>
<th>Protozoa</th>
<th>Helminths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unicellular</td>
<td>Multicellular</td>
</tr>
<tr>
<td>Motile trophozoite</td>
<td>Adult egg larva</td>
</tr>
<tr>
<td>inactive cyst</td>
<td></td>
</tr>
<tr>
<td>Multiplication</td>
<td>No multiplication in human host</td>
</tr>
<tr>
<td>Eosinophilia unusual</td>
<td>Eosinophilia (proportional to extent of tissue invasion)*</td>
</tr>
<tr>
<td>Indefinite life span</td>
<td>Definite life span</td>
</tr>
</tbody>
</table>

*Adult Ascaris (roundworm) does not cause eosinophilia; migratory larval stages of Ascaris, however, cause high-grade eosinophilia

#### Characteristics of Parasitic Disease
- symptoms are usually proportional to parasite burden
- tissue damage is due to the parasite and host immune response
- chronic infections may occur with or without overt disease
- immunocompromised hosts are more susceptible to manifestations of infection, reactivation of latent infections, and more severe disease
- eosinophilia may suggest a parasitic infection

#### Mechanisms of Parasitic Disease
1. mechanical obstruction (e.g. ascariasis, clonorchiasis)
2. competition with host for resources (e.g. anemia in hookworm disease, vitamin B12 deficiency in diphyllobothriasis)
3. cytotoxicity leading to abscesses and ulcers (e.g. amoebiasis, leishmaniasis)
4. inflammatory
  - acute hypersensitivity (e.g. pneumonitis in Loeffler's syndrome)
  - delayed hypersensitivity (e.g. egg granulomas in schistosomiasis)
  - cytokine-mediated (systemic illness of malaria, disseminated strongyloidiasis)
5. immune-mediated injury
  - autoimmune (e.g. myocarditis of Chagas disease, tissue destruction of mucocutaneous leishmaniasis)
  - immune complex (e.g. nephritis of malaria, schistosomiasis)
Transmission of Infectious Diseases

Table 6. Mechanism of Transmission

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Mode of Transmission</th>
<th>Examples</th>
<th>Preventative Measure</th>
</tr>
</thead>
</table>
| Contact      | Direct physical contact, or indirect contact with a fomite            | Skin-to-skin (MRSA)  
Sexual (N. gonorrhoeae, C. trachomatis, HSV, HIV)  
Blood-borne (HIV, HBV, HCV) | For patients in health care facilities: Contact precautions  
Barrier precautions  
Safe needlestick/sharp practices |
| Contact/Droplet | Respiratory droplets (>5 µm) can be projected short distances (≤2 m) and deposit on mucosal surfaces of the recipient (e.g. by coughing, sneezing, or talking); transmission can also occur by direct physical contact of respiratory fluids or indirect contact with a fomite contaminated with respiratory fluids | Influenza, mumps  
N. meningitidis, Bordetella pertussis | For patients in health care facilities: Contact/droplet precautions |
| Airborne     | Airborne droplet nuclei (<5 µm) remain infectious over time and distance | M. tuberculosis, VZV, measles | For patients in health care facilities: Airborne precautions |
| Food/Waterborne | Ingestion of contaminated food or water | V. cholerae, Salmonella, HAV, HEV | Prophylactic vaccinations where available  
Ensure clean food/water supply  
For patients in health care facilities: Contact precautions used for admitted patients with fecal incontinence when stool is unable to be contained in diapers |
| Zoonotic     | Disease transmission from animals to humans either directly or via an insect vector | Animals (rabies, Q fever)  
Arthropods (malaria, Lyme disease) | Prophylactic medications, vaccinations  
Protective clothing, insect repellent, mosquito nets, tick inspection |
| Vertical     | Spread of disease from parent to offspring | Congenital syndromes (TORCH infections)  
Perinatal (HIV, HBV, GBS) | Prenatal screening  
Prophylactic treatment |

Nosocomial Infections

- **nosocomial infections**: infections acquired >48 h after admission to a healthcare facility or within 30 d from discharge
- **risk factors**: prolonged hospital stay, antibiotic use, surgery, hemodialysis, intensive care, colonization with a resistant organism, immunodeficiency
- **patients with nosocomial infections** have higher mortality, longer hospital stays, and higher healthcare costs
- **hand hygiene** is an essential precaution

Table 7. Common Nosocomial Infectious Agents

<table>
<thead>
<tr>
<th>Bacteria</th>
<th>Characteristics</th>
<th>Manifestation</th>
<th>Investigations</th>
<th>Management</th>
</tr>
</thead>
</table>
| Methicillin-Resistant S. aureus (MRSA) | Gram-positive cocci | Skin and soft tissue infection  
Bacteremia  
Pneumonia  
Endocarditis  
Osteomyelitis | Admission screening culture from nares and peri-anal region identifies colonization  
Culture of infection site CXR | Contact precautions  
For infection: vancomycin or daptomycin or linezolid  
To decolonize: 2% chlorhexidine wash OD (+ rifampin + (doxycycline or TMP/SMX) + mupirocin cream bid to nares) x 7 d |
| Vancomycin-Resistant Enterococcus (VRE) | Majority are E. faecium  
Resistant if minimum inhibitory concentration of vancomycin is ≥32 µg/mL | Rarely causes disease in healthy people  
UTI  
Bacteremia  
Endocarditis  
Meningitis | Rectal or perirectal swab OR stool culture for colonization  
Culture of infected site | Contact precautions*  
Ampicillin if susceptible  
Otherwise, linezolid, tigecycline, or daptomycin depending on site of infection  
No effective decolonization methods identified |
Table 7. Common Nosocomial Infectious Agents (continued)

<table>
<thead>
<tr>
<th>Bacteria</th>
<th>Characteristics</th>
<th>Manifestation</th>
<th>Investigations</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clostridium difficile (C. difficile)</td>
<td>Releases exotoxins A and B Hypervirulent strain (NAP1/B1/027) has been responsible for increase in incidence and severity</td>
<td>Fever, nausea, abdominal pain Watery diarrhea ± occult blood Pseudomembranous colitis Severe: toxic megacolon Risk of bowel perforation Associated with antibiotic use Leukocytosis</td>
<td>Stool PCR for toxin A and B genes Stool immunoassay for toxins A and B (less sensitive than PCR) AXR (may see colonic dilatation) Sigmodioscopy for pseudomembranes; avoid if known colonic dilatation</td>
<td>Contact precautions Stop culprit antibiotic therapy (primarily fluoroquinolones and cephalosporins) Supportive therapy (IV fluids) Mild-moderate disease: metronidazole PO x 10-14 d Severe disease: vancomycin PD x 10-14 d Toxic megacolon: meropenem IV + vancomycin PO (as above) and general surgery consult</td>
</tr>
</tbody>
</table>

| Extended Spectrum β-lactam Producers (ESBL producing E. coli, K. pneumoniae) | Resistant to most β-lactam antibiotics except carbapenams e.g. penicillins, aztreonam, and cephalosporins | UTI Pulmonary infection Bacteremia Liver abscess in susceptible patients Meningitis | Blood, sputum, urine, or aspirated body fluid culture Imaging at infection site (CXR, CT, U/S) | Carbapenems or non-β-lactam antibiotics can be used for empiric therapy |

| *Note the use of contact precautions for VRE varies depending on institutional policies |

**Respiratory Infections**

**Pneumonia**

- see Pediatrics, P85

**Definition**

- infection of the lung parenchyma

**Etiology and Risk Factors**

- impaired lung defenses
  - poor cough/gag reflex (e.g. illness, drug-induced)
  - impaired mucociliary transport (e.g. smoking, cystic fibrosis)
  - immunosuppression (e.g. steroids, chemotherapy, AIDS/HIV, DM, transplant, cancer)
- increased risk of aspiration
  - impaired swallowing mechanism (e.g. impaired consciousness, neurologic illness causing dysphagia, mechanical obstruction)
- no organism identified in 75% of hospitalized cases, and >90% of ambulatory cases

**Table 8. Common Organisms in Pneumonia**

<table>
<thead>
<tr>
<th>Community-Acquired</th>
<th>Nosocomial</th>
<th>Aspiration</th>
<th>Immunocompromised Patients</th>
<th>Alcoholic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Typical Bacteria</td>
<td>E. coli GNB (e.g. E. coli) Pseudomonas aeruginosa S. aureus (including MRSA)</td>
<td>Oral anerobes (e.g. Bacteroides) Enteric GNB (e.g. E. coli) S. aureus Gastric contents (chemical pneumonitis)</td>
<td>Pneumocystis jiroveci Fungi (e.g. Cryptococcus) Nocardia CMV HSV TB</td>
<td>Klebsiella Enteric GNB S. aureus Oral anaerobes (aspiration)</td>
</tr>
<tr>
<td>Atypical Bacteria</td>
<td>GAS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mycoplasma</td>
<td>pneumoniae</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlamydia</td>
<td>pneumoniae</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Legionella</td>
<td>pneumophila</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viral</td>
<td>Influenza</td>
<td>virus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenovirus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*See Pediatrics P86, Table for Common Causes and Treatment of Pneumonia at Different Ages

**Clinical Features**

- cough (± sputum), fever, pleuritic chest pain, dyspnea, tachypnea, tachycardia
- elderly often present atypically; altered LOC is sometimes the only sign
- evidence of consolidation (dullness to percussion, bronchial breath sounds, crackles)
- features of parapneumonic effusion (decreased air entry, dullness to percussion)
- complications: ARDS, lung abscess, parapneumonic effusion/empyema, pleuritis ± hemorrhage
Investigations
- pulse oximetry to assess severity of respiratory distress
- CBC and differential, electrolytes, urea, Cr, ABG (if respiratory distress), troponin/CK, LFTs, urinalysis
- sputum Gram stain/C&S, blood C&S, ± serology/viral detection, ± pleural fluid C&S (if effusion >5 cm or respiratory distress)
- CXR/CT chest shows distribution (lobar consolidation or interstitial pattern), extent of infiltrate ± cavitation
- bronchoscopy ± washings for
  - (1) severely ill patients refractory to treatment and (2) immunocompromised patients

Treatment
- ABC, O₂, IV fluids, consider salbutamol (nebulized or MDI)
- determine prognosis and need for hospitalization and antibiotics

Criteria for Hospitalization

### Table 9. CURB 65 Score – Pneumonia Clinical Prediction Tool

<table>
<thead>
<tr>
<th>Component*</th>
<th>Measurement(s)</th>
<th>Points</th>
<th>Total Score</th>
<th>Mortality</th>
<th>Disposition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confusion</td>
<td>Altered mental status</td>
<td>1</td>
<td>0-1</td>
<td>&lt;5%</td>
<td>Can treat as outpatient</td>
</tr>
<tr>
<td>Urea/BUN</td>
<td>Urea &gt; 7 mmol/L or BUN &gt; 20 mg/dL</td>
<td>1</td>
<td>2-3</td>
<td>5-15%</td>
<td>Consider hospitalization</td>
</tr>
<tr>
<td>Respiratory Rate</td>
<td>&gt; 30 breaths/min</td>
<td>1</td>
<td>4-5</td>
<td>15-30%</td>
<td>Consider ICU</td>
</tr>
<tr>
<td>Blood Pressure</td>
<td>Systolic &lt; 90 or diastolic &lt; 60 mmHg</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>65 or older</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* A CURB-65 score may be applied in the community as its criteria depend on clinical assessment alone.

### Table 10. IDSA/ATS Community Acquired Pneumonia Treatment Guidelines 2007

<table>
<thead>
<tr>
<th>Setting</th>
<th>Circumstances</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outpatient</td>
<td>Previously well</td>
<td>Macrolide¹ OR Doxycycline</td>
</tr>
<tr>
<td></td>
<td>No antibiotic use in last 3 mo</td>
<td>Respiratory fluoroquinolone² OR β-lactam + Macrolide¹</td>
</tr>
<tr>
<td></td>
<td>Comorbidities²</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antibiotic use in last 3 mo (use different class)</td>
<td></td>
</tr>
<tr>
<td>Inpatient</td>
<td>Ward</td>
<td>Respiratory fluoroquinolone² OR β-lactam + (Macrolide¹ OR Respiratory fluoroquinolone²)</td>
</tr>
<tr>
<td></td>
<td>ICU</td>
<td></td>
</tr>
</tbody>
</table>

1. **Macrolide**: azithromycin, clarithromycin, erythromycin
2. **Comorbidities**: chronic heart, lung, liver, or renal disease, DM, alcoholism, malignancy, asplenia, immunocompromised
3. **Respiratory fluoroquinolone**: moxifloxacin, gemifloxacin, levofloxacin
4. **β-lactam**: ceftriaxone, ceftazidime, ampicillin/sulbactam

**IDSA**: Infectious Diseases Society of America

**ATS**: American Thoracic Society

### Table 11. IDSA/ATS Hospital/Ventilator/Healthcare-Associated Pneumonia Treatment Guidelines 2005

<table>
<thead>
<tr>
<th>Setting</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>No risk factors for multidrug resistance (MDR)</td>
<td>ceftriaxone OR levofloxacin, moxifloxacin, or ciprofloxacin OR ampicillin/sulbactam OR ertapenem</td>
</tr>
<tr>
<td>Early onset (&lt;5 d)</td>
<td></td>
</tr>
<tr>
<td>Late onset disease (&gt;5 d) or With risk factors for MDR: Antibiotic use in last 3 mo</td>
<td>antipseudomonal cefepime or ceftazidime</td>
</tr>
<tr>
<td>High frequency of antibiotic resistance in the community or in the specific hospital unit</td>
<td></td>
</tr>
<tr>
<td>Hospitalization &gt;1 d in past 3 mo</td>
<td></td>
</tr>
<tr>
<td>Residence in a nursing home or extended care facility</td>
<td></td>
</tr>
<tr>
<td>Dialysis within 30 d</td>
<td></td>
</tr>
<tr>
<td>Home wound care</td>
<td></td>
</tr>
<tr>
<td>Family member with multidrug-resistant pathogen</td>
<td></td>
</tr>
<tr>
<td>Immunosuppressive disease and/or therapy</td>
<td></td>
</tr>
<tr>
<td>Note: Always use directed therapy against specific organism if one is found on culture (e.g., blood, sputum, etc.)</td>
<td></td>
</tr>
<tr>
<td>Note: These guidelines may be less applicable in Canada given lower rates of antibiotic resistance among common nosocomial pathogens</td>
<td></td>
</tr>
</tbody>
</table>

Figure 6. Lobar, broncho, and interstitial pneumonia
Prevention
- Public Health Agency of Canada recommends the following
  - vaccine for influenza A and B annually for all ages ≥ 6 mo
  - pneumococcal polysaccharide vaccine (Pneumovax®) for all adults >65 yr and in younger patients 24 mo of age and older at high risk for invasive pneumococcal disease (e.g. functional or anatomic asplenia, congenital or acquired immunodeficiency)
  - pneumococcal conjugate vaccine (Prevnar-13®) for all children <5 yr, and for children and adolescents at high risk for invasive pneumococcal disease who are 5-17 yr and who have not previously received Prevnar-13® (CDC recommends giving Prevnar-13® to all adults at high risk for invasive pneumococcal disease)

Influenza

Definitions and Etiology
- influenza viruses A and B
- influenza A further divided into subtypes based on envelope glycoproteins
  - hemagglutinin (H) and neuraminidase (N)
- seasonal (epidemic) influenza
  - main circulating influenza viruses: influenza A (H1N1), influenza A (H3N2) and influenza B
  - associated with antigenic drift (gradual, minor changes due to random point mutations)
  - may create a new viral subtype resulting in a seasonal epidemic (disease prevalence is greater than expected)
  - outbreaks occur mainly during winter months (late December to early March)
- pandemic influenza
  - associated with antigenic shift: abrupt, major changes due to mixing of two different viral strains from different hosts
  - may create a new viral strain resulting in a pandemic outbreak (worldwide)
  - antigenic shift occurs only in type A
- transmission: droplet, possibly airborne

Treatment and Prevention
- primarily supportive unless severe infection or high-risk of complications
- neuraminidase inhibitors: zanamivir (Relenza®) and oseltamivir (Tamiflu®) for treatment and prophylaxis against types A and B
  - decreases duration (by ~ 1 d) and severity of symptoms if given within 48 h of onset
  - treatment beyond 48 h time window may be warranted in immunosuppressed and critically ill patients
- vaccine for influenza A and B viruses is recommended annually for all ages ≥ 6 mo
- vaccine is reformulated each year to reflect circulating influenza A and B strains

Table 12. Difference Between Influenza Strains

<table>
<thead>
<tr>
<th>Feature</th>
<th>Influenza A</th>
<th>Influenza B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Host(s)</td>
<td>Humans, birds, mammals</td>
<td>Humans only</td>
</tr>
<tr>
<td>Antigenic drift</td>
<td>Yes, new strains</td>
<td>Yes, new strains</td>
</tr>
<tr>
<td>Antigenic shift</td>
<td>Yes, new subtypes</td>
<td>No</td>
</tr>
<tr>
<td>Epidemics</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Pandemics</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Clinical Features
- incubation period 1-4 d and symptoms typically resolve in 7-10 days
- acute onset of systemic (fever, chills, myalgias, arthralgias, H/A, fatigue) and respiratory symptoms (cough, dyspnea, pharyngitis)
- complications: respiratory (viral pneumonia, secondary bacterial pneumonia, otitis media, sinusitis), muscular (rhabdomyolysis, myositis), neurologic (encephalitis, meningitis, transverse myelitis, Guillain-Barre syndrome)
- severe disease more likely in the elderly, children, pregnant women, patients with immunocompromise, asthma, COPD, CVD, diabetes and obesity

Investigations
- diagnosis is primarily clinical based on symptoms during the influenza season
- nasopharyngeal swabs for rapid antigen detection, DFA (Direct Fluorescent Antigen) detection, RT-PCR (gold standard)
- serology: rarely used for clinical management

Table 12. Difference Between Influenza Strains

<table>
<thead>
<tr>
<th>Feature</th>
<th>Influenza A</th>
<th>Influenza B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Host(s)</td>
<td>Humans, birds, mammals</td>
<td>Humans only</td>
</tr>
<tr>
<td>Antigenic drift</td>
<td>Yes, new strains</td>
<td>Yes, new strains</td>
</tr>
<tr>
<td>Antigenic shift</td>
<td>Yes, new subtypes</td>
<td>No</td>
</tr>
<tr>
<td>Epidemics</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Pandemics</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Conclusions: Evidence suggests no single item on clinical history or physical exam is sufficient to rule in or out pneumonia without chest x-ray. Vital sign abnormalities were correlated with a diagnosis of pneumonia. Findings on chest exam significantly raised the likelihood of pneumonia, but were uncommonly seen in studies.

Table 12. Difference Between Influenza Strains

<table>
<thead>
<tr>
<th>Feature</th>
<th>Influenza A</th>
<th>Influenza B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Host(s)</td>
<td>Humans, birds, mammals</td>
<td>Humans only</td>
</tr>
<tr>
<td>Antigenic drift</td>
<td>Yes, new strains</td>
<td>Yes, new strains</td>
</tr>
<tr>
<td>Antigenic shift</td>
<td>Yes, new subtypes</td>
<td>No</td>
</tr>
<tr>
<td>Epidemics</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Pandemics</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Clinical Features
- incubation period 1-4 d and symptoms typically resolve in 7-10 days
- acute onset of systemic (fever, chills, myalgias, arthralgias, H/A, fatigue) and respiratory symptoms (cough, dyspnea, pharyngitis)
- complications: respiratory (viral pneumonia, secondary bacterial pneumonia, otitis media, sinusitis), muscular (rhabdomyolysis, myositis), neurologic (encephalitis, meningitis, transverse myelitis, Guillain-Barre syndrome)
- severe disease more likely in the elderly, children, pregnant women, patients with immunocompromise, asthma, COPD, CVD, diabetes and obesity

Investigations
- diagnosis is primarily clinical based on symptoms during the influenza season
- nasopharyngeal swabs for rapid antigen detection, DFA (Direct Fluorescent Antigen) detection, RT-PCR (gold standard)
- serology: rarely used for clinical management

Treatment and Prevention
- primarily supportive unless severe infection or high-risk of complications
- neuraminidase inhibitors: zanamivir (Relenza®) and oseltamivir (Tamiflu®) for treatment and prophylaxis against types A and B
  - decreases duration (by ~ 1 d) and severity of symptoms if given within 48 h of onset
  - treatment beyond 48 h time window may be warranted in immunosuppressed and critically ill patients
- vaccine for influenza A and B viruses is recommended annually for all ages ≥ 6 mo
- vaccine is reformulated each year to reflect circulating influenza A and B strains

Conclusions: Evidence suggests no single item on clinical history or physical exam is sufficient to rule in or out pneumonia without chest x-ray. Vital sign abnormalities were correlated with a diagnosis of pneumonia. Findings on chest exam significantly raised the likelihood of pneumonia, but were uncommonly seen in studies.

Table 12. Difference Between Influenza Strains

<table>
<thead>
<tr>
<th>Feature</th>
<th>Influenza A</th>
<th>Influenza B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Host(s)</td>
<td>Humans, birds, mammals</td>
<td>Humans only</td>
</tr>
<tr>
<td>Antigenic drift</td>
<td>Yes, new strains</td>
<td>Yes, new strains</td>
</tr>
<tr>
<td>Antigenic shift</td>
<td>Yes, new subtypes</td>
<td>No</td>
</tr>
<tr>
<td>Epidemics</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Pandemics</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Clinical Features
- incubation period 1-4 d and symptoms typically resolve in 7-10 days
- acute onset of systemic (fever, chills, myalgias, arthralgias, H/A, fatigue) and respiratory symptoms (cough, dyspnea, pharyngitis)
- complications: respiratory (viral pneumonia, secondary bacterial pneumonia, otitis media, sinusitis), muscular (rhabdomyolysis, myositis), neurologic (encephalitis, meningitis, transverse myelitis, Guillain-Barre syndrome)
- severe disease more likely in the elderly, children, pregnant women, patients with immunocompromise, asthma, COPD, CVD, diabetes and obesity

Investigations
- diagnosis is primarily clinical based on symptoms during the influenza season
- nasopharyngeal swabs for rapid antigen detection, DFA (Direct Fluorescent Antigen) detection, RT-PCR (gold standard)
- serology: rarely used for clinical management

Treatment and Prevention
- primarily supportive unless severe infection or high-risk of complications
- neuraminidase inhibitors: zanamivir (Relenza®) and oseltamivir (Tamiflu®) for treatment and prophylaxis against types A and B
  - decreases duration (by ~ 1 d) and severity of symptoms if given within 48 h of onset
  - treatment beyond 48 h time window may be warranted in immunosuppressed and critically ill patients
- vaccine for influenza A and B viruses is recommended annually for all ages ≥ 6 mo
- vaccine is reformulated each year to reflect circulating influenza A and B strains

Conclusions: Evidence suggests no single item on clinical history or physical exam is sufficient to rule in or out pneumonia without chest x-ray. Vital sign abnormalities were correlated with a diagnosis of pneumonia. Findings on chest exam significantly raised the likelihood of pneumonia, but were uncommonly seen in studies.
Skin and Soft Tissue Infections

Cellulitis

Definition
• acute infection of the skin principally involving the dermis and subcutaneous tissue

Etiology
• common causative agents: S. aureus, β-hemolytic streptococci
• immunocompromised patients or water exposure: may also include GN rods and fungi
• risk factors
  ■ trauma with direct inoculation, recent surgery
  ■ peripheral vascular disease, lymphedema DM, cracked skin in feet/toes (tinea pedis)

Clinical Features
• pain, edema, erythema with indistinct borders ± regional lymphadenopathy, systemic symptoms (fevers, chills, malaise)
• can lead to ascending lymphangitis (visible red streaking in skin along lymphatics proximal to area of cellulitis)

Investigations
• CBC and differential, blood C&S if febrile
• skin swab ONLY if open wound with pus

Treatment
• antibiotics: cephalixin (broader coverage if risk factors for GN rods)
• if extensive erythema or systemic symptoms, consider cefazolin IV
• if MRSA is suspected, alternative therapy should be prescribed (see A Simplified Look at Antibiotics, ID47)
• limb rest and elevation may help reduce swelling

Necrotizing Fasciitis

Definition
• life- and limb-threatening infection of the deep fascia characterized by rapid spread

Etiology
• Two main forms
  ■ Type I: polymicrobial infection – aerobes and anaerobes (e.g. S. aureus, Bacteroides, Enterobacteriaceae)
  ■ Type II: monomicrobial infection with GAS, and less commonly S. aureus

Clinical Features
• pain out of proportion to clinical findings and beyond border of erythema
• edema, ± crepitus (subcutaneous gas from anaerobes), ± fever
• infection spreads rapidly
• patients may rapidly become very sick (tachycardia, hypotension, lightheadedness)
• late findings
  ■ skin turns dusky blue and black (secondary to thrombosis and necrosis)
  ■ induration, formation of hemorrhagic bullae

Investigations
• clinical/surgical diagnosis – do NOT wait for results of investigations before beginning treatment
• blood and tissue C&S
• serum CK (elevated CK usually means myonecrosis – a late sign)
• plain film x-ray (soft tissue gas may be visualized)
• surgical exploration for debridement of infected tissue

Treatment
• resuscitation with IV fluids
• emergency surgical debridement to confirm diagnosis and remove necrotic tissue (may require amputation)
• IV antibiotics
  ■ unknown organism: meropenem or piperacillin/tazobactam + clindamycin IV ± vancomycin if MRSA is considered
  ■ Type I (polymicrobial): piperacillin/tazobactam + clindamycin IV
  ■ Type II (monomicrobial): cefazolin (or doxycillin) + clindamycin IV; with confirmed GAS infection, penicillin G + clindamycin IV
  ■ with Type II, evaluate for streptococcal toxic shock syndrome and the need for IVIg
**Gastrointestinal Infections**

**Acute Diarrhea**

- See *Gastroenterology, G15 and Pediatrics, P33*

**Epidemiology**
- One of the top five leading causes of death worldwide, according to the World Health Organization
- Significant morbidity in developed countries (over 900,000 hospitalizations in the United States each year)

**Definition**
- Passage of ≥3 loose or liquid stools/d OR >200 g stool/d for >2 d but ≤14 d

**Approach to Acute Diarrhea**
- **Rationale**
  - The vast majority of acute diarrhea is caused by infection
  - In most cases, acute diarrheal illness is viral and/or self-limited, and lasts <3 d
  - Investigations are costly and are necessary only in certain circumstances
  - Therefore, the evaluation of acute diarrhea involves
    - Identifying characteristics of the illness or patient that warrant further investigation
    - Assessing volume status to determine appropriate method of rehydration

**Physical Exam**
- Volume status: appearance, level of alertness, pulse, BP, orthostatic vitals, JVP, mucous membranes, skin turgor, capillary refill
- Abdominal exam: pain, guarding, peritoneal signs

**Treatment**
- Rehydration is mainstay of treatment
  - Oral rehydration therapy
  - IV rehydration if oral intake insufficient to replace fluid loss
  - Antidiarrheal agents reduce duration of diarrhea: loperamide, bismuth subsalicylate
  - Delays excretion of causative pathogens
  - Contraindications: diarrhea with fever, bloody stool or diarrhea caused by *C. difficile*
  - Antibiotic therapy is rarely indicated because
    - Most acute diarrheal illness is viral and self-limited
    - Antibiotics can eradicate normal gut flora, predisposing patient to *C. difficile* infection
    - Antibiotics prolong the shedding of *Salmonella* and other causes of bacterial diarrhea
    - In EHEC infection, antibiotics may increase the risk of HUS

**Initial Assessment**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Blood in stool</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

**Investigations**
- **Routine Tests:**
  - Stool for fecal leukocytes
  - Stool C&S for *Campylobacter*, *Salmonella*, and *Shigella*

**Special Tests**
- **Stool C&S for EHEC, stool for Shiga toxin**
- **Stool for *C. difficile* toxins A and B**
- **Stool O&P for *Giardia*, *Cryptosporidium*, *E. histolytica***

**Indication**
- Recent use of antibiotics or hospitalized
- Age ≥65 yr with comorbidities
- Immunocompromised patients

**Diagnosis**
- Diarrhea >7 d
- Exposure to untreated water
- HSV

**Indications for Antimicrobial Therapy**

**Absolute Indications:**
- Infection with *S. typhi*, *Shigella*, *C. difficile*, *Cryptosporidium*, *E. histolytica*
- Immunocompromised patients

**Relative Indications:**
- Infection with *V. cholerae*, non-typhoid *Salmonella*, *Campylobacter*, *Yersinia*, *Giardia*, ETEC
- Decision to treat is determined by severity of illness (see Tables 13 and 14 for information on common pathogens)

Figure 7. Approach to acute diarrhea
### Table 13. Bacteria in Infectious Diarrhea

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Source or Mode of Transmission</th>
<th>Incubation</th>
<th>Clinical Features</th>
<th>Duration</th>
<th>Antimicrobial Therapy</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>B. cereus – Type A (emetic)</strong></td>
<td>Rice dishes</td>
<td>1-6 h</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>&lt; 12 h</td>
</tr>
<tr>
<td><strong>B. cereus – Type B (diarrheal)</strong></td>
<td>Meats, vegetables, dried beans, cereals</td>
<td>8-16 h</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>&lt; 24 h</td>
</tr>
<tr>
<td><strong>Campylobacter jejuni</strong></td>
<td>Uncooked meat, especially poultry</td>
<td>2-10 d</td>
<td>+</td>
<td>±</td>
<td>+</td>
<td>±</td>
</tr>
<tr>
<td><strong>Clostridium difficile</strong></td>
<td>Can be normally present in colon in small numbers (primary risk factor for disease is exposure to antimicrobials)</td>
<td>Unclear</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>–</td>
</tr>
<tr>
<td><strong>Clostridium perfringens</strong></td>
<td>Contaminated food, especially meat and poultry</td>
<td>8-12 h</td>
<td>±</td>
<td>–</td>
<td>–</td>
<td>±</td>
</tr>
<tr>
<td><strong>Enteroinvasive E. coli (EIEC)</strong></td>
<td>Contaminated food/water</td>
<td>1-3 d</td>
<td>+</td>
<td>±</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td><strong>Enterotoxigenic E. coli (ETEC)</strong></td>
<td>Contaminated food/water</td>
<td>1-3 d</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td><strong>Enterohemorrhagic E. coli (EHEC/i.e. O157:H7)</strong></td>
<td>Contamination of hamburger, raw milk, drinking, and recreational water</td>
<td>3-8 d</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>±</td>
</tr>
<tr>
<td><strong>Salmonella typhi</strong></td>
<td>Fecal-oral</td>
<td>10-14 d</td>
<td>+</td>
<td>±</td>
<td>+</td>
<td>±</td>
</tr>
<tr>
<td><strong>Salmonella non-typhoidal</strong> (i.e. S. typhimurium, S. enteritidis)</td>
<td>Contaminated animal food products, especially eggs, poultry, meat, milk</td>
<td>12-72 h</td>
<td>+</td>
<td>±</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><strong>Shigella dysenteriae</strong></td>
<td>Fecal-oral</td>
<td>1-4 d</td>
<td>+</td>
<td>±</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><strong>Staphylococcus aureus</strong></td>
<td>Unrefrigerated meat and dairy products (custard, pudding, potato salad, mayo)</td>
<td>2-4 h</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><strong>Vibrio cholerae</strong></td>
<td>Contaminated food/water, especially shellfish</td>
<td>1-3 d</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td><strong>Yersinia</strong></td>
<td>Contaminated food Unpasteurized milk</td>
<td>5 d</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>Up to 3 wk</td>
</tr>
</tbody>
</table>
Table 14. Parasites in Infectious Diarrhea

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Source of Mode of Transmission</th>
<th>Incubation</th>
<th>Clinical Features</th>
<th>Duration</th>
<th>Antimicrobial Therapy</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cryptosporidium</td>
<td>Fecal-oral</td>
<td>7 d</td>
<td>±</td>
<td>–</td>
<td>1-20 d</td>
<td>Paromomycin + nitazoxanide</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Immune reconstitution if immunosuppressed</td>
</tr>
<tr>
<td>Entamoeba histolytica</td>
<td>Worldwide</td>
<td>2-4 wk</td>
<td>±</td>
<td>+</td>
<td>Variable</td>
<td>Metronidazole + iodoquinol or paromomycin if symptomatic infection</td>
</tr>
<tr>
<td></td>
<td>endemic areas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Only iodoquinol or paromomycin for asymptomatic cyst passage</td>
</tr>
<tr>
<td></td>
<td>Fecal-oral</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>If untreated, potential for liver abscess</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sigmoidoscopy shows flat ulcers with yellow exudates</td>
</tr>
<tr>
<td>Giardia lamblia</td>
<td>Fecal-oral</td>
<td>1-4 wk</td>
<td>–</td>
<td>+</td>
<td>Variable</td>
<td>Metronidazole or nitazoxanide</td>
</tr>
<tr>
<td></td>
<td>Contaminated food/water</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Treatment of asymptomatic carriers not recommended</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Higher risk in: day care children, intake of untreated water (&quot;beaver fever&quot;), MSM, immunodeficiency (decreased IgA) May need duodenal biopsy</td>
</tr>
</tbody>
</table>

Table 15. Viruses in Infectious Diarrhea

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Source of Mode of Transmission</th>
<th>Incubation</th>
<th>Clinical Features</th>
<th>Duration</th>
<th>Antimicrobial Therapy</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norovirus</td>
<td>Fecal-oral</td>
<td>24 h</td>
<td>–</td>
<td>–</td>
<td>24 h</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Noroviruses includes Norwalk virus</td>
</tr>
<tr>
<td>Rotavirus</td>
<td>Fecal-oral</td>
<td>2-4 d</td>
<td>±</td>
<td>–</td>
<td>3-8 d</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Can cause severe dehydration</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Virtually all children are infected by 3 yr of age</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Oral vaccine given at 2 and 4 mo of age</td>
</tr>
</tbody>
</table>

Traveller’s Diarrhea

- see Acute Diarrhea, ID11

Epidemiology
- most common illness to affect travellers
- up to 50% of travellers to developing countries affected in first 2 wk and 10-20% after returning home

Etiology
- bacterial (80-90%): E. coli most common (ETEC), Campylobacter, Shigella, Salmonella, Vibrio (non-cholera); wide regional variation (e.g. Campylobacter more common in Southeast Asia)
- viral: norovirus, rotavirus, and astrovirus account for 5-8%
- protozoal (rarely): Giardia, Entamoeba histolytica, Cryptosporidium, and Cyclospora for ~10% in long-term travellers
- pathogen-negative traveller’s diarrhoea common despite exhaustive microbiological workup

Treatment
- rehydration is the mainstay of therapy
  - rehydrate with sealed beverages
  - in severe fluid loss use oral rehydration solutions (1 package in 1 L boiled or treated water)
  - treat symptoms: antidiarrheal agents (e.g. bismuth salicylate, loperamide)
  - empiric antibiotics in moderate or severe illness: ciprofloxacin or azithromycin or rifaximin
  - note: there is increasing fluoroquinolone resistance in causative agents, especially in South and Southeast Asia

Prevention
- proper hygiene practices
  - avoid consumption of: foods or beverages from establishments with unhygienic conditions (e.g. street vendors), raw fruits or vegetables without a peel, raw or undercooked meat and seafood
  - avoid untreated water
  - bismuth salicylate (Pepto-Bismol®): 60% effective (2 tablets qid according to CDC website)
  - CDC Guidelines: antibiotic prophylaxis not recommended
    - increased risk of infection with resistant organisms
    - high risk groups (e.g. immunocompromised) likely to be infected with pathogen not covered by standard antimicrobial agents

- Bismuth salicylate (Pepto-Bismol®) can cause patients to have black stools, which may be mistaken for melena
• Dukoral®: oral vaccine that offers protection against *V. cholerae* (efficacy ~80%) and ETEC (efficacy ~50-67%). Not recommended for routine use in travellers, but the PHAC recommends that it may be considered in short-term travellers >2 yr old who are high-risk (e.g. chronic illness) for whom there is an increased risk of serious consequences for traveller's diarrhea (e.g. chronic renal failure, CHF; type 1 DM, inflammatory bowel disease), immunosuppressed, history of repeat traveller's diarrhea, increased risk of acquiring traveller's diarrhea (gastric hypochlorhydria or young children >2 yr), or travellers to cholera endemic countries at increased risk of exposure.

- Two vaccines against *Salmonella typhi* are available and their effectiveness is estimated to be between 50-70%

### Chronic Diarrhea

- see Gastroenterology, G16

### Peptic Ulcer Disease (*H. pylori*)

- see Gastroenterology, G11

### Bone and Joint Infections

#### Septic Arthritis

**Routes of Infection**
- hematogenous
  - contiguous osteomyelitis common in children
- direct inoculation via skin/trauma
- iatrogenic (surgery, arthroscopy, arthrocentesis)

**Etiology**
- gonococcal
  - *N. gonorrhoeae*: previously accounted for 75% of septic arthritis in young sexually active adults
- non-gonococcal
  - *S. aureus*: affects all ages, rapidly destructive, accounts for most non-gonococcal cases of septic arthritis in adults (especially in those with rheumatoid arthritis)
  - *Streptococcus* species (Group A and B)
  - Gram-negatives: affect neonates, elderly, IV drug users, immunocompromised
  - *S. pneumoniae*: affects children
  - *Kingella kingae*: affects children aged <2 yr of age
  - *Haemophilus influenzae* type B (Hib) now rare due to Hib vaccine: consider in unvaccinated children
  - *Salmonella* spp.: characteristic of sickle cell disease
  - coagulase-negative *Staphylococcus* species: prosthetic joints
- if culture negative: partially-treated infection (prior to oral antibiotics), reactive arthritis, rheumatic fever, less common bacterial causes such as *Borrelia* spp. (Lyme disease) or *Tropheryma whippeli* (Whipple’s disease), and non-infectious causes

**Risk Factors**
- gonococcal
  - age (<40 yr), multiple partners, unprotected intercourse, MSM
- non-gonococcal
  - most affected children are previously healthy with no risk factors: occasionally preceding history of minor trauma
  - bacteremia (extra-articular infection with hematogenous seeding, endocarditis)
  - prosthetic joints/recent joint surgery
  - underlying joint disease (rheumatoid arthritis, osteoarthritis)
  - immunocompromise (DM, chronic kidney disease, alcoholism, cirrhosis)
  - loss of skin integrity (cutaneous ulcer, skin infection)
  - age >80 yr

**Clinical Features of Gonococcal Arthritis**
- two forms (although often overlap)
  - bacteremic form
  - systemic symptoms: fever, malaise, chills
  - gonococcal triad: migratory polyarthralgias, tenosynovitis, dermatitis (pustular skin lesions)
  - septic arthritis form
  - local symptoms in involved joint: swelling, warmth, pain, inability to bear weight, marked decrease in range of motion (see Rheumatology, RH5 for differential diagnosis)

**Medical Emergency**

Septic arthritis is a medical emergency! If untreated, rapid joint destruction will occur.

**Disseminated Gonococcal Infection Triad**
- Migratory arthralgias
- Tenosynovitis next to inflamed joint
- Pustular skin lesions
Clinical Features of Non-Gonococcal Arthritis

- acute onset of pain, swelling, warmth, decreased range of motion ± fever and chills
- most often in large weight-bearing joints (knee, hip, ankle) and wrists
- usually monoarticular (polymicrobial risk factors: rheumatoid arthritis, endocarditis, GBS)

Investigations
- consider rheumatologic causes for monoarthritis (see Rheumatology, RH3)
- gonococcal: blood C&S, as well as endocervical, urethral, rectal, and oropharyngeal testing
- non-gonococcal: blood C&S
- arthrocentesis (synovial fluid analysis) is mandatory: CBC and differential, Gram stain, C&S, examine for crystals
  - infectious = opaque, increased WBCs (>15,000/mm³); likelihood of infection increases with increasing WBCs, PMNs >90%, culture positive
  - growth of N. gonorrhoea from synovial fluid is successful in <50% of cases
- ± plain x-ray: assess for osteomyelitis, provides baseline to monitor treatment

Treatment
- medical
  - empiric IV antibiotics: specific choice depends on clinical scenario; for most adults, vancomycin + ceftriaxone is reasonable; for fully vaccinated children, cefazolin or cloxacillin IV unless MRSA is a consideration – delay may result in joint destruction
  - Gram stain and cultures guide subsequent treatment
  - gonococcal: ceftriaxone + azithromycin, for concurrent treatment of C. trachomatis
  - non-gonococcal: antibiotics against Streptococcus spp. (2-3 wk IV f/b PO), S. aureus (4 wk IV minimum), or GNB (4 wk)
- surgical drainage if (see Orthopedics, OR10)
  - persistent positive joint cultures on repeat arthrocentesis
  - hip joint involvement
  - prosthetic joint
- daily joint aspirations until culture sterile; no need to give intra-articular antibiotics
- physiotherapy

Prognosis
- gonococcal: responds well after 24-48 h of initiating antibiotics (usually complete recovery)
- non-gonococcal: in children, generally good outcome if treated promptly; in adults, up to 50% morbidity (decreased joint function/mobility)

Diabetic Foot Infections

Etiology
- neuropathy, peripheral vascular disease, and hyperglycemia contribute to foot ulcers that heal poorly, and are predisposed to infection
- organisms in mild infection: S. aureus, Streptococcus spp.
- organisms in moderate/severe infection: polymicrobial with aerobes (S. aureus, Streptococcus, Enterococcus, GNB) and anaerobes (Peptostreptococcus, Bacteroides, Clostridium)

Clinical Features
- not all ulcers are infected
- consider infection if: probe to bone (see below), ulcer present >30 d, recurrent ulcers, trauma, PVD, prior amputation, loss of protective sensation, renal disease, history of walking barefoot
- diagnosis of infected ulcer: ≥2 of the cardinal signs of inflammation (redness, warmth, swelling, pain) or the presence of pus
- ± crepitus, osteomyelitis, systemic toxicity
- visible bone or probe to bone → osteomyelitis
- infection severity
  - mild = superficial (no bone/joint involvement)
  - moderate = deep (beneath superficial fascia, involving bone/joint) or erythema >2 cm
  - severe = infection in a patient with systemic toxicity (fever, tachypnea, leukocytosis, tachycardia, hypotension)

Investigations
- curettage specimen from ulcer base, aspirate from an abscess or bone biopsy (results from superficial swabs do not represent organisms responsible for deeper infection)
- blood C&S if febrile
- assess for osteomyelitis by x-ray (although not sensitive in early stages) or MRI if high clinical suspicion
  - if initial x-ray normal, repeat 2-4 wk after initiating treatment to increase test sensitivity

Treatment
- evaluate for early surgical debridement ± revascularization or amputation
- eliminate/reduce pressure and provide regular local wound care
- mild: cephalexin or clindamycin

Does this Patient with Diabetes have Osteomyelitis of the Lower Extremity?
JAMA 2008;299:806-813

Study: Systematic literature review. 21 studies.
Population: 1,027 adult patients with DM being investigated for osteomyelitis.
Intervention: Various aspects of history, physical exam, laboratory tests, and diagnostic imaging studies versus bone biopsy.
Primary Outcome: Diagnostic utility.
Results: No studies examined any part of history taking. Temperature, ulcer characteristics (erythema, swelling, purulence), elevated WBC, skin swabs, and soft tissue cultures were not useful. Nuclear imaging has poor specificity for osteomyelitis (62%-88.5%), and MRIs have greater accuracy in detecting osteomyelitis.

<table>
<thead>
<tr>
<th>Finding</th>
<th>(+) LR</th>
<th>(-) LR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visualization of bone</td>
<td>9.2</td>
<td>0.70</td>
</tr>
<tr>
<td>Ulcer area &gt; 2 cm²</td>
<td>7.2</td>
<td>0.48</td>
</tr>
<tr>
<td>Probe-to-bone</td>
<td>6.4</td>
<td>0.39</td>
</tr>
<tr>
<td>Clinical judgment</td>
<td>5.5</td>
<td>0.54</td>
</tr>
<tr>
<td>ESR &gt; 70 mm/h</td>
<td>11</td>
<td>NS*</td>
</tr>
<tr>
<td>Plain radiographs</td>
<td>2.3</td>
<td>0.63</td>
</tr>
<tr>
<td>MRI</td>
<td>3.8</td>
<td>0.14</td>
</tr>
</tbody>
</table>

*NS = not significant
Cardiac Infections

Definition
- infection of cardiac endothelium, most commonly the valves
- classifications: acute vs. subacute, native valve vs. prosthetic valve, right sided vs. left sided
- leaflet vegetations are made of platelet-fibrin thrombi, WBCs, and bacteria

Risk Factors and Etiology
- predisposing conditions
  - high risk: prosthetic cardiac valve, previous IE, congenital heart disease (unrepaired, repaired within 6 mo, repaired with defects), cardiac transplant with valve disease (surgically constructed systemic-to-pulmonary shunts or conduits)
  - moderate risk: other congenital cardiac defects, acquired valvular dysfunction, hypertrophic cardiomyopathy
  - low/no risk: secundum ASD or surgically repaired ASD < VSD, PDA, MV prolapse, ischemic heart disease, previous CABG
- opportunity for bacteremia: IVDU, indwelling venous catheter, hemodialysis, poor dentition, DM, HIV
- frequency of valve involvement MV >> AV > TV > PV
- but in 50% of IVDU-related IE the tricuspid valve is involved

Table 16. Microbial Etiology of Infective Endocarditis Based on Risk Factors

<table>
<thead>
<tr>
<th>Native Valve</th>
<th>Intravenous Drug Users (IVDU)</th>
<th>Prosthetic Valve (recent surgery &lt; 2 mo)</th>
<th>Prosthetic Valve (remote surgery &gt; 2 mo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Streptococcus (36%)</td>
<td>S. aureus (68%)</td>
<td>S. aureus (36%)</td>
<td>Streptococcus (20%)</td>
</tr>
<tr>
<td>S. aureus (28%)</td>
<td>Streptococcus (13%)</td>
<td>S. epidermidis (17%)</td>
<td>S. aureus (20%)</td>
</tr>
<tr>
<td>Enterococcus (11%)</td>
<td>Enterococcus</td>
<td>Other</td>
<td>S. epidermidis (20%)</td>
</tr>
<tr>
<td>S. epidermidis</td>
<td>GNB</td>
<td>Enterococcus</td>
<td>Enterococcus (13%)</td>
</tr>
<tr>
<td>GNB</td>
<td>Candida</td>
<td>GNB</td>
<td>Other</td>
</tr>
<tr>
<td>Other</td>
<td>Other</td>
<td>Other</td>
<td>Other</td>
</tr>
</tbody>
</table>

Organisms in bold are the most common isolates
1. Streptococcus includes mainly viridans group streptococci
2. Other includes less common organisms such as:
   - Streptococcus gallolyticus (previously known as S. bovis; usually associated with underlying GI malignancy; cirrhosis)
   - Culture-negative organisms including nutritionally-deficient streptococci, HACEK, Bartonella, Coxiella, Chlamydia, Legionella, Brucella
   - Candida
3. IVDU endocarditis pathogens depend on substance used to dilute the drug (i.e. tap water = Pseudomonas, saliva = oral flora, toilet water = GI flora)

Clinical Features
- systemic
  - fever (80-90%), chills, weakness, rigors, night sweats, weight loss, anorexia
  - cardiac
    - dyspnea, chest pain, clubbing (subacute)
    - regurgitant murmur (new onset or increased intensity)
    - signs of CHF (secondary to acute MR, AR)
  - embolic/vascular
    - petechiae over legs, splinter hemorrhages (linear, reddish-brown lesion within nail bed)
    - Janeway lesions (painless, 5 mm, erythematous, hemorrhagic pustular lesions on soles/palms)
    - focal neurological signs (CNS emboli), HA (mycotic aneurysm)
    - splenomegaly (subacute)
    - microscopic hematuria, flank pain (renal emboli) ± active sediment
  - immune complex
    - Osler’s nodes (painful, raised, red/brown, 3-15 mm on digits)
    - glomerulonephritis
    - arthritis
    - Roth’s spots (retinal hemorrhage with pale centre)

Diagnosis
- Modified Duke Criteria, see Table 17
  - definitive diagnosis if: 2 major, OR 1 major + 3 minor, OR 5 minor
  - possible diagnosis if: 1 major + 1 minor, OR 3 minor
Table 17. Modified Duke Criteria

**Major Criteria (2)**

1. Positive blood cultures for IE
   - Typical microorganisms for IE from 2 separate blood cultures (Streptococcus viridans, HACEK group, Streptococcus gordonii (previously known as S. bovis), Staphylococcus aureus, community-acquired enterococci) OR
   - Persistently positive blood culture, defined as recovery of a microorganism consistent with IE from blood drawn > 12 h apart OR
   - All of 3 or a majority of 4 or more separate blood cultures, with first and last drawn > 1 h apart OR
   - Single positive blood culture for Coagulase-negative Staphylococci or antiphase IgG antibody titer > 1:800
2. Evidence of endocardial involvement
   - Positive echocardiogram for IE (oscillating intracardiac mass on valve or supporting structures, or in the path of regurgitant jets, or on implanted material in the absence of an alternative anatomic explanation OR abscess OR new partial dehiscence of prosthetic valve) OR
   - New valvular regurgitation (insufficient if increase or change in preexisting murmur)

**Minor Criteria (5)**

1. Predisposing condition (abnormal heart valve, IVDU)
2. Fever (38.0°C/100.4°F)
3. Vascular phenomena: major arterial emboli, septic pulmonary infarcts, mycotic aneurysms, ICH, conjunctival hemorrhages, Janeway lesions
4. Immunologic phenomena: glomerulonephritis, rheumatoid factor, Osler’s nodes, Roth’s spots
5. Positive blood culture but not meeting major criteria OR serologic evidence of active infection with organism consistent with IE

**Investigations**

- ECG: prolonged PR interval may indicate perivalvular abscess
- ECG: prolonged PR interval may indicate perivalvular abscess
- ECG: prolonged PR interval may indicate perivalvular abscess
- ECG: prolonged PR interval may indicate perivalvular abscess
- ECG: prolonged PR interval may indicate perivalvular abscess
- ECG: prolonged PR interval may indicate perivalvular abscess
- ECG: prolonged PR interval may indicate perivalvular abscess
- ECG: prolonged PR interval may indicate perivalvular abscess
- ECG: prolonged PR interval may indicate perivalvular abscess
- ECG: prolonged PR interval may indicate perivalvular abscess
- ECG: prolonged PR interval may indicate perivalvular abscess
- ECG: prolonged PR interval may indicate perivalvular abscess

**Treatment**

- Medical
  - Usually non-urgent and can wait for confirmation of etiology before initiating treatment
  - Empiric antibiotic therapy if patient is unstable; administer ONLY after blood cultures have been taken
    - First-line empiric treatment for native valve: vancomycin + gentamicin OR ceftriaxone
    - First-line empiric treatment for prosthetic valve: vancomycin + gentamicin + cefepime + rifampin
  - Targeted antibiotic therapy: antibiotic and duration (usually 4-6 wk) adjusted based on valve, organism, and sensitivities
  - Monitor for complications of IE (e.g. CHF, conduction block, new emboli) and complications of antibiotics (e.g. interstitial nephritis)
  - Prophylaxis only for high risk individuals listed above with dental procedures that may lead to bleeding OR invasive procedure of the respiratory tract that involves incision or biopsy of the respiratory mucosa, such as tonsillectomy and adenoidectomy OR procedures on infected skin, skin structure, or musculoskeletal tissue
    - Dental/respiratory: amoxicillin single dose 30-60 min prior; clindamycin if penicillin-allergic
    - Skin/soft tissue: cephalexin single dose 30-60 min prior; clindamycin if penicillin-allergic
    - (Modify based on etiology of skin/soft tissue infection)
  - Surgical
    - Most common indication is refractory CHF
    - Other indications include: valve ring abscess, fungal etiology, valve perforation, unstable prosthesis, ≥2 major emboli, antimicrobial failure (persistently positive blood cultures), mycotic aneurysm, Staphylococci on a prosthetic valve

**Prognosis**

- Adverse prognostic factors: CHF, prosthetic valve infection, valvular/myocardial abscess, embolization, persistent bacteremia, altered mental status prognostic factors: CHF, prosthetic valve infection, valvular/myocardial abscess
- Mortality: prosthetic valve IE (25-50%), non-IVDU S. aureus IE (30-45%), IVDU S. aureus or streptococcal IE (10-15%)
CNS Infections

Meningitis

• see Pediatrics, P59

Definition

• inflammation of the meninges

Etiology

Table 18. Common Organisms in Meningitis

<table>
<thead>
<tr>
<th>Bacterial</th>
<th>Viral</th>
<th>Fungal</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age 0-4 wk</td>
<td>Age 1-23 mo</td>
<td>Age &gt; 2 yr</td>
<td></td>
</tr>
<tr>
<td>GBS</td>
<td>GBS</td>
<td>S. pneumoniae</td>
<td>HSV-1, 2</td>
</tr>
<tr>
<td>E. coli</td>
<td>E. coli</td>
<td>N. meningitidis</td>
<td>VZV</td>
</tr>
<tr>
<td>N. meningitidis</td>
<td>N. meningitidis</td>
<td>L. monocytogenes</td>
<td>Enteroviruses</td>
</tr>
<tr>
<td>H. influenzae</td>
<td>H. influenzae</td>
<td>(age &gt;50 and comorbidities)</td>
<td>Parechoviruses</td>
</tr>
<tr>
<td>L. monocytogenes</td>
<td>L. monocytogenes</td>
<td></td>
<td>West Nile</td>
</tr>
</tbody>
</table>

Risk Factors

• lack of immunization against S. pneumoniae, H. influenzae type b in children
• most cases of bacterial meningitis are due to hematogenous spread from a mucosal surface (nasopharynx)
• direct extension from a parameningeal focus (otitis media, sinusitis) less common
• penetrating head trauma
• anatomical meningeal defects – CSF leaks
• previous neurosurgical procedures, shunts
• immunodeficiency (corticosteroids, HIV, asplenia, hypogammaglobulinemia, complement deficiency)
• contact with colonized or infected persons

Clinical Features

• neonates and children: fever, lethargy, irritability, vomiting, poor feeding
• older children and adults: fever, H/A, neck stiffness, confusion, lethargy, altered level of consciousness, seizures, focal neurological signs, N/V, photophobia, papilledema
• petechial rash in meningococcal meningitis, seen more frequently on trunk or lower extremities

Investigations

• blood work: CBC and differential, electrolytes (for SIADH), blood C&S
  • CSF: opening pressure, cell count + differential, glucose, protein, Gram stain, bacterial C&S
  • AFB, fungal C&S, cryptococcal antigen in immunocompromised patients, subacute illness, suggestive travel history or TB exposure
  • PCR for HSV, VZV, enteroviruses; in infants <6 mo, parechoviruses
  • WNV serology in blood and CSF during summer and early fall if viral cause suspected
  • imaging/neurologic studies: CT, MRI, EEG if focal neurological signs present

Table 19. Typical CSF Profiles for Meningitis

<table>
<thead>
<tr>
<th>CSF Analysis</th>
<th>Bacterial</th>
<th>Viral</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose (mmol/L)</td>
<td>Decreased</td>
<td>Normal</td>
</tr>
<tr>
<td>Protein (g/L)</td>
<td>Markedly Increased</td>
<td>Increased</td>
</tr>
<tr>
<td>WBC</td>
<td>500-10,000/µL</td>
<td>10-500/µL</td>
</tr>
<tr>
<td>Predominant WBC</td>
<td>Neutrophil</td>
<td>Lymphocytes</td>
</tr>
</tbody>
</table>

Treatment

• bacterial meningitis is a medical emergency: do not delay antibiotics for CT or LP
• empiric antibiotic therapy
  • age < wk: ampicillin + cefotaxime IV OR ampicillin ± an aminoglycoside IV
  • wk-3 mo: cefotaxime + vancomycin
  • age >3 mo: vancomycin
  • add ampicillin IV if risk factors for infection with L. monocytogenes present: age >50, alcoholism, immunocompromised
• steroids in acute bacterial meningitis: dexamethasone IV within 20 min prior to or with first dose of antibiotics
• continue in those patients with proven pneumococcal meningitis
• not recommended for patients with suspected bacterial meningitis in some resource-limited countries
• not recommended for neonatal meningitis

Brudzinski’s Sign

Passive neck flexion causes involuntary flexion of hips and knees

Kernig’s Sign

Resistance to knee extension when hip is flexed to 90º

Jolt Accentuation of H/A

Headache worsens when head turned horizontally at 2-3 rotations; more sensitive than Brudzinski’s and Kernig’s

CSF Gram Stain Findings

• S. pneumoniae – GP diplococci
• N. meningitidis – GN diplococci
• H. influenzae – Pleomorphic GN coccobacilli
• L. monocytogenes – GP rods

Does this Adult Patient Have Acute Meningitis?

From The Rational Clinical Examination

JAMA 2009; http://www.jamaevidence.com/content/3482857

Study: Systematic review of articles assessing the sensitivity and specificity of clinical exam maneuvers for the diagnosis of adult meningitis.

Results: In retrospective studies, sensitivity for headache was 60%, and 52% for nausea and vomiting. Sensitivity for physical examination findings is similarly low: fever, 83%, neck stiffness, 90%, altered mental status, 89%. Sensitivity for the combination of the classic triad of fever, neck stiffness, and altered mental status was 46%. In prospective studies, sensitivity of H/A was 92%, while sensitivity of N/V could not be pooled, and ranged from 32-70%. Brudzinski’s and Kernig’s signs had a sensitivity of 5% and Kernig’s sign only 5-9%. Jolt accentuation had a sensitivity of 97%.

Conclusions: Data were heterogeneous, and lacked standardization of clinical exam. No single item on clinical history or physical exam was sufficient to rule out meningitis, including Kernig’s and Brudzinski’s signs, or the absence of the classic triad of fever, neck stiffness, and altered mental status. Jolt accentuation has high sensitivity, but further research is needed. LP may be performed safely without CT head in patients without altered LOC, no recent seizure, no history of CNS disease, not immunocompromised, and <50 yr.
Prevention
- see Pediatrics, P59
- immunization
  - children: immunization against H. influenzae type B (Pentacel®), S. pneumoniae (Synflex®, Prevnar-13®), N. meningitidis (Menjugate®, Menactra®, Bexsero®)
  - adults: immunization against N. meningitidis in selected circumstances (outbreaks, travel, epidemics) and S. pneumoniae (Pneumovax®) for high-risk groups
- prophylaxis: close contacts of patients infected with H. influenzae type B should be treated with rifampin if they live with an inadequately immunized (<4 yr) or immunocompromised child (<18 yr); ciprofloxacin, rifampin, or ceftriaxone if close or household contact of a patient with N. meningitidis

Prognosis
- complications
  - H/A, seizures, cerebral edema, hydrocephalus, SIADH, residual neurological deficit (especially CN VIII), deafness, death
- mortality
  - S. pneumoniae 25%; N. meningitidis 5-10%; H. influenzae 5%
- worse prognosis if: extremes of age, delays in diagnosis and treatment, stupor or coma, seizures, focal neurological signs, septic shock at presentation

Encephalitis

Definition
- inflammation of the brain parenchyma

Etiology
- identified in only 40-70% of cases
- when cause is identified, the most common etiology is viral: HSV, VZV, EBV, CMV, enteroviruses, parechoviruses, West Nile and other arboviruses, influenza and other respiratory viruses, HIV, mumps, measles, rashes, polio
- bacteria: L. monocytogenes, Mycobacteria, spirochetes (Lyme, syphilis), Mycoplasma pneumoniae
- parasites: protozoa (e.g. Toxoplasma) and helminths (rare)
- fungi: e.g. Cryptococcus
- post-infectious (e.g. acute disseminated encephalomyelitis [ADEM])
- auto-antibody mediated encephalitis
  - anti-N-methyl-D-aspartate (NMDA) receptor encephalitis most common
  - in adults, most autoantibody-mediated encephalitis cases are associated with malignancy

Pathophysiology
- acute inflammatory disease of the brain due to direct invasion or pathogen-initiated immune response
- viruses may reach the CNS via peripheral nerves (e.g. rashes, HSV)
- herpes simplex encephalitis
  - acute, necrotizing, asymmetrical hemorrhagic process with lymphocytic and plasma cell reaction which usually involves the medial temporal and inferior frontal lobes
  - associated with HSV-1, but can also be caused by HSV-2
- influenza and other respiratory viruses are associated with acute necrotizing encephalopathy (ANE); likely mediated by pathogen-initiated immune response

Clinical Features
- constitutional: fever, chills, malaise, N/V
- meningal involvement (meningoencephalitis): H/A, nuchal rigidity
- parenchymal involvement: seizures, altered mental status, focal neurological signs
- herpes simplex encephalitis
  - acute onset (<1 wk) of focal neurological signs: hemiparesis, ataxia, aphasia, focal or generalized seizures
  - temporal lobe involvement: behavioural disturbance
  - usually rapidly progressive over several days and may result in coma or death
  - common sequela: memory and behavioural disturbances

Investigations
- CSF: opening pressure, cell count and differential, glucose, protein, Gram stain, bacterial C&S, PCR for HSV, VZV, EBV, enteroviruses/parechoviruses, M. pneumoniae, and selectively for other less common etiologies
- serology: may aid diagnosis of certain causes of encephalitis (e.g. EBV, West Nile virus, rashes, Bartonella henselae)
- imaging/neurologic studies: CT, MRI, EEG to define anatomical sites affected
- invasive testing: brain tissue biopsy may be required for culture, histological examination, and immunocytochemistry (if diagnosis not clear via non-invasive means)
- findings in herpes simplex encephalitis (must rule out due to high mortality)
  - CT/MRI: medial temporal lobe necrosis
  - EEG: early focal slowing, periodic discharges
Treatment
• general supportive care
• monitor vital signs carefully
• IV acyclovir empirically until HSV encephalitis ruled out

**Generalized Tetanus**

- see *Pediatrics, P4*

**Etiology and Pathophysiology**
- caused by *Clostridium tetani*: motile, spore forming, anaerobic GP bacillus
- found in soil, splinters, rusty nails, GI tract (humans and animals)
- traumatic implantation of spores into tissues with low oxygenation (e.g. puncture wounds, burns, nonsterile surgeries or deliveries)
- upon inoculation, spores transform into *C. tetani* bacilli that produce tetanus toxin
  - toxin travels via retrograde axonal transport to the CNS where it irreversibly binds presynaptic neurons to prevent the release of inhibitory neurotransmitters (e.g. GABA)
  - net effect is the disinhibition of spinal motor reflexes which results in tetany and autonomic hyperactivity

**Clinical Features**
- generalized tetanus
  - initially present with painful spasms of masseters (trismus or “lockjaw”)
  - sustained contraction of skeletal muscle with periodic painful muscle spasms (triggered by sensory stimuli, e.g. loud noises)
  - paralysis descends to involve large muscle groups (neck, abdomen)
  - apnea, respiratory failure, and death secondary to tonic contraction of pharyngeal and respiratory muscles
  - autonomic hyperactivity
    - diaphoresis, tachycardia, HTN, fever as illness progresses

**Investigations**
- primarily a clinical diagnosis, often although not always with a history of a traumatic wound and lack of immunization
- culture wounds, CK may be elevated

**Treatment**
- stop toxin production
  - wound debridement to clear necrotic tissue and spores
  - antimicrobial therapy: IV metronidazole; IV penicillin G is an effective alternative
  - neutralize unbound toxin with tetanus immune globulin (TIg)
  - supportive therapy: intubation, spasmolytic medications (benzodiazepines), quiet environment, cooling blanket
  - control autonomic dysfunction: α- and β-blockade (e.g. labetalol), magnesium sulfate

**Prevention**
- infection with *C. tetani* does not produce immunity – vaccinate patients on diagnosis
- tetanus toxoid vaccination (see *Pediatrics, P4* and *Emergency Medicine, ER17*)

**Rabies**

**Definition**
- acute progressive encephalitis caused by RNA virus (genus *Lyssavirus* of the Rhabdoviridae family)

**Etiology and Pathophysiology**
- any mammal can transmit the rabies virus
  - most commonly transmitted by raccoon, skunk, bat, fox, cat, and dog; monkeys also a risk in the developing world
- transmission: breaching of skin by teeth or direct contact of infectious tissue (saliva, neural tissue) with skin or mucous membranes
  - almost all cases due to bites
- virus travels via retrograde axonal transport from PNS to CNS
- virus multiplies rapidly in brain, then spreads to other organs, including salivary glands
- development of clinical signs occurs simultaneously with excretion of rabies virus in saliva
  - infected animal can transmit rabies virus as soon as it shows signs of disease

**Clinical Features**
- five stages of disease
  1. incubation period
    - 1-3 mo on average (can range from days to years)
2. prodrome (<1 wk)
   • influenza-like illness: low-grade fever, malaise, anorexia, N/V, H/A, sore throat
   • pain, pruritus, and paresthesia may occur at wound site
   • once prodromal symptoms develop, there is rapid, irreversible progression to death
     • progression from prodrome to coma and death may occur without an intervening acute
       neurologic syndrome
3. acute neurologic syndrome: 2 types (<1 wk)
   a. encephalitic (most common): hyperactivity, fluctuating LOC, hydrophobia, aerophobia,
      hypersalivation, fever, seizures
     • painful pharyngeal spasms on encountering gust of air or swallowing water cause aerophobia
       and hydrophobia, respectively
   b. paralytic: quadriplegia, loss of anal sphincter tone, fever
4. coma
   • complete flaccid paralysis, respiratory and cardiovascular failure
5. death (within days to weeks of initial symptoms)

**Investigations**
- purpose of diagnosis by investigations is to limit patient contact with others and to identify others
  exposed to the infectious source
- ante-mortem: direct immunofluorescence or PCR on multiple specimens: saliva, skin biopsy, serum,
  CSF
- post-mortem: direct immunofluorescence in nerve tissue, presence of Negri bodies (inclusion bodies in
  neurons)

**Treatment**
- post-exposure prophylaxis depends on regional prevalence (contact Public Health) and circumstances
  surrounding injury
- 3 general principles
  - wound care: clean wound promptly and thoroughly with soap and running water
  - passive immunization: HRIG infiltrated into wound site, with any remaining volume administered
    IM in anatomical site distant from vaccine administration
  - active immunization: inactivated human diploid cell rabies virus vaccine (series of 4 shots post-
    exposure if not pre-immunized)
- treatment is supportive once victim manifests signs and symptoms of disease

**Prevention**
- pre-exposure vaccination
  - recommended for high risk persons: laboratory staff working with rabies, veterinarians, animal and
    wildlife control workers, long-term travellers to endemic areas
  - eliminates need for HRIG following an exposure, and reduces number of HDCV PEP shots from 4
    to 2

---

**Systemic Infections**

**Sepsis and Septic Shock**

- see Respirology R33

**Definitions**
- systemic inflammatory response syndrome (SIRS): 2 or more of
  1. temperature <36°C/96.8°F or >38°C/100.4°F
  2. heart rate >90 beats/min
  3. respiratory rate >20 breaths/min or PaCO₂ <32 mmHg
  4. WBC <4 x 10⁹/L or >12 x 10⁹/L or >10% bands
- sepsis: SIRS + proven or provable infection
- severe sepsis: sepsis + signs of end-organ dysfunction and hypoperfusion
- septic shock: severe sepsis + hypotension (<90 mmHg sBP), despite adequate fluid resuscitation

**Pathophysiology**
- causative agents are identified in only 50-70% of cases
- when organisms are identified, GP and GN organisms are the cause in 90% of cases
- primary bloodstream infection or secondary bacteremia → local immune response → immune
  cells release pro-inflammatory cytokines → immune response spreads beyond local environment →
  unregulated, exaggerated systemic immune response → vasodilation and hypotension → involvement
  of tissues remote from the site of injury/infection resulting in multiple major organ dysfunction →
  periodic immunonparalysis

**Clinical Features**
- history: fever, chills, dyspnea, cool extremities, fatigue, malaise, anxiety, confusion
- physical: abnormal vitals (fever, tachypnea, tachycardia, hypotension), local signs of infection
Investigations
- CBC and differential, electrolytes, BUN, creatinine, liver enzymes, ABG, lactate, INR, PTT, FDP, blood C&S x2, urinalysis, urine C&S and cultures of any wounds or lines
- CXR (other imaging depends on suspicion of focus of infection)

Treatment (see Respirlogy, R34)
- respiratory support: O₂ ± intubation
- cardiovascular support: IV fluids, ± norepinephrine + ICU
- IV antibiotics (empirical, depends on suspected source)
  - start with broad spectrum antibiotics (piperacillin/tazobactam or meropenem) ± additional agents depending on patient risk factors, suspected etiology of infection, and local microbial susceptibilities
  - narrow once susceptibilities are known
- hydrocortisone IV in patients with septic shock unresponsive to fluid resuscitation and vasopressors

Leprosy (Hansen’s Disease)

Etiology
- *Mycobacterium leprae*: obligate intracellular bacteria, slow-growing (doubling time 12.5 d), survives in macrophages
- bacteria transmitted from nasal secretions, potentially via skin lesions
- invades skin and peripheral nerves leading to chronic granulomatous disease

Clinical Features
- lesions involve cooler body tissues (e.g. skin, superficial nerves, nose, eyes, larynx)
- spectrum of disease determined by host immune response to infection
  i. paucibacillary “tuberculoid” leprosy (intact cell-mediated immune response)
    - ≤5 hypoesthetic lesions, usually hypopigmented, well-defined, dry
    - early nerve involvement, enlarged peripheral nerves, neuropathic pain
    - may be self-limited, stable, or progress over time to multibacillary “lepromatous” form
  ii. multibacillary “lepromatous” leprosy (weak cell-mediated immune response)
    - ≥6 lesions, symmetrical distribution
    - leonine facies (nodular facial lesions, loss of eyebrows, thickened ear lobes)
    - extensive cutaneous involvement, late and insidious nerve involvement causing sensory loss at the face and extremities
  iii. borderline leprosy
    - lesions and progression lies between tuberculoid and lepromatous forms

Investigations
- skin biopsy down to fat or slit skin smears for AFB staining, PCR
- histologic appearance: intracellular bacilli in spherical masses (lepra cells), granulomas involving cutaneous nerves

Treatment (WHO Treatment Regimens)
- paucibacillary: dapsone daily + rifampin monthly x 6 mo
- single skin lesion paucibacillary: single dose of rifampicin, ofloxacin, and minocycline
- multibacillary: dapsone + rifampin monthly + clofazimine monthly x 12 mo AND low dose clofazimine once daily x 12 mo
- treatment of leprosy can cause an immune reaction to killed or dying bacteria (e.g. erythema nodosum leprosum and reversal reaction): symptomatic management with NSAIDs if mild, prednisone with 6-12 wk taper if severe; thalidomide for erythema nodosum leprosum. Neuritis of reactions can lead to permanent nerve damage.

Prognosis
- curable with WHO-approved treatment regimens
- complications: muscle atrophy, contractures, trauma/superinfection of lesions, crippling/loss of limbs, erythema nodosum leprosum, social stigmatization due to clofazimine hyperpigmentation
- long post-treatment follow-up warranted to monitor for relapse and immune reactions
Lyme Disease

Etiology/Epidemiology
- spirochete bacteria: *Borrelia burgdorferi* (N. America), *B. garinii*, *B. afzelii* (Europe and Asia)
- transmitted by Ixodes tick
- reported in 49 of the 50 U.S. states, but most cases occur in the Northeast, the Midwest, and Northern California
- in Canada, reported in southern and southeastern Quebec, southern and eastern Ontario, southeastern Manitoba, New Brunswick and Nova Scotia, as well as southern British Columbia
- small rodents (mice) serve as primary reservoir, while larger animals (white-tailed deer) serve as hosts for ticks
- human contact usually May-August in fields with low brush near wooded areas
- infection usually requires >36 h tick attachment

Clinical Features
- stage 1 (early localized stage: 7-14 d post-bite)
  - malaise, fatigue, H/A, myalgias
  - erythema migrans: expanding, non-pruritic bulls-eye (target) lesions (red with clear centre) on thigh/groin/axilla
- stage 2 (early disseminated stage): weeks post-infection
  - CNS: aseptic meningitis, CN palsies (CN VII palsy), peripheral neuritis
  - cardiac: transient heart block or myocarditis
  - stage 3 (late persistent stage: months to years post-infection)
    - may not have preceding history of early stage infection
    - MSK: chronic monoarticular or oligoarticular arthritis
    - acrodermatitis chronicum atrophicans (due to *B. afzelii*)
    - neurologic: encephalopathy, meningitis, neuropathy

Investigations
- serology: ELISA, Western blot

Prevention
- use of protective clothing (tuck pants into socks), insect repellent, inspection for ticks and prompt removal of tick
- doxycycline prophylaxis within 72 h of removal of an engorged, Ixodes scapularis tick in hyperendemic area (local rate of infection of ticks ≥20%) for patients >8 yr who are not pregnant or lactating

Treatment
- stage 1: doxycycline/amoxicillin/cefuroxime
- stage 2-3: ceftriaxone

Toxic Shock Syndrome

Etiology
- superantigens produced by some strains of *S. aureus* or GAS cause widespread T-cell activation and pro-inflammatory cytokine release (IL-1, IL-6, TNF)
- course of disease is precipitous and leads to acute fever, shock, multiorgan failure
- Staphylococcal TSS involves the production of superantigen TSST-1 (toxic shock syndrome toxin 1)
- Streptococcal TSS involves the production of superantigen SPEA, SPEB, SPEC

Risk Factors
- Staphylococcal: tampon use, nasal packing, wound infections (e.g. postpartum vaginal or Cesarean or other surgical infections)
- Streptococcal: minor trauma, surgical procedures, preceding viral illness (e.g. chickenpox), use of NSAIDs

Clinical Features and Investigations
- acute onset
- Staphylococcal TSS
  - T >38.9°C
  - sBP <90 mmHg
  - diffuse erythroderma with subsequent desquamation, especially on palms and soles
  - involvement of 3 or more organ systems: GI (vomiting, diarrhea), muscular (myalgia, increased CK), mucous membranes (hyperemia), renal, hepatic, hematologic (thrombocytopenia), CNS (disorientation)
  - isolation of *S. aureus* is not required for diagnosis (*S. aureus* is rarely recovered from blood in TSS)
• Streptococcal TSS
  ■ sBP <90 mmHg
  ■ isolation of GAS from a normally sterile site (e.g., blood, pleural, tissue biopsy, or surgical wound)
  ■ ≥2 of coagulopathy, liver involvement, ARDS, soft tissue necrosis (necrotizing fasciitis, myositis, gangrene), renal impairment, erythematous macular rash that may desquamate

Treatment
• supportive: fluid resuscitation
  • Staphylococcal: for methicillin-susceptible S. aureus: clindamycin + cloxacillin (IV); for MRSA: clindamycin + vancomycin x 10-14 d
  • Streptococcal: IV penicillin and clindamycin and ± IVlg

Cat Scratch Disease

Etiology
• Bartonella henselae: intracellular bacteria
• cat-to-human transmission via cat scratch/bite

Clinical Features
• skin lesion appears 3-10 d post-inoculation
• may be followed by fever, tender regional lymphadenopathy
• in some patients, organism may disseminate causing fever of unknown origin, hepatosplenomegaly, retinitis, encephalopathy
• usually self-limited

Investigations
• serology, PCR, lymph node biopsy

Treatment
• supportive in most cases
  • azithromycin x 10-14 d with lymphadenitis in patients with moderate-severe disease or immunodeficiency
  • Combination therapy consisting of doxycycline or azithromycin plus rifampin often used for disseminated disease (neuroterinitis, hepatosplenic involvement)

Rocky Mountain Spotted Fever

Etiology
• Rickettsia rickettsii: obligate intracellular GN organism
• reservoir hosts: rodents, dogs
• vectors: Dermacentor ticks
• organisms cause inflammation of endothelial lining of small blood vessels, leading to small hemorrhages and thrombi
• can cause widespread vasculitis leading to H/A, and CNS changes; can progress to death if treatment is delayed

Clinical Features
• usually occurs in summer following tick bite
• influenza-like prodrome: acute onset fever, H/A, myalgia, N/V, anorexia
• macular rash appearing on day 2-4 of fever
  ■ begins on wrists and ankles, then spreads centrally to arms/legs/trunk/palms/soles
  ■ occasionally “spotless” (10% of patients)

Investigations
• skin biopsy and serology (indirect fluorescent antibody test)

Treatment
• doxycycline, usually 5-7 d (treat for 3 d after defervescence)

West Nile Virus

Epidemiology
• virus has been detected throughout the United States and much of southern Canada
• overall case-fatality rates in severe cases is ~10%

Transmission
• primarily from mosquitoes that have fed on infected birds (crows, blue jays)
• transplacental, blood products (rare), organ transplantation
Clinical Features
- most are asymptomatic
- most symptomatic cases are mild (West Nile fever): acute onset of H/A, back pain, myalgia, anorexia, maculopapular non-pruritic rash involving chest, back, arms
- severe complications: encephalitis, meningoencephalitis, and acute flaccid paralysis (especially in those >60 yr)

Investigations
- IgM antibody in serum or CSF (cross reactivity with yellow fever and Japanese encephalitis vaccines, and with dengue fever and St. Louis virus infection); may not reflect current illness as IgM antibody can last for >6 mo
- viral isolation by PCR from CSF, tissue, blood, and fluids (all have low sensitivity)
- CSF: elevated lymphocytes and protein if CNS involvement

Treatment and Prevention
- treatment: supportive
- prevention: mosquito repellent (DEET), drain stagnant water, community mosquito control programs

Syphilis

Etiology
- *Treponema pallidum*: thick motile spirochetes historically detectable by dark-field microscopy
- transmitted sexually, vertically, or parenterally (rare)

Clinical Features
- see Dermatology, D31 and Gynecology, GY30
- multi-stage disease
  1. primary syphilis (3-90 d post-infection)
     - painless chancre at inoculation site (any mucosal surface)
     - regional lymphadenopathy
     - acute disease lasts 3-6 wk, 25% progress to secondary syphilis without treatment
     - maculo-papular non-pruritic rash including palms and soles
     - generalized lymphadenopathy, low grade fever, malaise, H/A, aseptic meningitis, ocular/otic syphilis
     - condylomata lata: painless, wart-like lesion on palate, vulva, or scrotum (highly infectious)
  2. secondary syphilis = systemic infection (2-8 wk following chancre)
     - AIDS: dissemination to the CNS, multiple systems involvement
     - CSF: elevated lymphocytes and protein if CNS involvement
     - VRDL and RPR Tests
     - Viruses (mononucleosis, hepatitis)
     - Drugs and substance abuse
     - Rheumatic fever
     - Lupus and leprosy
  3. latent syphilis
     - asymptomatic infection that follows untreated primary/secondary syphilis
     - early latent (<1 yr post-infection) or late latent/unknown duration (>1 yr post-infection)
     - increased transmission risk with early latent; longer treatment duration required for late latent
  4. tertiary syphilis (1-30 yr post-infection)
     - gummatous syphilis: nodular granulomas of skin, bone, liver, testes, brain
     - aortic aneurysm and aortic insufficiency
     - neurosyphilis: dementia, personality changes, Argyll-Robertson pupils, tabes dorsalis
  5. congenital syphilis
     - causes spontaneous abortions, stillbirths, congenital malformations, developmental delay, deafness
     - most infected newborns are asymptomatic
     - clinical manifestation in early infancy include rhinitis (snuffles), lymphadenopathy, hepatosplenomegaly, pseudoparalysis (bone pain associated with osteitis)
     - late onset manifestations (>2 yr of age) include saddle nose, saber shins, Glutton joints, Hutchinson’s teeth, mulberry molars, rhagades, CN VIII deafness, interstitial keratitis, juvenile paries

Investigations
- screening tests: CMIA, CLIA, EIA (treponemal), RPR, or VDRL (non-treponemal)
- confirmatory tests: TPPA, FTA-ABS, MHA-TP, TPI, dark field microscopy with silver stain (rarely)
- LP for neurosyphilis if: seropositive and symptoms of neurosyphilis or treatment failure/other tertiary symptoms, or with HIV and late latent/unknown duration syphilis; consider in others
- for congenital syphilis, LP is essential; long bone x-rays may also be helpful

Treatment
- for 1st, 2nd early latent: benzathine penicillin G 2.4 million units IM x 1
- for 3rd, late latent: benzathine penicillin G 2.4 million units IM weekly x 3
- if allergic to penicillin: doxycycline 100 mg PO bid x 14 d
- neurosyphilis: aqueous Penicillin G 18-24 million units/d IV x 14 d
- for congenital syphilis, penicillin G IV x 10 d
- see Family Medicine, FM43 for generalized STI workup
Tuberculosis

Etiology, Epidemiology, and Natural History

- 1/3 of the world’s population is infected with TB
- contracted by aerosolized inhalation of Mycobacterium tuberculosis, a slow growing aerobe (doubling time = 18 h) that can evade innate host defenses, survive, and replicate in macrophages
- inhalation and deposition in the lung can lead to one of the following outcomes
  1. immediate clearance of the pathogen
  2. latent TB: asymptomatic infection contained by host immune defenses (represents 95% of infected people)
  3. primary TB: symptomatic, active disease (represents 5% of infected people)
  4. secondary TB: symptomatic reactivation of previously dormant TB (represents 5-10% of those with latent TB, most often within the first 2-3 yr of initial infection) at a pulmonary or extrapulmonary site

Figure 8. Tuberculosis statistics
Canadian Tuberculosis Standards, 7th ed.

Risk Factors

- social and environmental factors
  - travel or birth in a country with high TB prevalence (e.g. Asia, Latin America, Sub-Saharan Africa, Eastern Europe)
  - Aboriginal (particularly Inuit), crowded living conditions, low SES/homeless, IVDU
  - personal or occupational contact
- host factors
  - immunocompromised/immunosuppressed (especially HIV, including extremes of age)
  - silicosis
  - chronic renal failure requiring dialysis
  - malignancy and chemotherapy
  - substance abuse (e.g. drug use, alcoholism, smoking)

Clinical Features

- primary infection usually asymptomatic, although progressive primary disease may occur, especially in children and immunosuppressed patients
- secondary infection/reactivation usually produces constitutional symptoms (fatigue, anorexia, night sweats, weight loss) and site-dependent symptoms
  1. pulmonary TB
     - chronic productive cough ± hemoptysis
     - CXR consolidation or cavitation, lymphadenopathy
     - non-resolving pneumonia despite standard antimicrobial therapy
  2. miliary TB
     - widely disseminated spread especially to lungs, abdominal organs, marrow, CNS
     - CXR: multiple small 2-4 mm millet seed-like lesions throughout lung
  3. extrapulmonary TB
     - lymphadenitis, pleurisy, pericarditis, hepatitis, peritonitis, meningitis, osteomyelitis (vertebral = Pott’s disease), adrenal (causing Addison’s disease), renal, ovarian

Investigations

- screening for latent TB
  - PPD/Mantoux skin tests
  - both tests diagnose prior TB exposure; neither can diagnose or exclude active disease
• IFN-γ release assay (IGRA)
  ◆ in patients previously infected with TB, T-cells produce increased amounts of IFN-γ when re-exposed to TB antigen
  ◆ detects antigen not present in the BCG vaccine or in most types of non-tuberculous-mycobacteria (NTM), therefore fewer false positives
• Canadian and American guidelines treat IGRA as equivalent to the TB skin test and preferable in patients with a history of BCG vaccination or who may not return for a skin test reading
• diagnostic tests/investigations for active pulmonary TB
  ◆ three sputum specimens (either spontaneous or induced) should be collected for acid-fast bacillus smear and culture, the three specimens can be collected on the same day, a minimum of 1 hour apart
  ◆ BAL
  ◆ CXR
    • nodular or alveolar infiltrates with cavitation (middle/lower lobe if primary, apical if secondary)
    • pleural effusion (usually unilateral and exudative) may occur independently of other radiographic abnormalities
    • hilar/mediastinal adenopathy (especially in children)
    • tuberculoma (semi-calcified well-defined solitary coin lesion 0.5-4 cm that may be mistaken for lung CA)
    • miliary TB (see clinical features)
    • evidence of past disease: calcified hilar and mediastinal nodes, calcified pulmonary focus, pleural thickening with calcification, apical scarring

Prevention
• primary prevention
  ◆ airborne isolation for active pulmonary disease
  ◆ BCG vaccine
    • ~80% effective against pediatric miliary and meningeal TB
    • effectiveness in adults debated (anywhere from 0-80%)
    • recommended in high-incidence communities in Canada for infants in whom there is no evidence of HIV infection or immunodeficiency; widely used in other countries
• secondary prevention (defer in pregnancy unless mother is high risk)
  ◆ likely INH-sensitive: isoniazid (INH) + pyridoxine (vit B6 to help prevent INH-associated neuropathy) x 9 mo
  ◆ likely INH-resistant: rifampin x 4 mo

Treatment of Active Infection
• empiric therapy: INH + rifampin + pyrazinamide + ethambutol + pyridoxine
• pulmonary TB: INH + rifampin + pyrazinamide + ethambutol + pyridoxine x 2 mo (initiation phase), then INH + rifampin + pyrazinamide + ethambutol + pyridoxine x 4 mo in fully susceptible TB (continuation phase), total 6 mo
• extrapulmonary TB: same regimen as pulmonary TB but increase to 12 mo in bone/joint, CNS, and miliary/disseminated TB + corticosteroids for meningitis, pericarditis
• empiric treatment of suspected MDR (multidrug resistant) or XDR (extensively drug-resistant) TB requires referral to a specialist
  ◆ MDR = resistance to INH and rifampin ± others
  ◆ XDR = resistance to INH + rifampin + fluoroquinolone + ≥1 of injectable, second-line agents
    • very difficult to treat, global public health threat, 5 documented cases in Canada from 1997-2008
    • suspect MDR TB if previous treatment, exposure to known MDR index case, or immigration from a high-risk area
• note: TB is a reportable disease to Public Health (please see Public Health Agency of Canada website for more information: www.phac-aspc.gc.ca/tbpc-latb/pubs/tb-canada-7/index-eng.php)

HIV and AIDS

Epidemiology

Canadian Situation (Public Health Agency of Canada, 2013)
  • estimated 71,300 Canadians living with HIV infection at the end of 2011, 25% unaware of HIV-positive status
  • 2,090 new infections were reported in 2013: MSM account for 49.3% of cases, IVDU 12.8%

Global Situation (WHO and UNAIDS Core Epidemiology Slides, July 2014)
  • estimated 35 million people living with HIV/AIDS in 2013
  • estimated 2.1 million newly infected in 2013
  • estimated 1.5 million AIDS-related deaths in 2013
**Definition and Pathophysiology**

- HIV is a retrovirus that causes progressive immune system dysfunction which predisposes patients to various opportunistic infections and malignancies.
- HIV virion includes an envelope (gp41 and gp120 glycoproteins), matrix (p17) and capsid (p24) enclosing 2 single-stranded copies of RNA + enzymes in its core.
- Virion glycoproteins bind CD4 and CXCR4/CCR5 on CD4+ T lymphocytes (T-helper cells) to fuse and enter the cells.
- RNA converted to dsDNA by viral reverse transcriptase; dsDNA is integrated into host genome by viral integrase.
- Virus DNA transcribed and translated using host cell machinery, post-translational modifications include proteolytic activity of virally encoded protease enzymes.
- Newly produced virions bud out of host cell, incorporating host cell membrane; additional maturation steps are required before virion is considered infectious.
- Exact mechanisms of CD4 depletion incompletely characterized but likely include direct viral cytopathic effects, apoptosis, and increased cell turnover.

**Modes of Transmission**

<table>
<thead>
<tr>
<th>HIV Invasion Site</th>
<th>Sub-Location</th>
<th>Transmission Medium</th>
<th>Transmission Probability per Exposure Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female genital tract</td>
<td>Vagina, ectocervix, endocervix</td>
<td>Semen</td>
<td>1 in 200 to 1 in 2,000</td>
</tr>
<tr>
<td>Male genital tract</td>
<td>Inner foreskin, penile urethra</td>
<td>Cervicovaginal and rectal secretions and desquamations</td>
<td>1 in 700 to 1 in 3,000</td>
</tr>
<tr>
<td>Intestinal tract</td>
<td>Rectum, Upper GI tract</td>
<td>Semen, Semen, Maternal blood/genital secretions (intrapartum), Breastmilk</td>
<td>1 in 20 to 1 in 300, 1 in 2,500, 1 in 5 to 1 in 10, 1 in 5 to 1 in 10</td>
</tr>
<tr>
<td>Placenta</td>
<td>Chorionic villi</td>
<td>Maternal blood (intrauterine)</td>
<td>1 in 10 to 1 in 20</td>
</tr>
<tr>
<td>Blood stream</td>
<td></td>
<td>Contaminated blood products, Sharp/needlestick injuries</td>
<td>95 in 100, 1 in 150</td>
</tr>
</tbody>
</table>

Adapted with permission from Macmillan Publishers Ltd. Nat Rev Immunology 2008;8:447-457

**Natural History**

**Acute (Infection) Retroviral Syndrome**

- 40-90% experience an acute “flu-like” illness (may include fever, pharyngitis, lymphadenopathy, rash, arthralgias, myalgias, H/A, GI symptoms, oral ulcers, weight loss) 2-6 wk post-exposure lasting 10-15 d
- Hematologic disturbances (lymphopenia, thrombocytopenia)
- 10-20% present with aseptic meningitis; HIV RNA and/or p24 may be detected in CSF
- Associated with a high level of plasma viremia and therefore high risk of transmission.
**Asymptomatic (Latent) Stage**
- during latent phase, HIV infects and replicates in CD4+ T lymphocytes (lymph nodes)
- normal CD4 count in adults: 500-1,100 cells/mm³
- CD4 count drops 60-100 cells/mm³ per year
- by 10 yr post-infection, 50% have AIDS, 30% demonstrate milder symptoms, and <20% are asymptomatic if left untreated

**AIDS Definition in Canada**
- HIV-positive AND
- one or more of the clinical illnesses that characterize AIDS, including: opportunistic infections (e.g. PJP (previously PCP), esophageal candidiasis, CMV, MAC, TB, toxoplasmosis), malignancy (Kaposi’s sarcoma, invasive cervical cancer), wasting syndrome OR
- CD4 <200 (or <15%); this is largely historical since ART can reverse CD4 count decline

**Table 21. Symptomatic Stage (CD4 count thresholds for classic clinical manifestations)**

<table>
<thead>
<tr>
<th>CD4 Counts</th>
<th>Possible Manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;500 cells/mm³</td>
<td>Often asymptomatic Constitutional symptoms: fever, night sweats, fatigue, weight loss Mucocutaneous lesions: seborrheic dermatitis, HSV, VZV (shingles), oral hairy leukoplakia (EBV), candidiasis (oral, esophageal, vaginal), Kaposi’s sarcoma (KS) Recurrent bacterial infections, especially pneumonia Pulmonary and extrapulmonary tuberculosis Lymphoma</td>
</tr>
<tr>
<td>&lt;200 cells/mm³</td>
<td>Pneumocystis jiroveci pneumonia (formerly PCP) KS Oral thrush Local and/or disseminated fungal infections: Cryptococcus neoformans, Coccidioides immitis, Histoplasma capsulatum</td>
</tr>
<tr>
<td>&lt;100 cells/mm³</td>
<td>Progressive multifocal leukoencephalopathy (PML) – JC virus CNS toxoplasmosis</td>
</tr>
<tr>
<td>&lt;50 cells/mm³</td>
<td>CMV infection: retinitis, colitis, cholangiopathy, CNS disease Mycobacterium avium complex (MAC) Bacillary angiomatosis (disseminated Bartonella) Primary central nervous system lymphoma (PCNSL)</td>
</tr>
</tbody>
</table>

**Laboratory Diagnosis**
- anti-HIV antibodies detectable after a median of 3 wk, virtually all by 3 mo (therefore 3 mo window period)
- initial screening test (3rd generation antibody test): enzyme linked immunosorbent assay (ELISA) detects serum antibody to HIV; sensitivity >99.5%
- increasingly, combination p24 antigen/HIV antibody tests (4th generation) used for screening; improved sensitivity in early or acute infection and sensitivity/specificity approach 100% for chronic infection
- confirmatory test: if positive screen, Western blot confirmation by detection of antibodies to at least two different HIV protein bands (p24, gp41, gp120/160); specificity >99.99%
- rapid (point of care) antibody tests: higher false positives, therefore need to confirm positive results with traditional serology
- p24 antigen: detection by ELISA may be positive during "window period"

**Management of the HIV-Positive Patient**
- verify positive HIV test
- complete baseline history and physical exam, then follow-up every 3-6 mo
- laboratory evaluation
  - routine CD4 count to measure status of the immune system
  - routine HIV-RNA levels (viral load)
    - also important indicator of effect of ART
  - baseline HIV resistance testing to guide ARV therapy
  - HLA-B*5701 genetic test to screen for abacavir hypersensitivity if considering abacavir in treatment regimen
  - CCR5 tropism testing if considering CCR5 antagonist in treatment regimen
  - baseline tuberculin skin test (PPD): induration greater than 5 mm is positive
  - baseline serologies (hepatitis A, B, and C, syphilis, toxoplasma, CMV, VZV)
  - routine biochemistry and hematology, CXR, urinalysis
  - annual fasting lipid profile and fasting glucose (due to ART side effects)
• education
  ■ regular follow-up on CD4 counts and viral loads (q3-6mo) as well as strict adherence to ART improves prognosis
  ■ prevention of further transmission through safer sex and clean needles for injection drug use
  ■ HIV superinfection (transmission of different HIV strains from another HIV+ person) does rarely occur so barrier protection during sex is still recommended
  ■ discuss importance of disclosing HIV status to partners including risk of criminal prosecution of non-disclosure in jurisdictions where applicable
  ■ connect to relevant community groups and resources
• health care maintenance
  ■ assessment of psychosocial concerns and referral to psychiatry or social work if appropriate
  ■ vaccines: influenza annually, 23-valent pneumococcal every 5 yr, HBV (if not immune), HAV (if seronegative)
  ■ annual screening (PAP smear, STIs)
  ■ management of comorbid conditions and provision of general primary care

Table 22. Prophylaxis Against Opportunistic Infections in HIV-infected Patients

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Indication for Prophylaxis</th>
<th>Prophylactic Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumocystis jiroveci</td>
<td>CD4 count &lt; 200 cells/mm² or history of oral candidiasis</td>
<td>TMP-SMX 1 SS or DS OD</td>
</tr>
<tr>
<td>Toxoplasma gondii</td>
<td>IgG antibody to Toxoplasma and CD4 count &lt; 100 cells/mm²</td>
<td>As per prophylaxis for pneumocystis</td>
</tr>
<tr>
<td>Mycobacterium tuberculosis</td>
<td>PPD reaction &gt; 5 mm or contact with case of active TB</td>
<td>INH + pyridoxine daily x 9 mo</td>
</tr>
<tr>
<td>Mycobacterium avium complex</td>
<td>CD4 count &lt; 50 cells/mm²</td>
<td>Azithromycin 1,200 mg q1wk</td>
</tr>
</tbody>
</table>

SS = single strength; DS = double strength

Anti-Retroviral Treatment

Overall Treatment Principles
• recommended that all HIV+ patients initiate combination ART to restore and preserve immune function, reduce morbidity, prolong survival and prevent transmission
• patients starting ART should be committed to treatment and understand the importance of adherence; poor compliance can lead to viral resistance; may defer treatment on the basis of clinical and psychosocial factors on case by case basis
• consider results of baseline resistance testing and complete ART history before (re-) initiating ART
• goal: keep viral load below limit of detection i.e. <40 copies/mL (undetectable); viral load should decrease 10-fold within 4-8 wk, be undetectable by 6 mo, and restore immunological function
• strong evidence against intermittent ART or ‘drug holidays’
• ART leads to 96% reduction in risk of transmitting HIV to sexual partners

ART Recommendations for Treatment of Naïve Patients
• 2 NRTIs + 1 INSTI/PI (boosted with ritonavir or cobicistat)

Treatment Failure
• defined clinically (HIV progression), immunologically (failure to increase CD4 count by 25-50 over first yr of treatment or CD4 decrease > 100 over 1 yr), or virologically (failure to achieve viral load <40 copies/mL after 6 mo)
• ensure that viral load >40 is not just a transient viremia or ‘blip’; confirm medication adherence, assess drug interactions, perform resistance testing

1° and 2° prophylaxis may be discontinued if CD4 count is above threshold for at least 6 mo while on ART

Anti-Retroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals
Purpose: To evaluate the efficacy of oral anti-retroviral prophylactic therapy in preventing HIV infection.
Study: Systematic review of 12 randomized controlled trials with 6 trials forming the core analysis.
Population: 9649 HIV-uninfected patients at high risk of contracting HIV including men who have sex with men, serodiscordant couples and others.
Outcome: New infection with HIV.
Results: Daily oral tenofovir disoproxil fumarate (TDF) plus emtricitabine (FTC) reduced the risk of HIV acquisition compared to placebo (RR 0.49; 95% CI 0.28-0.85). TDF alone also showed significant risk reduction in trials with fewer patients (RR 0.33; 95% CI 0.20-0.59). There was no significant increase in adverse events in any of the treatment groups. Sexual practices and adherence did not differ between treatment and placebo arms.
Conclusions: Pre-exposure prophylaxis with TDF with or without FTC effectively reduces the risk of HIV acquisition in high risk, HIV uninfected patients without causing significant adverse effects.

Reasons for Deterioration of a Patient with HIV/AIDS
• Opportunistic infections
• Neoplasms
• Medication-related toxicities
• Co-infections (e.g. HBV, HCV, STIs)
• Non-AIDS-related comorbidities (e.g. cardiovascular, renal, hepatic, neurocognitive, bone disease)

Treatment Failure
• Assess adherence
• Assess drug interactions
• Resistance testing
• Rule out opportunistic infections
• Rule out marrow suppression
• Construct new 3-drug regimen
### Table 23. Anti-Retroviral Drugs

<table>
<thead>
<tr>
<th>Class</th>
<th>Drugs</th>
<th>Mechanism</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nucleoside reverse transcriptase inhibitors (NRTIs)</td>
<td>zidovudine (AZT) lamivudine (3TC) stavudine (d4T) didanosine (ddi) abacavir (ABC) emtricitabine (FTC) tenofovir disoproxil fumarate (TDF)</td>
<td>Incorporated into the growing viral DNA chain, thereby competitively inhibiting reverse transcriptase and terminating viral DNA growth</td>
<td>Lactic acidosis Lipodystrophy Rash N/V/diarrhea Bone marrow suppression (AZT) Peripheral neuropathy (ddi, d4T) Drug-induced hypersensitivity (ABC) Pancreatitis (ddi/d4T) Myopathy (AZT)</td>
</tr>
<tr>
<td>Non-nucleoside reverse transcriptase inhibitors (NNRTIs)</td>
<td>efavirenz (EFZ) nevirapine (NVP) delavirdine (DLV) etravirine (ETR) rilpivirine (RPV)</td>
<td>Non-competitively inhibit function of reverse transcriptase, thereby preventing viral RNA replication</td>
<td>Rash, Stevens-Johnson syndrome CNS: dizziness, insomnia, somnolence, abnormal dreams (efavirenz) Hepatotoxicity (nevirapine – avoid in females with CD4 &gt;250, men with CD4 &gt;400) CYP3A4 interactions</td>
</tr>
<tr>
<td>Protease inhibitors (PIs)*</td>
<td>ritonavir (RTV) saquinavir (SQV) amprenavir (APV) nefavir (NFV) indinavir (IDV) atazanavir (ATV) fosamprenavir (FPV) lopinavir/ritonavir (Kaletra®) tipranavir (TPV) darunavir (DRV)</td>
<td>Prevent maturation of infectious virions by inhibiting the cleavage of polyproteins</td>
<td>Lipodystrophy, metabolic syndrome N/V/diarrhea Nephrolithiasis (indinavir) Rash (APV) Hyperbilirubinemia (atazanavir, indinavir) CYP3A4 interactions Hyperlipidemia</td>
</tr>
<tr>
<td>Fusion inhibitor</td>
<td>enfuvirtide (T-20)</td>
<td>Inhibit viral fusion with T-cells by inhibiting gp41, preventing cell infection</td>
<td>Injection site reactions, rash, infection, diarrhea, nausea, fatigue</td>
</tr>
<tr>
<td>CCR5 antagonist</td>
<td>maraviroc</td>
<td>Inhibit viral entry by blocking host CCR5 co-receptor</td>
<td>Fever, cough, dizziness</td>
</tr>
<tr>
<td>Integrase strand transfer inhibitors (INSTIs)</td>
<td>raltegravir elvitegravir dolutegravir</td>
<td>Inhibits integration of HIV DNA into the human genome thus preventing HIV replication</td>
<td></td>
</tr>
</tbody>
</table>

*Standard care is to pharmacologically boost most PIs with ritonavir to increase concentrations

**Single Tablet ART Regimens**
- reduces pill burden and increases adherence
- generally better tolerated

### Table 24. Single Tablet ART Regimens

<table>
<thead>
<tr>
<th>Name</th>
<th>Contents</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atripla®</td>
<td>efavirenz/tenofovir/emtricitabine</td>
<td>psychiatric events, vivid dreams</td>
</tr>
<tr>
<td>Complera®</td>
<td>rilpivirine/emtricitabine/tenofovir</td>
<td>good side effect profile</td>
</tr>
<tr>
<td>Stibild®</td>
<td>elvitegravir/cobicistat/emtricitabine/tenofovir</td>
<td>good side effect profile</td>
</tr>
<tr>
<td>Triumeq®</td>
<td>Dolutegravir/abacavir/ lamivudine</td>
<td>good side effect profile; use only in HLAB*507 negative patients</td>
</tr>
</tbody>
</table>

**Lactic Acidosis**
- Occurs secondary to mitochondrial toxicity
- Symptoms include abdominal pain, fatigue, N/V, muscle weakness

**Lipodystrophy**
- Body fat redistribution (mainly with old ARVs)
- Lipohypertrophy (e.g. dorsal fat pad, breast enlargement, increased abdominal girth) thought to be caused primarily by protease inhibitors
- Lipatrophy (e.g. facial thinning, decreased adipose tissue in the extremities) is thought to be caused by thymidine analogue NRTIs such as d4T and AZT
- Metabolic abnormalities: lipids (increased LDL, increased TGs), glucose (insulin resistance, type 2 DM), increased risk of CVD
Prevention of HIV Infection

- education, including harm-reduction
  - safer sexual practices: condoms for vaginal and anal sex, barriers for oral sex
  - harm reduction for injection drug users: avoid sharing needles
- treatment of HIV+ women with ART during the 2nd and 3rd trimester of pregnancy and AZT during delivery followed by treatment of the infant for 4-6 wk (decreases maternal-fetal transmission from 25% to <3%)
- universal blood and body precautions for health care workers
  - post-exposure prophylaxis (PEP) after occupational (e.g. needle-stick injury) and non-occupational (e.g. consensual sex, sexual assault) exposure to HIV: 2- or 3-drug regimen initiated immediately (<72 h) after exposure and continuing for 4 wk
- recent data has demonstrated efficacy of pre-exposure prophylaxis (oral PrEP or topical microbicides) in preventing HIV
- ART associated with 96% reduction in risk of transmitting HIV to sexual partners
- screening of blood and organ donation
Types of Testing

1. Nominal/Name-Based HIV Testing
   - person ordering the test knows the identity of the person being tested for HIV
   - HIV test is ordered using the name of the person being tested
   - person ordering the test is legally obligated to notify Public Health officials if test results are positive for HIV
   - test result is recorded in the health care record of the person being tested

2. Non-Nominal/Non-Identifying HIV Testing
   - similar to nominal/name-based testing on all points except:
     - HIV test is ordered using a code or the initials of the person being tested

3. Anonymous Testing
   - available at specialized clinics
   - person ordering the HIV test does not know the identity of the person being tested
   - HIV test is carried out using a unique non-identifying code that only the person being tested for HIV knows
   - test results are not recorded on the health care record of the person being tested
   - patient identification and notification of Public Health required to gain access to ART

HIV Pre- and Post-Test Counselling

- a diagnosis of HIV can be overwhelming and is often associated with stigma and discrimination
- consider pre- and post-test counselling, regardless of the results
- goals include: assessing risk, making informed decision to be tested, education to protect themselves and others from virus exposure, where to go for more information and support
- HIV+ patients should be connected with local support services

Fungal Infections

Skin and Subcutaneous Infections

Superficial Fungal Infections

- see Dermatology, D26

Dermatophytes

- see Dermatology, D26

Subcutaneous Fungal Infection

Pathophysiology

- fungi that naturally reside in soil and enter skin via traumatic break
- Sporothrix schenckii: most commonly affects gardeners injured by a rose thorn or splinter
  - causes subcutaneous nodule at point of entry
  - fungi may migrate up lymphatic vessels creating nodules along the way – “nodular lymphangitis”

Treatment

- oral azole (e.g. itraconazole)
- IV amphotericin B for severe or disseminated infection

Endemic Mycoses

Basics

- three major endemic mycoses in North America
  - histoplasmosis
  - blastomycosis
  - coccidioidomycosis
- thermally dimorphic organisms: mould in cold temperature (e.g. soil) and yeast at higher temperature (e.g. tissue)
- infection occurs through inhalation of spores (soil, bird droppings, vegetation) or inoculation injury
- all can cause pneumonia and may disseminate hematogenously
- may reactivate or disseminate during immunocompromised states

**Treatment**
- common to all endemic mycoses
  - oral azole (e.g. itraconazole for mild-moderate local infection)
  - IV amphotericin B for systemic infection

### Table 25. Endemic Mycoses

<table>
<thead>
<tr>
<th>Disease</th>
<th>Endemic Region</th>
<th>Clinical Features</th>
<th>Investigations</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Histoplasma capsulatum</em></td>
<td>Ohio and Mississippi River valleys in central USA, Ontario, Quebec; widespread</td>
<td>Asymptomatic (in most people)</td>
<td>Fungal culture, fungal stain Antigen detection (urine and serum) Serology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Primary pulmonary</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Fever, cough, chest pain, H/A, myalgia, anorexia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• CXR (acute): pulmonary infiltrates ± hilar lymphadenopathy</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• CXR (chronic): pulmonary infiltrates, cavitary disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Disseminated (rare)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Occurs primarily in immunocompromised patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Spread to bone marrow (pancytopenial), GI tract (ulcers), lymph nodes</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(lymphadenitis), skin, liver, adrenals, CNS</td>
<td></td>
</tr>
<tr>
<td><em>Blastomyces dermatitidis</em></td>
<td>States east of Mississippi River, Northern Ontario and along the Great Lakes</td>
<td>May be asymptomatic</td>
<td>Sputum smear and culture Direct examination of clinical specimens for characteristic broad-based budding yeast (sputum, tissue, purulent material)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Primary: acute or chronic pneumonia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Fever, cough, chest pain, chills, night sweats, weight loss</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• CXR (acute): lobar or segmental pneumonia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• CXR (chronic): lobar infiltrates, fibronodular interstitial disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Disseminated</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Spread to skin ( verrucous lesions that mimic skin cancer, ulcers, subcutaneous nodules), bones (osteomyelitis, osteolytic lesions), GU tract (prostatitis, epididymitis)</td>
<td></td>
</tr>
<tr>
<td><em>Coccidioides immitis</em></td>
<td>Deserts in southwest USA, northwest Mexico</td>
<td>Primary</td>
<td>Sputum culture Direct examination of clinical specimens for characteristic yeast (sputum, tissue, purulent material)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• “Valley fever”: subacute fever, chills, cough, chest pain, sore throat, fatigue that lasts for weeks to months</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Can develop hypersensitivity with arthralgias, erythema nodosum</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Disseminated</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Rare spread to skin (ulcers), joints (synovitis), bones (lytic lesions), meninges (meningitis)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Common opportunistic infection in patients with HIV</td>
<td></td>
</tr>
</tbody>
</table>

### Opportunistic Fungi

**Pneumocystis jiroveci** (formerly *P. carinii*)

**Pneumonia: PJP or PCP**

**Microbiology**
- unicellular fungi
- previously classified as a protozoa

**Transmission**
- rarely person-to-person transmission
- most disease is due to reactivation of latent infection acquired by the respiratory route or reinfection by a different genotype
  - causes clinical disease in immunocompromised patients (steroid use, HIV)
  - 80% lifetime risk without prophylaxis (TMP/SMX) in HIV patients with CD4 count <200 cells/mm³

**Clinical Features**
- symptoms of pneumonia: fever, nonproductive cough, progressive dyspnea
- classic CXR

**Investigations**
- demonstration of organism in induced sputum, bronchoalveolar lavage, or endotracheal aspirate (if intubated)
Opportunistic Fungi

Treatment and Prevention
- oxygen to keep SaO2 >90%
- antimicrobial options
  - TMP(SMX (PO or IV)
  - dapsone and TMP
  - clindamycin and primaquine
  - pentamidine (IV)
  - atovaquone
- corticosteroids used as adjuvant therapy in those with severe hypoxia (pO2 <70 mmHg or A-a gradient O2 >35 mmHg)
- prophylactic TMP(SMX for those at high risk of infection (HIV patients when CD4 <200 cells/mm3 or non-HIV immunocompromised patients under specific conditions)

Cryptococcus spp.

Microbiology
- encapsulated yeast found worldwide
- 2 human pathogenic species: C. gattii, C. neoformans

Transmission
- inhalation of airborne yeast from soil contaminated with pigeon droppings (C. neoformans) or certain tree species such as Eucalyptus or Douglas fir (C. gattii) may cause local infection in lung → asymptomatic or pneumonia
- may also spread hematogenously to the CNS, skin, bones, and other organs
- C. neoformans tends to affect immunocompromised hosts
- C. gattii tends to affect immunocompetent hosts

Clinical Features
- pulmonary
  - usually asymptomatic or self-limited pneumonitis
  - only 2% of HIV+ patients present with pulmonary symptoms including productive cough, chest tightness, and fever
- disseminated
  - frequently disseminates in HIV+ population
  - CNS: meningitis (leading cause of meningitis in patients with HIV)
  - skin: umbilicated papules that resemble large lesions of Molluscum contagiosum

Investigations
- serum cryptococcal antigen
- CSF for meningitis: India-ink stain, cryptococcal antigen test, culture to confirm

Treatment
- in patients with HIV who have cryptococcal meningitis or severe pulmonary disease:
  - amphotericin B (+ flucytosine) is used in the first 2 wk for induction therapy; limited duration due to side effects
  - switch to fluconazole for at least 8 wk as consolidation therapy, then continue at lower dose for prolonged maintenance

Candida albicans

Microbiology
- yeast forms with pseudohyphae germ tube formation at 37°C

Transmission
- normal flora of skin, mouth, vagina, and GI tract
- risk factors for overgrowth:
  - immunocompromised state (DM, corticosteroids)
  - ICU patients (broad-spectrum antibiotic use, central venous catheters, TPN)
  - obesity → maceration and moisture in intertriginous areas, pannus, under breasts

Clinical Features
- mucocutaneous
  - oral thrush, esophagitis (chest pain, odynophagia), vulvovaginitis (see Gynecology, GY26), balanitis, cutaneous (diaper rash, skin folds, folliculitis), chronic mucocutaneous
  - small satellite lesions beyond the margin of the rash
- invasive
  - candidemia, endophthalmitis, endocarditis, UTI (upper tract), hepatosplenic disease
**Parasitic Infections**

**Protozoa – Intestinal/Genitourinal Infections**

**Entamoeba histolytica (Amoebas)**

**Transmission**
- reservoir: infected humans
- cysts by fecal-oral and food/waterborne transmission in areas of poor sanitation
- seen in immigrants, travellers, institutionalized individuals, Aboriginal Canadians, MSM

**Clinical Features**
1. asymptomatic carriers
2. amoebic dysentery
   - abdominal pain, cramping, colitis, dysentery, low grade fever with bloody diarrhea secondary to local tissue destruction and ulceration of large intestine
3. amoebic abscesses (LINK to General Surgery “Liver Abscesses”)
   - most common in liver (hematologic spread); presents with RUQ pain, weight loss, fever, hepatomegaly
   - can also occur in lungs and brain

**Investigations**
- serology, fecal/serum antigen testing, stool exam (for cysts and trophozoites), colon biopsy
- E. histolytica indistinguishable microscopically from the non-pathogen E. dispar (distinguish by specific stool antigen detection)
Protozoa – Intestinal/Genitourinal Infections

Treatment and Prevention
- metronidazole
- for invasive disease or cyst elimination: follow with iodoquinol or paromomycin
- aspiration of hepatic abscess if risk of cyst rupture, poor response to medical therapy, or diagnostic uncertainty
- asymptomatic cyst shedding: iodoquinol or paromomycin alone
- good personal hygiene, purification of water supply by boiling, filtration (not chlorination)

Giardia lamblia

Transmission
- reservoir: infected humans and other mammals
- food/waterborne (especially in the Rockies) and fecal-oral transmission of infectious cysts
- risk factors: travel, camping, institutions, day care centres, MSM

Clinical Features
- giardiasis (“beaver fever”)
  - symptoms vary from asymptomatic to self-limited mild watery diarrhea to malabsorption syndrome (chronic giardiasis where the parasite coats the small intestine and thus prevents fat absorption)
  - nausea, malaise, abdominal cramps, bloating, flatulence, fatigue, weight loss, steatorrhea
  - no hematochezia (no invasion into intestinal wall), no mucous in stool

Investigations
- multiple stool samples (daily x 3 d) for microscopy, stool antigen used occasionally
- occasionally small bowel aspirate or biopsy

Treatment and Prevention
- metronidazole; nitazoxanide if symptomatic
- good personal hygiene and sanitation, water purification (iodine better than chlorination), outbreak investigation

Trichomonas vaginalis

Transmission
- sexual contact

Clinical Features
- often asymptomatic (10-50%), especially males (occasionally urethritis, prostatitis)
- trichomonas vaginitis (see Gynecology, GY26)
  - vaginal discharge (profuse, malodourous, yellow-green or grey, frothy), pruritus, dysuria, dyspareunia

Investigations
- wet mount (motile parasites), antigen detection, culture
- urine PCR to detect in males

Treatment
- metronidazole for patient and partner(s)

Cryptosporidium spp.

Transmission
- reservoir: infected humans and a wide variety of young animals
- fecal-oral transmission by ingestion of cysts; waterborne
- risk factors: summer and fall, young children (day care), MSM, contact with farm animals, immunodeficiency

Clinical Features
- range from self-limited watery diarrhea (immunocompetent) to chronic, severe, non-bloody diarrhea with N/V, abdominal pain, and anorexia resulting in weight loss and death (immunocompromised)

Investigations
- modified acid-fast stain of stool specimen, microscopic identification of oocysts in stool or tissue, stool antigen detection by direct fluorescent antibody

Treatment and Prevention
- supportive care
- in HIV, try HAART to restore immunity; if fails, try nitazoxanide
- good personal hygiene, water filtration
Blood and Tissue Infections

**Plasmodium spp. (Malaria)**

**Microbiology**
- species include: *P. falciparum* (most common and most lethal), *P. vivax, P. ovale, P. malariae, P. knowlesi*
- complex life cycle: human host for asexual reproduction and mosquito for sexual reproduction
- sporozoites from mosquitoes infect human liver cells, where they multiply and are released as merozoites; merozoites infect RBCs and cause disease
- *P. ovale* and *P. vivax* can produce dormant hypnozoites in the liver that may cause relapsing malarial attacks by reactivating (entering the erythrocytic cycle) after many months

**Transmission**
- reservoir: infected human
- transmission by the night-biting female *Anopheles* mosquito, vertical transmission, and blood transfusion
- occurs in tropical/subtropical regions (sub-Saharan Africa, Oceania, South Asia, Central America, Southeast Asia, South America)

**Clinical Features**
- flu-like prodrome
- paroxysms of high spiking fever and shaking chills (due to synchronous systemic lysis of RBCs) (lasts several hours)
  - *P. vivax* and *P. ovale*: chills and fever x48 h but can be variable
  - *P. malariae*: chills and fever x72 h but can be variable
  - *P. falciparum*: less predictable fever interval, can be highly variable (>90% ill within 30 d)
- abdominal pain, diarrhea, myalgia, H/A, and cough
- hepatosplenomegaly and thrombocytopenia without leukocytosis

**Complications**
- *P. falciparum*: CNS involvement (cerebral malaria = seizures and coma), severe anemia, acute kidney injury, ARDS, primarily responsible for fatal disease
- *P. knowlesi*, and rarely *P. vivax*, can be fatal

**Investigations**
- microscopy: blood smear q12-24h (x3) to rule out infection
  - thick smear (Giemsa stain) for presence of organisms
  - thin smear (Giemsa stain) for species identification and quantification of parasites
- rapid antigen detection tests

**Treatment and Prevention**
- *P. vivax, P. ovale*: chloroquine (and primaquine to eradicate liver forms)
- *P. vivax*, chloroquine resistant: atovaquone/proguanil + primaquine or quinine and doxycycline + primaquine
- *P. malariae, P. knowlesi*: chloroquine
- *P. falciparum*: most areas of the world show chloroquine resistance – check local resistance patterns
- artesinin combination therapy (e.g. artesunate + doxycycline or clindamycin or atovaquone/proguanil)
- atovaquone/proguanil combination (Malarone®)
- quinine + doxycycline or clindamycin
- mefloquine and artesinin resistance increasing in southeast Asia (check local resistance)
- prevention with antimalarial prophylaxis, covering exposed skin, bed nets, insect repellent

**Trypanosoma cruzi**

**Transmission**
- found in Mexico, South America, and Central America
- transmission by Reduviid insect vector (“Kissing Bug”), which defecates on skin and trypanastigotes in the stooil are rubbed into bite site by host
- also transmitted via placental transfer, organ donation, blood transfusion, and ingestion of contaminated food containing Reduviid insects (especially cane juice)

**Clinical Features**
- American trypanosomiasis (Chagas disease)
  - acute: usually asymptomatic, local swelling at site of inoculation (“Romana’s sign”; usually around one eye) with variable fever, lymphadenopathy, cardiomegaly, and hepatosplenomegaly
• chronic indeterminate phase: asymptomatic but increasing levels of antibody in blood; most infected persons (60-70%) remain in this phase, and do not go on to manifest a determinate form of Chagas disease
• chronic determinate: leads to chronic dilated cardiomyopathy, esophagomegaly, and megacolon 10-25 yr after acute infection in 30-40% of infected individuals

Investigations
• wet prep and Giemsa stain of thick and thin blood smear, serology, PCR

Treatment and Prevention
• acute: nifurtimox or benznidazole
• indeterminate: increasing trend to treat as acute infection for children and adults under age 50 years
• chronic determinate: symptomatic therapy, surgery as necessary including heart transplant, esophagectomy, and colectomy; there may be a benefit to antiparasitic treatment
• insect control, bed nets

Toxoplasma gondii

Transmission
• acquired through exposure to cat feces (oocysts), ingestion of undercooked meat (tissue cysts), vertical transmission, organ transplantation, gardening without gloves (cat oocyst exposure), whole blood transfusions

Clinical Features
• congenital
  • result of acute primary infection of mother during pregnancy (see Obstetrics, OB29, TORCH infection)
  • stillbirth (rare), chorioretinitis, blindness, seizures, severe developmental delay, microcephaly
  • initially asymptomatic infant may develop reactivation of chorioretinitis as adolescent or adult blurred vision, scotoma, ocular pain, photophobia, epiphora, hearing loss, developmental delay
• acquired
  • usually asymptomatic or mononucleosis-like syndrome in immunocompetent patient
  • infection remains latent for life unless reactivation due to immunosuppression
• immunocompromised (most commonly AIDS with CD4 <200)
  • encephalitis with focal CNS lesions seen as single or multiple ring-enhancing masses on CT (H/A and focal neurological signs)
  • lymph node, liver, and spleen enlargement and pneumonitis
  • chorioretinitis

Investigations
• serology, CSF Wright-Giemsa stain, antigen or DNA detection (PCR); pathology provides definitive diagnosis
• immunocompromised patients: consider CT scan (ring-enhancing lesion in cortex or deep nuclei) and ophthalmologic examination
• negative serology in many AIDS patients (false negative due to decreased lymphocyte population)

Treatment and Prevention
• no treatment if immunocompetent, not pregnant, no severe organ damage
• pregnancy: spiramycin to prevent transplacental transmission or pyrimethamine + sulfadiazine (add folinic acid), avoid undercooked meat and refrain from emptying cat litter boxes
• HIV: pyrimethamine + sulfadiazine (see Prophylaxis, ID30)
• eye disease, meningitis: corticosteroids
• proper hand hygiene, cook meat thoroughly to proper temperature
## Helminths

### Roundworms – Nematodes

<table>
<thead>
<tr>
<th>Nematode</th>
<th>Epidemiology</th>
<th>Transmission</th>
<th>Medical Importance</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascaris lumbricoides</td>
<td>Tropics</td>
<td>Human feces, ingestion of contaminated food or water containing eggs</td>
<td>Abdominal pain and intestinal obstruction from high worm burden</td>
<td>Mebendazole OR albendazole OR pyrantel pamoate</td>
</tr>
<tr>
<td>Trichuris trichiura (whipworm)</td>
<td>Tropics</td>
<td>Ingestion of eggs in soil</td>
<td>Diarrhea (+: mucus, blood), abdominal pain, rectal prolapse, stunted growth</td>
<td>Mebendazole OR albendazole</td>
</tr>
<tr>
<td>Onchocerca volvulus</td>
<td>Africa, Latin America</td>
<td>Blackfly bite</td>
<td>River blindness (onchocerciasis), dermatitis</td>
<td>Ivermectin + doxycycline</td>
</tr>
<tr>
<td>Wuchereria bancrofti</td>
<td>Tropics</td>
<td>Mosquito bite</td>
<td>Damage to lymphatics resulting in lymphadenopathy, lymphedema, and elephantiasis</td>
<td>Diethylcarbamazine + doxycycline</td>
</tr>
<tr>
<td>Loa Loa</td>
<td>Central Africa</td>
<td>Deer fly bite</td>
<td>Subcutaneous migration of worm, hypersensitivity in travelers</td>
<td>Diethylcarbamazine</td>
</tr>
<tr>
<td>Enterobius vermicularis (Pinworm)</td>
<td>Worldwide</td>
<td>Human host: fecal-oral self-inoculation and fomite person-to-person transfer</td>
<td>Adult worms live in cecum and deposit eggs in perianal skin</td>
<td>Sticky tape test: eggs adhere to tape applied to perianal skin (need 5-7 tests to rule out) Examination of perianal skin at night may reveal adult worms Usually no eosinophilia as no tissue invasion Mebendazole, albendazole; pyrantel in pregnancy Change underwear, bathe in morning, pajamas to bed, wash hands, trim fingernails Treat all family members simultaneously Reinfection common</td>
</tr>
<tr>
<td>Strongyloides stercoralis (Threadworm)</td>
<td>Subtropical, tropical, and temperate (including southern US)</td>
<td>Fecal contamination of soil: transmission via unbroken skin, walking barefoot</td>
<td>One of few worms able to multiply in human host Mostly asymptomatic infection or can have pruritic dermatitis at site of larval penetration Transient pulmonary symptoms during pulmonary migration of larvae (eosinophilic pneumonia = Löffler’s syndrome) Abdominal pain, diarrhea, pruritus ani, larva currens (itchy rash) Hyperinfection: occasional fatal cases caused by massive auto-infection in immunocompromised host; immunosuppressive therapy, including high-dose corticosteroids, is the most common risk factor for disseminated infection</td>
<td>Ivermectin, 200 µg/kg PO x 2 doses (albendazole 400 mg PO bid x 7 d, less effective)</td>
</tr>
</tbody>
</table>

**Figure 15. Life cycle of Enterobius**

1. Embryonated eggs ingested by humans
2. Larvae hatch in small intestine
3. Females migrate out anus at night

**Figure 16. Life cycle of Strongyloides**

1. Step on stool containing larvae
2. Larvae migrate to lungs via bloodstream
3. Larvae crawl up trachea and down to GI tract (cough/swallow)
4. Adult worms in intestine
5. Eggs produced in bowel
6. Larvae
7. Bowel movement containing larvae
Flatworms

Cestodes/Trematodes

Table 27. Cestodes/Trematodes (Flatworms)

<table>
<thead>
<tr>
<th>Species</th>
<th>Epidemiology</th>
<th>Transmission</th>
<th>Medical Importance</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taenia solium</td>
<td>Developing countries</td>
<td>Undercooked pork (larvae), human feces (eggs)</td>
<td>Taeniasis: mild abdominal symptoms</td>
<td>Corticosteroids + albendazole for cysticercosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cysticercosis: mass lesions in CNS, eyes, skin, seizures</td>
<td>Antiepileptics if seizures</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Taeniasis: mild abdominal symptoms</td>
<td>Praziquantel for adult tapeworm in gut (taeniasis)</td>
</tr>
<tr>
<td>Taenia saginata</td>
<td>Developing countries</td>
<td>Undercooked beef (larvae)</td>
<td>Mild GI symptoms</td>
<td>Praziquantel</td>
</tr>
<tr>
<td>Diphyllobothrium latum</td>
<td>Europe, North America, Asia</td>
<td>Raw fish</td>
<td>B12 deficiency leading to macrocytic anemia and posterior column deficits</td>
<td>Praziquantel</td>
</tr>
<tr>
<td>Echinococcus granulosus</td>
<td>Rural areas Sheep-raising countries</td>
<td>Dog feces (eggs)</td>
<td>Liver/lung cysts (enlarge between 1-20 yr; may cause mass effect or rupture) Risk of anaphylaxis if cystic fluid released during surgical evacuation</td>
<td>Albendazole ± praziquantel alone Surgery + perioperative albendazole Percutaneous aspiration + perioperative albendazole</td>
</tr>
</tbody>
</table>

Trematodes/Flukes

Schistosoma spp.

Species

- *S. mansoni*, *S. hematobium*, *S. japonicum*

Transmission

- larvae (cercariae), released from snails, penetrate unbroken skin in infested fresh water
- adult worms live in terminal venules of bladder/bowel passing eggs into urine/stool
- eggs must reach fresh water to hatch; schistosomes cannot multiply in or pass between humans
  - more common in individuals from sub-Saharan Africa, South America, Asia, Caribbean, Eastern Mediterranean/North Africa

Clinical Features

- most asymptomatic; symptoms seen in travellers (nonimmune)
- swimmer’s itch: pruritic skin rash at site of penetration (cercarial dermatitis)
- acute schistosomiasis (Katayama fever): hypersensitivity to migrating parasites (4-8 wk after infection)
  - fever, hives, H/A, weight loss, cough, abdominal pain, chronic diarrhea, high-grade eosinophilia

Complications of Chronic Infection

- *S. mansoni*, *S. japonicum*
  - worms in mesenteric vein, eggs in portal tracts of liver and bowel
  - heavy infections: intestinal polyps, portal and pulmonary HTN, splenomegaly (2x to portal HTN), hepatomegaly
- *S. hematobium*
  - worms in vesical plexus, eggs in distal ureter and bladder induce granulomas and fibrosis
  - hematuria and obstructive uropathy; associated with squamous cell bladder cancer
- neurologic complications: spinal cord neuroschistosomiasis (transverse myelitis), cerebral or cerebellar neuroschistosomiasis (increased ICP, focal CNS signs, seizures)
- pulmonary complications: granulomatous pulmonary endarteritis, pulmonary HTN, cor pulmonale; especially in patients with hepatosplenic involvement

Figure 17. Life cycle of Schistosoma
Investigations
- serology (high sensitivity and specificity), CBC (eosinophilia, anemia, thrombocytopenia)
- *S. mansoni*, *S. japonicum*: eggs in stool, liver U/S shows fibrosis, rectal biopsy
- *S. hematobium*: bladder biopsy, eggs in urine and occasionally stool, kidney and bladder U/S

Treatment and Prevention
- praziquantel
- add glucocorticoid if acute schistosomiasis or neurologic complications develop
- proper disposal of human fecal waste, molluscicide (pesticide against molluscs), avoidance of infected water
- do not swim in Lake Malawi

**Ectoparasites**
- scabies, lice
  - see *Dermatology*, D27-28

**Travel Medicine**

**General Travel Precautions**
- vector-borne: long sleeves, long pants, hats, repellents (containing permethrin) applied to clothes, belongings, and bed nets, and skin repellents (such as DEET) applied to exposed skin
- food/water: avoid eating raw meats/seafood, uncooked vegetables, and milk/dairy products; drink only bottled beverages, chlorinated water, boiled water
- recreation: caution swimming in schistosomiasis-endemic regions (Lake Malawi), fresh water rafting/kayaking, beaches that may contain human/animal waste products, near storm drains, after heavy rainfalls
- prophylaxis: malaria (chloroquine, mefloquine, atovaquone + proguanil, doxycycline), traveller’s diarrhea (bismuth salicylate)
- standard vaccines up to date (hepatitis B, MMR, tetanus/diphtheria, varicella, pertussis, polio, influenza)
- travel vaccines: hepatitis A/B, Japanese encephalitis, typhoid fever, yellow fever, Japanese Encephalitis
- sexual transmitted and blood-borne infections: safe sex practices, avoidance of percutaneous injury through razors, tattoos, piercings

**Infectious Diseases to Consider**
- vector borne: malaria, dengue fever, Chikungunya fever, yellow fever, spotted fever rickettsioses, West Nile virus, trypanosomiasis, Japanese encephalitis, tick-borne encephalitis, leishmaniasis
- sexually transmitted: HIV, HBV, acute HSV, syphilis, usual STIs
- zoonotic: rabies, hantavirus, tularemia, Q fever, anthrax, brucellosis
- airborne: TB
- food/water: HAV, HEV, brucellosis, typhoid, paratyphoid, amoebiasis, dysentery, traveller’s diarrhea, cholera, *Campylobacter* spp.
- soil/water: schistosomiasis, strongyloidiasis, leptospirosis, cutaneous larva migrans, histoplasmosis, paracoccidioidomycosis

**Fever in the Returned Traveller**

**Etiology**
- commonly identified causes of fever in returning traveller
  - parasitic: malaria (20–30%)
  - viral: non-specific mononucleosis-like syndrome (4-25%), dengue (5%), viral hepatitis (3%)
  - bacterial: typhoid from *Salmonella* (2-7%), rickettsioses (3%)
  - diverse group of causative pathogens: traveller’s diarrhea (10-20%), RTI (10-15%), UTI/STI (2-3%)
  - febrile illness in travellers can be caused by routine infections that are common in non-travellers (e.g. URTI, UTI)
- less commonly, fever can be due to non-infectious causes (e.g. DVT, PE)

**History**
- pre-travel preparation
- travel itinerary: when, where, why, what, who, how?
  - dates of travel (determine incubation period)
  - season of travel: wet or dry
  - destination: country, region (urban or rural), environment (jungle, desert, etc.)
  - purpose of trip

For up to date information on geographic and seasonal patterns of disease and travel advisories, check the websites for the United States Centers for Disease Control and Prevention (wwwnc.cdc.gov/travel/) or Foreign Affairs Canada (travel.gc.ca)
• persons visiting friends and family more likely to be exposed to local population and pathogens
  ▪ style of travel: lodgings, camping, adventure travelling
  ▪ local population: sick contacts
  ▪ transportation: use of animals
• exposure history
  ▪ street foods, untreated water: increased risk of traveller’s diarrhea, enteric fever
  ▪ uncooked meat/unpasteurized dairy: increased risk of parasitic infection
  ▪ body fluids (sexual contacts, tattoos, piercings, IVDU, other injections)
  ▪ increased risk of HBV, HCV, HIV, GC, C. trachomatis, syphilis
  ▪ animal/insect bites: increased risk of malaria, dengue, rickettsioses, rabies
• fever pattern
  ▪ incubation period: use the earliest and latest possible dates of exposure to narrow the differential diagnosis and exclude serious infections
    ▪ <21 d: consider malaria, typhoid fever, dengue fever, chikungunya, rickettsioses; exclude HBV, TB
    ▪ >21 d: consider malaria, TB, typhoid fever; exclude dengue fever, chikungunya, traveller’s diarrhea, rickettsioses
• body systems affected: GI, respiratory, CNS, skin

Investigations
• all travellers with fever should undergo the following tests
  ▪ blood work: CBC and differential, liver enzymes, electrolytes, creatinine, thick and thin blood smears (for malaria), blood C&S
  ▪ urine: urinalysis, urine C&S if dysuria or other localizing signs
• special tests based on symptoms, exposure history, and geography
  ▪ stool: C&S, O&P
  ▪ CXR
  ▪ dengue serology for IgM

Table 28. Fever in the Returned Traveller

<table>
<thead>
<tr>
<th>Illness</th>
<th>Geography/Timing</th>
<th>Pathogen</th>
<th>Incubation Period</th>
<th>Clinical Manifestations</th>
<th>Diagnosis</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malaria</td>
<td>Africa India, C. and S. America, SE Asia</td>
<td><em>Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, P. knowlesi</em></td>
<td>7-30 d to mo or years</td>
<td>Fever and flu-like illness, (shaking chills, H/A, muscle aches, and fatigue) NV and diarrhea Anemia and jaundice Plasmodium falciparum: (severe) kidney failure, seizures, mental confusion, prostration, coma, death, respiratory failure</td>
<td>Blood smear (thick and thin) x3 Rapid Diagnostic Test (with smear or PCR confirmation) Antigen detection PCR (mostly a research tool)</td>
<td>Artesunate (for severe disease) + malarone, doxycycline, or clindamycin Quinine sulfate + doxycycline or clindamycin Chloroquine + primaquine</td>
</tr>
<tr>
<td>Dengue</td>
<td>South East Asia Caribbean</td>
<td>Dengue viruses, <em>Dengue viruses</em></td>
<td>3 d to 2 wk</td>
<td>Sudden onset of fever, H/A, retro-orbital pain, myalgias, and arthralgias Leukopenia Thrombocytopenia Hemorrhagic manifestations (rare in travellers)</td>
<td>Anti-dengue IgM positivity</td>
<td>Symptom relief: Acetaminophen (avoid using NSAIDs because of anticoagulant properties)</td>
</tr>
<tr>
<td>Typhoid (enteric fever)</td>
<td>Global but mostly Indian subcontinent</td>
<td><em>Salmonella typhi, Salmonella paratyphi</em></td>
<td>3 to 60 d</td>
<td>Sustained fever 39°-40°C (102°-104°F) Abdominal pain, H/A, loss of appetite, cough, constipation</td>
<td>Stool, urine, or blood sample positive for <em>S. typhi</em> or <em>S. paratyphi</em></td>
<td>Quinolone antibiotic (e.g. ciprofloxacin), ceftriaxone, or macrolide</td>
</tr>
<tr>
<td>Tick Typhus</td>
<td>Mediterranean South Africa, India</td>
<td>Rickettsia</td>
<td>1 to 2 wk</td>
<td>Fever, H/A, fatigue, muscle aches, occasionally rash Eschar at site of tick bite Elevated blood enzyme</td>
<td>Serology Presence of classic tick eschar</td>
<td>Doxycycline</td>
</tr>
<tr>
<td>TB</td>
<td>Global</td>
<td><em>M. tuberculosis</em></td>
<td>Variable</td>
<td>Fever, cough, hemoptysis CXR Sputum culture and acid-fast stain</td>
<td>Ethambutol, isoniazid, pyrazinamide, rifampin, +/- pyridoxine (vit. B6)</td>
<td></td>
</tr>
<tr>
<td>Mononucleosis</td>
<td>Caribbean, C. and S. America</td>
<td>EBV or CMV</td>
<td>30 to 50 d</td>
<td>Malaise, fatigue, pharyngitis, lymphadenopathy, splenomegaly</td>
<td>Atypical lymphocytes on blood smear and positive heterophilic antibody (monospot) test</td>
<td>Acetaminophen or NSAIDs, fluids</td>
</tr>
<tr>
<td>Zika Virus Disease</td>
<td>Africa, SE Asia, S. America; spreading</td>
<td>Zika virus</td>
<td>Unknown, likely 3 to 12 d</td>
<td>Headache, malaise, muscle/joint pain, mild fever, rash, conjunctivitis</td>
<td>RT-PCR Serology</td>
<td>Rest, fluids, analgesics/antipyretics (avoid NSAIDs until Dengue ruled out)</td>
</tr>
</tbody>
</table>
Fever of Unknown Origin

Table 29. Classification of Fever of Unknown Origin (FUO) – Temp >38.3°C/101°F on several occasions

<table>
<thead>
<tr>
<th>Classification of FUO</th>
<th>Nosocomial FUO</th>
<th>Neutropenic FUO</th>
<th>HIV-associated FUO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration &gt;3 wk</td>
<td>Hospitalized patient</td>
<td>Neutrophil count &lt;500/mL or is expected to fail to that level in 1-2</td>
<td>HIV infections Duration &gt;4 wk for hospitalized patients</td>
</tr>
<tr>
<td>Diagnosis uncertain after 3 outpatient visits or 3 d in hospital or 1 wk of intensive ambulatory investigation</td>
<td>Diagnosis uncertain after 3 d of investigation, including at least 2 d incubation of cultures</td>
<td>Diagnosis uncertain after 3 d of investigation, including at least 2 d incubation of cultures</td>
<td>Diagnosis uncertain after 3 d of investigation, including at least 2 d incubation of cultures</td>
</tr>
</tbody>
</table>

Etiology of Classic FUO
- Infectious causes (~30%)
  - TB: extra-pulmonary (most common), miliary, pulmonary (if pre-existing disease)
  - Abscess: subphrenic, liver, splenic, pancreatic, perinephric, diverticular, pelvis, psoas
  - Osteomyelitis
  - Bacterial endocarditis (culture negative)
  - Uncommon: viral (CMV, EBV), bacterial (brucellosis, bartonellosis), fungal (histoplasmosis, cryptococcosis), parasitic (toxoplasmosis, leishmaniasis, amoebiasis, malaria)
- Neoplastic causes (~20%)
  - Most commonly lymphomas (especially non-Hodgkin's) and leukemias, also multiple myeloma, myelodysplastic syndrome
  - Solid tumors: RCC (most common), also breast, liver (hepatoma), colon, pancreas, or liver metastases
- Collagen vascular diseases (~30%)
  - SLE, RA, rheumatic fever, vasculitis (temporal arteritis, PAN), JRA, Still's disease
- Miscellaneous (~20%)
  - Drugs: factitious fever
  - Sarcoidosis, granulomatous hepatitis, IBD
  - Hereditary periodic fever syndromes (such as familial Mediterranean fever)
  - Venous thromboembolic disease: PE, DVT
  - Endocrine: thyroiditis, thyroid storm, adrenal insufficiency, pheochromocytoma
- Unknown in 30-50% despite detailed workup

Approach to Classic FUO
- Careful history: travel, environmental/occupational exposures, infectious contacts, medication history, immunizations, TB history, sexual history, past medical history, comprehensive review of systems (including symptoms that resolved before interview)
- Thorough physical exam: fever pattern, rashes (skin, mucous membranes), murmurs, arthritis, lymphadenopathy, organomegaly
- Initial investigations as appropriate
  - Blood work: CBC and differential, electrolytes, BUN, Cr, calcium profile, LFTs, ESR, CRP, muscle enzymes, RF, ANA, serum protein electrophoresis (SPEP), blood smear
  - Cultures: blood (x2 sets), urine, sputum, stool C&S, O&P, other fluids as appropriate
  - Serology: HIV, monospot, CMV, IgM
  - Imaging: CXR, abdominal imaging
- If there are diagnostic clues from any of the above steps, proceed with directed exam, biopsies or invasive testing as required, followed by directed treatment once a diagnosis is established
- If no diagnosis with the above, consider empiric therapy vs. watchful waiting
  - Without intervention: patients that remain undiagnosed despite extensive workup have good prognosis
  - Immunocompromised hosts have increased susceptibility to infections from pathogens that are typically low virulence, commensal, or latent
  - Type of immunodeficiency predicts probable spectrum of agents

Infectious Diseases Toronto Notes 2017
Factors that Compromise the Immune System

- general: age (very young or elderly), malnutrition
- immune disease: HIV/AIDS, malignancies, asplenia (functional or anatomic), hypogammaglobulinemia, neutropenia
- DM
- iatrogenic: corticosteroids, chemotherapy, radiation treatment, anti-TNF therapy, other immunosuppressive drugs (e.g. in transplant patients)

Table 30. Types of Immunodeficiency

<table>
<thead>
<tr>
<th>Type</th>
<th>Conditions</th>
<th>Vulnerable To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell-Mediated Immunity</td>
<td>HIV, Hodgkin's, hairy cell leukemia, cytotoxic drugs, SCID, DiGeorge syndrome</td>
<td>Latent viruses, Fungi, Parasites</td>
</tr>
<tr>
<td>Humoral Immunity</td>
<td>CLL, lymphosarcoma, multiple myeloma, nephrotic syndrome, protein-losing enteropathy, burns, sickle cell anemia, asplenia, splenectomy, selective lg deficiencies, Wiskott-Aldrich syndrome</td>
<td>Encapsulated organisms (S. pneumoniae, H. influenzae, N. meningitidis, Salmonella typhi, BBS)</td>
</tr>
<tr>
<td>Neutrophil Function</td>
<td>Myelodysplasia, paroxysmal nocturnal hemoglobinuria, radiation, cytotoxic drug therapy, C3 or C5 deficiencies, chronic granulomatous disease</td>
<td>Catalase-producing organisms (Staphylococcus, Serratia, Nocardia, Aspergillus)</td>
</tr>
</tbody>
</table>

Febrile Neutropenia

Definition
- fever (≥38.3°C/101°F or ≥38.0°C/100.4°F for ≥1 h) and one of
  - ANC <0.5 OR
  - ANC <1.0 but trending down to 0.5

Pathophysiology
- decreased neutrophil production
  - marrow: infection, aplastic/myelophthisic anemia, leukemia, lymphoma, myelodysplastic syndromes
  - iatrogenic: cancer chemotherapy, radiation, drugs
  - deficiencies: vitamin B₁₂, folate
  - increased peripheral neutrophil destruction
  - autoimmune: Felty's syndrome, SLE, antineutrophil antibodies
  - splenic sequestration

Epidemiology/Etiology
- most common life-threatening complication of cancer therapy
- 8 cases per 1,000 cancer patients per yr in the U.S.
- causative organism identified only 1/3 of the time
- GN (especially Pseudomonas) historically most common
- GP more common now
- fungal superinfection if neutropenia prolonged or if concurrent antibiotic use (especially Candida, Aspergillus)

Investigations
- examine for potential sites of infection: mucositis and line infections are most common
- do NOT perform DRE; examine perianal region
- blood C&S (x2 sets), urine C&S, culture all indwelling catheter ports, ± sputum C&S and NP swab for respiratory viruses
- CBC and differential, Cr, BUN, electrolytes, AST/ALT, total bilirubin

Treatment
- most hospitals have their own specific protocol; one example is presented below
Infections in Solid Organ Transplant Recipients

- infection is a leading cause of early morbidity/mortality in transplant recipients
- infection depends on degree of immunosuppression
- common infections <1 mo post-transplant
  - bacterial infection of wound/lines/lungs, herpetic stomatitis
- common infections >1 mo post-transplant
  - viral (especially CMV, EBV, VZV)
  - fungal (especially Aspergillus, Cryptococcus, P. jiroveci)
  - protozoan (especially Toxoplasma)
  - unusual bacterial/mycobacterial infections (especially TB, Nocardia, Listeria)

Prophylactic Vaccinations Given Before Transplant

- to all transplant patients: DTAp, pneumococcal, influenza, hepatitis A and B vaccines
- if low titre or poor documentation: MMR, polio, varicella vaccination (with booster 4-8 wk later)

Immune Reconstitution Syndrome

Definition

- a harmful inflammatory response directed against a previously acquired infection following a recovery of the immune system

Etiology

- paradoxical worsening of a successfully or partially treated opportunistic infection
- new onset response to a previously unidentified opportunistic infection
- the majority of cases are in HIV/AIDS or immunosuppressed patients starting anti-retroviral therapy or discontinuing immunosuppressive therapy; sudden recovery from an immunosuppressive state towards a pro-inflammatory state directed towards subclinical infection results in fever and inflammation
- can occur in response to multiple infections
  - Mycobacteria (tuberculosis, avium complex)
  - Cryptococcus
  - Pneumocystis
  - Toxoplasma
  - HBV and HCV
  - Herpes viruses (VZV reactivation, HSV, CMV)
  - JC virus (progressive multifocal leukoencephalopathy)
  - Molluscum contagiosum
- clinical features are dependent on the type and location of the pre-existing infection
- thought to be worse with quick increase in CD4 count and with lower pre-treatment CD4 count
- non-HIV conditions with documented IRS: solid organ transplant recipients, post-partum women, neutropenic patients, anti-TNF therapy
**Epidemiology**
- in HIV patients starting ART, IRS reported to affect ~10%

**Investigations**
- IRS is a diagnosis of exclusion
- rule out drug reaction, patient non-adherence, drug resistance

**Treatment**
- continue HAART therapy in HIV patients with mild-moderate symptoms, but consider discontinuation if symptoms are life-threatening or potentially irreversible
- treat underlying infection; initiate treatment for some infections prior to HAART initiation
- consider starting corticosteroids/NSAIDs to decrease inflammatory response

---

**A Simplified Look at Antibiotics**

- general overview, see Table 31 for more details

1. Penicillins

2. Cephalosporins (PO/IV)
   - 1st generation: cephalexin/cefazolin (mostly GP, some GN)
   - 2nd generation: cefuroxime/cefprozil (some GP and some GN, *anaerobes*)
   - 3rd generation: cefuroxime/cefotaxime, ceftriaxone (good Streptococcal coverage, mostly GN), and cefotaxime (no GP, mostly GN, *Pseudomonas*)
   - 4th generation: --/cefepime (most GP, most GN, *Pseudomonas*)

3. Aminoglycosides (GN aerobic bacilli)
   - gentamicin
   - tobramycin
   - amikacin

   - erythromycin
   - clarithromycin
   - azithromycin

5. Fluoroquinolones (GN – although resistance becoming a huge problem)
   - ciprofloxacin (+ *Pseudomonas*)
   - norfloxacin (for UTI only)
   - respiratory fluoroquinolones (some GP, GN, "atypicals", *Legionella, Mycoplasma, Chlamydia*, *Mycobacteria*)
     - levofloxacin, ofloxacin
     - moxifloxacin (+ *anaerobes*)

6. Carbapenems (broad coverage: GP, GN, and anaerobes)
   - imipenem (+ *Pseudomonas*)
   - meropenem (+ *Pseudomonas*)
   - ertapenem

---

**Figure 19. Penicillins**

- Penicillin G (IV)/Penicillin V (PO)
  - (most Streptococcus, *N. meningitidis*, many oral anaerobes except *B. fragilis*)
- Amoxicillin (IV)/Amoxicillin (PO)
  - *Enterococcus faecalis*
- Cloxacillin
  - *MSSA but + Streptococci*
- Amoxicillin-clavulanate
  - + β-lactamase producing organisms including anaerobes
- Piperacillin
  - *Pseudomonas*
- Piperacillin/tazobactam
  - + β-lactamase producing organisms including anaerobes
7. Others
- doxycycline/tetracycline (GP, syphilis, Chlamydiophila, Rickettsia, Mycoplasma)
- tigecycline (for resistant GP infections, GN, anaerobes, Chlamydiophila, Rickettsia, Mycoplasma)
- vancomycin (all GP and C. difficile – the oral form)
- linezolid (for resistant GP infections)
- daptomycin (for resistant GP infections)
- clindamycin (most GP, GN anaerobes)
- TMP/SMX (most S. aureus including: MRSA, GN aerobes, Pneumocystis)
- nitrofurantoin (GN bacilli, S. saprophyticus, Enterococcus)
- metronidazole (anaerobes including: C. difficile; Trichomonas, Entamoeba)
- treatment for C. difficile: metronidazole OR oral vancomycin; consider both in serious infection

Antimicrobials

Antibiotics

- empiric antibiotic therapy
  - choose antibiotic(s) to cover for most likely and lethal organisms for the type of infection prior to obtaining laboratory results (usually reserved for serious infections)
  - adjust antibiotic(s) based on C&S
    - if causative organism identified, use antibiotic to which organism is sensitive
    - if causative organism not identified, re-evaluate need for ongoing antimicrobial therapy (and continue with empiric antibiotic(s) if indicated)

Reasons for Combination Therapy
- Polymicrobial infection
- Empiric therapy pending culture results
- Synergy for difficult to treat pathogens (e.g. Enterococcus spp. causing endocarditis)
- To prevent emergence of resistance

Bactericidal Antibiotics  Bacteriostatic Antibiotics
"Very Finely Proficient At Cell Murder"  "ECSTaTC"
Vancomycin  Erythromycin (and other macrolides)
Fluoroquinolones  Clindamycin
Penicillin  Sulfamethoxazole
Aminoglycosides  Trimethoprim
Cephalosporins  Tetracyclines
Carbapenems  Chloramphenicol
Metronidazole  Daptomycin

©Stuart Jantzen 2012

Figure 20. Mechanism of action of antibiotics
### Table 31. Antibiotics

<table>
<thead>
<tr>
<th>Class and Drugs</th>
<th>Coverage</th>
<th>Mechanism of Action</th>
<th>Adverse Effects</th>
<th>Indications</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CELL WALL INHIBITORS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Penicillins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzyl penicillin - penicillin G IV/IM - penicillin V PO</td>
<td>GP except: Staphylococcus, Enterococcus, N. meningitidis, Oral anaerobes Syphilis</td>
<td>Bactericidal: β-lactam inhibits cell wall synthesis by binding penicillin binding protein (PBP) preventing cross-linking of peptidoglycan</td>
<td>Immediate allergy (IgE): anaphylaxis, urticaria</td>
<td>Listeria, H. influenzae, E. coli, K. pneumoniae</td>
<td>Mild to moderately severe infections caused by susceptible organisms including actinomycosis, streptococcal pharyngitis, streptococcal skin and soft tissue infections, pneumococcal pneumonia, syphilis</td>
</tr>
<tr>
<td>Aminopenicillin - ampicillin IV - amoxicillin PO (Amoxil®)</td>
<td>Same as penicillin AND Enterococcus Listeria selectively H. influenzae, E. coli, K. pneumoniae</td>
<td>See above</td>
<td>See above</td>
<td>Bacterial meningitis and endocarditis (IV ampicillin), acute otitis media (AOM), streptococcal pharyngitis, sinusitis, acute exacerbations of COPD, part of multidrug therapy for H. pylori treatment, Lyme disease, pneumococcal pneumonia; UTI (amoxicillin and ampicillin) for most enterococci and susceptible gram-negative pathogens</td>
<td>Hypersensitivity to penicillin or β-lactam antibiotics</td>
</tr>
<tr>
<td><strong>Aminopenicillin - ampicillin IV - amoxicillin PO (Amoxicillin®)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Same as penicillin AND Staphylococcus H. influenzae Enterococcus Anaerobes (oral and gut)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>β-lactamases produced by certain bacteria inactivate β-lactams Lactamase inhibitors prevent this process, preserving antibacterial effect of β-lactams</td>
<td>See above</td>
<td>Various β-lactamase producing bacteria including RTI, sinusitis, AOM, skin and soft tissue infections, UTI, and severe intra-abdominal and pelvic infections</td>
<td>Hypersensitivity to penicillin or cephalosporin History of Clavulin®- associated jaundice or hepatic dysfunction</td>
</tr>
<tr>
<td>β-lactam/β-lactamase inhibitor combinations - amoxicillin-clavulanate (Clavulin®, Augmentin®) - piperacillin/tazobactam (Zosyn®)</td>
<td>Methicillin-sensitive Staphylococcus aureus; streptococci</td>
<td>See above</td>
<td>See above</td>
<td>Bacterial infections caused by staphylococci and streptococci including skin and soft-tissue infections</td>
<td>Hypersensitivity to cloxacillin or any penicillin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cephalosporins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV 1° cephalaxin (Keflex®) - cefazolin (Ancef®)</td>
<td>GP Good with the exception of Enterococcus and MRSA</td>
<td>Bactericidal: β-lactam inhibits PBP, prevents cross-linking of peptidoglycan, less susceptible to penicillinasises</td>
<td>10% penicillin allergy cross-reactivity</td>
<td>Nephrotoxicity</td>
<td>Skin and soft tissue infections, prevention of surgical site infections (cefazolin); infections caused by susceptible organisms (especially Staph and Strep infections)</td>
</tr>
<tr>
<td>2° cefuroxime (Zinacef®) - cefotaxir (Fortaz®)</td>
<td>More coverage than 1° (not includes anaerobes)</td>
<td>See above</td>
<td>See above</td>
<td>Upper and lower respiratory tract infections; pneumococcal pneumonia; soft tissue infections</td>
<td></td>
</tr>
<tr>
<td>3° ceftriaxone (Rocephin®) - cefotaxime (Claforan®) - cefazidine (Fortaz®)</td>
<td>S. aureus + streptococcal coverage (cefotaxime and ceftriaxone) especially S. pneumoniae</td>
<td>See above</td>
<td>See above</td>
<td>-- 1% penicillin allergy cross-reactivity</td>
<td>Community-acquired pneumonia (cefotaxime, ceftriaxone); community-acquired bacterial meningitis (ceftriaxone, cefotaxime); abdominal and pelvic infections (cefotaxime or ceftriaxone in combination with metronidazole); once-daily administration makes ceftriaxone convenient for outpatient IV therapy</td>
</tr>
<tr>
<td>4° ceftazidime (Maxipine®)</td>
<td>Broad spectrum Broad coverage including Pseudomonas</td>
<td>See above</td>
<td>See above</td>
<td>Empirical therapy for febrile neutropenia</td>
<td></td>
</tr>
</tbody>
</table>
## Table 31. Antibiotics (continued)

<table>
<thead>
<tr>
<th>Class and Drugs</th>
<th>Coverage</th>
<th>Mechanism of Action</th>
<th>Adverse Effects</th>
<th>Indications</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>CELL WALL INHIBITORS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Carbapenems</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>imipenem (Primaxin®)</td>
<td>GP except MRSA GN including <em>Pseudomonas</em> + <em>Enterobacter</em>, ESBLs, anaerobes</td>
<td>β-lactam inhibits PBP and prevents cross-linking of peptidoglycan</td>
<td>Penicillin allergy cross-reactivity</td>
<td>Treatment of infections caused by GNB producing extended-spectrum β-lactamases, serious infections caused by susceptible organisms</td>
<td>Hypersensitivity to imipenem</td>
</tr>
<tr>
<td>meropenem (Merrem®)</td>
<td>See above; does not cover <em>Enterococcus</em></td>
<td>See above</td>
<td>See above</td>
<td>See above</td>
<td>Hypersensitivity to β-lactams</td>
</tr>
<tr>
<td>ertapenem (Invanz®)</td>
<td>GP except <em>Enterococcus</em>, MRSA GN including <em>Enterobacter</em> (but not <em>Pseudomonas</em>), anaerobes</td>
<td>See above</td>
<td>See above</td>
<td>See above; once-daily administration makes it convenient for outpatient IV therapy</td>
<td>Hypersensitivity to β-lactams</td>
</tr>
<tr>
<td><strong>Glycopeptides</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vancomycin (Vancocin®)</td>
<td>GP including MRSA, not VRE <em>C. difficile</em> if PO</td>
<td>Glycopeptide sterically inhibits cell wall synthesis</td>
<td>Red Man Syndrome Nephrotoxicity Ototoxicity Thrombocytopenia</td>
<td>Severe or life-threatening GP infections, patients with β-lactam allergy May only be taken orally for severe <em>C. difficile</em> infection</td>
<td>Hypersensitivity to vancomycin</td>
</tr>
<tr>
<td><strong>PROTEIN SYNTHESIS INHIBITORS (50S RIBOSOME)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Macrolides</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>erythromycin (Erybid®, Eryc®) <em>This agent is rarely used due to GI upset</em></td>
<td>GP except <em>Enterococcus</em> GN: <em>Legionella</em>, <em>B. pertussis</em> &quot;Atypicals&quot;: <em>Chlamydia</em>, <em>Mycoplasma</em></td>
<td>Binds to 50S ribosomal subunit inhibiting protein synthesis</td>
<td>GI upset Acute cholestatic hepatitis Prolonged QT</td>
<td>Susceptible RTI, pertussis, diphtheria, Legionnaires’ disease, skin and soft tissue infections</td>
<td>Hypersensitivity to erythromycin Concurrent therapy with astemizole, terfenadine</td>
</tr>
<tr>
<td>clarithromycin (Biaxin®)</td>
<td>See above, some mycobacteria</td>
<td>See above</td>
<td>See above</td>
<td>Susceptible RTI, skin infections, non-tuberculous mycobacterial infections, part of multidrug therapy for <em>H. pylori</em> treatment</td>
<td>Hypersensitivity to macrolides</td>
</tr>
<tr>
<td>azithromycin (Zithromax®)</td>
<td>See above, some mycobacteria</td>
<td>See above</td>
<td>See above</td>
<td>Susceptible RTI, acute exacerbations of COPD, community-acquired pneumonia, skin infections, Campylobacter infections if treatment indicated, chlamydia</td>
<td>Hypersensitivity to macrolides</td>
</tr>
<tr>
<td><strong>Lincosamides</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>clindamycin (Dalacin®)</td>
<td>GP except <em>Enterococcus</em>, most community-acquired MRSA Anaerobes</td>
<td>Inhibits peptide bond formation at 50S ribosome</td>
<td>Pseudomembranous colitis GI upset</td>
<td>Treatment of suspected or proven infections caused by GP, anaerobes including skin and skin structure infections, oropharyngeal infections, in combination with GN coverage for intra-abdominal and pelvic infections</td>
<td>Hypersensitivity to clindamycin Infants &lt;30 d</td>
</tr>
<tr>
<td>chloramphenicol</td>
<td>GP GN Anaerobes</td>
<td>Inhibits peptidyl transferase action of tRNA at 50S ribosome</td>
<td>Aplastic anemia Grey Baby Syndrome</td>
<td>Serious infections by susceptible organisms when suitable alternatives are not available including meningococcal disease in patients with anaphylaxis to β-lactams</td>
<td>Hypersensitivity to chloramphenicol</td>
</tr>
<tr>
<td>linezolid (Zyvoxam®)</td>
<td>GP including VRE + MRSA</td>
<td>Binds 50S ribosome and prevents functional 70S initiation complex</td>
<td>HTN (acts as MAOI) Risks with prolonged use: myelosuppression optic neuropathy, peripheral neuropathy</td>
<td>Vancomycin-resistant <em>Enterococcus faecium</em> infections including intra-abdominal, skin and skin structure, and urinary tract infections, MRSA infections as outpatient therapy</td>
<td>Hypersensitivity to linezolid</td>
</tr>
</tbody>
</table>
### Table 31. Antibiotics (continued)

<table>
<thead>
<tr>
<th>Class and Drugs</th>
<th>Coverage</th>
<th>Mechanism of Action</th>
<th>Adverse Effects</th>
<th>Indications</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PROTEIN SYNTHESIS INHIBITORS (30S RIBOSOME)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Aminoglycosides</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>gentamicin, tobramycin, amikacin (Amikin®)</td>
<td>GN (includes Pseudomonas)</td>
<td>Binds 30S subunit of ribosome inhibiting protein synthesis</td>
<td>Nephrotoxicity (reversible), Vestibular and ototoxicity (irreversible)</td>
<td>GN infections when alternatives do not exist, UTIs, used in low doses for synergy with β-lactams or with vancomycin for the treatment of serious enterococcal infections</td>
<td>Pre-existing hearing loss and renal dysfunction</td>
</tr>
<tr>
<td><strong>Tetracyclines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tetracycline (Apo-Tetra®, Nu-TetraT®), minocycline (Minocin®), doxycycline (Doxycin®), tigecycline (Tygacil®)</td>
<td>GP, Anaerobes, Atypicals: Chlamydia, Mycoplasma, Rickettsia, Barrella burgdorferi, Treponema</td>
<td>Binds 30S subunit of ribosome inhibiting protein synthesis</td>
<td>GI upset, Hepatotoxicity, Fanconi’s syndrome, Photosensitivity, Teratogenic, Yellow teeth and stunted bone growth in children</td>
<td>Rickettsial infections, Chlamydia, acne, PID (step-down), malaria prophylaxis (doxycycline)</td>
<td>Severe renal or hepatic dysfunction, Pregnancy or lactation, Children under 8 yr</td>
</tr>
<tr>
<td><strong>TOPOISOMERASE INHIBITORS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Fluoroquinolones (FQs)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ciprofloxacin (Cipro®), norfloxacin (Apo-Norflox®), ofloxacin (Floxin®), Respiratory FQs: levofloxacin (Levaquin®), moxifloxacin (Avelox®)</td>
<td>Poor GP activity, GN (includes Pseudomonas), Atypicals, Levofoxacin and Moxifloxacina, cover S. pneumoniae, Moxifloxacin also covers many anaerobes</td>
<td>Inhibits DNA gyrase</td>
<td>H/A, dizziness, Allergy, Seizures, Prolonged QT, Dysglycemia, (levofloxacin, moxifloxacin), Tendonitis, Tendon rupture</td>
<td>Upper and lower RTI (not ciprofloxacin unless susceptible organism isolated), UTI, prostatitis (not moxifloxacin), bone and joint infections for susceptible organisms, skin and soft tissue infections (levofloxacin, moxifloxacin), infectious diarrhea, meningococcal prophylaxis, intra-abdominal infections (moxifloxacin, ciprofloxacin in combination with metronidazole or clindamycin), febrile neutropenia prophylaxis (ciprofloxacin, levofloxacin) or ciprofloxacin in combination with amoxicillin-clavulanate low management of “low-risk” febrile neutropenia</td>
<td></td>
</tr>
<tr>
<td><strong>OTHER</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rifampin</td>
<td>GP cocci, N. meningitidis, H. influenzae, Mycobacteria</td>
<td>Inhibits RNA polymerase</td>
<td>Hepatic dysfunction, P450 enzyme induction, Orange tears/saliva/urine</td>
<td>Part of multidrug treatment for active TB, alone for treatment of latent TB, part of multidrug treatment of other mycobacterial infections, endocarditis involving prosthetic valve or other prosthetic device infections in combination with other antibiotic agents, prophylaxis for those exposed to people with N. meningitidis or HIB meningitis</td>
<td>Jaundice, Not to be used as monotherapy (except for prophylaxis)</td>
</tr>
<tr>
<td>Metronidazole (Flagyl®)</td>
<td>Anaerobes, Protozoa</td>
<td>Forms toxic metabolites in bacterial cell which damage microbial DNA</td>
<td>Disulfiram-type reaction with EtOH, Seizures, Periphera neuropathy</td>
<td>Protozoal infections (trichomoniasis, amoebiasis, giardiasis), bacterial vaginosis, anaerobic bacterial infections</td>
<td></td>
</tr>
<tr>
<td>Daptomycin</td>
<td>GP, including MRSA and VRE</td>
<td>Hypothesized to bind to cell wall and form channels leading to intracellular K⁺ depletion</td>
<td>Skeletal muscle injury at high doses (elevated CPK), Peripheral neuropathy</td>
<td>Bacteremia, endocarditis, skin and soft tissue, and other infections due to resistant GP infections including MRSA and VRE</td>
<td>Known hypersensitivity</td>
</tr>
</tbody>
</table>
Table 31. Antibiotics (continued)

<table>
<thead>
<tr>
<th>Class and Drugs</th>
<th>Coverage</th>
<th>Mechanism of Action</th>
<th>Adverse Effects</th>
<th>Indications</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANTI-METABOLITE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trimethoprim-Sulfamethoxazole (TMP/SMX) (Septra®, Bactrim®)</td>
<td>GP especially S. aureus (including most MRSA) GN: enteric Nocardia Other: Pneumocystis, Toxoplasmosis</td>
<td>Inhibits folic acid pathway (TMP inhibits DHFR and SMX competes with PABA)</td>
<td>Hepatitis Stevens-Johnson syndrome Bone marrow suppression Hyperkalemia Drug toxicity (increases free levels of many drugs, including glyburide, warfarin)</td>
<td>Susceptible UTI, RTI, GI infections, skin and soft tissue infections caused by staphylococcal species, treatment and prophylaxis of P. jiroveci pneumonia</td>
<td>Hypersensitivity to TMP-SMX, sulfa drugs</td>
</tr>
<tr>
<td>Nitrofurantoin (MacroBD®, (Macrodantin®)</td>
<td>Enterococcus, S. saprophyticus GN (coliforms)</td>
<td>Reactive metabolites inhibit ribosomal protein synthesis</td>
<td>Cholestasis, hepatitis Hemolysis if G6PD deficiency Interstitial lung disease with chronic use</td>
<td>Lower UTI; not pyelonephritis or bacteremia</td>
<td>hypersensitivity to nitrofurantoin Anuria, oliguria, or significant renal impairment Pregnant patients during labour and delivery or when labour imminent Infants &lt; 1 mo of age</td>
</tr>
<tr>
<td><strong>ANTI-MYCOBACTERIALS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>isoniazid (INH)</td>
<td>Mycobacteria</td>
<td>Inhibits mycolic acid synthesis</td>
<td>Hepatotoxicity Hepatitis Drug-induced SLE Peripheral neuropathy</td>
<td>Part of multidrug treatment for active TB, alone for treatment of latent TB</td>
<td>Drug-induced hepatitis or acute liver disease</td>
</tr>
</tbody>
</table>
rifampin (rif) | Mycobacteria | Inhibits RNA polymerase | Hepatotoxicity P450 enzyme inducer Orange tears, saliva, urine | Part of multidrug treatment for active TB, alone for treatment of latent TB, part of multidrug treatment of other mycobacterial infections | Jaundice Not to be used monotherapy (except for prophylaxis) |
|ethambutol | Mycobacteria | Inhibits mycolic acid synthesis | Loss of central and colour vision | Part of multidrug treatment for active TB and other mycobacterial infections | Renal failure |
|pyrazinamide (PZA) | Mycobacteria | Unknown | Hepatotoxicity Gout Gastric irritation | Part of multidrug treatment for active TB | Severe hepatic damage or acute liver disease Patients with acute gout |
| **SULFONES** | | | | | |
dapsone sulfoxone | M. leprae, P. jiroveci, Toxoplasma | Inhibit folic acid synthesis by competition with PABA | Rash Drug fever Agranulocytosis | Part of multidrug treatment for M. leprae, part of treatment for P. jiroveci pneumonia (with TMP), P. jiroveci pneumonia prophylaxis, toxoplasmosis prophylaxis with pyrimethamine | |

Table 32. Antibiotics for Selected Bacteria

<table>
<thead>
<tr>
<th>Pseudomonas</th>
<th>S. aureus</th>
<th>Enterococcus</th>
<th>H. influenzae</th>
<th>Anaerobes</th>
</tr>
</thead>
<tbody>
<tr>
<td>ciprofloxacin</td>
<td></td>
<td>cloxacillin (MSSA)</td>
<td>amoxicillin</td>
<td>metronidazole</td>
</tr>
<tr>
<td>gentamicin, tobramycin</td>
<td></td>
<td>ampicillin</td>
<td>amoxicillin-clavulanate</td>
<td>clindamycin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1º cephalosporin (MSSA)</td>
<td>2º/3º cephalosporin</td>
<td></td>
</tr>
<tr>
<td>piperacillin/tazobactam</td>
<td>clindamycin</td>
<td>vancomycin</td>
<td>macrolides (clarithromycin, azithromycin)</td>
<td>amoxicillin-clavulanate</td>
</tr>
<tr>
<td>ceftazidime</td>
<td>Cotrimoxazole (including MRSA)</td>
<td>nitrofurantoin (lower UTI)</td>
<td>levofloxacin</td>
<td>cefoxitin</td>
</tr>
<tr>
<td>cefepime</td>
<td>vancomycin (including MRSA)</td>
<td>linezolid for VRE</td>
<td>moxifloxacin</td>
<td>piperacillin/tazobactam</td>
</tr>
<tr>
<td>meropenem</td>
<td>linezolid (including MRSA)</td>
<td>daptomycin for VRE</td>
<td>moxifloxacin</td>
<td></td>
</tr>
<tr>
<td>imipenem</td>
<td>daptomycin (including MRSA)</td>
<td>tigecycline for VRE</td>
<td>erapenem, imipenem, meropenem</td>
<td></td>
</tr>
</tbody>
</table>
## Antivirals

### Table 33. Antivirals

<table>
<thead>
<tr>
<th>Class and Drugs</th>
<th>Coverage</th>
<th>Mechanism of Action</th>
<th>Adverse Effects</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANTI-HERPESVIRUS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>acyclovir</td>
<td>HSV-1,2</td>
<td>Guanosine analog inhibits viral DNA polymerase</td>
<td>PO well-tolerated</td>
<td>Hypersensitivity to acyclovir or valacyclovir</td>
</tr>
<tr>
<td>valacyclovir (Valtrex®) (prodrug of acyclovir)</td>
<td>VZV</td>
<td>See above</td>
<td>IV: nephrotoxicity, CNS</td>
<td></td>
</tr>
<tr>
<td>famciclovir (Famvir®)</td>
<td>HSV-1,2, VZV, HHV-6, EBV</td>
<td>See above</td>
<td>H/A, nausea</td>
<td>Hypersensitivity to famciclovir or penciclovir</td>
</tr>
<tr>
<td>ganciclovir (Cytovene®)</td>
<td>CMV</td>
<td>See above</td>
<td>Heme: neutropenia, thrombocytopenia, anemia</td>
<td>Hypersensitivity to ganciclovir or valganciclovir</td>
</tr>
<tr>
<td>valganciclovir (prodrug of ganciclovir)</td>
<td>HSV-1,2, VZV</td>
<td>Pyrophosphate analog inhibits viral DNA polymerase</td>
<td>Nephrotoxicity, Anemia, Electrolyte disturbance</td>
<td></td>
</tr>
<tr>
<td>foscarnet</td>
<td>CMV</td>
<td>Acyclovir-resistant HSV, VZV</td>
<td>See above</td>
<td>Hypersensitivity to foscarnet</td>
</tr>
<tr>
<td><strong>OTHER ANTIVIRALS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(pegylated) interferon-α-2a or-2b</td>
<td>Chronic hepatitis B or C HPV</td>
<td>Inhibits viral protein synthesis</td>
<td>“Flu-like” syndrome Depression Bone marrow suppression</td>
<td>Hypersensitivity to any interferon Cannot use in combination with ribavirin if renal impairment</td>
</tr>
<tr>
<td>ribavirin (Virazole®)</td>
<td>Chronic hepatitis C RSV Lassa fever</td>
<td>Guanosine analog with multiple postulated mechanisms of action</td>
<td>Hemolytic anemia Rash, conjunctivitis Highly teratogenic</td>
<td>Pregnancy, women who may become pregnant or their partners Renal impairment</td>
</tr>
<tr>
<td>Cidofovir</td>
<td>Adenovirus CMV retinitis Acyclovir and foscarnet resistant HSV</td>
<td>Deoxycytidine analogue inhibits DNA synthesis</td>
<td>Nephrotoxicity (proximal tubule dysfunction)</td>
<td>Renal failure; probenecid can reduce renal toxicity</td>
</tr>
<tr>
<td>lamivudine (Epivir®)</td>
<td>Chronic hepatitis B HIV</td>
<td>See HIV and AIDS, ID27</td>
<td>See HIV and AIDS, ID27</td>
<td>See HIV and AIDS, ID27</td>
</tr>
<tr>
<td>Tenofovir</td>
<td>Chronic hepatitis B HIV</td>
<td>See HIV and AIDS, ID27</td>
<td>See HIV and AIDS, ID27</td>
<td>See HIV and AIDS, ID27</td>
</tr>
<tr>
<td>Neuraminidase inhibitors: zanamivir (Relenza®) oseltamivir (Tamiflu®)</td>
<td>Influenza A and B: treatment and prophylaxis</td>
<td>Inhibits neuraminidase, an enzyme required for release of virus from infected cells and prevention of viral aggregation</td>
<td>GI: N/V, diarrhea Bronchospasm in zanamivir</td>
<td>Hypersensitivity to the neuraminidase inhibitors</td>
</tr>
</tbody>
</table>

## Antifungals

### Table 34. Antifungals

<table>
<thead>
<tr>
<th>Class and Drugs</th>
<th>Coverage</th>
<th>Mechanism of Action</th>
<th>Adverse Effects</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>POLYENES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>amphotericin B</td>
<td>Endemic mycoses: Histoplasmosis Blastomycosis Coccidioidomycosis Pulmonary Aspergillosis CNS: Cryptococcus</td>
<td>A polyene antimicrobial: inserts into fungal cytoplasmic membrane causing altered membrane permeability and cell death</td>
<td>Nephrotoxicity Hypo/hyperkalemia Infusion reactions: chills, fevers, H/A Peripheral phlebitis</td>
<td>Renal impairment</td>
</tr>
<tr>
<td>nystatin (oral, topical)</td>
<td>Candidiasis: mucocutaneous, GI, oral (thrush), vaginal</td>
<td>See above Not absorbed from the GI tract</td>
<td>GI: N/V, diarrhea Highly toxic if given IV</td>
<td></td>
</tr>
<tr>
<td><strong>IMIDAZOLES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>clotrimazole (Canesten®)</td>
<td>Oral and vulvovaginal candidiasis Dermatomycoses</td>
<td>All azoles: inhibit ergosterol synthesis and thereby alter fungal cell membrane permeability</td>
<td>Pruritis, skin irritation</td>
<td></td>
</tr>
<tr>
<td>miconazole (Monistat®, Micazole®)</td>
<td>Vulvovaginal candidiasis Dermatomycoses</td>
<td></td>
<td>Vaginal burning N/V</td>
<td></td>
</tr>
<tr>
<td>ketoconazole (Nizoral®)</td>
<td>Dermatomycoses Seborrheic dermatitis</td>
<td></td>
<td>Pruritis, skin irritation GI nonspecific Results in decreased androgen and testosterone synthesis</td>
<td>Cross-sensitivity with other azoles possible Hepatic dysfunction Pregnant women or those that may become pregnant</td>
</tr>
</tbody>
</table>
## Table 34. Antifungals (continued)

<table>
<thead>
<tr>
<th>Class and Drugs</th>
<th>Coverage</th>
<th>Mechanism of Action</th>
<th>Adverse Effects</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TRIAZoles</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fluconazole (Diflucan®)</td>
<td>Candida infections (mucosal and invasive) Cryptococcal meningitis (step-down therapy)</td>
<td>All azoles: inhibit ergosterol synthesis and thereby alter fungal cell membrane permeability</td>
<td>Elevated liver enzymes GI nonspecific</td>
<td>Cross-sensitivity with other azoles unknown</td>
</tr>
<tr>
<td>itraconazole (Sporanox®)</td>
<td>Sporotrichosis Onychomycoses Endemic mycoses: Histoplasmosis Blastomycosis Coccidioidomycosis</td>
<td></td>
<td>Elevated liver enzymes Rash GI nonspecific HTN Hyperkalemia Peripheral edema</td>
<td>Cross-sensitivity with other azoles unknown Severe ventricular dysfunction</td>
</tr>
<tr>
<td>voriconazole (Vfend®)</td>
<td>Aspergillosis Candidiasis</td>
<td>Visual disturbance (30%) Hepatotoxicity Cutaneous photosensitivity Cutaneous squamous cell carcinoma with long-term use in immunosuppressed patients Prolonged QT Periostitis Neurologic toxicity</td>
<td></td>
<td>Cross-sensitivity with other azoles unknown May avoid or alter doses if co-administered with other CYP3A4 substrates, rifampin, carbamazepine, long-acting barbiturates, ritonavir, efavirenz, sirolimus, rifabutin, ergot alkaloids</td>
</tr>
<tr>
<td>posaconazole (Posanol®, Noxafil®)</td>
<td>Candidiasis Aspergillosis Mucormycosis</td>
<td>Elevated liver enzymes H/A Prolonged QT</td>
<td></td>
<td>Co-administration of cisapride, ergot alkaloids, pimozide, quinidine, or sirolimus</td>
</tr>
<tr>
<td><strong>ALLYlamines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>terbinafine (Lamisil®)</td>
<td>Dermatomycoses Onychomycoses</td>
<td>Inhibits enzyme needed for ergosterol synthesis</td>
<td>Rash, local irritation GI nonspecific, transaminitis</td>
<td>Active liver disease</td>
</tr>
<tr>
<td><strong>EChINOCANDINS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>caspofungin micafungin anidulafungin</td>
<td>Refractory aspergillosis, candidemia (azole-resistant)</td>
<td>Inhibits 1-3 β-D-glucan synthesis (needed for fungal cell wall)</td>
<td>Hepatotoxicity Infusion and injection site reactions</td>
<td></td>
</tr>
</tbody>
</table>

---

**Figure 21. Mechanism of action of antifungals**

© Stefanie Spano 2012
# Antiparasitics

## Table 35. Antiparasitics

<table>
<thead>
<tr>
<th>Class and Drugs</th>
<th>Coverage</th>
<th>Mechanism of Action</th>
<th>Adverse Effects</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANTMALARIALS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>chloroquine</td>
<td>Malaria: treatment of erythrocytic phase of all five species of <em>Plasmodium</em> that infect humans</td>
<td>Inhibits parasite heme polymerase</td>
<td>CNS: blurred vision, retinopathy, dizziness</td>
<td>Hypersensitivity to chloroquine or other 4-aminoquinoline</td>
</tr>
<tr>
<td></td>
<td>Note: High resistance of <em>P. falciparum</em> and <em>P. vivax</em> in certain geographic areas</td>
<td></td>
<td>Non-specific GI (rare with prophylaxis)</td>
<td>Retinal or visual field changes due to 4-aminoquinoline</td>
</tr>
<tr>
<td>quinine</td>
<td>Malaria: treatment of all five species of <em>Plasmodium</em> that infect humans, including chloroquine-resistant <em>P. falciparum</em></td>
<td>Interferes with mitochondrial function</td>
<td>Cinchonism: ears (tinnitus, vertigo), eyes (visual disturbance), GI (N/V, diarrhea), CNS (H/A, fever)</td>
<td>Hypersensitivity to quinine, may have cross-sensitivity with quinidine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hypoglycemia</td>
<td>Patients with G6PD deficiency, tinnitus, optic neuritis, hypoglycemia, history of blackwater fever or thrombocytopenic purpura due to quinine use</td>
</tr>
<tr>
<td>mefloquine (Lariam®)</td>
<td>Malaria: prophylaxis</td>
<td>Inhibits mitochondrial electron transport and dihydrofolate reductase</td>
<td>CNS/Psych: irritability, nightmares, psychoses, suicide, depression, seizures, H/A</td>
<td>History of seizures, psychosis, severe anxiety or depression</td>
</tr>
<tr>
<td>primaquine</td>
<td>Malaria: treatment of liver hypnozoites of <em>P. vivax</em> and <em>P. ovale</em>, prophylaxis of all <em>Plasmodium</em> spp., Pneumocystis <em>jiroveci</em> (with clindamycin)</td>
<td>Interferes with mitochondrial function</td>
<td>Hemolytic anemia in G6PD deficient</td>
<td>GI non-specific G6PD deficiency</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GI upset (take with food)</td>
<td>Concurrent or recent use of quinacrine</td>
</tr>
<tr>
<td>atovaquone/proguanil (Malarone®)</td>
<td>Malaria: treatment and prophylaxis of <em>P. falciparum</em></td>
<td>Inhibits mitochondrial electron transport and dihydrofolate reductase</td>
<td>N/V, anorexia, diarrhea, abdominal pain (take with food)</td>
<td>Hypersensitivity to atovaquone or proguanil</td>
</tr>
<tr>
<td></td>
<td>Malaria: treatment of all <em>Plasmodium</em> spp.</td>
<td></td>
<td></td>
<td>Severe renal impairment</td>
</tr>
<tr>
<td></td>
<td>Severe malaria (IV artesunate)</td>
<td>Binds iron, leading to formation of free radicals that damage parasite proteins</td>
<td>Transient neurologic deficits (nystagmus, balance disturbance)</td>
<td>Transient neurotoxicity (at high doses of oral artesunate)</td>
</tr>
<tr>
<td></td>
<td>Typically used in combination with a longer-acting agent from above</td>
<td></td>
<td>Transient neurotoxicity (at high doses of oral artesunate)</td>
<td>Hypersensitivity to artesimins</td>
</tr>
<tr>
<td></td>
<td>Malaria: treatment primarily in endemic countries</td>
<td></td>
<td>Delayed hemolysis</td>
<td></td>
</tr>
<tr>
<td><strong>OTHER ANTI-PROTOZOAL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>iodoquin (Diodoquin®)</td>
<td>Amoebiasis: <em>E. histolytica</em>, <em>Dientamoeba fragilis</em>, <em>Balantidium coli</em>, * Blastocystis hominis*</td>
<td>Contact amoebicide that acts in intestinal lumen by uncertain mechanism</td>
<td>Gl: N/V, diarrhea, abdominal pain</td>
<td>Hypersensitivity to any 8-hydroxy-quinoline or iodine</td>
</tr>
<tr>
<td>metronidazole</td>
<td>Amoebiasis, <em>T. vaginalis</em>, <em>giardiasis</em>, <em>D. fragilis</em></td>
<td>See Antibiotics, ID47</td>
<td>CNS: H/A, seizures, encephalitis</td>
<td>Patients with hepatic damage or optic neuropathy</td>
</tr>
<tr>
<td>nitazoxanide</td>
<td><em>Cryptosporidium</em>, <em>giardiasis</em>, <em>cyclosporiasis</em></td>
<td>Interferes with parasite anaerobic metabolism</td>
<td>N/V, diarrhea, abdominal pain, H/A</td>
<td>Hypersensitivity to nitazoxanide</td>
</tr>
<tr>
<td><strong>ANTI-HELMINTHICS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>praziquantel</td>
<td><em>Schistosomiasis</em> and other flukes</td>
<td>Increases Ca²⁺ permeability of helminth cell membrane, causing paralysis and detachment</td>
<td>N/V, fever, dizziness</td>
<td>Ocular cysticercosis</td>
</tr>
<tr>
<td>mebendazole (Vermox®)</td>
<td><em>Intestinal roundworms</em>: <em>pinworm</em>, <em>whipworm</em>, <em>hookworm</em>, roundworm (e.g. <em>Ascaris</em>)</td>
<td>Inhibits glucose uptake into susceptible parasites</td>
<td>Elevated liver enzymes</td>
<td>Pregnancy Ocular cysticercosis or intraventricular cysticercosis</td>
</tr>
<tr>
<td>mebbendazole (Vermox®)</td>
<td><em>Hydatid disease</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mebendazole (Vermox®)</td>
<td><em>Intestinal roundworms</em>: <em>pinworm</em>, <em>whipworm</em>, <em>hookworm</em>, roundworm (e.g. <em>Ascaris</em>)</td>
<td>Inhibits microtubule formation and glucose uptake</td>
<td>Nonspecific Gl</td>
<td>Pregnancy, infants</td>
</tr>
<tr>
<td>ivermectin</td>
<td><em>Strongyloidiasis</em>, <em>Onchocerciasis</em>, <em>Scabies</em></td>
<td>Interferes with polarization of nerve and muscles cells in susceptible parasites leading to paralysis</td>
<td>Nausea, bloating, diarrhea, myalgias, lightheadedness, H/A</td>
<td>Hypersensitivity to ivermectin</td>
</tr>
<tr>
<td>diethylcarbamazine</td>
<td><em>Wuchereria bancrofti</em>, <em>Loa loa</em></td>
<td></td>
<td></td>
<td>Pregnancy Ocular cysticercosis</td>
</tr>
</tbody>
</table>

*Note: Marketed primarily in endemic countries.*
Infections in the Immunocompromised Host

Fever of Unknown Origin

Nosocomial Infections

Travel Medicine

Antimicrobials
MD Consult Drugs Online. Available from: http://home.mdconsult.com/das/drugs/.

Antivirals
# Acronyms

- MI

# Imaging Modalities

- Ultrasound
- Magnetic Resonance Imaging
- Positron Emission Tomography Scans
- Contrast Enhancement

# Chest Imaging

- Chest X-Ray
- Computed Tomography Chest
- Lung Abnormalities
- Pulmonary Vascular Abnormalities
- Pleural Abnormalities
- Mediastinal Abnormalities
- Tubes, Lines, and Catheters

# Abdominal Imaging

- Abdominal X-Ray
- Approach to Abdominal X-Ray
- Approach to Abdominal Computed Tomography
- Contrast Studies
- Specific Visceral Organ Imaging
- “itis” Imaging
- Angiography of Gastrointestinal Tract

# Genitourinary System and Adrenal

- Urological Imaging
- Gynecological Imaging
- Adrenal Mass

# Neuroradiology

- Modalities
- Approach to CT Head
- Selected Pathology

# Musculoskeletal System

- Modalities
- Approach to Bone X-Rays
- Trauma
- Arthritis
- Bone Tumour
- Infection
- Metabolic Bone Disease

# Nuclear Medicine

- Brain
- Thyroid
- Respiratory
- Cardiac
- Abdomen and Genitourinary System
- Bone

# Interventional Radiology

- Vascular Procedures
- Nonvascular Interventions

# Breast Imaging

- Modalities
- Breast Interventional Procedures
- Breast Findings

# References
# Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDG</td>
<td>18-fluorodeoxyglucose</td>
</tr>
<tr>
<td>AP</td>
<td>anteroposterior</td>
</tr>
<tr>
<td>ARDS</td>
<td>acute respiratory distress syndrome</td>
</tr>
<tr>
<td>AV</td>
<td>arteriovenous</td>
</tr>
<tr>
<td>AXR</td>
<td>abdominal x-ray</td>
</tr>
<tr>
<td>BOP</td>
<td>broncholiths obliterating</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>CSF</td>
<td>cerebrospinal fluid</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>CTA</td>
<td>computed tomographic angiogram</td>
</tr>
<tr>
<td>CVD</td>
<td>collagen vascular disease</td>
</tr>
<tr>
<td>CVP</td>
<td>central venous pressure</td>
</tr>
<tr>
<td>CXR</td>
<td>chest x-ray</td>
</tr>
<tr>
<td>DEKA</td>
<td>dual-energy x-ray angioplasty</td>
</tr>
<tr>
<td>DMSA</td>
<td>dimercaptosuccinic acid</td>
</tr>
<tr>
<td>DSA</td>
<td>digital subtraction angiography</td>
</tr>
<tr>
<td>DTPA</td>
<td>diethylene triamine pentaacetic acid</td>
</tr>
<tr>
<td>DWA</td>
<td>diffusion-weighted image</td>
</tr>
<tr>
<td>DCM</td>
<td>diethylaminoethylmagnetic dimer</td>
</tr>
<tr>
<td>ECO</td>
<td>endoscopic retrograde cholangiopancreatography</td>
</tr>
<tr>
<td>ERCP</td>
<td>endoscopic retrograde cholangiopancreatography</td>
</tr>
<tr>
<td>GI</td>
<td>gastroduodenal anastomosis</td>
</tr>
<tr>
<td>GPA</td>
<td>granulomatosis with polyangiitis</td>
</tr>
<tr>
<td>HCC</td>
<td>hepatocellular carcinoma</td>
</tr>
<tr>
<td>HIDA</td>
<td>hepatobiliary iminodiacetic acid</td>
</tr>
<tr>
<td>HMIPAD</td>
<td>hexamethylpropyleneamine oxime</td>
</tr>
<tr>
<td>HSQ</td>
<td>hysterosalpingo</td>
</tr>
<tr>
<td>IBD</td>
<td>inflammatory bowel disease</td>
</tr>
<tr>
<td>ICG</td>
<td>iliacocaval valve</td>
</tr>
<tr>
<td>IPV</td>
<td>intravenous pyelogram</td>
</tr>
<tr>
<td>KUB</td>
<td>kidneys, ureters, bladder</td>
</tr>
<tr>
<td>LA</td>
<td>left atrium</td>
</tr>
<tr>
<td>LV</td>
<td>left ventricle</td>
</tr>
<tr>
<td>MAA</td>
<td>microaggregated albumin</td>
</tr>
<tr>
<td>MAG3</td>
<td>meridolate</td>
</tr>
<tr>
<td>MCA</td>
<td>middle cerebral artery</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>MR</td>
<td>magnetic resonance angiogram</td>
</tr>
<tr>
<td>MS</td>
<td>multiple sclerosis</td>
</tr>
<tr>
<td>MUGA</td>
<td>multiple gated acquisition</td>
</tr>
<tr>
<td>PA</td>
<td>postanterior</td>
</tr>
<tr>
<td>PBD</td>
<td>percutaneous biliary drainage</td>
</tr>
<tr>
<td>PET</td>
<td>positron emission tomography</td>
</tr>
<tr>
<td>PFT</td>
<td>pulmonary function test</td>
</tr>
<tr>
<td>PICC</td>
<td>peripherally-inserted central catheter</td>
</tr>
<tr>
<td>POCUS</td>
<td>point-of-care ultrasound</td>
</tr>
<tr>
<td>PTA</td>
<td>percutaneous transluminal angioplasty</td>
</tr>
<tr>
<td>PTC</td>
<td>percutaneous transluminal angioplasty</td>
</tr>
<tr>
<td>RA</td>
<td>right atrium</td>
</tr>
<tr>
<td>RAVU</td>
<td>radioactive iodine uptake</td>
</tr>
<tr>
<td>RV</td>
<td>right ventricle</td>
</tr>
<tr>
<td>SPECT</td>
<td>single photon emission computed tomography</td>
</tr>
<tr>
<td>SVC</td>
<td>superior vena cava</td>
</tr>
<tr>
<td>TB</td>
<td>tuberculosis</td>
</tr>
<tr>
<td>TNK</td>
<td>tenecteplase</td>
</tr>
<tr>
<td>TRUS</td>
<td>transrectal ultrasound</td>
</tr>
<tr>
<td>TVUS</td>
<td>transvaginal ultrasound</td>
</tr>
<tr>
<td>U/S</td>
<td>ultrasound</td>
</tr>
<tr>
<td>VCU</td>
<td>voiding cystourethrogram</td>
</tr>
<tr>
<td>V/Q</td>
<td>ventilation/perfusion</td>
</tr>
</tbody>
</table>

## Imaging Modalities

### X-Ray Imaging
- x-rays, or Roentgen rays, are a form of electromagnetic energy of short wavelength
- as x-ray photons traverse matter, they can be absorbed (a process known as "attenuation") and/or scattered
- the density of a structure determines its ability to attenuate or "weaken" the x-ray beam
  - air < fat < water < bone < metal
- structures that have high attenuation (e.g. bone) appear white on the resulting images

### Plain Films
- x-rays pass through the patient and interact with a detection device to produce a 2-dimensional projection image
- structures closer to the film appear sharper and less magnified
- contraindications: pregnancy (relative)
- advantages: inexpensive, non-invasive, readily available, reproducible, fast
- disadvantages: radiation exposure, generally poor at distinguishing soft tissues

### Fluoroscopy
- continuous x-rays used for guiding angiographic and interventional procedures, in contrast examinations of the GI tract, and in the OR for certain surgical procedures (e.g. orthopedic, urological)
- on the fluoroscopic image, black and white are reversed so that bone and contrast agents appear dark and radiolucent structures appear light
- advantages: allows for real-time visualization of structures
- disadvantages: increased radiation dose; however, the use of pulsed fluoroscopy has reduced fluoroscopy time by 76% and radiation dose by 64% as compared with continuous fluoroscopy

### Computed Tomography
- x-ray beam opposite a detector moves in a continuous 360° arc as patient is advanced through the imaging system
- subsequent computer assisted reconstruction of anatomical structures from the axial plane
- attenuation is quantified in Hounsfield units:
  - subsequent computer assisted reconstruction of anatomical structures from the axial plane
  - adjusting the "window width" (range of Hounsfield units displayed) and "window level" (midpoint value of the window width) can maximally visualize certain anatomical structures (e.g. CT chest can be viewed using "lung", "soft tissue", and "bone" settings)
- contraindications: pregnancy (relative), contraindications to contrast agents (e.g. allergy, renal failure)
- advantages: delineates surrounding soft tissues, excellent at delineating bones and identifying lung/liver masses, may be used to guide biopsies, spiral/helical multidetector CT has fast data acquisition and allows 3D reconstruction, CTA is less invasive than conventional angiography
- disadvantages: high radiation exposure, soft tissue characterization is not as good in comparison with MRI, IV contrast injection, anxiety of patient when going through scanner, higher cost, and less available than plain film

### Typical Effective Doses from Diagnostic Medical Exposures (in adults)*

<table>
<thead>
<tr>
<th>Diagnostic Procedure Type</th>
<th>Equivalent Number of Chest X-Rays</th>
<th>Approximate Equivalent Period of Natural Background Radiation** (~3 mSv/yr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic Procedure Type</td>
<td>Equivalent Number of Chest X-Rays</td>
<td>Approximate Equivalent Period of Natural Background Radiation** (~3 mSv/yr)</td>
</tr>
<tr>
<td>X-Ray</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skull</td>
<td>5</td>
<td>12 d</td>
</tr>
<tr>
<td>Cerebral spine</td>
<td>10</td>
<td>3 wk</td>
</tr>
<tr>
<td>Thoracic spine</td>
<td>50</td>
<td>4 mo</td>
</tr>
<tr>
<td>Lumbar spine</td>
<td>75</td>
<td>8 mo</td>
</tr>
<tr>
<td>Chest (single PA film)</td>
<td>1</td>
<td>2 d</td>
</tr>
<tr>
<td>Shoulder</td>
<td>0.5</td>
<td>1 d</td>
</tr>
<tr>
<td>Mammography</td>
<td>20</td>
<td>7 wk</td>
</tr>
<tr>
<td>Abdomen</td>
<td>36</td>
<td>3 mo</td>
</tr>
<tr>
<td>Hip</td>
<td>35</td>
<td>3 mo</td>
</tr>
<tr>
<td>Pelvis</td>
<td>25</td>
<td>10 wk</td>
</tr>
<tr>
<td>Knee</td>
<td>0.25</td>
<td>&lt;1 d</td>
</tr>
<tr>
<td>MU</td>
<td>150</td>
<td>1 yr</td>
</tr>
<tr>
<td>Dual-energy x-ray</td>
<td></td>
<td></td>
</tr>
<tr>
<td>angiography/arteriography with CT</td>
<td>0.5/2</td>
<td>&lt;1.4 d / 1.4 d</td>
</tr>
<tr>
<td>Upper GI series</td>
<td>300</td>
<td>2 yr</td>
</tr>
<tr>
<td>Small bowel series</td>
<td>250</td>
<td>20 ma</td>
</tr>
<tr>
<td>Buttock/abdomen</td>
<td>400</td>
<td>2.7 yr</td>
</tr>
<tr>
<td>CT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Head</td>
<td>100</td>
<td>8 mo</td>
</tr>
<tr>
<td>Neck</td>
<td>150</td>
<td>1 yr</td>
</tr>
<tr>
<td>Spine</td>
<td>300</td>
<td>2 yr</td>
</tr>
<tr>
<td>Chest</td>
<td>250</td>
<td>2.3 yr</td>
</tr>
<tr>
<td>Chest (auricular projection)</td>
<td>750</td>
<td>5 yr</td>
</tr>
<tr>
<td>Concanary angiography</td>
<td>800</td>
<td>6.9 yr</td>
</tr>
<tr>
<td>Abdomen</td>
<td>400</td>
<td>2.7 yr</td>
</tr>
<tr>
<td>Pelvis</td>
<td>300</td>
<td>2 yr</td>
</tr>
</tbody>
</table>

### Radionuclide

<table>
<thead>
<tr>
<th>Radionuclide</th>
<th>Radioactivity (Bq)</th>
<th>Half-Life (t1/2)</th>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain (99mTc)</td>
<td>370</td>
<td>0.8 h</td>
<td>Skeletal</td>
</tr>
<tr>
<td>Bone (99mTc)</td>
<td>315</td>
<td>2.1 h</td>
<td>Skeletal</td>
</tr>
<tr>
<td>Thyroid (I-131)</td>
<td>240</td>
<td>7.6 h</td>
<td>Thyroid</td>
</tr>
<tr>
<td>Heart (I-131)</td>
<td>95</td>
<td>8.0 h</td>
<td>Heart</td>
</tr>
<tr>
<td>Cardiac risk test</td>
<td>670</td>
<td>3.0 h</td>
<td>Cardiac</td>
</tr>
<tr>
<td>(I-131)</td>
<td></td>
<td></td>
<td>Risk</td>
</tr>
<tr>
<td>Lung ventilation (I-133Xe)</td>
<td>25</td>
<td>2.0 h</td>
<td>Lung ventilation</td>
</tr>
<tr>
<td>Lung perfusion</td>
<td>100</td>
<td>8 h</td>
<td>Lung perfusion</td>
</tr>
<tr>
<td>(I-133Xe)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain (99mTc)</td>
<td>90-165</td>
<td>7.3 h</td>
<td>Brain</td>
</tr>
<tr>
<td>Liver (99mTc)</td>
<td>35</td>
<td>2.0 h</td>
<td>Liver</td>
</tr>
<tr>
<td>Liver (99mTc)</td>
<td>105</td>
<td>2.5 h</td>
<td>Liver</td>
</tr>
<tr>
<td>Liver (99mTc)</td>
<td>130</td>
<td>2.8 h</td>
<td>Liver</td>
</tr>
</tbody>
</table>

*Source: Radiology 2009;248:254-263
**Calculated using average natural background exposure in Canada (Health Canada: http://www.hc-sc.gc.ca/hl-vs/iyh-vsv/environ/expos-eng.php)
**Ultrasound**

- high frequency sound waves are transmitted from a transducer and passed through tissues; reflections of the sound waves are picked up by the transducer and transformed into images
- reflection (or “echo”) occurs when the sound waves pass through tissue interfaces of different acoustic densities
- structures are described based on their echogenicity; hyperechoic structures appear bright (U/S reflected) whereas hypoechoic structures appear dark (U/S waves not reflected back but pass through)
- higher U/S frequencies result in greater resolution but greater attenuation (i.e. deeper structures more difficult to visualize)
- artifacts: acoustic shadowing refers to the echo-free area located behind an interface that strongly reflects (e.g. tissue/air) or absorbs (e.g. tissue/bone) sound waves; enhancement refers to the increase in reflection amplitude (i.e. increased brightness) from objects that lie below a weakly attenuating structure (e.g. cyst)
- Duplex scan: grey-scale image that utilizes the Doppler effect to visualize the velocity of blood flow past the transducer
- Colour Doppler: assigns a colour based on the direction of blood flow
- advantages: relatively low cost, non-invasive, no radiation, real time imaging, may be used for guided biopsies, many different imaging planes (axial, sagittal), determines cystic versus solid
- disadvantages: highly operator-dependent, air in bowel may prevent imaging of midline structures in the abdomen, may be limited by patient habitus, poor for bone evaluation

**Magnetic Resonance Imaging**

- non-invasive technique that does not use ionizing radiation
- able to produce images in virtually any plane
- patient is placed in a magnetic field; protons (H+) align themselves along the plane of magnetization due to intrinsic polarity. A pulsed radiofrequency beam is subsequently turned on which deflects all the protons off their aligned axes due to absorption of energy from the radiofrequency beam. When the radiofrequency beam is turned off, the protons return to their pre-excitation axis, giving off the energy they absorbed. This energy is measured with a detector and interpreted by a computer to generate MR images
- the MR image reflects the signal intensity picked up by the receiver. This signal intensity is dependent on:
  1. hydrogen density: tissues with low hydrogen density (e.g. cortical bone, lung) generate little to no MR signal compared to tissues with high hydrogen density (e.g. water)
  2. magnetic relaxation times (T1 and T2): reflect quantitative alterations in MR signal strength due to intrinsic properties of the tissue and its surrounding chemical and physical environment

### Table 1. Differences Between Diffusion, T1- and T2-Weighted MR Imaging

<table>
<thead>
<tr>
<th>Imaging Techniques</th>
<th>Contrast Enhancements</th>
<th>Main Application</th>
<th>Advantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diffusion Weighted Imaging</td>
<td>Contrast dependent on the molecular motion of water Decreased diffusion is hyperintense (bright), whereas increased diffusion is hypointense (dark)</td>
<td>Neuroradiology</td>
<td>Sensitive for detection of acute ischemic stroke and differentiating an acute stroke from other neurologic pathologies Acute infarction appears hyperintense Abscess collections also show restricted diffusion</td>
</tr>
<tr>
<td>T1-Weighted</td>
<td>Fluid is hypointense (dark) and fat is hyperintense (bright)</td>
<td>Body soft tissues</td>
<td>Often considered an anatomic scan since they provide a reference for functional imaging</td>
</tr>
<tr>
<td>T2-Weighted</td>
<td>Fluid is hyperintense (bright) and fat is hypointense (dark)</td>
<td>Body soft tissues</td>
<td>Often considered a pathologic scan since they will highlight edematous areas associated with certain pathologies</td>
</tr>
</tbody>
</table>

**Positron Emission Tomography Scans**

- non-invasive technique that involves exposure to ionizing radiation (~7 mSv)
- nuclear medicine imaging technique that produces images of functional processes in the body
- current generation models integrate PET and CT technologies into a single imaging device (PET-CT) that collects both anatomic and functional information during a single acquisition
- posatron-producing radioisotope, such as 18FDG is chemically incorporated into a metabolically active molecule (e.g. glucose), injected into patient, which travels to target organ, accumulates in tissues of interest, and as radioactive substance begins to decay, gamma rays are produced which are detected by PET scanner
- contraindications: pregnancy
- advantages: shows metabolism and physiology of tissues (not only anatomic); in oncology allows diagnosis, staging, restaging; has predictive and prognostic value; can evaluate cardiac viability
- disadvantages: cost, ionizing radiation
Contrast Enhancement

Table 2. Contrast Agents

<table>
<thead>
<tr>
<th>Imaging Modality</th>
<th>Types</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>X-Ray/CT</td>
<td>1. Barium (oral or rectal)</td>
<td>Radioopaque substance which helps to delineate intraluminal anatomy, may demonstrate patency, lumen integrity, or large filling defects</td>
<td>Previous adverse reaction to contrast; barium enema is contraindicated in toxic megacolon, acute colitis, and suspected perforation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Iodine (IV injection)</td>
<td>Delineates intraluminal anatomy, may demonstrate patency, lumen integrity, or large filling defects; under fluoroscopy, may also give information on function of an organ</td>
<td>Risk of nephrogenic systemic fibrosis in patients with end-stage renal disease; Previous adverse reaction to contrast, renal failure, DM, pregnancy, multiple myeloma, severe heart failure and dehydration eGFR &lt; 60 may require preventative measures and follow up</td>
<td></td>
</tr>
<tr>
<td>MRI</td>
<td>Gadolinium-Chelates (IV injection)</td>
<td>Shortens T1 relaxation time, thereby increasing signal intensity in T1-weighted sequences; gadolinium has some effect on T2-relaxation time; highlights highly vascular structures (e.g. tumours)</td>
<td>Risk of nephrogenic systemic fibrosis in patients with end-stage renal disease; Previous adverse reaction to contrast or if end-stage renal disease (relative contraindication)</td>
<td></td>
</tr>
<tr>
<td>U/S</td>
<td>Microbubbles (IV injection)</td>
<td>Since gas is highly echogenic, the microbubbles allow for echo-enhancement of a tissue</td>
<td>Contraindicated in individuals with right-to-left cardiac shunts or people with known hypersensitivity reactions</td>
<td></td>
</tr>
</tbody>
</table>

Chest Imaging

Chest X-Ray

Standard Views
- PA: anterior chest against film plate to minimize magnification of the heart size
- lateral: better visualization of retrocardiac space and thoracic spine (more sensitive at picking up pleural effusions)
  - helps localize lesions when combined with PA view
- AP: for bedridden patients (generally a lower quality film than PA because of enlarged cardiac silhouette)
- lateral decubitus: to assess for pleural effusion and pneumothorax in bedridden patients; however, POCUS can also be utilized for both these purposes
- lordotic: angled beam allowing better visualization of apices normally obscured by the clavicles and anterior ribs

![Figure 1. CXR views](image)

Approach to CXR

Basics
- ID: patient name, MRN, sex, age
- date of exam
- markers: right and/or left
- technique: view (e.g. PA, AP, lateral), supine or erect
- indications for the study
- comparison: date of previous study for comparison (if available)
- quality of film: inspiration (6th anterior and 10th posterior ribs should be visible), penetration (thoracic spine should be visible) and rotation (clavicles vs. spinous process)
Analysis
- tubes and lines: check position and be alert for pneumothorax or pneumomediastinum
- soft tissues: neck, axillae, pectoral muscles, breasts/nipples, chest wall
  - nipple markers can help identify nipples (may mimic lung nodules)
  - amount of soft tissue, presence of masses and air (subcutaneous emphysema)
- abdomen (see Abdominal Imaging: MI10)
  - free air under the diaphragm, air-fluid levels, distention in small and large bowels
  - herniation of abdominal contents (i.e. diaphragmatic hernia)
- bones: C-spine, thoracic spine, shoulders, ribs, sternum, clavicles
  - lytic and blastic lesions and fractures
- mediastinum: trachea, heart, great vessels
  - cardiomegaly (cardiothoracic ratio >0.5), tracheal shift, tortuous aorta, widened mediastinum
- hila: pulmonary vessels, mainstem and segmental bronchi, lymph nodes
- lungs: lung parenchyma, pleura, diaphragm
  - comment on abnormal lung opacity, pleural effusions or thickening
  - right hemidiaphragm usually higher than left due to liver
  - right vs. left hemidiaphragm can be discerned on lateral CXR due to heart resting directly on left hemidiaphragm
- please refer to Toronto Notes’ website for supplementary material on how to approach a CXR

Anatomy

Localizing Lesions for Parenchymal Lung Disease
- silhouette sign: loss of normal interfaces due to lung pathology (consolidation, atelectasis, mass), which can be used to localize disease in specific lung segments; note that pleural or mediastinal disease can also produce the silhouette sign)
- spine sign: on lateral films, vertebral bodies should appear progressively radiolucent as one moves down the thoracic vertebral column; if they appear more radiopaque, it is an indication of pathology (e.g. consolidation in overlying left lower lobe)
- air bronchogram: branching pattern of air filled bronchi on a background of fluid filled airspaces

Table 3. Localization Using the Silhouette Sign

<table>
<thead>
<tr>
<th>Interface Lost</th>
<th>Location of Lung Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>SVC/right superior mediastinum</td>
<td>RUL</td>
</tr>
<tr>
<td>Right heart border</td>
<td>RML</td>
</tr>
<tr>
<td>Right hemidiaphragm</td>
<td>RLL</td>
</tr>
<tr>
<td>Aortic knob/left superior mediastinum</td>
<td>LUL</td>
</tr>
<tr>
<td>Left heart border</td>
<td>Lingula</td>
</tr>
<tr>
<td>Left hemidiaphragm</td>
<td>LLL</td>
</tr>
</tbody>
</table>

Legend
- a1 anterior 1st rib
- a2 anterior 2nd rib
- aa aortic arch
- apw aorto-pulmonary window
- as anterior airspace
- ca carina
- cl clavicle
- co coracoid process
- cpa costophrenic angle
- di diaphragm
- g gastric bubble
- ivc inferior vena cava
- la left atrium
- lbr left mainstem bronchus
- lpa left pulmonary artery
- lv left ventricle
- mf major fissure
- mi minor fissure
- p3 posterior 3rd rib
- p4 posterior 4th rib
- pa main pulmonary artery
- ra right atrium
- rbr right mainstem bronchus
- rpa right pulmonary artery
- rv right ventricle
- sc scapula
- sp spinous process
- st sternum
- svc superior vena cava
- tr trachea
- vb vertebral body

Figure 2. Location of fissures, mediastinal structures, and bony landmarks on CXR
Computed Tomography Chest

Approach to CT Chest
- soft tissue window
  - thyroid, chest wall, pleura
  - heart: chambers, coronary artery calcifications, pericardium
  - vessels: aorta, pulmonary artery, smaller vasculature
  - lymph nodes: mediastinal, axillary
- bone window
  - vertebrae, sternum, manubrium, ribs: fractures, lytic lesions, sclerosis
- lung window
  - trachea: patency, secretions
  - bronchial trees: anatomic variants, mucus plugs, airway collapse
  - lung parenchyma: fissures, nodules, fibrosis/interstitial changes
  - pleural space: effusions
- please refer to Toronto Notes’ website for supplementary material on how to approach a CT chest

Table 4. Types of CT Chest

<table>
<thead>
<tr>
<th>Advantage</th>
<th>Disadvantage</th>
<th>Contrast</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard</td>
<td>Scans full lung very quickly (&lt;1 min)</td>
<td>Poor at evaluating diffuse disease</td>
<td>±</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pleural and mediastinal abnormality</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lung cancer staging</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Follow up metastases</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Empyema vs. abscess</td>
</tr>
<tr>
<td>High Resolution</td>
<td>Thinner slices provide high definition of lung parenchyma</td>
<td>Only 5-10% lung is sampled</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Diffuse lung disease (e.g. sarcoidosis,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>hypersensitivity pneumonitis,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>pneumoconiosis)</td>
</tr>
<tr>
<td>Low Dose</td>
<td>1/5th the radiation</td>
<td>Decreased detail</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Screening</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Follow up infections, lung transplant,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>metastases</td>
</tr>
<tr>
<td>CTA</td>
<td>Iodinated contrast highlights vasculature</td>
<td>Contrast can cause severe allergic reaction and is nephrotoxic</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Aortic aneurysms</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Aortic dissection</td>
</tr>
</tbody>
</table>

Lung Abnormalities

Atelectasis
- pathogenesis: collapse of alveoli due to restricted breathing, blockage of bronchi, external compression, or poor surfactant
- findings
  - increased opacity of involved segmentlobe, vascular crowding, silhouette sign, air bronchograms
  - volume loss: fissure deviation, hilar/mediastinal displacement, diaphragm elevation
  - compensatory hyperinflation of remaining normal lung
- differential diagnosis
  - obstructive (most common): air distal to obstruction is reabsorbed causing alveolar collapse
    - post-surgical, endobronchial lesion, foreign body, inflammation (granulomatous infections, pneumoconiosis, sarcoidosis, radiation injury), or mucous plug (cystic fibrosis)
  - compressive
tumour, bulla, effusion, enlarged heart, lymphadenopathy
traction (cicatrization): due to scarring, which distorts alveoli and contracts the lung
adhesive: due to lack of surfactant
  - hyaline membrane disease, prematurity

DDx of Airspace Disease
- Pus (e.g. infections such as pneumonia, non-infectious inflammatory process)
- Fluid (e.g. pulmonary edema)
- Blood (e.g. pulmonary hemorrhage)
- Cells (e.g. bronchoalveolar carcinoma, lymphoma)
- Protein (e.g. alveolar proteinosis)
- passive (relaxation): a result of air or fluid in the pleural space
  - pleural effusion, pneumothorax
- management: in the absence of a known etiology, persisting atelectasis must be investigated (i.e. CT thorax) to rule out a bronchogenic carcinoma

**Consolidation**
- pathogenesis: fluid (water, blood), inflammatory exudates, protein, or tumour in alveoli
- findings
  - air bronchograms: lucent branching bronchi visible through opacification
  - airspace nodules: fluffy, patchy, poorly defined margins with later tendency to coalesce, may take on lobar or segmental distribution
  - silhouette sign
- differential diagnosis
  - fluid: pulmonary edema, blood (trauma, vasculitis, bleeding disorder, pulmonary infarct)
  - inflammatory exudates: bacterial infections, TB, allergic hypersensitivity alveolitis, BOOP, allergic bronchopulmonary aspergillosis, aspiration, sarcoidosis
  - protein: pulmonary alveolar proteinosis
  - tumour: bronchoalveolar carcinoma, lymphoma
- management: varies depending on the pattern of consolidation, which can suggest different etiologies; should also be done in the context of clinical picture

**Interstitial Disease**
- pathogenesis: pathological process involving the interlobular connective tissue (i.e. "scaffolding of the lung")
- findings
  - linear: fine lines caused by thickened connective tissue septae
    - Kerley A: long thin lines in upper lobes
    - Kerley B: short horizontal lines extending from lateral lung margin
    - Kerley C: diffuse linear pattern throughout lung
  - seen in pulmonary edema, lymphangitic carcinomatosis, and atypical interstitial pneumonias
  - nodular: 1-5 mm well-defined nodules distributed evenly throughout lung
  - seen in malignancy, pneumoconiosis and granulomatous disease (e.g. sarcoidosis, miliary TB)
  - reticular (honeycomb): parenchyma replaced by thin-walled cysts suggesting extensive destruction of pulmonary tissue and fibrosis
    - seen in IPF, asbestosis, and CVD
    - watch for pneumothorax as a complication
  - reticulonodular: combination of reticular and nodular patterns
  - may also see signs of airspace disease (atelectasis, consolidation)
- differential diagnosis
  - occupational/environmental exposure
    - inorganic: asbestosis, coal miner's pneumoconiosis, silicosis, berylliosis, talc pneumoconiosis
    - organic: hypersensitivity pneumonitis, bird fancier's lung, farmer's lung (mouldy hay), and other organic dust
  - autoimmune: CVD (e.g. rheumatoid arthritis, scleroderma, SLE, polymyositis, mixed connective tissue disease), IBD, celiac disease, vasculitis
  - drug-related: antibiotics (cephalosporins, nitrofurantoin), NSAIDs, phenytoin, carbamazepine, fluoxetine, amiodarone, chemotherapy (e.g. methotrexate), heroin, cocaine, methadone
  - infections: non-tuberculous mycobacteria, certain fungal infections
  - idiopathic: hypersensitivity pneumonitis, IPF, BOOP
  - for *Causes of Interstitial Lung Disease Classified by Distribution*, see *Respirology*, R13
- management: high resolution CT thorax and biopsy

**Pulmonary Nodule**
- findings: round opacity ± silhouette sign
  - note: do not mistake nipple shadows for nodules; if in doubt, repeat CXR with nipple markers
- differential diagnosis
  - extrapolumary density: nipple, skin lesion, electrode, pleural mass, bony lesion
  - solitary nodule
    - tumour: carcinoma, hamartoma, metastasis, bronchial adenoma
    - inflammation: histoplasmosa, tuberculosis, coccidioidomycosis
    - vascular: AV fistula, pulmonary varix (dilated pulmonary vein), infarct, embolism
  - multiple nodules: metastases, abscess, granulomatous lung disease (TB, fungal, sarcoid, rheumatoid nodules, silicosis, GPA)
- management: clinical information and CT appearance determine level of suspicion of malignancy
  - if high probability of malignancy, invasive testing (fine needle aspiration, transbronchial/ transthoracic biopsy) is indicated
  - if low probability of malignancy, repeat CXR or CT in 1-3 mo and then every 6 mo for 2 yr; if no change, then >99% chance benign

**DDx of Interstitial Lung Disease**
- FASSTEN (upper lung disease)
  - Farmer's lung (hypersensitivity pneumonitis)
  - Acute eosinophilic pneumonia
  - Asbestosis
  - Silicosis
  - TB
  - Eosinophilic granuloma (Langerhans cell histiocytosis)
  - Neurofibromatosis
- BAD RASH (lower lung disease)
  - BOOP
  - Asbestos
  - Drugs (nitrofurantoin, hydralazine, isoniazid, amiodarone, many chemotherapy drugs)
  - Rheumatological disease
  - Aspiration
  - Scleroderma
  - Hamman Rich (IPF) and idiopathic pulmonary fibrosis

**DDx for Cavitating Lung Nodule**
- WEIRD HOLES
  - GPA (Wegener's)
  - Embolic (pulmonary, septic)
  - Infection (anaerobes, pneumocystis, TB)
  - Rheumatoid (reiterotic nodules)
  - Developmental cysts (sequestration)
  - Histiocytosis
  - Oncological
  - Lymphangioleiomyomatosis
  - Environmental, occupational
  - Sarcoidosis
Table 5. Characteristics of Benign and Malignant Pulmonary Nodules

<table>
<thead>
<tr>
<th></th>
<th>Malignant</th>
<th>Benign</th>
</tr>
</thead>
<tbody>
<tr>
<td>Margin</td>
<td>Ill-defined/spiculated (“corona radiata”)</td>
<td>Well-defined</td>
</tr>
<tr>
<td>Contour</td>
<td>Lobulated</td>
<td>Smooth</td>
</tr>
<tr>
<td>Calcification</td>
<td>Eccentric or stippled</td>
<td>Diffuse, central, popcorn, concentric</td>
</tr>
<tr>
<td>Doubling Time</td>
<td>20-460 d</td>
<td>&lt;20 d or &gt;460 d</td>
</tr>
<tr>
<td>Other Features</td>
<td>Cavitation, collapse, adenopathy, pleural effusion, lytic bone lesions, smoking history</td>
<td></td>
</tr>
<tr>
<td>Size</td>
<td>&gt;3 cm</td>
<td>&lt;3 cm</td>
</tr>
<tr>
<td>Cavitation</td>
<td>Yes, especially with wall thickness &gt;15 mm, eccentric cavity and shaggy internal margins</td>
<td>No</td>
</tr>
<tr>
<td>Satellite Lesions</td>
<td>No</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Pulmonary Vascular Abnormalities

Pulmonary Edema
- Pathogenesis: fluid accumulation in the airspaces of the lungs
- Findings:
  - Vascular redistribution/enlargement, cephalization, pleural effusion, cardiomegaly (may be present in cardiogenic edema and fluid overloaded states)
  - Fluid initially collects in interstitium
    - Loss of definition of pulmonary vasculature
    - Peribronchial cuffing
    - Kerley B lines
    - Reticulonodular pattern
    - Thickening of interlobar fissures
  - As pulmonary edema progresses, fluid begins to collect in alveoli causing diffuse air space disease often in a “bat wing” or “butterfly” pattern in perihilar regions with tendency to spare the outermost lung fields
  - Differential diagnosis: cardiogenic (e.g. CHF), renal failure, volume overload, non-cardiogenic (e.g. ARDS)

Pulmonary Embolism
- Pathogenesis: arterial blockage in the lungs due to emboli from pelvic or leg veins, rarely from PICC lines, ports, or air, fat, or amniotic fluid (difficult to diagnose on imaging except by combination of clinical history and CXR and CT findings of ARDS)
- Findings:
  - CXR: Westermark sign (localized pulmonary oligemia), Hampton’s hump (triangular peripheral infarct), enlarged right ventricle and right atrium, atelectasis, pleural effusion, and rarely pulmonary edema
  - Definitive imaging study: CT pulmonary angiography to look for filling defect in contrast-filled pulmonary arteries (emboli can be seen up to 4th order arterial branching)
  - V/Q scan: not a diagnostic study

Pleural Abnormalities

Pleural Effusion

Table 6. Sensitivity of Plain Film Views for Pleural Effusion

<table>
<thead>
<tr>
<th>X-Ray Projection</th>
<th>Minimum Volume to Visualize</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lateral decubitus</td>
<td>25 mL: most sensitive</td>
</tr>
<tr>
<td>Upright lateral</td>
<td>50 mL: meniscus seen in the posterior costophrenic sulcus</td>
</tr>
<tr>
<td>PA</td>
<td>200 mL</td>
</tr>
<tr>
<td>Supine</td>
<td>Diffuse haziness</td>
</tr>
</tbody>
</table>

- A horizontal fluid level is seen only in a hydropneumothorax (i.e. both fluid and air within pleural cavity)
- Effusion may exert mass effect, shift trachea and mediastinum to opposite side, or cause atelectasis of adjacent lung
- U/S is superior to plain film for detection of small effusions and may also aid in thoracentesis, and POCUS is now standard of care in acute situations
- Fluid level >1 cm on lateral decubitus film is indication to perform thoracentesis
Pneumothorax
- pathogenesis: gas/air accumulation within the pleural space resulting in separation of the lung from the chest wall
- findings
  - upright chest film allows visualization of visceral pleura as curvilinear line paralleling chest wall, separating partially collapsed lung from pleural air
  - more obvious on expiratory (increased contrast between lung and air) or lateral decubitus films (air collects superiority)
  - more difficult to detect on supine film; look for the “deep (costophrenic) sulcus” sign, “double diaphragm” sign (dome and anterior portions of diaphragm outlined by lung and pleural air, respectively), hyperlucent hemithorax, sharpening of adjacent mediastinal structures
  - mediastinal shift may occur if tension pneumothorax
- differential diagnosis: spontaneous (tall and thin males, smokers), iatrogenic (lung biopsy, ventilation, CVP line insertion), trauma (associated with rib fractures), emphysema, malignancy, honeycomb lung
- management: needle decompression or chest tube insertion, repeat CXR to ensure resolution

Asbestos
- asbestos exposure may cause various pleural abnormalities including benign plaques (most common) that may calcify, diffuse pleural fibrosis, effusion, and malignant mesothelioma

Mediastinal Abnormalities

Mediastinal Mass
- the mediastinum is divided into four compartments; this provides an approach to the differential diagnosis of a mediastinal mass
- anterior border formed by the sternum and posterior border by the heart and great vessels
  - 4 Ts: see sidebar
    - cardiophrenic angle mass differential: thymic cyst, epicardial fat pad, foramen of Morgagni hernia
    - middle (extending behind anterior mediastinum to a line 1 cm posterior to the anterior border of the thoracic vertebral bodies)
      - esophageal carcinoma, esophageal duplication cyst, metastatic disease, lymphadenopathy (all causes), hiatus hernia, bronchogenic cyst
    - posterior (posterior to the middle line described above)
      - neurogenic tumour (e.g. neurofibroma, schwannoma), multiple myeloma, pheochromocytoma, neuroenteric cyst, thoracic duct cyst, lateral meningocele, Bochdalek hernia, extramedullary hematopoiesis
- superior boundaries (superiorly by thoracic inlet, inferiorly by plane of the sternal angle, anteriorly by manubrium, posteriorly by T1-T4, laterally by pleura)
- in addition, any compartment may give rise to lymphoma, lung cancer, aortic aneurysm or other vascular abnormalities, abscess, and hematoma

Enlarged Cardiac Silhouette
- heart borders
  - on PA view, right heart border is formed by right atrium; left heart border is formed by left atrium and left ventricle
  - on lateral view, anterior heart border is formed by right ventricle; posterior border is formed by left atrium (superior to left ventricle) and left ventricle
- cardiothoracic ratio = greatest transverse dimension of the central shadow relative to the greatest transverse dimension of the thoracic cavity
  - using a good quality erect PA chest film in adults, cardiothoracic ratio of >0.5 is abnormal
  - differential of ratio >0.5
    - cardiomegaly (myocardial dilatation or hypertrophy)
    - pericardial effusion
    - poor inspiratory effort/low lung volumes
    - pectus excavatum
  - ratio <0.5 does not exclude enlargement (e.g. cardiomegaly + concomitant hyperinflation)
- pericardial effusion: globular heart with loss of indentations on left mediastinal border
- RA enlargement: increase in curvature of right heart border and enlargement of SVC
- LA enlargement: straightening of left heart border; increased opacity of lower right side of cardiovascular shadow (double heart border); elevation of left main bronchus (specifically, the upper lobe bronchus on the lateral film), distance between left main bronchus and “double” heart border >7 cm, splayed carina (late sign)
- RV enlargement: elevation of cardiac apex from diaphragm; anterior enlargement leading to loss of retrosternal air space on lateral; increased contact of right ventricle against sternum
- LV enlargement: displacement of cardiac apex inferiorly and posteriorly - “boot-shaped” heart
**Tubes, Lines, and Catheters**

- ensure appropriate placement and assess potential complications of lines and tubes
- avoid mistaking a line/tube for pathology (e.g., oxygen rebreather mask for pneumothoraces)

**Central Venous Catheter**
- used for fluid and medication administration, vascular access for hemodialysis, and CVP monitoring
- tip must be located proximal to right atrium to prevent inducing arrhythmias or perforating wall of atrium
  - if monitoring CVP, catheter tip must be proximal to venous valves
  - tip of well-positioned central venous catheter projects over silhouette of SVC in a zone demarcated superiorly by the anterior first rib end and clavicle, and inferiorly by top of RA
- course should parallel course of SVC - if appears to bend as it approaches wall of SVC or appears perpendicular, catheter may damage and ultimately perforate wall of SVC
- complications: pneumothorax, bleeding (mediastinal, pleural), air embolism

**Endotracheal Tube**
- frontal chest film: tube projects over trachea and shallow oblique or lateral chest radiograph will help determine position in 3 dimensions
- progressive gaseous distention of stomach on repeat imaging is concerning for esophageal intubation
- tip should be located 4 cm above tracheal carina – avoids bronchus intubation and vocal cord irritation
- maximum inflation diameter <3 cm to avoid necrosis of tracheal mucosa and rupture – ensure diameter of balloon is less than tracheal diameter above and below balloon
- complications: aspiration (parenchymal opacities), pharyngeal perforation (subcutaneous emphysema, pneumomediastinum, mediastinitis)

**Nasogastric Tube**
- tip and sideport should be positioned distal to esphagogastic junction and proximal to gastric pylorus
- radiographic confirmation of tube is mandatory because clinical techniques for assessing tip position may be unreliable
- complications: aspiration (parenchymal opacities), intracranial perforation (trauma patients), pneumothorax

**Swan-Ganz Catheter**
- to monitor pulmonary capillary wedge pressure and to measure cardiac output for suspected LV dysfunction
- tip should be positioned within right or left main pulmonary arteries or in one of their large, lobar branches
- if tip is located more distally, increased risk of prolonged pulmonary artery occlusion resulting in pulmonary infarction or, rarely, pulmonary artery rupture
- complications: pneumothorax, bleeding (mediastinal, pleural), air embolism

**Chest Tube**
- in dorsal and caudal portion of pleural space to evacuate fluid
- in ventral and cephalad portions of pleural space to evacuate pneumothoraces
- tube may lie in tissue as long as functioning
- complications: lung perforation (mediastinal opacities)

---

**Abdominal Imaging**

**Abdominal X-Ray**

- AXR 3 most common views: left lateral decubitus, supine, erect upright (see Figure 16)
- indications
  - acute abdomen: bowel perforation, toxic megacolon, bowel ischemia, small bowel obstruction, large bowel obstruction
  - chronic symptoms: constipation, calcifications (gallstones, renal stones, urinary bladder stones, etc.)
  - not useful in: GI bleeds, chronic anemia, vague GI symptoms

**Anatomy**
- abdomen divided into 2 cavities
  - peritoneal cavity: lined by peritoneum that wraps around most of the bowel, the spleen, and most of the liver; forms a recess lateral to both the ascending and descending colon (paracolic gutters)
  - retroperitoneal cavity: contains several organs situated posterior to the peritoneal cavity; the contour of these can often be seen on radiographs
Table 7. Differentiating Small and Large Bowel

<table>
<thead>
<tr>
<th>Property</th>
<th>Small Bowel</th>
<th>Large Bowel</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mucosal Folds</td>
<td>Uninterrupted valvulae conniventes (or plicae circularis)</td>
<td>Interrupted haustra extend only partway across lumen</td>
</tr>
<tr>
<td>Location</td>
<td>Central</td>
<td>Peripheral (picture frame)</td>
</tr>
<tr>
<td>Maximum Diameter</td>
<td>3 cm</td>
<td>6 cm (9 cm at cecum)</td>
</tr>
<tr>
<td>Maximum Fold Thickness</td>
<td>3 mm</td>
<td>5 mm</td>
</tr>
<tr>
<td>Other</td>
<td>Rarely contains solid fecal material</td>
<td>Commonly contains solid fecal material</td>
</tr>
</tbody>
</table>

**Approach to Abdominal X-Ray**

- mnemonic: "Free ABDO"
- "Free": free air and fluid
  - free fluid
    - small amounts of fluid: increased distance between lateral fat stripes and adjacent colon may indicate free peritoneal fluid in the paracolic gutters
    - large amounts of fluid: diffuse increased opacification on supine film; bowel floats to centre of anterior abdominal wall
    - ascites and blood (hemoperitoneum) are the same density on the radiograph and therefore cannot be differentiated
    - free intraperitoneal air suggests rupture of a hollow viscus (anterior duodenum, transverse colon), penetrating trauma, or recent (<7 d) surgery
- "A": air in the bowel (can be normal, ileus, or obstruction)
  - volvulus – twisting of the bowel upon itself, from most to least common:
    - sigmoid: "coffee bean" sign (massively dilated sigmoid projects to right or mid-upper abdomen) with proximal dilation
    - cecal: massively dilated bowel loop projecting to left or mid-upper abdomen with small bowel dilatation
    - gastric: rare
    - transverse colon: rare (usually young individuals)
    - small bowel: "corkscrew sign" (rarely diagnosed on plain films, seen best on CT)
  - toxic megacolon
    - manifestation of fulminant colitis
    - extreme dilatation of colon (>6.5 cm) with mucosal changes (e.g. foci of edema, ulceration, pseudopolyps), loss of normal haustral pattern
- "B": bowel wall thickening
  - increased soft tissue density in bowel wall, thumb-like indentations in bowel wall ("thumb-printing"), or a picket-fence appearance of the valvulae conniventes ("stacked coin" appearance)
  - may be seen in IBD, infection, ischemia, hypoproteinemic states, and submucosal hemorrhage
- "D": densities
  - bones: look for gross abnormalities of lower ribs, vertebral column, and bony pelvis
  - abnormal calcifications: approach by location
    - RUQ: renal stone, adrenal calcification, gallstone, porcelain gallbladder
    - RLQ: ureteral stone, appendicolith, gallstone ileus
    - LQ: renal stone, adrenal calcification, tail of pancreas
    - LLQ: ureteral stone
    - central: aorta/aortic aneurysm, pancreas, lymph nodes
    - pelvis: phleboliths (i.e. calcified veins), uterine fibroids, bladder stones
- "O": organs
  - kidney, liver, gallbladder, spleen, pancreas, urinary bladder, psoas shadow
  - outlines can occasionally be identified because they are surrounded by more lucent fat, but all are best visualized with other imaging modalities (CT, MRI)
Table 8. Abnormal Air on Abdominal X-Ray

<table>
<thead>
<tr>
<th>Air</th>
<th>Appearance</th>
<th>Common Etiologies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extraluminal</td>
<td>Upright film: air under diaphragm</td>
<td>Perforated viscus</td>
</tr>
<tr>
<td>Intrapitoneal</td>
<td>Left lateral decubitus film: air between liver and abdominal wall</td>
<td>Post-operative (up to 10 d to be resorbed)</td>
</tr>
<tr>
<td>(pneumoperitoneum)</td>
<td>Supine film: gas outlines of structures not normally seen: Inner and outer bowel wall [Rigler’s sign]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Falculafermentation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peritoneal cavity (“football” sign)</td>
<td></td>
</tr>
<tr>
<td>Retroperitoneal</td>
<td>Gas outlining retroperitoneal structures allowing increased visualization: Pneum shadows</td>
<td>Perforation of retroperitoneal segments of bowel: duodenal ulcer, post-colonoscopy</td>
</tr>
<tr>
<td>Intra mural</td>
<td>Lucent air streaks in bowel wall, 2 types:</td>
<td></td>
</tr>
<tr>
<td>(pneumatosis intestinals)</td>
<td>1. Linear</td>
<td>1. Linear: ischemia, necrotizing enterocolitis</td>
</tr>
<tr>
<td></td>
<td>2. Rounded (cystoides type)</td>
<td>2. Rounded/cystoides (generally benign): primary (idiopathic), secondary to COPD</td>
</tr>
<tr>
<td>Intraluminal</td>
<td>Dilated loops of bowel, air-fluid levels</td>
<td>Adynamic (paralytic) ileus, mechanical bowel obstruction</td>
</tr>
<tr>
<td>Loculated</td>
<td>Mottled, localized in abnormal position without normal bowel features</td>
<td>Abscess (evaluate with CT)</td>
</tr>
<tr>
<td>Biliary</td>
<td>Air centrally over liver</td>
<td>Sphincterotomy, gallstone ileus, erosive peptic ulcer, cholangitis, emphysematous cholecystitis</td>
</tr>
<tr>
<td>Portal Venous</td>
<td>Air peripherally over liver in branching pattern</td>
<td>Bowel ischemia/infarction</td>
</tr>
</tbody>
</table>

Table 9. Adynamic Ileus vs. Mechanical Obstruction

<table>
<thead>
<tr>
<th>Feature</th>
<th>Adynamic Ileus</th>
<th>Mechanical Obstruction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calibre of Bowel Loops</td>
<td>Normal or dilated</td>
<td>Usually dilated</td>
</tr>
<tr>
<td>Air-Fluid Levels (ect and left lateral decubitus films only)</td>
<td>Same level in the same single loop</td>
<td>Multiple air fluid levels giving “step ladder” appearance, dynamic (indicating peristalsis present), “string of pearls” (row of small gas accumulations in the dilated valvulae conniventes)</td>
</tr>
<tr>
<td>Distribution of Bowel Gas</td>
<td>Air throughout GI tract is generalized or localized</td>
<td>Dilated bowel up to the point of obstruction (i.e. transition point)</td>
</tr>
<tr>
<td></td>
<td>In a localized ileus (e.g. pancreatitis, appendicitis), dilated “sentinel loop” remains in the same location on serial films, usually adjacent to the area of inflammation</td>
<td>No air distal to obstructed segment</td>
</tr>
<tr>
<td></td>
<td>“Hairpin” (180°) turns in bowel</td>
<td>‘Hairpin’ (180°) turns in bowel</td>
</tr>
</tbody>
</table>

Abdominal CT
- indications for plain CT: renal colic, hemorrhage
- indications for CT with contrast
  - IV contrast given immediately before or during CT to allow identification of arteries and veins
  - portal venous phase: indicated for majority of cases
  - biphasic (arterial and portal venous phases): liver, pancreas, bile duct tumours
  - caution: contrast allergy (may premedicate with steroids and antihistamine)
  - contraindication: impaired renal function, based on eGFR
  - oral contrast: barium or water soluble (water soluble if suspected perforation) given in most cases to demarcate GI tract
  - rectal contrast: given for investigation of colonic lesions

Approach to Abdominal Computed Tomography
- look through all images in gestalt fashion to identify any obvious abnormalities
- look at each organ/structure individually, from top to bottom evaluating size and shape of each area of increased or decreased density
- evaluate the following
  - soft tissue window
    - liver, gallbladder, spleen, and pancreas
    - adrenals, kidneys, ureters, and bladder
    - stomach, duodenum, small bowel mesentery, and colon/appendix
    - retroperitoneum: aorta, vena cava, and mesenteric vessels; look for adenopathy in vicinity of vessels
    - peritoneal cavity for fluid or masses
    - abdominal wall and adjacent soft tissue
  - lung window
    - visible lung (bases)
  - bone window
    - vertebrae, spinal cord, and bony pelvis

Colorectal Cancer: CT Colonography and Colonoscopy for Detection-Systematic Review and Meta-Analysis
Radiology 2011;259:393-405
Study: Systematic review and meta-analysis.
Population: 49 studies on 11,151 patients undergoing diagnostic study for detection of colorectal cancer (CRC).
Intervention: CT colonography (CTC) and optical colonoscopy (OC).
Main Outcome Measure: Sensitivity of CTC and OC for CRC.
Results: CTC has a sensitivity of 96.1% (95% CI 93.8%, 97.1%) and OC has a sensitivity of 94.7% (95% CI 90.4%, 97.2%) for the detection of CRC.
Conclusion: CTC is highly sensitive for the detection of CRC and may be a better modality for the initial investigation of suspected CRC, assuming reasonable specificity.
CT and Bowel Obstruction
• cause of bowel obstruction rarely found on plain films – CT is best choice for imaging
• the "3,6,9" rule is a very useful guide to determining when the bowel is dilated; the maximum diameter of the bowel is 3 cm for small bowel, 6 cm for large bowel, and 9 cm for cecum; this can also be useful to distinguish small and large bowel, and to assess for 'impending' cecal perforation (e.g. post-untreated Ogilvie's syndrome)
• closed-loop obstruction: an obstruction in two locations (usually small bowel) creating a loop of bowel segment obstructed both proximally and distally; complications (e.g. ischemia, perforation, necrosis) may occur quickly

CT Colonography (virtual colonoscopy)
• emerging imaging technique for evaluation of intraluminal colonic masses (i.e. polyps, tumours)
• two CT scans of the abdomen (prone and supine) after the instillation of carbon dioxide into a prepped colon
• computer reconstruction of 2D CT images into a 3D intraluminal view of the colon
• lesions seen on 3D images correlated with 2D axial images
• indications: surveillance in low-risk patients, incomplete colonoscopy, staging of obstructing colonic lesions

Contrast Studies
Table 10. Types of Contrast Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Organ</th>
<th>Procedure Description</th>
<th>Assessment</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cine Esophagram</td>
<td>Cervical esophagus</td>
<td>Contrast agent swallowed Recorded for later playback and analysis</td>
<td>Dysphagia, swallowing</td>
<td>Aspiration, webs (partial occlusion), Zenker’s diverticulum, cricopharyngeal bar, laryngeal tumour</td>
</tr>
<tr>
<td>Barium Swallow</td>
<td>Thoracic esophagus</td>
<td>Contrast agent swallowed under fluoroscopy, selective images captured</td>
<td>Dysphagia, rule out GERD, post esophageal surgery</td>
<td>Achalasia, hiatus hernia, esophagitis, cancer, esophageal tear</td>
</tr>
<tr>
<td>Upper GI Series</td>
<td>Thoracic esophagus, stomach, and duodenum</td>
<td>Double contrast study: 1. Barium to coat mucosa, then 2. Gas pills for distention Patient NPO after midnight</td>
<td>Dyspepsia, investigate possible upper GI bleed, weight loss/anemia, post gastric surgery</td>
<td>Ulcers, neoplasms, filling defects</td>
</tr>
<tr>
<td>Enterography &amp; Enteroctosy (MRI or CT)</td>
<td>Entire small bowel</td>
<td>Enteroctosy: patient drinks 1-2 L of sorbitol, psyllium, or barium solution to distend small bowel Enteroclysis: NJ tube used to pump barium, psyllium, or sorbitol contrast media directly into small bowel</td>
<td>IBD, malabsorption, weight loss/anemia, Meckel’s diverticulum</td>
<td>Neoplasms, IBD, malabsorption, infection</td>
</tr>
</tbody>
</table>

Specific Visceral Organ Imaging
Liver
• U/S: assessment of cysts, abscesses, tumours, biliary tree
• CT ± IV: most popular procedure for imaging the liver parenchyma (primary liver tumours, metastases, cysts, abscesses, trauma, cirrhosis)
• MR: also excellent in evaluation of primary liver tumours, liver metastases, and other parenchymal conditions, and is particularly helpful in differentiating common benign hepatic hemangiomas from primary liver tumours and metastases
• elastography: measures shear wave velocity by U/S (Fibroscan) or MRI (MR elastography) to non-invasively quantify liver fibrosis
• findings
  - advanced cirrhosis: liver small and irregular (fibrous scarring, segmental atrophy, regenerating nodules)
  - portal HTN: increased portal vein diameter, collateral veins, splenomegaly (≥12 cm), portal vein in situization of the umbilical vein
  - porto-systemic shunts: caput medusa, esophageal varices, spontaneous spleno-renal shunt
  - U/S: cirrhosis appears nodular and hyperchogenic with irregular areas of atrophy of the right lobe and hypertrophy of the caudate or left lobes
  - CT: fatty infiltration appears hypodense
  - in order to be visualized, some masses require contrast
• upon identifying a liver lesion on imaging (e.g. U/S), the follow-up imaging modality should be CT or MR. CT would be four-phase non-contrast, arterial, venous, and delayed to distinguish the common benign liver lesion hemangioma from other tumours

Liver Mass DDx
5 Hs
HCC
Hydatid cyst
Hemangioma
Hepatic adenoma
Hyperplasia (focal nodular)
**Table 11. Imaging of Liver Masses**

<table>
<thead>
<tr>
<th>Mass</th>
<th>U/S</th>
<th>CT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metastases</td>
<td>Multiple masses of variable echotexture</td>
<td>Usually low attenuation on contrast enhanced scan</td>
</tr>
<tr>
<td>HCC</td>
<td>Single/multiple masses, or diffuse infiltration</td>
<td>Hypervascular enhances in arterial and washes out in venous phase with portal venous tumour thrombus</td>
</tr>
<tr>
<td>Abscess</td>
<td>Poorly defined, irregular margin, hypoechoic contents</td>
<td>Low-attenuation lesion with an irregular enhancing wall</td>
</tr>
<tr>
<td>Hydatid Cyst</td>
<td>Simple/multiloculated cyst</td>
<td>Low-attenuation simple or multiloculated cyst; calcification</td>
</tr>
<tr>
<td>Hemangioma</td>
<td>Homogeneous hyperechoic mass</td>
<td>Peripheral globular enhancement in arterial phase scans; central-filling and persistent enhancement on delayed scans</td>
</tr>
<tr>
<td>Focal Nodular Hyperplasia</td>
<td>Well-defined mass, central scar seen in 50%</td>
<td>Hypervascular mass in arterial phase and isoa attenuation to liver in portal venous phase</td>
</tr>
<tr>
<td>Hepatic Adenoma</td>
<td>Most common in young women taking oral contraceptives. Well-defined mass with hyperechoic areas due to hemorrhage</td>
<td>Well-defined hypervascular lesion with enlarged central vessel becoming slightly isoattenuating in venous phase</td>
</tr>
</tbody>
</table>

**Spleen**
- U/S, CT, nuclear medicine scan (nuclear medicine only to distinguish ectopic splenic tissue from enhancing tumours)
- CT for splenic trauma (hemorrhage)

**Pancreas**
- tumours
  - U/S: mass is more echogenic than normal pancreatic tissue
  - CT: preferred modality for diagnosis/staging
- ductal dilatation secondary to stone/tumour
- MRCP: imaging of ductal system using MRI cholangiography; no therapeutic potential
- ERCP: endoscope to inject dye into the biliary tree and x-ray imaging to assess pancreatic and biliary ducts; therapeutic potential (stent placement, stone retrieval); acute pancreatitis is a complication in 5% of diagnostic procedures and 10% of therapeutic procedures

**Biliary Tree**
- U/S: bile ducts usually visualized only if dilated, secondary to obstruction (e.g. choledocholithiasis, benign stricture, mass)
- CT: dilated intrahepatic ductules seen as branching, tubular structures following pathway of portal venous system
- MRCP, ERCP, PTC: further evaluation of obstruction and possible intervention

**“itis” Imaging**

**Acute Cholecystitis**
- pathogenesis: inflammation of gallbladder resulting from sustained gallstone impaction in cystic duct or, in the case of acalculous cholecystitis, due to gallbladder ischemia or cholestasis (see General Surgery, GS47)
- best imaging modality: U/S (best sensitivity and specificity); nuclear medicine (HIDA scan) can help diagnose cases of acalculous or chronic cholecystitis
- findings: thick wall, pericholecystic fluid, gallstones, dilated gallbladder, positive sonographic Murphy’s sign
- management: cholecystectomy

**Acute Appendicitis**
- pathogenesis: luminal obstruction → bacterial overgrowth → inflammation/swelling → increased pressure → localized ischemia → gangrene/perforation → localized abscess or peritonitis (see General Surgery, GS27)
- best imaging modality: U/S or CT
- findings
  - U/S: thick-walled appendix, appendicolith, dilated fluid-filled appendix, non-compressible; may also demonstrate other causes of RLQ pain (e.g. ovarian abscess, IBD, ectopic pregnancy)
  - CT: enlargement of appendix (>6 mm in outer diameter), enhancement of appendiceal wall, adjacent inflammatory stranding, appendicolith; also facilitates percutaneous abscess drainage
- management: appendectomy

---

**Revised Estimates of Diagnostic Test Sensitivity and Specificity in Suspected Biliary Tract Disease**

*Arch Intern Med 1998;154:2573-2581*

**Purpose:** To assess the sensitivity and specificity of tests used to diagnose cholelithiasis and acute cholecystitis, including ultrasonography, oral cholecystography, radionuclide scanning with Technetium, MRI, CT.

**Study Characteristics:** Meta-analysis of 30 studies evaluating the use of different imaging modalities in the diagnosis of biliary tract disease.

**Participants:** No limits.

**Main Outcomes:** Sensitivity and specificity of the different imaging modalities, using the gold standard of surgery, autopsy, or 3 mo clinical follow-up for cholecystitis. For acute cholecystitis, pathologic findings, confirmation of an alternate disease, or clinical resolution during hospitalization for cholecystitis were used as the standard.

**Results:** For evaluating cholelithiasis, U/S had the best unadjusted sensitivity (0.87; 95% CI 0.85-0.89) and specificity (0.95; 95% CI 0.88-1.00) and adjusted (for verification bias) sensitivity (0.84; 95% CI 0.76-0.92) and specificity (0.99; 95% CI 0.97-1.00). For evaluating acute cholecystitis, radionuclide scanning has the best sensitivity (0.97; 95% CI 0.90-0.99) and specificity (0.90; 95% CI 0.86-0.95).

**Conclusions:** U/S is the test of choice for diagnosing cholelithiasis and radionuclide scanning is the superior test for diagnosing acute cholecystitis.
Acute Diverticulitis
- pathogenesis: erosion of the intestinal wall (most commonly rectosigmoid) by increased intraluminal pressure or inspissated food particles → inflammation and focal necrosis → micro- or macroscopic perforation (see General Surgery, GS31)
- best imaging modality: CT is modality of choice, although U/S is sometimes used
- contrast: oral and rectal contrast given before CT to opacify bowel
- findings:
  - cardinal signs: thickened wall, mesenteric infiltration, gas-filled diverticula, abscess
  - CT can be used for percutaneous abscess drainage before or in lieu of surgical intervention
  - sometimes difficult to distinguish from perforated cancer (therefore send abscess fluid for cytology and follow up with colonoscopy)
  - if chronic, may see fistula (most common to bladder) or sinus tract (linear or branching structures)
- management: ranges from antibiotic treatment to surgical intervention; can use imaging to follow progression

Acute Pancreatitis
- pathogenesis: activation of proteolytic enzymes within pancreatic cells leading to local and systemic inflammatory response (see Gastroenterology, G44); a clinical/biochemical diagnosis
- best imaging modality: imaging used to support diagnosis and evaluate for complications (diagnosis cannot be excluded by imaging alone)
  - U/S good for screening and follow-up
  - CT is useful in advanced stages and in assessing for complications (1st line imaging test)
- findings:
  - U/S: hypoechoic enlarged pancreas (if ileus present, gas obscures pancreas)
  - CT: enlarged pancreas, edema, stranding changes in surrounding fat with indistinct fat planes, mesenteric and Gerota’s fascia thickening; pseudocyst in lesser sac, abscess (gas or thick-walled fluid collection), pancreatic necrosis (low attenuation gas-containing non-enhancing pancreatic tissue), hemorrhage
- management: supportive therapy
  - CT-guided needle aspiration and/or drainage done for abscess when clinically indicated
  - pseudocyst may be followed by CT and drained if symptomatic

Chronic Pancreatitis
- pathogenesis: (see Gastroenterology, G45)
- best imaging modality: MRCP (can show calcification and duct obstruction)
- findings: U/S, CT scan, and MRI may show calcifications, ductal dilatation, enlargement of the pancreas and fluid collections (e.g. pseudocysts) adjacent to the gland

Angiography of Gastrointestinal Tract
- anatomy of the GI tract arterial blood supply branches
  - celiac artery: hepatic, splenic, gastroduodenal, left/right gastric
  - superior mesenteric artery: jejunal, ileal, ileo-colic, right colic, middle colic
  - inferior mesenteric artery: left colic, superior rectal
- imaging modalities
  - conventional angiogram: invasive (usual approach via femoral puncture), catheter used
    - flush arteriography: catheter injection into abdominal aorta, followed by selective arteriography of individual vessels
  - CT angiogram: modality of choice, non-invasive using IV contrast (no catheterization required)

Genitourinary System and Adrenal

Urological Imaging

KUB (Kidney, Ureter, and Bladder X-ray)
- a frontal supine radiograph of the abdomen
- indication: useful in evaluation of radio-opaque renal stones (all stones but uric acid and indinavir), indwelling ureteric stents/catheters, and foreign bodies in abdomen
- findings: addition of IV contrast excreted by the kidney (intravenous urogram) allows greater visualization of the urinary tract, but has been largely replaced by CT urography

Abdominal CT

Renal Masses
- Bozniak classification for cystic renal masses
  - class I-II: benign and can be disregarded
  - class IIIC: should be followed
  - class III-IV: suspicious for malignancy, requiring additional workup
Table 12. Bozniak Classification for Cystic Renal Masses

<table>
<thead>
<tr>
<th>Classes</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simple Renal Cysts</td>
<td></td>
</tr>
<tr>
<td>Class I</td>
<td>Fluid-attenuating well-defined lesion, no septation, no calcification, no solid components, hair thin wall</td>
</tr>
<tr>
<td>Class II</td>
<td>Same as class I + fine calcification or moderately thickened calcification in septae or walls; also includes hyperdense cysts (&lt;3 cm) that do not enhance with contrast</td>
</tr>
<tr>
<td>Complex Renal Cysts</td>
<td></td>
</tr>
<tr>
<td>Class III</td>
<td>Thick irregular walls ± calcifications ± septated, enhancing walls or septa with contrast</td>
</tr>
<tr>
<td>Renal Cell Carcinoma</td>
<td></td>
</tr>
<tr>
<td>Class IV</td>
<td>Same as class III + soft tissue enhancement with contrast (defined as &gt; 10 Hounsfield unit increase, characterizing vascularity) with de-enhancement in venous phase ± areas of necrosis</td>
</tr>
</tbody>
</table>

- **plain CT KUB indications**: general imaging of renal anatomy, renal colic symptoms, assessment of renal calculi (size and location), and hydronephrosis prior to urological treatment
- **CT urography indications**: investigation of cause of microscopic/gross hematuria, detailed assessment of urinary tracts (excretory phase), high sensitivity (95%) for uroepithelial malignancies of the upper urinary tracts, assessment of renal calculi
  - **phases**: unenhanced, excretory
  - **renal triphasic CT indications**: standard imaging for renal masses, allows accurate assessment of renal arteries and veins, better characterization of suspicious renal masses, especially in differentiating renal cell carcinoma from more benign masses, and pre-operative staging
    - **phases**: unenhanced, arterial and venous (nephrographic), excretory

**Ultrasound**
- **indications**: initial study for evaluation of kidney size and nature of renal masses (solid vs. cystic renal masses vs. complicated cysts); technique of choice for screening patients with suspected hydronephrosis (no IV contrast injection, no radiation to patient, and can be used in patients with renal failure); TRUS useful to evaluate prostate gland and guide biopsies; Doppler U/S to assess renal vasculature
- **findings**: solid renal masses are echogenic (bright on U/S), cystic renal masses have smooth well-defined walls with anechoic interior (dark on U/S), and complicated cysts have internal echoes within a thickened, irregular wall

**Retrograde Pyelography**
- **indications**: visualize the urinary collecting system via a cystoscope, ureteral catheterization, and retrograde injection of contrast medium, visualized by radiograph or fluoroscopy; ordered when the intrarenal collecting system and ureters cannot be opacified using intravenous techniques (patient with impaired renal function, high grade obstruction)
- **findings**: only yields information about the collecting systems (renal pelvis and associated structures), no information regarding the parenchyma of the kidney

**Voiding Cystourethrogram**
- **indications**: children with recurrent UTIs, hydronephrosis, hydroureter, suspected lower urinary tract obstruction or vesicoureteral reflux
- **findings**: contractility and evidence of vesicoureteric reflux

**Retrograde Urethrogram**
- **indications**: a small Foley catheter placed into penile urethral opening
- **indications**: used mainly to study strictures or trauma to the male urethra; first-line study if trauma with blood present at urethral meatus

**MRI**
- **advantages**: high spatial and tissue resolution, lack of exposure to ionizing radiation and nephrotoxic contrast agents
- **indications**: indicated over CT for depiction of renal masses in patients with previous nephon sparing surgery, patients requiring serial follow-up (less radiation dosage), patients with reduced renal function, patients with solitary kidneys, clinical staging of prostate cancer (endorectal coil MRI)

**Renal Nuclear Scan**

Table 13. Renal Scan Tests

<table>
<thead>
<tr>
<th>Type of Test</th>
<th>Uses</th>
<th>Radionuclide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renogram</td>
<td>assess renal function and collecting system: evaluation of renal failure, workup of urinary tract obstruction and renovascular HTN, investigation of renal transplant</td>
<td>IV 99mTc-pentetate (DTPA) or meriatriate (MAG3), and imaged at 1-3 s intervals with a gamma camera over the first 60 s to assess perfusion</td>
</tr>
<tr>
<td>Morphological</td>
<td>Assess renal anatomy: investigation of pyelonephritis and cortical scars</td>
<td>99mTc-DMSA 99mTc-glucolheptonate</td>
</tr>
</tbody>
</table>
Gynecological Imaging

Ultrasound
- transabdominal and transvaginal are the primary modalities, and are indicated for different scenarios
  - indications: good initial investigation for suspected pelvic pathology
  - TVUS provides enhanced detail of deeper/smaller structures by allowing use of higher frequency sound waves at reduced distances
  - indications: improved assessment of ovaries, first trimester development, and ectopic pregnancies

Hysterosalpingogram
- performed by x-ray images of the pelvis after cannulation of the cervix and subsequent injection of opacifying agent
- indications: useful for assessing pathology of the uterine cavity and fallopian tubes, evaluating uterine abnormalities (e.g. bicorneate uterus), or evaluation of fertility (absence of flow from tubes to peritoneal cavity indicates obstruction)

CT/MRI
- indications: evaluating pelvic structures, especially those adjacent to the adnexa and uterus
- invaluable for staging gynecological malignancies and detecting recurrence

Sonohysterogram
- saline infusion sonohysterogram involves instilling fluid into the uterine cavity transcervically to provide enhanced endometrial visualization during TVUS examination
- indications: abnormal uterine bleeding, uterine cavity abnormalities that are suspected or noted on TVUS (e.g. leiomyomas, polyps, synechiae), congenital abnormalities of the uterine cavity, infertility, recurrent pregnancy loss
- contraindications: pregnancy, pelvic infection

Table 14. Typical and Atypical Findings on a Sonohysterogram

<table>
<thead>
<tr>
<th>Finding</th>
<th>Typical</th>
<th>Atypical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyps</td>
<td>A well-defined, homogenous, polypoid lesion</td>
<td>Atypical features include cystic components,</td>
</tr>
<tr>
<td></td>
<td>to the endometrium with preservation of the</td>
<td>multiple polyps, broad base, hypoechogenicity</td>
</tr>
<tr>
<td></td>
<td>endometrial-myometral interface</td>
<td>or heterogeneity</td>
</tr>
<tr>
<td>Leiomyma</td>
<td>Well-defined, broad-based, hypoechoic, solid</td>
<td>Penetration or multilobulated surface</td>
</tr>
<tr>
<td></td>
<td>masses with shadowing. Overlying layer of endometrium is echogenic and distorts the endometrial-myometral interface</td>
<td></td>
</tr>
<tr>
<td>Hyperplasia and Cancer</td>
<td>Diffuse echogenic endometrial thickening without focal abnormality, although focal lesions can occur. Endometrial cancer is typically a diffuse process, but early cases can be focal and appear as a polypoid mass</td>
<td></td>
</tr>
<tr>
<td>Adhesions</td>
<td>Mobile, thin, echogenic bands that cut across the endometrial cavity</td>
<td>Thick, broad-based bands that can completely obliterate the endometrial cavity, as in Asherman’s syndrome</td>
</tr>
</tbody>
</table>

Adrenal Mass

- imaging modality: most often identified on CT scan as ‘incidentaloma’, can also use CT/MRI to distinguish benign from malignant masses

Table 15. Adrenal Mass Findings on CT and MRI

<table>
<thead>
<tr>
<th>Factors</th>
<th>Adrenocortical Adenoma</th>
<th>Adrenocortical Carcinoma</th>
<th>Pheochromocytoma</th>
<th>Metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diameter (CT)</td>
<td>Usually ≤3 cm</td>
<td>Usually ≥4 cm</td>
<td>Usually &gt;3 cm</td>
<td>Variable around &lt;3 cm</td>
</tr>
<tr>
<td>Shape (CT)</td>
<td>Smooth margins and round/oval</td>
<td>Irregular with unclear margins</td>
<td>Round/oval with clear margins</td>
<td>Oval/irregular with unclear margins</td>
</tr>
<tr>
<td>Texture (CT)</td>
<td>Homogeneous</td>
<td>Heterogeneous with mixed densities</td>
<td>Heterogeneous with cystic areas</td>
<td>Heterogeneous with mixed densities</td>
</tr>
<tr>
<td>Vascularity (CT)</td>
<td>Not highly vascular</td>
<td>Usually vascular</td>
<td>Usually vascular</td>
<td>Usually vascular</td>
</tr>
<tr>
<td>Washout of Contrast Medium on CT</td>
<td>≥50% at 10 min</td>
<td>&lt;50% at 10 min</td>
<td>&lt;50% at 10 min</td>
<td>&lt;50% at 10 min</td>
</tr>
<tr>
<td>Growth</td>
<td>Stable or very slow (&lt;1 cm/yr)</td>
<td>Usually rapid (&gt;2 cm/yr)</td>
<td>Slow (0.5-1 cm/yr)</td>
<td>Variable</td>
</tr>
<tr>
<td>Other Findings</td>
<td>Usually low density due to intracellular fat</td>
<td>Necrosis, calcifications, and hemorrhage</td>
<td>Hemorrhage</td>
<td>Occasionally hemorrhage</td>
</tr>
<tr>
<td>MRI on T2 Weighted Imaging</td>
<td>Isointense in relation to liver</td>
<td>Hyperintense in relation to liver</td>
<td>Markedly hyperintense in relation to liver</td>
<td>Hyperintense in relation to liver</td>
</tr>
</tbody>
</table>

Modality Based on Neuropathology

Presentation
- Cognitive decline = CT
- Cord compression = MRI
- Decreased level of consciousness = CT
- Fish bone/other swallowed foreign body = CT
- Low back pain, radiculopathy = MRI
- Multiple sclerosis = MRI
- Neck infection = CT
- Orbital infection = CT
- Rule out bleed = CT
- Rule out aneurysm = CTA, MRA
- Seizure = CT
- Sinusitis = CT
- Stroke = CT, MRI
- Trauma = CT
- Weakness, systemically unwell = CT
Neuroradiology

Modalities

- CT is the modality of choice for most neuropathology; even under circumstances when MRI is preferred, CT is frequently the initial study performed because of its speed, availability, and lower cost
  - acute head trauma: CT is best for visualizing “bone and blood”; MRI is used only when CT fails to detect an abnormality despite strong clinical suspicion
  - acute stroke: MRI ideal, CT most frequently used
  - suspected subarachnoid or intracranial hemorrhage
  - meningitis: rule out mass effect (e.g. cerebral herniation, shift) prior to lumbar puncture
  - tinnitus and vertigo: CT and MRI are used in combination to detect bony abnormalities and CN VIII tumours, respectively

Skull Films

- rarely performed, generally not indicated for non-penetrating head trauma
  - indications: screening for destructive bony lesions (e.g. metastases), metabolic disease, skull anomalies, post-operative changes and confirmation of hardware placement, skeletal surveys, multiple myeloma

CT

- indications: excellent study for evaluation of bony and intracranial abnormalities
  - often done first without and then with IV contrast to show vascular structures or anomalies
  - vascular structures and areas of blood-brain barrier impairment are opaque (e.g. hyperattenuating or white/show enhancement) with contrast injection
    - when in doubt, look for circle of Willis or confluence of sinuses to determine presence of contrast enhancement
  - posterior fossa can be obscured by extensive bony-related streak artifact
  - rule out skull fracture, epidural hematoma (lenticular shape), subdural hematoma (crescentic shape), subarachnoid hemorrhage, space occupying lesion, hydrocephalus, and cerebral edema
  - multiplanar imaging can be performed with newer generation of multidetector CT scanners

Myelography

- introduction of water-soluble, low-osmotic contrast media into subarachnoid space using lumbar puncture followed by x-ray or CT scan
  - indications: excellent study for disc herniations, traumatic nerve root avulsions, patients with contraindication to MRI

MRI

- indications: shows brain and spinal soft tissue anatomy in fine detail, clearly distinguishes white from grey matter (especially T1-weighted series), multiplanar reconstruction helpful in pre-operative assessment

Cerebral Angiography/CT Angiography/MR Angiography

- indications: evaluation of vascular lesions such as atherosclerotic disease, aneurysms, vascular malformations, arterial dissection
  - conventional DSA remains the gold standard for the assessment of neck and intracranial vessels; however, it is an invasive procedure requiring arterial (femoral) puncture; catheter manipulation has risk of vessel injury (e.g. dissection, occlusion, vasospasm, emboli)
  - MRA methods (phase contrast, time of flight, gadolinium-enhanced) and CTA are much less invasive without actual risk to intracranial or neck vessels
  - MRA and CTA are often used first as ‘screening tests’ for the assessment of subarachnoid hemorrhage, vasospasm, aneurysms

[Images of medical images related to neuroradiology: Figure 25. Epidural hematoma, Figure 26. Subdural hematoma, Figure 27. Subarachnoid hemorrhage, Figure 28. Intraparenchymal hemorrhage, Figure 29. Hydrocephalus: ventricular dilatation (may see periventricular low attenuation due to transependymal CSF flow)]
Table 16. Two Types of Hydrocephalus

<table>
<thead>
<tr>
<th>Type</th>
<th>Cause</th>
</tr>
</thead>
<tbody>
<tr>
<td>Communicating/Extra-Ventricular</td>
<td>Obstruction distal to the ventricles (e.g. at the level of the arachnoid granulations); imaging shows all ventricles dilated</td>
</tr>
<tr>
<td>Non-Communicating</td>
<td>Obstruction within the ventricular system (e.g. mass obstructing the aqueduct or foramen of Monro); imaging shows dilatation of ventricles proximal to the obstruction</td>
</tr>
</tbody>
</table>

Nuclear Medicine
- SPECT using $^{99m}$Tc-exametazime (HMPAO) and $^{99m}$Tc-bisicat (ECD) imaging assesses cerebral blood flow by diffusing rapidly across the blood brain barrier and becoming trapped within neurons proportional to cerebral blood flow
- 18FDG PET imaging assesses cerebral metabolic activity
- **indications:** differentiation of residual tumour vs. radiation necrosis; localizing of epileptic seizure foci; evaluation of atypical dementia

**Approach to CT Head**
- think anatomically, work from superficial to deep
- scan: confirm that the imaging is of the correct patient, whether contrast was used, if the patient is aligned properly, if there is artifact present
- skin/soft tissue: examine the soft tissue superficial to the skull, looking for thickening suggestive of hematoma or edema; also evaluate the ear, orbital contents (globe, fat, muscles), parotid, muscles of mastication (masseter, temporalis, pterygoids), visualized parotid, muscles of mastication (masseter, temporalis, pterygoids), visualized pharynx
- bone and airspace (use the bone window): check calvarium, visualize mandible, visualize C-spine (usually C1 and maybe part of C2) for fractures, absent bone, lytic/sclerotic lesions; inspect sinuses and mastoid air cells for opacity that may suggest fluid, pus, blood, tumour, or fracture; status of the orbital floor in cases of facial trauma (coronal series best)
- dura and subdural space: crescent-shaped hyperdensity in the subdural space suggests subdural hematoma; lentiform hyperdensity in the epidural space suggests epidural hematoma; check symmetry of dural thickness, where increased thickness may suggest the presence of blood
- parenchyma: asymmetry of the parenchyma suggests midline shift; poor contrast between grey and white matter suggests possible infarction, tumour, edema, infection, or contusion; hyperdensity in the parenchyma suggests enhancing lesions, intracerebral hemorrhage, or calcification; central grey matter nuclei (e.g. globus pallidus, putamen, internal capsule) should be visible, otherwise, suspect infarct, tumour, or infection
- ventricles/sulci/cisterns: examine position of ventricles for evidence of midline compression/shift; hyperdensities in the ventricles suggest ventricular/subdural hemorrhage; enlarged ventricles suggest hydrocephalus; obliteration of sulci may suggest presence of edema causing effacement, possible blood filling in the sulci, or tumour; cistern hyperdensities may suggest blood, pus, or tumour
- please refer to Toronto Notes’ website for supplementary material on how to approach a head CT

**Selected Pathology**
- see Neurosurgery, NS4 for intracranial mass lesions
- see Neurosurgery, NS29 and Plastic Surgery, PL29 for head trauma
- see Emergency Medicine, EM7 for vertebral trauma
- see Neurosurgery, NS27 and Orthopedics, OR22 for degenerative spinal abnormalities

**Cerebrovascular Disease** (see Neurology, N26 and Neurosurgery, NS17)
- pathogenesis of stroke: see Neurology, N48
- best imaging modality: infarcts best detected by MRI > CT
- findings of infarction
  - early changes
    - CT
      - usually normal within 6 h of infarction
      - edema (loss of grey-white matter differentiation – “insular ribbon” sign, effacement of sulci, mass effect)
      - within 24 h, development of low-density, wedge-shaped area of infarction extending to periphery (correlating to vascular territory distal to affected artery)
      - in case of ischemic stroke, may see hyperattenuating (bright) artery (hyperdense MCA sign) representing intravascular thrombus or embolus
      - in case of hemorrhagic stroke or transformation (common in basal ganglia and cortex), may see bright acute blood surrounded by edema
MRI
- edema with high signal on T2-weighted images and FLAIR image (loss of grey-white matter differentiation, effacement of sulci, mass effect)
- DWI shows acute high signal changes demonstrating restricted movement of water indicative of cytotoxic edema; usually indicates stroke damage before CT
- apparent diffusion coefficient image shows low signal intensity in acute ischemia (nadir 3-5 d, returns to baseline 1-4 wk)
- subacute changes on CT and MRI
- edema and mass effect more prominent
- gyral enhancement with contrast indicative of blood-brain barrier breakdown
- chronic changes on CT and MRI
- encephalomalacia (parenchymal volume loss) with dilatation of adjacent ventricles
- carotid artery disease
- best imaging modality: Duplex Doppler U/S
- other modalities: MRA or CTA if carotid angioplasty or endarterectomy is under consideration (conventional angiography reserved for inadequate MRA or CTA)

Multiple Sclerosis (see Neurology, N52)
- best imaging modality: MRI has high sensitivity in diagnosing MS (>90%) but low specificity (71-74%)
- findings
  - characteristic lesion on MRI is cerebral or spinal plaque
  - plaques typically found in periventricular region, corpus callosum (arranged at right angles to the corpus callosum), centrum semiavale, and to a lesser extent in deep white matter structures and basal ganglia
  - “Dawson’s fingers” refers to perivenular regions of demyelination that are seen to radiate outwards into the deep periventricular region
  - plaques usually have ovoid appearance, hyperintense on T2 and hypointense on T1
  - conventional T2 may underestimate plaque size and overall plaque burden – advanced techniques (diffusion tensor imaging and MR spectroscopy) can be of use
  - perivascular and interstitial edema may be prominent
  - spinal cord lesions typical of MS
    - little or no cord swelling
    - unequivocal hyperintensity on T2-weighted sequences
    - size at least 3 mm but less than 2 vertebral segments in length
    - occupy only part of the cord in cross-section
    - focal (i.e. clearly delineated and circumscribed on T2-weighted sequences)

CNS Infections
- leptomeningitis
  - pathogenesis: inflammation of the pia or arachnoid mater, most often secondary to hematogenous spread from infection or via organisms gaining access across areas not protected by the blood-brain barrier (choroid plexus or circumventricular organs)
  - pathogens include: S. pneumoniae, H. influenzae, N. meningitidis, L. monocytogenes
  - best imaging modality: MRI (T2-weighted/FLAIR) superior to CT
  - findings
    - meningeal enhancement (following the gyri/sulci, and/or basal cisterns), hydrocephalus (communicating), cerebral swelling, subdural effusion
    - a normal MRI does not rule out leptomeningitis
- herpes simplex encephalitis (see Infectious Diseases, ID19)
  - pathogenesis: inflammation of the brain parenchyma secondary to infection with herpes simplex virus, asymmetrically affects the limbic regions of the brain (i.e. temporal lobes, orbitofrontal region, insula, and cingulate gyrus)
  - best imaging modality: MRI (T1- and T2-weighted)
  - findings
    - acute (within 4-5 d): asymmetric high intensity lesions on T2 MRI in temporal and inferior frontal lobes strongly suggestive
    - DDx: infarct, tumour, status epilepticus, limbic encephalitis
    - CT may show low density in temporal lobe and insula; rarely basal ganglia involvement
    - long-term may show parenchymal loss to affected areas
- cerebritis/cerebral abscess
  - pathogenesis: an infection of the brain parenchyma (cerebritis) which can progress to a collection of pus (abscess), most frequently due to hematogenous spread of infectious organisms, commonly located in the distribution of the MCA
  - pathogens include: S. aureus (often in IV drug users, nosocomial), Streptococcus, Gram negative bacteria, Bacteroides
  - best imaging modality: MRI including DWI imaging series (abscess will be DWI positive); CT still used as a viable alternative
  - findings according to one of four stages of abscess formation
    - early cerebritis (1-3 d): inflammatory infiltrate with necrotic centre, low intensity on T1, high intensity on T2
    - late cerebritis (4-9 d): ring enhancement may be present
    - early capsule (10-13 d): ring enhancement
    - late capsule (14 d or greater): well demarcated ring-enhancing lesion, low intensity core, with mass effect; considerable edema around the lesion, seen as hyperintensity on T2

Figure 32. CT images of early infarct: (A) absence of left insular ribbon (B) hyperdense artery
Figure 33. DWI of patient with right frontotemporal infarct
Figure 34. T2-weighted FLAIR: (A) sagittal (B) axial images of multiple sclerosis with periventricular “Dawson’s Fingers”
Figure 35. T2-weighted (FLAIR) coronal image of herpes simplex virus encephalitis affecting temporal lobes
Musculoskeletal System

Modalities

- refer to MI2 for advantages and disadvantages of the following imaging modalities

Plain Film/X-Ray
- usually initial study used in evaluation of bone and joint disorders
- indications: fractures and dislocations, arthritis, assessment of malalignment, orthopedic hardware, and bone tumours (initial)
- minimum of two films orthogonal to each other (usually AP and lateral) to rule out a fracture
- image proximal and distal joints (particularly important with paired bones (e.g. radius/ulna)
- minimally effective in evaluating soft tissue injury

CT
- evaluation of fine bony detail
- indications: assessment of complex, comminuted, intra-articular or occult fractures including distal radius, scaphoid, skull, spine, acetabulum, calcaneus, and sacrum
- evaluation of soft tissue calcification/ossification

MRI
- indications: evaluation of internal derangement of joints (e.g. ligaments, joint capsule, menisci, labrum, cartilage), assessment of tendons and muscle injuries, characterization and staging of soft tissue and bony masses

Ultrasound
- indications: tendon injury (e.g. rotator cuff, Achilles tendon), detection of soft tissue masses and to determine whether cystic or solid, detection of foreign bodies, U/S guided biopsy and injections
- Doppler determines vascularity of structures

Nuclear Medicine (Bone Scintigraphy)
- determine the location and extent of bony lesions
- ⁹⁹ᵐTc-methylene diphosphonate localizes to areas of increased bone turnover or calcification – growth plate in children, tumours, infections, fractures, metabolic bone disease (e.g. Paget's), sites of reactive bone formation, and periostitis
- advantages: very sensitive, capable of imaging entire body with relatively low dose radiation
- disadvantages: low specificity, not widely available due to special requirements (e.g. gamma camera, radiopharmaceuticals)

Approach to Bone X-Rays

- identification: name, MRN, age of patient, type of study, region of investigation
- soft tissues: swelling, calcification/ossification
- joints: alignment, joint space, presence of effusion, osteophytes, erosions, bone density, overall pattern, and symmetry of affected joint
- bone: periosteum, cortex, medulla, trabeculae, density, articular surfaces, bone destruction, bone production, appearance of the edges or borders of any lesions

Trauma

Fracture/Dislocation
- description of fractures
- site of fracture (bone, region of bone, intra-articular vs. extra-articular)
- pattern of fracture line (simple vs. comminuted)
- displacement (distal fragment with reference to the proximal fragment)
- soft tissue involvement (calcification, gas, foreign bodies)
- type of fracture (stress vs. pathologic)
- for specific fracture descriptions and characteristics of fractures, see Orthopedics, OR4

Arthritis

Radiographic Hallmarks of Osteoarthritis
- joint space narrowing – typically non-uniform
- subchondral sclerosis
- subchondral cyst formation
- osteophytes

Radiographic Hallmarks of Rheumatoid Arthritis
- joint space narrowing – typically uniform
- soft tissue swelling
- erosions
- periarticular osteopenia

Figure 36. X-ray of first carpometacarpal joint: normal image (left) and osteoarthritis (right) with joint space narrowing and subchondral sclerosis

Figure 37. Rheumatoid arthritis (A) compared with osteoarthritis (B) changes on X-ray
Bone Tumour

Approach
- metastatic tumours to bone are much more common than primary bone tumours, particularly if age >40 yr
  - diagnosis usually requires a biopsy if primary not located
  - few benign tumours/lesions have potential for malignant transformation
  - MRI is good for tissue delineation and pre-operative assessment of surrounding soft tissues, neurovascular structures, and medullary/marrow involvement
  - plain film is less sensitive than other modalities but useful for assessing aggressiveness and constructing differential diagnosis

Considerations and Tumour Characteristics
- for specific bone tumours, see Orthopedics, OR45
- age – most common tumours by age group
  - <1 yr of age: metastatic neuroblastoma
  - 1-20 yr of age: Ewing's sarcoma in tubular bones
  - 10-30 yr of age: osteosarcoma and Ewing's tumour in flat bones
  - >40 yr of age: metastases, multiple myeloma, and chondrosarcoma
- multiplicity: metastases, myeloma, lymphoma, fibrous dysplasia, enchondromatosis
- location within bone
epiphysis: giant cell tumour, chondroblastoma, geode, eosinophilic granuloma, infection
metaphysis: simple bone cyst, aneurysmal bone cyst, enchondroma, chondromyxoid fibroma, nonossifying fibroma, osteosarcoma, chondrosarcoma
diaphysis: fibrous dysplasia, aneurysmal bone cyst, brown tumours, eosinophilic granuloma, Ewing's sarcoma
- expansile
  - aneurysmal bone cyst, giant cell tumour, enchondromas, brown tumours, metastases (especially renal and thyroid), plasmacytoma
- matrix mineralization
  - chondroid (popcorn calcification) or osseous
- margin/zone of transition: area between lesion and normal bone
cortex: intact, disturbed
- periosteal reaction: onion-skinning, sunburst, Codman's triangle, peristeal neocortex
- soft tissue mass

<table>
<thead>
<tr>
<th>Margination of lesions</th>
<th>Patterns of cortical disturbance</th>
<th>Patterns of medullary destruction</th>
<th>Periosteal new bone formation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Punched out</td>
<td>Expansile</td>
<td>Permeative</td>
<td>Onion-skin layered</td>
</tr>
<tr>
<td>Thin rim of sclerosis</td>
<td>Endosteal scalloping</td>
<td>Saucerization</td>
<td>Codman's Triangle</td>
</tr>
<tr>
<td>Thick rim of sclerosis</td>
<td>Invisible margin</td>
<td>Moth-eaten</td>
<td>Hair-on-end spiculated</td>
</tr>
<tr>
<td></td>
<td>Saucerization</td>
<td></td>
<td>Sunburst divergent</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Solid undulating</td>
</tr>
</tbody>
</table>

Figure 38. Radiographic appearance of bone remodelling and destruction processes

Table 17. Characteristics of Benign and Malignant Bone Lesions

<table>
<thead>
<tr>
<th>Benign</th>
<th>Malignant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thin sclerotic/sharp delineation of lesion</td>
<td>Poor delineation of lesion – wide zone of transition</td>
</tr>
<tr>
<td>Overlying cortex intact</td>
<td>Loss of overlying cortex/bony destruction</td>
</tr>
<tr>
<td>No or simple periosteal reaction</td>
<td>Periosteal reaction</td>
</tr>
<tr>
<td>No soft tissue mass</td>
<td>Soft tissue mass</td>
</tr>
</tbody>
</table>

Metastatic Bone Tumours
- all malignancies have potential to metastasize to bone
- metastases are 20-30x more common than primary bone tumours
- metastasis can cause a lytic or a sclerotic reaction when seeding to bone
- when a primary malignancy is first detected, a bone scan is often part of the initial workup
- may present with pathological fractures or pain
- biopsy or determination of primary is the only way to confirm the diagnosis
- most common metastatic bone tumours: breast, prostate, lung, see Orthopedics, OR45
### Infection

**Osteomyelitis**
- MRI is the imaging modality of choice for demonstrating bone, bone marrow, and soft tissue abnormalities.
- Plain film changes visible 8–10 days after process has begun:
  - Soft tissue swelling
  - Local periosteal reaction
  - Pockets of air (from anaerobes) may be seen in the tissues, may also suggest necrotizing fasciitis
  - Mottled and nonhomogeneous with a classic “moth-eaten” appearance
  - Cortical destruction

**Bone Abscess**
- Overlying cortex has periosteal new bone formation
- Sharply outlined radiolucent area with variable thickness in zone of transition
- Variable thickness periosteal sclerosis
- Sequestrum: a piece of dead bone within a Brodie’s abscess
- A sinus tract or cloaca may communicate between the abscess through the cortex to the surface of the bone
- Best modality: MRI for bone, bone marrow, and soft tissue abnormalities; CT for sequestra and cortical erosions

### Metabolic Bone Disease

**Osteoporosis**
- Reduction in amount of normal bone mass; fewer and thinner trabeculae; diffuse process affecting all bones
- DEXA: gold standard for measuring bone mineral density
  - T-score: the number of standard deviations from the young adult mean, most clinically valuable
    - Osteopenia: $-2.5 < T$-score $< -1$
    - Osteoporosis: $T$-score $\leq -2.5$
  - Z-score: the number of standard deviations from the age-matched mean
  - Risk of fracture: related to bone mineral density, age, history of previous fractures, steroid therapy
  - Diagnostic sensitivity of DEXA highest when bone mineral density measured at lumbar spine and proximal femur
- Appearance on plain film
  - Osteopenia: reduced bone density on plain films
  - May also be seen with osteomalacia, hyperparathyroidism, and disuse
  - Compression of vertebral bodies
  - Biconcave vertebral bodies (“codfish” vertebrae)
  - Long bones have appearance of thinned cortex and increased medullary cavity
  - Look for complications of osteoporosis (e.g. insufficiency fractures: hip, vertebrae, sacrum, pubic rami)
- See Endocrinology, E40

**Osteomalacia/Rickets**
- Reduction in bone mineral density; normal amount of bone, but reduced mineralization of normal osteoid
- Usually due to vitamin D deficiency, resulting in softening and bowing of long bones
- Similar to osteoporosis, initial radiological appearance of osteopenia (coarse and poorly defined bone texture)
- “Fuzzy”, ill-defined trabeculae
- Looser’s zones (pseudofracture)
  - Characteristic radiologic feature
  - Fissures or clefts at right angles to long bones and extending through cortex
- DDX: chronic renal disease, fibrous dysplasia, hyperthyroidism, Paget’s, osteodystrophy, X-linked hypophosphatemia
Figure 39. Osteomalacia, osteopenia, and osteoporosis

Hyperparathyroidism
- most common cause is renal failure (secondary hyperparathyroidism)
- chondrocalcinosis
- calcium crystal deposition in hyaline cartilage or fibrocartilage (including arteries and peri-articular soft tissue)
- resorption of bone typically in hands (subperiosteal and at tufts), sacroiliac joints (subchondral), skull ("salt and pepper" appearance), osteoclastoma (brown tumours)
- "rugger jersey spine": band-like osteosclerosis at superior/inferior margins of vertebral bodies

Paget’s Disease
- abnormal remodelling involving single or multiple bones – especially skull, spine, pelvis
- 3 phases: 1st phase = lytic; 2nd phase = mixed (lytic/sclerotic), 3rd phase = sclerotic
- features
  - coarsening of the trabeculae with bone expansion
  - bone softening/bowing
  - bone scan will reveal high activity, especially at bone ends
  - thickened cortex
- see Endocrinology, E44

### Nuclear Medicine

#### Brain

- 
  - $^{99m}$Tc-exametazime (HMPAO) and $^{99m}$Tc-bicisate (ECD) imaging used in SPECT to assess cerebral blood flow and cellular metabolism, taken up predominantly in grey matter; used for dementia, traumatic brain injury and to a lesser extent vasculitis, neuropsychiatric disorders and occasionally stroke; also the most commonly used tracers to confirm brain death (i.e. absent blood flow to the brain and absent uptake on delayed planar and SPECT images in brain and brainstem, assuming study is technically adequate); either tracer can be used for seizure imaging to assess for the most likely location of epileptogenic focus but usually must be made available for 24 hr and the patient followed by a nurse who is competent to administer the activity at the time of seizure
  - PET imaging assesses metabolic activity most commonly with 18FDG; used for dementia imaging, grade and stage of brain tumours, occasionally for seizure disorder imaging, and vasculitis; PET imaging with amyloid tracers for diagnosis of Alzheimer’s disease is becoming more common
  - CSF imaging, intrathecal administration of $^{111}$In-DTPA to evaluate CSF leak or to differentiate normal pressure hydrocephalus from brain atrophy
  - CSF shunt evaluation for obstruction (most commonly ventriculoperitoneal) with sterile or pyrogen free $^{99m}$Tc (usually) or $^{111}$In-DTPA; small quantity of activity is injected into the reservoir under sterile conditions and should flow freely into the peritoneal cavity by 45 min; maneuvers such as pumping the shunt, sitting the patient upright or ambulating are acceptable to encourage flow during this time
  - adrenergic imaging of the heart with MIBG has been used to differentiate dementias with autonomic dysfunction (i.e. Lewy Body and Parkinson’s disease) from other forms of dementia (i.e. autonomic impairment associated with decreased MIBG activity in the heart)
Thyroid

Radioactive Iodine Uptake (see Endocrinology, E21)
- index of thyroid function (trapping and organization of iodine)
- radioactive $^{131}$I given PO to fasting patient (small quantity)
- measure percentage of administered iodine taken up by thyroid
- increased RAIU: toxic multinodular goitre, toxic adenoma, Graves’ disease
- decreased RAIU: subacute thyroiditis, late Hashimoto’s disease, exogenous thyroid hormone or iodine, falsely decreased in patient with recent radiographic contrast studies, high dietary iodine (e.g. seaweed, taking a “thyroid vitamin”)
- important – iodine uptake helps in the differential of hyperthyroidism only, not hypothyroidism
  (exception is pediatrics)

Thyroid Imaging (Scintiscan)
- $^{99m}$Tc-pertechnetate IV or radioactive iodine ($^{131}$I); most Canadian sites use pertechnetate to reduce cost
- provides functional anatomic detail
- hot (hyperfunctioning) lesions: usually benign (e.g. adenoma, toxic multinodular goitre), cancer very unlikely (<1%)
- cold (hypofunctioning) lesions: cancer must be considered until biopsy negative even though only 6-10% are cancerous; decision to biopsy should be based on clinical and sonographic features
- isointense i.e. “warm” lesions: cancer must be considered as an isointense lesion may represent cold nodules superimposed on normal tissue; if cyst suspected, correlate with US

Radioiodine Ablation
- $^{131}$I for Graves’ disease, multinodular goitre, thyroid cancer (in the case of thyroid cancer, ablation performed at higher dose and after thyroidectomy)
- serum thyroglobulin used to detect recurrent thyroid cancer in a patient that has received ablation
- advice should be given for patient-specific precautions to remain away from family members and caregivers to reduce radiation exposure after thyroid ablation, do not initiate pregnancy for 6 mo, small risk of exophthalmos, thyroid storm, secondary malignancy

Pediatric Hypothyroidism
- pertechnetate thyroid scan can differentiate thyroid agenesis, hemiagenesis, lingual thyroid, organification defect, however should not wait for a diagnosis to start thyroid hormone replacement in a neonate; start immediately

Respiratory

V/Q Scan
examine areas of lung in which ventilation and perfusion do not match
- ventilation scan
  - patient breathes radioactive gas (nebulized $^{99m}$Tc-DTPA, $^{133}$Xe, or most commonly Technegas) through a closed system, filling alveoli proportionally to ventilation
  - ventilation scan defects indicate: airway obstruction (i.e. air trapping), chronic lung disease, bronchospasm, tumour mass obstruction
- perfusion scan
  - radiotracer injected IV ($^{99m}$Tc-MAA) $\rightarrow$ trapped in pulmonary capillaries (0.1% of arterioles occluded) according to blood flow
  - relatively contraindicated in severe pulmonary HTN, right-to-left shunt, previous history of pneumonectomy, small child. In these cases fewer particles are usually given
  - to rule out PE
  - indications: some institutions favour in pregnancy (lower radiation dose to breast than CT), or where CT contrast contraindicated (e.g. contrast allergy, renal failure)
  - areas of lung are well ventilated but not perfused (unmatched defect) are suspicious for acute infarction
  - defects are wedge-shaped, extend to periphery, usually bilateral and multiple
  - often reported as high probability (> 2 large i.e. segmental mismatched perfusion defects), intermediate, low, very low, or normal according to modified PIOPED II criteria although now are increasingly reported as PE present, indeterminate or normal
  - useful in finding clinically important emboli
  - decreased detection of incidentalomas commonly found on CT
  - not valid for assessment of PE when patients have consolidation and the test can be limited by ventilatory problems (e.g. COPD), much like CT
  - modified V/Q scan (perfusion only, lower dose contrast) may be used for pregnant patients if CXR is normal or if there are ventilatory problems
Cardiac

Myocardial Perfusion Scanning
• to investigate coronary artery disease (CAD), assess treatment of CAD, pre op risk stratification, viability testing
• $^{99m}$Tc-sestamibi, or $^{99m}$Tc-tetrofosmin are used most commonly, thallium 201 was used previously but largely discontinued due to high radiation doses to patients and unfavourable imaging characteristics; today thallium still used for viability studies
• injected at peak exercise (85% max predicted heart rate by the Bruce protocol, chest pain, ECG changes) or after persantine challenge (vasodilator), or dobutamine infusion (chronotrophic, again to 85% predicted heart rate); can be done as stress only protocol with optional rest or as stress and rest combined protocol (i.e. as 1 day or 2 day protocol)
• patients with left bundle usually given pharmacologic stress because EKG is difficult to interpret for ST changes and avoids a characteristic artifact
• pharmacologic stress contraindicated if BP is <90 systolic; persantine exacerbates asthma, so patients with asthma and wheeze who cannot exercise usually get dobutamine infusion; reverse persantine with aminophylline or caffeine
• persistent defect (at rest and stress) suggests infarction or myocardial scar; reversible defect (only during stress) suggests ischemia
• used to discriminate between reversible (ischemia) vs. irreversible (infarction) changes when other investigations are equivocal
• Courage trial indicates that patients with >10% ischemic myocardium benefit most from revascularization
• see Cardiology and Cardiac Surgery, C13

Radionuclide Ventriculography
• $^{99m}$Tc tagged to red blood cells, tagged albumin is also acceptable
• first pass through RV → pulmonary circulation → LV; provides information about RV function, presence of shunts
• cardiac MUGA scan sums multiple cardiac cycles, usually at least 200 beats
• evaluation of LV function and regional wall motion, ejection fraction
• images are obtained by gating (synchronizing) the count acquisitions to the ECG signal
• can assess diastolic dysfunction
• provides information on ejection fraction (normal = 50-65%), ventricular volume, and wall motion
• indications: most commonly to monitor potential cardiac toxicity with chemotherapy or herceptin, as a gold standard of ejection fraction in defibrillator work up

Abdomen and Genitourinary System

HIDA Scan (Cholescintigraphy)
• IV injection of $^{99m}$Tc-disofenin (DISIDA) or $^{99m}$Tc-mebrofenin which is bound to protein, taken up, and excreted by hepatocytes into biliary system
• can be performed in non-fasting state but prefer NPO after midnight
• indicated in workup of cholecystitis when abdominal ultrasound result is equivocal:
  • acute cholecystitis: no visualization of gallbladder at 4 h or 1 hour after administration of morphine
  • chronic cholecystitis: no visualization of gallbladder at 1 h but seen at 4 h or after morphine administration
• gallbladder visualized when cystic duct is patent (rules out acute cholecystitis with >99% certainty), usually seen by 30 min to 1 h
• differential diagnosis of obstructed cystic duct: acute/chronic cholecystitis, decreased hepatobiliary function (commonly due to alcoholism), bile duct obstruction, parenteral nutrition, fasting less than 4 h or more than 24 h
• also used to assess bile leaks post-operatively or in trauma
• gallbladder ejection fraction (>38% is normal) can be measured after a fatty meal or CCK to assess for biliary dyskinesia

RBC Scan
• IV injection of radiotracer with sequential images of the abdomen (99mTc RBCs)
• GI bleed
  • if bleeding acutely at <0.5 mL/min, the focus of activity in the images generally indicates the site of the acute bleed, look for a change in shape and location on sequential image, requires active bleeding to localize
  • if bleeding acutely at >0.5 mL/min, use angiography (more specific)
• liver lesion evaluation
  • hemangiomata has characteristic appearance; cold early (limited blood flow to lesion), fills in later (accumulation of tagged cells greater than surrounding liver parenchyma)
Other Important Nuclear Medicine Abdominal Tests
- Meckel's Scan: uses Tc 99m pertechnetate; give patient ranitidine premedication; Meckel's diverticulum contains gastric mucosa which will light up at the same time as the stomach and get brighter with time like stomach
- Indium 111 octreoscan: a somatostatin analog used for evaluation and staging of neuroendocrine tumours including carcinoid, gastrinoma and carcinoid tend to be more octreotide avid than insulinoma.
- Iodinated MIBG: a norepinephrine analog, used for pheochromocytoma, neuroblastoma and medullary thyroid cancer most commonly; limited cardiac applications as above
- solid and liquid gastric emptying: a standardized solid or liquid meal is labelled, usually with Tc 99m sulfur colloid and gastric emptying studied over time. There are normal ranges for solids and liquids

Urea Breath Test
- indication: diagnosis of gastric Helicobacter pylori infection
- patient administered 14C-labelled urea orally, urea metabolized by H. pylori to ammonia and 14CO2, 14C-labeled CO2 is measured via plastic filament detectors or liquid scintillation

Functional Renal Imaging
- evaluation of renal function and anatomy using 99mTc DTPA or Tc 99m MAG3
- frequently used to provide index of relative function between two kidneys
- frequently used in adults to assess for UP obstruction (by assessing the clearance half time with lasix), and assess renal transplants or as a nuclear GFR study in patients wanting to donate kidneys
- in children, imaging with Tc 99m DMSA is used to assess for pyelonephritis
- in children, the injection of tracer into the bladder via foley catheter is often used to assess for reflux

Bone
Bone Scan
- isotopes, usually 99mTc-diphosphonate
- radioactive tracer binds to hydroxyapatite of bone matrix
- increased binding when increased blood supply to bone and/or high bone turnover (active osteoblasts)
- indications: bone pain of unknown origin, staging or restaging of cancer with boney mets (or primary bone cancer), imaging of arthroplasty complications like loosening or infection, osteomyelitis imaging
- when used to assess for ostemyelitis, usually done in combination with gallium or white blood cell scan
- differential diagnosis of positive bone scan: bone metastases (breast, prostate, lung, thyroid), primary bone tumour, arthritis, fracture, infection, anemia, Paget's disease
- lytic lesions like multiple myeloma, renal cell cancer, eosinophilic granuloma: typically normal or cold (false negative); need a skeletal survey
- "superscan": increased bone uptake and poor renal uptake due to diffuse metastases (breast, prostate) or metabolic causes (i.e. renal osteodystrophy)

Interventional Radiology

Vascular Procedures
Angiography
- injection of contrast material through a catheter placed directly into an artery or vein to delineate vascular anatomy
- catheter can be placed into a large vessel (e.g. aorta, vena cava) for a "flush" or selectively placed into a branch vessel for more detailed examination of smaller vessels and specific organs
- indications: diagnosis of primary occlusive or stenotic vascular disease, aneurysms, coronary, carotid and cerebral vascular disease, PE, trauma, bleeding (GI, hemothysis, hematuria), vascular malformations, as part of endovascular procedures (endovascular aneurysm repair, thrombolysis, stenting, and angioplasties)
- complications (<5% of patients): puncture site hematoma, infection, pseudoaneurysm, AV fistula, dissection, thrombosis, embolic occlusion of a distal vessel
- due to improved technology, non-invasive evaluation of vascular structures is being performed more frequently (colour Doppler U/S, CTA, and MRA)
- see Neuroradiology, MI18

Percutaneous Transluminal Angioplasty and Stents
- introduction and inflation of a balloon into a stenosed or occluded vessel to restore distal blood supply
- common alternative to surgical bypass grafting with 5-yr patency rates similar to surgery, depending on site
- renal, iliac, femoral, mesenteric, subclavian, coronary, and carotid artery stenoses are amenable to treatment
- vascular stents may help improve long-term results by keeping the vessel wall patent after angioplasty
- stents are also used for angioplasty failure or complications

Chemoembolization delivers chemotherapy directly into the tumour through its feeding blood supply and traps the drug in place by embolization
• stent grafts (metal mesh covered with durable fabric) may provide an alternative treatment option for aneurysms and AV fistulas
• complications: similar to angiography, but also includes vessel rupture

**Thrombolytic Therapy**
• may be systemic (IV) or catheter directed
• infusion of a fibrinolytic agent (urokinase, streptokinase, TNK, tPA – used most commonly) via a catheter inserted directly into a thrombus
• can restore blood flow in a vessel obstructed with a thrombus or embolus
• indications: treatment of ischemic limb (most common indication), early treatment of MI or stroke to reduce organ damage, treatment of venous thrombosis (DVT or PE)
• complications: bleeding, stroke, distal embolus, reperfusion injury with myoglobinuria and renal failure if advanced ischemia present

**Embolization**
• injection of occluding material into vessels
• permanent agents: amplatzer plugs, coils, glue, and onyx
• temporary: gel foam, autologous blood clots
• indications: management of hemorrhage (epistaxis, trauma, GI bleed, GU bleed), treatment of arteriovenous malformation, pre-operative treatment of vascular tumours (bone metastases, renal cell carcinoma), varicocoele embolization for infertility, symptomatic uterine fibroids
• complications: post-embolization syndrome (pain, fever, leukocytosis), unintentional embolization of a non-target organ with resultant ischemia

**Inferior Vena Cava Filter**
• insertion of metallic "umbrellas" to mechanically trap emboli and prevent PE
• may be temporary (retrievable) or permanent
• inserted via femoral vein, jugular vein, or antecubital vein
• usually placed infrarenally to avoid renal vein thrombosis
• indications: contraindication to anticoagulation, failure of adequate anticoagulation (e.g. recurrent PE despite therapeutic anticoagulant levels), complication of anticoagulation

**Central Venous Access**
• variety of devices available
• PICC, external tunneled catheter (Hickman or dialysis catheters), subcutaneous port (Portacath™)
• indications: chemotherapy, TPN, long-term antibiotics, administration of fluids and blood products, blood sampling
• complications: venous thrombosis and central venous stenosis, infection including sepsis, pneumothorax

**Nonvascular Interventions**

**Percutaneous Biopsy**
• replaces open surgical procedure
• many sites are amenable to biopsy using U/S, fluoroscopy, CT or MR guidance
• complications: false negative (sampling error or tissue necrosis), pneumothorax in 30% of lung biopsies (chest tube required in ~5%), acute pancreatitis (pancreatic biopsies), bleeding from liver biopsies in patients with uncorrectable coagulopathies or ascites (can be minimized with transjugular approach)

**Abscess Drainage**
• placement of a drainage catheter into an infected fluid collection
• administer broad spectrum IV antibiotics prior to procedure
• routes: percutaneous (most common), transgluteal, transvaginal, transrectal
• complications: hemorrhage, injury to intervening structures (e.g. bowel), bacteremia, sepsis

**Percutaneous Biliary Drainage/Cholecystostomy**
• placement of drainage catheter ± metallic stent into obstructed biliary system (PBD) or gallbladder (cholecystostomy) for relief of jaundice or infection
• percutaneous gallbladder access can be used to crush or remove stones
• indications
  • cholecystostomy: acute cholecystitis
  • PBD: biliary obstruction secondary to stone or tumour, cholangitis
• complications
  • acute: sepsis, hemorrhage
  • long-term: tumour ingrowth and stent occlusion

**Percutaneous Nephrostomy**
• placement of catheter into renal collecting system
• indications: hydronephrosis, pyonephrosis, ureteric injury with or without urinary peritonitis (traumatic or iatrogenic)
• complications: bacteria and septic shock, hematuria due to pseudoaneurysm or AV fistulas, injury to adjacent organs

**Thrombolytic Therapy for Pulmonary Embolism**
Cochrane DB Syst Rev 2009;3:CD004437
Study: Systematic review of RCTs comparing thrombolytic therapy with placebo, heparin, or surgical intervention.
Patients: ETI patients with acute PE.
Intervention: Thrombolytics vs. heparin or placebo.
Outcome: Death rate, recurrence of PE, major and minor hemorrhagic events.
Results: Non-significant difference between thrombolytics and heparin or placebo in all measured outcomes. Rr-PA and heparin together reduced need for treatment for in-hospital events. Thrombolytics improved hemodynamic outcome, lung VQ scans, pulmonary angiography assessment, and echocardiograms greater than heparin
Need for further double-blinded RCTs.
Conclusion: We cannot conclude whether thrombolytic therapy is better than heparin for pulmonary embolism based on limited evidence found.

**Indications for Central Venous Access**
- FAT CAB
- Fluids
- Antibiotics
- TPN
- Chemotherapy
- Administration of blood
- Blood sampling

**Figure 41. Retrievable IVC filter**

**Figure 42. Femoral arteriogram: distal occlusion of superficial femoral artery**
Gastrostomy/Gastrojejunostomy

- Percutaneous placement of catheter directly into either stomach (gastrostomy) or through stomach into small bowel (transgastric jejunostomy)
- Indications: inability to eat (most commonly CNS lesion e.g. stroke) or esophageal obstruction, decompression in gastric outlet obstruction
- Complications: gastroesophageal reflux with aspiration, peritonitis, hemorrhage, bowel or solid organ injury

Radiofrequency Ablation

- U/S or CT guided probe is inserted into tumour, radiofrequency energy delivered through probe causes heat deposition and tissue destruction
- Indications: hepatic tumours (HCC and metastases), renal tumours
- Complications: destruction of neighbouring tissues and structures, bleeding

Breast Imaging

Modalities

Mammography

Description

- X-ray imaging of the breasts for screening in asymptomatic patients, or diagnosis of clinically-detected or screening-detected abnormalities (see General Surgery, GS56)
- Routine evaluation involves two standard views: cranio-caudal and medial-lateral-oblique

Indications

- Screening
  - Begin screening from age 50 q2 yr
  - No strong data to support screening >70 yr, but may continue screening if in good general health
  - If <50, screening is only recommended for those with high risk of breast cancer
  - Screening detects 2-8 cancers/1,000 women screened
- Surveillance
  - Follow-up of women with previous breast cancer
  - Diagnostic: includes mammography with special views and/or ultrasound
  - Work-up of an abnormality that may be suggestive of breast cancer including a lump or thickening, localized nodularity, dimpling or contour deformity, a persistent focal area of pain, and spontaneous serous or sanguinous nipple discharge from a single duct
  - Women with abnormal screening mammograms
  - Suspected complications of breast implants

Table 19. Breast Imaging Reporting and Data System (BI-RADS®) Mammography Categories

<table>
<thead>
<tr>
<th>Assessment Categories</th>
<th>Imaging Findings</th>
<th>Follow-Up Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>BI-RADS 0</td>
<td>Incomplete</td>
<td>Additional imaging</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comparison to prior films</td>
</tr>
<tr>
<td>BI-RADS 1</td>
<td>Negative</td>
<td>Routine screening</td>
</tr>
<tr>
<td>BI-RADS 2</td>
<td>Benign</td>
<td>Routine screening</td>
</tr>
<tr>
<td>BI-RADS 3</td>
<td>Probably benign</td>
<td>Unilateral mammogram at 6 mo</td>
</tr>
<tr>
<td></td>
<td>Likelihood of malignancy is &lt;2%</td>
<td></td>
</tr>
<tr>
<td>BI-RADS 4</td>
<td>Suspicious abnormality</td>
<td>Biopsy</td>
</tr>
<tr>
<td>BI-RADS 5</td>
<td>Highly suspicious of malignancy</td>
<td>Biopsy</td>
</tr>
<tr>
<td></td>
<td>Likelihood of malignancy is 95%</td>
<td></td>
</tr>
<tr>
<td>BI-RADS 6</td>
<td>Malignancy confirmed by biopsy</td>
<td>Definitive therapy</td>
</tr>
</tbody>
</table>

Breast Ultrasound

Indications

- Characterization of palpable abnormalities (ultrasound 1st line <30 yr and in lactating and pregnant women, >30 yr need mammogram 1st)
- Further characterization of mammographic findings
- Guidance for interventional procedures
Breast MRI

Description
• contrast enhanced MRI of the breasts
• sensitive for detecting invasive breast cancer (95-100%) but specificity variable (37-97%)
• for diagnosis, used only after mammography and U/S investigation
• use as a screening modality is limited to high risk patients, in conjunction with mammography

Indications
• “problem solving” of indeterminate findings following complete mammographic and ultrasound workup
• evaluation of patients with suspected silicone implant rupture and problems associated with breast implants
• evaluation of previously diagnosed breast cancer: positive margins, recurrence, response to chemotherapy
• High Risk Screening
  • known BRCA1 or BRCA2 mutation, or other gene predisposing to breast cancer or untested first-degree relative of a carrier of such a gene mutation
  • family history consistent with a hereditary breast cancer syndrome and/or estimated personal lifetime cancer risk >25%
  • high-risk marker on prior biopsy (atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ)
  • radiation therapy to chest (before age 30)

Breast Interventional Procedures

Description
• includes fine needle aspirate biopsy, core needle biopsy, stereotactic biopsy, MRI guided biopsy, abscess drainage, and cyst aspiration (see General Surgery, GS59)

Indications
• cystic mass: complex cyst, symptomatic, suspected abscess
• solid mass: confirm diagnosis of a lesion suspicious for malignancy (BI-RADS® Category 4 or 5)
• suspicious calcifications: confirm diagnosis of a lesion suspicious for malignancy (BI-RADS® Category 4 or 5) – stereotactic biopsy
• initial percutaneous biopsy procedure that was insufficient or discordant with imaging
• presurgical wire localization of a lesion

Breast Findings

Breast Masses
• definition: a space occupying lesion seen in two different projections; if seen in only a single projection it should be called an “asymmetry” until its three-dimensionality is confirmed

Table 20. Mammographic Features of Benign and Malignant Breast Masses

<table>
<thead>
<tr>
<th></th>
<th>Benign</th>
<th>Malignant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shape</td>
<td>Oval, round, lobular</td>
<td>Irregular</td>
</tr>
<tr>
<td>Margin</td>
<td>Circumscribed, well-defined</td>
<td>Indistinct, microlobulated, spiculated</td>
</tr>
<tr>
<td>Density</td>
<td>Radiolucent (oil cyst, lipoma, fibrolipoma, galactocele, hamartoma)</td>
<td>Radiodense</td>
</tr>
<tr>
<td>Calcifications (± mass)</td>
<td>Popcorn (hyalinizing fibroadenoma), lucent centred (oil cyst/fat necrosis), layering (milk of calcium), vascular, round, scattered</td>
<td>Pleomorphic (vary in size and shape), amorphous (indistinct), fine linear, coarse heterogeneous, regional, segmental, clustered</td>
</tr>
</tbody>
</table>

Other Findings
• tubular density/dilated duct: branching tubular structures usually represent enlarged ducts (milk ducts); if they are clearly identified as such, these densities are of little concern
• intramammary lymph node: typical lymph nodes are circumscribed, reniform and often have a fatty notch and centre; usually less than 1 cm, and usually seen in the outer, often upper part of the breast; when these characteristics (particularly fatty centre or notch) are well seen, the lesion is almost always benign and insignificant
• focal asymmetry: area of breast density with similar shape on two views, but completely lacking borders and conspicuity of a true mass; must be carefully evaluated with focal compression to exclude findings of a true mass or architectural distortion
• if focal compression shows mass-like character, or if the area can be palpated, biopsy generally recommended
Acronyms ........................................ 2

Basic Anatomy Review .......................... 2
- Anatomy of the Kidney
- Renal Structure and Function
- Renal Hemodynamics

Assessment of Renal Function ................. 5
- Measurement of Renal Function
- Urinalysis
- Urine Microscopy
- Urine Biochemistry

Electrolyte Disorders ............................. 7
- Sodium Homeostasis
- Hyponatremia
- Hypernatremia
- Diabetes Insipidus
- Potassium Homeostasis
- Hypokalemia
- Hyperkalemia
- Hyperphosphatemia
- Hypophosphatemia
- Hypermagnesemia
- Hypomagnesemia

Acid-Base Disorders .............................. 15
- Metabolic Acidosis
- Metabolic Alkalosis

Acute Kidney Injury .............................. 18
- Approach to AKI

Parenchymal Kidney Diseases .................. 19
- Glomerular Diseases
- Glomerular Syndromes
- Tubulointerstitial Disease
- Vascular Diseases of the Kidney
- Analgesic Nephropathies

Systemic Disease with Renal Manifestation . 31
- Diabetes
- Scleroderma
- Multiple Myeloma
- Malignancy

Chronic Kidney Disease ......................... 33
- Management of Chronic Kidney Disease

Hypertension ..................................... 34
- Hypertensive Nephrosclerosis
- Renovascular Hypertension
- Renal Parenchymal Hypertension

Cystic Diseases of the Kidney .................. 35
- Adult Polycystic Kidney Disease
- Autosomal Recessive Polycystic Kidney Disease
- Medullary Sponge Kidney
Acronyms

ACEI angiotensin converting enzyme inhibitor
ACR albumin to creatinine ratio
ADH antidiuretic hormone
AG union gap
AKI acute kidney injury
ANA antinuclear antibody
ARB angiotensin receptor blocker
ASA acetylsalicylic acid
ASOT anti-streptolysin-O titer
ATN acute tubular necrosis
AVM arteriovenous malformation
c-ANCA cytoplasmic antineutrophil cytoplasmic antibody
C&S culture and sensitivity
CHF congestive heart failure
CI chronic kidney disease
Cr creatinine
Ccr creatinine clearance
DM diabetes mellitus
DI diabetes insipidus
t-ANCA perinuclear anti-neutrophil cytoplasmic antibody
eGFR estimated glomerular filtration rate
ESR erythrocyte sedimentation rate
ESRD end-stage renal disease
FF filtration fraction
FKP focal segmental glomerulosclerosis
GBM glomerular basement membrane
GFR glomerular filtration rate
HCTZ hydrochlorothiazide
HPF high power field
HUS hemolytic uremic syndrome
IVP intravenous pyelogram
LOC level of consciousness
MDRD modification of diet in renal disease
NS normal saline
p-ANCA perinuclear anti-neutrophil cytoplasmic antibody
FOXD polycystic kidney disease
PTH parathyroid hormone
R&H routine and histology
RAAS renin-angiotensin-aldosterone system
RBF renal blood flow
RPF renal plasma flow
RCC renal cell carcinoma
RPGN rapidly progressive glomerulonephritis
RRT renal replacement therapy
RTA renal tubular acidosis
SIADH syndrome of inappropriate antidiuretic hormone
SLE systemic lupus erythematosus
TBW total body water
TIN tubulointerstitial nephritis
TPP thrombotic thrombocytopenic purpura
UAG urine albumin gap
UTI urinary tract infection

Basic Anatomy Review

Anatomy of the Kidney

- see Urology, U2

Renal Structure and Function

The Nephron
- basic structural and functional unit of the kidney, approximately 1 million per kidney
- 2 main components: glomerulus and attached renal tubule
- direction of blood flow: afferent arteriole → glomerular capillaries → efferent arteriole → vasa recta (the capillaries surrounding the tubules) → renal venules

Table 1. Major Kidney Functions

<table>
<thead>
<tr>
<th>Function</th>
<th>Mechanism</th>
<th>Affected Elements</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Waste Excretion</td>
<td>Glomerular filtration</td>
<td>Excretion of nitrogenous products of protein metabolism (urea, Cr)</td>
</tr>
<tr>
<td></td>
<td>Tubular secretion</td>
<td>Excretion of organic acids (urate) and organic bases (Cr)</td>
</tr>
<tr>
<td></td>
<td>Tubular catabolism</td>
<td>Breakdown and excretion of drugs (antibiotics, diuretics) and peptide hormones (most pituitary hormones, insulin, glucagon)</td>
</tr>
<tr>
<td>2. Electrolyte Balance and Osmoregulation</td>
<td>Tubular NaCl and water reabsorption</td>
<td>Controls volume status and osmolar balance</td>
</tr>
<tr>
<td></td>
<td>Tubular K⁺ secretion</td>
<td>Controls potassium concentration</td>
</tr>
<tr>
<td></td>
<td>Tubular H⁺ secretion</td>
<td>Acid-base balance</td>
</tr>
<tr>
<td></td>
<td>HCO₃⁻ secretion and reabsorption</td>
<td>Acid-base balance</td>
</tr>
<tr>
<td></td>
<td>Tubular Ca²⁺, Mg²⁺, PO₄³⁻ transport</td>
<td>Alters Ca²⁺, Mg²⁺, PO₄³⁻ homeostasis</td>
</tr>
<tr>
<td></td>
<td>Synthesize osmolytes</td>
<td>Increase osmolality of medullary cytoplasm to match medullary concentration gradient</td>
</tr>
<tr>
<td>3. Hormonal Synthesis</td>
<td>Erythropoietin production (cortex)</td>
<td>Red blood cell production</td>
</tr>
<tr>
<td></td>
<td>Vitamin D activation: 25(OH)D→1,25(OH)₂D (proximal tubule)</td>
<td>Calcium homeostasis</td>
</tr>
<tr>
<td></td>
<td>Renin production (juxtaglomerular apparatus)</td>
<td>Alters vascular resistance and aldosterone secretion</td>
</tr>
<tr>
<td>4. Blood Pressure Regulation</td>
<td>Na⁺ excretion</td>
<td>Alters ECF volume</td>
</tr>
<tr>
<td></td>
<td>Renin production</td>
<td>Alters vascular resistance</td>
</tr>
<tr>
<td>5. Glucose Homeostasis</td>
<td>Glucoseogenesis (from lactate, pyruvate, and amino acids)</td>
<td>Glucose supply maintained in prolonged starvation</td>
</tr>
<tr>
<td></td>
<td>Clearance and degradation of circulating insulin</td>
<td>Maintains glucose homeostasis</td>
</tr>
</tbody>
</table>

The Glomerulus
- site where blood constituents are filtered through to the kidney tubules for excretion or reabsorption
- filtration occurs across the glomerular filtration barrier (endothelium, GBM, podocytes) into Bowman’s space
- particles are selectively filtered by size (<60 kDa) and charge (negative charge repelled)
• consists of following cell types
  1. Mesangial cells
     • structural cells that support the vascular tree; they are also contractile and produce vasoactive substances to help control blood flow
  2. Capillary endothelial cells
     • one of the cells of the glomerular filtration barrier; help form the plasma filtration apparatus due to their sinusoidal nature and glycocalyx; contribute to the production of the GBM
  3. Visceral epithelium (podocytes)
     • one of the cells of the glomerular filtration barrier; help form the plasma filtration apparatus due to their interdigitated foot process that form slit diaphragms; contribute to the production of the GBM
  4. Parietal epithelium
     • lines the interior of Bowman’s capsule and contains a podocyte progenitor population
  5. Juxtaglomerular cells
     • smooth muscle cells in lining of afferent arteriole; produce, store and secrete renin

![Renal Homodynamic Parameters](image)

**Renal Homodynamic Parameters**
- RBF = 20% of CO, ~1 L/min
- RPF = RBF*(1-Hct)
- GFR = ~120 mL/min in healthy adult
  (99% of this volume is reabsorbed)
- FF = GFR/RPF (normally 20%)

**The Renal Tubules**
- reabsorption and secretion occur between the renal tubules and vasa recta forming urine for excretion
- each segment of the tubule selectively transports various solutes and water and is targeted by specific diuretics
Renal Hemodynamics

- **GFR**
  - GFR is the sum of the filtration across all nephrons
  - the rate of fluid transfer between glomerular capillaries and Bowman's space
  - average 180 L/day, of which 99% is reabsorbed, giving a urine output of 1.0-1.5 L/day to match oral fluid intake
  - normal urine output is 0.5-2.0 ml/kg/h in adults
  - GFR is highest in early adulthood, and decreases thereafter starting around age 40
  - renal autoregulation maintains constant GFR over mean arterial pressures of 70-180 mmHg
  - 2 mechanisms of autoregulation
    - myogenic mechanism: release of vasoactive factors such as prostaglandins in response to changes in perfusion pressure (e.g., ↓ perfusion pressure → afferent arteriolar constriction) → ↓ GFR
    - tubuloglomerular feedback: changes in Na+ delivery to macula densa lead to changes in afferent arteriolar tone (e.g., increased delivery causes arteriolar constriction)

- **FF**
  - percentage of RPF filtered across the glomeruli
  - expressed as a ratio: FF = GFR/RPF; normal = 0.2 or 20%
  - angiotensin II constricts renal efferent arterioles which increases FF, thereby maintaining GFR
  - renin is released from juxtaglomerular apparatus in response to decreased RPF and maintain sodium balance

![Figure 2. Tubular segments of the nephron](image)

![Figure 3. Renin-angiotensin-aldosterone system](image)
Assessment of Renal Function

Measurement of Renal Function

- clinically, GFR is estimated using serum creatinine concentration, [Cr]
- insulin clearance is the gold standard for measuring GFR, but very rarely used clinically
- most renal functions decline in parallel with a decrease in GFR
- Cr is a metabolite of creatine (intermediate in muscle metabolism), therefore increased muscle mass increases Cr production
- Cr is freely filtered at the glomerulus with little tubular reabsorption
- tubular secretion of Cr varies based on level of renal function (10% to >50%)
- Cr filtered = Cr excreted (at steady state)

Ways to Estimate GFR Using Serum Creatinine Concentration

1. Measure CrCl
   - calculation provides reasonable estimate of GFR
   - GFR/d = (urine [Cr] x 24 h urine volume)/plasma [Cr]
   - must use same units for urine [Cr] and plasma [Cr]

2. Estimate CrCl using Cockcroft-Gault formula
   - serum Cr used along with age, gender, and weight (kg) to estimate GFR
   - overestimate GFR when renal function severely impaired

3. Estimate GFR using MDRD formula
   - most common way in which GFR is estimated (MDRD 7 equation)
   - complex formula incorporating age, gender, serum Cr, and African descent, but does not include weight
   - GFR is reported as mL/min/1.73 m² body surface area
   - underestimation of GFR at near normal values

4. Estimate GFR using CKD-EPI equation
   - the best current equation
   - calculated using serum Cr, age, sex, and race
   - overestimate GFR

Limitations of Using Serum Cr Measurements

1. must be in steady state
   - constant GFR and rate of production of Cr from muscles
   - sudden injury (e.g. AKI) may reduce GFR substantially, however, serum Cr will not immediately reflect sudden reduction in GFR until new Cr steady-state is reached

2. GFR must fall substantially before plasma [Cr] rises above normal laboratory range
   - with progressive renal failure, remaining nephrons compensate with hyperfiltration
   - GFR is relatively preserved despite significant structural damage

3. plasma [Cr] is influenced by the rate of Cr production
   - lower production with smaller muscle mass (e.g. female, elderly, low weight)
   - for example, consider plasma [Cr] of 100 µmol/L in both of these patients
     - 20 yr old woman who weighs 50 kg, GFR = 144 mL/min
     - 80 yr old woman who weighs 50 kg, GFR = 30.6 mL/min
   - clinical correlation: GFR decreases with age but would not be reflected as a rise in serum Cr due to the age-associated decline in muscle mass

4. tubular secretion of Cr increases as GFR decreases
   - serum Cr and CrCl overestimate low GFR
   - certain drugs (cimetidine, trimethoprim) interfere with Cr secretion

5. errors in Cr measurement
   - very high bilirubin level causes [Cr] to be falsely low
   - acetocetate (a ketone body) and certain drugs (cefoxitin) create falsely high [Cr]

Measurement of Urea Concentration

- urea is the major end-product of protein metabolism
- plasma urea concentration reflects renal function but should not be used alone as it is modified by a variety of other factors
- urea production reflects dietary intake of protein and catabolic rate; increased protein intake or catabolism (sepsis, trauma, GI bleed) causes urea level to rise
- ECF volume depletion causes a rise in urea independent of GFR or plasma [Cr]
- in addition to filtration, a significant amount of urea is reabsorbed along the tubule
- reabsorption is increased in hypernatremic states
- typical ratio of urea to [Cr] in serum is 1:12 in SI units (using mmol/L for urea and µmol/L for Cr)
Urinalysis

- use dipstick in freshly voided urine specimen to assess the following:

1. Specific Gravity
   - ratio of the mass of equal volumes of urine/H₂O
   - range is 1.001 to 1.030
   - values <1.010 reflect dilute urine, values >1.020 reflect concentrated urine
   - value usually 1.010 in ESRD (isosthenuria: same specific gravity as plasma)

2. pH
   - urine pH is normally between 4.5-7.0; if persistently alkaline, consider
     - RTA
     - UTI with urease-producing bacteria (e.g. *Proteus*)

3. Glucose
   - freely filtered at glomerulus and reabsorbed in proximal tubule
   - causes of glucosuria include
     1. hyperglycemia >9-11 mmol/L leads to filtration that exceeds tubular resorption capacity
     2. increased GFR (e.g. pregnancy)
     3. proximal tubule dysfunction (e.g. Fanconi’s syndrome)

4. Protein
   - dipstick only detects albumin; other proteins (e.g. Bence-Jones, Ig, Tamm-Horsfall) may be missed
   - microalbuminuria (morning ACR of 2.0 - 20 mg/mmol) is not detected by standard dipstick, greater than these ranges would be macroalbuminuria (see *Diabetes*, NP31)
   - sulfosalicylic acid detects all protein in urine by precipitation
   - gold standard: 24 h timed urine collection for total protein

5. Leukocyte Esterase
   - enzyme found in WBC and detected by dipstick
   - presence of WBCs indicates infection (e.g. UTI) or inflammation (e.g. AIN)

6. Nitrites
   - nitrates in urine are converted by some bacteria to nitrites
   - high specificity but low sensitivity for UTI

7. Ketones
   - positive in alcoholic/diabetic ketoacidosis, prolonged starvation, fasting

8. Hemoglobin
   - positive in hemoglobinuria (hemolysis), myoglobinuria (rhabdomyolysis), and true hematuria (RBCs seen on microscopy)

### Urine Microscopy

#### Table 2. Comparison of Urinary Sediment Findings

<table>
<thead>
<tr>
<th>Active Sediment = Suggestive of Parenchymal Kidney Disease</th>
<th>Bland Sediment = Less Likely Parenchymal Kidney Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any one or more of the following seen on microscopy</td>
<td></td>
</tr>
<tr>
<td>Red cell casts</td>
<td>Only hyaline casts</td>
</tr>
<tr>
<td>White cell casts</td>
<td>Small quantities of crystals</td>
</tr>
<tr>
<td>Muddy-brown granular or epithelial cell casts</td>
<td>Small amount of bacteria</td>
</tr>
<tr>
<td>&gt;2 red cells per HPF</td>
<td>&lt;2 red cells per HPF</td>
</tr>
<tr>
<td>&gt;4 white cells per HPF</td>
<td>&lt;4 white cells per HPF</td>
</tr>
</tbody>
</table>

1. CELLS

**Erythrocytes**
- hematuria = greater than normal range of 2-3 RBCs per HPF
- dysmorphic RBCs and/or RBC casts suggest glomerular bleeding (e.g. proliferative GN)
- isomorphic RBCs, no casts suggest extraglomerular bleeding (e.g. bladder Ca)

**Leukocytes**
- pyuria = greater than upper limit of normal: 3 WBCs per HPF
- indicates inflammation or infection
- if persistent sterile pyuria present (i.e. negative culture), consider: chronic urethritis, prostatitis, interstitial nephritis, calculi, papillary necrosis, renal TB, viral infections
Electrolyte Disorders

Toronto Notes 2017NP7   Nephrology

Eosinophils
• detected using Wright's or Hansel's stain (not affected by urine pH)
• consider AIN, atheroembolic disease

Oval Fat Bodies
• renal tubular cells filled with lipid droplets
• seen in heavy proteinuria (e.g. nephrotic syndrome)

2. CASTS
• cylindrical structures formed by intratubular precipitation of Tamm-Horsfall mucoprotein; cells may be trapped within the matrix of protein

Table 3. Interpretation of Casts

<table>
<thead>
<tr>
<th>Casts</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyaline casts</td>
<td>Physiologic (concentrated urine, fever, exercise)</td>
</tr>
<tr>
<td>RBC casts</td>
<td>Glomerular bleeding (GN, vasculitis)</td>
</tr>
<tr>
<td>WBC casts</td>
<td>Infection (pyelonephritis)</td>
</tr>
<tr>
<td>Pigmented granular casts (heme granular casts, muddy brown)</td>
<td>Inflammation (interstitial nephritis)</td>
</tr>
<tr>
<td>Fatty casts</td>
<td>Nephrotic Syndrome (&gt;3.5 g/d)</td>
</tr>
</tbody>
</table>

3. CRYSTALS
• uric acid: consider acid urine, hyperuricosuria
• calcium phosphate: alkaline urine
• calcium oxalate: consider hyperoxaluria, ethylene glycol poisoning
• sulfur: sulfa-containing antibiotics

Urine Biochemistry

- commonly measure: Na⁺, K⁺, Cl⁻, osmolality, and pH
- no "normal" values; electrolyte excretion depends on intake and current physiological state
- results must be interpreted in the context of a patient's current state, for example:
  1. ECF volume depletion: expect low urine [Na⁺] (kidneys should be retaining Na⁺)
     • urine [Na⁺] >20 mmol/L suggests a renal problem or the action of a diuretic
     • urine [Na⁺] <20 mmol/L suggests a prerenal problem
  2. daily urinary potassium excretion rate should be decreased (<20 mmol/d) in hypokalemia
     • if higher than 20 mmol/d, suggests renal contribution to hypokalemia
- osmolality is useful to estimate the kidney's concentrating ability
- FENa refers to the fractional excretion of Na⁺
  • FENa <1% suggests the pathology is prerenal
- urine pH is useful to grossly assess renal acidification
  • low pH (<5.5) in the presence of low serum pH is an appropriate renal response
  • a high pH in this setting might indicate a renal acidification defect (e.g. RTA)

Electrolyte Disorders

Sodium Homeostasis

- hyponatremia and hypernatremia are disorders of water balance
  • hyponatremia usually suggests too much water in the ECF relative to Na⁺ content
  • hypernatremia usually suggests too little water in the ECF relative to Na⁺ content
- solutes (such as Na⁺, K⁺, glucose) that cannot freely traverse the plasma membrane contribute to effective osmolality and induce transcellular shifts of water
  • water moves out of cells in response to increased ECF osmolality
  • water moves into cells in response to decreased ECF osmolality
- ECF volume is determined by Na⁺ content rather than concentration
  • Na⁺ deficiency leads to ECF volume contraction
  • Na⁺ excess leads to ECF volume expansion
- clinical signs and symptoms of hyponatremia and hypernatremia are secondary to cells (especially in the brain) shrinking (hyponatremia) or swelling (hypernatremia)

Fractional Excretion of Sodium

\[
FENa = \frac{[Na^+]_{\text{urine}} \times [Cr]_{\text{plasma}}}{[Na^+]_{\text{plasma}} \times [Cr]_{\text{urine}}} \times 100
\]
Hyponatremia

- hyponatremia: serum [Na⁺] <135 mmol/L
- can be associated with hypo-osmolality (most common), iso-osmolality, or hyperosmolality
- consider if it is “appropriate” vs. “inappropriate” ADH secretion
- if appropriate ADH secretion, is it real vs. effective volume loss?

Table 4. Clinical Assessment of ECF Volume (Total Body Na⁺)

<table>
<thead>
<tr>
<th>Fluid Compartment</th>
<th>Hypovolemic</th>
<th>Hypervolemic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intravascular</td>
<td></td>
<td></td>
</tr>
<tr>
<td>JVP</td>
<td>Decreased</td>
<td>Increased</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>Orthostatic drop</td>
<td>Normal to increased</td>
</tr>
<tr>
<td>Auscultation of heart</td>
<td>Tachycardia</td>
<td>S3</td>
</tr>
<tr>
<td>Auscultation of lungs</td>
<td>Normal</td>
<td>Inspiratory crackles</td>
</tr>
<tr>
<td>Interstitial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin turgor</td>
<td>Decreased</td>
<td>Normal/increased</td>
</tr>
<tr>
<td>Edema (dependent)</td>
<td>Absent</td>
<td>Present</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine output</td>
<td>Decreased*</td>
<td>Variable</td>
</tr>
<tr>
<td>Body weight</td>
<td>Decreased</td>
<td>Increased</td>
</tr>
<tr>
<td>Hematocrit, serum protein</td>
<td>Increased</td>
<td>Decreased</td>
</tr>
</tbody>
</table>

*If there is a renal abnormality (e.g. osmotic diuresis), the urine output may be increased despite the presence of hypovolemia.

Hyponatremia

- Hyponatremia (between 100-135 mmol/L)
  - Most common cause of hyponatremia
  - Excess water in relation to sodium stores which can be decreased, normal, or increased
  - Categorized by volume status as determined by clinical assessment

- Hypovolemic
  - U₉₀ < 20 and Fe₉₀ > 1% (renal losses)
  - CHF
  - Cirrhosis and ascites
  - Nephrotic syndrome
  - Pregnancy
  - U₉₀ > 20
  - AKI, CKD

- Euvolemic
  - U₉₀ > 100 and Fe₉₀ > 10% (extra-renal losses)
  - SIADH (normal U₉₀)
  - Adrenal insufficiency
  - Hypothyroidism
  - U₉₀ < 100
  - Psychogenic polydipsia
  - Low solute "tea & toast"

- Hypervolemic
  - U₉₀ > 20
  - Diuretics (especially thiazides)
  - Salt-wasting nephropathy
  - U₉₀ < 10 and Fe₉₀ < 1% (extra-renal losses)
  - Diarrhea
  - Excessive sweating
  - Third spacing (e.g. peritonitis, pancreatitis, burns)

Figure 4. Approach to hyponatremia

Signs and Symptoms

- depend on degree of hyponatremia and more importantly, velocity of progression from onset
- hyponatremia = swollen cells
- acute hyponatremia (<24-48 h) more likely to be asymptomatic
- chronic hyponatremia (>24-48 h) less likely to be symptomatic due to adaptation
  - adaptation: normalization of brain volume through loss of cellular electrolytes (within hours) and organic osmolytes (within days)
- adaptation is responsible for the risks associated with overly rapid correction
- neurologic symptoms predominate (secondary to cerebral edema): headache, nausea, malaise, lethargy, weakness, muscle cramps, anorexia, somnolence, disorientation, personality changes, depressed reflexes, decreased LOC

Complications

- seizures, coma, respiratory arrest, permanent brain damage, brainstem herniation, death
- risk of brain cell shrinkage with rapid correction of hyponatremia
  - can develop osmotic demyelination of pontine and extrapontine neurons; may be irreversible (e.g. central pontine myelinolysis: cranial nerve palsies, quadriplegia, decreased LOC)
**Risk Factors for Osmotic Demyelination**
- rise in serum [Na⁺] with correction >8 mmol/L/24 hr if chronic hyponatremia
- associated hypokalemia and/or malnutrition (e.g. low muscle mass)
- if patient with hyponatremia and hypovolemia is given large volume of isotonic fluid (ADH is stimulated by hypovolemia; when hypovolemia is corrected, the ADH level falls suddenly causing sudden brisk water diuresis, and therefore rapid rise in serum Na⁺ level)
- patient with psychogenic polydipsia, deprived of water

**Investigations**
- ECF volume status assessment (see Table 4)
- serum electrolytes, glucose, Cr
- serum osmolality, urine osmolality
- urine Na⁺ (urine Na⁺ <10-20 mmol/L suggests volume depletion as the cause of hyponatremia)
- assess for causes of SIADH (see Table 5)
- TSH, free T4, and cortisol levels
- consider CXR and possibly CT chest if suspect pulmonary cause of SIADH (e.g. paraneoplastic syndrome by small cell lung cancer)
- consider CT head if suspect CNS cause of SIADH

**Treatment of Hyponatremia**
- general measures for all patients
  1. treat underlying cause (e.g. restore ECF volume if volume depleted, remove offending drug, treat pain, nausea, etc.)
  2. restrict free water intake
  3. promote free water loss
  4. carefully monitor serum Na⁺, urine volume, and urine tonicity
  5. ensure frequently that correction is not occurring too rapidly:
     - monitor urine output frequently: high output of dilute urine is the first sign of dangerously rapid correction of hyponatremia

**A. Known Acute (known to have developed over <24-48 h)**
- commonly occurs in hospital (dilute IV fluid, post-operative increased ADH)
- less risk from rapid correction since adaptation has not fully occurred
- if symptomatic
  - correct rapidly with 3% NaCl 1-2 cc/kg/h up to serum [Na⁺] = 125-130 mmol/L.
  - may need furosemide to address volume overload
- if asymptomatic, treatment depends on severity
  - if marked fall in plasma [Na⁺], treat as symptomatic

**B. Chronic or Unknown**
1. if severe symptoms (seizures or decreased LOC)
   - must partially correct acutely
   - aim for increase of Na⁺ by 1-2 mmol/L/h for 4-6 h
   - limit total rise to 8 mmol/L in 24 h
   - IV 3% NaCl at 1-2 cc/kg/h
   - may need furosemide
2. if asymptomatic
   - water restrict to <1 L/d fluid intake
   - consider IV 0.9% NS + furosemide (reduces urine osmolality, augments excretion of H₂O)
   - consider NaCl tablet or Oxocubes® as a source of Na⁺
3. refractory
   - furosemide and oral salt tablets
   - oral urea (osmotic aquaresis)
   - V2 receptor antagonists (e.g. tolvaptan)
4. always pay attention to patient’s ECF volume status – if already volume-expanded, unlikely to give NaCl (tablet or IV); if already volume-depleted, almost never appropriate to give furosemide

**C. Options for Treatment of Overly-Rapid Correction**
- give water (IV D5W)
- give ADH to stop water diuresis (DDAVP 1-2 µg IV)

**Impact of IV Solution on Serum [Na+]**
- formula to estimate the change in serum [Na⁺] caused by retention of 1 L of any infusate
  \[ \frac{\text{change in serum } [\text{Na}^+] = \text{infusate } [\text{Na}^+] - \text{serum } [\text{Na}^+]}{\text{TBW} + 1 \text{ L}} \]
- formula assumes there are no losses of water or electrolytes

**Concentration of [Na⁺] in Common Infusates**
- [Na⁺] in 0.45% NaCl = 77 mmol/L
- [Na⁺] in 0.9% NaCl = 154 mmol/L
- [Na⁺] in 3% NaCl = 513 mmol/L
- [Na⁺] in 5% NaCl = 855 mmol/L
- [Na⁺] in Ringer’s lactate = 130 mmol/L
- [Na⁺] in D5W = 0

**Correction of Na⁺ in hyponatremia should not exceed 8 mmol/L/24 hr unless definitely known to be <24-48 h duration; frequent monitoring of serum Na⁺ and urine output is essential**

**Beware of Rapid Correction of Hyponatremia**
- Inadvertent rapid correction of hyponatremia can easily occur (e.g. patient with hyponatremia due to SIADH from nausea)
- Anti-emetic given for relief of hyponatremia-induced nausea
- ADH quickly turned off in the absence of nausea, the kidneys rapidly excrete the excess free water, and the serum [Na⁺] rises rapidly
- Patient at risk of osmotic demyelination
- High output dilute urine (>100 cc/h, <100 mOsm/L) in the setting of hyponatremia is usually the first sign of dangerously rapid correction of serum sodium
SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION
1. urine that is inappropriately concentrated for the serum osmolality
2. high urine sodium (>20-40 mmol/L)
3. high FE

Correction of serum [Na+] in hypernatremia should not exceed 12 mmol/L/24 h

Hypernatremia

- hypernatremia: serum [Na+] >145 mmol/L
- too little water relative to total body Na⁺; always a hyperosmolar state
- usually due to N/E water loss, rarely due to hypertonic Na⁺ gain
- less common than hyponatremia because patients are protected against hypernatremia by thirst and release of ADH

Table 5. Disorders Associated with SIADH

<table>
<thead>
<tr>
<th>Cancer</th>
<th>Pulmonary</th>
<th>CNS</th>
<th>Drugs</th>
<th>Miscellaneous</th>
</tr>
</thead>
<tbody>
<tr>
<td>Small cell cancer</td>
<td>Pneumonia</td>
<td>Mass lesion</td>
<td>Antidepressants</td>
<td>Post-operative state</td>
</tr>
<tr>
<td>Bronchogenic carcinoma</td>
<td>Lung abscess</td>
<td>Encephalitis</td>
<td>TCAs</td>
<td>Pain</td>
</tr>
<tr>
<td>Pancreatic adenocarcinoma</td>
<td>TB</td>
<td>Subarachnoid hemorrhage</td>
<td>SSRIs</td>
<td>Severe nausea</td>
</tr>
<tr>
<td>Hodgkin’s lymphoma</td>
<td>Acute respiratory failure</td>
<td>Stroke</td>
<td>Antineoplastics</td>
<td>HIV</td>
</tr>
<tr>
<td>Thymoma</td>
<td>Asthma</td>
<td>Head trauma</td>
<td>Vincristine</td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td>COPD</td>
<td>Acute psychosis</td>
<td>Cyclophosphamide</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Positive pressure ventilation</td>
<td>Acute intermittent porphyria</td>
<td>Anti-epileptics</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Carbamazepine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Barbiturates</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chlorpropamide</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ACEI</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>DDVP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Oxytocin</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Nicotine</td>
<td></td>
</tr>
</tbody>
</table>

Signs and Symptoms
- with acute hypernatremia no time for adaptation, therefore more likely to be symptomatic
- adaptive response: cells import and generate new osmotically active particles to normalize size
- due to brain cell shrinkage: altered mental status, weakness, neuromuscular irritability, focal neurologic deficits, seizures, coma, death
- ± polyuria, thirst, signs of hypovolemia

Complications
- increased risk of vascular rupture resulting in intracranial hemorrhage
- rapid correction may lead to cerebral edema due to ongoing brain hyperosmolality

Treatment of Hypernatremia
- general measures for all patients
  - give free water (oral or IV)
  - treat underlying cause
  - monitor serum Na⁺ frequently to ensure correction is not occurring too rapidly
  - if evidence of hemodynamic instability, must first correct volume depletion with NS bolus
  - loss of water is often accompanied by loss of Na⁺, but a proportionately larger water loss
  - use formula to calculate free water H₂O deficit and replace
  - encourage patient to drink pure water, as oral route is preferred for fluid administration

<table>
<thead>
<tr>
<th>Fluid</th>
<th>Volume</th>
<th>Replacement</th>
</tr>
</thead>
<tbody>
<tr>
<td>D5W</td>
<td>1 L</td>
<td>1 L</td>
</tr>
<tr>
<td>NS</td>
<td>0.45%</td>
<td>500 mL</td>
</tr>
<tr>
<td>Osmol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Na⁺</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osmol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Na⁺</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

H₂O Deficit and TBW Equations

TBW = 0.6 x wt (kg) men
TBW = 0.5 x wt (kg) women

H₂O deficit = TBW x (Na⁺)plasma – 140 / 140

Correction of serum [Na⁺] in hypernatremia should not exceed 12 mmol/L/24 h

1 L D5W approximately equals 1 L of free water
1 L 0.45% NS approximately equals 500 mL of free water
• if unable to replace PO or NG, correct H₂O deficit with hypotonic IV solution (IV D5W, 0.45% NS [half normal saline], or 3.3% dextrose with 0.3% NaCl ["2/3 and 1/3"])
• use formula (see Hypotremia, NP8) to estimate expected change in serum Na⁺ with 1 L infusate
• aim to lower [Na⁺] by no more than 12 mmol/L in 24 h (0.5 mmol/L/h)
• must also provide maintenance fluids and replace ongoing losses
• general rule: give 2 cc/kg/h of free water to correct serum [Na⁺] by about 0.5 mmol/L/h or 12 mmol/L/d

Diabetes Insipidus

• collecting tubule is impermeable to water due to absence of ADH or impaired response to ADH
• defect in central release of ADH (central DI) or renal response to ADH (nephrogenic DI)

Etiology

• central DI: neurosurgery, granulomatous diseases, trauma, vascular events, and malignancy
• nephrogenic DI: lithium (most common), hypokalemia, hypercalcemia, and congenital

Diagnosis

• urine osmolality inappropriately low in patient with hypernatremia (Uosm <300 mOsm/kg)
• serum vasopressin concentration may be absent or low (central), or elevated (nephrogenic)
• dehydration test: H₂O deprivation until loss of 3% of body weight or until urine osmolality rises above plasma osmolality; if urine osmolality remains <300 (fails to concentrate urine), most likely DI
• administer DDAVP (exogenous ADH) (10 µg intranasally or 2 µg SC or IV)
  • central DI: diagnosed if there is rise in urine osmolality, fall in urine volume
  • treat with DDAVP
• nephrogenic DI: exogenous ADH fails to concentrate urine as kidneys do not respond
  • treat with water (IV D5W or PO water), thiazides may help as well (reduced ECF volume stimulates proximal tubular reabsorption of sodium and water, leading to less delivery of glomerular filtrate to ADH sensitive parts of renal tubule, and therefore lower urine volume results)

Potassium Homeostasis

• approximately 98% of total body K⁺ stores are intracellular
• normal serum K⁺ ranges from 3.5-5.0 mEq/L
• in response to K⁺ load, rapid removal from ECF is necessary to prevent life-threatening hyperkalemia
• insulin, catecholamines, and acid-base status influence K⁺ movement into cells
• aldosterone has a minor effect
• potassium excretion is regulated at the distal nephron
  • K⁺ excretion = urine flow rate x urine [K⁺]

Factors which Increase Renal K⁺ Loss

• hyperkalemia
• increased distal tubular urine flow rate and Na⁺ delivery (thiazides and loop diuretics)
• increased aldosterone activates epithelial sodium channels in cortical collecting duct, causing Na⁺ reabsorption and K⁺ excretion
• metabolic alkalosis (increases K⁺ secretion)
• hypomagnesemia
• increased non-reabsorbable anions in tubule lumen: HCO₃⁻, penicillin, salicylate (increased tubular flow rate increases K⁺ secretion)

Hypokalemia

• serum [K⁺] <3.5 mEq/L

Signs and Symptoms

• usually asymptomatic, particularly when mild (3.0-3.5 mmol/L)
• N/V, fatigue, generalized weakness, myalgia, muscle cramps, and constipation
• if severe: arrhythmias, muscle necrosis, and rarely paralysis with eventual respiratory impairment
• arrhythmias occur at variable levels of K⁺; more likely if digoxin use, hypomagnesemia, or CAD
• ECG changes are more predictive of clinical picture than serum [K⁺]
  • U waves most important (low amplitude wave following a T wave)
  • flattened or inverted T waves
  • depressed ST segment
  • prolongation of Q-T interval
  • with severe hypokalemia: P-R prolongation, wide QRS, arrhythmias; increases risk of digitalis toxicity
Figure 6. ECG changes in hypokalemia

Approach to Hypokalemia
1. Emergency measures: obtain ECG; if potentially life threatening, begin treatment immediately
2. Rule out transcellular shifts of K+ as cause of hypokalemia
3. Assess contribution of dietary K+ intake
4. Spot urine K:Cr (should be less than 1 in setting of hypokalemia)
   - If <1 consider GI loss
   - If >1 consider a renal loss
5. Consider 24 h K+ excretion
6. If renal K+ loss, check BP and acid-base status
7. May also assess plasma renin and aldosterone levels, serum [Mg2+]

Figure 7. Approach to hypokalemia

Treatment
- Treat underlying cause
- If true K+ deficit, potassium repletion
  - Oral sources – food, tablets (K-Dur”), KCl liquid solutions (preferable route if the patient tolerates PO medications)
  - IV – usually KCl in saline solutions, avoid dextrose solutions (may exacerbate hypokalemia via insulin release)
- Max 40 mmol/L via peripheral vein, 60 mmol/L via central vein, max infusion 20 mmol/h
- K+-sparking diuretics (triamterene, amiloride, spironolactone) can prevent renal K+ loss
- Restore Mg2+ if necessary
- If urine output and renal function are impaired, correct with extreme caution
- Risk of hyperkalemia with potassium replacement especially high in elderly, diabetics, and patients with decreased renal function
- Beware of excessive potassium repletion, especially if transcellular shift caused hypokalemia
Hyperkalemia

- serum [K+] >5.0 mEq/L

**Signs and Symptoms**
- usually asymptomatic but may develop nausea, palpitations, muscle weakness, muscle stiffness, paresthesias, areflexia, ascending paralysis, and hypoventilation
- impaired renal ammoniagenesis and metabolic acidosis
- ECG changes and cardiotoxicity (do not correlate well with serum [K+])
- peaked and narrow T waves
- decreased amplitude and eventual loss of P waves
- prolonged PR interval
- widening of QRS and eventual merging with T wave (sine-wave pattern)
- AV block
- ventricular fibrillation, asystole

**Approach to Hyperkalemia**
1. emergency measures: obtain ECG, if life threatening begin treatment immediately
2. rule out factitious hyperkalemia; repeat blood test
3. hold exogenous K+ (PO and IV) and any K+ retaining medications
4. assess potential causes of transcellular shift
5. estimate GFR (calculate CrCl using Cockcroft-Gault)

**Treatment**
- acute therapy is warranted if ECG changes are present or if patient is symptomatic regardless of [K+]
- tailor therapy to severity of increase in [K+] and ECG changes
  - [K+] <6.5 and normal ECG
  - treat underlying cause, stop K+ intake, increase the loss of K+ via urine and/or GI tract
  - [K+] between 6.5 and 7.0, no ECG changes: add insulin to above regimen
  - [K+] >7.0 and/or ECG changes: first priority is to protect the heart, add calcium gluconate to above

**1. Stabilize Myocardium**
- calcium gluconate 1-2 amps (10 mL of 10% solution) IV
- antagonizes the membrane action of hyperkalemia, protects cardiac conduction system, no effect on serum [K+]
- onset within minutes, lasts 30-60 min (may require repeat doses during treatment course of hyperkalemia)

**Table 6. Causes of Hyperkalemia**

<table>
<thead>
<tr>
<th>Factitious</th>
<th>Increased Intake</th>
<th>Transcellular Shift</th>
<th>Decreased Excretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample hemolysis*</td>
<td>Diet</td>
<td>Intravascular hemolysis</td>
<td>Decreased GFR</td>
</tr>
<tr>
<td>Sample taken from vein where IV KCl is running</td>
<td>KCI tabs</td>
<td>Rhabdomyolysis</td>
<td>Renal failure</td>
</tr>
<tr>
<td>Prolonged use of tourniquet</td>
<td>IV KCI</td>
<td>Tumor lysis syndrome</td>
<td>Low effective circulating volume</td>
</tr>
<tr>
<td>Leukocytosis (extreme)</td>
<td>Salt substitute</td>
<td>Insulin deficiency</td>
<td>NSAIDs in renal insufficiency</td>
</tr>
<tr>
<td>Thrombocytosis (extreme)</td>
<td></td>
<td>Acidemia</td>
<td>Normal GFR but hypoaldosteronism</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drugs</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>β-blockers</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Digitalis overdose (blocks Na+/K+ ATPase)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Succinylcholine</td>
<td></td>
</tr>
</tbody>
</table>

*Most common

**Table 7. Causes of Hyperkalemia with Normal GFR**

<table>
<thead>
<tr>
<th>Decreased Aldosterone Stimulus (low renin, low aldosterone)</th>
<th>Decreased Aldosterone Production (normal renin, low aldosterone)</th>
<th>Aldosterone Resistance (decreased tubular response)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Associated with diabetic nephropathy, NSAIDs, chronic interstitial nephritis, HIV</td>
<td>Adrenal insufficiency of any cause (e.g. Addison’s disease, AIDS, metastatic cancer) ACEI Angiotensin II receptor blockers</td>
<td>K+-sparring diuretics Spironolactone Amiloride Triamterene Renal tubulointerstitial disease</td>
</tr>
</tbody>
</table>

**Treatment of Hyperkalemia**
- C BIG K DROP
- C – Calcium gluconate
- BIG – β-agonist, Bicarbonate, Insulin, Glucose
- K – Kayexalate
- DROP – Diuretics, Dialysis

In patients with DM and increased [K+] and hyperglycemia, often just giving insulin to restore euglycemia is sufficient to correct the hyperkalemia
2. Shift K⁺ into Cells
- regular insulin (Insulin R) 10-20 U, give D50W before insulin
  - onset of action 15-30 min, lasts 1-2 h
  - monitor capillary blood glucose q1h because of risk of hypoglycemia
  - can repeat every 4-6 h
- caution giving D50W before insulin if hyperkalemia is severe as it can cause a serious arrhythmia
- NaHCO₃ 1-3 ampules (given as 3 ampules of 7.5% or 8.4% NaHCO₃ in 1 L D5W)
  - onset of action 15-30 min, transient effect, drives K⁺ into cells in exchange for H⁺
  - more effective if patient has metabolic acidosis
- β₂-agonist (Ventolin*) in nebulized form (dose = 2 cc or 10 mg inhaled) or 0.5 mg IV
  - onset of action 30-90 min, stimulates Na⁺/K⁺ ATPase
  - caution if patient has heart disease as may result in tachycardia

3. Enhance K⁺ Removal from Body
- via urine (preferred approach)
  - furosemide (≥40 mg IV), may need IV NS to avoid hypovolemia
  - fludrocortisone (synthetic mineralocorticoid) if suspect aldosterone deficiency
- via gastrointestinal tract
  - cation-exchange resins: calcium resin or sodium polystyrene sulfonate (Kayexalate*)
    - increasingly falling out of favour due to risk of colonic necrosis; works by binding Na⁺ in exchange for K⁺, and controversal how much K⁺ is actually removed
    - lactulose or sorbitol PO to avoid constipation (must ensure that patient has a bowel movement after resin is administered - main benefit may be the diarrhea caused by lactulose)
  - Kayexalate® enemas with tap water
  - dialysis (renal failure, life threatening hyperkalemia unresponsive to therapy)

### Hyperphosphatemia

#### Definition
- serum phosphate >1.45 mmol/L
- critical role in the development of secondary hyperparathyroidism and renal osteodystrophy in patients with advanced CKD and on dialysis

<table>
<thead>
<tr>
<th>Increased Phosphate Load</th>
<th>Reduced Renal Clearance</th>
<th>Pseudohyperphosphatemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>GI intake (rectal enema, GI bleeding)</td>
<td>Acute/chronic renal failure</td>
<td>Hyperglobulinemia</td>
</tr>
<tr>
<td>IV phosphate load (K-Phos®, blood transfusion)</td>
<td>Hyperparathyroidism</td>
<td>Hyperlipidemia</td>
</tr>
<tr>
<td>Endogenous phosphate (tumour lysis syndrome, rhabdomyolysis, hemolysis, lactic and ketocacidosis)</td>
<td>Acromegaly</td>
<td>Hyperbilirubinemia</td>
</tr>
<tr>
<td>Tumour calcinosis (ability of kidney to specifically clear phosphate is defective)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Clinical Features
- non-specific, include ectopic calcification, renal osteodystrophy

#### Treatment
- acute: hemodialysis if symptomatic; aluminum hydroxide (use with extreme caution in renal failure)
- chronic: low PO₄³⁻ diet, phosphate binders (e.g. CaCO₃ or lanthanum carbonate or sevelamer with meals)

### Hypophosphatemia

#### Definition
- serum phosphate <0.85 mmol/L

<table>
<thead>
<tr>
<th>Inadequate Intake</th>
<th>Renal Losses</th>
<th>Excessive Skeletal Mineralization</th>
<th>Shift into ICF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starvation</td>
<td>Hyperparathyroidism</td>
<td>Post parathyroidectomy</td>
<td>Recovery from metabolic acidosis</td>
</tr>
<tr>
<td>Malabsorption (diarrhea, steatorrhea)</td>
<td>Diuretics</td>
<td>(referred to as 'hungry bone syndrome')</td>
<td>Respiratory alkalosis</td>
</tr>
<tr>
<td>Antacid use</td>
<td>X-linked or AD hypophosphatemic rickets</td>
<td>Fanconi syndrome</td>
<td>Starvation refueling (stimulated by insulin)</td>
</tr>
<tr>
<td>Alcoholism</td>
<td>Early post-kidney transplant</td>
<td>Multiple myeloma</td>
<td></td>
</tr>
</tbody>
</table>

#### Clinical Features
- non-specific (CHF, coma, hypotension, weakness, defective clotting)
Treatment
- treat underlying cause
  - Oral PO₆⁻: 2-4 g/d divided bid-qid (start at 1 g/d to minimize diarrhea)
  - IV PO₆⁻: only for severely symptomatic patients or inability to tolerate oral therapy

**Hypermagnesemia**

Definition
- serum magnesium >0.85 mmol/L

Etiology
- AKI/CRF
- Mg²⁺-containing antacids or enemas
- IV administration of large doses of MgSO₄ (e.g. for preeclampsia; see Obstetrics, OB24)

Clinical Features
- rarely symptomatic
- drowsiness, hyporeflexia, respiratory depression, heart block, cardiac arrest, hypotension

Treatment
- discontinue Mg²⁺-containing products
- IV calcium (Mg²⁺-antagonist) for acute reversal of magnesium toxicity
- dialysis if renal failure

**Hypomagnesemia**

Definition
- serum magnesium <0.70 mmol/L

Etiology
- GI losses
- Starvation/malabsorption
- Vomiting/diarrhea
- Alcoholism
- Acute pancreatitis
- Excess renal loss
- 2º hyperaldosteronism due to cirrhosis and CHF
- Hyperglycemia
- Hypokalemia
- Hypercalcemia
- Loop and thiazide-type diuretics
- Nephrotic medications
- Proton-pump inhibitors
- Early post-renal transplant

Clinical Features
- seizures, paresis, Chvostek and Trousseau signs, ECG changes (widened QRS, prolonged PR, T-wave abnormalities), and arrhythmias including Torsades de pointes

Treatment
- treat underlying cause
- encourage increased dietary intake e.g. fruits
- oral Mg²⁺ salts unless patients have seizures or other severe symptoms
- Mg²⁺ IM/IV; cellular uptake of Mg²⁺ is slow, therefore repletion requires sustained correction
- discontinue diuretics
  - in patients requiring diuretics, use a K⁺-sparing diuretic to minimize magnesuria

You will be unable to correct hypokalemia or hypocalcemia without first supplementing magnesium if patient is hypomagnesemic

Acid-Base Disorders

- acid-base homeostasis influences protein function and can critically affect tissue and organ function with consequences to cardiovascular, respiratory, metabolic, and CNS function
- see Respirology, R6 for more information on respiratory acidosis/alkalosis
- normal concentration of HCO₃⁻ = 24 mEq/L (range: 22-30 mEq/L)
- normal pCO₂ = 40 mmHg (range: 36-44 mmHg)
- each acid base disorder has an appropriate compensation
  - inadequate compensation or overcompensation can indicate the presence of a second acid-base disorder (e.g. in metabolic acidosis, inadequate compensation means there is also respiratory acidosis; overcompensation means there is also respiratory alkalosis)
Approach

1. Identify the primary disturbance (see Figure 9)
   - respiratory acidosis, metabolic acidosis, respiratory alkalosis, metabolic alkalosis

2. Evaluate compensation. If compensation is not appropriate, a second acid-base disorder is likely present
   - compensation occurs in the same direction as the primary disturbance

3. Calculate Plasma AG
   - AG = \([Na^+] - ([HCO_3^-] + [Cl^-])\)
   - baseline = 12, normal range 10-14 mEq/L
   - AG can be altered by plasma albumin level: for each 10 g/L fall in albumin, lower baseline AG by 3 mEq/L (e.g. if plasma [albumin] = 20 g/L, expect AG = 6 mEq/L)

4. If AG elevated, compare increase in AG with decrease in HCO_3^-
   - if increase in AG < decrease in HCO_3^-, there is a coexisting non-AG metabolic acidosis
   - if increase in AG > decrease HCO_3^-, there is a coexisting metabolic acidosis

5. Calculate Osmolar Gap
   - osmolar gap = measured osmolality – calculated osmolality
   - calculated osmolality = (2 x [Na^+]) + [urea] + [glucose] (all units are in mmol/L)
   - normal osmolar gap <10
   - If OG >10, consider: methanol poisoning, ethylene glycol poisoning, or another cause of acidosis plus ethanol ingestion

Metabolic Acidosis

Etiology and Pathophysiology

1. Increased AG Metabolic Acidosis (4 types)
   1. Lactic acidosis (2 types)
      - L-lactic acid
        - type A: due to tissue hypoperfusion (any cause of shock), ischemic bowel, profound hypoxemia
        - type B: non-hypoxic – multiple causes; the most common is failure to metabolize normally produced lactic acid in the liver due to severe liver disease; other causes include: excessive alcohol intake, thiamine deficiency, metformin accumulation (metformin interferes with electron transport chain), certain anti-retrovirals, large tumours, mitochondrial myopathies
      - D-lactic acid: rare syndrome characterized by episodes of encephalopathy and metabolic acidosis
        - occurs in the setting of carbohydrate malabsorption (e.g. short bowel syndrome), colonic bacteria metabolize carbohydrate load into D-lactic acid, diminished colonic motility and impaired D-lactate metabolism
   2. Ketoacidosis
      - diabetic
      - starvation
      - alcoholic (decreased carbohydrate intake and vomiting)
3. Toxins
- methanol (toxic to brain and retina, can cause blindness and brain death): metabolized to formic acid
- ethylene glycol (toxic to brain and kidneys): metabolized to oxalic acid (envelope shaped crystals in urine) and multiple other acids
- salicylate (e.g. ASA) overdose: causes acidosis due to salicylic acid, and also accumulation of lactic acid (salicylate at toxic levels impairs electron transport chain) and ketoacid (salicylate activates fat breakdown)

4. Advanced renal failure (e.g. serum Cr increased at least 5x above baseline – a very low GFR causes anion retention, and renal disease leads to impaired bicarbonate production)

2. Normal AG Metabolic Acidosis (Hyperchloremic Acidosis)
- diarrhea (HCO$_3^-$ loss from GI tract)
- RTA
  - type I RTA (distal): inability to secrete H$^+$ in collecting duct, leading to impaired excretion of ammonium into urine
  - type II RTA (proximal): impaired HCO$_3^-$ reabsorption
  - type III RTA: combination of Types I and II and is extremely rare
  - type IV RTA: defective ammoniagenesis due to decreased aldosterone, hyporesponsiveness to aldosterone, or hyperkalemia
- to help distinguish renal causes from non-renal causes, use Urine AG = (Na$^+$ + K$^+$) – CI-
- calculation establishes the presence or absence of unmeasured positive ions (e.g. NH$_4^+$) in urine
- if UAG <0, suggests adequate NH$_4^+$ excretion in urine (likely nonrenal cause: diarrhea)
- if UAG >0, suggests problem is lack of NH$_4^+$ in urine (e.g. distal RTA)

### Treatment of Metabolic Acidosis
1. treat underlying cause
   - fluid resuscitation and insulin for DKA
   - restore tissue perfusion for Type A lactic acidosis
   - ethylene/foxepizole $\pm$ dialysis for methanol or ethylene glycol poisoning
   - alkaline diuresis $\pm$ dialysis if ASA overdose
2. correct coexisting disorders of K$^+$ (see Hyperkalemia, NP13)
3. consider treatment with exogenous alkali (e.g. NaHCO$_3$) if
   - severe reduction in [HCO$_3^-$] e.g. <8 mmol/L, especially with very low pH (<7)
   - no metabolizable anion (e.g. salicylate, formate, oxalate, or sulphate); note that lactate and ketoacid anions can be metabolized to HCO$_3^-$
- note: risks of sodium bicarbonate therapy
  - hypokalemia: causes K$^+$ to shift into cells (correct K$^+$ deficit first)
  - ECF volume overload: Na$^+$ load given with NaHCO$_3$ can exacerbate pulmonary edema
  - overshoot alkalemia: abrupt, poorly tolerated transition from overly aggressive alkali loading, partial conversion of accumulated organic anions to HCO$_3^-$, and persisting hyperventilation

### Metabolic Alkalosis

#### Pathophysiology
- requires initiating event and maintenance factors
  - precipitating factors
    - GI (vomiting, NG tube) or renal loss of H$^+$
    - exogenous alkali (oral or parenteral administration), milk alkali syndrome
    - diuretics (contraction alkalosis): decreased excretion of HCO$_3^-$, decreased ECF volume, therefore increased [HCO$_3^-$]
    - post-hypercapnia: renal compensation for respiratory acidosis is HCO$_3^-$ retention, rapid correction of respiratory disorder results in transient excess of HCO$_3^-$
- maintenance factors
  - volume depletion: reduced GFR and increase proximal reabsorption of NaHCO$_3^-$ and increased aldosterone
  - hyperaldosteronism (1st or 2nd): distal Na$^+$ reabsorption in exchange for K$^+$ and H$^+$ excretion leads to HCO$_3^-$ generation; aldosterone also promotes hypokalemia
  - hypokalemia: transeellular K$^+$/$\text{H}^+$ exchange; stimulus for ammoniagenesis and HCO$_3^-$ generation

#### Evaluate Compensation (identify co-existing respiratory acid-base disorders)
- hypoventilation (an upper limit to compensation exists – breathing cannot be stopped)

#### Treatment
- treat underlying cause
- correct underlying disease, replenish K$^+$ and Mg$^{2+}$ deficits, and possibly K$^+$-sparing diuretic
- saline sensitive metabolic alkalosis (most common)
  - volume repletion $\pm$ carbonic anhydrase inhibitor (e.g. acetazolamide) to facilitate loss of HCO$_3^-$ in urine
- saline resistant metabolic alkalosis
  - remove source of aldosterone or glucocorticoid $\pm$ spironolactone
Acute Kidney Injury

Definition
- abrupt decline in renal function leading to increased nitrogenous waste products normally excreted by the kidney
- formerly known as acute renal failure

Clinical Presentation
- azotemia (increased BUN, Cr)
- abnormal urine volume: formally <0.5 ml/kg/h for >6 h but can manifest as anuria, oliguria, or polyuria

Approach to AKI

Investigations
- blood work: CBC, electrolytes, Cr, urea (think prerenal if increase in urea is relatively greater than increase in Cr), Ca++, PO4
- urine dipstick: albumin, hemoglobin, WBCs, others: glucose, pH, urobilinogen, specific gravity
- urine volume, C&S, R&M: sediment, casts, crystals
- urinary indices: electrolytes, osmolality
- Foley catheterization (rule out bladder outlet obstruction)

Clues to Prerenal Etiology
- Clinical: Decreased BP, increased HR, and orthostatic HR and BP changes
- Increased [urea] >> Increased [Cr]
- Urine [Na+] < 10-20 mmol/L
- Urine osmolality > 500 mOsm/kg
- Fractional excretion of Na+ < 1%

Clues to Renal Etiology
- Appropriate clinical context
- Urinalysis positive for casts:
  - Pigmented granular – ATN
  - WBC – AN
  - RBC – GN
- Systemic features, anemia, thrombocytopenia, HTN, mild-moderate ECF volume overload

Clues to Postrenal Etiology
- Known solitary kidney
- Older man
- Recent retroperitoneal surgery
- Anuria
- Palpable bladder
- Ultrasound shows hydronephrosis

Diff erentiating Prerenal from ATN

<table>
<thead>
<tr>
<th>Prerenal</th>
<th>ATN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urealysis Normal</td>
<td>RBC, pigmented granular casts</td>
</tr>
<tr>
<td>Urine [Na+] &lt; 20 mEq/L</td>
<td>&gt; 20 mEq/L</td>
</tr>
<tr>
<td>Urine [Na+]/[Cl]</td>
<td>&lt; 20</td>
</tr>
<tr>
<td>Urine osmolality</td>
<td>&gt; 500</td>
</tr>
<tr>
<td>FeNa</td>
<td>&lt; 1%</td>
</tr>
</tbody>
</table>
Parenchymal Kidney Diseases

Fluid challenge (e.g., fluid bolus to rule out most prerenal causes)
Imaging: abdomen U/S (assess kidney size, hydronephrosis, postrenal obstruction)
Indications for renal biopsy
- Diagnosis is not certain
- Prerenal azotemia or ATN is unlikely
- Oliguria persists >4 wk

Treatment
1. Preliminary measures
   - Prerenal
     - Correct prerenal factors: optimize volume status and cardiac performance using fluids that will stay in the plasma subcompartment (NS, albumin, blood/plasma), hold ACEI/ARB (gently rehydrate when needed, e.g., CHF) and NSAIDs
   - Renal
     - Address reversible renal causes: discontinue nephrotoxic drugs, treat infection, and optimize electrolytes
     - Correct ECF volume, supportive care, consider corticosteroid or immunosuppressive therapy
   - Postrenal
     - Consider obstruction: structural (stones, strictures) vs. functional (neuropathy)
     - For obstruction to cause AKI, must have functional solitary kidney or obstruction affecting both kidneys
     - Treat with Foley catheter insertion, indwelling bladder catheter, nephrostomy, stenting
2. Treat complications
   - Fluid overload
   - NaCl restriction
   - High dose loop diuretics
   - Hyperkalemia (see Approach to Hyperkalemia, NP13)
   - Adjust dosages of medications cleared by kidney (e.g., amiodarone, digoxin, cyclosporin, tacrolimus, some antibiotics, and chemotherapeutic agents)
   - Dialysis
3. Definitive therapy depends on etiology

Prognosis
- High morbidity and mortality in patients with sustained AKI and multi-organ failure

Parenchymal Kidney Diseases

Glomerular Diseases

HISTOLOGICAL TERMS OF GLOMERULAR CHANGES

Extent of Changes
- Histological term describing the number of glomeruli affected in a given condition:
  - Diffuse: majority of glomeruli abnormal
  - Focal: some glomeruli affected
- Histological term describing the extent to which individual glomeruli are affected in a given condition
  - Global: entire glomerulus abnormal
  - Segmental: only part of the glomerulus abnormal

Types of Changes
- Proliferation: hyperplasia of one of the glomerular cell types (mesangial, endothelial, parietal epithelial), with or without inflammatory cell infiltration
  - Crescent formation: parietal epithelial cell proliferation and mononuclear cell infiltration form crescent-shape in Bowman’s space
- Membranous changes: capillary wall thickening due to immune deposits or alterations in basement membrane

CLINICAL PRESENTATION OF GLOMERULAR DISEASE

Important Points to Remember
- Glomerular diseases have diverse clinical presentations including hematuria, proteinuria, HTN, edema, and decreased GFR
- Each glomerulopathy presents as one of four major glomerular syndromes (these are NOT diagnoses)
  1. Asymptomatic urinary abnormalities
     - Proteinuria
     - Hematuria
  2. Nephritic syndrome
     - Acute GN
     - Rapidly progressive GN
3. nephrotic syndrome
4. ESRD
- glomerulopathies can be caused by a primary disease or can occur secondary to a systemic disease
- some glomerulopathies can present as more than one syndrome at different times

**The Nephritic-Nephrotic Spectrum**
- glomerular pathology can present with a clinical picture anywhere on a spectrum with pure nephritic and pure nephrotic syndromes at the extremes

**Figure 12. Spectrum of glomerular pathology**

<table>
<thead>
<tr>
<th>Proteinuria</th>
<th>Intermediate</th>
<th>Nephritic</th>
</tr>
</thead>
<tbody>
<tr>
<td>FSGS</td>
<td>Membranoproliferative GN</td>
<td>Diffuse proliferative GN</td>
</tr>
<tr>
<td>Membranous glomerulopathy</td>
<td>Focal proliferative GN</td>
<td>Crescentic GN</td>
</tr>
<tr>
<td>Minimal change</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Proteinuria**
- hallmark of nephrotic syndromes
- 24 h urine protein: gold standard to assess degree of proteinuria
- urine ACR: used to screen for diabetic nephropathy
- microalbuminuria
  - defined as ACR ≥2.0 mg/mmol
  - marker of vascular endothelial function
  - an important prognostic marker for kidney disease in DM and HTN (see *Diabetes, NP31*)
- microalbuminuria is the earliest sign of diabetic nephropathy
- composition of normal total urine protein
- upper limit of normal daily excretion of total protein is 150 mg/d
- upper limit of normal daily excretion of albumin is 30 mg/d
- the other normally excreted proteins are either filtered low molecular weight proteins (such as immunoglobulin light chains or β-2 microglobulin) or proteins secreted by the tubular epithelial cells (e.g. Tamm-Horsfall mucoprotein)

**Figure 13. Classification of proteinuria**

**Physiologic**
- Orthostatic
- Absence of proteinuria overnight
- Usually resolves spontaneously
- Transient (exercise, fever, CHF)

**Pathologic**

**Tubulointerstitial**
- <2 g/d
- e.g. Fanconi’s syndrome

**Glomerular**
- (loss of large proteins [albumin])
- e.g. multiple myeloma, amyloidosis, Waldenström’s macroglobulinemia

**Overflow**
- (overproduction of low molecular weight proteins)
- e.g. multiple myeloma, amyloidosis, Waldenström’s macroglobulinemia

**Primary**
- Minimal change GN
- Membranous GN
- FSGS
- Membranoproliferative GN
- Post-streptococcal GN
- IgA nephropathy

**Secondary**
- Systemic disease
- SLE, DM, vasculitis
- Infectious disease
- HIV, hepatitis B and C, bacterial endocarditis
- Hereditary/metabolic
- Alport’s, Fabry’s, sickle cell, PCKD
- Medications
- NSAIDs, gold, heavy metals
- Cancer
- Lymphoma, solid tumour
- Others
- Cryoglobulinemia, hypertensive nephrosclerosis

**Pathologic Proteinuria**

- Normally low molecular weight proteins (<60 kDa) pass through glomerular filtration barrier and are reabsorbed in proximal tubule
- Proximal tubule dysfunction causes impaired reabsorption and increased excretion of low molecular weight proteins
- Albumin (>60 kDa) is not affected; thus, edema is partly secondary to salt and water retention

**Glomerular**
- Normally, the filtration barrier is selectively permeable to size (<60 kDa) and charge (repels negative particles); thus, albumin is filtered to a very limited extent through a normal glomerulus
- Damage to any component of the glomerular filtration barrier results in loss of albumin and other high molecular weight proteins; thus, edema is secondary to hypoalbuminemia (low oncotic pressure), but also due to enhanced renal tubular reabsorption of filtered sodium and water (possibly due to filtered proteins stimulating the action of cortical collecting duct epithelial sodium channel)

**Overflow**
- Increased production of low molecular weight proteins which exceeds the reabsorptive capacity of the proximal tubule
- Plasma cell dyscrasias: produce light chain Ig (multiple myeloma, Waldenström’s macroglobulinemia, monoclonal gammopathy of undetermined significance)
Table 10. Daily Excretion of Protein

<table>
<thead>
<tr>
<th>Daily Excretion</th>
<th>Stage of Nephropathy</th>
<th>ACR</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;150 mg total protein (and &lt;30 mg albumin)</td>
<td>Normal</td>
<td>Less than 2.0 mg/mmol</td>
</tr>
<tr>
<td>30-300 mg albumin</td>
<td>Microalbuminuria</td>
<td>Greater than 2.0 mg/mmol</td>
</tr>
<tr>
<td>&gt;3500 mg total protein/1.73m² BSA</td>
<td>Nephrotic range proteinuria</td>
<td></td>
</tr>
<tr>
<td>Variable amount of proteinuria</td>
<td></td>
<td>Can be seen with glomerular disease</td>
</tr>
<tr>
<td>Up to 2000 mg per d</td>
<td>Possible tubular disease because of failure to reabsorb filtered proteins</td>
<td></td>
</tr>
</tbody>
</table>

**Investigations**
- urine R&M, C&S, urea, Cr
- further workup (if degree of proteinuria >0.5 g/d, casts, and/or hematuria)
  - CBC, glucose, electrolytes, 24 h urine protein, and Cr
  - urine and serum immunoelectrophoresis, abdominal/pelvic U/S
  - serology: ANA, RF, p-ANCA (MPO), c-ANCA (PR3), Hep B, Hep C, HIV, ASOT
- indications for nephrology referral
  - generally, if there is "heavy" proteinuria (ACR >30 mg/mmol), should refer to nephrologist
  - definitely if there is nephrotic syndrome: marked proteinuria >3.5 g/1.73m²/d with hypoalbuminemia (<35 g/L)

**HEMATURIA**
- hallmark of nephritic syndromes
- presence of blood or RBCs in urine
  - gross hematuria: pink, red, or tea-coloured urine
    - in gross hematuria, the urine should be centrifuged
      - if the sediment is red, true hematuria
      - if the supernatant is red, test for hemoglobin with a dipstick
        - if supernatant positive for hemoglobin: myoglobinuria or hemoglobinuria
      - if negative for hemoglobin: pseudohematuria; consider medications (e.g. rifampin), food dyes (e.g. beets), or metabolites (e.g. porphyria)
  - microscopic hematuria: blood in the urine that is invisible to the naked eye, >2-3 RBCs/HPF on microscopy

**Red Urine/Hematuria**

- **Hematological**
  - Coagulopathy, sickle cell
- **Renal**
  - Nephrolithiasis, trauma, tumour, prostatitis, urethritis
    - Dysuria or flank pain common
    - Isomorphic RBCs, no casts
    - Blood at beginning (urethritis) or end (prostate, bladder) of stream
- **Primary**
  - Membranoproliferative GN
  - Post-streptococcal GN
  - Rapidly-progressive GN
  - Interstitial nephritis (acute and chronic)
  - Papillary necrosis
  - IgA nephropathy
- **Secondary**
  - Connective tissue diseases
    - Granulomatosis with polyangiitis, Goodpasture’s, SLE, Chung-Strauss, HSP
  - Infection
    - Pyelonephritis
  - Hereditary
    - Alport’s, PKD

**Investigations for Hematuria**
- Hx and P/E: family history of nephrolithiasis, hearing loss (Alport Syndrome), cerebral aneurysm (PCKD), diet, recent URTI, irritative and obstructive urinary symptoms (UTI)
- urine R&M, C&S, urea, Cr
- renal U/S
- 24 h urine stone workup if there is a history of stone formation or if there is a stone noted on imaging: calcium, oxalate, citrate, magnesium, uric acid, cystine
- further workup (if casts and/or proteinuria): CBC, electrolytes, 24 h urine protein and Cr, serology (ANA, RF, C3, C4, p-ANCA, c-ANCA, ASOT)
- consider urology consult and possible cystoscopy if not clearly a nephrologic source for hematuria or if >50 yr of age
Glomerular Syndromes

1. ASYMPTOMATIC URINARY ABNORMALITIES

Clinical/Lab Features
- often have rapid decline in GFR, anemia, elevated inflammatory markers, ECF volume replete or mildly overloaded
- proteinuria (usually <2 g/d) and/or microscopic or macroscopic hematuria
  - isolated proteinuria
    - can be postural
    - occasionally can signal beginning of more serious GN (e.g. FSGS, IgA nephropathy, amyloid, diabetic nephropathy)
  - hematuria with or without proteinuria
    - IgA nephropathy (Berger's disease): most common type of primary glomerular disease worldwide, usually presents after viral URTI
    - hereditary nephritis (Alport Syndrome – Type IV collagen mutation): X-linked nephritis often associated with sensorineural hearing loss; proteinuria <2 g/d
    - thin basement membrane disease: usually autosomal dominant, without proteinuria; benign
    - benign recurrent hematuria: hematuria associated with febrile illness, exercise, or immunization; a diagnosis of exclusion after other possibilities are ruled out

2. NEPHRITIC SYNDROME

**Figure 15. Approach to nephritic syndrome**

**ACUTE NEPHRITIC SYNDROME**
- a subset of nephritic syndrome in which the clinical course proceeds over days
- etiology can be divided into low and normal complement levels
- frequently immune-mediated, with Ig and C3 deposits found in GBM

**Clinical/Lab Features**
- proteinuria (but <3.5 g/1.73 m²/d)
- abrupt onset hematuria (microscopic or macroscopic)
- azotemia (increased Cr and urea)
- RBC casts and/or dysmorphic RBCs in urine
- oliguria, HTN (due to salt and water retention)
- peripheral edema/puffy eyes
- smoky urine

**Treatment**
- depends on etiology
- pulse steroid therapy and other immunosuppression, BP control, monitoring for progression to end stage renal disease

**RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS/CRESCENTIC GLOMERULONEPHRITIS**
- a subset of nephritic syndrome in which the clinical course proceeds over weeks to months
- clinical diagnosis, not histopathological
- any cause of GN can present as RPGN (except minimal change disease)
- additional etiologies seen only as RPGN: anti-GBM Disease and granulomatosis with polyangiitis (previously called Wegener's granulomatosis)
- crescentic GN results from proliferation of parietal epithelial cells and is the most aggressive form of glomerular disease
Clinical/Lab Features
- fibrous crescents typically present on renal histopathology
- RBC casts and/or dysmorphic RBCs in urine
- classified by immunofluorescence staining
- Type I: Anti-GBM mediated (15% of cases)
- Type II: Immune Complex Mediated (24% of cases)
- Type III: Non-Immune Mediated (60% of cases)
- Type IV: Double Antibody Positive

Treatment and Prognosis
- treatment: underlying cause for postinfectious; corticosteroids + cyclophosphamide or other cytotoxic agent + plasmaphoresis in management of cases such as Anti-GBM Ab
- prognosis: 50% recovery with early treatment, depends on underlying cause

3. NEPHROTIC SYNDROME

Clinical/Lab Features
- heavy proteinuria (>3.5 g/1.73m2/d)
- hypoalbuminemia
- edema
- hyperlipidemia (elevated LDL cholesterol), lipiduria (fatty casts and oval fat bodies on microscopy)
- hypercoagulable state (due to antithrombin III, Protein C, and Protein S urinary losses)
- patient may report frothy urine
- glomerular pathology on renal biopsy
  - minimal change disease (or minimal lesion disease or nil disease) – e.g. glomeruli appear normal on light microscopy
  - membranous glomerulopathy
  - focal segmental glomerulosclerosis (FSGS)
  - membranoproliferative GN
  - nodular glomerulosclerosis
- each can be idiopathic or secondary to a systemic disease or drug (sirolimus can cause proteinuria without obvious glomerular pathology)

<table>
<thead>
<tr>
<th>Table 11. Nephrotic Syndrome</th>
<th>Minimal Change</th>
<th>Membranous Glomerulopathy</th>
<th>Focal Segmental Glomerulosclerosis</th>
<th>Membranoproliferative Glomerulonephritis</th>
<th>Nodular Glomerulosclerosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secondary Causes</td>
<td>Hodgkin’s lymphoma</td>
<td>HBV, SLE, solid tumours (lung, breast, GI)</td>
<td>Reflux nephropathy, HIV, HBV, obesity, sickle cell disease</td>
<td>HCV, malaria, SLE, leukemia, lymphoma, shunt nephritis</td>
<td>DM, amyloidosis</td>
</tr>
<tr>
<td>Drug Causes</td>
<td>NSAIDs</td>
<td>Gold, penicillamine</td>
<td>Heroin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapy</td>
<td>Steroids</td>
<td>Reduce BP, ACEI, for proteinuria</td>
<td>Steroids, ACEI/ARB</td>
<td>Aspirin®, ACEI, dipyridamole (Persantine®) – controversial</td>
<td>Treat underlying cause</td>
</tr>
</tbody>
</table>

4. END STAGE RENAL DISEASE
- see End Stage Renal Disease, NP56

INVESTIGATIONS FOR GLOMERULAR DISEASE
- blood work
  - first presentation: electrolytes, Cr, urea, albumin, fasting lipids
  - determining etiology: CBC, ESR, serum immunoelectrophoresis, anti-GBM Disease, C3, C4, ANA, p-ANCA, c-ANCA, cryoglobulins, HBV and HCV serology, ASOT (anti-streptolysin titres), VDRL, HIV
- urinalysis: RBCs, WBCs, casts, protein
- 24 h urine for protein and CrCl
- radiology
  - CXR (infiltrates, CHF, pleural effusion)
  - renal U/S
- renal biopsy (percutaneous or open) if heavy proteinuria or renal insufficiency and cause is not obviously diabetic nephropathy
- urine immunoelectrophoresis
  - for Bence-Jones protein if proteinuria present
SECONDARY CAUSES OF GLOMERULAR DISEASE

Amyloidosis
- nodular deposits of amyloid in mesangium, usually related to amyloid light chain (AL)
- presents as nephrotic range proteinuria with progressive renal insufficiency
- can be primary or secondary
- secondary causes: multiple myeloma, TB, rheumatoid arthritis, malignancy

Systemic Lupus Erythematosus (see Rheumatology, RH11)
- lupus nephritis can present as any of the glomerular syndromes
- nephrotic syndrome with an active sediment is most common presentation
- GN caused by immune complex deposition in capillary loops and mesangium with resulting renal injury
- serum complement levels are usually low during periods of active renal disease
- children and males with SLE are more likely to develop nephritis

ANCA-Associated Vasculitis
- c-ANCA most commonly associated with the clinical picture of granulomatosis with polyangiitis
- p-ANCA most commonly associated with the clinical picture of microscopic polyangiitis
- focal segmental necrotizing RPGN with no immune staining
- may be indolent or fulminant in progression
- vasculitis and granulomas rarely seen on renal biopsy
- treatment typically involves cyclophosphamide and prednisone

Cryoglobulinemia
- cryoglobulins: monoclonal IgM and polyclonal IgG which precipitate at reduced temperatures
- presents as purpura, fever, Raynaud’s phenomenon, and arthralgias
- at least 50% of patients have hepatitis C
- renal disease seen in 40% of patients (isolated proteinuria/hematuria progressing to nephritic syndrome)
- most patients have decreased serum complement (C4 initially)
- treat hepatitis C, plasmapheresis
- overall prognosis: 75% renal recovery
Shunt Nephritis
• immune-complex mediated nephritis associated with chronically infected ventriculoatrial shunts inserted for treatment of hydrocephalus
• presents as acute nephritic syndrome with decreased serum complement
• nephrotic range proteinuria in 25% of patients
• treat by removing shunt and administering appropriate antibiotics

HIV-Associated Renal Disease
1. direct nephrotoxic effect of HIV infection, anti-retroviral drugs (e.g. tenofovir, indinavir), and other drugs used to treat HIV-associated infections
2. HIV-associated nephropathy
   • histology: focal and segmental glomerular collapse with mesangial sclerosis; “collapsing FSGS”
   • tubular cystic dilation and tubulo-reticular inclusions
   • clinical features: predominant in African American men, heavy proteinuria, progressive renal insufficiency
   • prognosis: kidney failure within 1 yr without treatment
   • therapy: short-term, high dose steroids, ACEI, HAART

 Infective Endocarditis
• manifests as mild form of acute nephritic syndrome with decreased serum complement
• S. aureus is most common infecting agent
• treatment with appropriate antibiotics usually resolves GN

Hepatitis B
• can result in membranous nephropathy, polyarteritis nodosa, membranoproliferative GN

Hepatitis C
• can result in membranous nephropathy, cryoglobulinemia, and membranoproliferative GN

Syphilis
• can result in membranous GN

Tubulointerstitial Disease

TUBULOINTERSTITIAL NEPHRITIS

Definition
• cellular infiltrates affecting primarily the renal interstitium and tubular cells
• functional tubule defects are disproportionately greater than the decrease in GFR
• classified as acute or chronic

Signs and Symptoms
• manifestation of disease depends on site of tubule affected
  1. proximal tubule (e.g. multiple myeloma, heavy metals)
     • Fanconi syndrome: decreased reabsorption in proximal tubule causing glycosuria, aminoaciduria, phosphaturia, hyperuricosuria
     • proximal RTA (decreased bicarbonate absorption): Type II RTA
  2. distal tubule (e.g. amyloidosis, obstruction)
     • distal RTA (Type I RTA), usually hypokalemic
     • Na⁺-wasting nephropathy
     • ± hyperkalemia leading to type IV RTA (where reduced renal bicarbonate production is caused by hyperkalemia)
  3. collecting duct (e.g. sickle cell anemia, analgesics, PCKD)
     • urinary concentrating defect leading to mild nephrogenic DI
     • polyuria

1. ACUTE TUBULOINTERSTITIAL NEPHRITIS

Definition
• rapid (days to weeks) decline in renal function
• 10-20% of all AKI

Etiology
• hypersensitivity
  1. antibiotics: β-lactams, sulfonamides, rifampin, quinolones, cephalosporins, fluoroquinolones
  2. other: NSAIDs, allopurinol, furosemide, thiazides, triamterene, PPIs, acyclovir, phenytoin, cimetidine
• infections
  ■ bacterial pyelonephritis, Streptococcus, brucellosis, Legionella, CMV, EBV, toxoplasmosis, leptospirosis, HIV, Mycoplasma
• immune
  ■ SLE, acute allograft rejection, Sjögren’s syndrome, sarcoidosis, mixed essential cryoglobulinemia
• idiopathic

Pathophysiology
• acute inflammatory cell infiltrates into renal interstitium

Clinical Features
• AKI
  if hypersensitivity reaction: may see fever, skin rash, arthralgia, serum sickness-like syndrome (particularly rifampin)
  if pyelonephritis: flank pain and costovertebral angle (CVA) tenderness
  if drug reaction, AKI usually occurs 7-10 days after exposure
  other signs and symptoms based on underlying etiology
• HTN and edema are uncommon

Findings
• urine
  ■ mild, non-nephrotic range proteinuria and microscopic hematuria
  ■ sterile pyuria, WBC casts
  ■ eosinophils if AIN
• blood work
  ■ increased Cr and urea
  ■ eosinophilia if drug reaction
  ■ normal AG metabolic acidosis (RTA)
  ■ hypophosphatemia, hyperkalemia, hyponatremia
• gallium scan often shows intense signal due to inflammatory infiltrate
• renal biopsy definitive

Treatment
• treat underlying cause (e.g. stop offending medications, antibiotics if pyelonephritis)
• corticosteroids (may be indicated in allergic or immune disease)

Prognosis
• recovery within 2 wk if underlying insult can be eliminated
• the longer the patient is in renal failure, the less likely they will have a full renal recovery

2. CHRONIC TUBULOINTERSTITIAL NEPHRITIS

Definition
• characterized by slowly progressive renal failure, moderate proteinuria, and signs of abnormal tubule function

Etiology
• persistence or progression of acute TIN
• urinary tract obstruction: most important cause of chronic TIN (tumours, stones, bladder outlet obstruction, vesicoureteral reflux)
• chronic pyelonephritis due to vesicoureteral reflux or UTI with obstruction
• nephrotoxins
  ■ exogenous
    • analgesics: NSAIDs (common), acetaminophen
    • cisplatin, lithium, cyclosporine, tacrolimus
    • heavy metals (lead, cadmium, copper, lithium, mercury, arsenic)
    • Chinese herbs (aristolochic acid)
  ■ endogenous
    • hypercalcemia, hypokalemia, oxalate, uric acid
• vascular disease: ischemic nephrosclerosis, atheroembolic disease
• malignancies: multiple myeloma, lymphoma
• granulomatous: TB, sarcoidosis, granulomatosis with polyangitis
• immune: SLE, Sjögren’s, cryoglobulinemia, Anti-GBM Disease, amyloidosis, renal graft rejection, vasculitis
• hereditary: cystic diseases of the kidney, sickle cell disease
• others: radiation, Balkan (endemic) nephropathy

Pathophysiology
• fibrosis of interstitium with atrophy of tubules, mononuclear cell inflammation

Signs and Symptoms
• dependent on underlying etiology
Findings
- normal AG metabolic acidosis
- hyperkalemia (out of proportion to degree of renal insufficiency)
- polyuria, nocturia
- partial or complete Fanconi’s syndrome
- progressive renal failure with azotemia and uremia
- urine: mild proteinuria, few RBCs and WBCs, no RBC casts
- U/S: shrunken kidneys with irregular contours

Treatment
- stop offending agent or treat underlying disease
- supportive measures: correct metabolic disorders (Ca²⁺, PO₄³⁻) and anemia

3. ACUTE TUBULAR NECROSIS

Definition
- abrupt and sustained decline in GFR within minutes to days after ischemic/nephrotoxic insult
- GFR reduced (this serves the purpose of avoiding life-threatening urinary loss of fluid and electrolytes from non-functioning tubules)

Etiology

Clinical Presentation
- typically presents as an abrupt rise in urea and Cr after a hypotensive episode, sepsis, rhabdomyolysis, or administration of nephrotoxic drug
- most common cause of non-prerenal AKI in hospitalized patients
- urine: high FeNa, pigmented-granular casts

Risk Factors
- pre-existing chronic kidney disease, pre-existing cardiovascular disease, ECF volume depletion, multiple renal insults

Complications
- hyperkalemia: can occur rapidly and cause serious arrhythmias
- metabolic acidosis, decreased Ca²⁺, increased PO₄³⁻, hypoalbuminemia

Investigations
- blood work: CBC, electrolytes, Cr, urea, Ca²⁺, PO₄³⁻, blood gases
- urine: R&M, electrolytes, osmolality, microscopic urinalysis searching for pigmented granular casts
- ECG
- abdominal U/S
- rule out other causes of prerenal/postrenal azotemia and intrinsic AKI (GN, AIN, vasculitis)

Treatment
- largely supportive once underlying problem is corrected
- loop diuretics may help manage volume overload and reduce tubular metabolic requirements to allow for recovery (controversial)
- consider early dialysis in severe/rapidly progressing cases to prevent uremic syndrome

Figure 17. Etiology of ATN

Meta-Analysis: Effectiveness of Drugs for Preventing Contrast-Induced Nephropathy

Purpose: To determine the effectiveness of N-acetylcysteine, theophylline, fenoldopam, dopamine, iloprost, statin, furosemide, or mannitol on preventing nephropathy.

Study Selection: RCTs that used these agents in patients receiving iodinated contrast.

Results: In the 41 RCTs included N-acetylcysteine (RR=0.82 [0.44-0.88]) and theophylline (RR=0.49 [0.23-0.98]) reduced the risk of nephropathy more than saline alone. Furosemide increased the risk (RR=5.27 [1.40-19.26]). Other agents did not affect risk of nephropathy.

Conclusion: N-acetylcysteine is more renoprotective than hydration alone.
Prevention
- correct fluid balance before surgical procedures
- for patients with chronic renal disease requiring radiographic contrast:
  - give N-acetylcysteine 600-1200 mg PO bid day before and day of procedure, give intravenous isotonic fluid (either NaCl or NaHCO₃)
  - isotonic NaHCO₃ at 3 mL/kg over 1 h before procedure and 1 mL/kg/h for 6 h post-procedure if not contraindicated
  - avoid giving diuretics, ACEI, cyclosporine on morning of procedure if possible
- use renal-adjusted doses of nephrotoxic drugs in patients with renal insufficiency

Vascular Diseases of the Kidney

LARGE VESSEL DISEASE

Table 12. Summary of Vascular Diseases

<table>
<thead>
<tr>
<th>Large Vessel Disease</th>
<th>Medium Vessel Disease</th>
<th>Small Vessel Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute renal artery occlusion (infarct)</td>
<td>Kawasaki disease</td>
<td>Hypertensive nephrosclerosis</td>
</tr>
<tr>
<td>Renal artery stenosis (ischemia)</td>
<td>Polycystic nodosa</td>
<td>Atheroembolic renal disease</td>
</tr>
<tr>
<td>Renal vein thrombosis</td>
<td></td>
<td>Thrombotic microangiopathy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Scleroderma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Calcineurin inhibitor nephropathy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hemolytic Uremic Syndrome (HUS)</td>
</tr>
</tbody>
</table>

1. RENAL INFARCTION (ACUTE RENAL ARTERY OCCLUSION)
- important, potentially reversible cause of renal failure

Etiology
- abdominal trauma, surgery, embolism, vasculitis, extra-renal compression, hypercoagulable state, aortic dissection
- kidney transplant recipients more vulnerable

Signs and Symptoms (depend on presence of collateral circulation)
- fever, N/V, flank pain
- leukocytosis, elevated AST, ALP
- marked elevated LDH (LDH >4x upper limit of normal with minimal elevations in AST/ALT strongly suggestive)
- acute onset HTN (activation of RAAS) or sudden worsening of long-standing HTN
- renal dysfunction, e.g. elevated Cr (if bilateral, or solitary functioning kidney)

Investigations
- renal arteriography (more reliable but risk of atheroembolic renal disease)
- contrast-enhanced CT or MR angiography, duplex Doppler studies (operator dependent)

Treatment
- prompt localization of occlusion and restoration of blood flow
- anticoagulation, thrombolysis, percutaneous angioplasty or clot extraction, surgical thrombectomy
- medical therapy in the long-term to reduce risk (e.g. antihypertensives)

2. ISCHEMIC RENAL DISEASE (RENAL ARTERY STENOSIS)
- chronic renal impairment secondary to hemodynamically significant renal artery stenosis or microvascular disease
- significant cause of ESRD: 15% in patients >50 yr (higher prevalence if significant vascular disease)
- usually associated with large vessel disease elsewhere
- causes of renal artery stenosis
  - atherosclerotic plaques (90%): proximal 1/3 renal artery, usually males >55 yr, smokers
  - fibromuscular dysplasia (10%): distal 2/3 renal artery or segmental branches, usually young females (typical onset <30 yr)
- when there is decreased RBF, GFR is dependent on angiotensin II-induced efferent arteriolar constriction which raises the FF (GFR/RBF)
- most common cause of secondary HTN (“renovascular HTN”), 1-2% of all hypertensive patients
- etiology
  - decreased renal perfusion of one or both kidneys leads to increased renin release and subsequent angiotensin production
  - increased angiotensin raises blood pressure in two ways
    1. causes generalized arteriolar constriction
    2. release of aldosterone increases Na⁺ and water retention
- elevated blood pressure can in turn lead to further damage of kidneys and worsening HTN
Risk Factors
- >50 yr
- smoking
- other atherosclerotic disease (dyslipidemia, DM, diffuse atherosclerosis)

Signs and Symptoms
- severe/refractory HTN and/or hypertensive crises, with negative family history of HTN
- asymmetric renal size
- epigastric or flank bruits
- spontaneous hypokalemia (renin activation in under-perfused kidney)
- increasing Cr with ACEI/ARB
- flash pulmonary edema with normal LV function

Investigations
- must establish presence of renal artery stenosis and prove it is responsible for renal dysfunction
- duplex Doppler U/S (kidney size, blood flow); good screening test (operator dependent)
- digital subtraction angiography (risk of contrast nephropathy)
- CT or MR angiography (effective noninvasive tests to establish presence of stenosis, for MR avoid gadolinium contrast if eGFR <30 mL/min because of risk of systemic dermal fibrosis)
- ACEI renography (e.g. captopril renal scan)
- renal arteriography (gold standard)

Treatment
- surgical: percutaneous angioplasty ± stent, surgical revascularization, occasionally surgical bypass
- medical: BP lowering medications (ACEI is drug of choice if unilateral renal artery disease but contraindicated if bilateral renal artery disease)
- little or no benefit if therapy is late (e.g. kidney is already shrunken), however, therapy can be considered to save the opposite kidney if normal

3. RENAL VEIN THROMBOSIS

Etiology
- hypercoagulable states (e.g. nephrotic syndrome, especially membranous), ECF volume depletion, extrinsic compression of renal vein, significant trauma, malignancy (e.g. RCC), sickle cell disease
- clinical presentation determined by rapidity of occlusion and formation of collateral circulation

Signs and Symptoms
- acute: N/V, flank pain, hematuria, elevated plasma LDH, ± rise in Cr, sudden rise in proteinuria
- chronic: PE (typical first presenting symptom), increasing proteinuria and/or tubule dysfunction

Investigations
- renal venography (gold standard), CT or MR angiography, duplex Doppler U/S

Treatment
- thrombolytic therapy ± percutaneous thrombectomy for acute renal vein thrombosis
- anticoagulation with heparin then warfarin (1 yr or indefinitely, depending on risk factors)

MEDIUM VESSEL DISEASE

1. KAWASAKI DISEASE
- see Pediatrics, P92

2. POLYARTERITIS NODOSA
- see Rheumatology, RH19
- kidneys most commonly involved organ
- heterogenous impact on renal function
- pathologically can cause glomerular ischemia which manifests as mild proteinuria and hypertension

SMALL VESSEL DISEASE

1. HYPERTENSIVE NEPHROSCLEROSIS
- see Hypertension, NP34

2. ATHEROEMBOLIC RENAL DISEASE
- progressive renal insufficiency due to embolic obstruction of small- and medium-sized renal vessels by atheromatous emboli
- spontaneous or after renal artery manipulation (surgery, angiography, percutaneous angioplasty)
- anticoagulants and thrombolytics interfere with ulcerated plaque healing and can worsen disease
3. THROMBOTIC MICROANGIOPATHY

- see Hematology, H22
- etiologies include the spectrum of TTP-HUS, DIC, severe preeclampsia
- renal involvement more common in HUS than TTP
- renal involvement characterized by fibrin thrombi in glomerular capillary loops ± arterioles
- treatment
  - depends on cause
  - supportive therapy
  - TTP-HUS: plasma exchange, corticosteroids (splenectomy and rituximab if refractory)
- avoid platelet transfusions and ASA

4. CALCINEURIN INHIBITOR NEPHROPATHY

- cyclosporine and tacrolimus
- causes both acute reversible and chronic, largely irreversible nephrotoxicity
- major cause of kidney failure in other solid organ transplants (e.g. heart)
- acute: due to afferent and efferent glomerular capillary constriction leading to decreased GFR (tubular vacuolization)
  - prerenal azotemia
  - treatment: calcium channel blockers or prostaglandin analogs, reduce dose of cyclosporine or switch to another immunosuppressive drug
- chronic: result of obliterative arteriolopathy causing interstitial nephritis and CKD (striped fibrosis), less frequent now due to lower doses of calcineurin inhibitors

Analgesic Nephropathies

1. Vasomotor AKI

- clinically: develop prerenal azotemia within a few days of starting NSAID
- normally prostaglandins vasodilate afferent renal arteriole to maintain blood flow
- NSAIDs act by blocking cyclooxygenase enzyme, thereby preventing prostaglandin synthesis and causing renal ischemia
- more common in elderly, underlying renal disease, hypovolemia (diuretics, CHF, cirrhosis, nephrotic syndrome)
- treatment: discontinue NSAID, dialysis rarely needed

2. Acute Interstitial Nephritis

- fenoprofen (60%), ibuprofen, naproxen
- may be associated with minimal change glomerulopathy and nephrotic range proteinuria
- resolves eventually with discontinuation of NSAID, may require interval dialysis
- short-term high dose steroids (1 mg/kg/d of prednisone) may hasten recovery

3. Chronic Interstitial Nephritis

- due to excessive consumption of antipyretics (phenacetin or acetaminophen) in combination with NSAIDs
- seen in patients who also have emotional stress, psychiatric symptoms, and GI disturbance
- papillary necrosis
  - gross hematuria, flank pain, declining renal function
  - calyceal filling defect seen with IVP – “ring sign”
- increased risk of transitional cell carcinoma of renal pelvis
- good prognosis if discontinue analgesics

4. Acute Tubular Necrosis

- can be caused by acetaminophen
  - incidence of renal dysfunction is related to the severity of acetaminophen ingestion
- vascular endothelial damage can also occur
- both direct toxicity and ischemia contribute to the tubular damage
- renal function spontaneously returns to baseline within 1-4 wk
- dialysis may be required during the acute episode of ingestion

5. Other Effects of NSAIDs

- sodium retention (2º to reduced GFR)
- hyperkalemia, HTN (2º to hyporeninemic hypoaldosteronism)
- excess water retention (2º to loss of antagonistic effect of prostaglandins on ADH)
Systemic Disease with Renal Manifestation

Diabetes

- diabetic nephropathy: presence of microalbuminuria or overt nephropathy (e.g. macroalbuminuria) in patients with DM who lack indicators of other renal diseases
- most common cause of end-stage renal failure in North America
- 50% of patients with diabetes will develop nephropathy
- at diagnosis up to 30% of patients with type 2 DM havealbuminuria (75% microalbuminuria, 25% overt nephropathy)
- microalbuminuria is a risk factor for progression to overt nephropathy and cardiovascular disease
- once macroalbuminuria is established, renal function declines, 50% of patients reach ESRD within 7-10 yr
- associated with HTN and diabetic retinopathy (especially type 1 DM) and/or neuropathy (especially type 2 DM)
- indication of possible non-diabetic cause of renal disease in patients with DM
  - rising Cr with little/no proteinuria
  - lack of retinopathy or neuropathy (microvascular complications)
  - persistent hematuria (microscopic or macroscopic)
  - signs or symptoms of systemic disease
  - inappropriate time course; rapidly rising Cr, renal disease in a patient with short duration of DM
  - family history of non-diabetic renal disease (e.g. PCKD, Alport’s)

DIABETIC RENAL COMPLICATIONS

1. Progressive Glomerulosclerosis
- classic diabetic glomerular lesion: Kimmelstiel-Wilson nodular glomerulosclerosis (15-20%)
- more common lesion is diffuse glomerulosclerosis with a uniform increase in mesangial matrix

2. Accelerated Atherosclerosis
- common finding
- decreased GFR
- may increase angiotensin II production resulting in increased BP
- increased risk of ATN secondary to contrast media

3. Autonomic Neuropathy
- affects bladder leading to functional obstruction and urinary retention
- residual urine promotes infection
- obstructive nephropathy

4. Papillary Necrosis
- type 1 DM susceptible to ischemic necrosis of medullary papillae
- sloughed papillae may obstruct ureter
- can present as renal colic or with obstructive features ± hydronephrosis

2013 Canadian Diabetes Association Clinical Practice Guidelines on Chronic Kidney Disease in Diabetes

- screen for microalbuminuria with a random urine test for albumin to Cr ratio (ACR) and eGFR with a serum Cr (e.g. using MDRD equation)
  - type 1 DM: annually in post-pubertal individuals after 5 yr of diagnosis
  - type 2 DM: at diagnosis, then annually
  - if eGFR >60 mL/min or ACR <2.0 mg/mmol: there is no CKD, re-screen in 1 yr
  - if urine ACR >20.0 mg/mmol: diagnose CKD
  - if ACR <20.0 mg/mmol but >2.0 mg/mmol: order serum Cr for eGFR in 3 mo and 2 repeats of random urine ACRs over the next 3 mo; at 3 mo: if eGFR ≤60 ml/min or if >2/3 ACRs are >2.0 mg/mmol, diagnose CKD
- if CKD diagnosed, ordered urine R+M and dipstick, if negative then diagnose CKD in DM
- with CKD in DM: urine ACR and serum Cr (or eGFR) every 6 mo
- delay screening if transient cause of albuminuria or low eGFR
- evaluate for other causes of proteinuria, rule out non-diabetic renal disease
- avoid unnecessary potential nephrotoxins (NSAIDs, aminoglycosides, dye studies)

**Priorities in the Management of Patients with DM**

1. vascular protection for all patients with DM
   - ACEI, antiplatelet therapy (as indicated)
   - BP control, glycemic control, lifestyle modification, lipid control
2. optimization of BP in patients who are hypertensive
   - treat according to HTN guidelines
3. renal protection for DM patients with nephropathy (even in absence of HTN)
   - type 1 DM: ACEI
   - type 2 DM: CrCl >60 mL/min: ACEI or ARB – CrCl <60 mL/min: ARB
   - 2nd line agents: nondihydropyridine calcium channel blockers (diltiazem, verapamil)
   - combination of ACEI and ARB not recommended for proteinuria
   - check serum Cr and K+ levels within 1 wk of initiating ACEI or ARB and at time of acute illness
   - serum Cr can safely be allowed to rise up to 30% with initiation of ACEI or ARB, usually stabilizes after 2-4 wk, monitor for significant worsening of renal function or hyperkalemia
   - if >30% rise in serum Cr or hyperkalemia, discontinue medication and consider 2nd line agent
   - consider holding ACEI, ARB, and/or diuretic with acute illness and in women before becoming pregnant
   - consider referral to nephrologist if ACR >60 mg/mmol, eGFR <30 mL/min, progressive kidney function loss, unable to achieve BP targets, or unable to stay on ACEI or ARB

**Scleroderma**

- see *Rheumatology, RH13*
- 50% of scleroderma patients have renal involvement (mild proteinuria, high Cr, HTN)
- renal involvement usually occurs early in the course of illness
- histology: media thickened, “onion skin” hypertrophy of small renal arteries, fibrinoid necrosis of afferent arterioles and glomeruli
- 10-15% of scleroderma patients have a “scleroderma renal crisis” (occurs in first few years of disease):
  - malignant HTN, ARF, microangiopathy, volume overload, visual changes, HTN encephalopathy
  - treatment: BP control with ACEI slows progression of renal disease

**Multiple Myeloma**

- see *Hematology, H49*
- malignant proliferation of plasma cells in the bone marrow with the production of immunoglobulins
- patients may present with severe bone disease and renal failure
- light chains are filtered at the glomerulus and appear as Bence-Jones proteins in the urine (monoclonal light chains)
- kidney damage can occur by several mechanisms
  - hypercalcemia
  - light chain cast nephropathy or “myeloma kidney”
  - hyperuricemia
  - infection
  - secondary amyloidosis
  - monoclonal Ig deposition disease
  - diffuse tubular obstruction
- light chain cast nephropathy
  - large tubular casts in urine sediment (light chains + Tamm-Horsfall protein)
  - proteinuria and renal insufficiency, can progress rapidly to kidney failure
- monoclonal Ig deposition disease
  - deposits of monoclonal Ig in kidney, liver, heart, and other organs
  - mostly light chains (85-90%)
  - causes nodular glomerulosclerosis (similar to diabetic nephropathy)
- lab features: increased BUN, increased Cr, urine protein immunoelectrophoresis positive for Bence-Jones protein (not detected on urine dipstick)
- poor candidates for kidney transplantation
Malignancy

- cancer can have many different renal manifestations
- kidney transplantation cannot be performed unless malignancy is cured
  - solid tumors: mild proteinuria or membranous GN
  - lymphoma: minimal change GN (Hodgkin’s) or membranous GN (non-Hodgkin’s)
  - renal cell carcinoma
  - tumor lysis syndrome: hyperuricemia, diffuse tubular obstruction, hyperkalemia, hyperphosphatemia, hypocalcemia, lactic acidosis
  - chemotherapy (especially cisplatin): ATN or chronic TIN
  - pelvic tumors/mets: postrenal failure secondary to obstruction
  - 2+ amyloidosis
  - radiotherapy (radiation nephritis)

Conclusions: RAS blockade reduced CV outcomes in diabetic nephropathy as well as non-diabetic CKD.

Chronic Kidney Disease

Definition

- progressive and irreversible loss of kidney function
- abnormal markers (Cr, urea)
  - GFR <60 mL/min for >3 mo; or
  - kidney pathology seen on biopsy; or
  - ultrasound: small shrunken kidneys <9 cm (normal 10-13 cm), increased cortical echogenicity

Clinical Features

- volume overload and HTN
- electrolyte and acid-base balance disorders (e.g. metabolic acidosis)
- uremia

Table 14. Stages of CKD (KDIGO, 2013)

<table>
<thead>
<tr>
<th>GFR (mL/min/1.73m²)</th>
<th>Persistent Albuminuria Categories</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A1 ≤3 mg/mmol</td>
</tr>
<tr>
<td>G1 ≥90</td>
<td>1 if CKD</td>
</tr>
<tr>
<td>G2 60-89</td>
<td>1 if CKD</td>
</tr>
<tr>
<td>G3a 45-59</td>
<td>1</td>
</tr>
<tr>
<td>G3b 30-44</td>
<td>2</td>
</tr>
<tr>
<td>G4 15-29</td>
<td>3</td>
</tr>
<tr>
<td>G5 &lt;15 (kidney failure)</td>
<td>4+</td>
</tr>
</tbody>
</table>

The numbers in the boxes are a reflection of the risk of progression and are a guide to the frequency of monitoring/year "D" is added to G5 for patients requiring dialysis
Classification is based on cause, GFR, and amount of albuminuria
Rate of progression and risk of complications are determined by the cause of CKD

Management of Chronic Kidney Disease

- diet
  - preventing HTN and volume overload
  - Na+ and water restriction
  - preventing electrolyte imbalances
    - K+ restriction (40 mmol/d)
    - PO4+ restriction (1 g/d)
    - avoid extra-diary Mg++ (e.g. antacids)
  - preventing uremia and potentially delaying decline in GFR
  - protein restriction with adequate caloric intake in order to limit endogenous protein catabolism
- medical
  - adjust dosages of renally excreted medications
  - HTN: ACEI (target 140/90 mmHg without DM and 130/80 mmHg with DM), loop diuretics when GFR <25 mL/min
  - dyslipidemia: statins (target LDL <2 mmol/L)
  - calcium and phosphate disorders
    - calcium supplements (e.g. TUMS®) treats hypocalcemia when given between meals and binds phosphate when given with meals
    - consider calcitriol (1,25-dihydroxy-vitamin D) if hypocalcemic
    - sevelamer (phosphate binder) if both hypercalcemic and hyperphosphatemic

Incidence of Etiologies of CKD

- DM 42.9%
- HTN 26.4%
- Glomerulonephritis 9.9%
- Other/Unknown 7.7%
- Interstitial nephritis 4.0%
- Pyelonephritis 3.1%
- Secondary GN/Vasculitis 2.4%

Management of Complications of CKD

NEPHRON

N – Low-nitrogen diet
E – Electrolytes: monitor K+
P – pH, metabolic acidosis
H – HTN
R – RBCs: manage anemia with erythropoietin
O – Osteodystrophy: give calcium between meals (to increase Ca2+) and calcium with meals (to bind and decrease PD2+)
N – Nephrotoxins: avoid nephrotoxic drugs (ASA, gentamicin) and adjust doses of renally excreted medications

Renin Angiotension System Blockade and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Proteinuria: A Meta-Analysis

Am Heart J 2008;155:791-805

Purpose: To evaluate the role of RAS blockade in improving cardiovascular CV outcomes in patients with CKD

Study Selection: RCT that analyzed CV outcomes in patients with CKD/proteinuria treated with RAS blockade (ACEI/ARB). RAS blockade-based therapy was compared with placebo and control therapy (β-blocker, calcium-channel blockers, and other antihypertensive-based therapy) in the study.

Results: Twenty-five trials (n=45,758) were included. Compared to placebo, RAS blockade reduced the risk of heart failure in patients with diabetic nephropathy. In patients with non-diabetic CKD, RAS blockade decreased CV outcome compared to control therapy.

Conclusions: RAS blockade reduced CV outcomes in diabetic nephropathy as well as non-diabetic CKD.
Hypertension

- vitamin D analogues are being introduced in the near future
- cinacalcet for hyperparathyroidism (sensitizes parathryoid to Ca++, decreasing PTH)
- metabolic acidosis: sodium bicarbonate
- anemia: erythropoietin injections for Hb <90 g/L (9 g/dL) and target Hb between 90-105 g/L (9-10.5 g/dL)
- clotting abnormalities: DDAVP if patient has clinical bleeding or invasive procedures (acts to reverse platelet dysfunction)
- dialysis (hemodialysis, peritoneal dialysis)

Prevention of Progression
- as above
- control of HTN, DM (HbA1c <7%), cardiovascular risk factors (e.g. smoking cessation)
- avoid nephrotoxins such as NSAID's, COXIB's, IV contrast in patients with eGFR < 60 mL/min/1.73 m²
- address reversible causes of AKI

Hypertensive Nephrosclerosis

Table 15. Chronic vs. Malignant Nephrosclerosis

<table>
<thead>
<tr>
<th>Chronic Nephrosclerosis</th>
<th>Malignant Nephrosclerosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Histology</strong></td>
<td>Slow vascular sclerosis with ischemic changes affecting intralobular and afferent arterioles</td>
</tr>
<tr>
<td><strong>Clinical Picture</strong></td>
<td>Black race, underlying CKD, chronic hypertensive disease</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Urinalysis</strong></td>
<td>Mild proteinuria, normal urine sediment</td>
</tr>
<tr>
<td><strong>Therapy</strong></td>
<td>Blood pressure control, (target &lt;140/90) with frequent follow-up</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Prognosis</strong></td>
<td>Can progress to renal failure despite patient adherence</td>
</tr>
</tbody>
</table>

Renovascular Hypertension

Renal Parenchymal Hypertension

- HTN secondary to GN, AIN, diabetic nephropathy, or any other chronic renal disease
- mechanism of HTN not fully understood but may include
  - excess RAAS activation due to inflammation and fibrosis in multiple small intra-renal vessels
  - production of unknown vasopressors, lack of production of unknown vasodilators, or lack of clearance of endogenous vasopressor
  - ineffective sodium excretion with fluid overload

Investigations
- as well as investigations for renovascular HTN, additional tests may include
  - 24 h urinary estimations of CrCl and protein excretion
  - imaging (U/S, CT)
  - serology for collagen-vascular disease
  - renal biopsy

Treatment
- most chronic renal disease is irreversible, but treatment of HTN can slow the progression of renal insufficiency
- control ECF volume: Na+ restriction (2g/d intake), diuretic, dialysis with end-stage disease
- ACEI or ARB may provide added benefit (monitor K+ and Cr) if there is significant proteinuria (>300 mg/d)
Cystic Diseases of the Kidney

• characterized by epithelium-lined cavities filled with fluid or semisolid debris within the kidneys
• includes: simple cysts (present in 50% of population >50), medullary cystic kidney, medullary sponge kidney, polycystic kidney disease (autosomal dominant and recessive), and acquired cystic kidney disease (in chronic hemodialysis patients)

Adult Polycystic Kidney Disease

• autosomal dominant; at least 2 genes: PKD1 (chr 16p) and PKD2 (chr 4q)
• PKD1 (1:400), PKD2 (1:1,000) accounts for about 10% of cases of renal failure
• patients generally heterozygous for mutant PKD gene but accumulate a series of second ‘somatic hits’ precipitating the condition
• PKD gene defect leads to abnormal proliferation and apoptosis of tubular epithelial cells leading to cyst growth
• most common extrarenal manifestations: multiple asymptomatic hepatic cysts (33%), mitral valve prolapse (25%), cerebral aneurysm (10%), diverticulosis
• polycystic liver disease rarely causes liver failure
• less common extrarenal manifestations: cysts in pancreas, spleen, thyroid, ovary, seminal vesicles, and aorta

Signs and Symptoms
• often asymptomatic; discovered incidentally on imaging or by screening those with FHx
• acute abdominal flank pain/dull lumbar back pain
• hematuria (frequently initial sign is microscopic hematuria, otherwise gross hematuria)
• nocturia (urinary concentrating defect)
• rarely extra-renal presentation (e.g. ruptured berry aneurysm, diverticulitis)
• HTN (increased renin due to focal compression of intrarenal arteries by cysts) (60-75%)
• ± palpable kidneys

Common Complications
• urinary tract and cyst infections, HTN, chronic renal failure, nephrolithiasis (5-15%), flank and chronic back pain

Clinical Course
• polycystic changes are always bilateral and can present at any age
• clinical manifestations rare before age 20-25
• kidneys are normal at birth but may enlarge to 10x normal size
• variable progression to renal functional impairment (ESRD in up to 50% by age 60)

Investigations
• radiographic diagnosis: best accomplished by renal U/S (enlarged kidneys, multiple cysts throughout renal parenchyma, increased cortical thickness, splaying of renal calyces)
• CT abdo with contrast (for equivocal cases, occasionally reveals more cystic involvement)
• gene linkage analysis for PKD1 for asymptomatic carriers
• Cr, BUN, urine R&M (to assess for hematuria)

Treatment
• goal: to preserve renal function by prevention and treatment of complications
• educate patient and family about disease, its manifestations, and inheritance pattern
• genetic counselling: transmission rate 50% from affected parent
• prevention and early treatment of urinary tract and cyst infections (avoid instrumentation of GU tract)
• TMP/SMX, ciprofloxacin: able to penetrate cyst walls, achieve therapeutic levels
• adequate hydration to prevent stone formation
• avoid contact sports due to greater risk of injury to enlarged kidneys
• screen for cerebral aneurysms if family history of aneurysmal hemorrhages
• monitor blood pressure and treat HTN with ACEI
• dialysis or transplant for ESRD (disease does not recur in transplanted kidney)
• may require nephrectomy for symptomatic relief of pain or due to recurrent infections

Autosomal Recessive Polycystic Kidney Disease

• 1:20,000 incidence
• prenatal diagnosis by enlarged kidneys
• perinatal death from respiratory failure
• patients who survive perinatal period develop CHF, HTN, CKD
• treated with kidney and/or liver transplant
Medullary Sponge Kidney

- common, autosomal dominant, usually diagnosed in 4th-5th decades
- multiple cystic dilatations in the collecting ducts of the medulla
- renal stones, hematuria, and recurrent UTIs are common features
- an estimated 10% of patients who present with renal stones have medullary sponge kidney
- nephrocalcinosis on abdominal x-ray in 50% patients, often detect asymptomatic patients incidentally
- diagnosis: contrast filled medullary cysts on IVP leading to characteristic radial pattern (“bouquet of flowers”), “Swiss cheese” appearance on histological cross-section
- treat UTIs and stone formation as indicated
- does not result in renal failure

End Stage Renal Disease

- ESRD represents a decline in kidney function requiring renal replacement therapy which can occur over days to weeks (AKI), over months to years (CKD), or as a combination of the two

Presentation of End Stage Renal Disease

1. Volume Overload
   - due to increase in total body Na⁺ content
   - signs: weight gain, HTN, pulmonary or peripheral edema

2. Electrolyte Abnormalities
   - high
     - K⁺ (decreased renal excretion, increased tissue breakdown)
     - PO₄³⁻ (decreased renal excretion, increased tissue breakdown)
     - Ca²⁺ (rare; happens during recovery phase after rhabdomyolysis-induced AKI or in settings where hypercalcemia contributes to renal failure, such as in multiple myeloma or sarcoidosis)
     - uric acid
   - low
     - Na⁺ (failure to excrete excessive water intake)
     - Ca²⁺ (decreased Vitamin D activation, hyperphosphatemia, hypoalbuminemia)
     - HCO₃⁻ (especially with sepsis or severe heart failure)

3. Uremic Syndrome
   - manifestations result from retention of urea and other metabolites as well as hormone deficiencies

Figure 19. Signs and symptoms of end stage renal disease
Complications
- CNS: decreased LOC, stupor, seizure
- CVS: cardiomyopathy, CHF, arrhythmia, pericarditis, atherosclerosis
- GI: peptic ulcer disease, gastroesophageal reflux disease, AVM
- hematologic: anemia, bleeding tendency (platelet dysfunction), infections
- endocrine
  - decreased testosterone, estrogen, progesterone
  - increased FSH, LH
- metabolic
  - renal osteodystrophy: secondary increased PTH due to decreased Ca++, high PO4++, and low active vitamin D
  - osteitis fibrosa cystica
  - hypertriglyceridemia, accelerated atherogenesis
  - decreased insulin requirements, increased insulin resistance
- dermatologic: pruritus, ecchymosis, hematomas, calciphylaxis (vascular Ca++ deposition)

Renal Replacement Therapy

Dialysis

Indications for Dialysis in Chronic Kidney Disease

Table 16. Indications for Dialysis

<table>
<thead>
<tr>
<th>Absolute Indications</th>
<th>Relative Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume overload*</td>
<td>Anorexia</td>
</tr>
<tr>
<td>Hyperkalemia*</td>
<td>Decreased cognitive functioning</td>
</tr>
<tr>
<td>Severe metabolic acidosis*</td>
<td>Profound fatigue and weakness</td>
</tr>
<tr>
<td>Neurologic signs or symptoms of uremia (encephalopathy, neuropathy, seizures)</td>
<td>Severe anemia unresponsive to erythropoietin</td>
</tr>
<tr>
<td>Uremic pericarditis</td>
<td>Persistent severe pruritus</td>
</tr>
<tr>
<td>Refractory accelerated HTN</td>
<td>Restless leg syndrome</td>
</tr>
<tr>
<td>Clinically significant bleeding diathesis</td>
<td>Plasma Cr &gt; 1060 µmol/L or Urea &gt; 36 mmol/L</td>
</tr>
<tr>
<td>Persistent severe N/V</td>
<td></td>
</tr>
</tbody>
</table>

*Unresponsive to medications

- **hemodialysis**: blood is filtered across a semipermeable membrane removing accumulated toxic waste products, solutes, excess fluid (ultrafiltration), and restoring buffering agents to the bloodstream
  - available as intermittent (e.g. 3x/wk), continuous (CVVHD) or sustained low efficiency (SLED)
  - can be delivered at home or in-centre, nocturnal
  - vascular access can be achieved through a central line, an artificial graft, or an AV fistula
  - patients with CKD should be referred for surgery to attempt construction of a primary AV fistula when their eGFR is <20 mL/min, the serum Cr level quoted as >350 µmol/L, or within 1 yr of an anticipated need
- **peritoneal dialysis**: peritoneum acts as a semipermeable membrane similar to hemodialysis filter
  - advantages: independence, fewer stringent dietary restrictions, better rehabilitation rates
  - available as continuous ambulatory (CAPD; four exchanges per day) or cyclic (CCPD; machine carries out exchanges overnight)
  - refer patients with chronic renal disease to a nephrologist early on to facilitate treatment and plan in advance for renal replacement therapy (RRT)

Table 17. Peritoneal Dialysis vs. Hemodialysis

<table>
<thead>
<tr>
<th></th>
<th>Peritoneal Dialysis</th>
<th>Hemodialysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate</td>
<td>Slow</td>
<td>Fast</td>
</tr>
<tr>
<td>Location</td>
<td>Home</td>
<td>Hospital (usually)</td>
</tr>
<tr>
<td>Ultrafiltration</td>
<td>Osmotic pressure via dextrose dialysate</td>
<td>Hydrostatic pressure</td>
</tr>
<tr>
<td>Solute Removal</td>
<td>Concentration gradient and convection</td>
<td>Concentration gradient and convection</td>
</tr>
<tr>
<td>Membrane</td>
<td>Peritoneum</td>
<td>Semi-permeable artificial membrane</td>
</tr>
<tr>
<td>Method</td>
<td>Indwelling catheter in peritoneal cavity</td>
<td>Line from vessel to artificial kidney</td>
</tr>
<tr>
<td>Complications</td>
<td>Infection at catheter site</td>
<td>Vascular access (clots, collapse)</td>
</tr>
<tr>
<td></td>
<td>Bacterial peritonitis</td>
<td>Bacteremia</td>
</tr>
<tr>
<td></td>
<td>Metabolic effects of glucose</td>
<td>Bleeding due to heparin</td>
</tr>
<tr>
<td></td>
<td>Difficult to achieve adequate clearance in patients with large body mass</td>
<td>Hemodynamic stress of extracorporeal circuit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dehydration syndrome (headache, cerebral edema, hypotension, nausea, muscle cramps related to solute/ water flux over short time)</td>
</tr>
<tr>
<td>Preferred When</td>
<td>Young, high functioning, residual renal function</td>
<td>Bed-bound, comorbidities, no residual function</td>
</tr>
<tr>
<td></td>
<td>Success depends on presence of residual renal function</td>
<td>Residual renal function not as important</td>
</tr>
</tbody>
</table>

How to Write Dialysis Orders

**MUST BE INDIVIDUALIZED**
- Filter type (e.g. F80)
- Length (e.g. 4 h with or 2 h daily)
- Q Blood Flow (max 500 cc/min)
- Ultrafiltration (e.g. 2 L or to target dry weight)
- Na+ 140 (can be adjusted by starting at 155 and “ramping” down to minimize cramping)
- K+ (based on serum K+)
  - Serum K+ Dialysate
    - 4-6
    - 3.5-4
    - 2.5
    - <3.5
- Ca++ 1.25
- HCO3- 40
- Heparin (none, tight [500 U/h] or full [1000 U/h])
- IV fluid to support BP (e.g. NS)

When to Initiate Dialysis

**Ccr < 20 mL/min**
- Educate patient regarding dialysis; if not a candidate for peritoneal dialysis, make arrangements for AV fistula
- Ccr < 15 mL/min
- Weigh risk and benefits for initiating dialysis
- Ccr < 10 mL/min
- Dialysis should be initiated

**NOTE**
- Cockcroft-Gault equation (or MDRD equation) should be used to measure kidney function
- Monitor for uremic complications
- Significant benefits in quality of life can occur if dialysis started before Ccr <15 mL/min
- It is unclear whether patients who start dialysis early have increased survival
- A preemptive transplant can be considered if patient is stable, in order to avoid dialysis

Source: National Kidney Foundation Kidney Disease Outcomes Quality Initiative

Commonly Used Immunosuppressive Drugs

- Calcineurin inhibitors
  - Cyclosporine
  - Tacrolimus

- Antiproliferative medications
  - Mycophenolate mofetil
  - Azathioprine

- Other agents
  - Sirolimus
  - Proctorisine

- Anti-lymphocyte antibodies
  - Thymoglobulin
  - Basiliximab

Indications for Dialysis

**Refractory to medical therapy**

AE 10 U
- Acidity
- Electrolyte imbalance (K+), Intoxication
- Overload (fluid)
- Uremia (encephalopathy, pericarditis, urea >35-50 mM)
Renal Transplantation

- provides maximum replacement of GFR
- preferred modality of RRT in CKD, not AKI
- best way to reverse uremic signs and symptoms
- renal transplantation has been shown to have improved long-term patient survival over dialysis
- native kidneys usually left in situ
- 2 types: deceased donor, living donor (related or unrelated)
- living donor transplants have been shown to have better outcomes than deceased donor transplants
- kidney transplanted into iliac fossa, transplant renal artery anastomosed to external iliac artery of recipient
- 1 yr renal allograft survival rates ≥90%

Complications

- acute rejection: graft site tenderness, rise in Cr, oliguria, ± fever, although symptoms are uncommon
- leading causes of late allograft loss: interstitial fibrosis/tubular atrophy (IFTA) and death with functioning graft
- #1 cause of mortality in transplanted patients is cardiovascular disease
- immunosuppressant drug therapy: side effects include infections, malignancy (skin, Kaposis sarcoma, post-transplant lymphoproliferative disorder)
- de novo GN (usually membranous)
- new-onset DM (often due to prednisone use)
- cyclosporine or tacrolimus nephropathy
- chronic allograft nephropathy
- early allograft damage caused by episodes of acute rejection and acute peritransplant injuries
- immunologic and nonimmunologic factors (HTN, hyperlipidemia, age of donor, quality of graft, new onset DM)
- transplant glomerulopathy from antibody injury causes nephrotic proteinuria
- CMV (cytomegalovirus) infection and other opportunistic infections usually occur between 1 and 6 mo after transplant
- BK virus (polyoma virus) nephropathy can result from over-immunosuppression and lead to graft loss

Common Medications

Table 18. Common Medications in Nephrology

<table>
<thead>
<tr>
<th>Classification</th>
<th>Examples</th>
<th>Site of Action</th>
<th>Mechanism of Action (Secondary Effect)</th>
<th>Indication</th>
<th>Dosing</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loop Diuretics</td>
<td>furosemide (Lasix®), bumetanide (Bumex®), ethacrynic acid (Edecrin®), torsemide (Demadex®)</td>
<td>Thick ascending limb of Loop of Henle</td>
<td>± Na+/K+ exchange = renal and peripheral vasodilatory effects (K+ loss, H+ secretion, Ca2+ excretion)</td>
<td>Management of edema secondary to CHF, nephrotic syndrome, cirticotic ascites; ± free-water clearance (i.e., in SIADH-induced hypervolemia), ± BP (less effective due to short action)</td>
<td>furosemide: 20-80 mg IM/PO q6-8h (max 600 mg/d) until desired response; spironolactone: 25-100 mg PO OD/bid</td>
<td>Allergy in sulfon-sensitive individuals; Electrolyte abnormalities; hypokalemia, hypernatremia, hypercalcemia, hyperparathyroidism (with stone formation); Volume depletion with metabolic alkalosis; Precipitates gouty attacks</td>
</tr>
<tr>
<td>Thiazide Diuretics</td>
<td>hydrochlorothiazide (HCTZ) chlorothiazide (Diacid®), indapamide (Lozide®), metolazone (Zaroxolyn®), chlorothalidone (Hygroton®)</td>
<td>Distal convoluted tubule</td>
<td>± Na+/K+ exchange</td>
<td>Inhibit Na+/K+ transporter (K+ loss, H+ secretion, Ca2+ excretion)</td>
<td>HCTZ: 25-100 mg PO OD; metolazone: 2.5-50 mg PO OD</td>
<td>Hypokalemia, Increased serum urate levels; Precipitates gouty attacks, hyperparathyroidism; Elevated lipids; Glucose intolerance</td>
</tr>
<tr>
<td>Potassium-Sparing Diuretics</td>
<td>spironolactone (Aldactone®), triamterene (Dyrenium®), amiloride (Midamor®)</td>
<td>Cortical collecting duct (± Na+ reabsorption)</td>
<td>Aldosterone antagonist (spironolactone) Block Na+ channels (triamterene and amiloride)</td>
<td>Reduces K+ loss caused by other diuretics; Edema/hypertension, severe CHF, ascites (spironolactone), cystic fibrosis (amiloride); ↓ viscosity of secretions</td>
<td>spironolactone: 25-200 mg/d OD/bid; triamterene/amiloride: 100-400 mg/d OD/bid</td>
<td>Hypokalemia; Increased serum urate levels; Precipitates gouty attacks, hyperparathyroidism; Elevated lipids; Glucose intolerance</td>
</tr>
<tr>
<td>Combination Agents</td>
<td>Dyazide® (triamterene + HCTZ); Aldactazide® (spironolactone + HCTZ); Moduretic® (amiloride + HCTZ); Vasotec® (enalapril + HCTZ); Zestoretic® (lisinopril + HCTZ)</td>
<td>Combination of ACEI and thiazide: have a synergistic effect</td>
<td>Combine K+ sparing drug with thiazide to reduce hypokalemia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osmotic Diuretics</td>
<td>mannitol (Osmitrol®), glyceroluria</td>
<td>Renal tubules (proximal and collecting duct)</td>
<td>Non-reabsorbable solutes increase osmotic pressure of glomerular filtrate – inhibits reabsorption of water and ↑ urinary excretion of toxic materials</td>
<td>To ↓ intracranial or intraocular pressure; Mobilization of excess fluid in renal failure or edematous states</td>
<td>mannitol: 1-3 L 0.5-2 g/kg IV over 30-60 min</td>
<td>Transient volume expansion; Electrolyte abnormalities (↓ ↓ ↓ Na+, ↓ ↓ ↓ K+)</td>
</tr>
</tbody>
</table>

Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors.

NEJM 2016;374:940-950

Purpose: To assess whether there is a survival advantage to receiving a kidney from HLA-incompatible donors compared to remaining on the waiting list for a possible matched deceased donor kidney.

Study: Retrospective, multi-centre analysis

Population: 1025 individuals who received HLA-incompatible live donor kidneys compared to two different controls: individuals waiting and possibly receiving a deceased donor kidney (N=5125), or individuals ultimately not receiving a kidney transplant (N=5125).

Outcome: Survival, tracked for up to 8 years.

Results: Individuals who received HLA-incompatible kidneys had increased survival compared to other control group for time points at 1 year, 5 years, and 8 years post-transplant (p<0.001). After 8 years non-matched kidney recipients had 76.5% survival compared to 43.9% for individuals who ultimately did not receive a kidney transplant. Survival advantage was significant regardless of how the recipient anti-HLA antibodies were detected.

Conclusions: Individuals who received HLA-incompatible kidneys had significantly improved long-term survival compared to individuals who waited for compatible deceased donor kidneys.
Table 18. Common Medications in Nephrology (continued)

<table>
<thead>
<tr>
<th>Classification</th>
<th>Examples</th>
<th>Site of Action</th>
<th>Mechanism of Action (Secondary Effect)</th>
<th>Indication</th>
<th>Dosing</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACEI</td>
<td>ramipril (Altace®)</td>
<td>Lungs</td>
<td>Inhibits angiotensin converting enzyme, preventing formation of angiotensin II</td>
<td>HTN</td>
<td>ramipril: HTN; 2.5-20 mg PO OD</td>
<td>Cough, Asthma, Hyperkalemia</td>
</tr>
<tr>
<td></td>
<td>enalapril (Vasotec®)</td>
<td>Tissues diffusely</td>
<td>Prevents angiotensin II vasoconstricting action on vascular smooth muscle → net vasodilation</td>
<td>HTN</td>
<td>eprosartan 400-800 mg PO OD</td>
<td>Angiostenema, Agranulocytosis (captopril) A0</td>
</tr>
<tr>
<td></td>
<td>lisinopril (Prinivil®)</td>
<td>Tissues diffusely</td>
<td>Prevents angiotensin II vasoconstricting action on vascular smooth muscle → net vasodilation</td>
<td>HTN</td>
<td>olmesartan: HTN; 40-160 mg PO OD</td>
<td>A0, Teratogenic</td>
</tr>
<tr>
<td></td>
<td>losartan (Cozaar®)</td>
<td>Tissues diffusely</td>
<td>Prevents angiotensin II mediated aldosterone release from adrenal cortex and action on proximal renal tubules → ↑ Na⁺ and H₂O excretion</td>
<td>HTN</td>
<td>eprosartan 400-800 mg PO OD</td>
<td>A0, Teratogenic</td>
</tr>
<tr>
<td></td>
<td>valsartan (Diovan®)</td>
<td>Tissues diffusely</td>
<td>Prevents angiotensin II mediated aldosterone release from adrenal cortex and action on proximal renal tubules → ↑ Na⁺ and H₂O excretion</td>
<td>HTN</td>
<td>eprosartan 400-800 mg PO OD</td>
<td>A0, Teratogenic</td>
</tr>
<tr>
<td></td>
<td>candesartan (Atacand®)</td>
<td>Tissues diffusely</td>
<td>Prevents angiotensin II mediated aldosterone release from adrenal cortex and action on proximal renal tubules → ↑ Na⁺ and H₂O excretion</td>
<td>HTN</td>
<td>eprosartan 400-800 mg PO OD</td>
<td>A0, Teratogenic</td>
</tr>
<tr>
<td></td>
<td>irbesartan (Avapro®)</td>
<td>Vascular smooth muscle, adren al cortex, proximal tubules</td>
<td>Competitive inhibitor at the angiotensin II receptor: prevents action on vascular smooth muscle</td>
<td>HTN</td>
<td>olmesartan: HTN; 40-160 mg PO OD</td>
<td>Hyperkalemia</td>
</tr>
<tr>
<td></td>
<td>telmisartan (Micardis®)</td>
<td>Vascular smooth muscle, adren al cortex, proximal tubules</td>
<td>Competitive inhibitor at the angiotensin II receptor: prevents action on vascular smooth muscle</td>
<td>HTN</td>
<td>olmesartan: HTN; 40-160 mg PO OD</td>
<td>Hyperkalemia</td>
</tr>
<tr>
<td></td>
<td>valsartan (TenoArt®)</td>
<td>Vascular smooth muscle, adren al cortex, proximal tubules</td>
<td>Competitive inhibitor at the angiotensin II receptor: prevents action on vascular smooth muscle</td>
<td>HTN</td>
<td>olmesartan: HTN; 40-160 mg PO OD</td>
<td>Hyperkalemia</td>
</tr>
<tr>
<td></td>
<td>eprosartan (Teveten®)</td>
<td>Vascular smooth muscle, adren al cortex, proximal tubules</td>
<td>Competitive inhibitor at the angiotensin II receptor: prevents action on vascular smooth muscle</td>
<td>HTN</td>
<td>olmesartan: HTN; 40-160 mg PO OD</td>
<td>Hyperkalemia</td>
</tr>
<tr>
<td></td>
<td>olmesartan (Elmeler®)</td>
<td>Vascular smooth muscle, adren al cortex, proximal tubules</td>
<td>Competitive inhibitor at the angiotensin II receptor: prevents action on vascular smooth muscle</td>
<td>HTN</td>
<td>olmesartan: HTN; 40-160 mg PO OD</td>
<td>Hyperkalemia</td>
</tr>
<tr>
<td>Renin Antagonists</td>
<td>aliskiren (Rasilez®)</td>
<td>Direct renin antagonist</td>
<td>Inhibits renin production and activity</td>
<td>HTN</td>
<td>aliskiren 150-300 mg PO OD</td>
<td>Hyperkalemia</td>
</tr>
</tbody>
</table>

Landmark Nephrology Trials

<table>
<thead>
<tr>
<th>Trial</th>
<th>Reference</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>4D</td>
<td>NEJM 2005; 353:238-48</td>
<td>Patients with type 2 DM receiving maintenance hemodialysis were randomized to 20 mg of atorvastatin per day or matching placebo; no difference in composite index of death from cardiac causes, nonfatal myocardial infarction, and stroke</td>
</tr>
<tr>
<td>AASK</td>
<td>JAMA 2001; 285:2719-28</td>
<td>Ramipril, compared with amlopidine, slows progression of hypertensive renal disease and proteinuria and may benefit patients without proteinuria as well</td>
</tr>
<tr>
<td>ACCOMPLISH</td>
<td>NEJM 2008; 359:2417-20</td>
<td>Combination treatment with an ACEI and a CCB (benazepril-amlodipine) was more successful than a combination of ACEI and a thiazide diuretic (benazepril-HCTZ) in reducing cardiovascular events in patients with HTN who were at risk for such events</td>
</tr>
<tr>
<td>ACEI and Diabetic</td>
<td>NEJM 1993; 329:1456-62</td>
<td>Captopril protects against deterioration in renal function in insulin-dependent diabetic nephropathy and is significantly more effective than blood pressure control alone</td>
</tr>
<tr>
<td>ALERT</td>
<td>Lancet 2003; 361:2024-31</td>
<td>The use of fluvasatin in renal transplant recipients did not significantly decrease the risk of the occurrence of a major adverse cardiac event (defined as cardiac death, non-fatal MI, or coronary intervention procedure) compared with placebo; however, there was a significant reduction in cardiac deaths or non-fatal MI</td>
</tr>
<tr>
<td>ALTITUDE</td>
<td>Early Termination (Unpublished Results; protocol – AD7 2009; 24:1683-71)</td>
<td>Combining Alikiren with ACEI or ARB in high-risk patients with type 2 DM leads to increased incidence of nonfatal stroke, hyperkalemia, and hypotension</td>
</tr>
<tr>
<td>ASTRAL</td>
<td>NEJM 2008; 361:1953-62</td>
<td>Renal artery revascularization compared to medical therapy does not improve renal function, BP, renal or cardiovascular events, or mortality, and carries significant operative risks</td>
</tr>
<tr>
<td>AURORA</td>
<td>NEJM 2008; 390:1395-407</td>
<td>Patients receiving maintenance hemodialysis randomized to rosuvastatin 10 mg daily or placebo; rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary and point of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke</td>
</tr>
<tr>
<td>BENEDICT</td>
<td>NEJM 2004; 351:1941-51</td>
<td>Treatment with ACEI trandolapril alone or trandolapril combined with verapamil decreased the incidence of microalbuminuria in patients with type 2 DM and HTN with normalbuminuria</td>
</tr>
<tr>
<td>CHOR</td>
<td>NEJM 2006; 355:2085-98</td>
<td>Patients with CKD were randomly assigned to receive a dose of epoetin alfa targeted to achieve a hemoglobin level of 135 g/L or 113 g/L; the higher target group had an increased risk of death, myocardial infarction, hospitalization for congestive heart failure (without renal replacement therapy), or stroke</td>
</tr>
<tr>
<td>CDRAL</td>
<td>NEJM 2014; 370:13-22</td>
<td>Renal-artery stenting did not confer a significant benefit with respect to the prevention of renal or cardiac events when added to comprehensive, multifactorial medical therapy in people with atherosclerotic renal-artery stenosis and hypertension or chronic kidney disease</td>
</tr>
<tr>
<td>CREATE</td>
<td>NEJM 2008; 359:2071-84</td>
<td>Patients with CKD (15-35 mL/min) and mild to moderate anemia (110-125 g/L) were randomized to normal (130-150 g/L) or sub-normal (105-115 g/L) hemoglobin levels; early and complete correction of hemoglobin did not reduce the risk of cardiovascular events</td>
</tr>
<tr>
<td>DETAIL</td>
<td>NEJM 2004; 351:1952-61</td>
<td>The ARB telmisartan and the ACEI enalapril are equally effective in slowing renal function deterioration in type 2 DM with mild to moderate HTN and early nephropathy</td>
</tr>
<tr>
<td>ELITE-SYMPOPHY</td>
<td>NEJM 2007; 357:2562-75</td>
<td>Daclizumab induction, MMF, steroids, and low-dose tacrolimus effectively maintain stable renal function following renal transplantation, without the negative effects on renal function commonly reported for standard CNI regimens</td>
</tr>
<tr>
<td>FHN</td>
<td>NEJM 2010;363:2287-300</td>
<td>Patients were randomized to dialysis 6x/wk (frequent) or 3x/wk (conventional); frequent hemodialysis was associated with improvement in composite outcomes of death, or change in left ventricular mass and death, or change in a physical-health composite score; frequent hemodialysis caused more frequent interventions related to vascular access</td>
</tr>
<tr>
<td>HEMD</td>
<td>NEJM 2002; 347:2010-19</td>
<td>Use of high dose dialysis or high flux membranes versus standard dose or low flux in thrice-weekly dialysis does not improve survival or outcomes; possible benefit in cardiac-related outcomes with high flux membranes</td>
</tr>
</tbody>
</table>
### Landmark Nephrology Trials (continued)

<table>
<thead>
<tr>
<th>Trial</th>
<th>Reference</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>IDEAL</td>
<td>NEJM 2010; 363:629-19</td>
<td>Patients with progressive CKD and GFR between 10 and 15 mL/min randomized to initiate dialysis at GFR of 10-14 mL/min (early) or 5-7 mL/min (late); early initiation of dialysis in patients with stage G5 CKD was not associated with an improvement in survival or clinical outcomes</td>
</tr>
<tr>
<td>IDNT</td>
<td>NEJM 2001; 345:851-60</td>
<td>Treatment with irbesartan reduced the risk of developing end-stage renal disease and worsening renal function in patients with type 2 DM and diabetic nephropathy</td>
</tr>
<tr>
<td>IRMA</td>
<td>NEJM 2001; 345:670-8</td>
<td>Irbesartan is renoprotective independently of its blood pressure lowering effect in patients with type 2 DM and microalbuminuria</td>
</tr>
<tr>
<td>MDRD</td>
<td>Ann Intern Med 1995; 123:754-62</td>
<td>Patients with proteinuria of more than 1 g/d should have a target BP &lt;125/75 mmHg; patients with proteinuria of 0.25 to 1.0 g/d should have a target BP &lt;130/80 mmHg</td>
</tr>
<tr>
<td>ONTARGET</td>
<td>Lancet 2008; 372:547-53</td>
<td>Telmisartan and ramipril monotherapy reduced proteinuria and rise in Cr in patients with high vascular risk; combination of the two agents led to increased acute renal failure episodes, syncope, and hypotension</td>
</tr>
<tr>
<td>REIN</td>
<td>Lancet 1999; 354:359-64</td>
<td>In non-diabetic nephropathy, ACEI were renoprotective in patients with non-nephrotic range proteinuria</td>
</tr>
<tr>
<td>REIN2</td>
<td>Lancet 2005; 365:938-46</td>
<td>In non-diabetic nephropathy already on ACEI, no further benefit from intensified BP control (sBP/dBP&lt;130/80 mmHg) by adding a CCB versus conventional BP control (sBP/dBP&lt;90 mmHg) on ACEI alone</td>
</tr>
<tr>
<td>RENAAL</td>
<td>NEJM 2001; 345:861-9</td>
<td>Losartan conferred significant renal benefits in patients with type 2 DM and nephropathy and was generally well-tolerated</td>
</tr>
<tr>
<td>RENAL</td>
<td>NEJM 2008; 361:1627-38</td>
<td>High intensity continuous renal replacement therapy in AKI does not improve survival or outcomes compared to low intensity treatment, and is associated with higher rates of hypophosphatemia</td>
</tr>
<tr>
<td>Rituximab in Children with Steroid-Dependent Nephrotic Syndrome</td>
<td>JASN 2015; 26 D10:ASN14OB0799</td>
<td>Rituximab is non-inferior to steroids in maintaining remission in juvenile steroid dependent nephrotic syndrome</td>
</tr>
<tr>
<td>ROAD</td>
<td>JASN 2007; 18:1899-98</td>
<td>Uptitration of either ACEI benaenaspir or ARB losartan to optimal anti-proteinuria doses conferred benefit on renal outcome in patients without DM who had proteinuria and renal insufficiency</td>
</tr>
<tr>
<td>ROADMAP</td>
<td>NEJM 2011; 364:907-17</td>
<td>The use of the ARB olmesartan was more effective than placebo in delaying the onset of microalbuminuria in patients with type 2 DM, normal blood pressure, and good blood pressure control; however, a higher rate of fatal cardiovascular events was found amongst patients with preexisting coronary heart disease in the olmesartan group</td>
</tr>
<tr>
<td>SHARP</td>
<td>Lancet 2011; 377:2181-92</td>
<td>Randomized placebo-controlled trial in patients with CKD and no history of MI or coronary revascularization took simvastatin 20 mg plus ezetimibe 10 mg daily versus matching placebo; simvastatin 20 mg plus ezetimibe 10 mg daily resulted in reduction of LDL cholesterol with associated reduction of major atherosclerotic events in patients with CKD</td>
</tr>
<tr>
<td>SPRINT</td>
<td>NEJM 2015; 372:2103-2116</td>
<td>A lower blood pressure target of 120/80 reduced the risk of composite cardiovascular events in a hypertensive patient population</td>
</tr>
<tr>
<td>TREAT</td>
<td>NEJM 2008; 361:219-32</td>
<td>Patients with type 2 DM, CKD, and anemia were randomized to darbepoetin targeting a hemoglobin of 13 g/dL or placebo; darbepoetin did not reduce the risk of death, a cardiovascular event, or a renal event, and was associated with an increased risk of stroke</td>
</tr>
<tr>
<td>Tolvaptan in ADPKD</td>
<td>NEJM 2012; 367: 2407-18</td>
<td>Tolvaptan (vs. placebo) slowed the increase in total kidney volume and decline in kidney function over a 3-year period in patients with ADPKD but was associated with a higher discontinuation rate, due to adverse events</td>
</tr>
</tbody>
</table>

### References


Andregg HJ, Madias NE. Hypertonemia. NEJM 2002;346:1581-90.


Chabrier B, Tolvaptan (vs. placebo) slowed the increase in total kidney volume and decline in kidney function over a 3-year period in patients with ADPKD but was associated with a higher discontinuation rate, due to adverse events.
**Neurology**

Jane Liao, Anthony Wan, and Kirill Zaslavsky, chapter editors
Claudia Frankfurter and Inna Gong, associate editors
Brittany Prevost and Robert Vanner, EBM editors
Dr. Mark Boulos, Dr. Alfonso Fasano, Dr. Elizabeth Slow, and Dr. Peter Tai, staff editors

Acronyms ......................................................... 2
Approach to the Neurological Complaint .......................... 2
Lesion Localization
The Neurological Exam ........................................... 3
General Exam and Mental Status
Cranial Nerve Exam
Motor Exam
Sensory Exam
Coordination Exam and Gait

Basic Anatomy Review ......................................... 6
Lumbar Puncture .................................................. 9

Approach to Common Presentations ............................... 9
Weakness
Numbness/Altered Sensation
Gait Disturbance

Cranial Nerve Deficits ........................................... 11
CN I: Olfactory Nerve
CN II: Optic Nerve
CN III: Oculomotor Nerve
CN IV: Trochlear Nerve
CN V: Trigeminal Nerve
CN VI: Abducens Nerve

Neuro-Ophthalmology ........................................... 14
Abnormalities of Vision
Acute Visual Loss
Optic Neuritis
Anterior Ischemic Optic Neuropathy (AION)
Central Retinal Vein Occlusion
Optic Disc Edema
Optic Disc Atrophy

Abnormalities of Visual Field ................................... 15
Abnormalities of Eye Movements ................................ 15
Disorders of Gaze
Internuclear Ophthalmoplegia
Diplopia
Nystagmus
Abnormalities of Pupils

Nutritional Deficiencies and Toxic Injuries ................. 17
Seizure Disorders and Epilepsy .................................. 18
Seizure
Status Epilepticus

Behavioural Neurology ......................................... 20
Acute Confusional State/Delirium
Mild Neurocognitive Disorder (Mild Cognitive Impairment)
Major Neurocognitive Disorder (Formerly Dementia)
Major or Mild NCD due to Alzheimer’s Disease
Major or Mild NCD with Lewy Bodies (formerly Dementia with Lewy Bodies)
Major or Mild Frontotemporal NCD (formerly Frontotemporal Dementia)
Major or Mild Vascular NCD
Creutzfeldt-Jakob Disease
Aphasia
Agnosia

Mild Traumatic Brain Injury ................................... 28

Neuro-Oncology .................................................. 29
Paraneoplastic Syndromes
Tumours of the Nervous System

Movement Disorders ............................................. 29
Function of the Basal Ganglia
Overview of Movement Disorders
Movement Disorders
Parkinson’s Disease
Other Parkinsonian Disorders
Huntington’s Disease
Dystonia
Tic Disorders
Tourette’s Syndrome

Cerebellar Disorders ............................................. 34
Wernicke-Korsakoff Syndrome
Cerebellar Ataxias

Vertigo .............................................................. 35

Motor Neuron Disease ............................................ 35
Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease)
Other Motor Neuron Diseases

Peripheral Neuropathies ......................................... 36

Neuromuscular Junction Diseases ............................... 38
Myasthenia Gravis
Lambert-Eaton Myasthenic Syndrome
Botulism

Myopathies ........................................................... 40
Clinical Approach to Muscle Diseases
Myotonic Dystrophy

Pain Syndromes .................................................... 41
Approach to Pain Syndromes
Neuropathic Pain
Trigeminal Neuralgia
Postherpetic Neuralgia
Painful Diabetic Neuropathy
Complex Regional Pain Syndromes

Headache ............................................................. 44
Migraine Headaches

Sleep Disorders ..................................................... 46
Overview of Sleep
Disturbances of Alertness and Sleep

CNS Infections ..................................................... ID18

Spinal Cord Syndromes .......................................... NS27

Stroke .............................................................. 48
Pathophysiology
Assessment and Treatment of Ischemic Stroke
Primary and Secondary Prevention of Ischemic Stroke
Cerebral Hemorrhage

Neurocutaneous Syndromes ..................................... P84

Multiple Sclerosis ............................................... 52
Common Medications ............................................. 54

Landmark Neurology Trials .................................... 55

References .......................................................... 56
Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACA</td>
<td>anterior cerebral artery</td>
</tr>
<tr>
<td>ACh</td>
<td>acetylcholine</td>
</tr>
<tr>
<td>AD</td>
<td>Alzheimer's disease</td>
</tr>
<tr>
<td>ADL</td>
<td>activities of daily living</td>
</tr>
<tr>
<td>AED</td>
<td>antiepileptic drugs</td>
</tr>
<tr>
<td>AION</td>
<td>acute ischemic optic neuropathy</td>
</tr>
<tr>
<td>ALS</td>
<td>amyotrophic lateral sclerosis</td>
</tr>
<tr>
<td>AVM</td>
<td>arteriovenous malformation</td>
</tr>
<tr>
<td>AVPU</td>
<td>avert, verbal, pain, unresponsive</td>
</tr>
<tr>
<td>CJD</td>
<td>Creutzfeldt-Jakob disease</td>
</tr>
<tr>
<td>CN</td>
<td>cranial nerve</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>CRVO</td>
<td>central retinal vein occlusion</td>
</tr>
<tr>
<td>CSF</td>
<td>cerebrospinal fluid</td>
</tr>
<tr>
<td>CVD</td>
<td>cerebrovascular disease</td>
</tr>
<tr>
<td>DBS</td>
<td>deep brain stimulation</td>
</tr>
<tr>
<td>DLB</td>
<td>dementia with Lewy bodies</td>
</tr>
<tr>
<td>DM</td>
<td>diabetes mellitus</td>
</tr>
<tr>
<td>EDM</td>
<td>extracocular movement</td>
</tr>
<tr>
<td>EOH</td>
<td>ethanol</td>
</tr>
<tr>
<td>FEF</td>
<td>frontal eye field</td>
</tr>
<tr>
<td>FTDL</td>
<td>frontotemporal dementia</td>
</tr>
<tr>
<td>GBS</td>
<td>Guillain-Barre syndrome</td>
</tr>
<tr>
<td>GCA</td>
<td>giant cell arteritis</td>
</tr>
<tr>
<td>GCS</td>
<td>Glasgow coma scale</td>
</tr>
<tr>
<td>GPx</td>
<td>Gowers paralysis pain</td>
</tr>
<tr>
<td>GRP</td>
<td>Gowers paralysis pain</td>
</tr>
<tr>
<td>HD</td>
<td>Huntington's disease</td>
</tr>
<tr>
<td>IADL</td>
<td>instrumental activities of daily living</td>
</tr>
<tr>
<td>ICP</td>
<td>intracranial pressure</td>
</tr>
<tr>
<td>IHH</td>
<td>idiopathic intracranial hypertension</td>
</tr>
<tr>
<td>IND</td>
<td>internuclear ophthalmoplegia</td>
</tr>
<tr>
<td>IVG</td>
<td>intravenous immunoglobulin</td>
</tr>
<tr>
<td>JC</td>
<td>John Cunningham virus</td>
</tr>
<tr>
<td>LEMS</td>
<td>Lambert-Eaton myasthenic syndrome</td>
</tr>
<tr>
<td>LGB</td>
<td>lateral geniculate body</td>
</tr>
<tr>
<td>LMN</td>
<td>lower motor neuron</td>
</tr>
<tr>
<td>LOC</td>
<td>level of consciousness</td>
</tr>
<tr>
<td>LP</td>
<td>lumbar puncture</td>
</tr>
<tr>
<td>MCA</td>
<td>middle cerebral artery</td>
</tr>
<tr>
<td>MG</td>
<td>myasthenia gravis</td>
</tr>
<tr>
<td>MLF</td>
<td>medial longitudinal fasciculus</td>
</tr>
<tr>
<td>MMSE</td>
<td>mini mental status examination</td>
</tr>
<tr>
<td>MoCA</td>
<td>Montreal cognitive assessment</td>
</tr>
<tr>
<td>MS</td>
<td>multiple sclerosis</td>
</tr>
<tr>
<td>NCS</td>
<td>nerve conduction studies</td>
</tr>
<tr>
<td>NAJ</td>
<td>neuromuscular junction</td>
</tr>
<tr>
<td>NPH</td>
<td>normal pressure hydrocephalus</td>
</tr>
<tr>
<td>PCOAM</td>
<td>posterior communicating artery</td>
</tr>
<tr>
<td>PCWS</td>
<td>Parkinson's disease</td>
</tr>
<tr>
<td>PICA</td>
<td>posterior inferior cerebral artery</td>
</tr>
<tr>
<td>PMI</td>
<td>periodic limb movement in sleep</td>
</tr>
<tr>
<td>PPA</td>
<td>primary progressive aphasia</td>
</tr>
<tr>
<td>PPRF</td>
<td>paramedian pontine reticular formation</td>
</tr>
<tr>
<td>PSP</td>
<td>progressive supranuclear palsy</td>
</tr>
<tr>
<td>RAPOD</td>
<td>relative afferent pupillary defect</td>
</tr>
<tr>
<td>REM</td>
<td>rapid eye movement</td>
</tr>
<tr>
<td>RLS</td>
<td>restless legs syndrome</td>
</tr>
<tr>
<td>RDM</td>
<td>range of motion</td>
</tr>
<tr>
<td>SAH</td>
<td>subarachnoid hemorrhage</td>
</tr>
<tr>
<td>SDH</td>
<td>subdural hematoma</td>
</tr>
<tr>
<td>SNc</td>
<td>substantia nigra pars compacta</td>
</tr>
<tr>
<td>Shg</td>
<td>substantia nigra pars reticulata</td>
</tr>
<tr>
<td>STN</td>
<td>subthalamic nucleus</td>
</tr>
<tr>
<td>TBI</td>
<td>traumatic brain injury</td>
</tr>
<tr>
<td>TIA</td>
<td>transient ischemic attack</td>
</tr>
<tr>
<td>UMN</td>
<td>upper motor neuron</td>
</tr>
<tr>
<td>VEGF</td>
<td>vascular endothelial growth factor</td>
</tr>
<tr>
<td>VZV</td>
<td>varicella zoster virus</td>
</tr>
</tbody>
</table>

Approach to the Neurological Complaint

Lesion Localization

- **cortical**
  - contralateral paresis (with differential effect on face and arm vs leg)
  - UMN injury (hyperreflexia, Babinski sign, spasticity, no atrophy)
  - cortical sensory loss (hemisensory loss, position sense, two-point discrimination, graphesthesia, stereognosis)
  - dominant hemisphere (aphasia, alexia, agraphia, acalculia, left-right disorientation)
  - non-dominant hemisphere (hemineglect, dysprosody, amusia, constructional apraxia)
  - homonymous hemianopia/quadrantanopia
  - gaze deviation (eyes look toward side of infarct)
  - seizure
  - agnosia (visual, auditory)
  - apraxia
  - alien hand syndrome

- **subcortical**
  - internal capsule: contralateral paresis with equal face, arm, leg involvement without sensory/cortical deficits; contralateral dysmetria/clumsiness and leg paresis
  - basal ganglia: pill-rolling tremor, bradykinesia, festinating gait, hemiballismus, chorea, dystonic posture
  - thalamus: dense sensory loss, contralateral severe pain

- **brainstem** (bulbar)
  - crossed hemiplegia or sensory loss (i.e. ipsilateral face, contralateral body)
  - ipsilateral cerebellar (dysmetria, rapid alternating movements, tandem gait)
  - nystagmus toward lesion, diplopia, INO (impaired adduction on contralateral gaze)
  - dysphagia, dysarthria
  - hearing loss, vertigo

- **cerebellum**
  - ipsilateral ataxia (unsteadiness, incoordination)
  - dysmetria, intention tremor
  - dysdiadochokinesia
  - wide-based gait, truncal titubation (staggering, reeling, lurching)
  - scanning speech (explosive speech with noticeable pauses and accentuated syllables)
  - nystagmus, distorted smooth pursuit, oscillopsia

- **spinal cord**
  - bilateral motor and/or sensory deficits below the lesion without facial involvement
  - ataxia, sensory level (sharp line below which there is decreased sensation); suspended “cape-like” sensory level
  - UMN signs (flaccid paresis, hypotonia, hyperreflexia, atrophy, fasciculations) at level of lesion; UMN signs below lesion (marked spasticity and Babinski)
  - bowel, bladder, sexual dysfunction
  - saddle anesthesia
  - ataxia

- **nerve root**
  - multiple peripheral nerve involvement
  - myotomal/dermatomal deficits
  - back/neck pain radiating to leg/arm
• peripheral nerve
  ■ distal “stocking-glove distribution” sensory loss
  ■ LMN signs (hypotonia, hyporeflexia, fasciculations, atrophy)
  ■ neuromuscular junction
  ■ fluctuating/fatiguable ocular (diplopia) and proximal muscle weakness
  ■ bulbar involvement (dysphonia, dysarthria)

• muscle
  ■ symmetric proximal weakness (climbing stairs, getting up from chair) without sensory deficits
  ■ muscle tenderness
  ■ muscle atrophy

### The Neurological Exam

#### General Exam and Mental Status

- **vitals**: pulse (especially rhythm), BP, RR, temperature
- **H&N**: meningismus, head injury/bruises (signs of basal skull fracture: Battle's sign, raccoon eyes, hemotympanum, CSF rhinorrhea/otorrhea), tongue biting
- **CVS**: carotid bruits, heart murmurs
- **mental status**: orientation (person, place, time), LOC (GCS) (see Emergency Medicin, ER4)
  - GCS/15 – Motor/6, Verbal/5 (T= intubated), Eyes/4
- **cognition**
  - Folstein MMSE – /30 (note: dementia is a clinical diagnosis and is not diagnosed by cognitive testing)
  - MoCA – /30 (≥26 is considered normal)
  - frontal lobe testing (for perseveration – i.e. go/no-go test)
  - clock drawing

#### Cranial Nerve Exam

<table>
<thead>
<tr>
<th>Cranial Nerve</th>
<th>Recommended Physical Exams</th>
<th>Signs/Symptoms of Deficit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olfactory (CN I)</td>
<td>Odor sensation: test each nostril separately</td>
<td>Anosmia (can be associated with loss of taste)</td>
</tr>
<tr>
<td>Optic (CN II)</td>
<td>Visual acuity: test each eye individually; best corrected vision Test visual fields Assess pupils: direct and consensual pupillary reaction (afferent), swinging flashlight test (for RAPD) Fundoscopy: optic disc edema and pallor, venous pulsations, hemorrhages Colour vision testing ( Ishihara plates)</td>
<td>Blindness Absence of light reflexes, RAPD</td>
</tr>
<tr>
<td>Oculomotor (CN III)</td>
<td>Assess extraocular movements and nystagmus Test efferent limb of pupillary light response Assess size and shape of pupil; accommodation and saccadic eye movements Test for ptosis (levator palpebrae superioris)</td>
<td>Eyes deviated down and out; can demonstrate mydriasis</td>
</tr>
<tr>
<td>Trochlear (CN IV)</td>
<td>Test movement of superior oblique</td>
<td>Vertical diplopia; may tilt head towards unaffected side; affected eye cannot turn inward and downward</td>
</tr>
<tr>
<td>Trigeminal (CN V)</td>
<td>Test sensation above supraorbital ridge (V1), buccal area (V2), mandible (V3) Test corneal reflex (afferent limb) Assess motor function: temporalis, masseter, pterygoids, jaw jerk reflex</td>
<td>Loss of facial sensations and corneal reflex on stimulation ipsilaterally, weakness and wasting of muscles of mastication, deviation of open jaw to ipsilateral side; trigeminal neuralgia</td>
</tr>
<tr>
<td>Abduces (CN VI)</td>
<td>Test movement of lateral rectus</td>
<td>Horizontal diplopia, esotropia (convergent strabismus) and abductor paralysis of ipsilateral eye</td>
</tr>
<tr>
<td>Facial (CN VII)</td>
<td>Sensimotor nerve function: to muscles of facial expression Test efferent limb of corneal reflex Visceral sensory nerve function: to anterior 2/3 of the tongue Visceral motor nerve function: to salivary and lacrimal glands</td>
<td>Paralysis of ipsilateral upper and lower facial muscles Loss of lacrimation Decreased salivation, dry mouth Loss of taste to anterior 2/3 of the tongue ipsilaterally LMN lesion = ipsilateral facial weakness UNM lesion = contralateral facial weakness, sparing the brow bilaterally</td>
</tr>
</tbody>
</table>
**Table 1. Cranial Nerve Examination and Associated Deficits (continued)**

<table>
<thead>
<tr>
<th>Cranial Nerve</th>
<th>Recommended Physical Exams</th>
<th>Signs/Symptoms of Deficit</th>
</tr>
</thead>
</table>
| Vestibulocochlear (CN VIII) | Vestibular function - nystagmus, caloric reflexes  
Cochlear function - whisper test, Rinne, Weber | Vertigo, disequilibrium, and nystagmus  
Sensorineural hearing loss |
| Glossopharyngeal (CN IX) | Assess vocal cord function and gag reflex  
Assess taste to posterior third of the tongue (bitter and sour taste) | Loss of taste in posterior third of ipsilateral tongue  
Loss of gag reflex and dysphasia  
Unilateral lesion is rare |
| Vagus (CN X) | Assess vocal cord function and gag reflex  
Observe uvula deviation and palatal elevation  
Assess swallowing | Loss of gag reflex, dysphagia, hoarse voice  
Paralysis of soft palate (failed elevation)  
Deviations of uvula to contralateral side of lesions; anesthesis of pharynx and larynx ipsilaterally |
| Accessory (CN XI) | Assess strength of trapezius (shoulder shrug) and sternocleidomastoid muscles (head turn) | Ipsilateral shoulder weakness and turning head to opposite side |
| Hypoglossal (CN XII) | Inspect tongue for signs of lateral deviation, atrophy, fasciculations, asymmetry of movement and strength | Wasting of ipsilateral tongue muscles and deviation to ipsilateral side on protrusion |

**Motor Exam**

- **bulk**: atrophy, asymmetry
- **tone**: hypotonia (flaccid), hypertonia (spasticity, rigidity, parapronia), cogwheeling
- **power**: pronator drift, asymmetric forearm rolling test (satellite sign)
- **reflexes**: deep tendon reflexes, abdominal reflexes, primitive reflexes, Babinski sign, Hoffmann reflex, clonus
- **abnormal movements**: tremors, chorea, dystonia, dyskinesia, hemiballismus, myoclonus, atetosis, tics, fasciculations
- **abnormal posturing**: decorticate (upper extremity flexion, lower extremity extension), decerebrate (extremity extension)

**Table 2. Localization of Motor Deficits**

<table>
<thead>
<tr>
<th></th>
<th>LMN</th>
<th>UMN</th>
<th>Extrapyramidal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muscle Tone</td>
<td>Flaccid</td>
<td>Spastic</td>
<td>Rigid</td>
</tr>
<tr>
<td>Involuntary Movements</td>
<td>Fasciculations</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Reflexes</td>
<td>Decreased</td>
<td>Increased</td>
<td>Normal</td>
</tr>
<tr>
<td>Plantar Reflex</td>
<td>Down-going (flexor)</td>
<td>Up-going (extensor, i.e. Babinski sign)</td>
<td>Down-going (flexor)</td>
</tr>
</tbody>
</table>
| Pattern of Muscle Weakness | Proximal, distal, or focal | Pyramidal pattern: look for hemiparetic gait (flexed arm, extended legs) | Upper extremities: extendors weaker than flexors  
Lower extremities: flexors weaker than extendors | None |

**Table 3. Overview of Neuromuscular Diseases**

<table>
<thead>
<tr>
<th></th>
<th>Motor Neuron Disease (i.e. ALS)</th>
<th>Peripheral Neuropathy</th>
<th>Neuromuscular Junction</th>
<th>Myopathy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SIGNS AND SYMPTOMS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weakness</td>
<td>Segmental and asymmetrical, distal → proximal</td>
<td>Distal (except GBS) but may be asymmetrical</td>
<td>Proximal and fatigable (e.g. MG), or weak then recovers (e.g. LEMS)</td>
<td>Proximal</td>
</tr>
<tr>
<td>Fasciculations</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Reflexes</td>
<td>Increased</td>
<td>Decreased/absent</td>
<td>Normal</td>
<td>Normal (until late)</td>
</tr>
<tr>
<td>Sensory</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Autonomic*</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>TESTS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EMG</td>
<td>Denervation and reinnervation</td>
<td>Signs of demyelination ± axonal loss</td>
<td>Decremental response, Jitter on single fibre EMG</td>
<td>Small, short motor potentials</td>
</tr>
<tr>
<td>NCS</td>
<td>Normal</td>
<td>Abnormal</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>Muscle Enzyme</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Increased</td>
</tr>
</tbody>
</table>

*e.g. orthostatic hypotension, arthralgia, visual blurring, urinary hesitancy or incontinence, constipation, erectile dysfunction
Table 4. Approach to Strength Testing of Radiculopathies vs. Peripheral Neuropathies

How to use this table: For each nerve root, learn two (or more) peripheral nerves (and their associated muscles/movements). In radiculopathies, all associated peripheral nerves (and their movements) will be impaired, whereas in peripheral neuropathies, only one of the nerves (and its movement) will be impaired, sparing the other nerve. Particularly useful peripheral nerve “pairs” are bolded for emphasis.

<table>
<thead>
<tr>
<th>Root</th>
<th>Peripheral Nerve</th>
<th>Movement</th>
<th>Muscle</th>
</tr>
</thead>
<tbody>
<tr>
<td>C5</td>
<td>Axillary</td>
<td>Shoulder abduction</td>
<td>Biceps</td>
</tr>
<tr>
<td>C6</td>
<td>Musculocutaneous (C5/6) Radial (C6)</td>
<td>Elbow flexion</td>
<td>Brachioradialis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Elbow flexion</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wrist extension</td>
<td>Extensor carpi radialis longus</td>
</tr>
<tr>
<td>C7</td>
<td>Radial</td>
<td>Elbow extension</td>
<td>Triceps</td>
</tr>
<tr>
<td></td>
<td>Posterior interosseus</td>
<td>Finger extension</td>
<td>Extensor digitorum communis</td>
</tr>
<tr>
<td>C8, T1</td>
<td>Median</td>
<td>Thumb flexion</td>
<td>Flexor pollicis brevis (look for thanar wasting)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thumb abduction</td>
<td>Abductor pollicis brevis (look for thanar wasting)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Opposition</td>
<td>Opponens pollicis (look for thanar wasting)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ulnar</td>
<td>Finger abduction</td>
<td>First dorsal interosseous (look for wasting in first dorsal webbed space)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L2, 3, 4</td>
<td>Femoral</td>
<td>Hip flexion</td>
<td>Iliopsoas</td>
</tr>
<tr>
<td></td>
<td>Oburator</td>
<td>Hip adduction</td>
<td>Adductor muscles</td>
</tr>
<tr>
<td>L3, 4</td>
<td>Femoral (L3/4) Deep peroneal (L4/5)</td>
<td>Knee extension</td>
<td>Quadriceps</td>
</tr>
<tr>
<td></td>
<td>Deep peroneal</td>
<td>Dorsiflexion</td>
<td>Tibialis anterior</td>
</tr>
<tr>
<td>L5</td>
<td>Sciatic (L5, S1) Superficial peroneal Deep peroneal</td>
<td>Hip extension</td>
<td>Gluteus maximus</td>
</tr>
<tr>
<td></td>
<td>Tibial</td>
<td>Ankle inversion</td>
<td>Tibialis posterior</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ankle eversion</td>
<td>Peroneal muscles</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Big toe extension</td>
<td>Extensor hallucis longus</td>
</tr>
<tr>
<td>S1</td>
<td>Sciatic</td>
<td>Knee flexion</td>
<td>Hamstring muscles</td>
</tr>
<tr>
<td></td>
<td>Tibial</td>
<td>Plantar flexion</td>
<td>Gastrocnemius and soleus</td>
</tr>
</tbody>
</table>

Sensory Exam

- **primary sensation**
  - spinothalamic tract: crude touch, pain, temperature
  - dorsal column-medial lemniscus pathway: fine touch, vibration, proprioception

- **cortical sensation**
  - graphesthesia, stereognosis, extinction, 2-point discrimination

Coordination Exam and Gait

- **coordination exam**
  - finger-to-nose, heel-to-shin, rapid alternating movements

- **stance and gait**
  - gait: antalgic, hemiplegic, ataxic, apraxic, festinating, foot drop, broad-based
  - tandem gait (heel-to-toe walking)

- **Romberg test**
  - pull test for postural instability
Basic Anatomy Review

Medulla

1. Corticospinal tract
2. Spinohalamic tract
3. Medial lemniscus
4. Reticular formation
5. Nucleus of spinal tract of trigeminal (V) nerve (descending)
6. Spinal tract of trigeminal (V) nerve
7. Nucleus cuneatus
8. Fasciculus cuneatus
9. Nucleus gracilis
10. Fasciculus gracilis
11. Central canal
12. Arcuate fibres

Pons

13. Pontine nucleus
14. Abducens (VI) nerve fibres
15. Nucleus of facial (VII) nerve (motor)
16. Facial (VII) nerve fibres
17. Trigeminal (V) nerve fibres
18. Nucleus of abducens (VI) nerve
19. Nucleus of spinal tract of trigeminal (V) nerve
20. Lateral vestibular nucleus
21. Middle cerebellar peduncle
22. Fourth ventricle

Midbrain

23. Interpeduncular fossa
24. Oculomotor (III) nerve fibres
25. Cerebral peduncle
26. Substantia nigra
27. Red nucleus
28. Edinger-Westphal nuclei
29. Oculomotor (III) nucleus complex (motor)
30. Cerebral aqueduct
31. Pretectal area
32. Superior colliculus

Figure 1. Brainstem (axial view)

ROSTRAL

Optic nerve (CN II)
Internal carotid artery (ICA)
Middle cerebral artery (MCA)
Posterior communicating artery (PComm)
Posterior cerebral artery
Superior cerebellar artery (SCA)
Basilar artery
Anterior inferior cerebellar artery (AICA)
Posterior inferior cerebellar artery (PICA)
Anterior spinal artery

CAUDAL

Oculomotor nerve (CN III)
Trochlear nerve (CN IV)
Trigeminal nerve (CN V)
Abducens nerve (CN VI)
Facial nerve (CN VII)
Vestibulocochlear nerve (CN VIII)
Glossopharyngeal nerve (CN IX)
Hypoglossal nerve (CN XII)
Vagus nerve (CN X)
Accessory nerve (CN XI)

Figure 2. Brainstem (posterior view)
Basic Anatomy Review

Figure 3. Discriminative touch pathway (dorsal column) from body

Figure 4. Spinothalamic tract from body

Figure 5. Discriminative touch pathway (dorsal column) from face

Figure 6. Spinothalamic tract pathway from face

Figure 7. Corticospinal motor pathway
Figure 8. Sympathetic and parasympathetic pathway

**Sympathetic**
- Pupil dilation
- Constriction
- Lacrimal and salivary glands
- Modulate secretion
- Superior cervical ganglion
- Bronchodilation
- Coronary arteries and heart rate
- Glycogen utilization
- Liver
- Inhibit motility and enzyme secretion
- Bile secretion
- Adrenal medulla
- Release epinephrine
- Bladder
- Inhibit constriction
- Reproductive system
- Ejaculation
- Vasoconstriction
- Sweat glands stimulated

**Parasympathetic**
- Constriction
- Pupil constriction
- Lacrimal and salivary glands
- Modulate secretion
- Para sympathetic g. (salivation)
- Submaxillary g. (parotid secretion)
- Pterygopalatine g. (lacrimation)
- Otic g. (parotid secretion)
- Bronchodilation
- Secretion
- Coronary arteries and heart rate
- Vasoconstriction, deceleration
- Glycogen utilization
- Liver
- Stimulate motility and enzyme secretion
- Bile secretion
- Adrenal medulla
- Release epinephrine
- Bladder
- Constriction
- Reproductive system
- Erection
- Vasoconstriction
- Sweat glands stimulated

**Mystomes**
- C5 – Shoulder abduction/elbow flexion
- C6 – Wrist extensors
- C7 – Elbow extension
- C8 – Finger flexion
- T1 – Finger abduction
- T2-9 – Intercostal (abdominal reflexes)
- T9-10 – Upper abdominals
- T11-12 – Lower abdominals
- L2 – Hip flexion
- L3 – Hip adduction
- L4 – Knee extension and ankle dorsiflexion
- L5 – Ankle dorsiflexion and big toe extension
- S1 – Plantarflexion

Figure 9. Dermatome map
Lumbar Puncture

Indications
- diagnostic: CNS infection (meningitis, encephalitis), inflammatory disorder (MS, Guillain-Barré, vasculitis), subarachnoid hemorrhage (if CT negative), CNS neoplasm (neoplastic meningitis)
- therapeutic: to administer anesthesia, chemotherapy, contrast media; to decrease ICP (pseudotumour cerebri, NPH)

Contraindications
- mass lesion causing increased ICP, could lead to cerebral herniation; CT first if suspect mass lesion
- infection over LP site/suspected epidural abscess
- low platelets (<50,000) or treatment with anticoagulation (high INR or aPTT)
- uncooperative patient

Complications
- tonsillar hernation (rare)
- SDH (rare)
- transient 6th nerve palsy (rare)
- post-LP headache (5-40%): worse when upright, better supine; generally onset within 24 h
  - prevention: smaller gauge (i.e. 22) needle, reinsert stylet prior to needle removal, blunt-ended needle
  - symptomatic treatment: caffeine and sodium benzoate injection
  - corrective treatment: blood patch (autologous)
- spinal epidural hematoma
- infection

LP Tubes
- tube #1: cell count and differential: RBCs, WBCs, and differential
  - xanthochromia (yellow bilirubin pigmentation implies recent bleed into CSF, diagnostic of SAH)
- tube #2: chemistry: glucose (compare to serum glucose) and protein
- tube #3: microbiology: Gram stain and C&S
  - specific tests depending on clinical situation/suspicion
    - viral: PCR for herpes simplex virus (HSV) and other viruses
    - bacterial: polysaccharide antigens of H. influenzae, N. meningitidis, S. pneumoniae
    - fungal: cryptococcal antigen, culture
    - TB: acid-fast stain, TB culture, TB PCR
- tube #4: cytology: for evidence of malignant cells
- tube #5: cell count: compare RBC count to that of tube #1
  - note: tube 4 or 5 can be sent for repeat cell count

Table 5. Lumbar Puncture Interpretation (Normal vs. Various Infectious Causes)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Colour</th>
<th>Protein</th>
<th>Glucose</th>
<th>Cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>NORMAL</td>
<td>Clear</td>
<td>&lt;0.49 g/L</td>
<td>60% of serum glucose or &gt;3.0 mmol/L</td>
<td>0-5 x 10⁶/L</td>
</tr>
<tr>
<td>Viral Infection</td>
<td>Clear or opalescent</td>
<td>Normal or slightly increased &lt;0.45-1 g/L</td>
<td>Normal</td>
<td>&lt;1,000 x 10⁶/L, Lymphocytes mostly, some PMNs</td>
</tr>
<tr>
<td>Bacterial Infection</td>
<td>Opalescent yellow, may clot</td>
<td>&gt;1 g/L</td>
<td>Decreased (&lt;25% serum glucose or &lt;2.0 mmol/L)</td>
<td>&gt;1,000 x 10⁶/L, PMNs</td>
</tr>
<tr>
<td>Granulomatous Infection (tuberculosis, fungal)</td>
<td>Clear or opalescent</td>
<td>Increased but usually &lt;5 g/L</td>
<td>Decreased (usually &lt;2.0-4.0 mmol/L)</td>
<td>&lt;1,000 x 10⁶/L, Lymphocytes</td>
</tr>
</tbody>
</table>

Approach to Common Presentations

Weakness

Approach
- mode of onset: abrupt (vascular, toxic, metabolic), subacute (neoplastic, infective, inflammatory), insidious (hereditary, degenerative, endocrine, neoplastic)
- course: worse at onset (vascular), progressive (neoplastic, degenerative, infective), episodic (vascular, inflammatory), activity dependent (NM, muscular)
- pattern: objective vs. subjective, generalized vs. localized, asymmetric vs. symmetric, proximal vs. distal, UMN vs. LMN, peripheral vs. myotomal
- associated symptoms: sensory symptoms, cortical symptoms, spinal symptoms (i.e. bowel/bladder dysfunction), signs/symptoms specific to various etiologies
- history: family history, developmental history, medications, risk factors, recent/preceding exposures
- investigations for UMN: NCS/EMG
- investigations for UMN: imaging (brain and/or spinal cord)
Differential Diagnosis

- objective muscle weakness; also, differentiate between true muscle weakness vs. fatigue
  - generalized
    - myopathy (proximal > distal weakness)
      - endocrine: hypothyroidism, hyperthyroidism, Cushing’s syndrome
      - rheumatologic: polymyositis, vasculitis
      - infectious: HIV, CMV, influenza
      - other: collagen vascular disorders, steroids, statins, alcohol, electrolyte disorders
    - NMJ (MG, botulism, LEMS, organophosphate poisoning)
    - cachexia
  - localized
    - UMN (vasculitis, abscess, brain tumour, vitamin B12 deficiency, MS, stroke)
    - radicular pain (i.e. nerve root)
    - anterior horn cell (spinal muscular atrophy, ALS, polio, paraneoplastic, lead toxicity)
    - peripheral neuropathy (peroneal muscle atrophy, GBS, leprosy, amyloid, myeloma, DM, lead toxicity)

- no objective muscle weakness
  - chronic illness (cardiac, pulmonary, anemia, infection, malignancy)
  - depression, deconditioning

- if loss of passive motion, consider intra-articular, peri-articular, or extra-articular causes

Numbness/Altered Sensation

Approach
- positive sensory symptoms: paresthesia/dysesthesia = tingling, pins and needles, prickling, burning, stabbing
- negative sensory symptoms: hypoesthesia/anesthesia = numbness, diminution, or absence of feeling
- determine distribution of sensory loss:
  - nerve root vs. peripheral nerve
  - symmetric stocking-glove pattern (indicative of distal symmetric polyneuropathy)
  - dissociated sensory loss: dorsal column (fine touch, proprioception, vibration) vs. spinothalamic tract (pain and temperature)
- investigations: NCS, vitamin B12 levels, imaging based on associated findings

Differential Diagnosis
- cerebral: stroke, demyelination, tumour
  - associated symptoms: hemiplegia, aphasia, apraxia
- brainstem: stroke, demyelination, tumour
  - associated symptoms: diplopia, vertigo, dysarthria, dysphagia
- spinal cord/radiculopathy: cord infarction, tumour, MS, syringomyelia, vitamin B12 deficiency, disc lesion
  - associated symptoms: back/neck pain, weakness (paraparesis or Brown-Séquard pattern)
- neuropathy: focal compressive neuropathy (based on location and distribution), DM, uremia, vasculitis, vitamin B12 deficiency, HIV, Lyme disease, alcohol, paraneoplastic, amyloid

Gait Disturbance

Approach
1. Characterization of the gait disturbance
   - posture, stride length, width between feet, height of step, stability of pelvis, symmetry, arm swing, elaborate/inconsistent movements, standing from sitting
2. Identification of accompanying neurologic signs
   - full neurological exam required (diagnosis often can be made by P/E alone)
3. Identify red flags
   - sudden onset, cerebellar ataxia, paresis (hemi-, para- or quadri-), bowel/bladder incontinence
4. Workup
   - based on etiology – requires blood work, neuroimaging, and urgent neurologist referral

Central Motor Systems

3 components to the control of gait:
- Pyramidal: main outflow from cortex to spinal cord
- Extrapyramidal: basal ganglia inhibits excess movements
- Cerebellum: affects coordination of gait
Table 6. Types of Gait Disturbance

<table>
<thead>
<tr>
<th>Location</th>
<th>Description</th>
<th>Disorder</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visual Loss</td>
<td>Broadsided gait with tentative steps</td>
<td>Cataract surgery without lens replacement</td>
</tr>
<tr>
<td>Proprioceptive Loss</td>
<td>Sensory ataxia: wide-based with high stepping posture and positive Romberg</td>
<td>Demyelinating neuropathies, paraneoplastic syndrome, tabes dorsalis, MS, compressive myelopathy, B12 deficiency</td>
</tr>
<tr>
<td>Peripheral Nerve Disorder</td>
<td>Steppage gait</td>
<td>Acquired/hereditary peripheral neuropathy, compressive peroneal neuropathy, L4-5 radiculopathy</td>
</tr>
<tr>
<td>Myopathies</td>
<td>Waddling gait: broad based, short stepped gait with pronounced lumbar lordosis, rotation of pelvis</td>
<td>Progressive muscular dystrophy</td>
</tr>
<tr>
<td>Pyramidal/Corticospinal Tract Lesion</td>
<td>Spastic gait: spastic foot drop, circumsoduction, scissoring of legs or toe walking with bilateral circumsoduction</td>
<td>Unilateral: stroke (ischemic/hemorrhagic) Bilateral: cervical spondylosis, cerebal palsy, spinal cord tumour, combined spinal cord degeneration, MS, motor neuron disease</td>
</tr>
<tr>
<td>Basal Ganglia</td>
<td>1. Parkinsonian gait: small paces, stopped posture, reduced armwaving 2. Chorea/hemiballistic/dystonic gait</td>
<td>Infarct, Huntington’s, Sydenham’s chorea, Wilson’s disease, SLE, neuroleptic medications, polycytheria vera, genetic dystonia</td>
</tr>
<tr>
<td>Cerebellar Disorder</td>
<td>Cerebellar ataxic gait: wide-based without high stepping; veers to side of lesion Alcoholic gait</td>
<td>Primary and secondary neoplasm, toxins (alcohol), vitamin E deficiency, hypothyroid, hypoxia, hypoglycemia, paraneoplastic syndrome</td>
</tr>
</tbody>
</table>

Cranial Nerve Deficits

CN I: Olfactory Nerve

Clinical Features
- absence of sense of smell associated with a loss of taste

Differential Diagnosis
- nasal: physical obstruction
  - heavy smoking, chronic rhinitis, sinusitis, neoplasms, sepal deformity, choanal atresia, vestibular stenosis, foreign body
- olfactory neuroepithelial: destruction of receptors or their axon filaments
  - influenza, herpes simplex, interferon treatment of hepatitis C virus, atrophic rhinitis (leprosy)
- central: lesion of olfactory pathway
  - Kallmann syndrome, albinism, head injury, cranial surgery, SAH, chronic meningeval inflammation, meningeoma, aneurysm, PD, stroke, MS
- endocrine/metabolic
  - DM, adrenal hypo/hyperfunction, pseudohypoparathyroidism, hypothyroidism, renal/liver failure, vitamin deficiency

CN II: Optic Nerve

- see Neuro-Ophthalmology, N14

CN III: Oculomotor Nerve

Clinical Features
- ptosis, resting eye position is “down and out” (depressed and abducted), pupil dilated (mydriasis)
- vertical and horizontal diplopia; paralysis of adduction, elevation, and depression

Differential Diagnosis
- PComm aneurysm: early mydriasis, then CN III palsy
- cavernous sinus (internal carotid aneurysm, meningeoma, sinus thrombosis): associated with deficits in other CNs near the cavernous sinus
- midbrain lesion: complete unilateral CN III palsy with bilateral weakness of the superior rectus and pons with contralateral pyramidal signs ± mydriasis
- orbital lesion: associated with optic neuropathy, chemosis, proptosis
- other: inflammatory, infection, neoplasia, uncal herniation, trauma
**CN IV: Trochlear Nerve**

**Clinical Features**
- vertical and torsional diplopia; defect of intorsion and depression
- patient may complain of difficulty going down stairs or reading

**Differential Diagnosis**
- common: ischemic (DM, HTN), idiopathic, trauma (TBI or surgical), congenital
- other: cavernous sinus lesion, superior orbital fissure (tumour, granuloma)

**CN V: Trigeminal Nerve**

**Clinical Features**
- ipsilateral facial numbness, weakness of muscles of mastication (V3 only) with pterygoid deviation towards the side of the lesion

**Differential Diagnosis**
- **brainstem:** ischemia, tumour, syringobulbia, demyelination
- **peripheral:** tumour, aneurysm, chronic meningitis, metastatic infiltration of nerve
- **trigeminal ganglion:** acoustic neuroma, meningioma, fracture of middle fossa
- **cavernous sinus:** carotid aneurysm, meningioma, sinus thrombosis
- **trauma**
- note: other CN V lesions that cause facial pain = trigeminal neuralgia, herpes zoster

**CN VI: Abducens Nerve**

**Clinical Features**
- resting inward deviation (esotropia)
- horizontal diplopia; defect of lateral gaze

**Differential Diagnosis**
- **pons:** infarction, hemorrhage, demyelination, tumour: associated with facial weakness and contralateral pyramidal signs
- **tentorial orifice:** (compression, meningioma, trauma): false localizing sign of increased ICP
- **cavernous sinus:** carotid aneurysm, meningioma, sinus thrombosis
- **ischemia of CN VI:** DM, temporal arteritis, HTN, athersclerosis
- **congenital:** Duane’s syndrome

**CN VII: Facial Nerve**

**Clinical Features**
- **LMN lesion:** ipsilateral facial weakness (facial droop, flattening of forehead, inability to close eyes, flattening of nasolabial fold)
- **UMN lesion:** contralateral facial weakness with forehead sparing (due to bilateral frontalis innervation)
- impaired lacrimation, decreased salivation, numbness behind auricle, hyperacusis, taste dysfunction of anterior 2/3 of tongue

**Differential Diagnosis**
- **idiopathic** = Bell’s palsy, 80-90% of cases (see Otolaryngology, OT22)
- most often related to HSV, but other viruses may be implicated (CMV, herpes zoster, EBV)
- **other:** temporal bone fracture, EBV, Ramsay Hunt (VZV), otitis media/mastoiditis, sarcoidosis, DM mononeuropathy, parotid gland disease, Lyme meningitis, HIV
CN VIII: Vestibulocochlear Nerve

- see Otolaryngology, OT14

CN IX: Glossopharyngeal Nerve

Clinical Features
- unilateral lesion is rare
- taste dysfunction in posterior 1/3 of tongue
- absent gag reflex and dysphagia

Disorders
- glossopharyngeal neuralgia: sharp paroxysmal pain of posterior pharynx radiating to ear, triggered by swallowing
  - treated with carbamazepine or surgical ablation of CN IX

CN X: Vagus Nerve

Clinical Features
- oropharyngeal dysphagia (transfer dysphagia) due to palatal and pharyngeal weakness
  - neuromuscular causes of dysphagia
    - CNS: stroke, cerebral palsy, tumour, trauma, PD, AD, MS
    - CN: DM, laryngeal nerve palsy, polio, ALS
    - myopathic/NMJ: dermatomyositis, polymyositis, MG, sarcoidosis
  - other causes of dysphagia: see Gastroenterology, G8
  - dysarthria: inability to produce understandable speech due to impaired phonation and/or resonance

CN XI: Accessory Nerve

Clinical Features
- LMN lesion: paralysis of ipsilateral trapezius and sternocleidomastoid (ipsilateral shoulder drop, weakness on turning head to contralateral side)
- UMN lesion: paralysis of ipsilateral sternocleidomastoid and contralateral trapezius

CN XII: Hypoglossal Nerve

Clinical Features
- LMN lesion: tongue deviation towards lesion; ipsilateral tongue atrophy and fasciculations (if chronic)
- UMN lesion: tongue deviation away from lesion; absence of atrophy and fasciculations
Neuro-Ophthalmology

Abnormalities of Vision

- see Ophthalmology

Acute Visual Loss

- see Ophthalmology, OP3

Optic Neuritis

- see Optic Disc Edema below, Multiple Sclerosis, N52

Anterior Ischemic Optic Neuropathy (AION)

- see Optic Disc Edema
- non-arteritic (NAION): due to atherosclerosis
- arteritic (AAION): due to giant cell arteritis (see Rheumatology, RH20)

Amaurosis Fugax

- see Ophthalmology, OP35 and Stroke, N48

Central Retinal Vein Occlusion

- see Ophthalmology, OP22

Optic Disc Edema

<table>
<thead>
<tr>
<th>Optic Neuritis</th>
<th>Papilledema</th>
<th>AION</th>
<th>CRVO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>&lt;50 yr</td>
<td>Any</td>
<td>&gt;50 yr but usually &gt;70 yr</td>
</tr>
<tr>
<td>Vision</td>
<td>Rapidly progressive monocular central vision loss (4 – acuity and colour vision) with recovery</td>
<td>Late visual loss</td>
<td>Painless unilateral acute field defect over hours to days with ↓ colour vision</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Pain (especially with eye movement)</td>
<td>N/A, N/V, local neurological deficits</td>
<td>If GCA: N/A, scalp tenderness, jaw claudication, weight loss, fatigue</td>
</tr>
<tr>
<td>Pupil</td>
<td>RAPD</td>
<td>No RAPD</td>
<td>RAPD</td>
</tr>
<tr>
<td>Fundus</td>
<td>Disc swelling if anterior Normal disc if retrobulbar</td>
<td>Bilateral disc swelling, retinal hemorrhage, no venous pulsations</td>
<td>Pale segmental disc edema, retinal dot, flame hemorrhages</td>
</tr>
<tr>
<td>Etiologies</td>
<td>MS, viral</td>
<td>Increased ICP</td>
<td>Giant cell arteritis</td>
</tr>
<tr>
<td>Investigations</td>
<td>MRI with gadolinium</td>
<td>Emergent CT; LP if CT is normal to measure opening pressure</td>
<td>CBC, ESR, CRP, temporal artery biopsy</td>
</tr>
<tr>
<td>Treatment</td>
<td>IV methylprednisolone</td>
<td>Treat cause</td>
<td>Consider ASA if non-arteritic; steroids if arteritic</td>
</tr>
</tbody>
</table>

Optic Disc Atrophy

- etiologies: glaucoma, AION, compressive tumour, optic neuritis, Leber’s hereditary optic neuropathy, congenital
- presentation: disc pallor, low visual acuity, peripheral vision defect, decreased colour vision
- treatment: none (irreversible), aim to prevent
Abnormalities of Visual Field

Abnormalities of Eye Movements

Disorders of Gaze

Pathophysiology
- horizontal gaze: FEF → contralateral PPRF (midbrain/pons) → eyes saccade away from FEF
- vertical gaze: cortex → rostral interstitial nucleus in the MLF (midbrain)

Clinical Features
- unilateral lesion in one FEF → eyes deviate toward the side of the lesion
  - can be overcome with doll’s eye maneuver
  - cannot be overcome with doll’s eye maneuver if CN VI nucleus lesion as well
- seizure involving a FEF: eyes deviate away from the focus

Etiology
- common: infarcts (frontal or brainstem), MS, tumours

Internuclear Ophthalmoplegia

Pathophysiology
- results from a lesion in MLF which disrupts coordination between CN VI nucleus in pons and the contralateral CN III nucleus in midbrain → disrupts conjugate horizontal gaze

Clinical Features
- horizontal diplopia on lateral gaze, oscillopsia
- gaze away from the side of the lesion: ipsilateral adduction defect and contralateral abduction nystagmus
- cannot be overcome by caloric testing
- accommodation reflex intact
- may be bilateral (especially in MS)

Etiology
- common: MS, brainstem infarct

Investigations
- MRI

Bitemporal Hemianopsia DDx by Age
- Children: craniopharyngioma
- Middle aged (20s to 50s): pituitary mass
- Elderly (>60 yr): meningioma

In homonymous hemianopsia, more congruent deficits are caused by more posterior lesions; macular sparing may occur with occipital lesions

A lesion in a cerebral hemisphere causes eyes to “look away” from the hemiplegia, and to look towards the lesion

A lesion in the brainstem causes the eyes to “look toward” the side of the hemiplegia, and to look away from the lesion

Check all hemiplegic patients for homonymous hemianopsia (ipsilateral to side of hemiplegia)
Diplopia

Etiology – Monocular
• mostly due to relatively benign optical problems (refractive error, cataract) or functional

Etiology – Binocular (due to ocular misalignment)
• muscle: Graves’ ophthalmopathy, EOM restriction/entrapment
• neuromuscular junction: MG (see Myasthenia Gravis, N38)
• cranial nerve palsy (see Cranial Nerve Deficits, N11)
• INO (see Internuclear Ophthalmoplegia, N15)
• other
  ▪ orbital trauma (orbital floor fracture), tumour, infection, inflammation
  ▪ Miller-Fisher variant of GBS
  ▪ Wernicke’s encephalopathy
  ▪ leptomeningeal disease

Approach to Diplopia
• monocular (diplopia when one eye open) vs. binocular (diplopia when both eyes open)
• horizontal vs. vertical vs. oblique diplopia
• direction of gaze that exacerbates diplopia
• corrective head movements

Workup
• may observe isolated 4th or 6th nerve palsy for a few weeks, but workup if persistent or other symptoms develop
• indications for neuroimaging
  ▪ bilateral or multiple nerve involvement
  ▪ severe sudden onset headache (rule out aneurysm)

Nystagmus

• definition: rapid, involuntary, small amplitude movements of the eyes that are rhythmic in nature
• direction of nystagmus is labelled by the rapid component of the eye movement
• can be categorized by movement type (pendular, jerking, rotatory, coarse) or as physiological vs. pathological

<table>
<thead>
<tr>
<th>Table 8. Nystagmus Features</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Peripheral (Vestibular)</strong></td>
</tr>
<tr>
<td>Direction</td>
</tr>
<tr>
<td>Nystagmus</td>
</tr>
<tr>
<td>Gaze Fixation</td>
</tr>
<tr>
<td>Vertigo</td>
</tr>
<tr>
<td>Auditory Symptoms</td>
</tr>
<tr>
<td>Other Neurological Signs</td>
</tr>
<tr>
<td>DDx</td>
</tr>
</tbody>
</table>

Abnormalities of Pupils

• see Ophthalmology, OP28
Nutritional Deficiencies and Toxic Injuries

Nutritional Deficiencies and Toxic Injuries

- sufficient nutritional intake is required for optimal nervous system functioning; deficiencies in the following key nutrients, among others, may impair central and peripheral nervous system function (potential neurological symptoms are provided)

<table>
<thead>
<tr>
<th>Vitamin Deficiency</th>
<th>Neurological Clinical Manifestation</th>
<th>Investigation</th>
<th>Treatment*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin B12</td>
<td>Paresthesias and sensory ataxia are the most common initial symptoms Myelopathy (Subacute Combined Degeneration), peripheral neuropathy Neuropsychiatric: memory impairment, change in personality, delirium, and psychosis Optic neuropathy</td>
<td>Serum cobalamin Serum methylmalonic acid Serum homocysteine</td>
<td>IM Vitamin B12 1,000 µg for 5 d, then once per month or oral B12 1,000 µg/d</td>
</tr>
<tr>
<td>Folate</td>
<td>Myelopathy, peripheral neuropathy May be clinically indistinguishable from Vitamin B12 deficiency</td>
<td>Serum folate Homecysteine</td>
<td>Oral folate 1 mg tid initially; 1 mg daily thereafter</td>
</tr>
<tr>
<td>Copper</td>
<td>Myelopathy, pyramidal signs (e.g. brisk muscle stretch reflexes at the knees and extensor plantar responses) Severe sensory loss</td>
<td>Serum copper and ceruloplasmin; urinary copper</td>
<td>Discontinue zinc; oral copper 8 mg/d for 1 wk; 6 mg/d for 1 wk; 4 mg/d for 1 wk; 2 mg/d thereafter</td>
</tr>
<tr>
<td>Vitamin E</td>
<td>Ophthalmoplegia, retinopathy, spinocerebellar syndrome with peripheral neuropathy (with signs of cerebellar ataxia)</td>
<td>Serum vitamin E; ratio serum vitamin E to sum of cholesterol and triglycerides</td>
<td>Vitamin E 2,200 mg/kg/d oral or IM</td>
</tr>
<tr>
<td>Thiamine</td>
<td>Three manifestations include: beriberi (dry and wet), infantile beriberi, Wernicke-Korsakoff syndrome Alcoholism is a cause of reduced thiamine intake and deficiency</td>
<td>Clinical diagnosis; brain MRI</td>
<td>Thiamine 100 mg IV followed by 50-100 mg IV or IM until nutritional status stable</td>
</tr>
<tr>
<td>Pyridoxine (Vitamin B6)</td>
<td>Painful sensorimotor peripheral neuropathy</td>
<td>Serum pyridoxal phosphate</td>
<td>Pyridoxine 50-100 mg daily</td>
</tr>
<tr>
<td>Niacin (Vitamin B3)</td>
<td>Pellagra: Encephalopathy, dementia, coma, and peripheral neuropathy</td>
<td>Urinary excretion niacin metabolites</td>
<td>Nicotinic acid 25-50 mg daily oral or IM</td>
</tr>
</tbody>
</table>

*IM = intramuscular; IV = intravenous

- it is also important to consider occupational neurotoxic syndromes secondary to exposure to pesticides, solvents, and metals. Encephalopathy, extrapyramidal features, neurodegenerative diseases, and peripheral neuropathy are commonly encountered. Onset and progression of neurological diseases should be temporally related to neurotoxin exposure. Main toxins associated with neurotoxicity are listed below

<table>
<thead>
<tr>
<th>Toxin</th>
<th>Associated Occupations</th>
<th>Characteristic Neurological Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organic Solvents</td>
<td>Printer, spray painters, industrial cleaners, paint or glue manufacturers, graphic industry, electronic industry, plastic industry</td>
<td>Nausea, H/A, concentration difficulty Long-term exposure may lead to “chronic solvent-induced encephalopathy”, characterized by mild-to-severe cognitive impairment</td>
</tr>
<tr>
<td>Pesticides (e.g. insecticides, fungicides, rodenticides, fumigants, herbicides)</td>
<td>Agricultural work, pesticide manufacturing and formulating employees, highway and railway workers, green house, forestry and nursery workers</td>
<td>Parkinson’s disease risk increased by ~70% following pesticide exposure</td>
</tr>
<tr>
<td>Heavy Metals (e.g. lead, mercury, manganese, aluminum, arsenic)</td>
<td>Battery and metal production (e.g. solder, pipes), chemical and electronic application industries, steel manufacturing, welders, alloy workers, transportation, packaging, construction</td>
<td>Lead: delayed/reversed development, permanent learning disabilities, peripheral neuropathy, seizures, coma, death from encephalopathy (rare) Mercury: psychiatric disturbances, ataxia, visual loss, hearing loss, tiredness, memory disturbances Manganese: psychiatric symptoms, hallucinations (“manganese madness”), extrapyramidal features, dystonia, parkinsonism (manganism) Aluminum: implicated in Alzheimer’s pathogenesis Arsenic: sleeplessness/sleepiness, irritability, H/A, spasms in muscle extremities and muscle fatigue</td>
</tr>
<tr>
<td>Gases (e.g. carbon dioxide, nitrous oxide, formaldehyde)</td>
<td>Anesthesia, disinfection, manufacture of illuminating gas and water-gas</td>
<td>Cognitive/behavioural and emotional symptoms, parkinsonian syndromes</td>
</tr>
</tbody>
</table>

Neurologic Complications due to Toxic Injuries Related to Bariatric Surgery

- deficiencies of both fat- and water-soluble vitamins may occur following malabsorptive bariatric surgery
- patients who have undergone malabsorptive surgery should be monitored for late metabolic complications and neurological manifestations
Seizure Disorders and Epilepsy

Seizure

Definitions

- **seizure**: transient neurological dysfunction caused by excessive activity of cortical neurons, resulting in paroxysmal alteration of behavior and/or EEG changes
  - can be symptom of acute insult to the brain such as: alcohol and illicit drug use/withdrawal, brain injury/abnormality (tumour, trauma, vascular), CNS infection, fever (children), metabolic (hypoglycemia, electrolyte abnormalities, liver/renal failure), medications, OR be a manifestation of epilepsy

- **epilepsy**: chronic condition characterized by two or more unprovoked seizures, or underlying predisposition to seizures in a patient who has already had at least one seizure
  - etiologies: genetic, structural (e.g. prior stroke, tumour, meningoencephalitis, perinatal insult, vascular malformation, malformation of cortical development, neurodegenerative), or unknown

Classification

![Seizure Classification Diagram]

Clinical Features

- **Partial (focal) seizures**
  - simple or complex can secondarily generalize, or simple → complex → generalized seizures
  - **simple (focal without loss of awareness)**
    - motor: postural, phonatory, forceful turning of eyes and/or head, focal muscle rigidity/jerking ± Jacksonian march (spreading to adjacent muscle groups)
    - sensory: unusual sensations affecting vision, hearing, smell, taste, or touch
    - autonomic: epigastric discomfort, pallor, sweating, flushing, piloerection, pupillary dilatation
    - psychiatric: symptoms rarely occur without impairment of consciousness and are more commonly complex partial
  - **complex (focal with loss of awareness)**
    - patient may appear to be awake but with impairment of awareness
    - classic complex seizure is characterized by automatisms such as chewing, swallowing, lip-smacking, scratching, fumbling, running, disrobing, and other stereotypic movements
    - other forms: dysphasic, dysmnesic (déjà vu), cognitive (disorientation of time sense), affective (fear, anger), illusions, structured hallucinations (music, scenes, taste, smells), epigastric fullness

- **Generalized seizures**

- **Absence (petit mal)**: usually seen in children, unresponsive for 5-10 s with arrest of activity, staring, blinking or eye-rolling, no post-ictal confusion; 3 Hz spike and slow wave activity on EEG

- **Clonic**: repetitive rhythmic jerking movements

- **Tonic**: muscle rigidity in flexion or extension

- **Tonic-clonic (grand mal)**
  - may have prodrome of unease or irritability hours to days before the episode
  - tonic ictal phase: muscle rigidity
  - clonic ictal phase: repetitive violent jerking of face and limbs, tongue biting, cyanosis, frothing, incontinence
  - post-ictal phase: flaccid limbs, extensor plantar reflexes, headache, confusion, aching muscles, sore tongue, amnesia, elevated serum CK lasting hours; may have focal paralysis (Todd’s paralysis).

- **Myoclonic**: sporadic contractions localized to muscle groups of one or more extremities

- **Atonic**: loss of muscle tone leading to drop attack

Stroke is the most common cause of late-onset (≥50 yr) seizures, accounting for 50-80% of cases

Seizures and Dementia
Neurodegenerative diseases can underlie seizures; conversely, seizures can be a cause of dementia

Temporal lobe epilepsy is suggested by an aura of fear, olfactory or gustatory hallucinations, and visceral or déjà vu sensations

Frontoparietal cortex seizures are suggested by contralateral focal sensory or motor phenomena
Table 11. Classic Factors Differentiating Seizure, Syncope and Pseudoseizure

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Seizure</th>
<th>Syncope</th>
<th>Pseudoseizure* (Psychogenic non-epileptic seizure)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timing</td>
<td>Day or night</td>
<td>Day</td>
<td>Day; other people present</td>
</tr>
<tr>
<td>Onset</td>
<td>Sudden, in any position</td>
<td>Gradual; Upright position (not recurrent)</td>
<td>Provoked by emotional disturbance or suggestion</td>
</tr>
<tr>
<td>Prodrome</td>
<td>Possible specific aura</td>
<td>Lightheadedness, pallor, diaphoresis</td>
<td>Variable</td>
</tr>
<tr>
<td>Duration</td>
<td>Brief or prolonged</td>
<td>Brief</td>
<td>Often prolonged</td>
</tr>
<tr>
<td>Incontinence</td>
<td>Common</td>
<td>Possible but rare</td>
<td>Rare</td>
</tr>
<tr>
<td>Post-ictal</td>
<td>Occurs in tonic-clonic or complex partial</td>
<td>No</td>
<td>Variable, often none</td>
</tr>
<tr>
<td>Motor Activity</td>
<td>Synchronous, stereotypic, automatism (common in absence and complex partial), lateral tongue biting, eyes rolled back</td>
<td>Occasional brief jerks</td>
<td>Opisthotonus, rigidity, eye closure, irregular extremity movements, shaking head, pelvic thrust, crying, geotropich eye movements, tongue biting at the tip</td>
</tr>
<tr>
<td>Injury</td>
<td>Common</td>
<td>Rare unless from fall</td>
<td>Rare</td>
</tr>
<tr>
<td>EEG</td>
<td>Usually abnormal; ± interictal discharges</td>
<td>Normal</td>
<td>Normal</td>
</tr>
</tbody>
</table>

*Pseudoseizures do not rule out seizures (not uncommon to have both)

- alcoholic withdrawal seizures may occur up to 2 days from the last exposure to alcohol (see Emergency Medicine, ER54)

Investigations
- CBC, electrolytes, fasting blood glucose, Ca++, Mg++, PO4, liver enzymes, CK, prolactin
- also consider toxicology screen, EtOH level, AED level (if applicable)
- CT/MRI (if new seizure without identified cause or known seizure history with new neurologic signs/symptoms)
- LP (if fever or meningismus)
- EEG

Treatment
- avoid precipitating factors
- indications for antiepileptic drugs (AED): 2 or more unprovoked seizures, known organic brain disease, EEG with epileptiform activity, first episode of status epilepticus, abnormal neurologic examination or findings on neuroimaging
- psychosocial issues: stigma of seizures, education of patient and family, status of driver’s license, pregnancy issues
- safety issues: driving, operating heavy machinery, bathing, swimming alone
- refer for evaluation for possible surgical treatment if focal and refractory

Status Epilepticus

- definition: unremitting seizure or successive seizures without return to a baseline state of greater than 5 min
- complications: anoxia, cerebral ischemia and cerebral edema, MI, arrhythmias, cardiac arrest, rhabdomyolysis and renal failure, aspiration pneumonia/pneumonitis, death (20%)
- initial measures: ABCs, vitals, monitors, capillary glucose (STAT), ECG, nasal O2, IV NS, IV glucose, IV thiamine, ABGs (if respiratory distress/cyanotic)
- blood work: electrolytes, Ca++, Mg++, PO4, glucose, CBC, toxicology screen, EtOH level, AED levels
- focused history: onset, past history of seizures, drug and alcohol ingestion, past medical history, associated symptoms, witnesses/collarateral history
- physical exam (once seizures controlled): LOC, vitals, HEENT (nuchal rigidity, head trauma, tongue biting, papilledema), complete neurological exam, signs of neurocutaneous disorders, increased breath sounds, cardiac murmurs or arrhythmias, urinary incontinence, MSK exam (rule out injuries)
- post-treatment stabilization: CT head, EEG, Foley catheter to monitor urine output, urine toxicology screen, monitor for rhabdomyolysis, and IV fluids to maintain normal cerebral perfusion pressure

Antiepileptic Drugs
- focal and most generalized seizures
  - valproate (Depakene®), lamotrigine (Lamictal®), levetiracetam (Keppra®), topiramate (Topamax®), phenobarbital (Phenobarb®), primidone, zonisamide, rufinamide (Banzet®), felbamate, benzodiazepines
  - primarily focal seizures (± 2° generalization)
    - carbamazepine (Tegretol®), phenytoin (Dilantin®), gabapentin (Neurontin®), lacosamide (Vimpat®), oxcarbazepine (Trileptal®), eslicarbazepine acetate (Aptiom®), pregabalin (Lyrica®), tiagabine (Gabitril®), vigabatrin (Sabril®)
  - absence seizure: ethosuximide (Zarontin®)

DDx of Convulsions
- Syncope, pseudoseizure, hyperventilation, panic disorder, TIA, hypoglycemia, movement disorder, alcoholic blackouts, migraines (confusional, vertebrobasilar), narcolepsy (cataplexy)

Note that frontal seizures (rare) can look like a pseudoseizure due to odd motor activity that may occur

By law, the Ministry of Transportation in most provinces must be contacted for all patients who have had a seizure; patients will have their license suspended until seizure free for 6 mo; commercial drivers face a longer wait

EEG findings suggestive of epilepsy: abnormal spikes, polyspike discharges, spike-wave complexes

20-59% of first EEG are positive in epilepsy; 59-92% of epilepsy is picked up with repeated EEGs; normal interictal EEGs do not rule out epilepsy

Medical Emergency: Status epilepticus can cause irreversible brain damage without treatment

The most common causes of status epilepticus are failure to take AEDs and first presentation of epilepsy

Status epilepticus as a result of EtOH withdrawal is rare, despite it being a very common cause of seizures

Rule out non-convulsive status epilepticus in any patient who is still unconscious >20 min post-ictal; order a stat EEG if unsure

Complex partial status epilepticus can resemble schizophrenia or psychotic depression
Behavoural Neurology

- see Psychiatry, PS19

### Acute Confusional State/Delirium

#### Table 12. Selected Intracranial Causes of Acute Confusion

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Key Clinical Features</th>
<th>Investigations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vascular</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subarachnoid hemorrhage</td>
<td>Thunderclap H/A, increased ICP, meningismus</td>
<td>CT, LP Angiography if CT and LP negative</td>
</tr>
<tr>
<td>Stroke/TIA</td>
<td>Focal neurological signs</td>
<td>CT</td>
</tr>
<tr>
<td>Infectious</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningitis</td>
<td>Fever, H/A, nausea, photophobia, meningismus</td>
<td>CT, LP</td>
</tr>
<tr>
<td>Encephalitis</td>
<td>Fever, H/A, ± seizure</td>
<td>CT</td>
</tr>
<tr>
<td>Abscess</td>
<td>Increased ICP, Focal neurological signs</td>
<td>CT with contrast (often ring enhancing lesion)</td>
</tr>
<tr>
<td>Traumatic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse axonal shear, epidural hematoma, SDH</td>
<td>Trauma Hx, Increased ICP, Focal neurological signs</td>
<td>CT, MRI</td>
</tr>
<tr>
<td>Autoimmune</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute CNS vasculitis</td>
<td>Skin rash, active joints</td>
<td>ANA, ANCA, RF MRI Angiography CSF (test for presence of antibodies)</td>
</tr>
<tr>
<td>Paraneoplastic encephalitis (anti-NMDA-R)</td>
<td>Onset: Psychiatric features, memory loss, seizures Delayed: Movement disorder, and changes in BP, HR, and temperature</td>
<td>MRI Angiography</td>
</tr>
<tr>
<td>Neoplastic</td>
<td>Increased ICP, Focal neurological signs, Papilledema</td>
<td>CT, MRI</td>
</tr>
<tr>
<td>Seizure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Status epilepticic</td>
<td>See Seizure Disorders and Epilepsy, N18</td>
<td>EEG</td>
</tr>
<tr>
<td>Primary Psychiatric</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug-related, mood disorder, anxiety disorder</td>
<td>No organic signs or symptoms</td>
<td>No specific tests</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drugs (e.g. cocaine)</td>
<td>Chest pain, cough with black sputum, new-onset seizure, HTN, increased ICP, dyspnea</td>
<td>Vital signs Serum chemistry and electrolyte analysis</td>
</tr>
<tr>
<td>Medications (with anticholinergic side effects)</td>
<td>Flushing, dry skin and mucous membranes, mydriasis with loss of accommodation</td>
<td>Serum chemistry and electrolyte analysis</td>
</tr>
<tr>
<td>Neuroleptic Malignant Syndrome</td>
<td>Antipsychotic medication use, Muscle rigidity, Hyperthermia, Autonomic instability</td>
<td>Serum chemistry and electrolyte analysis</td>
</tr>
</tbody>
</table>

Teratogenicity of anticonvulsants includes neural tube defects, cleft palate, urogenital malformations, and heart defects. Advise patient planning pregnancy to take 5 mg/d of folinic acid. Optimize AEDs with lowest possible dose associated with good seizure control, preferably monotherapy if possible. Risk of fetal malformations with AEDs is 2x general population; highest risk associated with valproic acid and/or 2+ concurrent AEDs. Consider pre-conception AED levels if patient is well-controlled, monthly serum levels during pregnancy, and titrate AED to maintain pre-conception serum levels. Refer to high risk OB for intrapartum fetal screening.
Mild Neurocognitive Disorder (Mild Cognitive Impairment)

Definition
- cognitive impairment not meeting criteria of Major Neurocognitive Disorder
- measurable deficit in at least one cognitive domain reported by patient or others without impairment in ADLs
- amnestic (precursor to AD) vs. non-amnestic

Epidemiology
- mild NCD: 2-10% at age 65 yr and 5-25% by age 85 yr

Risk Factors
- vascular: hypertension, diabetes mellitus, obesity, cardiac disease, apolipoprotein E epsilon 4 genotype

Clinical Features
- cognitive impairment
  - particularly in amnestic subtype
  - important to ascertain that memory complaints represent change from baseline
  - patients with mild NCD are often troubled by memory symptoms in comparison to patients with dementia
- neuropsychiatric symptoms
  - depression (30%), irritability, anxiety, aggression, and apathy

Investigations
- establish a baseline for follow-up
- clinical interview with patient and his/her caregivers is the cornerstone of mild NCD evaluation
- neuropsychological testing
  - MMSE or MoCA; should not be used in isolation
  - if abnormal, follow-up in one year to monitor cognitive and functional decline
- neuroimaging
  - role uncertain
  - most advocate for a non-contrast brain CT to evaluate for structural abnormalities (CVD, SDH, NPH, or mass lesion)
- other testing
  - exclude treatable conditions and underlying psychiatric conditions

Treatment
- watch and wait
- no evidence for cholinesterase inhibitors, anti-inflammatory agents, vascular risk factor modification, exercise, cognitive interventions

Prognosis
- 10% progress to major NCD per yr
- typically progress to major NCD over a period of 2-3 yr

Major Neurocognitive Disorder (formerly Dementia)

- see Psychiatry, PS20 and Geriatric Medicine, GM4

Definition
- an acquired, generalized, and (usually) progressive impairment of cognitive function associated with impairment in ADLs/iADLs (i.e. shopping, food preparation, finances, medication management)
- diagnosis of major NCD requires presence of significant cognitive decline from a previous level of performance in one or more cognitive domains (complex attention, executive function, learning and memory, language, perceptual-motor, or social cognition) based on:
  - A) concern of the individual or a knowledgeable informant AND
  - B) a substantial impairment in cognitive performance either documented by standardized neuropsychological testing, or quantified clinical assessment
- see Psychiatry, PS19 for DSM-5 diagnostic criteria
- in comparison, mild NCD does not affect ADLs
  - mild NCD represents an intermediate stage between major NCD and normal aging

Epidemiology
- major NCD: 1-2% at age 65 yr and reaching as high as 30% by age 85 yr
- note
  - major NCD due to Alzheimer's disease is uncommon before age 60 yr
  - major NCD due to frontotemporal lobar degeneration has an earlier onset and represents a progressively smaller fraction of all NCDs with age

Causes of Neurocognitive Disorder

- NCD due to Alzheimer's disease
- Frontotemporal NCD
- NCD with Lewy bodies
- Vascular NCD
- Other causes of NCD (traumatic brain injury, substance/medication use, HIV infection, prion disease, Parkinson's disease, Huntington’s disease)

Frontotemporal Neurocognitive Disorder

- Frontal lobe
- Temporal lobe
- Executive function
- Behaviour: disinhibition, agitation
- Language: aphasia
- Memory: non-fluent progressive

Figure 10. Major NCD classification
Etiology
- see Table 13 for selected causes of major NCD
- reversible causes: alcohol (intoxication or withdrawal, Wernicke's encephalopathy), medication (benzodiazepines, anticholinergics), heavy metal toxicity, hepatic or renal failure, B12 deficiency, glucose, cortisol, thyroid dysfunction, NP, depression (pseudodementia), intracranial tumour, SDH, hypercalcaemia (secondary to elevated PTH)
- must rule out delirium

History
- “geriatric giants”
  - confusion/incontinence/falls
  - memory and safety (wandering, leaving doors unlocked, leaving stove on, losing objects, driving)
  - behavioural (mood, anxiety, psychosis, suicidal ideation, personality changes, aggression)
  - polypharmacy and compliance (sedative hypnotics, antipsychotics, antidepressants, anticholinergics)
- ADLs and IADLs
- cardiovascular, endocrine, neoplastic, renal ROS, head trauma history
- alcohol, smoking
- collateral history

Physical Exam
- blood pressure
- hearing and vision
- neurological exam with attention to signs of parkinsonism, UMN findings
- general physical exam with focus on CVD, patient-specific risk factors and history
- MMSE or MoCa, clock drawing, frontal lobe testing (go/no-go, word lists, similarities, proverb)

Investigations
- rule out reversible causes
  - CBC (note MCV for evidence of alcohol use and B12 deficiency), glucose, TSH, B12, RBC folate
  - electrolytes, LFTs, renal function, lipids, serum calcium
  - CT head, MRI as indicated, SPECT (optional)
  - as clinically indicated: VDRL, HIV, ANA, anti-dsDNA, ANCA, ceruloplasmin, copper, cortisol, toxicology, heavy metals
- issues to consider
  - failure to cope, fitness to drive, caregiver capacity and wellbeing, power of attorney, legal will, advanced medical directives, patient and caregiver safety

Table 13. Selected Causes of Major NCD (Dementia)

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Key Clinical Features</th>
<th>Investigations</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRIMARY DEGENERATIVE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alzheimer’s disease</td>
<td>Memory impairment</td>
<td>CT or MRI, SPECT</td>
</tr>
<tr>
<td></td>
<td>Aphasia, apraxia, agnosia</td>
<td></td>
</tr>
<tr>
<td>Dementia with Lewy bodies</td>
<td>Visual hallucinations</td>
<td>CT or MRI, SPECT</td>
</tr>
<tr>
<td></td>
<td>Parkinsonism</td>
<td></td>
</tr>
<tr>
<td>Frontotemporal dementia (e.g. Pick’s disease)</td>
<td>Behavioural presentation: Disinhibition, perseveration, decreased social awareness, mental rigidity, memory relatively spared Language presentation: Progressive non-fluent aphasia, semantic dementia</td>
<td>CT or MRI, SPECT</td>
</tr>
<tr>
<td>Huntington’s disease</td>
<td>Chorea</td>
<td>Genetic testing</td>
</tr>
<tr>
<td>VASCULAR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vascular cognitive impairment (previously Multi-infarct dementia)</td>
<td>Bradyphrenia without features of parkinsonism (slow thinking, slow rate of learning, slow gait) Dysexecutive syndrome May be abrupt onset Stepwise deterioration is classic but progressive deterioration is most common</td>
<td>CT or MRI, SPECT</td>
</tr>
<tr>
<td>CNS vasculitis</td>
<td>Systemic signs and symptoms of vasculitis</td>
<td>ANA, ANCA, RF</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CT or MRI, Angiography</td>
</tr>
</tbody>
</table>

Sensitivity and Specificity

<table>
<thead>
<tr>
<th>Tool</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>MMSE</td>
<td>87%</td>
<td>82%</td>
</tr>
<tr>
<td>Clinical Judgment</td>
<td>85%</td>
<td>82%</td>
</tr>
<tr>
<td>DSM IV</td>
<td>76%</td>
<td>80%</td>
</tr>
</tbody>
</table>

Vitamin B12 Deficiency Symptoms
- Macrocytic anaemia, pallor, SOB, fatigue, chest pain, palpitations
- Confusion or change in mental status (if advanced)
- Decreased vibration sense
- Distal numbness and paresthesia
- Weakness with UMN findings
- Diarrhea, anorexia

Major NCD Considerations for Management
- ABCDs
  - Affective disorders, ADLs
  - Behavioural problems
  - Caretaker, Cognitive medications and stimulation
  - Directives, Driving
  - Sensory enhancement (glasses/hearing aids)

Most common causes of rapidly progressive neurodegenerative dementia (less than 4 yr survival): CJD, frontal temporal lobar dementia, tauopathies, diffuse Lewy body disease, and AD
Arch Neurol 2009;66:201-207
Head turning sign: when patient looking at his/her caregiver for answers after being asked a question in clinical interviews
80% sensitivity, 98% specificity for diagnosis of cognitive impairment

Early Signs of Major NCD

<table>
<thead>
<tr>
<th>Major NCD</th>
<th>Normal Aging</th>
</tr>
</thead>
<tbody>
<tr>
<td>Forgetting the names of close relations</td>
<td>Forgetting the names of acquaintances</td>
</tr>
<tr>
<td>Increased frequency of forgetting</td>
<td>Briefly forgetting part of an experience</td>
</tr>
<tr>
<td>Repeating phrases/stories in the same conversation</td>
<td>Not putting away things properly</td>
</tr>
<tr>
<td>Unpredictable mood changes</td>
<td>Mood changes in response to appropriate causes</td>
</tr>
<tr>
<td>Decreased interest in activities and difficulty making choices</td>
<td>Changes in usual interests</td>
</tr>
</tbody>
</table>
Table 13. Selected Causes of Major NCD (Dementia) (continued)

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Key Clinical Features</th>
<th>Investigations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INFECTIOUS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic meningitis</td>
<td>Fever, H/A, nausea</td>
<td>CT, LP</td>
</tr>
<tr>
<td></td>
<td>Meningismus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Localizing neurological deficits</td>
<td></td>
</tr>
<tr>
<td>Chronic encephalitis</td>
<td>Fever, headache</td>
<td>CT or MRI</td>
</tr>
<tr>
<td>Chronic abscess</td>
<td>Increased ICP</td>
<td>CT with contrast</td>
</tr>
<tr>
<td></td>
<td>Localizing neurological deficits</td>
<td></td>
</tr>
<tr>
<td>HIV</td>
<td>See Infectious Diseases, ID27</td>
<td>HIV serology</td>
</tr>
<tr>
<td>Creutzfeldt-Jakob disease</td>
<td>Rapidly progressive, myoclonus</td>
<td>EEG, CT or MRI, LP</td>
</tr>
<tr>
<td>Syphilis</td>
<td>Ataxia, myoclonus, tabes dorsalis</td>
<td>LP, CT, or MRI, VDRL</td>
</tr>
<tr>
<td><strong>TRAUMATIC</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse axonal shear, epidural hematoma, subdural hematoma, SDH</td>
<td>Trauma Hx</td>
<td>CT</td>
</tr>
<tr>
<td></td>
<td>Increased ICP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Localizing neurological signs</td>
<td></td>
</tr>
<tr>
<td><strong>RHEUMATOLOGIC</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLE</td>
<td>See Rheumatology, RH11</td>
<td>MRI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ANA, anti-dsDNA</td>
</tr>
<tr>
<td><strong>NEOPLASTIC</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mass effect/edema, hemorrhage, seizure, Paraneoplastic encephalitis</td>
<td>Increased ICP</td>
<td>CT with contrast</td>
</tr>
<tr>
<td></td>
<td>Localizing neurological signs</td>
<td>MRI</td>
</tr>
<tr>
<td></td>
<td>Systemic symptoms of cancer</td>
<td>Anti-Hu antibodies</td>
</tr>
<tr>
<td><strong>OTHER</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal pressure hydrocephalus</td>
<td>Gait disturbances</td>
<td>CT or MRI</td>
</tr>
<tr>
<td></td>
<td>Urinary incontinence</td>
<td></td>
</tr>
<tr>
<td></td>
<td>See Neurosurgery, NS8</td>
<td></td>
</tr>
</tbody>
</table>

**Major or Mild NCD due to Alzheimer’s Disease**

- see Psychiatry, PS20

**Definition**
- beyond criterion for NCD, the core features of Alzheimer’s disease include an insidious onset and gradual progression of cognitive and behavioural symptoms
- typical presentation: amnestic
  - mild phase: impairment in memory and learning sometimes accompanied with deficits in executive function
  - moderate-severe phase: visuoconstructural/perceptual-motor ability and language may also be impaired
  - social cognition tends to be preserved until late in the course of the disease
- atypical nonamnestic presentation (one of the following):
  1. aphasia: language disturbance
  2. apraxia: impaired ability to carry out motor activities despite intact motor function
  3. agnosia: failure to recognize or identify objects despite intact sensory function

**Pathophysiology**
- genetic factors
  - minority (<7%) of AD cases are familial (autosomal dominant)
  - 3 major genes for autosomal dominant AD have been identified:
    - amyloid precursor protein (chromosome 21), presenilin 1 (chromosome 14), presenilin 2 (chromosome 1)
  - the E4 polymorphism of apolipoprotein E (APOE) is a susceptibility genotype (E2 is protective)
    - note: APOE cannot serve as a diagnostic marker because it is only a risk factor and neither necessary nor sufficient for disease occurrence
  - pathology (although not necessarily specific for AD)
    - gross pathology
      - diffuse cortical atrophy, especially frontal, parietal, and temporal lobes (hippocampi)

**Cholinesterase Inhibitors for Dementia with Lewy Bodies (DLB), Parkinson’s Disease Dementia (PDD) and Cognitive Impairment in Parkinson’s Disease (CIND-PD)**

*Study: Meta-analysis of RCTs assessing efficacy of treatment with cholinesterase inhibitors in DLB, PDD, and CIND-PD.*

*Results: The six trials (n=1,236) included demonstrated therapeutic benefit of cholinesterase inhibitors for global assessment, cognitive function, behavioural disturbance, and activities of daily living. Cholinesterase inhibitors were associated with increased adverse events (OR 1.64) and drop out (OR 1.94). Adverse events were more common with rivastigmine but not with donepezil. Fewer deaths occurred in the treatment group (OR 0.29).

*Conclusion: Current evidence supports use of cholinesterase inhibitors for patients with PDD but its role in DLB and CIND-PD is still unclear.*

**4 As and one D of AD**

- Anterograde amnesia
- Aphasia
- Apraxia
- Agnosia
- Disturbance in executive function
  (Anterograde amnesia plus at least one of the other features is required for AD diagnosis)

Down syndrome predisposes to early onset of Alzheimer’s (i.e. age of ~40) due to three copies of the amyloid gene (APP)
microscopic pathology
- senile plaques (extracellular deposits of amyloid in the grey matter of the brain)
- loss of synapses
- neurofibrillary tangles (intracytoplasmic paired helical filaments with amyloid and hyperphosphorylated Tau protein)
- loss of cholinergic neurons in nucleus basalis of Meynert that project diffusely throughout the cortex

biochemical pathology
- 50-90% reduction in action of choline acetyltransferase

Epidemiology
- 1/12 of population 65-75 yr of age
- up to 1/3 population >85 yr of age
- accounts for 60-90% of all dementias (depending on setting and diagnostic criteria)

Risk Factors
- age is the largest risk factor
- genetic susceptibility polymorphism: apolipoprotein E4 increases risk and decreases age of onset
- other factors include: traumatic brain injury, family history, Down syndrome, low education, and vascular risk factors (e.g. smoking, HTN, hypercholesterolemia, DM)

Clinical Features
- cognitive impairment
  - memory impairment for newly acquired information (early)
  - deficits in language, abstract reasoning, and executive function
- behavioural and psychiatric manifestations (80% of those with major NCD)
  - mild NCD: major depressive disorder and/or apathy
  - major NCD: psychosis, irritability, agitation, combativeness, and wandering
- motor manifestations (late)
  - gait disturbance, dysphagia, incontinence, myoclonus, and seizures

Investigations
- perform investigations to rule out other potentially reversible causes of dementia
- EEG: usually normal, may observe generalized slowing (nonspecific)
- MRI: preferential atrophy of the hippocampi and precuneus of the parietal lobe; dilatation of lateral ventricles; widening of cortical sulci
- SPECT: hypoperfusion in temporal and parietal lobes
- PET imaging using Pittsburgh compound B (PIB) as a tracer enables imaging of beta-amyloid plaque in neuronal tissue

Treatment
- acetylcholinesterase inhibitors have been shown to slow decline in cognitive function
  - donepezil, rivastigmine, galantamine
  - relative contraindications: bradycardia, heart block, arrhythmia, CHF, CAD, asthma, COPD, ulcers, or risk factors for ulcers and/or GI bleeding
  - galantamine is contraindicated in patients with hepatic/renal impairment
- memantine is an NMDA-receptor antagonist that has some benefits in later stage AD (i.e. when MMSE <17)
- symptomatic management
  1. pharmacologic
    - low dose neuroleptics for agitation (neuroleptics may worsen cognitive decline)
    - trazodone for sleep disturbance
    - antidepressants (SSRIs)
  2. non-pharmacologic
    - redirection
    - explore inciting factors for behaviour and modify behaviour of patient or caregiver
    - family support and day care facilities

Prognosis
- mean duration of survival after diagnosis is approximately 10 yr, reflecting the advanced age of the majority of individuals rather than the course of the disease
- in those who survive the full course, death commonly results from aspiration
Major or Mild NCD with Lewy Bodies (formerly Dementia with Lewy Bodies)

Definition
- A NCD characterized by progressive cognitive impairment (with early changes in complex attention and executive function) and recurrent complex visual hallucinations
- core diagnostic features
  - fluctuating cognition with pronounced variations in attention and alertness
  - recurrent visual hallucinations that are well formed and detailed
  - spontaneous features of parkinsonism, with onset subsequent to development of cognitive decline (rest tremor may be absent in DLB, but otherwise same classic features of Parkinson’s disease)
- suggestive/supportive features
  - rapid eye movement (REM) sleep behaviour disorder
  - severe sensitivity to neuroleptic medications (rigidity, neuroleptic malignant syndrome, extrapyramidal symptoms)
  - repeated falls, syncope, or transient episodes of unexplained loss of consciousness
  - auditory or other nonvisual hallucinations, systematic delusions, and depression

Etiology and Pathogenesis
- Lewy bodies (eosinophilic cytoplasmic inclusions) found in both cortical and subcortical structures
- mixed DLB and AD pathology is common

Diagnostically Suggestive Markers
- low striatal dopamine transporter uptake on SPECT or PET
- relative preservation of medial temporal structures on CT/MRI

Epidemiology
- 0.1-5% of the general elderly population
- Lewy bodies are present in 20-35% of all dementia cases (more common in males)

Treatment
- acetylcholinesterase inhibitors (e.g. donepezil)

Prognosis
- average duration of survival 5-7 yr

Major or Mild Frontotemporal NCD (formerly Frontotemporal Dementia)

Definition
- refers to a group of disorders caused by progressive cell degeneration in the brain’s frontal or temporal lobes
  - deficits in executive function (e.g. poor mental flexibility, abstract reasoning, response inhibition, planning/organization, increased distractibility) with relative sparing of learning, memory and perceptual-motor function
- there are several variants of FTD each with specific core symptoms
  - “probable” is distinguished from “possible” frontotemporal NCD by:
    - evidence of causative frontotemporal NCD genetic mutation, from either family history or genetic testing
    - evidence of disproportionate frontal and/or anterior temporal atrophy on MRI or CT
    - evidence of frontal and/or anterior temporal hypoperfusion or hypometabolism on PET or SPECT

Behavioural Variant FTD
- most common variant
- insidious onset: must show progressive deterioration of behaviour and/or cognition by observation or history
- typically early symptom presentation (i.e. within the first 3 yr)
- three out of the following symptoms must be present and persistent/recurring:
  - behavioural disinhibition (socially inappropriate behaviour, impulsive, careless)
  - apathy or inertia
  - loss of sympathy or empathy (diminished response to others’ needs/feelings, social interest)
  - preservative, stereotyped, or compulsive/ritualistic behaviour
  - hyperorality and dietary changes (binge eating, increased consumption of alcohol/cigarettes or inedible objects)
Language Variants (Primary Progressive Aphasia)
- prominent decline in language ability, in the form of speech production, word finding, object naming, grammar, or word comprehension
- three subtypes
  - nonfluent/agrammatic variant PPA (NFAV-PPA) or progressive nonfluent aphasia (PNFA): nonfluent, laboured articulation/speech, anomia, preserved single word comprehension, word-finding deficit, impaired repetition
  - semantic variant PPA (SV-PPA) or semantic dementia (SD): fluent, normal rate, anomia, impaired single word comprehension, intact repetition, use words of generalization (“thing”) or supraordinate categories (“animal” for “dog”)
  - logopenic progressive aphasia (LPA): naming difficulty and impaired repetition

FTD Movement Disorders
- corticobasal degeneration (CBD) (see Parkinsonism)
- progressive supranuclear palsy (PSP) (see Parkinsonism)

Etiology and Pathogenesis
- unknown, however there is likely a genetic/familial component (40% have family history of early onset NCD)
- genetic variants: MAPT gene (Tau), PGRN gene (progranulin), VCP gene, TARDBP gene (TDP-43), CHMP2D gene
- unlike AD, FTD does not show amyloid plaques or neurofibrillary tangles, instead it is characterized by severe atrophy and specific neuronal inclusion bodies
- gross changes: atrophy in the frontal and anterior temporal lobes; cortical thinning; possible ventricular enlargement
- histological changes: gliosis, swollen neurons, microvacuolation, inclusion bodies in neurons/glia (Tau or TDP-43)

Epidemiology
- fourth most common cause of dementia (5% of all dementia cases)
- common cause of early-onset NCD in individuals younger than 65 yr

Prognosis
- median survival being 6-11 yr after symptoms onset and 3-4 yr after diagnosis
- survival is shorter and decline is faster than in typical Alzheimer’s disease

Major or Mild Vascular NCD

Definition
- diagnosis of major or mild NCD with determination of CVD as the dominant if not exclusive pathology that accounts for the cognitive deficits
- vascular etiology suggested by one of the following:
  - onset of cognitive deficits is temporally related to one or more cerebrovascular events
  - evidence for decline is prominent in complex attention (including processing speed) and frontal-executive function
- neuroimaging evidence of cerebrovascular disease comprises one or more of the following:
  - one or more large vessel infarct or hemorrhage
  - a strategically placed single infarct or hemorrhage (e.g. angular gyrus, thalamus, basal forebrain)
  - two or more lacunar infarcts outside the brainstem
  - extensive and confluent white matter lesions
  - for mild vascular NCD: history of a single stroke or extensive white matter disease is sufficient
  - for major vascular NCD: history of two or more strokes, a strategically placed stroke, or a combination of white matter disease and one or more lacunae is generally necessary
  - associated features supporting diagnosis: personality and mood changes, abulia, depression, emotional lability, and psychomotor slowing

Etiology and Pathogenesis
- major risk factors are the same as those for CVD (i.e. HTN, DM, smoking, obesity, high cholesterol levels, high homocysteine levels, other risk factors for atherosclerosis, atrial fibrillation, and conditions increasing risk of cerebral emboli)
- major or mild vascular NCD with gradual onset and slow progression is generally due to small vessel disease leading to lesions in white matter, basal ganglia, and/or thalamus
- cognitive deficits can be attributed to disruption of cortical-subcortical circuits

Epidemiology
- second most common cause of NCD
- prevalence estimates for vascular dementia/NCD range from 0.2-13% (by age 70), 16% (ages 80+) to 44.6% (ages 90+)
- higher prevalence in African Americans compared to Caucasians and East Asians
- prevalence higher in males than in females
Creutzfeldt-Jakob Disease

- rare degenerative fatal brain disorder caused by prion proteins causing spongiform changes, astrocytosis, and neuronal loss
- most common forms are sporadic (85%), hereditary (5-10%), and acquired (<1%)
- investigations: CSF analysis, MRI brain (cortical and/or subcortical FLAIR changes), EEG (periodic complexes)
- definitive diagnosis is by brain biopsy
- no treatments currently exist

Aphasia

Definition

- an acquired disturbance of language characterized by errors in language production, writing, comprehension, or reading

Neuroanatomy of Aphasia

- Broca's area (posterior inferior frontal lobe) involved in language production (expressive)
- Wernicke's area (posterior superior temporal lobe) involved in comprehension of language (receptive)
- angular gyrus is responsible for relaying written visual stimuli to Wernicke's area for reading comprehension
- arcuate fasciculus association bundle connects Wernicke's and Broca's areas

Assessment of Language

- assessment of context
  - handedness (writing, drawing, toothbrush, scissors), education level, native language, learning difficulties
- assessment of aphasia
  - spontaneous speech (fluency, paraphasias, repetition, naming, comprehension – auditory and reading, writing, neologisms)

Figure 19. Aphasia classification

>99% of right-handed people have left hemisphere language representation
70% of left-handed people have left hemisphere language representation, 15% have right hemisphere representation, and 15% have bilateral representation

Types of Paraphasias
Semantic (“chair” for “table”)
Phonemic (“clable” for “table”)

Aphasia localizes the lesion to the dominant cerebral hemisphere
Mild Traumatic Brain Injury

Definition
• mild TBI = concussion
• trauma induced transient alteration in mental status that may involve loss of consciousness
• hallmarks of concussion: confusion and amnesia, which may occur within minutes
• loss of consciousness (if present) must be less than 30 min, initial GCS must be between 13-15, and post-traumatic amnesia must be less than 24 h

Epidemiology
• 75% of TBIs are estimated to be mild; remainder are moderate or severe (see Neurosurgery, NS30 and Emergency Medicine, ER8)
• highest rates in children 0-4 yr, adolescents 15-19 yr, and elderly >65 yr

Clinical Features
• impairments following mild TBI
  • somatic: headache, sleep disturbance, nausea, vomiting, blurred vision
  • cognitive dysfunction: attentional impairment, reduced processing speed, drowsiness, amnesia
  • emotion and behaviour: impulsivity, irritability, depression
• severe concussion: may precipitate seizure, bradycardia, hypotension, sluggish pupils
• associated conditions: brain contusion, diffuse axonal injury, C-spine injury

Apraxia

Definition
• inability to perform skilled voluntary motor sequences that cannot be accounted for by weakness, ataxia, sensory loss, impaired comprehension, or inattention

Clinicopathological Correlations

Table 14. Apraxia

<table>
<thead>
<tr>
<th>Description</th>
<th>Tests</th>
<th>Hemispheres</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ideomotor</td>
<td>Blowing out a match; combing one’s hair</td>
<td>Left</td>
</tr>
<tr>
<td>Ideational</td>
<td>Preparing and mailing an envelope</td>
<td>Right and left</td>
</tr>
<tr>
<td>Constructional*</td>
<td>Copying a figure</td>
<td>Right and left</td>
</tr>
<tr>
<td>Dressing*</td>
<td>Dressing</td>
<td>Right</td>
</tr>
</tbody>
</table>

*Refers specifically to the inability to carry out the learned movements involved in construction, drawing, or dressing; not merely the inability to construct, draw, or dress. Many skills aside from praxis are needed to carry out these tasks.

Agnosia

Definition
• disorder in the recognition of the significance of sensory stimuli in the presence of intact sensation and naming

Clinicopathological Correlations

Table 15. Agnosias

<table>
<thead>
<tr>
<th>Description</th>
<th>Lesion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aperceptual Visual Agnosia</td>
<td>Bilateral temporo-occipital cortex</td>
</tr>
<tr>
<td>Identification of objects</td>
<td>Inability to name an object presented visually 2º to distorted visual perception Recognition by touch remains intact</td>
</tr>
<tr>
<td>Bilateral inferior temporo-occipital junction</td>
<td>Bilateral inferior temporo-occipital junction</td>
</tr>
<tr>
<td>Prospagnosia</td>
<td>Bilateral temporo-occipital areas or right inferior temporo-occipital region</td>
</tr>
<tr>
<td>Colour Agnosia</td>
<td>Bilateral inferior temporo-occipital lesions</td>
</tr>
<tr>
<td>Impaired Stereognosis</td>
<td>Anterior parietal lobe in the hemisphere opposite the affected hand</td>
</tr>
<tr>
<td>Finger Agnosia</td>
<td>Dominant hemisphere parietal-occipital lesions</td>
</tr>
</tbody>
</table>

Parietal Lobe Lesions
• Lesions of the dominant parietal lobe are characterized by Gerstmann's syndrome: agraphia, finger agnosia, and left-right disorientation
• Lesions of the non-dominant parietal lobe are characterized by neglect, anosognosia, and asomatognosia
• Cortical sensory loss (graphesthesia, astereognosis, impaired 2 point discrimination and extinction) can be seen with left or right parietal lesions

Extent of retrograde amnesia correlates with severity of injury
• Regained from most distant to recent memories
Investigations
- neurological exam to identify focal neurologic deficits
- neurocognitive assessment
  - simple orientation questions are inadequate to detect cognitive changes
  - initial assessment of severity is determined by
    - Glasgow Coma Scale: mild: 13-15, moderate: 9-12, severe: 3-8
    - sideline evaluation: Standardized Assessment of Concussion, Westmead Post-Traumatic Amnesia Scale, Sport Concussion Assessment Tool
- neuroimaging
  - x-ray of skull: not indicated for routine evaluation of MTBI
  - CT head as indicated by Canadian CT Head Rules (see Emergency Medicine, ER8)
  - MRI not indicated in initial evaluation – indicated in presence of continued or worsening symptoms despite normal CT

Treatment
- observation for first 24 h after mild TBI in all patients because of risk of intracranial complications
- emergency department for assessment if any loss of consciousness or persistent symptoms
- hospitalization with normal CT if GCS <15, seizures, or bleeding diathesis; or abnormal CT scan
- early rehabilitation to maximize outcomes
  - OT, PT, SLP, vestibular therapy, driving, therapeutic recreation
  - pharmacological management of headaches, pain, depression
  - CBT, relaxation therapy
  - follow Return to Play guidelines (www.thinkfirst.ca)

Prognosis
- most recover from mild TBI with minimal treatment, but some experience long-term consequences
- athletes with a previous concussion are at increased risk of subsequent concussion and cumulative brain injury
- repeat TBI can lead to life threatening cerebral edema (controversially known as second impact syndrome) or permanent impairment
- sequelae include
  - post-concussion syndrome: dizziness, headache, neuropsychiatric symptoms, cognitive impairment (usually resolves within weeks to months)
  - post-traumatic headaches: begin within 7 d of injury
  - post-traumatic epilepsy: approximately 2% risk of epilepsy post-mild TBI, prophylactic anticonvulsants not effective
  - post-traumatic vertigo

Neuro-Oncology
Paraneoplastic Syndromes
- see Endocrinology, E48

Tumours of the Nervous System
- see Neurosurgery, NS37

Movement Disorders
Function of the Basal Ganglia
- the cerebral cortex initiates movement via excitatory (glutamatergic) projections to the striatum, which then activate two pathways: direct and indirect
  - direct: cortex → striatum → GPi/SNr → thalamus → motor cortex
    - activation of this pathway removes the inhibitory effect of the GPi on the thalamus, letting the thalamus activate the cortex and ultimately allowing movement
  - indirect: cortex → striatum → GPe → STN → GPi/SNr → thalamus → motor cortex
    - activation of this pathway causes inhibition of the thalamus and ultimately prevents movement
**Figure 20. Neural connections of the basal ganglia**

- Motor cortex
- Premotor cortex
- Supplementary motor area
- Substantia nigra pars compacta
- GABA enkephalin
- GABA substance P
- Ventrolateral thalamus

**INDIRECT PATHWAY**
- Subthalamic nucleus
- Globus pallidus pars interna
- Globus pallidus pars externa
- GABA

**DIRECT PATHWAY**
- Motor cortex
- Premotor cortex
- Supplementary motor area
- Substantia nigra pars compacta
- GABA enkephalin
- GABA substance P
- Ventrolateral thalamus

**Figure 21. Horizontal section of basal ganglia**

- Genu of corpus callosum
- Lateral ventricle
- Caudate nucleus
- Putamen
- Globus pallidus
- Thalamus
- Lateral ventricle (trigone)
- Splenium of corpus callosum
Overview of Movement Disorders

Table 16. Movement Disorder Definitions

<table>
<thead>
<tr>
<th>Condition</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akathisia</td>
<td>Subjective generalized restlessness relieved by voluntary stereotypic movements (e.g. squirming)</td>
</tr>
<tr>
<td>Asterixis</td>
<td>Transient loss of muscle tone (negative myoclonus)</td>
</tr>
<tr>
<td>Athetosis</td>
<td>Slow writhing movements, especially distally</td>
</tr>
<tr>
<td>Bradykinesia</td>
<td>Slow and/or small amplitude of movements</td>
</tr>
<tr>
<td>Chorea</td>
<td>Brief, flowing, irregular movements; can appear purposeful in milder forms</td>
</tr>
<tr>
<td>Dysdiadochokinesia</td>
<td>Inability to smoothly perform rapidly alternating movements</td>
</tr>
<tr>
<td>Dyskinesia</td>
<td>Any involuntary movement, but the term is often used to describe the stereotypical movements that come with long-term neuroleptic use (tardive dyskinesia)</td>
</tr>
<tr>
<td>Dystonia</td>
<td>Co-contraction of agonist and antagonist muscles causing sustained twisting movements which can be tonic (dystonic postures) or phasic (dystonic movements)</td>
</tr>
<tr>
<td>Freezing</td>
<td>Episodes of halted motor action, especially during repetitive actions (eg. walking)</td>
</tr>
<tr>
<td>Hemiballismus</td>
<td>Unilateral violent flinging movement</td>
</tr>
<tr>
<td>Myoclonus</td>
<td>Brief muscle group contraction that is either focal, segmental, or generalized</td>
</tr>
<tr>
<td>Myokymia</td>
<td>Spontaneous, fine, fascicular contraction of muscle</td>
</tr>
<tr>
<td>Tachykinies</td>
<td>Acceleration of movements</td>
</tr>
<tr>
<td>Tics</td>
<td>Stereotyped and brief repetitive actions due to inner urge; can be suppressed; can be phonic (vocal) or motor</td>
</tr>
<tr>
<td>Tremor</td>
<td>Rhythmic and involuntary alternating muscle contractions</td>
</tr>
</tbody>
</table>

Movement Disorders

1. Tremor

Table 17. Approach to Tremors

<table>
<thead>
<tr>
<th>Resting</th>
<th>Action-Postural</th>
<th>Action-Intention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body Part</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upright</td>
<td>Head&gt; Jaw&gt; LE&gt; Head</td>
<td>Head&gt; LE&gt; Tongue</td>
</tr>
<tr>
<td>Characteristics</td>
<td>3-7 Hz pill rolling</td>
<td>6-12 Hz fine tremor</td>
</tr>
<tr>
<td>Worse with Associated Sx</td>
<td>Rest while concentrating “TRAP”</td>
<td>Sustained posture (outstretched arms)</td>
</tr>
<tr>
<td>BDx</td>
<td>PD, Parkinsonism, Wilson’s disease, mercury poisoning</td>
<td>Physiologic, essential, hyperthyroidism, hyperglycemia, heavy metal poisoning, CO poisoning, drug toxicity, sedative/ alcohol withdrawal</td>
</tr>
<tr>
<td>Treatment</td>
<td>Carbidopa-levodopa (Sinemet®), surgery, DBS</td>
<td>Prannolol, primidone, topiramate, and other anticonvulsants</td>
</tr>
</tbody>
</table>

2. Chorea: Huntington’s disease (HD), HD-like syndromes, neuroacanthocytosis, SLE, APLA syndrome, Wilson’s disease, CVD, tardive dyskinesia, senile chorea, Sydenham’s chorea, pregnancy chorea (chorea gravidarum)

3. Dystonia
   - primary dystonia: familial, sporadic (torticollis, blepharospasm, writer’s cramp)
   - dystonia-plus syndromes: dopa-responsive dystonia, myoclonus-dystonia
   - secondary dystonia: thalamotomy, stroke, CNS tumour, demyelination, PNS injury, drugs/toxins (L-dopa, neuroleptics, anticonvulsants, Mn, CO, cyanide, methanol)
   - heredodegenerative dystonias: Parkinsonian disorders, Wilson’s disease, Huntington’s disease

4. Myoclonus
   - physiologic myoclonus: hiccups, nocturnal myoclonus
   - essential myoclonus: myoclonus-dystonia with minimal or no occurrence of dystonia
   - epileptic myoclonus
   - symptomatic myoclonus
   - degenerative disorders: Wilson’s disease, Huntington’s disease, Corticobasal degeneration
   - infectious disorders: CJD, viral encephalitis, AIDS-dementia complex
   - metabolic disorders: drug intoxication/withdrawal, hypoglycemia, hyponatremia, HHS, hepatic encephalopathy, uremia, hypoxia
   - focal brain damage: head injury, stroke, mass

Palatal myoclonus can result from lesion to the Dentato-Rubro-Olivary tract, and is associated with an audible clicking and tremor of other facial muscles.
Parkinson’s Disease

**Etiology**
- **sporadic**: combination of oxidative stress to dopaminergic neurons, environmental toxins (e.g., pesticides), accelerated aging, genetics
- **familial** (10%): autosomal dominant α-synuclein or LRRK2 mutations, autosomal recessive parkin, PINK1 or DJ-1 mutation (juvenile onset)
- **MPTP** (neurotoxin)

**Epidemiology**
- prevalence of 0.3% in industrialized countries, but rises with increased age
- second most common neurodegenerative disorder, after Alzheimer’s
- mean age of onset is 60 yr

**Associated Factors**
- risk: family history, male, head injury, rural living, exposure to certain neurotoxins
- protective: coffee drinking, smoking, NSAID use, estrogen replacement in post-menopausal women

**Pathophysiology**
- loss of dopaminergic neurons in pars compacta of substantia nigra, thus reduced dopamine in striatum leading to disinhibition of the indirect pathway and decreased activation of the direct pathway causing increased inhibition of cortical motor areas
- α-synucleinopathy: α-synuclein accumulates in Lewy bodies and causes neurotoxicity in substantia nigra

**Clinical Features**
- **positive motor**
  - resting tremor: asymmetric 4-5 Hz “pill-rolling” tremor, especially in hands
  - rigidity: lead-pipe rigidity with cogwheeling due to superimposed tremor
- **negative motor**
  - bradykinesia: slow, small amplitude movements, fatiguing of rapid alternating movements, difficulty initiating movement
  - related findings: masked facies, hypophonia, aprosody (monotonous speech), dysarthria, micrographia, shuffling gait with decreased arm swing
  - freezing of gait: occurs with walking triggered by initiating stride or barriers/destinations, lasting seconds
  - postural instability: late finding presenting as falls
  - cognition: bradyphrenia (slow to think/respond), dementia (late finding)
  - behavioural: decreased spontaneous speech, depression, sleep disturbances, anxiety
  - autonomic: constipation, urinary retention, sexual dysfunction, orthostatic hypotension, cliniostatic hypertension

**Treatment**
- **pharmacologic**
  - mainstay of treatment: levodopa/carbidopa (Sinemet®) or levodopa/benserazide (Prolopa®)
  - Levodopa is a dopamine precursor; carbidopa and benserazide decreases peripheral metabolism of levodopa, decreasing side effects and increasing half-life of levodopa
  - levodopa-related fluctuation: delayed onset of response (affected by mealtime), end-of-dose deterioration (“wearing-off”), random oscillations of on-off symptoms
  - major complication of levodopa is dyskinesia
  - treatment of early PD: dopamine agonists, amantadine, MAOIs
  - adjuncts: dopamine agonists, MAOIs, anticholinergics (especially if prominent tremors), COMT inhibitors
- **surgical**: thalamotomy, pallidotomy, DBS (thalamic, pallidal, subthalamic)
- **psychiatric**

**Other Parkinsonian Disorders**
- **NCD with Lewy bodies** *(see Behavioural Neurology, N25)*
- **progressive supranuclear palsy**: tauopathy with limited vertical gaze (dowgaze more specific), early falls, axial rigidity and akinesia, dysthria, and dysphagia
- **corticobasal syndrome**: tauopathy with varied presentations but classically presents with unilateral parkinsonism, dystonia/myoclonus, apraxia ± “alien limbs” phenomenon; may also present as progressive non-fluent aphasia
- **multiple system atrophy**: synucleinopathy presenting as either cerebellar predominant (MSA-C, previously olivopontocerebellar atrophy) or parkinsonism predominant (MSA-P; previously nigrostriatal degeneration); both are associated with early autonomic dysfunction (previously Shy-Drager syndrome)
- **vascular parkinsonism**: multi-infarct presentation with gait instability and lower body parkinsonism; less likely associated with tremor
**Huntington’s Disease**

**Etiology and Pathogenesis**
- genetics: autosomal dominant CAG repeats (with anticipation) in Huntington’s gene on Chromosome 4, which leads to accumulation of defective protein in neurons
- pathology: global cerebral atrophy, especially affecting the striatum, leading to increased activity of the direct pathway, and decreased activity of the indirect pathway

**Epidemiology**
- North American prevalence 4-8/100,000
- mean age of onset 35-44 yr; but varies with degree of anticipation from 5-70 yr

**Clinical Features**
- typical progression: insidious onset with clumsiness, fidgetiness, and irritability, progressing over 15 yr to major NCD, psychosis, and chorea
  - major NCD: progressive memory impairment and loss of intellectual capacity
  - chorea: begins as movement of eyebrows and forehead, shrugging of shoulders, and parakinesia (pseudo-purposeful movement to mask involuntary limb jerking)
  - progresses to dance-like or ballism, and in late stage is replaced by dystonia and rigidity
  - mood changes: irritability, depression, anhedonia, impulsivity, bouts of violence
- Juvenile-onset HD (Westphal variant) characterized by Parkinsonism and dystonia

**Investigations**
- MRI: enlarged ventricles, atrophy of cerebral cortex and caudate nucleus
- genetic testing
  - expansion of the cytosine-adenine-guanine (CAG) trinucleotide repeats in the HTT gene
  - CAG repeats on chromosome 4p16.3 that encodes the protein huntingtin

**Treatment**
- no disease altering treatment
- psychiatric symptoms: antidepressants and antipsychotics
- chorea: neuroleptics and benzodiazepines
- dystonia: botulinum toxin

**Dystonia**

**Epidemiology**
- third most common movement disorder after Parkinson’s disease and essential tremor

**Clinical Features**
- symptoms exacerbated by fatigue, stress, emotions; relieved by sleep or specific tactile/proprioceptive stimuli (‘geste antagoniste’, e.g. place hand on face for cervical dystonia)
- more likely to be progressive and generalize if younger onset or leg dystonia

**Treatment**
- local medical: botulinum toxin
- systemic medical: anticholinergics (benztropine), muscle relaxants (baclofen), benzodiazepines, dopamine depletors (tetrabenazine); dopamine for dopa-responsive dystonia
- surgical: surgical denervation of affected muscle, stereotactic thalamotomy (unilateral dystonia), posteroventral pallidotomy, or DBS

**Tic Disorders**

**Definition**
- a tic is a sudden, rapid, recurrent, nonrhythmic, stereotyped motor movement or vocalization
- common criteria
  - tics may wax and wane in frequency but have persisted for an extended period of time
  - onset before age 18 yr
  - disturbance is not attributable to the physiological effects of a substance or another medical condition

**Clinical Classification**
- **Tourette’s disorder**: multiple motor and one or more vocal tics that have persisted for more than 1 yr since onset
- **persistent (chronic) motor or vocal tic disorder**: single or multiple motor or vocal tics (but not both motor and vocal) that have persisted for more than 1 yr since onset
- **provisional tic disorder**: single or multiple motor and/or vocal tics present for <1 yr since first tic onset
- **other specified or unspecified tic disorder**: symptoms characteristic of a tic disorder but do not meet full criteria
- **secondary tic disorders**: encephalitis, CJD, Sydenham’s chorea, head trauma, drugs, mental retardation syndromes
Motor vs. Vocal Tics
- simple tics: short duration (milliseconds)
- complex tics: longer (seconds), more purposeful and often include a combination of simple tics
- motor tics
  - simple: blinking, head jerking, shoulder shrugging, extension of the extremities
  - dystonic: bruxism (grinding teeth), abdominal tension, sustained mouth opening
  - complex: copropraxia (obscene gestures), echopraxia (imitate gestures), throwing, touching
- vocal tics
  - simple: blowing, coughing, grunting, throat clearing
  - complex: coprolalia (shout obscenities), echolalia (repeat others' phrases), palilalia (repeat own phrases)

Treatment
- dopamine blockers, dopamine depletors (tetrabenazine), clonidine, clonazepam, DBS

**Tourette’s Syndrome (Gilles de la Tourette’s Syndrome)**

**Definition According to DSM V**
1. presence of both multiple motor and one or more vocal tics at some point during the illness, although not necessarily concurrently
2. tics may wax and wane in frequency but have persisted for more than 1 yr since first tic onset (with no tic-free periods greater than 3 mo)
3. onset is before age 18 yr
4. not due to effect of a substance or another medical condition

**Epidemiology**
- estimated prevalence among adolescents 3-8 per 1,000 school-age children; M:F = 2:1 to 4:1

**Signs and Symptoms**
- tics: wide variety that wax and wane in type and severity; can be voluntarily suppressed for some time but are preceded by unpleasant sensation that is relieved once tic is carried out
- can be worsened by anxiety, excitement, and exhaustion; better during calm focused activities
- psychiatric: compulsive behaviour (associated with OCD and ADHD), hyperactive behaviour, ‘rages’, sleep-wake disturbances, learning disabilities

**Treatment**
- same as tics (dopamine blockers, dopamine depletors, clonidine, clonazepam, DBS)

**Prognosis**
- typically begins between ages 4-6
- peak severity occurs between ages 10-12, with a decline in severity during adolescence (50% are tic-free by 18 yr of age)
- tic symptoms, however, can manifest similarly in all age groups and across the lifespan

**Cerebellar Disorders**

**Clinico-Anatomic Correlations**
- vermis: trunk/gait ataxia
- cerebellar lobe (i.e. lateral): rebound phenomenon, scanning dysarthria, dysdiadochokinesia, dysmetria, nystagmus

**Symptoms and Signs of Cerebellar Dysfunction**
- nystagmus: observe during extraocular movement testing (most common is gaze-evoked nystagmus)
- dysarthria (ataxic): abnormal modulation of speech velocity and volume – elicit scanning/telegraphic/slurred speech on spontaneous speech
- ataxia: broad-based, uncoordinated, lurching gait
- dysmetria: irregular placement of voluntary limb or ocular movement
- dysdiadochokinesia: impairment of rapid alternating movements (e.g. pronation – supination task)
- postural instability: truncal ataxia on sitting, titubation (rhythmic rocking of trunk and head), difficulty with tandem and broad-based gait
- intention tremor: typically orthogonal to intended movement, and increases as target is approached
- hypotonia: decreased resistance to passive muscular extension (occurs shortly after injury to lateral cerebellum)
- pendular patellar reflex: knee reflex causes pendular motion of leg (occurs after injury to cerebellar hemispheres); pendular reflexes at triceps
- rebound phenomenon: overcorrection after displacement of a limb
- hypometric and hypermetric saccades
Wernicke-Korsakoff Syndrome

- see Psychiatry, PS24
- note that alcohol can also cause a cerebellar ataxia separate from thiamine deficiency; this ataxia can be due to cerebellar atrophy or alcohol polyneuropathy

Cerebellar Ataxias

Congenital Ataxias
- early onset non-progressive ataxias associated with various syndromes as well as developmental abnormalities (e.g. Arnold-Chiari malformation, Dandy-Walker cysts)

Hereditary Ataxias
- autosomal recessive: includes Friedrich’s ataxia, ataxia telangiectasia, vitamin E deficiency
  - signs: gait and limb ataxia, weakness, areflexia, extensor plantar reflex, impaired proprioception and vibration, dysarthria
  - death in 10-20 yr from cardiomyopathy or kyphoscoliotic pulmonary restriction
- autosomal dominant: most commonly spinocerebellar ataxias (SCAs) (Over 30 types, most common SCAs due to CAG repeats)
  - signs: ataxia and dysarthria; chorea, polyneuropathy, pyramidal and/or extrapyramidal features, dementia

Acquired Ataxias
- neurodegeneration (e.g. multiple system atrophy)
- systemic: alcohol, celiac sprue, hypothyroidism, Wilson’s, thiamine deficiency
- toxins: carbon monoxide, heavy metals, lithium, anticonvulsants, solvents
- vascular: infarct, bleed, basilar migraine
- autoimmune: MS, Miller-Fischer (GBS)

Vertigo

- see Otolaryngology, OT12

Motor Neuron Disease

Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease)

Definition
- progressive neurodegenerative disease that causes UMN and LMN symptoms and is ultimately fatal

Etiology
- idiopathic (most), genetic (5-10% familial, especially SOD1 mutation, other: C9orf72, TARDDBP)

Pathology
- disorder of anterior horn cells of spinal cord, cranial nerve nuclei, and corticospinal tract

Epidemiology
- 5/100,000; incidence increases with age

Clinical Features
- limb motor symptoms: segmental and asymmetrical UMN and LMN symptoms
- bulbar findings: dysarthria (flaccid or spastic), dysphagia, tongue atrophy and fasciculations, facial weakness and atrophy
- pseudobulbar affect, frontotemporal dementia (up to 10%)
- sparing of sensation, ocular muscles, and sphincters

Investigations
- EMG: chronic denervation and reinnervation, fasciculations
- NCS: to rule out peripheral neuropathy (i.e. multifocal motor neuropathy with conduction block)
- CT/MRI: to rule out cord disease/compression

The only interventions that have been shown to extend survival in ALS are riluzole and use of BiPAP

Red Flags Inconsistent with ALS
Sensory sx, predominant pain, bowel or bladder incontinence, cognitive impairment, ocular muscle weakness

Denervation on EMG
Fibrillations, positive sharp waves, complex repetitive discharges; reinnervation — increased amplitude and duration of motor units
Treatment
• riluzole (modestly slows disease progression)
• symptomatic relief
  - spasticity/cramping: baclofen, tizanidine (Zanaflex®), regular exercise, and physical therapy
  - sialorrhea: TCA (i.e. amitriptyline), sublingual atropine drops, parotid/submandibular Botox* (rare)
  - pseudobulbar affect: dextromethorphan/quinidine, TCA, SSRI
• non-pharmacologic: high caloric diet, ventilatory support (especially BiPAP), early nutritional support
  (i.e. PEG tube), rehabilitation (PT, OT, SLP), psychosocial support

Prognosis
• median survival 3 yr; death due to respiratory failure

Other Motor Neuron Diseases
• degenerative
  - progressive muscular atrophy (progressive bulbar palsy): only LMN symptoms with asymmetric weakness, later onset than ALS, 5-10% of patients in ALS centres
  - primary lateral sclerosis (progressive pseudobulbar palsy): UMN symptoms, later onset, not fatal with variable disability; 5-10% of patients in ALS centres
  - spinal muscular atrophy: pediatric disease with symmetric LMN symptoms
• infectious
  - post-polio syndrome, West Nile infection: residual asymmetric muscle weakness, atrophy

Peripheral Neuropathies

Diagnostic Approach to Peripheral Neuropathies
1. differentiate: motor vs. sensory vs. autonomic vs. mixed
2. pattern of deficit: symmetry; focal vs. diffuse; upper vs. lower limb; cranial nerve involvement
3. temporal pattern: acute vs. chronic; relapsing/remitting vs. constant vs. progressive
4. history: PMH, detailed FHx, exposures (e.g. insects, toxins, sexual, travel), systemic symptoms
5. detailed peripheral neuro exam: LMN findings, differentiate between root and peripheral nerves, cranial nerves, respiratory status

Classification
• monoradiculopathy: dermatomal deficit due to single nerve root lesion
  - due to disc herniation or root compression causing radicular pain
  - little tactile anesthesia, as dermatomes overlap
• polyradiculopathy: multiple dermatome deficits due to multiple nerve root lesions
  - one type is cauda equina syndrome (lumbosacral roots)
• plexopathy: deficit matching distribution of a nerve plexus
  - brachial plexopathy
    - upper (C5-C7): LMN sx of shoulder and upper arm muscles (Erb’s palsy)
    - lower (C8-T1): LMN sx and sensory sx of forearm and hand (Klumpke’s palsy)
  - DDx: trauma, idiopathic neuritis, tumour infiltration, radiation, thoracic outlet syndrome (i.e. cervical rib)
• lumbosacral plexopathy (rare, especially unilateral)
  - DDx: idiopathic neuritis, infarction (i.e. DM), compression

Diabetic Neuropathies
• Peripheral neuropathy: pain or loss of sensation in a glove and stocking distribution (hands and feet affected before arms and legs)
• Autonomic: anhidrosis, orthostatic hypotension, impotence, gastroparesis, bowel and bladder dysfunction
• Mononeuropathy multiplex: nerve infarct or compression
• Cranial neuropathy: CN III (pupil sparing) > IV > VI
• Lumbosacral plexopathy

DDx of Demyelinating Neuropathy
GBS, CIDP, paraproteinemia, diphtheria, amiodarone, Charcot-Marie-Tooth, storage diseases, pressure-palsy predisposition, paraneoplastic

DDx of Motor Neuron Diseases
• Peripheral neuropathy: only LMN symptoms
• Primary lateral sclerosis: UMN symptoms, later onset, not fatal with variable disability
• Spinal muscular atrophy: pediatric disease with symmetric LMN symptoms
• Inflammatory myopathy: acute vs. chronic
• ALS: progressive muscular atrophy (only LMN symptoms with asymmetric weakness)

Figure 22. Pattern of distribution for peripheral neuropathies

Polyneuropathy  mononeuropathy (peroneal)  mononeuropathy multiplex  radiculopathy (C6)  plexopathy (brachial)
Peripheral Neuropathies

- mononeuropathy: single nerve deficit
  - carpal tunnel syndrome (most common): compression of median nerve at wrist
    - symptoms: wrist pain, paresthesia first 3 and 1/2 digits, ± radiation to elbow, worse at night
    - signs: Tinel's sign, Phalen's test, thenar muscle wasting, sensory deficit
    - EMG and NCS: slowing at wrist (both motor and sensory)
  - etiology: entrapment, pregnancy, DM, gammapathy, rheumatoid arthritis, thyroid disease
  - Bells palsy (most common cranial neuropathy): see Otolaryngology, OT22
  - other less common mononeuropathies due to entrapment/compression: ulnar (compression at elbow), median (at pronator teres), radial (at spiral groove of humerus), obturator (from childbirth), peroneal (due to crossing legs or surgical positioning), posterior tibial (tarsal canal)

- mononeuropathy multiplex: deficit affecting multiple discrete nerves (asymmetric)
  - must rule out vasculitis or collagen vascular disease; consider MMN (multifocal motor neuropathy) or MADSAM (multifocal acquired demyelinating sensory and motor neuropathy)

- polyneuropathy: symmetrical distal stocking-glove pattern
  - symmetrical distal sensorimotor deficit affecting longest fibres first (stocking-glove distribution), hypotonia; progression of dysesthesia early and weakness later
  - etiology: DM (most common), renal disease, substances, toxins, genetics, SLE, HIV, leprosy, alcohol, B12 deficiency, uremia
  - chronic inflammatory demyelinating polyneuropathy (CIDP)
    - chronic relapsing sensorimotor polyneuropathy with increase protein in CSF and demyelination (shown on EMG/NCS)
    - course is fluctuating, in contrast with the acute onset of GBS
    - treatment: first-line is prednisone; alternatives are plasmapheresis, IVIG, and azathioprine

Table 18. Differential Diagnosis of Symmetric Polyneuropathy

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Mechanism</th>
<th>Course</th>
<th>Modality</th>
<th>Investigations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vascular</td>
<td>PAN</td>
<td>Ischemic</td>
<td>Chronic</td>
<td>S/M</td>
</tr>
<tr>
<td></td>
<td>HIV</td>
<td>Axonal/demyelination</td>
<td>Chronic</td>
<td>S/A</td>
</tr>
<tr>
<td></td>
<td>Lyme</td>
<td>Axonal/demyelination</td>
<td>Chronic</td>
<td>M</td>
</tr>
<tr>
<td>Infectious</td>
<td>GBS</td>
<td>Demyelination</td>
<td>Acute</td>
<td>M</td>
</tr>
<tr>
<td></td>
<td>CIDP</td>
<td>Demyelination</td>
<td>Chronic</td>
<td>S/M</td>
</tr>
<tr>
<td>Hereditary</td>
<td>HMSN</td>
<td>Axonal/demyelination</td>
<td>Chronic</td>
<td>S/M</td>
</tr>
<tr>
<td>Neoplastic</td>
<td>Paraneoplastic</td>
<td>Axonal/demyelination</td>
<td>Chronic</td>
<td>S/M</td>
</tr>
<tr>
<td></td>
<td>Myeloma</td>
<td>Axonal/demyelination</td>
<td>Chronic</td>
<td>S/M</td>
</tr>
<tr>
<td></td>
<td>Lymphoma</td>
<td>Axonal</td>
<td>Chronic</td>
<td>M</td>
</tr>
<tr>
<td></td>
<td>Monoclonal gammopathy</td>
<td>Demyelination</td>
<td>Chronic</td>
<td>S/M</td>
</tr>
<tr>
<td>Toxin</td>
<td>EtOH</td>
<td>Axonal</td>
<td>Sub-acute</td>
<td>S/M</td>
</tr>
<tr>
<td></td>
<td>Heavy metals (i.e. lead)</td>
<td>Axonal</td>
<td>Sub-acute</td>
<td>S/M</td>
</tr>
<tr>
<td>Medications</td>
<td>Axonal</td>
<td>Sub-acute</td>
<td>S/M</td>
<td>Drug levels</td>
</tr>
<tr>
<td>Metabolic</td>
<td>DM</td>
<td>Ischemic/axonal</td>
<td>Chronic</td>
<td>S/A</td>
</tr>
<tr>
<td></td>
<td>Hypothyroidism</td>
<td>Axonal</td>
<td>Chronic</td>
<td>S/M</td>
</tr>
<tr>
<td></td>
<td>Renal failure</td>
<td>Axonal</td>
<td>Chronic</td>
<td>S/A</td>
</tr>
<tr>
<td>Nutritional</td>
<td>B12 deficiency</td>
<td>Axonal</td>
<td>Sub-acute</td>
<td>S/M</td>
</tr>
<tr>
<td>Other</td>
<td>Porphyria</td>
<td>Axonal</td>
<td>Sub-acute</td>
<td>M</td>
</tr>
<tr>
<td></td>
<td>Amyloid</td>
<td>Axonal</td>
<td>Sub-acute</td>
<td>S</td>
</tr>
</tbody>
</table>

A = axonotensive; CIDP = chronic inflammatory demyelinating polyneuropathy; GGT = gamma-glutamyl transferase; HMSN = hereditary motor sensory neuropathy; PAN = polyarteritis nodosa; RA = rheumatoid arthritis; S = sensory; SLE = systemic lupus erythematosus; SPEP = serum protein electrophoresis; NCS = neural conduction studies; IVIG = intravenous immunoglobulin; MMN = multifocal motor neuropathy; CIDP = chronic inflammatory demyelinating polyneuropathy.
Guillain-Barré Syndrome
- definition: acute rapidly evolving demyelinating inflammatory polyradiculoneuropathy that often starts in the distal lower limbs and ascends
- etiology
  - autoimmune attack and damage to peripheral nerve myelin
  - sometimes preceded by viral/bacterial infections
- signs and symptoms
  - sensory: distal and symmetric paresthesias, loss of proprioception and vibration sense, neuropathic pain
  - motor: weakness starting distally in legs, areflexia
  - autonomic: blood pressure dysregulation, arrhythmias, bladder dysfunction
- investigations
  - CSF: albuminocytologic dissociation (high protein, normal WBC)
  - EMG/NCS: conduction block, differential or focal (motor > sensory) slowing, decreased F-wave, sural sparing
- subtypes
  1. acute inflammatory demyelinating polyneuropathy (AIDP)
  2. acute motor-sensory axonal neuropathy (AMSAN)
  3. acute motor axonal neuropathy (AMAN)
- treatment
  - IVIG or plasmapheresis, ± pain management, monitor vitals and vital capacity
- prognosis
  - peak of symptoms at 2-3 wk, resolution at 4-6 wk
  - 5% mortality (higher if require ICU); up to 15% have permanent deficits

Neuromuscular Junction Diseases

Clinical Approach to Disorders of the Neuromuscular Junction

Table 19. Common Disorders of the Neuromuscular Junction

<table>
<thead>
<tr>
<th></th>
<th>Myasthenia Gravis</th>
<th>Lambert-Eaton</th>
<th>Botulism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ocular/Bulbar Paresis</td>
<td>+</td>
<td>–</td>
<td>++ (early)</td>
</tr>
<tr>
<td>Limb Weakness</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Fatigability</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Post-Exercise Enhancement</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Reflexes</td>
<td>N</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>Anticholinergic Sx</td>
<td>–</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>Sensory Sx</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Associated Conditions</td>
<td>Thymoma</td>
<td>Small cell carcinoma</td>
<td>GI S&amp;S</td>
</tr>
<tr>
<td>Repetitive EMG Stimulation</td>
<td>Decremental response</td>
<td>Incremental response</td>
<td>(rapid stimulation) (\downarrow) (slow stimulation)</td>
</tr>
</tbody>
</table>

Myasthenia Gravis

Etiology and Pathophysiology
- progressive autoimmune disorder due to anti-AChR or anti-MuSK antibodies, resulting in early saturation at the NMJ and inadequate muscle activation with increasing nerve stimulation
- 15% of patients with MG have associated thymic neoplasia, 85% have thymic hyperplasia

Epidemiology
- bimodal age of onset – 20s (mostly women) and 60s (mostly men)

Clinical Features
- fatigable, symmetric or asymmetric weakness without reflex changes, sensory changes, or coordination abnormalities
- ocular (diplopia/ptosis), bulbar (dysarthria/dysphagia), and/or proximal limb weakness
- symptoms may be exacerbated by infection, pregnancy, menses, and various drugs
- respiratory muscle weakness may lead to respiratory failure

Investigations
- edrophonium (Tensilon®) test
- assess for improvement over 2 min following edrophonium injection
- EMG
  - repetitive stimulation → decremental response
  - single fibre electromyography shows increased jitter (80-100% sensitivity)
• spirometry – forced vital capacity may be used to monitor adequacy of respiratory effort over time
• anti-acetylcholine receptor antibody assay (70-80% sensitivity)
• anti-MuSK antibody may be used if seronegative for anti-AChR antibody
• CT/MRI to screen for thymoma/thymic hyperplasia

Treatment
• thymectomy - 85% of patients show improvement or remission
• symptomatic relief
• acetylcholinesterase inhibitors (e.g. pyridostigmine)
• does not affect primary pathologic process so rarely results in control of disease when used alone
• immunosuppression
• steroids are mainstay of treatment (70-80% remission rate)
• azathioprine, cyclophosphamide, and mycophenolate as adjuncts or as steroid sparing therapy
• short-term immunomodulation (for crises) – IVIG and plasmapheresis

Prognosis
• 30% eventual spontaneous remission
• with treatment, life expectancy is equal to that of a person without MG, but quality of life may vary

Lambert-Eaton Myasthenic Syndrome

Etiology and Pathophysiology
• autoimmune disorder due to antibodies against presynaptic voltage-gated calcium channels, causing decreased ACh release at the NMJ
• 50-66% are associated with small cell carcinoma of the lung

Clinical Features
• weakness of skeletal muscles without sensory or coordination abnormalities, proximal and lower muscles more affected
• reflexes are diminished or absent, but increase after active muscle contraction
• bulbar and ocular muscles affected in 25% (vs. 90% in MG)
• prominent anticholinergic autonomic symptoms (dry mouth > impotence > constipation > blurred vision)

Investigations
• edrophonium test → no response
• EMG
  • rapid (>10 Hz) repetitive stimulation → incremental response
  • post-exercise facilitation → an incremental response with exercise
  • screen for malignancy, especially small cell lung cancer

Treatment
• tumour removal
• acetylcholine modulation
  • increased acetylcholine release (3,4-diaminopyridine)
  • decreased acetylcholine degradation (pyridostigmine)
• immunomodulation - steroids, plasmapheresis, IVIG

Botulism

Etiology and Pathophysiology
• caused by a toxin produced by spores of Clostridium botulinum bacteria, which can enter through wounds or by ingestion
• infantile botulism is the most common form, and is usually from ingestion of honey or corn syrup

Clinical Features
• occur 6–48 h after ingestion
• CN paralysis: ptosis, extraocular muscle weakness, dilated poorly reactive pupils, dysarthria, jaw weakness, dysphagia
• autonomic dysfunction: nausea, orthostatic hypotension, constipation (paralytic ileus), bladder distension
• anticholinergic symptoms: dry mouth, constipation, urinary retention
• spreads to trunk and limbs: symmetric weakness with paralysis and absent/decreased deep tendon reflexes
• pattern of paresis often starts with GI symptoms, then extraocular muscle weakness, then dysphagia, then limbs and respiratory involvement; all associated with dry mouth.
• rarely respiratory distress, potentially advancing to respiratory failure
Investigations
• blood test for toxin, stool culture
• CT/MRI to rule out stroke, lesion (normal in botulism)

Treatment
• botulinum anti-toxin – good prognosis with prompt treatment
• supportive therapy as required

Myopathies

Clinical Approach to Muscle Diseases

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Key Clinical Features</th>
<th>Key Investigations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inflammatory</td>
<td>Myalgias</td>
<td>CK</td>
</tr>
<tr>
<td>Dermatomyositis</td>
<td>Pharyngeal involvement</td>
<td>CK, endomysial infiltrates; necrosis</td>
</tr>
<tr>
<td>Dermatomyositis</td>
<td>Characteristic rashes</td>
<td>CK, perifascicular atrophy</td>
</tr>
<tr>
<td>Sarcoiosis</td>
<td>Myalgias</td>
<td>ACE level, CK, granulomas</td>
</tr>
<tr>
<td>Inclusion body</td>
<td>Weak quadriceps and deep finger flexors</td>
<td>CK, granulomas</td>
</tr>
<tr>
<td>Endocrine</td>
<td>Medication</td>
<td>CK, myoglobin</td>
</tr>
<tr>
<td>Thyroid (± or –)</td>
<td>ICU patient</td>
<td>Biopsy, selective loss of thick myosin</td>
</tr>
<tr>
<td>Cushing’s syndrome</td>
<td>Early onset (Duchenne and Becker)</td>
<td></td>
</tr>
<tr>
<td>Parathyroid (± or –)</td>
<td>Progressive proximal muscle weakness</td>
<td>Biopsy, dystrophin analysis: abnormal</td>
</tr>
<tr>
<td>Myotonic dystrophy</td>
<td>Distal myopathy</td>
<td>Genetic testing</td>
</tr>
<tr>
<td>Hereditary Dystrophy</td>
<td>Inflammatory myopathy</td>
<td>myoglobin</td>
</tr>
<tr>
<td>Duchenne (see Pediatrics, P43)</td>
<td>Early onset (Duchenne and Becker)</td>
<td>Dystrophin analysis: absent</td>
</tr>
<tr>
<td>Becker (see Pediatrics, P39)</td>
<td>Progressive proximal muscle weakness</td>
<td>Dystrophin analysis: normal</td>
</tr>
<tr>
<td>Hereditary Metabolic</td>
<td>Myalgias</td>
<td>lactate, lactate, serum/urinary myoglobin post-exercise</td>
</tr>
<tr>
<td>McAdie’s</td>
<td>Exercise-related myalgias, cramping and myoglobinuria</td>
<td>lactate, post-exercise</td>
</tr>
<tr>
<td>Hereditary Periodic Paralysis</td>
<td>Episodic weakness</td>
<td>Normal, ± K^-</td>
</tr>
<tr>
<td>Hereditary Mitochondrial</td>
<td>Myoclonus, generalized seizures, dementia</td>
<td>Biopsy, ragged red fibres, increased lactate</td>
</tr>
<tr>
<td>MERRF</td>
<td>Biopsy, ragged red fibres</td>
<td></td>
</tr>
<tr>
<td>MELAS</td>
<td>Pediatric onset, stroke-like symptoms, episodic vomiting, dementia</td>
<td></td>
</tr>
<tr>
<td>Keams Sayre</td>
<td>Progressive ophthalmoplegia, retinal pigment degeneration, cardiac conduction abnormalities</td>
<td></td>
</tr>
</tbody>
</table>

MELAS = mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; MERRF = mitochondrial encephalomyopathy with ragged red fibres
Myotonic Dystrophy

Etiology and Pathophysiology
• unstable trinucleotide (CTG) repeat in DMK gene (protein kinase) at 19q13.3, number of repeats correlates with severity of symptoms, autosomal dominant

Epidemiology
• most common adult muscular dystrophy, prevalence 3-5/100,000

Clinical Features
• appearance: ptosis, bifacial weakness, frontal baldness (including women), triangular face giving a drooping/dull appearance
• physical exam
  • distribution of weakness: distal weaker than proximal (in contrast to other myopathies), steppage gait
  • myotonia: delayed relaxation of muscles after exertion (elicit by tapping on thenar muscles with hammer)
  • cardiac: 90% have conduction defects (1° heart block; atrial arrhythmias)
  • respiratory: hypoventilation 2° to muscle weakness
  • ocular: subcapsular cataracts, retinal degeneration, decreased intraocular pressure
  • other: DM, infertility, testicular atrophy
• EMG: subclinical myotonia – long runs with declining frequency and amplitude

Treatment and Prognosis
• no cure, progressive, death usually around 50 yr
• management of myotonia: phenytoin

Pain Syndromes

Approach to Pain Syndromes

Definitions
• nociceptive pain: pain arising from normal activation of peripheral nociceptors
• neuropathic pain: pain arising from direct injury to neural tissue, bypassing nociceptive pathways
• spontaneous pain: unprovoked burning, shooting, or lancinating pain
• paresthesia: spontaneous abnormal non-painful sensation (e.g. tingling)
• dysesthesia: evoked pain with inappropriate quality or excessive quantity
• allodynia: a dysesthetic response to a non-noxious stimulus
• hyperalgesia: an exaggerated pain response to a noxious stimulus

Non-Pharmacological Management
• physical (PT, acupuncture, chiropractic manipulation, massage)
• psychoeducational (CBT, family therapy, education, psychotherapy)

Medical Pain Control
• combination multi-modal therapy is important
• primary analgesics: acetaminophen, NSAIDs (often used for soft tissue injuries, strains, sprains, headaches, and arthritis), opiates
• adjuvants: antidepressants (TCAs, SSRIs), anticonvulsants (gabapentin, carbamazepine, pregabalin), baclofen, sympatholytics (phenoxybenzamine), α2-adrenergic agonists (clonidine)

Surgical Pain Control
• peripheral ablation: nerve blocks, facet joint denervation
• direct delivery: implantable morphine pump
• central ablation: stereotactic thalamotomy, spinal tractotomy, or dorsal root entry lesion
• DBS or dorsal column stimulation

Neuropathic Pain

Definition
• pain resulting from a disturbance of the central or peripheral nervous system

Epidemiology
• affects up to 6% of people (2 million Canadians)
Symptoms and Signs
• hyperalgesia/allodynia
• subjectively described as burning, heat/cold, pricking, electric shock, perception of swelling, numbness
• can be spontaneous or stimulus evoked
• distribution may not fall along classical neuro-anatomical lines
• associated issues: sleep difficulty, anxiety/stress/mood alteration

Causes of Neuropathic Pain
• sympathetic: complex regional pain syndrome
• non-sympathetic: damage to peripheral nerves
  ▪ systemic disease: DM, thyroid disease, renal disease, rheumatoid arthritis, multiple sclerosis
  ▪ nutritional/toxicity: alcoholism, pernicious anemia, chemotherapy
  ▪ infectious: post-herpetic, HIV
  ▪ trauma/compression: nerve entrapment, trigeminal neuralgia, post-surgical, nerve injury, cervical/lumbar radiculopathy, plexopathy
• central: abnormal CNS activity
  ▪ phantom limb, post spinal cord injury, post stroke, MS

Treatment
• identify/treat underlying cause
• pharmacotherapy
  ▪ Stepwise approach (Canadian Pain Society, 2014)
    ◆ 1st line: Gabapentinoids, TCA, SNRI
    ◆ 2nd line: Tramadol, opioid analgesics
    ◆ 3rd line: Cannabinoids
    ◆ 4th line: Fourth-line agents: topical lidocaine (second line for postherpetic neuralgia), methadone, lamotrigine, lacosamide, tapentadol, botulinum toxin
  • common non-pharmacologic therapies
    ▪ neuropsychiatry: CBT, psychotherapy
    ▪ rehabilitation: physiotherapy
  • surgical therapies: dorsal column neurostimulator, DBS (thalamus)

Trigeminal Neuralgia

Clinical Features
• recurrent episodes of sudden onset, excruciating unilateral paroxysmal shooting “electric” pain in trigeminal root territory (V3>V2>V1)
• may have normal sensory exam
• pain lasts seconds/minutes over days/weeks; may remit for wk/mo
• triggers: touching face, eating, talking, cold wind, shaving, applying make-up

Etiology
• classic TN: idiopathic
• secondary TN: compression by tortuous blood vessel (superior cerebellar artery), cerebellopontine angle tumour (5%), MS (5%)

Epidemiology
• F>M; usually middle-aged and elderly

Diagnosis
• clinical diagnosis
• investigate for secondary causes, which are more likely if bilateral TN or associated sensory loss
  ◆ MRI to rule out structural lesion, MS, or vascular lesion

Treatment
• first line: carbamazepine or oxcarbazepine
• second line: baclofen or lamotrigine
• narcotics not generally recommended
• if medical treatment fails: trigeminal ganglion percutaneous technique, gamma knife, invasive percutaneous denervation (radiofrequency/glycerol), percutaneous balloon microcompression, microvascular decompression

Postherpetic Neuralgia

Clinical Features
• pain persisting in the region of a cutaneous outbreak of herpes zoster
• constant deep ache or burning, intermittent spontaneous lancinating/jabbing pain, allodynia
• distribution: thoracic, trigeminal, cervical > lumbar > sacral
• associated impaired sleep, decreased appetite, decreased libido
Etiology and Pathogenesis
• destruction of the sensory ganglion neurons (e.g. dorsal root, trigeminal, or geniculate ganglia) secondary to reactivation of herpes zoster infection

Epidemiology
• incidence in those with zoster increases with age (2% in <60 yr, 19% in >70 yr)
• risk factors: older age, greater acute pain, greater rash severity

Prevention
• varicella zoster vaccine (Varivax®) in childhood reduces incidence of varicella zoster
• herpes zoster vaccine (Zostavax®) reduces incidences of shingles, PHN, and other herpetic sequel (currently recommended in Canada for those >60 yr old)

Treatment
• medical: TCA (i.e. amitriptyline), anti-convulsants (i.e. pregabalin, gabapentin), analgesia (i.e. opiates, lidocaine patch), intrathecal methylprednisolone, topical capsaicin
  • early treatment of acute herpes zoster with antivirals (acyclovir; longer-acting famciclovir and valacyclovir more effective)
  • treatment of herpes zoster with corticosteroids DOES NOT decrease PHN
• surgical: spinal tractotomy, dorsal root entry zone lesion, DBS of thalamus

Painful Diabetic Neuropathy
• see Endocrinology, E13

Approach
• determine if pain is neuropathic or vascular
• more likely neuropathic if pain present at rest and improves with walking, pain is sharp/tingling, more in feet than calves

Treatment
• Level A: pregabalin
• Level B: venlafaxine, duloxetine, amitriptyline, gabapentin, valproate, rarely opioids, capsaicin

Complex Regional Pain Syndromes

Clinical Features
• presence of an initiating noxious event (MI, stroke)
• continuing pain, allodynia, or hyperalgesia with pain disproportionate to inciting event
• evidence during the course of symptoms of edema, changes in skin blood flow or abnormal vasomotor activity
• absence of conditions that would otherwise account for degree of pain and dysfunction
• other features can include edema, osteoporosis, hyperhidrosis, hair loss, fascial thickening

Classification
• CRPS type I (reflex sympathetic dystrophy): minor injuries of limb or lesions in remote body areas precede onset of symptoms
• CRPS type II (causalgia): injury of peripheral nerves precedes the onset of symptoms

Investigations
• trial of differential neural blockade may be helpful in diagnosis
• autonomic testing (evidence of sympathetic dysfunction)
• bone scan, plain radiography, MRI

Prevention
• early mobilization after injury/infarction

Treatment
• goal of treatment: to facilitate function
• conservative treatment: education, support groups, PT/OT, smoking cessation
• medical: topical capsaicin, TCA, NSAID, tender point injections with corticosteroid/lidocaine, gabapentin/pregabalin/lamotrigine, calcitonin or bisphosphonates, oral corticosteroids
• surgical: paravertebral sympathetic ganglion blockade
• refer to pain management clinic
Headache

• see Emergency Medicine, ER23 and Family Medicine, FM32

Clinical Approach

• history
  • pain characteristics: onset, frequency, duration, intensity, location, radiation, other specific features (e.g. worse in AM, worse with bending/cough/Valsalva)
  • associated symptoms: visual changes, change in mental status, nausea/vomiting, fever, meningismus, photophobia, phonophobia, TMJ popping/clicking, jaw claudication, neurological symptoms
  • precipitating/alloleviating factors (triggering factors, analgesics), medications (especially nitrates, CCBs, NSAIDs, anticoagulants), PMH, FHx
  • red flags (possible indications for CT scan/further investigation): new-onset headache (especially if age <5 or >50), quality worse/different than previous headaches, sudden and severe (‘thunderclap’), immunocompromised, fever, focal neurological deficits, trauma

• physical exam
  • vitals (including BP and temp), Kernig’s/Brudzinski’s, MSK examination of head and neck
  • HEENT: fundi (papilledema, retinal hemorrhages), red eye, temporal artery tenderness, sinus palpation, TMJ
  • full neurological exam (including LOC, orientation, pupils (symmetry), and focal neurological deficits)
  • red flags: papilledema, altered LOC, fever, meningismus, focal neurological deficits, signs of head trauma

Classification

• primary
  • tension, migraine, cluster, other autonomic cephalgias

• secondary
  • cervical OA, TMJ syndrome, SAH, ICH, stroke, venous sinus thrombosis, meningitis/encephalitis, trauma, increased ICP (space-occupying lesion, malignant HTN or pseudotumour cerebri), temporal arteritis, sinusitis, acute-angle closure glaucoma, pre- eclampsia, post LP, drugs/toxins (e.g. nitroglycerin use and analgesia withdrawal); all can be associated with serious morbidity or mortality

Table 21. Headaches – Selected Primary Types

<table>
<thead>
<tr>
<th></th>
<th>Tension-Type</th>
<th>Migraine</th>
<th>Cluster</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalence</td>
<td>70%</td>
<td>~10-20%</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Age of Onset</td>
<td>15-40</td>
<td>10-30</td>
<td>20-40</td>
</tr>
<tr>
<td>Sex Bias</td>
<td>F&gt;M</td>
<td>F&gt;M</td>
<td>M&gt;F</td>
</tr>
<tr>
<td>Family History</td>
<td>None</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Location</td>
<td>Bilateral frontal Nuchal-occipital</td>
<td>Unilateral &gt; bilateral Fronto-temporal</td>
<td>Retro-orbital</td>
</tr>
<tr>
<td>Duration</td>
<td>Minutes – days</td>
<td>Hours – days</td>
<td>10 min-2 h</td>
</tr>
<tr>
<td>Onset/Course</td>
<td>Gradual; worse in PM</td>
<td>Gradual; worse in PM</td>
<td>Daily attacks for weeks to months; more common early AM or late PM</td>
</tr>
<tr>
<td>Quality</td>
<td>Band-like; constant</td>
<td>Throbbing</td>
<td>Constant, aching, stabbing</td>
</tr>
<tr>
<td>Severity</td>
<td>Mild-moderate</td>
<td>Moderate-severe</td>
<td>Severe (wakes from sleep)</td>
</tr>
<tr>
<td>Triggers/Provoking</td>
<td>Depression Anxiety Noise Hunger Sleep deprivation</td>
<td>Nausea/vomiting Caffeine/alcohol Hunger Stress Sleep deprivation</td>
<td>Light EtOH</td>
</tr>
<tr>
<td>Palliating</td>
<td>Rest</td>
<td>Rest</td>
<td>Walking around</td>
</tr>
<tr>
<td>Associated Sx</td>
<td>No vomiting</td>
<td>Nausea/vomiting Photo/phonophobia Aura</td>
<td>Red watery eye Nasal congestion or rhinorrea Unilateral Horner’s</td>
</tr>
<tr>
<td>Management</td>
<td>Non-pharmaceutical Psychological counselling Physical modalities (e.g. heat, massage) Pharmacological Simple analgesics Tricyclic antidepressants</td>
<td>Acute Rx ASA NSAIDs Triptans Ergotamine Prophylaxis TCA Anticonvulsants Propranolol</td>
<td>Acute Rx O2 Sumatriptan (nasal or injection) Prophylaxis Verapamil Lithium Methysergide Prednisolone</td>
</tr>
</tbody>
</table>

Headache DDx

ER VISIT

Eye (acute angle closure glaucoma, sinusitis)

Recurrent/Chronic (migraine, tension, cluster, TMJ disease, cervical OA)

Vascular (SAH, ICH, temporal arteritis)

Infectious (meningitis, encephalitis)

Systemic (anemia, anoxia, CO, pre-eclampsia)

ICP (mass/abscess, HTN encephalopathy, pseudotumour cerebri)

Trauma (concussion, SDH, EDH)

Acute and Preventive Pharmacologic Treatment of Cluster Headache

Neurology 2010;75:463-473

Study: Meta-analysis of prospective, double-blind, RCTs of pharmacologic agents for prevention or treatment of CH

Results: 37 trials were included. Sumatriptan 6 mg SC, zolmitriptan nasal spray 5-10 mg, and 100% oxygen 6-12 L/min received Level A recommendation for acute treatment. For prevention, Level B recommendations were given for intranasal cromolyn 100 µg daily and subcutaneous steroid injections.

Conclusions: Sumatriptan, zolmitriptan, and mid flow oxygen are effective acute treatments for CH.

Antiepileptics in Migraine Prophylaxis: An Updated Cochrane Review

Cephalalgia 2015; 35:51-62

Purpose: To review the evidence for anticonvulsants in migraine prophylactics.

Study: Systematic meta-analysis of 37 published and 3 unpublished prospective, controlled trials of regular use of anticonvulsants to prevent migraines and or improve quality of life related to migraines.

Results: Sodium valproate and topiramate were associated with a reduction of 4 and 1 days of headache per month, respectively, and patients taking either drug were more than two times as likely to experience greater than 50% reduction in headache frequency, versus placebo. Neither drug was associated with undue rates of adverse events, though higher doses of topiramate were associated with increased adverse events. There is insufficient evidence of efficacy other antiepileptic drugs, including gabapentin, for migraine prophylaxis.

Conclusions: Daily sodium valproate 400 mg and topiramate 50 mg are well tolerated and effective in prophylactic treatment of migraine headache in adults.
Table 22. Prophylactic Management of Migraine Headaches

<table>
<thead>
<tr>
<th>Class</th>
<th>Drug</th>
<th>Evidence</th>
<th>Contraindications</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beta-blockers</td>
<td>Propranolol</td>
<td>A</td>
<td>Asthma, DM (mask hypoglycemia) CHF</td>
<td>Fatigue, Depression</td>
</tr>
<tr>
<td></td>
<td>Timolol</td>
<td>A</td>
<td>CHF</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metoprolol</td>
<td>B</td>
<td>CHF</td>
<td>Light-headedness</td>
</tr>
<tr>
<td>TCA</td>
<td>Amitriptyline</td>
<td>A</td>
<td>Heart disease, glaucoma “Avoid in elderly”</td>
<td>Sedation, Dry mouth, Weight gain, Light-headedness</td>
</tr>
<tr>
<td></td>
<td>Nortriptyline</td>
<td>C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCBs</td>
<td>Flunarizine</td>
<td>A</td>
<td>Depression, obesity</td>
<td>Weight gain, depression, PD (rare)</td>
</tr>
<tr>
<td></td>
<td>Verapamil</td>
<td>B</td>
<td>Heart disease</td>
<td>Weight gain (4.5-9 kg), constipation</td>
</tr>
<tr>
<td>AED</td>
<td>Valproate</td>
<td>A</td>
<td>Liver, renal, pancreatic disease</td>
<td>Weight gain, tremor, alopecia, teratogenic: neural tube defect</td>
</tr>
<tr>
<td></td>
<td>Topiramate + folic acid supplement</td>
<td>A</td>
<td>Renal disease</td>
<td>Paresthesia, weight loss, cognitive: memory loss, difficulty concentrating, renal stone (rare)</td>
</tr>
</tbody>
</table>

Table 23. Headaches – Selected Serious but Rare Secondary Types

<table>
<thead>
<tr>
<th>Meningeal Irritation</th>
<th>Increased ICP</th>
<th>Temporal Arteritis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age of Onset</td>
<td>Any age</td>
<td>Any age</td>
</tr>
<tr>
<td>Location</td>
<td>Generalized</td>
<td>Any location</td>
</tr>
<tr>
<td>Onset/Course</td>
<td>Meningitis: hours-days</td>
<td></td>
</tr>
<tr>
<td>SAH: thunderclap onset</td>
<td>Gradual; worse in AM</td>
<td>Variable</td>
</tr>
<tr>
<td>Severity</td>
<td>Severe</td>
<td>Severe</td>
</tr>
<tr>
<td>Provoking</td>
<td>Head movement</td>
<td>Lying down</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Associated Sx</td>
<td>Neck stiffness</td>
<td>N/V</td>
</tr>
<tr>
<td></td>
<td>Photophobia</td>
<td>Focal neuro symptoms</td>
</tr>
<tr>
<td></td>
<td>Focal deficits (e.g. CN palsies)</td>
<td>Decreased level of consciousness</td>
</tr>
<tr>
<td>Physical Signs</td>
<td>Kernig’s sign</td>
<td>Focal neuro symptoms</td>
</tr>
<tr>
<td></td>
<td>Brudzinski’s sign</td>
<td>Papilledema</td>
</tr>
<tr>
<td></td>
<td>Meningismus</td>
<td></td>
</tr>
<tr>
<td>Management</td>
<td>CT/MRI with gadolinium LP, antibiotics for bacterial meningitis</td>
<td>CT/MRI and treatment to reduce pressure</td>
</tr>
<tr>
<td></td>
<td></td>
<td>See Neurosurgery, NS4</td>
</tr>
<tr>
<td>Etiology</td>
<td>Meningitis, SAH</td>
<td>Tumour, IH, malignant HTN</td>
</tr>
</tbody>
</table>

IH = idiopathic intracranial HTN

Migraine Headaches

Definition (Common Migraine)
- ≥5 attacks fulfilling each of the following criteria
  - 4-72 h duration
  - 2 of the following: unilateral, pulsating, moderate-severe (interferes with daily activity), aggravated by routine physical activity
  - 1 of the following: nausea/vomiting, photophobia/phonophobia/osmophobia

Epidemiology
- 18% females, 6% males; frequency decreases with age (especially at menopause)

Etiology and Pathophysiology
- theories of migraine etiology
  - depolarizing wave of “cortical spreading depression” across the cerebral cortex that may cause an aura (e.g. visual symptoms due to wave through occipital cortex) and also activate trigeminal nerve afferent fibres
  - possible association with vasoconstriction/dilation
  - significant genetic contribution
- triggers: stress, sleep excess/deprivation, drugs (estrogen, nitroglycerin), hormonal changes, caffeine withdrawal, chocolate, tyramines (e.g. red wine), nitriles (e.g. processed meats)
Sleep Disorders

Signs and Symptoms
- stages of uncomplicated migraine
  1. prodrome (hours to days before headache onset)
  2. aura
  3. headache
  4. postdrome
- aura
  - fully reversible symptom of focal cerebral dysfunction lasting <60 min
  - examples: visual disturbance (fortification spectra – zigzags; scintillating scotomata – spots), unilateral paresthesia and numbness or weakness, aphasia
- prodrome/postdrome: appetite change, autonomic symptoms, altered mood, psychomotor agitation/retardation
- classification of migraines
  - common migraine: no aura
  - classic migraine: with aura (headache follows reversible aura within 60 min)
  - complicated migraine: with severe/persistent sensorimotor deficits
    - examples: basilar-type migraine (occipital headache with diplopia, vertigo, ataxia, and altered level of consciousness), hemiplegic/hemisensory migraine, ophthalmoplegic migraine
  - acephalgic migraine (i.e. migraine equivalent): aura without headache

Treatment
- avoid triggers
- mild to moderate migraine
  - 1st line: NSAIDs (ibuprofen, naproxen)
  - moderate to severe migraine
    - triptans (most effective), ergots (dihydroergotamine, DHE)
    - migraine prophylaxis: antimigrainous (divalproex, topiramate, gabapentin), TCA (amitriptyline, nortriptyline), propranolol, calcium channel blocker (verapamil)

Overview of Sleep

Definition
- newborn: 18 h sleep (50% REM), adolescents: 10 h, adults: 7-9 h but most get insufficient amounts
- many elderly have reduced sleep as a consequence of underlying sleep disorders

Sleep Architecture
- polysomnogram (PSG) measures: EEG, eye movements (electro-oculogram – EOG), EMG, respiratory effort, oxygenation, ECG

Table 24. Sleep Stage Characteristics

<table>
<thead>
<tr>
<th>Stage</th>
<th>EEG</th>
<th>EOG</th>
<th>Muscle Tone</th>
<th>Other Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Waking State</td>
<td>Alpha waves: high frequency (8-12 Hz), low voltage</td>
<td>Rapid, blinking</td>
<td>High</td>
<td></td>
</tr>
<tr>
<td>Stage N1 (~5%)</td>
<td>Less than 50% Alpha waves (see above), mixed with slow wave activity</td>
<td>Slow, roving eye movements</td>
<td>High, but gradually dropping</td>
<td>Marker for very light quality sleep or sleep disruption</td>
</tr>
<tr>
<td>Stage N2 (~50%)</td>
<td>K complexes (high voltage negative and positive discharges) with sleep spindles (11-16 Hz)</td>
<td>Still</td>
<td>High</td>
<td></td>
</tr>
<tr>
<td>Stage N3 (previously 3 and 4)/Slow Wave/ Delta Sleep (~20%)</td>
<td>Delta waves: low frequency (&lt;2 Hz), high voltage (&gt; 75 μV)</td>
<td>Still</td>
<td>Low</td>
<td>Homeostatic sleep Reduced BP, HR, cardiac output, RR Growth hormone release</td>
</tr>
<tr>
<td>Rapid Eye Movement (REM) Sleep (~25%)</td>
<td>Sawtooth waves, mixed frequency, low voltage</td>
<td>Rapid eye movements</td>
<td>Very low</td>
<td>Irregular respiration Arrhythmias, heart rate variation Classical dreaming state</td>
</tr>
</tbody>
</table>
Disturbances of Alertness and Sleep

Coma
- see Neurosurgery, NS33

Insomnia
- definition/criteria
  - difficulty initiating or maintaining sleep, or waking up earlier than desired (leading to sleep that is chronically non-restorative/poor quality) despite adequate opportunity and circumstances for sleep
- types
  - sleep state misperception, psychophysiological insomnia (learned sleep-preventing associations – i.e. clock watching), fatal familial insomnia (rare prion protein mutation causing autonomic dysfunction), idiopathic (life-long difficulty)
  - secondary causes:
    - psychiatric disorders (80% of psychiatric patients): anxiety and depression (see Psychiatry, PS27)
    - neurologic disorders: neurodegenerative disease, epilepsy, neuromuscular disorders, many others
    - sleep disorders: restless legs syndrome (sleep initiation difficulties), sleep apnea (sleep maintenance difficulties)
    - medical conditions: pregnancy, cardiorespiratory (COPD/HF), GERD, pain (arthritis, fibromyalgia, cancer)
    - drugs/toxins: caffeine, alcohol, stimulants, antidepressants, glucocorticoids, sedative withdrawal
- treatment
  - sleep log, sleep hygiene, stimulus control, sleep restriction, relaxation response, CBT

Sleep Apnea
- definition
  - disorder of breathing in sleep associated with sleep disruption and consequent excessive somnolence (or drowsiness)
- epidemiology
  - >2-4% of the population
  - correlated with obesity
  - significant morbidity: HTN, stroke, heart failure, sleepiness, mortality (accidents)
- types
  - obstructive sleep apnea
  - central sleep apnea: no effort to breath over 10 s
  - mixed apnea: starts as central, but eventually becomes obstructive
- etiology of central apnea: heart failure, opiates, brainstem pathology, myotonic dystrophy
- etiology of obstructive apnea: collapse of airway due to low muscle tone in deep and REM sleep
- diagnosis: apnea hypopnea index (AHI) or respiratory disturbance index (RDI) should be <5 in the normal state
- treatment: conservative measures, dental devices, CPAP (common), surgery (rare), ensure driving safety

Restless Leg Syndrome (RLS) and Periodic Limb Movement in Sleep (PLMS)
- definition
  - urge to move accompanied by uncomfortable sensations that begin or worsen with rest, are partially or totally relieved with movement, and are worse in evening/night; these features cannot be accounted for by another medical/behavioural condition
  - RLS refers to sensation
  - PLMS refers to the manifestation
- epidemiology: 10% North Americans, 90% of RLS have PLMS, 50% of patients with PLMS have RLS
- etiology: central (spasticity), peripheral nervous system (radiculopathy, neuropathy), pregnancy, iron deficiency, alcohol use
- treatment
  - underlying contributors (iron and B12 supplementation), dopaminergic agonists (first line), clonazepam (causes tachyphylaxis), opioids (only exceptional circumstances)
  - NOT recommended: levodopa/carbidopa (Sinemet®), causes augmentation

Narcolepsy
- definition/clinical features: excessive daytime sleepiness (all narcolepsy), cataplexy = loss of muscle tone with emotional stimuli (pathognomonic), sleep paralysis (unable to move upon wakening), hypnagogic hallucinations (vivid dreams or hallucinations at sleep onset)
- epidemiology: prevalence 1:2,000, onset in adolescence/early adulthood; life-long disorder
- etiology: presumed autoimmune attack on orexin/hypocretin system, post head injury, MS, hypothalamic tumours; rarely familial
- diagnosis: based on clinical history + multiple sleep latency test findings of short sleep latency <8 min and REM within 15 min of sleep onset on 2/4 naps
- treatment
  - sleep hygine and scheduled brief naps, restricted driving
  - alerting agents: modafinil (non-amphetamine stimulant), stimulant (i.e. methylphenidate)
  - antipataplectic: TCAs, SSRIs, sodium oxybate

Drug Effects on Wakefulness and Sleep
- Antihistamines associated with increased sleepiness
- Stimulants increase arousal
- Caffeine (an adenosine antagonist) increases wakefulness
- Benzodiazepines reduce slow wave sleep
- Antidepressants (TCA/MAO/SSRI) reduce REM, prolong REM latency
- Alcohol may hasten sleep onset but associated with increased arousals

Avoid sleep medications (especially in elderly patients) due to increased risk of falls, pseudodepression, and memory loss
Parasomnias
- **definition/clinical features:** unusual behaviours in sleep with clinical features appropriate to stage of sleep
- **etiology:** in elderly, REM sleep behaviour disorder may be associated with PD; in children, slow wave sleep arousals (sleep walking) may be associated with sleep disordered breathing
- **diagnosis:** clinical history in children, polysomnography in adults to exclude nocturnal seizures
- **treatment:** behavioural management (safety, adequate sleep); clonazepam for REM sleep behaviour, tonsillectomy if appropriate in children

Circadian Rhythm
- **definition/clinical features:** abnormalities based on time of day rather than sleep (i.e. jet lag, shift work)
- **diagnosis:** clinical history

CNS Infections
- see *Infectious Diseases, ID18*

Spinal Cord Syndromes
- see *Neurosurgery, NS27*

Stroke

Terminology
- **stroke:** sudden onset of neurological deficits of a vascular basis with infarction of CNS tissue
  - infarction is permanent tissue injury (confirmed by neuroimaging)
  - **TIA:** sudden onset of neurological deficits of a vascular basis without infarction (i.e. no imaging evidence of stroke)
  - may present with amaurosis fugax (transient monocular painless vision loss)

Pathophysiology
- two major types: ischemic (~80%) and hemorrhagic (~20%)

1. Ischemic
   - **arterial thrombosis:** thrombus formation in artery (local/in situ)
     - large vessel: stenosis or occlusion of the internal carotid artery, vertebral, or intracranial arteries
       - mechanism: insufficient blood flow beyond lesion (hemodynamic stroke)
       - underlying processes: atherosclerosis (most common cause), dissection, and vasculitis
     - small vessel/lacunar
       - mechanism: chronic HTN and DM cause vessel wall thickening and decreased luminal diameter
       - affects mainly small penetrating arteries (primarily basal ganglia, internal capsule, and thalamus)
   - cardioembolic: blockage of cerebral arterial blood flow due to particles originating from a cardiac source
     - atrial fibrillation (most common), rheumatic valve disease, prosthetic heart valves, recent MI, fibrous and infectious endocarditis
     - systemic hypoperfusion (global cerebral ischemia)
   - inadequate blood flow to brain, usually secondary to cardiac pump failure (e.g. cardiac arrest, arrhythmia, or MI)
     - primarily affects watershed areas (between the major cerebral arterial territories)

2. Hemorrhagic
   - intracerebral hemorrhage
     - mechanisms
       - hypertensive (most common): rupture of small microaneurysms (Charcot-Bouchard aneurysms) causing intraparenchymal hemorrhage; most common sites: putamen, thalamus, cerebellum, and pons
       - other: trauma, amyloid angiopathy (associated with lobar hemorrhage), vascular malformations, vasculitis, drug use (cocaine or amphetamines)
   - subarachnoid hemorrhage see *Neurosurgery, NS17*

Hypertension Encephalopathy
- Acute severe HTN (typically dBP >130 or sBP >200) can cause hypertensive encephalopathy – abnormal fundoscopic exam (papilledema, hemorrhages, exudates, cotton-wool spots), focal neurologic symptoms, N/V, visual disturbances, and change in LOC

Consider transfer of acute stroke patient to a designated stroke centre for neuroprotective or thrombolytic therapy if the patient is seen in first few hours

Cerebral venous sinus thrombosis should be considered in the differential diagnosis of stroke and headache. It is an uncommon cause of either, but is associated with high morbidity and mortality. Patients often present with headache alone, but can also have seizures, focal neurological deficits, or cranial nerve palsies. This is diagnosed with MRV or CTV. Treatment is typically anticoagulation with heparin initially, then transition to warfarin

20-40% of patients with ischemic stroke may develop hemorrhagic transformation within 1 wk after the initial infarction

Blood work should only delay treatment if patient is on anticoagulants, low platelet count suspected, abnormal electrolytes suspected, or any bleeding abnormality suspected
Stroke Syndromes According to Vascular Territory

- **ACA**: contralateral leg paresis, sensory loss, cognitive deficits (e.g. apathy, confusion, and poor judgment)
- **MCA**: proximal occlusion involves:
  1. contralateral weakness and sensory loss of face and arm
  2. cortical sensory loss
  3. may have contralateral homonymous hemianopia or quadrantanopia
  4. if dominant (usually left) hemisphere: aphasia
  5. if non-dominant (usually right) hemisphere: neglect
  6. eye deviation towards the side of the lesion and away from the weak side
- **PCA**
  1. contralateral hemianopia or quadrantanopia
  2. midbrain findings: CN III and IV palsy/pupillary changes, hemiparesis
  3. thalamic findings: sensory loss, amnesia, decreased level of consciousness
  4. if bilateral: cortical blindness or prosopagnosia
  5. hemiballismus
- **basilar artery**
  - proximal (usually thrombosis): impaired EOM, vertical nystagmus, reactive miosis, hemi- or quadriplegia, dysarthria, locked-in syndrome, coma
  - distal (usually embolic, i.e. top of the basilar syndrome): somnolence, memory and behaviour abnormalities, oculomotor deficit
- **PICA (lateral medullary or Wallenberg syndrome)**: ipsilateral ataxia, ipsilateral Horner’s, ipsilateral facial sensory loss, contralateral limb impairment of pain and temperature sensation, nystagmus, vertigo, nausea/vomiting, dysphagia, dysarthria, hiccup
- **medial medullary infarct** (anterior spinal artery, which can be associated with anterior cord infarct): contralateral hemisensory loss (facial sensory loss, contralateral limb impairment of pain and temperature sensation), nystagmus, peripheral facial weakness
- **lacunar infarcts** (deep hemispheric white matter; involving deep penetrating arteries of MCA, circle of Willis, basilar, and vertebral arteries)
  - pure motor hemiparesis (posterior limb of internal capsule): contralateral arm, leg, and face
  - pure sensory loss (ventral thalamic): hemisensory loss
  - ataxic hemiparesis (ventral pons or internal capsule): ipsilateral ataxia and leg paresis
  - dysarthria-clumsy hand syndrome (ventral pons or genu of internal capsule): dysarthria, facial weakness, dysphagia, mild hand weakness and clumsiness

---

**Figure 25. Vascular territories**

---

**Scale (NIHSS)**

The National Institute of Health Stroke Scale (NIHSS) is a standardized clinical examination that determines the severity of an acute stroke; it can also be used to monitor response to treatment over time. The scale uses 11 items that evaluate:

- Level of consciousness
- Visual system
- Motor system
- Sensory system
- Language abilities

Scoring (x/42):

- 0 = no stroke
- 1-4 = mild stroke
- 5-15 = moderate stroke
- 16-20 = moderate to severe stroke
- 21-24 = severe stroke

rtPA is typically considered if score ≥6, but some stroke neurologists will administer rtPA with lower NIH stroke scale scores.
Assessment and Treatment of Ischemic Stroke

General Assessment
- ABCs, full vital sign monitoring, capillary glucose (Accu-Chek®), urgent CODE STROKE if <4.5 h from symptom onset (for possible thrombolysis)
- level of consciousness (knows age, month, obeys commands), dysarthria, dysnomia (cannot name objects)
- gaze preference, visual fields, facial palsy
- arm drift, leg weakness, ataxia
- sensation to pinprick, extinction/neglect
- history
  - onset: time when last known to be awake and symptom free
  - mimics to rule out: seizure/post-ictal, hypoglycemia, migraine, conversion disorder
- investigations
  - non-contrast CT head (STAT): to rule out hemorrhage and assess extent of infarct
  - ECG: to rule out atrial fibrillation (cardioembolic cause)
  - carotid dopplers, echocardiogram
  - CBC, electrolytes, creatinine, PTT/INR, blood glucose, lipid profile
- imaging (i.e. CT ± MR or CT angiography) signs of stroke
  - loss of cortical white-grey differentiation
  - sulcal effacement (i.e. mass effect decreases visualization of sulci)
  - hypodensity of parenchyma
  - intracranial ribbon sign
  - hyperdense MCA sign

ACUTE STROKE MANAGEMENT

1. Thrombolysis
- rtPA (recombinant tissue plasminogen activator)
  - given within 4.5 h of acute ischemic stroke onset provided there are clinical indications and no contraindications to use
  - indications and contraindications (see sidebar)

2. Anti-Platelet Therapy
- give at presentation of TIA or stroke if rtPA not received
- antiplatelet agents
  - ASA: recommended dose 81 mg chewed
  - if patient intolerant to ASA, use other antiplatelet agent (i.e. clopidogrel)

3. Acute Anti-Coagulant Therapy
- for patients with TIA or stroke and atrial fibrillation, if rtPA not received:
  - recommend IV heparin (or ensuring INR between 2-3 if already anticoagulated on warfarin)
  - may delay initiation of oral anticoagulation depending on size of infarct and presence of petechial/frank hemorrhage

4. Intra-arterial Thrombectomy by Interventional Radiology
- early thrombectomy improves outcomes in ischemic stroke with large artery occlusions of the proximal anterior circulation

Other Acute Management Issues
- avoid hyperglycemia which can increase the infarct size
- lower temperature if febrile (febrile stroke: think septic emboli from endocarditis)
- prevent complications
  - NPO if dysphagia (to be reassessed by SLP)
  - DVT prophylaxis if bed-bound
  - initiate rehabilitation early

Blood Pressure Control
- do NOT lower the blood pressure unless the HTN is severe
- antihypertensive therapy is withheld for 48-72 hr (permisive hypertension) after thromboembolic stroke unless SBP >220 mmHg or DBP >120 mmHg, or in the setting of acute MI, renal failure, aortic dissection (IV labetalol first-line if needed)
- acutely elevated BP is necessary to maintain brain perfusion to the ischemic penumbra
- most patients with an acute cerebral infarct are initially hypertensive and their BP will fall spontaneously within 1-2 d

Etiological Diagnosis
- further investigations
  - additional neuroimaging (MRI)
  - vascular imaging: CTA/MRA/carotid dopplers
  - cardiac tests: echocardiogram, Holter monitoring
  - correct etiological diagnosis is critical for appropriate secondary prevention strategies

Aspect Score: 10-point quantitative score to assess ischemic changes on CT scan
- 10/10 is normal and <4/10 signifies high risk of bleed with rtPA
- Subtract 1 point for each of following structures if abnormal within the ischemic hemisphere: caudate, lentiform, insula, internal capsule, MCA 1, 2, 3, 4, 5, 6 regions

If rtPA given at stroke onset, delay acute antiplatelet/anticoagulation treatment by 24 h

Absolute Contraindications to rtPA
- NPO if dysphagia (to be reassessed by SLP)
- DVT prophylaxis if bed-bound
- initiate rehabilitation early

Factor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Cochrane DB Syst Rev, 2014;100(100980)
Purpose: To review the evidence comparing factor Xa inhibitors with vitamin K antagonists for prevention of embolic events in patients with atrial fibrillation.
Study: Systematic review search 1950-2011, inclusive. Results included 10 RCTs, 42,984 patients, follow-up for 12 weeks to 1.9 years.
Outcome: Stroke (hemorrhagic or ischemic) and non-CNS embolic event.
Results: Factor Xa inhibitor treatment resulted in significantly fewer embolic events than dose adjusted warfarin treatment (HR 0.91; 95% CI 0.87-0.94). There was no significant difference in rate of major bleeds between factor Xa inhibitors and warfarin treatment. Furthermore, factor Xa inhibitors resulted in significantly fewer intracranial bleeds and lower all-cause mortality.
Conclusions: Use of factor Xa inhibitors for anti-coagulation in patients with atrial fibrillation offered better protection against embolic events than warfarin. Factor Xa inhibitors also had equal or lower rates of adverse events.

High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
- NEJM, 2012;367:1495-1503
Method: Multicentre double-blind RCT.
Population: 4,731 patients with stroke or TIA within 1-6 months before study entry, LDL 100-190 mg/dL, no coronary heart disease.
Intervention: 80 mg atorvastatin PO OD or placebo.
Outcome: First non-fatal or fatal stroke over 5 yr. Results: Patients receiving atorvastatin had a lower rate of stroke (HR 0.29, 95% CI 0.21-0.38, p<0.001). There was a 15-year absolute reduction in risk of 5.3% (p<0.002). There was no significant change in mortality rate, but a small significant increase in the risk of hemorrhagic stroke.
Conclusions: High-dose atorvastatin decreases overall incidence of strokes and cardiovascular events in patients with a history of recent stroke or TIA.

Evaluating for Occlux Atrial Fibrillation – CRYSTAL AF Trial
Patients with a cryptogenic ischemic stroke or TIA and no evidence of atrial fibrillation on 24h and Holter monitoring may benefit from ambulatory cardiac monitoring with subcutaneous implantable loop recorder or external loop recorder for several weeks.
Primary and Secondary Prevention of Ischemic Stroke

**Anti-Platelet Therapy**
- **primary prevention**
  - no firm evidence for a protective role for antiplatelet agents for low-risk patients without a prior stroke/TIA

- **secondary prevention**
  - initial choice: ASA
  - if cerebrovascular symptoms while on ASA or if unable to tolerate ASA: Aggrenox® (ESPRIT trial), clopidogrel (CAPRIE trial)

**Carotid Stenosis**
- **primary prevention (asymptomatic)**
  - carotid endarterectomy is controversial; if stenosis >60%, risk of stroke is 2% per yr; carotid endarterectomy reduces the risk of stroke by 1% per yr (but 5% risk of complications)

- **secondary prevention (previous stroke/TIA in carotid territory)**
  - carotid endarterectomy clearly benefits those with symptomatic severe stenosis (70-99%), and is less beneficial for those with symptomatic moderate stenosis (50-69%) (NASCET trial), see Vascular Surgery. VS7

- according to the CREST trial, endarterectomy and carotid stenting have similar benefits in a composite endpoint of reduction of stroke, MI, and death; however, in the periprocedural period, stenting results in a higher rate of stroke, while endarterectomy results in a higher rate of MI

**Atrial Fibrillation**
- **primary and secondary prevention with anticoagulation**
  - classical risk stratification used CHADS2 score (0-6), but Stroke 2014 guidelines recommend that virtually all patients with atrial fibrillation without contraindication be anticoagulated
  - low risk, 1.9% annual stroke risk; antiplalet
  - intermediate risk, 2.8% annual stroke risk; anticoagulant or antiplatelet – patient specific decision
  - high risk, 4-18.2% annual stroke risk; anticoagulant

- **anticoagulation therapy**
  - warfarin (titrate to INR 2-3)
  - dabigatran (110 or 150 mg PO bid), apixaban (2.5 or 5 mg PO bid) or rivaroxaban (15 or 20 mg PO daily) may be alternatives to warfarin, but should be used cautiously; Praxbind reversal agent for dagibatran if necessary

**Hypertension**
- **primary prevention**
  - targets: BP <140/90 (or <130/80 for diabetics or renal disease); high risk but without diabetes, target SBP <120 (SPRINT trial)
  - ACEI: ramipril 10 mg PO OD is effective in patients at high risk for cardiovascular disease (HOPE trial)

- **secondary prevention**
  - ACEI and thiazide diuretics are recommended in patients with previous stroke/TIA (PROGRESS trial)

**Hypercholesterolemia**
- **primary prevention**
  - statins in patients with CAD or at high risk for cardiovascular events, even with normal cholesterol (CARE trial)

- **secondary prevention**
  - statins – high dose atorvastatin (SPARCL trial) but lower doses may be more appropriate if patient cannot tolerate high dose

**Diabetes**
- ideal management: HbA1c <7%, fasting blood glucose between 4 and 7

**Smoking**
- **primary prevention**: smoking increases risk of stroke in a dose-dependent manner

- **secondary prevention**: after smoking cessation, the risk of stroke decreases to baseline within 2-5 yr

**Physical Activity**
- beneficial effect of regular physical activity has a dose-related response in terms of intensity and duration of activity

**Stroke Rehabilitation**
- individualized based on severity and nature of impairment; may require inpatient program and continuation through home care or outpatient services

- multidisciplinary approach includes dysphagia assessment and dietary modifications, communication rehabilitation, cognitive and psychological assessments including screen for depression, therapeutic exercise programs, assessment of ambulation and evaluation of need for assistive devices, splints or braces, vocational rehabilitation
Cerebral Hemorrhage

- definition: intracranial bleeding into brain tissue
- etiology: head trauma, hemorrhagic stroke

Investigations

- general investigations: see Assessment and Treatment of Ischemic Stroke, N50
- further investigations
  - LP (if suspect subarachnoid hemorrhage despite negative CT)
  - may require cerebral angiogram if suspect aneurysm or AVM
  - if typical location for hypertensive hemorrhage, repeat CT head in 4-6 wk after hemorrhage has resolved to rule out an underlying lesion

Treatment

- medical
  - anti-hypertensives: no conclusive BP target ranges for managing ICH exist; 2010 AHA/ASA guidelines suggest that reducing sBP to as low as 140 mmHg with IV anti-hypertensives is safe and appropriate management (target sBP 140-160 systolic)
  - ICP lowering medical management (if necessary): see Neurosurgery, NS20
  - surgical: see Neurosurgery, NS20

Neurocutaneous Syndromes

- see Pediatrics, P84

Multiple Sclerosis

Definition

- a chronic inflammatory disease of the CNS characterized by relapsing remitting, or progressive neurologic symptoms due to inflammation, demyelination, and axonal degeneration

Clinical Patterns of MS

- relapsing remitting (RRMS) 85%, primary progressive (PPMS) 10%, progressive relapsing (PRMS) 5%, secondary progressive (SPMS)
- benign MS (BMS): retrospective diagnosis made after 15 years of mild disease, with no evidence of worsening (in functional ability and MRI)
- most RRMS goes on to become SPMS

MS Variants

- Devic’s = neuromyelitis optica (NMO): severe optic neuritis and extensive transverse myelitis extending >3 vertebral segments (NMO antibody positive)
- clinically isolated syndrome (CIS): single MS-like episode, which may progress to MS
- tumefactive MS: solitary lesion >2 cm mimicking neoplasms on MRI
- fulminant MS (Marburg): rapidly progressive and fatal MS associated with severe axonal damage, inflammation, and necrosis
- pediatric MS: onset of MS before the age of 18
  - epidemiology: rare (1.35-2.5 per 100,000 children)
  - presentation: more likely to present with isolated optic neuritis, isolated brainstem syndrome or symptoms of encephalopathy compared to adults
  - course: 98% have RRMS
  - diagnosis and treatment similar to adult MS
  - differential diagnosis: in the setting of nonspecific CSF abnormalities and MRI evidence of white matter lesion, rule out ADEM, optic neuritis, transverse myelitis, neuromyelitis optica, CNS malignancies, leukodystrophies, and mitochondrial disease
  - acute disseminated encephalomyelitis (ADEM): monophasic demyelinating disorder with multifocal neurologic symptoms seen mainly in children often following infection or vaccination

Etiology

- genetic
  - polygenetic: the HLA-DRB1 gene has been demonstrated to be a genetically susceptible area
  - 30% concordance for monozygotic twins, 2-4% risk in offspring of affected mother or father
- environmental
  - MS is more common in regions with less sun exposure and lower stores of vitamin D (Europe, Canada, US, New Zealand, SE Australia)
  - MS has also been linked to certain viruses (EBV is associated with MS)

ACE Inhibitor in Stroke Prevention – HOPE Trial

- study: Randomized, blinded, placebo-controlled trial. Mean follow-up 5 yr.
- patients: 9,297 patients ≥55 yr (mean age 68 yr, 73% men) who had evidence of vascular disease or DM plus one other cardiovascular risk factor and who were not known to have a low ejection fraction or heart failure.
- intervention: Ramipril 10 mg daily orally vs. matching placebo.
- main outcomes: Stroke, MI, or death from cardiovascular causes.
- results: Outcome
  - RR (95% CI) MNT (CI)
  - Stroke 32% (16-44) 67 (43-145)
  - MI, stroke, or CV mortality 22% (14-30) 26 (19-43)
- all-cause mortality: 16% (5-25) 56 (32-195)
- treatment with ramipril reduced the risk of stroke (2.4% vs. 4.9%, RR 0.68, p ≤ 0.001).
- conclusions: In adults at high risk for cardiovascular events, ramipril reduced the risk of stroke, as well as other vascular events and overall mortality. In addition, ACEI reduce risk of stroke beyond their hypertensive effect.
Epidemiology
- onset 17-35 yr; F:M = 3:1
- PPMS occurs in an older population with F=M

Diagnosis for RRMS
- demonstration of both dissemination in time and space based on the revised McDonald criteria (2010)
- dissemination in time: 2 or more attacks, simultaneous presence of asymptomatic gadolinium-enhancing and non-enhancing MRI lesions at any time, or a new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI
- dissemination in space: ≥2 T2 lesions on MRI in at least 2 of the 4 CNS regions (periventricular, juxtacortical, infratentorial, or spinal cord) or developing a second attack that implicates a different CNS region

Clinical Features
- symptoms include numbness, visual disturbance (optic neuritis), weakness, spasticity, diplopia (e.g. INO), impaired gait, vertigo, bladder dysfunction
- Lhermitte's sign: flexion of neck causes electric shock sensation down back into limbs indicating cervical cord lesion
- Uhthoff’s phenomenon: worsening of symptoms (classically optic neuritis) in heat
- SPMS: classically weakness of legs in pyramidal distribution paired with cerebellar findings of arms (i.e. intention tremor)
- symptoms not commonly found in MS: visual field defects, aphasia, apraxia, progressive hemiparesis
- relapse: acute/subacute onset of clinical dysfunction that peaks from days to weeks, followed by remission with variable symptom resolution (symptoms must last at least 24 h)
- in RRMS, average 0.4 to 0.6 relapses/yr, but higher disease activity in 1st yr of disease

Investigations
- MRI: demyelinating plaques appear as hyperintense lesions on T2 weighted MRI, with active lesions showing enhancement with gadolinium
- typical locations: periventricular, corpus callosum, cerebellar peduncles, brainstem, juxtacortical region, and dorsolateral spinal cord
- Dawson's fingers: periventricular lesions extending into corpus callosum
- cranial MRI is more sensitive than spinal MRI
- CSF: oligoclonal bands in 90%, increased IgG concentration
- evoked potentials (visual/auditory/somatosensory): delayed but well-preserved wave forms

Treatment
- acute treatment: methylprednisolone 1,000 mg IV daily x 3-7 d (no taper required); if poor response to corticosteroids may consider plasma exchange
- disease modifying therapy (DMT)
  - goals: decrease relapse rate, decrease progression of disability, slow accumulation of MRI lesions
  - first line: teriflunomide, interferon-β (injection: Betaseron®, Avonex®, Rebif®), glatiramer acetate (injection: Copaxone®), BG-12 (Tecfidera®)
  - second line: natalizumab (Tysabri®) (monthly IV infusion, fingolimod (Gilenya®)
  - increased risk of progressive multifocal leukoencephalopathy (PML)
  - CIS: early treatment with interferons may delay potential second attack
  - RRMS: DMT reduces rate of relapse by about 30%
  - PPMS/SPMS: no proven efficacy of DMTs
- symptomatic treatment
  - spasticity: baclofen, tizanidine, dantrolene, benzodiazepine, butalbital toxin
  - bladder dysfunction: oxybutynin
  - pain: TCA, carbamazepine, gabapentin
  - fatigue: amantadine, modafinil, methylphenidate
  - depression: antidepressant, lithium
  - constipation: high fibre intake, stool softener, laxatives
  - sexual dysfunction: sildenafil (Viagra®), tadalafil (Cialis®), vardenafil (Levitra®, Staxyn®)
- education and counselling: MS Society, support groups, psychosocial issues

Prognosis
- good prognostic indicators: female, young, RRMS, presenting with optic neuritis, low burden of disease on initial MRI, low rate of relapse early in disease
- PPMS: poor prognosis, higher rates of disability; poor response to therapy
# Common Medications

## Table 25. Common Medications – Major Issues

<table>
<thead>
<tr>
<th>Indications</th>
<th>Mechanism of Action/Class</th>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parkinson’s Disease</td>
<td>Dopamine precursor</td>
<td>levodopa +</td>
<td>Sinemet®</td>
<td>Carbidopa 25 mg/levodopa 100 mg PO tid Maximum 200 mg carbidopa and 2,000 mg levodopa per day</td>
<td>Narrow-angle glaucoma, use of MAO inhibitor in last 14 d, history of melanoma or undiagnosed skin lesions</td>
<td>Nausea, hypotension, hallucinations, dyskinesias in last 14 d, history of melanoma or undiagnosed skin lesions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>carbidopa</td>
<td></td>
<td>1.25 mg PO bid, increase by 2.5 mg/d q2-4wk, up to 10-30 mg PO tid</td>
<td>Concomitant use of potent inhibitors of CYP3A4, uncontrolled HTN, ischemic heart disease, peripheral vascular disease; caution with renal or hepatic disease</td>
<td>Hypotension, N/V, diziness, constipation, diarrhea, abdominal cramps, H/A, nasal congestion, drowsiness, hallucinations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>selegiline</td>
<td>Eldepryl®</td>
<td>5 mg PO bid</td>
<td>Concomitant use of meperidine or tricyclic antidepressants</td>
<td>H/A, insomnia, diziness, nausea, dry mouth, hallucinations, confusion, orthostatic hypotension, increased akinesia, risk of hypertensive crisis with tyramine-containing foods</td>
</tr>
<tr>
<td>Myasthenia Gravis</td>
<td>Acetylcholinesterase inhibitor</td>
<td>pyridostigmine</td>
<td>Mestinon®</td>
<td>600 mg/d PO divided in 5-6 doses Range 60-1,500 mg/d</td>
<td>GI or GU obstruction</td>
<td>Nausea, vomiting, diarrhea, abdominal cramps, increased peristalsis, increased salivation, increased bronchial secretions, miosis, diaphoresis, muscle cramps, fasciculations, muscle weakness</td>
</tr>
<tr>
<td>Acute Migraine</td>
<td>Triptan (selective 5-hydroxytryptamine receptor agonist)</td>
<td>sumatriptan</td>
<td>Imitrex®</td>
<td>25-100 mg PO pm, maximum 200 mg/d</td>
<td>Hemiplegic/basilar migraine, ischemic heart disease, CVD, uncontrolled HTN, use of ergotamine/5-HT1D agonist in past 24 h, use of MAO inhibitor in last 14 d, severe hepatic disease</td>
<td>Vertigo, chest pain, flushing, sensation of heat, hypertensive crisis, peripheral vascular disease, coronary artery vasospasm, cardiac arrest, nausea, vomiting, H/A, hyposalivation, fatigue</td>
</tr>
<tr>
<td></td>
<td>Ergot (5-HT1D receptor agonist)</td>
<td>dihydroergotamine</td>
<td>Migranal®</td>
<td>Nasal spray 0.5 mg/spray, maximum 4 sprays/d</td>
<td>Hemiplegic/basilar migraine, high-dose ASA therapy, uncontrolled HTN, ischemic heart disease, peripheral vascular disease, severe hepatic or renal dysfunction, use of triptans in last 24 h, use of MAO inhibitors in last 14 d</td>
<td>Coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, ventricular fibrillation; may cause significant rebound H/A</td>
</tr>
<tr>
<td>Migraine Prophylaxis</td>
<td>Anticonvulsant</td>
<td>topiramate</td>
<td>Topamax®</td>
<td>25 mg OD PO (in evening); may increase weekly by 25 mg/d to a max 50 mg bid</td>
<td>Uncompensated CHF, severe bradycardia or heart block, severe COPD or asthma</td>
<td>Sedation, mood disturbance, cognitive dysfunction, anorexia, nausea, diarrhea, paresthesias, metabolic acidosis, glycosuria, SJS/TEN</td>
</tr>
<tr>
<td></td>
<td>β-blocker</td>
<td>propranolol</td>
<td>Inderal®</td>
<td>80 mg/d divided every 6-8 h; increase by 20-40 mg/dose every 3-4 wk to max 160-240 mg/d in divided doses q8-6h</td>
<td>Fatigue, cognitive dysfunction, disturbed sleep, rashes, dyspepsia, dry eyes, heart failure, bronchospasm, risk of acute tachycardia and HTN if withdrawal</td>
<td>Drowsiness, H/A, unsteadiness, diziness, N/V, skin rash, agranulocytosis/aplastic anemia (rare)</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>Anticonvulsant for partial ± 2º generalization, generalized tonic-clonic</td>
<td>carbamazepine</td>
<td>Tegretol®</td>
<td>Start at 100-200 mg PO OD-tid, increase by 200 mg/d up to 800-1,200 mg/d</td>
<td>History of bone marrow depression, hepatic disease, hypersensitivity to the drug, use of MAO inhibitor in last 14 d</td>
<td>Hypersensitivity, pregnancy, breastfeeding; caution with P-450 interactions</td>
</tr>
<tr>
<td></td>
<td>Anticonvulsant for partial, tonic-clonic, status epilepticus</td>
<td>phenytoin</td>
<td>Dilantin®</td>
<td>100 mg PO tid, maintenance dose up to 200 mg PO tid SE: 10-15 mg/kg IV loading dose then maintenance doses of 100 mg PO or IV q6-8h</td>
<td>Hypersensitivity, pregnancy, breastfeeding; caution with P-450 interactions</td>
<td>Hypotension, SJS/TEN, SLE-type symptoms, gingival hypertrophy, peripheral neuropathy, H/A, blood dyscrasias, nystagmus, N/V, constipation, sedation, teratogenicity</td>
</tr>
<tr>
<td></td>
<td>Anticonvulsant for partial or generalized, absence seizures</td>
<td>valproic acid</td>
<td>Depakene®</td>
<td>10-15 mg/kg/d PO in divided doses, increase incrementally until therapeutic dose to max of 60 mg/kg/d</td>
<td>Hypersensitivity, hepatic disease, uraemia cycle disorders</td>
<td>Hepatic failure, H/A, somnolence, alopecia, N/V, diarrhea, tremor, diplopia, thrombocytopenia, hypothermia, pancreatitis, encaphalopathy</td>
</tr>
<tr>
<td></td>
<td>Anticonvulsant for absence seizures</td>
<td>ethosuximide</td>
<td>Zarontin®</td>
<td>500 mg/d PO, increase by 250 mg every 4-7 d to max 1.5 g/d in divided doses</td>
<td>Hypersensitivity (succinimides)</td>
<td>CNS depression, blood dyscrasias, SLE, SJS, GI symptoms</td>
</tr>
</tbody>
</table>

**Common Medications**
Table 25. Common Medications – Major Issues (continued)

<table>
<thead>
<tr>
<th>Indications</th>
<th>Mechanism of Action/Class</th>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke Prevention in AF</td>
<td>Anticoagulant (direct thrombin inhibitor)</td>
<td>dabigatran</td>
<td>Pradaxa®</td>
<td>110 mg PO bid or 150 mg PO bid</td>
<td>CrCl &lt;30 mL/min, significant hemostatic impairment or CNS lesions within 6 mo with high risk of bleeding</td>
<td>Dyspepsia, gastritis, bleeding</td>
</tr>
<tr>
<td></td>
<td>Anticoagulant (Factor Xa inhibitor)</td>
<td>rivaroxaban</td>
<td>Xarelto®</td>
<td>15 mg PO daily or 20 mg PO daily</td>
<td>Concomitant anticoagulant, hepatic disease, pregnancy, strong CYP3A4 and P-gp inhibitors e.g. itraconazole, ritonavir</td>
<td>Bleeding</td>
</tr>
<tr>
<td></td>
<td>Anticoagulant (Factor Xa inhibitor)</td>
<td>apixaban</td>
<td>Eliquis®</td>
<td>2.5 mg PO bid or 5 mg PO bid</td>
<td>Active bleeding, gastrointestinal bleeding, recent cerebral infarction, active peptic ulcer disease with recent bleeding, hepatic disease with coagulopathy</td>
<td>Bleeding (conjunctival, gastrointestinal, gingival, contusion, hemotoma, epistaxis, hematuria)</td>
</tr>
<tr>
<td>Mild to Moderate AD or DLB</td>
<td>Cholinesterase Inhibitor</td>
<td>donepezil</td>
<td>Aricept®</td>
<td>5 mg PO OD, may increase to 10 mg PO OD after 4-6 wk</td>
<td>Hypersensitivity to donepezil or to pyrrolidine derivatives</td>
<td>Diarrhea, N/V, insomnia, muscle cramps, fatigue, anorexia, HTN, syncope, AV block</td>
</tr>
<tr>
<td>Multiple Sclerosis</td>
<td>MS Disease Modifying Therapy</td>
<td>interferon-β-1b interferon-β-1a SC interferon-β-1a IM</td>
<td>Betaseron® Rebif® Avonex®</td>
<td>0.25 mg (8 MIU) every other day 44 µg SC 3 times/wk 30 µg IM once weekly</td>
<td>Pregnancy, hypersensitivity to natural or recombinant interferon-β Injection site reactions, injection site necrosis, flu-like symptoms (fever, chills, myalgia; tend to decrease over time)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MS Disease Modifying Therapy</td>
<td>glatiramer acetate</td>
<td>Copaxone®</td>
<td>20 mg SC OD</td>
<td>Hypersensitivity to glatiramer or mannitol Injection site reactions, nausea, transient chest pain, vasodilation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MS Disease Modifying Therapy</td>
<td>natalizumab</td>
<td>Tysabri®</td>
<td>300 mg IV given over 1 h, every 4 wk</td>
<td>Hypersensitivity to natalizumab, progressive multifocal leukoencephalopathy (PML) Rash, nausea, arthralgia, H/A, infections, rare risk of PML and melanoma</td>
<td></td>
</tr>
<tr>
<td>Spasticity (i.e. MS)</td>
<td>Muscle Relaxant – Antispastic</td>
<td>baclofen</td>
<td>Lioresal®</td>
<td>5 mg PO tid, increase by 15 mg/3 q3d to max dose 80 mg/d in three divided doses</td>
<td>Hypersensitivity to baclofen Transient drowsiness, daytime sedation, dizziness, weakness, fatigue, convulsions, constipation, nausea</td>
<td></td>
</tr>
</tbody>
</table>

**Landmark Neurology Trials**

<table>
<thead>
<tr>
<th>Trial</th>
<th>Reference</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>NASCET</td>
<td>NEJM 1991;7:445-53</td>
<td>Patients with symptomatic carotid stenosis of 70-99% benefited more from carotid endarterectomy than best medical therapy</td>
</tr>
<tr>
<td>Interferon-β Multiple Sclerosis Study Group Trial</td>
<td>Neurology 1993;43:655-61</td>
<td>Interferon-β-1b reduces relapse rate and severity of relapses in RRMS</td>
</tr>
<tr>
<td>NINDS rtPA</td>
<td>NEJM 1995;33:1581-7</td>
<td>rtPA reduces mortality and long-term disability when administered within 3 h of acute stroke</td>
</tr>
<tr>
<td>3 h of acute stroke</td>
<td>NEJM 2006;355:549-59</td>
<td>The observed benefit of statins in cardiovascular disease is also extended to patients with a recent stroke or TIA</td>
</tr>
<tr>
<td>SPARCL</td>
<td>NEJM 2008;359:1317-29</td>
<td>rtPA improved clinical outcomes when administered within 3 to 4.5 h of acute ischemic stroke</td>
</tr>
<tr>
<td>PROFESS</td>
<td>NEJM 2008;359:1238-51</td>
<td>ASA + dipyridamole and clopidogrel showed similar benefits in secondary stroke prevention</td>
</tr>
<tr>
<td>RELY</td>
<td>NEJM 2009;361:1139</td>
<td>Dabigatran superior to warfarin for stroke prevention in patients with atrial fibrillation</td>
</tr>
<tr>
<td>ROCKET-AF</td>
<td>NEJM 2011;365:883-891</td>
<td>Rivaroxaban noninferior to warfarin stroke prevention in patients with atrial fibrillation</td>
</tr>
<tr>
<td>ERS</td>
<td>NEJM 2011;365:981-992</td>
<td>Apixabam superior to warfarin for stroke prevention in patients with atrial fibrillation</td>
</tr>
<tr>
<td>CREST</td>
<td>NEJM 2010;363:11-23</td>
<td>Carotid stenting and endarterectomy had similar benefits in reduction of stroke, MI, and death in carotid stenosis, but in the periprocedural period, stenting had a higher rate of stroke, while endarterectomy had a higher rate of MI</td>
</tr>
<tr>
<td>INTERACT2</td>
<td>NEJM 2013;368:2355-65</td>
<td>Intensive lowering of blood pressure (sBP&lt;140) in spontaneous intracerebral hemorrhage did not improve mortality or severe disability but improved functional outcomes (odds ratio for greater disability, 0.87; 95% CI, 0.77 to 1.00; P=0.04)</td>
</tr>
<tr>
<td>MR CLEAN</td>
<td>NEJM 2015;372:11-20</td>
<td>Intra-arterial treatment (intra-arterial thrombolysis, mechanical treatment, or both) for emergency revascularization administered within 6 h after stroke onset was effective and safe for acute ischemic stroke caused by proximal intracranial occlusion of the anterior circulation</td>
</tr>
</tbody>
</table>
references


Traumatic Brain Injury

# Neurosurgery

Alan Chalil, Laureen Hachem, and Ryan Muir, chapter editors  
Dhruvin Hirpara and Sneha Raju, associate editors  
Valerie Lemieux and Simran Mundi, EBM editors  
Dr. Todd Mainprize and Dr. Eric Massicotte, staff editors

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acronyms</td>
<td>2</td>
</tr>
<tr>
<td>Basic Anatomy Review</td>
<td>2</td>
</tr>
<tr>
<td>Differential Diagnoses of Common Neurosurgical Presentations</td>
<td>3</td>
</tr>
<tr>
<td>Intracranial Pathology</td>
<td>4</td>
</tr>
<tr>
<td>Intracranial Pressure Dynamics</td>
<td>4</td>
</tr>
<tr>
<td>Herniation Syndromes</td>
<td>6</td>
</tr>
<tr>
<td>Idiopathic Intracranial Hypertension (Pseudotumour Cerebri)</td>
<td>7</td>
</tr>
<tr>
<td>Hydrocephalus</td>
<td>8</td>
</tr>
<tr>
<td>Tumours</td>
<td>10</td>
</tr>
<tr>
<td>Metastatic Tumours</td>
<td>10</td>
</tr>
<tr>
<td>Astrocytoma</td>
<td>10</td>
</tr>
<tr>
<td>Meningioma</td>
<td>10</td>
</tr>
<tr>
<td>Vestibular Schwannoma (Acoustic Neuroma)</td>
<td>10</td>
</tr>
<tr>
<td>Pituitary Adenoma</td>
<td>10</td>
</tr>
<tr>
<td>Cerebrospinal Fluid Fistulas</td>
<td>23</td>
</tr>
<tr>
<td>EXTRACRANIAL PATHOLOGY</td>
<td></td>
</tr>
<tr>
<td>Approach to Limb/Back Pain</td>
<td>OR23</td>
</tr>
<tr>
<td>Extradural Lesions</td>
<td>23</td>
</tr>
<tr>
<td>Root Compression</td>
<td>23</td>
</tr>
<tr>
<td>Cervical Disc Syndrome</td>
<td>23</td>
</tr>
<tr>
<td>Cervical Spondylosis</td>
<td>23</td>
</tr>
<tr>
<td>Lumbar Disc Syndrome</td>
<td>23</td>
</tr>
<tr>
<td>Cauda Equina Syndrome</td>
<td>23</td>
</tr>
<tr>
<td>Lumbar Spinal Stenosis</td>
<td>23</td>
</tr>
<tr>
<td>Neurogenic Claudication</td>
<td>23</td>
</tr>
</tbody>
</table>

Intradural Intramedullary Lesions 27  
Syringomyelia (Syinx) 27  
Spinal Cord Syndromes 27  
Peripheral Nerves 28  
SPECIALTY TOPICS  
**Neurotrauma** 29  
Trauma Assessment 29  
Head Injury 29  
Brain Injury 29  
Late Complications of Head/Brain Injury 29  
Spinal Cord Injury 29  
Fractures of the Spine 29  
Neurologically Determined Death 29  
Coma 29  
Persistent Vegetative State 29  
**Pediatric Neurosurgery** 34  
Spinal Dysraphism 34  
Intraventricular Hemorrhage 34  
Hydrocephalus in Pediatrics 34  
Dandy-Walker Malformation 34  
Chiari Malformations 34  
Craniosynostosis 34  
Pediatric Brain Tumours 34  
**Functional Neurosurgery** 37  
Movement Disorders 37  
Neuropsychiatric Disorders 37  
Chronic Pain 37  
**Surgical Management of Epilepsy** 39  
**Surgical Management for Trigeminal Neuralgia** 39  
**References** 40  

Toronto Notes 2017
### Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVF</td>
<td>arteriovenous fistula</td>
</tr>
<tr>
<td>AVM</td>
<td>arteriovenous malformation</td>
</tr>
<tr>
<td>BBB</td>
<td>blood brain barrier</td>
</tr>
<tr>
<td>CBF</td>
<td>cerebral blood flow</td>
</tr>
<tr>
<td>CSF</td>
<td>cerebrospinal fluid</td>
</tr>
<tr>
<td>CPA</td>
<td>cerebellar pontine angle</td>
</tr>
<tr>
<td>CVR</td>
<td>cerebral vascular resistance</td>
</tr>
<tr>
<td>DBS</td>
<td>deep brain stimulation</td>
</tr>
<tr>
<td>DI</td>
<td>diabetes insipidus</td>
</tr>
<tr>
<td>ECF</td>
<td>extracellular fluid</td>
</tr>
<tr>
<td>ECT</td>
<td>electroconvulsive therapy</td>
</tr>
<tr>
<td>EEG</td>
<td>electroencephalography</td>
</tr>
<tr>
<td>EMG</td>
<td>electromyography</td>
</tr>
<tr>
<td>EVD</td>
<td>external ventricular drain</td>
</tr>
<tr>
<td>GCS</td>
<td>Glasgow coma scale</td>
</tr>
<tr>
<td>GPA</td>
<td>globus pallidus pars interna</td>
</tr>
<tr>
<td>H/A</td>
<td>headache</td>
</tr>
<tr>
<td>ICF</td>
<td>intracellular fluid</td>
</tr>
<tr>
<td>ICH</td>
<td>intracerebral hemorrhage</td>
</tr>
<tr>
<td>ICP</td>
<td>intracranial pressure</td>
</tr>
<tr>
<td>IVM</td>
<td>intraventricular hemorrhage</td>
</tr>
<tr>
<td>LMAN</td>
<td>lower motor neuron</td>
</tr>
<tr>
<td>LOC</td>
<td>loss of consciousness</td>
</tr>
<tr>
<td>LP</td>
<td>lumbar puncture</td>
</tr>
<tr>
<td>MAP</td>
<td>mean arterial pressure</td>
</tr>
<tr>
<td>MLS</td>
<td>midline shift</td>
</tr>
<tr>
<td>NC</td>
<td>neurogenic claudication</td>
</tr>
<tr>
<td>NPH</td>
<td>normal pressure hydrocephalus</td>
</tr>
<tr>
<td>OPLI</td>
<td>ossification of posterior longitudinal ligament</td>
</tr>
<tr>
<td>PAG</td>
<td>periventricular grey matter</td>
</tr>
<tr>
<td>PET</td>
<td>positron emission tomography</td>
</tr>
<tr>
<td>PLL</td>
<td>posterior longitudinal ligament</td>
</tr>
<tr>
<td>PNET</td>
<td>primitive neuroectodermal tumor</td>
</tr>
<tr>
<td>PVE</td>
<td>periventricular grey matter</td>
</tr>
<tr>
<td>SAH</td>
<td>subarachnoid hemorrhage</td>
</tr>
<tr>
<td>SDH</td>
<td>subdural hemorrhage</td>
</tr>
<tr>
<td>SDADH</td>
<td>syndrome of inappropriate antidiuretic hormone</td>
</tr>
<tr>
<td>SPECT</td>
<td>single photon emission computed tomography</td>
</tr>
<tr>
<td>SRS</td>
<td>stereotactic radiosurgery</td>
</tr>
<tr>
<td>STN</td>
<td>subthalamic nucleus</td>
</tr>
<tr>
<td>UMN</td>
<td>upper motor neuron</td>
</tr>
<tr>
<td>VPL</td>
<td>ventral posterolateral</td>
</tr>
<tr>
<td>VPM</td>
<td>ventral posteromedial</td>
</tr>
<tr>
<td>WBRT</td>
<td>whole brain radiation therapy</td>
</tr>
</tbody>
</table>

### Basic Anatomy Review

#### Figure 1. Magnetic resonance imaging (MRI) neuroanatomy

**A. Sagittal Section**

- Superior sagittal sinus
- Corpus callosum
- Thalamus
- Hypothalamus
- Cerebral aqueduct
- Occipital lobe
- Tentorium
- Midbrain
- Fourth ventricle
- Cerebellum
- Pons
- Medulla
- Dens of C2
- Spinal cord
- Body of C3

**B. Axial Section**

- Frontal lobe
- Caudate lobe
- Lateral ventricle
- Putamen
- Internal capsule
- Insula
- Thalamus
- Cerebral Aqueduct
- Parietal lobe
- Occipital lobe

**Figure 2. Relationship of nerve roots to vertebral level in the cervical and lumbar spine**

- Note: AP views depict left-sided C4-5 and L4-5 disc herniation, and correlating nerve root impingement
Figure 3. Vascular supply of the brain. Please see legend for artery names. 3A. Circle of Willis, most common variant. 3B. Vascular territories of the brain and brainstem, sagittal view, seen laterally. 3C. Vascular territories of the brain and brainstem, sagittal view, seen medially.
# Intracranial Pathology

## Intracranial Pressure Dynamics

### Table 1. Approach to Intracranial Pathology

<table>
<thead>
<tr>
<th>Issue</th>
<th>Time Frame</th>
<th>Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vascular</td>
<td>Sudden</td>
<td>No H/A = occlusive</td>
</tr>
<tr>
<td></td>
<td></td>
<td>H/A = hemorrhagic</td>
</tr>
<tr>
<td>Metabolic</td>
<td>Hours to days</td>
<td>Affects entire CNS</td>
</tr>
<tr>
<td>Infectious</td>
<td>Days to weeks</td>
<td>Often a source of infection or immunodeficiency on history</td>
</tr>
<tr>
<td>Tumour</td>
<td>Months</td>
<td>Increased ICP:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Initially → H/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Constant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Progressive</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Severe</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Worse in morning and/or wakes from sleep</td>
</tr>
<tr>
<td></td>
<td></td>
<td>As ICP increases:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Blurry vision</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Projectile vomiting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Severely raised ICP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cushing’s reflex</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1. Bradycardia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2. HTN</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3. Respiratory irregularity</td>
</tr>
</tbody>
</table>

### Table 2. Consequences of Common Brain Lesions

<table>
<thead>
<tr>
<th>Location of Lesion</th>
<th>Consequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frontal Lobe</td>
<td>Usually large lesions produce symptoms</td>
</tr>
<tr>
<td></td>
<td>Disinhibition, abulia, apathy, executive dysfunction, deficits in orientation and judgment, ± primitive reflex re-emergence, ± contralateral upper motor neuron signs (upgoing Babinski reflex and pronator drift)</td>
</tr>
<tr>
<td>Frontal Eye Fields</td>
<td>Gaze deviation toward side of a destructive lesion</td>
</tr>
<tr>
<td></td>
<td>Gaze deviation away from irritative lesion (i.e. seizure)</td>
</tr>
<tr>
<td>Broca’s Area</td>
<td>Posterior inferior frontal gyrus of dominant hemisphere</td>
</tr>
<tr>
<td></td>
<td>Non-fluent, dysarthric, aphasia</td>
</tr>
<tr>
<td></td>
<td>Repetition impaired</td>
</tr>
<tr>
<td></td>
<td>Comprehension spared</td>
</tr>
<tr>
<td>Occipital Lobe</td>
<td>Contralateral homonamous hemianopsia</td>
</tr>
<tr>
<td>Parietal Lobe</td>
<td>Either side</td>
</tr>
<tr>
<td></td>
<td>Dominant side (Left)</td>
</tr>
<tr>
<td></td>
<td>Cortical sensory loss, lower homonamous quadrantanopia</td>
</tr>
<tr>
<td></td>
<td>Aphasics, Gerstmann’s syndrome</td>
</tr>
<tr>
<td></td>
<td>Hemispatial neglect, apraxias, agnosias</td>
</tr>
<tr>
<td></td>
<td>Non-dominant side (Right)</td>
</tr>
<tr>
<td>Temporal Lobe</td>
<td>Hippocampus: anterograde amnesia</td>
</tr>
<tr>
<td></td>
<td>Upper homonymous hemianopsia</td>
</tr>
<tr>
<td></td>
<td>Wernicke’s aphasia</td>
</tr>
<tr>
<td>Wernicke’s Area</td>
<td>Posterior superior temporal gyrus of dominant hemisphere</td>
</tr>
<tr>
<td></td>
<td>Fluent aphasia</td>
</tr>
<tr>
<td></td>
<td>Repetition impaired</td>
</tr>
<tr>
<td></td>
<td>Comprehension impaired</td>
</tr>
<tr>
<td>Basal Ganglia</td>
<td>Resting tremor</td>
</tr>
<tr>
<td></td>
<td>Chorea</td>
</tr>
<tr>
<td></td>
<td>Athetosis</td>
</tr>
<tr>
<td>Subthalamic Nucleus</td>
<td>Contralateral hemiballismus</td>
</tr>
<tr>
<td>Brainstem</td>
<td>Absent reflexes: oculocephalic, oculovestibular, corneal, gag, and cough</td>
</tr>
<tr>
<td></td>
<td>Dorsal midbrain: Parinaud’s syndrome (supranuclear upward gaze palsy)</td>
</tr>
<tr>
<td></td>
<td>Pontine base: locked-in syndrome</td>
</tr>
<tr>
<td></td>
<td>Below red nucleus: decerebrate posture</td>
</tr>
<tr>
<td></td>
<td>Above red nucleus: decorticate posture</td>
</tr>
<tr>
<td></td>
<td>Reticular activating system (midbrain): reduced level of arousal</td>
</tr>
<tr>
<td></td>
<td>Cerebellar pontine angle: tininitus, disequilibrium, ataxia and other CN V,VII,VIII deficits</td>
</tr>
<tr>
<td>Cerebellar Hemisphere</td>
<td>Intention tremor</td>
</tr>
<tr>
<td></td>
<td>Ipsilateral limb ataxia</td>
</tr>
<tr>
<td></td>
<td>Fall towards side of lesion</td>
</tr>
<tr>
<td>Cerebellar Vermis</td>
<td>Truncal ataxia</td>
</tr>
<tr>
<td></td>
<td>Dysarthria</td>
</tr>
</tbody>
</table>
ICP/Volume Relationship

- Monro-Kellie Doctrine: the brain is encased in a rigid skull with constant intracranial volume consisting of CSF, blood and brain
- the increase in one constituent will: 1) necessitate the redistribution of CSF, blood and/or brain and 2) increase ICP
- compensatory mechanisms initially maintain a normal ICP
  - immediate: egress of CSF through foramen magnum to spinal canal, displacement of venous blood from sinuses into jugular veins
  - late: displacement of arterial blood (decreased CPP) eventually leading to ischemia, increasing brain edema or expanding mass displaces parenchyma into compartments under less pressure (Table 3)
  - end: cessation of cerebral perfusion when ICP>MAP, cerebral herniation down into foramen magnum

Cerebral Blood Flow

- brain receives about 15% of cardiac output (~750 mL/min)
- CBF is the vital parameter for brain function and depends on cerebral perfusion pressure (CPP) and cerebral vascular resistance (CVR)
- CPP is dependent on the difference between mean arterial pressure (MAP) and Intracranial Pressure (ICP) (Normal CPP > 50 mmHg)
- cerebral autoregulation: mechanism that maintains constant CBF despite changes in CPP, unless:
  - high ICP such that CPP <40 mmHg
  - MAP >150 mmHg or MAP <50 mmHg
  - increased CO2 = increased CBF via vasodilation
  - O2 <50 mmHg = increased CBF via vasodilation
  - brain injury: e.g. SAH, severe trauma

ICP Measurement

- normal ICP 10-15 mmHg for adult, 3-7 mmHg for child, 1.5-6 mmHg for infant; varies with patient position
  - moderate elevation >20 mmHg
  - severe elevation >40 mmHg

Acute Monitoring

- indications include: severe TBI (GCS<8T) + abnormal CT; normal CT under some conditions
- methods: many methods, but “gold standard” is intraventricular catheter, aka external ventricular drain (EVD), is the most accurate and allows therapeutic drainage of CSF

Chronic Monitoring

- fibroptic monitor (intraventricular, intraparenchymal, subdural), subarachnoid bolt (Richmond screw), and epidural monitor

Elevated ICP

Etiology

- increased intracranial brain volume
  - intracranial mass (tumour, cyst)
  - cerebral edema
    - vasogenic: BBB compromised (encephalitis, meningitis, hypertensive encephalopathy, tumour, late ischemia, status epilepticus)
    - cytotoxic: BBB intact (cell death in: early ischemia, brain injury, encephalitis, status epilepticus)
    - interstitial: transudation of CSF into peri-ventricular white matter in hydrocephalus
    - osmotic: osmotic gradient increases intracerebral free H2O (acute hyponatremia, hepatic encephalopathy)
  - other space occupying lesions: depressed skull fracture, foreign body, pus/empyema
- increased intracranial blood volume
  - space occupying blood: epidural and subdural hematomas, intraparenchymal and subarachnoid hemorrhages
  - venous obstruction (venous sinus thrombosis, superior vena cava syndrome, cor pulmonale, venous sinus compression)
  - impaired autoregulation (hypotension, HTN, brain injury, status epilepticus)
  - vasodilatation (increased pCO2/decreased pO2/decreased extracellular pH)
  - cranial dependency
- increased intracranial CSF volume
  - increased production (rare): choroid plexus papilloma
  - hydrocephalus: obstructive vs non-obstructive (see Table 6)
  - idiopathic intracranial HTN (pseudotumour cerebri) – see Idiopathic Intracranial Hypertension, NS7
Clinical Features

Table 3. Clinical Features of Elevated ICP

<table>
<thead>
<tr>
<th>Clinical Features</th>
<th>Acutely Elevated ICP</th>
<th>Chronic Progressive Elevation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>Both aggravated by stooping, coughing, straining</td>
<td></td>
</tr>
<tr>
<td>Nausea and Vomiting</td>
<td>Morning headaches: vasodilatation due to increased CO₂ with recumbency</td>
<td></td>
</tr>
<tr>
<td>Level of Consciousness</td>
<td>Lethargy if ICP = dBP or midbrain compression</td>
<td>Normal or modestly reduced LOC, confusion</td>
</tr>
<tr>
<td>GCS</td>
<td>Significant decline in GCS</td>
<td>Can be unchanged or modestly decreased</td>
</tr>
<tr>
<td>Optic Disc Changes</td>
<td>Subtle changes suggesting papilledema (subtle elevations in disc margin, mild disc hyperemia) - often not affected initially, however visual obscurations, flickering or blurring can occur</td>
<td>Often full EOM</td>
</tr>
<tr>
<td>Visual Changes</td>
<td>Often not affected initially, however visual obscurations, flickering or blurring can occur</td>
<td>Optic atrophy/blindness due to chronic papilledema</td>
</tr>
<tr>
<td>Extra-Ocular Movements</td>
<td>CN VI palsy; due to long intracranial course, more sensitive to ICP changes and thus earlier sign of acutely increased ICP</td>
<td>Often full EOM</td>
</tr>
<tr>
<td>Herniation Syndromes</td>
<td>Often occur (see Table 4)</td>
<td>Present if acute on chronic presentation</td>
</tr>
<tr>
<td>Neurologic Deficits</td>
<td>Focal deficits present</td>
<td>Focal deficits can be present</td>
</tr>
</tbody>
</table>

Investigations
- Patients with suspected elevated ICP require an urgent CT/MRI to identify etiology, assess for midline shift/herniation
- ICP monitoring where appropriate

Herniation Syndromes

Table 4. Herniation Syndromes

<table>
<thead>
<tr>
<th>Herniation Syndrome</th>
<th>Definition</th>
<th>Etiology</th>
<th>Clinical Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Subfalcine</td>
<td>Cingulate gyrus herniates under falx</td>
<td>Lateral supratentorial lesion</td>
<td>Usually asymptomatic. \vspace{10pt} Warns of impending transtentorial herniation. Risk of ACA compression.</td>
</tr>
<tr>
<td>2. Central Tentorial (Axial)</td>
<td>Displacement of diencephalon through tentorial notch</td>
<td>Supratentorial midline lesion Diffuse cerebral swelling Late uncal herniation</td>
<td>Small pupils, moderately dilated, fixed (rostrocaudal deterioration), sequential failure of diencephalon, medulla. Decreased LOC (midbrain compression), EOM/upward gaze impairment (“sunset eyes”); compression of pretectum and superior colliculi (Parietalis’s syndrome) Risk of PCA compression Brainstem (Bretz) herniation: secondary to shearing of basilar artery perforating vessels Diabetes insipidus (traction on pituitary stalk and hypothalamus), end-stage sign</td>
</tr>
<tr>
<td>3. Lateral Tentorial (Uncal)</td>
<td>Uncus of temporal lobe herniates down through tentorial notch</td>
<td>Lateral supratentorial lesion (often rapidly expanding traumatic hematoma)</td>
<td>Ipsilateral non-reactive dilated pupil (earliest, most reliable sign) + ipsilateral EOM paralysis, ptosis (CN III compression) Decreased LOC (midbrain compression) Risk of PCA compression Contralateral hemiplegia = extensor (upgoing) plantar response ipsilateral hemiplegia (“ Kernohan’s notch” – a false localizing sign resulting from pressure from the edge of the tentorium on the contralateral cerebral peduncle)</td>
</tr>
<tr>
<td>4. Upward</td>
<td>Cerebellum vermis herniates through tentorial incisura</td>
<td>Posterior fossa mass, brainstem or cerebellar infarction, exacerbated by ventriculostomy or VP shunt</td>
<td>Cerebellar infarct (superior cerebellar artery [SCA] compression) Hydrocephalus/cerebral/sylvian aqueduct compression</td>
</tr>
<tr>
<td>5. Tonsillar</td>
<td>Cerebellum tonsils herniate through foramen magnum</td>
<td>Infratentorial lesion Following central tentorial herniation Following LP in presence of intracranial mass lesion</td>
<td>Neck stiffness and head tilt (tonsillar impaction) Decreased LOC (midbrain compression) Flaccid paralysis Respiratory irregularities, respiratory arrest (compression of medullary respiratory centres) Blood pressure instability (compression of medullary cardiovascular centres)</td>
</tr>
</tbody>
</table>
Treatment of Elevated ICP

• treatment principle: treat primary etiology (i.e. remove mass lesions, ensure adequate ventilation for example in ARDS)
• if elevated ICP persists following treatment of primary cause, consider therapy when ICP >20 mmHg
• targets: ICP <20 mmHg, CPP >65 mmHg, MAP >90 mmHg

### Table 5. Management of Elevated ICP

<table>
<thead>
<tr>
<th>Consideration</th>
<th>Intervention</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Conservative Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Position</td>
<td>Elevate head of bed at 30°</td>
<td>Increases 1. Jugular venous patency</td>
</tr>
<tr>
<td></td>
<td>Maintain neck in neutral position</td>
<td>2. intracranial venous outflow with minimal effect on MAP</td>
</tr>
<tr>
<td>Prevent Hypotension</td>
<td>PRN: fluid, vasopressors, dopamine, norepinephrine</td>
<td>Maintains CBF</td>
</tr>
<tr>
<td>Normocarbia</td>
<td>Ventilate to PCO2 35-40 mmHg</td>
<td>Prevents vasodilatation</td>
</tr>
<tr>
<td>Adequate O2</td>
<td>Target pO2 &gt;60 mmHg</td>
<td>Prevents hypoxic brain injury</td>
</tr>
<tr>
<td>Osmolar Diuresis</td>
<td>Mannitol 20% IV solution 1-1.5 g/kg, then 0.25 g/kg q8h to serum osmolality of 315-320</td>
<td>Increase serum tonicity → osmotically drives fluid out of brain</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Dexamethasone</td>
<td>Decrease vasogenic edema over subsequent days around brain tumour, abscess, blood</td>
</tr>
<tr>
<td><strong>Aggressive Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sedation</td>
<td>Light = barbiturates/codeine</td>
<td>Reduces sympathetic tone</td>
</tr>
<tr>
<td></td>
<td>Heavy = fentanyl/MgSO4</td>
<td>Reduces HTN induced by muscle contraction</td>
</tr>
<tr>
<td>Paralysis</td>
<td>Vecuronium</td>
<td>Reduces sympathetic tone</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reduces HTN induced by muscle contraction</td>
</tr>
<tr>
<td>Barbiturate-Induced Coma</td>
<td>Phentobarbital 10 mg/kg over 30 min, then 1 mg/kg q1h continuous infusion</td>
<td>Reduce CBF and metabolism</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Decreases mortality, but no affect on neurologic outcome</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No role for the use of hypothermia in head injury</td>
</tr>
<tr>
<td>Hyperventilate</td>
<td>Target PCO2 30-35 mmHg</td>
<td>Decreases CBF and thus ICP but use for brief periods only</td>
</tr>
<tr>
<td>Drain CSF</td>
<td>Insert EVD (if acute) or shunt</td>
<td>Reduces intracranial volume</td>
</tr>
<tr>
<td></td>
<td>Drain 3-5 mL CSF</td>
<td></td>
</tr>
<tr>
<td>Decompression</td>
<td>Decompressive craniectomy</td>
<td>Allows brain to swell while reducing risk of herniation</td>
</tr>
</tbody>
</table>

### Idiopathic Intracranial Hypertension (Pseudotumour Cerebri)

**Definition**
- raised ICP with papilledema, but without: mass, hydrocephalus, infection, or hypertensive encephalopathy (diagnosis of exclusion)

**Etiology**
- unknown (majority), but associated with:
  - dural sinus thrombosis
  - habits/diet: obesity, hypervitaminosis A
  - endocrine: reproductive age, menstrual irregularities, Addison's/Cushing's disease
  - hematologic: iron deficiency anemia, polycythemia vera
  - drugs: steroid withdrawal, tetracycline, amiodarone, lithium, nalidixic acid, oral contraceptive
  - risk factors overlap with those of venous sinus thrombosis; similar to those for gallstones (“fat, female, fertile, forties”)

**Epidemiology**
- incidence: general population ~1-2/100,000 per year; obese women of childbearing age 19-21/100,000

**Clinical Features**
- symptoms: H/A in >90%, nausea, pulsatile intracranial noise, impaired vision, diplopia can occur with CN VI palsy
- signs: CN VI palsy can occur (otherwise no neurologic deficits), visual acuity and field deficits, papilledema, optic atrophy
- morbidity: risk of blindness, which is not reliably correlated to duration, symptoms or clinical course
- clinical course: usually self-limited, recurrence in 10%, chronic in some
Hydrocephalus

Investigations
- MRI-brain (with and without contrast): slit like ventricles, but otherwise normal
  • rule out: venous sinus thrombosis, mass, infection, hydrocephalus
- LP findings: 1. Opening pressure >20 mm H2O 2. Normal CSF analysis
- ophthalmologic: fields, acuity, papilledema

Treatment
- lifestyle change: encourage weight loss, fluid/salt restriction
- pharmacotherapy: acetazolamide (decreases CSF production), thiazide diuretic, or furosemide; discontinue offending medications
- surgery: if above fail, serial LPs, shunts, optic nerve sheath decompression (if progressive impairment of visual acuity)
- long term: 2 yr follow-up, repeat imaging to rule out occult tumour, ophthalmology follow-up

Hydrocephalus

Definitions
- accumulation of excess CSF in the brain, functionally divided into obstructive and communicating
- flow of CSF: produced by choroid plexus, lateral ventricles → foramen of Monroe → 3rd ventricle → cerebral/sylvian aqueduct → 4th ventricle → foramina of Luschka (lateral) and Magendie (medial) → subarachnoid space where CSF is re-absorbed by arachnoid villi/granulations into dural venous sinuses

Etiology
- impaired CSF dynamics
  a. obstruction of CSF flow
  b. decreased CSF absorption
  c. increased CSF production (rarely in choroid plexus papilloma – 0.4-1% of intracranial tumours)
- congenital and acquired causes

Epidemiology
- estimated prevalence 1-1.5%; incidence of congenital hydrocephalus ~1-2/1,000 live births

Classification

Table 6. Classification of Hydrocephalus

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Definition</th>
<th>Etiology</th>
<th>Findings on CT/MRI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obstructive Hydrocephalus (Non-Communicating)</td>
<td>CSF Circulation blocked within ventricular system proximal to the arachnoid granulations</td>
<td>Acquired Aqueductal Stenosis: adhesions after infection, haemorrhage; gliosis, tumour (e.g. medulloblastoma) Intra-ventricular lesions: tumours, e.g. 3rd ventricle colloid cyst, haemato ma Mass causing tentorial herniation causing aqueduct/4th ventricle compression Others: neurosarcoidosis, abscess/granulomas, arachnoid cysts</td>
<td>Ventricular enlargement proximal to block (enlarged temporal horns, balloon ing frontal and/or occipital horns, enlarged 3rd to 4th ventricles) Periventricular hypodensity/ lucency (transependymal migration of CSF forced into extracellular space) Sulcal effacement, reduced visibility of sylvian and interhemispheric fissures</td>
</tr>
<tr>
<td>Non-Obstructive Hydrocephalus (Communicating)</td>
<td>Most commonly CSF absorption blocked at extraventricular site = arachnoid granulations, rarely CSF absorption is overwhelmed by increased production</td>
<td>Post-infectious (#1 cause) → meningitis, abscess, cystercerosis Post-haemorrhagic (#2 cause) → SAH, IVH, traumatic Leptomeningial carcinomatosis → metastatic meningitis Choroid plexus papilloma Idiopathic → normal pressure hydrocephalus</td>
<td>All ventricles dilated</td>
</tr>
<tr>
<td>Normal Pressure Hydrocephalus (NPH)</td>
<td>Persistent ventricular dilatation in the context of normal CSF pressure</td>
<td>Idiopathic (50%) Others: subarachnoid herniation, meningitis, trauma, radiation-induced</td>
<td>Enlarged ventricles without increased prominence of cerebral sulci</td>
</tr>
<tr>
<td>Hydrocephalus Ex Vacuo</td>
<td>Ventricular enlargement resulting from atrophy of surrounding brain tissue</td>
<td>Normal aging Degenerative dementias see Neurology N21 (Alzheimer’s, Frontal Temporal, Creutzfeldt-Jacob Disease)</td>
<td>Enlarged ventricles and sulci Cerebral atrophy</td>
</tr>
</tbody>
</table>

CSF production = CSF reabsorption = ~ 500 mL/d in normal adults
Normal CSF volume ~ 150 mL (50% spinal, 50% intracranial → 25 mL intraventricular, 50 mL subarachnoid)
Clinical Features
- acute hydrocephalus: signs and symptoms of acutely elevated ICP (see Table 3)
- chronic/gradual onset hydrocephalus: (weeks to months) (i.e. NPH) presents with a classic triad
  - Ataxia (magnetic gait) + apraxia (pressure of ventricle on lower extremity motor fibres → gait disturbance)
  - Incontinence (pressure on cortical bowel/bladder centre)
  - Dementia (pressure on frontal lobes)

Investigations
- imaging
  - CT/MRI findings (see Table 6)
  - ultrasound (through anterior fontanelle in infants): ventriculomegaly, size and location of lesions (e.g. IVH)
  - mantleradionuclide cisternography can test CSF flow and absorption rate (unreliable)
- ICP monitoring (e.g. LP, EVD) may be used to investigate NPH and test response to shunting (lumbar tap test)

Treatment
- external ventricular drain (EVD)
- intermittent LPs for transient communicating hydrocephalus (SAH, IVH in premature infants)
- surgical: surgical removal of obstruction (if possible) or excision of choroid plexus papilloma
- eliminating obstruction (i.e. excision of mass, posterior fossa decompression for Chiari Malformation)
- endoscopic
  - endoscopic third ventriculostomy (ETV) ± choroid plexus cauterylation (for obstructive hydrocephalus)
  - endoscopic placement of aqueductal stent
- shunt
  - ventriculoperitoneal (VP): most common shunt
  - ventriculoatrial (VA)
  - ventriculoatrial (VA)
  - lumboperitoneal: for communicating hydrocephalus and pseudotumour cerebi

Shunt Complications

<table>
<thead>
<tr>
<th>Complication</th>
<th>Etiology</th>
<th>Clinical Features</th>
<th>Investigations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obstruction (most common)</td>
<td>Obstruction by choroid plexus buildup of proteinaceous accretions, blood, cells (inflammatory or tumour) infection infection Disconnection or damage</td>
<td>Acute hydrocephalus signs and symptoms of increased ICP</td>
<td>“Shunt series” (plain x-rays of entire shunt that only rule-out disconnection, break, tip migration) CT Radionuclide “shuntogram”</td>
</tr>
<tr>
<td>Proximal Catheter Valve</td>
<td>S. epidermidis S. aureus P. acnes Gram-negative bacilli</td>
<td>Fever, N/V, anorexia, irritability Meningitis Peritonitis Signs and symptoms of shunt obstruction Shunt nephritis (VA shunt)</td>
<td>CBC Blood culture Tap shunt for CandS (LP usually NOT recommended)</td>
</tr>
<tr>
<td>Distal Catheter</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infection (3-6%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overshunting (10% over 6.5 yr)</td>
<td>Slit ventricle syndrome, collapse of ventricles leading to occlusion of shunt ports by ependymal lining Chronic or recurring headaches often relieved when lying down CT/MRI Subdural hematoma Collapsing brain tears bridging veins (especially common in NPH patients) Secondary craniostenosis (children): apposition and overlapping of the crani sutures in an infant following decompression of hydrocephalus</td>
<td>Asymptomatic Headaches, vomiting, somnolence</td>
<td>CT Clinical</td>
</tr>
<tr>
<td>Seizures (5.5% risk in 1st yr, 1.1% after 3rd yr)</td>
<td>Ventricular shunts only</td>
<td></td>
<td>EEG</td>
</tr>
<tr>
<td>Inguinal Hernia (17% incidence with VP shunt inserted in infancy)</td>
<td>Increased intraperitoneal pressure/fluid results in hernia becoming apparent</td>
<td></td>
<td>U/S</td>
</tr>
</tbody>
</table>

Complications of Specific Hydrocephalus Treatments
1. VP Shunt – intra-abdominal cysts, adhesions, ascites
2. VA Shunt – greater infection risk, septicemia, emboli
3. VPI Shunt – pleural effusion, hydrothorax, respiratory distress
4. LP Shunt – radiculopathy, CSF leaks, adhesions, arachnoiditis
5. ETV – 56% success rate, hypothalamic injury, traumatic basilar aneurysm
Tumours

**Classification**
- primary vs. metastatic, intra-axial (parenchymal) vs. extra-axial, supratentorial vs. infratentorial, adult vs. pediatric
- benign: non-invasive, but can be devastating due to expansion of mass in fixed volume of skull (mass effect)
- malignant: implies rapid growth, invasiveness, but rarely extracranial metastasis
- classification of nervous system tumours (* = most common)
  - neuroepithelial
    - astrocytic tumours: astrocytoma*, glioblastoma
    - oligodendrogial tumours: oligodendroglia
    - oligoastrocytic tumours: oligoastrocytoma
    - neuronal and mixed neuronal-glial tumours: ganglion cell tumours, cerebral neurocytomas/neuroblastosmas
  - embryonal tumours: medulloblastoma, primitive neuroectodermal tumours (PNET)
    - other: pineal, ependymal, and choroid plexus tumours
  - meningeal: meningiomas*, menenchymal, hemangioblastomas
  - cranial and parasinal nerves: schwannoma, neurofibroma
  - lymphomas and hematopoietic: primary CNS lymphoma, plasmacytoma
  - germ cell: germinomas, teratomas, choriocarcinomas
  - sellar region: craniopharyngiomas, spindle cell oncocytoma, pituitary adenomas*
  - cysts: epidermoid/dermoid cysts, colloid cysts
  - local extension: chordomas, glomus jugulare tumours
  - metastatic tumours*: lung (small cell),* breast*
- familial syndromes associated with CNS tumours
  - von Hippel-Lindau: hemangioblastoma of cerebellum, brainstem and spinal cord, retina; renal cysts, pheochromocytomas
  - tuberous sclerosis: giant cell astrocytoma; cortical tuber; superependymal nodules and calcifications on CT
  - neurofibromatosis type 1: optic glioma, neurofibroma astrocytoma
  - neurofibromatosis type 2: vestibular schwannoma, meningioma, ependymoma, astrocytoma
  - Li-Fraumeni: astrocytoma, PNET; many other tumours too (sarcomas, breast cancer, leukemia)
  - Turcot syndrome: glioblastoma multiforme, medulloblastoma, pineoblastoma
  - multiple endocrine neoplasia type 1 (MEN-1): pituitary adenoma

**Investigations**
- CT, MRI, stereotactic biopsy (tissue diagnosis), metastatic workup, tumour markers (i.e. germ cell tumours)

**Treatment**
- conservative: serial Hx, Px, imaging for slow growing/benign lesions
- medical: corticosteroids to reduce cytotoxic cerebral edema, pharmacologic (i.e. pituitary adenoma)
- surgical: total or partial excision (decompressive, palliative), shunt if hydrocephalus
- radiotherapy: conventional fractionated radiotherapy (XRT), stereotactic radiosurgery (e.g. Gamma Knife®)
- chemotherapy: e.g. alkylating agents (i.e. Vincristine, cyclophosphamide, etc.)
Table 8. Tumour Location: Etiology and Clinical Presentation

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Suprataenial (all grades)</th>
<th>Craniohypophysealoma (2-5%)</th>
<th>Others: pineal region tumours, choroid plexus tumours, ganglioglioma, IONET</th>
<th>Medulloblastoma (15-20%)</th>
<th>Cerbellar astrocytoma (15%)</th>
<th>Ependyma (9%)</th>
<th>Brainstem astrocytoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &lt;15 yr</td>
<td>(50%)</td>
<td>(35%)</td>
<td>(60% infratentorial)</td>
<td>(50%)</td>
<td>(15-20%)</td>
<td>(9%)</td>
<td>(15-20%)</td>
</tr>
<tr>
<td>Incidence: 2.5-10,000/yr</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60% infratentorial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age &gt;15 yr</td>
<td>High grade astrocytoma</td>
<td>Metastasis</td>
<td>Meningioma</td>
<td>Metastasis</td>
<td>Acoustic neuroma (schwannoma)</td>
<td>Hemangioblasto (2%)</td>
<td>Meningioma</td>
</tr>
<tr>
<td>80% supratentorial</td>
<td>(12-15%, e.g. GBM)</td>
<td>(15-30%, includes infratentorial)</td>
<td>(5-10%)</td>
<td>(5-10%)</td>
<td>(5-10%)</td>
<td>(2%)</td>
<td>(15-20%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Low grade astrocytoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pituitary adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dlgaoglioma embryos</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Other: colloid cyst, CNS lymphoma, dermoid/epidermoid cysts</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Clinical Presentation**

- **Shared Features** (from elevated ICP)
  - Headache: usually worse in AM and made worse with straining, coughing
  - Nausea/Vomiting
  - Papilledema
  - Diplopia - CN VI palsy

- **Specific Features**
  - Seizure: commonly the first symptom
  - Progressive neurological deficits (70%)
  - Frontal lobe: hemiparesis, dysphasia, personality changes, cognitive changes
  - Temporal lobe: auditory/olfactory hallucinations, memory deficits, contralateral superior quadrantanopsia
  - Mental Status Change: depression, apathy, confusion, lethargy
  - "Tumour TIA" - stroke like symptoms caused by a) occlusion of vessel by tumour cells, b) hemorrhage, c) Z "to steal phenomenon" - blood is shunted from ischemic regions to non-ischemic regions
  - Endocrine disturbance - with pituitary tumours (see Endocrinology, E19)
  - Brainstem involvement: cranial nerve deficits and long tract signs
  - Nausea/Vomiting: compression on vagal nucleus/area postrema
  - Diplopia: direct compression CN VI
  - Vertigo
  - Nystagmus
  - Truncal Ataxia + Titubation: cerebellar vermis lesions
  - Limb Ataxia, dysmetria, intention tremor: cerebellar hemisphere lesions
  - Obstructive hydrocephalus more common than supratentorial lesions

**Metastatic Tumours**

- most common brain tumour seen clinically
- 15-30% of cancer patients present with cerebral metastatic tumours
  - most common sources: lungs, breast
  - other sources: kidney, thyroid, stomach, prostate, testis, melanoma
  - hematogenous spread most common

**Location**

- 80% are hemispheric, often at grey-white matter junction or temporal-parietal-occipital lobe junction (likely emboli spreading to terminal MCA branches)

**Investigations**

- identify primary tumour
  - metastatic workup (CXR, CT chest/abdo, abdominal U/S, bone scan, mammogram)
  - CT with contrast – round, well-circumscribed, often ring enhancing, ++ edema, often multiple
  - MRI more sensitive, especially for posterior fossa
  - consider biopsy in unusual cases or if no primary tumour identified

**Treatment**

- medical
  - phenytoin (or levetiracetam) for seizure prophylaxis if patient presents with seizure
  - dexamethasone to reduce edema given with ranitidine
  - chemotherapy (e.g. small cell lung cancer), but difficult delivery across BBB
- radiation
  - stereotactic radiosurgery: for discrete, deep-seated/inoperable tumours
  - multiple lesions: use WBRT; consider stereotactic radiosurgery if <3 lesions
  - post-operative WBRT is commonly used
- surgical
  - single/solitary lesions: use surgery and radiation

**Prognosis**

- median survival without treatment once symptomatic is ~1 mo, with optimal treatment 6-9 mo but varies depending on primary tumour type
Astrocytoma

- most common primary intra-axial brain tumour, common in 4th-6th decades

Table 9. World Health Organization Astrocytoma Grading System

<table>
<thead>
<tr>
<th>Grade</th>
<th>Typical CT/MRI Findings</th>
<th>Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>I - Pilocytic astrocytoma</td>
<td>± mass effect, ± enhancement</td>
<td>&gt;10 yr, cure if gross total resection</td>
</tr>
<tr>
<td>II - Low grade/diffuse</td>
<td>Mass effect, no enhancement</td>
<td>5 yr</td>
</tr>
<tr>
<td>III - Anaplastic</td>
<td>Complex enhancement</td>
<td>1.5-2 yr</td>
</tr>
<tr>
<td>IV - Glioblastoma multiforme (GBM)</td>
<td>Necrosis (ring enhancement)</td>
<td>12 mo, 10% at 2 yr</td>
</tr>
</tbody>
</table>

Clinical Features
- sites: cerebral hemispheres >> cerebellum, brainstem, spinal cord
- symptoms: recent onset of new/worsening H/A, N/V, seizure, ± focal deficits or symptoms of increased ICP

Investigations
- CT/MRI with contrast: variable appearance depending on grade
  - hypodense on CT, hypointense on T1 MRI, hyperintense on T2 MRI
  - low grade: most do not enhance and have calcification on CT
  - high grade: most enhance with CT contrast dye/gadolinium

Treatment
- low grade diffuse astrocytoma
  - close follow-up, radiation, chemotherapy, and surgery all valid options
  - dedifferentiation to more malignant grade; typically occurs faster when diagnosed after age 45
  - surgery: not curative, trend towards better outcomes
  - radiotherapy alone or post-operative prolongs survival (retrospective evidence)
  - chemotherapy: usually reserved for tumour progression
- high grade astrocytomas (anaplastic astrocytoma and GBM)
  - goal is to prolong “quality” survival
  - surgery: gross total resection: maximal safe resection + fractionated radiation with 2 cm margin + concomitant and adjuvant temozolomide
    - except: nearing end-of-life; or extensive brainstem, bilateral, or dominant lobe GBM involvement
  - stereotactic biopsy if resection not possible, followed by fractionated radiation with 2 cm margin
  - expectant (based on functional impairment – Karnofsky score <70; patient’s/family’s wishes)
  - chemotherapy: ~20% response rate, temozolomide (agent of choice); better response to temozolomide predicted by MGMT gene hypermethylation
- multiple gliomas: WBRT ± chemotherapy

Meningioma

- most common primary intracranial tumour (14-19%), arise from arachnoid membrane
- often calcified, cause hyperostosis of adjacent bone
- classically see Psammoma bodies on histology
- location: 70% occur along the parasagittal convexity, falk cerebri, and sphenoid bone; other locations: tuberculum sellae, foramen magnum, olfactory groove, and CP angle

Clinical Features
- middle aged, slight female predominance (M:F = 1:1.8), high progesterone receptors (increase in size with pregnancy)
- many are asymptomatic; when symptoms occur focal neurologic deficits specific to location, ± seizures, symptoms of increased ICP

Investigations
- CT with contrast: homogeneous, densely enhancing, along dural border (“dural tail”), well circumscribed, usually solitary (10% multiple, likely with loss of NF2 gene/22q12 deletion)
- MRI with contrast: characterization of mass and provides a better assessment of the patency of dural venous sinuses
- angiography
  - most are supplied by external carotid feeders (meningeal vessels)
  - can assess venous sinus involvement, “tumour blush” commonly seen (prolonged contrast image)

Treatment
- conservative management: asymptomatic and/or non-progressive on CT/MRI
- surgery: curative if complete resection and indicated when symptomatic and/or documented growth on serial CT/MRI
• **endovascular**: embolization for highly vascularized, likely bloody, tumours to facilitate surgery
• **radiation**: SRS may be an option for lesions <3 cm partially occluding the superior sagittal sinus; SRS or XRT for non-resectable, recurrent atypical/malignant meningiomas

**Prognosis**
• >90% 5 yr survival, recurrence rate variable (often ~10-20%)
• depends on extent of resection (Simpson's classification)

---

### Vestibular Schwannoma (Acoustic Neura)

- slow-growing (average of 1-10 mm/yr), benign posterior fossa tumour (8-10% of tumours)
- arises from vestibular nerve of CN VIII in internal auditory canal, expanding into bony canal and cerebello-pontine angle (CPA)
- if bilateral, diagnostic of neurofibromatosis type II
- epidemiology: 1.5/100,000; all age groups affected, peaks at 4th-6th decades

**Clinical Features**
- **early clinical triad**: (tumour <2 cm) unilateral progressive hearing loss 98%, tinnitus, and disequilibrium (compression of CN VIII)
- **later clinical features**
  - tumour usually >2 cm: otalgia, facial numbness + weakness, changes to taste (due to CN V and VII compression)
  - tumour usually >4 cm: ataxia, H/A, N/V, diplopia, cerebellar signs (due to brainstem compression; ± obstructive hydrocephalus)

**Investigations**
- MRI with gadolinium or T2 FIESTA sequence (>98% sensitive/specific); CT with contrast 2nd choice
- audiogram, brainstem auditory evoked potentials, caloric tests

**Treatment**
- expectant: serial imaging (CT/MRI q6mo) and audiometry
- radiation: stereotactic radiosurgery or fractionated radiotherapy
- surgery: if lesion >3 cm, brainstem compression, edema, hydrocephalus
- curable if complete resection (almost always possible)
- operative complications: CSF leak, meningitis, required shunt; CN V, VII, VIII dysfunction (proportional to tumour size; only significant CNVIII disability if bilateral)

---

### Pituitary Adenoma

- primarily from anterior pituitary, 3rd-4th decades, M=F, associated with MEN-1 syndrome
- incidence in autopsy studies approximately 20%
- **classification**
  - microadenoma <1 cm; macroadenoma ≥1 cm
  - endocrine active (functional/secretory) vs. inactive (non-functional)
    - most common functional: prolactinomas, adrenocorticotropic, growth-hormone producing
  - differential diagnosis: parasellar tumours (e.g. craniopharyngioma, tuberculum sellae meningioma), carotid aneurysm

**Clinical Features**
- mass effects
- H/A
- bitemporal hemianopsia (compression of optic chiasm); hydrocephalus (3rd ventricle compression)
- invasive adenomas: CN III, IV, V1, V2, VI palsy (cavernous sinus compression); proptosis and chemosis (cavernous sinus occlusion)
- **endocrine effects** *(see Endocrinology, E19)*
  - hyperprolactinemia (prolactinoma): infertility, amenorrhea, galactorrhea, decreased libido
  - ACTH production: Cushing's disease, hyperpigmentation
  - GH production: acromegaly/gigantism
  - panhypopituitarism: due to compression of pituitary (hypothyroidism, hypoadrenalism, hypogonadism)
  - diabetes insipidus (DI) – rare, except in apoplexy
- **pituitary apoplexy** (sudden expansion of mass due to hemorrhage or necrosis)
  - abrupt onset H/A, visual disturbances, ophthalmoplegia, reduced mental status, panhypopituitarism and DI
  - CSF rhinorrhea and seizures (rare)
  - signs and symptoms of subarachnoid hemorrhage (rare)
Investigations
- formal visual fields, CN testing
- endocrine tests (prolactin level, TSH, 8 AM cortisol, fasting glucose, FSH/LH, IGF-1), electrolytes, urine electrolytes, and osmolarity
- imaging (MRI with and without contrast)

Treatment
- medical
  - for apoplexy: rapid corticosteroid administration ± surgical decompression
  - for prolactinoma: dopamine agonists (e.g., bromocriptine)
  - for Cushing’s: serotonin antagonist (cyproheptadine), inhibition of cortisol production (ketoconazole)
  - for acromegaly: somatostatin analogue (octreotide) ± bromocriptine
  - endocrine replacement therapy
- surgical
  - trans-sphenoidal, trans-ethmoidal, and less commonly trans-cranial approaches (i.e., for significant suprasellar extension)
- post-operative concerns: DI, adrenal insufficiency (AI), CSF leak
  - DI and AI: AM cortisol, serum sodium and osmolality, urine output and specific gravity (treatment: glucocorticoids; DI: desmopressin/DDAVP)
  - CSF rhinorrhea: test for beta transferrin

Sources of Pus/Infection
- four routes of microbial access to CNS
  1. hematogenous spread (most common): arterial and retrograde venous
    - adults: chest is #1 source (lung abscess, bronchectasis, empyema)
    - children: congenital cyanotic heart disease with R to L shunt
    - immunosuppression (AIDS – toxoplasmosis)
  2. direct implantation (dural disruption)
    - trauma
    - iatrogenic (e.g., following LP, post-operative)
    - congenital defect (e.g., dermal sinus)
  3. contiguous spread (adjacent infection): from air sinus, naso/oropharynx, surgical site (e.g., otitis media, mastoiditis, sinusitis, osteomyelitis, dental abscess)
  4. spread from PNS (e.g., viruses: rabies, herpes zoster)
- common examples
  - epidural abscess: in cranial and spinal epidural space, associated with osteomyelitis
    - treatment: immediate drainage and antibiotics, surgical emergency if cord compression
  - subdural empyema: bacterial/fungal infection, due to contiguous spread from bone or air sinus, progresses rapidly
    - treatment: surgical drainage and antibiotics, 20% mortality
  - meningitis, encephalitis (see Infectious Diseases, ID19)
  - cerebral abscess

Cerebral Abscess

Definition
- pus in brain substance, surrounded by tissue reaction (capsule formation)

Etiology
- modes of spread: 10-60% of patients have no cause identified
- pathogens
  - Streptococcus (most common), often anaerobic or microaerophilic
  - Staphylococcus (penetrating injury)
  - Gram-negatives, anaerobes (Bacteroides, Fusobacterium)
    - in neonates: Proteus and Citrobacter (exclusively)
  - immunocompromised: fungi and protozoa (Toxoplasma, Nocardia, Candida albicans, Listeria monocytogenes, Mycobacterium, and Aspergillus)

Risk Factors
- lung abnormalities (infection, AV fistulas; especially Osler-Weber-Rendu syndrome [i.e., hereditary hemorrhagic telangiectasia])
- congenital coronary heart disease: R-to-L shunt bypasses pulmonary filtration of micro-organisms
- bacterial endocarditis
- penetrating head trauma
- immunosuppression (e.g., AIDS)
- dental abscess
Clinical Features
- focal neurological signs and symptoms
  - H/A, decreased LOC; hemiparesis and seizures in 50%
  - mass effect, increased ICP and sequelae (cranial enlargement in children)
  - hemiparesis and seizures in 50%
  - ± signs and symptoms of systemic infection (low-grade fever, leukocytosis)

Complications
- with abscess rupture: ventriculitis, meningitis, venous sinus thrombosis
- CSF obstruction
- transtentorial herniation

Investigations
- CT scan often first test in emergency department
- MRI
  - imaging of choice
  - apparent diffusion coefficient (ADC) used to differentiate abscess (black) from tumour (white)
  - WBC/ESR may be normal, blood cultures rarely helpful and LP contraindicated if large mass
  - CSF: non-specific (high ICP, high WBC, high protein, normal carbohydrate), rarely helpful, usually negative culture

Treatment
- aspiration ± excision and send for Gram stain, acid fast bacillus (AFB), CandS, fungal culture
- excision preferable if location suitable
- antibiotics
  - empirically: vancomycin + ceftriaxone + metronidazole or chloramphenicol or rifampin (6-8 wk therapy)
  - revise antibiotics when CandS known
- anti-convulsants (1-2 yr)
- follow-up CT is critical (do weekly initially, more frequent if condition deteriorates)

Prognosis
- mortality with appropriate therapy ~10%, permanent deficits in ~50%

Blood

Table 10. Comparison of Epidemiology and Etiology of Intracranial Bleeds

<table>
<thead>
<tr>
<th>Types of Hematoma/Hemorrhage</th>
<th>Etiology</th>
<th>Epidemiology</th>
<th>Clinical Features</th>
<th>CT Features</th>
<th>Treatment</th>
<th>Prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidural Hematoma</td>
<td>Skull fracture causing middle meningeal bleed</td>
<td>M&gt;F (4:1), associated with trauma</td>
<td>Lucid interval before LOC</td>
<td>Hyperdense lenticular mass with sharp margins, usually limited by suture lines</td>
<td>Craniotomy</td>
<td>Good with prompt management (Note: respiratory arrest can occur from uncal herniation)</td>
</tr>
<tr>
<td>Acute SDH</td>
<td>Ruptured subarachnoid bridging vessels</td>
<td>Age &gt;50, associated with trauma</td>
<td>No lucid interval, hemiparesis, pupillary changes</td>
<td>Hyperdense crescentic mass, crossing suture lines</td>
<td>Craniotomy if bleed &gt;1 cm thick</td>
<td>Poor</td>
</tr>
<tr>
<td>Chronic SDH</td>
<td>Ruptured subarachnoid bridging vessels</td>
<td>Age &gt;50, EtOH abusers, anti-coagulated</td>
<td>Often asymptomatic, minor H/A, confusion, signs of increased ICP</td>
<td>Hyperdense crescentic mass, crossing suture lines</td>
<td>Burr hole to drain; craniotomy if recurs</td>
<td>Good</td>
</tr>
<tr>
<td>SAH</td>
<td>Trauma, spontaneous (aneurysms, idiopathic, AVM)</td>
<td>Age 55-60, 20% cases under age 45</td>
<td>Sudden onset thunderclap H/A, signs of increased ICP</td>
<td>Hyperdense blood in cisterns/fissures (sensitivity decreases over time)</td>
<td>Conservative: NP0, IV NS, ECG, Foley, BP 120-150, vasospasm prophylaxis (nimodipine); open vs. endovascular surgery to repair if rebleed</td>
<td>Poor: 50% mortality 30% of survivors have moderate to severe disability</td>
</tr>
<tr>
<td>ICH</td>
<td>HTN, vascular abnormality, tumours, infections, coagulopathy</td>
<td>Age &gt;55, male, drug use (cocaïne, EtOH, amphetamine)</td>
<td>TIA-like symptoms, signs of increased ICP</td>
<td>Hyperdense intraparenchymal collection</td>
<td>Medical: decrease BP; control ICP; Surgical: craniotomy</td>
<td>Poor: 44% mortality due to cerebral hlemiation</td>
</tr>
</tbody>
</table>

CT Density and MRI Appearance of Blood

<table>
<thead>
<tr>
<th>Time</th>
<th>CT</th>
<th>MRI T1</th>
<th>MRI T2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute (&lt;72 h)</td>
<td>Hyper. Grey Black</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subacute (&lt;3 wk)</td>
<td>Iso. White Black</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic (&gt;3 wk)</td>
<td>Hypo. Black Black</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MRI T1: “George Washington Bridge”
MRI T2: “Oreo” cookie – Black/White/Black
Extradural ("Epidural") Hematoma

Etiology
- temporal-parietal skull fracture: 85% are due to ruptured middle meningeal artery; remainder of cases are due to bleeding from middle meningeal vein, dural sinus, or bone/diploic veins

Epidemiology
- young adult, M:F = 4:1; rare before age 2 or after age 60
- 1-4% of traumatic head injuries

Clinical Features
- classic sequence (seen in <30%): post-traumatic reduced LOC, a lucid interval of several hours, then obtundation, hemiparesis, ipsilateral pupillary dilatation, and coma
- signs and symptoms depend on severity but can include H/A, N/V, amnesia, altered LOC, aphasia, seizures, HTN, and respiratory distress
- deterioration can take hours to days

Investigations
- CT without contrast: "lenticular-shaped" usually limited by suture lines but not limited by dural attachments

Treatment
- admission, close neurological observation with serial CT indicated if all of the following are present
  - small volume clot, minimal midline shift (MLS <5 mm), GCS >8, no focal deficit
  - otherwise, craniotomy to evacuate clot, follow up CT
  - mannitol pre-operative if elevated ICP or signs of brain herniation

Prognosis
- good with prompt management, as the brain is often not damaged
- worse prognosis if bilateral Babinski or decerebration pre-operative
- death is usually due to respiratory arrest from uncal herniation (injury to the midbrain)

Subdural Hematoma

Table 11. Comparison of Epidemiology and Etiology of Acute and Chronic SDH

<table>
<thead>
<tr>
<th></th>
<th>Acute SDH</th>
<th>Chronic SDH</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Time Course</strong></td>
<td>1-2 d after bleeding onset</td>
<td>≥15 d after bleeding onset</td>
</tr>
<tr>
<td><strong>Etiology</strong></td>
<td>Rupture of vessels that bridge the subarachnoid space (e.g. cortical artery, large vein, venous sinus) or cerebral laceration</td>
<td>Many start out as acute SDH Blood within the subdural space evokes an inflammatory response: Fibroblast invasion of clot and formation of neomembranes within days → growth of neocapillaries → fibrinolysis and liquefaction of blood clot (forming a hygroma). Course is determined by the balance of rebleeding from neomembranes and resorption of fluid</td>
</tr>
<tr>
<td><strong>Risk Factors</strong></td>
<td>Trauma, acceleration-deceleration injury, anticoagulants, alcohol, cerebral atrophy, infant head trauma</td>
<td>Older, alcoholics, patients with CSF shunts, anticoagulants, coagulopathies</td>
</tr>
<tr>
<td><strong>Clinical Features</strong></td>
<td>No lucid period, signs and symptoms can include: altered LOC, pupillary Irregularity, hemiparesis</td>
<td>Often due to minor injuries or no history of injury May present with minor H/A, confusion, language difficulties, TIA-like symptoms, symptoms of raised ICP ± seizures, progressive dementia, gait problem Obtundation disproportionate to focal deficit; &quot;the great imitator&quot; of dementia, tumours</td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td>CT: Hyperdense concave &quot;crescentic&quot; mass, crossing suture lines</td>
<td>CT: hypodense (liquefied clot), crescentic mass</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>Craniotomy if clinically symptomatic, if hematoma &gt; 1 cm thick, or if MLS &gt;5 mm (optimal if surgery &lt;4 h from onset Otherwise observe with serial imaging)</td>
<td>Seizure prophylaxis only if post-traumatic seizure Reverse coagulopathies Burr hole drainage of liquefied clot indicated if symptomatic or thickness &gt;1 cm; craniotomy if recurs more than twice</td>
</tr>
<tr>
<td><strong>Prognosis</strong></td>
<td>Poor overall since the brain parenchyma is often injured (mortality range is 50-90%, due largely to underlying brain injury) Prognostic factors: initial GCS and neurologica status, post operative ICP</td>
<td>Good overall as brain usually undamaged, but may require repeat drainage</td>
</tr>
</tbody>
</table>

Figure 15. Extradural hematoma on CT

Figure 16. Subdural hematoma on CT

Use of Drains vs. No Drains After Burr-Hole Evacuation of Chronic Subdural Hematoma: A Randomized Controlled Trial
Lancet 2009;374:1067-1073
Purpose: To examine the effect of drains on recurrence rates of chronic subdural hematoma (SDH) and clinical outcomes.
Study: RCT with 269 patients ≥18 yr of age with chronic SDH; half of the patients were randomly assigned to receive a subdural drain and the other half no drain after evacuation.
Results: Recurrence occurred in 9.3% of people with a drain and 24% without (p=0.003; 95% CI 0.14-0.70). Although rates of complications were the same between the study groups, mortality at 6 mo was 6.8% in the group receiving a drain and 18.1% in the group not receiving a drain (p=0.042; 95% CI 0.1-0.9). Conclusions: Use of drains after burr-hole drainage of chronic SDH is safe and associated with a reduced recurrence and mortality at 6 mo.
Cerebrovascular Disease

Ischemic Cerebral Infarction (80%)
- embolic, thrombosis of intracerebral arteries, vasculitis, hypercoagulability, etc. (see Neurology, N48)

Intracranial Hemorrhage (20%)
- SAH, spontaneous ICH, IVH

Clinical Features of Spontaneous SAH
- rapid onset (seconds) of severe “thunderclap” H/A usually following exertion and described as the “worst headache of my life” (up to 97% sensitive, 12-25% specific)
- N/V, photophobia
- meningismus (neck pain/stiffness, positive Kernig’s and Brudzinski’s sign)
- decreased LOC (due to either raised ICP, ischemia, seizure)
- focal deficits: cranial nerve palsies (CN III, IV), hemiparesis
- ocular hemorrhage in 20-40% (due to sudden raised ICP compressing central retinal vein)

Subarachnoid Hemorrhage

Definition
- bleeding into subarachnoid space (intracranial vessel between arachnoid and pia)

Etiology
- trauma (most common)
- spontaneous
  - ruptured aneurysms (75-80%)
  - idiopathic (14-22%)
  - AVMs (4-5%)
- coagulopathies (iatrogenic or primary), vasculitides, tumours, cerebral artery dissections (<5%)

Epidemiology
- ~10-28/100,000 population/yr
- peak age 55-60, 20% of cases occur under age 45

Risk Factors
- HTN
- pregnancy/parturition in patients with pre-existing AVMs, eclampsia
- oral contraceptive pill
- substance abuse (cigarette smoking, cocaine, alcohol)
- conditions associated with high incidence of aneurysms (see Intracranial Aneurysms, NS19)

Clinical Features of Spontaneous SAH
- sudden onset (seconds) of severe "thunderclap" H/A usually following exertion and described as the “worst headache of my life” (up to 97% sensitive, 12-25% specific)
- N/V, photophobia
- meningismus (neck pain/stiffness, positive Kernig’s and Brudzinski’s sign)
- decreased LOC (due to either raised ICP, ischemia, seizure)
- focal deficits: cranial nerve palsies (CN III, IV), hemiparesis
- ocular hemorrhage in 20-40% (due to sudden raised ICP compressing central retinal vein)

Figure 17. Aneurysms of the Circle of Willis

Hemicraniectomy in Older Patients with Extensive Middle-Cerebral-Artery Stroke
NEJM 2014;370:1091-1100

Purpose: To determine if early decompressive hemicraniectomy reduces mortality among patients >60 yr.

Study: 112 patients >60 yr (median age 70 yr) with malignant MCA infarction randomly assigned to conservative ICU treatment versus hemicraniectomy. Endpoint was survival without severe disability (modified Rankin scale score 0-4).

Results: The proportion of patients who survived without severe disability was 38% in the hemicraniectomy group and 18% in the control group (OR 2.91, 95% CI 1.06-7.49). Modified Rankin scale scores in hemicraniectomy versus control group in terms of percentages of patients: 0-2 (0%, 0%), 3 or moderate disability (17%, 3%), 4 or moderate severe disability (32%, 15%), 5 or severe disability (22%, 13%) and 6 or death (33%, 70%). Infections were more frequent in the hemicraniectomy group and herniation more frequent in the control group.

Conclusions: Hemicraniectomy increased survival without severe disability among patients >60 yr with a malignant MCA infarction.

Hunt and Hess Grade
(clinical grading scale for SAH)

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>No Sx or mild H/A and/or mild meningeal signs</td>
</tr>
<tr>
<td>2</td>
<td>Grade 1 + CN palsy</td>
</tr>
<tr>
<td>3</td>
<td>Confusion/lethargy, mild hemiparesis, or aphasia</td>
</tr>
<tr>
<td>4</td>
<td>GCS &lt;15 but &gt;8, moderate-severe hemiparesis, mild rigidity</td>
</tr>
<tr>
<td>5</td>
<td>Coma (GCS &lt;8), decerebrate, moribund appearance</td>
</tr>
</tbody>
</table>

Mortality of Grade 1-2: 20%, increased with grade
Cerebrovascular Disease

• reactive HTN
• sentinel bleeds
  ■ represents undiagnosed SAH
  ■ SAH-like symptoms lasting <1 d ("thunderclap H/A")
  ■ may have blood on CT or LP
  ■ ~30-60% of patients with full blown SAH give history suggestive of sentinel bleed within past 3 wk
• differential diagnosis: sentinel bleed, dissection/thrombosis of aneurysm, venous sinus thrombosis, benign cerebral vasculitis, benign exertional H/A

Investigations
• non-contrast CT – for diagnosis of SAH
  ■ 98% sensitive within 12 h, 93% within 24 h; 100% specificity
  ■ may be negative if small bleed or presentation delayed several days
  ■ acute hydrocephalus, IVH, ICH, infarct or large aneurysm may be visible
• lumbar puncture (highly sensitive) – for diagnosis of SAH if CT negative but high suspicion:
  ■ elevated opening pressure (>18 cm H2O)
  ■ bloody initially, xanthochromic supernatant with centrifugation ("yellow") by ~12 h, lasts 2 wk
  ■ RBC count usually >100,000/mm³ without significant drop from first to last tube (in contrast to traumatic tap)
  ■ elevated protein due to blood breakdown products
• four vessel cerebral angiography ("gold standard" for aneurysms)
  ■ demonstrates source of SAH in 80-85% of cases
  ■ angigram negative SAH: repeat angigram in 7-14 d, if negative → "perimesencephalic SAH"
• MRA and CTA: sensitivity up to 95% for aneurysms, CTA>MRA for smaller aneurysms and delineating adjacent bony anatomy

World Federation of Neurological Surgeons Grading of SAH

<table>
<thead>
<tr>
<th>WFNS Grade</th>
<th>GCS Score</th>
<th>Aphasia, Hemiparesis, or Hemiplegia</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 *</td>
<td>15</td>
<td>–</td>
</tr>
<tr>
<td>1</td>
<td>13-14</td>
<td>–</td>
</tr>
<tr>
<td>2</td>
<td>13-14</td>
<td>+</td>
</tr>
<tr>
<td>3</td>
<td>7-12</td>
<td>+ or –</td>
</tr>
<tr>
<td>4</td>
<td>3-6</td>
<td>+ or –</td>
</tr>
</tbody>
</table>

*Intact aneurysm


Background: Two rules for SAH diagnosis exist. A clinical prediction rule states that patients with acute severe H/A but without the clinical variables age >40 yr, neck pain, loss of consciousness, or onset of H/A with exertion are at low risk for SAH. An imaging prediction rule bases diagnosis on non-contrast cranial CT for patients within 6 h of H/A onset.

Methods: Matched case-control study of 55 patients at 21 emergency departments between 2000 and 2011, and diagnoses were verified by lumbar puncture.

Results: The clinical prediction rule for diagnosis of SAH was 97.1% sensitive, 22.7% specific, and had a negative likelihood ratio of 0.13. Using the imaging prediction rule resulted in a false negative rate of 20%.

Conclusions: Performing the clinical and imaging rules together has the potential for maximizing sensitivity of prediction and reducing rates of lumbar puncture, but using imaging alone can result in missed cases.

Calcium Antagonists for Aneurysmal Subarachnoid Hemorrhage Cochrane DB Syst Rev 2007;3:CD000277

Introduction: This study looked to review the evidence in regards to whether calcium antagonists improve the outcome in patients with aneurysmal subarachnoid hemorrhage.

Methods/Population: The review included 3,361 patients presenting with aneurysmal subarachnoid hemorrhage from 16 RCTs comparing treatment with calcium antagonists vs. control from 1980 to March 2006.

Results: The results were based mainly on one large trial of oral nimodipine, which showed a RR of 0.67 (95% CI 0.55-0.81) and the evidence for other calcium agents was not statistically significant.

Conclusion: The authors endorse the use of oral nimodipine in patients with aneurysmal subarachnoid hemorrhage.

Fisher Grade (SAH on CT scan)

<table>
<thead>
<tr>
<th>Grade</th>
<th>Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Normal scan</td>
</tr>
<tr>
<td>2</td>
<td>&lt;1 mm thick blood</td>
</tr>
<tr>
<td>3</td>
<td>&gt;1 mm thick blood</td>
</tr>
<tr>
<td>4</td>
<td>SAH + ICH or IVH</td>
</tr>
</tbody>
</table>

Treatment
• admit to ICU or NICU
  ■ oxygen/ventilation prn
  ■ NPO, bed rest, elevate head of bed 30°, minimal external stimulation, neurological vitals q1h
  ■ aim to maintain sBP = 120-150 (balance of vasospasm prophylaxis, risk of rebleed, risk of hypotension since CBF autoregulation impaired by SAH)
  ■ cardiac rhythm monitor, Foley prn, strict monitoring of ins and outs

Figure 18. Diagnosis of SAH

Figure 19. Approach to SAH
**Intracranial Aneurysms**

**Epidemiology**
- prevalence 1-4% (20% have multiple)
- F>M; age 35-65 yr

**Risk Factors**
- autosomal dominant polycystic kidney disease (15%)
- fibromuscular dysplasia (7-21%)
- AVMs
- connective tissue diseases (Ehlers-Danlos, Marfan)
- family history
- bacterial endocarditis
- Osler-Weber-Rendu syndrome (hereditary hemorrhagic telangiectasia)
- atherosclerosis and HTN
- trauma

**Types**
- saccular (berry)
  - most common type
  - located at branch points of major cerebral arteries (Circle of Willis)
- fusiform
  - atherosclerotic
  - more common in vertebrobasilar system, rarely rupture
- infectious
  - secondary to any infection of vessel wall, 20% multiple
  - 60% *Streptococcus* and *Staphylococcus*
  - 3-15% of patients with bacterial endocarditis
Table 12. Five Year Cumulative Rupture Risk in Unruptured Aneurysms Based on Size and Location

<table>
<thead>
<tr>
<th>Size</th>
<th>Cavernous Carotid</th>
<th>AC/MC/IC</th>
<th>Vertebrobasilar/PC/PComm</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;7 mm</td>
<td>0%</td>
<td>0%</td>
<td>2.5%</td>
</tr>
<tr>
<td>7-12 mm</td>
<td>0%</td>
<td>2.6%</td>
<td>14.5%</td>
</tr>
<tr>
<td>13-24 mm</td>
<td>3%</td>
<td>14.5%</td>
<td>18.4%</td>
</tr>
<tr>
<td>≥24 mm</td>
<td>6.4%</td>
<td>40%</td>
<td>50%</td>
</tr>
</tbody>
</table>

AC = anterior cerebral/arterial communicating artery; IC = internal carotid artery; MC = middle cerebral artery; PC = posterior cerebral artery; PComm = posterior communicating artery.

Clinical Presentation
- rupture (90%), most often SAH, but 30% ICH, 20% IVH, 3% subdural bleed
- sentinel hemorrhage ("thunderclap H/A") requires urgent clipping/coiling to prevent catastrophic bleed
- mass effect (giant aneurysms)
  - internal carotid or anterior communicating aneurysm may compress:
    - the pituitary stalk or hypophalamous causing hypopituitarism
    - the optic nerve or chiasm producing a visual field defect
- basilar artery aneurysm may compress midbrain, pons (limb weakness), or CN III
- posterior communicating artery aneurysm may produce CN III palsy
- intracavernous aneurysms (CN III, IV, V1, V2, VI)
- distal embolization (e.g. amaurosis fugax)
- seizures
- H/A (without hemorrhage)
- incidental CT or angiography finding (asymptomatic)

Investigations
- CT angiogram (CTA), magnetic resonance angiography (MRA), cerebral angiogram

Treatment
- ruptured aneurysms
  - overall trend towards better outcome with early surgery or coiling (48-96 h after SAH)
  - treatment options: surgical placement of clip across aneurysm neck, trapping (clipping of proximal and distal vessels), thrombosing using Guglielmi detachable coils (coiling) or flow diversion stents, wrapping (last resort)
  - choice of surgery vs. coiling not yet well defined: consider location, size, shape, and tortuosity of the aneurysm, patient comorbidities, age, and neurological condition; in general:
    - clipping: posterior > anterior circulation, deep/eloquent location, basilar artery bifurcation/apex, older age, presence of comorbidities, presence of vasospasm
    - clipping: superficial > deep, broad aneurysmal base, branching arteries at the aneurysm base, tortuosity/atherosclerosis of afferent vessels, dissection, hematoma, acute brainstem compression
- unruptured aneurysms
  - average 1% annual risk of rupture: risk dependent on size and location of aneurysm
  - no clear evidence on when to operate: need to weigh life expectancy
  - risk of morbidity/mortality of SAH (20%-50%) vs. surgical risk (2%-5%)
  - generally treat unruptured aneurysms >10 mm
  - consider treating when aneurysm 7-9 mm in middle-aged, younger patients or patients with a family history of aneurysms
  - follow smaller aneurysms with serial angiography

Intracerebral Hemorrhage

Definition
- hemorrhage within brain parenchyma, accounts for ~10% of strokes
- can dissect into ventricular system (IVH) or through cortical surface (SAH)

Etiology
- HTN (usually causes bleeds at putamen, thalamus, pons, and cerebellum)
- hemorrhagic transformation (reperfusion post stroke, surgery, strenuous exercise, etc.)
- vascular anomalies
  - aneurysms, AVMs, and other vascular malformations (see Vascular Malformations, NS21)
  - venous sinus thrombosis
  - arteriopathies (cerebral amyloid angiopathy, lipohyalinosis, vasculitis)
- tumors (1%): often malignant (e.g. GBM, lymphoma, metastases)
- drugs (amphetamine, cocaine, alcohol, anticoagulants, etc.)
- coagulopathy (iatrogenic, leukemia, TTP, aplastic anemia)
- CNS infections (fungal, granulomas, herpes simplex encephalitis)
- post trauma (immediate or delayed, frontal and temporal lobes most commonly injured via coup-contrecoup mechanism)
- eclampsia
- post-operative (post-carotid endarterectomy cerebral reperfusion, craniotomy)
- idiopathic

Development of the PHASES Score for Prediction of Risk of Rupture of Intracranial Aneurysms: A Pooled Analysis of Six Prospective Cohort Studies
Purpose: The construction of an algorithm for estimating 5 yr aneurysm rupture risk.
Study: Systematic review and analysis of patient data. 8,382 patients. 6 prospective cohort studies.
Outcome was SAH.
Results: Predictors of aneurysm rupture were age, HTN, history of subarachnoid hemorrhage, aneurysm size, aneurysm location, and geographical region. In North America and European populations, the 5 yr risk of rupture ranged from 0.25% in individuals <70 yr without vascular risk factors and with no ICA aneurysm <3 mm to >15% in patients >70 yr with HTN, a history of SAH, and >20 mm posterior circulation aneurysm. Finnish and Japanese people had a 3.6- and 2.9-fold higher risk of rupture, respectively, compared with North American and European populations.
Conclusions: The PHASES score may help to predict risk of rupture for incidental intracranial aneurysms.

Long-Term, Serial Screening for Intracranial Aneurysms in Individuals with a Family History of Intracranial Subarachnoid Hemorrhage: A Cohort Study
Lancet Neurol 2014;13:385-392
Purpose: To examine the yield of long-term serial screening for intracranial aneurysms for individuals with a positive family history of intracranial subarachnoid hemorrhage (gSAH) or more first degree relatives who have had anSAH or unruptured intracranial aneurysms.
Study: Screening results from April 1 1993 to April 1 2013 were reviewed in a cohort study. MRI or CTA was done from age 16-18 to 65-70 yr. After a negative screen, individuals were advised to contact the clinic in 5 yr for follow up.
Results: Aneurysms were identified in 11% of individuals at first screening (n=450), 8% at second screening (n=261), 5% at third screening (n=120), and 5% at fourth screening (n=63). Smoking (OR 2.7, 95% CI 1.2-5.9), history of previous aneurysms (3.9, 1.2-12.7), and familial history of aneurysms (3.5, 1.8-6.6) were significant risk factors for aneurysm at first screening. History of previous aneurysms was the only significant risk factor for aneurysms at follow-up screening (HR 4.5, 95% CI 1.1-18.7).
Conclusions: The benefit of long-term screening in individuals with a family history of gSAH is substantial up to and after 10 yr of follow-up and two initial negative screens.

Location of ICH
Basal Ganglia/Internal Capsule (50%)
Thalamus (15%)
Cerebral White Matter (15%)
Cerebellum/Brainstem – usually pons (15%)
Other (5%)
Epidemiology
• 12-15 cases/100,000 population/yr

Risk Factors
• increasing age (mainly >55 yr)
• male gender
• HTN
• Black/Asian > Caucasian
• previous CVA of any type (23x risk)
• both acute and chronic heavy alcohol use; cocaine, amphetamines
• liver disease
• anticoagulants

Clinical Features
• TIA-like symptoms often precede ICH, can localize to site of impending hemorrhage
• gradual onset of symptoms over minutes-hours, usually during activity
• H/A, N/V, and decreased LOC are common
• specific symptoms/deficits depend on location of ICH

Investigations
• hyperdense blood on non-contrast CT
• CTA routine, if spot sign demonstrated there is high likelihood of clot growth

Treatment
• medical
  • decrease MAP to pre-morbid level or by ~20% (target BP 140/90)
  • check PTI/INR, and correct coagulopathy
  • control raised ICP (see Intracranial Pressure Dynamics, NS4)
  • levetiracetam/phenytoin for seizure prophylaxis
  • follow electrolytes (SIADH common)
  • angiogram to rule out vascular lesion unless >45 yr, known HTN, and putamen/thalamic/posterior fossa ICH (yield ~0%)
• surgical
  • craniotomy with evacuation of clot, treatment of source of ICH (i.e. AVM, tumour, cavernoma), ventriculostomy to treat hydrocephalus
  • indications
    • symptoms of raised ICP or mass effect
    • rapid deterioration (especially if signs of brainstem compression)
    • favourable location (e.g. cerebellar, non-dominant hemisphere)
    • young patient (<50 yr)
    • if tumour, AVM, aneurysm, or cavernoma suspected (resection or clip to decrease risk of rebleed)
  • contraindications
    • small bleed: minimal symptoms, GCS >10
    • poor prognosis: massive hemorrhage (especially dominant lobe), low GCS/coma, lost brainstem function
    • medical reasons (e.g. very elderly, severe coagulopathy, difficult location [e.g. basal ganglia, thalamus])

Prognosis
• 30-d mortality rate 44%, mostly due to cerebral herniation
• rebleed rate 2-6%, higher if HTN poorly controlled

Vascular Malformations

Types
• arteriovenous malformations (AVMs)
• cavernous malformations (= cavernomas, cavernous hemangiomas/angiomas)
• venous angioma
• capillary telangiectasias
• arteriovenous fistula (AVF) (carotid-cavernous fistula, dural AVF, vein of Galen aneurysm)
• “angiographically occult vascular malformations” (any type, 10% of malformations)
Table 13. Comparison of Pathoetiology, Clinical Presentation, and Treatment of Arteriovenous Malformations, Cavernous Malformations, and Dural Fistula’s

<table>
<thead>
<tr>
<th>Arteriovenous Malformation</th>
<th>Cavernous Malformations</th>
<th>Dural Fistulas</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definition</strong></td>
<td>Benign vascular hamartoma consisting of irregular sinusoidal vascular channels located within the brain without intervening neural tissue or associated large arteries/veins</td>
<td>Fistula’s connecting dural arteries to dural veins or the dural sinus frequently described to occur at the transverse and cavernous sinuses, but can be found at every cranial dural sinus hypothesized to be related to venous sinus thrombosis formation, and subsequent microvascular shunt formation within the dura between arteries and veins</td>
</tr>
<tr>
<td><strong>Epidemiology</strong></td>
<td>Prevalence ~0.14%, M:F = 2:1, average age at diagnosis ~ 33 yr, 15-20% of patients with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome) will have cerebral AVMs</td>
<td>Prevalence of 0.1-0.2%, both sporadic and hereditary forms described</td>
</tr>
<tr>
<td><strong>Clinical Features</strong></td>
<td>Hemorrhage (40-60%): small AVMs are more likely to bleed due to direct high pressure AV connections. Seizures (50%): more common with larger AVMs Mass effect: focal neurological signs secondary to ischemia (high flow → “steal phenomena”). Localized headache, increased ICP. Bruit (especially with dural AVMs) May be asymptomatic (“silent”)</td>
<td>Seizures (60%), progressive neurological deficit (50%), hemorrhage (20%), H/A often an incidental finding. Hemorrhage risk less than AVM, usually minor bleeds</td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td>MRI (flow void), MRA. Angiography (7% will also have one or more associated aneurysms)</td>
<td>T2WI MRI (non-enhancing) gradient echo sequencing (best for diagnosis)</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>Decreases risk of future hemorrhage and seizure. Surgical excision is treatment of choice. SRS (stereotactic radiosurgery) is preferred for small (&lt;3 cm) or very deep lesions. Endovascular embolization (glue, balloon) can be curative (5%) or used as adjuvant to surgery or SRS in larger lesions. Conservative (e.g., palliative embolization, seizure control if necessary).</td>
<td>Surgical excision is appropriate for symptomatic lesions that are surgically accessible (supratentorial lesions are less likely to bleed than infratentorial lesions). Approach is dependent on size, location and symptoms, and includes: Conservative treatment. Neuroangiological endovascular interventions. Radiation therapy. Surgery. Combination of the above.</td>
</tr>
<tr>
<td><strong>Prognosis</strong></td>
<td>10% mortality, 30-50% morbidity (serious neurological deficit) per bleed. Risk of major bleed in untreated AVMs: 2-4% per year.</td>
<td>8.1% annual risk of hemorrhage. 6.9% annual risk for non-hemorrhagic neurological deficit. 10.4% mortality rate.</td>
</tr>
</tbody>
</table>
Cerebrospinal Fluid Fistulas

Etiology
- cranial or spinal
- traumatic: after head trauma, iatrogenic (post-transsphenoidal surgery, post skull base surgery)
- nontraumatic: high pressure (hydrocephalus, tumour), normal pressure (bone erosion secondary to infection, congenital defect)

Clinical Features
- otorrhea or rhinorrhea (clear fluid)
- low pressure headaches (worse when sitting up)
- confirmatory testing for CSF: beta transferrin test, quantitative glucose analysis of fluid, “ring sign”, “reservoir sign”

Investigations
- CT (detect pneumocephalus, fractures, skull base defects), water contrast CT cisternography

Treatment
- lower ICP (avoid straining, acetazolamide to reduce CSF production, modest fluid restriction)
- persistent leak: may require continuous lumbar drainage via percutaneous catheter
- surgical indications: traumatic leak lasting > 2wks, spontaneous leaks, delayed onset of leak after trauma or surgery, leaks complicated by meningitis

EXTRACRANIAL PATHOLOGY

Approach to Limb/Back Pain
- see Orthopedics, OR23

Extradural Lesions

Figure 21. Vascular supply of spinal cord
Root Compression

Differential Diagnosis
- herniated disc
- neoplasm (neurofibroma, schwannoma)
- synovial cyst, abscess
- hypertrophic bone/spur

Cervical Disc Syndrome

Etiology
- nucleus pulposus herniates through annulus fibrosus and impinges upon nerve root, most commonly at C6-C7 (C7 root)

Clinical Features
- pain in arm follows nerve root distribution, worse with neck extension, ipsilateral rotation, and lateral flexion (all compress the ipsilateral neural foramen)
- LMN signs and symptoms
- central cervical disc protrusion causes myelopathy as well as nerve root deficits

Investigations
- if red flags: C-spine x-ray, CT, MRI (imaging of choice)
- only consider EMG, nerve conduction studies if diagnosis uncertain and presenting more as peripheral nerve issue

Treatment
- conservative
  - no bedrest unless severe radicular symptoms
  - activity modification, patient education (reduce sitting, lifting)
  - physiotherapy, exercise programs focus on strengthening core muscles
  - analgesics, NSAIDs are more efficacious
  - avoid cervical manipulation, like traction
- surgical indications
  - anterior cervical disectomy is usual approach
  - intractable pain despite adequate conservative treatment for >3 mo
  - progressive neurological deficit

Prognosis
- 95% improve spontaneously in 4-8 wk

Table 14. Lateral Cervical Disc Syndromes

<table>
<thead>
<tr>
<th>Root Involved</th>
<th>C4-5</th>
<th>C5-6</th>
<th>C6-7</th>
<th>C7-T1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence</td>
<td>2%</td>
<td>19%</td>
<td>69%</td>
<td>10%</td>
</tr>
<tr>
<td>Sensory</td>
<td>Shoulder</td>
<td>Thumb</td>
<td>Middle finger</td>
<td>Ring finger, 5th finger</td>
</tr>
<tr>
<td>Motor</td>
<td>Deltoit, biceps, supraspinatus</td>
<td>Biceps</td>
<td>Triceps</td>
<td>Digital flexors, intrinsics</td>
</tr>
<tr>
<td>Reflex</td>
<td>No change</td>
<td>Biceps, brachioradialis</td>
<td>Triceps</td>
<td>Finger jerk (Hoffmann's sign)</td>
</tr>
</tbody>
</table>

Cervical Spondylosis

Definition
- progressive degenerative process of cervical spine leading to canal stenosis – congenital spinal stenosis, degeneration of intervertebral discs, hypertrophy of lamina, dura, or ligaments, subluxation, altered mobility, telescoping of the spine due to loss of height of vertebral bodies, alteration of normal lordotic curvature
- resultant syndromes: mechanical neck pain, radiculopathy (root compression), myelopathy (spinal cord compression)

Epidemiology
- typically begins at age 40-50, M>F, most commonly at the C5-C6 > C6-C7 levels

Pathogenesis
- any of: disc degeneration/herniation, osteophyte formation, ossification, and hypertrophy of ligaments
- pathophysiology includes static compression, dynamic compression, and vascular compromise
Clinical Features

- **Insidious onset** of mechanical neck pain exacerbated by excess vertebral motion (particularly rotation and lateral bending with a vertical compressive force – Spurling’s test)
- The earliest symptoms are gait disturbance and lower extremity weakness or stiffness
- Occipital H/A is common
- Radiculopathy may involve 1 or more roots, and symptoms include neck, shoulder and arm pain, paresthesias and numbness
- Cervical spondylotic myelopathy (CSM) may present with:
  - Weakness (upper > lower extremity), lower extremity weakness (corticospinal tracts) is most worrisome complaint
  - Decreased dexterity, loss of fine motor control
  - Sensory changes
  - UMN findings such as hyperreflexia, clonus, and Babinski reflex
  - Funicular pain, characterized by burning and stinging ± Lhermitté’s sign (lightning-like sensation down the back with neck flexion)

Investigations

- X-ray of cervical spine ± flexion/extension (alignment, fractures)
- MRI most useful for determination of compression of the neural element
- CT is only used for better determination of bony anatomy (i.e. OPLL)
- EMG/nerve conduction studies reserved for peripheral nerve investigation

Treatment

- Nonsurgical: prolonged immobilization with cervical bracing (limit movement to minimize cumulative trauma to spinal cord), bed rest, anti-inflammatory medications
- Surgical: anterior approach (anterior cervical discectomy or corpectomy), posterior approach (decompressive cervical laminectomy)
- Surgical indications: myelopathy with motor impairment, progressive neurologic impairment, intractable pain
- Complete remission almost never occurs. Surgical decompression may stop progression of disease

Lumbar Disc Syndrome

Etiology

- Posteriorly laterally herniated disc compressed nerve root exiting BELOW the level of the disc or the traversing nerve root
- Far lateral disc herniation compressed nerve root AT the level of the disc or the exiting nerve root
- Central herniation causes cauda equina or lumbar stenosis (neurogenic claudication)

Clinical Features

- Initial back pain, then leg pain > back pain
- Limited back movement (especially forward flexion) due to pain
- Motor weakness, dermatomal sensory changes, decreased reflexes
- Exacerbation with Valsalva; relief with flexing the knee or thigh
- Nerve root tension signs
  - Straight leg raise (SLR, Lasegue’s test) or crossed SLR (pain should occur at less than 60°) suggests L5, S1 root involvement
  - Femoral stretch test suggests L2, L3, or L4 root involvement

Investigations

- MRI is modality of choice
- X-ray spine (only to rule out other lesions), CT (bony anatomy)
- Myelogram and post-myelogram CT (only if MRI is contraindicated)

Treatment

- Conservative (same as cervical disc disease)
- Surgical indications: same as cervical disc + cauda equina syndrome

Prognosis

- 95% improve spontaneously within 4-8 wk
- Do not follow patients with serial MRIs; clinical status is more important at guiding management

### Table 15. Lateral Lumbar Disc Syndromes

<table>
<thead>
<tr>
<th>Root Involved</th>
<th>L3-4</th>
<th>L4-5</th>
<th>L5-S1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence</td>
<td>&lt;10%</td>
<td>45%</td>
<td>45%</td>
</tr>
<tr>
<td>Pain</td>
<td>Femoral pattern</td>
<td>Sciatic pattern</td>
<td>Sciatic pattern</td>
</tr>
<tr>
<td>Sensory</td>
<td>Medial leg</td>
<td>Dorsal foot to hallux</td>
<td>Lateral leg</td>
</tr>
<tr>
<td>Motor</td>
<td>Tibialis anterior (dorsiflexion)</td>
<td>Extensor hallucis longus (hallux extension)</td>
<td>Gastrocnemius, soleus (plantar flexion)</td>
</tr>
<tr>
<td>Reflex</td>
<td>Knee jerk</td>
<td>Medial hamstrings</td>
<td>Ankle jerk</td>
</tr>
</tbody>
</table>
Table 16. Differentiating Conus Medullaris Syndrome from Cauda Equina Syndrome

<table>
<thead>
<tr>
<th></th>
<th>Conus Medullaris Syndrome</th>
<th>Cauda Equina Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset</td>
<td>Sudden, bilateral</td>
<td>Gradual, unilateral</td>
</tr>
<tr>
<td>Spontaneous Pain</td>
<td>Rare, if present usually bilateral, symmetric in perineum or thighs</td>
<td>Severe, radicular type: in perineum, thighs, legs, back, or bladder</td>
</tr>
<tr>
<td>Sensory Deficit</td>
<td>Saddle; bilateral and symmetric; sensory dissociation</td>
<td>Saddle; no sensory dissociation; may be unilateral and asymmetric</td>
</tr>
<tr>
<td>Motor Deficit</td>
<td>Symmetric; paresis less marked; fasciculations may be present</td>
<td>Knee and ankle jerk may be absent</td>
</tr>
<tr>
<td>Reflexes</td>
<td>Only ankle jerk absent (preserved knee jerk)</td>
<td>Urinary retention and atomich anal sphincter prominent early, impotence frequent</td>
</tr>
<tr>
<td>Autonomic Symptoms (bladder dysfunction, impotence, etc.)</td>
<td>Urinary retention and atomich anal sphincter prominent early, impotence frequent</td>
<td>Sphincter dysfunction presents late; impotence less frequent</td>
</tr>
</tbody>
</table>

Cauda Equina Syndrome

**Etiology**
- compression or irritation of lumbosacral nerve roots below conus medullaris (below L2 level)
- decreased space in the vertebral canal below L2
- common causes: herniated disc ± spinal stenosis, vertebral fracture, and tumour

**Clinical Features**
- usually acute (develops in less than 24 h); rarely subacute or chronic
- motor (LMN signs)
  - weakness/paraparesis in multiple root distribution
  - reduced deep tendon reflexes (knee or ankle)
- autonomic
  - urinary retention (or overflow incontinence) and/or fecal incontinence due to loss of anal sphincter tone
- sensory
  - low back pain radiating to legs (sciatica) aggravated by Valsalva maneuver and by sitting; relieved by lying down
  - bilateral sensory loss or pain: depends on the level affected
  - saddle area (S2-S5) anesthesia
  - sexual dysfunction (late finding)

**Investigations**
- urgent MRI to confirm compression of S2-S3-S4 nerve root by a large disc herniation
- post-void residual very helpful to determine if true retention is present; volumes controversial but anything over 250 cc in a healthy individual is cause for concerns

**Treatment**
- surgical decompression (<48 h) to preserve bowel, bladder, and sexual function, and/or to prevent progression to paraplegia

**Prognosis**
- markedly improves with surgical decompression
- recovery correlates with function at initial presentation: if patient is ambulatory, likely to continue to be ambulatory; if unable to walk, unlikely to walk after surgery

Lumbar Spinal Stenosis

**Etiology**
- congenital narrowing of spinal canal combined with degenerative changes (herniated disc, hypertrophied facet joints, and ligamentum flavum)

**Clinical Features**
- gradually progressive back and leg pain with standing and walking that is relieved by sitting or lying down (neurogenic claudication – 60% sensitive)
- neurologic exam may be normal, including straight leg raise test

**Investigations**
- MRI is the optimal investigation to confirm and localize the level of stenosis (unlike nerve root compression which can be localized with clinical exam)

**Treatment**
- conservative: NSAIDs, analgesia
- surgical: laminectomy with root decompression (the role of fusion may need to be considered if the amount of bone removed with the laminectomy results in destabilization)
Neurogenic Claudication

Etiology
- ischemia of lumbosacral nerve roots secondary to vascular compromise and increased demand from exertion, often associated with lumbar stenosis

Clinical Features
- dermatomal pain/paresthesia/weakness of buttock, hip, thigh, or leg initiated by standing or walking
- slow relief with postural changes (sitting >30 min), NOT simply exertion cessation
- induced by variable degrees of exercise or standing
- may be elicited with lumbar extension, but may not have any other neurological findings, no signs of vascular compromise (e.g. ulcers, poor capillary refill, etc.)

Investigations
- bicycle test may help distinguish neurogenic claudication (NC) from vascular claudication (the waist-flexed individuals on the bicycle with NC can last longer)

Treatment
- same as for lumbar spinal stenosis

Intradural Intramedullary Lesions

Syringomyelia (Syrinx)

Definition
- cystic cavitation of the spinal cord
- presentation is highly variable, usually progresses over months to years
- initially pain, weakness, later atrophy and loss of pain and temperature sensation

Etiology
- 70% are associated with Chiari I malformation, 10% with basilar invagination
- post-traumatic
- tumour
- tethered cord

Clinical Features
- nonspecific features for any intramedullary spinal cord pathology
  - initially pain, weakness, atrophy, loss of pain and temperature in upper extremities (central syrinx) with progressive myelopathy over years
  - sensory loss with preserved touch and proprioception in a band-like distribution at the level of cervical syrinx
  - dysesthetic pain often occurs in the distribution of the sensory loss
  - LMN arm/hand weakness or wasting
  - painless neuropathic arthropathies (Charcot’s joints), especially in the shoulder and neck due to loss of pain and temperature sensation

Investigations
- MRI is best method, myelogram with delayed CT

Treatment
- treat underlying cause (e.g. posterior fossa decompression for Chiari I, surgical removal of tumour if causing a syrinx)
- rarely does the syrinx need to be shunted, only when progressive and size allows for insertion of tube

Spinal Cord Syndromes

Complete Spinal Cord Lesion
- bilateral loss of motor/sensory and autonomic function at ≥4 segments below lesion/injury, with UMN signs
- about 3% of patients with complete injuries will develop some recovery within 24 h, beyond 24 h, no distal function will recover

Incomplete Spinal Cord Lesion
- any residual function at ≥4 segments below lesion
- signs include sensory/motor function in lower limbs and “sacral sparing” (perianal sensation, voluntary rectal sphincter contraction)
Table 17. Comparison Between Incomplete Spinal Cord Lesion Syndromes

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Etiology</th>
<th>Motor</th>
<th>Sensory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brown–Séquard</td>
<td>Hemisection of cord</td>
<td>Ipsilateral LMN weakness at the lesion</td>
<td>Ipsilateral loss of vibration and proprioception</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ipsilateral UMN weakness at the lesion</td>
<td>Contralateral loss of pain and temperature</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Preserved light touch</td>
</tr>
<tr>
<td>Anterior Cord</td>
<td>Anterior spinal artery compression or occlusion</td>
<td>Bilateral LMN weakness at the lesion</td>
<td>Preserved vibration and proprioception</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bilateral UMN weakness below the lesion</td>
<td>Bilateral loss of pain and temperature</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Urinary retention</td>
<td>Preserved light touch</td>
</tr>
<tr>
<td>Central Cord</td>
<td>Syringomyelia, tumours, spinal hyperextension injury</td>
<td>Bilateral motor weakness: Upper limb weakness (LMN lesion) &gt; Lower limb weakness (UMN lesion)</td>
<td>Variable bilateral suspended sensory loss</td>
</tr>
<tr>
<td>(most common)</td>
<td></td>
<td>Urinary retention</td>
<td>Loss of pain and temperature &gt; loss of vibration and proprioception</td>
</tr>
<tr>
<td>Posterior Cord</td>
<td>Posterior spinal artery infarction, trauma</td>
<td>Preserved</td>
<td>Bilateral loss of vibration, proprioception, light touch at and below the lesion</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Preserved pain and temperature</td>
</tr>
</tbody>
</table>

Peripheral Nerves

- see Neurology, N36

Classification

Table 18. Seddon’s Classification of Peripheral Nerve Injury

<table>
<thead>
<tr>
<th>Nerve Injury</th>
<th>Description</th>
<th>Recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurapraxia (class I)</td>
<td>Axon structurally intact but fails to function</td>
<td>Within hours to months (average 6-8 wk)</td>
</tr>
<tr>
<td>Axonotmesis (class II)</td>
<td>Axon and myelin sheath disrupted but endoneurium and supporting structures intact → Wallerian degeneration of axon segment distal to injury</td>
<td>Spontaneous axonal recovery at 1 mm/d, max at 1-2 yr</td>
</tr>
<tr>
<td>Neurotmesis (class III)</td>
<td>Nerve completely transected</td>
<td>Need surgical repair for possibility of recovery</td>
</tr>
</tbody>
</table>

Etiology

- ischemia
- nerve entrapment – nerve compressed by nearby anatomic structures, often secondary to localized, repetitive mechanical trauma with additional vascular injury to nerve

Investigations

- clinical exam: power, sensation, reflexes, localization via Tinel’s sign (paresthesias elicited by tapping along the course of a nerve)
- electrophysiological studies: EMG, nerve conduction study (assess nerve integrity and monitoring recovery after 2-3 wk post-injury)
- labs: blood work, CSF
- imaging: C-spine, chest/bone x-rays, myelogram, CT, magnetic resonance neurography, angiogram if vascular damage is suspected

Treatment

- early neurosurgical consultation if injury is suspected

Table 19. Treatment by Injury Type

<table>
<thead>
<tr>
<th>Injury</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Entrapment</td>
<td>Conservative: prevent repeated stress/injury, physiotherapy, NSAIDs, local anesthesia/steroid injection</td>
</tr>
<tr>
<td></td>
<td>Surgical: nerve decompression ± transposition for progressive deficits, muscle weakness/atrophy, failure of medical management</td>
</tr>
<tr>
<td>Stretch/contusion</td>
<td>Follow-up clinically for recovery; exploration if no recovery in 3 mo</td>
</tr>
<tr>
<td>Axonotmesis</td>
<td>If no evidence of recovery, resect damaged segment</td>
</tr>
<tr>
<td></td>
<td>Prompt physical therapy and rehabilitation to increase muscle function, maintain joint ROM, maximize return of useful function</td>
</tr>
<tr>
<td></td>
<td>Recovery usually incomplete</td>
</tr>
<tr>
<td>Neurotmesis</td>
<td>Surgical repair of nerve sheath unless known to be intact (suture nerve sheaths directly if ends approximate or nerve graft [usually sural nerve])</td>
</tr>
<tr>
<td></td>
<td>Clean laceration: early exploration and repair</td>
</tr>
<tr>
<td></td>
<td>Contamination or associated injuries: tag initially with nonabsorbable suture, reapproach within 10 d</td>
</tr>
</tbody>
</table>
Complications
• neuropathic pain: with neuroma formation
• complex regional pain syndrome: with sympathetic nervous system involvement

SPECIALTY TOPICS

Neurotrauma

Trauma Management (see Emergency Medicine, ER8)

Indications for Intubation in Trauma
1. depressed LOC (patient cannot protect airway): usually GCS ≤8
2. need for hyperventilation
3. severe maxillofacial trauma: patency of airway is doubtful
4. need for pharmacologic paralysis for evaluation or management
   • if basal skull fracture suspected, avoid nasalotracheal intubation as may inadvertently enter brain
   • note: intubation prevents patient’s ability to verbalize for determining GCS

Trauma Assessment

Initial Management

ABCs of Trauma Management
• see Emergency Medicine, ER8

Neurological Assessment

Mini-History
• period of LOC, post-traumatic amnesia, loss of sensation/function, type of injury/accident

Neurological Exam
• GCS
• head and neck (lacerations, bruises, basal skull fracture signs, facial fractures, foreign bodies)
• spine (palpable deformity, midline pain/tenderness)
• eyes (papillary size and reactivity)
• brainstem (breathing pattern, CN palsies)
• cranial nerve exam
• motor exam, sensory exam (only if GCS is 15), reflexes
• sphincter tone
• record and repeat neurological exam at regular intervals

Investigations
• spinal injury precautions (cervical collar) are continued until C-spine is cleared
• C.T.L-spine x-rays
  • AP, lateral, odontoid views for C-spine (must see from C1 to T1; swimmer’s view if necessary) or CT
  • rarely done: oblique views looking for pars interarticularis fracture (“Scottie dog” sign)
• CT head and upper C-spine (whole C-spine if patient unconscious) look for fractures, loss of mastoid or sinus air spaces, blood in cisterns, pneumocephalus
• cross and type, ABG, CBC, drug screen (especially alcohol)
• chest and pelvic x-ray as indicated

Treatment

Treatment for Minor Head Injury
• observation over 24-48 h
• wake every hour
• judicious use of sedatives or pain killers during monitoring period

Treatment for Severe Head Injury (GCS ≤8)
• clear airway and ensure breathing (if GCS ≤8, intubate)
• secure C-spine
• maintain adequate BP
• monitor for clinical deterioration
• monitor and manage increased ICP if present (see Herniation Syndromes, NS6)
Admission required if
• skull fracture (indirect signs of basal skull fracture, see Head Injury)
• confusion, impaired consciousness, concussion with >5 min amnesia
• focal neurological signs, extreme H/A, vomiting, seizures
• unstable spine
• use of alcohol
• poor social support

Head Injury

Epidemiology
• M:F = 2-3:1

Pathogenesis
• acceleration/deceleration: contusions, subdural hematoma, axon and vessel shearing/mesencephalic hematoma
• impact: skull fracture, concussion, epidural hematoma
• penetrating: worse with high velocity and/or high missile mass
  • low velocity: highest damage to structures on entry/exit path
  • high velocity: highest damage away from missile tract

Scalp Injury
• rich blood supply
• considerable blood loss (vessels contract poorly when ruptured)
• minimal risk of infection due to rich vascularity

Skull Fractures
• depressed fractures: double density on skull x-ray (outer table of depressed segment below inner table of skull), CT with bone window is gold standard
• simple fractures (closed injury): no need for antibiotics, no surgery
• compound fractures (open injury): increased risk of infection, surgical debridement within 24 h is necessary
  • internal fractures into sinus may lead to meningitis, pneumocephalus
  • risk of operative bleed may limit treatment to antibiotics
• basal skull fractures: not readily seen on x-ray, rely on clinical signs
  • retroauricular ecchymoses (Battle’s sign)
  • periorbital ecchymosis (raccoon eyes)
  • hemotympanum
• CSF rhinorrhoea, otorrhea (suspect CSF if halo or target sign present); suspect with LeFort II/III midface fracture

Cranial Nerve Injury
• most traumatic causes of cranial nerve injury do not warrant surgical intervention
• surgical intervention
  • CN II: local eye/orbit injury
  • CN III, IV, VI: if herniation secondary to mass
  • CN VIII: repair of ossicles
• CN injuries that improve
  • CN I: recovery may occur in a few months; most do not improve
  • CN III, IV, VI: majority recover
  • CN VII: recovery with delayed lesions
  • CN VIII: vestibular symptoms improve over weeks, deafness usually permanent (except when resulting from hemotympanum)

Arterial Injury
• e.g. carotid-cavernous (C-C) fistula, carotid/vertebral artery dissection

Intracranial Bleeding
• see Blood, NS15 and Cerebrovascular Disease, NS17

Brain Injury

Primary Impact Injury
• mechanism of injury determines pathology: penetrating injuries, direct impact
  • low velocity: local damage
  • high velocity: distant damage possible (due to wave of compression), concussion
• concussion: a trauma-induced alteration in mental status
  • American Academy of Neurology (AAN) Classification
  • no parenchymal abnormalities on CT

Comparative Effectiveness of Using Computed Tomography Alone to Exclude Cervical Spine Injuries in Obtunded or Intubated Patients: Meta-Analysis of 14,327 Patients with Blunt Trauma
J Neurosurg 2011;115:541-549
Purpose: To determine the effectiveness of helical CT alone (vs. CT and adjunct imaging such as MRI) to diagnose acute unstable cervical spine injury following blunt trauma.
Results: 17 studies with 14,327 patients total. Sensitivity and specificity for modality CT were both >99.9% (95% CI 0.99-1.00 for both). The negative predictive value of a normal CT was 100% (95% CI 0.99-1.00) and accuracy was not affected by the global severity of injury, CT slice thickness, or study quality.
Conclusions: CT alone is sufficient to detect unstable cervical spine injuries in trauma patients and adjunct imaging is unnecessary with a negative CT scan result. Consequently, if a CT scan is negative for acute injury, the cervical collar may be removed from obtunded or intubated trauma patients.

The Canadian CT Head Rule for Patients with Minor Head Injury
Lancet 2001;357:1391-1396
CT Head is only required for patients with minor head injuries with any one of the following:
High Risk (for neurological intervention)
• GCS score <15 at 2 h after injury.
• Suspected open or depressed skull fracture.
• Any sign of basal skull fracture (hemotympanum, “raccoon” eyes, cerebrospinal fluid otorrhoea/ rhinorrhoea, Battle’s sign).
• Vomiting ≥2 episodes.
• Age ≥65 yr.
Medium Risk (for brain injury on CT)
• Amnesia after impact >30 min.
• Dangerous mechanism (pedestrian struck by motor vehicle, occupant ejected from motor vehicle, fall from height >3 feet or five stories).
Minor Head Injury is defined as witnessed loss of consciousness, definite amnesia, or witnessed disorientation in a patient with a GCS score of 13-15.

A Trial of Intracranial-Pressure Monitoring in Traumatic Brain Injury
NEJM 2012;367:2471-2481
Background: ICP monitoring is frequently used to monitor severe traumatic brain injury, but controversy exists over whether it is beneficial.
Methods: Study sample (n = 324 patients, ≥1 yr) consisted of those who had severe traumatic brain injury and were being treated in ICU in Bolivia or Ecuador. Patients were randomly assigned to one management group:
1. ICP-monitoring based management.
2. Management based on imaging and clinical examination.
Primary outcome was a composite of survival time, impaired consciousness, functional status (at 3, 6 mo), and neuropsychological status (at 8 mo).
Results: No significant difference between management groups based on primary outcome, 6-mo mortality, median length of ICU stay, or occurrence of serious adverse events. However, duration of brain-specific treatments (e.g. use of hypervolemic fluids or hyperventilation) higher in the imaging-clinical examination group (4.0 ± 2.1 vs. 3.4 ± 3.4, p = 0.002).
Conclusion: Maintaining monitored ICP at 20 mmHg or less is not superior to care based on imaging and clinical examination.
• coup (damage at site of blow) and contrecoup (damage at opposite site of blow)
  - acute decompression causes cavitation followed by a wave of acute compression
• contusion (hemorrhagic)
  - high density areas on CT ± mass effect
  - commonly occurs with brain impact on bony prominences (inferior frontal lobe, pole of temporal lobe)
• diffuse axonal injury/shearing
  - wide variety of damage results
  - may tear blood vessels (hemorrhagic foci)
  - often the cause of decreased LOC if no space-occupying lesion on CT

Secondary Pathologic Processes
• same subsequent biochemical pathways for each traumatic etiology
• delayed and progressive injury to the brain due to
  - high glutamate release → NMDA receptor activation → cytotoxic cascade
  - cerebral edema
  - intracranial hemorrhages
  - ischemia/infarction
  - raised ICP, intracranial HTN
  - hydrocephalus

Extracranial Conditions
• hypoxemia
  - due to trauma to the chest, upper airway, brainstem
  - extremely damaging to vulnerable brain cells
  - leads to ischemia, raised ICP
• hypercarbia
  - leads to raised ICP (secondary to vasodilation)
  - systemic hypotension
  - caused by blood loss (e.g. ruptured spleen)
  - loss of cerebral autoregulation leads to decreased CPP, ischemia
• hyperpyrexia
  - leads to increased brain metabolic demands → ischemia
• fluid and electrolyte imbalance
  - iatrogenic (most common)
  - SIADH caused by head injury
  - diabetes insipidus (DI)
  - may lead to cerebral edema and raised ICP
• coagulopathy

Intracranial Conditions
• raised ICP due to traumatic cerebral edema OR traumatic intracranial hemorrhage

Brain Injury Outcomes
• mildly traumatic (GCS 13-15): post-concussive symptoms: H/A, fatigue, dizziness
  - nausea, blurred vision, diplopia, memory impairment, tinnitus, irritability, low concentration; 50% at 6 wk, 14% at 1 yr
• moderately traumatic (GCS 9-12): proportional to age (>40) and CT findings; 60% good recovery; 26% moderately disabled, 7% severely disabled, 7% vegetative/dead
• severe (GCS ≤8): difficult to predict, correlates with post-resuscitation GCS (especially motor) and age

Late Complications of Head/Brain Injury
• seizures: 5% of head injury patients develop seizures
  - incidence related to severity and location of injury (increased with local brain damage or intracranial hemorrhage)
  - post-traumatic seizure may be immediate, early, or late
  - presence of early (within first wk) post-traumatic seizure raises incidence of late seizures
• meningitis: associated with CSF leak from nose or ear
• hydrocephalus: acute hydrocephalus or delayed normal pressure hydrocephalus (NPH)

Spinal Cord Injury
• see Orthopedics, OR22 and Emergency Medicine, ER9

NEUROGENIC AND SPINAL SHOCK
1. neurogenic shock: hypotension that follows SCI (sBP usually ≤80 mmHg) caused by
  - interruption of sympathetics (unopposed parasympathetics) below the level of injury
  - loss of muscle tone due to skeletal muscle paralysis below level of injury → venous pooling (relative hypovolemia)
  - blood loss from associated wounds (true hypovolemia)
2. spinal shock: transient loss of all neurologic function below the level of the spinal cord injury, causing flaccid paralysis and areflexia for variable periods

**Whiplash-Associated Disorders**
- definition: traumatic injury to the soft tissue structures in the region of the cervical spine due to hyperflexion, hyperextension, or rotational injury to the neck

**Initial Management of SCI**
- major causes of death in SCI are aspiration and shock
- the following patients should be treated as having a SCI until proven otherwise:
  - all victims of significant trauma
  - minor trauma patients with decreased LOC or complaints of neck or back pain, weakness, abdominal breathing, numbness/tingling, or priapism

**Stabilization and Initial Evaluation in the Hospital**
1. ABCs, immobilization (backboard/head strap), oxygenation, Foley catheter to uterometer, temperature regulation
2. hypotension: maintain sBP >90 mmHg with pressors (dopamine), hydration, and atropine
  - DVT prophylaxis
3. monitor CBC/electrolytes
4. focused history (see Trauma Assessment, NS29)
5. spine palpation: point tenderness or deformity
6. motor level assessment (including rectal exam for voluntary sphincter contraction)
7. sensory level assessment: pinprick, light touch, and proprioception
8. evaluation of reflexes
9. signs of autonomic dysfunction: altered level of perspiration, bowel or bladder incontinence, priapism
10. radiographic evaluation
   - 3 views C-spine x-rays (AP, lateral, and odontoid) to adequately visualize C1 to C7-T1 junction
   - flexion-extension views to disclose occult instability
   - CT scan (bony injuries) typically most trauma centres use CT as the modality of choice for looking at fractures, very sensitive with the high resolution scanners
   - MRI mandatory if neurologic deficits (soft tissue injuries)

**Medical Management Specific to SCI**
- option: methylprednisolone (given within 8 h of injury) this is controversial and you need to confer with Neurosurgery service
- ± decompression in acute, non-penetrating SCI

**Fractures of the Spine**

**FRACTURES AND FRACTURE-DISLOCATIONS OF THE THORACIC AND LUMBAR SPINE**
- assess ligamentous instability using flexion-extension x-ray views of ± MRI
- thoracolumbar spine unstable if 4/6 segments disrupted (3 columns divided into left and right)
  - anterior column: anterior half of vertebral body, disc, and anterior longitudinal ligament
  - middle column: posterior half of vertebral body, disc, and posterior longitudinal ligament
  - posterior column: posterior arch, facet joints, pedicle, lamina and supraspinous, interspinous, and ligamentum ligaments

**Types of Injury**

<table>
<thead>
<tr>
<th>Table 20. Denis Classification of Spinal Trauma</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fracture Type</strong></td>
</tr>
</tbody>
</table>
| Compression Fracture (58%) | Produced by flexion
Posterior ligament complex (supraspinous and interspinous ligaments, ligamentum flavum, and intervertebral joint capsules) remain intact
Fractures are stable but lead to kyphotic deformity |
| Burst Fracture (17%) | Stable: anterior and middle columns parted with bone retropulsed nearby
Hallmark is pedicle widening on AP x-ray
Spinal cord (seen on x-ray and CT); posterior column is uninjured
Unstable: same as the stable but with posterior column disruption (usually ligamentous) |
| Flexion Distraction Injury (6%) | Hyperflexion and distraction of posterior elements
Middle and posterior columns fail in distraction
Classic: Chance = horizontal fracture through posterior arch, pedicles, posterior vertebral body
Can be purely ligamentous, i.e. through PLL and disc |
| Fracture-Dislocation (6%) | Anterior and cranial dislocation of superior vertebral body → 3 column failure
Three types: (1) flexion-rotation, (2) flexion-distraction, (3) shear/hyperextension (rare) |
Management of Thoracolumbar Injury
- severity and management based on TLICS classification

FRACTURES OF THE CERVICAL SPINE

Types of Injury

Table 21. Fracture Patterns of the Cervical Spine

<table>
<thead>
<tr>
<th>Fracture Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1 Vertebral Fracture (Jefferson fracture)</td>
<td>Vertical compression forces the occipital condyles of the skull down on the C1 vertebra (atlas), pushing the lateral masses of the atlas outward and disrupting the ring of the atlas</td>
</tr>
<tr>
<td>Odontoid Fracture</td>
<td>Causes C1 and odontoid of C2 to move independently of C2 body</td>
</tr>
<tr>
<td></td>
<td>This occurs because</td>
</tr>
<tr>
<td></td>
<td>normally C1 vertebra and odontoid of C2 are a single functional unit</td>
</tr>
<tr>
<td></td>
<td>Alar and transverse ligaments on posterior aspect of odontoid usually remain intact after injury</td>
</tr>
<tr>
<td></td>
<td>Patients often report a feeling of instability and present holding their head with their hands</td>
</tr>
<tr>
<td>C2 Vertebral Fracture (hangman fracture)</td>
<td>Bilateral fracture through the pars interarticularis of C2 with subluxation of C2 on C3 (spondylolisthesis of axis)</td>
</tr>
<tr>
<td></td>
<td>Usually neurologically intact</td>
</tr>
<tr>
<td>Clay-Shoveler Fracture</td>
<td>Avulsion of spinous process, usually C6 or C7</td>
</tr>
</tbody>
</table>

Imaging
- AP spine x-ray (open-mouth and lateral view), CT

Treatment
- immobilization in cervical collar or halo vest until healing occurs (usually 2-3 mo)
- Type II and III odontoid fractures
- consider surgical fixation for comminution, displacement, or inability to maintain alignment with external immobilization
- confirm stability after recovery with flexion-extension x-rays

Neurologically Determined Death

Definition
- irreversible and diffuse brain injury resulting in absence of clinical brain function
- cardiovascular activity may persist for up to 2 wk

Criteria of Diagnosis
- prerequisites: no CNS depressant drugs/neuromuscular blocking agents, no drug intoxication/poisoning, temperature >32°C, no electrolyte/acid-base/endocrine disturbance
- absent brainstem reflexes: pupillary light reflex, corneal reflexes, oculocephalic response, caloric responses (e.g. no deviation of eyes to irrigation of each ear with 50 cc of ice water – allow 1 min after injection, 5 min between sides), pharyngeal and tracheal reflexes, cough with tracheal suctioning, absent respiratory drive at PaCO2 >60 mmHg or >20 mmHg above baseline (apnea test)
- 2 evaluations separated by time, usually performed by two specialists (e.g. anesthetist, neurologist, neurosurgeon)
- confirmatory testing: flat EEG, absent perfusion assessed with cerebral angiogram

Coma

Definition
- an unrousable state in which patients show no meaningful response to environmental stimuli

Pathophysiology
- lesions affecting the cerebral cortex bilaterally, the reticular activating system (RAS) or their connecting fibres
- focal supratentorial lesions do not alter consciousness except by herniation (compression on the brainstem or on the contralateral hemisphere) or by precipitating seizures

Classification
- structural lesions (tumour, pus, blood, infarction, CSF): 1/3 of comas
  - supratentorial mass lesion: leads to herniation
  - infratentorial lesion: compression of or direct damage to the RAS or its projections
• metabolic disorders/diffuse hemispheric damage: 2/3 of comas
  - deficiency of essential substrates (e.g. oxygen, glucose, vitamin B12)
  - exogenous toxins (e.g. drugs, heavy metals, solvents)
  - endogenous toxins/systemic metabolic diseases (e.g. uremia, hepatic encephalopathy, electrolyte imbalances, thyroid storm)
  - infections (meningitis, encephalitis)
  - trauma (concussion, diffuse shear axonal damage)

**Investigations and Management**
- ABCs
- labs: electrolytes, extended electrolytes, TSH, LFTs, Cr, BUN, toxin screen, glucose
- CT/MRI, LP, EEG

**Persistent Vegetative State**

**Definition**
- a condition of complete unawareness of the self and the environment accompanied by sleep-wake cycles with either complete or partial preservation of hypothalamic and brainstem autonomic function
- “awake but not aware”
- follows comatose state

**Etiology/Prognosis**
- most commonly caused by cardiac arrest or head injury
- due to irreversible loss of cerebral cortical function but intact brainstem function
- average life expectancy is 2-5 yr

**Pediatric Neurosurgery**

**Spinal Dysraphism**

**Table 22. Summary of Spinal Dysraphic Anomalies**

<table>
<thead>
<tr>
<th>Anomaly</th>
<th>Definition</th>
<th>Epidemiology</th>
<th>Etiology</th>
<th>Clinical Features</th>
</tr>
</thead>
</table>
| SPINA BIFIDA OCCULTA | Congenital absence of a spinous process and a variable amount of lamina   | 15-20% of the general population; most common at L5 or S1          | Failure of fusion of posterior neural arch                                   | No obvious clinical signs
|                      |                                                                         |                         |                                      | Presence of lumbosacral cutaneous abnormalities (dimple, sinus, port-wine stain, or hair tuft) should increase suspicion of an underlying anomaly (lipoma, dermoid, diastematomyelia) |
| MENINGOCELE          | Herniation of meningeal tissue and CSF through a defect in the spine, without associated herniation of neural tissue | 0.1-0.2% of live births | Primary failure of neural tube closure | Most common in lumbosacral area
| (SPINA BIFIDA APERTA)|                                                                         |                         |                                      | Usually no disability, low incidence of associated anomalies, and hydrocephalus |
| MYELOMENINGOCELE     | Herniation of meningeal and CNS tissue through a defect in the spine     | 0.1-0.2% of live births |                                      | Sensory and motor changes distal to anatomic level producing varying degrees of weakness |
| (SPINA BIFIDA APERTA)|                                                                         |                         |                                      | Urinary and fecal incontinence
|                      |                                                                         |                         |                                      | Hydrocephalus (85-95% of patients)
|                      |                                                                         |                         |                                      | Most have Type II Chiari malformation
|                      |                                                                         |                         |                                      | (see Chiari Malformations, NS36) |

**Investigations**
- Plain film: absence of the spinous process and minor amounts of the neural arch
- U/S, MRI to exclude spinal anomalies

**Treatment**
- Requires no treatment
- Surgical excision and tissue repair
- Surgical closure to preserve neurologic status and prevent CNS infections
- Closure in utero shown to decrease hydrocephalus and improve post natal motor scores

**Prognosis**
- Generally good prognosis
- Good prognosis with surgical treatment
- Operative mortality close to 0%, 95% 2-yr survival
- 80% have IQ >80 (but most are 80-95), 40-85% ambulatory, 3-10% have normal urinary continence
- Early mortality: usually due to Chiari malformation complications (respiratory arrest, aspiration), later mortality: due to shunt malfunction
**Intraventricular Hemorrhage**

- see *Pediatrics*, P68

**Hydrocephalus in Pediatrics**

**Etiology**
- congenital
  - aqueductal anomalies, primary aqueductal stenosis in infancy
  - secondary glossis due to intrauterine viral infections (mumps, varicella, TORCH)
  - Dandy-Walker malformation (2-4%)
  - Chiari malformation, especially Type II
  - myelomeningocele
- acquired
  - post meningitis
  - post hemorrhage (SAH, IVH)
  - masses (vascular malformation, neoplastic)

**Clinical Features**
- symptoms and signs of hydrocephalus are age related in pediatrics
- increased head circumference (HC), bulging anterior fontanelle, widened cranial sutures
- irritability, lethargy, poor feeding, and vomiting
- "cracked pot" sound on cranial percussion
- scalp vein dilation (increased collateral venous drainage)
- sunset sign – forced downward deviation of eyes
- episodic bradycardia and apnea

**Investigations**
- skull x-ray, U/S, CT, MRI, ICP monitoring

**Treatment**
- similar to adults (see *Hydrocephalus Treatment*, NS9)

**Dandy-Walker Malformation**

**Definition**
- atresia of foramina of Magendie and Luschka, resulting in:
  - complete or incomplete agenesis of the cerebellar vermis with widely separated, hypoplastic cerebellar hemispheres
  - posterior fossa cyst, enlarged posterior fossa
  - dilatation of 4th ventricle (also 3rd and lateral ventricles)
- associated anomalies
  - hydrocephalus (90%)
  - agenesis of corpus callosum (17%)
  - occipital encephalocele (7%)

**Epidemiology**
- 2-4% of pediatric hydrocephalus

**Clinical Features**
- 20% are asymptomatic, seizures occur in 15%
- symptoms and signs of hydrocephalus combined with a prominent occiput in infancy
- ataxia, spasticity, poor fine motor control common in childhood

**Investigations**
- ultrasound, CT, MRI

**Treatment**
- asymptomatic patients require no treatment
- associated hydrocephalus requires surgical treatment
  - e.g. ventriculoperitoneal (VP) shunt, cystoperitoneal (CP) shunt, lumboperitoneal (LP) shunt, ventriculoatrial (VA) shunt, lumbar drain

**Prognosis**
- 75-100% survival, 50% have normal IQ
**Chiari Malformations**

**Definition**
- malformations at the medullary-spinal junction

**Etiology**
- unclear, likely maldevelopment/dysgenesis during fetal life

**Categories**

**Table 23. Categories of Chiari Malformations**

<table>
<thead>
<tr>
<th>Type I</th>
<th>Type II</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definition</strong></td>
<td>Cerebellar tonsils lie below the level of the foramen magnum</td>
</tr>
<tr>
<td><strong>Epidemiology</strong></td>
<td>Average age at presentation: 15 yr</td>
</tr>
<tr>
<td><strong>Clinical Features</strong></td>
<td>Many are asymptomatic. Pain (69%), weakness (56%), numbness (52%), loss of temperature sensation (40%), Central cord syndrome (65%), Foramen magnum compression syndrome (22%), Cerebellar syndrome (11%), Syringomyelia (50%), Hydrocephalus (10%)</td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td>MRI</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>Symptomatic patients (early surgery recommended; &lt;2yr post symptom onset) → suboccipital craniectomy, duraplasty</td>
</tr>
</tbody>
</table>

**Craniosynostosis**

**Definition**
- premature closure of the cranial suture(s)

**Classification**
- sagittal (most common): long narrow head with ridging sagittal suture (scaphocephaly)
- coronal: expansion in superior and lateral direction (brachiocephaly)
- metopic (trigonocephaly)
- lambdoid: least common

**Epidemiology**
- 0.6/1,000 live births, most cases are sporadic; familial incidence is 2% of sagittal and 8% of coronal synostosis

**Clinical Features**
- skull deformity, raised ICP ± hydrocephalus
- ophthalmologic problems due to increased ICP or bony abnormalities of the orbit
- must differentiate between positional plagiocephaly (secondary to back sleeping)

**Investigations**
- plain radiographs, CT scan

**Treatment**
- parental counselling about nature of deformity, associated neurological symptoms
- surgery for cosmetic purposes, except in cases of elevated ICP (≥2 suture involved)
Pediatric Brain Tumours

- see Tumours, NS10

Epidemiology
- 20% of all pediatric cancers (second only to leukemia)
- 60% of pediatric brain tumours are infratentorial
- pediatric brain tumours arise from various cellular lineages
  - glia: low-grade astrocytoma (supra- or infratentorial), anaplastic astrocytoma, glioblastoma multiforme (largely supratentorial) (see Astrocytoma, NS12)
  - primitive nerve cells: supratentorial PNET
    - 90% of neonatal brain tumours, infratentorial (medulloblastoma), pineal gland (pineoblastoma)
  - non-neuronal cells: germ cell tumour, cranioopharyngioma, dermoid, meningioma, neurinoma (schwanoma), pituitary adenoma, others

Clinical Features
- vomiting, seizure, macrocrania, hydrocephalus
- developmental delay, poor feeding, failure to thrive
- often initially escapes diagnosis due to expandable cranium and neural plasticity in children

Table 24. Overview of Childhood Primary Brain Tumours

<table>
<thead>
<tr>
<th>Tumour Type</th>
<th>Common Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pilocytic (low grade) Astrocytoma</td>
<td>Usually in posterior fossa, well circumscribed, benign, good prognosis</td>
</tr>
<tr>
<td>Medulloblastoma</td>
<td>A primitive neuroectodermal tumour (PNET) in cerebellum compresses 4th ventricle then hydrocephalus, highly malignant</td>
</tr>
<tr>
<td>Ependymoma</td>
<td>In 4th ventricle → hydrocephalus</td>
</tr>
<tr>
<td>Hemangioblastoma</td>
<td>Often cerebellar, associated with von Hippel-Lindau syndrome with retinal angiomata, can produce EPO → secondary polycythemia</td>
</tr>
<tr>
<td>Cranioopharyngioma</td>
<td>Causes bitemporal hemianopsia (thus often confused with pituitary adenoma)</td>
</tr>
<tr>
<td>Most common supratentorial childhood tumour</td>
<td>Most common supratentorial childhood tumour</td>
</tr>
</tbody>
</table>

Functional Neurosurgery

Movement Disorders

- see Neurology, Tremor, N31, Parkinson's Disease, N32, Dystonia, N33, and Multiple Sclerosis, N52

Table 25. Surgical Targets for Movement Disorders

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Indications</th>
<th>Procedures</th>
<th>Outcomes</th>
<th>Morbidity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parkinson's Disease</td>
<td>Intractable contralateral bradykinesia/tremor; Failure of medical management (advanced disease) Drug-induced dyskinesias (see dystonia, below)</td>
<td>Simultaneous, bilateral surgery/stimulation is most common Preferred target: anterodorsal subthalamic nucleus (STN) Other targets: stereotactic ablation (pallidotomy)/stimulation of posteroventral globus pallidus pars interna (GPi) Caudal zona incerta Parkinsonian tremor: stereotactic ablation (thalamotomy/stimulation of ventral intermediate (Vim) nucleus of thalamus</td>
<td>39–48% improvement in Unified Parkinson's Disease Rating Scale (UPDRS) scores Reduced dosage of medications (STN) More effective than medical management in advanced PD Early intervention may reduce severity, course, and progression of disease Of little benefit for patients with atypical presentations</td>
<td>Intracerebral hemorrhage, infection, seizure (1%-4%) Paresthesias Involuntary movements Cognitive functioning: decreased lexical fluency, impaired executive function (STN &gt; GPi) Psychiatric: depression, mania, anxiety, apathy (STN &gt; GPi)</td>
</tr>
<tr>
<td>Dystonia</td>
<td>Contralateral primary (generalized) dystonias; cervical and tardive dystonias (GPi); Contralateral secondary dyskinesia (i.e. drug-induced: L-dopa, neuroleptics; STN)</td>
<td>Preferred target (primary dystonia): stereotactic ablation (pallidotomy/stimulation of posteroventral STN Secondary dystonia: stimulation of anterodorsal STN Stimulation of ventral posterior lateral (VPL) thalamic nucleus</td>
<td>Primary dystonia: 51% reduction in Burke-Fahn-Marsden Dystonia Scale (BFMDS) score Secondary dystonia: 62–89% improvement in dystonias Delayed effects: weeks to months</td>
<td>Intracerebral hemorrhage, infection, seizure (1%-4%) Minor effects on cognitive functioning (especially decreased lexical fluency; STN &gt; GPi)</td>
</tr>
<tr>
<td>Tremor</td>
<td>Contralateral appendicular ET (first disorder to be treated by DBS; DBS is viable alternative to Rx) Intention tremor (IT) resulting from demyelination of cerebellar outflow tracts (e.g. in multiple sclerosis) Brainstem tremor (Holmes tremor)</td>
<td>Preferred target: stereotactic ablation (thalamotomy/stimulation of Vim nucleus of thalamus Other targets: stimulation of caudal zona incerta Parkinsonian tremor: stimulation of anterodorsal STN</td>
<td>Durable reductions in essential tremor rating scale (ETRS) scores Reduced dosage of medications Conflicting data on vocal/facial tremor</td>
<td>Intracerebral hemorrhage, infection, seizure (1%-4%) Paresthesias/pain Dysarthria Ataxia Minor effects on cognitive functioning (especially decreased lexical fluency) Tolerance may develop over time</td>
</tr>
</tbody>
</table>
Neuropsychiatric Disorders

- see Neurology, N34 and Psychiatry for Tourette's Syndrome, Obsessive Compulsive Disorder and Depression

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Indications</th>
<th>Procedures</th>
<th>Outcomes</th>
<th>Morbidity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obsessive Compulsive Disorder (OCD)</td>
<td>Severe symptoms refractory to medical management</td>
<td>Anterior capsulotomy/stimulation of the anterior limb of the internal capsule (IC)</td>
<td>Currently under investigation</td>
<td>Intracerebral hemorrhages (1-2%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Reportedly 25-75% response rate</td>
<td>Mild effects on cognitive functioning</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Anxiety ± panic disorder (case report)</td>
</tr>
<tr>
<td>Tourette's Syndrome</td>
<td>Severe symptoms refractory to medical management</td>
<td>Stimulation of midline intralaminar nuclei of the thalamus</td>
<td>Stimulation of motor and limbic portions of GPi</td>
<td>Stimulation of the anterior limb of the IC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Currently under investigation</td>
<td>Intracerebral hemorrhages (1-2%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Reportedly &gt;70% reduction in vocal or motor tics + urge</td>
<td>Mild sexual dysfunction</td>
</tr>
<tr>
<td>Major Depressive Disorder (MDD)</td>
<td>Severe depression refractory to medical management and ECT</td>
<td>Stimulation of the subgenual cingulate cortex</td>
<td>Currently under investigation</td>
<td>Intracerebral hemorrhages (1-2%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Reportedly 60% response rate; 35% remission rate</td>
<td>Pain, H/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Worsening mood, irritability</td>
</tr>
</tbody>
</table>

Chronic Pain

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Indications</th>
<th>Procedures</th>
<th>Outcomes</th>
<th>Morbidity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuropathic Pain</td>
<td>Severe, intractable, organic neuropathic pain (e.g. post-stroke pain, phantom limb pain, trigeminal neuralgia, chronic low-back pain, complex regional pain syndrome)</td>
<td>Preferred target: stimulation of the contralateral VPL VPM thalamic nuclei ± periventricular/periaqueductal grey matter (PVG/PAG) Other targets: stimulation of the contralateral IC Stimulation of the contralateral motor cortex</td>
<td>47% improvement in perception of pain intensity Less favourable results in central pain syndromes and poorly localized pain</td>
<td>Intracerebral hemorrhages (1-2%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Anxiety ± panic disorder</td>
<td>Parathesia</td>
</tr>
<tr>
<td>Nociceptive Pain</td>
<td>Severe, intractable, organic nociceptive pain</td>
<td>Bilateral (most common) stimulation of the PVG/PAG</td>
<td>Reportedly 63% improvement in perception of pain intensity</td>
<td>Intracerebral hemorrhages (1-2%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Parathesia Anxiety ± panic disorder</td>
<td></td>
</tr>
</tbody>
</table>
Surgical Management of Epilepsy

- see Neurology, N19 for the medical treatment of epilepsy

Indications
- medically refractory seizures, usually defined as seizures resistant to two first line anti-seizure medications used in succession
- identification of a distinct epileptogenic region through clinical history, EEG, MRI, and neuropsychological testing; other localizing investigations include magnetoencephalography, SPECT, and PET
- if a distinct epileptogenic region cannot be identified, the patient may be a candidate for a palliative procedure such as corpus callosotomy

Procedure
- adults: resection of the hippocampus and parahippocampal gyrus for mesial temporal lobe epilepsy arising from mesial temporal sclerosis
- children: resection of an epileptogenic space-occupying lesion
- hemispherectomy and corpus callosotomy are less common

Outcomes
- 41-79% of adult patients are seizure free for 5 yr after temporal lobe resection
- 58-78% of children are seizure free after surgery
- surgery is associated with improvements in preexisting psychiatric conditions such as depression and anxiety, as well as improvement in quality of life

Morbidity
- 0.4-4% of surgical patients will have partial hemianopsia, aphasia, motor deficit, sensory deficit, or cranial nerve palsy following anteromedial temporal lobectomies
- most patients will have some decline in verbal memory following dominant temporal lobectomy and in visuospatial memory in non-dominant temporal resection
- the degree of memory decline stabilizes after 1-2 yr

Predictors
- positive predictive factors for seizure freedom following anteromedial temporal lobectomy
  - hippocampal sclerosis (unilateral)
  - focal localization of interictal epileptiform discharges
  - absence of pre-operative generalized seizures
  - tumoural cause
  - complete resection of the lesion

Surgical Management for Trigeminal Neuralgia

- reserved for cases refractory to medical management; see Neurology, N42 for medical management

Surgical Options
- trigeminal nerve branch procedures
  - local blocks (phenol, alcohol)
  - neurectomy of the trigeminal branch
  - nerve branches
    - V1 block at the supraorbital, supratrochlear nerves
    - V2 block at the foramen rotundum or infraorbital nerves
    - V3 block at the foramen ovale
  - percutaneous trigeminal rhizotomy
    - glycerol injection
    - mechanotrauma via catheter balloon
    - radiofrequency thermoablation
  - Gamma Knife® radiosurgery
  - microvascular decompression
    - posterior fossa craniotomy with microsurgical exploration of the root entry zone, displacement of the vessel impinging on the nerve with placement of non-absorbable Teflon® felt
Acronyms ............................................................ 2
Basic Anatomy Review ............................................ 2
Pregnancy .............................................................. 2
Diagnosis of Pregnancy
Maternal Physiologic Adaptations to Pregnancy .................. 3
Antepartum Care .................................................... 4
Preconception Counselling
Initial Prenatal Visit
Nausea and Vomiting
Hyperemesis Gravidarum
Subsequent Prenatal Visits
Prenatal Screening and Diagnostic Tests
Counselling of the Pregnant Woman ............................. 9
Nutrition
Lifestyle
Medications
Immunizations
Radiation
Antenatal Fetal Surveillance ....................................... 12
Fetal Movements
Obstetrical Hemorrhage ............................................ 13
Placenta Previa
Abruptio Placentae
Vasa Previa
Obstetrical Complications ......................................... 15
Preterm Labour
Premature Rupture of Membranes
Prolonged Pregnancy
Intrauterine Fetal Death
Intrauterine Growth Restriction
Macrosomia
Polyhydramnios/Oligohydramnios
Multi-Fetal Gestation and Malpresentation ....................... 21
Twin-Twin Transfusion Syndrome
Breech Presentation
Hypertensive Disorders of Pregnancy ........................... 23
Hypertension in Pregnancy
Medical Complications of Pregnancy ............................ 25
Iron and Folate Deficiency Anemia
Diabetes Mellitus
Group B Streptococcus
Urinary Tract Infection
Infections During Pregnancy
Venous Thromboembolism
Normal Labour and Delivery ...................................... 30
Definition of Labour
The Cervix
The Fetus
Four Stages of Labour
The Cardinal Movements of the Fetus During Delivery
Analgesic and Anesthetic Techniques in Labour and Birth
Fetal Monitoring in Labour
Induction of Labour ................................................ 36
Induction Methods
Augmentation of Labour
Abnormalities and Complications of Labour and Delivery .. 37
Meconium in Amniotic Fluid
Abnormal Progression of Labour (Dystocia)
Shoulder Dystocia
Umbilical Cord Prolapse
Uterine Rupture
Amniotic Fluid Embolus
Chorioamnionitis
Operative Obstetrics ................................................ 41
Operative Vaginal Delivery
Forceps
Vacuum Extraction
Lacerations
Episiotomy
Cesarean Delivery
Vaginal Birth After Cesarean
Puerperal Complications ......................................... 43
Postpartum Hemorrhage
Retained Placenta
Uterine Inversion
Postpartum Pyrexia
Mastitis
Postpartum Mood Alterations
Postpartum Care .................................................... 46
Breastfeeding and Drugs
Common Medications ............................................. 47
References ........................................................... 48
### Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AC</td>
<td>abdominal circumference</td>
</tr>
<tr>
<td>ACOG</td>
<td>American Congress of Obstetricians and Gynecologists</td>
</tr>
<tr>
<td>AG</td>
<td>amniotic fluid index</td>
</tr>
<tr>
<td>AGD</td>
<td>acute fatty liver of pregnancy</td>
</tr>
<tr>
<td>AM</td>
<td>amniotic fluid volume</td>
</tr>
<tr>
<td>AP</td>
<td>antero posterior</td>
</tr>
<tr>
<td>APS</td>
<td>antiphospholipid antibody syndrome</td>
</tr>
<tr>
<td>BPP</td>
<td>biophysical profile</td>
</tr>
<tr>
<td>C/S</td>
<td>Cesarean section</td>
</tr>
<tr>
<td>CPD</td>
<td>cephalopelvic disproportion</td>
</tr>
<tr>
<td>CTG</td>
<td>cardiotocography</td>
</tr>
<tr>
<td>CVS</td>
<td>chorionic villus sampling</td>
</tr>
<tr>
<td>D&amp;C</td>
<td>dilatation and curettage</td>
</tr>
<tr>
<td>DIC</td>
<td>disseminated intravascular coagulation</td>
</tr>
<tr>
<td>DVT</td>
<td>deep vein thrombosis</td>
</tr>
<tr>
<td>ECG</td>
<td>external cephalic version</td>
</tr>
<tr>
<td>EDC</td>
<td>estimated date of confinement</td>
</tr>
<tr>
<td>EFM</td>
<td>electronic fetal monitoring</td>
</tr>
<tr>
<td>EFW</td>
<td>estimated fetal weight</td>
</tr>
<tr>
<td>FDP</td>
<td>fetal degradation products</td>
</tr>
<tr>
<td>FHR</td>
<td>fetal heart rate</td>
</tr>
<tr>
<td>FPG</td>
<td>fasting plasma glucose</td>
</tr>
<tr>
<td>GA</td>
<td>gestational age</td>
</tr>
<tr>
<td>GBS</td>
<td>Group B Streptococcus</td>
</tr>
<tr>
<td>GDM</td>
<td>gestational diabetes melitus</td>
</tr>
<tr>
<td>GTN</td>
<td>gestational trophoblastic neoplasia</td>
</tr>
<tr>
<td>HC</td>
<td>head circumference</td>
</tr>
<tr>
<td>HELLP</td>
<td>hemolysis, elevated liver enzymes, low platelets</td>
</tr>
<tr>
<td>HG</td>
<td>infant growth factors</td>
</tr>
<tr>
<td>IAD</td>
<td>intramyometrial</td>
</tr>
<tr>
<td>IOL</td>
<td>induction of labour</td>
</tr>
<tr>
<td>IPS</td>
<td>integrated prenatal screen</td>
</tr>
<tr>
<td>IUFN</td>
<td>intrauterine fetal death</td>
</tr>
<tr>
<td>IGDR</td>
<td>intrauterine growth restriction</td>
</tr>
<tr>
<td>INR</td>
<td>intraventricular hemorrhage</td>
</tr>
<tr>
<td>I/S</td>
<td>lecithin-sphingomyelin ratio</td>
</tr>
<tr>
<td>LLD</td>
<td>left lateral decubitus position</td>
</tr>
<tr>
<td>LMP</td>
<td>last menstrual period</td>
</tr>
<tr>
<td>MSAFP</td>
<td>maternal serum α-fetoprotein</td>
</tr>
<tr>
<td>MSS</td>
<td>maternal serum screen</td>
</tr>
<tr>
<td>MTX</td>
<td>methotrexate</td>
</tr>
<tr>
<td>NIP</td>
<td>non-invasive prenatal testing</td>
</tr>
<tr>
<td>NST</td>
<td>non-stress test</td>
</tr>
<tr>
<td>NTDS</td>
<td>neural tube defects</td>
</tr>
<tr>
<td>NTUS</td>
<td>nuchal translucency ultrasound</td>
</tr>
<tr>
<td>OA</td>
<td>occiput anterior</td>
</tr>
<tr>
<td>OGT</td>
<td>oral glucose tolerance test</td>
</tr>
<tr>
<td>ONGTD</td>
<td>open neural tube defect</td>
</tr>
<tr>
<td>OP</td>
<td>occiput posterior</td>
</tr>
<tr>
<td>OT</td>
<td>occiput transverse</td>
</tr>
<tr>
<td>PAPP-A</td>
<td>pregnancy-associated plasma protein A</td>
</tr>
<tr>
<td>PG</td>
<td>plasma glucose</td>
</tr>
<tr>
<td>PPD</td>
<td>postpartum depression</td>
</tr>
<tr>
<td>PPH</td>
<td>postpartum hemorrhage</td>
</tr>
<tr>
<td>PPROM</td>
<td>preterm premature rupture of membranes</td>
</tr>
<tr>
<td>PROM</td>
<td>premature rupture of membranes</td>
</tr>
<tr>
<td>PTL</td>
<td>preterm labour</td>
</tr>
<tr>
<td>RDS</td>
<td>respiratory distress syndrome</td>
</tr>
<tr>
<td>ROM</td>
<td>rupture of membranes</td>
</tr>
<tr>
<td>SFH</td>
<td>symphysis fundal height</td>
</tr>
<tr>
<td>SOGC</td>
<td>Society of Obstetricians and Gynaecologists of Canada</td>
</tr>
<tr>
<td>SVD</td>
<td>spontaneous vaginal delivery</td>
</tr>
<tr>
<td>TENS</td>
<td>transcutaneous electrical nerve stimulation</td>
</tr>
<tr>
<td>TPN</td>
<td>total parenteral nutrition</td>
</tr>
<tr>
<td>UDI</td>
<td>urinary tract infection</td>
</tr>
<tr>
<td>VBAC</td>
<td>vaginal birth after Cesarean</td>
</tr>
<tr>
<td>IUFD</td>
<td>intrauterine fetal death</td>
</tr>
<tr>
<td>IUGR</td>
<td>intrauterine growth restriction</td>
</tr>
<tr>
<td>IVH</td>
<td>intraventricular hemorrhage</td>
</tr>
<tr>
<td>L/S</td>
<td>lecithin-sphingomyelin ratio</td>
</tr>
<tr>
<td>LLD</td>
<td>left lateral decubitus position</td>
</tr>
<tr>
<td>LMP</td>
<td>last menstrual period</td>
</tr>
<tr>
<td>MSAFP</td>
<td>maternal serum α-fetoprotein</td>
</tr>
<tr>
<td>MSS</td>
<td>maternal serum screen</td>
</tr>
<tr>
<td>MTX</td>
<td>methotrexate</td>
</tr>
<tr>
<td>NIP</td>
<td>non-invasive prenatal testing</td>
</tr>
<tr>
<td>NST</td>
<td>non-stress test</td>
</tr>
<tr>
<td>NTDS</td>
<td>neural tube defects</td>
</tr>
<tr>
<td>NTUS</td>
<td>nuchal translucency ultrasound</td>
</tr>
<tr>
<td>OA</td>
<td>occiput anterior</td>
</tr>
<tr>
<td>OGT</td>
<td>oral glucose tolerance test</td>
</tr>
<tr>
<td>ONGTD</td>
<td>open neural tube defect</td>
</tr>
<tr>
<td>OP</td>
<td>occiput posterior</td>
</tr>
<tr>
<td>OT</td>
<td>occiput transverse</td>
</tr>
<tr>
<td>PAPP-A</td>
<td>pregnancy-associated plasma protein A</td>
</tr>
<tr>
<td>PG</td>
<td>plasma glucose</td>
</tr>
<tr>
<td>PPD</td>
<td>postpartum depression</td>
</tr>
<tr>
<td>PPROM</td>
<td>preterm premature rupture of membranes</td>
</tr>
<tr>
<td>PROM</td>
<td>premature rupture of membranes</td>
</tr>
<tr>
<td>PTL</td>
<td>preterm labour</td>
</tr>
<tr>
<td>RDS</td>
<td>respiratory distress syndrome</td>
</tr>
<tr>
<td>ROM</td>
<td>rupture of membranes</td>
</tr>
<tr>
<td>SFH</td>
<td>symphysis fundal height</td>
</tr>
<tr>
<td>SOGC</td>
<td>Society of Obstetricians and Gynaecologists of Canada</td>
</tr>
<tr>
<td>SVD</td>
<td>spontaneous vaginal delivery</td>
</tr>
<tr>
<td>TENS</td>
<td>transcutaneous electrical nerve stimulation</td>
</tr>
<tr>
<td>TPN</td>
<td>total parenteral nutrition</td>
</tr>
<tr>
<td>UDI</td>
<td>urinary tract infection</td>
</tr>
<tr>
<td>VBAC</td>
<td>vaginal birth after Cesarean</td>
</tr>
</tbody>
</table>

### Basic Anatomy Review

**Placenta**
- Site of fetal nutritive, respiratory, and excretory function
- Discoid mass composed of fetal (chorion frondosum) and maternal (decidua basalis) tissues divided by fissures into cotyledons (lobules) on the uterine side
- Produces hormones such as progesterone, placental lactogen, estrogen, relaxin, β-hCG, and IGFs
- Poor implantation can lead to spontaneous abortion
- Abnormal location, implantation, or detachment can lead to antepartum hemorrhage
  
  *(see Obstetrical Hemorrhage, OB13)*

### Pregnancy

#### Diagnosis of Pregnancy

**History**
- Symptoms: amenorrhea, nausea and/or vomiting, breast tenderness, urinary frequency, and fatigue
- Obstetrical and gynecological history
- Obtain the year, location, mode of delivery, duration of labour, sex, gestational age, birth weight, and complications of every pregnancy; organize into GTPAL format
  - **Gravida (G)**
    - G: total number of pregnancies of any gestation (multiple gestation=one pregnancy)
      - Includes current pregnancy, abortions, ectopic pregnancies, and hydatidiform moles
**Maternal Physiologic Adaptations to Pregnancy**

**Physical Signs**
- Goodell's sign: softening of the cervix (4-6 wk)
- Chadwick's sign: bluish discoloration of the cervix and vagina due to pelvic vasculature engorgement (6 wk)
- Hegar's sign: softening of the cervical isthmus (6-8 wk)
- Uterine enlargement
- Breast engorgement, areola darkening, and prominent vascular patterns

**Investigations**
- β-hCG: peptide hormone composed of α and β subunits produced by placental trophoblastic cells – maintains the corpus luteum during pregnancy
  - positive in serum 9 d post-conception, positive in urine 28 d after first day of LMP
  - plasma levels usually double every 1.4-2.0d, peak at 8-10 wk, then fall to a plateau until delivery
  - levels less than expected suggest: ectopic pregnancy, abortion, inaccurate dates, and some normal pregnancies
  - levels greater than expected suggest: multiple gestation, molar pregnancy, Trisomy 21, or inaccurate dates
- U/S
  - transvaginal
    - 5 wk amenorrhea: gestational sac visible
    - 6 wk: fetal pole visible
    - 7-8 wk: fetal heart activity visible
  - transabdominal
    - 6-8 wk: intrauterine pregnancy visible

### Maternal Physiologic Changes During Pregnancy

<table>
<thead>
<tr>
<th>Compartment</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Skin</strong></td>
<td>Increased pigmentation of perineum and areola, chloasma (pigmentation changes under eyes and on bridge of nose), linea nigra (midline abdominal pigmentation), spider angiomata, palmar erythema due to increased estrogen, striae gravidarum due to connective tissue changes</td>
</tr>
<tr>
<td><strong>Cardiovascular</strong></td>
<td>Hyperdynamic circulation&lt;br&gt;Increased CO, HR, and blood volume&lt;br&gt;Decreased blood pressure: decreased PVR and decreased venous return from enlarging uterus compressing IVC and pelvic veins&lt;br&gt;Increased venous pressure leads to risk of varicose veins, hemorrhoids, leg edema</td>
</tr>
<tr>
<td><strong>Hematologic</strong></td>
<td>Hemodilution causes physiologic anemia and apparent decrease in hemoglobin and hematocrit&lt;br&gt;Increased leukocyte count but impaired function leads to improvement in autoimmune diseases&lt;br&gt;Gestational thrombocytopenia: mild: platelets &gt;70,000/µL and asymptomatic, normalizes within 2-12 wk following delivery&lt;br&gt;Hypocoagulable state: increased risk of DVT and PE but also decreased bleeding at delivery</td>
</tr>
<tr>
<td><strong>Respiratory</strong></td>
<td>Increased incidence of nasal congestion&lt;br&gt;Increased O2 consumption to meet increased metabolic requirements&lt;br&gt;Elevated diaphragm (i.e., patient appears more &quot;barrel-chested&quot;)&lt;br&gt;Increased minute ventilation leads to decreased CO2 resulting in mild respiratory alkalosis that helps CO2 diffuse across the placenta from fetal to maternal circulation&lt;br&gt;Decreased TLC, FRC, and RV&lt;br&gt;No change in VC and FEV</td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td>GERD due to increased intra-abdominal pressure and progesterone (causing decreased sphincter tone and delayed gastric emptying)&lt;br&gt;Increased gallstones due to progesterone causing increased gallbladder stasis&lt;br&gt;Constipation and hemorrhoids due to progesterone causing decreased GI motility</td>
</tr>
<tr>
<td><strong>Genitourinary</strong></td>
<td>Increased urinary frequency due to increased total urinary output&lt;br&gt;Increased incidence of UTI and pyelonephritis due to urinary stasis (see Urinary Tract Infection, OB28)&lt;br&gt;Glycosuria that can be physiologic especially in the 3rd trimester; must test for GDM&lt;br&gt;Ureters and renal pelvis dilation (R&gt;1) due to progesterone-induced smooth muscle relaxation and uterine enlargement&lt;br&gt;Increased CO and thus increased GFR leads to decreased creatinine (normal in pregnancy 35-44 mmol/L), uric acid, and BUN</td>
</tr>
<tr>
<td><strong>Neurologic</strong></td>
<td>Increased incidence of carpal tunnel syndrome and Bell’s palsy</td>
</tr>
<tr>
<td><strong>Endocrine</strong></td>
<td>Thyroid: moderate enlargement (not clinically detectable) and increased basal metabolic rate&lt;br&gt;Increased total thyroxine and thyroxine binding globulin (TBS)&lt;br&gt;Free thyroxine index and TSH levels are normal&lt;br&gt;Adrenal: maternal cortisol rises throughout pregnancy (total and free)&lt;br&gt;Calcium: decreased total maternal Ca2+ due to decreased albumin&lt;br&gt;Free (united Ca2+ (i.e., active) proportion remains the same due to parathyroid hormone (PTH), results in increased bone resorption and gut absorption, increased bone turnover (but no loss of bone density due to estrogen inhibition)</td>
</tr>
</tbody>
</table>
Antepartum Care

- provided by obstetrician, family doctor, midwife, or multidisciplinary team (based on patient preference and risk factors)

Preconception Counselling

- 3-8 wk GA is a critical period of organogenesis, so early preparation is vital
- past medical history: optimize illnesses and medications prior to pregnancy (see Medical Complications of Pregnancy, OB25, and Medications, OB10)
- supplementation
  - folic acid: encourage diet rich in folic acid and supplement 8-12 wk preconception until end of T1 to prevent NTDs
    - 0.4-1 mg daily in all women; 5 mg if previous NTD, antiepileptic medications, DM, or BMI >35 kg/m²
  - iron supplementation, prenatal vitamins
- risk modification
  - lifestyle: balanced nutrition and physical fitness
  - medications: discuss teratogenicity of medications so they may be adjusted or stopped if necessary
  - infection screening: rubella, HBsAg, VDRL, Pap smear, gonorrhea/chlamydia, HIV, TB testing based on travel and health care worker, history of varicella or vaccination, parvovirus immunity if exposed to small children, cytomegalovirus immunity if health care worker, toxoplasmosis serology if a cat or gardening last pertussis vaccine
  - genetic testing as appropriate for high risk groups (see Prenatal Screening, Table 2): consider genetics referral in known carriers, recurrent pregnancy loss/stillbirth, family members with developmental delay, birth anomalies, genetic diseases
  - social: smoking, alcohol, drug use, domestic violence (see Family Medicine, FM11, FM12, FM26)

Initial Prenatal Visit

- usually within 8-12 wk of the first day of LMP or earlier if <20 or >35 yr old, bleeding, very nauseous, or other risk factors present

History

- gestational age by dates from the first day of the LMP
  - Naegle’s rule: 1st day of LMP + 7 d – 3 mo
  - e.g. LMP = 1 Apr 2014, EDC = 8 Jan 2015 (modify if cycle >28 d by adding number of d >28)
  - if LMP unreliable, get a dating ultrasound which could coincide with nuchal translucency at ~12 wk
  - dates should change if T1 U/S is greater than 5 days in difference from LMP due date
  - history of present pregnancy (e.g. bleeding, N/V) and all previous pregnancies
  - past medical, surgical, and gynecological history
  - prescription and non-prescription medications
  - family history: genetic diseases, birth defects, multiple gestation, consanguinity
  - social history: smoking, alcohol, drug use, domestic violence (see Family Medicine, FM11, FM12, FM26)

Physical Exam

- complete physical exam to obtain baseline patient information – BP and weight important for interpreting subsequent changes

Investigations

- blood work
  - CBC, blood group and Rh status, antibody screen, infection screening as per preconception counselling
- urine R&amp;M, midstream urine C&amp;S
  - screen for bacteriuria and proteinuria
- pelvic exam
  - pap smear (only if required according to patient history and provincial screening guidelines), cervical or urine PCR for N. gonorrhoeae (GC) and C. trachomatis

Nausea and Vomiting

Epidemiology

- affects 50-90% of pregnant women
- often limited to T1 but may persist
Management
- rule out other causes of N/V
- weigh frequently, assess level of hydration, test urine for ketones

non-pharmacological
- avoid mixing fluids and solids, frequent small meals (bland, dry, salty better tolerated)
- electrolyte oral solutions (Pedialyte®, Gatorade®)
- stop prenatal vitamins (folic acid must continue until >12 wk)
- increase sleep/rest
- ginger (maximum 1,000 mg/d)
- acupuncture, acupressure

pharmacological
- first line: Diclectin® (10 mg doxylamine succinate with vitamin B6) 4 tablets PO daily to maximum of 8 tablets
- if no improvement, try dimenhydrinate (50-100 mg q4-6h PO), followed by hydroxyzine, pyridoxine, phenothiazine, or metoclopramide
- vitamin B6 lollipops
- if patient dehydrated, assess fluid replacement needs and resuscitate accordingly

severe/refractory
- consider homecare with IV fluids and parenteral anti-emetics, hospitalization

Hyperemesis Gravidarum

Definition
- intractable N/V, usually presents in T1 then diminishes; occasionally persists throughout pregnancy
- affects ~1% of pregnancies

Etiology
- multifactorial with hormonal, immunologic, and psychologic components
- rapidly rising β-hCG + estrogen levels may be implicated

Investigations
- rule out systemic causes: GI inflammation, pyelonephritis, thyrotoxicosis
- rule out other obstetrical causes: multiple gestation, GTN, HELLP syndrome
- CBC, electrolytes, BUN, creatinine, LFTs, urinalysis
- ultrasound

Management
- thiamine supplementation may be indicated
- non-pharmacological (see Nausea and Vomiting)
- pharmacological options
  - Diclectin® (for dosage, see Nausea and Vomiting)
  - Dimenhydrinate can be safely used as an adjunct to Diclectin® (1 suppository bid or 25 mg PO qid)
  - other adjuncts: hydroxyzine, pyridoxine, phenothiazine, metoclopramide
  - also consider: ondansetron or methylprednisolone
  - if severe: admit to hospital, NPO initially then small frequent meals, correct hypovolemia, electrolyte disturbance, and ketosis, TPN (if very severe) to reverse catabolic state

Complications
- maternal
  - dehydration, electrolyte and acid-base disturbances
  - Mallory-Weiss tear
  - Wernicke's encephalopathy, if protracted course
  - death
- fetal: usually none, IUGR is 15x more common in women losing >5% of pre-pregnancy weight

Subsequent Prenatal Visits

Timing
- for uncomplicated pregnancies, SOGC recommends q4-6wk until 30 wk, q2-3wk from 30 wk, and q1-2 from 36 wk until delivery

Assess at Every Visit
- estimated GA
- history: fetal movements, uterine bleeding, leaking, cramping, questions, concerns
- physical exam: BP, weight gain, SFH, Leopold's maneuvers (T3) for lie, position, and presentation of fetus
- investigations: urinalysis for glucosuria, proteinuria; fetal heart rate starting at 10-12 wk using Doppler U/S
Leopold’s Maneuvers
- performed after 30-32 wk gestation
- first maneuver: to determine which fetal part is lying furthest away from the pelvic inlet
- second maneuver: to determine the location of the fetal back
- third maneuver: to determine which fetal part is lying above the pelvic inlet
- fourth maneuver: to locate the fetal brow

Figure 2. Leopold’s maneuvers (T3)
Reprinted with permission from Essentials of Clinical Examination Handbook, 6th ed. Lincoln, McSheffrey, Tran, Wong

Prenatal Screening and Diagnostic Tests

Screening Tests
- testing should only occur following counselling and with the informed consent from the patient

Table 2. High-Risk Population Screening Tests

<table>
<thead>
<tr>
<th>Disease (Inheritance)</th>
<th>Population(s) at Risk</th>
<th>Screening Test(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thalassemia (AR)</td>
<td>Mediterranean, South East Asian, Western Pacific, African, Middle Eastern, Caribbean, South American</td>
<td>CBC (MCV and MCH), Hb electrophoresis, or HPLC</td>
</tr>
<tr>
<td>Sickle Cell (AR)</td>
<td>African, Caribbean, Mediterranean, Middle Eastern, Indian, South American</td>
<td>CBC (MCV and MCH), Hb electrophoresis, or HPLC</td>
</tr>
<tr>
<td>Cystic Fibrosis (CF) (AR)</td>
<td>Family history of CF in patient or partner or medical condition linked to CF like male infertility</td>
<td>CFTR gene DNA analysis</td>
</tr>
<tr>
<td>Tay Sachs Disease (AR)</td>
<td>Ashkenazi Jewish*, French Canadians, Cajun</td>
<td>Enzyme assay HEXA, or DNA analysis</td>
</tr>
<tr>
<td>Fragile X Syndrome (X-linked)</td>
<td>Family history – confirmed or suspected</td>
<td>DNA analysis: FMR-1 gene</td>
</tr>
</tbody>
</table>

AR = autosomal recessive; HEXA = hexosaminidase A; HPLC = high performance liquid chromatography
* If both partners are Ashkenazi Jewish, test for Canavan disease and Familial Dysautonomia (FD); if family history of a specific condition, look for carrier status: e.g. Gaucher, CF, Bloom syndrome, Niemann-Pick disease, etc. In all cases, if both partners positive, refer for genetic counselling

Table 3. Gestation-Dependent Screening Investigations

<table>
<thead>
<tr>
<th>Gestational Age (wk)</th>
<th>Investigations</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8-12</td>
<td>Dating U/S, possible Pap smear, chlamydia/gonorrhea cultures, urine C&amp;S, HIV, VDRL, HepBSAg, Rubella IgG, Parvovirus IgM or IgG if high risk (small child at home or daycare worker/primary teacher), Varicella IgG if no history of disease/immunization, CBC, blood group and screen</td>
<td>Measures cell free fetal DNA in maternal circulation</td>
</tr>
<tr>
<td>&gt;10</td>
<td>NIFT</td>
<td></td>
</tr>
<tr>
<td>10-12</td>
<td>CVS</td>
<td></td>
</tr>
<tr>
<td>11-14</td>
<td>FTS IPS Part 1</td>
<td>Measures</td>
</tr>
<tr>
<td>11-14</td>
<td>Nuchal translucency U/S</td>
<td>1. Nuchal translucency on U/S</td>
</tr>
<tr>
<td>15-16 to term</td>
<td>Amniocentesis</td>
<td>2. β-hCG</td>
</tr>
<tr>
<td>15-20</td>
<td>IPS Part 2 (or MSAFP only for patients who did FTS earlier)</td>
<td>Measures</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1. MSAFP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2. β-hCG</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3. Unconjugated estrogen (estriol or µE3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4. Inhibin A</td>
</tr>
</tbody>
</table>

Routine T2 U/S at 18-22 wk Helps
Determine
- Number of fetuses
- GA (if no prior U/S)
- Location of placenta
- Fetal anomalies
Table 3. Gestation-Dependent Screening Investigations (continued)

<table>
<thead>
<tr>
<th>Gestational Age (wk)</th>
<th>Investigations</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>15-20</td>
<td>MSS (or MSAFP only for patients who did FTS earlier)</td>
<td>Measures 1. MSAFP 2. β-hCG 3. Unconjugated estrogen (estradiol or µE3) 4. Inhibin A</td>
</tr>
<tr>
<td>18-20 to term</td>
<td>Fetal movements (quickening)</td>
<td></td>
</tr>
<tr>
<td>18-20</td>
<td>U/S for dates, fetal growth, and anatomy assessment</td>
<td></td>
</tr>
<tr>
<td>24-28</td>
<td>Gestational Diabetes Screen 50 g OGCT</td>
<td>See Diabetes Mellitus, OB26</td>
</tr>
<tr>
<td>28</td>
<td>Repeat CBC RhG for all Rh negative women</td>
<td></td>
</tr>
<tr>
<td>35-37</td>
<td>GBS screen</td>
<td>See Group B Streptococcus, OB27</td>
</tr>
<tr>
<td>6 wk postpartum</td>
<td>Discuss contraception, menses, breastfeeding, depression, mental health, support Physical exam: breast exam, pelvic exam including Pap smear (only if due as per provincial screening)</td>
<td></td>
</tr>
</tbody>
</table>

Ultrasound Screening
- 8-12 wk GA: Dating Ultrasound (most accurate form of pregnancy dating)
  - measurement of crown-rump length (margin of error ± 5 d)
  - change EDC to U/S date if >5 d discrepancy from EDC based on LMP
- 11-14 wk GA: NTUS
  - measures the amount of fluid behind the neck of the fetus
  - early screen for Trisomy 21 (may also detect cardiac and other aneuploidies like Turner’s syndrome)
  - NT measurement is necessary for the FTS and IPS Part 1
- 18-20 wk GA: Growth and Anatomy U/S (margin of error ± 10 d)
  - earlier or subsequent ultrasounds performed when medically indicated

Non-Invasive Prenatal Testing (NIPT)
- analyses maternal blood for circulating cell free fetal DNA (ccfDNA) at 10 wk GA onwards. Requires dating ultrasound for accuracy

Advantage
- in high risk women (>age 35) highly sensitive for Trisomy 21 (99.5%), specificity (>99.8%) can also look for trisomy 18, 13 and some X and Y disorders as well as common microdeletions
- not harmful to the pregnancy, results available in 7-10 day

Disadvantages
- does not screen for oNTD
- high cost to patient (only covered in some provinces in certain cases)
- unclear how accurate yet in low risk women (<35)
- need to confirm with invasive testing
- Does not test for all aneuploidy

Table 4. Comparison of FTS, MSS, and IPS

<table>
<thead>
<tr>
<th>FTS</th>
<th>MSS</th>
<th>IPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>11-14 wk</td>
<td>15-20 wk</td>
<td>11-13 wk U/S-Nuchal Translucency</td>
</tr>
<tr>
<td>11-14 wk U/S</td>
<td>FTS blood</td>
<td>15-20 wk: MSAFP blood including inhibin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Risk estimate for</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Down syndrome (Trisomy 21): increased NT, increased β-hCG, decreased PAPP-A</td>
<td>1. oNTD: increased MSAFP (sensitivity 80-90%)</td>
<td></td>
</tr>
<tr>
<td>2. Trisomy 18: increased NT, decreased PAPP-A, decreased β-hCG</td>
<td>2. Trisomy 21: decreased MSAFP, increased β-hCG, decreased µE3, decreased inhibin (sensitivity 80%)</td>
<td></td>
</tr>
</tbody>
</table>

Note: does not measure risk of open neural tube defect (oNTD) and should be combined with MSAFP at 15-20 wk Useful when patient wants results within the first trimester More accurate estimate of Down syndrome risk than MSS, sensitivity ~85% (when combined with age) 5% false positive rate Patients with positive screen should be offered CVS, amniocentesis, or NIPT (covered in some provinces, self-pay in others)

Risk estimate for oNTD, Trisomy 21, Trisomy 18 Sensitivity ~85-90% 2% false positive rate Patients with positive screen should be offered U/S, amniocentesis, or NIPT (covered in some provinces, self-pay in others)

Note: In twins, FTS, MSS, and IPS are not applicable; screen with NT, NIPT for chromosomal abnormalities and MSAFP for oNTDs
Diagnostic Tests

Indications
- age >35 yr (increased risk of chromosomal anomalies)
- risk factors in current pregnancy
  - abnormal U/S
  - abnormal prenatal screen (IPS, FTS, or MSS)
- past history/family history of
  - chromosomal anomaly or genetic disease
  - either parent a known carrier of a genetic disorder or balanced translocation
  - consanguinity
- >3 spontaneous abortions

Rh Antibody Titre
- A positive titre (≥1:16) indicates an increased risk of fetal hemolytic anemia

AMNIOCENTESIS
- U/S-guided transabdominal extraction of amniotic fluid

Indications
- identification of genetic anomalies (15-16 wk gestation) as per indications above
- confirmation of positive NIPT testing
- positive FTS/IPS
- assessment of fetal lung maturity (T3) via the L/S ratio (lecithin:sphingomyelin)
  - if >2:1, RDS is less likely to occur

Advantages
- also screens for oNTD (acetylcholinesterase and amniotic AFP) – 96% accurate
- in women >35 yr, the risk of chromosomal anomaly (1/180) is greater than the risk of miscarriage from the procedure
- more accurate genetic testing than CVS

Disadvantages
- 1/400-1/500 risk of procedure related pregnancy loss
- results take 14-28 d; FISH can be done on chromosomes X, Y, 21, 13, 18 to give preliminary results in 48 h

CHORIONIC VILLUS SAMPLING
- biopsy of fetal-derived chorion using a transabdominal needle or transcervical catheter at 10-12 wk

Advantages
- enables pregnancy to be terminated earlier than with amniocentesis
- rapid karyotyping and biochemical assay within 48 h, including FISH analysis
- high sensitivity and specificity

Disadvantages
- 1-2% risk of procedure related pregnancy loss
- does not screen for oNTD
- 1-2% incidence of genetic mosaicism “false negative” results

ISOIMMUNIZATION SCREENING

Definition
- isoimmunization: antibodies (Ab) produced against a specific RBC antigen (Ag) as a result of antigenic stimulation with RBC of another individual

Etiology
- maternal-fetal circulation normally separated by placental barrier, but sensitization can occur and can affect the current pregnancy, or more commonly, future pregnancies
- Anti-Rh Ab produced by a sensitized Rh-negative mother can lead to fetal hemolytic anemia
- Risk of isoimmunization of an Rh-negative mother with an Rh-positive ABO-compatible infant is 16% sensitization routes
- incompatible blood transfusions
- previous fetal-maternal transplacental hemorrhage (e.g. ectopic pregnancy, abruption)
- invasive procedures in pregnancy (e.g. prenatal diagnosis, cerclage, D&C)
- any type of abortion
- labour and delivery

Investigations
- screening with indirect Coombs test at first visit for blood group, Rh status, and antibodies
- Kleihauer-Betke test used to determine extent of fetomaternal hemorrhage by estimating volume of fetal blood volume that entered maternal circulation
- detailed U/S for hydrops fetalis
- MCA dopplers are done to assess degree of fetal anemia or if not available bilirubin is measured by serial amniocentesis to assess the severity of hemolysis
- cordocentesis for fetal Hb should be used cautiously (not first line)
Prophylaxis
- exogenous Rh IgG (Rhogam® or WinRho®) binds to Rh antigens of fetal cells and prevents them from contacting maternal immune system
- Rhogam® (300 µg) given to all Rh negative and antibody screen negative women in the following scenarios
  - routinely at 28 wk GA (provides protection for ~12 wk)
  - within 72 h of the birth of an Rh positive fetus
  - with any invasive procedure in pregnancy (CVS, amniocentesis)
  - in ectopic pregnancy
  - with miscarriage or therapeutic abortion
  - with an antepartum hemorrhage
- a Betke-Kleihauer test or Flow cytometry can be used to determine whether more than 300 µg of RhIg is required (>30 ml fetal blood)
- if Rh negative and Ab screen positive, follow mother with serial monthly Ab titres throughout pregnancy +ultrasounds± serial amniocentesis as needed (Rhogam® has no benefit)

Treatment
- falling biliary pigment warrants no intervention (usually indicative of either unaffected or mildly affected fetus)
- intrauterine transfusion of O-negative pRBCs may be required for severely affected fetus or early delivery of the fetus for exchange transfusion

Complications
- anti-Rh IgG can cross the placenta and cause fetal RBC hemolysis resulting in fetal anemia, CHF, edema, ascites
- severe cases can lead to fetal hydrops (edema in at least two fetal compartments due to fetal heart failure secondary to anemia) or erythroblastosis fetalis (moderate to severe immune-mediated hemolytic anemia)

Counselling of the Pregnant Woman

Nutrition
- Canada’s Food Guide to Healthy Eating suggests
  - 3-4 servings of milk products daily (greater if multiple gestation)
  - a daily caloric increase of ~100 cal/d in the 1st trimester, ~300 cal/d in the second and third trimesters and ~450 cal/d during lactation
  - daily multivitamin should be continued in the 2nd trimester for women who do not consume an adequate diet; otherwise routine vitamin supplementation is not necessary (avoid excess vitamin A)
- nutrients important during pregnancy
  - folate: 0.4 mg/d for first 12 wk (5 mg/d if high risk)
    - supports increase in blood volume, growth of maternal and fetal tissue, decreases incidence of NTD
    - foods rich in folic acid include: spinach, lentils, chick peas, asparagus, broccoli, peas, brussels sprouts, corn, and oranges
  - calcium: 1200-1500 mg/d
    - maintains integrity of maternal bones, skeletal development of fetus, breast milk production
  - vitamin D: 1,000 IU
    - promotes calcium absorption
  - iron: 0.8 mg/d in T1, 4-5 mg/d in T2, and >6 mg/d in T3
    - supports maternal increase in blood cell mass, supports fetal and placental tissue
    - required amounts exceed normal body stores and typical intake, and therefore need supplemental iron
    - iron is the only known nutrient for which requirements during pregnancy cannot be met by diet alone (see Iron Deficiency Anemia, OB25)
  - essential fatty acids – supports fetal neural and visual development
    - contained in vegetable oils, margarines, peanuts, fatty fish

Caffeine
- diuretic and stimulant that readily crosses placenta
- less than 300 mg/d is not thought to contribute to miscarriage or preterm birth (ACOG)
  - relationship between caffeine and IUGR is unknown (ACOG)
  - SOGC states 1-2 cups/d are safe during pregnancy

Herbal Teas and Preparations
- not enough scientific information about safety of various herbs and herbal products to recommend their use during pregnancy
- some herbal teas can have toxic or pharmacological effects on the mother or fetus
- chamomiles have been reported to exhibit adverse effects on the uterus
- raspberry leaf tea often used at term to promote labour
Foodborne Illnesses

- microbiological contamination of food may occur through cross-contamination and/or improper food handling
  - listeriosis (Listeria monocytogenes) and toxoplasmosis (Toxoplasma gondii) are of concern during pregnancy
  - avoid consumption of raw meats, fish, shellfish, poultry, hotdogs, raw eggs, and unpasteurized dairy products
  - avoid unpasteurized soft cheeses, deli meats, smoked salmon, and pates as they may be sources of Listeria
- chemical contamination of food
  - current guideline for mercury of 0.5 ppm in fish is not considered harmful for the general population, including pregnant women
  - Health Canada advises pregnant women to limit consumption of top predator fish such as shark, swordfish, king mackerel, tilefish

Lifestyle

- exercise under physician guidance; “talk test” = should be able to speak while exercising; avoid supine position after 20 weeks GA
- absolute contraindications
  - ruptured membranes, preterm labour, hypertensive disorders of pregnancy, incompetent cervix, IU(IU), multiple gestations (≥3), placenta previa after 28th wk, persistent 2nd or 3rd trimester bleeding, uncontrolled type I DM, uncontrolled thyroid disease, or other serious cardiovascular, respiratory, or systemic disorder
- relative contraindications
  - previous preterm birth, mild/moderate cardiovascular or respiratory disorder, anemia (Hb ≤10 g/dL), malnutrition or eating disorder, twin pregnancy after 28th wk, other significant medical conditions
- weight gain: optimal gain depends on pre-pregnancy BMI (varies from 6.8-18.2 kg)
- work: strenuous work, extended hours and shift work during pregnancy may be associated with greater risk of low birth weight, prematurity, and spontaneous abortion
- air travel is acceptable in second trimester; airline cut off for travel is 36-38 wk gestation depending on the airline, to avoid giving birth on the plane
- sexual intercourse: may continue, except in patients at risk for: abortion, preterm labour, or placenta previa; breast stimulation may induce uterine activity and is discouraged in high-risk patients near term
- smoking: assist/encourage to reduce or quit smoking
  - increased risk of decreased birth weight, placenta previa/abruption, spontaneous abortion, preterm labour, stillbirth
- alcohol: no amount of alcohol is safe in pregnancy; encourage abstinence from alcohol during pregnancy; alcohol increases incidence of abortion, stillbirth, and congenital anomalies
  - fetal alcohol syndrome (see Pediatrics, P24)
  - cocaine: microcephaly, growth retardation, prematurity, abruptio placenta

Medications

- most drugs cross the placenta to some extent
- very few drugs are teratogenic, but very few drugs have proven safety in pregnancy
- use any drug with caution and only if necessary
- analgesics: acetaminophen preferable to ASA or ibuprofen

Table 5. Documented Adverse Effects, Contraindicated

<table>
<thead>
<tr>
<th>Contraindicated Medication</th>
<th>Adverse Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACEI</td>
<td>Fetal renal defects, IU(IU), oligohydramnios</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>Stains infant’s teeth, may affect long bone development</td>
</tr>
<tr>
<td>Retinoids (e.g. Accutane®)</td>
<td>CNS, craniofacial, cardiac, and thymic anomalies</td>
</tr>
<tr>
<td>Misoprostol</td>
<td>Mobius syndrome (congenital facial paralysis with or without limb defects, spontaneous abortion, preterm labour)</td>
</tr>
</tbody>
</table>
Table 6. Documented Adverse Effects, Weigh Benefits vs. Risks, and Consider Medication Change

<table>
<thead>
<tr>
<th>Medication</th>
<th>Adverse Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenytoin</td>
<td>Fetal hydantoin syndrome in 5-10% (IUGR, mental retardation, facial dysmorphogenesis, congenital anomalies)</td>
</tr>
<tr>
<td>Valproate</td>
<td>oNTD in 1%</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>oNTD in 1-2%</td>
</tr>
<tr>
<td>Lithium</td>
<td>Ebstein’s cardiac anomaly, goitre, hyponatremia</td>
</tr>
<tr>
<td>Warfarin</td>
<td>Increased incidence of spontaneous abortion, stillbirth, prematurity, IUGR, fetal warfarin syndrome (nasal hypoplasia, epiphyseal stippling, optic atrophy, mental retardation, intracranial hemorrhage)</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>Maternal liver damage (acute fatty liver)</td>
</tr>
<tr>
<td>Sulpha drugs</td>
<td>Anti-folate properties, therefore theoretical risk in T1; risk of kernicterus in T3</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>Grey baby syndrome (fetal circulatory collapse Z” to toxic accumulation)</td>
</tr>
</tbody>
</table>

Immunizations

Intrapartum
- Administration is dependent on the risk of infection vs. risk of immunization complications
- Safe: tetanus toxoid, diphtheria, influenza, hepatitis B, pertussis
- Avoid live vaccines (risk of placental and fetal infection): polio, measles/mumps/rubella, varicella
- Contraindicated: oral typhoid
- The public health agency of Canada recommends:
  - All pregnant women receive the influenza vaccine
  - All pregnant women at 26 weeks of pregnancy or later, who have not received a dose of pertussis-containing vaccine in adulthood, should receive Tdap vaccination in pregnancy

Postpartum
- Rubella vaccine for all non-immune mothers
- Hepatitis B vaccine should be given to infant within 12 h of birth if maternal status unknown or positive
  - Follow-up doses at 1 and 6 mo
- Any vaccine required/recommended is generally safe postpartum

Radiation

- Ionizing radiation exposure is considered teratogenic at high doses
  - If indicated for maternal health, should be done
- Imaging not involving direct abdominal/pelvic high dosage is not associated with adverse effects
  - Higher dosage to fetus: plain x-ray of lumbar spine/abdomen/pelvis, barium enema, CT abdomen, pelvis, lumbar spine
- Most investigations involve minimal radiation exposure
- Radioactive isotopes of iodine are contraindicated
- No known adverse effects from U/S or MRI (long-term effects of gadolinium unknown, avoid if possible)

Table 7. Approximate Fetal Doses from Common Diagnostic Procedures

<table>
<thead>
<tr>
<th>Examination</th>
<th>Estimated Fetal Dose (rad)</th>
<th>Number of Exams Safe in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plain Film</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdomen</td>
<td>0-14</td>
<td>35</td>
</tr>
<tr>
<td>Pelvis</td>
<td>0-11</td>
<td>45</td>
</tr>
<tr>
<td>Lumbar spine</td>
<td>0-17</td>
<td>29</td>
</tr>
<tr>
<td>Thoracic spine</td>
<td>0.009</td>
<td>555</td>
</tr>
<tr>
<td>Chest (2 views)</td>
<td>&lt;0.001</td>
<td>5000</td>
</tr>
<tr>
<td>CT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdomen</td>
<td>0-8</td>
<td>6</td>
</tr>
<tr>
<td>Pelvis</td>
<td>2-5</td>
<td>2</td>
</tr>
<tr>
<td>Lumbar spine</td>
<td>0-24</td>
<td>20</td>
</tr>
<tr>
<td>Chest</td>
<td>0.006</td>
<td>833</td>
</tr>
</tbody>
</table>

Adapted from: Cohen Keren, et al. 2003 and Valentin 2000

Radiation in Pregnancy
- Necessary amount to cause miscarriage: >5 rads
- Necessary amount to cause malformations: >20-30 rads
Antenatal Fetal Surveillance

Fetal Movements

- patients will generally first notice fetal movement ("quickening") at 18-20 wk in primigravidas; can occur 1-2 wk earlier in multigravidas; can occur 1-2 wk later if placenta is implanted on the anterior wall of uterus
- if the patient is concerned about decreased fetal movement, she is counselled to choose a time when the fetus is normally active to count movements (usually recommended after 26 wk)
- all high risk women should be told to do FM counts
  - if there is a subjective decrease in fetal movement, try drinking juice, eating, changing position, or moving to a quiet room and count for 2 h; ≥6 movements in 2 h expected
  - if there are <6 movement counts in 2 h, patient should present to labour and delivery triage

NON-STRESS TEST

Definition
- FHR tracing ≥20 min using an external Doppler to assess FHR and its relationship to fetal movement (see Fetal Monitoring in Labour, OB33)

Indication
- any suggestion of uteroplacental insufficiency or suspected compromise in fetal well-being

Table 8. Classification of Antepartum Non-Stress Test

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Normal NST (Previously &quot;Reactive&quot;)</th>
<th>Atypical NST (Previously &quot;Non-Reactive&quot;)</th>
<th>Abnormal NST (Previously &quot;Non-Reactive&quot;)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>110-160 bpm</td>
<td>100-160 bpm or &gt;160 bpm for &lt;30 min Rising baseline</td>
<td>Bradycardia &lt;100 bpm Tachycardia &gt;160 for &gt;30 min Erratic baseline</td>
</tr>
<tr>
<td>Variability</td>
<td>6-25 bpm (moderate) ≤5 (absent or minimal) for &lt;40 min</td>
<td>5 (absent or minimal) for 40-80 min ≤5 for 80 min Sinusoidal 29 bpm for &gt;10 min</td>
<td></td>
</tr>
<tr>
<td>Decelerations</td>
<td>None or occasional variable &lt;30 s</td>
<td>Variable decelerations 30-60 s duration</td>
<td>Variable decelerations &gt;60 s Late deceleration(s)</td>
</tr>
<tr>
<td>Accelerations in Term Fetus</td>
<td>2 accelerations with acme of ≥15 bpm, lasting 15 s over &lt;40 min of testing</td>
<td>2 accelerations with acme of ≥15 bpm, lasting 15 s in 40-80 min &lt;2 accelerations with acme of ≥15 bpm, lasting 15 s in &gt;80 min</td>
<td></td>
</tr>
<tr>
<td>Accelerations in Preterm Fetus (&lt;32 wk)</td>
<td>&gt;2 accelerations with acme of &gt;10 bpm, lasting 10 s in &lt;40 min</td>
<td>&lt;2 accelerations with acme of &gt;10 bpm, lasting 10 s in 40-80 min &lt;2 accelerations with acme of &gt;10 bpm, lasting 10 s in &gt;80 min</td>
<td></td>
</tr>
</tbody>
</table>

Action
- FURTHER ASSESSMENT OPTIONAL, based on total clinical picture
- FURTHER ASSESSMENT REQUIRED
- URGENT ACTION REQUIRED

Adapted from: SOGC, Fetal Health Surveillance: Antepartum and Intrapartum Consensus Guideline, September 2007

Operating Characteristics
- false positive rate depends on duration; false negative rate = 0.2-0.3%

Interpretation
- normal: at least 2 accelerations of FHR >15 bpm from the baseline lasting >15 s, in 20 min
- abnormal: <2 accelerations of FHR in 40 min
- if no observed accelerations or fetal movement in the first 20 min, stimulate fetus (fundal pressure, acoustic/vibratory stimulation) and continue monitoring for 30 min
- if NST abnormal, then perform BPP

BIOPHYSICAL PROFILE

Definition
- U/S assessment of the fetus ± NST

Indications
- abnormal or atypical NST
- post-term pregnancy
- decreased fetal movement
- IUGR
- any other suggestion of fetal distress or uteroplacental insufficiency
Operating Characteristics
- false positive rate ≤30%, false negative rate = 0.1%

**Table 9. Scoring of the BPP**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Reassuring (2 points)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tone (Limb Extension then Flexion)</td>
<td>At least one episode of limb extension followed by flexion</td>
</tr>
<tr>
<td>Movement</td>
<td>Three discrete movements</td>
</tr>
<tr>
<td>Breathing</td>
<td>At least one episode of breathing lasting at least 30 s</td>
</tr>
<tr>
<td>AFV*</td>
<td>Fluid pocket of 2 cm in 2 axes</td>
</tr>
</tbody>
</table>

*AFV is a marker of chronic hypoxia, all other parameters indicate acute hypoxia

**Interpretation**
- 8: perinatal mortality rate 1:1,000; repeat BPP as clinically indicated
- 6: perinatal mortality 31:1,000; repeat BPP in 24 h
- 0-4: perinatal mortality rate 200:1,000; deliver fetus if benefits of delivery outweigh risks

---

**Obstetrical Hemorrhage**

**Definition**
- vaginal bleeding from 20 wk to term

**Differential Diagnosis**
- bloody show (shedding of cervical mucus plug) – most common etiology in T3
- placenta previa
- abruptio placentae – most common pathological etiology in T3
- vasa previa
- cervical lesion (cervicitis, polyp, ectropion, cervical cancer)
- uterine rupture
- other: bleeding from bowel or bladder, abnormal coagulation

**Table 10. Comparison of Placenta Previa and Abruptio Placentae**

<table>
<thead>
<tr>
<th>Placenta Previa</th>
<th>Abruptio Placentae</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definition</td>
<td>Premature separation of a normally implanted placenta after 20 wk GA</td>
</tr>
<tr>
<td>Etiology</td>
<td>Idiopathic</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>0.5-0.8% of all pregnancies</td>
</tr>
<tr>
<td>Risk Factors</td>
<td>1-2% of all pregnancies</td>
</tr>
<tr>
<td>History of placenta previa (4-8% recurrence risk)</td>
<td>Previous abruption (recurrence rate 5-16%)</td>
</tr>
<tr>
<td>Multiparity</td>
<td>Maternal HTN (chronic or gestational HTN in 50% of abruptions) or vascular disease</td>
</tr>
<tr>
<td>Increased maternal age</td>
<td>Cigarette smoking (&gt;1 pack/d), excessive alcohol consumption, cocaine</td>
</tr>
<tr>
<td>Multiple gestation</td>
<td>Multiparity and/or maternal age &gt; 35 yr</td>
</tr>
<tr>
<td>Uterine tumour (e.g. fibroids) or other uterine anomalies</td>
<td>PPROM</td>
</tr>
<tr>
<td>Uterine scar due to previous abortion, C/S, D&amp;C, myomectomy</td>
<td>Rapid decompression of a distended uterus (polyhydramnios, multiple gestation)</td>
</tr>
<tr>
<td><strong>Bleeding</strong></td>
<td><strong>PAINLESS</strong></td>
</tr>
<tr>
<td><strong>Usually PAINFUL</strong></td>
<td><strong>Usually PAINFUL</strong></td>
</tr>
</tbody>
</table>

---

**Placenta Previa**

**Definition**
- placenta implanted in the lower segment of the uterus, presenting ahead of the leading pole of the fetus
- placental position is described in relation to the internal os as “mm away” or “mm of overlap”

**Clinical Features**
- PAINLESS bright red vaginal bleeding (recurrent), may be minimized and cease spontaneously, but can become catastrophic
- mean onset of bleeding is 30 wk GA, but onset depends on degree of previa
- **physical exam**
  - uterus soft and non-tender
  - presenting fetal part high or displaced
  - FHR usually normal
  - shock/anemia correspond to degree of apparent blood loss
• complications
  ■ fetal
  ◆ perinatal mortality low but still higher than with a normal pregnancy
  ◆ prematurity (bleeding often dictates early C/S)
  ◆ intrauterine hypoxia (acute or IUGR)
  ◆ fetal malpresentation
  ◆ PPROM
  ◆ risk of fetal blood loss from placenta, especially if incised during C/S
  ■ maternal
  ◆ <1% maternal mortality
  ◆ hemorrhage and hypovolemic shock, anemia, acute renal failure, pituitary necrosis (Sheehan syndrome)
  ◆ placenta accreta – especially if previous uterine surgery, anterior placenta previa
  ◆ hysterectomy

Investigations
• transvaginal U/S is more accurate than transabdominal U/S at diagnosing placenta previa at any gestational age if the placenta lies between 20 mm of overlap and 20 mm away from the internal os after 20 wk transvaginal ultrasounds should be repeated in the third trimester as continued change in the placental location is likely

Management
• goal: keep pregnancy intrauterine until the risk of delivery < risk of continuing pregnancy
  • stabilize and monitor
    ◆ maternal stabilization: large bore IV with hydration, O₂ for hypotensive patients
    ◆ maternal monitoring: vitals, urine output, blood loss, blood work (hematocrit, CBC, INR/PTT, platelets, fibrinogen, FDP type and cross match)
    ◆ electronic fetal monitoring
    ◆ U/S assessment: when fetal and maternal condition permit, determine fetal viability, gestational age, and placentation/position
    ◆ Rhogam® if mother is Rh negative
    ◆ determine extent of fetomaternal transfusion so that appropriate dose of Rhogam® can be given
    ◆ GA <37 wk and minimal bleeding: expectant management
      ◆ admit to hospital
      ◆ limited physical activity, no douches, enemas, or sexual intercourse
      ◆ consider corticosteroids for fetal lung maturity
      ◆ delivery when fetus is mature or hemorrhage dictates
    ◆ GA ≥37 wk, profuse bleeding, or L/S ratio is >2:1 – deliver by C/S

Abruptio Placentae

Definition
• premature partial or total placental detachment caused by bleeding at the decidual-placental interface
• occurring >20 wks gestation

Clinical Features
• classification
  ◆ total (fetal death inevitable) vs. partial
  ◆ external/revealed/apparent: blood dissects downward toward cervix
  ◆ internal/concealed/occult (20%): blood dissects upward toward fetus
  ◆ most are mixed
• presentation
  ◆ usually PAINFUL (80%) vaginal bleeding (bleeding not always present if abruption is concealed), uterine tenderness, uterine contractions/hypertonus
  ◆ pain: sudden onset, constant, localized to lower back and uterus
  ◆ shock/anemia out of proportion to apparent blood loss
  ◆ ± fetal distress, fetal demise (15% present with demise), bloody amniotic fluid (fetal presentation typically normal)
  ◆ ± coagulopathy

Complications
• fetal complications: perinatal mortality 25-60%, prematurity, intrauterine hypoxia
• maternal complications: <1% maternal mortality, DIC (in 20% of abruptions), acute renal failure, anemia, hemorrhagic shock, pituitary necrosis (Sheehan syndrome), amniotic fluid embolus

Investigations
• clinical diagnosis, U/S not sensitive for diagnosing abruption (sensitivity = 15%)
Management
• maternal stabilization: large bore IV with hydration, O2 for hypotensive patients
• maternal monitoring: vitals, urine output, blood loss, blood work (hematocrit, CBC, PTT/PT, platelets, fibrinogen, FDP, type and cross match)
• EFM
• blood products on hand (red cells, platelets, cryoprecipitate) because of DIC risk
• Rhogam® if Rh negative
  • Kleihauer-Betke test may confirm abruption
• mild abruption
  • GA <37 wk: use serial Hct to assess concealed bleeding, deliver when fetus is mature or when hemorrhage dictates
  • GA ≥37 wk: stabilize and deliver
• moderate to severe abruption
  • hydrate and restore blood loss and correct coagulation defect if present
  • vaginal delivery if no contraindication and no evidence of fetal or maternal distress OR fetal demise
  • C/S if live fetus and fetal or maternal distress develops with fluid/blood replacement, labour fails to progress or if vaginal delivery otherwise contraindicated

**Vasa Previa**

**Definition**
• unprotected fetal vessels pass over the cervical os; associated with velamentous insertion of cord into membranes of placenta or succenturiate (accessory) lobe

**Epidemiology**
• 1 in 5,000 deliveries – higher in twin pregnancies

**Clinical Features**
• PAINLESS vaginal bleeding and fetal distress (tachy- to bradyarrhythmia)
• 50% perinatal mortality, increasing to 75% if membranes rupture (most infants die of exsanguination)

**Investigations**
• Apt test (NaOH mixed with the blood) can be done immediately to determine if the source of bleeding is fetal (supernatant turns pink) or maternal (supernatant turns yellow)
• Wright stain on blood smear and look for nucleated red blood cells (in cord, not maternal blood)

**Management**
• emergency C/S (since bleeding is from fetus, a small amount of blood loss can have catastrophic consequences)

**Obstetrical Complications**

**Preterm Labour**

**Definition**
• labour between 20 and 37 wk gestation

**Etiology**
• idiopathic (most common)
• maternal: infection (recurrent pyelonephritis, untreated bacteriuria, chorioamnionitis), HTN, DM, chronic illness, mechanical factors, previous obstetric, gynecological, and abdominal surgeries, socio-environmental (poor nutrition, smoking, drugs, alcohol, stress)
• maternal-fetal: PPROM (common), polyhydramnios, placenta previa, placental abruption, or placental insufficiency
• fetal: multiple gestation, congenital abnormalities of fetus, fetal hydrops, stress
• uterine: incompetent cervix, excessive enlargement (hydramnios, multiple gestation), malformations (intracavitary leiomyomas, septate uterus, mullerian duct abnormalities)

**Epidemiology**
• preterm labour complicates about 10% of pregnancies

**Risk Factors**
• prior history of spontaneous PTL is the most important risk factor
• prior history cervical excisions (LEEPs/cone biopsy) or mechanical dilatation (D&C)
• cervical length: measured by transvaginal U/S (cervical length >30 mm has high negative predictive value for PTL before 34 wk)
• identification of bacterial vaginosis and ureaplasma urealyticum infections; routine screening not supported by current data but it is reasonable to screen high risk women
• family history of preterm birth
Predicting PTL
- fetal fibronectin: a glycoprotein in amniotic fluid and placental tissue
  - positive if >50 ng/mL; NPV > PPV
  - in symptomatic women (i.e. preterm contractions), fetal fibronectin is most effectively combined with US detecting cervical length
  - if cervical length is not short and fetal fibronectin is negative, preterm labour is highly unlikely

Clinical Features
- regular contractions (2 in 10 min, >6/h)
- cervix >1 cm dilated, >80% effaced, or length <2.5 cm

Management
A. Initial
- transfer to appropriate facility if stable
- hydration (NS at 150 mL/h)
- bed rest in LLDP
- sedation (morphine)
- avoid repeated pelvic exams (increased infection risk)
- U/S examination of fetus (GA, BPP, position, placenta location, estimated fetal weight)
- prophylactic antibiotics; (for GBS) important to consider if PPROM (e.g. erythromycin controversial but may help to delay delivery)

B. Suppression of Labour – Tocolysis
- does not inhibit preterm labour completely, but may delay delivery (used for <48 h) to allow for betamethasone valerate (Celestone®) and/or transfer to appropriate centre for care of the premature infant
- requirements (all must be satisfied)
  - preterm labour
  - live, immature fetus, intact membranes, cervical dilatation of <4 cm
  - absence of maternal or fetal contraindications
- contraindications
  - maternal: bleeding (placenta previa or abruption), maternal disease (HTN, DM, heart disease), preclampsia or eclampsia, choioamnionitis
  - fetal: erythroblastosis fetalis, severe congenital anomalies, fetal distress/demise, IUGR, multiple gestation (relative)
- agents
  - calcium channel blockers: nifedipine
    - 20 mg PO loading dose followed by 20 mg PO 90 min later
    - 20 mg can be continued q3-8h for 72 h or to a max of 180 mg
  - 10 mg PO q20min x 4 doses
  - contraindications: nifedipine allergy, hypotension, hepatic dysfunction, concurrent beta-mimetics or MgSO4 use, transdermal nitrates, or other antihypertensive medications
  - prostaglandin synthesis inhibitors: indomethacin
    - 1st line for early preterm labour (<30 wk GA) or polyhydramnios
  - 50-100 mg PR loading dose followed by 50 mg q6h x 8 doses for 48 hours
  - magnesium sulphate
    - was previously used for tocolysis; currently, only indicated for prevention of eclampsia or for neuroprotection if preterm delivery is inevitable between 24 and 31+6 wks GA for neuroprotection
    - 4 g IV loading dose followed by 1g q1h maintenance until birth

C. Enhancement of Fetal Pulmonary Maturity
- betamethasone valerate (Celestone®) 12 mg IM q24h x 2 doses or dexamethasone 6 mg IM q12h x 4 doses
  - 28-36+6 wk GA: reduces incidence of RDS
  - 24-28 wk GA: reduces severity of RDS, overall mortality and rate of IVH
  - specific maternal contraindications: active TB

D. Cervical Cerclage
- definition: placement of cervical sutures at the level of the internal os, usually at the end of the first trimester or in the second trimester and removed in the third trimester
- indications: cervical incompetence (i.e. cervical dilatation and effacement in the absence of increased uterine contractility)
  - emerging evidence indicates that progesterone suppositories are superior to cerclage in preventing preterm labour not due to cervical incompetence, (neither is effective in multiple gestations)
  - diagnosis of cervical incompetence
    - obstetrical Hx: silent cervical dilation, 2nd trimester losses, procedures on cervix
    - ability of cervix to hold an inflated Foley catheter during a hysterosonogram
  - proven benefit in the prevention of PTL in women with primary structural abnormality of the cervix (e.g. conization of the cervix, connective tissue disorders)
Prognosis

- Prematurity is the leading cause of perinatal morbidity and mortality
- 30 wk or 1,500 g (3.3 lb) = 90% survival
- 33 wk or 2,000 g (4.4 lb) = 99% survival
- Morbidity due to asphyxia, hypoxia, sepsis, RDS, intraventricular cerebral hemorrhage, thermal instability, retinopathy of prematurity, bronchopulmonary dysplasia, necrotizing enterocolitis

Prevention of Preterm Labour

- Currently there are no agents approved by Health Canada to arrest preterm labour
- Preventative measures: good prenatal care, identify pregnancies at risk, treat silent vaginal infection or UTI, patient education
- Transvaginal ultrasound of cervical length is recommended only for high-risk pregnancies and only before 30 weeks GA

Premature Rupture of Membranes

Definitions

- PROM: prelabour rupture of membranes at any GA
- Prolonged ROM: >24 h elapsed between rupture of membranes and onset of labour
- Preterm ROM: ROM occurring before 37 wk gestation
- PPROM: preterm (before 37 wk) AND prelabour rupture of membranes

Risk Factors

- Maternal: multiparity, cervical incompetence, infection (cervicitis, vaginitis, STI, UTI), family history of PROM, low socioeconomic class/poor nutrition
- Fetal: congenital anomaly, multiple gestation
- Other risk factors associated with PTL

Clinical Features

- History of fluid gush or continued leakage

Investigations

- Sterile speculum exam (avoid introduction of infection)
  - Pooling of fluid in the posterior fornix
  - May observe fluid leaking out of cervix on cough/Valsalva (“cascade”)
  - Nitrazine (basic amniotic fluid turns nitrazine paper blue)
  - Low specificity as can be positive with blood, urine, or semen
  - Ferring (high salt in amniotic fluid evaporates, looks like ferns under microscope)
  - U/S to rule out fetal anomalies, assess GA, presentation and BPP

Management

- Admit for expectant management and monitor vital q4h, daily BPP and WBC count
- Avoid introducing infection by minimizing examinations
  - Consider administration of betamethasone valerate (Celestone®) to accelerate maturity if <34 wk and up to 36+6 weeks if no evidence of infection
  - Consider tocolysis for 48 h to permit administration of steroids if PPROM induces labour
- Screen women for UTIs, STIs, GBS carriage and treat with appropriate antibiotics if positive
- If not in labour or labour not indicated, consider antibiotics: penicillins or macrolide antibiotics are the antibiotics of choice
- Deliver urgently if evidence of fetal distress and/or chorioamnionitis

Table 11. PROM Management

<table>
<thead>
<tr>
<th>Degree of Prematurity</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;24 wk</td>
<td>Consider termination (poor outcome due to pulmonary hypoplasia)</td>
</tr>
<tr>
<td>24-25 wk</td>
<td>Individual consideration with counselling of parents regarding risks to preterm infants</td>
</tr>
<tr>
<td>26-34 wk</td>
<td>Expectant management as prematurity complications are significant</td>
</tr>
<tr>
<td>34-36 wk</td>
<td>“Grey zone” where risk of death from RDS and neonatal sepsis is the same</td>
</tr>
<tr>
<td>≥37 wk</td>
<td>Induction of labour since the risk of death from sepsis is greater than RDS</td>
</tr>
</tbody>
</table>

Prognosis

- Varies with gestational age
- 90% of women with PROM at 28-34 wk GA go into spontaneous labour within 1 wk
- 50% of women with PROM at ≤26 wk GA go into spontaneous labour within 1 wk
- Complications: cord prolapse, intrauterine infection (chorioamnionitis), premature delivery, limb contracture
**Prolonged Pregnancy**

**Definition**
- pregnancy >42 wk GA

**Epidemiology**
- 41 wk GA: up to 27%
- >42 wk GA: 5.5%

**Etiology**
- most cases idiopathic
- anencephalic fetus with no pituitary gland
- placental sulfatase deficiency (X-linked recessive condition in 1/2,000-1/6,000 infants) – rare

**Clinical Features**
- postmaturity syndrome (10-20% of post-term pregnancies): fetal weight loss, reduced subcutaneous fat, scaling, dry skin from placental insufficiency, long thin body, open-eyed, alert and worried look, long nails, palms and soles wrinkled
- with increasing GA, higher rates of: intrauterine infection, asphyxia, meconium aspiration syndrome, placental insufficiency, placental aging and infarction, macrosomia, dystocia, fetal distress, operative deliveries, pneumonia, seizures, and requirement of NICU admission, and stillbirth

**Management**
- GA 39 wk with advanced maternal age (>40yo): consideration should be given to IOL due to increased risk of stillbirth
- GA 40-41 wk: expectant management
  - no evidence to support IOL or C/S unless other risk factors for morbidity are present (see prognosis)
- GA >41 wk: offer IOL if vaginal delivery is not contraindicated
  - IOL shown to decrease C/S, fetal heart rate changes, meconium staining, macrosomia, and death when compared with expectant management
- GA >41 wk and expectant management elected: serial fetal surveillance
  - fetal movement count by the mother
  - BPP q3-4d
- if AFI is decreased, labour should be induced

**Prognosis**
- if >42 wk, perinatal mortality 2-3x higher (due to progressive uteroplacental insufficiency)
- morbidity increased with HTN in pregnancy, DM, abortion, IUGR, and multiple gestation

---

**Intrauterine Fetal Death**

**Definition**
- fetal death in utero after 20 wk GA

**Epidemiology**
- occurring in 1% of pregnancies

**Etiology**
- 50% idiopathic
- 50% secondary to HTN, DM, erythroblastosis fetalis, congenital anomalies, umbilical cord or placental complications, intrauterine infection, APS

**Clinical Features**
- decreased perception of fetal movement by mother
- SFH and maternal weight not increasing
- absent fetal heart tones on Doppler (not diagnostic)
- high MSAFP
- on U/S: no fetal heart rate. Depending on timing of death may see skull collapse, brain tissue retraction, empty fetal bladder, non-filled aorta, poor visualization of midline flax

**Management**
- diagnosis: absent cardiac activity and fetal movement on U/S required for diagnosis
- determine secondary cause
  - maternal: HbA1c, fasting glucose, TSH, Kleihauer-Betke, VDRL, ANA, CBC, anticardiolipins, antibody screens, INR/PTT, serum/urine toxicology screens, cervical and vaginal cultures, TORCH screen
  - fetal: karyotype, cord blood, skin biopsy, genetics evaluation, autopsy, amniotic fluid culture for CMV, parvovirus B19, herpes
  - placenta: pathology, bacterial cultures

---

**DIC: Generalized Coagulation and Fibrinolysis Leading to Depletion of Coagulation Factors**

**Obstetrical Causes**
- Abruption
- Gestational HTN
- Fetal demise
- PPH

**DIC-specific Blood Work**
- Platelets
- aPTT and PT
- FDP
- Fibrinogen

**Treatment**
- Treat underlying cause
- Supportive
- Fluids
- Blood products
- FFP, platelets, cryoprecipitate
- Consider anti-coagulation as VTE prophylaxis
Treatment
• <12 wk: dilation and curettage
• 13-20 wk: induction of labour
• ≥20 wk: non-surgical management
• monitor for maternal coagulopathy (10% risk of DIC)
• parental psychological care/bereavement support as per hospital protocol
• comprehensive discussion within 3 mo about final investigation and post-mortem results, help make plans for future pregnancies

Intrauterine Growth Restriction

Definition
• infant weight <10th percentile for GA or <2,500 g at term

Etiology/Risk Factors
• 50% unknown
• maternal causes
  ■ malnutrition, smoking, drug abuse, alcoholism, cyanotic heart disease, type 1 DM, SLE, pulmonary insufficiency, previous IUGR (25% risk, most important risk factor), chronic HTN
  ■ maternal-fetal
    ▪ any disease causing placental insufficiency
    ▪ includes gestational HTN, chronic renal insufficiency, gross placental morphological abnormalities (infarction, hemorrhangiosis, placenta previa, abnormal cord insertion), prolonged gestation
  ■ fetal causes
    ▪ TORCH infections, multiple gestation, congenital anomalies / chromosomal abnormalities (10%)

Clinical Features
• symmetric/type I (25-30%): occurs early in pregnancy
  ■ reduced growth of both head and abdomen
  ■ head:abdomen ratio may be normal (>1 up to 32 wk; =1 at 32-34 wk; <1 after 34 wk GA)
  ■ usually associated with congenital anomalies or TORCH infections
  ■ asymmetric/type II (70%): occurs late in pregnancy
  ■ fetal abdomen is disproportionately smaller than fetal head
  ■ brain is spared, therefore head:abdomen ratio increased
  ■ usually associated with placental insufficiency
  ■ more favourable prognosis than type I
• complications
  ■ prone to meconium aspiration, asphyxia, polycythemia, hypoglycemia, hypocalcemia, hyperphosphatemia hyponatremia, and mental retardation
  ■ greater risk of perinatal morbidity and mortality

Investigations
• SFH measurements at every antepartum visit
• if mother at high risk or SFH lags >2 cm behind GA
  ■ U/S for biparietal diameter, head and abdominal circumference ratio, femur length, fetal weight, and AFV (decrease associated with IUGR), decrease in the rate of growth
  ■ ± BPP
  ■ Doppler analysis of umbilical cord blood flow

Management
• prevention via risk modification prior to pregnancy is ideal
• modify controllable factors: smoking, alcohol, nutrition, and treat maternal illness
• bed rest in LLDP
• serial BPP (monitor fetal growth) and determine cause of IUGR, if possible
• delivery when extrauterine existence is less dangerous than continued intrauterine existence (abnormal function tests, absent growth, severe oligohydramnios) especially if GA >34 wk
• liberal use of C/S since IUGR fetus withstands labour poorly

Macrosomia

Definition
• infant weight >90th percentile for a particular GA or >4,000 g

Etiology/Risk Factors
• maternal obesity, GDM, past history of macrosomic infant, prolonged gestation, multiparity

Clinical Features
• increased risk of perinatal mortality
• CPD and birth injuries (shoulder dystocia, fetal bone fracture) more common
• complications of DM in labour (see Table 15, OB27)
Investigations
- serial SFH
- further investigations if mother at high risk or SFH >2 cm ahead of GA
- U/S predictors
  - polyhydramnios
  - third trimester AC >1.5 cm/wk
  - HC/AC ratio <100th percentile
  - FL/AC ratio <20th percentile

Management
- prophylactic C/S is a reasonable option where EFW >5,000 g in non-diabetic woman and EFW >4,500 g in diabetic woman
- no evidence that prophylactic C/S improves outcomes
- risks and benefits of early induction (risk of C/S vs. risk of dystocia) must be weighed in diabetic mothers, as current research is unclear

---

## Polyhydramnios/Oligohydramnios

**Table 12. Polyhydramnios and Oligohydramnios**

<table>
<thead>
<tr>
<th>Polyhydramnios</th>
<th>Oligohydramnios</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definition</td>
<td>Definition</td>
</tr>
<tr>
<td>AFI &gt;25 cm</td>
<td>AFI &lt;5 cm</td>
</tr>
<tr>
<td>U/S: single deepest pocket &gt;8 cm</td>
<td>U/S: single deepest pocket ≤2 cm</td>
</tr>
<tr>
<td>Etiology</td>
<td>Etiology</td>
</tr>
<tr>
<td>Idiopathic most common</td>
<td>Idiopathic most common</td>
</tr>
<tr>
<td>Maternal</td>
<td>Maternal</td>
</tr>
<tr>
<td>Type 1 DM: abnormalities of transchorionic flow</td>
<td>Uteroplacental insufficiency (preeclampsia, nephropathy)</td>
</tr>
<tr>
<td>Maternal-fetal</td>
<td>Medications (AEm)</td>
</tr>
<tr>
<td>Chorioangiomas</td>
<td>Fetal</td>
</tr>
<tr>
<td>Multiple gestation</td>
<td>Congenital urinary tract anomalies (renal agenesis, obstruction, posterior urethral valves)</td>
</tr>
<tr>
<td>Fetal</td>
<td>Demise/chronic hypoxemia (blood shunt away from kidneys to perfuse brain)</td>
</tr>
<tr>
<td>Chromosomal anomaly (up to 2/3 of fetuses have severe polyhydramnios)</td>
<td>IUGR</td>
</tr>
<tr>
<td>Respiratory: cystic adenomatoid malformed lung</td>
<td>Ruptured membranes: prolonged amniotic fluid leak</td>
</tr>
<tr>
<td>CNS: anencephaly, hydrocephalus, meningocoele</td>
<td>Amniotic fluid normally decreases after 35 wk</td>
</tr>
<tr>
<td>GI: tracheoesophageal fistula, duodenal atresia, facial clefts (interfere with swallowing)</td>
<td></td>
</tr>
<tr>
<td>Epidemiology</td>
<td>Epidemiology</td>
</tr>
<tr>
<td>Occur in 0.2-1.6% of all pregnancies</td>
<td>Occur in ~4.5% of all pregnancies</td>
</tr>
<tr>
<td>Severe form in &lt;0.7%</td>
<td>Severe form in &lt;0.7%</td>
</tr>
<tr>
<td>Common in pregnancies &gt;41 wk (~12%)</td>
<td>Common in pregnancies &gt;41 wk (~12%)</td>
</tr>
<tr>
<td>Clinical Features and Complications</td>
<td>Clinical Features and Complications</td>
</tr>
<tr>
<td>Uterus large for dates, difficulty palpating fetal parts and hearing FHR</td>
<td>Uterus small for dates</td>
</tr>
<tr>
<td>Maternal complications</td>
<td>Fetal complications</td>
</tr>
<tr>
<td>Pressure symptoms from overdistended uterus (dyspnea, edema, hydrenephrosis)</td>
<td>15-25% have fetal anomalies</td>
</tr>
<tr>
<td>Obstetrical complications</td>
<td>Amniotic fluid bands (T1) can lead to Potter's facies, limb deformities, abdominal wall defects</td>
</tr>
<tr>
<td>Cord prolapse, placental abruption, malpresentation, preterm labour, uterine dysfunction, and PPH</td>
<td>Obstetrical complications</td>
</tr>
<tr>
<td></td>
<td>Cord compression</td>
</tr>
<tr>
<td></td>
<td>Increased risk of adverse fetal outcomes</td>
</tr>
<tr>
<td></td>
<td>Pulmonary hypoplasia (late-onset)</td>
</tr>
<tr>
<td></td>
<td>Marker for infants who may not tolerate labour well</td>
</tr>
<tr>
<td>Management</td>
<td>Management</td>
</tr>
<tr>
<td>Determine underlying cause</td>
<td>Always warrants admission and investigation</td>
</tr>
<tr>
<td>Screen for maternal disease/infection</td>
<td>Rule out ROM</td>
</tr>
<tr>
<td>Complete fetal U/S evaluation</td>
<td>Fetal monitoring (NST, BPP)</td>
</tr>
<tr>
<td>Depends on severity</td>
<td>U/S Doppler studies (umbilical cord and uterine artery)</td>
</tr>
<tr>
<td>Mild to moderate cases require no treatment</td>
<td>Maternal hydration with oral or IV fluids to help increase amniotic fluid</td>
</tr>
<tr>
<td>If severe, hospitalize and consider therapeutic amniocentesis</td>
<td>Injection of fluid via amniocentesis will improve condition for ~1 wk – may be most helpful for visualizing any associated fetal anomalies</td>
</tr>
<tr>
<td></td>
<td>Consider delivery if term</td>
</tr>
<tr>
<td></td>
<td>Amnio-infusion may be considered during labour via intrauterine catheter</td>
</tr>
<tr>
<td>Prognosis</td>
<td>Prognosis</td>
</tr>
<tr>
<td>2-5 fold increase in risk of perinatal mortality</td>
<td>Poorer with early onset</td>
</tr>
<tr>
<td>High mortality related to congenital malformations and pulmonary hypoplasia when diagnosed during T2</td>
<td></td>
</tr>
</tbody>
</table>
Multi-Fetal Gestation and Malpresentation

Epidemiology
- incidence of twins is 1/80 and triplets 1/6,400 in North America
- 2/3 of twins are dizygotic (fraternal)
  - risk factors for dizygotic twins: IVF, increased maternal age, newly discontinued OCP, ethnicity (e.g. certain African regions)
- monozygous twinning occurs at a constant rate worldwide (1/250)
- determine zygosity by number of placentas, thickness of membranes, sex, blood type

Clinical Features

Table 13. Complications Associated with Multiple Gestation

<table>
<thead>
<tr>
<th>Maternal</th>
<th>Uteroplacental</th>
<th>Fetal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperemesis gravidum</td>
<td>Increased PROM/PTL</td>
<td>Prematurity*</td>
</tr>
<tr>
<td>GDM</td>
<td>Polyhydramnios</td>
<td>IUGR</td>
</tr>
<tr>
<td>Gestational HTN</td>
<td>Placenta previa</td>
<td>Malpresentation</td>
</tr>
<tr>
<td>Anemia</td>
<td>Placental abruption</td>
<td>Congential anomalies</td>
</tr>
<tr>
<td>Increased physiological stress on all systems</td>
<td>PPROM (uterine atony)</td>
<td>Twin-twin transfusion</td>
</tr>
<tr>
<td>Increased compressive symptoms</td>
<td>Umbilical cord prolapse</td>
<td>Increased perinatal morbidity and mortality</td>
</tr>
<tr>
<td>C/S</td>
<td>Cord anomalies</td>
<td>Twin interlocking (twin A breech, twin B vertex)</td>
</tr>
<tr>
<td>(velamentous insertion, 2 vessel cord)</td>
<td>Polyhydramnios</td>
<td>Single fetal demise</td>
</tr>
</tbody>
</table>

*Most common cause of perinatal mortality in multiple gestation

Management
- U/S determination of chorionicity must be done within first trimester (ideally 8-12 wk GA)
- increased antenatal surveillance
  - serial U/S q 2-3wk from 24 wk GA to assess growth (uncomplicated diamniotic dichorionitic)
  - increased frequency of ultrasounds in monochorionic diamniotic and monochorionic monoamniotic twins
  - Doppler flow studies weekly if discordant fetal growth (>30%)
  - BPP as needed
- may attempt vaginal delivery if twin A presents as vertex, otherwise C/S (40-50% of all twin deliveries, 15% of cases have twin A delivered vaginally and twin B delivered by C/S)
- mode of delivery depends on fetal weights, GA, presentation

Figure 4. Classification of twin pregnancies

*Indicates time of cleavage
Twin-Twin Transfusion Syndrome

Definition
- formation of placental intertwinn vascular anastomoses cause arterial blood from donor twin to pass into veins of the recipient twin

Epidemiology
- 10% of monochorionic twins
- concern if >30% discordance in estimated fetal weight

Clinical Features
- donor twin: IUGR, hypovolemia, hypotension, anemia, oligohydramnios
- recipient twin: hypervolemia, HTN, CHF, polycytemia, edema, polyhydramnios, kernicterus in neonatal period

Investigations
- detected by U/S screening, Doppler flow analysis

Management
- therapeutic serial amniocentesis to decompress polyhydramnios of recipient twin and decrease pressure in cavity and on placenta
- intrauterine blood transfusion to donor twin if necessary
- laparoscopic occlusion of placental vessels
- fetoscopic laser ablation of placental vascular anastomoses when indicated and if available

Breech Presentation

Definition
- fetal buttocks or lower extremity is the presenting part as determined on U/S
- complete (10%): hips and knees both flexed
- frank (60%): hips flexed, knees extended, buttocks present at cervix
- most common type of breech presentation
- most common breech presentation to be delivered vaginally
- incomplete (30%): both or one hip flexed and both or one knee present below the buttocks, feet or knees present first (foottling breech, kneeling breech)

Epidemiology
- occurs in 3-4% of pregnancies at term (25% <28 wk)

Risk Factors
- maternal: pelvis (contracted), uterus (shape abnormalities, intrauterine tumours, fibroids, previous breech), pelvic tumours causing compression, grand multiparity
- maternal-fetal: placenta (previa), amniotic fluid (poly-/oligohydramnios)
- fetal: prematurity, multiple gestation, congenital malformations (found in 6% of breeches; 2-3% if in vertex presentations), abnormalities in fetal tone and movement, aneuploidy, hydrocephalus, anencephalus

Management
- ECV: repositioning of singleton fetus within uterus under U/S guidance
  - overall success rate of 65%
  - criteria: >36 wk GA, singleton, unengaged presenting part, reactive NST, not in labour
  - contraindications: previous T3 bleed, prior classical C/S, previous myomectomy, oligohydramnios, PROM, placenta previa, abnormal U/S, suspected IUGR, HTN, uteroplacental insufficiency, nuchal cord
  - risks: abruption, cord compression, cord accident, ROM, labour, fetal bradycardia requiring C/S (<1% risk), alloimmunization, fetal death 1:5,000
  - method: tocometry, followed by U/S guided transabdominal manipulation of fetus with constant fetal heart monitoring
  - if patient Rh negative, give Rhogam® prior to procedure
  - better prognosis if multiparous, good fluid volume, small baby, skilled obstetrician, posterior placenta
    - pre- or early labour ultrasound to assess type of breech presentation, fetal growth, estimated weight, placenta position, attitude of fetal head (flexed is preferable); if ultrasound unavailable, recommend C/S
- ECV and elective C/S should be presented as options with the risks and benefits outlined; obtain informed consent

Criteria for Vaginal Breech Delivery
- Frank or complete breech, GA >36 wk
- EFW 2,500-3,800 g based on clinical and U/S assessment (5.5—8.5 lb)
- Fetal head flexed
- Continuous fetal monitoring
- 2 experienced obstetricians, assistant, and anesthetist present
- Ability to perform emergency C/S within 30 min if required
Hypertensive Disorders of Pregnancy

Hypertension in Pregnancy

- hypertensive disorders of pregnancy are classified as either pre-existing or gestational HTN

PRE-EXISTING HYPERTENSION

Definition
- BP >140/90 prior to 20 wk GA, persisting >7 wk postpartum
- essential HTN is associated with an increased risk of gestational HTN, abruptio placentae, IUGR, and IUFD

GESTATIONAL HTN

Definition
- sBP >140 or dBP >90 developing after 20th wk GA in the absence of proteinuria in a woman known to be normotensive before pregnancy

Risk Factors
- maternal factors
  - primigravida (80-90% of gestational HTN), first conception with a new partner, PMHx or FHx of gestational HTN
  - DM, chronic HTN, or renal insufficiency
  - obesity
  - antiphospholipid syndrome
  - extremes of maternal age (<18 or >35 yr)
  - previous stillbirth or IUFD
- fetal factors
  - IUGR or oligohydramnios
  - GTN
  - multiple gestation
  - fetal hydrops "mirror syndrome"

Clinical Evaluation of HTN in Pregnancy
- in general, clinical evaluation should include the mother and fetus
- evaluation of mother
  - body weight
  - central nervous system
    - presence and severity of headache
    - visual disturbances – blurring, scotomata
    - tremulousness, irritability, somnolence
    - hyperreflexia
  - hematologic
    - bleeding, petechiae
  - hepatic
    - RUQ or epigastric pain
  - severe N/V
  - renal
    - urine output and colour
    - non-dependent edema (i.e. hands and face)

Evidence
- vaginal breech delivery
  - method for vaginal breech delivery
    - encourage effective maternal pushing efforts
    - at delivery of after-coming head, assistant must apply suprapubic pressure to flex and engage fetal head
    - delivery can be spontaneous or assisted; avoid fetal traction
    - apply fetal manipulation only after spontaneous delivery to level of umbilicus
  - C/S recommended if: the breech has not descended to the perineum in the second stage of labour after 2 h, in the absence of active pushing, or if vaginal delivery is not imminent after 1 h of active pushing
  - contraindications to vaginal breech delivery:
    - cord presentation
    - clinically inadequate maternal pelvis
    - fetal factors incompatible with vaginal delivery (e.g. hydrocephalus), macrosomia, fetal growth restriction

Prognosis
- regardless of route of delivery, breech infants have lower birth weights and higher rates of perinatal mortality, congenital anomalies, abortion, and cord prolapse

Vaginal Delivery of Breech Presentation

Objectives: To discuss risks and benefits of trial of labour versus planned C/S, with selection criteria, management, and delivery techniques for trial of vaginal breech birth.

Evidence: Randomized trials, prospective cohort studies and select cohort studies from Medline search for long-term outcomes and epidemiology of vaginal breech delivery.

Summary: Higher risk of perinatal mortality and short-term neonatal morbidity can be associated with vaginal breech birth as compared to elective C/S. However, careful case selection (including term singleton breech fetuses and clinically adequate maternal pelvis) and labour management may achieve a similar safety level as elective C/S (~2 per 1,000 births perinatal mortality, ~2% short-term neonatal morbidity). Specific protocols for vaginal breech delivery should be followed: continuous fetal heart monitoring, assessment for adequate progress in labour, no induction of labour recommended, emergency C/S available, if required, and health care providers with requisite skills and experience. Informed consent for the preferred delivery method should be obtained.
• evaluation of fetus
  ◦ fetal movement
  ◦ fetal heart rate tracing – NST
  ◦ ultrasound for growth
  ◦ BPP
  ◦ Doppler flow studies

Laboratory Evaluation of Gestational Hypertension
• CBC
• PT, INR, fibrinogen – especially if surgery or regional anaesthetics are planned
• ALT, AST
• creatinine, uric acid
• 24 h urine collection for protein or albumin/creatinine ratio

Complications
• maternal
  • liver and renal dysfunction
  • seizure “eclampsia”
  • abruptio placentae
• left ventricular failure/pulmonary edema
• DIC (release of placental thromboplastin consumptive coagulopathy)
• HELLP syndrome
• hemorraghic stroke (50% of deaths)
• fetal (2º to placental insufficiency)
• IUGR, prematurity, abruptio placentae, IUFD

Management
• for non-severe HTN (149-159/90 to 105) target a BP of 130-155/80-105 in women without comorbidities or <140/90 in women with comorbidities
• for both pre-existing and gestational HTN, labetalol 100-400 mg PO bid-tid, nifedipine XL preparation 20-60 mg PO od, or α-methyladopa 250-500 mg PO bid-qid
• for severe HTN (BP>160/110), give one of:
  ◦ labetalol 20 mg IV then 20-80 mg IV q30min (max 300 mg)(then switch to oral)
  ◦ nifedipine 5-10 mg capsule q30min
  ◦ hydralazine 5 mg IV, repeat 5-10 mg IV q30min or 0.5 to 10 mg/hr IV, to a maximum of 20 mg IV (or 30 mg IM)
• no ACEI, ARBs, diuretics, prazosin, or atenolol
• pre-existing HTN and gestational HTN without any deterioration can be followed until 37 wk then decide to induce shortly thereafter

PREECLAMPSIA

Definition
• pre-existing or gestational HTN with new onset proteinuria or adverse conditions

Risk Factors
• nulliparity
• preeclampsia in a previous pregnancy
• age >40 yr or <18 yr
• FHx of preeclampsia
• chronic HTN
• chronic renal disease
• antiphospholipid antibody syndrome or inherited thrombophilia
• vascular or connective tissue disease
• DM (pre-gestational and gestational)
• obesity
• hydrops fetalis “mirror syndrome”
• unexplained fetal growth restriction
• abruptio placentae
• there is a potential for further deterioration to severe preeclampsia as defined above

Management
• depends on GA, possible threat of seizures
• if stable and no adverse factors, may admit and follow, ± decide to deliver as approaching 34-36 wk (must weigh risks of fetal prematurity vs. risks of developing severe preeclampsia/eclampsia)
• for severe preeclampsia, stabilize and deliver
• if severe preeclampsia during labour, increase maternal monitoring: hourly input and output, urine dip q12h, hourly neurological vitals, and increase fetal monitoring (continuous FHR monitoring)
• antihypertensive therapy
  ◦ labetalol 20 mg IV then 20-80 mg IV q30min (max 300 mg)(then switch to oral)
  ◦ nifedipine 5-10 mg capsule q30min
  ◦ hydralazine 5 mg IV, repeat 5-10 mg IV q30min or 0.5 to 10 mg/hr IV, to a maximum of 20 mg IV (or 30 mg IM)
  ◦ MgSO₄ is the recommended first-line treatment for eclampsia.
• seizure prevention
  ■ MgSO₄
  ■ postpartum management
  • risk of seizure highest in first 24 h postpartum – continue MgSO₄ for 12-24 h after delivery
  • vitals q1h
  • consider HELLP syndrome
  • most return to a normotensive BP within 2 wk

ECLAMPSIA

Definition
• the occurrence of one or more generalized convulsions and/or coma in the setting of preeclampsia and in the absence of other neurologic conditions

Epidemiology
• an eclamptic seizure occurs in approximately 0.5% of mildly preeclamptic women and 2-3% of severely preeclamptic women

Risk Factors
• same as risk factors for preeclampsia

Clinical Manifestations
• eclampsia is a clinical diagnosis
• typically tonic-clonic and lasting 60-75 s
• symptoms that may occur before the seizure include persistent frontal or occipital headache, blurred vision, photophobia, right upper quadrant or epigastric pain, and altered mental status
• in up to one third of cases, there is no proteinuria or blood pressure <140/90 mmHg prior to the seizure
• in general, women with typical eclamptic seizures who do not have focal neurologic deficits or prolonged coma do not require diagnostic evaluation including imaging

Management
• ABCs
• roll patient into LLDP
• supplemental O₂ via face mask to treat hypoxemia due to hypoventilation during convulsive episode
• aggressive antihypertensive therapy for sustained diastolic pressures ≥105 mmHg or systolic blood pressures ≥160 mmHg with hydralazine or labetalol
• prevention of recurrent convulsions: to prevent further seizures and the possible complications of repeated seizure activity (e.g. rhabdomyolysis, metabolic acidosis, aspiration pneumonitis, etc.)
• MgSO₄ is now the drug of choice, with previously used agents including diazepam and phenytoin
• the definitive treatment of eclampsia is DELIVERY, irrespective of gestational age, to reduce the risk of maternal morbidity and mortality from complications of the disease
• mode of delivery is dependent on clinical situation and fetal-maternal condition

Medical Complications of Pregnancy

Iron and Folate Deficiency Anemia

<table>
<thead>
<tr>
<th>Table 14. Iron Deficiency and Folate Deficiency Anemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iron Deficiency Anemia</td>
</tr>
<tr>
<td>Etiology</td>
</tr>
<tr>
<td>Epidemiology</td>
</tr>
<tr>
<td>Clinical Features</td>
</tr>
<tr>
<td>Investigations</td>
</tr>
</tbody>
</table>
| Management                                            | Prevention (non-anemic): 30 mg elemental iron/d (met by most prenatal vitamins)
|                                                        | Treatment (anemic): 30-120 mg elemental iron/d
|                                                        | 325 mg fumarate = 106 mg elemental Fe²⁺; 325 mg fumarate sulfate = 65 mg elemental Fe²⁺; 325 mg ferrous gluconate = 36 mg elemental Fe²⁺
|                                                        | Polysaccharide-Iron Complex = 150 mg elemental Fe/capsule |
|                                                        | Prevention: 0.4-1 mg folic acid PO daily for 1-3 mo preconceptually and throughout T1, or 5 mg folic acid per day with past history of oNTD, DM, or antiepileptic medication use |
| Complications                                         | Maternal: anemia, CHF, infection, slower recuperation, preterm labour
|                                                        | Fetal: decreased oxygen carrying capacity leading to fetal distress, IUGR, and low birth weight |
| Notes                                                 | Maternal: decreased blood volume, N/V, anorexia
|                                                        | Fetal: neural tube defects in T1, low birth weight, prematurity |
|                                                       | Mother needs 1 g of elemental iron per fetus; this amount exceeds normal stores + dietary intake
|                                                       | Minimum daily requirement is 0.4 mg
|                                                       | Most often associated with iron deficiency anemia
|                                                       | Folic acid is necessary for closure of neural tube during early fetal development (by day 28 of gestation) |
## Diabetes Mellitus

### Epidemiology
- 2-4% of pregnancies are complicated by DM

### Classification of Diabetes Mellitus
- type 1 and type 2 DM (see Endocrinology, E7)
- GDM: onset of DM during pregnancy (usually around 24-28 wk GA)

### Etiology
- type 1 and type 2 DM
- GDM: anti-insulin factors produced by placenta and high maternal cortisol levels create increased peripheral insulin resistance → leading to GDM and/or exacerbating pre-existing DM

### MANAGEMENT

#### A. TYPE 1 AND TYPE 2 DM

##### Preconception
- pre-plan and refer to high-risk clinic
- optimize glycemic control
- counsel patient on potential risks and complications
- evaluate for diabetic retinopathy, neuropathy, CAD

##### Pregnancy
- if already on oral medication, generally switch to insulin therapy
  - continuing glyburide or metformin controversial
  - teratogenicity unknown for other oral anti-hyperglycemics
- tight glycemic control
  - insulin dosage may need to be adjusted in T2 due to increased demand and increased insulin resistance
- monitor as for normal pregnancy plus initial 24 h urine protein and creatinine clearance, retinal exam, HbA1c
  - HbA1c > 140% of pre-pregnancy value associated with increased risk of spontaneous abortion and congenital malformations
- increased fetal surveillance (BPP, NST), consider fetal ECHO to look for cardiac abnormalities

##### Labour
- timing of delivery depends on fetal and maternal health and risk factors (i.e. must consider size of baby, lung maturity, maternal blood glucose, and blood pressure control)
- can wait for spontaneous labour if blood glucose well-controlled and BPP normal
- induce by 38-39 wk
- type of delivery
  - increased risk of cephalopelvic disproportion (CPD) and shoulder dystocia with babies >4,000 g (8.8 lbs)
  - consider elective C/S for predicted birthweight >4,500 g (9.9 lbs) (controversial)
- monitoring
  - during labour monitor blood glucose q1h with patient on insulin and dextrose drip
  - aim for blood glucose between 3.5-6.5 mmol/L to reduce the risk of neonatal hypoglycemia

##### Postpartum
- insulin requirements dramatically drop with expulsion of placenta (source of insulin antagonists)
- no insulin is required for 48-72 h postpartum in most type 1 DM
- monitor glucose q6h, restart insulin at two-thirds of pre-pregnancy dosage when glucose >8 mmol/L

#### B. GESTATIONAL DM

##### Screening and Diagnosis
- all pregnant women between 24-28 wk GA (or at any stage if high risk)
- 2 screening options
  - 1-step screening with fasting 75 g OGTT; GDM if ≥1 of:
    - FPG ≥ 5.1 mmol/L
    - 1 h PG ≥ 10.0 mmol/L
    - 2 h PG ≥ 8.5 mmol/L
  - 2-step screening (recommended by the Canadian Diabetes Association)
    - Step 1: Perform a random nonfasting 50 g OGCT
      - 1 h PG < 7.8 mmol/L is normal
      - 1 h PG ≥ 11.1 mmol/L is GDM
      - if 1 h PG 7.8-11.0 mmol/L, proceed to Step 2
    - Step 2: Perform a fasting 75 g OGTT, GDM if ≥1 of:
      - FPG ≥ 5.3 mmol/L
      - 1 h PG ≥ 10.6 mmol/L
      - 2 h PG ≥ 9.0 mmol/L

### Monitoring Glucose Levels
- Frequent measurements of blood glucose during pregnancy are advised for women with type 1 or 2 DM to help prevent or treat both hypoglycemia and hyperglycemia, and also improves neonatal outcome
- Aim for FPG ≤ 5.3 mmol/L (95 mg/dL), 1 h post prandial
- PG ≤ 7.0 mmol/L (126 mg/dL), 2 h post prandial PG ≤ 7.0 mmol/L (120 mg/dL)
- Most women can be followed with monthly HbA1c determinations

### Risk Factors for GDM
- Age > 25 yr
- Obesity
- Ethnicity (Aboriginal, Hispanic, Asian, African)
- F/I of DM
- Previous history of GDM
- Previous child with birthweight > 4.0 kg
- Polycystic ovarian syndrome
- Current use of glucocorticoids
- Essential HTN or pregnancy-related HTN

### Post-prandial blood glucose values seem to be the most effective at determining the likelihood of macrosomia or other adverse pregnancy outcomes
Management
- first line is management through diet modification and increased physical activity
- initiate insulin therapy if glycemic targets not achieved within 2 wk of lifestyle modification alone
- glycemic targets: FPG <5.3 mmol/L, 1h PG <7.8 mmol/L, 2h PG <6.7 mmol/L
- oral agents can be used in pregnancy but is off-label and should be discussed with patient
- stop insulin and diabetic diet postpartum
- follow up with 75 g OGTT by 3 months postpartum, counsel about lifestyle modifications, and perform glucose challenge test q2 yr

Prognosis
- most maternal and fetal complications are related to hyperglycemia and its effects

Long-Term Maternal Complications
- type 1 and type 2 DM: risk of progressive retinopathy and nephropathy
- GDM: 50% risk of developing type 2 DM in next 20 yr

Table 15. Complications of DM in Pregnancy

<table>
<thead>
<tr>
<th>Maternal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obstetric</td>
</tr>
<tr>
<td>HTN/preeclampsia (especially if pre-existing nephropathy/proteinuria): insulin resistance is implicated in etiology of HTN Polyhydramnios: maternal hyperglycemia leads to fetal hyperglycemia, which leads to fetal polyuria (a major source of amniotic fluid)</td>
</tr>
<tr>
<td>Diabetic Emergencies</td>
</tr>
<tr>
<td>Hypoglycemia</td>
</tr>
<tr>
<td>Ketoacidosis</td>
</tr>
<tr>
<td>Diabetic coma</td>
</tr>
<tr>
<td>Delayed Organ Maturity</td>
</tr>
<tr>
<td>Fetal lung immaturity: hyperglycemia interferes with surfactant synthesis (respiratory distress syndrome)</td>
</tr>
<tr>
<td>End-Organ Involvement or Deterioration (occur in type 1 DM and type 2 DM, not in GDM)</td>
</tr>
<tr>
<td>Retinopathy</td>
</tr>
<tr>
<td>Nephropathy</td>
</tr>
<tr>
<td>Congenital Anomalies (occur in type 1 DM and type 2 DM, not in GDM)</td>
</tr>
<tr>
<td>2-7x increased risk of cardiac (VSD), NTD, GU (cystic kidneys), GI (anal atresia), and MSK (sacral agenesis) anomalies due to hyperglycemia</td>
</tr>
<tr>
<td>Note: Pregnancies complicated by GDM do not manifest an increased risk of congenital anomalies because GDM develops after the critical period of organogenesis (in T1)</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td>Pyelonephritis/UTI: glucosuria provides a culture medium for E. coli and other bacteria Increased incidence of spontaneous abortion (in type 1 DM and type 2 DM, not in GDM): related to pre-conception glycemic control</td>
</tr>
<tr>
<td>Labour and Delivery</td>
</tr>
<tr>
<td>Preterm labour/prematurity: most commonly in patients with HTN/preeclampsia Preterm labour is associated with poor glycemic control but the exact mechanism is unknown Increased incidence of stillbirth Birth trauma: due to macrosomia, can lead to difficult vaginal delivery and shoulder dystocia</td>
</tr>
<tr>
<td>Neonatal</td>
</tr>
<tr>
<td>Hypoglycemia: due to pancreatic hyperplasia and excess insulin secretion in the neonate Hyperbilirubinemia and jaundice: due to prematurity and polycythemia Hypocalcemia: exact pathophysiology not understood, may be related to functional hypoparathyroidism Polycythemia: hyperglycemia stimulates fetal erythropoietin production</td>
</tr>
</tbody>
</table>

Group B Streptococcus

Epidemiology
- 15-40% vaginal carrier rate

Risk Factors (for neonatal disease)
- GBS bacteriuria during current pregnancy even if treated
- previous infant with invasive GBS disease
- preterm labour <37 wk
- ruptured membranes >18 h before delivery
- intrapartum maternal temperature ≥38°C
- positive GBS screen between 35-37 weeks GA in current pregnancy

Clinical Features
- not harmful to mother
- risk of vertical transmission (neonatal sepsis, meningitis or pneumonia, and death)

Indications for Intrapartum Antibiotic GBS Prophylaxis
Centres for Disease Control and Prevention. Prevention of Perinatal Group B Streptococcal Disease. MMWR 2010;59(RR-10):14
- Previous infant with invasive GBS disease.
- GBS bacteriuria during any trimester of the current pregnancy.
- Unknown GBS status at the onset of labour (culture not done, incomplete, or results unknown) and any of the following:
  - Delivery at <37 wk gestation.
  - Amniotic membrane rupture >18 h.
  - Intrapartum temperature ≥38.0°C (≥ 100.4°F).
- Intrapartum nucleic-acid amplification test positive for GBS.
Investigations
• offer screening to all women at 35-37 wk with vaginal and anorectal swabs for GBS culture

Treatment
• treatment of maternal GBS at delivery decreases neonatal morbidity and mortality
• indications for antibiotic prophylaxis: positive GBS screen, GBS in urine, or previous infant with GBS disease or GBS status unknown and one of the other risk factors
• antibiotics for GBS prophylaxis
  • penicillin G 5 million units IV then 2.5 million units IV q4h until delivery
  • penicillin allergic but not at risk for anaphylaxis: cefazolin 2 g IV then 1 g q8h
  • penicillin allergic and at risk for anaphylaxis: vancomycin 1 g IV q12h until delivery
• if fever, broad spectrum antibiotic coverage is advised

Urinary Tract Infection

Epidemiology
• most common medical complication of pregnancy
• asymptomatic bacteriuria in 2-7% of pregnant women, more frequently in multiparous women
• note: asymptomatic bacteriuria should be treated in pregnancy due to increased risk of pyelonephritis and preterm labour

Etiology
• increased urinary stasis from mechanical and hormonal (progesterone) factors
• organisms include GBS as well as those that occur in non-pregnant women

Clinical Features
• may be asymptomatic
• dysuria, urgency, and frequency in cystitis
• fever, flank pain, and costovertebral angle tenderness in pyelonephritis

Investigations
• urinalysis, urine C&S
• cystoscopy and renal function tests in recurrent infections

Management
• uncomplicated UTI
  • first line: amoxicillin (250-500 mg PO q8h x 7 d)
  • alternatives: nitrofurantoin (100 mg PO bid x 7 d)
  • follow with monthly urine cultures
• pyelonephritis
• hospitalization and IV antibiotics

Prognosis
• complications if untreated: acute cystitis, pyelonephritis, and possible preterm labour
• recurrence is common
# Infections During Pregnancy

## Table 16. Infections During Pregnancy

<table>
<thead>
<tr>
<th>Infection</th>
<th>Agent</th>
<th>Source of Transmission</th>
<th>Greatest Transmission Risk to Fetus</th>
<th>Effects on Fetus</th>
<th>Effects on Mother</th>
<th>Diagnosis</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chicken Pox</td>
<td>Varicella zoster virus (herpes family)</td>
<td>To mom: direct, respiratory To baby: transplacental</td>
<td>13-30 wk GA, and 5 d pre- to 2 d post-delivery</td>
<td>Congenital varicella syndrome (limb aplasia, cataractis, cutaneous scars, cutaneous atrophy, IU5R, hydrops), preterm labour</td>
<td>Fever, malaise, vesicular pruritic lesions</td>
<td>Clinical, +/- vesicle fluid culture, +/- serology</td>
<td>VZIG for mother if exposed, decreases congenital varicella syndrome Note: do not administer vaccine during pregnancy (live attenuated vaccine)</td>
</tr>
<tr>
<td>*CMV</td>
<td>DNA virus (herpes family)</td>
<td>To mom: blood/organ transfusion, sexual contact To baby: transplacental, during delivery, breast milk</td>
<td>T1-T3</td>
<td>5-10% develop CNS involvement (mental retardation, cerebral calcification, microcephalus, microophalmy, deafness, choriorretinitis)</td>
<td>Asymptomatic or flu-like</td>
<td>Serologic screen; isolate virus from urine or secretion culture</td>
<td>No specific treatment; maintain good hygiene and avoid high risk situations</td>
</tr>
<tr>
<td>Erythema Infection (Fifth Disease)</td>
<td>Parovirus B19</td>
<td>To mom: respiratory, infected blood products To baby: transplacental</td>
<td>10-20 wk GA</td>
<td>Spontaneous abortion (SA), stillbirth, hydrops in utero</td>
<td>Flu-like, rash, arthritis; often asymptomatic</td>
<td>Serology, viral PCR, maternal AFP; if IgM present, follow fetus with US for hydrops</td>
<td>If hydrops occurs, consider fetal transfusion</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>DNA virus</td>
<td>To mom: blood, saliva, semen, vaginal secretions To baby: transplacental, breast milk</td>
<td>T3 10% vertical if asymptomatic and HBsAg +ve; 85-90% if HBsAg and HBsAb +ve</td>
<td>Prematurity, low birth weight, neonatal death</td>
<td>Fever, N/V, fatigue, jaundice, elevated liver enzymes</td>
<td>Serologic screening for all pregnancies</td>
<td>Rx neonate with HBIG and vaccine (at birth, 1, 6 mo); 90% effective</td>
</tr>
<tr>
<td>*Herpes Simplex Virus</td>
<td>DNA virus</td>
<td>To mom: intemate mucocutaneous contact To baby: transplacental, during delivery</td>
<td>Delivery (if genital lesions present); less commonly in utero</td>
<td>Disseminated herpes (20%); CNS sequelae (35%); self-limited infection</td>
<td>Painful vesicular lesions</td>
<td>Clinical diagnosis</td>
<td>Acyclovir for symptomatic women, suppressive therapy at 36 wk controversial Suggested C/S if active genital lesions, even if remote from vulva</td>
</tr>
<tr>
<td>HIV</td>
<td>RNA retrovirus</td>
<td>To mom: blood, semen, vaginal secretions To baby: in utero, during delivery, breast milk</td>
<td>1/3 in utero, 1/3 at delivery, 1/3 breastfeeding</td>
<td>IU5R, preterm labour, PROM</td>
<td>See Infectious Diseases, ID27</td>
<td>Serology, viral PCR All pregnant women are offered screening</td>
<td>Triple anti-retroviral therapy decreases transmission to &lt;1% Elective C/S: no previous antiviral Rx or monotherapy only, viral load unknown or &gt; 500 RNA copies/mL, unknown prenatal care, patient request</td>
</tr>
<tr>
<td>*Rubella</td>
<td>ssRNA togavirus</td>
<td>To mom: respiratory droplets (highly contagious) To baby: transplacental</td>
<td>T1</td>
<td>SA or congenital rubella syndrome (hearing loss, cataracts, CV lesions, MR, IU5R, hepatitis, CNS defects, osseous changes)</td>
<td>Rash (90%), fever, posterior auricular or occipital lymphadenopathy, arthralgia</td>
<td>Serologic testing; all pregnant women screened (immune if titre &gt; 1:16); infection if IgM present or &gt;4x increase in IgG</td>
<td>No specific treatment; offer vaccine following pregnancy Do not administer during pregnancy (live attenuated vaccine)</td>
</tr>
<tr>
<td>Syphilis</td>
<td>Spirochete (Treponema pallidum)</td>
<td>To mom: sexual contact To baby: transplacental</td>
<td>T1-T3</td>
<td>Risk of preterm labour, multisystem involvement, fetal death</td>
<td>See Infectious Diseases, ID25</td>
<td>VDRL screening for all pregnancies; if positive, requires confirmatory testing</td>
<td>Pen G 2.4 million U IM x 1 dose if early syphilis, 3 doses if late syphilis; monitor VDRL, monthly if Pen G allergic; Clindamycin 900 mg IV q8h</td>
</tr>
<tr>
<td>*Toxoplasmosis</td>
<td>Protozoa (Toxoplasma gondii)</td>
<td>To mom: raw meat, unpasteurized goat’s milk, cat feces/urine To baby: transplacental</td>
<td>T3 (but most severe if infected in T1); only concern if primary infection during pregnancy</td>
<td>Congenital toxoplasmosis (chorioretinitis, microphalmy, intracranial calcification, MR, microphalmy) NB: 75% initially asymptomatic at birth</td>
<td>Majority subclinical; may have flu-like symptoms</td>
<td>IgM and IgG serology; PCR of amniotic fluid</td>
<td>Self-limiting in mother; spiramycin decreases fetal morbidity but not rate of transmission</td>
</tr>
</tbody>
</table>

* Indicates TORCH infection
Venous Thromboembolism

Epidemiology
• incidence of 12.1/10,000 (DVT), and 5.4/10,000 (PE)
• increased risk VTE throughout pregnancy with highest risk of DVT in third trimester and post-partum period and highest risk of PE post-partum (first 6 weeks)

Risk Factors
• previous VTE, age >35, obesity, infection, bedrest/immobility, shock/dehydration, thrombophilias
(see Hematology, H35)

Table 17. Risk Factors for VTE Specific to Pregnancy

<table>
<thead>
<tr>
<th>Hypercoagulability</th>
<th>Stasis</th>
<th>Endothelial</th>
</tr>
</thead>
<tbody>
<tr>
<td>II, V, VII, IX, X, XII, fibrinogen</td>
<td>Increased Factors</td>
<td>Increased venous tone</td>
</tr>
<tr>
<td>Increased platelet aggregation</td>
<td>Increased resistance to activated protein C</td>
<td>50% decrease in venous flow in lower extremity by T3</td>
</tr>
<tr>
<td>Decreased protein S, tPA, factors XI, XIII</td>
<td>Antithrombin can be normal or reduced</td>
<td>Uterus is mechanical impediment to venous return</td>
</tr>
</tbody>
</table>

Clinical Features
• most DVTs occur in the iliofemoral or calf veins with a predilection for the left leg
• signs of a pulmonary embolism are non-specific (as in non-pregnant women)
• unexplained spontaneous fetal loss

Investigations
• duplex venous Doppler sonography for DVT
• CXR and V/Q scan or spiral CT for PE

Management
• before initiating treatment, obtain a baseline CBC including platelets, and aPTT
• warfarin is contraindicated during pregnancy due to its potential teratogenic effects
• unfractionated heparin
  • bolus of 5,000 IU followed by an infusion of ~30,000 IU/24h
  • measure aPTT 6 h after the bolus
  • maintain aPTT at a therapeutic level (1.5-2x normal)
  • repeat q24h once therapeutic
• heparin-induced thrombocytopenia (HIT) uncommon (3%) but serious complication
• LMWH can also be used in pregnancy
• compression stockings
• poor evidence to support a recommendation for or against avoidance of prolonged sitting
• VTE prophylaxis
  • women on long-term anticoagulation: full therapeutic anticoagulation throughout pregnancy and for 6-12 wk postpartum
  • women with a non-active PMHx of VTE: unfractionated heparin regimens suggested
  • insufficient evidence in pregnancy to recommend routine use of LMWH for all patients
  • current prophylaxis regimens for acquired thrombophilias (e.g. APS syndrome) include low dose Aspirin® in conjunction with prophylactic heparin

Normal Labour and Delivery

Definition of Labour
• true labour: regular, painful contractions of increasing intensity associated with progressive dilatation and effacement of cervix and descent of presenting part, or progression of station
  • preterm (>20 to <36+6 wk GA)
  • term (37-41+6 wk GA)
  • postterm (>42 wk GA)
• false labour (Braxton-Hicks contractions): irregular contractions, with unchanged intensity and long intervals, occur throughout pregnancy and not associated with any cervical dilatation, effacement, or descent
  • often relieved by rest or sedation
The Cervix

- dilatation: latent phase (0-4 cm, variable time); active phase (4-10 cm)
- effacement: thinning of the cervix by percentage or length of cervix (cm)
- consistency: firm vs. soft
- position: posterior, mid or anterior
- application: contact between the cervix and presenting part (i.e. well or poorly applied)

  see Bishop Score (Table 22, OB36)

The Fetus

- fetal lie: orientation of the long axis of the fetus with respect to the long axis of the uterus (longitudinal, transverse, oblique)
- fetal presentation: fetal body part closest to the birth canal
  - breech (complete, frank, incomplete) (see Figure 5, OB22)
  - cephalic (vertex/occiput, face, asynclitic, brow)
  - transverse (shoulder)
  - compound (fetal extremity prolapses along with presenting part)
  - all except vertex are considered malpresentations (see Obstetrical Complications, OB15)
- fetal position: position of presenting part of the fetus relative to the maternal pelvis
  - OA: most common presentation (“normal”) – left OA most common
  - OP: most rotate spontaneously to OA; may cause prolonged second stage of labour
  - OT: leads to arrest of dilatation
    - normally, fetal head enters maternal pelvis and engages in OT position
    - subsequently rotates to OA position (or OP in a small percentage of cases)
- attitude: flexion/extension of fetal head relative to shoulders
  - brow presentation: head partially extended (requires C/S)
  - face presentation: head fully extended
    - mentum posterior always requires C/S, mentum anterior can deliver vaginally
- station: position of presenting bony part relative to ischial spines – determined by vaginal exam
  - at ischial spines = station 0 = engaged
  - -1 to -5 cm above ischial spines or
  - +1 to +5 cm below ischial spines
  - alternatively stations can be placed on a scale from -3 to +3

Maternal Triage Assessment
ID: Age, GPA, EDC, GA, GBS, Rh, Ser
CC: 4 key questions:
- Contractions: Since when, how close (q x min), how long [x s], how painful
- Bleeding: Since when, how much (pads), colour (pink/mucous—show vs. brownish vs. bright red ± clots), pain?, last U/S, trauma/intercourse?
- Fluid (ROM): Since when, large gush vs. trickles, soaked pants?, clear vs. green vs. red?, continuous?
- FM: As much as usual?, When last movement?, Kick counts (it's still for 1-2 h, cold juice, feel FM – should have 6 movements in 2 h)

Pregfix: Any complications (HTN, GDM, infections), IPS/FTS screening, last U/S (BPP score, growth/estimated fetal weight, position), last vaginal exam

POBHx: Every previous pregnancy and outcome: Year, SVD/CS/miscarriage-abortion, baby size, length of labour, use of vacuum or forceps, complications

PMNix: Meds, Allergies, Stix
O/E: Maternal vitals, fetal heart tracing (baseline, variability, presence of accelerations/decelerations), Leopold’s, vaginal exam, U/S

Reference Point for Describing Fetal Position
- Occiput for cephalic presentation
- Sacrum for breech presentation
- Mentum for face presentation

Figure 6. Fetal positions
Four Stages of Labour

First Stage of Labour (0 – 10 cm cervical dilation)
- latent phase
  - uterine contractions typically infrequent and irregular
  - slow cervical dilation (usually to 4 cm) and effacement
- active phase
  - rapid cervical dilatation to full dilatation (nulliparous ≥ 1.0 cm/h, multiparous ≥ 1.2 cm/h)
  - phase of maximum slope on cervical dilatation curve
  - painful, regular contractions q2-3min, lasting 45-60 s
  - contractions strongest at fundus

Second Stage of Labour (10 cm dilation – delivery of the baby)
- from full dilatation to delivery of the baby, duration varies based on parity, contraction quality, and type of analgesia
- mother feels a desire to bear down and push with each contraction
- women may choose a comfortable position that enhances pushing efforts and delivery
  - upright (semi-sitting, squatting) and LLDP are supported in the literature
  - progress measured by descent

Third Stage of Labour (delivery of the baby – delivery of the placenta)
- from baby’s birth to separation and expulsion of the placenta
- can last up to 30 min before intervention indicated
- demonstrated by gush of fresh blood, umbilical cord lengthening, uterine fundus changing shape (firm and globular) and rising upward
- active management: start oxytocin IV drip, or give 10 U IM or 5 mg IV push after delivery of anterior shoulder in anticipation of placental delivery, otherwise give after delivery of placenta
- routine oxytocin administration in third stage of labour can reduce the risk of PPH by >40%

Fourth Stage of Labour
- first postpartum hour
- monitor vital signs and bleeding, repair lacerations
- ensure uterus is contracted (palpate uterus and monitor uterine bleeding)
- inspect placenta for completeness and umbilical cord for presence of 2 arteries and 1 vein
- 3rd and 4th stages of labour most dangerous to the mother (i.e. hemorrhage)

The Cardinal Movements of the Fetus During Delivery

1. Head floating, before engagement
2. Engagement, descent, flexion
3. Further descent, internal rotation
4. Complete rotation, beginning extension
5. Complete extension
6. Restitution (external rotation)
7. Delivery of anterior shoulder
8. Delivery of posterior shoulder

Figure 7. Cardinal movements of fetus during delivery
Adapted from illustration in Williams Obstetrics, 19th ed
Analgesic and Anesthetic Techniques in Labour and Birth

- pain or anxiety leads to high endogenous catecholamines, which produce a direct inhibitory effect on uterine contractility

Non-Pharmacologic Pain Relief Techniques
- reduction of painful stimuli
  - maternal movement, position change, counter-pressure, abdominal compression
- activation of peripheral sensory receptors
  - superficial heat and cold
  - immersion in water during labour
  - touch and massage, acupuncture, and acupressure
- TENS
  - intradermal injection of sterile water
  - aromatherapy
- enhancement of descending inhibitory pathways
  - attention focusing and distraction
  - hypnosis
  - music and audio analgesia
  - biofeedback

Pharmacologic Methods (see Anesthesia and Perioperative Medicine, A26)
- nitrous oxide (e.g. self-administered Entonox®)
- narcotics (usually combined with anti-emetic)
- pudendal nerve block
- perineal infiltration with local anesthetic
- regional anesthesia (epidural block, combined spinal-epidural, spinal)

Fetal Monitoring in Labour

- see online Fetal Heart Rate Tutorial

Vaginal Exam
- membrane status
- cervical effacement (thinning), dilatation, consistency, position, application
- fetal presenting part, position, station
- bony pelvis size and shape
- monitor progress of labour at regular intervals and document in a partogram

Intrapartum Fetal Monitoring
- intermittent fetal auscultation with Doppler device q15-30min for 1 min in first stage active phase following a contraction, q5min during second stage when pushing has begun
- continuous electronic FHR monitoring reserved for abnormal auscultation, prolonged labour, and labour which is induced or augmented, meconium present, multiple gestation/fetal complication
  - use of continuous electronic monitoring shown to lead to higher intervention rates and no improvement in outcome for the neonate when used routinely in all patients (ie no risk factors)
  - techniques for continuous monitoring include external (Doppler) vs. internal (fetal scalp electrode) monitoring
  - fetal scalp sampling should be used in conjunction with electronic FHR monitoring and contraction monitoring (CTG) to resolve the interpretation of abnormal or atypical patterns

Electronic FHR Monitoring
- FHR measured by Doppler; contractions measured by tocometer
- described in terms of baseline FHR, variability (short-term, long-term), and periodicity (accelerations, decelerations)

- Baseline FHR
  - normal range is 110-160 bpm
  - parameter of fetal well-being vs. distress

- Variability
  - physiologic variability is a normal characteristic of FHR
  - variability is measured over a 15 min period and is described as: absent, minimal (<6 bpm), moderate (6-25 bpm), marked (>25 bpm)
  - normal variability indicates fetal acid-base status is acceptable
  - can only be assessed by electronic fetal monitoring (CTG)
  - variability decreases intermittently even in healthy fetus
- see Table 19, OB34

Approach to the Management of Abnormal FHR

- POISON – ER
  - Position (left lateral decubitus position)
  - O2 (100% by mask)
  - IV fluids (corrects maternal hypotension)
  - Fetal Scap stimulation
  - Fetal Scap electrode
  - Fetal Scap pH
  - Stop Oxytocin
  - Notify MD
  - Vaginal Exam to rule out cord prolapse
  - Rule out fever, dehydration, drug effects, prematurity
- If above fails, consider C/S
• Periodicity
• accelerations: increase of ≥15 bpm for ≥15 s, in response to fetal movement or uterine contraction (or ≥10 bpm for ≥10 s if <32 wk GA)
• decelerations: 3 types, described in terms of shape, onset, depth, duration, recovery, occurrence, and impact on baseline FHR and variability

Table 18. Factors Affecting Fetal Heart Rate

<table>
<thead>
<tr>
<th>Maternal Factors</th>
<th>Fetal Tachycardia (FHR &gt;160 bpm)</th>
<th>Fetal Bradycardia (FHR &lt;110 bpm)</th>
<th>Decreased Variability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever, hyperthermia, anemia, dehydration</td>
<td>Hypothermia, hypotension, hypoglycemia, position, umbilical cord occlusion</td>
<td>Hypoxia</td>
<td>Anesthesia</td>
</tr>
</tbody>
</table>

Table 19. Comparison of Decelerations

<table>
<thead>
<tr>
<th>Early Decelerations</th>
<th>BPM</th>
<th>Variable Deceleration</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Uniform shape with onset early in contraction, returns to baseline by end of contraction, mirrors contraction (nadir occurs at peak of contraction)</td>
<td>160</td>
<td>FHR (baseline)</td>
</tr>
<tr>
<td>• Gradual deceleration and return to baseline</td>
<td>140</td>
<td></td>
</tr>
<tr>
<td>• Often repetitive; no effect on baseline FHR or variability</td>
<td>120</td>
<td></td>
</tr>
<tr>
<td>• Benign, due to vagal response to head compression</td>
<td>100</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Variable Decelerations</th>
<th>BPM</th>
<th>Complicated Variable Decelerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Variable in shape, onset, and duration</td>
<td>160</td>
<td>FHR drop &lt;70 bpm for &gt;60 s</td>
</tr>
<tr>
<td>• Most common type of periodicity seen during labour</td>
<td>140</td>
<td>Loss of variability or decrease in baseline after deceleration</td>
</tr>
<tr>
<td>• Often with abrupt drop in FHR &gt;15 bpm below baseline (&gt;15 s, &lt;2 min); usually no effect on baseline FHR or variability</td>
<td>120</td>
<td>Biphasic deceleration</td>
</tr>
<tr>
<td>• Due to cord compression or, in second stage, forcible pushing with contractions</td>
<td>100</td>
<td>Slow return to baseline</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Late Decelerations</th>
<th>BPM</th>
<th>Late Deceleration</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Uniform shape with onset, nadir, and recovery occurring after peak of contraction, slow return to baseline</td>
<td>160</td>
<td>FHR</td>
</tr>
<tr>
<td>• May cause decreased variability and change in baseline FHR</td>
<td>140</td>
<td></td>
</tr>
<tr>
<td>• Due to fetal hypoxia and acidemia, maternal hypotension, or uterine hypotension</td>
<td>120</td>
<td></td>
</tr>
<tr>
<td>• Usually a sign of uteroplacental insufficiency (an ominous sign)</td>
<td>100</td>
<td></td>
</tr>
</tbody>
</table>

Continuous CTG as a Form of EFM for Fetal Assessment During Labour

Cochrane DB Syst Rev 2013;5:CD006066
Purpose: To examine the effectiveness of continuous electronic fetal monitoring or cardiotocography during labour.
Selection Criteria: Randomized and quasi-randomized controlled trials comparing continuous CTG (with and without fetal blood sampling) to a) no fetal monitoring, b) intermittent auscultation, or c) intermittent CTG.
Results: 13 trials, 37,000 women. Continuous CTG compared with intermittent auscultation showed no difference in overall perinatal death rate or cerebral palsy rates. Nonetheless, neonatal seizures were halved (RR 0.50, 95% CI 0.31-0.80) and there was a significant increase in Cesarean sections with CTG (RR 1.63, 95% CI 1.29-2.07) and instrumental vaginal birth (RR 1.15, 95% CI 1.01-1.33).
Conclusion: Continuous CTG may reduce the incidence of neonatal seizures, but has no effect on cerebral palsy rates, infant mortality, or other measures of neonatal well-being. Continuous CTG was also associated with an increase in Cesarean sections and instrumental deliveries.

Rule of 60s Suggesting Severe Variable Decelerations
Deceleration to <60 bpm >60 bpm below baseline >60 s in duration with slow return to baseline
Table 20. Classification of Intrapartum EFM Tracings

<table>
<thead>
<tr>
<th></th>
<th>Normal Tracing (Category 1)</th>
<th>Atypical Tracing* (Category 2)</th>
<th>Abnormal Tracing* (Category 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline</strong></td>
<td></td>
<td>Bradycardia 100-110 bpm</td>
<td>Bradycardia &lt;100 bpm</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tachycardia &gt;160 for 30-80 min</td>
<td>Tachycardia &gt;160 bpm for &gt;80 min</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rising baseline</td>
<td>Erratic baseline</td>
</tr>
<tr>
<td><strong>Variability</strong></td>
<td></td>
<td>≤5 bpm for 40-80 min</td>
<td>&lt;5 bpm for &gt;80 min</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥25 bpm for &gt;10 min</td>
<td></td>
</tr>
<tr>
<td><strong>Decelerations</strong></td>
<td></td>
<td>Repetitive (≥3) uncomplicated variable decelerations</td>
<td>Repetitive (≥3) complicated variable decelerations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Occasional late decelerations</td>
<td>Any prolonged deceleration (2-3 min)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Any prolonged deceleration (≥3 min)</td>
<td></td>
</tr>
<tr>
<td><strong>Accelerations</strong></td>
<td></td>
<td>Absent with scalp stimulation</td>
<td>Nearly absent</td>
</tr>
<tr>
<td><strong>Action</strong></td>
<td>EFM may be interrupted for ≤30 min if mother/fetus stable</td>
<td>Further assessment required</td>
<td>Action required: review clinical situation, obtain scalp pH, prepare for possible delivery</td>
</tr>
</tbody>
</table>

Adapted from SOGC Guidelines, September 2008

*Previous classification was “reassuring” vs. “non-reassuring”, but distinction is now made between tracings that have some concerning changes but do not require immediate action (atypical) versus those with major concerns requiring immediate intervention (abnormal)

Fetal Scalp Blood Sampling
- cervix must be adequately dilated
- indicated when atypical or abnormal fetal heart rate is suggested by clinical parameters including heavy meconium or moderately to severely abnormal FHR patterns, including unexplained low variability, repetitive late decelerations, complex variable decelerations, fetal cardiac arrhythmias
- done by measuring pH or more recently fetal lactate:
  - pH ≥7.25: normal, repeat if abnormal FHR persists
  - pH 7.21-7.24: repeat assessment in 30 min or consider delivery if rapid fall since last sample
  - pH ≤7.20: indicates fetal acidosis, delivery is indicated
- contraindications:
  - known or suspected fetal blood dyscrasia (hemophilia, von Willebrand disease)
  - active maternal infection (HIV, genital herpes)

Fetal Oxygenation
- uterine contractions during labour decrease uteroplacental blood flow, which results in reduced oxygen delivery to the fetus
- most fetuses tolerate this reduction in flow and have no adverse effects
- distribution of oxygen to the fetus depends on maternal, uteroplacental, and fetal factors
- fetal response to hypoxia/asphyxia:
  - decreased movement, tone, and breathing activities
  - anaerobic metabolism (decreased pH)
  - transient fetal bradycardia followed by fetal tachycardia
  - redistribution of fetal blood flow
    - increased flow to brain, heart, and adrenals
    - decreased flow to kidneys, lungs, gut, liver, and peripheral tissues
    - increase in blood pressure

Table 21. Factors Affecting Fetal Oxygenation

<table>
<thead>
<tr>
<th>Factor</th>
<th>Mechanism</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal</td>
<td>Decreased maternal oxygen carrying capacity</td>
<td>Significant anemia (iron deficiency, hemoglobinopathies), carboxyhemoglobin (smokers)</td>
</tr>
<tr>
<td></td>
<td>Decreased uterine blood flow</td>
<td>Hypotension (blood loss, sepsis), regional anesthesia, maternal positioning</td>
</tr>
<tr>
<td></td>
<td>Chronic maternal conditions</td>
<td>Vasculopathies (SLE, type 1 DM, chronic HTN), antiphospholipid syndrome, cyanotic heart disease, COPD</td>
</tr>
<tr>
<td>Uteroplacental</td>
<td>Uterine hypertonus</td>
<td>Placental abruption, hyperstimulation secondary to oxytocin, prostaglandins, or normal labour</td>
</tr>
<tr>
<td></td>
<td>Uteroplacental dysfunction</td>
<td>Placental abruption, placental infarction (dysfunction marked by IUGR, oligohydramnios, abnormal Doppler studies), chorioamnionitis, placental edema (OM, hydrops), placental senescence (post-dates)</td>
</tr>
<tr>
<td>Fetal</td>
<td>Cord compression</td>
<td>Oligohydramnios, cord prolapse, or entanglement</td>
</tr>
<tr>
<td></td>
<td>Decreased fetal oxygen carrying capacity</td>
<td>Significant anemia (isoimmunization, feto-maternal bleed), carboxyhemoglobin (exposure to smokers)</td>
</tr>
</tbody>
</table>
Induction of Labour

Definition
• artificial initiation of labour in a pregnant woman prior to spontaneous initiation to deliver the fetus and placenta

Prerequisites for Labour Induction
• capability for C/S if necessary
• maternal
  • inducible/ripe cervix: short, thin, soft, anterior cervix with open os
  • if cervix is not ripe, use prostaglandin vaginal insert (Cervidil®), prostaglandin gel (Prepidil®), misoprostol (Cytotec®) or Foley catheter
• fetal
  • normal fetal heart tracing
  • cephalic presentation
  • adequate fetal monitoring available
• likelihood of success determined by Bishop score (Table 22)
• cervix considered unfavourable if <6
• cervix favourable if ≥6
• score of 9-13 associated with high likelihood of vaginal delivery

Table 22. Bishop Score

<table>
<thead>
<tr>
<th>Cervical Characteristic</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Position</td>
<td>Posterior</td>
<td>Mid</td>
<td>Anterior</td>
<td>–</td>
</tr>
<tr>
<td>Consistency</td>
<td>Firm</td>
<td>Medium</td>
<td>Soft</td>
<td>–</td>
</tr>
<tr>
<td>Effacement (%)</td>
<td>0-30</td>
<td>40-50</td>
<td>60-70</td>
<td>≥80</td>
</tr>
<tr>
<td>Dilatation (cm)</td>
<td>0</td>
<td>1-2</td>
<td>3-4</td>
<td>≥5</td>
</tr>
<tr>
<td>Station of Fetal Head</td>
<td>–3</td>
<td>–2</td>
<td>–1, 0</td>
<td>+1, +2, +3</td>
</tr>
</tbody>
</table>

Indications
• post-dates pregnancy (generally >41 wk) = most common reason for induction
• maternal factors
  • DM = second most common reason for induction
  • gestational HTN
  • other maternal medical problems, e.g. renal or lung disease, chronic hypertension, cholestasis or pregnancy
  • maternal age over 40
• maternal-fetal factors
  • isoimmunization, PROM, chorioamnionitis, post-term pregnancy
• fetal factors
  • suspected fetal jeopardy as evidenced by biochemical or biophysical indications
  • fetal demise, IU/GR, oligo/polyhydraminos, anomalies requiring surgical intervention, twins
  • previous still birth, low PAPP-A

Risks
• failure to achieve labour and/or vaginal birth
• uterine hyperstimulation with fetal compromise or uterine rupture
• maternal side effects to medications
• uterine atony and PPH

Contraindications
• maternal
  • prior classical or inverted T-incision C/S or uterine surgery (e.g. myomectomy)
  • unstable maternal condition
  • active maternal genital herpes
  • invasive cervical carcinoma
  • pelvic structure deformities
• maternal-fetal
  • placenta previa or vasa previa
  • cord presentation
• fetal
  • fetal distress, malpresentation /abnormal lie, preterm fetus without lung maturity

Consider the Following Before Induction
• Induction for induction
• Contraindications
• GA
• Cervical favourability
• Fetal presentation
• Potential for CPD
• Fetal well-being/FHR
• Membrane status

Induction is indicated when the risk of continuing pregnancy exceeds the risks associated with induced labour and delivery

Induction vs. Augmentation
Induction is the artificial initiation of labour
Augmentation promotes contractions when spontaneous contractions are inadequate
Induction Methods

CERVICAL RIPENING

Definition
- use of medications or other means to soften, efface, and dilate the cervix, increases likelihood of successful induction
- ripening of an unfavourable cervix (Bishop score <6) is warranted prior to induction of labour

Methods
- intravaginal prostaglandin PGE2 gel (Prostin® gel): long and closed cervix
- recommended dosing interval of prostaglandin gel is every 6 to 12 h up to 3 doses
- intravaginal PGE2 (Cervidil®): long and closed cervix, may use if ROM
- continuous release, can be removed if needed
- controlled release PGE2
- intravaginal PGE1 Misoprostol (Cytotec®): long and closed cervix
- inexpensive, stored at room temperature
- more commonly used in 2nd trimester termination of pregnancy
- Foley catheter placement to mechanically dilate the cervix

INDUCTION OF LABOUR

Amniotomy
- artificial rupture of membranes (amniotomy) to stimulate prostaglandin synthesis and secretion; may try this as initial measure if cervix is open and soft, the membranes can be felt, and if the head is present at the cervix
- few studies address the value of amniotomy alone for induction of labour
- amniotomy plus intravenous oxytocin: more women delivered vaginally at 24 h than amniotomy alone (relative risk = 0.03) and had fewer instrumental vaginal deliveries (relative risk = 5.5)

Oxytocin
- oxytocin (Pitocin®): 10 U in 1 L NS, run at 0.5-2 mU/min IV increasing by 1-2 mU/min q20-60min to a max of 36-48 mU/min
- reduces rate of unsuccessful vaginal deliveries within 24 h when used alone (8.3% vs. 54%, RR 0.16)
- ideal dosing regime of oxytocin is not known
- current recommendations: use the minimum dose to achieve active labour and increase q30min as needed
- reassessment should occur once a dose of 20 mU/min is reached
- potential complications
- hyperstimulation/tetanic contraction (may cause fetal distress or rupture of uterus)
- uterine muscle fatigue, uterine atony (may result in PPH)
- vasopressin-like action causing anti-diuresis

Augmentation of Labour

- augmentation of labour is used to promote adequate contractions when spontaneous contractions are inadequate and cervical dilatation or descent of fetus fails to occur
- oxytocin (0.5-2 mU/min IV increasing by 1-2 mU/min q20-60min to a max of 36-48 mU/min)

Abnormalities and Complications of Labour and Delivery

Meconium in Amniotic Fluid

Epidemiology
- present early in labour in 10% of pregnancies
- in general, meconium may be present in up to 25% of all labours; usually NOT associated with poor outcome, but extra care is required at time of delivery to avoid aspiration. Concern if fluid changes from clear to meconium stained. Always abnormal if seen in preterm patient

Etiology
- likely cord compression ± uterine hypertonia
- may indicate undiagnosed breech
- increasing meconium during labour may be a sign of fetal distress

Features
- may be watery or thicker (particulate)
- light yellow/green or dark green-black in colour
Treatment
- call respiratory therapy, neonatology, or pediatrics to delivery room
- oropharynx suctioning upon head expulsion or immediately after delivery if baby not breathing spontaneously (do NOT stimulate infant before)
- consider amnioinfusion of ~800 mL of IV NS over 50-80 min during active stage of labour and a maintenance dose of ~3 mL/min until delivery
- closely monitor FHR for signs of fetal distress

*Note that suprapubic pressure and McRobert’s maneuver together will resolve 90% of cases

Abnormal Progression of Labour (Dystocia)

Definition
- expected patterns of descent of the presenting part and cervical dilatation fail to occur in the appropriate time frame; can occur in all stages of labour
- during active phase: >4 h of <0.5 cm/h
- during 2nd stage: >1 h with no descent during active pushing

Etiology
- Power (leading cause): contractions (hypotonic, incoordinate), inadequate maternal expulsive efforts
- Passenger: fetal position, attitude, size, anomalies (hydrocephalus)
- Passage: pelvic structure (CPD), maternal soft tissue factors (tumours, full bladder or rectum, vaginal septum)
- Psyche: hormones released in response to stress may contribute to dystocia; psychological and physiological stress should be evaluated as part of the management once dystocia has been diagnosed

Management
- confirm diagnosis of labour (rule out false labour)
- search for factors of CPD
- diagnosed if adequate contractions measured by intrauterine pressure catheter (IUPC) with no descent/dilatation for >2 h
- management: if CPD ruled out, IV oxytocin augmentation ± amniotomy

Risks of Dystocia
- inadequate progression of labour is associated with an increased incidence of:
  - maternal stress
  - maternal infection
  - postpartum hemorrhage
  - need for neonatal resuscitation
  - fetal compromise (from uterine hyperstimulation)
  - uterine rupture
  - hypotension

Shoulder Dystocia

Definition
- fetal anterior shoulder impacted above symphysis pubis after fetal head has been delivered
- life threatening emergency

Etiology/Epidemiology
- incidence 0.15-1.4% of deliveries
- occurs when breadth of shoulders is greater than biparietal diameter of the head

Risk Factors
- maternal: obesity, DM, multiparity, previous shoulder dystocia
- fetal: prolonged gestation, macrosomia (especially if associated with GDM)
- labour
  - prolonged 2nd stage
  - instrumental midpelvic delivery

Presentation
- “turtle sign”: head delivered but retracts against inferior portion of pubic symphysis
- complications
  - fetal
    - hypoxic ischemic encephalopathy (chest compression by vagina or cord compression by pelvis can lead to hypoxia)
    - brachial plexus injury (Erb’s palsy: C5-C7; Klumpke’s palsy: C8-T1), 90% resolve within 6 mo
    - fracture (clavicle, humerus, cervical spine)
    - death
  - maternal
    - perineal injury
    - PPH (uterine atony, lacerations)
    - uterine rupture
Treatment
• goal: to displace anterior shoulder from behind symphysis pubis; follow a stepwise approach of maneuvers until goal achieved
• other options
  ▪ clidotomy (deliberate fracture of neonatal clavicle)
  ▪ Zavanelli maneuver: replacement of fetus into uterine cavity and emergent C/S
  ▪ symphysisiotomy

Prognosis
• 1% risk of long-term disability for infant

### Umbilical Cord Prolapse

**Definition**
- descent of the cord to a level adjacent to or below the presenting part, causing cord compression between presenting part and pelvis

**Etiology/Epidemiology**
- increased incidence with prematurity/PROM, fetal malpresentation (~50% of cases), low-lying placenta, polyhydramnios, multiple gestation, CPD
- incidence: 1/200 – 1/400 deliveries

**Presentation**
- visible or palpable cord
- FHR changes (variable decelerations, bradycardia, or both)

**Treatment**
- emergency C/S
- O2 to mother, monitor fetal heart
- alleviate pressure of the presenting part on the cord by elevating fetal head with a pelvic exam (maintain this position until C/S)
- keep cord warm and moist by replacing it into the vagina ± applying warm saline soaks
- roll mom onto all fours
- position mother in Trendelenburg or knee-to-chest position
- if fetal demise or too premature (<22 wk), allow labour and delivery

### Uterine Rupture

**Etiology/Epidemiology**
- associated with previous uterine scar (in 40% of cases), hyperstimulation with oxytocin, grand multiparity, and previous intrauterine manipulation
- generally occurs during labour, but can occur earlier with a classical incision
- 0.5-0.8% incidence, up to 12% with classical incision

**Presentation**
- prolonged fetal bradycardia – most common presentation
- acute onset of constant lower abdominal pain, may not have pain if receiving epidural analgesia
- hyper or hypotonic uterine contractions
- vaginal bleeding
- intra-abdominal hemorrhage
- sudden loss of fetal descent

**Risk Factors**
- uterine scarring (i.e. previous uterine surgeries including Cesarean (especially classical incision), perforation with D&G, myomectomy)
- excessive uterine stimulation (i.e. protracted labour, oxytocin, prostaglandins)
- uterine trauma (i.e. operative equipment, ECV)
- multiparity
- uterine abnormalities
- placenta abruption

**Treatment**
- rule out placental abruption
- immediate delivery for fetal survival
- maternal stabilization (may require hysterectomy), treat hypovolemia

**Complications**
- maternal mortality 1-10%
- maternal hemorrhage, shock, DIC
- amniotic fluid embolus
- hysterectomy if uncontrollable hemorrhage
- fetal distress, associated with 50% fetal mortality

---

*1/3 of protraction disorders progress into 2º arrest of dilatation due to CPD
2/3 of protraction disorders develop into 2º abruption of dilatation due to CPD
• 1% risk of long-term disability for infant

---

*In Canada (2013), lifetime risk of maternal death is 1 in 5,200
**Amniotic Fluid Embolus**

**Definition**
- amniotic fluid debris in maternal circulation triggering an anaphylactoid immunologic response

**Etiology/Epidemiology**
- rare intrapartum or immediate postpartum complication
- 60-80% maternal mortality rate, accounts for 10% of all maternal deaths
- leading cause of maternal death in induced abortions and miscarriages
- 1/8,000-1/80,000 births

**Risk Factors**
- placental abruption
- rapid labour
- multiparity
- uterine rupture
- uterine manipulation

**Differential Diagnosis**
- pulmonary embolus, drug-induced anaphylaxis, septic shock, eclampsia, HELLP syndrome, abruption, chronic coagulopathy

**Presentation**
- sudden onset of respiratory distress, cardiovascular collapse (hypotension, hypoxia), and coagulopathy
- seizure in 10%
- ARDS and left ventricular dysfunction seen in survivors

**Management**
- supportive measures (high flow O₂, ventilation support, fluid resuscitation, inotropic support, ± intubation), coagulopathy correction
- ICU admission

**Chorioamnionitis**

**Definition**
- infection of the chorion, amnion, and amniotic fluid typically due to ascending infection by organisms of normal vaginal flora

**Etiology/Epidemiology**
- incidence 1-5% of term pregnancies and up to 25% in preterm deliveries
- ascending from vagina
- predominant microorganisms include: GBS, *Bacteroides* and *Prevotella* species, *E. coli*, and anaerobic *Streptococcus*

**Risk Factors**
- prolonged ROM, long labour, multiple vaginal exams during labour, internal monitoring
- bacterial vaginosis and other vaginal infections

**Clinical Features**
- maternal fever, maternal or fetal tachycardia, uterine tenderness, foul, and purulent cervical discharge

**Investigations**
- CBC: leukocytosis
- amniotic fluid: leukocytes or bacteria

**Treatment**
- IV antibiotics
  - ampicillin (2 g IV q6h) and gentamicin (1.5 mg/kg q8h)
  - anaerobic coverage (i.e. clindamycin if C/S)
  - expedient delivery regardless of gestational age

**Complications**
- bacteremia of mother or fetus, wound infection if C/S, pelvic abscess, infant meningitis
Operative Obstetrics

Operative Vaginal Delivery

Definition
- forceps or vacuum extraction

Indications
- fetal
  - atypical or abnormal fetal heart rate tracing, evidence of fetal compromise
  - consider if second stage is prolonged as this may be due to poor contractions or failure of fetal head to rotate
- maternal
  - need to avoid voluntary expulsive effort (e.g. cardiac/cerebrovascular disease)
  - exhaustion, lack of cooperation, and excessive analgesia may impair pushing effort

Contraindications
- non-vertex cephalic presentation (i.e. Brow or face)
- unengaged head
- cervix incompletely dilated

Forceps

Outlet Forceps Position
- head visible between labia in between contractions
- sagittal suture in or close to AP diameter
- rotation cannot exceed 45°

Low Forceps Position
- presenting part at station +2 or greater
- subdivided based on whether rotation less than or greater than 45 degrees

Mid Forceps Position
- presenting part below spine but above station +2

Types of Forceps
- Simpson or Tucker-McLane forceps for OA presentations
- Kielland (rotational) forceps when rotation of head is required
- Piper forceps for breech

Vacuum Extraction

- traction instrument used as alternative to forceps delivery; aids maternal pushing
- contraindications: <34 wk GA (<2500 g), fetal head deformed, fetus requires rotation, fetal condition (e.g. bleeding disorder)

Table 23. Advantages and Disadvantages of Forceps versus Vacuum Extraction

<table>
<thead>
<tr>
<th></th>
<th>Forceps</th>
<th>Vacuum Extraction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advantages</td>
<td>Higher overall success rate for vaginal delivery</td>
<td>Easier to apply</td>
</tr>
<tr>
<td></td>
<td>Decreased incidence of fetal morbidity</td>
<td>Less anesthesia required</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Less maternal soft-tissue injury compared to forceps</td>
</tr>
<tr>
<td>Disadvantages</td>
<td>Greater incidence of maternal injury</td>
<td>Contraindicated if fetus at risk for coagulation defect</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Suitable only for vertex presentations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maternal pushing required</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Contraindicated in preterm delivery</td>
</tr>
<tr>
<td>Complications</td>
<td>Maternal: anesthesia risk, lacerations, injury to bladder, uterus, or bone, pelvic nerve damage, PPH, infections</td>
<td>Increased incidence of cephalohematoma and retinal hemorrhages, and jaundice compared to forceps</td>
</tr>
<tr>
<td></td>
<td>Fetal: fractures, facial nerve palsy, trauma to face/scalp, intracranial hemorrhage, cephalohematoma, cord compression</td>
<td>Subgaleal hemorrhage, Subaponeurotic hemorrhage, Soft tissue trauma</td>
</tr>
</tbody>
</table>

Prerequisites for Operative Vaginal Delivery

ABCD
- Anesthesia (adequate)
- Bladder empty
- Cervix fully dilated and effaced with ROM
- Determine position of fetal head
- Equipment ready (including facilities for emergent C/S)
- Fontanelle (posterior fontanelle midway between thighs)
- Gentle traction
- Handle elevated
- Incision (episiotomy)
- Once jaw visible remove forceps
- Knowledgeable operator

Figure 8. Types of forceps

A. Simpson forceps
B. Tucker-McLane forceps
C. Kielland forceps
D. Piper forceps

Limits for Trial of Vacuum
- After 3 pulls over 3 contractions with no progress
- After 3 pop-offs with no obvious cause
- 20 min and delivery is not imminent
**Lacerations**

- first degree: involves skin and vaginal mucosa but not underlying fascia and muscle  
- second degree: involves fascia and muscles of the perineal body but not the anal sphincter  
- third degree: involves the anal sphincter (partial IIIa or complete IIIb)  
- fourth degree: extends through the anal sphincter into the rectal mucosa

**Episiotomy**

**Definition**

- incision in the perineal body at the time of delivery  
- essentially a controlled second degree laceration  
- midline: incision through central tendinous portion of perineal body and insertions of superficial transverse perineal and bulbocavernous muscle  
  - heals better, but increases risk of 3rd/4th degree tears  
- mediolateral: incision through bulbocavernousus, superficial transverse perineal muscle, and levator ani  
  - reduced risk of extensive tear but more painful  
  - easier to repair

**Indications**

- to relieve obstruction of the unyielding perineum  
- to expedite delivery (e.g. abnormal FHR pattern)  
- instrumental delivery  
- controversial between practitioners as to whether it is preferable to make a cut or let the perineum tear as needed  
- current evidence suggests letting perineum tear and then repair as needed (restricted use)

**Complications**

- infection, hematoma, extension into anal musculature or rectal mucosa, fistula formation, incontinence

**Cesarean Delivery**

**Epidemiology**

- incidence 20-25%

**Indications**

- maternal: obstruction, active herpetic lesion on vulva, invasive cervical cancer, previous uterine surgery (past C/S is most common), underlying maternal illness (eclampsia, HELLP syndrome, heart disease)  
- maternal-fetal: failure to progress, placental abruption or previa, vasa previa  
- fetal: abnormal fetal heart tracing, malpresentation, cord prolapse, certain congenital anomalies

**Types of Cesarean Incisions**

- skin  
  - transverse (i.e. Pfannenstiel)  
  - decreased exposure and slower entry  
  - improved strength and cosmesis  
  - vertical midline  
  - rapid peritoneal entry and increased exposure  
  - increased dehiscence  
- uterine  
  - low transverse (most common): in noncontractile lower segment  
  - decreased chance for rupture in subsequent pregnancies  
  - low vertical  
  - used for very preterm infants, poorly developed maternal lower uterine segment  
  - classical (rare): in thick, contractile segment  
  - used for transverse lie, fetal anomaly, >2 fetuses, lower segment adhesions, obstructing fibroid, morbidly obese patients

**Risks/Complications**

- complications related to general anesthesia* (e.g. aspiration)  
- hemorrhage (average blood loss ~1,000 cc)  
- infection (UTI, wound, endometritis)  
  - single dose prophylactic antibiotic should be used (e.g. cefazolin 1-2 g)  
- injury to surrounding structures (bowel, bladder, ureter, uterus)  
- thromboembolism (DVT, PE)  
- increased recovery time/hospital stay  
- maternal mortality (<0.1%)
**Vaginal Birth After Cesarean**

**TRIAL OF LABOUR AFTER CESAREAN**

- should be recommended if no contraindications after previous low transverse incision
- success rate varies with indication for previous C/S (generally 60-80%)
- risk of uterine rupture (<1% with low transverse incision)

**Contraindications**
- previous classical, inverted T, or unknown uterine incision, or complete transection of uterus (6% risk of rupture)
- history of uterine surgery (e.g. myomectomy) or previous uterine rupture
- multiple gestation
- non-vertex presentation or placenta previa
- inadequate facilities or personnel for emergency C/S

**Puerperal Complications**

- puerperium: 6 wk period of adjustment after pregnancy when pregnancy-induced anatomic and physiologic changes are reversed

**Postpartum Hemorrhage**

**Definition**
- loss of >500 mL of blood at the time of vaginal delivery, or >1,000 mL with C/S
- early (immediate) – within first 24 h postpartum
- late (delayed) – after 24 h but within first 6 wk

**Epidemiology**
- incidence 5-15%

**Etiology (4 Ts)**

1. **Tone** (uterine atony)
   - most common cause of PPH
   - avoid by giving oxytocin with delivery of the anterior shoulder or placenta
   - occurs within first 24 h
   - due to
     - overdistended uterus (polyhydramnios, multiple gestations, macrosomia)
     - uterine muscle exhaustion (prolonged or rapid labour, grand multiparity, oxytocin use, general anaesthetic)
     - uterine distortion (fibroids, placenta previa, placental abruption)
     - intra-amniotic infection (fever, prolonged ROM)

2. **Tissue**
   - retained placental products (membranes, cotyledon or succenturiate lobe)
   - retained blood clots in an atomic uterus
   - gestational trophoblastic neoplasia
   - abnormal placentation

3. **Trauma**
   - laceration (vagina, cervix, uterus), episiotomy, hematoma (vaginal, vulvar, retroperitoneal), uterine rupture, uterine inversion

4. **Thrombin**
   - coagulopathy (pre-existing or acquired)
   - most identified prior to delivery (low platelets increases risk)
   - includes hemophilia, DIC, Aspirin® use, ITP, TTP, vWD (most common)
   - therapeutic anti-coagulation

**Investigations**
- assess degree of blood loss and shock by clinical exam
- explore uterus and lower genital tract for evidence of tone, tissue, or trauma
- may be helpful to observe red-topped tube of blood – no clot in 7-10 min indicates coagulation problem

**Management**
- ABCs, call for help
- 2 large bore IVs, run crystalloids wide open
- CBC, coagulation profile, cross and type pRBCs
- treat underlying cause
- Foley catheter to empty bladder and monitor urine output
**Medical Therapy**

- **oxytocin 5U IV bolus (20-40 U/250 mL in crystalloid) with delivery of anterior shoulder or infusion of 20 U in 1000mL crystalloid @ 50mL/hr or can give 10 U IM if CV collapse or IV access not possible**
- **methylergonovine maleate (ergotamine) 0.25 mg IM/IMM q5min up to 1.25 mg; can be given as IV bolus of 0.125 mg (may exacerbate HTN)**
- **carboprost (Hemabate®), a synthetic PGF-1α analog 250 µg IM/IMM q15min to max 2 mg (major prostaglandin side effects and contraindicated in cardiovascular, pulmonary, renal, and hepatic dysfunction)**
- **misoprostol 600-800 µg po/sl (faster) or pr/pv (side effect: pyrexia if >600 µg)**
- **tranexamic acid (Cyklokapron®) 1 g IV, an antifibrinolytic**

**Local Control**

- **bimanual massage: elevate the uterus and massage through patient's abdomen**
- **uterine packing (mesh with antibiotic treatment)**
- **Bakri Balloon for tamponade: may slow hemorrhage enough to allow time for correction of coagulopathy or for preparation of an OR**

**Surgical Therapy (Intractable PPH)**

- **D&C (beware of vigorous scraping which can lead to Asherman's syndrome)**
- **embolization of uterine artery or internal iliac artery by interventional radiologist**
- **laparotomy with bilateral ligation of uterine artery (may be effective), internal iliac artery (not proven), ovarian artery, or hypogastric artery, compression sutures (B-Lynch or Cho sutures)**
- **hysterectomy last option with angiographic embolization if post-hysterectomy bleeding**

---

**Retained Placenta**

**Definition**

- placenta undelivered after 30 min postpartum

**Etiology**

- placenta separated but not delivered
- abnormal placental implantation (placenta accreta, placenta increta, placenta percreta)

**Risk Factors**

- placenta previa, prior C/S, post-pregnancy curettage, prior manual placental removal, uterine infection

**Clinical Features**

- risk of postpartum hemorrhage and infection

**Investigations**

- explore uterus
- assess degree of blood loss

**Management**

- 2 large bore IVs, type and screen
- Brant maneuver (firm traction on umbilical cord with one hand applying suprapubic pressure cephalad to avoid uterine inversion by holding uterus in place)
- **oxytocin 10 IU in 20 mL NS into umbilical vein**
- manual removal if above fails
- D&C if required
- **Ancef 2 g IV if manual removal or D&C**

---

**Uterine Inversion**

**Definition**

- inversion of the uterus through cervix ± vaginal introitus

**Etiology/Epidemiology**

- often iatrogenic (excess cord traction with fundal placenta)
- excessive use of uterine tocolytics
- more common in grand multiparous (lax uterine ligaments)
- 1/1,500-1/2,000 deliveries

**Clinical Features**

- can cause profound vasovagal response with bradycardia, vasodilation, and hypovolemic shock
- shock may be disproportionate to maternal blood loss

**Management**

- urgent management essential, call anesthesia
- ABCs: initiate IV crystalloids
Puerperal Complications

can use tocolytic drug (see Management of Preterm Labour, OB16) or nitroglycerin IV to relax uterus and aid replacement
replace uterus without removing placenta
remove placenta manually and withdraw slowly
IV oxytocin infusion (only after uterus replaced)
re-explore uterus
may require general anesthetic ± laparotomy

Postpartum Pyrexia

Definition
• fever >38°C on any 2 of the first 10 d postpartum, except the first day

Etiology
• endometritis
• wound infection (check C/S and episiotomy sites)
• mastitis/engorgement
• UTI
• atelectasis
• pneumonia
• DVT, pelvic thrombophlebitis

Investigations
• detailed history and physical exam, relevant cultures
• for endometritis: blood and genital cultures

Treatment
• depends on etiology
  • infection: empiric antibiotics, adjust when sensitivities available
    • endometritis: clindamycin + gentamycin IV
    • mastitis: cloxacillin or cephalexin
    • wound infection: cephalexin, frequent sitz baths for episiotomy site infection
    • DVT: anticoagulants
  • prophylaxis against post-C/S endometritis: administer 2g of Cephazolin IV 30 minutes prior to skin incision

ENDOMETRITIS
• definition: infection of uterine myometrium and parametrium
• clinical features: fever, chills, abdominal pain, uterine tenderness, foul-smelling discharge, or lochia
• treatment: depends on infection severity; oral antibiotics if well, IV with hospitalization in moderate to severe cases

VENOUS THROMBOEMBOLISM
• see Venous Thromboembolism, OB30

Mastitis

• definition: inflammation of mammary glands
• must rule out inflammatory carcinoma, as indicated
• differentiate from mammary duct ectasia: mammary duct(s) beneath nipple clogged and dilated ± ductal inflammation ± nipple discharge (thick, grey to green), often postmenopausal women

Table 24. Lactational vs. Non-Lactational Mastitis

<table>
<thead>
<tr>
<th></th>
<th>Lactational</th>
<th>Non-Lactational</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidemiology</td>
<td>More common than non-lactational</td>
<td>Periductal mastitis most common</td>
</tr>
<tr>
<td></td>
<td>Often 2-3 wk postpartum</td>
<td>Mean age 32 yr</td>
</tr>
<tr>
<td>Etiology</td>
<td>S. aureus</td>
<td>May be sterile</td>
</tr>
<tr>
<td></td>
<td></td>
<td>May be infected with S. aureus or other anaerobes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Smoking is risk factor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>May be associated with mammary duct ectasia</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Unilateral localized pain</td>
<td>Subareolar pain</td>
</tr>
<tr>
<td></td>
<td>Tenderness</td>
<td>May have subareolar mass</td>
</tr>
<tr>
<td></td>
<td>Erythema</td>
<td>Discharge (variable colour)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nipple inversion</td>
</tr>
<tr>
<td>Treatment</td>
<td>Heat or ice packs</td>
<td>Broad-spectrum antibiotics and I&amp;O</td>
</tr>
<tr>
<td></td>
<td>Continued nursing/pumping</td>
<td>Total duct excision (definitive)</td>
</tr>
<tr>
<td></td>
<td>Antibiotics (cloxacillin/cephalexin) (Erythromycin if pen-allergic)</td>
<td></td>
</tr>
<tr>
<td>Abscess</td>
<td>Fluctuant mass</td>
<td>If mass does not resolve, FNA to exclude cancer and US to assess presence of abscess</td>
</tr>
<tr>
<td></td>
<td>Pusulent nipple discharge</td>
<td>Treatment includes antibiotics, aspiration, or I&amp;O (tends to recur)</td>
</tr>
<tr>
<td></td>
<td>Fever, leukocytosis</td>
<td>May develop mammary duct fistula</td>
</tr>
<tr>
<td></td>
<td>Discontinue nursing, IV antibiotics (nafcillin/oxacillin), I&amp;O usually required</td>
<td>A minority of non-lactational abscesses may occur peripherally in breast with no associated periductal mastitis (usually S. aureus)</td>
</tr>
</tbody>
</table>
### Postpartum Mood Alterations

#### POSTPARTUM BLUES
- 40-80% of new mothers, onset day 3-10; extension of the "normal" hormonal changes and adjustment to a new baby
- self-limited, should resolve by 2 wk
- manifested by mood lability, depressed affect, increased sensitivity to criticism, tearfulness, fatigue, irritability, poor concentration/despondency, anxiety, insomnia

#### POSTPARTUM DEPRESSION
- definition: major depression occurring in a woman within 6 mo of childbirth (see Psychiatry, PS12)
- epidemiology: 10-15%, risk of recurrence 50%
  - risk factors
    - personal or family history of depression (including PPD)
    - prenatal depression or anxiety
    - stressful life situation
    - poor support system
    - unwanted pregnancy
    - colicky or sick infant
  - clinical features: suspect if the "blues" last beyond 2 wk, or if the symptoms in the first 2 wk are severe (e.g. extreme disinterest in the baby, suicidal or homicidal/infanticidal ideation)
  - assessment: Edinburgh Postnatal Depression Scale or other
  - treatment: antidepressants, psychotherapy, supportive care, ECT if refractory
  - prognosis: interferes with bonding and attachment between mother and baby so it can have long-term effects

#### POSTPARTUM PSYCHOSIS
- definition: onset of psychotic symptoms over 24-72 h within first month postpartum, can present in the context of depression
- epidemiology: rare (0.2%)

### Postpartum Care

#### Postpartum Office Visit at 6 Weeks

**Care of Mother (The 10 Bs)**
- Be careful: do not use douches or tampons for 4-6 wk post-delivery
- Be fit: encourage gradual increases in walking, Kegel exercises
- Birth control: assess for use of contraceptives; breastfeeding is NOT an effective method of birth control (see Gynecology, GY16, for more detail about different contraceptive options postpartum)
- Bladder: assess for urinary incontinence, maintain high fluid intake
- Blood pressure: especially if gestational HTN
- Blood tests: glucose, CBC (for anemia as sign of hematomas, retained placenta)
- Blues (see Postpartum Mood Alterations)
- Bowel: fluids and high-fibre foods, bulk laxatives; for hemorrhoids/perineal tenderness: pain meds, doughnut cushion, Sitz baths, ice compresses
- Breast and pelvic exam: watch for Staphylococcal or Streptococcal mastitis/abscess, ± Pap smear at 6 wk

**Physiological Changes Postpartum**
- uterus weight rapidly diminishes through catabolism, cervix loses its elasticity and regains firmness
  - should involute ~1 cm below umbilicus per day in first 4-5 d, reaches non-pregnant state in 4-6 wk postpartum
- ovulation resumes in ~45 d for non-lactating women and within 3-6 mo for lactating women and sometimes later
- lochia: normal vaginal discharge postpartum, uterine decidual tissue sloughing
  - decreases and changes in colour from red (lochia rubra; presence of erythrocytes, 3-4 d) → pale (lochia serosa) → white / yellow (lochia alba; residual leukorrhea) over 3-6 wk
  - foul-smelling lochia suggests endometritis

**Breastfeeding Problems**
- inadequate milk: consider domperidone
- breast engorgement: cool compress, manual expression/pumping
- nipple pain: clean milk off nipple after feeds, moisture cream, topical steroid if needed
- mastitis: treat promptly (see Postpartum Pyrexia, OB45)
- inverted nipples: makes feeding difficult
- maternal medications: may require pediatric consultation (see Breastfeeding and Drugs)
**Bladder Dysfunction**
- pelvic floor prolapse can occur after vaginal delivery
- stress or urge urinary incontinence common
- increased risk with instrumental delivery or prolonged second stage
- conservative management: pelvic floor retraining with Kegel exercises/pelvic physiotherapy, vaginal cone, or pessaries, lifestyle modifications (e.g. limit fluid, caffeine intake)
- surgical management: minimally invasive procedures (tension-free vaginal tape, transobturator tape, midurethral sling)

**Puerperal Pain**
- “after pains” common in first 3 d due to uterine contractions; encourage simple analgesia
- ice packs can be used on perineum if painful
- encourage regular analgesia and stool softener

### Breastfeeding and Drugs

#### Table 25. Drug Safety During Breastfeeding

<table>
<thead>
<tr>
<th>Drug Name (Brand Name)</th>
<th>Safe During Breastfeeding</th>
<th>Contraindicated When Breastfeeding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analgesics (e.g. acetaminophen, NSAIDs)</td>
<td></td>
<td>Chloramphenicol (bone marrow suppression)</td>
</tr>
<tr>
<td>Anticoagulants (e.g. heparin)</td>
<td></td>
<td>Cyclophosphamide (immune system suppression)</td>
</tr>
<tr>
<td>Antidepressants (e.g. sertraline, fluoxetine, TCAs)</td>
<td></td>
<td>Sulphonamides (in G6PD deficiency, can lead to hemolysis)</td>
</tr>
<tr>
<td>Antiepileptics (e.g. phenytoin, carbamazepine, valproic acid)</td>
<td></td>
<td>Nitrofurantoin (in G6PD deficiency, can lead to hemolysis)</td>
</tr>
<tr>
<td>Antihistamines</td>
<td></td>
<td>Tetracycline</td>
</tr>
<tr>
<td>Antimicrobials (e.g. penicillins, aminoglycosides, cephalosporins)</td>
<td></td>
<td>Lithium</td>
</tr>
<tr>
<td>β-adrenergics (e.g. propanolol, labetalol)</td>
<td></td>
<td>Phenotion</td>
</tr>
<tr>
<td>Insulin</td>
<td></td>
<td>Bromocriptine</td>
</tr>
<tr>
<td>Steroids</td>
<td></td>
<td>Anti-neoplasics and immunosuppressants</td>
</tr>
<tr>
<td>OCP (low dose) – although may decrease breast milk production</td>
<td></td>
<td>Psychotropic drugs (relative contraindication)</td>
</tr>
</tbody>
</table>

#### Table 26. Common Medications

<table>
<thead>
<tr>
<th>Drug Name (Brand Name)</th>
<th>Dosing Schedule</th>
<th>Indications/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betamethasone valerate</td>
<td>12 mg IM q4h x 2 doses</td>
<td>Enhancement of fetal pulmonary maturity for PTL</td>
</tr>
<tr>
<td>Carboprost (Hemabate®)</td>
<td>0.25 mg IM/MM q5min; max 2 mg</td>
<td>Treatment of uterine atony</td>
</tr>
<tr>
<td>Cefazolin</td>
<td>2 g IV then 1 g q6h</td>
<td>GBS prophylaxis (penicillin allergic and not at risk for anaphylaxis)</td>
</tr>
<tr>
<td>Clexane</td>
<td>900 mg IV q4h</td>
<td>Used in endomtritis</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>6 mg IM q12h x 4 doses</td>
<td>Enhancement of fetal pulmonary maturity for PTL</td>
</tr>
<tr>
<td>Dinoprostone (Cervidil® - PGE2 impregnated thread)</td>
<td>10 mg P/G (remove after 3 h) max 3 doses</td>
<td>Induction of labour</td>
</tr>
<tr>
<td>Dexamethasone (Decadron®)</td>
<td>2 tabs qhs + 1 tab qAM + 1 tab qPM max 8 tabs/d</td>
<td>Each tablet contains 10 mg dexamethasone with vitamin B6</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>500 mg IV q8h</td>
<td>GBS prophylaxis (penicillin allergic and at risk for anaphylaxis)</td>
</tr>
<tr>
<td>Folic acid</td>
<td>0.4-1 mg PO OD x 3-4 weeks</td>
<td>Prevention of dNTD</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>50 mg/m² IM or 50 mg PO x 1 dose</td>
<td>For ectopic pregnancy or medical abortion</td>
</tr>
<tr>
<td>Methylenoxanamine maleate (Ergotrame®)</td>
<td>0.25 mg IM/MM q6min up to 1.25 mg or IV baks x 1 dose</td>
<td>Treatment of uterine atony</td>
</tr>
<tr>
<td>Misoprostol (Cytotec®)</td>
<td>600-1000 µg PR x 1 dose</td>
<td>For treatment of PPH</td>
</tr>
<tr>
<td>Mifepristone</td>
<td>10 mg PO OD</td>
<td>For medical abortion/retained products of conception</td>
</tr>
<tr>
<td>Oxytocin</td>
<td>0.5-2.0 ml/min IV, or 10 U/L NS increase by 1-2 ml/min q20-60min max 30-60 ml/min</td>
<td>Augmentation of labour (also induction of labour)</td>
</tr>
<tr>
<td>Penicillin G</td>
<td>5 million U IV then 2.5 million U IV q4h until delivery</td>
<td>GBS prophylaxis</td>
</tr>
<tr>
<td>PGF2α gel (Prostin® gel)</td>
<td>0.5 mg PV q6-12h; max 3 doses</td>
<td>Induction of labour</td>
</tr>
<tr>
<td>Rh IgG (Rhogam®)</td>
<td>300 µg IM x 1 dose</td>
<td>Given to Rh negative women</td>
</tr>
</tbody>
</table>

Misoprostol (Cytotec®) is also indicated to protect against NSAID-induced gastric ulcers in non-pregnant individuals. The use of misoprostol for cytoprotection is contraindicated in pregnancy; warn female patients of this contraindication.
# Acronyms
- OP
- OP1

# Basic Anatomy Review
- \[ \text{2} \]

# Differential Diagnoses of Common Presentations
- Loss of Vision
  - Red Eye
  - Ocular Pain
  - Floaters
  - Flashes of Light (Photopsia)
  - Photophobia (Severe Light Sensitivity)
  - Diplopia (Double Vision)
- Ocular Problems in the Contact Lens Wearer
  - Acute Painless Vision Loss
- \[ \text{3} \]

# Ocular Emergencies
- \[ \text{5} \]

# The Ocular Examination
- \[ \text{5} \]

# Optics
- \[ \text{7} \]

# The Orbit
- \[ \text{9} \]

# Lacrimal Apparatus
- \[ \text{10} \]

# Lids and Lashes
- \[ \text{11} \]

# Conjunctiva
- \[ \text{13} \]

# Sclera
- \[ \text{15} \]

# Cornea
- \[ \text{16} \]

# The Uveal Tract
- \[ \text{19} \]

# Lens
- \[ \text{20} \]

# Vitreous
- Posterior Vitreous Detachment
- Vitreous Hemorrhage
- Endophthalmitis and Vitritis
- \[ \text{21} \]

# Retina
- Central/Branch Retinal Artery Occlusion
- Central/Branch Retinal Vein Occlusion
- Retinal Detachment
- Retinitis Pigmentosa
- Age-Related Macular Degeneration
- \[ \text{22} \]

# Glaucoma
- Primary Open-Angle Glaucoma
- Normal Tension Glaucoma
- Secondary Open Angle Glaucoma
- Primary Angle-Closure Glaucoma
- Secondary Angle-Closure Glaucoma
- \[ \text{25} \]

# Pupils
- Pupillary Light Reflex
- Pupil Abnormalities
- Dilated Pupil (Mydriasis)
- Constricted Pupil (Miosis)
- Relative Afferent Pupillary Defect
- \[ \text{28} \]

# Malignancies
- Lid Carcinoma
- Malignant Melanoma
- Metastases
- \[ \text{31} \]

# Ocular Manifestations of Systemic Disease
- HIV/AIDS
- Other Systemic Infections
- Diabetes Mellitus
- Hypertension
- Multiple Sclerosis
- TIA/Amaurosis Fugax
- Graves’ Disease
- Connective Tissue Disorders
- Giant Cell Arteritis/Temporal Arteritis
- Sarcoidosis
- \[ \text{32} \]

# Pediatric Ophthalmology
- Strabismus
- Amblyopia
- Leukocoria
- Retinoblastoma
- Retinopathy of Prematurity
- Nasolacrimal System Defects
- Ophthia (Neonatorum
- Congenital Glaucoma
- \[ \text{36} \]

# Ocular Trauma
- Blunt Trauma
- Penetrating Trauma
- Hyphema
- Blow-Out Fracture
- Chemical Burns
- \[ \text{39} \]

# Ocular Drug Toxicity
- \[ \text{41} \]

# Common Medications
- \[ \text{42} \]

# References
- \[ \text{44} \]
Acronyms

AION, anterior ischemic optic neuropathy
AMD, age-related macular degeneration
BCVA, best corrected visual acuity
BRVO, branch retinal vein occlusion
C:D, cup to disc ratio
CMV, cytomegalovirus
CRAO, central retinal artery occlusion
D, diopter
dM, diabetes mellitus
DR, diabetic retinopathy
EOM, extraocular movement
FML, fluoromethalone
GAT, Goldmann applanation tonometry
GCA, giant cell arteritis
HRT, Heidelberg retinal tomography
INO, internuclear ophthalmoplegia
INR, intraocular pressure
IOP, intraocular pressure
LASIK, laser-assisted in situ keratomileusis
MS, multiple sclerosis
OCT, optical coherence tomography
RD, retinal detachment
POAG, primary open-angle glaucoma
PRK, photorefractive keratectomy
PVD, posterior vitreous detachment
RAPD, relative afferent pupillary defect
RD, retinal detachment
RPE, retinal pigment epithelium
SLE, systemic lupus erythematosus
SPK, superficial punctate keratitis
TIA, transient ischemic attack
VEGF, vascular endothelial growth factor
YAG, yttrium aluminum garnet

Basic Anatomy Review

Figure 1. Anatomy of the eye

Figure 2. Layers of the retina
Figure 3. Tear drainage from the eye (lacrimal apparatus)

Differential Diagnoses of Common Presentations

Loss of Vision

- Transient ischemic attack (TIA)
- Migraine with aura

- Cornea/Anterior Segment: Corneal edema, Hyphaema, Acute angle-closure glaucoma, Trauma/foreign body
- Vitreous/Retina/Optic Nerve: Vitreous hemorrhage, RD, Retinal artery/vein occlusion, Acute macular lesion, Optic neuritis, Temporal arteritis, Anterior ischemic optic neuropathy (AION)
- Cortical/Other: Occipital infarction/hemorrhage, Cortical blindness, Functional (non-organic, diagnosis of exclusion)

- Transient (seconds to hours)
- Acute (seconds to days)
- Chronic (weeks to months)

- Vitreous/Retina/Optic Nerve: AMD, DR, Retinal vascular insufficiency
- Cortical/Other: Pituitary adenoma, Medication-induced (sildenafil, amiodarone), Nutritional deficiency, Papilledema

Red Eye

- lids/orbit/lacrimal system
  - Hordeolum/chalazion
  - Blepharitis
  - Entropion/ectropion
  - Foreign body/laceration
  - Dacryocystitis/dacryoadenitis
- Conjunctiva/sclera
  - Subconjunctival hemorrhage
  - Conjunctivitis
  - Dry eyes
  - Pterygium
  - Episcleritis/scleritis
  - Preseptal/orbital cellulitis
- Cornea
  - Foreign body (including contact lens)
  - Keratitis
  - Abrasion, laceration
  - Ulcer
- Anterior chamber
  - Anterior uveitis (iritis, iridocyclitis)
  - Acute glaucoma
  - Hyphaema (blood in anterior chamber)
  - Hypopyon (pus in anterior chamber)

- Other
  - Trauma
  - Post-operative
  - Endophthalmitis
  - Pharmacologic (e.g. prostaglandin analogs)

Top 3 Differential Diagnosis of Acute Loss of Vision
- Vitreous hemorrhage
- Retinal artery/vein occlusion
- Retinal detachment

Top 3 Differential Diagnosis of Chronic Loss of Vision
Reversible
- Cataract
- Refractive error
- Corneal dystrophy
Irreversible
- AMD
- Glaucoma
- DR

Note: Anti-VEGF treatment for exudative AMD and diabetic macular edema may reverse some vision loss.
Ocular Pain

- differentiate from eye fatigue (asthenopia)
- ocular surface disease
- herpes zoster prodrome
- trauma/foreign body
- blepharitis
- keratitis
- corneal abrasion, corneal ulcer
- acute glaucoma
- acute uveitis
- scleritis
- episcleritis
- optic neuritis

Floaters

- PVD (often secondary to age-related vitreous syneresis)
- vitreous hemorrhage
- retinal tear/detachment
- intermediate uveitis (pars planitis)
- posterior uveitis (chorioretinitis)

Flashes of Light (Photopsia)

- PVD (often secondary to age-related vitreous syneresis)
- retinal tear/detachment
- migraine with aura

Photophobia (Severe Light Sensitivity)

- corneal abrasion, corneal ulcer
- keratitis
- acute angle-closure glaucoma
- iritis
- meningitis, encephalitis
- migraine
- subarachnoid hemorrhage (SAH)

Diplopia (Double Vision)

- binocular diplopia (occurs with both eyes open, eliminated with occlusion of either eye)
- strabismus
- CN palsy (III, IV, VI)
  - ischemia (DM)
  - tumour
  - trauma
- myasthenia gravis
- muscle restriction/entrapment
- thyroid ophthalmopathy
- INO
  - multiple sclerosis
  - brainstem infarct
- monocular diplopia (occurs with one eye open, remains with occlusion of unaffected eye)
- refractive error/astigmatism
- strands of mucus in tear film
- keratoconus
- cataracts
- dislocated lens
- peripheral laser iridotomy

Ocular Problems in the Contact Lens Wearer

- solution hypersensitivity
- tight lens syndrome
- corneal abrasion
- giant papillary conjunctivitis/contact lens allergy
- SPK from dry eyes
- limbal stem cell deficiency
- corneal neovascularization
- sterile corneal infiltrates (immunologic)
- infected ulcers (Pseudomonas, Acanthamoeba)

Acute Painless Vision Loss

- vitreous hemorrhage
- retinal artery/vein occlusion
- RD
- AION
- optic neuritis
- amaurosis fugax/TIA/stroke
Table 1. Common Differential Diagnoses of Red Eye

<table>
<thead>
<tr>
<th></th>
<th>Conjunctivitis</th>
<th>Acute Iritis</th>
<th>Acute Glaucoma</th>
<th>Keratitis (Corneal Abrasion/Ulcer)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discharge</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bacterial: purulent</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Viral: serous/mucoid</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Allergic: mucus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain</td>
<td>± (± dull/achy)</td>
<td>++ (nausea)</td>
<td>++</td>
<td>+ (sharp)</td>
</tr>
<tr>
<td>Photophobia</td>
<td>No</td>
<td>++</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Blurred Vision</td>
<td>No</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Pupil</td>
<td>Normal</td>
<td>Smaller</td>
<td>Fixed in mid-dilation</td>
<td>Same or smaller</td>
</tr>
<tr>
<td>Injection</td>
<td>Conjunctiva with</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>limbal Pallor</td>
<td>Ciliary flush</td>
<td>Diffuse</td>
<td>Diffuse</td>
<td></td>
</tr>
<tr>
<td>Cornea</td>
<td>Normal</td>
<td>Keratic precipitates</td>
<td>Cloudy</td>
<td>Infiltrate, edema,</td>
</tr>
<tr>
<td>IOP</td>
<td>Normal</td>
<td>Varies</td>
<td>Increased markedly</td>
<td>Normal or increased</td>
</tr>
<tr>
<td>Anterior Chamber</td>
<td>Normal</td>
<td>++ Cells and flare</td>
<td>Shallow</td>
<td>Cells and flare or normal</td>
</tr>
<tr>
<td>Other</td>
<td>Large, tender pre-auricular node(s) if viral</td>
<td>Posterior synechiae</td>
<td>Coloured halos Nausea and vomiting</td>
<td></td>
</tr>
</tbody>
</table>

Ocular Emergencies

These require urgent consultation to an ophthalmologist for management

Sight Threatening
- lid/globe lacerations
- chemical burn
- corneal ulcer
- gonococcal conjunctivitis
- acute iritis
- acute glaucoma
- CRAO
- intraocular foreign body
- RD (especially when macula threatened)
- endophthalmitis
- GCA

Life Threatening
- proptosis (rule out cavernous sinus fistula or thrombosis)
- CN III palsy with dilated pupil (intracranial aneurysm or externally compressive neoplastic lesion)
- papilledema (elevated increased intracranial pressure work up)
- orbital cellulitis
- leukocoria: white reflex (absent red reflex, must rule out retinoblastoma)

Visual Acuity – Distance
- Snellen Acuity (Figure 5) = testing distance (usually 20 ft or 6 m) smallest line patient can read on the chart
  - e.g. 20/40 = what the patient can see at 20 feet (numerator), what a “normal” person can see at 40 feet (denominator)
- distance visual acuity should be tested with distance glasses on in order to obtain best corrected visual acuity
- testing hierarchy for low vision: Snellen acuity (20/x) → counting fingers at a given distance (CF) → hand motion (HM) → light perception with projection (LP with projection) → light perception (LP) → no light perception (NLP)
- legal blindness is BCVA that is ≤20/200 in best eye
- minimum visual requirements to operate a non-commercial automobile in Ontario are: 20/50 BCVA with both eyes open and examined together, 120° continuous horizontal visual field, and 15° continuous visual field above and below fixation

Normal Infant and Child Visual Acuity
- 0-12 mo: 20/120
- 1-2 yr: 20/80
- 2-4 yr: 20/20
Visual Acuity – Near
- use pocket vision chart (Rosenbaum Pocket Vision Screener)
- record Jaeger (I) or Point number and testing distance (usually 30 cm) e.g. J2 @ 30 cm
- conversion to distance VA possible (e.g. immobile patient, no distance chart available)

Visual Acuity for Infants, Children, Non-English Speakers, and Dysphasics
- newborns
  - VA cannot be tested conventionally
- 3 mo-3 yr (can only assess visual function, not acuity)
  - test each eye for fixation symmetry using an interesting object
  - normal function noted as "CSM" = central, steady, and maintained
- 3 yr until alphabet known
  - pictures or letter cards/charts such as HOTV or Sheridan-Gardner test (children point to optotypes on a provided matching card)
  - tumbling “E” chart

Colour Vision
- test with Ishihara pseudoisochromatic plates
- record number of correctly identified plates presented to each eye, specify incorrect plates
- important for testing optic nerve function (e.g. optic neuritis, chloroquine use, thyroid ophthalmopathy)
- note: red-green colour blindness is sex-linked and occurs in 7-10% of males

VISUAL FIELDS
- test “visual fields by confrontation” (4 quadrants, each eye tested separately) for estimation of visual field loss
- accurate, quantifiable assessment with automated visual field testing (Humphrey or Goldmann) or Tangent Screen
- use Amsler grid (each eye tested separately) to check for central or paracentral scotomas (blindspots) in patients with AMD

PUPILS
- use reduced room illumination with patient focusing on distant fixed object to prevent near reflex
- examine pupils for shape, size, symmetry, and reactivity to light (both direct and consensual response)
- test for RAPD with swinging flashlight test, check by reverse RAPD if one pupil non-reactive
- test pupillary constriction portion of near reflex by bringing object close to patient’s nose
- "normal" pupil testing often noted as PERRLA (pupils equal, round, and reactive to light and accommodation)

ANTERIOR CHAMBER DEPTH
- shine light tangentially from temporal side
- if >2/3 of nasal side of iris in shadow → shallow anterior chamber

The van Herick Method (Slit Lamp technique)
- shine thin-angled slit beam onto the peripheral cornea of each eye, view at a 60° angle from the beam
- estimate depth between the posterior surface of the cornea and the iris as a proportion of corneal thickness
- ratios ≤1/4 implies risk of occludable angle; however, if >1/4 this does not rule out.
- gonioscopy, as performed by an ophthalmologist, is gold-standard for assessing anterior chamber depth

EXTRAOCULAR MUSCLES

Alignment
- Hirschberg corneal reflex test
- examine in primary position of gaze (i.e. straight ahead) with patient focusing on distant object
- shine light into patient’s eyes from ~30 cm away
- corneal light reflex should be at the same position on each cornea
- strabismus testing as indicated (cover test, cover-uncover test, prism testing) (see Strabismus, OP6)

Movement
- examine movement of eyeball through six cardinal positions of gaze
- ask patient if diplopia or pain is present in any position of gaze
- observe for horizontal, vertical, or rotatory nystagmus (rhythmic, oscillating movements of the eye)
- resolving horizontal nystagmus at end-gaze is usually normal

Diplopia
- See Neurology – Neuro-ophthalmology Diplopia
SLIT-LAMP EXAMINATION

Ocular Adnexa
- lids, lashes, lacrimal system

Anterior Segment
- conjunctiva / sclera
- cornea
  - fluorescein dye: stains de-epithelialized cornea; dye appears fluorescent green with cobalt blue filtered light
  - Rose Bengal dye: stains devitalized corneal epithelium
- anterior chamber / angle (Van Herick)
- iris / pupil
- lens (assess for cataract)
- anterior vitreous

Posterior Segment (requires 78D or 90D lens)
- vitreous
- optic disc (colour, C:D ratio, sharpness of disc margin)
- macula (~1.5-2 disc diameters temporal to disc), fovea (foveal light reflex)
- retinal vessels
- retinal background

TONOMETRY
- measurement of IOP
- normal range is 9-21 mmHg (average 15 mmHg)
- IOP has diurnal variation, so always record the time of day at which the measurement was taken
- commonly measured by
  - Goldmann Applanation Tonometry (GAT): clinical gold standard, performed using the slit-lamp with special tip (prism)
  - Tono-Pen®: benefit is portability and use of disposable probe tips; use when cornea is scarred/asymmetric (GAT inaccurate)
  - air puff (non-contact and least reliable)
- use topical anesthetic for GAT and Tono-Pen®; apply fluorescein dye when using GAT

DIRECT OPHTHALMOSCOPY
- best performed with pupils dilated (for list of mydriatics and cycloplegics see Table 11, OP42)
  1. assess red reflex
     - light reflected off the retina produces a "red reflex" when viewed from ~1 foot away
     - anything that interferes with the passage of light will diminish the red reflex (e.g. large vitreous hemorrhage, cataract, retinoblastoma)
  2. examine the posterior segment of the eye
     - vitreous
     - optic disc (colour, C:D ratio, sharpness of disc margin)
     - macula (~1.5-2 disc diameters temporal to disc), fovea (foveal light reflex)
     - retinal vessels
     - retinal background
- contraindications to pupillary dilatation
  - shallow anterior chamber – can precipitate acute angle-closure glaucoma
  - iris-supported anterior chamber lens implant
  - potential neurologic abnormality requiring pupil evaluation
  - use caution with cardiovascular disease – mydriatics may cause tachycardia

Optics

REFRACTION
- two techniques used
  - flash/streak retinoscopy: refractive error determined objectively by the examiner using lenses and retinoscope
  - manifest: subjective trial using loose lenses or a phoropter (device the patient looks through that is equipped with lenses)
  - cycloplegic: manifest refraction with accommodation temporarily paralyzed with mydriatics
- a typical lens prescription would contain
  - sphere power in dioptre (measurement of refractive power of lens, equal to reciprocal of focal length in metres)
  - cylinder power in dioptre to correct astigmatism
  - axis of cylinder in degrees
  - "add" (bifocal/progressive reading lens) for presbyopes
  - e.g. -1.50 + 1.00 x 120 degrees, add +2.00
REFRACTIVE EYE SURGERY
- permanently alters corneal refractive properties by ablating tissue to change curvature of the cornea
- used for correction of myopia, hyperopia, and astigmatism
- common types include PRK and LASIK
- potential risks/side-effects: infection, under/overcorrection, decreased night vision (nyctalopia), corneal haze, dry eyes, regression, complete sever of corneal flap (LASIK only)

<table>
<thead>
<tr>
<th>Pathophysiology</th>
<th>Clinical Features</th>
<th>Treatment</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emmetropia</td>
<td>Image of distant objects focus exactly on the retina</td>
<td>No refractive error</td>
<td></td>
</tr>
<tr>
<td>Myopia</td>
<td>Globe too long relative to refractive mechanisms, or refractive mechanisms too strong</td>
<td>“Near-sightedness” Usually presents in 1st or 2nd decade, stabilizes in 2nd and 3rd decade; rarely begins after age 25 except in patients with DM or cataracts</td>
<td>Correct with negative dioptr/ concave/“negative” lenses to diverge light rays</td>
</tr>
<tr>
<td>Myopia</td>
<td>Light rays from distant object focus behind retina → blurring of (distance) vision</td>
<td>“Farsightedness” Youth: usually do not require glasses (still have sufficient accommodative ability to focus image on retina), but may develop accommodative esotropia (see Strabismus, OP36) 30s-40s: blurring of near vision due to decreased accommodation, may need reading glasses &gt;50s: blurring of distance vision due to severely decreased accommodation</td>
<td>When symptomatic, correct with positive dioptr/convex/“plus” lenses to converge light rays</td>
</tr>
<tr>
<td>Hyperopia</td>
<td>Globe too short relative to refractive mechanisms, or refractive mechanisms too weak</td>
<td>“Near-sightedness” Youth: usually do not require glasses (still have sufficient accommodative ability to focus image on retina), but may develop accommodative esotropia (see Strabismus, OP36) 30s-40s: blurring of near vision due to decreased accommodation, may need reading glasses &gt;50s: blurring of distance vision due to severely decreased accommodation</td>
<td>When symptomatic, correct with positive dioptr/convex/“plus” lenses to converge light rays</td>
</tr>
<tr>
<td>Astigmatism</td>
<td>Light rays not refracted uniformly in all meridians due to non-spherical surface of cornea or non-spherical lens (e.g. football-shaped)</td>
<td>Affects ~30% of population, with prevalence increasing with age Mild astigmatism unnoticeable Higher amounts of astigmatism may cause blurry vision, squinting, asthenopia, or headaches</td>
<td>Correct with cylindrical lens (if regular), try contact lens (if irregular)</td>
</tr>
<tr>
<td>Presbyopia</td>
<td>Normal aging process (&gt;40 yr) Hardening/reduced deformability of lens results in decreased accommodative ability Accommodative power is 14D at age 10, diminishes to 3.5D by age 40 yr Near images cannot be focused onto the retina (focus is behind the retina as in hyperopia)</td>
<td>If initially emmetropic, person begins to hold reading material farther away, but distance vision remains unaffected</td>
<td>Correct with positive dioptr/convex/“plus” lenses for reading</td>
</tr>
<tr>
<td>Anisometropia</td>
<td>Difference in refractive errors between eyes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**The Orbit**

**Globe Displacement**

Table 3. Exophthalmos (Proptosis) and Enophthalmos

<table>
<thead>
<tr>
<th>Exophthalmos (Proptosis)</th>
<th>Enophthalmos</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anterior displacement (protrusion) of the globe</td>
<td>Posterior displacement (retraction) of the globe</td>
</tr>
<tr>
<td>Exophthalmos generally refers to an endocrine etiology or protrusion of &gt;18 mm (as measured by a Hertel exophthalmometer)</td>
<td></td>
</tr>
<tr>
<td>Proptosis generally refers to other etiologies (e.g. cellulitis) or protrusion of &lt;18 mm</td>
<td></td>
</tr>
</tbody>
</table>

**Investigations**

| CT/MRI head/orbits, ultrasound orbits, thyroid function tests | CT/MRI orbits |

**Etiology**

- Note: rule out pseudoxophthalmos (e.g. lid retraction)
- Graves’ disease (unilateral or bilateral, most common cause in adults)
- Orbital cellulitis (unilateral, most common cause in children)
- 1° or 2° orbital tumours
- Orbital/retrorublar hemorrhage
- Cavernous sinus thrombosis or fistula

**Treatment**

- Surgical drainage of abscess with close follow-up, especially in children
- Admit, blood cultures x2, orbital CT, IV antibiotics (ceftriaxone + vancomycin) for 1 wk
- Orbital/retrobulbar hemorrhage
- Orbital cellulitis (unilateral, most common cause in children)
- Congenital abnormality
- Metastatic disease

**Preseptal Cellulitis**

- Infection of soft tissue anterior to orbital septum

**Etiology**

- Usually follows periorbital trauma or dermal infection

**Clinical Features**

Table 4. Clinical Features of Preseptal and Orbital Cellulitis

<table>
<thead>
<tr>
<th>Finding</th>
<th>Preseptal Cellulitis</th>
<th>Orbital Cellulitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>May be present</td>
<td>Present</td>
</tr>
<tr>
<td>Lid edema</td>
<td>Moderate to severe</td>
<td>Severe</td>
</tr>
<tr>
<td>Conjunctival injection</td>
<td>Absent</td>
<td>Present</td>
</tr>
<tr>
<td>Chemosis</td>
<td>Absent or mild</td>
<td>Marked</td>
</tr>
<tr>
<td>Proptosis</td>
<td>Absent</td>
<td>Present</td>
</tr>
<tr>
<td>Pain on eye movement</td>
<td>Absent</td>
<td>Present</td>
</tr>
<tr>
<td>Ocular mobility</td>
<td>Normal</td>
<td>Decreased</td>
</tr>
<tr>
<td>Vision</td>
<td>Normal</td>
<td>Diminished ± diplopia</td>
</tr>
<tr>
<td>RAPD</td>
<td>Absent</td>
<td>May be seen if severe</td>
</tr>
<tr>
<td>Leukocytosis</td>
<td>Moderate</td>
<td>Marked</td>
</tr>
<tr>
<td>ESR</td>
<td>Normal or elevated</td>
<td>Elevated</td>
</tr>
<tr>
<td>Additional findings</td>
<td>Skin infection</td>
<td>Sinusitis, dental abscess</td>
</tr>
</tbody>
</table>

**Treatment**

- Systemic antibiotics (suspect H. influenzae in children; S. aureus or Streptococcus in adults)
- e.g. amoxicillin-clavulanic acid
- If severe or child <1 yr, treat as orbital cellulitis

**Orbital Cellulitis**

- **OCULAR and MEDICAL EMERGENCY**
- Inflammation of orbital contents posterior to orbital septum
- Common in children, elderly, and immunocompromised

**Etiology**

- Usually secondary to sinus/facial/tooth infections or trauma, can also arise from preseptal cellulitis

**Clinical Features (see Table 4)**

**Treatment**

- Admit, blood cultures x2, orbital CT, IV antibiotics (ceftriaxone + vancomycin) for 1 wk
- Surgical drainage of abscess with close follow-up, especially in children

**Complications**

- Optic nerve inflammation, cavernous sinus thrombosis, meningitis, and brain abscess with possible loss of vision, death
Lacrimal Apparatus

- Tear film made up of three layers
  - Outer oily layer (reduces evaporation)
  - Middle watery layer (forms the bulk of the tear film)
  - Inner mucinous layer (aids with tear adherence to cornea)
- Tears drain from the eyes through the upper and lower lacrimal puncta → superior and inferior canaliculi → lacrimal sac → nasolacrimal duct → nasal cavity behind inferior concha (Figure 3)

Dry Eye Syndrome (Keratoconjunctivitis Sicca)

Etiology
- Aqueous-deficient (lacrimal pathology)
  - Sjögren syndrome (autoimmune etiology e.g. RA, SLE)
  - Non-Sjögren syndrome (idiopathic age-related disease; lacrimal gland scarring e.g. trachoma; decreased secretion e.g. contact lenses, CN VII palsy, anticholinergics, antihistamines, diuretics, ß-blockers)
- Evaporative (normal lacrimal function, excessive evaporation of aqueous layer)
  - Meibomian gland dysfunction (posterior blepharitis)
  - Vitamin A deficiency (xerophthalmia with goblet cell dysgenesis)
  - Eyelid abnormalities e.g. ectropion, CN VII palsy (decreased blinking)
- Preserved topical ocular medications
- Contact lenses, allergic conjunctivitis
- Mixed etiologies is common

Clinical Features
- Dry eyes, red eyes, foreign body sensation, blurred vision, tearing
- Slit-lamp exam: decreased tear meniscus, decreased tear break-up time (normally should be 10 s), punctate staining of cornea with fluorescein

Investigations
- Surface damage observed with fluorescein/Rose Bengal staining
- Decreased distance in Schirmer's test

Complications
- Erosions and scarring of cornea

Treatment
- Medical: preservative-free artificial tears up to q1h and ointment at bedtime (preservative toxicity becomes significant if used >q1h PRN), mild corticosteroid
- For severe cases, cyclosporine ophthalmic emulsion 0.05% (Restasis®) can be used
- Procedural: punctual occlusion (punctal plug insertion), lid taping, tarsorrhaphy (sew lids together) if severe
- Treat underlying cause

Epiphora (Excessive Tearing)

Etiology
- Emotion, pain
- Environmental stressor (cold, wind, pollen, sleep deprivation)
- Lid/lash malposition: ectropion, entropion, trichiasis
- Inflammatory: conjunctivitis, dacyroadenitis, uveitis, keratitis, corneal foreign body
- Dry eyes (reflex tearing)
- Lacrimal drainage obstruction (congenital failure of canalization, aging, rhinitis, dacyrocystitis)
- Paradoxical gustatory lacrimation reflex (crocodile tears)

Investigations
- Using fluorescein dye, examine for punctual reflux by pressing on canaliculi
- Jones dye test: fluorescein placed in conjunctival cul-de-sac, and cotton applicator placed in nose to detect flow (i.e. rule out lacrimal drainage obstruction)

Treatment
- Lid repair for ectropion or entropion
- Eyelash removal for trichiasis
- Punctal irrigation (dilation and irrigation)
- Nasolacrimal duct probing (infants)
- Tube placement: temporary (Crawford) or permanent (Jones)
- Surgical: dacryocystorhinostomy – forming a new connection between the lacrimal sac and the nasal cavity
**Dacryocystitis**

- acute or chronic infection of the lacrimal sac
- most commonly due to obstruction of the nasolacrimal duct
- commonly associated with *S. aureus, S. pneumoniae, Pseudomonas* species

**Clinical Features**

- pain, swelling, redness over lacrimal sac at medial canthus
- epiphora, crusting, ± fever
- digital pressure on the lacrimal sac may extrude pus through the punctum
- in the chronic form, epiphora may be the only symptom

**Treatment**

- warm compresses, nasal decongestants, systemic and topical antibiotics
- if chronic, obtain cultures by aspiration
- once infection resolves, consider dacryocystorhinostomy

**Dacryoadenitis**

- inflammation of the lacrimal gland (outer third of upper eyelid)
- acute causes: *S. aureus, mumps, EBV, herpes zoster, N. gonorrhoeae*
- chronic causes (often bilateral): lymphoma, leukemia, sarcoidosis, tuberculosis, thyroid ophthalmopathy

**Clinical Features**

- pain, swelling, tearing, discharge, redness of the outer region of the upper eyelid
- chronic form is more common and may present as painless enlargement of the lacrimal gland

**Treatment**

- supportive: warm compresses, oral NSAIDs
- systemic antibiotics if bacterial cause
- if chronic, treat underlying disorder

**Lids and Lashes**

**Lid Swelling**

**Etiology**

- commonly due to allergy, with shriveling of skin between episodes
- dependent edema on awakening (e.g. CHF, renal or hepatic failure)
- orbital venous congestion due to mass or cavernous sinus fistula
- dermatochalasis (loose skin due to aging or heredity)
- lid cellulitis, thyroid disease (e.g. myxedema), trauma, chemosis

**Ptosis**

- drooping of upper eyelid

**Etiology**

- aponeurotic: disinsertion or dehiscence of levator aponeurosis (most common)
  - associated with advancing age, trauma, surgery, pregnancy, chronic lid swelling
- mechanical
  - incomplete opening of eyelid due to mass or scarring
- neuromuscular
  - myasthenia gravis (neuromuscular palsy), myotonic dystrophy
  - CN III palsy
  - Horner's syndrome (see Constricted Pupil, Horner's Syndrome, OP30)
- congenital
- pseudoptosis (e.g. dermatochalasis, enophthalmos, contralateral exophthalmos)
- drugs (e.g. high dose opioids, heroin abuse, pregabalin)

**Treatment**

- surgery (e.g. blepharoplasty, levator resection, Müller's muscle resection, frontalis sling)
**Trichiasis**

- eyelashes turned inwards
- may result from entropion, involutional age change, chronic inflammatory lid diseases (e.g. blepharitis), trauma, burns
- patient complains of red eye, foreign body sensation, significant discomfort, tearing
- may result in corneal ulceration and scarring

**Treatment**

- topical lubrication, repeat eyelash epilation, electrolysis, cryotherapy

---

**Entropion**

- lid margin turns in towards globe causing tearing, foreign body sensation, and red eye
- most commonly affects lower lid
- may cause corneal abrasions with secondary corneal scarring

**Etiology**

- involutional (aging)
- cicatricial (herpes zoster, surgery, trauma, burns)
- orbicularis oculi muscle spasm
- congenital

**Treatment**

- lubricants, evert lid with tape, surgery

---

**Ectropion**

- lid margin turns outward from globe causing tearing and possibly exposure keratitis

**Etiology**

- involutional (aging)
- paralytic (CN VII palsy)
- cicatricial (burns, trauma, surgery)
- mechanical (lid edema, tumour, herniated fat)
- congenital

**Treatment**

- topical lubrication, eyelid taping overnight, surgery

---

**Hordeolum (Stye)**

- acute inflammation of eyelid gland: either Meibomian glands (internal lid), glands of Zeis (modified sweat gland) or Moll (modified sebaceous gland in external lid)
- infectious agent is usually S. aureus
- painful, red swelling of lid

**Treatment**

- warm compresses, lid care, gentle massage
- topical antibiotics are typically ineffective
- usually resolves within 2 weeks, but may require incision and drainage.

---

**Chalazion**

- chronic granulomatous inflammation of Meibomian gland often preceded by an internal hordeolum
- acute inflammatory signs are usually absent
- differential diagnosis: basal cell carcinoma, sebaceous cell adenoma, Meibomian gland carcinoma

**Treatment**

- warm compresses
- if no improvement after 1 mo, consider incision and curettage
- chronic recurrent lesion must be biopsied to rule out malignancy

---

*Tips for Entropion*

Forced lid closure: Ask patient to tighten lid then open. In entropion, lid rolls inwards

*Tips for Ectropion*

Snapback test: Pull eyelid inferiorly. In ectropion, lid remains away from globe

*Hordeolum vs. Chalazion*

Hordeolums are due to an infectious etiology, whereas chalazions are granulomatous inflammation.
**Blepharitis**
- inflammation of lid margins

**Etiology**
- two main types
  - staphylococcal (S. aureus): ulcerative, dry scales
  - seborrheic: no ulcers, greasy scales

**Clinical Features**
- itching, tearing, foreign body sensation
- thickened, red lid margins, crusting, discharge with pressure on lids (“toothpaste sign”)

**Complications**
- recurrent hordeola
- conjunctivitis
- keratitis (from poor tear film)
- corneal ulceration and neovascularization

**Treatment**
- warm compresses and lid scrubs with diluted “baby shampoo”
- topical or systemic antibiotics as needed
- if severe, ophthalmologist may prescribe a short course of topical corticosteroids, omega-3 fatty acids

**Xanthelasma**
- eyelid xanthoma (lipid deposits in dermis of lids)
- appear as pale, slightly elevated yellowish plaques or streaks
- most commonly on the medial upper lids, often bilateral
- associated with hyperlipidemia (~50% of patients)
- common in the elderly, more concerning in the young

**Treatment**
- excision for cosmesis only, commonly recurs

**Conjunctiva**
- thin, vascular mucous membrane
- bulbar conjunctiva: lines sclera to limbus (junction between cornea and sclera)
- palpebral (tarsal) conjunctiva: lines inner surface of eyelid

**Pinguecula**
- yellow-white subepithelial deposit of hyaline and elastic tissue adjacent to the nasal or temporal limbus, sparing the cornea
- associated with sun and wind exposure, aging
- benign, sometimes enlarges slowly
- may be irritating due to abnormal tear film formation over the deposits
- surgery for cosmesis only
- irritative symptoms may be treated with lubricating drops

**Pterygium**
- fibrovascular, triangular, wing-like encroachment of epithelial tissue onto the cornea,
- may induce astigmatism, decrease vision
- excision for chronic inflammation, threat to visual axis, cosmesis
- irritative symptoms may be treated with lubricating drops
- one-third recur after excision, lower recurrence with conjunctival autograft (~5%)

**Subconjunctival Hemorrhage**
- blood beneath the conjunctiva, otherwise asymptomatic
- idiopathic or associated with trauma, Valsalva maneuver, bleeding disorders, HTN, anticoagulation
- give reassurance if no other ocular findings, resolves spontaneously in 2-3 wk
- 360 degree involvement should be highly suspicious for globe rupture
- if recurrent, consider medical/hematologic workup
Conjunctivitis

Etiology
• infectious
• bacterial, viral, chlamydial, gonococcal, fungal, parasitic
• non-infectious
• allergic: atopic, seasonal, giant papillary conjunctivitis (contact lens wearers)
• toxic: irritants, dust, smoke, irradiation
• secondary to another disorder: dacryocystitis, dacryoadenitis, cellulitis, systemic inflammatory disease

Clinical Features
• red eye (conjunctival injection often with limbal pallor), chemosis, corneal subepithelial infiltrates
• itching, foreign body sensation, tearing, discharge, crusting of lashes in the morning, lid edema
• ± preauricular and/or submandibular nodes
• follicles: pale lymphoid elevations of the conjunctiva, overlain by vessels
• papillae: fibrovascular elevations of the conjunctiva with central network of finely branching vessels (cobblestone appearance)

ALLERGIC CONJUNCTIVITIS
Atopic
• associated with rhinitis, asthma, dermatitis, hay fever
• small papillae, chemosis, thickened and erythematous lids, corneal neovascularization
• seasonal (pollen, grasses, plant allergens)
• treatment: cool compresses, antihistamine, mast cell stabilizer (e.g. ketotifen, olopatadine), topical corticosteroids

Giant Papillary Conjunctivitis
• immune reaction to mucus debris on lenses in contact lens wearers
• large papillae form on superior palpebral conjunctiva
• treatment: clean, change or discontinue use of contact lens, topical corticosteroids

Vernal Conjunctivitis
• large papillae (cobblestones) form on superior palpebral conjunctiva with corneal ulcers and keratitis
• seasonal (warm weather)
• occurs in children, lasts for 5-10 yr then resolves
• treatment: consider topical steroid, topical cyclosporine (by ophthalmologist)

VIRAL CONJUNCTIVITIS (Pink Eye)
• presents with itchiness, pain and swelling
• serous discharge, lid edema, follicles, pseudomembranes
• subepithelial corneal infiltrates
• preauricular node often palpable and tender
• initially unilateral, often progresses to the other eye
• mainly due to adenovirus – highly contagious for up to 12 d

Treatment
• cool compresses, topical lubrication
• usually self-limiting (7-12 d)
• proper hygiene is important to prevent transmission

BACTERIAL CONJUNCTIVITIS
• purulent discharge, lid swelling, papillae, conjunctival injection, chemosis
• common agents include S. aureus, S. pneumoniae, H. influenzae and M. catarrhalis
• in neonates or if sexually active must consider N. gonorrhoeae (invades cornea to cause keratitis)
• C. trachomatis is the most common cause in neonates

Treatment
• topical broad-spectrum antibiotic
• systemic antibiotics if indicated, especially in neonates and children
• usually a self-limited course of 10-14 d if no treatment, 1-3 d with treatment

GONOCOCCAL AND CHLAMYDIAL CONJUNCTIVITIS
• caused by N. gonorrhoeae and C. trachomatis, respectively
• affects sexually active individuals, neonates (ophthalmia neonatorum) in first 5 days of life when caused by gonorrhea (shorter incubation period) and days 3-14 of life when caused by chlamydia (longer incubation period)
• newborn prophylaxis with 0.5% erythromycin ointment no longer recommended
• causes trachoma and inclusion conjunctivitis (different serotypes)
Trachoma
• leading infectious cause of blindness in the world
• severe keratoconjunctivitis leads to corneal abrasion, ulceration, and scarring
• initially, follicles on superior palpebral conjunctiva
• treatment: oral azithromycin and topical tetracycline

Inclusion Conjunctivitis
• chronic conjunctivitis with follicles and subepithelial infiltrates
• most common cause of conjunctivitis in newborns
• newborn prophylaxis with 0.5% erythromycin ointment no longer recommended
• treatment: oral azithromycin, tetracycline, doxycycline

Sclera
• white fibrous outer protective coat of the eye, composed of irregularly distributed collagen bundles
• continuous with the cornea anteriorly and the dura of the optic nerve posteriorly
• episclera is a thin layer of vascularized tissue between the sclera and conjunctiva

Episcleritis
• immunologically mediated inflammation of episclera
• 1/3 bilateral; simple (80%) or nodular (20%)
• more frequent in women than men (3:1)

Etiology
• mostly idiopathic
• associated with collagen vascular diseases, infections (herpes zoster, herpes simplex, syphilis), inflammatory bowel disease, rosacea, atopy

Clinical Features
• may have discomfort and pain associated with red eye (often interpalpebral), sectoral or diffuse injection of radially-directed vessels, chemosis, small mobile nodules
• blanches with topical phenylephrine (constricts superficial conjunctival vessels)

Treatment
• generally self-limited, recurrent in 2/3 of cases
• topical steroid for 3-5 d if painful (prescribed and monitored by ophthalmologist)
• oral NSAID

Scleritis
• usually bilateral; diffuse, nodular, or necrotizing
• anterior scleritis: pain radiating to face, may cause scleral thinning, in some cases necrotizing
• posterior scleritis: rapidly progressive blindness, may cause exudative RD
• more common in women and elderly

Etiology
• may be a manifestation of systemic disease
• collagen vascular disease, e.g. SLE, RA, ankylosing spondylitis
• granulomatous, e.g. tuberculosis, sarcoidosis, syphilis
• metabolic, e.g. gout, thyrotoxicosis
• infectious, e.g. S. aureus, S. pneumoniae, P. aeruginosa, herpes zoster
• chemical or physical agents, e.g. thermal, alkali, or acid burns
• idiopathic

Clinical Features
• severe pain, photophobia, red eye, decreased vision
• pain is best indicator of disease progression
• inflammation of scleral, episcleral, and conjunctival vessels
• may have anterior chamber cells and flare, corneal infiltrate, scleral thinning, scleral edema
• sclera may have a blue hue (best seen in natural light), due to rearranged scleral fibres
• failure to blanch with topical phenylephrine

Treatment
• vision threatening – needs to be referred to ophthalmology
• systemic NSAID or topical or systemic steroid
• treat underlying etiology

Scleral Perforation
• Asymptomatic anterior necrotizing scleritis without inflammation
• Strongly associated with RA
• May result in scleral thinning
• Traumatic perforation can easily occur – examine eye very gently

Preventing Ophthalmia Neonatorum
Paediatr Child Health 2015;20(2):93-96
The use of silver nitrate as prophylaxis for neonatal ophthalmia was instituted in the late 1800s to prevent the devastating effects of neonatal ocular infection with Haemophilus gonocecal. At that time – during the preantibiotic era – many countries made such prophylaxis mandatory by law. Today, neonatal gonococcal ophthalmia is rare in Canada, but ocular prophylaxis for this condition remains mandatory in some provinces/territories. Silver nitrate drops are no longer available and erythromycin, the only ophthalmic antibiotic eye ointment currently available for use in newborns, is of questionable efficacy. Ocular prophylaxis is not effective in preventing chlamydial conjunctivitis. Applying medication to the eyes of newborns may result in mild eye irritation and has been perceived by some parents as interfering with mother-infant bonding. Physicians caring for newborns should advocate for rescinding mandatory ocular prophylaxis laws. More effective means of preventing ophthalmia neonatorum include screening all pregnant women for gonorrhea and chlamydia infection, and treatment and follow-up of those found to be infected. Mothers who were not screened should be tested at delivery. Infants of mothers with untreated gonococcal infection at delivery should receive ceftriaxone. Infants exposed to chlamydia at delivery should be followed closely for signs of infection.
Cornea

- function
  - transmission of light
  - refraction of light (2/3 of total refractive power of eye)
  - barrier against infection, foreign bodies
- transparency due to avascularity, uniform collagen structure and deturgescence (relative dehydration)
- 6 layers (anterior to posterior): epithelium, Bowman's membrane, stroma, Duas layer, Descemet's membrane, endothelium (dehydrates the cornea; dysfunction leads to corneal edema)
- extensive sensory fibre network (V1 distribution); therefore abrasions are very painful

Foreign Body

- foreign material in or on cornea
- may have associated rust ring if metallic
- patients may note pain, tearing, photophobia, foreign body sensation, red eye
- signs include foreign body, conjunctival injection, epithelial defect that stains with fluorescein, corneal edema, anterior chamber cells/flare

Complications
- abrasion, infection, ulcer, scarring, rust ring, secondary iritis

Treatment
- remove under magnification using local anesthetic and sterile needle or refer to ophthalmology for removal under magnification (depending on depth and location)
- treat as per corneal abrasion

Corneal Abrasion

- epithelial defect usually due to trauma (e.g. fingernails, paper, twigs), contact lens (Figure 14)

Clinical Features (Table 5)
- pain, redness, tearing, photophobia, foreign body sensation
- de-epithelialized area stains with fluorescein dye
- pain relieved with topical anesthetic (DO NOT use for treatment- risk of corneal melt)

Complications
- abrasion, infection, recurrent erosion, secondary iritis

Treatment
- topical antibiotic (drops or ointment), abrasion from organic material should be covered against pseudomonas
- consider topical NSAID (caution due to risk of corneal melt with prolonged use), cycloplegic (relieves pain and photophobia by paralyzing ciliary muscle), patch
- most abrasions clear spontaneously within 24-48 h

Recurrent Erosions

- recurrent episodes of pain, photophobia, foreign body sensation with a spontaneous corneal epithelial defect
- usually occurs upon awakening
- associated with improper adherence of epithelial cells to the underlying basement membrane

Etiology
- previous traumatic corneal abrasion
- corneal dystrophy
- idiopathic

Treatment
- as for corneal abrasion until re-epithelialization occurs
- topical hypertonic saline ointment at bedtime for 3 mo, topical lubrication
- bandage contact lens, anterior stromal puncture or phototherapeutic keratectomy for chronic recurrences
**Corneal Ulcer**

**Etiology**
- local necrosis of corneal tissue due to infection
- infection is usually bacterial, rarely viral, fungal, or protozoan (*Acanthamoeba*)
- secondary to corneal exposure, abrasion, foreign body, contact lens use (50% of ulcers)
- also associated with conjunctivitis, blepharitis, keratitis, vitamin A deficiency

**Clinical Features**
- pain, photophobia, tearing, foreign body sensation, decreased VA (if central ulcer)
- corneal opacity that necroses and forms an excavated ulcer with infiltrative base
- overlying corneal epithelial defect that stains with fluorescein
- may develop corneal edema, conjunctival injection, anterior chamber cells/flare, hypopyon, corneal hypoesthesia (in viral keratitis)
- bacterial ulcers may have purulent discharge, viral ulcers may have watery discharge

**Complications**
- decreased vision, corneal perforation, iritis, endophthalmitis

**Investigations**
- Seidel test: fluorescein drop on the cornea under cobalt blue filter is used to detect leaking penetrating lesions; any aqueous leakage will dilute the green stain at site of wound

**Treatment**
- urgent referral to ophthalmology
- culture prior to treatment
- topical antibiotics every hour
- must treat vigorously to avoid complications

<table>
<thead>
<tr>
<th>Table 5. Corneal Abrasion vs. Corneal Ulcer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Abrasion</strong></td>
</tr>
<tr>
<td><strong>Time Course</strong></td>
</tr>
<tr>
<td><strong>History of Trauma</strong></td>
</tr>
<tr>
<td><strong>Cornea</strong></td>
</tr>
<tr>
<td><strong>Iris Detail</strong></td>
</tr>
<tr>
<td><strong>Corneal Thickness</strong></td>
</tr>
<tr>
<td><strong>Extent of Lesion</strong></td>
</tr>
</tbody>
</table>

**Herpes Simplex Keratitis**
- usually HSV type 1 (90% of population are carriers)
- may be triggered by stress, fever, sun exposure, immunosuppression

**Clinical Features**
- pain, tearing, foreign body sensation, red eye, may have decreased vision, eyelid edema
- corneal hypoesthesia
- dendritic (thin and branching) lesion with terminal end bulbs in epithelium that stains with fluorescein

**Complications**
- corneal scarring (can lead to loss of vision)
- chronic interstitial keratitis due to penetration of virus into stroma
- secondary iritis, secondary glaucoma

**Treatment**
- topical antiviral such as trifluridine, or systemic antiviral such as acyclovir
- dendritic debridement
- NO STEROIDS initially – may exacerbate condition
- ophthalmologist must exercise caution if adding topical steroids for chronic keratitis or iritis

**Figure 13. Corneal abrasion vs. ulcer**

An abrasion appears clear while an ulcer is more opaque

**Steroid treatment for ocular disorders should only be prescribed and supervised by an ophthalmologist, as they can impair corneal healing, exacerbate herpetic keratitis, and elevate IOP**
Herpes Zoster Ophthalmicus

- dermatitis in the dermatomal distribution of (CN V1) that is typically unilateral and respects the midline
- Hutchinson’s sign: if tip of nose is involved (nasociliary branch of V1) then globe will be involved in ~75% of cases
- if no nasal involvement, eye is involved in 1/3 of patients

Clinical Features
- pain, tearing, photophobia, red eye
- corneal edema, pseudodendrite, SPK
- corneal hypoesthesia

Complications
- corneal keratitis, ulceration, perforation and scarring
- secondary iritis, secondary glaucoma, cataract
- muscle palsies (rare) due to CNS involvement
- occasionally severe post-herpetic neuralgia

Treatment
- oral antiviral (acyclovir, valcyclovir, or famciclovir) immediately
- topical steroids, cycloplegia as indicated for keratitis, iritis
- erythromycin ointment if conjunctival involvement

Keratoconus

- bilateral paracentral thinning (ectasia) and bulging of the cornea resulting in a conical shape
- usually sporadic but can be associated with Down’s syndrome, atopy, contact lens use and vigorous eye rubbing
- associated with breaks in Descemet’s and Bowman’s membrane
- results in decreased vision from irregular astigmatism, scarring and stromal edema

Treatment
- attempt correction with spectacles and/or rigid gas permeable contact lens
- corneal collagen cross-linking treatment to halt disease progression
- intrastromal corneal ring segments can help flatten the corneal cone
- penetrating keratoplasty (corneal transplant) as last resort

Arcus Senilis

- hazy white ring in peripheral cornea, <2 mm wide, clearly separated from limbus
- common, bilateral, benign corneal degeneration due to lipid deposition, part of the aging process
- may be associated with hypercholesterolemia if age <40 yr, check lipid profile
- no associated visual symptoms, complications or treatment necessary

Kayser-Fleischer Ring

- brown-yellow-green pigmented ring in peripheral cornea, starting inferiorly
- due to deposition of copper pigment in Descemet’s membrane
- associated with Wilson’s disease
- no associated symptoms or complications of ring
- treat underlying disease
The Uveal Tract

- uveal tract (from anterior to posterior) = iris, ciliary body, choroid
- vascularized, pigmented middle layer of the eye, between the sclera and the retina

Uveitis

- uveal inflammation which may involve one, two, or all three parts of the tract
- idiopathic or associated with autoimmune, infectious, granulomatous, malignant causes
- should be managed by an optometrist or ophthalmologist
- anatomically classified as anterior uveitis, intermediate uveitis, posterior uveitis, or panuveitis based on primary site of inflammation

Table 6. Anatomic Classification of Uveitis

<table>
<thead>
<tr>
<th>Location</th>
<th>Anterior Uveitis (Iritis)</th>
<th>Intermediate Uveitis</th>
<th>Posterior Uveitis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Inflammation of iris, usually accompanied by cyclitis (inflammation of ciliary body), both = iridocyclitis</td>
<td>The vitreous is the major site of the inflammation</td>
<td>Inflammation of the choroid and/or retina</td>
</tr>
<tr>
<td>Etiology</td>
<td>Usually idiopathic</td>
<td>Mostly idiopathic, secondary causes include sarcoidosis, Lyme disease, and multiple sclerosis</td>
<td>Bacterial: syphilis, tuberculosis Viral: herpes simplex virus, CMV in AIDS Fungal: histoplasmosis, candidiasis Parasitic: toxoplasmosis (most common cause), toxocara Immunosuppression may predispose to any of the above infections Autoimmune: Behçet’s disease (triad of oral ulcers, genital ulcers, and posterior uveitis) Malignancies (masquerade syndrome): metastatic lesions, malignant melanoma</td>
</tr>
<tr>
<td>Clinical Features</td>
<td>Photophobia (due to reactive spasm of inflamed iris muscle), ocular pain, tenderness of the globe, brow ache (ciliary muscle spasm), decreased VA, lacrimation Ciliary flush (perilimbal conjunctival injection), miosis (spasm of sphincter muscle) Anterior chamber “cells” (WBC in anterior chamber due to anterior segment inflammation) and “flare” (protein precipitates in anterior chamber secondary to inflammation), hypopyon (collection of neutrophilic exudates inferiorly in the anterior chamber) Occasionally keratic precipitates (clumps of cells on corneal endothelium) Iritis typically reduces IOP because ciliary body inflammation causes decreased aqueous production; however, severe iritis, or iritis from herpes simplex and zoster may cause an inflammatory glaucoma (trabeculitis)</td>
<td>Insidious onset of blurred vision, accompanied by vitreous floaters Initial symptoms are usually unilateral but inflammatory changes are usually bilateral and asymmetric Associated with anterior uveitis, most severe cases of secondary intermediate uveitis Vitreous cells, condensations, and snowballs (vitreous aggregates of inflammatory cells) Posterior segment “snowbank” = grey-white fibrovascular plaque at the pars plana</td>
<td>Painless as choroid has no sensory innervation Often no conjunctival or scleral injection present Decreased VA Floaters (debris and inflammatory cells) Vitreous cells and opacities Hypopyon formation</td>
</tr>
<tr>
<td>Complications</td>
<td>Inflammatory glaucoma</td>
<td>Cystoid macular edema (30% of cases), cataract, and glaucoma</td>
<td>Macular edema Viritis Neovascularization Visual field loss/scotoma</td>
</tr>
<tr>
<td>Treatment</td>
<td>Mydriatics: dilate pupil to prevent formation of posterior synechiae and to decrease pain from ciliary spasm Steroids: topical, sub-tenon, or systemic Systemic analgesia</td>
<td>Systemic or sub-tenon/intravitreal steroids and immunosuppressive agents Vitrectomy, cryotherapy, or laser photocoagulation to the “snowbank”</td>
<td>Steroids: sub-tenon, intravitreal, or systemic if indicated (e.g. threat of vision loss)</td>
</tr>
</tbody>
</table>
Lens

- consists of an outer capsule surrounding a soft cortex and a firm inner nucleus

Cataracts

- any opacity of the lens, regardless of etiology
- most common cause of reversible blindness worldwide
- types: nuclear sclerosis, cortical, posterior subcapsular

Etiology
- acquired
  - age-related (over 90% of all cataracts)
  - cataract associated with systemic disease (may have juvenile onset)
    - DM
    - metabolic disorders (e.g. Wilson’s disease, galactosemia, homocystinuria)
    - hypocalcemia
  - traumatic (may be rosette shaped)
  - intraocular inflammation (e.g. uveitis)
  - toxic (steroids, phenothiazines)
  - radiation
- congenital
  - high myopia
  - present with altered red reflex or leukocoria
  - treat promptly to prevent amblyopia

Clinical Features
- gradual, painless, progressive decrease in VA
- glare, dimness, halos around lights at night, monocular diplopia
- “second sight” phenomenon: patient is more myopic than previously noted, due to increased refractive power of the lens (in nuclear sclerosis only)
  - patient may read without previously needed reading glasses
- diagnosis by slit-lamp exam
- may impair view of retina during fundoscopy

Treatment
- medical: no role for medical management
- surgical: definitive treatment
  - indications for surgery
    - to improve visual function in patients whose vision loss leads to functional impairment
    - to aid management of other ocular disease (e.g. cataract that prevents adequate retinal exam or laser treatment of DR)
  - congenital or traumatic cataracts
  - phacoemulsification (phaco = lens)
  - most commonly used surgical technique
  - post-operative complications
    - RD, endophthalmitis, dislocated IOL, macular edema, glaucoma, posterior capsular opacification

Dislocated Lens (Ectopia Lentis)

Etiology
- associated with Marfan’s Syndrome, Ehlers-Danlos type VI, homocystinuria, syphilis, lens coloboma (congenital cleft due to failure of ocular adnexa to complete growth)
- traumatic

Clinical Features
- decreased VA
- may get monocular diplopia
- iridodendesis (quivering of iris with movement)
- direct ophthalmoscopy may elicit abnormal red reflex

Complications
- cataract, glaucoma, uveitis

Treatment
- surgical correction ± lens replacement

Figure 16. Types of cataracts

Femtosecond Laser-Assisted Cataract Surgery Compared with Conventional Cataract Surgery


Purpose: Compare the safety and efficacy of femtosecond laser-assisted to conventional phacoemulsification cataract surgery.

Methods: Non-randomized prospective trial of 400 patients undergoing cataract surgery comparing phacoemulsification time and intraoperative complication rates with intention to treat analysis.

Results: Effective phacoemulsification time was reduced by 70% in the femtosecond laser treated group (P<0.0001) seen in all grades of cataract severity and there was no significant difference in intraoperative complication rates between groups.

Conclusion: Femtosecond laser-assisted cataract surgery may allow greater efficiency and short-term safety when compared to conventional surgery. Long term safety is not yet known.
**Vitreous**

- clear gel (99% water plus collagen fibrils, glycosaminoglycans, and hyaluronic acid) that fills the posterior segment of eye
- normally adherent to optic disc, pars plana, and along major retinal blood vessels

**Posterior Vitreous Detachment**

**Etiology**
- central vitreous commonly shrinks and liquefies with age (syneresis)
- during syneresis, molecules that hold water condense causing vitreous floaters
- liquid vitreous moves between posterior vitreous gel and retina
- vitreous is peeled away and separates from the internal limiting membrane of the neurosensory retina posterior to the vitreous base

**Clinical Features**
- floaters, flashes of light

**Complications**
- traction at areas of abnormal vitreo-retinal adhesions may cause retinal tears/detachment
- retinal tears/detachment may cause vitreous hemorrhage if bridging retinal blood vessel is torn
- complications more common in high myopes and following ocular trauma (blunt or perforating)

**Treatment**
- acute onset of PVD requires a dilated fundus exam to rule out retinal tears/detachment
- no specific treatment available for floaters/flash of light

**Vitreous Hemorrhage**

- bleeding into the vitreous cavity

**Etiology**
- PDR
- retinal tear/detachment
- PVD
- retinal vein occlusion
- trauma

**Clinical Features**
- sudden loss of VA
- may be preceded by “shower” of many floaters and/or flashes of light
- ophthalmoscopy: no red reflex if large hemorrhage, retina not visible due to blood in vitreous

**Treatment**
- ultrasound (B-scan) to rule out RD
- expectant: in non-urgent cases (e.g. no RD), blood usually resorbs in 3-6 mo
- surgical: vitrectomy ± RD repair ± retinal endolaser to possible bleeding sites/vessels

**Endophthalmitis and Vitritis**

- intraocular infection: acute, subacute, or chronic

**Etiology**
- most commonly a post-operative complication; risk following cataract surgery is <0.1%
- also due to penetrating injury to eye (risk is 3-7%), endogenous spread, and intravitreal injections
- etiology usually bacterial, may be fungal

**Clinical Features**
- painful, red eye, photophobia, discharge
- severely reduced VA, lid edema, proptosis, corneal edema, anterior chamber cells/flare, hypopyon, reduced red reflex
- may have signs of a ruptured globe (severe subconjunctival hemorrhage, hyphema, decreased IOP, etc.)

**Treatment** (see Ocular Trauma, OP39)
- OCULAR EMERGENCY: presenting vision best indicates prognosis
- LP or worse: admission, immediate vitrectomy, and intravitreal antibiotics to prevent loss of vision
- HM or better: vitreous tap for culture and intravitreal antibiotics
topical fortified antibiotics
Retina

• composed of two parts (Figure 2)
  ■ neurosensory retina: comprises 9 of the 10 retinal layers, including the photoreceptors and the ganglion cell layer
  ■ retinal pigmented epithelium (RPE) layer: external to neurosensory retina
  ■ macula: rich in cones (for colour vision); most sensitive area of retina
  ■ fovea: centre of macula; responsible for detail, fine vision, lacks retinal vessels
  ■ optic disc: collection of retinal nerve fibre layers forming optic nerve (CN2)
  ■ ora serrata: irregularly-shaped, anterior margin of the retina (cannot be visualized with direct ophthalmoscope)

Central/Branch Retinal Artery Occlusion

Etiology

• emboli from carotid arteries or heart (e.g. arrhythmia, endocarditis, valvular disease)
• thrombus
• temporal arteritis

Clinical Features

• sudden, painless, (except in GCA), severe monocular loss of vision
• RAPD
• patient may have experienced transient episodes in the past (amaurosis fugax)
• fundoscopy
  ■ “cherry-red spot”
  ■ retinal pallor
  ■ cotton wool spots (retinal infarcts)
  ■ cholesterol emboli (Hollenhorst plaques) – usually located at arteriole bifurcations
• thrombus occurs within the lumen of the blood vessel
• decrease IOP
  ■ topical β-blockers
  ■ IV acetazolamide
  ■ IV mannitol (draws fluid from eye)
• drainage aqueous – anterior chamber paracentesis (carries risk of infection, lens puncture)
• Nd:YAG laser embolectomy
• intra-arterial or intra-venous thrombolysis

Central/Branch Retinal Vein Occlusion

second most frequent “vascular” retinal disorder after DR
• usually a manifestation of a systemic disease (e.g. HTN, DM)
• thrombus occurs within the lumen of the blood vessel

Predisposing Factors

• arteriosclerotic vascular disease
• HTN
• DM
• glaucoma
• hyperviscosity (e.g. polycythemia rubra vera, sickle-cell disease, lymphoma, leukemia)
• drugs (e.g. oral contraceptive pill, diuretics)

Clinical Features

• painless, monocular, gradual or sudden vision loss
• ± RAPD
• fundoscopy
  ■ “blood and thunder” appearance
  ■ diffuse retinal hemorrhages, cotton wool spots, venous engorgement, swollen optic disc, macular edema
• two fairly distinct groups
  ■ venous stasis/non-ischemic retinopathy
  ■ no RAPD, VA ~20/80
  ■ mild hemorrhage, few cotton wool spots
  ■ resolves spontaneously over weeks to months
  ■ may regain normal vision if macula intact
  ■ RAPD, VA ~20/80
  ■ diffuse hemorrhages, cotton wool spots
  ■ resolves slowly due to retinal vein occlusion

Treatment for a central retinal artery occlusion (CRAO) must be initiated within 2 h of symptom onset for any hope of restoring vision
hemorrhagic/ischemic retinopathy
- usually older patient with deficient arterial supply
- RAPD, VA <20/200, reduced peripheral vision
- more hemorrhages, cotton wool spots, congestion
- poor visual prognosis

Complications
- neovascularization of retina and iris (secondary rubeosis), leading to secondary glaucoma
- vitreous hemorrhage
- macular edema

Treatment
- treatment available for complications of CRVO/BRVO including retinal laser photocoagulation and anti-VEGF and/or corticosteroid injection

Retinal Detachment
- cleavage in the plane between the neurosensory retina and the RPE
  - three types
    - rhegmatogenous (most common)
      - caused by a tear or hole in the neurosensory retina, allowing fluid from the vitreous to pass into the subretinal space
      - tears may be caused by PVD, degenerative retinal changes, trauma, or iatrogenically
    - tractional
      - caused by vitreal, epiretinal, or subretinal membrane pulling the neurosensory retina away from the underlying RPE
      - found in conditions such as DR, CRVO, sickle cell disease, ROP, and ocular trauma
    - exudative
      - caused by damage to the RPE resulting in fluid accumulation in the subretinal space
      - main causes are intraocular tumours, posterior uveitis, central serous retinopathy

Clinical Features
- sudden onset
- flashes of light
  - due to mechanical stimulation of the retinal photoreceptors
- floaters
- hazy spots in the line of vision which move with eye position, due to drops of blood from torn vessels bleeding into the vitreous
- curtain of blackness/peripheral field loss
  - darkness in one field of vision when the retina detaches in that area
- loss of central vision (if macula “off”)
- decreased IOP (usually 4-5 mmHg lower than the other, normal eye)
- ophthalmoscopy: detached retina is grey-white with surface blood vessels, loss of red reflex
  - ± RAPD

Treatment
- prophylactic: symptomatic tear (floaters) can be sealed off with laser/cryotherapy
- therapeutic
  - rhegmatogenous
    - scleral buckle procedure
    - pneumatic retinopexy
    - vitrectomy plus injection of gas (injection of silicone oil in cases of recurrent detachment)
  - tractional
    - vitrectomy ± membrane removal/scleral buckling/injection of intraocular gas or silicone oil as necessary
  - exudative
    - treat underlying cause

Complications
- loss of vision, vitreous hemorrhage, recurrent RD
- a RD is an emergency, especially if the macula is still attached (macula “on”)
- prognosis for visual recovery varies inversely with the amount of time the retina is detached and whether the macula is attached or not

Retinitis Pigmentosa
- hereditary degenerative disease of the retina manifested by rod > cone photoreceptor degeneration and retinal atrophy
- many forms of inheritance, most commonly autosomal recessive (60%)
Clinical Features
- night blindness, decreased peripheral vision (“tunnel vision”), decreased central vision (macular changes), glare (from posterior subcapsular cataracts, common)

Investigations
- fundoscopy: areas of “bone-spicule” pigment clumping in mid-periphery of retina, narrowed retinal arterioles, pale optic disc
- electrophysiological tests: electroretinography (ERG) and electrooculography (EOG) assist in diagnosis

Treatment
- no treatments available to reverse the condition; cataract extraction improves visual function; vitamin A and vitamin E supplementation can reduce progression of disease in some patients

Age-Related Macular Degeneration
- leading cause of irreversible blindness in the Western world, associated with increasing age, usually bilateral but asymmetric

Classification
- Non-Exudative/“Dry” (Non-Neovascular) AMD
  - most common type of AMD (90% of cases)
  - slowly progressive loss of visual function
  - drusen: yellow-white deposits between the RPE and Bruch’s membrane (area separating inner choroidal vessels from RPE)
  - RPE atrophy: coalescence of depigmented RPE, clumps of focal hyperpigmentation, or hypopigmentation
  - may progress to neovascular AMD

- Exudative/“Wet” (Neovascular) AMD
  - 10% of AMD, but 80% of AMD that results in severe vision loss
  - choroidal neovascularization: drusen predisposes to breaks in Bruch’s membrane causing subsequent growth and proliferation of new, fine choroidal vessels
  - may lead to serous detachment of overlying RPE and retina, hemorrhage and lipid precipitates into subretinal space
  - can also lead to an elevated subretinal mass due to fibrous metaplasia of hemorrhagic RD leads to disciform scarring and severe central vision loss

Risk Factors
- female
- increasing age
- family history
- smoking
- Caucasian race
- blue irides

Clinical Features
- variable degree of progressive central vision loss
- metamorphopsia (distorted vision characterized by straight parallel lines appearing convergent or wavy) due to macular edema

Investigations
- Amsler grid: held at normal reading distance with glasses on, assesses macular function
- fluorescein angiography: assess type and location of choroidal neovascularization – pathologic new vessels leak dye
- OCT retinal imaging

Treatment
- non-neovascular “dry” AMD
  - monitor, Amsler grid allows patients to check for metamorphopsia
  - low vision aids (e.g. magnifiers, closed-circuit television)
  - anti-oxidants, green leafy vegetables
  - sunglasses/visors
  - see Age-related Eye Disease Study 2 (AREDS2) in sidebar
- neovascular “wet” AMD
  - see Common Medications, OP42
  - intravitreal injection of anti-VEGF
    - pegaptanib (Macugen®), ranibizumab (Lucentis®), bevacizumab (Avastin®), aflibercept (Eylea®) (see VEGF Inhibitors, OP43)
  - laser photocoagulation for neovascularization
  - no definitive treatment for disciform scarring
  - photodynamic therapy with verteporfin (Visudyne®)
    - IV injection of verteporfin followed by low intensity laser to area of choroidal neovascularization

Age-Related Macular Degeneration 2 (AREDS2)
- Lutein + zeaxanthin and omega-3 fatty acids for AMD: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.
- Addition of lutein + zeaxanthin, DHA + EPA, or both to the AREDS formulation in primary analyses didn’t reduce risk of progression to advanced AMD. However, because of the potential increased incidence of lung cancer in former smokers, lutein + zeaxanthin could be an appropriate carotenoid substitute in the AREDS formulation.
**Glaucoma**

**Definition**
- progressive, pressure-sensitive, optic neuropathy involving characteristic structural changes to optic nerve head with associated visual field changes
- commonly associated with high IOP, but not required for diagnosis

**Background**
- aqueous is produced by the ciliary body and drains into the episcleral veins via the trabecular meshwork and the Canal of Schlemm
- an isolated increase in IOP is termed ocular hypertension (OHT) - should be followed for increased risk of developing glaucoma
- pressures >21 mmHg are at increased risk of developing glaucoma
- loss of peripheral vision most commonly precedes central vision loss
- Structural changes commonly precedes functional changes

**Investigations**
- VA testing
- slit-lamp exam to assess anterior chamber depth with goniscopic lens to assess angle patency
- ophthalmoscopy to assess the disc features
- tonometry to measure IOP
- visual field testing
- pachymetry to measure corneal thickness
- follow-up includes optic disc examination, IOP measurement, and visual field testing to monitor course of disease

**Figure 18. Glaucomatous damage**

- **Optic nerve head damage**
  - Pallor and cupping of optic disc (C:D ratio 0.2-0.3)
  - Concentric enlargement (C:D ratio 0.5)
  - Superior expansion
  - Advanced/total cupping

- **Visual field changes**
  - Small paracentral scotoma
  - Arcuate defect
  - Temporal central island

**Figure 19. Aqueous flow and sites of potential resistance**

- Average IOP = 15 ± 3 mmHg
- Normal C:D = <0.4
- Suspect glaucoma if C:D ratio >0.6, C:D ratio differs between eyes by >0.2, or cup approaches disc margin

---

**Ten Year Follow-Up of Age-Related Macular Degeneration in the Age-Related Eye Disease Study: AREDS 2014 Report No. 36**

**Study**: Randomized clinical trial.

**Objective**: To describe 10 yr progression rates to intermediate or advanced AMD.

**Patients**: Age-related eye disease study (AREDS) participants were observed for an additional 5 yr after RCT completion. Participants aged 55-80 yr with no AMD or AMD of varying severity (n = 4,757) were followed up in the AREDS trial for a median duration of 6.5 yr. When the trial ended, 3,549 of the 4,203 surviving participants were followed for 5 additional yr.

**Intervention**: Treatment with antioxidant vitamins and minerals.

**Main Outcome**: Development of varying stages of AMD and changes in visual acuity.

**Results**: The risk of progression to advanced AMD increased with increasing age (p<0.01) and severity of drusen. Women (p=0.005) and current smokers (p<0.001) were at increased risk of neovascular AMD. In the oldest participants with the most severe AMD status at baseline, the risks of developing neovascular AMD and central geographic atrophy by 10 yr were 46.1% and 26.0%, respectively. Similarly, rates of progression to large drusen increased with increasing severity of drusen at baseline, with 70.9% of participants with bilateral medium drusen progressing to large drusen and 13.8% to advanced AMD in 10 yr. Median visual acuity at 10 yr in eyes that had large drusen at baseline but never developed advanced AMD was 20/20; eyes that developed advanced AMD had a median visual acuity of 20/200.

**Conclusion**: The natural history of AMD demonstrates relentless loss of vision in persons who developed advanced AMD.
**Primary Open-Angle Glaucoma**

- most common form, >95% of all glaucoma cases
- due to obstruction of aqueous drainage within the trabecular meshwork and its drainage into the Canal of Schlemm
- insidious and asymptomatic, screening is critical for early detection

**Major Risk Factors**
- ocular hypertension (IOP>21 mmHg)
- age: prevalence at 40 yr is 1-2% and at 80 yr is 10%
- ethnicity: African descent
- familial (2-3x increased risk); polygenic
- thin central cornea (OHTS trial)

**Minor Risk Factors**
- myopia
- HTN
- DM
- hyperthyroidism (Graves’ disease)
- chronic topical ophthalmic steroid use in steroid responders – yearly eye exams recommended if >4 wk of steroid use
- previous ocular trauma
- anemia/hemodynamic crisis (ask about blood transfusions in past)

**Clinical Features**
- asymptomatic initially
- insidious, painless, gradual rise in IOP due to restriction of aqueous outflow
- bilateral, but usually asymmetric
- earliest signs are optic disc changes
  - increased C:D ratio (vertical C:D >0.6)
  - significant C:D asymmetry between eyes (>0.2 difference)
  - thinning, notching of the neuroretinal rim
  - flame shaped disc hemorrhage
  - 360° of peripapillary atrophy
  - nerve fibre layer defect
  - large vessels become nasally displaced
- visual field loss
- slow, progressive, irreversible loss of peripheral vision
- paracentral defects, arcuate scotoma, and nasal step are characteristics (Figure 19)
- late loss of central vision if untreated

**Treatment**
- medical treatment: decrease IOP by increasing the drainage and/or decreasing the production of aqueous (see Glaucoma Medications, Table 12, OP42)
  - increase aqueous outflow
    - topical cholinergics
    - topical prostaglandin analogues
    - topical α-adrenergics
  - decrease aqueous production
    - topical β-blockers
    - topical and oral carbonic anhydrase inhibitor
    - topical α-adrenergics
  - laser trabeculoplasty, cyclophotocoagulation in order to achieve selective destruction of ciliary body (for refractory cases)
  - trabeculectomy: creation of a new outflow tract from anterior chamber to under conjunctiva forming a bleb
  - minimally invasive glaucoma surgery (MIGS): implantation of IOP lowering drainage devices (e.g. iStent) through an ab interno microincisional approach during cataract surgery
  - serial optic nerve head examinations, IOP measurements, and visual field testing to monitor disease course

**Normal Tension Glaucoma**

- POAG with IOP in normal range
- often found in women >60 but may occur earlier
- associated with migraines, peripheral vasospasm, systemic nocturnal hypotension, sleep apnea
- damage to optic nerve may be due to vascular insufficiency

**Treatment**
- treat reversible causes
Secondary Open Angle Glaucoma

- increased IOP secondary to ocular/systemic disorders that obstruct the trabecular meshwork
- steroid-induced glaucoma
- traumatic glaucoma
- pigmentary dispersion syndrome
- pseudoexfoliation syndrome

Primary Angle-Closure Glaucoma

- 5% of all glaucoma cases
- peripheral iris bows forward obstructing aqueous access to the trabecular meshwork
- sudden forward shift of the lens-iris diaphragm causes pupillary block, and results in impaired drainage leading to a sudden rise in IOP

Risk Factors
- hyperopia: small eye, big lens – large lens crowds the angle
- age >70 yr
- female
- family history
- more common in people of Asian and Inuit descent
- mature cataracts
- shallow anterior chamber
- pupil dilation (topical and systemic anticholinergics, stress, darkness)

Clinical Features
- red, painful eye = RED FLAG
- unilateral, but other eye increased risk
- decreased visual acuity, vision acutely blurred from corneal edema
- halos around lights
- nausea and vomiting, abdominal pain
- fixed, mid-dilated pupil
- marked increase in IOP; may be noticeable even to palpation (＞40 mmHg)
- shallow anterior chamber ± cells in anterior chamber

Complications
- irreversible loss of vision within hours to days if untreated
- permanent peripheral anterior synchia, resulting in permanent angle closure

Treatment
- OCULAR EMERGENCY: refer to ophthalmologist for acute angle closure glaucoma
  - aqueous suppressants and hyperosmotic agents
  - medical treatment (see Glaucoma Medications, Table 12, OP42)
    - miotic drops (pilocarpine) to reverse pupillary block
    - multiple topical IOP-lowering agents
    - hyperosmotic agents such as oral glycerine, or IV mannitol
    - laser iridotomy is definitive

Secondary Angle-Closure Glaucoma

Uveitis
- inflamed iris adheres to lens (posterior synchia)

Neovascular Glaucoma
- abnormal blood vessels develop on surface of iris (rubeosis iridis), in the angle, and within the trabecular meshwork
- due to retinal ischemia associated with PDR or CRVO
- treatment with laser therapy to retina reduces neovascular stimulus to iris and angle vessels

Rule of Fours
1/4 of general population using topical steroid for 4 wk, 4 x/d will develop an increase in IOP

A. Open angle with normal aqueous flow
B. Closed angle with abnormal aqueous flow

1. Ciliary flow
2. Ciliary body
3. Cornea
4. Lens
5. Blocked trabecular meshwork

Figure 20. Normal open angle vs. angle-closure glaucoma

Angiotensin Converting Enzyme (ACE) inhibitors
BACH
β-blockers, dorzolamide, brimonidine, pilocarpine, and epinephrine vs. each other and placebo.
Main Outcome: Reduction of progression or prevention of onset of visual field defects.
Results: Meta-analysis on all trials that tested drugs against placebo or untreated controls demonstrated that lowering IOP reduces incidence of glaucomatous visual field defects, with an odds ratio of 0.32 (95% CI 0.47-0.81). However, this result is of limited practical use since different therapies were pooled. No single drug demonstrated significant visual field protection. However, as a class, β-blockers showed borderline significance in reducing onset of glaucoma in patients with OHT when compared to placebo, with an OR of 0.67 (95% CI 0.45-1.00).
Conclusion: Lowering IOP can reduce progression of visual field defects in patients with OHT.
Pupils

- pupil size is determined by the balance between the sphincter muscle and the dilator muscle
- sphincter muscle is innervated by the parasympathetic nervous system carried by CN III
- dilator muscle is innervated by the sympathetic nervous system (SNS)
  - first order neuron = hypothalamus → brainstem → spinal cord
  - second order/preganglionic neuron = spinal cord → sympathetic trunk via internal carotid artery → superior cervical ganglion in neck
  - third order/postganglionic fibres originate in the superior cervical ganglion, neurotransmitter is norepinephrine
    - as a diagnostic test, 4-10% cocaine prevents the re-uptake of norepinephrine, and will cause dilation of normal pupil, but not one with loss of sympathetic innervation (Horner's Syndrome)
- see Neurology, Figure 8, N8

Pupillary Light Reflex

- light shone directly into eye travels along optic nerve (CN II, afferent limb) → optic tracts → bilateral midbrain
- impulses enter bilaterally in midbrain via pretectal area and Edinger-Westphal nuclei
- nerve impulses then travel down CN III (efferent limb) bilaterally to reach the ciliary ganglia, and finally to the iris sphincter muscle, which results in the direct and consensual light reflexes

\[ \text{a1 – Pupillary dilator muscle contraction (Mydriasis)} \]
\[ \text{β2 – Ciliary muscle relaxation (Non-accommodation); increased aqueous humour production} \]
\[ \text{M3 – Pupillary sphincter contraction (Miosis); increased ciliary muscle contraction (Accommodation)} \]

Pupil Abnormalities

Denervation Hypersensitivity
- when post-ganglionic fibres are damaged, the understimulated end-organ attempts to compensate by developing an excess of neuroreceptors and becomes hypersensitive
- pupil will constrict with 0.125% pilocarpine (cholinergic agonist), normal pupil will not
- postganglionic sympathetic lesions (this test is used to differentiate between pre- and post-ganglionic lesions in Horner’s syndrome)
  - pupil will dilate with 0.125% epinephrine, normal pupil will not

Local Disorders of Iris
- posterior synechiae (adhesions between iris and lens) due to iritis can present as an abnormally shaped pupil
- ischemic damage (e.g. post-acute angle-closure glaucoma) usually occurs at 3 and 9 o’clock positions resulting in a vertically oval pupil that reacts poorly to light
- trauma (e.g. post-intraocular surgery)

Anisocoria
- unequal pupil size
- idiopathic/physiologic anisocoria
- 20% of population
- round, regular, <1 mm difference
- pupils reactive to light and accommodation
- responds normally to mydiatrics/miotics
- post eye surgery
- see Table 7 for other causes of anisocoria
Patient with Anisocoria

Relevant history and examination with specific attention to:
- History of ocular trauma
- Check old photographs (ptosis, ocular deviation, long standing anisocoria)
- Use of topical medications
- Exposure to toxins and drugs
- Associated ocular and neurologic symptoms/signs

Which pupil is abnormal? Examine pupils in light and dark

Table 7. Summary of Conditions Causing Anisocoria

<table>
<thead>
<tr>
<th>Features</th>
<th>Site of Lesion</th>
<th>Light and Accommodation</th>
<th>Anisocoria</th>
<th>Mydriatics/Miotics</th>
<th>Effect of Pilocarpine</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABNORMAL MIOTIC PUPIL (impaired pupillary dilation)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Argyll-Robertson Pupil</td>
<td>Irregular, usually bilateral</td>
<td>Midbrain</td>
<td>Poor in light; better to accommodation</td>
<td>Dilates/Constricts</td>
<td></td>
</tr>
<tr>
<td>Horner’s Syndrome</td>
<td>Round, unilateral, ptosis, anhydrosis, pseudoenophthalmos</td>
<td>Sympathetic system</td>
<td>Both brisk</td>
<td>Greater in dark</td>
<td>Dilates/Constricts</td>
</tr>
</tbody>
</table>

ABNORMAL MYDRIATIC PUPIL (impaired pupillary constriction)

<table>
<thead>
<tr>
<th>Features</th>
<th>Site of Lesion</th>
<th>Light and Accommodation</th>
<th>Anisocoria</th>
<th>Mydriatics/Miotics</th>
<th>Effect of Pilocarpine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adie’s Tonic Pupil</td>
<td>Irregular, larger in bright light</td>
<td>Ciliary ganglion</td>
<td>Poor in light, better to accommodation</td>
<td>Greater in light</td>
<td>Dilates/Constricts</td>
</tr>
<tr>
<td>CN III Palsy</td>
<td>Round</td>
<td>Superficial CN III</td>
<td>± fixed (acutely) at 7-9 mm</td>
<td>Greater in light</td>
<td>Dilates/Constricts</td>
</tr>
<tr>
<td>Mydriatic Pupil</td>
<td>Round, uni- or bilateral</td>
<td>Iris sphincter</td>
<td>Fixed at 7-8 mm</td>
<td>Greater in light</td>
<td>No effect</td>
</tr>
</tbody>
</table>
**Dilated Pupil (Mydriasis)**

**Sympathetic Stimulation**
- fight or flight response
- mydriatic drugs: epinephrine, dipivefrin (Propine®), phenylephrine

**Parasympathetic Understimulation**
- cycloplegics/mydriatics: atropine, tropicamide, cyclopentolate (parasympatholytic)
- CN III palsy
  - eye deviated down and out with ptosis present
  - etiology includes stroke, neoplasm, aneurysm, acute rise in ICP, DM (may spare pupil), trauma
- CN III palsy will respond to drugs (e.g. pilocarpine), unlike a pupil dilated from medication (mydriatics)

**Horner's Syndrome**
- 80% unilateral, F>M
- pupil is tonic or reacts poorly to light (both direct and consensual) but constricts with accommodation
- caused by benign lesion in ciliary ganglion; results in denervation hypersensitivity of parasympathetically innervated constrictor muscle
- dilute (0.125%) solution of pilocarpine will constrict tonic pupil but have no effect on normal pupil
- long-standing Adie's pupils are smaller than unaffected eye

**Acute Angle-Closure Glaucoma**
- fixed, mid-dilated pupil

**Adie's Tonic Pupil**
- 80% unilateral, F>M
- pupil is tonic or reacts poorly to light (both direct and consensual) but constricts with accommodation
- caused by benign lesion in ciliary ganglion; results in denervation hypersensitivity of parasympathetically innervated constrictor muscle
- dilute (0.125%) solution of pilocarpine will constrict tonic pupil but have no effect on normal pupil
- long-standing Adie's pupils are smaller than unaffected eye

**Trauma**
- damage to iris sphincter from blunt or penetrating trauma
- iris transillumination defects may be apparent using ophthamoscope or slit-lamp
- pupil may be dilated (traumatic mydriasis) or irregularly shaped from tiny sphincter ruptures

**Senile Miosis**
- decreased sympathetic stimulation with age

**Parasympathetic Stimulation**
- local or systemic medications such as:
  - cholinergic agents: pilocarpine, carbachol
  - cholinesterase inhibitor: phospholine iodide
  - opiates, barbiturates

**Horner's Syndrome**
- lesion in sympathetic pathway
- difference in pupil size greater in dim light, due to decreased innervation of adrenergics to iris dilator muscle
- associated with ptosis, anhydrosis of ipsilateral face/neck
- application of cocaine 4–10% (blocks reuptake of norepinephrine) to eye does not result in pupil dilation (vs. physiologic anisocoria), therefore confirms diagnosis
- hydroxyamphetamine 1% (stimulates norepinephrine release) will dilate pupil if central or preganglionic lesion, not postganglionic lesion
- postganglionic lesions result in denervation hypersensitivity, which will cause pupil to dilate with 0.125% epinephrine, whereas normal pupil will not
- causes: carotid or subclavian aneurysm, brainstem infarct, demyelinating disease, cervical or mediastinal tumour, Pancoast tumour, goitre, cervical lymphadenopathy, surgical sympathectomy, Lyme disease, cervical ribs, tabes dorsalis, cervical vertebral fractures

**Iritis**
- miotic pupil initially
- later, may be irregularly shaped pupil due to posterior synchia
- later stages non-reactive to light

**Argyll-Robertson Pupil**
- both pupils irregular and <3 mm in diameter, ± ptosis
- does not respond to light stimulation
- responds to accommodation (light-near dissociation)
- suggestive of neurosyphilis or other conditions (DM, encephalitis, MS, chronic alcoholism, CNS degenerative diseases)

**Other Causes**
- optic neuritis, retinal lesions
Relative Afferent Pupillary Defect

- also known as Marcus Gunn pupil
- impairment of direct pupillary response to light, caused by a lesion in visual afferent (sensory) pathway anterior to optic chiasm
- differential diagnosis: large RD, BRAO, CRAO, CRVO, advanced glaucoma, optic nerve compression, optic neuritis (most common)
- pupil reacts poorly to light and better to accommodation
- test: swinging flashlight
  - if light is shone in the affected eye, direct and consensual response to light is decreased
  - if light is shone in the unaffected eye, direct and consensual response to light is normal
  - if the light is moved quickly from the unaffected eye to the affected eye, “paradoxical” dilation of both pupils occurs
  - observe red reflex, especially in patients with dark irides
- if the defect is bilateral there is no RAPD, as dilation is measured relative to the other eye

Malignancies

- uncommon site for 1st malignancies
- see Retinoblastoma, OP38

Lid Carcinoma

Etiology
- basal cell carcinoma (rodent ulcer) (90%)
  - spread via local invasion, rarely metastasizes
  - ulcerated centre, indurated base with pearly rolled edges, telangiectasia
- squamous cell carcinoma (<5%)
  - spread via local invasion, may also spread to nodes and metastasize
  - ulceration, keratosis of lesion
- sebaceous cell carcinoma (1-5%)
  - often masquerades as chronic blepharitis or recurrent chalazion
  - highly invasive, metastasize
- Kaposi's sarcoma, malignant melanoma, Merkel cell tumour, metastatic tumour
**Malignant Melanoma**

- most common 1st intraocular malignancy in adults
- more prevalent in Caucasians
- arise from uveal tract, 90% choroidal melanoma
- hepatic metastases predominate

**Treatment**

- imaging to investigate spread
- depending on the size of the tumour, either radiotherapy, enucleation, limited surgery

**Metastases**

- most common intraocular malignancy in adults
- most commonly from breast and lung in adults, neuroblastoma in children
- usually infiltrate the choroid, but may also affect the optic nerve or extraocular muscles
- may present with decreased or distorted vision, irregularly shaped pupil, iritis, hyphema

**Treatment**

- local radiation, chemotherapy
- enucleation if blind, painful eye

---

**HIV/AIDS**

- up to 75% of patients with AIDS have ocular manifestations

**External Ocular Signs**

- Kaposi's sarcoma
  - secondary to human herpes virus 8 (HHV-8), affects conjunctiva of lid or globe
  - differential diagnosis: subconjunctival hemorrhage (non-clearing), hemangioma
- multiple molluscum contagiosum
- herpes simplex/zoster keratitis

**Retina**

- HIV retinopathy (most common)
  - cotton wool spots in >50% of HIV patients
  - intraretinal hemorrhage
  - CMV retinitis
  - ocular opportunistic infection developed when severely immunocompromised (CD4 count ≤50)
  - a necrotizing retinitis, with retinal hemorrhage and vasculitis, “brushfire” or “pizza pie” appearance
  - presents with scotomas (macular involvement and RD), blurred vision, and floaters
  - untreated infection will progress to other eye in 4-6 wk
  - treatment: virostatic agents (e.g. gancyclovir or foscarnet) via IV or intravitreal injection
  - necrotizing retinitis
    - from herpes simplex virus, herpes zoster, toxoplasmosis
    - disseminated choroiditis
    - *Pneumocystis carinii*, *Mycobacterium avium intracellulare*, *Candida*

---

**Other Systemic Infections**

- herpes zoster
  - see *Herpes Zoster*, OP18
- candidal endophthalmitis
  - fluffy, white-yellow, superficial retinal infiltrate that may eventually result in vitritis
  - may present with inflammation of the anterior chamber
  - treatment: systemic amphotericin B, oral fluconazole
• toxoplasmosis
  ■ focal, grey-yellow-white, chorioretinal lesions with surrounding vasculitis and vitreous infiltration (vitreous cells)
  ■ can be congenital (transplacental) or acquired (caused by Toxoplasma gondii protozoa transmitted through raw meat and cat feces)
  ■ congenital form more often causes visual impairment (more likely to involve the macula)
  ■ treatment: pyrimethamine, sulfonamide, folic acid, or clindamycin. Consider adding steroids if severe inflammation (iritis, macular or optic nerve involvement)

**Diabetes Mellitus**

• most common cause of blindness in young people in North America
• loss of vision due to
  • progressive microangiopathy leading to macular edema
  • progressive DR → neovascularization → traction → RD and vitreous hemorrhage
  • neovascularization of iris leading to neovascular glaucoma (poor prognosis)
  • macular ischemia

**DIABETIC RETINOPATHY**

**Background**
• altered vascular permeability (loss of pericytes, breakdown of blood-retinal barrier, thickening of basement membrane)
• predisposition to retinal vessel obstruction (CRAO, CRVO, and BRVO)

**Classification**
• non-proliferative: increased vascular permeability and retinal ischemia
  • microaneurysms
  • dot and blot hemorrhages
  • hard exudates (lipid deposits), non-specific for DR
  • macular edema
• advanced non-proliferative (or pre-proliferative)
  • non-proliferative findings plus:
    • venous beading (in ≥ 2 of 4 retinal quadrants)
    • intraretinal microvascular anomalies (IRMA) in 1 of 4 retinal quadrants
      – IRMA: dilated, leaky vessels within the retina
    • cotton wool spots (nerve fibre layer infarcts)
• proliferative
  • 5% of patients with DM will reach this stage
  • neovascularization of iris (rubeosis iridis) can lead to neovascular glaucoma
  • vitreous hemorrhage, bleeding from fragile new vessels, fibrous tissue can contract causing tractional RD
  • high risk of severe vision loss secondary to vitreous hemorrhage, RD

**Screening Guidelines for Diabetic Retinopathy**
• type 1 DM
  • screen for retinopathy beginning annually 5 yr after disease onset
  • annual screening indicated for all patients over 12 yr and/or entering puberty
• type 2 DM
  • initial examination at time of diagnosis, then annually
• pregnancy
  • ocular exam in 1st trimester, close follow-up throughout as pregnancy can exacerbate DR
  • gestational diabetics are not at risk for DR

**Treatment**
• Diabetic Control and Complications Trial (DCCT)
  • tight control of blood sugar decreases frequency and severity of microvascular complications
  • blood pressure control
  • focal laser for clinically significant macular edema
  • intravitreal injection of corticosteroid or anti-VEGF for foveal involved diabetic macular edema
  • panretinal laser photocoagulation for PDR: reduces neovascularization, hence reducing the angiogenic stimulus from ischemic retina by decreasing retinal metabolic demand → reduces risk of blindness
  • vitrectomy for non-clearing vitreous hemorrhage and tractional RD in PDR
  • vitrectomy before vitreous hemorrhage does not improve the visual prognosis

**Lens Changes**
• earlier onset of senile nuclear sclerotic and cortical cataracts
• may get hyperglycemic cataract, due to sorbitol accumulation (rare)
• changes in blood glucose levels (poor control) can suddenly cause refractive changes by 3–4 dipters
Extraocular Muscle Palsy
- usually CN III infarct
- pupil usually spared in diabetic CN III palsy, but ptosis is observed
- may involve CN IV and VI
- usually recover within few months

Optic Neuropathy
- visual acuity loss due to infarction of optic disc/nerve

Hypertension
- retinopathy is the most common ocular manifestation
- chronic HTN retinopathy: arteriovenous (AV) nicking, blot retinal hemorrhages, microaneurysms, cotton wool spots
- acute HTN retinopathy: retinal arteriolar spasm, superficial retinal hemorrhage, cotton wool spots, optic disc edema

Multiple Sclerosis
- see Neurology, N52

Clinical Features
- blurred vision and decreased colour vision: secondary to optic neuritis
- central scotoma: due to damage to papillomacular bundle of retinal nerve fibres
- diplopia: secondary to INO
- RAPD, ptosis, nystagmus, uveitis, optic atrophy, optic neuritis
- white matter demyelinating lesions of optic nerve on MRI

Treatment
- IV steroids with taper to oral form for optic neuritis
  - white matter demyelinating lesions of optic nerve on MRI
  - acute HTN retinopathy: retinal arteriolar spasm, superficial retinal hemorrhage, cotton wool spots, optic disc edema
  - chronic HTN retinopathy: arteriovenous (AV) nicking, blot retinal hemorrhages, microaneurysms, cotton wool spots

Table 8. Keith-Wagener-Barker Classification

<table>
<thead>
<tr>
<th>Group</th>
<th>Characteristic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>Mild arterial narrowing</td>
</tr>
<tr>
<td>Group 2</td>
<td>Obvious arterial narrowing with focal irregularities</td>
</tr>
<tr>
<td>Group 3</td>
<td>Group 2 characteristics plus:</td>
</tr>
<tr>
<td></td>
<td>Cotton wool spots</td>
</tr>
<tr>
<td></td>
<td>Hemorrhage and/or exudate</td>
</tr>
<tr>
<td>Group 4</td>
<td>Group 3 plus papilledema</td>
</tr>
</tbody>
</table>
TIA/Amaurosis Fugax

- sudden, transient blindness from intermittent vascular compromise
- ipsilateral carotid most frequent embolic source
- typically monocular, lasting <5-10 min
- Hollenhorst plaques (glistening microemboli seen at branch points of retinal arterioles)

Graves’ Disease

- ophthalmopathy occurs despite control of thyroid gland status
- ocular manifestations occur secondary to sympathetic overdrive and/or specific inflammatory infiltrate of the orbital tissue

Clinical

- initial inflammatory phase is followed by a quiescent cicatricial phase

Treatment

- treat hyperthyroidism
- monitor for corneal exposure and maintain corneal hydration
- manage diplopia, proptosis and compressive optic neuropathy with one or a combination of:
  - steroids (during acute phase)
  - orbital bony decompression
  - external beam radiation of the orbit
- consider strabismus and/or eyelid surgical procedures once acute phase subsides

Connective Tissue Disorders

- RA, juvenile idiopathic arthritis, SLE, Sjögren syndrome, ankylosing spondylitis, polyarteritis nodosa
- most common ocular manifestation: dry eyes (keratoconjunctivitis sicca)

Giant Cell Arteritis/Temporal Arteritis

- see Rheumatology, RH20

Clinical Features

- more common in women >60 yr
- abrupt monocular loss of vision, pain over the temporal artery, jaw claudication, scalp tenderness, constitutional symptoms, and past medical history of polymyalgia rheumatica
- ischemic optic atrophy
- 50% lose vision in other eye if untreated

Diagnosis

- temporal artery biopsy + increased ESR (ESR can be normal, but likely 80-100 in first hour), increased CRP
- if biopsy of one side is negative, biopsy the other side

Treatment

- high dose corticosteroid to relieve pain and prevent further ischemic episodes
- if diagnosis of GCA is suspected clinically: start treatment + perform temporal artery biopsy to confirm diagnosis within 2 wk of initial presentation (DO NOT WAIT TO TREAT)

Sarcoidosis

- granulomatous uveitis with large “mutton fat” keratitic precipitates and posterior synechiae
- neurosarcoidosis: optic neuropathy, oculomotor abnormalities, visual field loss

Treatment

- steroids and mydriatics
Pediatric Ophthalmology

Strabismus

- ocular misalignment in one or both eyes, can be found in up to 3% of children
- classification
  - manifest (constant) vs. latent (hidden) alignment.
  - comitant (deviation equal in all positions of gaze) vs. incomitant (deviation worse in certain positions)
  - described in direction of deviation relative to the fixating eye
- distinguish from pseudostrabismus (prominent epicanthal folds, hypertelorism)
- complications: amblyopia, cosmesis

HETEROTROPIA

- manifest deviation
  - deviation not corrected by the fusion mechanism (i.e. deviation is apparent when the patient is using both eyes)

Types

- exo- (lateral deviation), eso- (medial deviation)
- hyper- (upward deviation), hypo- (downward deviation)
- esotropia = “crossed-eyes”; exotropia = “wall-eyed”

Tests

- Hirschberg test (corneal light reflex): positive if the light reflex on both corneas is asymmetrical
  - light reflex lateral to central cornea indicates esodeviation; light reflex medial to central cornea indicates exodeviation
  - false positives occur if visual axis and anatomic pupillary axis of the eye are not aligned (angle κ)
- cover test
- the deviation can be quantified using prisms

HETEROPHORIA

- latent deviation
  - deviation corrected in the binocular state by the fusion mechanism (i.e. deviation not seen when patient is focusing with both eyes)
  - Hirschberg test will be normal (light reflexes symmetrical)
  - very common – majority are asymptomatic
  - may be exacerbated or become manifest with asthenopia (eye strain, fatigue)

Tests

- cover-uncover test
- alternate cover test
  - alternating the cover between both eyes reveals the total deviation, both latent and manifest
  - maintain cover over one eye for 2-3 s before rapidly shifting to other eye

Figure 25. Cover and cover-uncover tests for detection of tropias and phorias
Table 9. Paralytic vs. Non-Paralytic Strabismus

<table>
<thead>
<tr>
<th>Clinical Characteristics</th>
<th>Paralytic Strabismus</th>
<th>Nonparalytic Strabismus</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definition</strong></td>
<td>Incomitant strabismus</td>
<td>Concomitant strabismus</td>
</tr>
<tr>
<td><strong>Onset</strong></td>
<td>Often sudden but may be gradual or congenital</td>
<td>Usually gradual or shortly after birth; rarely sudden</td>
</tr>
<tr>
<td><strong>Age of Onset</strong></td>
<td>Any age; most often acquired</td>
<td>Usually during infancy</td>
</tr>
<tr>
<td><strong>Etiology</strong></td>
<td>Reduction or restriction in range of eye movements due to: Neural (CN III, IV, VI): ischemia (e.g. DM), MS, aneurysm, brain tumour, trauma</td>
<td>Develops early in childhood</td>
</tr>
<tr>
<td></td>
<td>Muscular: myasthenia gravis (neuromuscular junction pathology), Graves’ disease</td>
<td>No restriction in range of eye movements</td>
</tr>
<tr>
<td></td>
<td>Structural: restriction or entrapment of extraocular muscles due to orbital inflammation, tumour, fracture of the orbital wall</td>
<td>Monocular, alternating, or intermittent</td>
</tr>
<tr>
<td><strong>Diplopia</strong></td>
<td>Common</td>
<td>Uncommon; image from the misaligned eye is suppressed</td>
</tr>
<tr>
<td><strong>Visual Acuity in Other Eye</strong></td>
<td>Usually unaffected in the other eye, unless CN II is involved</td>
<td>Deviated eye may become amblyopic if not treated when the child is young</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Amblyopia treatment rarely successful after age 8-10 yr</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Amblyopia usually does not develop if child has alternating strabismus or intermittency, which allows neural pathways for both eyes to develop</td>
</tr>
<tr>
<td><strong>Possibility of Amblyopia</strong></td>
<td>Uncommon</td>
<td>Common</td>
</tr>
<tr>
<td><strong>Neurologic Findings or Systemic Disease</strong></td>
<td>May be present</td>
<td>Usually absent</td>
</tr>
</tbody>
</table>

**Accommodative Esotropia**
- normal response to approaching object is the triad of the near reflex: convergence, accommodation and miosis
- hyperopes must constantly accommodate – excessive accommodation can lead to esotropia in young children via over-activation of the near reflex
- average age of onset is 2.5 yr
- usually reversible with correction of refractive error

**Non-Accommodative Esotropia**
- accounts for 50% of childhood strabismus
- most are idiopathic
- may be due to monocular visual impairment (e.g. cataract, corneal scarring, anisometropia, retinoblastoma) or divergence insufficiency (ocular misalignment that is greater at distance fixation than at near fixation)

**Amblyopia**

**Definition**
- a neurodevelopmental visual disorder with unilateral (or less commonly, bilateral) reduction of best corrected visual acuity that cannot be attributed only and directly to the effect of a structural abnormality of the eye.
- it is caused by abnormal visual experience early in life and cannot be remedied immediately by spectacle glasses alone
- in approximately half of the cases, amblyopia is secondary to strabismus (mainly esotropia). Other causes may include uncorrected refractive errors, anisometropia (asymmetric refractive errors), and concomitant structural ocular problems

**Detection**
- “Holler Test”: young child upset if good eye is covered
- quantitative visual acuity by age 3-4 yr using picture charts and/or matching game (Sheridan-Gardiner), testing each eye separately
- amblyopia treatment less successful after age 8-10 yr, but a trial should be given no matter what age
- prognosis: 90% will have good vision restored and maintained if treated <4 yr old
Etiology and Management

- strabismus
  - correct with glasses for accommodative esotropia
  - occlusion therapy (see below)
  - surgery: recession (weakening) – moving muscle insertion further back on the globe; or resection (strengthening) – shortening the muscle
  - botulinum toxin for single muscle weakening
  - after ocular alignment is restored (glasses, surgery, botulinum toxin), patching is frequently necessary to maintain vision until ~8 yr of age

- anisometropia
  - amblyopia usually in the more hyperopic eye
  - the more emmetropic (normal refraction) eye receives a clear image while the less emmetropic eye receives a blurred image; input from the blurred eye is cortically suppressed and visual pathway fails to develop normally
  - treat with glasses to correct refractive error
  - patching is required if visual acuity difference persists after 4-8 wk of using glasses

- deprivation amblyopia
  - occlusion due to ptosis, cataract, retinoblastoma, corneal opacity
  - occlusion amblyopia: prolonged patching of good eye may cause it to become amblyopic

Occlusion Therapy

- patching the good eye to force the brain to use the non-dominant eye and redevelop its vision
- atropine cycloplegic drops to impair accommodation and blur vision of the better seeing eye

Risks

- permanent loss of vision in the affected eye
- possibility of injury to “remaining” good eye
- safety glasses or polycarbonate lenses recommended if visual acuity in worse eye is <20/50
- loss of stereopsis

Leukocoria

- white reflex (red reflex is absent)

Differential Diagnosis

- cataract
- retinoblastoma
- retinal coloboma
- ROP
- persistent hyperplastic primary vitreous or persistent fetal vasculature
- Coats’ disease (exudative retinal telangiectasis)
- toxocariasis
- RD

Retinoblastoma

- most common primary intraocular malignancy in children
- incidence: 1/15,000; sporadic or genetic transmission; screening of siblings/offspring essential
- unilateral (2/3) or bilateral (1/3)
- malignant – direct or hematogenous spread
- diagnosis
  - often presents with leukocoria or strabismus
  - U/S or CT scan may demonstrate calcified mass (present in most cases)

Treatment

- radiotherapy, chemotherapy combined with laser, cryopexy, and/or enucleation

Retinopathy of Prematurity

- vasoproliferative retinopathy that is a major cause of blindness in the developed world

Risk Factors

- non-black race (black infants have lower risk of developing ROP)
- low gestational age, birth weight <1500 g
- high oxygen exposure after birth (iatrogenic)

Classification (ROP Staging)

- stage 1: faint demarcation line at the junction between the vascularized and avascular retina
- stage 2: elevated ridge
• stage 3: extra-retinal fibrovascular tissue extending into vitreous
• stage 4: partial RD (4A: macula “on”, 4B: macula “off”)
• stage 5: total RD
• plus (+) disease: dilatation and tortuosity of retinal vessels
• threshold disease: stage 3+ in zones 1 or 2 with 5 continuous or 8 cumulative clock hours of ROP involvement

Treatment
• threshold disease is treated with cryotherapy or laser (laser is now the standard treatment, with better refractive outcome), off label anti-VEGF intravitreal injections
• ROP beyond threshold level is either watched carefully (usually stage 4A) or treated with vitrectomy/scleral buckle

Prognosis
• higher incidence of myopia among ROP infants, even if treated successfully
• stage 4B and 5 have poor prognosis for visual outcome despite treatment

Nasolacrimal System Defects
• congenital obstruction of the nasolacrimal duct (failure of canalization), usually occurs at 1-2 mo of age
• epiphora, crusting, discharge, recurrent conjunctivitis
• can have reflux of mucopurulent material from lacrimal punctum when pressure is applied over lacrimal sac

Treatment
• massage over lacrimal sac at medial corner of eyelid
• vast majority spontaneously resolve in 9-12 mo, otherwise consider referral for duct probing

Ophthalmia Neonatorum
• newborn conjunctivitis in first mo of life
• causes
  ▪ toxic: silver nitrate, erythromycin
  ▪ infectious: bacterial (e.g. N. gonorrhoeae – most common, C. trachomatis), herpes simplex virus
• diagnose using stains and cultures

Treatment
• systemic antibiotics with possible hospitalization if infectious etiology
• topical prophylaxis, most commonly with erythromycin (or silver nitrate), is required by law at birth

Congenital Glaucoma
• due to inadequate development of the filtering mechanism of the anterior chamber angle

Clinical Features
• cloudy cornea, increased IOP
• photophobia, epiphora
• buphthalmos (large cornea, “ox eye”, secondary to increased IOP), blepharospasm

Treatment
• filtration surgery is required soon after birth to prevent blindness

Ocular Trauma

Blunt Trauma
• caused by blunt object such as fist, squash ball
• history: injury, ocular history, drug allergy, tetanus status
• exam: VA first, pupil size and reaction, EOM (diplopia), external and slit-lamp exam, ophthalmoscopy
• if VA normal or slightly reduced, globe less likely to be perforated
• if VA reduced may be perforated globe, corneal abrasion, lens dislocation, retinal tear
• bone fractures
  ▪ blow out fracture: restricted EOM, diplopia, enophthalmos (sunken eye)
  ▪ ethmoid fracture: subcutaneous emphysema of lid
• lids: swelling, laceration, emphysema
• conjunctiva: subconjunctival hemorrhage
• cornea: abrasion – detect with fluorescein staining and cobalt blue filter using slit-lamp or ophthalmoscope

Refer if You Observe Any of These Signs
• Decreased VA
• Shallow anterior chamber
• Hyphema
• Abnormal pupil
• Ocular misalignment
• Retinal damage

Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity (ROP)
NEJM 2011;364:603-615
Study: Randomized controlled clinical trial.
Patients: 150 infants born at gestational age <30 wk and birth weight ≤1500 g.
Intervention: Randomized to conventional laser therapy or intravitreal bevacizumab monotherapy.
Main Outcome: Recurrence of ROP in one or both eyes requiring retreatment before 54 wk postmenstrual age.
Results: ROP recurrence was lower in the bevacizumab group (6 of 140 eyes [4%]) vs. the laser-therapy group (32 of 146 eyes [22%]) (p=0.002). A significant treatment effect was found for zone I ROP (p=0.003).
Conclusions: Intravitreal bevacizumab monotherapy is beneficial for infants with zone I state 3+ ROP and allows continued development of peripheral retinal vessels following treatment.

Gonococcal infection is the most serious threat to sight as it can rapidly penetrate corneal epithelium, causing corneal ulceration

Epiphora in children – rule out congenital glaucoma

Always test VA first – medicolegal protection
Penetrating Trauma

- include ruptured globe ± prolapsed iris, intraocular foreign body
- rule out intraocular foreign body, especially if history of “metal striking metal”, orbit CT

**OCULAR EMERGENCY:** initial management - REFER IMMEDIATELY
- ABCs
- don’t press on eye globe!
- don’t check IOP if possibility of globe rupture
- check vision, diplopia
- apply rigid eye shield to minimize further trauma
- keep head elevated 30-45° to keep IOP down
- keep NPO
- tetanus status
- give IV antibiotics
  - selecting appropriate agents depends on the mechanism of injury; Gram-positive bacteria are more commonly involved than Gram-negative; retained intraocular foreign objects increase the risk of infections with Bacillus species, whereas exposure to vegetable matter increase the risk of a fungal etiology

Hyphema

- blood in anterior chamber often due to damage to root of the iris
- may occur with blunt trauma

**Treatment**
- refer to ophthalmology
- shield and bedrest x 5 d or as determined by ophthalmologist
- sleep with head upright
- may need surgical drainage if hyphema persists or if re-bleed

**Complications**
- risk of re-bleed highest on days 2-5, resulting in secondary glaucoma, corneal staining, and iris necrosis
- never prescribe Aspirin®, as it increases the risk of a re-bleed

Blow-Out Fracture

- see **Plastic Surgery, PL31**
- blunt trauma causing fracture of orbital floor and herniation of orbital contents into maxillary sinus
- orbital rim remains intact
- inferior rectus and/or inferior oblique muscles may be incarcerated at fracture site
- infraorbital nerve courses along the floor of the orbit and may be damaged

**Clinical Features**
- pain and nausea at time of injury
- diplopia, restriction of EOM
- infraorbital and upper lip paresthesia (CN V2)
- enophthalmos (sunken eye), periorbital ecchymoses

**Investigations**
- plain films: Waters’ view and lateral
- CT: anteroposterior and coronal view of orbits

**Treatment**
- refrain from coughing, blowing nose
- systemic antibiotics may be indicated
- surgery if fracture >50% orbital floor, diplopia not improving, or enophthalmos >2 mm
- may delay surgery if the diplopia improves
Chemical Burns

- alkali burns have a worse prognosis than acid burns because acids coagulate tissue and inhibit further corneal penetration
- poor prognosis if cornea opaque, likely irreversible stromal damage
- even with a clear cornea initially, alkali burns can progress for weeks (thus, very guarded prognosis)

Treatment

- immediately irrigate at site of accident with water or buffered solution
  - IV drip for at least 20-30 min with eyelids retracted in emergency department
  - swab upper and lower fornices to remove possible particulate matter
- do not attempt to neutralize because the heat produced by the reaction will damage the cornea
- cycloplegic drops to decrease iris spasm (pain) and prevent secondary glaucoma (due to posterior synechiae formation)
- topical antibiotics and patching
- topical steroids (by ophthalmologist) to decrease inflammation, use for <2 wk (in the case of a persistent epithelial defect)

Table 10. Drugs with Ocular Toxicity

<table>
<thead>
<tr>
<th>Drug</th>
<th>Ocular toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amiodarone</td>
<td>Corneal microdeposits and superficial keratopathy (vortex keratopathy)</td>
</tr>
<tr>
<td></td>
<td>Rare: ischemic optic neuropathy</td>
</tr>
<tr>
<td>Atropine, benztropine</td>
<td>Pupillary dilation (risk of angle closure glaucoma)</td>
</tr>
<tr>
<td>Bisphosphonates</td>
<td>Inflammatory eye disease (iritis, scleritis, episcleritis)</td>
</tr>
<tr>
<td>Chloroquine, hydroxychloroquine</td>
<td>Bull’s eye maculopathy</td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>Anterior subcapsular cataract</td>
</tr>
<tr>
<td>Contraceptive pills</td>
<td>Decreased tolerance to contact lenses</td>
</tr>
<tr>
<td></td>
<td>Migraine</td>
</tr>
<tr>
<td></td>
<td>Optic neuritis</td>
</tr>
<tr>
<td></td>
<td>Central vein occlusion, benign increase intracranial pressure</td>
</tr>
<tr>
<td>Digitalis</td>
<td>Yellow vision</td>
</tr>
<tr>
<td></td>
<td>Blurred vision</td>
</tr>
<tr>
<td>Ethambutol</td>
<td>Optic neuropathy</td>
</tr>
<tr>
<td>Haloperidol (Haldol®)</td>
<td>Oculogyric crises</td>
</tr>
<tr>
<td>Indomethacin</td>
<td>Superficial keratopathy</td>
</tr>
<tr>
<td>Interferon</td>
<td>Retinal hemorrhages and cotton wool spots</td>
</tr>
<tr>
<td>Isoniazid</td>
<td>Optic neuropathy</td>
</tr>
<tr>
<td>Nalidixic acid</td>
<td>Papilledema</td>
</tr>
<tr>
<td>Steroids</td>
<td>Posterior subcapsular cataracts</td>
</tr>
<tr>
<td></td>
<td>Glaucoma</td>
</tr>
<tr>
<td></td>
<td>Papilledema (systemic steroids)</td>
</tr>
<tr>
<td></td>
<td>Increased severity of HSV infections (geographic ulcers)</td>
</tr>
<tr>
<td></td>
<td>Predisposition to fungal infections</td>
</tr>
<tr>
<td>Sulphonamides, NSAIDs</td>
<td>Stevens-Johnson syndrome</td>
</tr>
<tr>
<td>Tamsulosin (Flomax®)</td>
<td>Intraoperative Floppy Iris Syndrome, which can complicate cataract surgery</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>Papilledema (associated with pseudotumour cerebri)</td>
</tr>
<tr>
<td>Thioridazine</td>
<td>Pigmentary degeneration of retina</td>
</tr>
<tr>
<td>Vigabatin</td>
<td>Retinal deposition with macular sparing, peripheral visual field loss</td>
</tr>
<tr>
<td>Vitamin A toxicity</td>
<td>Papilledema</td>
</tr>
<tr>
<td>Vitamin D toxicity</td>
<td>Band keratopathy</td>
</tr>
</tbody>
</table>
TOPICAL OCULAR DIAGNOSTIC DRUGS

Fluorescein Dye
- water soluble orange-yellow dye
- green under cobalt blue light (ophthalmoscope or slit-lamp)
- absorbed in areas of epithelial loss (ulcer or abrasion)
- also stains mucus and contact lenses

Rose Bengal Stain
- stains devitalized epithelial cells and mucus

Anesthetics
- e.g. proparacaine HCl 0.5%, tetracaine 0.5%
- indications: removal of foreign body and sutures, tonometry, examination of painful cornea
- toxic to corneal epithelium (inhibit mitosis and migration) and can lead to corneal ulceration and scarring with prolonged use, therefore NEVER prescribe

Mydriatics
- dilate pupils
- two classes
  - cholinergic blocking (e.g. tropicamide – Mydriacyl®)
    - dilation plus cycloplegia (loss of accommodation) by paralysis of iris sphincter and the ciliary body
    - indications: refraction, ophthalmoscopy, therapy for iritis
  - adrenergic stimulating (e.g. phenylephrine HCl 2.5%)
    - stimulate pupillary dilator muscles, no effect on accommodation
    - usually used with tropicamide for additive effects
    - side effects: HTN, tachycardia, arrhythmias

Table 11. Mydriatic Cycloplegic Drugs and Duration of Action

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Duration of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tropicamide (Mydriacyl®) 0.5%, 1%</td>
<td>4-5 h</td>
</tr>
<tr>
<td>Cyclopentolate HCl 0.5%, 1%</td>
<td>3-6 h</td>
</tr>
<tr>
<td>Homatropine HBr 1%, 2%</td>
<td>3-7 d</td>
</tr>
<tr>
<td>Atropine sulfate 0.5%, 1%</td>
<td>1-2 wk</td>
</tr>
<tr>
<td>Scopolamine HBr 0.25%, 5%</td>
<td>1-2 wk</td>
</tr>
</tbody>
</table>

GLAUCOMA MEDICATIONS

Table 12. Glaucoma Medications

<table>
<thead>
<tr>
<th>Drug Category</th>
<th>Dose</th>
<th>Effect</th>
<th>Comment/Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-Agonist</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2. Selective: ↓ aqueous production + ↑ uveoscleral outflow</td>
<td></td>
</tr>
<tr>
<td>β-Blocker</td>
<td></td>
<td>↓ aqueous production</td>
<td></td>
</tr>
<tr>
<td>Non-selective</td>
<td>1 gtt OS/OD qp/bid</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bronchospasm (caution in asthma/COPD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑ CHF; Bradycardia, hypotension; depression, heart block, impotence</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carbonic Anhydrase Inhibitor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 gtt OS/OD tid</td>
<td>↓ aqueous production</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diamox®; 500 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PD bid</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Must ask about sulfa allergy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Generally local side effects with topical preparations</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Oral: diuresis, fatigue, paresthesias, GI upset, etc.</td>
</tr>
<tr>
<td>Parasympathomimetic (cholinergic stimulating)</td>
<td>1-2 gtt OS/OD tid/qd</td>
<td>↑ TM outflow</td>
<td>Miosis; ↓ night vision; ↑ GI motility, brow ache, headache; ↑ heart rate</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostaglandin Analogues</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 gtt OS/OD qhs</td>
<td>↑ uveoscleral outflow</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(uveoscleral responsible for 20% of drainage)</td>
<td>Iris colour change; Periorbital skin pigmentation; Lash growth; Conjunctival hyperemia</td>
</tr>
</tbody>
</table>

*timolol* + dorzolamide; Xalacom® = timolol + latanoprost; Cosopt® = timolol + brimonidine; Duotray® = timolol + travaprost; gtt = drop, gtt's = drops
WET AGE-RELATED MACULAR DEGENERATION MEDICATIONS

VEGF Inhibitors
- block VEGF which prevents ocular angiogenesis and further development of choroidal neovascularization
- administered via intravitreal injections
- pegaptanib (Macugen®) is a selective anti-VEGF targeting VEGF isoform 165 (no longer widely used)
- ranibizumab (Lucentis®) is a non-selective anti-VEGF agent
- aflibercept (Eylea®) is a VEGF "trap" agent that binds VEGF-A and placental growth factor
- bevacizumab (Avastin®) is another non-selective anti-VEGF agent but is only FDA approved for metastatic breast cancer, colorectal cancer, and non-small cell lung cancer; therefore, its widespread ophthalmologic use is off-label

TOPICAL OCULAR THERAPEUTIC DRUGS

NSAIDs
- used for less serious chronic inflammatory conditions
- e.g. ketorolac (Acular®), diclofenac (Voltaren®), nepafenac (Nevanac®) drops

Anti-Histamines
- used to relieve red and itchy eye, often in combination with decongestants
- sodium cromoglycate – stabilizes membranes

Decongestants
- weak adrenergic stimulating drugs (vasoconstrictor)
- e.g. naphazoline, phenylephrine (Isoprin®)
- rebound vasodilation with overuse; rarely can precipitate angle closure glaucoma

Antibiotics
- indications: bacterial conjunctivitis, keratitis, or blepharitis
- commonly as topical drops or ointments, may give systemically
- e.g. sulfonamide (sodium sulfacetamide, sulfisoxazole), gentamicin (Garamycin®), erythromycin, tetracycline, bacitracin, polymyxin B, fluoroquinolones (ciprofloxacin [Ciloxan®], ofloxacin [Ocuflox®], moxifloxacin [Vigamox®], gatifloxacin [Zymar®])

Corticosteroids
- e.g. fluorometholone (FML®), betamethasone, dexamethasone (Maxidex®), prednisolone (Predsol® 0.5%, Pred Forte® 1%), rimexolone (Vexol®), loteprednol etabonate 0.5% (Lotamax®), difluprednate (Durezol®)
- primary care physicians should avoid prescribing topical corticosteroids due to risk of glaucoma, cataracts, and reactivation of HSV keratitis
- complications
  - potentiates HSV keratitis and fungal keratitis as well as masks symptoms
  - increased IOP, more rapidly in steroid responders (within weeks)
  - posterior subcapsular cataract (within months)
References


<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acronyms</td>
<td>2</td>
</tr>
<tr>
<td>Basic Anatomy Review</td>
<td>2</td>
</tr>
<tr>
<td>Fractures – General Principles</td>
<td>4</td>
</tr>
<tr>
<td>Fracture Description</td>
<td></td>
</tr>
<tr>
<td>Approach to Fractures</td>
<td></td>
</tr>
<tr>
<td>Fracture Healing</td>
<td></td>
</tr>
<tr>
<td>General Fracture Complications</td>
<td></td>
</tr>
<tr>
<td>Articular Cartilage</td>
<td>6</td>
</tr>
<tr>
<td>Orthopedic X-Ray Imaging</td>
<td>7</td>
</tr>
<tr>
<td>Orthopedic Emergencies</td>
<td>8</td>
</tr>
<tr>
<td>Trauma Patient Workup</td>
<td></td>
</tr>
<tr>
<td>Open Fractures</td>
<td></td>
</tr>
<tr>
<td>Cauda Equina Syndrome</td>
<td></td>
</tr>
<tr>
<td>Compartment Syndrome</td>
<td></td>
</tr>
<tr>
<td>Osteomyelitis</td>
<td></td>
</tr>
<tr>
<td>Septic Joint</td>
<td></td>
</tr>
<tr>
<td>Shoulder</td>
<td>10</td>
</tr>
<tr>
<td>Shoulder Dislocation</td>
<td></td>
</tr>
<tr>
<td>Rotator Cuff Disease</td>
<td></td>
</tr>
<tr>
<td>Acromioclavicular Joint Pathology</td>
<td></td>
</tr>
<tr>
<td>Clavicle Fracture</td>
<td></td>
</tr>
<tr>
<td>Frozen Shoulder (Adhesive Capsulitis)</td>
<td></td>
</tr>
<tr>
<td>Humerus</td>
<td>15</td>
</tr>
<tr>
<td>Proximal Humeral Fracture</td>
<td></td>
</tr>
<tr>
<td>Humeral Shaft Fracture</td>
<td></td>
</tr>
<tr>
<td>Distal Humeral Fracture</td>
<td></td>
</tr>
<tr>
<td>Elbow</td>
<td>17</td>
</tr>
<tr>
<td>Supracondylar Fracture</td>
<td></td>
</tr>
<tr>
<td>Radial Head Fracture</td>
<td></td>
</tr>
<tr>
<td>Olecranon Fracture</td>
<td></td>
</tr>
<tr>
<td>Elbow Dislocation</td>
<td></td>
</tr>
<tr>
<td>Epicondylitis</td>
<td></td>
</tr>
<tr>
<td>Forearm</td>
<td>19</td>
</tr>
<tr>
<td>Radius and Ulna Shaft Fractures</td>
<td></td>
</tr>
<tr>
<td>Monteggia Fracture</td>
<td></td>
</tr>
<tr>
<td>Nightstick Fracture</td>
<td></td>
</tr>
<tr>
<td>Galeazzi Fracture</td>
<td></td>
</tr>
<tr>
<td>Wrist</td>
<td>20</td>
</tr>
<tr>
<td>Colles’ Fracture</td>
<td></td>
</tr>
<tr>
<td>Smith’s Fracture</td>
<td></td>
</tr>
<tr>
<td>Complications of Wrist Fractures</td>
<td></td>
</tr>
<tr>
<td>Scaphoid Fracture</td>
<td></td>
</tr>
<tr>
<td>Hand</td>
<td>PL22</td>
</tr>
<tr>
<td>Spine</td>
<td>22</td>
</tr>
<tr>
<td>Fractures of the Spine</td>
<td></td>
</tr>
<tr>
<td>Cervical Spine</td>
<td></td>
</tr>
<tr>
<td>Thoracolumbar Spine</td>
<td></td>
</tr>
<tr>
<td>Pelvis</td>
<td>26</td>
</tr>
<tr>
<td>Pelvic Fracture</td>
<td></td>
</tr>
<tr>
<td>Hip</td>
<td>27</td>
</tr>
<tr>
<td>Hip Dislocation</td>
<td></td>
</tr>
<tr>
<td>Hip Fracture</td>
<td></td>
</tr>
<tr>
<td>Arthritis of the Hip</td>
<td></td>
</tr>
<tr>
<td>Hip Dislocation Post-Total Hip Arthroplasty</td>
<td></td>
</tr>
<tr>
<td>Femur</td>
<td>30</td>
</tr>
<tr>
<td>Femoral Diaphysis Fracture</td>
<td></td>
</tr>
<tr>
<td>Distal Femoral Fracture</td>
<td></td>
</tr>
<tr>
<td>Knee</td>
<td>31</td>
</tr>
<tr>
<td>Evaluation of Knee</td>
<td></td>
</tr>
<tr>
<td>Cruciate Ligament Tears</td>
<td></td>
</tr>
<tr>
<td>Collateral Ligament Tears</td>
<td></td>
</tr>
<tr>
<td>Meniscal Tears</td>
<td></td>
</tr>
<tr>
<td>Quadriceps/Patellar Tendon Rupture</td>
<td></td>
</tr>
<tr>
<td>Dislocated Knee</td>
<td></td>
</tr>
<tr>
<td>Patella</td>
<td>34</td>
</tr>
<tr>
<td>Patellar Fracture</td>
<td></td>
</tr>
<tr>
<td>Patellar Dislocation</td>
<td></td>
</tr>
<tr>
<td>Patellofemoral Syndrome (Chondromalacia Patellae)</td>
<td></td>
</tr>
<tr>
<td>Tibia</td>
<td>36</td>
</tr>
<tr>
<td>Tibial Plateau Fracture</td>
<td></td>
</tr>
<tr>
<td>Tibial Shaft Fracture</td>
<td></td>
</tr>
<tr>
<td>Ankle</td>
<td>37</td>
</tr>
<tr>
<td>Evaluation of Ankle and Foot Complaints</td>
<td></td>
</tr>
<tr>
<td>Ankle Fracture</td>
<td></td>
</tr>
<tr>
<td>Ankle Ligamentous Injuries</td>
<td></td>
</tr>
<tr>
<td>Foot</td>
<td>38</td>
</tr>
<tr>
<td>Talar Fracture</td>
<td></td>
</tr>
<tr>
<td>Calcaneal Fracture</td>
<td></td>
</tr>
<tr>
<td>Achilles Tendonitis</td>
<td></td>
</tr>
<tr>
<td>Achilles Tendon Rupture</td>
<td></td>
</tr>
<tr>
<td>Plantar Fasciitis (Heel Spur Syndrome)</td>
<td></td>
</tr>
<tr>
<td>Bunions (Hallux Valgus)</td>
<td></td>
</tr>
<tr>
<td>Metatarsal Fracture</td>
<td></td>
</tr>
<tr>
<td>Pediatric Orthopedics</td>
<td>41</td>
</tr>
<tr>
<td>Fractures in Children</td>
<td></td>
</tr>
<tr>
<td>Stress Fractures</td>
<td></td>
</tr>
<tr>
<td>Epiphyseal Injury</td>
<td></td>
</tr>
<tr>
<td>Slipped Capital Femoral Epiphysis</td>
<td></td>
</tr>
<tr>
<td>Developmental Dysplasia of the Hip</td>
<td></td>
</tr>
<tr>
<td>Legg-Calvé-Perthes Disease (Coxa Plana)</td>
<td></td>
</tr>
<tr>
<td>Osgood-Schlatter Disease</td>
<td></td>
</tr>
<tr>
<td>Congenital Talipes Equinovarus (Club Foot)</td>
<td></td>
</tr>
<tr>
<td>Scoliosis</td>
<td></td>
</tr>
<tr>
<td>Bone Tumours</td>
<td>45</td>
</tr>
<tr>
<td>Benign Active Bone Tumours</td>
<td></td>
</tr>
<tr>
<td>Benign Aggressive Bone Tumours</td>
<td></td>
</tr>
<tr>
<td>Malignant Bone Tumours</td>
<td></td>
</tr>
<tr>
<td>Common Medications</td>
<td>48</td>
</tr>
<tr>
<td>References</td>
<td>49</td>
</tr>
</tbody>
</table>
### Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABI</td>
<td>ankle brachial index</td>
</tr>
<tr>
<td>AC</td>
<td>acromioclavicular</td>
</tr>
<tr>
<td>ACL</td>
<td>anterior cruciate ligament</td>
</tr>
<tr>
<td>AN</td>
<td>anterior interosseous nerve</td>
</tr>
<tr>
<td>AP</td>
<td>anterior posterior</td>
</tr>
<tr>
<td>ARDS</td>
<td>acute respiratory distress syndrome</td>
</tr>
<tr>
<td>AVN</td>
<td>avascular necrosis</td>
</tr>
<tr>
<td>CA</td>
<td>coracoacromial</td>
</tr>
<tr>
<td>CC</td>
<td>coracoclavicular</td>
</tr>
<tr>
<td>CRPS</td>
<td>complex regional pain syndrome</td>
</tr>
<tr>
<td>DDH</td>
<td>developmental dysplasia of the hip</td>
</tr>
<tr>
<td>DRIJ</td>
<td>distal radioulnar joint</td>
</tr>
<tr>
<td>DVT</td>
<td>deep vein thrombosis</td>
</tr>
<tr>
<td>EDH</td>
<td>ethanol/alcohol</td>
</tr>
<tr>
<td>FAI</td>
<td>femoroacetabular impingement</td>
</tr>
<tr>
<td>FODSH</td>
<td>fall on outstretched hand</td>
</tr>
<tr>
<td>GA</td>
<td>general anesthetic</td>
</tr>
<tr>
<td>HD</td>
<td>heterotopic ossification</td>
</tr>
<tr>
<td>IgD</td>
<td>incision and drainage</td>
</tr>
<tr>
<td>IM</td>
<td>intramedullary</td>
</tr>
<tr>
<td>LCL</td>
<td>lateral collateral ligament</td>
</tr>
<tr>
<td>MCL</td>
<td>medial collateral ligament</td>
</tr>
<tr>
<td>MT</td>
<td>metatarsal</td>
</tr>
<tr>
<td>MTP</td>
<td>metatarsophalangeal</td>
</tr>
<tr>
<td>MVC</td>
<td>motor vehicle collision</td>
</tr>
<tr>
<td>NVS</td>
<td>neurovascular status</td>
</tr>
<tr>
<td>NVB</td>
<td>non-weight bearing</td>
</tr>
<tr>
<td>OA</td>
<td>osteoarthritis</td>
</tr>
<tr>
<td>ORIF</td>
<td>open reduction internal fixation</td>
</tr>
<tr>
<td>PCL</td>
<td>posterior cruciate ligament</td>
</tr>
<tr>
<td>PIN</td>
<td>posterior interosseous nerve</td>
</tr>
<tr>
<td>RA</td>
<td>rheumatoid arthritis</td>
</tr>
<tr>
<td>ROM</td>
<td>range of motion</td>
</tr>
<tr>
<td>RSD</td>
<td>reflex sympathetic dystrophy</td>
</tr>
<tr>
<td>SCFE</td>
<td>slipped capital femoral epiphysis</td>
</tr>
<tr>
<td>SLAP</td>
<td>superior lateral, anterior posterior</td>
</tr>
<tr>
<td>SN</td>
<td>sensitivity</td>
</tr>
<tr>
<td>TKA</td>
<td>total knee arthroplasty</td>
</tr>
<tr>
<td>TSA</td>
<td>total shoulder arthroplasty</td>
</tr>
<tr>
<td>WB</td>
<td>weight bearing</td>
</tr>
<tr>
<td>#</td>
<td>fracture</td>
</tr>
</tbody>
</table>

### Basic Anatomy Review

**Figure 1. Median, musculocutaneous, and ulnar nerves: innervation of upper limb muscles**

© Lori Waters 2005
**Basic Anatomy Review**

**Toronto Notes 2017**

**Figure 2.** (Left) Blood supply to the upper limb, (Right) Axillary and radial nerves: innervation of the upper limb

**Table 1. Sensory and Motor Innervation of the Nerves in the Upper and Lower Extremities**

<table>
<thead>
<tr>
<th>Nerve</th>
<th>Motor</th>
<th>Sensory</th>
<th>Nerve Roots</th>
</tr>
</thead>
<tbody>
<tr>
<td>Axillary</td>
<td>Deltoid/Teres Minor</td>
<td>Lateral Upper Arm (Sergeant’s Patch)</td>
<td>C5, C6</td>
</tr>
<tr>
<td>Musculocutaneous</td>
<td>Biceps/Brachialis</td>
<td>Lateral Forearm</td>
<td>C5, C6</td>
</tr>
<tr>
<td>Radial</td>
<td>Triceps</td>
<td>Lateral Dorsum of the Hand</td>
<td>T5, C6, C7, C8</td>
</tr>
<tr>
<td>Median</td>
<td>Wrist Flexors and Abductors</td>
<td>Volar Thumb to Radial half of 4th Digit</td>
<td>C6, C7</td>
</tr>
<tr>
<td>Ulnar</td>
<td>Wrist Flexors and Adductors</td>
<td>Medial Forearm Medial Dorsum and Volar of Hand</td>
<td>C8, T1</td>
</tr>
<tr>
<td>Tibial</td>
<td>Ankle Plantar Flexion Knee Flexion</td>
<td>Sole of Foot</td>
<td>L5, S1</td>
</tr>
<tr>
<td>Superficial Peroneal</td>
<td>Ankle Eversion</td>
<td>Dorsum of Foot</td>
<td>L5, S1</td>
</tr>
<tr>
<td>Deep Peroneal</td>
<td>Ankle Dorsiflexion and Inversion</td>
<td>1st Web Space</td>
<td>L5, S1</td>
</tr>
<tr>
<td>Sural</td>
<td></td>
<td>Lateral Foot</td>
<td>S1, S2</td>
</tr>
<tr>
<td>Saphenous</td>
<td></td>
<td>Anteromedial Ankle</td>
<td>L3, L4</td>
</tr>
</tbody>
</table>
Fractures – General Principles

Fracture Description

1. Name of Injured Bone

2. Integrity of Skin/Soft Tissue
   - closed: skin/soft tissue over and near fracture is intact
   - open: skin/soft tissue over and near fracture is lacerated or abraded, fracture exposed to outside (or contaminated - such as the bowel) environment, or contaminated (i.e. bowel)
   - signs: continuous bleeding from puncture site or fat droplets in blood are suggestive of an open fracture

3. Location (Figure 5)
   - epiphysseal: end of bone, forming part of the adjacent joint
   - metaphysseal: the flared portion of the bone at the ends of the shaft
   - diaphysseal: the shaft of a long bone (proximal, middle, distal)
   - physis: growth plate
4. Orientation/Fracture Pattern
- transverse: fracture line perpendicular (<30° of angulation) to long axis of bone; result of direct high energy force
- oblique: angular fracture line (30°-60° of angulation); result of angular or rotational force
- butterfly: fracture site fragment which looks like a butterfly
- segmental: a separate segment of bone bordered by fracture lines; result of high energy force
- spiral: complex, multi-planar fracture line; result of rotational force; low energy
- comminuted-multi-fragmentary: >2 fracture fragments
- intra-articular: fracture line crosses articular cartilage and enters joint
- avulsion: tendon or ligament tears/pulls off bone fragment; often in children, high energy
- compression/impacted: impaction of bone; typical sites are vertebrae or proximal tibia
- torus: a buckle fracture of one cortex, often in children (see Figure 50, OR41)
- greenstick: an incomplete fracture of one cortex, often in children (see Figure 50, OR41)
- pathologic: fracture through bone weakened by disease/tumor

5. Alignment of Fracture Fragments
- nondisplaced: fracture fragments are in anatomic alignment
- displaced: fracture fragments are not in anatomic alignment
- distracted: fracture fragments are separated by a gap (opposite of impacted)
- impacted: fracture fragments are compressed, resulting in shortened bone
- angulated: direction of fracture apex (e.g. varus/valgus)
- translated/shifted: percentage of overlapping bone at fracture site
- rotated: fracture fragment rotated about long axis of bone

---

### Approach to Fractures

1. Clinical Assessment
   - ABCs, primary survey and secondary survey (ATLS protocol)
     - rule out other fractures/injuries
     - rule out open fracture
   - AMPLE history (minimum): Allergies, Medications, Past medical history, Last meal, Events surrounding injury
     - mechanism of injury
     - previous significant injury or surgery to affected area
     - consider pathologic fracture with history of only minor trauma
   - physical exam: look (deformity, soft tissue integrity); feel (maximal tenderness, NVS-document best possible neurovascular exam, avoid ROM/moving injured area to prevent exacerbation)

2. Analgesia
3. Imaging (see Orthopedic X-Ray Imaging, OR7)
4. Splint Extremity
5. Management: Closed vs. Open Reduction
   1. obtain the reduction (for appropriate IV sedation see Table 27, OR48)
     - closed reduction
       - apply traction in the long axis of the limb
       - reverse the mechanism that produced the fracture
       - reduce with IV sedation and muscle relaxation (fluoroscopy can be used if available)
     - indications for open reduction
       - "NO CAST"
       - other indications include
         - failed closed reduction
         - not able to cast or apply traction due to site (e.g. hip fracture)
         - pathologic fractures
         - potential for improved function with ORIF
     - ALWAYS re-check and document NVS after reduction and obtain post-reduction x-ray
2. maintain the reduction
   - external stabilization: splints, casts, traction, external fixator
   - internal stabilization: percutaneous pinning, extramedullary fixation (screws, plates, wires), IM fixation (rods)
   - follow-up: evaluate bone healing
3. rehabilitate to regain function and avoid joint stiffness

## Fracture Healing

### Normal Healing

| Weeks 0-3 | Hematoma, macrophages surround fracture site |
| Weeks 3-6 | Osteoclasts remove sharp edges, callus forms within hematoma |
| Weeks 6-12 | Bone forms within the callus, bridging fragments |
| Months 6-12 | Cortical gap is bridged by bone |
| Years 1-2 | Normal architecture is achieved through remodelling |

Figure 6. Stages of bone healing

### Evaluation of Healing: Tests of Union

- clinical: no longer tender to palpation or stressing on physical exam
- x-ray: trabeculae cross fracture site, visible callus bridging site on at least 3 of 4 cortices

### General Fracture Complications

<table>
<thead>
<tr>
<th>Early</th>
<th>Late</th>
</tr>
</thead>
<tbody>
<tr>
<td>Local</td>
<td></td>
</tr>
<tr>
<td>Compartment syndrome</td>
<td>Mal-/non-union</td>
</tr>
<tr>
<td>Neurological injury</td>
<td>AVN</td>
</tr>
<tr>
<td>Vascular injury</td>
<td>Osteomyelitis</td>
</tr>
<tr>
<td>Infection</td>
<td>HD</td>
</tr>
<tr>
<td>Implant failure</td>
<td>Post-traumatic OA</td>
</tr>
<tr>
<td>Fracture blisters</td>
<td>Joint stiffness/adhesive capsulitis</td>
</tr>
<tr>
<td>Systemic</td>
<td>CRPS type I/RSD</td>
</tr>
<tr>
<td>Sepsis</td>
<td></td>
</tr>
<tr>
<td>DVT</td>
<td></td>
</tr>
<tr>
<td>PE</td>
<td></td>
</tr>
<tr>
<td>ARDS secondary to fat embolism</td>
<td></td>
</tr>
<tr>
<td>Hemorrhagic shock</td>
<td></td>
</tr>
</tbody>
</table>

## Articular Cartilage

### Properties

- 2-4 mm layer covering ends of articulating bones, provides nearly frictionless surface
- avascular (nutrition from synovial fluid), aneural, alymphatic

### ARTICULAR CARTILAGE DEFECTS

#### Etiology

- overt trauma, repetitive minor trauma (such as repetitive ankle sprains or patellar maltracking); common sports injury
- degenerative conditions such as early stage OA or osteochondritis dissecans

#### Clinical Features

- similar to symptoms of OA (joint line pain with possible effusion, etc.)
- often have predisposing factors, such as ligament injury, malalignment of the joint (varus/valgus), obesity, bone deficiency (AVN, osteochondritis dissecans, ganglion bone cysts), inflammatory arthropathy, and familial osteoarthropathy
- may have symptoms of locking or catching related to the torn/displaced cartilage

#### Investigations

- x-ray (to rule out bony defects and check alignment)
- MRI
- diagnostic arthroscopy (treatment is often guided by what is seen during arthroscopy)
Table 3. Outerbridge Classification of Chondral Defects

<table>
<thead>
<tr>
<th>Grade</th>
<th>Chondral Damage</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Softening and swelling of cartilage</td>
</tr>
<tr>
<td>II</td>
<td>Fragmentation and fissuring &lt;1/2” in diameter</td>
</tr>
<tr>
<td>III</td>
<td>Fragmentation and fissuring &gt;1/2” in diameter</td>
</tr>
<tr>
<td>IV</td>
<td>Erosion of cartilage down to bone</td>
</tr>
</tbody>
</table>

Treatment
- Individualized
  - Patient factors (age, skeletal maturity, activity level, etc.)
  - Defect factors (Outerbridge Classification, subchondral bone involvement, etc.)
- Non-operative
  - Rest, NSAIDs, bracing
- Operative
  - Microfracture, osteochondral grafting (autograft or allograft), autologous chondrocyte implantation

Orthopedic X-Ray Imaging

General Principles
- X-ray 1 joint above and 1 below
- Obtain at least 2 orthogonal views ± specialized views

Table 4. Orthopedic X-Ray Imaging

<table>
<thead>
<tr>
<th>Site</th>
<th>Injury</th>
<th>X-Ray Views</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shoulder</td>
<td>Anterior dislocation</td>
<td>AP</td>
</tr>
<tr>
<td></td>
<td>Posterior dislocation</td>
<td>Axillary ± stress view with 10 lb in hand</td>
</tr>
<tr>
<td></td>
<td>AC</td>
<td>Trans-scapular</td>
</tr>
<tr>
<td></td>
<td>Frozen shoulder</td>
<td>Zanca view (10-15 cephalic tilt)</td>
</tr>
<tr>
<td>Arm</td>
<td>Humerus #</td>
<td>AP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lateral</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trans-scapular</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Axillary</td>
</tr>
<tr>
<td>Elbow/Forearm</td>
<td>Supracondylar #</td>
<td>AP</td>
</tr>
<tr>
<td></td>
<td>Radial head #</td>
<td>Lateral</td>
</tr>
<tr>
<td></td>
<td>Monteggia #</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Night stick #</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Galeazzi #</td>
<td></td>
</tr>
<tr>
<td>Wrist</td>
<td>Colles’ #</td>
<td>AP</td>
</tr>
<tr>
<td></td>
<td>Smith #</td>
<td>Lateral</td>
</tr>
<tr>
<td></td>
<td>Scaphoid #</td>
<td>Scaphoid (wrist extension and ulnar deviation x 2 wk)</td>
</tr>
<tr>
<td>Pelvis</td>
<td>Pelvic #</td>
<td>AP pelvis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inlet and outlet views</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Judet views (obturator and iliac oblique for acetabular #)</td>
</tr>
<tr>
<td>Hip</td>
<td>Femoral head/neck #</td>
<td>AP</td>
</tr>
<tr>
<td></td>
<td>Intertrochanteric #</td>
<td>Lateral</td>
</tr>
<tr>
<td></td>
<td>Arthritis</td>
<td>Frog-leg lateral</td>
</tr>
<tr>
<td></td>
<td>SCFE</td>
<td>Dunn</td>
</tr>
<tr>
<td></td>
<td>FAI</td>
<td></td>
</tr>
<tr>
<td>Knee</td>
<td>Knee dislocation</td>
<td>AP standing, lateral</td>
</tr>
<tr>
<td></td>
<td>Femur/tibia #</td>
<td>Skyline – tangential view with knees flexed at 45° to see patellofemoral joint</td>
</tr>
<tr>
<td></td>
<td>Patella #</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patella dislocation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patella femoral syndrome</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tibia shaft #</td>
<td></td>
</tr>
<tr>
<td>Ankle</td>
<td>Ankle #</td>
<td>AP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lateral</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mortise view: ankle at 15° of internal rotation</td>
</tr>
<tr>
<td>Foot</td>
<td>Talar #</td>
<td>AP</td>
</tr>
<tr>
<td></td>
<td>Calcanial #</td>
<td>Lateral Harris Axial</td>
</tr>
<tr>
<td>Spine</td>
<td>Compression #</td>
<td>AP spine</td>
</tr>
<tr>
<td></td>
<td>Burst #</td>
<td>AP odontoid</td>
</tr>
<tr>
<td></td>
<td>Cervical spine #</td>
<td>Lateral</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oblique</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Swimmer’s view: lateral view with arm abducted 180° to evaluate C7-T1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>spine flexion/extension view: evaluate subluxation of cervical vertebrae</td>
</tr>
</tbody>
</table>
Orthopedic Emergencies

Trauma Patient Workup

Etiology
- high energy trauma e.g. MVC, fall from height
- may be associated with spinal injuries or life-threatening visceral injuries

Clinical Features
- local swelling, tenderness, deformity of the limbs, and instability of the pelvis or spine
- decreased level of consciousness, hypotension/hypovolemic shock
- consider involvement of EtOH or other substances

Investigations
- trauma survey (see Emergency Medicine. ER7, ER15)
- x-rays: lateral cervical spine, AP chest, AP pelvis, AP and lateral of all bones suspected to be injured
- CT: is also utilized to inspect for musculoskeletal injuries in the trauma setting
- other views of pelvis: AP, inlet, and outlet; Judet views for acetabular fracture (for Classification of Pelvic Fractures see Table 18, OR27)

Treatment
- ABCDEs and initiate resuscitation for life threatening injuries
- assess genitourinary injury (rectal exam/vaginal exam mandatory)
- external or internal fixation of all fractures
- DVT prophylaxis

Complications
- hemorrhage – life threatening (may produce signs and symptoms of hypovolemic shock)
- fat embolism syndrome (SOB, hypoxemia, petechial rash, thrombocytopenia, and neurological symptoms)
- venous thrombosis – DVT and PE
- bladder/urethral/bowel injury
- neurological damage
- persistent pain/stiffness/limp/weakness in affected extremities
- post-traumatic OA of joints with intra-articular fractures
- sepsis if missed open fracture

Open Fractures

- fractured bone and hematoma in communication with the external or contaminated environment

Emergency Measures
- ABCs, primary survey and resuscitation as needed
- removal of obvious foreign material
- irrigate with normal saline if grossly contaminated
- cover wound with sterile dressings
- immediate IV antibiotics
- tetanus toxoid or immunoglobulin as needed
- immediate IV antibiotics
- removal of obvious foreign material
- NPO and prepare for OR (blood work, consent, ECG, CXR)
  - operative irrigation and debridement within 6-8 h to decrease risk of infection
  - traumatic wound often left open to drain but vacuum-assisted closure dressing may be used
  - re-examine with repeat irrigation and debridement in 48 h

Table 5. Gustilo Classification of Open Fractures

<table>
<thead>
<tr>
<th>Gustilo Grade</th>
<th>Length of Open Wound</th>
<th>Description</th>
<th>Prophylactic Antibiotic Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>&lt;1 cm</td>
<td>Minimal contamination and soft tissue injury Simple or minimally comminuted fracture</td>
<td>First generation cephalosporin (cefazolin) for 3 d If allergy use floroquinolone If MRSA positive use vancomycin</td>
</tr>
<tr>
<td>II</td>
<td>1-10 cm</td>
<td>Moderate contamination Moderate soft tissue injury</td>
<td>As per Grade I</td>
</tr>
<tr>
<td>III*</td>
<td>&gt; 10 cm</td>
<td>IIIA: Extensive soft tissue injury with adequate ability of soft tissue to cover wound IIIB: Extensive soft tissue injury with periosteal stripping and bone exposure; inadequate soft tissue to cover wound IIIC: Vascular injury/compromise</td>
<td>First generation cephalosporin (cefazolin) for 3 d plus Gram-negative coverage (gentamicin) for at least 3 d For soil contamination, penicillin is added for clostridial coverage</td>
</tr>
</tbody>
</table>

*Any high energy, comminuted fracture, shot gun, farmyard/soil/water contamination, exposure to oral flora, or fracture >8 h old is immediately classified as Grade III

Antibiotics for Preventing Infection in Open Limb Fractures

Cochrane DB Syst Rev 2004:1:CD003764

Purpose: To review the evidence regarding the effectiveness of antibiotics in the initial treatment of open fractures of the limbs.

Methods: Rando(zized or quasi randomized controlled trials comparing antibiotic treatment with placebo or no treatment in preventing acute wound infection were identified and reviewed. Data were extracted and pooled for analysis.

Results: Eight studies (n=1,106) were reviewed. The use of antibiotics had a protective effect against early infection compared with no antibiotics or placebo (RRR=0.43, 95% CI 0.29, 0.65, ARR=0.07, 95% CI 0.03=0.10).

Conclusions: Antibiotics reduce the incidence of early infections in open fractures of the limbs.
Cauda Equina Syndrome

- see Neurosurgery, NS26

Compartment Syndrome

- increased interstitial pressure in an anatomical compartment (forearm, calf) where muscle and tissue are bounded by fascia and bone (fibro-osseous compartment) with little room for expansion
- interstitial pressure exceeds capillary perfusion pressure leading to muscle necrosis (in 4-6 h) and eventually nerve necrosis

Etiology

- intracompartmental: fracture (particularly tibial shaft or paediatric supracondylar and forearm fractures)
  - Reperfusion injury, crush injury or ischemia
- extracompartmental: constrictive dressing (circumferential cast), poor position during surgery, circumferential burn

Clinical Features

- pain out of proportion to injury (typically first symptom)
- pain with active contraction of compartment
- pain with passive stretch (most sensitive)
- swollen, tense compartment
- suspicious history
- 5 Ps: late sign – do not wait for these to develop to make the diagnosis!

Investigations

- usually not necessary as compartment syndrome is a clinical diagnosis
- in children or unconscious patients where clinical exam is unreliable, compartment pressure monitoring with catheter AFTER clinical diagnosis is made (normal = 0 mmHg; elevated ≥30 mmHg or [measured pressure – dBP] ≤30 mmHg)

Treatment

- non-operative
  - remove constrictive dressings (casts, splints), elevate limb at the level of the heart
- operative
  - urgent fasciotomy
  - 48-72 h post-operative: wound closure ± necrotic tissue debridement

Complications

- Volkmann’s ischemic contracture: ischemic necrosis of muscle, followed by secondary fibrosis and finally calcification; especially following supracondylar fracture of humerus
- rhabdomyolysis, renal failure secondary to myoglobinuria

Osteomyelitis

- bone infection with progressive inflammatory destruction

Etiology

- most commonly caused by Staphylococcus aureus
- mechanism of spread: hematogenous (most common) vs. direct-inoculation vs. contiguous focus
- risk factors: recent trauma/surgery, immunocompromised patients, DM, IV drug use, poor vascular supply, peripheral neuropathy

Plain Film Findings of Osteomyelitis

- Soft tissue swelling
- Lytic bone destruction
- Periosteal reaction (formation of new bone, especially in response to #)*
- *Generally not seen on plain films until 10-12 d after onset of infection

*Increased pressure in an anatomical compartment (forearm, calf) where muscle and tissue are bounded by fascia and bone (fibro-osseous compartment) with little room for expansion.
Clinical Features
• symptoms: pain and fever
• on exam: erythema, tenderness, edema common ± abscess/draining sinus tract; impaired function/WB

Diagnosis
• see Medical Imaging, MI23
• workup includes: WBC and diff, ESR, CRP, blood culture, aspirate culture/bone biopsy

Table 6. Treatment of Osteomyelitis

<table>
<thead>
<tr>
<th>Acute Osteomyelitis</th>
<th>Chronic Osteomyelitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV antibiotics 4-6 wk; started empirically and adjusted after obtaining blood and aspirate cultures ± surgery (I&amp;D) for abscess or significant involvement ± hardware removal (if present)</td>
<td>Surgical debridement Antibiotics: both local (e.g. antibiotic beads) and systemic (IV)</td>
</tr>
</tbody>
</table>

Septic Joint

• joint infection with progressive destruction if left untreated

Etiology
• most commonly caused by Staphylococcus aureus in adults
• consider coagulase-negative Staphylococcus in patients with prior joint replacement
• consider Neisseria gonorrhoeae in sexually active adults and newborns
• most common route of infection is hematogenous
• risk factors: young/elderly (age >80 yr), RA, prosthetic joint, recent joint surgery, skin infection/ulcer, IV drug use, previous intra-articular corticosteroid injection, immune compromise (cancer, DM, alcoholism)

Clinical Features
• inability/refusal to bear weight, localized joint pain, erythema, warmth, swelling, pain on active and passive ROM, ± fever

Investigations
• x-ray (to rule out fracture, tumour, metabolic bone disease), ESR, CRP, WBC, blood cultures
• joint aspirate: cloudy yellow fluid, WBC >50,000 with >90% neutrophils, protein level >4.4 mg/dL, joint glucose level < 60% blood glucose level, no crystals, positive Gram stain results
• listen for heart murmur (to reduce suspicion of infective endocarditis, use Duke Criteria)

Treatment
• IV antibiotics, empiric therapy (based on age and risk factors), adjust following joint aspirate C&S results
• non-operative
  • therapeutic joint aspiration, serially if necessary (if early diagnosis and joint superficial)
  • operative
  • arthroscopic/open irrigation and irrigation and drainage ± decompression

Shoulder

Shoulder Dislocation

• complete separation of the glenohumeral joint; may be anterior or posterior

Investigations
• anterior dislocation x-rays (AP, trans-scapular, axillary views)
• posterior dislocation x-rays (AP, trans-scapular, axillary) or CT scan
Table 7. Anterior and Posterior Shoulder Dislocation

<table>
<thead>
<tr>
<th>MECHANISM</th>
<th>Anterior Shoulder Dislocation (&gt;90%)</th>
<th>Posterior Shoulder Dislocation (5%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abducted arm is externally rotated/hyperextended, or blow to posterior shoulder</td>
<td>Adducted, internally rotated, flexed arm</td>
<td></td>
</tr>
<tr>
<td>Involuntary, usually traumatic; voluntary, atraumatic</td>
<td>FOOSH</td>
<td></td>
</tr>
<tr>
<td>3 Es (epileptic seizure, ErOH, electrocution)</td>
<td>Blow to anterior shoulder</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CLINICAL FEATURES</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>Pain, arm slightly abducted and externally rotated with inability to internally rotate</td>
</tr>
<tr>
<td>Shoulder Exam</td>
<td>“Squared off” shoulder</td>
</tr>
<tr>
<td>Positive apprehension test: patient looks apprehensive with gentle shoulder abduction and external rotation to 90° since humeral head is pushed anteriorly and recreates feeling of anterior dislocation (see Figure 13)</td>
<td></td>
</tr>
<tr>
<td>Positive relocation test: a posteriorly directed force applied during the apprehension test elicits apprehension since anterior subluxation is prevented</td>
<td></td>
</tr>
<tr>
<td>Positive sulcus sign: presence of subacromial indentation with distal traction on humerus indicates inferior shoulder instability (see Figure 13)</td>
<td></td>
</tr>
<tr>
<td>Neurovascular Exam Including</td>
<td></td>
</tr>
<tr>
<td>Axillary nerve: sensory patch over deltoid and deltoid contraction</td>
<td>Full neurovascular exam as per anterior shoulder dislocation</td>
</tr>
<tr>
<td>Musculocutaneous nerve: sensory patch on lateral forearm and biceps contraction</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RADIOGRAPHIC FINDINGS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Axillary View</td>
<td>Humeral head is anterior</td>
</tr>
<tr>
<td>Humeral head is posterior</td>
<td></td>
</tr>
<tr>
<td>Trans-scapular Y View</td>
<td>Humeral head is anterior to centre of “Mercedes-Benz” sign</td>
</tr>
<tr>
<td>Humeral head is posterior to centre of “Mercedes-Benz” sign</td>
<td></td>
</tr>
<tr>
<td>AP View</td>
<td>Sub-coracoid lie of the humeral head is most common</td>
</tr>
<tr>
<td>Partial vacancy of glenoid fossa (vacant glenoid sign) and &gt;6 mm space between anterior glenoid rim and humeral head (positive rim sign), humeral head may resemble a light bulb due to internal rotation (light bulb sign)</td>
<td></td>
</tr>
<tr>
<td>Hill-Sachs and Bony Bankart Lesions</td>
<td>± Hill-Sachs lesion: compression fracture of posterior humeral head due to forceful impact on an anteriorly dislocated humeral head against the glenoid rim (see Figure 12)</td>
</tr>
<tr>
<td>± bony Bankart lesion: avulsion of the anterior glenoid labrum (with attached bone fragments) from the glenoid rim (see Figure 12)</td>
<td></td>
</tr>
<tr>
<td>± reverse Hill-Sachs lesion (75% of cases): divot in anterior humeral head</td>
<td></td>
</tr>
<tr>
<td>± reverse bony Bankart lesion: avulsion of the posterior glenoid labrum from the bony glenoid rim</td>
<td></td>
</tr>
</tbody>
</table>

| TREATMENT | |
| Closed reduction with IV sedation and muscle relaxation |
| Traction-countertraction: assistant stabilizes torso with a folded sheet wrapped across the chest while the surgeon applies gentle steady traction |
| Stimson: while patient lies prone with arm hanging over table edge, hang a 5 lb weight on wrist for 15-20 min |
| Hippocratic method: place heel into patient’s axilla and apply traction to arm |
| Cunningham’s method: low risk, low pain; if not successful try above methods |
| Obtain post-reduction x-rays |
| Check post-reduction NVS |
| sling in abduction and external rotation x 3 wk, followed by shoulder rehabilitation (dynamic stabilizer strengthening) |
| Closed reduction with sedation and muscle relaxation |
| Inferior traction on a flexed elbow with pressure on the back of the humeral head |
| Obtain post-reduction x-rays |
| Check post-reduction NVS |
| Sling x 3 wk (avoid abduction and external rotation), followed by shoulder rehabilitation (dynamic stabilizer strengthening) |

Prognosis
- recurrence rate depends on age of first dislocation |
- <20 yr = 65-95%; 20-40 yr = 60-70%; >40 yr = 2-4% |

Specific Complications
- rotator cuff or capsular or labral tear (Bankart/SLAP lesion), shoulder stiffness |
- injury to axillary nerve/artery, brachial plexus |
- recurrent/unreduced dislocation (most common complication)
Rotator Cuff Disease

- rotator cuff consists of 4 muscles that act to stabilize humeral head within the glenoid fossa

Table 8. Rotator Cuff Muscles (SITS)

<table>
<thead>
<tr>
<th>Muscle</th>
<th>Proximal</th>
<th>Muscle Attachments</th>
<th>Nerve Supply</th>
<th>Muscle Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supraspinatus</td>
<td>Scapula</td>
<td>Greater tuberosity of humerus</td>
<td>Supraspinacu nerve</td>
<td>Abduction</td>
</tr>
<tr>
<td>Infraspinatus</td>
<td>Scapula</td>
<td>Greater tuberosity of humerus</td>
<td>Supraspinacu nerve</td>
<td>External rotation</td>
</tr>
<tr>
<td>Teres Minor</td>
<td>Scapula</td>
<td>Greater tuberosity of humerus</td>
<td>Axillary nerve</td>
<td>External rotation</td>
</tr>
<tr>
<td>Subscapularis</td>
<td>Scapula</td>
<td>Lesser tuberosity of humerus</td>
<td>Subscapular nerve</td>
<td>Internal rotation and adduction</td>
</tr>
</tbody>
</table>

SPECTRUM OF DISEASE: IMPINGEMENT, TENDONITIS, MICRO OR MACRO TEARS

Etiology
- anything that leads to a narrow subacromial space
- most commonly, a relative imbalance of rotator cuff and larger shoulder muscles allowing for superior translation and subsequent wear of the rotator cuff muscle tendons
  - glenohumeral muscle weakness leading to abnormal motion of humeral head
  - scapular muscle weakness leading to abnormal motion of acromion
  - acromial abnormalities such as congenital narrow space or osteophyte formation or Type III acromion morphology
  1. outlet/subacromial impingement: “painful arc syndrome”, compression of rotator cuff tendons (primarily supraspinatus) and subacromial bursa between the head of the humerus and the undersurface of acromion, AC joint, and CA ligament
  2. bursitis and tendinitis
  3. rotator cuff thinning and tear if left untreated

Clinical Features
- insidious onset, but may present as an acute exacerbation of chronic disease, night pain and difficulty sleeping on affected side
- pain worse with active motion (especially overhead); passive movement generally permitted
- weakness and loss of ROM especially between 90°~130° (e.g. trouble with overhead activities)
- tenderness to palpation over greater tuberosity
- rule out bicep tendinosis: Speed test; SLAP lesion: O’Brien’s test

Investigations
- x-ray: AP view may show high riding humerus relative to glenoid indicating large tear, evidence of chronic tendinitis
- MRI: coronal/sagittal oblique and axial orientations are useful for assessing full/partial tears and tendinopathy ± arthrogram: geyser sign (injected dye leaks out of joint through rotator cuff tear)
- arthrogram: can assess full thickness tears, difficult to assess partial tears

Returning to the bedside: Using the history and physical examination to identify rotator cuff tears

<table>
<thead>
<tr>
<th>Bigliani Classification of Acromion Morphology</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Type I – flat</td>
</tr>
<tr>
<td>• Type II – curved</td>
</tr>
<tr>
<td>• Type III – hooked</td>
</tr>
</tbody>
</table>

Screening Out Rotator Cuff Tears
- No night pain (SN 97.7%)                    |
- No painful arc (SN 97.5%)                   |
- No impingement signs (SN 97.2%)             |
- No weakness

© Lori Waters 2005
© Andreea Margineanu 2012

Figure 12. Shoulder maneuvers

Figure 13. Muscles of the rotator cuff
Treatment
- non-operative
  - for mild ("wear") or moderate ("tear") cases
  - physiotherapy, NSAIDs ± steroid injection
- operative
  - indication: severe ("repair")
  - impingement that is refractory to 2-3 mo physiotherapy and 1-2 corticosteroid injections
  - arthroscopic or open surgical repair (i.e. acromioplasty, rotator cuff repair)

**Table 9. Rotator Cuff Special Tests**

<table>
<thead>
<tr>
<th>Test</th>
<th>Examination</th>
<th>Positive Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jobe’s Test</td>
<td>Supraspinatus: place the shoulder in 90° of abduction and 30° of forward flexion and internally rotate the arm so that the thumb is pointing toward the floor</td>
<td>Weakness with active resistance suggests a supraspinatus tear</td>
</tr>
<tr>
<td>Lift-off Test</td>
<td>Subscapularis: internally rotate arm so dorsal surface of hand rests on lower back; patient instructed to actively lift hand away from back against examiner resistance (use Belly Press Test if too painful)</td>
<td>Inability to actively lift hand away from back suggests a subscapularis tear</td>
</tr>
<tr>
<td>Posterior-Cuff Test</td>
<td>Infraspinatus and teres minor: arm positioned at patient’s side in 90° of flexion; patient instructed to externally rotate arm against the resistance of the examiner</td>
<td>Weakness with active resistance suggests posterior cuff tear</td>
</tr>
<tr>
<td>Neer’s Test</td>
<td>Rotator cuff impingement: passive shoulder flexion</td>
<td>Pain elicited between 130-170° suggests impingement</td>
</tr>
<tr>
<td>Hawkins-Kennedy Test</td>
<td>Rotator cuff impingement: shoulder flexion to 90° and passive internal rotation</td>
<td>Pain with internal rotation suggests impingement</td>
</tr>
<tr>
<td>Painful Arc Test</td>
<td>Rotator cuff tendinopathy: patient instructed to actively abduct the shoulder</td>
<td>Pain with abduction &gt; 90° suggests tendinopathy</td>
</tr>
<tr>
<td>Speed’s Test</td>
<td>Apply resistance to the forearm when the arm is in forward flexion with the elbows fully extended.</td>
<td>Pain in the bicipital groove</td>
</tr>
<tr>
<td>O’Brien’s Test</td>
<td>SLAP lesion: forward flexion of the arm to 90 degrees while keeping the arm extended. Arm is adducted 10-15 degrees. Internally rotate the arm so thumb is facing down and apply a downward force. Repeat the test with arm externally rotated</td>
<td>Pain or clicking in the glenohumeral joint in internal rotation but not external rotation</td>
</tr>
</tbody>
</table>

**Figure 14. Rotator Cuff tests**
Acromioclavicular Joint Pathology

- subluxation or dislocation of AC joint
- 2 main ligaments attach clavicle to scapula: AC and CC ligaments

Mechanism
- fall onto shoulder with adducted arm or direct trauma to point of shoulder

Clinical Features
- pain with adduction of shoulder and/or palpation over AC joint
- palpate step deformity between distal clavicle and acromion (with dislocation)
- limited ROM

Investigations
- x-rays: bilateral AP, Zanca view (10-15° cephalic tilt), axillary

Treatment
- non-operative
  - sling 1-3 wk, ice, analgesia, early ROM and rehabilitation
- operative
  - indication: Rockwood Class IV-VI (III if labourer or high level athlete)
  - number of different approaches involving AC/CC ligament reconstruction or screw/hook plate insertion

<table>
<thead>
<tr>
<th>Grade</th>
<th>Features</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Joint sprain, absence of complete tear of either ligament</td>
<td>Non-operative</td>
</tr>
<tr>
<td>II</td>
<td>Complete tear of AC ligament, incomplete tear of CC ligament, without marked elevation of lateral clavicular head</td>
<td>Non-operative</td>
</tr>
</tbody>
</table>
| III   | Complete tear of AC and CC ligaments, >5 mm elevation at AC joint, superior aspect of acromion is below the inferior aspect of the clavicle | Most non-operative, operative if labourer or high level athlete

Will heal with step deformity, although most fully functional in 4-6 mo

| IV-VI | Based on the anatomical structure the displaced clavicle is in proximity with | Operative in most cases |

Clavicle Fracture

- incidence: proximal (5%), middle (80%), or distal (15%) third of clavicle
- common in children (unites rapidly without complications)

Mechanism
- fall on shoulder (87%), direct trauma to clavicle (7%), FOOSH (6%)

Clinical Features
- pain and tenting of skin
- arm is clasped to chest to splint shoulder and prevent movement

Investigations
- evaluate NVS of entire upper limb
- x-ray: AP, 45° cephalic tilt (superior/inferior displacement), 45° caudal tilt (AP displacement)
- CT: useful for medial physeal fractures and sternoclavicular injury

Treatment
- medial and middle third clavicle fractures
- simple sling x 1-2 wk
- early ROM and strengthening once pain subsides
- if fracture is shortened >2 cm consider ORIF
- distal third clavicle fractures
- undisplaced (with ligaments intact): sling x 1-2 wk
- displaced (CC ligament injury): ORIF

Specific Complications (see General Fracture Complications, OR6)
- cosmetic bump usually only complication
- shoulder stiffness, weakness with repetitive activity
- pneumothorax, brachial plexus injuries, and subclavian vessel (all very rare)
**Frozen Shoulder (Adhesive Capsulitis)**

- disorder characterized by progressive pain and stiffness of the shoulder usually resolving spontaneously after 18 mo

**Mechanism**
- primary adhesive capsulitis
  - idiopathic, usually associated with DM
  - usually resolves spontaneously in 9-18 mo
- secondary adhesive capsulitis
  - due to prolonged immobilization
  - shoulder-hand syndrome: CRPS/RSD characterized by arm and shoulder pain, decreased motion, and diffuse swelling
  - following MI, stroke, shoulder trauma
  - poorer outcomes

**Clinical Features**
- gradual onset (weeks to months) of diffuse shoulder pain with:
  - decreased active AND passive ROM
  - pain worse at night and often prevents sleeping on affected side
  - increased stiffness as pain subsides: continues for 6-12 mo after pain has disappeared

**Investigations**
- x-ray: AP (neutral, internal/external rotation), scapular Y, axillary
  - may be normal, or may show demineralization from disease

**Treatment**
- freezing phase
  - active and passive ROM (physiotherapy)
    - NSAIDs and steroid injections if limited by pain
  - thawing phase
    - manipulation under anesthesia and early physiotherapy
    - arthroscopy for debridement/decompression

**Humerus**

**Proximal Humeral Fracture**

**Mechanism**
- young: high energy trauma (MVC)
- elderly: FOOSH from standing height in osteoporotic individuals

**Clinical Features**
- proximal humeral tenderness, deformity with severe fracture, swelling, painful ROM, bruising extends down arm and chest

**Investigations**
- test axillary nerve function (deltoid contraction and skin over deltoid)
- x-rays: AP, trans-scapular, axillary are essential
- CT scan: to evaluate for articular involvement and fracture displacement

**Classification**
- Neer classification is based on 4 fracture locations or ‘parts’
- displaced: displacement >1 cm and/or angulation >45°
- the Neer system regards the number of displaced fractures, not the fracture line, in determining classification
- ± dislocated/subluxed: humeral head dislocated/subluxed from glenoid

**Treatment**
- treat osteoporosis if needed
- non-operative
  - nondisplaced: broad arm sling immobilization, begin ROM within 14 d to prevent stiffness
  - minimally displaced (85% of patients) - closed reduction with sling immobilization x 2 wk, gentle ROM
- operative
  - ORIF (anatomic neck fractures, displaced, associated dislocated glenohumeral joint)
  - hemiarthroplasty or reverse TSA may be necessary, especially in elderly

**Specific Complications (see General Fracture Complications, OR6)**
- AVN, nerve palsy (45%; typically axillary nerve), malunion, post-traumatic arthritis

**Conditions Associated with an Increased Incidence of Adhesive Capsulitis**
- Prolonged immobilization (most significant)
- Female gender
- Age >60 yr
- DM (fix)
- Cervical disc disease
- Hyperthyroidism
- Stroke
- MI
- Trauma and surgery
- Autoimmune disease

**Stages of Adhesive Capsulitis**
1. Freezing phase: gradual onset, diffuse pain (lasts 6-9 mo)
2. Freezing phase: decreased ROM impacting functioning (lasts 4-9 mo)
3. Thawing phase: gradual return of motion (lasts 5-26 mo)

**Neer Classification**
- Based on 4 parts of humerus
  - Greater Tuberosity
  - Lesser Tuberosity
  - Humeral Head
  - Shaft
- One-part fracture: any of the 4 parts with none displaced
- Two-part fracture: any of the 4 parts with 1 displaced
- Three-part fracture: displaced fracture of surgical neck + displaced greater tuberosity or lesser tuberosity
- Four-part fracture: displaced fracture of surgical neck + both tuberosities

**Anatomic neck fractures** disrupt blood supply to the humeral head and AVN of the humeral head may ensue
Humeral Shaft Fracture

Mechanism
• high energy: direct blows/MVC (especially young); low energy: FOOSH, twisting injuries, metastases (in elderly)

Clinical Features
• pain, swelling, weakness ± shortening, motion/crepitus at fracture site
• must test radial nerve function before and after treatment: look for drop wrist, sensory impairment dorsum of hand

Investigations
• x-ray: AP and lateral radiographs of the humerus including the shoulder and elbow joints

Treatment
• in general, humeral shaft fractures are treated non-operatively
• non-operative
  ▪ ± reduction; can accept deformity due to compensatory ROM of shoulder
  ▪ hanging cast (weight of arm in cast provides traction across fracture site) with collar and cuff sling immobilization until swelling subsides, then Sarmiento functional brace, followed by ROM
• operative
  ▪ indications: see “NO CAST” (OR5), pathological fracture, “floating elbow” (simultaneous unstable humeral and forearm fractures)
  ▪ ORIF: plating (most common), IM rod insertion, external fixation

Specific Complications (see General Fracture Complications, OR6)
• radial nerve palsy: expect spontaneous recovery in 3-4 mo, otherwise send for EMG
• non-union: most frequently seen in middle 1/3
• decreased ROM
• compartment syndrome

Distal Humeral Fracture

Mechanism
• young: high energy trauma (MVC)
• elderly: FOOSH

Clinical Features
• elbow pain and swelling
• assess brachial artery

Investigations
• x-ray: AP and lateral of humerus and elbow
• CT scan: helpful when suspect shear fracture of capitulum or trochlea

Classification
• supracondylar, distal single column, distal bicondylar and coronal shear fractures

Treatment
• goal is to restore ROM 30-130° flexion (unsatisfactory outcomes in 25%)
• non-operative
  ▪ cast immobilization (in supination for lateral condyle fracture; pronation for medial condyle fractures)
• operative
  ▪ indications: displaced, supracondylar, bicondylar
  ▪ closed reduction and percutaneous pinning; ORIF; total elbow arthroplasty (bicondylar in elderly)
Elbow

Supracondylar Fracture

• subclass of distal humerus fracture: extra-articular, fracture proximal to capitulum and trochlea, usually transverse
• most common in pediatric population (peak age ~7 yr old), rarely seen in adults
• AIN (median nerve) injury commonly associated with extension type

Mechanism
• >96% are extension injuries via FOOSH (e.g. fall off monkey bars); <4% are flexion injuries

Clinical Features
• pain, swelling, point tenderness
• neurovascular injury: assess median and radial nerves, radial artery (check radial pulse)

Investigations
• x-ray: AP, lateral of elbow
  ■ disruption of anterior humeral line suggests supracondylar fracture
  ■ fat pad sign: a sign of effusion and can be indicative of occult fracture

Treatment
• reduction indications: evidence of arterial obstruction, unacceptable angulation, displaced (>50%)
• non-operative
  ■ nondisplaced: long arm plaster slab in 90° flexion x 3 wk
• operative
  ■ indications: displaced, vascular injury, open fracture
  ■ requires percutaneous pinning followed by limb cast with elbow flexed <90o
  ■ in adults, ORIF is necessary

Specific Complications (see General Fracture Complications, OR6)
• stiffness is most common
• brachial artery injury (kinking can occur if displaced fracture), median or ulnar nerve injury, compartment syndrome (leads to Volkmann’s ischemic contracture), malalignment cubitus varus (distal fragment tilted into varus)

Radial Head Fracture

• a common fracture of the upper limb in young adults

Mechanism
• FOOSH with elbow extended and forearm pronated

Clinical Features
• marked local tenderness on palpation over radial head (lateral elbow)
• decreased ROM at elbow, ± mechanical block to forearm pronation and supination
• pain on pronation/supination

Investigations
• x-ray: enlarged anterior fat pad ("sail sign") or the presence of a posterior fat pad indicates effusion which could occur with occult radial head fractures

Table 11. Classification and Treatment of Radial Head Fractures

<table>
<thead>
<tr>
<th>Mason Class</th>
<th>Radiographic Description</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Nondisplaced fracture</td>
<td>Elbow slab or sling x 3-5 d with early ROM</td>
</tr>
<tr>
<td>2</td>
<td>Displaced fracture</td>
<td>ORIF if: angulation &gt;30°, involves ≥1/3 of the radial head, or if ≥3 mm of joint incongruity exists</td>
</tr>
<tr>
<td>3</td>
<td>Comminuted fracture</td>
<td>Radial head excision ± prosthesis (if ORIF not feasible)</td>
</tr>
<tr>
<td>4</td>
<td>Comminuted fracture with posterior elbow dislocation</td>
<td>Radial head excision ± prosthesis</td>
</tr>
</tbody>
</table>

Specific Complications (see General Fracture Complications, OR6)
• myositis ossificans – calcification of muscle
• recurrent instability (if MCL injured and radial head excised)
Olecranon Fracture

Mechanism
• direct trauma to posterior aspect of elbow (fall onto the point of the elbow) or FOOSH

Clinical Features
• localized pain, palpable defect
• ± loss of active extension due to avulsion of triceps tendon

Investigations
• x-ray: AP and lateral (require true lateral to determine fracture pattern)

Treatment
• non-operative
  • non-displaced (<2 mm, stable): cast x 3 wk (elbow in 90° flexion) then gentle ROM
• operative
  • displaced: ORIF (plate and screws or tension band wiring) and early ROM if stable

Elbow Dislocation

• third most common joint dislocation after shoulder and patella
• anterior capsule and collateral ligaments disrupted

Mechanism
• elbow hyperextension via FOOSH or valgus/supination stress during elbow flexion
• usually the radius and ulna are dislocated together, or the radius head dislocates and the ulna remains (“Monteggia”)
• 80% are posterior/posterolateral, anterior are rare and usually devastating

Clinical Features
• elbow pain, swelling, deformity
• flexion contracture
• ± absent radial or ulnar pulses

Investigations
• x-ray: AP and lateral views

Treatment
• assess NVS before reduction: brachial artery, median and ulnar nerves (can become entrapped during manipulation)
• non-operative
  • closed reduction under conscious sedation (post-reduction x-rays required)
  • Parvin’s method: patient lies prone with arm hanging down; apply gentle traction downwards on wrist, as olecranon slips distally, gently lift up the arm at elbow to reduce joint
  • long-arm splint with forearm in neutral rotation and elbow in 90° flexion
• early ROM (<2 wk)
• operative
  • indications: complex dislocation or persistent instability after closed reduction
  • ORIF

Specific Complications (see General Fracture Complications, OR6)
• stiffness (loss of extension), intra-articular loose body, neurovascular injury (ulnar nerve, median nerve, brachial artery), radial head fracture
• recurrent instability uncommon

Epicondylitis

• lateral epicondylitis = “tennis elbow”, inflammation of the common extensor tendon as it inserts into the lateral epicondyle
• medial epicondylitis = “golfer’s elbow”, inflammation of the common flexor tendon as it inserts into the medial epicondyle

Mechanism
• repeated or sustained contraction of the forearm muscles/chronic overuse

Clinical Features
• point tenderness over humeral epicondyle and/or distal to it
• pain upon resisted wrist extension (lateral epicondylitis) or wrist flexion (medial epicondylitis)
• generally a self-limited condition, but may take 6-18 mo to resolve
Forearm

Radius and Ulna Shaft Fractures

Mechanism
- high energy direct or indirect (MVA, fall from height, sports) trauma
- fractures usually accompanied by displacement due to high force

Clinical Features
- deformity, pain, swelling
- loss of function in hand and forearm

Investigations
- x-ray: AP and lateral of forearm ± oblique of elbow and wrist
- CT if fracture is close to joint

Treatment
- goal is anatomic reduction since imperfect alignment significantly limits forearm pronation and supination
- ORIF with plates and screws; closed reduction with immobilization usually yields poor results for displaced forearm fractures (except in children)

Specific Complications (see General Fracture Complications, OR6)
- soft tissue contracture resulting in limited forearm rotation – surgical release of tissue may be warranted

Monteggia Fracture

- fracture of the proximal ulna with radial head dislocation and proximal radioulnar joint injury
- more common and better prognosis in the pediatric age group when compared to adults

Mechanism
- direct blow on the posterior aspect of the forearm
- hyperpronation
- fall on the hyperextended elbow

Clinical Features
- pain, swelling, decreased rotation of forearm ± palpable lump at the radial head
- ulna angled apex anterior and radial head dislocated anteriorly (rarely the reverse deformity occurs)

Investigations
- x-ray: AP, lateral elbow, wrist and forearm

Treatment
- adults: ORIF of ulna with indirect radius reduction in 90% of patients (ORIF of radius if unsuccessful)
- splint and early post-operative ROM if elbow completely stable, otherwise immobilization in plaster with elbow flexed for 6 wk
- pediatrics: attempt closed reduction and immobilization in plaster with elbow flexed for Bado Type I-III, surgery for Type IV

Specific Complications (see General Fracture Complications, OR6)
- PIN: most common nerve injury; observe for 3 mo as most resolve spontaneously
- radial head instability/redislocation
- radioulnar synostosis

Bado Type Classification of Monteggia Fractures
- Based on the direction of displacement of the dislocated radial head, generally the same direction as the apex of the ulnar fracture
- Type I: anterior dislocation of radial head and proximal/middle third ulnar fracture (60%)
- Type II: posterior dislocation of radial head and proximal/middle third ulnar fracture (15%)
- Type III: lateral dislocation of radial head and metaphyseal ulnar fracture (20%)
- Type IV – combined: proximal fracture of the ulna and radius, dislocation of the radial head in any direction (<5%)
**Nightstick Fracture**

- isolated fracture of ulna without dislocation of radial head

**Mechanism**
- direct blow to forearm (e.g. holding arm up to protect face)

**Treatment**
- non-operative
  - non-displaced
  - below elbow cast (x 10 d) followed by forearm brace (~8 wk)
- operative
  - displaced
  - ORIF if >50% shaft displacement or >10° angulation

**Galeazzi Fracture**

- fracture of the distal radial shaft with disruption of the DRUJ
  - most commonly in the distal 1/3 of radius near junction of metaphysis/diaphysis

**Mechanism**
- hand FOOSH with axial loading of pronated forearm or direct wrist trauma

**Clinical Features**
- pain, swelling, deformity and point tenderness at fracture site

**Investigations**
- x-ray: AP, lateral elbow, wrist and forearm
  - shortening of distal radius >5 mm relative to the distal ulna
  - widening of the DRUJ space on AP
  - dislocation of radius with respect to ulna on true lateral

**Treatment**
- all cases are operative
  - ORIF of radius; afterwards assess DRUJ stability by balloting distal ulna relative to distal radius
  - if DRUJ is stable and reducible, splint for 10-14 d with early ROM encouraged
  - if DRUJ is unstable, ORIF or percutaneous pinning with long arm cast in supination x 6 wk

**Wrist**

**Colles’ Fracture**

- extra-articular transverse distal radius fracture (~2 cm proximal to the radiocarpal joint) with dorsal displacement ± ulnar styloid fracture
  - most common fracture in those >40 yr, especially in women and those with osteoporotic bone

**Mechanism**
- FOOSH

**Clinical Features**
- “dinner fork” deformity
  - swelling, ecchymoses, tenderness

**Investigations**
- x-ray: AP and lateral wrist

**Treatment**
- goal is to restore radial height (13 mm), radial inclination (22°), volar tilt (11°) as well as DRUJ stability and useful forearm rotation
  - non-operative
    - closed reduction (think opposite of the deformity)
      - hematoma block (sterile prep and drape, local anesthetic injection directly into fracture site) or conscious sedation
      - closed reduction: 1) traction with extension (exaggerate injury), 2) traction with ulnar deviation, pronation, flexion (of distal fragment – not at wrist)
      - dorsal slab/below elbow cast for 5-6 wk
    - x-ray at 1 wk, 3 wk and at cessation of immobilization to ensure reduction is maintained
    - obtain post-reduction films immediately; repeat reduction if necessary

- displaced intra-articular fracture
- Comminuted
- Severe osteoporosis
- Dorsal angulation >5° or volar tilt >20°
- >5 mm radial shortening

**ORIF Colles’ Fracture if Post-Reduction Demonstrates**
- Radial shortening >3 mm or
- Dorsal tilt >10° or
- Intra-articular displacement/step-off >2 mm
• operative
  ■ indication: failed closed reduction, or loss of reduction
  ■ percutaneous pinning, external fixation or ORIF

**Smith’s Fracture**

• volar displacement of the distal radius (i.e. reverse Colles’ fracture)

**Mechanism**
• fall onto the back of the flexed hand

**Investigations**
• x-ray: AP and lateral wrist

**Treatement**
• usually unstable and needs ORIF
• if patient is poor operative candidate, may attempt non-operative treatment
  ■ closed reduction with hematoma block (reduction opposite of Colles’)
  ■ long-arm cast in supination x 6 wk

**Complications of Wrist Fractures**

• most common complications are poor grip strength, stiffness, and radial shortening
• distal radius fractures in individuals <40 yr of age are usually highly comminuted and are likely to require ORIF
• 80% have normal function in 6-12 mo

**Table 12. Early and Late Complications of Wrist Fractures**

<table>
<thead>
<tr>
<th>Early Complications</th>
<th>Late Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Difficult reduction</td>
<td>Malunion, radial shortening</td>
</tr>
<tr>
<td>Compartment syndrome</td>
<td>Painful wrist secondary to ulnar prominence</td>
</tr>
<tr>
<td>Extensor pollicis longus tendon rupture</td>
<td>Frozen shoulder (“shoulder-hand syndrome”)</td>
</tr>
<tr>
<td>Acute carpal tunnel syndrome</td>
<td>Post-traumatic arthritis</td>
</tr>
<tr>
<td>Finger swelling with venous block</td>
<td>Carpal tunnel syndrome</td>
</tr>
<tr>
<td>Complications of a tight cast/splint</td>
<td>CRPS/RSD</td>
</tr>
</tbody>
</table>

**Scaphoid Fracture**

**Epidemiology**
• common in young men; not common in children or in patients beyond middle age
• most common carpal bone injured
• may be associated with other carpal or wrist injuries (e.g. Colles’ fracture)

**Mechanism**
• FOOSH: impaction of scaphoid on distal radius, most commonly resulting in a transverse fracture through the waist (65%), distal (10%), or proximal (25%) scaphoid

**Clinical Features**
• pain with resisted pronation
• tenderness in the anatomical "snuff box", over scaphoid tubercle, and pain with long axis compression into scaphoid
• usually nondisplaced

**Investigations**
• x-ray: AP, lateral, scaphoid views with wrist extension and ulnar deviation
• ± CT or MRI
• bone scan rarely used
• note: a fracture may not be radiologically evident up to 2 wk after acute injury, so if a patient complains of wrist pain and has anatomical snuff box tenderness but a negative x-ray, treat as if positive for a scaphoid fracture and repeat x-ray 2 wk later to rule out a fracture; if x-ray still negative order CT or MRI

**Treatment**
• early treatment critical for improving outcomes
• non-operative
  ■ non-displaced (<1 mm displacement/<15° angulation): long-arm thumb spica cast x 4 wk then short arm cast until radiographic evidence of healing is seen (2-3 mo)
• operative
  ■ displaced: ORIF with headless/countersink compression screw is the mainstay treatment
Specific Complications (see General Fracture Complications, OR6)
• most common: non-union/mal-union (use bone graft from iliac crest or distal radius with fixation to heal)
• AVN of the proximal fragment
• delayed union (recommend surgical fixation)
• scaphoid nonunion advanced collapse (SNAC) – chronic nonunion leading to advanced collapse and arthritis of wrist

Prognosis
• proximal fifth fracture: AVN rate 100%; proximal third fracture: AVN rate 33%
• waist fractures have healing rates of 80-90%
• distal third fractures have healing rates close to 100%

Hand
• see Plastic Surgery, PL22

Spine

Fractures of the Spine
• see Neurosurgery, NS32

Cervical Spine

General Principles
• C1 (atlas): no vertebral body, no spinous process
• C2 (axis): odontoid = dens
• 7 cervical vertebrae; 8 cervical nerve roots
• nerve root exits above vertebra (i.e. C4 nerve root exits above C4 vertebra), C8 nerve root exits below C7 vertebra
• radiculopathy = impingement of nerve root
• myelopathy = impingement of spinal cord

Special Testing
• compression test: pressure on head worsens radicular pain
• distraction test: traction on head relieves radicular symptoms
• Valsalva test: Valsalva maneuver increases intrathecal pressure and causes radicular pain
Table 13. Cervical Radiculopathy/Neuropathy

<table>
<thead>
<tr>
<th>Root</th>
<th>C5</th>
<th>C6</th>
<th>C7</th>
<th>C8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Motor</td>
<td>Deltoid</td>
<td>Biceps Brachioradialis</td>
<td>Triceps Brachioradialis</td>
<td>Interossei Digital flexors</td>
</tr>
<tr>
<td>Sensory</td>
<td>Axillary nerve (patch over lateral deltoid)</td>
<td>Thumb</td>
<td>Index and middle finger</td>
<td>Ring and little finger</td>
</tr>
<tr>
<td>Reflex</td>
<td>Biceps Brachioradialis</td>
<td>Triceps</td>
<td>Finger jerk</td>
<td></td>
</tr>
</tbody>
</table>

X-Rays for C-Spine
- AP spine: alignment
- AP odontoid: atlantoaxial articulation
- lateral
  - vertebral alignment: posterior vertebral bodies should be aligned (translation >3.5 mm is abnormal)
  - angulation: between adjacent vertebral bodies (>11° is abnormal)
  - disc or facet joint widening
  - anterior soft tissue space (at C3 should be ≤3 mm; at C4 should be ≤8-10 mm)
- oblique: evaluate pedicles and intervertebral foramen
- ± swimmer's view: lateral view with arm abducted 180° to evaluate C7-T1 junction if lateral view is inadequate
- ± lateral flexion/extension view: evaluate subluxation of cervical vertebrae

Differential Diagnosis of C-Spine Pain
- neck muscle strain, cervical spondylosis, cervical stenosis, RA (spondylitis), traumatic injury, whiplash, myofascial pain syndrome

C-SPINE INJURY
- see Neurosurgery, NS31

Thoracolumbar Spine

General Principles
- spinal cord terminates at conus medullaris (L1/2)
- individual nerve roots exit below pedicle of vertebra (i.e. L4 nerve root exits below L4 pedicle)

Special Tests
- straight leg raise: passive lifting of leg (30-70°) reproduces radicular symptoms of pain radiating down posterior/lateral leg to knee ± into foot
- Lasegue maneuver: dorsiflexion of foot during straight leg raise makes symptoms worse or, if leg is less elevated, dorsiflexion will bring on symptoms
- femoral stretch test: with patient prone, flexing the knee of the affected side and passively extending the hip results in radicular symptoms of unilateral pain in anterior thigh

Table 14. Lumbar Radiculopathy/Neuropathy

<table>
<thead>
<tr>
<th>Root</th>
<th>L4</th>
<th>L5</th>
<th>S1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Motor</td>
<td>Quadriceps (knee extension + hip adduction)</td>
<td>Extensor hallucis longus</td>
<td>Peroneus longus + brevis (ankle eversion)</td>
</tr>
<tr>
<td>Sensory</td>
<td>Medial malleolus</td>
<td>1st dorsal web space and lateral leg</td>
<td>Lateral foot</td>
</tr>
<tr>
<td>Screening Test</td>
<td>Squat and Rise</td>
<td>Heel Walking</td>
<td>Walking on Toes</td>
</tr>
<tr>
<td>Reflex</td>
<td>Knee (patellar)</td>
<td>Medial hamstring*</td>
<td>Ankle (Achilles)</td>
</tr>
<tr>
<td>Test</td>
<td>Femoral stretch</td>
<td>Straight leg raise</td>
<td>Straight leg raise</td>
</tr>
</tbody>
</table>

Differential Diagnosis of Back Pain
1. mechanical or nerve compression (>90%)
   - degenerative (disc, facet, ligament)
   - peripheral nerve compression (disc herniation)
   - spinal stenosis (congenital, osteophyte, central disc)
   - cauda equina syndrome
2. others (<10%)
   - neoplastic (primary, metastatic, multiple myeloma)
   - infectious (osteomyelitis, TB)
   - metabolic (osteoporosis)
   - traumatic fracture (compression, distraction, translation, rotation)
   - spondyloarthropathies (ankylosing spondylitis)
   - referred (aorta, renal, ureter, pancreas)
DEGENERATIVE DISC DISEASE
• loss of vertebral disc height with age resulting in
  ■ bulging and tears of annulus fibrosus
  ■ change in alignment of facet joints
  ■ osteophyte formation

Mechanism
• compression over time with age

Clinical Features
• axial back pain without radicular symptoms
• pain worse with axial loading and flexion
• negative straight leg raise

Investigations
• x-ray, MRI, provocative discography

Treatment
• non-operative
  ■ staying active with modified activity
  ■ back strengthening
  ■ NSAIDs
  ■ do not treat with opioids; no proven efficacy of spinal traction or manipulation
• operative – rarely indicated
  ■ decompression ± fusion
  ■ no difference in outcome between non-operative and surgical management at 2 yr

SPINAL STENOSIS
• narrowing of spinal canal <10 mm
• congenital (idiopathic, osteopetrosis, achondroplasia) or acquired (degenerative, iatrogenic – post spinal surgery, ankylosing spondylosis, Paget’s disease, trauma)

Clinical Features
• ± bilateral back and leg pain
• neurogenic claudication
• ± motor weakness
• normal back flexion; difficulty with back extension (Kemp sign)
• positive Straight leg raise, pain not worse with Valsalva

Investigations
• CT/MRI reveals narrowing of spinal canal, but gold standard = CT myelogram

Treatment
• non-operative
  ■ vigorous physiotherapy (flexion exercises, stretch/strength exercises), NSAIDs, lumbar epidural steroids
• operative
  ■ indication: non-operative failure >6 mo
  ■ decompressive surgery

Table 15. Differentiating Claudication

<table>
<thead>
<tr>
<th></th>
<th>Neurogenic</th>
<th>Vascular</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aggravation</strong></td>
<td>With standing or exercise</td>
<td>Walking set distance</td>
</tr>
<tr>
<td></td>
<td>Walking distance variable</td>
<td></td>
</tr>
<tr>
<td><strong>Alleviation</strong></td>
<td>Change in position (usually flexion, sitting, lying down)</td>
<td>Stop walking</td>
</tr>
<tr>
<td><strong>Time</strong></td>
<td>Relief in ~10 min</td>
<td>Relief in ~2 min</td>
</tr>
<tr>
<td><strong>Character</strong></td>
<td>Neurogenic ± neurological deficit</td>
<td>Muscular cramping</td>
</tr>
</tbody>
</table>

MECHANICAL BACK PAIN
• back pain NOT due to prolapsed disc or any other clearly defined pathology

Clinical Features
• dull backache aggravated by activity and prolonged standing
• morning stiffness
• no neurological signs

Treatment
• symptomatic (analgesics, physiotherapy)
• prognosis: symptoms may resolve in 4-6 wk, others become chronic

Cauda equina syndrome and ruptured aortic aneurysms are causes of low back pain that are considered surgical emergencies
LUMBAR DISC HERNIATION
- tear in annulus fibrosus allows protrusion of nucleus pulposus causing either a central, posterolateral, or lateral disc herniation, most commonly at L5-S1 > L4-5 > L3-4
- 3:1 male to female
- only 5% become symptomatic
- usually a history of flexion-type injury

Clinical Features
- back dominant pain (central herniation) or leg dominant pain (lateral herniation)
- tenderness between spinous processes at affected level
- muscle spasm ± loss of normal lumbar lordosis
- neurological disturbance is segmental and varies with level of central herniation
  - motor weakness (L4, L5, S1)
  - diminished reflexes (L4, S1)
  - diminished sensation (L4, L5, S1)
- positive straight leg raise
- positive contralateral SLR
- positive Lasegue and Bowstring sign
- cauda equina syndrome (present in 1-10%): surgical emergency

Investigations
- x-ray, MRI, consider a post-void residual volume to check for urinary retention; post-void >100 mL should heighten suspicion for cauda equina syndrome

Treatment
- non-operative
  - symptomatic
    - extension protocol
    - NSAIDS
- operative
  - indication: progressive neurological deficit, failure of symptoms to resolve within 3 mo or cauda equina syndrome due to central disc herniation
  - surgical discectomy
- prognosis
  - 90% of patients improve in 3 mo with non-operative treatment

Table 16. Types of Low Back Pain

<table>
<thead>
<tr>
<th></th>
<th>Disc Origin</th>
<th>Facet Origin</th>
<th>Spinal Stenosis</th>
<th>Root Compression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain Dominance</td>
<td>Back</td>
<td>Back</td>
<td>Leg</td>
<td>Leg</td>
</tr>
<tr>
<td>Aggravation</td>
<td>Flexion</td>
<td>Extension, standing, walking</td>
<td>Exercise, extension, walking, standing</td>
<td>Flexion</td>
</tr>
<tr>
<td>Onset</td>
<td>Gradual</td>
<td>More sudden</td>
<td>Congenital or acquired</td>
<td>Acute leg ± back pain</td>
</tr>
<tr>
<td>Duration</td>
<td>Long (weeks, months)</td>
<td>Shorter (days, weeks)</td>
<td>Acute or chronic history (weeks to months)</td>
<td>Short episodes Attacks (minutes)</td>
</tr>
<tr>
<td>Treatment</td>
<td>Relief of strain, exercise</td>
<td>Relief of strain, exercise</td>
<td>Relief of strain, exercise + surgical decompression if progressive or severe deficit</td>
<td>Relief of strain, exercise + surgical decompression if progressive or severe deficit</td>
</tr>
</tbody>
</table>

SPONDYLOLYSIS

Definition
- defect in the pars interarticularis with no movement of the vertebral bodies

Mechanism
- trauma: gymnasts, weightlifters, backpackers, loggers, labourers
**Clinical Features**
- activity-related back pain, pain with unilateral extension (Michelis' test)

**Investigations**
- oblique x-ray: “collar” break in the “Scottie dog’s” neck
- bone scan
- CT scan

**Treatment**
- non-operative
  - activity restriction, brace, stretching exercise

**Adult Isthmic Spondylolisthesis**

**Definition**
- defect in pars interarticularis causing a forward translation or slippage of one vertebra on another
- usually at L5-S1, less commonly at L4-5

**Mechanism**
- congenital (children), degenerative (adults), traumatic, pathological, teratogenic

**Clinical Features**
- lower back pain radiating to buttocks relieved with sitting
- neurogenic claudication
- L5 radiculopathy
- Meyerding Classification (percentage of slip)

**Investigations**
- x-ray (AP, lateral, obliques flexion-extension views), MRI

**Treatment**
- non-operative
  - activity restriction, bracing, NSAIDS
- operative
  - see Table 17

**Table 17. Classification and Treatment of Spondylolisthesis**

<table>
<thead>
<tr>
<th>Class</th>
<th>Percentage of Slip</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0-25%</td>
<td>Symptomatic operative fusion only for intractable pain</td>
</tr>
<tr>
<td>2</td>
<td>25-50</td>
<td>Same as above</td>
</tr>
<tr>
<td>3</td>
<td>50-75</td>
<td>Decompression for spondylolisthesis and spinal fusion</td>
</tr>
<tr>
<td>4</td>
<td>75-100</td>
<td>Same as above</td>
</tr>
<tr>
<td>5</td>
<td>&gt;100</td>
<td>Same as above</td>
</tr>
</tbody>
</table>

**Specific Complications**
- may present as cauda equina syndrome due to roots being stretched over the edge of L5 or sacrum

---

**Pelvis**

**Pelvic Fracture**

**Mechanism**
- young: high energy trauma, either direct or by force transmitted longitudinally through the femur
- elderly: fall from standing height, low energy trauma
- lateral compression, vertical shear, or anteroposterior compression fractures

**Clinical Features**
- pain, inability to bear weight
- local swelling, tenderness
- deformity of lower extremity
- pelvic instability
Investigations
- x-ray: AP pelvis, inlet and outlet views, Judet views (obturator and iliac oblique for acetabular fracture)
- 6 cardinal radiographic lines of the acetabulum: ilioischial line, iliopectineal line, tear drop, roof, posterior rim, anterior rim
- CT scan useful for evaluating posterior pelvic injury and acetabular fracture
- assess genitourinary injury (rectal exam, vaginal exam, hematuria, blood at urethral meatus)
- if involved, the fracture is considered an open fracture

Classification

Table 18. Tile Classification of Pelvic Fractures

<table>
<thead>
<tr>
<th>Type</th>
<th>Stability</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Rotationally stable</td>
<td>A1: fracture not involving pelvic ring (ex: avulsion or iliac wing fracture)</td>
</tr>
<tr>
<td></td>
<td>Vertically stable</td>
<td>A2: minimally displaced fracture of pelvic ring (e.g. ramus fracture)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A3: transverse sacral fracture</td>
</tr>
<tr>
<td>B</td>
<td>Rotationally unstable</td>
<td>B1: open book (external rotation)</td>
</tr>
<tr>
<td></td>
<td>Vertically stable</td>
<td>B2: lateral compression – ipsilateral</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B2-1: with anterior ring rotation/displacement through ipsilateral rami</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B2-2: with anterior ring rotation/displacement through non-ipsilateral rami (bucket-handle)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B3: bilateral</td>
</tr>
<tr>
<td>C</td>
<td>Rotationally unstable</td>
<td>C1: unilateral</td>
</tr>
<tr>
<td></td>
<td>Vertically unstable</td>
<td>C1-1: iliac fracture, C1-2: sacroiliac fracture-dislocation C1-3: sacral fracture</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C2: bilateral with 1 side type B and 1 side type C</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C3: bilateral both sides type C</td>
</tr>
</tbody>
</table>

Treatment
- ABCDEs
- non-operative treatment: protected weight bearing
- indication: stable fracture
- emergency management
  - IV fluids/blood
  - pelvic binder/sheeting
  - external fixation vs. emergent angiography/embolization
  - ± laparotomy (if FAST/DPL positive)
- operative treatment: ORIF
  - indications
    - unstable pelvic ring injury
    - disruption of anterior and posterior SI ligament
    - symphysis diastasis >2.5 cm
    - vertical instability of the posterior pelvis
    - open fracture

Specific Complications (see General Fracture Complications, OR6)
- hemorrhage (life-threatening)
- injury to rectum or urogenital structures
- obstetrical difficulties, sexual and voiding dysfunction
- persistent SI joint pain
- post-traumatic arthritis of the hip with acetabular fractures
- high risk of DVT/PE

Hip Dislocation
- full trauma survey (see Emergency Medicine, Patient Assessment/Management, ER2)
- examine for neurovascular injury PRIOR to open or closed reduction
- reduce hip dislocations within 6 h to decrease risk of AVN of the femoral head
- hip precautions (no extreme hip flexion, adduction, internal or external rotation) for 6 wk post-reduction
- see Hip Dislocation Post-Total Hip Arthroplasty, OR29

ANTERIOR HIP DISLOCATION
- mechanism: posteriorly directed blow to knee with hip widely abducted
- clinical features: shortened, abducted, externally rotated limb
- treatment
  - closed reduction under conscious sedation/GA
  - post-reduction CT to assess joint congruity
POSTERIOR HIP DISLOCATION
- most frequent type of hip dislocation
- mechanism: severe force to knee with hip flexed and adducted
  - e.g. knee into dashboard in MVC
- clinical features: shortened, adducted, internally rotated limb
- treatment
  - closed reduction under conscious sedation/GA only if no associated femoral neck fracture or ipsilateral displacement
  - ORIF if unstable, intra-articular fragments or posterior wall fracture
  - post-reduction CT to assess joint congruity and fractures
  - if reduction is unstable, put in traction x 4-6 wk

COMPLICATIONS FOR ALL HIP DISLOCATIONS
- post-traumatic OA
- AVN of femoral head
- fracture of femoral head, neck, or shaft
- sciatic nerve palsy in 25% (10% permanent)
- HO
- thromboembolism – DVT/PE

Hip Fracture

General Features
- acute onset of hip pain
- unable to weight-bear
- shortened and externally rotated leg
- painful ROM

Table 19. Overview of Hip Fractures

<table>
<thead>
<tr>
<th>Fracture Type</th>
<th>Definition</th>
<th>Mechanism</th>
<th>Special Clinical Features</th>
<th>Investigations</th>
<th>Treatment</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Femoral Neck (Subcapital)</td>
<td>Intracapsular (See Garden Classification, Table 20)</td>
<td>Young: MVC, fall from height, Elderly: fall from standing, rotational force</td>
<td>Same as general</td>
<td>X-Ray: AP hip, AP pelvis, cross table lateral hip</td>
<td>See Table 20</td>
<td>DVT, non-union, AVN, dislocation</td>
</tr>
<tr>
<td>Intertrochanteric</td>
<td>Extracapsular fracture including the greater and lesser trochanters and transitional bone between the neck and shaft</td>
<td>Same as femoral neck fracture Direct or indirect force transmitted to the intertrochanteric area</td>
<td>Ecchymosis at back of upper thigh</td>
<td>X-Ray: AP pelvis, AP/lateral hip</td>
<td>Closed reduction under fluoroscopy then dynamic hip screw or IM nail</td>
<td>DVT, varus displacement of proximal fragment, malrotation, non-union, failure of fixation device</td>
</tr>
<tr>
<td>Stable: intact posterosmedial cortex Unstable: non-intact posterosmedial cortex</td>
<td>Fracture begins at or below the lesser trochanter and involves the proximal femoral shaft</td>
<td>Young: high energy trauma Elderly: osteoporotic bone + fall, pathological fracture</td>
<td>Ecchymosis at back of upper thigh</td>
<td>X-Ray: AP pelvis, AP/lateral hip and femur</td>
<td>Closed/open under fluoroscopy then plate fixation or IM nail</td>
<td>Malalignment, non-union, wound infection</td>
</tr>
<tr>
<td>Subtrochanteric</td>
<td>Fracture begins at or below the lesser trochanter and involves the proximal femoral shaft</td>
<td>Young: high energy trauma Elderly: osteoporotic bone + fall, pathological fracture</td>
<td>Ecchymosis at back of upper thigh</td>
<td>X-Ray: AP pelvis, AP/lateral hip and femur</td>
<td>Closed/open under fluoroscopy then plate fixation or IM nail</td>
<td>Malalignment, non-union, wound infection</td>
</tr>
</tbody>
</table>

Figure 35. Subcapital, intertrochanteric, subtrochanteric fractures

Table 20)

X-Ray Features of Subcapital Hip Fractures
- Disruption of Shenton’s line (a radiographic line drawn along the upper margin of the obturator foramen, extending along the inferomedial side of the femoral neck)
- Altered neck-shaft angle (normal is 120-130°)

DVT Prophylaxis in Hip Fractures
LMWH (i.e. enoxaparin 40 mg SC bid), fondaparinux, low dose heparin on admission, do not give < 12 h before surgery

AVN of Femoral Head
- Distal to proximal blood supply along femoral neck to head (medial and lateral femoral circumflex arteries)
- Susceptible to AVN if blood supply disrupted
- Etiology: femoral neck fracture, chronic systemic steroid use, SCFE, Legg-Calvé-Perthes, SLE, RA

ROchester Method to Reduce Posterior Dislocations
- Patient lying supine with hip and knee flexed on injured side
- Surgeon stands on patient’s injured side
- Surgeon passes one arm under patient’s flexed knee, reaching to place that hand on patient’s other knee (thus supporting patient’s injured leg)
- With other hand, surgeon grasps patient’s ankle on injured side, applying traction, while assistant stabilizes pelvis
- Reduction via traction, internal rotation, then external rotation once femoral head clears acetabular rim

Normal joint Subcapital fracture Intertrochanteric fracture Subtrochanteric fracture

© Sean Wang 2017
Table 20. Garden Classification of Femoral Neck Fractures

<table>
<thead>
<tr>
<th>Type</th>
<th>Displacement</th>
<th>Extent</th>
<th>Alignment</th>
<th>Trabeculae</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>None</td>
<td>“Incomplete”</td>
<td>Valgus or neutral</td>
<td>Malaligned</td>
<td>Internal fixation to prevent displacement (valgus impacted fracture)</td>
</tr>
<tr>
<td>II</td>
<td>None</td>
<td>Complete</td>
<td>Neutral</td>
<td>Aligned</td>
<td>Internal fixation to prevent displacement</td>
</tr>
</tbody>
</table>
| III  | Some         | Complete | Varus     | Malaligned | Young: ORIF  
Elderly: hemi-/total hip arthroplasty |
| IV   | Complete     | Complete | Varus     | Aligned    | Young: ORIF  
Elderly: hemi-/total hip arthroplasty |

Arthritis of the Hip

Etiology
- OA, inflammatory arthritis, post-traumatic arthritis, late effects of congenital hip disorders, or septic arthritis

Clinical Features
- pain (groin, medial thigh) and stiffness aggravated by activity, better with rest in OA
- RA: morning stiffness >1 h, multiple joint swelling, hand nodules
- decreased ROM (internal rotation is lost first)
- crepitus
- effusion
- ± fixed flexion contracture leading to apparent limb shortening (Thomas test)
- ± Trendelenburg sign

Investigations
- x-ray: weight bearing views of affected joint  
  - OA: joint space narrowing, subchondral sclerosis, subchondral cysts, osteophytes  
  - RA: osteopenia, erosion, joint space narrowing, subchondral cysts,  
  - blood work: ANA, RF

Treatment
- non-operative  
  - weight reduction, activity modification, physiotherapy, analgesics, walking aids  
  - operative  
  - indication: advanced disease  
  - realign = osteotomy; replace = arthroplasty; fuse = arthrodesis  
- complications with arthroplasty: component loosening, dislocation, HO, thromboembolism, infection, neurovascular injury, limb length discrepancy  
- arthroplasty is standard of care in most patients with hip arthritis

Hip Dislocation Post-Total Hip Arthroplasty

- occurs in 1-4% of primary THA and 10-16% of revision THAs  
- risk factors: neurological impairment, post-traumatic arthritis, revision surgery, substance abuse

Mechanism
- THA that is unstable when hip is flexed, adducted and internally rotated, or extended and externally rotated (avoid flexing hip >90° or crossing legs for ~6 wk after surgery)

Investigations
- x-ray: AP pelvis, AP and lateral hip
Femur Diaphysis Fracture

Mechanism
• high energy trauma (MVC, fall from height, gunshot wound)
  ■ pathologic as a result malignancy, osteoporosis, bisphosphonate use
  ■ in children, can result from low energy trauma (spiral fracture)

Clinical Features
• shortened, externally rotated leg (if fracture displaced)
• inability to weight-bear
• often open injury, always a Gustilo III (see Table 5, OR8)
• Winquist and Hansen classification

Investigations
• x-ray: AP pelvis, AP/lateral hip, femur, knee

Treatment
• non-operative (uncommon)
  ■ indication: non-displaced femoral shaft fractures in co-morbid patients
  ■ long leg cast
• operative
  ■ ORIF with anterograde IM nail (most common) or retrograde IM nail, external fixator for unstable patients, open fractures, or highly vascular areas, or plate and screws for open growth plates within 24 h
  ■ early mobilization and strengthening

Complications
• blood loss
• fat embolism leading to ARDS
• extensive soft tissue damage
• ipsilateral hip dislocation/fracture (2-6%)
• nerve injury

Distal Femoral Fracture

• fractures from articular surface to 5cm above metaphyseal flare

Mechanism
• direct high energy force or axial loading
  • three types: extra articular, partial articular, complete articular

Clinical Features
• extreme pain
• knee effusion (hemarthrosis)
• neurovascular deficits can occur with displaced fracture

Investigations
• x-ray: AP, lateral
• CT, angiography if diminished pulses
Treatment
• non-operative (uncommon)
  ■ indication: non-displaced extra-articular fracture
  • hinged knee brace
• operative
  ■ indication: displaced fracture, intra-articular fracture, non-union
  • ORIF or retrograde IM nail if supracondylar and non-committed
  • early mobilization and strengthening

Specific Complications (see General Fracture Complications, OR6)
• femoral artery tear
• popliteal artery injury
• nerve injury
• extensive soft tissue injury
• angulation deformities

Knee

Evaluation of Knee

Common Complaints
• locking, instability and swelling
  ■ torn meniscus/loose body in joint
  • pseudo-locking: limited ROM without mechanical block
  • effusion, muscle spasm after injury, arthritis
  • painful clicking (audible)
  ■ torn meniscus
  • giving way: instability
  ■ cruciate ligament or meniscal tear, patellar dislocation

Special Tests of the Knee
• anterior and posterior drawer tests
  • demonstrate ACL and PCL, respectively
  • if able to sublux tibia anteriorly (anterior drawer test), then ACL may be torn
  • if able to sublux tibia posteriorly (posterior drawer test), then PCL may be torn
  • anterior drawer test for ACL: 25.0 positive likelihood ratio, 0.30 negative likelihood ratio

• Lachmann test
  • demonstrates torn ACL
  • hold knee in 10–20° flexion, stabilizing the femur
  • try to sublux tibia anteriorly on femur
  • similar to anterior drawer test, more reliable due to less muscular stabilization
  • for ACL: 25.0 positive likelihood ratio, 0.1 negative likelihood ratio

• Thessaly test
  • demonstrates meniscal tear
  • patient stands flat footed on one leg while the examiner provides his or her hands for balance. The patient then flexes the knee to 20° and rotates the femur on the tibia medially and laterally three times while maintaining the 20° flexion
  • positive for a meniscal tear if the patient experiences medial or lateral joint line discomfort
  • for medial meniscus: 29.67 positive likelihood ratio, 0.11 negative likelihood ratio
  • for lateral meniscus: 23.0 positive likelihood ratio, 0.083 negative likelihood ratio

• posterior sag sign
  • demonstrates torn PCL
  • may give a false positive anterior draw sign
  • flex knees and hips to 90°, hold ankles and knees
  • view from the lateral aspect
  • if one tibia sags posteriorly compared to the other, its PCL is torn

• pivot shift sign
  • demonstrates torn ACL
  • start with the knee in extension
  • internally rotate foot, slowly flex knee while palpating and applying a valgus force
  • if incompetent ACL, tibia will sublux anteriorly on femur at start of maneuver. During flexion, the tibia will reduce and externally rotate about the femur (the “pivot”)
  • reverse pivot shift (start in flexion, externally rotate, apply valgus and extend knee) suggests torn PCL
  • composite assessment for ACL: 25.0 positive likelihood ratio, 0.04 negative likelihood ratio
  • composite assessment for PCL: 21.0 positive likelihood ratio, 0.05 negative likelihood ratio

On physical exam of the knee, do not forget to evaluate the hip
**Knee**

- **collateral ligament stress test**
  - palpate ligament for "opening" of joint space while testing
  - with knee in full extension, apply valgus force to test MCL, apply varus force to test LCL
  - repeat tests with knee in 20° flexion to relax joint capsule
  - opening in 20° flexion due to MCL damage only
  - opening in 20° of flexion and full extension is due to MCL, cruciate, and joint capsule damage

- **tests for meniscal tear**
  - joint line tenderness
    - joint line pain when palpated
    - palpate one side at a time and watch patient's eyes
    - for meniscal tear: 0.9 positive likelihood ratio, 1.1 negative likelihood ratio
  - crouch compression test
    - joint line pain when squatting (anterior pain suggests patellofemoral pathology)
  - McMurray's test useful collaborative information
    - with knee in flexion, palpate joint line for painful "pop/click"
    - internally rotate foot, varus stress, and extend knee to test lateral meniscus
    - externally rotate foot, valgus stress, and extend knee to test medial meniscus
    - for meniscal tear: 1.3 positive likelihood ratio, 0.8 negative likelihood ratio
  - composite assessment for meniscal tears: 2.7 positive likelihood ratio, 0.4 negative likelihood ratio

### X-Rays
- AP standing, lateral
- skyline: tangential view with knees flexed at 45° to see patellofemoral joint
- 3-foot standing view: useful in evaluating leg length and varus/valgus alignment
- Ottawa Knee Rules ([see Emergency Medicine, ER16](#))

---

### Cruciate Ligament Tears

- ACL tear much more common than PCL tear

**Table 21. Comparison of ACL and PCL Injuries**

<table>
<thead>
<tr>
<th></th>
<th>Anterior Cruciate Ligament</th>
<th>Posterior Cruciate Ligament</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anatomy</strong></td>
<td>From medial wall of lateral femoral condyle to the anteromedial and posterolateral intercondylar eminence of the tibial plateau</td>
<td>Lateral wall of medial femoral condyle to posterior intercondylar eminence of the tibial plateau</td>
</tr>
<tr>
<td><strong>Mechanism</strong></td>
<td>Sudden deceleration, hyperextension and internal rotation of tibia on femur (i.e. &quot;plant and turn&quot;)</td>
<td>Sudden posterior displacement of tibia when knee is flexed or hyperextended (e.g. dashboard MVC injury)</td>
</tr>
<tr>
<td><strong>History</strong></td>
<td>Audible &quot;pop&quot; Immediate swelling Knee &quot;giving way&quot; Inability to continue activity</td>
<td>Audible &quot;pop&quot; Immediate swelling Pain with push off Cannot descend stairs</td>
</tr>
<tr>
<td><strong>Physical</strong></td>
<td>Effusion (hemarthrosis) Posterolateral joint line tenderness Positive anterior drawer Positive Lachmann Pivot shift Test for MCL, meniscal injuries</td>
<td>Effusion (hemarthrosis) Anteromedial joint line tenderness Positive posterior drawer Reverse pivot shift Other ligamentous, bony injuries</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>Stable knee with minimal functional impairment: immobilization 2-4 wk with early ROM and strengthening High demand lifestyle: ligament reconstruction</td>
<td>Unstable knee or young person/high-demand lifestyle: ligament reconstruction</td>
</tr>
</tbody>
</table>

---

### Collateral Ligament Tears

**Mechanism**
- valgus force to knee = MCL tear
- varus force to knee = LCL tear

**Clinical Features**
- swelling/effusion
- tenderness above and below joint line medially (MCL) or laterally (LCL)
- joint laxity with varus or valgus force to knee
  - laxity with endpoint suggests partial tear
  - laxity with no endpoint suggests a complete tear
- test for other injuries (e.g. O’Donoghue's unhappy triad), common peroneal nerve injury

**Investigations**
- x-ray: AP and lateral; MRI
Knee

**Treatment**
- non-operative
  - partial tear: immobilization x 2-4 wk with early ROM and strengthening
  - complete tear: immobilization at 30° flexion
- operative
  - indication: multiple ligamentous injuries
  - surgical repair of ligaments

**Meniscal Tears**
- medial tear much more common than lateral tear

**Mechanism**
- twisting force on knee when it is partially flexed (e.g. stepping down and turning)
- requires moderate trauma in young person but only mild trauma in elderly due to degeneration

**Clinical Features**
- immediate pain, difficulty weight-bearing, instability, and clicking
- increased pain with squatting and/or twisting
- effusion (hemarthrosis) with insidious onset (24-48 h after injury)
- joint line tenderness medially or laterally
- locking of knee (if portion of meniscus mechanically obstructing extension)

**Investigations**
- MRI, arthroscopy

**Treatment**
- non-operative
  - indication: not locked
  - ROM and strengthening (NSAIDs)
- operative
  - indication: locked or failed non-operative treatment
  - arthroscopic repair/partial meniscectomy

**Quadriceps/Patellar Tendon Rupture**

**Mechanism**
- sudden forceful contraction of quadriceps during an attempt to stop
- more common in obese patients and those with pre-existing degenerative changes in tendon
- DM, SLE, RA, steroid use, renal failure on dialysis

**Clinical Features**
- inability to extend knee or weight-bear
- possible audible “pop”
- patella in lower or higher position with palpable gap above or below patella respectively
- may have an effusion

**Investigations**
- ask patient to straight leg raise (unable with complete rupture)
- knee x-ray to rule out patellar fracture, MRI to distinguish between complete and partial tears
- lateral view: patella alta with patella tendon rupture, patella baja (infera) with quadriceps tendon rupture

**Treatment**
- non-operative
  - indication: incomplete tears with preserved extension of knee
  - immobilization in brace
- operative
  - indication: complete ruptures with loss of extensor mechanism
  - early surgical repair: better outcomes compared with delayed repair (>6 wk post injury)
  - delayed repair complicated by quadriceps contracture, patella migration, and adhesions

Partial ligamentous tears are much more painful than complete ligamentous tears

Meniscal repair is done if tear is peripheral with good vascular supply, is a longitudinal tear and 1-4cm in length

Partial meniscectomy is done with tears not amenable to repair (complex, degenerative, radial)

Tissue Sources for ACL Reconstruction
- Hamstring
- Middle 1/3 patellar tendon (bone-patellar-bone)
- Allograft (e.g. cadaver)

ACL tear more common than PCL tear
MCL tear more common than LCL tear

Patella alta = high riding patella
Patella baja (infera) = low riding patella
Dislocated Knee

Mechanism
• high energy trauma
• by definition, caused by tears of multiple ligaments

Clinical Features
• classified by relation of tibia with respect to femur
  ■ anterior, posterior, lateral, medial, rotary
• knee instability
• effusion
• pain
• ischemic limb
• Schenck classification

Investigations
• x-ray: AP, lateral, skyline
• associated radiographic findings include tibial plateau fracture dislocations, proximal fibular fractures, and avulsion of fibular head
• ABI (abnormal if <0.9)
• arteriogram or CT angiogram if abnormal vascular exam (such as abnormal pedal pulses)

Treatment
• urgent closed reduction
• complicated by interposed soft tissue
• assessment of peroneal nerve, tibial artery, and ligamentous injuries
• emergent operative repair if vascular injury, open fracture or dislocation, non-reducible dislocation, compartment syndrome
• knee immobilization x 6-8 wk

Specific Complications
• high incidence of associated injuries
• popliteal artery tear
• peroneal nerve injury
• capsular tear
• chronic: instability, stiffness, post-traumatic arthritis

Patella

Patellar Fracture

Mechanism
• direct blow to the patella: fall, MVC (dashboard)
• indirect trauma by sudden flexion of knee against contracted quadriceps

Clinical Features
• marked tenderness
• inability to extend knee or straight leg raise
• proximal displacement of patella
• patellar deformity
• ± effusion/hemarthrosis

Investigations
• x-rays: AP, lateral, skyline
• do not confuse with bipartite patella: congenitally unfused ossification centres with smooth margins on x-ray at superolateral corner

Treatment
• non-operative
  • indication: non-displaced (step-off <2-3 mm and fracture gap <1-4 mm)
    ■ straight leg immobilization 1-4 wk with hinged knee brace, weight bearing as tolerated
    ■ progress in flexion after 2-3 wk
    ■ physiotherapy: quadriceps strengthening when pain has subsided
• operative
  • indication: displaced (>2 mm), comminuted, disrupted extensor mechanism
    ■ ORIF, if comminuted may require partial/complete patellectomy
  • goal: restore extensor mechanism with maximal articular congruency
Patellar Dislocation

Mechanism
- usually a non-contact twisting injury
- lateral displacement of patella after contraction of quadriceps at the start of knee flexion in an almost straight knee joint
- direct blow, e.g. knee/helmet to knee collision

Risk Factors
- young, female
- obesity
- high-riding patella (patella alta)
- genu valgus
- Q-angle (quadriceps angle) ≥20°
- shallow intercondylar groove
- weak vastus medialis
- tight lateral retinaculum
- ligamentous laxity (Ehlers-Danlos)

Clinical Features
- knee catches or gives way with walking
- severe pain, tenderness anteromedially from rupture of capsule
- weak knee extension or inability to extend leg unless patella reduced
- positive patellar apprehension test
  - passive lateral translation results in guarding and patient apprehension
- often recurrent, self-reducing
- concomitant MCL injury
- increased Q-angle
- J-sign

Investigations
- x-rays: AP, lateral, skyline view of patella
- check for fracture of medial patella (most common) and lateral femoral condyle
- CT-scan
- MRI – best to assess articular cartilage

Treatment
- non-operative first
  - NSAIDs, activity modification, and physical therapy
  - short-term immobilization for comfort then 6 wk controlled motion
  - progressive weight bearing and isometric quadriceps strengthening
  - operative
  - indication: if recurrent or if loose bodies present
  - surgical tightening of medial capsule and release of lateral retinaculum, possible tibial tuberosity transfer, or proximal tibial osteotomy

Patellofemoral Syndrome (Chondromalacia Patellae)

- syndrome of anterior knee pain associated with idiopathic articular changes of patella

Risk Factors
- malalignment causing patellar maltracking (Q angle ≥20°, genu valgus)
- post-trauma
- deformity of patella or femoral groove
- recurrent patellar dislocation, ligamentous laxity
- excessive knee strain (athletes)

Mechanism
- softening, erosion and fragmentation of articular cartilage, predominantly medial aspect of patella
- commonly seen in active young females

Clinical Features
- deep, aching anterior knee pain
  - exacerbated by prolonged sitting (theatre sign), strenuous athletic activities, stair climbing, squatting or kneeling
  - insidious onset and vague in nature
  - sensation of instability, pseudolocking
  - pain with extension against resistance through terminal 30-40°
  - pain with compression of patella with knee ROM or resisted knee extension
  - swelling rare, minimal if present
  - palpable crepitus

Investigations
- x-ray: AP, lateral, skyline – may find chondrosis, lateral patellar tilt, patella alta/baja, or shallow sulcus
- CT-scan
- MRI – best to assess articular cartilage

- syndrome of anterior knee pain associated with idiopathic articular changes of patella

Risk Factors
- malalignment causing patellar maltracking (Q angle ≥20°, genu valgus)
- post-trauma
- deformity of patella or femoral groove
- recurrent patellar dislocation, ligamentous laxity
- excessive knee strain (athletes)

Mechanism
- softening, erosion and fragmentation of articular cartilage, predominantly medial aspect of patella
- commonly seen in active young females

Clinical Features
- deep, aching anterior knee pain
  - exacerbated by prolonged sitting (theatre sign), strenuous athletic activities, stair climbing, squatting or kneeling
  - insidious onset and vague in nature
  - sensation of instability, pseudolocking
  - pain with extension against resistance through terminal 30-40°
  - pain with compression of patella with knee ROM or resisted knee extension
  - swelling rare, minimal if present
  - palpable crepitus

Investigations
- x-ray: AP, lateral, skyline – may find chondrosis, lateral patellar tilt, patella alta/baja, or shallow sulcus
- CT-scan
- MRI – best to assess articular cartilage

Patellofemoral Syndrome (Chondromalacia Patellae)
Tibia

Tibial Plateau Fracture

Mechanism
- varus/valgus load ± axial loading (e.g. fall from height)
- femoral condyles driven into proximal tibia
- can result from minor trauma in osteoporotics

Clinical Features
- frequency: lateral > bicondylar > medial
- medial fractures require higher energy – often have concomitant vascular injuries
- knee effusion
- inability to bear weight
- swelling
- associated with compartment syndrome, ACL injury and meniscal tears
- Schatzker classification

Investigations
- x-ray: AP, lateral, oblique
- CT: pre-operative planning, identify articular depression and comminution
- ABI if any differences in pulses between extremities

Treatment

<table>
<thead>
<tr>
<th>Approach #1 (based on amount of depression seen on x-ray)</th>
<th>Non-operative indication (if depression on x-ray is &lt; 3 mm): straight leg immobilization x 4-6 wk with progressive ROM weight bearing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approach #2 (based on varus/valgus instability)</td>
<td>Non-operative indication (if minimal varus/valgus instability [&lt;15°]): straight leg immobilization x 4-6 wk with progressive ROM weight bearing</td>
</tr>
<tr>
<td></td>
<td>Operative indication (if depression is &gt; 3 mm): ORIF often requiring bone grafting to elevate depressed fragment</td>
</tr>
<tr>
<td></td>
<td>Operative indication (if significant varus/valgus instability [&gt;15°]): ORIF often requiring bone grafting to elevate depressed fragment</td>
</tr>
</tbody>
</table>

Specific Complications (see General Fracture Complications, OR6)
- ligamentous injuries
- meniscal lesions
- AVN
- infection
- OA

Tibial Shaft Fracture

- most common long bone fracture and open fracture

Mechanism
- low energy pattern: torsional injury
- high energy: including MVC, falls, sporting injuries

Clinical Features
- pain, inability to weight bear
- open vs. closed
- neurovascular compromise

Investigations
- x-ray: AP, lateral
- full length, plus knee and ankle

Schatzker Classification

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Involvement of lateral/plateau split fracture</td>
</tr>
<tr>
<td>II</td>
<td>Lateral split-depressed fracture</td>
</tr>
<tr>
<td>III</td>
<td>Involvement of lateral/plateau pure depression fracture</td>
</tr>
<tr>
<td>IV</td>
<td>Medial plateau fracture</td>
</tr>
<tr>
<td>V</td>
<td>Bicondylar plateau fracture</td>
</tr>
<tr>
<td>VI</td>
<td>Bicondylar with metaphyseal/diaphyseal involvement</td>
</tr>
</tbody>
</table>

Figure 45. Tibial shaft fracture treated with IM nail and screws
Treatment

- non-operative
  - indication: closed and minimally displaced or adequate closed reduction
    - long leg cast x 8-12 wk, functional brace after
  - operative
    - indication: displaced or open
      - if displaced and closed: ORIF with IM nail, plate and screws, or external fixator
      - if open: antibiotics, I&D, external fixation or IM nail, and vascularized coverage of soft tissue defects

Specific Complications (see General Fracture Complications, OR6)

- high incidence of neurovascular injury and compartment syndrome
- poor soft tissue coverage (critical to outcome)

Ankle

Evaluation of Ankle and Foot Complaints

Special Tests

- anterior drawer: examiner attempts to displace the foot anteriorly against a fixed tibia
- talar tilt: foot is stressed in inversion and angle of talar rotation is evaluated by x-ray

X-Ray

- AP, lateral
- mortise view: ankle at 15° of internal rotation
  - gives true view of ankle joint
  - joint space should be symmetric with no talar tilt
- Ottawa Ankle Rules should guide x-ray use (see Emergency Medicine, ER17); nearly 100% sensitivity
- ± CT to better characterize fractures

Ankle Fracture

Mechanism

- pattern of fracture depends on the position of the ankle when trauma occurs
- generally involves
  - ipsilateral ligamentous tears or transverse bony avulsion
  - contralateral shear fractures (oblique or spiral)
- classification systems
  - Danis-Weber
  - Lauge-Hansen: based on foot’s position and motion relative to leg

Treatment

- non-operative
  - indication: non-displaced, no history of dislocation, usually lateral sided injury only
  - below knee cast, NWB
- operative
  - indications
    - any fracture-dislocation: restore vascularity, minimize articular injury, reduce pain and skin pressure
    - most of type B, and all of type C
    - trimalleolar (medial, posterior, lateral) fractures
    - talar tilt >10°
    - medial clear space on x-ray greater than superior clear space
    - open fracture/open joint injury
  - ORIF

Complications

- high incidence of post-traumatic arthritis
Ankle Ligamentous Injuries

- see Figure 47 for ankle ligaments

Medial Ligament Complex (deltoid ligament)
- varus heel
- marked swelling, bruising on heel/sole
- 75% intra-articular and 10% are bilateral
- 10% of fractures associated with compression fractures of thoracic or lumbar spine (rule out spine injury)

Lateral Ligament Complex (Anterior Talofibular, Calcaneofibular, Posterior Talofibular)
- inversion injury, >90% of all ankle sprains
- ATF most commonly and severely injured if ankle is plantar flexed
- swelling and tenderness anterior to lateral malleolus
- ++ ecchymoses
- may have significant medial talar tilt on inversion stress x-ray

Treatment
- non-operative
  - microscopic tear (Grade I)
    - rest, ice, compression, elevation
  - macroscopic tear (Grade II)
    - strap ankle in dorsiflexion and eversion x 4-6 wk
    - physiotherapy: strengthening and proprioceptive retraining
  - complete tear (Grade III)
    - below knee walking cast x 4-6 wk
    - physiotherapy: strengthening and proprioceptive retraining
- surgical intervention may be required if chronic symptomatic instability develops

Foot

Talar Fracture

Mechanism
- axial loading or hyperdorsiflexion (MVC, fall from height)
- 60% of talus covered by articular cartilage
- talar neck is most common fracture of talus (50%)
- tenuous blood supply runs distal to proximal along talar neck
  - high risk of AVN with displaced fractures

Investigations
- x-ray: AP, lateral, Canale view
- CT to better characterize fracture
- MRI can clearly define extent of AVN

Treatment
- non-operative
  - indication: non-displaced
    - NWB, below knee cast x 6 wk
  - operative
    - indication: displaced
      - ORIF (high rate of nonunion, AVN)
      - neck fracture: Pin (nondisplaced) or ORIF

Calcaneal Fracture

- most common tarsal fracture

Mechanism
- high energy, axial loading: fall from height onto heels
- 10% of fractures associated with compression fractures of thoracic or lumbar spine (rule out spine injury)
- 75% intra-articular and 10% are bilateral

Clinical Features
- marked swelling, bruising on heel/sole
- wider, shortened, flatter heel when viewed from behind
- varus heel

With a history of significant trauma from axial loading of lower limb always consider spinal injuries, femoral neck, tibial plateau, and talus/ calcaneal fractures
Investigations
- x-rays: AP, lateral, oblique (Broden’s view) Harris axial
- loss of Bohler’s angle
- CT: gold-standard, assess intra-articular extension

Treatment
- closed vs. open reduction is controversial
- NWB cast x 3 mo with early ROM and strengthening

Achilles Tendonitis

Mechanism
- chronic inflammation from activity or poor-fitting footwear
- may also develop heel bumps (retrocalcaneobursitis or Haglund deformity)

Clinical Features
- pain, stiffness, and crepitus with ROM
- thickened tendon, palpable bump

Investigations
- x-ray: lateral, evaluate bone spur and calcification; U/S, MRI (to assess degenerative change)

Treatment
- non-operative
  - rest, NSAIDs, shoe wear modification (orthotics, open back shoes)
  - heel sleeves and pads are mainstay of non-operative treatment
  - gentle gastrocnemius-soleus stretching, eccentric training with physical therapy, deep tissue calf massage
  - shockwave therapy in chronic tendonitis
  - DO NOT inject steroids (risk of tendon rupture)

Achilles Tendon Rupture

Mechanism
- loading activity, stop-and-go sports (e.g. squash, tennis, basketball)
- secondary to chronic tendonitis, steroid injection

Clinical Features
- audible pop, sudden pain with push off movement
- pain or inability to plantar flex
- palpable gap
- apprehensive toe off when walking
- weak plantar flexion strength
- Thompson test: with patient prone, squeeze calf, normal response is plantar flexion
  - no passive plantar flexion is positive test = ruptured tendon

Investigations
- x-ray (to rule out other pathology), U/S or MRI (for partial vs complete ruptures)

Treatment
- non-operative
  - indication: low athletic demand or elderly
  - cast foot in plantar flexion (to relax tendon) x 8-12 wk
- operative
  - indication: high athletic demand
  - surgical repair; then cast as above x 6-8 wk

Complications of Achilles Tendon Rupture
- infection
- sural nerve injury
- Re-rupture: surgical repair decreases likelihood of re-rupture compared to non-operative management

Plantar Fasciitis (Heel Spur Syndrome)

- inflammation of plantar aponeurosis at calcaneal origin
- common in athletes (especially runners, dancers)
- also associated with obesity, DM, seronegative and seropositive arthritis

Mechanism
- repetitive strain injury causing microtears and inflammation of plantar fascia
- common in athletes (especially runners, dancers)
- also associated with obesity, DM, seronegative and seropositive arthritis

Figure 48. X-ray of bony heel spur
Clinical Features
- insidious onset of heel pain, pain when getting out of bed and stiffness
- intense pain when walking from rest that subsides as patient continues to walk, worse at end of day with prolonged standing
- swelling, tenderness over sole
- greatest at medial calcaneal tubercle and 1-2 cm distal along plantar fascia
- pain with toe dorsiflexion (stretches fascia)

Investigations
- plain radiographs to rule out fractures
- often see bony exostoses (heel spurs) at insertion of fascia into medial calcaneal tubercle
- spur is secondary to inflammation, not the cause of pain

Treatment
- non-operative
  - pain control and stretching programs are first line
  - rest, ice, NSAIDs, steroid injection
  - physiotherapy: Achilles tendon and plantar fascia stretching, extracorporeal shockwave therapy
  - orthotics with heel cup – to counteract pronation and disperse heel strike forces
- operative
  - indication: failed non-operative treatment
  - endoscopic surgical release of fascia
  - spur removal is not required

### Bunions (Hallux Valgus)

- bony deformity characterized by medial displacement of first metatarsal and lateral deviation of hallux

#### Mechanism
- valgus alignment on 1st MTP (hallux valgus) causes eccentric pull of extensor and intrinsic muscles
- many associated deformities in foot from altered mechanics
- reactive exostosis forms with thickening of the skin creating a bunion
- most often associated with poor-fitting footwear (high heel and narrow toe box)
- can be hereditary (70% have family history)
- 10x more frequent in women

#### Clinical Features
- painful bursa over medial eminence of 1st MT head
- pronation (rotation inward) of great toe
- numbness over medial aspect of great toe

#### Investigations
- x-ray: standing AP/lateral/sesamoid view, NWB oblique

#### Treatment
- indications: painful corn or bunion, overriding 2nd toe
- non-operative (first line)
  - properly fitted shoes (low heel) and toe spacer
- operative: goal is to restore normal anatomy, not cosmetic reasons alone
  - osteotomy with realignment of 1st MTP joint (Chevron Procedure)
  - arthrodesis

### Metatarsal Fracture

- as with the hand, 1st, 4th, 5th MT are relatively mobile, while the 2nd and 3rd are fixed
- use Ottawa Foot Rules to determine need for x-ray

#### Table 22. Types of Metatarsal Fractures

<table>
<thead>
<tr>
<th>Fracture Type</th>
<th>Mechanism</th>
<th>Clinical Features</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avulsion of Base of 5th MT</td>
<td>Sudden inversion followed by</td>
<td>Tender base of 5th MT</td>
<td>Requires ORIF if displaced</td>
</tr>
<tr>
<td>Midshaft 5th MT (Jones Fracture)</td>
<td>contraction of peroneus brevis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shaft 2nd, 3rd MT (March Fracture)</td>
<td>Stress injury</td>
<td>Painful shaft of 5th MT</td>
<td>*NWB BK cast x 6 wk ORIF if athlete</td>
</tr>
<tr>
<td>1st MT</td>
<td>Trauma</td>
<td>Painful 1st MT</td>
<td>ORIF if displaced otherwise</td>
</tr>
<tr>
<td>Tarso-MT Fracture – Dislocation</td>
<td>Fall onto plantar flexed foot or</td>
<td>Shortened forefoot prominent base</td>
<td>*NWB BK cast x 3 wk then walking cast x 2 wk</td>
</tr>
<tr>
<td>(Lisfranc Fracture)</td>
<td>direct crush injury</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*NWB BK = Non weight bearing, below knee

---

**Figure 49. Hallux valgus**

Normal angle <15º

Hallux Valgus angle >15º

---

Ottawa Ankle and Foot Rules
(see Emergency Medicine, ER17)
X-rays only required if:
- Pain in the midfoot zone AND bony tenderness over the navicular or base of the fifth metatarsal OR inability to weight bear both immediately after injury and in the ER
Fractures in Children

• type of fracture
  ■ thicker, more active periosteum results in pediatric specific fractures: greenstick (one cortex), torus (i.e. ‘buckle’; impacted cortex) and plastic (bowing)
  ■ distal radius fracture most common in children (phalanges second), the majority are treated with closed reduction and casting
  ■ adults fracture through both cortices
• epiphyseal growth plate
  ■ weaker part of bone, susceptible to fractures
  ■ plate often mistaken for fracture on x-ray and vice versa (x-ray opposite limb for comparison), especially in elbow
  ■ tensile strength of bone < ligaments in children, therefore clinician must be confident that fracture and/or growth plate injury have been ruled out before diagnosing a sprain
  ■ intra-articular fractures have worse consequences in children because they usually involve the growth plate
• anatomic reduction
  ■ gold standard with adults
  ■ may cause limb length discrepancy in children (overgrowth)
  ■ accept greater angular deformity in children (remodelling minimizes deformity)
• time to heal
  ■ shorter in children
  ■ always be aware of the possibility of child abuse
  ■ make sure stated mechanism compatible with injury
  ■ high index of suspicion with fractures in non-ambulating children (<1 yr); look for other signs, including x-ray evidence of healing fractures at different sites and different stages of healing

Stress Fractures

Mechanism
• insufficiency fracture
  ■ stress applied to a weak or structurally deficient bone
• fatigue fracture
  ■ repetitive, excessive force applied to normal bone
  ■ most common in adolescent athletes
  ■ tibia is most common site

Diagnosis
• localized pain and tenderness over the involved bone
• plain films may not show fracture for 2 wk
• bone scan positive in 12-15 d

Treatment
• rest from strenuous activities to allow remodelling (can take several months)

Epiphyseal Injury

Table 23. Salter-Harris Classification of Epiphyseal Injury

<table>
<thead>
<tr>
<th>SALT(E)r–Harris Type</th>
<th>Description</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>I (Straight through; Stable)</td>
<td>Transverse through growth plate</td>
<td>Closed reduction and cast immobilization (except SCFE – ORIF); heals well, 95% do not affect growth</td>
</tr>
<tr>
<td>II (Above)</td>
<td>Through metaphysis and along growth plate</td>
<td>Closed reduction and cast if anatomic; otherwise ORIF</td>
</tr>
<tr>
<td>III (Low)*</td>
<td>Through epiphysis to plate and along growth plate</td>
<td>Anatomic reduction by ORIF to prevent growth arrest, avoid fixation across growth plate</td>
</tr>
<tr>
<td>IV (Through and through)*</td>
<td>Through epiphysis and metaphysis</td>
<td>Closed reduction and cast if anatomic; otherwise ORIF</td>
</tr>
<tr>
<td>V (Ram)*</td>
<td>Crush injury of growth plate</td>
<td>High incidence of growth arrest; no specific treatment</td>
</tr>
</tbody>
</table>

* Types III – IV are more likely to cause growth arrest and progressive deformity
**Slipped Capital Femoral Epiphysis**

- type I Salter-Harris epiphyseal injury at proximal hip
- most common adolescent hip disorder, peak incidence at pubertal growth spurt
- risk factors: male, obese (#1 factor), hypothyroid (risk of bilateral involvement)

**Etiology**
- multifactorial
  - genetic: autosomal dominant, black children at highest risk
  - cartilaginous physis hypertrophies too rapidly under growth hormone effects
  - sex hormone secretion, which stabilizes physis, has not yet begun
  - overweight: mechanical stress
  - trauma: causes acute slip

**Clinical Features**
- acute: sudden, severe pain with limp
- chronic (typically): groin and anterior thigh pain, may present with knee pain
  - positive Trendelenburg sign on affected side, due to weakened gluteal muscles
- tender over joint capsule
- restricted internal rotation, abduction, flexion
  - Whitman's sign: obligatory external rotation during passive flexion of hip
- Loder classification: stable vs. unstable (provides prognostic information)
  - unstable means patient cannot ambulate even with crutches

**Investigations**
- x-ray: AP, frog-leg, lateral radiographs both hips
  - posterior and medial slip of epiphysis
  - disruption of Klein’s line
  - AP view may be normal or show widened/lucent growth plate compared with opposite side

**Treatment**
- operative
  - mild/moderate slip: stabilize physis with pins in current position
  - severe slip: ORIF or pin physis without reduction and osteotomy after epiphyseal fusion

**Complications**
- AVN (roughly half of unstable hips), chondrolysis (loss of articular cartilage, resulting in narrowing of joint space), pin penetration, premature OA, loss of ROM

**Developmental Dysplasia of the Hip**

- abnormal development of hip resulting in dysplasia and subluxation/dislocation of hip
- most common orthopedic disorder in newborns

**Etiology**
- due to ligamentous laxity, muscular underdevelopment, and abnormal shallow slope of acetabular roof
- spectrum of conditions
  - dislocated femoral head completely out of acetabulum
  - dislocatable head in socket
  - head subluxates out of joint when provoked
  - dysplastic acetabulum, more shallow and more vertical than normal
  - painless (if painful suspect septic dislocation)

**Physical Exam**
- diagnosis is clinical
  - limited abduction of the flexed hip (<50-60°)
  - affected leg shortening results in asymmetry in skin folds and gluteal muscles, wide perineum
- Barlow’s test (for dislocatable hip)
  - flex hips and knees to 90° and grasp thigh
  - fully adduct hips, push posteriorly to try to dislocate hips
- Ortolani’s test (for dislocated hip)
  - initial position as above but try to reduce hip with fingertips during abduction
  - positive test: palpable clunk is felt (not heard) if hip is reduced
- Galeazzi’s sign
  - knees at unequal heights when hips and knees flexed
  - dislocated hip on side of lower knee
  - difficult test if child <1 yr
  - Trendelenburg test and gait useful if older (>2 yr)
**Investigations**
- U/S in first few months to view cartilage (bone is not calcified in newborns until 4-6 mo)
- follow up radiograph after 3 mo
- x-ray signs (at 4-6 mo): false acetabulum, acetabular index >25°, broken Shenton's line, femoral neck above Hilgenreiner's line, ossification centre outside of inner lower quadrant (quadrants formed by intersection of Hilgenreiner's and Perkin's line)

**Treatment**
- 0-6 mo: reduce hip using Pavlik harness to maintain abduction and flexion
- 6-18 mo: reduction under GA, hip spica cast x 2-3 mo (if Pavlik harness fails)
- >18 mo: open reduction; pelvic and/or femoral osteotomy

**Complications**
- redislocation, inadequate reduction, stiffness
- AVN of femoral head

---

**Legg-Calvé-Perthes Disease (Coxa Plana)**

- idiopathic AVN of femoral head, presents at 4-8 yr of age
- 12% bilateral, M>F = 5:1, 1/1,200
- associations
  - family history
  - low birth weight
  - abnormal pregnancy/delivery
  - ADHD in 33% of cases, delayed bone age in 89%
  - second-hand smoke exposure
  - Asian, Inuit, Central European
- key features
  - AVN of proximal femoral epiphysis, abnormal growth of the physis, and eventual remodelling of regenerated bone

**Clinical Features**
- child with antalgic or Trendelenburg gait ± pain
- intermittent knee, hip, groin, or thigh pain
- flexion contracture (stiff hip): decreased internal rotation and abduction of hip
- limb length discrepancy (late)

**Investigations**
- x-ray: AP pelvis, frog leg laterals
- may be negative early (if high index of suspicion, move to bone scan or MRI)
- eventually, characteristic collapse of femoral head (diagnostic)

**Treatment**
- goal is to preserve ROM and keep femoral head contained in acetabulum
- non-operative
  - physiotherapy: ROM exercises
  - brace in flexion and abduction x 2-3 yr (controversial)
- operative
  - femoral or pelvic osteotomy (>8 yr of age or severe)
  - prognosis better in males, <5 yr, <50% of femoral head involved, abduction >30°
  - 60% of involved hips do not require operative intervention
- natural history is early onset OA and decreased ROM

---

**Osgood-Schlatter Disease**

- inflammation of patellar ligament at insertion point on tibial tuberosity
- M>F
- age of onset: boys 12-15 yr; girls 8-12 yr

**Mechanism**
- repetitive tensile stress on insertion of patellar tendon over the tibial tuberosity causes minor avulsion at the site and subsequent inflammatory reaction (tibial tubercle apophysitis)

**Clinical Features**
- tender lump over tibial tuberosity
- pain on resisted leg extension
- anterior knee pain exacerbated by jumping or kneeling, relieved by rest

**Investigations**
- x-ray: lateral knee: fragmentation of the tibial tubercle, ± ossicles in patellar tendon
Treatment

- benign, self-limited condition, does not resolve until growth halts
- non-operative (majority)
  - may restrict activities such as basketball or cycling
  - NSAIDs, rest, flexibility, isometric strengthening exercises
  - casting if symptoms do not resolve with conservative management
- operative: ossicle excision in refractory cases (patient is skeletally mature with persistent symptoms)

**Congenital Talipes Equinovarus (Club Foot)**

- congenital foot deformity
- muscle contractures resulting in CAVE deformity
- bony deformity: talar neck medial and plantar deviated; varus calcaneus and rotated medially around talus; navicular and cuboid medially displaced
- 1-2/1,000 newborns, 50% bilateral, occurrence M>F, severity F>M

**Etiology**

- intrinsic causes (neurologic, muscular, or connective tissue diseases) vs. extrinsic (intrauterine growth restriction), may be idiopathic, neurogenic, or syndrome-associated
- fixed deformity

**Physical Exam**

- examine hips for associated DDH
- examine knees for deformity
- examine back for dysraphism (unfused vertebral bodies)

**Treatment**

- largely non-operative via Ponseti Technique (serial manipulation and casting)
  - correct deformities in CAVE order
    - change strapping/cast q1-2wk
    - surgical release in refractory case (rare)
      - delayed until 3-4 mo of age
  - 3 yr recurrence rate = 5-10%
  - mild recurrence common; affected foot is permanently smaller/stiffer than normal foot with calf muscle atrophy

**Scoliosis**

- lateral curvature of spine with vertebral rotation
- age: 10-14 yr
- more frequent and more severe in females

**Etiology**

- idiopathic: most common (90%)
- congenital: vertebrae fail to form or segment
- neuromuscular: UMN or LMN lesion, myopathy
- postural: leg length discrepancy, muscle spasm
- other: osteochondrodystrophies, neoplastic, traumatic

**Clinical Features**

- ± back pain
- primary curve where several vertebrae affected
- secondary curves above and below fixed 1st curve to try and maintain normal position of head and pelvis
- asymmetric shoulder height when bent forward
- Adam’s test: rib hump when bent forward
- prominent scapulae, creased flank, asymmetric pelvis
- associated posterior midline skin lesions in neuromuscular scolioses
  - café-au-lait spots, dimples, neurofibromas
  - axillary freckling, hemangiomas, hair patches
- associated pes cavus or leg atrophy
- apparent leg length discrepancy

**Investigations**

- x-ray: 3-foot standing, AP, lateral
  - measure curvature: Cobb angle
  - may have associated kyphosis

**Etiology**

- structural or fixed scoliosis, bending forwards makes the curve more obvious

**Scoliosis screening is not recommended in Canada** (Grieg A, et al. 2010; Health Canada, 1994)
Treatment
• based on Cobb angle
  ■ <25°: observe for changes with serial radiographs
  ■ >25° or progressive: bracing (many types) that halt/slow curve progression but do NOT reverse deformity
  ■ >45°, cosmetically unacceptable or respiratory problems: surgical correction (spinal fusion)

Bone Tumours

• primary bone tumours are rare after 3rd decade
• metastases to bone are relatively common after 3rd decade

Clinical Features
• malignant (primary or metastasis): local pain and swelling (wk – mo), worse on exertion and at night, ± soft tissue mass
• benign: usually asymptomatic
• minor trauma often initiating event that calls attention to lesion

Table 24. Distinguishing Benign from Malignant Bone Lesions on X-Ray

<table>
<thead>
<tr>
<th>Benign</th>
<th>Malignant</th>
</tr>
</thead>
<tbody>
<tr>
<td>No periosteal reaction</td>
<td>Acute periosteal reaction</td>
</tr>
<tr>
<td></td>
<td>• Codman’s triangle</td>
</tr>
<tr>
<td></td>
<td>• “Onion skin”</td>
</tr>
<tr>
<td></td>
<td>• “Sunburst”</td>
</tr>
<tr>
<td>Thick endosteal reaction</td>
<td>Broad border between lesion and normal bone</td>
</tr>
<tr>
<td>Well developed bone formation</td>
<td>Varied bone formation</td>
</tr>
<tr>
<td>Intraosseous and even calcification</td>
<td>Extraosseous and irregular calcification</td>
</tr>
</tbody>
</table>


Diagnosis
• malignancy is suggested by rapid growth, warmth, tenderness, lack of sharp definition
• staging should include
  ■ blood work including liver enzymes
  ■ CT chest
  ■ bone scan
  ■ bone biopsy
  ■ should be referred to specialized centre prior to biopsy
  • classified into benign, benign aggressive, and malignant
  ■ MRI of affected bone

Benign Active Bone Tumours

BONE-FORMING TUMOURS

Osteoid Osteoma
• bone tumour arising from osteoblasts
• peak incidence in 2nd and 3rd decades, M:F = 2:1
• proximal femur and tibia diaphysis most common locations
• not known to metastasize
• radiographic findings: small, round radiolucent nidus (<1.5 cm) surrounded by dense sclerotic bone (“bull’s-eye”)
• symptoms: produces severe intermittent pain from prostaglandin secretion and COX1/2 expression, mostly at night (diurnal prostaglandin production), thus is characteristically relieved by NSAIDs
• treatment: NSAIDs for night pain; surgical resection of nidus

FIBROUS LESIONS

Fibrous Cortical Defect
• or non-ossifying fibroma; fibrous bone lesion
• most common benign bone tumour in children, typically asymptomatic and an incidental finding
• occur in as many as 35% of children, peak incidence between 2-25 yr old, higher prevalence in males
• femur and proximal tibia most common locations, 50% of patients have multiple defects usually bilateral, symmetrical
• radiographic findings: diagnostic, metaphyseal eccentric ‘bubbly’ lytic lesion near physis; thin smooth/lobulated well-defined sclerotic margin
• treatment: most lesions resolve spontaneously
Osteochondroma
- cartilage capped bony tumour
- 2nd and 3rd decades, M:F = 1.8:1
- most common of all benign bone tumours – 45%
- 2 types: sessile (broad based and increased risk of malignant degeneration) vs. pedunculated (narrow stalk)
- metaphysis of long bone near tendon attachment sites (usually distal femur, proximal tibia, or proximal humerus)
  - radiographic findings: cartilage-capped bony spur on surface of bone (“mushroom” on x-ray)
  - may be multiple (hereditary, autosomal dominant form) – higher risk of malignant change
- generally very slow growing and asymptomatic unless impinging on neurovascular structure (‘painless mass’)
  - growth usually ceases when skeletal maturity is reached
- malignant degeneration occurs in 1-2% (becomes painful or rapidly grows)
- treatment: typically observation; surgical excision if symptomatic

Enchondroma
- hyaline cartilage tumour; majority asymptomatic, presenting as incidental finding or pathological fracture
- 2nd and 3rd decades
- 60% occur in the small tubular bones of the hand and foot; others in femur (20%), humerus, ribs
- benign cartilagenous growth, an abnormality of chondroblasts, develops in medullary cavity
  - single/multiple enlarged rarefied areas in tubular bones
  - lytic lesion with sharp margination and irregular central calcification (stippled/punctate/popcorn appearance)
- malignant degeneration to chondrosarcoma occurs in 1-2% (pain in absence of pathologic fracture is an important clue)
- not known to metastasize
- treatment: observation with serial x-rays; surgical curettage if symptomatic or lesion grows

Cystic Lesions

Unicameral/Solitary Bone Cyst
- most common cystic lesion; serous fluid filled lesion
- children and young adults, peak incidence during first 2 decades, M:F = 2:1
- proximal humerus and femur most common
- symptoms: asymptomatic, or local pain; complete pathological fracture (50% presentations) or incidental detection
- radiographic findings: lytic translucent area on metaphyseal side of growth plate, cortex thinned/expanded; well defined lesion
- treatment: aspiration followed by steroid injection; curettage ± bone graft indicated if re-fracture likely

Benign Aggressive Bone Tumours

Giant Cell Tumours/Aneurysmal Bone Cyst/Osteoblastoma
- affects patients of skeletal maturity, peak 3rd decade
- osteoblastoma: found in the distal femur, proximal tibia, distal radius, sacrum, tarsal bones, spine
- giant cell tumour: pulmonary metastases in 3%
- aneurysmal bone cysts: either solid with fibrous/granular tissue, or blood-filled
- radiographic findings
  - giant cell tumour: eccentric lytic lesions, in epiphyses adjacent to subchondral bone; may break through cortex; T2 MRI enhances fluid within lesion (hyper-intense signal)
  - aneurysmal bone cyst: expanded with honeycomb shape
  - osteoblastoma: often nonspecific; calcified central nidus (>2 cm) with radiolucent halo and sclerosis
- symptoms: local tenderness and swelling, pain may be progressive (giant cell tumours), ± symptoms of nerve root compression (osteoblastoma)
- 15% recur within 2 yr of surgery

Treatment
- intralesional curettage + bone graft or cement
- wide local excision of expendable bones
Malignant Bone Tumours

Table 25. Most Common Malignant Tumour Types for Age

<table>
<thead>
<tr>
<th>Age</th>
<th>Tumour</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1</td>
<td>Neuroblastoma</td>
</tr>
<tr>
<td>1-10</td>
<td>Ewing’s of tubular bones</td>
</tr>
<tr>
<td>10-30</td>
<td>Osteosarcoma, Ewing’s of flat bones</td>
</tr>
<tr>
<td>30-40</td>
<td>Reticulum cell sarcoma, fibrosarcoma, periosteal osteosarcoma, malignant giant cell tumour, lymphoma</td>
</tr>
<tr>
<td>&gt;40</td>
<td>Metastatic carcinoma, multiple myeloma, chondrosarcoma</td>
</tr>
</tbody>
</table>

Osteosarcoma
- malignant bone tumour
- most frequently diagnosed in 2nd decade of life (60%), 2nd most common primary malignancy in adults
- history of Paget’s disease (elderly patients), previous radiation treatment
- predilection for sites of rapid growth: distal femur (45%), proximal tibia (20%), and proximal humerus (15%)
- invasive, variable histology; frequent metastases without treatment (lung most common)
- painful symptoms: progressive pain, night pain, poorly defined swelling, decreased ROM
- radiographic findings
  - characteristic periosteal reaction: Codman’s triangle (see Figure 56) or “sunburst” spicule formation (tumour extension into periosteum)
  - destructive lesion in metaphysis may cross epiphyseal plate
- management: complete resection (limb salvage, rarely amputation), neo-adjuvant chemo; bone scan – rule out skeletal metastases, CT chest – rule out pulmonary metastases
- prognosis: 70% (high-grade); 90% (low-grade)

Chondrosarcoma
- malignant chondrogenic tumour
- primary (2/3 cases)
  - previous normal bone, patient >40 yr; expands into cortex to give pain, pathological fracture, flecks of calcification
- secondary (1/3 cases)
  - malignant degeneration of pre-existing cartilage tumour such as enchondroma or osteochondroma
  - age range 25-45 yr and better prognosis than primary chondrosarcoma
- symptoms: progressive pain, uncommonly palpable mass
- radiographic findings: in medullary cavity, irregular “popcorn” calcification
- treatment: unresponsive to chemotherapy, treat with aggressive surgical resection + reconstruction; regular follow-up x-rays of resection site and chest
- prognosis: 10-yr survival 90% low-grade, 20-40% high-grade

Ewing’s Sarcoma
- malignant small round cell sarcoma
- most occur between 5-25 yr old
- florid periosteal reaction in metaphyses of long bone with diaphyseal extension
- metastases frequent without treatment
- signs/symptoms: presents with pain, mild fever, erythema and swelling, anemia, increased WBC, ESR, LDH (mimics an infection)
- radiographic findings: moth-eaten appearance with periosteal lamellated pattern (‘onion-skinning’)
- treatment: resection, chemotherapy, radiation
- prognosis ~ 70%, worst prognostic factor is distant metastases

Multiple Myeloma
- proliferation of neoplastic plasma cells
- most common primary malignant tumour of bone in adults (~43%)
- 90% occur in people >40 yr old, M:F = 2:1, African-Americans (twice as common)
- signs/symptoms: localized bone pain (cardinal early symptom), compression/pathological fractures, renal failure, nephritis, high incidence of infections (e.g. pyelonephritis/pneumonia), systemic (weakness, weight loss, anorexia)
- labs: anemia, thrombocytopenia, increased ESR, hypercalcemia, increased Cr
- radiographic findings: multiple, “punched-out” well-demarcated lesions, no surrounding sclerosis, marked bone expansion
- diagnosis
  - serum/urine immunoelctrophoresis (monoclonal gammopathy)
  - CT-guided biopsy of lytic lesions at multiple bony sites
- treatment: chemotherapy, bisphosphonates, radiation, surgery for symptomatic lesions or impending fractures – debulking, internal fixation
- prognosis: 5 yr survival 30%; 10 yr survival 11%

see Hematology: H49
**Bone Metastases**
- Most common cause of bone lesions in adults; typically age >40
- 2/3 from breast or prostate; also consider thyroid, lung, kidney
- Usually osteolytic; prostate occasionally osteoblastic
- May present with mechanical pain and/or night pain, pathological fracture, hypercalcemia
- Bone scan for MSK involvement, MRI for spinal involvement may be helpful
- Treatment; pain control, bisphosphonates, stabilization of impending fractures if Mirel’s Criteria >8 (ORIF, IM rod, bone cement)

### Table 26. Mirel’s Criteria for Impeding Fracture Risk and Prophylactic Internal Fixation

<table>
<thead>
<tr>
<th>Variable</th>
<th>Number Assigned</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site</td>
<td>Upper arm</td>
</tr>
<tr>
<td></td>
<td>Lower extremity</td>
</tr>
<tr>
<td></td>
<td>Peritrochanteric</td>
</tr>
<tr>
<td>Pain</td>
<td>Mild</td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
</tr>
<tr>
<td></td>
<td>Severe</td>
</tr>
<tr>
<td>Lesion</td>
<td>Blastic</td>
</tr>
<tr>
<td></td>
<td>Mixed</td>
</tr>
<tr>
<td></td>
<td>Lytic</td>
</tr>
<tr>
<td>Size</td>
<td>&lt;1/3 bone diameter</td>
</tr>
<tr>
<td></td>
<td>1/3-2/3 diameter</td>
</tr>
<tr>
<td></td>
<td>&gt;2/3 diameter</td>
</tr>
</tbody>
</table>

### Table 27. Common Medications

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Schedule</th>
<th>Indications</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>cefazolin (Ancef®)</td>
<td>1-2 g IV q8h</td>
<td>Prophylactically before orthopedic surgery</td>
<td>First generation cephalosporin; do not use with penicillin allergy</td>
</tr>
<tr>
<td>heparin</td>
<td>5000 IU SC q12h</td>
<td>To prevent venous thrombosis and pulmonary emboli</td>
<td>Monitor platelets, follow PTT which should rise 1.5-2x</td>
</tr>
<tr>
<td>LMWH dalteparin (Fragnxin®)</td>
<td>5000 IU SC 30-40 mg SC bid 2.5 mg SC OD</td>
<td>DVT prophylaxis especially in hip and knee surgery</td>
<td>Fixed dose, no monitoring, improved bioavailability, increased bleeding rates</td>
</tr>
<tr>
<td>fondaparinux (Arixtra®)</td>
<td>0.02-0.04 mg/kg IV</td>
<td>Conscious sedation for short procedures</td>
<td>Medication used during fracture reduction – monitor for respiratory depression</td>
</tr>
<tr>
<td>oral anticoagulants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dabigatran (Pradaxa®)</td>
<td>2.5 mg PO x1 then 220 mg PO OD</td>
<td>DVT prophylaxis especially TKA and THA</td>
<td>Predictable, no monitoring, oral administration; no antidote</td>
</tr>
<tr>
<td>rivaroxaban (Xarelto®)</td>
<td>10 mg PO x1 then 220 mg PO OD</td>
<td>DVT prophylaxis especially TKA and THA</td>
<td>Predictable, no monitoring, oral administration; no antidote</td>
</tr>
<tr>
<td>apixaban</td>
<td>2.5 mg PO x1 then 220 mg PO OD</td>
<td>DVT prophylaxis especially TKA and THA</td>
<td>Predictable, no monitoring, oral administration; no antidote</td>
</tr>
<tr>
<td>midazolam (Versed®)</td>
<td>0.02-0.04 mg/kg IV</td>
<td>Conscious sedation for short procedures</td>
<td>Medication used during fracture reduction – monitor for respiratory depression</td>
</tr>
<tr>
<td>fentanyl (Sublimaze®)</td>
<td>0.5-3 µg/kg IV</td>
<td>Conscious sedation for short procedures</td>
<td>Short acting anesthetic used in conjunction with midazolam (Versed®)</td>
</tr>
<tr>
<td>triamcinolone (Aristocort®)</td>
<td>0.1-1 mL of 25 mg/mL</td>
<td>Suspension (injected into inflamed joint or bursa); amount varies by joint size</td>
<td>Potent anti-inflammatory effect; increased pain for 24 h, rarely causes fat necrosis and skin depigmentation</td>
</tr>
<tr>
<td>naproxen (Aleve®, Naprosyn®)</td>
<td>250-500 mg bid</td>
<td>Pain due to inflammation, arthritis, soft tissue injury</td>
<td>NSAID, may cause gastric erosion and bleeding</td>
</tr>
<tr>
<td>misoprostol (Cytotec®)</td>
<td>200 µg qid</td>
<td>Prophylaxis of HD after TKA and THA</td>
<td>Use with indomethacin</td>
</tr>
<tr>
<td>indomethacin (Indocid®)</td>
<td>25 mg PO x1 then 220 mg PO OD</td>
<td>Prophylaxis of HD after TKA and THA</td>
<td>Use with misoprostol</td>
</tr>
<tr>
<td>ibuprofen (Advil®, Motrin®)</td>
<td>200-400 mg tid</td>
<td>Pain (including post-operative), inflammation (including arthritis)</td>
<td>NSAID, may cause gastric erosion and bleeding</td>
</tr>
<tr>
<td>propofol (Diprivan®)</td>
<td>1-2 mg/kg IV maintenance 0.5 mg/kg</td>
<td>Conscious sedation for short procedures</td>
<td>Short acting anesthetic often used in conjunction with fentanyl (Sublimaze®)</td>
</tr>
</tbody>
</table>
Acronyms

ABR  auditory brainstem response  EBV  Epstein-Barr virus
AC  air conduction  FAP  familial adenomatous polyposis
ADM  acute otitis media  FESS  functional endoscopic sinus surgery
BAHA  bone anchored hearing aid  FNA  fine needle aspiration
BC  bone conduction  GERD  gastroesophageal reflux disease
CHL  conductive hearing loss  GPA  granulomatosis with polyangiitis
CPA  cerebellopontine angle  H&N  head and neck
EAC  external auditory canal  HL  hearing loss

HPV  human papillomavirus  SCC  squamous cell carcinoma
INCS  intranasal corticosteroids  SCM  sternocleidomastoid
MEI  middle ear inflammation  SNHL  sensorineural hearing loss
OEM  otitis media with effusion  SRT  speech reception threshold
OSA  obstructive sleep apnea  TEF  tracheoesophageal fistula
RA  rheumatoid arthritis  TM  tympanic membrane
URTI  upper respiratory tract infection

Basic Anatomy Review

Ear

Figure 1. Surface anatomy of the external ear; anatomy of ear

Figure 2. Normal appearance of right tympanic membrane on otoscopy
**Nose**

Figure 3. Nasal anatomy

Figure 4. Nasal septum and its arterial supply (see Epistaxis, OT26 for detailed blood supply)

Figure 5. Anatomy of the four paranasal sinuses: maxillary, ethmoid, sphenoid, and frontal

Reprinted from: Dhillon RS, East CA. Ear, Nose and Throat and Head and Neck Surgery, 2nd ed. Copyright 1999, with permission from Elsevier

**Throat**

Figure 6. Anatomy of a normal larynx; superior view of larynx on indirect laryngoscopy
**Head and Neck**

Figure 7. Extratemporal segment of facial nerve
Branches of facial nerve (in order from superior to inferior)
To Zunbar By Mtor Car

Figure 8. Blood supply to the face
Branches of the external carotid artery (in order from inferior to superior)
Some Angry Lady Figured Out PMS

![Diagram of the head and neck region with labeled structures](image-url)

- Temporal branch
- Zygomatic branch
- Buccal branch
- Styloid process
- Mastoid process
- Stylomastoid foramen
- Facial n. (CN VII)
- Posterior belly of digastric m.
- Parotid gland
- Mandibular branch
- Marginal mandibular branch
- Cervical branch

![Diagram of the neck region with labeled structures](image-url)

- Posterior belly of digastric m.
- Prem. belly digastric m.
- Ant. belly digastric m.
- Hyoid bone
- Sternohyoid m.
- Omohyoid m.
- Anterior triangle
- Trapezius m.
- Common carotid a. bifurcation
- Internal carotid a.
- External carotid a.
- Common carotid a.
- Thyroid cartilage
- Median cricothyroid ligament
- Cricoid cartilage
- Clavicle
- Trachea

**Figure 9. Anatomy of the neck**

© M. Romanova 2010
© Inessa Stanishevskaya 2012 after
© Kateryna Procinier 2014, after
Anatomical Triangles of the Neck

Anterior triangle
- bounded by anterior border of SCM, midline of neck, and lower border of mandible
- divided into
  - submental triangle: bounded by both anterior bellies of digastric and hyoid bone
  - digastric triangle: bounded by anterior and posterior bellies of digastric and inferior border of mandible
  - carotid triangle: bounded by sternocleidomastoid, anterior border of omohyoid, and posterior belly of digastric
    - contains: tail of parotid, submandibular gland, hypoglossal nerve, carotid bifurcation, and lymph nodes

Posterior triangle
- bounded by posterior border of sternocleidomastoid, anterior border of trapezius, and middle third of clavicle
- divided into
  - occipital triangle: superior to posterior belly of the omohyoid
  - subclavian triangle: inferior to posterior belly of omohyoid
  - contains: spinal accessory nerve and lymph nodes

Table 1. Lymphatic Drainage of Nodal Groups and Anatomical Triangles of Neck

<table>
<thead>
<tr>
<th>Nodal Group/Level</th>
<th>Location</th>
<th>Drainage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Suboccipital (S)</td>
<td>Base of skull, posterior</td>
<td>Posterior scalp</td>
</tr>
<tr>
<td>2. Retroauricular (R)</td>
<td>Superficial to mastoid process</td>
<td>Scalp, temporal region, external auditory meatus, posterior pinna</td>
</tr>
<tr>
<td>3. Parotid-preauricular (P)</td>
<td>Anterior to ear</td>
<td>External auditory meatus, anterior pinna, soft tissue of frontal and temporal regions, root of nose, eyelids, palpebral conjunctiva</td>
</tr>
<tr>
<td>4. Submental (Level IA)</td>
<td>Anterior bellies (midline) of digastric muscles, tip of mandible, and hyoid bone</td>
<td>Floor of mouth, anterior tongue, anterior mandibular alveolar ridge, lower lip</td>
</tr>
<tr>
<td>5. Submandibular (Level IB)</td>
<td>Anterior belly of digastric muscle, stylohyoid muscle, body of mandible</td>
<td>Oral cavity, anterior nasal cavity, soft tissues of the mid-face, submandibular gland</td>
</tr>
<tr>
<td>6. Upper jugular (Levels IIA and IIB)</td>
<td>Skull base to inferior border of hyoid bone along SCM muscle</td>
<td>Oral cavity, nasal cavity, naso/or/o/hypopharynx, larynx, parotid glands</td>
</tr>
<tr>
<td>7. Middle jugular (Level III)</td>
<td>Inferior border of hyoid bone to inferior border of cricoid cartilage along SCM muscle</td>
<td>Oral cavity, naso/or/o/hypopharynx, larynx</td>
</tr>
<tr>
<td>8. Lower jugular* (Level IV)</td>
<td>Inferior border of cricoid cartilage to clavicle along SCM muscle</td>
<td>Hypopharynx, thyroid, cervical esophagus, larynx</td>
</tr>
<tr>
<td>9. Posterior triangle** (Levels VA and VB)</td>
<td>Posterior border of SCM, anterior border of trapezius, from skull base to clavicle</td>
<td>Nasopharynx and oropharynx, cutaneous structures of the posterior scalp and neck</td>
</tr>
<tr>
<td>10. Anterior compartment*** (Level VI)</td>
<td>Hyoid bone (midline) to suprasternal notch between the common carotid arteries</td>
<td>Thyroid gland, glottic and subglottic larynx, apex of piriform sinus, cervical esophagus</td>
</tr>
</tbody>
</table>

*Vinchow node: left lower jugular (level IV) supraclavicular node
**Includes some supravclavicular nodes
***Includes pretracheal, pretracheal, paratracheal, and parathyroidal nodes

Table 1. Lymphatic Drainage of Nodal Groups and Anatomical Triangles of Neck

Function of Facial Nerve
- “Ears, Tears, Face, Taste”
- Ears: stapedius muscle
- Tears: lacrimation (lacrimal gland) and salivation (parotid)
- Face: muscles of facial expression
- Taste: sensory anterior 2/3 of tongue (via chorda tympani)

6. Strap Muscles of the Neck
- Thyrohyoid
- Omohyoid
- Sternohyoid
- Sternothyroid

Figure 10. Anatomy of the thyroid gland
Dizziness

True Vertigo
- Peripheral (Vestibular)
  - Benign paroxysmal positional vertigo (BPPV)
  - Labyrinthitis
  - Meniere’s disease
  - Vestibular neuronitis
  - Autoimmune inner ear disease
  - Cholesteatoma
  - Otoxic drug exposure
  - Perilymph fistula
  - Recurrent vestibulopathy
  - Superior semicircular canal dehiscence
  - Temporal bone fracture

Non-Vertiginous
- Central
  - Cerebrovascular disorders
  - Cardiac
  - Migrainous vertigo
- Organic Diseases
  - Vertebrobasilar insufficiency
  - Arthrythmias
  - Multiple sclerosis
  - Transient ischemic attacks
  - Wallenberg’s syndrome
  - Vertebrobasilar hypoperfusion
  - Anemia
  - Perihemispheric infarction
  - Cerebellar abscess
  - Trauma: cerebellar contusion
- Functional
  - Toxic: alcohol, hypnotics, drugs
  - CPA tumours
  - Posterior fossa tumours
  - Glomus tumours

Common causes in bold

True nystagmus and vertigo caused by a peripheral lesion will never last longer than a couple of weeks because of compensation from the cerebellum (unless there is a history of cerebellar ischemia/stroke). Central lesions do not compensate, hence nystagmus and vertigo will persist.

Figure 11. Differential diagnosis of dizziness

Otalgia

External Ear
- Infection
  - Auricular cellulitis
  - External canal abscess
  - Herpes simplex/zoster
  - Otitis externa
  - Trauma
    - Burns
    - Frostbite
    - Hematoma
    - Lacerations
  - Other
    - Cerumen impaction
    - Foreign body
    - Neoplasm of external canal

Middle/Inner Ear
- Infection
  - AOM
  - Mastoiditis
  - Myringitis
  - Otitis media with effusion
  - Skull base infections
  - Trauma
    - Barotrauma
    - Traumatic perforation
  - Other
    - Cholesteatoma
    - Neoplasm
    - Wegener's granulomatosis

Referred Pain
- Infection
  - Ramsay Hunt syndrome
  - Tonsillitis
  - Tracheitis
  - Trauma
  - Cervical arthritis
  - Thyroiditis
  - Other
    - Glossopharyngeal neuralgia
    - Neoplasm of oral cavity, larynx, pharynx
    - Teeth
    - TMJ syndrome
    - Trauma

Figure 12. Differential diagnosis of otalgia
Hearing Loss

Figure 13. Differential diagnosis of hearing loss

Tinnitus

Figure 14. Differential diagnosis of tinnitus
### Nasal Obstruction

#### Table 2. Differential Diagnosis of Nasal Obstruction

<table>
<thead>
<tr>
<th>Acquired</th>
<th>Congenital</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nasal Cavity</strong></td>
<td><strong>Nasal Cavity</strong></td>
</tr>
<tr>
<td>Rhinitis</td>
<td>Nasal dermoid cyst</td>
</tr>
<tr>
<td>Acute/chronic</td>
<td>Encephalocele</td>
</tr>
<tr>
<td>Vasomotor</td>
<td>Gloma</td>
</tr>
<tr>
<td>Allergic</td>
<td>Choanal atresia</td>
</tr>
<tr>
<td>Rhinosinusitis</td>
<td></td>
</tr>
<tr>
<td>Foreign bodies</td>
<td></td>
</tr>
<tr>
<td>Enlarged turbinates</td>
<td></td>
</tr>
<tr>
<td>Tumour</td>
<td></td>
</tr>
<tr>
<td>Benign: polyps, inverting papilla</td>
<td>Esthesioneuroblastoma (olfactory neuroblastoma)</td>
</tr>
<tr>
<td>Malignant</td>
<td>Adenocarcinoma</td>
</tr>
</tbody>
</table>

| **Nasal Septum**          | **Nasal Septum**                |
| Septal deviation          | Septal deviation                |
| Septal hematoma/abscess   | Septal hematoma/abscess         |
| Dislocated septum         | Dislocated septum               |

| **Nasopharynx**           |                                 |
| Adenoid hypertrophy       |                                 |
| Tumour                    |                                 |
| Benign: juvenile nasopharyngeal angiofibroma (JNA), polyps | Malignant: nasopharyngeal carcinoma |

| **Systemic**              |                                 |
| Granulomatous diseases, diabetes, vasculitis | |

### Hoarseness

#### Table 3. Differential Diagnosis of Hoarseness

<table>
<thead>
<tr>
<th>Infectious</th>
<th>Acute/chronic laryngitis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Laryngotracheobronchitis (croup)</td>
</tr>
</tbody>
</table>

| **Inflammatory**          | GERD                             |
|                           | Vocal cord polyps/nodules        |
|                           | Lifestyle: smoking, chronic EtOH use |

| **Trauma**                | External laryngeal trauma        |
|                           | Endoscopy and endotracheal tube (e.g. intubation granuloma) |

| **Neoplasia**             | Benign tumour                    |
|                           | Papillomas (HPV infection)       |
|                           | Minor salivary gland tumours     |
|                           | Other                            |
|                           | Malignant tumours (e.g. thyroid) |
|                           | SCC                              |
|                           | Other                            |

| **Cysts**                 | Retention cysts                  |

| **Systemic**              | Endocrine                        |
|                           | Hypothyroidism                   |
|                           | Myasthenia                       |

| **Neurologic**            | Central lesions                  |
| (vocal cord paralysis due to superior ± recurrent laryngeal nerve injury) | Cerebrovascular accident (CVA) |
|                           | Head injury                      |
|                           | Multiple sclerosis (MS)          |
|                           | Skull base tumours               |
|                           | Arnold-Chiari malformation       |
|                           | Peripheral lesions               |
|                           | Unilateral                       |
|                           | Lung malignancy                  |
|                           | Iatrogenic injury: thyroid, parathyroid surgery, carotid endarterectomy, patent ductus arteriosus (PDA) ligation Bilateral Iatrogenic injury: bilateral thyroid surgery, forceps delivery Neurovascular Myasthenia gravis |

| **Functional**            | Psychogenic aphonia (hysterical aphonia) |

| **Congenital**            | Laryngomalacia                   |
|                           | Laryngeal web                    |
|                           | Laryngeal atresia                |
Hearing

Neck Mass

Normal Hearing Physiology

- **conductive pathway** (EAC to cochlea): air conduction of sound down the EAC → vibration of TM → sequential vibration of middle ear ossicles (malleus, incus, stapes) → transmission of amplified vibrations from stapes footplate to the oval window of the cochlea → transmitted vibrations via cochlear fluid create movement along the basilar membrane within the cochlea

- **neural pathway** (nerve to brain): basilar membrane vibration stimulates overlying hair cells in the organ of Corti → stimulation of bipolar neurons in the spiral ganglion of the cochlear division of CN VIII → cochlear nucleus → superior olivary nucleus → lateral lemniscus → inferior colliculus → Sylvian fissure of temporal lobe

Types of Hearing Loss

1. **Conductive Hearing Loss**
   - conduction of sound to the cochlea is impaired
   - can be caused by external or middle ear disease

2. **Sensorineural Hearing Loss**
   - defect in the conversion of sound into neural signals or in the transmission of those signals to the cortex
   - can be caused by disease of the inner ear (cochlea), acoustic nerve (CN VIII), brainstem, or cortex

3. **Mixed Hearing Loss**
   - combination of conductive and sensorineural hearing loss

Auditory Acuity

- whispered-voice test: mask one ear and whisper into the other
- tuning fork tests (see Table 4; audiogram is of greater utility)
  - Rinne test
    - 512 Hz tuning fork is struck and held firmly on mastoid process to test BC; the tuning fork is then placed beside the pinna to test AC
    - If AC > BC → positive Rinne (normal)
  - Weber test
    - 512 Hz tuning fork is held on vertex of head and patient states whether it is heard centrally (Weber negative) or is lateralized to one side (Weber right, Weber left)
    - can place vibrating fork on patient's chin while they clench their teeth, or directly on teeth to elicit more reliable response
    - will only lateralize if difference in hearing loss between ears is >6 dB

Figure 15. Differential diagnosis of a neck mass
Table 4. The Interpretation of Tuning Fork Tests

<table>
<thead>
<tr>
<th>Examples</th>
<th>Weber</th>
<th>Rinne</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal or bilateral sensorineural hearing</td>
<td>Central</td>
<td>AC&gt;BC (+) bilaterally</td>
</tr>
<tr>
<td>Right-sided conductive hearing loss, normal left ear</td>
<td>Lateralizes to right</td>
<td>BC&gt;AC (-) right</td>
</tr>
<tr>
<td>Right-sided sensorineural hearing loss, normal left ear</td>
<td>Lateralizes to left</td>
<td>AC&gt;BC (+) bilaterally</td>
</tr>
<tr>
<td>Right-sided severe sensorineural hearing loss or dead right ear, normal left ear</td>
<td>Lateralizes to left</td>
<td>BC&gt;AC (-) right*</td>
</tr>
</tbody>
</table>

*A vibrating tuning fork on the mastoid stimulates the cochlea bilaterally, therefore in this case the left cochlea is stimulated by the Rinne test on the right (e.g. a false negative test). These tests are not valid if the ear canals are obstructed with cerumen (e.g. will create conductive loss).

**Pure Tone Audiometry**

- A threshold is the lowest intensity level at which a patient can hear the tone 50% of the time
- Thresholds are obtained for each ear at frequencies of 250, 500, 1000, 2000, 4000, and 8000 Hz
- Air conduction thresholds are obtained with headphones and measure outer, middle, inner ear, and auditory nerve function
- Bone conduction thresholds are obtained with bone conduction oscillators which bypass the outer and middle ear

**Degree of Hearing Loss**

- Determined on basis of the pure tone average (PTA) at 500, 1000, and 2000 Hz

---

**PURE TONE PATTERNS**

1. **Conductive Hearing Loss** (Figure 16B and 16C)
   - BC in normal range
   - AC outside of normal range
   - Gap between AC and BC thresholds >10 dB (an air-bone gap)

2. **Sensorineural Hearing Loss** (Figure 16D and 16E)
   - Both air and bone conduction thresholds below normal
   - Gap between AC and BC <10 dB (no air-bone gap)

3. **Mixed Hearing Loss**
   - Both air and bone conduction thresholds below normal
   - Gap between AC and BC thresholds >10 dB (an air-bone gap)
Speech Audiometry

Speech Reception Threshold
- lowest hearing level at which patient is able to repeat 50% of two syllable words which have equal emphasis on each syllable (spondee words)
- SRT and best pure tone threshold in the 500 to 2000 Hz range (frequency range of human speech) usually agree within 5 dB; if not, suspect a retrococlear lesion or functional hearing loss
- used to assess the reliability of the pure tone audiometry

Speech Discrimination Test
- percentage of words the patient correctly repeats from a list of 50 monosyllabic words
- tested at 40 dB above the patient’s SRT; therefore degree of hearing loss is taken into account
- rollover effect: a decrease in discrimination as sound intensity increases; typical of a retrococlear lesion (e.g. acoustic neuroma)
- investigate further if scores differ more than 20% between ears as asymmetry may indicate a retrococlear lesion
- best predictor of hearing aid response: a poor discrimination score indicates significant neural degeneration and hearing aids may not be the best option for the patient

Impedance Audiometry

Tympanogram
- the Eustachian tube equalizes the pressure between the external and middle ear
- tympanograms graph the compliance of the middle ear system against a pressure gradient ranging from to –400 to +200 mmH₂O
- tympanogram peak occurs at the point of maximum compliance: where the pressure in the external canal is equivalent to the pressure in the middle ear
- normal range: ~100 to +50 mmH₂O

Static Compliance
- volume measurement reflecting overall stiffness of the middle ear system
- normal range: 0.3-1.6 cc
- negative middle ear pressure and abnormal compliance indicate middle ear pathology
- in a type B curve, ear canal volumes of >2 cc in children and 2.5 cc in adults indicate TM perforation or presence of a patent ventilation tube

Acoustic Stapedial Reflexes
- stapedius muscle contracts in response to loud sound
- acoustic reflex threshold = 70-100 dB greater than hearing threshold; if hearing threshold >85 dB, reflex likely absent
- stimulating either ear causes bilateral and symmetrical reflexes
- for reflex to be present, CN VII must be intact and no conductive hearing loss in monitored ear
- if reflex is absent without conductive or severe sensorineural loss, suspect CN VII lesion
- acoustic reflex decay test = ability of stapedius muscle to sustain contraction for 10 s at 10 dB
- normally, little reflex decay occurs at 500 and 1000 Hz
- with cochlear hearing loss, acoustic reflex thresholds are 25-60 dB
- with retrococlear hearing loss (acoustic neuroma), absent acoustic reflexes or marked reflex decay (>50%) within 5 s
Auditory Brainstem Response

• measures neuroelectric potentials (waves) in response to a stimulus in five different anatomic sites (see Order of Neural Pathway sidebar on OT9; this test can be used to determine the site of lesion
• delay in brainstem response suggests cochlear or retrocochlear abnormalities
• does not require volition or co-operation of patient (therefore of value in children and malingers)

Otoacoustic Emissions

• objective test of hearing where a series of clicks is presented to the ear and the cochlea generates an echo which can be measured
• often used in newborn screening
• can be used to uncover normal hearing in malingering patients
• absence of emissions can be due to hearing loss or fluid in the middle ear

Aural Rehabilitation

• dependent on degree of hearing loss, communicative requirements, motivation, expectations, and physical and mental abilities
• negative prognostic factors
  ■ poor speech discrimination
  ■ narrow dynamic range (recruitment)
  ■ unrealistic expectations
• types of hearing aids
  ■ BTE: behind-the-ear (with occlusive mould or open fit which allows natural sound to pass – for milder hearing losses)
  ■ ITE: in-the-ear, placed in concha
  ■ ITC: in-the-canal, placed entirely in ear canal
  ■ CIC: contained-in-canal, placed deeply in ear canal
  ■ bone conduction – bone-anchored hearing aid (BAHA): attached to the skull
  ■ contralateral routing of signals (CROS)
• assistive listening devices
  ■ direct/indirect audio output
  ■ infrared, FM radio, or induction loop systems
  ■ telephone, television, or alerting devices
• cochlear implants
  ■ electrode is inserted into the cochlea to allow direct stimulation of the auditory nerve
  ■ for profound bilateral sensorineural hearing loss not rehabilitated with conventional hearing aids
  ■ established indication: post-lingually deafened adults, pre- and post-lingually deaf children

Vertigo

Evaluation of the Dizzy Patient

• vertigo: illusion of rotational, linear, or tilting movement of self or environment
• vertigo is produced by peripheral (inner ear) or central (brainstem-cerebellum) stimulation
• it is important to distinguish vertigo from other potential causes of “dizziness” (see Figure 11, OT6)

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Peripheral</th>
<th>Central</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imbalance</td>
<td>Moderate-severe</td>
<td>Mild-moderate</td>
</tr>
<tr>
<td>Nausea and Vomiting</td>
<td>Severe</td>
<td>Variable</td>
</tr>
<tr>
<td>Auditory Symptoms</td>
<td>Common</td>
<td>Rare</td>
</tr>
<tr>
<td>Neurologic Symptoms</td>
<td>Rare</td>
<td>Common</td>
</tr>
<tr>
<td>Compensation</td>
<td>Rapid</td>
<td>Slow</td>
</tr>
<tr>
<td>Nystagmus</td>
<td>Unidirectional</td>
<td>Bidirectional</td>
</tr>
<tr>
<td></td>
<td>Horizontal or rotatory</td>
<td>Horizontal or vertical</td>
</tr>
</tbody>
</table>
Table 6. Differential Diagnosis of Vertigo Based on History

<table>
<thead>
<tr>
<th>Condition</th>
<th>Duration</th>
<th>Hearing Loss</th>
<th>Tinnitus</th>
<th>Aural Fullness</th>
<th>Other Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benign Paroxysmal Positional Vertigo (BPPV)</td>
<td>Seconds</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Ménière’s Disease</td>
<td>Minutes to hours</td>
<td>Unilateral, fluctuating</td>
<td>+</td>
<td>Pressure/warmth</td>
<td>–</td>
</tr>
<tr>
<td>Labyrinthitis/Vestibular Neuritis</td>
<td>Hours to days</td>
<td>Unilateral</td>
<td>±-Whistling</td>
<td>–</td>
<td>May have recent AOM</td>
</tr>
<tr>
<td>Acoustic Neuroma</td>
<td>Chronic</td>
<td>Progressive</td>
<td>+</td>
<td>–</td>
<td>Ataxia CN VII palsy</td>
</tr>
</tbody>
</table>

Table 7. Differential Diagnosis of Vertigo Based on Time Course

<table>
<thead>
<tr>
<th>Time Course</th>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recurrent, lasting</td>
<td>BPPV</td>
</tr>
<tr>
<td>Single episode, lasting minutes to hours</td>
<td>Migraine, transient ischemia of the labyrinth or brainstem</td>
</tr>
<tr>
<td>Recurrent to hours</td>
<td>Ménière’s</td>
</tr>
<tr>
<td>Prolonged</td>
<td>Vestibular neuritis, MS, brainstem/cerebellum infarct</td>
</tr>
<tr>
<td>Acoustic neuroma</td>
<td>Chronic</td>
</tr>
</tbody>
</table>

**Benign Paroxysmal Positional Vertigo**

**Definition**
- acute attacks of transient rotatory vertigo lasting seconds to minutes initiated by certain head positions, accompanied by torsional (i.e., rotatory) nystagmus (geotropic = fast phase towards the floor)
- most common form of positional vertigo (50% of patients with peripheral vestibular dysfunction)

**Etiology**
- due to canalithiasis (migration of free floating otoliths within the endolymph of the semicircular canal) or cupulolithiasis (otolith attached to the cupula of the semicircular canal)
  - can affect each of the 3 semicircular canals, although the posterior canal is affected in >90% of cases
  - causes: head injury, viral infection (URTI), degenerative disease, idiopathic
  - results in slightly different signals being received by the brain from the two balance organs resulting in sensation of movement

**Diagnosis**
- history (time course, provoking factors, associative symptoms)
- positive Dix-Hallpike maneuver (sensitivity 82%, specificity 71%)

**Dix-Hallpike Positional Testing (see website for video and illustrations)**
- the patient is rapidly moved from a sitting position to a supine position with the head hanging over the end of the table, turned to one side at 45° and neck extended 20° holding the position for 20 s
- onset of vertigo and rotary nystagmus indicate a positive test for the dependent side
- other diagnostic testing is not indicated in posterior canal BPPV

**Treatment**
- reassure patient that process resolves spontaneously
- particle repositioning maneuvers
  - Epley maneuver (performed by MD or by patient with the help of devices such as the DizzyFIX™)
  - Brandt-Daroff exercises (performed by patient)
- surgery for refractory cases
- anti-emetics for N/V
- drugs to suppress the vestibular system delay eventual recovery and are therefore not used

**Ménière’s Disease (Endolymphatic Hydrops)**

**Definition**
- episodic attacks of tinnitus, hearing loss, aural fullness, and vertigo lasting minutes to hours

**Proposed Etiology**
- inadequate absorption of endolymph leads to endolymphatic hydrops (over accumulation) that distorts the membranous labyrinth

**Epidemiology**
- peak incidence 40-60 yr
- bilateral in 35% of cases
Clinical Features
- episodic vertigo, fluctuating low frequency SNHL, tinnitus, and aural fullness
- ± drop attacks (Tumarkin crisis), ± N/V
- vertigo disappears with time (min to h), but hearing loss remains
- early in the disease: fluctuating SNHL
- later stages: persistent tinnitus and progressive hearing loss
- attacks come in clusters and can be debilitating to the patient
- triggers: high salt intake, caffeine, stress, nicotine, and alcohol

Treatment
- acute management may consist of bed rest, antiemetics, antivertiginous drugs (e.g. betahistine [Serc’]
  meclizine, dimenhydramine), and anticholinergics (e.g. scopolamine)
- long-term management may include
  - medical
    - low salt diet, diuretics (e.g. hydrochlorothiazide, triamterene, amiloride)
    - Serc’ prophylactically to decrease intensity of attacks
    - intratympanic gentamicin to destroy vestibular end-organ, results in complete SNHL
    - intratympanic glucocorticoids (e.g. dexamethasone) may improve vertigo symptoms
  - surgical
    - selective vestibular neurectomy or labyrinthectomy
    - potential benefit for endolymphatic sac decompression or sacculotomy
- must monitor opposite ear as bilaterality occurs in 35% of cases

Vestibular Neuronitis (Labyrinthitis)

Definition
- acute onset of disabling vertigo often accompanied by N/V and imbalance without hearing loss that
  resolves over days leaving a residual imbalance that lasts days to weeks
- vestibular neuronitis: inflammation of the vestibular portion of CNVIII
- labyrinthitis: inflammation of both vestibular and cochlear portions

Etiology
- thought to be due to a viral infection (e.g. measles, mumps, herpes zoster) or post-viral syndrome
- only ~30% of cases have associated URTI symptoms
- labyrinthitis may occur as a complication of acute and chronic otitis media, bacterial meningitis, 
  cholesteatoma, and temporal bone fractures

Clinical Features
- acute phase
  - severe vertigo with N/V and imbalance lasting 1-5 d
  - irritative nystagmus (fast phase towards the offending ear)
  - ataxia: patient tends to veer towards affected side
  - tinnitus and hearing loss in labyrinthitis
- convalescent phase
  - imbalance and motion sickness lasting days to weeks
  - spontaneous nystagmus away from affected side
  - gradual vestibular adaptation requires weeks to months

Treatment
- acute phase
  - bed rest, antivertiginous drugs
  - corticosteroids (methylprednisolone) ± antivirals
  - bacterial infection: treat with IV antibiotics, drainage of middle ear, ± mastoidectomy
- convalescent phase
  - progressive ambulation especially in the elderly
  - vestibular exercises: involve eye and head movements, sitting, standing, and walking

Acoustic Neuroma (Vestibular Schwannoma)

Definition
- schwannoma of the vestibular portion of CN VIII

Pathogenesis
- starts in the internal auditory canal and expands into cerebellopontine angle (CPA), compressing 
  cerebellum and brainstem
- when associated with type 2 neurofibromatosis (NF2): bilateral acoustic neuromas, juvenile cataracts, 
  meningiomas, and ependymomas

Clinical Features
- usually presents with unilateral SNHL (chronic) or tinnitus
- dizziness and unsteadiness may be present, but true vertigo is rare as tumour growth occurs slowly and 
  thus compensation occurs

Acoustic neuroma is the most common intracranial tumour causing SNHL and the most common cerebellopontine angle tumour
In the elderly, unilateral tinnitus or SNHL is acoustic neuroma until proven otherwise
Drop Attacks (Tumarkin’s Otolithic Crisis)
are sudden falls occurring without warning and without LOC, where patients experiences 
feeling of being pushed down into the ground
Before proceeding with gentamicin treatment, 
perform a gadolinium enhanced MRI to rule out CPA tumour as the cause of symptoms
• facial nerve palsy and trigeminal (V1) sensory deficit (corneal reflex) are late complications
• risk factors: exposure to loud noise, childhood exposure to low-dose radiation, history of parathyroid adenoma

Diagnosis
• MRI with gadolinium contrast (gold standard)
• audiogram (to assess SNHL)
• poor speech discrimination relative to the hearing loss
• stapedial reflex absent or significant reflex decay
• ABR: increase in latency of the 5th wave
• vestibular tests: normal or asymmetric caloric weakness (an early sign)

Treatment
• expectant management if tumour is very small, or in elderly
• definitive management is surgical excision
• other options: gamma knife, radiation

Tinnitus

Definition
• an auditory perception in the absence of an acoustic stimuli, likely related to loss of input to neurons in central auditory pathways and resulting in abnormal firing

History
• subjective vs. objective (see Figure 14, OT7)
• continuous vs. pulsatile (vascular in origin)
• unilateral vs. bilateral
• associated symptoms: hearing loss, vertigo, aural fullness, otalgia, otorrhea

Investigations
• audiology
• if unilateral
  • ABR, gadolinium enhanced MRI to exclude a retrocochlear lesion
  • CT to diagnose glomus tympanicum (rare)
  • MRI or angiogram to diagnose AVM
• if suspect metabolic abnormality: lipid profile, TSH, zinc levels

Treatment
• if a cause is found, treat the cause (e.g. drainage of middle ear effusion, embolization or excision of AVM)
• with no treatable cause: 50% will improve, 25% worsen, 25% remain the same
• avoid loud noise, ototoxic meds, caffeine, smoking
• tinnitus clinics
• identify situations where tinnitus is most bothersome (e.g. quiet times), mask tinnitus with soft music or “white noise”
• hearing aid if coexistent hearing loss
• tinnitus instrument: combines hearing aid with white noise masker
• trial of tocainamide

Diseases of the External Ear

Cerumen Impaction

Etiology
• ear wax: a mixture of secretions from ceruminous and pilosebaceous glands, squames of epithelium, dust, and debris

Risk Factors
• hairy or narrow ear canals, in-the-ear hearing aids, cotton swab usage, osteomata

Clinical Features
• hearing loss (conductive)
• ± tinnitus, vertigo, otalgia, aural fullness

Treatment
• water or cerumenolytic drops (bicarbonate solution, olive oil, glycerine, Cerumenol®, Cerumenex®)
• manual debridement (by MD)

Syringing
Indications
• Totally occlusive cerumen with pain, decreased hearing, or tinnitus

Contraindications
• Active infection
• Previous ear surgery
• Only hearing ear
• TM perforation

Complications
• Otitis externa
• TM perforation
• Pain
• Vertigo
• Tinnitus
• Otitis media

Method
• Establish that TM is intact
• Gently pull the pinna superiorly and posteriorly
• Using lukewarm water, aim the syringe nozzle upwards and posteriorly to irrigate the ear canal
Exostoses

Definition
• bony protuberances in the external auditory canal composed of lamellar bone

Etiology
• possible association with swimming in cold water

Clinical Features
• usually an incidental finding
• if large, they can cause cerumen impaction or otitis externa

Treatment
• no treatment required unless symptomatic

Otitis Externa

Etiology
• bacterial (90% of OE): *Pseudomonas aeruginosa*, *Pseudomonas vulgaris*, *E. coli*, *S. aureus*
• fungal: *Candida albicans*, *Aspergillus niger*

Risk Factors
• associated with swimming ("swimmer’s ear")
• mechanical cleaning (Q-tips®), skin dermatitis, aggressive scratching
• devices that occlude the ear canal: hearing aids, headphones, etc.
• allergic contact dermatitis, dermatologic conditions (psoriasis, atopic dermatitis)

Clinical Features
• acute
  • pain aggravated by movement of auricle (traction of pinna or pressure over tragus)
  • otorrhea (sticky yellow purulent discharge)
  • conductive hearing loss ± aural fullness 2º to obstruction of external canal by swelling and purulent debris
  • posterior auricular lymphadenopathy
  • complicated OE exists if the pinna and/or the periauricular soft tissues are erythematous and swollen
• chronic
  • pruritus of external ear ± excoriation of ear canal
  • atrophic and scaly epidermal lining, ± otorrhea, ± hearing loss
  • wide meatus but no pain with movement of auricle
  • tympanic membrane appears normal

Treatment
• clean ear under magnification with irrigation, suction, dry swabbing, and C&S
• bacterial etiology
  • antipseudomonal otic drops (e.g. ciprofloxacin) or a combination of antibiotic and steroid (e.g. Cipro HC®)
  • do not use aminoglycoside if the tympanic membrane (TM) is perforated because of the risk of ototoxicity
  • introduction of fine gauze wick (pope wick) if external canal edematous
  • ± 3% acetic acid solution to acidify ear canal (low pH is bacteriostatic)
  • systemic antibiotics if either cervical lymphadenopathy or cellulitis is present
• fungal etiology
  • repeated debridement and topical antifungals (gentian violet, Mycostatin® powder, boric acid, Locacorten®, Vioform® drops)
• ± analgesics
• chronic otitis externa (pruritus without obvious infection) → corticosteroid alone (e.g. diprosalic acid)

Malignant (Necrotizing) Otitis Externa (Skull Base Osteomyelitis)

Definition
• osteomyelitis of the temporal bone

Epidemiology
• occurs in elderly diabetics and immunocompromised patients

Etiology
• rare complication of otitis externa
• *Pseudomonas* infection in 99% of cases
Clinical Features
• otalgia and purulent otorrhea that is refractory to medical therapy
• granulation tissue on the floor of the auditory canal

Complications
• cranial nerve palsy (most commonly CN VII>CN X>CN XI)
• systemic infection, death

Management
• imaging: high resolution temporal bone CT scan, gadolinium enhanced MRI, technetium scan
• requires hospital admission, debridement, IV antibiotics, hyperbaric O2
• may require OR for debridement of necrotic tissue/bone

Diseases of the Middle Ear

Acute Otitis Media and Otitis Media with Effusion
• see Pediatric Otolaryngology, OT38

Chronic Otitis Media
Definition
• an ear with TM perforation in the setting of recurrent or chronic ear infections

Benign
• dry TM perforation without active infection

Chronic Serous Otitis Media
• continuous serous drainage (straw-coloured)

Chronic Suppurative Otitis Media
• persistent purulent drainage through a perforated TM

Cholesteatoma
Definition
• a cyst composed of keratinized desquamated epithelial cells occurring in the middle ear, mastoid, and temporal bone
• two types: congenital and acquired

Congenital
• presents as a “small white pearl” behind an intact tympanic membrane (anterior and medial to the malleus) or as a conductive hearing loss
• believed to be due to aberrant migration of external canal ectoderm during development
• not associated with otitis media/Eustachian tube dysfunction

Acquired (more common)
• primary cholesteatoma
  • frequently associated with retraction pockets in the pars flaccida (may lead to attic cholesteatomas which are difficult to visualize)
  • often has crusting or desquamated debris on lateral surface
• secondary cholesteatoma
  • pearly mass evident behind TM, frequently associated with marginal perforation
  • may appear as skin that have replaced the mucosa of the middle ear
• the associated chronic inflammatory process causes progressive destruction of surrounding bony structures

Clinical Features
• history of otitis media (especially if unilateral), ventilation tubes, ear surgery
• symptoms
  • progressive hearing loss (predominantly conductive although may get sensorineural hearing loss in late stage)
  • otalgia, aural fullness, fever
• signs
  • retraction pocket in TM, may contain keratin debris
  • TM perforation
  • granulation tissue, polyp visible on otoscopy
  • malodourous, unilateral otorrhea
Complications

Table 8. Complications of Cholesteatoma

<table>
<thead>
<tr>
<th>Local</th>
<th>Intracranial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ossicular erosion: conductive hearing loss</td>
<td>Meningitis</td>
</tr>
<tr>
<td>Inner ear erosion: SNHL, dizziness, and/or labyrinthitis</td>
<td>Sigmoid sinus thrombosis</td>
</tr>
<tr>
<td>Temporal bone infection: mastoiditis, petrotis</td>
<td>Intracranial abscess (subdural, epidural, cerebellar)</td>
</tr>
<tr>
<td>Facial paralysis</td>
<td></td>
</tr>
</tbody>
</table>

Investigations

- audiogram and CT scan

Treatment

- there is no conservative therapy for cholesteatoma
- surgical: mastoidectomy ± tympanoplasty ± ossicular reconstruction

Mastoiditis

Definition

- infection (usually subperiosteal) of mastoid air cells, most commonly seen approximately two weeks after onset of untreated or inadequately treated acute suppurative otitis media
- more common in children than adults

Etiology

- acute mastoiditis caused by the same organisms as AOM: S. pneumoniae, H. influenzae, M. catarrhalis, S. pyogenes, S. aureus, P. aeruginosa

Clinical Features

- otorrhea
- tenderness to pressure over the mastoid
- retroauricular swelling with protruding ear
- fever, hearing loss, ± TM perforation (late)
- CT radiologic findings: opacification of mastoid air cells by fluid and interruption of normal trabeculations of cells (coalescence)

Treatment

- IV antibiotics with myringotomy and ventilation tubes – usually all that is required acutely
- cortical mastoidectomy
- debridement of infected tissue allowing aeration and drainage
- indications for surgery
- failure of medical treatment after 48 h
- symptoms of intracranial complications
- aural discharge persisting for 4 wk and resistant to antibiotics

Otosclerosis

Definition

- fusion of stapes footplate to oval window so that it cannot vibrate

Etiology

- autosomal dominant, variable penetrance approximately 40%
- F>M, progresses during pregnancy (hormone responsive)

Clinical Features

- progressive conductive hearing loss first noticed in teens and 20s (may progress to sensorineural hearing loss if cochlea involved)
- ± pulsatile tinnitus
- tympanic membrane normal ± pink blush (Schwartz's sign) associated with the neovascularization of otosclerotic bone
- characteristic dip at 2000 Hz (Carhart's notch) on audiogram (see Figure 16C, OT10)

Treatment

- monitor with serial audiograms if coping with loss
- hearing aid (air conduction, bone conduction, BAHA)
- stapedectomy or stapedotomy (with laser or drill) with prosthesis is definitive treatment
Diseases of the Inner Ear

Congenital Sensorineural Hearing Loss

Hereditary Defects
- non-syndrome associated (70%)
  - often idiopathic, autosomal recessive
  - connexin 26 (GJB2) most common
- syndrome associated (30%)
  - Waardenburg: white forelock, heterochromia iridis (each eye different colour), wide nasal bridge, and increased distance between medial canthi
  - Pendred: deafness associated with thyroid gland disorders, SLC26A4 gene, enlarged vestibular aqueducts
  - Treacher-Collins: first and second branchial cleft anomalies
  - Alport: hereditary nephritis

Prenatal TORCH Infections
- toxoplasmosis, others (e.g. HIV, syphilis), rubella, CMV, HSV

Perinatal
- Rh incompatibility
- anoxia
- hyperbilirubinemia
- birth trauma (hemorrhage into inner ear)

Postnatal
- meningitis, mumps, measles

High Risk Factors (for hearing loss in newborns)
- low birth weight/prematurity
- perinatal anoxia (low APGARs)
- kernicterus: bilirubin >25 mg/dL
- craniofacial abnormality
- family history of deafness in childhood
- 1st trimester illness: TORCH infections
- neonatal sepsis
- ototoxic drugs
- perinatal infection, including post-natal meningitis
- consanguinity
- 50-75% of newborns with SNHL have at least one of the above risk factors and 90% of these have spent time in the NICU

Treatment
- presence of any risk factor: ABR study performed before leaving NICU and at 3 mo adjusted age
- early rehabilitation improves speech and school performance

Presbycusis

Definition
- SNHL associated with aging (starting in 5th and 6th decades)

Etiology
- hair cell degeneration
- age related degeneration of basilar membrane, possibly genetic etiology
- cochlear neuron damage
- ischemia of inner ear

Clinical Features
- progressive, bilateral hearing loss initially at high frequencies, then middle frequencies
- loss of discrimination of speech especially with background noise present – patients describe people as mumbling
- recruitment phenomenon: inability to tolerate loud sounds
- tinnitus

Treatment
- hearing aid if patient has difficulty functioning, hearing loss >30-35 dB, and good speech discrimination
- ± lip reading, auditory training, auditory aids (doorbell and phone lights)
Sudden Sensorineural Hearing Loss

Clinical Features
- presents as a sudden onset of significant SNHL (usually unilateral) ± tinnitus, aural fullness
- usually idiopathic, rule out other causes
- autoimmune causes (e.g. ESR, rheumatoid factor, ANA)
- MRI to rule out tumour and/or CT to rule out ischemic/hemorrhagic stroke if associated with any other focal neurological signs (e.g. vertigo, ataxia, abnormality of CN V or VII, weakness)

Treatment
- Intratympanic or oral corticosteroids within 3 d of onset: prednisone 1 mg/kg/d for 10-14 d

Prognosis
- depends on degree of hearing loss
- 70% resolve within 10-14 d
- 20% experience partial resolution
- 10% experience permanent hearing loss

Autoimmune Inner Ear Disease

Etiology
- idiopathic
- may be associated with systemic autoimmune diseases (e.g. rheumatoid arthritis, SLE), vasculitides (e.g. GPA, polyarteritis nodosa), and allergies

Epidemiology
- most common between ages 20-50

Clinical Features
- rapidly progressive or fluctuating bilateral SNHL
- ± tinnitus, aural fullness, vestibular symptoms (e.g. ataxia, disequilibrium, vertigo)

Investigations
- autoimmune workup: CBC, ESR, ANA, rheumatoid factor

Treatment
- high-dose corticosteroids: treat early for at least 30 d
- consider cytotoxic medication for steroid non-responders

Drug Ototoxicity

Aminoglycosides
- streptomycin and gentamicin (vestibulotoxic), kanamycin, and tobramycin (cochleotoxic)
- toxic to hair cells by any route: oral, IV, and topical (if the TM is perforated)
- destroys sensory hair cells: outer first, inner second (therefore otoacoustic emissions are lost first)
- high frequency hearing loss develops earliest
- ototoxicity occurs days to weeks post-treatment
- must monitor with peak and trough levels when prescribed, especially if patient has neutropenia and/or history of ear or renal problems
- q24h dosing recommended (with amount determined by creatinine clearance)
- aminoglycoside toxicity displays saturable kinetics, therefore, once daily dosing presents less risk than divided daily doses
- duration of treatment is the most important predictor of ototoxicity
- treatment: immediately stop aminoglycosides

Salicylates
- hearing loss with tinnitus, reversible if discontinued

Antimalarials (Quinines)
- hearing loss with tinnitus
- reversible if discontinued but can lead to permanent loss

Others
- many antineoplastic agents are ototoxic (weigh risks vs. benefits)
- loop diuretics
Noise-Induced Sensorineural Hearing Loss

Pathogenesis
- 85-90 dB over months or years or single sound impulses >135 dB can cause cochlear damage
- bilateral SNHL initially and most prominently at 4000 Hz (resonant frequency of the temporal bone), known as “boilermaker’s notch” on audiogram, extends to higher and lower frequencies with time (see Figure 16D, OT10)
- speech reception not altered until hearing loss >30 dB at speech frequency, therefore considerable damage may occur before patient complains of hearing loss
- difficulty with speech discrimination, especially in situations with competing noise

Phases of Hearing Loss
- dependent on: intensity of sound and duration of exposure
  - temporary threshold shift
  - when exposed to loud sound, decreased sensitivity or increased threshold for sound
  - may have associated aural fullness and tinnitus
  - with removal of noise, hearing returns to normal
- permanent threshold shift
  - hearing does not return to previous state

Treatment
- hearing aid
- prevention
  - ear protectors: muffs, plugs
  - limit exposure to noise with frequent rest periods
  - regular audiologic follow-up

Temporal Bone Fractures

Table 9. Features of Temporal Bone Fractures

<table>
<thead>
<tr>
<th></th>
<th>Transverse (1)</th>
<th>Longitudinal (2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extension</td>
<td>Into bony labyrinth and internal auditory meatus</td>
<td>Into middle ear</td>
</tr>
<tr>
<td>Incidence</td>
<td>10-20%</td>
<td>70-90%</td>
</tr>
<tr>
<td>Etiology</td>
<td>Frontal/occipital trauma</td>
<td>Lateral skull trauma</td>
</tr>
<tr>
<td>CN Pathology</td>
<td>CN VII palsy (50%)</td>
<td>CN VII palsy (10-20%)</td>
</tr>
<tr>
<td>Hearing Loss</td>
<td>SNHL due to direct cochlear injury</td>
<td>CHL secondary to ossicular injury</td>
</tr>
<tr>
<td>Vestibular Symptoms</td>
<td>Sudden onset vestibular symptoms due to direct semicircular canal injury (vertigo, spontaneous nystagmus)</td>
<td>Rare</td>
</tr>
<tr>
<td>Other Features</td>
<td>Intact external auditory meatus, TM ± hemotympanum</td>
<td>Torn TM or hemotympanum</td>
</tr>
<tr>
<td></td>
<td>Spontaneous nystagmus</td>
<td>Bleeding from external auditory canal</td>
</tr>
<tr>
<td></td>
<td>CSF leak in Eustachian tube to nasopharynx ± rhinorrhea (risk of meningitis)</td>
<td>Step formation in external auditory canal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CSF otorrhea</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Battle’s sign = mastoid ecchymoses</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Raccoon eyes = periorbital ecchymoses</td>
</tr>
</tbody>
</table>

- characterized as longitudinal or transverse relative to the long axis of the petrous temporal bone
- temporal bone fractures are rarely purely transverse or longitudinal (often a mixed picture)

Diagnosis
- otoscopy
- do not syringe or manipulate external auditory meatus due to risk of inducing meningitis via TM perforation
- CT head
- audiology, facial nerve tests (for transverse fractures), Schirmer’s test (of lacrimation), stapedial reflexes if CN VII palsy
- if suspecting CSF leak: look for halo sign, send fluid for β-2 transferrin or β trace protein (prostaglandin D synthase)

Treatment
- ABCs
- medical: expectant, prevent otogenic meningitis
- surgical: explore temporal bone, indications
  - CN VII palsy (immediate and complete)
  - gunshot wound
  - depressed fracture of external auditory meatus
  - early meningitis (mastoidectomy)
  - bleeding intracranially from sinus
  - CSF otorrhea (may resolve spontaneously)

Temporal Bone Fractures

- Frontal/occipital trauma
- Lateral skull trauma
- Sudden onset vestibular symptoms due to direct semicircular canal injury (vertigo, spontaneous nystagmus)
- Torn TM or hemotympanum
- Bleeding from external auditory canal
- Step formation in external auditory canal
- CSF otorrhea
- Battle’s sign = mastoid ecchymoses
- Raccoon eyes = periorbital ecchymoses

- Hemotympanum can be indicative of temporal bone trauma
- Signs of Basilar Skull Fracture
  - Battle’s Sign: ecchymosis of the mastoid process of the temporal bone
  - Raccoon Eyes
  - CSF Rhinorrhea/Otorrhea
  - Cranial Nerve Involvement: facial palsy → CN VII, nystagmus → CN VI, facial numbness → CN V
Complications
- AOM ± labyrinthitis ± mastoiditis
- meningitis/epidural abscess/brain abscess
- post-traumatic cholesteatoma

Facial Nerve (CN VII) Paralysis

Peripheral Facial Paralysis (PFP)
- mononeuropathy of the facial nerve where there is weakening in the facial muscles, which alter the facial symmetry and functions
- can have a detectable cause (secondary facial nerve palsy) or may be idiopathic (primary)

Etiology
- supranuclear and nuclear (MS, poliomyelitis, cerebral tumours)
- infranuclear

Treatment
- treat according to etiology plus provide corneal protection with artificial tears, nocturnal lid taping, tarsorrhaphy, gold weighting of upper lid
- facial paralysis that does not resolve with time or with medical treatment will often be referred for possible reanimation techniques to restore function
- common reanimation techniques include
  - direct facial nerve anastomosis
  - interpositional grafts
  - anastomosis to other motor nerves
  - muscle transpositions

Table 10. Differential Diagnosis of Peripheral Facial Paralysis (PFP)

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Incidence (of PFP)</th>
<th>Findings</th>
<th>Investigations</th>
<th>Treatment, Follow-up, and Prognosis (Px)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bell's Palsy</td>
<td>80-90%</td>
<td>Acute onset, Number of ear, Schirmer's test, Recurrence, Hyperacusis</td>
<td>Stapedial reflex absent</td>
<td>Rx: Protect the eye to prevent exposure keratitis with patching or tarsorrhaphy Systemic steroids may lessen degeneration and hasten recovery Consider antiviral (acyclovir)</td>
</tr>
<tr>
<td></td>
<td>Idiopathic, HSV</td>
<td>P/E</td>
<td>Hearing studies</td>
<td>F/U: Spontaneous remission should begin within 3 wk of onset Delayed (3-6 mo) recovery portends at least some functional loss</td>
</tr>
<tr>
<td></td>
<td>infection of the facial nerve</td>
<td></td>
<td>MRI with gadolinium – enhancement of CN VII and VIII High resolution CT</td>
<td></td>
</tr>
<tr>
<td>Diagnosis of exclusion</td>
<td></td>
<td>Hx</td>
<td>Stapedial reflex absent</td>
<td>Rx: Avoid touching lesions to prevent spread of infection Systemic steroids can relieve pain, vertigo, avoid postherpetic neuralgia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hx Acute onset, Number of ear, Schirmer's test, Recurrence</td>
<td>Hearing studies</td>
<td>F/U: 2-4 wk</td>
</tr>
<tr>
<td></td>
<td>Ramsay Hunt Syndrome (Herpes Zoster Oticus)</td>
<td>Hyperacusis, SNHL Severe pain of pinna, mouth, or face</td>
<td>Stapedial reflex absent</td>
<td>Rx: Poorer prognosis than Bell’s palsy; 22% recover completely, 66% incomplete paralysis 10% complete paralysis</td>
</tr>
<tr>
<td></td>
<td>Varicella zoster infection of CN VII/VIII</td>
<td>Vesicles on pinna, external canal (rupture 3-7 d after onset of pain)</td>
<td>Hearing studies</td>
<td>F/U: 2-4 wk</td>
</tr>
<tr>
<td></td>
<td>4.5-9%</td>
<td>Hx Hyperacusis, SNHL, Severe pain of pinna, mouth, or face</td>
<td>MRI with gadolinium (86% of facial nerves enhance)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Risk Factors: DM, Pregnancy Viral prodrome (50%)</td>
<td>P/E Vesicles on pinna, external canal (rupture 3-7 d after onset of pain)</td>
<td>Viral ELISA studies to confirmMRI with gadolinium (86% of facial nerves enhance)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>40%</td>
<td>P/E Trauma to side of head Neuro findings consistent with epidural/subdural bleed</td>
<td>Stapedial reflex absent</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Iatrogenic</td>
<td>Hx Blow to side of head</td>
<td>Skull x-rays CT head</td>
<td>Px: Injury usually due to stretch or impingement; may recover with time</td>
</tr>
<tr>
<td></td>
<td>50%</td>
<td>P/E Trauma to side of head Neuro findings consistent with epidural/subdural bleed</td>
<td>Stapedial reflex absent</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Longitudinal (90%)</td>
<td>Hx Blow to frontal or occipital area</td>
<td>Skull x-rays CT head</td>
<td>Px: Nerve transection more likely</td>
</tr>
<tr>
<td></td>
<td>20%</td>
<td>P/E Trauma to front or back of head</td>
<td>Stapedial reflex absent</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Transverse (10%)</td>
<td>Hx Blow to side of head</td>
<td>Skull x-rays CT head</td>
<td></td>
</tr>
<tr>
<td></td>
<td>40%</td>
<td>P/E Trauma to side of head Neuro findings consistent with epidural/subdural bleed</td>
<td>Stapedial reflex absent</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Iatrogenic</td>
<td>Variable (depending on level of injury)</td>
<td>Stapedial reflex absent</td>
<td></td>
</tr>
<tr>
<td></td>
<td>50%</td>
<td>Hx Blow to front or occipital area</td>
<td>Skull x-rays CT head</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TEMPORAL BONE FRACTURE</td>
<td>Rarely a patient has a single type of fracture</td>
<td>Stapedial reflex absent</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Longitudinal (90%)</td>
<td>Hx Blow to side of head</td>
<td>Skull x-rays CT head</td>
<td>Px: Exploration if complete nerve paralysis No exploration if any movement present Source: Paul Warrick, MD</td>
</tr>
<tr>
<td></td>
<td>Transverse (10%)</td>
<td>Hx Blow to frontal or occipital area</td>
<td>Skull x-rays CT head</td>
<td>Px: Nerve transection more likely</td>
</tr>
</tbody>
</table>
Rhinitis

Definition
• inflammation of the lining (mucosa) of the nasal cavity

Table 11. Classification of Rhinitis

<table>
<thead>
<tr>
<th>Inflammatory</th>
<th>Non-Inflammatory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perennial non-allergic</td>
<td>Rhinitis medicamentosa</td>
</tr>
<tr>
<td>Asthma, ASA sensitivity</td>
<td>Topical decongestants</td>
</tr>
<tr>
<td>Allergic</td>
<td>Hormonal</td>
</tr>
<tr>
<td>Seasonal</td>
<td>Pregnancy</td>
</tr>
<tr>
<td>Perennial</td>
<td>Estrogens</td>
</tr>
<tr>
<td>Atrophic</td>
<td>Thyroid</td>
</tr>
<tr>
<td>Primary: <em>Klebsiella ozena</em> (especially in elderly)</td>
<td>Idiopathic vasomotor</td>
</tr>
<tr>
<td>Acquired: post-surgery if too much mucosa or turbinate has been resected</td>
<td></td>
</tr>
<tr>
<td>Infectious</td>
<td></td>
</tr>
<tr>
<td>Viral: e.g. rhinovirus, influenza, parainfluenza, etc.</td>
<td></td>
</tr>
<tr>
<td>Bacterial: e.g. <em>S. aureus</em></td>
<td></td>
</tr>
<tr>
<td>Fungal</td>
<td></td>
</tr>
<tr>
<td>Granulomatous: TB, syphilis, leprosy</td>
<td></td>
</tr>
<tr>
<td>Non-infectious</td>
<td></td>
</tr>
<tr>
<td>Sarcoidosis</td>
<td></td>
</tr>
<tr>
<td>GPA</td>
<td></td>
</tr>
<tr>
<td>Irritant</td>
<td></td>
</tr>
<tr>
<td>Dust</td>
<td></td>
</tr>
<tr>
<td>Chemicals</td>
<td></td>
</tr>
<tr>
<td>Pollution</td>
<td></td>
</tr>
</tbody>
</table>

Table 12. Nasal Discharge: Character and Associated Conditions

<table>
<thead>
<tr>
<th>Character</th>
<th>Associated Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Watery/mucoid</td>
<td>Allergic, viral, vasomotor, CSF leak (halo sign)</td>
</tr>
<tr>
<td>Mucopurulent</td>
<td>Bacterial, foreign body</td>
</tr>
<tr>
<td>Serosanguinous</td>
<td>Neoplasia</td>
</tr>
<tr>
<td>Bloody</td>
<td>Trauma, neoplasia, bleeding disorder, hypertension/vascular disease</td>
</tr>
</tbody>
</table>

Allergic Rhinitis (i.e. Hay Fever)

Definition
• rhinitis characterized by an IgE-mediated hypersensitivity to foreign allergens
• acute-and-seasonal or chronic-and-perennial
• perennial allergic rhinitis often confused with recurrent colds

Etiology
• when allergens contact the respiratory mucosa, specific IgE antibody is produced in susceptible hosts
• concentration of allergen in the ambient air correlates directly with the rhinitis symptoms

Epidemiology
• age at onset usually <20 yr
• more common in those with a personal or family history of allergies/atopy

Clinical Features
• nasal: obstruction with pruritus, sneezing
• clear rhinorrhea (containing increased eosinophils)
• itching of eyes with tearing
• frontal headache and pressure
• mucosa: swollen, pale, “boggy”
• seasonal (summer, spring, early autumn)
  • pollens from trees
  • lasts several weeks, disappears, and recurs following year at same time
• perennial
  • inhaled: house dust, wool, feathers, foods, tobacco, hair, mould
  • ingested: wheat, eggs, milk, nuts
  • occurs intermittently for years with no pattern or may be constantly present

Complications
• chronic sinusitis/polyps
• serous otitis media
Diagnosis
- history
- direct exam
- allergy testing

Treatment
- education: identification and avoidance of allergen
- nasal irrigation with saline
- antihistamines (e.g. diphenhydramine, fexofenadine)
- oral decongestants (e.g. pseudoephedrine, phenylpropanolamine)
- topical decongestant (may lead to rhinitis medicamentosa)
- other topicals: steroids (fluticasone), disodium cromoglycate, antihistamines, ipratropium bromide
- oral steroids if severe
- desensitization by allergen immunotherapy

Vasomotor Rhinitis
- neurovascular disorder of nasal parasympathetic system (vidian nerve) affecting mucosal blood vessels
- nonspecific reflex hypersensitivity of nasal mucosa
- caused by
  - temperature change
  - alcohol, dust, smoke
  - stress, anxiety, neurosis
  - endocrine: hypothyroidism, pregnancy, menopause
  - parasympathomimetic drugs
  - beware of rhinitis medicamentosa: reactive vasodilation due to prolonged use (>5 d) of nasal drops and sprays (Dristan®, Otrivin®)

Clinical Features
- chronic intermittent nasal obstruction, varies from side to side
- rhinorrhea: thin, watery
- mucosa and turbinates: swollen
- nasal allergy must be ruled out

Treatment
- elimination of irritant factors
- parasympathetic blocker (Atrovent® nasal spray)
- steroids (e.g. beclomethasone, fluticasone)
- surgery (often of limited lasting benefit): electrocautery, cryosurgery, laser treatment, or removal of inferior or middle turbinates
- vidian neurectomy (rarely done)
- symptomatic relief with exercise (increased sympathetic tone)

Pathogenesis of Rhinosinusitis
- ostial obstruction or dysfunctional cilia permit stagnant mucous and, consequently, infection
- all sinuses drain to a common prechamber under the middle meatus called the osteomeatal complex

Definition
- inflammation of the mucosal lining of the sinuses and nasal passages

Classification
- acute: <4 wk
- subacute: 4-8 wk
- chronic: >8-12 wk
Table 13. Etiologies of Rhinosinusitis

<table>
<thead>
<tr>
<th>Etiologies</th>
<th>Inflammation</th>
<th>URTI</th>
<th>Allergy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ostial Obstruction</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanical</td>
<td>Severe</td>
<td>PA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deviation</td>
<td>Lymphoma, leukemia</td>
<td>Immunosuppressed patients (e.g. neutropenics, diabetics, HIV)</td>
</tr>
<tr>
<td></td>
<td>Turbinate hypertrophy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Polyps</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tumours</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adenoid hypertrophy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Foreign body</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Congenital abnormalities (e.g. cleft palate)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immune</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cystic fibrosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Immotile cilia (e.g. Kartagener’s syndrome)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct Extension</td>
<td>Dental</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trauma</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Facial fractures</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Acute Bacterial Rhinosinusitis

Definition
- bacterial infection of the paranasal sinuses and nasal passages lasting >7 d
- clinical diagnosis requiring ≥2 major symptoms, at least one of the symptoms is either nasal obstruction or purulent/dischcoloured nasal discharge
  - **major symptoms**
    - facial pain/pressure/fullness
    - nasal obstruction
    - purulent/dischcoloured nasal discharge
    - hyposmia/anosmia
  - **minor symptoms**
    - headache
    - halitosis
    - fatigue
    - dental pain
    - cough
    - ear pain/fullness

Etiology
- bacteria: *S. pneumoniae* (35%), *H. influenzae* (35%), *M. catarrhalis*, *S. aureus*, anaerobes (dental)
- children are more prone to a bacterial etiology, but viral is still more common
- maxillary sinus most commonly affected
- must rule out fungal causes (mucormycosis) in immunocompromised hosts (especially if painless, black or pale mucosa on examination)

Clinical Features
- sudden onset of:
  - nasal blockage/congestion and/or purulent nasal discharge/posterior nasal drip
  - ± facial pain or pressure, hyposmia, sore throat
- persistent/worsening symptoms >5-7 d or presence of purulence for 3-4 d with high fever
- speculum exam: erythematous mucosa, mucopurulent discharge, pus originating from the middle meatus
- predisposing factors: viral URTI, allergy, dental disease, anatomical defects
- differentiate from acute viral rhinosinusitis (course: <10 d, peaks by 3 d)

Diagnosis
- along with clinical criteria, can confirm radiographically and/or endoscopically using antral puncture for bacterial cultures

Management
- depends on symptom severity (i.e. intensity/duration of symptoms, impact on quality of life)
- mild-moderate: INCS
  - if no response within 72 h, add antibiotics
- severe: INCS + antibiotics
- antibiotics
  - 1st line: amoxicillin x 10 d (TMP-SMX or macrolide if penicillin allergy)
  - if no response to 1st line antibiotics within 72 h, switch to 2nd line
    - 2nd line: fluoroquinolones or amoxicillin-clavulanic acid inhibitors
- adjuvant therapy (saline or HOCL (pediatric sinusitis) irrigation, analgesics, oral/topical decongestant)
- may provide symptomatic relief
- CT indicated only if complications are suspected
Chronic Rhinosinusitis

Definition
- inflammation of the mucosa of paranasal sinuses and nasal passages >8-12 wk
- diagnosis requiring ≥2 major symptoms for >8-12 wk and ≥1 objective finding of inflammation of the paranasal sinuses (CT/endoscopy)

Etiology
- unclear etiology but the following may contribute or predispose
  - inadequate treatment of acute rhinosinusitis
  - bacterial colonization/biofilms
    - *S. aureus*, enterobacteriaceae, *Pseudomonas*, *S. pneumoniae*, *H. influenzae*, β-hemolytic streptococci
  - fungal infection (e.g. *Aspergillus*, *Zygomycetes*, *Candida*)
  - anatomic abnormality (e.g. lost ostia patency, deviated septum – predisposing factors)
  - allergy/allergic rhinitis
  - ciliary disorder (e.g. cystic fibrosis, Kartagener syndrome)
  - chronic inflammatory disorder (e.g. GPA)
  - untreated dental disease

Clinical Features (similar to acute, but less severe)
- chronic nasal obstruction
- purulent anterior/posterior nasal discharge
- facial congestion/fullness
- facial pain/pressure
- hyposmia/anosmia
- halitosis
- chronic cough
- maxillary dental pain

Management
- identify and address contributing or predisposing factors
- obtain CT or perform endoscopy
- if polyps present: INCS, oral steroids ± antibiotics (if signs of infection), refer to otolaryngologist/H&N surgeon
- if polyps absent: INCS, antibiotics, saline irrigation, oral steroids (severe cases)
- antibiotics for 3-6 wk
  - amoxillin-clavulanic acid inhibitors, fluoroquinolone (moxifloxacin), macrolide (clarithromycin), clindamycin, Flagyl® (metronidazole)
- surgery if medical therapy fails or fungal sinusitis: FESS, balloon sinoplasty

Complications
- same as acute sinusitis, mucocele

Epistaxis

Blood Supply to the Nasal Septum (see Figure 4, OT3)
1. Superior posterior septum
   - internal carotid → ophthalmic → anterior/posterior ethmoidal
2. Posterior septum
   - external carotid → internal maxillary → sphenopalatine artery → nasopalatine
3. Lower anterior septum
   - external carotid → facial artery → superior labial artery → nasal branch
   - these arteries all anastomose to form Kiesselbach's plexus, located at Little's area (anterior-inferior portion of the cartilaginous septum)
- bleeding from above middle turbinate is internal carotid, and from below is external carotid
Table 14. Etiology of Epistaxis

<table>
<thead>
<tr>
<th>Type</th>
<th>Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Local</td>
<td>Trauma (most common)</td>
</tr>
<tr>
<td></td>
<td>Fractures: facial, nasal</td>
</tr>
<tr>
<td></td>
<td>Self-induced: digital, foreign body</td>
</tr>
<tr>
<td></td>
<td>Iatrogenic: nasal, sinus, orbit surgery</td>
</tr>
<tr>
<td></td>
<td>Barometric changes</td>
</tr>
<tr>
<td></td>
<td>Nasal dryness: dry air ± septal deformities</td>
</tr>
<tr>
<td></td>
<td>Septal perforation</td>
</tr>
<tr>
<td></td>
<td>Chemical: cocaine, nasal sprays, ammonia, etc.</td>
</tr>
<tr>
<td>Systemic</td>
<td>Coagulopathies</td>
</tr>
<tr>
<td></td>
<td>Meds: anticoagulants, NSAIDs</td>
</tr>
<tr>
<td></td>
<td>Hemophilias, von Willebrand’s</td>
</tr>
<tr>
<td></td>
<td>Hematological malignancies</td>
</tr>
<tr>
<td></td>
<td>Liver failure, uremia</td>
</tr>
<tr>
<td></td>
<td>Vascular: HTN, atherosclerosis, Osler-Weber-Rendu (hereditary hemorrhagic telangiectasia)</td>
</tr>
<tr>
<td></td>
<td>Others: GPA, SLE</td>
</tr>
</tbody>
</table>

Investigations
- CBC, PT/PTT (if indicated)
- x-ray, CT as needed

Treatment
- locate bleeding and achieve hemostasis

1. ABCs
- lean patient forward to minimize swallowing blood and avoid airway obstruction
- apply constant firm pressure for 20 min on cartilaginous part of nose (not bony pyramid)
- if significant bleeding, assess vitals for signs of hemorrhagic shock ± IV NS, cross-match blood

2. Determine Site of Bleeding
- anterior/posterior hemorrhage defined by location in relationship to bony septum
- visualize nasal cavity with speculum
- use cotton pledget with topical lidocaine ± topical decongestant (i.e. Otrivin*) to help identify area of bleeding (often anterior septum)
- if suspicious bleeding disorder, coagulation workup (platelet number and platelet function assay)

3. Control the Bleeding
- first line topical vasoconstrictors (Otrivin*)
- if first line fails and bleeding adequately visualized, cauterize with silver nitrate
- do not cauterize both sides of the septum at one time due to risk of septal perforation from loss of septal blood supply

A. Anterior hemorrhage treatment
- if failure to achieve hemostasis with cauterization
  - place anterior pack* with half inch Vaseline*-soaked ribbon gauze strips layered from nasal floor toward nasal roof extending to posterior choanae or lubricated absorbable packing (i.e. Gelfoam wrapped in Surgicel*) for 2-3 d
  - can also attempt packing with Merocel® or nasal tampons of different shapes
  - can also apply Floseal® (hemostatic matrix consisting of topical human thrombin and cross-linked gelatin) if other methods fail

B. Posterior hemorrhage treatment
- if unable to visualize bleeding source, then usually posterior source
  - place posterior pack* using a Foley catheter, gauze pack, or Epistat* balloon
  - subsequently, layer anterior packing bilaterally
  - admit to hospital with packs in for 3-5 d
  - watch for complications: hypoxemia (naso-pulmonic reflex), toxic shock syndrome (Rx: remove packs immediately), pharyngeal fibrosis/stenosis, alar/septal necrosis, aspiration

C. If anterior/posterior packs fail to control epistaxis
- ligation or embolization of culprit arterial supply by interventional radiology
- ± septoplasty

*antibiotics for any posterior pack or any pack left for >48 h because of risk of toxic shock syndrome

4. Prevention
- prevent drying of nasal mucosa with humidifiers, saline spray, or topical ointments
- avoidance of irritants
- medical management of HTN and coagulopathies
Hoarseness

Definitions
• hoarseness: change in voice quality, ranging from voice harshness to voice weakness; reflects abnormalities anywhere along the vocal tract from oral cavity to lungs
• dysphonia: a general alteration in voice quality
• aphony: no sound emanates from vocal folds

Acute Laryngitis

Definition
• <2 wk inflammatory changes in laryngeal mucosa

Etiology
• viral: influenza, adenovirus, HSV
• bacterial: Group A Streptococcus
• mechanical acute voice strain → submucosal hemorrhage → vocal cord edema → hoarseness
• environmental: toxic fume inhalation

Clinical Features
• URTI symptoms, hoarseness, aphony, cough attacks, ± dyspnea
• true vocal cords erythematous/edematous with vascular injection and normal mobility

Treatment
• usually self-limited, resolves within ~1 wk
• voice rest
• humidification
• hydration
• avoid irritants (e.g. smoking)
• treat with antibiotics if there is evidence of coexistent bacterial pharyngitis

Chronic Laryngitis

Definition
• >2 wk inflammatory changes in laryngeal mucosa

Etiology
• repeated attacks of acute laryngitis
• chronic irritants (dust, smoke, chemical fumes)
• chronic voice strain
• chronic rhinosinusitis with postnasal drip
• chronic EtOH use
• esophageal disorders: GERD, Zenker’s diverticulum, hiatus hernia
• systemic: allergy, hypothyroidism, Addison’s disease

Clinical Features
• chronic dysphonia: rule out malignancy
• cough, globus sensation, frequent throat clearing 2° to GERD
• laryngoscopy: cords erythematous, thickened with ulceration/granuloma formation, and normal mobility

Treatment
• remove offending irritants
• treat related disorders (e.g. antisecretory therapy for GERD)
• speech therapy with voice rest
• ± antibiotics ± steroids to decrease inflammation
• laryngoscopy to rule out malignancy

Vocal Cord Polyps

Definition
• structural manifestation of vocal cord irritation
• acutely, polyp forms 2° to capillary damage in the subepithelial space during extreme voice exertion

Etiology
• most common benign tumour of vocal cords
• voice strain (muscle tension dysphonia)
• laryngeal irritants (GERD, allergies, tobacco)
Hoarseness

Epidemiology
- 30-50 yr of age
- M>F

Clinical Features
- hoarseness, aphonia, cough attacks ± dyspnea
- pedicled or sessile polyp on free edge of vocal cord
- typically polyp asymmetrical, soft, and smooth
- more common on the anterior 1/3 of the vocal cord
- intermittent respiratory distress with large polyps

Treatment
- avoid irritants
- endoscopic laryngeal microsurgical removal if persistent or if high risk of malignancy

Vocal Cord Nodules

Definition
- vocal cord callus
- i.e. “screamer's or singer's nodules”

Etiology
- early nodules occur 2º to submucosal hemorrhage
- mature nodules result from hyalinization which occurs with long-term voice abuse
- chronic voice strain
- frequent URTI, smoke, EtOH

Epidemiology
- frequently in singers, children, bartenders, and school teachers
- F>M

Clinical Features
- hoarseness worst at end of day
- on laryngoscopy
  - often bilateral
  - at the junction of the anterior 1/3 and posterior 2/3 of the vocal cords – point of maximal cord vibration
- chronic nodules may become fibrotic, hard, and white

Treatment
- voice rest
- hydration
- speech therapy
- avoid irritants
- surgery rarely indicated for refractory nodules

Benign Laryngeal Papillomas

Etiology
- HPV types 6, 11
- possible hormonal influence, possibly acquired during delivery

Epidemiology
- biphasic distribution: 1) birth to puberty (most common laryngeal tumour) and 2) adulthood

Clinical Features
- hoarseness and airway obstruction
- can seed into tracheobronchial tree
- highly resistant to complete removal
- some juvenile papillomas resolve spontaneously at puberty
- may undergo malignant transformation
- laryngoscopy shows wart-like lesions in supraglottic larynx and trachea

Treatment
- microdebridement or CO₂ laser
- adjuvants under investigation: interferon, cidofovir, acyclovir
- HPV vaccine may prevent/decrease the incidence but more research is needed

Laryngeal Carcinoma
- see Neoplasms of the Head and Neck, OT34
Salivary Glands

Sialadenitis

Definition
- inflammation of salivary glands

Etiology
- viral most common (mumps)
- bacterial causes: S. aureus, S. pneumoniae, H. influenzae
- obstructive vs. non-obstructive
- obstructive infection involves salivary stasis and bacterial retrograde flow

Predisposing Factors
- HIV
- anorexia/bulimia
- Sjögren's syndrome
- Cushings, hypothyroidism, DM
- hepatic/renal failure
- meds that increase stasis: diuretics, TCAs, β-blockers, anticholinergics, antibiotics
- sialolithiasis (can cause chronic sialadenitis)

Clinical Features
- acute onset of pain and edema of parotid or submandibular gland that may lead to marked swelling
- ± fever
- ± leukocytosis
- ± suppurative drainage from punctum of the gland

Investigations
- U/S imaging to differentiate obstructive vs. non-obstructive sialadenitis

Treatment
- bacterial: treat with cloxacinil ± abscess drainage, sialogogues
- viral: no treatment

Sialolithiasis

Definition
- ductal stone (mainly hydroxyapatite) in adults, sand/sludge in children, leading to chronic sialadenitis
- 80% in submandibular gland, <20% in parotid gland, ~1% in sublingual gland

Risk Factors
- any condition causing duct stenosis or a change in salivary secretions (e.g. dehydration, diabetes, EtOH, hypercalcemia, psychiatric medication)

Clinical Features
- pain and tenderness over involved gland
- intermittent swelling related to meals
- digital palpation reveals presence of calculus

Investigations
- U/S ± sialogram

Treatment
- may resolve spontaneously
- encourage salivation to clear calculus
- massage, analgesia, antibiotics, sialogogues (e.g. lemon wedges, sour lemon candies), warm compresses
- remove calculi endoscopically, by dilating duct or orifice, or by excision through floor of the mouth
- gland preserving surgery has long-term symptom improvement and favourable gland retention rates

Salivary Gland Neoplasms

Etiology
- anatomic distribution
- parotid gland: 70-85%
- submandibular gland: 8-15%
- sublingual gland: 1%
- minor salivary glands, most concentrated in hard palate: 5-8%
- malignant (see Table 15, OT31 and Table 16, OT35)
- benign
• benign mixed (pleomorphic adenoma): 80%
• Warthin's tumour (5-10% bilateral, M>F): 10%
• cysts, lymph nodes and adenomas: 10%
• oncocytoma: <1%

Epidemiology
• 3-6% of all head and neck neoplasms in adults
• mean age at presentation: 55-65
• M=F

Parotid Gland Neoplasms

Clinical Features
• 80% benign (pleomorphic adenoma: most common), 20% malignant (mucoepidermoid: most common)
• if bilateral, suggests benign process (Warthin's tumour, Sjögren's, bulimia, mumps) or possible lymphoma
• facial nerve involvement (i.e. facial paralysis): increases risk of malignancy

Investigations
• FNA biopsy
• CT, U/S, or MRI to determine extent of tumour

Treatment
• treatment of choice is surgery for all salivary gland neoplasms – benign and malignant
• pleomorphic adenomas are excised due to risk of malignant transformation (5% risk over prolonged period of time)
• superficial tumour
  • superficial parotidectomy above plane of CN VII ± radiation
  • incisional biopsy contraindicated
• deep lesion
  • near-total parotidectomy sparing as much of CN VII as possible
  • if CN VII involved then it is removed and cable grafted
• complications of parotid surgery
  • hematoma, infection, salivary fistula, temporary facial paresis, Frey’s syndrome (gustatory sweating)

Prognosis
• benign: excellent, <5% of pleomorphic adenomas may recur
• malignant: dependent on stage and type of malignancy (see Table 16, OT35)

Approach to a Neck Mass

• ensure that the neck mass is not a normal neck structure (hyoid, transverse process of C1 vertebra, prominent carotid bulb)
• any neck mass persisting for >2 wk should be investigated for possible neoplastic causes

Table 15. Acquired Causes of Neck Lumps According to Age

<table>
<thead>
<tr>
<th>Age (yr)</th>
<th>Possible Causes of Neck Lump</th>
</tr>
</thead>
<tbody>
<tr>
<td>20-40</td>
<td>1. Inflammatory 2. Congenital 3. Neoplastic</td>
</tr>
<tr>
<td>&gt;40</td>
<td>1. Neoplastic 2. Inflammatory 3. Congenital</td>
</tr>
</tbody>
</table>

Differential Diagnosis
• congenital
  • lateral (branchial cleft cyst, lymphatic/venous/venolymphatic malformation)
  • midline (thyrroglossal duct cyst, dermoid cyst, laryngocele, thyroid/thymus anomaly, vascular malformation)
• infectious/inflammatory
  • reactive lymphadenopathy (20 to tonsillitis, pharyngitis)
  • infectious mononucleosis
  • Kawasaki, Kikuchi, Kimura, Cat Scratch, Castleman’s
  • HIV
  • salivary gland calculi, sialadenitis
  • thyroditis
• granulomatous disease
  • mycobacterial infections
  • sarcoidosis

A mass sitting above an imaginary line drawn between the mastoid process and angle of the mandible is a parotid neoplasm until proven otherwise.

DDx Parotid Tumour

Benign
• Pleomorphic adenoma
• Warthin’s tumour (more common in men)
• Benign lymphoepithelial cysts (viral etiology e.g. HIV)
• Oncocytoma

Malignant
• Mucoepidermoid carcinoma
• Adenoid cystic carcinoma
• Acinic cell carcinoma

Frey's syndrome is a post-operative complication characterized by gustatory sweating. It is due to aberrant innervation of cutaneous sweat glands by parasympathetic nerve fibres that are divided during surgery.
• neoplastic
  ■ lymphoma
  ■ salivary gland tumours
  ■ thyroid tumours
  ■ metastatic malignancy ("unknown primary")

### Evaluation

#### Investigations
- history and physical (including nasopharynx and larynx)
- all other investigations and imaging are dependent upon clinical suspicion following history and physical
- laboratory investigations
  ■ WBC: infection vs. lymphoma
  ■ Mantoux TB test
  ■ thyroid function tests and scan
- imaging
  ■ neck U/S
  ■ CT scan
  ■ angiography: vascularity and blood supply to mass
- biopsy: for histologic examination
  ■ FNA: least invasive
  ■ needle biopsy
  ■ open biopsy: for lymphoma
- identification of possible primary tumour (rule out a metastatic lymph node from an "unknown primary")
  ■ panendoscopy: nasopharyngoscopy, laryngoscopy, esophagoscopy, bronchoscopy with washings, and biopsy of suspicious lesions
  ■ biopsy of normal tissue of nasopharynx, tonsils, base of tongue, and hypopharynx
  ■ primary identified 95% of time → stage and treat
  ■ primary occult 5% of time: excisional biopsy of node for histologic diagnosis → manage with radiotherapy and/or neck dissection (squamous cell carcinoma)

### Congenital Neck Masses

#### Brachial Cleft Cysts/Sinuses/Fistulae

##### Embryology
- at the 6th wk of development, the 2nd branchial arch grows over the 3rd and 4th arches and fuses with the neighbouring caudal pre-cardial swelling forming the cervical sinus
- 3 types of malformations
  1. branchial fistula: persistent communication between skin and GI tract
  2. branchial sinus: blind-ended tract opening to skin
  3. branchial cyst: persistent cervical sinus with no external opening

##### Clinical Features
- 2nd branchial cleft malformations most common
  ■ sinuses and fistulae present in infancy as a small opening anterior to the sternocleidomastoid muscle
  ■ cysts present as a smooth, painless, slowly enlarging lateral neck mass, often following a URTI
  ■ 1st branchial cleft malformations present as sinus/fistula or cyst in preauricular area or on face over angle of mandible
  ■ 3rd branchial cleft malformations present as recurrent thyroiditis or thyroid abscess and have a tract leading usually to the left pyriform sinus. Air on CT scan in or near the thyroid gland is pathognomonic for this anomaly.
  ■ there is controversy whether or not 4th branchial cleft anomalies exist, as they may be remnants of the thyrothymic axis

##### Treatment
- surgical removal of cyst or fistula tract
- if infected: allow infection to settle before removal (antibiotics may be required)
Figure 19. Branchial cleft cysts

**Thyroglossal Duct Cysts**

**Embryology**
- thyroid originates as ventral midline diverticulum at base of tongue caudal to junction of 3rd and 4th branchial arches (foramen cecum) and migrates down to inferior aspect of neck
- thyroglossal duct cysts are vestigial remnants of tract

**Clinical Features**
- usually presents in childhood or during 20–40s as a midline cyst that enlarges with URTI and elevates with swallowing and tongue protrusion

**Treatment**
- pre-operative antibiotics to reduce inflammation (infection before surgery is a well described cause of recurrence)
- small potential for neoplastic transformation so complete excision of cyst and tissue around tract up to foramen cecum at base of tongue with removal of central portion of hyoid bone (Sistrunk procedure) recommended
Lymphatic, Venous or Mixed Venolymphatic Malformations

Definition
- lymphatic malformation arising from vestigial lymph channels of neck

Clinical Features
- commonly identified in many fetuses but regress before birth and never cause a clinical problem
- usually present by age 2
- can be macrocystic (composed of large thin-walled cysts, usually below level of mylohyoid muscle) or microcystic (composed of minute cysts, usually above level of mylohyoid muscle)
- usually painless, soft, compressible
- infection or trauma causes a sudden increase in size

Treatment
- can regress spontaneously after bacterial infection, therefore do not plan surgical intervention until several months after infection
- macrocystic lesions can be treated by sclerotherapy or surgical excision
- microcystic lesions are difficult to treat, but can be debulked if it will not cause loss of function of normal structures, or injected with sclerotherapy in surrounding tissues

Neoplasms of the Head and Neck

Pre-Malignant Disease
- leukoplakia
  - hyperkeratosis of oral mucosa
  - risk of malignant transformation 5-20%
- erythroplakia
  - red superficial patches adjacent to normal mucosa
  - commonly associated with epithelial dysplasia
  - associated with carcinoma in situ or invasive tumour in 40% of cases
- dysplasia
  - histopathologic presence of mitoses and prominent nucleoli
  - involvement of entire mucosal thickness = carcinoma in situ
  - associated progression to invasive cancer in 15-30% of cases

Investigations
- initial metastatic screen includes CXR
- scans of liver, brain, and bone only if clinically indicated
- CT scan is superior to MRI for the detection of pathologic nodal disease and bone cortex invasion
- MRI is superior to discriminate tumour from mucus and to detect bone marrow invasion
- ± PET scans

Treatment
- treatment depends on
  - histologic grade of tumour
  - stage
  - physical and psychological health of patient
  - facilities available
  - expertise and experience of the medical and surgical oncology team
- in general
  - 1st surgery for malignant oral cavity tumours with radiotherapy reserved for salvage or poor prognostic indicators
  - 1st radiotherapy for nasopharynx, oropharynx, hypopharynx, larynx malignancies with surgery reserved for salvage
  - palliative chemotherapy for metastatic or incurable disease
  - concomitant chemotherapy increases survival in advanced disease
  - chemotherapy has a role as induction therapy prior to surgery and radiation
  - panendoscopy to detect primary disease when lymph node metastasis is identified
  - anti-EGFR treatment (cetuximab, panitumumab) has a role as concurrent therapy with radiation for SCC of the head and neck (for advanced local and regional disease)

Prognosis
- synchronous tumours occur in 9-15% of patients
- late development of 2nd primary most common cause of post-treatment failure after 36 mo
### Table 16. Quick Look-Up Summary of Head and Neck Malignancies – Etiology and Epidemiology

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Epidemiology</th>
<th>Risk Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral Cavity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>95% SCC others: sarcoma, melanoma, minor salivary gland tumour</td>
<td>Mean age: 50-60 yr M&gt;F Most common site of H&amp;N cancers 50% on anterior 2/3 of tongue</td>
<td>Smoking/EtOH Poor oral hygiene Leukoplakia, erythroplasia Lichen planus, chronic inflammation Sun exposure – lip HPV infection</td>
</tr>
<tr>
<td><strong>Nose and Paranasal Sinus</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75-80% SCC Adenocarcinoma (2nd most common) and mucoepidermoid 99% in maxillary/ethmoid sinus 10% arise from minor salivary glands</td>
<td>Mean age: 50-70 yr Rare tumours ↓ incidence in last 5-10 yr</td>
<td>Wood/shoe/textile industry Hardwood dust (nasal/ethmoid sinus) Nickel, chromium (maxillary sinus) Air pollution Chronic rhinosinusitis</td>
</tr>
<tr>
<td><strong>Carcinoma of the Pharynx – Subtypes (Nasopharynx, Oropharynx, Hypopharynx, and Larynx)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nasopharynx</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>90% SCC ~ 10% lymphoma</td>
<td>Mean age: 50-59 yr M:F = 2.6:1 Incidence 0.8 per 100,000 100x increased incidence in Southern Chinese</td>
<td>Epstein-Barr virus (EBV) Salted fish Nickel exposure Poor oral hygiene Genetic – Southern Chinese</td>
</tr>
<tr>
<td><strong>Oropharynx</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>95% SCC – poorly differentiated Up to 70% of oropharyngeal cancer (OPC) attributable to HPV</td>
<td>Mean age: 50-70 yr Patients with HPV+ OPC are approximately 10 yrs younger Prevalence of HPV+ OPC has increased by 225% from 1988 to 2004. M:F = 4:1</td>
<td>Smoking/EtOH HPV 16 infection: increased sexual encounters, specifically oral sex</td>
</tr>
<tr>
<td><strong>Hypopharynx</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>95% SCC 3 sites 1. pyriform sinus (60%) 2. post-cricoid (30%) 3. post pharyngeal wall (10%)</td>
<td>Mean age: 50-70 yr M&gt;F 9-10% of all H&amp;N cancer</td>
<td>Smoking/EtOH</td>
</tr>
<tr>
<td><strong>Larynx</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCC most common 3 sites 1. supraglottic (30-35%) 2. glottic (60-65%) 3. subglottic (1%)</td>
<td>Mean age: 45-75 yr M:F = 10:1 45% of all H&amp;N cancer</td>
<td>Smoking/EtOH HPV 16 infection strongly associated with the risk of laryngeal squamous cell cancers</td>
</tr>
<tr>
<td><strong>Salivary Gland</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40% mucoepidermoid 30% adenoid cystic 5% acinic cell 5% malignant mixed 5% lymphoma</td>
<td>Mean age: 55-65 yr M=F 3-6% of all H&amp;N cancer Rate of malignancy: Parotid 15-25% Submandibular 37-43% Minor salivary &gt;80%</td>
<td></td>
</tr>
<tr>
<td><strong>Thyroid (90% benign – 10% malignant)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;80% papillary 5-15% follicular 5% medullary &lt;5% anaplastic 1-5% hürthle cell 1-2% metastatic</td>
<td>Children Adults &lt; 30 or &gt;60 yr Nodules more common in females Malignancy more common in males</td>
<td>Radiation exposure Family history – papillary CA or multiple endocrine neoplasia – MEN II Older age Male Papillary – Gardner’s, Cowden’s, familial adenomatous polyposis (FAP)</td>
</tr>
<tr>
<td><strong>Parathyroid</strong></td>
<td>Mean age: 44-55 yr Rare tumour</td>
<td></td>
</tr>
<tr>
<td>Table 17. Quick Look-Up Summary of Head and Neck Malignancies – Diagnosis and Treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-----------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td><strong>Clinical Features</strong></td>
<td><strong>Investigations</strong></td>
<td><strong>Treatment</strong></td>
</tr>
<tr>
<td>Oral Cavity</td>
<td>Biopsy</td>
<td>1st surgery</td>
</tr>
<tr>
<td>Asymptomatic neck mass (30%)</td>
<td>CT</td>
<td>local resection ± neck dissection ± reconstruction ± radiation</td>
</tr>
<tr>
<td>Non-healing ulcer ± bleeding</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dysphagia, sialorrhrea, dysphonia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral fetor, atopia, leukoplakia, or erythroplakia (pre-malignant changes or CIS)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nose and Paranasal Sinus</td>
<td>CT/MRI</td>
<td>Surgery and radiation</td>
</tr>
<tr>
<td>Early symptoms:</td>
<td>Biopsy</td>
<td></td>
</tr>
<tr>
<td>Unilateral nasal obstruction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epistaxis, rhinorrhea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Late symptoms:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2o to invasion of nose, orbit, nerves, oral cavity, skin, skull base, criconform plate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>Nasopharyngoscopy</td>
<td>1st radiation, chemoradiation</td>
</tr>
<tr>
<td>Cervical nodes (60-90%)</td>
<td>Biopsy</td>
<td>Surgery for limited or recurrent disease</td>
</tr>
<tr>
<td>Nasal obstruction, epistaxis</td>
<td>CT/MRI</td>
<td></td>
</tr>
<tr>
<td>Unilateral otitis media ± hearing loss</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CN III to IX, X to XII (25%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proptosis, voice change, dysphagia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oropharynx</td>
<td>Biopsy</td>
<td>1st radiation</td>
</tr>
<tr>
<td>Odynophagia, atopia</td>
<td>CT/MRI</td>
<td></td>
</tr>
<tr>
<td>Ulcerated/enlarged tonsil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fixed tongue/trismus/dysarthria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral fetor, bloody sputum</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV+ OPC predominantly arises at base of tongue or tonsillar region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervical lymphadenopathy (60%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distant mets: lung/bone/liver (7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>Biopsy</td>
<td>1st radiation</td>
</tr>
<tr>
<td>Dysphagia, odynophagia</td>
<td>Pharyngoscopy</td>
<td></td>
</tr>
<tr>
<td>Otalgia, hoarseness</td>
<td>CT</td>
<td>2nd surgery</td>
</tr>
<tr>
<td>Oropharynxulopathy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salivary Gland</td>
<td>FNA</td>
<td>1st surgery</td>
</tr>
<tr>
<td>Painless mass (occ. pain is possible)</td>
<td>MRI/CT/U/S</td>
<td></td>
</tr>
<tr>
<td>CN VII palsy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervical lymphadenopathy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parathyroid</td>
<td>Sestamibi</td>
<td>1st surgery</td>
</tr>
<tr>
<td>Increased serum Ca²⁺</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neck mass</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone disease, renal disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreatitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parathyroid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean survival: 6-7 yr</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Thyroid Carcinoma**

**Table 18. Bethesda Classification of Thyroid Cytology**

<table>
<thead>
<tr>
<th>Category</th>
<th>Risk of Malignancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-diagnostic or unsatisfactory</td>
<td>Unknown</td>
</tr>
<tr>
<td>Benign</td>
<td>0-3%</td>
</tr>
<tr>
<td>Follicular lesion of undetermined significance/Atypia of undetermined significance</td>
<td>5-15%</td>
</tr>
<tr>
<td>Follicular/hürthle cell neoplasms</td>
<td>15-30%</td>
</tr>
<tr>
<td>Suspicious for malignancy</td>
<td>60-75%</td>
</tr>
<tr>
<td>Malignant</td>
<td>97-99%</td>
</tr>
</tbody>
</table>

**Table 19. Thyroid Carcinoma**

<table>
<thead>
<tr>
<th>Papillary</th>
<th>Follicular</th>
<th>Medullary</th>
<th>Anaplastic</th>
<th>Lymphoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence (% of all thyroid cancers)</td>
<td>70-80%</td>
<td>10-15%</td>
<td>1 to 2% (90% sporadic, 10% familial – test for RET germline mutation)</td>
<td>&lt;2%</td>
</tr>
</tbody>
</table>

**Prognosis**

- 98% at 10 yr
- 50% at 10 yr
- 20% at 10 yr if detected when clinically palpable
- 20-35% at 1 yr
- 13% at 10 yr
- 5 yr survival
- Stage IE 55%-80%
- Stage IIE 20%-50%
- Stage III/IV 15%-35%

**Treatment**

- Small tumours: Near total thyroidectomy or lobectomy
  - Diffuse/bilateral: Total thyroidectomy
  - ± neck dissection ± post-operative I\(^{131}\) treatment
- Small tumours: Near total thyroidectomy/lobectomy/ isthmectomy
  - Large/diffuse tumours: Total thyroidectomy
- Total thyroidectomy
  - Median and/or lateral compartment node neck dissection (based on serum calcitonin)
  - Modified neck dissection
  - Post-operative thyroxine, radiotherapy
  - Tracheostomy
  - Screen relatives
- Radiation and chemotherapy
- Small tumours: Total thyroidectomy ± external beam
- Non-surgical
  - Combined radiation
  - Chemotherapy (CHOP**)

**Approach to Thyroid Nodule**

- all patients with thyroid nodules require evaluation of serum TSH and ultrasound
- intermediate-high suspicion nodule >1 cm and low suspicion nodule >1.5 cm should undergo FNA
- nodules <1 cm with clinical symptoms or lymphadenopathy may require further evaluation
- when performing repeat FNA on initially non-diagnostic nodules, US指导下 FNA should be employed
- nuclear scanning has minimal value in the investigation of the thyroid nodule

**Table 20. Management of the Thyroid Nodule**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiiodine therapy</td>
<td>For the treatment of hyperthyroidism or as adjuvant treatment after surgery in the treatment of intermediate-high risk papillary or follicular carcinoma</td>
</tr>
<tr>
<td>Chemotherapy and/or radiotherapy</td>
<td>Recurrent/residual Medullary CA, Anaplastic CA or thyroid lymphoma</td>
</tr>
<tr>
<td>Surgical excision</td>
<td>Nodule that is suspicious on FNA cytology</td>
</tr>
<tr>
<td></td>
<td>Malignancy other than anaplastic CA or thyroid lymphoma</td>
</tr>
<tr>
<td></td>
<td>Mass that on FNA is benign but increasing in size on serial imaging and/or &gt; 3-4 cm in size</td>
</tr>
<tr>
<td></td>
<td>Hyperthyroidism not amenable to medical therapy</td>
</tr>
</tbody>
</table>

**Post-Operative Radioactive Iodine Ablation – I\(^{131}\)**

Adjuvant therapy: decrease recurrent disease
RAI therapy: treat persistent cancer

*S symptoms = fever, night sweats, chills, weight loss >10% in 6 mo  ** CHOP = cyclophosphamide, adriamycin, vincristine, prednisone

*US findings: cystic: risk of malignancy <1%; solid: risk of malignancy ~10%; solid with cystic components: risk of malignancy same as if solid
Clinical Features

- triad of otalgia, fever (especially in younger children), and conductive hearing loss
- rarely tinnitus, vertigo, and/or facial nerve paralysis
- otorrhea if tympanic membrane perforated
- infants/toddlers
- ear-tugging (this alone is not a good indicator of pathology)
- hearing loss, balance disturbances (rare)
- irritable, poor sleeping
- vomiting and diarrhea
- anorexia

- otoscopy of TM
  - hyperemia
  - bulging, pus may be seen behind TM
  - loss of landmarks: handle and long process of malleus not visible

Pathogenesis

- obstruction of Eustachian tube → air absorbed in middle ear → negative pressure (an irritant to middle ear mucosa) → edema of mucosa with exudate/effusion → infection of exudate from nasopharyngeal secretions
**Diagnosis**
- **history**
  - acute onset of otalgia or ear tugging in a preverbal child, otorrhea, decreased hearing
  - unexplained irritability, fever, upper respiratory symptoms, poor sleeping, anorexia, N/V, and diarrhea
- **physical**
  - febrile
  - MEE on otoscopy: immobile tympanic membrane, acute otorrhea, loss of bony landmarks, opacification of TM, air-fluid level behind TM
  - MEI on otoscopy: bulging TM with marked discolouration (hemorrhagic, red, grey, or yellow)

**Management**
- supportive care and symptom management: maintain hydration, analgesic and antipyretic (acetaminophen, ibuprofen)
- watchful waiting: in a generally healthy child >6 mo of age with unilateral non-severe suspected AOM
  - without MEE, OR with MEE but non-bulging or mildly erythematous TM
  - consider viral etiology
  - reassess in 24–48h if not clinically improved (or earlier if worsening)
- mildly ill (alert, responsive, no rigors, mild otalgia, fever <39 °C, <48h illness) with MEE present
  - AND bulging TM
  - recommend analgesia
  - observe and follow-up in 24–48h – if not improved or worsening, treat with antimicrobials
- antimicrobials indicated: infants <6 mo of age, or in a generally healthy child >6 mo of age with suspected AOM and the following features
  - moderately or severely ill (irritable, difficulty sleeping, poor antipyretic response, severe otalgia) OR
  - fever ≥39 °C OR >48h of symptoms
  - treat with antimicrobials: 10d course if 6mo to 2yr old, 5d if ≥2yr old
  - perforated TM with purulent drainage
  - treat with antimicrobials for 10d
- referral to otolaryngology for myringotomy and tympanostomy tubes may be warranted for recurrent infections

**Treatment**
- antimicrobial agents for AOM
  - 5 day course of appropriate dose antimicrobial recommended for most ≥ 2 yr old with uncomplicated AOM. 10d course for 6–23 mo, and perforated TM or recurrent AOM
  - 1st line treatment (no penicillin allergy)
    - amoxicillin: 5 day course of 45mg/kg/d to 60mg/kg/d divided 3x/d, or 75 mg/kg/d to 90 mg/kg/d divided 2x/d
  - 2nd line treatment
    - cefuroxime: 30 mg/kg/d divided 2x/d
    - cefuroxime axetil: 30 mg/kg/d divided 2–3x/d (also is 1st line for penicillin allergy)
    - ceftriaxone: 50 mg/kg IM (or IV) x 3 doses (also is 1st line for penicillin allergy)
    - azithromycin: 10 mg/kg OD x 1 dose, then 5 mg/kg OD x 4 doses
    - clarithromycin: 15 mg/kg/d divided 2x/d
  - if initial therapy fails (i.e. no symptomatic improvement after 2-3 d)
    - amoxicillin-clavulanate: 45mg/kg/d to 60mg/kg/d (7:1 formulation, 400mg/5mL suspension) for 10 d for child weighing ≤35kg, or 500mg tablets 3x/d for 10 d for child weighing >35kg
  - if AOM-related symptoms do not resolve with amoxicillin/clavulanate, a course of ceftriaxone 50 mg/kg/d intramuscularly (or intravenously) 1/d x 3 doses could be considered

**Complications**
- extracranial
  - hearing loss and speech delay (secondary to persistent MEE), TM perforation, extension of suppurrative process to adjacent structures (mastoiditis, petrositis, labyrinthitis), cholesteatoma, facial nerve palsy, middle ear atelectasis, ossicular necrosis, vestibular dysfunction, persistent effusion (often leading to hearing loss)
- intracranial
  - meningitis, epidural and brain abscess, subdural empyma, lateral and cavernous sinus thrombosis, carotid artery thrombosis, facial nerve paralysis
- other
  - mastoiditis, labyrinthitis, sigmoid sinus thrombophlebitis

---

**Otitis Media with Effusion**

**Definition**
- presence of fluid in the middle ear without signs or symptoms of ear infection

**Epidemiology**
- most common cause of pediatric hearing loss
- not exclusively a pediatric disease
- follows AOM frequently in children
- middle ear effusions have been shown to persist following an episode of AOM for 1 mo in 40% of children, 2 mo in 20%, and >3 mo in 10% (i.e. 90% of children clear the fluid within 3 mo – observe for 3 mo before considering myringotomy and tubes)
Risk Factors
• same as AOM

Clinical Features
• conductive hearing loss ± tinnitus
  • confirm with audiogram and tympanogram (flat) (see Figure 16B, OT10 and Figure 17B, OT11)
• fullness – blocked ear
• ± pain, low grade fever
• otoscopy of tympanic membrane
  • discoloration – amber or dull grey with "glue" ear
  • meniscus fluid level behind TM
  • air bubbles
  • retraction pockets/TM atelectasis
• most reliable finding with pneumatic otoscope is immobility

Complications of Otitis Media with Effusion
• hearing loss, speech delay, learning problems in young children
• chronic mastoiditis
• ossicular erosion
• cholesteatoma especially when retraction pockets involve pars flaccida
• retraction of tympanic membrane, atelectasis, ossicular fixation

Treatment
• expectant: 90% resolve by 3 mo
  • watchful waiting for 3 mo from onset, or 3 mo from diagnosis if onset unknown
• document hearing loss with audiogram
• no clinical evidence that antihistamines, decongestants, or antibiotics clear disease faster
  • recommend against intranasal or systemic steroids, systemic antibiotics, antihistamines, decongestants for OME treatment
• surgery: myringotomy ± ventilation tubes (tympanostomy tubes recommended) ± adenoidectomy (not recommended in <4yr old unless nasal obstruction, chronic adenoiditis; recommended in ≥ 4yr old)
• ventilation tubes to equalize pressure and drain ear

Adenoid Hypertrophy
• size peaks at age 5 and resolves by age 12
• increase in size with repeated URTI and allergies

Clinical Features
• nasal obstruction
  • adenoid facies (open mouth, high arched palate, narrow midface, malocclusion)
  • history of hypernasal voice and snoring
  • long-term mouth breather; minimal air escape through nose
• choanal obstruction
  • chronic rhinosinusitis/rhinitis
  • obstructive sleep apnea
• chronic inflammation
  • nasal discharge, post-nasal drip, and cough
  • cervical lymphadenopathy

Diagnosis
• enlarged adenoids on nasopharyngeal exam (usually with flexible nasopharyngoscope)
• enlarged adenoid shadow on lateral soft tissue x-ray

Complications
• Eustachian tube obstruction leading to serous otitis media
• interference with nasal breathing, necessitating mouth-breathing
• malocclusion
• sleep apnea/respiratory disturbance
• orofacial developmental abnormalities

Adenoidectomy

Indications for Adenoidectomy
• chronic upper airway obstruction with sleep disturbance/apnea ± cor pulmonale
• chronic nasopharyngitis resistant to medical treatment
• chronic serous otitis media and chronic suppurative otitis media (with 2nd set of tubes)
• recurrent acute otitis media resistant to antibiotics
• suspicion of nasopharyngeal malignancy
• persistent rhinorrhea secondary to nasal obstruction
Contraindications
• uncontrollable coagulopathy
• recent pharyngeal infection
• conditions that predispose to velopharyngeal insufficiency (cleft palate, impaired palatal function, or enlarged pharynx)

Complications
• bleeding, infection
• velopharyngeal insufficiency (hypernasal voice or nasal regurgitation)
• scarring of Eustachian tube orifice

Sleep-Disordered Breathing in Children

Definition
• spectrum of sleep-related breathing abnormalities ranging from snoring to OSA

Epidemiology
• peak incidence between 2-8 yr when tonsils and adenoids are the largest relative to the pharyngeal airway

Etiology
• due to a combination of anatomic and neuromuscular factors
  ■ adenotonsillar hypertrophy
  ■ craniofacial abnormalities
  ■ neuromuscular hypotonia (i.e. cerebral palsy, Down syndrome)
  ■ obesity

Clinical Features
• heavy snoring, mouth breathing, pauses or apnea, enuresis, excessive daytime sleepiness, behavioural/learning problems, diagnosis of ADHD, morning headache, failure to thrive, sleeping with neck hyperextended, cyanosis

Investigations
• flexible nasopharyngoscopy for assessment of nasopharynx and adenoids
• polysomnography (apnea-hypopnea index >1/h considered abnormal)
  ■ children: Mild OSA≥1to <5/hr; Moderate OSA≥5/hr to <10/hr; Severe OSA≥10/hr
  ■ adults: Mild OSA 5.1/hr to 15/hr; Moderate OSA 15.1/hr to 30/hr; Severe OSA>30.1/hr

Treatment
• nonsurgical: CPAP, BiPAP, sleep hygiene, weight loss in overweight/obese child with OSA
• surgical: bilateral tonsillectomy and adenoidectomy is first surgery of choice
  ■ if persistent obstructive sleep apnea following tonsillectomy and adenoidectomy, consider adenoid regrowth
  ■ if these fail and not tolerant of PAP therapy, consider lingual tonsillectomy, midline glossectomy, or other surgeries targeting areas of resistance as required (STAR surgery); surgery may be guided by Drug-Induced Sleep Endoscopy (DISE) or CINE-MRI to localize site of resistance

Acute Tonsillitis

• see Pediatrics, P57

Peritonsillar Abscess (Quinsy)

Definition
• cellulitis of space behind tonsillar capsule extending onto soft palate leading to abscess

Etiology
• bacterial: Group A strep (GAS) (50% of cases), S. pyogenes, S. aureus, H. influenzae, and anaerobes

Epidemiology
• can develop from acute tonsillitis with infection spreading into plane of tonsillar bed
• unilateral
• most common in 15-30 yr age group

Clinical Features
• trismus (due to irritation and reflex spasm of the medial pterygoid) is the most reliable indicator of peritonsillar abscess
• fever and dehydration
• sore throat, dysphagia, and odynophagia
• extensive peritonsillar swelling but tonsil may appear normal

Quinsy Triad
• Trismus
• Uvular deviation
• Dysphonia (“hot potato voice”)
edema of soft palate
uvular deviation
dysphonia (edema → failure to elevate palate) 2º to CN X involvement
unilateral referred otalgia
cervical lymphadenitis

Complications
- aspiration pneumonia 2º to spontaneous rupture of abscess
- airway obstruction
- lateral dissection into parapharyngeal and/or carotid space
- bacteremia
- retropharyngeal abscess

Treatment
- secure airway
- surgical drainage (incision or needle aspiration) with C&S
- warm saline irrigation
- IV penicillin G x 10 d if cultures positive for GAS
- add PO/IV metronidazole or clindamycin x 10 d if culture positive for Bacteroides
- consider tonsillectomy after second episode

Other Sources of Parapharyngeal Space Infections
- pharyngitis
- acute suppurative parotitis (see Salivary Glands, OT30)
- AOM
- mastoiditis (Bezold's abscess)
- odontogenic infection

Tonsillectomy

Absolute Indications
- most common indication: sleep-disordered breathing
- 2nd most common indication: recurrent throat infections
- tonsillar hypertrophy causing upper airway obstruction, obstructive sleep apnea, severe dysphagia, or cardiopulmonary complications such as cor pulmonale
- suspicion of malignancy (e.g. lymphoma, squamous cell carcinoma)
- orofacial/dental deformity
- hemorrhagic tonsillitis

Relative Indications (To Reduce Disease Burden)
- recurrent throat infection with a frequency of at least 7 episodes in the past year, at least 5 episodes per year for 2 yr, or at least 3 episodes per year for 3 yr, with documentation in the medical record for each episode of sore throat and 1 or more of the following: temperature >38.3°C, cervical adenopathy, tonsillar exudate, or positive test for Group A β-hemolytic Streptococcus (Paradise Criteria)
- chronic tonsillitis with halitosis (bad breath) or sore throat ± tonsilloliths (clusters of material that form in the crevices of the tonsils)
- complications of tonsillitis: quinsy/peritonsillar abscess, parapharyngeal abscess, retropharyngeal abscess
- failure to thrive

Relative Contraindications
- velopharyngeal insufficiency: overt or submucous/covert cleft of palate, impaired palatal function due to neurological or neuro-muscular abnormalities
- hematologic: coagulopathy, anemia
- infectious: active local infection without urgent obstructive symptoms

Complications
- hemorrhage: primary (within 24 h); secondary (within first 7-10 d)
- odynophagia and/or otalgia; dehydration 20 to odynophagia
- infection
- atlantoaxial subluxation (Grisel's syndrome) - rare

Airway Problems in Children

Differential Diagnosis by Age Group

Neonates (Obligate Nose Breathers)
- extralaryngeal
  - choanal atresia (e.g. CHARGE syndrome)
  - nasopharyngeal dermoid, glioma, encephalocele
  - glossoptosis: Pierre-Robin sequence, Down syndrome, lymphatic malformation, hemangioma
laryngeal
  - laryngomalacia: most common cause of stridor in children
  - vocal cord palsy (due to trauma or Arnold-Chiari malformation)
  - glottic web
  - subglottic stenosis
  - laryngeal cleft
  - laryngoele

tracheal
  - tracheoesophageal fistula
  - tracheomalacia
  - vascular rings
  - complete tracheal rings

2-3 Months
  - congenital
    - laryngomalacia
    - vascular: subglottic hemangioma (more common), innominate artery compression, double aortic arch
    - laryngeal papilloma
  - acquired
    - subglottic stenosis: post-intubation
    - tracheal granulation: post-intubation
    - tracheomalacia: post-tracheotomy and TEF repair

Infants – Sudden Onset
  - foreign body aspiration
  - croup
  - bacterial tracheitis
  - caustic ingestion
  - epiglottitis

Children and Adults
  - infection
    - Ludwig's angina
    - peritonsillar/parapharyngeal abscess
    - retropharyngeal abscess
  - neoplastic
    - squamous cell carcinoma (SCC) (adults): larynx, hypopharynx
    - retropharyngeal: lymphoma, neuroblastoma
    - nasopharyngeal: carcinoma, rhabdomyosarcoma
  - allergic
    - angioneurotic edema
    - polyps (suspect cystic fibrosis in children)
  - trauma
    - laryngeal fracture, facial fracture
    - burns and lacerations
    - post-intubation
    - caustic ingestion
  - congenital
    - lingual thyroglossal duct cyst
    - lingual tonsil hypertrophy
    - lingual thyroid

Signs of Airway Obstruction

Stridor
  - note quality, timing (inspiratory or expiratory)
  - body position important
    - lying prone: double aortic arch
    - lying supine: laryngomalacia, glossoptosis
  - site of stenosis
    - vocal cords or above: inspiratory stridor
    - subglottic and extrathoracic trachea: biphasic stridor
    - distal tracheobronchial tree: expiratory stridor

Respiratory Distress
  - nasal flaring
  - supraclavicular and intercostal indrawing
  - sternal retractions
  - use of accessory muscles of respiration
  - tachypnea
  - cyanosis
  - altered LOC
Feeding Difficulty and Aspiration
- supraglottic lesion
- laryngomalacia
- vocal cord paralysis
- laryngeal cleft → aspiration pneumonia
- TEF

**Acute Laryngotracheobronchitis (Croup)**
- inflammation of tissues in subglottic space ± tracheobronchial tree
- swelling of mucosal lining and associated with thick, viscous, mucopurulent exudate which compromises upper airway (subglottic space narrowest portion of upper airway)
- normal function of ciliated mucous membrane impaired

**Etiology**
- viral: parainfluenzae I (most common), II, III, influenza A and B, RSV

**Clinical Features**
- age: 4 mo-5 yr
- preceded by URTI symptoms
- generally occurs at night
- biphasic stridor and croupy cough (loud, sea-lion bark)
- appear less toxic than epiglottitis
- supraglottic area normal
- rule out foreign body and subglottic stenosis
- “steeple-sign” on AP x-ray of neck
- if recurrent croup, think subglottic stenosis

**Treatment**
- racemic epinephrine via MDI q1-2h, prn (only if in respiratory distress)
- systemic corticosteroids (e.g. dexamethasone 0.5 mg/kg, prednisone)
- adequate hydration
- close observation for 3-4 h
- intubation if severe (use smaller endotracheal tube than expected for age)
- hospitalize if poor response to steroids after 4 h and persistent stridor at rest
- consider alternate diagnosis if poor response to therapy (e.g. bacterial tracheitis)
- if recurrent episodes of croup-like symptoms, perform high kv croup series xray AP and LAT when well to rule out underlying subglottic stenosis and consider bronchoscopy for definitive diagnosis

**Acute Epiglottitis**
- acute inflammation causing swelling of supraglottic structures of the larynx without involvement of vocal cords

**Etiology**
- H. influenzae type b
- relatively uncommon condition due to Hib vaccine

**Clinical Features**
- any age, most commonly 1-4 yr
- rapid onset
- toxic-looking, fever, anorexia, restlessness
- cyanotic/pale, inspiratory stridor, slow breathing, lungs clear with decreased air entry
- prefers sitting up (“tripod” posture), open mouth, drooling, tongue protruding, sore throat, dysphagia

**Investigations and Management**
- investigations and physical exam may lead to complete obstruction, thus preparations for intubation or tracheotomy must be made prior to any manipulation
- stat ENT/anesthesia consult(s)
- WBC (elevated), blood and pharyngeal cultures after intubation
- lateral neck radiograph (only done if patient stable)

**Treatment**
- secure airway
- IV access with hydration
- antibiotics: IV cefuroxime, cefotaxime, or ceftriaxone
- moist air
- extubate when leak around tube occurs and afebrile
- watch for meningitis

**Signs of Croup**
- The 3 Ss
  - Stridor
  - Subglottic swelling
  - Seal bark cough

**Acute epiglottitis is a medical emergency**

**When managing epiglottitis, it is important not to agitate the child, as this may precipitate complete obstruction**

**Thumb sign:** cherry-shaped epiglottic swelling seen on lateral neck radiograph
Subglottic Stenosis

Congenital
- diameter of subglottis <4 mm in neonate (due to thickening of soft tissue of subglottic space or maldevelopment of cricoid cartilage)

Acquired
- following prolonged, repeated, or traumatic intubation
  - most commonly due to endotracheal intubation; nasal intubation is less traumatic and preferred in long-term intubation as it puts less pressure on the subglottis (tube sits at different orientation) and there is less movement
  - subglottic stenosis is related to duration of intubation and pressure of the endotracheal tube cuff
- can also be due to foreign body, infection (e.g. TB, diphtheria, syphilis), or chemical irritation

Clinical Features
- biphasic stridor
- respiratory distress
- recurrent/prolonged croup

Diagnosis
- rigid laryngoscopy and bronchoscopy

Treatment
- if soft stenosis: divide tissue with knife or laser, dilate with balloon ± steroids
- if firm stenosis: laryngotracheoplasty

Laryngomalacia
- short aryepiglottic folds, omega-shaped epiglottis, pendulous mucosa
- caused by indrawing of supraglottis on inspiration leading to laryngopharyngeal reflux of acid

Clinical Features
- high-pitched inspiratory stridor at 1-2 wk
- constant or intermittent and more pronounced supine and following URTI
- usually mild but when severe can be associated with cyanosis or feeding difficulties, leading to failure to thrive

Treatment
- observation ± proton pump inhibitor (to break the acid reflux cycle that leads to edema and worse airway obstruction) is usually sufficient as symptoms spontaneously subside by 12-18 mo in >90% of cases
- if severe, division of the aryepiglottic folds (supraglottoplasty) provides relief

Foreign Body

Ingested
- usually stuck at cricopharyngeus
- coins, toys, batteries (emergency)
- presents with drooling, dysphagia, stridor if very large

Aspirated
- usually stuck at right main bronchus
- peanuts, carrot, apple core, popcorn, balloons
- presentation
  - stridor if lodged in trachea
  - unilateral “asthma” if bronchial, therefore often misdiagnosed as asthma
  - if totally occludes airway: cough, lobar pneumonia, atelectasis, mediastinal shift, pneumothorax, death

Diagnosis and Treatment
- sudden onset, not necessarily febrile or elevated WBC
- any patient with suspected foreign body should be kept NPO immediately
- older patient: inspiratory-expiratory chest x-ray (if patient is stable)
- younger patient: right and left decubitus chest x-rays. Lack of lung deflation while resting on dependent side suggests foreign body blocking bronchus.
- bronchoscopy or esophagoscopy with removal

Laryngomalacia is the most common cause of stridor in infants

Foreign body inhalation is the most common cause of accidental death in children

Batteries MUST be ruled out as a foreign body (vs. coins) as they are lethal and can erode through the esophagus. Batteries have a halo sign around the rim on AP x-ray and a step deformity on lateral x-ray
Deep Neck Space Infection

- most commonly arise from an infection of the mandibular teeth, tonsils, parotid gland, deep cervical lymph nodes, middle ear, or the sinuses
- often a rapid onset and may progress to fatal complications

Etiology
- usually mixed aerobes and anaerobes that represent the flora of the oral cavity, upper respiratory tract, and certain parts of the ears and eyes

Clinical Features
- sore throat or pain and trismus
- dysphagia and odynophagia
- stridor and dyspnea
- late findings may include dysphonia and hoarseness
- swelling of the face and neck, erythema
- asymmetry of the oropharynx with purulent oral discharge
- lymphadenopathy

Diagnosis
- lateral cervical view plain radiograph
- CT
- MRI

Treatment
- secure the airway
- surgical drainage
- maximum doses of IV systemic antimicrobials regimens according to the site of infection

Common Medications

Table 21. Antibiotics

<table>
<thead>
<tr>
<th>Generic Name (Brand Name)</th>
<th>Dose</th>
<th>Indications</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>amoxicillin (Amoxil®, Amox®, Amox®)</td>
<td>Adult: 500 mg PO tid Children: 75-90 mg/kg/d in 2 divided doses</td>
<td>Streptococcus, Pneumococcus, H. influenzae, Proteus coverage</td>
<td>May cause rash in patients with infectious mononucleosis</td>
</tr>
<tr>
<td>piperacillin with tazobactam (Zosyn®)</td>
<td>3 g PO q6h</td>
<td>Gram-positive and negative aerobes and anaerobes plus Pseudomonas coverage</td>
<td>May cause pseudomembranous colitis</td>
</tr>
<tr>
<td>ciprofloxacin (Cipro®, Cloxan®)</td>
<td>500 mg PO bid</td>
<td>Pseudomonas, Streptococci, MRSA, and most Gram-negative; no anaerobic coverage</td>
<td>Animal studies suggest that systemic quinolones may cause cartilage necrosis in children</td>
</tr>
<tr>
<td>erythromycin (Erythrocin®, EryPed®, Statcin®, T-Stat®, Erybid®, Novorythro Encap®)</td>
<td>500 mg PO qid</td>
<td>Alternative to penicillin</td>
<td>Ototoxic</td>
</tr>
</tbody>
</table>

Table 22. Otic Drops

<table>
<thead>
<tr>
<th>Generic Name (Brand Name)</th>
<th>Dose</th>
<th>Indications</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>ciprofloxacin (Ciprodex®)</td>
<td>4 gtt in affected ear bid</td>
<td>For otitis externa and complications of otitis media Pseudomonas, Streptococci, MRSA, and most Gram-negative; no anaerobic coverage</td>
<td></td>
</tr>
<tr>
<td>neomycin, polymyxin B sulfate, and hydrocortisone (Cortisporin Otic®)</td>
<td>5 gtt in affected ear tid</td>
<td>For otitis externa Used for inflammatory conditions which are currently infected or at risk of bacterial infections</td>
<td>May cause hearing loss if placed in inner ear</td>
</tr>
<tr>
<td>hydrocortisone and acetic acid (VoSol HC®)</td>
<td>5-10 gtt in affected ear tid</td>
<td>For otitis media</td>
<td>Bactericidal by lowering pH</td>
</tr>
<tr>
<td>tobramycin and dexamethasone (TobraDex®)</td>
<td>5-10 gtt in affected ear bid</td>
<td>For chronic suppurative otitis media</td>
<td>Risk of vestibular or cochlear toxicity</td>
</tr>
</tbody>
</table>
### Table 23. Nasal Sprays

<table>
<thead>
<tr>
<th>Generic Name (Brand Name)</th>
<th>Indications</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Steroid</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>flunisolide (Rhinolar®)</td>
<td>Allergic rhinitis</td>
<td>Requires up to 4 wk of consistent use to have effect</td>
</tr>
<tr>
<td>budesonide (Rhinocort®)</td>
<td>Chronic sinusitis</td>
<td>Long-term use</td>
</tr>
<tr>
<td>triamcinolone (Nasacort®)</td>
<td></td>
<td>Dries nasal mucosa; may cause minor bleeding</td>
</tr>
<tr>
<td>beclomethasone (Beconase®)</td>
<td></td>
<td>Patient should stop if epistaxis</td>
</tr>
<tr>
<td>mometasone furoate, monohydrate (Nasonex®)</td>
<td></td>
<td>May sting</td>
</tr>
<tr>
<td>fluticasone furoate (Avamys®)</td>
<td></td>
<td>Flonase® and Nasonex® not absorbed systemically</td>
</tr>
<tr>
<td><strong>Antihistamine</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>levocabastine (Livostin®)</td>
<td>Allergic rhinitis</td>
<td>Immediate effect</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If no effect by 3 d then discontinue</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Use during allergy season</td>
</tr>
<tr>
<td><strong>Decongestant</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>xylometazoline (Otrivin®)</td>
<td>Acute sinusitis</td>
<td>Careful if patient has hypertension</td>
</tr>
<tr>
<td>oxymetazoline (Dristan®)</td>
<td>Rhinitis</td>
<td>Short-term use (&lt;5 d)</td>
</tr>
<tr>
<td>phenylephrine (Neosynephrine®)</td>
<td></td>
<td>If long-term use, can cause decongestant addiction (i.e. rhinitis medicamentosa)</td>
</tr>
<tr>
<td><strong>Antibiotic/Decongestant</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>framycetin, gramicidin, phenylephrine (Soframycin®)</td>
<td>Acute sinusitis</td>
<td></td>
</tr>
<tr>
<td><strong>Anticholinergic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ipratropium bromide (Atrovent®)</td>
<td>Vasomotor rhinitis</td>
<td>Careful not to spray into eyes as can cause burning or precipitation of narrow angle glaucoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Increased rate of epistaxis when combined with topical nasal steroids</td>
</tr>
<tr>
<td><strong>Lubricants</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>saline, NeilMed®, Rhinaris®, Secaris®, Polysporin®, Vaseline®</td>
<td>Dry nasal mucosa</td>
<td>Use prn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rhinaris® and Secaris® may cause stinging</td>
</tr>
</tbody>
</table>

Source: Dr. MM Carr
Acronyms ...................................................... 3
Pediatric Quick Reference Values .................. 3
Primary Care .................................................. 3
Visit Overview
Routine Immunization
Growth and Development
Nutrition
Injury Prevention Counselling
Common Complaints ................................. 8
Breath Holding Spells
Circumcision
Crying/Fussing Child
Infantile Colic
Dentition and Caries
Enuresis
Encopresis
Toilet Training
Failure to Thrive
Obesity
Poison Prevention
Rashes
Sleep Disturbances
Sudden Infant Death Syndrome
Child Abuse and Neglect .......................... 14
Physical Abuse
Sexual Abuse
Neglect
Adolescent Medicine ................................. 15
Cardiology ................................................... 16
Congenital Heart Disease
Acyanotic Congenital Heart Disease
Cyanotic Congenital Heart Disease
Congestive Heart Failure
Dysrhythmias
Heart Murmurs
Infective Endocarditis
Development ................................................. 22
Approach to Global Developmental Delay
Intellectual Disability
Language Delay
Specific Learning Disorder
Fetal Alcohol Spectrum Disorder
Attention Deficit Hyperactivity Disorder
Autism Spectrum Disorder
Motor Delay
Endocrinology ................................................ 25
Antidiuretic Hormone
Diabetes Mellitus
Growth
Hypercalcaemia/Hypocalcaemia/Rickets
Hyperthyroidism and Hypothyroidism
Sexual Development
Gastroenterology .......................................... 32
Vomiting
Gastroesophageal Reflux
Tracheoesophageal Fistula
Pyloric Stenosis
Duodenal Atresia
Malrotation of the Intestine
Diarrhea
Gastroenteritis
Toddler’s Diarrhea
Lactase Deficiency (Lactose Intolerance)
Irritable Bowel Syndrome
Celiac Disease
Milk Protein Allergy
Inflammatory Bowel Disease
Cystic Fibrosis
Constipation
Abdominal Pain
Chronic Abdominal Pain
Abdominal Mass
Upper Gastrointestinal Bleeding
Lower Gastrointestinal Bleeding
Genetics, Dysmorphisms, and Metabolism .......... 39
Genetics
Genetic Anomalies
Approach to the Dysmorphic Child
Genetic Syndromes
Metabolic Diseases
Hematology ................................................... 45
Approach to Anemia
Physiologic Anemia
Iron Deficiency Anemia
Vitamin K Deficiency
Anemia of Chronic Disease
Sickle Cell Disease
Thalassemia
Hereditary Spherocytosis
Glucose-6-Phosphate Dehydrogenase
Deficiency
Bleeding Disorders
Immune Thrombocytopenic Purpura
Hemophilia
von Willebrand’s Disease
Oncology ....................................................... 48
Lymphadenopathy
Leukemia
Lymphoma
Brain Tumours
Wilms’ Tumour (Nephroblastoma)
Neuroblastoma
Bone Tumours
Cancer Predisposition Syndromes
Pediatrics

Infectious Diseases .......................... 51
Fever
Acute Otitis Media
Otitis Media with Effusion
Gastroenteritis
HIV Infection
Infectious Pediatric Exanthems
Infectious Mononucleosis
Infectious Pharyngitis/Tonsillitis
Meningitis
Mumps
Pertussis
Pneumonia
Periorbital (Preseptal) and Orbital Cellulitis
Sexually Transmitted Infection
Sinusitis
Urinary Tract Infection

Neonatology ................................. 63
Gestational Age and Size
Routine Neonatal Care
Neonatal Resuscitation

Common Conditions of Neonates ........ 65
Apnea
Bleeding Disorders in Neonates
Bronchopulmonary Dysplasia
Cyanosis
Diaphragmatic Hernia
Hypoglycemia
Intraventricular Hemorrhage
Jaundice
Necrotizing Enterocolitis
Persistent Pulmonary Hypertension of the Newborn
Respiratory Distress in the Newborn
Retinopathy of Prematurity
Sepsis in the Neonate
Skin Conditions of the Neonate

Fluids and Electrolytes .................... 74
Approach to Infant/Child with Dehydration

Nephrology ................................ 76
Common Pediatric Renal Diseases
Hemolytic Uremic Syndrome
Nephritic Syndrome
Nephrotic Syndrome
Hypertension in Childhood

Neurology ................................. 81
Seizure Disorders
Febrile Seizures
Recurrent Headache
Hyponatremia
Cerebral Palsy
Neurocutaneous Syndromes

Respirology ............................... 84
Approach to Dyspnea
Upper Respiratory Tract Diseases
Lower Respiratory Tract Diseases
Pneumonia
Bronchiolitis
Asthma
Cystic Fibrosis

Rheumatology ............................. 88
Evaluation of Limb Pain
Growing Pains
Transient Synovitis of the Hip
Septic Arthritis and Osteomyelitis
Juvenile Idiopathic Arthritis
Reactive Arthritis
Lyme Arthritis
Systemic Lupus Erythematous Vasculitides

Neurosurgery ............................. NS34
Spinal Dysraphism
Intraventricular Hemorrhage
Hydrocephalus in Pediatrics
Dandy-Walker Malformation
Chiari Malformations
Craniosynostosis
Pediatric Brain Tumours

Orthopedics ............................. OR41
Fractures in Children
Stress Fractures
Epiphyseal Injury
Slipped Capital Femoral Epiphysis
Developmental Dysplasia of the Hip
Legg-Calvé-Perthes Disease (Coxa Plana)
Osgood-Schlatter Disease
Congenital Talipes Equinovarus (Club Foot)
Scoliosis

Otolaryngology .......................... OT38
Acute Otitis Media
Otitis Media with Effusion
Adenoid Hypertrophy
Adenoidectomy
Sleep-Disordered Breathing in Children
Acute Tonsillitis
Peritonsillar Abscess (Quinsy)
Tonsillectomy
Airway Problems in Children
Signs of Airway Obstruction
Acute Laryngotracheobronchitis (Croup)
Acute Epiglottitis
Subglottic Stenosis
Laryngomalacia
Foreign Body
Deep Neck Space Infection

Plastic Surgery .......................... PL36
 Craniofacial Anomalies
Congenital Hand Anomalies

Psychiatry ............................... PS35
Developmental Concepts
Mood Disorders
Anxiety Disorders
Autism Spectrum Disorder
Attention Deficit Hyperactivity Disorder
Oppositional Defiant Disorder
Conduct Disorder
Intermittent Explosive Disorder

Urology ................................. U36
Congenital Abnormalities
Nephroblastoma (Wilms’ Tumour)
Cryptorchidism/Ectopic Testes
Disorders of Sexual Differentiation
Enuresis
Circumcision

Common Medications .................... 92

References ............................... 93
Acronyms

AAP American Academy of Pediatrics
ABG arterial blood gas
ACE angiotensin converting enzyme
ALL acute lymphoblastic leukemia
ALPS autoimmune lymphoproliferative syndrome
AMM acute myelogenous leukemia
ANA antinuclear antibody
AOM acute otitis media
ARB alcohol-related birth defects
ARND alcohol-related neurodevelopmental disorder
ASD atrial septal defect
ASOT antistreptolysin-o titre
ATN acute tubular necrosis
AVM arteriovenous malformation
AVP arginine vasopressin
BAP brief hospital stay
C2F chronic myelogenous leukemia
CMV cytomegalovirus
CP cerebral palsy
CPPS chronic prostatitis
CSF cerebrospinal fluid
DS Down syndrome
DSD disorder of sexual differentiation
EBV Epstein-Barr virus
EMG electromyography
FAS fetal alcohol syndrome
FTT failure to thrive
G6PD glucose-6-phosphate dehydrogenase
GHD growth hormone deficiency
GHDN growth hormone deficiency newborn
GABA glucose-6-phosphate dehydrogenase
HPA human platelet antigen
ICH intracranial hemorrhage
IPPC intrapartum period
IPSS intrapartum period
JIA juvenile idiopathic arthritis
KM large for gestational age
LAH left atrial hypertrophy
LGA left ventricular hypertrophy
LH anterior chamber
LSP left spatial border
MDI metformin diethylamino
MICR methylcellulose
MINI multiple infarct dementia
MVH medium volume
P3RA positive pressure ventilation
PPV positive pressure ventilation
PUVA psoralen + UVA
RAU right upper sternal border
RAS renal artery stenosis
RSBB right bundle branch block
RDS respiratory distress syndrome
RF rheumatoid factor
RLR Ringer’s lactate
RLS restless legs syndrome
RVP right ventricular hypertrophy
RVOT right ventricular outflow tract obstruction
SAD small for gestational age
SADH syndrome of inappropriate antidiuretic hormone
SCHD schizophrenia
SLE systemic lupus erythematosus
SMA spinal muscular atrophy
SPD social phobia
SPP syndrome of inappropriate antidiuretic hormone
TBI traumatic brain injury
TTP thrombotic thrombocytopenic purpura
TSS toxic shock syndrome
UAE unilateral asymptomatic pregnancy
UA umbilical artery
UVR ultraviolet B
VUR vesicoureteral reflux
WBC white blood cell
WPW Wolff-Parkinson-White

Pediatric Quick Reference Values

Table 1. Average Vitals at Various Ages

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Pulse (bpm)</th>
<th>Respiratory Rate (br/min)</th>
<th>sBP (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1</td>
<td>110-160</td>
<td>30-40</td>
<td>70-90</td>
</tr>
<tr>
<td>1-2</td>
<td>100-150</td>
<td>25-35</td>
<td>80-95</td>
</tr>
<tr>
<td>2-5</td>
<td>95-140</td>
<td>25-35</td>
<td>80-100</td>
</tr>
<tr>
<td>5-12</td>
<td>80-120</td>
<td>20-25</td>
<td>90-110</td>
</tr>
<tr>
<td>&gt;12</td>
<td>60-100</td>
<td>15-20</td>
<td>110-120</td>
</tr>
</tbody>
</table>

Primary Care

Visit Overview

- schedule
  - newborn (within 1 wk post-discharge), 1, 2, 4, 6, 9, 12, 15, 18, 24 mo
  - annually between age 2-5; every 1-2 years between age 6-18
- content
  - history and physical exam including growth, development, and nutrition
  - routine immunizations
  - counseling and anticipatory guidance
**Routine Immunization**

Table 2. Publicly Funded Immunization Schedule for Ontario, August 2011

<table>
<thead>
<tr>
<th>Age</th>
<th>DTaP-IPV</th>
<th>dTaP-IPV</th>
<th>Pneu-C-13</th>
<th>Rot-1</th>
<th>Men-C-C</th>
<th>MMR</th>
<th>Var</th>
<th>MMRV</th>
<th>Men-C-ACYW</th>
<th>HepB</th>
<th>HPV-4</th>
<th>Tdap</th>
<th>Inf</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 mo</td>
<td>✓/IM</td>
<td>✓/IM</td>
<td>✓/PO</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 mo</td>
<td>✓/IM</td>
<td>✓/IM</td>
<td>✓/PO</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 mo</td>
<td>✓/IM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 mo</td>
<td></td>
<td>✓/IM</td>
<td>✓/IM</td>
<td>✓/SC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15 mo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓/SC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18 mo</td>
<td>✓/IM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4-6 yr</td>
<td>✓/IM</td>
<td></td>
<td>✓/IM</td>
<td>✓/SC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 7</td>
<td></td>
<td></td>
<td>✓/IM</td>
<td>✓/IM</td>
<td>✓/SC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14-16 yr</td>
<td></td>
<td></td>
<td>✓/IM</td>
<td>✓/IM</td>
<td>✓/IM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Every autumn</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓/IM</td>
</tr>
</tbody>
</table>

**Vaccine**

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Adverse Reaction</th>
<th>Contraindication</th>
</tr>
</thead>
<tbody>
<tr>
<td>DTaP-IPV</td>
<td>Prolonged crying</td>
<td>Evolving unstable neurologic disease</td>
</tr>
<tr>
<td></td>
<td>Hypotonic unresponsive state (rare)</td>
<td>Hyporesponsive/hyponatremic following previous vaccine</td>
</tr>
<tr>
<td></td>
<td>Seizure on day of vaccine (rare)</td>
<td>Anaphylactic reaction to neomycin or streptomycin</td>
</tr>
<tr>
<td>Rot-1</td>
<td>Cough</td>
<td>History of intussusception</td>
</tr>
<tr>
<td></td>
<td>Diarrhea, vomiting</td>
<td>Immune compromised</td>
</tr>
<tr>
<td></td>
<td>History of prematurity</td>
<td>Abdominal disorder (e.g. Meckel’s diverticulum)</td>
</tr>
<tr>
<td></td>
<td>Received blood products (e.g. immunoglobulin) within 42 days</td>
<td></td>
</tr>
<tr>
<td>MMR</td>
<td>Measles-like rash (7-14 d)</td>
<td>Pregnancy</td>
</tr>
<tr>
<td></td>
<td>Lymphadenopathy, arthralgia, arthritis</td>
<td>Immune compromised infants (except healthy HIV positive children)</td>
</tr>
<tr>
<td></td>
<td>Parotitis (rare)</td>
<td>Anaphylactic reaction to gelatin</td>
</tr>
<tr>
<td></td>
<td>Especially painful injection</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Transient thrombocytopenia (1/30,000)</td>
<td></td>
</tr>
<tr>
<td>Var</td>
<td>Mild varicella-like papules or vesicles; 2 weeks may get local or generalized rash</td>
<td>Pregnant or planning to get pregnant within 3 mo</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anaphylactic reaction to gelatin</td>
</tr>
<tr>
<td>HepB</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anaphylactic reaction to Baker’s yeast</td>
</tr>
<tr>
<td>MMRV</td>
<td>Same as MMR and Var vaccines</td>
<td>Same as MMR and Var vaccines</td>
</tr>
<tr>
<td>dTAP</td>
<td></td>
<td>1st trimester pregnancy</td>
</tr>
<tr>
<td>Inf</td>
<td>Malaise, myalgia</td>
<td>&lt;6 months of age</td>
</tr>
<tr>
<td></td>
<td>Febrile seizure when given with Pneu-C 13 or DTaP</td>
<td>Immune compromised</td>
</tr>
<tr>
<td></td>
<td>Hypersensitivity reaction</td>
<td>Egg-allergic individuals – Live attenuated influenza vaccine is not recommended for those with an egg allergy. In these individuals, trivalent or quadrivalent vaccine can be given in environment where anaphylaxis can be managed</td>
</tr>
<tr>
<td>HPV-4</td>
<td>Pruritis</td>
<td></td>
</tr>
<tr>
<td>MenB*</td>
<td>Anaphylactic reaction to MenB vaccine or its components in the past</td>
<td></td>
</tr>
</tbody>
</table>

**Vaccination in Cases of Asplenia or Hypoasplenia (such as Sickle Cell Disease)**
- Should receive all routine immunizations, including the yearly influenza vaccine
- No vaccines are contraindicated
- Susceptible to infection by encapsulated bacteria ("SHNE KISS" – S. pneumoniae, H. influenzae, N. meningitidis, E. coli, Klebsiella, Salmonella, Group B Streptococcus), so must add:
  - Meningococcal-C-Conjugate at age ≥2 yr
  - Quadrivalent Men-P-ACYW at least 2 wk later
  - Booster of Men-P-ACYW q2 yr
  - Pneumococcal polysaccharide vaccine (Pneu-P-23) at age ≥2 yr
  - Single booster of Pneu-P-23 at age ≥3 yr
  - Consider single booster HB at age >5 yr

**Growth and Development**

- **Growth**
  - growth is not linear
  - most rapid growth during first 2 yr and at puberty
  - tissues grow at different times
    - first 2 yr = CNS; mid-childhood = lymphoid tissue; puberty = gonads
  - measurement of growth
    - premature infants (<37 wk) use corrected GA until age 2
    - body proportion = upper/lower segment ratio (use symphysis pubis as midpoint)
      - newborn = 1.7, adult male = 0.9, adult female = 1.0

**Injection site**

Infants (<12 mo): anterolateral thigh

---

*Currently only publicly funded for select groups (asplenia, antibody/complement deficiencies, cochlear implant recipients, HIV, close contacts with infected individuals)*

dTaP = diphtheria, tetanus, acellular pertussis vaccine; DTaP-IPV = diphtheria, tetanus, acellular pertussis, inactivated polio vaccine (i.e. Pentacel™, Pentaxim™); HepB = hepatitis B vaccine; Hib = Haemophilus influenzae type b conjugate vaccine; HPV-4 = human papillomavirus vaccine; Inf = influenza vaccine; MMR = measles, mumps, rubella vaccine; Men- = multicomponent meningococcal B vaccine; Men-C- = meningococcal c conjugate vaccine; MMRV = measles, mumps, rubella, varicella vaccine; Pneu-C-13 = pneumococcal 13-valent conjugate vaccine; Rot-1 = rotavirus oral vaccine; Var = varicella vaccine
### Average Growth Parameters

**Table 3. Parameter of Average Growth at Birth**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Normal</th>
<th>Growth</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth Weight</td>
<td>3.25 kg (7 lbs)</td>
<td>Gain 20-30 g/d (term neonate)</td>
<td>Weight loss (up to 10% of birth weight) in first 7 d of life is normal Neonate should regain birth weight by ~10-14 d of age</td>
</tr>
<tr>
<td>Length/Height</td>
<td>50 cm (20 in)</td>
<td>25 cm in 1st yr 12 cm in 2nd yr 8 cm in 3rd yr then 4-7 cm/yr until puberty 1/2 adult height at 2 yr</td>
<td>Measure supine length until 2 yr of age, then measure standing height</td>
</tr>
<tr>
<td>Head Circumference</td>
<td>35 cm (14 in)</td>
<td>2 cm/mo for 1st 3 mo 1 cm/mo at 3-6 mo 0.5 cm/mo at 6-12 mo</td>
<td>Measure around occipital, parietal, and frontal prominences to obtain the greatest circumference</td>
</tr>
</tbody>
</table>

### Reflexes

**Table 4. Reflexes**

<table>
<thead>
<tr>
<th>Reflex</th>
<th>Maneuver to Elicit Reflex</th>
<th>Appropriate Reflex Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moro</td>
<td>Infant placed semi-upright, head supported by examiner’s hand; sudden withdrawal of supported head with immediate return of support</td>
<td>Abduction and extension of the arms, opening of the hands, followed by flexion and adduction of arms</td>
</tr>
<tr>
<td>Galant</td>
<td>Infant held in vertical suspension and one side of back is stroked along paravertebral line</td>
<td>Pelvis will move in the direction of stimulated side</td>
</tr>
<tr>
<td>Grasp</td>
<td>Placement of examiner’s finger in infant’s palm</td>
<td>Flexion of infant’s fingers</td>
</tr>
<tr>
<td>ATNR</td>
<td>Turn infant’s head to one side</td>
<td>“Fencing” posture (extension of ipsilateral leg and arm and flexion of contralateral arm)</td>
</tr>
<tr>
<td>Placing</td>
<td>Dorsal surface of infant’s foot placed touching edge of table</td>
<td>Flexion followed by extension of ipsilateral limb up onto table (resembles primitive walking)</td>
</tr>
<tr>
<td>Rooting</td>
<td>Tactile stimulus near mouth</td>
<td>Infant turns head and opens mouth to suck on same side that cheek was stroked</td>
</tr>
<tr>
<td>Parachute</td>
<td>Tilt infant to side while in sitting position</td>
<td>Ipsilateral arm extension, present by 6-8 mo</td>
</tr>
</tbody>
</table>

*ATNR = asymmetric tonic neck reflex*

### Developmental Milestones

**Table 5. Developmental Milestones**

<table>
<thead>
<tr>
<th>Age*</th>
<th>Gross Motor</th>
<th>Fine Motor</th>
<th>Speech and Language</th>
<th>Adaptive and Social Skills</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mo</td>
<td>Turns head side to side when supine</td>
<td>Hands fist, thumb in fist</td>
<td>Cries, startles to loud noises</td>
<td>Calms when comforted</td>
</tr>
<tr>
<td>2 mo</td>
<td>Briefly raises head when prone, holds head erect when upright</td>
<td>Pulls at clothes</td>
<td>Variety of sounds (e.g. coos, gurgles)</td>
<td>Smiles responsively, recognizes and calms down to familiar voice, follows movement with eyes</td>
</tr>
<tr>
<td>4 mo</td>
<td>Lifts head and chest when prone, holds head steady when supported sitting, rolls prone to supine</td>
<td>Briefly holds object when placed in hand, reaches for midline objects</td>
<td>Turns head towards sounds</td>
<td>Laughs responsively, follows moving toy or person with eyes, responds to people with excitement (e.g. leg movement)</td>
</tr>
<tr>
<td>6 mo</td>
<td>Tripod sit, pivots in prone position</td>
<td>Unlar or raking grasp, transfers objects from hand to hand, brings objects to mouth</td>
<td>Babbles</td>
<td>Stranger anxiety, beginning of object permanence</td>
</tr>
<tr>
<td>9 mo</td>
<td>Sits well without support, crawls, pulls to stand, stands with support</td>
<td>Early pincer grasp with straight wrist</td>
<td>“Mama, dada” – appropriate, imitates 1 word, responds to “no” regardless of tone</td>
<td>Plays games (e.g. peek-a-boo), reaches to be picked up</td>
</tr>
<tr>
<td>12 mo</td>
<td>Gets into sitting position without help, stands without support, walks while holding on</td>
<td>Neat pincer grasp, releases ball with throw</td>
<td>2 words, follows 1-step command, uses facial expression, sounds, actions to make needs known</td>
<td>Responds to own name, separation anxiety begins</td>
</tr>
</tbody>
</table>

*Use corrected GA until 2 yr*
Table 5. Developmental Milestones (continued)

<table>
<thead>
<tr>
<th>Age*</th>
<th>Gross Motor</th>
<th>Fine Motor</th>
<th>Speech and Language</th>
<th>Adaptive and Social Skills</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 mo</td>
<td>Walks without support, crawls up stairs/steps</td>
<td>Picks up and eats finger foods, scribbles, stacks 2 blocks</td>
<td>4-5 words, points to needs/wants</td>
<td>Looks to see how others react (e.g. after falling)</td>
</tr>
<tr>
<td>18 mo</td>
<td>Runs, walks forward pulling toys or carrying objects</td>
<td>Tower of 3 cubes, scribbling, eats with spoon</td>
<td>10 words, follows simple commands</td>
<td>Shows affection towards others, points to show interest in something</td>
</tr>
<tr>
<td>24 mo</td>
<td>Climbs up and down steps with 2 feet per step, runs, kicks ball</td>
<td>Tower of 6 cubes, undresses</td>
<td>2-3 word phrases, uses “I, me, you”, 50% intelligible, understands 2-step commands</td>
<td>Parallel play, helps to dress</td>
</tr>
<tr>
<td>3 yr</td>
<td>Rides tricycle, climbs up 1 foot per step, down 2 feet per step, stands on one foot briefly</td>
<td>Copies a circle, turns pages one at a time, puts on shoes, dress/undress fully except buttons</td>
<td>Combines 3 or more words into sentence, recognizes colours, plural, counts to 10, 75% intelligible</td>
<td>Knows sex and age, shares some of the time, plays make-believe games</td>
</tr>
<tr>
<td>4 yr</td>
<td>Hops on 1 foot, climbs down 1 foot per step</td>
<td>Copies a cross, uses scissors, buttons clothes</td>
<td>Speech 100% intelligible, uses past tense, understands 3-part directions</td>
<td>Cooperative play, fully toilet-trained by day, tries to comfort someone who is upset</td>
</tr>
<tr>
<td>5 yr</td>
<td>Skips, rides bicycle</td>
<td>Copies a triangle and square, prints name, ties shoelaces</td>
<td>Fluent speech, future tense, alphabet, retells sequence of a story</td>
<td>Cooperates with adult requests most of the time, separates easily from caregiver</td>
</tr>
</tbody>
</table>

*Use corrected GA until 2 yr

## Nutrition

### Dietary Requirements

<table>
<thead>
<tr>
<th>Weight</th>
<th>&lt; 10 kg</th>
<th>10-20 kg</th>
<th>&gt; 20 kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Needs</td>
<td>100 kcal/kg/d</td>
<td>1,000 cal + 50 kcal/kg/d for each kg &gt;10</td>
<td>1,500 cal + 20 kcal/kg/d for each kg &gt;20</td>
</tr>
</tbody>
</table>

### Dietary Recommendations

- **0-6 mo:** breast milk or formula
  - exclusive breast milk during first 6 mo recommended over formula unless contraindicated
  - breastfed infants require supplements: vitamin D (400-800 IU/d), fluoride (after 6 mo if not sufficient in water), iron (6-12 mo, only if not receiving fortified cereals/meat/meat alternatives)
- **>6 mo:** solid food introduction – do not delay beyond 9 mo
  - 2-3 new foods per wk with a few days in between each food to allow time for adverse reaction identification
  - suggested order of introduction
    - meat, meat alternatives, and iron-enriched cereal (rice cereal is least allergenic)
    - pureed vegetables
    - fruit
- **9-12 mo:** finger foods and switch to homogenized (3.25%) milk
  - feed child based on hunger/satiety cues; encourage self-feeding and introduce open cup
  - foods to avoid
    - honey until past 12 mo (risk of botulism)
    - added sugar, salt
    - excessive milk (i.e. no more than 16 oz/d after 1 yr)
    - juice (not nutritious, too much sugar) maximum 4-6 oz (1/2 cup) daily
    - anything that is a choking hazard (chunks, round foods like grapes)

### 2 yrs: switch to 2% milk

- content of breast milk
  - colostrum (first few days): clear, rich in nutrients (i.e. high protein, low fat), immunoglobulin
  - mature milk: 70:30 whey:casein ratio, fat from dietary butterfat, carbohydrate from lactose
- advantages
  - easily digested, low renal solute load
  - immunologic
    - contains IgA, macrophages, active lymphocytes, lysoenzymes, lactoferrin (which inhibits E. coli growth in intestine)
    - lower pH promotes growth of *Lactobacillus* in GI tract
- parent-child bonding
- economical, convenient

---

Peanut Allergies in Children

*NEJM* 2015;373(9):803-813

**Study:** 640 children identified as “at risk to peanut allergy” due to severe eczema, egg allergy, or both were split into two cohorts depending on their pre-existing sensitivty to peanut extract on skin-prick test. These two cohorts were randomized to peanut consumption or avoidance up until 60 mo of age.

**Results:** In the cohort with negative skin-prick test at start of study, prevalence of peanut allergy at 60 mo of age was 13.7% in peanut avoidance and 1.9% in the peanut consumption group. In cohort with positive skin-prick test at start of study, prevalence of peanut allergy at 60 mo of age was 35.3% in peanut avoidance and 10.6% in peanut consumption group.

**Conclusion:** Early introduction of peanuts significantly decreased prevalence of peanut allergies in children deemed “at risk to peanut allergy”.

---

Dietary Exposures and Allergy Prevention in High-Risk Infants

*Pediatri Child Health* 2013;18(10):545-549

There is no evidence that restriction of highly allergenic foods is beneficial in the first year of life. Later introduction of peanut, fish, or egg does not prevent, and may increase the risk of developing food allergy. There is also no evidence that dietary restrictions during pregnancy or breastfeeding are protective to the child.
• maternal contraindications
  ▪ chemotherapy or radioactive compounds
  ▪ HIV/AIDS, active untreated TB, herpes in breast region
  ▪ >0.5 g/kg/d of alcohol or illicit drugs
  ▪ medications known to cross to breast milk
  ▪ OCPs are not a contraindication to breastfeeding (estrogen may decrease lactation, but is not dangerous to infant)
  ▪ MotherRisk™ Program – valuable research and counselling on reproductive risk or safety of drugs and chemicals
• breastfeeding jaundice (first 1-2 wk): due to lack of maternal milk production and subsequent infant dehydation (see jaundice, P69)
• breast milk jaundice (0.5% of newborns, persists up to 4-6 mo): rare, glucuronyl transferase inhibitor in breast milk inhibits conjugation of bilirubin, increases enterohepatic circulation of bilirubin
  • baby presents healthy and thriving, and jaundice (secondary to unconjugated bilirubin) resolves
• poor weight gain: consider dehydration or FTT
• oral candidiasis (thrush): treat baby with antifungal such as nystatin; can occur in breast or bottle-fed infants

Table 6. Common Formulas Compared to Breast Milk

<table>
<thead>
<tr>
<th>Type of Nutrition</th>
<th>Indications</th>
<th>Content (as compared to breast milk)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cow’s Milk-Based Formulas</td>
<td>Prematurity</td>
<td>Lower whey:casein ratio</td>
</tr>
<tr>
<td>(Enfamil®, Similac®)</td>
<td>Transition into breastfeeding</td>
<td>Plant fats instead of dietary butterfat</td>
</tr>
<tr>
<td>Fortified Formula</td>
<td>Low birth weight</td>
<td>Higher calories and vitamins A, C, D, K</td>
</tr>
<tr>
<td></td>
<td>Prematurity</td>
<td>May only be used in hospital due to risk of fat-soluble vitamin toxicity</td>
</tr>
<tr>
<td>Soy Protein (Isomil®, Prosobee®)</td>
<td>Galactosemia</td>
<td>Corn syrup solids or sucrose in place of lactose</td>
</tr>
<tr>
<td>(Good Start®)</td>
<td>Desire for vegetarian/vegan diet*</td>
<td></td>
</tr>
<tr>
<td>Partially Hydrolyzed Proteins</td>
<td>Delayed gastric emptying</td>
<td>Protein is 100% whey with no casein</td>
</tr>
<tr>
<td>(Good Start®)</td>
<td>Risk of cow milk protein allergy</td>
<td></td>
</tr>
<tr>
<td>Protein Hydrolysate (Nutramigen®, Alimentum®, Pregestimil®, Portagen®)</td>
<td>Malabsorption</td>
<td>Protein is 100% casein with no whey</td>
</tr>
<tr>
<td></td>
<td>Food allergy</td>
<td>Com syrup solids, sucrose, or tapioca starch instead of lactose</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Expensive</td>
</tr>
<tr>
<td>Amino Acid (Neocate®, PurAminoTM)</td>
<td>Food allergy</td>
<td>Free amino acids (no protein)</td>
</tr>
<tr>
<td></td>
<td>Short gut</td>
<td>Com syrup solids instead of lactose</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Very expensive</td>
</tr>
<tr>
<td>Metabolic</td>
<td>Inborn errors of metabolism</td>
<td>Various different compositions for children with galactosemia, propionic acidemia, etc.</td>
</tr>
</tbody>
</table>

* 10-35% of children with cow’s milk protein allergy also have reactions to soy-based formula

Injury Prevention Counselling

• injuries are the leading cause of death in children >1 yr of age
• main causes: motor vehicle crashes, burns, drowning, falls, choking, infanticide

Table 7. Injury Prevention Counselling

<table>
<thead>
<tr>
<th>0-6 mo</th>
<th>6-12 mo</th>
<th>1-2 yr</th>
<th>2-5 yr</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do not leave alone on bed, on changing table, or in tub</td>
<td>Install stair barriers</td>
<td>Never leave unattended</td>
<td>Bicycle helmet</td>
</tr>
<tr>
<td>Keep crib rails up</td>
<td>Discourage use of walkers</td>
<td>Keep pot handles turned to back of stove</td>
<td>Never leave unsupervised at home, driveway, or pool</td>
</tr>
<tr>
<td>Check water temperature before bathing</td>
<td>Avoid play areas with sharp-edged tables and corners</td>
<td>Caution with whole grapes, nuts, raw carrots, hotdogs, etc. due to choking hazard</td>
<td>Teach bike safety, stranger safety, and street safety</td>
</tr>
<tr>
<td>Do not hold hot liquid and infant at the same time</td>
<td>Cover electrical outlets</td>
<td>No running while eating</td>
<td>Swimming lessons (&gt;4 yr), sunscreen (from 6 mo), fences around pools</td>
</tr>
<tr>
<td>Check milk temperature before feeding</td>
<td>Unplug appliances when not in use</td>
<td>Appropriate car seats</td>
<td>Appropriate car seats</td>
</tr>
<tr>
<td>Appropriate car seats are required before leaving hospital</td>
<td>Keep small objects, plastic bags, cleaning products, and medications out of reach</td>
<td>Supervise during feeding</td>
<td></td>
</tr>
</tbody>
</table>

Note: This list is not exhaustive. For more details, see Rourke Baby Record (http://www.rourkebabynote.ca/pdf/RBR2011Ont_Eng.pdf)
Common Complaints

Breath Holding Spells

- epidemiology: 0.1-5% of healthy children 6 mo-4 yr of age, usually start during first year of life
- etiology: child is provoked (usually by anger, injury, or fear) → holds breath and becomes silent → spontaneously resolves or loses consciousness
- types
  - cyanotic (more common), usually associated with anger/frustration
  - pallid, usually associated with pain/surprise
- management
  - usually resolves spontaneously and rarely progresses to seizure
  - help child control response to frustration and avoid drawing attention to spell
  - commonly associated with iron deficiency anemia, improves with supplemental iron

Circumcision

- elective procedure
  - not covered by OHIP in Ontario, but recent evidence shows show risks vs benefit → not clearly different; no clear position by CPS in 2015 statement
  - benefits: prevention of phimosis and slightly reduced incidence of UTI, STI, balanitis, cancer of the penis
  - complications (<1%): local infection, bleeding, urethral injury
  - contraindications: presence of genital abnormalities (e.g. hypospadias) or known bleeding disorder

Crying/Fussing Child

- history
  - description of baseline feeding, sleeping, crying patterns
  - infectious symptoms: fever, tachypnea, rhinorrhea, ill contacts
  - feeding intolerance: gastroesophageal reflux with esophagitis, N/V, diarrhea, constipation
  - trauma
  - recent immunizations (vaccine reaction) or medications (drug reactions), including maternal drugs taken during pregnancy (neonatal withdrawal syndrome) and drugs that may be transferred via breast milk
  - inconsistent history, pattern of numerous emergency department visits, high-risk social situations all raise concern of maltreatment

Table 8. Physical Exam and Differential Diagnosis

<table>
<thead>
<tr>
<th>Organ System</th>
<th>Possible Examination Findings</th>
<th>Possible Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEENT</td>
<td>Bulging fontanelle, bulging and erythematous TM</td>
<td>Meningitis, shaken baby syndrome, hydrocephalus</td>
</tr>
<tr>
<td></td>
<td>Blepharospasm, tearing</td>
<td>Corneal abrasion, glaucoma</td>
</tr>
<tr>
<td></td>
<td>Retinal hemorrhage</td>
<td>Retinal vein occlusion</td>
</tr>
<tr>
<td></td>
<td>Droophonygeal infections</td>
<td>Thrush, gingivostomatitis, herpangina, otitis media</td>
</tr>
<tr>
<td>Neurological</td>
<td>Irritability or lethargy</td>
<td>Meningitis, shaken baby syndrome</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Poor perfusion</td>
<td>Sepsis, anomalous coronary artery, meningitis, myocarditis, CHF</td>
</tr>
<tr>
<td></td>
<td>Tachycardia</td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Tachypnea</td>
<td>Pneumonia, CHF</td>
</tr>
<tr>
<td></td>
<td>Grunting</td>
<td>Respiratory disease, response to pain</td>
</tr>
<tr>
<td>Abdominal</td>
<td>Mass, empty RLQ</td>
<td>Intussusception</td>
</tr>
<tr>
<td>Genitourinary</td>
<td>Scrotal swelling</td>
<td>Incarcerated hernia, testicular torsion</td>
</tr>
<tr>
<td></td>
<td>Perineal swelling</td>
<td>Hair tourniquet</td>
</tr>
<tr>
<td>Rectal</td>
<td>Anal fissure</td>
<td>Constipation or diarrhea</td>
</tr>
<tr>
<td></td>
<td>Hemorrhage positive stool</td>
<td>Intussusception, NEC, volvulus</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>Pain tenderness or decreased movement</td>
<td>Fracture, syphilis, osteomyelitis, toe/foot hair tourniquet</td>
</tr>
</tbody>
</table>

Infantile Colic

- definition: unexplained paroxysms of irritability and crying for >3 h/d, >3 d/wk for >3 wk in an otherwise healthy, well-fed baby (rule of 3s)
- epidemiology: 10% of infants; usual onset 10 d to 3 mo of age with peak at 6-8 wk
- etiology: lag in development of normal peristaltic movement in gastrointestinal tract; other theories suggest a lack of self-soothing mechanisms or extreme of normal
management
- parental relief, rest, and reassurance
- hold baby, soother, car ride, music, vacuum, check diaper
- medications (Ovomaltine® drops, grape water) have no proven benefit, some evidence for probiotics
- if breastfeeding, elimination of cow’s milk protein from mother’s diet (effective in very small percentage of cases)
- check for otitis media, cow’s milk intolerance, GI problem, fracture
- try casein hydrolysate formula (Nutramigen®)
- time – all resolve, most in the first 2-3 mo of life

Dentition and Caries

Dentition
- primary dentition (20 teeth)
  - first tooth at 5-9 mo (lower incisor), then 1/mo
  - 6-8 central teeth by 1 yr
  - assessment by dentist 6 mo after eruption of first tooth and certainly by 1 yr of age (Grade B recommendation)
- secondary dentition (32 teeth)
  - first adult tooth is 1st molar at 6 yr, then lower incisors

Caries
- milk caries: decay of superior front teeth and back molars in first 4 yr of life
- cause: often due to prolonged feeding (e.g. put to bed with bottle, prolonged breastfeeding)
- prevention
- no bottle at bedtime, clean teeth after last feed
- minimize juice and sweetened pacifier
- clean teeth with soft damp cloth or toothbrush and water
- water fluoridation

Enuresis

Definition
- involuntary urinary incontinence by day and/or night in child >5 yr

General Approach
- should be evaluated if dysuria, change in colour, odour, stream, secondary or diurnal, change in gait, stool incontinence

Primary Nocturnal Enuresis
- definition: involuntary loss of urine at night, bladder control has never been attained
- epidemiology: boys > girls; 10% of 6 yr olds, 3% of 12 yr olds, 1% of 18 yr olds
- etiology: developmental disorder or maturational lag in bladder control while asleep
- management
  - time and reassurance (~20% resolve spontaneously each yr)
  - behaviour modification (limiting fluids, voiding prior to sleep), bladder retention exercises, scheduled toileting overnight has limited effectiveness
  - conditioning: “wet” alarm wakes child upon voiding (70% success rate)
  - medications (considered second line therapy, may be used for sleepovers/camp): DDAVP oral tablets (high relapse rate, costly), imipramine (Tofranil®) (rarely used, lethal if overdose, cholinergic side effects)

Secondary Enuresis
- definition: involuntary loss of urine at night, develops after child has sustained period of bladder control (>6 mo)
- etiology: inorganic regression due to stress or anxiety (e.g. birth of sibling, significant loss, family discord), focused on other activities, secondary to organic disease (UTI, DM, DI, neuromuscular bladder, CP, seizures, pinworms)
- management: treat underlying cause

Diurnal Enuresis
- definition: daytime wetting (60-80% also wet at night)
- etiology: micturition deferral (holding urine until last minute) due to psychosocial stressor (e.g. shy), structural anomalies (e.g. ectopic ureteral site, neuromuscular bladder), UTI, constipation, CNS disorders, DM
- management: treat underlying cause, behavioural (scheduled toileting, double voiding, good bowel program, sitting backwards on toilet, charting/incentive system, relaxation/biofeedback), pharmacotherapy
**Encopresis**

- definition: fecal incontinence in a child >4 yr old, at least once per mo for 3 mo
- prevalence: 1-1.5% of school-aged children (rare in adolescence); M:F = 6:1 in school-aged children
- causes: chronic constipation (retentive encopresis), Hirschsprung disease, hypothyroidism, hypercalcemia, spinal cord lesions, anorectal malformations, bowel obstruction

**Retentive Encopresis**

- definition: child holds bowel movement, develops constipation, leading to fecal impaction and seepage of soft or liquid stool (overflow incontinence)
- etiology
  - physical: painful stooling often secondary to constipation
  - emotional: disturbed parent-child relationship, coercive toilet training, social stressors
- clinical presentation
  - history
    - crosses legs or stands on toes to resist urge to defecate
    - distressed by symptoms, soiling of clothes
    - toilet training coercive or lacking in motivation
    - may show oppositional behaviour
    - abdominal pain
  - physical exam
    - digital rectal exam: large fecal mass in rectal vault
    - anal fissures (result from passage of hard stools)
  - palpable stool in LLQ
- management
  - complete clean-out of bowel: PEG 3350 given orally is most effective, enemas and suppositories may be second line therapies, but these are invasive and often less effective
  - maintenance of regular bowel movements (see Constipation Treatment, P36)
  - assessment and guidance regarding psychosocial stressors
  - behavioural modification
- complications: recurrence, toxic megacolon (requires >3-12 mo to treat), bowel perforation

**Toilet Training**

- 90% of children attain bladder control before bowel control
- generally, females train earlier than males
- 25% by 2 yr (in North America), 98% by 3 yr have daytime bladder control
- signs of toilet readiness
  - ambulating independently, stable on potty, desire to be independent or to please caregivers (i.e. motivation), sufficient expressive and receptive language skills (2-step command level), can stay dry for several hours (large enough bladder), can recognize need to go, able to remove clothing

**Failure to Thrive**

- definition
  - weight <3rd percentile, falls across two major percentile curves, or <80% of expected weight for height and age
  - inadequate caloric intake most common factor in poor weight gain
  - may have other nutritional deficiencies (e.g. protein, iron, vitamin D)
  - factors affecting physical growth: genetics, intrauterine factors, nutrition, endocrine hormones, chronic infections/diseases, psychosocial factors
- clinical presentation
  - history
    - nutritional intake
    - current symptoms
    - past illnesses
    - family history: growth, puberty, parental height and weight including mid-parental height
    - psychosocial history
  - physical exam
    - growth parameters, plotted: height, weight, head circumference, arm span
    - vital signs
    - complete head to toe exam
    - dysmorphic features or evidence of chronic disease
    - upper to lower segment ratio
    - sexual maturity staging
    - signs of maltreatment or neglect
  - investigations (as indicated by clinical presentation)
    - CBC, blood smear, electrolytes, T4, TSH
    - bone age x-ray
    - chromosomes/karyotype
    - chronic illness: chest (CXR, sweat Cl-), cardiac (CXR, ECG, Echo), GI (celiac screen, inflammatory markers, malabsorption), renal (urinalysis), liver (enzymes, albumin)

### Mid-Parental Height

- Boys target height = (father ht + mother ht + 13) / 2
- Girls target height = (father ht + mother ht – 13) / 2

**Note:** height should be taken in cm

### Clinical Signs of FTT

**SMALL KID**

- Subcutaneous fat loss
- Muscle atrophy
- Alopecia
- Lethargy
- Lagging behind normal
- Kussmaul
- Infection (recurrent)
- Dermatitis
Table 9. Failure to Thrive Patterns

<table>
<thead>
<tr>
<th>Growth Parameters</th>
<th>Suggestive Abnormality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decreased Wt</td>
<td>Normal Ht Normal HC Caloric insufficiency Decreased intake</td>
</tr>
<tr>
<td>Decreased Wt</td>
<td>Decreased Ht Normal HC Structural dystrophies Endocrine disorder</td>
</tr>
<tr>
<td>Decreased Wt</td>
<td>Decreased Ht Decreased HC Intrauterine insult Genetic abnormality</td>
</tr>
</tbody>
</table>

BA = bone age; CA = chronological age; HC = head circumference; Ht = height; Wt = weight

Non-Organic FTT (90%)
- most common cause of FTT
- results from complex factors in parent-child relationship
  - dietary intake, knowledge about feeding, improper mixing of formula, economic factors
  - feeding environment
    - parent-child interaction, attachment
    - child behaviours, hunger/satiety cues
  - social factors: stress, poverty
- management
  - most as outpatient using multidisciplinary approach: primary care physician, dietitian, psychologist, social work, CAS
  - medical: otoromotor problems, iron-deficiency anemia, gastroesophageal reflux
  - nutritional: educate about age-appropriate foods, calorie boosting, mealtime schedules and environment; goal to reach 90-110% IBW, correct nutritional deficiencies, and promote catch-up growth/development
  - behavioural: positive reinforcement, mealtime environment

Organic FTT (10%)
- inadequate intake: non-organic, vomiting, otoromotor dysfunction, anorexia
- excessive consumption: CHD, CF, hyperthyroidism
- abnormal utilization: inborn errors of metabolism
- excessive output: IBD, celiac, malabsorption
- management: treat specific cause

Energy Requirements
- see Nutrition, P6

Obesity
- definition: BMI >95th percentile for age and height
- risk factors: genetic predisposition (e.g. both parents obese – 80% chance of obese child)
- etiology: organic causes are rare (<5%), but may include Prader-Willi, Carpenter, Turner, Cushing syndromes, hypothyroidism
- complications: association with HTN, dyslipidemia, slipped capital femoral epiphysis, type 2 DM, asthma, obstructive sleep apnea, gynecomastia, polycystic ovarian disease, early menarche, irregular menses, psychological trauma (e.g. bullying, decreased self-esteem, unhealthy coping mechanisms, depression)
- childhood obesity often persists into adulthood
- management
  - encouragement and reassurance; engagement of entire family
  - diet: qualitative changes (do not encourage weight loss, but allow for linear growth to catch up with weight), special diets used by adults and very low calorie diets are not encouraged
  - behaviour modification: increase activity, change eating habits/meal patterns
  - education: multidisciplinary approach, dietitian, counselling
  - surgery and pharmacotherapy are rarely used in children
  - increase physical activity (30 min/day), reduce screen time

Poison Prevention
- keep all types of medicines, vitamins, and chemicals locked up in a secure container
- potentially dangerous: medications, illicit drugs, drain cleaners, furniture polish, insecticides, cosmetics, nail polish remover, automotive products
- do not store any chemicals in juice, soft drink, or water bottles
- keep alcoholic beverages out of reach: 3 oz hard liquor can kill a 2 yr old
- always read labels before administering medicine to ensure correct medication drug and dose and/or speak with a pharmacist or healthcare provider

Screen Time Guidelines (Canadian Society for Exercise Physiology)
- Screen time is not recommended for children under 2 yr
- <1 h/d screen time is appropriate for children aged 2-5 yr
- <2 h/d screen time is appropriate for children 5-17 yr

• <1 h/d screen time is appropriate for children aged 2-5 yr
• <2 h/d screen time is appropriate for children 5-17 yr

• keep alcoholic beverages out of reach: 3 oz hard liquor can kill a 2 yr old
• do not store any chemicals in juice, soft drink, or water bottles
• keep alcoholic beverages out of reach: 3 oz hard liquor can kill a 2 yr old
• always read labels before administering medicine to ensure correct medication drug and dose and/or speak with a pharmacist or healthcare provider
### Rashes

#### Table 10. Common Pediatric Rashes

<table>
<thead>
<tr>
<th>Type of Rash</th>
<th>Differential</th>
<th>Appearance</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diaper Dermatitis</td>
<td>Irritant contact dermatitis</td>
<td>Shiny, red macules/patches, no skin fold involvement</td>
<td>Eliminate direct skin contact with urine and feces, allow periods of rest without a diaper; frequent diaper changes; topical barriers (petrolatum, zinc oxide or paste); short-term low-potency topical corticosteroids (severe cases)</td>
</tr>
<tr>
<td>Seborheic dermatitis</td>
<td>Yellow, greasy macules/patches on erythema, scales</td>
<td>Short-term, low-potency topical corticosteroids</td>
<td></td>
</tr>
<tr>
<td>Candidal dermatitis</td>
<td>Erythematous macerated papules/plaques, satellite lesions, involvement of skin folds</td>
<td>Antifungal agents (e.g. clotrimazole, nystatin)</td>
<td></td>
</tr>
<tr>
<td>Other Dermatitis</td>
<td>Atopic dermatitis</td>
<td>Erythematous, papules/plaques, oozing, excretion, lichenification, classic areas of involvement</td>
<td>Eliminate exacerbating factors, maintain skin hydration, corticosteroids, topical calcineurin inhibitor, daily baths</td>
</tr>
<tr>
<td>Nummular dermatitis</td>
<td>Annular erythematous plaques, oozing, crusting</td>
<td>Avoid irritant if identified, potent topical steroid in emollient base, short-term systemic steroids ± antibiotics (severe)</td>
<td></td>
</tr>
<tr>
<td>Allergic contact dermatitis</td>
<td>Red papules/plaques/vesicles/bullae, only in area of allergen</td>
<td>Mild: soothing lotion (e.g. calamine lotion); Moderate: low-to-intermediate potency topical corticosteroids; Severe: systemic corticosteroids and antihistamine</td>
<td></td>
</tr>
<tr>
<td>Irritant contact dermatitis</td>
<td>Morphology depends on irritant</td>
<td>Avoid skin contact</td>
<td></td>
</tr>
<tr>
<td>Dyshidrotic dermatitis</td>
<td>Papulovesicular, cracking/fissuring, hands and feet (&quot;tapioca pudding&quot;)</td>
<td>Mild/moderate: medium/potent topical corticosteroids; Severe: systemic corticosteroids, local PUVA or UVA treatments</td>
<td></td>
</tr>
<tr>
<td>Infectious</td>
<td>Scabies</td>
<td>Polymorphic (red excoriated papules/nodes, burrows), in web spaces/folds, very pruritic; Often affects multiple family members</td>
<td>Permethrin (Nix®) 5% cream for patient and family (2 applications, 1 wk apart)</td>
</tr>
<tr>
<td>Impetigo</td>
<td>Honey-coloured crusts or superficial bullae</td>
<td>Oral antibiotics (e.g. cephalaxin/erythromycin); Topical if mild: fucidic acid or mupirocin cream</td>
<td></td>
</tr>
<tr>
<td>Tinea corporis</td>
<td>Round erythematous plaques, central clearing and scaly border</td>
<td>Topical anti-fungal for skin, systemic anti-fungals for nails/head</td>
<td></td>
</tr>
</tbody>
</table>

Pediatric Exanthems (see Infectious Pediatric Exanthems, P55)

Drug Reactions (see Dermatology, D21)

Acne (see Dermatology, D11)

### Sleep Disturbances

#### Types of Sleep Disturbances
- insufficient sleep quantity
  - difficulty falling asleep (e.g. limit setting sleep disorder)
  - preschool and older children
  - bedtime resistance
  - due to caregiver’s inability to set consistent bedtime rules and routines
  - often exacerbated by child’s oppositional behaviours
- poor sleep quality
  - frequent arousals (e.g. sleep-onset association disorder)
  - infants and toddlers
  - child learns to fall asleep only under certain conditions or associations (e.g. with parent, held, rocked or fed, with light on, in front of television), and loses ability to self-soothe
  - during the normal brief arousal periods of sleep (<90-120 min), child cannot fall back asleep because same conditions are not present

#### Nap Patterns
- 2/d at 1 yr
- 1/d at 2 yr: 2-3 h
- 0.5/d at 5 yr: 1.7 h

#### Daily Sleep Requirement
- <6 mo: 16 h
- 6 mo: 14.5 h
- 12 mo: 13.5 h
- 2 yr: 13 h
- 4 yr: 11.5 h
- 6 yr: 9.5 h
- 12 yr: 8.5 h
- 18 yr: 8 h

#### Management
- Infantile:
  - Avoid irritant if identified, potent topical steroid in emollient base, short-term systemic steroids ± antibiotics (severe)
- Mild: soothing lotion (e.g. calamine lotion)
- Moderate: low-to-intermediate potency topical corticosteroids
- Severe: systemic corticosteroids and antihistamine

#### Prevention
- Identify and address any underlying causes of sleep disturbance
- Use consistent bedtime routines
- Create a sleep-conducive environment
- Gradual bedtime routines
- Caffeine and other stimulants
- Sleep hygiene
- Limit electronic devices before bedtime
- Sleep space
- Sleep environment
- Sleep habits
- Sleep hygiene
- Sleep environment
- Sleep habits
- Caffeine and other stimulants
- Sleep hygiene
- Sleep environment
- Sleep habits
- Caffeine and other stimulants
- Sleep hygiene
- Sleep environment
- Sleep habits
- Caffeine and other stimulants
- Sleep hygiene
- Sleep environment
- Sleep habits
- Caffeine and other stimulants
- Sleep hygiene
- Sleep environment
- Sleep habits
- Caffeine and other stimulants
- Sleep hygiene
- Sleep environment
- Sleep habits
- Caffeine and other stimulants
- Sleep hygiene
- Sleep environment
- Sleep habits
- Caffeine and other stimulants
- Sleep hygiene
- Sleep environment
- Sleep habits
obstructive sleep apnea
  - epidemiology: 1-5% of preschool aged children, more common in African American children
  - definition: partial or intermittent complete airway obstruction during sleep causing disrupted ventilation and sleep pattern
  - features: snoring/gasping/noisy breathing during sleep and irritable/tired/hyperactive during the day
  - sequelae: cardiovascular (HTN/LV remodelling due to sympathetic activation), growth, cognitive, and behavioural deficits
  - risk factors: adenotonsillar hypertrophy, obesity
  - management: watchful waiting, weight reduction, airway pressure devices, or surgery depending on the cause
  - adenotonsillectomy does not improve executive function or attention but reduces symptoms and improves behaviour, quality of life, and polysomnographic findings

parasomnias
  - episodic nocturnal behaviours (e.g. sleepwalking, sleep terrors, nightmares)
  - often involves cognitive disorientation and autonomic/skeletal muscle disturbance

Management of Sleep Disturbances
  - set strict bedtimes and "wind-down" routines
  - do not send child to bed hungry
  - positive reinforcement for: limit setting sleep disorder
  - always sleep in own bed, in a dark, quiet, and comfortable room
  - do not use bedroom for timeouts
  - systematic ignoring and gradual extinction for: sleep-onset association disorder

Nightmares
  - epidemiology: common in boys, 4-7 yr old
  - associated with REM sleep (anytime during night)
  - features: upon awakening, child is alert and clearly recalls frightening dream ± associated with daytime stress/anxiety
  - management: reassurance

Night Terrors
  - epidemiology: 15% of children have occasional episodes
  - abrupt sitting up, eyes open, screaming
  - clinical features: occurs in early hours of sleep, stage 4 of sleep; signs of panic and autonomic arousal, no memory of event, inconsolable, stress/anxiety can aggravate them
  - course: remits spontaneously at puberty
  - management: reassurance for parents, ensure child is safe (e.g. if sleepwalks)

Sudden Infant Death Syndrome

Definition
  - sudden and unexpected death of an infant <12 mo of age in which the cause of death cannot be found by history, examination, or a thorough postmortem and death scene investigation

Epidemiology
  - 0.5/1,000 (leading cause of death between 1-12 mo of age); M:F = 3:2
  - more common in children placed in prone position
  - in full term infants, peak incidence is 2-4 mo, 95% of cases occur by 6 mo
  - increase in deaths during peak RSV season
  - most deaths occur between midnight and 8 AM

Risk Factors
  - prematurity, smoking in household, socially disadvantaged, higher incidence in Aboriginals and African Americans
  - risk of SIDS is increased 3-5x in siblings of infants who have died of SIDS
  - bedsharing: sleeping on a sofa, sleeping with an infant after consumption of alcohol/street drugs or extreme fatigue; sleeping on a surface with a fixed wall (couch/sofa), infant sleeping with someone other than primary caregiver

Prevention
  - “Back to Sleep, Front to Play” (place infant on back when sleeping)
  - allow supervised play time daily in prone position (“tummy time”)
  - alarms, monitors not recommended – increase anxiety, do not prevent life-threatening events
  - avoid overheating and overdressing
  - appropriate infant bedding (firm mattress; avoid loose bedding, pillows, stuffed animals, and crib bumper pads)
  - no smoking
  - pacifiers appear to have a protective effect; do not reinsert if falls out during sleep

Brief Resolved Unexplained Events (BRUE)
A group of conditions often marked by an episode of apnea, cyanosis, change in tone, or change in mental status occurring in a child, where an observer fears the child may be dying. There is no clear connection between most BRUEs and SIDS. Evaluating for a cause of the BRUE (e.g. infection, cardiac, neurologic) is guided by history, physical exam, and period of observation.
Child Abuse and Neglect

Definition
• an act of commission (physical, sexual, or psychological abuse) or omission (neglect) by a caregiver that harms a child

Legal Duty to Report
• upon reasonable grounds to suspect abuse and/or neglect, physicians are required by legislation to contact the CAS to personally disclose all information relevant to the child safety concern
• duty to report overrides patient confidentiality; physician is protected against liability

Ongoing Duty to Report
• if there are additional reasonable grounds to suspect abuse and/or neglect, a further report to the CAS must be made

Risk Factors
• environmental factors: social isolation, poverty, domestic violence
• caregiver factors: personal history of abuse, psychiatric illness, substance abuse, single parent family, poor social and vocational skills, below average intelligence
• child factors: difficult temperament, disability, special needs (e.g. developmental delay), premature

Management of Physical Abuse, Child Abuse, and Neglect
• report all suspicions to CAS; request emergency visit if imminent risk to child or any siblings in the home
• acute medical care: hospitalize for medical evaluation or treatment of injuries if indicated
• arrange consultation to social work and appropriate follow-up
• may need to discharge child directly to CAS or to responsible guardian under CAS supervision

Physical Abuse

History
• history that is not compatible with physical findings, or history not reproducible
• delay in seeking medical attention that is unexplained by other factors

Physical Exam
• physical findings not explained by underlying medical condition
• growth parameters (weight, height, head circumference)
• recurrent or multiple injuries not explained by accidental injury or child’s development level
• patterned skin injuries: belt buckle, hand prints, burns that do not match provided history
• injury location: bruises on areas with abundant soft-tissue cushioning, such as abdomen, buttocks, genitalia, fleshy part of cheeks; bruises on ears, neck or feet; posterior rib/metaphyseal/scapular/vertebral/ternal fractures (more suspicious for non-accidental injuries); bruises that do not fit described cause; immersion burns (e.g. hot water)
• altered mental status: head injury, poisoning
• head trauma is the leading cause of death in child maltreatment (e.g. acceleration-deceleration forces [shaking], direct force application [blow or impact])

Investigations
• document all injuries on a body diagram: type, location, size, shape, colour, pattern
  • photography of skin injuries is ideal (police or hospital photography preferred; do not use physician’s personal camera)
• rule out medical causes of bruising/fracture with appropriate investigations:
  • if fractures evident: Ca2+, Mg2+, PO43-, ALP, PTH, Vitamin D, renal function, and bone density
  • if bruising present: CBC, INR, PT, von Willebrand factor, factors VII/IX/X/XIII
• screen for abdominal trauma (transaminases and amylase): if increased, abdo CT recommended
• skeletal survey in children <2 yr
• bone scan can be beneficial for assessing rib fractures (not helpful for skull or metaphyseal region due to active bone growth) – consider bone scan if equivocal findings on initial skeletal survey
• dilated eye examination by pediatric ophthalmologist to rule out retinal hemorrhage
• be aware of “red herrings” (e.g. Mongolian blue spots vs. bruises)
• neuroimaging: CT and/or MRI

Sexual Abuse

Epidemiology
• peak ages at 2-6 yr and 12-16 yr
• most perpetrators are male and known to child
  • in decreasing order: family member, non-relative known to victim, stranger

History
• diagnosis usually depends on child disclosing to someone or forensic interview done by a trained individual
• psychosocial: specific or generalized fears, depression, nightmares, social withdrawal, lack of trust, low self-esteem, school failure, sexually aggressive behaviour, advanced sexual knowledge, sexual preoccupation or play

Physical Exam
• recurrent UTIs, pregnancy, STIs, vaginitis, vaginal bleeding, pain, genital injury, enuresis

Investigations
• depend on presentation, age, sex, and pubertal development of child
  - sexual assault examination kit within 24 h if prepubertal, within 72 h if pubertal
  - rule out STI, UTI, pregnancy (consider STI prophylaxis or emergency contraception)
  - rule out other injuries (vaginal/anal/oral penetration, fractures, head trauma)
  - investigations to rule out drug and alcohol screen e.g. Rohypnol, 'Liquid G'; etc.

Prevalence of depression: 1-2% in pre-pubertal children and 6-8% in adolescents

Neglect

History
• from child and each caregiver separately (if possible)

Physical Exam
• head to toe (do not force), growth parameters, nutrition status
• dental care
• emotional state

Investigations
• blood tests to rule out medical conditions (e.g. thrombocytopenia or coagulopathy)

Adolescent Medicine

Adolescent History (HEEADSSS)
• tailor your history according to the clinical context

Home: Who do you live with? What kind of place do you live in?

Education/Employment: What grade are you in? What are your favourite subjects? What was your average on your last report card? Who are your favourite teachers?

Eating: Tell me about your meals/snacks in a typical day. Have you ever gone on a diet? What are your favourite and least favourite foods? (see Psychiatry, Eating Disorders, PS30)

Activities: What do you do after school? On the weekends? How much time do you spend on the computer/watching TV every day? Do you use social media (i.e. Facebook, Twitter, Instagram, etc.)? What do you do with your friends outside of school?

Drugs: Which seems to be more popular at your school, alcohol or drugs? How often do you drink/smoke marijuana/take other drugs? Do you smoke cigarettes? When you drink, do you usually get drunk? Have you ever passed out or not been able to remember what happened while you were drinking? Has anything bad ever happened to you while you were drunk or stoned? (see Psychiatry, Substance Abuse, PS21)

Sexuality: Are you romantically interested in anyone? When you think about having sex with someone, do you think about girls, boys, or both? Have you ever had sex with anyone? Whether the answer is yes or no, the next question is: What activities would you include in the term ‘having sex’? What do you do to prevent getting a STI/getting pregnant/getting someone pregnant? Has anyone ever given you money, drugs, or other stuff in exchange for sex? (see Gynecology, Sexually Transmitted Infections, GY27)

Suicidality/Depression: On a scale of 1 to 10, where 1 is so sad that you might kill yourself and 10 is the happiest you could be, where are you most days? Do you ever get into a car with a driver who has been drinking? Do you always wear a seatbelt/bicycle helmet? Are you being bullied at school? Has anyone ever touched you in an unwanted way?

Date rape comprises 80% of sexual assault in teenagers

Rates of drug use in high school students who have used in the past year: alcohol (58.2%), cannabis (25.6%), tobacco (11.7%)

Prevalence of depression: 1-2% in pre-pubertal children and 6-8% in adolescents

See Normal and Abnormal Pubertal Development, P30
PRENATAL CIRCULATION

Before Birth
- shunting deoxygenated blood
  - ductus arteriosus: connection between pulmonary artery and aorta
- shunting oxygenated blood
  - foramen ovale: connection between right and left atria
  - ductus venosus: connection between umbilical vein and inferior vena cava

At Birth
- with first breath, lungs open up → pulmonary resistance decreases → pulmonic blood flow increases
- separation of low resistance placenta → systemic circulation becomes a high resistance system → ductus venosus closure
- increased pulmonic flow → increased left atrial pressures → foramen ovale closure
- increased oxygen concentration in blood after first breath → decreased prostaglandins → ductus arteriosus closure
- closure of fetal shunts and changes in vascular resistance → infant circulation assumes normal adult flow

Epidemiology
- 8/1,000 live births have CHD, which may present as a heart murmur, heart failure, or cyanosis; VSD is the most common lesion

Investigations
- Echo, ECG, CXR
- pre and postductal oxygen saturations, 4 limb BPs, hyperoxia test

CYANOTIC VS. ACYANOTIC CONGENITAL HEART DISEASE
- cyanosis: blue mucous membranes, nail beds, and skin secondary to an absolute concentration of deoxygenated hemoglobin of at least 30 g/dL.
- acyanotic heart disease (i.e. L to R shunt, obstruction occurring beyond lungs): blood passes through pulmonic circulation → oxygenation takes place → low levels of deoxygenated blood in systemic circulation → no cyanosis
- cyanotic heart disease (i.e. R to L shunt): blood bypasses the lungs → no oxygenation occurs → high levels of deoxygenated hemoglobin enters the systemic circulation → cyanosis
Figure 2. Common congenital heart diseases

Acyanotic Congenital Heart Disease

1. LEFT-TO-RIGHT SHUNT LESIONS
- extra blood is displaced through a communication from the left to the right side of the heart → increased pulmonary blood flow → increased pulmonary pressures
- shunt volume is dependent upon three factors: (1) size of defect, (2) pressure gradient between chambers or vessels, and (3) peripheral outflow resistance
- untreated shunts can result in pulmonary vascular disease, left ventricular dilatation and dysfunction, right ventricular HTN and RVH, and ultimately R to L shunts

Atrial Septal Defect
- 3 types: ostium primum (common in DS), ostium secundum (most common type, 50-70%), sinus venosus (defect located at entry of superior vena cava into right atrium)
- epidemiology: 6-8% of congenital heart lesions
- natural history
  - 80-100% spontaneous closure rate if ASD diameter <8 mm
  - if remains patent, CHF and pulmonary HTN can develop in adult life
- clinical presentation
  - history: often asymptomatic in childhood
  - physical exam: grade 2-3/6 pulmonic outflow murmur, widely split and fixed S2
  - children with large ASDs may have signs of heart failure (tachypnea, FTT, hepatomegaly, pulmonary rales/retractions)
- investigations
  - ECG: RAD, mild RVH, RBBB
  - CXR: increased pulmonary vasculature, cardiac enlargement
  - Echo: test of choice
- management: elective surgical or catheter closure between 2-5 yr of age

Ventricular Septal Defect
- most common congenital heart defect (30-50%)
  - small VSD (majority)
    - clinical presentation
      - history: asymptomatic, normal growth and development
      - physical exam: early systolic to holosystolic murmur, best heard at LLSS, thrill
      - investigations: ECG and CXR are normal; Echo to confirm diagnosis
      - management: most close spontaneously
  - moderate-to-large VSD
    - epidemiology: CHF by 2 mo; late secondary pulmonary HTN if left untreated
    - clinical presentation
      - history: delayed growth, decreased exercise tolerance, recurrent URTIs or “asthma” episodes
      - physical exam: holosystolic murmur at LLSS, mid-diastolic rumble at apex, size of VSD is inversely related to intensity of murmur
    - investigations
      - ECG: LVH, LAH, RVH
      - CXR: increased pulmonary vasculature, cardiomegaly, CHF
      - Echo: diagnostic
    - management: treatment of CHF and surgical closure by 1 yr old

Characteristic CXR Findings in CHD
- Boot-shaped heart: tetralogy of Fallot, tricuspid atresia
- Egg-shaped heart: transposition of great arteries
- “Snowman” heart: total anomalous pulmonary venous return
Patent Ductus Arteriosus
- patent vessel between descending aorta and left pulmonary artery (normally, functional closure within first 15 h of life, anatomical closure within first days of life)
- epidemiology
  - 5-10% of all congenital heart defects
  - delayed closure of ductus is common in premature infants (1/3 of infants <1,750 g); this is different from PDA in term infants
- natural history: spontaneous closure common in premature infants, less common in term infants
- clinical presentation
  - history: asymptomatic, or have apneic or bradycardic spells, poor feeding, accessory muscle use, CHF
  - physical exam: tachycardia, bounding pulses, hyperactive precordium, wide pulse pressure, continuous “machinery” murmur best heard at left infraclavicular area
- investigations
  - ECG: may show left atrial enlargement, LVH, RVH
  - CXR: normal to mildly enlarged heart, increased pulmonary vasculature, prominent pulmonary artery
  - Echo: diagnostic
- management
  - indomethacin (Indocid®): antagonizes prostaglandin E2, which maintains ductus arteriosus patency; only effective in premature infants
  - catheter or surgical closure if PDA causes respiratory compromise, FTT, or persists beyond 3rd mo of life

2. OBSTRUCTIVE LESIONS
- present with decreased urine output, pallor, cool extremities and poor pulses, shock, or sudden collapse

Coarctation of the Aorta
- definition: narrowing of aorta (almost always at the level of the ductus arteriosus)
- epidemiology: commonly associated with bicuspid aortic valve (50%); Turner syndrome (35%)
- clinical presentation
  - history: often asymptomatic
  - physical exam
    - blood pressure discrepancy between upper and lower extremities (increased suspicion/severity if >20 mmHg difference)
    - diminished or delayed femoral pulses relative to brachial (i.e. brachial-femoral delay)
    - possible systolic murmur with late peak at apex, left axilla, and left back
    - if severe, presents with shock in the neonatal period when the ductus arteriosus closes
- investigations: ECG shows RVH early in infancy, LVH later in childhood; Echo or MRI for diagnosis
- prognosis: can be complicated by HTN; if associated with other lesions (e.g. PDA, VSD) can lead to CHF
- management: give prostaglandins to keep ductus arteriosus patent for stabilization and perform surgical correction in neonates; for older infants and children balloon arterioplasty may be an alternative to surgical correction

Aortic Stenosis
- 4 types: valvular (75%), subvalvular (20%), supravalvular, and idiopathic hypertrophic subaortic stenosis (5%)
- clinical presentation
  - history: often asymptomatic, but may be associated with CHF, exertional chest pain, syncope, or sudden death
  - physical exam: SEM at RUSB with aortic ejection click at the apex (only for valvular stenosis)
- investigations: Echo for diagnosis
- management: valvular stenosis is usually treated with balloon valvuloplasty, patients with subvalvular or supravalvular stenosis require surgical repair, exercise restriction required

Pulmonary Stenosis
- 3 types: valvular (90%), subvalvular, or supravalvular
- definition of critical pulmonary stenosis: inadequate pulmonary blood flow, dependent on ductus for oxygenation, progressive hypoxia and cyanosis
- natural history: may be part of other congenital heart lesions (e.g. Tetralogy of Fallot) or in association with syndromes (e.g. congenital rubella, Noonan syndrome)
- clinical presentation
  - history: spectrum from asymptomatic to CHF
  - physical exam: wide split S2 on expiration, SEM at LUSB, pulmonary ejection click (for valvular lesions)
- investigations
  - ECG; RVH
  - CXR: post-stenotic dilation of the main pulmonary artery
  - Echo: diagnostic
- management: surgical repair if critically ill or if symptomatic in older infants/children
Cyanotic Congenital Heart Disease

- systemic venous return re-enters systemic circulation directly
- most prominent feature is cyanosis (O₂ sat < 75%)
- hyperoxic test differentiates between cardiac and other causes of cyanosis
  - obtain preductal, right radial ABG in room air, then repeat after the child inspires 100% O₂
  - if PaO₂ improves to greater than 150 mmHg, cyanosis less likely cardiac in origin
- pre-ductal and post-ductal pulse oximetry
  - > 5% difference suggests R to L shunt

1. RIGHT-TO-LEFT SHUNT LESIONS

Tetralogy of Fallot
- epidemiology: 10% of all CHD, most common cyanotic heart defect diagnosed beyond infancy with peak incidence at 2-4 mo of age
- pathophysiology
  - embryological defect due to anterior and superior deviation of the outlet septum leading to: VSD, RVOTO (i.e. pulmonary stenosis ± subpulmonary valve stenosis), over-riding aorta, and RVH
    - infants may initially have a L → R shunt (therefore no cyanosis); however, RVOTO is progressing, leading to increasing R → L shunting with hypoxemia and cyanosis
    - degree of RVOTO determines the direction and degree of shunt and, therefore, the extent of clinical cyanosis and degree of RVH
- clinical presentation
  - history: hypoxic "tet" spells
    - during exertional states (crying, exercise) the increasing pulmonary vascular resistance and decrease in systemic resistance causes an increase in right-to-left shunting
    - clinical features include paroxysms of rapid and deep breathing, irritability and crying, increasing cyanosis, decreased intensity of murmur (decreased flow across RVOTO)
    - if severe, can lead to decreased level of consciousness, seizures, death
  - physical exam
    - single loud S₂ due to severe pulmonary stenosis (i.e. RVOTO), SEM at LSB
- investigations
  - ECG: RAD, RVH
  - CXR: boot-shaped heart, decreased pulmonary vasculature, right aortic arch (in 20%)
  - Echo: diagnostic
  - management of spells: O₂, knee-chest position, fluid bolus, morphine sulfate, propranolol
treatment: surgical repair at 4-6 mo of age; earlier if marked cyanosis or "tet" spells

2. OTHER CYANOTIC CONGENITAL HEART DISEASES

Transposition of the Great Arteries (TGA)
- epidemiology: 3-5% of all congenital cardiac lesions, most common cyanotic CHD in neonates
- pathophysiology: parallel pulmonary and systemic circulations
  - systemic: body → RA → RV → aorta → body
  - pulmonary: lungs → LA → LV → pulmonary artery → lungs
  - survival is dependent on mixing through PDA, ASD, or VSD
- physical exam
  - neonates: ductus arteriosus closure causes rapidly progressive severe hypoxemia unresponsive to oxygen therapy, acidosis, and death
  - VSD present: cyanosis is not prominent; CHF within first weeks of life
  - VSD absent: no murmur
- investigations
  - ECG: RAD, RVH, or may be normal
  - CXR: egg-shaped heart with narrow mediastinum ("egg on a string")
  - Echo: diagnostic
- management
  - symptomatic neonates: prostaglandin E1 infusion to keep ductus open until balloon atrial septostomy
  - surgical repair: arterial switch performed in the first two weeks in those without a VSD while LV muscle is still strong

Total Anomalous Pulmonary Venous Return
- epidemiology: 1-2% of CHD
- pathophysiology
  - all pulmonary veins drain into right-sided circulation (systemic veins, RA)
  - no direct oxygenated pulmonary venous return to left atrium
  - often associated with obstruction at connection sites
  - ASD must be present for oxygenated blood to shunt into the LA and systemic circulation
- management: surgical repair in all cases and required urgently for severe cyanosis
Truncus Arteriosus
- pathophysiology
  - single great vessel gives rise to the aorta, pulmonary, and coronary arteries
  - truncal valve overlies a large VSD
  - potential for coronary ischemia with fall in pulmonary vascular resistance
- management: surgical repair within first 6 wk of life

Hypoplastic Left Heart Syndrome
- epidemiology: 1-3% of CHD; most common cause of death from CHD in first month of life
- pathophysiology: LV hypoplasia may include atretic or stenotic mitral and/or aortic valve, small ascending aorta, and coarctation of the aorta with resultant systemic hypoperfusion
- systemic circulation is dependent on ductus patency; upon closure of the ductus, infant presents with circulatory shock and metabolic acidosis
- management
  - intubate and correct metabolic acidosis
  - IV infusion of prostaglandin E1 to keep ductus open
  - surgical palliation (overall survival 50% to late childhood) or heart transplant

Congestive Heart Failure
- see Cardiology and Cardiac Surgery, C34

Etiology
- CHD
- cardiomyopathy (primary or secondary)
- high output circulatory states (e.g. anemia, AVMs, cor pulmonale, hyperthyroidism)
- non-cardiac (e.g. sepsis, renal failure)
- pressure overload (e.g. aortic stenosis/co-arctation, pulmonary stenosis, HTN)
- volume overload (e.g. L to R shunt, valve insufficiency)

History
- infant: weak cry, irritability, feeding difficulties, early fatigue, diaphoresis while sleeping or eating, respiratory distress, lethargy, FTT
- child: decreased exercise tolerance, fatigue, decreased appetite, respiratory distress, frequent URTIs or "asthma" episodes
- orthopnea, paroxysmal nocturnal dyspnea, pedal/dependent edema are all uncommon in children

Physical Findings
- 4 key features: tachycardia, tachypnea, cardiomegaly, hepatomegaly
- FTT
- alterations in peripheral pulses, four limb blood pressures (in some CHDs)
- dysmorphic features associated with congenital syndromes

Investigations
- CXR: cardiomegaly, pulmonary venous congestion
- ECG: sinus tachycardia, signs of underlying cause (heart block, atrial enlargement, hypertrophy, ischemia/infarct)
- Echo: structural and functional assessment
- blood work: CBC, electrolytes, BUN, Cr, LFTs

Management
- general: sitting up, O2, sodium and water restriction, increased caloric intake
- pharmacologic: diuretics, afterload reduction (e.g. ACEI), β-blockers; digoxin rarely used
- curative: correction of underlying cause

Dysrhythmias
- see Cardiology and Cardiac Surgery, C16
- can be transient or permanent, congenital (structurally normal or abnormal), or acquired (toxin, infection, infarction)

Sinus Arrhythmia
- phasic variations with respiration (present in almost all normal children)

Sinus Tachycardia
- rate of impulses arising from sinus node is elevated (>150 bpm in infants, >100 bpm in older children)
- characterized by: beat-to-beat heart rate variability with changes in activity, P waves present/normal, PR constant, QRS narrow
- etiology: HTN, fever, anxiety, sepsis, anemia/hypoxia, PE, drugs, etc.
- differentiate from SVT (see below) by slowing the sinus rate (vagal massage, β-blockers) to identify sinus P waves
Premature Atrial Contractions
• may be normal variant or can be caused by electrolyte disturbances, hyperthyroidism, cardiac surgery, digitalis toxicity

Premature Ventricular Contractions
• common in adolescents
• benign if single, uniform, disappear with exercise, and no associated structural lesions
• if not benign, may degenerate into more severe dysrhythmias

Supraventricular Tachycardia
• abnormally rapid heart rhythm originating above the ventricles – most frequent sustained dysrhythmia in children
• no beat-to-beat HR variability, >220 bpm (infants) or >180 bpm (children), P waves absent/abnormal, PR indeterminable, QRS usually narrow
• pre-excitation syndromes (subset of SVT): WPW syndrome, congenital defect (see Cardiology and Cardiac Surgery, C21)

Complete Heart Block
• congenital heart block can be caused by maternal anti-Ro or anti-La (e.g. mother with SLE)
• often diagnosed in utero (may lead to development of fetal hydrops)
• clinical symptoms related to level of block (the lower the block, the slower the heart rate and greater the symptoms of inadequate cardiac output)
• symptomatic patients need a pacemaker

Heart Murmurs
• 50-80% of children have audible heart murmurs at some point in their childhood
• most childhood murmurs are functional (e.g. “innocent”) without associated structural abnormalities and have normal ECG and radiologic findings
• in general, murmurs can become audible or accentuated in high output states (e.g. fever, anemia)

Table 11. Differentiating Heart Murmurs

<table>
<thead>
<tr>
<th>Innocent</th>
<th>Pathological</th>
</tr>
</thead>
<tbody>
<tr>
<td>History and Physical</td>
<td>Asymptomatic</td>
</tr>
<tr>
<td>Timing</td>
<td>SEM</td>
</tr>
<tr>
<td>Grade/Quality</td>
<td>&lt;3/6; soft/blowing/vibratory</td>
</tr>
<tr>
<td>Splitting</td>
<td>Physiologic S2</td>
</tr>
<tr>
<td>Extra Sounds/Clicks</td>
<td>None</td>
</tr>
<tr>
<td>Change of Position</td>
<td>Murmur varies</td>
</tr>
</tbody>
</table>

Table 12. Five Innocent Heart Murmurs

<table>
<thead>
<tr>
<th>Type</th>
<th>Etiology</th>
<th>Location</th>
<th>Description</th>
<th>Age</th>
<th>Differential Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral Pulmonary Stenosis</td>
<td>Flow into pulmonary branch arteries from main, larger, artery</td>
<td>Left upper sternal border</td>
<td>Neonates, low-pitched, radiates to axilla and back</td>
<td>Neonates, usually disappears by 3-6 mo</td>
<td>PDA Pulmonary stenosis</td>
</tr>
<tr>
<td>Still’s Murmur</td>
<td>Flow across the pulmonic valve leaflets</td>
<td>Left lower sternal border</td>
<td>High-pitched, vibratory, LLB or apex, SEM</td>
<td>3-6 yr</td>
<td>Subaortic stenosis Small VSD</td>
</tr>
<tr>
<td>Venous Hum</td>
<td>Altered flow in veins</td>
<td>Infraclavicular (R&gt;L)</td>
<td>Infraclavicular hum, continuous, R&gt;L</td>
<td>3-6 yr</td>
<td>PDA</td>
</tr>
<tr>
<td>Pulmonary Ejection</td>
<td>Flow through the pulmonic valve</td>
<td>Left upper sternal border</td>
<td>Soft, blowing, LUSB, SEM</td>
<td>8-14 yr</td>
<td>ASD Pulmonary stenosis</td>
</tr>
<tr>
<td>Supraclavicular Arterial Bruit</td>
<td>Turbulent flow in the carotid arteries</td>
<td>Supraclavicular</td>
<td>Low intensity, above clavicles</td>
<td>Any age</td>
<td>Aortic stenosis Bicuspid aortic valve</td>
</tr>
</tbody>
</table>

Infective Endocarditis
• see Infectious Diseases, ID16
Development

Approach to Global Developmental Delay

• also known as Early Developmental Impairment

Definition
• performance significantly below average in two or more domains of development (gross motor, fine motor, speech/language, cognitive, social/personal, activities of daily living) in a child <5 yr of age
• predict a diagnosis of intellectual disability in the future

Epidemiology
• 5-10% of children have neurodevelopmental delay
• careful evaluation can reveal a cause in 50-70% of cases

Etiology
• CNS abnormalities (meningitis/encephalitis, brain malformation, trauma, etc.)
• sensory deficits (hearing, vision)
• environmental (psychosocial neglect, lead exposure, antenatal drug or alcohol exposure, etc.)
• genetic/chromosomal disorders (DS, Fragile X, etc.)
• metabolic disorders (inborn errors of metabolism, hypothyroidism, iron deficiency, etc.)
• obstetrical (prematurity, HIE, TORCH infections, etc.)
• sleep disorders
• seizures

Clinical Presentation
• history
  ■ intrauterine exposures, perinatal events
  ■ detailed developmental milestones: rate of acquisition, regression of skills
  ■ associated problems: feeding, seizures, behaviour, sleep
  ■ family history, consanguinity
  ■ social history
• physical exam
  ■ dysmorphic features, hepatosplenomegaly, neurocutaneous markers, growth parameters, detailed neurological examination
• investigations (guided by history and physical examination)
  ■ neurodevelopmental assessment, neuroimaging, vision and hearing test, EEG, sleep study
  ■ OT, PT, and/or SLP assessments
  ■ psychosocial evaluation
  ■ blood work (lead, CBC, ferritin, TSH)
  ■ genetics consultation (microarray, Fragile X testing, testing for inborn errors of metabolism)

Management
• dependent on specific area of delay
• therapy services (e.g. speech and language therapy for language delay, OT and/or PT for motor delay), early intervention services (e.g. infant development services, Ontario Early Years Centres)

Intellectual Disability

Definition
• state of functioning that begins in childhood and is characterized by limitations in both intelligence and adaptive skills
• historically defined as an IQ <70
• often preceded by diagnosis of global developmental delay

Epidemiology
• 1% of general population; M:F = 1.5:1

Clinical Presentation
• history
  ■ well below average general intellectual functioning
  ■ significant deficits in adaptive functioning in at least 2 of: communication, self-care, home-living, social skills, self-direction, academic skills, work, leisure, health, safety
• physical exam
  ■ check growth, dysmorphic features, complete physical exam
• investigations
  ■ standardized psychology assessment (includes IQ test and measure of adaptive functioning)
  ■ vision, hearing, and neurologic assessment
  ■ genetic and metabolic testing as indicated

Classification of Intellectual Disability

<table>
<thead>
<tr>
<th>Severity</th>
<th>% Cases</th>
<th>IQ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>85</td>
<td>50-70</td>
</tr>
<tr>
<td>Moderate</td>
<td>10</td>
<td>35-49</td>
</tr>
<tr>
<td>Severe</td>
<td>3-4</td>
<td>20-34</td>
</tr>
<tr>
<td>Profound</td>
<td>1-2</td>
<td>&lt;20</td>
</tr>
</tbody>
</table>
Management
- main objective: enhance adaptive functioning level
- requires an interprofessional team with strong case coordination
- emphasize community-based treatment and early intervention
- individual/family therapy; behaviour management services, therapy services (e.g. OT, SLP), medications for associated conditions
- education: life skills, vocational training, communication skills, family education
- psychosocial support for individual and family; respite care

Prognosis
- higher rates of sensory deficits, motor impairment, behavioural/emotional disorders, seizures, psychiatric illness

**Language Delay**

**Definition**
- no universally accepted definition, but often identified around 18 mo of age with enhanced well baby visit
- if formally tested, performance on a standardized assessment of language is at least one standard deviation below mean of age
- can be expressive (ability to produce or use language), receptive (ability to understand language), or both

**Epidemiology**
- M>F
- ~10-15% of 2 yr old children have a language delay, but only 4-5% remain delayed after 3 yr of age
- ~6-8% of school-aged children have specific language impairment (many of whom were not identified before school entry)

**Etiology**
- cognitive disability
- constitutional language delay
- genetic/metabolic: DS, Fragile X syndrome, Williams syndrome, hypothyroidism, PKU, etc.
- hearing impairment
- mechanical problems: cleft palate, cranial nerve palsy
- medical condition: seizure disorder (includes acquired epileptic aphasia), CR TORCH infection, iron deficiency, lead poisoning, etc.
- autism spectrum disorder
- psychosocial: neglect or abuse
- selective mutism

**Clinical Presentation**
- history
  - concerns about hearing, delay in language development or regression in previously normal language development
  - delayed language milestones, presence of red flags, regression
  - must determine if language delay is expressive, receptive, or mixed
  - risk factors for hearing loss (hereditary, recurrent AOM) and language delay
- physical exam
  - guided by history: look for abnormal growth, dysmorphisms, unusual social interactions (lack of eye contact, not pointing)
  - include full exam of the external/internal ear (e.g. TM scarring), oral pharynx (e.g. cleft palate), and neurologic system (including tone)
- investigations
  - use of language specific screens in primary care setting: The Early Language Milestone, CAT/CLAMS, MCHAT, etc.
  - all children with suspected language delay MUST be referred to an audiologist for a hearing assessment
  - CBC (to rule out anemia), venous blood lead levels, genetic/metabolic workup as indicated

**Management**
- specific to etiology
- often multidisciplinary and requires appropriate referrals: early intervention services, special education services, SLP, OHNS and dental professionals, general support services
- prevention: parents can read aloud to their child, engage in dialogic reading, avoid baby talk, narrate daily activities, etc.

**Prognosis**
- depends on etiology
- if language delay persists beyond 5 yr old, more likely to have difficulties in adulthood
- persistent language delay is associated with poor academic performance, behavioural problems, social isolation
Specific Learning Disorder

**Definition**
- specific and persistent failure to acquire academic skills despite conventional instruction, adequate intelligence, and sociocultural opportunity
- a significant discrepancy between a child's intellectual ability and their academic performance
- types: reading (dyslexia), writing, mathematics (dyscalculia)

**Epidemiology**
- prevalence: 10%
- high incidence of psychiatric comorbidity: anxiety, dysthymia, conduct disorder, major depressive disorder, oppositional defiant disorder, ADHD

**Etiology**
- pathogenesis is unknown, likely genetic factors involved
- learning disabilities may be associated with a number of conditions:
  - genetic/metabolic: Turner syndrome, Klinefelter syndrome
  - perinatal: prematurity, low birth weight, birth trauma/hypoxia
  - postnatal: CNS damage, hypoxia, environmental toxins, FAS, psychosocial deprivation (understimulation), malnutrition
- poor visual acuity is NOT a cause

**Risk Factors**
- positive family history, prematurity, other developmental and mental health conditions, neurologic disorders (e.g. seizure disorders, neurofibromatosis), history of CNS infection/irradiation/traumatic injury

**Clinical Presentation**
- history and physical exam
  - school difficulties (academic achievement, behaviour, attention, social interaction)
  - development of negative self-concept → reluctance to participate even in areas of strength
  - social issues: overt hostility towards parents/teachers; difficulties making friends, bullying, and anxiety
  - look for dysmorphisms, complete physical exam
- investigations
  - standardized tests for IQ
  - individual scores on achievement tests in reading, mathematics, or written expression (WISC III, WRAT) >2 SD below that expected for age, education, and IQ

**Management**
- provide quality instruction for specific learning disability
- support student by modifying the curriculum and/or providing accommodations (e.g. scribe for writing, extra time for tests, photocopied notes, etc.)
- consider grade retention in certain students (no guidelines exist, very rare in Ontario)
- specialized education placements that can provide educational remediation

**Prognosis**
- limited information available about persistence of learning disabilities over time
- low self-esteem, poor social skills, 40% school drop-out rate

### Fetal Alcohol Spectrum Disorder

**Definition**
- term describing the range of effects of prenatal exposure to alcohol, including physical, mental, behavioural, and learning disabilities
- no “safe” level of alcohol consumption during pregnancy has been established
- spectrum includes: FAS, partial FAS, ARBD, and ARND

**Epidemiology**
- prevalence of FAS and FASD is 0.1% and 1.0%, respectively
- most common preventable cause of intellectual disability

**Pathogenesis**
- specific mechanism of FASD is unknown, but hypotheses include nutritional deficits, toxic effects of acetaldehyde, alteration of placental transport, abnormal protein synthesis, and altered cerebral neurotransmission
**Diagnosis**
- often misdiagnosed or missed entirely
- diagnosis of FAS, ARBD, and ARND all require evidence of maternal drinking during pregnancy
- criteria for diagnosis of FAS
  - growth deficiency: low birth weight and/or decelerating weight over time not due to nutrition
  - characteristic pattern of facial anomalies: short palpebral fissures, flattened philtrum, thin upper lip, flat midface
  - CNS dysfunction: microcephaly and/or neurobehavioural dysfunction (hyperactivity, fine motor problems, attention deficits, learning disabilities, cognitive disabilities, difficulties in adaptive functioning, etc.)
- criteria for diagnosis of ARBD
  - congenital anomalies, including malformations and dysplasias of the cardiac, skeletal, renal, ocular, and auditory systems
- criteria for diagnosis of ARND
  - complex pattern of behavioural or cognitive abnormalities inconsistent with developmental level that cannot be explained by familial background or environment alone

**Management**
- early diagnosis is essential to prevent secondary disabilities
- no cure, but individuals with FASD and their families should be linked to community resources and services to improve outcome

**Prognosis**
- secondary disabilities include unemployment, mental health problems, difficulties with the law, inappropriate sexual behaviour, disrupted school experience, peer problems

---

**Attention Deficit Hyperactivity Disorder**
- see Psychiatry, Neurodevelopmental Disorders, PS37

---

**Autism Spectrum Disorder**
- see Psychiatry, Neurodevelopmental Disorders, PS37

---

**Motor Delay**
- see Cerebral Palsy, P83 and Muscular Dystrophy, P43

---

**Endocrinology**

**Diabetes Insipidus**
- see Endocrinology, E18 and Nephrology, NP11

**Syndrome of Inappropriate Antidiuretic Hormone**
- see Endocrinology, E18 and Nephrology, NP10

---

**Diabetes Mellitus**

**DIABETES MELLITUS TYPE 1**
- see Endocrinology, Disorders of Glucose Regulation, E6

**Epidemiology**
- most common form of DM in children, M:F
- variable prevalence internationally, affects ~1:4,000 children in Canada
- can present at any age, but bimodal peaks at 5-7 yr old and at puberty

**Clinical Presentation**
- can present as polyuria (often manifested as nocturia or secondary enuresis), polydipsia, weight loss (lack of insulin leading to a catabolic state), polyphagia, DKA (~20%) (see Endocrinology, E11)
Management

- Patients and families are best managed with a family-centred pediatric multidisciplinary team able to provide education, ongoing care, and psychosocial support surrounding survival skills, meal plans, and insulin injections as a cornerstone of treatment.
- Blood glucose monitoring is especially important in children as they are more susceptible to hypoglycemia.
- If DKA present: ABCs, admit, monitors, correct fluid losses, administer insulin and restore glucose gradually, correct electrolyte disturbances, identify/treat precipitating event, avoid complications (i.e., cerebral edema).
- Low threshold to investigate (CT/MRI) and treat DKA, as cerebral edema is a major concern.
- See Endocrinology, E11
- Screen for micro- and macrovascular complications (regular ophthalmology assessments, BP, microalbuminuria), concurrent autoimmune diseases (thyroiditis, celiac disease, etc.), and mental health issues (depression, eating disorders).

Prognosis

- No cure currently.
- Short-term complications:
  - Hypoglycemia
  - Due to missed/delayed meals, excess insulin or exercise, illness
  - Can lead to seizures and/or coma
  - Reversed with PO/IV glucose or 1M glucagon
  - Hyperglycemia
  - Due to intercurrent illness, diet-to-insulin mismatch
  - Risk of end-organ damage
  - DKA: Due to missed insulin doses, infection; most common cause of death.
- Long-term complications:
  - Microvascular: Retinopathy, nephropathy, neuropathy
  - Macrovascular: Metabolic syndrome, CVD, CAD, PVD
  - Increased risk of other autoimmune diseases.

Diabetes Mellitus Type 2

- See Family Medicine, FM21, Endocrinology, E7
- Impaired glucose metabolism due to increased peripheral insulin resistance.
- Rare before 10 yr of age, but more common in older children/adolescents.
- Prevalence is rising mainly due to the increased incidence of childhood obesity.
- Risk factors: Obesity, positive family history, female gender, certain ethnic groups.
- Clinical presentation may be similar to that of type 1 DM, though most children are asymptomatic.
- May present in DKA or hyperglycemic hyperosmotic nonketotic state.
- Management:
  - Initiate lifestyle modification program, including diet, weight loss, physical activity (moderate-to-vigorous activity for at least 60 min/d; screen time less than 2 h/d).
  - Glycemic target: HbA1c ≤7%.
  - If glycemic targets not achieved within 3–6 mo from diagnosis with lifestyle intervention alone, either metformin, glimepiride, or insulin should be initiated.
  - Monitor HbA1c every 3 mo.
  - Advise patient to monitor finger-stick blood glucose levels if on medication with risk of hypoglycemia, are changing medication regimen, have not met treatment goals, or have intercurrent illness.
- Prognosis: Includes microvascular and macrovascular complications similar to type 1 DM.

Growth

Approach to Short Stature

Definition

- Short stature: Height <3rd percentile.
- Poor growth evidenced by growth deceleration (height crosses major percentile lines, growth velocity <25th percentile).

Epidemiology

- ~2.5% of the population by definition.

Etiology

- See sidebar.
Clinical Presentation
- history and physical exam
  - plot on growth curve (special growth charts available for Turner syndrome, achondroplasia, DS)
  - assess for dysmorphic features, disproportionate short stature
  - risk factors for GH deficiency: previous head trauma, history of intracranial bleed or infection, head surgery or irradiation, positive family history, breech delivery
  - decreased growth velocity may be more worrisome than actual height
- investigations
  - calculate mid-parental height: children are usually in a percentile between their parents’ height
  - AP x-ray of left hand and wrist for bone age
  - remaining investigations guided by history and physical (e.g. TSH, sweat chloride, etc.)

Management
- depends on severity of problem as perceived by parents/child
- no treatment for non-pathological short stature, except for idiopathic short stature
- GH therapy: if administered at an early age, can help patients achieve adult height
- requirements
  - GH shown to be deficient by 2 different stimulation tests
  - growth velocity <3rd percentile or height <<3rd percentile
  - bone age x-rays show unfused epiphyses/delayed bone age
- support and management of resultant self-image issues, social anxiety, etc.

Short Stature DDx
- ABCDEFG
  - Alone (neglected infant)
  - Bone dysplasias (rickets, scoliosis, mucopolysaccharidoses)
  - Chromosomal (Turner, Down)
  - Delayed growth (constitutional)
  - Endocrine (low GH, Cushing, hypothyroid)
  - Familial
  - GI malabsorption (celiac, Crohn’s)

4 Questions to Ask when Evaluating Short Stature
- Is there IUGR?
- Is the growth proportionate?
- Is the growth velocity normal?
- Is bone age delayed?

Figure 7. Approach to the child with short stature

TALL STATURE
- height greater than two SD above the mean for a given age, sex, and race

Etiology
- constitutional/familial
- endocrine: Beckwith-Wiedemann syndrome, hyperthyroidism, hypophyseal gigantism, precocious puberty
- genetic: homocystinuria, Klinefelter syndrome, Marfan syndrome, Sotos syndrome

Hypercalcemia/Hypocalcemia/Rickets
- see Endocrinology, E37

Hyperthyroidism and Hypothyroidism
- may be congenital or acquired (for acquired causes, see Endocrinology, E22)

CONGENITAL HYPERTHYROIDISM
- also known as neonatal Graves’ disease
Epidemiology
• ~1:25,000 neonates, M=F

Etiology
• results from transplacental passage of maternal thyroid stimulating antibodies from mother with a history of Graves' disease

Clinical Presentation
• history and physical exam
  ■ clinical manifestations may be masked if mother on antithyroid treatment
  ■ may present with tachycardia with CHF, heart murmur, goitre, craniosynostosis, irritability, poor feeding, FTT
• investigations:
  ■ serum levels of TSH and free T4 in all infants with suspected congenital hyperthyroidism or infants born to mothers with Graves’ disease

Management
• methimazole until antibodies cleared
• symptomatic treatment as needed (e.g. β-blockers to control tachycardia)

Prognosis
• if prompt and adequate treatment given, most neonates improve rapidly
• antibodies usually spontaneously cleared by 2-3 mo of life
• fetal or neonatal hyperthyroidism may have adverse effects on CNS development, leading to developmental and behaviour problems

CONGENITAL HYPOTHYROIDISM

Epidemiology
• incidence: 1:4,000-1:20,000 newborn births; F:M = 2:1
• one of the most common preventable causes of intellectual disability

Etiology
• may be classified as permanent primary, central, or transient hypothyroidism
• ~85% of primary cases are sporadic (mostly thyroid dysgenesis), remaining 15% hereditary (mostly inborn errors of thyroid synthesis)
• causes of transient hypothyroidism: maternal antibody-mediated, iodine deficiency (rare in developed countries), prenatal exposure to antithyroid medications

Clinical Presentation
• history and physical exam
  ■ usually asymptomatic in neonatal period because maternal T4 crosses the placenta
  ■ prolonged jaundice, constipation, sluggish, hoarse cry, lethargy, poor feeding, macroGLOSSIA, coarse facial features, large fontanelles, umbilical hernia
• investigations
  ■ diagnosis through newborn screening of TSH or free T4; abnormal results should be confirmed with serum levels from venipuncture

Management
• thyroxine replacement

Prognosis
• excellent outcome if treatment started within 1-2 mo of birth
• if treatment started after 3-6 mo of age, may result in permanent developmental delay and/or disability (mild to profound)

Sexual Development

AMBIGUOUS GENITALIA

Definition
• newborn or child whose gender is difficult to assign based on the appearance of genitalia
• subtype of DSD: a condition in which development of chromosomal, gonadal, or anatomic sex is atypical
• subtypes: 46,XX DSD, 46,XY DSD, ovotesticular DSD (true hermaphrodite)

Epidemiology
• incidence of genital abnormalities at birth is as high as 1:300
• prevalence of complex anomalies with true sexual ambiguity much lower at ~1:5,000
Etiology
- 46,XY DSD
  - inborn error of testosterone biosynthesis or Leydig cell hypoplasia
  - 5α-reductase deficiency, androgen receptor deficiency or insensitivity
  - LH/hCG unresponsiveness
- 46,XX DSD
  - virilizing CAH (most common)
  - maternal source: virilizing ovarian or adrenal tumours, untreated maternal CAH, placental aromatase deficiency
  - ovotesticular DSD
    - both ovarian follicles and seminiferous tubules in the same patient with a 46,XX karyotype
    - mixed gonadal dysgenesis

Risk Factors
- parental consanguinity, positive family history of ambiguous genitalia, early childhood illness/death, or primary amenorrhea, maternal medications during pregnancy (e.g. androgens, progesterones, danazol, phenytoin, aminogluthethimide, endocrine disruptors)

Clinical Presentation
- history
  - thorough obstetrical history, including prenatal screens and maternal medications
  - family history: autosomal recessive pattern may suggest CAH, X-linked recessive pattern may suggest androgen insensitivity syndrome
- physical exam
  - male pseudohermaphrodite (XY): small phallus, hypospadias, undescended testicles
  - female pseudohermaphrodite (XX): clitoral hypertrophy, labioscrotal fusion
  - look for concurrent midline defects, dysmorphic features, and congenital abnormalities
- investigations
  - karyotype and genetic workup as indicated
  - blood work: electrolytes and renin (evidence of salt-wasting in CAH); 17-OH-progesterone, androgens, FSH, and LH
  - imaging: abdominal U/S to look for uterus, testicles, ovaries

Management
- avoid announcement of probable sex or use of personal pronouns until all tests are complete
- continuous psychosocial support for parents and child during development
- elective surgical reconstruction of genitalia is sometimes possible

CONGENITAL ADRENAL HYPERPLASIA

Definition
- autosomal recessive disorder characterized by the partial or total defect of various synthetic enzymes of the adrenal cortex required for cortisol and aldosterone production

Epidemiology
- occurs in ~1:15,000 live births
- most common cause of ambiguous genitalia

Etiology
- for biosynthetic pathways of adrenal cortex, see Endocrinology, E29
- 21-OH responsible for ~95% of CAH cases
- results in ↓ cortisol and aldosterone production with shunting toward ↑↑ androgens
- cortisol deficiency leads to elevated ACTH, which causes adrenal hyperplasia
- rarer causes include deficiencies in 11-OH, cholesterol desmolase, 17-OH, and 3-HSD

Clinical Presentation
- depends on which enzyme in cortisol synthesis pathway is defective
- presentation of 21-OH deficiency can be divided into
  - classic deficiency with salt wasting: inadequate aldosterone resulting in FTT, hyperkalemia, hypotension, hypoglycemia, acidosis
  - classic deficiency without salt wasting: simple virilizing type
  - non-classic: signs/symptoms of androgen excess (e.g. amenorrhea, precocious puberty, etc.)
- 21-OH deficiency screening is part of many newborn screening programs across North America
- high serum levels of 17-OH progesterone in random blood sample diagnostic for 21-OH deficiency

Management
- correct any abnormalities in fluids, electrolytes, or serum glucose
- provide glucocorticoids/mineralocorticoids as necessary, extra glucocorticoids in times of stress
- psychosocial support

Prognosis
- complications if untreated include virilization, acne, salt wasting, hypotension
NORMAL PUBERTAL DEVELOPMENT

Physiology
- puberty occurs with the maturation of the HPG axis
- ↑ pulsatile release of GnRH → ↑ release of LH and FSH → maturation of gonads, release of sex steroids → secondary sexual characteristics
- adrenal production of androgens also required

Females
- onset: age 8-13 yr old (may start as early as 7 yr in girls of African descent)
- usual sequence
  1. thelarche: breast budding
  2. pubarche: axillary hair, body odour, mild acne
  3. growth spurt
  4. menarche: mean age 12.5 yr; indicates that growth spurt is almost complete; menses may be irregular in duration and length of cycle
- early puberty is common and often constitutional, late puberty is rare (rule out organic causes)

Males
- onset: age 9-14 yr old
- usual sequence
  1. testicular enlargement
  2. penile enlargement
  3. pubarche: axillary and facial hair, body odour, mild acne
  4. growth spurt: occurs later in boys
- early puberty is uncommon (rule out organic causes), late puberty is common and often constitutional
- gynecomastia (transient development of breast tissue) is a common self-limited condition seen in 50% of males during puberty (but any discharge from nipple or fixed mass should be investigated)

Tanner Staging
- scale used in pediatrics that defines physical measurements of development based on external primary and secondary sex characteristics

Figure 8. Tanner staging

PRECOCIOUS PUBERTY

Definition
- development of secondary sexual characteristics 2-2.5 SD before population mean
- <8 yr old for females, <9 yr old for males

Epidemiology
- 1/10,000; F>M
**Etiology**
- usually idiopathic in females (90%), more suggestive of pathology in males (50%)
- central (GnRH dependent)
  - hypergonadotropic hypergonadism; hormone levels as in normal puberty
  - premature activation of the HPG axis
  - differential diagnosis: idiopathic or constitutional (most common in females), CNS disturbances (tumours, hamartomas, post-meningitis, increased ICP, radiotherapy), NF, primary severe hypothyroidism
- peripheral (GnRH independent)
  - hypogonadotropic hypogonadism
  - differential diagnosis: adrenal disorders (CAH, adrenal neoplasm), testicular/ovarian tumour, gonadotropin/hCG secreting tumour (hepatoblastoma, intracranial teratoma, germinoma), exogenous steroid administration, McCune-Albright syndrome, aromatase excess syndrome, rarely hypothyroidism (Van Wyk-Grumbach syndrome)

**Clinical Presentation**
- history
  - symptoms of puberty, family history of precocious puberty, medical illness
- physical exam
  - growth velocity
    - prepubertal: 4 to 6 cm/yr
    - growth spurt: boys 8-10 cm/yr, girls 6-8 cm/yr
  - complete physical exam, including Tanner staging and neurological assessment
- investigations
  - initial screening tests: bone age, serum hormone levels (estradiol, testosterone, LH, FSH, TSH, free T4, DHEA-S, 17-OH-progesterone)
  - secondary tests: MRI head, pelvic U/S, β-hCG, GnRH, and/or ACTH stimulation test

**Management**
- indications for medical intervention to delay progression of puberty: rapid advancement of puberty, early age, risk of compromise of final adult height, psychological
- central causes: goals are to preserve height and alleviate psychosocial stress; GnRH agonists (e.g. leuprolide) most effective
- peripheral causes: goal is to limit effects of elevated sex steroids; treat underlying cause; medications that decrease the production of a specific sex steroid or block its effects (e.g. ketoconazole, spironolactone, tamoxifen, anastrozole), surgical intervention

**DELAYED PUBERTY**

**Definition**
- failure to develop secondary sex characteristics by 2-2.5 SD beyond the population mean
  - for males: lack of testicular enlargement by 14 yr old
  - for females: lack of breast development by 13 yr old OR absence of menarche by 16 yr old or within 5 yr of pubertal onset

**Epidemiology**
- M>F

**Etiology**
- usually constitutional delay in males, more suggestive of pathology in females
- central causes
  - constitutional delay in activation of HPG axis (most common)
  - hypergonadotropic hypogonadism
- peripheral causes
  - hypergonadotropic hypogonadism (e.g. primary gonadal failure, gonadal damage, Turner syndrome, hormone deficiency, androgen insensitivity syndrome, etc.)

**Clinical Presentation**
- history: weight loss, short stature, family history of puberty onset, medical illness, high performance athletes (females)
- physical exam: growth velocity (minimum 4 cm/yr), Tanner staging, neurological exam, complete physical exam
- investigations
  - initial screening tests: bone age, serum hormone levels (estradiol, testosterone, LH, FSH, TSH, free T4, IGF-1), CBC, electrolytes, BUN, Cr, LFTs, liver enzymes, ESR, CRP, urinalysis
  - secondary tests: MRI head, pelvic U/S, karyotype, IBD panel, celiac disease panel, LH levels following GnRH agonist

**Management**
- identify and treat underlying cause
- hormonal replacement: cyclic estradiol and progesterone for females, testosterone for males
Gastroenterology

Vomiting

History
• characteristic of emesis (e.g. projectile, bilious, bloody)
• pattern of emesis (e.g. association with feeds, cyclic, morning)
• associated symptoms (e.g. anorexia, diarrhea, etc.)
• red flags: bilious or bloody emesis, projectile vomit, abdominal distension and tenderness, high fever, signs of dehydration
• note that vomiting without diarrhea is most likely not gastroenteritis.
  ▪ post tussive vomiting is also common with coughing fits in children

Physical Findings
• vital signs to determine clinical status and hydration state

Investigations
• CBC, electrolytes, BUN, Cr, amylase, lipase, glucose done routinely
• in sick child, add: ESR, venous blood gases, C&S (blood, stool), imaging

Table 13. Common Differential Diagnosis, Associated Findings, and Diagnostic Approach Based on Age

<table>
<thead>
<tr>
<th>Cause</th>
<th>Suggestive Findings</th>
<th>Diagnostic Approach</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEOBATES – NON-BILIOUS</td>
<td>Vomiting, excessive secretions soon after birth (e.g. drooling, choking, respiratory distress), inability to feed, inability to advance NG tube</td>
<td>Inability to advance NG tube, CXR, upper GI series with water-soluble contrast</td>
</tr>
<tr>
<td>Pyloric stenosis</td>
<td>Projectile vomiting immediately after feeding, dehydrated, palpable “olive” in RUQ, decreased stools, hunger</td>
<td>U/S of pylorus, upper GI study (if U/S not diagnostic) Electrolytes, ABG (hyponatremic, hypochloremic metabolic alkalosis)</td>
</tr>
<tr>
<td>GERD</td>
<td>Fussiness after feeds, spit ups, arching of back, poor weight gain</td>
<td>Empiric trial of acid suppression, pH monitoring study, upper GI study, endoscopy</td>
</tr>
<tr>
<td>Sepsis</td>
<td>Fever, lethargy, tachycardia, tachypnea, widening pulse pressure</td>
<td>CBC, cultures (blood, urine, CSF), CXR</td>
</tr>
<tr>
<td>Inborn error of metabolism</td>
<td>Poor feeding, FTT, jaundice, hepatosplenomegaly, cardiomyopathy, dysmorphia, developmental delay</td>
<td>Electrolytes, ABG (hyponatremic, hyperkalemic metabolic acidosis), lactate, ammonia, LFTs, BUN, Cr, serum glucose, bilirubin, PT/PTT, CBC</td>
</tr>
<tr>
<td>NEOBATES – BILIOUS</td>
<td>Bilious emesis, abdominal distension, pain, bloody stool, shock</td>
<td>AXR, upper GI series, contrast enema</td>
</tr>
<tr>
<td>Malrotation with volvulus</td>
<td>Bilious emesis, abdominal distension, pain, bloody stool, shock</td>
<td>AXR, upper GI series (‘double bubble’ sign)</td>
</tr>
<tr>
<td>Duodenal atresia</td>
<td>Bilious emesis, abdominal distension, often seen in DS, jaundice, polyhydramnios during pregnancy. Hypokalemic, hypochloremic metabolic alkalosis.</td>
<td>AXR, upper GI series (‘double bubble’ sign)</td>
</tr>
<tr>
<td>Hirschsprung’s disease</td>
<td>Bilious emesis, abdominal distension, pain, failure to pass stool</td>
<td>AXR, upper GI series, contrast enema, rectal biopsy</td>
</tr>
</tbody>
</table>

CHILDREN AND ADOLESCENTS

Gastroenteritis | Diarrhea, fever, sick contact, recent travel | CBC, stool culture |
Appendicitis | Periumbilical discomfort that later localizes to RUQ, fever, anorexia | Abdominal U/S |
Intussusception | Colicky progressive abdominal pain, drawing of legs up to chest, lethargy, bloody “red currant jelly” stool (Triad) | Abdominal U/S |
Non-GI infection (e.g. meningitis) | Fever, localized findings depending on cause | Cultures (CSF, blood, urine), brain imaging, CXR |
Increased ICP | Nocturnal waking, progressive recurrent headache worse with Valsalva, nuchal rigidity | Brain CT without contrast Therapeutic LP in idiopathic intracranial HTN |
Toxic ingestion | Finding possibly varying by substance- toxicidrome, often a history of ingestion | Qualitative and sometimes quantitative levels (urine, blood) |
Pregnancy | Amenorrhea, morning sickness, bloating, breast tenderness | Urine β-hCG |
Cyclic vomiting | At least 3 self-limited episodes of vomiting lasting 12 h, 7 d between episodes, no organic cause of vomiting | Diagnosis of exclusion |

Management
• rehydration (see Fluids and Electrolytes, P74)
• treat underlying cause
**Gastroesophageal Reflux**

**Epidemiology**
- extremely common in infancy (up to 50%)

**Clinical Presentation**
- vomiting typically soon after feeding, non-bilious, rarely contains blood, small volume (<30 mL)

**Investigations**
- thriving baby requires no investigation
- investigations required if concomitant FTT, feeding aversion, recurrent cough, pneumonia or bronchospasm, GI blood loss or symptoms persist after 18 mo

**Management**
- conservative: thickened feeds, frequent and smaller feeds, elevation of head
- medical
  - short-term parenteral feeding to enhance weight gain
  - ranitidine, PPI: decreases gastric acidity, decreases esophageal irritation
  - domperidone, metoclopramide: improves gastric emptying and GI motility; safety concerns and limited efficacy, should be reserved for children with gastroparesis contributing to GERD
- surgical: indicated for failure of medical therapy (Nissen fundoplication)

**Complications**
- esophagitis, strictures, Barrett’s esophagus, FTT, aspiration, oral feeding aversion

**Tracheoesophageal Fistula**
- see General Surgery, GS64

**Pyloric Stenosis**
- see General Surgery, GS62

**Duodenal Atresia**
- see General Surgery, GS63

**Malrotation of the Intestine**
- see General Surgery, GS63

**Diarrhea**
- definition of diarrhea varies with diet and age (stool normalcy difficult to define in children)
  - infants → increase in stool frequency to twice as often per day; older children → 3+ loose or watery stools/d
  - duration: acute: <2 wk; chronic: >2 wk

**Pathophysiology**
- osmotic: due to non-absorbable solutes in GI tract (e.g. lactose intolerance)
- secretory: increased secretion of Cl⁻ ions and water in intestinal lumen (e.g. bacterial toxin)
- malabsorption: less time for absorption due to increased motility or less villi to absorb (e.g. short bowel syndrome)

**History**
- frequency, duration, quality of diarrhea
- associated symptoms (e.g. fever, abdominal pain, hematochezia, etc.)
- recent antibiotic use or recent travel
- elements of diet

**Physical Findings**
- vital signs to determine clinical status and hydration state
Investigations
- acute diarrhea
  - stool for C&S, O&P, electron microscopy for viruses, *C. difficile* toxin, microscopy (leukocytes suggestive of invading pathogen), blood and urine cultures, blood work
- chronic diarrhea
  - serial heights, weights, growth percentiles
  - if child growing well and thriving, workup is limited (stool cultures as above, stool reducing substances)
  - red flags: poor growth, chronic rash, other serious infections, hospitalizations for dehydration
  - require full workup (as per below)
  - urinalysis, urine culture
  - CBC, differential, ESR/CRP, smear, electrolytes, total protein, albumin, carotene, Ca++, PO4-, Mg++, Fe, ferritin, folate, fat-soluble vitamins, PTT, INR
  - sweat chloride, celiac screen, thyroid function tests, urine VMA and HVA, HIV test, lead levels
  - CXR, upper GI series and follow-through
  - specialized tests: endoscopy, small bowel biopsy

Differential Diagnosis

### Table 14. Differential Diagnosis of Diarrhea

<table>
<thead>
<tr>
<th>Infectious</th>
<th>Non-infectious</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute</strong></td>
<td></td>
</tr>
<tr>
<td>Rotavirus</td>
<td></td>
</tr>
<tr>
<td>Norwalk</td>
<td></td>
</tr>
<tr>
<td>Enteric adenovirus</td>
<td></td>
</tr>
<tr>
<td>Salmonella</td>
<td><em>Giardia lamblia</em></td>
</tr>
<tr>
<td>Campylobacter</td>
<td><em>Entamoeba histolytica</em></td>
</tr>
<tr>
<td>Shigella</td>
<td></td>
</tr>
<tr>
<td>Pathogenic <em>E. coli</em></td>
<td></td>
</tr>
<tr>
<td>Yersinia</td>
<td><em>C. difficile</em></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Chronic</strong></td>
<td></td>
</tr>
<tr>
<td>0 – 3 mo</td>
<td>3 mo – 3 yr</td>
</tr>
<tr>
<td>3 – 18 yr</td>
<td>Uncommon</td>
</tr>
<tr>
<td>No FTT</td>
<td></td>
</tr>
<tr>
<td>GI infection</td>
<td>GI infection</td>
</tr>
<tr>
<td>Toddler’s diarrhea</td>
<td>Lactase deficiency</td>
</tr>
<tr>
<td></td>
<td>Irritable bowel syndrome</td>
</tr>
<tr>
<td></td>
<td>Drug-induced</td>
</tr>
<tr>
<td></td>
<td>Chronic constipation</td>
</tr>
<tr>
<td></td>
<td>UTI</td>
</tr>
<tr>
<td>FTT</td>
<td></td>
</tr>
<tr>
<td>Disaccharidase deficiency</td>
<td>IBD</td>
</tr>
<tr>
<td>Cow’s milk protein intolerance</td>
<td>Endocrine (thyrotoxicosis, Addison’s)</td>
</tr>
<tr>
<td>CF</td>
<td>Neoplastic (pheochromocytoma, lymphoma)</td>
</tr>
<tr>
<td></td>
<td>Short bowel syndrome</td>
</tr>
<tr>
<td></td>
<td>Schwachman-Diamond syndrome</td>
</tr>
</tbody>
</table>

**Gastroenteritis**

**History**
- non-specific: diarrhea, vomiting, fever, anorexia, headache, myalgias, abdominal cramps
- bacterial and parasitic agents more common in older children (2–4 yr)
- recent infectious contacts: symptoms usually begin 24–48 h after exposure

**Physical Exam**
- febrile
- dehydrated: must assess extent (see *Approach to Infant/Child with Dehydration, P74*)

**Investigations**
- not usually necessary in young children
- stool analysis: leukocytes/erythrocytes suggest bacterial or parasitic etiology; pH <6 and presence of reducing substances suggests viral etiology

**Complications**
- viral gastroenteritis usually self-limiting (lasts 3–7 d in most cases)
- adverse effects related to hypovolemia, shock, tissue acidosis, and rapid onset and over-correction of electrolyte imbalances
- death in severe dehydration (rare in developed countries)
Table 15. Gastroenteritis

<table>
<thead>
<tr>
<th>Viral Infection</th>
<th>Bacterial Infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etiology</td>
<td>Most common cause of gastroenteritis</td>
</tr>
<tr>
<td>Commonly: rotaviruses (most common), enteric adenovirus, norovirus (typically older children)</td>
<td>Salmonella, Campylobacter, Shigella, pathogenic E. coli, Yersinia, C. difficile</td>
</tr>
<tr>
<td>Clinical Presentation</td>
<td>Associated with URTIs</td>
</tr>
<tr>
<td>Resolves in 3-7 d</td>
<td>Severe abdominal pain</td>
</tr>
<tr>
<td>Slight fever, malaise, vomiting, vague abdominal pain</td>
<td>High fever</td>
</tr>
<tr>
<td>Risk Factors</td>
<td>Day care, young age, sick contacts, immunocompromised</td>
</tr>
<tr>
<td>Bacterial infection: travel, poorly cooked meat, poorly refrigerated foods, antibiotics</td>
<td></td>
</tr>
<tr>
<td>Management</td>
<td>Prevention and treatment of dehydration most important (see Dehydration, P74)</td>
</tr>
<tr>
<td>Early refeeding advisable, with age-appropriate diet upon completion of rehydration</td>
<td>Ondansetron for suspected gastroenteritis with mild to moderate dehydration or failed ORT and significant vomiting</td>
</tr>
<tr>
<td>Antibiotic or antiparasitic therapy when indicated, antidiarrheal medications not indicated</td>
<td>Notify Public Health authorities if appropriate</td>
</tr>
<tr>
<td>Promote regular hand-washing and return to school 24 h after last diarrheal episode to prevent transmission</td>
<td>Rotavirus vaccine</td>
</tr>
</tbody>
</table>

Toddler’s Diarrhea

Epidemiology
- most common cause of chronic diarrhea during infancy
- onset between 6-36 mo of age, ceases spontaneously between 2-4 yr

Clinical Presentation
- diagnosis of exclusion in thriving child
- 4-6 bowel movements per day
- diet history (e.g. excess juice intake overwhelms small bowel resulting in disaccharide malabsorption)
- stool may contain undigested food particles
- excoriated diaper rash

Management
- reassurance that it is self-limiting
- 4Fs (adequate Fibre, normal Fluid intake, 35-40% Fat, discourage excess Fruit juice)

Lactase Deficiency (Lactose Intolerance)

Clinical Presentation
- chronic, watery diarrhea and abdominal pain, bloating associated with dairy intake
- primary lactose intolerance: crampy abdominal pain with loose stool (older children, usually of East Asian and African descent)
- secondary lactose intolerance: older infant, persistent diarrhea (post viral/bacterial infection, celiac disease, or IBD)

Diagnosis
- trial of lactose-free diet
- watery stool, acid pH, positive reducing sugars
- positive breath hydrogen test if >6 yr

Management
- lactose-free diet, soy formula
- lactase-containing tablets/capsules/drops (e.g. Lacteeze®, Lactaid®)

Irritable Bowel Syndrome
- see Gastroenterology, G23

Celiac Disease
- see Gastroenterology, G18
- in children: presents at any age, usually 6-24 mo with the introduction of gluten in the diet
- FIT with poor appetite, irritability, apathy, rickets, wasted muscles, flat buttocks, rarely distended abdomen
- GI symptoms: anorexia, N/V, edema, anemia, abdominal pain
- non-GI manifestations: iron-deficiency anemia, dermatitis herpetiformis, dental enamel hypoplasia, osteopenia/osteoporosis, short stature, delayed puberty, behavioural changes
- associated with other autoimmune disorders

A Celiac disease diet must avoid gluten present in “BROW” foods
B - Barley
R - Rye
O - Oats (controversial)
W - Wheat

Celiac disease is associated with an increased prevalence of IgA deficiency. Since tTG is an IgA-detecting test, you must order an accompanying tTG level

Prevention and treatment of dehydration most important (see Dehydration, P74)
Ondansetron for suspected gastroenteritis with mild to moderate dehydration or failed ORT and significant vomiting
Antibiotic or antiparasitic therapy when indicated, antidiarrheal medications not indicated
Notify Public Health authorities if appropriate
Promote regular hand-washing and return to school 24 h after last diarrheal episode to prevent transmission
Rotavirus vaccine

Toddler’s Diarrhea

Epidemiology
- most common cause of chronic diarrhea during infancy
- onset between 6-36 mo of age, ceases spontaneously between 2-4 yr

Clinical Presentation
- diagnosis of exclusion in thriving child
- 4-6 bowel movements per day
- diet history (e.g. excess juice intake overwhelms small bowel resulting in disaccharide malabsorption)
- stool may contain undigested food particles
- excoriated diaper rash

Management
- reassurance that it is self-limiting
- 4Fs (adequate Fibre, normal Fluid intake, 35-40% Fat, discourage excess Fruit juice)

Lactase Deficiency (Lactose Intolerance)

Clinical Presentation
- chronic, watery diarrhea and abdominal pain, bloating associated with dairy intake
- primary lactose intolerance: crampy abdominal pain with loose stool (older children, usually of East Asian and African descent)
- secondary lactose intolerance: older infant, persistent diarrhea (post viral/bacterial infection, celiac disease, or IBD)

Diagnosis
- trial of lactose-free diet
- watery stool, acid pH, positive reducing sugars
- positive breath hydrogen test if >6 yr

Management
- lactose-free diet, soy formula
- lactase-containing tablets/capsules/drops (e.g. Lacteeze®, Lactaid®)

Irritable Bowel Syndrome
- see Gastroenterology, G23

Celiac Disease
- see Gastroenterology, G18
- in children: presents at any age, usually 6-24 mo with the introduction of gluten in the diet
- FIT with poor appetite, irritability, apathy, rickets, wasted muscles, flat buttocks, rarely distended abdomen
- GI symptoms: anorexia, N/V, edema, anemia, abdominal pain
- non-GI manifestations: iron-deficiency anemia, dermatitis herpetiformis, dental enamel hypoplasia, osteopenia/osteoporosis, short stature, delayed puberty, behavioural changes
- associated with other autoimmune disorders

A Celiac disease diet must avoid gluten present in “BROW” foods
B - Barley
R - Rye
O - Oats (controversial)
W - Wheat

Celiac disease is associated with an increased prevalence of IgA deficiency. Since tTG is an IgA-detecting test, you must order an accompanying tTG level

Prevention and treatment of dehydration most important (see Dehydration, P74)
Ondansetron for suspected gastroenteritis with mild to moderate dehydration or failed ORT and significant vomiting
Antibiotic or antiparasitic therapy when indicated, antidiarrheal medications not indicated
Notify Public Health authorities if appropriate
Promote regular hand-washing and return to school 24 h after last diarrheal episode to prevent transmission
Rotavirus vaccine

Toddler’s Diarrhea

Epidemiology
- most common cause of chronic diarrhea during infancy
- onset between 6-36 mo of age, ceases spontaneously between 2-4 yr

Clinical Presentation
- diagnosis of exclusion in thriving child
- 4-6 bowel movements per day
- diet history (e.g. excess juice intake overwhelms small bowel resulting in disaccharide malabsorption)
- stool may contain undigested food particles
- excoriated diaper rash

Management
- reassurance that it is self-limiting
- 4Fs (adequate Fibre, normal Fluid intake, 35-40% Fat, discourage excess Fruit juice)

Lactase Deficiency (Lactose Intolerance)

Clinical Presentation
- chronic, watery diarrhea and abdominal pain, bloating associated with dairy intake
- primary lactose intolerance: crampy abdominal pain with loose stool (older children, usually of East Asian and African descent)
- secondary lactose intolerance: older infant, persistent diarrhea (post viral/bacterial infection, celiac disease, or IBD)

Diagnosis
- trial of lactose-free diet
- watery stool, acid pH, positive reducing sugars
- positive breath hydrogen test if >6 yr

Management
- lactose-free diet, soy formula
- lactase-containing tablets/capsules/drops (e.g. Lacteeze®, Lactaid®)

Irritable Bowel Syndrome
- see Gastroenterology, G23

Celiac Disease
- see Gastroenterology, G18
- in children: presents at any age, usually 6-24 mo with the introduction of gluten in the diet
- FIT with poor appetite, irritability, apathy, rickets, wasted muscles, flat buttocks, rarely distended abdomen
- GI symptoms: anorexia, N/V, edema, anemia, abdominal pain
- non-GI manifestations: iron-deficiency anemia, dermatitis herpetiformis, dental enamel hypoplasia, osteopenia/osteoporosis, short stature, delayed puberty, behavioural changes
- associated with other autoimmune disorders

A Celiac disease diet must avoid gluten present in “BROW” foods
B - Barley
R - Rye
O - Oats (controversial)
W - Wheat

Celiac disease is associated with an increased prevalence of IgA deficiency. Since tTG is an IgA-detecting test, you must order an accompanying tTG level

Prevention and treatment of dehydration most important (see Dehydration, P74)
Ondansetron for suspected gastroenteritis with mild to moderate dehydration or failed ORT and significant vomiting
Antibiotic or antiparasitic therapy when indicated, antidiarrheal medications not indicated
Notify Public Health authorities if appropriate
Promote regular hand-washing and return to school 24 h after last diarrheal episode to prevent transmission
Rotavirus vaccine
Milk Protein Allergy

Pathophysiology
• immune-mediated mucosal injury (IgE- and non-IgE-mediated)

Clinical Presentation
• up to 50% of children intolerant to cow's milk may be intolerant to soy protein as well
• often history of atopy
• can present as
  ▪ proctocolitis: mild diarrhea, small amounts of bloody stools (common presentation in young infant)
  ▪ enterocolitis: vomiting, diarrhea, anemia, hematochezia
  ▪ enteropathy: chronic diarrhea, hypoalbuminemia

Management
• casein hydrolysate formula (dairy-free e.g. Nutramigen®, Pregestimil®) or mother may remove all milk protein from diet and continue breastfeeding (with adequate calcium and vit D intake)
• often outgrow by 1 yr of age

Inflammatory Bowel Disease

• see Gastroenterology, G19

Cystic Fibrosis

• see Respirology, P84

Constipation
• decreased stool frequency (<3 stools/wk) and/or stool fluidity (hard, pellet-like)

FUNCTIONAL CONSTIPATION
• 99% of cases of constipation
• Rome III criteria; ≥2 of the following
  ▪ ≤2 defections in the toilet/wk
  ▪ ≥1 episode of fecal incontinence/wk
  ▪ history of retentive posturing or excessive volitional stool retention
  ▪ history of painful or hard bowel movements
  ▪ large fecal mass in rectum
  ▪ history of large diameter stools that may obstruct toilet

Pathophysiology
• lack of fibre in diet or change in diet, poor fluid intake, behavioural
  ▪ infants: often occurs when introducing cow's milk after breast milk due to high fat and solute content, lower water content
  ▪ toddlers/older children: can occur during toilet training, or due to pain on defecation, leading to withholding of stool
  ▪ two crucial time periods: toilet training and starting school

Management
• education: explanation of mechanism of functional constipation for parents/older children
• clean out: PEG 3350 flakes (1-1.5 g/kg/d, max 100 g/d), picosalax, PEGlyte™
• maintenance: adequate fluid intake (if <6 mo, 150 mL/kg/d), adequate dietary fibre (fruit, vegetables, whole grains), stool softening (PEG 3350, mineral oil), appropriate toilet training technique (dedicated time for defecation: 3-10 min, 1-2 x/d)
• children should be treated for at least 6 mo, and should not be weaned from maintenance therapy until they are having regular bowel movements without difficulty
• regular follow-up with ongoing support and encouragement is essential

Complications
• pain retention cycle: anal fissures + pain withhold passing stool chronic dilatation ± overflow incontinence

HIRSCHSPRUNG’S DISEASE (Congenital Aganglionic Megacolon)
• see General Surgery, GS64
OTHER ORGANIC DISORDERS CAUSING CONSTIPATION
• endocrine: hypothyroidism, DM, hypercalcemia
• neurologic: spinal cord abnormalities/trauma, NF
• anatomic: bowel obstruction, anus (imperforate, atresia, stenosis, anteriorly displaced)
• drugs: lead, chemotherapy, opioids
• others

Abdominal Pain

ACUTE ABDOMINAL PAIN

History
• description of pain (location, radiation, duration, constant vs. colicky, relation to meals)
• associated symptoms: N/V, diarrhea, fever

Physical Exam
• abdominal exam, rectal exam, rash

Investigations
• CBC, differential, urinalysis to rule out UTI

Table 16. Differential Diagnosis of Acute Abdominal Pain

<table>
<thead>
<tr>
<th>Gastrointestinal</th>
<th>Hepatobiliary Tract</th>
<th>Genitourinary</th>
<th>Hematologic</th>
<th>Miscellaneous</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastroenteritis</td>
<td>Cholecystitis</td>
<td>UTI</td>
<td>Henoch-Schönlein purpura</td>
<td>DKA</td>
</tr>
<tr>
<td>Appendicitis</td>
<td>Pancreatitis</td>
<td>Nephrolithiasis</td>
<td>Sickle cell crisis</td>
<td>Pneumonia</td>
</tr>
<tr>
<td>Meckel’s diverticulum</td>
<td></td>
<td>Testicular torsion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mesenteric adenitis</td>
<td></td>
<td>Ovarian torsion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ileus</td>
<td></td>
<td>Ectopic pregnancy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intestinal obstruction (incarcerated hernia, intussusception, volvulus)</td>
<td></td>
<td>PID</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malabsorption</td>
<td></td>
<td>Endometriosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IBS</td>
<td></td>
<td>Menstruation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

APPENDICITIS
• see General Surgery, GS27
• most common cause of acute abdomen after 5 yr of age
• clinical features: low grade fever, abdominal pain, anorexia, N/V (after onset of pain), peritoneal signs (generalized peritonitis is a common presentation in infants/young children)
• treatment: surgical
• complications: perforation (common in young children), abscess

INTUSUSCEPTION
• telescoping of segment of bowel into distal segment causing ischemia and necrosis

Epidemiology
• 90% idiopathic, children with CF or GJ tube at significantly increased risk; M:F = 3:1
• 50% between 3-12 mo, 75% before 2 yr of age

Pathophysiology
• usual site: ileocecal junction; jejunum in children with GJ tubes
• lead point of telescoping segment may be swollen Peyer’s patches, Meckel’s diverticulum, polyp, malignancy, HSP, structural abnormalities

Clinical Presentation
• “classic triad” (<25% patients) - abdominal pain, palpable mass, red currant jelly stools
• often preceded by URTI
• sudden onset of recurrent, paroxysmal, severe periumbilical pain with pain-free intervals
• later vomiting (may be bilious) and rectal bleeding (late finding)
• shock and dehydration; lethargy may be only presenting symptom

Diagnosis
• U/S, air enema

Management
• air enema can be therapeutic (reduces intussusception in 75% of cases), reduction under hydrostatic pressure, surgery rarely needed
• recurrence rate 10-15%, need to consider pathologic lead point
Chronic Abdominal Pain

Epidemiology
• prevalence: 10% of school children (peak at 8-10 yr), F>M

Etiology
• organic (<10%)
  • gastrointestinal
    - constipation (cause vs. effect), infectious
    - IBD, esophagitis, peptic ulcer disease, lactose intolerance
    - anatomic anomalies, masses
    - pancreatic, hepatobiliary
    - celiac disease
  • genitourinary causes: recurrent UTI, nephrolithiasis, chronic PID, Mittelschmerz
  • neoplastic
• functional abdominal pain (90%): can be diagnosed when there are no alarm symptoms or signs, physical exam is normal, and stool sample tests are negative for occult blood; no further testing is required, unless high suspicion for organic cause

Clinical Presentation
• clustering episodes of vague, crampy periumbilical/epigastric pain, vivid pain description
• seldom awakens child from sleep, less common on weekends
• aggravated by exercise, alleviated by rest
• psychological factors related to onset and/or maintenance of pain, school avoidance
• psychiatric comorbidity: anxiety, somatoform, mood, learning disorders, sexual abuse, eating disorders, elimination disorders
• diagnosis of exclusion

Investigations
• fecal occult blood and others based on clinical suspicion (CBC, ESR, urinalysis, etc.)

Management
• continue to attend school
• manage any emotional or family problems, counselling, CBT
• trial of high fibre diet, trial of lactose-free diet
• possible role for amitriptyline
• reassurance

Prognosis
• pain resolves in 30-50% of children within 2-6 wk of diagnosis
• 30-50% of children with functional abdominal pain have functional pain as adults (e.g. IBS)

Abdominal Mass

Table 17. Differential Diagnosis for Abdominal Mass

<table>
<thead>
<tr>
<th>Benign</th>
<th>Malignant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal (note: 50% of abdominal masses in newborn are renal in origin)</td>
<td>Neoplasm (Wilms' tumour)</td>
</tr>
<tr>
<td>Hydronephrosis</td>
<td>Nephroblastoma (Wilms' tumour)</td>
</tr>
<tr>
<td>Polycystic kidney disease</td>
<td>Renal cell carcinoma</td>
</tr>
<tr>
<td>Hamartoma</td>
<td></td>
</tr>
<tr>
<td>Adrenal</td>
<td>Neuroblastoma</td>
</tr>
<tr>
<td>Ovarian</td>
<td></td>
</tr>
<tr>
<td>Ovarian cysts</td>
<td>Ovarian tumours</td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>Hepatomegaly/spilenomegaly</td>
<td>Lymphoma</td>
</tr>
<tr>
<td>Pyloric stenosis</td>
<td>Rhabdomyosarcoma</td>
</tr>
<tr>
<td>Abdominal hernia</td>
<td>Retropertoneal sarcoma</td>
</tr>
<tr>
<td>Teratoma</td>
<td></td>
</tr>
<tr>
<td>Fecal impaction</td>
<td></td>
</tr>
</tbody>
</table>

Upper Gastrointestinal Bleeding

• see Gastroenterology, G25
Lower Gastrointestinal Bleeding

- see Gastroenterology, G27

**Etiology**
- acute
  - infectious (bacterial, parasitic)
  - antibiotic-induced (*C. difficile*)
  - NEC in preterm infants
  - anatomic
  - malrotation/volvulus, intussusception
  - Meckel's diverticulitis
  - anal fissures, hemorrhoids
  - vascular/hematologic
  - HSP
  - HUS
  - coagulopathy
- chronic
  - anal fissures (most common)
  - colitis
  - IBD
  - allergic (milk protein)
  - structural
  - polyps (most are hamartomas)
  - neoplasms (rare)
  - coagulopathy

**Physical Exam**
- hemodynamic status, evidence of FTT, fever
- anal and rectal exam: tags, fissures, anal fistulas, polyps, foreign body, blood per rectum
- stool appearance
- NG aspirate
- lower GI bleed may present as melena (if it involves the small bowel) or hematochezia

**Investigations**
- stool cultures (C&S, *C. difficile* toxin)
- urinalysis and microscopy
- CBC, smear, differential, ESR, CRP, electrolytes, urea, Cr, INR, PTT, albumin, iron studies, amoeba titers
- radiologic investigations (including abdominal x-ray to rule out obstruction)
- Meckel's radionuclide scan

**Management**
- acute stabilization: ABCs, volume and blood replacement, bowel rest (NPO, NG tube)
- once stable, endoscopy and/or surgery as indicated

Genetics, Dysmorphisms, and Metabolism

**Genetics**

**MECHANISMS OF INHERITANCE**

**Mendelian Inheritance**
- disorders caused by mutation of one or both copies (alleles) of a gene, inherited in one of two patterns
  - autosomal: encoded by genes on one of 22 pairs of autosomes (chromosomes 1-22)
  - X-linked: encoded by a gene on the X chromosome

**Triplet Repeat Expansions**
- disorder in which trinucleotide repeats in certain genes exceed the normal number and result in altered gene expression or production of an abnormal protein (e.g. Fragile X syndrome, spinocerebellar ataxias, myotonic dystrophy, Huntington disease)

**Imprinting Disorders**
- imprinting: epigenetic process that involves methylation or acetylation of DNA, affecting gene expression
- imprinted genes are expressed entirely from either the maternal or paternal allele, depending on the gene (parent-of-origin gene expression)
- occur when a mutation disrupts the normally expressed allele of imprinted gene (e.g. Prader-Willi syndrome, Angelman syndrome, Beckwith-Wiedemann syndrome)

**Mitochondrial Inheritance**
- disorders caused by mutations of the DNA present in mitochondria
- inheritance pattern: mother passes on the defect to all her children; father can not pass on defect since embryo only receives mitochondria from the mother (in the egg)
METHODS OF GENETIC TESTING

- microarray analysis
  - a microarray is a collection of DNA probes attached to a solid surface
  - microarray analysis can identify small deletions or duplications of genetic material anywhere in the genome
  - indicated when there is developmental delay + one or more major malformations
- FISH: usually to identify a gain or loss of chromosomal material
- karyotype: microscopic analysis of all 46 chromosomes with a special stain that shows large changes in the number or structure of chromosomes
- sanger sequencing: the ‘gold-standard’ method for identification of single nucleotide variants in short DNA sequences (e.g. the exons of the gene(s) known to cause suspected syndrome)
- next generation sequencing: high-throughput method to sequence exomes or whole-genomes; useful when genetic syndrome is suspected, but diagnosis is unclear

Genetic Anomalies

Minor and Major Anomalies

- minor anomaly: an unusual anatomic feature that is of no serious medical or cosmetic consequence to the patient
- major anomaly: anomaly that creates significant medical, surgical, or cosmetic problems for the patient

Mechanism for Anomalies

- malformation: results from an intrinsically abnormal developmental process (e.g. polydactyly)
- disruption: results from the extrinsic breakdown of, or interference with, an originally normal developmental process (e.g. amniotic band disruption sequence)
- deformation: alteration of the final form of a structure by mechanical forces (e.g. Potter deformation sequence)
- dysplasia: abnormal development that results in abnormal organization of cells into tissues (e.g. bone dysplasia)

Multiple Anomalies

- association: non-random occurrence of multiple independent anomalies that appear together more than would be predicted by chance but are not believed to have a single etiology (e.g. VACTERL)
- sequence: related anomalies that come from a single initial major anomaly or precipitating factor that changes the development of other surrounding or related tissues or structures (e.g. Potter sequence)
- syndrome: a pattern of anomalies that occur together and are caused by a single known or unknown cause (e.g. Down syndrome)

Approach to the Dysmorphic Child

- genetic disorders are the most common cause of infant death in developed countries

General Approach to the Dysmorphic Child

- Are the anomalies major or minor?
- What is the mechanism underlying the anomaly?
- Do the anomalies fit as part of an association, sequence, or syndrome?

History

- prenatal/obstetric history (see Obstetrics, OB6) with particular attention to potential teratogenic exposures
- complete 3 generation family pedigree: consanguinity, stillbirths, neonatal deaths, specific illnesses, intellectual disability, multiple miscarriages, ethnicity
Physical Exam

Figure 9. Physical exam of the dysmorphic child

Investigations
- screening for TORCH infections
- serial photographs if child is older
- x-rays for bony abnormalities
- cytogenetic studies
  - karyotype if recognized syndrome
  - chromosome microarray analysis (array comparative genomic hybridization) if developmental delay with one or more congenital anomalies
  - FISH if microdeletion syndrome or trisomy suspected
- biochemistry: specific enzyme assays
- single gene testing

Management
- prenatal counselling and assessing risk of recurrence
- referral for specialized pediatric or genetic care

Genetic Syndromes

Table 18. Common Genetic Syndromes

<table>
<thead>
<tr>
<th>Disease</th>
<th>Trisomy 21</th>
<th>Trisomy 18</th>
<th>Trisomy 13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence</td>
<td>1:600-800 live births</td>
<td>1:6,000 live births F:M = 3:1</td>
<td>1:10,000 live births</td>
</tr>
<tr>
<td>Cranium/Brain</td>
<td>Mild microcephaly, flat occiput, 3rd fontanelle, brachycephaly</td>
<td>Microcephaly, prominent occiput</td>
<td>Microcephaly, sloping forehead, occipital scalp defect, holoprosencephaly</td>
</tr>
<tr>
<td>Eyes</td>
<td>Uplifting palpebral fissures, inner epicanthal folds, speckled irs, refractive errors (myopia), acquired cataracts, nystagmus, strabismus</td>
<td>Microphthalmia, hypotelorism, iris coloboma, retinal anomalies</td>
<td>Microphthalmia, corneal abnormalities</td>
</tr>
<tr>
<td>Ears</td>
<td>Low-set, small, overlapped upper helix, frequent AOM, hearing loss</td>
<td>Low-set, malformed</td>
<td>Low-set, malformed</td>
</tr>
<tr>
<td>Facial Features</td>
<td>Protruding tongue, large cheeks, low flat nasal bridge, small nose</td>
<td>Cleft lip/palate Small mouth, micrognathia</td>
<td>60-80% cleft lip and palate</td>
</tr>
<tr>
<td>Skeletal/MSK</td>
<td>Short stature Excess nuchal skin Joint hyperflexibility (80%) including dysplastic hips, vertebral anomalies, atlantoaxial instability</td>
<td>Short stature Clenched fist with overlapping digits, hypoplastic nails, clinodactyly, polydactyly</td>
<td>Severe growth retardation Polydactyly, clenched hand</td>
</tr>
<tr>
<td>Cardiac Defect</td>
<td>50%, particularly atrioventricular septal defect</td>
<td>60% (VSD, PDA, ASD)</td>
<td>80% (VSD, PDA, ASD)</td>
</tr>
<tr>
<td>GI</td>
<td>Duodenal/esophageal/anal atresia, TEF, Hirschsprung’s disease, chronic constipation</td>
<td>Hernia, TEF</td>
<td></td>
</tr>
<tr>
<td>GU</td>
<td>Cryptorchidism, rarely fertile</td>
<td>Polycystic kidneys, cryptorchidism</td>
<td>Polycystic kidneys</td>
</tr>
</tbody>
</table>
### Table 18. Common Genetic Syndromes (continued)

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>CNS</th>
<th>Other Features</th>
<th>Prognosis/Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trisomy 21</td>
<td>Hypotonia at birth, Low IQ, developmental delay, hearing problems, Onset of Alzheimer’s disease in 40s</td>
<td>Hypertonia</td>
<td>Prognosis: long-term management per AAP Guidelines (Health Supervision of Children with Down syndrome), recommend chromosomal analysis, CBC, Echo, yearly thyroid test, atlanto-occipital x-ray at 2 yr, sleep study, hearing test, and ophthalmology assessment</td>
</tr>
<tr>
<td>Trisomy 18</td>
<td>Hypo- or hypertonia, Seizures, deafness, Severe developmental delay</td>
<td>SGA, Rocker-bottom feet</td>
<td>13% 1-year survival, 10% ten-year survival</td>
</tr>
<tr>
<td>Trisomy 13</td>
<td>Hypotonia</td>
<td>Transverse palmar crease, clinodactyly, and absent middle phalanx of the 5th finger</td>
<td>Profound intellectual disability in survivors</td>
</tr>
</tbody>
</table>

#### Other Features
- **Trisomy 21**: Hypotonia at birth, Low IQ, developmental delay, hearing problems, Onset of Alzheimer’s disease in 40s.
- **Trisomy 18**: Hypertonia, Hypo- or hypertonia, Seizures, deafness, Severe developmental delay.
- **Trisomy 13**: Hypotonia, Transverse palmar crease, clinodactyly, and absent middle phalanx of the 5th finger.

#### Prognosis/Management
- **Trisomy 21**: Prognosis: long-term management per AAP Guidelines (Health Supervision of Children with Down syndrome), recommend chromosomal analysis, CBC, Echo, yearly thyroid test, atlanto-occipital x-ray at 2 yr, sleep study, hearing test, and ophthalmology assessment.
- **Trisomy 18**: 13% 1-year survival, 10% ten-year survival.
- **Trisomy 13**: Profound intellectual disability in survivors.

### Table 19. Most Common Sex Chromosome Disorders

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Genotype</th>
<th>Incidence</th>
<th>Phenotype</th>
<th>IQ and Behaviour</th>
<th>Gonad and Reproductive Function</th>
<th>Diagnosis/Prognosis/Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fragile X Syndrome</td>
<td>X-linked</td>
<td>1:3,600 males, 1:6,000 females</td>
<td>Overgrowth: prominent jaw, forehead, and nasal bridge with long and thin face, large protuberant ears, macroorchidism, hyperextensibility, and high arched palate</td>
<td>Mild to moderate intellectual disability, 20% of affected males have normal IQ</td>
<td>Premutation carrier females at risk of developing premature ovarian failure</td>
<td>Molecular testing of FMR1 gene: overamplification of the trinucleotide repeat, length of segment is proportional to severity of clinical phenotype (genetic anticipation)</td>
</tr>
<tr>
<td>Klinefelter Syndrome</td>
<td>Genetic anticipation CGG trinucleotide repeat on X chromosome measurable by molecular analysis</td>
<td>1:1,000 live male births</td>
<td>Tall, slim, underweight</td>
<td>Mild intellectual disability Behavioural or psychiatric disorders – anxiety, shyness, aggressive behaviour, antisocial acts</td>
<td>Male carriers may demonstrate tremor/ataxia syndrome in later life</td>
<td>Infertility due to hyponadism/hypospermia</td>
</tr>
<tr>
<td>Turner Syndrome</td>
<td>45.X (most common)</td>
<td>1:4,000 live female births</td>
<td>Short stature, webbed neck, low posterior hair line, wide carrying angle</td>
<td>Mild intellectual disability to normal intelligence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Noonan Syndrome</td>
<td>46,XX or 46,XY</td>
<td>1:2,000 male and female live births</td>
<td>Certain phenotypic features similar to females with Turner syndrome; therefore, sometimes called the ”male Turner syndrome”, although it affects both males and females</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Incidence
- **Fragile X Syndrome**: 1:3,600 males, 1:6,000 females.
- **Klinefelter Syndrome**: 1:1,000 live male births
- **Turner Syndrome**: 1:4,000 live female births
- **Noonan Syndrome**: 1:2,000 male and female live births

#### Phenotype
- **Fragile X Syndrome**: Overgrowth: prominent jaw, forehead, and nasal bridge with long and thin face, large protuberant ears, macroorchidism, hyperextensibility, and high arched palate.
- **Klinefelter Syndrome**: Tall, slim, underweight.
- **Turner Syndrome**: Short stature, webbed neck, low posterior hair line, wide carrying angle.
- **Noonan Syndrome**: Certain phenotypic features similar to females with Turner syndrome; therefore, sometimes called the ”male Turner syndrome”, although it affects both males and females.

#### IQ and Behaviour
- **Fragile X Syndrome**: Mild to moderate intellectual disability.
- **Klinefelter Syndrome**: Mild intellectual disability Behavioural or psychiatric disorders – anxiety, shyness, aggressive behaviour, antisocial acts.
- **Turner Syndrome**: Mild intellectual disability to normal intelligence.
- **Noonan Syndrome**: Moderate intellectual disability in 25% of patients.

#### Gonad and Reproductive Function
- **Fragile X Syndrome**: Premutation carrier females at risk of developing premature ovarian failure.
- **Klinefelter Syndrome**: Infertility due to hyponadism/hypospermia.
- **Turner Syndrome**: Streak ovaries with deficient follicles, infertility, primary amenorrhea, impaired development of secondary sexual characteristics.
- **Noonan Syndrome**: Delayed puberty.

#### Diagnosis/Prognosis/Management
- **Fragile X Syndrome**: Molecular testing of FMR1 gene: overamplification of the trinucleotide repeat, length of segment is proportional to severity of clinical phenotype (genetic anticipation).
- **Klinefelter Syndrome**: Increased risk of germ cell tumours and breast cancer Management: testosterone in adolescence.
- **Turner Syndrome**: Normal life expectancy if no complications.
- **Noonan Syndrome**: Molecular testing of PTPN11 gene Management: affected males may require testosterone replacement therapy at puberty.
Table 20. Other Genetic Syndromes

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>DiGeorge Syndrome</th>
<th>Prader-Willi Syndrome</th>
<th>Angelman Syndrome</th>
<th>CHARGE Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Genotype</strong></td>
<td>Microdeletions of chromosome region 22q11 (Deletion)</td>
<td>Lack of expression of genes on paternal chromosome 15q11-13 due to deletion, maternal uniparental disomy of chromosome 15, or imprinting defect</td>
<td>Lack of expression of genes on maternal chromosome 15q11-13 due to deletion or inactivation or paternal uniparental disomy</td>
<td>2/3 of children with CHARGE have been found to have a CHD7 mutation on chromosome 8</td>
</tr>
<tr>
<td><strong>Incidence</strong></td>
<td>1:4000; Second most common genetic diagnosis (next to DS)</td>
<td>1:15,000</td>
<td>1:10,000</td>
<td>1:10,000</td>
</tr>
<tr>
<td><strong>Clinical Features</strong></td>
<td>“CATCH 22”</td>
<td>“H-O”: Hypotonia and weakness, Hypoponadism, obsessive</td>
<td>Ataxia with severe intellectual disability, seizures, tremulousness, hypotonia Midface hypoplasia, fair hair, uncontrollable laughter</td>
<td>“CHARGE”</td>
</tr>
<tr>
<td></td>
<td>Cyanotic CHD</td>
<td>Hyperphagia, Obesity</td>
<td></td>
<td>C Coloboma</td>
</tr>
<tr>
<td></td>
<td>Anomalies: craniofacial anomalies</td>
<td>Short stature, almond-shaped eyes, small hands and feet with tapering of fingers</td>
<td></td>
<td>H Congenital Heart disease</td>
</tr>
<tr>
<td></td>
<td>Typically micognathia and low set ears</td>
<td>Developmental delay (variable)</td>
<td></td>
<td>A Choanal Atresia</td>
</tr>
<tr>
<td></td>
<td>Tympanic hypoplasia: “immunodeficiency” recurrent infections</td>
<td>Hypopigmentation, type 2 DM</td>
<td></td>
<td>R Mental Retardation</td>
</tr>
<tr>
<td></td>
<td>Cognitive impairment</td>
<td></td>
<td></td>
<td>G GU anomalies</td>
</tr>
<tr>
<td></td>
<td>Hypoparathyroidism, hypocalcemia</td>
<td></td>
<td></td>
<td>E Ear anomalies</td>
</tr>
<tr>
<td></td>
<td>22q11 microdeletions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>High risk for psychiatric disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**DUCHEINNE MUSCULAR DYSTROPHY**

**Epidemiology**
- 1:4,000 males

**Etiology**
- one type of muscular dystrophy characterized by progressive skeletal and cardiac muscle degeneration
- X-linked recessive: 1/3 spontaneous mutations, 2/3 inherited mutations
- missing structural protein (dystrophin) → muscle fibre fragility → fibre breakdown → necrosis and regeneration

**Clinical Presentation**
- proximal muscle weakness by age 3, positive Gower’s sign, waddling gait, toe walking
- pseudohypertrophy of calf muscles (muscle replaced by fat) and wasting of thigh muscles
- decreased reflexes
- non-progressive delayed motor and cognitive development (dysfunctional dystrophin in brain)
- cardiomyopathy

**Diagnosis**
- molecular genetic studies of dystrophin gene (DMD) (first line)
- family history (pedigree analysis)
- increased CK (50-100x normal) and lactate dehydrogenase
- elevated transaminases
- muscle biopsy, EMG

**Management**
- supportive (e.g. physiotherapy, wheelchairs, braces), prevent obesity
- cardiac health monitoring and early intervention
- bone health monitoring and intervention (vitamin D, bisphosphonates)
- steroids (e.g. prednisone or deflazacort)
- surgical (for scoliosis)
- gene therapy trials underway

**Complications**
- patient usually wheelchair-bound by 12 yr of age
- early flexion contractures, scoliosis, osteopenia of immobility, increased risk of fracture
- death due to pneumonia/respiratory failure or CHF in 2nd-3rd decade

**Metabolic Diseases**
- inherited disorders of metabolism; often autosomal recessive
- infants and older children may present with FTT or developmental delay
- universal newborn screening in Ontario includes metabolic disorders
Table 21. Metabolic Disorders

<table>
<thead>
<tr>
<th>Examples of Conditions</th>
<th>Organic and Amino Acid Disorders</th>
<th>Carbohydrate Disorders</th>
<th>Fatty Acid Disorders</th>
<th>Organelle Disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>PKU</td>
<td>Galactosemia</td>
<td>MCAD deficiency</td>
<td>Mucopolysaccharidoses</td>
<td></td>
</tr>
<tr>
<td>Tyrosinemia</td>
<td>GSDs: von Gierke’s, Pompe’s, Car’s, Andersen, McArdle</td>
<td>Carnitine deficiency</td>
<td>Congenital disorders of glycosylation</td>
<td></td>
</tr>
<tr>
<td>Homocystinuria</td>
<td></td>
<td></td>
<td>Lysosomal storage diseases: Hurler’s, Niemann-Pick, Tay-Sachs, Gaucher, Fabry, Krabbe</td>
<td></td>
</tr>
<tr>
<td>MSUD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alkaptonuria</td>
<td>Sweet-smelling urine (MSUD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urea cycle defects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical Manifestations</th>
<th>Irritability, lethargy, poor feeding</th>
<th>Vomiting and acidosis after feeding initiation</th>
<th>Lethargy, poor feeding</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Seizures</td>
<td>Growth retardation, FTT</td>
<td>Seizures/early-onset severe epilepsy</td>
</tr>
<tr>
<td></td>
<td>Intellectual disability</td>
<td></td>
<td>Acute and chronic encephalopathy</td>
</tr>
<tr>
<td></td>
<td>Vomiting and acidosis after feeding</td>
<td></td>
<td>Developmental delay</td>
</tr>
<tr>
<td></td>
<td>initiation</td>
<td></td>
<td>Bone crises (Gaucher)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Deafness, blindness</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Laboratory Findings</th>
<th>Hypoglycemic hyperammonemia, high anion gap (organic acidemia)</th>
<th>Hypoglycemia, hyperlipidemia (GSD)</th>
<th>Hypoketotic hypoglycemia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normoglycemic hyperammonemia, normal anion gap (urea cycle defects)</td>
<td>Elevated free fatty acids</td>
<td>Elevated urine oligosaccharides (oligosaccharidoses) and glycosaminoglycans (mucopolysaccharidoses)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Physical Exam</th>
<th>Hypotonia/Hypertonia</th>
<th>Infantile cataracts (galactosemia)</th>
<th>Hepatomegaly</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Microcephaly, musty odour, eczema, hypoglycemia (PKU)</td>
<td>Hepatomegaly (galactosemia)</td>
<td>Hypotonia</td>
</tr>
<tr>
<td></td>
<td>Dark urine, pigmented sclerae, arthralgias (alkaptonuria)</td>
<td>Muscle weakness/cramping</td>
<td>Dysemorphic facial features</td>
</tr>
<tr>
<td></td>
<td>Lens subluxation, marfanoid appearance (homocystinuria)</td>
<td></td>
<td>Macrocephaly (Tay-Sachs, Hurler’s)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatosplenomegaly (not Tay-Sachs)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cherry-red spot on macula (Niemann-Pick, Tay-Sachs, Gaucher’s)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Corneal clouding (Hurler’s)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Infantile cataract (Fabry)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Peripheral neurethropy (Fabry, Krabbe)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Spasticity</td>
</tr>
</tbody>
</table>

Initial Investigations
- important to send lab studies at initial presentation in order to facilitate immediate diagnosis and treatment
- check newborn screening results
- electrolytes, ABGs (calculate anion gap, rule out acidosis)
- CBC with differential and smear
- blood glucose (hypoglycemia seen with organic acidemia, fatty acid oxidation defects, and GSDs)
- lactate, ammonium (hyperammonemia with urea cycle defects), plasma Ca²⁺ and Mg²⁺
- routine urinalysis: ketonuria must be investigated
- carnitine levels with acylcarnitine profile
- others: urate, urine nitroprusside, plasma amino acid screen, urine organic acids, CSF glycine, free fatty acids (3-β-hydroxybutyrate ratio >4 in fatty acid oxidation defect)
- storage diseases: urine mucopolysaccharide and oligosaccharide screen

Treatment
- varies according to inborn error of metabolism
- dietary restrictions, supplementation, enzyme replacement therapy, gene therapy, liver transplant, stem cell transplant

PHENYLKETONURIA

Epidemiology
- 1:10,000; autosomal recessive disease

Etiology
- deficiency of phenylalanine hydroxylase prevents conversion of phenylalanine to tyrosine leading to build up of toxic metabolites
- mothers who have PKU may have infants with congenital abnormalities

Clinical Presentation
- baby is normal at birth, then develops a musty odour, eczema, hypertonia, tremors, and mental retardation
- hypopigmentation due to low tyrosine (fair hair, blue eyes)

Management
- PKU screening at birth
- dietary restriction of phenylalanine starting within the first 10 d of life
- duration of dietary restriction controversial – lifelong or until end of puberty; should be resumed during pregnancy to maintain normal phenylalanine levels
- large neutral amino acid (tyrosine) replacement, BH4 enzyme treatment, phenylalanine lyase treatment are other options
GALACTOSEMIA

Epidemiology
• 1:60,000; autosomal recessive disease

Etiology
• most commonly due to deficiency of galactose-1-phosphate uridylyltransferase leading to an inability to process lactose/galactose

Clinical Presentation
• signs of liver and renal failure, jaundice, FTT, and cataracts with ingestion of lactose/galactose

Management
• elimination of galactose from the diet (e.g. dairy, breast milk)
• most infants are fed a soy-based diet

Complications
• increased risk of sepsis, especially E. coli
• if the diagnosis is not made at birth, liver and brain damage may become irreversible

Hematology

Approach to Anemia

Physiologic Anemia
• high Hb (>170 g/L) and reticulocyte count at birth is caused by a hypoxic environment in utero
• after birth, levels start to fall due to shorter fetal RBC lifespan, decreased RBC production (during first 6-8 wk of life, there is virtually no erythropoiesis due to new O₂ rich environment), and increasing blood volume secondary to growth
• lowest levels about 100 g/L at 8-12 wk age (earlier and more exaggerated in premature infants); levels rise spontaneously with activation of erythropoiesis
• usually no treatment required

Iron Deficiency Anemia
• most common cause of childhood anemia
• full term infants exhaust iron reserves by 6 mo of age
• premature infants have lower reserves, therefore exhausted by 2-3 mo of age
• common diagnosis between 6 mo-3 yr and 11-17 yr due to periods of rapid growth and increased iron requirements; adolescents also have poor diet and menstrual losses

Etiology
• children at risk (premature, LBW, low SES, etc.)
• dietary risk factors: whole cow milk in first year of life
• age >6 mo: <2 servings/d of iron-fortified cereal, red meat, or legumes
• age <12 mo: use of low-iron formula (<10 mg/L), primary diet of cow, goat, or soy milk

Normal Hb Values by Age

<table>
<thead>
<tr>
<th>Age</th>
<th>Hb Range (g/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newborn</td>
<td>137-201</td>
</tr>
<tr>
<td>2 wk</td>
<td>130-200</td>
</tr>
<tr>
<td>3 mo</td>
<td>95-145</td>
</tr>
<tr>
<td>6 mo-6 yr</td>
<td>105-140</td>
</tr>
<tr>
<td>7-12 yr</td>
<td>110-160</td>
</tr>
<tr>
<td>Adult female</td>
<td>120-160</td>
</tr>
<tr>
<td>Adult male</td>
<td>140-180</td>
</tr>
</tbody>
</table>
• age 1-5 yr: >16-20 oz/d of non-fortified milk
• blood loss
  ■ iatrogenic: repeated blood sampling (especially in hospitalized neonates)
  ■ allergic: cow milk protein-induced colitis

**Clinical Manifestation**
• usually asymptomatic until marked anemia, pallor, fatigue, pica (eating non-food materials), tachycardia, systolic murmur, angular cheilitis, koilonychias

**Investigations**
• CBC: low Hb, MCV, and MCH, reticulocyte count normal or high (absolute number low)
• Mentzer index (MCV/RBC) can help distinguish iron deficiency anemia from thalassemia
  ■ ratio <13 suggests thalassemia; ratio >13 suggests iron deficiency
• blood smear: hypochromic, microcytic RBCs, pencil shaped cells, poikilocytosis
• iron studies: low ferritin, other (low iron, high total iron binding capacity, high transferrin, low transferrin saturation)
• initial therapy: trial of iron

**Prevention**
• breastfed term infants: begin iron supplementation (1 mg/kg/d) at 4-6 mo, continuing until able to eat ≥2 feeds/d of iron-rich foods
• non-breastfed (<50% of diet) term infants: give iron-fortified formula from birth
• premature infants: give iron supplements from 1 mo through to 1 yr of age
• no cow’s milk until 9-12 mo, early introduction of red meat and iron-rich vegetables: total daily iron should be 11 mg (age 6-12 mo), 7 mg (age 1-3 yr)
• universal screening of Hb levels recommended at 9 mo

**Management**
• encourage diverse, balanced diet, limit homogenized milk to 16-20 oz/d
• oral iron therapy: 6 mg/kg/d elemental iron, divided bid to tid, for 3 mo
  ■ increased reticulocyte count in 2-3 d (peaks day 5-7)
  ■ increased hemoglobin in 4-30 d
  ■ repletion of iron stores in 1-3 mo
  ■ repeat hemoglobin levels after 1 mo of treatment
• poor response to oral iron therapy: non-compliance, medication intolerance, ongoing blood loss, IBD, celiac disease, incorrect diagnosis

**Complications**
• can cause irreversible effects on development if untreated (behavioural and intellectual deficiencies)
• angular cheilitis, glossitis, koilonychia (spoon nails)

---

**Vitamin K Deficiency**

**Etiology**
• hemorrhagic disease of the newborn due to relative deficiencies of vitamin K-dependent coagulation factors
  ■ generalized bleeding; GI/intracranial hemorrhage
• IM injection at birth, can also be given orally (3 doses: at birth, 2-4 wk, 6-8 wk) but infants at higher risk of HDNB
• reason for administration at birth:
  ■ human milk contains small amounts of vitamin K, and infants require ingestion of large volumes of human milk to promote GI bacterial colonization
  ■ until few days after birth, susceptible to vitamin K deficiency

---

**Anemia of Chronic Disease**
• see Hematology, H13

**Sickle Cell Disease**
• see Hematology, H20

**Thalassemia**
• see Hematology, H18
**Hematology Toronto Notes 2017**

### Hereditary Spherocytosis
- see Hematology, H22

**Glucose-6-Phosphate Dehydrogenase Deficiency**
- see Hematology, H23

### Bleeding Disorders
- see Hematology, H27

#### Table 22. Evaluation of Abnormal Bruising/Bleeding

<table>
<thead>
<tr>
<th></th>
<th>PFA</th>
<th>PT</th>
<th>PTT</th>
<th>VIII:C</th>
<th>vWF</th>
<th>Platelets</th>
<th>Fibrinogen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemophilia A</td>
<td>N</td>
<td>N</td>
<td>↑</td>
<td>↓</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>Hemophilia B</td>
<td>N</td>
<td>N</td>
<td>↑</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>von Willebrand Disease</td>
<td>↑</td>
<td>N</td>
<td>N or ↑</td>
<td>↓</td>
<td>N</td>
<td>↓</td>
<td>N</td>
</tr>
<tr>
<td>DIC</td>
<td>N or ↑</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>N</td>
<td>↓</td>
<td>N</td>
</tr>
<tr>
<td>Vitamin K Deficiency</td>
<td>N</td>
<td>↑</td>
<td>↑</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>↑</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>↓</td>
<td>N</td>
</tr>
</tbody>
</table>

DIC = disseminated intravascular coagulation; PFA = platelet function assay; VIII:C = Factor VIII coagulant activity; vWF = von Willebrand Factor

### Immune Thrombocytopenic Purpura

**Epidemiology**
- most common cause of thrombocytopenia in childhood
- peak age: 2-6 yr, M:F
- incidence 5:100,000 children per year

**Etiology**
- caused by autoantibodies that bind to platelet membranes → Fc-receptor mediated splenic uptake → destruction of platelets

**Clinical Presentation**
- 50% present 1-3 wk after viral illness (URTI, chicken pox)
- sudden onset of petechiae, purpura, epistaxis in an otherwise well child
- clinically significant bleed in only 3% (severe bleed more likely with platelet count <10) with <0.5% risk of intracranial bleed
- no lymphadenopathy, no hepatosplenomegaly
- labs: thrombocytopenia with normal RBC, WBC
- bone marrow aspirate only if atypical presentation (≥1 cell line abnormal, hepatosplenomegaly)
- differential diagnosis: leukemia, drug-induced thrombocytopenia, HIV, infection (viral), autoimmune (SLE, ALPS)

**Management**
- observation vs. pharmacologic intervention highly debated; spontaneous recovery in >70% of cases within 3 mo
- treatment with IVIg or prednisone if mucosal or internal bleeding, platelets <10, or at risk of significant bleeding (surgery, dental procedure, concomitant vasculitis or coagulopathy)
- life-threatening bleed: additional platelet transfusion ± emergency splenectomy
- persistent (>3-12 mo) or chronic (>12 mo): re-evaluate; treat if symptoms persist
- supportive: avoid contact sports and ASA/NSAIDs

### Hemophilia
- see Hematology, H31

### von Willebrand’s Disease
- see Hematology, H30
**Oncology**

- cancer is the second most common cause of death after injuries in children after 1 yr of age
- cause is rarely known, but increased risk for children with: chromosomal syndromes (e.g. Trisomy 21), cancer predisposition syndromes (e.g. Li-Fraumeni syndrome), prior malignancies, neurocutaneous syndromes, immunodeficiency syndromes, family history, exposure to radiation, chemicals, biologic agents
- leukemias are the most common type of pediatric malignancy (30%) followed by brain tumours (25%), and lymphomas (15%)
- some malignancies are more prevalent in certain age groups
  - newborns: neuroblastoma, Wilms' tumour, retinoblastoma
  - infancy and childhood: leukemia, neuroblastoma, CNS tumours, Wilms' tumour, retinoblastoma
  - adolescence: lymphoma, gonadal tumours, germ cell tumours, bone tumours
- unique treatment considerations in pediatrics because radiation, chemotherapy, and surgery can impact growth and development, endocrine function, and fertility
- good prognosis: treatments have led to remarkable improvements in overall survival and cure rates for many pediatric cancers (>80%)

**Lymphadenopathy**

**Clinical Presentations**

- features of malignant lymphadenopathy: firm, discrete, non-tender, enlarging, immobile ± suspicious mass/imaging findings ± constitutional symptoms
- fluctuance, warmth, or tenderness are more suggestive of benign nodes (infection)

**Differential Diagnosis**

- infection
  - viral: URTI, EBV, CMV, adenovirus, HIV
  - bacterial: *S. aureus*, GAS, anaerobes, *Mycobacterium* (e.g. TB), cat scratch disease (*Bartonella*)
  - other: fungal, protozoan, *Rickettsia*
- autoimmune: rheumatoid arthritis, SLE, serum sickness
- malignancy: lymphoma, leukemia, metastatic solid tumours
- storage diseases: Niemann-Pick, Gaucher's
- other: sarcoidosis, Kawasaki disease, histiocytoses

**Investigations**

- generalized lymphadenopathy
  - CBC and differential, blood culture
  - uric acid, LDH
  - ANA, RF, ESR
  - EBV/CMV/HIV serology
  - toxoplasma titre
  - fungal serology
  - CXR
  - TB tests
  - biopsy
- regional lymphadenopathy
  - period of observation if asymptomatic
  - trial of oral antibiotics
  - ultrasound
  - biopsy (especially if persistent >6 wk and/or constitutional symptoms)

**Leukemia**

- see Hematology, H37

**Epidemiology**

- mean age of diagnosis 2-5 yr but can occur at any age
- heterogeneous group of diseases
  - ALL (80%)
  - AML (15%)
  - CML (<5%)
- children with DS are 15x more likely to develop leukemia

**Clinical Presentation**

- infiltration of leukemic cells into bone marrow results in bone pain and bone marrow failure (anemia, neutropenia, thrombocytopenia)
- infiltration into tissues results in lymphadenopathy, hepatosplenomegaly, CNS manifestations, testicular disease
- fever, fatigue, weight loss, bruising, and easy bleeding
- hyperleukocytosis (total WBC >100 x 10^9/L) is a medical emergency
  - presents clinically with respiratory or neurological distress caused by hyperviscosity of blood and leukostasis
  - risk of ICH, pulmonary leukostasis syndrome, tumour lysis syndrome
- management: fluids, allopurinol/rasburicase, fresh frozen plasma/platelets to correct thrombocytopenia, induction chemotherapy, avoid transfusing RBCs unless symptomatic (and then use very small volumes)
Management
- combination chemotherapy using non-cross resistant chemotherapy agents, allogeneic stem cell transplantation for high-grade or recurrent disease
- supportive care and management of treatment complications
  - febrile neutropenia: see Infectious Diseases, ID45
  - tumour lysis syndrome: see Hematology, H52

Prognosis
- 80-90% 5 yr event-free survival for ALL, 50-60% 5-yr survival for AML
- patients are stratified into standard risk and high risk based on WBC and age; other prognostic factors include presence of CNS/testicular disease, immunophenotype, cytogenetics, and initial response to therapy (most important prognostic variable)

Lymphoma
- see Hematology, H45

Epidemiology
- Hodgkin lymphoma: incidence is bimodal, peaks at ages 15-34 and >50 yr old
- non-Hodgkin lymphoma: incidence peaks at 7-11 yr

Clinical Presentation
- Hodgkin lymphoma
  - most common presentation is persistent, painless, firm, cervical or supraclavicular lymphadenopathy
  - can present as persistent cough or dyspnea (secondary to mediastinal mass) or less commonly as splenomegaly, axillary, or inguinal lymphadenopathy
  - constitutional symptoms in 30% of children
  - lymph nodes become sequentially involved as disease spreads
- non-Hodgkin lymphoma
  - generally categorized into lymphoblastic, large cell, and Burkitt's/Burkitt's-like lymphoma
  - rapidly growing tumour with distant metastases (unlike adult non-Hodgkin lymphoma)
  - signs and symptoms related to disease site: most commonly abdomen, chest (mediastinal mass), head and neck region

Management
- Hodgkin lymphoma
  - combination chemotherapy and radiation
  - aimed at limiting cumulative doses of anthracyclines (toxic to heart) and alkylators (risk of second malignancy, infertility) and limiting dose and field of radiation
  - increasing role for use of PET scanning to assess early disease response and plan therapy
- non-Hodgkin lymphoma
  - combination chemotherapy
  - no added benefit of radiation in pediatric protocols

Prognosis
- Hodgkin lymphoma: >90% 5 yr survival
- non-Hodgkin lymphoma: 75-90% 5 yr survival

Brain Tumours
- see Neurosurgery, NS11

Wilms’ Tumour (Nephroblastoma)

Epidemiology
- usually diagnosed between 2-5 yr; M=F
  - most common primary renal neoplasm of childhood
  - 5-10% of cases both kidneys are affected (simultaneously or in sequence)

Differential Diagnosis
- hydronephrosis, polycystic kidney disease, renal cell carcinoma, neuroblastoma

Clinical Presentation
- 80% present with asymptomatic, unilateral abdominal mass
- may also present with HTN, gross hematuria, abdominal pain, vomiting
- may have pulmonary metastases at time of diagnosis (respiratory symptoms)
Associated Congenital Abnormalities
- WAGR syndrome (Wilms' tumour, Aniridia, Genital anomalies, mental Retardation) with 11p13 deletion
- Beckwith-Wiedemann syndrome:
  - characterized by enlargement of body organs (especially tongue), hemihypertrophy, renal medullary cysts, and adrenal cytomegaly
  - also at increased risk for developing hepatoblastoma, and less commonly adrenocortical tumours, neuroblastomas, and rhabdomyosarcomas
- Denys-Drash syndrome: characterized by gonadal dysgenesis and nephropathy leading to renal failure

Management
- staging ± nephrectomy
- chemotherapy, radiation for higher stages

Prognosis
- 90% long-term survival

Neuroblastoma

Epidemiology
- most common cancer occurring in first year of life
- neural crest cell tumour arising from sympathetic tissues (neuroblasts)

Clinical Presentation
- can originate from any site in sympathetic nervous system, presenting as mass in neck, chest, or abdomen (most common site is adrenal gland)
- signs and symptoms of disease vary with location of tumour
  - thoracic: dyspnea, Horner's syndrome
  - abdomen: palpable mass
  - spinal cord compression
- metastases are common at presentation (>50% present with advanced stage disease):
  - usually to bone or bone marrow (presents as bone pain, limp)
  - can also present with periorbital ecchymoses, abdominal pain, emesis, fever, weight loss, anorexia, hepatalogy, "blueberry muffin" skin nodules
  - paraneoplastic: HTN, palpitations, sweating (from excessive catecholamines), diarrhea, FTT (from vasoactive intestinal peptide secretion), opsomyoclonus

Management
- depends on prognostic factors and may include combination of: surgery, radiation, chemotherapy, autologous stem cell transplantation, immunotherapy

Prognosis
- prognosis is often poor due to late detection
- good prognostic factors
  - "age and stage" are important determinants of better outcome: <18 mo, stage I, II, IV-S disease ("S" designates a "Special" classification only pertaining to infants)
  - primary site: posterior mediastinum and neck
  - low serum ferritin
  - more differentiated histology
  - tumour cell markers: aneuploidy, absent MYCN oncogene amplification

Bone Tumours
- see Orthopedics, OR45

Cancer Predisposition Syndromes
- suspected in cases of multiple primary neoplasms, especially early onset for cancer type and/or family history consistent with known cancer predisposition syndrome (critical to obtain family history and refer if syndrome suspected)
- cancer predisposition syndromes with pediatric onset include Li-Fraumeni syndrome (soft tissue sarcomas, osteosarcoma, CNS tumours and adrenal cortical carcinoma), hereditary retinoblastoma and Fanconi anemia (leukemias)
Infectious Diseases

Fever

Definition
- fever: a practical definition is >38°C/100.4°F oral or rectal
- fever without a source/focus: acute febrile illness (typically <10 d duration) with no cause of fever even after careful history and physical
- fever of unknown origin: daily or intermittent fevers for at least 2 consecutive weeks of uncertain cause after careful history and physical, and initial laboratory assessment

Etiology
- infectious: anatomic approach (CNS, ears, upper and lower respiratory tract, GI, GU, skin, soft tissue, bones and joints, etc.)
- inflammatory: mainly autoimmune (Kawasaki disease, JIA, IBD, SLE, etc.)
- malignancy: childhood cancers (leukemia, lymphoma, neuroblastoma, etc.)
- miscellaneous: dehydration, drugs and toxins, post-immunization, familial dysautonomia, factitious disorder, etc.

Diagnosis
- history: duration, height and pattern of fever, associated symptoms, exposures, constitutional symptoms, recent antipyretic use, ethnic or genetic background, day care, sick contacts, travel, tick bites, age of child
- physical exam: toxic vs. non-toxic, vitals, growth, complete exams of the skin, HEENT, chest, abdomen, lymph nodes, genitalia
- investigations: guided by history, physical exam, and clinical suspicion

Evaluation of Neonates and Infants with Fever
- several protocols exist that attempt to identify neonates and young infants at low risk of serious bacterial infection (e.g. Rochester Criteria)
  - such protocols are not as sensitive in the 1-28 d age group; therefore, febrile neonates should be considered high risk regardless of clinical presentation and laboratory findings

Management
- admit to hospital if appropriate
- treat the source if known
- replace fluid losses (e.g. from vomiting, diarrhea, etc.); maintenance fluid needs are higher in febrile child
- reassure parents that most fevers are benign and self-limited
- antipyretics (acetaminophen and/or ibuprofen) are not necessary in most cases, but can be given if child is uncomfortable

![Image of fever management flowchart]

NOTES
1. SWU = Septic Workup
2. Partial Septic Workup = blood C&S, CBC and differential, urine R&M, C&S, LP, CXR if respiratory symptoms, stool C&S if GI symptoms
3. Follow-up is crucial – if adequate follow-up is not assured, a more aggressive diagnostic and therapeutic approach may be indicated
4. Low-risk (Rochester) criteria
5. Considerable practice variation exists in terms of empiric antibiotic treatment
6. Important principles – the younger the child, the greater the difficulty to clinically assess the degree of illness

Figure 11. Approach to the febrile child
Acute Otitis Media

All of:
1. presence of middle ear effusion
2. presence of middle ear inflammation
3. acute onset of symptoms of middle ear effusion and inflammation

Epidemiology
- 60-70% of children have at least 1 episode of AOM before 3 yr of age
- 18 mo-6 yr most common age group
  - 22% of children in this age range will develop AOM in the first week of a viral URI
  - one third of children have had ≥3 episodes by age 5, peak incidence January to April

Etiology
- S. pneumoniae: 32% of cases (decreasing since the introduction of PCV7 and PCV 13)
- H. influenzae (non-typeable): >50% of refractory AOM
- M. catarrhalis: 14% of cases - less virulent
- GAS
- viral – more likely to spontaneously resolve
- less common - anaerobes (newborns), Gram-negative enterics (infants)

Predisposing Factors
- Eustachian tube dysfunction/obstruction
  - swelling of tubal mucosa: URTI, allergic rhinitis, chronic rhinosinusitis
  - obstruction/infiltration of Eustachian tube ostium: adenoid hypertrophy (not due to obstruction but by maintaining a source of infection), barotrauma (sudden changes in air pressure)
  - inadequate tensor palatini function: cleft palate (even after repair)
- abnormal Eustachian tube: gentic syndromes such as DS, Crouzon, Apert
- disruption of action of cilia of Eustachian tube: Kartagener’s syndrome, CF
- immunosuppression/deficiency due to chemotherapy, steroids, DM, hypogammaglobulinemia, CF

Risk Factors
- prolonged bottle feeding, while laying down and/or shorter duration of breast feeding
  - pacifier use
  - second-hand smoke
- crowded living conditions (day care/group child care facilities) or sick contacts
- family history of otitis media
- orofacial abnormalities
- immunodeficiency
- ethnicity – First Nations and Inuit
  - FOR recurrent AOM: lower levels of secretory IgA or persistent biofilms in the middle ear

Pathogenesis
- obstruction of Eustachian tube → air absorbed in middle ear → negative pressure (an irritant to middle ear mucosa) → edema of mucosa with exudate/effusion → infection of exudate from nasopharyngeal secretions

Clinical Features
- triad of otalgia, fever (especially in younger children), and conductive hearing loss
- rarely tinnitus, vertigo, and/or facial nerve paralysis
- otorrhea if tympanic membrane perforated
- infants/toddlers: ear-tugging (this alone is not a good indicator of pathology), hearing loss, balance disturbances (rare), irritable, poor sleeping, vomiting and diarrhea, anorexia
- otoscopy of TM: hyperemia, bulging, pus may be seen behind TM, loss of landmarks (e.g. handle and long process of malleus not visible)

Diagnosis
- most important criteria for AOM is a bulging TM (all children with bulging TM had AOM and only 8% of children with non-bulging TM had AOM) – Reference: Shaitz N, Hoberman A, Rockette HE, Kurs-Lasky M 2012

Infectious Diseases
Pediatrics Toronto Notes 2017
Acute Otitis Media
All of:
1. presence of middle ear effusion...

Clinical Assessment of AOM in Pediatrics
JAMA 2010;304:2161-2169
In assessment of AOM in pediatrics, ear pain is the most useful symptom with a LR between 3.0 and 7.3. Useful otoscopic signs include erythematous (LR 8.4, 95% CI 7-11), cloudy (LR 34, 95% CI 28-42), bulging (LR 51, 95% CI 36-73), and immobile tympanic membrane on pneumatic otoscopy (LR 31, 95% CI 26-37).
Management

• 1st line
  ■ amoxicillin 75-90 mg/kg/d divided into two doses: safe, effective, and inexpensive. Use high doses to overcome MIC for penicillin binding proteins (method of resistance)
  ■ if penicillin allergic: macrolide (clarithromycin, azithromycin – high resistance), trimethoprim-sulphamethoxazole (Bactrim®)
• 2nd line
  ■ amoxicillin-clavulanic acid (Clavulin®)
  ■ cephalosporins: cefuroxime axetil (Ceftin®), ceftriaxone (Rocephin®), cefaclor (Ceclor®), cefixime (Suprax®)
  ■ AOM deemed unresponsive if clinical signs/symptoms and otoscopic findings persist beyond 48 h of antibiotic treatment
  ■ use second line treatment for otitis-conjunctivitis syndrome (AOM with bacterial conjunctivitis) because H. influenzae and M. catarrhalis are more likely pathogens which are Beta lactamase producing, so Amoxil is ineffective
• symptomatic therapy: antipyretics/analgesics (e.g. acetaminophen), decongestants (may relieve nasal congestion but does not treat AOM)
• prevention: parent education about risk factors, pneumococcal and influenza vaccines, surgery (e.g. tympanostomy tubes)
  ■ choice of surgical therapy for recurrent AOM on whether local factors (Eustachian tube dysfunction) are responsible (use ventilation tubes), or regional disease factors (tonsillitis, adenoid hypertrophy, sinusitis) are responsible

Complications

• extracranial: hearing loss and speech delay (secondary to persistent middle ear effusion), TM perforation, extension of suppurative process to adjacent structures (mastoiditis, petrositis, labyrinthitis), cholesteatoma, facial nerve palsy, middle ear atelectasis, ossicular necrosis, vestibular dysfunction
• intracranial: meningitis, epidural and brain abscess, subdural empyema, lateral and cavernous sinus thrombosis, carotid artery thrombosis

Management of Acute Otitis Media

With or without fever and may or may not manifest other signs of middle ear dysfunction (e.g. vomiting) or pain, depending on age and verbal skills

Suspected acute otitis media

>6 mo of age, generally healthy

Acute onset of illness

Perforated tympanic membrane with purulent drainage

Treat with antimicrobials for 10 d

Mildly ill

Alert, responsive, no rigor, responding to antipyretics, mild otalgia, able to sleep

<39°C in absence of antipyretics

<48 h of illness

Bulging tympanic membrane

Moderately or severely ill

Irritable, difficulty sleeping, poor response to antipyretics, severe otalgia

OR >=39°C in absence of antipyretics

OR >48 h of symptoms

Consider viral etiology such as RSV, influenza, etc. or other infection

Reassess in 24-48 h if not clinically improved or if worsening, to verify presence of effusion and signs of middle ear inflammation such as bulging tympanic membrane

Treat with antimicrobials for 10 d if 6 mo-2 yr of age and for 5 d if >=2 yr

Without MEE

OR with MEE but non-bulging or mildly erythematous tympanic membrane

After discussing with caregivers, observe for 24-48 h and ensure follow-up medical care (recommned analgesia)

If not clinically improved or if worsening, treat with antimicrobials (10 d if 6 mo-2 yr of age and 5 d if >=2 yr)

MEE present

AND

Bulging tympanic membrane

>6 mo of age, generally healthy

Acute onset of illness

Without MEE

OR with MEE but non-bulging or mildly erythematous tympanic membrane

Consider viral etiology such as RSV, influenza, etc. or other infection

Reassess in 24-48 h if not clinically improved or if worsening, to verify presence of effusion and signs of middle ear inflammation such as bulging tympanic membrane

Treat with antimicrobials for 10 d if 6 mo-2 yr of age and for 5 d if >=2 yr

Figure 12. Management of acute otitis media

Flow diagram for the management of children with suspected and confirmed acute otitis media – from CPS statement Feb 2016
Otitis Media with Effusion

Definition
- presence of fluid in the middle ear without signs or symptoms of ear infection

Epidemiology
- most common cause of pediatric hearing loss
- not exclusively a pediatric disease
- follows AOM frequently in children
- middle ear effusions have been shown to persist following an episode of AOM for 1 mo in 40% of children, 2 mo in 20%, and >3 mo in 10%

Risk Factors
- same as AOM

Clinical Features
- conductive hearing loss ± tinnitus
- fullness – blocked ear
- ± pain, low grade fever
- otoscopy of TM
  - discolouration – amber or dull grey
  - meniscus fluid level behind TM
  - air bubbles
  - retraction pockets/TM atelectasis
  - flat tympanogram
- most reliable finding with pneumatic otoscopy is immobility

Treatment
- expectant: 90% resolve by 3 mo
- document hearing loss with audiogram (see Otolaryngology Figure 16B and Figure 17B, OT10-11)
- no statistical proof that antihistamines, decongestants, antibiotics clear disease faster
- surgery: myringotomy ± ventilation tubes ± adenoidectomy (if enlarged or on insertion of second set of tubes after first set falls out)
- ventilation tubes to equalize pressure and drain ear

Complications of OME
- hearing loss, speech delay, learning problems in young children
- chronic mastoiditis
- osicular erosion
- cholesteatoma especially when retraction pockets involve pars flaccida
- retraction of tympanic membrane, atelectasis, ossicular fixation

Gastroenteritis
- see Gastroenterology, P34

HIV Infection
- see Infectious Diseases, ID27
### Table 23. Common Infectious Pediatric Exanthems

<table>
<thead>
<tr>
<th>Disease</th>
<th>Pathogen(s)</th>
<th>Incubation Period</th>
<th>Communicability</th>
<th>Mode of Transmission</th>
<th>Rash</th>
<th>Associated Features</th>
<th>Management</th>
<th>Outcomes and Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erythema Infectiosum (i.e. Fifth Disease/Slapped Cheek)</td>
<td>Parvovirus B19</td>
<td>4-14 d</td>
<td>Low risk of transmission once symptomatic</td>
<td>Respiratory secretions or infected blood</td>
<td>Appearance: uniform, erythematous maculopapular ‘tac’ rash Timing: 10-17 d after symptoms (immune response) Distribution: bilateral cheeks (‘slapped cheeks’) with circumoral sparing; may affect trunk and extremities</td>
<td>Initial 7-10 d of flu-like illness and fever Rash may be warm, non-tender, and pruritic Less common presentations include ‘gloves and socks syndrome’ or STAR complex (sore throat, arthritis, rash)</td>
<td>Supportive</td>
<td>Rash fades over days to week, but may reappear months later with sunlight, exercise Aplastic crisis</td>
</tr>
<tr>
<td>Gianotti-Crosti Syndrome (i.e. Papular Acrodermatitis)</td>
<td>EBV and Hep B (majority)</td>
<td>Variable</td>
<td>None</td>
<td>—</td>
<td>Appearance: asymptomatic symmetric papules Distribution: face, cheeks, extensor surfaces of the extremities, spares trunk</td>
<td>Vinal prodrome May have lymphadenopathy and/or hepatosplenomegaly</td>
<td>Supportive</td>
<td>Pain control</td>
</tr>
<tr>
<td>Hand, Foot, and Mouth Disease</td>
<td>Coxsackie group A</td>
<td>3-5 d</td>
<td>Likely 1-7 d after symptoms but may be up to months</td>
<td>Direct and indirect contact with infected bodily fluids, fecal-oral</td>
<td>Appearance: vesicles and pustules on an erythematous base Distribution: acral. but may extend up the extremity</td>
<td>Enanthem: vesicles in the POSTERIOR oral cavity (pharynx, tongue)</td>
<td>Supportive</td>
<td>Mainly dehydration</td>
</tr>
<tr>
<td>Herpes Simplex</td>
<td>HSV 1,2</td>
<td>1-26 d</td>
<td>Direct contact, often through saliva for HSV-1 and sexual contact for HSV-2</td>
<td>Direct contact, often through saliva for HSV-1 and sexual contact for HSV-2</td>
<td>Grouped vesicles on an erythematous base</td>
<td>Enanthem: vesicles/erosions in the ANTERIOR oral cavity (buccal mucosa, tongue) May present with herpetic whitlow (autoinoculation)</td>
<td>Mainly supportive Consider oral or topical antivirals</td>
<td>Local: secondary skin infections, keratitis, gingivostomatitis CNS: encephalitis Disseminated hepatitis, DIC Ezema herpeticum</td>
</tr>
<tr>
<td>Kawasaki Disease</td>
<td>See P92</td>
<td></td>
<td></td>
<td>Airborne</td>
<td>Appearance: erythematous maculopapular Timing: 3 d after start of symptoms Distribution: starts at hairline and spreads downwards with sparing of palms and soles</td>
<td>Prodrome of cough, coryza, conjunctivitis (3 Cs) Enanthem: Koplik’s spots 1-2 d before rash Desquamation Positive serology for measles IgM</td>
<td>Infected: supportive Unimmunized contacts: measles vaccine within 72 h of exposure or IgG within 6 d of exposure Respiratory isolation, report to Public Health Prevention: MMR vaccine</td>
<td>Secondary bacterial infections: AOM, sinusitis, pneumonia Encephalitis Rare: myocarditis, pericarditis, thrombocytopenia, Stevens-Johnson syndrome, GN, subacute sclerosing panencephalitis</td>
</tr>
<tr>
<td>Measles</td>
<td>Morbillivirus</td>
<td>8-13 d</td>
<td>4 d before and after rash</td>
<td>Airborne</td>
<td>Appearance: erythematous maculopapular Timing: 3 d after start of symptoms Distribution: starts at hairline and spreads downwards with sparing of palms and soles</td>
<td>Prodrome of cough, coryza, conjunctivitis (3 Cs) Enanthem: Koplik’s spots 1-2 d before rash Desquamation Positive serology for measles IgM</td>
<td>Infected: supportive Unimmunized contacts: measles vaccine within 72 h of exposure or IgG within 6 d of exposure Respiratory isolation, report to Public Health Prevention: MMR vaccine</td>
<td>Secondary bacterial infections: AOM, sinusitis, pneumonia Encephalitis Rare: myocarditis, pericarditis, thrombocytopenia, Stevens-Johnson syndrome, GN, subacute sclerosing panencephalitis</td>
</tr>
<tr>
<td>Disease</td>
<td>Pathogen(s)</td>
<td>Incubation Period</td>
<td>Communicability</td>
<td>Mode of Transmission</td>
<td>Rash</td>
<td>Associated Features</td>
<td>Management</td>
<td>Outcomes and Complications</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------</td>
<td>-------------------</td>
<td>-----------------</td>
<td>---------------------------------------------------------------------------------------</td>
<td>-------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Non-Specific Enteroviral Exanthems</strong></td>
<td>Enteroviruses</td>
<td>Variable</td>
<td>Variable</td>
<td>Direct and indirect contact with infected bodily fluids</td>
<td>Polymorphous rash (macules, papules, vesicles, petechiae, urticaria)</td>
<td>Systemic involvement is rare, but possible</td>
<td>Supportive Diagnosis confirmed using viral cultures (NP and rectal swabs)</td>
<td>Self-limiting</td>
</tr>
<tr>
<td><strong>Roseola</strong></td>
<td>HHV 6</td>
<td>5-15 d</td>
<td>Unknown</td>
<td>—</td>
<td>Appearance: blanching, pink, maculopapular</td>
<td>High grade fever Common: irritability, anorexia, lymphadenopathy, erythematous TM and pharynx, Nagayama spots (erythematous papules on soft palate and uvula) Less common: cough, coryza, bulging fontanelles</td>
<td>Supportive</td>
<td>CNS: febrile seizures (10-25%), aseptic meningitis Thrombocytopenia</td>
</tr>
<tr>
<td><strong>Rubella</strong></td>
<td>Rubivirus</td>
<td>14-21 d</td>
<td>7 d before and after eruptions</td>
<td>Droplet</td>
<td>Appearance: pink, maculopapular Timing: 1-5 d after start of symptoms Distribution: starts on face and spreads to neck and trunk</td>
<td>Prodrome of low grade fever and occipital retroauricular nodes STAR complex (sore throat, arthritis, rash) Positive serology for rubella IgM. Caution to pregnant women with exposure</td>
<td>Infected: supportive Prevention: MMR vaccine Report to Public Health</td>
<td>Excellent prognosis with acquired disease Arthritis may last days to weeks Encephalitis Irreversible defects in congenitally infected patients (i.e. congenital rubella syndrome)</td>
</tr>
<tr>
<td><strong>Scarlet Fever</strong></td>
<td>See P58</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Varicella</strong></td>
<td>Varicella zoster virus</td>
<td>0-21 d</td>
<td>1-2 d pre-eruptions and 5 d post-eruption</td>
<td>Mainly airborne, but also through direct contact with vesicle fluid</td>
<td>Appearance: groups of skin lesions, polymorphic, from macules to papules to vesicles to crusts Timing: 1-3 d after start of symptoms Distribution: generalized</td>
<td>Significant pruritis Enanthem: vesicular lesions which may become pustular or ulcerate. Caution to pregnant women</td>
<td>Supportive Avoid salicylates (due to risk of Reye syndrome) Consider antivirals Respiratory and contact isolation, report to Public Health Prevention: varicella vaccine</td>
<td>Skin: bacterial suprainfection, necrotizing fasciitis CNS: acute encephalitis and cerebellar ataxia Systemic: hepatitis, DIC Congenital varicella syndrome if intrapartum infection</td>
</tr>
</tbody>
</table>
Infectious Mononucleosis

Definition
• systemic viral infection caused by EBV with multivisceral involvement; often called "the great imitator"

Epidemiology
• peak incidence between 15-19 yr old
• ~50% of children in developed countries have a primary EBV infection by 5 yr old, but <10% of children develop clinical infection

Etiology
• EBV: a member of herpeviridae
• transmission is mainly through infected saliva ("kissing disease") and sexual activity (less commonly); incubation period of 1-2 mo

Risk Factors
• infectious contacts, sexually active, multiple sexual partners in the past

History
• prodrome: 2-3 d of malaise, anorexia
• infants and young children: often asymptomatic or mild disease
• older children and adolescents: malaise, fatigue, fever, sore throat, abdominal pain (often LUQ), headache, myalgia

Physical Exam
• classic triad: febrile, generalized non-tender lymphadenopathy, pharyngitis/tonsillitis (exudative)
• ± hepatosplenomegaly
• ± periorbital edema, ± rash (urticarial, maculopapular, or petechial) – more common after inappropriate treatment with β-lactam antibiotics
• any "-itis" (including arthritis, hepatitis, nephritis, myocarditis, meningitis, encephalitis, etc.)

Investigations
• heterophil antibody test (Monospot® test)
  ■ 85% sensitive in adults and older children, but only 50% sensitive if <4 yr of age
  ■ false positive results with HIV, SLE, lymphoma, rubella, parvovirus
• EBV titres
• CBC and differential, blood smear: reactive lymphocytes, lymphocytosis, Downey cells ± anemia ± thrombocytopenia
• throat culture to rule out streptococcal pharyngitis

Management
• supportive: adequate rest, hydration, saline gargles, and analgesics for sore throat
• splenic enlargement is often not clinically apparent so all patients should avoid contact sports for 6-8 wk
• if airway obstruction secondary to nodal and/or tonsillar enlargement is present (especially younger children), admit for steroid therapy
• acyclovir does NOT reduce duration of symptoms or result in earlier return to school/work

Prognosis
• most acute symptoms resolve in 1-2 wk, though fatigue may last for months
• short-term complications: splenic rupture, Guillain-Barré syndrome

Infectious Pharyngitis/Tonsillitis

Definition
• inflammation of the pharynx, especially the tonsils if present, causing a sore throat

Etiology
• viral (~80%): adenoviruses, enteroviruses, coxsackie, upper respiratory tract viruses, EBV, CMV
• bacterial (~20%): mainly GAS, M. pneumoniae (older children), N. gonorrhoeae (sexually active), C. diphtheriae (unvaccinated), Fusobacterium necrophorum (anaerobe causing Lemierre syndrome)
• fungal: Candida

Epidemiology
• season: GAS pharyngitis more common in late winter or early spring; viral all year long
• age: GAS pharyngitis peak incidence at 5-12 yr of age and uncommon <3 yr; viral pharyngitis affects all ages

History
• GAS: sore throat (may be severe), fever, malaise, headache, abdominal pain, N/V, absence of other URTI symptoms
• viral: sore throat (often mild), conjunctivitis, cough, rhinorrhea, hoarseness, diarrhea, flu-like symptoms (fever, malaise, myalgias)
Physical Exam

- GAS: febrile, pharyngeal/tonsillar erythema and exudates, enlarged (>1 cm) and tender anterior cervical lymph nodes, palatal petechiae, strawberry tongue, scarlatiniform rash
- viral: afebrile, absent/mild tonsillar exudates, minor and non-tender adenopathy, viral exanthems

Investigations

- no single sign or symptom reliably identifies GAS as the causative organism in children with sore throat
- scores are used to predict if throat culture will be positive (e.g. McIsaac Criteria)
  - these score systems have not been found to be sensitive or specific enough to diagnose GAS in children and adolescents with sore throat
- suspected diagnosis of GAS pharyngitis should be confirmed with a rapid streptococcal antigen test and a follow-up throat culture if the rapid test is negative

Management

- antibiotics (for GAS/S. pyogenes)
  - penicillin V or amoxicillin or erythromycin (if penicillin allergy) x 10 d
  - can prevent rheumatic fever if given within 9 d of symptoms; does NOT alter risk of post-streptococcal GN
- supportive: hydration and acetaminophen for discomfort due to pain and/or fever
- follow-up: if uncomplicated course, no follow-up or post-antibiotic throat cultures needed
- prophylaxis: consider tonsillectomy for proven, recurrent streptococcal tonsillitis

Complications

- preventable with antibiotics: AOM, sinusitis, cervical adenitis, mastoiditis, retropharyngeal/peritonsillar abscess, sepsis
- immune-mediated complications: scarlet fever, acute rheumatic fever, post-streptococcal GN, reactive arthritis, pediatric autoimmune neuropsychiatric disorder associated with group A streptococci (i.e. PANDAS)

SCARLET FEVER

- diffuse erythematous eruption
- delayed-type hypersensitivity reaction to pyrogenic exotoxin produced by GAS
- acute onset of fever, sore throat, strawberry tongue
- 24-48 h after pharyngitis, rash begins in the groin, axillae, neck, antecubital fossa; Pastia’s lines may be accentuated in flexural areas
- within 24 h, sandpaper rash becomes generalized with perioral sparing, non-pruritic, non-painful, blanchable
- rash fades after 3-4 d, may be followed by desquamation
- treatment is penicillin, amoxicillin, or erythromycin x 10 d

RHEUMATIC FEVER

- inflammatory disease due to antibody cross-reactivity following GAS infection
- affects ~1:10,000 children in developed world; much more prevalent in developing nations; peak incidence at 5-15 yr of age
- mainly a clinical diagnosis based on Jones Criteria (revised)
  - requires 2 major OR 1 major and 2 minor PLUS evidence of preceding strep infection (history of scarlet fever, GAS pharyngitis culture, positive rapid Ag detection test, ASOTs)
- treatment: penicillin or erythromycin for acute course x 10 d, prednisone if severe carditis
- secondary prophylaxis with daily penicillin or erythromycin
- complications
  - acute: myocarditis, conduction system aberrations (sinus tachycardia, atrial fibrillation), valvulitis (acute MR), pericarditis
  - chronic: valvular heart disease (mitral and/or aortic insufficiency/stenosis), infectious endocarditis ± thromboembolic phenomenon
  - onset of symptoms usually after 10-20 yr latency from acute carditis of rheumatic fever

POST-STREPTOCOCCAL GLOMERULONEPHRITIS

- most common in children aged 4-8 yr old; M>F
- antigen-antibody mediated complement activation with diffuse, proliferative GN
- occurs 1-3 wk following initial GAS infection (skin or throat)
- clinical presentation varies from asymptomatic, microscopic and macroscopic hematuria (cola-coloured urine) to all features of nephritic syndrome (see Nephritic Syndrome, P77)
- diagnosis is confirmed with elevated serum antibody titres against streptococcal antigens (ASOT, anti-DNAse B), low serum complement (C3)
- management
  - symptomatic: fluid and sodium restrictions; loop diuretics for HTN and edema
  - in severe cases, may require dialysis if renal function significantly impaired
  - treat with penicillin or erythromycin if evidence of persistent GAS infection
  - 95% of children recover completely within 1-2 wk; 5-10% have persistent hematuria
Meningitis

Definition
- inflammation of the meninges surrounding the brain and spinal cord

Epidemiology
- peak age: 6-12 mo; 90% of cases occur in children <5 yr old

Etiology
- viral: enteroviruses, HSV
- bacterial: age-related variation in specific pathogens
- fungal and parasitic meningitis also possible
- most often due to hematogenous spread or direct extension from a contiguous site

Risk Factors
- unvaccinated
- immunocompromised: asplenia, DM, HIV, prematurity
- recent or current infections: AOM, sinusitis, orbital cellulitis
- neuroanatomical: congenital defects, dermal sinus, neurosurgery, cochlear implants, recent head trauma
- exposures: day care centres, household contact, recent travel

History
- signs and symptoms variable and dependent on age, duration of illness, and host response to infection
- infants: fever, lethargy, irritability, poor feeding, vomiting, diarrhea, respiratory distress, seizures
- children: fever, headache, photophobia, N/V, confusion, back/neck pain/stiffness, lethargy, irritability

Physical Exam
- infants: toxic, hypothermia, bulging anterior fontanelle, respiratory distress, apnea, petechial/purpuric rash, jaundice
- children: toxic, LOC, nuchal rigidity, Kernig's and Brudzinski's signs, focal neurologic findings, petechial/purpuric rash

Investigations
- blood work: CBC, electrolytes, Cr, BUN, glucose, C&S
- LP required for definitive diagnosis
  - Gram stain, bacterial C&S, WBC count and differential, RBC count, glucose, protein concentration
  - acid-fast stain if suspect TB
  - PCR for specific bacteria if available (helpful if already treated with antibiotics)
  - urinalysis and urine C&S in infants, Gram stain and culture of petechial/purpuric lesions
  - HSV and enterovirus PCR if suspected

Table 24. CSF Findings of Meningitis

<table>
<thead>
<tr>
<th>Component</th>
<th>Normal Child</th>
<th>Normal Newborn</th>
<th>Bacterial Meningitis</th>
<th>Viral Meningitis</th>
<th>Herpes Meningitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC (×10^6)</td>
<td>0-6</td>
<td>0-30</td>
<td>&gt;1,000 (cloudy, xanthochromic)</td>
<td>100-500*</td>
<td>10-1,000</td>
</tr>
<tr>
<td>Neutrophils (%)</td>
<td>0</td>
<td>2-3</td>
<td>&gt;50</td>
<td>&lt;40</td>
<td>&lt;50</td>
</tr>
<tr>
<td>Glucose (mmol/L)</td>
<td>2.2-4.4</td>
<td>1.8-6.7</td>
<td>&lt;1.66</td>
<td>&gt;1.66</td>
<td>&gt;1.66</td>
</tr>
<tr>
<td>Protein (mg/dL)</td>
<td>0.2-0.3</td>
<td>0.19-1.49</td>
<td>&gt;1.0</td>
<td>0.50-1.0</td>
<td>&gt;0.75</td>
</tr>
<tr>
<td>RBC (×10^6)</td>
<td>0-2</td>
<td>0-2</td>
<td>0-10</td>
<td>0-2</td>
<td>10-50</td>
</tr>
</tbody>
</table>

*Lymphtocytes predominate

Management
- supportive care
  - preservation of adequate cerebral perfusion by maintaining normal BP and managing ↑ ICP
  - close monitoring of fluids, electrolytes, glucose, acid-base disturbances, coagulopathies
- bacterial meningitis
  - if suspected or cannot be excluded, commence empiric antibiotic therapy while awaiting cultures or if LP contraindicated or delayed
  - isolation with appropriate infection control procedures until 24 h after culture-sensitive antibiotic therapy
  - fluid restrict if any concern for SIADH
  - hearing test
  - report to Public Health; prophylactic antibiotics for close contacts of Hib and N. meningitidis meningitis
Table 25. Antibiotic Management of Bacterial Meningitis

<table>
<thead>
<tr>
<th>Age</th>
<th>Main Pathogens</th>
<th>Antibiotics</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 to 28 d</td>
<td>GBS, E. coli, Listeria</td>
<td>Ampicillin + cefotaxime</td>
</tr>
<tr>
<td>28 to 90 d</td>
<td>Overlap of neonatal pathogens and those seen</td>
<td>Cefotaxime + Vancomycin (+ Ampicillin if</td>
</tr>
<tr>
<td></td>
<td>in older children</td>
<td>immunocompromised)</td>
</tr>
<tr>
<td>&gt; 90 d</td>
<td>*S. pneumoniae, N. meningitidis</td>
<td>Ceftriaxone ± Vancomycin If Penicillin allergic:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vancomycin + Rifampin</td>
</tr>
</tbody>
</table>

- viral meningitis
  • mainly supportive (except for HSV)
  • acyclovir for HSV meningitis
  • report to Public Health
- prophylaxis: appropriate vaccinations significantly decrease incidence of bacterial meningitis (see Routine Immunization, P4)

Complications
- mortality: neonate 15-20%, children 4-8%; pneumococcus > meningococcus > Hib
- acute: SIADH, subdural effusion/empyema, brain abscess, disseminated infection (osteomyelitis, septic arthritis, abscess), shock/DIC
- chronic: hearing loss, neuromotor/cognitive delay, learning disabilities, neurological deficit, seizure disorder, hydrocephalus

Mumps

Definition
- acute, self-limited viral infection that is most commonly characterized by adenitis and swelling of the parotid glands

Epidemiology
- incidence in Ontario has declined since introduction of two-dose MMR vaccination schedule
- average of 25 reported cases per yr
- majority of reported cases in children between 5-10 yr of age

Etiology
- mumps virus (RNA virus of the genus Rubulavirus in the Paramyxoviridae family)
- transmission via respiratory droplets, direct contact, fomites
- incubation period: 14-25 d
- infectivity period: 7 d pre-parotitis to 5 d post-parotitis
- upper respiratory tract lymph nodes salivary glands, gonads, pancreas, meninges, kidney, heart, thyroid

History
- non-specific prodome of fever, headache, malaise, myalgias (especially neck pain)
- usually followed within 48 h by parotid swelling secondary to parotitis (bilateral, preauricular, ear pushed up and out)
- parotid gland is tender and pain worsened with spicy or sour foods
- one third of infections do not cause clinically apparent salivary gland swelling and may simply present as an URTI

Investigations
- clinical diagnosis, but may be confirmed with IgM positive serology within 4 wk of acute infection
  • may also use PCR or viral cultures from oral secretions, urine, blood, and CSF
  • blood work: CBC (leukopenia with relative lymphocytosis), serum amylase (elevated)

Management
- mainly supportive: analgesics, antipyretics, warm or cold packs to parotid may be soothing
- admit to hospital if serious complications (meningitis, pancreatitis)
- droplet precautions recommended until 5 d after onset of parotid swelling
- prophylaxis: routine vaccination (see Routine Immunization, P4)

Complications
- common: aseptic meningitis, orchitis/oophoritis
- less common: encephalitis, pancreatitis, thyroiditis, myocarditis, arthritis, GN, ocular complications, hearing impairment
Pertussis

Definition
- prolonged respiratory illness characterized by paroxysmal coughing and inspiratory “whoop”

Epidemiology
- ~10 million children <1 yr old affected worldwide, causes up to 400,000 deaths/yr
- greatest incidence among children <1 yr (not fully immunized) and adolescents (waning immunity)

Etiology
- *Bordetella pertussis*: Gram negative pleomorphic rod
- highly contagious; transmitted via respiratory droplets released during intense coughing
- incubation period: 6-20 d; most contagious during catarrhal phase but may remain contagious for weeks after

History
- prodromal catarrhal stage
  - lasts 1-7 d; URTI symptoms (coryza, mild cough, sneezing) with NO or LOW-GRADE fever
- paroxysmal stage
  - lasts 4-6 wk; characterized by paroxysms of cough (“100 day cough”), sometimes followed by inspiratory whoop (“whooping cough”)
  - infants <6 mo may present with post-tussive apnea, whoop is often absent
  - onset of attacks precipitated by yawning, sneezing, eating, physical exertion
  - ± post-tussive emesis, may become cyanotic before whoop
  - vomiting after whooping episodes
- convalescent stage;
  - lasts 1-2 wk; characterized by occasional paroxysms of cough, but decreased frequency and severity
  - non-infectious but cough may last up to 6 mo

Investigations
- NP specimen using aspirate or NP swab
  - gold standard: culture using special media (Regan-Lowe agar)
  - PCR to detect pertussis antigens
- blood work: CBC (lymphocytosis) and serology (antibodies against *B. pertussis*)

Management
- admit if paroxysms of cough are associated with cyanosis and/or apnea and give O₂
- supportive care
- antimicrobial therapy indicated if B. pertussi isolated, or symptoms present for <21 d
  - use macrolide antibiotics (azithromycin, erythromycin, or clarithromycin)
  - droplet isolation until 5 d of treatment and report to Public Health
  - prophylaxis
    - macrolide antibiotics for all household contacts
    - prevention with vaccination in infants and children (Pentacel®), and booster in adolescents (Adacel*) (see Routine Immunization, P4)

Complications
- pressure-related from paroxysms: subconjunctival hemorrhage, rectal prolapse, hernias, epistaxis
- respiratory: sinusitis, pneumonia, aspiration, atelectasis, pneumon Mediastinum, pneumothorax, alveolar rupture
- neurological: seizures (~3%), encephalopathy, ICH
- mortality: ~0.3%; highest risk in infants <6 mo old

Pneumonia
- see Respirology, P85

Periorbital (Preseptal) and Orbital Cellulitis
- see Ophthalmology, OP9

Sexually Transmitted Infections
- see Family Medicine, FM42 and Gynecology, GY27
Sinusitis

- see Family Medicine, FM44
- complication of ≤10% of URTIs in children
- clinical diagnosis
- diagnostic imaging is NOT required to confirm diagnosis in children
  - routine CT not recommended, but consider if suspect complications of sinusitis, persistent/recurrent disease, need for surgery
- antibiotic therapy for all children (although nearly half resolve spontaneously within 4 wk)
- complications: preseptal/orbital (preseptal/orbital cellulitis, orbital abscess, osteomyelitis, etc.), intracranial (meningitis, abscess, etc.), Pott’s Puffy tumour

Urinary Tract Infection

Definition

- infection of the urinary bladder (cystitis) and/or kidneys (pyelonephritis)

Epidemiology

- overall prevalence in infants and young children presenting with fever is 7%
- <4-6 wk old: more common in boys
- >1 yr old: females have two- to four-fold higher prevalence

Etiology

- majority (>95%) have a single cause (~70% E. coli)
- Gram-negative bacilli: E. coli, Klebsiella, Proteus, Enterobacter, Pseudomonas
- Gram-positive cocci: S. saprophyticus, Enterococcus

Risk Factors

- non-modifiable: female gender, Caucasian, previous UTIs, family history
- modifiable: urinary tract abnormalities (VUR, neurogenic bladder, obstructive uropathy, posterior urethral valve), dysfunctional voiding, repeated bladder catheterization, uncircumcised males, labial adhesions, sexually active, constipation, toilet training

History

- infants and young child: often just fever or non-specific symptoms (poor feeding, irritability, FTT, jaundice if <28 d old, vomiting)
- older child: fever, urinary symptoms (dysuria, urgency, frequency, incontinence, hematuria), abdominal pain and/or flank pain

Physical Exam

- infants and young child: toxic vs non-toxic, febrile, FTT, jaundice; look for external genitalia abnormalities (phimosis, labial adhesions) and lower back signs of occult myelodysplasia (e.g. hair tufts), which may be associated with neurogenic bladder
- older child: febrile, suprapubic and/or CVA tenderness, abdominal mass (enlarged bladder or kidney); may present with short stature, FTT, or HTN secondary to renal scarring from previously unrecognized or recurrent UTIs

Investigations

- sterile urine specimen
  • clean catch, catheterization, suprapubic aspiration or ‘Tap and Rub’ technique
  • urinalysis (leukocyte esterase, nitrites, erythrocytes, hemoglobin), microscopy (bacteria and leukocytes, erythrocytes), C&S
- diagnosis established if urinalysis suggests infection AND if ≥50,000 colony-forming units per mL of a uropathogen cultured

Management

- admit if: <2 mo old, urosepsis, persistent vomiting, inability to tolerate oral medication, moderate-severe dehydration, immunocompromised, complex urologic pathology; inadequate follow-up, failure to respond to outpatient therapy
- supportive care: maintenance of hydration and adequate pain control
- antibiotics
  • base on local antimicrobial susceptibility patterns
  • commence broad empiric therapy until results of urine C&S known, and then tailor as appropriate
  • neonates: IV ampicillin and gentamicin
  • infants and older children: oral antibiotics (based on local E. coli sensitivity) if outpatient; IV ampicillin and gentamicin if inpatient
  • duration 7-10 d
- imaging
  • renal and bladder U/S for all febrile infants (<2 yr) with UTIs looking for anatomical abnormalities, hydronephrosis, abscess
  • VCUG not recommended after 1st febrile UTI unless U/S reveals hydrenephrosis, obstructive uropathies or other signs suggestive of high-grade VUR
• follow-up: outpatients to return in 24-48 h if no clinical response and seek prompt medical evaluation for future febrile illnesses
• prophylaxis: generally not recommended unless higher grades of VUR

Complications
• long-term morbidity: focal renal scarring develops in 8% of patients; long-term significance unknown

Neonatology

Gestational Age and Size

Definitions
• classification by GA
  • preterm: <37 wk
  • near-term: 35-37 wk
  • term: 37-42 wk
  • post-term: >42 wk
• classification by birth weight
  • SGA: 2 SD < mean weight for GA or <10th percentile
  • AGA: within 2 SD of mean weight for GA
  • LGA: 2 SD > mean weight for GA or >90th percentile

Table 26. Abnormalities of Gestational Age and Size

<table>
<thead>
<tr>
<th>Features</th>
<th>Causes</th>
<th>Problems</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Term Infants</td>
<td>Spontaneous: cause unknown</td>
<td>RDS, apnea of prematurity, chronic lung disease, bronchopulmonary dysplasia</td>
</tr>
<tr>
<td>&lt;37 wk</td>
<td>Maternal disease: HTN, DM, cardiac and renal disorders</td>
<td>Feeding difficulties, NEC</td>
</tr>
<tr>
<td></td>
<td>Fetal conditions: multiple pregnancy, congenital abnormalities, macromelia, red blood cell isomunization, fetal infection</td>
<td>Hypocalcemia, hypoglycemia, hypothermia</td>
</tr>
<tr>
<td></td>
<td>Pregnancy issues: placental insufficiency, placenta previa, uterine malformations, previous preterm birth, infection, placental abruption</td>
<td>Anemia, jaundice</td>
</tr>
<tr>
<td></td>
<td>Behavioural and psychological contributors: smoking, EOH, drug use, psychosocial stressors</td>
<td>Retinopathy of prematurity</td>
</tr>
<tr>
<td></td>
<td>Sociodemographic factors: age, socioeconomic</td>
<td>ICH/IVH</td>
</tr>
<tr>
<td></td>
<td>conditions</td>
<td>PDA</td>
</tr>
<tr>
<td>Post-Term Infants</td>
<td>Most cases unknown</td>
<td>Increased risk of stillbirth or neonatal death</td>
</tr>
<tr>
<td>&gt;42 wk</td>
<td>Increased in first pregnancies</td>
<td>Fetal &quot;postmaturity syndrome&quot;: impaired growth due to placental dysfunction</td>
</tr>
<tr>
<td>Leathery skin</td>
<td>Previous post-term birth</td>
<td>Meconium aspiration</td>
</tr>
<tr>
<td>Meconium staining</td>
<td>Genetic factors</td>
<td></td>
</tr>
<tr>
<td>SGA Infants</td>
<td>Extrinsic causes: placental insufficiency, poor nutrition, HTN, multiple pregnancies, drugs, EOH, smoking</td>
<td>Perinatal hypoxia</td>
</tr>
<tr>
<td>&lt;10th percentile</td>
<td>Genetic factors</td>
<td>Hypoglycemia, hypocalcemia, hypothermia, hyperviscosity (polycythemia), jaundice, hypomotility</td>
</tr>
<tr>
<td>Asymmetric (head-sparing):</td>
<td>late onset, growth arrest</td>
<td>PDA</td>
</tr>
<tr>
<td></td>
<td>Symmetric: early onset, lower growth</td>
<td></td>
</tr>
<tr>
<td>LGA Infants</td>
<td>Intrinsic causes: maternal infections (TORCH), congenital abnormalities, syndromal, idiopathic</td>
<td></td>
</tr>
<tr>
<td>&gt;90th percentile</td>
<td>Maternal DM</td>
<td>Birth trauma, perinatal depression (meconium aspiration)</td>
</tr>
<tr>
<td></td>
<td>Racial or familial factors</td>
<td>RDS, TTN</td>
</tr>
<tr>
<td></td>
<td>Increasing parity</td>
<td>Jaundice, polycythemia</td>
</tr>
<tr>
<td></td>
<td>Previous LGA infant, high BMI, large pregnancy weight gain</td>
<td>Hypoglycemia, hypocalcemia</td>
</tr>
<tr>
<td></td>
<td>Certain syndromes</td>
<td></td>
</tr>
</tbody>
</table>

Routine Neonatal Care

1. erythromycin ointment: applied to both eyes for prophylaxis of ophthalmia neonatorum (of questionable efficacy)
2. vitamin K IM: prophylaxis against HDNB
3. newborn screening tests in Ontario
   • in Ontario, newborn screening tests for
   • metabolic disorders (amino acid disorders, organic acid disorders, fatty acid oxidation defects, biotinidase deficiency, galactosemia)
   • blood disorders (SCD, other hemoglobinopathies)
   • endocrine disorders (CAH, congenital hypothyroidism)
   • others (CF, severe combined immunodeficiency)
   • congenital hearing loss
4. if mother Rh negative: send cord blood for blood group and direct antiglobulin test
5. if mother hepatitis B surface antigen positive: HBIG and start hepatitis B vaccine series
Neonatal Resuscitation

- assess Apgar score at 1 and 5 min
- if <7 at 5 min then reassess q5min, until >7
- do not wait to assign Apgar score before initiating resuscitation

Table 27. Apgar Score

<table>
<thead>
<tr>
<th>Sign</th>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart Rate</td>
<td>Absent</td>
<td>&lt;100/min</td>
<td>&gt;100/min</td>
</tr>
<tr>
<td>Respiratory Effort</td>
<td>Absent</td>
<td>Slow, irregular</td>
<td>Good, crying</td>
</tr>
<tr>
<td>Irritability</td>
<td>No response</td>
<td>Grimace</td>
<td>Cough/cry</td>
</tr>
<tr>
<td>Tone</td>
<td>Limp</td>
<td>Some flexion of extremities</td>
<td>Active motion</td>
</tr>
<tr>
<td>Colour</td>
<td>Blue, pale</td>
<td>Body pink, extremities blue (acrocyanosis)</td>
<td>Completely pink</td>
</tr>
</tbody>
</table>

Initial Resuscitation

- anticipation: know maternal history, history of pregnancy, labour, and delivery
- steps to take for all infants
  - warm (radiant heater, warm blankets) and dry the newborn (remove wet blankets)
  - position and clear airway (“sniffing” position)
  - stimulate infant: rub lower back gently or flick soles of feet EXCEPT if meconium present (in which case tracheal suction first)
  - assess breathing and heart rate

Table 28. Interventions Used in Neonatal Resuscitation

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Schedule</th>
<th>Indications</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epinephrine</td>
<td>0.1-0.3 mL/kg/dose of 1:10,000 (0.01-0.03 mg/kg) IV</td>
<td>HR &lt; 60 and not rising</td>
<td>Side effects: tachycardia, HTN, cardiac arrhythmias</td>
</tr>
<tr>
<td>(adrenaline)</td>
<td>0.5-1 mL/kg/dose of 1:10,000 (0.05-0.1 mg/kg) endotracheally can be considered while awaiting IV access</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluid Bolus</td>
<td>10 mL/kg</td>
<td>May need to be repeated</td>
<td>Evidence of hypovolemia</td>
</tr>
<tr>
<td>(NS, whole blood, Ringer’s lactate)</td>
<td>Can be repeated q3-5 min pm</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Approach to the Depressed Newborn

- a depressed newborn lacks one or more of the following characteristics of a normal newborn
  - pulse >100 bpm
  - cries when stimulated
  - actively moves all extremities
  - has a good strong cry
  - approximately 10% of newborn babies require assistance with breathing after delivery

Table 29. Etiology of Respiratory Depression in the Newborn

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory Problems</td>
<td>RDS/hyaline membrane disease</td>
</tr>
<tr>
<td></td>
<td>Pulmonary hypoplasia</td>
</tr>
<tr>
<td></td>
<td>CNS depression</td>
</tr>
<tr>
<td></td>
<td>MAS</td>
</tr>
<tr>
<td></td>
<td>Pneumonia</td>
</tr>
<tr>
<td></td>
<td>Pneumothorax</td>
</tr>
<tr>
<td></td>
<td>Pleural effusions</td>
</tr>
<tr>
<td></td>
<td>Congenital malformations</td>
</tr>
<tr>
<td>Anemia (severe)</td>
<td>Erythroblastosis fetalis</td>
</tr>
<tr>
<td></td>
<td>Secondary hydrops fetalis</td>
</tr>
<tr>
<td>Maternal Causes</td>
<td>Drugs/anesthesia (opiates, magnesium sulphate)</td>
</tr>
<tr>
<td></td>
<td>DM</td>
</tr>
<tr>
<td></td>
<td>Maternal myasthenia gravis</td>
</tr>
<tr>
<td>Congenital Malformations/Birth Injury</td>
<td>Nuchal cord, perinatal depression</td>
</tr>
<tr>
<td></td>
<td>Bilateral phrenic nerve injury</td>
</tr>
<tr>
<td></td>
<td>Potter’s sequence</td>
</tr>
<tr>
<td>Shock</td>
<td>Antepartum hemorrhage</td>
</tr>
<tr>
<td>CHD</td>
<td>Transposition of the great arteries with intact ventricular septum</td>
</tr>
<tr>
<td>Other</td>
<td>Hypothermia</td>
</tr>
<tr>
<td></td>
<td>Hypoglycemia</td>
</tr>
<tr>
<td></td>
<td>Infection</td>
</tr>
</tbody>
</table>
Diagnosis
- vital signs
- detailed maternal history: include prenatal care, illnesses, use of drugs, labour, previous high risk pregnancies, infections during pregnancy, current infections, duration of ruptured membranes, blood type and Rh status, amniotic fluid status, GA, meconium, Apgar scores
- clinical findings (observe for signs of respiratory distress such as cyanosis, tachypnea, retractions, grunting, temperature instability)
- laboratory results (CBC, ABG, blood type, glucose)
- transillumination of chest to evaluate for pneumothorax
- CXR

Management
- see Neonatal Resuscitation, identify and treat underlying cause

Common Conditions of Neonates

Apnea

Definition
- “periodic breathing”: normal respiratory pattern seen in newborns in which periods of rapid respiration are alternated with pauses lasting 5-10 s
- “apnea”: absence of respiratory gas flow for >20 s (or less if associated with bradycardia or desaturation)
  - 3 types
    - central: no chest wall movement, no signs of obstruction
    - obstructive: chest wall movement continues against obstructed upper airway, no airflow
    - mixed: combination of central and obstructive apnea

Differential Diagnosis
- in term infants, apnea requires full workup as it can be associated with sepsis
- other causes
  - CNS
  - apnea of prematurity (<34 wk): combination of CNS immaturity and obstructive apnea; resolves by 36 wk GA; diagnosis of exclusion
  - seizures
  - ICH
  - hypoxic injury
  - infectious: sepsis, meningitis, NEC
  - GI: GERD, aspiration with feeding
  - metabolic: hypoglycemia, hyponatremia, hypocalcemia, inborn error of metabolism
  - cardiovascular: anemia, hypovolemia, PDA, heart failure
  - medications: morphine

Management
- O₂, ventilatory support, maintain normal blood gases
- tactile stimulation
- correct underlying cause
- medications: methylxanthines (caffeine) stimulate the CNS and diaphragm and are used for apnea of prematurity (not in term infants)

Bleeding Disorders in Neonates

Clinical Presentation
- oozing from the umbilical stump, excessive bleeding from peripheral venipuncture/heel stick sites/IV sites, large caput succedaneum, cephalohematomas (in absence of significant birth trauma), subgaleal hemorrhage and prolonged bleeding following circumcision

Etiology
- 4 major categories
  - increased platelet destruction: maternal ITP or SLE, infection/sepsis, DIC, neonatal alloimmune thrombocytopenia, autoimmune thrombocytopenia
  - decreased platelet production/function: pancytopenia, bone marrow replacement, Fanconi anemia, Trisomy 13 and 18
  - metabolic: congenital thyrotoxicosis, inborn error of metabolism
  - coagulation factor deficiencies (see Hematology, H31): hemophilia A/B, HDNB
Common Conditions of Neonates

NEONATAL ALLOIMMUNE THROMBOCYTOPENIA

Epidemiology
• 1 per 4,000-5,000 live births

Pathophysiology
• platelet equivalent of Rh disease of the newborn
• occurs when mother is negative for HPA and fetus is positive
• development of maternal IgG antibodies against HPA antigens on fetal platelets

Clinical Presentation
• petechiae, purpura, thrombocytopenia in otherwise healthy neonate
• severe disease can lead to intracranial bleeding

Diagnosis
• maternal and paternal platelet typing and identification of platelet alloantibodies

Treatment
• IVIg to mother prenatally starts in second trimester ± steroids ± fetal platelet transfusions
• treat neonate with IVIg
• if transfusion required should be with washed maternal platelets or donor HPA negative platelets

AUTOIMMUNE THROMBOCYTOPENIA

Pathophysiology
• caused by antiplatelet antibodies from maternal ITP or SLE
• passive transfer of antibodies across placenta

Clinical Presentation
• similar presentation to neonatal alloimmune thrombocytopenia, but thrombocytopenia usually less severe

Treatment
• steroids to mother for 10-14 d prior to delivery or IVIg to mother before delivery
• treat neonate with IVIg (usually if platelets <60,000)
• transfusion of infant with maternal/donor platelets only in severe cases, as antibodies will destroy transfused platelets

HEMORRHAGIC DISEASE OF THE NEWBORN

Pathophysiology
• caused by vitamin K deficiency
• factors II, VII, IX, X are vitamin K-dependent, therefore both PT and PTT are abnormal

Etiology and Clinical Presentation
• neonates at risk of vitamin K deficiency if: vitamin K poorly transferred across the placenta; maternal use of antiepileptics; insufficient bacterial colonization of colon at birth to synthesize vitamin K; breastfed (vitamin K intake inadequate in breastfed infants)
• neonate may present with hematomas, ICH (causing apnea or seizures), internal bleeding, hematuria, bruising, prolonged bleeding (often from mucous membranes, umbilicus, circumcision, and venipunctures)

Prevention
• vitamin K IM administration at birth to all newborns

Bronchopulmonary Dysplasia

Definition
• also known as chronic lung disease
• clinically defined as O₂ requirement for >28 d plus persistent need for oxygen and/or ventilatory support at 36 wk corrected GA
• damage to developing lungs with prolonged intubation/ventilation, high levels O₂, infections

Investigations
• CXR findings may demonstrate decreased lung volumes, areas of atelectasis, signs of inflammation, and hyperinflation
Treatment
• no good treatments
• gradual wean from ventilator, optimize nutrition
• dexamethasone may help decrease inflammation and encourage weaning, but use of dexamethasone is associated with increased risk of adverse neurodevelopmental outcomes

Prognosis
• chronic respiratory failure may lead to pulmonary HTN, poor growth, and right-sided heart failure
• patients with bronchopulmonary dysplasia may continue to have significant impairment and deterioration in lung function late into adolescence
• some lung abnormalities may persist into adulthood including airway obstruction, airway hyperreactivity, and emphysema
• associated with increased risk of adverse neurodevelopmental outcomes

Cyanosis

Management
• ABGs
  • elevated CO₂ suggests respiratory cause
  • hyperoxia test (to distinguish between cardiac and respiratory causes of cyanosis): get baseline PaO₂ in room air, then PaO₂ on 100% O₂ for 10-15 min
  • PaO₂ <150 mmHg: suggests cyanotic CHD or possible PPHN (see Cardiology, P16)
  • PaO₂ >150 mmHg: suggests cyanosis likely due to respiratory or non-cardiac cause
• CXR: look for respiratory abnormalities (respiratory tract malformations, evidence of shunting, pulmonary infiltrates) and cardiac abnormalities (cardiomegaly, abnormalities of the great vessels)

Diaphragmatic Hernia

• see General Surgery, GS62

Definition
• developmental defect of the diaphragm with herniation of abdominal organs into thorax
• associated with pulmonary hypoplasia and PPHN

Clinical Presentation
• respiratory distress, cyanosis
• scaphoid abdomen and barrel-shaped chest
• affected side dull to percussion and breath sounds absent, may hear bowel sounds instead
• heart sounds shifted to contralateral side
• asymmetric chest movements, trachea deviated away from affected side
• may present outside of neonatal period
• often associated with other anomalies (cardiovascular, CNS, chromosomal abnormalities)
• CXR: bowel loops in thorax (usually left side), displaced mediastinum
Treatment
• immediate intubation required at birth: DO NOT bag mask ventilate because air will enter stomach and further compress lungs
• place large bore orogastric tube to decompress bowel
• initial stabilization and management of pulmonary hypoplasia and PPHN, hemodynamic support and surgery when stable

Hypoglycemia
Definition
• glucose <2.6 mmol/L.

Etiology
• decreased carbohydrate stores: premature, SGA, RDS, maternal HTN
• endocrine: hormonal deficiencies (GH, cortisol, epinephrine), insulin excess (infant of diabetic mother, Beckwith-Wiedemann syndrome/islet cell hyperplasia), HPA axis suppression (panhypopituitarism)
• inborn errors of metabolism: fatty acid oxidation defects, galactosemia
• miscellaneous: sepsis, hypothermia, polycythemia

Clinical Findings
• signs often non-specific and subtle: lethargy, poor feeding, irritability, tremors, apnea, cyanosis, seizures

Management
• identify and monitor infants at risk (pre-feed blood glucose checks)
• begin oral feeds as soon as possible after birth and ensure regular feeds
• if significant and/or symptomatic hypoglycemia, provide glucose IV and titrate according to blood sugar levels
• if persistent hypoglycemia or no predisposing cause, send “critical blood work” during an episode of hypoglycemia: ABG, ammonia, β-hydroxybutyrate, cortisol, free fatty acids, GH, insulin, lactate, urine dipstick for ketones

Intraventricular Hemorrhage
Definition
• hemorrhage originating in the periventricular subependymal germinal matrix

Epidemiology
• incidence and severity inversely proportional to GA
• 50% of IVH occurs within 8 h of birth; 90% occurs by day 3

Risk Factors
• prematurity (<32 wk), BW <1,500 g, need for vigorous resuscitation at birth, pneumothorax, ventilated preterm infants, hemodynamic instability, RDS, coagulopathy

Clinical Presentation
• many infants with IVH are asymptomatic
• subtle signs: apnea, bradycardia, changes in tone or activity, altered LOC
• catastrophic presentation: bulging fontanelle, sudden drop in hematocrit, acidosis, seizures, hypotension

Classification
• Papile classification
• parenchymal hemorrhage may also occur in the absence of IVH
• routine head U/S screening of all preterm infants <32 wk or <1,500 g gestation throughout NICU stay
• consider MRI at term for extremely LBW infants

Management of Acute Hemorrhage
• supportive care to maintain blood volume and acid-base status
• avoid fluctuations in blood pressure and cerebral blood flow
• follow-up with serial imaging

Prognosis
• outcome depends on grade of IVH
• short-term sequelae for severe IVH: mortality, extension of bleed, posthemorrhagic hydrocephalus, posthemorrhagic infarction, cyst formation
• possible long-term major neurological sequelae: CP, cognitive deficits, motor deficits, visual and hearing impairment
• Grades I and II hemorrhages have a relatively favourable prognosis
• greatest morbidity and mortality is seen with Grade IV hemorrhage and posthemorrhagic hydrocephalus requiring ventriculoperitoneal shunt placement
Jaundice

Clinical Presentation
• Jaundice is visible at serum bilirubin levels of 85–120 µmol/L; visual assessment is often misleading
• Look at sclera, tip of nose in natural light
• Jaundice more severe/prolonged (due to increased retention of bilirubin in the circulation) with: prematurity, acidosis, hypoalbuminemia, dehydration, hemolysis
• Always pathologic if:
  - It occurs within 24 h of birth
  - Conjugated hyperbilirubinemia is present
  - Unconjugated bilirubin rises rapidly or is excessive for patient’s age and weight
  - Persistent jaundice lasts beyond 1-2 wk of age

Figure 14. Approach to neonatal hyperbilirubinemia

PHYSIOLOGIC JAUNDICE

Epidemiology
• Term infants: onset 3–4 d of life, resolution by 10 d of life
• Premature infants: higher peak and longer duration

Pathophysiology
• Increased hematocrit and decreased RBC lifespan
• Immature glucuronyl transferase enzyme system (slow conjugation of bilirubin)
• Increased enterohepatic circulation

Breastfeeding Jaundice
• Common; due to a lack of milk production → dehydration → exaggerated physiologic jaundice

Breast Milk Jaundice
• 1 per 200 breastfed infants
• Glucuronyl transferase inhibitor found in breast milk
• Onset 7 d of life, peak at 2-3 wk of life, usually resolved by 6 wk

Table 30. Risk Factors for Jaundice

<table>
<thead>
<tr>
<th>Maternal Factors</th>
<th>Perinatal Factors</th>
<th>Neonatal Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethnic group (e.g., Asian, native American) Complications during pregnancy (infant of diabetic mother, Rh or ABO incompatibility) Breastfeeding Family history/previous child required phototherapy</td>
<td>Birth trauma (cephalohematoma, ecchymoses) Prematurity</td>
<td>Difficulty establishing breastfeeding Infection (sepsis, hepatitis) Genetic factors Polycythemia Drugs TPN</td>
</tr>
</tbody>
</table>
Table 31. Causes of Neonatal Jaundice by Age

<table>
<thead>
<tr>
<th>&lt;24 h</th>
<th>24-72 h</th>
<th>72-96 h</th>
<th>Prolonged (&gt;1 wk)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALWAYS PATHOLOGIC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemolytic</td>
<td>Physiologic, polycythemia</td>
<td>Physiologic ± breastfeeding</td>
<td>Breast milk jaundice</td>
</tr>
<tr>
<td>Rh or ABO incompatibility</td>
<td>Dehydration (breastfeeding jaundice)</td>
<td>Sepsis</td>
<td>Prolonged physiologic jaundice in prematurity</td>
</tr>
<tr>
<td>Sepsis</td>
<td>Hemolysis</td>
<td></td>
<td>Hypothyroidism</td>
</tr>
<tr>
<td>Congenital infection (TORCH)</td>
<td>G6PD deficiency</td>
<td></td>
<td>Neonatal hepatitis</td>
</tr>
<tr>
<td>Severe bruising/hemorrhage</td>
<td>Pyruvate kinase deficiency</td>
<td></td>
<td>Conjugation dysfunction</td>
</tr>
<tr>
<td></td>
<td>Spherocytosis</td>
<td></td>
<td>e.g. Gilbert syndrome, Crigler-Najjar syndrome</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Inborn errors of metabolism</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>e.g. galactosemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Biliary tract obstruction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>e.g. biliary atresia</td>
</tr>
</tbody>
</table>

PATHOLOGIC JAUNDICE
- all cases of conjugated hyperbilirubinemia; some cases of unconjugated hyperbilirubinemia are pathologic

Investigations
- unconjugated hyperbilirubinemia
  - hemolytic workup: CBC, reticulocyte count, blood group (mother and infant), peripheral blood smear, Coombs test
  - if baby is unwell or has fever: septic workup (CBC and differential, blood and urine cultures ± LP, CXR)
  - other: G6PD screen (especially in males), TSH
- conjugated hyperbilirubinemia must be investigated without delay
  - consider liver enzymes (AST, ALT), coagulation studies (PT, PTT), serum albumin, ammonia, TSH, TORCH screen, septic workup, galactosemia screen (erythrocyte galactose-1-phosphate uridyltransferase levels), metabolic screen, abdominal U/S, HIDA scan, sweat chloride

TREATMENT OF UNCONJUGATED HYPERBILIRUBINEMIA
- to prevent kernicterus
- breastfeeding does not usually need to be discontinued, ensure adequate feeds and hydration
- lactation consultant support, mother to pump after feeds
- treat underlying causes (e.g. sepsis)
- phototherapy (blue-green wavelength, not UV light)
  - insoluble unconjugated bilirubin is converted to excretable form via photoisomerization
  - serum bilirubin should be monitored during and immediately after therapy (risk of rebound because photoisomerization reversible when phototherapy discontinued)
  - contraindicated in conjugated hyperbilirubinemia: results in “bronzed” baby
  - side effects: skin rash, diarrhea, eye damage (eye shield used routinely for prevention), dehydration
  - use published guidelines and nomogram for initiation of phototherapy
- exchange transfusion
  - indications: high bilirubin levels as per published graphs based on age, weeks gestation
  - most commonly performed for hemolytic disease and G6PD deficiency
  - use of IVIg in case of severe hyperbilirubinemia (DAT+) becoming evidence-based practice

KERNICTERUS

Etiology
- unconjugated bilirubin concentrations exceed albumin binding capacity and bilirubin is deposited in the brain resulting in permanent damage (typically basal ganglia or brainstem)
- incidence increases as serum bilirubin levels increase above 340 µmol/L
- can occur at lower levels in presence of sepsis, meningitis, hemolysis, hypoxia, acidosis, hypothermia, hypoglycemia, and prematurity

Clinical Presentation
- up to 15% of infants have no obvious neurologic symptoms
- early stage: lethargy, hypotonia, poor feeding, emesis (bilirubin encephalopathy)
- mid stage: hypertonia, high pitched cry, opisthotonic posturing (back arching), bulging fontanelle, seizures, pulmonary hemorrhage
- late stage (first year and beyond)
  - hypotonia, delayed motor skills, extrapyramidal abnormalities (choreoathetoid CP), gaze palsy, mitral regurgitation, sensorineural hearing loss

Prevention
- exchange transfusion, IVIg if indicated
**BILIARY ATRESIA**

**Definition**
- atresia of the extrahepatic bile ducts which leads to cholestasis and increased conjugated bilirubin after the first week of life
- progressive obliterator cholangiopathy

**Epidemiology**
- incidence: 1:10,000-15,000 live births
- associated anomalies in 10-35% of cases: situs inversus, congenital heart defects, polysplenia

**Clinical Presentation**
- dark urine, pale stool, jaundice (persisting for >2 wk), abdominal distention, hepatomegaly

**Diagnosis**
- conjugated hyperbilirubinemia, abdominal U/S, operative cholangiogram
- HIDA scan (may be bypassed in favour of biopsy if timing of diagnosis is critical)
- liver biopsy

**Treatment**
- surgical resection of necrotic bowel and surgery for complications (e.g. perforation, strictures)
- peritoneal drain/surgery if perforation
- serial AXRs detect early perforation (40% mortality in perforated NEC)
- antibiotics (usually ampicillin, gentamicin ± metronidazole if risk of perforation ≥ 7-10 d)
- NPO (7-10 d), vigorous IV fluid resuscitation, decompression with NG tube, supportive therapy
- TPN
- peritoneal drain/surgery if perforation
- surgical resection of necrotic bowel and surgery for complications (e.g. perforation, strictures)

**Necrotizing Enterocolitis**

**Definition**
- intestinal inflammation associated with focal or diffuse ulceration and necrosis
- primarily affecting terminal ileum and colon

**Epidemiology**
- affects 1-5% of preterm newborns admitted to NICU

**Pathophysiology**
- postulated mechanism of bowel ischemia: mucosal damage and enteral feeding → bacterial growth → bowel necrosis/gangrene/perforation

**Risk Factors**
- prematurity (immature defenses)
- asphyxia, shock (poor bowel perfusion)
- hyperosmolar feeds
- enteral feeding with formula (breast milk can be protective)
- sepsis

**Clinical Presentation**
- usually presents at 2-3 wk of age
- distended abdomen
- increased amount of gastric aspirate/vomitus with bile staining
- frank or occult blood in stool
- feeding intolerance
- diminished bowel sounds
- signs of bowel perforation (sepsis, shock, peritonitis, DIC)

**Investigations**
- AXR: pneumonitis intestinalis (intramural air is a hallmark of NEC), free air, fixed loops, ileus, thickened bowel wall, portal venous gas
- CBC, ABG, lactate, blood culture, electrolytes
- high or low WBC, low platelets, hyponatremia, acidosis, hypoxia, hypercapnea

**Treatment**
- NPO (7-10 d), vigorous IV fluid resuscitation, decompression with NG tube, supportive therapy
- TPN
- antibiotics (usually ampicillin, gentamicin ± metronidazole if risk of perforation ≥ 7-10 d)
- serial AXRs detect early perforation (40% mortality in perforated NEC)
- peritoneal drain/surgery if perforation
- surgical resection of necrotic bowel and surgery for complications (e.g. perforation, strictures)
**Persistent Pulmonary Hypertension of the Newborn**

**Definition**
- persistence of fetal circulation as a result of persistent elevation of pulmonary vascular resistance
- classified as primary (absence of risk factors) or secondary

**Epidemiology**
- incidence 1.9/1,000 live births

**Clinical Presentation**
- usually presents within 12 h of birth with severe hypoxemia/cyanosis; may have only mild respiratory distress

**Pathophysiology**
- elevated pulmonary pressures cause R → L shunt through PDA, foramen ovale → decreased pulmonary blood flow and hypoxemia → further pulmonary vasoconstriction

**Risk Factors**
- secondary PPHN: asphyxia, MAS, RDS, sepsis, pneumonia, structural abnormalities (e.g. diaphragmatic hernia, pulmonary hypoplasia)
- more common in term or post-term infants

**Investigations**
- measure pre- and post-ductal oxygen levels
- hyperoxia test to exclude CHD
- ECG (RV strain)
- Echo reveals increased pulmonary arterial pressure and a R → L shunt across PDA and patent foramen ovale; also used to rule out other cardiac defects

**Treatment**
- maintain good oxygenation (SaO₂ >95%) in at-risk infants
- O₂ given early and tapered slowly, minimize stress and metabolic demands, maintain normal blood gases, circulatory support
- mechanical ventilation, high frequency oscillation in a sedated muscle-relaxed infant
- nitric oxide, surfactant
- extracorporeal membrane oxygenation used in some centres when other therapy fails

**Respiratory Distress in the Newborn**

**Clinical Presentation**
- tachypnea: RR >60/min; tachycardia: HR >160/min
- grunting, subcostal/intercostal indrawing, nasal flaring
- dusky, central cyanosis
- decreased air entry, crackles on auscultation

**Differential Diagnosis of Respiratory Distress**
- pulmonary: RDS (Respiratory Distress Syndrome), TTN (Transient Tachypnea of the Newborn), MAS (Meconium Aspiration Syndrome), pleural effusion, pneumothorax, congenital lung malformations
- infectious: sepsis, pneumonia
- cardiac: CHD (cyanotic, acyanotic), PPHN
- hematologic: blood loss, polycythemia
- anatomic: TEF, congenital diaphragmatic hernia, mucous or meconium plug, upper airway obstruction (see Otolaryngology, OT41)
- metabolic: hypoglycemia, inborn errors of metabolism
- neurologic: CNS damage (trauma, hemorrhage), drug withdrawal syndromes

**Investigations**
- CXR, ABG (or venous blood gas from umbilical venous line)
- CBC, blood cultures, blood glucose
- ECG if indicated
### Table 32. Distinguishing Features of RDS, TTN, MAS

<table>
<thead>
<tr>
<th></th>
<th>RDS</th>
<th>TTN</th>
<th>MAS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Etiology</strong></td>
<td>Surfactant deficiency → poor lung compliance due to high alveolar</td>
<td>Delayed resorption of fetal lung fluid → accumulation of fluid in</td>
<td>Meconium is sterile but causes airway obstruction, chemical</td>
</tr>
<tr>
<td></td>
<td>surface tension → atelectasis → ↓ surface area for gas exchange →</td>
<td>peribronchial lymphatics and vascular spaces → tachypnea</td>
<td>inflammation, and surfactant inactivation leading to chemical</td>
</tr>
<tr>
<td></td>
<td>hypoxia + acidosis → respiratory distress</td>
<td>“Wet lung syndrome”</td>
<td>pneumonitis</td>
</tr>
<tr>
<td></td>
<td>“Hyaline membrane disease”</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gestational Age</strong></td>
<td>Preterm</td>
<td>Usually term and late preterm</td>
<td>Term and post-term</td>
</tr>
<tr>
<td><strong>Risk Factors</strong></td>
<td>Maternal DM</td>
<td>Maternal DM</td>
<td>Meconium-stained amniotic fluid</td>
</tr>
<tr>
<td></td>
<td>Preterm delivery</td>
<td>Maternal asthma</td>
<td>Post-term delivery</td>
</tr>
<tr>
<td></td>
<td>Male sex</td>
<td>Male sex</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LBW</td>
<td>Macrosomia (&gt;4,500 g)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acidosis, sepsis</td>
<td>Elective Cesarean section or short labour</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypothermia</td>
<td>Late preterm delivery</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Second born twin</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Presentation</strong></td>
<td>Respiratory distress within first few hours of life, worsens over next 24-72 h</td>
<td>Tachypnea within the first few hours of life ± retractions, grunting, nasal flaring</td>
<td>Respiratory distress within hours of birth</td>
</tr>
<tr>
<td></td>
<td>24-72 h</td>
<td>Often NO hypoxia or cyanosis</td>
<td>Small airway obstruction, chemical pneumonitis tachypnea, barrel chest with audible crackles</td>
</tr>
<tr>
<td></td>
<td>Hypoxia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cyanosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CXR Findings</strong></td>
<td>Homogeneous infiltrates</td>
<td>Perihilar infiltrates</td>
<td>Hyperinflation</td>
</tr>
<tr>
<td></td>
<td>Air bronchograms</td>
<td>“Wet silhouette”: fluid in fissures</td>
<td>Petchy atelectasis</td>
</tr>
<tr>
<td></td>
<td>Decreased lung volumes</td>
<td></td>
<td>Patchy and coarse infiltrates</td>
</tr>
<tr>
<td></td>
<td>May resemble pneumonia (GBS)</td>
<td></td>
<td>10-20% have pneumothorax</td>
</tr>
<tr>
<td></td>
<td>If severe, “white-out” with no differentiation of cardiac border</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Prevention</strong></td>
<td>Prenatal corticosteroids (e.g. Celestone® 12 mg q24h × 2 doses) if</td>
<td>Where possible, avoidance of elective Cesarean delivery, particularly before 38 wk GA</td>
<td>If infant is depressed at birth, intubate and suction below vocal cords</td>
</tr>
<tr>
<td></td>
<td>risk of preterm delivery &lt; 34 wk Monitor lecithin:sphingomyelin (L/S)</td>
<td></td>
<td>Avoidance of factors associated with in utero passage of meconium (e.g. post term delivery)</td>
</tr>
<tr>
<td></td>
<td>ratio with amniocentesis, L/S &gt; 2:1 indicates lung maturity</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>Resuscitation</td>
<td>Supportive Oxygen if hypoxic</td>
<td>Resuscitation</td>
</tr>
<tr>
<td></td>
<td>Oxygen</td>
<td>Ventilator support (e.g. CPAP)</td>
<td>Oxygen</td>
</tr>
<tr>
<td></td>
<td>Ventilation</td>
<td>Of fluids and NG tube feeds if too tachypneic to feed orally</td>
<td>Ventilatory support</td>
</tr>
<tr>
<td></td>
<td>Surfactant (decreases alveolar surface tension, improves lung</td>
<td></td>
<td>Surfactant</td>
</tr>
<tr>
<td></td>
<td>compliance, and maintains functional residual capacity)</td>
<td></td>
<td>Inhaled nitric oxide</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Extracorporeal membrane oxygenation for PPHN</td>
</tr>
<tr>
<td><strong>Complications</strong></td>
<td>In severe prematurity and/or prolonged ventilation, increased risk of bronchopulmonary dysplasia</td>
<td>Hypoxemia</td>
<td>Hypoxemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypercapnea</td>
<td>Hypercapnea</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Acidosis</td>
<td>Acidosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PPHN</td>
<td>PPHN</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pneumothorax</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pneumomediastinum</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chemical pneumonitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Secondary surfactant inhibition</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Respiratory failure</td>
</tr>
<tr>
<td><strong>Prognosis</strong></td>
<td>Dependent on GA at birth and severity of underlying lung disease; long-term risks of chronic lung disease</td>
<td>Recovery usually expected in 24-72 h</td>
<td>Dependent on severity, mortality up to 20%</td>
</tr>
</tbody>
</table>

**PNEUMONIA**

- see Respirology, P85
- consider in infants with prolonged or premature rupture of membranes, maternal fever, or if mother is GBS positive
- suspect if infant exhibits respiratory distress, temperature instability, or WBC is low, elevated, or left-shifted
- symptoms may be non-specific
- CXR: hazy lung and/or distinct infiltrates (may be difficult to differentiate from RDS)

**Retinopathy of Prematurity**

- see Ophthalmology, OP38
Sepsis in the Neonate

Table 33. Sepsis Considerations in the Neonate

<table>
<thead>
<tr>
<th>Early Onset (&lt;72 h)</th>
<th>Late Onset (72 h – 28 d)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vertical transmission, 95% present within 24 h after birth</td>
<td>Acquired after birth</td>
</tr>
<tr>
<td>Risk factors:</td>
<td>Most common in preterm infants in NICU (most commonly due to coagulase negative Staphylococcus)</td>
</tr>
<tr>
<td>Maternal infection: UTI, GBS positive, previous child with GBS sepsis or meningitis</td>
<td>Other pathogens implicated include GBS, anaerobes, E. coli, Klebsiella</td>
</tr>
<tr>
<td>Maternal fever/leukocytosis/chorioamnionitis</td>
<td></td>
</tr>
<tr>
<td>Prolonged rupture of membranes (&gt;18 h)</td>
<td></td>
</tr>
<tr>
<td>Preterm labour</td>
<td></td>
</tr>
<tr>
<td>Pathogens: GBS, E. coli, Listeria most common</td>
<td></td>
</tr>
<tr>
<td>Pneumonia more common with early onset sepsis</td>
<td></td>
</tr>
</tbody>
</table>

Signs of Sepsis
- no reliable absolute indicator of occult bacteremia in infants <3 mo, most specific result has been WBC <5
- temperature instability (hypo/hyperthermia)
- respiratory distress, cyanosis, apnea
- tachycardia/bradycardia
- lethargy, irritability
- poor feeding, vomiting, abdominal distension, diarrhea
- hypotonia, seizures, lethargy
- jaundice, hepatomegaly, petechiae, purpura

Skin Conditions of the Neonate

Table 34. Common Neonatal Skin Conditions

<table>
<thead>
<tr>
<th>Neonatal Skin Condition</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vasomotor Response (Cutis Marmorata, Acrocyanosis)</td>
<td>Transient mottling when exposed to cold; usually normal, particularly if premature</td>
</tr>
<tr>
<td>Vormix Caseosa</td>
<td>Soft, creamy, white layer covering baby at birth</td>
</tr>
<tr>
<td>Congenital Dermal Melanocytosis (‘Mongolian Spots’)</td>
<td>Slate grey macules over lower back and buttocks (may look like bruises); common in dark skinned infants</td>
</tr>
<tr>
<td>Capillary Hemangioma</td>
<td>Raised red lesion, which increases in size after birth and involutes; 50% resolved by 5 yr, 90% by 9 yr</td>
</tr>
<tr>
<td>Erythema Toxicum</td>
<td>Yellow-white papules/pustules surrounded by erythema, eosinophils within the lesions; common rash, resolves by 2 wk</td>
</tr>
<tr>
<td>Milia</td>
<td>Lesions 1-2 mm firm white pearly papules on nasal bridge, cheeks, and palate; self-resolving</td>
</tr>
<tr>
<td>Transient Pustular Melanosis</td>
<td>Brown macular base with pustules, seen more commonly in African American infants; may be present at birth</td>
</tr>
<tr>
<td>Nevus Simplex (Salmon Patch)</td>
<td>Transient macular vascular malformation of the eyelids and/or neck (“Angel Kiss” or “Stork Bite”); most lesions disappear by 1 yr of life</td>
</tr>
<tr>
<td>Neonatal Acne</td>
<td>Inflammatory papules and pustules mainly on face; self-resolving usually within 4 mo</td>
</tr>
</tbody>
</table>

Fluids and Electrolytes

Approach to Infant/Child with Dehydration

Etiology
- decreased intake: poor oral intake during acute illness, breastfeeding difficulties, eating disorders
- increased losses: common sites include GI tract (diarrhea, vomiting, bleeding), skin/mucous membranes (fever, burns, hemorrhage, stomatitis), urine (osmotic diuresis [e.g. hyperglycemia, DKA], diuretic therapy, DI, post-obstructive/post ATN recovery diuresis), and respiratory tract (tachypnea, bronchiolitis, pneumonia)

Management
- if suspect dehydration based on history (acute illness, decreased number of wet diapers, lethargy, changes in mental status, increased thirst, etc.), you must:
1) Determine the degree of extracellular volume contraction

<table>
<thead>
<tr>
<th>Table 35. Assessment of Degree of Extracellular Volume Contraction Based on Physical Exam</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>&lt; 2 yr</td>
</tr>
<tr>
<td>&gt; 2 yr</td>
</tr>
<tr>
<td>Pulse</td>
</tr>
<tr>
<td>Blood Pressure</td>
</tr>
<tr>
<td>Urine Output</td>
</tr>
<tr>
<td>Oral Mucosa</td>
</tr>
<tr>
<td>Anterior Fontanelle</td>
</tr>
<tr>
<td>Eyes</td>
</tr>
<tr>
<td>Skin Turgor</td>
</tr>
<tr>
<td>Capillary Refill</td>
</tr>
</tbody>
</table>

* Note that percentages refer to percent loss of pre-illness body weight

2) Determine the likely electrolyte disturbance
- dependent on etiology of dehydration and type of fluid loss (isotonic vs. hypertonic vs. hypotonic)

<table>
<thead>
<tr>
<th>Table 36. Electrolyte Content of Various Bodily Fluids</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bodily Fluid</td>
</tr>
<tr>
<td>-------------</td>
</tr>
<tr>
<td>Saliva</td>
</tr>
<tr>
<td>Gastric Juice</td>
</tr>
<tr>
<td>Pancreatic Juice</td>
</tr>
<tr>
<td>Bile</td>
</tr>
<tr>
<td>Small Bowel</td>
</tr>
<tr>
<td>Large Bowel</td>
</tr>
<tr>
<td>Sweat</td>
</tr>
</tbody>
</table>

- for moderate and severe dehydration, initial investigations should include urinalysis and blood work examining electrolyte (Na⁺, K⁺, Cl⁻), glucose, and acid-base (blood pH, pCO₂, HCO₃⁻) disturbances, and impaired renal function (creatinine, BUN)

3) Determine if the child requires PO or IV rehydration
- dehydrated child must receive adequate fluid management, including replacement of ongoing losses and maintenance fluids
- ORT indication: mild to moderate dehydration caused by diarrhea
  - advantages: ↓ cost, no IV needed, no increase in incidence of iatrogenic hyper/hyponatremia, parental involvement in therapy
- IV rehydration indications: indications for IV rehydration therapy: severe dehydration requiring close monitoring and frequent assessment of electrolytes, inability to tolerate ORT (e.g. vomiting, alteration in mental status, ileus, monosaccharide malabsorption, etc.), inability to provide ORT, failure of ORT in providing adequate rehydration (e.g. persistent diarrhea or vomiting)

4) Return the child to a normal volume and electrolyte status by replacing current deficits and ongoing losses

Figure 17. Algorithm for deficit replacement and replacement of ongoing losses in the dehydrated child
5) Provide the appropriate fluid and electrolyte maintenance daily requirements

Table 37. Maintenance Fluid Requirements

<table>
<thead>
<tr>
<th>Body Weight</th>
<th>100:50:20 Rule (24 h maintenance fluids)</th>
<th>4:2:1 Rule (hourly rate of maintenance fluids)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-10 kg</td>
<td>100 cc/kg/d</td>
<td>4 cc/kg/h</td>
</tr>
<tr>
<td>11-20 kg</td>
<td>1000 cc + 50 cc/kg/d for every kg &gt; 10 kg</td>
<td>40 cc + 2 cc/kg/h for every kg &gt; 10 kg</td>
</tr>
<tr>
<td>&gt;20 kg</td>
<td>1500 cc + 20 cc/kg/d for every kg &gt; 20 kg</td>
<td>60 cc + 1 cc/kg/h for every kg &gt; 20 kg</td>
</tr>
</tbody>
</table>

- in children, all maintenance fluids should have a dextrose component due to their higher risk of hypoglycemia, especially if they are NPO
- common IV fluid combinations used in pediatrics
  - newborn: D10W
  - first month of life: D5W/0.45 2 NS + KCl 20 mEq/L (only add KCl if voiding well)
  - children: D5W/NS + KCl 20 mEq/L or D5W/0.45 NS + KCl 20 mEq/L; NS bolus for dehydration
- most important thing to remember when correcting Na aberrations due to fluid deficits
  - risk of cerebral edema with rapid rehydration with hypotonic or isotonic solutions (i.e. NS), therefore replace fluid slowly with close monitoring; aim to adjust (increase or decrease) plasma [Na+] by no more than 12 mmol/L/d
  - management depends on etiology, severity of symptoms, and timing (acute vs. chronic)

6) Continue to monitor fluid and electrolyte status

- accurate monitoring of daily fluid intake (PO and IV) and ongoing losses (urine output, diarrhea, emesis, drains)
- if child receiving >50% of maintenance fluids through IV, serum electrolyte values should be monitored daily and therapy adjusted accordingly
- avoid iatrogenic hyper/hyponatremia, keep the possibility of SIADH in mind

---

**Nephrology**

**Common Pediatric Renal Diseases**

Table 38. Common Manifestations of Renal Disease

<table>
<thead>
<tr>
<th>Neonate</th>
<th>Common Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flank Mass</td>
<td>Hydronephrosis, polycystic disease (autosomal dominant or recessive subtypes), tumour</td>
</tr>
<tr>
<td>Hematuria</td>
<td>Renal vein thrombosis, asphyxia, malformation, trauma</td>
</tr>
<tr>
<td>Anuria/Oliguria</td>
<td>Bilateral renal agenesis, obstruction, asphyxia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Child and Adolescent</th>
<th>Common Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cola/Red-Coloured Urine</td>
<td>Acute GN (post-streptococcal, HSP, IgA nephropathy, etc.), hemoglobinuria (hemolyis), myoglobinuria (rhabdomyolysis)</td>
</tr>
<tr>
<td>Gross Hematuria</td>
<td>Urologic disease (nephrolithiasis, trauma, etc.), UTI, acute GN</td>
</tr>
<tr>
<td>Edema</td>
<td>Nephrotic syndrome, nephritis, acute/chronic renal failure, consider cardiac or liver disease</td>
</tr>
<tr>
<td>HTN</td>
<td>GN, renal failure, dysplasia (consider coarctation, drugs, endocrine causes)</td>
</tr>
<tr>
<td>Polyuria</td>
<td>DM, central and nephrogenic DI, renal Fanconi’s syndrome (genetic/metabolic/acquired causes), hypercalcinemia, polyuric renal failure (renal dysplasia)</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>Orthostatic, nephrotic syndrome (MCD, etc.), GN</td>
</tr>
<tr>
<td>Oliguria</td>
<td>Dehydration, ATN, interstitial nephritis, acute or chronic kidney disease (i.e. renal failure)</td>
</tr>
<tr>
<td>Urgency</td>
<td>UTI, vulvovaginitis</td>
</tr>
</tbody>
</table>

**Hemolytic Uremic Syndrome**

**Definition**

- simultaneous occurrence of the triad of 1) non-immune microangiopathic hemolytic anemia, 2) thrombocytopenia, and 3) acute renal injury

**Epidemiology**

- annual incidence of 1-2 per 100,000 in Canada
- most common cause of acute renal failure in children

**Etiology**

- diarrhea positive HUS: 90% of pediatric HUS from *E. coli* O157:H7, shiga toxin, or verotoxin
- diarrhea negative HUS: other bacteria, viruses, drugs, familial/genetic
Pathophysiology
- toxin binds, invades, and destroys colonic epithelial cells, causing bloody diarrhea
- toxin enters the systemic circulation, attaches to, and invades endothelial cells (especially in kidney), causing a release of endothelial products (e.g. von Willebrand factor, platelet aggregating factor)
- platelet/fibrin thrombi form in multiple organ systems (e.g. kidney, pancreas, brain, etc.) resulting in thrombocytopenia
- RBCs are forced through occluded vessels, resulting in fragmented RBCs (schistocytes) that are removed by the reticuloendothelial system (hemolytic anemia)

History and Physical Exam
- history: initial presentation of abdominal pain and diarrhea, followed by bloody diarrhea; within 5-7 d begins to show signs of anemia, thrombocytopenia, and renal insufficiency
- physical exam: pallor, jaundice (hemolysis), edema, petechiae, HTN

Investigations
- CBC (anemia, thrombocytopenia), blood smear (schistocytes), electrolytes, renal function, urinalysis (microscopic hematuria), stool cultures, and verotoxin/shigella toxin assay

Management
- mainly supportive: nutrition, hydration, ventilation (if necessary), blood transfusion for symptomatic anemia
- monitor electrolytes and renal function: dialysis if electrolyte abnormality (hyperkalemia) cannot be corrected, fluid overload, or uremia
- steroids are not helpful
- antibiotics are contraindicated because death of bacteria leads to increased toxin release and worse clinical course

Prognosis
- <5% mortality, 5-25% long-term renal damage (HTN, proteinuria, decreased renal function)

Nephritic Syndrome

Definition
- acute or chronic syndrome affecting the kidney, characterized by glomerular injury and inflammation, and defined by hematuria (>5 RBCs per high-powered microscope field) and the presence of dysmorphic RBCs and RBC casts on urinalysis
- often accompanied by at least one of proteinuria (<50 mg/kg/d), edema, HTN, azotemia, and oliguria

Epidemiology
- highest incidence in children aged 5-15 yr old

Etiology
- humoral immune response to a variety of etiologic agents → immunoglobulin deposition → complement activation, leukocyte recruitment, release of growth factors/cytokines → glomerular inflammation and injury → porous podocytes → hematuria + RBC casts ± proteinuria
- HTN secondary to fluid retention and increased renin secretion by ischemic kidneys

Table 39. Major Causes of Nephritic Syndrome

<table>
<thead>
<tr>
<th></th>
<th>Decreased C3</th>
<th>Normal C3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary (idiopathic)</td>
<td>Post-infectious GN (most common cause of acute GN in pediatrics)</td>
<td>IgA nephropathy</td>
</tr>
<tr>
<td></td>
<td>Membranoproliferative</td>
<td>Idiopathic rapidly progressive GN</td>
</tr>
<tr>
<td></td>
<td>Type I (50-80%)</td>
<td>Anti-GBM disease</td>
</tr>
<tr>
<td></td>
<td>Type II (&gt; 80%)</td>
<td></td>
</tr>
<tr>
<td>Secondary (systemic disease)</td>
<td>SLE</td>
<td>HSP (very common)</td>
</tr>
<tr>
<td></td>
<td>Bacterial endocarditis</td>
<td>Granulomatosis with polyangiitis</td>
</tr>
<tr>
<td></td>
<td>Abscess or shunt nephritis</td>
<td>Goodpasture’s syndrome</td>
</tr>
<tr>
<td></td>
<td>Cryoglobulinemia</td>
<td></td>
</tr>
</tbody>
</table>

History and Physical Exam
- often asymptomatic; some overlap in clinical findings for nephritic and nephrotic syndrome
- gross hematuria, mild-moderate edema, oliguria, HTN
- signs and symptoms suggestive of underlying systemic causes (e.g. fever, arthralgias, rash, dyspnea, pulmonary hemorrhage)

Investigations
- urine
  - dipstick (hematuria, 0 to 2+ proteinuria) and microscopy (>5 RBCs per high-powered microscope field, acanthocytes, RBC casts)
  - first morning urine protein/creatinine ratio (<200 mg/mmol)
• blood work
  ■ impaired renal function (↑ Cr and BUN) resulting in ↓ pH and electrolyte abnormalities (hyperkalemia, hyperphosphatemia, hypocalcemia)
  ■ mild anemia on CBC (secondary to hematuria)
  ■ hypoalbuminemia (secondary to proteinuria)
  ■ appropriate investigations to determine etiology: C3/C4 levels, serologic testing for recent streptococcal infection (ASOT, anti-hyaluronidase, anti-streptokinase, anti-NAD, anti-DNAse B), ANA, anti-DNA antibodies, ANCA, serum IgA levels, anti-GRM antibodies
  ■ renal biopsy should be considered only in the presence of acute renal failure, no evidence of streptococcal infection, normal C3/C4

Management
• treat underlying cause
• symptomatic
  ■ renal insufficiency: supportive (dialysis if necessary), proper hydration
  ■ HTN: salt and fluid restriction (but not at expense of renal function), ACEI or ARBs for chronic persistent HTN (not acute cases because ACEI or ARBs may decrease GFR further)
  ■ edema: salt and fluid restriction, possibly diuretics (avoid if significant intravascular depletion)
  ■ corticosteroids if indicated: IgA nephropathy, lupus nephritis, etc.

Prognosis
• dependent on underlying etiology
• complications include HTN, heart failure, pulmonary edema, chronic kidney injury (requiring renal transplant)

**Nephrotic Syndrome**

**Definition**
• clinical syndrome affecting the kidney, characterized by significant proteinuria, peripheral edema, hypoalbuminemia, and hyperlipidemia

**Epidemiology**
• highest incidence in children 2-6 yr old, M>F

**Etiology**
• primary (idiopathic): nephrotic syndrome in the absence of systemic disease (most common cause in pediatrics)
  ■ glomerular inflammation ABSENT on renal biopsy: MCD (85%), focal segmental glomerular sclerosis
  ■ glomerular inflammation PRESENT on renal biopsy: membranoproliferative GN, IgA nephropathy
• secondary: nephrotic syndrome associated with systemic disease or due to another process causing glomerular injury (<10% in pediatrics)
  ■ autoimmune: SLE, DM, rheumatoid arthritis
  ■ genetic: sickle cell disease, Alport syndrome
  ■ infections: hepatitis B/C, post-streptococcal, infective endocarditis, HUS, HIV
  ■ malignancies: leukemia, lymphoma
  ■ medications: captopril, penicillamine, NSAIDs, antiepileptics
  ■ vasculitides: HSP, granulomatosis with polyangiitis
  ■ congenital: congenital nephropathy of the Finnish type, Denys-Drash syndrome, etc.

**History and Physical Exam**
• non-specific symptoms such as irritability, malaise, fatigue, anorexia, or diarrhea
• edema
  ■ often first sign; detectable when fluid retention exceeds 3-5% of body weight
  ■ starts periorbital and often pretilial → edematous areas are white, soft, and pitting
  ■ gravity dependent: periorbital edema ↓ and pretilial edema ↑ over the day
  ■ anasarca may develop (i.e. marked periorbital and peripheral edema, ascites, pleural effusions, scrotal/labial edema)
• decrease in effective circulating volume (e.g. tachycardia, HTN, oliguria, etc.)
• foamy urine is a possible sign of proteinuria
Investigations

- urine
  - urine dipstick (3 to 4+ proteinuria, microscopic hematuria) and microscopy (oval fat bodies, hyaline casts)
  - first morning urine protein/creatinine ratio (>200 mg/mmol)
- blood work
  - diagnostic: hypoalbuminemia (<25 g/L), hyperlipidemia/hypercholesterolemia (total cholesterol >5 mmol/L)
  - secondary: electrolytes (hypocalcemia, hyperkalemia, hyponatremia), renal function (↑ BUN and Cr), coagulation profile (↑ PT/PTT)
  - appropriate investigations to rule out secondary causes: CBC, blood smear, C3/C4, ANA, hepatitis B/C titres, ASOT, HIV serology, etc.
- consider renal biopsy if: HTN, gross hematuria, renal function, low serum C3/C4, no response to steroids after 4 wk of therapy, frequent relapses (>2 in 6 mo), presentation before first year of life (high likelihood of congenital nephrotic syndrome), presentation ≥12 yr (rule out more serious renal pathology than MCD)

Management

- MCD: oral prednisone 2 mg/kg/d (or equivalent) for up to 12 wk → varicella status should be known before starting
- consider cytotoxic agents, immunomodulators, or high-dose pulse corticosteroid if steroid resistant
- symptomatic
  - edema: salt and fluid restriction, possibly diuretic (avoid if significant intravascular depletion); furosemide + albumin for anasarca
  - hyperlipidemia: generally resolves with remission; limit dietary fat intake; consider statin therapy if persistently nephrotic
  - hypoalbuminemia: IV albumin and furosemide not routinely given; consider if refractory edema
  - abnormal BP: control BP; fluid resuscitation if severe intravascular depletion; ACEI or ARBs for persistent HTN
- diet: no added salt; monitor caloric intake and supplement with Ca2+ and Vit D if on corticosteroids
- daily weights and BP to assess therapeutic progress
- secondary infections: treat with appropriate antimicrobials; antibiotic prophylaxis not recommended; pneumococcal vaccine at diagnosis and varicella vaccine after remission; varicella Ig + acyclovir if exposed while on corticosteroids
- secondary hypercoagulability: mobilize, avoid hypoconcentration due to hypovolemia, prompt sepsis treatment; heparin if thrombi occur

Prognosis

- generally good: 80% of children responsive to corticosteroids
- up to 2/3 experience relapse, often multiple times; sustained remission with normal kidney function usually by adolescence
- complications: ↑ risk of infections (spontaneous peritonitis, cellulitis, sepsis); hypercoagulability due to decreased intravascular volume and antithrombin III depletion (PE, renal vein thrombosis); intravascular volume depletion, leading to hypotension, shock, renal failure; side effects of drugs

Hypertension in Childhood

Definition

- HTN: sBP and/or dBP ≥95th percentile for sex, age, and height on ≥3 occasions
- pre-HTN: sBP and/or dBP ≥90th percentile but <95th percentile OR BP ≥120/80 irrespective of age, gender, and height

<table>
<thead>
<tr>
<th>Table 40. 95th Percentile Blood Pressures (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Female</strong></td>
</tr>
<tr>
<td>Age (Yr)</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>6</td>
</tr>
<tr>
<td>12</td>
</tr>
<tr>
<td>17</td>
</tr>
</tbody>
</table>


Epidemiology

- prevalence: 3-5% for HTN, 7-10% for pre-HTN; M>F
- increasing prevalence of pre-HTN over the last 25+ years
Etiology
- primary HTN
  - diagnosis of exclusion
  - most common in older children (≥10 yr), especially if positive family history, overweight, and only mild HTN
  - responsible for ~90% of cases of HTN in adolescents, rarely in young children
- secondary HTN
  - identifiable cause of HTN (most likely etiology depends on age)
  - responsible for majority of childhood HTN
- always consider white coat HTN for all ages

Table 41. Etiology of Secondary HTN by Age Group

<table>
<thead>
<tr>
<th>System</th>
<th>Neonates</th>
<th>1 mo-6 yr</th>
<th>7-12 yr</th>
<th>&gt;13 yr</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endocrine/Metabolic</td>
<td>CAH</td>
<td>Wilms’ tumour († renin) Neuroblastoma († catecholamines)</td>
<td>Endocrinopathies*</td>
<td>Endocrinopathies*</td>
</tr>
<tr>
<td>Renal</td>
<td>Congenital renal disease</td>
<td>Renal parenchymal disease</td>
<td>Renal parenchymal disease</td>
<td>Renal parenchymal disease</td>
</tr>
<tr>
<td>Vascular</td>
<td>Coarctation of the aorta</td>
<td>Coarctation of the aorta</td>
<td>RAS</td>
<td>Renovascular abnormalities</td>
</tr>
<tr>
<td>Drugs</td>
<td>Corticosteroids Cyclosporine and tacrolimus</td>
<td>Corticosteroids OCP Cyclosporine and tacrolimus</td>
<td>Corticosteroids OCP Cyclosporine and tacrolimus</td>
<td>Recreational drugs (amphetamine, cocaine, etc.)</td>
</tr>
</tbody>
</table>

*Note: may include hyperthyroidism, hyperparathyroidism, Cushing’s syndrome, primary hyperaldosteronism/Conn’s syndrome, pheochromocytoma

Risk Factors
- primary HTN: male gender, positive family history, obesity, obstructive sleep apnea, African American, prematurity/LBW
- secondary HTN: history of renal disease, abdominal trauma, family history of autoimmune diseases, umbilical artery catheterization

History
- often asymptomatic, but can include FTT, fatigue, epistaxis
- symptoms of hypertensive emergency
  - neurologic: headache, seizures, focal complaints, change in mental status, visual disturbances
  - cardiovascular: symptoms of MI or heart failure (chest pain, palpitations, cough, SOB)
- symptoms of secondary HTN: guided by etiology; ask about medications and recreational drugs (current and past)

Physical Exam
- BP measurement (make sure correct cuff size is used), plot on growth chart, BMI
- look for signs of hypertensive emergency (e.g. full neurologic exam, ophthalmoscopy, precordial exam, peripheral pulses, perfusion status)
- look for signs of secondary HTN

Investigations
- laboratory
  - urine dipstick for hematuria and/or proteinuria (renal disease), urine catecholamines (pheochromocytoma, neuroblastoma)
  - blood work: renal function tests (electrolytes, Cr, BUN), consider renin and aldosterone levels (RAS, Conn’s syndrome, Wilms’ tumour)
  - other specific hormones if indicated on history and physical
- imaging: Echo (coarctation, heart function), abdominal U/S (RAS, abdominal mass), renal radionuclide imaging (renal scarring)

Management
- treat underlying cause
- non-pharmacologic: modify concurrent cardiovascular risk factors (weight reduction, exercise, salt restriction, smoking cessation)
- pharmacologic: gradual lowering of BP using thiazide diuretics; no antihypertensives have been formally studied in children; if hypertensive emergencies use hydralazine, labetalol, sodium nitroprusside
- management of end-organ damage (e.g. retinopathy, LVH)
- consider referral to specialist

Prognosis
- end-organ damage (similar to adults) including LVH, CHF, cerebrovascular insults, renal disease, retinopathy
Neurology

Seizure Disorders

• see Neurology, N18

Differential Diagnosis of Seizures in Children
• benign febrile seizure
• CNS: infection, tumour, HIE, trauma, hemorrhage
• metabolic: hypoglycemia, hypocalcemia, hypernatremia
• idiopathic epilepsy and epileptic syndromes
• others: neurocutaneous syndromes, AVM, drug ingestions/withdrawal
• seizure mimics

Investigations
• lab tests: CBC, electrolytes, calcium, magnesium, glucose
• toxicology screen if indicated
• EEG
• CT/MRI, if indicated (focal neurological deficit or has not returned to baseline several hours after seizure)
• consider LP if first-time non-febrile seizure (not indicated for determining recurrence risk of benign febrile seizures or to determine seizure type or epileptic syndrome)

CHILDHOOD EPILEPSY SYNDROMES

Infantile Spasms
• brief, repeated symmetric contractions of neck, trunk, extremities (flexion and extension) lasting 10-30 s
• occur in clusters; often associated with developmental delay; onset 4-8 mo
• 20% unknown etiology (usually good response to treatment); 80% due to metabolic or developmental abnormalities, encephalopathies, or are associated with neurocutaneous syndromes (usually poor response to treatment)
• can develop into West syndrome (infantile spasms, psychomotor developmental arrest, and hypsarrhythmia) or Lennox-Gastaut (see below)
• typical EEG: hypsarrhythmia (high voltage slow waves, spikes and polyspikes, background disorganization)
• management: ACTH, vigabatrin, benzodiazepines

Lennox-Gastaut
• characterized by triad of 1) multiple seizure types, 2) diffuse cognitive dysfunction, and 3) slow generalized spike and slow wave EEG
• onset commonly 3-5 yr of age
• seen with underlying encephalopathy and brain malformations
• management: valproic acid, benzodiazepines, and ketogenic diet; however, response often poor

Juvenile Myoclonic Epilepsy (Janz Syndrome)
• myoclonus particularly in morning; frequently presents as generalized tonic-clonic seizures
• adolescent onset (12-16 yr of age); autosomal dominant with variable penetrance
• typical EEG: 3.5-6 Hz irregular spike and wave, increased with photic stimulation
• management: lifelong treatment (valproic acid); excellent prognosis

Childhood Absence Epilepsy
• multiple daily absence seizures lasting <30 s without post-ictal state that may resolve spontaneously or become generalized in adolescence
• peak age of onset 6-7 yr, F>M, strong genetic predisposition
• typical EEG: 3 Hz spike and wave
• management: valproic acid or ethosuximide

Benign Focal Epilepsy of Childhood with Rolandic/Centrotemporal Spikes
• focal motor seizures involving tongue, mouth, face, upper extremity usually occuring in sleep-wake transition state; remains conscious, but aphasic post-ictally
• onset peaks at 5-10 yr of age; 16% of all non-febrile seizures; remits spontaneously in adolescence without sequelae
• typical EEG: repetitive spikes in centrotemporal area with normal background
• management: frequent seizures controlled by carbamazepine, no medication if infrequent seizures
General Approach to Treatment
• education for patient and parents including education and precautions in daily life (e.g. buddy system, showers instead of baths)
• medication
  • initiate: treatment with drug appropriate to seizure type; often if >2 unprovoked afebrile seizures within 6-12 mo
  • optimize: start with one drug and increase dosage until seizures controlled
  • if no effect, switch to another before adding a second antiepileptic drug
  • continue antiepileptic drug therapy until patient free of seizures for >2 yr, then wean over 4-6 mo
• ketogenic diet (high fat diet): used in patients who do not respond to polytherapy or who do not wish to take medication (valproic acid contraindicated in conjunction with ketogenic diet because may increase hepatotoxicity)
• legal obligation to report to Ministry of Transportation if patient wishes to drive

Generalized and Partial Seizures
• see Neurology, N18

Febrile Seizures

Epidemiology
• most common cause of seizure in children (3-5% of children)
• M>F; age 6 mo-6 yr

Clinical Presentation
• often with associated illness or fever and family history
• no evidence of CNS infection/inflammation before or after seizure; no history of non-febrile seizures

Table 42. Comparison of Typical and Atypical Febrile Seizures

<table>
<thead>
<tr>
<th>Simple/Typical (70-80%)</th>
<th>Complex/Atypical (20-30%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All of the following:</td>
<td>At least one of the following:</td>
</tr>
<tr>
<td>Duration &lt;15 min (95% &lt;5 min)</td>
<td>Duration &gt;15 min</td>
</tr>
<tr>
<td>Generalized tonic-clonic</td>
<td>Focal onset or focal features during seizure</td>
</tr>
<tr>
<td>No recurrence in 24 h period</td>
<td>Recurrent seizures (&gt;1 in 24 h period)</td>
</tr>
<tr>
<td>No neurological impairment or developmental delay before or after seizure</td>
<td>Previous neurological impairment or neurological deficit after seizure</td>
</tr>
</tbody>
</table>

Workup
• history: determine focus of fever, description of seizure, medications, trauma history, development, family history
• physical exam: LOC, signs of meningitis, neurological exam, head circumference, focus of infection
• septic workup including LP if suspecting meningitis (strongly consider if child <12 mo; consider if child is 12-18 mo; only if meningeal signs present if child >18 mo)
• if typical febrile seizure, investigations only for determining focus of fever
• EEG/CT/MRI brain not warranted unless atypical febrile seizure or abnormal neurologic findings

Management
• counsel and reassure patient and parents
  • febrile seizures do not cause brain damage
  • very small risk of developing epilepsy: 9% in child with multiple risk factors; 2% in child with typical febrile seizures compared to 1% in general population
  • 33% chance of recurrence (mostly within 1 yr of first seizure and in children <1 yr old)
  • antipyretics and fluids for comfort (though neither prevent seizure)
  • prophylaxis with antiepileptic drugs not recommended
  • if high risk for recurrent or prolonged seizures, have rectal or sublingual lorazepam at home
  • treat underlying cause of fever

Recurrent Headache
• see Neurology, N44

Differential Diagnosis
• primary headache: tension, migraine, cluster
• secondary headache: see Neurology, N44

General Assessment
• if unremarkable history and neurological and general physical exam is negative, most likely diagnosis is migraine or tension headache
• CT or MRI if history or physical reveals red flags
• inquire about level of disability, academic performance, after-school activities

Ketogenic Diet and other Dietary Treatments for Epilepsy
Gastroenterol Clin N Am 2010;39:1213-26
Study: Systematic review of all studies of ketogenic and related diets. Included the review of 4 RCTs, 6 prospective studies, and 5 retrospective studies.
Population: Adults and children with diagnosed epilepsy of any type.
Intervention: Ketogenic diet, control (placebo diet, any treatment with known antiepileptic properties).
Main Outcome Measure: Seizure control at 3, 6, 12 mo.
Results: Studies showed a response rate of at least 30-50% seizure reduction at 3 mo. This response was maintained for up to a year. A range of side effects were reported. The most frequent were gastrointestinal effects (30%).
Conclusion: The ketogenic diet is a valid option for people with medically-intractable epilepsy.
Hypotonia

- decreased resistance to passive movements – “floppy baby”

Differential Diagnosis

- central: chromosomal (DS, Prader-Willi, Fragile X syndrome), metabolic (hypoglycemia, kernicterus), perinatal problems (asphyxia, ICH), endocrine (hypothyroidism, hypopituitarism), systemic illness (TORCH infection, sepsis, dehydration), CNS malformations, dysmorphic syndromes
- peripheral: motor neuron (spinal muscular atrophy, polio), peripheral nerve (Charcot-Marie-Tooth syndrome) neuromuscular junction (myasthenia gravis), muscle fibre (mitochondrial myopathy, muscular dystrophy, myotonic dystrophy)

History and Physical Exam

- proper assessment of tone requires accurate determination of GA
- differentiate between UMN and LMN lesion: spontaneous posture (spontaneous movement, movement against gravity, frog-leg position); muscle weakness; joint mobility (hypermobility); muscle bulk; presence of fasciculations
- postural maneuvers
  - traction response: pull to sit, look for flexion of arms to counteract traction and head lag
  - axillary suspension: suspend infant by holding at axilla and lifting; hypotonic babies will slip through grasp because of low shoulder girdle tone
  - ventral suspension: infant is prone and supported under the abdomen by one hand; infant should be able to hold up extremities; inverted “U” posturing demonstrates hypotonia
- dysmorphic features, cognitive ability, reflexes, strength

Investigations

- rule out systemic disorders (e.g. electrolytes, ABG, blood glucose, CK, and serum/urine investigations for multiple etiologies including mitochondrial causes)
- neuroimaging: MRI/MRA when indicated
- EMG, muscle biopsy/NCS
- chromosome analysis, genetic testing, metabolic testing, neuromuscular testing

Treatment

- depends on etiology: some treatments available for specific diagnosis
- counsel parents on prognosis and genetic implications
- refer patients for specialized care, refer for rehabilitation, OT, PT, assess feeding ability

Cerebral Palsy

Definition

- a symptom complex, not a disease
- non-progressive central motor impairment syndrome due to insult to or anomaly of the immature CNS
- incidence: 1.5-2.5/1,000 live births (industrialized nations)
- life expectancy is dependent on the degree of mobility and intellectual impairment, not on severity of CNS lesion

Etiology

- often obscure, no definite etiology identified in 1/3 of cases
- 10% related to intrapartum asphyxia; 10% due to postnatal insult (infections, asphyxia, prematurity with IVH and trauma)
- association with LBW babies

Clinical Presentation

- general signs: delay in motor milestones, developmental delay, learning disabilities, visual/hearing impairment, seizures, microcephaly, uncoordinated swallow (aspiration)

Table 43. Types of Cerebral Palsy

<table>
<thead>
<tr>
<th>Type</th>
<th>% of Total</th>
<th>Characteristics</th>
<th>Area of Brain Involved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spastic</td>
<td>70-80%</td>
<td>Truncal hypotonia in first yr Increased tone, increased reflexes, clonus Can affect one limb (monoplegia), one side of body (hemiplegia), both legs (diplegia), or both arms and legs (quadriplegia)</td>
<td>UMN of pyramidal tract Diplegia associated with periventricular leukomalacia in premature babies Quadriplegia associated with HE (asphyxia), higher incidence of intellectual disability</td>
</tr>
<tr>
<td>Athetoid/ Dyskinetic</td>
<td>10-15%</td>
<td>Athetosis (involuntary writhing movements) ± chorea (involuntary jerky movements) Can involve face, tongue (results in dysarthria)</td>
<td>Basal ganglia (may be associated with kernicterus)</td>
</tr>
<tr>
<td>Ataxic</td>
<td>&lt;5%</td>
<td>Poor coordination, poor balance (wide based gait) Can have intention tremor</td>
<td>Cerebellum</td>
</tr>
<tr>
<td>Mixed</td>
<td>10-15%</td>
<td>More than one of the above motor patterns</td>
<td></td>
</tr>
</tbody>
</table>
Investigations
• may include metabolic screen, chromosome studies, serology, neuroimaging (MRI), EMG, EEG (if seizures), ophthalmology assessment, audiology assessment

Treatment
• maximize potential through multidisciplinary services such as primary care physician, OT, PT, SLP, school supports, etc.
• orthopedic management (e.g. dislocations, contractures, rhizotomy)
• management of symptoms: spasticity (baclofen, Botox®), constipation (stool softeners)

Neurocutaneous Syndromes
• characterized by tendency to form tumours of the CNS, PNS, viscera, and skin

NEUROFIBROMATOSIS TYPE I
• autosomal dominant but 50% are the result of new mutations
• also known as von Recklinghausen disease
• incidence 1:3,000, mutation in NF1 gene on 17q11.2 (codes for neurofibromin protein)
• learning disorders, abnormal speech development, and seizures are common
• diagnosis of NF-1 requires 2 or more of
  • ≥6 café-au-lait spots (>5 mm if prepubertal, >1.5 cm if postpubertal)
  • ≥2 neurofibromas of any type or one plexiform neurofibroma
  • ≥2 Lisch nodules (hamartomas of the iris)
  • optic glioma
  • freckling in the axillary or inguinal region
  • a distinctive bony lesion (e.g. sphenoid dysplasia, cortical thinning of long bones)
  • a first degree relative with confirmed NF-1

NEUROFIBROMATOSIS TYPE II
• autosomal dominant
• incidence 1:33,000
• characterized by predisposition to form intracranial, spinal tumours
• diagnosed when bilateral vestibular schwannomas are found, or a first-degree relative with NF-2 and either unilateral vestibular schwannoma, or any two of the following: meningioma, glioma, schwannoma, neurofibroma, posterior subcapsular lenticular opacities.
• treatment consists of monitoring for tumour development and surgery

Respirology

Approach to Dyspnea
• determine if patient is sick or not sick; ABCs
• history: onset, previous episodes, precipitating events, associated symptoms, past medical/family history of respiratory disease
• physical exam: vitals, SpO₂, evidence of cyanosis, respiratory, cardiovascular
• investigations: CBC and differential, electrolytes, BUN, Cr, NP swab, ABG, CXR, ECG (based on clinical findings)
Upper Respiratory Tract Diseases

- see Otolaryngology, OT40
- diseases above the thoracic inlet characterized by inspiratory stridor, hoarseness, and suprasternal retractions
- differential diagnosis of stridor: croup, bacterial tracheitis, epiglottitis, foreign body aspiration, subglottic stenosis (congenital or iatrogenic), laryngomalacia/tracheomalacia (collapse of airway cartilage on inspiration)

Table 44. Common Upper Respiratory Tract Infections in Children

<table>
<thead>
<tr>
<th></th>
<th>Croup (Laryngotracheobronchitis)</th>
<th>Bacterial Tracheitis</th>
<th>Epiglottitis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anatomy</strong></td>
<td>Subglottic laryngitis</td>
<td>Subglottic tracheitis</td>
<td>Supraglottic laryngitis</td>
</tr>
<tr>
<td><strong>Epidemiology</strong></td>
<td>Common in children &lt; 6 yr, with peak incidence between 7-36 mo</td>
<td>Rare</td>
<td>Very rare – due to Hib vaccination</td>
</tr>
<tr>
<td></td>
<td>Common in fall and early winter</td>
<td>All age groups</td>
<td>Usually older (2-6 yr)</td>
</tr>
<tr>
<td><strong>Etiology</strong></td>
<td>Parainfluenza (75%)</td>
<td>S. aureus</td>
<td>H. influenzae</td>
</tr>
<tr>
<td></td>
<td>Influenza A and B</td>
<td>H. influenzae</td>
<td>β-hemolytic strep</td>
</tr>
<tr>
<td></td>
<td>RSV</td>
<td>α-hemolytic strep</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adenovirus</td>
<td>Pneumococcus</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>M. catarrhalis</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Presentation</strong></td>
<td>Common prodrome: rhinorrhea, pharyngitis, cough ± low-grade fever</td>
<td>Similar symptoms as croup, but more rapid deterioration with high fever</td>
<td>Toxic appearance</td>
</tr>
<tr>
<td></td>
<td>Hoarse voice</td>
<td>Toxic appearance</td>
<td>Rapid progression</td>
</tr>
<tr>
<td></td>
<td>Barking cough</td>
<td>Does not respond to croup treatments</td>
<td>4 Ds – drooling, dysphagia, dysphonia, distress</td>
</tr>
<tr>
<td></td>
<td>Stridor</td>
<td></td>
<td>Stridor</td>
</tr>
<tr>
<td></td>
<td>Worse at night</td>
<td></td>
<td>Tripod position</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sternal recession</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Anxious</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Fever (&gt;38°C)</td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td>Clinical diagnosis</td>
<td>Clinical diagnosis</td>
<td>Clinical diagnosis</td>
</tr>
<tr>
<td></td>
<td>CXR in atypical presentation: “steeple sign” from subglottic narrowing</td>
<td>Endoscopy: definitive diagnosis</td>
<td>Avoid examining the throat</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>to prevent further respiratory exacerbation</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>Stridor at rest is an EMERGENCY</td>
<td>Usually requires intubation</td>
<td>Intubation</td>
</tr>
<tr>
<td></td>
<td>No evidence for humidified O₂</td>
<td>IV antibiotics</td>
<td>Antibiotics</td>
</tr>
<tr>
<td></td>
<td>Racemic epinephrine: nebulized, 1-3 doses, q1-2h</td>
<td>Intubation if unresponsive to treatment</td>
<td>Prevented with Hib vaccine</td>
</tr>
</tbody>
</table>

Lower Respiratory Tract Diseases

- obstruction of airways below thoracic inlet, produces more expiratory sounds
- classic symptom: wheezing

Differential Diagnosis of Wheezing

- common: asthma (recurrent wheezing episodes, identifiable triggers, typically over 6 yr), bronchiolitis (first episode of wheezing, usually under 1 yr), recurrent aspiration (often neurological impairment), pneumonia (fever, cough, malaise)
- uncommon: foreign body (acute unilateral wheezing and coughing), CF (prolonged wheezing, unresponsive to therapy), bronchopulmonary dysplasia (often develops after prolonged ventilation in the newborn)
- rare: CHF, mediastinal mass, bronchiolitis obliterans, tracheobronchial anomalies

Pneumonia

Etiology

- inflammation of pulmonary tissue, associated with consolidation of alveolar spaces

Clinical Presentation

- incidence is greatest in first year of life with viral causes being most common in children <5 yr
- fever, cough, tachypnea
- CXR: diffuse, streaky infiltrates bilaterally
- bacterial causes may present with cough, fever, chills, dyspnea, more dramatic CXR changes (e.g. lobar consolidation, pleural effusion)
Management
• supportive therapy: hydration, antipyretics, humidified O₂

Table 45. Common Causes and Treatment of Pneumonia at Different Ages

<table>
<thead>
<tr>
<th>Age</th>
<th>Bacterial</th>
<th>Viral</th>
<th>Atypical Bacteria</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neonates</td>
<td>GBS</td>
<td>CMV</td>
<td>Mycoplasma hominis</td>
<td>Ampicillin + gentamicin / tobramycin (add erythromycin if suspect Chlamydia)</td>
</tr>
<tr>
<td></td>
<td>E. coli</td>
<td>Herpes</td>
<td>Ureaplasma urealyticum</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Listeria</td>
<td>virus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-3 mo</td>
<td>S. aureus</td>
<td>CMV, RSV</td>
<td>Chlamydia trachomatis</td>
<td>Cefuroxime OR ampicillin ± erythromycin OR clarithromycin</td>
</tr>
<tr>
<td>3 mo-5 yr</td>
<td>S. pneumoniae</td>
<td>RSV</td>
<td>Mycoplasma pneumoniae</td>
<td>Amoxicillin (if mild) OR ampicillin OR cefuroxime</td>
</tr>
<tr>
<td>3 mo-5 yr</td>
<td>H. influenzae</td>
<td>Adenovirus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;5 yr</td>
<td>S. pneumoniae</td>
<td>Influenza</td>
<td>Mycoplasma pneumoniae</td>
<td>Erythromycin OR clarithromycin (1st line) OR ampicillin OR cefuroxime</td>
</tr>
<tr>
<td></td>
<td>H. influenzae</td>
<td></td>
<td>Chlamydia pneumoniae</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. aureus</td>
<td></td>
<td>Legionella pneumophila</td>
<td></td>
</tr>
</tbody>
</table>

Bronchiolitis

Definition
• LRTI, usually in children <2 yr, that has wheezing and signs of respiratory distress

Epidemiology
• the most common LRTI in infants, affects 50% of children in first 2 yr of life; peak incidence at 6 mo, winter or early spring
• increased incidence of asthma in later life

Etiology
• RSV (>50%), parainfluenza, influenza, rhinovirus, adenovirus, M. pneumoniae (rare)

Clinical Presentation
• prodrome of URTI with cough and/or rhinorrhea, possible fever
• feeding difficulties, irritability
• wheezing, crackles, respiratory distress, tachypnea, tachycardia, retractions, poor air entry; symptoms often peak at 3-4 d

Investigations
• CXR (only in severe disease, poor response to therapy, chronic episode): air trapping, peribronchial thickening, atelectasis, increased linear markings
• NP swab: direct detection of viral antigen (immunofluorescence)
• WBC can be normal

Treatment
• self-limiting disease with peak symptoms usually lasting 2-3 wk
• mild to moderate distress
  • supportive: PO or IV hydration, antipyretics for fever, regular or humidified high flow O₂
  • severe distress
    • as above ± intubation and ventilation as needed
    • consider rebetol (Ribavirin®) in high risk groups: bronchopulmonary dysplasia, CHD, congenital lung disease, immunodeficient
  • monthly RSV-Ig or palivizumab (monoclonal antibody against the F-glycoprotein of RSV) is protective against severe disease in high risk groups; case fatality rate <1%
  • antibiotics have no therapeutic value unless there is secondary bacterial pneumonia
• indications for hospitalization
  • hypoxia: O₂ saturation <92% on initial presentation
  • persistent resting tachypnea >60/min and retractions after several salbutamol masks
  • past history of chronic lung disease, hemodynamically significant cardiac disease, neuromuscular problem, immunocompromised
  • young infants <6 mo old (unless extremely mild)
  • significant feeding problems
  • social problem (e.g. inadequate care at home)

Bronchodilators for Bronchiolitis
Cochrane DB Syst Rev 2010;12:CD001266
Study: Meta-analysis of prospective, randomized, double-blinded, placebo-controlled trials.
Patients: 1,912 infants (28 trials) up to 24 mo old with bronchiolitis.
Intervention: Bronchodilators (including albuterol, salbutamol, terbutaline, pranopium bromide, and adrenergic agents) given oral, subcutaneous, or nebulized vs. placebo.
Main Outcome: Oxygen saturation.
Results: No clinically significant difference for infants treated with bronchodilators vs. placebo for bronchiolitis. Given the costs and side effects, it is not recommended to use bronchodilators as management for bronchiolitis in infants.
Asthma

Definition

- see Respirology, R7
- inflammatory disorder of the airways characterized by recurrent episodes of reversible small airway obstruction, resulting from airway hyperresponsiveness to endogenous and exogenous stimuli
- very common, presents most often in early childhood
- associated with other atopic diseases such as allergic rhinitis or atopic dermatitis

Clinical Presentation

- episodic bouts of wheezing, dyspnea, tachypnea, cough (usually at night/early morning, with activity, or cold exposure)
- physical exam may reveal hyper-resonant chest, prolonged expiration, wheeze

Triggers

- URTI (viral or Mycoplasma), weather (cold exposure, humidity changes), allergens (pets), irritants (cigarette smoke), exercise, emotional stress, drugs (ASA, β-blockers)

Classification

- mild: occasional attacks of wheezing or coughing (<2/wk); symptoms respond quickly to inhaled bronchodilator; never needs systemic corticosteroids
- moderate: more frequent episodes with symptoms persisting and chronic cough; decreased exercise tolerance; sometimes needs systemic corticosteroids
- severe: daily and nocturnal symptoms; frequent ED visits and hospitalizations; usually needs systemic corticosteroids

Management

- acute
  - O₂ (keep O₂ saturation >94%) and fluids if dehydrated
  - β₂-agonists: salbutamol (Ventolin®) MDI + spacer (nebulized or IV in very severe episodes with impending respiratory failure), 5 puffs (<20 kg) or 10 puffs q20min for first hour (>20 kg)
  - ipratropium bromide (Atrovent®) if severe; MDI + spacer, 3 puffs (<20 kg) or 6 puffs (>20 kg) q20min with salbutamol, or add to first 3 salbutamol masks (0.25 mg if <20 kg, 0.5 mg if >20 kg)
  - steroids: prednisone (1-2 mg/kg x 5 d) or dexamethasone (0.3 mg/kg/d x 5 d or 0.6 mg/kg/d x 2 d); in severe disease, use IV steroids
  - continue to observe; can discharge patient if asymptomatic for 2-4 h after last dose
- chronic
  - education, emotional support, avoid allergens or irritants, develop an “action plan”
  - exercise program (e.g. swimming)
  - monitor respiratory function with peak flow meter (improves self-awareness of status)
  - PFTs for children >6 yr
  - reliever therapy: short acting β₂-agonists (e.g. salbutamol)
  - controller therapy (first line therapy for all children): low dose daily inhaled corticosteroids
  - second line therapy for children <12 yr: moderate dose of daily inhaled corticosteroids
  - second line therapy for children >12 yr: leukotriene receptor antagonist OR long acting β₂-agonist in conjunction with low dose inhaled corticosteroids; leukotriene receptor antagonist monotherapy may be considered an alternative second line therapy
  - severe asthma unresponsive to first and second line treatments: injection immunotherapy
  - aerochamber for children using daily inhaled corticosteroids
  - indications for hospitalization
    - ongoing need for supplemental O₂
    - persistently increased work of breathing
    - β₂-agonists are needed more often than q4h after 4-8 h of conventional treatment
    - patient deteriorates while on systemic steroids

Cystic Fibrosis

- see Respirology, R12

Etiology

- 1 per 3,000 live births, mostly Caucasians
- autosomal recessive, CFTR gene found on chromosome 7 (AF508 mutation in 70%, but >1,600 different mutations identified) resulting in a dysfunctional chloride channel on the apical membrane of cells
- leads to relative dehydration of airway secretions, resulting in impaired mucociliary transport and airway obstruction
Clinical Presentation
- neonatal: meconium ileus, prolonged jaundice, antenatal bowel perforation
- infancy: pancreatic insufficiency with steatorrhea and FTT (despite voracious appetite), anemia, hypoproteinemia, hyponatremia
- childhood: heat intolerance, wheezing or chronic cough, recurrent chest infections (S. aureus, P. aeruginosa, H. influenzae), hemoptysis, nasal polyps, distal intestinal obstruction syndrome, rectal prolapse, clubbing of fingers
- older patients: COPD, infertility (males), decreased fertility (female)

Investigations
- sweat chloride test x 2 (>60 mEq/L)
  - false positive tests: malnutrition, atopic dermatitis, hypothyroidism, hypoparathyroidism, GSD, adrenal insufficiency, G6PD, Klinefelter syndrome, technical issues, autonomic dysfunction, familial cholestasis syndrome
  - false negative tests: technical problem with test, malnutrition, skin edema, mineralocorticoids

Management
- nutritional counseling: high calorie diet, pancreatic enzyme replacements, fat soluble vitamin supplements
- management of chest disease: physiotherapy, postural drainage, exercise, bronchodilators, aerosolized DNase and inhaled hypertonic saline, antibiotics (e.g. cephalosporin, claxacillin, ciprofloxacin, inhaled tobramycin depending on sputum C&S), lung transplantation
- genetic counseling

Complications
- respiratory failure, pneumothorax (poor prognostic sign), cor pulmonale (late), pancreatic fibrosis with DM, gallstones, cirrhosis with portal HTN, infertility (male)
- early death (current median survival in Canada is 46.6 yr)

Rheumatology

Evaluation of Limb Pain

<p>| Table 46. Differential Diagnosis of Limb Pain |</p>
<table>
<thead>
<tr>
<th>Cause</th>
<th>&lt;3 yr</th>
<th>3-10 yr</th>
<th>&gt;10 yr</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trauma</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Infectious</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Septic arthritis</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Osteomyelitis</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Inflammatory</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transient synovitis</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>JIA</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Spondyloarthritis</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>SLE</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Dermatomyositis</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>HSP</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Anatomic/Orthopedic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Legg-Calvé-Perthes disease</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Slipped capital femoral epiphysis</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osgood-Schlatter disease</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neoplastic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Bone tumour</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Hematologic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemophilia (hemarthrosis)</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Sickle cell anemia</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Pain Syndromes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Growing pains</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Fibromyalgia</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Complex regional pain syndrome</td>
<td>x</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- must rule out infection, malignancy, and acute orthopedic conditions
History
- demographics (age, gender)
- pattern of onset and progression of symptoms (including acuity and chronicity)
- morning stiffness, limp/weight-bearing status, night pain
- joint involvement (type, distribution) \( \pm \) spine (axial) involvement
- extra-articular manifestations and systemic symptoms
- functional status – activities of daily living
- family history (arthritis, IBD, psoriasis, spondyloarthropathies, uveitis, bleeding disorders, sickle cell anemia)
- past medical illness, intercurrent infection, travel, sick contact history, joint injury

Physical Exam
- growth parameters
- screening examination (pediatric gait, arms, legs, spine exam)
- joint exam: inspection/palpation (swelling, erythema, warmth, tenderness, deformity), ROM
- adjacent structures (bone, tendon, muscle, skin)
- leg length
- neurologic exam

Investigations
- basic: CBC and differential, blood smear, ESR, CRP, x-ray
- as indicated: blood (ANA, RF, culture, viral/bacterial serology, CK, PTT, sickle cell screen, immunoglobulins, complement), urinalysis, synovial fluid (cell count, Gram stain, culture), TB skin test, imaging, bone marrow aspiration, slit lamp exam

Growing Pains

Epidemiology
- age 2-12 yr, M=F

Clinical Presentation
- diagnosis of exclusion
- intermittent, non-articular pain in childhood with normal physical exam findings
- pain at night, often bilateral and limited to the calf, shin, or thigh; typically short-lived
- relieved by heat, massage, mild analgesics
- child is well, asymptomatic during the day, no functional limitation
- possible family history of growing pains

Management
- lab investigations not necessary if typical presentation; reassurance and supportive management

Transient Synovitis of the Hip

Epidemiology
- age 3-10 yr, M>F

Clinical Presentation
- afebrile or low-grade fever, pain typically occurs in hips, knees (referred from hip); painful limp but full ROM (pain not as pronounced as in joint or bone infections)
- symptoms resolve over 7-10 d

Investigations
- WBC within normal limits; ESR and CRP may be mildly elevated
- joint effusions may be seen on imaging
- diagnosis of exclusion (rule out septic arthritis and osteomyelitis)

Treatment
- symptomatic and anti-inflammatory medications

Red Flags for Limb Pain
- fever, pinpoint pain/tenderness, pain out of proportion to degree of inflammation, night pain, weight loss, erythema
**Septic Arthritis and Osteomyelitis**

- **MEDICAL EMERGENCY**
- see Orthopedics OR

### Table 47. Microorganisms and Treatment Involved in Septic Arthritis/Osteomyelitis

<table>
<thead>
<tr>
<th>Age</th>
<th>Pathogens</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neonate</td>
<td>GAS, S. aureus, Gram negative bacilli</td>
<td>cloxacin + aminoglycoside or cefotaxime</td>
</tr>
<tr>
<td>Infant (1-3 mo)</td>
<td>Strep. spp., Staph. spp., H. influenzae</td>
<td>cloxacin + cefotaxime</td>
</tr>
<tr>
<td>Child</td>
<td>S. aureus, S. pneumoniae, GAS</td>
<td>cefazolin</td>
</tr>
<tr>
<td>Adolescent</td>
<td>As above; also N. gonorrhoeae</td>
<td>cefazolin</td>
</tr>
<tr>
<td>Sickle cell disease</td>
<td>As above; also Salmonella</td>
<td>cefazolin</td>
</tr>
</tbody>
</table>

GAS = group A Strept; GBS = group B Strept  
Adapted from Tse SML, Laxer RM. Pediatrics in Review 2006;27:170-179

**Juvenile Idiopathic Arthritis**

- a heterogenous group of conditions characterized by persistent arthritis in children <16 yr
- diagnosis: arthritis in ≥1 joint(s); duration ≥6 wk; onset age <16 yr old; exclusion of other causes of arthritis; classification defined by features/number of joints affected in the first 6 mo of onset

**Systemic Arthritis (Still’s Disease)**

- onset at any age, M=F
- once or twice daily fever spikes (>38.5°C) ≥2 d/wk; children usually acutely unwell during fever episodes
- extra-articular features: erythematous “salmon-coloured” maculopapular rash, lymphadenopathy, hepatosplenomegaly, leukocytosis, thrombocytosis, anemia, serositis
- arthritis may occur weeks to months later
- high ESR, CRP, WBC, platelet count

**Oligoarticular Arthritis (1-4 joints)**

- onset early childhood, F>M
- persistent: affects no more than 4 joints during the disease course
- extended: affects more than 4 joints after the first 6 mo
- typically affects large joints: knees > ankles, elbows, wrists; hip involvement unusual
- ANA positive ~60-80%, RF negative
- screening eye exams for asymptomatic anterior uveitis (occurs in ~30%)
- complications: knee flexion contracture, quadriceps atrophy, leg-length discrepancy, growth disturbances

**Polyarticular Arthritis (5 or more joints)**

- uveitis is present in 10% of patients
- RF negative
  - onset: 2-4 yr and 6-12 yr, F>M
  - symmetrical involvement of large and small joints of hands and feet, TMJ, cervical spine
- RF positive
  - onset: late childhood/early adolescence, F>M
  - similar to the aggressive form of adult rheumatoid arthritis
  - severe, rapidly destructive, symmetrical arthritis of large and small joints
  - may have rheumatoid nodules at pressure points (elbows, knees)
  - unremitting disease, persists into adulthood

**Enthesitis-Related Arthritis**

- onset: late childhood/adolescence, M>F
- arthritis and/or enthesitis (inflammation at the site where tendons or ligaments attach to the bone)
- weight bearing joints, especially hip and intertarsal joints
- risk of developing ankylosing spondylitis in adulthood

**Psoriatic Arthritis**

- onset: 2-4 yr and 9-11 yr, F>M
- arthritis and psoriasis OR arthritis and at least two of:
  - dactylitis, nail pitting or other abnormalities, or family history of psoriasis in a 1st degree relative
  - asymmetric or symmetrical small or large joint involvement
Management
- goals of therapy: eliminate inflammation, prevent joint damage, promote normal growth and development as well as normal function, minimize medication toxicity
- exercise to maintain ROM and muscle strength
- multidisciplinary approach: OT/PT, social work, orthopedics, ophthalmology, rheumatology
- 1st line drug therapy: NSAIDs, intra-articular corticosteroids
- 2nd line drug therapy: DMARDs (methotrexate, sulfasalazine, lefunamide), corticosteroids (acute management of severe arthritis, systemic symptoms of JIA, topical eye drops for uveitis), biologic agents

**Reactive Arthritis**
- see Rheumatology, RH23
- arthritis (typically the knee) follows bacterial infection, especially with Salmonella, Shigella, Yersinia, Campylobacter, Chlamydia, and most commonly Streptococcus (post-streptococcal reactive arthritis)
- typically resolves spontaneously
- may progress to chronic illness or Reiter’s syndrome (urethritis, conjunctivitis)

**Lyme Arthritis**
- see Infectious Diseases, ID23
- caused by spirochete Borrelia burgdorferi
- incidence highest among 5-10 yr olds
- do not treat children <8 yr old with doxycycline (may cause permanent tooth discolouration)

**Systemic Lupus Erythematosus**
- see Rheumatology, RH11
- autoimmune illness affecting multiple organ systems
- incidence 1/1,000, more commonly age >10, F:M = 10:1
- childhood-onset SLE vs. adult-onset SLE: children have more active disease, are more likely to have renal disease, and children receive more intensive drug therapy and have a poorer prognosis

**Vasculitides**

**HENOCH-SCHÖNLEIN PURPURA**
- most common vasculitis of childhood, peak incidence 4-10 yr, M:F = 2:1
- vasculitis of small vessels
- often have history of URTI 1-3 wk before onset of symptoms

**Clinical Presentation**
- clinical triad: 1) palpable purpura, 2) abdominal pain, 3) arthritis
- skin: palpable, non-thrombocytopenic purpura in lower extremities and buttocks, edema, scrotal swelling
- joints: arthritis/artralgia involving large joints associated with painful edema
- GI: abdominal pain, GI bleeding, intussusception
- renal: microscopic hematuria, IgA nephropathy, proteinuria, HTN, renal failure in <5%

**Management**
- mainly supportive
- anti-inflammatory medications for joint pain, corticosteroids for select patients
- monitor for protein on urinalysis every month for 6 mo, checking for renal disease, which may develop late (immunosuppressive therapy if severe)

**Prognosis**
- self-limited, resolves within 4 wk
- recurrence in about one-third of patients
- long-term prognosis dependent on severity of nephritis
KAWSASKI DISEASE
- acute vasculitis of unknown etiology (likely triggered by infection)
- medium-sized vasculitis with predilection for coronary arteries
- most common cause of acquired heart disease in children in developed countries
- peak age: 3 mo-5 yr; Asians > Blacks > Caucasians

Diagnostic Criteria
- fever persisting ≥5 d AND ≥4 of the following features
  1. bilateral, non-exudative conjunctival injection
  2. oral mucous membrane changes (fissured lips, strawberry tongue, injected pharynx)
  3. changes of the peripheral extremities
     - acute phase: extremity changes including edema of hands and feet or erythema of palms or soles
     - subacute phase: periungual desquamation
  4. polymorphous rash
  5. cervical lymphadenopathy >1.5 cm in diameter (usually unilateral)
- exclusion of other diseases (e.g. scarlet fever, measles)
- atypical Kawasaki disease: fever persisting ≥5 d and 2-3 of the above criteria
- further evaluation dictated by CRP, ESR, and supplemental laboratory criteria

Management
- initial therapy: IVIG (2g/kg) and high (anti-inflammatory) dose of ASA
- once afebrile >48 hours: low (anti-platelet) dose of ASA until platelets normalize, or longer if coronary artery involvement
- IVlg within 10 d of onset reduces risk of coronary aneurysm formation
- baseline 2D-Echo and follow up periodic 2D-Echo (usually at 2, 6 wk)

Complications
- coronary artery vasculitis with aneurysm formation occurs in 20-25% of untreated children, <5% if receive IVlg within 10 d of fever
- 50% of aneurysms regress within 2 yr
- anticoagulation for multiple or large coronary aneurysms
- risk factors for coronary disease: male, age <1 or >9 yr, fever >10 d, Asian or Hispanic ethnicity, thrombocytopenia, hyponatremia

---

Common Medications

Table 48. Commonly Used Medications in Pediatrics

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Schedule</th>
<th>Indications</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>acetaminophen</td>
<td>10-15 mg/kg/dose PO q4-8h pm</td>
<td>Analgesic, antipyretic</td>
<td>Not to exceed 60 mg/kg/d in neonates or 75 mg/kg/d in older children to a max of 4 g/d Causes hepatotoxicity at high doses</td>
</tr>
<tr>
<td>amoxicillin</td>
<td>80-90 mg/kg/d PO divided q8h</td>
<td>Otitis media</td>
<td></td>
</tr>
<tr>
<td>dexamethasone</td>
<td>0.6 mg/kg PO x 1 0.6 mg/kg/d PO for 2 d</td>
<td>Croup Acute asthma</td>
<td></td>
</tr>
<tr>
<td>fluticasone (Flovent®)</td>
<td>Moderate dose – 250-500 µg/d divided bid High dose – &gt;500 µg/d divided bid</td>
<td>Asthma</td>
<td></td>
</tr>
<tr>
<td>ibuprofen</td>
<td>5-10 mg/kg/dose PO q6-8h</td>
<td>Analgesic, antipyretic</td>
<td>Cautious use in patients with liver impairament, history of GI bleeding or ulcers</td>
</tr>
<tr>
<td>iron</td>
<td>6 mg/kg/d elemental iron OD or divided tid</td>
<td>Anemia</td>
<td>SE: dark stool, constipation, dark urine</td>
</tr>
<tr>
<td>omeprazole</td>
<td>0.7-3.3 mg/kg/d (max dose 20 mg/d) OD or divided bid/tid</td>
<td>GERD SE: headache, diarrhea, nausea, abdominal pain</td>
<td></td>
</tr>
<tr>
<td>ondansetron</td>
<td>0.15 mg/kg/dose (max dose 16 mg) q4-8h up to 3x</td>
<td>Post-operative N/V Gastroenteritis Cyclic vomiting</td>
<td>SE: QTc prolongation, orally disintegrating tablets contain phenylalanine (caution in PKU patients)</td>
</tr>
<tr>
<td>phenobarbital</td>
<td>3-5 mg/kg/d PO OD or bid</td>
<td>Seizures</td>
<td>SE: CNS depression</td>
</tr>
<tr>
<td>polyethylene glycol 3350 (PEG)</td>
<td>Disimpaction: 1-1.5 g/kg/d x 3 d Maintenance: starting dose at 0.4-1 g/kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>prednisone/ prednisolone</td>
<td>1-2 mg/kg/d PO x 5 d 3-4 mg/kg/d PO then taper to 1-2 mg/kg/d PO once platelet count &gt;30 x 109/L 60 mg/m²/d PO</td>
<td>Asthma ITP Nephrotic syndrome Oral prednisone is bitter tasting, consider using prednisolone</td>
<td></td>
</tr>
<tr>
<td>salbutamol (Ventolin®)</td>
<td>0.01-0.03 mL/kg/dose in 3 mL NS via nebulizer q0.5-4h pm 100-200 µg/dose pm, max 4-8 puffs frequency q4h</td>
<td>Acute asthma Can cause tachycardia, hypokalemia, restlessness</td>
<td></td>
</tr>
</tbody>
</table>

References

Neonatology

Nephrology

Neurology

Oncology

Respirology

Rheumatology

Web-Based Resources
http://www.cda-adc.ca.
http://www.aboutkidshealth.ca.
http://www.publichealth.gc.ca.
http://www.cps.ca.
# Acronyms

<table>
<thead>
<tr>
<th>Acronyms</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plastic Surgery</td>
<td>2</td>
</tr>
<tr>
<td>PL</td>
<td>2</td>
</tr>
</tbody>
</table>

# Basic Anatomy Review

<table>
<thead>
<tr>
<th>Basic Anatomy Review</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin</td>
<td>2</td>
</tr>
<tr>
<td>Hand</td>
<td>2</td>
</tr>
<tr>
<td>Brachial Plexus</td>
<td>2</td>
</tr>
<tr>
<td>Face</td>
<td>2</td>
</tr>
</tbody>
</table>

# Skin Lesions and Masses

<table>
<thead>
<tr>
<th>Skin Lesions and Masses</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Differential Diagnosis of Skin Lesions/Masses</td>
<td>5</td>
</tr>
<tr>
<td>Surgical Management of Malignant Skin Lesions</td>
<td>5</td>
</tr>
</tbody>
</table>

# Basic Surgical Techniques

<table>
<thead>
<tr>
<th>Basic Surgical Techniques</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sutures and Suturing</td>
<td>6</td>
</tr>
<tr>
<td>Excision</td>
<td>6</td>
</tr>
<tr>
<td>Skin Biopsy Types and Techniques</td>
<td>6</td>
</tr>
</tbody>
</table>

# Wounds

<table>
<thead>
<tr>
<th>Wounds</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Causal Conditions</td>
<td>8</td>
</tr>
<tr>
<td>Principles of Wound Healing</td>
<td>8</td>
</tr>
<tr>
<td>Infected Wounds</td>
<td>8</td>
</tr>
<tr>
<td>Dressings</td>
<td>8</td>
</tr>
<tr>
<td>Reconstruction</td>
<td>8</td>
</tr>
</tbody>
</table>

# Soft Tissue Infections

<table>
<thead>
<tr>
<th>Soft Tissue Infections</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erysipelas</td>
<td>14</td>
</tr>
<tr>
<td>Cellulitis</td>
<td>14</td>
</tr>
<tr>
<td>Necrotizing Fasciitis</td>
<td>14</td>
</tr>
</tbody>
</table>

# Ulcers

<table>
<thead>
<tr>
<th>Ulcers</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lower Limb Ulcers</td>
<td>15</td>
</tr>
<tr>
<td>Pressure Ulcers</td>
<td>15</td>
</tr>
</tbody>
</table>

# Burns

<table>
<thead>
<tr>
<th>Burns</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burn Injuries</td>
<td>17</td>
</tr>
<tr>
<td>Pathophysiology of Burn Wounds</td>
<td>17</td>
</tr>
<tr>
<td>Diagnosis and Prognosis</td>
<td>17</td>
</tr>
<tr>
<td>Indications for Transfer to Burn Centre</td>
<td>17</td>
</tr>
<tr>
<td>Acute Care of Burn Patients</td>
<td>17</td>
</tr>
<tr>
<td>Special Considerations</td>
<td>17</td>
</tr>
</tbody>
</table>

# Hand

<table>
<thead>
<tr>
<th>Hand</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Traumatic Hand</td>
<td>22</td>
</tr>
<tr>
<td>General Management</td>
<td>22</td>
</tr>
<tr>
<td>Hand Infections</td>
<td>22</td>
</tr>
<tr>
<td>Amputations</td>
<td>22</td>
</tr>
<tr>
<td>Tendons</td>
<td>22</td>
</tr>
<tr>
<td>Fractures and Dislocations</td>
<td>22</td>
</tr>
<tr>
<td>Dupuytren's Disease</td>
<td>22</td>
</tr>
<tr>
<td>Median Nerve Compression</td>
<td>22</td>
</tr>
</tbody>
</table>

# Brachial Plexus

<table>
<thead>
<tr>
<th>Brachial Plexus</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>28</td>
</tr>
</tbody>
</table>

# Craniofacial Injuries

<table>
<thead>
<tr>
<th>Craniofacial Injuries</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approach to Facial Injuries</td>
<td>29</td>
</tr>
<tr>
<td>Mandibular Fractures</td>
<td>29</td>
</tr>
<tr>
<td>Maxillary Fractures</td>
<td>29</td>
</tr>
<tr>
<td>Nasal Fractures</td>
<td>29</td>
</tr>
<tr>
<td>Zygomatic Fractures</td>
<td>29</td>
</tr>
<tr>
<td>Orbital Floor Fractures</td>
<td>29</td>
</tr>
</tbody>
</table>

# Breast

<table>
<thead>
<tr>
<th>Breast</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anatomy</td>
<td>32</td>
</tr>
<tr>
<td>Breast Reduction</td>
<td>32</td>
</tr>
<tr>
<td>Mastopexy (Breast Lift)</td>
<td>32</td>
</tr>
<tr>
<td>Breast Augmentation</td>
<td>32</td>
</tr>
<tr>
<td>Gynecomastia</td>
<td>32</td>
</tr>
<tr>
<td>Breast Reconstruction</td>
<td>32</td>
</tr>
</tbody>
</table>

# Aesthetic Surgery

<table>
<thead>
<tr>
<th>Aesthetic Surgery</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aesthetic Procedures</td>
<td>36</td>
</tr>
</tbody>
</table>

# Pediatric Plastic Surgery

<table>
<thead>
<tr>
<th>Pediatric Plastic Surgery</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craniofacial Anomalies</td>
<td>36</td>
</tr>
<tr>
<td>Congenital Hand Anomalies</td>
<td>36</td>
</tr>
</tbody>
</table>

# References

<table>
<thead>
<tr>
<th>References</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>38</td>
</tr>
</tbody>
</table>
Acronyms

- ABI: ankle-brachial index
- ABG: arterial blood gas
- APL: abductor pollicis longus
- ARDS: acute respiratory distress syndrome
- ATLS: advanced trauma life support
- BMR: basal metabolic rate
- CHF: congestive heart failure
- CMC: carpo-metacarpal
- CO: carbon monoxide
- CSF: cerebrospinal fluid
- CVD: cerebrovascular disease
- CXR: chest x-ray
- D5W: 5% dextrose in water
- DIEP: deep inferior epigastric perforator
- DIP: distal interphalangeal joint
- DM: diabetes mellitus
- EMG: electromyography
- ENT: ear, nose, throat
- EPB: extensor pollicis brevis
- FDP: flexor digitorum profundus
- FDS: flexor digitorum superficialis
- FTSG: full thickness skin graft
- GBS: group B Streptococcus
- HTN: hypertension
- I&D: incision and drainage
- ICP: intracranial pressure
- ICU: intensive care unit
- IGAP: inferior gluteal artery perforator
- IGF: intravenous immunoglobulin
- IP: interphalangeal
- IVg: intravenous immunoglobulin
- MCP: metacarpal
- MF: metacarpal phalangeal joint
- NS: normal saline
- NSAIDs: nonsteroidal anti-inflammatory drugs
- OM: otitis media
- OR: operating room
- ORIF: open reduction internal fixation
- PIP: proximal interphalangeal joint
- PMN: polymorphonuclear
- RA: rheumatoid arthritis
- RL: Ringer's lactate
- RGM: range of motion
- SGAP: superior gluteal artery perforator
- SIADH: syndrome of inappropriate antidiuretic hormone
- SIEA: superficial inferior epigastric artery
- SLO: speech language pathology
- SOF: superior orbital fissure
- STSG: split thickness skin graft
- TBSA: total body surface area
- TRAM: transverse rectus abdominus myocutaneous
- TMJ: temporomandibular joint
- UV: ultraviolet
- AB: superficial palmar arch
- B: Deep palmar arch
- C: Ulnar artery
- D: Radial artery

Basic Anatomy Review

Skin

Figure 1. Split and full thickness skin grafts

Hand

Figure 3. Carpal bones

Figure 4. Sensory distribution in the hand
**Basic Anatomy Review**

**Figure 5.** Flexor tendon insertion at PIP and DIP

**Figure 6.** Extensor mechanism of digits

**Figure 7.** Carpal tunnel

**Figure 8.** Extensor compartment of the wrist (dorsal view and cross-sectional view)

---

**Nail anatomy**

- **Flexor Tendons**
  - All require OR repair

- **Extensor Tendons**
  - ER repair unless proximal/multiple tendons

**Carpal Bone Mnemonic**

- So Long to Pinky. Here Comes The Thumb.
- Scaphoid
- Lunate
- Triquetrum
- Pisiform
- Hamate
- Capitate
- Trapezoid
- Trapezium

1. Extensor retinaculum
2. Abductor pollicis longus
3. Extensor pollicis brevis

**Compartment 2**
4. Extensor carpi radialis brevis
5. Extensor carpi radialis longus

**Compartment 3**
6. Extensor pollicis longus (EPL tendon passes around Lister’s tubercle)

**Compartment 4**
7. Extensor digitorum
8. Extensor indicis

**Compartment 5**
9. Extensor digiti minimi

**Compartment 6**
10. Extensor carpi ulnaris
Brachial Plexus

Figure 9. Brachial plexus anatomy

Face

Figure 10. Skull and facial bones
Skin Lesions and Masses

Differential Diagnosis of Skin Lesions/Masses

- for background information and medical management (see Dermatology, D5)
- for biopsy techniques, see Skin Biopsy Types and Techniques, PL7

Surgical Management of Malignant Skin Lesions

- surgical treatment for all malignant skin lesions involve total excision of the primary lesion
- excision margin of lesion depends on the type of lesion, the lesion diameter and (for melanoma) the lesion depth
- for decisions regarding reconstruction using flaps or skin grafts, see Reconstruction, PL11

Precursors of Malignant Lesions

Table 1. Precursors

<table>
<thead>
<tr>
<th>Basal Cell Carcinoma</th>
<th>Squamous Cell Carcinoma</th>
<th>Malignant Melanoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nevus sebaceous of Jadassohn</td>
<td>Actinic keratosis</td>
<td>Lentigo maligna</td>
</tr>
<tr>
<td></td>
<td>Bowen’s disease</td>
<td>Giant congenital nevus</td>
</tr>
<tr>
<td></td>
<td>Bowenoid papulosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paget’s disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Leukoplakia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Erythroplasia</td>
<td></td>
</tr>
</tbody>
</table>

Surgical Margins

Table 2. Surgical Margins for Basal Cell Carcinoma

<table>
<thead>
<tr>
<th>Type of Lesion</th>
<th>Surgical Margins</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Risk (&lt;20 mm trunk; &lt; 6 mm face, hands, feet)</td>
<td>3 mm</td>
</tr>
<tr>
<td>High Risk (&gt;20 mm trunk; &gt;6 mm face, hands, feet)</td>
<td>3-5 mm</td>
</tr>
</tbody>
</table>

Table 3. Surgical Margins for Squamous Cell Carcinoma

<table>
<thead>
<tr>
<th>Diameter or Location of Lesion</th>
<th>Surgical Margins</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤2 cm</td>
<td>1-2 cm</td>
</tr>
<tr>
<td>&gt;2 cm</td>
<td>2 cm</td>
</tr>
<tr>
<td>High risk (facial)</td>
<td>1 cm</td>
</tr>
<tr>
<td>Low risk (elsewhere)</td>
<td>1-2 cm</td>
</tr>
</tbody>
</table>

Table 4. Surgical Margins for Malignant Melanoma

<table>
<thead>
<tr>
<th>Depth of Lesion</th>
<th>Surgical Margins</th>
</tr>
</thead>
<tbody>
<tr>
<td>In situ</td>
<td>0.5 cm</td>
</tr>
<tr>
<td>&lt;1 mm</td>
<td>1 cm</td>
</tr>
<tr>
<td>1.01-1.99 mm</td>
<td>1-2 cm</td>
</tr>
<tr>
<td>≥2 mm</td>
<td>2 cm</td>
</tr>
</tbody>
</table>
Basic Surgical Techniques

Sutures and Suturing

ANESTHESIA
- irritate before injecting anesthetic, followed by debridement and more vigorous irrigation

**Table 5. Toxic Limit and Duration of Action (1 cc of 1% solution contains 10 mg lidocaine)**

<table>
<thead>
<tr>
<th></th>
<th>Without Epinephrine</th>
<th>With Epinephrine (vasoconstrictor, limits bleeding)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lidocaine (Xylocaine)*</td>
<td>5 mg/kg, lasts 45-60 min</td>
<td>7 mg/kg, lasts 2-6 h</td>
</tr>
<tr>
<td>Bupivacaine (Marcaine)+ for longer analgesic effect</td>
<td>2 mg/kg, lasts 2-4 h</td>
<td>3 mg/kg, lasts 3-7 h</td>
</tr>
</tbody>
</table>

* Lidocaine toxicity symptoms include circumoral numbness, light-headedness and drowsiness followed by tremors and seizures. Cardiac and respiratory signs are late findings.

- for example, when using 1% lidocaine without epinephrine in a 70 kg patient:
  - toxic limit = $5 \times 70 = 350$ mg
  - max bolus injection = $350 \div 10 = 35$ cc (may add more after 30 min)

IRRIGATION AND DEBRIDEMENT
- irrigate copiously with a physiologic solution such as Ringer’s lactate or normal saline to remove surface clots, foreign material, and bacteria
- use a 19 gauge needle and 35 cc syringe to generate ~18 psi when irrigating
- debride all obviously devitalized tissue; irregular or ragged wounds must be excised to produce sharp wound edges that will assist healing when approximated
- wounds left unapproximated ≥8 h should be debrided to ensure wound edges are optimized for healing

SUTURES
- use of a particular suture material is highly dependent on surgeon preference; however, skin should be closed with a non-absorbable material when traumatic mechanisms are involved

**Table 6. Suture Materials: Absorbable vs. Non-absorbable and Monofilament vs. Multifilament**

<table>
<thead>
<tr>
<th>Suture Materials</th>
<th>Uses</th>
<th>Examples</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absorbable</td>
<td>Deep sutures under short-term tension</td>
<td>Plain gut®, Vicryl®, Polysorb®, chromic gut, fast absorbing gut</td>
<td>Loses at least 50% of their strength in 4 wk; eventually absorbed</td>
</tr>
<tr>
<td></td>
<td>Skin closure in children</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-absorbable</td>
<td>Skin closure</td>
<td>Nylon, polypropylene (Prolene), stainless steel, silk, ticon, ethibond</td>
<td>Lower likelihood of wound dehiscence, more difficult to tie, makes track marks</td>
</tr>
<tr>
<td></td>
<td>Sites of long-term tension</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monofilament</td>
<td>Everyday use and optimal for contaminated and infected wounds (lower likelihood of bacterial trapping in suture material)</td>
<td>Monoabs®, Monocryl®, Biosyn®, Prolene</td>
<td>Slides through tissue with less friction; more memory/stiffness</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multifilament</td>
<td>AVOID in contaminated wounds (increased likelihood of bacterial trapping)</td>
<td>Vicryl® and Silk, Ticon, Ethibond</td>
<td>Less memory/stiffness thus easier to work with</td>
</tr>
</tbody>
</table>

BASIC SUTURING TECHNIQUES

Basic Suture Methods
- simple interrupted: can be used in almost all situations
- sub-cuticular: good cosmetic result but weak, used in combination with deep sutures; not used in trauma
- vertical mattress: for areas difficult to evert (e.g. solar palm of the hand)
- horizontal mattress: evertion, time saving
- continuous over and over (i.e. “running”, “baseball stitch”): time saving, good for hemostasis

Other Skin Closure Materials
- tapes: may be indicated for superficial wounds and those with opposable edges. Tape cannot be used on actively bleeding wounds. When placed across the incision, will prevent surface marks and can be used primarily or after surface sutures have been removed
- skin adhesives: e.g. 2-octylcyanoacrylate (e.g. Dermabond®) works well on small areas without much tension or shearing; may cause irreversible tattooing
- staples: steel-titanium alloys that incite minimal tissue reaction (healing is comparable to wounds closed by suture)

Steps to Ensuring Good Suturing Cosmesis
- Incisions should be made along relaxed skin tension lines
- Attain close apposition of wound edges
- Minimize tension on skin by closing in layers
- Evert wound edges
- Use appropriately sized suture for skin closure (5-0, 6-0 on face; 3-0, 4-0 elsewhere)
- Ensure equal width and depth of tissue on both sides
- Remove sutures within 5-7 d from the face, 10-14 d from scalp/torso/extremities
Excision

• plan your incision along relaxed skin tension lines to minimize appearance of scar
• use elliptical incision to prevent "dog ears" (beaped up skin at end of incision) so the length of the ellipse should be approximately 3x the width
• if needed, undermine skin edges to decrease wound tension
• use layered closure including dermal sutures when wound is deeper than superficial (decreases tension)

Skin Biopsy Types and Techniques

SHAVE BIOPSY
• used for superficial lesions where sampling of the full thickness of the dermis is not necessary or practical
• most suitable lesions for shave biopsies are either elevated above the skin or have pathology confined to the epidermis (e.g. seborrheic or actinic keratoses, skin tags, warts, and superficial basal cell or squamous cell carcinomas)
• rapid, requires little training, and does not require sutures for closure
• heals by secondary intent (moist dressings should be used)
• should not be used for pigmented lesions – an unsuspected melanoma cannot be properly staged if partially removed

NEEDLE BIOPSY
• 21 G for lymph node biopsy
• Trucut needle biopsy for breast masses suspected for carcinoma

INCISIONAL BIOPSY
• can either be a punch biopsy or can be an ellipse within the lesion
• gives pathologists a portion of the lesion and the border with normal skin too
• punch biopsies involve the removal of a core-shaped piece of tissue to allow sampling of the deep dermis, performed with round, disposable knives ranging in diameter from 2-10 mm
• punch biopsies can be used for the diagnosis and treatment of small pigmented lesions and atypical moles
• punch biopsy wounds can be closed with suture or left to heal by secondary intention. Punches greater than 3 mm may produce scarring and are best closed with one or two sutures
• punch biopsies have a low incidence of infection, bleeding, nonhealing, significant scarring

EXCISIONAL BIOPSY
• performed for lesions that require complete removal for diagnostic or therapeutic purposes
• performed for lesions that cannot be adequately punch biopsied due to size, depth, or location
• best for small lesions that are easily removed and primarily closed
• requires the greatest amount of expertise and time
• always requires sutures for closure

TECHNIQUE

General
• all shave and punch biopsies performed in clinic are done using aseptic technique, but are not sterile
• sterile gloves are indicated for biopsies and excisions in all patients

Preparing the Site
• common skin antiseptics (betadine, chlorhexidine) can be used to prepare the biopsy site
• chlorhexidine is used in concentrations ranging from 0.5-4%. The higher concentration cannot be used on the face as it could get into the eyes or ears and may burn or cause damage. Most chlorhexidine preps also do contain alcohol which can be flammable, so allow to dry before the biopsy and certainly before using any cautery
• Betadine® (7.5% povidone – iodine) may be safer for the head and neck (as to avoid the above problems with chlorhexidine/alcohol) around the eyes and ears
• mark the intended lesion and surgical margins with a surgical marker since they may be temporarily obliterated following injection of the anesthetic
• for all biopsies, a sterile drape technique is indicated. A fenestrated surgical drape is placed around the biopsy site after the area is cleansed and anesthetized

Anesthesia
• most commonly used local anesthetic is 1% or 2% lidocaine (with epinephrine)
• small amounts of epinephrine are added to constrict blood vessels, decrease bleeding, prolong anesthesia, and limit lidocaine toxicity. The local with epinephrine can be injected directly into the lesion
• local anesthetics with epinephrine may be used anywhere in the body (including the digits – except if the digits have been significantly injured and could have vascular compromise – e.g. saw injury)
• epinephrine should be avoided in patients with history of vascular compromise
Wounds

Causal Conditions

- laceration: cut or torn tissue
- abrasion: superficial skin layer is removed, variable depth
- contusion: injury caused by forceful blow to the skin and soft tissue; entire outer layer of skin intact yet injured
- avulsion: tissue/limb forcefully separated from surrounding tissue, either partially or fully; “de-gloving”
- puncture wounds: cutaneous opening relatively small as compared with depth (e.g. needle)
- includes bite wounds
- crush injuries: caused by compression
- thermal and chemical wounds

Principles of Wound Healing

- wound: disruption of the normal anatomical relationships of tissue as a result of injury

FACTORS INFLUENCING WOUND HEALING

Local (reversible/controllable)
- mechanical (local trauma, significant crush, avulsion, tension)
- blood supply (ischemia/circulation)
- temperature
- technique and suture materials
- retained foreign body
- infection
- venous HTN
- peripheral vascular disease
- PVD
- hematoma/seroma (↑ infection rate)

General (often irreversible)
- age
- nutrition (protein, vitamin C, O₂)
- smoking
- chronic illness (e.g. DM, cancer, CVD)
- immunosuppression (steroids, chemo)
- collagen vascular disease
- tissue irradiation

STAGES OF WOUND HEALING

- growth factors released by tissues play an important role
- scar is mature once it has completed the final stage, usually after 1-2 yr

<table>
<thead>
<tr>
<th>PHASE</th>
<th>PROCESS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Inflammatory Phase (Reactive) (Days 1-6)</td>
<td>1. Hemostasis – vasoconstriction + platelet plug&lt;br&gt;2. Chemotaxis – migration of macrophages and PMN</td>
</tr>
<tr>
<td>• Limits damage, prevents further injury&lt;br&gt;• Debris and organisms cleared via inflammatory response:&lt;br&gt;  - Neutrophils (24-48 h)&lt;br&gt;  - Macrophages: critical to wound healing by orchestrating growth factors for collagen production (48-96 h)&lt;br&gt;  - Lymphocytes: role poorly defined (5-7 d)</td>
<td></td>
</tr>
<tr>
<td>2. Proliferative Phase (Regenerative) (Day 4 – Week 3)</td>
<td>1. Collagen synthesis (mainly type III)&lt;br&gt;2. Angiogenesis&lt;br&gt;3. Epithelialization</td>
</tr>
<tr>
<td>• Fibroblasts attracted and activated by macrophage growth factors&lt;br&gt;• Reparative process: re-epithelialization, matrix synthesis, angiogenesis (relieves ischemia)&lt;br&gt;• Tensile strength begins to increase at 4-5 d</td>
<td></td>
</tr>
<tr>
<td>• Increasing collagen organization and stronger crosslinks&lt;br&gt;• Type I collagen replaces Type III until normal 4:1 ratio achieved&lt;br&gt;• Peak tensile strength at 60 d – 80% of preinjury strength</td>
<td></td>
</tr>
</tbody>
</table>

Figure 14. Stages of wound healing

ABNORMAL HEALING

Hypertrophic Scar
- definition: scar remains roughly within boundaries of original scar<br>red, raised, widened, frequently pruritic<br>common sites: back, shoulder, sternum
• treatment: scar massage, pressure garments, silicone gel sheeting, corticosteroid injection, surgical excision if other options fail (however, may still recur)
• will often improve slowly over time

**Keloid Scar**
- definition: scar grows outside boundaries of original scar
- red, raised, widened, frequently pruritic
- caused by 1. genetic factors (highest rates in African Americans, Asians), 2. endocrine factors and/or 3. excess tension on wound or delayed closure (as in burn wounds)
- common sites: back, shoulders, deltoid, ear, anlge of mandible
- treatment: multimodal therapy, including pressure garments, silicone gel sheeting, corticosteroid injection, surgical excision with post-surgical management if other options fail (however, there is a high chance of recurrence), fractional carbon dioxide ablative laser, radiation

**Spread Scar**
- characterized by having the exactly same order of collagen fibers as normal scars
- clinically, a typical spread scar is flat, wide and often dented
- treatment: surgical excision and closure

**Chronic Wound**
- fails to achieve primary wound healing within 4-6 wk
- common chronic wounds include diabetic, pressure and venous stasis ulcers
- treatment: may heal with meticulous wound care; may also require surgical intervention
- Marjolin’s ulcer: squamous cell carcinoma arising in a chronic wound secondary to genetic changes caused by chronic inflammation → always consider biopsy of chronic wound

**WOUND HEALING**

**Healing (First Intention)**
- definition: wound closure by direct approximation of edges within hours of wound creation (i.e. with sutures, staples, skin graft, etc.)
- indication: recent (<6 h, longer with facial wounds), clean wounds
- contraindications: animal/human bites (except on face), crush injuries, infection, long time lapse since injury (>6-8 h), retained foreign body

**Spontaneous Healing (Second Intention)**
- definition: wound left open to heal spontaneously (epithelialization 1 mm/d from wound margins in concentric pattern), contraction (myofibroblasts) and granulation – maintained in inflammatory phase until wound closed; requires dressing changes; inferior cosmetic result
- indication: when 1st closure not possible or indicated (see Primary Healing)

**Delayed Primary Healing (Third Intention)**
- definition: intentionally interrupt healing process (e.g. with packing), then wound can be closed at 4-10 d post-injury after granulation tissue has formed and there is <10^5 bacteria/gram of tissue
- indication: contaminated (high bacterial count), long time lapse since initial injury, severe crush component with significant tissue devitalization, closure of fasciectomy wounds
- prolongation of inflammatory phase decreases bacterial count and lessens chance of infection after closure

**Infected Wounds**

**Definitions**
- contamination: the presence of nonreplicating microorganisms within a wound
- colonization: the presence of replicating microorganisms within a wound
- infection: greater than 10^7 microorganisms in a wound without intact epithelium, a wound may also be infected with small amounts of a very virulent organism (e.g. GBS)

**Management of Acute Contaminated Wound (<24 h)**
- cleanse and irrigate open wound with physiologic solution (NS or RL) using sufficient pressure
- evaluate for injury to underlying structures (vessels, nerve, tendon and bone)
- control active bleeding; previously closed wounds may require suture removal in order to drain any pus and allow for thorough irrigation and debridement
- debridement: removal of foreign material, devitalized tissue, old blood
  - surgical debridement: blade and irrigation if indicated
- systemic antibiotics are commonly indicated for obvious infection. Risk factors include wound older than 8 h, severely contaminated, human/animal bites, immunocompromised, involvement of deeper structures (e.g. joints, fractures)
- ± tetanus toxoid 0.5 mL IM ± tetanus immunoglobulin 250 U deep IM (see Table 7 and Table 8)
- ± post-exposure treatment of
  - hepatitis B, HIV, hepatitis C (if titres confirmed at 6 mo)
• re-evaluate in 24–48 h for signs of superficial or deep infection
  • if evidence of infection, open infected portion of wound by removing sutures (i.e. erythema, warmth, pain, discharge), swab sample for culture and sensitivity, irrigate wound and allow healing secondary intention

Table 7. Risks for Tetanus

<table>
<thead>
<tr>
<th>Wound Characteristics</th>
<th>Tetanus-Prone</th>
<th>Not Tetanus-Prone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time since injury</td>
<td>&gt; 6 h</td>
<td>&lt; 6 h</td>
</tr>
<tr>
<td>Depth of injury</td>
<td>&gt; 1 cm</td>
<td>&lt; 1 cm</td>
</tr>
<tr>
<td>Mechanism of Injury</td>
<td>Crush, burn, gunshot, frostbite, puncture through clothing, farming injury</td>
<td>Sharp cut (e.g. clean knife, clean glass)</td>
</tr>
</tbody>
</table>

Devitalized tissue Present Not present
Contamination (e.g. soil, dirt, saliva, grass) Yes No
Retained foreign body Yes No

Table 8. Tetanus Immunization Recommendations

<table>
<thead>
<tr>
<th>History of Tetanus Immunization</th>
<th>Clean, Minor Wounds</th>
<th>All Other Wounds</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Td or Tdap*</td>
<td>Tig**</td>
</tr>
<tr>
<td>Uncertain or &lt; 3 doses of immunization</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>3 doses received in immunization series</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

* 0.5 mL of combined tetanus and diphtheria toxoids ± acellular pertussis

** Tetanus immune globulin, 250 U given at a separate site from Td/Tdap

Management of Contaminated Wounds (> 24 h, including ulcers)
• irrigation and debridement
  • traumatic tattooing can occur if foreign materials left in wound
• systemic antibiotics indicated if there is concern of infection (e.g. redness, swelling, pain, clinically unwell)
• topical antimicrobials: beneficial for minor wounds, but no additional benefit for wounds requiring systemic antibiotics. May aid in healing of chronic wounds
• closure: final closure via secondary intention (most common), delayed wound closure (3º closure), skin graft or flap; successful closure depends on bacterial count of ≤10^9/cm^2 prior to closure and frequent dressing changes

BITES
• see Emergency Medicine, ER47

Dog and Cat Bites
• pathogens: Pasteurella multocida, S. aureus, S. viridans
• investigations
  • radiographs prior to therapy to rule out foreign body (e.g. tooth) or fracture
  • culture for aerobic and anaerobic organisms, Gram stain
• treatment: Clavulin* (500 mg PO q8h started immediately – amoxicillin + clavulanic acid)
  • consider rabies prophylaxis if animal has symptoms of rabies or unknown animal
  • ± rabies Ig (20 IU/kg around wound, or IM) and 1 of the 3 types of rabies vaccines (1.0 mL IM in deltoid, repeat on days 3, 7, 14, 28)
• aggressive irrigation with debridement
• healing by secondary intention is mainstay of treatment
• only consider primary closure for bite wounds on the face; otherwise primary closure is contraindicated
• contact Public Health if animal status unknown

Human Bites
• pathogens: Staphylococcus > β-hemolytic Streptococcus > Eikenella corrodens > Bacteroides
• mechanism: most commonly over dorsum of MCP from a punch in mouth; ”fight-bite”
• serious, as mouth has 10^9 microorganisms/mL, which get trapped in joint space when fist unclenches and overlying skin forms an air-tight covering ideal for anaerobic growth – can lead to septic arthritis
• investigations
  • radiographs prior to therapy to rule out foreign body (e.g. tooth) or fracture
  • culture for aerobic and anaerobic organisms, Gram stain
• treatment
  • urgent surgical exploration of joint, drainage and debridement of infected tissue
  • wound must be copiously irrigated
  • Clavulin* 500 mg PO q8h or (if penicillin allergy) clindamycin 300 mg PO q6h + ciprofloxacin 500 mg PO q12h + secondary closure
  • splint
Dressings

- dressing selection depends on the wound characteristics and surgeon preference
  - as the wound progresses through healing it will require different types of dressings, therefore, routine inspection is recommended
  - principles of dressing may want to add that the old principle of wound healing was to dry it if it was wet and wet it if it was dry but now we choose the principle of moist interactive wound healing we also need. A basic classification of dressings like films foams alginate etc.
    - clean vs. infected wounds
      - clean wounds can be dressed with non-adherent dressing (which is non-adhering to epithelializing tissue); requires secondary dressing
      - infected wounds may need debridement and antibiotics and can be dressed with iodine gauge, silver-containing, or antimicrobial dressings
    - wide-based vs. cavitary/tunnelling wounds
      - cavitary or tunnelling wounds (i.e. through a fascial layer) can be packed with saline-soaked (non-infected)
      - infected wounds require irrigation and debridement prior to appropriate dressing care (e.g. betadine-soaked (infected) ribbon gauze, or other easily retrievable one-piece moisture providing dressing

Table 9. Recommended Dressings for Wound Type

<table>
<thead>
<tr>
<th>Wound Depth</th>
<th>Exudate Level</th>
<th>Dressing Material</th>
</tr>
</thead>
<tbody>
<tr>
<td>Superficial</td>
<td>Lightly exuding</td>
<td>Films (Opsite®), hydrogels (Intrasite®, Nu-gel®, Duoderm®)</td>
</tr>
<tr>
<td></td>
<td>Any exudate level</td>
<td>Contact layers</td>
</tr>
<tr>
<td>Superficial to Deep</td>
<td>Light to moderately exuding</td>
<td>Amorphous gels, hydrogels, hydrocolloids (Duoderm®, Tegaderm®), collagen, hypertonic saline gauze (Mesalt®)</td>
</tr>
<tr>
<td></td>
<td>Moderately to heavily exuding</td>
<td>Foams (Mepilex®, Allevyn®), alginates (Sorbsan®, Kaltostat®), hypertonic saline gauze, hydrofibre (Aquacel®)</td>
</tr>
</tbody>
</table>

Table adapted from Grabb & Smith’s Plastic Surgery, 6th ed. Chapter 3, Table 3.3

Reconstruction

RECONSTRUCTION LADDER

Definition
- an approach to wound management with successively more complex methods of treatment
- surgeons should start with the least complex method and progressively increase in complexity as appropriate

SKIN GRAFTS

Definition
- skin that is harvested from a donor site and transferred to the recipient site and that does not carry its own blood supply. Survival requires the generation of new blood vessels from the recipient site bed. They are classified according to the depth of dermis they contain: full thickness (entire epidermis + dermis) vs. split-thickness (epidermis + partial dermis)

Donor Site Selection
- must consider size, hair pattern, texture, thickness of skin, and colour (facial grafts best if taken from “blush zones” above clavicle e.g. pre/post auricular or neck)
- partial thickness grafts usually taken from inconspicuous areas (e.g. buttocks, lateral thighs, etc.)

Partial Thickness Skin Graft Survival
- 3 phases of skin graft “take”
  1. plasmatic imbibition: diffusion of nutrition from recipient site (first 48 h)
  2. inosculuation: vessels in graft connect with those in recipient bed (day 2-3)
  3. neovascular ingrowth: graft revascularized (day 3-5)
- requirements for survival
  - well-vascularized bed (unsuitable beds include: bone, tendon, heavily irradiated, infected wounds)
  - good contact between graft and recipient bed. Staples, sutures, splinting and pressure dressings are used to prevent movement of the graft and hematoma/seroma formation
  - bed: well-vascularized (unsuitable: bone, tendon, heavily irradiated, infected wounds, etc.)
  - contact between graft and recipient bed: fully immobile (decreased shearing and hematoma formation)
  - staples, sutures, splinting, and appropriate dressings (pressure) are used to prevent movement of graft and hematoma or seroma formation
  - site: low bacterial count (<10³/cm², to prevent infection)
Classification of Skin Grafts
1. by species
   - autograft: from same individual
   - allograft (homograft): from same species, different individual
   - xenograft (heterograft): from different species (e.g. porcine)
2. by thickness: see Table 10

Table 10. Skin Grafts

<table>
<thead>
<tr>
<th></th>
<th>Split Thickness Skin Graft</th>
<th>Full Thickness Skin Graft</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definition</td>
<td>Epidermis and part of dermis</td>
<td>Epidermis and all of dermis</td>
</tr>
<tr>
<td>Donor Site</td>
<td>More sites</td>
<td>Donor sites limited by the ability to use primary closure</td>
</tr>
<tr>
<td>Healing of Donor Site</td>
<td>Re-epithelialization via dermal appendages in graft and wound edges</td>
<td>Primary closure</td>
</tr>
<tr>
<td>Re-Harvesting</td>
<td>~10 d (faster on scalp)</td>
<td>N/A</td>
</tr>
<tr>
<td>Graft Take</td>
<td>More reliable and better survival; shorter nutrient diffusion distance</td>
<td>Lower rate of survival (thicker, slower vascularization)</td>
</tr>
<tr>
<td>Contraction*</td>
<td>Less 1st contraction, greater 2nd contraction (less with thicker graft)</td>
<td>Greater 1st contraction, less 2nd contraction</td>
</tr>
<tr>
<td>Aesthetic</td>
<td>Poor</td>
<td>Good</td>
</tr>
<tr>
<td>Comments</td>
<td>Can be meshed for greater area</td>
<td>May use on face and fingers</td>
</tr>
<tr>
<td>Advantage</td>
<td>Takes well in less favourable conditions</td>
<td>Resists contraction, better colour match</td>
</tr>
<tr>
<td></td>
<td>Can cover a larger area</td>
<td>May use on face and fingers</td>
</tr>
<tr>
<td></td>
<td>Can be meshed for greater area</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Allows for extravasation of blood/serum</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Potential for healing in less favourable environment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Large number of donor sites</td>
<td></td>
</tr>
<tr>
<td>Disadvantages</td>
<td>Contracts significantly, abnormal pigmentation, high susceptibility to trauma</td>
<td>Requires well vascularized bed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Must remove fat from graft before application</td>
</tr>
<tr>
<td>Uses</td>
<td>Large areas of skin, granulating tissue beds</td>
<td>Face (colour match), site where thick skin or decreased contracture is desired (e.g. finger)</td>
</tr>
</tbody>
</table>

*Primary: immediate reduction in size upon harvesting. Secondary: reduction in size once graft placed on wound bed and healing has occurred.

- meshed grafts (split thickness grafts can be meshed after harvest by a mesher to either 1.5:1 or 3:1)
- advantages
  - prevents accumulation of fluids (e.g. hematoma, seroma)
  - covers a larger area
  - best for contaminated recipient site
- disadvantages
  - poor cosmesis ("alligator hide" appearance)
  - has significant contraction
- common reasons for graft loss: hematoma/seroma, infection, mechanical force (e.g. shearing, pressure)

OTHER GRAFTS

Table 11. Various Tissue Grafts

<table>
<thead>
<tr>
<th>Graft Type</th>
<th>Use</th>
<th>Preferred Donor Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone</td>
<td>Repair rigid defects</td>
<td>Cranial, rib, iliac, fibula</td>
</tr>
<tr>
<td>Cartilage</td>
<td>Restore contour of ear and nose</td>
<td>Ear, nasal septum, costal cartilage</td>
</tr>
<tr>
<td>Tendon</td>
<td>Repair or replace a damaged tendon</td>
<td>Palmaris longus, plantaris (present in 85% population)</td>
</tr>
<tr>
<td>Nerve</td>
<td>Conduit for regeneration across nerve gap</td>
<td>Sural, antebrachial cutaneous, medial brachial cutaneous</td>
</tr>
<tr>
<td>Vessel</td>
<td>Bridge vascular gaps</td>
<td>Forearm or foot vessels for small vessels, saphenous vein for larger vessels</td>
</tr>
<tr>
<td>Dermis</td>
<td>Contour restoration (± fat for bulk)</td>
<td>Thick skin of buttock or abdomen</td>
</tr>
<tr>
<td>Fat</td>
<td>Contour restoration</td>
<td>Abdomen, any area with fat available</td>
</tr>
<tr>
<td>Nipple</td>
<td>To create a new nipple on a reconstructed breast</td>
<td>Nipple</td>
</tr>
</tbody>
</table>
**FLAPS**

- **definition:** tissue transferred from one site to another with a known blood supply (random, pedicled or named); not dependent on neovascularization, unlike a graft
- **may consist of:** skin, subcutaneous tissue, fascia, muscle, tendon, bone, other tissue (e.g. omentum)
- **classification:** based on blood supply to skin (random, axial) and anatomic location (local, regional, distant)
- **indications for flaps**
  - replaces tissue loss due to trauma or surgery (reconstruction)
  - provides skin and temporary soft tissue coverage through which surgery can be carried out later
  - to aid healing or treatment of infection by providing vascularized tissue to a poorly vascularized bed
- **complications:** flap loss due to hematoma, seroma, infection, poor flap design, extrinsic compression (dressing too tight) or vascular failure/thrombosis, fat necrosis (in free and pedicled flaps)

**Random Pattern Flaps**

- blood supply by dermal and subdermal plexus to skin and subdermal tissue with random vascular supply
- limited length:width ratio to ensure adequate blood supply (typically 3:1 in the head and neck, 1-2:1 elsewhere)
- flap choice is often a combination of available tissue, type of tissue needed, location of reconstruction site with respect to donor site, and surgeon preference
- **types**
  - **rotation:** semicircular tissue rotated around a pivot point for defect closure; commonly used on sacral pressure sores, scalp and cheek defects
  - **transposition:** tissue is transposed (i.e. Lifted up from its native location and brought into the defect) around a pivot point from one location to another; commonly used on certain areas of the face using adjacent areas of excess skin laxity
  - **Z-plasty:** two triangular flaps are repositioned; used to reorient a scar, lengthen the line of a scar or to break up a scar
  - **advancement flaps** (V-Y, Y-V): defect is closed with unidirectional tissue advancement
    - single/bipedicle V-Y flaps: wounds with lax surrounding tissue; the pedicle is the deep tissue underlying the flap

**Axial Pattern Flaps (Arterialized)**

- flap contains a well defined artery and vein
- allows greater length:width ratio (5-6:1)
- **types**
  - **peninsular flap:** skin and vessel intact in pedicle
  - **island flap:** vessel intact, pedicle is better defined
  - **free flap:** vascular supply Anastomosed at recipient site by microsurgical techniques
  - can be sub-classified according to tissue content of flap
    - e.g. musculocutaneous/myocutaneous (e.g. transverse rectus abdominal myocutaneous) vs. fasciocutaneous

**Free Flaps**

- transplanting expendable donor tissue from one part of the body to another by isolating and dividing a dominant artery and vein to a flap and performing a microsurgical anastomosis between these and the vessels in the recipient wound
- survival rates >95%
- types: muscle and skin (common), bone, jejunum, omentum, fascia
- e.g. radial forearm, scapular, latissimus dorsi
Table 12. Characteristics of Healthy Free Flap

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Normal</th>
<th>Arterial Insufficiency</th>
<th>Venous Insufficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colour</td>
<td>Pink</td>
<td>Pale</td>
<td>Purple or blue</td>
</tr>
<tr>
<td>Temperature</td>
<td>Warm</td>
<td>Cool</td>
<td>Warm or cool</td>
</tr>
<tr>
<td>Arterial Pulse (Doppler)</td>
<td>+</td>
<td>–</td>
<td>±</td>
</tr>
<tr>
<td>Turgor</td>
<td>Soft, but with some firmness</td>
<td>Decreased tissue firmness</td>
<td>Increased (tissue firmness with tissue stiffness)</td>
</tr>
<tr>
<td>Capillary Refill</td>
<td>2-5 seconds</td>
<td>&gt; 5 seconds</td>
<td>&lt;2 seconds</td>
</tr>
</tbody>
</table>

**Soft Tissue Infections**

Table 13. Classification of Soft Tissue Infections by Depth

<table>
<thead>
<tr>
<th>Infection</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erysipelas</td>
<td>Superficial with upper dermis and superficial lymphatics involvement</td>
</tr>
<tr>
<td>Cellulitis</td>
<td>Full thickness of skin with subcutaneous tissue involvement</td>
</tr>
<tr>
<td>Fasciitis</td>
<td>Fascia</td>
</tr>
<tr>
<td>Myositis</td>
<td>Muscle</td>
</tr>
</tbody>
</table>

**Erysipelas**

**Definition**
- acute skin infection that is more superficial than cellulitis

**Etiology**
- typically caused by Group A β-hemolytic Streptococcus

**Clinical Features**
- intense erythema, induration, and sharply demarcated borders (differentiates it from other skin infections)

**Treatment**
- penicillin or first generation cephalosporin (e.g. cefazolin or cephalixin)

**Cellulitis**

**Definition**
- non-suppurative infection of skin and subcutaneous tissues

**Etiology**
- skin flora most common organisms: S. aureus, β-hemolytic Streptococcus
- immunocompromised: Gram-negative rods and fungi

**Clinical Features**
- source of infection
  - trauma, recent surgery
  - PVD, DM – cracked skin in feet/toes
  - foreign bodies (IV, orthopedic pins)
  - systemic symptoms (fever, chills, malaise)
- pain, tenderness, edema, erythema with poorly defined margins, regional lymphadenopathy
- can lead to ascending lymphangitis (visible red streaking in skin proximal to area of cellulitis)

**Investigations**
- CBC, blood cultures
- culture and Gram stain a collection/aspirate from wound if open wound
- plain radiographs show soft tissue edema only

**Treatment**
- antibiotics: first line – cephalixin 500 mg PO q6h or cloxacillin 500 mg PO q6h x 7 d; if complicated (e.g. lymphangitis, DM, severe infection, oral antibiotic therapy failure) consider IV cefazolin 1-2 g q8h or IV cloxacillin, IV penicillin). All patients should have reassessment in 48 hours for resolution if on a oral antibiotic
- outline area of erythema to monitor success of treatment
- immobilize and splint (hands)
Necrotizing Fasciitis

Definition
• rapidly spreading, very painful infection of the fascia with necrosis of surrounding tissues
• some bacteria create gas that can be felt as crepitus and can be seen on x-rays
• infection spreads rapidly along deep fascial plane and is limb and life threatening

Etiology
• Type I: polymicrobial (less aggressive)
• Type II: monomicrobial, usually β-hemolytic Streptococcus

Clinical Features
• pain out of proportion to clinical findings and beyond border of erythema
  • edema, tenderness, ± crepitus (subcutaneous gas from anaerobes)
  • overlying skin changes including blistering and ecchymoses
  • disorganized physiology
  • patients may look deceptively well at first, but may rapidly become very sick/toxic
  • late findings
    • skin turns dusky blue and black (secondary to thrombosis and necrosis)
    • induration, formation of bullae
    • cutaneous gangrene, subcutaneous emphysema

Investigations
• a clinical diagnosis
• CT scan only if suspect it is not necrotizing fasciitis (looking for abscess, gas collection, myonecrosis and possible source of infection)
• severely elevated CK: usually means myonecrosis (late sign)
• bedside incision, exploration, and incisional biopsy when ruling out conditions, clinical presentation is not supportive or difficult exam
• during incisional biopsy, often see “dish water pus” (Group A infection) and a hemostat easily passed along fascial plane (fascial biopsy to rule out in equivocal situations)

Treatment
• vigorous resuscitation (ABCs)
• urgent surgical debridement: remove all necrotic tissue, copious irrigation with plans for repeat surgery in 24-48 hours
• IV antibiotics: as appropriate for clinical scenario; consider penicillin 4 million IU IV q4h and/or clindamycin 900 mg IV q6h until final cultures available (the combination can be synergistic if Group A strep)
• urgent consultation with infectious disease specialist is recommended

Ulcers

Lower Limb Ulcers

Traumatic Ulcers (Acute)
• failure of wound to heal, usually due to compromised blood supply and unstable scar, secondary to pressure or bacterial colonization/infection
• usually over bony prominence ± edema ± pigmentation changes ± pain
• treatment: involvement of vascular surgery. Any debridement of ulcer and compromised tissues must be preceded by ABIs and vascular Doppler. Ulcers or compromised tissues left to heal via secondary intention with dressings, may need reconstruction with local or distant flap in select cases, vascular status of limb must be assessed clinically and via vascular studies (i.e. ABI, duplex doppler)

Non-Traumatic Ulcers (Chronic)

Table 14. Venous vs. Arterial vs. Diabetic Ulcers

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Venous (70% of vascular ulcers)</th>
<th>Arterial</th>
<th>Diabetic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cause</td>
<td>Valvular incompetence</td>
<td>2º to small and/or large vessel disease (be aware of risk factors)</td>
<td>Peripheral neuropathy; decreased sensation</td>
</tr>
<tr>
<td></td>
<td>Venous HTN</td>
<td></td>
<td>Atherosclerosis: microvascular disease</td>
</tr>
<tr>
<td>History</td>
<td>Dependent edema, trauma</td>
<td>Arteriosclerosis, claudication</td>
<td>DM</td>
</tr>
<tr>
<td></td>
<td>Rapid onset ± thrombophlebitis, varicosities</td>
<td>Usually &gt;45 yr Slowed progression</td>
<td>Peripheral neuropathy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Trauma/pressure</td>
</tr>
<tr>
<td>Common Distribution</td>
<td>Medial malleolus (“Gaiter” locations)</td>
<td>Distal locations (e.g. lower limb, feet)</td>
<td>Pressure point distribution (more likely metatarsal headsheads)</td>
</tr>
</tbody>
</table>
### Table 14. Venous vs. Arterial vs. Diabetic Ulcers (continued)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Venous (70% of vascular ulcers)</th>
<th>Arterial</th>
<th>Diabetic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Appearance</strong></td>
<td>Yellow exudates, Granulation tissue, Varicose veins, Brown discoloration of surrounding skin</td>
<td>Pale/white, necrotic base ± dry eschar covering</td>
<td>Necrotic base</td>
</tr>
<tr>
<td><strong>Wound Margins</strong></td>
<td>Irregular</td>
<td>Even (“punched out”)</td>
<td>Irregular or “punched out” or deep</td>
</tr>
<tr>
<td><strong>Depth</strong></td>
<td>Superficial</td>
<td>Deep</td>
<td>Superficial/deep</td>
</tr>
<tr>
<td><strong>Surrounding Skin</strong></td>
<td>Venous stasis discoloration (brown)</td>
<td>Thin shiny dry skin, hairless, cool</td>
<td>Thin dry skin ± hyperkeratotic border</td>
</tr>
<tr>
<td><strong>Pulses</strong></td>
<td>Normal distal pulses</td>
<td>Decreased or no distal pulses</td>
<td>Decreased pulses likely (Take caution in calcified vessels)</td>
</tr>
<tr>
<td><strong>Vascular Exam</strong></td>
<td>ABI &gt;0.9</td>
<td>ABI &lt;0.9</td>
<td>ABI is inaccurately high (due to PVD)</td>
</tr>
<tr>
<td></td>
<td>Doppler; abnormal venous system</td>
<td>Palor on elevation, rubor on dependency</td>
<td>Usually associated with arterial disease (microvascular/macrovacular disease)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Delayed venous filling</td>
<td></td>
</tr>
<tr>
<td><strong>Pain</strong></td>
<td>Moderately painful</td>
<td>Extremely painful</td>
<td>Painless (if neuropathy)</td>
</tr>
<tr>
<td></td>
<td>Increased with leg dependency, decreased with elevation</td>
<td>Decreased with dependency, increased with leg elevation and exercise (claudication)</td>
<td>No claudication or rest pain</td>
</tr>
<tr>
<td></td>
<td>No rest pain</td>
<td>Rest pain</td>
<td>Associated paresthesia, anesthesia</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>Leg elevation, rest</td>
<td>Rest, no elevation, no compression</td>
<td>Control DM</td>
</tr>
<tr>
<td></td>
<td>Compression at 30 mmHg (stockings or elastic bandages)</td>
<td>Moist wound dressing ± topical and/or systemic antibiotics if infected</td>
<td>Careful wound care</td>
</tr>
<tr>
<td></td>
<td>Most wound dressings</td>
<td>Modify risk factors (smoking, diet, exercise, etc.)</td>
<td>Foot care</td>
</tr>
<tr>
<td></td>
<td>± topical, systemic antibiotics if infected</td>
<td>Vascular surgical consultation (angioplasty or bypass)</td>
<td>Orthotics, off loading</td>
</tr>
<tr>
<td></td>
<td>± skin grafts</td>
<td>Treat underlying conditions (DM, proximal arterial occlusion, etc.)</td>
<td>Early intervention for infections (topical and/or systemic antibiotics if infected)</td>
</tr>
</tbody>
</table>

---

### Pressure Ulcers

**Common Sites**
- over bony prominences; 95% on lower body

**Stages of Development**
1. Hyperemia: disappears 1 h after pressure removed
2. Ischemia: follows 2-6 h of pressure
3. Necrosis: follows >6 h of pressure
4. Ulcer: necrotic area breaks down – N.B. skin is like tip of an iceberg

**Classification (National Pressure Ulcer Advisory Panel 2014)**
- Stage I: nonblanchable erythema present >1 h after pressure relief, skin intact
- Stage II: partial-thickness skin loss
- Stage III: full-thickness skin loss into subcutaneous tissue
- Stage IV: full-thickness skin loss into muscle, bone, tendon, or joint
  - if an eschar is present, must fully debride before staging possible

**Prevention**
- Good nursing care (clean dry skin, frequent repositioning), special beds or pressure relief surface, proper nutrition, activity, early identification of individuals at risk (e.g. immobility, incontinence, paraplegia, immunocompromised, DM, etc.)

**Treatment**
- Depends on individual patient and condition
- Treat underlying medical issues including nutrition
- Continue with preventative measures (pressure relief, assess for pressure points e.g. wheelchairs, manage continence issues, divert contaminants e.g. urine and feces)
- Wound debridement, moisture retentive or antimicrobial dressing, regular reassessment
- Systemic antibiotics for infections
- Assess for possible reconstruction

**Complications**
- cellulitis, osteomyelitis, sepsis, gangrene

---

**ABI in diabetics can be falsely normal due to incomparable arteries secondary to plaques/calciﬁcation**

**All chronic ulcers require vascular studies, and a vascular consult, to assess for venous insufficiency, to rule in/out arterial pathology and to find out the potential role of vascular surgical management**
Burns

Burn Injuries

Causal Conditions

- thermal (flame contact, scald)
- chemical
- radiation (UV, medical/therapeutic)
- electrical

Most Common Etiology

- children: scald burns
- adults: flame burns

Table 15. Skin Function and Burn Injury

<table>
<thead>
<tr>
<th>Skin Function</th>
<th>Consequence of Burn Injury</th>
<th>Intervention Required</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thermoregulation</td>
<td>Prone to lose body heat</td>
<td>Must keep patient covered and warm</td>
</tr>
<tr>
<td>Control of fluid loss</td>
<td>Loss of large amounts of water and protein from the skin and other body tissues</td>
<td>Adequate fluid resuscitation is imperative</td>
</tr>
<tr>
<td>Mechanical barrier to bacterial invasion and immunological organ</td>
<td>High risk of infection</td>
<td>Antimicrobial dressings (systemic antibiotics if signs of specific infection present) Tetanus prophylaxis if not already administered</td>
</tr>
</tbody>
</table>

Pathophysiology of Burn Wounds

- amount of tissue destruction is based on temperature, time of exposure, and specific heat of the causative agent
- zone of hyperemia: vasodilation from inflammation; entirely viable, cells recover within 7 d; contributes to systemic consequences seen with major burns
- zone of stasis (edema): decreased perfusion; microvascular sludging and thrombosis of vessels results in progressive tissue necrosis → cellular death in 24-48 h without proper treatment
  - factors favouring cell survival: moist, aseptic environment, rich blood supply
  - zone where appropriate early intervention has most profound effect in minimizing injury
- zone of coagulation (ischemia): no blood flow to tissue → irreversible cell damage → cellular death/necrosis

Diagnosis and Prognosis

- burn size
  - % of TBSA burned: role of 9s for 2° and 3° burns only (children <10 yr old use Lund-Browder chart)
  - for patchy burns, surface area covered by patient’s palm (fingers closed) represents approximately 1% of TBSA
- age: more complications if <3 or >60 yr old
- depth: difficult to assess initially – history of etiologic agent and time of exposure helpful (see Table 16)
- location: face and neck, hands, feet, perineum are critical areas requiring special care of a burn unit (see Indications for Transfer to Burn Centre, PL19)
- inhalation injury: can severely compromise respiratory system, affect fluid requirement estimation (underestimate), mortality secondary to ARDS
- associated injuries (e.g. fractures)
- comorbid factors (e.g. concurrent disability, alcoholism, seizure disorders, chronic renal failure) can exacerbate extent of injury, other trauma

Figure 16. Zones of thermal injury

Skin surface

Epidermis

Dermis: Nerves Vessels

Zone of hyperemia

Zone of stasis

Zone of coagulation

Blood vessels and nerves are found in the dermis

Prognosis best determined by burn size (TBSA), age of patient, presence/absence of inhalation injury

Circumferential burns can restrict respiratory excursion and/or blood flow to extremities and require escharotomy

TBSA does not include areas with 1° burns
Figure 17. Rule of 9s for TBSA

Table 16. Burn Depth (1st, 2nd, 3rd degree)

<table>
<thead>
<tr>
<th>Nomenclature</th>
<th>Traditional Nomenclature</th>
<th>Depth</th>
<th>Clinical Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erythema/Superficial</td>
<td>First degree</td>
<td>Epidermis</td>
<td>Painful, sensation intact, erythema, blanchable</td>
</tr>
<tr>
<td>Superficial-Partial Thickness</td>
<td>Second degree</td>
<td>Into superficial dermis</td>
<td>Painful, sensation intact, erythema, blisters with clear fluid, blanchable, hair follicles present</td>
</tr>
<tr>
<td>Deep-Partial Thickness</td>
<td>Second degree</td>
<td>Into deep (reticular) dermis</td>
<td>Insensate, difficult to distinguish from full thickness, does not blanch, some hair follicles still attached, softer than full thickness burn</td>
</tr>
<tr>
<td>Full Thickness</td>
<td>Third degree</td>
<td>Through epidermis and dermis</td>
<td>Insensate (nerve endings destroyed), hard leathery eschar that is black, grey, white, or cherry red in colour, hairs do not stay attached, may see thrombosed veins</td>
</tr>
<tr>
<td></td>
<td>Fourth degree</td>
<td>Injury to underlying tissue structures</td>
<td>(e.g. muscle, bone)</td>
</tr>
</tbody>
</table>
Indications for Transfer to Burn Centre

American Burn Association Criteria
- patients with partial or full-thickness burns that involve the hands, feet, genitalia, face, eyes, ears, and/or major joints or perineum
- partial thickness burns ≥20% TBSA in patients aged 10-50 yr old
- partial thickness burns ≥10% TBSA in children aged <10 or adults aged ≥50 yr old
- full thickness burns ≥5% TBSA in patients of all ages
- electrical burns, including lightening (internal injury underestimated by TBSA), and chemical burns
- inhalation injury (high risk of mortality and may lead to respiratory distress)
- burn injuries in patients with medical comorbidities, could complicate management and recovery
- any patient with simultaneous trauma plus burns should be stabilized for trauma first, then triaged appropriately to burn centre
- any patients with burn injury and who will require special emotional, social, and rehabilitation intervention
- children with burns in a hospital not equipped with pediatric care specialists

Acute Care of Burn Patients
- adhere to ATLS protocol
- resuscitation using Parkland formula to restore plasma volume and cardiac output, Parkland formula is a starting estimate and patients may require more volume. Other formulas exist but the Parkland formula is predominately used in North America
  - 4 cc/kg X %TBSA (greater than first degree) X wt(kg) (1/2 within first 8 h of sustaining burn, 1/2 in next 16 h)
- extra fluid administration required if
  - burn >80% TBSA
  - 4° burns
  - associated traumatic injury
  - electrical burn
  - inhalation injury
  - delayed start of resuscitation
  - pediatric burns
- monitor resuscitation
  - urine output is best measure: maintain at >0.5 cc/kg/h (adults) and 1.0 cc/kg/h
  - (children <12 yr)
  - maintain a clear sensorium, HR <120/min, MAP >70 mmHg
- burn specific care
  - relieve respiratory distress: intubation and/or escharotomy
  - Escharotomy in circumferential extremity burn including digits
  - prevent and/or treat burn shock: 2 large bore IVs for fluid resuscitation
  - insert Foley catheter to monitor urine output
  - identify and treat immediate life-threatening conditions (e.g. inhalation injury, CO poisoning)
  - determine TBSA affected first, since depth is difficult to determine initially (easier to determine after 24 h)
- tetanus prophylaxis if needed
  - all patients with burns >10% TBSA, or deeper than superficial partial thickness, need 0.5 cc tetanus toxoid
  - also give 250 U of tetanus Ig if prior immunization is absent/unclear, or the last booster >10 yr ago
- baseline laboratory studies (Hb, U/A, BUN, CXR, electrolytes, Cr, glucose, CK ECG, cross-match if traumatic injury, ABG, carboxyhemoglobin)
- cleanse, debride, and treat the burn injury (antimicrobial dressings)
- early excision and grafting important for outcome

Respiratory Problems
- 3 major causes
  - burn eschar encircling chest
  - distress may be apparent immediately
  - perform escharotomy to relieve constriction
  - CO poisoning
  - may present immediately or later
  - treat with 100% O₂ by facemask (decreases half-life of carboxyhemoglobin from 210 to 59 min) until carboxyHb <10%
  - smoke inhalation leading to pulmonary injury
    - chemical injury to alveolar basement membrane and pulmonary edema (insidious onset)
    - risk of pulmonary insufficiency (up to 48 h) and pulmonary edema (48–72 h)
    - watch for secondary bronchopneumonia (3–25 d) leading to progressive pulmonary insufficiency
    - intubate patient with any signs of inhalation injuries

Inhalation Injuries 101
- Indicators of inhalation injury
- Injury in a closed space
- Facial burn
- Singed nasal hair/eyebrows
- Soot around nares/oral cavity
- Hoarseness
- Conjunctivitis
- Tachypnea
- Carbon particles in sputum
- Elevated blood CO levels (i.e. brighter red)
- Suspected inhalation injury requires immediate intubation due to impending airway edema; failure to diagnose inhalation injury can result in airway swelling and obstruction, which, if untreated, can lead to death
- Neither CXR or ABG can be used to rule out inhalation injury
- Direct bronchoscopy now used for diagnosis
- Signs of CO poisoning (headache, confusion, coma, arrhythmias)
Burn Wound Healing

Table 17. Burn Shock Resuscitation (Parkland Formula)

<table>
<thead>
<tr>
<th>Time Period</th>
<th>Calculations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hour 0-24</td>
<td>4 cc RL/kg/% TBSA with 1/2 of total in first 8 h from time of injury and 1/2 of total in next 16 h from time of injury</td>
</tr>
<tr>
<td>Hour 24-30</td>
<td>0.35-0.5 cc plasma/kg/%TBSA</td>
</tr>
<tr>
<td>&gt;Hour 30</td>
<td>DSW at rate to maintain normal serum sodium</td>
</tr>
</tbody>
</table>

*Do not forget to add maintenance fluid to resuscitation.

Table 18. Burn Wound Healing

<table>
<thead>
<tr>
<th>Depth</th>
<th>Healing</th>
</tr>
</thead>
<tbody>
<tr>
<td>First degree</td>
<td>No scarring; complete healing</td>
</tr>
<tr>
<td>Second degree (Superficial partial)</td>
<td>Spontaneously re-epithelialize in 7 to 14 d from retained epidermal structures ± residual skin discoloration; hypertrophic scarring uncommon; grafting rarely required</td>
</tr>
<tr>
<td>Deep second degree (Deep partial)</td>
<td>Re-epithelialize in 14-35 d from retained epidermal structures; hypertrophic scarring frequent; grafting recommended to expedite healing</td>
</tr>
<tr>
<td>Third degree (Full thickness)</td>
<td>Re-epithelialize from the wound edge; grafting flap necessary to replace dermal integrity, limit hypertrophic scarring</td>
</tr>
<tr>
<td>Fourth degree</td>
<td>Often results in amputations; if not requiring amputation, needs flap for coverage after debridement (do not re-epithelialize – cannot graft)</td>
</tr>
</tbody>
</table>

Treatment

- 3 stages:
  1. assessment: depth determined
  2. management: specific to depth of burn and associated injuries
  3. rehabilitation

- first degree
  - treatment aimed at comfort
    - topical creams (pain control, keep skin moist) ± aloe
    - oral NSAIDs (pain control)
  - superficial second degree/partial thickness
    - daily dressing changes with topical antimicrobials (such as polysporin); leave blisters intact unless circulation impaired or unless over joint inhibiting motion
  - deep second degree/deep partial thickness and third degree/full thickness
    - prevent infection and sepsis (significant complication and cause of death in patients with burns)
      - most common organisms: S. aureus, P. aeruginosa, and C. albicans
        - day 1-3 (rare): Gram-positive
        - day 3-5: Gram-negative (Proteus, Klebsiella)
      - topical antimicrobials: treat colonized wounds (from skin flora, gut flora or caregiver)
      - remove dead tissue
      - surgically debride necrotic tissue, excise to viable (bleeding) tissue

Table 19. Antimicrobial Dressings for Burns

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Pain with Application</th>
<th>Penetration</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silver nitrate (0.5% solution)</td>
<td>None</td>
<td>Minimal</td>
<td>May cause methemoglobinemia, stains (black), leaches sodium from wounds</td>
</tr>
<tr>
<td>Nanocrystalline silver-coated dressing (Acticoat&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>None or transient</td>
<td>Medium, does not penetrate eschar</td>
<td>May stain, producing a pseudoeschar or facial discoloration (argyria-like symptoms); raised liver enzymes</td>
</tr>
<tr>
<td>Silver sulfadiazine (cream) (Flamazine&lt;sup&gt;®&lt;/sup&gt;, Silvadene&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>Minimal</td>
<td>Medium, penetrates eschar poorly</td>
<td>Most commonly used</td>
</tr>
<tr>
<td>Mafenide acetate (solution/cream) (Sulfamylon&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>Moderate</td>
<td>Well, penetrates eschar</td>
<td>Mild inhibition of epithelialization, may cause metabolic acidosis with wide application</td>
</tr>
</tbody>
</table>

- early excision and grafting is the mainstay of treatment for deep/full thickness burns
- initial dressing should decrease bacterial proliferation
- prevention of wound contractures: pressure dressings, joint splints, early physiotherapy
Other Considerations in Burn Management

- **Vascular Permeability and Edema**
- **Immunosuppression**
- **Renal Failure (2nd to ↓ Renal Blood Flow)**
- **Progressive Pulmonary Insufficiency**
- **Increased Gut Mucosal Permeability (GI Bleed Risk)**
- **Hypermetabolism**
- **Altered Hemodynamics (↓ CO, ↑ SVR)**

**Figure 19. Systemic effects of severe burns**

- **nutrition**
  - hypermetabolism: TBSA >40% have BMR 2-2.5x predicted
  - consider nutritional supplementation e.g. calories, vitamin C, vitamin A, Ca^{2+}, Zn^{2+}, Fe^{2+}
- **immunosuppression and sepsis**
  - must keep bacterial count <10^8 bacteria/g of tissue (blood culture may not be positive)
  - signs of sepsis: sudden onset of hyper/hyperthermia, unexpected CHF or pulmonary edema, development of ARDS, ileus >48 h post-burn, mental status changes, azotemia, thrombocytopenia, hypofibrinogenemia, hyper/hypoglycemia (especially if burn >40% TBSA)
- **GI bleed may occur with burns >40% TBSA (usually subclinical)**
  - treatment: tube feeding or NPO if there is a GI bleed, antacids, H2 blockers (preventative)
  - renal failure secondary to under resuscitation, drugs, myoglobin, etc.
  - progressive pulmonary insufficiency
  - can occur after: smoke inhalation, pneumonia, cardiac decompensation, sepsis
  - wound contracture and hypertrophic scarring (outcomes optimized with timely wound closure, splinting, pressure garments) and physiotherapy

**Special Considerations**

**CHEMICAL**
- major categories: acid burns, alkaline burns, phosphorous burns, chemical injection injuries
- common agents: cement, hydrofluoric acid, phenol, tar
- mechanism of injury: chemical solutions coagulate tissue protein leading to necrosis
  - acids → coagulation necrosis
  - alkalines → saponification followed by liquefactive necrosis
- severity related to: type of chemical (alkali worse than acid), temperature, volume, concentration, contact time, site affected, mechanism of chemical action, degree of tissue penetration
- burns are deeper than they initially appear and may progress with time

**Treatment (General)**
- ABCs, monitoring
- remove contaminated clothing and brush off any dry powders before irrigation
- irrigation with water for 1-2 h under low pressure (contraindicated in heavy metal burns, such as sodium, potassium, magnesium, and lithium; in these cases soak in mineral oil instead)
- inspect eyes, if affected: wash with saline and refer to ophthalmology
- inspect nails, hair and webspaces
- correct metabolic abnormalities and tetanus prophylaxis if necessary
- contact poison control line if necessary
- local wound care 12 h after initial dilution (debridement)
- wound closure same as for thermal burn
- beware of underestimated fluid resuscitation, renal, liver, and pulmonary damage

**Special Burns and Treatments**

<table>
<thead>
<tr>
<th>Burn Type</th>
<th>Treatment Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acid Burn</td>
<td>Water irrigation, followed by dilute solution of sodium bicarbonate</td>
</tr>
<tr>
<td>Hydrofluoric Acid</td>
<td>Water irrigation; clip fingernails to avoid acid trapping; topical calcium gel ± subcutaneous injection of calcium gluconate ± 10% calcium gluconate IV depending on amount of exposure and pain</td>
</tr>
<tr>
<td>Sulfuric Acid</td>
<td>Treat with soap/lime prior to irrigation, as direct water exposure produces extreme heat</td>
</tr>
<tr>
<td>Tar</td>
<td>Remove with repeated application of petroleum-based antibiotic ointments (e.g. Polysporin®)</td>
</tr>
</tbody>
</table>

**ELECTRICAL BURNS**
- depth of burn depends on voltage and resistance of the tissue (injury more severe in tissues with high resistance)
- often presents as small punctate burns on skin with extensive deep tissue damage which requires debridement
- electrical burns require ongoing monitoring as latent injuries can occur
- watch for system specific damages and abnormalities
  - abdominal: intraperitoneal damage
  - bone: fractures and dislocations especially of the spine and shoulder
  - cardiopulmonary: anoxia, ventricular fibrillation, arrhythmias
  - muscle: myoglobinuria indicates significant muscle damage → compartment syndrome
  - neurological: seizures and spinal cord damage
  - ophthalmology: cataract formation (late complication)
  - renal: ATN resulting from toxic levels of myoglobin and hemoglobin
  - vascular: vessel thrombosis → tissue necrosis (increased Cr, K⁺ and acidiy), decrease in RBC (beware of hemorrhages/delayed vessel rupture)

**Treatment**
- ABCs, primary and secondary survey, treat associated injuries
- beware of cardiac arrhythmias (continue cardiac monitoring)
- monitor: hemochromogenuria, compartment syndrome, urine output
- wound management: topical agent with good penetrating ability (silver sulfadiazine or mafenide acetate)
- beware of hemorrhages/delayed vessel rupture
- amputations frequently required

**FROSTBITE**
- see *Emergency Medicine, ER46*

---

### Hand

#### Traumatic Hand

| Table 20. Key Features of the History and Physical Exam of the Injured Hand |
|-----------------------------|------------------------------------------------------------------------------|
| **HISTORY**                |                                                                              |
| Key Questions              | Age, Time and place of accident, Mechanism of injury, Tetanus status         |
| Hand dominance             |                                                                              |
| Occupation                 |                                                                              |
| **PHYSICAL EXAM**          |                                                                              |
| Observation                | Position of finger, Deformity, Bruising or swelling, Sweating pattern, Anatomical structures beneath |
| Vascular Status            | Radial and ulnar arteries, Allen’s Test, Hard to palpate but you can assess capillary refill (<2-3 s) |
| Digital arteries           | Oxygen saturation monitor to verify perfusion                                |
| Temperature and skin turgor| For each test, need to compare both sides                                     |
| Sensory (see Figure 4)     | Median nerve, Ulnar nerve, Radial nerve, Digital nerves                      |
| Motor Function             | Median nerve, Ulnar nerve, Radial nerve                                       |
| Range of Motion            | Tendons, bones, joints, nerves                                              |
| Tendons                    | FDP, Stabilize PIP in extension, ask patient to flex fingers (at DIP)        |
| Palpation                  | Bones, Instability or abnormal alignment, Instability may indicate ligamentous injury or dislocation |
|                          | Joints, FDS, Stabilize non-exam fingers in extension (neutralizes FDP) and ask patient to flex examination finger |

**Compartment Syndrome**
- Watch out for these signs with a closed or open injury: tense, painful extremity (worse on passive stretch), paresthesia/paralysis, pallor, distal pulselessness (often late in process), and contracture (irreversible ischemia)
- Intracompartmental pressures can be measured (normal pressure = up to 12 mmHg), (abnormal is 30-40 mmHg), but a clinical diagnosis is an indication for an emergent fasciotomy; if untreated, end result is ischemic contracture of the extremity (Volkmann’s contracture)

**Approach to Hand Lacerations**
- **TIN AX**
  - Tetanus prophylaxis
  - Irrigate with NS (copious irrigation and debridement in a timely manner)
  - NPO (NPO if you are considering replanting or urgently OR, otherwise most operations are done as elective procedures)
  - Antibiotic prophylaxis (controversial – most require no ABx, mainly needed for animal bites and dirty wounds)
- **X-rays**
  - **Allen’s Test:** You need to exsanguinate the hand by having the patient open and close the hand. Then, while patient’s hand is firmly closed, occlude both radial and ulnar arteries. Once fist is open, release either artery and assess collateral flow
- **High pressure injection injury, e.g. pain gun,** is deceptively benign-looking (small pinpoint hole on finger pad) often with few clinical signs. Intense pain and tenderness, along the course the foreign material traveled, is present a few hours after the injury. Definitive treatment is exposure and removal of foreign material
General Management

Nerves
• test the nerve function BEFORE putting in local anesthesia
• direct repair for a clean injury within 14 d and without concurrent major injuries → otherwise secondary repair
• epineural repair of all digital nerves with minimal tension
• post-operative: dress wound, elevate hand and immobilize
• Tinel’s sign (cutaneous percussion over the repaired nerve) produces paresthesias and defines level of nerve regeneration
  - Wallerian degeneration occurs in the first 2 wk, which is why there is no Tinel’s sign till after this time period
  - a peripheral nerve regenerates at 1 mm/d
  - paresthesias felt at area of percussion because regrowth of myelin (Schwann cells) is slower than axonal regrowth → percussion on exposed free-end of axon generates paresthesia

Vessels
• often associated with nerve injury (anatomical proximity)
• control bleeding with direct pressure and hand elevation
• if digit devascularized, optimal repair within 6 h
• close skin then dress, immobilize, and splint hand with fingertips visible
• monitor colour, capillary refill, skin turgor, fingertip temperature post-revascularization

Tendons
• most tendon lacerations require primary repair
• many extensors are repaired in the emergency room, flexors are repaired in the operating room within 2 wk
• avoid excessive immobilization after repair (specific protocols for flexors to minimize stiffness and facilitate rehabilitation

Bones
• see Fractures and Dislocations, PL26

Nailbed
• subungal hematomas >50% of the nail surface area need to be drained, done so under a digital block by puncturing nail plate
• is suspicious, remove nail to examine underlying nailbed under digital block anesthesia
• irrigate wound and nail thoroughly
• suture repair of nailbed with chromic suture
• replace cleaned nail, which acts as splint for any underlying distal phalangeal fracture and prevents adhesion formation between nail fold and nailbed

Hand Infections

Principles
• trauma is most common cause
• 5 cardinal signs: rubor (red), calor (hot), tumour (swollen), dolor (painful) and functio laesa (loss of function)
• 90% caused by Gram-positive organisms
• most common organisms (in order) – S. aureus, S. viridans, Group A Streptococcus, S. epidermidis, and Bacteroides melaninogenicus (MRSA is becoming more common)

TYPES OF INFECTIONS

Deep Palmar Space Infections
• uncommon, there are 9 spaces in the hand, the most commonly involved are thenar or mid-palm space

Felon
• definition: subcutaneous abscess in the fingertip that commonly occurs following a puncture wound into the pad of digit; may be associated with osteomyelitis (akin to compartment syndrome and can lead to skin necrosis)
• treatment: elevation, warm soaks, cloxacillin 500 mg PO q6h (if in early stage); if obvious abscess or pressure on the overlying skin or failure to resolve with conservative measures, then needs I&D; take cultures/gram stain and PO cloxacillin

Flexor Tendon Sheath Infection
• Staphylococcus > Streptococcus > Gram-negative rods
• definition: acute tenosynovitis commonly caused by a penetrating injury and can lead to tendon necrosis and rupture if not treated; it is often suppurative; however, early on there can be very little pus
• **Clinical Features**: Kanavel’s 4 cardinal signs
  1. Point tenderness along flexor tendon sheath
  2. Severe pain on passive extension of DIP
  3. Fusiform swelling of entire digit
  4. Flexed posture (increased comfort)

• **Treatment**
  - OR incision and drainage, irrigation, IV antibiotics, and resting hand splint until infection resolves

**Herpetic Whitlow**
- HSV-1, HSV-2
- **Definition**: Painful vesicle(s) around fingertip
  - Often found in medical/dental personnel and children
- **Clinical Features**: Can be associated with fever, malaise and lymphadenopathy
  - Patient is infectious until lesion has completely healed
- **Treatment**: Routine culture and viral prep protection (cover), consider oral acyclovir; do not break blisters

**Paronychia**
- **Acute** = *Staphylococcus*; **Chronic** = *Candida*
- **Definition**: Infection (granulation tissue) of soft tissue around fingernail (within the paronychium and/or beneath eponychial fold)
- **Etiology**
  - Acute paronychia: A “hangnail”, artificial nails, and nail biting
  - Chronic paronychia: Prolonged exposure to moisture
- **Treatment**
  - Acute paronychia: Warm compresses and cephalexin 500 mg PO q6h if caught early and drainage if abscess present – can usually drain with a #11 blade directed into the abscess from underneath the paronychial fold
  - Chronic paronychia: Anti-fungals with possible debridement and marsupialization, removal of nail plate

**Amputations**

**Hand or Finger**
- Emergency management: Injured patient and amputated part require attention
  - **Patient**: X-rays (stump and amputated part), NPO, clean wound and irrigate with NS, dress stump with nonadherent, cover with dry sterile dressing, tetanus and antibiotic prophylaxis (cephalosporin/erythromycin)
  - **Amputated Part**: X-rays, gently irrigate with RL, wrap amputated part in a NS/RL soaked sterile gauze and place inside waterproof plastic bag, place in a container, then place container on ice
- **Indications for Replantation**
  - **Age**: Children often better results than adults
  - **Level of Injury**: Thumb and multiple digit amputations are higher priority
  - **Nature of Injury**: Clean cut injuries have greater success; avulsion and crush injuries are relative contraindications to replant
- If replant contraindicated, manage stump with revision amputation
  - Involves deriding amputating end, trimming back the bone and nerve endings and gently closing the skin
  - Commonly done in the emerge under digital block

**Tendons**

**Common Extensor Tendon Deformities**

<table>
<thead>
<tr>
<th>Injury</th>
<th>Definition</th>
<th>Zone</th>
<th>Etiology/Clinical Features</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mallet Finger</td>
<td>DIP flexed with loss of active extension</td>
<td>1</td>
<td>There are bony and non-bony mallets Bony: Fracture of distal phalanx distal to tendon insertion Non-bony: Forced flexion of the extended DIP leading to extensor tendon rupture at DIP (e.g. sudden blow to tip of the finger)</td>
<td>Splint DIP in extension for 6 wk followed by 2 wk of night splinting; if inadequate improvement after 6 wk, check splinting routine and recommend 4 more wk of continuous splinting. If there is a bony component that is displaced the patient may require ORIF</td>
</tr>
<tr>
<td>Boutonniere Deformity</td>
<td>PIP flexed, DIP hyperextended</td>
<td>3</td>
<td>Injury or disease affecting the extensor tendon insertion into the dorsal base of the middle phalanx Associated with RA or trauma (laceration, volar dislocation, acute forceful flexion of PIP)</td>
<td>Splint PIP in extension and allow active DIP motion</td>
</tr>
<tr>
<td>Swan Neck Deformity</td>
<td>PIP hyperextended, DIP flexed</td>
<td>3</td>
<td>Trauma (PIP volar plate injury) Associated with RA and old, untreated mallet deformity Splint to prevent PIP hyperextension or DIP flexion</td>
<td>Corrective procedures involve tendon rebalancing or arthrodesis/arthroplasty</td>
</tr>
</tbody>
</table>
Figure 20. (A) Mallet finger deformity (B) Boutonniere deformity (C) Swan neck deformity

Tenosynovitis (zone 7; most common cause of radial wrist pain)
- **definition**: inflammation of the tendon and/or its sheath. Most common is DeQuervain tenosynovitis (inflammation of the extensor tendons in the 1st dorsal compartment [APL and EPB])
- **clinical features**
  - +ve Finkelstein’s test (pain over the radial styloid induced by making fist, with thumb in palm, and ulnar deviation of wrist)
  - pain localized to the 1st extensor compartment
  - tenderness and crepitus over radial styloid may be present
  - differentiate from CMC joint arthritis (CMC joint arthritis will have a positive grind test, whereby crepitus and pain are elicited by axial pressure to the thumb)
- **treatment**
  - mild: NSAIDs, splinting and steroid injection into the tendon sheath (successful in over 60% of cases) severe: surgical release of stenotic tendon sheaths (APL and EPB); ganglion cyst

Ganglion Cyst
- **definition**
  - fluid-filled synovial lining that protrudes between carpal bones or from a tendon sheath; most commonly carpal in origin
  - most common soft tissue tumour of hand and wrist (60% of masses)
- **clinical features**
  - most common around scapholunate ligament junction
  - 3 times more common in women than in men
  - more common in younger individuals
  - can be large or small – may drain internally so size may wax and wane
  - often non-tender although tenderness increased when cyst smaller (from increased pressure within smaller cyst sac)
- **treatment**
  - conservative treatment: do nothing
  - aspiration (recurrence rate 65%)
  - consider operative excision of cyst and stalk (recurrence rate 5.9% for dorsal wrist ganglion, 30% for volar)
  - steroids if painful (done in combination with aspiration as results are no better than aspiration alone)

Common Flexor Tendon Deformities
- flexor tendon zones (important for prognosis of tendon lacerations)
  - “no-man’s land”
  - between distal palmar crease and mid-middle phalanx
  - zone where superficialis and profundus lie enmeshed together
  - recovery of glide very difficult after injury

Stenosing Tenosynovitis (trigger finger/thumb)
- **definition**: inflammation of synovium causes size discrepancy between tendon and sheath/pulley (most commonly at A-1 pulley) = locking of thumb or finger in flexion/extension
- **etiology**: idiopathic or associated with RA, DM, hypothyroidism, gout, and pregnancy
- **clinical features**
  - thumb, ring and long fingers most commonly affected
  - patient complains of catching, snapping or locking of affected finger
  - tenderness to palpation/nodule at palmar aspect of MCP over A-1 pulley
  - women are 4 times more likely than men to be affected
- **nonsurgical treatment**
  - NSAIDs
  - steroid injection
  - injections less likely to be successful in patients with DM or symptoms greater than 6 mo
  - splint
- **surgical treatment**
  - indicated if no relief of symptoms or minimal relief with steroids
  - incise A-1 flexor pulley to permit unrestricted, full active finger motion
Fractures and Dislocations

- for fracture principles, see Orthopedics, OR4

**FRACTURES**
- about 90% of hand fractures are stable in flexion (splint to prevent extension)
- **position of safety**
  - wrist extension 0-30°
  - MCP flexion 70-90°
  - IP full extension
- this is done if you want to immobilize a fracture but are not sure whether there are other injuries
- stiffness secondary to immobilization is the most important complication; Tx = early motion

**Distal Phalanx Fractures**
- most commonly fractured bone in the hand
- usual mechanism is crush injury and thus accompanied by soft tissue injury
- subungual hematoma is common and must be decompressed if there is involvement of >50% of the nail surface area
- injury involving >50% of the nail surface area often suggests a nail bed laceration, in which the patient would benefit from surgery
- treatment consists of 3 wk of digital splinting (immobilize the DIPJ with a STAX splint)

**Proximal and Middle Phalanx Fractures**
- check for: rotation, scissoring (overlap of fingers on making a fist), shortening of digit
- undisplaced or minimally displaced: closed reduction (if extra-articular) buddy tape to neighbouring stable digit, elevate hand, motion in guarded fashion early, splinted for 2-3 wk
- displaced, nonreducible, not stable with closed reduction, or rotational or scissoring deformity: percutaneous pins (K-wires) or ORIF, and splint

**Metacarpal Fractures**
- generally accept varying degrees of deviation before reduction required: up to 10° (D2), 20° (D3), 30° (D4), or 40° (D5)
- **Boxer’s fracture**: acute angulation of the neck of the 5th metacarpal into palm
  - mechanism: blow on the distal-dorsal aspect of closed fist
  - loss of prominence of metacarpal head, volar displacement of head
  - up to 30-40° angulation may be acceptable
  - if greater angulation, closed reduction should be considered to decrease the angle
  - if stable ulnar gutter splint for 4-6 wk
- **Bennett’s fracture**: two-piece fracture/dislocation of the base of the thumb metacarpal
  - unstable fracture
  - abductor pollicis longus pulls MC shaft proximally and radially causing adduction of thumb
  - treat with percutaneous pinning or ORIF followed by, thumb spica x 6 wk
- **Rolando fracture**: T- or Y-shaped fracture of the base of the thumb metacarpal
- treated like a Bennett’s fracture

**DISLOCATIONS**
- must be reduced as soon as possible
- dislocation vs. subluxation
  - dislocation: severe injury where articular surfaces of a joint are no longer in contact with one another
  - subluxation: articular surfaces of a joint are partially out of place (i.e. “partial dislocation” – often unstable and requires reduction)

**PIP and DIP Dislocations (PIP more common than DIP)**
- usually dorsal dislocation (commonly from hyperextension)
- if closed dislocation: closed reduction and splinting (ideally in full extension if stable, or PIPJ in flexion if unstable) or buddy taping and early mobilization (prolonged immobilization causes stiffness)
- open injuries are treated with wound care, closed or open reduction, irrigation and debridement, and antibiotics

**MCP Dislocations (relatively rare)**
- dorsal dislocations much more common than volar dislocations
- dorsal dislocation of proximal phalanx on metacarpal head; most commonly index finger (hyperextension)
- two types of dorsal dislocation
  - simple (reducible with manipulation): treat with closed reduction and splinting for 2-4 wk at 60-70° MCP flexion
  - complex (irreducible - most commonly due to volar plate blocking the reduction): treat with open reduction
**Ulnar Collateral Ligament (UCL) Injury**
- forced abduction of thumb (e.g. ski pole injury)
- Skier’s thumb: acute UCL injury – if stable treated with splint x 6-8 wk, if unstable patient may have Stener lesion
- Gamekeeper’s thumb: chronic UCL injury, often requires open repair and tendon graft for stabilization
- Stener Lesion: the distal portion of the UCL can detach and flip superficial to the adductor aponeurosis and will not appropriately heal – requires open repair
- evaluation: radially deviate thumb MCP joint in full extension and at 30° flexion and compare with noninjured hand. UCL rupture is presumed if injured side deviates more than 30° in full extension or more than 15° in flexion

**Dupuytren’s Disease**

**Definition**
- contraction of longitudinal palmar fascia, forming nodules (usually painless), fibrous cords and flexion contractures at the MCP and interphalangeal joints
- flexor tendons not involved
- Dupuytren's diathesis: early age of onset, strong family history, involvement of multiple digits, and involvement of sites other than palmar aspect of hand, including the plantar fascia (Ledderhose's) and the penis (Peyronie's) – (see Urology, U30)

**Epidemiology**
- genetic disorder, unusual in patients from African and Asian countries, high incidence in northern Europeans, men > women, often presents in 5th-7th decade of life, associated with but not caused by alcohol use and DM

**Clinical Features**
- order of digit involvement (most common to least common): ring > little > long > thumb > index

**Treatment**
- stages
  1. palmar pit or nodule: no surgery
  2. palpable band/cord with no limitation of extension of either MCP or PIP: no surgery
  3. lack of extension at MCP or PIP: treatment includes needle aponeurotomy, collagenase injection or surgical fasciectomy
  4. irreversible periarticular joint changes/scarring: surgical treatment possible but poorer prognosis compared to stage 3

**Median Nerve Compression**

**Definition**
- median nerve compression at the level of the flexor retinaculum

**Etiology**
- median nerve entrapment at wrist
- primary cause is idiopathic
- secondary causes: space occupying lesions (tumours, hypertrophic synovial tissue, fracture callus, and osteophytes), metabolic and physiological (pregnancy, hypothyroidism, acromegaly, and RA)
- job/hobby related repetitive trauma, especially forced wrist flexion

**Epidemiology**
- female: male = 4:1, most common entrapment neuropathy

**Clinical Features**
- sensory loss in median nerve distribution (see Figure 4)
- discriminative touch often lost first
- classically, patient awakened at night with numb/painful hand, relieved by shaking/dangling/rubbing
- decreased light touch and 2point discrimination, especially fingertips
- advanced cases: thenar wasting/weakness due to involvement of the motor branch of the nerve
- ± Tinel's sign (tingling sensation on percussion of nerve)
- ± Phalen's sign (wrist flexion induces symptoms)

**Investigations**
- clinical diagnosis
- NCV and EMG may confirm, but do not exclude, the diagnosis
Treatment
• avoid repetitive wrist and hand motion, wrist splints at night and when repetitive wrist motion required
• conservative: night time splinting to keep wrist in neutral position
• medical: NSAIDs, local corticosteroids injection, oral corticosteroids
• surgical decompression: transverse carpal ligament incision to decompress median nerve
• indications for surgery: persistent signs and symptoms of median nerve compression not relieved by conservative management

Brachial Plexus

Etiology
• common causes of brachial plexus injury: complication of childbirth and trauma
• other causes of injury: compression from tumours, ectopic ribs

Common Palsies

Table 22. Named Neonatal Palsies of the Brachial Plexus

<table>
<thead>
<tr>
<th>Palsy</th>
<th>Location of Injury</th>
<th>Mechanism of Injury</th>
<th>Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duchenne-Erb Palsy</td>
<td>Upper brachial plexus (C5-C6)</td>
<td>Head/shoulder distraction (e.g. motorcycle)</td>
<td>“Waiter’s tip deformity” (shoulder internal rotation, elbow extension, wrist flexion)</td>
</tr>
<tr>
<td>Klumpke’s Palsy</td>
<td>Lower brachial plexus (C7-T1)</td>
<td>Traction on abducted arm</td>
<td>“Claw hand” May include Horner’s syndrome</td>
</tr>
</tbody>
</table>

Differential Diagnosis of Adult Acquired Brachial Plexus Palsies
• trauma (blunt, penetrating)
• thoracic outlet syndrome
  • neurogenic: associated with cervical rib; compression of C8/T1
  • vascular: pain or sensory symptoms without cervical rib; cessation of radial pulse with provocative maneuvers
• tumour
  • schwannoma: well-defined margins makes it easier for total resection
  • neurofibromas: associated with neurofibromatosis type I
  • other: e.g. Pancoast syndrome (apical lung tumour)
• neuropathy (compressive, post-irradiation, viral, diabetic, idiopathic)

Investigations
• EMG
• MRI: gold standard for identifying soft tissue masses and nerve roots
• CT myelogram: controversial, although some people think that it is better than MRI for identification of nerve root avulsion
• closed injuries: initially, CT myelogram or MRI (and follow recovery of function); may require additional imaging 6-12 weeks after initial imaging for potential surgical management (nerve transfer, tendon transfer, etc)
• open injuries: OR for immediate exploration

Management

Table 23. Management of Brachial Plexus Injuries

<table>
<thead>
<tr>
<th>Type</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Closed Injuries</td>
<td></td>
</tr>
<tr>
<td>Concussive/compressive</td>
<td>Usually improves (unless expanding mass, e.g. hematoma)</td>
</tr>
<tr>
<td>Traction/stretch</td>
<td>If no continued insult, follow for 3-4 mo for improvement</td>
</tr>
<tr>
<td>Obstetric palsy</td>
<td>Surgery if no significant improvement and/or residual paresis at 6 mo of age</td>
</tr>
<tr>
<td>Open Injuries</td>
<td></td>
</tr>
<tr>
<td>Sharp or vascular injury</td>
<td>Explore immediately in OR</td>
</tr>
</tbody>
</table>
Craniofacial Injuries

- low velocity vs. high velocity injuries determine degree of damage
- fractures cause bruising, swelling and tenderness → loss of function
- management: most can wait ~5 d for swelling to decrease before ORIF required

Approach to Facial Injuries

- ATLS protocol
- inspect, palpate, clinical assessment for injury to underlying structures (e.g. facial nerve, bony injuries, septal hematoma, ocular involvement, etc)
- tetanus prophylaxis
- radiological evaluation: CT scan with fine cuts through the orbit
- wound irrigation with NS/RL and remove foreign materials
- conservative debridement of detached or nonviable tissue
- repair when patient's general condition allows (for significant soft tissue injury: <8 h preferable)
- consider intracranial trauma; rule out skull fracture

Investigations

- CT (gold standard)
  - axial and coronal (specifically request 1.5 mm cuts): for fractures of upper and middle face, as well as mandible
  - indicated for significant head trauma, suspected facial fractures, pre-operative assessment
- panorex radiograph: shows entire upper and lower jaw; best for isolated mandible fracture but patient must be able to sit; however, if high clinical suspicion and negative panorex, CT should be done

Treatment Goals

- consultation when indicated (dentistry, ophthalmology)
- re-establish normal occlusion if occlusion is an issue
- normal eye function (extraocular eye movements and vision)
- restore stability of face and appearance

Mandibular Fractures

- often two points of injury since it is a ring structure (includes fractures and dislocations)
- commonly at sites of weakness (condylar neck, angle of mandible,)

Etiology

- anterior force: bilateral fractures
- lateral force: ipsilateral subcondylar and contralateral angle or body fracture
- note: classified as open if fracture into tooth bearing area (alveolus)

Clinical Features

- pain, swelling, difficulty opening mouth (“trismus”)
- malocclusion, asymmetry of dental arch
- damaged, loose, or lost teeth
- palpable “step” along mandible
- numbness in V3 distribution
- intra-oral lacerations or hematoma (sublingual)
- chin deviating toward side of a fractured condyle

Classification

<table>
<thead>
<tr>
<th>Areas/Boundaries</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symphysis</td>
<td>Midline of the mandible; between the central incisors from the alveolar process through the inferior border of the mandible</td>
</tr>
<tr>
<td>Body</td>
<td>From the symphysis to the distal alveolar border of the third molar</td>
</tr>
<tr>
<td>Angle</td>
<td>Triangular region between the anterior border of the masseter and the posterosuperior insertion of the masseter distal to the third molar</td>
</tr>
<tr>
<td>Ramus</td>
<td>Part of the mandible that extends posterosuperiorly into the condylar and coronoid processes</td>
</tr>
<tr>
<td>Condylar*</td>
<td>Area of condylar process of mandible</td>
</tr>
<tr>
<td>Subcondylar</td>
<td>Area below the condylar neck (i.e. sigmoid notch) of the mandible</td>
</tr>
<tr>
<td>Coronoid Process</td>
<td>Area of the coronoid process of mandible</td>
</tr>
</tbody>
</table>

*Most common mandibular fracture type
Treatment
- maxillary and mandibular arch bars wired together (intramaxillary fixation) or ORIF ideally managed within 24hr
- antibiotics from initial presentation to fracture reduction

Maxillary Fractures

Table 25. Le Fort Classification

<table>
<thead>
<tr>
<th></th>
<th>Le Fort I</th>
<th>Le Fort II</th>
<th>Le Fort III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alternative Name</td>
<td>Guérin fracture</td>
<td>Pyramidal fracture</td>
<td>Craniofacial dysjunction</td>
</tr>
<tr>
<td>Type of Fracture</td>
<td>Horizontal</td>
<td>Pyramidal</td>
<td>Transverse</td>
</tr>
<tr>
<td>Structures Involved</td>
<td>Pinna aperture</td>
<td>Nasal bones</td>
<td>Nasofrontal suture</td>
</tr>
<tr>
<td></td>
<td>Maxillary sinus</td>
<td>Medial orbital wall</td>
<td>Zygomaticofrontal suture</td>
</tr>
<tr>
<td></td>
<td>Pterygoid plates</td>
<td>Maxilla</td>
<td>Zygomatic arch</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pterygoid plates</td>
<td></td>
</tr>
<tr>
<td>Anatomical Result</td>
<td>Maxilla divided into 2 segments</td>
<td>Maxillary teeth and midsection of the maxilla separated from upper face</td>
<td>Detach entire midfacial skeleton from cranial base</td>
</tr>
</tbody>
</table>

Nasal Fractures

Etiology
- lateral force → more common, good prognosis
- anterior force → can produce more serious injuries
- most common facial fracture

Clinical Features
- epistaxis/hemorrhage, deviation/flattening of nose, swelling, periorbital ecchymosis, tenderness over nasal dorsum, crepitus, septal hematoma, respiratory obstruction, subconjunctival hemorrhage

Treatment
- treated for airway or cosmetic issues
- always inspect for and drain septal hematoma as this is a cause of septal necrosis and perforation – completed in the ER with small incision in the septal mucosa followed by packing
- closed reduction with Asch or Walsham forceps under anaesthesia, pack nostrils with petroleum or nonadhesive gauze packing, nasal splint for 7 d
- best reduction immediately (<6 h) or when swelling subsides (5-7 d)
- rhinoplasty may be necessary later for residual deformity (30%)

Zygomatic Fractures

Classification
1. fracture restricted to zygomatic arch
2. depressed fracture of zygomatic complex (zygoma)
3. unstable fracture of zygomatic complex (tetrapod fracture) – separations occur at maxilla, frontal bone, temporal bone and orbital rim

Clinical Features
- flattening of malar prominence (view from above)
- pain over fractures on palpation
- numbness in V2 distribution (infraorbital and superior dental nerves)
- palpable step deformity in bony orbital rim (especially inferiorly)
- often associated with fractures of the orbital floor
- ipsilateral epistaxis; trismus

Treatment
- if undisplaced, stable and no symptoms, then soft diet; no treatment necessary
- ophthalmologic evaluation if suspected globe injury
- undisplaced zygomatic arch fractures can be elevated using Gillies approach (leverage on the anterior part of the zygomatic arch via a temporal incision) or Keane approach (elevation through upper buccal sulcus incision); stabilization often unnecessary
- ORIF for displaced or unstable fractures of zygomatic complex
Orbital Floor Fractures

• see Ophthalmology, OP40

Definition
• fracture of floor of orbit: may be a “pure blow out fracture” which has an intact orbital rim or can be associated with other fractures (orbital rim fracture and/or zygoma )

Etiology
• blunt force to eyeball → sudden increase in intraorbital pressure (e.g. baseball or fist)

Clinical Features
• check visual fields and visual acuity for injury to globe
• periorbital edema and bruising, subconjunctival hemorrhage
• ptosis, exophthalmos, exorbitism, enophthalmos, or hypoglobus
• orbital rim step-offs with possible infraorbital nerve anesthesia
• vertical dystopia (abnormal displacement of the entire orbital cone in the vertical plane) – assessed by comparing the symmetry of the two pupils by a horizontal line running through the pupil of the unaffected eye
• orbital entrapment
  • clinical diagnosis that is a surgical emergency
  • diplopia with vertical gaze: diplopia looking up or down (entrapment of inferior rectus), limited EOM
  • severe pain or nausea and vomiting with upward globe movement
  • requires urgent ophthalmology evaluation if there are associated visual acuity changes

Investigations
• CT (diagnostic): axial and coronal views – with fine cuts through orbit
• diagnostic maneuver for entrapment is forced duction test (pulling on inferior rectus muscle with forceps to ensure full ROM) under local anesthesia in the ER or OR

Treatment
• surgical repair indicated if: for entrapment (urgent), floor defect >1 cm, any size defect with enophthalmos or persistent diplopia (>10 d)
• reconstruction of orbital floor with bone graft or alloplastic material
• after repair, assess for diplopia: may require additional surgery for strabismus

Complications
• persistent diplopia
• enophthalmos

Superior Orbital Fissure Syndrome
• fracture of SOF causing ptosis, proptosis, anesthesia in V1 distribution, and painful ophthalmoplegia (paralysis of CN III, IV, VI)
• uncommon complication seen in Le Fort II and III fractures (1/130)
• recovery time reported as 4.8-23 wk following operative reduction of fractures

Orbital Apex Syndrome
• fracture through optic canal with involvement of CN II at apex of orbit
• symptoms are the same as SOF syndrome plus vision loss
• treatment is urgent decompression of fracture in optic canal (posterior craniotomy for decompression) or steroids
Breast

Anatomy

Vascular Supply

- innervated in a dermatomal pattern from branches of the thoracic intercostal nerves (T3-6)
  - medially innervated from anterior cutaneous branches of I-VI intercostal nerves
  - laterally innervated from lateral cutaneous nerve branches II-VII intercostal nerves
- lateral and upper portions of the breast innervated by lower fibres of the cervical plexus (C3, C4)
  - supplied by anterior and lateral cutaneous branches of intercostal nerve IV
  - additional innervation by cutaneous branches of intercostal nerves III and VI

Breast Reduction

Indications

- symptomatic (general symptoms)
  - musculoskeletal pain (back, strap, neck), chronic headache, paresthesia in upper limb, rashes under the breast, breast discomfort and physical impairment
- breast reduction methods can be classified based on pedicle (i.e. blood supply to the nipple/areolar complex) and skin resection pattern (i.e. the resultant scar)
Table 26. Types of Pedicles

<table>
<thead>
<tr>
<th>Pedicle</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inferior Pedicle</td>
<td>Most commonly used technique; versatile use in small to large breast reduction.</td>
</tr>
<tr>
<td></td>
<td>Critiqued for boxy shape breast along with more extensive scarring (wise pattern skin resection).</td>
</tr>
<tr>
<td></td>
<td>Recommended pedicle width 6-8 cm, 8-10 cm in large breasts.</td>
</tr>
<tr>
<td>Superior Pedicle</td>
<td>Pedicle derived from the internal mammary perforator of the second intercostal space.</td>
</tr>
<tr>
<td></td>
<td>Pedicle must be thinned to permit inset.</td>
</tr>
<tr>
<td>Central Pedicle</td>
<td>Modified from the inferior pedicle.</td>
</tr>
<tr>
<td></td>
<td>Blood supply derived from flow through glandular component rather than dermal component.</td>
</tr>
<tr>
<td>Medial Pedicle</td>
<td>Modified from horizontal bipedicle (Strombeck) techniques.</td>
</tr>
<tr>
<td></td>
<td>Blood supplied from internal mammary perforator from third intercostal and potentially fourth intercostal space.</td>
</tr>
<tr>
<td>Superomedial Pedicle</td>
<td>Incorporate the descending artery from second intercostal space as medial pedicle base extended superolaterally to breast meridian.</td>
</tr>
<tr>
<td>Lateral Pedicle</td>
<td>Supplied by perforators from lateral thoracic artery.</td>
</tr>
</tbody>
</table>

Table 27. Types of Skin Resections/Scar Options

<table>
<thead>
<tr>
<th>Indications</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inverted T Pattern</td>
<td>Large breasts. Breasts with poor quality skin that are challenging to remodel.</td>
</tr>
<tr>
<td></td>
<td>Commonly used in association with inferior pedicle.</td>
</tr>
<tr>
<td></td>
<td>Large portion of skin removed in horizontal and vertical direction.</td>
</tr>
<tr>
<td></td>
<td>Skin integrity important to shape and hold breast parenchyma.</td>
</tr>
<tr>
<td>Vertical Pattern</td>
<td>Skin must be healthy and easy to remodel.</td>
</tr>
<tr>
<td></td>
<td>Used in association with superior or medial pedicle.</td>
</tr>
<tr>
<td></td>
<td>Parenchyma needed to shape skin.</td>
</tr>
<tr>
<td></td>
<td>No horizontal scar.</td>
</tr>
<tr>
<td></td>
<td>Small to moderate reductions.</td>
</tr>
</tbody>
</table>

**Mastopexy (Breast Lift)**

**Definition**
- aesthetic procedure of the breast used to correct for breast ptosis by modifying the contour and size of the breast along with elevating the position of the nipple

**Clinical Grading of Ptosis (Regnault Ptosis Grade Scale)**
1. minor ptosis (1st degree)
   - nipple at inframammary fold
2. moderate ptosis (2nd degree)
   - nipple below inframammary fold, but above lower breast contour
3. severe ptosis (3rd degree)
   - nipple below inframammary fold and at lower breast contour
4. glandular ptosis
   - nipple above inframammary fold, but breast hangs below fold
5. pseudoptosis
   - nipple above inframammary fold, but breast is hypoplastic and hangs below the fold
Skin/Scar Options

Table 28. Timing of immediate reconstruction vs. delayed reconstruction

<table>
<thead>
<tr>
<th>Indications</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Circumareolar Mastopexy</td>
<td>Nipple located 1-2.5 cm too low&lt;br&gt;Originally described as &quot;donut mastopexy&quot;&lt;br&gt;Reduce areolar diameter while simultaneously raising nipple (&lt;2 cm)&lt;br&gt;Can correct nipple position asymmetry when used unilaterally&lt;br&gt;Also increase infra-areolar skin display in ptotic breasts</td>
</tr>
<tr>
<td>Vertical Mastopexy</td>
<td>Grade I - III ptosis&lt;br&gt;Larger removal than circumareolar&lt;br&gt;Raises nipple position and reduce circumareolar skin tension&lt;br&gt;Larger angle between vertical limb and limb length increase with more lower pole skin</td>
</tr>
<tr>
<td>Inverted T Mastopexy</td>
<td>Most effective in grade II to III ptosis caused by skin excess attributed to large weight loss&lt;br&gt;Large removal of skin in return for greater scar burden&lt;br&gt;Facilitate nipple elevation and parenchymal redistribution, fixation and autoaugmentation techniques</td>
</tr>
</tbody>
</table>

Breast Augmentation

Definition
- procedure designed to increase the size of the breast

Choice of Incision
- position of incision individualized since no single incision is best for all
- 3 commonly used types of incision: periareolar, inframammary crease, axillary

Type of Implant
- silicone or saline-filled implants
- subclassified into
  - surface (smooth or textured)
  - shape (round or anatomic with varying projections)
  - can also be classified as having higher or low profile

Location of Implant
- implants are commonly placed in the following positions
  1. submuscular positions
     - implant placed below pectoralis major muscle
  2. subglandular position
     - implant placed deep to glandular breast tissue but superficial to muscle
  3. subfascial
     - implant placed below the fascia

Gynecomastia

Definition
- benign enlargement of the male breast due to proliferation of the glandular tissue

Clinical Classification
- gynecomastia can be further classified into
  1. idiopathic
  2. physiologic
     - neonatal: circulating maternal estrogens via placenta
     - pubertal: relative excess of plasma estradiol versus testosterone
     - elderly: decrease circulating testosterone, peripheral aromatization of testosterone to estrogen
  3. pathologic
     - excess estrogen, androgen deficiency, deficient production or action of testosterone (i.e. Klinefelter's syndrome, androgen resistance)
  4. pharmacologic
     - drugs that may interfere with estrogen-testosterone balance include: estrogens, estrogen-like compounds (marijuana, heroin), gonadotropins, inhibitors of testosterone
  5. congenital breast deformity
  6. massive weight loss gynecomastia

Surgical Options
- surgery is the accepted management for gynecomastia
- surgery addresses the three components (breast, fat, skin)
- often involves a combination of liposuction (to remove the fatty portion) and surgical excision through a small periareolar incision (to remove the glandular component)
- patients with significant skin excess may also require skin excision as well
Breast Reconstruction

- reconstruction of the breast after cancer or trauma to recreate the breast which is similar to the contralateral breast
- reconstruction can be completed immediately (at the same time as mastectomy), or delayed (as a separate surgery days, months or years after initial surgery)
- there are alloplastic and autogenous methods of reconstruction each with its advantages and disadvantages

### Table 29. Timing of immediate reconstruction vs delayed reconstruction

<table>
<thead>
<tr>
<th></th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immediate Reconstruction</td>
<td>Generally best aesthetic outcome and can preserve nipple</td>
<td>Skin viability assessment may be compromised</td>
</tr>
<tr>
<td></td>
<td>Does not require creation of additional skin</td>
<td>Increased post-op complications compared to delayed reconstruction</td>
</tr>
<tr>
<td>Delayed Reconstruction</td>
<td>Allows patient to receive adjuvant radiotherapy before definitive reconstruction</td>
<td>Loss of skin, volume, lateral border or breast, and natural landmarks including IMF</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Likely requires more stages for completion</td>
</tr>
</tbody>
</table>

### Table 30. Alloplastic reconstruction vs autogenous reconstruction

<table>
<thead>
<tr>
<th></th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alloplastic</td>
<td>One stage reconstruction with implant</td>
<td>Size restriction in reconstruction</td>
</tr>
<tr>
<td>Reconstruction</td>
<td>Two stage reconstruction with expander and implant</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Latissimus Dorsi Flap</td>
<td></td>
</tr>
<tr>
<td>Autogenous</td>
<td>TRAM (Transverse Rectus Abdominis Muscle) Flap</td>
<td>Higher incidence of long term donor site morbidity compared to DIEP</td>
</tr>
<tr>
<td>Reconstruction</td>
<td>DIEP (Deep Inferior Epigastric Perforator) Flap</td>
<td>Weakness in rectus abdominis, hernia, etc</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Nipple Reconstruction
- final step of breast reconstruction
- nipple reconstruction is usually done as the final step when the patient is satisfied with breast mound creation
- reconstruction can be conducted with local anesthetic
- it can be done by either a flap or a graft

### Skate Flap
- pedicle is elevated above breast mound, and the lateral most aspects of the flap are wrapped around the central aspect of flap
- defect is mainly closed by skin graft

### CV Flap
- utilizes a C flap and two V flaps for nipple reconstruction
- diameter of C flap becomes the diameter of reconstructed nipple
- width of V flaps dictate projection of reconstructed nipple
- CV closed with primary closure

### Nipple Graft from Contralateral Breast
- two methods for nipple graft
  1. distal aspect of nipple removed transversely, and defect closed with purse string suture
  2. nipple divided in half longitudinally, and folded over and closed with primary closure

### Areolar Reconstruction
- tattooing vs. skin grafts
- tattooing: conducted 3–4 months after nipple reconstruction, after projection has stabilized
- skin grafts: full thickness skin grafts commonly taken from inner aspect of thigh
## Aesthetic Surgery

### Aesthetic Procedures

**Table 31. Aesthetic Procedures**

<table>
<thead>
<tr>
<th>Location</th>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Head/Neck</td>
<td>Hair transplants</td>
<td>Aesthetic improvement of hair growth patterns using hair follicle grafts or flaps</td>
</tr>
<tr>
<td></td>
<td>Otoplasty</td>
<td>Surgical correction of protruding ears</td>
</tr>
<tr>
<td></td>
<td>Forehead/Brow lift</td>
<td>Surgical procedure to lift the forehead and eyebrows</td>
</tr>
<tr>
<td></td>
<td>Rhytidectomy</td>
<td>Surgical procedure to reduce wrinkling and sagging of the face and neck; “face lift”</td>
</tr>
<tr>
<td></td>
<td>Blepharoplasty</td>
<td>Surgical procedure to shape or modify the appearance of eyelids by removing excess eyelid skin ± fat pads</td>
</tr>
<tr>
<td></td>
<td>Rhinoplasty</td>
<td>Surgical reconstruction of the nose ± nasal airway</td>
</tr>
<tr>
<td></td>
<td>Genioplasty</td>
<td>Chin augmentation via osteotomy or synthetic implant to improve contour</td>
</tr>
<tr>
<td></td>
<td>Lip augmentation</td>
<td>Procedure to create fuller lips and to reduce wrinkles around the mouth using fillers or fat</td>
</tr>
<tr>
<td>Skin</td>
<td>Chemical peel</td>
<td>Application of one or more exfoliating agents to the skin resulting in destruction of portions of the epidermis and/or dermis with subsequent tissue regeneration</td>
</tr>
<tr>
<td></td>
<td>Dermabrasion</td>
<td>Skin resurfacing with a rapidly rotating abrasive tool; often used to reduce scars, irregular skin surfaces and fine lines</td>
</tr>
<tr>
<td></td>
<td>Laser resurfacing</td>
<td>Application of laser to the skin which ultimately results in collagen reconfiguration and subsequent skin shrinking and tightening; often used to reduce scars and wrinkles</td>
</tr>
<tr>
<td></td>
<td>Injectable fillers</td>
<td>An injectable substance is used to decrease frown lines, wrinkles, and nasolabial folds; substances include collagen, fat, hyaluronic acid, and calcium hydroxyapatite (most common substances include hyaluronic acid and fat)</td>
</tr>
<tr>
<td>Other</td>
<td>Abdominoplasty</td>
<td>Removal of excess skin and repair of rectus muscle laxity (rectus diastasis); “tummy tuck”</td>
</tr>
<tr>
<td></td>
<td>Calf augmentation</td>
<td>Augmentation of calf muscle with implants</td>
</tr>
<tr>
<td></td>
<td>Liposuction</td>
<td>Surgical removal of adipose tissue for body contouring (not a weight loss procedure)</td>
</tr>
</tbody>
</table>

## Pediatric Plastic Surgery

### Craniofacial Anomalies

**Table 32. Pediatric Craniofacial Anomalies**

<table>
<thead>
<tr>
<th>Definition</th>
<th>Epidemiology</th>
<th>Clinical Features</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cleft Lip</td>
<td>Failure of fusion of maxillary and medial nasal processes</td>
<td>1 in 1000 live births; (1 in 800 Caucasians, increased in Asians, decreased in Blacks)</td>
<td>Surgery (3 mo): Millard Tennison-Randall, or Fisher (additional correct surgeries usually required later on - especially for nasal deformity)</td>
</tr>
<tr>
<td>Cleft Palate</td>
<td>Failure of fusion of lateral palatine/median palatine processes and nasal septum</td>
<td>Isolated cleft palate: 0.5 per 1000 (no racial variation)</td>
<td>Special bottles for feeding; Speech pathologist Surgery (6-9 mo): Von Langenbeck or Furlow Z-Plasty ENT consult - often recurrent otitis media, requiring myringotomy tubes</td>
</tr>
<tr>
<td>Craniosynostosis</td>
<td>Premature fusion of ≥1 cranial sutures</td>
<td>1 in 2000 live newborns; M:F = 52:48 Syndromes include: Crouzon’s, Apert’s, Saethre-Chotzen, Carpenter’s, Pfeiffer’s Jackson-Weiss and Boston-type syndromes</td>
<td>Multidisciplinary team (including neurosurgery, ENT, genetics, dentistry, pediatrics, SLIP); The type, timing and procedure are dependent on which sutures (lambdoid, sagittal etc.) are involved; Early surgery prevents secondary deformities; † ICP is an indication for emergent surgery</td>
</tr>
</tbody>
</table>
# Congenital Hand Anomalies

## Table 33. American Society for Surgery of the Hand (ASSH) Classification of Congenital Hand Anomalies

<table>
<thead>
<tr>
<th>Classification</th>
<th>Example</th>
<th>Features</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Failure of Formation</strong></td>
<td>Transverse absence (congenital amputation)</td>
<td>At any level (often below elbow/wrist)</td>
<td>Early prosthesis</td>
</tr>
<tr>
<td>Longitudinal absence (phocomelia)</td>
<td>Absent humerus</td>
<td>Thalidomide association</td>
<td></td>
</tr>
<tr>
<td>Radial deficiency (radial club hand)</td>
<td>Radial deviation</td>
<td>Thumb hypoplasia M&gt;F</td>
<td>Physiotherapy + splinting Soft tissue release if splinting fails Distraction osteogenesis (Ilizarov) ± wedge osteotomy Tendon transfer Pollicization</td>
</tr>
<tr>
<td>Thumb hypoplasia</td>
<td>Degree ranges from small thumb with all components to complete absence</td>
<td>Depends on degree – may involve no treatment, webspace deepening, tendon transfer, or pollicization of index finger</td>
<td></td>
</tr>
<tr>
<td>Ulnar club hand</td>
<td>Rare, compared to radial club hand</td>
<td>Stable wrist</td>
<td>Splinting and soft tissue stretching therapies Soft tissue release (if above fails) Correction of angulation (Ilizarov distraction)</td>
</tr>
<tr>
<td>Cleft hand</td>
<td>Autosomal dominant Often functionally normal (depending on degree)</td>
<td>First web space syndactyly release Osteotomy/tendon transfer of thumb (if hypoplastic)</td>
<td></td>
</tr>
<tr>
<td><strong>Failure of Differentiation/ Separation</strong></td>
<td>Syndactyly</td>
<td>Fusion of ≥2 digits 1/3,000 live births M:F = 2:1 Classified as partial/complete Simple (skin only) vs. complex (osseous or cartilaginous bridges)</td>
<td>Surgical separation before 6-12 mo of age May require a skin graft to cover the fingers Usually good result</td>
</tr>
<tr>
<td>Symbrachydactyly</td>
<td>Short fingers with short nails at fingertips</td>
<td>Digital separation Webspace deepening</td>
<td></td>
</tr>
<tr>
<td>Camptodactyly</td>
<td>Congenital flexion contracture (usually at PIP, especially 5th digit)</td>
<td>Early splinting Volar release Arthroplasty (rarely)</td>
<td></td>
</tr>
<tr>
<td>Clinodactyly</td>
<td>Radial or ulnar deviation Often middle phalanx</td>
<td>None (usually); if severe, osteotomy with grafting</td>
<td></td>
</tr>
<tr>
<td><strong>Duplication</strong></td>
<td>Polydactyly</td>
<td>Congenital duplication of digits May be radial (increased in Aboriginals and Asians) or central or ulnar (increased in Blacks)</td>
<td>Amputation of least functional digit Usually &gt;1 yr of age (when functional status can be assessed)</td>
</tr>
<tr>
<td>Overgrowth</td>
<td>Macroductyly</td>
<td>Rare</td>
<td>None (if mild) Soft tissue/bony reduction</td>
</tr>
<tr>
<td>Undergrowth</td>
<td>Brachydactyly</td>
<td>Short phalanges</td>
<td>Removal of nonfunctional stumps Osteotomies/tendon transfers Distraction osteogenesis Phalangeal/free toe transfer</td>
</tr>
<tr>
<td>Symbrachydactyly</td>
<td>Short webbed fingers</td>
<td>As above + syndactyly release</td>
<td></td>
</tr>
<tr>
<td>Brachysyndactyly</td>
<td>i.e. amniotic (annular) band syndrome</td>
<td>Variety of presentations</td>
<td>Urgent release for acute, progressive edema distal to band in newborn Other reconstruction is case specific</td>
</tr>
<tr>
<td><strong>Generalized Skeletal Abnormality</strong></td>
<td></td>
<td>Variety of presentations</td>
<td>Treatment depends on etiology</td>
</tr>
</tbody>
</table>
References


# Population Health and Epidemiology

**Acronyms** ........................................ 2

**Public Health Context** ......................... 2
Public Health Services in Canada
Legislation and Public Health in Canada

**Determinants of Health** ....................... 3
Concepts of Health
Vulnerable Populations
Disease Prevention
Health Promotion Strategies

**Measurements of Health and Disease**
in a Population. ................................. 7

**Epidemiology** ................................. 8
Interpreting Test Results
Effectiveness of Interventions

**Types of Study Design** ....................... 11
Qualitative vs. Quantitative
Quantitative Research Methods
Observational Study Designs
Experimental Study Designs
Summary Study Designs

**Methods of Analysis** ......................... 14
Distributions
Data Analysis
Common Statistical Tests
Causation
Assessing Evidence

**Health Services Research** ................... 17
Continuous Quality Improvement
Cost Analysis

**Outbreak of Infectious Diseases** .......... 18
Definitions
Steps to Control an Outbreak
Infection Control Targets

**Environmental Health** ..................... 20
Risk Assessment
Air
Water
Soil
Food

**Occupational Health** ....................... 23
Taking an Occupational Health History
Occupational Hazards
Workplace Legislation
Workplace Health Promotion and Protection
Workplace Disease Prevention and Identification
Workplace Treatment and Rehabilitation

**Appendix – Mandatory Reporting** ........ 24
Reportable Diseases
Other Reportable Conditions

**References** ..................................... 26

---

For more detail on topics covered in this chapter, use website [http://phprimer.afmc.ca/](http://phprimer.afmc.ca/) as a resource.
### Acronyms

<table>
<thead>
<tr>
<th>AR</th>
<th>attributable risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAS</td>
<td>Children’s Aid Society</td>
</tr>
<tr>
<td>CBA</td>
<td>cost benefit analysis</td>
</tr>
<tr>
<td>CEA</td>
<td>cost effectiveness analysis</td>
</tr>
<tr>
<td>CFR</td>
<td>case fatality rate</td>
</tr>
<tr>
<td>CPHO</td>
<td>Chief Public Health Officer</td>
</tr>
<tr>
<td>DALY</td>
<td>disability adjusted life years</td>
</tr>
<tr>
<td>EBM</td>
<td>evidence based medicine</td>
</tr>
<tr>
<td>HC</td>
<td>Health Canada</td>
</tr>
<tr>
<td>FP</td>
<td>false positives</td>
</tr>
<tr>
<td>FN</td>
<td>false negatives</td>
</tr>
<tr>
<td>INR</td>
<td>infant mortality ratio</td>
</tr>
<tr>
<td>ITT</td>
<td>intention to treat analysis</td>
</tr>
<tr>
<td>LICO</td>
<td>low income cut-off</td>
</tr>
<tr>
<td>LR</td>
<td>likelihood ratio</td>
</tr>
<tr>
<td>MHO</td>
<td>Medical Health Officer</td>
</tr>
<tr>
<td>MDR</td>
<td>Medical Officer of Health</td>
</tr>
<tr>
<td>MMR</td>
<td>maternal mortality ratio</td>
</tr>
<tr>
<td>MGDS</td>
<td>Material Safety Data Sheets</td>
</tr>
<tr>
<td>NNT</td>
<td>number needed to treat</td>
</tr>
<tr>
<td>NPV</td>
<td>negative predictive value</td>
</tr>
<tr>
<td>OR</td>
<td>odds ratio</td>
</tr>
<tr>
<td>PHAC</td>
<td>Public Health Agency of Canada</td>
</tr>
<tr>
<td>PP</td>
<td>per protocol analysis</td>
</tr>
<tr>
<td>PPR</td>
<td>positive predictive value</td>
</tr>
<tr>
<td>PIVL</td>
<td>potential years of life lost</td>
</tr>
<tr>
<td>QALY</td>
<td>quality adjusted life years</td>
</tr>
<tr>
<td>QI</td>
<td>quality improvement</td>
</tr>
<tr>
<td>RCT</td>
<td>randomized controlled trial</td>
</tr>
<tr>
<td>RR</td>
<td>relative risk</td>
</tr>
<tr>
<td>SMR</td>
<td>standardized mortality ratio</td>
</tr>
<tr>
<td>SN</td>
<td>sensitivity</td>
</tr>
<tr>
<td>SP</td>
<td>specificity</td>
</tr>
<tr>
<td>TP</td>
<td>true positives</td>
</tr>
<tr>
<td>TN</td>
<td>true negatives</td>
</tr>
<tr>
<td>WHMIS</td>
<td>Workplace Hazardous Materials Information System</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>WSIB</td>
<td>Workplace Safety and Insurance Board</td>
</tr>
</tbody>
</table>

### Public Health Context

- see [Ethical, Legal, and Organizational Medicine, ELOM2](#) Overview of Canadian Healthcare System for the organization of health care in Canada including the legal foundation and historical context

### Definitions

- **population health**
  - refers to the health of defined groups of people, their health determinants, trends in health, and health inequalities
  - influenced by: physical, biological, social, environmental, and economic factors; personal health behaviours; health care services
  - broader scope vs. public health, accounts for socio-economic, policy, historical issues
- **public health**
  - “efforts organized by society to protect, promote, and restore the peoples’ health” and prevent morbidity and mortality
  - refers to the practices, programs, policies, institutions, and disciplines required to achieve the desired state of population health
- **epidemiology**
  - “study of the distribution […] of determinants of disease, health-related states, and events in populations”
- **public health and preventive medicine** (formerly called community medicine)
  - the postgraduate study of health and disease in the population or a specified community
  - 5 year Royal College specialty training
  - goal: to identify and address health problems and evaluate the extent to which health services and others address these issues


### Public Health Services in Canada

**Mission:** to promote and protect the health of Canadians through leadership, partnership, innovation, and action in public health” (Public Health Agency of Canada)

- local public health units and services within regional health authorities (in most provinces except Ontario, where local public health units are either autonomous or within local government) provide programs and activities for health protection, promotion, and disease prevention at local and regional levels
- catchment-area populations range widely (100s–1,000,000s), covering areas of 15 km² to 1.5 million km²
- the “core functions” of public health include six essential activities (The Organization of Health Services in Canada. AFMC Primer on Population Health, Accessed: March 25, 2016)
  1. **health protection**: take measures to address potential risks to health at the population level, including through regulation and advising government (e.g. safe water & food supply)
  2. **health surveillance**: monitoring and predict health outcomes and determinants with systematic, longitudinal data collection
  3. **disease and injury prevention**: address infectious disease through preventive (e.g. vaccination, droplet protection) and control (e.g. quarantine) measures; reduce morbidity through lifestyle improvement
  4. **population health assessment**: studying and engaging with a community to understand their needs and produce better policies and services
  5. **health promotion**: positively advocate for health through broad community and government measures (e.g. policy, interventions, community organizing)
  6. **emergency preparedness and response**: developing protocols and infrastructure for natural (e.g. hurricane) and man-made (e.g. toxic waste spill) disasters


The Association of Faculties of Medicine of Canada Public Health Educators’ Network. The Organization of Health Services in Canada. AFMC Primer on Population Health.
Legislation and Public Health in Canada

Table 1. Legislation and Public Health in Canada

<table>
<thead>
<tr>
<th>Federal</th>
<th>Provincial</th>
<th>Municipal (Ontario)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health Canada</td>
<td>Legislation is in the form of Acts and Regulations</td>
<td>Local boards of health deliver programs mandated by provincial and municipal or regional legislation</td>
</tr>
<tr>
<td>• Provides health services to First Nations, Aboriginal peoples, the Canadian military, and veterans</td>
<td>Each province has its own Public Health Act or equivalent (e.g., the Health Protection and Promotion Act in Ontario)</td>
<td>Boards of health are responsible for the delivery of most public health services, such as:</td>
</tr>
<tr>
<td>• Approves new drugs and medical devices</td>
<td>• Designates the creation of geographic areas for the provision of public health services</td>
<td>• Infectious disease control, including the follow-up of reported diseases and management of outbreaks</td>
</tr>
<tr>
<td>Canadian Food Inspection Agency</td>
<td>• Gives powers to the Chief Medical Officer of Health to control public health hazards</td>
<td>• Inspection of food premises including those in hospitals, nursing homes, and restaurants</td>
</tr>
<tr>
<td>• Monitors food products</td>
<td>• Specifies infectious diseases to be reported to public health units by physicians, laboratories, and hospitals (see Appendix, PH24)</td>
<td>• Family health services including pre-conception, preschool, school-aged, and adult health programs</td>
</tr>
<tr>
<td>• Deals with animal-related infections</td>
<td>• Has the ability to mandate programs that address public health issues, environmental health, and chronic disease prevention</td>
<td>• Tobacco control legislation enforcement</td>
</tr>
<tr>
<td>• Regulates food labeling</td>
<td>• Oversees immigration screening, protects Canadian borders (e.g., airport health inspection)</td>
<td>• Assessment and management of local environmental health risks</td>
</tr>
<tr>
<td>Public Health Agency of Canada (main government of Canada agency responsible for public health)</td>
<td>• Liases with the World Health Organization (WHO) on global health issues</td>
<td>• Collection and dissemination of local health status reports</td>
</tr>
<tr>
<td>• An independent body created to strengthen public health capacity</td>
<td></td>
<td>• Public dental health services to children</td>
</tr>
<tr>
<td>• Focuses on preventing chronic diseases, preventing injuries, and responding to public health emergencies and infectious disease outbreaks</td>
<td></td>
<td>• By-laws may be approved by municipal governments to facilitate public health issues</td>
</tr>
<tr>
<td>• Oversees immigration screening, protects Canadian borders (e.g., airport health inspection)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Determinants of Health

**Concepts of Health**

- **wellness**: “state of dynamic physical, mental, social, and spiritual well-being that enables a person to achieve full potential and have an enjoyable life”
- **disease**: “abnormal, medically-defined changes in the structure or function of the human body”
- **illness**: “an individual's experience or subjective perception of a lack of physical or mental well-being and consequent inability to function normally in social roles”
- **illness behaviour**: an individual's actions resulting from and responding to their illness, including their interactions or avoidance of the health care system
- **sickness**: views the individual and their society hold towards a health condition, affecting their thoughts and actions
- **impairment**: “any loss or abnormality of psychological, physiological, or anatomical structure or function”
- **disability**: “any restriction or lack of ability to perform an activity within the range considered normal for a human being”
- **handicap**: a disadvantage for an individual arising due to impairment and disability
  - “limits or prevents the fulfillment of an individual's normal role as determined by society and depend on age, sex, social, and cultural factors”
- **health equity**: when all people have “the opportunity to attain their full health potential” and no one is “disadvantaged from achieving this potential because of their social position or other socially determined circumstance.” Health inequities are systematic differences in the health of individuals/groups which are considered unjust
- **health equality**: defined as where populations have equal or similar health status. Health inequalities are systematic differences in the health of groups that do not necessarily carry a moral judgement

**Determinants of Health**

- 1974: the Honourable Marc Lalonde, federal Minister of Health, publishes A New Perspective on the Health of Canadians which outlines four factors that determine health: “human biology, environment, lifestyle, and health care organizations.” The idea of determinants of health has since been expanded and refined to include many additional factors


**Definitions of Health**

- First multidimensional definition of health, as defined by the WHO in 1948: “state of complete physical, mental and social well-being and not merely the absence of disease or infirmity.”
- WHO updated the definition (socio-ecological definition) of health in 1986: “The ability to identify and to realise aspirations, to satisfy needs, and to change or cope with the environment. Health is therefore a resource for everyday life, not the objective of living. Health is a positive concept emphasizing social and personal resources, as well as physical capacities” (Ottawa Charter for Health Promotion)
- Other definitions of health have since been proposed that incorporate other dimensions of health (e.g. “Health is a social, economic, and political issue and above all a fundamental human right” – The People’s Charter for Health)

**Determinants of Health**

- Income and social status
- Social support networks
- Education and literacy
- Employment and working conditions
- Social and work environments
- Physical environment
- Personal health practices and coping skills
- Healthy child development
- Biology, genetics, and epigenetics
- Health services
- Gender
- Culture

Cultural Safety
- cultural safety: “interactions with people from different cultures that treat them respectfully in a manner that acknowledges relevant differences but does not create a sense of discrimination”
- cultural sensitivity: “being aware of (and understanding) the characteristic values and perceptions of your own culture and the way in which this may shape your approach to patients from other cultures”


Vulnerable Populations

Table 2. Health Determinants of Vulnerable Populations

<table>
<thead>
<tr>
<th>Definition</th>
<th>Psychosocial/ Socioeconomic</th>
<th>Physical</th>
<th>Environment</th>
<th>Individual Behaviour</th>
<th>Population-Specific Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aboriginal Peoples</td>
<td>Four specific groups:</td>
<td>Low income</td>
<td>Crowded housing</td>
<td>Smoking</td>
<td>Mental health awareness</td>
</tr>
<tr>
<td></td>
<td>First Nations Status Indians (registered under the Indian Act), non-Status Indians, Métis, and Inuit</td>
<td>Family violence</td>
<td>Inefficient ventilation</td>
<td>Substance misuse</td>
<td>Aboriginal-specific DM initiatives</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Low education status</td>
<td>Environmental toxins</td>
<td>Excessive gambling</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Unemployment</td>
<td>(botulism)</td>
<td>Poor nutrition</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Homelessness</td>
<td>TB declining</td>
<td>Sedentary lifestyle</td>
<td>Substance abuse treatment programs</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Longer length of disability</td>
<td>but prevalence higher than rest of population</td>
<td>High BMI</td>
<td></td>
</tr>
<tr>
<td>Isolated Seniors</td>
<td>Individuals &gt;65 yr</td>
<td>Elder abuse</td>
<td>Low hazard tolerance</td>
<td>Inactivity</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lack of emotional support Isolation</td>
<td>Institutionalization</td>
<td>Polypharmacy</td>
<td>Mental health promotion</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mobility issues</td>
<td>Medical comorbidities</td>
<td>Preventing abuse and neglect</td>
</tr>
<tr>
<td>Children in Poverty</td>
<td>Based on Low Income Cut Offs (LICD)</td>
<td>Low income</td>
<td>Housing availability</td>
<td>Poor supervision</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LICD is an income threshold below which a family will likely devote a larger share of its income on the necessities of food, shelter and clothing than the average family</td>
<td>Family dysfunction</td>
<td>Unsafe housing</td>
<td>Food insecurity</td>
<td>Improvements in family income most significant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lack of educational opportunities</td>
<td>Lack of recreational space</td>
<td>High risk behaviours</td>
<td>Early childhood education</td>
</tr>
</tbody>
</table>

Social Determinants: Indigenous People’s Health in Canada
- Colonization: subjugation of Indigenous peoples by the Europeans, leading to the loss of lands, cultural practices, and self-governance
- Residential schools: placement of children from Indigenous groups in church-run, government-funded schools for the purpose of assimilation, resulting in loss of identity, alienation, and abuse, with long-lasting consequences of higher rates of addictions, abusive relationships, and suicide
- Treaties and Land Claims: inadequate services for those living on reserves leading to poverty and poor quality infrastructure; reflected in disproportionate burden of infectious diseases (e.g. pertussis, Chlamydia, hepatitis, shigellosis)
- Traditional Approach to Healing: restoring balance in the four realms of spiritual, emotional, mental and physical health of a person acting as an individual, as well as a member of a family, community and nation
- Ideas represented by medicine wheel of First Nations peoples, the Learning Blanket of Inuit peoples, and the Metis tree model of Holistic Lifelong Learning
- Contrast to Western medicine focus of treating illness, leading to challenges for practitioners of Western medicine to meet Aboriginal patients’ needs
- National Aboriginal Health Organization (NAHO) offers 8 guidelines on practicing culturally safe health care for Aboriginal patients including need to allow Aboriginal patients access to ceremony, song, and prayer; the need for information and for family support; guidelines for the appropriate disposal of body parts and for handling death

New Immigrants to Canada
- Mandatory medical exams on entry to Canada by a designated medical practitioner.
- Complete medical examination for all persons of all ages
- Chest x-ray and report for persons 11 yr of age and over
- Urinalysis for persons 5 yr of age and over
- Syphilis serology for persons
- 15 yr of age and over
- HIV testing for applicants 15 yr of age and over, as well as for those children who have received blood or blood products, have a known HIV-positive mother, or have an identified risk. An ELISA HIV screening test should be done for HIV 1 and HIV 2
- Serum creatinine if the applicant has hypertension (resting blood pressure greater than 140/90 mmHg), a history of treated hypertension, DM, autoimmune disorder, persistent proteinuria, or kidney disorder

Table 2. Health Determinants of Vulnerable Populations (continued)

<table>
<thead>
<tr>
<th>Definition</th>
<th>Psychosocial/ Socioeconomic</th>
<th>Physical</th>
<th>Environment</th>
<th>Individual Behaviour</th>
<th>Population-Specific Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>People with Disabilities</td>
<td>Includes impairments, activity limitations, and participation restrictions</td>
<td>Low income Low education status Discrimination Sigma</td>
<td>Institutionalization Barriers to access Transportation challenges</td>
<td>Substance misuse Poor nutrition Inactivity Dependency for ADLs</td>
<td>Transportation support Multidisciplinary care Unique support for individuals with specific disabilities (e.g. Trisomy 21)</td>
</tr>
<tr>
<td>New Immigrants</td>
<td>Person born outside of Canada who has been granted the right to live in Canada permanently by immigration authorities</td>
<td>Access to community services Cultural perspectives (including reliance on alternative health practices)</td>
<td>Exposure to diseases and conditions in country of origin (e.g. smoke from wood fires, incidence of TB, etc.)</td>
<td>Employment, ESL Healthy Newcomer Effect (health worsens over time to match that of the general population) Cultural or religious expectations</td>
<td>Women’s health Mental health Infectious diseases (syphilis blood test, CXR, HIV) Dental and vision screening Vaccinations Cancer screening</td>
</tr>
<tr>
<td>Homeless Persons</td>
<td>An individual who lacks permanent housing</td>
<td>Low income Food insecurity Mental illness</td>
<td>Exposure to temperature extremes Infections such as West Nile Virus</td>
<td>Substance misuse Violence</td>
<td>Safe housing Addictions support Mental health</td>
</tr>
<tr>
<td>Refugee Health</td>
<td>Forced to flee country of origin because of a well-founded fear of persecution and given protection by the Government of Canada</td>
<td>Post-traumatic stress disorders Depression Adjustment problems Partial health coverage via Interim Federal Health Program</td>
<td>Diseases and conditions in country of origin (e.g. malaria, TB, onchocerciasis, etc.) Direct and indirect effects of war</td>
<td>Employment ESL Longstanding prior lack of access to health care (chronically neglected problems) Cultural or religious expectations</td>
<td>Vaccinations Women’s health Mental health Infectious diseases Dental and vision screening Political advocacy</td>
</tr>
</tbody>
</table>

Note: this chart delineates the major challenges faced by each group, but the issues listed are not unique to each population


### Disease Prevention

#### Natural History of Disease

- course of a disease from onset to resolution
  1. pathological onset
  2. presymptomatic stage: from onset to first appearance of symptoms/signs
  3. clinically manifest disease: may regress spontaneously, be subject to remissions and relapses, or progress to death

#### Disease Prevention Strategies

- measures aimed at preventing the occurrence, interrupting through early detection and treatment, or slowing the progression of disease/mitigating the sequelae

### Ottawa Charter for Health Promotion (1986)

- Health promotion: the process of enabling people to increase control over and improve their health
- The charter states that governments and health care providers should be involved in a health promotion process that includes:
  1. Building healthy public policy
  2. Creating supportive environments
  3. Strengthening community action
  4. Developing personal skills
  5. Re-orienting health services

---

Basic Concepts in Prevention, Surveillance, and Health Promotion. AFMC Primer on Population Health (http://phprimer.ahmc.ca/Part1-TheoryThinkingAboutHealthChapter1BasicConceptsPreventionSurveillanceAndHealthPromotion/Thestagessofprevention)
Screening (Secondary Prevention)

- "presumptive identification of unrecognized disease or defect by the application of tests, examinations, or other procedures which can be applied rapidly"

- types of screening
  - mass screening: screening all members of a population for a disease (e.g. phenylketonuria (PKU) and hypothyroidism in all newborns)
  - selective screening: screening of targeted subgroups of the population at risk for a disease (e.g. mammography in women >50 yr old)
  - multiphasic screening: the use of many measurements and investigations to look for many disease entities (e.g. periodic health exam)

- bias in screening
  - lead-time: false improvement in survival time caused by changing the starting point of measurement (lead time), as opposed to real improvements measured from the original starting point (e.g. due to better therapy)
  - lead-time bias: overestimation of survival time ‘from diagnosis’ when the estimate is made from the time of screening, instead of the later time when the disease would have been diagnosed without screening
  - length-time bias: overestimation of the survival time due to screening at one time point including more stable cases than aggressive cases of disease, who may have shorter survival times

---

**Table 4. Ideal Criteria for Screening Tests**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Test</th>
<th>Health Care System</th>
</tr>
</thead>
<tbody>
<tr>
<td>Causes significant suffering and/or death</td>
<td>High specificity and sensitivity</td>
<td>Adequate capacity for reporting, follow-up, and treatment of positive screens</td>
</tr>
<tr>
<td>Natural history must be understood</td>
<td>Safe, rapid, easy, relatively inexpensive</td>
<td>Cost effective</td>
</tr>
<tr>
<td>Must have an asymptomatic stage that can be detected by a test</td>
<td>Acceptable to providers and to population</td>
<td>Sustainable program</td>
</tr>
<tr>
<td>Early detection and intervention must result in improved outcomes</td>
<td>Incidence is not too high or too low</td>
<td>Clear policy guidelines</td>
</tr>
<tr>
<td>Incidence is not too high or too low</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


The Association of Faculties of Medicine of Canada Public Health Educators’ Network. Concepts of Health and Illness. AFMC Primer on Population Health

---

**Health Promotion Strategies**

**Table 5. Disease Prevention vs. Health Promotion Approach**

<table>
<thead>
<tr>
<th>Disease Prevention</th>
<th>Health Promotion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health = absence of disease</td>
<td>Health = positive and multidimensional concept</td>
</tr>
<tr>
<td>Medical model (passive role)</td>
<td>Participatory model of health</td>
</tr>
<tr>
<td>Aimed mainly at high-risk groups in the population</td>
<td>Aimed at the population in its total environment</td>
</tr>
<tr>
<td>One-shot strategy, aimed at a specific pathology</td>
<td>Diverse and complementary strategies aimed at a network of issues/determinants</td>
</tr>
<tr>
<td>Directive and persuasive strategies enforced in target groups</td>
<td>Facilitating and enabling approaches by incentives offered to the population</td>
</tr>
<tr>
<td>Focused mostly on individuals and groups of subjects</td>
<td>Focused on a person’s health status and environment</td>
</tr>
<tr>
<td>Led by professional groups from health disciplines</td>
<td>Led by non-professional organizations, civic groups, local, municipal, regional, and national governments</td>
</tr>
</tbody>
</table>


---

**Healthy Public Policy**

- characterized by an explicit concern for health and equity in all areas of policy and by an accountability for health impact
- main aim: to create a supportive environment to enable people to lead healthy lives, thereby making healthy choices easier for citizens
- government sectors must take into account health as an essential factor when formulating policy and should be accountable for the health consequences of their policy decisions

**Methods**

- fiscal: imposing additional costs (e.g. taxes on tobacco and alcohol)
- legislative: implementing legal deterrents (e.g. smoking bans, legal alcohol drinking age)
- social: improving health beyond providing universally funded health care (e.g. providing affordable housing)

Source: International Conference on Health Promotion, Adelaide, South Australia (1998)
Behaviour Change

- health education serves to
  - increase knowledge and skills
  - encourage positive behaviour changes and discourage unhealthy choices
- health education is an important component of eliciting behaviour change
- behaviour is a result of three factors
  1. predisposing factors: knowledge, attitude, beliefs, values, intentions
  2. enabling factors: skills, supports
  3. reinforcing factors: health care professionals and the social context of family and community

**Health Belief Model (1975)**

- "behaviours undertaken by individuals in order to remain healthy […] are a function of a set of interacting beliefs"
- beliefs include: (i) individual’s perception of their susceptibility to a disease, (ii) severity of the disease, (iii) efficacy of proposed change/action, (iv) benefits and costs of health-related actions
- beliefs are modified by socio-demographic and psychosocial variables
- individuals must be in a state of readiness
- behaviour can be stimulated by cues to action, which are triggers that can encourage preventive health decisions and actions (e.g. physician recommendation, public advertising)

**Stages of Change Model**

- provides a framework in which the Health Belief Model is applied to facilitating behaviour change (e.g. quitting smoking)

![Figure 3. Stages of change model](source)

**Risk Reduction Strategies**

- **risk reduction**: lower the risk to health without eliminating it (e.g. avoiding sun to lower risk of skin cancer)
- **harm reduction**: tolerance of some degree of risk behaviour, while aiming to minimize the adverse outcomes associated with these behaviours (e.g. needle exchange programs)


**Measurements of Health and Disease in a Population**

**MEASURES OF DISEASE OCCURRENCE**

**Incidence Rate**

- number of new cases in a population per unit of person-time

**Prevalence**

- total number of cases in a population over a defined period of time
- two forms of prevalence
  - **point prevalence**: assessed at one point in time
  - **period prevalence**: as above, but all cases over defined time window (including ‘incident’ ones) are included
- depends on **incidence rate** and disease duration from onset to termination (cure or death)
- favours the inclusion of chronic over acute cases and may underestimate disease burden if those with short disease duration are missed
- prevalence studies are cross-sectional and provide weak evidence for causal inferences
- prevalence figures are useful for determining the extent of a disease and can aid in the planning of facilities and services

**Example of Harm Reduction Strategy**

**Summary of Findings from the Evaluation of a Pilot Medically Supervised Injection Facility (MSIF)**

**Background**: The study discusses the outcomes among a population of illicit drug users (IDUs) after initiating a supervised safe injection facility in Vancouver in September 2001. Due to the Canadian government's grants, such an evaluation of its results was conducted over a 3 year period.

**Study Population**: IDUs in the Vancouver area were allowed to inject previously obtained illicit drugs under the supervision of nurses and physicians. IDUs were offered addiction counseling and supports for appropriate community resources. A random sample of 670 IDUs was recruited and monitored from Dec 2003 - July 2004.

**Results**: Characteristics of IDUs who used the safe injecting facility included age <30 yr, history of drug use, homelessness, daily heroin, and/or cocaine injection, and recent history of overdose. MSA measures of public order problems were taken 6 wk before and 12 wk after initiation of the safe injecting facility. It was found that the mean number of IDUs injecting daily in public, along with the mean number of publically discarded syringes were reduced by approximately half.

**Conclusions**: Overall, it has been found that the safer injecting facility in Vancouver has been successful in attracting IDUs at increased risk of HIV, overdose, and public injection of substances. This has resulted in lower incidences of public drug use, publicly discarded syringes and sharing of needles. Other studies associated with this one have demonstrated that there has been no increase in the drug dealing, drug related crimes, or rates of new IDUs in the area surrounding the safer injecting facility.

**Incidence and Prevalence**

- **Incidence** = \( \frac{\text{# of new cases in a time interval}}{\text{total person-time at risk}} \) (measures the rate of new infections)
- **Prevalence** = \( \frac{\text{# of existing cases}}{\text{total person-time at risk}} \) (measures the frequency of disease at a point in time)

*For Canada in 2011:*

- HIV incidence rate is 9.5 per 100,000 people
- HIV prevalence is 213 per 100,000 people

**Top 5 Causes of Mortality in Canada, 2012, by Sex**

- **Female**
  - Cancer
  - Heart disease
  - Stroke
  - COPD/chronic lower respiratory disease
  - Alzheimer’s
- **Male**
  - Cancer
  - Heart disease
  - Accidents
  - Stroke
  - COPD/chronic lower respiratory disease

Age Standardized Rate
- adjustment of the crude rate of a health-related event using a “standard” population
- standard population is one with a known number of persons in each age and sex group
- standardization prevents bias which could be made by comparing crude rates from two dissimilar populations (e.g. crude death rates over a number of decades are not comparable as the population age distribution has changed with time)

MEASURES OF MORTALITY

Life Expectancy
- “the expected number of years to be lived by a newborn based on age-specific mortality rates at a selected time”
- usually qualified by country, gender, and age

Crude Death Rate
- mortality from all causes of death per 1,000 in the population

Infant Mortality Rate (IMR)
- number of deaths among children under 1 yr of age reported during a given time period divided by the number of live births reported during the same time period and expressed per 1,000 live births per year

Maternal Mortality Rate (MMR)
- “number of deaths of women during pregnancy and due to puerperal causes [...] per 1000 live births in the same year”

MEASURES OF DISEASE BURDEN

Potential Years of Life Lost (PYLL)
- calculated for a population using the difference between the actual age at death and a standard/expected age at death
- increased weighting of mortality at a younger age

Disability Adjusted Life Year (DALY)
- life expectancy weighted by amount of disability experienced
- both premature death and time spent with disability accounted for; these disabilities can be physical or mental

Quality Adjusted Life Year (QALY)
- years of life weighted by utility (similar to quality of life), ranging from 0 to 1 assigned to a year of life based on perceived quality of life; a yr in “perfect” health is considered equal to 1 QALY, the value of a year in ill health would be lowered based on the burden of disease
- it is possible to have “states worse than death” for example QALY <0 for extremely serious conditions

For additional rate calculations see Outbreak of Infectious Diseases, PH19

Consult the Public Health Agency of Canada for examples and latest statistics

Bias
• systematic error causing results to differ from correct values/inferences
• can occur at any point in study execution (e.g. collection, analysis, interpretation, publication, or review of data)
  • sampling bias: occurs with the selection of a sample that does not truly represent the population
  • sampling procedures should be chosen to prevent or minimize bias
  • measurement bias: systematic error arising from inaccurate measurements of subjects
  • recall bias: bias in individuals’ responses when reporting on past exposures/events
    • e.g. individuals with disease may be more likely to incorrectly recall/believe they were exposed to a possible risk factor than those who are free of disease

Confounder
• a variable that is related to both the exposure and outcome but is not a mediator in the exposure-outcome relationship
• distorts the estimated effect of an exposure if not accounted for in the study design/analysis (e.g. late maternal age could be a confounder in an investigation of birth order >4 and risk of developing Trisomy 21)
• randomization, stratification, matching, and regression modelling can help minimize confounder effects

Interpreting Test Results

<table>
<thead>
<tr>
<th>TP = True positive</th>
<th>TN = True negative</th>
<th>FP = False positive</th>
<th>FN = False negative</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Disease</strong></td>
<td><strong>Test Result</strong></td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>Present</td>
<td>TP</td>
<td>FP</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>FN</td>
<td>TN</td>
<td></td>
</tr>
</tbody>
</table>

Sensitivity = TP/(TP+FN)
Specificity = TN/(TN+FP)

Likelihood Ratio (LR)
• Likelihood that a given test result would be expected in a patient with disease compared with the likelihood that the same result would be expected in a patient without disease
• LR+ indicates how much the probability of disease increases if the test is positive
• LR- indicates how much the probability of disease decreases if the test is negative

LR+ = Sensitivity = [TP/(TP+FN)]
LR- = Specificity = [FP/(TN+FP)]

Positive Predictive Value (PPV)
• Proportion of people with a positive test who have the disease
PPV = TP
TP + FP

Negative Predictive Value (NPV)
• Proportion of people with a negative test who are free of disease
NPV = TN
TN + FN

Advanced Neoplasia

<table>
<thead>
<tr>
<th>Test Result</th>
<th>Positive</th>
<th>Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present</td>
<td>68</td>
<td>147</td>
</tr>
<tr>
<td>Negative</td>
<td>216</td>
<td>2234</td>
</tr>
<tr>
<td>Total</td>
<td>284</td>
<td>2381</td>
</tr>
</tbody>
</table>

Sensitivity = 68/284 = 23.9%
Specificity = 2234/2381 = 93.8%

Figure 4. Understanding sensitivity and specificity
Figure 4a. Hypothetical population
Figure 4b. Results of diagnostic test on hypothetical population
Figure 4c. Sensitivity of test (e.g. 24/30 = 80% sensitive)
Figure 4d. Specificity of test (e.g. 56/70 = 80% specific)

Figure 5. Interpreting test results: Practical example using FOBT testing in advanced colon cancer


Sensitivity
• proportion of people with disease who have a positive test

Specificity
• proportion of people without disease who have a negative test

Pre-Test Probability
• the probability a particular patient has a given disease before a test/assessment results are known
**Post-Test Probability**
- a revision of the probability of disease after a patient has been interviewed/examined/tested
- calculation process can be explicit using results from epidemiologic studies, knowledge of the accuracy of tests, and a nomogram/Bayes’ theorem
- the post-test probability from clinical examination is the basis of consideration when ordering diagnostic tests or imaging studies
  - after each iteration the resultant post-test probability becomes the pre-test probability when considering new investigations

**Effectiveness of Interventions**

**Effectiveness, Efficacy, Efficiency**
- three measurements indicating the relative value (beneficial effects vs. harmful effects) of an intervention
  - **efficacy**: the extent to which a specific intervention produces a beneficial result under ideal conditions (e.g. RCT)
    - ideal conditions include adherence, close monitoring, access to health resources, etc.
  - **effectiveness**: measures the benefit of an intervention under usual conditions of clinical care
    - considers both the efficacy of an intervention and its actual impact on the real world, taking into account access to the intervention, whether it is offered to those who can benefit from it, its proper administration, acceptance of intervention, and degree of adherence to intervention
  - **efficiency**: a measure of economy of an intervention with known effectiveness
    - considers the optimal use of resources (e.g. money, time, personnel, equipment, etc.)

### Table: Disease (e.g. lung CA)

<table>
<thead>
<tr>
<th>Exposure (e.g. smoking)</th>
<th>Present</th>
<th>Absent</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present</td>
<td>A</td>
<td>B</td>
<td>A + B</td>
</tr>
<tr>
<td>Absent</td>
<td>C</td>
<td>D</td>
<td>C + D</td>
</tr>
<tr>
<td>Total</td>
<td>A + C</td>
<td>B + D</td>
<td>A + B + C + D</td>
</tr>
</tbody>
</table>

**Case-Control Study**

- **odds ratio (OR)**\(^*\) = \(\frac{A \times B}{C \times D} = \frac{A \times D}{B \times C}\)

**Cohort Study**

- **relative risk (RR)**\(^*\) = \(\frac{A}{A + B} = \frac{A + C}{A + B + C + D}\)
- **attributable risk (AR)**\(^*\*) = \(\frac{A}{A + B} = \frac{A - C}{A + B - C + D}\)

\(^*\)Ratio of the odds in favour of the health outcome among the exposed to the odds in favour among the unexposed

\(^*\*)Ratio of the risk of a health outcome among the exposed to the risk among the unexposed

\(^*\*\)Rate of health outcome in exposed individuals that can be attributed to the exposure

**Number Needed to Treat (NNT)**
- number of patients who need to be treated to achieve one additional favourable outcome
- only one of many factors that should be taken into account in clinical or health system decision making (e.g. must take into account cost, ease, feasibility of intervention)
- a condition with death as a potential outcome can have a higher NNT (and be acceptable), as compared to an intervention to prevent an outcome with low morbidity, in which a low NNT would be necessary

**Number Needed to Harm (NNH)**
- number of patients who, if they received the experimental treatment, would lead to one additional patient being harmed, compared with patients who received the control treatment

**Adherence (formerly compliance)**
- degree to which a patient follows a treatment plan

**Coverage**
- extent to which the services rendered cover the potential need for these services in a community

**Equations to Assess Effectiveness**

- **CER** = control group event rate
- **EER** = experimental group event rate
- **RR** = EER/CER
- **ARR** = CER – EER
- **NNT** = 1/ARR

**Sensitivity and specificity are characteristics of the test**

- **LR** depends on the test characteristics, not the prevalence
- **PVV** and **NPV** depend on the prevalence of the disease in the population

**Figure 6. Fagan’s likelihood ratio nomogram: Practical example using PSA levels to calculate post-test probability of prostate cancer**

**Beware**

- Do not be swayed by a large RR or odds ratio, as it may appear to be large if event rate is small to begin with. In these cases AR is more important (e.g. a drug which lowers an event which occurs in 0.1% of a population to 0.05% can boast a RR of 50%, and yet the AR is only 0.05%, which is not nearly as impressive)

**NNT**

- Consult http://www.thennt.com for quick summaries of evidence-based medicine (includes NNT, LR, and risk assessments)
Types of Study Design

Qualitative vs. Quantitative

Table 6. Qualitative vs. Quantitative Study Designs

<table>
<thead>
<tr>
<th>Qualitative</th>
<th>Quantitative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Often used to generate hypothesis (Why? What does it mean?)</td>
<td>Often tests hypothesis (What? How much/many?)</td>
</tr>
<tr>
<td>&quot;Bottom up&quot; approach</td>
<td>&quot;Top down&quot; approach</td>
</tr>
<tr>
<td>Observation → pattern → tentative hypothesis → theory</td>
<td>Theory → hypothesis → observation → confirmation</td>
</tr>
<tr>
<td>Sampling approach to obtain representative coverage of ideas, concepts, or experiences</td>
<td>Sampling approach to obtain representative coverage of people in the population</td>
</tr>
<tr>
<td>Narrative: rich, contextual, and detailed information from a small number of participants</td>
<td>Numeric: frequency, severity, and associations from a large number of participants</td>
</tr>
</tbody>
</table>

Source: Adapted from http://phprimer.afmc.ca

Quantitative Research Methods

Formulating a Research Question

PICOC
Population/Patient Characteristics
Intervention/Exposure of Interest
Comparison Group or Control Group
Outcome that you are trying to prevent or achieve

Observational Study Designs

- observational studies involve neither the manipulation of the exposure of interest nor randomization of the study subjects
- there are two main subtypes of observational studies: descriptive and analytic studies

Descriptive Studies
- describe the events and rates of disease with respect to person, place and time and to estimate disease frequency and time trends
- can be used to generate an etiologic hypothesis and for policy planning

Analytic Studies
- observational studies used to test a specific hypothesis
- includes ecological studies, cohort studies, case-control studies, and cross-sectional studies

An example of an ecological fallacy would be concluding that red wine drinking leads to lower risk of death from CVS disease after an ecological study shows that countries with a higher rate of red wine consumption have a lower rate of death from CVS causes.
<table>
<thead>
<tr>
<th>Type of Study</th>
<th>Ecological</th>
<th>Cross-Sectional</th>
<th>Case-Control</th>
<th>Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definition</td>
<td>Units of analysis are populations or groups of people, rather than individuals</td>
<td>Use individual data on exposures and outcomes gathered at the same time</td>
<td>Samples a group of people who already have a particular outcome (cases) and compares them to a similar sample group without that outcome (controls)</td>
<td>Subjects are sampled and, as a group, classified on the basis of presence or absence of exposure to a particular risk factor</td>
</tr>
<tr>
<td>Subjects</td>
<td>Aggregated groups (e.g. cities)</td>
<td>Sample of a population</td>
<td>Two or more samples of individuals with and without the outcome(s) of interest (i.e. cases and controls)</td>
<td>One or more cohorts Cohort: group of people with common characteristics (e.g. year of birth, region of residence) Divided into measured exposed vs. non-exposed groups</td>
</tr>
<tr>
<td>Methods</td>
<td>Descriptions of the average exposure or risk of disease for a population Can use regression models to test associations between area-level predictors and aggregate outcomes</td>
<td>Collect information from each person at one particular time Tabulate the numbers in groups (e.g. by presence or absence of disease/factor of interest) Make tables and compare groups Estimate prevalence Use regression models to test associations between predictors and outcomes of interest</td>
<td>Select sample of cases of a specific disease during a specific time frame Representative of spectrum of clinical disease Select control(s) Represent the general population To minimize risk of bias, may select more than one control group and/or match controls to cases (e.g. age, gender) Assess past exposures (e.g. EMR, questionnaire) Association can be concluded between the risk factor and the disease (odds ratio)</td>
<td>Collect information on factors from all persons at the beginning of the study Subjects are followed for a specific period of time to determine development of disease in each exposure group Prospective: measuring from the exposure at present to the future outcomes Retrospective: measuring forward in time from exposures in the past to later outcomes Use statistical models to test associations between exposures and disease or other measured outcomes Provides estimates of incidence, relative risk, attributable risk</td>
</tr>
<tr>
<td>Advantages</td>
<td>Quick, easy to do Uses readily available data Generates hypothesis</td>
<td>Determines association between variables Quick and uses fewer resources Surveys with validated questions allows comparison between studies</td>
<td>Often used when disease in population is rare (less than 10% of population) due to increased efficiency or when time to develop disease is long Less costly and time consuming</td>
<td>Shows an association between risk factor(s) and outcome(s) Stronger evidence for causation Can consider a variety of exposures and outcomes</td>
</tr>
<tr>
<td>Disadvantages</td>
<td>Poor generalizability to individual level (not direct assessment of causal relationship) Ecological fallacy: an incorrect inference from groups to individuals Confounding</td>
<td>Does not allow for assessment of temporal relationship or offer strong evidence for causation between variables Confounding Selection bias Recall bias (see Bias, PH9)</td>
<td>Recall bias (see Bias, PH9) Confounding Selection bias for cases and controls Only one outcome can be measured</td>
<td>Confounding may occur due to individuals self-selecting the exposure, or unknown/unmeasured factors are associated with the measured exposure and outcome Cost and duration of time needed to follow cohort Selection bias</td>
</tr>
<tr>
<td>Examples</td>
<td>A study looking at the association between smoking rates and lung cancer rates in different countries at the population level without individual data on both factors</td>
<td>A study that examines the distribution of BMI by age in Ontario at a particular point in time</td>
<td>A famous case control study published by Sir Richard Doll demonstrated the link between tobacco smoking exposure and lung cancer cases at the individual level</td>
<td>A famous cohort study is the Framingham Heart Study, which assessed the long-term cardiovascular risks of diet, exercise, medications such as ASA, etc.</td>
</tr>
</tbody>
</table>

Experimental Study Designs

- not discussed here are non-randomized control trials (e.g. allocation by clinic or other non-random basis – performed when randomization is not possible)

**RANDOMIZED CONTROLLED TRIAL (RCT)**

**Definition**
- subjects are assigned by random allocation to two or more groups, one of which is the control group, the other group(s) receive(s) an intervention

**Subjects**
- individuals are selected using explicit inclusion/exclusion criteria with recruitment targets guided by sample size calculations

**Methods**
- random allocation of individuals into two or more treatment groups through a centralized concealed process
- method of assessment to reduce bias
  - single-blind: subject does not know group assignment (intervention or placebo)
  - double-blind: subject and observer both unaware of group assignment
  - triple-blind: subject, observer, and analyst unaware of group assignment
- one group receives placebo or standard therapy
- one or more groups receive(s) the intervention(s) under study
- baseline covariates and outcome(s) are measured and the groups are compared
- all other conditions are kept the same between groups

**Advantages**
- “gold standard” of studies, upon which the practice of EBM is founded
- provides the strongest evidence for effectiveness of intervention
- with sufficient sample size and appropriate randomization, threats to validity are minimized
- randomization is one of few methods that can address selection bias and confounding (including unmeasured confounders)
- allows prospective assessment of the effects of intervention

**Disadvantages**
- some exposures are not amenable to randomization (e.g. cannot randomize subjects to poverty/wealth or to harmful exposures such as smoking) due to ethical or feasibility concerns
- can be difficult to randomly allocate groups (e.g. communities, neighbourhoods)
- difficult to study rare events, since RCTs would require extremely large sample sizes
- contamination, co-intervention, and loss to follow up can all limit causal inferences
- can have poor generalizability
- costly


**Summary Study Designs**

**META-ANALYSIS**

**Definition**
- a form of statistical analysis that synthesizes the results of independent studies addressing a common research question, as identified through systematic review

**Subjects**
- all the studies identified through the review (or all subjects used in original studies for individual-level meta-analysis)

**Methods**
- selection of relevant studies from the published literature which meet quality criteria
- statistical models used to combine the results of each independent study
- provides a summary statistic of overall results as well as graphic representation of included studies (forest plot)

**Advantages**
- attempts to overcome the problem of reduced power due to small sample sizes of individual studies
- ability to control for inter-study variation
- can address questions (e.g. subgroup analyses) that the original studies were not powered to answer
Methods of Analysis

**Disadvantages**
- sources of bias may not be controlled for
- reliance on published studies may increase the potential conclusion of an effect as it can be difficult to publish studies that show no significant results (publication bias)
- the decision to include/reject a particular study is subjective

**11. Distribution curves**

**Type I (α) Error**

“There is an effect” where in reality there is none


**Methods of Analysis**

**Distributions**

- distribution describes the probability of events
- normal (Gaussian) or non-normal (binomial, gamma, skewed, etc.)
- characteristics of the normal distribution
  - mean = median = mode
  - 67% of observations fall within one standard deviation of the mean
  - 95% of observations fall within two standard deviations of the mean
- measures of central tendency
  - mean: sum of each observations’ data (e.g. ages) divided by total number of observations
  - median: value at the 50th percentile, this is a better reflection of the central tendency for a skewed distribution
  - mode: most frequently observed value in a series
- measures of dispersion
  - range: the largest value minus the smallest value
  - variance: a measure of the spread of data
  - standard deviation: the average distance of data points from the mean (the positive square root of variance)
- given the mean and standard deviation of a normal or binomial distribution curve, a description of the entire distribution of data is obtained

**Data Analysis**

**Statistical Hypotheses**

- null (H₀)
  - the default hypothesis, often that there is no relationship between two variables
- alternative (H₁)
  - the hypothesis that we are interested in, often that there is a relationship between two variables
  - we can find evidence against H₀ but we can never ‘prove’ H₁

**Type I Error (α Error)**

- the null hypothesis is falsely rejected (i.e. concluding an intervention X is effective when it is not, or declaring an observed difference to be real rather than by chance)
- the probability of this error is denoted by the p-value
- studies tend to be designed to minimize this type of error, since a type I error can have larger clinical significance than a type II error

**Type II Error (β Error)**

- the null hypothesis is falsely accepted (i.e. stating intervention X is not effective when it is, or declaring an observed difference/effect to have occurred by chance when it is present)
- by convention a higher level of error is often accepted for most studies
- can also be used to calculate statistical power

**Power**

- probability of correctly rejecting a null hypothesis when it is in fact false (i.e. the probability of finding a specified difference to be statistically significant at a given p-value)
- power increases with an increase in sample size
- power = 1 - β, and is therefore equal to the probability of a true positive result

**Statistical Significance**

- the probability that the statistical association found between the variables is due to random chance alone (i.e. that there is no association)
- the preset probability is set sufficiently low that one would act on the result; frequently p<0.05
- when statistical tests result in a probability less than the preset limit, the results are said to be statistically significant (denoted by the α-value)

**Example Calculation**

Data set: 17, 14, 17, 10, 7
Mean = \(\frac{(17 + 14 + 17 + 10 + 7)}{5} = 13\)
Median = write the list in order, median is the number in the middle
\(= 7, 10, 14, 17, 17 = 14\)
Mode (number repeated more often) = 17
Range = 17 - 7 = 10
Variance = \(\frac{[(17 - 13)^2 + (14 - 13)^2 + (10 - 13)^2 + (17 - 13)^2]}{5}\)
\(= 19.5\)
Standard Deviation = \(\sqrt{19.5} = 4.42\)

**Statistical Hypotheses**

- null (H₀)
- alternative (H₁)

**Type I Error (α Error)**

- “There is an effect” where in reality there is none

**Statistical Significance**

- the probability that the statistical association found between the variables is due to random chance alone (i.e. that there is no association)
- the preset probability is set sufficiently low that one would act on the result; frequently p<0.05
- when statistical tests result in a probability less than the preset limit, the results are said to be statistically significant (denoted by the α-value)
Clinical Significance
• measure of clinical usefulness (e.g. 1 mmHg BP reduction may be statistically significant, but may not be clinically significant)
• depends on factors such as cost, availability, patient compliance, and side effects in addition to statistical significance

Confidence Interval (CI)
• provides a range of values within which the true population result (e.g. the mean) lies
• frequently reported as 95% CI (i.e. 95% chance that the true value is within this data range)
• bounded by the upper and lower confidence limits

Data
• information collected from a sample of a population
• there are 4 overall levels of measurement for quantitative data listed with examples
  • categorical (e.g. gender, marital status)
  • ordinal (e.g. low, medium, high)
  • interval (e.g. °C, time of day)
  • ratio (e.g. serum cholesterol, hemoglobin, age)

Validity/Accuracy (of a measurement tool)
• how closely a measurement reflects the entity it claims to measure

Reliability/Precision
• how consistent multiple measurements are when the underlying subject of measurement has not changed
• may be assessed by different observers at the same time (inter-rater reliability) or by the same observer under different conditions (test-retest reliability)

Internal Validity
• degree to which the findings of the sample truly represent the findings in the study population
• dependent on the reliability, accuracy, and absence of other biases

External Validity (i.e. Generalizability)
• degree to which the results of the study can be generalized to other situations or populations

Common Statistical Tests

<table>
<thead>
<tr>
<th>Table 8. Statistical Tests</th>
<th>Two-sample Z-Test</th>
<th>Analysis of Variance (ANOVA)</th>
<th>Chi-Squared Test (χ²)</th>
<th>Linear Regression</th>
<th>Logistic Regression</th>
<th>Pearson product-moment correlation (Pearson’s r)</th>
</tr>
</thead>
<tbody>
<tr>
<td>What are you trying to show?</td>
<td>Compare the mean values of an outcome variable between two groups (e.g. difference in average BP between men and women)</td>
<td>Compare the mean values of an outcome variable between two or more groups (e.g. difference in average BP between persons in three towns)</td>
<td>Test the correspondence between a theoretical frequency distribution and an observed frequency distribution (e.g. if one sample of 20 patients is 30% hypertensive and another comparison group of 25 patients is 60% hypertensive, a chi-squared test determines if this variation is more than expected due to chance alone)</td>
<td>Looks at associations between two or more variables (e.g. age and blood pressure)</td>
<td>Shows how a change in one explanatory variable affects the status (e.g. ill vs. non-ill) of the outcome variable</td>
<td>Assesses the strength of the linear relationship between two variables. Ranges from -1 (negative association, i.e. increases in one variable are associated with decreases in another) to 1 (positive association, increases in one variable are associated with increases in the other). A correlation of 0 indicates no relationship</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>What kind of variables do you measure?</th>
<th>Continuous data</th>
<th>Continuous data</th>
<th>Categorical (2 or more)/ordinal</th>
<th>Continuous</th>
<th>Categorical (outcomes usually dichotomous)</th>
<th>Continuous</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Dependent Variable</th>
<th>Continuous data</th>
<th>Continuous data</th>
<th>Categorical (2 or more)/ordinal</th>
<th>Continuous</th>
<th>Categorical (outcomes usually dichotomous)</th>
<th>Continuous</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Independent Variable</th>
<th>Dichotomous</th>
<th>Categorical/Ordinal (2 or more)</th>
<th>Categorical/Ordinal (2 or more)</th>
<th>Continuous/Ordinal</th>
<th>Categorical/Ordinal</th>
<th>Continuous/Ordinal</th>
</tr>
</thead>
</table>

| Assumptions | Data follow a normal distribution | Equal variances | Data are independent | “Normal” distribution of dependent variable’s error term | Data are independent | Expected counts must be at least 5 for all cells in n x n table | Data are independent | Dependent variable’s error term has “normal” distribution | Linear relationship between variables | Homoskedasticity | No influential values | Data are independent | Linearity (on logit scale) | No influential values | Model has adequate goodness-of-fit | Data are independent | Underlying relationship is linear | Data for both variables are Normally distributed | Data are independent |

A wider confidence interval implies more variance than a tighter confidence interval given the same critical value.

Good reliability
Good accuracy

Poor reliability
Poor accuracy

Figure 12. Validity vs. reliability.

What’s the difference between Pearson and Spearman correlation?
Different types of correlation are used for different levels of measurement. Pearson is for continuous and Normal data, Spearman is for ordinal or non-Normal data. There are other forms of correlation for other levels of measurement (e.g. Tetrachoric/polychoric).
Causation

Criteria for Causation (Sir Bradford Hill)
1. **strength of association**: the frequency with which the factor is found in the disease and the frequency with which it occurs in the absence of disease
2. **consistency**: is it the same relationship seen with different populations or study design?
3. **specificity**: is the association particular to your intervention and measured outcome?
4. **temporal relationship**: did the exposure occur before the onset of the disease?
5. **biological gradient**: finding a dose response relationship between the exposure-outcome
6. **biological plausibility**: does the association/causation make biological sense?
7. **coherence**: can the relationship be explained/accounted for based on what we know about science, logic, etc.?
8. **experimental evidence**: does experimental evidence support the association (e.g. is there improvement)?
9. **analogy**: do other established associations provide a model for this type of the relationship?

**Note**: Not all criteria must be fulfilled to establish scientific causation, and the modern practice of EBM emphasizes ‘experimental evidence’ as superior to other criteria for experimental causation review. However many causation questions in health cannot be answered with experimental methods.


Assessing Evidence

- critical appraisal is the process of systematically examining research evidence to assess validity, results, and relevance before using it to inform a decision

![Figure 13. Pyramid of pre-appraised evidence](image)

A. Are the results of the study valid?
   - see below for classifications of evidence that has already been assessed; see sidebar for assessing primary studies

B. What are the results?
   - what was the impact of the treatment effect?
   - how precise was the estimate of treatment effect?
   - what were the confidence intervals and power of the study?

C. Will the results help me in caring for my patients?
   - are the results clinically significant?
   - can I apply the results to my patient population?
   - were all clinically important outcomes considered?
   - are the likely treatment benefits worth the potential harm and costs?
Health Services Research

Continuous Quality Improvement

Quality Improvement (QI)
- a means of evaluating and improving processes; focusing more on systems and systematic biases, which are thought to cause variation in quality
- measures to increase efficiency of action with the purpose of achieving optimal quality

Quality Assurance
- process to guarantee the quality of health care through improvement and attainment of set standards
- “five-stage process of quality assurance” (Public Health and Preventative Medicine in Canada, Shah)
  1. formulation of working goals
  2. procedural changes to implement those goals
  3. regular comparison of current performance with original goals
  4. development of solutions to bring performance closer to goals
  5. documentation of quality assurance activities

Quality Control
- a process of surveying the quality of all factors involved in the process to maintain standards

Continuous Quality Improvement
- the process of ongoing service/product refinement via the vigilant review of expectant issue detrimental to the system and regular incorporation of improvements

Quality Management
- combination of several process (assurance, control, improvement) to maintain consistent quality

Total Quality Management
- management principle for advancing quality while minimizing additional expenditures
- focuses on the entire system rather than discrete elements

Audit
- methodical analysis of a quality system by quality auditors
- to determine whether quality processes and results comply with goals, and whether processes have been implemented effectively

Systems Analyses Tools
1. 5 Why: brainstorming to simplify the process of change; continue asking ‘why’ until the root of the problem is discovered
2. Ishikawa Diagrams (i.e. Fishbone Diagrams): identify generic categories of problems that have an overall contribution on the effect

Levels of Evidence: Classifications Cited in Guidelines/Consensus Statements

Level I evidence: based on RCTs (or meta-analysis of RCTs) big enough to have low risk of incorporating FP or FN results
Level II evidence: based on RCTs too small to provide Level I evidence; may show positive trends that are non-significant, or have a high risk of FN results
Level III evidence: based on non-randomized, controlled or cohort studies; case series; case-controlled; or cross-sectional studies
Level IV evidence: based on opinion of respected authorities or expert committees, as published consensus conferences/guidelines
Level V evidence: opinions of the individuals who have written/reviewed the guidelines (i.e. Level IV evidence), based on experience/knowledge of literature/peer discussion

Notes: These 5 levels of evidence are not direct evaluations of evidence quality or credibility; they reflect the nature of the evidence. While RCTs tend to be most credible (with < III), level III evidence gains credibility when multiple studies from different locations and/or time periods report consistent findings. Level IV and V evidence reflects decision-making that is necessary but in the absence of published evidence.
3. **Defect check sheets**: consider all defects and tally up the number of times the defect occurs

4. **Pareto Chart**: x vs. y chart; x-axis = defect categories, y-axis = frequency; plot cumulative frequency on the right y-axis
   - purpose is to highlight most important among large set of factors contributing to defects/poor quality

**Precede-Proceed Model**
- tool for designing, implementing, and evaluating health interventions/programs

<table>
<thead>
<tr>
<th>PRECEDE Phase</th>
<th>PROCEED Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 1 – Identify the ultimate desired result</td>
<td>Phase 5 – Implementation (design and conduct the intervention)</td>
</tr>
<tr>
<td>Phase 2 – Identify health issues and their behavioural and environmental determinants. Set priorities among them.</td>
<td>Phase 6 – Process Evaluation (determine if the program is implemented as planned)</td>
</tr>
<tr>
<td>Phase 3 – Identify the predisposing, enabling, and reinforcing factors that affect the behaviours and environmental determinants</td>
<td>Phase 7 – Impact Evaluation (measure intermediate objectives – predisposing, enabling, and reinforcing factors)</td>
</tr>
<tr>
<td>Phase 4 – Identify the administrative and policy factors that influence what can be implemented</td>
<td>Phase 8 – Outcome Evaluation (measure desired result)</td>
</tr>
</tbody>
</table>

**Cost Analysis**

**Cost Benefit Analysis (CBA)**
- an analysis which compares the total expected costs with the total expected benefits of actions in order to choose the most profitable or beneficial options
- costs are controlled for inflation and market changes so that the effect of the change is evaluated over a consistent, preset financial value

**Cost Effectiveness Analysis (CEA)**
- ratio of the change in cost (numerator) to change in effect (denominator) in response to a new strategy or practice
  - some examples of changes in effect (denominator) could be years of life gained or sight-years gained
  - the numerator highlights the cost of the health gain
  - the most commonly used outcome measure is quality-adjusted life years (QALY) (see *Quality Adjusted Life Year, PH8*)
- can be used where an extensive cost benefit analysis is not applicable or appropriate

**Outbreak of Infectious Diseases**

**Definitions**

**Endemic**
- consistent existence of infectious agent or disease in a given population or area (i.e. usual rate of disease)

**Outbreak**
- incidence of new cases beyond the usual frequency of disease in a particular population or community over a given period of time
- an epidemic that is in a confined location, has a short duration, or begins acutely
Epidemic
- an outbreak or excessive rate of disease that rapidly spreads to a large number of individuals (e.g. SARS epidemic)

Pandemic
- epidemic over a wide area, crossing international boundaries, and affecting an even larger number of people

Attack Rate
- cumulative incidence of infection within a defined group observed during a specific period of time in an epidemic
- calculated by dividing the total number of people who develop clinical disease by the population at risk, usually expressed as a percentage

Secondary Attack Rate
- the proportion of individuals who develop disease as a result of exposure to primary contacts during the incubation period
- infectiousness reflects the ease of disease transmission and is usually measured by the secondary attack rate

Virulence
- extent of sickness caused in host by a disease-causing agent
- ratio comparing those with the disease who are critically affected over the total number of individuals in the population who have the disease

Case-Fatality Rate (CFR)
- proportion of individuals with the disease who perish as a result of the illness
- most frequently applied to a specific outbreak of acute disease in which all patients have been followed for an adequate period of time to include all attributable deaths
- must be clearly differentiated from the mortality rate

Mortality Rate/Crude Death Rate
- estimation of the portion of the population that dies during a specified period from all causes of death

Steps to Control an Outbreak

Adopted from AFMC Primer on Population Health

1. Determine whether an outbreak

2. Develop case definitions and identify outbreak cases
   - consider history, signs, symptoms, test results, and timing to balance sensitivity and specificity in case definition
   - consider engaging in active surveillance to identify additional cases

3. Develop hypotheses regarding outbreak cause/source and implement initial control measures
   - identify source, population at risk
   - manage cases, including appropriate isolation
   - reinforce importance of routine and additional precautions

4. Test hypotheses using surveillance data or special studies
   - describe cases by person, place, and time to create a line listing
   - plot an epidemic curve:
     - histogram with time on the x-axis and number of cases on the y-axis
     - often follows a characteristic pattern based on the nature of the exposure and/or infectious agent:
       - point source epidemic: exposure is brief and not continuous or propagated (e.g. single contaminated dish at a picnic)
       - extended source epidemic: exposure may be continuous (or intermittent if peaks are irregular) and lasts for days or weeks (e.g. ongoing or intermittent contamination of drinking water)
       - propagated epidemic: series of peaks demonstrating only a few cases initially, but then ongoing person-to-person transmission (e.g. influenza virus)

5. Re-evaluate hypothesis and adjust control measures

6. Create and implement plans for future prevention and control
   - examples include prevention of transmission in the environment (e.g. handwashing and sterilization techniques), immunization of hosts, and education of health care professionals and the public
Infection Control Targets

- interventions should target host, agent, environment, and their interactions

![Diagram of the Epidemiology Triad]

Environmental Health

Definition
- study of the association between environmental factors, both constructed and natural, and health
- environmental exposures
  - four common hazards: chemical, biological, physical, and radiation
  - four main reservoirs: air, food, water, and soil
  - three main routes: inhalation, ingestion, or absorption (skin)
  - usually divided into two main settings
    - workplace (including schools): may see high level exposure in healthy individuals (see Occupational Health, PH23)
    - non-workplace: lower levels of exposure over longer period of time. Affects vulnerable populations more severely, such as at extremes of age, immuno-suppressed. May be teratogenic.
- health impacts of the environment also include factors such as urban planning and how individuals interact with the built environment (e.g. safe pedestrian and bicycle paths can facilitate more active lifestyles)

![Table of Environmental Health Jurisdiction]

<table>
<thead>
<tr>
<th>Public Health Unit</th>
<th>Enforcement of water and food safety regulations (including restaurant food safety)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sanitation</td>
</tr>
<tr>
<td></td>
<td>Assessment of local environmental risks</td>
</tr>
<tr>
<td></td>
<td>Monitoring and follow-up of reportable diseases</td>
</tr>
<tr>
<td>Municipal Government</td>
<td>Waste disposal</td>
</tr>
<tr>
<td></td>
<td>Recycling</td>
</tr>
<tr>
<td></td>
<td>Water and sewage treatment/collection/distribution</td>
</tr>
<tr>
<td>Provincial and Territorial Government</td>
<td>Water and air quality standards</td>
</tr>
<tr>
<td></td>
<td>Industrial emission regulation</td>
</tr>
<tr>
<td></td>
<td>Toxic waste disposal</td>
</tr>
<tr>
<td>Federal Government</td>
<td>Designating and regulating toxic substances</td>
</tr>
<tr>
<td></td>
<td>Regulating food products (e.g. Health Canada)</td>
</tr>
<tr>
<td></td>
<td>Setting policy for pollutants that can travel across provincial boundaries</td>
</tr>
<tr>
<td>International</td>
<td>Multilateral agreements (e.g. Kyoto Protocol, UN Convention on Climate Change)</td>
</tr>
<tr>
<td></td>
<td>International Joint Commission</td>
</tr>
</tbody>
</table>

**Risk Assessment**

Adopted from p.250, Sixth Edition of “A Dictionary of Epidemiology” by Miquel Porta

**Hazard Identification**
- what is the hazard involved?
- assess potential hazards by taking environmental health history

**Risk Characterization**
- is the identified agent likely to elicit the patient’s current symptoms?
- review known health impacts of the hazard and identify specific properties that contribute to or diminish adverse effects (e.g. evaluate threshold levels)

**Exposure Assessment**
- is the patient’s exposure to the environmental agent sufficient to have caused the current symptoms?
- quantify exposure through direct measurement or by reviewing frequency and nature of contact with hazard

**Air**

**Biological Hazards**
- moulds thrive in moist areas; 10-15% of the population allergic
- bacteria survive as spores and aerosols, can be distributed through ventilation systems (e.g. Legionella)
- dust mites (year-round) and pollens (seasonal) can trigger upper and lower-airway symptoms

**Chemical Hazards**
- ground-level ozone
  - main component of smog with levels increasing in major cities
  - worsens asthma, irritates upper airway
- carbon monoxide (fossil fuel-related, common byproduct of combustion)
  - aggravates cardiac disease at low levels
  - headache, nausea, dizziness at moderate levels
  - fatal at high levels
- sulphur dioxide (fossil fuel-related), nitrogen oxides
  - contribute to acid rain and exacerbate breathing difficulties
- organic compounds at high levels (e.g. benzene, methane chloride, tetrachloroethylene)
  - tend to be fat-soluble, easily absorbed through skin and difficult to excrete
- heavy metal emissions (e.g. nickel, cadmium, chromium)
  - variety of health effects: upper airway disease, asthma, decreased lung function
- second-hand tobacco smoke
  - respiratory problems, increase risk of lung cancer
  - particulates associated with decreased lung function, asthma, upper airway irritation

**Radiation Hazards**
- sound waves
  - ionizing radiation
  - radon is naturally produced by soil containing uranium or radium, can contaminate indoor air and is associated with a small proportion of lung cancers
- ultraviolet radiation is increasing due to ozone layer destruction and increases risk of skin cancer
  - non-ionizing radiation
  - visible light, infrared, microwave

**Water**

**Biological Hazards**
- mostly due to human and animal waste
- Aboriginal Canadians, rural Canadians at higher risk
- bacteria: *Escherichia coli* (e.g. Walkerton, ON), *Salmonella*, *Pseudomonas*, *Shigella*
- protozoa: *Giardia*, *Cryptosporidium* (e.g. North Battleford, SK)

**Chemical/Industrial Hazards**
- chlorination by-products (e.g. chloriform can cause cancer at high levels)
- volatile organic compounds, heavy metals, pesticides, and other industrial waste products can be present in groundwater
- fluoride at high levels (greater than that of municipal fluoridation) can cause skeletal fluorosis


**The Walkerton Tragedy**

In May 2000, the drinking water system in the town of Walkerton, ON, became contaminated with *Escherichia coli* O157:H7 and *Campylobacter jejuni*. Over 2,300 individuals became ill; 27 people developed hemolytic uremic syndrome and 7 individuals died in the outbreak.


**To Fluoridate or Not**

At the recommended concentration of 0.8-1.0 mg/L, fluoride reduces cavities by 18-40%, and there is little risk of fluorosis unless other exposures (e.g. toothpaste, rinses, mouthwash, etc.) are swallowed. Opposition raises concerns that the intake is not easily controlled, and that children, and others may be more susceptible to health problems. However, public health experts strongly support fluoridation as an effective measure to prevent dental caries at the community level and reduce dental health inequities.
Biological Hazards
- biological contamination: tetanus, *Pseudomonas*

Chemical Hazards
- contamination sources: rupture of underground storage tanks, use of pesticides and herbicides, percolation of contaminated water runoffs, leaching of wastes from landfills, dust from smelting and coal burning power plants, residue of industrial waste/development (e.g. urban agriculture), lead deposition, leakage of transformers
- most common chemicals: petroleum hydrocarbons, solvents, lead, pesticides, motor oil, other industrial waste products
- infants and toddlers at highest risk of exposure due to hand-mouth behaviours
- dependent on contaminant: leukemia, kidney damage, liver toxicity, neuromuscular blockade, developmental damage to the brain and nervous system, skin rash, eye irritation, headache, nausea, fatigue

### Food

Biological Hazards

<table>
<thead>
<tr>
<th>Source</th>
<th>Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Salmonella</em> Raw eggs, poultry, meat</td>
<td>GI symptoms</td>
</tr>
<tr>
<td><em>Campylobacter</em> Raw poultry, raw milk</td>
<td>Joint pain, GI symptoms</td>
</tr>
<tr>
<td><em>Escherichia coli</em> Various including meat, sprouts, cold cuts</td>
<td>Watery or bloody diarrhea</td>
</tr>
<tr>
<td><em>Listeria monocytogenes</em> Unpasteurized cheeses, prepared salads, canned foods</td>
<td>Listeriosis: nausea, vomiting, fever, headache, rarely meningitis or encephalitis</td>
</tr>
<tr>
<td><em>Clostridium botulinum</em> Unpasteurized honey, canned foods</td>
<td>Dizziness, weakness, respiratory failure, GI symptoms: thirst, nausea, constipation</td>
</tr>
<tr>
<td><em>Prion (BSE</em>)* Beef and beef products</td>
<td>Creutzfeldt-Jakob disease</td>
</tr>
</tbody>
</table>

*BSE = bovine spongiform encephalopathy*

- other biological food contaminants include
  - viruses, mould toxins (e.g. aflatoxin has been associated with liver cancer), parasites (e.g. *Toxoplasmosis*, tapeworm), paralytic shellfish poisoning (rare), genetically modified organisms (controversial as to health risks/benefits)

Chemical Hazards
- many persistent organic pollutants are fat-soluble and undergo bioamplification
- drugs (antibiotics, hormones)
- inadequately prepared herbal medications
- food additives and preservatives
  - nitrates highest in cured meats; can be converted to carcinogenic nitrosamines
  - sulphites commonly used as preservatives; associated with sulphite allergy (hives, nausea, shock)
- pesticide residues
  - older pesticides (e.g. DDT) have considerable human health effects
  - polychlorinated biphenyls (PCBs)
    - effects (severe acne, numbness, muscle spasm, bronchitis) much more likely to be seen in occupationally exposed individuals than in the general population
- dioxins and furans
  - levels highest in fish and marine mammals, also present in breast milk can cause immunosuppression, liver disease, respiratory disease
Occupational Health

• a field involved in the prevention of illness or injury and the promotion of health in the work environment
• services encompass “health promotion and protection (primary prevention), disease prevention (secondary prevention), and treatment and rehabilitation (tertiary prevention)” (Shah)
• occupational disease may be more difficult to recognize than occupational injury

Taking an Occupational Health History

• current and previous duties at place of employment
• exposures
  ▪ identification: screen for chemical, metal, dust, biological, and physical hazards as well as psychological stressors; review relevant workplace MSDS
  ▪ assessment: duration, concentration, route, exposure controls (e.g. ventilation, personal protective equipment)
• temporal relationship: changes in symptoms in relationship to work environment
• presence of similar symptoms in co-workers
• non-work exposures: home, neighbourhood, hobbies

Occupational Hazards

Table 12. Occupational Hazards

<table>
<thead>
<tr>
<th>Physical</th>
<th>Chemical</th>
<th>Biological</th>
<th>Psychosocial</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Trauma (e.g. fractures, lacerations)</td>
<td>• Organic solvents (e.g. benzene, methyl alcohol; most toxic is carbon tetrachloride)</td>
<td>• Exposure to bacteria, viruses, fungi, protozoa, Rickettsia</td>
<td>• Workload stressors</td>
</tr>
<tr>
<td>• Noise (e.g. hearing loss)</td>
<td>• Mineral dusts (e.g. silica leads to silicosis and predisposition to TB, asbestos leads to diffuse fibrosis and mesothelioma, coal leads to pneumoconiosis)</td>
<td>• Blood should be considered a potentially toxic substance due to blood-borne infectious diseases (e.g. HIV, hepatitis B)</td>
<td>• Responsibility</td>
</tr>
<tr>
<td>• Temperature</td>
<td>• Heavy metals (e.g. nickel, cadmium, mercury, lead)</td>
<td>• Consider exposure to disease in endemic countries, travellers from endemic countries, or recent travel history in the setting of acute onset of symptoms (e.g. malaria, SARS, TB)</td>
<td>• Fear of job loss</td>
</tr>
<tr>
<td>• Heat cramps, heat exhaustion, heat stroke</td>
<td>• Gases (e.g. halogen gases, sulphur dioxide, carbon monoxide, nitrogen oxides)</td>
<td></td>
<td>• Geographical isolation</td>
</tr>
<tr>
<td>• Hypothermia, frostbite</td>
<td>• Second-hand smoke (cancerous factor for lung cancer, lung disease, heart disease, asthma exacerbations; may be linked to miscarriage)</td>
<td></td>
<td>• Shift work</td>
</tr>
<tr>
<td>• Air pressure (barotrauma, decompression sickness)</td>
<td>• Skin diseases (major portion of compensations, e.g. contact dermatitis, occupational acne, pigmentation disorders)</td>
<td></td>
<td>• Bullying</td>
</tr>
<tr>
<td>• Ergonomic</td>
<td></td>
<td></td>
<td>• Harassment (sexual/non-sexual)</td>
</tr>
<tr>
<td>• Repetitive use/avulsion injuries, excessive force, awkward postures, poorly designed physical work environment</td>
<td></td>
<td></td>
<td>• Incurs high cost from absenteeism, poor productivity, mental illness (e.g. post-traumatic stress disorder)</td>
</tr>
<tr>
<td>• Tendinitis, bursitis, carpal tunnel syndrome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Radiation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Non-ionizing: visible light, infrared</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Ionizing: UV, x-rays, y rays</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Electricity</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Workplace Legislation

• universal across Canada for corporate responsibility in the workplace: due diligence, application of Workplace Hazardous Materials Information System (WHMIS), existence of joint health and safety committees in the workplace with representatives from workers and management
• jurisdiction in Canada is provincial (90% of Canadian workers), except for 16 federally regulated industries (e.g. airports, banks, highway transport) under the Canada Labour Code
• Ontario’s Occupational Health and Safety Act
  • sets out rights of workers and duties of employers, procedures for workplace hazards, and law enforcement
  • workers have the right to
    • participate (e.g. have representatives on joint health and safety committees)
    • know (e.g. be trained and have information about workplace hazards)
    • refuse work (e.g. workers can decline tasks they feel are overly dangerous)
      – note: For some occupations, this right is restricted if, for example, danger/risk is normal part of work or refusal would endanger others (e.g. police, firefighters, some health care workers)
    • stop work (e.g. `certified’ workers can halt work they feel is dangerous to other workers)
Appendix – Mandatory Reporting

Workplace Health Promotion and Protection

- pro-active preventative health measures can reduce workplace illness or injury
  - identifying workplace hazards (e.g. through material safety data sheets [MSDS])
  - assessing risk
  - reducing exposure: changes to work environment including elimination, substitution, and isolation of hazard (e.g. engineering controls) more effective than changes to how people work (e.g. administrative controls) and personal protective equipment

Workplace Disease Prevention and Identification

- avoid the development of disease with pro-active worker health surveillance
  - periodic examinations to facilitate diagnosis before symptoms develop
    - PFT for asthma (e.g. occupational dust exposure)
    - audiograms for hearing loss (e.g. occupational noise exposure)
  - substance misuse screening useful if concern surrounds decreased employee functioning

Workplace Treatment and Rehabilitation

- treatment of the disease or injury to facilitate safe and timely return to the workforce
- may require rehabilitation, retraining, change in job duties, and/or workers' compensation (WSIB)
- advise relevant authorities if necessary (e.g. report notifiable diseases to public health, conditions impeding driving to Ministry of Transportation, see Other Reportable Conditions, PH25)

Appendix – Mandatory Reporting

Reportable Diseases

As an essential part of the health system, physicians in Canada are required by law to report certain diseases to public health for the following reasons

1. to control the outbreak
   - if the disease presents an outbreak threat (e.g. measles, Salmonella, respiratory diseases in institutions)

2. to prevent spread
   - if the disease presents a significant threat to individuals or a subset of the population (e.g. Lassa Fever)

3. for surveillance
   - if the disease is preventable with immunization (e.g. polio, diphtheria, congenital rubella)

4. if infected individuals require education, treatment and/or partner notification (e.g. gonorrhea, TB)

5. reporting details (website, office etc.)
   - some are more urgent than others (must contact MOH)
   - physicians should also report unlisted diseases that appear in clusters
The following list is based on the reportable diseases in Ontario for 2015. Each province will have similar legislation.

**Note:** Diseases marked * (and Influenza in institutions) should be reported immediately to the Medical Officer of Health by either telephone (24 hours a day, 7 days a week) or fax (Mon-Fri, 8:30 am – 4:30 pm only). Other diseases can be reported the next working day by fax, phone or mail.

Source: Health Protection and Promotion Act, O. Reg. 559/91, amended to O. Reg. 49/07 (update)

<table>
<thead>
<tr>
<th>Acquired Immunodeficiency</th>
<th>Haemophilus influenza b disease, invasive*</th>
<th>Q Fever*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Syndrome (AIDS)</td>
<td>Hantavirus pulmonary syndrome*</td>
<td></td>
</tr>
<tr>
<td>Acute flaccid paralysis &lt; 15 yr</td>
<td>Hemorrhagic fever*, including:</td>
<td></td>
</tr>
<tr>
<td>Amoebiasis</td>
<td>1. Ebola virus disease*</td>
<td></td>
</tr>
<tr>
<td>Anthrax*</td>
<td>2. Marburg virus disease*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Other viral causes*</td>
<td></td>
</tr>
<tr>
<td>Botulism*</td>
<td>Hepatitis, viral*:</td>
<td></td>
</tr>
<tr>
<td>Brucellosis*</td>
<td>1. Hepatitis A*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Hepatitis B</td>
<td></td>
</tr>
<tr>
<td>Campylobacter enteritis</td>
<td>3. Hepatitis C</td>
<td></td>
</tr>
<tr>
<td>Chancroid</td>
<td>3. HCV [Hepatitis C]</td>
<td></td>
</tr>
<tr>
<td>Chickenpox (Varicella)</td>
<td>3. HCV [Hepatitis C]</td>
<td></td>
</tr>
<tr>
<td>Chlamydia trachomatis infections</td>
<td>Herpes (neonatal) and HIV removed</td>
<td></td>
</tr>
<tr>
<td>Cholera*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clostridium difficile* associated disease (CDAD) outbreaks in public hospitals</td>
<td>Influenza</td>
<td>Tetanus</td>
</tr>
<tr>
<td>Creutzfeldt-Jakob Disease, all types</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cryptosporidiosis*</td>
<td>Lassa virus*</td>
<td>Trichinosis</td>
</tr>
<tr>
<td>Cyclosporiasis*</td>
<td>Legionellosis*</td>
<td>Tuberculosis, active and latent</td>
</tr>
<tr>
<td>Diphtheria*</td>
<td>Listeriosis*</td>
<td>Tularemia*</td>
</tr>
<tr>
<td>Encephalitis*, including:</td>
<td></td>
<td>Typhoid Fever*</td>
</tr>
<tr>
<td>1. Primary, viral*</td>
<td>Lyme Disease</td>
<td>Verotoxin-producing E. coli infection indicator conditions, including Hemolytic Uremic Syndrome (HUS)*</td>
</tr>
<tr>
<td>2. Post-infectious</td>
<td>Malaria</td>
<td></td>
</tr>
<tr>
<td>3. Vaccine-related</td>
<td>Measles*</td>
<td></td>
</tr>
<tr>
<td>4. Subacute sclerosing panencephalitis</td>
<td>Meningitis, acute*:</td>
<td></td>
</tr>
<tr>
<td>5. Unspecified</td>
<td>1. Bacterial*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Viral*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Other*</td>
<td></td>
</tr>
<tr>
<td>Food poisoning, all causes*</td>
<td>Meningococcal disease, invasive*</td>
<td></td>
</tr>
<tr>
<td>Gastroenteritis, institutional outbreaks*</td>
<td>Mumps</td>
<td></td>
</tr>
<tr>
<td>Giardiasis, except asymptomatic cases*</td>
<td>Ophthalmia neonatorum</td>
<td></td>
</tr>
<tr>
<td>Gonorrhea</td>
<td>Paralytic shellfish poisoning</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paratyphoid fever*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pertussis (whooping cough)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Plague*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pneumococcal disease, invasive</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Poliomyelitis, acute*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pertussis/Ornithosis</td>
<td></td>
</tr>
</tbody>
</table>

### Other Reportable Conditions

- in addition to reporting diseases, physicians have a legal responsibility to report certain conditions. The list below highlights some reportable conditions for Ontario, but is not exhaustive. See your jurisdiction's regulatory body for the full list.

**Child Abuse – to local Children’s Aid Society (CAS)**
- all child abuse and neglect where reasonable grounds to suspect exist (including physical harm, emotional harm, sexual harm, and neglect)
- duty to report is ongoing: if additional reasonable grounds are suspect, a further report to CAS is necessary

**Unfit to Drive – to provincial Ministry of Transportation**
- all patients with a medical condition (e.g. dementia, untreated epilepsy) that may impede their driving ability
- if a physician does not report and the driver gets into an accident, the physician may be held liable

**Unfit to Fly – to federal Ministry of Transportation**
- all patients believed to be flight crew members or air traffic controller with a medical or optometric condition that is likely to constitute a hazard to aviation safety

**Gunshots Wounds – to local police service**
- all patients with a gunshot or stab wounds
- self-inflicted knife wounds are not reportable

References


Canadian Institute for Health Information. Available from: http://www.cihi.ca.


Health Protection and Promotion Act, R.S.O. 1990, c. H.7

Health Protection and Promotion Act, R.S.O. 1990, c. H.7; O. Reg. 559/91, amended to O. Reg. 49/07.


# Psychiatry

**Acronyms** ................................ 2

**Psychiatric Assessment** ........................ 2
History
Mental Status Exam

**Assessment and Plan** ......................... 4

**Suicide** .................................. 4

**Psychotic Disorders** ......................... 6
Differential Diagnosis of Psychosis
Schizophrenia
Schizophreniform Disorder
Brief Psychotic Disorder
Schizoaffective Disorder
Delusional Disorder

**Mood Disorders** ............................. 9
Mood Episodes
Depressive Disorders
Postpartum Mood Disorders
Bipolar Disorders

**Anxiety Disorders** ............................ 13
Panic Disorder
Agoraphobia
Generalized Anxiety Disorder
Phobic Disorders
Obsessive-Compulsive Disorder

**Trauma- and Stressor-Related Disorders** .... 17
Post-Traumatic Stress Disorder
Adjustment Disorder

**Bereavement** .................................. 18

**Neurocognitive Disorders** .................... 19
Delirium
Major Neurocognitive Disorder (Dementia)

**Substance-Related and Addictive Disorders** . 21
Nicotine
Alcohol
Opioids
Cocaine
Amphetamines
Cannabis
Hallucinogens
“Club Drugs”

**Somatic Symptom and Related Disorders** .... 27
Somatic Symptom Disorder
Illness Anxiety Disorder
Conversion Disorder (Functional Neurological Symptom Disorder)

**Dissociative Disorders** ....................... 28
Dissociative Identity Disorder
Dissociative Amnesia
Depersonalization/Derealization Disorder

**Sleep Disorders** ............................. 29

**Sexuality and Gender** ....................... 30
Gender Dysphoria
Paraphilic Disorders

**Eating Disorders** ............................. 30
Anorexia Nervosa
Bulimia Nervosa
Binge-Eating Disorder
Avoidant/Restrictive Food Intake Disorder

**Personality Disorders** ....................... 33

**Child Psychiatry** ............................. 35
Developmental Concepts
Mood Disorders
Anxiety Disorders

**Neurodevelopmental Disorders** ............. 37
Autism Spectrum Disorder
Attention Deficit Hyperactivity Disorder

**Disruptive, Impulse Control, and Conduct Disorder** .... 39
Oppositional Defiant Disorder
Conduct Disorder
Intermittent Explosive Disorder

**Psychotherapy** ............................... 40
Other Therapies

**Pharmacotherapy** ............................ 42
Antipsychotics
Antidepressants
Mood Stabilizers
Anxiolytics

**Somatic Therapies** ........................... 49
Electroconvulsive Therapy
Repetitive Transcranial Magnetic Stimulation (rTMS)
Neurosurgical Treatments
Other Therapy Modalities

**Canadian Legal Issues** ...................... 50
Common Forms
Consent
Community Treatment Order (CTO)
Duty to Inform/Warn

**References** ................................. 52

---

Diagnostic Criteria reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. © 2013 American Psychiatric Association
### Acronyms

- **5-HT**: serotonin
- **ACh**: acetylcholine
- **ACT**: assertive community treatment
- **ADHD**: attention deficit hyperactivity disorder
- **AN**: anorexia nervosa
- **ASD**: autism spectrum disorder
- **ASPD**: antisocial personality disorder
- **BN**: bulimia nervosa
- **CBT**: cognitive behavioral therapy
- **CD**: conduct disorder
- **CRA**: community reinforcement approach
- **CT**: cognitive therapy
- **CTO**: community treatment order
- **DA**: dopamine
- **DBT**: dialectical behavior therapy
- **D2**: dopamine
- **ECT**: electroconvulsive therapy
- **EPS**: extrapyramidal symptoms
- **EPI**: exposure to psychosocial interference
- **ER**: exposure to psychosocial interference
- **GAD**: generalized anxiety disorder
- **GMHC**: general medical condition
- **GMC**: general medical condition
- **IPT**: interpersonal therapy
- **MAOI**: monoamine oxidase inhibitor
- **MDD**: major depressive disorder
- **MDE**: major depressive episode
- **MET**: motivational enhancement therapy
- **MSE**: mental status examination
- **MST**: magnetic stimulation therapy
- **MTR**: medication trials
- **NOS**: not otherwise specified
- **NRM**: nonresistant major depression
- **NMS**: neuroleptic malignant syndrome
- **OA**: organic: alcohol use or withdrawal
- **PD**: personality disorder
- **PO**: pervasive developmental disorder
- **PSC**: post-traumatic stress disorder
- **PTSD**: post-traumatic stress disorder
- **RAN**: Cocaine Anonymous
- **SAD**: seasonal affective disorder
- **SAMHSA**: substance abuse and mental health services administration
- **SSRI**: selective serotonin reuptake inhibitors
- **SSRI**: selective serotonin reuptake inhibitors
- **SNR**: selective serotonin receptor agonists
- **SRO**: social role
- **SSRI**: selective serotonin reuptake inhibitors
- **TC**: tricyclic antidepressant
- **TP**: tricyclic antidepressant
- **TCA**: tricyclic antidepressant
- **TD**: tardive dyskinesia
- **TP**: tardive dyskinesia

### Psychiatric Assessment

#### History

##### Identifying Data
- Necessary: name, sex, age, ethnicity, marital status, occupation/source of financial support, place and type of residency
- Adjunct: makeup of household, religion, education, referral source, known or unknown to treatment team

##### Reliability of Patient as a Historian
- Indicate if, and for what content; utilize collateral source (e.g. parent, teacher) if patient unable/unwilling to cooperate

##### Chief Complaint
- In patient's own words, duration

##### History of Present Illness
- Reason for seeking help (that day), current symptoms (onset, duration and course), stressors, supports, functional status, relevant associated symptoms (pertinent positives and negatives)
- Safety screen: is the patient endangering self or others? Dependents at home (e.g. children, pets), ability to drive safely, ability to care for self (e.g. eating, hygiene, taking medications)

##### Psychiatric Functional Inquiry
- Mood: depression, mania
- Anxiety: worries, panic attacks, phobias, history of trauma
- Obsessive-compulsive: obsessions, compulsions
- Psychosis: hallucinations, delusions
- Risk assessment: suicidal ideation, plan, intent, history of attempts (see Suicide, PS4)
- Organic: EtOH/drug use or withdrawal, illness, dementia

##### Past Psychiatric History
- All previous psychiatric diagnoses, psychiatric contacts, treatments (pharmacological and non-pharmacological), and hospitalizations
- Include past suicide attempts, substance use/abuse, and problems/encounters with the legal system

##### Past Medical/Surgical History
- All medical, surgical, neurological (e.g. head trauma, seizures), and psychosomatic illnesses
- Current medications, allergies

##### Family Psychiatric/Medical History
- Family members: ages, occupations, personalities, medical or genetic illnesses and treatments, relationships with parents/siblings
- Family psychiatric history: any past or current psychiatric illnesses and hospitalizations, suicide, substance abuse

##### Past Personal/Developmental History (as relevant)
- Prenatal and perinatal history (desired vs. unwanted pregnancy, maternal and fetal health, domestic violence, maternal substance use and exposures, complications of pregnancy/delivery)
- Early childhood to age 3 (developmental milestones, activity/attention level, family stability, attachment figures)
- Middle childhood to age 11 (school performance, peer relationships, fire-setting, stealing, incontinence)
- Late childhood to adolescence (drugs/alcohol, legal problems, peer and family relationships)
- History of physical or sexual abuse
- Adulthood (education, occupation, relationships)
- Personality before current illness, recent changes in personality
- Psychosexual history (puberty, first sexual encounter, romantic relationships, gender roles, sexual dysfunction)

### Screening Questions for Major Psychiatric Disorders
- Have you been feeling down, depressed or hopeless?
- Do you feel anxious or worry about things?
- Have there been a time in your life where you have felt euphoric, extremely talkative, had a lot of energy, and a decreased need for sleep?
- Do you see or hear things that you think other people cannot?
- Have you ever thought of harming yourself or committing suicide?

### Psychiatric Functional Inquiry

- **MOAPS**
  - Mood
  - Organic (e.g. substances and organic disease)
  - Anxiety
  - Psychosis
  - Safety

- **Always Remember to Ask About Abuse**
  - See Family Medicine, FM26
Mental Status Exam

General Appearance
- dress, grooming, posture, gait, physical characteristics, body habitus, apparent vs. chronological age, facial expression (e.g., sad, suspicious), tattoos, piercings (if numerous or atypical), acute distress or relaxed

Behavior
- psychomotor activity (agitation, retardation), abnormal movements or lack thereof (tremors, akathisia, tardive dyskinesia, paralysis), attention level and eye contact, attitude toward examiner (ability to interact, level of cooperation)

Speech
- rate (e.g., pressured, slowed), rhythm/fluency, volume, tone, articulation, quantity, spontaneity

Mood and Affect
- mood: subjective emotional state (in patient's own words)
- affect: objective emotional state inferred from emotional responses to stimuli; described in terms of
  - quality (euthymic, depressed, elevated, anxious, irritable)
  - range (full, restricted, flat, blunted)
  - stability (fixed, labile)
  - mood congruence (inferred by reader by comparing mood and affect descriptions)
  - appropriateness to thought content
- some clinicians use 0-10 scales when rating mood to help get a subjective norm for each patient that can help establish changes over time and with treatment

Thought Process/Form
- coherence (coherent, incoherent)
- logic (logical, illogical)
- stream
  - goal-directed: clearly answers questions in a linear, organized, logical fashion
  - circumstantial: speech that is indirect and delayed in reaching its goal; eventually comes back to the point
  - tangential: speech is oblique or irrelevant; does not come back to the original point
  - loosening of associations/derealiment: illogical shifting between topics
  - flight of ideas: quickly skipping from one idea to another where the ideas are marginally connected, usually associated with mania
  - word salad: jumble of words lacking meaning or logical coherence
- perseveration: repetition of the same verbal or motor response to stimuli
- echolalia: repetition of phrases or words spoken by someone else
- thought blocking: sudden cessation of flow of thought and speech
- clang associations: speech based on sound such as rhyming or punning
- neologism: use of novel words or of existing words in a novel fashion

Thought Content
- suicidal ideation/homicidal ideation
  - frequency and pervasiveness of thoughts, formulation of plan, means to plan, intent, active vs. passive, protective factors
- preoccupations, ruminations: reflections/thoughts at length, not fixed or false
- obsession: recurrent and persistent thought, impulse, or image which is intrusive or inappropriate and unwanted
  - cannot be stopped by logic or reason
  - causes marked anxiety and distress
  - common themes: contamination, orderliness, sexual, pathological doubt/worry/guilt
  - magical thinking: belief that thinking something will make it happen; normal in children and certain cultures
  - ideas of reference: similar to delusion of reference, but less fixed (the reality of the belief is questioned)
  - overvalued ideas: unusual/odd beliefs that are not of delusional proportions
  - first rank symptoms of schizophrenia: thought insertion/withdrawal/broadcasting
  - delusion: a fixed false belief that is out of keeping with a person's cultural or religious background and is firmly held despite incontrovertible proof to the contrary

Perception
- hallucination: sensory perception in the absence of external stimuli that is similar in quality to a true perception
  - auditory (most common), visual, gustatory, olfactory, tactile
  - illusion: misperception of a real external stimulus (such as mistaking a coat on a rack as a person late at night)
- depersonalization: change in self-awareness such that the person feels unreal, distant, or detached from his or her body, and/or unable to feel emotion
- derealization: feeling that the world/outer environment is unreal
Cognition
• level of consciousness (alert, reduced, obtunded)
• orientation: time, place, person
• memory: immediate, recent, remote
• global evaluation of intellect (below average, average, above average, in keeping with person's education)
• intellectual functions: attention, concentration, calculation, abstraction (proverb interpretation, similarities test), language, communication
• MMSE/MOCA useful as standard screening assessments of cognition

Insight
• patient's ability to realize that he or she has a physical or mental illness and to understand its implications (none limited, partial, full)

Judgment
• patient's ability to understand relationships between facts and draw conclusions that determine one's actions

Assessment and Plan

Historical Multiaxial Model
• since DSM-5, this Model is no longer used for psychiatric diagnosis. Instead, relevant psychiatric and medical diagnoses are simply listed. Nevertheless, we offer it here as a possible framework for psychiatric patient assessment, as many physicians still employ it

Multiaxial Assessment
• Axis I: differential diagnosis of DSM-5 clinical disorders
• Axis II: personality disorders, developmental disability
• Axis III: general medical conditions potentially relevant to understanding/management of the mental disorder
• Axis IV: psychosocial and environmental issues
• Axis V: Global Assessment of Functioning (GAF, 0 to 100) incorporating effects of axes I to IV

After History and MSE, the assessment and plan is recorded

Assessment/Problem Formulation
• identify predominant symptom cluster (mood, anxiety, psychosis, organic) causing the most distress/interference, persist when other symptom categories do not present (e.g. psychosis in the absence of mood symptoms)
• dominating symptoms will direct differential
• consider current issues as they relate to an individual's factors in three domains: biological, psychological, and social
• for each category: predisposing, precipitating, perpetuating, and protecting factors are considered

Approach to Management
• consider short-term and long-term, and three types: biological (e.g. pharmacotherapy), psychological (e.g. CBT), and social (e.g. support group)

Suicide

Importance
• must be screened for in every encounter; part of risk assessment along with violent/homicidal ideation

Approach
• ask every patient – e.g. "Have you had any thoughts of wanting to harm or kill yourself?"
• classify ideation
  • passive ideation: would rather not be alive but has no active plan for suicide
    • e.g. "I'd rather not wake up" or "I would not mind if a car hit me"
  • active ideation
    • e.g. "I think about killing myself"
• assess risk
  • plan: "Do you have a plan as to how you would end your life?"
  • intent: "Do you think you would actually carry out this plan?" "If not, why not?"
• past attempts: highest risk if previous attempt in past year
• ask about lethality, outcome, medical intervention
• assess suicidal ideation
  • onset and frequency of thoughts: "When did this start?" or "How often do you have these thoughts?"
  • control over suicidal ideation: "How do you cope when you have these thoughts?" "Could you call someone for help?"
  • intention: "Do you want to end your life?" or "Do you wish to kill yourself?"
  • intended lethality: "What do you think would happen if you actually took those pills?"
  • access to means: "How will you get a gun?" or "Which bridge do you think you would go to?"
• time and place: "Have you picked a date and place? Is it in an isolated location?"
• provocative factors: "What makes you feel worse (e.g. being alone)?"
suicide Toronto Notes 2017

PS5 Psychiatry

Suicide

- protective factors: “What keeps you alive (e.g. friends, family, pets, faith, therapist)?”
- final arrangements: “Have you written a suicide note? Made a will? Given away your belongings?”
- practiced suicide or aborted attempts: “Have you ever put the gun to your head?” “Held the medications in your hand?” “Stood at the bridge?”
- ambivalence: “I wonder if there is a part of you that wants to live, given that you came here for help?”

Assessment of Suicide Attempt
- setting (isolated vs. others present/chance of discovery)
- planned vs. impulsive attempt, triggers/stressors
- substance use/intoxication
- medical attention (brought in by another person vs. brought in by self to ED)
- time lag from suicide attempt to ED arrival
- expectation of lethality, dying
- reaction to survival (guilt/remorse vs. disappointment/self-blame)

Epidemiology
- attempted:completed = 20:1
- M:F = 1:4 for attempts, 3:1 for completed

Risk Factors
- epidemiologic factors
  - age: increases after age 14, second most common cause of death for ages 15-24, highest rates of completion in persons >65 yr
  - sex: male
  - race/ethnic background: white or Native Canadians
  - marital status: widowed/divorced
  - living situation: alone; no children <18 yr old in the household
  - other: stressful life events, access to firearms
- psychiatric disorders
  - mood disorders (15% lifetime risk in depression; higher in bipolar)
  - anxiety disorders (especially panic disorder)
  - schizophrenia (10-15% risk)
  - substance abuse (especially alcohol – 15% lifetime risk)
  - eating disorders (5% lifetime risk)
  - adjustment disorder
  - conduct disorder
  - personality disorders (borderline, antisocial)
- past history
  - prior suicide attempt
  - family history of suicide attempt/completion

Clinical Presentation
- symptoms associated with suicide
  - hopelessness
  - anhedonia
  - insomnia
  - severe anxiety
  - impaired concentration
  - psychomotor agitation
  - panic attacks

Management
- proper documentation of the clinical encounter and rationale for management is essential
- higher risk (hospitalization needs to be strongly considered)
  - patients with a plan and intention to act on the plan, access to lethal means, recent social stressors, and symptoms suggestive of a psychiatric disorder
  - do not leave patient alone; remove potentially dangerous objects from room
  - if patient refuses to be hospitalized, complete form for involuntary admission (Form 1)
- lower risk
  - patients who are not actively suicidal, with no plan or access to lethal means
  - discuss protective factors and supports in their life, remind them of what they live for, promote survival skills that helped them through previous suicide attempts
  - make a safety plan that could include an agreement that they will:
    - not harm themselves
    - avoid alcohol, drugs, and situations that may trigger suicidal thoughts
    - follow-up with you at a designated time
    - contact a health care worker, call a crisis line, or go to an emergency department if they feel unsafe or if their suicidal feelings return or intensify
- depression: consider hospitalization if symptoms severe or if psychotic features are present; otherwise outpatient treatment with good supports and SSRIs/SNRIs
- alcohol-related: usually resolves with abstinence for a few days; if not, suspect depression
- personality disorders: crisis intervention, may or may not hospitalize
- schizophrenia/psychosis: hospitalization might be necessary
- parasuicide/self-mutilation: long-term psychotherapy with brief crisis intervention when necessary
Psychotic Disorders

Definition
- characterized by a significant impairment in reality testing
- delusions or hallucinations (with/without insight into their pathological nature)
- behaving in a disorganized way so that it is reasonable to infer that reality testing is disturbed

Differential Diagnosis of Psychosis

Approach
- differentiate among psychotic disorders and distinguish them from other primary diagnoses with psychotic features
- consider symptoms, persistence, and time
- symptoms: what symptoms exist? The primary diagnosis needs full criteria to be met
  - mood: depressive episodes with psychotic features, manic episodes with psychotic features
    - psychotic: consider symptoms in Criterion A of schizophrenia, such as delusions, hallucinations, disorganized speech, grossly disorganized/catatonic behaviour, negative symptoms (i.e. diminished emotional expression or avolition)
  - persistence: is there a time when certain symptom clusters are present without other clusters?
    - e.g. if there is a period of time with mood symptoms but not psychotic symptoms, consider mood disorder
    - e.g. if two weeks where psychotic symptoms persist in the absence of mood symptoms, consider schizoaffective disorder
  - time: how long have the symptoms been present?

Table 1. Differentiating Psychotic Disorders

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Psychotic Symptoms</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brief Psychotic Disorder</td>
<td>≥ 1 positive symptoms of criterion A</td>
<td>&lt; 1 mo</td>
</tr>
<tr>
<td>Schizophreniform Disorder</td>
<td>Criterion A</td>
<td>1-6 mo</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>Criterion A</td>
<td>&gt; 6 mo</td>
</tr>
<tr>
<td>Schizoaffective Disorder</td>
<td>Criterion A + major mood episode, but ≥ 2 wk psychic without mood symptoms</td>
<td>&gt; 1 mo</td>
</tr>
<tr>
<td>Delusional Disorder</td>
<td>Non-bizarre delusions, hallucinations</td>
<td>&gt; 1 mo</td>
</tr>
<tr>
<td>2° to Substance Intoxication/Withdrawal</td>
<td>Delusions or hallucinations</td>
<td>During intoxication/withdrawal, not &gt; 1 mo without use</td>
</tr>
<tr>
<td>2° to Mood Disorder</td>
<td>Mood symptoms dominant + delusions/hallucinations (mood congruent)</td>
<td>Psychosis may be present for the duration of the mood episode</td>
</tr>
</tbody>
</table>

Schizophrenia

DSM-5 Diagnostic Criteria for Schizophrenia
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013. American Psychiatric Association
A. two (or more) of the following, each present for a significant portion of time during a 1 mo period (or less if successfully treated). At least one of these must be (1), (2), or (3)
1. delusions
2. hallucinations
3. disorganized speech (e.g. frequent derailment or incoherence)
4. grossly disorganized or catatonic behaviour
B. decreased level of function: for a significant portion of time since onset, one or more major areas affected (e.g. work, interpersonal relations, self-care) is markedly decreased (or if childhood/adolescent onset, failure to achieve expected level)
C. at least 6 mo of continuous signs of the disturbance. Must include at least 1 mo of symptoms (or less if successfully treated) that meet Criterion A (i.e. active-phase symptoms) and may include periods of prodromal or residual symptoms (during which, disturbance may manifest by only negative symptoms or by two or more Criterion A symptoms present in an attenuated form (e.g. odd beliefs, unusual perceptual experiences)
D. rule out schizoaffective disorder and depressive or bipolar disorder with psychotic features because either 1) no major depressive or manic episodes have occurred concurrently with the active-phase symptoms, or 2) if mood episodes have occurred during active-phase symptoms, they have been present for a minority of the total duration of the active and residual periods of the illness
E. rule out other causes: GMS, substances (e.g. drug of abuse, medication)
F. if history of autism spectrum disorder or communication disorder of childhood onset, the additional diagnosis of schizophrenia is made only if prominent delusions or hallucinations are also present for at least 1 mo (or less if successfully treated)

specifiers: type of episode (e.g. first episode, multiple episodes, continuous), with catatonia, current severity based on quantitative assessment of primary symptoms of psychosis (in acute episode, in partial remission, in full remission)
Epidemiology
- prevalence: 0.3-0.7%, M:F = 1:1
- mean age of onset: females late-20s; males early- to mid-20s
- suicide risk: 10% die by suicide, 30% attempt suicide

Etiology
- multifactorial: disorder is a result of interaction between both biological and environmental factors
  - genetic: 40% concordance in monozygotic (MZ) twins; 46% if both parents have schizophrenia; 10% of dizygotic (DZ) twins, siblings, children affected; vulnerable genes include Disrupted-in-Schizophrenia 1 (DISC1); neuregulin 1 (NRG 1); dystrobrevin binding protein / dysbindin (DTNBPI); catechol-O-methyltransferase (COMT); d-amino acid oxidase activator (DAOA); metabotropic glutamate receptor 3 (GRM3); and brain-derived neurotrophic factor (BDNF)
  - neurochemistry ("dopamine hypothesis"): excess activity in the mesolimbic dopamine pathway may mediate the positive symptoms of psychosis, while decreased dopamine in the prefrontal cortex may mediate negative and cognitive symptoms. GABA, glutamate, and ACh dysfunction are also thought to be involved
  - neuroanatomy: decreased frontal lobe function; asymmetric temporal/limbic function; decreased basal ganglia function; subtle changes in thalamus, cortex, corpus callosum, and ventricles; cytoarchitectural abnormalities
  - neuroendocrinology: abnormal growth hormone, prolactin, cortisol, and ACTH
  - neuropsychology: global defects seen in attention, language, and memory suggest disrupted connectivity of neural networks
  - environmental: indirect evidence of cannabis use, geographical variance, winter season of birth, obstetrical complications, and prenatal viral exposure

Pathophysiology
- neurodegenerative theory: natural history may be a rapid or gradual decline in function and ability to communicate
  - glutamate system may mediate progressive degeneration by excitotoxic mechanism which leads to production of free radicals
- neurodevelopmental theory: abnormal development of the brain from prenatal life
  - neurons fail to migrate correctly, make inappropriate connections, and apoptose in later life

Comorbidity
- substance-related disorders
- anxiety disorders
- reduced life expectancy secondary to medical comorbidities (e.g. obesity, diabetes, metabolic syndrome, CV/pulmonary disease)

Management of Schizophrenia
- biological / somatic
  - acute treatment and maintenance: antipsychotics (haloperidol, risperidone, olanzapine, paliperonide; clozapine if refractory); often regiments of IM q2-4 wk used in severe cases to ensure compliance
  - adjunctive: ± mood stabilizers (for aggression/impulsiveness - lithium, valproate, carbamazepine) ± anxiolytics ± ECT
  - treat for at least 1-2 years after the first episode, at least 5 years after multiple episodes (relapse causes severe deterioration)
- psychosocial
  - psychotherapy (individual, family, group), supportive, CBT (see Table 14, PS41)
  - ACT (Assertive Community Treatment); mobile mental health teams that provide individualized treatment in the community and help patients with medication adherence, basic living skills, social support, job placements, resources
  - social skills training, employment programs, disability benefits
  - housing (group home, boarding home, transitional home)

Course and Prognosis
- majority of individuals display some type of prodromal phase
- course is variable: some individuals have exacerbations and remissions while others remain chronically ill; accurate prediction of the long-term outcome is not possible
- negative symptoms may be prominent early in the illness and may become more prominent and more disabling later on; positive symptoms appear and typically diminish with treatment
- over time: 1/3 improve, 1/3 remain the same, 1/3 worsen
Schizophreniform Disorder

Diagnosis
- criteria A, D, and E of schizophrenia are met; an episode of the disorder lasts for at least 1 mo but less than 6 mo
- if the symptoms have extended past 6 mo the diagnosis becomes schizophrenia
- specifiers: with/without good prognostic features (e.g. acute onset, confusion, good premorbid functioning, absence of blunt/flat affect), with catatonia, current severity based on quantitative assessment of primary symptoms of psychosis

Treatment
- similar to acute schizophrenia

Prognosis
- better than schizophrenia; begins and ends more abruptly; good pre- and post-morbid function

Brief Psychotic Disorder

Diagnosis
- criteria A1-A4, D, and E of schizophrenia are met; an episode of the disorder lasts for at least 1 d, but less than 1 mo with eventual full return to premorbid level of functioning
- specifiers: with/without marked stressors, with postpartum onset, with catatonia, current severity
- can occur after a stressful event or postpartum (see Postpartum Mood Disorders, PS12)

Treatment
- secure environment, antipsychotics, anxiolytics

Prognosis
- good, self-limiting, should return to pre-morbid function within 1 mo

Schizoaffective Disorder

DSM-5 Diagnostic Criteria for Schizoaffective Disorder
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013. American Psychiatric Association
A. concurrent psychosis (crteria A of schizophrenia) and major mood episode - uninterrupted period of illness
B. delusions or hallucinations for 2 or more wk in the absence of a major mood episode during the lifetime duration of the illness
C. major mood episode symptoms are present for the majority of the total duration of the active and residual periods of the illness
D. the disturbance is not attributable to the effects of a substance or another medical condition
- specifiers: bipolar type, depressive type, with catatonia, type of episode, severity

Epidemiology
- one-third as prevalent as schizophrenia; schizoaffective disorder bipolar type more common in young adults, schizoaffective disorder depressive type more common in older adults
- depressive symptoms correlated with higher suicide risk

Treatment
- antipsychotics, mood stabilizers, antidepressants

Prognosis
- between that of schizophrenia and of mood disorder

Delusional Disorder

DSM-5 Diagnostic Criteria for Delusional Disorder
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013. American Psychiatric Association
A. the presence of one (or more) delusions with a duration of 1 mo or longer
B. criterion A for schizophrenia has never been met
- Note: hallucinations, if present, are not prominent and are related to the delusional theme
C. apart from the impact of the delusion(s) or its ramifications, functioning is not markedly impaired, and behaviour is not obviously bizarre or odd
D. if manic or major depressive episodes have occurred, these have been brief relative to the duration of the delusional periods
E. the disturbance is not attributable to the physiological effects of a substance or another medical condition and is not better explained by another mental disorder
- subtypes: erotomanic, grandiose, jealous, persecutory, somatic, mixed, unspecified
- further specify: bizarre content, type of episode (e.g. first episode, multiple episode), severity
**Mood Disorders**

**Definitions**
- accurate diagnosis of a mood disorder requires a careful past medical and psychiatric history to detect past mood episodes and to rule out whether these episodes were secondary to substance use, a medical condition, a loss, etc
- mood episodes represent a combination of symptoms comprising a predominant mood state that is abnormal in quality or duration (e.g. major depressive, manic, mixed, hypomanic). DSM-5 Criteria for mood episodes are listed below
- types of mood disorders include
  - depressive (major depressive disorder, persistent depressive disorder)
  - bipolar (bipolar I/II disorder, cyclothymia)
  - secondary to general medical condition, substances, medications, other psychiatric issue

**Medical Workup of Mood Disorder**
- routine screening: physical exam, CBC, thyroid function test, extended electrolytes, urinalysis, drug screen, medications list
- additional screening: neurological consultation, chest X-ray, ECG, CT head

**Mood Episodes**

**DSM-5 Diagnostic Criteria for Major Depressive Episode**
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013. American Psychiatric Association

A. ≥5 of the following symptoms have been present during the same 2 wk period and represent a change from previous functioning: at least one of the symptoms is either 1) depressed mood or 2) loss of interest or pleasure (anhedonia)

**Note:** do not include symptoms that are clearly attributable to another medical condition

- depressed mood most of the day, nearly every day, as indicated by either subjective report or observation made by others
- markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day
- significant and unintentional weight loss/weight gain, or decrease/increase in appetite nearly every day
- insomnia or hypersomnia nearly every day
- psychomotor agitation or retardation nearly every day
- fatigue or loss of energy nearly every day
- feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick)
- diminished ability to think or concentrate, or indecisiveness, nearly every day
- recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide

B. the symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning

C. the episode is not attributable to the direct physiological effects of a substance or a GMC

**DSM-5 Criteria for Manic Episode**
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013. American Psychiatric Association

A. a distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased goal-directed activity or energy, lasting ≥1 wk and present most of the day, nearly every day (or any duration if hospitalization is necessary)

B. during the period of mood disturbance and increased energy or activity, ≥3 of the following symptoms have persisted (4 if the mood is only irritable) and have been present to a significant degree and represent a noticeable change from usual behaviour

- inflated self-esteem or grandiosity
- decreased need for sleep (e.g. feels rested after only 3 h of sleep)
- more talkative than usual or pressure to keep talking
- flight of ideas or subjective experience that thoughts are racing
- distractibility (i.e. attention too easily drawn to unimportant or irrelevant external stimuli)
- increase in goal-directed activity (either socially, at work or school, or sexually) or psychomotor agitation
- excessive involvement in pleasurable activities that have a high potential for painful consequences (e.g. engaging in unrestrained spending sprees, sexual indiscretions, or foolish business investments)

C. the mood disturbance is sufficiently severe to cause marked impairment in social or occupational functioning or to necessitate hospitalization to prevent harm to self or others, or there are psychotic features

D. the episode is not attributable to the physiological effects of a substance or another medical condition

**Criteria for Depression (≥5)**

**MSIGECAPS**

- Mood: depressed
- Sleep: increased/decreased
- Interest: decreased
- Guilt
- Energy: decreased
- Concentration: decreased
- Appetite: increased/decreased
- Psychomotor: agitation/retardation
- Suicidal ideation

**Criteria for Mania (≥3)**

**GST PAID**

- Grandiosity
- Sleep (decreased need)
- Talkative
- Pleasurable activities, Painful consequences
- Activity
- Ideas (flight of)
- Distractible
Mood Disorders

Note: A full manic episode that emerges during antidepressant treatment but persists at a fully syndromal level beyond the physiological effect of that treatment is sufficient evidence for a manic episode, and therefore, a bipolar I diagnosis.

Note: Criteria A-D constitute a manic episode. At least one lifetime manic episode is required for the diagnosis of bipolar I disorder.

Hypomanic Episode
- criterion A and B of a manic episode is met, but duration is ≥4 d
- episode associated with an uncharacteristic change in functioning that is observable by others but not severe enough to cause marked impairment in social or occupational functioning or to necessitate hospitalization
- absence of psychotic features (if these are present the episode is, by definition, manic)

Mixed Features
- an episode specifier in bipolar or depression that indicates the presence of both depressive and manic symptoms concurrently, classified by the disorder and primary mood episode component (e.g. bipolar disorder, current episode manic, with mixed features)
- clinical importance due to increased suicide risk
- if found in patient diagnosed with major depression, high index of suspicion for bipolar disorder
- while meeting the full criteria for a major depressive episode, the patient has on most days ≥3 of criteria B for a manic episode
- while meeting the full criteria for a manic/hypomanic episode, the patient has on most days ≥3 of criteria A for a depressive episode (the following criterion A cannot count: psychomotor agitation, insomnia, difficulties concentrating, weight changes)

Depressive Disorders

MAJOR DEPRESSIVE DISORDER

DSM-5 Diagnostic Criteria for Major Depressive Disorder (MDD)
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013. American Psychiatric Association

A. presence of a MDE
B. the MDE is not better accounted for by schizoaffective disorder and is not superimposed on schizophrenia, schizophreniform disorder, delusional disorder, or psychotic disorder NOS
C. there has never been a manic episode or a hypomanic episode

Note: This exclusion does not apply if all of the manic-like, or hypomanic-like episodes are substance or treatment-induced or are due to the direct physiological effects of another medical condition

Specifiers:
- with anxious distress
- mixed features
- melancholic features
- atypical features
- mood-congruent psychotic features
- mood-incongruent psychotic features
- catatonia
- peripartum onset
- seasonal pattern

Epidemiology
- lifetime prevalence: 12%
- peak prevalence age 15-25 yr (M:F = 1:2)

Etiology
- biological
  - genetic: 65-75% MZ twins; 14-19% DZ twins, 2-4 fold increased risk in first-degree relatives
  - neurotransmitter dysfunction: decreased activity of 5-HT, NE, and DA at neuronal synapse; changes in GABA and glutamate; various changes detectable by fMRI
  - neuroendocrine dysfunction: excessive HPA axis activity
  - neuroanatomy and neurophysiology: decreased hippocampal volume, increased size of ventricles; decreased REM latency and slow-wave sleep; increased REM length
  - immunologic: increased pro-inflammatory cytokines IL-6 and TNF
  - secondary to medical condition, medication, substance use disorder
- psychosocial
  - psychodynamic (e.g. low self-esteem, unconscious aggression towards self or loved ones, disordered attachment)
  - cognitive (e.g. distorted schemata, Beck's cognitive triad: negative views of the self, the world, and the future)
  - environmental factors (e.g. job loss, bereavement, history of abuse or neglect, early life adversity)
  - comorbid psychiatric diagnoses (e.g. anxiety, substance abuse, developmental disability, dementia, eating disorder)

Risk Factors
- sex: F>M, 2:1
- family history: depression, alcohol abuse, suicide attempt or completion
- childhood experiences: loss of parent before age 11, negative home environment (abuse, neglect)
- personality: neuroticism, insecure, dependent, obsessional
- recent stressors: illness, financial, legal, relational, academic
- lack of intimate, confiding relationships or social isolation
- low socioeconomic status

Antidepressants for Depression in Medical Illness
Cochrane DB Syst Rev 2010; Issue 3
This systematic review and meta-analysis of 51 RCTs (3,603 patients) compared antidepressants to placebo in patients with a physical disorder (e.g. cancer, MI who have been diagnosed as depressed (including major depression, adjustment disorder, and dysthymia).

Conclusions: Antidepressants, including SSRIs and TCAs, cause a significant improvement in patients with a physical illness, as compared to placebo.
Depression in the Elderly
- affects about 15% of community residents >65 yr old; up to 50% in nursing homes
- high suicide risk due to social isolation, chronic medical illness, decreased independence
- suicide peak: males aged 80-90; females aged 50-65
- dysphoria may not be a reliable indicator of depression in those >85 yr
- often present with somatic complaints (e.g. changes in weight, sleep, energy) or anxiety symptoms
- may have prominent cognitive changes after onset of mood symptoms (dementia syndrome of depression)
- see Table 3, PS21, for a comparison of delirium and dementia

Treatment
- lifestyle: increased aerobic exercise, mindfulness-based stress reduction, zinc supplementation
- biological: SSRIs, SNRIs, other antidepressants, somatic therapies (see Pharmacotherapy, PS42, and Somatic Therapies, PS49)
  - 1st line pharmacotherapy: sertraline, escitalopram, venlafaxine, mirtazapine
  - for partial or non-response can change class or add augmenting agent: bupropion, quetiapine-XR, aripiprazole, lithium
  - typical response to antidepressant treatment: physical symptoms improve at 2 wk, mood/cognition by 4 wk, if no improvement after 4 wk at a therapeutic dosage alter regimen
  - ECT: currently fastest and most effective treatment for MDD. Consider in severe, psychotic or treatment-resistant cases
  - rTMS: early data support efficacy equivalent to ECT with good safety and tolerability
  - phototherapy: especially if seasonal component, shift work, sleep dysregulation
- psychological
  - individual therapy (interpersonal, CBT), family therapy, group therapy
  - social: vocational rehabilitation, social skills training
  - experimental: magnetic seizure therapy, deep brain stimulation, vagal nerve stimulation, ketamine

Prognosis
- one year after diagnosis of MDD without treatment: 40% of individuals still have symptoms that are sufficiently severe to meet criteria for MDD, 20% continue to have some symptoms that no longer meet criteria for MDD, 40% have no mood disorder

PERSISTENT DEPRESSIVE DISORDER

DSM-5 Diagnostic Criteria for Persistent Depressive Disorder
Note: in DSM-IV-TR this was referred to as Dysthymia
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013. American Psychiatric Association

A. depressed mood for most of the day, for more days than not, as indicated either by subjective account or observation by others, for ≥2 yr

B. presence, while depressed, of ≥2 of the following
  - poor appetite or overeating
  - insomnia or hypersomnia
  - low energy or fatigue
  - low self-esteem
  - poor concentration or difficulty making decisions
  - feelings of hopelessness

C. during the 2 yr period (1 yr for children or adolescents) of the disturbance, the person has never been without the symptoms in criteria A and B for more than 2 mo at a time

D. criteria for a major depressive disorder may be continuously present for 2 yr

E. there has never been a manic episode or a hypomanic episode, and criteria have never been met for cyclothymic disorder

F. the disturbance is not better explained by a persistent schizoaffective disorder, schizophrenia, delusional disorder, or other specified or unspecified schizophrenia spectrum and other psychotic disorder

G. the symptoms are not due to the direct physiological effects of a substance or another medical condition

H. the symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning

Epidemiology
- lifetime prevalence: 2.3%; M=F

Treatment
- psychological
  - traditionally psychotherapy was the principal treatment for persistent depressive disorder; recent evidence suggests some benefit but generally inferior to pharmacological treatment. Combinations of the two may be most efficacious
- biological
  - antidepressant therapy: SSRIs (e.g. sertraline, paroxetine), TCAs (e.g. imipramine) as an outpatient

St. John's Wort for Major Depression
Cochrane DB Syst Rev 2008;4:CD000448
Study: Systematic review of trials that were (1) randomized, double-blinded (2) with patients with major depression (3) comparing St. John's wort (hypericum extracts) with placebo or standard antidepressants and (4) included clinical outcomes.

Patients: 5,489 patients with major depression.

Outcomes: 1. Effectiveness: treatment response measured by a depression scale 2. Safety: the proportion of patients who dropped out due to adverse effects.

Intervention: St. John's wort vs. placebo; St. John's wort vs. standard antidepressants.

Results: 29 trials, 5,489 patients, with 18 comparisons with placebo and 17 with antidepressants. St John's wort is more effective than placebo (response rate ratio = 1.87), and similarly effective as antidepressants (RRR = 1.02). Less adverse effects with hypericum extracts. However, the effect size is dependent on the country of origin.

Cognitive Therapy vs. Medications in the Treatment of Moderate to Severe Depression
Arch Gen Psychiatry 2005;62:409-416
Study: Randomized control trial.

Patients: 240 outpatients with moderate to severe MDD, aged 18-70.

Intervention: 16 wk of paroxetine with or without augmentation with lithium carbonate or desipramine hydrochloride (n = 120) versus cognitive behavioural therapy (n=60). Response up to 8 wk was controlled by pill placebo (n=60).

Main Outcomes: The Hamilton Depression Rating scale was used to determine response to treatment.

Results: At 8 wk, 50% (95%CI 41-59%) of patients on medication and 43% (95%CI 31-56%) of patients on CBT had responded in comparison to 25% (95%CI 16-38%) of patients on pill placebo. There was no significant difference between medication and CBT. At 16 wk, 46% of patients on medication and 40% of patients on CBT achieved remission.

Summary: There is no difference in efficacy between CBT vs. paroxetine in the treatment of moderate to severe depression.
Postpartum Mood Disorders

Postpartum “Blues”
- transient period of mild depression, mood instability, anxiety, decreased concentration; considered to be normal changes in response to fluctuating hormonal levels, the stress of childbirth, and the increased responsibilities of motherhood
- occurs in 50-80% of mothers; begins 2-4 d postpartum, usually lasts 48 h, can last up to 10 d
- does not require psychotropic medication
- usually mild or absent: feelings of inadequacy, anhedonia, thoughts of harming baby, suicidal thoughts

MAJOR DEPRESSIVE DISORDER WITH PERIPARTUM ONSET (POSTPARTUM DEPRESSION)

Clinical Presentation
- MDD with onset during pregnancy or within 4 wk following delivery
- typically lasts 2-6 mo; residual symptoms can last up to 1 yr
- may present with psychosis (rare, 0.2%), usually associated with mania, but also with MDE
- severe symptoms include extreme disinterest in baby, suicidal and infanticidal ideation

Epidemiology
- occurs in 10% of mothers, risk of recurrence 50%

Risk Factors
- previous history of a mood disorder (postpartum or otherwise), family history of mood disorder
- psychosocial factors: stressful life events, unemployment, marital conflict, lack of social support, unwanted pregnancy, colicky or sick infant

Treatment
- psychotherapy (CBT or IPT)
- short-term safety of maternal SSRIs for breastfeeding infants established; long-term effects unknown
- if depression severe or psychotic symptoms present, consider ECT

Prognosis
- impact on child development: increased risk of cognitive delay, insecure attachment, behavioural disorders
- treatment of mother improves outcome for child at 8 mo through increased mother-child interaction

Bipolar Disorders

BIPOLAR I / BIPOLAR II DISORDER

Definition
- Bipolar I Disorder
  - disorder in which at least one manic episode has occurred
  - if manic symptoms lead to hospitalization, or if there are psychotic symptoms, the diagnosis is BP I
  - commonly accompanied by at least 1 MDE but not required for diagnosis
  - time spent in mood episodes: 53% asymptomatic, 32% depressed, 9% cycling/mixed, 6% hypo/manic
- Bipolar II Disorder
  - disorder in which there is at least 1 MDE, 1 hypomanic and no manic episodes
  - while hypomania is less severe than mania, Bipolar II is not a “milder” form of Bipolar I
  - time spent in mood episodes: 46% asymptomatic, 50% depressed, 1% cycling/mixed, 2% hypo/manic
- Bipolar II is often missed due to the severity and chronicity of depressive episodes and low rates of spontaneous reporting and recognition of hypomanic episodes

Classification
- classification of bipolar disorder involves describing the disorder (I or II) and the current or most recent mood episode as either manic, hypomanic, or depressed
- specifiers: with anxious distress, depressed with mixed features, hypo/manic with mixed features, melancholic features, atypical features, mood-congruent or -incongruent psychotic features, catatonia, peripartum onset, seasonal pattern, rapid cycling (4+ mood episodes in 1 yr)

Epidemiology
- lifetime prevalence: 1% BPI, 1.1% BPII, 2.4% Subthreshold BPD; M:F = 1:1
- age of onset: teens to 20s, usually MDE first, manic episode 6-10 years after, average age of first manic episode 32 yr

Risk Factors
- genetic: 60-65% of bipolar patients have family history of major mood disorders, especially bipolar disorders
- clinical features of MDE history favouring bipolar over unipolar diagnosis: early age of onset (<25 yr), increased number of MDEs, psychotic symptoms, postpartum onset, anxiety disorders (especially separation, panic), antidepressant failure due to early ‘poop out’ or hypomanic symptoms, early impulsivity and aggression, substance abuse, cyclothymic temperament
Treatment
• **lifestyle:** psychoeducation regarding cycling nature of illness, ensure regular check ins, develop early warning system, “emergency plan” for manic episodes, promote stable routine (sleep, meals, exercise)
• **biological:** lithium, anticonvulsants, antipsychotics, ECT (if refractory); monotherapy with antidepressants should be avoided
  - mood stabilizers vary in their ability to “treat” (reduce symptoms acutely) or “stabilize” (prevent relapse and recurrence) manic and depressive symptoms; multi-agent therapy is common
  - treating mania: lithium, valproate, carbamazepine (2nd line), SGA, ECT, benzodiazepines (for acute agitation)
  - preventing mania: same as above but usually at lower dosages, minus benzodiazepines
  - treating depression: lithium, lamotrigine, quetiapine, antidepressants (only with mood stabilizer), ECT
  - preventing depression: same as above plus aripiprazole, valproate (note: quetiapine first line in treating bipolar II depression)
  - mixed episode or rapid cycling: multi-agent therapy, lithium or valproate + SGA (lurasidone, aripiprazole, olanzapine)
• **psychological:** supportive or psychodynamic psychotherapy, CBT, IPT or interpersonal social rhythm therapy, family therapy
• **social:** vocational rehabilitation, consider leave of absence from school/work, assess capacity to manage finances, drug and EtOH cessation, sleep hygiene, social skills training, education and recruitment of family members

Course and Prognosis
• high suicide rate (15% mortality from suicide), especially in mixed states
• BP I and II are chronic conditions with a relapsing and remitting course featuring alternating manic and depressive episodes; depressive symptoms tend to occur more frequently and last longer than manic episodes
• can achieve high level of functioning between episodes
• may switch rapidly between depression and mania without any period of euthymia in between
• high recurrence rate for mania – 90% will have a subsequent episode in the next 5 yr
• long term follow up of BP I – 15% well, 45% well with relapses, 30% partial remission, 10% chronically ill

**CYCLOTHYMIA**

Diagnosis
• presence of numerous periods of hypomanic and depressive symptoms (not meeting criteria for full hypomanic episode or MDE) for ≥2 yr; never without symptoms for ≥2 mo
• never have met criteria for MDE, manic or hypomanic episodes
• symptoms are not due to the direct physiological effects of a substance or GMC
• symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning

Treatment
• similar to Bipolar I: mood stabilizer ± psychotherapy, avoid antidepressant monotherapy, treat any comorbid substance use disorder

### Anxiety Disorders

**Definition**
- anxiety is a universal human characteristic involving tension, apprehension, or even terror which serves as an adaptive mechanism to warn about an external threat
- manifestations of anxiety are a result of the activation of the sympathetic nervous system and can be described through
  - physiology: main brain structure involved is the amygdala (fear conditioning); neurotransmitters involved include 5-HT, cholecystokinin, epinephrine, norepinephrine, DA
  - psychology: one’s perception of a given situation is distorted which causes one to believe it is threatening in some way
  - behaviour: once feeling threatened, one responds by escaping or facing the situation, thereby causing a disruption in daily functioning
- anxiety becomes pathological when:
  - fear is greatly out of proportion to risk/severity of threat
  - response continues beyond existence of threat or becomes generalized to other similar or dissimilar situations
  - social or occupational functioning is impaired
  - often comorbid with substance use and depression

**Lithium**
- among few agents with proven efficacy in preventing suicide attempts and completions

**Monotherapy**
- with antidepressants should be avoided in patients with bipolar depression as patients can switch from depression into mania

**The 4 L’s for Bipolar Depression**
- Lithium, Lamotrigine, Lurasidone, Seroquel

**A Randomized Controlled Trial of Cognitive Therapy for Bipolar Disorder: Focus on Long-Term Change**
*J Clin Psychiatry* 2006;67:277-286

- **Study:** Randomized, blinded clinical trial
- **Patients:** 52 patients with DSM-IV bipolar 1 or 2 disorder
- **Intervention:** Patients allocated to either a 6 mo trial of cognitive therapy (CT) with emotive techniques or treatment as usual. Both groups received mood stabilizers.
- **Main Outcomes:** Relapse rates, dysfunctional attitudes, psychosocial functioning, hopelessness, self-control, medication adherence. Patients were assessed by independent raters blinded to treatment group.
- **Results:** At 6 mo, CT patients experienced fewer depressive symptoms and fewer dysfunctional attitudes. There was a non-significant (p=0.06) trend to greater time to depressive relapse. At 12 mo follow-up, CT patients had lower Young Mania Rating scores and improved behavioural self-control. At 18 mo, CT patients reported less severity of illness.
- **Conclusions:** CT appears to provide benefits in the 12 mo after completion of therapy.
Differential Diagnosis

Table 2. Differential Diagnosis of Anxiety Disorders

<table>
<thead>
<tr>
<th>Category</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td>Post-MI, arrhythmia, congestive heart failure, pulmonary embolus, mitral valve prolapse</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Asthma, COPD, pneumonia, hyperventilation</td>
</tr>
<tr>
<td>Endocrine</td>
<td>Hyperthyroidism, pheochromocytoma, hypoglycemia, hyperadrenalism, hyperparathyroidism</td>
</tr>
<tr>
<td>Metabolic</td>
<td>Vitamin B12 deficiency, porphyria</td>
</tr>
<tr>
<td>Neurologic</td>
<td>Neoplasm, vestibular dysfunction, encephalitis</td>
</tr>
<tr>
<td>Substance-Induced</td>
<td>Intoxication (caffeine, amphetamines, cocaine, thyroid preparations, OTC for colds/decongestants), withdrawal (benzodiazepines, alcohol)</td>
</tr>
<tr>
<td>Other Psychiatric Disorders</td>
<td>Psychotic disorders, mood disorders, personality disorders (OCF, somatoform disorders)</td>
</tr>
</tbody>
</table>

Medical Workup of Anxiety Disorder
- routine screening: physical exam, CBC, thyroid function test, electrolytes, urinalysis, urine drug screening
- additional screening: neurological consultation, chest X-ray, ECG, CT head

Panic Disorder

DSM-5 Diagnostic Criteria for Panic Disorder
Represented with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013, American Psychiatric Association
A. recurrent unexpected panic attacks - a panic attack is an abrupt surge of intense fear or intense discomfort that reaches a peak within minutes, and during which time four (or more) of the following symptoms occur
- palpitations, pounding heart, or accelerated heart rate
- sweating
- trembling or shaking
- sensations of shortness of breath or smothering
- feelings of choking
- chest pain or discomfort
- nausea or abdominal distress
- feeling dizzy, unsteady, light-headed, or faint
- chills or heat sensations
- paresthesias (numbness or tingling sensations)
- derealization (feelings of unreality) or depersonalization (being detached from oneself)
- fear of losing control or “going crazy”
- fear of dying
B. 1 mo (or more) of “anxiety about panic attacks” - at least one of the attacks has been followed by one or both of the following:
- persistent concern or worry about additional panic attacks or their consequences
- a significant maladaptive change in behaviour related to the attacks
C. the disturbance is not attributable to the physiological effects of a substance or another medical condition
D. the disturbance is not better explained by another mental disorder

Epidemiology
- prevalence: 2-5% (one of the top five most common reasons to see a family doctor); M:F = 1:2-3
- onset: average early-mid 20s, familial pattern

Treatment
- psychological
  - CBT: interoceptive exposure (eliciting symptoms of a panic attack and learning to tolerate the symptoms without coping strategies); cognitive restructuring (addressing underlying beliefs regarding the panic attacks), relaxation techniques (visualization, box-breathing)
- pharmacological
  - SSRIs: fluoxetine, citalopram, paroxetine, fluvoxamine, sertraline
  - SNRI: venlafaxine
  - with SSRIs/SNRIs start with low doses, titrate up slowly
- anxiety disorders often require treatment at higher doses for a longer period of time than depression (i.e. full response may take up to 12 wk)
- treat for up to 1 year after symptoms resolve to avoid relapse
- to prevent non-compliance due to physical side effects, explain symptoms to expect prior to initiation of therapy
- other antidepressants (mirtazapine, MAOIs)
- consider avoiding bupropion or TCAs due to stimulating effects (exacerbate anxious symptoms)
- benzodiazepines (short-term, low dose, regular schedule, long half-life, avoid prn usage)

Prognosis
- 6-10 yr post-treatment: 30% well, 40-50% improved, 20-30% no change or worse
- clinical course: chronic, but episodic with psychosocial stressors
Agoraphobia

DSM-5 Diagnostic Criteria for Agoraphobia
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013. American Psychiatric Association

A. marked fear or anxiety about two (or more) of the following five situations:
   - using public transportation
   - being in open spaces
   - being in enclosed places
   - standing in line or being in a crowd
   - being outside of the home alone

B. the individual fears or avoids these situations because of thoughts that escape might be difficult or help might not be available in the event of developing panic-like symptoms or other incapacitating or embarrassing symptoms

C. the agoraphobic situations almost always provoke fear or anxiety

D. the agoraphobic situations are actively avoided, require the presence of a companion, or are endured with intense fear or anxiety

E. the fear or anxiety is out of proportion to the actual danger posed by the agoraphobic situations and to the sociocultural context

F. the fear, anxiety, or avoidance is persistent, typically lasting ≥6 mo

G. the fear, anxiety, or avoidance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning

H. if another medical condition is present, the fear, anxiety, or avoidance is clearly excessive

I. the fear, anxiety, or avoidance is not better explained by the symptoms of another mental disorder and are not related exclusively to obsessions, perceived defects or flaws in physical appearance, reminders of traumatic events, or fear of separation

Note: agoraphobia is diagnosed irrespective of the presence of panic disorder. If an individual’s presentation meets criteria for panic disorder and agoraphobia, both diagnoses should be assigned

Treatment
• as per panic disorder

Generalized Anxiety Disorder

DSM-5 Diagnostic Criteria for Generalized Anxiety Disorder
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013. American Psychiatric Association

A. excessive anxiety and worry (apprehensive expectation), occurring more days than not for at least 6 mo, about a number of events or activities (such as work or school performance)

B. the individual finds it difficult to control the worry

C. the anxiety and worry are associated with three (or more) of the following six symptoms (with at least some symptoms having been present for more days than not for the past 6 mo)
   1. restlessness or feeling keyed up or on edge
   2. being easily fatigued
   3. difficulty concentrating or mind going blank
   4. irritability
   5. muscle tension
   6. sleep disturbance (difficulty falling or staying asleep, or restless, unsatisfying sleep)

D. the anxiety, worry, or physical symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning

E. the disturbance is not attributable to the physiological effects of a substance or another medical condition

F. the disturbance is not better explained by another mental disorder

Epidemiology
• 1 yr prevalence: 3-8%; M:F = 1:2
• if considering only those receiving inpatient treatment, ratio is 1:1
• most commonly presents in early adulthood

Treatment
• lifestyle: caffeine and EtOH avoidance, sleep hygiene
• psychological: CBT including relaxation techniques, mindfulness
• biological
   • SSRIs and SNRIs are 1st line (paroxetine, escitalopram, sertraline, venlafaxine XL)
   • 2nd line: buspirone (tid dosing), bupropion (caution due to stimulating effects)
   • add-on benzodiazepines (short-term, low dose, regular schedule, long half-life, avoid prn usage)
   • β-blockers not recommended

Prognosis
• chronically anxious adults become less so with age
• depends on pre-morbid personality functioning, stability of relationships, work, and severity of environmental stress
• difficult to treat
**Phobic Disorders**

**Specific Phobia**
- definition: marked and persistent (> 6 mo) fear that is excessive or unreasonable, cued by presence or anticipation of a specific object or situation
- lifetime prevalence 12-16%; M:F ratio variable
- types: animal/insect, environment (heights, storms), blood/injection/injury, situational (airplane, closed spaces), other (loud noise, clowns)

**Social Phobia (Social Anxiety Disorder)**
- definition: marked and persistent (> 6 mo) fear of social or performance situations in which one is exposed to unfamiliar people or to possible scrutiny by others; fearing he/she will act in a way that may be humiliating or embarrassing (e.g. public speaking, initiating or maintaining conversation, dating, eating in public)
- 12-month prevalence rate may be as high as 7%; M:F ratio approximately equal

**Diagnostic Criteria for Phobic Disorders**
- exposure to stimulus almost invariably provokes an immediate anxiety response; may present as a panic attack
- person recognizes fear as excessive or unreasonable
- situations are avoided or endured with anxiety/distress
- significant interference with daily routine, occupational/social functioning, and/or marked distress

**Treatment**
- psychological
  - cognitive behaviour therapy (focusing on both *in vivo* and virtual exposure therapy, gradually facing feared situations)
  - behavioural therapy is more efficacious than medication
- biological
  - SSRIs/SNRIs (e.g. fluoxetine, paroxetine, sertraline, venlafaxine), MAOIs
  - β-blockers or benzodiazepines in acute situations (e.g. public speaking)

**Prognosis**
- chronic

---

**Obsessive-Compulsive Disorder**

**DSM-5 Diagnostic Criteria for Obsessive-Compulsive Disorder**
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013. American Psychiatric Association
A. presence of obsessions, compulsions, or both
- obsessions are defined by (1) and (2)
  1. recurrent and persistent thoughts, urges, or images that are experienced, at some time during the disturbance, as intrusive and unwanted, and cause marked anxiety or distress in most individuals
  2. the individual attempts to ignore or suppress such thoughts, urges, or images, or to neutralize them with some other thought or action (i.e. by performing a compulsion; see below)
- compulsions are defined by (1) and (2)
  1. repetitive behaviours (e.g. hand washing, ordering, checking) or mental acts (e.g. praying, counting, repeating words silently) that the individual feels driven to perform in response to an obsession or according to rules that must be applied rigidly
  2. behaviours mental acts are aimed at preventing or reducing anxiety or distress, or preventing some dreaded event or situation; however, these behaviours or mental acts are not connected in a realistic way with what they are designed to neutralize or prevent, or are clearly excessive
B. the obsessions or compulsions are time-consuming (e.g. take >1 h/d) or cause clinically significant distress or impairment in social, occupational, or other important areas of functioning
C. the obsessive-compulsive symptoms are not attributable to the physiological effects of a substance or another medical condition
D. the disturbance is not better explained by the symptoms of another mental disorder

**Epidemiology**
- 12 mo prevalence 1.1-1.8%; females affected at slightly higher rates than males
- rate of OCD in first-degree relatives is higher than in the general population

**Treatment**
- CBT: exposure with response prevention (ERP) – involves exposure to feared situations with the addition of preventing the compulsive behaviours; cognitive strategies include challenging underlying beliefs
- pharmacotherapy: SSRIs/SNRIs (12-16 week trials, higher doses vs. depression), clomipramine; adjunctive antipsychotics (risperidone)

**Prognosis**
- tends to be refractory and chronic
**Trauma- and Stressor-Related Disorders**

**Post-Traumatic Stress Disorder**

**DSM-5 Diagnostic Criteria for Post-Traumatic Stress Disorder**

A. exposure to actual or threatened death, serious injury, or sexual violence in one (or more) of the following ways
   1. directly experiencing the traumatic event(s)
   2. witnessing, in person, the event(s) as it occurred to others
   3. learning that the traumatic event(s) occurred to a close family member or close friend. In cases of actual or threatened death of a family member or friend, the event(s) must have been violent or accidental
   4. experiencing repeated or extreme exposure to aversive details of the traumatic event(s) (e.g. first responders collecting human remains; police officers repeatedly exposed to details of child abuse)

B. presence of one (or more) of the following intrusion symptoms associated with the traumatic event(s), beginning after the traumatic event(s) occurred
   1. recurrent, involuntary, and intrusive distressing memories of the traumatic event(s)
   2. recurrent distressing dreams in which the content and/or affect of the dream are related to the traumatic event(s)
   3. dissociative reactions (e.g. flashbacks) in which the individual feels or acts as if the traumatic event(s) were occurring
   4. intense or prolonged psychological distress at exposure to internal or external cues that symbolize or resemble an aspect of the traumatic event(s)
   5. marked physiological reactions to internal or external cues that symbolize or resemble an aspect of the traumatic event(s)

C. persistent avoidance of stimuli associated with the traumatic event(s), beginning after the traumatic event(s) occurred, as evidenced by one or both of the following
   1. avoidance of or efforts to avoid distressing memories, thoughts, or feelings about or closely associated with the traumatic event(s)
   2. avoidance of or efforts to avoid external reminders (people, places, conversations, activities, objects, situations) that arouse distressing memories, thoughts, or feelings about or closely associated with the traumatic event(s)

D. negative alterations in cognitions and mood associated with the traumatic event(s), beginning or worsening after the traumatic event(s) occurred, as evidenced by two (or more) of the following
   1. inability to remember an important aspect of the traumatic event(s)
   2. persistent and exaggerated negative beliefs or expectations about oneself, others, or the world
   3. persistent, distorted cognitions about the cause or consequences of the traumatic event(s) that lead the individual to blame himself/herself or others
   4. persistent negative emotional state (e.g. fear, horror, anger, guilt, or shame)
   5. markedly diminished interest or participation in significant activities
   6. feelings of detachment or estrangement from others
   7. persistent inability to experience positive emotions

E. marked alterations in arousal and reactivity associated with the traumatic event(s), beginning or worsening after the traumatic event(s) occurred, as evidenced by two (or more) of the following
   1. irritable behaviour and angry outbursts (with little or no provocation) typically expressed as verbal or physical aggression toward people or objects
   2. reckless or self-destructive behaviour
   3. hypervigilance
   4. exaggerated startle response
   5. problems with concentration
   6. sleep disturbance (e.g. difficulty falling or staying asleep or restless sleep)

F. duration of the disturbance (criteria B, C, D, and E) is more than 1 mo

G. the disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning

H. the disturbance is not attributable to the physiological effects of a substance or another medical condition

**Epidemiology**
- prevalence of 7% in general population
- men's trauma is most commonly combat experience/physical assault; women's trauma is usually physical or sexual assault

**Treatment**
- psychotherapy, CBT
  - ensure safety and stabilize: emotional regulation techniques (e.g. breathing, relaxation)
  - once coping mechanisms established, can explore/mourn trauma - challenge dysfunctional beliefs, etc.
  - reconnect and integrate - exposure therapy, etc.
• biological  
  ■ SSRIs (e.g. paroxetine, sertraline)
  ■ prazosin (for treating disturbing dreams and nightmares)
  ■ benzodiazepines (for acute anxiety)
  ■ adjunctive atypical antipsychotics (risperidone, olanzapine)
  ■ eye movement desensitization and reprocessing (EMDR): an experimental method of reprocessing memories of distressing events by recounting them while using a form of dual attention stimulation such as eye movements, bilateral sound, or bilateral tactile stimulation (its use is controversial because of limited evidence)

Complications  
• substance abuse, relationship difficulties, depression, impaired social and occupational functioning disorders, personality disorders

### Adjustment Disorder

**Definition**  
• a diagnosis encompassing patients who have difficulty coping with a stressful life event or situation and develop acute, often transient, emotional or behavioural symptoms that resemble less severe versions of other psychiatric conditions

**DSM-5 Diagnostic Criteria for Adjustment Disorder**  
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013. American Psychiatric Association

A. the development of emotional or behavioural symptoms in response to an identifiable stressor(s) occurring within 3 mo of the onset of the stressor(s)
B. these symptoms or behaviours are clinically significant as evidenced by either of the following:
  • marked distress that is in excess of what would be expected from exposure to the stressor
  • significant impairment in social or occupational (academic) functioning
C. the stress-related disturbance does not meet criteria for another mental disorder and is not merely an exacerbation of a pre-existing mental disorder
D. the symptoms do not represent normal bereavement
E. once the stressor (or its consequences) has terminated, the symptoms do not persist for more than an additional 6 mo
  • specifiers: with depressed mood, with anxiety, with mixed anxiety/depression, with conduct disturbance, with mixed disturbance of conduct/emotions, unspecified

**Classification**  
• types of stressors
  • single (e.g. termination of romantic relationship)
  • multiple (e.g. marked business difficulties and marital problems)
  • recurrent (e.g. seasonal business crises)
  • continuous (e.g. living in a crime-ridden neighbourhood)
  • developmental events (e.g. going to school, leaving parental home, getting married, becoming a parent, failing to attain occupational goals, retirement)

**Epidemiology**  
• F:M 2:1, prevalence 2-8% of the population

**Treatment**  
• brief psychotherapy: individual or group (particularly useful for patients dealing with unique and specific medical issues; e.g. colostomy or renal dialysis groups), crisis intervention
• biological
  • benzodiazepines may be used for those with significant anxiety symptoms (short-term, low-dose, regular schedule)

### Bereavement

**Clinical Presentation**  
• bereavement is a normal psychological and emotional reaction to a significant loss, also called grief or mourning
• length and characteristics of “normal” bereavement are variable between individuals/cultures
• normal response: protest → searching and acute anguish → despair and detachment → reorganization
• presence of the following symptoms may indicate abnormal grief/presence of MDD
  • guilt about things other than actions taken or not taken by the survivor at the time of death
  • thoughts of death other than the survivor feeling that they would be better off dead or should have died with the deceased person; morbid preoccupation with worthlessness
  • marked psychomotor retardation; prolonged and marked functional impairment
  • hallucinatory experiences other than thinking that the survivor hears the voice of or transiently sees the image of the deceased person
  • dysphoria that is pervasive and independent of thoughts or triggers of the deceased, absence of mood reactivity

**Risk Factors for Poor Bereavement Outcome**  
• Poor social supports
• Unanticipated death or lack of preparation for death
• Highly dependent relationship with deceased
• High initial distress
• Other concurrent stresses and losses
• Death of a child
• Pre-existing psychiatric disorders, especially depression and separation anxiety
• after 12 mo, if patient continues to yearn/long for the deceased, experience intense sorrow/emotional pain in response to the death, remain preoccupied with the deceased or with their circumstance of death, then may start to consider a diagnosis of “persistent complex bereavement disorder”
• if a patient meets criteria for MDD, even in the context of a loss or bereavement scenario, they are still diagnosed with MDD

Treatment
• support and watchful waiting should be first line, as well as education and normalization of the grief process
• screen for increased alcohol, cigarette and drug use
• normal grief should not be treated with antidepressant or antianxiety medication, as it is important to allow the person to experience the whole mourning process to achieve resolution
• psychosocial: for those needing additional support, complex grief/bereavement, or significant MDD, grief therapy (individual or group) is indicated
• pharmacotherapy: if MDD present, past history of mood disorders, severe or autonomous symptoms

Neurocognitive Disorders

Delirium

• see Neurology, N20 and Geriatric Medicine, GM4

DSM-5 Diagnostic Criteria for Delirium
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013, American Psychiatric Association
A. attention and awareness: disturbance in attention (i.e. reduced ability to direct, focus, sustain, and shift attention) and awareness (reduced orientation to the environment)
B. acute and fluctuating: disturbance develops over short period of time (usually hours to days), represents a change from baseline attention and awareness, and tends to fluctuate in severity during the course of a day
C. cognitive changes: an additional disturbance in cognition (e.g. memory deficit, disorientation, language, visuospatial ability, or perception)
D. not better explained: disturbances in criteria A and C are not better explained by another neurocognitive disorder (pre-existing, established, or evolving) and do not occur in the context of a severely reduced level of arousal (e.g. coma)
E. direct physiological cause: evidence that disturbance is a direct physiological consequence of another medical condition, substance intoxication or withdrawal (i.e. due to a drug of abuse or medication), toxin, or is due to multiple etiologies
• Note: can have HYPERactive, HYPOactive, or MIXED presentation

Clinical Presentation and Assessment
• common symptoms
  • distractibility, disorientation (time, place, rarely person)
  • misinterpretations, illusions, hallucinations
  • speech/language disturbances (dysarthria, dysnomia, dysgraphia)
  • affective symptoms (anxiety, fear, depression, irritability, anger, euphoria, apathy)
  • shifts in psychomotor activity (groping/picking at clothes, attempts to get out of bed when unsafe, sudden movements, sluggishness, lethargy)
• Folstein Mini Mental Status Exam or Montreal Cognitive Assessment are helpful to assess baseline of altered mental state (i.e. score will improve as symptoms resolve)

Risk Factors
• hospitalization (incidence 10-56%)
• previous delirium
• nursing home residents (incidence 60%)
• polypharmacy (e.g. anticholinergics)
• old age (especially males)
• severe illness (e.g. cancer, AIDS)
• recent anesthesia or surgery
• substance abuse
• pre-existing cognitive impairment, brain pathology, psychiatric illness

Investigations
• standard: CBC and differential, electrolytes, Ca++, PO₄-, Mg++, glucose, ESR, LFTs, Cr, BUN, TSH, vitamin B₁₂, folate, albumin, urine C&S, R&M
• as indicated: ECG, CXR, CT head, toxicology/heavy metal screen, VDRL, HIV, LP, blood cultures, EEG (typically abnormal - generalized slowing or fast activity, can also be used to rule out underlying seizures or post-ictal states as etiology)
• indications for CT head: focal neurological deficit, acute change in status, anticoagulant use, acute incontinence, gait abnormality, history of cancer

Bereavement is associated with a significant increase in morbidity and mortality acutely following the loss, with effects seen up to 1 yr after

Loneliness is the most common symptom that continues to persist in normal bereavement and may last several years

Confusion Assessment Method (CAM) for Diagnosis of Delirium
Highly sensitive and specific method to diagnosis delirium
Part 1: an assessment instrument that screens for overall cognitive impairment
Part 2: includes four features found best able to distinguish delirium from other cognitive impairments
Need (1) + (2) + (3 or 4)
(1) Acute onset and fluctuating course
(2) Inattention
(3) Disorganized thinking
(4) Altered level of consciousness - hypperactive or hyproactive

Visual hallucinations are organic until proven otherwise

Etiology of Delirium
• Infectious (encephalitis, meningitis, UTI, pneumonia)
• Withdrawal (alcohol, barbiturates, benzodiazepines)
• Acute metabolic disorder (electrolyte imbalance, hepatic or renal failure)
• Trauma (head injury, post-operative)
• CNS pathology (stroke, hemorrhage, tumour, seizure disorder, Parkinson's)
• Hypoxia (anemia, cardiac failure, pulmonary embolus)
• Deficiencies (vitamin B₁₂, folic acid, thiamine)
• Endocrinopathies (thyroid, glucose, parathyroid, adrenal)
• Acute vascular (shock, vasculitis, hypertensive encephalopathy)
• Toxins: substance use, sedatives, opioids (especially morphine), anesthetics, anticholinergics, anticonvulsants, dopaminergic agents, steroids, insulin, glibenclamide, antibiotics (especially quinolones), NSAIDs
• Heavy metals (arsenic, lead, mercury)
Management
- identify and manage underlying cause
  - identify and treat underlying cause immediately
  - stop all non-essential medications
  - maintain nutrition, hydration, electrolyte balance and monitor vitals
- optimize the environment
  - environment: quiet, well-lit, near window for cues regarding time of day
  - optimize hearing and vision
  - room near nursing station for closer observation; constant care if patient jumping out of bed, pulling out lines
  - family member present for reassurance and re-orientation
  - frequent orientation - calendar, clock, reminders
- pharmacotherapy
  - low dose, high potency antipsychotics: haloperidol has the most evidence; reasonable alternatives include risperidone, olanzapine (more sedating, less QT prolongation), quetiapine (if EPS), aripiprazole
  - benzodiazepines only to be used in alcohol withdrawal delirium; otherwise, can worsen delirium
  - try to minimize anticholinergic side effects
  - physical restraints to maintain safety only if necessary

Prognosis
- up to 50% 1 yr mortality rate after episode of delirium

Major Neurocognitive Disorder (Dementia)

- see Neurology, N21

DSM-5 Diagnostic Criteria for Major Neurocognitive Disorder

Republished with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013. American Psychiatric Association

A. evidence of significant cognitive decline from a previous level of performance in one or more cognitive domains (complex attention, executive function, learning and memory, language, perceptual-motor, or social cognition) based on
  1. concern of the individual, a knowledgeable informant, or the clinician that there has been a significant decline in cognitive function; and
  2. substantial impairment in cognitive performance, preferably documented by standardized neuropsychological testing or, in its absence, another quantified clinical assessment

B. cognitive deficits interfere with independence in everyday activities (i.e. at a minimum, requiring assistance with complex instrumental activities of daily living such as paying bills or managing medications)

- Note: if do not interfere in B, and impairments are mild-moderate in A, considered “mild neurocognitive disorder”; see Neurology, N21

C. cognitive deficits do not occur exclusively in the context of a delirium

D. cognitive deficits are not better explained by another mental disorder (e.g. major depressive disorder, schizophrenia)

Specify whether due to

<table>
<thead>
<tr>
<th>Alzheimer’s disease</th>
<th>Normal pressure hydrocephalus</th>
<th>Huntington’s disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fronttemporal lobar degeneration</td>
<td>Substance/medication use</td>
<td>Another medical condition</td>
</tr>
<tr>
<td>Lewy body disease</td>
<td>HIV infection</td>
<td>Multiple etiologies</td>
</tr>
<tr>
<td>Vascular disease</td>
<td>Prion disease</td>
<td>Unspecified</td>
</tr>
<tr>
<td>Traumatic brain injury</td>
<td>Parkinson’s disease</td>
<td></td>
</tr>
</tbody>
</table>

Epidemiology
- prevalence increases with age: 10% in patients >65 yr of age; 25% in patients >85 yr of age
- prevalence is increased in people with Down’s syndrome and head trauma
- Alzheimer’s disease comprises >50% of cases; vascular causes comprise approximately 15% of cases (other causes of dementia neurocognitive disorder – see Neurology, N22)
- average duration of illness from onset of symptoms to death is 8–10 yr

Subtypes
- with or without behavioural disturbance (e.g. wandering, agitation)
- early-onset: age of onset <65 yr
- late-onset: age of onset >65 yr

Investigations (rule out reversible causes)
- standard: see Delirium, PS19
  - as indicated: VDRL, HIV, SPECT, CT head in dementia
  - indications for CT head: same as for delirium, plus: age <60, rapid onset (unexplained decline in cognition or function over 1-2 mo), dementia of relatively short duration (<2 yr), recent significant head trauma, unexplained neurological symptoms (new onset of severe headache/seizures)
Management
• see Neurology, N20 for further management
• treat underlying medical problems and prevent others
• provide orientation cues for patient (e.g. clock, calendar)
• provide education and support for patient and family (e.g. day programs, respite care, support groups, home care)
• consider long-term care plan (nursing home) and power of attorney/living will
• inform Ministry of Transportation about patient’s inability to drive safely
• consider pharmacological therapy
  - cholinesterase inhibitors (e.g. donepezil [Aricept®], rivastigmine, galantamine) for mild to severe disease
  - NMDA receptor antagonist (e.g. memantine) for moderate to severe disease
  - low-dose neuroleptics (e.g. risperidone, quetiapine), antidepressants or trazodone if behavioural or emotional symptoms prominent – start low and go slow
  - reassess pharmacological therapy every 3 mo

Table 3. Comparison of Dementia, Delirium, and Pseudodementia of Depression

<table>
<thead>
<tr>
<th></th>
<th>Dementia/Major Neurocognitive Disorder</th>
<th>Delirium</th>
<th>Pseudodementia of Depression</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Onset</strong></td>
<td>Gradual/step-wise decline</td>
<td>Acute (h-d)</td>
<td>Subacute</td>
</tr>
<tr>
<td><strong>Duration</strong></td>
<td>Months-years</td>
<td>Days-weeks</td>
<td>Variable</td>
</tr>
<tr>
<td><strong>Natural History</strong></td>
<td>Progressive</td>
<td>Fluctuating, reversible</td>
<td>Recurrent</td>
</tr>
<tr>
<td></td>
<td>Usually irreversible</td>
<td>High morbidity/mortality in very old</td>
<td>Usually reversible</td>
</tr>
<tr>
<td><strong>Level of Consciousness</strong></td>
<td>Normal</td>
<td>Fluctuating (over 24 h)</td>
<td>Normal</td>
</tr>
<tr>
<td><strong>Attention</strong></td>
<td>Not initially affected</td>
<td>Decreased (wandering, easy distraction)</td>
<td>Difficulty concentrating</td>
</tr>
<tr>
<td><strong>Orientation</strong></td>
<td>Intact initially</td>
<td>Impaired (usually to time and place), fluctuates</td>
<td>Intact</td>
</tr>
<tr>
<td><strong>Behaviour</strong></td>
<td>Disinhibition, impairment in ADL/IADL, personality change, loss of social graces</td>
<td>Severe agitation/retardation</td>
<td>Importuning, self-harm/suicide</td>
</tr>
<tr>
<td><strong>Psychomotor</strong></td>
<td>Normal</td>
<td>Fluctuates between extremes</td>
<td>Slowing</td>
</tr>
<tr>
<td><strong>Sleep Wake Cycle</strong></td>
<td>Fragmented sleep at night</td>
<td>Reversed sleep wake cycle</td>
<td>Early morning awakening</td>
</tr>
<tr>
<td><strong>Mood and Affect</strong></td>
<td>Labile but not usually anxious</td>
<td>Anxious, irritable, fluctuating</td>
<td>Depressed, stable</td>
</tr>
<tr>
<td><strong>Cognition</strong></td>
<td>Decreased executive functioning, paucity of thought</td>
<td>Fluctuating preceded by mood changes</td>
<td>Fluctuating</td>
</tr>
<tr>
<td><strong>Memory Loss</strong></td>
<td>Recent, eventually remote</td>
<td>Marked recent</td>
<td>Recent</td>
</tr>
<tr>
<td><strong>Language</strong></td>
<td>Agnosia, aphasia, decreased comprehension, repetition, speech (echolalia, palilalia)</td>
<td>Dysnomia, dysgraphia, speech rambling, irrelevant, incoherent, subject changes</td>
<td>Not affected</td>
</tr>
<tr>
<td><strong>Delusions</strong></td>
<td>Compensatory</td>
<td>Nightmarish and poorly formed</td>
<td>Nihilistic, somatic</td>
</tr>
<tr>
<td><strong>Hallucinations</strong></td>
<td>Variable</td>
<td>Visual common</td>
<td>Less common, auditory predominates</td>
</tr>
<tr>
<td><strong>Quality of Hallucinations</strong></td>
<td>Vacuous/bland</td>
<td>Frightening/bizarre</td>
<td>Self-deprecatory</td>
</tr>
<tr>
<td><strong>Medical Status</strong></td>
<td>Variable</td>
<td>Acute illness, drug toxicity</td>
<td>Rule out systemic illness, medications</td>
</tr>
</tbody>
</table>

Substance-Related and Addictive Disorders

Overview
• a neurobiological disorder involving compulsive drug seeking and drug taking, despite adverse consequences, with loss of control over drug use (think issues with the “3 Cs”: compulsive, consequences, control)
• dependence is the hallmark of substance use disorders and comes in the following forms:
  - behavioural: substance-seeking activities and pathological use patterns
  - physical: physiologic withdrawal effects without use
  - psychological: continuous or intermittent cravings for the substance to avoid dysphoria or attain drug state
• abuse: drug use that deviates from the approved social or medical pattern, usually causing impairment or disruption to function in self or others
• these disorders are usually chronic with a relapsing and remitting course
Epidemiology
- 47% of those with substance abuse have mental health problems
- 29% of those with a mental health disorder have a substance use disorder
- 47% of those with schizophrenia and 25% of those with an anxiety disorder have a substance use disorder

Etiology
- almost all drugs (and activities) of abuse increase dopamine in the nucleus accumbens, an action that contributes to their euphoric properties and, with repeated use, to their ability to change signalling pathways in the brain's reward system
- substance use disorders arise from multifactorial interactions between genes (personality, neurobiology) and environment (low socioeconomic status, substance-using peers, abuse history, chronic stress)

Diagnosis
- substance use disorders are measured on a continuum from mild to severe based on the number of criteria met within 12 mo
  - mild: 2-3
  - moderate: 4-5
  - severe: 6 or more
- each specific substance is addressed as a separate use disorder and diagnosed utilizing the same overarching criteria (e.g. a single patient may have moderate alcohol use disorder, and a mild stimulant use disorder)
- criteria for substance use disorders (PEC WITH MCAT)
  - use despite Physical or psychological problem (e.g. alcoholic liver disease or cocaine related nasal problems)
  - failures in important External roles at work/school/home
  - Craving or a strong desire to use substance
  - Withdrawal
  - continued use despite Interpersonal problems
  - Tolerance, needing to use more substance to get same effect
  - use in physically Hazardous situations
  - More substance used or for longer period than intended
  - unsuccessful attempts to Cut down
  - Activities given up due to substance
  - excessive Time spent on using or finding substance

Classification of Substances

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Intoxication</th>
<th>Withdrawal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depressants</td>
<td>Alcohol, opioids, barbiturates, benzodiazepines, GHB</td>
<td>Euphoria, slurred speech, disinhibition, confusion, poor coordination, coma (severe)</td>
</tr>
<tr>
<td>Stimulants</td>
<td>Amphetamines, methylphenidate, MDMA, cocaine</td>
<td>Euphoria, mania, psychomotor agitation, anxiety, psychosis (especially paranoia), insomnia, cardiovascular complications (stroke, MI, arrhythmias), seizure</td>
</tr>
<tr>
<td>Hallucinogens</td>
<td>LSD, mescaline, psilocybin, PCP, ketamine, ibogaine, salvia</td>
<td>Distortion of sensory stimuli and enhancement of feelings, psychosis (+ + visual hallucinations), delirium, anxiety (panic), poor coordination</td>
</tr>
</tbody>
</table>

General Approach to Assessment
- must be appropriate to the patient's current state of change (see Population Health and Epidemiology, Health Promotion Strategies, PH6, for Prochaska's Stages of Change Model)
- patients will only change when the pain of change appears less than the pain of staying the same
- provider can help by providing psychoeducation (emphasize neurobiologic model of addiction), motivation, and hope
- principles of motivational interviewing (see Psychotherapy, PS40)
  - non-judgmental stance
  - space for patient to talk and reflect
  - offer accurate empathic reflections back to patient to help frame issues

General Approach to Treatment
- encourage and offer referral to evidence based services
  - social: 12-step programs (alcoholics anonymous, narcotics anonymous), family education and support
  - psychological therapy: addiction counselling, motivational enhancement therapy (MET), CBT, contingency management, group therapy, family therapy, marital counselling
  - medical management (differs depending on substance): acute detoxification, pharmacologic agents to aid maintenance
  - harm reduction whenever possible: safe-sex practices, avoid driving while intoxicated, avoiding substances with child care, safe needle practices/exchange, pill-testing kits, reducing tobacco use
  - comorbid psychiatric conditions: many will resolve with successful treatment of the substance use disorder but patients who meet full criteria for another disorder should be treated for that disorder with psychological and pharmacologic therapies

Questions to Characterize Substance Use and Risk Assessment
- When was the last time you used?
- How long can you go without using?
- By what route (oral ingestion, insufflation, smoking, IV) do you usually use?
- Are there any triggers that you know will cause you to use?
- How has your substance use affected your work, school, relationships?
- Substances can be very expensive, how do you support your drug use?
- Have you experienced medical or legal consequences of your use?
- Any previous attempts to cut down or quit, did you experience any withdrawal symptoms?
Nicotine

- see Family Medicine, FM11

Alcohol

- see Family Medicine, FM12 and Emergency Medicine, ER54

History

- CAGE validated screening questionnaire
  
  C ever felt the need to Cut down on drinking?
  
  A ever felt Annoyed at criticism of your drinking?
  
  G ever feel Guilty about your drinking?
  
  E ever need a drink first thing in morning (Eye opener)?
  
  - for men, a score of ≥2 is a positive screen; for women, a score of ≥1 is a positive screen
  
  - if positive CAGE, then assess further to distinguish among problem drinking and alcohol use disorder

<table>
<thead>
<tr>
<th>Table 4. Canada’s Low-Risk Alcohol Drinking Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate Drinking</td>
</tr>
<tr>
<td>Men: 3 or less/d (≤15/wk)</td>
</tr>
<tr>
<td>Women: 2 or less/d (≤10/wk)</td>
</tr>
<tr>
<td>Elderly: 1 or less/d</td>
</tr>
</tbody>
</table>

Alcohol Intoxication

- legal limit for impaired driving is 10.6 mmol/L (50 mg/dL) reached by 2-3 drinks/h for men and 1-2 drinks/h for women
- coma can occur with >60 mmol/L (non-tolerant drinkers) and 90-120 mmol/L (tolerant drinkers)

Alcohol Withdrawal

- occurs within 12-48 h after prolonged heavy drinking and can be life-threatening
- alcohol withdrawal can be described as having 4 stages, however not all stages may be experienced
  
  - stage 1 (onset 12-18 h after last drink): “the shakes” tremor, sweating, agitation, anorexia, cramps, diarrhea, sleep disturbance
  
  - stage 2 (onset 7-48 h): alcohol withdrawal seizures, usually tonic-clonic, non-focal and brief
  
  - stage 3 (onset 48 h): visual, auditory, olfactory or tactile hallucinations
  
  - stage 4 (onset 3-5 d): delirium tremens, confusion, delusions, hallucinations, agitation, tremors, autonomic hyperactivity (fever, tachycardia, HTN)
- course: almost completely reversible in young, elderly often left with cognitive deficits
- mortality rate 20% if untreated

Management of Alcohol Withdrawal

- monitor using the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-A) scoring system
  
  - areas of assessment include
    
    - physical (5): nausea and vomiting, tremor, agitation, paroxysmal sweats, headache/fullness in head
    
    - psychological/cognitive (2): anxiety, orientation/clouding of sensorium
    
    - perceptual (3): tactile disturbances, auditory disturbances, visual disturbances
    
    - all categories are scored from 0-7 (except: orientation/sensorium 0-4), maximum score of 67
    
    - mild <10, moderate 10-20, severe >20

<table>
<thead>
<tr>
<th>Table 5. CIWA-A Scale Treatment Protocol for Alcohol Withdrawal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Protocol</td>
</tr>
<tr>
<td>Diazepam 20 mg PO q1-2 hr until CIWA-A &lt; 10 points</td>
</tr>
<tr>
<td>Observe 1-2 h after last dose and re-assess on CIWA-A scale</td>
</tr>
<tr>
<td>Thiamine 100 mg IM then 100 mg PO OD for 3 d</td>
</tr>
<tr>
<td>Supportive care (hydration and nutrition)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>History of Withdrawal Seizures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diazepam 20 mg PO q1h for minimum of three doses regardless of subsequent CIWA scores</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>If age &gt;65 or patient has severe liver disease, severe asthma or respiratory failure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use a short acting benzodiazepine</td>
</tr>
<tr>
<td>Lorazepam PO/SL/IM 1-4 mg q1-2h</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>If Hallucinations are present</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haloperidol 2-5 mg IM/PO q1-4h – max 5 doses/d or atypical antipsychotics (olanzapine, risperidone)</td>
</tr>
<tr>
<td>Diazepam 20 mg x 3 doses as seizure prophylaxis (haloperidol lowers seizure threshold)</td>
</tr>
</tbody>
</table>

Admit to Hospital if

- Still in withdrawal after >80 mg of diazepam
- Delirium tremens, recurrent arrhythmias, or multiple seizures
- Medically ill or unsafe to discharge home

Confabulations: the fabrication of imaginary experiences to compensate for memory loss

Make sure to ask about other alcohols: mouthwash, rubbing alcohol, methanol, ethylene glycol, aftershave (may be used as a cheaper alternative)

A “Standard Drink”

- Spirit (40%): 1.5 oz. or 43 mL
- Table Wine (12%): 5 oz. or 142 mL
- Fortified Wine (18%): 3 oz or 85 mL

- Regular Beer (5%): 12 oz. or 341 mL
- OR
  
  - 1 pint of beer = 1.5 SD
  
  - 1 bottle of wine = 5 SD
  
  - “26-er” = 8 SD
  
  - “40 oz.” = 27 SD

Delirium Tremens

- (alcohol withdrawal delirium)
  
  - Autonomic hyperactivity (diaphoresis, tachycardia, increased respiration)
  
  - Hand tremor
  
  - Insomnia
  
  - Psychomotor agitation
  
  - Anxiety
  
  - Nausea or vomiting
  
  - Tonic-clonic seizures
  
  - Visual/tactile/auditory hallucinations
  
  - Persecutory delusions
Wernicke-Korsakoff Syndrome
- alcohol-induced amnestic disorders due to thiamine deficiency
- necrotic lesions: mammillary bodies, thalamus, brainstem
- Wernicke’s encephalopathy (acute and reversible): triad of nystagmus (CN VI palsy), ataxia, and confusion
- Korsakoff’s syndrome (chronic and only 20% reversible with treatment): anterograde amnesia and confabulations; cannot occur during an acute delirium or dementia and must persist beyond usual duration of intoxication/withdrawal
- management
  - Wernicke’s: thiamine 100 mg PO OD x 1-2 wk
  - Korsakoff’s: thiamine 100 mg PO bid/tid x 3-12 mo

Treatment of Alcohol Use Disorder
- non-pharmacological
  - see General Approach to Treatment, PS4
- pharmacological
  - naltrexone (Revia®): opioid antagonist, shown to be successful in reducing the “high” associated with alcohol, moderately effective in reducing cravings, frequency or intensity of alcohol binges
  - disulfiram (Antabuse®): prevents oxidation of alcohol (blocks acetaldehyde dehydrogenase); with alcohol consumption, acetaldehyde accumulates to cause a toxic reaction (vomiting, tachycardia, death); if patient relapses, must wait 48 h before restarting Antabuse®, prescribed only when treatment goal is abstinence. RCT evidence is generally poor or negative
  - acamprosate (Campral®): NMDA glutamate receptor antagonist; useful in maintaining abstinence and decreasing cravings

Opioids
- types of opioids: heroin, morphine, oxycodone, Tylenol #3® (codeine), hydromorphone, fentanyl
- major risks associated with the use of contaminated needles: increased risk of hepatitis B and C, bacterial endocarditis, HIV/AIDS

Acute Intoxication
- direct effect on receptors in CNS resulting in decreased pain perception, sedation, decreased sex drive, nausea/vomiting, decreased GI motility (constipation and anorexia), and respiratory depression

Toxic Reaction
- typical syndrome includes shallow respirations, miosis, bradycardia, hypothermia, decreased level of consciousness
- management
  - ABCs
  - IV glucose
  - naloxone hydrochloride (Narcan®): 0.4 mg up to 2 mg IV for diagnosis
  - treatment: intubation and mechanical ventilation, ± naloxone drip, until patient alert without naloxone (up to >48 h with long-acting opioids)
  - caution with longer half-life; may need to observe for toxic reaction for at least 24 h

Withdrawal
- symptoms: depression, insomnia, drug-craving, myalgias, nausea, chills, autonomic instability (lacrimation, rhinorrhea, piloerction)
- onset: 6-12 h; duration: 5–10 d
- complications: loss of tolerance (overdose on relapse), miscarriage, premature labour
- management: long-acting oral opioids (methadone, buprenorphine), α-adrenergic agonists (clonidine)

Treatment of Opioid Use Disorder
- see General Approach to Treatment, PS4
- long-term treatment may include withdrawal maintenance treatment with methadone (opioid agonist) or buprenorphine (mixed agonist-antagonist)
- Suboxone® formulation includes naloxone in addition to buprenorphine, in an effort to prevent injection of the drug. When naloxone is injected, it will precipitate opiate withdrawal and block the opiate effect of buprenorphine; however, it will not have this antagonist action when taken sublingually
Cocaine

- street names: blow, C, coke, crack, flake, freebase, rock, snow
- alkaloid extracted from leaves of the coca plant; blocks presynaptic uptake of dopamine (causing euphoria), norepinephrine and epinephrine (causing vasospasm, HTN)
- self-administered by inhalation, insufflation, or intravenous route

Intoxication

- elation, euphoria, pressured speech, restlessness, sympathetic stimulation (e.g. tachycardia, mydriasis, sweating)
- prolonged use may result in paranoia and psychosis

Overdose

- medical emergency: HTN, tachycardia, tonic-clonic seizures, dyspnea, and ventricular arrhythmias
- treatment with IV diazepam to control seizures
- beta-blockers (incl. labetalol or propranolol) are not recommended because of risk from unopposed alpha-adrenergic stimulation

Withdrawal

- initial “crash” (1-48 h): increased sleep, increased appetite
- withdrawal (1-10 wk): dysphoric mood plus fatigue, irritability, vivid unpleasant dreams, insomnia or hypersomnia, psychomotor agitation or retardation
- complications: relapse, suicide (significant increase in suicide during withdrawal period)
- management: supportive management

Treatment of Cocaine Use Disorder

- see General Approach to Treatment, PS4
- no pharmacologic agents have widespread evidence or acceptance of use

Complications

- cardiovascular: arrhythmias, MI, CVA, ruptured AAA
- neurologic: seizures
- psychiatric: psychosis, paranoia, delirium, suicidal ideation
- other: nasal septal deterioration, acute/chronic lung injury “crack lung”, possible increased risk of connective tissue disease

Amphetamines

- includes prescription medications for ADHD such as Ritalin® and Adderall®
- intoxication characterized by euphoria, improved concentration, sympathetic and behavioural hyperactivity and at high doses can mimic psychotic mania, can eventually cause coma
- chronic use can produce a paranoid psychosis which can resemble schizophrenia with agitation, paranoia, delusions and hallucinations
- withdrawal symptoms include dysphoria, fatigue, and restlessness
- treatment of amphetamine induced psychosis: antipsychotics for acute presentation, benzodiazepines for agitation, β-blockers for tachycardia, hypertension

Cannabis

- cannabis (marijuana) is the most commonly used illicit drug
- psychoactive substance: delta-9-tetrahydrocannabinol (Δ9-THC)
- intoxication characterized by tachycardia, conjunctival vascular engorgement, dry mouth, altered sensorium, increased appetite, increased sense of well-being, euphoria/laughter, muscle relaxation, impaired performance on psychomotor tasks including driving
- high doses can cause depersonalization, paranoia, anxiety and may trigger psychosis and schizophrenia if predisposed
- chronic use associated with tolerance and an apathetic, amotivational state, increases risk of later manic episodes
- cessation following heavy use produces a significant withdrawal syndrome: irritability, anxiety, insomnia, decreased food intake
- treatment of cannabis use disorder: see General Approach to Treatment, PS4
Hallucinogens

- **types of hallucinogens by primary action**
  - 5-HT2A agonists: LSD, mescaline (peyote), psilocybin mushrooms, DMT (ayahuasca)
  - NMDA antagonists: PCP, ketamine
  - κ-opioid agonists: salvia divinorum, ibogaine
- **5-HT2A agonists** are most commonly used; intoxication characterized by tachycardia, HTN, mydriasis, tremor, hyperpyrexia, and a variety of perceptual, mood and cognitive changes (rarely, if ever, deadly; treat vitals symptomatically)
- **psychological effects of high doses**: depersonalization, derealization, paranoia, and anxiety (panic with agoraphobia)
- **tolerance develops rapidly** (hours-days) to most hallucinogens so physical dependency is virtually impossible, although psychological dependency and problematic usage patterns can still occur
- **no specific withdrawal syndrome characterized**
- **management of acute intoxication**
  - support, reassurance, diminished stimulation; benzodiazepines or high potency antipsychotics seldom required (if used, use small doses), minimize use of restraints
- **long term adverse effects**: controversial role in triggering psychiatric disorders, particularly mood or psychosis, thought to be chiefly in individuals with genetic or other risk factors

**Hallucinogen Persisting Perception Disorder**: DSM-5 diagnosis characterized by long lasting, spontaneous, intermittent recurrences of visual perceptual changes reminiscent of those experienced with hallucinogen exposure

**“Club Drugs”**

Table 6. The Mechanism and Effects of Common “Club Drugs”

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mechanism</th>
<th>Effect</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDMA (“Ecstasy”, “X”, “E”)</td>
<td>Acts on serotonergic and dopaminergic pathways, properties of a hallucinogen and stimulant</td>
<td>Enhanced sensorium; feelings of well-being, empathy</td>
<td>Sweating, tachycardia fatigue, muscle spasms (especially jaw clenching), ataxia, hyperthermia, arrhythmias, DIC, rhabdomyolysis, renal failure, seizures, death</td>
</tr>
<tr>
<td>Gamma Hydroxybutyrate (GHB, “G”, “Liquid Ecstasy”)</td>
<td>Biphasic dopamine response (inhibition then release) and releases opiate-like substance</td>
<td>Euphoric effects, increased aggression, impaired judgment</td>
<td>Sweating, tachycardia, fatigue, muscle spasms (especially jaw clenching), ataxia, severe withdrawal from abrupt cessation of high doses: tremor, seizures, psychosis</td>
</tr>
<tr>
<td>Flunitrazepam (Rohypnol®, “Roofties”, “Rope”, “The Forget Pill”)</td>
<td>Potent benzodiazepine, rapid oral absorption</td>
<td>Sedation, psychomotor impairment, amnestic effects, decreased sexual inhibition</td>
<td>CNS depression with EKG</td>
</tr>
<tr>
<td>Ketamine (“Special K”, “Kit-Kat”)</td>
<td>NMDA receptor antagonist, rapid-acting general anesthetic used in pediatrics and by veterinarians</td>
<td>“Dissociative” state, profound amnesia/analgesia; hallucinations and sympathomimetic effects</td>
<td>Psychological distress, accidents due to intensity of experience and lack of bodily control, in overdose, decreased LOC, respiratory depression, catatonia</td>
</tr>
<tr>
<td>Methamphetamine (“speed”, “meth”, “chalk”, “ice”, “crystal”)</td>
<td>Amphetamine stimulant, induces norpinephrine, dopamine, and serotonin release</td>
<td>Rush begins in min, effects last 6-8 h, increased activity, decreased appetite, general sense of well-being, tolerance occurs quickly, users often binge and crash</td>
<td>Short-term use: high agitation, rage, violent behaviour; occasionally hyperthermia and convulsions; Long-term use: addiction, anxiety, confusion, insomnia, paranoia, auditory and tactile hallucinations (especially formication), delusions, mood disturbance, suicidal and homicidal thoughts, stroke, may be contaminated with lead, and IV users may present with acute lead poisoning</td>
</tr>
<tr>
<td>Phencyclidine (“PCP”, “angel dust”)</td>
<td>Not understood, used by veterinarians to immobilize large animals</td>
<td>Amnestic, euphoric, hallucinatory state</td>
<td>Horizontal/vertical nystagmus, myoclonus, ataxia, autonomic instability (treat with diazepam IV), prolonged agitated psychosis (treat with haloperidol); high risk for suicide; violence towards others; High dose can cause coma</td>
</tr>
</tbody>
</table>

**Purpose**: To review the evidence for cannabis use and occurrence of psychotic or affective mental health outcomes.

**Results**: There was an increased risk of any psychotic outcome in individuals who had ever used cannabis (pooled adjusted odds ratio = 1.41, 95% CI 1.20-1.63). Findings were consistent with a dose-response effect, with greater risk in people who used cannabis more frequently (2.08, 95% CI 1.54-2.84). Findings for depression, suicidal thoughts, and anxiety outcomes were less consistent. In both cases (psychotic and affective outcomes), a substantial confounding effect was present.

**Conclusions**: The findings are consistent with the view that cannabis increases risk of psychotic outcomes independent of transient intoxication effects, although evidence is less strong for affective outcomes. Although cannabis use and the development of psychosis are strongly associated, it is difficult to determine causality and it is possible that the association results from confounding factors or bias. The authors did conclude that there is sufficient evidence to warn young people that using cannabis could increase their risk of developing a psychotic illness later in life.
Somatic Symptom and Related Disorders

General Characteristics
- Physical signs and symptoms lacking objective medical support in the presence of psychological factors that are judged to be important in the initiation, exacerbation, or maintenance of the disturbance
- Cause significant distress or impairment in functioning
- Symptoms are produced unconsciously and are not the result of malingering or factitious disorder, which are disorders of voluntary “faking” of symptoms (or intentionally inducing, e.g. injecting feces) for secondary gain
- Primary gain: somatic symptom represents a symbolic resolution of an unconscious psychological conflict; serves to reduce anxiety and conflict with no external incentive
- Secondary gain: the sick role; external benefits obtained or unpleasant duties avoided (e.g. work)

Management of Somatic Symptom and Related Disorders
- Brief, regular scheduled visits with GP to facilitate therapeutic relationship and help patient feel cared for
- Limit number of physicians involved in care, minimize medical investigations; coordinate necessary investigations
- Emphasis on what the patient can change and control; the psychosocial coping skills, not their physical symptoms (functional recovery > explanation of symptoms)
- Do not tell patient it is “all in their head,” emphasize these disorders are real entities or functional in nature
- Psychotherapy: CBT, mindfulness interventions, biofeedback, conflict resolution
- Minimize psychotropic drugs: anxiolytics in short-term only, antidepressants for comorbid depression and anxiety

Somatic Symptom Disorder

DSM-5 Diagnostic Criteria for Somatic Symptom Disorder
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013, American Psychiatric Association
A. One or more somatic symptoms that are distressing or result in significant disruption of daily life
B. Excessive thoughts, feelings, or behaviors related to the somatic symptoms or associated health concerns as manifested by at least one of the following
   1. Disproportionate and persistent thoughts about the seriousness of one's symptoms
   2. Persistently high level of anxiety about health or symptoms
   3. Excessive time and energy devoted to these symptoms or health concerns
C. Although any one somatic symptom may not be continuously present, the state of being symptomatic is persistent (typically >6 mo)
   - Specify: with predominant pain (previously pain disorder) for those whose somatic symptom is primarily pain
   - Patients have physical symptoms and believe these symptoms represent the manifestation of a serious illness
   - Persistent belief despite negative medical investigations and may develop different symptoms over time
   - Lifetime prevalence may be around 5-7% in the general adult population
   - Females tend to report more somatic symptoms than males do, cultural factors may influence sex ratio
   - Complications: anxiety and depression commonly comorbid (up to 80%), unnecessary medications or surgery
   - Often a misdiagnosis for an insidious illness so rule out all organic illnesses (e.g. multiple sclerosis)

Illness Anxiety Disorder
- Preoccupation with fear of having, or the idea that one has, a serious disease, to the point of causing significant impairment
- Convictions persist despite negative investigations and medical reassurance
- Somatic symptoms are mild or not present
- There is a high level of anxiety about health and the individual is easily alarmed about personal health status
- Person engages in maladaptive behavior such as excessive physical checking or total healthcare avoidance
- Duration is >6 mo; onset in 3rd-4th decade of life
- A new diagnostic entity so epidemiology is not well known; however, it is likely less common than SSD
- Possible role for SSRIs due to generally high level of anxiety
Conversion Disorder (Functional Neurological Symptom Disorder)

- one or more symptoms or deficits affecting voluntary motor or sensory function that mimic a neurological or GMC (e.g. impaired coordination, local paralysis, double vision, seizures, or convulsions)
- does not need to be preceded by a psychological event as per previous DSM criteria, however this is still worth exploring as many patients will present after such an event or related to a medical diagnosis in a first-degree relative
- 2-5/100,000 in general population; 5% of referrals to neurology clinics
- more common in rural populations and in individuals with little medical knowledge
- spontaneous remission in 95% of acute cases, 50% of chronic cases (>6 mo)
- incompatible findings detected from specific neurological testing can help differentiate between functional and neurological origin (e.g. Hoover’s sign, dermatome testing)

Table 7. Differential of Somatic Symptom and Related Disorders

<table>
<thead>
<tr>
<th></th>
<th>Somatic Symptom Disorder</th>
<th>Illness Anxiety Disorder</th>
<th>Conversion Disorder</th>
<th>Factitious Disorder</th>
<th>Malingering</th>
</tr>
</thead>
<tbody>
<tr>
<td>Somatic Symptoms</td>
<td>Present</td>
<td>Mild or absent</td>
<td>Neurologic, voluntary motor or sensory</td>
<td>Psychological or physical</td>
<td>Psychological or physical</td>
</tr>
<tr>
<td>Symptoms Produced</td>
<td>Unconsciously</td>
<td>Unconsciously</td>
<td>Unconsciously</td>
<td>Consciously</td>
<td>Consciously</td>
</tr>
<tr>
<td>Physical Findings</td>
<td>Absent</td>
<td>Absent</td>
<td>Incompatible</td>
<td>Possible, attempts to falsify</td>
<td>Possible, attempts to falsify</td>
</tr>
</tbody>
</table>

Dissociative Disorders

Definition

- severe dissociation resulting in breakdown of integrated functions of consciousness and perception of self
- differential diagnosis: PTSD, acute stress disorder, borderline personality disorder, somatic symptom disorder, substance abuse, GMC (various neurologic disorders including complex/partial seizures, migraine, Cotard syndrome)

Dissociative Identity Disorder

- disruption of identity characterized by two or more distinct personality states or an experience of possession
- can manifest as sudden alterations in sense of self and agency (ego-dystonic emotions, behaviours, speech)
- features recurrent episodes of amnesia (declarative or procedural)

Dissociative Amnesia

- inability to recall important autobiographical information, usually of a traumatic or stressful nature, that is inconsistent with normal forgetting and not attributable to a psychiatric disorder or medical illness
- localized/selective amnesia: failure to recall all/some events during a prescribed period of time
- generalized amnesia: (more rare) complete loss of memory for one’s life history, ± procedural knowledge, ± semantic knowledge. Usually sudden onset. Often presents with perplexity, disorientation, aimless wandering

Depersonalization/Derealization Disorder

- persistent or recurrent episodes of one or both of:
  - depersonalization: experiences of detachment from oneself, feelings of unreality, or being an outside observer to one’s thoughts, feelings, speech, and actions (can feature distortions in perception including time, as well as emotional and physical numbness)
  - derealization: experiences of unreality or detachment with respect to the surroundings (e.g. feeling as if in a dream, or that the world is not real, external visual world is foggy or distorted)
- transient (seconds-hours) experiences of this nature are quite common in the general population
- episodes can range from hours-years, patients are often quite distressed and verbalize concern of “going crazy”
Sleep Disorders

• for more information regarding normal sleep cycles and the illnesses described, see Neurology, Sleep Disorders, N46

Overview
• adequate sleep is essential to normal functioning; deprivation can lead to cognitive impairment and increased mortality
• circadian rhythms help regulate mood and cognitive performance
• neurotransmitters commonly implicated in psychiatric illnesses also regulate sleep
  ▪ acetylcholine activity and decreased activity of monoamine neurotransmitters is associated with greater REM sleep
  ▪ decreased adrenergic and cholinergic activity are associated with NREM sleep
• depression is associated with decreased Δ (deep, slow-wave) sleep, decreased REM latency, and increased REM density
  ▪ criteria
    ▪ must cause significant distress or impairment in normal functioning
    ▪ not due to a GMC or medications/drugs (unless specified)

Management
• pharmacological treatments are illness-specific
  ▪ non-benzodiazepines preferable (e.g. trazodone, zolpidem, quetiapine), but benzodiazepines a short term option
  ▪ medication should not be prescribed without having first made a diagnosis and considering major psychiatric illnesses (major depression and alcohol use disorders are common etiologies)
• sleep hygiene is a simple, effective, but often underutilized method for addressing sleep disturbances; recommendations include
  ▪ waking up and going to bed at the same time every day, including on weekends
  ▪ avoiding long periods of wakefulness in bed
  ▪ not using bed for non-sleep activities (reading, TV, work)
  ▪ avoiding napping
  ▪ discontinuing or reducing consumption of alcohol, caffeine, drugs
  ▪ exercising at least 3–4x per week (but not in the evening, if this interferes with sleep)

Table 8. Major DSM-5 Sleep-Wake Disorders
Note: For more information regarding specific disorders, see Neurology, Sleep Disorder, N46; Family Medicine, Sleep Disorders, FM45; and Respirology, Sleep Apnea, R31

<table>
<thead>
<tr>
<th>Category</th>
<th>Disorder</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Uncategorized)</td>
<td>Insomnia disorder</td>
<td>Difficulty sleeping</td>
</tr>
<tr>
<td></td>
<td>Hypersomnia disorder</td>
<td>Feeling sleepy throughout the day</td>
</tr>
<tr>
<td></td>
<td>Narcolepsy</td>
<td>Recurrent attacks of irresistible need to sleep</td>
</tr>
<tr>
<td></td>
<td>Circadian rhythm sleep-wake disorders</td>
<td>Insomnia or excessive sleepiness due to misalignment or alteration in endogenous circadian rhythm</td>
</tr>
<tr>
<td></td>
<td>Restless legs syndrome</td>
<td>Uncomfortable, frequent urge to move legs at night</td>
</tr>
<tr>
<td>Substance/medication-induced sleep disorder</td>
<td>Disturbance in sleep (insomnia or daytime sleepiness) caused by substance/medication intoxication or withdrawal</td>
<td></td>
</tr>
<tr>
<td>Breathing-related sleep disorders</td>
<td>Obstructive sleep apnea hypopnea</td>
<td>Breathing issues due to obstruction</td>
</tr>
<tr>
<td></td>
<td>Central sleep apnea</td>
<td>Breathing issues due to aberrant brain signaling</td>
</tr>
<tr>
<td></td>
<td>Sleep-related hypoventilation</td>
<td>Breathing issues due to decreased responsiveness to carbon dioxide levels</td>
</tr>
<tr>
<td>Parasomnias</td>
<td>Non-rapid eye movement sleep arousal disorders</td>
<td>Incomplete awakening from sleep, complex motor behaviour without conscious awareness; amnesia regarding episodes; includes symptoms of Sleepwalking: rising from bed and walking about, blank face, unresponsive, awakened with difficulty</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sleep terrors: recurrent episodes of abrupt terror arousals from sleep, usually beginning with a panicky scream, intense fear and autonomic arousal, relative unresponsiveness to comfort during episodes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Specifiers: sleep-related sexual behaviour (sexsomnia) and sleep-related eating</td>
</tr>
<tr>
<td></td>
<td>Nightmare disorder</td>
<td>Repeated extended, extremely dysphoric, often very vivid, well-remembered dreams that usually involve significant threats; rapid orientation and alertness on awakening with autonomic arousal</td>
</tr>
<tr>
<td></td>
<td>Rapid eye movement sleep behaviour disorder</td>
<td>Arousal during sleep, associated with vocalization and/or complex motor behaviours; can cause violent injuries; rapid orientation and alertness on awakening</td>
</tr>
</tbody>
</table>
Sexuality and Gender

Gender Dysphoria

Definition
• the distress that may coincide with conflict between one's experienced/expressed gender and one's assigned gender

Typical Presentation
• strong and persistent cross-gender identification
• desire to be rid of primary/secondary sex characteristics and to gain the primary/secondary sex characteristics of their identified gender
• repeated stated desire or insistence that one is of the opposite sex
• preference for cross-dressing, cross-gender roles in make-believe play
• intense desire to participate in the stereotypical games and pastimes of the opposite sex
• strong preference for playmates of the opposite sex
• significant distress or impairment in functioning and persistent discomfort with his or her sex or gender role

Treatment
• psychotherapy
• hormonal therapy
• sexual reassignment surgery

Paraphilic Disorders

Definition
• intense and persistent sexual interest other than sexual interest in genital stimulation or preparatory fondling with phenotypically normal, physically mature, consenting human partners
• paraphilic disorder: paraphilia that causes distress or functional impairment to the individual, or a paraphilia whose realization entails personal harm, or risk of harm to others
• subtypes: voyeuristic, exhibitionistic, frotteuristic, sexual masochism, sexual sadism, pedophilic, fetishistic, transvestic, other specified paraphilic disorder, unspecified paraphilic disorder
• rarely self-referred; come to medical attention through interpersonal or legal conflict
• person usually has more than one paraphilia; 5% of paraphilias attributed to women
• typical presentation
• begins in childhood or early adolescence; increasing in complexity and stability with age
• chronic, decreases with advancing age but may increase with stress

Treatment
• anti-androgen drugs
• behaviour modification
• psychotherapy

SEXUAL DYSFUNCTION
• see Gynecology, GY33 and Urology, U34

Eating Disorders

Epidemiology
• anorexia nervosa (AN): 1% of adolescent and young adult females; onset 13-20 yr old
• bulimia nervosa (BN): 2-4% of adolescent and young adult females; onset 16-18 yr old
• F:M=10:1; mortality 5-10%

Etiology
• multifactorial: psychological, sociological, and biological associations
• individual: perfectionism, lack of control in other life areas, history of sexual abuse
• personality: obsessive-compulsive, histrionic, borderline
• familial: maintenance of weight equilibrium and control in dysfunctional family
• cultural factors: prevalent in industrialized societies, idealization of thinness in the media
• genetic factors
  • AN: 6% prevalence in siblings, with one study of twin pairs finding concordance in 9 of 12 monozygotic pairs versus concordance in 1 of 14 dizygotic pairs
  • BN: higher familial incidence of affective disorders than the general population
Risk Factors
- physical factors: obesity, chronic medical illness (e.g. DM)
- psychological factors: individuals who by career choice are expected to be thin, family history (mood disorders, eating disorders, substance abuse), history of sexual abuse (especially for BN), homosexual males, competitive athletes, concurrent associated mental illness (depression, OCD, anxiety disorder [especially panic and agoraphobia], substance abuse [specifically for BN])

Anorexia Nervosa

DSM-5 Diagnostic Criteria for Anorexia Nervosa
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013. American Psychiatric Association
A. intake and weight: restriction of energy intake relative to requirements, leading to a significantly low body weight in the context of age, sex, developmental trajectory, and physical health. Significantly low weight is defined as a weight that is less than minimally normal or, for children and adolescents, less than that minimally expected
B. fear or behaviour: intense fear of gaining weight or of becoming fat, or persistent behaviour that interferes with weight gain, even though at a significantly low weight
C. perception: disturbance in the way in which one's body weight or shape is experienced, undue influence of body weight or shape on self-evaluation, or persistent lack of recognition of the seriousness of the current low body weight
- specifiers: partial remission, full remission, severity based on BMI (mild = BMI >17 kg/m², moderate = BMI 16-16.99 kg/m², severe = BMI 15-15.99 kg/m², extreme = BMI <15 kg/m²), type (restricting = during last 3 mo no episodes of binge-eating or purging vs. binge-eating/purging type = in last 3 mo have participated in recurrent episodes of binge-eating/purging)

Management
- psychotherapy; individual, group, family (gold standard); address food and body perception, coping mechanisms, health effects
- medications of little value
- outpatient and inpatient programs are available
- inpatient hospitalization for treatment of eating disorders is rarely on an acute basis (unless there is a concurrent psychiatric reason for emergent admission e.g. suicide risk)
- criteria to admit to medical ward for hospitalization: <65% of standard body weight (<85% of standard body weight for adolescents), hypovolemia requiring intravenous fluid, heart rate <40 bpm, abnormal serum chemistry, or if actively suicidal
- agree on target body weight on admission and reassure this weight will not be surpassed
- monitor for complications of AN (see Table 9, PS33)
- monitor for refeeding syndrome
- potentially life-threatening metabolic response to refeeding in severely malnourished patients resulting in severe shifts in fluid and electrolyte levels
- complications include hypophosphatemia, congestive heart failure, cardiac arrhythmias, delirium, and death
- prevention: slow refeeding, gradual increase in nutrition, supplemental phosphorus, and close monitoring of electrolytes and cardiac status

Prognosis
- early intervention much more effective (adolescent onset has much better prognosis than adult onset)
- 1 in 10 adolescents continue to have anorexia nervosa as adults
- with treatment, 70% resume a weight of at least 85% of expected levels and about 50% resume normal menstrual function
- eating peculiarities and associated psychiatric symptoms are common and persistent
- long-term mortality: 10-20% of patients hospitalized will die in next 10-30 yr (secondary to severe and chronic starvation, metabolic or cardiac catastrophes, with a significant proportion committing suicide)

Bulimia Nervosa

DSM-5 Diagnostic Criteria for Bulimia Nervosa
Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013. American Psychiatric Association
A. recurrent episodes of binge-eating: an episode of binge-eating is characterized by both of the following
- eating, in a discrete period of time, an amount of food that is definitely larger than what most individuals would eat during a similar period of time and under similar circumstances
- a sense of lack of control over eating during the episode
B. recurrent inappropriate compensatory behaviour in order to prevent weight gain, such as self-induced vomiting, misuse of laxatives, diuretics, enemas, or other medications, fasting, or excessive exercise
C. the binge-eating and inappropriate compensatory behaviours both occur, on average, at least once a week for 3 mo
D. self-evaluation is unduly influenced by body shape and weight
E. the disturbance does not occur exclusively during episodes of AN
- specifiers: partial remission, full remission, severity (measured in # of inappropriate compensatory behaviours/wk: mild = 1-3, moderate = 4-7, severe = 8-13, extreme = 14+)
**Associated Features**
- fatigue and muscle weakness due to repetitive vomiting and fluid/electrolyte imbalance
- tooth decay
- swollen appearance around angle of jaw and puffiness of eye sockets due to fluid retention
- reddened knuckles, Russell's sign (knuckle callus from self-induced vomiting)
- trouble concentrating
- weight fluctuation over time

**Management**
- admission for significant electrolyte abnormalities
- biological: treatment of starvation effects, SSRIs (fluoxetine most evidence) as adjunct
- psychological: develop trusting relationship with therapist to explore personal etiology and triggers, CBT, family therapy, recognition of health risks
- social: challenge destructive societal views of women, use of hospital environment to provide external patterning for normative eating behaviour

**Prognosis**
- relapsing/remitting disease
- good prognostic factors: onset before age 15, achieving a healthy weight within 2 yr of treatment
- poor prognostic factors: later age of onset, previous hospitalizations, individual and familial disturbance
- 60% good treatment outcome, 30% intermediate outcome, 10% poor outcome

---

**Binge-Eating Disorder**

**Definition**
- recurrent episodes of binge-eating (as defined by criteria A of BN) that are associated with eating much more rapidly than normal, eating until feeling uncomfortably full, eating large amounts when not physically hungry, eating alone because embarrassed by how much one is eating, feeling disgusted with self/depressed, very guilty afterwards at least once/wk x 3 mo
- not associated with any compensatory behaviours
- dieting usually follows binge-eating (vs. BN where dysfunctional dieting typically precedes binge-eating)
- associated with health consequences (e.g. increased risk of weight gain, obesity)

**Epidemiology**
- F:M = 2:1
- begins in adolescence or young-adulthood

**Treatment**
- CBT

---

**Avoidant/Restrictive Food Intake Disorder**

**Definition**
- eating/feeding disturbance to the extent of persistent failure to meet appropriate nutritional and/or energy needs, resulting in significant weight loss/growth failure and nutritional deficiencies. Patients experience disturbances in psychosocial functioning and may become dependent on enteral feeding/oral nutritional supplementation
  - does not occur during an episode of AN or BN
  - no evidence of distress in the way in which one's body weight or shape is experienced

**Risk Factors**
- temperament (e.g. anxiety disorders), environment (e.g. familial anxiety), genetic (e.g. history of GI conditions)
- begins in infancy and can persist into adulthood

**Treatment**
- watchful waiting
- behaviour modification
- psychotherapy

---

**Points for Differentiating Between Eating Disorders**
- AN of binge-eating/purging type (significantly low body weight) takes priority over a BN diagnosis (body weight not in criteria)
- BN requires compensatory behaviours
- Binge eating disorder does not involve compensatory behaviours
- Avoidant/restrictive food intake disorder does not involve disturbances in body image
Personality Disorders

- in the literature, personality and its disorders are better understood using a trait-based dimensional approach (e.g. 5 major traits such as extraversion, agreeableness, conscientiousness, neuroticism, and openness to experiences rated on a continuum of dysfunctional effects) rather than discrete categories; however, the discrete categories still remain in the current DSM and will be referenced here

General Information
- an enduring pattern of inner experience and behaviour that deviates markedly from the expectations of the individual's culture; manifested in two or more of: cognition, affect, interpersonal functioning, inflexible and pervasive across a range of situations
- pattern is stable and well established by adolescence or early adulthood (vs. a sudden onset)
- associated with many complications, such as depression, suicide, violence, brief psychotic episodes, multiple drug use, and treatment resistance
- relationship building and establishing boundaries are important; focus should be placed on validating, finding things to be truly empathetic about, and speaking to the patient's strengths
- mainstay of treatment is psychotherapy, add pharmacotherapy to treat associated axis I disorders (i.e. depression, anxiety, substance abuse)

Classification
- personality disorders are divided into three clusters (A, B, and C), with shared features among disorders within each

Table 9. Physiologic Complications of Eating Disorders

<table>
<thead>
<tr>
<th>System</th>
<th>Starvation/Restriction</th>
<th>Binge-Purge</th>
</tr>
</thead>
<tbody>
<tr>
<td>General</td>
<td>Low BP, low HR, significant orthostatic changes ± syncopal episodes, low temperature, vitamin deficiencies</td>
<td>Russell's sign (knuckle callus)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Parotid gland enlargement</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Perioral and palatal petechiae</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Loss of dental enamel and caries</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aspiration pneumonia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Metabolic alkalosis secondary to hypokalemia and loss of acid</td>
</tr>
<tr>
<td>Endocrine</td>
<td>Primary or secondary amenorrhea, decreased T/Tr</td>
<td></td>
</tr>
<tr>
<td>Neurologic</td>
<td>Seizure (decreased Ca²⁺, Mg²⁺, PO₄³⁻)</td>
<td></td>
</tr>
<tr>
<td>Cutaneous</td>
<td>Dry skin, lanugo hair, hair loss or thinning, brittle nails, yellow skin from high carotene</td>
<td></td>
</tr>
<tr>
<td>GI</td>
<td>Constipation, GERD, delayed gastric emptying</td>
<td>Acute gastric dilation/rupture, pancreatitis, GERD, hematemesis secondary to Mallory-Weiss tear</td>
</tr>
<tr>
<td>CVS</td>
<td>Arrhythmias, CHF</td>
<td>Arrhythmias, cardiomyopathy (from use of ipecac), sudden cardiac death (decreased K⁺)</td>
</tr>
<tr>
<td>MSK</td>
<td>Osteoporosis secondary to hypogonadism</td>
<td>Muscle wasting</td>
</tr>
<tr>
<td>Renal</td>
<td>Pre-renal failure (hypovolemia), renal calculi</td>
<td>Renal failure (electrolyte disturbances)</td>
</tr>
<tr>
<td>Extremities</td>
<td>Pedal edema (decreased albumin)</td>
<td>Pedal edema (decreased albumin)</td>
</tr>
<tr>
<td>Lab Values</td>
<td>Starvation: decreased RBCs, decreased WBCs, decreased LH, decreased FSH, decreased estrogen, decreased testosterone, increased growth hormone, increased cholesterol Dehydration: increased BUN</td>
<td>Vomiting: decreased Na⁺, decreased K⁺, decreased Cl⁻, decreased H⁺, increased amylase; hypokalemia with metabolic alkalosis Laxatives: decreased Na⁺, decreased K⁺, decreased Cl⁻, increased H⁺; metabolic acidosis</td>
</tr>
</tbody>
</table>

Important electrolytes in eating disorders: K, Mg, P, Mg²⁺, Ca²⁺, PO₄³⁻, Cl⁻, H⁺, H₂O

Personality disorders with familial associations: Schizotypal, Antisocial, and Borderline

A flag for personality disorders in clinical setting is the reaction that a patient is eliciting in you
### Table 10. Description and Diagnosis of Personality Disorders

#### Cluster A “Mad” Personality Disorders
- **Diagnosis requires 4 of:**
  1. Suspicions that others are exploiting or deceiving them
  2. Unforgiving (bears grudges)
  3. Spousal infidelity suspected without justification
  4. Perceive attacks on character, counterattacks quickly
  5. Enemies or friends? Preoccupied with acquaintance trustworthiness
  6. Confiding in others is feared
  7. Threats interpreted in benign remarks

#### Paranoid Personality Disorder (0.5-3%)
- Pervasive distrust and suspiciousness of others, interpret motives as malevolent
- Blame problems on others and seem angry and hostile
- Diagnosis requires 4 of: **SUSPECT**
  1. Detached/flat affect, emotionally cold
  2. Indifference to praise or criticism
  3. Sexual experiences of little interest
  4. Tasks done solitarily
  5. Absence of close friends (other than first-degree relatives)
  6. child desires nor enjoys close relationships (including family)
  7. Takes pleasure in few (if any) activities

#### Schizoid Personality Disorder
- Neither desires nor enjoys close relationships including being a part of a family; prefers to be alone
- Lifelong pattern of social withdrawal
- Seen as eccentric and reclusive with restricted affect
- Diagnosis requires 4 of: **DISTANT**
  1. Detached/flat affect, emotionally cold
  2. Indifferent to praise or criticism
  3. Sexual experiences of little interest
  4. Tasks done solitarily
  5. Absence of close friends (other than first-degree relatives)
  6. child desires nor enjoys close relationships (including family)
  7. Takes pleasure in few (if any) activities

#### Cluster B “Bad” Personality Disorders
- **Diagnosis requires 3+ of:**
  1. Sense of superiority, needs constant admiration, lacks empathy, but with fragile sense of self. Consider themselves “special” and will exploit others for personal gain
  2. Requires excessive admiration
  3. Arrogant
  4. Needs to be special (and associate with other specials)
  5. Dreams of success, power, beauty, love
  6. Interpersonally exploitative
  7. Others (lacks empathy, unable to recognize feelings/needs of)
  8. Sense of entitlement
  9. Envious (or believes others are envious)

#### Borderline Personality Disorder (2-4%)
- Unstable moods and behaviour, feel alone in the world, problems with self-image. History of repeated suicide attempts, self-harm behaviours. Inpatients commonly report history of sexual abuse. Tends to fizzle out as patients age. DBT is the principal treatment *(see Psychotherapy, PS40)*
- *10% suicide rate*
- Diagnosis requires 5+ of: **IMPULSIVE**
  1. Impulsive (min. 2 self-damaging ways, e.g. sex/drugs/spending)
  2. Mood/affect instability
  3. Paranoia or dissociation under stress
  4. Unstable self-image
  5. Labile intense relationships
  6. Suicidal gestures / self-harm
  7. Inappropriate anger
  8. Avoiding abandonment (real or imagined, frantic efforts to)
  9. Impatience (feelings of)

#### Antisocial Personality Disorder (M: 3%, F: 1%)
- Lack of remorse for actions, manipulative and deceitful, often violate the law. May appear charming on first impression. Pattern of disregard for others and violation of others’ rights must be present before age 15; however, for the diagnosis of ASPD patients must be at least 18. Strong association with Conduct Disorder, history of trauma/abuse common *(see Child Psychiatry)*
- Diagnosis requires 5+ of: **CORRUPT**
  1. Cannot conform to law
  2. Obligations ignored (irresponsible)
  3. Reckless disregard for safety
  4. Remorseless
  5. Underhanded (deceitful)
  6. Planning insufficient (impulsive)
  7. Temper (irritable and aggressive)

#### Narcissistic Personality Disorder (2%)
- Sense of superiority, needs constant admiration, lacks empathy, but with fragile sense of self. Consider themselves “special” and will exploit others for personal gain
- Diagnosis requires 5+ of: **GRANDIOSE**
  1. Brandiose
  2. Requires excessive admiration
  3. Arrogant
  4. Needs to be special (and associate with other specials)
  5. Dreams of success, power, beauty, love
  6. Interpersonally exploitative
  7. Others (lacks empathy, unable to recognize feelings/needs of)
  8. Sense of entitlement
  9. Envious (or believes others are envious)

#### Histrionic Personality Disorder (1.3-3%)
- Attention-seeking behaviour and excessively emotional. Are dramatic, flamboyant, and extroverted. Cannot form meaningful relationships. Often sexually inappropriate
- Diagnosis requires 5+ of: **ACTRESSS**
  1. Appearance used to attract attention
  2. Centre of attention (else uncomfortable)
  3. Theatrical
  4. Relationships (believed to be more intimate than they are)
  5. Easily influenced
  6. Seductive behaviour
  7. Shallow expression of emotions (which rapidly shift)
  8. Speech (impressionistic and vague)
Table 10. Description and Diagnosis of Personality Disorders (continued)

<table>
<thead>
<tr>
<th>Cluster C “Sad”</th>
<th>Obsessive-Compulsive Personality Disorder (3-10%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avoidant Personality Disorder (0.5-1.6%)</td>
<td>Preoccupation with orderliness, perfectionism, and mental and interpersonal control. Is inflexible, closed-off, and inefficient. Diagnosis requires 4 + of: SCRIMPER</td>
</tr>
<tr>
<td>Timid and socially awkward with a pervasive sense of inadequacy and fear of criticism. Fear of embarrassing or humiliating themselves in social situations so remain withdrawn and socially inhibited. Diagnosis requires 4 + of: CRINES</td>
<td></td>
</tr>
<tr>
<td>1. Criticism or rejection preoccupies thoughts in social situations</td>
<td></td>
</tr>
<tr>
<td>2. Restraint in relationships due to fear of being shamed</td>
<td></td>
</tr>
<tr>
<td>3. Inhibited in new relationships due to fear of inadequacy</td>
<td></td>
</tr>
<tr>
<td>4. Needs to be sure of being liked before engaging socially</td>
<td></td>
</tr>
<tr>
<td>5. Gets around occupational activities requiring interpersonal contact</td>
<td></td>
</tr>
<tr>
<td>6. Embarrassment prevents new activity or taking risks</td>
<td></td>
</tr>
<tr>
<td>7. Self-viewed as unappealing or inferior</td>
<td></td>
</tr>
</tbody>
</table>

| Dependent Personality Disorder (1.6-6.7%) | |
| Pervasive and excessive need to be taken care of, excessive fear of separation, clinging and submissive behaviours. Difficulty making everyday decisions. Useful to set regulated treatment schedule (regular, brief visits) and being firm about in between issues. Encourage patient to do more for themselves, engage in own problem-solving |
| Diagnosis requires 5 of: RELIANCE |
| 1. Reassurance required for everyday decisions |
| 2. Expressing disagreement difficult |
| 3. Life responsibilities assumed by others |
| 4. Initiating projects difficult (because no confidence) |
| 5. Alone feels helpless and uncomfortable when alone |
| 6. Nurture goes to excessive lengths to obtain |
| 7. Companionship sought urgently |
| 8. Exaggerated fears of being left to care for self |

Table 11. Key Differences Among Schizoid, Schizotypal, and Schizophrenia

<table>
<thead>
<tr>
<th>Schizoid</th>
<th>Schizotypal</th>
<th>Schizophrenia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thought Form</td>
<td>Organized</td>
<td>Organized, but vague and circumstantial</td>
</tr>
<tr>
<td>Thought Content</td>
<td>No psychosis</td>
<td>No psychosis, may have ideas of reference, paranoid ideation, odd beliefs and magical thinking</td>
</tr>
<tr>
<td>Relationships</td>
<td>Solitary, NO desire for social relationships</td>
<td>Lacks close relationships, INTERESTED in relationships but socially inept</td>
</tr>
</tbody>
</table>

Child Psychiatry

Developmental Concepts

- **temperament**: a child’s innate psycho-physiological and behavioural characteristics (e.g. emotionality, activity, and sociability); spectrum from "difficult" to "slow-to-warm-up" to "easy temperament"
- **parental fit**: the congruence between parenting style (authoritative, permissive) and child’s temperament
- **attachment**: special relationship between child and primary caretaker(s); develops during first year, the caretaker’s attachment style is the best predictor of their child’s attachment style, refer to Table 12
- **separation anxiety** (normal between 10-18 mo): where separation from attachment figure results in distress

Table 12. Attachment Models

<table>
<thead>
<tr>
<th>Parent/Caregiver</th>
<th>Attachment Type</th>
<th>Features in Child</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loving, consistently available, sensitive, and receptive</td>
<td>Secure</td>
<td>Freely explores and engages strangers well (as long as mother in close proximity), upset with caregiver’s departure, happy with return</td>
</tr>
<tr>
<td>Rejection, unavailable psychologically, insensitive responses</td>
<td>Insecure (avoidant)</td>
<td>Ignores caregiver, shows little emotion with arrival or departure, little exploration</td>
</tr>
<tr>
<td>Inconsistent, insensitive responses, role reversal</td>
<td>Insecure (ambivalent/resistant)</td>
<td>Clingy but inconsolable, often displays anger or helplessness, little exploration</td>
</tr>
<tr>
<td>Frightening, dissociated, sexualized, or atypical</td>
<td>Disorganized</td>
<td>Simultaneous approach/avoidance and stress related straining behaviour</td>
</tr>
</tbody>
</table>

Tips for the Child Interview

- Use language the child will understand (i.e. don’t ask about feeling of worthlessness, ask about whether they feel like they’re a bad kid)
- Children in some cultures are taught to be quiet and avoid eye contact with adults who are authority figures (do not mistake with depression)
- Use developmentally-appropriate questions (i.e. don’t ask about lack of interest in activities, ask children whether they feel bored)
MAJOR DEPRESSIVE DISORDER

Epidemiology
- pre-pubertal 1-2% (no gender differences); post-pubertal 4-18% (F:M = 2:1)

Clinical Presentation
- see Mood Disorders, PS9
  - only difference in diagnostic criteria is that irritable mood may replace depressed mood
  - physical factors: insomnia (children), hypersomnia (adolescents), somatic complaints, substance abuse, decreased hygiene
  - psychological factors: irritability, boredom, anhedonia, low self-esteem, deterioration in academic performance, social withdrawal, lack of motivation, listlessness
  - comorbid diagnoses: anxiety, ADHD, ODD, conduct disorder, and eating disorders

Treatment
- majority never seek treatment
- individual (CBT, IPT)/family therapy and education, modified school program
- SSRIs (strongest evidence for fluoxetine)
- close follow-up for adolescents starting SSRIs to monitor for increased suicidal ideation or behaviour
- in severe depression, best evidence for combined pharmacotherapy and psychotherapy
- ECT: only in adolescents who have severe illness, psychotic features, catatonic features, persistently suicidal
  - light therapy, self-help books

Prognosis
- prolonged episodes, up to 1-2 yr
- adolescent onset predicts chronic mood disorder; up to 2/3 will have another depressive episode within 5 yr
- complications: negative impact on family and peer relationships, school failure, significantly increased risk of suicide attempt (10%) or completion (however, suicide risk low for pre-pubertal children), substance abuse

DISRUPTIVE MOOD DYSREGULATION DISORDER

Clinical Presentation
- severe, developmentally inappropriate, recurrent verbal or behavioural temper outbursts at least 3x per wk
- mood is predominantly irritable or angry in between outbursts, as observable by others
- these symptoms occur before 10 yr, have been occurring for 12 mo, with no more than 3 consecutive mo free from symptoms
- high rates of comorbidities; ADHD, ODD, anxiety disorders, depressive disorders

BIPOLAR DISORDER

Clinical Presentation
- see Bipolar Disorder, PS12
- mixed presentation and psychotic symptoms (hallucinations and delusions) more common in adolescent population than adult population
- unipolar depression may be an early sign of adult bipolar disorder
- ~30% of psychotic depressed adolescents receive a bipolar diagnosis within 2 yr of presentation
- associated with rapid onset of depression, psychomotor retardation, mood-congruent psychosis, affective illness in family, pharmacologically-induced mania

Treatment
- pharmacotherapy: mood stabilizers and/or antipsychotics
- psychotherapy: CBT, Family Focused Therapy

Anxiety Disorders

- lifetime prevalence 10-20%; F:M = 2:1

Clinical Presentation
- children and adolescents rarely vocalize their anxiety but instead exhibit behavioural manifestations
- school problems, recurrent physical symptoms (abdominal pain, headaches) especially in mornings, social and relationship problems, social withdrawal and isolation, family conflict, difficulty with sleep initiation, temper tantrums, irritability and mood symptoms, alcohol and drug use in adolescent

Differential Diagnosis
- depressive disorders, ODD, truancy
- clinical judgment important to differentiate developmentally normal from pathological anxiety
- for school avoidance, differentiate fear of general performance and humiliation. Consider anxiety about separation, and rule out bullying and school refusal due to learning disorder
Course and Prognosis
• better prognosis with later age of onset, lower co-morbidities, early initiation of treatment, ability to maintain school attendance and peer relationships, absence of social anxiety disorder
• with treatment, up to 80% of children will not meet criteria for their anxiety disorder at 3 yr follow-up, but up to 30% will meet criteria for another psychiatric disorder

Treatment
• similar principles for most childhood anxiety disorders due to overlapping symptomatology and frequent comorbidity
• family psychotherapy, predictive and supportive environment
• CBT: child and parental education, relaxation techniques (e.g. deep breathing), exposure/desensitization, recognizing and correcting anxious thoughts
• pharmacotherapy: SSRIs (e.g. fluoxetine), benzodiazepines (alprazolam, clonazepam have evidence – use with caution due to addictive and abuse potential as well as disinhibiting effect, especially in neurodevelopmental delay)
  • fluvoxamine and sertraline also have good evidence, particularly for OCD

SEPARATION ANXIETY DISORDER
• excessive and developmentally inappropriate anxiety on real, threatened, or imagined separation from primary caregiver or home, with physical or emotional distress for at least 4 wk (e.g. worries of something happening to parent or themselves if separated)
• school refusal (75%) and comorbid major depression common (2/3)
• persistent worry, refusal to sleep alone, clinging, nightmares involving separation, somatic symptoms

SOCIAL ANXIETY DISORDER (SOCIAL PHOBIA)
• anxiety, fear, and/or avoidance provoked by situations where child feels under the scrutiny of others
• must distinguish between shy child, child with issues functioning socially (e.g. autism), and child with social anxiety
  • diagnosis only if anxiety interferes significantly with routine, social, academic functioning, or if markedly distressed. Must occur in settings with peers, not just adults
• features: temper tantrums, freezing, clinging behaviour, mutism, excessively timid, stays on periphery, refuses to be involved in group play
• significant implication for future quality of life if untreated; lower levels of satisfaction in leisure activities, higher rates of school dropout, poor workplace performance, increased rates of remaining single

SELECTIVE MUTISM
• consistent failure to speak in specific social situations where speaking is expected, despite speaking in other situations
• the disturbance interferes with educational or occupational achievement or with social communication

GENERALIZED ANXIETY DISORDER
• diagnostic criteria same as adults (see Generalized Anxiety Disorder, PS15)
  • note: only 1 item is required in children for Criteria C
• often redo tasks, show dissatisfaction with their work, and tend to be perfectionistic
• often fearful in multiple settings and expect more negative outcomes when faced with academic or social challenges, and require reassurance and support to take on new tasks

SPECIFIC PHOBIA
• common phobias in childhood: fear of heights, small animals, doctors, dentists, darkness, loud noises, thunder, and lightning

Neurodevelopmental Disorders

Autism Spectrum Disorder

Diagnosis
• persistent deficits in social communication and interaction, manifested in three areas
  • social-emotional reciprocity: ranging, for example, from abnormal social approach and failure of normal back-and-forth conversation, to reduced sharing of interests, emotions, or affect, to failure to initiate or respond to social interactions
  • nonverbal communicative behaviours: ranging, for example, from poorly integrated verbal and nonverbal communication, to abnormalities in eye contact and body language or deficits in understanding and use of gestures, to a total lack of facial expressions and nonverbal communication
  • developing, maintaining, and understanding relationships: ranging, for example, from difficulties adjusting behaviour to suit various social contexts, to difficulties in sharing imaginative play or in making friends, to absence of interest in peers
• restricted, repetitive patterns of behaviour, interests, or activities. Two or more of: stereotyped or repetitive motor movements, insistence on sameness, highly restricted fixated interests, hyper-/hypo-reactivity to sensory input

Fluoxetine, Cognitive-Behavioural Therapy and Their Combination for Adolescents with Depression: Treatment for Adolescents with Depression Study (TADS): Randomized Controlled Trial
JAMA. 2004;292:807-820
Study: Randomized controlled trial at 13 US academic and community clinics between spring 2000-summer 2003.
Patients: 439 patients ages 12-17 with a primary DSM-IV diagnosis of major depressive disorder.
Outcomes: Children’s Depression Rating Scale-Revised (CDRSR) total score.
Interventions: 12 wk of (1) fluoxetine (10-40 mg/d), (2) CBT, (3) CBT + fluoxetine (10-40 mg/d), or (4) placebo.
Results: Fluoxetine with CBT had a statistically significant CDRSR score as compared to placebo (p=0.001) with a 71% response rate. This combination was greater than fluoxetine alone (p=0.02), and CBT alone (p=0.01). Fluoxetine alone was greater than CBT alone (p=0.01).

Neurodevelopmental Disorders Toronto Notes 2017
PS37 Psychiatry

Attachment type can be assessed in infants 10-18 mo of age using the Strange Situation test, in which the child is stressed by the caregiver being removed from the situation and the stranger staying. Attachment style is measured by the child’s behaviour during the reunion with the caregiver.

Fluoxetine treatment problems may present as a child who is difficult to soothe, has difficulty sleeping, problems feeding, tantrums, or behavioural problems.

The shy child is quiet and reluctant to participate but slowly ‘warms up’.
Neurodevelopmental Disorders

- symptoms must be present in early developmental period
- symptoms cause clinically significant impairment in social, occupational, or other important areas of current functioning
- not better explained by intellectual disability or global developmental delay
- specifiers
  - current severity: requiring very substantial support, requiring substantial support, requiring support
  - ± language impairment, ± intellectual impairment
  - associated with known medical or genetic condition or environmental factors (i.e. Rett’s disorder)

Differential Diagnosis
- developmental disability, childhood schizophrenia, social phobia, OCD, communication disorder, non-verbal learning disorder, ADHD, abuse, hearing or visual impairment, seizure disorder, motor impairment

Management
- hearing and vision test to rule out impairment
- psychological testing to assess intellectual functioning and learning
- chromosomal analysis to rule out abnormalities (e.g. Trisomy 21, Fragile X syndrome)
- rule out psychotic disorders, social problems, depression, anxiety, abuse

Treatment
- team-based: school, psychologist, occupational therapist, physiotherapist, speech and language therapy, pediatrics, psychiatry
- psychosocial: family education and support, school programming, behaviour management, social skills training
- treat concomitant disorders such as ADHD, tics, OCD, anxiety, depression, and seizure disorder
- pharmacotherapy: atypical antipsychotics (for irritability, aggression, agitation, self-mutilation, tics), SSRIs (for anxiety, depression), stimulants (for associated inattention and hyperactivity)

Prognosis
- variable, but improves with early intervention
- better if IQ >60 and able to communicate

Attention Deficit Hyperactivity Disorder

- prevalence: 5-12% of school-aged children; M:F = 4:1, although girls may be under-diagnosed
- girls tend to have inattentive/distractable symptoms; boys have impulsive/hyperactive symptoms

Etiology
- genetic: 75% heritability, dopamine candidate genes DAT1, DRD4
- neurobiology: decreased catecholamine transmission, low prefrontal cortex (PFC) activity, increased beta activity on EEG
- cognitive: developmental disability, poor inhibitory control, and other errors of executive function

Diagnosis
- differential: learning disorders, hearing/visual defects, thyroid, atopic conditions, congenital problems (fetal alcohol syndrome, Fragile X), lead poisoning, history of head injury, traumatic life events (abuse)
- diagnosis requires: onset before age 12, persistent symptoms >6 mo, symptoms present in at least two settings (i.e. home, school, work), interferes with academic, family, and social functioning, and is divided into 3 subtypes
- combined type: 6 or more symptoms of inattention and ≥6 symptoms of hyperactivity-impulsivity
- predominantly inattentive type: ≥6 symptoms of inattention
- predominantly hyperactive-impulsive type: ≥6 symptoms of hyperactivity-impulsivity
- for older adolescents (>17 yr) or adults, 5 symptoms required
- does not occur exclusively during the course of another psychiatric disorder

<table>
<thead>
<tr>
<th>Table 13. Core Symptoms of ADHD (DSM-5)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inattention</strong></td>
</tr>
<tr>
<td>Careless mistakes</td>
</tr>
<tr>
<td>Cannot sustain attention in tasks or play</td>
</tr>
<tr>
<td>Does not listen when spoken to directly</td>
</tr>
<tr>
<td>Fails to complete tasks</td>
</tr>
<tr>
<td>Disorganized</td>
</tr>
<tr>
<td>Avoids, dislikes tasks that require sustained mental effort</td>
</tr>
<tr>
<td>Loses things necessary for tasks or activities</td>
</tr>
<tr>
<td>Distractible</td>
</tr>
<tr>
<td>Forgetful</td>
</tr>
</tbody>
</table>
Features
- difficult to differentiate from highly variable normative behaviour before age 4, but often identified upon school entry
- rule out developmental delay, sensory impairments, genetic syndromes, encephalopathies or toxins (alcohol, lead)
- increased risk of substance abuse, depression, anxiety, academic failure, poor social skills, comorbid CD and/or ODD, adult ASPD
- associated with family history of ADHD, difficult temperamental characteristics

Treatment
- non-pharmacological: parent management, anger control strategies, positive reinforcement, social skills training, individual/family therapy, behaviour therapy, tutors, classroom intervention, exercise routines, extracurricular activities, omega-3 fatty acids
- pharmacological: first line: stimulants (methylphenidate, amphetamine salts); second line: atomoxetine; third line/adjunct: nonstimulants (a-agonists; clonidine, guanfacine, NDRI; bupropion)
- for comorbid symptoms: antidepressants, antipsychotics

Prognosis
- 70-80% continue into adolescence, but hyperactive symptoms usually abate
- 65% continue into adulthood; secondary personality disorders and compensatory anxiety disorders are identifiable

Disruptive, Impulse Control, and Conduct Disorder

Oppositional Defiant Disorder
- prevalence: 2-16%, M=F after puberty

Diagnosis
- pattern of negativistic/hostile and defiant behaviour for ≥6 mo with ≥4 of
  - angry/irritable mood: easily loses temper, touchy or easily annoyed, often angry and resentful
  - argumentative/defiant: argues with adults/authority figure, defies requests/rules, deliberately annoys, blames others for their own mistakes or misbehaviour
  - vindictiveness: spiteful or vindictive twice in past 6 mo
  - behaviour causes significant impairment in social, academic, or occupational functioning
  - behaviours do not occur exclusively during the course of a psychotic or mood disorder
  - criteria not met for conduct disorder (CD); if ≥18 yr, criteria not met for ASPD
  - may progress to CD, differentiated by an absence of destructive or physically aggressive behaviour
  - features that typically differentiate ODD from transient developmental stage: onset <8 yr, chronic duration (>6 mo), frequent intrusive behaviour
  - impact of ODD: poor school performance, few friends, strained parent/child relationships, risk of later mood disorders

Treatment
- parent: management training, psychoeducation and family therapy to reduce punitive parenting and parent-child conflict
- behavioural therapy: to teach, practice, and reinforce prosocial behaviour
- social: school/day-care interventions
- pharmacotherapy for comorbid disorders

Conduct Disorder
- prevalence: 1.5-3.4% (M:F = 4:12:1)

Etiology
- parental/familial factors: parental psychopathology (e.g. ASPD, substance abuse), child-rearing practices (e.g. child abuse, discipline), low socioeconomic status (SES), family violence
- child factors: difficult temperament, ODD, learning problems, neurobiology

A Systematic Review and Analysis of Long-Term Outcomes in Attention Deficit Hyperactivity Disorder: Effects of Treatment and Non-Treatment

Study: Systematic review of 261 studies.
Purpose: To determine the long-term outcomes of ADHD and whether there is an effect on long-term outcomes with treatment.
Population: Patients with diagnosed or symptomatic presentation of ADHD.
Interventions: No treatment (control), treatment (pharmacological, non-pharmacological, and multi-modal).
Outcome Groups: Drug use/addictive behaviour, academic outcomes, antisocial behaviour, social function, occupation, self-esteem, driving outcomes, services use, obesity.
Results: Untreated participants with ADHD had poorer outcomes vs. non-ADHD participants in 74% (n=249) of studies, while 26% (n=89) showed similar outcomes. 72% (n=37) of studies showed a benefit from ADHD treatment vs. untreated ADHD and 23% (n=15) showed no benefit. Treatment of ADHD was found to be beneficial in studies looking at driving (100%), obesity (100%), self-esteem (90%), social function (83%), academic outcomes (71%), drug use/addictive behaviour (67%), antisocial behaviour (50%), and occupation (33%).
Conclusions: Overall, people with ADHD have poorer long-term outcomes than controls (those without ADHD). For those with ADHD, treatment improves long-term outcomes.
Diagnosis
• differential: ADHD, depression, head injury, substance abuse
• diagnosis: use multiple sources (Achenbach Child Behavioural Checklist, Teacher’s Report Form)
  • pattern of behaviour that violates rights of others and age appropriate social norms with ≥3 criteria noted in past 12 mo and ≥1 in past 6 mo
  • aggression to people and animals: bullying, initiating physical fights, use of weapons, forced sex, cruel to people and/or animals, stealing while confronting a person (e.g. armed robbery)
  • destruction of property: arson, deliberately destroying others’ property
  • deceitfulness or theft: breaking and entering, conning others, stealing nontrivial items without confrontation
  • violation of rules: out all night before age 13, often truant from school before age 13, runaway ≥2 times at least overnight or for long periods of time
  • disturbance causes clinically significant impairment in social, academic, or occupational functioning
• if ≥18 yr, criteria not met for ASPD
• diagnostic types
  • childhood onset: at least one criterion prior to age 10
  • poor prognosis: associated with ODD, aggressiveness, impulsiveness
  • adolescent onset: absence of any criteria until age 10
  • better prognosis: least aggressive, gang-related delinquency
  • mild, moderate, severe

Treatment
• early intervention necessary and more effective; long-term follow-up required
• psychosocial: parent management training, anger replacement training, CBT, family therapy, education/employment programs, social skills training,
• pharmacotherapy: for comorbid disorders

Prognosis
• poor prognostic indicators include early-age onset, high frequency, variety of behaviours, pervasiveness (i.e. in home, school, community), comorbid ADHD, early sexual activity, substance abuse
• 50% of CD children become adult ASPD

Intermittent Explosive Disorder

Diagnosis
• recurrent behavioural outbursts representing a failure to control aggressive impulses in children >6 yr, manifested as either
  • verbal or physical aggression that does not damage others or property, occurring 2+ times per wk for 3 mo
  • 3 outbursts involving physical damage to another person, animal or piece of property in the last 12 mo
• outbursts are out of proportion to triggers or provocation, are not premeditated, and not for primary gain
• outbursts cause clinically significant impairment in social, academic, or occupational functioning

See Pediatrics
• Child Abuse, P14
• Chronic Abdominal Pain, P37
• Developmental Delay, P22
• Intellectual Disability, P22
• Learning Disabilities, P24
• Sleep Disturbances, P12

See Neurology
• Tic Disorders, N33
• Tourette’s Syndrome, N34

Psychotherapy

• treatment in which a person with mental or physical difficulties aims to achieve symptomatic relief through talks with another person
• psychotherapy is delivered by a specially trained social worker, nurse, psychologist, psychiatrist, counsellor or general practitioner
• various types of therapy exist because of diverse theories of human psychology and mental illness etiology

Common Factors of Psychotherapy
• good evidence that effective psychotherapy creates observable changes in brain circuitry and connectivity, similar to those observed with successful pharmacologic and other treatment modalities
• studies suggest that up to 30-70% of therapy outcome is due to common factors with only 10-40% from specific factors
• common factors are: warmth (unconditional positive regard), accurate empathy, genuineness, goodness of fit
### Table 14. Summary of Psychotherapeutic Modalities

<table>
<thead>
<tr>
<th>Type</th>
<th>Indications</th>
<th>Approach, Technique and Theory</th>
<th>Ideal Candidates</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Psychoanalytic/Psychedynamic</strong></td>
<td>Psychoneuroses; anxiety, obsessional thinking, compulsive or conversion disorders, depressive states</td>
<td>Theory: Exploration of meaning of early experiences and how they affect emotions and patterns of behaviour. Recollection (remembering), repetition (reliving with the analyst), working through (gaining insight). Techniques: free association, dream interpretation, transference analysis.</td>
<td>Psychologically minded, highly motivated, wish to understand selves and not just relieve symptoms. Able to withstand difficult emotions without fleeing or self-destructive acts. High level of function.</td>
<td>Time intensive: Classically: 4-5 times/wk for 3-7 yr. Psychodynamically oriented therapy: 2-3 times/wk for fewer years.</td>
</tr>
<tr>
<td><strong>Supportive</strong></td>
<td>Adjustment disorders, psychosomatic disorders, severe psychotic or personality disorders</td>
<td>Ameliorate symptoms through behavioural or environmental restructuring to aid adaptation and facilitate coping. Help patients feel safe, secure, and encouraged.</td>
<td>Individuals in crisis or with severe symptoms in acute or chronic settings. Low insight, low motivation, &quot;weak&quot; ego systems.</td>
<td>Variable (single session to years, though often short-intermittent).</td>
</tr>
<tr>
<td><strong>Interpersonal</strong></td>
<td>Mood disorders, bulimia nervosa</td>
<td>Focuses on how interpersonal relationships impact symptoms. 4 key problem areas addressed: grief and loss, role transitions, conflict, interpersonal deficits. Break the interpersonal cycle: depression, self-esteem, social withdrawal.</td>
<td>Individuals with depression or bipolar disorder with some insight and difficult social functioning. Absence of severe psychotic process, personality disorder, or comorbid substance abuse.</td>
<td>12-20 wk</td>
</tr>
<tr>
<td><strong>Behavioural</strong></td>
<td>Most mental health disorders benefit from specific application of behavioural therapy (e.g. behavioural activation for depression; exposure therapy for phobias; contingency management for anorexia nervosa, substance use disorder)</td>
<td>Systematic Desensitization: mastering anxiety-provoking situations by approaching them gradually and in a relaxed state that limits anxiety. Flooding: confronting feared stimulus for prolonged periods until it is no longer frightening. Positive Reinforcement: strengthening behaviour and causing it to occur more frequently by rewarding it. Negative Reinforcement: causing behaviour to occur more frequently by removing a noxious stimulus when desired behaviour occurs. Extinction: causing a behaviour to diminish by not rewarding it. Punishment (aversive therapy): causing a behaviour to diminish by applying a noxious stimulus.</td>
<td>Individuals with motivation to change and specific symptoms that are amenable to change. Global areas of dysfunction such as personality disorder are difficult to treat with behavioural therapy.</td>
<td>Usually short term (weeks-months).</td>
</tr>
<tr>
<td><strong>Cognitive Therapy</strong></td>
<td>Depression, anxiety, panic disorder, personality disorders, and somatoform disorders</td>
<td>Moods/emotions are influenced by one’s thoughts and psychiatric disturbances are often caused by habitual errors in thinking. Therapy helps patient make explicit their inaccurate automatic thoughts and correct assumptions with a more balanced perspective. Uses thought records (often charts with column headings including “situation,” “feeling,” “thought,” “cognitive distortion”) to help monitor thoughts, the situations they occur in, and the feelings they might provoke due to their underlying cognitive errors.</td>
<td>Motivated patients who will comply with homework, openness to changing core beliefs.</td>
<td>First course - usually 15-25 wk. Maintenance therapy can be carried out over years.</td>
</tr>
<tr>
<td><strong>Cognitive Behavioural Therapy</strong></td>
<td>Most mental health disorders including: mood, anxiety, OCD, personality, eating, substance use, psychotic disorders</td>
<td>Combines theory and method from Cognitive and Behavioural therapies to teach the patient to change connections between thinking patterns, habitual behaviours, and mood/anxiety problems.</td>
<td>Individuals with motivation to change and are able to participate in homework.</td>
<td>Typically 6-18 wk, 1 hr sessions. Maintenance sessions can be added over time.</td>
</tr>
<tr>
<td><strong>Dialectical Behavioural Therapy</strong></td>
<td>Borderline Personality Disorder</td>
<td>Therapy that combines CBT techniques with Buddhist Zen mindfulness practices and dialectical philosophy. Focuses on 4 types of skills: mindfulness, emotion regulation, interpersonal effectiveness, and distress tolerance. Involves 4 components: individual therapy, group skills training, phone consultations, and a consultation team.</td>
<td>Patients with severe problems of emotional dysregulation, impulsivity, and self-harm. Patients with borderline personality disorder or borderline personality trait.</td>
<td>Typically 1 yr.</td>
</tr>
<tr>
<td><strong>Motivational Interviewing</strong></td>
<td>Substance use disorders</td>
<td>Spirit of MI (CAPE): Compassion, Acceptance, Partnership, Evocation. Principles of MI (RULE): Resist “righting reflex”, Understand client and their reasons for change, Listen, Empower by conveying hope and supporting autonomy. Techniques of MI (DARS): Open-ended questions, Affirmations to validate client, Reflections (the skill of accurate empathy), Summaries to help client organize self.</td>
<td>Patients with problematic substance use, maladaptive behaviour patterns (therapy disengagement, medication noncompliance, poor health habits).</td>
<td>Brief interventions (efficacy with as little as 15 min, single sessions), better result with more sessions. Addiction is a chronic condition, often need boosters over time.</td>
</tr>
<tr>
<td><strong>Motivational Enhancement Therapy (MET)</strong></td>
<td>Techniques can be applied to facilitate behavioural change in most psychological problems</td>
<td>MET = 4 sessions</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Other Therapies

• group psychotherapy
  ■ aims to promote self-understanding, acceptance, social skills
• family therapy
  ■ family system considered more influential than individual, especially for children
  ■ focus on here and now, re-establishing parental authority, strengthening normal boundaries, and rearranging alliances
• narrative psychotherapy
  ■ an integrative approach that attempts to understand the patient’s experience as a whole
• hypnosis
  ■ mixed evidence for treatment of pain, phobias, anxiety, and smoking cessation
• mindfulness-based cognitive therapy (MBCT)/stress reduction (MBSR)
  ■ derived from Buddhist meditative and philosophical practices; aims to help people attend to thoughts, behviours, and emotions in the moment and non-judgmentally using guided breathing exercises. Emerging evidence for treating adjustment disorder, MDD, anxiety, pain disorders, insomnia, substance relapse prevention

Pharmacotherapy

Antipsychotics

• “antipsychotics” and “neuroleptics” are terms used interchangeably
• overall mechanism of action: block, to varying degrees, dopamine activity in target brain pathways (see sidebar)
• indications: for managing agitation, sleep, psychosis and mania reduction, mood stabilizing - used in schizophrenia and other psychotic disorders, mood disorders with or without psychosis, violent behaviour, autism, Tourette’s, somatoform disorders, dementia, OCD
• onset: immediate calming effect and decrease in agitation; thought disorder responds in 2-4 wk
• rational use
  ■ no reason to combine antipsychotics
  ■ choosing an antipsychotic
    ■ all antipsychotics are equally effective, except for clozapine (considered to be most effective in treatment-refractory psychosis)
    ■ atypical antipsychotics (SGA) are as effective as typical (first generation) antipsychotics but are thought to have better side effect profiles
    ■ choose a drug that the patient has responded to in the past or that was used successfully in a family member
• route: PO, short-acting or long-acting depot IM injections, sublingual
• if no response in 4-6 weeks, switch drugs; if response, titrate dose
• duration: minimum 6 mo, usually for life

Long-Acting Preparations

• antipsychotics formulated in oil for IM injection (see Table 15)
• received on an outpatient basis
• indications: individuals with schizophrenia or other chronic psychosis who relapse because of non-adherence
• dosing: start at low dosages, then titrate every 2-4 wk to maximize safety and minimize side effects
• should be exposed to oral form prior to first injection
• side effects: risk of EPS, parkinsonism, increased risk of NMS

Canadian Guidelines for the Treatment of Acute Psychosis in the Emergency Setting

• haloperidol 5 mg IM ± lorazepam 2 mg IM
• loxapine 25 mg ± lorazepam 2 mg IM
• olanzapine 2.5-10 mg (PO, IM, quick dissolve)
• risperidone 2 mg (M-tab, liquid)

Dopamine Pathways Affected by Antipsychotics

<table>
<thead>
<tr>
<th>Pathway</th>
<th>Effects</th>
<th>Associated Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesolimbic</td>
<td>Emotion: origin, reward</td>
<td>5-HT1 receptors, low dopamine causes positive symptoms of schizophrenia (delusions, hallucinations)</td>
</tr>
<tr>
<td>Meso cortical</td>
<td>Cognition: executive function</td>
<td>LOW dopamine causes negative symptoms of schizophrenia</td>
</tr>
<tr>
<td>Nigrostriatal</td>
<td>Movement</td>
<td>LOW dopamine causes EPS</td>
</tr>
</tbody>
</table>

Typical (First Generation) vs. Atypical (Second Generation) Antipsychotics

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Typical</th>
<th>Atypical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Block postsynaptic dopamine receptors (D2)</td>
<td>Block postsynaptic dopamine receptors (D2)</td>
<td>Block serotonergic receptors (5-HT2)</td>
</tr>
<tr>
<td>Block serotonergic receptors (5-HT2)</td>
<td>Block serotonergic receptors (5-HT2)</td>
<td>Block postsynaptic dopamine receptors (D2)</td>
</tr>
<tr>
<td>Tardive syndromes in long term</td>
<td>Fewer EPS</td>
<td>Fewer EPS</td>
</tr>
<tr>
<td>Emotional stability</td>
<td>Mood stabilizing effects</td>
<td>Mood stabilizing effects</td>
</tr>
<tr>
<td>Expensive</td>
<td>Few injectable forms available</td>
<td>Expensive</td>
</tr>
<tr>
<td>Metabolic side effects (weight gain, hyperglycemia, lipid abnormalities)</td>
<td>Metabolic side effects (weight gain, hyperglycemia, lipid abnormalities)</td>
<td>Metabolic side effects (weight gain, hyperglycemia, lipid abnormalities)</td>
</tr>
<tr>
<td>Exacerbation (or new onset of obsessive behaviour)</td>
<td>Exacerbation (or new onset of obsessive behaviour)</td>
<td>Exacerbation (or new onset of obsessive behaviour)</td>
</tr>
</tbody>
</table>
Table 15. Common Antipsychotic Agents

<table>
<thead>
<tr>
<th></th>
<th>Starting Dose</th>
<th>Maintenance</th>
<th>Maximum</th>
<th>Relative Potency (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Typicals</strong> (in order of potency from high to low)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haloperidol (Haldol)</td>
<td>2.5-10 mg IM q4-8h</td>
<td>Based on clinical effect</td>
<td>20 mg/d PO</td>
<td>2</td>
</tr>
<tr>
<td>Fluphenazine enanthate (Meprobate, Modecate for IM formulation)</td>
<td>2.5-10 mg/d PO</td>
<td>1-5 mg PO qhs</td>
<td>20 mg/d PO</td>
<td>2</td>
</tr>
<tr>
<td>Zuclopenthixol HCl (Clozepix®)</td>
<td>20-30 mg/d PO</td>
<td>20-40 mg/d PO</td>
<td>100 mg/d PO</td>
<td>4</td>
</tr>
<tr>
<td>Zuclopenthixol acetate (Acuphase®)</td>
<td>50-150 mg IM q48-72h</td>
<td>400 mg IM (q2wk)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zuclopenthixol decanoate (Gloxipol Depot®)</td>
<td>100 mg IM q1-4wk</td>
<td>150-300 mg IM q2wk</td>
<td>600 mg IM/qwk</td>
<td></td>
</tr>
<tr>
<td>Perphenazine (Trilafon®)</td>
<td>8-16 mg PO b/tid</td>
<td>4-8 mg PO t/qid</td>
<td>64 mg/d PO</td>
<td>10</td>
</tr>
<tr>
<td>Loxapine HCl (Loxitane®)</td>
<td>10 mg PO tid</td>
<td>60-100 mg/d PO</td>
<td>250 mg/d PO</td>
<td>10</td>
</tr>
<tr>
<td>Chlorpromazine (Largactil®)</td>
<td>10-25 mg PO b/tqid</td>
<td>400 mg/d PO</td>
<td>1000 mg/d PO</td>
<td>100</td>
</tr>
<tr>
<td><strong>Atypicals</strong> (in order of potency from high to low)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risperidone (Risperdal®, Risperdal Consta® for IM long acting preparation, Risperdal M-Tab for melting form – placed on tongue)</td>
<td>1-2 mg OD/bid</td>
<td>4-8 mg/d PO</td>
<td>8 mg/d PO</td>
<td>2</td>
</tr>
<tr>
<td>Paliperidone (Invega®)</td>
<td>3 mg/d PO</td>
<td>3-12 mg /d PO</td>
<td>12 mg/d PO</td>
<td>4</td>
</tr>
<tr>
<td>Olanzapine (Zyprexa®, Zydis® for melting form – placed on tongue, Zyprexa Intramuscular®)</td>
<td>5 mg/d PO</td>
<td>10-20 mg/d PO</td>
<td>30 mg/d PO</td>
<td>5</td>
</tr>
<tr>
<td>Asenapine (Saphris®)</td>
<td>5 mg SL bid</td>
<td>5-10 mg SL bid</td>
<td>10 mg bid</td>
<td>5</td>
</tr>
<tr>
<td>Ziprasidone (Zeldox®)</td>
<td>20 mg bid PO</td>
<td>40-80 mg bid PO</td>
<td>160 mg/d PO</td>
<td>6</td>
</tr>
<tr>
<td>Aripiprazole (Abilify®)</td>
<td>10-15 mg/d PO</td>
<td>10-15 mg/d PO</td>
<td>30 mg/d PO</td>
<td>7.5</td>
</tr>
<tr>
<td>Quetiapine (Seroquel®, Seroquel XR® for extended release®)</td>
<td>25 mg PO bid</td>
<td>400-800 mg/d PO</td>
<td>800 mg/d PO</td>
<td>75</td>
</tr>
<tr>
<td>Clozapine (Clozaril®)</td>
<td>25 mg PO bid</td>
<td>300-600 mg/d PO</td>
<td>600 mg/d PO</td>
<td>100</td>
</tr>
</tbody>
</table>

Table 16. Commonly Used Atypical Antipsychotics

<table>
<thead>
<tr>
<th>Risperidone (Risperdal®)</th>
<th>Olanzapine (Zyprexa®, Zydis®)</th>
<th>Quetiapine (Seroquel®, Zydis®)</th>
<th>Clozapine (Clozaril®)</th>
<th>Aripiprazole (Abilify®)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Advantages</strong></td>
<td>Lower incidence of EPS than typical antipsychotics at lower doses (&lt; 8 mg)</td>
<td>Associated with less weight gain compared to clozapine and olanzapine</td>
<td>Associated with less weight gain compared to clozapine and olanzapine</td>
<td>Mood stabilizing</td>
</tr>
<tr>
<td><strong>Disadvantages</strong></td>
<td>SE: insomnia, agitation, EPS, H/A, anxiety, prolactin, constipation, dizziness, weight gain</td>
<td>SE: mild sedation, insomnia, dizziness, minimal anticholinergic, early AST and ALT elevation, restlessness</td>
<td>SE: H/A, sedation, dizziness, constipation</td>
<td>Most sedating of first line atypicals</td>
</tr>
<tr>
<td><strong>Comments</strong></td>
<td>Quick dissolve (M-tabs), and long-acting (Consta®) formulations available</td>
<td>Quick dissolve formulation (Zydis®) used commonly in ER setting for better compliance IM form available</td>
<td>Weekly blood counts for 6 mo, then q2wk</td>
<td>Do not use with drugs which may cause bone marrow suppression due to risk of agranulocytosis</td>
</tr>
</tbody>
</table>
Table 17. Side Effects of Antipsychotics

<table>
<thead>
<tr>
<th>System</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticholinergic</td>
<td>Dry mouth, urinary retention, constipation, blurred vision, toxic-confusional states</td>
</tr>
<tr>
<td>α-adrenergic Blockade</td>
<td>Orthostatic hypotension, impotence, failure to ejaculate</td>
</tr>
<tr>
<td>Dopaminergic Blockade</td>
<td>Extrapyramidal syndromes, galactorrhea, amenorrhea, impotence, weight gain</td>
</tr>
<tr>
<td>Anti-histamine</td>
<td>Sedation</td>
</tr>
<tr>
<td>Hematologic</td>
<td>Agranulocytosis (clozapine)</td>
</tr>
<tr>
<td>Hypersensitivity Reactions</td>
<td>Liver dysfunction, blood dyscrasias, skin rashes, neuroleptic malignant syndrome, altered temperature regulation (hypothermia or hyperthermia)</td>
</tr>
<tr>
<td>Endocrine</td>
<td>Metabolic syndrome</td>
</tr>
</tbody>
</table>

Neuroleptic Malignant Syndrome

- **psychiatric emergency**
  - due to massive dopamine blockade; increased incidence with high potency and depot neuroleptics
- **risk factors**
  - medication factors: sudden increase in dosage, starting a new drug
  - patient factors: medical illness, dehydration, exhaustion, poor nutrition, external heat load, male, young adults
- **clinical presentation**
  - mental status changes (usually occur first), fever, autonomic reactivity, rigidity
  - develops over 24-72 h
  - labs: increased creatine phosphokinase, leukocytosis, myoglobinuria
- **treatment**: supportive - discontinue drug, hydration, cooling blankets, dantrolene (hydrantoin derivative, used as a muscle relaxant), bromocriptine (DA agonist)
- **mortality**: 5%

Extrapyramidal Symptoms

- incidence related to increased dose and potency
- acute (early-onset; reversible) vs. tardive (late-onset; often irreversible)

Table 18. Extrapyramidal Symptoms

<table>
<thead>
<tr>
<th>Onset</th>
<th>Dystonia</th>
<th>Akathisia</th>
<th>Pseudoparkinsonism</th>
<th>Dyskinesia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute or Tardive</td>
<td>Within 5 d</td>
<td>&lt;90 d</td>
<td>Acute: within 30 d</td>
<td>&gt;90 d</td>
</tr>
<tr>
<td>Risk Group</td>
<td>Acute: Young Asian and Black males</td>
<td>Motor restlessness; crawling sensation in legs relieved by walking; very distressing, increased risk of suicide and poor adherence</td>
<td>Tremor; rigidity (cogwheeling); akinesia; postural instability (decreased/absent arm-swing, stopped posture, shuffling gait, difficulty pivoting)</td>
<td>Purposeless, constant movements, involving facial and mouth musculature, or less commonly – the limbs</td>
</tr>
<tr>
<td>Presentation</td>
<td>Sustained abnormal posture; torsions, twisting, contraction of muscle groups; muscle spasms (e.g. oculogyric crisis, laryngospasm, torticollis)</td>
<td>Elderly females</td>
<td>Elderly females</td>
<td>Tardive: no good treatment; may try clozapine; discontinue drug or reduce dose</td>
</tr>
</tbody>
</table>

Anticholinergic Agents

- types
  - benztpotrine (Cogentin*) 2 mg PO, IM, or IV OD (~1-6 mg)
  - amantadine (Symmetrel*) 100 mg PO bid (100-400 mg)
  - diphenhydramine (Benadryl*) 25-50 mg PO/IM qid
- do not always prescribe with neuroleptics
- give anticholinergic agents only if at high risk for acute EPS or if acute EPS develops
- do not give these for tardive syndromes because they worsen the condition

Antidepressants

- onset of effect
  - relief of neurovegetative/physical symptoms: 1-3 wk
  - relief of emotional/cognitive symptoms: 2-6 wk
- taper TCAa slowly (over weeks-months) because they can cause withdrawal reactions
- tapering of any antidepressant is usually required and is based on the medication’s half-life and the patient’s individual sensitivity (e.g. fluoxetine does not require a slow taper due to long half life)

Metabolic and Cardiovascular Adverse Effects

- Associated with Antipsychotic Drugs
  - Nat Rev Endocrinol 2012;8:114-126
  - Study: Review.
  - Conclusions: All antipsychotics can cause cardiovascular and metabolic side effects, such as obesity, dyslipidemia, hyperglycemia and metabolic syndrome. Olanzapine and clozapine are most likely to cause these side effects. The mechanism that underlie the metabolic and cardiovascular effects is not fully understood, however, the histamine, dopamine, serotonin, and muscarinic receptors are implicated.

Features of Neuroleptic Malignant Syndrome

- **FARM**
  - Fever
  - Autonomic changes (e.g. increased HR/BP, sweating)
  - Rigidity of muscles
  - Mental status changes (e.g. confusion)
  - FARM symptoms are also seen in SS
  - SS can be distinguished from NMS by the following:
    - SS: Twitchy, shivering, restless
    - NMS: Severe global rigidity
  - Flushed, sweaty
  - Pallor
  - Vomiting, diarrhea, abdominal pain
  - No GI symptoms

QT Prolongation is an important side effect of antipsychotics; ECGs should be obtained prior to initiating a new medication and to monitor side effects

- **Typicals**: chlorpromazine and haloperidol
  - warrant cardiac monitoring

- **Atypicals**: ziprasidone has the highest risk among atypicals, clozapine also warrants monitoring

Selective Serotonin Reuptake Inhibitors (SSRIs) vs. Other Antidepressants for Depression

- Cochrane DB Syst Rev 2004, Issue 3
  - This systematic review of 88 RCTs compared the efficacy of SSRIs with other kinds of antidepressants in the treatment of patients with depressive disorders.
  - Conclusions: There is no significant difference in the effectiveness of SSRIs vs. TCAs. Consider relative patient acceptability, toxicity, and cost when choosing.

How Long to Treat?

- 6-12 mo: if first or second episode
  - 2 yr-indefinitely if third episode, elderly, psychotic features, refractory depression,
  - >2 episodes in 5 yr
• must be vigilant over the first 2 wk of therapy; neurovegetative symptoms may start to resolve while emotional and cognitive symptoms may not (patients may be particularly at risk for suicidal behaviour during this time; in children/adolescents, paroxetine and venlafaxine increase restlessness and suicide ideation, so are not prescribed)

• treatment of bipolar depression
  • patients with bipolar disorder should only be treated with an antidepressant if combined with a mood stabilizer or antipsychotic; monotherapy with antidepressants is not advisable as the depression can turn into mania

Table 19. Common Antidepressants

<table>
<thead>
<tr>
<th>Class</th>
<th>Drug</th>
<th>Daily Starting Dose (mg)</th>
<th>Therapeutic Dose (mg)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSRI</td>
<td>fluoxetine (Prozac®)</td>
<td>20</td>
<td>20-80</td>
<td>Useful for anxiety states, OCD, eating disorders, seasonal depression, typical and atypical depression</td>
</tr>
<tr>
<td></td>
<td>fluvoxamine (Luvox®)</td>
<td>50-100</td>
<td>150-300</td>
<td>All SSRIs have similar effectiveness but consider side effect profiles and half-lives</td>
</tr>
<tr>
<td></td>
<td>paroxetine (Paxil®)</td>
<td>10</td>
<td>20-60</td>
<td>Sertraline, citalopram, and escitalopram have the fewest drug-interactions and are sleep-wake neutral</td>
</tr>
<tr>
<td></td>
<td>sertraline (Zoloft®)</td>
<td>50</td>
<td>50-200</td>
<td>Fluoxetine and paroxetine are the most activating drugs (recommend taking in the AM)</td>
</tr>
<tr>
<td></td>
<td>citalopram (Celexa®)</td>
<td>20</td>
<td>20-40</td>
<td>Fluoxetine does not require a taper due to long half-life and is the most used in children as it has most evidence</td>
</tr>
<tr>
<td></td>
<td>escitalopram (Cipralex®)</td>
<td>10</td>
<td>10-20</td>
<td>Fluoxetine and paroxetine are the most activating drugs (recommend taking in the AM)</td>
</tr>
<tr>
<td>SNRI</td>
<td>venlafaxine (Effexor®)</td>
<td>37.5-75</td>
<td>75-225</td>
<td>Useful for depression, anxiety disorders</td>
</tr>
<tr>
<td></td>
<td>duloxetine (Cymbalta®)</td>
<td>40</td>
<td>40-60</td>
<td>Useful for depression, anxiety disorders</td>
</tr>
<tr>
<td>NDRI</td>
<td>bupropion (Wellbutrin®)</td>
<td>100</td>
<td>300-450</td>
<td>Useful for depression, seasonal depression</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Causes less sexual dysfunction (may reverse effects of SSRIs/SNRIs), weight gain, and sedation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Increased risk of seizures at higher doses</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Contraindicated with history of seizure, stroke brain tumour, brain injury, closed head injury</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Not recommended for anxiety disorder treatment because of stimulating effects</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Important to specify formulation, as available in IR, SR, XL (longest)</td>
</tr>
<tr>
<td>TCA (3º) Amines</td>
<td>amitriptyline (Elavil®)</td>
<td>75-100</td>
<td>150-300</td>
<td>Useful for OCD (clomipramine), melancholic depression</td>
</tr>
<tr>
<td></td>
<td>imipramine (Tofran®)</td>
<td>75-100</td>
<td>150-300</td>
<td>Useful for OCD (clomipramine), melancholic depression</td>
</tr>
<tr>
<td>TCA (2º) Amines</td>
<td>nortriptyline (Aventyl®)</td>
<td>75-100</td>
<td>150-300</td>
<td>Useful for OCD (clomipramine), melancholic depression</td>
</tr>
<tr>
<td></td>
<td>desipramine (Norpramin®)</td>
<td>100-200</td>
<td>150-300</td>
<td>Useful for OCD (clomipramine), melancholic depression</td>
</tr>
<tr>
<td>MAOI</td>
<td>phenelzine (Nardil®)</td>
<td>45</td>
<td>60-90</td>
<td>Useful for moderate/severe depression that does not respond to SSRI, atypical depression</td>
</tr>
<tr>
<td></td>
<td>tranylcypromine (Pamate®)</td>
<td>30</td>
<td>10-60</td>
<td>Useful for moderate/severe depression that does not respond to SSRI, atypical depression</td>
</tr>
<tr>
<td>RIMA</td>
<td>moclobemide (Manerix®)</td>
<td>300</td>
<td>300-600</td>
<td>Useful for depression unresponsive to other therapies</td>
</tr>
<tr>
<td>NASSA</td>
<td>mirtazapine (Remeron®)</td>
<td>15</td>
<td>15-45</td>
<td>Useful in depression with prominent features of insomnia, agitation, or cachexia</td>
</tr>
</tbody>
</table>

MAOI = monoamine oxidase inhibitors; NASSA = noradrenergic and specific serotonin antagonists; NDRI = norepinephrine and dopamine reuptake inhibitors; RIMA = reversible inhibition of MAO-A; SNRI = serotonin and norepinephrine reuptake inhibitors; SSRI = selective serotonin reuptake inhibitors; TCA = tricyclic antidepressants

Treatment Approach for Depression

- **optimization:** ensuring adequate drug doses for the individual
- **augmentation:** the addition of a medication that is not considered an antidepressant to an antidepressant regimen (e.g. thyroid hormone, lithium, atypical antipsychotics [specifically: olanzapine, risperidone, aripiprazole])
- **combination:** the addition of another antidepressant to an existing treatment regimen (e.g. the addition of bupropion to an SSRI or SNRI)
- **substitute:** change in the primary antidepressant (within or outside a class)
- **note:** it is important to fully treat depression symptoms in order to decrease relapse rates and severity
Table 20. Features of Commonly Used Antidepressant Classes

<table>
<thead>
<tr>
<th>SSRI</th>
<th>SNRI</th>
<th>TCA</th>
<th>MAOI</th>
<th>NDRI</th>
<th>RIMA</th>
<th>NASSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Examples</td>
<td>Fluoxetine, Sertraline, Citalopram</td>
<td>Venlafaxine, Duloxetine</td>
<td>Amitriptyline, Clomipramine</td>
<td>Phenezine</td>
<td>Bupropion</td>
<td>Moclobemide</td>
</tr>
</tbody>
</table>

Mode of Action
- Block serotonin reuptake only
- Block norepinephrine and serotonin reuptake
- Block norepinephrine and serotonin reuptake
- Irreversible inhibition of monoamine oxidase A and B
- Leads to norepinephrine and serotonin accumulation
- Reversible inhibitor of monoamine oxidase A
- Leads to norepinephrine and serotonin accumulation
- Enhance central noradrenergic and serotonergic activity by inhibiting presynaptic α2-adrenergic receptors

Side Effects
- Fewer than TCA, therefore increased compliance
- CNS: restlessness, tremor, insomnia, headache, drowsiness
- GI: N/V, diarrhea, abdominal cramps, weight loss
- Sexual dysfunction: impotence, anorgasmia
- CVS: Increased HR, conduction delay, serotonin syndrome, EPS, SIADH

Risk in Overdose
- Relatively safe in OD
- Tachycardia and N/V seen in acute overdose
- Toxic in OD: 3 times therapeutic dose is lethal
- Presentation: anticholinergic effects, CNS stimulation, then depression and seizures
- ECG: prolonged QT (duration reflects severity)
- Treatment: activated charcoal, cathartics, supportive treatment, IV diazepam for seizure, physostigmine salicylate for coma
- Do not give ippecac, as it can cause rapid neurologic deterioration and seizures
- Mild symptoms with overdose

Drug Interactions
- SSRIIs inhibit P450 enzymes, therefore will affect levels of drugs metabolized by P450 system
- MAOI, SSRI: Does not seem to inhibit P450 system
- MAOI, SSRI: EtOH
- EtOH: Hypertensive crises with noradrenergic medications (e.g. TCA, decongestants, amphetamines)
- Serotonin syndrome with serotonergic drugs (e.g. SSRIs, tryptophan, dextromethorphan)
- MAOI: Drugs that reduce seizure threshold: antipsychotics, systemic steroids, quinoline antibiotics, antimalarial drugs
- MAOI, SSRI, TCA Opioids
- MAOI, SSRI, SNRI, RIMA

Serotonin Syndrome
- Thought to be due to over-stimulation of the serotonergic system
- Can result from medication combinations such as SSRI+MAOI, SSRI+tryptophan, MAOI+meperidine, MAOI+tryptophan
- Rare but potentially life-threatening adverse reaction to SSRIs, especially when switching from an SSRI to an MAOI
- Symptoms include nausea, diarrhea, palpitations, chills, restlessness, confusion, and lethargy but can progress to myoclonus, hyperthermia, rigor and hypertonicity
- Treatment: discontinue medication and administer emergency medical care as needed
- Important to distinguish from NMS

Discontinuation Syndrome
- Caused by the abrupt cessation of an antidepressant; most commonly with paroxetine, fluvoxamine, and venlafaxine (drugs with shortest half-lives)
- Symptoms usually begin within 1–3 d and include: anxiety, insomnia, irritability, mood lability, nausea/vomiting, dizziness, headache, dystonia, tremor, chills, fatigue, lethargy, and myalgia
- Treatment: symptoms may last between 1–3 wk, but can be relieved within 24 h by restarting antidepressant therapy at the same dose the patient was taking and initiating a slow taper over several weeks
- Consider using a drug with a longer half-life such as fluoxetine
Mood Stabilizers

General Prescribing Information
• examples: lithium, lamotrigine, divalproex, carbamazepine
• used in conjunction with atypical antipsychotics for managing episodes of bipolar disorder - depression, mania, stabilization
• vary in their ability to “treat” (reduce symptoms acutely) or “stabilize” (prevent relapse and recurrence) manic and depressive symptoms; multi-agent therapy is common
• before initiating, get baseline: CBC, ECG (if patient >45 yr old or cardiovascular risk), urinalysis, BUN, Cr, electrolytes, TSH
• before initiating lithium: screen for pregnancy, thyroid disease, seizure disorder, neurological, renal, cardiovascular diseases
• full effects not for 2-4 wk, thus may need acute coverage with benzodiazepines or antipsychotics

Specific Prescribing Information
• detailed pharmacological guidelines available online from the Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD)
• for clinical information for treating bipolar disorder (see Mood Disorders, PS9)

Table 21. Commonly Used Mood Stabilizers

<table>
<thead>
<tr>
<th>Indications</th>
<th>Lithium</th>
<th>Lamotrigine (Lamictal®)</th>
<th>Divalproex (Epival®)</th>
<th>Carbamazepine (Tegretol®)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st line</td>
<td>Acute mania (monotherapy or with adjunct SGA)</td>
<td>Bipolar I depression (monotherapy)</td>
<td>Acute mania (monotherapy or with adjunct SGA)</td>
<td>Bipolar I depression (monotherapy)</td>
</tr>
<tr>
<td>Bipolar II depression (monotherapy or in combination with SSRI, divalproex, or bupropion)</td>
<td>Bipolar II depression (monotherapy or with adjunct SGA)</td>
<td>Bipolar II depression (combination with SSRI or lithium)</td>
<td>Bipolar II depression (combination with SSRI or lithium)</td>
<td></td>
</tr>
<tr>
<td>Bipolar disorder maintenance (monotherapy or adjunct SGA)</td>
<td>Bipolar disorder maintenance (monotherapy or adjunct SGA)</td>
<td>Bipolar disorder maintenance (monotherapy or adjunct SGA)</td>
<td>Bipolar disorder maintenance (monotherapy or adjunct SGA)</td>
<td></td>
</tr>
</tbody>
</table>

Mode of Action
• Unknown
• Therapeutic response within 7-14 d
• May inhibit 5-HT3 receptors
• May potentiate DA activity
• Depresses synaptic transmission
• Raises seizure threshold
• Depresses synaptic transmission
• Raises seizure threshold

Dosage
• Adult: 600-1500 mg/d
• Geriatric: 150-600 mg/d
• Usually daily dosing
• Starting: 12.5-15 mg/d
• Daily dose: 100-200 mg/d
• Dose adjusted in patients taking other anticonvulsants
• Not recommended for: Acute mania as monotherapy
• Note: very slow titration due to risk of Stevens-Johnson Syndrome
• Note: very slow titration due to risk of Stevens-Johnson Syndrome
• 17-50 mmol/L
• Therapeutic levels are for seizure prophylaxis
• 350-700 μmol/L

Therapeutic Level
• Adult: 0.8-1.0 mmol/L (1.0-1.25 mmol/L for acute mania)
• Geriatric: 0.5-0.8 mmol/L
• Monitoring serum levels until therapeutic (always wait 12 h after dose)
• Monitor serum levels until therapeutic response is established
• Dosing based on therapeutic response
• LFTs weekly × 1 mo, then monthly, due to risk of liver dysfunction
• Weekly blood counts for first month, due to risk of agranulocytosis

Side Effects
• GI: N/V, diarrhea, stomach pain
• GU: polyuria, polydipsia, GN, renal failure, nephrogenic DI
• CNS: fine tremor, lethargy, fatigue, headache
• Hematologic: reversible leukocytosis
• Other: taperogenic (Bartien’s anomaly), weight gain, edema, psoriasis, hypothyroidism, hair thinning, muscle weakness, ECG changes

Interactions
• NSAIDs decrease clearance
• OCP
• OCP
Lithium Toxicity
- clinical diagnosis as toxicity can occur at therapeutic levels
- common causes: overdose, sodium/fluid loss, concurrent medical illness
- clinical presentation
  - GI: severe nausea/vomiting and diarrhea
  - cerebellar: ataxia, slurred speech, lack of coordination
  - cerebral: drowsiness, myoclonus, tremor, upper motor neuron signs, seizures, delirium, coma
- management
  - discontinue lithium for several doses and begin again at a lower dose when lithium level has fallen to a non-toxic range
  - serum lithium levels, BUN, electrolytes
  - saline infusion
  - hemodialysis if lithium >2 mmol/L, coma, shock, severe dehydration, failure to respond to treatment after 24 h, or deterioration

Anxiolytics
- anxiolytics mask or alleviate symptoms; they do not cure them
- indications
  - short-term treatment of transient forms of anxiety disorders, insomnia, alcohol withdrawal (especially delirium tremens), barbiturate withdrawal, organic brain syndrome (acute agitation in delirium), EPS and akathisia due to antipsychotics, seizure disorders, musculoskeletal disorders
- relative contraindications
  - major depression (except as an adjunct to other treatment), history of drug/alcohol abuse, caution in pregnancy/breastfeeding
- mechanism of action
  - benzodiazepines: potentiate binding of GABA to its receptors; results in decreased neuronal activity
  - buspirone: partial agonist of 5-HT1A receptors

Benzodiazepines
- should be used for limited periods (weeks-months) to avoid dependence
- all benzodiazepines are sedating; be wary with use in the elderly
- have similar efficacy, so choice depends on half-life, metabolites and route of administration, OD or bid
- taper slowly over weeks-months because they can cause withdrawal reactions
  - low dose withdrawal: tachycardia, HTN, panic, insomnia, anxiety, impaired memory and concentration, perceptual disturbances
  - high dose withdrawal: hyperpyrexia, seizures, psychosis, death
- avoid alcohol because of potentiation of CNS depression; caution with drinking and driving/machinery use
- side effects
  - CNS: drowsiness, cognitive impairment, reduced motor coordination, memory impairment
  - physical dependence, tolerance
- withdrawal
  - symptoms: anxiety, insomnia, autonomic hyperactivity (less common)
  - onset: 1-2 d (short-acting), 2-4 d (long-acting)
  - duration: weeks-months
  - complications with above 50 mg diazepam/day: seizures, delirium, arrhythmias, psychosis
  - management: taper with long-acting benzodiazepine
  - similar to but less severe than alcohol withdrawal; can be fatal
- overdose
  - commonly used drug in overdose
    - overdose is rarely fatal
    - benzodiazepines are more dangerous and may cause death when combined with alcohol, other CNS depressants or TCAs

Benzodiazepine Antagonist – Flumazenil (Anexate®)
- use for suspected benzodiazepine overdose
- specific antagonist at the benzodiazepine receptor site
**Somatic Therapies**

### Electroconvulsive Therapy

- Various methodological improvements have been made since the first treatment in 1938 to reduce adverse effects.
- Modern ECT: induction of a generalized seizure using an electrical pulse through scalp electrodes while the patient is under general anesthesia with a muscle relaxant.
- Considerations: unilateral vs. bilateral electrode placement, pulse rate, dose, number and spacing of treatments.
- Usual course is 6-12 treatments, 2-3 treatments per week.
- Indications:
  - Depression refractory to adequate pharmacological trial (MDD or Bipolar I depression).
  - High suicide risk.
  - Medical risk in addition to depression (dehydration, electrolytes, pregnancy).
  - Previous good response to ECT.
  - Familial response to ECT.
  - Elderly.
  - Psychotic depression.
  - Catatonic features.
  - Marked vegetative features.
  - Acute schizophrenia unresponsive to medication.
  - OCD refractory to conventional treatment.
- Side effects: Risk of anesthesia, memory loss (may be retrograde and/or anterograde, tends to resolve by 6-9 mo, permanent impairment controversial), headaches, myalgias.
- Unilateral ECT causes less memory loss than bilateral but may not be as effective.
- Contraindications: Increased intracranial pressure, recent (<2 wk) MI (not absolute but requires special monitoring).

### Magnetic Seizure Therapy (MST)

- Seizure induction by magnetic current induction rather than direct stimulation.
- Early studies demonstrate efficacy for depression as well as anxiety; reduced memory side effects vs. ECT.

### Repetitive Transcranial Magnetic Stimulation (rTMS)

- Noninvasive production of focal electrical currents in select brain areas using magnetic induction.
- Indications: Strong evidence for treatment-resistant depression, pain disorders; possibly efficacious for anxiety disorders, eating disorders, substance use disorders.
- Adverse effects: Common - transient local discomfort, hearing issues, cognitive changes; rare - seizure, syncope, mania induction.

---

**Table 22. Common Anxiolytics**

<table>
<thead>
<tr>
<th>Class</th>
<th>Drug</th>
<th>Dose Range</th>
<th>t½ (h)</th>
<th>Appropriate Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzodiazepines</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long-acting</td>
<td>clonazepam (Rivotril®)</td>
<td>0.25-4</td>
<td>18-50</td>
<td>Akathisia, generalized anxiety, seizure prevention, panic disorder</td>
</tr>
<tr>
<td></td>
<td>diazepam (Valium®)</td>
<td>2-40</td>
<td>30-100</td>
<td>Generalized anxiety, seizure prevention, muscle relaxant, alcohol withdrawal</td>
</tr>
<tr>
<td></td>
<td>chlordiazepoxide (Librium®)</td>
<td>5-300</td>
<td>30-100</td>
<td>Sleep, anxiety, alcohol withdrawal</td>
</tr>
<tr>
<td></td>
<td>flurazepam (Dalmane®)</td>
<td>15-30</td>
<td>50-160</td>
<td>Sleep</td>
</tr>
<tr>
<td>Short-acting</td>
<td>alprazolam (Xanax®)</td>
<td>0.5-5.0</td>
<td>10-20</td>
<td>Panic disorder, high dependency rate</td>
</tr>
<tr>
<td></td>
<td>lorazepam (Ativan®)</td>
<td>0.5-6.0</td>
<td>10-20</td>
<td>Sleep, generalized anxiety, akathisia, muscle relaxant, alcohol withdrawal, sublingual available for very rapid action</td>
</tr>
<tr>
<td></td>
<td>oxazepam (Serax®)</td>
<td>10-120</td>
<td>8-12</td>
<td>Sleep, generalized anxiety, alcohol withdrawal</td>
</tr>
<tr>
<td></td>
<td>temazepam (Restoril®)</td>
<td>7.5-30</td>
<td>8-20</td>
<td>Sleep</td>
</tr>
<tr>
<td></td>
<td>triazolam (Halcion®)</td>
<td>0.125-0.5</td>
<td>1.5-5</td>
<td>Shortest t½, rapid sleep, but rebound insomnia</td>
</tr>
<tr>
<td>Azapirones</td>
<td>zopiclone (Imovane®)</td>
<td>5-7.5</td>
<td>3.8-6.5</td>
<td>Sleep</td>
</tr>
</tbody>
</table>
### Neurosurgical Treatments

**Ablative/Lesion Procedures**
- used for intractable MDD or OCD, efficacy ranges from 25-75% depending on procedure
- adverse effects: related to lesion location and size, high risk of suicide in those who are not helped by surgery

**Deep Brain Stimulation**
- placement of small electrode leads in specific brain areas to alter neuronal signaling, usually for intractable MDD
- response rates (>50% symptom reduction) of 40-70%, adverse effects related to surgical risks and poor treatment response

**Vagus Nerve Stimulation**
- direct, intermittent electrical stimulation of left cervical vagus nerve via implanted pulse generator
- used for chronic, recurrent MDD that has failed previous therapy and ECT; slow onset, approximately 30% response rate at 1 yr

### Other Therapy Modalities

**Phototherapy (Light Box Therapy)**
- bright light source exposure, best in morning, for 30-60 minutes (usually 10 000 lux)
- proposed mechanisms: reverses pathological alterations in circadian rhythm through action on suprachiasmatic nucleus
- indications: SAD, non-seasonal depression (as augmentation), sleep disorders
- adverse effects: mania induction, reaction with photosensitizing drug or photosensitive eye or skin conditions

**Aerobic Exercise**
- moderate-intense aerobic exercise is associated with acute increased secretion of serotonin, phenethylamine, BDNF, endogenous opioids and cannabinoids (likely this combination is what contributes to the “runner’s high”)
- long term increases grey matter in multiple areas, as well as improvements in cognition, memory, and stress tolerance
- indications: ongoing research suggests efficacy as adjunctive treatment for MDD; may be helpful in PTSD, schizophrenia

### Canadian Legal Issues

#### Table 23. Common Forms Under the Mental Health Act (in Ontario)

<table>
<thead>
<tr>
<th>Form</th>
<th>Who Signs</th>
<th>When</th>
<th>Expiration Date</th>
<th>Right of Patient to Review Board Hearing</th>
<th>Options Before Form Expires</th>
</tr>
</thead>
<tbody>
<tr>
<td>Form 1: Application by physician to hospitalize a patient for psychiatric assessment against his/her will to a schedule 1 facility (Form 42 given to patient)</td>
<td>Any MD</td>
<td>Within 7 d after examination of the patient</td>
<td>72 h after hospitalization Void if not implemented within 7 d</td>
<td>No</td>
<td>Form 3 + 30 or voluntary admission or Send home ± follow-up</td>
</tr>
<tr>
<td>Form 2: Order for a psychiatric assessment against his/her will which is ordered by Justice of the Peace</td>
<td>Justice of the Peace</td>
<td>No statutory time restriction</td>
<td>7 d from when completed Purpose of form is complete once patient brought to hospital</td>
<td>No</td>
<td>Form 1 + 42 or Send home ± follow-up</td>
</tr>
<tr>
<td>Form 3: Certificate of involuntary admission to a schedule 1 facility (Form 30 given to patient, notice to rights advisor)</td>
<td>Attending MD (different than MD who completed Form 1)</td>
<td>Before expiration of Form 1 Any time to change status of a voluntary patient</td>
<td>14 d</td>
<td>Yes</td>
<td>Form 4 + 30 or Voluntary admission (Form 5)</td>
</tr>
<tr>
<td>Form 4: Certificate of renewal of involuntary admission to a schedule 1 facility (original Form 30 given to patient, notice to rights advisor)</td>
<td>Attending MD following patient on Form 3</td>
<td>Prior to expiration of Form 3</td>
<td>First: 1 mo Second: 2 mo Third: 3 mo (max)</td>
<td>Yes</td>
<td>Form 4 + 30 or Voluntary admission (Form 5)</td>
</tr>
</tbody>
</table>
Table 23. Common Forms Under the Mental Health Act (in Ontario) continued

<table>
<thead>
<tr>
<th>Form</th>
<th>Who Signs</th>
<th>When</th>
<th>Expiration Date</th>
<th>Right of Patient to Review Board Hearing</th>
<th>Options Before Form Expires</th>
</tr>
</thead>
<tbody>
<tr>
<td>Form 5: Change to informal/voluntary status</td>
<td>Attending MD following patient on Form 3/4</td>
<td>Whenever deemed appropriate</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Form 30: Notice to patient that they are now under involuntary admission on either Form 3 or 4. Original to the patient, copy to chart</td>
<td>Attending MD</td>
<td>Whenever Form 3 or Form 4 filled</td>
<td>N/A</td>
<td>Yes</td>
<td>N/A</td>
</tr>
<tr>
<td>Form 33: Notice to patient that patient is incapable of consenting to treatment of mental disorder, and/or management of property and/or disclosure of health information (original copy to patient)</td>
<td>Attending MD</td>
<td>Whenever deemed appropriate</td>
<td>N/A</td>
<td>Yes</td>
<td>N/A</td>
</tr>
</tbody>
</table>

* Schedule 1 Facilities: Able to provide intensive inpatient and outpatient care

Consent

- see Ethical, Legal, and Organizational Medicine, ELOM6

Community Treatment Order (CTO)

- purpose: a CTO orders a person suffering from a serious mental disorder to receive treatment and supervision in the community. Based on a comprehensive plan outlining medications, appointments, and other care believed necessary to allow the person to live in the community (vs. in a psychiatric facility, where things are more restrictive)
- intended for those who
  - due to their serious mental disorder, experience a pattern of admission to a psychiatric facility where condition is usually stabilized
  - after being released, these patients often lack supervision and stop treatment, leading to destabilization
  - due to the destabilization of their condition, these patients usually require re-admission to hospital
  - if CTO violated (e.g. treatment not taken), patient brought in by police to hospital for treatment as per CTO
- criteria for a physician to issue a CTO
  - patient with a prior history of hospitalization
  - a community treatment plan for the person has been made
  - examination by a physician within the previous 72 h before entering into the CTO plan
  - ability of the person subject to the CTO to comply with it
  - consultation with a rights advisor and consent of the person or the person’s substitute decision maker
- CTOs are valid for 6 mo unless they are renewed or terminated at an earlier date such as
  - where the person fails to comply with the CTO
  - when the person or his/her substitute decision-maker withdraws consent to the community treatment plan
- CTO process is consent-based and all statutory protections governing informed consent apply
- the rights of a person subject to a CTO include
  - the right to a review by the Consent and Capacity Board with appeal to the courts each time a CTO is issued or renewed
  - a mandatory review by the Consent and Capacity Board every second time a CTO is renewed
  - the right to request a re-examination by the issuing physician to determine if the CTO is still necessary for the person to live in the community
  - the right to review findings of incapacity to consent to treatment
  - provisions for rights advice

Duty to Inform/Warn

- see Ethical, Legal, and Organizational Medicine, ELOM6

CTO Legislature

- Ontario passed CTO legislation on December 1, 2000 (known as “Brian’s Law”)
- Similar CTOs have been implemented in Saskatchewan (1995), Manitoba (1997), and British Columbia (1999)
References


Koch T. A tour of the psychotropics, 4th ed. Toronto: Mental Health Service, St Michael's Hospital.


Stoner DC, Pace HA, Aperjanp. a clinical review of a second-generation antipsychotic. Clinical Therapeutics 2012;34:1032-43.


# Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>R1</td>
<td>Respirology</td>
</tr>
</tbody>
</table>

# Approach to the Respiratory Patient

<table>
<thead>
<tr>
<th>Section</th>
<th>Subsection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Anatomy Review</td>
<td></td>
</tr>
<tr>
<td>Differential Diagnoses of Common Presentations</td>
<td></td>
</tr>
<tr>
<td>Pulmonary Function Tests</td>
<td></td>
</tr>
<tr>
<td>Chest X-Rays</td>
<td></td>
</tr>
<tr>
<td>Arterial Blood Gases</td>
<td></td>
</tr>
</tbody>
</table>

# Diseases of Airway Obstruction

<table>
<thead>
<tr>
<th>Disease</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumonia</td>
<td></td>
</tr>
<tr>
<td>Asthma</td>
<td></td>
</tr>
<tr>
<td>Chronic Obstructive Pulmonary Disease</td>
<td></td>
</tr>
<tr>
<td>Bronchiectasis</td>
<td></td>
</tr>
<tr>
<td>Cystic Fibrosis</td>
<td></td>
</tr>
</tbody>
</table>

# Interstitial Lung Disease

<table>
<thead>
<tr>
<th>Disease</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unknown Etiologic Agents</td>
<td></td>
</tr>
<tr>
<td>Known Etiologic Agents</td>
<td></td>
</tr>
</tbody>
</table>

# Pulmonary Vascular Disease

<table>
<thead>
<tr>
<th>Disease</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary Hypertension</td>
<td></td>
</tr>
<tr>
<td>Pulmonary Embolism</td>
<td></td>
</tr>
<tr>
<td>Pulmonary Vasculitis</td>
<td></td>
</tr>
<tr>
<td>Pulmonary Edema</td>
<td></td>
</tr>
</tbody>
</table>

# Diseases of the Mediastinum and Pleura

<table>
<thead>
<tr>
<th>Disease</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mediastinal Masses</td>
<td></td>
</tr>
<tr>
<td>Mediastinitis</td>
<td></td>
</tr>
<tr>
<td>Pleural Effusions</td>
<td></td>
</tr>
<tr>
<td>Complicated Effusion</td>
<td></td>
</tr>
<tr>
<td>Empyema</td>
<td></td>
</tr>
<tr>
<td>Atelectasis</td>
<td></td>
</tr>
<tr>
<td>Pneumothorax</td>
<td></td>
</tr>
<tr>
<td>Asbestos-Related Pleural Disease and Mesothelioma</td>
<td></td>
</tr>
</tbody>
</table>

# Respiratory Failure

- Hypoxemic Respiratory Failure
- Hypercapnic Respiratory Failure
- Acute Respiratory Distress Syndrome

# Neoplasms

- Lung Cancer
- Approach to the Solitary Pulmonary Nodule

# Sleep-Related Breathing Disorders

- Hypoventilation Syndromes
- Sleep Apnea

# Introduction to Intensive Care

- Intensive Care Unit Basics
- Organ Failure
- Shock
- Sepsis

# Common Medications

# Landmark Respirology Trials

# References
Approach to the Respiratory Patient

Basic Anatomy Review

Figure 1. Lung lobes and bronchi

Figure 2. Respiration patterns in normal and disease states
Differential Diagnoses of Common Presentations

Table 1. Differential Diagnosis of Dyspnea

<table>
<thead>
<tr>
<th>ACUTE DYSPNEA (MINUTES-HOURS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac causes</td>
</tr>
<tr>
<td>Ischemic heart disease</td>
</tr>
<tr>
<td>CHF exacerbation</td>
</tr>
<tr>
<td>Cardiac tamponade</td>
</tr>
<tr>
<td>Pulmonary causes</td>
</tr>
<tr>
<td>Upper airway obstruction (anaphylaxis, foreign body)</td>
</tr>
<tr>
<td>Airway disease (asthma, COPD exacerbation, bronchitis)</td>
</tr>
<tr>
<td>Pneumothorax (ARDS, pneumonia)</td>
</tr>
<tr>
<td>Pulmonary vascular disease (PE, vasculitis)</td>
</tr>
<tr>
<td>Pleural disease (pneumothorax, tension pneumothorax)</td>
</tr>
<tr>
<td>Respiratory control (metabolic acidosis, ASA toxicity)</td>
</tr>
<tr>
<td>Psychiatric causes</td>
</tr>
<tr>
<td>Anxiety/psychosomatic</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CHRONIC DYSPNEA (WEEKS-MONTHS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac causes</td>
</tr>
<tr>
<td>Valvular heart disease</td>
</tr>
<tr>
<td>Decreased CO</td>
</tr>
<tr>
<td>Respiratory causes</td>
</tr>
<tr>
<td>Parenchymal lung disease (interstitial disease)</td>
</tr>
<tr>
<td>Pulmonary vascular disease (pulmonary HTN, vasculitis)</td>
</tr>
<tr>
<td>Pleural disease (effusion)</td>
</tr>
<tr>
<td>Airway disease (asthma, COPD)</td>
</tr>
<tr>
<td>Metabolic causes</td>
</tr>
<tr>
<td>Severe anemia</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
</tr>
<tr>
<td>Neuromuscular and chest wall disorders</td>
</tr>
<tr>
<td>Deconditioning, obesity, pregnancy, neuromuscular disease</td>
</tr>
</tbody>
</table>

Table 2. Differential Diagnosis of Chest Pain

(see Cardiology and Cardiac Surgery C4 and Emergency Medicine ER21)

<table>
<thead>
<tr>
<th>NONPNEUMITIC</th>
<th>PLEURITIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary</td>
<td>Pulmonary</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>Pneumonia</td>
</tr>
<tr>
<td>PE</td>
<td>PE</td>
</tr>
<tr>
<td>Neoplasm</td>
<td>Pneumothorax</td>
</tr>
<tr>
<td>Cardiac</td>
<td>Hemorrhax</td>
</tr>
<tr>
<td>MI</td>
<td>Neoplasm</td>
</tr>
<tr>
<td>Myocarditis/pericarditis</td>
<td>TB</td>
</tr>
<tr>
<td>Esophageal</td>
<td>Empyema</td>
</tr>
<tr>
<td>GERD</td>
<td>Cardiac</td>
</tr>
<tr>
<td>Spasm</td>
<td>Pericarditis</td>
</tr>
<tr>
<td>Esophagitis</td>
<td>Dressler’s syndrome</td>
</tr>
<tr>
<td>Ulceration</td>
<td>GI</td>
</tr>
<tr>
<td>Achalasia</td>
<td>Subphrenic abscess</td>
</tr>
<tr>
<td>Neoplasm</td>
<td>Pancreatitis</td>
</tr>
<tr>
<td>Esophageal rupture</td>
<td>MSK</td>
</tr>
<tr>
<td>Mediastinal</td>
<td>Costochondritis</td>
</tr>
<tr>
<td>Lymhoma</td>
<td>Fractured rib</td>
</tr>
<tr>
<td>Thymoma</td>
<td>Myositis</td>
</tr>
<tr>
<td>Subdiaphragmatic</td>
<td>Herpes zoster</td>
</tr>
<tr>
<td>PUD</td>
<td></td>
</tr>
<tr>
<td>Gastritis</td>
<td></td>
</tr>
<tr>
<td>Bilary colic</td>
<td></td>
</tr>
<tr>
<td>Pancreatitis</td>
<td></td>
</tr>
<tr>
<td>Vascular</td>
<td></td>
</tr>
<tr>
<td>Dissecting aortic aneurysm</td>
<td></td>
</tr>
<tr>
<td>MSK</td>
<td></td>
</tr>
<tr>
<td>Costochondritis</td>
<td></td>
</tr>
<tr>
<td>Skin</td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td></td>
</tr>
<tr>
<td>Ribs</td>
<td></td>
</tr>
</tbody>
</table>

Table 3. Differential Diagnosis of Hemoptysis

<table>
<thead>
<tr>
<th>Airway Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute or chronic bronchitis</td>
</tr>
<tr>
<td>Bronchiectasis</td>
</tr>
<tr>
<td>Bronchogenic CA</td>
</tr>
<tr>
<td>Bronchial carcinoma tumour</td>
</tr>
<tr>
<td>Parenchymal Disease</td>
</tr>
<tr>
<td>Pneumonia</td>
</tr>
<tr>
<td>TB</td>
</tr>
<tr>
<td>Lung abscess</td>
</tr>
<tr>
<td>Vascular Disease</td>
</tr>
<tr>
<td>PE</td>
</tr>
<tr>
<td>Elevated pulmonary venous pressure:</td>
</tr>
<tr>
<td>LVF</td>
</tr>
<tr>
<td>Mitral stenosis</td>
</tr>
<tr>
<td>Vascular malformation</td>
</tr>
<tr>
<td>Vasculitis</td>
</tr>
<tr>
<td>Goodpasture’s syndrome</td>
</tr>
<tr>
<td>Idiopathic pulmonary hemosiderosis</td>
</tr>
<tr>
<td>Miscellaneous</td>
</tr>
<tr>
<td>Impaired coagulation</td>
</tr>
<tr>
<td>Pulmonary endometriosis</td>
</tr>
</tbody>
</table>

Table 4. Differential Diagnosis of Cough

<table>
<thead>
<tr>
<th>Airway Irritants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhaled smoke, dusts, fumes</td>
</tr>
<tr>
<td>Postnasal drip (upper airway cough syndrome)</td>
</tr>
<tr>
<td>Aspiration</td>
</tr>
<tr>
<td>Gastric contents (GERD)*</td>
</tr>
<tr>
<td>Oral secretions</td>
</tr>
<tr>
<td>Foreign body</td>
</tr>
<tr>
<td>Airway Disease</td>
</tr>
<tr>
<td>URI including postnasal drip and sinusitis*</td>
</tr>
<tr>
<td>Acute or chronic bronchitis</td>
</tr>
<tr>
<td>Bronchiectasis</td>
</tr>
<tr>
<td>Neoplasm</td>
</tr>
<tr>
<td>External compression by node or mass lesion</td>
</tr>
<tr>
<td>Asthma*</td>
</tr>
<tr>
<td>COPD</td>
</tr>
<tr>
<td>Parenchymal Disease</td>
</tr>
<tr>
<td>Pneumonia</td>
</tr>
<tr>
<td>Lung abscess</td>
</tr>
<tr>
<td>Interstitial lung disease</td>
</tr>
<tr>
<td>CHF</td>
</tr>
<tr>
<td>Drug-induced (e.g. ACEI)</td>
</tr>
</tbody>
</table>

**“Big Three” causes of chronic cough**

Adapted from: Weinberger SE. Principles of pulmonary medicine, 5th ed. 2008. With permission from Elsevier

Common Causes of Clubbing
- Pulmonary: Lung CA, bronchiectasis, pulmonary fibrosis, abscess, CF, empyema (NOT COPD)
- Cardiac: Cyanotic heart disease, endocarditis, A-V fistula
- GI: IBD, celiac, cirrhosis
- Endocrine: Graves’
- Other: Other malignancy, primary hypothyroid osteoarthropathy

Coughing is not seen in COPD – if present, think malignancy

Figure 3. Signs of nail clubbing

- Normal
- Clubbed

Hemoptysis
- Most common cause is bronchitis
- 90% of massive hemoptysis is from the bronchial arteries
- Considered “massive” if >600 mL/24 h

Most Common Causes of Chronic Cough in the Non-smoking Patient (cough > 3 mo with normal CXR)
- GERD
- Asthma
- Postnasal drip
- ACEI
Pulmonary Function Tests

- useful in differentiating the pattern of lung disease (obstructive vs. restrictive)
- assess lung volumes, flow rates, and diffusion capacity (Figures 4A and 4B)
- note: normal values for FEV1 are approximately ±20% of the predicted values (for age, sex, and height); ethnicity may affect predicted values

Table 5. Comparison of Lung Flow and Volume Parameters in Lung Disease

<table>
<thead>
<tr>
<th>Obstructive</th>
<th>Restrictive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decreased flow rates (most marked during expiration)</td>
<td>Decreased lung compliance</td>
</tr>
<tr>
<td>Air trapping (increased RV/TLC)</td>
<td>Decreased lung volumes</td>
</tr>
<tr>
<td>Hyperinflation (increased FRC, TLC)</td>
<td></td>
</tr>
</tbody>
</table>

DDx

- Asthma, COPD, CF, bronchiolitis, bronchiectasis*
- ILD, pleural disease, neuromuscular disease, chest wall disease

Table 6. Common Respirology Procedures

<table>
<thead>
<tr>
<th>Technique</th>
<th>Purpose</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plethysmography</td>
<td>Measure FRC</td>
<td>After a normal expiration the patient inhales against a closed mouthpiece</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Resultant changes in the volume and pressure of the plethysmograph are used to</td>
</tr>
<tr>
<td></td>
<td></td>
<td>calculate the volume of gas in the thorax</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Useful for patients with air trapping</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Helium dilution</td>
<td>Measure FRC</td>
<td>A patient breathes from a closed circuit containing a known concentration and</td>
</tr>
<tr>
<td></td>
<td></td>
<td>volume of helium</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Since the amount of helium remains constant, FRC is determined based on the</td>
</tr>
<tr>
<td></td>
<td></td>
<td>final concentration of the helium in the closed system</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Only includes airspaces that communicate with the bronchial tree</td>
</tr>
<tr>
<td>Bronchoscopy</td>
<td>Diagnosis and therapy</td>
<td>A flexible or rigid bronchoscope is used for visualization of a patient’s airways. Allows for:</td>
</tr>
</tbody>
</table>
Figure 5. Interpreting PFTs

**Chest X-Rays**

- see Medical Imaging, MI4

<table>
<thead>
<tr>
<th>Pattern</th>
<th>Signs</th>
<th>Common DDx</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consolidation (&quot;Airspace disease&quot;)</td>
<td>Air bronchogram, Silhouette sign, Less visible blood vessels</td>
<td>Acute: water (pulmonary edema), pus (pneumonia), blood (hemorrhage) Chronic: neoplasm (lymphoma), inflammatory (eosinophilic pneumonia), infection (TB, fungal)</td>
</tr>
<tr>
<td>Reticular (&quot;Interstitial disease&quot;)</td>
<td>Increased linear markings, Honeycombing (IPF)</td>
<td>ILD (IPF, collagen vascular disease, asbestos, drugs)</td>
</tr>
<tr>
<td>Nodular</td>
<td>Cavitary vs. non-cavitary</td>
<td>Cavitary: neoplasm (primary vs. metastatic lung cancer), infectious (anaerobic or Gram negative, TB, fungal), inflammatory (RA, Granulomatosis with Polyangiitis (GPA))</td>
</tr>
</tbody>
</table>

Non-cavitary: above + sarcoïd, Kaposis sarcoma (in HIV), silicosis and other pneumoconioses

**Arterial Blood Gases**

- provides information on acid-base and oxygenation status
- see Nephrology, NP15

**Approach to Acid-Base Status**

1. Is the pH acidic (pH <7.35), alkalemic (pH >7.45), or normal (pH 7.35-7.45)?
2. What is the primary disturbance?
   - metabolic: change in HCO₃⁻ and pH in same direction
   - respiratory: change in HCO₃⁻ and pH in opposite directions
3. Is there appropriate compensation? (see Table 8)
   - metabolic compensation occurs over 2-3 d reflecting altered renal HCO₃⁻ production and excretion
   - respiratory compensation through ventilatory control of P.CO₂ occurs immediately
   - inadequate compensation may indicate a second acid-base disorder
Table 8. Expected Compensation for Specific Acid-Base Disorders

<table>
<thead>
<tr>
<th>Disturbance</th>
<th>PCO₂ (mmHg) (normal ~40)</th>
<th>HCO₃⁻ (mmHg) (normal ~24)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory Acidosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute</td>
<td>↑ 10</td>
<td>↑ 1</td>
</tr>
<tr>
<td>Chronic</td>
<td>↑ 10</td>
<td>↑ 3</td>
</tr>
<tr>
<td>Respiratory Alkalosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute</td>
<td>↓ 10</td>
<td>↓ 2</td>
</tr>
<tr>
<td>Chronic</td>
<td>↓ 10</td>
<td>↓ 5</td>
</tr>
<tr>
<td>Metabolic Acidosis</td>
<td>↓ 1</td>
<td>↓ 1</td>
</tr>
<tr>
<td>Metabolic Alkalosis</td>
<td>↑ 5-7</td>
<td>↑ 10</td>
</tr>
</tbody>
</table>

4. if there is metabolic acidosis, what is the anion gap and osmolar gap?
   - anion gap = [Na⁺]−[(Cl⁻)+[HCO₃⁻]]; normal ≤10-15 mmol/L
   - osmolar gap = measured osmolarity – calculated osmolarity = measured – (2[Na⁺] + glucose + urea); normal ≤10 mmol/L

5. if anion gap is increased, is the change in bicarbonate the same as the change in anion gap?
   - if not, consider a mixed metabolic picture

Table 9. Differential Diagnosis of Respiratory Acidosis

<table>
<thead>
<tr>
<th>Increased P CO₂ secondary to hypoventilation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory Centre Depression (Decreased RR)</td>
</tr>
<tr>
<td>Drugs (anesthesia, sedatives, narcotics)</td>
</tr>
<tr>
<td>Trauma</td>
</tr>
<tr>
<td>Increased ICP</td>
</tr>
<tr>
<td>Encephalitis</td>
</tr>
<tr>
<td>Stroke</td>
</tr>
<tr>
<td>Central apnea</td>
</tr>
<tr>
<td>Supplemental O₂ in chronic CO₂ retainers (e.g. COPD)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Neuromuscular Disorders (Decreased Vital Capacity)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myasthenia gravis</td>
</tr>
<tr>
<td>Guillain-Barré syndrome</td>
</tr>
<tr>
<td>Poliomyelitis</td>
</tr>
<tr>
<td>Muscular dystrophies</td>
</tr>
<tr>
<td>ALS</td>
</tr>
<tr>
<td>Myopathies</td>
</tr>
<tr>
<td>Chest wall disease (obesity, kyphoscoliosis)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lung Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD</td>
</tr>
<tr>
<td>Asthma</td>
</tr>
<tr>
<td>Pulmonary edema</td>
</tr>
<tr>
<td>Pneumothorax</td>
</tr>
<tr>
<td>Pneumonia</td>
</tr>
<tr>
<td>ILD (late stage)</td>
</tr>
<tr>
<td>ARDS</td>
</tr>
</tbody>
</table>

| Mechanical Hypoventilation (Inadequate Mechanical Ventilation) |

- see Nephrology, NP16 for differential diagnosis of metabolic acidosis and alkalosis
Diseases of Airway Obstruction

Pneumonia

- see Infectious Diseases, ID7, ID34

Asthma

- see Family Medicine, FM16 and Pediatrics, P85

Definition

- chronic inflammatory disorder of the airways resulting in episodes of reversible bronchospasm causing airflow obstruction
- associated with reversible airflow limitation and airway hyper-responsiveness to endogenous or exogenous stimuli

Epidemiology

- common, 7-10% of adults, 10-15% of children
- most children with asthma significantly improve in adolescence
- often family history of atopy (asthma, allergic rhinitis, eczema)
- occupational asthma (organic allergies, isocyanates, animals, etc.)

At Sea Level on Room Air

\[ F_{\text{IO}_2} = 0.21 \]
\[ P_{\text{aw}} = 760 \text{ mmHg} \]
\[ P_{\text{HbO}_2} = 47 \text{ mmHg} \]
\[ RQ = 0.8 \]

Thus, A-aDO₂ Gradient on Room Air

\[ A-aDO₂ = (150 – 1.25 \times [P_{\text{CO}_2}] – P_{\text{O}_2}) \]

Diffusion Capacity for CO

\[ DL_CO \] decreases with:
- Decreased surface area (e.g. emphysema)
- Decreased hemoglobin
- Interstitial lung disease
- Pulmonary vascular disease

\[ DL_CO \] increases with:
- Asthma
- Pulmonary hemorrhage
- Polycythemia
- Increased pulmonary blood volume

Pulmonary Shunt

Occurs when the capillary networks of the alveoli are perfused, yet there is a lack of adequate ventilation (and thus oxygenation) in that alveolus or group of alveoli. Thus this blood enters the pulmonary venous system without being oxygenated

Airway Obstruction (decreased FEV₁)

- Asthma
- COPD (chronic bronchitis, emphysema)
- Bronchiectasis (obstructive or mixed)
- Cystic fibrosis (obstructive or mixed)

Red Flags

Severe tachypnea/tachycardia, respiratory muscle fatigue, diminished expiratory effort, cyanosis, silent chest, decreased LOC

Central cyanosis is not detectable until SaO₂ is <85%. It is more easily detected in polycythemia and less readily detectable in anemia
Pathophysiology
- airway obstruction → V/Q mismatch → hypoxemia → ↑ ventilation → ↓ P.CO₂ → ↑ pH and muscle fatigue → ↓ ventilation, ↑ P.CO₂/↓ pH

Signs and Symptoms
- dyspnea, wheezing, chest tightness, cough (especially nocturnal), sputum
- symptoms can be paroxysmal or persistent
- signs of respiratory distress
- pulsus paradoxus

Exacerbations mild, infrequent

Controller therapy

5.
4.
2.
1.

Emergency Management of Asthma

• see Emergency Medicine, ER29
  1. inhaled β₂-agonist first line (MDI route and spacer device recommended)
  2. systemic steroids (PO or IV if severe)
  3. if severe add anticholinergic therapy ± magnesium sulphate
  4. rapid sequence intubation in life-threatening cases (plus 100% O₂, monitors, IV access)
  5. SC/IV adrenaline if caused by anaphylaxis, IV salbutamol if unresponsive
  6. corticosteroid therapy at discharge

Table 11. Criteria for Determining if Asthma is Well Controlled

<table>
<thead>
<tr>
<th>Daytime symptoms &lt;4 d/wk</th>
<th>Night-time symptoms &lt;1 night/wk</th>
<th>Physical activity normal</th>
<th>Exacerbations mild, infrequent</th>
</tr>
</thead>
<tbody>
<tr>
<td>No asthma-related absence from work/school</td>
<td>β₂-agonist use &lt;4 times/wk</td>
<td>FEV₁ or PEF &gt;90% of personal best</td>
<td>PEF diurnal variation &lt;10-15%</td>
</tr>
</tbody>
</table>

Adapted from: Can Respir J 2012; 19:127-164

Investigations
- O₂ saturation
- ABGs (consider in acute exacerbation, along with peak flows, in Emergency Department)
- decreased P.O₂ during attack (V/Q mismatch)
- decreased P.CO₂ in mild asthma (hyperventilation)
- normal or increased P.CO₂ is an ominous sign: patient is no longer able to hyperventilate (worsened airway obstruction or respiratory muscle fatigue)
- PFTs (do when stable)

Table 12. Pulmonary Function Criteria for Diagnosis of Asthma

<table>
<thead>
<tr>
<th>Preferred Measurement</th>
<th>Alternative Measurements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spirometry</td>
<td></td>
</tr>
<tr>
<td>Showing Reversible</td>
<td>Peak Expiratory Flow</td>
</tr>
<tr>
<td>Airway Obstruction</td>
<td>Variability</td>
</tr>
<tr>
<td>(1) ↓ FEV₁/FVC below</td>
<td></td>
</tr>
<tr>
<td>lower limit of normal</td>
<td>(1) ↓ in PEF after a</td>
</tr>
<tr>
<td>Adults: &lt;0.75 to 0.8</td>
<td>bronchodilator or course</td>
</tr>
<tr>
<td>in adults</td>
<td>of controller therapy</td>
</tr>
<tr>
<td>Children age 6+ :</td>
<td>Adults: PEF ↑ 60 L/min</td>
</tr>
<tr>
<td>↓ &lt;0.8-0.9</td>
<td>(min. 20%) OR</td>
</tr>
<tr>
<td></td>
<td>Diurnal variation &gt;8%</td>
</tr>
<tr>
<td></td>
<td>for twice daily readings</td>
</tr>
<tr>
<td></td>
<td>(20% for multiple daily</td>
</tr>
<tr>
<td></td>
<td>readings)</td>
</tr>
<tr>
<td>AND</td>
<td>Children age 6+ : PEF ↑</td>
</tr>
<tr>
<td></td>
<td>20%</td>
</tr>
<tr>
<td>(2) ↑ FEV₁ ≥12%</td>
<td>(1) Methacholine challenge:</td>
</tr>
<tr>
<td>(min. 200 mL in adults)</td>
<td>Pober 20 &lt;4 mg/mL (4-16 mg/mL is</td>
</tr>
<tr>
<td>after bronchodilator</td>
<td>borderline; &gt;16 mg/mL is</td>
</tr>
<tr>
<td>or controller therapy</td>
<td>negative) OR</td>
</tr>
<tr>
<td></td>
<td>(2) Post-exercise: ↓ FEV₁</td>
</tr>
<tr>
<td></td>
<td>≥10-15%</td>
</tr>
</tbody>
</table>

Adapted from: Can Respir J 2012; 19:127-164

Treatment
- environment: avoid triggers
- patient education: features of the disease, goals of treatment, self-monitoring
- pharmacological
- symptomatic relief in acute episodes: short-acting β₂-agonist, anticholinergic bronchodilators, oral steroids, addition of a long acting β₂-agonist
- long-term prevention: inhaled/oral corticosteroids, anti-allergic agents, long-acting β₂-agonists, long-acting anticholinergics, methylxanthine, LTRA, anti-IgE antibodies (e.g. omalizumab)

Asthma Triggers
- URIs
- Allergens (pet dander, house dust, moulds, cockroach)
- Irritants (cigarette smoke, air pollution)
- Drugs (NSAIDs, β-blockers)
- Preservatives (sulphites, MSG)
- Other (emotion/anxiety, cold air, exercise, GERD)

Asthma Action Plan
Is a written plan developed by patients and their physicians which includes signs and symptoms for patients to recognize their current level of respiratory distress (denoted as ‘green’, ‘yellow’, or ‘red/emergency’ zones) and the personalized treatment options for each zone

Signs of Poor Asthma Control
- Daytime Sx >4 times/wk
- Activities reduced
- Nighttime Sx >1 time/wk
- GP visits
- ER visits
- Rescue puffer (SABA) use >4 times/wk
- School and work absences
Guidelines for Asthma Management

**Figure 9. Guidelines for asthma management**

1. **If a Beta-2 agonist is required, consider LABA for night-time symptoms**

2. **LTRA in Addition to Usual Care for Acute Asthma in Adults and Children**
   - **Purpose:** To determine if the addition of LTRA is beneficial to patients with acute asthma receiving inhaled bronchodilators and systemic corticosteroids.
   - **Methods:** RCTs in Cochrane Airways Group's Specialised Register of trials that compared LTRAs and standard vs. placebo and standard in people with acute asthma of any age.
   - **Results:** 8 trials, 1,470 adults and 470 children. For oral treatment, no significant difference between LTRAs and control in hospital admission (RR 0.86; 95% CI 0.66-1.11). LTRAs improved FEV1 in adults (mean difference 0.08; 95% CI 0.01-0.14) but not in children. No significant difference in adverse events between LTRAs and control (RR 0.81; 95% CI 0.52-1.28). Similar results were found for intravenous treatment.
   - **Conclusions:** Currently, there is no evidence to support routine use of LTRAs in acute asthma.

**Chronic Obstructive Pulmonary Disease**

- **see** [Family Medicine, FM16](#)

**Definition**

- progressive and irreversible condition of the lung characterized by chronic obstruction to airflow with many patients having periodic exacerbations, gas trapping, lung hyperinflation, and weight loss
- 2 subtypes: chronic bronchitis and emphysema (usually coexist to variable degrees)
- gradual decrease in FEV1 over time with episodes of acute exacerbations

**Table 13. Clinical and Pathologic Features of COPD**

<table>
<thead>
<tr>
<th>Chronic Bronchitis</th>
<th>Emphysema</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Defined Clinically</strong></td>
<td><strong>Defined Pathologically</strong></td>
</tr>
<tr>
<td>Productive cough on most days for at least 3 consecutive months in 2 successive years</td>
<td>Dilatation and destruction of air spaces distal to the terminal bronchiole without obvious fibrosis</td>
</tr>
<tr>
<td>Obstruction is due to narrowing of the airway lumen by mucosal thickening and excess mucus</td>
<td>Decreased elastic recoil of lung parenchyma causes decreased expiratory driving pressure, airway collapse, and air trapping</td>
</tr>
<tr>
<td></td>
<td>2 Types</td>
</tr>
<tr>
<td></td>
<td>1) <strong>Centriacinar</strong> (respiratory bronchioles predominantly affected)</td>
</tr>
<tr>
<td></td>
<td>Typical form seen in smokers, primarily affects upper lung zones</td>
</tr>
<tr>
<td></td>
<td>2) <strong>Panacinar</strong> (respiratory bronchioles, alveolar ducts, and alveolar sacs affected)</td>
</tr>
<tr>
<td></td>
<td>Accounts for about 1% of emphysema cases</td>
</tr>
<tr>
<td></td>
<td>α1-antitrypsin deficiency, primarily affects lower lobes</td>
</tr>
</tbody>
</table>

*Note that both chronic bronchitis and emphysema can exist without obstruction. Only if obstruction is also present is it termed COPD*

**Risk Factors**

- smoking is #1 risk factor
- others
- environmental: air pollution, occupational exposure, exposure to wood smoke or other biomass fuel for cooking
- treatable factors: α1-antitrypsin deficiency, bronchial hyperactivity
- demographic factors: age, family history, male sex, history of childhood respiratory infections, low socioeconomic status

**Complications of COPD**

- Polyglobulism 2° to hypoxemia
- Chronic hypoxemia
- Pulmonary HTN from vasoconstriction
- Cor pulmonale
- Pneumothorax due to rupture of emphysematous bullae

**CD Retainers**

- On AQL retainers have chronically elevated CO levels with a normal pH. Maintain O2 Sat between 88-92% to prevent Haldane effect, worsening V/Q mismatch, and decreased respiratory drive

- Remember, first line therapy for COPD is smoking cessation

- α1-Antitrypsin Deficiency
  - Inherited disorder of defective production of α1-antitrypsin, a protein produced by hepatocytes. Acts in the alveolar tissue by inhibiting the action of proteases from destroying alveolar tissue. When deficient, proteases can destroy lung alveoli resulting in emphysema
Signs and Symptoms

Table 14. Clinical Presentation and Investigations for Chronic Emphysema

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Signs</th>
<th>Investigations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bronchitis (Blue Bloaters*)</td>
<td>Chronic productive cough</td>
<td>Cyanosis (2nd to hypoxemia and hypercapnia)</td>
</tr>
<tr>
<td></td>
<td>Pursuant sputum</td>
<td>Perihedral edema from RVF (cor pulmonale)</td>
</tr>
<tr>
<td></td>
<td>Hemoptysis</td>
<td>Crackles, wheezes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prolonged expiration if obstructive</td>
</tr>
</tbody>
</table>

Emphysema (Pink Puffers*)

<table>
<thead>
<tr>
<th>Signs</th>
<th>Investigations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pink skin</td>
<td>PFT: ↓ FEV₁, ↓ FEV₁/FVC ↑ TLC (hyperinflation)</td>
</tr>
<tr>
<td>Purse-lip breathing</td>
<td>↑ RV (gas trapping)</td>
</tr>
<tr>
<td>Accessory muscle use</td>
<td>↑ DLco</td>
</tr>
<tr>
<td>Cachectic appearance due to anoxemia and increased work of breathing</td>
<td>CXR: ↑ AP diameter ↓ heart shadow ↓ retrosternal space</td>
</tr>
<tr>
<td>Hyperinflation/barrel chest, hyperresonant percussion</td>
<td>Bullae ↓ peripheral vascular markings</td>
</tr>
<tr>
<td>Decreased breath sounds</td>
<td></td>
</tr>
<tr>
<td>Decreased diaphragmatic excursion</td>
<td></td>
</tr>
</tbody>
</table>

*Note that the distinction between “blue bloaters” and “pink puffers” is more of historical than practical interest as most COPD patients have elements of both.

Table 15. Treatment of Stable COPD

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROLONG SURVIVAL</td>
<td></td>
</tr>
<tr>
<td>Smoking cessation</td>
<td>Nicotine replacement, bupropion, varenicline</td>
</tr>
<tr>
<td>Vaccination</td>
<td>Influenza, pneumococcal vaccine</td>
</tr>
<tr>
<td>Home oxygen</td>
<td>Prevents cor pulmonale and decreases mortality if used &gt;15h/d; indicated if (1) P:O₂ &lt; 55 mmHg or (2) &lt; 60 mmHg with cor pulmonale or polycythemia</td>
</tr>
</tbody>
</table>

SYMPTOMATIC RELIEF (no mortality benefit)

| Bronchodilators (mainstay of current drug therapy, used in combination) | Short-acting anticholinergics (e.g. ipratropium bromide) and short-acting β2-agonists (e.g. salbutamol, terbutaline) |
| | SABAs: rapid onset but significant side effects at high doses (e.g. hypokalemia) |
| Short-acting anticholinergics more effective than SABas with fewer side effects but slower onset; take regularly rather than PRN |
| LABAs (e.g. salmeterol, formoterol, indacaterol) and long-acting anticholinergics (e.g. tiotropium bromide, glycopyrronium bromide) |
| More sustained effects for moderate to severe COPD |
| Inhaled corticosteroid (ICS) + LABA combination (e.g. Advair®: fluticasone + salmeterol, Symbicort®: budenoside + formoterol) |
| ICS/LABA increases effectiveness vs. LABA alone |
| Theophylline: weak bronchodilator; limited evidence to suggest combination with bronchodilator |
| Side effects: nervous tremor, nausea/vomiting/diarrhea, tachycardia, arrhythmias, sleep changes |
| PDE4 inhibitor: roflumilast (Daxas®) anti-inflammatory medication useful in COPD with chronic bronchitis, severe airflow obstruction, frequent exacerbations |

Corticosteroids

| | ICS monotherapy has been shown to increase the incidence of pneumonia in COPD; ICS should only be used with a LABA in combination in patients with a history of exacerbations |
| | Oral steroids are important when treating exacerbations; chronic systemic glucocorticoids are generally not recommended due to unfavourable benefit to risk ratio |

Surgical

| | Lung volume reduction surgery (resection of emphysematous parts of lung, associated with higher mortality if FEV₁ < 20%, lung transplant |

Other

| | Patient education, eliminate respiratory irritants/allergens (occupational/environmental), exercise rehabilitation to improve physical endurance |
**Acute Exacerbations of COPD**

- **definition**: sustained (>48 h) worsening of dyspnea, cough, or sputum production leading to an increased use of medications
- **in addition**, defined as either purulent or non-purulent (to predict need for antibiotic therapy)
- **etiology**: viral URI, bacteria, air pollution, CHE, PE, MI must be considered
- **management**: ABCs, consider assisted ventilation if decreasing LOC or poor ABGs
- **O₂**: target 88-92% SaO₂ for CO2: retainers
- bronchodilators by MDI with spacer or nebulizer
- SABA + anticholinergic, e.g. salbutamol and ipratropium bromide via nebulizers × 3 back-to-back q15min
- systemic corticosteroids: IV solumedrol or oral prednisone
- antibiotics for exacerbations with increased sputum production and at least one of the following: increased dyspnea or sputum purulence
- simple exacerbation (no risk factors): amoxicillin, 2nd or 3rd generation cephalosporin, macrolide, or TMP/SMX
- complicated exacerbation (one of: FEV₁ ≤50% predicted, ≥4 exacerbations per year, ischemic heart disease, home O₂ use, chronic oral steroid use): fluoroquinolone or β-lactam + β-lactamase inhibitor (amoxicillin/clavulanate)
- post exacerbation: rehabilitation with general conditioning to improve exercise tolerance
- **ICU admission**
- for life threatening exacerbations
- ventilatory support
- non-invasive: NPPV, BIPAP
- conventional mechanical ventilation

**Prognosis in COPD**

- **prognostic factors**
  - level of dyspnea is the single best predictor
  - development of complications, e.g. hypoxemia or cor pulmonale
- **3 yr survival**
  - FEV₁ <1 L = 50%
  - FEV₁ <0.75 L = 33%
- **BODE Index** for risk of death in COPD
  - greater score = higher probability the patient will die from COPD; score can also be used to predict hospitalization
- 10 point index consisting of four factors
  - Body mass index (BMI): <21 (+1 point)
  - Obstruction (FEV₁): 50-64% (+1), 36-49% (+2), <35% (+3)
  - Dyspnea (MRC scale): walks slower than people of same age on level surface, stops occasionally (+1), stops at 100 yards or a few minutes on the level (+2), too breathless to walk or breathless when dressing/un dressing (+3)
  - Exercise capacity (6 minute walk distance): 250-349 m (+1), 150-249 m (+2), <149 m (+3)
**Bronchiectasis**

**Definition**
- irreversible dilatation of airways due to inflammatory destruction of airway walls resulting from persistently infected mucus
- usually affects medium sized airways
- *P. aeruginosa* is the most common pathogen; *S. aureus*, *H. influenzae*, and nontuberculous mycobacteria also common

**Table 16. Etiology and Pathophysiology of Bronchiectasis**

<table>
<thead>
<tr>
<th>Obstruction</th>
<th>Post-Infectious (results in dilatation of bronchial walls)</th>
<th>Impaired Defenses (leads to interference of drainage, chronic infections, and inflammation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumour</td>
<td>Pneumonia</td>
<td>Hypogammaglobulinemia</td>
</tr>
<tr>
<td>Foreign body</td>
<td>TB</td>
<td>CF</td>
</tr>
<tr>
<td>Thick mucus</td>
<td>Measles</td>
<td>Defective leukocyte function</td>
</tr>
<tr>
<td>Pertussis</td>
<td>Allergic bronchopulmonary aspergillosis</td>
<td>(Kartagener’s syndrome; bronchiectasis, sinusitis, situs inversus)</td>
</tr>
<tr>
<td></td>
<td>Nontuberculous mycobacterium (NTM)</td>
<td></td>
</tr>
</tbody>
</table>

**Signs and Symptoms**
- chronic cough, purulent sputum (but 10–20% have dry cough), hemoptysis (can be massive), recurrent pneumonia, local crackles (inspiratory and expiratory), wheezes
- clubbing
- may be difficult to differentiate from chronic bronchitis

**Investigations**
- PFTs: often demonstrate obstructive pattern but may be normal
- CXR
  - nonspecific: increased markings, linear atelectasis, loss of volume in affected areas
  - specific: “tram tracking” – parallel narrow lines radiating from hilum, cystic spaces, honeycomb like structures
  - high-resolution thoracic CT (diagnostic, gold standard)
    - 87–97% sensitivity, 93–100% specificity
    - "signet ring": dilated bronchi with thickened walls where diameter bronchus > diameter of accompanying artery
  - sputum cultures (routine + AFB)
  - serum lg levels
  - sweat chloride if cystic fibrosis suspected (upper zone predominant)

**Treatment**
- vaccination: influenza and pneumococcal vaccination
- antibiotics (oral, IV, inhaled): routinely used for mild exacerbations, driven by sputum sensitivity; macrolides may be used chronically for an anti-inflammatory effect
- inhaled antibiotics (tobramycin) used chronically to suppress *Pseudomonas* and reduce exacerbations
- inhaled corticosteroids: decrease inflammation and improve FEV; however, may increase risk of exacerbations
- oral corticosteroids for acute, major exacerbations
- chest physiotherapy, breathing exercises, physical exercise
- pulmonary resection: in selected cases with focal bronchiectasis

**Cystic Fibrosis**

- see *Pediatrics*, P87

**Pathophysiology**
- chloride transport dysfunction: thick secretions from exocrine glands (lung, pancreas, skin, reproductive organs) and blockage of secretory ducts

**Clinical Features**
- results in severe lung disease, pancreatic insufficiency, diabetes, and azoospermia
- other manifestations: meconium ileus in infancy, distal ileal obstruction in adults, sinusitis, liver disease
- chronic lung infections
  - *S. aureus*: early
  - *P. aeruginosa*: most common
  - *B. cepacia*: worse prognosis but less common
  - *Aspergillus fumigatus*

**Investigations**
- sweat chloride test
- Increased concentrations of NaCl and K⁺ ([Cl⁻] >60 mmol/L is diagnostic in children)
- Heterozygotes have normal sweat tests (and no symptoms)
- PFTs
  - Early: airflow limitation in small airways
  - Late: severe airflow obstruction, hyperinflation, gas trapping, decreased DLOD (very late)
- ABGs
  - Hypoxemia, hypercapnia later in disease with eventual respiratory failure and cor pulmonale
- CXR
  - Hyperinflation, increased pulmonary markings (especially upper lobes)

**Treatment**
- Chest physiotherapy and postural drainage
- Bronchodilators (salbutamol ± ipratropium bromide)
- Inhaled mucolytic (reduces mucus viscosity), hypertonic saline DNase
- Inhaled antibiotics (tobramycin, colistin, aztreonam)
- Antibiotics (e.g. ciprofloxacin)
- Lung transplant
- Pancreatic enzyme replacements, high calorie diet

**Prognosis**
- Depends on: infections (cepacia colonization), FEV₁, acute pulmonary exacerbations, lung transplant vs. non-lung transplant

---

**Interstitial Lung Disease**

**Definition**
- A group of disorders which cause progressive scarring of lung tissue
- This scarring can eventually impair lung function and gas exchange

**Pathophysiology**
- Inflammatory and/or fibrosing process in the alveolar walls → distortion and destruction of normal alveoli and microvasculature
- Typically associated with
  - Lung restriction (decrease in TLC and VC)
  - Decreased lung compliance (increased or normal FEV₁/FVC)
  - Impaired diffusion (decreased DLOD)
  - Hypoxemia due to V/Q mismatch (usually without hypercapnia until end stage)
  - Pulmonary HTN and cor pulmonale occur with advanced disease secondary to hypoxemia and blood vessel destruction

**Etiology**
- >100 known disorders can cause ILD
- Majority due to unknown agents or cause

---

**Table 17. Interstitial Lung Diseases**

<table>
<thead>
<tr>
<th>Unknown Etiology</th>
<th>Known Etiology</th>
<th>Inherited Disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Idiopathic interstitial pneumonias</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UIP (usual interstitial pneumonia e.g. IPF)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSIP (non-specific interstitial pneumonia)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIP (lymphocytic interstitial pneumonia)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COP (cryptogenic organizing pneumonia e.g. BOOP)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DIP (desquamative interstitial pneumonia)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPPE (idiopathic pulmonary pararenchymal fibroelastosis)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AFOP (acute fibrosing and organizing pneumonia)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarcoidosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Langerhans-cell histiocytosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(eosinophilic granuloma)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphangioleiomyomatosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ILD Associated with Systemic Rheumatic Diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sclerodema</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polymyositis/dermatomyositis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-synthetase syndromes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mixed connective tissue disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Environment/Occupation Associated ILD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypersensitivity pneumonitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Farmer’s lung</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Air conditioner/humidifier lung</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bird breeder’s lung</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumoconioses (inorganic dust)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Silicosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asbestosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coal worker’s pneumoconiosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic beryllium disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumonitis from gases/fumes/vapour</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ILD Associated with Drugs or Treatments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antibiotics (nitrofurantoin)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-inflammatory agents (methotrexate)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular drugs (amiodarone)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutropenia agents (chemotherapy agents)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Illicit drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ILD Associated with Pulmonary Vasculitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Granulomatosis with Polyangitis (GPA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goodpasture’s syndrome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Idiopathic pulmonary hemosiderosis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Known Etiology**
- FASSTEN and BAD RASH
- Upper Lung Disease (FASSTEN)
  - Farmer’s lung (hypersensitivity pneumonitis)
  - Arthritis (spondylitis)
  - Sarcoidosis
  - Silicosis
  - TB
  - Eosinophilic granuloma (Langerhans-cell histiocytosis)
  - Neurofibromatosis
- Lower Lung Disease (BAD RASH)
  - Bronchial asthma (bronchiolitis obliterans with organizing pneumonia (BOOP))
  - Asbestosis
  - Drugs (nitrofurantoin, hydralazine, INH, amiodarone, many chemotherapeutic agents)
  - Rheumatologic disease
  - Aspiration
  - Scleroderma
  - Hamman Rich (acute interstitial pneumonia) and IPF
- Chronic eosinophilic pneumonia
- Pulmonary alveolar proteinosis
Signs and Symptoms
- dyspnea, especially on exertion
- nonproductive cough
- crackles (dry, fine, end-inspiratory)
- clubbing (especially in IPF and asbestosis)
- features of cor pulmonale
- note that signs and symptoms vary with underlying disease process
  - e.g. sarcoidosis is seldom associated with crackles and clubbing

Investigations
- CXR/high resolution CT (see Medical Imaging, MI7)
  - usually decreased lung volumes
  - reticular, nodular, or reticulonodular pattern (nodular <3 mm)
  - hilar/mediastinal adenopathy (especially in sarcoidosis)
- PFTs
  - restrictive pattern: decreased lung volumes and compliance
  - normal or increased FEV₁/FVC (>70-80%), e.g. flow rates are often normal or high when corrected for absolute lung volume
  - DLCO decreased due to V/Q mismatch (less surface area for gas exchange ± pulmonary vascular disease)
- ABGs
  - hypoxemia and respiratory alkalosis may be present with progression of disease
- other
  - bronchoscopy, bronchoalveolar lavage, lung biopsy
  - ESR, ANA (lupus), RF (RA), serum-precipitating antibodies to inhaled organic antigens (hypersensitivity pneumonitis), c-ANCA (GPA), anti-GBM (Goodpasture's)

Unknown Etiologic Agents

IDIOPATHIC PULMONARY FIBROSIS

Definition
- pulmonary fibrosis of unknown cause with usual interstitial pneumonia (UIP) pattern on biopsy (or inferred from CT)
- a progressive, irreversible condition
- commonly presents over age 50, incidence rises with age; males > females
- most cases associated with honeycomb lung on CT
- differential diagnosis includes NSIP, COP, desquamative interstitial pneumonitis (DIP), lymphocytic interstitial pneumonitis (LIP), Sjögren's disease

Signs and Symptoms
- commonly presents over age 50, incidence rises with age; males > females
- dyspnea on exertion, nonproductive cough, constitutional symptoms, late inspiratory fine crackles at lung bases, clubbing

Investigations
- labs (nonspecific, autoimmune serology usually negative)
- CXR: reticular or reticulonodular pattern with lower lung predominance; may appreciate honeycombing in advanced disease
- high resolution CT: lower zone peripheral reticular markings, traction bronchiectasis, honeycombing; ground glass, consolidation, or nodules should not be prominent in IPF
- biopsy: rarely for UIP as honeycombing usually makes radiologic diagnosis possible

Treatment
- O₂
- pirfenidone and nintedanib can slow disease progression
- lung transplantation for advanced disease
- mean survival of 3-5 yr after diagnosis

SARCOIDOSIS

Definition
- idiopathic non-infectious granulomatous multi-system disease with lung involvement in 90%
- characterized pathologically by non-caseating granulomas
- numerous HLA antigens have been shown to play a role and familial sarcoidosis is now recognized

Epidemiology
- typically affects young and middle-aged patients
- higher incidence among people of African descent and from northern latitudes e.g. Scandinavia, Canada
Signs and Symptoms
- asymptomatic, cough, dyspnea, fever, arthralgia, malaise, erythema nodosum, chest pain
- chest exam often normal
- common extrapulmonary manifestations
  - cardiac (arrhythmias, sudden death)
  - eye involvement (anterior or posterior uveitis)
  - skin involvement (skin papules, erythema nodosum, lupus pernio)
  - peripheral lymphadenopathy
  - arthralgia
  - hepatomegaly ± splenomegaly
- less common extra-pulmonary manifestations involve bone, CNS, kidney
- two acute sarcoïd syndromes
  - Löfgren syndrome: fever, erythema nodosum, bilateral hilar lymphadenopathy, arthralgias
  - Heerfordt-Waldenstrom syndrome: fever, parotid enlargement, anterior uveitis, facial nerve palsy

Investigations
- CBC (cytopenias from spleen or marrow involvement)
- serum electrolytes, creatinine, liver enzymes, calcium (hypercalcemia/hypercalciuria due to vitamin D activation by granulomas)
- hypergammaglobulinemia, occasionally RF positive
- elevated serum ACE (non-specific and non-sensitive)
- CXR: predominantly nodular opacities especially in upper lung zones ± hilar adenopathy
- PFTs: normal, obstructive pattern, restrictive pattern with normal flow rates and decreased DLco, or mixed obstructive/restrictive pattern
- ECG: to rule out conduction abnormalities
- slit-lamp eye exam: to rule out uveitis

Diagnosis
- biopsy
  - transbronchial lung biopsy, transbronchial lymph node aspiration, endobronchial ultrasound guided surgical (EBUS) biopsy, or mediastinoscopic lymph node biopsy for granulomas
- in ~75% of cases, transbronchial biopsy shows granulomas in the parenchyma even if the CXR is normal

Staging
- radiographic, based on CXR
  - Stage 0: normal radiograph
  - Stage I: bilateral hilar lymphadenopathy ± right paratracheal lymphadenopathy
  - Stage II: bilateral hilar lymphadenopathy and diffuse interstitial disease
  - Stage III: interstitial disease only (reticulonodular pattern or nodular pattern)
  - Stage IV: pulmonary fibrosis (honeycombing)

Treatment
- 85% of stage I resolve spontaneously
- 50% of stage II resolve spontaneously
- steroids for symptoms, declining lung function, hypercalcemia, or involvement of eye, CNS, kidney, or heart (not for abnormal CXR alone)
- methotrexate or other immunosuppressives occasionally used

Prognosis
- approximately 10% mortality secondary to progressive fibrosis of lung parenchyma

Known Etiologic Agents

**HYPERSENSITIVITY PNEUMONITIS**
- also known as extrinsic allergic alveolitis
- non-IgE mediated inflammation of lung parenchyma (acute, subacute, and chronic forms)
- caused by sensitization to inhaled agents, usually organic dust
- pathology: airway-centred, poorly formed granulomas and lymphocytic inflammation
- exposure usually related to occupation or hobby
  - Farmer's Lung (*Thermophilic actinomycetes*)
  - Bird Breeder's/Bird Fancier's Lung (immune response to bird IgA)
  - Humidifier Lung (*Aureobasidium pullulans*)
  - Sauna Taker's Lung (*Aureobasidium spp.*)

**Signs and Symptoms**
- acute presentation: (4–6 h after exposure)
  - dyspnea, cough, fever, chills, malaise (lasting 18–24 h)
  - CXR: diffuse infiltrates
  - type III (immune complex) reaction
- subacute presentation: more insidious onset than acute presentation
chronic presentation
- insidious onset
- dyspnea, cough, malaise, anorexia, weight loss
- PFTs: progressively restrictive
- CXR: predominantly upper lobe reticulonodular pattern
- type IV (cell mediated, delayed hypersensitivity) reaction (see Rheumatology, RH2)
- in both acute and chronic reactions, serum precipitins may be detectable (neither sensitive nor specific)

Treatment
- early diagnosis: avoidance of further exposure is critical as chronic changes are irreversible
- systemic corticosteroids can relieve symptoms and speed resolution

PNEUMOCONIOSES
- reaction to inhaled inorganic dusts 0.5-5 µm in size
- no effective treatment, therefore key is exposure prevention through the use of protective equipment
- smoking cessation, annual influenza and pneumococcal vaccination, rehabilitation, lung transplant for endstage disease

Table 18. Pneumoconioses

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Symptoms</th>
<th>Investigations</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asbestosis</td>
<td>Insidious onset</td>
<td>CXR</td>
<td>Asbestos exposure increases risk of bronchogenic CA and malignant mesothelioma</td>
</tr>
<tr>
<td></td>
<td>Dyspnea</td>
<td>Lower &gt; upper lobe</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cough: paroxysmal, non-productive</td>
<td>Reticulonodular pattern, may develop IPF-like honeycombing</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cough: paroxysmal, non-productive</td>
<td>Asbestos exposure can also cause pleural and diaphragmatic plaques (= calcification), pleural effusion, round atelectasis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clubbing (much more likely in asbestosis than silicosis or CWP)</td>
<td>Microscopic examination reveals ferruginous bodies: yellow-brown rod-shaped structures which represent asbestos fibres coated in macrophages</td>
<td></td>
</tr>
<tr>
<td>Silicosis</td>
<td>Dyspnea, cough, and wheezing</td>
<td>CXR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Silicosis</td>
<td>Silicosis</td>
<td>Mycobacterial infection (e.g. TB)</td>
</tr>
<tr>
<td></td>
<td>Upper &gt; lower lobe</td>
<td>Early: nodular disease (simple pneumoconiosis), lung function usually normal</td>
<td></td>
</tr>
<tr>
<td>Coal Worker’s Pneumoconiosis (CWP)</td>
<td>Pathologic hallmark is coal macule</td>
<td>Late: nodules coalesce into masses (progressive massive fibrosis)</td>
<td>Caplan’s syndrome: rheumatoid arthritis and CWP present as larger nodules</td>
</tr>
<tr>
<td></td>
<td>Simple CWP</td>
<td>Possible hilar lymph node enlargement (frequently calcified, especially “egg shell” calcification)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>No signs or symptoms, usually normal</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lung function</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Complicated CWP (also known as progressive massive fibrosis)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dyspnea</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Course: few patients progress to complicated CWP</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

INTERSTITIAL LUNG DISEASE ASSOCIATED WITH DRUGS OR TREATMENTS

Drug-Induced
- antineoplastic agents: bleomycin, mitomycin, busulfan, cyclophosphamide, methotrexate, chlorambucil, BCNU (carmustine)
- antibiotics: nitrofurantoin, penicillin, sulfonamide
- cardiovascular drugs: amiodarone, tocainide
- anti-inflammatory agents: methotrexate, penicillamine
- gold salts
- illicit drugs (heroin, methadone)
- rituximab, anti-TNF-α agents (infliximab, etanercept, adalimumab)

Radiation-Induced
- early pneumonitis: approximately 6 wk post-exposure
- late fibrosis: 6-12 mo post-exposure
- infiltrates conform to the shape of the radiation field
Pulmonary Vascular Disease

Pulmonary Hypertension

Definition
- mean pulmonary arterial pressure >25 mmHg at rest and >30 mmHg with exercise, or a systolic pulmonary artery pressure of >40 mmHg at rest
- in the past, pulmonary HTN was classified as primary or secondary pulmonary HTN, but this classification was modified to a more clinically useful, treatment based classification

Table 19. World Health Organization Classification of Pulmonary Hypertension

<table>
<thead>
<tr>
<th>Classification</th>
<th>Some Causes</th>
<th>Treatment Options</th>
<th>Consider in All Patients with PH</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Pulmonary Arterial HTN</td>
<td>Idiopathic&lt;br&gt;Collagen vascular disease (scleroderma, SLE, RA)&lt;br&gt;Congenital systemic-to-pulmonary shunts (Eisenmenger syndrome)&lt;br&gt;Persistent pulmonary hypertension of the newborn (PPHN)&lt;br&gt;Portopulmonary HTN&lt;br&gt;HF infection&lt;br&gt;Drugs and toxins (e.g. anorexigens)&lt;br&gt;Pulmonary veno-occlusive disease&lt;br&gt;Schistosomiasis&lt;br&gt;Pulmonary capillary hemangiomatosis&lt;br&gt;Sickle cell disease</td>
<td>No effective treatment CCBs or advanced therapy often needed&lt;br&gt;The latter includes: prostanoids, endothelin receptor antagonists, PDE5 inhibitors&lt;br&gt;Lung transplantation</td>
<td></td>
</tr>
<tr>
<td>II. Pulmonary HTN due to Left Heart Disease</td>
<td>Left-sided atrial or ventricular heart disease (e.g. LV dysfunction)&lt;br&gt;Left-sided valvular heart disease (e.g. aortic stenosis, mitral stenosis)&lt;br&gt;Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies</td>
<td>Treat underlying heart disease</td>
<td></td>
</tr>
<tr>
<td>III. Pulmonary HTN due to Lung Disease and/or Hypoxia</td>
<td>Parenchymal lung disease (COPD, interstitial fibrosis, cystic fibrosis)&lt;br&gt;Chronic alveolar hypoxia (chronic high altitude, alveolar hypoventilation disorders, sleep-disordered breathing)</td>
<td>Treat underlying cause of hypoxia and correct with supplemental oxygen (proven mortality benefit)</td>
<td></td>
</tr>
<tr>
<td>IV. Chronic Thromboembolic Pulmonary HTN (CTEPH)</td>
<td>Thromboembolic obstruction of proximal pulmonary arteries&lt;br&gt;Obstruction of distal pulmonary arteries – PE (thrombus, foreign material, tumour, in situ thrombosis)</td>
<td>Anticoagulation, thromboendarterectomy</td>
<td></td>
</tr>
<tr>
<td>V. Pulmonary HTN with Unclear Multifactorial Mechanisms</td>
<td>Hematologic disorders&lt;br&gt;Systemic disorders (e.g. sarcoidosis)&lt;br&gt;Metabolic disorders&lt;br&gt;Extrinsic compression of central pulmonary veins (tumour, adenopathy, fibrosing mediastinitis)&lt;br&gt;Chronic hemolytic anemia&lt;br&gt;Segmental pulmonary hypertension</td>
<td>Treat underlying cause</td>
<td></td>
</tr>
</tbody>
</table>


IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION (PRIMARY PULMONARY HYPERTENSION)

Definition
- pulmonary HTN in the absence of a demonstrable cause
- exclude
  - left-sided cardiac valvular disease
  - myocardial disease
  - congenital heart disease
  - any clinically significant parenchymal lung disease
  - systemic connective-tissue disease
  - chronic thromboembolic disease

Epidemiology
- usually presents in young females (20-40 yr); mean age of diagnosis is 36 yr
- most cases are sporadic; familial predisposition in 10% of cases, some linked to mutations in BMPR2
- may be associated with the use of anorexic drugs (e.g. Aminorex®, Fenfluramine®), amphetamines, and cocaine
Signs and Symptoms

Table 20. Signs and Symptoms of Pulmonary Hypertension

<table>
<thead>
<tr>
<th>Symptoms of underlying disease</th>
<th>Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td>If RV failure: right sided S3, increased JVP, positive HJR, peripheral edema, TR</td>
<td>Systolic murmur (tricuspid regurgitation [TR])</td>
</tr>
<tr>
<td></td>
<td>Reynaud’s phenomenon</td>
</tr>
</tbody>
</table>

Investigations
- CXR: enlarged central pulmonary arteries, cardiac changes due to RV enlargement (filling of retrosternal air space)
- ECG
- RVH/right-sided strain (see Cardiology and Cardiac Surgery, C7)
- 2-D echo doppler assessment of right ventricular systolic pressure
- cardiac catheterization: direct measurement of pulmonary artery pressures (necessary to confirm diagnosis)
- PFTs to asses for underlying lung disease: DLCO usually reduced; volumes and flows normal
- CT angiogram to assess lung parenchyma and possible PE
- V/Q scan ± pulmonary angiogram to rule out thromboembolic disease
- serology: ANA positive in 30% of patients with primary pulmonary HTN; other serologic markers can be used in the appropriate clinical setting

Treatment
- see Table 19

Prognosis
- 2-3 yr mean survival from time of diagnosis
- survival decreases to approximately 1 yr if severe pulmonary HTN or right-heart failure

Pulmonary Embolism

Definition
- lodging of a blood clot in the pulmonary arterial tree with subsequent increase in pulmonary vascular resistance, impaired V/Q matching, and possibly reduced pulmonary blood flow

Etiology and Pathophysiology
- one of the most common causes of preventable death in the hospital
- proximal leg thrombi (popliteal, femoral, or iliac veins) are the source of most clinically recognized pulmonary emboli
- thrombi often start in calf, but must propagate into proximal veins to create a sufficiently large thrombus for a clinically significant PE
- fewer than 30% of patients have clinical evidence of DVT (e.g. leg swelling, pain, or tenderness)
- always suspect PE if patient develops fever, sudden dyspnea, chest pain, or collapse 1-2 wk after surgery

Risk Factors
- stasis
  - immobilization: paralysis, stroke, bed rest, prolonged sitting during travel, immobilization of an extremity after fracture
  - obesity, CHF
  - chronic venous insufficiency
- endothelial cell damage
- post-operative injury, trauma
- hypercoagulable states
  - underlying malignancy (particularly adenocarcinoma)
  - cancer treatment (chemotherapy, hormonal)
  - exogenous estrogen administration (OCP, HRT)
  - pregnancy, post-partum
  - prior history of DVT/PE, family history
  - nephrotic syndrome
- coagulopathies: Factor V Leiden, Prothrombin 20210A variant, inherited deficiencies of antithrombin/protein C/protein S, antiphospholipid antibody, hyperhomocysteinemia, increased Factor VIII levels, and myeloproliferative disease
- increasing age
Investigations (if highly suspicious, go straight to CT angiogram)
- see Emergency Medicine, ER33

### Table 21. Common Investigations for Pulmonary Embolism

<table>
<thead>
<tr>
<th>Investigation</th>
<th>Purpose/Utility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary Angiogram</td>
<td>Filling defect indicative of embolus; negative angiogram excludes clinically relevant PE</td>
</tr>
<tr>
<td>Gold Standard</td>
<td>More invasive, and harder to perform than CT, therefore done infrequently</td>
</tr>
<tr>
<td>D-Dimer</td>
<td>Highly sensitive D-dimer result can exclude DVT/PE if pretest probability is already low</td>
</tr>
<tr>
<td></td>
<td>Little value if pretest probability is high</td>
</tr>
<tr>
<td></td>
<td>If D-dimer positive, will need further evaluation with compression U/S (for DVT) and/or CT (for PE)</td>
</tr>
<tr>
<td>CT Angiogram</td>
<td>Both sensitive and specific for PE</td>
</tr>
<tr>
<td></td>
<td>Diagnosis and management uncertain for small filling defects</td>
</tr>
<tr>
<td></td>
<td>CT may identify an alternative diagnosis if PE is not present</td>
</tr>
<tr>
<td></td>
<td>CT scanning of the proximal leg and pelvic veins can be done at the same time and may be helpful</td>
</tr>
<tr>
<td>Venous Duplex U/S or Doppler</td>
<td>With leg symptoms</td>
</tr>
<tr>
<td></td>
<td>Positive test rules in proximal DVT</td>
</tr>
<tr>
<td></td>
<td>Negative test rules out proximal DVT</td>
</tr>
<tr>
<td></td>
<td>Without leg symptoms</td>
</tr>
<tr>
<td></td>
<td>Positive test rules in proximal DVT</td>
</tr>
<tr>
<td></td>
<td>Negative test does not rule out a DVT: patient may have non-occlusive or call DVT</td>
</tr>
<tr>
<td>ECG</td>
<td>Findings not sensitive or specific</td>
</tr>
<tr>
<td></td>
<td>Sinus tachycardia most common; may see non-specific ST segment and T wave changes</td>
</tr>
<tr>
<td></td>
<td>RV strain, RAD, RBBB, S1-Q3-T3 with massive embolization</td>
</tr>
<tr>
<td>CXR</td>
<td>Frequently normal; no specific features</td>
</tr>
<tr>
<td></td>
<td>Atelectasis (subsegmental), elevation of a hemidiaphragm</td>
</tr>
<tr>
<td></td>
<td>Pleural effusion; usually small</td>
</tr>
<tr>
<td></td>
<td>Hampton’s hump: cone-shaped area of peripheral opacification representing infarction</td>
</tr>
<tr>
<td></td>
<td>Westermark’s sign: dilated proximal pulmonary artery with distal oligemia/decreased vascular markings (difficult to assess without prior films)</td>
</tr>
<tr>
<td></td>
<td>Dilatation of proximal PA: rare</td>
</tr>
<tr>
<td>V/Q Scan</td>
<td>Very sensitive but low specificity</td>
</tr>
<tr>
<td></td>
<td>Order scan if</td>
</tr>
<tr>
<td></td>
<td>CXR normal, no COPD</td>
</tr>
<tr>
<td></td>
<td>Contraindication to CT (contrast allergy, renal dysfunction, pregnancy)</td>
</tr>
<tr>
<td></td>
<td>Avoid V/Q scan if</td>
</tr>
<tr>
<td></td>
<td>CXR abnormal or COPD</td>
</tr>
<tr>
<td></td>
<td>Inpatient</td>
</tr>
<tr>
<td></td>
<td>Suspect massive PE</td>
</tr>
<tr>
<td>Results</td>
<td>Normal: excludes the diagnosis of PE</td>
</tr>
<tr>
<td></td>
<td>High probability: most likely means PE present, unless pre-test probability is low</td>
</tr>
<tr>
<td></td>
<td>60% of V/Q scans are nondiagnostic</td>
</tr>
<tr>
<td>Echocardiogram</td>
<td>Useful to assess massive or chronic PE</td>
</tr>
<tr>
<td></td>
<td>Not routinely done</td>
</tr>
<tr>
<td>ABG</td>
<td>No diagnostic use in PE (insensitive and nonspecific)</td>
</tr>
<tr>
<td></td>
<td>May show respiratory alkalosis (due to hyperventilation)</td>
</tr>
</tbody>
</table>

### Treatment
- admit for observation (patients with DVT only are often sent home on LMWH)
- oxygen: supplemental O₂ if hypoxemic or short of breath
- pain relief: analgesics if chest pain – narcotics or acetaminophen
- acute anticoagulation: therapeutic-dose SC LMWH or IV heparin – start ASAP
- anticoagulation stops clot propagation, prevents new clots and allows endogenous fibrinolytic system to dissolve existing thromboemboli over months get baseline CBC, INR, aPTT ± renal function ± liver function
- for SC LMWH: dalteparin 200 U/kg once daily, enoxaparin 1 mg/kg bid or 1.5mg/kg once daily, or tinzaparin 175 U/kg once daily – no lab monitoring – avoid or reduce dose in renal dysfunction
- for IV heparin: bolus of 75 U/kg (usually 5,000 U) followed by infusion starting at 20 U/kg/h – aim for aPTT 2-3x control
- rivaroxaban is accepted alternative for acute PE
- long-term anticoagulation
- warfarin: start the same day as LMWH/heparin – overlap warfarin with LMWH/heparin for at least 5 d and until INR in target range of 2-3 for at least 2 d
- LMWH instead of warfarin for pregnancy, active cancer, or high bleeding risk patients
- direct thrombin inhibitors: can treat from outset with rivaroxaban; dabigatran has been shown to have lower bleeding risk than warfarin; no monitoring required, however agents not reversible, so avoid if bleeding concerns
- IV thrombolytic therapy
  - if patient has massive PE (hypotension or clinical right heart failure) and no contraindications
  - hastens resolution of PE but may not improve survival or long-term outcome and doubles risk of major bleeding
- interventional thrombolytic therapy
  - massive PE is preferentially treated with catheter-directed thrombolysis by an interventional radiologist
  - works better than IV thrombolytic therapy and fewer contraindications
  - IV catheter: only if recent proximal DVT + absolute contraindication to anticoagulation
- duration of long-term anticoagulation: individualized, however generally
  - if reversible cause for PE (surgery, injury, pregnancy, etc.): 3-6 mo
  - if PE unprovoked: 6 mo to indefinite
  - if ongoing major risk factor (active cancer, antiphospholipid antibody, etc.): indefinite

### Thromboprophylaxis
- mandatory for most hospital patients: reduces DVT, PE, all-cause mortality, cost-effective
- start ASAP
- continue at least until discharge or recommend extending for 35 d post-operatively, if major orthopedic surgery

#### Table 22. VTE Risk Categories and Prophylaxis (see Hematology, H35)

<table>
<thead>
<tr>
<th>Risk Group</th>
<th>Prophylaxis Options</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Thrombosis Risk</td>
<td></td>
</tr>
<tr>
<td>Medical patients: fully mobile</td>
<td></td>
</tr>
<tr>
<td>Surgery: ≈15 min, fully mobile</td>
<td></td>
</tr>
<tr>
<td>No specific prophylaxis</td>
<td></td>
</tr>
<tr>
<td>Frequent ambulation</td>
<td></td>
</tr>
<tr>
<td>Moderate Thrombosis Risk</td>
<td></td>
</tr>
<tr>
<td>Most general, gynecologic, urologic surgery</td>
<td></td>
</tr>
<tr>
<td>Sick medical patients</td>
<td></td>
</tr>
<tr>
<td>LMWH</td>
<td></td>
</tr>
<tr>
<td>Low dose unfractionated heparin</td>
<td></td>
</tr>
<tr>
<td>Fondaparinux</td>
<td></td>
</tr>
<tr>
<td>High Thrombosis Risk</td>
<td></td>
</tr>
<tr>
<td>Arthroplasty, hip fracture surgery</td>
<td></td>
</tr>
<tr>
<td>Major trauma, spinal cord injury</td>
<td></td>
</tr>
<tr>
<td>LMWH</td>
<td></td>
</tr>
<tr>
<td>Fondaparinux</td>
<td></td>
</tr>
<tr>
<td>Warfarin (INR 2-3)</td>
<td></td>
</tr>
<tr>
<td>Dabigatran</td>
<td></td>
</tr>
<tr>
<td>Apixaban</td>
<td></td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td></td>
</tr>
<tr>
<td>Low dose unfractionated heparin</td>
<td></td>
</tr>
</tbody>
</table>

#### High Bleeding Risk
- Neurosurgery, intracranial bleed
- Active bleeding
- LMWH or low dose heparin when bleeding risk decreases

### Pulmonary Vasculitis

#### Table 23. Pulmonary Vasculitis

<table>
<thead>
<tr>
<th>Disease</th>
<th>Definition</th>
<th>Pulmonary Features</th>
<th>Extra-pulmonary Features</th>
<th>Investigations</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granulomatosis with Polyangiitis (GPA, previously Wegener’s Granulomatosis) (see Nephrology, NP22)</td>
<td>Systemic vasculitis of medium and small arteries</td>
<td>Necrotizing granulomatous lesions of the upper and lower respiratory tract</td>
<td>Focal necrotizing lesions of arteries and veins; crescentic glomerulonephritis</td>
<td>CXR: nodules, cavities, and alveolar opacities c-ANCA Tissue confirmation</td>
<td>Corticosteroids and cyclophosphamide or rituximab</td>
</tr>
<tr>
<td>Eosinophilic Granulomatosis with Polyangiitis (EGPA, Churg-Strauss)</td>
<td>Multisystem disorder characterized by allergic rhinitis, asthma, and prominent peripheral eosinophilia</td>
<td>Asthma Infiltrates</td>
<td>Life-threatening systemic vasculitis involving the pericardium and heart, kidneys, skin, and PNS (mononeuritis multiplex)</td>
<td>Peripheral eosinophilia is the most common finding p-ANCA may be positive Biopsy involved tissue</td>
<td>Corticosteroids</td>
</tr>
<tr>
<td>anti-GBM Disease (Goodpasture’s) (see Nephrology, NP24)</td>
<td>A disorder characterized by diffuse alveolar hemorrhage and glomerulonephritis caused by anti-GBM antibodies, which cross-react with basement membranes of the kidney and lung</td>
<td>Hemoptysis May follow an influenza infection</td>
<td>Anemia</td>
<td>CXR: may see alveolar infiltrates if hemorrhage is profuse ELISA test with anti-GBM antibodies Renal biopsy/Indirect immunofluorescence shows linear staining</td>
<td>Acutely: corticosteroids, plasmapheresis Immunosuppressive therapy Severe cases: bilateral nephrectomy</td>
</tr>
<tr>
<td>Systemic Lupus Erythematosus, Rheumatoid Arthritis, Scleroderma</td>
<td>See Rheumatology, RH17</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Pulmonary Edema

- see Cardiology and Cardiac Surgery, C36

Diseases of the Mediastinum and Pleura

Mediastinal Masses

Definition
- mediastinum: bound by the thoracic inlet, diaphragm, sternum, vertebral bodies, and the pleura
- can be broken down into 3 compartments: anterior, middle, and posterior

Etiology and Pathophysiology
- diagnosis is aided by location and patient’s age
- anterior compartment: more likely to be malignant
  - “Four Ts” (see sidebar), lymphoma, lipoma, pericardial cyst
- middle compartment
  - pericardial cyst, bronchogenic cyst/tumour, lymphoma, lymph node enlargement, aortic aneurysm
- posterior compartment
  - neurogenic tumours, meningocele, enteric cysts, lymphoma, diaphragmatic hernias, esophageal tumour, aortic aneurysm

Signs and Symptoms
- 50% asymptomatic (mainly benign); when symptomatic, 50% are malignant
- chest pain, cough, dyspnea, recurrent respiratory infections
- hoarseness, dysphagia, Horner’s syndrome, facial/upper extremity edema (SVC compression)
- paraneoplastic syndromes (e.g. myasthenia gravis [thymomas])

Investigations
- CXR (compare to previous)
- CT with contrast (anatomic location, density, relation to mediastinal vascular structures)
- MRI: specifically indicated in the evaluation of neurogenic tumours
- U/S (best for assessment of structures in close proximity to the heart and pericardium)
- radionuclide scanning: $^{131}$I (for thyroid), gallium (for lymphoma)
- biochemical studies: thyroid function, serum calcium, phosphate, PTH, AFP, $\beta$-hCG
- biopsy (mediastinoscopy, percutaneous needle aspiration)

Management
- excision if symptomatic enlarging benign masses or concerns of malignancy
- resect bronchogenic cysts and localized neurogenic tumours via minimally invasive video assisted procedures
- exploration via sternotomy or thoracotomy
- diagnostic biopsy rather than major operation if mass is likely to be a lymphoma, germ cell tumour, or unresectable invasive malignancy
- ± post-operative radiotherapy/chemotherapy if malignant

Mediastinitis

- most common causes: post-operative complications of cardiovascular or thoracic surgical procedures

Acute
- etiology
- complication of endoscopy (e.g. esophageal perforation providing entry point for infection)
- esophageal or cardiac surgery
- tumour necrosis
- signs and symptoms
- fever, substernal pain
- pneumomediastinum, mediastinal compression
- Hamman’s sign (auscultatory “crunch” during cardiac systole)
- treatment
- antibiotics, drainage, ± surgical closure of perforation

Chronic
- usually granulomatous process or fibrosis related to previous infection (e.g. histoplasmosis, TB, sarcoidosis, syphilis)
Pleural Effusions

Definition
- excess amount of fluid in the pleural space (normally up to 25 mL)

Etiology
- disruption of normal equilibrium between pleural fluid formation/entry and pleural fluid absorption/exit
- pleural effusions are classified as transudative or exudative
  - distinguish clinically using Light’s Criteria, which has a sensitivity of 98% and specificity of 83% for identifying exudative pleural effusions

Table 24. Laboratory Values in Transudative and Exudative Pleural Effusion

<table>
<thead>
<tr>
<th>Light’s Criteria</th>
<th>Modified Light’s Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein – Pleural/Serum</td>
<td>&gt;0.5</td>
</tr>
<tr>
<td>LDH – Pleural/Serum</td>
<td>&gt;0.6</td>
</tr>
<tr>
<td>Pleural LDH</td>
<td>&gt;0.45 upper limit of N serum LDH</td>
</tr>
</tbody>
</table>

Exudate = any one criterion

Transudative Pleural Effusions
- pathophysiology: alteration of systemic factors that affect the formation and absorption of pleural fluid (e.g. increased capillary hydrostatic pressure, decreased plasma oncotic pressure)
- etiology
  - CHF: usually right-sided or bilateral
  - cirrhosis
  - nephrotic syndrome, protein losing enteropathy, cirrhosis
  - pulmonary embolism (may cause transudative but more often causes exudative effusion)
  - peritoneal dialysis, hypothyroidism, CF, urinothorax

Exudative Pleural Effusions
- pathophysiology: increased permeability of pleural capillaries or lymphatic dysfunction
- etiology (see Table 25)

Exudative Pleural Effusion Etiologies

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infectious</td>
<td>Parapneumonic effusion (associated with bacterial pneumonia, lung abscess)</td>
</tr>
<tr>
<td></td>
<td>Empyema (bacterial, fungal, TB)</td>
</tr>
<tr>
<td></td>
<td>TB pleuritis</td>
</tr>
<tr>
<td></td>
<td>Viral infection</td>
</tr>
<tr>
<td>Malignancy</td>
<td>Lung carcinoma (35%)</td>
</tr>
<tr>
<td></td>
<td>Lymphoma (10%)</td>
</tr>
<tr>
<td></td>
<td>Metastases: breast (25%), ovary, kidney</td>
</tr>
<tr>
<td></td>
<td>Mesothelioma</td>
</tr>
<tr>
<td>Inflammatory</td>
<td>Collagen vascular diseases: RA, SLE</td>
</tr>
<tr>
<td></td>
<td>Pulmonary embolism</td>
</tr>
<tr>
<td></td>
<td>Post-CABG</td>
</tr>
<tr>
<td></td>
<td>Drug reaction</td>
</tr>
<tr>
<td>Intra-Abdominal</td>
<td>Subphrenic abscess</td>
</tr>
<tr>
<td></td>
<td>Pancreatic disease (elevated pleural fluid amylase)</td>
</tr>
<tr>
<td></td>
<td>Meigs’ syndrome (ascites and hydrothorax associated with an ovarian fibroma or other pelvic tumour)</td>
</tr>
<tr>
<td>Intra-Thoracic</td>
<td>Esophageal perforation (elevated fluid amylase)</td>
</tr>
<tr>
<td>Trauma</td>
<td>Chylothorax: thoracic duct disrupted and chyle accumulates in the pleural space due to trauma, tumour</td>
</tr>
<tr>
<td></td>
<td>Hemothorax: rupture of a blood vessel, commonly by trauma or tumours</td>
</tr>
<tr>
<td></td>
<td>Pneumothorax (spontaneous, traumatic, tension)</td>
</tr>
</tbody>
</table>

Signs and Symptoms
- often asymptomatic
- dyspnea: varies with size of effusion and underlying lung function
- pleuritic chest pain
- inspection: trachea deviates away from effusion, ipsilateral decreased expansion
- percussion: decreased tactile fremitus, dullness
- auscultation: decreased breath sounds, bronchal breathing and egophony at upper level, pleural friction rub
Investigations
- **CXR**
  - must have >200 mL of pleural fluid for visualization on PA film
  - lateral: >50 mL leads to blunting of posterior costophrenic angle
  - PA: blunting of lateral costophrenic angle
  - dense opacification of lung fields with concave meniscus
  - decubitus: fluid will shift unless it is loculated
  - supine: fluid will appear as general haziness
- **CT** may be helpful in differentiating parenchymal from pleural abnormalities, may identify underlying lung pathology
- **U/S:** detects small effusions and can guide thoracentesis
- **thoracentesis:** indicated if pleural effusion is a new finding; be sure to send off blood work (LDH, glucose, protein) at the same time for comparison
  - risk of re-expansion pulmonary edema if >1.5 L of fluid is removed
  - inspect for colour, character, and odour of fluid
- **analyze fluid**
- pleural biopsy: indicated if suspect TB, mesothelioma, or other malignancy (and if cytology negative)
- treatment depends on cause, ± drainage if symptomatic
- **CT** can be helpful in differentiating parenchymal from pleural abnormalities, assessing for pleural nodules and/or fluid loculation

### Table 26. Analysis of Pleural Effusion

<table>
<thead>
<tr>
<th>Measure</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein, LDH</td>
<td>Transudate vs. exudate</td>
</tr>
<tr>
<td>Gram stain, Ziehl-Nielsen stain (TB), culture</td>
<td>Looking for specific organisms</td>
</tr>
<tr>
<td>Cell count differential</td>
<td>Neutrophils vs. lymphocytes (lymphocytic effusion in TB, cancer, lymphoma, serositis)</td>
</tr>
<tr>
<td>Cytology</td>
<td>Malignancy, infection</td>
</tr>
<tr>
<td>Glucose (low)</td>
<td>RA, TB, empyema, malignancy, esophageal rupture</td>
</tr>
<tr>
<td>Rheumatoid factor, ANA, complement</td>
<td>Collagen vascular disease</td>
</tr>
<tr>
<td>Amylase</td>
<td>Pancreatitis, esophageal perforation, malignancy</td>
</tr>
<tr>
<td>pH</td>
<td>Empyema &lt;7.2, TB, and mesothelioma &lt;7.3</td>
</tr>
<tr>
<td>Blood</td>
<td>Mostly traumatic, malignancy, PE with infarction, TB</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>Chylothorax from thoracic duct leakage, mostly due to trauma, lung CA, or lymphoma</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>Distinguish between chylous and chyliform effusion (seen in inflammation, e.g. TB, RA)</td>
</tr>
</tbody>
</table>

### Treatment
- thoracentesis
- treat underlying cause
- consider indwelling pleural catheter or pleurodesis in refractory effusions

## Complicated Effusion
- persistent bacteria in the pleural space but fluid is non-purulent
- neutrophils, pleural fluid acidosis (pH <7.00), and high LDH
- often no bacteria grown since rapidly cleared from pleural space
- fibrin layer leading to loculation of pleural fluid
- treatment: antibiotics and drainage, treat as an empyema

## Empyema

### Definition
- pus in pleural space or an effusion with organisms seen on a Gram stain or culture (e.g. pleural fluid is grossly purulent)
- positive culture is not required for diagnosis

### Etiology
- contiguous spread from lung infection (most commonly anaerobes) or infection through chest wall (e.g. trauma, surgery)

### Signs and Symptoms
- fever, pleuritic chest pain
Diseases of the Mediastinum and Pleura

Investigations
- CT chest
- thoracentesis
- PMNs (lymphocytes in TB) ± visible organisms on Gram stain

Treatment
- antibiotic therapy for at least 4-6 wk (rarely effective alone)
- complete pleural drainage with chest tube
- if loculated, more difficult to drain – may require surgical drainage with video-assisted thorascopic surgery (VATS), or surgical removal of fibrin coating to allow lung re-expansion (decortication)

Atelectasis
- see General Surgery, GS10

Pneumothorax

Definition
- presence of air in the pleural space

Pathophysiology
- entry of air into pleural space raises intrapleural pressure causing partial lung deflation

Etiology
- traumatic: penetrating or non-penetrating chest injuries
- iatrogenic (central venous catheter, thoracentesis, mechanical ventilation with barotrauma)
- spontaneous (no history of trauma)
  - primary (no underlying lung disease)
  - secondary (underlying lung disease)
    - rupture of subpleural bleb which migrates along bronchioalveolar sheath to the mediastinum then to the intrapleural space
    - necrosis of lung tissue adjacent to pleural surface (e.g. pneumonia, abscess, PCP, lung CA, emphysema)

Signs and Symptoms
- can be asymptomatic
- acute-onset pleuritic chest pain, dyspnea
- tachypnea, tachycardia
- tracheal deviation (contralateral deviation in tension pneumothorax)
- ipsilateral diminished chest expansion
- decreased tactile/vocal fremitus
- hyperresonance
- ipsilateral diminished breath sounds

Investigations
- CXR
  - small: separation of visceral and parietal pleura seen as fine crescentic line parallel to chest wall at apex
  - large: increased density and decreased volume of lung on side of pneumothorax
- see Medical Imaging, MI8

Treatment
- small pneumothoraces (<20% with no signs of respiratory/circulatory collapse) resolve spontaneously; breathing 100% oxygen accelerates resorption of air
- small intercostal tube with Heimlich valve for most spontaneous pneumothoraces
- large pneumothoraces or those complicating underlying lung disease require placement of a chest tube connected to underwater seal ± suction
- for repeated episodes: pleurodesis with sclerosing agent or apical bullectomy and abrasion
- treat underlying cause (e.g. antibiotic for PCP)

Asbestos-Related Pleural Disease and Mesothelioma

Etiology and Pathophysiology
- benign manifestations of asbestos exposure:
  - “benign asbestos pleural effusion”
    - exudative effusion, typically ~10 yr after exposure, resolves
  - pleural plaques, usually calcified
    - marker of exposure; usually an asymptomatic radiologic finding

- see Emergency Medicine, ER11
• mesothelioma
  ■ primary malignancy of the pleura
  ■ decades after asbestos exposure (even with limited exposure)
  ■ smoking not a risk factor, but asbestos and smoking synergistically increase risk of lung cancer

**Signs and Symptoms**
• persistent chest pain, dyspnea, cough, bloody pleural effusion, weight loss

**Investigations**
• biopsy (pleuroscopic or open)
• needle biopsy may seed needle tract with tumor

**Treatment**
• resection (extrapleural pneumonectomy) requires careful patient selection; rarely successful (average survival <1 yr)

---

### Respiratory Failure

**Definition**
• failure of respiratory system to maintain normal blood gases
• hypoxemic (P.O₂ <60 mmHg)
• hypercapnic (P.CO₂ >50 mmHg)
• acute vs. chronic (compensatory mechanisms activated)

**Signs and Symptoms**
• signs of underlying disease
• hypoxemia: restlessness, confusion, cyanosis, coma, cor pulmonale
• hypercapnia: headache, dyspnea, drowsiness, asterixis, warm periphery, plethora, increased ICP (secondary to vasodilatation)

**Investigations**
• serial ABGs
• CXR and/or CT, bronchoscopy to characterize underlying cause if unclear

### Hypoxemic Respiratory Failure

**Definition**
• P.O₂ decreased, P.CO₂ normal or decreased

**Treatment**
• reverse the underlying pathology
• oxygen therapy: maintain oxygenation (if shunt present, supplemental O₂ is less effective; see *Anesthesia and Perioperative Medicine, A10*, for oxygen delivery systems)
• ventilation, BiPAP and PEEP/CPAP (see *Anesthesia and Perioperative Medicine, A10*): positive pressure can recruit alveoli and redistribute lung fluid
• improve cardiac output: ± hemodynamic support (fluids, vasopressors, inotropes), reduction of O₂ requirements

#### Table 27. Approach to Hypoxemia

<table>
<thead>
<tr>
<th>Type of Hypoxemia</th>
<th>Settings</th>
<th>P.CO₂</th>
<th>A-aDO₂</th>
<th>Oxygen Therapy</th>
<th>Ventilation, BiPAP and PEEP</th>
<th>Improved Cardiac Output</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Low F.O₂</td>
<td>Postop, high altitude</td>
<td>N or ↓</td>
<td>N</td>
<td>Improves</td>
<td>No change</td>
<td>No change</td>
</tr>
<tr>
<td>2. Hypoventilation</td>
<td>Drug overdose</td>
<td>↑</td>
<td>N</td>
<td>Improves</td>
<td>Improves with ventilation</td>
<td>No change</td>
</tr>
<tr>
<td>3a. Shunt (intrapulmonary)</td>
<td>ARDS, pneumonia</td>
<td>N or ↓</td>
<td>↑</td>
<td>No change</td>
<td>Improves (except if one-sided)</td>
<td>Improves</td>
</tr>
<tr>
<td>3b. Shunt (Right to Left)</td>
<td>Pulmonary HTN</td>
<td>N or ↓</td>
<td>↑</td>
<td>No change</td>
<td>Worsens</td>
<td>Worsens</td>
</tr>
<tr>
<td>4. Low Mixed Venous O₂ Content</td>
<td>Shock</td>
<td>↓</td>
<td>↑</td>
<td>Improves or no change</td>
<td>Worsens</td>
<td>Improves</td>
</tr>
<tr>
<td>5. V/Q Mismatch</td>
<td>COPD</td>
<td>N or ↑</td>
<td>↑</td>
<td>Improves (small amounts)</td>
<td>Often improves</td>
<td>Improves</td>
</tr>
<tr>
<td>6. Diffusion Impairment</td>
<td>ILD, emphysema</td>
<td>N</td>
<td>↑</td>
<td>Improves</td>
<td>Improves with positive pressure</td>
<td>No change or worsens</td>
</tr>
</tbody>
</table>

Reprinted with permission from Dr. Ian Fraser
**Hypercapnic Respiratory Failure**

- PaCO2 increased, PaO2 decreased

**Pathophysiology**
- increased CO2 production: fever, sepsis, seizure, acidosis, carbohydrate load
- alveolar hypoventilation: COPD, asthma, CF, chest wall disorder, dead space ventilation (rapid shallow breathing)
  - inefficient gas exchange results in inadequate CO2 removal in spite of normal or increased minute volume
- hypoventilation
  - central: brainstem stroke, hypothyroidism, severe metabolic alkalosis, drugs (opiates, benzodiazepines)
  - neuromuscular: myasthenia gravis, Guillain-Barré, phrenic nerve injury, muscular dystrophy, polymyositis, kyphoscoliosis
  - muscle fatigue

**Treatment**
- reverse the underlying pathology
- if PaCO2 >50 mmHg and pH <7.35 consider noninvasive or mechanical ventilation
- correct exacerbating factors
  - NTT/ETT suction: clearance of secretions
  - bronchodilators: reduction of airway resistance
  - antibiotics: treatment of infections
- maintain oxygenation (see above)
- diet: increased carbohydrate can increase P,CO2 in those with mechanical or limited alveolar ventilation; high lipids decrease P,CO2

**Acute Respiratory Distress Syndrome**

- clinical syndrome characterized by severe respiratory distress, hypoxemia, and noncardiogenic pulmonary edema
- The Berlin Criteria (JAMA 2012; 307:2526-2533) for ARDS
  - acute onset
    - within 7 d of a defined event, such as sepsis, pneumonia, or patient noticing worsening of respiratory symptoms
    - usually occurs within 72 h of presumed trigger
    - bilateral opacities consistent with pulmonary edema on either CT or CXR
    - not fully explained by cardiac failure/fluid overload, but patient may have concurrent heart failure
    - objective assessment of cardiac function (e.g. echocardiogram) should be performed even if no clear risk factors

**Etiology**
- direct lung injury
- airway: aspiration (gastric contents, drowning), pneumonia, inhalation injury (oxygen toxicity, nitrogen dioxide, smoke)
- circulation: embolism (fat, amniotic fluid), reperfusion injury
- indirect lung injury
- circulation: sepsis, shock, trauma, blood transfusion, pancreatitis
- neurogenic: head trauma, intracranial hemorrhage, drug overdose (narcotics, sedatives, TCAs)

**Pathophysiology**
- disruption of alveolar capillary membranes → leaky capillaries → interstitial and alveolar pulmonary edema → reduced compliance, V/Q mismatch, shunt, hypoxemia, pulmonary HTN

**Clinical Course**

A. Exudative Phase
- first 7 d of illness after exposure to ARDS precipitant
- alveolar capillary endothelial cells and type I pneumocytes are injured, resulting in loss of normally tight alveolar barrier
- patients develop dyspnea, tachypnea, increased work of breathing
  - these result in respiratory fatigue and eventually respiratory failure (see Hypoxic Respiratory Failure, R25)

B. Fibroproliferative Phase
- after day 7
- may still experience dyspnea, tachypnea, fatigue, and hypoxemia
- most patients clinically improve and are able to wean off mechanical ventilation

**Risk Factors for Aspiration Pneumonia**

<table>
<thead>
<tr>
<th>Categories</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decreased level of consciousness</td>
<td>Alcoholism</td>
</tr>
<tr>
<td>Upper GI tract disorders</td>
<td>Dysphagia, esophageal disorders</td>
</tr>
<tr>
<td>Mechanical instrumentation</td>
<td>Intubation, nasogastric tube, feeding tubes</td>
</tr>
<tr>
<td>Neurologic conditions</td>
<td>Dementia, Parkinson disease</td>
</tr>
<tr>
<td>Others</td>
<td>Protracted vomiting</td>
</tr>
</tbody>
</table>
• some patients develop fibrotic lung changes that may require long-term support on supplemental oxygen or even mechanical ventilation
• if fibrosis present, associated with increased mortality

**Treatment**
• based on ARDS network (*see Landmark Respiratory Trials, R37*)
• treat underlying disorder (e.g. antibiotics if infection present)
• mechanical ventilation using low tidal volumes (<6 mL/kg) to prevent barotrauma
  ▪ use optimal amount of PEEP (positive end-expiratory pressure) to keep airways open and allow the use of lower F:O:
  ▪ may consider using prone ventilation, ± inhaled nitric oxide, short term paralytics (<48 h) or ECMO (extracorporeal membrane oxygenation) if conventional treatment is failing
• fluids and inotropic therapy (e.g. dopamine, vasopressin) if cardiac output inadequate
• pulmonary-arterial catheter now seldom used for monitoring hemodynamics
• mortality: 30-40%, usually due to non-pulmonary complications
• sequelae of ARDS include residual pulmonary impairment, severe debilitation, polyneuropathy and psychologic difficulties, which gradually improve over time
• most survivors eventually regain near-normal lung function, often with mildly reduced diffusion capacity

## Neoplasms

### Lung Cancer

**Classification**
• lung tumours can be classified as primary or secondary, benign or malignant, endobronchial or parenchymal
• bronchogenic carcinoma (epithelial lung tumours) are the most common type of primary lung tumour (other types make up less than 1%)
  ▪ small cell lung cancer (SCLC): 10-15%
  ▪ non-small-cell lung cancer (NSCLC): 85-90%
    ▪ squamous cell carcinoma: arise from the proximal respiratory epithelium
    ▪ adenocarcinoma: incidence is increasing; most common subtype in nonsmokers
      – mucinous adenocarcinomas: grows along the alveolar wall in the periphery; may arise at sites of previous lung scarring
    ▪ large cell undifferentiated cancer: diagnosis of exclusion
• benign epithelial lung tumours can be classified as papillomas or adenomas

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>Incidence</th>
<th>Correlation with Smoking</th>
<th>Location</th>
<th>Histology</th>
<th>Metastasis</th>
<th>5 Yr Survival Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCLC</td>
<td>10-15%</td>
<td>Strong</td>
<td>Central</td>
<td>oat cell, neuroendocrine</td>
<td>disseminated at presentation origin in endobronchial cells</td>
<td>1% (poorest prognosis)</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>M: 35%</td>
<td>Weak</td>
<td>Peripheral</td>
<td>glandular, mucin producing</td>
<td>early, distant</td>
<td>12% (60% for mucinous adenocarcinoma, a subtype, with a resectable solitary lesion)</td>
</tr>
<tr>
<td>F: 40%</td>
<td></td>
<td></td>
<td></td>
<td>intercellular bridges</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Squamous Cell Carcinoma (SCC)</td>
<td>30%</td>
<td>Strong</td>
<td>Central</td>
<td>keratin, intercellular bridges</td>
<td>local invasion and distant spread, may cavitate</td>
<td>25%</td>
</tr>
<tr>
<td>Large Cell Carcinoma</td>
<td>10-15%</td>
<td>Strong</td>
<td>Peripheral</td>
<td>anaplastic, undifferentiated</td>
<td>early, distant</td>
<td>13%</td>
</tr>
</tbody>
</table>

**Risk Factors**
• cigarette smoking: the relative risk of developing lung cancer is 10-30 times higher for smokers than for nonsmokers
• other risk factors include cigar smoking, pipe smoking, second-hand smoke, asbestos without smoking (relative risk is 5), asbestos with smoking (relative risk is 92), metals (e.g. chromium, arsenic, nickel), radon gas, ionizing radiation, genetics

**Signs and Symptoms**
• may be due to primary lesion, metastasis, or paraneoplastic syndrome
• primary lesion
  ▪ cough (75%): beware of chronic cough that changes in character
  ▪ dyspnea (60%)
- chest pain (45%)
- hemoptysis (35%)
- other pain (25%)
- clubbing (21%)
- constitutional symptoms: anorexia, weight loss, fever, anemia

**Metastasis**
- lung hilum, mediastinum, pleura: pleural effusion, atelectasis, wheezing
- pericardium: pericardial effusion, pericardial tamponade
- esophageal compression: dysphagia
- phrenic nerve: paralyzed diaphragm
- recurrent laryngeal nerve: hoarseness
- superior vena cava syndrome
  - obstruction of SVC causing neck and facial swelling, as well as dyspnea and cough
  - other symptoms: hoarseness, tongue swelling, epistaxis, and hemoptysis
- physical findings: dilated neck veins, increased number of collateral veins covering the anterior chest wall, cyanosis, edema of the face, arms, and chest, Pemberton's sign (facial flushing, cyanosis, and distension of neck veins upon raising both arms above head)
  - milder symptoms if obstruction is above the azygos vein
- lung apex (Pancoast tumour): Horner's syndrome, brachial plexus palsy (most commonly C8 and T1 nerve roots)
- rib and vertebral: erosion
- distant metastasis to brain, bone, liver, adrenals

**Paraneoplastic syndromes**
- a group of disorders associated with malignant disease, not related to the physical effects of the tumour itself
- most often associated with SCLC

### Table 29. Paraneoplastic Syndromes

<table>
<thead>
<tr>
<th>System</th>
<th>Clinical Presentation</th>
<th>Associated Malignancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skeletal</td>
<td>Clubbing, hypertrophic pulmonary osteoarthropathy (HOPOA)</td>
<td>Non-small cell lung cancer (NSCLC)</td>
</tr>
<tr>
<td>Dermatologic</td>
<td>Acanthosis nigricans, Dermatomyositis</td>
<td>Bronchogenic cancer</td>
</tr>
<tr>
<td>Endocrine</td>
<td>Hypercalcaemia (osteolysis or PTHrP)</td>
<td>Squamous cell cancer</td>
</tr>
<tr>
<td></td>
<td>Hypophosphatemia</td>
<td>Squamous cell cancer</td>
</tr>
<tr>
<td></td>
<td>Hypoglycaemia</td>
<td>Sarcoma</td>
</tr>
<tr>
<td></td>
<td>Cushing’s syndrome (ACTH)</td>
<td>Small cell lung cancer (SCLC)</td>
</tr>
<tr>
<td></td>
<td>Somatostatinoma syndrome (SIAH)</td>
<td>Bronchial carcinoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SCLC</td>
</tr>
<tr>
<td>Neuromyopathic</td>
<td>Lambert-Eaton syndrome, Polymyositis</td>
<td>SCLC</td>
</tr>
<tr>
<td></td>
<td>Subacute cerebellar degeneration</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Spinocebellar degeneration</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peripheral neuropathy</td>
<td></td>
</tr>
<tr>
<td>Vascular/Hematologic</td>
<td>Nonbacterial endocarditis</td>
<td>Bronchogenic cancer</td>
</tr>
<tr>
<td>Renal</td>
<td>Nephrotic syndrome</td>
<td></td>
</tr>
</tbody>
</table>

### Investigations
- initial diagnosis
  - imaging: CXR, CT chest + upper abdomen, PET scan, bone scan
  - cytology: sputum
  - biopsy: bronchoscopy, EBUS, CT-guided percutaneous needle biopsy, mediastinoscopy
- staging workup
  - TMN staging system: T – primary tumour (size); N – regional lymph nodes; M – distant metastasis
  - blood work: electrolytes, LFTs, calcium, ALP
  - imaging: CXR, CT thorax and upper abdomen, bone scan, neuroimaging
  - invasive: bronchoscopy (EBUS), mediastinoscopy, mediastinotomy, thoracotomy
  - screen adenocarcinoma for EGFR and ALK mutations

### Endobronchial Ultrasound (EBUS)
- Allows visualization of peri-bronchial structures and distal peripheral lung lesions
- Provides detailed assessment of the airway wall layers
- Allows for guided biopsies of lymph nodes and tumours
- Used for diagnosis and staging
Table 30. SCLC vs. NSCLC

<table>
<thead>
<tr>
<th>Stage</th>
<th>Definition</th>
<th>Treatment</th>
<th>Median Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCLC</td>
<td>Limited stage: Confined to single radiation port (one hemithorax and regional lymph nodes)</td>
<td>Radiation ± chemotherapy ± prophylactic to brain</td>
<td>1-2 yr (12 wk without treatment)</td>
</tr>
<tr>
<td></td>
<td>Extensive stage: Extension beyond a single radiation port</td>
<td>Chemotherapy</td>
<td>6 mo (5 wk without treatment)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stage</th>
<th>TNM</th>
<th>Treatment</th>
<th>5 Yr Survival (%)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>T1a-T1bN0M0</td>
<td>1st line is complete surgical resection with possible post-operative adjuvant chemotherapy with stage IB and stage II; radiotherapy for non-surgical candidates</td>
<td>50-73</td>
</tr>
<tr>
<td>IB</td>
<td>T2aN0M0 or T2bN0M0</td>
<td></td>
<td>36-46</td>
</tr>
<tr>
<td>II</td>
<td>T2bN1M0 or T3N0M0</td>
<td></td>
<td>25-36</td>
</tr>
<tr>
<td>III</td>
<td>T1a-T2bN2M0 or T3N1-2M0 or T4N0-1M0</td>
<td>Combined modality approach (concurrent chemotherapy followed by surgery)</td>
<td>19-24</td>
</tr>
<tr>
<td>IV</td>
<td>T4N2M0 or T1-4N3M0</td>
<td></td>
<td>7-9</td>
</tr>
</tbody>
</table>

* Depends on clinical vs. pathologic stage
Refer to AJCC Cancer Staging Manual, 7th ed. 2010 for complete TNM classification

Treatment
- options include surgery, radiotherapy, chemotherapy, and palliative care for end-stage disease
- surgery not usually performed for SCLC since it is generally non-curable
- contraindications for surgery
  - spread to contralateral lymph nodes or distant sites
    - patients with potentially resectable disease must undergo mediastinal node sampling since CT thorax is not accurate in 20-40% of cases
  - poor pulmonary status (e.g. unable to tolerate resection of lung)
  - chemotherapy (used in combination with other treatments)
    - common agents: etoposide, platinum agents (e.g. cisplatinum), ifosfamide, vincristine, anthracyclines, paclitaxel, irinotecan, gefitinib (an endothelial growth factor receptor inhibitor)
  - complications
    - acute: tumor lysis syndrome, infection, bleeding, myelosuppression, hemorrhagic cystitis (cyclophosphamide), cardiotoxicity (doxorubicin), renal toxicity (cisplatin), peripheral neuropathy (vincristine)
    - chronic: neurologic damage, leukemia, additional primary neoplasms

Approach to the Solitary Pulmonary Nodule
- see Medical Imaging, MI7

Definition
- a round or oval, sharply circumscribed radiographic lesion up to 3 cm, which may or may not be calcified, and is surrounded by normal lung
- can be benign or malignant

Table 31. Differential Diagnosis for Benign vs. Malignant Solitary Nodule

<table>
<thead>
<tr>
<th>Benign (70%)</th>
<th>Malignant (30%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infectious granuloma (histoplasmosis, coccidiodymycosis, TB, atypical mycobacteria)</td>
<td>Bronchogenic carcinoma</td>
</tr>
<tr>
<td>Other infections (bacterial abscess, PCP, aspergillosis)</td>
<td>Squamous cell carcinoma</td>
</tr>
<tr>
<td>Benign neoplasms (hamartoma, lipoma, fibroma)</td>
<td>Large cell carcinoma</td>
</tr>
<tr>
<td>Vascular (AV malformation, pulmonary varix)</td>
<td>Small cell carcinoma</td>
</tr>
<tr>
<td>Developmental (bronchogenic cyst)</td>
<td>Metastatic lesions</td>
</tr>
<tr>
<td>Inflammatory (granulomatosis with polyangiitis, rheumatoid nodule, sarcoidosis)</td>
<td>Breast</td>
</tr>
<tr>
<td>Other (infarct, pseudotumour, rounded atelectasis, lymph nodes, amyloidoma)</td>
<td>Head and neck</td>
</tr>
</tbody>
</table>

Hamartomas
- 10% of benign lung lesions
- Composed of tissues normally present in lung (fat, epithelium, fibrous tissue, and cartilage), but they exhibit disorganized growth
- Peak incidence is age 60, more common in men
- Usually peripheral and clinically silent
- CXR shows clustered “popcorn” pattern of calcification (pathognomonic for hamartoma)
Investigations

• CXR: always compare with previous CXR
• CT densitometry and contrast enhanced CT of thorax
• sputum cytology: usually poor yield
• biopsy (bronchoscopic or percutaneous) or excision (thoracoscopic or thoracotomy): if clinical and radiographic features do not help distinguish between benign or malignant lesion
  • if at risk for lung cancer, biopsy may be performed regardless of radiographic features
  • if a biopsy is non-diagnostic, whether to observe, re-biopsy, or resect will depend on the level of suspicion
• watchful waiting: repeat CXR and/or CT scan at 3, 6, 12 mo
• PET scan can help distinguish benign from malignant nodules

Table 32. CXR Characteristics of Benign vs. Malignant Solitary Nodule

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Benign</th>
<th>Malignant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size</td>
<td>&lt;3 cm, round, regular</td>
<td>&gt;3 cm, irregular, spiculated</td>
</tr>
<tr>
<td>Margins</td>
<td>Smooth margin</td>
<td>Ill-defined or notched margin</td>
</tr>
<tr>
<td>Features</td>
<td>Calcified pattern: central, “popcorn” pattern if hamartoma, usually no cavitation; if cavitating, wall is smooth and thin, no other lung pathology</td>
<td>Usually not calcified; if calcified, pattern is eccentric, no satellite lesions, cavitation with thick wall, may have pleural effusions, lymphadenopathy</td>
</tr>
<tr>
<td>Doubling Time</td>
<td>Doubles in &lt;1 mo or &gt;2 yr</td>
<td>Doubles in &gt;1 mo or &lt;2 yr</td>
</tr>
</tbody>
</table>

Figure 11. Evaluation of a solitary pulmonary nodule
Adapted from Patel et al 2013 & Fleischner Society 2005.
Sleep-Related Breathing Disorders

Hypoventilation Syndromes

- primary alveolar hypoventilation: idiopathic
- obesity-hypoventilation syndrome (Pickwickian syndrome)
- respiratory neuromuscular disorders

Sleep Apnea

Definition
- episodic decreases in airflow during sleep
- quantitatively measured by the Apnea/Hypopnea Index (AHI) = # of apneic and hypopneic events per hour of sleep
- sleep apnea generally accepted to be present if AHI >15

Classification
- obstructive (OSA)
- caused by transient, episodic obstruction of the upper airway
- absent or reduced airflow despite persistent respiratory effort
- central (CSA) (see Neurology: N7)
- caused by transient, episodic decreases in CNS drive to breathe
- no airflow because no respiratory effort
- Cheyne-Stokes Respiration: a form of CSA in which central apneas alternate with hyperpneas to produce a crescendo-decrescendo pattern of tidal volume; seen in severe LV dysfunction, brain injury, and other settings (see Figure 2)
- mixed (MSA)
- features of both OSA and CSA
- loss of hypoxic and hypercapnic drives to breathe secondary to “resuscitative breathing”
- overcompensatory hyperventilation upon awakening from OSA induced hypoxia

Risk Factors
- for OSA: obesity, upper airway abnormality, neuromuscular disease, hypothyroidism, alcohol/sedative use, nasal congestion, sleep deprivation
- for CSA: LV failure, brainstem lesions, encephalitis, encephalopathy, myxedema, high altitude

Signs and Symptoms
- obtain history from spouse/partner
- secondary to repeated arousals and fragmentation of sleep: daytime somnolence, personality and cognitive changes, snoring
- secondary to hypoxemia and hypercapnia: morning headache, polycythemia, pulmonary/systemic HTN, cor pulmonale/CHF, nocturnal angina, arrhythmias
- the typical presentation for OSA is a middle-aged obese male who snores
- CSA can be due to neurological disease

Investigations
- sleep study (polysomnography)
- evaluates sleep stages, airflow, ribcage movement, ECG, SaO₂, limb movements
- indications
  - excessive daytime sleepiness
  - unexplained pulmonary HTN or polycythemia
  - daytime hypercapnia
  - titration of optimal nasal CPAP
  - assessment of objective response to other interventions

Treatment
- modifiable factors: weight loss, decreased alcohol/sedatives, nasal decongestion, treatment of underlying medical conditions
- OSA or MSA: nasal CPAP, postural therapy (e.g. no supine sleeping), dental appliance, uvulopalatopharyngoplasty, tonsillectomy
- CSA or hypoventilation syndromes: nasal BiPAP/CPAP, respiratory stimulants, adaptive servventilation (e.g. progesterone) in select cases
- tracheostomy rarely required and should be used as last resort for OSA

Complications
- depression, weight gain, decreased quality of life, workplace and vehicular accidents, cardiac complications (e.g. HTN), reduced work/social function
Introduction to Intensive Care

• goal is to provide stabilization for critically ill patients: hemodynamic, respiratory or cardiac instability, or need for close monitoring

Intensive Care Unit Basics

Lines and Catheters

• arterial lines
  • monitor beat-to-beat blood pressure variations, obtain blood for routine ABGs
  • common sites are the radial and femoral arteries
• central venous catheter (central line)
  • administer IV fluids, monitor CVP, insert pulmonary artery catheters
  • administer TPN and agents too irritating for peripheral line
• common sites: internal jugular vein, subclavian vein, femoral vein
• pulmonary arterial catheter
• balloon guides the catheter from a major vein to the right heart
• measures pulmonary capillary wedge pressure (PCWP) via a catheter wedged in distal pulmonary artery
• PCWP reflects the LA and LV diastolic pressure (barring pulmonary venous or mitral valve disease)
• indications (now used infrequently due to associated complications)
  • diagnosis of shock states, primary pulmonary HTN, valvular disease, intracardiac shunts, cardiac tamponade, PE
  • assessment of hemodynamic response to therapies
  • differentiation of high- versus low-pressure pulmonary edema
  • management of complicated MI, multiorgan system failure and/or severe burns, or hemodynamic instability after cardiac surgery
• absolute contraindications
  • tricuspid or pulmonary valve mechanical prosthesis
  • right heart mass (thrombus or tumour)
  • tricuspid or pulmonary valve endocarditis

Table 33. Useful Equations and Cardiopulmonary Parameters

<table>
<thead>
<tr>
<th>Equation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSA = [Ht (cm) + Wt (kg) – 60]/100</td>
<td>Body surface area</td>
</tr>
<tr>
<td>PCWP = LVEDP</td>
<td>Pulmonary capillary wedge pressure</td>
</tr>
<tr>
<td>SV = CO / HR</td>
<td>Stroke volume</td>
</tr>
<tr>
<td>SVI = (CI / HR)</td>
<td>Stroke volume index</td>
</tr>
<tr>
<td>SVRI = [(MAP – RAP) 80]/CI</td>
<td>Systemic vascular resistance index</td>
</tr>
<tr>
<td>P.F ratio = P.dP / F.dP</td>
<td>Pulmonary vascular resistance</td>
</tr>
<tr>
<td>MAP = sBP – dBP</td>
<td>Mean arterial pressure</td>
</tr>
<tr>
<td>RV Ejection Fraction = SV / RVEDV</td>
<td>Right ventricular ejection fraction</td>
</tr>
<tr>
<td>SVI = CI / HR</td>
<td>Stroke volume index</td>
</tr>
<tr>
<td>PCWP = LVEDP</td>
<td>Pulmonary capillary wedge pressure</td>
</tr>
</tbody>
</table>

Organ Failure

Table 34. Types of Organ Failure

<table>
<thead>
<tr>
<th>Type of Failure</th>
<th>Clinical Presentation</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory Failure (see Respiratory Failure, R25)</td>
<td>Hypoxemia, Hypercapnea</td>
<td>Treat underlying cause (e.g. lung disease, shunt, V/Q mismatch, drug-related, cardiac) Manage mechanical ventilation settings Supplemental oxygen</td>
</tr>
<tr>
<td>Cardiac Failure (see Cardiology and Cardiac Surgery, C24)</td>
<td>Hypotension, Decreased urine output, Altered mental status, Arrhythmia, Hypoxia</td>
<td>Treat underlying cause (e.g. bradycardia, tachycardia, blood loss, adrenal insufficiency) Volume resuscitation Vasopressors Inotropes Intra-aortic balloon pump</td>
</tr>
<tr>
<td>Coagulopathy (see Hematology, H55)</td>
<td>Increased INR or FPTT, Low platelet count, Bleeding, bruising</td>
<td>Treat underlying cause (e.g. thrombocytopenia, drug-related, immune-related, DIC) Transfusion of blood products, clotting factors</td>
</tr>
<tr>
<td>Liver Failure (see Gastroenterology, G35)</td>
<td>Elevated transaminases, bilirubin, Coagulopathy, Jaundice, Mental alteration (encephalopathy), Hypoglycemia</td>
<td>Treat underlying cause (e.g. viral hepatitis, drug related, metabolic) Liver transplant Lactulose</td>
</tr>
<tr>
<td>Renal Failure (see Nephrology, NP38)</td>
<td>Elevated creatinine, Reduced urine output, Signs of volume overload (e.g. CHF, effusions)</td>
<td>Treat underlying cause (e.g. shock, drug-related, obstruction) Correct volume and electrolyte status, eliminate toxins Diuretics Dialysis</td>
</tr>
</tbody>
</table>
Shock

- see Emergency Medicine, ER3
- inadequate tissue perfusion potentially resulting in end organ injury
  - categories of shock
    - hypovolemic: hemorrhage, dehydration, vomiting, diarrhea, interstitial fluid redistribution
    - cardiogenic: myopathic (myocardial ischemia ± infarction), mechanical, arrhythmic, pharmacologic
    - obstructive: massive PE (saddle embolus), pericardial tamponade, constrictive pericarditis, increased intrathoracic pressure (e.g. tension pneumothorax)
    - distributive: sepsis, anaphylactic reaction, neurogenic, endocrinologic, toxic

Quick SOFA (qSOFA) Criteria
- Respiratory rate > 22/min
- Altered mentation
- Systolic blood pressure < 100 mmHg

≥ 2 criteria on either qSOFA or SOFA score should not delay or defer investigation or treatment of infection or any other aspect of care deemed necessary by the practitioners.

Table 35. Changes Seen in Different Classes of Shock

<table>
<thead>
<tr>
<th>Category</th>
<th>Hypovolemic</th>
<th>Cardiogenic</th>
<th>Obstructive</th>
<th>Distributive</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR</td>
<td>↑</td>
<td>↑, N, or ↓</td>
<td>↑</td>
<td>↑ or ↓</td>
</tr>
<tr>
<td>BP</td>
<td>↓</td>
<td>↔</td>
<td>↔</td>
<td>↓</td>
</tr>
<tr>
<td>JVP</td>
<td>↓</td>
<td>↑</td>
<td>↑ or ↓</td>
<td>↓</td>
</tr>
<tr>
<td>Extremities</td>
<td>Cold</td>
<td>Cold</td>
<td>N or Cold</td>
<td>Warm</td>
</tr>
<tr>
<td>Other</td>
<td>Look for visible hemorrhage or signs of dehydration</td>
<td>Bilateral crackles on chest exam</td>
<td>Depending on cause, may see pulsus paradoxus, Kussmaul’s sign, or tracheal deviation</td>
<td>Look for obvious signs of infection or anaphylaxis</td>
</tr>
</tbody>
</table>

Sepsis

- the leading cause of death in noncoronary ICU settings is multi-organ failure due to sepsis
- the predominant theory is that sepsis is attributable to uncontrollable immune system activation

Definitions
- the Third International Consensus Definition for Sepsis and Septic Shock (Singer et al. JAMA 2016: 315(8), 801-810) significantly revised sepsis definitions
- sepsis: life threatening organ dysfunction caused by dysregulated host response to infection (see Table 36)
- septic shock: a subset of sepsis, where sufficient circulatory and/or cellular/metabolic abnormalities substantially increase mortality. Clinically defined as sepsis with persisting hypotension requiring vasopressors to maintain MAP ≥65 mmHg and having a serum lactate ≥2 mmol/L (18 mg/dL) despite adequate fluid resuscitation

Signs and Symptoms
- new guidelines recommend the use of quick SOFA (qSOFA) criteria and SOFA score to replace SIRS criteria
- in patients with suspected infection, bedside application of qSOFA criteria identifies individuals with high likelihood of poor outcomes, including prolonged ICU stay and/or death
- a positive qSOFA (≥2 criteria) should prompt application of the SOFA score, and further evaluation of possible infection and organ dysfunction
- in the context of suspected infection, a SOFA score ≥2 reflects an overall mortality risk of 10%
- the absence of ≥2 criteria on either qSOFA or SOFA score should not delay or defer investigation or treatment of infection or any other aspect of care deemed necessary by the practitioners

Systemic Inflammatory Response Syndrome (SIRS): generalized inflammatory reaction caused by infectious and noninfectious entities, manifested by two or more of:
- Body temperature >38°C or <36°C
- Heart rate >90/min
- Respiratory rate >20/min or P,CO₂ <32 mmHg
- WBC >12,000 cells/mL or <4,000 cells/mL or >10% bands

Quick SOFA (qSOFA) Criteria
- Respiratory rate ≥22/min
- Altered mentation
- Systolic blood pressure ≤100 mmHg
### Table 36. Sequential (Sepsis-Related) Organ Failure Assessment (SOFA) Score

<table>
<thead>
<tr>
<th>System</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Respiratory</strong></td>
<td></td>
</tr>
<tr>
<td>Baseline PO2/FIO2, mmHg</td>
<td>&gt;400</td>
</tr>
<tr>
<td></td>
<td>400</td>
</tr>
<tr>
<td></td>
<td>300</td>
</tr>
<tr>
<td></td>
<td>200</td>
</tr>
<tr>
<td></td>
<td>100</td>
</tr>
<tr>
<td><strong>Coagulation</strong></td>
<td></td>
</tr>
<tr>
<td>Platelets, x10^9/µL</td>
<td>&gt;150</td>
</tr>
<tr>
<td></td>
<td>150</td>
</tr>
<tr>
<td></td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>20</td>
</tr>
<tr>
<td><strong>Liver</strong></td>
<td></td>
</tr>
<tr>
<td>Bilirubin, µmol/L/mg/dL</td>
<td>&lt;20</td>
</tr>
<tr>
<td></td>
<td>20-32</td>
</tr>
<tr>
<td></td>
<td>33-101</td>
</tr>
<tr>
<td></td>
<td>102-204</td>
</tr>
<tr>
<td></td>
<td>&gt;204</td>
</tr>
<tr>
<td><strong>Cardiovascular</strong></td>
<td></td>
</tr>
<tr>
<td>MAP ≥70 mmHg</td>
<td></td>
</tr>
<tr>
<td>MAP &lt;70 mmHg</td>
<td></td>
</tr>
<tr>
<td>Dopamine &lt;5* or dobutamine</td>
<td></td>
</tr>
<tr>
<td>(any dose)/a</td>
<td></td>
</tr>
<tr>
<td>Dopamine 5.1-15* or epiinephrine</td>
<td>&lt;0.1*</td>
</tr>
<tr>
<td>or norepinephrine</td>
<td></td>
</tr>
<tr>
<td>&lt;0.1*</td>
<td></td>
</tr>
<tr>
<td>Dopamine &gt;15 or epiinephrine</td>
<td></td>
</tr>
<tr>
<td>or norepinephrine &gt;0.1a</td>
<td></td>
</tr>
</tbody>
</table>

**Central Nervous System**

<table>
<thead>
<tr>
<th>Glasgow coma scale score</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
</tr>
<tr>
<td>13-14</td>
</tr>
<tr>
<td>10-12</td>
</tr>
<tr>
<td>6-9</td>
</tr>
<tr>
<td>&lt;6</td>
</tr>
</tbody>
</table>

**Renal**

<table>
<thead>
<tr>
<th>Creatinine, µmol/L/mg/dL</th>
<th>&lt;110</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urine output, mL/d</td>
<td>&lt;500</td>
</tr>
</tbody>
</table>

*Catecholamine doses are given as µg/kg/min for at least 1 hr

Table adapted from Singer et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315(8): 801-810.

---

### Figure 12. Approach to sepsis

Figure adapted from Singer et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315(8): 801-810.

#### Treatment

- Identify the cause and source of infection: blood, sputum, urine Gram stain, and C&S
- Initiate empiric antibiotic therapy
- Monitor, restore, and maintain hemodynamic function

#### Surviving Sepsis (adapted from International Guidelines for Management of Severe Sepsis and Septic Shock 2012)

- Adjustments of cardiac preload, afterload, and contractility to balance oxygen delivery with demand
- Initial resuscitation (goals during first 6 hrs of resuscitation for sepsis induced hypotension persisting after initial fluid challenge or blood lactate ≥ 4 mmol/L)
- Maintain CVP 8-12 mmHg with IV crystalloids/colloids
  - Maintain MAP ≥ 65 mmHg with use of vasopressor agents, first line: norepinephrine
  - Urine output ≥ 0.5 mL/kg/hr
  - Central venous (SVC) or mixed oxygen saturation 70% or 65% respectively

---

### Goal-Directed Resuscitation for Patients with Early Septic Shock

**NEJM 2014**: 371:1486-1506

**Study**: Prospective, randomized controlled trial

**Population**: 1600 patients in Australia and New Zealand presenting to the emergency department with early septic shock.

**Intervention**: Patients were randomized to receive Early goal-directed therapy (EGDT) or usual care.

**Outcome**: The primary outcome was all-cause mortality within 90 days of randomization.

**Results**: The rate of death did not significantly differ between patients treated with EGDT or usual care (absolute risk difference EGDT versus usual care = -0.3%, 95% CI: -4.1 to 3.8%, P=0.90). EGDT-treated patients received more intravenous fluids, vasopressor infusions, red blood cell transfusions, and dobutamine (P<0.0001 for all). Survival time, in-hospital mortality, duration of organ support, and length of hospital stay did not significantly differ between patients randomized to EGDT or usual care.

**Conclusions**: EGDT did not improve all-cause mortality at 90 days in patients presenting to the emergency department with early septic shock.

---

### Glucocorticosteroids for sepsis: systematic review with meta-analysis and trial sequential analysis

**Intens Care Med 2015**: 41(7): 1222-1234

**Study**: Systematic review and trial sequential analysis of 35 randomized clinical trials.

**Population**: 4682 adult patients with SIRS, sepsis, severe sepsis or septic shock.

**Results**: 33 of 35 trials analyzed had a high risk of bias. There was no statistically significant effect on morality of glucocorticosteroids given at any dose when compared to placebo (RR 0.99, TSA adjusted CI 0.74-1.08). No effect was identified in subgroup analysis based on high (>500 mg) or low (<500 mg) dosing or stratification by degree of sepsis. Serious adverse events besides mortality were not altered by glucocorticosteroid treatment (RR 1.02; TSA-adjusted CI 0.7-1.48).

**Conclusions**: There is no definitive evidence for or against the use of glucocorticosteroids in septic patients. Larger and better designed randomized controlled trials ongoing and in future are required.
- in patients with elevated lactate levels target resuscitation to normalize lactate
- corticosteroid replacement therapy not indicated if adequate hemodynamic stability achieved with fluid resuscitation and vasopressor therapy
- infection control
  - prompt diagnosis of infection
  - cultures as clinically indicated prior to antibiotic therapy if no significant delay
- imaging studies performed promptly to confirm possible infectious source
- antibiotic therapy
- administer effective IV antimicrobials within first hour of recognition of sepsis
  - choice of anti-infective therapy should consider activity against all likely pathogens and penetrance of adequate concentration into tissue presumed to be source of infection
  - antimicrobial regimen should be reassessed daily for potential desescalation
- surgical source control when appropriate
- supportive oxygenation and ventilation using lung-protective regimen
- early nutritional support: enteral route is used to preserve function of intestinal mucosal barrier
- DVT/PE prophylaxis
- advanced care planning, including the communication of likely outcome and realistic goals of treatment with patients and families

### Common Medications

#### Table 37. Common Medications for Respiratory Diseases

<table>
<thead>
<tr>
<th>Drug</th>
<th>Typical Adult Dose</th>
<th>Indications</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>β₂-AGONISTS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Short-Acting</strong></td>
<td>salbutamol/albuterol (Ventolin®, Airomir®) (light blue/n/a MDI or diskus), terbutaline (Bricanyl®) (blue turbuhaler)</td>
<td>1-2 puffs q4-6h prn</td>
<td>Bronchodilator in acute reversible airway obstruction</td>
</tr>
<tr>
<td><strong>Long-Acting</strong></td>
<td>salmeterol (Serevent®) (green diskus), formoterol (Oxeze®, Foradil®) (blue/green turbuhaler or aerosolizer) indacaterol (Onbrez®) (blue/white breezhaler)</td>
<td>1-2 puffs bid 1 puff daily</td>
<td>Maintenance treatment (prevention of bronchospasm) in COPD, asthma</td>
</tr>
<tr>
<td><strong>Combination Long-Acting β₂-Agonist and Inhaled Corticosteroid</strong></td>
<td>fluticasone and salmeterol (Advair®) (purple MDI or diskus) budesonide and formoterol (Symbicort®) (red turbuhaler) Mometasone and formoterol (Zenhale®) (blue MDI)</td>
<td>1 puff bid 2 puffs bid</td>
<td>COPD and asthma</td>
</tr>
<tr>
<td><strong>Combination Short-Acting β₂-Agonist and Short-Acting Anti-Cholinergic</strong></td>
<td>ipratropium/salbutamol (Combivent®, Respimat®) (orange respimat)</td>
<td>1 puff qid</td>
<td>Bronchodilator used in COPD, bronchitis and emphysema</td>
</tr>
<tr>
<td><strong>Combination Long-Acting β₂-Agonist and Long-Acting Anti-Cholinergic</strong></td>
<td>umeclidinium/vilanterol (Anoro®) (red ellipta) aclidinium/formoterol (Duaklir®) (yellow inhaler) tiotropium/olodaterol (Inspiolto®) (green respimat) indacaterol/glycopyronium (Ultibro®) (yellow breezhaler)</td>
<td>1 puff daily 1 puff bid 1 puff daily 1 puff daily</td>
<td>Bronchodilator used in COPD, bronchitis and emphysema</td>
</tr>
</tbody>
</table>

#### ANTICHOLINERGICS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Typical Adult Dose</th>
<th>Indications</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Short-Acting Anti-Cholinergic</strong></td>
<td>ipratropium bromide (Atrovent®, Clear/green MDI)</td>
<td>2-3 puffs qid</td>
<td>Bronchodilator used in COPD, bronchitis and emphysema</td>
</tr>
<tr>
<td><strong>Long-Acting Anti-Cholinergic</strong></td>
<td>tiotropium bromide (Spiriva®) (green handhaler or respimat) glycopyronium bromide (Seebri®) (orange breezhaler), umeclidinium (Incлюsion®) (green ellipta), aclidinium (Genuair®, Tudorza®) (green inhaler)</td>
<td>1 puff qam 1 puff daily</td>
<td>Bronchodilator used in COPD, bronchitis and emphysema</td>
</tr>
</tbody>
</table>
### Common Medications for Respiratory Diseases (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Typical Adult Dose</th>
<th>Indications</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CORTICOSTEROIDS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Inhaled</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fluticasone (Flovent®) (orange/peach MDI or diskus)</td>
<td>2-4 puffs bid</td>
<td>Maintenance treatment of asthma</td>
<td>H/A, fever, N/V, MSK pain, URl, throat irritation, growth velocity reduction in children/adolescents, HPA axis suppression, increased pneumonia risk in COPD</td>
</tr>
<tr>
<td>budesonide (Pulmicort®) (brown turbuhaler)</td>
<td>2 puffs bid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ciclesonide (Alvesco®) (red MDI)</td>
<td>1 puff daily or bid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>beclomethasone (QVAR®, Vanceril®) (brown MDI)</td>
<td>1-4 puffs bid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mometasone (Asmanex®) (pink/grey/brown twisthaler)</td>
<td>1 puff daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td>fluticasone furoate (Arnuity®) (orange ellipta)</td>
<td>1 puff daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Systemic</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>prednisone (Apo-prednisone®, Deltasone®)</td>
<td>Typically 40-60 mg per day PO</td>
<td>Acute exacerbation of COPD; severe, persistent asthma, PCP Status asthmaticus</td>
<td>Endocrine (hirsutism, DM/glucose intolerance, Cushing’s syndrome, HPA axis suppression), GI (increased appetite, indigestion), ocular (cataracts, glaucoma), edema, AVN, osteoporosis, H/A, psychiatric (anxiety, insomnia), easy bruising</td>
</tr>
<tr>
<td>methylprednisolone (Depo-Medrol®, Solu-Medrol®)</td>
<td>125 mg q8h IV (sodium succinate) loading dose 2 mg/kg then 0.5-1 mg/kg q6h for 5 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ADJUNCT AGENTS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>theophylline (Uniphyll®)</td>
<td>400-600 mg OD</td>
<td>Treatment of symptoms of reversible airway obstruction due to COPD</td>
<td>GI upset, diarrhea, N/V, anxiety, H/A, insomnia, muscle cramp, tremor, tachycardia, PVCs, arrhythmias</td>
</tr>
<tr>
<td><strong>LEUKOTRIENE ANTAGONISTS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>montelukast (Singular®), zafirlukast (Accolate®)</td>
<td>10 mg PO qhs, now only available as once daily slow release 20 mg bid</td>
<td>Prophylaxis and chronic treatment of asthma</td>
<td>H/A, dizziness, fatigue, fever, rash, dyspepsia, cough, flu-like symptoms</td>
</tr>
<tr>
<td><strong>ANTI-IgE MONOCLONAL ANTIBODIES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>omalizumab (Xolair®)</td>
<td>150-375 mg SC q2-4wk</td>
<td>Moderate-severe persistent asthma</td>
<td>H/A, sinusitis, pharyngitis, URl, viral infection, thrombocytopenia, anaphylaxis</td>
</tr>
<tr>
<td><strong>PDE-4 INHIBITORS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>roflumilast (Daxas®)</td>
<td>500 µg PO OD</td>
<td>Severe emphysema, with frequent exacerbations</td>
<td>Weight loss, suicidal ideation</td>
</tr>
<tr>
<td><strong>ANTIBIOTICS – COMMUNITY ACQUIRED PNEUMONIA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Macrolide</strong></td>
<td>erithromycin, azithromycin</td>
<td>250-500 mg PO tid x 7-10 d</td>
<td>Alternate to doxycline or fluoroquinolone</td>
</tr>
<tr>
<td>clarithromycin</td>
<td>500 mg PO x 1 dose, then 250 mg OD x 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1,000 mg od or 500 mg PO bid x 7-10 d</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Doxycycline</strong></td>
<td></td>
<td>100 mg PO bid x 7-10 d</td>
<td>Alternate to macrolide or fluoroquinolone</td>
</tr>
<tr>
<td><strong>Fluoroquinolone</strong></td>
<td>levofloxacin (Levaquin®), maxillloxacin (Avelox®)</td>
<td>500 mg PO OD x 7-10 d</td>
<td>Alternate to macrolide or doxycline</td>
</tr>
</tbody>
</table>
### Table 37. Common Medications for Respiratory Diseases (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Typical Adult Dose</th>
<th>Indications</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANTIBIOTICS – HOSPITAL ACQUIRED PNEUMONIA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3rd gen Cephalosporin</td>
<td>ceftiraxone (Rocephin®)</td>
<td>1-2 g IV OD x 7-10 d</td>
<td>Combine with fluoroquinolone or macrolide</td>
</tr>
<tr>
<td>Fluoroquinolone</td>
<td>levofloxacin</td>
<td>750 mg PO OD x 5 d</td>
<td>Combination with 3rd gen cephalosporin</td>
</tr>
<tr>
<td></td>
<td>moxifloxacin</td>
<td>400 mg PO OD x 7 d (5 d for AECOPD)</td>
<td></td>
</tr>
<tr>
<td>Piperacillin/Tazobactam</td>
<td>Tazocin®)</td>
<td>4.5 g IV q8-8h x 7-10 d</td>
<td>Suspect Pseudomonas</td>
</tr>
<tr>
<td>Vancomycin (Vancocin®)</td>
<td></td>
<td>1 g IV bid x 7-10 d</td>
<td>Suspect MRSA</td>
</tr>
<tr>
<td>Macrolide</td>
<td>azithromycin</td>
<td>500 mg IV OD x 2 d, then 500 mg PO OD x 5 d</td>
<td>Suspect Legionella</td>
</tr>
<tr>
<td></td>
<td>clarithromycin</td>
<td>1,000 mg od or 500 mg PO bid x 7-10 d</td>
<td></td>
</tr>
<tr>
<td><strong>ICU MEDICATIONS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pressors/Inotropes</td>
<td>norepinephrine (Levophed®)</td>
<td>0.5-30 µg/min IV</td>
<td>Acute hypotension</td>
</tr>
<tr>
<td></td>
<td>phenylephrine</td>
<td>0.5 µg/kg/min IV</td>
<td>Severe hypotension</td>
</tr>
<tr>
<td></td>
<td>dobutamine</td>
<td>2-20 µg/kg/min IV</td>
<td>Inotropic support</td>
</tr>
<tr>
<td>Sedatives/Analgesia</td>
<td>fentanyl (opiod class)</td>
<td>50-100 µg then 50-unlimited µg/h IV</td>
<td>Sedation and/or analgesia</td>
</tr>
<tr>
<td></td>
<td>propofol (anesthetic)</td>
<td>1-3 mg/kg then 0.3-5 mg/kg/h IV</td>
<td>Sedation and/or analgesia</td>
</tr>
</tbody>
</table>

See Infectious Diseases, ID26 – for the management of pulmonary tuberculosis

---

**Landmark Respirology Trials**

<table>
<thead>
<tr>
<th>Trial</th>
<th>Reference</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARDS Network</td>
<td>NEJM 2000; 342:1301-8</td>
<td>Mortality decreased in ARDS patients ventilated with a low tidal volume strategy</td>
</tr>
<tr>
<td>Berlin Criteria</td>
<td>JAMA 2012; 307:2526-33</td>
<td>The new definition of ARDS, better predicts mortality</td>
</tr>
<tr>
<td>CPAP and Apnea</td>
<td>NEJM 2005; 353:2025-33</td>
<td>CPAP ameliorates symptoms of sleep apnea but does not affect mortality in CHF</td>
</tr>
<tr>
<td>EINSTEIN-PE</td>
<td>NEJM 2012; 366:1287-97</td>
<td>Fixed dose of rixivabarin was non-inferior to standard therapy (Vit K antagonist) initial and long-term treatment of PE</td>
</tr>
<tr>
<td>Emphysema Treatment Trial</td>
<td>NEJM 2003; 348:2059-73</td>
<td>Lung volume reduction surgery benefits patients with upper lobe disease and low exercise capacity</td>
</tr>
<tr>
<td>IELCAP</td>
<td>NEJM 2006; 355:1763-71</td>
<td>High survival rate in patients with early stage lung cancer detected by low dose CT screening</td>
</tr>
<tr>
<td>Lung Health</td>
<td>JAMA 1994; 272:1497-505</td>
<td>Aggressive smoking intervention significantly decreases the age-related decline in FEV1 in middle-aged smokers with mild airways obstruction</td>
</tr>
<tr>
<td>OSCILLATE</td>
<td>NEJM 2013; 368: 795-805</td>
<td>Early high-frequency oscillatory ventilation in patients with moderate to severe ARDS might increase in-hospital mortality</td>
</tr>
<tr>
<td>ILD</td>
<td>NEJM 1978; 298:801-9</td>
<td>Interstitial lung disease subsets have different prognoses and response to treatment (e.g. desquamative but not usual interstitial pneumonia respond well to corticosteroids)</td>
</tr>
<tr>
<td>POET-COPD</td>
<td>NEJM 2011; 364:1093-103</td>
<td>Tiotropium decreases the number of moderate-to-severe exacerbations in comparison to salmeterol</td>
</tr>
<tr>
<td>REDUCE</td>
<td>JAMA 2013; 309: 2223-2231</td>
<td>5 d course of glucocorticoids is non-inferior to a 14 d course for treatment of acute COPD exacerbations</td>
</tr>
<tr>
<td>ROFLUMILAST</td>
<td>Lancet 2009; 374:695-703</td>
<td>Phosphodiesterase-4 inhibitor improves FEV1 when used as add-on therapy in COPD patients on tiotropium or salmeterol</td>
</tr>
<tr>
<td>TORCH</td>
<td>NEJM 2007; 356:775-89</td>
<td>Combination of inhaled steroids and long-acting ß2-agonists improves COPD symptoms, reduces exacerbations, and shows a trend to lowers mortality</td>
</tr>
<tr>
<td>UPLIFT</td>
<td>NEJM 2008; 359:1543-54</td>
<td>Tiotropium improves symptoms of COPD with fewer exacerbations, but does not affect FEV1 decline</td>
</tr>
</tbody>
</table>
Acronyms ........................................ 2
Anatomy of Joint Pathology ................. 2
Basics of Immunology ........................ 2
                Immune Mechanisms of Disease
                Immunogenetics and Disease
Differential Diagnoses of Common
                Presentations .......................... 3
Synovial Fluid Analysis ....................... 4
Septic Arthritis ............................... 5
Degenerative Arthritis: Osteoarthritis ..... 5
Seropositive Rheumatic Disease ............. 6
Connective Tissue Disorders ................. 8
                Rheumatoid Arthritis
                Systemic Lupus Erythematosus
                Antiphospholipid Antibody Syndrome
                Scleroderma (i.e. Systemic Sclerosis)
                Idiopathic Inflammatory Myopathy
                Sjögren’s Syndrome
                Mixed Connective Tissue Disease
                Overlap Syndrome
Vasculitides ..................................... 17
                Small Vessel Non-ANCA Associated Vasculitis
                Small Vessel ANCA-Associated Vasculitis
                Medium Vessel Vasculitis
                Large Vessel Vasculitis
Seronegative Rheumatic Disease .......... 21
                Ankylosing Spondylitis
                Enteropathic Arthritis
                Psoriatic Arthritis
                Reactive Arthritis
Crystal-Induced Arthropathies .......... 24
                Gout
                Pseudogout (Calcium Pyrophosphate
                Dihydrate Disease)
Non-Articular Rheumatism ................ 26
                Polymyalgia Rheumatica
                Fibromyalgia
Common Medications ..................... 28
Landmark Rheumatology Trials ........... 30
References ............................... 31
Acronyms
Ab antibody
ACPA anti-citrullinated protein antibodies
Ag antigen
ANA antinuclear antibody
ANCA antineutrophil cytoplasmic antibody
Anti-RAF anti-smooth muscle antibodies
Anti-Sm anti-Smith antibodies
APLA antiphospholipid antibody syndrome
AS ankylosing spondylitis
AVN avascular necrosis
BUN blood urea nitrogen
CBC complete blood count
CCB calcium channel blocker
CYP cytochrome P450
CNM carpal tunnel syndrome
CNS central nervous system
CTD connective tissue disease
CPPD calcium pyrophosphate dihydrate
CRP C-reactive protein
DEXA dual energy X-ray absorptiometry
dIP distal interphalangeal joint
DM diabetes mellitus
DMARD disease-modifying anti-rheumatic drug
DMMA double stranded DNA
DNA double stranded DNA
ECASER entero-coated acetylsalicylic acid
ESR erythrocyte sedimentation rate
GC glicizin gonorrheae gonccoccus
Hb hemoglobin
HLA human leukocyte antigen
IA intra-articular
IBD inflammatory bowel disease
IE infective endocarditis
ILD interstitial lung disease
ITP idiopathic thrombocytopenic purpura
MCP metacarpal phalangeal joint
MDT mixed connective tissue disease
MHC major histocompatibility complex
MPO myeloperoxidase
MTN metatarsal phalangeal joint
MTX methotrexate
OA osteoarthritis
PAN polyarteritis nodosa
PII proximal interphalangeal joint
PM polyarthritis
PMN polymorphonuclear leukocyte
PMR polymyalgia rheumatica
PnA psoriatic arthritis
PTT partial thromboplastin time
RA rheumatoid arthritis
RBC red blood cell
RAA reactive arthritis
RF rheumatoid factor
ROM range of motion
SS sacrolitic
SLE systemic lupus erythematosus
SNRI serotonin-norepinephrine reuptake inhibitors
SSA Sjögren’s syndrome A
SSB Sjögren’s syndrome B
TfN tumour necrosis factor
U/A urinalysis
ULN upper limit of normal
U-SPa undifferentiated spondyloarthropathy
VDRL venereal disease research
VBC white blood cell

Anatomy of Joint Pathology

Figure 1. Structure of normal, degenerative, and inflammatory joint

Basics of Immunology

Immune Mechanisms of Disease

<table>
<thead>
<tr>
<th>Type</th>
<th>Pathophysiology</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immediate Hypersensitivity (Type I)</td>
<td>Formation of IgE → release of immunologic mediators from basophils/mast cells → diffuse inflammation</td>
<td>Asthma, Allergic rhinitis, Anaphylaxis</td>
</tr>
<tr>
<td>Cytotoxic (Type II)</td>
<td>Formation of Ab → deposit and bind to Ag on cell surface → phagocytosis or lysis of target cell</td>
<td>Autoimmune hemolytic anemia, Anti glomerular membrane disease (Goodpasture’s syndrome), Graves’ disease, pemphigus vulgaris, rheumatic fever, ITP</td>
</tr>
<tr>
<td>Immune Complex (Type III)</td>
<td>Formation and deposition of Ag-Ab complexes → activate complement → leukocyte recruitment and activation → tissue injury</td>
<td>SLE, PAN, post-streptococcal glomerulonephritis, serum sickness, viral hepatitis</td>
</tr>
<tr>
<td>Cell-Mediated/Delayed Hypersensitivity (Type IV)</td>
<td>Release of cytokines by sensitized T-cells and T-cell mediated cytotoxicity</td>
<td>Contact dermatitis, insect venom, mycobacterial proteins</td>
</tr>
</tbody>
</table>

Immunogenetics and Disease

- cell surface molecules called HLAs play a role in mediating immune reactions
- MHC are genes on the short arm of chromosome 6 that encode HLA molecules
- certain HLA haplotypes are associated with increased susceptibility to autoimmune diseases
Table 2. Classes of MHCs

<table>
<thead>
<tr>
<th>MHC Class</th>
<th>Types</th>
<th>Location</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>HLA-A, B, C</td>
<td>All cells</td>
<td>Recognized by CD8+ (cytotoxic) T-lymphocytes</td>
</tr>
<tr>
<td>II</td>
<td>HLA-DR, DQ, DR</td>
<td>Ag presenting cells (mononuclear phagocytes, B cells, etc.)</td>
<td>Recognized by CD4+ (helper) T-lymphocytes</td>
</tr>
<tr>
<td>III</td>
<td>Some components of the complement cascade</td>
<td>In plasma</td>
<td>Chemotaxis, opsonization, lysis of bacteria and cells</td>
</tr>
</tbody>
</table>

Table 3. HLA-Associated Rheumatic Disease

<table>
<thead>
<tr>
<th>HLA Type</th>
<th>Associated Conditions</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>B27</td>
<td>Ankylosing Spondylitis (AS)</td>
<td>Relative risk 20x for developing AS and ReA</td>
</tr>
<tr>
<td></td>
<td>Reactive Arthritis (ReA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enteropathic arthritis (EA)</td>
<td></td>
</tr>
<tr>
<td>DR4, DR1</td>
<td>Rheumatoid Arthritis (RA)</td>
<td>In RA, relative risk = 2-10x; found in 93% of patients</td>
</tr>
<tr>
<td>DR3</td>
<td>Sjögren’s syndrome (SS)</td>
<td>DR3 is associated with the production of anti-Ro/SSA and anti-La/SSB antibodies</td>
</tr>
<tr>
<td></td>
<td>Systemic Lupus Erythematosus (SLE)</td>
<td></td>
</tr>
</tbody>
</table>

Differential Diagnoses of Common Presentations

Joint Pain

Articular

Inflammatory

Non-inflammatory

Seropositive

SLE

Scleroderma

DDM/PM

SS

Seronegative

Crystal
gout

Pseudogout

Hydroxyapatite

Infectious/Septic

Gonococcal

Non-gonococcal

Lyme disease

Viral

Mycobacterial

Fungal

Degenerative

Primary OA

Secondary Metabolic

Hemophilic

Trauma

Localized Bursitis

Capsulitis

Muscle strain

Generalized

PMR

Fibromyalgia

Myofascial pain syndrome

Non-Articular

CAUSES OF JOINT PAIN

Soft Tissue

Sepsis

OA

Fracture

Tendon/muscle

Ephiphysis

Referral

Tumour

Ischemia

Seropositive arthritides

Seronegative arthritides

Urate (gout)/other crystal

Extra-articular rheumatism (PMR/ fibromyalgia)

Patterns of Joint Involvement

• Symmetrical vs. asymmetrical

• Small vs. large

• Mono vs. oligo (2-4 joints) vs. polyarticular (>5 joints)

• Axial vs. peripheral
Table 6. Symptoms of Inflammatory Arthritis vs. Degenerative Arthritis

<table>
<thead>
<tr>
<th>Inflammatory</th>
<th>Degenerative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain at rest, relieved by motion</td>
<td>Pain with motion, relieved by rest</td>
</tr>
<tr>
<td>Morning stiffness &gt; 1 h</td>
<td>Morning stiffness &lt; 1/2 h</td>
</tr>
<tr>
<td>Warmth, swelling, erythema</td>
<td>Joint instability, buckling, locking</td>
</tr>
<tr>
<td>Mal alignment/deformity</td>
<td>Bony enlargement, mal alignment/deformity</td>
</tr>
<tr>
<td>Extra-articular manifestations</td>
<td>Evening pain</td>
</tr>
</tbody>
</table>

Table 7. Seropositive vs. Seronegative Rheumatic Diseases

<table>
<thead>
<tr>
<th></th>
<th>Seropositive</th>
<th>Seronegative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td>F&gt;M</td>
<td>M&gt;F</td>
</tr>
<tr>
<td>Peripheral Arthritis</td>
<td>Symmetrical</td>
<td>Usually asymmetrical</td>
</tr>
<tr>
<td></td>
<td>Small (PIP, MCP) and medium joints</td>
<td>Usually larger joints, lower extremities (exception: PsA)</td>
</tr>
<tr>
<td></td>
<td>(wrist, knee, ankle, elbow) common</td>
<td>DIP in PsA</td>
</tr>
<tr>
<td></td>
<td>DIP less often involved</td>
<td>Dactylitis (“sausage digit”)</td>
</tr>
<tr>
<td>Pelvic/Axial Disease</td>
<td>No (except for C-spine)</td>
<td>Yes</td>
</tr>
<tr>
<td>Enthesitis</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Extra-Articular</td>
<td>Nodules</td>
<td>Iritis (anterior uveitis)</td>
</tr>
<tr>
<td></td>
<td>Vasculitis</td>
<td>Oral ulcers</td>
</tr>
<tr>
<td></td>
<td>Sicca</td>
<td>Gastrointestinal</td>
</tr>
<tr>
<td></td>
<td>Raynaud’s phenomenon</td>
<td>Dermatologic features</td>
</tr>
<tr>
<td></td>
<td>Rashes, internal organ involvement</td>
<td>Genitourinary inflammation</td>
</tr>
<tr>
<td></td>
<td>(lung, cardiac)</td>
<td></td>
</tr>
</tbody>
</table>

**Synovial Fluid Analysis**

- synovial fluid is an ultrafiltrate of plasma plus hyaluronic acid; it lubricates joint surfaces and nourishes articular cartilage

**Indications**
- diagnostic tests advised if crystal arthritis or hemoarthritis is suspected or if there is unexplained joint, bursa or tendon sheath swelling
- therapeutic: drainage of blood, purulent or tense effusions; corticosteroid injection

**Contraindications**
- absolute: open lesion or suspected infection of overlying skin or soft tissue
- relative: bleeding diathesis, thrombocytopenia, prosthetic joint

**Synovial Fluid Analysis**
- most important to assess the 3 Cs: culture and order gram stain, cell count (WBC) and differential, and crystal analysis
- other parameters to consider are listed in Table 8

**Table 8. Synovial Fluid Analysis**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Normal</th>
<th>Non-Inflammatory</th>
<th>Inflammatory</th>
<th>Infectious</th>
<th>Hemorrhagic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colour</td>
<td>Pale yellow</td>
<td>Pale yellow</td>
<td>Pale yellow</td>
<td>Yellow to white</td>
<td>Red/brown</td>
</tr>
<tr>
<td>Clarity</td>
<td>Clear</td>
<td>Clear</td>
<td>Opaque</td>
<td>Opaque</td>
<td>Sanguinous</td>
</tr>
<tr>
<td>Viscosity</td>
<td>High (due to hyaluronic acid)</td>
<td>High</td>
<td>Low</td>
<td>Low or paradoxically high if purulent</td>
<td>Variable</td>
</tr>
<tr>
<td>WBC/mm³</td>
<td>&lt;200</td>
<td>&lt;2,000</td>
<td>≥2,000</td>
<td>Higher cell counts (particularly &gt;50,000) suggestive</td>
<td>Variable</td>
</tr>
<tr>
<td>% PMN</td>
<td>&lt;25%</td>
<td>&lt;25%</td>
<td>≥25%</td>
<td>&gt;75%</td>
<td>Variable</td>
</tr>
<tr>
<td>Culture/GrGram Stain</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Usually positive</td>
<td>–</td>
</tr>
<tr>
<td>Examples</td>
<td>Trauma DA</td>
<td>Neuropathy</td>
<td>Hypertrophic – arthropathy</td>
<td>Seropositive Seronegative Crystal arthropathies</td>
<td>S. aureus Gram negative GC → difficult to culture</td>
</tr>
</tbody>
</table>
**Septic Arthritis**

- Septic arthritis is a medical emergency because it can lead to rapid joint destruction and has a 10-15% risk of mortality.
- Most commonly caused by bacterial infection (gram positive cocci > gram negative bacilli).
- Consider empiric antibiotic therapy, until septic arthritis is excluded from history, physical examination and synovial fluid analysis.
- Poor prognostic factors include: older age, immunocompromised, delay in treatment, previously damaged joint, joint prosthesis.
- See Gonococcal Arthritis, Infectious Diseases, ID14 and Orthopedics, OR10.
- Most common method is hematogenous spreading from other infection such as skin infection or pneumonia.
- Knee and hip most common joints affected.
- Risk factors: very young, portal of entry, recent infection.

**Degenerative Arthritis: Osteoarthritis**

**Definition**
- Progressive deterioration of articular cartilage and surrounding joint structures caused by genetic, metabolic, biochemical, and biomechanical factors with secondary components of inflammation.

**Classification (based on etiology)**
- Primary (idiopathic)
  - Most common, unknown etiology.
- Secondary
  - Post-traumatic or mechanical.
  - Post-inflammatory (e.g. RA) or post-infectious.
  - Heritable skeletal disorders (e.g. scoliosis).
  - Endocrine disorders (e.g. acromegaly, hyperparathyroidism, hypothyroidism).
  - Metabolic disorders (e.g. gout, pseudogout, hemochromatosis, Wilson’s disease, ochronosis).
  - Neuropathic (e.g. Charcot joints)
    - Atypical joint trauma due to peripheral neuropathy (e.g. diabetes mellitus, syphilis).
  - Avascular necrosis (AVN).
  - Other (e.g. congenital malformation).

**Pathophysiology**
- The process appears to be initiated by abnormalities in biomechanical forces and/or, less often, in cartilage.
- Elevated production of pro-inflammatory cytokines is important in OA progression.
- Tissue catabolism > repair.
- Genetics, alignment (bow-legged, knock-kneed), joint deformity (hip dysplasia), joint injury (meniscal or ligament tears), obesity, environmental, mechanical loading, age and gender factors contribute, but mechanism is unknown.
- Now considered to be a systemic musculoskeletal disorder rather than a focal disorder of synovial joints.

**Epidemiology**
- Most common arthropathy (accounts for ~75% of all arthritis).
- Increased prevalence with increasing age (35% of 30 yr olds, 85% of 80 yr olds).

**Risk Factors**
- Genetic predisposition, advanced age, obesity (for knee and hand OA), female, trauma.

**Signs and Symptoms**
- Localized to affected joints (not a systemic disease).
- Pain is often insidious, gradually progressive, with intermittent flares and remissions, neuropathic pain may also be present.
- Fatigue, poor sleep, impact on mood (depression, anxiety).

**Table 9. Signs and Symptoms of OA**

<table>
<thead>
<tr>
<th>Signs</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joint line tenderness; stress pain ± joint effusion</td>
<td>Joint pain with motion; relieved with rest</td>
</tr>
<tr>
<td>Bony enlargement at affected joints</td>
<td>Short duration of stiffness (&lt;1/2 h) after immobility</td>
</tr>
<tr>
<td>Malalignment/deformity (angulation)</td>
<td>Joint instability/buckling</td>
</tr>
<tr>
<td>Limited ROM</td>
<td>Joint locking due to “joint mouse” (bone or cartilage fragment)</td>
</tr>
<tr>
<td>Crepitus on passive ROM</td>
<td>Loss of function or other internal derangements (e.g. meniscal tear)</td>
</tr>
<tr>
<td>Inflammation (mild if present)</td>
<td>Periarticular muscle atrophy</td>
</tr>
<tr>
<td>Periarticular muscle atrophy</td>
<td></td>
</tr>
</tbody>
</table>

**Figure 3. Common sites of joint involvement in OA**
- 1. Shoulder and elbow.
- 4. Ankle.
- 5. First MTP joint.
- 6. Wrist.
- 7. Finger.

**Figure 4. Hand findings in OA**
- 1. Thumb squaring.
- 2. Heberden’s nodes.

**Figure 5. Septic arthritis**
- Septic arthritis is a medical emergency; it leads to rapid joint destruction, and there is a 10-15% risk of mortality.

**Figure 6. OA of MCP joints can be seen in hemochromatosis or CPPD related disease (chondrocalcinosis).**
Joint Involvement
• generalized osteoarthritis: 3+ joint groups
• asymmetric (knees usually affected bilaterally)
• hand
  ▪ DIP (Heberden's nodes = osteophytes → enlargement of joints)
  ▪ PIP (Bouchard's nodes)
  ▪ CMC (usually thumb squaring)
  ▪ 1st MCP (other MCPs are usually spared)
• hip
  ▪ usually presents as groin pain ± dull or sharp pain in the trochanteric area, internal rotation and abduction are lost first
  ▪ pain can radiate to the anterior thigh, but generally does not go below the knee
• knee
  ▪ initial narrowing of one compartment, medial > lateral; seen on standing x-rays, often patellar-femoral joint involved
• foot
  ▪ common in first MTP and midfoot
• lumbar spine
  ▪ very common, especially L4-L5, L5-S1
  ▪ degeneration of intervertebral discs and facet joints
  ▪ reactive bone growth can contribute to neurological impingement (e.g. sciatica, neurogenic claudication) or spondylolisthesis (forward or backward movement of one vertebra over another)
• cervical spine
  ▪ commonly presents with neck pain that radiates to scapula, especially in mid-lower cervical area (C5 and C6)

Investigations
• blood work
  ▪ normal CBC and ESR, CRP
  ▪ negative RF and ANA
• radiology: 4 hallmark findings, see sidebar
• synovial fluid: non-inflammatory (see Table 8)

Treatment
• presently no treatment alters the natural history of OA
• prevention: prevent sports injury, healthy weight management

non-pharmacological therapy
• weight loss (minimum 5-10 lb loss) if overweight
• physiotherapy: heat/cold, low impact exercise programs
• occupational therapy: aids, splints, cane, walker, bracing

pharmacological therapy (see Table 33)
• oral: acetaminophen/NSAIDs, glucosamine ± chondroitin (nutraceuticals not proven)
• treat neuropathic pain if present (anti-depressants, anti-epileptics, etc.)
• joint injections: corticosteroid (effective for short term treatment), hyaluronic acid (evidence of long term benefits)
• topical: capsaicin, NSAIDs

surgical treatment
• joint debridement, osteotomy, total and/or partial joint replacement, fusion (see Orthopedics, OR6)

Seropositive Rheumatic Disease
• diagnosis vs. classification in rheumatology
  ▪ diagnostic criteria are often dependent on disease progression and evolution over time, as early objective measures are often unavailable
  ▪ classification criteria are derived from studying patients with long-term diseases and clear diagnoses in order to determine which criteria have good specificity in the early prediction of certain diagnoses
• seropositive arthropathies are characterized by the presence of a serologic marker such as positive RF or ANA
• a small subset of the vasculitides, the small vessel ANCA-associated vasculitides, have a measurable serological component, but they are often considered a separate entity from seropositive disease by experts
Table 10. Autoantibodies and their Prevalence in Rheumatic Diseases

<table>
<thead>
<tr>
<th>Autoantibody</th>
<th>Disease</th>
<th>Healthy Controls</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>RF</td>
<td>RA 80%</td>
<td>&lt;5%</td>
<td>Autoantibodies directed against Fc domain of IgG</td>
</tr>
<tr>
<td></td>
<td>SS 50%</td>
<td>10-20%</td>
<td>Sensitive in RA (can be negative early in disease course), levels correlate with disease activity</td>
</tr>
<tr>
<td></td>
<td>SLE 20%</td>
<td>&gt;65</td>
<td>Present in most seropositive diseases</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Non-specific; may be present in IE, TB, hepatitis C, silicosis, sarcoidosis</td>
</tr>
<tr>
<td>Anti-CCP</td>
<td>RA 80%</td>
<td></td>
<td>Specific for RA (94-98%) May be useful in early disease and to predict aggressive disease</td>
</tr>
<tr>
<td>ANA</td>
<td>SLE 98%</td>
<td>High titers &lt;5%</td>
<td>Ab against nuclear components (DNA, RNA, histones, centromere)</td>
</tr>
<tr>
<td></td>
<td>MCTD 100%</td>
<td>Low titers</td>
<td>Sensitive but not specific for SLE</td>
</tr>
<tr>
<td></td>
<td>SS 40-70%</td>
<td>Up to 30%</td>
<td>Given high false positive rate - only measure when high pre-test probability of CTD</td>
</tr>
<tr>
<td></td>
<td>CREST 60-80%</td>
<td>(Often seen in other CTDs)</td>
<td></td>
</tr>
<tr>
<td>Anti-dsDNA</td>
<td>SLE 50-70%</td>
<td>0%</td>
<td>Specific for SLE (95%) Levels correlate with disease activity (i.e. SLE flare)</td>
</tr>
<tr>
<td>Anti-Sm</td>
<td>SLE &lt;30%</td>
<td>0%</td>
<td>Specific but not sensitive for SLE</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Does not correlate with SLE disease activity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>If positive, will remain positive through disease course</td>
</tr>
<tr>
<td>Anti-Ro (SSA)</td>
<td>SS 40-95%</td>
<td>0.5%</td>
<td>Subacute cutaneous SLE (74%) May be only Ab present in ANA negative SLE</td>
</tr>
<tr>
<td></td>
<td>SSc 21%</td>
<td></td>
<td>Increases risk of having child with neonatal lupus syndrome</td>
</tr>
<tr>
<td></td>
<td>SLE 32%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>RA 15%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-La (SSB)</td>
<td>SS 40%</td>
<td>0%</td>
<td>Usually occurs with anti-Ro Specific for SS and SLE when anti-Ro is also positive</td>
</tr>
<tr>
<td></td>
<td>SLE 10%</td>
<td></td>
<td>Increases risk of having child with neonatal lupus syndrome</td>
</tr>
<tr>
<td>Antiphospholipid Ab (LAC, aCLA, aB2GP)</td>
<td>APLS 100%</td>
<td>&lt;5%</td>
<td>By definition present in APLS Only small subset of SLE patients develop clinical syndrome of APLA</td>
</tr>
<tr>
<td></td>
<td>SLE 31-40%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-Histone</td>
<td>Drug-induced SLE</td>
<td>0%</td>
<td>Highly specific for drug-induced SLE</td>
</tr>
<tr>
<td></td>
<td>SLE 95%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SLE 30-80%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-RNP</td>
<td>MCTD</td>
<td></td>
<td>High titres present in MCTD; present in many other CTD (especially SLE)</td>
</tr>
<tr>
<td></td>
<td>SLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-Centromere</td>
<td>CREST &gt;80%</td>
<td>0%</td>
<td>Specific for CREST, cutaneous variant of systemic sclerosis</td>
</tr>
<tr>
<td>Anti-Topoisomerase I (formerly Scl-70)</td>
<td>Diffuse SSc 26-76%</td>
<td>0%</td>
<td>Specific for SSc Increased risk pulmonary fibrosis in SSc</td>
</tr>
<tr>
<td>Anti-Jo1</td>
<td>PM</td>
<td>0%</td>
<td>Less frequent for DMM</td>
</tr>
<tr>
<td></td>
<td>DMM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>c-ANCA</td>
<td>Active GPA</td>
<td>0%</td>
<td>Specific and sensitive</td>
</tr>
<tr>
<td></td>
<td>&gt;90%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-ANCA</td>
<td>GPA 10%</td>
<td>0%</td>
<td>Nonspecific and poor sensitivity (found in ulcerative colitis, PAN, microscopic polyangiitis, Churg-Strauss, rapidly progressive glomerulonephritis)</td>
</tr>
<tr>
<td></td>
<td>Other vasculitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-Mi-2</td>
<td>DMM 15-20%</td>
<td>0%</td>
<td>Specific but not sensitive (not available in all centres)</td>
</tr>
<tr>
<td>Ab Against RBCs, WBCs, or Platelets</td>
<td>SLE</td>
<td></td>
<td>Perform direct Coomb’s test Test Hb, reticulocyte, leukocyte and platelet count, antiplatelet Abs</td>
</tr>
<tr>
<td>Anti-mitochondria</td>
<td>Primary biliary cholangitis</td>
<td>0%</td>
<td>Sensitive and specific</td>
</tr>
</tbody>
</table>

* note: some individuals in the normal population test positive for RF and/or ANA, but do not have the conditions listed in Table 10
Connective Tissue Disorders

Table 11. Features of Seropositive Arthropathies

<table>
<thead>
<tr>
<th></th>
<th>RA</th>
<th>SLE</th>
<th>Scleroderma</th>
<th>Dermatomyositis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CLINICAL FEATURES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **History**    | Symmetrical polyarthritis (small joint involvement) | Multisystemic disease: rash, photosensitivity, Raynaud’s, alopecia, cardiac and pulmonary serositis, CNS symptoms, glomerulonephritis | Skin tightness, stiffness of fingers, Raynaud’s, heartburn, dysphagia, pulmonary HTN, renal crisis with new onset HTN or hypertensive urgency/emergency, dyspnea on exertion | Heliotrope rash (periorbital), Gottron’s papules (violaceous papules over knuckles and IP joints) ± polikiferma
|                | Morning stiffness (>1 h) |                     |                                     |                                      |
| **Physical Examination** |                     |                      |                                     |                                      |
| **Effused joints** | Effused joints       | Confirm historical findings (rash, serositis, renal, CVS, etc.) ± effused (typically small) joints (can be minimal, look for soft tissue swelling) | Skin tightness on dorsum of hand, facial skin tightening, telangiectasia, calcinosis, non-effused joint, inspiratory crackles | Rash, proximal muscle weakness, inspiratory crackles |
| **Tenosynovitis**   | Tenosynovitis        |                      |                                     |                                      |
| **Subcutaneous nodules** | Subcutaneous nodules |                      |                                     |                                      |
| **Joint deformities** | Joint deformities    |                      |                                     |                                      |
| **Bone-on-bone crepitus** | Bone-on-bone crepitus in advanced disease |                      |                                     |                                      |
| **LABORATORY**     |                     |                      |                                     |                                      |
| **Non-Specific**   | ↑ ESR in 50-60%      | ↑ ESR                | ↑ ESR                               | Possible increased ESR               |
|                    | ↑ platelets          | ↓ platelets (autoimmune) | ↓ Hb (autoimmune) | ↓ Hb Normal WBC                      |
|                    | ↓ Hb                 | ↓ WBC (leukopenia, lymphopenia) | ↓ WBC Normal WBC |                                      |
| **Specific**       | RF +ve in ~80%       | ANA +ve in 98%       | ANA +ve in >90%                     | CK elevated in 80%                   |
|                    | Anti-CCP +ve in ~80% | Anti-dsDNA +ve in 50-70% | Anti-topoisomerase 1 (diffuse) | ANA +ve in 33% anti-Jo-1, anti-Mi-2 |
|                    |                      | Anti-SM +ve in 30%   | Anti-centromere (usually in CREST, see RH13) | Muscle biopsy                        |
|                    |                      | ↓ C3, C4, total hemolytic complement |                      | EMG MRI                              |
|                    |                      | False positive VDRL (in SLE subtypes) |                      |                                      |
|                    |                      | ↑ PTT (in SLE subtypes, e.g. APLA) |                      |                                      |
| **Radiographs**    | Periarticular osteopenia | Non-erosive osteopenia | Non-pulmonary fibrosis               | ± esophageal dysmotility             |
|                    | Joint space narrowing | ± soft tissue swelling | ± esophageal dysmotility             | ± esophageal dysmotility             |
|                    | Erosions             | ± pulmonary fibrosis  | ± esophageal dysmotility             | ± esophageal dysmotility             |
|                    | Absence of bone repair |                      | ± esophageal dysmotility             | ± esophageal dysmotility             |
|                    | Symmetric/concentric | ± pulmonary fibrosis  | ± esophageal dysmotility             | ± esophageal dysmotility             |

Rheumatoid Arthritis

**Definition**
- chronic, symmetric, erosive synovitis of peripheral joints (e.g. wrists, MCPs, MTPs)
- characterized by a number of extra-articular features

Table 12. 2010 ACR/EULAR Classification Criteria for RA

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Score</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Joint involvement (swollen or tender)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 large joint (shoulders, elbows, hips, knees, and ankles)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>2-10 large joints</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>1-3 small joints (MCPs, PIPs, wrists, 2nd-5th MTPs)</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>4-10 small joints</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>&gt;10 joints (at least 1 small joint)</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Total score of ≥6: define RA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Serology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative RF and negative Anti-CCP</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Low-positive RF or low-positive Anti-CCP (&lt;3 ULN)</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>High-positive RF or high-positive Anti-CCP (≥3 ULN)</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Must have ≥1 joint with definite clinical swelling, not better explained by other disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Acute phase reactants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal CRP and normal ESR</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Abnormal CRP and abnormal ESR</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>4. Duration of symptoms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;6 wk</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>≥6 wk</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

RA is an independent risk factor for atherosclerosis and CV disease. RA is associated with increased overall mortality/morbidity from all causes: CV disease, neoplasms (especially lymphoma), infection

Common Presentation
- Morning stiffness >1 h, improves with use
- Symmetric joint involvement
- Initially involves small joints of hands and feet
- Constitutional symptoms
Pathophysiology
- autoimmune disorder, unknown etiology
- complex interaction of genes and environment leading to breakdown of immune tolerance: many pathways result in autoreactivity leading to a final common pathway to synovial inflammation
  - genetic predisposition: HLA-DR4/DR1 association (93% of patients have either HLA type), cytokine promoters, T cell signaling
  - induction of enzymes that convert arginine to citrulline caused by environmental stress (cigarette smoking)
- RA: propensity for immune reactivity to neoepitopes created by protein citrullination and production of anti-citrullinated protein antibodies
- once inflammatory process is established, synovium organizes itself into an invasive tissue that degrades cartilage and bone
- progressive bone destruction with absence of bone repair in response to inflammation
  - elevated TNF levels increases osteoclasts and decreases osteoblasts at the site of inflammation
  - upregulation of RANK ligand increases osteoclast-mediated destruction

Epidemiology
- most common inflammatory arthritis: prevalence 1% of population
- F:M = 3:1
- age of onset 20-40 yr

Signs and Symptoms
- variable course of exacerbations and remissions
- morning stiffness >1 h, improves with use, worsens with rest
- polyarthritis: symmetric joint involvement (tender, swollen), small joints affected, most commonly in hands and feet (MCP,PIP,MTP)
- extra-articular (systemic) symptoms: profound fatigue, depression, myalgia, weight loss
- limitation of function and decrease in global functional status
- complications of chronic synovitis
  - signs of mechanical joint damage: loss of motion, instability, deformity, crepitus, joint deformities
    - swan neck deformity, boutonnière deformity
    - ulnar deviation of MCP, radial deviation of wrist joint
    - hammer toe, mallet toe, claw toe
  - flexion contractures
  - atlanto-axial and subaxial subluxation
  - C-spine instability
  - neurological impingement (long tract signs)
  - difficult/dangerous intubation: risk of worsening subluxation and damage to spinal cord
- limited shoulder mobility, spontaneous tears of the rotator cuff leading to chronic spasm
- tenosynovitis → may cause rupture of tendons
- carpal tunnel syndrome
- ruptured Baker’s cyst (outpouching of synovium behind the knee); presentation similar to acute DVT
- poor prognostic factors Include: young age of onset, high RF titer, elevated ESR, activity of >20 joints, and presence of extra-articular features

Table 13. Extra-Articular Features of RA Classified by Underlying Pathophysiology

<table>
<thead>
<tr>
<th>System</th>
<th>Vasculitic</th>
<th>Lymphocytic Infiltrate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin</td>
<td>Periungual infarction, cutaneous ulcers, palpable purpura</td>
<td>Rheumatoid nodules (may have vasculitic component)</td>
</tr>
<tr>
<td>Ocular</td>
<td>Episcleritis, scleritis</td>
<td>Keratoconjunctivitis sicca</td>
</tr>
<tr>
<td>Head and Neck</td>
<td>Xerostomia, Hashimoto’s thyroiditis (see Endocrinology, E27)</td>
<td></td>
</tr>
<tr>
<td>Cardiac</td>
<td>Peri-/myocarditis, valvular disease, conduction defects</td>
<td></td>
</tr>
<tr>
<td>Pulmonary</td>
<td>Pulmonary fibrosis, pleural effusion, pleuritis, pulmonary nodules</td>
<td></td>
</tr>
<tr>
<td>Neurologic</td>
<td>Peripheral neuropathy: sensory stocking-glove, mononeuritis multiplex</td>
<td></td>
</tr>
<tr>
<td>Hematologic</td>
<td>Splenomegaly, neutropenia (Felt’s syndrome)</td>
<td></td>
</tr>
<tr>
<td>Renal</td>
<td>Amyloidosis – caused by accumulation of abnormal proteins</td>
<td></td>
</tr>
</tbody>
</table>

Classification of Global Functional Status in RA
- Class I: able to perform usual ADLs (self-care, vocational, avocational)
- Class II: able to perform self-care and vocational activities, restriction of avocational activities
- Class III: able to perform self-care, restriction of vocational and avocational activities
- Class IV: limited ability to perform self-care, vocational, and avocational activities
Investigations

- blood work
  - RF: sensitivity 80% but non-specific; may not be present at onset of symptoms; levels DO NOT correlate with disease activity
  - can be associated with more erosions, more extra-articular manifestations, and worse function
  - anti-CCP: sensitivity 80% but more specific (94-98%); may precede onset of symptoms
  - increased disease activity is associated with decreased Hb (anemia of chronic disease), increased platelets, ESR, CRP, and RF
- imaging
  - x-rays may be normal at onset
  - first change is periarticular osteopenia, followed by erosions
  - U/S (with power doppler), MRI may be used to image hands to detect early synovitis and erosions
  - MRI T1 inflamed synovium is hypointense and hyperintense on T1; bone marrow edema can be seen as well as areas of increased uptake gadolinium contrast

Treatment

- goals of therapy: remission or lowest possible disease activity
  - key is early diagnosis and early intervention with DMARDs
  - “window of opportunity” = early treatment within first 3 mo of disease may allow better control/remission
  - assess poor prognostic factors at baseline (RF positive, functional limitations and extra-articular features)
- behavioural
  - exercise program (isometrics and active, gentle ROM exercise during flares, aquatic/aerobic/strengthening exercise between flares), assistive devices as needed
  - job modification may be necessary
- pharmacologic: alter disease progression
  - only DMARDs and biologics (not analgesics or NSAIDs) can alter the course of RA
  - DMARDs
    - methotrexate (MTX) is the gold standard and is first-line unless contraindicated
      - low dose (5-10 mg/d) for use in RA patients
      - severe RA: add low dose prednisone to DMARDs
    - corticosteroids
      - local: injections to control symptoms in a specific joint
      - systemic (prednisone)
        - low dose (5-10 mg/d) useful for short-term to improve symptoms if NSAIDs ineffective, to bridge gap until DMARDs take effect
        - severe RA: add low dose prednisone to DMARDs
        - do baseline DEXA bone density scan and consider bone supportive pharmacologic therapy if using corticosteroids >3 mo at 7.5mg/d
      -Side Effects of Steroids
        - Cushingoid features
        - Hypertension
        - Diabetes mellitus
        - Osteoporosis
        - Impaired wound healing
        - Endometrial thickening and neoplasms
        - Gallbladder disease
        - Acne
        - Cataracts, glaucoma
        - PUD
        - Susceptibility to infection
        - Easy bruising
        - Acne
        - Hyperlipidemia
        - Hypokalemia, hyperglycemia
        - Mood swings
      - DMARDs, prednisone and biologics alter the course of RA but not analgesics or NSAIDs

Follow-Up Management and Clinical Outcomes

- follow-up every 3-6 mo, then 6-12 mo after inflammation has been suppressed
- examine joints for active inflammation – if active, consider adjusting medications, PT/OT
- if assessment reveals joint damage – consider analgesia, referral to PT/OT, surgical options
- outcome depends on disease activity, joint damage, physical functional status, psychological health, and comorbidities
- functional capacity is a useful tool for determining therapeutic effectiveness: many tools for evaluation have been validated
- patients with RA have an increased prevalence of other serious illnesses: infection (e.g. pulmonary, skin, joint), renal impairment, lymphoproliferative disorders, cardiovascular disease (correlates with disease activity and duration)
- increased risk of premature mortality, decreased life expectancy (most mortality not directly caused by RA)

Surgical Therapy

- indicated for structural joint damage
- surgical options include: synovectomy, joint replacement, joint fusion, reconstruction/tendon repair
Systemic Lupus Erythematosus

- see Nephrology, NP24

Definition
- chronic inflammatory multi-system disease of unknown etiology
- characterized by production of autoantibodies and diverse clinical manifestations

Table 14. Diagnostic Criteria of SLE*

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLINICAL</td>
<td></td>
</tr>
<tr>
<td>Malar rash</td>
<td>Classic “butterfly rash”, sparing of nasolabial folds, no scarring</td>
</tr>
<tr>
<td>Discoid rash</td>
<td>May cause scarring due to invasion of basement membrane</td>
</tr>
<tr>
<td>Photosensitivity</td>
<td>Skin rash in reaction to sunlight</td>
</tr>
<tr>
<td>Oral/nasal ulcers</td>
<td>Usually painless</td>
</tr>
<tr>
<td>Arthritis</td>
<td>Symmetric, involving ≥2 small or large peripheral joints, non-erosive</td>
</tr>
<tr>
<td>Serositis</td>
<td>Pleuritis or pericarditis</td>
</tr>
<tr>
<td>Neurologic disorder</td>
<td>Seizures or psychosis</td>
</tr>
<tr>
<td>LABORATORY</td>
<td></td>
</tr>
<tr>
<td>Renal disorder</td>
<td>Proteinuria (&gt;0.5 g/d or 3+)</td>
</tr>
<tr>
<td>Hematologic disorder</td>
<td>Cellular casts (RBC, Hb, granular, tubular, mixed)</td>
</tr>
<tr>
<td>Immunologic disorder</td>
<td>Hemolytic anemia, leukopenia, lymphopenia, thrombocytopenia</td>
</tr>
<tr>
<td>ANA</td>
<td>Anti-dsDNA or anti-Sm or antiphospholipid Ab (anticardiolipin Ab, SLE anticoagulant) or false positive VDRL with 6 mo confirmatory negative</td>
</tr>
</tbody>
</table>

*Note: “4, 7, 11” rule: 4 (or more) out of 11 criteria (4 lab, 7 clinical) must be present, serially or simultaneously, for diagnosis

Etiology and Pathophysiology
- production of cytotoxic autoantibodies and immune complex formation
- multi-factorial etiology
- genetics
  - common association with HLA-B8/DR3; ~10% have positive family history
  - strong association with defects in apoptotic clearance → fragments of nuclear particles captured by antigen-presenting cells → develop anti-nuclear antibodies
  - cytokines involved in inflammatory process and tissue injury: B-lymphocyte stimulator (BlyS), IL-6, IL-17, IL-18, TNF-α
- environment
  - UV radiation, cigarette smoking, infection, vitamin D deficiency
- estrogen
  - increased incidence after puberty, decreased incidence after menopause
  - men with SLE have higher concentration of estrogenic metabolites
- infection
  - viral (non-specific stimulant of immune response)
- drug-induced
  - anti-hypertensives (hydralazine), anti-convulsants (phenytoin), anti-arrhythmics (procainamide), isoniazid, biologics, oral contraceptive pills
  - anti-histone Ab are commonly seen in drug-induced SLE
- symptoms resolve with discontinuation of offending drug

Epidemiology
- prevalence: 0.05% overall
- F:M = 10:1
- age of onset in reproductive yr (13–40)
- more common and severe in African-Americans and Asians
- bimodal mortality pattern
  - early (within 2 yr)
    - active SLE, active nephritis, infection secondary to steroid use
  - late (>10 yr)
    - inactive SLE, inactive nephritis, atherosclerosis likely due to chronic inflammation

Signs and Symptoms
- characterized by periods of exacerbation and remission

Figure 7. Multi-factorial etiology of SLE
Table 15. Symptoms of SLE

<table>
<thead>
<tr>
<th>System</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic</td>
<td>Fatigue, malaise, weight loss, fever, lymphadenopathy</td>
</tr>
<tr>
<td>Renal</td>
<td>HTN, peripheral edema, glomerulonephritis, renal failure</td>
</tr>
<tr>
<td>Dermatologic</td>
<td>Photosensitivity, malar rash, discoid rash, oral ulcers, alopecia (hair loss), purpura, panniculitis (inflammation of subcutaneous fat and muscle tissue), urticaria</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>Polyarthralgias, polyarthrytis, myalgias, AVN; reducible deformities of hand = Jaccoud’s arthritis</td>
</tr>
<tr>
<td>Ophthalmic</td>
<td>Keratoconjunctivitis sicca, episcleritis, scleritis, coid bodies (cotton wool exudates on funduscopy = infarction of nerve cell layer of retina)</td>
</tr>
<tr>
<td>Vascular</td>
<td>Raynaud’s phenomenon, livedo reticularis (mottled discolouration of skin due to narrowing of blood vessels, characteristic lacy or net-like appearance), thrombosis, vasculitis</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Pleuritis, ILD, pulmonary HTN, PE, alveolar hemorrhage</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Pancreatitis, SLE enteropathy, hepatitis, hepatomegaly, splenomegaly</td>
</tr>
<tr>
<td>Neurologic</td>
<td>H/A, depression, psychosis, seizures, cerebritis, transverse myelitis, peripheral neuropathy, stroke</td>
</tr>
<tr>
<td>Life/Organ-Threatening</td>
<td>Cardiac: coronary vasculitis, malignant HTN, tamponade</td>
</tr>
<tr>
<td></td>
<td>Hematologic: hemolytic anemia, neutropenia, thrombocytopenia, TTP, thrombosis</td>
</tr>
<tr>
<td></td>
<td>Neurologic: seizures, CVA, stroke</td>
</tr>
<tr>
<td></td>
<td>Respiratory: pulmonary hypertension, pulmonary hemorrhage, emboli</td>
</tr>
</tbody>
</table>

Investigations
- ANA (sensitivity 98%, but poor specificity) used as a screening test, ANA titres are not useful to follow disease course
- anti-dsDNA and anti-Sm are specific (95-99%)
- anti-dsDNA titre and serum complement (C3, C4) are useful to monitor treatment response in patients who are clinically and serologically concordant (anti-dsDNA, C3, and C4 also fluctuates with disease activity)
- antiphospholipid Ab (anti-cardiolipin Ab, SLE anticoagulant, Anti-β2 glycoprotein-I Ab), may cause increased risk of clotting and increased aPTT

Treatment
- goals of therapy
  - treat early and avoid long-term steroid use, if unavoidable see Endocrinology, E41 for osteoporosis management
  - if high doses of steroids necessary for long-term control, add steroid-sparing agents and taper when possible
  - treatment is tailored to organ system involved and severity of disease
  - all medications used to treat SLE require periodic monitoring for potential toxicity
- dermatologic
  - sunscreen, avoid UV light and estrogens
  - topical steroids, hydroxychloroquine
- musculoskeletal
  - NSAIDs ± gastroprotective agent for arthritis (also beneficial for pleuritis and periartitis)
  - hydroxychloroquine improves long-term control and prevents flares
  - bisphosphonates, calcium, vitamin D to combat osteoporosis
- organ-threatening disease
  - high-dose oral prednisone or IV methylprednisolone in severe disease
  - steroid-sparing agents: azathioprine, MTX, mycophenolate mofetil
  - IV cyclophosphamide for serious organ involvement (e.g. cerebritis or lupus nephritis)
  - see Nephrology, NP24 for clinical features of lupus nephritis

Antiphospholipid Antibody Syndrome

Definition
- multi-system vasculopathy manifested by recurrent thromboembolic events, spontaneous abortions, and thrombocytopenia
- often presents with migraine-type H/As
- circulating antiphospholipid autoantibodies interfere with coagulation
- primary APLS: occurs in the absence of other disease
- secondary APLS: occurs in the setting of a connective tissue disease (including SLE), malignancy, drugs (hydralazine, procainamide, phenytoin, interferon, quinidine), and infections (HIV, TB, hepatitis C, infectious mononucleosis)
- catastrophic APLS: development within 1 wk of small vessel thrombotic occlusion in ≥ 3 organ systems with positive antiphospholipid Ab (high mortality)
Table 16. Classification Criteria of APLS*

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CLINICAL</strong></td>
<td></td>
</tr>
<tr>
<td>Vascular thrombosis</td>
<td>Arterial: stroke/TIA, multi-infarct dementia, MI, valvular incompetence, limb ischemia. Venous: DVT, PE, renal and retinal vein thrombosis. Must be confirmed by imaging or histopathology.</td>
</tr>
<tr>
<td>Pregnancy morbidity</td>
<td>Fetal death (&gt;10 wk GA), recurrent spontaneous abortions (&lt;10 wk GA) or premature birth (&lt;34 wk GA).</td>
</tr>
<tr>
<td><strong>LABORATORY</strong></td>
<td></td>
</tr>
<tr>
<td>SLE anticoagulant</td>
<td>Prolonged aPTT not corrected by the addition of normal plasma.</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>IgG and/or IgM.</td>
</tr>
<tr>
<td>Anti-β2 glycoprotein-I Ab</td>
<td>IgG and/or IgM.</td>
</tr>
<tr>
<td>ANA</td>
<td>Most sensitive test (98%), not specific.</td>
</tr>
</tbody>
</table>

* 1 clinical and 1 laboratory criteria must be present. J Thromb Haemost 2000;4:295-306

**Manifestations of APLA**
- Thromboembolic events
- Spontaneous abortions
- Thrombocytopenia
- Associated with livedo reticularis, migraine headaches

**Arterial and venous thrombosis are usually mutually exclusive**

**Scleroderma (i.e. Systemic Sclerosis)**

**Definition**
- A non-inflammatory autoimmune disorder characterized by widespread small vessel vasculopathy, production of autoantibodies, and fibroblast dysfunction causing fibrosis.

**Figure 8. Forms of scleroderma**

Table 17. The American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Criteria for Scleroderma*

<table>
<thead>
<tr>
<th>Item</th>
<th>Sub-item</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Skin thickening of fingers of both hands extending proximal to the MCP (sufficient criterion)</td>
<td></td>
<td>9</td>
</tr>
<tr>
<td>2. Skin thickening of the fingers</td>
<td>Puffy fingers</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Sclerodactyly</td>
<td>4</td>
</tr>
<tr>
<td>3. Fingertip lesions</td>
<td>Digital tip ulcers</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Fingertip pitting scars</td>
<td>3</td>
</tr>
<tr>
<td>4. Telangiectasia</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>5. Abnormal nailfold capillaries</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>6. Pulmonary arterial HTN ± ILD (max score 2)</td>
<td>Pulmonary arterial HTN</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>ILD</td>
<td>2</td>
</tr>
<tr>
<td>7. Raynaud’s phenomenon</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>8. Scleroderma related Ab</td>
<td>Anticentromere</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Anti-topoisomerase I</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anti-RNA polymerase III</td>
<td></td>
</tr>
</tbody>
</table>

* Score of ≥9 is sufficient to classify a patient as having definite scleroderma (sensitivity 0.95, specificity 0.93). Arthritis & Rheum 2013;65(11):2717-2747

**CREST Syndrome**
- Calcinosis
- Raynaud’s phenomenon
- Esophageal dysmotility
- Sclerodactyly
- Telangiectasia

**Scleroderma is the most common cause of secondary Raynaud’s phenomenon**
Etiology and Pathophysiology
- idiopathic vasculopathy (not vasculitis) leading to atrophy and fibrosis of tissues
  - intimal proliferation and media mucinous degeneration → progressive obliteration of vessel lumen → fibrotic tissue
  - resembles malignant HTN
  - lung disease is the most common cause of morbidity and mortality

Epidemiology
- F:M = 3-4:1, peaking in 5th and 6th decades
- associated with HLA-DR1
- associated with environmental exposure (silica, epoxy resins, toxic oil, aromatic hydrocarbons, polyvinyl chloride)
- limited systemic sclerosis has a higher survival prognosis (>70% at 10 yr) than diffuse systemic sclerosis (40-60% at 10 yr)

Signs and Symptoms

### Table 18. Clinical Manifestations of Scleroderma

<table>
<thead>
<tr>
<th>System</th>
<th>Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dermatologic</td>
<td>Painless non-pitting edema → skin tightening</td>
</tr>
<tr>
<td></td>
<td>Ulcerations, calcification, periungual erythema, hypopigmentation, pruritus, telangiectasias</td>
</tr>
<tr>
<td></td>
<td>Characteristic face: mask-like facies with tight lips, beak nose, radial perion digital furrows</td>
</tr>
<tr>
<td>Vascular</td>
<td>Raynaud’s phenomenon → digital pits, gangrene</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Distal esophageal hypomotility → dysphagia</td>
</tr>
<tr>
<td></td>
<td>Loss of lower esophageal sphincter function → GERD, ulcerations, strictures</td>
</tr>
<tr>
<td></td>
<td>Small bowel hypomotility → bacterial overgrowth, diarrhea, cramping, malabsorption, weight loss</td>
</tr>
<tr>
<td>Renal</td>
<td>Mild proteinuria, Cr elevation, HTN</td>
</tr>
<tr>
<td></td>
<td>“Scleroderma renal crisis” (10-15%) may lead to malignant arterial HTN, oliguria, and microangiopathic hemolytic anemia</td>
</tr>
<tr>
<td>Pulmonary</td>
<td>Interstitial fibrosis, pulmonary HTN, pleurisy, pleural effusions</td>
</tr>
<tr>
<td>Cardiac</td>
<td>Left ventricular dysfunction, pericarditis, pericardial effusion, arrhythmias</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>Polyarthralgies</td>
</tr>
<tr>
<td></td>
<td>“Resorption of distal tufts” (radiological finding)</td>
</tr>
<tr>
<td></td>
<td>Proximal weakness 2º to disuse, atrophy, low grade myopathy</td>
</tr>
<tr>
<td>Endocrine</td>
<td>Hypothyroidism</td>
</tr>
</tbody>
</table>

Investigations
- blood work
  - CBC, Cr, ANA
  - anti-topoisomerase 1/anti-Scl-70: specific but not sensitive for diffuse systemic sclerosis
  - anti-centromere: favours diagnosis of CREST (limited systemic sclerosis)
- PFT
  - assess for interstitial lung disease
  - imaging
    - CXR for fibrosis, echo for pulmonary HTN

Treatment
- dermatologic
  - good skin hygiene
  - low-dose prednisone (>20 mg may provoke renal crisis if susceptible), MTX (limited evidence)
- vascular
  - patient education on cold avoidance
  - vasodilators (CCBs, local nitroglycerine cream, systemic PGE: inhibitors, PDE5 inhibitors)
- gastrointestinal
  - GERD: PPIs are first line, then H2-receptor agonists
  - small bowel bacterial overgrowth: broad spectrum antibiotics (tetracycline, metronidazole)
- renal disease
  - ACEI for hypertensive crisis
  - see Nephrology, NP32 for scleroderma renal crisis
- pulmonary
  - early interstitial disease: cyclophosphamide
  - pulmonary HTN: vasodilators e.g. bosentan, epoprostenol, PDE5 inhibitors
- cardiac
  - pericarditis: systemic steroids
- musculoskeletal
  - arthritis: NSAIDs
  - myositis: systemic steroids
Idiopathic Inflammatory Myopathy

Definition
- autoimmune diseases characterized by proximal muscle weakness ± pain
- muscle becomes damaged by a non-suppurative lymphocytic inflammatory process

Classification
- PM/DMM
- adult and juvenile form
- associated with malignancy
  - increased risk of malignancy: age >50, DMM>PM, normal CK, refractory disease
  - associated with other connective tissue disease, Raynaud's phenomenon, autoimmune disorders

Inclusion Body Myositis
- age >50, M>F, slowly progressive, vacuoles in cells on biopsy
- suspect when patient unresponsive to treatment
- distal as well as proximal muscle weakness
- muscle biopsy positive for inclusion bodies

POLYMYOSITIS/DERMATOMYOSITIS

Table 19. Classification Criteria for PM/DMM*

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Symmetric proximal muscle weakness</td>
<td>Typical involvement of shoulder girdle and hip girdle</td>
</tr>
<tr>
<td>2. Elevated muscle enzymes</td>
<td>↑ CK, aldolase, LDH, AST, ALT</td>
</tr>
<tr>
<td>3. EMG changes</td>
<td>Short polyphasic motor units, high frequency repetitive discharge, insertional irritability</td>
</tr>
<tr>
<td>4. Muscle biopsy</td>
<td>Segmental fibre necrosis, basophilic regeneration, perivascular inflammation (DMM), endomysial inflammation (PM) and atrophy</td>
</tr>
<tr>
<td>5. Typical rash of dermatomyositis</td>
<td>Required for diagnosis of DMM (see below)</td>
</tr>
</tbody>
</table>

*Definite if 4 present, probable if 3 present  NEJM 1975;292:403-407

Etiology and Pathophysiology
- PM is CD8 cell-mediated muscle necrosis, found in adults
- DMM is B-cell and CD4 immune complex-mediated peri-fascicular vascular abnormalities

Signs and Symptoms
- progressive symmetrical proximal muscle weakness (shoulder and hip) developing over weeks to months
  - difficulty lifting head off pillow, arising from chair, climbing stairs
- dermatological
  - DMM has characteristic dermatological features (F>M, children and adults)
    - Gottron's papules
      - pink-violaceous, flat-topped papules overlying the dorsal surface of the interphalangeal joints
    - Gottron's sign
      - erythematous, smooth or scaly patches over the dorsal IPs, MCPs, elbows, knees, or medial malleoli
    - heliotrope rash: violaceous rash over the eyelids; usually with edema
    - shawl sign: poikilodermatous erythematous rash over neck, upper chest, and shoulders
    - mechanic's hands: dark, dry, thick scale on palmar and lateral surface of digits
    - periungual erythema
  - cardiac
    - arrhythmias, CHF, conduction defect, ventricular hypertrophy, pericarditis
  - gastrointestinal
    - oropharyngeal and lower esophageal dysphagia, reflux
  - pulmonary
    - weakness of respiratory muscles, ILD, aspiration pneumonia

Investigations
- blood work: CK, ANA, anti-Jo-1 (DMM), anti-Mi-2, anti-SRP
- imaging: MRI may be used to localize biopsy site
- EMG, muscle biopsy
Treatment
- non-pharmacological treatment
  - physical therapy and occupational therapy
- pharmacological treatment
  - high-dose corticosteroid (1-2 mg/kg/d) and slow taper
  - add immunosuppressive agents (azathioprine, MTX, cyclosporine)
  - IVlg if severe or refractory
  - hydroxychloroquine for DMM rash
- malignancy surveillance
  - detailed history and physical (breast, pelvic, and rectal exam)
  - CXR, abdominal and pelvic U/S, fecal occult blood, Pap test, mammogram ± CT scan (thoracic, abdominal, pelvic)

Sjögren’s Syndrome

Definition
- autoimmune condition characterized by dry eyes (keratoconjunctivitis sicca/xerophthalmia) and dry mouth (xerostomia), caused by lymphocytic infiltration of salivary and lacrimal glands
- may evolve into systemic disorder with diminished exocrine gland activity in respiratory tract and skin
- primary and secondary form (associated with RA, SLE, DMM, and HIV)
- prevalence, F >> M, 40-60 yo
- increased risk of non-Hodgkin’s lymphoma

Table 20. American College of Rheumatology Classification for Sjögren’s*

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Positive serum anti-SSA/Ro and/or anti-SSB/La or positive RF and</td>
<td>Focus scores are histopathologic grading systems</td>
</tr>
<tr>
<td>ANA titer&gt;1:320</td>
<td>Strongly associated with phenotypic ocular and serological</td>
</tr>
<tr>
<td>2. Labial salivary gland biopsy with focal lymphocytic sialadenitis</td>
<td>component’s of Sjögren’s</td>
</tr>
<tr>
<td>with focus score ≥1 focus /4mm²</td>
<td>Ocular staining score based on fluorescein dye examination of conjunctiva</td>
</tr>
<tr>
<td>3. Keratoconjunctivitis sicca with ocular staining score &gt;3</td>
<td>and comea to determine clinical changes</td>
</tr>
</tbody>
</table>

*Classification criteria is met in patients with signs/symptoms of Sjögren’s, who have at least 2 of the above features

Signs and Symptoms
- “sicca complex”: dry eyes (keratoconjunctivitis sicca/xerophthalmia), dry mouth (xerostomia)
- staphylococcal blepharitis
- dental caries, oral candidiasis, angular cheilitis (inflammation and fissuring at the labial commissures of the mouth)
- systemic complications
  - sinusitis
  - autoimmune thyroid dysfunction
  - arthralgias, arthritis
  - subclinical diffuse ILD, xerotrachea leading to chronic dry cough
  - renal disease, glomerulonephritis
  - palpable purpura, vasculitis
  - peripheral neuropathy
  - lymphoma risk greatly increased

Treatment
- ocular
  - artificial tears or surgical punctal occlusion for dry eyes
- oral
  - good dental hygiene, hydration
  - parasympathomimetic agents that stimulate salivary flow (e.g. pilocarpine)
  - topical nystatin or clotrimazole x 4-6 wk for oral candidiasis
  - systemic, e.g. hydroxychloroquine, corticosteroids

Mixed Connective Tissue Disease
- syndrome with features of 3 different connective tissue diseases (e.g. SLE, scleroderma, PM)
- common symptoms: Raynaud’s phenomenon, swollen fingers
- blood work: anti-RNP (see Table 10)
- treatment is generally guided by the severity of symptoms and organ system involvement
- prognosis
- 50-60% will evolve into SLE
- 40% will evolve into scleroderma
- only 10% will remain as MCTD for the rest of their lives
- cardiac involvement (arrhythmia) common, renal or lung involvement rare
**Overlap Syndrome**

- syndrome with sufficient diagnostic features of 2+ different connective tissue diseases

**Vasculitides**

- inflammation and subsequent necrosis of blood vessels leading to tissue ischemia or infarction of any organ system
- diagnosis
  - clinical suspicion: suspect in cases of unexplained multiple organ ischemia or systemic illness with no evidence of malignancy or infection; constitutional symptoms such as fever, weight loss, anorexia, fatigue
  - labs non-specific: anemia, increased WBC and ESR, abnormal U/A
  - investigations: biopsy if tissue accessible; angiography if tissue inaccessible
- treatment generally involves corticosteroids and/or immunosuppressive agents

### Table 21. Classification of Vasculitides and Characteristic Features

<table>
<thead>
<tr>
<th>Classification</th>
<th>Characteristic Features</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SMALL VESSEL</strong></td>
<td></td>
</tr>
<tr>
<td>Non-ANCA-associated</td>
<td>Immune complex-mediated (most common mechanism)</td>
</tr>
<tr>
<td>Predominantly cutaneous vasculitis</td>
<td>Also known as hypersensitivity/leukocytoclastic vasculitis</td>
</tr>
<tr>
<td>IgA vasculitis (formerly Henoch-Schönlein purpura (HSP)) (see Pediatrics, P91)</td>
<td>Vascular deposition of IgA causing systemic vasculitis (skin, GI, renal), usually self-limiting, most common in childhood</td>
</tr>
<tr>
<td>Cryoglobulinemic vasculitis (CV)</td>
<td>Systemic vasculitis caused by circulating cryoproteins forming immune complexes; 50-80% of cases are due to Hepatitis C, 5-10% are due to a CTD (SLE, RA, SS), 5-10% are due to a lymphoproliferative disorder and the remaining 5-10% are idiopathic or “essential”. CV may be associated with underlying infection (e.g. hepatitis C) or connective tissue disease</td>
</tr>
<tr>
<td>ANCA-associated (i.e. PR3-ANCA)</td>
<td>Granulomatous inflammation of vessels of respiratory tract and kidneys, initially have URTI symptoms; most common in middle age</td>
</tr>
<tr>
<td>Granulomatosis with polyangiitis (GPA, formerly Wegener’s) pR3 (c-ANCA) &gt; MPO (p-ANCA)</td>
<td>Granulomatous inflammation of vessels with hypereosinophilia and eosinophilic tissue infiltration, frequent lung involvement (asthma, allergic rhinitis), associated with MPO-ANCA in 40-50% of cases. Other manifestations include peripheral neuropathy (70%), GI involvement, myocarditis and rarely coronary arteritis; average age 40s</td>
</tr>
<tr>
<td>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) (50% ANCA positive)</td>
<td>Pauci-immune necrotizing vasculitis, affecting kidneys (necrotizing glomerulonephritis), lungs (capillaritis and alveolar hemorrhage), skin; most common in middle age</td>
</tr>
<tr>
<td>Microangiopathic polyangiitis (70% ANCA positive, usually MPO)</td>
<td>Pauci-immune necrotizing vasculitis, affecting kidneys (necrotizing glomerulonephritis), lungs (capillaritis and alveolar hemorrhage), skin; most common in middle age</td>
</tr>
<tr>
<td><strong>MEDIUM VESSEL</strong></td>
<td></td>
</tr>
<tr>
<td>Polyarteritis nodosa</td>
<td>Segmental, non-granulomatous necrotizing inflammation</td>
</tr>
<tr>
<td>Kawasaki disease (see Pediatrics, P92)</td>
<td>Unknown etiology in most cases, any age (average 40-50s), M&gt;F</td>
</tr>
<tr>
<td><strong>LARGE VESSEL</strong></td>
<td></td>
</tr>
<tr>
<td>GCA/Temporal arteritis</td>
<td>Inflammation predominantly of the aorta and its branches</td>
</tr>
<tr>
<td>Takayasu’s arteritis</td>
<td>“Pulseless disease”, unequal peripheral pulses, chronic inflammation, most often the aorta and its branches Usually young adults of Asian descent, F&gt;M, risk of aortic aneurysm</td>
</tr>
<tr>
<td><strong>OTHER VASCULITIDES</strong></td>
<td></td>
</tr>
<tr>
<td>Buerger’s disease (“Thromboangiitis Obliterans”)</td>
<td>Inflammation and clotting of small and medium-sized arteries and veins of distal extremities, may lead to distal claudication and gangrene, most important etiologic factor is cigarette smoking. Most common in young Asian males</td>
</tr>
<tr>
<td>Behçet’s disease</td>
<td>Multi-system disorder presenting with ocular involvement (uveitis), recurrent oral and genital ulceration, venous thrombosis, skin and joint involvement, more common in Mediterranean and Asia, average age 30 yr old, M&gt;F</td>
</tr>
<tr>
<td>Vasculitis mimicry (i.e. pseudovasculitis)</td>
<td>Cholesterol emboli, atrial myxoma, bacterial endocarditis (SBE), APLS</td>
</tr>
</tbody>
</table>

**Features of Small Vessel Vasculitis**

- Palpable purpura
- Vesicles
- Chronic urticaria
- Superficial ulcers (erosions)

**Features of Medium Vessel Vasculitis**

- Livedo reticularis
- Erythema nodosum
- Raynaud’s phenomenon
- Nodules
- Digital infarcts
- Ulcers

**Churg-Strauss Triad**

- Allergic rhinitis and asthma (often quiescent at time of vasculitis)
- Eosinophilic infiltrative disease resembling pneumonia
- Systemic vasculitis often monoclonal multiplex/peripheral neuropathy and peripheral eosinophilia
Vasculitides

Small Vessel Non-ANCA Associated Vasculitis

CUTANEOUS VASCULITIS
- subdivided into
  - drug-induced vasculitis
  - serum sickness reaction
  - vasculitis associated with other underlying primary diseases (CTD, infections, malignancies-hematologic> solid tumours)

Etiology and Pathophysiology
- cutaneous vasculitis following
  - drug exposure (allopurinol, gold, sulfonamides, penicillin, phenytoin)
  - viral or bacterial infection
  - idiopathic causes
- small vessels involved (post-capillary venules most frequently)
- usually causes a leukocytoclastic vasculitis: debris from neutrophils
- sometimes due to cryoglobulins which precipitate in cold temperatures

Signs and Symptoms
- palpable purpura ± vesicles and ulceration, urticaria, macules, papules, bullae, subcutaneous nodules
- renal or joint involvement may occur, especially in children

Investigations
- vascular involvement (both arteriole and venule) established by skin biopsy

Treatment
- stop possible offending drug
- NSAID, low dose corticosteroids
- immunosuppressive agents in resistant cases
- usually self-limiting

Small Vessel ANCA-Associated Vasculitis

GRANULOMATOSIS WITH POLYANGIITIS
(GPA, formerly known as Wegener’s Granulomatosis)

Definition
- granulomatous inflammation of vessels that may affect the upper airways (rhinitis, sinusitis), lungs (pulmonary nodules, infiltrates), and kidneys (glomerulonephritis, renal failure)
- highly associated with c-ANCA by indirect immunofluorescence (IIF) and pR3-ANCA by ELISA; however, changes in ANCA levels do not predict remission or relapse
- incidence 2-3 per 100,000; more common in Northern latitudes

Table 22. Classification Criteria for GPA*

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Nasal or oral involvement</td>
<td>Inflammation, ulcers, epistaxis</td>
</tr>
<tr>
<td>2. Abnormal findings on CXR</td>
<td>Nodules, cavitations, etc.</td>
</tr>
<tr>
<td>3. Urinary sediment</td>
<td>Microscopic hematuria ± RBC casts</td>
</tr>
<tr>
<td>4. Biopsy of involved tissue</td>
<td>Lungs show granulomas, kidneys show necrotizing segmental glomerulonephritis</td>
</tr>
</tbody>
</table>

*Diagnosed if 2 or more of the above 4 criteria present

American College of Rheumatology, 1990

Classic Features of GPA
- Necrotizing granulomatous vasculitis of lower and upper respiratory tract
- Focal segmental glomerulonephritis
Etiology
- pathogenesis depends on genetic susceptibility and environmental triggers (e.g. infection)
  - dysregulated immune response due to loss of B and T-cell tolerance
  - acute vascular injury mediated by neutrophils and monocytes

Signs and Symptoms
- systemic
  - malaise, fever, weakness, weight loss
- HEENT
  - sinusitis or rhinitis, nasal crusting and bloody nasal discharge, nasoseptal perforation, saddle nose deformity
  - proptosis due to: inflammation/vasculitis involving extra-ocular muscles, granulomatous retrobulbar space occupying lesions or direct extension of masses from the upper respiratory tract
  - hearing loss due to involvement of CN VIII
- pulmonary
  - cough, hemoptyis, granulomatous upper respiratory tract masses
- renal
  - hematuria, proteinuria, elevated creatinine
- other
  - joint, skin, eye complaints, vasculitic neuropathy

Investigations
- blood work: anemia (normal MCV), increased WBC, increased Cr, increased ESR, elevated platelet count, ANCA (PR3 > MPO)
- urinalysis: proteinuria, hematuria, RBC casts
- CXR: pneumonitis, lung nodules, infiltrations, cavitary lesions
- biopsy: renal (segmental necrotizing glomerulonephritis), lung (granulomas, tracheobronchial erosion)
- c-ANCA and ESR often correlate with disease activity and used to monitor response to treatment in some patients

Treatment
- for severe, life or organ threatening disease disease
  - pulse methylprednisolone x 3 days followed by prednisone 1 mg/kg/d PO + cyclophosphamide 2 mg/kg/d PO for 36 mo OR rituximab 375 mg/m² followed by high dose MTX (20-25 mg PO/SC weekly) or azathioprine (2 mg/kg/d PO OD)
  - consider plasmapheresis in patients with rapidly deteriorating renal failure or pulmonary hemorrhage

Medium Vessel Vasculitis

POLYARTERITIS NODOSA

Definition
- systemic, necrotizing vasculitis of medium sized vessels
- ANCA negative
- 5-10% associated with hepatitis B positivity
- incidence 0.7 per 100,000; affects individuals between 40-60 yr; M:F = 2:1

Table 23. Classification Criteria for PAN*

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Weight loss</td>
<td>&gt;4 kg, not due to dieting or other factors</td>
</tr>
<tr>
<td>2. Myalgias, weakness, or leg tenderness</td>
<td>Diffuse myalgias or weakness</td>
</tr>
<tr>
<td>3. Livedo reticularis</td>
<td>Mottled, reticular pattern over skin</td>
</tr>
<tr>
<td>4. Neuropathy</td>
<td>Mononeuropathy, mononeuropathy multiplex, or polyneuropathy</td>
</tr>
<tr>
<td>5. Testicular pain or tenderness</td>
<td>Not due to infection, trauma, or other causes</td>
</tr>
<tr>
<td>6. dBP &gt;90 mmHg</td>
<td>Development of HTN with dBP &gt;90 mmHg</td>
</tr>
<tr>
<td>7. Elevated Cr or BUN</td>
<td>Cr &gt;130 µmol/L (1.5 mg/dL), BUN &gt;14.3 mmol/L (40 mg/dL)</td>
</tr>
<tr>
<td>8. Hepatitis B positive</td>
<td>Presence of hepatitis B surface antigen or Ab</td>
</tr>
<tr>
<td>9. Arteriographic abnormality</td>
<td>Commonly aneuysms</td>
</tr>
<tr>
<td>10. Biopsy of artery</td>
<td>Presence of granulocytes and/or mononuclear leukocytes in the artery wall</td>
</tr>
</tbody>
</table>

*Diagnosed if 3 or more of the above 10 criteria present American College of Rheumatology, 1990

Etiology and Pathophysiology
- focal panmural necrotizing inflammatory lesions in small and medium-sized arteries
- thrombosis, aneurysm, or dilatation at lesion site may occur
- healed lesions show proliferation of fibrous tissue and endothelial cells that may lead to luminal occlusion
Investigations
- blood work: CBC, ESR, Cr, BUN, p-ANCA, hepatitis B serology
- imaging: angiography
- arterial biopsy

Treatment
- prednisone 1 mg/kg/d PO and cyclophosphamide 2 mg/kg/d PO
- ± anti-viral therapy to enhance clearance of hepatitis B virus

Large Vessel Vasculitis

GCA/TEMPORAL ARTERITIS

Table 24. Classification Criteria for GCA*

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Age at onset ≥50</td>
<td>Many cases event ≥70 yrs</td>
</tr>
<tr>
<td>2. New H/A</td>
<td>Often temporal</td>
</tr>
<tr>
<td>3. Temporal artery abnormality</td>
<td>Temporal artery tenderness or decreased pulsations, not due to arteriosclerosis</td>
</tr>
<tr>
<td>4. Elevated ESR</td>
<td>ESR ≥50 mm/h</td>
</tr>
<tr>
<td>5. Abnormal artery biopsy</td>
<td>Mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cells</td>
</tr>
</tbody>
</table>

*Diagnosed if 3 or more of the above 5 criteria present
American College of Rheumatology, 1990

Epidemiology
- most frequent vasculitis in North America
- patients >50 yr
- F:M = 2:1
- North-South gradient (predominance in Northern Europe/US)
- affects extracranial arteries

Signs and Symptoms
- new onset temporal H/A ± scalp tenderness due to inflammation of involved portion of the temporal or occipital arteries
- sudden, painless loss of vision and/or diplopia due to narrowing of the ophthalmic or posterior ciliary arteries (PCA more common); can affect both eyes
- tongue and jaw claudication (pain in muscles of mastication on prolonged chewing)
- PMR (proximal myalgia, constitutional symptoms, elevated ESR) occurs in 30% of patients
- aortic arch syndrome (involvement of subclavian and brachial branches of aorta resulting in pulseless disease), aortic aneurysm ± rupture are late complications
- constitutional symptoms and shoulder/pelvic girdle pain and stiffness

Investigations
- diagnosis made by clinical suspicion, increased ESR, increased CRP, temporal artery biopsy, possible U/S or MRI

Treatment
- if suspect GCA, immediately start high dose prednisone 1 mg/kg in divided doses for approximately 4 wk, and then tapering prednisone as symptoms resolve; highly effective in treatment and in prevention of blindness and other vascular complications
- consider low dose ASA to help decrease visual loss

Prognosis
- increased risk of thoracic aortic aneurysm and aortic dissection
- yearly CXR ± abdominal U/S as screening

Medical Emergency
Untreated, GCA can lead to permanent blindness in 20-25% of patients
Treat on clinical suspicion
Seronegative Rheumatic Disease

Table 25. A Comparison of the Spondyloarthopathies*

<table>
<thead>
<tr>
<th>Feature</th>
<th>Ankylosing Spondylitis (AS)</th>
<th>Psoriatic Arthritis (PsA)</th>
<th>Reactive Arthritis (ReA)</th>
<th>Enteropathic Arthritis (EA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>M:F</td>
<td>3:1</td>
<td>1:1</td>
<td>8:1</td>
<td>1:1</td>
</tr>
<tr>
<td>Age of Onset</td>
<td>20s</td>
<td>35-45</td>
<td>20s</td>
<td>Any</td>
</tr>
<tr>
<td>Peripheral Arthritis</td>
<td>25%</td>
<td>96%</td>
<td>90%</td>
<td>Common</td>
</tr>
<tr>
<td>Distribution</td>
<td>Axial, LE</td>
<td>Any</td>
<td>LE</td>
<td>LE</td>
</tr>
<tr>
<td>Sacroiliitis</td>
<td>100%</td>
<td>40%</td>
<td>80%</td>
<td>20%</td>
</tr>
<tr>
<td>Dactylitis</td>
<td>Uncommon</td>
<td>Common</td>
<td>Occasional</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Enthesitis</td>
<td>Common</td>
<td>Common</td>
<td>Common</td>
<td>Less Common</td>
</tr>
<tr>
<td>Skin Lesions</td>
<td>Rare</td>
<td>100%</td>
<td>Psoriasis eventually 70% at onset of arthritis</td>
<td>Occasional Keratoderma blennorrhagica</td>
</tr>
<tr>
<td>Uveitis</td>
<td>Common</td>
<td>Occasional</td>
<td>20%</td>
<td>Rare</td>
</tr>
<tr>
<td>Urethritis</td>
<td>Rare</td>
<td>Uncommon</td>
<td>Common</td>
<td>Rare</td>
</tr>
<tr>
<td>HLA-B27</td>
<td>90-95%</td>
<td>40%</td>
<td>80%</td>
<td>30%</td>
</tr>
</tbody>
</table>

*For patients with ≥3 mo back pain and age at onset <45 yr

Table 27. Types of Back Pain

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mechanical</th>
<th>Inflammatory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Past History</td>
<td>±</td>
<td>+</td>
</tr>
<tr>
<td>Family History</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>Onset</td>
<td>Acute</td>
<td>Insidious</td>
</tr>
<tr>
<td>Age</td>
<td>15-90 yr</td>
<td>&lt;45 yr</td>
</tr>
<tr>
<td>Sleep Disturbance</td>
<td>±</td>
<td>+</td>
</tr>
<tr>
<td>Morning Stiffness</td>
<td>&lt;30 min</td>
<td>&gt;1 h</td>
</tr>
<tr>
<td>Involvement of Other Systems</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>Exercise</td>
<td>Worse</td>
<td>Better</td>
</tr>
<tr>
<td>Rest</td>
<td>Better</td>
<td>Worse</td>
</tr>
<tr>
<td>Radiation of Pain</td>
<td>Anatomic (L5-S1)</td>
<td>Diffuse (thoracic, buttock)</td>
</tr>
<tr>
<td>Sensory Symptoms</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>Motor Symptoms</td>
<td>+</td>
<td>–</td>
</tr>
</tbody>
</table>

Ankylosing Spondylitis

Definition
- chronic inflammatory arthritis involving the sacroiliac joints and vertebrae
- enthesitis is a major feature
- prototypical spondyloarthropathy

Table 26. ASAS Classification Criteria for Axial Spondyloarthritis*

<table>
<thead>
<tr>
<th>AS Features</th>
<th>Sacroiliitis on Imaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLA-B27 positive</td>
<td>Active (acute) inflammation on MRI highly suggestive of sacroiliitis associated with AS</td>
</tr>
<tr>
<td>Inflammatory back pain</td>
<td>Definite radiographic sacroilitis ≥ grade 2 bilaterally or grade 3-4 unilaterally</td>
</tr>
<tr>
<td>Arthritis</td>
<td></td>
</tr>
<tr>
<td>Enthesitis (heel)</td>
<td></td>
</tr>
<tr>
<td>Uveitis</td>
<td></td>
</tr>
<tr>
<td>Dactylitis</td>
<td></td>
</tr>
<tr>
<td>Psoriasis</td>
<td></td>
</tr>
<tr>
<td>Crohn’s disease/colitis</td>
<td></td>
</tr>
<tr>
<td>Good response to NSAIDs</td>
<td></td>
</tr>
<tr>
<td>Family history of AS</td>
<td></td>
</tr>
<tr>
<td>Elevated CRP</td>
<td></td>
</tr>
</tbody>
</table>

*For patients with ≥3 mo back pain and age at onset <45 yr

Etiology and Pathophysiology
- inflammation → osteopenia → erosion → ossification → osteoproliferation (syndesmophytes)

Epidemiology
- M:F = 3:1; females have milder disease which may be under-recognized and more peripheral arthritis and upper spine spondylitis
- 90-95% of patients have HLA-B27 (9% HLA-B27 positive in general population)

Table 27. Types of Back Pain

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mechanical</th>
<th>Inflammatory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Past History</td>
<td>±</td>
<td>+</td>
</tr>
<tr>
<td>Family History</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>Onset</td>
<td>Acute</td>
<td>Insidious</td>
</tr>
<tr>
<td>Age</td>
<td>15-90 yr</td>
<td>&lt;45 yr</td>
</tr>
<tr>
<td>Sleep Disturbance</td>
<td>±</td>
<td>+</td>
</tr>
<tr>
<td>Morning Stiffness</td>
<td>&lt;30 min</td>
<td>&gt;1 h</td>
</tr>
<tr>
<td>Involvement of Other Systems</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>Exercise</td>
<td>Worse</td>
<td>Better</td>
</tr>
<tr>
<td>Rest</td>
<td>Better</td>
<td>Worse</td>
</tr>
<tr>
<td>Radiation of Pain</td>
<td>Anatomic (L5-S1)</td>
<td>Diffuse (thoracic, buttock)</td>
</tr>
<tr>
<td>Sensory Symptoms</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>Motor Symptoms</td>
<td>+</td>
<td>–</td>
</tr>
</tbody>
</table>
Seronegative Rheumatic Disease

Signs and Symptoms

- axial
  - mid and lower back stiffness, morning stiffness >1 h, night pain, persistent buttock pain, painful sacroiliac joint (+ FABER test)
  - spinal restriction (decreased ROM): lumbar (decreased Schöber), thoracic (decreased chest wall expansion, normal >5 cm at T4), cervical (global decrease, often extension first)
  - postural changes: decreased lumbar lordosis + increased thoracic kyphosis + increased cervical flexion = increased occiput to wall distance (>5 cm)

- peripheral
  - asymmetrical large joint arthritis, most often involving lower limb
  - enthesitis: tenderness over tibial tuberosity, or Achilles tendon and plantar fascia insertions into the calcaneus

- extra-articular manifestations
  - ophthalmic: acute anterior uveitis is common (25-30% patients)
  - renal: amyloidosis (late and rare), IgA nephropathy
  - gastrointestinal: IBD
  - cardiac: aortitis, aortic regurgitation, pericarditis, conduction disturbances, heart failure (rare)
  - respiratory: apical fibrosis (rare)
  - neurologic: cauda equina syndrome (rare)
  - skin: psoriasis

Investigations

- x-ray of SI joint: “pseudowidening” of joint due to erosion with joint sclerosis → bony fusion (late), symmetric sacroiliitis
- x-ray of spine: “squaring of edges” from erosion and sclerosis on corners of vertebral bodies (shiny corner sign) leading to ossification of outer fibres of annulus fibrosis (bridging syndesmophytes) → “bamboo spine” radiographically
- MRI of spine: assess activity in early disease; detection of cartilage changes, bone marrow edema, bone erosions, and subchondral bone changes. Best seen on T2 STIR (short tau inversion recovery) images (suppress fat and see bone edema)

Treatment

- non-pharmacological therapy
  - prevent fusion from poor posture and disability through: exercise (e.g. swimming), postural and deep breathing exercises, outpatient PT, smoking cessation
- pharmacological therapy
  - NSAIDs (first line of treatment)
  - glucocorticoids (topical eye drops, local injections)
  - DMARDs only for peripheral arthritis (sulfasalazine, MTX)
  - anti-TNF agents for axial and peripheral involvement
  - manage extra-articular manifestations
- surgical therapy
  - hip replacement, vertebral osteotomy for marked deformity

Prognosis

- spontaneous remissions and relapses are common and can occur at any age
- function may be excellent despite spinal deformity
- favourable prognosis if female and age of onset >40 yr
- early onset with hip disease may lead to severe disability; may require arthroplasty

Enteropathic Arthritis

- see Gastroenterology, Inflammatory Bowel Disease, G19
- MSK manifestations in the setting of either ulcerative colitis or Crohn's disease include peripheral arthritis (large joint, asymmetrical), spondylitis, and hypertrophic osteoarthritis
- non-arthritic MSK manifestations can occur 2+ to steroid treatment of bowel inflammation (arthralgia, myalgia, osteoporosis, AVN)
- NSAIDs should be used cautiously as they may exacerbate bowel disease

Table 28. Comparing Features of Spondylitis vs. Peripheral Arthritis in EA

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Spondylitis</th>
<th>Peripheral Arthritis</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLA-B27 Association</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Gender</td>
<td>M&gt;F</td>
<td>M=F</td>
</tr>
<tr>
<td>Onset Before IBD</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Parallels IBD Course</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Type of IBD</td>
<td>UC=CD</td>
<td>CD</td>
</tr>
</tbody>
</table>
Psoriatic Arthritis

Definition
• arthritic inflammation associated with psoriasis

Etiology and Pathophysiology
• unclear but many genetic, immunologic, and some environmental factors involved (e.g. bacterial, viral, and trauma)

Epidemiology
• psoriasis affects 1% of population
• arthropathy in 15% of patients with psoriasis
• 15-20% of patients will develop joint disease before skin lesions appear

Signs and Symptoms
• dermatologic
  ■ well-demarcated erythematous plaques with silvery scale
  ■ nail involvement: pitting, transverse or longitudinal ridging, discoloration, subungual hyperkeratosis, onycholysis, and oil drops
• musculoskeletal
  ■ 5 general patterns
    • asymmetric oligoarthritis (most common – 70%)
    • arthritis of DIP joints with nail changes
    • destructive in small joints
    • symmetric polyarthrits (similar to RA)
    • sacroiliitis and spondylitis (usually older, male patients)
  ■ other findings: dactylitis, enthesopathy
• ophthalmic
  ■ conjunctivitis, iritis (anterior uveitis)
• cardiac and respiratory (late findings)
  ■ aortic insufficiency
  ■ apical lung fibrosis
  ■ neurologic
  ■ cauda equina syndrome
• radiologic
  ■ floating syndesmophytes
  ■ pencil-in-cup appearance at IP joints
  ■ osteolysis, periositis

Treatment
• treat skin lesions (e.g. steroid cream, salicylic and/or retinoic acid, tar, UV light)
• NSAIDs or IA steroids
• DMARDs, biologic therapies to minimize erosive disease (use early if peripheral joint involvement)

Table 29. CASPAR Criteria for PsA*

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Evidence of psoriasis</td>
<td>Current, past, or family history</td>
</tr>
<tr>
<td>2. Psoriatic nail dystrophy</td>
<td>Onycholysis, pitting, hyperkeratosis</td>
</tr>
<tr>
<td>3. Negative results for RF</td>
<td></td>
</tr>
<tr>
<td>4. Dactylitis</td>
<td>Current or past history</td>
</tr>
<tr>
<td>5. Radiological evidence</td>
<td>Juxta articular bone formation on hand or foot x-rays</td>
</tr>
</tbody>
</table>

* To meet the CASPAR (Classification criteria for Psoriatic Arthritis) criteria, a patient must have inflammatory articular disease (joint, spine, or entheseal) with >3 points from the above 5 categories

Reactive Arthritis

Definition
• one of the seronegative spondyloarthropathies in which patients have a peripheral arthritis (>1 mo duration) accompanied by one or more extra-articular manifestations that appears shortly after certain infections of the GI or GU tracts
• this term should not be confused with rheumatic fever or viral arthritides.

Etiology
• onset following an infectious episode either involving the GI or GU tract
  ■ GI: Shigella, Salmonella, Campylobacter, Yersinia, C. Difficile species
  ■ GU: Chlamydia (isolated in 16-44% of ReA cases), Mycoplasma species
• acute clinical course
  ■ 1-4 wk post-infection
  ■ lasts weeks to years
  ■ often recurring
  ■ spinal involvement persists

**Epidemiology**
• in HLA-B27 patients, axial > peripheral involvement
• M>F

**Signs and Symptoms**
• musculoskeletal
  ■ peripheral arthritis, asymmetric pattern, spondylitis, Achilles tendinitis, planter fasciitis, dactylitis
• ophthalmic
  ■ iritis (anterior uveitis), conjunctivitis
• dermatologic
  ■ keratoderma blennorrhagicum (hyperkeratotic skin lesions on palms and soles) and balanitis cinerina (small, shallow, painless ulcers of glans penis and urethral meatus) are diagnostic
• gastrointestinal
  ■ oral ulcers, diarrhea
• urethritis and cervicitis
  ■ sterile pyuria; presence not related to site of initiating infection

**Investigations**
• diagnosis is clinical plus laboratory
• blood work: normocytic, normochromic anemia, and leukocytosis
• sterile cultures
• serology: HLA-B27 positive

**Treatment**
• antibiotics for non-articular infections
• NSAIDs, physical therapy, exercise
• local therapy
  ■ joint protection
  ■ IA steroid injection
  ■ topical steroid for ocular involvement
• systemic therapy
  ■ corticosteroids, sulfasalazine, MTX (for peripheral joint involvement only)
  ■ TNF-α inhibitors for spinal inflammation

**Prognosis**
• self-limited, typically 3-5 mo, varies based on pathogen and patient’s genetic background
• chronic in 15-20% of cases

---

**Crystal-Induced Arthropathies**

**Table 30. Gout vs. Pseudogout**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Gout</th>
<th>Pseudogout</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>M&gt;F</td>
<td>M=F</td>
</tr>
<tr>
<td>Age</td>
<td>Middle-aged males</td>
<td></td>
</tr>
<tr>
<td>Post-menopausal females</td>
<td>Age &gt;60 yr</td>
<td></td>
</tr>
<tr>
<td>Onset of Disease</td>
<td>Acute</td>
<td>Acute/insidious</td>
</tr>
<tr>
<td>Crystal Type</td>
<td>Monosodium urate, Negative birefringence (yellow when parallel to compensator filter), needle-shaped</td>
<td>CPPD, Positive birefringence (blue when parallel), rhomboid-shaped</td>
</tr>
<tr>
<td>Distribution</td>
<td>First MTP classically; also midfoot, ankle, knee, or polyanterial</td>
<td>Knee, wrist; monoarticular, or polyanterial if chronic</td>
</tr>
<tr>
<td>Radiology (note findings are non-specific)</td>
<td>Erosions, Chondrocalcinosis, OA (knee, wrist, 2nd and 3rd MCP)</td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td>Acute: NSAIDs, corticosteroids, colchicine Chronic: ± allopurinol, fuboxostat</td>
<td>NSAIDs, corticosteroids</td>
</tr>
</tbody>
</table>

---

**Gout**

**Definition**
• derangement in purine metabolism resulting in hyperuricemia; monosodium urate crystal deposits in tissues (tophi) and synovium (microtophi)
**Etiology and Pathophysiology**
- uric acid can be obtained from the diet or made endogenously by xanthine oxidase, which converts xanthine to uric acid
- an excess of uric acid results in hyperuricemia
- uric acid can deposit in the tissues (tophi), synovium (microtophi) and bones, where they can crystalize to form monosodium urate crystals that lead to gout
- both modifiable and non-modifiable risk factors contribute to gout
- non-modifiable risk factors include: genetic mutations, male gender and advanced age
- modifiable risk factors include: diet (alcohol, purine rich foods such as meats and seafoods, fructose/sugar sweetened foods (see list of precipitants below)
- other risk factors: renal failure, metabolic syndrome, diuretics

**Clinical Features**
- single episode progressing to recurrent episodes of acute inflammatory arthritis
- **acute gouty arthritis**
  - severe pain, redness, joint swelling, usually involving lower extremities
  - joint mobility may be limited
  - attack will subside spontaneously within several days to weeks; may recur
- **tophi**
  - urate deposits on cartilage, tendons, bursae, soft tissues, and synovial membranes
  - common sites: first MTP, ear helix, olecranon bursae, tendon insertions (common in Achilles tendon)
- **kidney**
  - gouty nephropathy
  - uric acid calculi

**Investigations**
- joint aspirate: >90% of joint aspirates show crystals of monosodium urate (negatively birefringent, needle-shaped)
- x-rays may show tophi as soft tissue swelling, punched-out lesions, erosion with “over-hanging”
- correlated with hyperuricemia in the blood
- may see elevated WBC and ESR (nonspecific)

**Treatment**
- **acute gout**
  - NSAIDs: high dose, then taper as symptoms improve
  - corticosteroids: IA, oral, or intra-muscular (if renal, cardiovascular, or GI disease and/or if NSAIDs contraindicated or failed)
  - colchicine within first 12 h but effectiveness limited by narrow therapeutic range
  - allopurinol can worsen an acute attack (do not start during acute flare)
- **chronic gout**
  - conservative
    - avoid foods with high purine content (e.g. visceral meats, sardines, shellfish, beans, peas)
    - avoid drugs with hyperuricemic effects (e.g. pyrazinamide, ethambutol, thiazide, alcohol)
  - medical
    - antihyperuricemic drugs (allopurinol and febuxostat): decrease uric acid production by inhibiting xanthine oxidase
    - uricosuric drugs (probencid, sulfinpyrazone): very rarely used in combination with allopurinol or febuxostat in patients in whom hyperuricemia is not controlled with the latter
    - prohylaxis prior to starting antihyperuricemic drugs (colchicine/low-dose NSAID)
  - in renal disease secondary to hyperuricemia, use low-dose allopurinol and monitor Cr
  - indications for treatment with antihyperuricemic medications include
    - recurrent attacks (more than 2-3/yr), tophi, bone erosions, urate kidney stones
    - perhaps in renal dysfunction with very high urate load (controversial)

**Pseudogout (Calcium Pyrophosphate Dihydrate Disease)**

**Definition**
- joint inflammation caused by calcium pyrophosphate crystals

**Etiology and Pathophysiology**
- acute inflammatory arthritis due to phagocytosis of IgG-coated CPPD crystals by neutrophils and subsequent release of inflammatory mediators within joint space
- more frequently polyarticular
- slower in onset in comparison to gout, lasts up to 3 wk but is self-limited
Risk Factors
• old age, advanced OA, neuropathic joints
• other associated conditions: hyperparathyroidism, hypothyroidism, hypomagnesemia, hypophosphatemia (low ALP), DM, hemochromatosis

Signs and Symptoms
• affects knees, wrists, MCPs, hips, shoulders, elbows, ankles, big toe
• multiple manifestations
• asymptomatic crystal deposition (seen on radiograph only)
• acute crystal arthritis (self-limited flares of acute inflammatory arthritis resembling gout)
• pseudo-OA (progressive joint degeneration, sometimes with episodes of acute inflammatory arthritis)
• pseudo-RA (symmetrical polyarticular pattern with morning stiffness and constitutional symptoms)
• acute may be triggered by dehydration, acute illness, surgery, trauma

Investigations
• must aspirate joint to rule out septic arthritis, gout
• CPPD crystals: present in 60% of patients, often only a few crystals, positive birefringence (blue) and rhomboid shaped
• x-rays show chondrocalcinosis in 75%; radiodensities in fibrocartilaginous structures (e.g. knee meniscus) or linear radiodensities in hyaline articular cartilage

Treatment
• joint aspiration, rest, and protection
• NSAIDs: also used for maintenance therapy
• prophylactic colchicine PO (controversial)
• IA or oral steroids to relieve inflammation

Non-Articular Rheumatism

Definition
• disorders that primarily affect soft tissues or periarticular structures
• includes bursitis, tendinitis, tenosynovitis, fibromyalgia, and PMR

Polymyalgia Rheumatica

Definition
• characterized by pain and stiffness of the proximal extremities (girdle area)
• closely related to GCA (15% of patients with PMR develop GCA)
• no muscle weakness

Table 31. PMR Classification Criteria Scoring Algorithm*

<table>
<thead>
<tr>
<th>Points without U/S (0-6)</th>
<th>Points with Abnormal U/S**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morning stiffness duration &gt;45 min</td>
<td>2</td>
</tr>
<tr>
<td>Hip pain or limited ROM</td>
<td>1</td>
</tr>
<tr>
<td>Absence of RF or ACPA</td>
<td>2</td>
</tr>
<tr>
<td>Absence of other joint involvement</td>
<td>1</td>
</tr>
<tr>
<td>At least one shoulder with subdeltoid and/or biceps tenosynovitis and/or glenohumeral synovitis (either posterior or axillary) and at least one hip with synovitis and/or trochanteric bursitis on U/S</td>
<td>N/A</td>
</tr>
<tr>
<td>Both shoulders with subdeltoid bursitis, biceps tenosynovitis, or gleno-humeral synovitis on U/S</td>
<td>N/A</td>
</tr>
</tbody>
</table>

*Required criteria: age ≤50 yr, bilateral shoulder aching, and abnormal ESR/CRP
**A score of 4 or more is categorized as PMR in the algorithm without U/S and a score of 5 or more is categorized as PMR in the algorithm with U/S
***Optional U/S criteria
Ann Rheum Dis 2012;71:484-492

Epidemiology
• incidence 50 per 100,000 per year in those >50 yr
• age of onset typically >50 yr, F:M = 2:1

Signs and Symptoms
• constitutional symptoms prominent (fever, weight loss, malaise)
• pain and stiffness of symmetrical proximal muscles (neck, shoulder and hip girdles, thighs)
• gel phenomenon (stiffness after prolonged inactivity)
• physical exam reveals tender muscles, but no weakness or atrophy
Investigations
- blood work: often shows anemia, elevated platelets, elevated ESR and CRP, and normal CK; up to 5% of PMR reported with normal inflammatory markers

Treatment
- goal of therapy: symptom relief
- start with prednisone dose of 15-20 mg PO OD, reconsider diagnosis if no response within several days
- taper slowly over 1 yr period with closely monitoring
- relapses should be diagnosed and treated on clinical basis; do not treat a rise in ESR as a relapse
- treat relapses aggressively (50% relapse rate)
- monitor for steroid side effects, glucocorticoid-induced osteoporosis prevention, and follow for symptoms of GCA

Fibromyalgia

Definition
- chronic (>3 mo), widespread (axial, left- and right-sided, upper and lower segment), non-articular pain with characteristic tender points

Diagnosis

Table 32. 2010 ACR Preliminary Diagnostic Criteria for Fibromyalgia

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Comments</th>
</tr>
</thead>
</table>
| Widespread Pain Index = number of areas in which the patient had pain over the last week (max score = 19): |\[
\begin{align*}
\text{L and R: shoulder girdle, upper arm, lower arm, hip, upper leg, lower leg, jaw} \\
\text{One Area: chest, abdomen, upper back, lower back, neck}
\end{align*}
\]
Symptom Severity Score = sum of: | A patient satisfies diagnostic criteria for fibromyalgia if the following 3 conditions are met: |\[
\begin{align*}
\text{a) severity of fatigue} \\
\text{b) waking unrefreshed} \\
\text{c) cognitive symptoms over the past week} \\
\text{d) extent of somatic symptoms (IBS, H/A, abdominal pain/ cramps, dry mouth, fever, hives, ringing in ears, vomiting, heartburn, dry eyes, SOB, loss of appetite, rash, hair loss, easy bruising, etc.)}
\end{align*}
\]
all (a-d) rated on 0-3 scale: 0 = no problem, 1 = mild, 2 = moderate, 3 = severe | 1. Widespread Pain Index (WPI) > 7 and Symptom Severity (SS) scale score ≥ 5 or WPI 3–6 and SS scale score ≥ 9 | 2. Symptoms have been present at a similar level for at least 3 mo | 3. The patient does not have a disorder that would otherwise explain the pain

Epidemiology
- F:M = 3:1
- primarily ages 25-45 yr, some adolescents
- prevalence of 2-5% in general population
- overlaps with chronic fatigue syndrome and myofascial pain syndrome
- strong association with psychiatric illness

Signs and Symptoms
- widespread aching, stiffness
- easy fatigability
- sleep disturbance: non-restorative sleep, difficulty falling asleep, and frequent wakening
- symptoms aggravated by physical activity, poor sleep, emotional stress
- patient feels that joints are diffusely swollen although joint examination is normal
- neurologic symptoms of hyperalgesia, paresthesias
- associated with irritable bowel or bladder syndrome, migraines, tension H/A, restless leg syndrome, obesity, depression, and anxiety
- physical exam should reveal only tenderness with palpation of soft tissues, with no specificity for trigger/tender points

Investigations
- blood work: includes TSH and ESR; all typically normal unless unrelated, underlying illness present
- serology: do not order ANA or RF unless there is clinical suspicion for a connective tissue disease
- laboratory sleep assessment

Differential Diagnosis
- diagnosis of exclusion
- rule out other disorders by history and physical exam (RA, SLE, PMR, myositis, hypothyroidism, hyperparathyroidism, neuropathies)
Treatment

- **non-pharmacological therapy**
  - education
  - exercise program (walking, aquatic exercises), physical therapy (good posture, stretching, muscle strengthening, massage)
  - stress reduction, CBT
  - no evidence for alternative medicine such as biofeedback, meditation, acupuncture

- **pharmacological therapy**
  - low dose tricyclic antidepressant (e.g. amitriptyline)
    - for sleep restoration
    - select those with lower anticholinergic side effects
  - SNRI: duloxetine, milnacipran
  - anticonvulsant: pregabalin, gabapentin
  - analgesics may be beneficial for pain that interferes with sleep (NSAIDs, not narcotics)

Prognosis

- variable; usually chronic, unless diagnosed and treated early

### Table 33. Clinical Features of Inflammatory Myopathy vs. Polymyalgia Rheumatica vs. Fibromyalgia

<table>
<thead>
<tr>
<th>Polymyositis</th>
<th>PMR</th>
<th>Fibromyalgia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidemiology</td>
<td>F &gt; M, 40-50 yrs</td>
<td>F &gt; M, &gt; 50 yrs</td>
</tr>
<tr>
<td>Muscle involvement</td>
<td>Proximal muscle</td>
<td>Proximal muscle</td>
</tr>
<tr>
<td>Weakness</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Pain</td>
<td>Painless</td>
<td>Painful</td>
</tr>
<tr>
<td>Stiffness</td>
<td>Mild</td>
<td>Significant morning and gelling stiffness (shoulders, neck, hips)</td>
</tr>
<tr>
<td>Investigations</td>
<td>Muscle biopsy, CK, EMG, R/O malignancy</td>
<td>ESR/CRP R/O giant cell arthritis</td>
</tr>
<tr>
<td>ESR/CRP</td>
<td>Usually normal</td>
<td>Markedly elevated</td>
</tr>
<tr>
<td>Treatment</td>
<td>High dose steroids, immunosuppressants</td>
<td>Low dose steroids</td>
</tr>
</tbody>
</table>

### Common Medications

#### Table 34. Common Medications for Osteoarthritis

<table>
<thead>
<tr>
<th>Class</th>
<th>Generic Drug Name</th>
<th>Trade Name</th>
<th>Dosing (PO)</th>
<th>Indications</th>
<th>Contraindications</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analgesic</td>
<td>acetaminophen</td>
<td>Tylenol®</td>
<td>500 mg tid q4h (3 g daily max)</td>
<td>1st line</td>
<td></td>
<td>Hepatotoxicity, Overdose, Potentiates warfarin</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>ibuprofen</td>
<td>Advil®, Motrin®, Voltaren®</td>
<td>200-600 mg tid, 25-50 mg tid, 50-75/200 mg tid, 125-500 mg bid, 7.5-15 mg OD</td>
<td>2nd line</td>
<td>GI bleed, Renal impairment, Allergy to ASA, NSAIDs, Pregnancy (T3)</td>
<td>Nausea, tinnitus, vertigo, rash, dyspepsia, GI bleed, PUD, hepatitis, renal failure, HTN, nephrotic syndrome</td>
</tr>
<tr>
<td>COX-2 INHIBITORS</td>
<td>celecoxib</td>
<td>Celebrex®</td>
<td>200 mg DD</td>
<td>High risk for GI bleed: age &gt;65 Hx of GI bleed, PUD</td>
<td>Renal impairment, Sulfa allergy (celecoxib) Cardiovascular disease</td>
<td>Delayed ulcer healing, Renal/hepatic impairment, Rash</td>
</tr>
<tr>
<td>Other Treatments</td>
<td>Combination analgesics (acetaminophen + codeine, acetaminophen + NSAIDs)</td>
<td>Enhanced short-term effect compared to acetaminophen alone More adverse effects: sedation, constipation, nausea, GI upset</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IA corticosteroid injection</td>
<td>Short-term (weeks-months) decrease in pain and improvement in function Used for management of an IA inflammatory process when infection has been ruled out</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IA hyaluronic acid q6mo</td>
<td>Used for mild-moderate OA of the knees, however little supporting evidence, and not considered to be effective Precaution with chicken/egg allergy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Topical NSAIDs</td>
<td>25% v/v topical diclofenac (Pennsaid®)</td>
<td>May use for patients who fail acetaminophen treatment and who wish to avoid systemic therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capsaicin cream</td>
<td>Mild decrease in pain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucosamine sulfate ± chondroitin</td>
<td>Limited clinical studies. No regulation by Health Canada</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Common Medications

#### General Medications

**Common Medications**

<table>
<thead>
<tr>
<th>Generic Drug Name</th>
<th>Trade Name</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COMMONLY USED</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hydroxychloroquine</td>
<td>Plaquenil®</td>
<td>400 mg PO OD initially 200-400 mg PO OD maintenance (6.5 mg/kg ideal body weight per day)</td>
<td>Retinal disease, G6PD deficiency</td>
<td>GI symptoms, skin rash, macular damage, neuromyopathy Requires regular ophthalmological screening to monitor for retinopathy</td>
</tr>
<tr>
<td>sulfasalazine</td>
<td>Salazopyrin® Azulfidine® (US)</td>
<td>1000 mg PO bid-tid</td>
<td>Sulf/ASA allergy, kidney disease, G6PD deficiency</td>
<td>GI symptoms, rash, H/A, leukopenia</td>
</tr>
<tr>
<td>methotrexate</td>
<td>Rheumatrex® Folex/Mexate®</td>
<td>7.5-25 mg PO/IM/SC weekly</td>
<td>Bone marrow suppression, liver disease, significant lung disease, immunodeficiency, pregnancy, EtOH abuse</td>
<td>Oral ulcers, GI symptoms, cirrhosis, myelosuppression, pneumonitis, tubular necrosis</td>
</tr>
<tr>
<td>lefunomide</td>
<td>Arava®</td>
<td>10-20 mg PO OD</td>
<td>Liver disease</td>
<td>Alopecia, GI symptoms, liver dysfunction, pulmonary infiltrates</td>
</tr>
<tr>
<td><strong>NOT COMMONLY USED</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cyclosorpine</td>
<td>Neoral®</td>
<td>2.5-3 mg/kg/d divided and given in 2 doses PO</td>
<td>Kidney/liver disease, infection, HTN</td>
<td>HTN, decreased renal function, hair growth, tremors, bleeding</td>
</tr>
<tr>
<td>gold (injectable)</td>
<td>Solganal® Myocrysine®</td>
<td>50 mg IM q1wk after gradual introduction</td>
<td>IBD, kidney/liver disease</td>
<td>Rash, mouth soreness/ulcers, proteinuria, marrow suppression</td>
</tr>
<tr>
<td>azathioprine</td>
<td>Imuran®</td>
<td>2.5 mg/kg/d PO once daily</td>
<td>Kidney/liver disease TPMT deficiency</td>
<td>Rash, pancytopenia (especially WBC, T, AST, ALT), biliary stasis, vomiting, diarrhea</td>
</tr>
<tr>
<td>cyclophosphamide</td>
<td>Cytoxan®</td>
<td>1 g/m2/mo IV as per protocol</td>
<td>Kidney/liver disease</td>
<td>Cardiotoxicity, GI symptoms, hemorrhagic cystitis, nephrotoxicity, bone marrow suppression, sterility</td>
</tr>
</tbody>
</table>

#### Newer DMARDs (Biologics)

<table>
<thead>
<tr>
<th>Generic Drug Name</th>
<th>Trade Name</th>
<th>Dosing</th>
<th>Mechanism of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NEWER DMARDs (Biologics)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>etanercept</td>
<td>Enbrel®</td>
<td>25 mg biweekly or 50 mg weekly SC</td>
<td>Fusion protein of TNF receptor and Fc portion of IgG</td>
</tr>
<tr>
<td>inflicimab</td>
<td>Remicade®</td>
<td>3-5 mg/kg IV q8wk</td>
<td>Chimeric mouse/human monoclonal anti-TNF</td>
</tr>
<tr>
<td>adalimumab</td>
<td>Humira®</td>
<td>40 mg SC q2wk</td>
<td>Monoclonal anti-TNF</td>
</tr>
<tr>
<td>golimumab</td>
<td>Simponi®</td>
<td>50 mg SC q mo</td>
<td>Monoclonal anti-TNF</td>
</tr>
<tr>
<td>certolizumab</td>
<td>Cimzia®</td>
<td>400 mg SC q2wk x3 then 200 mg SC q4wk</td>
<td>PEGylated monoclonal anti-TNF</td>
</tr>
<tr>
<td>Apremilast</td>
<td>Otezla®</td>
<td>Day 1: 10mg (AM), titrate up to 30mg BID by Day 6</td>
<td>Inhibitor of PDE4 which inhibits production of TNF alpha</td>
</tr>
<tr>
<td>abatacept</td>
<td>Orencia®</td>
<td>IV infusion</td>
<td>Costimulation modulator of T-cell activation</td>
</tr>
<tr>
<td>rituximab</td>
<td>Rituxan®</td>
<td>2 IV infusions, 2 wk apart</td>
<td>Causes B-cell depletion, binds to CD20</td>
</tr>
<tr>
<td>tocilizumab</td>
<td>Actemra®</td>
<td>4-8 mg/kg IV q4wk</td>
<td>Interleukin-6 receptor antagonist</td>
</tr>
<tr>
<td>Tofacitinib</td>
<td>Xeljanz®</td>
<td>5mg BID</td>
<td>Inhibits the JAK enzyme and thus interferes with JAK-STAT signaling pathway</td>
</tr>
</tbody>
</table>

**Risks of Biologics**

- Reactivation of TB or hepatitis B. Patients require negative TB skin test, chest x-ray and negative hepatitis B virus serology prior to starting any of these medications.
- Increased risk of: serious infections, worsening heart failure, multiple sclerosis, and positive auto-antibodies.
## Landmark Rheumatology Trials

<table>
<thead>
<tr>
<th>Trial</th>
<th>Reference</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RHEUMATOID ARTHRITIS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATTEST</td>
<td>Ann Rheum Dis 2008; 67:1096-103</td>
<td>Abatacept and infliximab have similar efficacy in RA patients who have failed MTX</td>
</tr>
<tr>
<td>ATTRACT</td>
<td>Lancet 1999; 354:1932-9</td>
<td>Infliximab and MTX combined are more effective than MTX alone for patients with active RA</td>
</tr>
<tr>
<td>CIMESTRA</td>
<td>Arthritis Rheum 2006; 54:1401-9</td>
<td>Combination of MTX and sulfasalazine is superior to either alone</td>
</tr>
<tr>
<td>COMET</td>
<td>Lancet 2008; 372:375-82</td>
<td>Etanercept add-on therapy increases rates of remission in early RA</td>
</tr>
<tr>
<td>ERA</td>
<td>NEJM 2000; 343:1586-93</td>
<td>Etanercept more rapidly decreases symptoms in early RA compared to MTX</td>
</tr>
<tr>
<td>European Leflunomide Study Group</td>
<td>Lancet 1999; 353:259-66</td>
<td>Leflunomide is equivalent to sulfasalazine and superior to placebo</td>
</tr>
<tr>
<td>FIN-RACo</td>
<td>Lancet 1999; 353:1568-73</td>
<td>Combination therapy with DMARDs improves remission rates in early RA</td>
</tr>
<tr>
<td>Infliximab and MTX</td>
<td>NEJM 2000; 343:1594-602</td>
<td>Infliximab combined with MTX reduces joint damage in RA</td>
</tr>
<tr>
<td>Leflunomide Rheumatoid Arthritis Investigators Group</td>
<td>Arthritis Rheum 1999; 159:2542-50</td>
<td>Leflunomide is equivalent to MTX therapy and superior to placebo</td>
</tr>
<tr>
<td>PREMIER</td>
<td>Arthritis Rheum 2006; 54:26-37</td>
<td>Combination therapy with adalimumab and MTX is superior to either alone in patients with early RA</td>
</tr>
<tr>
<td>Swefot</td>
<td>Lancet 2009; 374:459-66</td>
<td>Anti-TNF agents are more effective second-line therapy than DMARDs in patients who fail MTX</td>
</tr>
<tr>
<td><strong>OSTEOARTHRITIS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAIT</td>
<td>NEJM 2006; 354:795-808</td>
<td>Glucosamine, chondroitin, and the combination of both are no more effective than placebo in treatment of knee OA</td>
</tr>
<tr>
<td><strong>SLE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belimumab</td>
<td>Lancet 2011; 377:721-31</td>
<td>Treatment with belimumab reduces the incidence of BILAG A and B flares in patients with SLE compared to placebo</td>
</tr>
<tr>
<td>BILAG open-RCT</td>
<td>Rheumatology 2010; 49:723-32</td>
<td>Low dose cyclosporine and azathioprine are equivalent in efficacy as maintenance therapy for SLE</td>
</tr>
<tr>
<td>Mycophenylate mofetil or intravenous cyclophosphamide</td>
<td>NEJM 2005; 353:2219-28</td>
<td>Mycophenylate mofetil is more efficacious than cyclophosphamide in inducing remission of SLE nephritis</td>
</tr>
<tr>
<td><strong>CONNECTIVE TISSUE DISEASES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Azathioprine or MTX maintenance for ANCA-associated vasculitis</td>
<td>NEJM 2008; 359:2790-803</td>
<td>MTX and azathioprine are equally safe and effective as maintenance agents in ANCA vasculitis</td>
</tr>
<tr>
<td>Cyclophosphamide in scleroderma lung disease</td>
<td>NEJM 2006; 354:2655-66</td>
<td>Cyclophosphamide therapy leads to transient improvements in lung function, skin scores, and overall health in patients with scleroderma</td>
</tr>
<tr>
<td>Etanercept plus standard therapy for granulomatosis with polyangiitis</td>
<td>NEJM 2005; 352:351-61</td>
<td>Etanercept is not effective in inducing remission in patients with ANCA vasculitis</td>
</tr>
<tr>
<td>Mycophenylate mofetil vs. azathioprine for maintenance in ANCA-associated vasculitis</td>
<td>JAMA 2010; 304:2381-8</td>
<td>Mycophenylate mofetil is less effective than azathioprine for maintaining disease in ANCA-associated vasculitis</td>
</tr>
<tr>
<td>Rituximab versus cyclophosphamide for ANCA-associated vasculitis</td>
<td>NEJM 2010; 363:221-32</td>
<td>Rituximab is not inferior to cyclophosphamide for induction of remission in ANCA vasculitis</td>
</tr>
<tr>
<td><strong>GOUT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Febuxostat vs. allopurinol</td>
<td>NEJM 2005; 353:2450-61</td>
<td>Febuxostat is more effective than allopurinol at lowering serum urate, and has similar effectiveness on flare reduction</td>
</tr>
<tr>
<td><strong>ANKYLOSING SPONDYLITIS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adalimumab</td>
<td>Arthritis Rheum 2006; 54:2136-46</td>
<td>Adalimumab induced partial remission in 22% of AS patients</td>
</tr>
<tr>
<td>ASSERT (rituximab)</td>
<td>Arthritis Rheum 2005; 52:582-91</td>
<td>Sixty percent of patients treated with rituximab had a clinical response to the medication</td>
</tr>
<tr>
<td>ATLAS (adalimumab)</td>
<td>J Rheumatol 2008; 35:1346-53</td>
<td>Compared to placebo, adalimumab significantly reduces pain and fatigue in AS patients</td>
</tr>
<tr>
<td>Infliximab in AS</td>
<td>Lancet 2002; 359:1187-93</td>
<td>Infliximab induces regression of symptoms in 50% of patients and is superior to placebo</td>
</tr>
<tr>
<td>SPINE (etanercept)</td>
<td>Ann Rheum Dis 2011; 70:799-804</td>
<td>Etanercept has short-term efficacy for patients with advanced AS and reduces disease severity</td>
</tr>
<tr>
<td>Sulfasalazine</td>
<td>Arthritis Rheum 1995; 38:618-27</td>
<td>Sulfasalazine is superior to placebo in treatment of patients with seronegative spondyloarthritis</td>
</tr>
</tbody>
</table>
References

Klinkhoff A. Diagnosis and management of inflammatory polyarthritis. CMAJ 2000;162:1833-1838.
Reid G, Esdaile JM. Getting the most out of radiology. CMAJ 2000;162:1318-1325.
Shojania K. What laboratory tests are needed? CMAJ 2000;162:1157-1163.
# Urology

Matthew Da Silva, Ryan Sun, and Weining Yang, chapter editors  
Dhruvin Hirpara and Sneha Raju, associate editors  
Valerie Lemieux and Simran Mundi, EBM editors  
Dr. Sender Herschorn and Dr. Armando Lorenzo, staff editors

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acronyms</td>
<td>2</td>
</tr>
<tr>
<td>Basic Anatomy Review</td>
<td>2</td>
</tr>
<tr>
<td>Urologic History</td>
<td>3</td>
</tr>
<tr>
<td>Hematuria (Blood in the Urine)</td>
<td>4</td>
</tr>
<tr>
<td>Macroscopic (Gross) Hematuria</td>
<td></td>
</tr>
<tr>
<td>Microscopic Hematuria</td>
<td></td>
</tr>
<tr>
<td>Lower Urinary Tract Dysfunction</td>
<td>5</td>
</tr>
<tr>
<td>Voiding</td>
<td></td>
</tr>
<tr>
<td>Urinary Incontinence</td>
<td></td>
</tr>
<tr>
<td>Urinary Retention</td>
<td></td>
</tr>
<tr>
<td>Benign Prostatic Hyperplasia</td>
<td></td>
</tr>
<tr>
<td>Urethral Stricture</td>
<td></td>
</tr>
<tr>
<td>Neurogenic Bladder</td>
<td></td>
</tr>
<tr>
<td>Dysuria</td>
<td></td>
</tr>
<tr>
<td>Hydronephrosis</td>
<td></td>
</tr>
<tr>
<td>Post-Obstructive Diuresis</td>
<td></td>
</tr>
<tr>
<td>Overactive Bladder</td>
<td>11</td>
</tr>
<tr>
<td>Infectious and Inflammatory Diseases</td>
<td>12</td>
</tr>
<tr>
<td>Urinary Tract Infection</td>
<td></td>
</tr>
<tr>
<td>Recurrent/Chronic Cystitis</td>
<td></td>
</tr>
<tr>
<td>Interstitial Cystitis (Painful Bladder or Bladder Pain Syndrome)</td>
<td></td>
</tr>
<tr>
<td>Acute Pyelonephritis</td>
<td></td>
</tr>
<tr>
<td>Prostatitis/Prostatodynia</td>
<td></td>
</tr>
<tr>
<td>Epididymitis and Orchitis</td>
<td></td>
</tr>
<tr>
<td>Urethritis</td>
<td></td>
</tr>
<tr>
<td>Stone Disease</td>
<td>17</td>
</tr>
<tr>
<td>Approach to Renal Stones</td>
<td></td>
</tr>
<tr>
<td>Urological Neoplasms</td>
<td>20</td>
</tr>
<tr>
<td>Approach to Renal Mass</td>
<td></td>
</tr>
<tr>
<td>Benign Renal Neoplasms</td>
<td></td>
</tr>
<tr>
<td>Malignant Renal Neoplasms</td>
<td></td>
</tr>
<tr>
<td>Carcinoma of the Renal Pelvis and Ureter</td>
<td></td>
</tr>
<tr>
<td>Bladder Carcinoma</td>
<td></td>
</tr>
<tr>
<td>Prostate Cancer</td>
<td></td>
</tr>
<tr>
<td>Prostate Cancer Screening</td>
<td></td>
</tr>
<tr>
<td>Testicular Tumours</td>
<td></td>
</tr>
<tr>
<td>Penile Tumours</td>
<td></td>
</tr>
<tr>
<td>Scrotal Mass</td>
<td>29</td>
</tr>
<tr>
<td>Penile Complaints</td>
<td>30</td>
</tr>
<tr>
<td>Erectile Dysfunction</td>
<td></td>
</tr>
<tr>
<td>Trauma</td>
<td>32</td>
</tr>
<tr>
<td>Renal Trauma</td>
<td></td>
</tr>
<tr>
<td>Bladder Trauma</td>
<td></td>
</tr>
<tr>
<td>Urethral Injuries</td>
<td></td>
</tr>
<tr>
<td>Infertility</td>
<td>34</td>
</tr>
<tr>
<td>Female Factors</td>
<td></td>
</tr>
<tr>
<td>Male Factors</td>
<td></td>
</tr>
<tr>
<td>Pediatric Urology</td>
<td>36</td>
</tr>
<tr>
<td>Congenital Abnormalities</td>
<td></td>
</tr>
<tr>
<td>Nephroblastoma (Wilms’ Tumour)</td>
<td></td>
</tr>
<tr>
<td>Cryptorchidism/Ectopic Testes</td>
<td></td>
</tr>
<tr>
<td>Disorders of Sexual Differentiation</td>
<td></td>
</tr>
<tr>
<td>Enuresis</td>
<td></td>
</tr>
<tr>
<td>Selected Urological Procedures</td>
<td>40</td>
</tr>
<tr>
<td>Bladder Catheterization</td>
<td></td>
</tr>
<tr>
<td>Circumcision</td>
<td></td>
</tr>
<tr>
<td>Cystoscopy</td>
<td></td>
</tr>
<tr>
<td>Radical Prostatectomy</td>
<td></td>
</tr>
<tr>
<td>Transurethral Resection of the Prostate</td>
<td></td>
</tr>
<tr>
<td>Extracorporeal Shock Wave Lithotripsy</td>
<td></td>
</tr>
<tr>
<td>Common Medications</td>
<td>42</td>
</tr>
<tr>
<td>References</td>
<td>44</td>
</tr>
</tbody>
</table>
Figure 3. Essential male genitourinary tract anatomy
Urologic History

- follow the OPQRSTUVW approach
  - note that pain may not be limited to the genital region (e.g. lower abdomen, CVA)
- inquire about risk factors: past urologic disease (e.g. UTI, stones, STI, cancers, anatomic abnormalities), family Hx, medications, lifestyle factors (smoking, alcohol, inactivity), trauma, previous surgical procedures
- urinary habits
  - frequency of voiding, incontinence, nocturia
  - specific urinary symptoms include
    - storage symptoms: frequency, nocturia, urgency, incontinence, urge (rush to toilet), stress (leak with cough/laugh)
    - voiding symptoms: straining, hesitancy, dysuria, intermittency, post-void dribbling, reduced stream, feeling of incomplete voiding
  - hematuria: blood clots, red/pink tinged urine
- sexual function
  - scrotal mass: see Scrotal Mass, U29
  - ED: see Erectile Dysfunction, U30
  - infertility: see Infertility, U34
- associated symptoms
  - N/V
  - bowel dysfunction
- constitutional symptoms
  - fever, chills, unintentional weight loss, night sweats, fatigue, malaise

Always ask about sexual function on history. Change in erectile function can be one of the first symptoms that there is concomitant vascular disease. If there is new onset ED, consider screening for DM and CAD risk factors.
Hematuria (Blood in the Urine)

Macroscopic (Gross) Hematuria

Definition
- blood in the urine that can be seen with the naked eye

Classification
- see Nephrology, NP21

Etiology

<table>
<thead>
<tr>
<th>Table 1. Etiology by Age Group</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age [yr]</strong></td>
</tr>
<tr>
<td>0-20</td>
</tr>
<tr>
<td>20-40</td>
</tr>
<tr>
<td>40-60</td>
</tr>
<tr>
<td>&gt; 60</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2. Etiology by Type</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pseudohematuria</strong></td>
</tr>
<tr>
<td>Vaginal bleeding</td>
</tr>
<tr>
<td>Dyes (beets, rhodamine B in candy and juices)</td>
</tr>
<tr>
<td>Hemoglobin (hemolytic anemia)</td>
</tr>
<tr>
<td>Myoglobin (rhabdomyolysis)</td>
</tr>
<tr>
<td>Drugs (rifampin, phenazopyridine, phenytoin)</td>
</tr>
<tr>
<td>Porphyria</td>
</tr>
<tr>
<td>Laxatives (phenolphthalein)</td>
</tr>
</tbody>
</table>

History
- inquire about timing of hematuria in urinary stream
  - initial: anterior urethra
  - terminal: bladder neck and prostatic urethra
  - total: bladder and/or above
- associated symptoms (storage and voiding)
  - pyuria, dysuria: UTI
  - flank pain, radiation: ureteral obstruction
- recent UTI: postinfectious glomerulonephritis, IgA nephropathy

Investigations
- CBC (rule out anemia, leukocytosis), electrolytes, Cr, BUN, INR, PTT
- urine studies
  - U/A, C&S, cytology
- imaging
  - CT (with contrast) has largely replaced IVP to investigate upper tracts
  - consider contraindications: allergy, renal insufficiency, pregnancy
  - U/S alone may not be sufficient
  - cystoscopy to investigate lower tract (possible retrograde pyelogram)

Acute Management of Severe Bladder Hemorrhage
- manual irrigation via catheter with normal saline to remove clots
- Continuous Bladder Irrigation (CBI) using large (22-26 Fr) 3-way Foley to help prevent clot formation
- cystoscopy if active bleeding
  - identify resectable tumours
  - coagulate obvious sites of bleeding
- refractory bleeding
  - intravesical agents
  - continuous intravesical irrigation with 1% aluminum potassium sulfate solution as needed
  - intravesical instillation of 1% silver nitrate solution
  - intravesical instillation of 1-4% formalin (requires GA and pre-procedure cystogram to rule out reflux)
  - embolization or ligation of iliac arteries
  - cystectomy and diversion (rarely performed)

Gross, painless hematuria in adults is bladder cancer until proven otherwise
**Microscopic Hematuria**

**Definition**
- blood in the urine that is not visible to the naked eye
- $\geq 2$ RBCs/HPF on urinalysis of at least two separate samples

**Figure 6. Workup of asymptomatic microscopic hematuria**

Based on CUA Guidelines. Alternatively, the AUA recommends cystoscopy and CT urogram for all patients with confirmed microscopic hematuria; follow-up for negative workup is urinalysis yearly for two years, with repeat anatomic evaluation if microscopic hematuria persists.

**Lower Urinary Tract Dysfunction**
- see Gynecology, GY46 for relevant female topics
- The lower urinary tract consists of the bladder and urethra. LUTD frequently involves both parts

**Voiding**
- two phases of lower urinary tract function
  1. storage phase (bladder filling and urine storage)
     - accommodation and compliance
     - no involuntary contraction(s)
  2. voiding phase (bladder emptying)
     - coordinated detrusor contraction
     - synchronous relaxation of outlet sphincters
     - no anatomic obstruction
- voiding dysfunction can therefore be classified as
  - failure to store: due to bladder or outlet
  - failure to void: due to bladder or outlet
- three types of symptoms
  - storage (formerly known as irritative)
  - voiding (formerly known as obstructive)
  - post-voiding

**Urinary Incontinence**

**Definition**
- involuntary leakage of urine

**Etiology**
- urgency incontinence
  - detrusor overactivity
    - CNS lesion, inflammation/infection (cystitis, stone, tumour), bladder neck obstruction (tumour, stone), BPH, idiopathic
  - decreased compliance of bladder wall (inability to store urine)
    - CNS lesion, fibrosis
    - sphincter/urethral problem
• stress urinary incontinence (SUI)
  ■ common in women; seen in men after prostate cancer treatment or pelvic operations
  ■ urethral hypermobility
  ◦ weakened pelvic floor and musculofascial urethral and vaginal supporting mechanisms allows bladder neck and urethra to descend with increased intra-abdominal pressure
  ◦ urethra is pulled open by greater motion of posterior wall of outlet relative to anterior wall
  ■ associated with childbirth, pelvic surgery, aging, levator muscle weakness, obesity
  ■ intrinsic sphincter deficiency (ISD): weakness of the urethra and associated smooth and striated muscle elements
  ■ pelvic surgery, neurologic problem, aging and hypoestrogen state
  ■ ISD and urethral hypermobility frequently co-exist
  ■ mixed incontinence
  ■ combination of stress and urgency incontinence
  ■ overflow incontinence
  ◦ is a term sometimes used to describe urinary incontinence associated with urinary retention; for causes of urinary retention see Table 4
  ◦ use of the term should be accompanied by the associated pathophysiology (e.g. BPH with overflow incontinence)

**Epidemiology**
- variable prevalence in women: 25-45%
- F:M = 2:1
- more frequent in the elderly, affecting 5-15% of those living in the community and 50% of nursing home residents

**Table 3. Urinary Incontinence: Types and Treatments**

<table>
<thead>
<tr>
<th>Type</th>
<th>Urgency</th>
<th>Stress</th>
<th>Mixed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definition</td>
<td>Involuntary leakage of urine preceded by a sudden, strong urge to void</td>
<td>Involuntary leakage of urine with sudden increases in intra-abdominal pressure</td>
<td>Urinary leakage associated with urgency and increased intra-abdominal pressure</td>
</tr>
<tr>
<td>Etiology</td>
<td>Bladder (detrusor overactivity)</td>
<td>Urethra/sphincter weakness, post-partum pelvic musculature weakness</td>
<td>Combination of bladder and sphincter issues</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Hx, Urodynamics</td>
<td>Hx, Urodynamics Stress test (have patient bear down/cough)</td>
<td>Hx, Urodynamics Stress test</td>
</tr>
<tr>
<td>Therapy</td>
<td>Lifestyle changes (fluid alterations, diet, etc.) Bladder habit training Anticholinergics Beta 3 agonist Botulinum toxin A Neurmodulation</td>
<td>Weight loss Kegel exercises Bulking agents Surgery (slings, tension-free vaginal tape, retropubic urethropexy, artificial sphincter)</td>
<td>Combination of management of urgency and stress incontinence</td>
</tr>
</tbody>
</table>

**Urinary Retention**

**Table 4. Etiology of Urinary Retention**

<table>
<thead>
<tr>
<th>Outflow Obstruction</th>
<th>Bladder Innervation</th>
<th>Pharmacologic</th>
<th>Infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bladder neck or urethra: calculus, clot, foreign body, neoplasm, neurologic (ODD) Prostate: BPH, prostate cancer Urethra: stricture, phimosis, traumatic disruption Miscellaneous: constipation, pelvic mass</td>
<td>Intracranial: CVA, tumour, Parkinson’s, cerebral palsy Spinal cord: injury, disc herniation, MS DM Post-abdominal or pelvic surgery</td>
<td>Anticholinergics Narcotics Antihypertensives (ganglionic blockers, methyldopa) OTC cold medications containing ephedrine or pseudoephedrine Antihistamines Psychosomatic substances (e.g. ecstasy)</td>
<td>GU: UTI, prostatitis, abscess, genital herpes Infected foreign body Varicella zoster</td>
</tr>
</tbody>
</table>

**Clinical Features**
- suprapubic pain, incomplete emptying, weak stream
- palpable and/or perceptible bladder (suprapubic)
- possible purulent/bloody meatal discharge
- increased size of prostate or reduced anal sphincter tone on DRE
- neurological: presence of abnormal or absent deep tendon reflexes, reduced “anal wink”, saddle anesthesia

**Investigations**
- CBC, electrolytes, Cr, BUN, U/A and urine C&S, U/S, cystoscopy, urodynamic studies, PVR
Treatment
- treat underlying cause
- catheterization
  - acute retention
    - immediate catheterization to relieve retention; leave Foley in to drain bladder; follow-up to determine cause; closely monitor fluid status and electrolytes (risk of POD)
  - chronic retention
    - intermittent catheterization by patient may be used; definitive treatment depends on etiology
- suprapubic catheter if obstruction precludes urethral catheter
- for post-operative patients with retention:
  - encourage ambulation
  - α-blockers to relax bladder neck outlet
  - may need catheterization
  - definitive treatment will depend on etiology

Benign Prostatic Hyperplasia

Definition
- periurethral hyperplasia of stroma and epithelium in prostatic transition zone
- prostatic smooth muscle cells play a role in addition to hyperplasia

Etiology
- etiology unknown
  - DHT required (converted from testosterone by 5-a reductase)
  - possible role of impaired apoptosis, estrogens, other growth factors

Epidemiology
- age-related, extremely common (50% of 50 yr olds, 80% of 80 yr olds)
- 25% of men will require treatment

Clinical Features
- result from outlet obstruction and compensatory changes in detrusor function
- voiding and storage symptoms
- DRE
  - prostate is smooth, rubbery, and may be symmetrically enlarged
- complications
  - retention
  - overflow incontinence
  - hydronephrosis
  - renal insufficiency
  - infection
  - gross hematuria
  - bladder stones

Investigations
- Hx, assessing LUTS and impact on QOL
  - may include self-administered questionnaires (IPSS or AUA symptom index for severity, progression, and treatment response)
- P/E, including DRE
- U/A to exclude UTI
- Cr to assess renal function
- renal U/S to assess for hydronephrosis
- PSA to rule out malignancy (see Prostate Cancer Screening, U26)
- uroflowmetry to measure flow rate (optional)
- PVR (optional)
- consider cystoscopy or bladder ultrasound prior to potential surgical management to evaluate outlet and prostate volume
- biopsy if suspicious for malignancy, i.e. elevated PSA or abnormal DRE

Initial alpha-adrenergic antagonist monotherapy for score <20, combination therapy for score >20
Treatment

Table 5. Treatment of BPH

<table>
<thead>
<tr>
<th>Conservative</th>
<th>Medical</th>
<th>Surgical</th>
<th>Minimally Invasive Surgical Therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic patients or symptomatic without bother</td>
<td>Moderate to severe symptoms that are distressing for patient</td>
<td>Significant symptom burden, acute urinary retention, refractory hematuria, recurrent infections</td>
<td>Patients who wish to avoid or may not tolerate surgery</td>
</tr>
<tr>
<td>Watchful waiting: 50% of patients improve spontaneously</td>
<td>α-adrenergic antagonists: reduce stratal smooth muscle tone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lifestyle modifications (e.g. evening fluid restriction, planned voiding)</td>
<td>Laser ablation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>α-reductase inhibitor: block conversion of testosterone to DHT; act to reduce prostate size</td>
<td>TURP (see U41)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combination is synergistic</td>
<td>TURP (prostate &lt; 30 g)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-cholinergic agents or Beta-3 agonist (for storage LUTS, without elevated PVR)</td>
<td>Open prostatectomy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microwave therapy</td>
<td>TUNA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostatic stent (not commonly used)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Lower Urinary Tract Dysfunction

Urethral Stricture

Definition
- decrease in urethral calibre due to scar formation in urethra (may also involve corpus spongiosum)
- M>F

Etiology
- congenital
  - failure of normal canalization (i.e. posterior urethral valves)
  - trauma
  - instrumentation/catheterization (most common)
  - external trauma (e.g. burns, straddle injury)
  - foreign body
  - infection
  - long-term indwelling catheter
  - STI (gonococcal or chlamydial disease)
  - inflammation
  - balanitis xerotica obliterans (BXO; lichen sclerosis or chronic progressive sclerosing dermatosis of the male genitalia) causing meatal and urethral stenosis

Clinical Features
- voiding and storage symptoms
- urinary retention
- hydronephrosis
- related infections: recurrent UTI, secondary prostatitis/epididymitis

Investigations
- laboratory findings
- flow rates <10 mL/s (normal ~20 mL/s) on uroflowmetry
- urine culture usually negative, but U/A may show pyuria
- radiologic findings
- RUG and VCUG will demonstrate location
- cystoscopy

Treatment
- urethral dilatation
- temporarily increases lumen size by breaking up scar tissue
- healing will often reform scar tissue, recurrence of stricture
- visual internal urethrotomy (VIU)
- endoscopically incise stricture
- equal success rates to dilation with mid bulbular strictures <2 cm
- high rate of recurrence (30-80%), avoid in younger patients
- open surgical reconstruction
- complete stricture excision with anastomosis, ± urethroplasty depending on location and size of stricture

Men with planned cataract surgery should avoid starting α-adrenergic antagonists until after their surgery due to the risk of intraoperative floppy iris syndrome

BPH Surgery

Absolute Indication
- Renal failure with obstructive uropathy
- Refractory urinary retention

Relative Indications
- Recurrent UTI
- Recurrent hematuria refractory to medical treatment
- Renal insufficiency (rule out other causes)
- Bladder stones

Finasteride for Benign Prostatic Hyperplasia

Cochrane DB Syst Rev 2010;10:CD006015

Purpose: To examine the effectiveness and safety of finasteride versus placebo or other active control for the treatment of urinary tract symptoms.

Summary of Findings:
1. Finasteride improved urinary symptoms more than placebo in trials >1 yr duration and significantly lowered the risk of BPH progression.
2. Compared with α-blockers, finasteride was less effective than either doxazosin or tamsulosin, but equally as effective as tamsulosin.
3. Symptom improvement with finasteride + doxazosin is equal to doxazosin alone.
4. Finasteride treatment resulted in an increased risk of ejaculation disorder, impotence and lowered libido compared with placebo.
5. Compared with doxazosin and terazosin, finasteride had a lower risk of asthma, dizziness, and postural hypotension.

Microwave Thermotherapy for Benign Prostatic Hyperplasia

Cochrane DB Syst Rev 2012;9:CD004135

Purpose: To evaluate the efficacy and safety of microwave thermotherapy for the treatment of benign prostatic obstruction.

Selection Criteria: RCTs evaluating transurethral microwave therapy (TUMT) for men with symptomatic BPH with multiple comparison groups.

Results: 15 studies, 1,585 patients, mean age 68.8 yr, 3-60 mo duration. Mean urinary symptom scores decreased by 69% with TUMT and 77% with TURP. The pooled mean peak urinary flow increased by 70% with TUMT and 119% with TURP. Compared with TURP, TUMT was associated with decreased risks for retrograde ejaculation, treatment for strictures, hematuria, blood transfusions and transurethral resection syndrome, but increased risk for dysuria, urinary retention and treatment for BPH symptoms.

Conclusions: Overall, microwave thermotherapy techniques are effective alternatives to TURP and α-blockers for treating symptomatic BPH, although less effective than TURP in improving symptom score and urinary flow.
Neurogenic Bladder

Definition
• dysfunction of the urinary bladder due to deficiency in some aspect of its innervation

Neurophysiology

Table 6. Efferent Sympathetic, Parasympathetic, and Somatic Nerve Supply

<table>
<thead>
<tr>
<th>Nerve Fibres</th>
<th>Nerve Roots</th>
<th>Neurotransmitter/Receptor</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sympathetic</td>
<td>T10-L2</td>
<td>NA/Adrenergic</td>
<td>Trigone, internal sphincter, proximal urethra</td>
</tr>
<tr>
<td>Somatic (Pudendal)</td>
<td>S2-4</td>
<td>ACh/Nicotinic</td>
<td>External sphincter</td>
</tr>
<tr>
<td>Parasympathetic</td>
<td>S2-4</td>
<td>ACh/Muscarinic (M2, M3)</td>
<td>Detrusor</td>
</tr>
</tbody>
</table>

- stretch receptors in the bladder wall relay information to PMC and activate micturition reflex (normally inhibited by cortical input)
- micturition
  - stimulation of parasympathetic neurons (bladder contraction)
  - inhibition of sympathetic and somatic neurons (internal and external sphincter relaxation, respectively)
  - urine storage
  - opposite of micturition
- voluntary action of external sphincter ( pudendal nerve roots S2-S4) can inhibit urge to urinate
- cerebellum, basal ganglia, thalamus, and hypothalamus all have input at PMC in the brainstem

Examples of Neurologic Voiding Dysfunction
• neurogenic detrusor overactivity (NDO)(formerly termed detrusor hyperreflexia)
  - lesion above PMC (e.g. stroke, tumour, MS, Parkinson’s disease)
  - loss of voluntary inhibition of voiding
  - intact pathway inferior to PMC maintains coordination of bladder and sphincter
• detrusor sphincter dyssynergia (DSD)
  - suprasacral lesion of spinal cord (e.g. trauma, MS, arteriovenous malformation, transverse myelitis)
  - loss of coordination between detrusor and sphincter (detrusor contracts on closed sphincter and vice versa)
  - component of detrusor overactivity as well
• detrusor atony/areflexia
  - lesion of sacral cord or peripheral efferents (e.g. trauma, DM, disc herniation, MS, congenital spinal cord abnormality, post abdominoperineal resection)
  - flaccid bladder which fails to contract
  - may progress to poorly compliant bladder with high pressures
• peripheral autonomic neuropathy
  - deficient bladder sensation → increasing residual urine → decompensation (e.g. DM, neurosyphilis, herpes zoster)
• muscular lesion
  - can involve detrusor, smooth/striated sphincter

Neuro-Urologic Evaluation
• Hx and P/E (urologic and general neurologic)
• U/A, renal profile
• imaging
  - U/S to rule out hydronephrosis and stones; occasionally CT scanning with or without contrast
• cystoscopy
• urodynamic studies
  - uroflowmetry to assess flow rate, pattern
  - filling CMG to assess capacity, compliance, detrusor overactivity
  - voiding CMG (pressure-flow study) to assess bladder contractility and extent of bladder outflow obstruction
  - video study to visualize bladder/bladder neck/urethra during CMG using x-ray contrast
• EMG and video ascertains presence of coordinated or uncoordinated voiding, allows accurate diagnosis of DSD

Treatment
• goals of treatment
  - prevent renal deterioration
  - prevent infections
  - achieve social continence
  - clean intermittent catheterization (CIC)
• treatment options depend on status of bladder and urethra
  • bladder hyperactivity → anticholinergic medications to relax bladder (see Urinary Incontinence, U5)
    • if refractory
      – botulinum toxin injections into bladder wall
      – occasionally augmentation cystoplasty (enlarging bladder volume and improving compliance by grafting section of detubularized bowel onto the bladder)
      – occasionally urinary diversion (ileal conduit or continent diversion) in severe cases if bladder management unsuccessful
  • flaccid bladder → CIC

## Dysuria

### Definition
- painful urination

### Etiology

#### Table 7. Differential Diagnosis of Dysuria

<table>
<thead>
<tr>
<th>Category</th>
<th>Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infectious</td>
<td>Cystitis, urethritis, prostatitis, epididymitis/orchitis (if associated with lower tract inflammation), cervicitis, vulvovaginitis, perineal inflammation/infection, TB, vestibulitis</td>
</tr>
<tr>
<td>Neoplasm</td>
<td>Kidney, bladder, prostate, penis, vagina/vulva, BPH</td>
</tr>
<tr>
<td>Calculi</td>
<td>Bladder stone, urethral stone, ureteral stone</td>
</tr>
<tr>
<td>Inflammatory</td>
<td>Seronegative arthropathies (reactive arthritis: arthritis, uveitis, urethritis), drug side effects, autoimmune disorders, chronic pelvic pain syndrome (CPPS), interstitial cystitis</td>
</tr>
<tr>
<td>Hormonal</td>
<td>Endometriosis, hypoestrogenism</td>
</tr>
<tr>
<td>Trauma</td>
<td>Catheter insertion, post-coital cystitis (honeymoon cystitis)</td>
</tr>
<tr>
<td>Psychogenic</td>
<td>Somatization disorder, depression, stress/anxiety disorder</td>
</tr>
<tr>
<td>Other</td>
<td>Contact sensitivity, foreign body, radiation/chemical cystitis, diverticulum</td>
</tr>
</tbody>
</table>

### Investigations
- focused Hx and P/E to determine cause (fever, d/c, conjunctivitis, CVA tenderness, back/joint pain)
  - any d/c (urethral, vaginal, cervical) should be sent for gonococcus/chlamydia testing; wet mount if vaginal d/c
  - U/A and urine C&S
  - if suspect infection, may start empiric ABx treatment (see Table 9, U12)
  - ± imaging of urinary tract (tumour, stones)

## Hydronephrosis

• the upper urinary tract consists of the kidneys and ureters

### Definition
- dilation of the renal pelvis and calyces caused by the impairment in antegrade urine flow

### Etiology
- mechanical
  - congenital: see Congenital Abnormalities, U36
  - acquired
    - intrinsic: trauma, inflammation and bleeding, calculi, urologic neoplasms, BPH, urethral stricture, phimosis, previous urological surgery
    - extrinsic: trauma, neoplasms (uterine fibroid; colorectal, uterine, and cervical malignancies; lymphoma), aortic aneurysm, pregnancy (gravid uterus)
  - functional
    - neuropathic: neurogenic bladder, diabetic neuropathy, spinal cord disease
    - pharmacologic: α-adrenergic agonists
    - hormonal: pregnancy (progesterone decreases ureteral tone)

### Investigations
- focused Hx, inquiring about pain (flank, lower abdomen, testes, labia), U/O, medication use, pregnancy, trauma, fever, Hx of UTIs, calculi, PID, and urological surgery
- CBC, electrolytes, Cr, BUN, U/A, C&S
- imaging studies (U/S is >90% sensitive and specific)
  - MAG3 diuretic renogram: evaluates differential renal function and demonstrates if functional obstruction exists

### Treatment
- hydronephrosis can be physiologic
- treatment should be guided at improving symptoms, treating infections, or improving renal function
- urgent treatment may require percutaneous nephrostomy tube or ureteral stenting to relieve pressure
Overactive Bladder

Definition
- polyuria resulting from relief of severe chronic obstruction
- >3 L/24 h or >200 cc/h over each of two consecutive hours

Pathophysiology
- physiologic POD secondary to excretion of retained urea, Na+, and H2O (high osmotic load) after relief of obstruction
  - self-limiting; usually resolves in 48 h with PO fluids but may persist to pathologic POD
- pathologic POD is a Na+-wasting nephropathy secondary to impaired concentrating ability of the renal tubules due to
  - decreased reabsorption of NaCl in the thick ascending limb and urea in the collecting tubule
  - increased medullary blood flow (solute washout)
  - increased flow and solute concentration in the distal nephrons

Management
- admit patient and closely monitor hemodynamic status and electrolytes (Na+ and K+ q6-12h and replace prn; follow Cr and BUN to baseline)
- monitor U/O q2h and ensure total fluid intake <U/O by replacing every 1 mL U/O with 0.5 mL 1/2 NS IV (PO fluids if physiologic POD)
- avoid glucose-containing fluid replacement (iatrogenic diuresis)

Overactive Bladder

Definition
- a symptom complex that includes urinary urgency with or without urgency incontinence, urinary frequency (voiding ≥8 times in a 24 hr period), and nocturia (awakening ONE or more times at night to void)

Etiology
- multiple etiologies proposed
- symptoms usually associated with involuntary contractions of the detrusor muscle. The overactivity of the muscle could be neurogenic, myogenic or idiopathic

Epidemiology
- F:M= 1:1
- prevalence increases with age. 42% in males 75 years old or older; 31% in females 75 years old or older

Diagnosis
- the diagnostic process should document symptoms that define overactive bladder and exclude other disorders that could cause of the patient’s symptoms
- minimal requirements for the process consist of
  - focused history including past genitourinary disorders and conditions outlined in Table 8,
  - questionnaires of LUTS for women and diaries of urination frequency, volume and pattern
  - P/E including genitourinary, pelvic and rectal examination
  - urinalysis to rule out hematuria and infection
- in some patients, the following investigations could be considered
  - bladder scan for residual urine in patients with risk factors of urinary retention
  - cystoscopy to rule out recurrent infections, carcinoma in situ and other intravesical abnormalities
  - urodynamics to rule out obstruction in older men

Treatment
- non-pharmacological: behaviour therapies such as bladder training, bladder control strategies, pelvic floor muscle training, fluid management, and avoidance of caffeine, alcohol
- pharmacological
  - anti-muscarinics such as oxybutynin hydrochloride, tolterodine, solifenacin, fesoterodine, or trospium
  - β3-adrenoceptor agonist such as mirabegron
- refractory patients may be treated with
  - neuromuscular-junction inhibition such as botulinum toxin bladder injection
- other interventional procedures include
  - percutaneous tibial nerve stimulation (not used commonly in Canada)
  - sacral neuromodulation
Table 8. Conditions that Could Contribute to Symptoms of Overactive Bladder

<table>
<thead>
<tr>
<th>Lower Urinary Tract Conditions</th>
<th>Neurological Conditions</th>
<th>Systemic Diseases</th>
<th>Functional and Behavioural</th>
<th>Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>UTI, obstruction, impaired bladder contractility</td>
<td>Stroke, MS, dementia, diabetic neuropathy</td>
<td>CHF, sleep disorders (primarily nocturia)</td>
<td>Excessive caffeine and alcohol, constipation, impaired mobility</td>
<td>Diuretics, anticholinergic agents, narcotics, calcium-channel blocker, cholinesterase inhibitors</td>
</tr>
</tbody>
</table>

Table 9. Antibiotic Treatment of Urological Infections

<table>
<thead>
<tr>
<th>Condition</th>
<th>Drug</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urethritis</td>
<td>Non-Gonococcal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>azithromycin (1 g PO) OR doxycycline (100 mg PO bid)</td>
<td>x 1</td>
</tr>
<tr>
<td>Gonococcal</td>
<td>ceftriaxone (250 mg IM) AND treat for Chlamydia trachomatis</td>
<td>x 1</td>
</tr>
<tr>
<td>Simple, Uncomplicated UTI</td>
<td>TMP-SMX (160 mg/800 mg PO bid) OR nitrofurantoin (100 mg PO bid)</td>
<td>3 d</td>
</tr>
<tr>
<td>Complicated UTI</td>
<td>ciprofloxacin (1 g PO daily OR 400 mg IV q12h) OR ampicillin (1 g IV q6h) + gentamicin (1 mg/kg IV q8h) (used for relatively short courses because of toxicity) OR ceftriaxone (1-2 g IV q24h)</td>
<td>up to 2-3 wk</td>
</tr>
<tr>
<td>Recurrent/Chronic Cystitis</td>
<td>Prophylactic Treatment Continuous: TMP-SMX (40 mg/200 mg PO qHS OR 3x/wk) OR nitrofurantoin (50-100 mg PO qHS) Post-Coital: TMP-SMX (40 mg/200 mg-80 mg/400 mg) OR nitrofurantoin (50-100 mg PO qd)</td>
<td>6-12 mo</td>
</tr>
<tr>
<td>Acute Prostatitis</td>
<td>ciprofloxacin (500-750 mg PO bid) OR TMP-SMX (160 mg/800 mg PO bid) OR IV therapy with gentamicin and ampicillin, penicillin with β-lactamase inhibitor, 3rd gen cephalosporin, OR a fluoroquinolone</td>
<td>2-4 wk</td>
</tr>
<tr>
<td>Chronic Prostatitis</td>
<td>ciprofloxacin (500 mg PO bid)</td>
<td>4-6 wk</td>
</tr>
<tr>
<td>Epididymitis/Orchitis</td>
<td>&lt;35 yr ceftriaxone (200 mg IM) AND doxycycline (100 mg PO bid) ≥35 yr ofloxacin (300 mg PO bid)</td>
<td>x 1</td>
</tr>
<tr>
<td>Acute Uncomplicated Pyelonephritis</td>
<td>ciprofloxacin (500 mg PO bid) OR ceftriaxone (1 g IV) OR ciprofloxacin (400 mg IV) OR IV therapy with a fluoroquinolone, gentamicin and ampicillin, extended spectrum cephalosporin, extended spectrum penicillin, OR a carbapenem</td>
<td>7 d</td>
</tr>
</tbody>
</table>

Urinary Tract Infection

- for UTIs during pregnancy, see Obstetrics, OB28

Definition
- symptoms suggestive of UTI + evidence of pyuria and bacteriuria on U/A or urine C&S
- if asymptomatic + 100,000 CFU/mL = asymptomatic bacteriuria; only requires treatment in certain patients (e.g. pregnancy)
Classification
- uncomplicated: lower UTI in a setting of functionally and structurally normal urinary tract
- complicated: structural and/or functional abnormality, male patients, immunocompromised, diabetic, iatrogenic complication, pregnancy, pyelonephritis, catheter-associated
- recurrent: see Recurrent/Chronic Cystitis

Risk Factors
- stasis and obstruction
  - residual urine due to impaired urine flow e.g. PUVs, reflux, medication, BPH, urethral stricture, cystocele, neurogenic bladder
- foreign body
  - introduce pathogen or act as nidus of infection e.g. catheter, instrumentation
- decreased resistance to organisms
  - DM, malignancy, immunosuppression, spermicide use, estrogen depletion, antimicrobial use
- other factors
  - trauma, anatomic abnormalities, female, sexual activity, menopause, fecal incontinence

Clinical Features
- storage symptoms: frequency, urgency, dysuria
- voiding symptoms: hesitancy, post-void dribbling
- other: suprapubic pain, hematuria, foul-smelling urine
- pyelonephritis – if present: typically presents with more severe symptoms (e.g. fever/chills, CVA tenderness, flank pain)

Organisms
- typical organisms: KEEPS (E. coli 75-95%)
- atypical organisms
  - tuberculosis (TB)
  - Chlamydia trachomatis
  - Mycoplasma (Ureaplasma urealyticum)
  - fungi (Candida)

Indications for Investigations
- pyelonephritis
- persistence of pyuria/symptoms following adequate antibiotic therapy
- severe infection with an increase in Cr
- recurrent/persistent infections
- atypical pathogens (urea splitting organisms)
- Hx of structural abnormalities/decreased flow

Investigations
- U/A, urine C&S
  - UA: leukocytes ± nitrites ± hematuria
  - C&S: midstream, catheterized, or suprapubic aspirate
- if hematuria present, retest post-treatment, if persistent need hematuria workup (see Microscopic Hematuria, U5)
- U/S, CT scan if indicated

Prevention of UTIs
- Maintain good hydration (try cranberry juice)
- Wipe from front to back to avoid contamination of the urethra with feces from the rectum
- Avoid feminine hygiene sprays and scented douches
- Empty bladder immediately before and after intercourse

Treatment
- see Table 9, U12, Antibiotic Treatment of Urological Infections
- if febrile, consider admission with IV therapy and rule out obstruction

Recurrent/Chronic Cystitis

Definition
- ≥3 UTIs/yr

Etiology
- bacterial reinfection (80%) vs. bacterial persistence (relapse)
  - bacterial reinfection
    - recurrence of infection with either 1) a different organism, 2) the same organism if cultured >2 wk following therapy, or 3) with any organism with an intermittent sterile culture
  - bacterial persistence
    - same organism cultured within 2 wk of sensitivity-based therapy

Investigations
- assess predisposing factors as described above
- investigations may include cystoscopy, U/S, CT
Treatment
• lifestyle changes (limit caffeine intake, increase fluid/H2O intake)
• ABx: continuous vs. post-coital
• post-menopausal women: consider topical or systemic estrogen therapy
• no treatment for asymptomatic bacteriuria except in pregnant women or patients undergoing urinary tract instrumentation

Interstitial Cystitis
(Painful Bladder or Bladder Pain Syndrome)

Definition
• bladder pain, chronic urgency and frequency without other reasonable causation

Classification
• non-ulcerative (more common)
• ulcerative

Etiology
• unknown
  • theories: increased epithelial permeability, autoimmune, neurogenic, defective GAG layer overlying mucosa

Epidemiology
• prevalence: 20/100,000
• 90% of cases are in females
• mean age at onset is 40 yr (non-ulcerative tends to affect a younger to middle-aged population, while ulcerative tends to be seen in middle-aged to older)

Clinical Features
• bladder pain, increase with filling and relief with emptying
• glomerulations (submucosal petechiae) or Hunner's lesions (ulcers) on cystoscopic examination
• urinary urgency
• negative U/A, urine C&S, and urine cytology

Differential Diagnosis
• UTI, vaginitis, bladder tumour
• radiation/chemical/eosinophilic/TB cystitis
• eosinophilic/TB cystitis
• bladder calculi

Investigations
• Hx, P/E, urinalysis with microscopy

Treatment
• first-line: patient empowerment (diet, lifestyle, stress management), pain management
• second-line
  • oral: pentosan polysulfate sodium, amitriptyline, cimetidine, hydroxyzine
  • intravesical: dimethylsulfoxide (DMSO), heparin, lidocaine
• third-line: cystoscopy with bladder hydrodistention (traditionally diagnostic) under GA, treat Hunner's lesions if present
• other: neuromodulation, cyclosporine A, intradetrusor botulinum toxin
• surgery (last resort): augmentation cystoplasty, or urinary diversion ± cystectomy

Acute Pyelonephritis

Definition
• infection of the renal parenchyma with local and systemic manifestations
• clinical diagnosis of flank pain, fever and elevated WBC

Etiology
• ascending (usually GN bacilli) or hematogenous route (usually GP cocci)
• causative microorganisms
  • gram positives: Enterococcus faecalis, S. aureus, S. saprophyticus
  • intravesical: E. coli (most common), Klebsiella, Proteus, Pseudomonas, Enterobacter
• common underlying causes of pyelonephritis
  • stones, strictures, prostatic obstruction, vesicoureteric reflux, neurogenic bladder, catheters, DM, sickle-cell disease, PKD, immunosuppression, post-renal transplant, instrumentation, pregnancy
Clinical Features
- rapid onset (<24 h)
- LUTS including frequency, urgency, hematuria; NOT dysuria unless concurrent cystitis
- fever, chills, nausea, vomiting, myalgia, malaise
- CVA tenderness and/or exquisite flank pain

Investigations
- U/A, urine C&S
- CBC and differential: leukocytosis, left shift
- imaging indicated if suspicious of complicated pyelonephritis or symptoms do not improve with 48-72 h of treatment
  - abdominal/pelvic U/S
  - CT
- nuclear medicine: DMSA scan can be used to help secure the diagnosis
  - a photopenic defect indicates active infection or scar; if normal alternative diagnoses should be considered

Treatment
- hemodynamically stable
  - outpatient oral ABx treatment ± single initial IV dose (see Table 9, U12)
- severe or non-resolving
  - admit, hydrate, and treat with IV ABx (see Table 9, U12)
- emphysematous pyelonephritis
  - most patients receive nephrectomy after IV ABx started and patient stabilized
  - consider temporization with nephrostomy tubes
- renal obstruction
  - admit for emergent stenting or percutaneous nephrostomy tube

Epidemiology
- most common urologic diagnosis in men <50 yr
- prevalence 2-12%

Classification

Table 10. Comparison of the Three Types of Prostatitis

<table>
<thead>
<tr>
<th>Category I: Acute Bacterial Prostatitis</th>
<th>Category II: Chronic Bacterial Prostatitis</th>
<th>Category III: Chronic Pelvic Pain Syndrome (CPPS) (Abacterial)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etiology</td>
<td>Recurrent exacerbations of acute prostatitis-like signs and symptoms Recurrent UTI with same organism</td>
<td>Divided into inflammatory (IIIA) and non-inflammatory (IIIB) Intraprostatic reflux of urine ± urethral hypertension Multifactorial (immunological, neuropathic, neuroendocrine, psychosocial)</td>
</tr>
<tr>
<td>Clinical Features</td>
<td>Pelvic pain, storage LUTS, ejaculatory pain, post- ejaculatory pain</td>
<td>Pelvic pain, storage LUTS, ejaculatory pain, post- ejaculatory pain</td>
</tr>
<tr>
<td>Investigations</td>
<td>E: as per Category I + pelvic floor Urine C&amp;S: 4-glass test VB1 (voided bladder): initial (urethra) P/VB2: midstream (bladder) EPS (expressed prostatic secretions): not usually performed VB3: post-massage/DRE</td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td>Same as per Category II NIH-CPSI score* Consider psychological assessment</td>
<td></td>
</tr>
</tbody>
</table>

* NIH-CPSI: National Institute of Health Chronic Prostatitis Symptom Index

Cystoscopic evaluation is not necessary to make a diagnosis. Nitrofurantoin has poor tissue penetration and therefore is not used to treat pyelonephritis (requires post-renal uroconcentration)

**Prostatitis/Prostatodynia**

4-Glass Test: Prostatic source is suggested when colony counts in EPS and VB3 exceed those of VB1 and VB2 by 10x

It is not recommended to do a serum PSA during acute bacterial prostatitis

Phytotherapy (quercetin, cernilton)

Anti-inflammatories

Supportive measures

Trial of ABx therapy if newly diagnosed Multimodal treatment strategy may include: β-blocker Anti-inflammatories Phytotherapy (quercetin, cernilton)
Epididymitis and Orchitis

Etiology
• common infectious causes
  ■ <35 yr: N. gonorrhoeae or Chlamydia trachomatis
  ■ ≥35 yr or penetrative anal intercourse: GI organisms (especially E. coli)
• other causes
  ■ mumps infection may involve orchitis, post-parotitis
  ■ TB
  ■ syphilis
  ■ granulomatous (autoimmune) in elderly men
  ■ amiodarone (involves only head of epididymis)
• chemical: reflux of urine into ejaculatory ducts

Risk Factors
• UTI
• unprotected sexual contact
• instrumentation/catheterization
• increased pressure in prostatic urethra (straining, voiding, heavy lifting) may cause reflux of urine along vas deferens → sterile epididymitis
• immunocompromise

Clinical Features
• sudden onset scrotal pain and swelling ± radiation along cord to flank
• scrotal erythema and tenderness
• fever
• storage symptoms, purulent d/c
• reactive hydrocele

Investigations
• U/A, urine C&S
• ± urethral d/c: Gram stain/culture
• if diagnosis uncertain, must do
  ■ colour-flow Doppler U/S to rule out testicular torsion

Treatment
• rule out torsion (see Investigations Table 24, U29)
• see Table 9, U12 for ABx therapy
• scrotal support, bed rest, ice, analgesia

Complications
• if severe → testicular atrophy
• 30% have persistent infertility problems

Urethritis

Etiology
• infectious or inflammatory (e.g. reactive arthritis)

Table 11. Infectious Urethritis: Gonococcal vs. Non-Gonococcal

<table>
<thead>
<tr>
<th>Causative Organism</th>
<th>Diagnosis</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neisseria gonorrhoeae</td>
<td>Hx of sexual contact, thick, profuse, yellow-grey purulent d/c, LUTS Gram stain (GN diplococci), urine PCR and/or culture from urethral specimen</td>
<td>See Table 9, U12</td>
</tr>
<tr>
<td>Usually Chlamydia trachomatis</td>
<td>Hx of sexual contact, mucoid whitish purulent d/c, + storage LUTS Gram stain demonstrates &gt;4 PMN/oil immersion field, no evidence of N. gonorrhoeae, urine PCR and/or culture from urethral specimen</td>
<td>See Table 9, U12</td>
</tr>
</tbody>
</table>

Prehn’s Sign: pain may be relieved with elevation of testicles in epididymitis but not in testicular torsion (poor sensitivity, especially in children)

If unsure between diagnoses of epididymitis and torsion, always go to OR
Remember: torsion >6 h has poor prognosis

Inadequately treated acute epididymitis may lead to chronic epididymitis or epididymo-orchitis

Reactive Arthritis (formerly known as Reiter’s syndrome)
Urethritis, uveitis (or conjunctivitis), and arthritis (can’t pee, can’t see, can’t climb a tree)

If culture negative or unresponsive to treatment consider: Ureaplasma urealyticum, Mycoplasma genitalium, Trichomonas vaginalis, HSV, or adenovirus
Epidemiology
- prevalence: ~8% and increasing
- M:F = 2:1
- peak incidence 30-50 yr of age
- recurrence rate: 10% at 1 yr, 50% at 5 yr, 60-80% lifetime

Risk Factors
- hereditary: RTA, Glucose-6-phosphate dehydrogenase deficiency, cystinuria, xanthinuria, oxaluria, etc.
- lifestyle: minimal fluid intake; excess vitamin C, oxalate, purines, calcium
- medications: loop diuretics (furosemide, bumetanide), acetazolamide, topiramate, zonisamide, indinavir, acyclovir, sulfadiazine, triamterene
- medical conditions: UTI (with urea-splitting organisms: Proteus, Pseudomonas, Providencia, Klebsiella, Mycoplasma, Serratia, S. aureus), myeloproliferative disorders, IBD, gout, DM, hypercalcemia disorders (hyperparathyroidism, tumour lysis syndrome, sarcoidosis, histoplasmosis), obesity (BMI >30)

Clinical Features
- urinary obstruction → upstream distention → pain
  - flank pain from renal capsular distention (non-colicky)
  - severe waxing and waning pain radiating from flank to groin, testis, or tip of penis due to stretching of collecting system or ureter (ureteral colic)
  - writhing, never comfortable, nausea, vomiting, hematuria (90% microscopic), diaphoresis, tachycardia, tachypnea
- occasionally symptoms of trigonal irritation (frequency, urgency)
- bladder stones result in: storage and voiding LUTS, terminal hematuria, suprapubic pain
- if fever, rule out concurrent pyelonephritis and/or obstruction

Table 12. Differential Diagnosis of Renal Colic

<table>
<thead>
<tr>
<th>GU</th>
<th>Abdominal</th>
<th>Neurological</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pyelonephritis</td>
<td>AAA</td>
<td>Radiculitis (L1): herpes zoster, nerve root compression</td>
</tr>
<tr>
<td>Ureteral obstruction from other cause: UPJ</td>
<td>Bowel ischemia</td>
<td></td>
</tr>
<tr>
<td>obstruction, clot colic secondary to gross hematuria, sloughed papillae</td>
<td>Pancreatititis</td>
<td></td>
</tr>
<tr>
<td>Gynecological: ectopic pregnancy, torsion/rupture of ovarian cyst, PID</td>
<td>Other acute abdominal crisis (appendicitis, cholecystitis, diverticulitis)</td>
<td></td>
</tr>
</tbody>
</table>

Location of Stones
- calyx: may cause flank discomfort, persistent infection, persistent hematuria, or remain asymptomatic
- pelvis: tend to cause obstruction at UPJ, may cause persistent infection
- ureter: <5 mm diameter will pass spontaneously in 75% of patients

Stone Pathogenesis
- supersaturation of stone constituents (at appropriate temperature and pH)
- stasis, low flow, and low volume of urine (dehydration)
- crystal formation and stone nidus
- loss of inhibitory factors
  - citrate (forms soluble complex with calcium)
  - magnesium (forms soluble complex with oxalate)
  - pyrophosphate
  - Tamm-Horsfall glycoprotein

Key Points in Stone Hx
- Diet (especially FLUID INTAKE)
- Predisposing medical conditions
- Predisposing medications
- Previous episodes/investigations/treatments
- Family Hx (1st degree relative)
**Approach to Renal Stones**

**Investigations**

**Table 13. Investigations for Renal Stones**

<table>
<thead>
<tr>
<th>Who gets it?</th>
<th>CBC, Uric Acid, U/A, Urine C&amp;S</th>
<th>KUB x-ray</th>
<th>CT Scan</th>
<th>Abdominal Ultrasound</th>
<th>Cystoscopy</th>
<th>PTH, 24 h urine x 2 for volume, Cr, Ca(^{2+}), Na(^{+}), PO(^{4-}), Mg(^{2+}), oxalate, citrate, ± cystine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Why is it done?</td>
<td>May show signs of infection, ± sensitivities</td>
<td>90% of stones are radiopaque Good for follow-up</td>
<td>Distinguish radiolucent stone from soft tissue filling defect X-ray comparison</td>
<td>Identify and follow-up stone without radiation exposure Visualize hydronephrosis</td>
<td>Visualize bladder</td>
<td>Need to rule out metabolic cause for stones</td>
</tr>
<tr>
<td>Cautions</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

**Cautions**
- Do not mistake phleboliths for stones!
- Radiation (especially if female of child bearing age) Must be a non-contrast scan
- Do not mistake bladder for stones!

**Indications for Admission to Hospital**
- Intractable pain
- Intractable vomiting
- Fever (suggests infection)
- Compromised renal function (including single kidney, bilateral obstructing stone)
- Pregnancy

**Indications for PCNL**
- Size >2 cm
- Staghorn
- UPJ obstruction with correction of obstruction
- Calyceal diverticulum
- Cystine stones (poorly fragmented with ESWL)
- Anatomical abnormalities
- Failure of less invasive modalities

**Treatment – Acute**
- medical
  - analgesic ± antiemetic
  - NSAIDs help lower intra-ureteral pressure
  - medical expulsion therapy (MET)
    - α-blockers: increase rate of spontaneous passage in distal ureteral stones
    - ± Abs for bacteriuria
    - IV fluids if vomiting (note: IV fluids do NOT promote stone passage)
- interventional
  - required if obstruction endangers patient, e.g. sepsis, renal failure
  - first line: ureteric stent (via cystoscopy)
  - second line: image-guided percutaneous nephrostomy
- admit if necessary
  - *Indications for Admission to Hospital*

**Treatment – Elective**
- medical
  - likely conservative if ureteral stone <10 mm or kidney stone <5 mm and no complications/symptoms well controlled
    - stones <5 mm especially likely to pass spontaneously
  - PO fluids to increase urine volume to >2 L/d (3–4 L if cystine) and MET
  - specific to stone type (see Table 14)
  - periodic imaging to monitor stone position and assess for hydronephrosis
  - progress to interventional stone removal methods if symptoms worsen or fail to improve (indicating stone passage)

**Stones and Infection**
- If septic, urgent decompression via ureteric stent or percutaneous nephrostomy is indicated. Definitive treatment of the stone should be delayed until the sepsis has cleared

**Dissolution therapy**
- Uric acid stone
- Non-urate acid stone
- ESWL
- Nephrostomy

**Approach to renal stone**

Figure 8. Approach to renal stone

Although hypercalciuria is a risk factor for stone formation, decreasing dietary calcium is NOT recommended to prevent stone formation. Low dietary calcium leads to increased GI oxalate absorption and higher urine levels of calcium oxalate

24 h urine collections must be done AFTER discontinuing stone preventing/promoting medications

Detailed metabolic studies are NOT recommended unless complex patient (recurrent stone formers, pregnancy, pediatrics, strong family Hx, underlying kidney or systemic disease, etc.)

Discontinue stone preventing/promoting medications

Indications for Admission to Hospital
- Intractable pain
- Intractable vomiting
- Fever suggests infection
- Compromised renal function (including single kidney, bilateral obstructing stone)
- Pregnancy
• interventional
  ■ kidney
    ◆ may stent prior to ESWL if stone is 1.5-2.5 cm
    ◆ ESWL if stone <2 cm
    ◆ PCNL if stone >2 cm
  ■ ureteral stones >10 mm
  • ESWL and URS are both first line treatment modalities for all locations
    – URS has significantly greater stone-free rates for stones at all locations in ureter, but also has higher complication rates (ureter perforation, stricture formation, etc.)
  • PCNL is second line treatment
  • laparoscopic or open stone removal (very rare)
  • bladder
    ◆ transurethral stone removal or cystolitholapaxy
    ◆ remove outflow obstruction (TURP or stricture dilatation)

**Prevention**
• dietary modification
  ■ increase fluid (>2 L/d), K+ intake
  ■ reduce animal protein, oxalate, Na+, sucrose, and fructose intake
  ■ avoid high-dose vitamin C supplements
• medications
  ■ thiazide diuretics for hypercalciuria
  ■ allopurinol for hyperuricosuria
  ■ potassium citrate for hypocitraturia, hyperuricosuria

**Table 14. Stone Classification**

<table>
<thead>
<tr>
<th>Type of Stone</th>
<th>Calcium (75-85%)</th>
<th>Uric Acid (5-10%)</th>
<th>Struvite (5-10%)</th>
<th>Cystine (1%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etiology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypercalciuria</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperuricosuria (25% of patients with Ca2+ stones)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperoxaluria (&lt;5% of patients)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypocitraturia (12% of patients)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other causes:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypermagnesemia – associated with hyperoxaluria and hypocitraturia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High dietary Na+</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased urinary proteins</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High urinary pH, low urine volume (e.g. GI water loss)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperparathyroidism, obesity, gout, DM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uric acid precipitates in low volume, acidic urine with a high uric acid concentration:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperuricosuria alone</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drugs (ASA, thiazides)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diet (purine rich red meats)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperuricosuria with hyperuricemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gout</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High rate of cell turnover or cell death (leukemia, cytotoxic drugs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infection with urea-splitting organisms (Proteus, Pseudomonas, Providencia, Klebsiella, Mycoplasma, Serratia, S. aureus) results in alkaline urinary pH and precipitation of struvite (magnesium ammonium phosphate)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autosomal recessive deficit in small bowel mucosal absorption and renal tubular absorption of dibasic amino acids results in &quot;COLA&quot; in urine (cystine, oromithine, lysine, arginine)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Key Features**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Medical if stone &lt;5 mm and no complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procedure/Surgical treatment if stone &gt;5 mm or presence of complications</td>
<td>Fluids to increase urine volume to &gt;2 L/d For calcium stones: cellulose phosphate, orthophosphate for absorptive causes Calcium oxalate: thiazides, ± potassium citrate, ± allopurinol Calcium struvite: ABx (stone must be removed to treat infection)</td>
</tr>
<tr>
<td>Increased fluid intake</td>
<td>Alkalization of urine to pH 6.5 to 7 (bicarbonate, potassium citrate) ± allopurinol</td>
</tr>
<tr>
<td>Complete stone clearance</td>
<td>ABx for 6 wk Regular follow-up urine cultures</td>
</tr>
<tr>
<td>Increased fluid intake (3-4 L of urine/d)</td>
<td>Alkalize urine (bicarbonate, potassium citrate), Penicillin/α-MPG or Captotril (form complex with cystine) ESWL not effective</td>
</tr>
</tbody>
</table>

**Alpha-blockers as Medical Expulsive Therapy for Ureteral Stones**

Cochrane Database Syst Rev 2014;4:CD008509

**Purpose:** To determine whether or not alpha-blockers compared with other pharmacological treatments or placebo improve stone clearance rates and other clinically relevant outcomes in patients presenting with symptoms of stones less than 10mm confirmed by imaging.

**Results/Conclusions:** 32 RCTs, 5,184 participants. Although patients using alpha-blockers were more likely to experience adverse effects compared to standard therapy, stone-free rates were significantly higher in the alpha-blocker group (RR 1.48, 95% CI 1.33-1.64), expulsive time was 2.91 days shorter, and there was a reduction in the number of pain episodes (MD -0.48, 95% CI -0.94 to -0.01), the need for analgesic medication (MD -38.17, 95% CI -74.93 to -1.41), and hospitalization (RR 0.35, 95% CI 0.13-0.87). Alpha blockers should therefore be offered as a primary treatment modality for ureteral stones.
Urological Neoplasms

Approach to Renal Mass

Figure 9. Workup of a renal mass

*Imaging modality may be different in cases of contrast allergy or elevated creatinine

Benign Renal Neoplasms

CYSTIC KIDNEY DISEASE

- simple cyst: usually solitary or unilateral
  - very common: up to 50% at age 50
  - usually incidental finding on abdominal imaging
  - Bosniak Classification is used to stratify for risk of malignancy based on cyst features from contrast CT

- polycystic kidney disease
  - autosomal recessive: multiple bilateral cysts, often leading to early renal failure in infants
  - autosomal dominant: progressive bilateral disease leading to HTN and renal failure, adult-onset

- medullary sponge kidney: cystic dilatation of the collecting ducts
  - usually benign course, but patients are predisposed to stone disease

- von Hippel-Lindau syndrome: multiple bilateral cysts or clear cell carcinomas (50% incidence of RCC)
  - renal cysts, cerebellar, spinal and retinal hemangioblastomas, pancreatic and epididymal cysts, pheochromocytomas

Table 15. Bosniak Classification of Renal Cysts

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
<th>Features</th>
<th>Risk of Malignancy</th>
<th>Management Plan</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Simple cyst</td>
<td>Round, no septations, no calcifications, no solid component</td>
<td>Near zero</td>
<td>Follow-up usually not required</td>
</tr>
<tr>
<td>II</td>
<td>Simple cyst</td>
<td>A few thin septa, no true enhancement, well-margined, uniform high attenuation, &lt;3 cm</td>
<td>Minimal</td>
<td>Follow-up usually not required</td>
</tr>
<tr>
<td>IIF</td>
<td>Minimally complex cyst with extra features that require follow-up</td>
<td>Still well-marginated and non-enhancing, but now multiple thin septa or some thickening/calcification of septa/wall, &gt;3 cm</td>
<td>5-20%</td>
<td>Requires follow-up with imaging q6-12mo If the lesion evolves, may require surgical resection</td>
</tr>
<tr>
<td>III</td>
<td>Complex cyst</td>
<td>Thicker or more irregular walls with measurable enhancement</td>
<td>&gt;50%</td>
<td>Requires surgical resection</td>
</tr>
<tr>
<td>IV</td>
<td>Clearly malignant</td>
<td>Class III + enhancing soft-tissue components</td>
<td>&gt;90%</td>
<td>Requires surgical resection</td>
</tr>
</tbody>
</table>
Table 16. Benign Renal Masses

<table>
<thead>
<tr>
<th>Angiomyolipoma (Renal Hamartoma)</th>
<th>Renal Oncocytoma</th>
<th>Renal Adenoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidemiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1% of adult renal tumours</td>
<td>3-7% of renal tumours</td>
<td>Most common benign renal neoplasm</td>
</tr>
<tr>
<td>F&gt;M 20% associated with tuberous sclerosis (especially if multiple, recurrent)</td>
<td>M&gt;F Oncocytomas also found in adrenal, thyroid and parathyroid glands</td>
<td>M:F = 3:1</td>
</tr>
<tr>
<td>Characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clonal neoplasm consisting of blood vessels (angio-), smooth muscle (-myo-), and fat (-lipoma)</td>
<td>Spherical, capsulated with possible central scar Histologically organized aggregates of eosinophilic cells originating from intercalated cells of collecting duct</td>
<td>Small cortical lesions &lt; 1 cm Majority are solitary but can be multifocal</td>
</tr>
<tr>
<td>May extend into regional lymphatics and other organs and become symptomatic</td>
<td>Incidental finding on CT Difficult to distinguish from RCC on imaging – treated as RCC until proven otherwise</td>
<td>Incidental finding on CT Rarely symptomatic Controversy as to whether this represents benign or pre-malignant neoplasm</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative attenuation (&lt;20 HU) on CT is pathognomonic Rare presentation of hematuria, flank pain, and palpable mass (same as RCC)</td>
<td>Incidental finding on CT</td>
<td>If mass &gt;3 cm, likely not a benign adenoma; will require partial/radical nephrectomy due to increased likelihood of malignancy</td>
</tr>
<tr>
<td>Management</td>
<td>Partial/radical nephrectomy for large masses HIFU or RFA for smaller masses</td>
<td></td>
</tr>
<tr>
<td>May consider surgical excision or embolization if symptomatic (pain, bleeding) or higher risk of bleeding (e.g. pregnancy) Potential role for mTOR inhibitors in unresectable/metastatic disease Follow with serial U/S</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Malignant Renal Neoplasms

RENAL CELL CARCINOMA

Etiology
- cause unknown
- originates from proximal convoluted tubule epithelial cells in clear cell subtype (most common)
- hereditary forms seen with von Hippel-Lindau syndrome and hereditary papillary renal carcinoma

Epidemiology
- 85% of primary malignant tumours in kidney
- M:F = 3:2
- peak incidence at 50-60 yr of age

Pathology
- histological subtypes: clear cell (75-85%), papillary (10-15%), chromophobic (5-10%), collecting duct sarcomatoidal elements in any subtype is a poor prognostic factor

Risk Factors
- top 3 risk factors: smoking, HTN, obesity
- miscellaneous: horseshoe kidney, acquired renal cystic disease
- role of environmental exposures (aromatic hydrocarbons, etc.) remains an unproven risk factor for development of RCC

Clinical Features
- usually asymptomatic: frequently diagnosed incidentally by U/S or CT
- poor prognostic indicators: weight loss, weakness, anemia, bone pain
- classic “too late triad” found in 10-15% gross hematuria 50% flank pain <50% palpable mass <30%
- was called the “internist’s tumour” because of paraneoplastic symptomatology – now called the “radiologist's tumour” because of incidental diagnosis via imaging
- metastases: seen in a 1/3 of new cases; additional 20-40% will go on to develop metastases (mostly for late presentations or large tumours)
- bone, brain, lung and liver most common site
- may invade renal veins and inferior vena cava lumen. This may result in ascites, hepatic dysfunction, right atrial tumour, and pulmonary emboli

Investigations
- routine labs for paraneoplastic syndromes (CBC, ESR, LFTs, extended electrolytes)
- U/A
- renal U/S: solid vs. cystic lesion
- contrast-enhanced CT: higher sensitivity than U/S for detection of renal masses and for staging purposes
- MRE: useful for evaluation of vascular extension
- renal biopsy: to confirm diagnosis if considering observation or other non-surgical therapy

Staging
- involves CT, CXR, liver enzymes and LFTs, bone/head imaging (if symptoms dictate)
Table 17. 2010 TNM Classification of Renal Cell Carcinoma

<table>
<thead>
<tr>
<th>T</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1</td>
<td>tumour &lt; 7 cm, confined to renal parenchyma</td>
<td>N0: no regional lymph node metastasis</td>
</tr>
<tr>
<td>T1a</td>
<td>&lt; 4 cm</td>
<td>N1: metastasis in regional lymph nodes</td>
</tr>
<tr>
<td>T1b</td>
<td>4-7 cm</td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>tumour &gt; 7 cm, confined to renal parenchyma</td>
<td></td>
</tr>
<tr>
<td>T2a</td>
<td>7-10 cm</td>
<td></td>
</tr>
<tr>
<td>T2b</td>
<td>&gt; 10 cm</td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>tumour extends into major veins or perinephric tissues, but NOT into ipsilateral adrenal or beyond Gerota’s fascia</td>
<td>T3a: into renal vein or sinus fat</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T3b: into infradiaphragmatic IVC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T3c: into supradiaphragmatic IVC</td>
</tr>
<tr>
<td>T4</td>
<td>tumour extends beyond Gerota’s fascia including extension into ipsilateral adrenal</td>
<td>T4a: invading adrenal gland, not into vertebral bodies or diaphragm</td>
</tr>
</tbody>
</table>

**Treatment**

- **surgical**
  - radical nephrectomy: en bloc removal of kidney, tumour, ipsilateral adrenal gland (in upper pole tumours) and intact Gerota’s capsule and paraaortic lymphadenectomy
  - partial nephrectomy (parenchyma-sparing): small tumour (roughly <4 cm) or solitary kidney/ bilateral tumours
  - surgical removal of solitary metastasis may be considered
  - ablative techniques (cryoablation, RFA)
  - palliative radiation to painful bony lesions
  - therapy for advanced stage
    - tyrosine kinase inhibitors for metastatic disease (e.g. sunitinib, sorafenib)
    - anti-angiogenesis/anti-VEGF (e.g. bevacizumab)
    - mTOR inhibitors (e.g. temsirolimus, everolimus)
    - high-dose IL-2 (high toxicity but able to induce long-term cure in 5-7% of patients)
    - IFN-α: monotherapy has been largely replaced by molecularly targeted agents listed above

**Prognosis**

- stage at diagnosis most important prognostic factor
- T1: 90-100% 5 yr survival
- T2-T3: 60% 5 yr survival
- metastatic disease: <5% 10 yr survival

**Carcinoma of the Renal Pelvis and Ureter**

**Etiology**

- risk factors include
  - smoking
  - chemical/dietary exposures (industrial dyes and solvents; aristolochic acid)
  - analgesic abuse (acetaminophen, ASA, and phenacetin)
  - smoking

**Epidemiology**

- rare: accounts for 5% of all urothelial cancers
  - frequently multifocal, 2-5% are bilateral
  - M:F = 3:1
  - relative incidence: bladder:renal ureter = 100:10:1

**Pathology**

- 85% are papillary urothelial carcinoma; others include SCC and adenocarcinoma
- UCC of ureter and renal pelvis are histologically similar to bladder UCC

**Clinical Features**

- gross/microscopic hematuria
- flank pain
- storage or voiding symptoms (dysuria only if lower urinary tract involved)
- flank mass ± hydronephrosis (10-20%)

**Investigations**

- IVP/CT urogram
- cystoscopy and retrograde pyelogram

**Treatment**

- radical nephroureterectomy with cuff of bladder
- distal ureterectomy for distal ureteral tumours with concomitant ureteral reimplant
- emerging role for endoscopic laser ablation in patients with low grade disease, poor baseline renal health
Bladder Carcinoma

Etiology
- unknown, but environmental risk factors include
  - smoking (main factor – implicated in 60% of new cases)
  - aromatic amines: naphthylamines, benzidine, tryptophan, phenacetin metabolites
  - cyclophosphamide
  - prior Hx of radiation treatment to the pelvis
  - Schistosoma hematoabium infection (associated with SCC)
  - chronic irritation: cystitis, chronic catheterization, bladder stones (associated with SCC)
  - aristolochic acid: associated with Balkan Nephropathy (renal failure, upper tract urothelial cancer)
  - and Chinese Herbal Nephropathy

Epidemiology
- 2nd most common urological malignancy
- M:F = 3:1, more common among whites than blacks
- mean age at diagnosis is 65 yr

Pathology
- classification
  - urothelial carcinoma (UC) >90%
  - SCC 5-7%
  - adenocarcinoma 1%
  - others <1%
- stages and prognoses of urothelial carcinoma at diagnosis
  - non-muscle invasive (75%) → >80% overall survival
    - 15% of these will progress to invasive UCC
    - the majority of these patients will have recurrence
  - invasive (25%) → 50-60% 5 yr survival
    - 85% have no prior Hx of superficial UCC (i.e. de novo)
    - 50% have occult metastases at diagnosis, and most of these will develop overt clinical evidence of metastases within 1 yr – lymph nodes, lung, peritoneum, liver
- carcinoma in situ → flat, non-papillary erythematous lesion characterized by dysplasia confined to urothelium
  - more aggressive, worse prognosis
  - usually multifocal
  - may progress to invasive UCC

Clinical Features
- asymptomatic (20%)
- hematuria (key symptom: 85-90% at the time of diagnosis)
- pain (50%) → location determined by size/extent of tumour (i.e. flank, suprapubic, perineal, abdominal, etc.)
- clot retention (17%)
- storage urinary symptoms → consider carcinoma in situ
- palpable mass on bimanual exam → likely muscle invasion
- obstruction of ureters → hydronephrosis and uremia (nausea, vomiting, and diarrhea)

Investigations
- U/A, urine C&S, urine cytology
- Ultrasound
- CT scan with contrast → look for filling defect
- cystoscopy with biopsy (gold standard)
- biopsy to establish diagnosis and to determine depth of penetration
- specific bladder tumour markers (e.g. NMP-22, BTA, Immunocyt, FDP)

Grading
- low grade: <=10% invasive, 60% recur
- high grade: 50-80% are invasive or should progress to invasive over time

Staging
- for invasive disease: CT or MRI, CXR, LFTs, extended electrolytes (Ca^2+, Mg^2+, PO_4^3-) (metastatic workup)
### Table 18. 2010 TNM Classification of Bladder Carcinoma

<table>
<thead>
<tr>
<th>T</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX:   Primary tumour cannot be assessed</td>
<td>NX: Lymph nodes cannot be assessed</td>
<td>M0: No distant metastasis</td>
</tr>
<tr>
<td>T0:   No evidence of primary tumour</td>
<td>NO: No lymph node metastasis</td>
<td>M1: Distant metastasis</td>
</tr>
<tr>
<td>T1:   Tumour invades subepithelial connective tissue</td>
<td>N1: Single regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac, or presacral lymph node)</td>
<td></td>
</tr>
<tr>
<td>T2a: Tumour invades muscularis propria</td>
<td>N2: Multiple regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac, or presacral lymph node metastasis)</td>
<td></td>
</tr>
<tr>
<td>T2b: Tumour invades deep muscularis propria (outer half)</td>
<td>N3: Lymph node metastasis to the common iliac lymph nodes</td>
<td></td>
</tr>
<tr>
<td>T3:   Tumour invades perivesical tissue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T3a: Microscopically</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T3b: Macroscopically (extravesical mass)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T4:   Tumour invades any of the following: prostatic stroma, seminal vesicles, uterus, vagina, pelvic wall, abdominal wall</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T4a: Tumour invades prostatic stroma, uterus, vagina</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T4b: Tumour invades pelvic wall, abdominal wall</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Figure 11. Urothelial carcinoma of bladder**

**Treatment**
- superficial (non-muscle invasive) disease: Tis, Ta, T1
  - low-grade disease
    - single dose mitomycin C within 24 hours of resection reduces recurrence rates
  - high-grade
    - TURBT ± intravesical chemotherapy (e.g. BCG, mitomycin C) to decrease recurrence rate
    - maintenance with intravesical chemotherapy with BCG for 3 cycles every 3 mo, may be continued for 2-3 yr
- invasive disease: T2a, T2b, T3
  - radical cystectomy + pelvic lymphadenectomy with urinary diversion (e.g. ileal conduit, Indiana pouch, ileal neobladder) or TURBT + chemoradiation (bladder sparing) for small tumours with non-obstructed ureters
  - neo-adjuvant chemotherapy prior to cystectomy may also be done
  - use of adjuvant chemotherapy after definitive local treatment is controversial
- advanced/metastatic disease: T4a, T4b, N+, M+
  - initial combination of systemic chemotherapy ± irradiation ± surgery

**Prognosis**
- depends on stage, grade, size, number of lesions, recurrence and presence of CIS
  - T1: 90% 5 yr survival
  - T2: 55% 5 yr survival
  - T3: 30% 5 yr survival
  - T4/N+/M+: <5% 5 yr survival

### Prostate Cancer

**Etiology**
- not known
- risk factors
  - increased incidence in persons of African descent
  - high dietary fat = 2x risk
  - family Hx
    - 1st degree relative = 2x risk
    - 1st and 2nd degree relatives = 9x risk

**Figure 12. Ileal conduit, Indiana pouch, ileal neobladder**
Epidemiology
- most prevalent cancer in males
- 3rd leading cause of male cancer deaths (following lung and colon)
- up to 50% risk of CaP at age 50
- lifetime risk of death from CaP is 3%
- 75% diagnosed between ages of 60 and 85; mean age at diagnosis is 72

Pathology
- adenocarcinoma
  - >95%, often multifocal
- urothelial carcinoma of the prostate (4.5%)
  - associated with UCC of bladder; does NOT follow TNM staging below; not hormone-responsive
- endometrial (rare)
  - carcinoma of the utricle

Anatomy (see Figure 7, U7)
- 60-70% of nodules arise in the peripheral zone
- 10-20% arise in the transition zone
- 5-10% arise in the central zone

Clinical Features
- usually asymptomatic
- most commonly detected by DRE, elevated PSA, or as an incidental finding on TURP
  - DRE: hard irregular nodule or diffuse dense induration involving one or both lobes
  - PSA: see Prostate Cancer Screening, U26
- locally advanced disease
  - storage and voiding symptoms, ED (all uncommon without spread)
  - metastatic disease
    - bony metastases to axial skeleton common
    - visceral metastases are less common (liver, lung, and adrenal gland most common sites)
    - leg pain and edema with nodal metastases obstructing lymphatic and venous drainage

Methods of Spread
- local invasion
- lymphatic spread to regional nodes
  - obturator > iliac > presacral/para-aortic
- hematogenous dissemination occurs early

Investigations
- DRE
- PSA elevated in the majority of patients with CaP
- TRUS-guided needle biopsy
- bone scan may be omitted in untreated CaP with PSA <10 ng/mL
- CT scanning to assess metastases
- MRI: being investigated for possible role in detection, staging, MRI-guided biopsying and active surveillance

Table 19. 2010 TNM Classification of Prostate Carcinoma

<table>
<thead>
<tr>
<th>T</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1a: clinically undetectable tumour, normal DRE and TRUS</td>
<td>NX: regional lymph nodes were not assessed</td>
<td>M0: no distant metastasis</td>
</tr>
<tr>
<td>T1b: tumour incidental histologic finding in &lt;5% of tissue resected</td>
<td>NO: no regional lymph node metastasis</td>
<td>M1a: nonregional lymph nodes</td>
</tr>
<tr>
<td>T1c: tumour identified by needle biopsy (due to elevated PSA level)</td>
<td>N1: spread to regional lymph nodes</td>
<td>M1b: bone(s)</td>
</tr>
<tr>
<td>T2: palpable, confined to prostate</td>
<td></td>
<td>M1c: other site(s) with or without bone disease</td>
</tr>
<tr>
<td>T2a: tumour involving &lt; one half of one lobe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T2b: tumour involving &gt; one half of one lobe, but not both lobes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T2c: tumour involving both lobes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T3: tumour extends through prostate capsule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T3a: extracapsular extension (unilateral or bilateral)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T3b: tumour invading seminal vesicle(s)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T4: tumour invades adjacent structures (besides seminal vesicles)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 20. Prostate Cancer Mortality Risk

<table>
<thead>
<tr>
<th>Low Risk</th>
<th>Intermediate Risk</th>
<th>High Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSA</td>
<td>(if any of following)</td>
<td>(if any of following)</td>
</tr>
<tr>
<td>&lt;10</td>
<td>10-20</td>
<td>&gt;20</td>
</tr>
<tr>
<td>Gleason Score</td>
<td>7</td>
<td>8-10</td>
</tr>
<tr>
<td>Stage</td>
<td>pT1-2a</td>
<td>pT2b-T2c</td>
</tr>
</tbody>
</table>
Treatment

- T1/T2 (localized, low-risk)
  - if adequate life expectancy or no other significant comorbidities, consider active surveillance vs. definitive local treatment (RP, brachytherapy, or EBRT)
  - active surveillance for low risk, small volume Gleason 6 prostate cancer
  - no difference in cure rate between definitive treatment modalities
  - in older population: watchful waiting + palliative treatment for symptomatic progression

- T1/T2 (intermediate or high-risk)
  - definitive therapy over active surveillance

- T3, T4
  - EBRT + androgen deprivation therapy or RP + adjuvant EBRT

- N >0 or M >0
  - requires hormonal therapy/palliative radiotherapy for metastases; may consider combined androgen blockade
  - bilateral orchiectomy – removes 90% of testosterone
  - GnRH agonists (e.g. leuprolide, goserelin)
  - GnRH antagonist (e.g. degarelix)
  - estrogens (e.g. diethylstilbestrol [DES])
  - antiandrogens (e.g. bicalutamide)
  - local irradiation of painful secondaries or half-body irradiation

- hormone-refractory prostate cancer
  - chemotherapy: docetaxel, cabazitaxel, sipuleucel-T

Prostate Cancer Screening

Digital Rectal Exam

- should be included as part of initial screening
- suspicious findings: abnormal feeling, nodularity, focal lesion, discrete change in texture/fullness/symmetry

Prostate Specific Antigen

- glycoprotein produced by epithelial cells of prostate gland
- leaks into circulation in setting of disrupted glandular architecture
- value of <4 ng/mL traditionally considered as cut-off to differentiate normal from pathologic value, but no single justifiable cutpoint
- measured serum PSA is a combination of free (15%) and bound PSA (85%)
- PSA velocity, PSA density, and frectotal PSA: all intended to increase sensitivity and specificity of serum PSA values
- association of increased CaP rates with decreased free are total PSA, elevated PSA velocity and density

Screening Recommendations

- conflicting evidence regarding mortality reduction with PSA-based screening and debate regarding overdiagnosis/overtreatment
- Long-Term Care and United States Preventative Services Task Force all recommend against PSA testing as a population-wide screening tool
• however, serum PSA screening recommended in any man with >10 yr life-expectancy and any of the following
  ■ suspicious finding on DRE
  ■ moderate-severe LUTS
  ■ high risk individuals
  ■ investigating secondary carcinoma of unknown origin to rule out CaP as primary

**Canadian Urological Association Guidelines (2011) re: CaP Screening**
- harms and benefits of PSA testing must be explained to the patient and an informed, shared decision to test must be established
- initial screening should include both serum PSA and DRE
- all men should be offered screening at age 50 if >10 yr life-expectancy
- high-risk individuals (family Hx of CaP or African ancestry) should be offered screening at age 40 if >10 yr life-expectancy
- standard has been annual screening, but q2-4yr screening acceptable
- no strict cutpoint for when to biopsy; decision to biopsy should be based on more than a single PSA value
- AUA guidelines recommend against universal routine PSA screening for CaP

**Testicular Tumours**

**Etiology/Risk Factors**
- cryptorchidism, atrophy, sex hormones, HIV infection, infertility, family Hx, past Hx of testicular cancer

**Epidemiology**
- rare, but most common solid malignancy in young males 15-35 yr
- any solid testicular mass or acute hydrocoele in young patient – must rule out malignancy
- slightly more common in right testis (corresponds with slightly higher incidence of right-sided cryptorchidism)
- 2-3% bilateral (simultaneously or successively)

**Pathology**
- primary
  ■ 1% of all malignancies in males
  ■ cryptorchidism has increased risk (10-40x) of malignancy
  ■ 95% are germ cell tumours (all are malignant)
    - seminoma (35%) → classic, anaplastic, spermatocytic
    - NSGCT → embryonal cell carcinoma (20%), teratoma (5%), choriocarcinoma (<1%), yolk sac (<<1%), mixed cell type (40%)
  ■ 5% are non-germ cell tumours (usually benign) → Leydig (testosterone, precocious puberty), Sertoli (gynecomastia, decreased libido)
- secondary
  ■ male >50 yr
  ■ usually lymphoma or metastases (e.g. lung, prostate, GI)

**Clinical Features**
- painless testicular enlargement (painful if intratesticular hemorrhage or infarction)
- dull, heavy ache in lower abdomen, anal area or scrotum
- associated hydrocoele (10%)
- coincidental trauma (10%)
- infertility (rarely presenting complaint)
- gynecomastia due to secretory tumour effects
- supracavicular and inguinal lymphadenopathy
- abdominal mass (retroperitoneal lymph node mets)

**Methods of Spread**
- local spread follows lymphatics
  - right → medial, paracaval, anterior and lateral nodes
  - left → left lateral and anterior paraaortic nodes
  - “cross-over” metastases from right to left are fairly common, but no reports from left to right
- hematogenous most commonly to lung, liver, bones, and kidney

**Investigations**
- diagnosis is established by pathological evaluation of specimen obtained by radical inguinal orchidectomy
- tumour markers (β-hCG, LDH, AFP)
  - β-hCG and AFP are positive in 85% of non-seminomatous tumours
  - elevated marker levels return to normal post-operatively if no metastasis
  - β-hCG positive in 7% of pure seminomas, AFP never elevated with seminoma
• testicular U/S (hypoechoic area within tunica albuginea = high suspicion of testicular cancer)
• evidence of testicular microlithiasis is not a risk factor for testicular cancer
• needle aspiration contraindicated

Staging
• clinical: CXR (lung mets), markers for staging (β-hCG, AFP, LDH), CT abdomen/pelvis (retroperitoneal lymphadenopathy)
  • Stage I: disease limited to testis, epididymis, or spermatic cord
  • Stage II: disease limited to the retroperitoneal nodes
  • Stage III: disease metastatic to supradiaphragmatic nodal or visceral sites

Table 22. 2010 TNM Classification of Testicular Carcinoma

<table>
<thead>
<tr>
<th></th>
<th>T</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1</td>
<td>limited to testis and epididymis without vascular/lymphatic invasion</td>
<td>N0: no regional lymph node metastasis</td>
<td>M0: no distant mets</td>
</tr>
<tr>
<td>T2</td>
<td>limited to testis and epididymis with vascular/lymphatic invasion</td>
<td>N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension, or multiple lymph nodes, none more than 2 cm in greatest dimension</td>
<td>M1: distant mets</td>
</tr>
<tr>
<td>T3</td>
<td>invasion of the spermatic cord ± vascular/lymphatics</td>
<td>N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension</td>
<td>M1a: nonregional lymph node(s) or pulmonary mets</td>
</tr>
<tr>
<td>T4</td>
<td>invasion of the scrotum ± vascular/lymphatics</td>
<td>N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension</td>
<td>M1b: distant mets other than to regional lymph nodes and lung</td>
</tr>
</tbody>
</table>

Management
• orchiectomy through inguinal ligament for all stages
• consider sperm banking, testicular prosthesis
• adjuvant therapies

Prognosis
• 99% cured with stage I and II disease
• 70-80% complete remission with advanced disease

Penile Tumours

Epidemiology
• rare (<1% of cancer in males in U.S.)
• most common in 6th decade

Benign
• cyst, hemangioma, nevus, papilloma

Pre-Malignant
• balanitis xerotica obliterans, leukoplakia, Buschke-Lowenstein tumour (large condyloma)

Pre-invasive Cancer
• carcinoma in situ
  • Bowen’s disease → crusted, red plaques on the shaft
  • erythroplasia of Queyrat → velvet red, ulcerated plaques on the glans
  • treatment options: local excision, laser, radiation, topical 5-fluorouracil
Malignant
- risk factors
  - chronic inflammatory disease
  - STI
  - phimosis
  - uncircumcised penis
- 2% of all urological cancers
- SCC (>95%), basal cell, melanoma, Paget’s disease of the penis (extremely rare)
- definitive diagnosis requires full thickness biopsy of lesion
- lymphatic spread (superficial/deep inguinal nodes → iliac nodes) >> hematogenous

Treatment
- wide surgical excision with tumour-free margins (dependent on extent and area of penile involvement)
  ± lymphadenectomy
- consider less aggressive treatment modalities in CIS (cryotherapy, laser therapy, etc.) if available

### Scrotal Mass

#### Table 23. Differentiating between Scrotal Masses

<table>
<thead>
<tr>
<th>Condition</th>
<th>Pain</th>
<th>Palpation</th>
<th>Additional Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Torsion</td>
<td>+</td>
<td>Diffuse tenderness</td>
<td>Absent cremaster reflex, negative Prehn’s sign</td>
</tr>
<tr>
<td>Epididymitis (U16)</td>
<td>+</td>
<td>Epidydrial tenderness</td>
<td>Present cremaster reflex, positive Prehn’s sign</td>
</tr>
<tr>
<td>Orchitis (U16)</td>
<td>+</td>
<td>Diffuse tenderness</td>
<td>Present cremaster reflex, positive Prehn’s sign</td>
</tr>
<tr>
<td>Hydrocele</td>
<td>–</td>
<td>Testis not separable from hydrocele, cord palpable</td>
<td>Transillumination, Hx of trauma</td>
</tr>
<tr>
<td>Spermatocele</td>
<td>–</td>
<td>Testis separable from spermatocele, cord palpable</td>
<td>Transillumination</td>
</tr>
<tr>
<td>Varicocele</td>
<td>–</td>
<td>Bag of worms</td>
<td>No transillumination, increases in size with Valsalva, decrease in size if supine</td>
</tr>
<tr>
<td>Indirect Inguinal</td>
<td>– (± if strangulated)</td>
<td>Testis separable from hernia, cord not palpable, cough impulse may transmit, may be reducible</td>
<td>No transillumination</td>
</tr>
<tr>
<td>Tumour</td>
<td>– (± if hemorrhagic)</td>
<td>Hard lump/nodule</td>
<td></td>
</tr>
<tr>
<td>Generalized/Dependant edema</td>
<td>–</td>
<td>Diffuse swelling</td>
<td>Often post-operative or immobilized, check for liver dysfunction</td>
</tr>
<tr>
<td>Idiopathic</td>
<td>–</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Table 24. Benign Scrotal Masses

<table>
<thead>
<tr>
<th>Type</th>
<th>Varicocele</th>
<th>Spermatocele</th>
<th>Hydrocele</th>
<th>Testicular Torsion</th>
<th>Inguinal Hernia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definition</td>
<td>Dilatation and tortuosity of pampiniform plexus</td>
<td>A benign, sperm filled epididymal retention cyst</td>
<td>Collection of serous fluid that results from a defect or irritation in the tunica vaginalis</td>
<td>Twisting of the testicle causing venous occlusion and engorgement as well as arterial ischemia and infarction</td>
<td>Pruritus of abdominal contents through the inguinal canal into the scrotum</td>
</tr>
<tr>
<td>Etiology</td>
<td>15% of men Due to incompetent valves in the testicular veins 90% left sided</td>
<td>Multiple theories, including: Distal obstruction Aneuryosomal dilations of the epididymis Agglutinated germ cells</td>
<td>Usually idiopathic Found in 5-10% testicular tumours Associated with trauma/infection Communicating: patent processus vaginalis, changes size during day (peds) Non-communicating: non-patient processus vaginalis (adult)</td>
<td>Trauma Cryptorchidism “Bell clapper deformity” Many occur in sleep (50%) Necrosis of glands in 5-6 h</td>
<td>Indirect (through internal ring, often into scrotum); congenital Direct (through external ring, rarely into scrotum); abdominal muscle weakness</td>
</tr>
<tr>
<td>Hx/P/E</td>
<td>“Bag of worms” Often painless Pulsates with Valsalva</td>
<td>Non-tender, cystic mass Transilluminates</td>
<td>Non-tender, intrascrotal mass Cystic Transilluminates</td>
<td>Acute onset severe scrotal pain, swelling GI upset cases Retracted and transverse testicle (horizontal lie) Negative Prehn’s sign Absent cremasteric reflex</td>
<td>A small bulge in the groin that may increase in size with Valsalva and disappear when lying down Can present as a swollennor enlarged scrotum Discomfort or sharp pain – especially when straining, lifting, or exercising</td>
</tr>
<tr>
<td>Investigations</td>
<td>P/E Valsalva</td>
<td>P/E U/S to rule out tumour</td>
<td>U/S to rule out tumour</td>
<td>U/S with colour flow Doppler probe over testicular artery Decrease uptake on 99mTc-pertechnetate scintilletion scan (doughnut sign)</td>
<td>Hx and P/E Invagination of the scrotum Valsalva</td>
</tr>
<tr>
<td>Treatment</td>
<td>Conservative Surgical ligation of testicular veins Percutaneous vein occlusion (balloon, sclerosing agents) Repair my improve sperm count/motility 50-75%</td>
<td>Conservative Avoid needle aspiration as it can lead to infection, reaccumulation and spilling of irritating sperm within scrotum Excise if symptomatic</td>
<td>Conservative Needle drainage Surgical</td>
<td>Emergency surgical exploration and bilateral orchiectomy Orchiectomy if poor prognosis</td>
<td>Surgical repair</td>
</tr>
</tbody>
</table>
TORSION OF TESTICULAR APPENDIX
• twisting of testicular/epididymal vestigial appendix

Signs and Symptoms
• clinically similar to testicular torsion, but vertical lie and cremaster reflex preserved
• “blue dot sign”
  • blue infarcted appendage seen through scrotal skin (can usually be palpated as small, tender lump)

Treatment
• analgesia – most will subside over 5-7 d
• surgical exploration and excision if refractory pain

HEMATOCELE
• trauma with bleed into tunica vaginalis
• U/S helpful to exclude fracture of testis which requires surgical repair

Penile Complaints

Table 25. Penile Complaints

<table>
<thead>
<tr>
<th>Type</th>
<th>Peyronie’s Disease</th>
<th>Priapism</th>
<th>Paraphimosis</th>
<th>Phimosis</th>
<th>Premature Ejaculation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definition</td>
<td>Benign curvature of penile shaft secondary to fibrous thickening of tunica albuginea</td>
<td>Prolonged erection lasting &gt;4 h in the absence of sexual excitement/desire</td>
<td>Foreskin caught behind glans leading to edema → inability to reduce foreskin</td>
<td>Inability to retract foreskin over glans penis</td>
<td>Ejaculation prior to when one or both partners desire it, either before or soon after penetration</td>
</tr>
<tr>
<td>Etiology</td>
<td>Etiology unknown</td>
<td>Trauma/repeated inflammation</td>
<td>Ischemic (common)</td>
<td>Trauma</td>
<td>Congenital (90% natural separation by age 3)</td>
</tr>
<tr>
<td></td>
<td>Trauma/repeated inflammation</td>
<td>Associated with DM, vascular disease, autoimmunity, Dupuytren’s contracture, erectile dysfunction</td>
<td>Thromboembolic (sickle cell)</td>
<td>Medications</td>
<td>Balanitis</td>
</tr>
<tr>
<td></td>
<td>Associated with DM, vascular disease, autoimmunity, Dupuytren’s contracture, erectile dysfunction</td>
<td>Non-Ischemic Trauma</td>
<td>Medications</td>
<td>Neurogenic</td>
<td>Poor Hygiene</td>
</tr>
<tr>
<td></td>
<td>50% idiopathic</td>
<td>Ischemic (common)</td>
<td>Trauma</td>
<td>Infectious (balanitis, balanoposthitis)</td>
<td>Congenital (90% natural separation by age 3)</td>
</tr>
<tr>
<td>Hx/P/E</td>
<td>Penile curvature/shortening</td>
<td>Painful erection ± signs of necrosis</td>
<td>Painful, swollen glans penis, foreskin Constricting band proximal to corona</td>
<td>Limitation and pain when attempting to retract foreskin</td>
<td>Psychological factors</td>
</tr>
<tr>
<td>Investigations</td>
<td>Hx and P/E</td>
<td>Painful, swollen glans penis, foreskin Constricting band proximal to corona</td>
<td>Balanoposthitis (infection of prepuce)</td>
<td>Balanoposthitis (infection of prepuce)</td>
<td>Primary: no period of acceptable control</td>
</tr>
<tr>
<td></td>
<td>Hx and P/E</td>
<td>Constricting band proximal to corona</td>
<td>Dysuria, decreased urinary stream in children</td>
<td>Congenital (90% natural separation by age 3)</td>
<td>Secondary: symptoms after a period of control, not associated with general medical condition</td>
</tr>
</tbody>
</table>

Erectile Dysfunction

Definition
• consistent (>3 mo duration) or recurrent inability to obtain or maintain an adequate erection for satisfactory sexual performance

Physiology
• erection involves the coordination of psychologic, neurologic, hemodynamic, mechanical, and endocrine components
• nerves: sympathetic (T11-L2), parasympathetic (S2-4), somatic (dorsal penile/pudendal nerves [S2-4])
• erection ("POINT")
  • parasympathetics → NO release → increased cGMP within corpora cavernosa leading to:
    1. arteriolar dilatation
    2. sinusoidal smooth muscle relaxation → increased arterial inflow and compression of penile venous drainage (decreased venous outflow)

Testosterone deficiency is an uncommon cause of ED

Erections POINT AND SHOOT
parasympathetics = point; and sympathetics/ somatics = shoot

Acute scrotal swelling/pain in young boys is torsion until proven otherwise

Transillumination refers to light being transmitted through tissue (i.e. due to excess fluid)

Differential of a Benign Scrotal Mass
HIS BITS
Hydrocele
Infection (epididymitis/orchitis)
Sperm (spermatocele)
Blood (hematocele)
Intratesticular (hernia)
Torsion
Some veins (varicocele)
• emission (“SHOOT”)
  ▪ sensory afferents from glans
  ▪ secretions from prostate, seminal vesicles, and ejaculatory ducts enter prostatic urethra (sympathetics)
• ejaculation (“SHOOT”)
  ▪ bladder neck closure (sympathetic)
  ▪ spasmotic contraction of bulbo-cavernosus and pelvic floor musculature (somatic)
  ▪ detumescence
  ▪ sympathetic nerves, norepinephrine, endothelin-1 → arteriolar and sinusoidal constriction → penile flaccidity

Classification

Table 26. Classification of Erectile Dysfunction

<table>
<thead>
<tr>
<th>Proportion</th>
<th>Psychogenic*</th>
<th>Organic*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset</td>
<td>10%</td>
<td>90%</td>
</tr>
<tr>
<td>Frequency</td>
<td>Sudden</td>
<td>Gradual</td>
</tr>
<tr>
<td>Variation</td>
<td>With partner and circumstance</td>
<td>No</td>
</tr>
<tr>
<td>Age</td>
<td>Younger</td>
<td>Older</td>
</tr>
<tr>
<td>Organic Risk Factors (HTN, DM, dyslipidemia)</td>
<td>No organic risk factors</td>
<td>Risk factors present</td>
</tr>
<tr>
<td>Nocturnal/AM Erection</td>
<td>Present</td>
<td>Absent</td>
</tr>
</tbody>
</table>

*Combination can co-exist

Etiology (“IMPOTENCE”)

• Iatrogenic: pelvic surgery, pelvic radiation
• Mechanical: Peyronie’s, post-priapism
• Psychological: depression, stress, anxiety, PTSD, widower syndrome
• Occlusive: arterial HTN, DM, smoking, hyperlipidemia, PVD, impaired veno-occlusion
• Trauma: penile/pelvic, bicycling
• Extra factors: renal failure, cirrhosis, COPD, sleep apnea, malnutrition
• Neurogenic: CNS (e.g. Parkinson’s, MS, spinal cord injury; Guillain-Barré, spina bifida, stroke), PNS (e.g. DM, peripheral neuropathy)
• Chemical: antihypertensives, sedatives, antidepressants, antipsychotics, anxiolytics, anticholinergics, antihistamines, anti-androgens (including 5-a reductase inhibitors), statins, GnRH agonists, illicit drugs
• Endocrine: DM, hypogonadism, hyperprolactinemia, hypo/hyperthyroid

Diagnosis

• complete Hx (include sexual, medical, and psychosocial aspects)
• self-administered questionnaires (e.g. International Index of Erectile Function, Sexual Health Inventory for Men Questionnaire, ED Intensity Scale, ED Impact Scale)
• focused P/E, including vascular and neurologic examinations, secondary sexual characteristics
• lab investigations, dependent on clinical picture
  ▪ risk factor evaluation: fasting blood glucose or HbA1c, cholesterol profile
  ▪ optional: TSH, CBC, U/A, testosterone (free and total), prolactin, LH
• specialized testing including nocturnal penile tumescence monitoring usually unnecessary
• evaluation of penile vasculature only relevant with past history of trauma (i.e. pelvic fracture)

Treatment

• can often be managed by family doctor, see sidebar for when to refer
• must fully inform patient/partner of options, benefits and complications
• non-invasive
  ▪ lifestyle changes (alcohol, smoking), psychological (sexual counselling and education)
  ▪ change precipitating medications
  ▪ treat underlying causes (DM, CVD, HTN, endocrinopathies)
• minimally invasive
  ▪ oral medication (see Common Medications, U42)
    ▪ sildenafil, tadalafil, vardenafil, avanafil (not available in Canada): inhibits PDE-5 to increase intracavernosal cyclic GMP levels
    ▪ all three have similar effectiveness, difference in onset of action is not clinically significant
    ▪ tadalafil has longer half-life, no cyanopsia, and can be taken on empty or full stomach
  ▪ vacuum devices: draw blood into penis via negative pressure, then put ring at base of penis
  ▪ MUSE: male urethral suppository for erection – vasoactive substance (PGE1) capsule inserted into urethra
• invasive
  ▪ intracavernous vasodilator injection/self-injection
    ▪ triple therapy (papaverine, phentolamine, PGE1) or PGE1 alone
    ▪ complications: priapism (overdose), thickening of tunica albuginea at site of repeated injections (Peyronie’s plaque) and hematoma
  ▪ surgical
    ▪ penile implant (last resort): malleable or inflatable
    ▪ penile artery reconstruction (in young men with isolated vascular lesion – investigational)
Trauma

• see Emergency Medicine, ER7

Renal Trauma

Classification According to Severity
• minor
  ▪ contusions and superficial lacerations/hematomas: 90% of all blunt traumas, surgical exploration seldom necessary
• major
  ▪ laceration that extends into medulla and collecting system, major renal vascular injury, shattered kidney

Etiology
• 80% blunt (MVC, assaults, falls) vs. 20% penetrating (stab wounds and gunshots)

Clinical Features
• mechanism of injury raises suspicion
• can be hemodynamically unstable secondary to renal vascular injury and/or other sustained injuries: ABCs
• upper abdominal tenderness, flank tenderness, flank contusions, lower rib/vertebral transverse process fracture

Investigations
• U/A
  ▪ hematuria: requires workup but degree does not correlate with the severity of injury
• imaging
  ▪ CT (contrast, triphasic) if patient stable: look for renal laceration, extravasation of contrast, retroperitoneal hematoma, and associated intra-abdominal organ injury

Staging (does not necessarily correlate well with clinical status)
• I: contusion/hematoma
• II: <1 cm laceration without urinary extravasation
• III: >1 cm laceration without urinary extravasation
• IV: laceration causing urinary extravasation and/or main arterial or vein injury with contained hematoma
• V: shattered kidney or avulsion of pedicle

Treatment
• microscopic hematuria + isolated well-staged minor injuries → no hospitalization
• gross hematuria + contusion/minor lacerations → hospitalize, bedrest, repeat CT if bleeding persists
• surgical intervention/minimally invasive angiography and embolization
  ▪ absolute indications
    ▪ hemorrhage and hemodynamic instability
  ▪ relative indications
    ▪ non-viable tissue and major laceration
    ▪ urinary extravasation
    ▪ vascular injury
    ▪ expanding or pulsating peri-renal mass
    ▪ laparotomy for associated injury
• follow-up with U/S or CT before discharge, and at 6 wk

Complications
• HTN in 5% of renal trauma

Bladder Trauma

Classification
• contusions: no urinary extravasation, damage to mucosa or muscularis
• intraperitoneal ruptures: often involve the bladder dome
• extraperitoneal ruptures: involve anterior or lateral bladder wall in full bladder

Etiology
• blunt (MVC, falls, and crush injury) vs. penetrating trauma to lower abdomen, pelvis, or perineum
• blunt trauma is associated with pelvic fracture in 97% of cases
Clinical Features
- abdominal tenderness, distention, peritonitis, and inability to void
- can be hemodynamically unstable secondary to pelvic fracture, other sustained injuries: ABCs
- suprapubic pain

Investigations
- U/A: gross hematuria in 90%
- imaging (including CT cystogram and post-drainage films for extravasation)

Treatment
- penetrating trauma → surgical exploration
- contusion → urethral catheter until hematuria completely resolves
- extraperitoneal bladder perforations → typically non-operative with foley insertion, and follow with cystograms
  ▪ surgery if: infected urine, rectal/vaginal perforation, bony spike into bladder, laparotomy for concurrent injury; bladder neck involvement, persistent urine leak and failed conservative management
- intraperitoneal rupture usually requires surgical repair and suprapubic catheterization

Complications
- complications of bladder injury itself are rare
- mortality is around 20%, and is usually due to associated injuries rather than bladder rupture

Urethral Injuries

Etiology
- posterior urethra
  ▪ common site of injury is junction of membranous and prostatic urethra due to blunt trauma, MVCs, pelvic fracture
  ▪ shearing force on fixed membranous and mobile prostatic urethra
- anterior urethra
  ▪ straddle injury can crush bulbar urethra against pubic rami
- other causes
  ▪ iatrogenic (instrumentation, prosthesis insertion), penile fracture, masturbation with urethral manipulation
- always look for associated bladder rupture

Clinical Features
- blood at urethral meatus
- high-riding prostate on DRE
- swelling and butterfly perineal hematoma
- penile and/or scrotal hematoma
- sensation of voiding without U/O
- distented bladder

Investigations
- must perform RUG or cystoscopy prior to catheterization

Treatment
- simple contusions
  ▪ no treatment
- partial urethral disruption
  ▪ very gentle attempt at catheterization by urologist
  ▪ with no resistance to catheterization → Foley x 2-3 wk
  ▪ with resistance to catheterization → suprapubic cystostomy or urethral catheter alignment
- periodic flow rates/urethrograms to evaluate for stricture formation
- complete disruption
  ▪ immediate repair if patient stable, delayed repair if unstable (suprapubic tube in interim)

Complications
- stricture
Infertility

Definition
• failure to conceive after one year of unprotected, properly timed intercourse
• incidence
  • 15% of all couples (35–40% female, 20% male, 25–30% combined)

Female Factors
• see Gynecology, GY23

Male Factors

Male Reproduction
• hypothalamic-pituitary-testicular axis (HPTA)
  • pulsatile GnRH from hypothalamus acts on anterior pituitary stimulating release of LH and FSH
  • LH acts on Leydig (interstitial) cells → testosterone synthesis and secretion
  • FSH acts on Sertoli cells → structural and metabolic support to developing spermatogenic cells
  • FSH and testosterone support germ cells (responsible for spermatogenesis)
  • sperm route: epididymis → vas deferens → ejaculatory ducts → prostatic urethra

Etiology
• idiopathic (40–50% infertile males)
• testicular
  • varicocele (35–40% infertile males)
  • tumour
  • congenital (Klinefelter’s triad: small, firm testes, gynecomastia, and azoospermia)
  • post-infectious (epididymo-orchitis, STIs, mumps)
  • uncorrected torsion
  • cryptorchidism (<5% of cases)
• obstructive
  • iatrogenic (surgery: see below)
  • infectious (gonorrhea, chlamydia)
  • trauma
  • congenital (absence of vas deferens, CF)
  • bilateral ejaculatory duct obstruction, epididymal obstructions
  • Kartagener’s syndrome (autosomal recessive disorder causing defect in action of cilia)
• endocrine (see Endocrinology, E45)
  • HPTA (2–3%) e.g. Kallmann’s syndrome (congenital hypothalamic hypogonadism), excess prolactin, excess androgens, excess estrogens
• other
  • retrograde ejaculation secondary to surgery
  • medications
  • drugs: marijuana, cocaine, tobacco, alcohol
  • increased testicular temperature (sauna, hot baths, tight pants or underwear)
  • chronic disease: e.g. liver, renal
  • unexplained infertility

History
• age of both partners
• medical: past illness, DM, trauma, CF, genetic syndromes, STIs, cryptorchidism
• surgical: vasectomy, herniorrhaphy, orchidopexy, prostate surgery
• fertility: pubertal onset, previous pregnancies, duration of infertility, treatments
• sexual: libido, erection/ejaculation, timing, frequency
• family Hx
• medications: cytotoxic agents, GnRH agonists, anabolic steroids, nitrofurantoin, cimetidine, sulfasalazine, spironolactone, α-blockers
• social Hx: alcohol, tobacco, cocaine, marijuana
• occupational exposures: radiation, heavy metals

Physical Exam
• general appearance: sexual development, gynecomastia, obesity
• scrotal exam: size, consistency, and nodularity of testicles; palpation of cord for presence of vas deferens; DRE; valsalva for varicocele
**Investigations**
- semen analysis (SA) at least 2 specimens, collected 1-2 weeks apart
- hormonal evaluation
  - indicated with abnormal SA (rare to be abnormal with normal SA)
  - testosterone and FSH
  - serum LH and prolactin are measured if testosterone or FSH are abnormal
- genetic evaluation
  - chromosomal studies (Klinefelter’s syndrome – XXY)
  - genetic studies (Y-chromosome microdeletion, CF gene mutation)
  - immunologic studies (antisperm antibodies in ejaculate and blood)
- testicular biopsy
- scrotal U/S (varicocele, testicular size)
- vasography (assess patency of vas deferens)

**Treatment**
- assessment of partner
- lifestyle
  - regular exercise, healthy diet
  - eliminate alcohol, tobacco and illicit drugs
- medical
  - endocrine therapy (see Endocrinology, E46)
  - treat retrograde ejaculation
  - discontinue anti-sympathomimetic agents, may start α-adrenergic stimulation (phenylephrine, pseudoephedrine, or ephedrine)
  - treat underlying infections
- surgical
  - varicocelectomy (if indicated)
  - vasovasostomy (vasectomy reversal) or epididymovasostomy
  - transurethral resection of blocked ejaculatory ducts
- assisted reproductive technologies (ART)
  - refer to infertility specialist
  - sperm washing + intrauterine insemination (IUI)
  - in vitro fertilization (IVF)
  - intracytoplasmic sperm injection (ICSI) after CF screening of patient and partner in patients with congenital bilateral absence of vas deferens

**Semen Analysis**

- Absent/low volume ejaculate, positive for sperm
- +ve for sperm, r/o short abstinence period, incomplete collection
- Post-ejaculatory urination
- +ve for sperm, -ve for sperm
- Retrograde ejaculation
- Transrectal U/S

**Azospermia**

- Serum FSH
  - Low
  - High
- Bilateral testicular atrophy
- Normal or unilateral testicular atrophy

**Hypogonadotropic hypogonadism**

- Primary testicular failure
  - Abnormal
  - Normal
- Abnormal anatomy
- Normal anatomy

**Obstruction**

- Testicular biopsy
- Failure of emission
- Determine level of obstruction

**Normal Semen Values**
- Volume: 2-6 mL
- Concentration: >15 million sperm/mL
- Motility: >40% adequate forward progression
- Liquification: complete in 20 min
- pH: 7.2-7.8
- WBC: <10/HPF or <106 WBC/mL semen

**Common Terminology on SA**
- Teratospermia: Abnormal morphology
- Azoospermia: Absent sperm
- Oligospermia: Decreased sperm count
- Normospermia: Normal sperm count
- Mixed types: i.e. oligoasthenospermia

**Mutation of cystic fibrosis transmembrane conductance regulator (CFTR) gene is associated with congenital bilateral absence of vas deferens and epididymal cysts, even if patient manifests no symptoms of CF**

**WHO Guidelines Male Infertility Factors**

**Sperm Count**
- Systemic factor
- Psychological illness
- Endocrinopathy
- Retrograde ejaculation
- Medications
- Chronic disease
- Obstructive
- Unexplained
- Narcotics
- Testicular

**Figure 15. Infertility work up**
Pediatric Urology

Congenital Abnormalities

- not uncommon; 1/200 have congenital abnormalities of the GU tract
- six common presentations of congenital urological abnormalities

1. ANTENATAL HYDRONEPHROSIS

Epidemiology
- 1-5% fetal U/S, some detectable as early as first trimester
- most common urological consultation in perinatal period and one of most common U/S abnormalities of pregnancy

Differential Diagnosis
- UPJ or UVJ obstruction
- MCDS
- VUR
- PUVs (only in boys)
- duplication anomalies
- ureterocele
- ectopic ureter

Treatment
- antenatal in utero intervention rarely indicated unless evidence of lower urinary tract obstruction with oligohydramnios

2. POSTERIOR URETHRAL VALVES

Epidemiology
- the most common congenital obstructive urethral lesion in male infants

Pathophysiology
- abnormal mucosal folds at the distal prostatic urethra causing varying degrees of obstruction

Clinical Presentation
- dependent on age
  - antenatal: bilateral hydronephrosis, distended bladder, oligohydramnios
  - neonatal (recognized at birth): palpable abdominal mass (distended bladder, hydronephrosis), urinary ascites (transudation of retroperitoneal urine), respiratory distress (pulmonary hypoplasia from oligohydramnios), weak urinary stream
  - neonatal (not recognized at birth): within weeks present with urosepsis, dehydration, electrolyte abnormalities, failure to thrive; rule out pyloric stenosis, which may present similarly
  - toddlers: UTIs or voiding dysfunction
  - school-aged boys: voiding dysfunction → urinary incontinence
- associated findings include renal dysplasia and secondary VUR

Investigations
- most commonly recognized on prenatal U/S → bilateral hydronephrosis, thickened bladder, dilated posterior urethra (“keyhole sign”), oligohydramnios in a male fetus
- VCUG → dilated and elongated posterior urethra, trabeculated bladder, VUR

Treatment
- immediate catheterization to relieve obstruction, followed by cystoscopic resection of PUV when baby is stable
- if resection of PUV is not possible, vesicostomy is indicated

3. URETEROPELVIC JUNCTION OBSTRUCTION

Etiology
- unclear: adynamic ureteral segment, stenosis, strictures, extrinsic compression, aberrant blood vessels
- can rarely be secondary to tumour, stone, etc, in children

Epidemiology
- the most common congenital defect of the ureter
- M:F = 2:1
- up to 40% bilateral, which may be associated with worse prognosis
Clinical Presentation
• symptoms depend on severity and age at diagnosis (mostly asymptomatic finding on antenatal U/S)
  ■ infants: abdominal mass, urinary infection
  ■ children: pain, vomiting, failure to thrive
• some cases are diagnosed after puberty and into adulthood
  ■ in adolescents and adults, the symptoms may be triggered by episodes of increased diuresis, such as following alcohol ingestion (Dietl’s crisis)

Investigations
• antenatal: serial U/S most common, and renal scan ± furosemide

Treatment
• surgical correction (pyeloplasty), consider nephrectomy if <15% differential renal function

4. VESICOURETERAL REFLUX

Definition
• retrograde passage of urine from the bladder, through the UVJ, into the ureter

Classification
• primary reflux: incompetent or inadequate closure of UVJ
  ■ lateral ureteral insertion, short submucosal segment
• secondary reflux: abnormally high intravesical pressure resulting in failure of UVJ closure
  ■ often associated with anatomic (PUV) or functional (neuropathic) bladder dysfunction

Epidemiology
• estimated ~1% of newborns, but not well known
• incidence and clinical relevance higher in children with febrile UTIs and prenatal hydronephrosis
• risk factors: race (white > black), female gender, age (<2 yr), genetic predisposition

Investigations
• focused Hx, particularly of voiding dysfunction (frequency, urgency, diurnal enuresis, constipation, encopresis)
• also screen for infections (UTI, pyelonephritis, urosepsis) and renal failure (uremia, HTN)
• initial evaluation of renal status, growth parameters, and blood pressure is warranted in any child with VUR due to relatively high incidence of renal scarring
  ■ height, weight, blood pressure
  ■ serum Cr
  ■ U/A, C&S
  ■ renal U/S
  ■ DMSA renal scan if at high risk (greater sensitivity in detecting structural defects associated with dysplasia, renal scarring or pyelonephritis; entails radiation exposure)
  ■ sibling family screening is controversial

Treatment
• spontaneous resolution in 60% of primary reflux
  ■ in lower grades (I-III), goal is to prevent infection or renal damage via medical treatment
• medical treatment: daily ABx prophylaxis at half the treatment dose for acute infection (see Table 9, U12 - TMP/SMX, trimethoprim, amoxicillin, or nitrofurantoin)
• surgical treatment: ureteral reimplantation ± ureteroplasty, or subureteral injection with bulking agents (Deflux® or Macroplastique®)
  ■ indications include failure of medical management, renal scarring (e.g. renal insufficiency, HTN), breakthrough UTIs, persistent high grade (IV or V) reflux

5. HYPOSPADIAS

Definition
• a condition in which the urethral meatus opens on the ventral side of the penis, proximal to the normal location in the glans penis
• depending on severity, may result in difficulty directing urinary stream, having intercourse or depositing sperm in vagina

Epidemiology
• very common; 1/300 live male births
• distal hypospadias more common than proximal
• white >> black
• may be associated with ventral penile curvature, disorders of sexual differentiation, undescended testicles or inguinal hernia
Treatment
• early surgical correction; optimal repair before 2 yr
• neonatal circumcision should be deferred because the foreskin may be utilized in the correction

6. EXSTROPHY-EPISPADIAS COMPLEX

Definition
• a spectrum of defects depending on the timing of the rupture of the cloacal membrane
  - bladder extrophy: congenital defect of a portion of lower abdominal and anterior bladder wall, with exposure of the bladder lumen
  - cloacal extrophy
    - exposed bladder and bowel with imperforate anus
    - associated with spina bifida in >50%
  - epispadias (least severe)
    - urethra opens on dorsal aspect of the penis, often associated with penile curvature

Etiology
• represents failure of closure of the cloacal membrane, resulting in the bladder and urethra opening directly through the abdominal wall

Epidemiology
• rare: incidence 1/30,000, M:F = 3:1 predominance
• high morbidity → multiple reconstructive surgeries, incontinence, infertility, reflux

Treatment
• surgical correction at birth
• later corrections for incontinence, VUR, and low bladder capacity may be needed

Nephroblastoma (Wilms’ Tumour)

Etiology
• arises from abnormal proliferation of metanephric blastema

Epidemiology
• 5% of all childhood cancers, 5% bilateral
• most common primary malignant renal tumour of childhood
• average age of incidence is 3 yr

Clinical Features
• abdominal mass: large, firm, unilateral (80%)
• HTN (25%)
• flank tenderness
• microscopic hematuria
• nausea/vomiting

Treatment
• always investigate contralateral kidney and renal vein (for tumour thrombus)
• unilateral disease: radical nephrectomy ± radiation ± chemotherapy
• bilateral disease: nephron-sparing surgery following neoadjuvant chemotherapy

Prognosis
• 5 yr survival 80%

Cryptorchidism/Ectopic Testes

Definition
• abnormal location of testes somewhere along the normal path of descent (external inguinal ring > inguinal canal > abdominal)
• Denis Browne pouch (between external oblique fascia and Scarpa’s fascia) most common
• differential diagnosis:
  - retractile testes
  - atrophic testes
  - disorders of sexual differentiation (bilateral impalpable gonads)

Epidemiology
• 2.7% of full term newborns
• 0.7-0.8% at 1 yr
Treatment

- orchiopexy
- hormonal therapy not proven to be of benefit over standard surgical treatment

Prognosis

- reduction in fertility
  - untreated bilateral cryptorchidism: ~100% infertility
  - paternity rates: 53%, 90%, and 93% in formerly bilateral cryptorchid, formerly unilateral cryptorchid, and normal men, respectively
- increased malignancy risk
  - intraabdominal > inguinal
  - surgical correction facilitates testicular monitoring and may reduce malignancy risk
- increased risk of testicular torsion (reduced by surgical correction)

Disorders of Sexual Differentiation

Definition

- formerly known as intersex disorders: considered social emergency
- abnormal genitalia for chromosomal sex due to the undermasculinization of males or the virilization of females

Classification

1. 46 XY DSD
   - defect in testicular synthesis of androgens
   - androgen resistance in target tissues
   - palpable gonad
2. 46 XX DSD
   - most due to CAH (21-hydroxylase deficiency most common enzymatic defect) → shunt in steroid biosynthetic pathway leading to excess androgens
   - undiagnosed and untreated CAH can be associated with life-threatening electrolyte abnormalities in the newborn (salt-wasting CAH)
3. ovotesticular DSD
4. mixed gonadal dysgenesis (46 XY/45 XO most common karyotype)
   - presence of Y chromosome → partial testis determination to varying degrees

Diagnosis

- thorough family Hx noting any consanguinity
- maternal Hx, especially medication/drug use during pregnancy (maternal hyperandrogenemia)
- P/E: palpable gonad (= chromosomal male), hyperpigmentation, evidence of dehydration, HTN, stretched phallus length, position of urethral meatus
- laboratory tests
  - plasma 17-OH-progesterone (after 36 h of life) → increased in CAH
  - plasma 11-deoxycortisol → increased in 11-β-hydroxylase deficiency
  - basal adrenal steroid levels
  - serum testosterone and DHT pre- and post-hCG stimulation (2,000 IU/d for 4 d)
  - serum electrolytes
  - chromosomal evaluation including sex karyotype
- U/S of adrenals, gonads, uterus, and fallopian tubes
- endoscopy and genitography of urogenital sinus

Treatment

- steroid supplementation as indicated (e.g. CAH)
- sex assignment after extensive family consultation
  - must consider capacity for sexually functioning genitalia in adulthood, fertility potential, and psychological impact
- reconstruction of external genitalia between 6 and 12 mo
- long-term psychological guidance and support for both patient and family

Enuresis

- see Pediatrics, P9
Selected Urological Procedures

Bladder Catheterization

- catheter size measured by the French (Fr) scale – circumference in mm
- each 1 mm increase in diameter = approximately 3 Fr increase (standard size 14-18 Fr)
- should be removed as soon as possible to reduce the risk of UTI

Continuous Catheterization

- indications
  - accurate monitoring of U/O
  - relief of urinary retention due to medication, neurogenic bladder, or intravesical obstruction
  - temporary therapy for urinary incontinence
  - perineal wounds
  - clot prevention (22-24 Fr) for CBI
  - post-operative

Alternatives to Continuous Catheterization

- intermittent catheterization
  - PVR measurement
  - to obtain sterile diagnostic specimens for U/A, urine C&S
  - management of neurogenic bladder or chronic urinary retention
- condom catheter
- suprapubic catheter

Causes of Difficult Catheterizations and Treatment

- patient discomfort → use sufficient lubrication (+ xylocaine)
- collapsing catheter → lubrication as above ± firmer or larger catheter (silastic catheter)
- meatal/urethral stricture → dilate with progressively larger catheters/balloon catheter
- BPH → use coudé catheter as angled tip can help navigate around enlarged prostate
- urethral disruption/obstruction → filiform and followers or suprapubic catheterization
- anxious patient → anxiolytic medication

Complications of Catheterization

- infection: UTI
- meatal/urethral trauma

Contraindications

- trauma: blood at the urinary meatus, scrotal hematoma, pelvic fracture, and/or high riding prostate

Circumcision

Definition

- removal of some or all of the foreskin from the penis

Epidemiology

- 30% worldwide
- frequency varies with geography, religious affiliation, socioeconomic status

Medical Indications

- phimosis and recurrent paraphimosis
- recurrent UTIs (particularly in infants and in association with other urinary abnormalities)
- balanitis xerotica obliterans or other chronic inflammatory conditions

Contraindications

- unstable or sick infant
- congenital genital abnormalities (hypospadias)
- family Hx of bleeding disorders warrants laboratory investigation prior to circumcision

Complications

- bleeding
- infection
- penile entrapment, skin bridges
- fistula
- glans injury
- penile sensation deficits

Continuous Catheterization

- indications
  - accurate monitoring of U/O
  - relief of urinary retention due to medication, neurogenic bladder, or intravesical obstruction
  - temporary therapy for urinary incontinence
  - perineal wounds
  - clot prevention (22-24 Fr) for CBI
  - post-operative

Alternatives to Continuous Catheterization

- intermittent catheterization
  - PVR measurement
  - to obtain sterile diagnostic specimens for U/A, urine C&S
  - management of neurogenic bladder or chronic urinary retention
- condom catheter
- suprapubic catheter

Causes of Difficult Catheterizations and Treatment

- patient discomfort → use sufficient lubrication (+ xylocaine)
- collapsing catheter → lubrication as above ± firmer or larger catheter (silastic catheter)
- meatal/urethral stricture → dilate with progressively larger catheters/balloon catheter
- BPH → use coudé catheter as angled tip can help navigate around enlarged prostate
- urethral disruption/obstruction → filiform and followers or suprapubic catheterization
- anxious patient → anxiolytic medication

Complications of Catheterization

- infection: UTI
- meatal/urethral trauma

Contraindications

- trauma: blood at the urinary meatus, scrotal hematoma, pelvic fracture, and/or high riding prostate

Circumcision

Definition

- removal of some or all of the foreskin from the penis

Epidemiology

- 30% worldwide
- frequency varies with geography, religious affiliation, socioeconomic status

Medical Indications

- phimosis and recurrent paraphimosis
- recurrent UTIs (particularly in infants and in association with other urinary abnormalities)
- balanitis xerotica obliterans or other chronic inflammatory conditions

Contraindications

- unstable or sick infant
- congenital genital abnormalities (hypospadias)
- family Hx of bleeding disorders warrants laboratory investigation prior to circumcision

Complications

- bleeding
- infection
- penile entrapment, skin bridges
- fistula
- glans injury
- penile sensation deficits
Cystoscopy

Objective
• endoscopic inspection of the lower urinary tract (urethra, prostate, bladder, and ureteral orifices), samples for cytology
• scopes can be flexible or rigid

Indications
• gross hematuria
• LUTS (storage or voiding)
• urethral and bladder neck strictures
• bladder stones
• bladder tumour surveillance
• evaluation of upper tracts with retrograde pyelography (ureteric stents, catheters)

Complications
• during procedure
  ■ bleeding
  ■ anesthetic-related
  ■ perforation (rare)
• post-procedure (short-term)
  ■ infections, e.g. epididymo-orchitis (rare)
  ■ urinary retention
• post-procedure (long-term)
  ■ stricture

Radical Prostatectomy

Objective
• the removal of the entire prostate and prostatic capsule via a lower midline abdominal incision, laparoscopically or robotically
  ■ internal iliac and obturator vessel lymph nodes may also be dissected and sent for pathology (dependent on risk: clinical stage, grade, PSA)
  ■ seminal vesicle vessels are also partially or completely removed

Indications
• treatment for localized prostate cancer

Complications
• immediate (intraoperative)
  ■ blood loss
  ■ rectal injury (extremely rare)
  ■ ureteral injury (extremely rare)
• perioperative
  ■ lymphocele formation if concurrent pelvic lymphadenectomy performed
• late
  ■ moderate to severe urinary incontinence (3-10%)
  ■ mild urinary incontinence (20%)
  ■ ED (~50%, depending on whether one, both, or neither of the neurovascular bundles are involved in extracapsular extension of tumour)

Transurethral Resection of the Prostate

Objective
• to partially resect the periurethral portion of the prostate (transition zone) to decrease symptoms of urinary tract obstruction
• accomplished via a transurethral (cystoscopic) approach using an electrocautery loop, irrigation (glycine), and illumination

Indications
• obstructive uropathy (large bladder diverticula, renal insufficiency)
• refractory urinary retention
• recurrent UTIs
• recurrent gross hematuria
• bladder stones
• intolerance/failure of medical therapy
Complications
- acute
  - intra- or extraperitoneal rupture of the bladder
  - rectal perforation
  - incontinence
  - incision of the ureteral orifice (with subsequent reflux or ureteral stricture)
  - hemorrhage
  - epididymitis
  - sepsis
  - transurethral resection syndrome (also called "post-TURP syndrome")
    - caused by absorption of a large volume of the hypotonic irrigation solution used, usually through perforated venous sinusoids, leading to a hypervolemic hyponatremic state
    - characterized by dilutional hyponatremia, confusion, nausea, vomiting, HTN, bradycardia, visual disturbances, CHF, and pulmonary edema
    - treat with diuresis and (if severe) hypertonic saline administration
- chronic
  - retrograde ejaculation (>75%)
  - ED (5-10% risk increases with increasing use of cautery)
  - incontinence (<1%)
  - urethral stricture
  - bladder neck contracture

Extracorporeal Shock Wave Lithotripsy

Objective
- to treat renal and ureteral calculi (proximal, middle or distal) which cannot pass through the urinary tract naturally
- shockwaves focused onto stone → fragmentation, allowing stone fragments to pass spontaneously and less painfully

Indications
- potential first-line therapy for renal and ureteral calculi <2.5 cm
- individuals with calculi in solitary kidney
- individuals with HTN, DM or renal insufficiency
- *patient preference and wait-times play a large role in stone management

Contraindications
- acute UTI or urosepsis
- bleeding disorder or coagulopathy
- pregnancy
- obstruction distal to stone (ESWL can be used after stent or nephrostomy inserted)

Complications
- bacteriuria
- bacteremia
- post-procedure hematuria
- ureteric obstruction (by stone fragments)
- peri-nephric hematoma

Common Medications

Table 27. Erectile Dysfunction Medications

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mechanism</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>sildenafil</td>
<td>Phosphodiesterase inhibitor</td>
<td>Severe hypotension (very rare)</td>
</tr>
<tr>
<td>tadalafil</td>
<td>Selective inhibition of PDE5 (enzyme which degrades cGMP)</td>
<td>Contraindicated if Hx of priapism, or in conditions predisposing to priapism</td>
</tr>
<tr>
<td>vardenafil (PDE5is for use when some erection present)</td>
<td>Leads to sinusoidal smooth muscle relaxation and erection</td>
<td>(leukemia, myelofibrosis, polycythemia, sickle cell disease)</td>
</tr>
<tr>
<td>alprostadil (MUSE®), PGE + phentolamine + papaverine mixture</td>
<td>Prostaglandin E1</td>
<td>Penile pain</td>
</tr>
<tr>
<td>alprostadil, papaverine (intracavemosal injection)</td>
<td>Activation of cAMP, relaxing sinusoidal smooth muscle Local release (urethral suppository)</td>
<td>Presyncope</td>
</tr>
<tr>
<td>triple therapy also used: papaverine, phentolamine, PGE</td>
<td>See above</td>
<td>See above</td>
</tr>
</tbody>
</table>

A Comparison of Treatment Modalities for Renal Calculi Between 100 and 300 mm2: Are Shockwave Lithotripsy, Ureteroscopy, and Percutaneous Nephrolithotomy Equivalent?

J Endourol 2011;25:487-495

Purpose: To describe the outcomes of a series of patients who underwent shockwave lithotripsy (SWL), ureteroscopy (URS) or percutaneous nephrolithotomy (PCNL).

Methods: Patients treated for intermediate-sized upper tract calculi (100-300 mm²) at a single tertiary centre were included. Demographic and clinical data were collected from a prospectively maintained database.

Results: Of 137 patients, 38.7%, 29.9%, and 31.4% were treated with SWL, URS, and PCNL, respectively. Stone-free rate (85.3%) and single treatment success rate (85.3%) were highest for PCNL compared to SWL and URS (p<0.001). When allowing for up to two SWL treatments, success rates became equivalent for the three treatment groups (p=0.88). Auxiliary treatments were more frequent after SWL compared to URS and PCNL. Clavien grade complications did not differ between the three groups.

Conclusion: Up to two SWL treatments have equivalent success rate as compared to URS and PCNL. Hence, multiple SWL treatments may be a reasonable therapeutic option for patients who prefer SWL or who are not good candidates for alternative therapies.
### Table 28. Benign Prostatic Hyperplasia Medications

<table>
<thead>
<tr>
<th>Drug</th>
<th>Class</th>
<th>Mechanism</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>terazosin, doxazosin</td>
<td>α1 blockers</td>
<td>α-adrenergic antagonists reduce stromal smooth muscle tone Reduce Dynamic component of bladder outlet obstruction</td>
<td>Presyncope Leg edema Retrograde ejaculation Headache Asthenia Nasal congestion</td>
</tr>
<tr>
<td>tamsulosin, alfuzosin, silodosin</td>
<td>α1A selective</td>
<td>Blocks conversion of testosterone to DHT Reduces static component of bladder outlet obstruction Reduces prostatic volume</td>
<td>Sexual dysfunction PSA decreases</td>
</tr>
<tr>
<td>finasteride, dutasteride</td>
<td>5α reductase inhibitor</td>
<td>Blocks conversion of testosterone to DHT Reduces static component of bladder outlet obstruction Reduces prostatic volume</td>
<td>Sexual dysfunction PSA decreases</td>
</tr>
</tbody>
</table>

### Table 29. Prostatic Carcinoma Medications (N>0, M>0)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Class</th>
<th>Mechanism</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>leuprolide, goserelin</td>
<td>GnRH agonist</td>
<td>Initially stimulates LH, increasing testosterone and causing “flare” (initially increases bone pain) Later causes low testosterone</td>
<td>Hot flashes Headache Decreased libido</td>
</tr>
<tr>
<td>*diethylstilbestrol (DES)</td>
<td>Estrogens</td>
<td>Inhibit LH and cytotoxic effect on tumour cells</td>
<td>Increased risk of cardiovascular events (no longer available commercially in North America)</td>
</tr>
<tr>
<td>*cyproterone acetate</td>
<td>Steroidal antiandrogen</td>
<td>Competes with DHT for intracellular receptors: 1. Prevent flare produced by GnRH agonist 2. Use for complete androgen blockade 3. May preserve potency</td>
<td></td>
</tr>
<tr>
<td>flutamide, bicalutamide</td>
<td>Non-steroidal antiandrogen</td>
<td>As above</td>
<td>Hepatotoxic: AST/ALT monitoring</td>
</tr>
<tr>
<td>*ketoconazole, spironolactone</td>
<td>Steroidogenesis inhibitors</td>
<td>Blocks multiple enzymes in steroid pathway, including adrenal androgens</td>
<td>GI symptoms Hyperkalemia Gynecomastia</td>
</tr>
</tbody>
</table>

*Very rarely used

### Table 30. Continence Agents and Overactive Bladder Medications

<table>
<thead>
<tr>
<th>Drug</th>
<th>Class</th>
<th>Mechanism</th>
<th>Indication</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>oxybutynin</td>
<td>Antispasmonic</td>
<td>Inhibits action of ACh on smooth muscle Decreases frequency of uninhibited detrusor contraction Diminishes initial urge to void</td>
<td>Overactive bladder Urge incontinence + urgency + frequency</td>
<td>Dry mouth Blurred vision Constipation Supraventricular tachycardia</td>
</tr>
<tr>
<td>oxybutynin, tolterodine, trospium, solifenacin, darifenacin fesoterodine</td>
<td>Anticholinergic</td>
<td>Muscarinic receptor antagonist Selective for bladder Increases bladder volume Decreases detrusor pressure</td>
<td>Overactive bladder Urge incontinence + urgency + frequency</td>
<td>As above</td>
</tr>
<tr>
<td>mirabegron</td>
<td>β3 agonist</td>
<td>Beta sympathetic receptor blocker in the bladder; relaxes bladder during storage phase</td>
<td>Overactive bladder Urge incontinence + urgency + frequency</td>
<td>Blood pressure should be monitored</td>
</tr>
<tr>
<td>imipramine</td>
<td>Tricyclic antidepressant</td>
<td>Symptomomimetic effects: urinary sphincter contraction Anticholinergic effects: detrusor relaxation</td>
<td>Stress and urge incontinence</td>
<td>As above Weight gain Orthostatic hypotension Prolonged PR interval</td>
</tr>
<tr>
<td>Botulinum toxin A bladder injections</td>
<td>Neurotoxin</td>
<td>Prevents the release of neurotransmitters</td>
<td>Refractory OAB incontinence both neurogenic and non-neurogenic</td>
<td>Urinary retention, UTI</td>
</tr>
</tbody>
</table>

Note: All anti-cholinergics are equally effective and long-acting formulations are better tolerated. Newer muscarinic M3 receptor specific agents (solifenacin, darifenacin) are equally efficacious as older drugs, however, RCTs based on head-to-head comparison to long acting formulations are lacking.
References

General Information

Common Presenting Problems

Overactive Bladder

Benign Renal Neoplasm

Urological Emergencies

Medications

EBM
Acronyms ........................................ 2

Peripheral Arterial Disease (PAD) ............... 2
Acute Arterial Ischemia
Chronic Arterial Occlusion/Insufficiency

Aortic Disease .................................. 4
Aortic DisSECTION
Aortic Aneurysm

Carotid Stenosis ................................. 7

Peripheral Venous Disease ....................... 8
Deep Venous Thromboembolism
Superficial Venous Thrombosis
Varicose Veins
Chronic Venous Insufficiency

Lymphedema ...................................... 10

References ....................................... 11
Peripheral Arterial Disease (PAD)

Acute Arterial Ischemia

Definition
- acute occlusion of a peripheral artery, usually without a history of claudication
- urgent management required
  - skeletal muscle can tolerate 6 h of ischemia before irreversible damage and myonecrosis; exception is in acute-on-chronic occlusion, where previously developed collaterals allow more time
  - tends to be lower extremity > upper extremity; femoropopliteal > aortoiliac

Etiology and Risk Factors
- embolism vs. thrombosis
  - examples of conditions that predispose to embolism are: arrhythmias, endocarditis, and arterial aneurysms
  - existing atherosclerotic plaques (i.e. chronic PAD) can rupture causing thrombosis
  - previous vascular grafts/reconstructions can fail and thrombose leading to acute presentation
  - hypercoagulable states can contribute to arterial thrombosis

Clinical Features

<table>
<thead>
<tr>
<th>Table 1. Arterial Embolism vs. Thrombosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Presentation</strong></td>
</tr>
<tr>
<td><strong>Onset</strong></td>
</tr>
<tr>
<td><strong>Loss of Function/Sensation</strong></td>
</tr>
<tr>
<td><strong>Hx of Claudication</strong></td>
</tr>
<tr>
<td><strong>Atrophic Changes</strong></td>
</tr>
<tr>
<td><strong>Contralateral Limb Pulses</strong></td>
</tr>
</tbody>
</table>

Investigations
- history and physical exam are essential; depending on degree of ischemia one may have to forego investigations and go straight to the operating room
- ABI: extension of physical exam, easily performed at bedside
- ECG, troponin: rule out recent MI or arrhythmia
- CBC: rule out leukocytosis, thrombocytosis or recent drop in platelets in patients receiving heparin (may suggest heparin induced thrombocytopenia syndrome or HITS)
- PT/INR, PTT: patient anticoagulated/sub-therapeutic INR
- Echo: identify wall motion abnormalities, intracardiac thrombus, valvular disease, aortic dissection (Type A)
- CT angiogram: underlying atherosclerosis, aneurysm, aortic dissection
- conventional catheter based angiography: can be obtained in OR; prelude to thrombolysis, as part of endovascular intervention or for planning treatment
Table 2. Clinical Categories of Acute Limb Ischemia

<table>
<thead>
<tr>
<th>Grade</th>
<th>Category</th>
<th>Sensory Loss</th>
<th>Motor Deficit</th>
<th>Prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Viable</td>
<td>None</td>
<td>None</td>
<td>No immediate threat</td>
</tr>
<tr>
<td>IIA</td>
<td>Marginally threatened</td>
<td>None or minimal (toes)</td>
<td>None</td>
<td>Salvageable if promptly treated</td>
</tr>
<tr>
<td>IIB</td>
<td>Immediately threatened</td>
<td>More than toes</td>
<td>Mild/moderate</td>
<td>Salvageable if promptly revascularized</td>
</tr>
<tr>
<td>III</td>
<td>Irreversible</td>
<td>Profound, anesthetic</td>
<td>Profound, paralysis (rigor)</td>
<td>Major tissue loss</td>
</tr>
</tbody>
</table>

Treatment
- Immediate heparinization with 5000 IU bolus (80 Units/kg) and continuous infusion to titrate PTT to 70-90 s
- If impaired neurovascular status: emergent revascularization
- If intact neurovascular status: time for work up (including angiogram-CTA)
- Definitive treatment
- Embolus: embolectomy
- Thrombus: thrombectomy ± bypass graft ± endovascular therapy
- Irreversible ischemia (complete loss of power or sensation, absent venous and arterial dopplers, rigor): primary amputation
- Identify and treat underlying cause
- Continue heparin post-operatively, start oral anticoagulant post-operative day 1 x 3 mo depending on underlying etiology

Complications
- Compartment syndrome with prolonged ischemia; requires 4-compartment (anterior/lateral/superficial and deep posterior) fasciotomy
- Risk of arrhythmia and death with reperfusion injury
- Renal failure and multi-organ failure due to toxic metabolites from ischemic muscle

Prognosis
- 12-15% mortality rate
- 5-40% morbidity rate (amputation)

Chronic Arterial Occlusion/Insufficiency

Definition
- Chronic ischemia due to inadequate arterial supply to meet cellular metabolic demands (during walking (claudication) or at rest (limb threat/critical limb ischemia))

Etiology and Risk Factors
- Predominantly due to atherosclerosis (for pathogenesis, see Cardiology and Cardiac Surgery, C26); primarily occurs in the lower extremities
- Major risk factors: smoking, DM, older age
- Minor risk factors: HTN, hyperlipidemia, obesity, sedentary lifestyle, PMHx or FMHx CAD/CVD

Clinical Features
- Claudication: must differentiate vascular from neurogenic claudication or MSK (see Table 1)
  1. Pain with exertion: usually in calves or any exercising muscle group
  2. Relieved by short rest: 2-5 min, and no postural changes necessary
  3. Reproducible: same distance or time to elicit pain, same location of pain, same amount of rest to relieve pain
- Critical limb ischemia (CLI)
  1. Includes rest pain, night pain, tissue loss (ulceration or gangrene)
  2. Pain most commonly over the forefoot, waking person from sleep, and often relieved by hanging foot off bed
  3. Ankle pressure <40 mmHg, toe pressure <30 mmHg, ABI <0.40
    - Pulses may be absent at some locations, bruits may be present
    - Signs of poor perfusion: hair loss, hypertrophic nails, atrophic muscle, ulcersations and infections, slow capillary refill, prolonged pallor with elevation and rubor on dependency, venous toughening (collapse of superficial veins of foot)

Investigations
- Non-invasive
- Routine blood work, fasting metabolic profile
- ABI: take highest brachial and highest ankle (dorsalis pedis artery or posterior tibial artery) pressures for each side generally (see Table 3) (may be falsely normal or elevated in those with calcified vessels e.g. diabetics)
- CTA and MRA
  - excellent for large arteries (aorta, iliac, femoral, popliteal) but may have difficulty with tibial arteries (especially in the presence of disease)
  - may have difficulty with tibial arteries (especially in the presence of disease)
  - require IV injection of nephrotoxic contrast (iodinated contrast for CT, gadolinium for MR)
  - used primarily for planning interventions
  - invasive
    - arteriography: superior resolution to CTA/MRA, better for tibial arteries, can be done intraoperatively or as part of endovascular intervention

<table>
<thead>
<tr>
<th>Table 3. Ankle-Brachial Indices</th>
<th>Degree of Ischemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABI Recording</td>
<td></td>
</tr>
<tr>
<td>&gt;1.20</td>
<td>Suspect wall calcification (most common in diabetics)</td>
</tr>
<tr>
<td>&gt;0.95</td>
<td>Normal/no ischemia</td>
</tr>
<tr>
<td>0.50-0.80</td>
<td>Claudication range</td>
</tr>
<tr>
<td>&lt;0.40</td>
<td>Possible critical ischemia</td>
</tr>
</tbody>
</table>

**Treatment**
- conservative
  - risk factor modification (smoking cessation, HbA1c control, treatment of HTN, hyperlipidemia (statin), antplatelet therapy [ECASA])
  - exercise program (30 min 3x/wk): improves collateral circulation and oxygen extraction at the muscle level
  - foot care (especially in DM): keep wounds clean/dry, avoid trauma and pressure on wounds
- pharmacotherapy
  - antiplatelet agents (e.g. ECASA, clopidogrel)
  - cilostazol (cAMP-phosphodiesterase inhibitor with antplatelet and vasodilatory effects): improves walking distance for some patients with claudication (not available in Canada)
- surgical/endovascular
  - indications: severe lifestyle impairment, vocational impairment, critical ischemia
  - revascularization
    - endovascular (angioplasty ± stenting)
    - endarterectomy: removal of plaque and repair with patch (usually distal aorta or common/profunda femoral)
    - bypass graft sites: aortofemoral, axillofemoral, femoropopliteal, distal arterial – graft choices: vein graft (reversed or in situ), synthetic (polytetrafluoroethylene graft (e.g. Gore-Tex) or Dacron)
    - amputation: if not suitable for revascularization, persistent serious infections/gangrene, unremitting rest pain poorly controlled with analgesics

**Prognosis**
- claudication: conservative therapy: 60-80% improve, 20-30% stay the same, 5-10% deteriorate, 5% will require intervention within 5 yr, <4% will require amputation
- for patients with CLI (rest pain, night pain, ulceration or gangrene): high risk of limb loss and predicts for increased mortality (carries 25% risk of death at 1 yr)

**Aortic Disease**

**Aortic Dissection**

**Definition**
- tear in aortic intima allowing blood to dissect into the media
- Stanford classification: Type A (involve the ascending aorta) vs. Type B (do not)
- acute <2 wk (initial mortality 1% per hour for Type A dissections)
- chronic >2 wk

**Etiology**
- most common: HTN → degenerative/cystic changes → damage to aortic media
- other: connective tissue disease (e.g. Marfan’s, Ehlers-Danlos), cystic medial necrosis, atherosclerosis, congenital conditions (e.g. coarctation of aorta, bicuspid aortic valves, patent ductus arteriosus), infection (e.g. syphilis), trauma, arteritis (e.g. Takayasu’s)
Epidemiology
- M:F = 3.2:1
- small increased incidence in African-Canadians (related to higher incidence of HTN); lowest incidence in Asians
- peak incidence 50-65 yr old; 20-40 yr old with connective tissue diseases

Clinical Features
- sudden onset tearing chest pain that radiates to back with:
  - HTN (75-85% of patients)
  - asymmetric BPs and pulses between arms (>30 mmHg difference indicates poor prognosis)
  - ischemic syndromes due to occlusion of aortic branches: coronary (MI), carotids (ischemic stroke, Horner’s syndrome), splanchic (mesenteric ischemia), renal (AKI), peripheral (ischemic leg), intercostal vessels (spinal cord ischemia)
  - “unseating” of aortic valve cusps (new diastolic murmur in 20-30%) in Type A dissection
  - rupture into pleura (dyspnea, hemoptyisis) or retroperitoneum (hypotension, shock) or pericardium (cardiac tamponade)
  - syncope
  - aortic dissection is ‘the great imitator’ thus increased risk to patient and MD (medicolegal)

Investigations
- CXR: pleural cap (pleural effusion in lung apices), widened mediastinum, left pleural effusion with extravasation of blood
- TEE: can visualize aortic valve and thoracic aorta but not abdominal aorta
- ECG: LVH ± ischemic changes, pericarditis, heart block
- CTA (gold standard), aortography, MRA: 100% sensitive and specific
- Blood work: lactate (elevated in ischemic gut, shock), amylase (rule out pancreatitis), troponin (rule out MI)

Treatment
- Type A dissection needs referral to cardiac surgeon for urgent repair
  - Type B dissection is managed medically with selective intervention for complications or refractory symptoms/progression despite medical therapy – may be a subset of patients who could be well treated with early aortic stent-grafting after initial medical stabilization- evolving area of the literature
  - pharmacologic
  - acute therapy is typically with intravenous antihypertensives titrated to BP measured by arterial line in critical care setting
  - may transition to oral meds after initial control
  - β-blocker to lower BP and decrease cardiac contractility
  - use nondihydropyridine CCB if there is a clear contraindication to β-blockers
  - target sBP of 110 mmHg and HR <60 bpm- need to manage hypertension and pain-failure to do so is a relative indication for surgical intervention
  - ACEI and/or other vasodilators if insufficient BP or HR control
- surgical
  - urgent surgical consult if thoracic aortic dissection diagnosed or highly suspected
  - Type A to cardiac surgery, Type B to vascular surgery
  - resection of segment with intimo-intimal reconstitution of flow through true lumen; replacement of the affected aorta with prosthetic graft
  - post-operative complications: renal failure, intestinal ischemia, stroke, paraplegia, persistent leg ischemia, death
  - 2/3 of patients die of operative or post-operative complications
  - Type A: requires emergent surgery with cardiopulmonary bypass;
    - initial mortality rate without surgery is 3% per h for first 24 h, 30% 1 wk, 80% 2 wk
  - Type B: managed medically in absence of spinal/mesenteric/limb malperfusion syndrome
    - <10-20% require urgent operation for complications or persistent symptoms (chest pain)
    - treatment can be surgical or endovascular (now more often endovascular)
    - require follow-up over time to monitor for aneurysmal degeneration
    - role for early endovascular intervention controversial (2013 INSTEAD trial)
- with treatment, 60% 5 yr survival, 40% 10 yr survival

Aortic Aneurysm

Definition of Aneurysm
- localized dilatation of an artery having a diameter at least 1.5x that of the expected normal diameter
- true aneurysm: involving all vessel wall layers (intima, media, adventitia)
- false aneurysm (also known as pseudo-aneurysm): disruption of the aortic wall or the anastomotic site between vessel and graft with containment of blood by a fibrous capsule made of surrounding tissue
- aneurysms can rupture, thrombose, embolize, erode, and fistulize

ACC/AHA 2005 Guidelines define an AAA when the minimum AP diameter of abdominal aorta ≥3.0 cm

Figure 2. Classification of aortic dissection (black arrow indicates where the dissection begins)
Classification
- thoracic aortic aneurysm (TAA): ascending, transverse arch, descending
- thoracoabdominal
- abdominal aortic aneurysm (AAA): 90-98% are infrarenal
- suprarenal: involves one or more visceral arteries, but does not involve the chest
- pararenal: renal arteries arise from aneurysmal aorta, but the SMA origin is not aneurysmal
- juxtarenal: the renal arteries originate from normal aorta, but are immediately adjacent to aneurysmal aorta (there is no nonaneurysmal aorta distal to the origin of the renal arteries)
- infrarenal: the aneurysm originates distal to the renal arteries (there is nonaneurysmal aorta distal to the origins of the renal arteries)

Etiology and Risk Factors
- risk factors: smoking, HTN, PVD, CAD, CVD, age >70, family history
- degenerative
- traumatic
- mycotic (Salmonella, Staphylococcus, usually suprarenal aneurysms)
- connective tissue disorder (Marfan syndrome, Loey-Dietz Syndrome, Ehlers-Danlos syndrome)
- vasculitis
- infectious (syphilis, fungal)
- ascending thoracic aneurysms are associated with bicuspid aortic valve

Clinical Features
- most commonly in the abdominal aorta
- common presentation: due to acute expansion or rupture
  - syncope
  - pain (chest, abdominal, flank, back)
  - hypotension
  - palpable pulsatile mass above the umbilicus
  - airway or esophageal obstruction, hoarseness (left recurrent laryngeal nerve paralysis), hemoptysis, or hemorrhage (indicates thoracic or thoracoabdominal aortic aneurysm)
  - distal pulses may be intact
- 75% asymptomatic (discovered incidentally)
- uncommon presentations
  - ureteric obstruction and hydronephrosis (often with inflammatory aortic aneurysm)
  - gastrointestinal bleed (duodenal mucosal hemorrhage, aortoduodenal fistula-most commonly a result of previous aortic surgery)
  - aortocaval fistula
  - distal embolization (blue toe syndrome) occurs in <1% of AAAs

Investigations
- blood work: CBC, electrolytes, urea, creatinine, PTT, INR, type and cross
- abdominal U/S (approaching 100% sensitivity, up to ±0.6 cm accuracy in size determination) – useful for screening and surveillance
- CTA with contrast (accurate visualization, size determination, EVAR planning)
- peripheral arterial doppler/duplex (rule out aneurysms elsewhere, e.g. popliteal)

Treatment
- conservative (for asymptomatic aneurysms that do not meet the size threshold for repair)
  - cardiovascular risk factor reduction: smoking cessation; control of HTN, DM, hyperlipidemia, regular exercise watchful waiting, U/S surveillance with frequency depending on size and location
- surgical
  - indications
    - ruptured
    - symptomatic
    - prophylaxis when risk of rupture is greater than risk of surgery (size >5.5 cm for AAA)
    - repair may result in improved morbidity and mortality
Carotid Stenosis

Definition
narrowing of the internal carotid artery lumen due to atherosclerotic plaque formation, usually near common carotid bifurcation into internal and external carotids

Risk Factors
• for atherosclerosis: HTN, smoking, DM, CVD or CAD, dyslipidemia, older age

Clinical Features
• may be asymptomatic
• symptomatic stenosis may present as TIA, RIND, or stroke
• permanent or temporary retinal insufficiency or infarct (see Ophthalmology, OP22)

Investigations
• CBC, PT/INR, PTT (hypercoagulable states)
• fundoscopy: cholesterol emboli in retinal vessels (Hollenhorst plaques)
• auscultation over carotid bifurcation for bruits (do not correlate with degree of stenosis)
• carotid duplex: determines severity of disease (mild/moderate/severe stenosis or occlusion)
• catheter-based angiogram: “gold standard” but invasive and 1/200 risk of stroke (i.e. only used now during carotid angioplasty and stenting)
• MRA: safer than angiogram, may overestimate stenosis
• CTA

Treatment
• risk reduction - control of HTN, lipids, DM
• pharmacological - antiplatelet agents (ASA ± dipyridamole, clopidogrel) ~25% relative risk reduction
• surgical - carotid endarterectomy (generally if symptomatic and >70% stenosis)
• endovascular angioplasty ± stenting

Prognosis

Table 4. Symptomatic Carotid Stenosis: North American Symptomatic Carotid Endarterectomy Trial (NASCET)

<table>
<thead>
<tr>
<th>% Stenosis on Angiogram</th>
<th>Risk of Major Stroke or Death</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Medical Rx</td>
</tr>
<tr>
<td>70-99%</td>
<td>26% over 2 yr</td>
</tr>
<tr>
<td>50-69%</td>
<td>22% over 5 yr</td>
</tr>
<tr>
<td>&lt;50%</td>
<td>Surgery has no benefit with 5% complication rate</td>
</tr>
</tbody>
</table>

Endovascular aneurysm repair (EVAR)
– newer procedure; high success rates in patients with suitable anatomy
– advantages: preferred to open surgery in ruptured AAA for patients with suitable anatomy, decreased morbidity and mortality, procedure time, need for transfusion, ICU admissions, length of hospitalization, and recovery time
– disadvantages: endoleak rates as high as 20-30%, device failure increasing as longer follow-up periods are achieved, re-intervention rates 10-30%, cost-effectiveness is an issue, radiation exposure (especially in younger patients due to need for life-long follow up)
– complications
• early: immediate conversion to open repair (<1%), groin hematoma, arterial thrombosis, iliac artery rupture, and thromboemboli
• late: endoleak, graft kinking, migration, thrombosis, rupture of aneurysm

Ascending Aortic Aneurysms
– symptomatic, enlarging, diameter >6 cm or >2x normal lumen size, >4.5 cm and aortic regurgitation (annulooaortic ectasia); ≥4.5-5 cm in Marfan syndrome

Risk of rupture depends on: size, family history of rupture, rate of enlargement (>1 cm/yr in diameter), symptoms, and comorbidities (HTN, COPD, dissection), smoking
elective AAA repair mortality 2-5% for open repair (1-2% for EVAR); elective TAA repair mortality <10% (highest with proximal aortic and thoracoabdominal repairs)
surgical options
– open surgery (laparotomy or retroperitoneal) with graft replacement
– complications
• early: renal failure, spinal cord injury (paraparesis or paraplegia), impotence, arterial thrombosis, anastomotic rupture or bleeding, peripheral emboli
• late: graft infection/thrombosis, aortoenteric fistula, anastomotic (pseudo) aneurysm

Long-Term Comparison of Endovascular and Open Repair of Abdominal Aortic Aneurysm
Purpose: Determine if EVAR reduces long-term mortality and mortality vs. open repair.
Methods: Randomly assigned patients (n=881) with asymptomatic AAA to EVAR vs. open repair and followed them for 8 yrs.
Results: EVAR showed reduced in perioperative mortality at 2 yrs (hazard ratio, 0.63; 95% CI, 0.40 to 0.93; P = 0.04) and 3 yrs (hazard ratio, 0.72; 95% CI, 0.51 to 1.00; P = 0.05). There was no significant difference in aneurysm-related deaths between groups (P = 0.22). EVAR led to increased survival in pts <70 yrs & open repair led to increased survival in pts >70 yrs (P = 0.05).
Conclusion: EVAR and open repair have similar long-term survival. EVAR has periporative survival advantage that is sustained for several years. EVAR led to increased long-term survival among younger patients but not older patients.

Prevention of Disabling and Fatal Strokes by Successful Carotid Endarterectomy in Patients Without Recent Neurological Symptoms: Randomized Controlled Trial
Study: Asymptomatic Carotid Surgery Trial (ACST), a RCT with follow-up at 5 yr.
Patients: 3,120 asymptomatic patients with significant carotid artery stenoses were randomized equally between immediate carotid endarterectomy (CEA) and indefinite deferral of CEA and were followed for up to 5 yrs (mean 3.4 yrs).
Main Outcome: Any stroke (including fatal or disabling).
Conclusions: In asymptomatic patients with significant carotid artery stenosis, immediate CEA reduced the net 5-yr stroke risk from about 12% to about 6%. Half of this 5 yr benefit involved disabling or fatal strokes.
<table>
<thead>
<tr>
<th>% Stenosis on Angiogram</th>
<th>Medical Rx</th>
<th>Medical + Surgical Rx</th>
</tr>
</thead>
<tbody>
<tr>
<td>70-99%</td>
<td>26% over 2 yr</td>
<td>9% over 2 yr</td>
</tr>
<tr>
<td>60-99%</td>
<td>11% over 5 yr</td>
<td>5.1% over 5 yr (ACAS)</td>
</tr>
<tr>
<td>50-69%</td>
<td>11.8% over 5 yr</td>
<td>6.4% over 5 yr (ACST)</td>
</tr>
</tbody>
</table>

### Peripheral Venous Disease

#### Deep Venous Thromboembolism

- see Hematology, H35

#### Superficial Venous Thrombosis

**Definition**

- thrombosis of a superficial vein; usually spontaneous but can follow venous cannulation

**Etiology**

- infectious: suppurative phlebitis (complication of IV cannulation; associated with fever/chills)
- trauma
- inflammatory: varicose veins, migratory superficial thrombophlebitis, Buerger's disease, SLE
- hematologic: polycythemia, thrombocytosis
- neoplastic: occult malignancy (especially pancreatic)
- idiopathic

**Clinical Features**

- most common in greater saphenous vein and its tributaries
- pain and cord-like swelling along course of involved vein
- areas of induration, erythema, and tenderness correspond to dilated and often thrombosed superficial veins
- complications
  - simultaneous DVT (up to 20% of cases), PE (rare unless DVT)
  - recurrent superficial thrombophlebitis

**Investigations**

- non-invasive tests (e.g. Doppler) to exclude associated DVT

**Treatment**

- conservative
  - moist heat, compression bandages, mild analgesic, anti-inflammatory and anti-platelet (e.g. ASA), ambulation
- surgical excision of involved vein
  - indication: failure of conservative measures (symptoms that persist over 2 wk)
  - suppurative thrombophlebitis: broad-spectrum IV antibiotics and excision

---

### Varicose Veins

**Definition**

- distention of tortuous superficial veins resulting from incompetent valves in the deep, superficial, or perforator systems

**Etiology**

- primary (99% of cases) varicosities: venous valve incompetence or obstruction
  - contributing factors: increasing age, systemic hormonal contraceptive use, prolonged standing, pregnancy, obesity
- secondary varicosities: DVT, malignant pelvic tumours with venous compression, congenital anomalies, arteriovenous fistulae, trauma

**Epidemiology**

- primary varicose veins are the most common form of venous disorder of lower extremity
- 65% of north American adult population gets some degree of venous insufficiency
Peripheral Venous Disease

Clinical Features (Not Correlated with Varicosity Size)
- diffuse aching, fullness/tightness, nocturnal cramping
  - aggravated by prolonged standing (end of day), premenstrual
- visible long, dilated and tortuous superficial veins along thigh and leg (greater or short saphenous veins and tributaries)
- ulceration, hyperpigmentation, and induration (ie-lipodermatosclerosis)
- Brodie-Trendelenburg test (valvular competence test)
  - with patient supine, raise leg and compress saphenous vein at thigh, have patient stand – if veins fill quickly from top down then incompetent valves; use multiple tourniquets to localize incompetent veins (can get same information with standing venous ultrasound looking for reflux)
- often the degree of symptoms do not correlate with the clinical findings

Complications
- recurrent superficial thrombophlebitis
- hemorrhage: external or subcutaneous
- ulceration, eczema, lipodermatosclerosis, and hyperpigmentation

Treatment
- largely a cosmetic problem
- conservative: elastic compression stockings
- surgical: high ligation and stripping of the long saphenous vein and its tributaries, ultrasound-guided foam sclerotherapy, endovenous laser therapy
- indications for surgery: symptomatic varix (pain, bleeding, recurrent thrombophlebitis), tissue changes (hyperpigmentation, ulceration), failure of conservative treatment, cosmetic

Prognosis
- benign course with predictable complications
- almost 100% symptomatic relief with treatment if varicosities are primary
- good cosmetic results with treatment
- significant post-operative recurrence

Chronic Venous Insufficiency

Definition
- venous insufficiency and skin damage

Etiology
- calf muscle pump dysfunction and valvular incompetence (reflux) due to phlebitis, varicosities, or DVT
- venous obstruction

Clinical Features
- pain (most common), ankle and calf edema – relieved by foot elevation
- pruritus, brownish hyperpigmentation (hemosiderin deposits)
- stasis dermatitis, subcutaneous fibrosis if chronic (lipodermatosclerosis)
- ulceration: shallow, above medial malleolus, weeping (wet), painless, irregular outline
- signs of DVT/varicose veins/thrombophlebitis

Investigations
- not required if conservative treatment only
- Doppler U/S (most commonly used in pre-operative assessment)
- venography or ambulatory venous pressure measurement (not often used)

Treatment
- conservative
  - elastic compression stockings, ambulation, periodic rest-elevation, avoid prolonged standing
  - ulcers: multilayer compression bandage, antibiotics prn
- surgical
  - if conservative measures fail, or if recurrent/large ulcers to reduce the risk of recurrence
  - surgical ligation of perforators in region of ulcer (GSV/LSV ligation and stripping)
- endovenous: laser or radiofrequency ablation, or foam sclerotherapy
Lymphedema

Definition
- obstruction of lymphatic drainage resulting in edema with high protein content

Etiology
- primary
  - Milroy's syndrome: congenital hereditary lymphedema
  - lymphedema praecox (75% of cases): starts in adolescence
  - lymphedema tarda: starts >35 yr
- secondary
  - infection: filariasis (#1 cause worldwide)
  - malignant infiltration: axillary, groin or intrapelvic
  - radiation/surgery (axillary, groin lymph node removal): #1 cause in North America

Clinical Features
- classically non-pitting edema
- impaired limb mobility, discomfort/pain, psychological distress

Treatment
- avoid limb injury (can precipitate or worsen lymphedema)
- skin hygiene
  - daily skin care with moisturizers
  - early medical assessment and treatment for infection (topical for fungal infection; systemic for bacterial infection)
- external support
  - intensive: compression bandages
  - maintenance: compression garment
- exercise
  - gentle daily exercise of affected limb, gradually increasing ROM
  - must wear a compression sleeve/bandages when doing exercises
- massage: manual lymph drainage therapy

Prognosis
- if left untreated becomes resistant to treatment due to subcutaneous fibrosis
- cellulitis causes rapid increase in swelling and worsening lymphedema (destruction of additional lymphatics)
Guidelines
Schneider PA, Camerota AJ. Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies. Am J Cardiol 2001;87(Suppl):3D-13D.
Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC), Eur Heart J 2011;32:2851-2906.

Vascular Surgery
Schneider PA, Camerota AJ. Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies. Am J Cardiol 2001;87(Suppl):3D-13D.
Antithrombotics; C51
Antibiotics; ID47, ID48
Anticoagulant Therapy; H57
Antidepressants; PS44
Antidiuretic Hormone; E18
Antifungals; ID53
Antimicrobials; ID48
Antiparasitics; ID05
Antiphospholipid Antibody Syndrome; RH12
Antitussive Therapy; H56
Antipsychotics; PS42
Antiviral; ID53
Anemia; GS10
Anxiety; ER22, FM15
Disorders; PS13, PS36
Anxieties; PS48
Aortic Aneurysm; VS5
Aortic Disease; VS4
Aortic Dissection; ER22, VS4
Aphasia; N27
Aplastic Anemia; H17
Apnea; P65
Appendicitis; GS27
Appendix; GS27
Apraxia; N28
Arcus Senilis; OP18
Arrhythmias; C16
Arterial Blood Gases; R5
Arterial Ischemia; VS2
Arteriovenous Malformations; NS22
Artery Disease; E5
Arthritis; MI21
Hip; OR29
Articular Cartilage; OR6
Asbestos
Pleur; Disease; R24
Ascending Cholangitis; G43
Ascites; G39
Aspergillus spp.; ID36
Aspiration; A5
Assessing Evidence; PH16
Atopic Dermatitis; D13
Asthma; ER29, FM16, P87, R7
Astrocytoma; NS12
Atelectasis; GS10
Atopic Dermatitis; D13
Atrial Fibrillation; ER31
Attention Deficit Hyperactivity Disorder; PS38
Atypical Hyperplasia; GS56
Auditory Brainstem Response; OT12
Aural Rehabilitation; OT12
Autism Spectrum Disorder; PS37
Autoimmune
Chronic Active Hepatitis; G31
Hemolytic Anemia; H22
Inner Ear Disease; OT20
Pancreatitis; G46
Autonomic Pharmacology; CP10
AV Conduction Blocks; ER30
β-Thalassemia Intermedia; H20
β-Thalassemia Major; H19
β-Thalassemia Minor (Thalassemia Trait); H19
Back Pain; ER24
Bacterial Infections; D25
Rhinovirus; OT25
Vaginosis; FM51
Bacteriology; ID2
Bariatric Surgery; GS20
Barrett’s Esophagus; G7
Bartholin Gland Abscess; GS31
Basal Cell Carcinoma; D34
Bed Bugs; D28
Behavioural Neurology; N20
Benign Active Bone Tumours; OR45
Aggressive Bone Tumours; OR46
Breast Lesions; GS55
Laryngeal Papillomas; OT29
Paroxysmal Positional Vertigo; OT13
Prostatic Hyperplasia; FM17, U7
Renal Neoplasms; U20
Bereavement; PS18
Biliary Colic; GS47
Biliary Tract; G3, G40, GS46
Binge-Eating Disorder; PS32
Bipolar Disorders; PS12
Bites; ER47, PL10
Bladder Carcinoma; U23
Bladder Catheterization; U40
Bladder Trauma; U32
Bleeding Disorders in Neonates; P65
Blepharitis; OP13
Blood; NS15
Arterial Blood Gases; R5
Film Interpretation; H3
Products; H52
Supply to the Face; OT4
Transfusion
Delayed Reactions; H55
Reactions; H54
Blow-Out Fracture; OP40
Blunt Trauma; OP39
Bone Marrow Aspiration; H5
Bone Marrow Biopsy; H5
Bone Tumours; MI22, OR45
Bone X-Rays; MI21
Botulism; N39
Bowen’s Disease; D35
Brachial Cleft Cysts; OT32
Brachial Plexus; PL4, PL28
Bradyarrhythmias; C18
Bradydyssrhythmias; ER30
Brain Injury; ER9, NS30
Brain Tumours; NS37
Branch Retinal Artery Occlusion; OP22
Branch Retinal Vein Occlusion; OP22
Breast; GS55, MI30
Anatomy; PL32
Augmentation; PL34
Cancer; FM3, GS56
Feeding; OB47
Imaging; MI29
Reconstruction; PL35
Reduction; PL32
Breath Holding Spells; P8
Breech Presentation; OB22
Brief Psychotic Disorder; PS8
Bronchiectasis; R12
Broncholithiasis; P66
Bronchitis; FM18, FM50
Bronchopulmonary Dysplasia; P66
Brown Macule; D5
Bulimia Nervosa; PS31
Bulla; D5
Bullous Pemphigoid; D19
Bunions; OR40
Burns; ER46, PL17
Calcaneal Fracture; OR38
Calcium Homeostasis; E36
Cancer
Breast; FM3
Cervical; FM5
Colorectal; FM4, GS34
Colorectal Cancer Syndromes; GS33
Gallbladder; GS50
Lung; FM4
Predisposition Syndromes; P50
Renal Pelvis; U22
Screening; FM3
Ureter; U22
Candida albicans; ID35
Candidiasis; D31
Cannabis; PS25
Capacity; ELOM6
Carbuncles; D26
Cardiac
Anatomy; C3
Anxiety; C24
Biomarkers; C11
Catheterization; C14
Diagnostic Tests; C5
Dermatitis; D13
Dermatitis Herpetiformis; D20
Dermatologic
  Emergencies; ER43
  Therapies; D44
Dermatophytoses; D26
Determinants of Health; PH3
Developmental Dysplasia of the Hip; OR42
Diabetes Insipidus; E18, NP11
Diabetes Medications; E49
Diabetes Mellitus; E7, FM21, NP31, OB26, OP33, P25
  Acute Complications; E11
  Gestational Diabetes Mellitus; OB26
  Insulin Formulations; E9
  Insulin Regimens; E10
  Macrovascular Complications; E12
  Microvascular Complications; E12
  Other Complications; E13
  Pre-Diabetes; E6
Type 1; E7
Type 2; E7
Diabetic
  Emergencies; ER34
  Foot Infections; ID15
  Ketoacidosis; ER34
Dialysis; NP37
Diarrhea; FM50, G14, ID11, P33
Dilated Cardiomyopathy; C40
Diplopia
  Acute Complications; E11
  Gestational Diabetes Mellitus; OB26
  Insulin Formulations; E9
  Insulin Regimens; E10
  Macrovascular Complications; E12
  Microvascular Complications; E12
  Other Complications; E13
  Pre-Diabetes; E6
  Type 1; E7
  Type 2; E7
Diseases
  Airway Obstruction; R7
  Hair Density; D37
  External Ear; OT15
  Inner Ear; OT19
  Middle Ear; OT17
  Dislocated Lens; OP20
  Dislocations; PL26
  Disorders of Gaze; N15
  Disorders of Sexual Differentiation; U39
  Disorders of the Nail Apparatus; D39
  Disorders of the Spine; NS3
  Disseminated Intravascular Coagulation; H32
  Dissociative Disorders; PS28
  Distal Femoral Fracture; OR30
  Distal Humeral Fracture; OR16
  Disturbances of Alertness; N47
  Disturbances of Sleep; N47
  Diverticular Disease; GS31
  Diverticulitis; GS31
  Diverticulosis; GS31
  Dizziness; ER39, FM25, OT6
  Domestic Violence; ER28
  Dose-Response; CP7
  Dressings; PL11
  Driving Competency; GM11
  Drug Administration; CP2
  Drug Eruptions; D21
  Bullous; D22
  Exanthematous; D21
  Fixed Drug Eruption; D23
  Photosensitivity Reaction; D23
  Pustular; D22
  Urticarial; D22
  Drug-Induced Liver Disease; GS2
  Drug Interactions; CP10
  Drug Nomenclature; CP2
  Drug Ototoxicity; GT20
  Drug Response; CP10
  Drug Safety During Breastfeeding; OB47
  Dry Eye Syndrome; OP10
  DSM-5 Diagnostic Criteria
    Adjustment Disorder; PS18
    Agoraphobia; PS15
    Anorexia Nervosa; PS31
    Bulimia Nervosa; PS31
    Delirium; PS19
    Generalized Anxiety Disorder; PS15
    Major Depressive Disorder; PS10
    Major Neurocognitive Disorder; PS20
    Obsessive-Compulsive Disorder; PS16
    Panic Disorder; PS14
    Persistent Depressive Disorder; PS11
    Post-Traumatic Stress Disorder; PS17
    Schizoaffective Disorder; PS8
    Schizophrenia; PS6
  Sleep-Wake Disorders; PS29
  Duodenal Ulcers; GS18
  Duodenum; G3, G10, GS18
  Dupuytren’s Disease; PL27
  Dural Fistulas; NS22
  Dyshidrotic Dermatitis; D15
  Dyslipidemia; E2, FM9
  Medications; E50
  Dysmenorrhea; GY6, GY13
  Dysmorphic Child; P40
  Dyspareunia; GY8
  Dyspepsia; FM27, G5, G10
  Dyshidrosis; G5, G8
  Dysphagia; ER26, FM27, P84, R3
  Dysrhythmias; P20
  Dysuria; OB25
  Enophthalmos; GY6, GY13
  Erythema Nodosum; D42
  Erythrocytosis; H6
  Ectopic Pregnancy; GY21
  Ectopic Testes; U38
  Aceretropion; OP12
  Effectiveness of Interventions; PH10
  Effects of Drugs; CP7
  Elbow Dislocation; OR18
  Elder Abuse; GM4
  Electrical Pacing; C24
  Electrocardiogram Changes; ER23
  Electrocardiography; C5
    Classical Approach; C6
    POQRSU Approach; C9
  Electroconvulsive Therapy; PS49
  Electrolytes; ER36, NP7, P74
  Electrophysiology Studies; C24
  Elevated Intracranial Pressure; NS5
  Emergency Postcoital Contraception; GY20
  Empyema; R23
  Encephalitis; ID19
  Encopresis; P10
  Endemic Mycoses; ID33
  Endocrine
    Disorders; A6
    Glands Disorders; E35
    Neoplasm; E35
    Organs; E2
  End of Life Care; ELM13, GM12
  Endometrial Biopsy; GY9
  Endometriosis; GY13
  Endophthalmitis; OP21
  Endotracheal Tube; MI10
  End Stage Renal Disease; NP36
  Enophthalmos; OP9
  Entamoeba histolytica; ID36
  Enteral Nutrition; G47
  Enteropathic Arthritis; RH22
  Entropion; OP12
  Enuresis; P9
  Environmental
    Health; PH20
    Injuries; ER45
    Eosinophilia; H11
    Epicondylitis; OR18
    Epidemiology; PH8
    Epididymitis; U16
    Epidural; A20, NS16
    Epiglottitis; OT44
    Epilepsy; N18, NS39
    Epiphora; OP10
    Epiphysial Injury; OR41
    Episcleritis; OP15
    Episiotomy; OB42
    Epistaxis; ER39, OT26
    Erectile Dysfunction; FM29, U30
    Erysipelas; D26, PL14
  Ear Anatomy; OT2
  Eating Disorders; PS30
  Echocardiography; C12
  Eclampsia; OB25
  Preeclampsia; OB24
  Echocardiography; C12
Intraoperative Management
Blood Pressure; A13
Fluid Balance and Resuscitation; A13
Heart Rate; A12
IV Fluids; A14
Temperature; A12
Intrauterine
Device; GY19
Fetal Death; OB18
Growth Restriction; OB19
Intraventricular Hemorrhage; P68
Intussusception; GS64
Iron Metabolism; H13
Irritable Bowel Syndrome; G23
Ischemic
Heart Disease; C25
Stroke; N50
Ishikawa Diagram; PH18
Isoimmunization Screening; OB8
“itis” Imaging; MI14

J
Jaundice; G6, G40, P69
Jejunum; G3
Joint Pain; ER24, FM37, RH3
Juvenile Idiopathic Arthritis; P90

K
Kawasaki Disease; P92
Kayser-Fleischer Ring; OP18
Keloids; D7
Keratoacanthoma; D35
Keratoconus; OP18
Kidney Disease
Adult Polycystic; NP35
Kidney Injury; NP18
Knee; OR31
Known Etiologic Agents; R15

L
Labour; OB33
Labyrinthitis; OT14
Lacrimal Apparatus; OP10
Lactose Intolerance; P35
Lambert-Eaton Myasthenic Syndrome; N39
Language Delay; P23
Large Bowel; G3
Obstruction; GS29, GS30
Large Intestine; GS29
Large Vessel Vasculitis; RH20
Laryngeal Carcinoma; OT29
Laryngitis; OT28
Laryngomalacia; OT45
Laryngotracheobronchitis; OT44
Lead Poisoning; H17
Le Fort Classification; PL30
Legal; ELOM5
Issues; PS50
Legg-Calvé-Perthes Disease; OR43
Leopold’s Maneuvers; OB6
Leprosy; ID22
Leukemia; P48
Lymphoblastic; H43
Myeloid; H37
Leukemoid Reaction; H12
Leukocoria; OP38
Leukoplakia; D33
Lice; D28, FM51
Lichen Planus; D16
Lichen Simplex Chronicus; D16
Lid Carcinoma; OP31
Lid Swelling; OP11
Limb Pain; P88
Lipid Transport; E2
Lipoma; D10
Liver; G3, G28, GS42
Abscesses; GS43
Cysts; GS43
Disease; H32
Failure; G35
Transplantation; GS45
Local Infiltration; A23
Loss of Consciousness; C4
Loss of Vision; OP3
Low Back Pain; FM38, OR25
Lower GI Bleed; G5
Lower Limb Ulcers; PL15
Lower Urinary Tract Dysfunction; U5
Low High-Density Lipoprotein; E4
Lumbar Disc Syndrome; NS25
Lymph
Puncture; N9
Spinal Stenosis; NS26
Lund-Browder Diagram; PL18
Lung
Abnormalities; M16
Cancer; FM4, R27
Transplantation; GS17
Luteinizing Hormone; E17
Lyme Arthritis; P91
Lyme Disease; ID23
Lymphadenopathy; H12, P48
Lymphatic Venolymphatic Malformations; OT34
Lymphedema; VS10
Lymphoid Malignancies; H43
Lymphomas; H45, P49
Lymphopenia; H11
Lymphoplasmacytic Lymphoma; H51
Lynch Syndrome; GS34

M
Macroscopic; U4
Macrosomia; OB19
Macular Degeneration
Age-Related; OP24
Magnetic Resonance Imaging; C16, MI3
Major Neurocognitive Disorder; N21, PS20
Malabsorption; G16
Malaria; ID38
Maldigestion; G16
Male; GY24, U34
Reproductive Endocrinology; E45
Malformations; OT34
Malignant
Hyperthermia; A28
Melanoma; D35, OP32
Renal Neoplasms; U21
Skin Lesions; PL5
Skin Tumours; D34
Mallampati Classification; A3
Mallory-Weiss Tear; G26
Malrotation; GS63
Mandibular Fractures; PL29
Mastitis; FM51, OB45
Mastoiditis; OT18
Mastopexy; PL33
Maxillary Fractures; PL30
Meckel’s Diverticulum; GS62
Meconium in Amniotic Fluid; OB37
Median Nerve Compression; PL27
Mediastinal
Abnormalities; M19
Masses; R21
Mediastinitis; R21
Medium Vessel Vasculitis; RH19
Medullary Sponge Kidney; NP36
Ménière’s Disease; OT13
Meningioma; NS12
Meningitis; ID18, PS9
Meniscal Tears; OR33
Menopause; FM40, GY34
Menstrual Cycle; GY4
Mental Status; PS3
Mesothelioma; R24
Metabolic
Acidosis; NP16
Alkalosis; NP17
Bone Disease; E40, MI23
Diseases; P43
Syndrome; E14
<table>
<thead>
<tr>
<th>N</th>
<th>M</th>
<th>O</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nails; D39</td>
<td>Miose; OP30</td>
<td>Obese; A6, FM7, P11</td>
</tr>
<tr>
<td>Nasal</td>
<td>Mixed Connective Tissue Disease; RH16</td>
<td>Observational Study Designs; PH11</td>
</tr>
<tr>
<td>Anatomy; OT3 Fractures; PL30</td>
<td>Multiple Myeloma; H49, NP32</td>
<td>Obstetrical Hemorrhage; OB13</td>
</tr>
<tr>
<td>Obstruction; OT8</td>
<td>Multiple Sclerosis; N52, OP34</td>
<td>Obstructive Sleep Apnea; A6</td>
</tr>
<tr>
<td>Nasogastric Tube; MI10</td>
<td>Mumps; P60</td>
<td>Occupational Health; PH23</td>
</tr>
<tr>
<td>Nasolacrimal System Defects; OP39</td>
<td>Neurology; DM3</td>
<td>Ocular Drug Toxicity; OP41</td>
</tr>
<tr>
<td>Nausea/Vomiting; G5</td>
<td>Neurological Exam; N3</td>
<td>Ocular Emergencies; OP5</td>
</tr>
<tr>
<td>Near Drowning; ER46</td>
<td>Neurologically Determined Death; NS33</td>
<td>Ocular Pain; OP4</td>
</tr>
<tr>
<td>Neck</td>
<td>NeuroMuscular Junction Syndromes; N38</td>
<td>Ocular Trauma; OP39</td>
</tr>
<tr>
<td>Mass; OT9, OT31</td>
<td>Neurodevelopmental Disorders; PS37</td>
<td>Odynophagia; G5</td>
</tr>
<tr>
<td>Triangles of the Neck; OT5</td>
<td>Neurofibromatosis; D24</td>
<td>Oligophylymmas; OB20</td>
</tr>
<tr>
<td>Congenital Neck Mass; OT32</td>
<td>Neurogenic Claudication; NS27</td>
<td>Oliguria; GS10</td>
</tr>
<tr>
<td>Neck Trauma; ER12</td>
<td>Neurocognitive Disorders; PS19</td>
<td>Omphalocoele; GS63</td>
</tr>
<tr>
<td>Necrotizing Enterocolitis; P71</td>
<td>with Lewy Bodies; N25</td>
<td>Open-Angle Glaucoma; OP26</td>
</tr>
<tr>
<td>Necrotizing Fasciitis; ID10, PL15</td>
<td>Neurocutaneous Syndromes; P84</td>
<td>Open Fractures; OR8</td>
</tr>
<tr>
<td>Neglect; ER60, P14</td>
<td>Neurodevelopmental Disorders; PS37</td>
<td>Ophthalmia Neonatorum; OP39</td>
</tr>
<tr>
<td>Negligence; ELOM10</td>
<td>Neurofibromatosis; D24</td>
<td>Ophthalmologic Emergencies; ER42</td>
</tr>
<tr>
<td>Nematodes; ID40</td>
<td>Neurogenic Bladder; U9</td>
<td>Opioids; PS24</td>
</tr>
<tr>
<td>Neonatology; P63</td>
<td>Neurogenic Claudication; NS27</td>
<td>Opportunistic Fungi; ID34</td>
</tr>
<tr>
<td>Neoplasms; GY48</td>
<td>Neurological Complaint</td>
<td>Oppositional Defiant Disorder; PS39</td>
</tr>
<tr>
<td>Head; OT34</td>
<td>Lesion Localization; N2</td>
<td>Optics; OP7</td>
</tr>
<tr>
<td>Neck; OT34</td>
<td>Neurological Exam; N3</td>
<td>Disc Atrophy; N14</td>
</tr>
<tr>
<td>Nephritic Syndrome; P77</td>
<td>Neurologically Determined Death; NS33</td>
<td>Disc Edema; N14</td>
</tr>
<tr>
<td>Nephroblastoma; P49, U38</td>
<td>NeuroMuscular Junction Diseases; N38</td>
<td>Oral Ulcer; D5</td>
</tr>
<tr>
<td>Nephrolithiasis; ER42</td>
<td>Neuro-Ophthalmology; N14</td>
<td>Orbit; OP9</td>
</tr>
<tr>
<td>Nephritic Syndrome; P78</td>
<td>Neuropathic Pain; N41</td>
<td>Orbital Cellulitis; OP9</td>
</tr>
<tr>
<td>Nerve Roots; NS2</td>
<td>Neuropsychiatric Disorders; NS38</td>
<td>Orbital Floor Fractures; PL31</td>
</tr>
<tr>
<td>Neuroanatomy; NS2</td>
<td>Neuroradiology; MI18</td>
<td>Orbitalis; U16</td>
</tr>
<tr>
<td>Neuroblastoma; P50</td>
<td>Neurosurgical Treatments; PS50</td>
<td>Organ Failure; R32</td>
</tr>
<tr>
<td>Neurocognitive Disorders; PS19</td>
<td>Non-Alcoholic Fatty Liver Disease; G34</td>
<td>Orthopedic</td>
</tr>
<tr>
<td>with Lewy Bodies; N25</td>
<td>Neurologically Determined Death; NS33</td>
<td>Injuries; ER15</td>
</tr>
<tr>
<td>Neurocutaneous Syndromes; P84</td>
<td>Neuro-Ophthalmologic Emergencies; ER42</td>
<td>X-Ray Imaging; OR7</td>
</tr>
<tr>
<td>Neurodevelopmental Disorders; PS37</td>
<td>Osteoarthritis; FM40, RH5</td>
<td>Osgood-Schlatter Disease; OR43</td>
</tr>
<tr>
<td>Neurofibromatosis; D24</td>
<td>Neurosurgical Treatments; PS50</td>
<td>Osteomalacia; E42, MI23</td>
</tr>
<tr>
<td>Neurogenic Bladder; U9</td>
<td>Neurotrauma; NS29</td>
<td>Osteomyelitis; OR9, P90</td>
</tr>
</tbody>
</table>
Prolonged Pregnancy; OB18
Prostate Cancer; U24
Prostate Cancer Screening; U26
Prostatitis; U15
Prostatodynia; U15
Proteinuria; NP20
Protozoa; ID36
Proximal Humeral Fracture; OR15
Pruritus; D42, GY6
Pseudogout; D42
Pseudocholinesterase
Abnormal; A29
Pseudotumour Cerebri; NS7
Psoriasis; D17
Psoriatic Arthritis; RH23
Psychiatric Assessment; PS6
Psychiatric Emergencies; PS6
Psoriatic Arthritis; ID20
Psoriasis; ID20
Pseudotumour Cerebri; D5
Pylonephritis; U14
Pupil
Pyelonephritis; OP31
Pus; OP31
Pure Tone Audiometry; OP31
Pupillary Light Reflex; OP31
Puerperal Complications; OB43
Pulmonary
Edema; GS11
Embolism; ER22, ER33, R18
Embolus; GS11
Function Tests; R4
Hypertension; RH21
Hypertension of the Newborn; P72
Hypertension of the Newborn; P72
Vascular Abnormalities; MI8
Vascular Disease; R20
Vasculitis; R20
Pupils
Abnormalities; OP28
Pulmonary Light Reflex; OP28
Pure Tone Audiometry; OT10
Pus; NS14
Posture; D5
Pustule; D5
Pylonephritis; U14
Quadriceps Tendon Rupture; OR33
Rabies; ID20
Radial Head Fracture; OR17
Radical Prostatectomy; U41
Radionuclide Ventriculography; MI26
Radius Shaft Fractures; OR19
Rapid Primary Survey; ER2
Rapid Sequence Induction; A15
Rashes; FM41, P12
Reactive Arthritis; P91, RH23
Reconstruction; PL11
Rectal Prolapse; GS41
Recurrent Headache; P82
Red Blood Cells; H52
Red Eye; OP3, OP5
Red Papule; D5
Red Scales; D5
Relative Afferent Pupillary Defect; OP31
Renal
Colic; ER42
Function; NP2, NP5
Hemodynamics; NP4
Mass; U20
Osteodystrophy; E43
Parenchymal Hypertension; NP34
Replacement Surgery; NP37
Stones; U18
Structure; NP2
Transplantation; NP38
Trauma; U32
Repetitive Transcranial Magnetic Stimulation; PS49
Respiratory
Dysfunction; PH24
Respiratory Distress; PH24
Respiratory Disease; ELOM11
Respiratory Distress; ER57
Respiratory Distress; ER57
Distress in the Newborn; P72
Distress Syndrome; R26
Failure; GS12, R25
Tract Diseases; P85
Restrictive Cardiomyopathy; C42
Resuscitation; ER4
Retained Placenta; OB44
Retina; OP2, OP22
Retinal Detachment; OP23
Retinitis Pigmentosa; OP23
Retinoblastoma; OP38
Retinopathy
Prematurity; OP38
Reversing Agents; A17
Rheumatic Fever; C43
Rheumatoid Arthritis; RH8
Rhinorrhea; FM19, FM49, OT23
Rhinosinusitis; OT24
Rickets; E42, MI23
Rings; G9
Rocky Mountain Spotted Fever; ID24
Rosaee; D12
Rotator Cuff Disease; OR12
Roundworms; ID40
Routine
Immunization; P4
Induction; A15
Rule of 9s
Total Body Surface Area; PL18
Sarcoïdosis; OP35
Scabies; D27
Scaphoid Fracture; OR21
Scarring Arachnodactyly; D38
Schistosoma spp.; ID41
Schizoaffective Disorder; PS8
Schizophrenia; PS6
Schizophreniform Disorder; PS8
Sclera; OP15
Scleritis; OP15
Scleroderma; NP32, RH13
Sclerosing Adenosis; GS55
Scoliosis; OR44
Scrotal Mass; U29
Seborrheic Dermatitis; D15
Secondary
Biliary Cirrhosis; G42
Survey; ER5
Second Trimester Bleeding; GY8
Seizures; ER25
Disorders; N18, P81
Seniors; GM2
Sepsis; ER38, ID21, R33
Neonate; P74
Septic
Arthritis; ID14, P90
Joint; OR10
Shock; ID21
Sero-negative Rheumatic Disease; RH4, RH21
Sero-positive Rheumatic Disease; RH4, RH6
Sexual Abuse; P14
Sexual Assault; ER27
Sexual Development; P28
Sexuality
Gender; PS30
Sexual Dysfunction; GY33
Sexually Transmitted Infections; D31, FM42, GY27
Shingles; D29
Shock; R33
Short Gut Syndrome; GS25
Shortness of Breath; ER26
Shoulder Dislocation; OR10
Sialadenitis; OT30
Sialolithiasis; OT30
Sick Euthyroid Syndrome; E27
Sickle Cell Disease; H20
Sideroblastic Anemia; H16
Signs of Airway Obstruction; OT43
Sinuses; OT32
Sinositis; FM44, FM49, P62
Sjögren’s Syndrome; RH16
Skin
Anatomy; D2
Biopsy; PL7
Function; D3
Trypanosoma cruzi; ID38
Tuberculosis; ID26
Tube Thoracostomy; GS16
Tubulointerstitial Disease; NP25
Tumour Lysis Syndrome; H52
Tumours; NS10
Twin Pregnancies; OB21

U
Ulcerative Colitis; G19, G20, G21, GS29
Ulcers; PL15
Ulna Shaft Fractures; OR19
Ultrasound; GY8, MI3
Umbilical
   Cord Prolapse; OB39
   Hernias; GS63
Unknown Etiologic Agents; R14
Upper GI Bleed; G5
Urethral
   Injuries; U33
   Stricture; U8
Urethritis; U16
Urinalysis; NP6
Urinary
   Incontinence; U5
   Retention; U6
   Tract Infection; OB28, P62, U12
Urine
   Biochemistry; NP7
   Microscopy; NP6
Urogynecology; GY36
Urological
   Imaging; MI15
   Neoplasms; U20
   Procedures; U40
   Emergencies; ER40
Urticaria; D41
Usual Ductal Hyperplasia; GS55
Uterine
   Bleeding; GY6, GY11
   Inversion; OB44
   Rupture; OB39
Uterus; GY38
Uveal Tract; OP19
Uveitis; OP19

V
Vacuum Extraction; OB41
Vagina; GY47
Vaginal Birth
   After Cesarean; OB43
Vaginal
   Bleeding; ER40
   Delivery; OB41
   Valve
   Prosthesis; C43
   Repair; C43
   Replacement; C43
Valvular Disease; C44
Valvular Heart Disease; C43
Varicose Veins; VS8
Vasa Previa; OB15
Vascular
   Diseases of the Kidney; NP28
   Lesions; D9
   Malformations; NS21
   Neurocognitive Disorder; N26
Vasculitides; P91, RH17
Vasomotor Rhinitis; OT24
Venous Thromboembolism; ER32, H35, OB30
Venous Venolymphatic Malformations; OT34
Ventricular Assist Devices; C38
Ventricular Tachydysrhythmias; ER31
Verruca
   Palmaris; D30
   Planae; D30
   Plantaris; D30
   Vulgaris; D30
Vertigo; ER39, OT12
Vesicle; D5
Vesiculobullous Diseases; D19
Vestibular Neuronitis; OT14
Vestibular Schwannoma; NS13, OT14
Viral
   Hepatitis; G28
   Infections; D29
Virology; ID4
Visual Field
   Abnormalities; N15
Vitamin
   B12 Deficiency; H24
   K Deficiency; H32, P46
Vitiligo; D24
Vitreous; OP21
   Hemorrhage; OP21
Vitritis; OP21
Vocal Cord
   Nodules; OT29
   Polyps; OT28
Voiding; U5
Volvulus; GS36
Vomiting; G5, P32
von Recklinghausen’s Disease; D24
von Willebrand Disease; H30
Vulnerable Populations; PH4
Vulva; GY46
Vulvovaginal Candidiasis; FM51
Vulvovaginitis; GY26

W
Waldenstrom’s Macroglobulinemia; H51
Warts; D30
Weakness; N9
Webs; G9
Wernicke-Korsakoff Syndrome; N35
West Nile Virus; ID24
Wilms’ Tumour; P49, U38
Wilson’s Disease; G32
Wounds; GS8, PL8
   Surgical Site Infection; GS8
   Care; GS8
   Dehiscence; GS9
   Hemorrhage; GS9
   Management; ER17
   Wrist Fractures; OR21

X
Xanthelasma; OP13

Y
Yeast Infections; D31

Z
Zygomatic Fractures; PL30
For 32 years, Toronto Notes has been a premier study resource for the Canadian MCCQE Part I and USMLE Step II medical licensing exams. This edition provides concise, comprehensive, and up-to-date information on the objectives covered by these exams, including the most recent best practice guidelines and up-to-date clinical trials for clinical practice. An excellent resource for clinical rotations, Toronto Notes 2017 contains 30 specialty-specific chapters.